DrugMAP Full Data Download File Title - DrugMAP drug to drug therapeutic target (DTT) mapping with mode of action information in raw format Version 1.01 (2022.07.20) Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB) College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Any question about data provided here, please contact with: Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn) DI: Drug_ID DN: Drug_Name TI: DTT_ID TN: DTT_Name MA: MOA RN: Reference_Name RU: Reference_URL DM02A65 DI DM02A65 DM02A65 DN Temazepam DM02A65 TI TTPTXIN DM02A65 TN Translocator protein (TSPO) DM02A65 MA Modulator DM02A65 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM02A65 RU https://www.fda.gov/ DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTEF5MJ DM02AWV TN ATP-binding cassette transporter C9 (ABCC9) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTP835K DM02AWV TN ATP-binding cassette transporter C8 (ABCC8) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM03CP7 DI DM03CP7 DM03CP7 DN Calcipotriol DM03CP7 TI TTK59TV DM03CP7 TN Vitamin D3 receptor (VDR) DM03CP7 MA Antagonist DM03CP7 RN Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59. DM03CP7 RU https://pubmed.ncbi.nlm.nih.gov/18393827 DM04LR2 DI DM04LR2 DM04LR2 DN Floxuridine DM04LR2 TI TTU6BFZ DM04LR2 TN Candida Thymidylate synthase (Candi TMP1) DM04LR2 MA Inhibitor DM04LR2 RN Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86. DM04LR2 RU https://pubmed.ncbi.nlm.nih.gov/10482907 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT TI TTZPO1L DM053KT TN Substance-P receptor (TACR1) DM053KT MA Antagonist DM053KT RN Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46. DM053KT RU https://pubmed.ncbi.nlm.nih.gov/19354254 DM05968 DI DM05968 DM05968 DN Otilonium bromide DM05968 TI TTXHYV6 DM05968 TN Voltage-gated L-type calcium channel (L-CaC) DM05968 MA Blocker DM05968 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM05968 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM05FXR DI DM05FXR DM05FXR DN Meclofenamic acid DM05FXR TI TTK0943 DM05FXR TN Prostaglandin G/H synthase (COX) DM05FXR MA Inhibitor DM05FXR RN Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. DM05FXR RU https://pubmed.ncbi.nlm.nih.gov/7825862 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E TI TT94IAG DM0659E TN Cannabinoid receptor (CB) DM0659E MA Binder DM0659E RN (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106. DM0659E RU https://pubmed.ncbi.nlm.nih.gov/12450575 DM06HG5 DI DM06HG5 DM06HG5 DN Levomethadyl Acetate DM06HG5 TI TTKWM86 DM06HG5 TN Opioid receptor mu (MOP) DM06HG5 MA Agonist DM06HG5 RN Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. DM06HG5 RU https://pubmed.ncbi.nlm.nih.gov/10911931 DM07K2I DI DM07K2I DM07K2I DN Eprosartan DM07K2I TI TT8DBY3 DM07K2I TN Angiotensin II receptor type-1 (AGTR1) DM07K2I MA Antagonist DM07K2I RN Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. DM07K2I RU https://pubmed.ncbi.nlm.nih.gov/18855637 DM07TX3 DI DM07TX3 DM07TX3 DN Cefotetan DM07TX3 TI TTJP4SM DM07TX3 TN Bacterial Penicillin binding protein (Bact PBP) DM07TX3 MA Binder DM07TX3 RN In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. DM07TX3 RU https://pubmed.ncbi.nlm.nih.gov/17488372 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A TI TTZAYWL DM07U2A TN Estrogen receptor (ESR) DM07U2A MA Modulator DM07U2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM07U2A RU https://www.fda.gov/ DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O TI TTPTXIN DM08E9O TN Translocator protein (TSPO) DM08E9O MA Agonist DM08E9O RN Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8. DM08E9O RU https://pubmed.ncbi.nlm.nih.gov/19782064 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTFEZ5Q DM0AQ83 TN Coagulation factor IX (F9) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTCIHJA DM0AQ83 TN Coagulation factor Xa (F10) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AUCH DI DM0AUCH DM0AUCH DN Reslizumab DM0AUCH TI TTPREZD DM0AUCH TN Interleukin-5 (IL5) DM0AUCH MA Modulator DM0AUCH RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DM0AUCH RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DM0BQRS DI DM0BQRS DM0BQRS DN Spinosad DM0BQRS TI TT9JZPU DM0BQRS TN Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR) DM0BQRS MA Modulator DM0BQRS RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM0BQRS RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM0C9IL DI DM0C9IL DM0C9IL DN Ranolazine DM0C9IL TI TTP86E2 DM0C9IL TN Plasminogen (PLG) DM0C9IL MA Modulator DM0C9IL RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DM0C9IL RU https://pubmed.ncbi.nlm.nih.gov/23694890 DM0CVXA DI DM0CVXA DM0CVXA DN Mechlorethamine DM0CVXA TI TTUTN1I DM0CVXA TN Human Deoxyribonucleic acid (hDNA) DM0CVXA MA Intercalator DM0CVXA RN Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62. DM0CVXA RU https://pubmed.ncbi.nlm.nih.gov/19480393 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ TI TTUWYEA DM0D9YJ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM0D9YJ MA Binder DM0D9YJ RN Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98. DM0D9YJ RU https://pubmed.ncbi.nlm.nih.gov/11324679 DM0DQM5 DI DM0DQM5 DM0DQM5 DN Amlexanox DM0DQM5 TI TT78R5H DM0DQM5 TN Heat shock protein 90 alpha (HSP90A) DM0DQM5 MA Inhibitor DM0DQM5 RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM0DQM5 RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM0DTF7 DI DM0DTF7 DM0DTF7 DN Zonisamide DM0DTF7 TI TTRK8B9 DM0DTF7 TN Sodium channel unspecific (NaC) DM0DTF7 MA Blocker DM0DTF7 RN Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8. DM0DTF7 RU https://pubmed.ncbi.nlm.nih.gov/18782687 DM0DXA8 DI DM0DXA8 DM0DXA8 DN Droperidol DM0DXA8 TI TTEX248 DM0DXA8 TN Dopamine D2 receptor (D2R) DM0DXA8 MA Binder DM0DXA8 RN Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. DM0DXA8 RU https://pubmed.ncbi.nlm.nih.gov/12505540 DM0E6S3 DI DM0E6S3 DM0E6S3 DN Suvorexant DM0E6S3 TI TT9N02I DM0E6S3 TN Orexin receptor type 2 (HCRTR2) DM0E6S3 MA Modulator DM0E6S3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0E6S3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0EP7M DI DM0EP7M DM0EP7M DN Minaprine DM0EP7M TI TT0K1SC DM0EP7M TN 5-HT 2B receptor (HTR2B) DM0EP7M MA Antagonist DM0EP7M RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM0EP7M RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM0EZ9Q DI DM0EZ9Q DM0EZ9Q DN Pramlintide DM0EZ9Q TI TTVIMDE DM0EZ9Q TN Glucagon-like peptide 1 receptor (GLP1R) DM0EZ9Q MA Agonist DM0EZ9Q RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM0EZ9Q RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM0FB1J DI DM0FB1J DM0FB1J DN Sertraline DM0FB1J TI TT3ROYC DM0FB1J TN Serotonin transporter (SERT) DM0FB1J MA Inhibitor DM0FB1J RN Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6. DM0FB1J RU https://pubmed.ncbi.nlm.nih.gov/17877739 DM0FSIM DI DM0FSIM DM0FSIM DN Diphtheria-tetanus vaccine DM0FSIM TI TTXT4D5 DM0FSIM TN Bacterial Cell membrane (Bact CM) DM0FSIM RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM0FSIM RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM0GOUD DI DM0GOUD DM0GOUD DN Urokinase DM0GOUD TI TTGY7WI DM0GOUD TN Urokinase-type plasminogen activator (PLAU) DM0GOUD MA Modulator DM0GOUD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0GOUD RU https://www.fda.gov/ DM0GQ8N DI DM0GQ8N DM0GQ8N DN Amobarbital DM0GQ8N TI TT1MPAY DM0GQ8N TN GABA(A) receptor alpha-1 (GABRA1) DM0GQ8N MA Antagonist DM0GQ8N RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0GQ8N RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0GUSX DI DM0GUSX DM0GUSX DN Ranitidine DM0GUSX TI TTQHJ1K DM0GUSX TN Histamine H2 receptor (H2R) DM0GUSX MA Antagonist DM0GUSX RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM0GUSX RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM0HAC8 DI DM0HAC8 DM0HAC8 DN Cerliponase Alfa DM0HAC8 TI TTOVYPT DM0HAC8 TN Tripeptidyl-peptidase I (TPP1) DM0HAC8 MA Modulator DM0HAC8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0HAC8 RU https://www.fda.gov/ DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TT6EO5L DM0HS92 TN Erbb2 tyrosine kinase receptor (HER2) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTGKNB4 DM0HS92 TN Epidermal growth factor receptor (EGFR) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTL7C8Q DM0HS92 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM0HS92 MA Inhibitor DM0HS92 RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DM0HS92 RU https://pubmed.ncbi.nlm.nih.gov/11288107 DM0HXDS DI DM0HXDS DM0HXDS DN Pentostatin DM0HXDS TI TTLP57V DM0HXDS TN Adenosine deaminase (ADA) DM0HXDS MA Inhibitor DM0HXDS RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DM0HXDS RU https://pubmed.ncbi.nlm.nih.gov/10887639 DM0J2ZT DI DM0J2ZT DM0J2ZT DN Safinamide mesylate DM0J2ZT TI TTGP7BY DM0J2ZT TN Monoamine oxidase type B (MAO-B) DM0J2ZT MA Inhibitor DM0J2ZT RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0J2ZT RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0JE6N DI DM0JE6N DM0JE6N DN Metixene DM0JE6N TI TTZ9SOR DM0JE6N TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0JE6N MA Modulator DM0JE6N RN Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603. DM0JE6N RU https://www.ncbi.nlm.nih.gov/pubmed/22135383 DM0JXFL DI DM0JXFL DM0JXFL DN Temocapril hydrochloride DM0JXFL TI TTL69WB DM0JXFL TN Angiotensin-converting enzyme (ACE) DM0JXFL MA Modulator DM0JXFL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM0JXFL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM0KAE6 DI DM0KAE6 DM0KAE6 DN Kombiglyze XR/Komboglyze FDC DM0KAE6 TI TTDIGC1 DM0KAE6 TN Dipeptidyl peptidase 4 (DPP-4) DM0KAE6 MA Modulator DM0KAE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM0KAE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM0KYI4 DI DM0KYI4 DM0KYI4 DN Mebutamate DM0KYI4 TI TTEX6LM DM0KYI4 TN GABA(A) receptor gamma-3 (GABRG3) DM0KYI4 MA Modulator DM0KYI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0KYI4 RU https://www.fda.gov/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTFCQYU DM0L594 TN Sinus node I(f) channel (SA node IfC) DM0L594 MA Modulator DM0L594 RN Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228. DM0L594 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448693/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTKLW9S DM0L594 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DM0L594 MA Inhibitor DM0L594 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0L594 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTAWNKZ DM0LPI9 TN Norepinephrine transporter (NET) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTMQO60 DM0LPI9 TN Rho-associated protein kinase (ROCK) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTZN7RP DM0LPI9 TN Rho-associated protein kinase 1 (ROCK1) DM0LPI9 MA Inhibitor DM0LPI9 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0LRU9 DI DM0LRU9 DM0LRU9 DN Fendrix DM0LRU9 TI TT3J5ZI DM0LRU9 TN Cell mediated immunity response (CMIR) DM0LRU9 RN Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7. DM0LRU9 RU https://pubmed.ncbi.nlm.nih.gov/22981848 DM0MQ35 DI DM0MQ35 DM0MQ35 DN Spectinomycin DM0MQ35 TI TTQ8KVI DM0MQ35 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0MQ35 MA Binder DM0MQ35 RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DM0MQ35 RU https://pubmed.ncbi.nlm.nih.gov/11014183 DM0N3L7 DI DM0N3L7 DM0N3L7 DN Ethopropazine DM0N3L7 TI TTTIBOJ DM0N3L7 TN Histamine H1 receptor (H1R) DM0N3L7 MA Modulator DM0N3L7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N3L7 RU https://www.fda.gov/ DM0N85H DI DM0N85H DM0N85H DN Vidarabine DM0N85H TI TTNE7KG DM0N85H TN Adenosine A2b receptor (ADORA2B) DM0N85H MA Modulator DM0N85H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N85H RU https://www.fda.gov/ DM0N9WA DI DM0N9WA DM0N9WA DN Calcitonin Human DM0N9WA TI TTLWS2O DM0N9WA TN Calcitonin receptor (CALCR) DM0N9WA MA Modulator DM0N9WA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N9WA RU https://www.fda.gov/ DM0NATE DI DM0NATE DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork DM0NATE TI TTZOPHG DM0NATE TN Insulin (INS) DM0NATE MA Modulator DM0NATE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0NATE RU https://www.fda.gov/ DM0P63W DI DM0P63W DM0P63W DN Guanidine Hydrochloride DM0P63W TI TTQ8AFT DM0P63W TN Adrenergic receptor Alpha-2 (ADRA2) DM0P63W MA Modulator DM0P63W RN Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54. DM0P63W RU https://www.ncbi.nlm.nih.gov/pubmed/24908653 DM0PMGJ DI DM0PMGJ DM0PMGJ DN Polyestradiol Phosphate DM0PMGJ TI TT2A0DR DM0PMGJ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM0PMGJ MA Modulator DM0PMGJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0PMGJ RU https://www.fda.gov/ DM0Q8MZ DI DM0Q8MZ DM0Q8MZ DN Trimethadione DM0Q8MZ TI TT729IR DM0Q8MZ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM0Q8MZ MA Blocker DM0Q8MZ RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DM0Q8MZ RU https://pubmed.ncbi.nlm.nih.gov/17291698 DM0QD4W DI DM0QD4W DM0QD4W DN Aprotinin DM0QD4W TI TTEMV5X DM0QD4W TN Serine protease unspecific (SP) DM0QD4W MA Modulator DM0QD4W RN Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32. DM0QD4W RU https://pubmed.ncbi.nlm.nih.gov/16279145 DM0QJDC DI DM0QJDC DM0QJDC DN Lixisenatide DM0QJDC TI TTVIMDE DM0QJDC TN Glucagon-like peptide 1 receptor (GLP1R) DM0QJDC MA Modulator DM0QJDC RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM0QJDC RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM0QV1J DI DM0QV1J DM0QV1J DN Baclofen DM0QV1J TI TTDCVZW DM0QV1J TN Gamma-aminobutyric acid B receptor (GABBR) DM0QV1J MA Modulator DM0QV1J RN Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9. DM0QV1J RU https://pubmed.ncbi.nlm.nih.gov/10354414 DM0QZBN DI DM0QZBN DM0QZBN DN Ibandronate DM0QZBN TI TTIKWV4 DM0QZBN TN Geranyltranstransferase (FDPS) DM0QZBN MA Modulator DM0QZBN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0QZBN RU https://www.fda.gov/ DM0R4Z5 DI DM0R4Z5 DM0R4Z5 DN MCB-3837 DM0R4Z5 TI TT9SL3Q DM0R4Z5 TN Polypeptide deformylase (PDF) DM0R4Z5 MA Inhibitor DM0R4Z5 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM0R4Z5 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM0REZS DI DM0REZS DM0REZS DN Virulizin DM0REZS TI TTD2MLN DM0REZS TN Natural killer cell activation (NKA) DM0REZS MA Modulator DM0REZS RN Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26. DM0REZS RU https://pubmed.ncbi.nlm.nih.gov/15891881 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 TI TT5HONZ DM0RKS4 TN Calcium channel unspecific (CaC) DM0RKS4 MA Modulator DM0RKS4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0RKS4 RU https://www.fda.gov/ DM0RXF5 DI DM0RXF5 DM0RXF5 DN Hyqvia DM0RXF5 TI TTXFI1K DM0RXF5 TN Hyaluronidase (HYAL) DM0RXF5 MA Modulator DM0RXF5 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0RXF5 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0S9Z1 DI DM0S9Z1 DM0S9Z1 DN Nemonoxacin DM0S9Z1 TI TTN6J5F DM0S9Z1 TN Bacterial DNA gyrase (Bact gyrase) DM0S9Z1 MA Inhibitor DM0S9Z1 RN Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53. DM0S9Z1 RU https://pubmed.ncbi.nlm.nih.gov/25079302 DM0SYAN DI DM0SYAN DM0SYAN DN Almitrine DM0SYAN TI TTWK8D0 DM0SYAN TN Sodium pump subunit alpha-1 (ATP1A1) DM0SYAN MA Binder DM0SYAN RN Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9. DM0SYAN RU https://pubmed.ncbi.nlm.nih.gov/2527061 DM0T3YH DI DM0T3YH DM0T3YH DN Indinavir DM0T3YH TI TT5FNQT DM0T3YH TN Human immunodeficiency virus Protease (HIV PR) DM0T3YH MA Inhibitor DM0T3YH RN Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80. DM0T3YH RU https://pubmed.ncbi.nlm.nih.gov/19168402 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U TI TTR6W5O DM0TI4U TN Adrenergic receptor beta-1 (ADRB1) DM0TI4U MA Antagonist DM0TI4U RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM0TI4U RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM0VEC1 DI DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 TI TTEX248 DM0VEC1 TN Dopamine D2 receptor (D2R) DM0VEC1 MA Agonist DM0VEC1 RN Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. DM0VEC1 RU https://pubmed.ncbi.nlm.nih.gov/2897449 DM0VQN3 DI DM0VQN3 DM0VQN3 DN Ofloxacin DM0VQN3 TI TTN6J5F DM0VQN3 TN Bacterial DNA gyrase (Bact gyrase) DM0VQN3 MA Modulator DM0VQN3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0VQN3 RU https://www.fda.gov/ DM0WX6I DI DM0WX6I DM0WX6I DN Primidone DM0WX6I TI TT1MPAY DM0WX6I TN GABA(A) receptor alpha-1 (GABRA1) DM0WX6I MA Antagonist DM0WX6I RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0WX6I RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0Y49P DI DM0Y49P DM0Y49P DN Olanzapine/fluoxetine combination DM0Y49P TI TT8G3Z7 DM0Y49P TN Serotoninnorepinephrinedopamine reuptake (SNDR) DM0Y49P MA Antagonist DM0Y49P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM0Y49P RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB TI TTAN6JD DM0YJSB TN Glutamate receptor AMPA (GRIA) DM0YJSB MA Suppressor DM0YJSB RN Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84. DM0YJSB RU https://pubmed.ncbi.nlm.nih.gov/11020764 DM0YWJC DI DM0YWJC DM0YWJC DN Safinamide DM0YWJC TI TTGP7BY DM0YWJC TN Monoamine oxidase type B (MAO-B) DM0YWJC MA Inhibitor DM0YWJC RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DM0YWJC RU https://pubmed.ncbi.nlm.nih.gov/17874969 DM0YZC6 DI DM0YZC6 DM0YZC6 DN Fulvestrant DM0YZC6 TI TTZAYWL DM0YZC6 TN Estrogen receptor (ESR) DM0YZC6 MA Antagonist DM0YZC6 RN Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. DM0YZC6 RU https://pubmed.ncbi.nlm.nih.gov/19466750 DM0ZRMQ DI DM0ZRMQ DM0ZRMQ DN Clomocycline DM0ZRMQ TI TTQ8KVI DM0ZRMQ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0ZRMQ MA Binder DM0ZRMQ RN Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5. DM0ZRMQ RU https://pubmed.ncbi.nlm.nih.gov/18219717 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 TI TTZ9SOR DM13495 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM13495 MA Modulator DM13495 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM13495 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM13P4C DI DM13P4C DM13P4C DN Salsalate DM13P4C TI TT8NGED DM13P4C TN Prostaglandin G/H synthase 1 (COX-1) DM13P4C MA Inhibitor DM13P4C RN New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15. DM13P4C RU https://pubmed.ncbi.nlm.nih.gov/9711054 DM13PQW DI DM13PQW DM13PQW DN Rilmenidine DM13PQW TI TT2NUT5 DM13PQW TN Adrenergic receptor alpha-2C (ADRA2C) DM13PQW MA Modulator DM13PQW RN Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50. DM13PQW RU https://pubmed.ncbi.nlm.nih.gov/8921215 DM13VTW DI DM13VTW DM13VTW DN Flucytosine DM13VTW TI TTU6BFZ DM13VTW TN Candida Thymidylate synthase (Candi TMP1) DM13VTW MA Inhibitor DM13VTW RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DM13VTW RU https://pubmed.ncbi.nlm.nih.gov/16964330 DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTZFYLI DM14MAE TN Dopamine D1 receptor (D1R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTEX248 DM14MAE TN Dopamine D2 receptor (D2R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14RF5 DI DM14RF5 DM14RF5 DN Secobarbital DM14RF5 TI TT1MPAY DM14RF5 TN GABA(A) receptor alpha-1 (GABRA1) DM14RF5 MA Antagonist DM14RF5 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM14RF5 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM154EB DI DM154EB DM154EB DN Lypressin DM154EB TI TTPFZJ1 DM154EB TN Vasopressin V1 receptor (V1R) DM154EB MA Modulator DM154EB RN Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9. DM154EB RU https://pubmed.ncbi.nlm.nih.gov/3628176 DM15F0X DI DM15F0X DM15F0X DN Gefitinib DM15F0X TI TTGKNB4 DM15F0X TN Epidermal growth factor receptor (EGFR) DM15F0X MA Inhibitor DM15F0X RN Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. DM15F0X RU https://pubmed.ncbi.nlm.nih.gov/14760365 DM15HAT DI DM15HAT DM15HAT DN Leuprorelin acetate DM15HAT TI TT8R70G DM15HAT TN Gonadotropin-releasing hormone receptor (GNRHR) DM15HAT MA Agonist DM15HAT RN Clinical pipeline report, company report or official report of Takeda (2009). DM15HAT RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 TI TTUWYEA DM15HL8 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM15HL8 MA Binder DM15HL8 RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM15HL8 RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX TI TTTIBOJ DM17ONX TN Histamine H1 receptor (H1R) DM17ONX MA Antagonist DM17ONX RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DM17ONX RU https://pubmed.ncbi.nlm.nih.gov/19210904 DM1A6RV DI DM1A6RV DM1A6RV DN Interferon beta-1a DM1A6RV TI TT4TZ8J DM1A6RV TN Interferon-beta (IFNB1) DM1A6RV MA Modulator DM1A6RV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1A6RV RU https://www.fda.gov/ DM1A9W3 DI DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 TI TT26PHO DM1A9W3 TN Mineralocorticoid receptor (MR) DM1A9W3 MA Binder DM1A9W3 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DM1A9W3 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DM1A9XO DI DM1A9XO DM1A9XO DN Sertaconazole DM1A9XO TI TTTSOUD DM1A9XO TN Candida Cytochrome P450 51 (Candi ERG11) DM1A9XO MA Inhibitor DM1A9XO RN Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. DM1A9XO RU https://pubmed.ncbi.nlm.nih.gov/19275277 DM1AF5U DI DM1AF5U DM1AF5U DN Acetazolamide DM1AF5U TI TTHQPL7 DM1AF5U TN Carbonic anhydrase I (CA-I) DM1AF5U MA Modulator DM1AF5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1AF5U RU https://www.fda.gov/ DM1AGXN DI DM1AGXN DM1AGXN DN Paromomycin DM1AGXN TI TTQ8KVI DM1AGXN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM1AGXN MA Binder DM1AGXN RN Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. DM1AGXN RU https://pubmed.ncbi.nlm.nih.gov/19438282 DM1BKA6 DI DM1BKA6 DM1BKA6 DN Opicapone DM1BKA6 TI TTKWFB8 DM1BKA6 TN Catechol-O-methyl-transferase (COMT) DM1BKA6 MA Inhibitor DM1BKA6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1BKA6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf DM1BS03 DI DM1BS03 DM1BS03 DN Sifalimumab DM1BS03 TI TTMQB37 DM1BS03 TN Interferon alpha/beta receptor 2 (IFNAR2) DM1BS03 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1BS03 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W TI TTB2MXP DM1BV7W TN Angiotensinogenase renin (REN) DM1BV7W MA Inhibitor DM1BV7W RN Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. DM1BV7W RU https://pubmed.ncbi.nlm.nih.gov/19617271 DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TTRA79S DM1CI9R TN Cholesterol synthesis (Chole synth) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TT0Z6Y2 DM1CI9R TN ATP-citrate synthase (ACLY) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1D8XY DI DM1D8XY DM1D8XY DN Dantrolene DM1D8XY TI TT9YXM1 DM1D8XY TN Ryanodine receptor (RYR) DM1D8XY MA Modulator DM1D8XY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1D8XY RU https://www.fda.gov/ DM1D90W DI DM1D90W DM1D90W DN Tropicamide DM1D90W TI TTQ3JTF DM1D90W TN Muscarinic acetylcholine receptor M4 (CHRM4) DM1D90W MA Antagonist DM1D90W RN The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59. DM1D90W RU https://pubmed.ncbi.nlm.nih.gov/17594079 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTF1QVM DM1DBV5 TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM1DBV5 MA Inhibitor DM1DBV5 RN Clinical pipeline report, company report or official report of Takeda (2009). DM1DBV5 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTLOKXP DM1DBV5 TN Gastric H(+)/K(+) ATPase (Proton pump) DM1DBV5 MA Modulator DM1DBV5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1DBV5 RU https://www.fda.gov/ DM1DP7T DI DM1DP7T DM1DP7T DN Levonorgestrel DM1DP7T TI TTUV8G9 DM1DP7T TN Progesterone receptor (PGR) DM1DP7T MA Binder DM1DP7T RN Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24. DM1DP7T RU https://pubmed.ncbi.nlm.nih.gov/19289570 DM1DX4Q DI DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q TI TTML2WA DM1DX4Q TN Tubulin (TUB) DM1DX4Q MA Inhibitor DM1DX4Q RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM1DX4Q RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM1ECNJ DI DM1ECNJ DM1ECNJ DN GS-7340 DM1ECNJ TI TT84ETX DM1ECNJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1ECNJ MA Inhibitor DM1ECNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM1ECNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf DM1EF73 DI DM1EF73 DM1EF73 DN Methysergide DM1EF73 TI TTWJBZ5 DM1EF73 TN 5-HT 2C receptor (HTR2C) DM1EF73 MA Antagonist DM1EF73 RN Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8. DM1EF73 RU https://pubmed.ncbi.nlm.nih.gov/18396470 DM1F42Z DI DM1F42Z DM1F42Z DN Oxatomide DM1F42Z TI TTTIBOJ DM1F42Z TN Histamine H1 receptor (H1R) DM1F42Z MA Antagonist DM1F42Z RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM1F42Z RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM1FDN8 DI DM1FDN8 DM1FDN8 DN Mizolastine DM1FDN8 TI TTTIBOJ DM1FDN8 TN Histamine H1 receptor (H1R) DM1FDN8 MA Antagonist DM1FDN8 RN Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56. DM1FDN8 RU https://pubmed.ncbi.nlm.nih.gov/18498541 DM1FX74 DI DM1FX74 DM1FX74 DN Bretylium DM1FX74 TI TTR6W5O DM1FX74 TN Adrenergic receptor beta-1 (ADRB1) DM1FX74 MA Antagonist DM1FX74 RN Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. DM1FX74 RU https://pubmed.ncbi.nlm.nih.gov/2859811 DM1I3D5 DI DM1I3D5 DM1I3D5 DN Lepirudin DM1I3D5 TI TT6L509 DM1I3D5 TN Coagulation factor IIa (F2) DM1I3D5 MA Inhibitor DM1I3D5 RN Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50. DM1I3D5 RU https://pubmed.ncbi.nlm.nih.gov/10560805 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTQ13Z5 DM1I93C TN Muscarinic acetylcholine receptor M3 (CHRM3) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTZ9SOR DM1I93C TN Muscarinic acetylcholine receptor M1 (CHRM1) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTYEG6Q DM1I93C TN Muscarinic acetylcholine receptor M2 (CHRM2) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TTK8CXU DM1IB4Q TN 5-HT 1B receptor (HTR1B) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TT6MSOK DM1IB4Q TN 5-HT 1D receptor (HTR1D) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IFGT DI DM1IFGT DM1IFGT DN Chlorproguanil DM1IFGT TI TT9SL3Q DM1IFGT TN Polypeptide deformylase (PDF) DM1IFGT MA Inhibitor DM1IFGT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1IFGT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1IQRP DI DM1IQRP DM1IQRP DN Udenafil DM1IQRP TI TTJ0IQB DM1IQRP TN Phosphodiesterase 5A (PDE5A) DM1IQRP MA Inhibitor DM1IQRP RN Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42. DM1IQRP RU https://pubmed.ncbi.nlm.nih.gov/19465935 DM1IS6U DI DM1IS6U DM1IS6U DN Tenofovir DM1IS6U TI TT84ETX DM1IS6U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1IS6U MA Inhibitor DM1IS6U RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM1IS6U RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM1JEGF DI DM1JEGF DM1JEGF DN Albiglutide DM1JEGF TI TTVIMDE DM1JEGF TN Glucagon-like peptide 1 receptor (GLP1R) DM1JEGF MA Modulator DM1JEGF RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM1JEGF RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM1KS78 DI DM1KS78 DM1KS78 DN Talazoparib DM1KS78 TI TTEBCY8 DM1KS78 TN Poly [ADP-ribose] polymerase (PARP) DM1KS78 MA Inhibitor DM1KS78 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1KS78 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1M0Q4 DI DM1M0Q4 DM1M0Q4 DN Procaterol DM1M0Q4 TI TT2CJVK DM1M0Q4 TN Adrenergic receptor beta-2 (ADRB2) DM1M0Q4 MA Agonist DM1M0Q4 RN Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91. DM1M0Q4 RU https://pubmed.ncbi.nlm.nih.gov/17646734 DM1MBYQ DI DM1MBYQ DM1MBYQ DN Ganciclovir DM1MBYQ TI TTIU7X1 DM1MBYQ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM1MBYQ MA Inhibitor DM1MBYQ RN Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. DM1MBYQ RU https://pubmed.ncbi.nlm.nih.gov/19563015 DM1N62C DI DM1N62C DM1N62C DN Quetiapine DM1N62C TI TTEX248 DM1N62C TN Dopamine D2 receptor (D2R) DM1N62C MA Agonist DM1N62C RN Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. DM1N62C RU https://pubmed.ncbi.nlm.nih.gov/19217900 DM1NG5W DI DM1NG5W DM1NG5W DN Hydrogen peroxide DM1NG5W TI TTELIN2 DM1NG5W TN PTPN1 messenger RNA (PTPN1 mRNA) DM1NG5W MA Inhibitor DM1NG5W RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DM1NG5W RU https://pubmed.ncbi.nlm.nih.gov/10091683 DM1NOEK DI DM1NOEK DM1NOEK DN Metreleptin DM1NOEK TI TT0HD6V DM1NOEK TN Leptin receptor (LEPR) DM1NOEK MA Modulator DM1NOEK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM1NOEK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM1O3BY DI DM1O3BY DM1O3BY DN Mecasermin DM1O3BY TI TTHRID2 DM1O3BY TN Insulin-like growth factor I receptor (IGF1R) DM1O3BY MA Inhibitor DM1O3BY RN IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45. DM1O3BY RU https://pubmed.ncbi.nlm.nih.gov/12845531 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTCBFJO DM1OFHN TN Insulin receptor (INSR) DM1OFHN MA Stimulator DM1OFHN RN New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/18840004 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTEX248 DM1OFHN TN Dopamine D2 receptor (D2R) DM1OFHN MA Antagonist DM1OFHN RN Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/4015674 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTROQ37 DM1P6FR TN MAPK/ERK kinase kinase (MAP3K) DM1P6FR MA Modulator DM1P6FR RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTZCRP3 DM1P6FR TN ERK activator kinase (MEK) DM1P6FR MA Inhibitor DM1P6FR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1P6FR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1QLST DI DM1QLST DM1QLST DN Trimazosin DM1QLST TI TT34BHT DM1QLST TN Adrenergic receptor alpha-1D (ADRA1D) DM1QLST MA Modulator DM1QLST RN The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50. DM1QLST RU https://pubmed.ncbi.nlm.nih.gov/6199597 DM1R5X4 DI DM1R5X4 DM1R5X4 DN Becaplermin DM1R5X4 TI TTI7421 DM1R5X4 TN Platelet-derived growth factor receptor beta (PDGFRB) DM1R5X4 MA Modulator DM1R5X4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1R5X4 RU https://www.fda.gov/ DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT6HPVC DM1RBYG TN Guanylate cyclase (GC) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT23PYC DM1RBYG TN Soluble guanylate cyclase (GCS) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/8638522 DM1S4AG DI DM1S4AG DM1S4AG DN Lumiracoxib DM1S4AG TI TTVKILB DM1S4AG TN Prostaglandin G/H synthase 2 (COX-2) DM1S4AG MA Inhibitor DM1S4AG RN Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8. DM1S4AG RU https://pubmed.ncbi.nlm.nih.gov/19251789 DM1SC8M DI DM1SC8M DM1SC8M DN Trimipramine DM1SC8M TI TTAWNKZ DM1SC8M TN Norepinephrine transporter (NET) DM1SC8M MA Inhibitor DM1SC8M RN Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. DM1SC8M RU https://pubmed.ncbi.nlm.nih.gov/16388933 DM1SRQT DI DM1SRQT DM1SRQT DN Aceprometazine DM1SRQT TI TTTIBOJ DM1SRQT TN Histamine H1 receptor (H1R) DM1SRQT MA Antagonist DM1SRQT RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM1SRQT RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM1TJ8F DI DM1TJ8F DM1TJ8F DN Diethylcarbamazine DM1TJ8F TI TT2J34L DM1TJ8F TN Arachidonate 5-lipoxygenase (5-LOX) DM1TJ8F MA Inhibitor DM1TJ8F RN Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. DM1TJ8F RU https://pubmed.ncbi.nlm.nih.gov/10518442 DM1TMA3 DI DM1TMA3 DM1TMA3 DN Imiquimod DM1TMA3 TI TTRJ1K4 DM1TMA3 TN Toll-like receptor 7 (TLR7) DM1TMA3 MA Agonist DM1TMA3 RN Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85. DM1TMA3 RU https://pubmed.ncbi.nlm.nih.gov/19516264 DM1UE67 DI DM1UE67 DM1UE67 DN TOCOTRIENOL DM1UE67 TI TTPADOQ DM1UE67 TN HMG-CoA reductase (HMGCR) DM1UE67 MA Inhibitor DM1UE67 RN Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7. DM1UE67 RU https://pubmed.ncbi.nlm.nih.gov/12656204 DM1UJO0 DI DM1UJO0 DM1UJO0 DN Pitavastatin calcium DM1UJO0 TI TTPADOQ DM1UJO0 TN HMG-CoA reductase (HMGCR) DM1UJO0 MA Inhibitor DM1UJO0 RN Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203. DM1UJO0 RU https://pubmed.ncbi.nlm.nih.gov/11304935 DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F TI TTWORX6 DM1UV7F TN Influenza Polymerase acidic endonuclease (Influ PA) DM1UV7F MA Inhibitor DM1UV7F RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1UV7F RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TTK8R02 DM1V329 TN Vasopressin V2 receptor (V2R) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TT4TFGN DM1V329 TN Vasopressin V1a receptor (V1AR) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS TI TT9IK2Z DM1V5ZS TN N-methyl-D-aspartate receptor (NMDAR) DM1V5ZS MA Antagonist DM1V5ZS RN Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. DM1V5ZS RU https://pubmed.ncbi.nlm.nih.gov/18311896 DM1WL9O DI DM1WL9O DM1WL9O DN Glycodiazine DM1WL9O TI TTG140O DM1WL9O TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DM1WL9O MA Binder DM1WL9O RN Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52. DM1WL9O RU https://pubmed.ncbi.nlm.nih.gov/141035 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTQ8AFT DM1WXA6 TN Adrenergic receptor Alpha-2 (ADRA2) DM1WXA6 MA Agonist DM1WXA6 RN Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/18821454 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTWG9A4 DM1WXA6 TN Adrenergic receptor alpha-2A (ADRA2A) DM1WXA6 MA Agonist DM1WXA6 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1XBHS DI DM1XBHS DM1XBHS DN Pentazocine DM1XBHS TI TTN4QDT DM1XBHS TN Opioid receptor (OPR) DM1XBHS MA Antagonist DM1XBHS RN Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8. DM1XBHS RU https://pubmed.ncbi.nlm.nih.gov/10562966 DM1XBWR DI DM1XBWR DM1XBWR DN N-acetyl-D-glucosamine DM1XBWR TI TTDM6HZ DM1XBWR TN Alpha-N-acetylglucosaminidase (NAGLU) DM1XBWR MA Activator DM1XBWR RN Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51. DM1XBWR RU https://pubmed.ncbi.nlm.nih.gov/19622275 DM1XHYJ DI DM1XHYJ DM1XHYJ DN Etidronic acid DM1XHYJ TI TTCWXFA DM1XHYJ TN Protein-tyrosine phosphatase sigma (R-PTP-sigma) DM1XHYJ MA Inhibitor DM1XHYJ RN Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. DM1XHYJ RU https://pubmed.ncbi.nlm.nih.gov/8992885 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTB8JQ7 DM1XT4N TN Electron transport complex III (Complex III) DM1XT4N MA Inhibitor DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTULV0X DM1XT4N TN Reactive oxygen species (ROS) DM1XT4N MA Modulator DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1Y2JH DI DM1Y2JH DM1Y2JH DN Inulin DM1Y2JH TI TTZOPHG DM1Y2JH TN Insulin (INS) DM1Y2JH MA Modulator DM1Y2JH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1Y2JH RU https://www.fda.gov/ DM1Y69Q DI DM1Y69Q DM1Y69Q DN Interleukin-3 DM1Y69Q TI TT5TQ2W DM1Y69Q TN Granulocyte colony-stimulating factor (CSF3) DM1Y69Q MA Modulator DM1Y69Q RN Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30. DM1Y69Q RU https://pubmed.ncbi.nlm.nih.gov/1618595 DM1YA7M DI DM1YA7M DM1YA7M DN Sulfonamides DM1YA7M TI TT4ILYC DM1YA7M TN Bacterial Dihydropteroate synthetase (Bact folP) DM1YA7M MA Binder DM1YA7M RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM1YA7M RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM1YB0R DI DM1YB0R DM1YB0R DN OZ277 DM1YB0R TI TTZVSJ2 DM1YB0R TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DM1YB0R MA Inhibitor DM1YB0R RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1YB0R RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1YBHK DI DM1YBHK DM1YBHK DN Rifabutin DM1YBHK TI TTHKJLN DM1YBHK TN DNA-directed RNA polymerase (RNAP) DM1YBHK MA Modulator DM1YBHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1YBHK RU https://www.fda.gov/ DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM TI TTYSN63 DM1YBRM TN 5-HT 2 receptor (5HT2R) DM1YBRM MA Antagonist DM1YBRM RN Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92. DM1YBRM RU https://pubmed.ncbi.nlm.nih.gov/19590258 DM1YEPS DI DM1YEPS DM1YEPS DN Volanesorsen DM1YEPS TI TTXOZQ1 DM1YEPS TN ApoC-III messenger RNA (APOC3 mRNA) DM1YEPS MA Inhibitor DM1YEPS RN Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173. DM1YEPS RU https://pubmed.ncbi.nlm.nih.gov/31350288 DM1YVZT DI DM1YVZT DM1YVZT DN Rituximab DM1YVZT TI TTUE541 DM1YVZT TN Leukocyte surface antigen Leu-16 (CD20) DM1YVZT RN Clinical pipeline report, company report or official report of Genentech (2009). DM1YVZT RU http://www.gene.com/gene/pipeline/status/ DM20K91 DI DM20K91 DM20K91 DN Travoprost DM20K91 TI TTT2ZAR DM20K91 TN Prostaglandin F2-alpha receptor (PTGFR) DM20K91 MA Agonist DM20K91 RN Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. DM20K91 RU https://pubmed.ncbi.nlm.nih.gov/19232013 DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TT0MV2T DM20LIM TN Melanocortin receptor 1 (MC1R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TTD0CIQ DM20LIM TN Melanocortin receptor 4 (MC4R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20R5F DI DM20R5F DM20R5F DN Spiramycin DM20R5F TI TTLFGBV DM20R5F TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM20R5F MA Binder DM20R5F RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM20R5F RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM20VMW DI DM20VMW DM20VMW DN Ethylestrenol DM20VMW TI TTS64P2 DM20VMW TN Androgen receptor (AR) DM20VMW MA Modulator DM20VMW RN Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6. DM20VMW RU https://www.ncbi.nlm.nih.gov/pubmed/6539197 DM20VSK DI DM20VSK DM20VSK DN Istradefylline DM20VSK TI TTM2AOE DM20VSK TN Adenosine A2a receptor (ADORA2A) DM20VSK MA Modulator DM20VSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20VSK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf DM214Q8 DI DM214Q8 DM214Q8 DN Talbutal DM214Q8 TI TTEX6LM DM214Q8 TN GABA(A) receptor gamma-3 (GABRG3) DM214Q8 MA Modulator DM214Q8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM214Q8 RU https://www.fda.gov/ DM215WE DI DM215WE DM215WE DN MK-1439 DM215WE TI TT84ETX DM215WE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM215WE MA Inhibitor DM215WE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM215WE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM21C09 DI DM21C09 DM21C09 DN Nitrendipine DM21C09 TI TTFK1JQ DM21C09 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM21C09 MA Blocker DM21C09 RN Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80. DM21C09 RU https://pubmed.ncbi.nlm.nih.gov/19408308 DM23D7J DI DM23D7J DM23D7J DN Tiaprofenic acid DM23D7J TI TTVKILB DM23D7J TN Prostaglandin G/H synthase 2 (COX-2) DM23D7J MA Inhibitor DM23D7J RN Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. DM23D7J RU https://pubmed.ncbi.nlm.nih.gov/2277128 DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX TI TTN4QDT DM23HCX TN Opioid receptor (OPR) DM23HCX MA Agonist DM23HCX RN Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9. DM23HCX RU https://pubmed.ncbi.nlm.nih.gov/19021937 DM25FL8 DI DM25FL8 DM25FL8 DN Methimazole DM25FL8 TI TT52XDZ DM25FL8 TN Thyroid peroxidase (TPO) DM25FL8 MA Inhibitor DM25FL8 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DM25FL8 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DM25HP1 DI DM25HP1 DM25HP1 DN Sermorelin DM25HP1 TI TTG4R8V DM25HP1 TN Growth hormone-releasing hormone receptor (GHRHR) DM25HP1 MA Binder DM25HP1 RN Sermorelin: a better approach to management of adult-onset growth hormone insufficiency Clin Interv Aging. 2006;1(4):307-8. DM25HP1 RU https://pubmed.ncbi.nlm.nih.gov/18046908 DM264B3 DI DM264B3 DM264B3 DN Dimenhydrinate DM264B3 TI TTTIBOJ DM264B3 TN Histamine H1 receptor (H1R) DM264B3 MA Antagonist DM264B3 RN Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6. DM264B3 RU https://pubmed.ncbi.nlm.nih.gov/18849063 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTTDVOJ DM26CQR TN Tropomyosin-related kinase A (TrkA) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTXABCW DM26CQR TN NT-3 growth factor receptor (TrkC) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTKN7QR DM26CQR TN BDNF/NT-3 growth factors receptor (TrkB) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26E4B DI DM26E4B DM26E4B DN Moexipril DM26E4B TI TTL69WB DM26E4B TN Angiotensin-converting enzyme (ACE) DM26E4B MA Inhibitor DM26E4B RN Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83. DM26E4B RU https://pubmed.ncbi.nlm.nih.gov/19255851 DM26KR1 DI DM26KR1 DM26KR1 DN Copper dotatate Cu-64 DM26KR1 TI TTZ6T9E DM26KR1 TN Somatostatin receptor type 2 (SSTR2) DM26KR1 MA Binder DM26KR1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM26KR1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf DM26PRD DI DM26PRD DM26PRD DN Reboxetine DM26PRD TI TTAWNKZ DM26PRD TN Norepinephrine transporter (NET) DM26PRD MA Inhibitor DM26PRD RN Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. DM26PRD RU https://pubmed.ncbi.nlm.nih.gov/11249515 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y TI TTUV8G9 DM27U4Y TN Progesterone receptor (PGR) DM27U4Y MA Modulator DM27U4Y RN Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40. DM27U4Y RU https://pubmed.ncbi.nlm.nih.gov/11108884 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T TI TTZAYWL DM27Z5T TN Estrogen receptor (ESR) DM27Z5T MA Modulator DM27Z5T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM27Z5T RU https://www.fda.gov/ DM28D05 DI DM28D05 DM28D05 DN Oritavancin DM28D05 TI TT4ILYC DM28D05 TN Bacterial Dihydropteroate synthetase (Bact folP) DM28D05 MA Inhibitor DM28D05 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM28D05 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM28MU7 DI DM28MU7 DM28MU7 DN Tolnaftate DM28MU7 TI TTE14XG DM28MU7 TN Squalene monooxygenase (SQLE) DM28MU7 MA Inhibitor DM28MU7 RN Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81. DM28MU7 RU https://pubmed.ncbi.nlm.nih.gov/1416865 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG TI TTLWPVF DM28UJG TN Sodium/glucose cotransporter 2 (SGLT2) DM28UJG MA Modulator DM28UJG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM28UJG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM295PR DI DM295PR DM295PR DN Ofatumumab DM295PR TI TTUE541 DM295PR TN Leukocyte surface antigen Leu-16 (CD20) DM295PR RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM295PR RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM29GAD DI DM29GAD DM29GAD DN Lumefantrine DM29GAD TI TTWK8D0 DM29GAD TN Sodium pump subunit alpha-1 (ATP1A1) DM29GAD MA Binder DM29GAD RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM29GAD RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM2AOTZ DI DM2AOTZ DM2AOTZ DN Perazine DM2AOTZ TI TTEX248 DM2AOTZ TN Dopamine D2 receptor (D2R) DM2AOTZ MA Modulator DM2AOTZ RN Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87. DM2AOTZ RU https://pubmed.ncbi.nlm.nih.gov/15582454 DM2AQ5N DI DM2AQ5N DM2AQ5N DN Spironolactone DM2AQ5N TI TT26PHO DM2AQ5N TN Mineralocorticoid receptor (MR) DM2AQ5N MA Modulator DM2AQ5N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2AQ5N RU https://www.fda.gov/ DM2AR7L DI DM2AR7L DM2AR7L DN Meloxicam DM2AR7L TI TTVKILB DM2AR7L TN Prostaglandin G/H synthase 2 (COX-2) DM2AR7L MA Inhibitor DM2AR7L RN Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7. DM2AR7L RU https://pubmed.ncbi.nlm.nih.gov/9219316 DM2BTFN DI DM2BTFN DM2BTFN DN Desirudin Recombinant DM2BTFN TI TT6L509 DM2BTFN TN Coagulation factor IIa (F2) DM2BTFN MA Modulator DM2BTFN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2BTFN RU https://www.fda.gov/ DM2C48U DI DM2C48U DM2C48U DN Anisindione DM2C48U TI TT6L509 DM2C48U TN Coagulation factor IIa (F2) DM2C48U MA Modulator DM2C48U RN Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. DM2C48U RU https://pubmed.ncbi.nlm.nih.gov/12680483 DM2C4RF DI DM2C4RF DM2C4RF DN Betrixaban DM2C4RF TI TTCIHJA DM2C4RF TN Coagulation factor Xa (F10) DM2C4RF MA Modulator DM2C4RF RN Company report (Portola) DM2C4RF RU https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ DM2DMPO DI DM2DMPO DM2DMPO DN Kanamycin DM2DMPO TI TTQ8KVI DM2DMPO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM2DMPO MA Binder DM2DMPO RN SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38. DM2DMPO RU https://pubmed.ncbi.nlm.nih.gov/12081641 DM2EN6G DI DM2EN6G DM2EN6G DN Propantheline DM2EN6G TI TTZ9SOR DM2EN6G TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2EN6G MA Antagonist DM2EN6G RN Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805. DM2EN6G RU https://pubmed.ncbi.nlm.nih.gov/15337834 DM2ET1M DI DM2ET1M DM2ET1M DN Succinylcholine DM2ET1M TI TTQ13Z5 DM2ET1M TN Muscarinic acetylcholine receptor M3 (CHRM3) DM2ET1M MA Antagonist DM2ET1M RN The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. DM2ET1M RU https://pubmed.ncbi.nlm.nih.gov/19020136 DM2EXC5 DI DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 TI TTT2ZAR DM2EXC5 TN Prostaglandin F2-alpha receptor (PTGFR) DM2EXC5 MA Agonist DM2EXC5 RN Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5. DM2EXC5 RU https://pubmed.ncbi.nlm.nih.gov/21396362 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TT8NGED DM2F8XZ TN Prostaglandin G/H synthase 1 (COX-1) DM2F8XZ MA Inhibitor DM2F8XZ RN The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18612540 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTCFSPE DM2F8XZ TN Carbonic anhydrase VI (CA-VI) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTSYM0R DM2F8XZ TN Carbonic anhydrase XII (CA-XII) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTANPDJ DM2F8XZ TN Carbonic anhydrase II (CA-II) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTUNARX DM2F8XZ TN Carbonic anhydrase (CA) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18501600 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTZHA0O DM2F8XZ TN Carbonic anhydrase IV (CA-IV) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTHQPL7 DM2F8XZ TN Carbonic anhydrase I (CA-I) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2FGRT DI DM2FGRT DM2FGRT DN Clavulanate DM2FGRT TI TTHI19T DM2FGRT TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM2FGRT MA Inhibitor DM2FGRT RN A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9. DM2FGRT RU https://pubmed.ncbi.nlm.nih.gov/19505232 DM2FHG3 DI DM2FHG3 DM2FHG3 DN Pramiracetam DM2FHG3 TI TTH18TF DM2FHG3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2FHG3 MA Modulator DM2FHG3 RN Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Article first published online: 5 OCT 2004. DM2FHG3 RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430030503/abstract DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE TI TT3ROYC DM2G9AE TN Serotonin transporter (SERT) DM2G9AE MA Modulator DM2G9AE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2G9AE RU https://www.fda.gov/ DM2HG4X DI DM2HG4X DM2HG4X DN Prednisone DM2HG4X TI TTYRL6O DM2HG4X TN Glucocorticoid receptor (NR3C1) DM2HG4X MA Agonist DM2HG4X RN Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22. DM2HG4X RU https://pubmed.ncbi.nlm.nih.gov/8619627 DM2HKC4 DI DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 TI TTYRL6O DM2HKC4 TN Glucocorticoid receptor (NR3C1) DM2HKC4 MA Binder DM2HKC4 RN Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. DM2HKC4 RU https://pubmed.ncbi.nlm.nih.gov/12861354 DM2HRKE DI DM2HRKE DM2HRKE DN Pentosan polysulfate DM2HRKE TI TTCEKVZ DM2HRKE TN Fibroblast growth factor-4 (FGF4) DM2HRKE MA Modulator DM2HRKE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2HRKE RU https://www.fda.gov/ DM2HU9I DI DM2HU9I DM2HU9I DN Triamterene DM2HU9I TI TTQM7TE DM2HU9I TN Amiloride-sensitive sodium channel (ENaC) DM2HU9I MA Blocker DM2HU9I RN Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. DM2HU9I RU https://pubmed.ncbi.nlm.nih.gov/11509829 DM2JGQ3 DI DM2JGQ3 DM2JGQ3 DN Trametinib DM2JGQ3 TI TTROQ37 DM2JGQ3 TN MAPK/ERK kinase kinase (MAP3K) DM2JGQ3 MA Modulator DM2JGQ3 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2JGQ3 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2JTS5 DI DM2JTS5 DM2JTS5 DN Follitropin beta DM2JTS5 TI TTZFDBT DM2JTS5 TN Follicle-stimulating hormone receptor (FSHR) DM2JTS5 MA Binder DM2JTS5 RN Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5. DM2JTS5 RU https://pubmed.ncbi.nlm.nih.gov/18851846 DM2L3D5 DI DM2L3D5 DM2L3D5 DN Tertatolol DM2L3D5 TI TTSQIFT DM2L3D5 TN 5-HT 1A receptor (HTR1A) DM2L3D5 MA Inhibitor DM2L3D5 RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DM2L3D5 RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DM2M3ZA DI DM2M3ZA DM2M3ZA DN Glycopyrrolate DM2M3ZA TI TTZ9SOR DM2M3ZA TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2M3ZA MA Antagonist DM2M3ZA RN Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701. DM2M3ZA RU https://pubmed.ncbi.nlm.nih.gov/17687267 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K TI TTJL8VG DM2NA4K TN Corticosteroid-binding globulin (SERPINA6) DM2NA4K MA Binder DM2NA4K RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM2NA4K RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTJP4SM DM2NLS9 TN Bacterial Penicillin binding protein (Bact PBP) DM2NLS9 MA Inhibitor DM2NLS9 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTU6BFZ DM2NLS9 TN Candida Thymidylate synthase (Candi TMP1) DM2NLS9 MA Inhibitor DM2NLS9 RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/12494465 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTN6J5F DM2NLS9 TN Bacterial DNA gyrase (Bact gyrase) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTIXTO3 DM2NLS9 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NUH3 DI DM2NUH3 DM2NUH3 DN Imipramine DM2NUH3 TI TTAWNKZ DM2NUH3 TN Norepinephrine transporter (NET) DM2NUH3 MA Inhibitor DM2NUH3 RN Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. DM2NUH3 RU https://pubmed.ncbi.nlm.nih.gov/19059298 DM2OVDT DI DM2OVDT DM2OVDT DN Tecfidera DM2OVDT TI TTK3Q4W DM2OVDT TN NFE2-related factor 2 pathway (Nrf2 pathway) DM2OVDT MA Inhibitor DM2OVDT RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2OVDT RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2OZ3G DI DM2OZ3G DM2OZ3G DN Ixabepilone DM2OZ3G TI TTML2WA DM2OZ3G TN Tubulin (TUB) DM2OZ3G MA Stablizer DM2OZ3G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2OZ3G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2P6VD DI DM2P6VD DM2P6VD DN Thrombin/fibrinogen matrix patch DM2P6VD TI TTWODQF DM2P6VD TN Fibrin (FG) DM2P6VD MA Modulator DM2P6VD RN Fibrin sealant patch for repair of acute type a aortic dissection. J Card Surg. 2013 Nov;28(6):736-41. DM2P6VD RU https://pubmed.ncbi.nlm.nih.gov/23957708 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE TI TTML2WA DM2POTE TN Tubulin (TUB) DM2POTE MA Binder DM2POTE RN Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74. DM2POTE RU https://pubmed.ncbi.nlm.nih.gov/19527023 DM2PSBE DI DM2PSBE DM2PSBE DN Focetria A(H1N1) DM2PSBE TI TT3J5ZI DM2PSBE TN Cell mediated immunity response (CMIR) DM2PSBE RN Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393. DM2PSBE RU https://pubmed.ncbi.nlm.nih.gov/23381200 DM2PYNR DI DM2PYNR DM2PYNR DN Phenindione DM2PYNR TI TTEUC8H DM2PYNR TN Vitamin K epoxide reductase complex 1 (VKORC1) DM2PYNR MA Inhibitor DM2PYNR RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DM2PYNR RU https://pubmed.ncbi.nlm.nih.gov/17955831 DM2QBHP DI DM2QBHP DM2QBHP DN Eteplirsen DM2QBHP TI TTWLFXU DM2QBHP TN Dystrophin messenger RNA (DMD mRNA) DM2QBHP MA Modulator DM2QBHP RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM2QBHP RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM2QDX1 DI DM2QDX1 DM2QDX1 DN Oxamniquine DM2QDX1 TI TTB1TZG DM2QDX1 TN Schistosoma Deoxyribonucleic acid (Schist DNA) DM2QDX1 MA Modulator DM2QDX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2QDX1 RU https://www.fda.gov/ DM2QHZU DI DM2QHZU DM2QHZU DN Sulindac DM2QHZU TI TTFBNVI DM2QHZU TN Aldose reductase (AKR1B1) DM2QHZU MA Inhibitor DM2QHZU RN Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8. DM2QHZU RU https://pubmed.ncbi.nlm.nih.gov/6409111 DM2R68E DI DM2R68E DM2R68E DN Ramipril DM2R68E TI TTL69WB DM2R68E TN Angiotensin-converting enzyme (ACE) DM2R68E MA Inhibitor DM2R68E RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM2R68E RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT7BQRM DM2R86O TN Sphingosine-1 phosphate receptor (S1PR) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT9JZCK DM2R86O TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2RBWK DI DM2RBWK DM2RBWK DN Belladonna DM2RBWK TI TTH18TF DM2RBWK TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2RBWK MA Modulator DM2RBWK RN Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4. DM2RBWK RU https://pubmed.ncbi.nlm.nih.gov/19586361 DM2RX0I DI DM2RX0I DM2RX0I DN Abametapir DM2RX0I TI TT1GHVO DM2RX0I TN Matrix metalloproteinase (MMP) DM2RX0I MA Inhibitor DM2RX0I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM2RX0I RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf DM2SR1J DI DM2SR1J DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine DM2SR1J TI TTY4IQ9 DM2SR1J TN Corynebacterium Mutated CRM197 (Cory mTOX) DM2SR1J MA Binder DM2SR1J RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2SR1J RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TTY8Z2E DM2TEOL TN Proton-coupled folate transporter (SLC46A1) DM2TEOL MA Modulator DM2TEOL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DM2TEOL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TT09I7D DM2TEOL TN Solute carrier family 19 member 1 (SLC19A1) DM2TEOL MA Modulator DM2TEOL RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DM2TEOL RU https://pubmed.ncbi.nlm.nih.gov/9525913 DM2TO9R DI DM2TO9R DM2TO9R DN Desflurane DM2TO9R TI TTAN6JD DM2TO9R TN Glutamate receptor AMPA (GRIA) DM2TO9R MA Antagonist DM2TO9R RN Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91. DM2TO9R RU https://pubmed.ncbi.nlm.nih.gov/11323344 DM2U4XQ DI DM2U4XQ DM2U4XQ DN ALCURONIUM DM2U4XQ TI TTLA931 DM2U4XQ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2U4XQ MA Inhibitor DM2U4XQ RN Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29. DM2U4XQ RU https://pubmed.ncbi.nlm.nih.gov/17722904 DM2WE5K DI DM2WE5K DM2WE5K DN Ceruletide DM2WE5K TI TTVFO0U DM2WE5K TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2WE5K MA Agonist DM2WE5K RN Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. DM2WE5K RU https://pubmed.ncbi.nlm.nih.gov/18537882 DM2XVNI DI DM2XVNI DM2XVNI DN Levormeloxifene DM2XVNI TI TTZAYWL DM2XVNI TN Estrogen receptor (ESR) DM2XVNI MA Modulator DM2XVNI RN Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001 Jul;21(4):302-47. DM2XVNI RU https://pubmed.ncbi.nlm.nih.gov/11410933 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW TI TTUTN1I DM2YGNW TN Human Deoxyribonucleic acid (hDNA) DM2YGNW MA Breaker DM2YGNW RN Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. DM2YGNW RU https://pubmed.ncbi.nlm.nih.gov/10576292 DM2ZGAN DI DM2ZGAN DM2ZGAN DN Mesoridazine DM2ZGAN TI TTEX248 DM2ZGAN TN Dopamine D2 receptor (D2R) DM2ZGAN MA Agonist DM2ZGAN RN Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. DM2ZGAN RU https://pubmed.ncbi.nlm.nih.gov/16135699 DM30SGU DI DM30SGU DM30SGU DN Simvastatin DM30SGU TI TTPADOQ DM30SGU TN HMG-CoA reductase (HMGCR) DM30SGU MA Inhibitor DM30SGU RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM30SGU RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM30SXV DI DM30SXV DM30SXV DN Idursulfase DM30SXV TI TTNY2AP DM30SXV TN Iduronate 2-sulfatase (IDS) DM30SXV MA Modulator DM30SXV RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM30SXV RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM32B5U DI DM32B5U DM32B5U DN Upadacitinib DM32B5U TI TT6DM01 DM32B5U TN Janus kinase 1 (JAK-1) DM32B5U MA Modulator DM32B5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM32B5U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf DM32GSJ DI DM32GSJ DM32GSJ DN Incruse ellipta DM32GSJ TI TTOXS3C DM32GSJ TN Muscarinic acetylcholine receptor (CHRM) DM32GSJ MA Antagonist DM32GSJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM32GSJ RU http://www.gsk.ca/english/html/media-centre/2014-04-17.html DM32YAI DI DM32YAI DM32YAI DN Dimethindene DM32YAI TI TTTIBOJ DM32YAI TN Histamine H1 receptor (H1R) DM32YAI MA Antagonist DM32YAI RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DM32YAI RU https://pubmed.ncbi.nlm.nih.gov/19308787 DM346QI DI DM346QI DM346QI DN Capreomycin Sulfate DM346QI TI TTIA0J5 DM346QI TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DM346QI MA Modulator DM346QI RN The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93. DM346QI RU https://www.ncbi.nlm.nih.gov/pubmed/20154709 DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTDIGC1 DM34TXO TN Dipeptidyl peptidase 4 (DPP-4) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTLWPVF DM34TXO TN Sodium/glucose cotransporter 2 (SGLT2) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM35M8J DI DM35M8J DM35M8J DN Thioridazine DM35M8J TI TTEX248 DM35M8J TN Dopamine D2 receptor (D2R) DM35M8J MA Antagonist DM35M8J RN Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. DM35M8J RU https://pubmed.ncbi.nlm.nih.gov/15695070 DM36LAJ DI DM36LAJ DM36LAJ DN Emedastine DM36LAJ TI TTTIBOJ DM36LAJ TN Histamine H1 receptor (H1R) DM36LAJ MA Antagonist DM36LAJ RN Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. DM36LAJ RU https://pubmed.ncbi.nlm.nih.gov/19558341 DM38VYQ DI DM38VYQ DM38VYQ DN Pentolinium DM38VYQ TI TT4H1MQ DM38VYQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM38VYQ MA Antagonist DM38VYQ RN Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. DM38VYQ RU https://pubmed.ncbi.nlm.nih.gov/8516349 DM3906J DI DM3906J DM3906J DN Bedaquiline DM3906J TI TT19K0L DM3906J TN Mycobacterium Proton pump (MycB Prop) DM3906J MA Modulator DM3906J RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM3906J RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTJ0IQB DM3ADGP TN Phosphodiesterase 5A (PDE5A) DM3ADGP MA Inhibitor DM3ADGP RN cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/19546307 DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTVQ6R9 DM3ADGP TN C1 esterase inhibitor (SERPING1) DM3ADGP MA Modulator DM3ADGP RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TTGKNB4 DM3BH1Y TN Epidermal growth factor receptor (EGFR) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT6EO5L DM3BH1Y TN Erbb2 tyrosine kinase receptor (HER2) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT1QFLA DM3BH1Y TN Eukaryotic elongation factor 2 kinase (eEF-2K) DM3BH1Y MA Inhibitor DM3BH1Y RN Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/27756261 DM3BS97 DI DM3BS97 DM3BS97 DN Macrolides DM3BS97 TI TTLFGBV DM3BS97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM3BS97 MA Binder DM3BS97 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM3BS97 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM3BVAE DI DM3BVAE DM3BVAE DN Obinutuzumab DM3BVAE TI TTUE541 DM3BVAE TN Leukocyte surface antigen Leu-16 (CD20) DM3BVAE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM3BVAE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTSZLWK DM3C5GZ TN Aromatase (CYP19A1) DM3C5GZ MA Inhibitor DM3C5GZ RN Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/16279787 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTIQUX7 DM3C5GZ TN Steroid 11-beta-hydroxylase (CYP11B1) DM3C5GZ MA Inhibitor DM3C5GZ RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM3DSVJ DI DM3DSVJ DM3DSVJ DN Incadronate DM3DSVJ TI TTIKWV4 DM3DSVJ TN Geranyltranstransferase (FDPS) DM3DSVJ MA Inhibitor DM3DSVJ RN Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. DM3DSVJ RU https://pubmed.ncbi.nlm.nih.gov/11160603 DM3ED1A DI DM3ED1A DM3ED1A DN Tavaborole DM3ED1A TI TT37GL6 DM3ED1A TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DM3ED1A MA Inhibitor DM3ED1A RN An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007 Jun 22;316(5832):1759-61. DM3ED1A RU https://pubmed.ncbi.nlm.nih.gov/17588934 DM3FXMA DI DM3FXMA DM3FXMA DN Naloxone DM3FXMA TI TTKWM86 DM3FXMA TN Opioid receptor mu (MOP) DM3FXMA MA Antagonist DM3FXMA RN OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. DM3FXMA RU https://pubmed.ncbi.nlm.nih.gov/19332974 DM3FXPS DI DM3FXPS DM3FXPS DN Liraglutide DM3FXPS TI TTVIMDE DM3FXPS TN Glucagon-like peptide 1 receptor (GLP1R) DM3FXPS MA Agonist DM3FXPS RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM3FXPS RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM3GB6S DI DM3GB6S DM3GB6S DN Halobetasol propionate DM3GB6S TI TTP3UTW DM3GB6S TN Steroid hormone receptor ERR (ESRR) DM3GB6S MA Modulator DM3GB6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3GB6S RU https://www.fda.gov/ DM3JCVS DI DM3JCVS DM3JCVS DN Terazosin DM3JCVS TI TT34BHT DM3JCVS TN Adrenergic receptor alpha-1D (ADRA1D) DM3JCVS MA Antagonist DM3JCVS RN Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95. DM3JCVS RU https://pubmed.ncbi.nlm.nih.gov/12496995 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP TI TTLP57V DM3JDRP TN Adenosine deaminase (ADA) DM3JDRP MA Inhibitor DM3JDRP RN Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. DM3JDRP RU https://pubmed.ncbi.nlm.nih.gov/15485311 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC TI TTR6W5O DM3KJBC TN Adrenergic receptor beta-1 (ADRB1) DM3KJBC MA Agonist DM3KJBC RN Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. DM3KJBC RU https://pubmed.ncbi.nlm.nih.gov/19460844 DM3KN7V DI DM3KN7V DM3KN7V DN Bifonazole DM3KN7V TI TTTSOUD DM3KN7V TN Candida Cytochrome P450 51 (Candi ERG11) DM3KN7V MA Inhibitor DM3KN7V RN Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. DM3KN7V RU https://pubmed.ncbi.nlm.nih.gov/17027909 DM3NC4M DI DM3NC4M DM3NC4M DN Quercetin DM3NC4M TI TTPOI4B DM3NC4M TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DM3NC4M MA Inhibitor DM3NC4M RN Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7. DM3NC4M RU https://pubmed.ncbi.nlm.nih.gov/12576520 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G TI TT84ETX DM3NF5G TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3NF5G MA Modulator DM3NF5G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3NF5G RU https://www.fda.gov/ DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH TI TTEX248 DM3NUMH TN Dopamine D2 receptor (D2R) DM3NUMH MA Agonist DM3NUMH RN Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. DM3NUMH RU https://pubmed.ncbi.nlm.nih.gov/17501690 DM3NXRU DI DM3NXRU DM3NXRU DN Timolol DM3NXRU TI TTR6W5O DM3NXRU TN Adrenergic receptor beta-1 (ADRB1) DM3NXRU MA Antagonist DM3NXRU RN Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. DM3NXRU RU https://pubmed.ncbi.nlm.nih.gov/17154662 DM3O6CY DI DM3O6CY DM3O6CY DN Micardis telmisartan DM3O6CY TI TT8DBY3 DM3O6CY TN Angiotensin II receptor type-1 (AGTR1) DM3O6CY MA Antagonist DM3O6CY RN The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61. DM3O6CY RU https://pubmed.ncbi.nlm.nih.gov/16208149 DM3O8QY DI DM3O8QY DM3O8QY DN Degarelix DM3O8QY TI TT8R70G DM3O8QY TN Gonadotropin-releasing hormone receptor (GNRHR) DM3O8QY MA Inhibitor DM3O8QY RN Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60. DM3O8QY RU https://pubmed.ncbi.nlm.nih.gov/16033265 DM3OBQF DI DM3OBQF DM3OBQF DN Belimumab DM3OBQF TI TTWMIDN DM3OBQF TN B-cell-activating factor (TNFSF13B) DM3OBQF RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM3OBQF RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM3P5DA DI DM3P5DA DM3P5DA DN Rofecoxib DM3P5DA TI TTVKILB DM3P5DA TN Prostaglandin G/H synthase 2 (COX-2) DM3P5DA MA Inhibitor DM3P5DA RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM3P5DA RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM3P6V7 DI DM3P6V7 DM3P6V7 DN Furazolidone DM3P6V7 TI TTS1W4A DM3P6V7 TN Bacterial Deoxyribonucleic acid (Bact DNA) DM3P6V7 MA Modulator DM3P6V7 RN Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5. DM3P6V7 RU https://www.ncbi.nlm.nih.gov/pubmed/1174533 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C TI TT3ROYC DM3PD2C TN Serotonin transporter (SERT) DM3PD2C MA Modulator DM3PD2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3PD2C RU https://www.fda.gov/ DM3PZXN DI DM3PZXN DM3PZXN DN Taliglucerase alfa DM3PZXN TI TT1B5PU DM3PZXN TN Glucosylceramidase (GBA) DM3PZXN MA Modulator DM3PZXN RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM3PZXN RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM3Q1SM DI DM3Q1SM DM3Q1SM DN Obeticholic acid DM3Q1SM TI TTS4UGC DM3Q1SM TN Farnesoid X-activated receptor (FXR) DM3Q1SM MA Modulator DM3Q1SM RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM3Q1SM RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM3SRJZ DI DM3SRJZ DM3SRJZ DN Belotecan hydrocholoride DM3SRJZ TI TTGTQHC DM3SRJZ TN DNA topoisomerase I (TOP1) DM3SRJZ MA Modulator DM3SRJZ RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DM3SRJZ RU https://pubmed.ncbi.nlm.nih.gov/19422222 DM3TABW DI DM3TABW DM3TABW DN Oxyphencyclimine DM3TABW TI TTH18TF DM3TABW TN Muscarinic acetylcholine receptor M5 (CHRM5) DM3TABW MA Binder DM3TABW RN Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. DM3TABW RU https://pubmed.ncbi.nlm.nih.gov/1426023 DM3TPY8 DI DM3TPY8 DM3TPY8 DN Interferon Alfa-2b, Recombinant DM3TPY8 TI TTMQB37 DM3TPY8 TN Interferon alpha/beta receptor 2 (IFNAR2) DM3TPY8 MA Binder DM3TPY8 RN Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3. DM3TPY8 RU https://pubmed.ncbi.nlm.nih.gov/19362369 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTI7421 DM3U7SZ TN Platelet-derived growth factor receptor beta (PDGFRB) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTRLW2X DM3U7SZ TN Fibroblast growth factor receptor 1 (FGFR1) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT8FYO9 DM3U7SZ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTX41N9 DM3U7SZ TN Tyrosine-protein kinase Kit (KIT) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTUTJGQ DM3U7SZ TN Vascular endothelial growth factor receptor 2 (KDR) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT1VAUK DM3U7SZ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT4DXQT DM3U7SZ TN Proto-oncogene c-Ret (RET) DM3U7SZ MA Inhibitor DM3U7SZ RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/20117004 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTIHYA4 DM3U7SZ TN Thrombopoietin receptor (MPL) DM3U7SZ MA Modulator DM3U7SZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT037IE DM3U7SZ TN Aryl hydrocarbon receptor (AHR) DM3U7SZ MA Modulator DM3U7SZ RN A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/16222321 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 TI TTR6W5O DM3UZ95 TN Adrenergic receptor beta-1 (ADRB1) DM3UZ95 MA Antagonist DM3UZ95 RN Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. DM3UZ95 RU https://pubmed.ncbi.nlm.nih.gov/18612186 DM3VFPD DI DM3VFPD DM3VFPD DN Troglitazone DM3VFPD TI TTZMAO3 DM3VFPD TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM3VFPD MA Agonist DM3VFPD RN Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. DM3VFPD RU https://pubmed.ncbi.nlm.nih.gov/12594814 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS TI TTJP4SM DM3VOGS TN Bacterial Penicillin binding protein (Bact PBP) DM3VOGS MA Binder DM3VOGS RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM3VOGS RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM3VR1L DI DM3VR1L DM3VR1L DN Selegiline hydrochloride DM3VR1L TI TTGP7BY DM3VR1L TN Monoamine oxidase type B (MAO-B) DM3VR1L MA Modulator DM3VR1L RN Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. DM3VR1L RU https://pubmed.ncbi.nlm.nih.gov/16939381 DM3VS7Z DI DM3VS7Z DM3VS7Z DN Imidazole salicylate DM3VS7Z TI TTTEJMY DM3VS7Z TN Tromboxane A2 synthesis (TA2 synth) DM3VS7Z MA Modulator DM3VS7Z RN Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4. DM3VS7Z RU https://pubmed.ncbi.nlm.nih.gov/8566739 DM3W15N DI DM3W15N DM3W15N DN Calcium carbimide DM3W15N TI TTCTAOJ DM3W15N TN Acetaldehyde dehydrogenase (ALDH) DM3W15N MA Inhibitor DM3W15N RN Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8. DM3W15N RU https://pubmed.ncbi.nlm.nih.gov/2185581 DM3WKQ4 DI DM3WKQ4 DM3WKQ4 DN Rasagiline DM3WKQ4 TI TTGP7BY DM3WKQ4 TN Monoamine oxidase type B (MAO-B) DM3WKQ4 MA Inhibitor DM3WKQ4 RN Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59. DM3WKQ4 RU https://pubmed.ncbi.nlm.nih.gov/19526291 DM3XNUI DI DM3XNUI DM3XNUI DN Tazobactam DM3XNUI TI TTHI19T DM3XNUI TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM3XNUI MA Inhibitor DM3XNUI RN Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9. DM3XNUI RU https://pubmed.ncbi.nlm.nih.gov/19576305 DM3XU74 DI DM3XU74 DM3XU74 DN Dornase Alfa DM3XU74 TI TTUTN1I DM3XU74 TN Human Deoxyribonucleic acid (hDNA) DM3XU74 MA Breaker DM3XU74 RN Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45. DM3XU74 RU https://pubmed.ncbi.nlm.nih.gov/18031106 DM3XYD1 DI DM3XYD1 DM3XYD1 DN Tegaserod DM3XYD1 TI TT07C3Y DM3XYD1 TN 5-HT 4 receptor (HTR4) DM3XYD1 MA Agonist DM3XYD1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM3XYD1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4087K DI DM4087K DM4087K DN Saprisartan DM4087K TI TT8DBY3 DM4087K TN Angiotensin II receptor type-1 (AGTR1) DM4087K MA Antagonist DM4087K RN Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. DM4087K RU https://pubmed.ncbi.nlm.nih.gov/10579749 DM40EF6 DI DM40EF6 DM40EF6 DN Penicillamine DM40EF6 TI TTT3ZC9 DM40EF6 TN Human immunodeficiency virus Tat protein (HIV tat) DM40EF6 MA Inhibitor DM40EF6 RN Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6. DM40EF6 RU https://pubmed.ncbi.nlm.nih.gov/11959100 DM41GRA DI DM41GRA DM41GRA DN Ceftazidime DM41GRA TI TTJP4SM DM41GRA TN Bacterial Penicillin binding protein (Bact PBP) DM41GRA MA Binder DM41GRA RN New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. DM41GRA RU https://pubmed.ncbi.nlm.nih.gov/18318877 DM42HXN DI DM42HXN DM42HXN DN Atracurium DM42HXN TI TTJSZTB DM42HXN TN Nicotinic acetylcholine receptor (nAChR) DM42HXN MA Antagonist DM42HXN RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM42HXN RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B TI TT85JMW DM42W1B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM42W1B MA Binder DM42W1B RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM42W1B RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM43AN2 DI DM43AN2 DM43AN2 DN Fructose DM43AN2 TI TTMS54D DM43AN2 TN Fragile histidine triad protein (FHIT) DM43AN2 MA Inhibitor DM43AN2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM43AN2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM458UM DI DM458UM DM458UM DN Captopril DM458UM TI TTL69WB DM458UM TN Angiotensin-converting enzyme (ACE) DM458UM MA Inhibitor DM458UM RN Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8. DM458UM RU https://pubmed.ncbi.nlm.nih.gov/12182524 DM45OJN DI DM45OJN DM45OJN DN Mometasone DM45OJN TI TTYRL6O DM45OJN TN Glucocorticoid receptor (NR3C1) DM45OJN MA Agonist DM45OJN RN Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. DM45OJN RU https://pubmed.ncbi.nlm.nih.gov/12503693 DM471KJ DI DM471KJ DM471KJ DN Omeprazole DM471KJ TI TTLOKXP DM471KJ TN Gastric H(+)/K(+) ATPase (Proton pump) DM471KJ MA Modulator DM471KJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM471KJ RU https://www.fda.gov/ DM473VD DI DM473VD DM473VD DN Mivacurium DM473VD TI TTF4E0J DM473VD TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM473VD MA Antagonist DM473VD RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM473VD RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM48K0X DI DM48K0X DM48K0X DN Carfilzomib DM48K0X TI TTU7ZMG DM48K0X TN Proteasome (PS) DM48K0X MA Modulator DM48K0X RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM48K0X RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT TI TTWK8D0 DM48QOT TN Sodium pump subunit alpha-1 (ATP1A1) DM48QOT MA Binder DM48QOT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM48QOT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TTOD7B3 DM49DUI TN Retinoic acid receptor (RAR) DM49DUI MA Binder DM49DUI RN Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/11586072 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TT1Q3IE DM49DUI TN Retinoic acid receptor gamma (RARG) DM49DUI MA Agonist DM49DUI RN Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/15615532 DM49IGF DI DM49IGF DM49IGF DN Pefloxacin DM49IGF TI TT0IHXV DM49IGF TN DNA topoisomerase II (TOP2) DM49IGF MA Inhibitor DM49IGF RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DM49IGF RU https://pubmed.ncbi.nlm.nih.gov/3282749 DM49VEW DI DM49VEW DM49VEW DN Penicillin G Benzathine DM49VEW TI TTJP4SM DM49VEW TN Bacterial Penicillin binding protein (Bact PBP) DM49VEW MA Modulator DM49VEW RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DM49VEW RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DM4AK0Q DI DM4AK0Q DM4AK0Q DN Interferon alfa-n1 DM4AK0Q TI TTMQB37 DM4AK0Q TN Interferon alpha/beta receptor 2 (IFNAR2) DM4AK0Q MA Binder DM4AK0Q RN Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7. DM4AK0Q RU https://pubmed.ncbi.nlm.nih.gov/9537453 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTOJI4S DM4AMQZ TN Calcium-dependent chloride channel anoctamin (ANO) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTRLZHP DM4AMQZ TN cAMP-dependent chloride channel (CFTR) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4BDON DI DM4BDON DM4BDON DN Methylprednisolone DM4BDON TI TTYRL6O DM4BDON TN Glucocorticoid receptor (NR3C1) DM4BDON MA Modulator DM4BDON RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4BDON RU https://www.fda.gov/ DM4BOAS DI DM4BOAS DM4BOAS DN Velaglucerase alfa DM4BOAS TI TT1B5PU DM4BOAS TN Glucosylceramidase (GBA) DM4BOAS MA Modulator DM4BOAS RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM4BOAS RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM4CF18 DI DM4CF18 DM4CF18 DN Menotropins DM4CF18 TI TTZFDBT DM4CF18 TN Follicle-stimulating hormone receptor (FSHR) DM4CF18 MA Binder DM4CF18 RN The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. DM4CF18 RU https://pubmed.ncbi.nlm.nih.gov/7872378 DM4DMBT DI DM4DMBT DM4DMBT DN Chlorthalidone DM4DMBT TI TTS087L DM4DMBT TN Solute carrier family 12 member 1 (SLC12A1) DM4DMBT MA Blocker DM4DMBT RN The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. DM4DMBT RU https://pubmed.ncbi.nlm.nih.gov/15134800 DM4E8O9 DI DM4E8O9 DM4E8O9 DN Umeclidinium DM4E8O9 TI TTH18TF DM4E8O9 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM4E8O9 MA Modulator DM4E8O9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354). DM4E8O9 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354 DM4EGV0 DI DM4EGV0 DM4EGV0 DN Linaclotide DM4EGV0 TI TTLDPRG DM4EGV0 TN Guanylyl cyclase C (GUCY2C) DM4EGV0 MA Activator DM4EGV0 RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DM4EGV0 RU https://pubmed.ncbi.nlm.nih.gov/17979603 DM4ES8F DI DM4ES8F DM4ES8F DN Penbutolol DM4ES8F TI TTR6W5O DM4ES8F TN Adrenergic receptor beta-1 (ADRB1) DM4ES8F MA Antagonist DM4ES8F RN beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8. DM4ES8F RU https://pubmed.ncbi.nlm.nih.gov/12058352 DM4EWNS DI DM4EWNS DM4EWNS DN Cinoxacin DM4EWNS TI TT0IHXV DM4EWNS TN DNA topoisomerase II (TOP2) DM4EWNS MA Inhibitor DM4EWNS RN The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. DM4EWNS RU https://pubmed.ncbi.nlm.nih.gov/10411577 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTNDSF4 DM4F29C TN Proto-oncogene c-Met (MET) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTSZ6Y3 DM4F29C TN Proto-oncogene c-Ros (ROS1) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTPMQSO DM4F29C TN ALK tyrosine kinase receptor (ALK) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTKA5LP DM4F29C TN HGF/Met signaling pathway (HGF/Met pathway) DM4F29C MA Inhibitor DM4F29C RN Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907. DM4F29C RU https://pubmed.ncbi.nlm.nih.gov/26345996 DM4I8O7 DI DM4I8O7 DM4I8O7 DN Bunazosin DM4I8O7 TI TT34BHT DM4I8O7 TN Adrenergic receptor alpha-1D (ADRA1D) DM4I8O7 MA Modulator DM4I8O7 RN Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. DM4I8O7 RU https://pubmed.ncbi.nlm.nih.gov/15867947 DM4IAKR DI DM4IAKR DM4IAKR DN MD-1100 DM4IAKR TI TTLDPRG DM4IAKR TN Guanylyl cyclase C (GUCY2C) DM4IAKR MA Activator DM4IAKR RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM4IAKR RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4IF32 DI DM4IF32 DM4IF32 DN Pyrazinamide DM4IF32 TI TTVTX4N DM4IF32 TN Bacterial Fatty acid synthetase I (Bact inhA) DM4IF32 MA Inhibitor DM4IF32 RN Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7. DM4IF32 RU https://pubmed.ncbi.nlm.nih.gov/10973326 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ TI TTUWYEA DM4K7GQ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4K7GQ MA Binder DM4K7GQ RN A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/1945852 DM4KDYJ DI DM4KDYJ DM4KDYJ DN Nortriptyline DM4KDYJ TI TT3ROYC DM4KDYJ TN Serotonin transporter (SERT) DM4KDYJ MA Modulator DM4KDYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4KDYJ RU https://www.fda.gov/ DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TT84ETX DM4KI7O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4KI7O MA Inhibitor DM4KI7O RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM4KI7O RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TTGJCWZ DM4KI7O TN Fms-like tyrosine kinase 3 (FLT-3) DM4KI7O MA Binder DM4KI7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM4KI7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM4L59B DI DM4L59B DM4L59B DN Teprotumumab DM4L59B TI TTHRID2 DM4L59B TN Insulin-like growth factor I receptor (IGF1R) DM4L59B MA Antagonist DM4L59B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM4L59B RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf DM4L6EU DI DM4L6EU DM4L6EU DN Trandolapril DM4L6EU TI TTL69WB DM4L6EU TN Angiotensin-converting enzyme (ACE) DM4L6EU MA Inhibitor DM4L6EU RN Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7. DM4L6EU RU https://pubmed.ncbi.nlm.nih.gov/19424161 DM4L8H3 DI DM4L8H3 DM4L8H3 DN Loracarbef DM4L8H3 TI TTJP4SM DM4L8H3 TN Bacterial Penicillin binding protein (Bact PBP) DM4L8H3 MA Binder DM4L8H3 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DM4L8H3 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TT3ROYC DM4LECQ TN Serotonin transporter (SERT) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TTSQIFT DM4LECQ TN 5-HT 1A receptor (HTR1A) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LOD0 DI DM4LOD0 DM4LOD0 DN Alglucosidase alfa DM4LOD0 TI TT95ICL DM4LOD0 TN Mannose-6-phosphate receptor (M6PR) DM4LOD0 MA Binder DM4LOD0 RN Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35. DM4LOD0 RU https://pubmed.ncbi.nlm.nih.gov/19542901 DM4LSNE DI DM4LSNE DM4LSNE DN Procaine DM4LSNE TI TTPC4TU DM4LSNE TN 5-HT 3A receptor (HTR3A) DM4LSNE MA Antagonist DM4LSNE RN Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70. DM4LSNE RU https://pubmed.ncbi.nlm.nih.gov/18035290 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTV5CGO DM4LSPN TN Phosphodiesterase 4 (PDE4) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTZCG4L DM4LSPN TN Phosphodiesterase 3 (PDE3) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A TI TT6NHYC DM4LT8A TN Pneumocystis carinii Dihydropteroate synthase (PC DHPS) DM4LT8A MA Modulator DM4LT8A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4LT8A RU https://www.fda.gov/ DM4LTKV DI DM4LTKV DM4LTKV DN Dalfopristin DM4LTKV TI TTUWYEA DM4LTKV TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4LTKV MA Binder DM4LTKV RN The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9. DM4LTKV RU https://pubmed.ncbi.nlm.nih.gov/15991995 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG TI TTUWYEA DM4M1SG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4M1SG MA Binder DM4M1SG RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM4M1SG RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM4MDJY DI DM4MDJY DM4MDJY DN Fluvastatin DM4MDJY TI TTPADOQ DM4MDJY TN HMG-CoA reductase (HMGCR) DM4MDJY MA Inhibitor DM4MDJY RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM4MDJY RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM4ME02 DI DM4ME02 DM4ME02 DN Ticarcillin DM4ME02 TI TTJP4SM DM4ME02 TN Bacterial Penicillin binding protein (Bact PBP) DM4ME02 MA Binder DM4ME02 RN Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7. DM4ME02 RU https://pubmed.ncbi.nlm.nih.gov/8360977 DM4NTMO DI DM4NTMO DM4NTMO DN TRYPAN BLUE DM4NTMO TI TTELIN2 DM4NTMO TN PTPN1 messenger RNA (PTPN1 mRNA) DM4NTMO MA Inhibitor DM4NTMO RN Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6. DM4NTMO RU https://pubmed.ncbi.nlm.nih.gov/15050628 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 TI TTUTN1I DM4O2Z7 TN Human Deoxyribonucleic acid (hDNA) DM4O2Z7 MA Modulator DM4O2Z7 RN O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/9714064 DM4O90W DI DM4O90W DM4O90W DN Insulin-lispro DM4O90W TI TTCBFJO DM4O90W TN Insulin receptor (INSR) DM4O90W MA Binder DM4O90W RN Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2. DM4O90W RU https://pubmed.ncbi.nlm.nih.gov/10601956 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTRMX3V DM4ONW5 TN Janus kinase 2 (JAK-2) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TT6DM01 DM4ONW5 TN Janus kinase 1 (JAK-1) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTJSQEF DM4ONW5 TN Tyrosine-protein kinase (PTK) DM4ONW5 MA Inhibitor DM4ONW5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM4PF81 DI DM4PF81 DM4PF81 DN Mitomycin A DM4PF81 TI TTUTN1I DM4PF81 TN Human Deoxyribonucleic acid (hDNA) DM4PF81 RN Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42. DM4PF81 RU https://pubmed.ncbi.nlm.nih.gov/11495594 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC TI TT90XZ8 DM4PRFC TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM4PRFC MA Modulator DM4PRFC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PRFC RU https://www.fda.gov/ DM4PUDW DI DM4PUDW DM4PUDW DN L-glutamic acid DM4PUDW TI TT9IK2Z DM4PUDW TN N-methyl-D-aspartate receptor (NMDAR) DM4PUDW MA Antagonist DM4PUDW RN Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603. DM4PUDW RU https://pubmed.ncbi.nlm.nih.gov/18923069 DM4PVDY DI DM4PVDY DM4PVDY DN Durvalumab DM4PVDY TI TT8ZLTI DM4PVDY TN Programmed cell death 1 ligand 1 (PD-L1) DM4PVDY MA Modulator DM4PVDY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PVDY RU https://www.fda.gov/ DM4PXF6 DI DM4PXF6 DM4PXF6 DN Desoximetasone DM4PXF6 TI TTP3UTW DM4PXF6 TN Steroid hormone receptor ERR (ESRR) DM4PXF6 MA Modulator DM4PXF6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PXF6 RU https://www.fda.gov/ DM4QFXJ DI DM4QFXJ DM4QFXJ DN Sodium Tetradecyl Sulfate DM4QFXJ TI TTZUXYS DM4QFXJ TN Vitamin K-dependent protein C (PROC) DM4QFXJ MA Inhibitor DM4QFXJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM4QFXJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM4QTBN DI DM4QTBN DM4QTBN DN Isotretinoin DM4QTBN TI TTOD7B3 DM4QTBN TN Retinoic acid receptor (RAR) DM4QTBN MA Agonist DM4QTBN RN Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402. DM4QTBN RU https://pubmed.ncbi.nlm.nih.gov/14501777 DM4RK0G DI DM4RK0G DM4RK0G DN Divalproex sodium DM4RK0G TI TTT2LD9 DM4RK0G TN GABA transaminase (ABAT) DM4RK0G MA Inhibitor DM4RK0G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM4RK0G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 TI TTJP4SM DM4S3O8 TN Bacterial Penicillin binding protein (Bact PBP) DM4S3O8 MA Binder DM4S3O8 RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM4UHZF DI DM4UHZF DM4UHZF DN Vestronidase alfa DM4UHZF TI TTHS7CM DM4UHZF TN Beta-glucuronidase (GUSB) DM4UHZF MA Modulator DM4UHZF RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM4UHZF RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM4V6JA DI DM4V6JA DM4V6JA DN Cilazapril DM4V6JA TI TTL69WB DM4V6JA TN Angiotensin-converting enzyme (ACE) DM4V6JA MA Inhibitor DM4V6JA RN Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. DM4V6JA RU https://pubmed.ncbi.nlm.nih.gov/18423812 DM4V6RL DI DM4V6RL DM4V6RL DN Ritodrine DM4V6RL TI TT2CJVK DM4V6RL TN Adrenergic receptor beta-2 (ADRB2) DM4V6RL MA Modulator DM4V6RL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4V6RL RU https://www.fda.gov/ DM4VAOG DI DM4VAOG DM4VAOG DN Gadobenate dimeglumine DM4VAOG TI TTFNGC9 DM4VAOG TN Serum albumin (ALB) DM4VAOG MA Binder DM4VAOG RN Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7. DM4VAOG RU https://pubmed.ncbi.nlm.nih.gov/18655261 DM4W9B3 DI DM4W9B3 DM4W9B3 DN Fosamprenavir DM4W9B3 TI TT5FNQT DM4W9B3 TN Human immunodeficiency virus Protease (HIV PR) DM4W9B3 MA Inhibitor DM4W9B3 RN Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410. DM4W9B3 RU https://pubmed.ncbi.nlm.nih.gov/19515730 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TTCT6F7 DM4WVC5 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM4WVC5 MA Inhibitor DM4WVC5 RN Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/24900456 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TT48WR6 DM4WVC5 TN Integrin alpha-L (ITGAL) DM4WVC5 MA Modulator DM4WVC5 RN Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/23215542 DM4YMIS DI DM4YMIS DM4YMIS DN Aldesleukin DM4YMIS TI TTF89GD DM4YMIS TN Interleukin-2 (IL2) DM4YMIS MA Modulator DM4YMIS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4YMIS RU https://www.fda.gov/ DM4YWCZ DI DM4YWCZ DM4YWCZ DN Nalmefene DM4YWCZ TI TTN4QDT DM4YWCZ TN Opioid receptor (OPR) DM4YWCZ MA Antagonist DM4YWCZ RN Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. DM4YWCZ RU https://pubmed.ncbi.nlm.nih.gov/19001155 DM4ZBK6 DI DM4ZBK6 DM4ZBK6 DN Fedratinib DM4ZBK6 TI TTRMX3V DM4ZBK6 TN Janus kinase 2 (JAK-2) DM4ZBK6 MA Inhibitor DM4ZBK6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM4ZBK6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DM4ZLFD DI DM4ZLFD DM4ZLFD DN Glucosamine DM4ZLFD TI TTRYK0X DM4ZLFD TN Interleukin-1 beta (IL1B) DM4ZLFD MA Inhibitor DM4ZLFD RN Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98. DM4ZLFD RU https://pubmed.ncbi.nlm.nih.gov/19626664 DM4ZS8M DI DM4ZS8M DM4ZS8M DN Nefazodone DM4ZS8M TI TTWJBZ5 DM4ZS8M TN 5-HT 2C receptor (HTR2C) DM4ZS8M MA Antagonist DM4ZS8M RN Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. DM4ZS8M RU https://pubmed.ncbi.nlm.nih.gov/16433010 DM50ILT DI DM50ILT DM50ILT DN Fostemsavir DM50ILT TI TTBYP1X DM50ILT TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DM50ILT MA Inhibitor DM50ILT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM50ILT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf DM50PMY DI DM50PMY DM50PMY DN Minodronate DM50PMY TI TTIKWV4 DM50PMY TN Geranyltranstransferase (FDPS) DM50PMY MA Inhibitor DM50PMY RN Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64. DM50PMY RU https://pubmed.ncbi.nlm.nih.gov/20394422 DM51FY6 DI DM51FY6 DM51FY6 DN Tacrine DM51FY6 TI TT1RS9F DM51FY6 TN Acetylcholinesterase (AChE) DM51FY6 MA Inhibitor DM51FY6 RN Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19. DM51FY6 RU https://pubmed.ncbi.nlm.nih.gov/12139368 DM51OQW DI DM51OQW DM51OQW DN Oxprenolol DM51OQW TI TTR6W5O DM51OQW TN Adrenergic receptor beta-1 (ADRB1) DM51OQW MA Antagonist DM51OQW RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM51OQW RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM51TYR DI DM51TYR DM51TYR DN Esmolol DM51TYR TI TTR6W5O DM51TYR TN Adrenergic receptor beta-1 (ADRB1) DM51TYR MA Antagonist DM51TYR RN Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55. DM51TYR RU https://pubmed.ncbi.nlm.nih.gov/19150530 DM51Z9E DI DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E TI TTJP4SM DM51Z9E TN Bacterial Penicillin binding protein (Bact PBP) DM51Z9E MA Modulator DM51Z9E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM51Z9E RU https://www.fda.gov/ DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TTZA1NY DM53IP1 TN GABA(A) receptor beta-2 (GABRB2) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TT1MPAY DM53IP1 TN GABA(A) receptor alpha-1 (GABRA1) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 TI TTJP4SM DM53PV8 TN Bacterial Penicillin binding protein (Bact PBP) DM53PV8 MA Binder DM53PV8 RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM53PV8 RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM53SRA DI DM53SRA DM53SRA DN Prochlorperazine DM53SRA TI TTEX248 DM53SRA TN Dopamine D2 receptor (D2R) DM53SRA MA Antagonist DM53SRA RN In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102. DM53SRA RU https://pubmed.ncbi.nlm.nih.gov/18992311 DM560Y3 DI DM560Y3 DM560Y3 DN Morantel tartrate DM560Y3 TI TTHDSE2 DM560Y3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM560Y3 MA Inhibitor DM560Y3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM560Y3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 TI TTTIBOJ DM56YN7 TN Histamine H1 receptor (H1R) DM56YN7 MA Antagonist DM56YN7 RN Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. DM56YN7 RU https://pubmed.ncbi.nlm.nih.gov/19236123 DM57O90 DI DM57O90 DM57O90 DN Zolgensma DM57O90 TI TT8QL6X DM57O90 TN Survival motor neuron protein (SMN1) DM57O90 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DM57O90 RU https://www.fda.gov/vaccines-blood-biologics/zolgensma DM584TM DI DM584TM DM584TM DN Butacaine DM584TM TI TTRK8B9 DM584TM TN Sodium channel unspecific (NaC) DM584TM MA Modulator DM584TM RN WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers. DM584TM RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1 DM58QS1 DI DM58QS1 DM58QS1 DN Botulinum Toxin Type B DM58QS1 TI TTG25NJ DM58QS1 TN Vesicle-associated membrane protein (VAMP) DM58QS1 MA Binder DM58QS1 RN Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7. DM58QS1 RU https://pubmed.ncbi.nlm.nih.gov/19401804 DM58VQX DI DM58VQX DM58VQX DN Telavancin DM58VQX TI TT7EFHR DM58VQX TN Corticotropin-releasing factor receptor 1 (CRHR1) DM58VQX MA Antagonist DM58VQX RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DM58VQX RU https://pubmed.ncbi.nlm.nih.gov/17109611 DM58WKG DI DM58WKG DM58WKG DN Panobinostat DM58WKG TI TT6R7JZ DM58WKG TN Histone deacetylase 1 (HDAC1) DM58WKG MA Inhibitor DM58WKG RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DM58WKG RU https://pubmed.ncbi.nlm.nih.gov/19721445 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT TI TTPTXIN DM59AZT TN Translocator protein (TSPO) DM59AZT MA Agonist DM59AZT RN Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40. DM59AZT RU https://pubmed.ncbi.nlm.nih.gov/2574062 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1290U DM59JCN TN Coagulation factor VIII (F8) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1O264 DM59JCN TN Coagulation factor Va (F5) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTND3XS DM5A31S TN Bacterial Ribosome (Bact RIBS) DM5A31S MA Modulator DM5A31S RN Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/22354310 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTOVFH2 DM5A31S TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM5A31S MA Inhibitor DM5A31S RN The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/30346216 DM5A38V DI DM5A38V DM5A38V DN Metharbital DM5A38V TI TTEX6LM DM5A38V TN GABA(A) receptor gamma-3 (GABRG3) DM5A38V MA Modulator DM5A38V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5A38V RU https://www.fda.gov/ DM5BS98 DI DM5BS98 DM5BS98 DN Ampiroxicam DM5BS98 TI TTK0943 DM5BS98 TN Prostaglandin G/H synthase (COX) DM5BS98 MA Modulator DM5BS98 RN Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. DM5BS98 RU https://pubmed.ncbi.nlm.nih.gov/16540287 DM5CL9Z DI DM5CL9Z DM5CL9Z DN Certolizumab DM5CL9Z TI TTF8CQI DM5CL9Z TN Tumor necrosis factor (TNF) DM5CL9Z MA Inhibitor DM5CL9Z RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM5CL9Z RU https://pubmed.ncbi.nlm.nih.gov/18321156 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTAN6JD DM5D6WZ TN Glutamate receptor AMPA (GRIA) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTEX248 DM5D6WZ TN Dopamine D2 receptor (D2R) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5DWMU DI DM5DWMU DM5DWMU DN Rimantadine DM5DWMU TI TTXT3PU DM5DWMU TN Influenza M2 protein (Influ M) DM5DWMU MA Inhibitor DM5DWMU RN Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104. DM5DWMU RU https://pubmed.ncbi.nlm.nih.gov/19215710 DM5EN79 DI DM5EN79 DM5EN79 DN Levamisole DM5EN79 TI TTMR5UV DM5EN79 TN Alkaline phosphatase tissue-nonspecific (ALPL) DM5EN79 MA Inhibitor DM5EN79 RN Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9. DM5EN79 RU https://pubmed.ncbi.nlm.nih.gov/18719742 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTHC7JD DM5F47O TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTMVBWH DM5F47O TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTCJ2X8 DM5F47O TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F84A DI DM5F84A DM5F84A DN Pipecuronium DM5F84A TI TTF4E0J DM5F84A TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM5F84A MA Antagonist DM5F84A RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DM5F84A RU https://pubmed.ncbi.nlm.nih.gov/18633030 DM5FL14 DI DM5FL14 DM5FL14 DN Amifostine DM5FL14 TI TT0C9DV DM5FL14 TN Toxic reactive metabolite (TRM) DM5FL14 MA Modulator DM5FL14 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM5FL14 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5FLTY DI DM5FLTY DM5FLTY DN Risedronate DM5FLTY TI TTIKWV4 DM5FLTY TN Geranyltranstransferase (FDPS) DM5FLTY MA Inhibitor DM5FLTY RN Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14. DM5FLTY RU https://pubmed.ncbi.nlm.nih.gov/12086478 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTEF5MJ DM5FSJA TN ATP-binding cassette transporter C9 (ABCC9) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTP835K DM5FSJA TN ATP-binding cassette transporter C8 (ABCC8) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5GT1M DI DM5GT1M DM5GT1M DN EVANS BLUE DM5GT1M TI TTFNGC9 DM5GT1M TN Serum albumin (ALB) DM5GT1M MA Modulator DM5GT1M RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM5GT1M RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM5GVHU DI DM5GVHU DM5GVHU DN Quinolones DM5GVHU TI TT0IHXV DM5GVHU TN DNA topoisomerase II (TOP2) DM5GVHU MA Inhibitor DM5GVHU RN The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64. DM5GVHU RU https://pubmed.ncbi.nlm.nih.gov/15822188 DM5I1CE DI DM5I1CE DM5I1CE DN Valacyclovir Hydrochloride DM5I1CE TI TTIU7X1 DM5I1CE TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM5I1CE MA Modulator DM5I1CE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5I1CE RU https://www.fda.gov/ DM5I621 DI DM5I621 DM5I621 DN Methyldopa DM5I621 TI TTEX248 DM5I621 TN Dopamine D2 receptor (D2R) DM5I621 MA Agonist DM5I621 RN Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. DM5I621 RU https://pubmed.ncbi.nlm.nih.gov/17485976 DM5IKUF DI DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF TI TTEX248 DM5IKUF TN Dopamine D2 receptor (D2R) DM5IKUF MA Agonist DM5IKUF RN Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. DM5IKUF RU https://pubmed.ncbi.nlm.nih.gov/18626630 DM5IXKQ DI DM5IXKQ DM5IXKQ DN Vismodegib DM5IXKQ TI TT8J1S3 DM5IXKQ TN Smoothened homolog (SMO) DM5IXKQ MA Modulator DM5IXKQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM5IXKQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM5J1NH DI DM5J1NH DM5J1NH DN Alcaftadine DM5J1NH TI TTTIBOJ DM5J1NH TN Histamine H1 receptor (H1R) DM5J1NH MA Antagonist DM5J1NH RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5J1NH RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5J64S DI DM5J64S DM5J64S DN Miglustat DM5J64S TI TTPHEX3 DM5J64S TN Ceramide glucosyltransferase (UGCG) DM5J64S MA Inhibitor DM5J64S RN Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54. DM5J64S RU https://pubmed.ncbi.nlm.nih.gov/17919546 DM5JQ0D DI DM5JQ0D DM5JQ0D DN Streptokinase DM5JQ0D TI TTP86E2 DM5JQ0D TN Plasminogen (PLG) DM5JQ0D MA Activator DM5JQ0D RN Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61. DM5JQ0D RU https://pubmed.ncbi.nlm.nih.gov/19123085 DM5JTPU DI DM5JTPU DM5JTPU DN Albumin Human DM5JTPU TI TTFNGC9 DM5JTPU TN Serum albumin (ALB) DM5JTPU MA Modulator DM5JTPU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5JTPU RU https://www.fda.gov/ DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN TI TT9JZCK DM5JVAN TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5JVAN MA Modulator DM5JVAN RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5JVAN RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5JVS3 DI DM5JVS3 DM5JVS3 DN Isoniazid DM5JVS3 TI TTVTX4N DM5JVS3 TN Bacterial Fatty acid synthetase I (Bact inhA) DM5JVS3 MA Inhibitor DM5JVS3 RN Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17. DM5JVS3 RU https://pubmed.ncbi.nlm.nih.gov/19151923 DM5JWV9 DI DM5JWV9 DM5JWV9 DN Tiazofurin DM5JWV9 TI TTL7C8Q DM5JWV9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5JWV9 MA Inhibitor DM5JWV9 RN In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30. DM5JWV9 RU https://pubmed.ncbi.nlm.nih.gov/9703919 DM5KYPJ DI DM5KYPJ DM5KYPJ DN Butorphanol DM5KYPJ TI TT27RFC DM5KYPJ TN Opioid receptor delta (OPRD1) DM5KYPJ MA Agonist DM5KYPJ RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DM5KYPJ RU https://pubmed.ncbi.nlm.nih.gov/15942128 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI TI TTAWNKZ DM5L6HI TN Norepinephrine transporter (NET) DM5L6HI MA Inhibitor DM5L6HI RN Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. DM5L6HI RU https://pubmed.ncbi.nlm.nih.gov/18568443 DM5LJCI DI DM5LJCI DM5LJCI DN Eptinezumab DM5LJCI TI TTAFORY DM5LJCI TN Calcitonin gene-related peptide (CALC) DM5LJCI MA Inhibitor DM5LJCI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM5LJCI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf DM5M4NT DI DM5M4NT DM5M4NT DN Ethacrynate sodium DM5M4NT TI TTS087L DM5M4NT TN Solute carrier family 12 member 1 (SLC12A1) DM5M4NT MA Modulator DM5M4NT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5M4NT RU https://www.fda.gov/ DM5NM6E DI DM5NM6E DM5NM6E DN NADH DM5NM6E TI TTTJF7V DM5NM6E TN NADH dehydrogenase (MT-ND3) DM5NM6E MA Binder DM5NM6E RN Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47. DM5NM6E RU https://pubmed.ncbi.nlm.nih.gov/1472079 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTFBNVI DM5OGK0 TN Aldose reductase (AKR1B1) DM5OGK0 MA Inhibitor DM5OGK0 RN Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/11522497 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTXHYV6 DM5OGK0 TN Voltage-gated L-type calcium channel (L-CaC) DM5OGK0 MA Blocker DM5OGK0 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DM5OHYE DI DM5OHYE DM5OHYE DN Bacitracin DM5OHYE TI TT2EDHU DM5OHYE TN Insulin-degrading enzyme (IDE) DM5OHYE MA Inhibitor DM5OHYE RN Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7. DM5OHYE RU https://pubmed.ncbi.nlm.nih.gov/15509750 DM5OY70 DI DM5OY70 DM5OY70 DN Iron Dextran DM5OY70 TI TTQO71U DM5OY70 TN Hemoglobin (HB) DM5OY70 MA Activator DM5OY70 RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DM5OY70 RU https://pubmed.ncbi.nlm.nih.gov/18760066 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TT3ROYC DM5PCS7 TN Serotonin transporter (SERT) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TTAWNKZ DM5PCS7 TN Norepinephrine transporter (NET) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB TI TTQ8KVI DM5PDRB TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM5PDRB MA Binder DM5PDRB RN Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10702385 DM5PFIJ DI DM5PFIJ DM5PFIJ DN Givosiran DM5PFIJ TI TTG1FXO DM5PFIJ TN ALAS1 messenger RNA (ALAS1 mRNA) DM5PFIJ MA Inhibitor DM5PFIJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM5PFIJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf DM5PU6O DI DM5PU6O DM5PU6O DN Oxcarbazepine DM5PU6O TI TTN9VTF DM5PU6O TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM5PU6O MA Blocker DM5PU6O RN Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24. DM5PU6O RU https://pubmed.ncbi.nlm.nih.gov/19087113 DM5PVQE DI DM5PVQE DM5PVQE DN Paroxetine DM5PVQE TI TT3ROYC DM5PVQE TN Serotonin transporter (SERT) DM5PVQE MA Modulator DM5PVQE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5PVQE RU https://www.fda.gov/ DM5QF9V DI DM5QF9V DM5QF9V DN Tamsulosin DM5QF9V TI TTNGILX DM5QF9V TN Adrenergic receptor alpha-1A (ADRA1A) DM5QF9V MA Modulator DM5QF9V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5QF9V RU https://www.fda.gov/ DM5QWEL DI DM5QWEL DM5QWEL DN Guanabenz DM5QWEL TI TTQ8AFT DM5QWEL TN Adrenergic receptor Alpha-2 (ADRA2) DM5QWEL MA Agonist DM5QWEL RN Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5. DM5QWEL RU https://pubmed.ncbi.nlm.nih.gov/9284427 DM5SQ1G DI DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G TI TT2NUT5 DM5SQ1G TN Adrenergic receptor alpha-2C (ADRA2C) DM5SQ1G MA Modulator DM5SQ1G RN Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7. DM5SQ1G RU https://pubmed.ncbi.nlm.nih.gov/6321209 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTP835K DM5SXUV TN ATP-binding cassette transporter C8 (ABCC8) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTEF5MJ DM5SXUV TN ATP-binding cassette transporter C9 (ABCC9) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP TI TTZOVE0 DM5SYZP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5SYZP MA Blocker DM5SYZP RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DM5SYZP RU https://pubmed.ncbi.nlm.nih.gov/11196553 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US TI TTZAYWL DM5T6US TN Estrogen receptor (ESR) DM5T6US MA Agonist DM5T6US RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DM5T6US RU https://pubmed.ncbi.nlm.nih.gov/19434891 DM5TVS3 DI DM5TVS3 DM5TVS3 DN Vinblastine DM5TVS3 TI TTJ2PTI DM5TVS3 TN Tubulin beta-2 chain (TUBB2) DM5TVS3 MA Inhibitor DM5TVS3 RN Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20. DM5TVS3 RU https://pubmed.ncbi.nlm.nih.gov/12795526 DM5UGDK DI DM5UGDK DM5UGDK DN Mephenytoin DM5UGDK TI TTZOVE0 DM5UGDK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5UGDK MA Blocker DM5UGDK RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DM5UGDK RU https://pubmed.ncbi.nlm.nih.gov/19552484 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 TI TTTIBOJ DM5URA2 TN Histamine H1 receptor (H1R) DM5URA2 MA Antagonist DM5URA2 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM5URA2 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM5V9U1 DI DM5V9U1 DM5V9U1 DN Gadofosveset DM5V9U1 TI TTFNGC9 DM5V9U1 TN Serum albumin (ALB) DM5V9U1 MA Modulator DM5V9U1 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM5V9U1 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTYEG6Q DM5VWOB TN Muscarinic acetylcholine receptor M2 (CHRM2) DM5VWOB MA Antagonist DM5VWOB RN Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/19565307 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTOXS3C DM5VWOB TN Muscarinic acetylcholine receptor (CHRM) DM5VWOB MA Antagonist DM5VWOB RN Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/12235229 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTQ13Z5 DM5VWOB TN Muscarinic acetylcholine receptor M3 (CHRM3) DM5VWOB MA Antagonist DM5VWOB RN Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/9846649 DM5WFNP DI DM5WFNP DM5WFNP DN Abarelix DM5WFNP TI TT8R70G DM5WFNP TN Gonadotropin-releasing hormone receptor (GNRHR) DM5WFNP MA Modulator DM5WFNP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5WFNP RU https://www.fda.gov/ DM5X7VY DI DM5X7VY DM5X7VY DN Pyrimethamine DM5X7VY TI TTVC37M DM5X7VY TN Folate receptor alpha (FOLR1) DM5X7VY MA Modulator DM5X7VY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5X7VY RU https://www.fda.gov/ DM5XH2C DI DM5XH2C DM5XH2C DN Methotrexate Sodium DM5XH2C TI TTYZVDJ DM5XH2C TN Dihydrofolate reductase (DHFR) DM5XH2C MA Modulator DM5XH2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5XH2C RU https://www.fda.gov/ DM5XHVR DI DM5XHVR DM5XHVR DN Insulin Lyspro recombinant DM5XHVR TI TTCBFJO DM5XHVR TN Insulin receptor (INSR) DM5XHVR MA Binder DM5XHVR RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM5XHVR RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM5XLTY DI DM5XLTY DM5XLTY DN Spirapril DM5XLTY TI TTL69WB DM5XLTY TN Angiotensin-converting enzyme (ACE) DM5XLTY MA Inhibitor DM5XLTY RN Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. DM5XLTY RU https://pubmed.ncbi.nlm.nih.gov/16126915 DM5XPIJ DI DM5XPIJ DM5XPIJ DN Leuprolide DM5XPIJ TI TT0ID4A DM5XPIJ TN Leutinizing-hormone-releasing hormone (GNRH1) DM5XPIJ MA Activator DM5XPIJ RN Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22. DM5XPIJ RU https://pubmed.ncbi.nlm.nih.gov/19025432 DM5YBO1 DI DM5YBO1 DM5YBO1 DN Levalbuterol DM5YBO1 TI TT2CJVK DM5YBO1 TN Adrenergic receptor beta-2 (ADRB2) DM5YBO1 MA Antagonist DM5YBO1 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM5YBO1 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM602WT DI DM602WT DM602WT DN Idelalisib DM602WT TI TTGBPJE DM602WT TN PI3-kinase delta (PIK3CD) DM602WT MA Inhibitor DM602WT RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM602WT RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTGP7BY DM6034S TN Monoamine oxidase type B (MAO-B) DM6034S MA Inhibitor DM6034S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DM6034S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTZPO1L DM6034S TN Substance-P receptor (TACR1) DM6034S MA Antagonist DM6034S RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6034S RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TT32XQJ DM6034S TN Monoamine oxidase (MAO) DM6034S MA Inhibitor DM6034S RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6034S RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR TI TTS087L DM60QMR TN Solute carrier family 12 member 1 (SLC12A1) DM60QMR MA Blocker DM60QMR RN Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74. DM60QMR RU https://pubmed.ncbi.nlm.nih.gov/7733229 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 TI TTJ3E9X DM61TA4 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM61TA4 MA Inhibitor DM61TA4 RN How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13. DM61TA4 RU https://pubmed.ncbi.nlm.nih.gov/12209159 DM62B78 DI DM62B78 DM62B78 DN Olodaterol DM62B78 TI TT2CJVK DM62B78 TN Adrenergic receptor beta-2 (ADRB2) DM62B78 MA Modulator DM62B78 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM62B78 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM62MUZ DI DM62MUZ DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium DM62MUZ TI TTGXKP7 DM62MUZ TN Samarium (SAM) DM62MUZ MA Modulator DM62MUZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62MUZ RU https://www.fda.gov/ DM62UG5 DI DM62UG5 DM62UG5 DN Vemurafenib DM62UG5 TI TTWCGQT DM62UG5 TN Serine/threonine-protein kinase B-raf (BRAF) DM62UG5 MA Modulator DM62UG5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM62UG5 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM62UHC DI DM62UHC DM62UHC DN Meropenem DM62UHC TI TTJP4SM DM62UHC TN Bacterial Penicillin binding protein (Bact PBP) DM62UHC MA Modulator DM62UHC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62UHC RU https://www.fda.gov/ DM63QS9 DI DM63QS9 DM63QS9 DN Nystatin DM63QS9 TI TTQKWA4 DM63QS9 TN Fungal Cell membrane ergosterol (Fung CME) DM63QS9 MA Modulator DM63QS9 RN Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation DM63QS9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304795 DM65AGJ DI DM65AGJ DM65AGJ DN Oxymorphone DM65AGJ TI TTN4QDT DM65AGJ TN Opioid receptor (OPR) DM65AGJ MA Modulator DM65AGJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094). DM65AGJ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7094 DM65KL8 DI DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 TI TTP3UTW DM65KL8 TN Steroid hormone receptor ERR (ESRR) DM65KL8 MA Modulator DM65KL8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM65KL8 RU https://www.fda.gov/ DM671NG DI DM671NG DM671NG DN Progabide DM671NG TI TTDCVZW DM671NG TN Gamma-aminobutyric acid B receptor (GABBR) DM671NG MA Agonist DM671NG RN Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47. DM671NG RU https://pubmed.ncbi.nlm.nih.gov/9443561 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTK0943 DM672AH TN Prostaglandin G/H synthase (COX) DM672AH MA Inhibitor DM672AH RN Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/19075637 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTPADOQ DM672AH TN HMG-CoA reductase (HMGCR) DM672AH MA Inhibitor DM672AH RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTS64P2 DM67VKL TN Androgen receptor (AR) DM67VKL MA Antagonist DM67VKL RN Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/15177053 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTKN8W0 DM67VKL TN Glucose-6-phosphate dehydrogenase (G6PD) DM67VKL MA Inhibitor DM67VKL RN Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/3776114 DM69XMQ DI DM69XMQ DM69XMQ DN RG-7446 DM69XMQ TI TT8ZLTI DM69XMQ TN Programmed cell death 1 ligand 1 (PD-L1) DM69XMQ RN PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673. DM69XMQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/ DM6A0X7 DI DM6A0X7 DM6A0X7 DN Pravastatin DM6A0X7 TI TTPADOQ DM6A0X7 TN HMG-CoA reductase (HMGCR) DM6A0X7 MA Inhibitor DM6A0X7 RN A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9. DM6A0X7 RU https://pubmed.ncbi.nlm.nih.gov/11996957 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW TI TTVKILB DM6A4NW TN Prostaglandin G/H synthase 2 (COX-2) DM6A4NW MA Inhibitor DM6A4NW RN The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17. DM6A4NW RU https://pubmed.ncbi.nlm.nih.gov/19470170 DM6AN32 DI DM6AN32 DM6AN32 DN Trovafloxacin DM6AN32 TI TTN6J5F DM6AN32 TN Bacterial DNA gyrase (Bact gyrase) DM6AN32 MA Modulator DM6AN32 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6AN32 RU https://www.fda.gov/ DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTJQOD7 DM6AUFY TN 5-HT 2A receptor (HTR2A) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTEX248 DM6AUFY TN Dopamine D2 receptor (D2R) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUHV DI DM6AUHV DM6AUHV DN Fostamatinib DM6AUHV TI TTOU65C DM6AUHV TN Tyrosine-protein kinase SYK (SYK) DM6AUHV MA Modulator DM6AUHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DM6AUHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TT38RM1 DM6AVR4 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM6AVR4 MA Antagonist DM6AVR4 RN Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/9787163 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TTULVH8 DM6AVR4 TN Tyrosinase (TYR) DM6AVR4 MA Inhibitor DM6AVR4 RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/19159217 DM6CLBN DI DM6CLBN DM6CLBN DN Danaparoid DM6CLBN TI TTCIHJA DM6CLBN TN Coagulation factor Xa (F10) DM6CLBN MA Inhibitor DM6CLBN RN Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. DM6CLBN RU https://pubmed.ncbi.nlm.nih.gov/12402196 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TTU3X26 DM6D7N8 TN Iodothyronine deiodinase type I (DIO1) DM6D7N8 MA Inhibitor DM6D7N8 RN Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17712320 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TT52XDZ DM6D7N8 TN Thyroid peroxidase (TPO) DM6D7N8 MA Inhibitor DM6D7N8 RN Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17497002 DM6DEK9 DI DM6DEK9 DM6DEK9 DN Stavudine DM6DEK9 TI TT84ETX DM6DEK9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6DEK9 MA Inhibitor DM6DEK9 RN Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. DM6DEK9 RU https://pubmed.ncbi.nlm.nih.gov/15183338 DM6ECN9 DI DM6ECN9 DM6ECN9 DN Aluminium DM6ECN9 TI TTWK8D0 DM6ECN9 TN Sodium pump subunit alpha-1 (ATP1A1) DM6ECN9 MA Binder DM6ECN9 RN The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. DM6ECN9 RU https://pubmed.ncbi.nlm.nih.gov/14507470 DM6EL5Q DI DM6EL5Q DM6EL5Q DN Glucarpidase DM6EL5Q TI TTX81QL DM6EL5Q TN Toxic methotrexate (TM) DM6EL5Q MA Modulator DM6EL5Q RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM6EL5Q RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 TI TTR6W5O DM6EUL5 TN Adrenergic receptor beta-1 (ADRB1) DM6EUL5 MA Antagonist DM6EUL5 RN beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. DM6EUL5 RU https://pubmed.ncbi.nlm.nih.gov/19439240 DM6F1PU DI DM6F1PU DM6F1PU DN Vortioxetine DM6F1PU TI TT3ROYC DM6F1PU TN Serotonin transporter (SERT) DM6F1PU MA Inhibitor DM6F1PU RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM6F1PU RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM6FG1P DI DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P TI TTK59TV DM6FG1P TN Vitamin D3 receptor (VDR) DM6FG1P MA Antagonist DM6FG1P RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DM6FG1P RU https://pubmed.ncbi.nlm.nih.gov/19249988 DM6HX9B DI DM6HX9B DM6HX9B DN Nevirapine DM6HX9B TI TT84ETX DM6HX9B TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6HX9B MA Modulator DM6HX9B RN HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9. DM6HX9B RU https://www.ncbi.nlm.nih.gov/pubmed/22266819 DM6I2WQ DI DM6I2WQ DM6I2WQ DN Amezinium DM6I2WQ TI TT2NUT5 DM6I2WQ TN Adrenergic receptor alpha-2C (ADRA2C) DM6I2WQ MA Modulator DM6I2WQ RN Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. DM6I2WQ RU https://pubmed.ncbi.nlm.nih.gov/7197970 DM6I5GR DI DM6I5GR DM6I5GR DN Promethazine DM6I5GR TI TTTIBOJ DM6I5GR TN Histamine H1 receptor (H1R) DM6I5GR MA Antagonist DM6I5GR RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM6I5GR RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM6IR3P DI DM6IR3P DM6IR3P DN Liothyronine DM6IR3P TI TTTSEPU DM6IR3P TN Thyroid hormone receptor alpha (THRA) DM6IR3P MA Antagonist DM6IR3P RN Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32. DM6IR3P RU https://pubmed.ncbi.nlm.nih.gov/17827792 DM6KI0D DI DM6KI0D DM6KI0D DN Repirinast DM6KI0D TI TT7CXIM DM6KI0D TN Histamine receptor (HR) DM6KI0D MA Modulator DM6KI0D RN Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90. DM6KI0D RU https://pubmed.ncbi.nlm.nih.gov/1378339 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTN6J5F DM6KZMG TN Bacterial DNA gyrase (Bact gyrase) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTIXTO3 DM6KZMG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTABD5E DM6KZMG TN DNA replication (DNA repli) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTRVWAT DM6KZMG TN Staphylococcus DNA gyrase A (Stap-coc gyrA) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 TI TTIJQ3O DM6L4H2 TN Cytochrome P450 3A (CYP3A) DM6L4H2 MA Modulator DM6L4H2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535). DM6L4H2 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535 DM6L5VO DI DM6L5VO DM6L5VO DN Methsuximide DM6L5VO TI TT729IR DM6L5VO TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM6L5VO MA Blocker DM6L5VO RN Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. DM6L5VO RU https://pubmed.ncbi.nlm.nih.gov/11641441 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU TI TTVKILB DM6LOQU TN Prostaglandin G/H synthase 2 (COX-2) DM6LOQU MA Inhibitor DM6LOQU RN Pfizer. Product Development Pipeline. March 31 2009. DM6LOQU RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6MO9X DI DM6MO9X DM6MO9X DN Insulin Zinc Susp Recombinant Human DM6MO9X TI TTZOPHG DM6MO9X TN Insulin (INS) DM6MO9X MA Modulator DM6MO9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6MO9X RU https://www.fda.gov/ DM6N4PR DI DM6N4PR DM6N4PR DN Cerulenin DM6N4PR TI TT7AOUD DM6N4PR TN Fatty acid synthase (FASN) DM6N4PR MA Inhibitor DM6N4PR RN Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91. DM6N4PR RU https://pubmed.ncbi.nlm.nih.gov/19382912 DM6NZ2P DI DM6NZ2P DM6NZ2P DN Pegvaliase DM6NZ2P TI TTGSVH2 DM6NZ2P TN Phenylalanine hydroxylase (PAH) DM6NZ2P MA Modulator DM6NZ2P RN Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227. DM6NZ2P RU https://pubmed.ncbi.nlm.nih.gov/30146451 DM6OZQV DI DM6OZQV DM6OZQV DN Daclizumab DM6OZQV TI TTF89GD DM6OZQV TN Interleukin-2 (IL2) DM6OZQV MA Modulator DM6OZQV RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM6OZQV RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM6PR40 DI DM6PR40 DM6PR40 DN Paramethasone DM6PR40 TI TTJL8VG DM6PR40 TN Corticosteroid-binding globulin (SERPINA6) DM6PR40 MA Binder DM6PR40 RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM6PR40 RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM6Q4B0 DI DM6Q4B0 DM6Q4B0 DN Anistreplase DM6Q4B0 TI TTP86E2 DM6Q4B0 TN Plasminogen (PLG) DM6Q4B0 MA Activator DM6Q4B0 RN Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. DM6Q4B0 RU https://pubmed.ncbi.nlm.nih.gov/9360848 DM6Q7U4 DI DM6Q7U4 DM6Q7U4 DN Lenalidomide DM6Q7U4 TI TTF8CQI DM6Q7U4 TN Tumor necrosis factor (TNF) DM6Q7U4 MA Inhibitor DM6Q7U4 RN Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. DM6Q7U4 RU https://pubmed.ncbi.nlm.nih.gov/19370685 DM6QFSV DI DM6QFSV DM6QFSV DN Erdosteine DM6QFSV TI TT3NKIB DM6QFSV TN Pancreatic elastase 1 (CELA1) DM6QFSV MA Modulator DM6QFSV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM6QFSV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TTQ8AFT DM6RZ9Q TN Adrenergic receptor Alpha-2 (ADRA2) DM6RZ9Q MA Agonist DM6RZ9Q RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/11164065 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TT7HC21 DM6RZ9Q TN Membrane copper amine oxidase (AOC3) DM6RZ9Q MA Inhibitor DM6RZ9Q RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6S0HB DI DM6S0HB DM6S0HB DN TachoComb DM6S0HB TI TTWODQF DM6S0HB TN Fibrin (FG) DM6S0HB MA Modulator DM6S0HB RN Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2011 Jan-Feb;58(105):187-91. DM6S0HB RU https://pubmed.ncbi.nlm.nih.gov/21510312 DM6S157 DI DM6S157 DM6S157 DN Guanadrel Sulfate DM6S157 TI TTVIREA DM6S157 TN Adrenergic receptor (ADR) DM6S157 MA Modulator DM6S157 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6S157 RU https://www.fda.gov/ DM6T2J3 DI DM6T2J3 DM6T2J3 DN Neostigmine DM6T2J3 TI TT1RS9F DM6T2J3 TN Acetylcholinesterase (AChE) DM6T2J3 MA Inhibitor DM6T2J3 RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DM6T2J3 RU https://pubmed.ncbi.nlm.nih.gov/19472276 DM6T924 DI DM6T924 DM6T924 DN Gabapentin DM6T924 TI TTDCVZW DM6T924 TN Gamma-aminobutyric acid B receptor (GABBR) DM6T924 MA Antagonist DM6T924 RN Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33. DM6T924 RU https://pubmed.ncbi.nlm.nih.gov/16871066 DM6TS1N DI DM6TS1N DM6TS1N DN Phendimetrazine DM6TS1N TI TTBRKXS DM6TS1N TN Adrenergic receptor alpha-1B (ADRA1B) DM6TS1N MA Antagonist DM6TS1N RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM6TS1N RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTI2WET DM6U9CQ TN Platelet-derived growth factor receptor (PDGFR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTUTJGQ DM6U9CQ TN Vascular endothelial growth factor receptor 2 (KDR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTX41N9 DM6U9CQ TN Tyrosine-protein kinase Kit (KIT) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6VM38 DI DM6VM38 DM6VM38 DN Reserpine DM6VM38 TI TTNZRI3 DM6VM38 TN Synaptic vesicle amine transporter (SLC18A2) DM6VM38 MA Blocker DM6VM38 RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DM6VM38 RU https://pubmed.ncbi.nlm.nih.gov/19571144 DM6VOWQ DI DM6VOWQ DM6VOWQ DN Fomepizole DM6VOWQ TI TT5AHZ0 DM6VOWQ TN Alcohol dehydrogenase 1A (ADH1A) DM6VOWQ MA Modulator DM6VOWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VOWQ RU https://www.fda.gov/ DM6VZFQ DI DM6VZFQ DM6VZFQ DN Pirfenidone DM6VZFQ TI TTR9XHZ DM6VZFQ TN Transforming growth factor beta 1 (TGFB1) DM6VZFQ MA Modulator DM6VZFQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VZFQ RU https://www.fda.gov/ DM6W8V5 DI DM6W8V5 DM6W8V5 DN Lisdexamfetamine DM6W8V5 TI TTIU98M DM6W8V5 TN Trace amine-associated receptor-1 (TAAR1) DM6W8V5 MA Modulator DM6W8V5 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM6W8V5 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 TI TTVKILB DM6WJO9 TN Prostaglandin G/H synthase 2 (COX-2) DM6WJO9 MA Inhibitor DM6WJO9 RN Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. DM6WJO9 RU https://pubmed.ncbi.nlm.nih.gov/17603251 DM6XFHS DI DM6XFHS DM6XFHS DN SPI-1005 DM6XFHS TI TTFNGC9 DM6XFHS TN Serum albumin (ALB) DM6XFHS MA Binder DM6XFHS RN Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. DM6XFHS RU https://pubmed.ncbi.nlm.nih.gov/7945407 DM6Y3AN DI DM6Y3AN DM6Y3AN DN Micafungin DM6Y3AN TI TT0SFXH DM6Y3AN TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM6Y3AN MA Modulator DM6Y3AN RN An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74. DM6Y3AN RU https://pubmed.ncbi.nlm.nih.gov/24265229 DM6YWBF DI DM6YWBF DM6YWBF DN Herbimycin A DM6YWBF TI TT6PKBN DM6YWBF TN Proto-oncogene c-Src (SRC) DM6YWBF MA Inhibitor DM6YWBF RN In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73. DM6YWBF RU https://pubmed.ncbi.nlm.nih.gov/7967714 DM6ZPLQ DI DM6ZPLQ DM6ZPLQ DN Novolimus DM6ZPLQ TI TTCJG29 DM6ZPLQ TN Serine/threonine-protein kinase mTOR (mTOR) DM6ZPLQ MA Inhibitor DM6ZPLQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DM6ZPLQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DM70BU5 DI DM70BU5 DM70BU5 DN Thalidomide DM70BU5 TI TTF8CQI DM70BU5 TN Tumor necrosis factor (TNF) DM70BU5 MA Inhibitor DM70BU5 RN Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5. DM70BU5 RU https://pubmed.ncbi.nlm.nih.gov/19099634 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTJQOD7 DM70DTN TN 5-HT 2A receptor (HTR2A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTSQIFT DM70DTN TN 5-HT 1A receptor (HTR1A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70IK5 DI DM70IK5 DM70IK5 DN Marinol DM70IK5 TI TT6OEDT DM70IK5 TN Cannabinoid receptor 1 (CB1) DM70IK5 MA Agonist DM70IK5 RN Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411. DM70IK5 RU https://pubmed.ncbi.nlm.nih.gov/19226257 DM72JXH DI DM72JXH DM72JXH DN Losartan DM72JXH TI TT8DBY3 DM72JXH TN Angiotensin II receptor type-1 (AGTR1) DM72JXH MA Antagonist DM72JXH RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DM72JXH RU https://pubmed.ncbi.nlm.nih.gov/19513646 DM749I3 DI DM749I3 DM749I3 DN Ubrogepant DM749I3 TI TTY6O0Q DM749I3 TN Calcitonin gene-related peptide receptor (CGRPR) DM749I3 MA Antagonist DM749I3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM749I3 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf DM74LZK DI DM74LZK DM74LZK DN Cromoglicate DM74LZK TI TT78R5H DM74LZK TN Heat shock protein 90 alpha (HSP90A) DM74LZK MA Inhibitor DM74LZK RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM74LZK RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM74SVE DI DM74SVE DM74SVE DN Dasiglucagon DM74SVE TI TT9O6WS DM74SVE TN Glucagon receptor (GCGR) DM74SVE MA Agonist DM74SVE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM74SVE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf DM75CXN DI DM75CXN DM75CXN DN Avanafil DM75CXN TI TTJ0IQB DM75CXN TN Phosphodiesterase 5A (PDE5A) DM75CXN MA Modulator DM75CXN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM75CXN RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM76VHG DI DM76VHG DM76VHG DN Regadenoson DM76VHG TI TTM2AOE DM76VHG TN Adenosine A2a receptor (ADORA2A) DM76VHG MA Modulator DM76VHG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM76VHG RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM783CH DI DM783CH DM783CH DN Levobupivacaine DM783CH TI TTRK8B9 DM783CH TN Sodium channel unspecific (NaC) DM783CH MA Blocker DM783CH RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DM783CH RU https://pubmed.ncbi.nlm.nih.gov/11094008 DM78G6F DI DM78G6F DM78G6F DN HTF 919 DM78G6F TI TT07C3Y DM78G6F TN 5-HT 4 receptor (HTR4) DM78G6F MA Agonist DM78G6F RN 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58. DM78G6F RU https://pubmed.ncbi.nlm.nih.gov/11874527 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME TI TTTIBOJ DM78IME TN Histamine H1 receptor (H1R) DM78IME MA Agonist DM78IME RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM78IME RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM78NWP DI DM78NWP DM78NWP DN Dostarlimab DM78NWP TI TTNBFWK DM78NWP TN Programmed cell death protein 1 (PD-1) DM78NWP MA Inhibitor DM78NWP RN Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. DM78NWP RU https://pubmed.ncbi.nlm.nih.gov/33251877 DM79F6G DI DM79F6G DM79F6G DN Adenosine triphosphate DM79F6G TI TT3PJMV DM79F6G TN Tyrosine-protein kinase ABL1 (ABL) DM79F6G MA Inhibitor DM79F6G RN Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. DM79F6G RU https://pubmed.ncbi.nlm.nih.gov/18056932 DM79NTF DI DM79NTF DM79NTF DN Propranolol DM79NTF TI TTR6W5O DM79NTF TN Adrenergic receptor beta-1 (ADRB1) DM79NTF MA Antagonist DM79NTF RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM79NTF RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM79NZ5 DI DM79NZ5 DM79NZ5 DN Insulin determir DM79NZ5 TI TTZOPHG DM79NZ5 TN Insulin (INS) DM79NZ5 MA Modulator DM79NZ5 RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DM79NZ5 RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM79VXT DI DM79VXT DM79VXT DN PF-04971729 DM79VXT TI TTLWPVF DM79VXT TN Sodium/glucose cotransporter 2 (SGLT2) DM79VXT MA Modulator DM79VXT RN Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8. DM79VXT RU https://www.ncbi.nlm.nih.gov/pubmed/25754396 DM79XDW DI DM79XDW DM79XDW DN Cephalosporin DM79XDW TI TTLP6GN DM79XDW TN Bacterial DD-carboxypeptidase (Bact vanYB) DM79XDW MA Binder DM79XDW RN A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31. DM79XDW RU https://pubmed.ncbi.nlm.nih.gov/11171967 DM79Y2T DI DM79Y2T DM79Y2T DN ATryn antithrombin DM79Y2T TI TT6L509 DM79Y2T TN Coagulation factor IIa (F2) DM79Y2T MA Modulator DM79Y2T RN Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779. DM79Y2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/ DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW TI TTPD1CN DM7A8TW TN Niemann-Pick C1-like protein 1 (NPC1L1) DM7A8TW MA Inhibitor DM7A8TW RN Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107. DM7A8TW RU https://pubmed.ncbi.nlm.nih.gov/19552506 DM7AVGW DI DM7AVGW DM7AVGW DN Ocriplasmin DM7AVGW TI TTPJ921 DM7AVGW TN Fibronectin (FN1) DM7AVGW MA Inhibitor DM7AVGW RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM7AVGW RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM7BN0X DI DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X TI TTLOKXP DM7BN0X TN Gastric H(+)/K(+) ATPase (Proton pump) DM7BN0X MA Modulator DM7BN0X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7BN0X RU https://www.fda.gov/ DM7C8YV DI DM7C8YV DM7C8YV DN Plicamycin DM7C8YV TI TTX2AYW DM7C8YV TN RNA synthesis (hRNA synth) DM7C8YV MA Modulator DM7C8YV RN Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85. DM7C8YV RU https://pubmed.ncbi.nlm.nih.gov/7827085 DM7DSYP DI DM7DSYP DM7DSYP DN Cefprozil DM7DSYP TI TTJP4SM DM7DSYP TN Bacterial Penicillin binding protein (Bact PBP) DM7DSYP MA Binder DM7DSYP RN Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8. DM7DSYP RU https://pubmed.ncbi.nlm.nih.gov/15949076 DM7EN8I DI DM7EN8I DM7EN8I DN Diflunisal DM7EN8I TI TTVKILB DM7EN8I TN Prostaglandin G/H synthase 2 (COX-2) DM7EN8I MA Inhibitor DM7EN8I RN Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. DM7EN8I RU https://pubmed.ncbi.nlm.nih.gov/11315375 DM7EUK3 DI DM7EUK3 DM7EUK3 DN Delapril DM7EUK3 TI TTL69WB DM7EUK3 TN Angiotensin-converting enzyme (ACE) DM7EUK3 MA Modulator DM7EUK3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM7EUK3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTP362L DM7EVLC TN Solute carrier family 12 member 3 (SLC12A3) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTS087L DM7EVLC TN Solute carrier family 12 member 1 (SLC12A1) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7F1PA DI DM7F1PA DM7F1PA DN Nebivolol DM7F1PA TI TTR6W5O DM7F1PA TN Adrenergic receptor beta-1 (ADRB1) DM7F1PA MA Antagonist DM7F1PA RN Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. DM7F1PA RU https://pubmed.ncbi.nlm.nih.gov/19443516 DM7F5OW DI DM7F5OW DM7F5OW DN Mepyramine maleate DM7F5OW TI TTTIBOJ DM7F5OW TN Histamine H1 receptor (H1R) DM7F5OW MA Antagonist DM7F5OW RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DM7F5OW RU https://pubmed.ncbi.nlm.nih.gov/19552055 DM7G0EP DI DM7G0EP DM7G0EP DN Fosmidomycin DM7G0EP TI TTLH4J3 DM7G0EP TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM7G0EP MA Binder DM7G0EP RN Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7. DM7G0EP RU https://pubmed.ncbi.nlm.nih.gov/12621040 DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW TI TTGM6VW DM7GCVW TN Tyrosine-protein kinase BTK (ATK) DM7GCVW MA Inhibitor DM7GCVW RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7GCVW RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7HUNW DI DM7HUNW DM7HUNW DN Testosterone DM7HUNW TI TTS64P2 DM7HUNW TN Androgen receptor (AR) DM7HUNW MA Agonist DM7HUNW RN Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24. DM7HUNW RU https://pubmed.ncbi.nlm.nih.gov/18406296 DM7HXWT DI DM7HXWT DM7HXWT DN Nilotinib DM7HXWT TI TTS7G69 DM7HXWT TN Fusion protein Bcr-Abl (Bcr-Abl) DM7HXWT MA Modulator DM7HXWT RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM7HXWT RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM7I64Z DI DM7I64Z DM7I64Z DN Almogran DM7I64Z TI TT6MSOK DM7I64Z TN 5-HT 1D receptor (HTR1D) DM7I64Z MA Agonist DM7I64Z RN Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75. DM7I64Z RU https://pubmed.ncbi.nlm.nih.gov/11768838 DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU TI TTOVFH2 DM7ICNU TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM7ICNU MA Modulator DM7ICNU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ICNU RU https://www.fda.gov/ DM7ISKJ DI DM7ISKJ DM7ISKJ DN Nisoldipine DM7ISKJ TI TT5HONZ DM7ISKJ TN Calcium channel unspecific (CaC) DM7ISKJ MA Blocker DM7ISKJ RN RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12. DM7ISKJ RU https://pubmed.ncbi.nlm.nih.gov/19536471 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT0WAIE DM7IW9J TN Melatonin receptor type 1A (MTNR1A) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT32JK8 DM7IW9J TN Melatonin receptor type 1B (MTNR1B) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7J2TA DI DM7J2TA DM7J2TA DN Methazolamide DM7J2TA TI TTHQPL7 DM7J2TA TN Carbonic anhydrase I (CA-I) DM7J2TA MA Modulator DM7J2TA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597). DM7J2TA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597 DM7J6OR DI DM7J6OR DM7J6OR DN Tocilizumab DM7J6OR TI TT0E5SK DM7J6OR TN Interleukin 6 receptor (IL6R) DM7J6OR MA Modulator DM7J6OR RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM7J6OR RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM7JHX0 DI DM7JHX0 DM7JHX0 DN Butethal DM7JHX0 TI TT1MPAY DM7JHX0 TN GABA(A) receptor alpha-1 (GABRA1) DM7JHX0 MA Antagonist DM7JHX0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7JHX0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 TI TTWK8D0 DM7JT24 TN Sodium pump subunit alpha-1 (ATP1A1) DM7JT24 MA Binder DM7JT24 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7JT24 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7K5GD DI DM7K5GD DM7K5GD DN Lutropin alfa DM7K5GD TI TT2O4W9 DM7K5GD TN Luteinizing hormone receptor (LHCGR) DM7K5GD MA Binder DM7K5GD RN Lutropin alfa. Drugs. 2008;68(11):1529-40. DM7K5GD RU https://pubmed.ncbi.nlm.nih.gov/18627209 DM7MDBE DI DM7MDBE DM7MDBE DN Vericiguat DM7MDBE TI TTWNFC2 DM7MDBE TN Soluble guanylyl cyclase (GUCY2D) DM7MDBE MA Modulator DM7MDBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM7MDBE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf DM7MT6E DI DM7MT6E DM7MT6E DN Prasugrel DM7MT6E TI TTZ1DT0 DM7MT6E TN P2Y purinoceptor 12 (P2RY12) DM7MT6E MA Inhibitor DM7MT6E RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM7MT6E RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM7NKEV DI DM7NKEV DM7NKEV DN Thioguanine DM7NKEV TI TTCAQMW DM7NKEV TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DM7NKEV MA Intercalator DM7NKEV RN Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9. DM7NKEV RU https://pubmed.ncbi.nlm.nih.gov/19244103 DM7NPJS DI DM7NPJS DM7NPJS DN Paliperidone DM7NPJS TI TT85JO3 DM7NPJS TN 5-HT receptor (5HTR) DM7NPJS MA Antagonist DM7NPJS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM7NPJS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TT9V5JH DM7OKQV TN Phospholipase A2 (PLA2G1B) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTQ6VF4 DM7OKQV TN Ferrochelatase (FECH) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTMF541 DM7OKQV TN Liver carboxylesterase (CES1) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTPREZD DM7P1J4 TN Interleukin-5 (IL5) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma DM7P1J4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTXH9AD DM7P1J4 TN Interleukin 5 receptor alpha (IL5RA) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. DM7P1J4 RU https://www.ncbi.nlm.nih.gov/pubmed/22136436 DM7PQIK DI DM7PQIK DM7PQIK DN Nitrofurantoin DM7PQIK TI TTS1W4A DM7PQIK TN Bacterial Deoxyribonucleic acid (Bact DNA) DM7PQIK MA Breaker DM7PQIK RN On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. DM7PQIK RU https://pubmed.ncbi.nlm.nih.gov/8607796 DM7Q41G DI DM7Q41G DM7Q41G DN Pyruvic acid DM7Q41G TI TTT2LD9 DM7Q41G TN GABA transaminase (ABAT) DM7Q41G MA Inhibitor DM7Q41G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7Q41G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTRMX3V DM7Q98D TN Janus kinase 2 (JAK-2) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TT6DM01 DM7Q98D TN Janus kinase 1 (JAK-1) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTPRL03 DM7Q98D TN Urokinase plasminogen activator surface receptor (PLAUR) DM7Q98D MA Inhibitor DM7Q98D RN Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/24763226 DM7QG0M DI DM7QG0M DM7QG0M DN Raxibacumab DM7QG0M TI TT3YGCD DM7QG0M TN Bacterial Protective antigen (Bact pagA) DM7QG0M MA Modulator DM7QG0M RN Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. DM7QG0M RU https://pubmed.ncbi.nlm.nih.gov/21383241 DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TTK8CXU DM7RE8P TN 5-HT 1B receptor (HTR1B) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TT6MSOK DM7RE8P TN 5-HT 1D receptor (HTR1D) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTS7G69 DM7RJXL TN Fusion protein Bcr-Abl (Bcr-Abl) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTI2WET DM7RJXL TN Platelet-derived growth factor receptor (PDGFR) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTX41N9 DM7RJXL TN Tyrosine-protein kinase Kit (KIT) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTN6ORK DM7RJXL TN Mcl-1 messenger RNA (MCL-1 mRNA) DM7RJXL RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM7RJXL RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM7RNP3 DI DM7RNP3 DM7RNP3 DN Enbrel DM7RNP3 TI TTF8CQI DM7RNP3 TN Tumor necrosis factor (TNF) DM7RNP3 MA Modulator DM7RNP3 RN Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61. DM7RNP3 RU https://www.ncbi.nlm.nih.gov/pubmed/11451976 DM7SJD6 DI DM7SJD6 DM7SJD6 DN Methylphenidate DM7SJD6 TI TTVBI8W DM7SJD6 TN Dopamine transporter (DAT) DM7SJD6 MA Blocker DM7SJD6 RN Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5. DM7SJD6 RU https://pubmed.ncbi.nlm.nih.gov/15950015 DM7SWIA DI DM7SWIA DM7SWIA DN Triprolidine DM7SWIA TI TTTIBOJ DM7SWIA TN Histamine H1 receptor (H1R) DM7SWIA MA Antagonist DM7SWIA RN Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9. DM7SWIA RU https://pubmed.ncbi.nlm.nih.gov/18938221 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ TI TTTIBOJ DM7U5QJ TN Histamine H1 receptor (H1R) DM7U5QJ MA Antagonist DM7U5QJ RN Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4. DM7U5QJ RU https://pubmed.ncbi.nlm.nih.gov/12056673 DM7UP8X DI DM7UP8X DM7UP8X DN Pegfilgrastim DM7UP8X TI TTC70AJ DM7UP8X TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM7UP8X MA Binder DM7UP8X RN Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. DM7UP8X RU https://pubmed.ncbi.nlm.nih.gov/15082029 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO TI TTS5K1M DM7VTQO TN Hepatitis B virus Reverse transcriptase (HBV RT) DM7VTQO MA Modulator DM7VTQO RN Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7. DM7VTQO RU https://pubmed.ncbi.nlm.nih.gov/24610871 DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S TI TTPMQSO DM7W94S TN ALK tyrosine kinase receptor (ALK) DM7W94S MA Inhibitor DM7W94S RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7W94S RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7WI4Q DI DM7WI4Q DM7WI4Q DN Quinagolide DM7WI4Q TI TTEX248 DM7WI4Q TN Dopamine D2 receptor (D2R) DM7WI4Q MA Agonist DM7WI4Q RN Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. DM7WI4Q RU https://pubmed.ncbi.nlm.nih.gov/12055141 DM7YCK3 DI DM7YCK3 DM7YCK3 DN Thiabendazole DM7YCK3 TI TTHDSE2 DM7YCK3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM7YCK3 MA Inhibitor DM7YCK3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM7YCK3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM7YMIT DI DM7YMIT DM7YMIT DN Methohexital DM7YMIT TI TT1MPAY DM7YMIT TN GABA(A) receptor alpha-1 (GABRA1) DM7YMIT MA Antagonist DM7YMIT RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7YMIT RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 TI TTG90S6 DM7YPM1 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM7YPM1 MA Modulator DM7YPM1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7YPM1 RU https://www.fda.gov/ DM7ZWNY DI DM7ZWNY DM7ZWNY DN Porfimer Sodium DM7ZWNY TI TTH0DUS DM7ZWNY TN Low-density lipoprotein receptor (LDL-R) DM7ZWNY MA Modulator DM7ZWNY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ZWNY RU https://www.fda.gov/ DM804UR DI DM804UR DM804UR DN Hyoscyamine DM804UR TI TTH18TF DM804UR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM804UR MA Antagonist DM804UR RN Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82. DM804UR RU https://pubmed.ncbi.nlm.nih.gov/3126798 DM80OEZ DI DM80OEZ DM80OEZ DN Iobenguane I-123 DM80OEZ TI TTAWNKZ DM80OEZ TN Norepinephrine transporter (NET) DM80OEZ MA Inhibitor DM80OEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DM80OEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DM80OZ5 DI DM80OZ5 DM80OZ5 DN Halothane DM80OZ5 TI TTAN6JD DM80OZ5 TN Glutamate receptor AMPA (GRIA) DM80OZ5 MA Antagonist DM80OZ5 RN Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45. DM80OZ5 RU https://pubmed.ncbi.nlm.nih.gov/17828284 DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTST7KB DM819JF TN Fibroblast growth factor receptor 3 (FGFR3) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTRLW2X DM819JF TN Fibroblast growth factor receptor 1 (FGFR1) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTGJVQM DM819JF TN Fibroblast growth factor receptor 2 (FGFR2) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM82Z30 DI DM82Z30 DM82Z30 DN Topiramate DM82Z30 TI TT0MYE2 DM82Z30 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM82Z30 MA Antagonist DM82Z30 RN Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. DM82Z30 RU https://pubmed.ncbi.nlm.nih.gov/15934870 DM83MOK DI DM83MOK DM83MOK DN Glassia DM83MOK TI TTA7UJC DM83MOK TN Alpha-1-antitrypsin (SERPINA1) DM83MOK MA Inhibitor DM83MOK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM83MOK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM84ZXF DI DM84ZXF DM84ZXF DN Lorazepam DM84ZXF TI TTPTXIN DM84ZXF TN Translocator protein (TSPO) DM84ZXF MA Modulator DM84ZXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM84ZXF RU https://www.fda.gov/ DM87XSN DI DM87XSN DM87XSN DN REGN-727 DM87XSN TI TTBRG7E DM87XSN TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM87XSN RN Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. DM87XSN RU https://pubmed.ncbi.nlm.nih.gov/22633824 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN TI TTCIHJA DM89JLN TN Coagulation factor Xa (F10) DM89JLN MA Inhibitor DM89JLN RN Pfizer. Product Development Pipeline. March 31 2009. DM89JLN RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTY84UG DM89QE1 TN Acetyl-CoA carboxylase 2 (ACACB) DM89QE1 MA Activator DM89QE1 RN AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/19428322 DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTMHCGA DM89QE1 TN Solute carrier family 47 member 1 (SLC47A1) DM89QE1 MA Modulator DM89QE1 RN Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/16850272 DM8AI9U DI DM8AI9U DM8AI9U DN Loxapine DM8AI9U TI TTEX248 DM8AI9U TN Dopamine D2 receptor (D2R) DM8AI9U MA Antagonist DM8AI9U RN Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. DM8AI9U RU https://pubmed.ncbi.nlm.nih.gov/8665533 DM8ANCF DI DM8ANCF DM8ANCF DN Muromonab DM8ANCF TI TTZAT79 DM8ANCF TN T-cell surface glycoprotein CD3 epsilon (CD3E) DM8ANCF MA Binder DM8ANCF RN Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. DM8ANCF RU https://pubmed.ncbi.nlm.nih.gov/14664658 DM8BKU9 DI DM8BKU9 DM8BKU9 DN Acitretin DM8BKU9 TI TTH8FZW DM8BKU9 TN Signal transducer and activator of transcription 3 (STAT3) DM8BKU9 MA Inhibitor DM8BKU9 RN Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4. DM8BKU9 RU https://pubmed.ncbi.nlm.nih.gov/16737614 DM8C3GN DI DM8C3GN DM8C3GN DN Denopamine DM8C3GN TI TTEX248 DM8C3GN TN Dopamine D2 receptor (D2R) DM8C3GN MA Modulator DM8C3GN RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8C3GN RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8C43Q DI DM8C43Q DM8C43Q DN Cycrimine DM8C43Q TI TTZ9SOR DM8C43Q TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8C43Q MA Binder DM8C43Q RN Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42. DM8C43Q RU https://pubmed.ncbi.nlm.nih.gov/2573609 DM8DQV9 DI DM8DQV9 DM8DQV9 DN Pelubiprofen DM8DQV9 TI TTK0943 DM8DQV9 TN Prostaglandin G/H synthase (COX) DM8DQV9 MA Modulator DM8DQV9 RN Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. DM8DQV9 RU https://pubmed.ncbi.nlm.nih.gov/21809372 DM8DZC1 DI DM8DZC1 DM8DZC1 DN Dyphylline DM8DZC1 TI TTZ97H5 DM8DZC1 TN Phosphodiesterase 4A (PDE4A) DM8DZC1 MA Inhibitor DM8DZC1 RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DM8DZC1 RU https://pubmed.ncbi.nlm.nih.gov/7925603 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z TI TTJP4SM DM8EU0Z TN Bacterial Penicillin binding protein (Bact PBP) DM8EU0Z MA Binder DM8EU0Z RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DM8EU0Z RU https://pubmed.ncbi.nlm.nih.gov/6335600 DM8HBJI DI DM8HBJI DM8HBJI DN Coagulation Factor IX DM8HBJI TI TTCIHJA DM8HBJI TN Coagulation factor Xa (F10) DM8HBJI MA Activator DM8HBJI RN Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24. DM8HBJI RU https://pubmed.ncbi.nlm.nih.gov/16086639 DM8HDOL DI DM8HDOL DM8HDOL DN Phytonadione DM8HDOL TI TT76OLR DM8HDOL TN Vitamin K-dependent gamma-carboxylase (GGCX) DM8HDOL MA Cofactor DM8HDOL RN Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85-101. DM8HDOL RU https://pubmed.ncbi.nlm.nih.gov/18374191 DM8HJX6 DI DM8HJX6 DM8HJX6 DN Tipranavir DM8HJX6 TI TT5FNQT DM8HJX6 TN Human immunodeficiency virus Protease (HIV PR) DM8HJX6 MA Modulator DM8HJX6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8HJX6 RU https://www.fda.gov/ DM8HLO5 DI DM8HLO5 DM8HLO5 DN Canakinumab DM8HLO5 TI TTRYK0X DM8HLO5 TN Interleukin-1 beta (IL1B) DM8HLO5 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM8HLO5 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM8HO1L DI DM8HO1L DM8HO1L DN Pyridostigmine DM8HO1L TI TT1RS9F DM8HO1L TN Acetylcholinesterase (AChE) DM8HO1L MA Inhibitor DM8HO1L RN Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. DM8HO1L RU https://pubmed.ncbi.nlm.nih.gov/19257799 DM8JRH0 DI DM8JRH0 DM8JRH0 DN Cangrelor DM8JRH0 TI TTZ1DT0 DM8JRH0 TN P2Y purinoceptor 12 (P2RY12) DM8JRH0 MA Antagonist DM8JRH0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328). DM8JRH0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328 DM8JXPZ DI DM8JXPZ DM8JXPZ DN Glibenclamide DM8JXPZ TI TTP835K DM8JXPZ TN ATP-binding cassette transporter C8 (ABCC8) DM8JXPZ MA Modulator DM8JXPZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8JXPZ RU https://www.fda.gov/ DM8K1XO DI DM8K1XO DM8K1XO DN Hydrocortamate DM8K1XO TI TTYRL6O DM8K1XO TN Glucocorticoid receptor (NR3C1) DM8K1XO MA Modulator DM8K1XO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8K1XO RU https://www.fda.gov/ DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI TI TTVTX4N DM8K3EI TN Bacterial Fatty acid synthetase I (Bact inhA) DM8K3EI MA Inhibitor DM8K3EI RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DM8K3EI RU https://pubmed.ncbi.nlm.nih.gov/17227913 DM8KSQH DI DM8KSQH DM8KSQH DN Phenoxybenzamine DM8KSQH TI TTEX248 DM8KSQH TN Dopamine D2 receptor (D2R) DM8KSQH MA Antagonist DM8KSQH RN Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6. DM8KSQH RU https://pubmed.ncbi.nlm.nih.gov/19232942 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 TI TTXZEAJ DM8L9D4 TN Leukotriene A-4 hydrolase (LTA4H) DM8L9D4 MA Inhibitor DM8L9D4 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM8L9D4 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM8LRU2 DI DM8LRU2 DM8LRU2 DN Revolade/Promacta DM8LRU2 TI TTIHYA4 DM8LRU2 TN Thrombopoietin receptor (MPL) DM8LRU2 MA Agonist DM8LRU2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM8LRU2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM8LX76 DI DM8LX76 DM8LX76 DN Penicillin V Potassium DM8LX76 TI TTJP4SM DM8LX76 TN Bacterial Penicillin binding protein (Bact PBP) DM8LX76 MA Modulator DM8LX76 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8LX76 RU https://www.fda.gov/ DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O TI TTZAYWL DM8MC6O TN Estrogen receptor (ESR) DM8MC6O MA Modulator DM8MC6O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8MC6O RU https://www.fda.gov/ DM8MNVO DI DM8MNVO DM8MNVO DN Tolcapone DM8MNVO TI TTKWFB8 DM8MNVO TN Catechol-O-methyl-transferase (COMT) DM8MNVO MA Inhibitor DM8MNVO RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DM8MNVO RU https://pubmed.ncbi.nlm.nih.gov/11346021 DM8QB0T DI DM8QB0T DM8QB0T DN GSK2592984A DM8QB0T TI TT3J5ZI DM8QB0T TN Cell mediated immunity response (CMIR) DM8QB0T RN Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80. DM8QB0T RU https://pubmed.ncbi.nlm.nih.gov/20941447 DM8QB1D DI DM8QB1D DM8QB1D DN Olaparib DM8QB1D TI TTEBCY8 DM8QB1D TN Poly [ADP-ribose] polymerase (PARP) DM8QB1D MA Modulator DM8QB1D RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM8QB1D RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM8QM5U DI DM8QM5U DM8QM5U DN Anidulafungin DM8QM5U TI TT0SFXH DM8QM5U TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM8QM5U MA Modulator DM8QM5U RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM8QM5U RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM8QTJI DI DM8QTJI DM8QTJI DN Loteprednol etabonate DM8QTJI TI TTP3UTW DM8QTJI TN Steroid hormone receptor ERR (ESRR) DM8QTJI MA Modulator DM8QTJI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8QTJI RU https://www.fda.gov/ DM8RFNJ DI DM8RFNJ DM8RFNJ DN Pitolisant DM8RFNJ TI TT9JNIC DM8RFNJ TN Histamine H3 receptor (H3R) DM8RFNJ MA Agonist DM8RFNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM8RFNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H TI TTPTXIN DM8RZ9H TN Translocator protein (TSPO) DM8RZ9H MA Agonist DM8RZ9H RN New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9. DM8RZ9H RU https://pubmed.ncbi.nlm.nih.gov/18265473 DM8S6T7 DI DM8S6T7 DM8S6T7 DN Ivosidenib DM8S6T7 TI TTV2A1R DM8S6T7 TN Oxalosuccinate decarboxylase (IDH1) DM8S6T7 MA Inhibitor DM8S6T7 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8S6T7 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8SMD1 DI DM8SMD1 DM8SMD1 DN Tazarotene DM8SMD1 TI TT1Q3IE DM8SMD1 TN Retinoic acid receptor gamma (RARG) DM8SMD1 MA Binder DM8SMD1 RN Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31. DM8SMD1 RU https://pubmed.ncbi.nlm.nih.gov/10828316 DM8SXYG DI DM8SXYG DM8SXYG DN Lamotrigine DM8SXYG TI TTN9VTF DM8SXYG TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM8SXYG MA Blocker DM8SXYG RN The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. DM8SXYG RU https://pubmed.ncbi.nlm.nih.gov/19579915 DM8SY60 DI DM8SY60 DM8SY60 DN Butoconazole DM8SY60 TI TTTSOUD DM8SY60 TN Candida Cytochrome P450 51 (Candi ERG11) DM8SY60 MA Inhibitor DM8SY60 RN Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5. DM8SY60 RU https://pubmed.ncbi.nlm.nih.gov/2184984 DM8TUPF DI DM8TUPF DM8TUPF DN Milrinone DM8TUPF TI TTZCG4L DM8TUPF TN Phosphodiesterase 3 (PDE3) DM8TUPF MA Modulator DM8TUPF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8TUPF RU https://www.fda.gov/ DM8V75C DI DM8V75C DM8V75C DN ABIRATERONE DM8V75C TI TTRA5BZ DM8V75C TN Steroid 17-alpha-monooxygenase (S17AH) DM8V75C MA Modulator DM8V75C RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM8V75C RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTVKILB DM8VCBE TN Prostaglandin G/H synthase 2 (COX-2) DM8VCBE MA Inhibitor DM8VCBE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTMWT8Z DM8VCBE TN C-X-C chemokine receptor type 1 (CXCR1) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TT30C9G DM8VCBE TN C-X-C chemokine receptor type 2 (CXCR2) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTCTE1G DM8VCBE TN Interleukin-8 (IL8) DM8VCBE MA Inhibitor DM8VCBE RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19560921 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT TI TTKWM86 DM8WAHT TN Opioid receptor mu (MOP) DM8WAHT MA Modulator DM8WAHT RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM8WBAH DI DM8WBAH DM8WBAH DN Dexmethylphenidate hydrochloride DM8WBAH TI TTVBI8W DM8WBAH TN Dopamine transporter (DAT) DM8WBAH MA Inhibitor DM8WBAH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8WBAH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM8WCXM DI DM8WCXM DM8WCXM DN Befunolol hci DM8WCXM TI TTVIREA DM8WCXM TN Adrenergic receptor (ADR) DM8WCXM MA Modulator DM8WCXM RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8WCXM RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R TI TTDIGC1 DM8WI3R TN Dipeptidyl peptidase 4 (DPP-4) DM8WI3R MA Inhibitor DM8WI3R RN Clinical pipeline report, company report or official report of Takeda (2009). DM8WI3R RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH TI TTCJG29 DM8X2EH TN Serine/threonine-protein kinase mTOR (mTOR) DM8X2EH MA Inhibitor DM8X2EH RN Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. DM8X2EH RU https://pubmed.ncbi.nlm.nih.gov/19620795 DM8X4A1 DI DM8X4A1 DM8X4A1 DN Methantheline DM8X4A1 TI TTH18TF DM8X4A1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8X4A1 MA Antagonist DM8X4A1 RN Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. DM8X4A1 RU https://pubmed.ncbi.nlm.nih.gov/19160231 DM8XI09 DI DM8XI09 DM8XI09 DN Methyldopate Hydrochloride DM8XI09 TI TTQ8AFT DM8XI09 TN Adrenergic receptor Alpha-2 (ADRA2) DM8XI09 MA Modulator DM8XI09 RN Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders DM8XI09 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447877 DM8XP26 DI DM8XP26 DM8XP26 DN Rolapitant DM8XP26 TI TTZPO1L DM8XP26 TN Substance-P receptor (TACR1) DM8XP26 MA Antagonist DM8XP26 RN Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44. DM8XP26 RU https://pubmed.ncbi.nlm.nih.gov/24969614 DM8Y2RU DI DM8Y2RU DM8Y2RU DN Cenegermin DM8Y2RU TI TTEDJN4 DM8Y2RU TN Low-affinity nerve growth factor receptor (NGFR) DM8Y2RU MA Agonist DM8Y2RU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8Y2RU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8YU2F DI DM8YU2F DM8YU2F DN Mepenzolate DM8YU2F TI TTH18TF DM8YU2F TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8YU2F MA Antagonist DM8YU2F RN Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22. DM8YU2F RU https://pubmed.ncbi.nlm.nih.gov/7623487 DM8YXKW DI DM8YXKW DM8YXKW DN Dihydroxyaluminium DM8YXKW TI TT8RDXP DM8YXKW TN Troponin C (TN-C) DM8YXKW MA Stimulator DM8YXKW RN A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12. DM8YXKW RU https://pubmed.ncbi.nlm.nih.gov/19350363 DM8ZHP1 DI DM8ZHP1 DM8ZHP1 DN MCI-186 DM8ZHP1 TI TTJGNVC DM8ZHP1 TN Apoptosis regulator Bcl-2 (BCL-2) DM8ZHP1 MA Regulator (upregulator) DM8ZHP1 RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DM8ZHP1 RU https://pubmed.ncbi.nlm.nih.gov/17604499 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 TI TTK59TV DM8ZVJ7 TN Vitamin D3 receptor (VDR) DM8ZVJ7 MA Agonist DM8ZVJ7 RN Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94. DM8ZVJ7 RU https://pubmed.ncbi.nlm.nih.gov/11050002 DM8ZXT6 DI DM8ZXT6 DM8ZXT6 DN Oxymetazoline DM8ZXT6 TI TTQ8AFT DM8ZXT6 TN Adrenergic receptor Alpha-2 (ADRA2) DM8ZXT6 MA Agonist DM8ZXT6 RN Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. DM8ZXT6 RU https://pubmed.ncbi.nlm.nih.gov/11481271 DM90TJP DI DM90TJP DM90TJP DN Sapropterin hydrochloride DM90TJP TI TTGSVH2 DM90TJP TN Phenylalanine hydroxylase (PAH) DM90TJP MA Modulator DM90TJP RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM90TJP RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM90WJH DI DM90WJH DM90WJH DN Interferon alfacon-1 DM90WJH TI TTMQB37 DM90WJH TN Interferon alpha/beta receptor 2 (IFNAR2) DM90WJH MA Binder DM90WJH RN Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46. DM90WJH RU https://pubmed.ncbi.nlm.nih.gov/19291790 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 TI TTTIBOJ DM92AH3 TN Histamine H1 receptor (H1R) DM92AH3 MA Antagonist DM92AH3 RN Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9. DM92AH3 RU https://pubmed.ncbi.nlm.nih.gov/18502826 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X TI TTQ8AFT DM93L4X TN Adrenergic receptor Alpha-2 (ADRA2) DM93L4X MA Agonist DM93L4X RN Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95. DM93L4X RU https://pubmed.ncbi.nlm.nih.gov/12503262 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TT0PG8F DM93VBZ TN Cyclin-dependent kinase 4 (CDK4) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TTO0FDJ DM93VBZ TN Cyclin-dependent kinase 6 (CDK6) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TT8FYO9 DM958QB TN Platelet-derived growth factor receptor alpha (PDGFRA) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TTX41N9 DM958QB TN Tyrosine-protein kinase Kit (KIT) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM96SE0 DI DM96SE0 DM96SE0 DN Haloperidol DM96SE0 TI TTEX248 DM96SE0 TN Dopamine D2 receptor (D2R) DM96SE0 MA Antagonist DM96SE0 RN Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85. DM96SE0 RU https://pubmed.ncbi.nlm.nih.gov/12112400 DM98IXF DI DM98IXF DM98IXF DN Triamcinolone DM98IXF TI TTYRL6O DM98IXF TN Glucocorticoid receptor (NR3C1) DM98IXF MA Modulator DM98IXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM98IXF RU https://www.fda.gov/ DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TT3ROYC DM9BI7M TN Serotonin transporter (SERT) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TTAWNKZ DM9BI7M TN Norepinephrine transporter (NET) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TT0PG8F DM9CIUW TN Cyclin-dependent kinase 4 (CDK4) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TTO0FDJ DM9CIUW TN Cyclin-dependent kinase 6 (CDK6) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9EQC0 DI DM9EQC0 DM9EQC0 DN Oxidized glutathione DM9EQC0 TI TTEP6RV DM9EQC0 TN Glutathione reductase (GR) DM9EQC0 MA Inhibitor DM9EQC0 RN The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401. DM9EQC0 RU https://pubmed.ncbi.nlm.nih.gov/7788561 DM9FKSR DI DM9FKSR DM9FKSR DN Oxitropium bromide DM9FKSR TI TTH18TF DM9FKSR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM9FKSR MA Modulator DM9FKSR RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM9FKSR RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM9G7BS DI DM9G7BS DM9G7BS DN Cyclizine DM9G7BS TI TTTIBOJ DM9G7BS TN Histamine H1 receptor (H1R) DM9G7BS MA Antagonist DM9G7BS RN Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. DM9G7BS RU https://pubmed.ncbi.nlm.nih.gov/12657913 DM9GH25 DI DM9GH25 DM9GH25 DN Arcitumomab DM9GH25 TI TTPX7I5 DM9GH25 TN Carcinoembryonic antigen CGM1 (CD66d) DM9GH25 RN In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87. DM9GH25 RU https://pubmed.ncbi.nlm.nih.gov/18413884 DM9GP85 DI DM9GP85 DM9GP85 DN Tesamorelin DM9GP85 TI TTG4R8V DM9GP85 TN Growth hormone-releasing hormone receptor (GHRHR) DM9GP85 MA Binder DM9GP85 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM9GP85 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTLM12X DM9HOKG TN Matrix metalloproteinase-2 (MMP-2) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMX39J DM9HOKG TN Matrix metalloproteinase-1 (MMP-1) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMTWOS DM9HOKG TN Matrix metalloproteinase-7 (MMP-7) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HPW3 DI DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 TI TTSZLWK DM9HPW3 TN Aromatase (CYP19A1) DM9HPW3 MA Inhibitor DM9HPW3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DM9HPW3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DM9HQ5U DI DM9HQ5U DM9HQ5U DN Tagraxofusp DM9HQ5U TI TTENHJ0 DM9HQ5U TN Interleukin 3 receptor alpha (IL3RA) DM9HQ5U MA Modulator DM9HQ5U RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM9HQ5U RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM9J04X DI DM9J04X DM9J04X DN Butalbital DM9J04X TI TT1MPAY DM9J04X TN GABA(A) receptor alpha-1 (GABRA1) DM9J04X MA Antagonist DM9J04X RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM9J04X RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM9J6C2 DI DM9J6C2 DM9J6C2 DN Tetracaine DM9J6C2 TI TT90XZ8 DM9J6C2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM9J6C2 MA Inhibitor DM9J6C2 RN Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38. DM9J6C2 RU https://pubmed.ncbi.nlm.nih.gov/14975698 DM9JOYP DI DM9JOYP DM9JOYP DN Palifermin DM9JOYP TI TTGJVQM DM9JOYP TN Fibroblast growth factor receptor 2 (FGFR2) DM9JOYP MA Binder DM9JOYP RN Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87. DM9JOYP RU https://pubmed.ncbi.nlm.nih.gov/19456212 DM9JXB7 DI DM9JXB7 DM9JXB7 DN Retapamulin DM9JXB7 TI TTUWYEA DM9JXB7 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM9JXB7 MA Inhibitor DM9JXB7 RN Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7. DM9JXB7 RU https://pubmed.ncbi.nlm.nih.gov/17562806 DM9KHZL DI DM9KHZL DM9KHZL DN Heparin Sodium DM9KHZL TI TT4QPUL DM9KHZL TN Antithrombin-III (ATIII) DM9KHZL MA Modulator DM9KHZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DM9KHZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DM9KJLZ DI DM9KJLZ DM9KJLZ DN Foscavir DM9KJLZ TI TTIU7X1 DM9KJLZ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM9KJLZ MA Inhibitor DM9KJLZ RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DM9KJLZ RU https://pubmed.ncbi.nlm.nih.gov/19275707 DM9KZDO DI DM9KZDO DM9KZDO DN Esterified estrogens DM9KZDO TI TTZAYWL DM9KZDO TN Estrogen receptor (ESR) DM9KZDO MA Modulator DM9KZDO RN Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8. DM9KZDO RU https://pubmed.ncbi.nlm.nih.gov/20850731 DM9NJ52 DI DM9NJ52 DM9NJ52 DN Fosinopril DM9NJ52 TI TTL69WB DM9NJ52 TN Angiotensin-converting enzyme (ACE) DM9NJ52 MA Inhibitor DM9NJ52 RN Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8. DM9NJ52 RU https://pubmed.ncbi.nlm.nih.gov/19185642 DM9NSWT DI DM9NSWT DM9NSWT DN Guanethidine DM9NSWT TI TTT04VN DM9NSWT TN Adrenergic neuron (AD neuro) DM9NSWT MA Blocker DM9NSWT RN Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70. DM9NSWT RU https://pubmed.ncbi.nlm.nih.gov/19646091 DM9O8DT DI DM9O8DT DM9O8DT DN L-tyrosine DM9O8DT TI TTUHP71 DM9O8DT TN Tyrosine 3-monooxygenase (TH) DM9O8DT MA Binder DM9O8DT RN Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5. DM9O8DT RU https://pubmed.ncbi.nlm.nih.gov/16581181 DM9OZWQ DI DM9OZWQ DM9OZWQ DN Lovastatin DM9OZWQ TI TTPADOQ DM9OZWQ TN HMG-CoA reductase (HMGCR) DM9OZWQ MA Inhibitor DM9OZWQ RN Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46. DM9OZWQ RU https://pubmed.ncbi.nlm.nih.gov/12082550 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH TI TT34BHT DM9PLRH TN Adrenergic receptor alpha-1D (ADRA1D) DM9PLRH MA Antagonist DM9PLRH RN The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. DM9PLRH RU https://pubmed.ncbi.nlm.nih.gov/19002123 DM9PVX8 DI DM9PVX8 DM9PVX8 DN Rucaparib DM9PVX8 TI TTEBCY8 DM9PVX8 TN Poly [ADP-ribose] polymerase (PARP) DM9PVX8 MA Modulator DM9PVX8 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM9PVX8 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM9Q8SO DI DM9Q8SO DM9Q8SO DN Fibrinolysin DM9Q8SO TI TTWODQF DM9Q8SO TN Fibrin (FG) DM9Q8SO MA Modulator DM9Q8SO RN FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2. DM9Q8SO RU https://pubmed.ncbi.nlm.nih.gov/14075642 DM9QWAH DI DM9QWAH DM9QWAH DN Ceftolozane/tazobactam DM9QWAH TI TTHI19T DM9QWAH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM9QWAH MA Modulator DM9QWAH RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM9QWAH RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TTS087L DM9S2JW TN Solute carrier family 12 member 1 (SLC12A1) DM9S2JW MA Blocker DM9S2JW RN Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/18769054 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TT26PHO DM9S2JW TN Mineralocorticoid receptor (MR) DM9S2JW MA Agonist DM9S2JW RN Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/16188378 DM9U4FO DI DM9U4FO DM9U4FO DN Benzonatate DM9U4FO TI TTZOVE0 DM9U4FO TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM9U4FO MA Blocker DM9U4FO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9U4FO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9UB0P DI DM9UB0P DM9UB0P DN Oxaprozin DM9UB0P TI TTK0943 DM9UB0P TN Prostaglandin G/H synthase (COX) DM9UB0P MA Inhibitor DM9UB0P RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DM9UB0P RU https://pubmed.ncbi.nlm.nih.gov/17409433 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK TI TT4ILYC DM9UCJK TN Bacterial Dihydropteroate synthetase (Bact folP) DM9UCJK MA Inhibitor DM9UCJK RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM9UCJK RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM9UTDE DI DM9UTDE DM9UTDE DN Morniflumate DM9UTDE TI TTK0943 DM9UTDE TN Prostaglandin G/H synthase (COX) DM9UTDE MA Modulator DM9UTDE RN Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. DM9UTDE RU https://pubmed.ncbi.nlm.nih.gov/1659152 DM9Y6X7 DI DM9Y6X7 DM9Y6X7 DN Clodronate DM9Y6X7 TI TTU5A6Q DM9Y6X7 TN Adenine nucleotide translocator 1 (SLC25A4) DM9Y6X7 MA Inhibitor DM9Y6X7 RN Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. DM9Y6X7 RU https://pubmed.ncbi.nlm.nih.gov/11961144 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TT3ROYC DM9YSNQ TN Serotonin transporter (SERT) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TTAWNKZ DM9YSNQ TN Norepinephrine transporter (NET) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9ZMQH DI DM9ZMQH DM9ZMQH DN Clocortolone DM9ZMQH TI TT9V5JH DM9ZMQH TN Phospholipase A2 (PLA2G1B) DM9ZMQH MA Inducer DM9ZMQH RN Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8. DM9ZMQH RU https://pubmed.ncbi.nlm.nih.gov/6986236 DMA04JS DI DMA04JS DMA04JS DN Antazoline DMA04JS TI TTTIBOJ DMA04JS TN Histamine H1 receptor (H1R) DMA04JS MA Antagonist DMA04JS RN Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6. DMA04JS RU https://pubmed.ncbi.nlm.nih.gov/19205365 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD TI TTIU7X1 DMA13GD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMA13GD MA Modulator DMA13GD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA13GD RU https://www.fda.gov/ DMA16BR DI DMA16BR DMA16BR DN Vorapaxar DMA16BR TI TTL935N DMA16BR TN Proteinase activated receptor 1 (F2R) DMA16BR MA Antagonist DMA16BR RN In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8. DMA16BR RU https://pubmed.ncbi.nlm.nih.gov/19572350 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 TI TTANPDJ DMA17D0 TN Carbonic anhydrase II (CA-II) DMA17D0 MA Inhibitor DMA17D0 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMA17D0 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTN9VTF DMA2GHJ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTCRJKY DMA2GHJ TN Voltage-gated calcium channel (Cav) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2Z4F DI DMA2Z4F DMA2Z4F DN Minoxidil DMA2Z4F TI TT1VOHK DMA2Z4F TN Potassium channel unspecific (KC) DMA2Z4F MA Modulator DMA2Z4F RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA2Z4F RU https://www.fda.gov/ DMA47C6 DI DMA47C6 DMA47C6 DN Rimiterol DMA47C6 TI TTMXGCW DMA47C6 TN Adrenergic receptor beta-3 (ADRB3) DMA47C6 MA Modulator DMA47C6 RN Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8. DMA47C6 RU https://pubmed.ncbi.nlm.nih.gov/10940 DMA4MRX DI DMA4MRX DMA4MRX DN Perphenazine DMA4MRX TI TTEX248 DMA4MRX TN Dopamine D2 receptor (D2R) DMA4MRX MA Antagonist DMA4MRX RN CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93. DMA4MRX RU https://pubmed.ncbi.nlm.nih.gov/18075468 DMA5OBU DI DMA5OBU DMA5OBU DN Human neutral insulin DMA5OBU TI TTCBFJO DMA5OBU TN Insulin receptor (INSR) DMA5OBU MA Binder DMA5OBU RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMA5OBU RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMA5QPM DI DMA5QPM DMA5QPM DN Zemaira DMA5QPM TI TTA7UJC DMA5QPM TN Alpha-1-antitrypsin (SERPINA1) DMA5QPM MA Inhibitor DMA5QPM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMA5QPM RU https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira DMA5XGH DI DMA5XGH DMA5XGH DN Isradipine DMA5XGH TI TT5HONZ DMA5XGH TN Calcium channel unspecific (CaC) DMA5XGH MA Modulator DMA5XGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA5XGH RU https://www.fda.gov/ DMA630M DI DMA630M DMA630M DN Vaccinia immune globulin DMA630M TI TTOP3CH DMA630M TN Immunoglobulin unspecific (Ig) DMA630M MA Modulator DMA630M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMA630M RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMA65ER DI DMA65ER DMA65ER DN Nipradilol DMA65ER TI TTMXGCW DMA65ER TN Adrenergic receptor beta-3 (ADRB3) DMA65ER MA Modulator DMA65ER RN Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69. DMA65ER RU https://pubmed.ncbi.nlm.nih.gov/6150128 DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TT4C8EA DMA6S1D TN Dopamine D3 receptor (D3R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TTEX248 DMA6S1D TN Dopamine D2 receptor (D2R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA7PEW DI DMA7PEW DMA7PEW DN Verapamil DMA7PEW TI TT729IR DMA7PEW TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMA7PEW MA Blocker DMA7PEW RN Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93. DMA7PEW RU https://pubmed.ncbi.nlm.nih.gov/15821157 DMA7QTC DI DMA7QTC DMA7QTC DN Lactoferrin DMA7QTC TI TTM1TDX DMA7QTC TN Tryptase alpha/beta-1 (Tryptase) DMA7QTC MA Inhibitor DMA7QTC RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMA7QTC RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMA8DPN DI DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN TI TTTIBOJ DMA8DPN TN Histamine H1 receptor (H1R) DMA8DPN MA Modulator DMA8DPN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA8DPN RU https://www.fda.gov/ DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TTW0CMT DMA8FS5 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMA8FS5 MA Blocker DMA8FS5 RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TT1VOHK DMA8FS5 TN Potassium channel unspecific (KC) DMA8FS5 MA Inhibitor DMA8FS5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMA8J1G DI DMA8J1G DMA8J1G DN Rifampin DMA8J1G TI TTIJ5EB DMA8J1G TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMA8J1G MA Inhibitor DMA8J1G RN Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67. DMA8J1G RU https://pubmed.ncbi.nlm.nih.gov/11751823 DMA8LM5 DI DMA8LM5 DMA8LM5 DN Cyclopentolate DMA8LM5 TI TTH18TF DMA8LM5 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMA8LM5 MA Antagonist DMA8LM5 RN High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76. DMA8LM5 RU https://pubmed.ncbi.nlm.nih.gov/19486927 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTKWM86 DMA9DHW TN Opioid receptor mu (MOP) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTQW87Y DMA9DHW TN Opioid receptor kappa (OPRK1) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9REV DI DMA9REV DMA9REV DN Elosulfase alfa DMA9REV TI TTT9YPO DMA9REV TN N-acetylgalactosamine 6 sulfatase (GALNS) DMA9REV MA Modulator DMA9REV RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMA9REV RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAB6PM DI DMAB6PM DMAB6PM DN Factor 8 DMAB6PM TI TT1290U DMAB6PM TN Coagulation factor VIII (F8) DMAB6PM MA Modulator DMAB6PM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMAB6PM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMAB9QE DI DMAB9QE DMAB9QE DN Nivolumab DMAB9QE TI TTNBFWK DMAB9QE TN Programmed cell death protein 1 (PD-1) DMAB9QE MA Modulator DMAB9QE RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAB9QE RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMABVE9 DI DMABVE9 DMABVE9 DN Sulfanilamide DMABVE9 TI TT4ILYC DMABVE9 TN Bacterial Dihydropteroate synthetase (Bact folP) DMABVE9 MA Modulator DMABVE9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMABVE9 RU https://www.fda.gov/ DMAC130 DI DMAC130 DMAC130 DN Inotuzumab ozogamicin DMAC130 TI TTM6QSK DMAC130 TN B-cell receptor CD22 (CD22) DMAC130 RN Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36. DMAC130 RU https://pubmed.ncbi.nlm.nih.gov/23633004 DMAE6LK DI DMAE6LK DMAE6LK DN Topetecan DMAE6LK TI TTGTQHC DMAE6LK TN DNA topoisomerase I (TOP1) DMAE6LK MA Inhibitor DMAE6LK RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMAE6LK RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMAE84F DI DMAE84F DMAE84F DN Alclometasone DMAE84F TI TTJL8VG DMAE84F TN Corticosteroid-binding globulin (SERPINA6) DMAE84F MA Binder DMAE84F RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DMAE84F RU https://pubmed.ncbi.nlm.nih.gov/2508442 DMAF1NB DI DMAF1NB DMAF1NB DN Isocarboxazid DMAF1NB TI TT3WG5C DMAF1NB TN Monoamine oxidase type A (MAO-A) DMAF1NB MA Inhibitor DMAF1NB RN MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. DMAF1NB RU https://pubmed.ncbi.nlm.nih.gov/7612154 DMAFBCY DI DMAFBCY DMAFBCY DN Mequitazine DMAFBCY TI TTTIBOJ DMAFBCY TN Histamine H1 receptor (H1R) DMAFBCY MA Antagonist DMAFBCY RN Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. DMAFBCY RU https://pubmed.ncbi.nlm.nih.gov/18697448 DMAGFOD DI DMAGFOD DMAGFOD DN Semaglutide DMAGFOD TI TTVIMDE DMAGFOD TN Glucagon-like peptide 1 receptor (GLP1R) DMAGFOD MA Agonist DMAGFOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAGFOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMAH70G DI DMAH70G DMAH70G DN Molindone DMAH70G TI TTEX248 DMAH70G TN Dopamine D2 receptor (D2R) DMAH70G MA Binder DMAH70G RN Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083. DMAH70G RU https://pubmed.ncbi.nlm.nih.gov/17253473 DMAHEFY DI DMAHEFY DMAHEFY DN Nafarelin DMAHEFY TI TT8R70G DMAHEFY TN Gonadotropin-releasing hormone receptor (GNRHR) DMAHEFY MA Agonist DMAHEFY RN Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45. DMAHEFY RU https://pubmed.ncbi.nlm.nih.gov/19233456 DMAHJEF DI DMAHJEF DMAHJEF DN Betamethasone DMAHJEF TI TTYRL6O DMAHJEF TN Glucocorticoid receptor (NR3C1) DMAHJEF MA Agonist DMAHJEF RN The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. DMAHJEF RU https://pubmed.ncbi.nlm.nih.gov/16824511 DMAHMT9 DI DMAHMT9 DMAHMT9 DN Glutathione DMAHMT9 TI TT3C1VN DMAHMT9 TN Enzyme unspecific (Enz) DMAHMT9 MA Modulator DMAHMT9 RN Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41. DMAHMT9 RU https://pubmed.ncbi.nlm.nih.gov/9372907 DMAHOVJ DI DMAHOVJ DMAHOVJ DN Crizanlizumab DMAHOVJ TI TTE5VG0 DMAHOVJ TN P-selectin (SELP) DMAHOVJ MA Inhibitor DMAHOVJ RN Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. DMAHOVJ RU https://pubmed.ncbi.nlm.nih.gov/31933169 DMAHSU0 DI DMAHSU0 DMAHSU0 DN Selexipag DMAHSU0 TI TTOFYT1 DMAHSU0 TN Prostacyclin receptor (PTGIR) DMAHSU0 MA Agonist DMAHSU0 RN Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80. DMAHSU0 RU https://pubmed.ncbi.nlm.nih.gov/22362844 DMAHZKR DI DMAHZKR DMAHZKR DN Protokylol Hydrochloride DMAHZKR TI TTR6W5O DMAHZKR TN Adrenergic receptor beta-1 (ADRB1) DMAHZKR MA Modulator DMAHZKR RN N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. DMAHZKR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668481 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV TI TTFK1JQ DMAI7ZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMAI7ZV MA Blocker DMAI7ZV RN Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24. DMAI7ZV RU https://pubmed.ncbi.nlm.nih.gov/19590189 DMAKIDV DI DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV TI TTUV8G9 DMAKIDV TN Progesterone receptor (PGR) DMAKIDV MA Agonist DMAKIDV RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMAKIDV RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMAKXW9 DI DMAKXW9 DMAKXW9 DN PLEGRIDY DMAKXW9 TI TT4TZ8J DMAKXW9 TN Interferon-beta (IFNB1) DMAKXW9 MA Modulator DMAKXW9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAKXW9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 TI TTPTXIN DMAL4G0 TN Translocator protein (TSPO) DMAL4G0 MA Modulator DMAL4G0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAL4G0 RU https://www.fda.gov/ DMALNG0 DI DMALNG0 DMALNG0 DN RHuEPO DMALNG0 TI TTAUX24 DMALNG0 TN Erythropoietin Receptor (EPOR) DMALNG0 MA Stimulator DMALNG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMALNG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMANBR7 DI DMANBR7 DMANBR7 DN L-alanyl-l-glutamine DMANBR7 TI TTI7S12 DMANBR7 TN Glutamine receptor (GluR) DMANBR7 MA Modulator DMANBR7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMANBR7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI TI TTRA5BZ DMANBZI TN Steroid 17-alpha-monooxygenase (S17AH) DMANBZI MA Modulator DMANBZI RN CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/25560485 DMANL0D DI DMANL0D DMANL0D DN Latamoxef DMANL0D TI TT85JMW DMANL0D TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMANL0D MA Binder DMANL0D RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DMANL0D RU https://pubmed.ncbi.nlm.nih.gov/9841767 DMAO80I DI DMAO80I DMAO80I DN Pralatrexate DMAO80I TI TT9SL3Q DMAO80I TN Polypeptide deformylase (PDF) DMAO80I MA Inhibitor DMAO80I RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMAO80I RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMAOL2S DI DMAOL2S DMAOL2S DN Voriconazole DMAOL2S TI TTTSOUD DMAOL2S TN Candida Cytochrome P450 51 (Candi ERG11) DMAOL2S MA Modulator DMAOL2S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAOL2S RU https://www.fda.gov/ DMAP58Y DI DMAP58Y DMAP58Y DN Peginterferon alfa-2b DMAP58Y TI TTSIUJ9 DMAP58Y TN Interferon-alpha 2 (IFNA2) DMAP58Y MA Modulator DMAP58Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAP58Y RU https://www.fda.gov/ DMAP8MV DI DMAP8MV DMAP8MV DN Iron DMAP8MV TI TTQO71U DMAP8MV TN Hemoglobin (HB) DMAP8MV MA Activator DMAP8MV RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DMAP8MV RU https://pubmed.ncbi.nlm.nih.gov/18760066 DMAPV1B DI DMAPV1B DMAPV1B DN Glatiramer acetate DMAPV1B TI TTLCMWF DMAPV1B TN MHC class II antigen DRB1*1 (HLA-DRB1) DMAPV1B MA Binder DMAPV1B RN Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. DMAPV1B RU https://pubmed.ncbi.nlm.nih.gov/15371592 DMAQ2LK DI DMAQ2LK DMAQ2LK DN Teicoplanin DMAQ2LK TI TTXT4D5 DMAQ2LK TN Bacterial Cell membrane (Bact CM) DMAQ2LK MA Inhibitor DMAQ2LK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAQ2LK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAQ469 DI DMAQ469 DMAQ469 DN Gonadorelin DMAQ469 TI TT8R70G DMAQ469 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAQ469 MA Agonist DMAQ469 RN Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29. DMAQ469 RU https://pubmed.ncbi.nlm.nih.gov/17308138 DMAS02L DI DMAS02L DMAS02L DN Alpha-acetyldigoxin DMAS02L TI TTYHPRQ DMAS02L TN Sodium pump (NaP) DMAS02L MA Modulator DMAS02L RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMAS02L RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TTG0MT6 DMASDQ6 TN Interleukin-17 (IL17) DMASDQ6 MA Modulator DMASDQ6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMASDQ6 RU https://www.fda.gov/ DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TT69OHW DMASDQ6 TN Interleukin 17 receptor (IL17R) DMASDQ6 MA Antagonist DMASDQ6 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMASDQ6 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMAT2XH DI DMAT2XH DMAT2XH DN Nabumetone DMAT2XH TI TTVKILB DMAT2XH TN Prostaglandin G/H synthase 2 (COX-2) DMAT2XH MA Inhibitor DMAT2XH RN Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96. DMAT2XH RU https://pubmed.ncbi.nlm.nih.gov/11701998 DMAT8CG DI DMAT8CG DMAT8CG DN Goserelin DMAT8CG TI TT0ID4A DMAT8CG TN Leutinizing-hormone-releasing hormone (GNRH1) DMAT8CG MA Activator DMAT8CG RN Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9. DMAT8CG RU https://pubmed.ncbi.nlm.nih.gov/19244174 DMAUHQX DI DMAUHQX DMAUHQX DN Methdilazine DMAUHQX TI TTTIBOJ DMAUHQX TN Histamine H1 receptor (H1R) DMAUHQX MA Antagonist DMAUHQX RN Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4. DMAUHQX RU https://pubmed.ncbi.nlm.nih.gov/2858829 DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TTUDR0C DMAWJIN TN Iron (Fe) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TT8X5NO DMAWJIN TN Calcium (Ca) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWU35 DI DMAWU35 DMAWU35 DN Amtolmetin guacil DMAWU35 TI TTK0943 DMAWU35 TN Prostaglandin G/H synthase (COX) DMAWU35 MA Modulator DMAWU35 RN Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18. DMAWU35 RU https://pubmed.ncbi.nlm.nih.gov/16396699 DMAY7H4 DI DMAY7H4 DMAY7H4 DN Valdecoxib DMAY7H4 TI TTVKILB DMAY7H4 TN Prostaglandin G/H synthase 2 (COX-2) DMAY7H4 MA Inhibitor DMAY7H4 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DMAY7H4 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DMAY96V DI DMAY96V DMAY96V DN Methacycline DMAY96V TI TTQ8KVI DMAY96V TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMAY96V MA Binder DMAY96V RN Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6. DMAY96V RU https://pubmed.ncbi.nlm.nih.gov/18220943 DMAYEU1 DI DMAYEU1 DMAYEU1 DN Demecarium bromide DMAYEU1 TI TT1RS9F DMAYEU1 TN Acetylcholinesterase (AChE) DMAYEU1 MA Inhibitor DMAYEU1 RN The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. DMAYEU1 RU https://pubmed.ncbi.nlm.nih.gov/12641839 DMAYL0T DI DMAYL0T DMAYL0T DN Phenylbutazone DMAYL0T TI TTVKILB DMAYL0T TN Prostaglandin G/H synthase 2 (COX-2) DMAYL0T MA Inhibitor DMAYL0T RN COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. DMAYL0T RU https://pubmed.ncbi.nlm.nih.gov/15939622 DMAYX6P DI DMAYX6P DMAYX6P DN Sulfoxone DMAYX6P TI TT915ZD DMAYX6P TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMAYX6P MA Inhibitor DMAYX6P RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMAYX6P RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMB08GE DI DMB08GE DMB08GE DN Sulfamethoxazole DMB08GE TI TT4ILYC DMB08GE TN Bacterial Dihydropteroate synthetase (Bact folP) DMB08GE MA Inhibitor DMB08GE RN In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52. DMB08GE RU https://pubmed.ncbi.nlm.nih.gov/7786001 DMB0EUX DI DMB0EUX DMB0EUX DN Gliquidone DMB0EUX TI TTG140O DMB0EUX TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMB0EUX MA Binder DMB0EUX RN Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. DMB0EUX RU https://pubmed.ncbi.nlm.nih.gov/12670661 DMB0VY8 DI DMB0VY8 DMB0VY8 DN Pancuronium DMB0VY8 TI TTJSZTB DMB0VY8 TN Nicotinic acetylcholine receptor (nAChR) DMB0VY8 MA Antagonist DMB0VY8 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMB0VY8 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTZ9SOR DMB19L8 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMB19L8 MA Antagonist DMB19L8 RN The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/18685832 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTMXGCW DMB19L8 TN Adrenergic receptor beta-3 (ADRB3) DMB19L8 MA Agonist DMB19L8 RN Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/19199918 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTQ8AFT DMB1CZ8 TN Adrenergic receptor Alpha-2 (ADRA2) DMB1CZ8 MA Agonist DMB1CZ8 RN Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17874970 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TT7QNVC DMB1CZ8 TN Glucose-dependent insulinotropic receptor (GPR119) DMB1CZ8 MA Agonist DMB1CZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMB1CZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTNET8J DMB1CZ8 TN G-protein coupled receptor 55 (GPR55) DMB1CZ8 MA Agonist DMB1CZ8 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTMSFAW DMB1CZ8 TN Cannabinoid receptor 2 (CB2) DMB1CZ8 MA Agonist DMB1CZ8 RN Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/18524639 DMB1IU4 DI DMB1IU4 DMB1IU4 DN Lenvatinib DMB1IU4 TI TTUTJGQ DMB1IU4 TN Vascular endothelial growth factor receptor 2 (KDR) DMB1IU4 MA Inhibitor DMB1IU4 RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DMB1IU4 RU https://pubmed.ncbi.nlm.nih.gov/18764727 DMB39LO DI DMB39LO DMB39LO DN Metolazone DMB39LO TI TTP362L DMB39LO TN Solute carrier family 12 member 3 (SLC12A3) DMB39LO MA Blocker DMB39LO RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMB39LO RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMB3ZSK DI DMB3ZSK DMB3ZSK DN Deslanoside DMB3ZSK TI TTWK8D0 DMB3ZSK TN Sodium pump subunit alpha-1 (ATP1A1) DMB3ZSK MA Binder DMB3ZSK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB3ZSK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB47TQ DI DMB47TQ DMB47TQ DN Alseroxylon DMB47TQ TI TTNZRI3 DMB47TQ TN Synaptic vesicle amine transporter (SLC18A2) DMB47TQ MA Blocker DMB47TQ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMB47TQ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMB4AVP DI DMB4AVP DMB4AVP DN Pamidronate DMB4AVP TI TTIKWV4 DMB4AVP TN Geranyltranstransferase (FDPS) DMB4AVP MA Inhibitor DMB4AVP RN Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24. DMB4AVP RU https://pubmed.ncbi.nlm.nih.gov/18782552 DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTN6J5F DMB4HCT TN Bacterial DNA gyrase (Bact gyrase) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTIXTO3 DMB4HCT TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HFI DI DMB4HFI DMB4HFI DN Alkavervir DMB4HFI TI TTNZRI3 DMB4HFI TN Synaptic vesicle amine transporter (SLC18A2) DMB4HFI MA Modulator DMB4HFI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HFI RU https://www.fda.gov/ DMB4OLE DI DMB4OLE DMB4OLE DN Propofol DMB4OLE TI TTDP1UC DMB4OLE TN Fatty acid amide hydrolase (FAAH) DMB4OLE MA Inhibitor DMB4OLE RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMB4OLE RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMB4SFH DI DMB4SFH DMB4SFH DN Mepyramine DMB4SFH TI TTTIBOJ DMB4SFH TN Histamine H1 receptor (H1R) DMB4SFH MA Antagonist DMB4SFH RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DMB4SFH RU https://pubmed.ncbi.nlm.nih.gov/19552055 DMB6VEG DI DMB6VEG DMB6VEG DN Nelarabine DMB6VEG TI TTUBNVO DMB6VEG TN DNA synthesis (DNA synth) DMB6VEG MA Binder DMB6VEG RN Nelarabine. Drugs. 2008;68(4):439-47. DMB6VEG RU https://pubmed.ncbi.nlm.nih.gov/18318562 DMB8CNL DI DMB8CNL DMB8CNL DN Lindane DMB8CNL TI TTAN6JD DMB8CNL TN Glutamate receptor AMPA (GRIA) DMB8CNL MA Antagonist DMB8CNL RN NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20. DMB8CNL RU https://pubmed.ncbi.nlm.nih.gov/18834901 DMB8PF3 DI DMB8PF3 DMB8PF3 DN CT-102 DMB8PF3 TI TTI2WET DMB8PF3 TN Platelet-derived growth factor receptor (PDGFR) DMB8PF3 MA Activator DMB8PF3 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMB8PF3 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMB920Z DI DMB920Z DMB920Z DN Ceritinib DMB920Z TI TTPMQSO DMB920Z TN ALK tyrosine kinase receptor (ALK) DMB920Z MA Modulator DMB920Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397). DMB920Z RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397 DMBAPFG DI DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG TI TTZHA0O DMBAPFG TN Carbonic anhydrase IV (CA-IV) DMBAPFG MA Modulator DMBAPFG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBAPFG RU https://www.fda.gov/ DMBAUED DI DMBAUED DMBAUED DN Anileridine DMBAUED TI TTKWM86 DMBAUED TN Opioid receptor mu (MOP) DMBAUED MA Agonist DMBAUED RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMBAUED RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMBCM8L DI DMBCM8L DMBCM8L DN Nicergoline DMBCM8L TI TTQ8AFT DMBCM8L TN Adrenergic receptor Alpha-2 (ADRA2) DMBCM8L MA Antagonist DMBCM8L RN Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35. DMBCM8L RU https://pubmed.ncbi.nlm.nih.gov/16201147 DMBCYF5 DI DMBCYF5 DMBCYF5 DN Pirmenol DMBCYF5 TI TTRK8B9 DMBCYF5 TN Sodium channel unspecific (NaC) DMBCYF5 MA Modulator DMBCYF5 RN Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71. DMBCYF5 RU https://pubmed.ncbi.nlm.nih.gov/2164163 DMBDAZV DI DMBDAZV DMBDAZV DN Amlodipine DMBDAZV TI TTFK1JQ DMBDAZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMBDAZV MA Blocker DMBDAZV RN A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. DMBDAZV RU https://pubmed.ncbi.nlm.nih.gov/18217647 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 TI TTEX248 DMBDPY0 TN Dopamine D2 receptor (D2R) DMBDPY0 MA Antagonist DMBDPY0 RN Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. DMBDPY0 RU https://pubmed.ncbi.nlm.nih.gov/18970411 DMBEP7G DI DMBEP7G DMBEP7G DN Fomivirsen sodium DMBEP7G TI TT4SCBE DMBEP7G TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMBEP7G MA Modulator DMBEP7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBEP7G RU https://www.fda.gov/ DMBESUA DI DMBESUA DMBESUA DN Tucatinib DMBESUA TI TT6EO5L DMBESUA TN Erbb2 tyrosine kinase receptor (HER2) DMBESUA MA Inhibitor DMBESUA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBESUA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf DMBEX4O DI DMBEX4O DMBEX4O DN Methylergonovine DMBEX4O TI TTZFYLI DMBEX4O TN Dopamine D1 receptor (D1R) DMBEX4O MA Antagonist DMBEX4O RN Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. DMBEX4O RU https://pubmed.ncbi.nlm.nih.gov/15930499 DMBFE74 DI DMBFE74 DMBFE74 DN Milnacipran DMBFE74 TI TTAWNKZ DMBFE74 TN Norepinephrine transporter (NET) DMBFE74 MA Inhibitor DMBFE74 RN Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63. DMBFE74 RU https://pubmed.ncbi.nlm.nih.gov/19620845 DMBFZ6L DI DMBFZ6L DMBFZ6L DN Remdesivir DMBFZ6L TI TTV1095 DMBFZ6L TN COVID-19 RNA-directed RNA polymerase (RdRp) DMBFZ6L MA Inhibitor DMBFZ6L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBFZ6L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf DMBGWPH DI DMBGWPH DMBGWPH DN Medroxyprogesterone DMBGWPH TI TTUV8G9 DMBGWPH TN Progesterone receptor (PGR) DMBGWPH MA Agonist DMBGWPH RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMBGWPH RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 TI TTEX248 DMBGZI3 TN Dopamine D2 receptor (D2R) DMBGZI3 MA Antagonist DMBGZI3 RN Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. DMBGZI3 RU https://pubmed.ncbi.nlm.nih.gov/19374860 DMBHMOX DI DMBHMOX DMBHMOX DN Palonosetron DMBHMOX TI TTPC4TU DMBHMOX TN 5-HT 3A receptor (HTR3A) DMBHMOX MA Antagonist DMBHMOX RN Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34. DMBHMOX RU https://pubmed.ncbi.nlm.nih.gov/19436621 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y TI TTPTXIN DMBHO9Y TN Translocator protein (TSPO) DMBHO9Y MA Agonist DMBHO9Y RN Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22. DMBHO9Y RU https://pubmed.ncbi.nlm.nih.gov/10357248 DMBI4JG DI DMBI4JG DMBI4JG DN Isosorbide dinitrate DMBI4JG TI TT6HPVC DMBI4JG TN Guanylate cyclase (GC) DMBI4JG MA Stimulator DMBI4JG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMBI4JG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMBI9ZJ DI DMBI9ZJ DMBI9ZJ DN Falecalcitrol DMBI9ZJ TI TTK59TV DMBI9ZJ TN Vitamin D3 receptor (VDR) DMBI9ZJ MA Agonist DMBI9ZJ RN Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66. DMBI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/11003160 DMBIYNH DI DMBIYNH DMBIYNH DN ETI-204 DMBIYNH TI TTRLPUB DMBIYNH TN Bacillus anthracis Protective antigen (Anthrax PA) DMBIYNH RN Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. DMBIYNH RU https://pubmed.ncbi.nlm.nih.gov/25645849 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TT06AWU DMBKX3C TN Phosphodiesterase 3A (PDE3A) DMBKX3C MA Inhibitor DMBKX3C RN Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/20005117 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TTQ6VDM DMBKX3C TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMBKX3C MA Inhibitor DMBKX3C RN Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/12873512 DMBL79I DI DMBL79I DMBL79I DN Proguanil DMBL79I TI TT9SL3Q DMBL79I TN Polypeptide deformylase (PDF) DMBL79I MA Inhibitor DMBL79I RN Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6. DMBL79I RU https://pubmed.ncbi.nlm.nih.gov/9380737 DMBLX7U DI DMBLX7U DMBLX7U DN Evinacumab DMBLX7U TI TTUO98L DMBLX7U TN Angiopoietin-related protein 3 (ANGPTL3) DMBLX7U MA Inhibitor DMBLX7U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMBLX7U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf DMBMUWZ DI DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ TI TT84ETX DMBMUWZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBMUWZ MA Modulator DMBMUWZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMBMUWZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMBNI20 DI DMBNI20 DMBNI20 DN Ulipristal DMBNI20 TI TTUV8G9 DMBNI20 TN Progesterone receptor (PGR) DMBNI20 MA Modulator DMBNI20 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMBNI20 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMBNKST DI DMBNKST DMBNKST DN Nadroparin calcium DMBNKST TI TTCIHJA DMBNKST TN Coagulation factor Xa (F10) DMBNKST MA Modulator DMBNKST RN Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81. DMBNKST RU https://pubmed.ncbi.nlm.nih.gov/113585 DMBP5N3 DI DMBP5N3 DMBP5N3 DN Cantharidin DMBP5N3 TI TTFLH0E DMBP5N3 TN Serine/threonine PP1-alpha (PPP1CA) DMBP5N3 MA Inhibitor DMBP5N3 RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMBP5N3 RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMBQEGT DI DMBQEGT DMBQEGT DN Buprenorphine + naloxone DMBQEGT TI TTKWM86 DMBQEGT TN Opioid receptor mu (MOP) DMBQEGT MA Agonist DMBQEGT RN Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. DMBQEGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/ DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X TI TTZ1DT0 DMBR01X TN P2Y purinoceptor 12 (P2RY12) DMBR01X MA Antagonist DMBR01X RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMBR01X RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMBR5Q7 DI DMBR5Q7 DMBR5Q7 DN Rolitetracycline DMBR5Q7 TI TTQ8KVI DMBR5Q7 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMBR5Q7 MA Binder DMBR5Q7 RN Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16. DMBR5Q7 RU https://pubmed.ncbi.nlm.nih.gov/18501371 DMBS370 DI DMBS370 DMBS370 DN Tofacitinib DMBS370 TI TTT7PJU DMBS370 TN Janus kinase 3 (JAK-3) DMBS370 MA Modulator DMBS370 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMBS370 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 TI TTSQIFT DMBS632 TN 5-HT 1A receptor (HTR1A) DMBS632 MA Agonist DMBS632 RN Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204. DMBS632 RU https://pubmed.ncbi.nlm.nih.gov/16594259 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF TI TTHC7JD DMBSHMF TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMBSHMF MA Modulator DMBSHMF RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMBSHMF RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMBSK7X DI DMBSK7X DMBSK7X DN Isoflurophate DMBSK7X TI TT1RS9F DMBSK7X TN Acetylcholinesterase (AChE) DMBSK7X MA Inhibitor DMBSK7X RN Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502. DMBSK7X RU https://pubmed.ncbi.nlm.nih.gov/12837382 DMBSXI0 DI DMBSXI0 DMBSXI0 DN Dienestrol DMBSXI0 TI TTZAYWL DMBSXI0 TN Estrogen receptor (ESR) DMBSXI0 MA Agonist DMBSXI0 RN Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. DMBSXI0 RU https://pubmed.ncbi.nlm.nih.gov/18976723 DMBT3AI DI DMBT3AI DMBT3AI DN Belantamab mafodotin DMBT3AI TI TTZ3P4W DMBT3AI TN B-cell maturation protein (TNFRSF17) DMBT3AI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBT3AI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf DMBT7MI DI DMBT7MI DMBT7MI DN Gentamicine sulfate DMBT7MI TI TTUWYEA DMBT7MI TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMBT7MI MA Binder DMBT7MI RN The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9. DMBT7MI RU https://pubmed.ncbi.nlm.nih.gov/12217690 DMBUH26 DI DMBUH26 DMBUH26 DN Rituximab DMBUH26 TI TTUE541 DMBUH26 TN Leukocyte surface antigen Leu-16 (CD20) DMBUH26 RN [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8. DMBUH26 RU https://pubmed.ncbi.nlm.nih.gov/19061730 DMBUNVW DI DMBUNVW DMBUNVW DN Prednicarbate DMBUNVW TI TTP3UTW DMBUNVW TN Steroid hormone receptor ERR (ESRR) DMBUNVW MA Modulator DMBUNVW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBUNVW RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTTSEPU DMBVEC7 TN Thyroid hormone receptor alpha (THRA) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTGER3L DMBVEC7 TN Thyroid hormone receptor beta (THRB) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBW7VH DI DMBW7VH DMBW7VH DN Methyprylon DMBW7VH TI TT1MPAY DMBW7VH TN GABA(A) receptor alpha-1 (GABRA1) DMBW7VH MA Antagonist DMBW7VH RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMBW7VH RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ TI TTZVSJ2 DMBXVMZ TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMBXVMZ MA Inhibitor DMBXVMZ RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMBXVMZ RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMBXWU8 DI DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 TI TTV3NH6 DMBXWU8 TN Calmodulin (CALM) DMBXWU8 MA Inhibitor DMBXWU8 RN Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. DMBXWU8 RU https://pubmed.ncbi.nlm.nih.gov/6186851 DMBYCU0 DI DMBYCU0 DMBYCU0 DN Metyrosine DMBYCU0 TI TTUHP71 DMBYCU0 TN Tyrosine 3-monooxygenase (TH) DMBYCU0 MA Binder DMBYCU0 RN Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8. DMBYCU0 RU https://pubmed.ncbi.nlm.nih.gov/1677640 DMBYNW0 DI DMBYNW0 DMBYNW0 DN MK-3475 DMBYNW0 TI TTNBFWK DMBYNW0 TN Programmed cell death protein 1 (PD-1) DMBYNW0 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMBYNW0 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMBZIVP DI DMBZIVP DMBZIVP DN Tubocurarine DMBZIVP TI TTF4E0J DMBZIVP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMBZIVP MA Antagonist DMBZIVP RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMBZIVP RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMBZWQL DI DMBZWQL DMBZWQL DN Clemastine DMBZWQL TI TTTIBOJ DMBZWQL TN Histamine H1 receptor (H1R) DMBZWQL MA Antagonist DMBZWQL RN Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. DMBZWQL RU https://pubmed.ncbi.nlm.nih.gov/18548114 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ TI TT84ETX DMC0GSJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC0GSJ MA Modulator DMC0GSJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC0GSJ RU https://www.fda.gov/ DMC128O DI DMC128O DMC128O DN Anileridine Hydrochloride DMC128O TI TTKWM86 DMC128O TN Opioid receptor mu (MOP) DMC128O MA Modulator DMC128O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC128O RU https://www.fda.gov/ DMC1NBW DI DMC1NBW DMC1NBW DN Thiazolidinedione DMC1NBW TI TTZMAO3 DMC1NBW TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMC1NBW MA Agonist DMC1NBW RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMC1NBW RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMC3JST DI DMC3JST DMC3JST DN Clorazepate DMC3JST TI TTPTXIN DMC3JST TN Translocator protein (TSPO) DMC3JST MA Modulator DMC3JST RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC3JST RU https://www.fda.gov/ DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOI92F DMC3YUA TN Multidrug resistance-associated protein 1 (ABCC1) DMC3YUA MA Stimulator DMC3YUA RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/18845662 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOJI4S DMC3YUA TN Calcium-dependent chloride channel anoctamin (ANO) DMC3YUA MA Antagonist DMC3YUA RN Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/29471754 DMC4GEI DI DMC4GEI DMC4GEI DN Ospemifene DMC4GEI TI TTZAYWL DMC4GEI TN Estrogen receptor (ESR) DMC4GEI MA Modulator DMC4GEI RN Clinical pipeline report, company report or official report of Shionogi (2011). DMC4GEI RU http://www.shionogi.co.jp/index_e.html DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME TI TTT04VN DMC50ME TN Adrenergic neuron (AD neuro) DMC50ME MA Blocker DMC50ME RN Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. DMC50ME RU https://pubmed.ncbi.nlm.nih.gov/5431666 DMC5AST DI DMC5AST DMC5AST DN Butabarbital DMC5AST TI TT1MPAY DMC5AST TN GABA(A) receptor alpha-1 (GABRA1) DMC5AST MA Antagonist DMC5AST RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMC5AST RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN TI TTPTXIN DMC7XDN TN Translocator protein (TSPO) DMC7XDN MA Agonist DMC7XDN RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMC7XDN RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTS64P2 DMC8VNH TN Androgen receptor (AR) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTVKILB DMC8VNH TN Prostaglandin G/H synthase 2 (COX-2) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT8NGED DMC8VNH TN Prostaglandin G/H synthase 1 (COX-1) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT5ZWB6 DMC8VNH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC9O43 DI DMC9O43 DMC9O43 DN Sevoflurane DMC9O43 TI TTAN6JD DMC9O43 TN Glutamate receptor AMPA (GRIA) DMC9O43 MA Antagonist DMC9O43 RN Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35. DMC9O43 RU https://pubmed.ncbi.nlm.nih.gov/19247760 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTJ0IQB DMCA9QP TN Phosphodiesterase 5A (PDE5A) DMCA9QP MA Inhibitor DMCA9QP RN Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/12646997 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTSKMI8 DMCA9QP TN Phosphodiesterase 4D (PDE4D) DMCA9QP MA Inhibitor DMCA9QP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCBJSR DI DMCBJSR DMCBJSR DN Sunitinib DMCBJSR TI TTUTJGQ DMCBJSR TN Vascular endothelial growth factor receptor 2 (KDR) DMCBJSR MA Modulator DMCBJSR RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMCBJSR RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMCD9YG DI DMCD9YG DMCD9YG DN Prazosin DMCD9YG TI TTG28O6 DMCD9YG TN Adrenergic receptor Alpha-1 (ADRA1) DMCD9YG MA Antagonist DMCD9YG RN Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33. DMCD9YG RU https://pubmed.ncbi.nlm.nih.gov/19566752 DMCDYW7 DI DMCDYW7 DMCDYW7 DN Nicardipine DMCDYW7 TI TT5HONZ DMCDYW7 TN Calcium channel unspecific (CaC) DMCDYW7 MA Blocker DMCDYW7 RN Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20. DMCDYW7 RU https://pubmed.ncbi.nlm.nih.gov/19569065 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT3WG5C DMCEUJD TN Monoamine oxidase type A (MAO-A) DMCEUJD MA Inhibitor DMCEUJD RN Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. DMCEUJD RU https://pubmed.ncbi.nlm.nih.gov/19423952 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT32XQJ DMCEUJD TN Monoamine oxidase (MAO) DMCEUJD MA Inhibitor DMCEUJD RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCEUJD RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 TI TTJP4SM DMCEW64 TN Bacterial Penicillin binding protein (Bact PBP) DMCEW64 MA Modulator DMCEW64 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCEW64 RU https://www.fda.gov/ DMCEZ1B DI DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B TI TTJSZTB DMCEZ1B TN Nicotinic acetylcholine receptor (nAChR) DMCEZ1B MA Modulator DMCEZ1B RN Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31. DMCEZ1B RU https://pubmed.ncbi.nlm.nih.gov/12008000 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTRZQE3 DMCFE9I TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCFE9I MA Inhibitor DMCFE9I RN Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/18851693 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTBH0VX DMCFE9I TN Histone deacetylase (HDAC) DMCFE9I MA Inhibitor DMCFE9I RN Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/19564914 DMCH7RU DI DMCH7RU DMCH7RU DN Pheniramine DMCH7RU TI TTTIBOJ DMCH7RU TN Histamine H1 receptor (H1R) DMCH7RU MA Antagonist DMCH7RU RN Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. DMCH7RU RU https://pubmed.ncbi.nlm.nih.gov/11526976 DMCH80F DI DMCH80F DMCH80F DN Polythiazide DMCH80F TI TTP362L DMCH80F TN Solute carrier family 12 member 3 (SLC12A3) DMCH80F MA Blocker DMCH80F RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMCH80F RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMCHV4I DI DMCHV4I DMCHV4I DN Rifapentine DMCHV4I TI TTHKJLN DMCHV4I TN DNA-directed RNA polymerase (RNAP) DMCHV4I MA Binder DMCHV4I RN Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. DMCHV4I RU https://pubmed.ncbi.nlm.nih.gov/9661035 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH TI TTCIHJA DMCIJBH TN Coagulation factor Xa (F10) DMCIJBH MA Modulator DMCIJBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359). DMCIJBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359 DMCJN1P DI DMCJN1P DMCJN1P DN Plerixafor DMCJN1P TI TTBID49 DMCJN1P TN C-X-C chemokine receptor type 4 (CXCR4) DMCJN1P MA Antagonist DMCJN1P RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMCJN1P RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMCKL5V DI DMCKL5V DMCKL5V DN Efalizumab DMCKL5V TI TT48WR6 DMCKL5V TN Integrin alpha-L (ITGAL) DMCKL5V RN [Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9. DMCKL5V RU https://pubmed.ncbi.nlm.nih.gov/19436973 DMCKPUR DI DMCKPUR DMCKPUR DN Alfaferone DMCKPUR TI TT95SOA DMCKPUR TN Interferon alpha (IFNA) DMCKPUR MA Modulator DMCKPUR RN Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7. DMCKPUR RU https://pubmed.ncbi.nlm.nih.gov/21739360 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 TI TT2CJVK DMCKYZ5 TN Adrenergic receptor beta-2 (ADRB2) DMCKYZ5 MA Agonist DMCKYZ5 RN Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. DMCKYZ5 RU https://pubmed.ncbi.nlm.nih.gov/19095863 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK TI TTB6UM0 DMCL2OK TN Fatty aldehyde dehydrogenase (ALDH3A2) DMCL2OK MA Inhibitor DMCL2OK RN Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. DMCL2OK RU https://pubmed.ncbi.nlm.nih.gov/16545872 DMCLHO0 DI DMCLHO0 DMCLHO0 DN Bethanechol DMCLHO0 TI TTH18TF DMCLHO0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCLHO0 MA Agonist DMCLHO0 RN Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97. DMCLHO0 RU https://pubmed.ncbi.nlm.nih.gov/19298254 DMCLR6G DI DMCLR6G DMCLR6G DN Pegloticase DMCLR6G TI TTZ1SWF DMCLR6G TN Uric acid (URA) DMCLR6G MA Modulator DMCLR6G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCLR6G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA TI TTGKNB4 DMCMBHA TN Epidermal growth factor receptor (EGFR) DMCMBHA MA Inhibitor DMCMBHA RN Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. DMCMBHA RU https://pubmed.ncbi.nlm.nih.gov/19627157 DMCME17 DI DMCME17 DMCME17 DN Lisuride DMCME17 TI TTEX248 DMCME17 TN Dopamine D2 receptor (D2R) DMCME17 MA Agonist DMCME17 RN Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. DMCME17 RU https://pubmed.ncbi.nlm.nih.gov/17706566 DMCMETN DI DMCMETN DMCMETN DN MLN9708 DMCMETN TI TTU7ZMG DMCMETN TN Proteasome (PS) DMCMETN MA Modulator DMCMETN RN Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. DMCMETN RU https://pubmed.ncbi.nlm.nih.gov/20160034 DMCN61Z DI DMCN61Z DMCN61Z DN Interferon beta-1b DMCN61Z TI TTMQB37 DMCN61Z TN Interferon alpha/beta receptor 2 (IFNAR2) DMCN61Z MA Binder DMCN61Z RN Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170. DMCN61Z RU https://pubmed.ncbi.nlm.nih.gov/19590215 DMCO5JZ DI DMCO5JZ DMCO5JZ DN SR141716A DMCO5JZ TI TT6OEDT DMCO5JZ TN Cannabinoid receptor 1 (CB1) DMCO5JZ MA Antagonist DMCO5JZ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMCO5JZ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMCOAVT DI DMCOAVT DMCOAVT DN Emepronium DMCOAVT TI TTH18TF DMCOAVT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCOAVT MA Modulator DMCOAVT RN Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. DMCOAVT RU https://pubmed.ncbi.nlm.nih.gov/7616431 DMCOLUP DI DMCOLUP DMCOLUP DN Levallorphan DMCOLUP TI TTF4E0J DMCOLUP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMCOLUP MA Antagonist DMCOLUP RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMCOLUP RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMCOZJY DI DMCOZJY DMCOZJY DN Tenapanor DMCOZJY TI TTFZVPO DMCOZJY TN Sodium/hydrogen exchanger 3 (SLC9A3) DMCOZJY MA Modulator DMCOZJY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCOZJY RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TTTSOUD DMCR1MV TN Candida Cytochrome P450 51 (Candi ERG11) DMCR1MV MA Modulator DMCR1MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCR1MV RU https://www.fda.gov/ DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TT4LXBC DMCR1MV TN Hedgehog signaling pathway (HS pathway) DMCR1MV MA Inhibitor DMCR1MV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCR1MV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCRQHB DI DMCRQHB DMCRQHB DN Edrophonium DMCRQHB TI TT1RS9F DMCRQHB TN Acetylcholinesterase (AChE) DMCRQHB MA Inhibitor DMCRQHB RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DMCRQHB RU https://pubmed.ncbi.nlm.nih.gov/19472276 DMCS6M5 DI DMCS6M5 DMCS6M5 DN Voxelotor DMCS6M5 TI TTQO71U DMCS6M5 TN Hemoglobin (HB) DMCS6M5 MA Modulator DMCS6M5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCS6M5 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf DMCSLZ4 DI DMCSLZ4 DMCSLZ4 DN Sodium zirconium cyclosilicate DMCSLZ4 TI TTB0SC6 DMCSLZ4 TN Potassium (K) DMCSLZ4 MA Binder DMCSLZ4 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMCSLZ4 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMCT31R DI DMCT31R DMCT31R DN Carbinoxamine DMCT31R TI TTTIBOJ DMCT31R TN Histamine H1 receptor (H1R) DMCT31R MA Antagonist DMCT31R RN Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. DMCT31R RU https://pubmed.ncbi.nlm.nih.gov/7513381 DMCT3I8 DI DMCT3I8 DMCT3I8 DN Ifosfamide DMCT3I8 TI TTUTN1I DMCT3I8 TN Human Deoxyribonucleic acid (hDNA) DMCT3I8 MA Modulator DMCT3I8 RN Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. DMCT3I8 RU https://www.ncbi.nlm.nih.gov/pubmed/15827549 DMCTE9R DI DMCTE9R DMCTE9R DN Mexiletine DMCTE9R TI TTZOVE0 DMCTE9R TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMCTE9R MA Blocker DMCTE9R RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DMCTE9R RU https://pubmed.ncbi.nlm.nih.gov/11196553 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTOP832 DMCUT21 TN Solute carrier family 23 member 2 (SLC23A2) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTJBPN3 DMCUT21 TN Biliverdin reductase A (BLVRA) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCV109 DI DMCV109 DMCV109 DN Etanercept DMCV109 TI TTF8CQI DMCV109 TN Tumor necrosis factor (TNF) DMCV109 MA Modulator DMCV109 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMCV109 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTX09M4 DMCVJ86 TN Ribonucleotide reductase (RIR) DMCVJ86 MA Inhibitor DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTJP4SM DMCVJ86 TN Bacterial Penicillin binding protein (Bact PBP) DMCVJ86 MA Binder DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTJQOD7 DMCVPXO TN 5-HT 2A receptor (HTR2A) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTEX248 DMCVPXO TN Dopamine D2 receptor (D2R) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 TI TTBUYHA DMCX0K3 TN Extracellular calcium-sensing receptor (CASR) DMCX0K3 MA Agonist DMCX0K3 RN Clinical pipeline report, company report or official report of Amgen (2009). DMCX0K3 RU http://www.amgen.com/science/pipe.jsp DMCY0TI DI DMCY0TI DMCY0TI DN Carglumic acid DMCY0TI TI TT42M75 DMCY0TI TN Carbamoyl-phosphate synthetase I (CPS1) DMCY0TI MA Activator DMCY0TI RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCY0TI RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCY8AF DI DMCY8AF DMCY8AF DN Arbutamine DMCY8AF TI TTR6W5O DMCY8AF TN Adrenergic receptor beta-1 (ADRB1) DMCY8AF MA Stimulator DMCY8AF RN Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47. DMCY8AF RU https://pubmed.ncbi.nlm.nih.gov/8723169 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK TI TT6EYVN DMCYANK TN Peripheral carotid chemoreceptor (PCC) DMCYANK MA Stimulator DMCYANK RN Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8. DMCYANK RU https://pubmed.ncbi.nlm.nih.gov/16024517 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT TI TTMNI76 DMCYVDT TN Calcium-activated potassium channel (KCN) DMCYVDT MA Activator DMCYVDT RN Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. DMCYVDT RU https://pubmed.ncbi.nlm.nih.gov/16859676 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE TI TT5FH9Y DMCZGRE TN Human immunodeficiency virus Integrase (HIV IN) DMCZGRE MA Modulator DMCZGRE RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMCZGRE RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMCZIHT DI DMCZIHT DMCZIHT DN Asasantin DMCZIHT TI TTK0943 DMCZIHT TN Prostaglandin G/H synthase (COX) DMCZIHT MA Inhibitor DMCZIHT RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMCZIHT RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMCZQGK DI DMCZQGK DMCZQGK DN Demecolcine DMCZQGK TI TT1EDJZ DMCZQGK TN Microtubule-associated protein (MAP) DMCZQGK MA Modulator DMCZQGK RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMCZQGK RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMD072M DI DMD072M DMD072M DN Fosfestrol DMD072M TI TTZAYWL DMD072M TN Estrogen receptor (ESR) DMD072M MA Modulator DMD072M RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DMD072M RU https://pubmed.ncbi.nlm.nih.gov/19422222 DMD157S DI DMD157S DMD157S DN Montelukast DMD157S TI TTGKOY9 DMD157S TN Leukotriene CysLT1 receptor (CYSLTR1) DMD157S MA Antagonist DMD157S RN Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94. DMD157S RU https://pubmed.ncbi.nlm.nih.gov/19515388 DMD1B8Z DI DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z TI TTR6W5O DMD1B8Z TN Adrenergic receptor beta-1 (ADRB1) DMD1B8Z MA Agonist DMD1B8Z RN Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. DMD1B8Z RU https://pubmed.ncbi.nlm.nih.gov/18275933 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW TI TTKRD0G DMD1QXW TN Endothelin A receptor (EDNRA) DMD1QXW MA Antagonist DMD1QXW RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMD1QXW RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMD1VZL DI DMD1VZL DMD1VZL DN Pemafibrate DMD1VZL TI TTJ584C DMD1VZL TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD1VZL MA Agonist DMD1VZL RN Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810. DMD1VZL RU https://pubmed.ncbi.nlm.nih.gov/28929345 DMD2K4I DI DMD2K4I DMD2K4I DN Fludiazepam DMD2K4I TI TTPTXIN DMD2K4I TN Translocator protein (TSPO) DMD2K4I MA Agonist DMD2K4I RN Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. DMD2K4I RU https://pubmed.ncbi.nlm.nih.gov/2857046 DMD2NV7 DI DMD2NV7 DMD2NV7 DN Pindolol DMD2NV7 TI TTR6W5O DMD2NV7 TN Adrenergic receptor beta-1 (ADRB1) DMD2NV7 MA Antagonist DMD2NV7 RN Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. DMD2NV7 RU https://pubmed.ncbi.nlm.nih.gov/17433471 DMD2WPG DI DMD2WPG DMD2WPG DN Trientine DMD2WPG TI TTEYTKG DMD2WPG TN Carbonic anhydrase XIV (CA-XIV) DMD2WPG MA Inhibitor DMD2WPG RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD2WPG RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4381 DI DMD4381 DMD4381 DN Terbutaline DMD4381 TI TT2CJVK DMD4381 TN Adrenergic receptor beta-2 (ADRB2) DMD4381 MA Agonist DMD4381 RN Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11. DMD4381 RU https://pubmed.ncbi.nlm.nih.gov/239414 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTG28O6 DMD59GI TN Adrenergic receptor Alpha-1 (ADRA1) DMD59GI MA Antagonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTSQIFT DMD59GI TN 5-HT 1A receptor (HTR1A) DMD59GI MA Agonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 TI TTJP4SM DMD5JU8 TN Bacterial Penicillin binding protein (Bact PBP) DMD5JU8 MA Binder DMD5JU8 RN Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21. DMD5JU8 RU https://pubmed.ncbi.nlm.nih.gov/14970246 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX TI TTVIREA DMD5LBX TN Adrenergic receptor (ADR) DMD5LBX MA Modulator DMD5LBX RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMD5LBX RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TT0PG8F DMD7L94 TN Cyclin-dependent kinase 4 (CDK4) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TTO0FDJ DMD7L94 TN Cyclin-dependent kinase 6 (CDK6) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT4NVEM DMD7X1O TN DNA topoisomerase II beta (TOP2B) DMD7X1O MA Inhibitor DMD7X1O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7X1O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT0IHXV DMD7X1O TN DNA topoisomerase II (TOP2) DMD7X1O MA Modulator DMD7X1O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMD7X1O RU https://www.fda.gov/ DMD8Q3J DI DMD8Q3J DMD8Q3J DN Gemfibrozil DMD8Q3J TI TTOF3WZ DMD8Q3J TN Lipoprotein lipase (LPL) DMD8Q3J MA Activator DMD8Q3J RN Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64. DMD8Q3J RU https://pubmed.ncbi.nlm.nih.gov/16511610 DMD9WSC DI DMD9WSC DMD9WSC DN Memantine DMD9WSC TI TT9IK2Z DMD9WSC TN N-methyl-D-aspartate receptor (NMDAR) DMD9WSC MA Modulator DMD9WSC RN The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32. DMD9WSC RU https://pubmed.ncbi.nlm.nih.gov/12973747 DMDBX5F DI DMDBX5F DMDBX5F DN Ivermectin DMDBX5F TI TTSNVHO DMDBX5F TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMDBX5F MA Activator DMDBX5F RN Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95. DMDBX5F RU https://pubmed.ncbi.nlm.nih.gov/18755283 DMDBZMV DI DMDBZMV DMDBZMV DN Vitamin B6 DMDBZMV TI TTN451K DMDBZMV TN Aromatic-L-amino-acid decarboxylase (DDC) DMDBZMV MA Cofactor DMDBZMV RN Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4. DMDBZMV RU https://pubmed.ncbi.nlm.nih.gov/15965967 DMDEA85 DI DMDEA85 DMDEA85 DN Trimetrexate DMDEA85 TI TT9SL3Q DMDEA85 TN Polypeptide deformylase (PDF) DMDEA85 MA Inhibitor DMDEA85 RN Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6. DMDEA85 RU https://pubmed.ncbi.nlm.nih.gov/11036028 DMDEXQ0 DI DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 TI TT7RJY8 DMDEXQ0 TN Xanthine dehydrogenase/oxidase (XDH) DMDEXQ0 MA Inhibitor DMDEXQ0 RN Clinical pipeline report, company report or official report of Takeda (2009). DMDEXQ0 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMDEZI3 DI DMDEZI3 DMDEZI3 DN Pegvisomant DMDEZI3 TI TTKMAZ6 DMDEZI3 TN Growth hormone receptor (GHR) DMDEZI3 MA Antagonist DMDEZI3 RN Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72. DMDEZI3 RU https://pubmed.ncbi.nlm.nih.gov/19549743 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z TI TTOXS3C DMDF79Z TN Muscarinic acetylcholine receptor (CHRM) DMDF79Z MA Agonist DMDF79Z RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DMDF79Z RU https://pubmed.ncbi.nlm.nih.gov/14722259 DMDH9KX DI DMDH9KX DMDH9KX DN Megestrol DMDH9KX TI TTUV8G9 DMDH9KX TN Progesterone receptor (PGR) DMDH9KX MA Binder DMDH9KX RN Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8. DMDH9KX RU https://pubmed.ncbi.nlm.nih.gov/14687437 DMDHCK9 DI DMDHCK9 DMDHCK9 DN Trumenba DMDHCK9 TI TTUW6OP DMDHCK9 TN Complement factor H (CFH) DMDHCK9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMDHCK9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 TI TTML2WA DMDI269 TN Tubulin (TUB) DMDI269 MA Inhibitor DMDI269 RN Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. DMDI269 RU https://pubmed.ncbi.nlm.nih.gov/16296875 DMDI6R4 DI DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 TI TT6L509 DMDI6R4 TN Coagulation factor IIa (F2) DMDI6R4 MA Inhibitor DMDI6R4 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMDI6R4 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMDIC39 DI DMDIC39 DMDIC39 DN Fosfosal DMDIC39 TI TTK0943 DMDIC39 TN Prostaglandin G/H synthase (COX) DMDIC39 MA Modulator DMDIC39 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMDIC39 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMDINC4 DI DMDINC4 DMDINC4 DN Thiothixene DMDINC4 TI TTEX248 DMDINC4 TN Dopamine D2 receptor (D2R) DMDINC4 MA Antagonist DMDINC4 RN Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. DMDINC4 RU https://pubmed.ncbi.nlm.nih.gov/3039860 DMDINFS DI DMDINFS DMDINFS DN Sanguinarine DMDINFS TI TTQ38E9 DMDINFS TN Sodium/potassium-transporting ATPase (SPT ATPase) DMDINFS MA Modulator DMDINFS RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMDINFS RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMDIYFZ DI DMDIYFZ DMDIYFZ DN Telotristat ethyl DMDIYFZ TI TTDJBV3 DMDIYFZ TN Tryptophan hydroxylase (TPH) DMDIYFZ MA Modulator DMDIYFZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMDIYFZ RU https://www.fda.gov/ DMDJMA3 DI DMDJMA3 DMDJMA3 DN Rizatriptan DMDJMA3 TI TT6MSOK DMDJMA3 TN 5-HT 1D receptor (HTR1D) DMDJMA3 MA Agonist DMDJMA3 RN An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. DMDJMA3 RU https://pubmed.ncbi.nlm.nih.gov/12434581 DMDK7T9 DI DMDK7T9 DMDK7T9 DN SBC-102 DMDK7T9 TI TTS8T1M DMDK7T9 TN Lysosomal acid lipase (LIPA) DMDK7T9 MA Modulator DMDK7T9 RN A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20. DMDK7T9 RU https://pubmed.ncbi.nlm.nih.gov/26352813 DMDKE4N DI DMDKE4N DMDKE4N DN Secretin DMDKE4N TI TTOBVIN DMDKE4N TN Secretin receptor (SCT) DMDKE4N MA Binder DMDKE4N RN False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2. DMDKE4N RU https://pubmed.ncbi.nlm.nih.gov/19245850 DMDKF3M DI DMDKF3M DMDKF3M DN Raloxifene DMDKF3M TI TTZAYWL DMDKF3M TN Estrogen receptor (ESR) DMDKF3M MA Modulator DMDKF3M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMDKF3M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMDKXTO DI DMDKXTO DMDKXTO DN Cobicistat/darunavir DMDKXTO TI TTIJQ3O DMDKXTO TN Cytochrome P450 3A (CYP3A) DMDKXTO MA Modulator DMDKXTO RN Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206. DMDKXTO RU https://pubmed.ncbi.nlm.nih.gov/24343782 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTSCIUP DMDL27I TN Oxytocin receptor (OTR) DMDL27I MA Modulator DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TT4TFGN DMDL27I TN Vasopressin V1a receptor (V1AR) DMDL27I MA Agonist DMDL27I RN Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9334232 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTL9MHW DMDL27I TN Vasopressin V1b receptor (V1BR) DMDL27I MA Agonist DMDL27I RN The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9322919 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTK8R02 DMDL27I TN Vasopressin V2 receptor (V2R) DMDL27I MA Agonist DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG TI TT85JMW DMDNJHG TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMDNJHG MA Binder DMDNJHG RN Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/12519203 DMDO279 DI DMDO279 DMDO279 DN Phenprocoumon DMDO279 TI TTEUC8H DMDO279 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMDO279 MA Inhibitor DMDO279 RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMDO279 RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMDPM7R DI DMDPM7R DMDPM7R DN Y-25130 DMDPM7R TI TTNXLKE DMDPM7R TN 5-HT 3 receptor (5HT3R) DMDPM7R MA Antagonist DMDPM7R RN The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305. DMDPM7R RU https://pubmed.ncbi.nlm.nih.gov/1654255 DMDPYI5 DI DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 TI TTLUQ8E DMDPYI5 TN Hormone sensitive lipase (LIPE) DMDPYI5 MA Modulator DMDPYI5 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMDPYI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMDRKH2 DI DMDRKH2 DMDRKH2 DN Thiamphenicol DMDRKH2 TI TTLFGBV DMDRKH2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMDRKH2 MA Modulator DMDRKH2 RN The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13. DMDRKH2 RU https://pubmed.ncbi.nlm.nih.gov/18646313 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU TI TT1MPAY DMDRQZU TN GABA(A) receptor alpha-1 (GABRA1) DMDRQZU MA Antagonist DMDRQZU RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDRQZU RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDRT0E DI DMDRT0E DMDRT0E DN Idoxuridine DMDRT0E TI TT4823K DMDRT0E TN Virus Deoxyribonucleic acid (Viru DNA) DMDRT0E MA Binder DMDRT0E RN Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. DMDRT0E RU https://pubmed.ncbi.nlm.nih.gov/10392098 DMDSWAG DI DMDSWAG DMDSWAG DN Methylphenobarbital DMDSWAG TI TT1MPAY DMDSWAG TN GABA(A) receptor alpha-1 (GABRA1) DMDSWAG MA Antagonist DMDSWAG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDSWAG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDTC7R DI DMDTC7R DMDTC7R DN Phenindamine DMDTC7R TI TTTIBOJ DMDTC7R TN Histamine H1 receptor (H1R) DMDTC7R MA Antagonist DMDTC7R RN The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. DMDTC7R RU https://pubmed.ncbi.nlm.nih.gov/7650688 DMDU0BV DI DMDU0BV DMDU0BV DN Pivmecillinam DMDU0BV TI TTJP4SM DMDU0BV TN Bacterial Penicillin binding protein (Bact PBP) DMDU0BV MA Binder DMDU0BV RN Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7. DMDU0BV RU https://pubmed.ncbi.nlm.nih.gov/19104012 DMDVP3B DI DMDVP3B DMDVP3B DN Pregabalin DMDVP3B TI TTFK1JQ DMDVP3B TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMDVP3B MA Modulator DMDVP3B RN Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. DMDVP3B RU https://pubmed.ncbi.nlm.nih.gov/16641316 DMDWICP DI DMDWICP DMDWICP DN Succinic acid DMDWICP TI TTJUWVB DMDWICP TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMDWICP MA Inhibitor DMDWICP RN Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68. DMDWICP RU https://pubmed.ncbi.nlm.nih.gov/19300440 DMDX1ZC DI DMDX1ZC DMDX1ZC DN Cinolazepam DMDX1ZC TI TTPTXIN DMDX1ZC TN Translocator protein (TSPO) DMDX1ZC MA Binder DMDX1ZC RN Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18. DMDX1ZC RU https://pubmed.ncbi.nlm.nih.gov/2889679 DMDYA31 DI DMDYA31 DMDYA31 DN Pretomanid DMDYA31 TI TT08ESN DMDYA31 TN Mycobacterium Mycolic acid synthase (MycB cma) DMDYA31 MA Inhibitor DMDYA31 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMDYA31 RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT TI TT729IR DMDZ9LT TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMDZ9LT MA Blocker DMDZ9LT RN Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. DMDZ9LT RU https://pubmed.ncbi.nlm.nih.gov/19005061 DMDZY54 DI DMDZY54 DMDZY54 DN Fremanezumab DMDZY54 TI TTY6O0Q DMDZY54 TN Calcitonin gene-related peptide receptor (CGRPR) DMDZY54 MA Modulator DMDZY54 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMDZY54 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DME0F98 DI DME0F98 DME0F98 DN Ovine corticotropin-releasing hormone DME0F98 TI TTVIREA DME0F98 TN Adrenergic receptor (ADR) DME0F98 MA Modulator DME0F98 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME0F98 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTZOVE0 DME0TC8 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TT4FDG6 DME0TC8 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DME0TC8 MA Inhibitor DME0TC8 RN Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/17134896 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTRK8B9 DME0TC8 TN Sodium channel unspecific (NaC) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME1DJX DI DME1DJX DME1DJX DN Baquting DME1DJX TI TTWODQF DME1DJX TN Fibrin (FG) DME1DJX MA Modulator DME1DJX RN Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals. DME1DJX RU http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm DME1LQN DI DME1LQN DME1LQN DN Streptomycin DME1LQN TI TTQ8KVI DME1LQN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DME1LQN MA Binder DME1LQN RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DME1LQN RU https://pubmed.ncbi.nlm.nih.gov/11014183 DME2H5T DI DME2H5T DME2H5T DN Cilastatin DME2H5T TI TTYUENF DME2H5T TN Dehydropeptidase I (DPEP1) DME2H5T MA Inhibitor DME2H5T RN Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31. DME2H5T RU https://pubmed.ncbi.nlm.nih.gov/16493791 DME2PY5 DI DME2PY5 DME2PY5 DN Midodrine DME2PY5 TI TTG28O6 DME2PY5 TN Adrenergic receptor Alpha-1 (ADRA1) DME2PY5 MA Agonist DME2PY5 RN Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505. DME2PY5 RU https://pubmed.ncbi.nlm.nih.gov/11482743 DME2XG3 DI DME2XG3 DME2XG3 DN Carbenicillin Indanyl Sodium DME2XG3 TI TTJP4SM DME2XG3 TN Bacterial Penicillin binding protein (Bact PBP) DME2XG3 MA Modulator DME2XG3 RN Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. DME2XG3 RU https://www.ncbi.nlm.nih.gov/pubmed/6821456 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 TI TT2B6EV DME4RA8 TN Histamine N-methyltransferase (HNMT) DME4RA8 MA Inhibitor DME4RA8 RN Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/17222819 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTTIBOJ DME5Y64 TN Histamine H1 receptor (H1R) DME5Y64 MA Antagonist DME5Y64 RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/16083326 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTHM0R1 DME5Y64 TN Steryl-sulfatase (STS) DME5Y64 MA Inhibitor DME5Y64 RN Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/11860358 DME6G97 DI DME6G97 DME6G97 DN Lefamulin DME6G97 TI TTLFGBV DME6G97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DME6G97 MA Inhibitor DME6G97 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DME6G97 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf DME78OA DI DME78OA DME78OA DN Biperiden DME78OA TI TTZ9SOR DME78OA TN Muscarinic acetylcholine receptor M1 (CHRM1) DME78OA MA Antagonist DME78OA RN Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92. DME78OA RU https://pubmed.ncbi.nlm.nih.gov/10907719 DME7KRM DI DME7KRM DME7KRM DN Oxiconazole DME7KRM TI TTTSOUD DME7KRM TN Candida Cytochrome P450 51 (Candi ERG11) DME7KRM MA Inhibitor DME7KRM RN Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9. DME7KRM RU https://pubmed.ncbi.nlm.nih.gov/12823944 DME8FZ9 DI DME8FZ9 DME8FZ9 DN Methoxsalen DME8FZ9 TI TTAQ6ZW DME8FZ9 TN Cytochrome P450 2A6 (CYP2A6) DME8FZ9 MA Binder DME8FZ9 RN Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. DME8FZ9 RU https://pubmed.ncbi.nlm.nih.gov/6372701 DME9JNL DI DME9JNL DME9JNL DN Propericiazine DME9JNL TI TTBRKXS DME9JNL TN Adrenergic receptor alpha-1B (ADRA1B) DME9JNL MA Binder DME9JNL RN Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. DME9JNL RU https://pubmed.ncbi.nlm.nih.gov/6149771 DMEADRK DI DMEADRK DMEADRK DN Hexylcaine DMEADRK TI TTZOVE0 DMEADRK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMEADRK MA Blocker DMEADRK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEADRK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEAOYJ DI DMEAOYJ DMEAOYJ DN Ponesimod DMEAOYJ TI TT9JZCK DMEAOYJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMEAOYJ MA Agonist DMEAOYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMEAOYJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW TI TTS1W4A DMEBOFW TN Bacterial Deoxyribonucleic acid (Bact DNA) DMEBOFW MA Modulator DMEBOFW RN The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4. DMEBOFW RU https://www.ncbi.nlm.nih.gov/pubmed/945233 DMEBQAO DI DMEBQAO DMEBQAO DN Lumasiran DMEBQAO TI TTS58YO DMEBQAO TN HAO1 messenger RNA (HAO1 mRNA) DMEBQAO MA Inhibitor DMEBQAO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEBQAO RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf DMEBY2D DI DMEBY2D DMEBY2D DN Beriplast-P DMEBY2D TI TTWODQF DMEBY2D TN Fibrin (FG) DMEBY2D MA Modulator DMEBY2D RN Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23. DMEBY2D RU https://pubmed.ncbi.nlm.nih.gov/15953052 DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TTKWM86 DMECB4H TN Opioid receptor mu (MOP) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TT35UGH DMECB4H TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECBWN DI DMECBWN DMECBWN DN Riluzole DMECBWN TI TTN9VTF DMECBWN TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMECBWN MA Blocker DMECBWN RN Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90. DMECBWN RU https://pubmed.ncbi.nlm.nih.gov/12440368 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TT6L509 DMECRX1 TN Coagulation factor IIa (F2) DMECRX1 MA Inhibitor DMECRX1 RN New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/11479484 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TTRTKPV DMECRX1 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMECRX1 MA Inhibitor DMECRX1 RN 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/12937775 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TT6EO5L DMEDU7B TN Erbb2 tyrosine kinase receptor (HER2) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TTGKNB4 DMEDU7B TN Epidermal growth factor receptor (EGFR) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTOVXHF DMEFRTZ TN Human Deoxyribonucleic acid minor groove (hDNA min) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTUTN1I DMEFRTZ TN Human Deoxyribonucleic acid (hDNA) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEGIQ6 DI DMEGIQ6 DMEGIQ6 DN Nitrazepam DMEGIQ6 TI TT1MPAY DMEGIQ6 TN GABA(A) receptor alpha-1 (GABRA1) DMEGIQ6 MA Antagonist DMEGIQ6 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMEGIQ6 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTR6YA2 DMEH3O7 TN Bacterial RNA polymerase sigma factor SigA (Bact sigA) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTS31JH DMEH3O7 TN Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TT79JGK DMEH3O7 TN Mycobacterium RNA polymerase (MycB RNAP) DMEH3O7 MA Inhibitor DMEH3O7 RN Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. DMEH3O7 RU https://pubmed.ncbi.nlm.nih.gov/28559332 DMEH7YU DI DMEH7YU DMEH7YU DN Lanadelumab DMEH7YU TI TTMF8H9 DMEH7YU TN Plasma kallikrein (KLKB1) DMEH7YU MA Modulator DMEH7YU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMEH7YU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT3ROYC DMEHCY5 TN Serotonin transporter (SERT) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT5TPI6 DMEHCY5 TN Opioid receptor sigma 1 (OPRS1) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEJKRF DI DMEJKRF DMEJKRF DN Motexafin gadolinium DMEJKRF TI TTLPJWH DMEJKRF TN Thioredoxin reductase (PRDX5) DMEJKRF MA Modulator DMEJKRF RN Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9. DMEJKRF RU https://pubmed.ncbi.nlm.nih.gov/19121624 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTQOD3G DMEMBJC TN Folate receptor (FOLR) DMEMBJC MA Binder DMEMBJC RN Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/16859665 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTY8Z2E DMEMBJC TN Proton-coupled folate transporter (SLC46A1) DMEMBJC MA Modulator DMEMBJC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DMEMBJC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TT09I7D DMEMBJC TN Solute carrier family 19 member 1 (SLC19A1) DMEMBJC MA Modulator DMEMBJC RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/9525913 DMEMV9D DI DMEMV9D DMEMV9D DN Trimeprazine DMEMV9D TI TTTIBOJ DMEMV9D TN Histamine H1 receptor (H1R) DMEMV9D MA Antagonist DMEMV9D RN Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40. DMEMV9D RU https://pubmed.ncbi.nlm.nih.gov/16291162 DMEN6X7 DI DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 TI TTH18TF DMEN6X7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEN6X7 MA Antagonist DMEN6X7 RN Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204. DMEN6X7 RU https://pubmed.ncbi.nlm.nih.gov/19526284 DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TT8NGED DMENSL5 TN Prostaglandin G/H synthase 1 (COX-1) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTVKILB DMENSL5 TN Prostaglandin G/H synthase 2 (COX-2) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTYZVDJ DMENSL5 TN Dihydrofolate reductase (DHFR) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMEO794 DI DMEO794 DMEO794 DN Galantamine DMEO794 TI TT1RS9F DMEO794 TN Acetylcholinesterase (AChE) DMEO794 MA Inhibitor DMEO794 RN [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. DMEO794 RU https://pubmed.ncbi.nlm.nih.gov/19504422 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTF45NW DMEPWYA TN Strychnine-binding glycine receptor (GLRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT1MPAY DMEPWYA TN GABA(A) receptor alpha-1 (GABRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZA1NY DMEPWYA TN GABA(A) receptor beta-2 (GABRB2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZ8EM9 DMEPWYA TN Glycine receptor (GlyR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTNJYV2 DMEPWYA TN Gamma-aminobutyric acid receptor (GAR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT06RH5 DMEPWYA TN GABA(A) receptor gamma-2 (GABRG2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMER9YA DI DMER9YA DMER9YA DN Galsulfase DMER9YA TI TTESQTG DMER9YA TN N-acetylgalactosamine-4-sulfatase (G4S) DMER9YA MA Modulator DMER9YA RN Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94. DMER9YA RU https://pubmed.ncbi.nlm.nih.gov/22669363 DMETVFJ DI DMETVFJ DMETVFJ DN Omalizumab DMETVFJ TI TTDGEC0 DMETVFJ TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMETVFJ MA Modulator DMETVFJ RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMETVFJ RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMETWAU DI DMETWAU DMETWAU DN Hyaluronidase (ovine) DMETWAU TI TTYTVXF DMETWAU TN Hyaluronic acid (HA) DMETWAU MA Modulator DMETWAU RN Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97. DMETWAU RU https://pubmed.ncbi.nlm.nih.gov/16226510 DMETYK5 DI DMETYK5 DMETYK5 DN Triazolam DMETYK5 TI TTPTXIN DMETYK5 TN Translocator protein (TSPO) DMETYK5 MA Modulator DMETYK5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMETYK5 RU https://www.fda.gov/ DMEV954 DI DMEV954 DMEV954 DN Sulfinpyrazone DMEV954 TI TTOI92F DMEV954 TN Multidrug resistance-associated protein 1 (ABCC1) DMEV954 MA Modulator DMEV954 RN Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40. DMEV954 RU https://pubmed.ncbi.nlm.nih.gov/18180270 DMEVXY6 DI DMEVXY6 DMEVXY6 DN Heparin Calcium DMEVXY6 TI TT4QPUL DMEVXY6 TN Antithrombin-III (ATIII) DMEVXY6 MA Modulator DMEVXY6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEVXY6 RU https://www.fda.gov/ DMEWC7N DI DMEWC7N DMEWC7N DN Prazepam DMEWC7N TI TTPTXIN DMEWC7N TN Translocator protein (TSPO) DMEWC7N MA Modulator DMEWC7N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEWC7N RU https://www.fda.gov/ DMEWUPF DI DMEWUPF DMEWUPF DN Salmon Calcitonin DMEWUPF TI TTLWS2O DMEWUPF TN Calcitonin receptor (CALCR) DMEWUPF MA Binder DMEWUPF RN Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95. DMEWUPF RU https://pubmed.ncbi.nlm.nih.gov/19540427 DMEXMYK DI DMEXMYK DMEXMYK DN Alpelisib DMEXMYK TI TTEUNMR DMEXMYK TN PI3-kinase alpha (PIK3CA) DMEXMYK MA Inhibitor DMEXMYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMEXMYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf DMEYHG9 DI DMEYHG9 DMEYHG9 DN Elotuzumab DMEYHG9 TI TT7ILZ1 DMEYHG9 TN SLAM family member 7 SLAMF7 (CS1) DMEYHG9 RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DMEYHG9 RU https://pubmed.ncbi.nlm.nih.gov/25764988 DMEYLH9 DI DMEYLH9 DMEYLH9 DN Ribavirin DMEYLH9 TI TTL7C8Q DMEYLH9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEYLH9 MA Inhibitor DMEYLH9 RN Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13. DMEYLH9 RU https://pubmed.ncbi.nlm.nih.gov/16293677 DMEZ2KH DI DMEZ2KH DMEZ2KH DN Ocrelizumab DMEZ2KH TI TTUE541 DMEZ2KH TN Leukocyte surface antigen Leu-16 (CD20) DMEZ2KH RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMEZ2KH RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMEZFXR DI DMEZFXR DMEZFXR DN Desoxyribonuclease DMEZFXR TI TT3C1VN DMEZFXR TN Enzyme unspecific (Enz) DMEZFXR MA Modulator DMEZFXR RN Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52. DMEZFXR RU https://pubmed.ncbi.nlm.nih.gov/486431 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR TI TT26PHO DMF0NQR TN Mineralocorticoid receptor (MR) DMF0NQR MA Modulator DMF0NQR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMF0NQR RU https://www.fda.gov/ DMF1X5P DI DMF1X5P DMF1X5P DN Proflavine DMF1X5P TI TTS1W4A DMF1X5P TN Bacterial Deoxyribonucleic acid (Bact DNA) DMF1X5P MA Binder DMF1X5P RN Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19. DMF1X5P RU https://pubmed.ncbi.nlm.nih.gov/19364280 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC TI TTPADOQ DMF28YC TN HMG-CoA reductase (HMGCR) DMF28YC MA Inhibitor DMF28YC RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DMF28YC RU https://pubmed.ncbi.nlm.nih.gov/11523064 DMF29Q5 DI DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 TI TTWG9A4 DMF29Q5 TN Adrenergic receptor alpha-2A (ADRA2A) DMF29Q5 MA Agonist DMF29Q5 RN alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51. DMF29Q5 RU https://pubmed.ncbi.nlm.nih.gov/19527774 DMF2JDG DI DMF2JDG DMF2JDG DN Dromostanolone DMF2JDG TI TTS64P2 DMF2JDG TN Androgen receptor (AR) DMF2JDG MA Binder DMF2JDG RN Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34. DMF2JDG RU https://pubmed.ncbi.nlm.nih.gov/15351799 DMF2KLU DI DMF2KLU DMF2KLU DN Oxybutynin hydrochloride DMF2KLU TI TTOXS3C DMF2KLU TN Muscarinic acetylcholine receptor (CHRM) DMF2KLU MA Modulator DMF2KLU RN Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66. DMF2KLU RU https://pubmed.ncbi.nlm.nih.gov/10347840 DMF3AN7 DI DMF3AN7 DMF3AN7 DN Loratadine DMF3AN7 TI TTTIBOJ DMF3AN7 TN Histamine H1 receptor (H1R) DMF3AN7 MA Antagonist DMF3AN7 RN Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6. DMF3AN7 RU https://pubmed.ncbi.nlm.nih.gov/19452709 DMF3GM2 DI DMF3GM2 DMF3GM2 DN Somatropin recombinant DMF3GM2 TI TTKMAZ6 DMF3GM2 TN Growth hormone receptor (GHR) DMF3GM2 MA Binder DMF3GM2 RN Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7. DMF3GM2 RU https://pubmed.ncbi.nlm.nih.gov/16466607 DMF3VXA DI DMF3VXA DMF3VXA DN Zotepine DMF3VXA TI TTJQOD7 DMF3VXA TN 5-HT 2A receptor (HTR2A) DMF3VXA MA Inhibitor DMF3VXA RN Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501. DMF3VXA RU https://pubmed.ncbi.nlm.nih.gov/11170639 DMF54ZG DI DMF54ZG DMF54ZG DN Sulpiride DMF54ZG TI TTEX248 DMF54ZG TN Dopamine D2 receptor (D2R) DMF54ZG MA Antagonist DMF54ZG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMF54ZG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMF5EK1 DI DMF5EK1 DMF5EK1 DN Vilanterol DMF5EK1 TI TT2CJVK DMF5EK1 TN Adrenergic receptor beta-2 (ADRB2) DMF5EK1 MA Modulator DMF5EK1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). DMF5EK1 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353 DMF5HU6 DI DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 TI TT85JMW DMF5HU6 TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMF5HU6 MA Binder DMF5HU6 RN Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41. DMF5HU6 RU https://pubmed.ncbi.nlm.nih.gov/16495632 DMF5XQH DI DMF5XQH DMF5XQH DN Methoxamine DMF5XQH TI TTBRKXS DMF5XQH TN Adrenergic receptor alpha-1B (ADRA1B) DMF5XQH MA Stimulator DMF5XQH RN Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2. DMF5XQH RU https://pubmed.ncbi.nlm.nih.gov/19373756 DMF5ZB3 DI DMF5ZB3 DMF5ZB3 DN OspA lipoprotein DMF5ZB3 TI TTM6QSK DMF5ZB3 TN B-cell receptor CD22 (CD22) DMF5ZB3 MA Binder DMF5ZB3 RN Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14. DMF5ZB3 RU https://pubmed.ncbi.nlm.nih.gov/10067697 DMF6Y0L DI DMF6Y0L DMF6Y0L DN Polatuzumab vedotin DMF6Y0L TI TTBN5I7 DMF6Y0L TN B-cell-specific glycoprotein B29 (CD79B) DMF6Y0L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMF6Y0L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTHC7JD DMF6Z5T TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTCJ2X8 DMF6Z5T TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TTQ8KVI DMF8DNE TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMF8DNE MA Binder DMF8DNE RN Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/18060665 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TT38DW5 DMF8DNE TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMF8DNE MA Binder DMF8DNE RN Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/1105242 DMF8Y74 DI DMF8Y74 DMF8Y74 DN Hydroxyzine DMF8Y74 TI TTTIBOJ DMF8Y74 TN Histamine H1 receptor (H1R) DMF8Y74 MA Antagonist DMF8Y74 RN Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71. DMF8Y74 RU https://pubmed.ncbi.nlm.nih.gov/19057127 DMF9G7L DI DMF9G7L DMF9G7L DN Dibucaine DMF9G7L TI TTZOVE0 DMF9G7L TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMF9G7L MA Blocker DMF9G7L RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMF9G7L RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMF9O6B DI DMF9O6B DMF9O6B DN Gallium nitrate DMF9O6B TI TTRYK0X DMF9O6B TN Interleukin-1 beta (IL1B) DMF9O6B MA Inhibitor DMF9O6B RN Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41. DMF9O6B RU https://pubmed.ncbi.nlm.nih.gov/16122880 DMFA5MY DI DMFA5MY DMFA5MY DN Metoclopramide DMFA5MY TI TTEX248 DMFA5MY TN Dopamine D2 receptor (D2R) DMFA5MY MA Antagonist DMFA5MY RN Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6. DMFA5MY RU https://pubmed.ncbi.nlm.nih.gov/18457824 DMFA9MV DI DMFA9MV DMFA9MV DN Efinaconazole DMFA9MV TI TTTSOUD DMFA9MV TN Candida Cytochrome P450 51 (Candi ERG11) DMFA9MV MA Inhibitor DMFA9MV RN Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25. DMFA9MV RU https://pubmed.ncbi.nlm.nih.gov/25527861 DMFAOKP DI DMFAOKP DMFAOKP DN Fenoldopam DMFAOKP TI TTZFYLI DMFAOKP TN Dopamine D1 receptor (D1R) DMFAOKP MA Agonist DMFAOKP RN Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9. DMFAOKP RU https://pubmed.ncbi.nlm.nih.gov/18591870 DMFB97P DI DMFB97P DMFB97P DN Dihydrotachysterol DMFB97P TI TTK59TV DMFB97P TN Vitamin D3 receptor (VDR) DMFB97P MA Antagonist DMFB97P RN In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92. DMFB97P RU https://pubmed.ncbi.nlm.nih.gov/8380156 DMFC41K DI DMFC41K DMFC41K DN Tafluprost DMFC41K TI TTT2ZAR DMFC41K TN Prostaglandin F2-alpha receptor (PTGFR) DMFC41K MA Modulator DMFC41K RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFC41K RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L TI TTE0A2F DMFC71L TN Dopamine D4 receptor (D4R) DMFC71L MA Modulator DMFC71L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFC71L RU https://www.fda.gov/ DMFCLYW DI DMFCLYW DMFCLYW DN Moxisylyte DMFCLYW TI TT34BHT DMFCLYW TN Adrenergic receptor alpha-1D (ADRA1D) DMFCLYW MA Modulator DMFCLYW RN Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5. DMFCLYW RU https://pubmed.ncbi.nlm.nih.gov/8866639 DMFD9Q6 DI DMFD9Q6 DMFD9Q6 DN Cetrorelix DMFD9Q6 TI TT8R70G DMFD9Q6 TN Gonadotropin-releasing hormone receptor (GNRHR) DMFD9Q6 MA Antagonist DMFD9Q6 RN Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33. DMFD9Q6 RU https://pubmed.ncbi.nlm.nih.gov/19301301 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTQ13Z5 DMFDC0Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFDC0Q MA Antagonist DMFDC0Q RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTOXS3C DMFDC0Q TN Muscarinic acetylcholine receptor (CHRM) DMFDC0Q MA Antagonist DMFDC0Q RN Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/23435542 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTUV8G9 DMFEGB0 TN Progesterone receptor (PGR) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTDSB34 DMFEGB0 TN G-protein coupled estrogen receptor 1 (GPER1) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEHXD DI DMFEHXD DMFEHXD DN Natamycin DMFEHXD TI TTAH0B3 DMFEHXD TN Fungal Cell membrane (Fung CM) DMFEHXD MA Binder DMFEHXD RN Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401. DMFEHXD RU https://pubmed.ncbi.nlm.nih.gov/18165687 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTZVSJ2 DMFETDK TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMFETDK MA Inhibitor DMFETDK RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTAN6JD DMFETDK TN Glutamate receptor AMPA (GRIA) DMFETDK MA Agonist DMFETDK RN GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/12171573 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTP86E2 DMFGND4 TN Plasminogen (PLG) DMFGND4 MA Inhibitor DMFGND4 RN The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/12007600 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTXAGYU DMFGND4 TN Tissue-type plasminogen activator (PLAT) DMFGND4 MA Inhibitor DMFGND4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFGQ2S DI DMFGQ2S DMFGQ2S DN Erythrityl Tetranitrate DMFGQ2S TI TT6HPVC DMFGQ2S TN Guanylate cyclase (GC) DMFGQ2S MA Stimulator DMFGQ2S RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMFGQ2S RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMFH15Z DI DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z TI TTUTN1I DMFH15Z TN Human Deoxyribonucleic acid (hDNA) DMFH15Z MA Modulator DMFH15Z RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMFH15Z RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A TI TT6L509 DMFI46A TN Coagulation factor IIa (F2) DMFI46A MA Inhibitor DMFI46A RN Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. DMFI46A RU https://pubmed.ncbi.nlm.nih.gov/12496240 DMFI8A7 DI DMFI8A7 DMFI8A7 DN Tranexamic acid DMFI8A7 TI TTP86E2 DMFI8A7 TN Plasminogen (PLG) DMFI8A7 MA Inhibitor DMFI8A7 RN Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8. DMFI8A7 RU https://pubmed.ncbi.nlm.nih.gov/17666018 DMFIC0M DI DMFIC0M DMFIC0M DN Cinalukast DMFIC0M TI TTGKOY9 DMFIC0M TN Leukotriene CysLT1 receptor (CYSLTR1) DMFIC0M MA Antagonist DMFIC0M RN Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5. DMFIC0M RU https://pubmed.ncbi.nlm.nih.gov/9042047 DMFIQ2H DI DMFIQ2H DMFIQ2H DN Migalastat DMFIQ2H TI TTIS03D DMFIQ2H TN Alpha-galactosidase A (GLA) DMFIQ2H MA Modulator DMFIQ2H RN AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45. DMFIQ2H RU https://pubmed.ncbi.nlm.nih.gov/25440006 DMFJ2OG DI DMFJ2OG DMFJ2OG DN Collagenase DMFJ2OG TI TTK982E DMFJ2OG TN Collagen (CO) DMFJ2OG MA Breaker DMFJ2OG RN Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2. DMFJ2OG RU https://pubmed.ncbi.nlm.nih.gov/17577383 DMFJ8LT DI DMFJ8LT DMFJ8LT DN Ibutamoren DMFJ8LT TI TTWDC17 DMFJ8LT TN Growth hormone secretagogue receptor 1 (GHSR) DMFJ8LT MA Modulator DMFJ8LT RN Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. DMFJ8LT RU https://www.ncbi.nlm.nih.gov/pubmed/7624358 DMFJH5Q DI DMFJH5Q DMFJH5Q DN Mephentermine DMFJH5Q TI TTEX248 DMFJH5Q TN Dopamine D2 receptor (D2R) DMFJH5Q MA Agonist DMFJH5Q RN Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. DMFJH5Q RU https://pubmed.ncbi.nlm.nih.gov/10722 DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TTAWNKZ DMFJTDI TN Norepinephrine transporter (NET) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TT3ROYC DMFJTDI TN Serotonin transporter (SERT) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJZN0 DI DMFJZN0 DMFJZN0 DN Romosozumab DMFJZN0 TI TTYRO4F DMFJZN0 TN Sclerostin (SOST) DMFJZN0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFJZN0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG TI TT3ROYC DMFK9HG TN Serotonin transporter (SERT) DMFK9HG MA Inhibitor DMFK9HG RN Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7. DMFK9HG RU https://pubmed.ncbi.nlm.nih.gov/19566691 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY TI TTJ584C DMFKXDY TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFKXDY MA Agonist DMFKXDY RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMFKXDY RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMFLUTR DI DMFLUTR DMFLUTR DN Glucagon recombinant DMFLUTR TI TT9O6WS DMFLUTR TN Glucagon receptor (GCGR) DMFLUTR MA Binder DMFLUTR RN Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. DMFLUTR RU https://pubmed.ncbi.nlm.nih.gov/17462598 DMFMBZ4 DI DMFMBZ4 DMFMBZ4 DN Zanamivir DMFMBZ4 TI TT50QJ3 DMFMBZ4 TN Influenza Neuraminidase (Influ NA) DMFMBZ4 MA Inhibitor DMFMBZ4 RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMFMBZ4 RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMFMDOB DI DMFMDOB DMFMDOB DN Carteolol DMFMDOB TI TTR6W5O DMFMDOB TN Adrenergic receptor beta-1 (ADRB1) DMFMDOB MA Agonist DMFMDOB RN Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. DMFMDOB RU https://pubmed.ncbi.nlm.nih.gov/11138729 DMFMZ3G DI DMFMZ3G DMFMZ3G DN Choriogonadotropin alfa DMFMZ3G TI TT2O4W9 DMFMZ3G TN Luteinizing hormone receptor (LHCGR) DMFMZ3G MA Modulator DMFMZ3G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFMZ3G RU https://www.fda.gov/ DMFN07X DI DMFN07X DMFN07X DN Nilutamide DMFN07X TI TTS64P2 DMFN07X TN Androgen receptor (AR) DMFN07X MA Antagonist DMFN07X RN CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22. DMFN07X RU https://pubmed.ncbi.nlm.nih.gov/18339851 DMFNAEM DI DMFNAEM DMFNAEM DN Sulfaphenazole DMFNAEM TI TTR40YJ DMFNAEM TN S-mephenytoin 4-hydroxylase (CYP2C9) DMFNAEM MA Modulator DMFNAEM RN Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9. DMFNAEM RU https://www.ncbi.nlm.nih.gov/pubmed/9819219 DMFNH7L DI DMFNH7L DMFNH7L DN Pentobarbital DMFNH7L TI TT1MPAY DMFNH7L TN GABA(A) receptor alpha-1 (GABRA1) DMFNH7L MA Antagonist DMFNH7L RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFNH7L RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFO843 DI DMFO843 DMFO843 DN Fluspirilene DMFO843 TI TTEX248 DMFO843 TN Dopamine D2 receptor (D2R) DMFO843 MA Antagonist DMFO843 RN Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. DMFO843 RU https://pubmed.ncbi.nlm.nih.gov/11842444 DMFOIA8 DI DMFOIA8 DMFOIA8 DN Nesiritide DMFOIA8 TI TTJME02 DMFOIA8 TN Atrial natriuretic peptide receptor A (NPR1) DMFOIA8 MA Binder DMFOIA8 RN The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9. DMFOIA8 RU https://pubmed.ncbi.nlm.nih.gov/14736964 DMFOTZ7 DI DMFOTZ7 DMFOTZ7 DN Racecadotril DMFOTZ7 TI TT8CYO4 DMFOTZ7 TN Endopeptidase (ENP) DMFOTZ7 MA Modulator DMFOTZ7 RN A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol. 2012 May 30;3:93. DMFOTZ7 RU https://pubmed.ncbi.nlm.nih.gov/22661949 DMFOVSD DI DMFOVSD DMFOVSD DN Brompheniramine DMFOVSD TI TTTIBOJ DMFOVSD TN Histamine H1 receptor (H1R) DMFOVSD MA Antagonist DMFOVSD RN Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14. DMFOVSD RU https://pubmed.ncbi.nlm.nih.gov/8151062 DMFP6MV DI DMFP6MV DMFP6MV DN Fidaxomicin DMFP6MV TI TTIJ5EB DMFP6MV TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMFP6MV MA Modulator DMFP6MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFP6MV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFQ320 DI DMFQ320 DMFQ320 DN Ipratropium DMFQ320 TI TTQ13Z5 DMFQ320 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFQ320 MA Modulator DMFQ320 RN Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69. DMFQ320 RU https://www.ncbi.nlm.nih.gov/pubmed/22767057 DMFQCB1 DI DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 TI TTEUC8H DMFQCB1 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMFQCB1 MA Inhibitor DMFQCB1 RN Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9. DMFQCB1 RU https://pubmed.ncbi.nlm.nih.gov/2424118 DMFQEA6 DI DMFQEA6 DMFQEA6 DN Pembrolizumab DMFQEA6 TI TTNBFWK DMFQEA6 TN Programmed cell death protein 1 (PD-1) DMFQEA6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMFQEA6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMFR201 DI DMFR201 DMFR201 DN Vibegron DMFR201 TI TTMXGCW DMFR201 TN Adrenergic receptor beta-3 (ADRB3) DMFR201 MA Agonist DMFR201 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMFR201 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I TI TTLWPVF DMFRM1I TN Sodium/glucose cotransporter 2 (SGLT2) DMFRM1I MA Modulator DMFRM1I RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMFRM1I RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMFS63G DI DMFS63G DMFS63G DN Enfortumab DMFS63G TI TTPO9EG DMFS63G TN Nectin cell adhesion molecule 4 (NECTIN4) DMFS63G MA Inhibitor DMFS63G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFS63G RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf DMFSWGH DI DMFSWGH DMFSWGH DN Econazole DMFSWGH TI TTTSOUD DMFSWGH TN Candida Cytochrome P450 51 (Candi ERG11) DMFSWGH MA Inhibitor DMFSWGH RN Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. DMFSWGH RU https://pubmed.ncbi.nlm.nih.gov/18694951 DMFT73E DI DMFT73E DMFT73E DN Chorionic Gonadotropin DMFT73E TI TT2O4W9 DMFT73E TN Luteinizing hormone receptor (LHCGR) DMFT73E MA Modulator DMFT73E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFT73E RU https://www.fda.gov/ DMFUAXT DI DMFUAXT DMFUAXT DN H1N1 pandemic influenza A vaccine DMFUAXT TI TT3J5ZI DMFUAXT TN Cell mediated immunity response (CMIR) DMFUAXT RN How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014. DMFUAXT RU http://www.flu.gov/about_the_flu/h1n1/ DMFWKG1 DI DMFWKG1 DMFWKG1 DN Nandrolone DMFWKG1 TI TTS64P2 DMFWKG1 TN Androgen receptor (AR) DMFWKG1 MA Agonist DMFWKG1 RN Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4. DMFWKG1 RU https://pubmed.ncbi.nlm.nih.gov/15931869 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTXT21W DMFX9O6 TN Immunoglobulin gamma Fc receptor IIA (FCGR2A) DMFX9O6 MA Antagonist DMFX9O6 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTYT93M DMFX9O6 TN MAP kinase p38 (MAPK12) DMFX9O6 MA Inhibitor DMFX9O6 RN Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18764722 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT TI TTLFGBV DMFXEWT TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMFXEWT MA Binder DMFXEWT RN Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/15554968 DMFY307 DI DMFY307 DMFY307 DN Hexafluronium bromide DMFY307 TI TTEB0GD DMFY307 TN Cholinesterase (BCHE) DMFY307 MA Inhibitor DMFY307 RN Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90. DMFY307 RU https://pubmed.ncbi.nlm.nih.gov/6711267 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 TI TTK0943 DMFYBD0 TN Prostaglandin G/H synthase (COX) DMFYBD0 MA Modulator DMFYBD0 RN Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64. DMFYBD0 RU https://pubmed.ncbi.nlm.nih.gov/12708604 DMFYZKN DI DMFYZKN DMFYZKN DN Enprofylline DMFYZKN TI TTZ97H5 DMFYZKN TN Phosphodiesterase 4A (PDE4A) DMFYZKN MA Inhibitor DMFYZKN RN Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62. DMFYZKN RU https://pubmed.ncbi.nlm.nih.gov/3034059 DMFZBMQ DI DMFZBMQ DMFZBMQ DN Chloroxine DMFZBMQ TI TTQW87Y DMFZBMQ TN Opioid receptor kappa (OPRK1) DMFZBMQ MA Inhibitor DMFZBMQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFZBMQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT84ETX DMG0H8K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT5FH9Y DMG0H8K TN Human immunodeficiency virus Integrase (HIV IN) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG1DTE DI DMG1DTE DMG1DTE DN Penfluridol DMG1DTE TI TT729IR DMG1DTE TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMG1DTE MA Blocker DMG1DTE RN Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. DMG1DTE RU https://pubmed.ncbi.nlm.nih.gov/11784784 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S TI TTUTN1I DMG281S TN Human Deoxyribonucleic acid (hDNA) DMG281S MA Modulator DMG281S RN Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905. DMG281S RU https://www.ncbi.nlm.nih.gov/pubmed/20719935 DMG2KI4 DI DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 TI TTYRL6O DMG2KI4 TN Glucocorticoid receptor (NR3C1) DMG2KI4 MA Modulator DMG2KI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG2KI4 RU https://www.fda.gov/ DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTELV3W DMG2KW7 TN Transformation-sensitive protein p120 (TRPA1) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTXDKTO DMG2KW7 TN Long transient receptor potential channel 8 (TRPM8) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2SKR DI DMG2SKR DMG2SKR DN Tedizolid DMG2SKR TI TTUWYEA DMG2SKR TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMG2SKR MA Modulator DMG2SKR RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMG2SKR RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMG2YBD DI DMG2YBD DMG2YBD DN Trifluridine DMG2YBD TI TTU6BFZ DMG2YBD TN Candida Thymidylate synthase (Candi TMP1) DMG2YBD MA Inhibitor DMG2YBD RN Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703. DMG2YBD RU https://pubmed.ncbi.nlm.nih.gov/18600528 DMG3F94 DI DMG3F94 DMG3F94 DN Mestranol DMG3F94 TI TTZAYWL DMG3F94 TN Estrogen receptor (ESR) DMG3F94 MA Agonist DMG3F94 RN Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9. DMG3F94 RU https://pubmed.ncbi.nlm.nih.gov/18374427 DMG592Q DI DMG592Q DMG592Q DN Solifenacin DMG592Q TI TTQ13Z5 DMG592Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMG592Q MA Antagonist DMG592Q RN Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. DMG592Q RU https://pubmed.ncbi.nlm.nih.gov/19446545 DMG594T DI DMG594T DMG594T DN Ibritumomab DMG594T TI TTUE541 DMG594T TN Leukocyte surface antigen Leu-16 (CD20) DMG594T RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMG594T RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMG60XN DI DMG60XN DMG60XN DN Phentermine DMG60XN TI TTAWNKZ DMG60XN TN Norepinephrine transporter (NET) DMG60XN MA Inhibitor DMG60XN RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMG60XN RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMG629M DI DMG629M DMG629M DN Rivastigmine DMG629M TI TT1RS9F DMG629M TN Acetylcholinesterase (AChE) DMG629M MA Modulator DMG629M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMG629M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMG6OYJ DI DMG6OYJ DMG6OYJ DN Lorcaserin DMG6OYJ TI TTWJBZ5 DMG6OYJ TN 5-HT 2C receptor (HTR2C) DMG6OYJ MA Agonist DMG6OYJ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMG6OYJ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMG6ZU4 DI DMG6ZU4 DMG6ZU4 DN Lanreotide acetate DMG6ZU4 TI TTZ6T9E DMG6ZU4 TN Somatostatin receptor type 2 (SSTR2) DMG6ZU4 MA Modulator DMG6ZU4 RN Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. DMG6ZU4 RU https://pubmed.ncbi.nlm.nih.gov/16262568 DMG7SQK DI DMG7SQK DMG7SQK DN Rescinnamine DMG7SQK TI TTL69WB DMG7SQK TN Angiotensin-converting enzyme (ACE) DMG7SQK MA Inhibitor DMG7SQK RN Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. DMG7SQK RU https://pubmed.ncbi.nlm.nih.gov/16431399 DMG814N DI DMG814N DMG814N DN Saquinavir DMG814N TI TT5FNQT DMG814N TN Human immunodeficiency virus Protease (HIV PR) DMG814N MA Inhibitor DMG814N RN PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. DMG814N RU https://pubmed.ncbi.nlm.nih.gov/19040279 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 TI TTP3UTW DMG8K57 TN Steroid hormone receptor ERR (ESRR) DMG8K57 MA Modulator DMG8K57 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG8K57 RU https://www.fda.gov/ DMG8MLJ DI DMG8MLJ DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine DMG8MLJ TI TTY4IQ9 DMG8MLJ TN Corynebacterium Mutated CRM197 (Cory mTOX) DMG8MLJ MA Binder DMG8MLJ RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMG8MLJ RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U TI TT5FH9Y DMG9B1U TN Human immunodeficiency virus Integrase (HIV IN) DMG9B1U MA Modulator DMG9B1U RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMG9B1U RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMG9HIA DI DMG9HIA DMG9HIA DN Urofollitropin DMG9HIA TI TTZFDBT DMG9HIA TN Follicle-stimulating hormone receptor (FSHR) DMG9HIA MA Binder DMG9HIA RN Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71. DMG9HIA RU https://pubmed.ncbi.nlm.nih.gov/16026112 DMGA9X0 DI DMGA9X0 DMGA9X0 DN Sodium nitroprusside DMGA9X0 TI TT23PYC DMGA9X0 TN Soluble guanylate cyclase (GCS) DMGA9X0 MA Modulator DMGA9X0 RN Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805. DMGA9X0 RU https://www.ncbi.nlm.nih.gov/pubmed/22482042 DMGAZHU DI DMGAZHU DMGAZHU DN Quattvaxem DMGAZHU TI TT3J5ZI DMGAZHU TN Cell mediated immunity response (CMIR) DMGAZHU RN Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9. DMGAZHU RU https://pubmed.ncbi.nlm.nih.gov/15705477 DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 TI TT34BHT DMGB035 TN Adrenergic receptor alpha-1D (ADRA1D) DMGB035 MA Agonist DMGB035 RN Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364. DMGB035 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/ DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT3WG5C DMGB5RE TN Monoamine oxidase type A (MAO-A) DMGB5RE MA Inhibitor DMGB5RE RN Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/19275775 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TTGP7BY DMGB5RE TN Monoamine oxidase type B (MAO-B) DMGB5RE MA Inhibitor DMGB5RE RN Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/16927039 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT32XQJ DMGB5RE TN Monoamine oxidase (MAO) DMGB5RE MA Inhibitor DMGB5RE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMGB5RE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMGBKVD DI DMGBKVD DMGBKVD DN Gamma hydroxybutyric acid DMGBKVD TI TTDCVZW DMGBKVD TN Gamma-aminobutyric acid B receptor (GABBR) DMGBKVD MA Modulator DMGBKVD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGBKVD RU https://www.fda.gov/ DMGBPSH DI DMGBPSH DMGBPSH DN Homatropine Methylbromide DMGBPSH TI TTH18TF DMGBPSH TN Muscarinic acetylcholine receptor M5 (CHRM5) DMGBPSH MA Antagonist DMGBPSH RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMGBPSH RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMGC5DB DI DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB TI TTJ584C DMGC5DB TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGC5DB MA Agonist DMGC5DB RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMGC5DB RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMGCHDS DI DMGCHDS DMGCHDS DN Sulfamethizole DMGCHDS TI TT4ILYC DMGCHDS TN Bacterial Dihydropteroate synthetase (Bact folP) DMGCHDS MA Inhibitor DMGCHDS RN Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34. DMGCHDS RU https://pubmed.ncbi.nlm.nih.gov/2372557 DMGCSVF DI DMGCSVF DMGCSVF DN Fluticasone DMGCSVF TI TTYRL6O DMGCSVF TN Glucocorticoid receptor (NR3C1) DMGCSVF MA Antagonist DMGCSVF RN Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60. DMGCSVF RU https://pubmed.ncbi.nlm.nih.gov/18536783 DMGD3YH DI DMGD3YH DMGD3YH DN Naldemedine Tosylate DMGD3YH TI TTKWM86 DMGD3YH TN Opioid receptor mu (MOP) DMGD3YH MA Antagonist DMGD3YH RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMGD3YH RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMGDKXN DI DMGDKXN DMGDKXN DN Sitagliptin DMGDKXN TI TTDIGC1 DMGDKXN TN Dipeptidyl peptidase 4 (DPP-4) DMGDKXN MA Inhibitor DMGDKXN RN Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. DMGDKXN RU https://pubmed.ncbi.nlm.nih.gov/19545590 DMGE0CW DI DMGE0CW DMGE0CW DN Glutethimide DMGE0CW TI TTVG215 DMGE0CW TN Debrisoquine 4-hydroxylase (CYP2D6) DMGE0CW MA Inducer DMGE0CW RN A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78. DMGE0CW RU https://pubmed.ncbi.nlm.nih.gov/18818183 DMGEATB DI DMGEATB DMGEATB DN Siltuximab DMGEATB TI TTT1V78 DMGEATB TN Interleukin-6 (IL6) DMGEATB RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGEATB RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTW640A DMGECIJ TN B-lymphocyte surface antigen B4 (CD19) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTUN7MC DMGECIJ TN T-cell surface glycoprotein CD3 (CD3) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGEMB7 DI DMGEMB7 DMGEMB7 DN Hydrocortisone DMGEMB7 TI TTYRL6O DMGEMB7 TN Glucocorticoid receptor (NR3C1) DMGEMB7 MA Modulator DMGEMB7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGEMB7 RU https://www.fda.gov/ DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWG9A4 DMGFB0E TN Adrenergic receptor alpha-2A (ADRA2A) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TT2NUT5 DMGFB0E TN Adrenergic receptor alpha-2C (ADRA2C) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWM4TY DMGFB0E TN Adrenergic receptor alpha-2B (ADRA2B) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFPU2 DI DMGFPU2 DMGFPU2 DN Linezolid DMGFPU2 TI TTLFGBV DMGFPU2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMGFPU2 MA Binder DMGFPU2 RN Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. DMGFPU2 RU https://pubmed.ncbi.nlm.nih.gov/19351617 DMGFV3Z DI DMGFV3Z DMGFV3Z DN Nizatidine DMGFV3Z TI TTQHJ1K DMGFV3Z TN Histamine H2 receptor (H2R) DMGFV3Z MA Antagonist DMGFV3Z RN Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7. DMGFV3Z RU https://pubmed.ncbi.nlm.nih.gov/18979143 DMGFWSM DI DMGFWSM DMGFWSM DN Zaleplon DMGFWSM TI TT1MPAY DMGFWSM TN GABA(A) receptor alpha-1 (GABRA1) DMGFWSM MA Modulator DMGFWSM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGFWSM RU https://www.fda.gov/ DMGIZF5 DI DMGIZF5 DMGIZF5 DN Hydroxyflutamide DMGIZF5 TI TTS64P2 DMGIZF5 TN Androgen receptor (AR) DMGIZF5 MA Antagonist DMGIZF5 RN Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. DMGIZF5 RU https://pubmed.ncbi.nlm.nih.gov/17392714 DMGKT2L DI DMGKT2L DMGKT2L DN Pro-urokinase DMGKT2L TI TTGY7WI DMGKT2L TN Urokinase-type plasminogen activator (PLAU) DMGKT2L MA Modulator DMGKT2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMGKT2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMGKV9D DI DMGKV9D DMGKV9D DN Hydroxocobalamin DMGKV9D TI TTCQ21Y DMGKV9D TN Methylmalonyl-CoA mutase (MMUT) DMGKV9D MA Cofactor DMGKV9D RN Vitamin B12. Nippon Rinsho. 1999 Oct;57(10):2205-10. DMGKV9D RU https://pubmed.ncbi.nlm.nih.gov/10540863 DMGL19D DI DMGL19D DMGL19D DN Enzalutamide DMGL19D TI TTS64P2 DMGL19D TN Androgen receptor (AR) DMGL19D MA Modulator DMGL19D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGL19D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMGLAX1 DI DMGLAX1 DMGLAX1 DN Halcinonide DMGLAX1 TI TTP3UTW DMGLAX1 TN Steroid hormone receptor ERR (ESRR) DMGLAX1 MA Modulator DMGLAX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGLAX1 RU https://www.fda.gov/ DMGLP6S DI DMGLP6S DMGLP6S DN Sarpogrelate DMGLP6S TI TTJQOD7 DMGLP6S TN 5-HT 2A receptor (HTR2A) DMGLP6S MA Antagonist DMGLP6S RN Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30. DMGLP6S RU https://pubmed.ncbi.nlm.nih.gov/19557588 DMGLUQS DI DMGLUQS DMGLUQS DN Rilonacept DMGLUQS TI TTRYK0X DMGLUQS TN Interleukin-1 beta (IL1B) DMGLUQS MA Modulator DMGLUQS RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGLUQS RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGLX0T DI DMGLX0T DMGLX0T DN Grepafloxacin DMGLX0T TI TTN6J5F DMGLX0T TN Bacterial DNA gyrase (Bact gyrase) DMGLX0T MA Modulator DMGLX0T RN Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5. DMGLX0T RU https://www.ncbi.nlm.nih.gov/pubmed/11796384 DMGLZ26 DI DMGLZ26 DMGLZ26 DN Practolol DMGLZ26 TI TTR6W5O DMGLZ26 TN Adrenergic receptor beta-1 (ADRB1) DMGLZ26 MA Antagonist DMGLZ26 RN Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412. DMGLZ26 RU https://pubmed.ncbi.nlm.nih.gov/1335153 DMGM2Z6 DI DMGM2Z6 DMGM2Z6 DN Lonafarnib DMGM2Z6 TI TTXQKM3 DMGM2Z6 TN Farnesyl protein transferase (Ftase) DMGM2Z6 MA Modulator DMGM2Z6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMGM2Z6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf DMGMB30 DI DMGMB30 DMGMB30 DN Ganirelix DMGMB30 TI TT8R70G DMGMB30 TN Gonadotropin-releasing hormone receptor (GNRHR) DMGMB30 MA Antagonist DMGMB30 RN Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32. DMGMB30 RU https://pubmed.ncbi.nlm.nih.gov/17579202 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V TI TTMI6F5 DMGMF6V TN Transient receptor potential cation channel V1 (TRPV1) DMGMF6V MA Agonist DMGMF6V RN Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71. DMGMF6V RU https://pubmed.ncbi.nlm.nih.gov/17217056 DMGMNH3 DI DMGMNH3 DMGMNH3 DN Dalbavancin DMGMNH3 TI TTXMY0J DMGMNH3 TN Pancreatic triacylglycerol lipase (PNLIP) DMGMNH3 MA Inhibitor DMGMNH3 RN Pfizer. Product Development Pipeline. March 31 2009. DMGMNH3 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMGN1PW DI DMGN1PW DMGN1PW DN Indapamide DMGN1PW TI TT846HF DMGN1PW TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMGN1PW MA Blocker DMGN1PW RN Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. DMGN1PW RU https://pubmed.ncbi.nlm.nih.gov/16556441 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY TI TTVKILB DMGN4BY TN Prostaglandin G/H synthase 2 (COX-2) DMGN4BY MA Modulator DMGN4BY RN Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/22714712 DMGN5QD DI DMGN5QD DMGN5QD DN Protirelin DMGN5QD TI TT4J8MF DMGN5QD TN Thyrotropin-releasing hormone receptor (TRHR) DMGN5QD MA Modulator DMGN5QD RN Company report (takeda) DMGN5QD RU https://www.takeda.com/csr/reports/pdf/index/ar2010_04_en.pdf DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTIVDM3 DMGNYIH TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMGNYIH MA Modulator DMGNYIH RN The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/22428574 DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTQ29KF DMGNYIH TN Voltage-gated potassium channel Kv7 (KCNQ) DMGNYIH MA Activator DMGNYIH RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC TI TTIV96N DMGO2MC TN Fatty acid-binding protein 1 (FABP1) DMGO2MC MA Inhibitor DMGO2MC RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DMGO2MC RU https://pubmed.ncbi.nlm.nih.gov/18533710 DMGO72P DI DMGO72P DMGO72P DN Oseltamivir DMGO72P TI TT50QJ3 DMGO72P TN Influenza Neuraminidase (Influ NA) DMGO72P MA Inhibitor DMGO72P RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMGO72P RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMGOVHA DI DMGOVHA DMGOVHA DN Cenobamate DMGOVHA TI TTIG65Q DMGOVHA TN Voltage-gated sodium channel (Nav) DMGOVHA MA Inhibitor DMGOVHA RN Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182. DMGOVHA RU https://pubmed.ncbi.nlm.nih.gov/31063770 DMGOXPQ DI DMGOXPQ DMGOXPQ DN DP-VPA DMGOXPQ TI TTNJYV2 DMGOXPQ TN Gamma-aminobutyric acid receptor (GAR) DMGOXPQ MA Modulator DMGOXPQ RN DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3. DMGOXPQ RU https://pubmed.ncbi.nlm.nih.gov/12137414 DMGP8AX DI DMGP8AX DMGP8AX DN Thiopental DMGP8AX TI TTDP1UC DMGP8AX TN Fatty acid amide hydrolase (FAAH) DMGP8AX MA Inhibitor DMGP8AX RN The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. DMGP8AX RU https://pubmed.ncbi.nlm.nih.gov/12839875 DMGQ0ZI DI DMGQ0ZI DMGQ0ZI DN Pralidoxime chloride DMGQ0ZI TI TT1RS9F DMGQ0ZI TN Acetylcholinesterase (AChE) DMGQ0ZI MA Modulator DMGQ0ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQ0ZI RU https://www.fda.gov/ DMGQFYB DI DMGQFYB DMGQFYB DN Mecamylamine DMGQFYB TI TTJSZTB DMGQFYB TN Nicotinic acetylcholine receptor (nAChR) DMGQFYB MA Antagonist DMGQFYB RN Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. DMGQFYB RU https://pubmed.ncbi.nlm.nih.gov/12080428 DMGQIPT DI DMGQIPT DMGQIPT DN Caspofungin DMGQIPT TI TT0SFXH DMGQIPT TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMGQIPT MA Modulator DMGQIPT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQIPT RU https://www.fda.gov/ DMGQU0Y DI DMGQU0Y DMGQU0Y DN Piperacetazine DMGQU0Y TI TTEX248 DMGQU0Y TN Dopamine D2 receptor (D2R) DMGQU0Y MA Modulator DMGQU0Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQU0Y RU https://www.fda.gov/ DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 TI TTPTXIN DMGR5Z3 TN Translocator protein (TSPO) DMGR5Z3 MA Agonist DMGR5Z3 RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMGR5Z3 RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTYEG6Q DMGS4QH TN Muscarinic acetylcholine receptor M2 (CHRM2) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ3JTF DMGS4QH TN Muscarinic acetylcholine receptor M4 (CHRM4) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ13Z5 DMGS4QH TN Muscarinic acetylcholine receptor M3 (CHRM3) DMGS4QH MA Modulator DMGS4QH RN Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/12540494 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TTN4QDT DMGS80V TN Opioid receptor (OPR) DMGS80V MA Agonist DMGS80V RN Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/14742749 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TT9IK2Z DMGS80V TN N-methyl-D-aspartate receptor (NMDAR) DMGS80V MA Antagonist DMGS80V RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/12507405 DMGSRN1 DI DMGSRN1 DMGSRN1 DN Mipomersen DMGSRN1 TI TTN1IE2 DMGSRN1 TN APOB messenger RNA (APOB mRNA) DMGSRN1 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMGSRN1 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMGTW1I DI DMGTW1I DMGTW1I DN Pirarubicin DMGTW1I TI TTUTN1I DMGTW1I TN Human Deoxyribonucleic acid (hDNA) DMGTW1I MA Modulator DMGTW1I RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGTW1I RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGU74E DI DMGU74E DMGU74E DN Cholecalciferol DMGU74E TI TTK59TV DMGU74E TN Vitamin D3 receptor (VDR) DMGU74E MA Binder DMGU74E RN [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20. DMGU74E RU https://pubmed.ncbi.nlm.nih.gov/18406498 DMGUC9T DI DMGUC9T DMGUC9T DN HEV-239 DMGUC9T TI TT3J5ZI DMGUC9T TN Cell mediated immunity response (CMIR) DMGUC9T RN The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14. DMGUC9T RU https://pubmed.ncbi.nlm.nih.gov/25714510 DMGUX67 DI DMGUX67 DMGUX67 DN Ibopamine hci DMGUX67 TI TTEX248 DMGUX67 TN Dopamine D2 receptor (D2R) DMGUX67 MA Modulator DMGUX67 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGUX67 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGUZ0W DI DMGUZ0W DMGUZ0W DN MELARSOPROL DMGUZ0W TI TT2SUAQ DMGUZ0W TN Cysteine protease (CYP) DMGUZ0W MA Inhibitor DMGUZ0W RN On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide s... J Med Chem. 2009 Sep 24;52(18):5662-72. DMGUZ0W RU https://pubmed.ncbi.nlm.nih.gov/19715342 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU TI TT84ETX DMGV8QU TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGV8QU MA Modulator DMGV8QU RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGV8QU RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N TI TTUTJGQ DMGVH6N TN Vascular endothelial growth factor receptor 2 (KDR) DMGVH6N MA Modulator DMGVH6N RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMGVH6N RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMGVJLB DI DMGVJLB DMGVJLB DN GMA-161 DMGVJLB TI TT7KTSR DMGVJLB TN Immunoglobulin gamma Fc receptor III (FCGR3) DMGVJLB MA Antagonist DMGVJLB RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMGVJLB RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMGVUO5 DI DMGVUO5 DMGVUO5 DN Tislelizumab DMGVUO5 TI TTNBFWK DMGVUO5 TN Programmed cell death protein 1 (PD-1) DMGVUO5 RN Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. DMGVUO5 RU https://pubmed.ncbi.nlm.nih.gov/33044117 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTCJG29 DMGW1ID TN Serine/threonine-protein kinase mTOR (mTOR) DMGW1ID MA Inhibitor DMGW1ID RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTGQUFK DMGW1ID TN PI3K/AKT/mTOR pathway (PAm pathway) DMGW1ID MA Inhibitor DMGW1ID RN The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/24952746 DMGWR0C DI DMGWR0C DMGWR0C DN Sintilimab DMGWR0C TI TTNBFWK DMGWR0C TN Programmed cell death protein 1 (PD-1) DMGWR0C MA Inhibitor DMGWR0C RN Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346. DMGWR0C RU https://pubmed.ncbi.nlm.nih.gov/30742278 DMGXENV DI DMGXENV DMGXENV DN Saxagliptin DMGXENV TI TTDIGC1 DMGXENV TN Dipeptidyl peptidase 4 (DPP-4) DMGXENV MA Inhibitor DMGXENV RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMGXENV RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTZAYWL DMGY0UT TN Estrogen receptor (ESR) DMGY0UT MA Agonist DMGY0UT RN Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/11919305 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTOM3J0 DMGY0UT TN Estrogen receptor beta (ESR2) DMGY0UT MA Agonist DMGY0UT RN Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/10611350 DMGZOVN DI DMGZOVN DMGZOVN DN Benztropine DMGZOVN TI TTZ9SOR DMGZOVN TN Muscarinic acetylcholine receptor M1 (CHRM1) DMGZOVN MA Antagonist DMGZOVN RN Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60. DMGZOVN RU https://pubmed.ncbi.nlm.nih.gov/18417307 DMGZQEF DI DMGZQEF DMGZQEF DN Mifepristone DMGZQEF TI TTYRL6O DMGZQEF TN Glucocorticoid receptor (NR3C1) DMGZQEF MA Modulator DMGZQEF RN The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8. DMGZQEF RU https://pubmed.ncbi.nlm.nih.gov/17509631 DMH07Y3 DI DMH07Y3 DMH07Y3 DN Letrozole DMH07Y3 TI TTSZLWK DMH07Y3 TN Aromatase (CYP19A1) DMH07Y3 MA Inhibitor DMH07Y3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DMH07Y3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DMH0QKA DI DMH0QKA DMH0QKA DN GDC-0199 DMH0QKA TI TTJGNVC DMH0QKA TN Apoptosis regulator Bcl-2 (BCL-2) DMH0QKA MA Modulator DMH0QKA RN ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DMH0QKA RU https://pubmed.ncbi.nlm.nih.gov/23291630 DMH0ZJE DI DMH0ZJE DMH0ZJE DN Mitomycin DMH0ZJE TI TTUTN1I DMH0ZJE TN Human Deoxyribonucleic acid (hDNA) DMH0ZJE MA Binder DMH0ZJE RN Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8. DMH0ZJE RU https://pubmed.ncbi.nlm.nih.gov/19608391 DMH15UV DI DMH15UV DMH15UV DN Tetrahydrofolic acid DMH15UV TI TTQOD3G DMH15UV TN Folate receptor (FOLR) DMH15UV MA Binder DMH15UV RN Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001 Apr 15;102(2):115-20. DMH15UV RU https://pubmed.ncbi.nlm.nih.gov/11323021 DMH1KMT DI DMH1KMT DMH1KMT DN Polidocanol DMH1KMT TI TTT6K3S DMH1KMT TN Endothelium of blood vessels (Endothelium) DMH1KMT MA Modulator DMH1KMT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMH1KMT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B TI TTL69WB DMH1M9B TN Angiotensin-converting enzyme (ACE) DMH1M9B MA Inhibitor DMH1M9B RN Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83. DMH1M9B RU https://pubmed.ncbi.nlm.nih.gov/19572914 DMH2NMY DI DMH2NMY DMH2NMY DN Mepivacaine DMH2NMY TI TTRK8B9 DMH2NMY TN Sodium channel unspecific (NaC) DMH2NMY MA Blocker DMH2NMY RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DMH2NMY RU https://pubmed.ncbi.nlm.nih.gov/11094008 DMH4CFE DI DMH4CFE DMH4CFE DN Antithymocyte globulin DMH4CFE TI TTBGTFN DMH4CFE TN T-cell surface glycoprotein CD1a (CD1A) DMH4CFE MA Binder DMH4CFE RN Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6. DMH4CFE RU https://pubmed.ncbi.nlm.nih.gov/17283492 DMH4IVU DI DMH4IVU DMH4IVU DN Haloprogin DMH4IVU TI TTAH0B3 DMH4IVU TN Fungal Cell membrane (Fung CM) DMH4IVU MA Binder DMH4IVU RN Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. DMH4IVU RU https://pubmed.ncbi.nlm.nih.gov/4608935 DMH5W0G DI DMH5W0G DMH5W0G DN Dipivefrin DMH5W0G TI TTR6W5O DMH5W0G TN Adrenergic receptor beta-1 (ADRB1) DMH5W0G MA Antagonist DMH5W0G RN Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53. DMH5W0G RU https://pubmed.ncbi.nlm.nih.gov/8803576 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB TI TTQHJ1K DMH61ZB TN Histamine H2 receptor (H2R) DMH61ZB MA Antagonist DMH61ZB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMH61ZB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMH6IKO DI DMH6IKO DMH6IKO DN Lusutrombopag DMH6IKO TI TTIHYA4 DMH6IKO TN Thrombopoietin receptor (MPL) DMH6IKO MA Agonist DMH6IKO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMH6IKO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV TI TTEUC8H DMH75KV TN Vitamin K epoxide reductase complex 1 (VKORC1) DMH75KV MA Inhibitor DMH75KV RN Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7. DMH75KV RU https://pubmed.ncbi.nlm.nih.gov/19562511 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TT85JO3 DMH7GN8 TN 5-HT receptor (5HTR) DMH7GN8 MA Modulator DMH7GN8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TTNXLKE DMH7GN8 TN 5-HT 3 receptor (5HT3R) DMH7GN8 MA Modulator DMH7GN8 RN Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/7498299 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTANPDJ DMH7IDQ TN Carbonic anhydrase II (CA-II) DMH7IDQ MA Inhibitor DMH7IDQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH7IDQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTHQPL7 DMH7IDQ TN Carbonic anhydrase I (CA-I) DMH7IDQ MA Modulator DMH7IDQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMH7IDQ RU https://www.fda.gov/ DMH7MUV DI DMH7MUV DMH7MUV DN Zalcitabine DMH7MUV TI TT84ETX DMH7MUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMH7MUV MA Inhibitor DMH7MUV RN A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54. DMH7MUV RU https://pubmed.ncbi.nlm.nih.gov/9833673 DMH7OIA DI DMH7OIA DMH7OIA DN Infliximab DMH7OIA TI TTF8CQI DMH7OIA TN Tumor necrosis factor (TNF) DMH7OIA RN Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. DMH7OIA RU https://pubmed.ncbi.nlm.nih.gov/18414459 DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TTZAYWL DMHA18P TN Estrogen receptor (ESR) DMHA18P MA Modulator DMHA18P RN Pfizer. Product Development Pipeline. March 31 2009. DMHA18P RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TT57ID8 DMHA18P TN Respiratory syncytial virus protein F (RSV F) DMHA18P MA Modulator DMHA18P RN Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. DMHA18P RU https://pubmed.ncbi.nlm.nih.gov/19562644 DMHAQCO DI DMHAQCO DMHAQCO DN Trichlormethiazide DMHAQCO TI TTS087L DMHAQCO TN Solute carrier family 12 member 1 (SLC12A1) DMHAQCO MA Blocker DMHAQCO RN Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. DMHAQCO RU https://pubmed.ncbi.nlm.nih.gov/17414671 DMHAUO0 DI DMHAUO0 DMHAUO0 DN Acetyldigitoxin DMHAUO0 TI TTWK8D0 DMHAUO0 TN Sodium pump subunit alpha-1 (ATP1A1) DMHAUO0 MA Modulator DMHAUO0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHAUO0 RU https://www.fda.gov/ DMHCI9S DI DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S TI TTP3UTW DMHCI9S TN Steroid hormone receptor ERR (ESRR) DMHCI9S MA Modulator DMHCI9S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCI9S RU https://www.fda.gov/ DMHCTAL DI DMHCTAL DMHCTAL DN Cryptenamine Acetates DMHCTAL TI TTH18TF DMHCTAL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHCTAL MA Modulator DMHCTAL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCTAL RU https://www.fda.gov/ DMHD4PE DI DMHD4PE DMHD4PE DN Desvenlafaxine DMHD4PE TI TT3ROYC DMHD4PE TN Serotonin transporter (SERT) DMHD4PE MA Modulator DMHD4PE RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMHD4PE RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMHDF7B DI DMHDF7B DMHDF7B DN Thiamylal DMHDF7B TI TTEX6LM DMHDF7B TN GABA(A) receptor gamma-3 (GABRG3) DMHDF7B MA Modulator DMHDF7B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHDF7B RU https://www.fda.gov/ DMHERIJ DI DMHERIJ DMHERIJ DN Capromab DMHERIJ TI TT9G4N0 DMHERIJ TN Glutamate carboxypeptidase II (GCPII) DMHERIJ RN Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28. DMHERIJ RU https://pubmed.ncbi.nlm.nih.gov/17161036 DMHF4IQ DI DMHF4IQ DMHF4IQ DN Trimethaphan DMHF4IQ TI TT4H1MQ DMHF4IQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMHF4IQ MA Antagonist DMHF4IQ RN Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40. DMHF4IQ RU https://pubmed.ncbi.nlm.nih.gov/7963258 DMHFJDT DI DMHFJDT DMHFJDT DN Procyclidine DMHFJDT TI TTH18TF DMHFJDT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHFJDT MA Antagonist DMHFJDT RN Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol. 2004 May 1;196(3):327-36. DMHFJDT RU https://pubmed.ncbi.nlm.nih.gov/15094303 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTSQIFT DMHG57U TN 5-HT 1A receptor (HTR1A) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTEX248 DMHG57U TN Dopamine D2 receptor (D2R) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHIDCJ DI DMHIDCJ DMHIDCJ DN Octreotide DMHIDCJ TI TTZ6T9E DMHIDCJ TN Somatostatin receptor type 2 (SSTR2) DMHIDCJ MA Binder DMHIDCJ RN Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. DMHIDCJ RU https://pubmed.ncbi.nlm.nih.gov/19537708 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TTGP7BY DMHIDUE TN Monoamine oxidase type B (MAO-B) DMHIDUE MA Inhibitor DMHIDUE RN Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34. DMHIDUE RU https://pubmed.ncbi.nlm.nih.gov/18539478 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TT32XQJ DMHIDUE TN Monoamine oxidase (MAO) DMHIDUE MA Inhibitor DMHIDUE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHIDUE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHJV0X DI DMHJV0X DMHJV0X DN Pertuzumab DMHJV0X TI TT6EO5L DMHJV0X TN Erbb2 tyrosine kinase receptor (HER2) DMHJV0X MA Inhibitor DMHJV0X RN Clinical pipeline report, company report or official report of Roche (2009). DMHJV0X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMHJVOL DI DMHJVOL DMHJVOL DN Nabi-HB DMHJVOL TI TT6KSF7 DMHJVOL TN Hepatitis B virus Large envelope protein (HBV S) DMHJVOL MA Modulator DMHJVOL RN Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report. DMHJVOL RU http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117658.pdf DMHKS94 DI DMHKS94 DMHKS94 DN Valaciclovir DMHKS94 TI TTIU7X1 DMHKS94 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMHKS94 MA Inhibitor DMHKS94 RN Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15. DMHKS94 RU https://pubmed.ncbi.nlm.nih.gov/19239637 DMHL7OB DI DMHL7OB DMHL7OB DN Uracil mustard DMHL7OB TI TTUTN1I DMHL7OB TN Human Deoxyribonucleic acid (hDNA) DMHL7OB MA Modulator DMHL7OB RN Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8. DMHL7OB RU https://pubmed.ncbi.nlm.nih.gov/8625472 DMHLP9C DI DMHLP9C DMHLP9C DN Felypressin DMHLP9C TI TT4TFGN DMHLP9C TN Vasopressin V1a receptor (V1AR) DMHLP9C MA Agonist DMHLP9C RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMHLP9C RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTJX3UE DMHM7JS TN Somatostatin receptor type 3 (SSTR3) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTIND6G DMHM7JS TN Somatostatin receptor type 1 (SSTR1) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTZ6T9E DMHM7JS TN Somatostatin receptor type 2 (SSTR2) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TT2BC4G DMHM7JS TN Somatostatin receptor type 5 (SSTR5) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT9SL3Q DMHM93Y TN Polypeptide deformylase (PDF) DMHM93Y MA Inhibitor DMHM93Y RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT1MPAY DMHM93Y TN GABA(A) receptor alpha-1 (GABRA1) DMHM93Y MA Antagonist DMHM93Y RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TTBZ7OD DMHM93Y TN Protein kinase C epsilon (PRKCE) DMHM93Y MA Stimulator DMHM93Y RN Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957. DMHM93Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760692/ DMHMP05 DI DMHMP05 DMHMP05 DN Carprofen DMHMP05 TI TTVKILB DMHMP05 TN Prostaglandin G/H synthase 2 (COX-2) DMHMP05 MA Inhibitor DMHMP05 RN Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. DMHMP05 RU https://pubmed.ncbi.nlm.nih.gov/17181139 DMHN027 DI DMHN027 DMHN027 DN Levothyroxine DMHN027 TI TTTSEPU DMHN027 TN Thyroid hormone receptor alpha (THRA) DMHN027 MA Antagonist DMHN027 RN Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23. DMHN027 RU https://pubmed.ncbi.nlm.nih.gov/18816177 DMHNQOG DI DMHNQOG DMHNQOG DN Zafirlukast DMHNQOG TI TTGKOY9 DMHNQOG TN Leukotriene CysLT1 receptor (CYSLTR1) DMHNQOG MA Antagonist DMHNQOG RN Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45. DMHNQOG RU https://pubmed.ncbi.nlm.nih.gov/12512231 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR TI TTK59TV DMHO0AR TN Vitamin D3 receptor (VDR) DMHO0AR MA Antagonist DMHO0AR RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMHO0AR RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMHOAUG DI DMHOAUG DMHOAUG DN Rimegepant DMHOAUG TI TTY6O0Q DMHOAUG TN Calcitonin gene-related peptide receptor (CGRPR) DMHOAUG MA Antagonist DMHOAUG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMHOAUG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TT27RFC DMHP21E TN Opioid receptor delta (OPRD1) DMHP21E MA Binder DMHP21E RN Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12. DMHP21E RU https://pubmed.ncbi.nlm.nih.gov/14998329 DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TTKWM86 DMHP21E TN Opioid receptor mu (MOP) DMHP21E MA Inhibitor DMHP21E RN Clinical pipeline report, company report or official report of signaturerx. DMHP21E RU http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids DMHP8FI DI DMHP8FI DMHP8FI DN Methscopolamine bromide DMHP8FI TI TTQ13Z5 DMHP8FI TN Muscarinic acetylcholine receptor M3 (CHRM3) DMHP8FI MA Modulator DMHP8FI RN Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43. DMHP8FI RU https://www.ncbi.nlm.nih.gov/pubmed/7693670 DMHP9BL DI DMHP9BL DMHP9BL DN Etelcalcetide DMHP9BL TI TTBUYHA DMHP9BL TN Extracellular calcium-sensing receptor (CASR) DMHP9BL MA Modulator DMHP9BL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHP9BL RU https://www.fda.gov/ DMHPRWG DI DMHPRWG DMHPRWG DN Exjade DMHPRWG TI TTUDR0C DMHPRWG TN Iron (Fe) DMHPRWG MA Modulator DMHPRWG RN Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. DMHPRWG RU https://pubmed.ncbi.nlm.nih.gov/17927285 DMHPWOM DI DMHPWOM DMHPWOM DN Diphenidol DMHPWOM TI TTQ3JTF DMHPWOM TN Muscarinic acetylcholine receptor M4 (CHRM4) DMHPWOM MA Antagonist DMHPWOM RN Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6. DMHPWOM RU https://pubmed.ncbi.nlm.nih.gov/18395442 DMHR8KW DI DMHR8KW DMHR8KW DN Alvimopan DMHR8KW TI TTKWM86 DMHR8KW TN Opioid receptor mu (MOP) DMHR8KW MA Antagonist DMHR8KW RN Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. DMHR8KW RU https://pubmed.ncbi.nlm.nih.gov/19574601 DMHRG8Q DI DMHRG8Q DMHRG8Q DN Carbidopa DMHRG8Q TI TTN451K DMHRG8Q TN Aromatic-L-amino-acid decarboxylase (DDC) DMHRG8Q MA Inhibitor DMHRG8Q RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMHRG8Q RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 TI TTJP4SM DMHSJB4 TN Bacterial Penicillin binding protein (Bact PBP) DMHSJB4 MA Binder DMHSJB4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMHSJB4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TT4DXQT DMHSY1I TN Proto-oncogene c-Ret (RET) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTUTJGQ DMHSY1I TN Vascular endothelial growth factor receptor 2 (KDR) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTX41N9 DMHSY1I TN Tyrosine-protein kinase Kit (KIT) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTN6J5F DMHT34O TN Bacterial DNA gyrase (Bact gyrase) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTIXTO3 DMHT34O TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHTB31 DI DMHTB31 DMHTB31 DN Carphenazine DMHTB31 TI TTEX248 DMHTB31 TN Dopamine D2 receptor (D2R) DMHTB31 MA Antagonist DMHTB31 RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMHTB31 RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO TI TTG28O6 DMHTEAO TN Adrenergic receptor Alpha-1 (ADRA1) DMHTEAO MA Antagonist DMHTEAO RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMHTEAO RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMHTXSL DI DMHTXSL DMHTXSL DN Arbekacin DMHTXSL TI TTA4FIU DMHTXSL TN Ribosome A (hRA) DMHTXSL MA Modulator DMHTXSL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMHTXSL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTC1GLB DMHTYK3 TN Interleukin-23 (IL23) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTRTK6Y DMHTYK3 TN Interleukin-12 alpha (IL12A) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TT9SL3Q DMHTYK3 TN Polypeptide deformylase (PDF) DMHTYK3 MA Inhibitor DMHTYK3 RN Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/12384337 DMHVBG1 DI DMHVBG1 DMHVBG1 DN Naftifine DMHVBG1 TI TTE14XG DMHVBG1 TN Squalene monooxygenase (SQLE) DMHVBG1 MA Inhibitor DMHVBG1 RN Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7. DMHVBG1 RU https://pubmed.ncbi.nlm.nih.gov/8834895 DMHVJFK DI DMHVJFK DMHVJFK DN Misoprostol DMHVJFK TI TTOFYT1 DMHVJFK TN Prostacyclin receptor (PTGIR) DMHVJFK MA Antagonist DMHVJFK RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMHVJFK RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMHVL0J DI DMHVL0J DMHVL0J DN Azelaic Acid DMHVL0J TI TT2A0DR DMHVL0J TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMHVL0J MA Inhibitor DMHVL0J RN Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. DMHVL0J RU https://pubmed.ncbi.nlm.nih.gov/3207614 DMHVWIK DI DMHVWIK DMHVWIK DN Cefepime DMHVWIK TI TTHWB7G DMHVWIK TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMHVWIK MA Modulator DMHVWIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHVWIK RU https://www.fda.gov/ DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P TI TTJP4SM DMHWE7P TN Bacterial Penicillin binding protein (Bact PBP) DMHWE7P MA Binder DMHWE7P RN Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/11959556 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTJ584C DMHY3IP TN Peroxisome proliferator-activated receptor alpha (PPARA) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTZMAO3 DMHY3IP TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHZCPO DI DMHZCPO DMHZCPO DN Ibrutinib DMHZCPO TI TTGM6VW DMHZCPO TN Tyrosine-protein kinase BTK (ATK) DMHZCPO MA Inhibitor DMHZCPO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DMHZCPO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DMHZJCG DI DMHZJCG DMHZJCG DN Pentamidine DMHZJCG TI TTM1TDX DMHZJCG TN Tryptase alpha/beta-1 (Tryptase) DMHZJCG MA Inhibitor DMHZJCG RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMHZJCG RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMHZV7X DI DMHZV7X DMHZV7X DN Golimumab DMHZV7X TI TTF8CQI DMHZV7X TN Tumor necrosis factor (TNF) DMHZV7X RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHZV7X RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMI0GDH DI DMI0GDH DMI0GDH DN Oxybuprocaine DMI0GDH TI TTRK8B9 DMI0GDH TN Sodium channel unspecific (NaC) DMI0GDH MA Blocker DMI0GDH RN Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. DMI0GDH RU https://pubmed.ncbi.nlm.nih.gov/19429093 DMI0RHA DI DMI0RHA DMI0RHA DN Inebilizumab DMI0RHA TI TTW640A DMI0RHA TN B-lymphocyte surface antigen B4 (CD19) DMI0RHA MA Inhibitor DMI0RHA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMI0RHA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf DMI18HW DI DMI18HW DMI18HW DN Benzocaine DMI18HW TI TTRK8B9 DMI18HW TN Sodium channel unspecific (NaC) DMI18HW MA Blocker DMI18HW RN Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94. DMI18HW RU https://pubmed.ncbi.nlm.nih.gov/17967784 DMI2QPE DI DMI2QPE DMI2QPE DN Didanosine DMI2QPE TI TT84ETX DMI2QPE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI2QPE MA Inhibitor DMI2QPE RN The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. DMI2QPE RU https://pubmed.ncbi.nlm.nih.gov/19412117 DMI347A DI DMI347A DMI347A DN Lamivudine DMI347A TI TT84ETX DMI347A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI347A MA Modulator DMI347A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI347A RU https://www.fda.gov/ DMI40NL DI DMI40NL DMI40NL DN Tolazoline DMI40NL TI TTEX248 DMI40NL TN Dopamine D2 receptor (D2R) DMI40NL MA Antagonist DMI40NL RN Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31. DMI40NL RU https://pubmed.ncbi.nlm.nih.gov/16368348 DMI4EL5 DI DMI4EL5 DMI4EL5 DN Ketorolac DMI4EL5 TI TTK0943 DMI4EL5 TN Prostaglandin G/H synthase (COX) DMI4EL5 MA Inhibitor DMI4EL5 RN Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. DMI4EL5 RU https://pubmed.ncbi.nlm.nih.gov/17369458 DMI53FU DI DMI53FU DMI53FU DN Gaboxadol DMI53FU TI TTGXH6N DMI53FU TN GABA(A) receptor delta (GABRD) DMI53FU MA Modulator DMI53FU RN Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6. DMI53FU RU https://www.ncbi.nlm.nih.gov/pubmed/16368265 DMI5678 DI DMI5678 DMI5678 DN Pirbuterol DMI5678 TI TT2CJVK DMI5678 TN Adrenergic receptor beta-2 (ADRB2) DMI5678 MA Agonist DMI5678 RN Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. DMI5678 RU https://pubmed.ncbi.nlm.nih.gov/17594727 DMI5DW1 DI DMI5DW1 DMI5DW1 DN Hesperidin DMI5DW1 TI TT4FDG6 DMI5DW1 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMI5DW1 MA Inhibitor DMI5DW1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMI5DW1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMI5OXG DI DMI5OXG DMI5OXG DN Latanoprost DMI5OXG TI TTT2ZAR DMI5OXG TN Prostaglandin F2-alpha receptor (PTGFR) DMI5OXG MA Agonist DMI5OXG RN PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70. DMI5OXG RU https://pubmed.ncbi.nlm.nih.gov/19384589 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTGJCWZ DMI6E0R TN Fms-like tyrosine kinase 3 (FLT-3) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTRFOXJ DMI6E0R TN Protein kinase C gamma (PRKCG) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6GKT DI DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT TI TTYHPRQ DMI6GKT TN Sodium pump (NaP) DMI6GKT MA Modulator DMI6GKT RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMI6GKT RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMI6HUW DI DMI6HUW DMI6HUW DN Terbinafine DMI6HUW TI TTM9XSU DMI6HUW TN Candida Squalene epoxidase (Candi ERG1) DMI6HUW MA Modulator DMI6HUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI6HUW RU https://www.fda.gov/ DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S TI TT0LF7H DMI782S TN Fibroblast growth factor receptor (FGFR) DMI782S MA Inhibitor DMI782S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf DMI783H DI DMI783H DMI783H DN Vonvendi DMI783H TI TT3SZBT DMI783H TN von Willebrand factor (VWF) DMI783H MA Replacement DMI783H RN Clinical pipeline report, company report or official report of Vonvendi. DMI783H RU https://www.vonvendi.com/ DMI7DZ2 DI DMI7DZ2 DMI7DZ2 DN Prilocaine DMI7DZ2 TI TTZOVE0 DMI7DZ2 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMI7DZ2 MA Blocker DMI7DZ2 RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMI7DZ2 RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMI7FVQ DI DMI7FVQ DMI7FVQ DN Metyrapone DMI7FVQ TI TTIQUX7 DMI7FVQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMI7FVQ MA Inhibitor DMI7FVQ RN Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21. DMI7FVQ RU https://pubmed.ncbi.nlm.nih.gov/11869873 DMI9FBP DI DMI9FBP DMI9FBP DN Imipenem DMI9FBP TI TTHWB7G DMI9FBP TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMI9FBP MA Binder DMI9FBP RN A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31. DMI9FBP RU https://pubmed.ncbi.nlm.nih.gov/11061029 DMI9PRJ DI DMI9PRJ DMI9PRJ DN Diflorasone DMI9PRJ TI TT9V5JH DMI9PRJ TN Phospholipase A2 (PLA2G1B) DMI9PRJ MA Inhibitor DMI9PRJ RN Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. DMI9PRJ RU https://pubmed.ncbi.nlm.nih.gov/19013475 DMIBH7M DI DMIBH7M DMIBH7M DN L-tryptophan DMIBH7M TI TTZJYKH DMIBH7M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIBH7M MA Binder DMIBH7M RN Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38. DMIBH7M RU https://pubmed.ncbi.nlm.nih.gov/16834326 DMIBNG2 DI DMIBNG2 DMIBNG2 DN Picrotoxin DMIBNG2 TI TT1MPAY DMIBNG2 TN GABA(A) receptor alpha-1 (GABRA1) DMIBNG2 MA Antagonist DMIBNG2 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMIBNG2 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTIMJ02 DMICA9H TN ATP-binding cassette transporter G2 (ABCG2) DMICA9H MA Inhibitor DMICA9H RN The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/8596047 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTSXVID DMICA9H TN Nuclear factor NF-kappa-B (NFKB) DMICA9H MA Activator DMICA9H RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTPMQSO DMICDLV TN ALK tyrosine kinase receptor (ALK) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTSZ6Y3 DMICDLV TN Proto-oncogene c-Ros (ROS1) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIEU69 DI DMIEU69 DMIEU69 DN Salmeterol DMIEU69 TI TT2CJVK DMIEU69 TN Adrenergic receptor beta-2 (ADRB2) DMIEU69 MA Agonist DMIEU69 RN Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65. DMIEU69 RU https://pubmed.ncbi.nlm.nih.gov/19059068 DMIFYLX DI DMIFYLX DMIFYLX DN Bopindolol DMIFYLX TI TTMXGCW DMIFYLX TN Adrenergic receptor beta-3 (ADRB3) DMIFYLX MA Modulator DMIFYLX RN Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. DMIFYLX RU https://pubmed.ncbi.nlm.nih.gov/2439825 DMIG6FY DI DMIG6FY DMIG6FY DN Amdinocillin DMIG6FY TI TTHWB7G DMIG6FY TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMIG6FY MA Inhibitor DMIG6FY RN Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22. DMIG6FY RU https://pubmed.ncbi.nlm.nih.gov/18390656 DMIG8DW DI DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW TI TTYRL6O DMIG8DW TN Glucocorticoid receptor (NR3C1) DMIG8DW MA Agonist DMIG8DW RN Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505. DMIG8DW RU https://pubmed.ncbi.nlm.nih.gov/23936221 DMIHRNA DI DMIHRNA DMIHRNA DN Tolazamide DMIHRNA TI TTG140O DMIHRNA TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMIHRNA MA Blocker DMIHRNA RN Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4. DMIHRNA RU https://pubmed.ncbi.nlm.nih.gov/8799949 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC TI TT9IK2Z DMIJATC TN N-methyl-D-aspartate receptor (NMDAR) DMIJATC MA Antagonist DMIJATC RN Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. DMIJATC RU https://pubmed.ncbi.nlm.nih.gov/11861810 DMIJC9X DI DMIJC9X DMIJC9X DN Osilodrostat DMIJC9X TI TTIQUX7 DMIJC9X TN Steroid 11-beta-hydroxylase (CYP11B1) DMIJC9X MA Modulator DMIJC9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMIJC9X RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf DMIJRF0 DI DMIJRF0 DMIJRF0 DN Anisotropine Methylbromide DMIJRF0 TI TTH18TF DMIJRF0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMIJRF0 MA Binder DMIJRF0 RN Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8. DMIJRF0 RU https://pubmed.ncbi.nlm.nih.gov/13966843 DMIK367 DI DMIK367 DMIK367 DN Procarbazine DMIK367 TI TTUTN1I DMIK367 TN Human Deoxyribonucleic acid (hDNA) DMIK367 RN Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86. DMIK367 RU https://pubmed.ncbi.nlm.nih.gov/18840549 DMIKFEL DI DMIKFEL DMIKFEL DN Levomepromazine DMIKFEL TI TTEX248 DMIKFEL TN Dopamine D2 receptor (D2R) DMIKFEL MA Modulator DMIKFEL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIKFEL RU https://www.fda.gov/ DMIKHN0 DI DMIKHN0 DMIKHN0 DN Meticillin DMIKHN0 TI TTJP4SM DMIKHN0 TN Bacterial Penicillin binding protein (Bact PBP) DMIKHN0 MA Binder DMIKHN0 RN A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58. DMIKHN0 RU https://pubmed.ncbi.nlm.nih.gov/16946250 DMINO7Z DI DMINO7Z DMINO7Z DN Perhexiline DMINO7Z TI TTDL0NY DMINO7Z TN Carnitine O-palmitoyltransferase I (CPT1B) DMINO7Z MA Inhibitor DMINO7Z RN Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97. DMINO7Z RU https://pubmed.ncbi.nlm.nih.gov/17445089 DMINOX3 DI DMINOX3 DMINOX3 DN Vincristine DMINOX3 TI TTYFKSZ DMINOX3 TN Tubulin beta (TUBB) DMINOX3 MA Modulator DMINOX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMINOX3 RU https://www.fda.gov/ DMINRKW DI DMINRKW DMINRKW DN Clomipramine DMINRKW TI TT3ROYC DMINRKW TN Serotonin transporter (SERT) DMINRKW MA Inhibitor DMINRKW RN Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. DMINRKW RU https://pubmed.ncbi.nlm.nih.gov/19366379 DMINZ4W DI DMINZ4W DMINZ4W DN Tetrahydrobiopterin DMINZ4W TI TTUHP71 DMINZ4W TN Tyrosine 3-monooxygenase (TH) DMINZ4W MA Cofactor DMINZ4W RN Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20. DMINZ4W RU https://pubmed.ncbi.nlm.nih.gov/17982884 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTANPDJ DMIO1K0 TN Carbonic anhydrase II (CA-II) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTSYM0R DMIO1K0 TN Carbonic anhydrase XII (CA-XII) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTCFSPE DMIO1K0 TN Carbonic anhydrase VI (CA-VI) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTEYTKG DMIO1K0 TN Carbonic anhydrase XIV (CA-XIV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTZHA0O DMIO1K0 TN Carbonic anhydrase IV (CA-IV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTUNARX DMIO1K0 TN Carbonic anhydrase (CA) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO4V5 DI DMIO4V5 DMIO4V5 DN VRX496 DMIO4V5 TI TTXVOJ5 DMIO4V5 TN Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) DMIO4V5 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMIO4V5 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TTKRD0G DMIOGBU TN Endothelin A receptor (EDNRA) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TT3ZTGU DMIOGBU TN Endothelin B receptor (EDNRB) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOZ29 DI DMIOZ29 DMIOZ29 DN Glycine DMIOZ29 TI TTKJEMQ DMIOZ29 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMIOZ29 MA Antagonist DMIOZ29 RN Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78. DMIOZ29 RU https://pubmed.ncbi.nlm.nih.gov/19562643 DMIP3ZV DI DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV TI TT2CJVK DMIP3ZV TN Adrenergic receptor beta-2 (ADRB2) DMIP3ZV MA Agonist DMIP3ZV RN Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75. DMIP3ZV RU https://pubmed.ncbi.nlm.nih.gov/19334040 DMIR5QP DI DMIR5QP DMIR5QP DN Azlocillin DMIR5QP TI TTJP4SM DMIR5QP TN Bacterial Penicillin binding protein (Bact PBP) DMIR5QP MA Binder DMIR5QP RN Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8. DMIR5QP RU https://pubmed.ncbi.nlm.nih.gov/2515794 DMIRMVB DI DMIRMVB DMIRMVB DN Methadyl Acetate DMIRMVB TI TTKWM86 DMIRMVB TN Opioid receptor mu (MOP) DMIRMVB MA Agonist DMIRMVB RN Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9. DMIRMVB RU https://pubmed.ncbi.nlm.nih.gov/6268422 DMISH0Z DI DMISH0Z DMISH0Z DN Mogamulizumab DMISH0Z TI TT7HQD0 DMISH0Z TN C-C chemokine receptor type 4 (CCR4) DMISH0Z MA Inhibitor DMISH0Z RN Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9. DMISH0Z RU https://pubmed.ncbi.nlm.nih.gov/21154168 DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX TI TTK8CXU DMIT8LX TN 5-HT 1B receptor (HTR1B) DMIT8LX MA Modulator DMIT8LX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIT8LX RU https://www.fda.gov/ DMITQS0 DI DMITQS0 DMITQS0 DN Lopinavir DMITQS0 TI TTLFGBV DMITQS0 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMITQS0 MA Modulator DMITQS0 RN Company report (JMI Laboratories) DMITQS0 RU http://www.jmilabs.com/data/posters/ICAAC2013%5CE-144.pdf DMITSEH DI DMITSEH DMITSEH DN Isoetharine DMITSEH TI TT2CJVK DMITSEH TN Adrenergic receptor beta-2 (ADRB2) DMITSEH MA Modulator DMITSEH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMITSEH RU https://www.fda.gov/ DMIUW25 DI DMIUW25 DMIUW25 DN Granisetron DMIUW25 TI TTNXLKE DMIUW25 TN 5-HT 3 receptor (5HT3R) DMIUW25 MA Antagonist DMIUW25 RN New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7. DMIUW25 RU https://pubmed.ncbi.nlm.nih.gov/17034670 DMIUX3D DI DMIUX3D DMIUX3D DN Methyl aminolevulinate DMIUX3D TI TTQ6VF4 DMIUX3D TN Ferrochelatase (FECH) DMIUX3D MA Activator DMIUX3D RN Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43. DMIUX3D RU https://pubmed.ncbi.nlm.nih.gov/19447864 DMIUYFH DI DMIUYFH DMIUYFH DN Sulfapyridine DMIUYFH TI TT4ILYC DMIUYFH TN Bacterial Dihydropteroate synthetase (Bact folP) DMIUYFH MA Inhibitor DMIUYFH RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMIUYFH RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMIVJ0D DI DMIVJ0D DMIVJ0D DN Pseudoephedrine DMIVJ0D TI TTEX248 DMIVJ0D TN Dopamine D2 receptor (D2R) DMIVJ0D MA Stimulator DMIVJ0D RN Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2. DMIVJ0D RU https://pubmed.ncbi.nlm.nih.gov/11772135 DMIWFRL DI DMIWFRL DMIWFRL DN Tolvaptan DMIWFRL TI TTK8R02 DMIWFRL TN Vasopressin V2 receptor (V2R) DMIWFRL MA Antagonist DMIWFRL RN Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84. DMIWFRL RU https://pubmed.ncbi.nlm.nih.gov/19196236 DMIXC7G DI DMIXC7G DMIXC7G DN Zoledronate DMIXC7G TI TTIKWV4 DMIXC7G TN Geranyltranstransferase (FDPS) DMIXC7G MA Modulator DMIXC7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIXC7G RU https://www.fda.gov/ DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTUTJGQ DMIYDT4 TN Vascular endothelial growth factor receptor 2 (KDR) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTNDSF4 DMIYDT4 TN Proto-oncogene c-Met (MET) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z TI TT1RS9F DMIYG7Z TN Acetylcholinesterase (AChE) DMIYG7Z MA Modulator DMIYG7Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMIYG7Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMIYJFV DI DMIYJFV DMIYJFV DN Nicorandil DMIYJFV TI TTEF5MJ DMIYJFV TN ATP-binding cassette transporter C9 (ABCC9) DMIYJFV MA Activator DMIYJFV RN A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6. DMIYJFV RU https://pubmed.ncbi.nlm.nih.gov/15978900 DMIZ1E8 DI DMIZ1E8 DMIZ1E8 DN Galcanezumab DMIZ1E8 TI TTY6O0Q DMIZ1E8 TN Calcitonin gene-related peptide receptor (CGRPR) DMIZ1E8 MA Modulator DMIZ1E8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMIZ1E8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIZ6W2 DI DMIZ6W2 DMIZ6W2 DN Norfloxacin DMIZ6W2 TI TTN6J5F DMIZ6W2 TN Bacterial DNA gyrase (Bact gyrase) DMIZ6W2 MA Modulator DMIZ6W2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIZ6W2 RU https://www.fda.gov/ DMJ01D8 DI DMJ01D8 DMJ01D8 DN Colforsin daropate hci DMJ01D8 TI TTULOB6 DMJ01D8 TN Cathelicidin antimicrobial peptide (CAMP) DMJ01D8 MA Modulator DMJ01D8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJ01D8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT84ETX DMJ0QOW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJ0QOW MA Inhibitor DMJ0QOW RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT90XZ8 DMJ0QOW TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMJ0QOW MA Inhibitor DMJ0QOW RN Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/15044438 DMJ13KI DI DMJ13KI DMJ13KI DN Terconazole DMJ13KI TI TTTSOUD DMJ13KI TN Candida Cytochrome P450 51 (Candi ERG11) DMJ13KI MA Inhibitor DMJ13KI RN Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. DMJ13KI RU https://pubmed.ncbi.nlm.nih.gov/1951574 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTH029C DMJ2AH4 TN Retinoic acid receptor RXR-gamma (RXRG) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTOD7B3 DMJ2AH4 TN Retinoic acid receptor (RAR) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTRTKPV DMJ2AH4 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMJ2AH4 MA Binder DMJ2AH4 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMJ2O7B DI DMJ2O7B DMJ2O7B DN Gemtuzumab ozogamicin DMJ2O7B TI TTJVYO3 DMJ2O7B TN Myeloid cell surface antigen CD33 (CD33) DMJ2O7B RN Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205. DMJ2O7B RU https://pubmed.ncbi.nlm.nih.gov/19503782 DMJ3I1Q DI DMJ3I1Q DMJ3I1Q DN Niflumic acid DMJ3I1Q TI TTVKILB DMJ3I1Q TN Prostaglandin G/H synthase 2 (COX-2) DMJ3I1Q MA Inhibitor DMJ3I1Q RN Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. DMJ3I1Q RU https://pubmed.ncbi.nlm.nih.gov/17485303 DMJ47QC DI DMJ47QC DMJ47QC DN Thyrotropin DMJ47QC TI TT6NYJA DMJ47QC TN Thyrotropin receptor (TSHR) DMJ47QC MA Modulator DMJ47QC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ47QC RU https://www.fda.gov/ DMJ4AWC DI DMJ4AWC DMJ4AWC DN Cyclothiazide DMJ4AWC TI TTANPDJ DMJ4AWC TN Carbonic anhydrase II (CA-II) DMJ4AWC MA Inhibitor DMJ4AWC RN Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82. DMJ4AWC RU https://pubmed.ncbi.nlm.nih.gov/8914012 DMJ6H1Z DI DMJ6H1Z DMJ6H1Z DN Quinestrol DMJ6H1Z TI TTZAYWL DMJ6H1Z TN Estrogen receptor (ESR) DMJ6H1Z MA Modulator DMJ6H1Z RN The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007 Mar;40(3):674-84. DMJ6H1Z RU https://pubmed.ncbi.nlm.nih.gov/17174166 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H TI TTJP4SM DMJ7A0H TN Bacterial Penicillin binding protein (Bact PBP) DMJ7A0H MA Binder DMJ7A0H RN Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. DMJ7A0H RU https://pubmed.ncbi.nlm.nih.gov/17540669 DMJ7IQX DI DMJ7IQX DMJ7IQX DN Crestor/TriLipix DMJ7IQX TI TTPADOQ DMJ7IQX TN HMG-CoA reductase (HMGCR) DMJ7IQX MA Inhibitor DMJ7IQX RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJ7IQX RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJ8A3Z DI DMJ8A3Z DMJ8A3Z DN Florbetapir F-18 DMJ8A3Z TI TTE4KHA DMJ8A3Z TN Amyloid beta A4 protein (APP) DMJ8A3Z MA Modulator DMJ8A3Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMJ8A3Z RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMJ8NMC DI DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC TI TT1MPAY DMJ8NMC TN GABA(A) receptor alpha-1 (GABRA1) DMJ8NMC MA Antagonist DMJ8NMC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJ8NMC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJ90O5 DI DMJ90O5 DMJ90O5 DN Medrysone DMJ90O5 TI TTP3UTW DMJ90O5 TN Steroid hormone receptor ERR (ESRR) DMJ90O5 MA Modulator DMJ90O5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ90O5 RU https://www.fda.gov/ DMJ93CT DI DMJ93CT DMJ93CT DN Inotersen DMJ93CT TI TTC1I86 DMJ93CT TN Transthyretin (TTR) DMJ93CT MA Antisense DMJ93CT RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMJ93CT RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMJ9G23 DI DMJ9G23 DMJ9G23 DN ISIS 1570 DMJ9G23 TI TTA1L39 DMJ9G23 TN ICAM1 messenger RNA (ICAM1 mRNA) DMJ9G23 RN US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. DMJ9G23 RU http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true DMJAOT1 DI DMJAOT1 DMJAOT1 DN Polyoxidonium DMJAOT1 TI TT3J5ZI DMJAOT1 TN Cell mediated immunity response (CMIR) DMJAOT1 MA Modulator DMJAOT1 RN Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60. DMJAOT1 RU https://pubmed.ncbi.nlm.nih.gov/12717555 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT32XQJ DMJAPE7 TN Monoamine oxidase (MAO) DMJAPE7 RN Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19562136 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT6HPVC DMJAPE7 TN Guanylate cyclase (GC) DMJAPE7 MA Inhibitor DMJAPE7 RN Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19473193 DMJBOCR DI DMJBOCR DMJBOCR DN Levacecarnine HCL DMJBOCR TI TTDL0NY DMJBOCR TN Carnitine O-palmitoyltransferase I (CPT1B) DMJBOCR MA Activator DMJBOCR RN Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74. DMJBOCR RU https://pubmed.ncbi.nlm.nih.gov/19608647 DMJCP1Y DI DMJCP1Y DMJCP1Y DN Yohimbine DMJCP1Y TI TTQ8AFT DMJCP1Y TN Adrenergic receptor Alpha-2 (ADRA2) DMJCP1Y MA Antagonist DMJCP1Y RN Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9. DMJCP1Y RU https://pubmed.ncbi.nlm.nih.gov/19640235 DMJDB0Y DI DMJDB0Y DMJDB0Y DN Dezocine DMJDB0Y TI TTQW87Y DMJDB0Y TN Opioid receptor kappa (OPRK1) DMJDB0Y MA Antagonist DMJDB0Y RN Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. DMJDB0Y RU https://pubmed.ncbi.nlm.nih.gov/16433932 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTAN6JD DMJDYNQ TN Glutamate receptor AMPA (GRIA) DMJDYNQ MA Modulator DMJDYNQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTVPQTF DMJDYNQ TN Glutamate receptor AMPA 1 (GRIA1) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT9HLZ0 DMJDYNQ TN Glutamate receptor AMPA 2 (GRIA2) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT82EZV DMJDYNQ TN Glutamate receptor AMPA 3 (GRIA3) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTPJR0G DMJDYNQ TN Glutamate receptor AMPA 4 (GRIA4) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO TI TTAWNKZ DMJE6KO TN Norepinephrine transporter (NET) DMJE6KO MA Inhibitor DMJE6KO RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMJE6KO RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT85JO3 DMJFP6G TN 5-HT receptor (5HTR) DMJFP6G MA Modulator DMJFP6G RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTWJBZ5 DMJFP6G TN 5-HT 2C receptor (HTR2C) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTK8CXU DMJFP6G TN 5-HT 1B receptor (HTR1B) DMJFP6G MA Antagonist DMJFP6G RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/8863519 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTCPG9S DMJFP6G TN 5-HT 1E receptor (HTR1E) DMJFP6G MA Antagonist DMJFP6G RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0MI3F DMJFP6G TN 5-HT 1F receptor (HTR1F) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/9225282 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTRUFDT DMJFP6G TN 5-HT 5A receptor (HTR5A) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/7988681 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT6MSOK DMJFP6G TN 5-HT 1D receptor (HTR1D) DMJFP6G MA Antagonist DMJFP6G RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/1652050 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0K1SC DMJFP6G TN 5-HT 2B receptor (HTR2B) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTJQOD7 DMJFP6G TN 5-HT 2A receptor (HTR2A) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFZDL DI DMJFZDL DMJFZDL DN Naphazoline DMJFZDL TI TTEX248 DMJFZDL TN Dopamine D2 receptor (D2R) DMJFZDL MA Agonist DMJFZDL RN Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52. DMJFZDL RU https://pubmed.ncbi.nlm.nih.gov/10481510 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD TI TTIU7X1 DMJHLSD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJHLSD MA Inhibitor DMJHLSD RN Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8. DMJHLSD RU https://pubmed.ncbi.nlm.nih.gov/15452407 DMJHN0A DI DMJHN0A DMJHN0A DN Icosapent DMJHN0A TI TTK0943 DMJHN0A TN Prostaglandin G/H synthase (COX) DMJHN0A MA Binder DMJHN0A RN Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. DMJHN0A RU https://pubmed.ncbi.nlm.nih.gov/12562875 DMJI3BA DI DMJI3BA DMJI3BA DN Peginterferon alfa-2a DMJI3BA TI TTSIUJ9 DMJI3BA TN Interferon-alpha 2 (IFNA2) DMJI3BA MA Modulator DMJI3BA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJI3BA RU https://www.fda.gov/ DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TTAN6JD DMJIA6T TN Glutamate receptor AMPA (GRIA) DMJIA6T MA Agonist DMJIA6T RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TT1MPAY DMJIA6T TN GABA(A) receptor alpha-1 (GABRA1) DMJIA6T MA Antagonist DMJIA6T RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW TI TTYRL6O DMJIBAW TN Glucocorticoid receptor (NR3C1) DMJIBAW MA Antagonist DMJIBAW RN PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. DMJIBAW RU https://pubmed.ncbi.nlm.nih.gov/19138736 DMJKROX DI DMJKROX DMJKROX DN Luvox DMJKROX TI TT3ROYC DMJKROX TN Serotonin transporter (SERT) DMJKROX MA Modulator DMJKROX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJKROX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJL10P DI DMJL10P DMJL10P DN Isoxyl DMJL10P TI TT6RIOV DMJL10P TN Acyl-CoA desaturase (SCD) DMJL10P MA Binder DMJL10P RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMJL10P RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMJMVKI DI DMJMVKI DMJMVKI DN Metipranolol DMJMVKI TI TTR6W5O DMJMVKI TN Adrenergic receptor beta-1 (ADRB1) DMJMVKI MA Antagonist DMJMVKI RN Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81. DMJMVKI RU https://pubmed.ncbi.nlm.nih.gov/15969634 DMJNV4O DI DMJNV4O DMJNV4O DN Tirbanibulin DMJNV4O TI TTHVQ4N DMJNV4O TN Tubulin polymerization (TubP) DMJNV4O MA Inhibitor DMJNV4O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMJNV4O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf DMJO6GV DI DMJO6GV DMJO6GV DN Abciximab DMJO6GV TI TT38RM1 DMJO6GV TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMJO6GV MA Modulator DMJO6GV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJO6GV RU https://www.fda.gov/ DMJOQM3 DI DMJOQM3 DMJOQM3 DN Eflornithine DMJOQM3 TI TTUMGNO DMJOQM3 TN Ornithine decarboxylase (ODC1) DMJOQM3 MA Inhibitor DMJOQM3 RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMJOQM3 RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMJPD06 DI DMJPD06 DMJPD06 DN Lmw heparin DMJPD06 TI TTCIHJA DMJPD06 TN Coagulation factor Xa (F10) DMJPD06 MA Modulator DMJPD06 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJPD06 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJPR2B DI DMJPR2B DMJPR2B DN Glisoxepide DMJPR2B TI TTG140O DMJPR2B TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMJPR2B MA Blocker DMJPR2B RN Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. DMJPR2B RU https://pubmed.ncbi.nlm.nih.gov/16174795 DMJSBT6 DI DMJSBT6 DMJSBT6 DN Silodosin DMJSBT6 TI TTNGILX DMJSBT6 TN Adrenergic receptor alpha-1A (ADRA1A) DMJSBT6 MA Inhibitor DMJSBT6 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMJSBT6 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMJTEMW DI DMJTEMW DMJTEMW DN Lubiprostone DMJTEMW TI TT30NW6 DMJTEMW TN Chloride channel protein 2 (CLC-2) DMJTEMW MA Activator DMJTEMW RN Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24. DMJTEMW RU https://pubmed.ncbi.nlm.nih.gov/19233902 DMJTIYK DI DMJTIYK DMJTIYK DN Ipilimumab DMJTIYK TI TTI2S1D DMJTIYK TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJTIYK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMJTIYK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 TI TTJP4SM DMJUNY5 TN Bacterial Penicillin binding protein (Bact PBP) DMJUNY5 MA Binder DMJUNY5 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DMJUVE6 DI DMJUVE6 DMJUVE6 DN Bulevirtide DMJUVE6 TI TTWZRY5 DMJUVE6 TN Sodium/bile acid cotransporter (SLC10A1) DMJUVE6 MA Inhibitor DMJUVE6 RN Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605. DMJUVE6 RU https://pubmed.ncbi.nlm.nih.gov/32926353 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT6PKBN DMJV2EK TN Proto-oncogene c-Src (SRC) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TTS7G69 DMJV2EK TN Fusion protein Bcr-Abl (Bcr-Abl) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT860QF DMJV2EK TN LCK tyrosine protein kinase (LCK) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT2B9KF DMJV2EK TN Fyn tyrosine protein kinase (FYN) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJW0VS DI DMJW0VS DMJW0VS DN Tilidine DMJW0VS TI TTN4QDT DMJW0VS TN Opioid receptor (OPR) DMJW0VS MA Modulator DMJW0VS RN Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8. DMJW0VS RU https://pubmed.ncbi.nlm.nih.gov/15627429 DMJWRQP DI DMJWRQP DMJWRQP DN Zanubrutinib DMJWRQP TI TTGM6VW DMJWRQP TN Tyrosine-protein kinase BTK (ATK) DMJWRQP MA Inhibitor DMJWRQP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMJWRQP RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG TI TT27RFC DMJX6ZG TN Opioid receptor delta (OPRD1) DMJX6ZG MA Agonist DMJX6ZG RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DMJX6ZG RU https://pubmed.ncbi.nlm.nih.gov/15942128 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC TI TTJP4SM DMJXDGC TN Bacterial Penicillin binding protein (Bact PBP) DMJXDGC MA Binder DMJXDGC RN Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74. DMJXDGC RU https://pubmed.ncbi.nlm.nih.gov/15747584 DMJXIC9 DI DMJXIC9 DMJXIC9 DN Anagliptin DMJXIC9 TI TTDIGC1 DMJXIC9 TN Dipeptidyl peptidase 4 (DPP-4) DMJXIC9 MA Modulator DMJXIC9 RN Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30. DMJXIC9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/ DMJYCVW DI DMJYCVW DMJYCVW DN Warfarin DMJYCVW TI TTEUC8H DMJYCVW TN Vitamin K epoxide reductase complex 1 (VKORC1) DMJYCVW MA Inhibitor DMJYCVW RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMJYCVW RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TT4C8EA DMJYDVK TN Dopamine D3 receptor (D3R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TTEX248 DMJYDVK TN Dopamine D2 receptor (D2R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYN25 DI DMJYN25 DMJYN25 DN Tenecteplase DMJYN25 TI TTP86E2 DMJYN25 TN Plasminogen (PLG) DMJYN25 MA Activator DMJYN25 RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMJYN25 RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMJZHT1 DI DMJZHT1 DMJZHT1 DN Tadalafil DMJZHT1 TI TTJ0IQB DMJZHT1 TN Phosphodiesterase 5A (PDE5A) DMJZHT1 MA Inhibitor DMJZHT1 RN Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. DMJZHT1 RU https://pubmed.ncbi.nlm.nih.gov/19487219 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 TI TT1VOHK DMK08L3 TN Potassium channel unspecific (KC) DMK08L3 MA Blocker DMK08L3 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK08L3 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK0O7U DI DMK0O7U DMK0O7U DN Flutamide DMK0O7U TI TTS64P2 DMK0O7U TN Androgen receptor (AR) DMK0O7U MA Antagonist DMK0O7U RN Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. DMK0O7U RU https://pubmed.ncbi.nlm.nih.gov/12231070 DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TT3ROYC DMK1GBJ TN Serotonin transporter (SERT) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TTSQIFT DMK1GBJ TN 5-HT 1A receptor (HTR1A) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1LZD DI DMK1LZD DMK1LZD DN Methoxy polyethylene glycol-epoetin beta DMK1LZD TI TTAUX24 DMK1LZD TN Erythropoietin Receptor (EPOR) DMK1LZD MA Activator DMK1LZD RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMK1LZD RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMK2GZX DI DMK2GZX DMK2GZX DN Avapritinib DMK2GZX TI TT8FYO9 DMK2GZX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMK2GZX MA Inhibitor DMK2GZX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK2GZX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTZPO1L DMK2PBD TN Substance-P receptor (TACR1) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTPC4TU DMK2PBD TN 5-HT 3A receptor (HTR3A) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK4OL7 DI DMK4OL7 DMK4OL7 DN Zinostatin stimalamer DMK4OL7 TI TTUTN1I DMK4OL7 TN Human Deoxyribonucleic acid (hDNA) DMK4OL7 MA Modulator DMK4OL7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMK4OL7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMK54YG DI DMK54YG DMK54YG DN Griseofulvin DMK54YG TI TT7PBUD DMK54YG TN Fungal Microtubule (Fung MicroTU) DMK54YG MA Inducer DMK54YG RN Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8. DMK54YG RU https://pubmed.ncbi.nlm.nih.gov/12537173 DMK57GB DI DMK57GB DMK57GB DN Ethinamate DMK57GB TI TTANPDJ DMK57GB TN Carbonic anhydrase II (CA-II) DMK57GB MA Inhibitor DMK57GB RN Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. DMK57GB RU https://pubmed.ncbi.nlm.nih.gov/1460006 DMK659W DI DMK659W DMK659W DN Enteric-coated mycophenolate sodium DMK659W TI TTCAQMW DMK659W TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMK659W MA Inhibitor DMK659W RN Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8. DMK659W RU https://pubmed.ncbi.nlm.nih.gov/14723604 DMK6XAV DI DMK6XAV DMK6XAV DN Bitolterol DMK6XAV TI TTMXGCW DMK6XAV TN Adrenergic receptor beta-3 (ADRB3) DMK6XAV MA Modulator DMK6XAV RN Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. DMK6XAV RU https://pubmed.ncbi.nlm.nih.gov/3895171 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TTAWNKZ DMK7F9S TN Norepinephrine transporter (NET) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TT3ROYC DMK7F9S TN Serotonin transporter (SERT) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7HFI DI DMK7HFI DMK7HFI DN Mefenamic acid DMK7HFI TI TTVKILB DMK7HFI TN Prostaglandin G/H synthase 2 (COX-2) DMK7HFI MA Inhibitor DMK7HFI RN Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62. DMK7HFI RU https://pubmed.ncbi.nlm.nih.gov/9758208 DMK7IWL DI DMK7IWL DMK7IWL DN Relugolix DMK7IWL TI TT8R70G DMK7IWL TN Gonadotropin-releasing hormone receptor (GNRHR) DMK7IWL MA Antagonist DMK7IWL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK7IWL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTR6W5O DMK7MEY TN Adrenergic receptor beta-1 (ADRB1) DMK7MEY MA Agonist DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TT2CJVK DMK7MEY TN Adrenergic receptor beta-2 (ADRB2) DMK7MEY MA Modulator DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTGW72V DMK7MEY TN Interleukin-12 beta (IL12B) DMK7MEY MA Modulator DMK7MEY RN A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/21447719 DMK8U72 DI DMK8U72 DMK8U72 DN Labetalol DMK8U72 TI TTG28O6 DMK8U72 TN Adrenergic receptor Alpha-1 (ADRA1) DMK8U72 MA Antagonist DMK8U72 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMK8U72 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMKA8J4 DI DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 TI TTUV8G9 DMKA8J4 TN Progesterone receptor (PGR) DMKA8J4 MA Binder DMKA8J4 RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMKA8J4 RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTZFYLI DMKAEQW TN Dopamine D1 receptor (D1R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTE0A2F DMKAEQW TN Dopamine D4 receptor (D4R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTEX248 DMKAEQW TN Dopamine D2 receptor (D2R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTS2PH3 DMKAEQW TN Dopamine D5 receptor (D5R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O TI TT8NGED DMKB79O TN Prostaglandin G/H synthase 1 (COX-1) DMKB79O MA Inhibitor DMKB79O RN Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. DMKB79O RU https://pubmed.ncbi.nlm.nih.gov/16846546 DMKB9FI DI DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI TI TT958S6 DMKB9FI TN Ras-related protein Rab-9A (RAB9A) DMKB9FI MA Inhibitor DMKB9FI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKB9FI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTK25J1 DMKBJWP TN Adenosine A1 receptor (ADORA1) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTM2AOE DMKBJWP TN Adenosine A2a receptor (ADORA2A) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBOS2 DI DMKBOS2 DMKBOS2 DN Levosimendan DMKBOS2 TI TT8RDXP DMKBOS2 TN Troponin C (TN-C) DMKBOS2 MA Stimulator DMKBOS2 RN Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30. DMKBOS2 RU https://pubmed.ncbi.nlm.nih.gov/19520657 DMKBTFG DI DMKBTFG DMKBTFG DN Cefozopran DMKBTFG TI TT4ILYC DMKBTFG TN Bacterial Dihydropteroate synthetase (Bact folP) DMKBTFG MA Inhibitor DMKBTFG RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMKBTFG RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMKBW5C DI DMKBW5C DMKBW5C DN Talimogene Laherparepvec DMKBW5C TI TTNYZG2 DMKBW5C TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMKBW5C MA Modulator DMKBW5C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKBW5C RU https://www.fda.gov/ DMKBYWI DI DMKBYWI DMKBYWI DN Trifluoperazine DMKBYWI TI TTV3NH6 DMKBYWI TN Calmodulin (CALM) DMKBYWI MA Inhibitor DMKBYWI RN Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. DMKBYWI RU https://pubmed.ncbi.nlm.nih.gov/14531016 DMKCIUZ DI DMKCIUZ DMKCIUZ DN Daratumumab DMKCIUZ TI TTPURFN DMKCIUZ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMKCIUZ RN Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. DMKCIUZ RU https://pubmed.ncbi.nlm.nih.gov/26308596 DMKDU16 DI DMKDU16 DMKDU16 DN Daptomycin DMKDU16 TI TT4ILYC DMKDU16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMKDU16 MA Binder DMKDU16 RN Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57. DMKDU16 RU https://pubmed.ncbi.nlm.nih.gov/15271353 DMKE6YT DI DMKE6YT DMKE6YT DN Incobotulinum toxin A DMKE6YT TI TTZJD1B DMKE6YT TN Acetylcholine release (Ach rele) DMKE6YT MA Modulator DMKE6YT RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMKE6YT RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMKE7L9 DI DMKE7L9 DMKE7L9 DN Doxacurium DMKE7L9 TI TTS5WZF DMKE7L9 TN Neuronal acetylcholine receptor alpha (NACHRA) DMKE7L9 MA Antagonist DMKE7L9 RN Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. DMKE7L9 RU https://pubmed.ncbi.nlm.nih.gov/8572329 DMKECZD DI DMKECZD DMKECZD DN Temozolomide DMKECZD TI TTUTN1I DMKECZD TN Human Deoxyribonucleic acid (hDNA) DMKECZD MA Modulator DMKECZD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKECZD RU https://www.fda.gov/ DMKER83 DI DMKER83 DMKER83 DN Hesperetin DMKER83 TI TTF8P9I DMKER83 TN Diacylglycerol acyltransferase 1 (DGAT1) DMKER83 MA Inhibitor DMKER83 RN In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60. DMKER83 RU https://pubmed.ncbi.nlm.nih.gov/15114505 DMKEX7O DI DMKEX7O DMKEX7O DN Plecanatide DMKEX7O TI TTLDPRG DMKEX7O TN Guanylyl cyclase C (GUCY2C) DMKEX7O MA Modulator DMKEX7O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKEX7O RU https://www.fda.gov/ DMKEY6S DI DMKEY6S DMKEY6S DN Margetuximab DMKEY6S TI TT6EO5L DMKEY6S TN Erbb2 tyrosine kinase receptor (HER2) DMKEY6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMKEY6S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf DMKFQJP DI DMKFQJP DMKFQJP DN Triflupromazine DMKFQJP TI TT0K1SC DMKFQJP TN 5-HT 2B receptor (HTR2B) DMKFQJP MA Antagonist DMKFQJP RN Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. DMKFQJP RU https://pubmed.ncbi.nlm.nih.gov/497523 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTZ3IFB DMKGH0R TN Phosphogluconate dehydrogenase (PGD) DMKGH0R MA Inhibitor DMKGH0R RN Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/12818683 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTWDC17 DMKGH0R TN Growth hormone secretagogue receptor 1 (GHSR) DMKGH0R MA Agonist DMKGH0R RN GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/11796511 DMKI2XC DI DMKI2XC DMKI2XC DN Sulfacytine DMKI2XC TI TT4ILYC DMKI2XC TN Bacterial Dihydropteroate synthetase (Bact folP) DMKI2XC MA Inhibitor DMKI2XC RN Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. Urology. 1976 Mar;7(3):267-71. DMKI2XC RU https://pubmed.ncbi.nlm.nih.gov/769287 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB TI TTZAYWL DMKI7RB TN Estrogen receptor (ESR) DMKI7RB MA Modulator DMKI7RB RN The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. DMKI7RB RU https://pubmed.ncbi.nlm.nih.gov/17448265 DMKINJO DI DMKINJO DMKINJO DN Gentamicin DMKINJO TI TTOVFH2 DMKINJO TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMKINJO MA Modulator DMKINJO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKINJO RU https://www.fda.gov/ DMKITQE DI DMKITQE DMKITQE DN Amoxapine DMKITQE TI TTAWNKZ DMKITQE TN Norepinephrine transporter (NET) DMKITQE MA Inhibitor DMKITQE RN Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. DMKITQE RU https://pubmed.ncbi.nlm.nih.gov/7845548 DMKJ485 DI DMKJ485 DMKJ485 DN Pioglitazone DMKJ485 TI TTZMAO3 DMKJ485 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMKJ485 MA Agonist DMKJ485 RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMKJ485 RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMKJ8LB DI DMKJ8LB DMKJ8LB DN Josamycin DMKJ8LB TI TTUWYEA DMKJ8LB TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMKJ8LB MA Binder DMKJ8LB RN The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14. DMKJ8LB RU https://pubmed.ncbi.nlm.nih.gov/12860123 DMKLAYG DI DMKLAYG DMKLAYG DN Altretamine DMKLAYG TI TTUTN1I DMKLAYG TN Human Deoxyribonucleic acid (hDNA) DMKLAYG MA Breaker DMKLAYG RN Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. DMKLAYG RU https://pubmed.ncbi.nlm.nih.gov/18305940 DMKLJRD DI DMKLJRD DMKLJRD DN Fospropofol disodium DMKLJRD TI TTAN6JD DMKLJRD TN Glutamate receptor AMPA (GRIA) DMKLJRD MA Modulator DMKLJRD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMKLJRD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMKLSHF DI DMKLSHF DMKLSHF DN Bambuterol DMKLSHF TI TT2CJVK DMKLSHF TN Adrenergic receptor beta-2 (ADRB2) DMKLSHF MA Agonist DMKLSHF RN Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. DMKLSHF RU https://pubmed.ncbi.nlm.nih.gov/18065099 DMKM3SX DI DMKM3SX DMKM3SX DN Sulfamerazine DMKM3SX TI TT4ILYC DMKM3SX TN Bacterial Dihydropteroate synthetase (Bact folP) DMKM3SX MA Inhibitor DMKM3SX RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMKM3SX RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMKMBES DI DMKMBES DMKMBES DN Plazomicin DMKMBES TI TTUQ7WN DMKMBES TN Mitochondrial rRNA methyltransferase 2 (MRM2) DMKMBES MA Inhibitor DMKMBES RN In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. DMKMBES RU https://pubmed.ncbi.nlm.nih.gov/29091224 DMKMJHE DI DMKMJHE DMKMJHE DN Cemiplimab DMKMJHE TI TTNBFWK DMKMJHE TN Programmed cell death protein 1 (PD-1) DMKMJHE MA Modulator DMKMJHE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKMJHE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKMWQG DI DMKMWQG DMKMWQG DN Olopatadine DMKMWQG TI TTTIBOJ DMKMWQG TN Histamine H1 receptor (H1R) DMKMWQG MA Antagonist DMKMWQG RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMKMWQG RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMKN345 DI DMKN345 DMKN345 DN Charybdotoxin DMKN345 TI TTMNI76 DMKN345 TN Calcium-activated potassium channel (KCN) DMKN345 MA Blocker DMKN345 RN Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8. DMKN345 RU https://pubmed.ncbi.nlm.nih.gov/16741254 DMKOJSN DI DMKOJSN DMKOJSN DN Necitumumab DMKOJSN TI TTGKNB4 DMKOJSN TN Epidermal growth factor receptor (EGFR) DMKOJSN MA Modulator DMKOJSN RN Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. DMKOJSN RU https://pubmed.ncbi.nlm.nih.gov/21154166 DMKOXFE DI DMKOXFE DMKOXFE DN Doxylamine DMKOXFE TI TTTIBOJ DMKOXFE TN Histamine H1 receptor (H1R) DMKOXFE MA Antagonist DMKOXFE RN First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22. DMKOXFE RU https://pubmed.ncbi.nlm.nih.gov/17539447 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TTTIBOJ DMKQTBA TN Histamine H1 receptor (H1R) DMKQTBA MA Antagonist DMKQTBA RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TT2B6EV DMKQTBA TN Histamine N-methyltransferase (HNMT) DMKQTBA MA Inhibitor DMKQTBA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 TI TTG28O6 DMKR3C5 TN Adrenergic receptor Alpha-1 (ADRA1) DMKR3C5 MA Agonist DMKR3C5 RN Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6. DMKR3C5 RU https://pubmed.ncbi.nlm.nih.gov/18763151 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TTQVOEI DMKS1DV TN Angiotensin II receptor type-2 (AGTR2) DMKS1DV MA Inhibitor DMKS1DV RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TT8DBY3 DMKS1DV TN Angiotensin II receptor type-1 (AGTR1) DMKS1DV MA Inhibitor DMKS1DV RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTV9MQG DMKSQG0 TN Gamma-aminobutyric acid uptake (GABAU) DMKSQG0 MA Inhibitor DMKSQG0 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMKSQG0 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTPRKM0 DMKSQG0 TN GABA transporter GAT-1 (SLC6A1) DMKSQG0 MA Inhibitor DMKSQG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DMKSQG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TT6ZFQ4 DMKSTWR TN Rotamase B (PPIB) DMKSTWR MA Binder DMKSTWR RN Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/15355356 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TTL2ADK DMKSTWR TN Rotamase A (PPIA) DMKSTWR MA Binder DMKSTWR RN Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009 Jan 14;131(1):147-52. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/19128175 DMKUOQV DI DMKUOQV DMKUOQV DN Burosumab DMKUOQV TI TT2IZ4K DMKUOQV TN Fibroblast growth factor-23 (FGF23) DMKUOQV MA Modulator DMKUOQV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKUOQV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKV4NL DI DMKV4NL DMKV4NL DN Flavoxate DMKV4NL TI TTH18TF DMKV4NL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMKV4NL MA Antagonist DMKV4NL RN Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8. DMKV4NL RU https://pubmed.ncbi.nlm.nih.gov/8842386 DMKVOYF DI DMKVOYF DMKVOYF DN Penicillin V DMKVOYF TI TTJP4SM DMKVOYF TN Bacterial Penicillin binding protein (Bact PBP) DMKVOYF MA Binder DMKVOYF RN Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40. DMKVOYF RU https://pubmed.ncbi.nlm.nih.gov/7541399 DMKVWGE DI DMKVWGE DMKVWGE DN Dexbrompheniramine DMKVWGE TI TTTIBOJ DMKVWGE TN Histamine H1 receptor (H1R) DMKVWGE MA Antagonist DMKVWGE RN H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13. DMKVWGE RU https://pubmed.ncbi.nlm.nih.gov/9811372 DMKWB73 DI DMKWB73 DMKWB73 DN Epoetin alfa DMKWB73 TI TTAUX24 DMKWB73 TN Erythropoietin Receptor (EPOR) DMKWB73 MA Agonist DMKWB73 RN 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12. DMKWB73 RU https://pubmed.ncbi.nlm.nih.gov/19229970 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TT0WAIE DMKWFBT TN Melatonin receptor type 1A (MTNR1A) DMKWFBT MA Binder DMKWFBT RN The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/15796769 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TTJLP0R DMKWFBT TN Quinone reductase 2 (NQO2) DMKWFBT MA Inhibitor DMKWFBT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKXJZ7 DI DMKXJZ7 DMKXJZ7 DN Suprofen DMKXJZ7 TI TT8NGED DMKXJZ7 TN Prostaglandin G/H synthase 1 (COX-1) DMKXJZ7 MA Inhibitor DMKXJZ7 RN Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. DMKXJZ7 RU https://pubmed.ncbi.nlm.nih.gov/11885959 DMKXY2R DI DMKXY2R DMKXY2R DN Ibutilide DMKXY2R TI TT1VOHK DMKXY2R TN Potassium channel unspecific (KC) DMKXY2R MA Modulator DMKXY2R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKXY2R RU https://www.fda.gov/ DMKY8V1 DI DMKY8V1 DMKY8V1 DN Propiomazine DMKY8V1 TI TTTIBOJ DMKY8V1 TN Histamine H1 receptor (H1R) DMKY8V1 MA Antagonist DMKY8V1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKY8V1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKYD5N DI DMKYD5N DMKYD5N DN Zuclopenthixol DMKYD5N TI TTEX248 DMKYD5N TN Dopamine D2 receptor (D2R) DMKYD5N MA Antagonist DMKYD5N RN An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. DMKYD5N RU https://pubmed.ncbi.nlm.nih.gov/10222441 DMKZEIB DI DMKZEIB DMKZEIB DN Felbinac DMKZEIB TI TTK0943 DMKZEIB TN Prostaglandin G/H synthase (COX) DMKZEIB MA Modulator DMKZEIB RN A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7. DMKZEIB RU https://pubmed.ncbi.nlm.nih.gov/6254545 DMKZROL DI DMKZROL DMKZROL DN Saralasin Acetate DMKZROL TI TT8DBY3 DMKZROL TN Angiotensin II receptor type-1 (AGTR1) DMKZROL MA Modulator DMKZROL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKZROL RU https://www.fda.gov/ DML0B41 DI DML0B41 DML0B41 DN Naloxegol DML0B41 TI TTKWM86 DML0B41 TN Opioid receptor mu (MOP) DML0B41 MA Modulator DML0B41 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DML0B41 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DML0D1P DI DML0D1P DML0D1P DN Reteplase DML0D1P TI TTP86E2 DML0D1P TN Plasminogen (PLG) DML0D1P MA Activator DML0D1P RN Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. DML0D1P RU https://pubmed.ncbi.nlm.nih.gov/18673235 DML0RAE DI DML0RAE DML0RAE DN Methoxyflurane DML0RAE TI TT1MPAY DML0RAE TN GABA(A) receptor alpha-1 (GABRA1) DML0RAE MA Antagonist DML0RAE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DML0RAE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DML1538 DI DML1538 DML1538 DN Diazoxide DML1538 TI TT1VOHK DML1538 TN Potassium channel unspecific (KC) DML1538 MA Modulator DML1538 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DML1538 RU https://www.fda.gov/ DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 TI TTPC4TU DML2A03 TN 5-HT 3A receptor (HTR3A) DML2A03 MA Antagonist DML2A03 RN Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. DML2A03 RU https://pubmed.ncbi.nlm.nih.gov/19471254 DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB TI TT06AWU DML2NIB TN Phosphodiesterase 3A (PDE3A) DML2NIB MA Inhibitor DML2NIB RN Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3. DML2NIB RU https://pubmed.ncbi.nlm.nih.gov/17391155 DML4ZOT DI DML4ZOT DML4ZOT DN Lidocaine DML4ZOT TI TTN9VTF DML4ZOT TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DML4ZOT MA Blocker DML4ZOT RN Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6. DML4ZOT RU https://pubmed.ncbi.nlm.nih.gov/19378524 DML53ZJ DI DML53ZJ DML53ZJ DN Mirtazapine DML53ZJ TI TTWJBZ5 DML53ZJ TN 5-HT 2C receptor (HTR2C) DML53ZJ MA Antagonist DML53ZJ RN Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57. DML53ZJ RU https://pubmed.ncbi.nlm.nih.gov/18083778 DML5VQ0 DI DML5VQ0 DML5VQ0 DN Fenoprofen DML5VQ0 TI TTK0943 DML5VQ0 TN Prostaglandin G/H synthase (COX) DML5VQ0 MA Inhibitor DML5VQ0 RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DML5VQ0 RU https://pubmed.ncbi.nlm.nih.gov/17409433 DML60TN DI DML60TN DML60TN DN Sotalol DML60TN TI TTR6W5O DML60TN TN Adrenergic receptor beta-1 (ADRB1) DML60TN MA Antagonist DML60TN RN beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. DML60TN RU https://pubmed.ncbi.nlm.nih.gov/19259968 DML6OE7 DI DML6OE7 DML6OE7 DN Tbo-Filgrastim DML6OE7 TI TTC70AJ DML6OE7 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DML6OE7 MA Modulator DML6OE7 RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DML6OE7 RU https://pubmed.ncbi.nlm.nih.gov/23370234 DML6SRO DI DML6SRO DML6SRO DN Alacepril DML6SRO TI TTL69WB DML6SRO TN Angiotensin-converting enzyme (ACE) DML6SRO MA Modulator DML6SRO RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DML6SRO RU https://pubmed.ncbi.nlm.nih.gov/17309302 DML72VJ DI DML72VJ DML72VJ DN GW685698X DML72VJ TI TTYRL6O DML72VJ TN Glucocorticoid receptor (NR3C1) DML72VJ MA Agonist DML72VJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DML72VJ RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DML8KTN DI DML8KTN DML8KTN DN Danazol DML8KTN TI TTZAYWL DML8KTN TN Estrogen receptor (ESR) DML8KTN MA Antagonist DML8KTN RN Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7. DML8KTN RU https://pubmed.ncbi.nlm.nih.gov/2326286 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TTMXGCW DML8QSZ TN Adrenergic receptor beta-3 (ADRB3) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TT2NUT5 DML8QSZ TN Adrenergic receptor alpha-2C (ADRA2C) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML97WV DI DML97WV DML97WV DN Pemirolast DML97WV TI TTTIBOJ DML97WV TN Histamine H1 receptor (H1R) DML97WV MA Antagonist DML97WV RN The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. DML97WV RU https://pubmed.ncbi.nlm.nih.gov/18463425 DML9TI0 DI DML9TI0 DML9TI0 DN Ombitasvir + paritaprevir + ritonavir DML9TI0 TI TTWXB3E DML9TI0 TN Hepatitis C virus NS3 helicase (HCV NS3) DML9TI0 MA Modulator DML9TI0 RN HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy DML9TI0 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632384 DMLB0EZ DI DMLB0EZ DMLB0EZ DN Tamoxifen DMLB0EZ TI TTZAYWL DMLB0EZ TN Estrogen receptor (ESR) DMLB0EZ MA Antagonist DMLB0EZ RN Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86. DMLB0EZ RU https://pubmed.ncbi.nlm.nih.gov/18991792 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ TI TTKWFB8 DMLBVKQ TN Catechol-O-methyl-transferase (COMT) DMLBVKQ MA Inhibitor DMLBVKQ RN Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. DMLBVKQ RU https://pubmed.ncbi.nlm.nih.gov/11440283 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTVBI8W DMLDQFV TN Dopamine transporter (DAT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTAWNKZ DMLDQFV TN Norepinephrine transporter (NET) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT3ROYC DMLDQFV TN Serotonin transporter (SERT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT8G3Z7 DMLDQFV TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMLDQFV MA Inhibitor DMLDQFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDQFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLE7IO DI DMLE7IO DMLE7IO DN Tigecycline DMLE7IO TI TTQ8KVI DMLE7IO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMLE7IO MA Binder DMLE7IO RN Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. DMLE7IO RU https://pubmed.ncbi.nlm.nih.gov/16863487 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK TI TTJP4SM DMLEDNK TN Bacterial Penicillin binding protein (Bact PBP) DMLEDNK MA Binder DMLEDNK RN Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/2112536 DMLFX7K DI DMLFX7K DMLFX7K DN LCZ696 DMLFX7K TI TT5TKPM DMLFX7K TN Neutral endopeptidase (MME) DMLFX7K MA Modulator DMLFX7K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMLFX7K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMLFZHD DI DMLFZHD DMLFZHD DN Aclarubicin DMLFZHD TI TT0IHXV DMLFZHD TN DNA topoisomerase II (TOP2) DMLFZHD MA Inhibitor DMLFZHD RN Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. DMLFZHD RU https://pubmed.ncbi.nlm.nih.gov/12375883 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP TI TTANPDJ DMLHESP TN Carbonic anhydrase II (CA-II) DMLHESP MA Inhibitor DMLHESP RN Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8. DMLHESP RU https://pubmed.ncbi.nlm.nih.gov/10731484 DMLHOA0 DI DMLHOA0 DMLHOA0 DN Xatral DMLHOA0 TI TTNGILX DMLHOA0 TN Adrenergic receptor alpha-1A (ADRA1A) DMLHOA0 MA Antagonist DMLHOA0 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMLHOA0 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTV5CGO DMLHSE3 TN Phosphodiesterase 4 (PDE4) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTZCG4L DMLHSE3 TN Phosphodiesterase 3 (PDE3) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLJ634 DI DMLJ634 DMLJ634 DN Sodium lauryl sulfate DMLJ634 TI TTFNGC9 DMLJ634 TN Serum albumin (ALB) DMLJ634 MA Binder DMLJ634 RN Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. DMLJ634 RU https://pubmed.ncbi.nlm.nih.gov/16085141 DMLK2QH DI DMLK2QH DMLK2QH DN Nateglinide DMLK2QH TI TT1VOHK DMLK2QH TN Potassium channel unspecific (KC) DMLK2QH MA Modulator DMLK2QH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLK2QH RU https://www.fda.gov/ DMLKFC4 DI DMLKFC4 DMLKFC4 DN Quinupristin DMLKFC4 TI TTIB7O8 DMLKFC4 TN Bacterial Integral membrane LmrP (Bact lmrP) DMLKFC4 MA Modulator DMLKFC4 RN The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80. DMLKFC4 RU https://pubmed.ncbi.nlm.nih.gov/11577166 DMLKSE0 DI DMLKSE0 DMLKSE0 DN Hexachlorophene DMLKSE0 TI TTAO7YK DMLKSE0 TN Plasmodium Glutamate dehydrogenase (Malaria gdh) DMLKSE0 MA Inhibitor DMLKSE0 RN Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000. DMLKSE0 RU https://pubmed.ncbi.nlm.nih.gov/19531491 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 TI TT5FNQT DMLMXE0 TN Human immunodeficiency virus Protease (HIV PR) DMLMXE0 MA Inhibitor DMLMXE0 RN Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. DMLMXE0 RU https://pubmed.ncbi.nlm.nih.gov/19323590 DMLNCE0 DI DMLNCE0 DMLNCE0 DN Cetuximab DMLNCE0 TI TTGKNB4 DMLNCE0 TN Epidermal growth factor receptor (EGFR) DMLNCE0 RN Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14. DMLNCE0 RU https://pubmed.ncbi.nlm.nih.gov/12479268 DMLNMEA DI DMLNMEA DMLNMEA DN Estradiol valerate/dienogest DMLNMEA TI TTUV8G9 DMLNMEA TN Progesterone receptor (PGR) DMLNMEA MA Modulator DMLNMEA RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMLNMEA RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT32JK8 DMLOQ1V TN Melatonin receptor type 1B (MTNR1B) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT0WAIE DMLOQ1V TN Melatonin receptor type 1A (MTNR1A) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTHBTOP DMLOS5R TN PI3-kinase gamma (PIK3CG) DMLOS5R MA Modulator DMLOS5R RN BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30. DMLOS5R RU https://www.ncbi.nlm.nih.gov/pubmed/24170767 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTGBPJE DMLOS5R TN PI3-kinase delta (PIK3CD) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTEUNMR DMLOS5R TN PI3-kinase alpha (PIK3CA) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB TI TT7RJY8 DMLPAOB TN Xanthine dehydrogenase/oxidase (XDH) DMLPAOB MA Inhibitor DMLPAOB RN Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1. DMLPAOB RU https://pubmed.ncbi.nlm.nih.gov/5324754 DMLPSWQ DI DMLPSWQ DMLPSWQ DN Niraparib Tosylate DMLPSWQ TI TTVDSZ0 DMLPSWQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMLPSWQ MA Modulator DMLPSWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLPSWQ RU https://www.fda.gov/ DMLS39E DI DMLS39E DMLS39E DN Proparacaine DMLS39E TI TT90XZ8 DMLS39E TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMLS39E MA Modulator DMLS39E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLS39E RU https://www.fda.gov/ DMLSUWZ DI DMLSUWZ DMLSUWZ DN PSI-7977 DMLSUWZ TI TTMVBWH DMLSUWZ TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMLSUWZ MA Modulator DMLSUWZ RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLSUWZ RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 TI TTOM3J0 DMLT0E1 TN Estrogen receptor beta (ESR2) DMLT0E1 MA Antagonist DMLT0E1 RN Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85. DMLT0E1 RU https://pubmed.ncbi.nlm.nih.gov/19036900 DMLUA9D DI DMLUA9D DMLUA9D DN Simeprevir DMLUA9D TI TTHC7JD DMLUA9D TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMLUA9D MA Modulator DMLUA9D RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLUA9D RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLVSYX DI DMLVSYX DMLVSYX DN Remimazolam DMLVSYX TI TTEX6LM DMLVSYX TN GABA(A) receptor gamma-3 (GABRG3) DMLVSYX MA Agonist DMLVSYX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMLVSYX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf DMLW57T DI DMLW57T DMLW57T DN Teniposide DMLW57T TI TT0IHXV DMLW57T TN DNA topoisomerase II (TOP2) DMLW57T MA Modulator DMLW57T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLW57T RU https://www.fda.gov/ DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTC1GLB DMLW9HG TN Interleukin-23 (IL23) DMLW9HG MA Modulator DMLW9HG RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMLW9HG RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTQTX98 DMLW9HG TN Interleukin-37 (IL37) DMLW9HG MA Inhibitor DMLW9HG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLW9HG RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TT8DBY3 DMLWQ27 TN Angiotensin II receptor type-1 (AGTR1) DMLWQ27 MA Inhibitor DMLWQ27 RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMLWQ27 RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TTQVOEI DMLWQ27 TN Angiotensin II receptor type-2 (AGTR2) DMLWQ27 MA Inhibitor DMLWQ27 RN The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993). DMLWQ27 RU http://www.sciencedirect.com/science/article/pii/S0960894X00806885 DMLZNIQ DI DMLZNIQ DMLZNIQ DN Sarecycline DMLZNIQ TI TTOVFH2 DMLZNIQ TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMLZNIQ MA Inhibitor DMLZNIQ RN Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. DMLZNIQ RU https://pubmed.ncbi.nlm.nih.gov/30397052 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TTGP7BY DMM0HR1 TN Monoamine oxidase type B (MAO-B) DMM0HR1 MA Inhibitor DMM0HR1 RN Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. DMM0HR1 RU https://pubmed.ncbi.nlm.nih.gov/19542488 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TT32XQJ DMM0HR1 TN Monoamine oxidase (MAO) DMM0HR1 MA Inhibitor DMM0HR1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMM0HR1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMM0PDO DI DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO TI TT1VOHK DMM0PDO TN Potassium channel unspecific (KC) DMM0PDO MA Modulator DMM0PDO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMM0PDO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMM0XGL DI DMM0XGL DMM0XGL DN Idarubicin DMM0XGL TI TT0IHXV DMM0XGL TN DNA topoisomerase II (TOP2) DMM0XGL MA Modulator DMM0XGL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM0XGL RU https://www.fda.gov/ DMM13DI DI DMM13DI DMM13DI DN Tasosartan DMM13DI TI TT8DBY3 DMM13DI TN Angiotensin II receptor type-1 (AGTR1) DMM13DI MA Antagonist DMM13DI RN Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. DMM13DI RU https://pubmed.ncbi.nlm.nih.gov/11046101 DMM1JL9 DI DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 TI TTP3UTW DMM1JL9 TN Steroid hormone receptor ERR (ESRR) DMM1JL9 MA Modulator DMM1JL9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM1JL9 RU https://www.fda.gov/ DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK TI TTNE7KG DMM2NSK TN Adenosine A2b receptor (ADORA2B) DMM2NSK MA Modulator DMM2NSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM2NSK RU https://www.fda.gov/ DMM32GT DI DMM32GT DMM32GT DN Risankizumab DMM32GT TI TTC1GLB DMM32GT TN Interleukin-23 (IL23) DMM32GT MA Inhibitor DMM32GT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMM32GT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf DMM3950 DI DMM3950 DMM3950 DN Sodium chloride DMM3950 TI TTQ8AFT DMM3950 TN Adrenergic receptor Alpha-2 (ADRA2) DMM3950 MA Agonist DMM3950 RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DMM3950 RU https://pubmed.ncbi.nlm.nih.gov/11164065 DMM39BF DI DMM39BF DMM39BF DN Mitoxantrone DMM39BF TI TT0IHXV DMM39BF TN DNA topoisomerase II (TOP2) DMM39BF MA Modulator DMM39BF RN Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. DMM39BF RU https://pubmed.ncbi.nlm.nih.gov/9450803 DMM3L6Z DI DMM3L6Z DMM3L6Z DN Ketobemidone DMM3L6Z TI TTN4QDT DMM3L6Z TN Opioid receptor (OPR) DMM3L6Z MA Modulator DMM3L6Z RN The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4. DMM3L6Z RU https://pubmed.ncbi.nlm.nih.gov/8878254 DMM4FXA DI DMM4FXA DMM4FXA DN Asfotase alfa DMM4FXA TI TTMR5UV DMM4FXA TN Alkaline phosphatase tissue-nonspecific (ALPL) DMM4FXA MA Modulator DMM4FXA RN Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. DMM4FXA RU https://pubmed.ncbi.nlm.nih.gov/22397652 DMM4QOJ DI DMM4QOJ DMM4QOJ DN Metadoxine DMM4QOJ TI TTPRKM0 DMM4QOJ TN GABA transporter GAT-1 (SLC6A1) DMM4QOJ MA Modulator DMM4QOJ RN Company report (Alcobra pharma) DMM4QOJ RU http://www.alcobra-pharma.com/products.cfm?productID=163127 DMM4U9G DI DMM4U9G DMM4U9G DN R0-93877 DMM4U9G TI TT07C3Y DMM4U9G TN 5-HT 4 receptor (HTR4) DMM4U9G MA Agonist DMM4U9G RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMM4U9G RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTEX248 DMM58JY TN Dopamine D2 receptor (D2R) DMM58JY MA Agonist DMM58JY RN Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/19011428 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTLA931 DMM58JY TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMM58JY MA Binder DMM58JY RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM765C DI DMM765C DMM765C DN Nitroprusside DMM765C TI TTC9IZL DMM765C TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMM765C MA Antagonist DMM765C RN Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem. 1996 Mar 8;271(10):5545-51. DMM765C RU https://pubmed.ncbi.nlm.nih.gov/8621413 DMM7CHK DI DMM7CHK DMM7CHK DN Trimethoprim DMM7CHK TI TTYZVDJ DMM7CHK TN Dihydrofolate reductase (DHFR) DMM7CHK MA Modulator DMM7CHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM7CHK RU https://www.fda.gov/ DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTUE541 DMM9BJD TN Leukocyte surface antigen Leu-16 (CD20) DMM9BJD MA Immunostimulant DMM9BJD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM9BJD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTW640A DMM9BJD TN B-lymphocyte surface antigen B4 (CD19) DMM9BJD MA Immunostimulant DMM9BJD RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMM9BJD RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT1RS9F DMMAWLU TN Acetylcholinesterase (AChE) DMMAWLU MA Inhibitor DMMAWLU RN Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/12213312 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT9IK2Z DMMAWLU TN N-methyl-D-aspartate receptor (NMDAR) DMMAWLU MA Antagonist DMMAWLU RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMMAWY1 DI DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 TI TT84ETX DMMAWY1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMAWY1 MA Modulator DMMAWY1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMAWY1 RU https://www.fda.gov/ DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 TI TTJP4SM DMMC345 TN Bacterial Penicillin binding protein (Bact PBP) DMMC345 MA Binder DMMC345 RN Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32. DMMC345 RU https://pubmed.ncbi.nlm.nih.gov/9352657 DMMC45B DI DMMC45B DMMC45B DN Teriparatide DMMC45B TI TT6F7GZ DMMC45B TN Parathyroid hormone (PTH) DMMC45B MA Modulator DMMC45B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMC45B RU https://www.fda.gov/ DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE TI TT4ILYC DMMD9QE TN Bacterial Dihydropteroate synthetase (Bact folP) DMMD9QE MA Binder DMMD9QE RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTKLV96 DMME8LH TN Retinoic acid receptor RXR-beta (RXRB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT6PEUO DMME8LH TN Retinoic acid receptor RXR-alpha (RXRA) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTISP28 DMME8LH TN Retinoic acid receptor beta (RARB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTH029C DMME8LH TN Retinoic acid receptor RXR-gamma (RXRG) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT1Q3IE DMME8LH TN Retinoic acid receptor gamma (RARG) DMME8LH MA Modulator DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMMF8U0 DI DMMF8U0 DMMF8U0 DN Atezolizumab DMMF8U0 TI TT8ZLTI DMMF8U0 TN Programmed cell death 1 ligand 1 (PD-L1) DMMF8U0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMF8U0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf DMMFCIH DI DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH TI TT30C9G DMMFCIH TN C-X-C chemokine receptor type 2 (CXCR2) DMMFCIH MA Modulator DMMFCIH RN Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44. DMMFCIH RU https://www.ncbi.nlm.nih.gov/pubmed/3895959 DMMFVB3 DI DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 TI TTUCK4B DMMFVB3 TN Phospholipase A2 inhibitory protein (PA2IP) DMMFVB3 MA Agonist DMMFVB3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMMFVB3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMMFWOJ DI DMMFWOJ DMMFWOJ DN Probenecid DMMFWOJ TI TTTQR47 DMMFWOJ TN Solute carrier family 22 member 8 (SLC22A8) DMMFWOJ MA Blocker DMMFWOJ RN Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158. DMMFWOJ RU https://pubmed.ncbi.nlm.nih.gov/12605306 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z TI TTPC4TU DMMG26Z TN 5-HT 3A receptor (HTR3A) DMMG26Z MA Antagonist DMMG26Z RN Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24. DMMG26Z RU https://pubmed.ncbi.nlm.nih.gov/19135415 DMMHNU2 DI DMMHNU2 DMMHNU2 DN (S)-(+)-Dimethindene maleate DMMHNU2 TI TTTIBOJ DMMHNU2 TN Histamine H1 receptor (H1R) DMMHNU2 MA Antagonist DMMHNU2 RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DMMHNU2 RU https://pubmed.ncbi.nlm.nih.gov/19308787 DMMHR1U DI DMMHR1U DMMHR1U DN Denileukin diftitox DMMHR1U TI TTAJU0S DMMHR1U TN Interleukin 2 receptor (IL2R) DMMHR1U MA Binder DMMHR1U RN Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. DMMHR1U RU https://pubmed.ncbi.nlm.nih.gov/18684057 DMMHYLB DI DMMHYLB DMMHYLB DN H5N1 influenza vaccine DMMHYLB TI TT3J5ZI DMMHYLB TN Cell mediated immunity response (CMIR) DMMHYLB RN Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. DMMHYLB RU https://pubmed.ncbi.nlm.nih.gov/17672124 DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO TI TTYRL6O DMMIAXO TN Glucocorticoid receptor (NR3C1) DMMIAXO MA Modulator DMMIAXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMIAXO RU https://www.fda.gov/ DMMIHVP DI DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP TI TTIU98M DMMIHVP TN Trace amine-associated receptor-1 (TAAR1) DMMIHVP MA Modulator DMMIHVP RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMMIHVP RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMMIQ20 DI DMMIQ20 DMMIQ20 DN Patiromer calcium DMMIQ20 TI TTB0SC6 DMMIQ20 TN Potassium (K) DMMIQ20 MA Binder DMMIQ20 RN Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. DMMIQ20 RU https://pubmed.ncbi.nlm.nih.gov/21208974 DMMIQ7G DI DMMIQ7G DMMIQ7G DN Rosuvastatin DMMIQ7G TI TTPADOQ DMMIQ7G TN HMG-CoA reductase (HMGCR) DMMIQ7G MA Inhibitor DMMIQ7G RN New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. DMMIQ7G RU https://pubmed.ncbi.nlm.nih.gov/12539816 DMMJ1IS DI DMMJ1IS DMMJ1IS DN Prolixin decanoate DMMJ1IS TI TTK8CXU DMMJ1IS TN 5-HT 1B receptor (HTR1B) DMMJ1IS MA Modulator DMMJ1IS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMJ1IS RU https://www.fda.gov/ DMMJQSH DI DMMJQSH DMMJQSH DN Lanthanum carbonate DMMJQSH TI TTHOTF6 DMMJQSH TN Phosphate (PHO) DMMJQSH MA Modulator DMMJQSH RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMMJQSH RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMMJTYW DI DMMJTYW DMMJTYW DN Darbepoetin alfa DMMJTYW TI TTAUX24 DMMJTYW TN Erythropoietin Receptor (EPOR) DMMJTYW MA Agonist DMMJTYW RN A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. DMMJTYW RU https://pubmed.ncbi.nlm.nih.gov/10406949 DMMJVXZ DI DMMJVXZ DMMJVXZ DN LU302146 DMMJVXZ TI TTKRD0G DMMJVXZ TN Endothelin A receptor (EDNRA) DMMJVXZ MA Antagonist DMMJVXZ RN Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S. DMMJVXZ RU https://pubmed.ncbi.nlm.nih.gov/12193103 DMMKHBJ DI DMMKHBJ DMMKHBJ DN Cefotaxime DMMKHBJ TI TTLP6GN DMMKHBJ TN Bacterial DD-carboxypeptidase (Bact vanYB) DMMKHBJ MA Inhibitor DMMKHBJ RN Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307. DMMKHBJ RU https://pubmed.ncbi.nlm.nih.gov/17661704 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E TI TT84ETX DMMN36E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMN36E MA Inhibitor DMMN36E RN Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6. DMMN36E RU https://pubmed.ncbi.nlm.nih.gov/19442129 DMMP3Y2 DI DMMP3Y2 DMMP3Y2 DN Yn-968D1 DMMP3Y2 TI TTUTJGQ DMMP3Y2 TN Vascular endothelial growth factor receptor 2 (KDR) DMMP3Y2 MA Inhibitor DMMP3Y2 RN YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80. DMMP3Y2 RU https://pubmed.ncbi.nlm.nih.gov/21443688 DMMP5SI DI DMMP5SI DMMP5SI DN Revefenacin DMMP5SI TI TTOXS3C DMMP5SI TN Muscarinic acetylcholine receptor (CHRM) DMMP5SI MA Antagonist DMMP5SI RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMMP5SI RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMMPCFX DI DMMPCFX DMMPCFX DN Recombinant human endostatin DMMPCFX TI TTRPKQG DMMPCFX TN Beta-catenin (CTNNB1) DMMPCFX MA Modulator DMMPCFX RN Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. DMMPCFX RU https://pubmed.ncbi.nlm.nih.gov/25232946 DMMPG5V DI DMMPG5V DMMPG5V DN NERIDRONIC ACID DMMPG5V TI TTIKWV4 DMMPG5V TN Geranyltranstransferase (FDPS) DMMPG5V MA Inhibitor DMMPG5V RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMMPG5V RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTSZ6Y3 DMMPTLH TN Proto-oncogene c-Ros (ROS1) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTPMQSO DMMPTLH TN ALK tyrosine kinase receptor (ALK) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTKN7QR DMMPTLH TN BDNF/NT-3 growth factors receptor (TrkB) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTXABCW DMMPTLH TN NT-3 growth factor receptor (TrkC) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTTDVOJ DMMPTLH TN Tropomyosin-related kinase A (TrkA) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMQ8ZG DI DMMQ8ZG DMMQ8ZG DN Furosemide DMMQ8ZG TI TTS087L DMMQ8ZG TN Solute carrier family 12 member 1 (SLC12A1) DMMQ8ZG MA Blocker DMMQ8ZG RN Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60. DMMQ8ZG RU https://pubmed.ncbi.nlm.nih.gov/17414583 DMMQHOZ DI DMMQHOZ DMMQHOZ DN Oxyphenonium DMMQHOZ TI TTZ9SOR DMMQHOZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMMQHOZ MA Antagonist DMMQHOZ RN Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62. DMMQHOZ RU https://pubmed.ncbi.nlm.nih.gov/10430538 DMMRV29 DI DMMRV29 DMMRV29 DN Telaprevir DMMRV29 TI TTHC7JD DMMRV29 TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMMRV29 MA Modulator DMMRV29 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMMRV29 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMMSDOY DI DMMSDOY DMMSDOY DN Stiripentol DMMSDOY TI TTEX6LM DMMSDOY TN GABA(A) receptor gamma-3 (GABRG3) DMMSDOY MA Modulator DMMSDOY RN Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16. DMMSDOY RU https://pubmed.ncbi.nlm.nih.gov/16650136 DMMSOLA DI DMMSOLA DMMSOLA DN Propoxyphene Hydrochloride DMMSOLA TI TTKWM86 DMMSOLA TN Opioid receptor mu (MOP) DMMSOLA MA Modulator DMMSOLA RN Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. DMMSOLA RU https://www.ncbi.nlm.nih.gov/pubmed/10690289 DMMTAJC DI DMMTAJC DMMTAJC DN Potassium chloride DMMTAJC TI TTS087L DMMTAJC TN Solute carrier family 12 member 1 (SLC12A1) DMMTAJC MA Modulator DMMTAJC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMTAJC RU https://www.fda.gov/ DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTZPWGN DMMU6BJ TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMMU6BJ MA Blocker DMMU6BJ RN Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/19445797 DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTPLQO0 DMMU6BJ TN Voltage-gated potassium channel Kv4.3 (KCND3) DMMU6BJ MA Blocker DMMU6BJ RN Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/18815938 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TTVKILB DMMUCG4 TN Prostaglandin G/H synthase 2 (COX-2) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TT8NGED DMMUCG4 TN Prostaglandin G/H synthase 1 (COX-1) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUOLJ DI DMMUOLJ DMMUOLJ DN Varenicline DMMUOLJ TI TTL1ATN DMMUOLJ TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMMUOLJ MA Modulator DMMUOLJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMMUOLJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMMV0KW DI DMMV0KW DMMV0KW DN Ephedrine DMMV0KW TI TTEX248 DMMV0KW TN Dopamine D2 receptor (D2R) DMMV0KW MA Agonist DMMV0KW RN The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7. DMMV0KW RU https://pubmed.ncbi.nlm.nih.gov/17159617 DMMVNZ0 DI DMMVNZ0 DMMVNZ0 DN Masoprocol DMMVNZ0 TI TT6EO5L DMMVNZ0 TN Erbb2 tyrosine kinase receptor (HER2) DMMVNZ0 MA Modulator DMMVNZ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMVNZ0 RU https://www.fda.gov/ DMMWSUL DI DMMWSUL DMMWSUL DN Lomustine DMMWSUL TI TTUTN1I DMMWSUL TN Human Deoxyribonucleic acid (hDNA) DMMWSUL MA Inhibitor DMMWSUL RN Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33. DMMWSUL RU https://pubmed.ncbi.nlm.nih.gov/17665847 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET TI TTYRL6O DMMWZET TN Glucocorticoid receptor (NR3C1) DMMWZET MA Agonist DMMWZET RN Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72. DMMWZET RU https://pubmed.ncbi.nlm.nih.gov/19375647 DMMX2E6 DI DMMX2E6 DMMX2E6 DN Pemetrexed DMMX2E6 TI TTU6BFZ DMMX2E6 TN Candida Thymidylate synthase (Candi TMP1) DMMX2E6 MA Inhibitor DMMX2E6 RN Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40. DMMX2E6 RU https://pubmed.ncbi.nlm.nih.gov/19362945 DMMYLTI DI DMMYLTI DMMYLTI DN Thyrotropin Alfa DMMYLTI TI TT6NYJA DMMYLTI TN Thyrotropin receptor (TSHR) DMMYLTI MA Binder DMMYLTI RN Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34. DMMYLTI RU https://pubmed.ncbi.nlm.nih.gov/19602784 DMMYPWO DI DMMYPWO DMMYPWO DN Alefacept DMMYPWO TI TT5KSBY DMMYPWO TN Surface glycoprotein LFA-3 (CD58) DMMYPWO MA Modulator DMMYPWO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMYPWO RU https://www.fda.gov/ DMMYZ3D DI DMMYZ3D DMMYZ3D DN Tositumomab DMMYZ3D TI TTUE541 DMMYZ3D TN Leukocyte surface antigen Leu-16 (CD20) DMMYZ3D RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMMYZ3D RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMMZB0K DI DMMZB0K DMMZB0K DN Prifinium DMMZB0K TI TTH18TF DMMZB0K TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMZB0K MA Modulator DMMZB0K RN Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther. 1995 Jul;274(1):378-84. DMMZB0K RU https://pubmed.ncbi.nlm.nih.gov/7616422 DMMZPWT DI DMMZPWT DMMZPWT DN Levocabastine DMMZPWT TI TTTIBOJ DMMZPWT TN Histamine H1 receptor (H1R) DMMZPWT MA Antagonist DMMZPWT RN Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62. DMMZPWT RU https://pubmed.ncbi.nlm.nih.gov/18680729 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ TI TTZFTY4 DMMZSXQ TN Amidophosphoribosyltransferase (PPAT) DMMZSXQ MA Inhibitor DMMZSXQ RN IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77. DMMZSXQ RU https://pubmed.ncbi.nlm.nih.gov/17662091 DMMZXIW DI DMMZXIW DMMZXIW DN Rabeprazole DMMZXIW TI TTF1QVM DMMZXIW TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMMZXIW MA Inhibitor DMMZXIW RN Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23. DMMZXIW RU https://pubmed.ncbi.nlm.nih.gov/10555605 DMN0LP8 DI DMN0LP8 DMN0LP8 DN Polymyxin B Sulfate DMN0LP8 TI TT4ILYC DMN0LP8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMN0LP8 MA Binder DMN0LP8 RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMN0LP8 RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMN0S1G DI DMN0S1G DMN0S1G DN HEGF DMN0S1G TI TTGKNB4 DMN0S1G TN Epidermal growth factor receptor (EGFR) DMN0S1G MA Activator DMN0S1G RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMN0S1G RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMN1XVC DI DMN1XVC DMN1XVC DN Lutetium Lu 177 dotatate DMN1XVC TI TTIND6G DMN1XVC TN Somatostatin receptor type 1 (SSTR1) DMN1XVC MA Antagonist DMN1XVC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMN1XVC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMN3E57 DI DMN3E57 DMN3E57 DN Levodopa DMN3E57 TI TTEX248 DMN3E57 TN Dopamine D2 receptor (D2R) DMN3E57 MA Modulator DMN3E57 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639). DMN3E57 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH TI TT5FNQT DMN3GCH TN Human immunodeficiency virus Protease (HIV PR) DMN3GCH MA Modulator DMN3GCH RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMN3GCH RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ TI TTZAYWL DMN3UXQ TN Estrogen receptor (ESR) DMN3UXQ MA Agonist DMN3UXQ RN Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9. DMN3UXQ RU https://pubmed.ncbi.nlm.nih.gov/19553606 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 TI TTK59TV DMN4CV5 TN Vitamin D3 receptor (VDR) DMN4CV5 MA Antagonist DMN4CV5 RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMN4CV5 RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMN4H2O DI DMN4H2O DMN4H2O DN Zithromax DMN4H2O TI TTUWYEA DMN4H2O TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMN4H2O MA Modulator DMN4H2O RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMN4H2O RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMN5T2A DI DMN5T2A DMN5T2A DN Ciclopirox DMN5T2A TI TTJQFBG DMN5T2A TN HIF-prolyl hydroxylase (HPH) DMN5T2A MA Modulator DMN5T2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMN5T2A RU https://www.fda.gov/ DMN63DZ DI DMN63DZ DMN63DZ DN Moxetumomab pasudotox DMN63DZ TI TTM6QSK DMN63DZ TN B-cell receptor CD22 (CD22) DMN63DZ MA Modulator DMN63DZ RN Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405. DMN63DZ RU https://pubmed.ncbi.nlm.nih.gov/22003067 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TT90XZ8 DMN6CAG TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMN6CAG MA Inhibitor DMN6CAG RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TTEX248 DMN6CAG TN Dopamine D2 receptor (D2R) DMN6CAG MA Antagonist DMN6CAG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMN6DXL DI DMN6DXL DMN6DXL DN Risperidone DMN6DXL TI TTEX248 DMN6DXL TN Dopamine D2 receptor (D2R) DMN6DXL MA Antagonist DMN6DXL RN Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8. DMN6DXL RU https://pubmed.ncbi.nlm.nih.gov/19566763 DMN6QO5 DI DMN6QO5 DMN6QO5 DN Gliclazide DMN6QO5 TI TTP835K DMN6QO5 TN ATP-binding cassette transporter C8 (ABCC8) DMN6QO5 MA Blocker DMN6QO5 RN Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. DMN6QO5 RU https://pubmed.ncbi.nlm.nih.gov/11574406 DMN7SDE DI DMN7SDE DMN7SDE DN Methyclothiazide DMN7SDE TI TTS087L DMN7SDE TN Solute carrier family 12 member 1 (SLC12A1) DMN7SDE MA Blocker DMN7SDE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMN7SDE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTNJYV2 DMN7Y9K TN Gamma-aminobutyric acid receptor (GAR) DMN7Y9K MA Inhibitor DMN7Y9K RN Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/9301675 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTPTXIN DMN7Y9K TN Translocator protein (TSPO) DMN7Y9K MA Inhibitor DMN7Y9K RN Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/18729350 DMN9CWF DI DMN9CWF DMN9CWF DN Salbutamol DMN9CWF TI TT2CJVK DMN9CWF TN Adrenergic receptor beta-2 (ADRB2) DMN9CWF MA Agonist DMN9CWF RN Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8. DMN9CWF RU https://pubmed.ncbi.nlm.nih.gov/11772115 DMN9RPO DI DMN9RPO DMN9RPO DN Nafcillin DMN9RPO TI TTJP4SM DMN9RPO TN Bacterial Penicillin binding protein (Bact PBP) DMN9RPO MA Binder DMN9RPO RN Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10. DMN9RPO RU https://pubmed.ncbi.nlm.nih.gov/2387996 DMNA8HM DI DMNA8HM DMNA8HM DN Pyrithione Zinc DMNA8HM TI TTG5TOX DMNA8HM TN Fungal Proton pump (FPPCM) DMNA8HM MA Modulator DMNA8HM RN Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrob Agents Chemother. 1978 Jul;14(1):60-8. DMNA8HM RU https://www.ncbi.nlm.nih.gov/pubmed/28693 DMNAKLY DI DMNAKLY DMNAKLY DN Remikiren DMNAKLY TI TTB2MXP DMNAKLY TN Angiotensinogenase renin (REN) DMNAKLY MA Inhibitor DMNAKLY RN Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9. DMNAKLY RU https://pubmed.ncbi.nlm.nih.gov/16189286 DMNARJT DI DMNARJT DMNARJT DN Ioflupane I-123 DMNARJT TI TTVBI8W DMNARJT TN Dopamine transporter (DAT) DMNARJT MA Modulator DMNARJT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNARJT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNC64R DI DMNC64R DMNC64R DN Antegren DMNC64R TI TT4BT06 DMNC64R TN Integrin alpha-4 (ITGA4) DMNC64R RN Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7. DMNC64R RU https://pubmed.ncbi.nlm.nih.gov/9736917 DMND304 DI DMND304 DMND304 DN Miltefosine DMND304 TI TT9V5JH DMND304 TN Phospholipase A2 (PLA2G1B) DMND304 MA Inhibitor DMND304 RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMND304 RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMNDJT5 DI DMNDJT5 DMNDJT5 DN Bromodiphenhydramine DMNDJT5 TI TTTIBOJ DMNDJT5 TN Histamine H1 receptor (H1R) DMNDJT5 MA Antagonist DMNDJT5 RN Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8. DMNDJT5 RU https://pubmed.ncbi.nlm.nih.gov/1973150 DMNER5S DI DMNER5S DMNER5S DN Bleomycin DMNER5S TI TTUTN1I DMNER5S TN Human Deoxyribonucleic acid (hDNA) DMNER5S MA Breaker DMNER5S RN Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. DMNER5S RU https://pubmed.ncbi.nlm.nih.gov/6177398 DMNEXZF DI DMNEXZF DMNEXZF DN Cefamandole DMNEXZF TI TTJP4SM DMNEXZF TN Bacterial Penicillin binding protein (Bact PBP) DMNEXZF MA Binder DMNEXZF RN The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54. DMNEXZF RU https://pubmed.ncbi.nlm.nih.gov/9419181 DMNF0G8 DI DMNF0G8 DMNF0G8 DN Rh-alphaglucosidase DMNF0G8 TI TTXWASR DMNF0G8 TN Intestinal maltase-glucoamylase (MGAM) DMNF0G8 MA Modulator DMNF0G8 RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMNF0G8 RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR TI TTL69WB DMNFUZR TN Angiotensin-converting enzyme (ACE) DMNFUZR MA Inhibitor DMNFUZR RN Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8. DMNFUZR RU https://pubmed.ncbi.nlm.nih.gov/19557238 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG TI TT0IHXV DMNH3PG TN DNA topoisomerase II (TOP2) DMNH3PG MA Modulator DMNH3PG RN Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/16101488 DMNHTZI DI DMNHTZI DMNHTZI DN Protriptyline DMNHTZI TI TTAWNKZ DMNHTZI TN Norepinephrine transporter (NET) DMNHTZI MA Inhibitor DMNHTZI RN Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55. DMNHTZI RU https://pubmed.ncbi.nlm.nih.gov/3494977 DMNI0KO DI DMNI0KO DMNI0KO DN Denosumab DMNI0KO TI TT9E8HR DMNI0KO TN Osteoclast differentiation factor (ODF) DMNI0KO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMNI0KO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 TI TTV1ZSQ DMNIJT0 TN Adenylate cyclase type 1 (ADCY1) DMNIJT0 MA Binder DMNIJT0 RN Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8. DMNIJT0 RU https://pubmed.ncbi.nlm.nih.gov/16497164 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z TI TTR6W5O DMNKG1Z TN Adrenergic receptor beta-1 (ADRB1) DMNKG1Z MA Antagonist DMNKG1Z RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMNKG1Z RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMNKT8Z DI DMNKT8Z DMNKT8Z DN Pachycarpine DMNKT8Z TI TTRK8B9 DMNKT8Z TN Sodium channel unspecific (NaC) DMNKT8Z MA Modulator DMNKT8Z RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNKT8Z RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNL0E6 DI DMNL0E6 DMNL0E6 DN Pipobroman DMNL0E6 TI TTUTN1I DMNL0E6 TN Human Deoxyribonucleic acid (hDNA) DMNL0E6 MA Binder DMNL0E6 RN Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. DMNL0E6 RU https://pubmed.ncbi.nlm.nih.gov/5556760 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TT8NGED DMNL98G TN Prostaglandin G/H synthase 1 (COX-1) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TTVKILB DMNL98G TN Prostaglandin G/H synthase 2 (COX-2) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTZA1NY DMNLHAC TN GABA(A) receptor beta-2 (GABRB2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTNJYV2 DMNLHAC TN Gamma-aminobutyric acid receptor (GAR) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT06RH5 DMNLHAC TN GABA(A) receptor gamma-2 (GABRG2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT1MPAY DMNLHAC TN GABA(A) receptor alpha-1 (GABRA1) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTGXH6N DMNLHAC TN GABA(A) receptor delta (GABRD) DMNLHAC MA Inhibitor DMNLHAC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTEX6LM DMNLHAC TN GABA(A) receptor gamma-3 (GABRG3) DMNLHAC MA Modulator DMNLHAC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLHAC RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNMHBV DI DMNMHBV DMNMHBV DN Penicillin DMNMHBV TI TTJP4SM DMNMHBV TN Bacterial Penicillin binding protein (Bact PBP) DMNMHBV MA Modulator DMNMHBV RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMNMHBV RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TT4C8EA DMNMW9R TN Dopamine D3 receptor (D3R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TTEX248 DMNMW9R TN Dopamine D2 receptor (D2R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMXR8 DI DMNMXR8 DMNMXR8 DN Procainamide DMNMXR8 TI TT05DLS DMNMXR8 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMNMXR8 MA Modulator DMNMXR8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMXR8 RU https://www.fda.gov/ DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT5L2VC DMNO38U TN Kallikrein-related peptidase (KLK) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT2WR1T DMNO38U TN Cationic trypsinogen (PRSS1) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TTU7ZMG DMNO38U TN Proteasome (PS) DMNO38U MA Modulator DMNO38U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNO38U RU https://www.fda.gov/ DMNOBFQ DI DMNOBFQ DMNOBFQ DN Mebeverine DMNOBFQ TI TTH18TF DMNOBFQ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOBFQ MA Antagonist DMNOBFQ RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMNOBFQ RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMNOKBV DI DMNOKBV DMNOKBV DN Phenytoin DMNOKBV TI TTRK8B9 DMNOKBV TN Sodium channel unspecific (NaC) DMNOKBV MA Blocker DMNOKBV RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMNOKBV RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTR6W5O DMNOSWU TN Adrenergic receptor beta-1 (ADRB1) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTH18TF DMNOSWU TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F TI TTSZLWK DMNP60F TN Aromatase (CYP19A1) DMNP60F MA Inhibitor DMNP60F RN Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8. DMNP60F RU https://pubmed.ncbi.nlm.nih.gov/12199354 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 TI TTUTN1I DMNPZL4 TN Human Deoxyribonucleic acid (hDNA) DMNPZL4 MA Breaker DMNPZL4 RN Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8. DMNPZL4 RU https://pubmed.ncbi.nlm.nih.gov/19561552 DMNQXV8 DI DMNQXV8 DMNQXV8 DN LGX818 DMNQXV8 TI TTWCGQT DMNQXV8 TN Serine/threonine-protein kinase B-raf (BRAF) DMNQXV8 MA Modulator DMNQXV8 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNQXV8 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNSJ7V DI DMNSJ7V DMNSJ7V DN Tropisetron DMNSJ7V TI TTPC4TU DMNSJ7V TN 5-HT 3A receptor (HTR3A) DMNSJ7V MA Antagonist DMNSJ7V RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMNSJ7V RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMNUC42 DI DMNUC42 DMNUC42 DN Sulodexide DMNUC42 TI TT4QPUL DMNUC42 TN Antithrombin-III (ATIII) DMNUC42 MA Activator DMNUC42 RN Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. DMNUC42 RU https://pubmed.ncbi.nlm.nih.gov/9436179 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST TI TTJP4SM DMNUWST TN Bacterial Penicillin binding protein (Bact PBP) DMNUWST MA Binder DMNUWST RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DMNUWST RU https://pubmed.ncbi.nlm.nih.gov/6335600 DMNVKU6 DI DMNVKU6 DMNVKU6 DN Crisaborole DMNVKU6 TI TTV5CGO DMNVKU6 TN Phosphodiesterase 4 (PDE4) DMNVKU6 MA Modulator DMNVKU6 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMNVKU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMNWZJG DI DMNWZJG DMNWZJG DN Leucovorin Calcium DMNWZJG TI TTYZVDJ DMNWZJG TN Dihydrofolate reductase (DHFR) DMNWZJG MA Modulator DMNWZJG RN Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26. DMNWZJG RU https://www.ncbi.nlm.nih.gov/pubmed/2448654 DMNXY5K DI DMNXY5K DMNXY5K DN Peramivir DMNXY5K TI TT50QJ3 DMNXY5K TN Influenza Neuraminidase (Influ NA) DMNXY5K MA Inhibitor DMNXY5K RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DMNXY5K RU https://pubmed.ncbi.nlm.nih.gov/19067613 DMNYOIX DI DMNYOIX DMNYOIX DN Olaratumab DMNYOIX TI TT8FYO9 DMNYOIX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMNYOIX MA Modulator DMNYOIX RN A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. DMNYOIX RU https://pubmed.ncbi.nlm.nih.gov/24452395 DMNYPGS DI DMNYPGS DMNYPGS DN Tioconazole DMNYPGS TI TTTSOUD DMNYPGS TN Candida Cytochrome P450 51 (Candi ERG11) DMNYPGS MA Inhibitor DMNYPGS RN Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6. DMNYPGS RU https://pubmed.ncbi.nlm.nih.gov/15625110 DMNZBRY DI DMNZBRY DMNZBRY DN Capreomycin DMNZBRY TI TTIA0J5 DMNZBRY TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMNZBRY MA Binder DMNZBRY RN Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15. DMNZBRY RU https://pubmed.ncbi.nlm.nih.gov/17564727 DMNZCI1 DI DMNZCI1 DMNZCI1 DN YM443 DMNZCI1 TI TT1RS9F DMNZCI1 TN Acetylcholinesterase (AChE) DMNZCI1 MA Modulator DMNZCI1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNZCI1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNZSC1 DI DMNZSC1 DMNZSC1 DN Candicidin DMNZSC1 TI TTQKWA4 DMNZSC1 TN Fungal Cell membrane ergosterol (Fung CME) DMNZSC1 MA Modulator DMNZSC1 RN Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans DMNZSC1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT3WG5C DMNZWL7 TN Monoamine oxidase type A (MAO-A) DMNZWL7 MA Inhibitor DMNZWL7 RN Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5. DMNZWL7 RU https://pubmed.ncbi.nlm.nih.gov/12457375 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT32XQJ DMNZWL7 TN Monoamine oxidase (MAO) DMNZWL7 MA Inhibitor DMNZWL7 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMNZWL7 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMO091F DI DMO091F DMO091F DN Balsalazide DMO091F TI TT8NGED DMO091F TN Prostaglandin G/H synthase 1 (COX-1) DMO091F MA Inhibitor DMO091F RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMO091F RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMO14SG DI DMO14SG DMO14SG DN Mebendazole DMO14SG TI TTYFKSZ DMO14SG TN Tubulin beta (TUBB) DMO14SG MA Binder DMO14SG RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMO14SG RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TTT2LD9 DMO2K0J TN GABA transaminase (ABAT) DMO2K0J MA Inhibitor DMO2K0J RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TT6L509 DMO2K0J TN Coagulation factor IIa (F2) DMO2K0J MA Inhibitor DMO2K0J RN New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/11794963 DMO381I DI DMO381I DMO381I DN Acamprosate DMO381I TI TTAN6JD DMO381I TN Glutamate receptor AMPA (GRIA) DMO381I MA Agonist DMO381I RN Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37. DMO381I RU https://pubmed.ncbi.nlm.nih.gov/19523047 DMO4PVE DI DMO4PVE DMO4PVE DN Apraclonidine DMO4PVE TI TTQ8AFT DMO4PVE TN Adrenergic receptor Alpha-2 (ADRA2) DMO4PVE MA Agonist DMO4PVE RN Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents. DMO4PVE RU https://pubmed.ncbi.nlm.nih.gov/11867401 DMO50U2 DI DMO50U2 DMO50U2 DN Naratriptan DMO50U2 TI TTK8CXU DMO50U2 TN 5-HT 1B receptor (HTR1B) DMO50U2 MA Agonist DMO50U2 RN Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9. DMO50U2 RU https://pubmed.ncbi.nlm.nih.gov/18223456 DMO5SZX DI DMO5SZX DMO5SZX DN Diphenoxylate DMO5SZX TI TTKWM86 DMO5SZX TN Opioid receptor mu (MOP) DMO5SZX MA Agonist DMO5SZX RN Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. DMO5SZX RU https://pubmed.ncbi.nlm.nih.gov/18192961 DMO6315 DI DMO6315 DMO6315 DN Vonoprazan DMO6315 TI TTLOKXP DMO6315 TN Gastric H(+)/K(+) ATPase (Proton pump) DMO6315 MA Modulator DMO6315 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008 DMO6315 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020973s022lbl.pdf DMO946V DI DMO946V DMO946V DN Ticlopidine DMO946V TI TTQL5VC DMO946V TN Platelet-activating factor receptor (PTAFR) DMO946V MA Modulator DMO946V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMO946V RU https://www.fda.gov/ DMO95XI DI DMO95XI DMO95XI DN Insulin, porcine DMO95XI TI TTCBFJO DMO95XI TN Insulin receptor (INSR) DMO95XI MA Binder DMO95XI RN Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9. DMO95XI RU https://pubmed.ncbi.nlm.nih.gov/12038982 DMO9WDS DI DMO9WDS DMO9WDS DN Altropane DMO9WDS TI TTVBI8W DMO9WDS TN Dopamine transporter (DAT) DMO9WDS MA Inhibitor DMO9WDS RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMO9WDS RU https://pubmed.ncbi.nlm.nih.gov/9593103 DMOA4VW DI DMOA4VW DMOA4VW DN Insulin-detemir DMOA4VW TI TTZOPHG DMOA4VW TN Insulin (INS) DMOA4VW MA Modulator DMOA4VW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOA4VW RU https://www.fda.gov/ DMOAD2Y DI DMOAD2Y DMOAD2Y DN Dupilumab DMOAD2Y TI TTDWHC3 DMOAD2Y TN Interleukin 4 receptor alpha (IL4R) DMOAD2Y RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMOAD2Y RU https://pubmed.ncbi.nlm.nih.gov/23688323 DMOB2F3 DI DMOB2F3 DMOB2F3 DN Heptabarbital DMOB2F3 TI TTAN6JD DMOB2F3 TN Glutamate receptor AMPA (GRIA) DMOB2F3 MA Antagonist DMOB2F3 RN A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15. DMOB2F3 RU https://pubmed.ncbi.nlm.nih.gov/9008265 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTOGPL1 DMOB58Q TN Cytomegalovirus Terminase UL56 (CMV TRM1) DMOB58Q MA Inhibitor DMOB58Q RN The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/21752907 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTZHSBO DMOB58Q TN Cytomegalovirus Terminase (CMV TRM) DMOB58Q MA Inhibitor DMOB58Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY TI TT6PEUO DMOBIKY TN Retinoic acid receptor RXR-alpha (RXRA) DMOBIKY MA Modulator DMOBIKY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOBIKY RU https://www.fda.gov/ DMOBLGK DI DMOBLGK DMOBLGK DN Tromethamine DMOBLGK TI TTBFROQ DMOBLGK TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMOBLGK MA Inhibitor DMOBLGK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOBLGK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMODHQI DI DMODHQI DMODHQI DN Budipine DMODHQI TI TTGP7BY DMODHQI TN Monoamine oxidase type B (MAO-B) DMODHQI MA Modulator DMODHQI RN Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. DMODHQI RU https://pubmed.ncbi.nlm.nih.gov/10370904 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 TI TTZAYWL DMODJ40 TN Estrogen receptor (ESR) DMODJ40 MA Agonist DMODJ40 RN 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. DMODJ40 RU https://pubmed.ncbi.nlm.nih.gov/19237207 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I TI TTZAYWL DMOEM2I TN Estrogen receptor (ESR) DMOEM2I MA Agonist DMOEM2I RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMOEM2I RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMOERGM DI DMOERGM DMOERGM DN Abaloparatide DMOERGM TI TTFPD47 DMOERGM TN Parathyroid hormone 1 receptor (PTH1R) DMOERGM MA Modulator DMOERGM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOERGM RU https://www.fda.gov/ DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TT5L2VC DMOF2C6 TN Kallikrein-related peptidase (KLK) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TTMF8H9 DMOF2C6 TN Plasma kallikrein (KLKB1) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF7AT DI DMOF7AT DMOF7AT DN Streptozocin DMOF7AT TI TTUTN1I DMOF7AT TN Human Deoxyribonucleic acid (hDNA) DMOF7AT MA Breaker DMOF7AT RN Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90. DMOF7AT RU https://pubmed.ncbi.nlm.nih.gov/19561381 DMOFP18 DI DMOFP18 DMOFP18 DN Ryzodeq DMOFP18 TI TTCBFJO DMOFP18 TN Insulin receptor (INSR) DMOFP18 MA Modulator DMOFP18 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMOFP18 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX TI TTIHYA4 DMOGFIX TN Thrombopoietin receptor (MPL) DMOGFIX MA Agonist DMOGFIX RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMOGFIX RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMOGNXY DI DMOGNXY DMOGNXY DN Sarilumab DMOGNXY TI TT0E5SK DMOGNXY TN Interleukin 6 receptor (IL6R) DMOGNXY MA Modulator DMOGNXY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOGNXY RU https://www.fda.gov/ DMOGREH DI DMOGREH DMOGREH DN Suplatast tosilate DMOGREH TI TTGPK5Y DMOGREH TN T(H2) cytokine production (TH2 produ) DMOGREH MA Modulator DMOGREH RN Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45. DMOGREH RU https://pubmed.ncbi.nlm.nih.gov/10756224 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT0JESD DMOH8VY TN Erbb4 tyrosine kinase receptor (Erbb-4) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT6EO5L DMOH8VY TN Erbb2 tyrosine kinase receptor (HER2) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TTGKNB4 DMOH8VY TN Epidermal growth factor receptor (EGFR) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMOHK1E DI DMOHK1E DMOHK1E DN Docosanol DMOHK1E TI TT1JL7D DMOHK1E TN Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) DMOHK1E MA Modulator DMOHK1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOHK1E RU https://www.fda.gov/ DMOHS9P DI DMOHS9P DMOHS9P DN Phenacemide DMOHS9P TI TTRK8B9 DMOHS9P TN Sodium channel unspecific (NaC) DMOHS9P MA Blocker DMOHS9P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOHS9P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOI1ZF DI DMOI1ZF DMOI1ZF DN Choline alfoscerate DMOI1ZF TI TTH18TF DMOI1ZF TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOI1ZF MA Modulator DMOI1ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMOI1ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTEX248 DMOIFW0 TN Dopamine D2 receptor (D2R) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTJQOD7 DMOIFW0 TN 5-HT 2A receptor (HTR2A) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIX5S DI DMOIX5S DMOIX5S DN Azilsartan DMOIX5S TI TT8DBY3 DMOIX5S TN Angiotensin II receptor type-1 (AGTR1) DMOIX5S MA Modulator DMOIX5S RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMOIX5S RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMOJ0V6 DI DMOJ0V6 DMOJ0V6 DN Metoprolol DMOJ0V6 TI TTR6W5O DMOJ0V6 TN Adrenergic receptor beta-1 (ADRB1) DMOJ0V6 MA Antagonist DMOJ0V6 RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMOJ0V6 RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMOJ4ZI DI DMOJ4ZI DMOJ4ZI DN Butenafine DMOJ4ZI TI TTM9XSU DMOJ4ZI TN Candida Squalene epoxidase (Candi ERG1) DMOJ4ZI MA Modulator DMOJ4ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOJ4ZI RU https://www.fda.gov/ DMOJZQ9 DI DMOJZQ9 DMOJZQ9 DN Loperamide DMOJZQ9 TI TT27RFC DMOJZQ9 TN Opioid receptor delta (OPRD1) DMOJZQ9 MA Binder DMOJZQ9 RN Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8. DMOJZQ9 RU https://pubmed.ncbi.nlm.nih.gov/6319884 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTFK8YB DMOK965 TN Bacterial DNA topoisomerase 4A (Bact parC) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTN6J5F DMOK965 TN Bacterial DNA gyrase (Bact gyrase) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTZAYWL DMOKCVI TN Estrogen receptor (ESR) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTOM3J0 DMOKCVI TN Estrogen receptor beta (ESR2) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H TI TTZ1DT0 DMOL54H TN P2Y purinoceptor 12 (P2RY12) DMOL54H MA Antagonist DMOL54H RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMOL54H RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMOL5IU DI DMOL5IU DMOL5IU DN Mesalazine DMOL5IU TI TT8NGED DMOL5IU TN Prostaglandin G/H synthase 1 (COX-1) DMOL5IU MA Inhibitor DMOL5IU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOL5IU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOL793 DI DMOL793 DMOL793 DN Trifarotene DMOL793 TI TT1Q3IE DMOL793 TN Retinoic acid receptor gamma (RARG) DMOL793 MA Agonist DMOL793 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMOL793 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTH18TF DMOLNCZ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ3JTF DMOLNCZ TN Muscarinic acetylcholine receptor M4 (CHRM4) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ13Z5 DMOLNCZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTZ9SOR DMOLNCZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTYEG6Q DMOLNCZ TN Muscarinic acetylcholine receptor M2 (CHRM2) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNHF DI DMOLNHF DMOLNHF DN Melphalan DMOLNHF TI TTUTN1I DMOLNHF TN Human Deoxyribonucleic acid (hDNA) DMOLNHF MA Modulator DMOLNHF RN Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94. DMOLNHF RU https://www.ncbi.nlm.nih.gov/pubmed/2155711 DMOM8AL DI DMOM8AL DMOM8AL DN Scopolamine DMOM8AL TI TTOXS3C DMOM8AL TN Muscarinic acetylcholine receptor (CHRM) DMOM8AL MA Antagonist DMOM8AL RN The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63. DMOM8AL RU https://pubmed.ncbi.nlm.nih.gov/19272427 DMOMBJW DI DMOMBJW DMOMBJW DN Moricizine DMOMBJW TI TTZOVE0 DMOMBJW TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOMBJW MA Blocker DMOMBJW RN From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. DMOMBJW RU https://pubmed.ncbi.nlm.nih.gov/8780326 DMOMK1V DI DMOMK1V DMOMK1V DN Halofantrine DMOMK1V TI TTV3NH6 DMOMK1V TN Calmodulin (CALM) DMOMK1V MA Modulator DMOMK1V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOMK1V RU https://www.fda.gov/ DMOMLHJ DI DMOMLHJ DMOMLHJ DN Lymecycline DMOMLHJ TI TTQ8KVI DMOMLHJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOMLHJ MA Binder DMOMLHJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMOMLHJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMOMP9U DI DMOMP9U DMOMP9U DN Cetirizine DMOMP9U TI TTTIBOJ DMOMP9U TN Histamine H1 receptor (H1R) DMOMP9U MA Antagonist DMOMP9U RN Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7. DMOMP9U RU https://pubmed.ncbi.nlm.nih.gov/19537525 DMOP0BL DI DMOP0BL DMOP0BL DN Ambenonium DMOP0BL TI TT1RS9F DMOP0BL TN Acetylcholinesterase (AChE) DMOP0BL MA Inhibitor DMOP0BL RN Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. DMOP0BL RU https://pubmed.ncbi.nlm.nih.gov/18033235 DMOPGHQ DI DMOPGHQ DMOPGHQ DN Indiplon DMOPGHQ TI TT1MPAY DMOPGHQ TN GABA(A) receptor alpha-1 (GABRA1) DMOPGHQ MA Agonist DMOPGHQ RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMOPGHQ RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMOPZDT DI DMOPZDT DMOPZDT DN Perindopril DMOPZDT TI TTL69WB DMOPZDT TN Angiotensin-converting enzyme (ACE) DMOPZDT MA Inhibitor DMOPZDT RN Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7. DMOPZDT RU https://pubmed.ncbi.nlm.nih.gov/19514543 DMOQK8Z DI DMOQK8Z DMOQK8Z DN Arbidol DMOQK8Z TI TTF4CAM DMOQK8Z TN Influenza Hemagglutinin (Influ HA) DMOQK8Z MA Inhibitor DMOQK8Z RN Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92. DMOQK8Z RU https://pubmed.ncbi.nlm.nih.gov/19446151 DMOQVU9 DI DMOQVU9 DMOQVU9 DN Hydroxyurea DMOQVU9 TI TTBWDI0 DMOQVU9 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMOQVU9 MA Modulator DMOQVU9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOQVU9 RU https://www.fda.gov/ DMORPBA DI DMORPBA DMORPBA DN Ergoloid mesylate DMORPBA TI TT32XQJ DMORPBA TN Monoamine oxidase (MAO) DMORPBA MA Modulator DMORPBA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMORPBA RU https://www.fda.gov/ DMOSQGU DI DMOSQGU DMOSQGU DN Nalbuphine DMOSQGU TI TTQW87Y DMOSQGU TN Opioid receptor kappa (OPRK1) DMOSQGU MA Modulator DMOSQGU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOSQGU RU https://www.fda.gov/ DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 TI TT5HONZ DMOSW35 TN Calcium channel unspecific (CaC) DMOSW35 MA Blocker DMOSW35 RN Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. DMOSW35 RU https://pubmed.ncbi.nlm.nih.gov/18974361 DMOTQ1I DI DMOTQ1I DMOTQ1I DN Ondansetron DMOTQ1I TI TTNXLKE DMOTQ1I TN 5-HT 3 receptor (5HT3R) DMOTQ1I MA Agonist DMOTQ1I RN Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70. DMOTQ1I RU https://pubmed.ncbi.nlm.nih.gov/9831410 DMOU1PK DI DMOU1PK DMOU1PK DN Praziquantel DMOU1PK TI TTCYE56 DMOU1PK TN Glutathione-dependent PGD synthase (HPGDS) DMOU1PK MA Inhibitor DMOU1PK RN X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5. DMOU1PK RU https://pubmed.ncbi.nlm.nih.gov/16511012 DMOUC09 DI DMOUC09 DMOUC09 DN Norepinephrine DMOUC09 TI TTR6W5O DMOUC09 TN Adrenergic receptor beta-1 (ADRB1) DMOUC09 MA Stimulator DMOUC09 RN Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. DMOUC09 RU https://pubmed.ncbi.nlm.nih.gov/10075057 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTIU7X1 DMOUMDV TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMOUMDV MA Inhibitor DMOUMDV RN Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/19228073 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTP3QRF DMOUMDV TN Thymidine kinase 1 (TK1) DMOUMDV MA Inhibitor DMOUMDV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOVAIX DI DMOVAIX DMOVAIX DN Meropenem + vaborbactam DMOVAIX TI TTHI19T DMOVAIX TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMOVAIX MA Inhibitor DMOVAIX RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOVAIX RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOVH1M DI DMOVH1M DMOVH1M DN Oxytetracycline DMOVH1M TI TTQ8KVI DMOVH1M TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOVH1M MA Binder DMOVH1M RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMOVH1M RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMOVY05 DI DMOVY05 DMOVY05 DN Ketotifen DMOVY05 TI TTTIBOJ DMOVY05 TN Histamine H1 receptor (H1R) DMOVY05 MA Antagonist DMOVY05 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMOVY05 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMOWEBU DI DMOWEBU DMOWEBU DN Pegaptanib DMOWEBU TI TTIPJCB DMOWEBU TN Neuropilin-1 (NRP1) DMOWEBU RN Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32. DMOWEBU RU https://pubmed.ncbi.nlm.nih.gov/16518379 DMOWK6B DI DMOWK6B DMOWK6B DN Aprobarbital DMOWK6B TI TTAN6JD DMOWK6B TN Glutamate receptor AMPA (GRIA) DMOWK6B MA Binder DMOWK6B RN Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8. DMOWK6B RU https://pubmed.ncbi.nlm.nih.gov/12039632 DMOWLVG DI DMOWLVG DMOWLVG DN Nitazoxanide DMOWLVG TI TT0F5P8 DMOWLVG TN Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) DMOWLVG MA Modulator DMOWLVG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWLVG RU https://www.fda.gov/ DMOWZ6B DI DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B TI TTTSOUD DMOWZ6B TN Candida Cytochrome P450 51 (Candi ERG11) DMOWZ6B MA Modulator DMOWZ6B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWZ6B RU https://www.fda.gov/ DMOX3LB DI DMOX3LB DMOX3LB DN Fosphenytoin DMOX3LB TI TTZOVE0 DMOX3LB TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOX3LB MA Blocker DMOX3LB RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMOX3LB RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMOXJKF DI DMOXJKF DMOXJKF DN Dapiprazole DMOXJKF TI TTEX248 DMOXJKF TN Dopamine D2 receptor (D2R) DMOXJKF MA Antagonist DMOXJKF RN Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. DMOXJKF RU https://pubmed.ncbi.nlm.nih.gov/14578408 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TT3PQ2Y DMOY7W3 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TTZVSJ2 DMOY7W3 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOYJFK DI DMOYJFK DMOYJFK DN Valrubicin DMOYJFK TI TT0IHXV DMOYJFK TN DNA topoisomerase II (TOP2) DMOYJFK MA Inhibitor DMOYJFK RN Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5. DMOYJFK RU https://pubmed.ncbi.nlm.nih.gov/3041237 DMP0OVQ DI DMP0OVQ DMP0OVQ DN Gestrinone DMP0OVQ TI TTZAYWL DMP0OVQ TN Estrogen receptor (ESR) DMP0OVQ MA Modulator DMP0OVQ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMP0OVQ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMP0UK2 DI DMP0UK2 DMP0UK2 DN Vecuronium DMP0UK2 TI TTF4E0J DMP0UK2 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMP0UK2 MA Antagonist DMP0UK2 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMP0UK2 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMP1I6Y DI DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y TI TTPMQSO DMP1I6Y TN ALK tyrosine kinase receptor (ALK) DMP1I6Y MA Inhibitor DMP1I6Y RN CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90. DMP1I6Y RU https://pubmed.ncbi.nlm.nih.gov/21575866 DMP1QTS DI DMP1QTS DMP1QTS DN Idecabtagene vicleucel DMP1QTS TI TTZ3P4W DMP1QTS TN B-cell maturation protein (TNFRSF17) DMP1QTS MA CAR-T-Cell-Therapy DMP1QTS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP1QTS RU https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel DMP2LZ8 DI DMP2LZ8 DMP2LZ8 DN MLN0002 DMP2LZ8 TI TT7ZMI1 DMP2LZ8 TN Integrin alpha-4/beta-7 (ITGA4/B7) DMP2LZ8 MA Modulator DMP2LZ8 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMP2LZ8 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMP45ME DI DMP45ME DMP45ME DN Lisocabtagene maraleucel DMP45ME TI TTW640A DMP45ME TN B-lymphocyte surface antigen B4 (CD19) DMP45ME MA CAR-T-Cell-Therapy DMP45ME RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP45ME RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel DMP54C7 DI DMP54C7 DMP54C7 DN Bacampicillin DMP54C7 TI TTJP4SM DMP54C7 TN Bacterial Penicillin binding protein (Bact PBP) DMP54C7 MA Binder DMP54C7 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMP54C7 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TT0PG8F DMP5A4T TN Cyclin-dependent kinase 4 (CDK4) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TTO0FDJ DMP5A4T TN Cyclin-dependent kinase 6 (CDK6) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP6G8T DI DMP6G8T DMP6G8T DN Topotecan DMP6G8T TI TTGTQHC DMP6G8T TN DNA topoisomerase I (TOP1) DMP6G8T MA Modulator DMP6G8T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6G8T RU https://www.fda.gov/ DMP6M1N DI DMP6M1N DMP6M1N DN Pirenzepine DMP6M1N TI TTZ9SOR DMP6M1N TN Muscarinic acetylcholine receptor M1 (CHRM1) DMP6M1N MA Antagonist DMP6M1N RN Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31. DMP6M1N RU https://pubmed.ncbi.nlm.nih.gov/19427366 DMP6SC2 DI DMP6SC2 DMP6SC2 DN Irinotecan DMP6SC2 TI TTGTQHC DMP6SC2 TN DNA topoisomerase I (TOP1) DMP6SC2 MA Modulator DMP6SC2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6SC2 RU https://www.fda.gov/ DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TTKRD0G DMP79A1 TN Endothelin A receptor (EDNRA) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TT3ZTGU DMP79A1 TN Endothelin B receptor (EDNRB) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP7LK1 DI DMP7LK1 DMP7LK1 DN Guggulsterone DMP7LK1 TI TTS4UGC DMP7LK1 TN Farnesoid X-activated receptor (FXR) DMP7LK1 MA Antagonist DMP7LK1 RN Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8. DMP7LK1 RU https://pubmed.ncbi.nlm.nih.gov/19102680 DMP8HEL DI DMP8HEL DMP8HEL DN Mitiglinide DMP8HEL TI TTG140O DMP8HEL TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMP8HEL MA Blocker DMP8HEL RN Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51. DMP8HEL RU https://pubmed.ncbi.nlm.nih.gov/17359941 DMP9HBO DI DMP9HBO DMP9HBO DN Sucralfate DMP9HBO TI TTGKIED DMP9HBO TN Fibroblast growth factor-2 (FGF2) DMP9HBO MA Modulator DMP9HBO RN Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14. DMP9HBO RU https://pubmed.ncbi.nlm.nih.gov/7720996 DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC TI TTML2WA DMPAZHC TN Tubulin (TUB) DMPAZHC MA Inhibitor DMPAZHC RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMPAZHC RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 TI TTOF3WZ DMPC1J7 TN Lipoprotein lipase (LPL) DMPC1J7 MA Activator DMPC1J7 RN Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95. DMPC1J7 RU https://pubmed.ncbi.nlm.nih.gov/17495091 DMPC2QY DI DMPC2QY DMPC2QY DN CNTO-1959 DMPC2QY TI TTC1GLB DMPC2QY TN Interleukin-23 (IL23) DMPC2QY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMPC2QY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTPTXIN DMPCG2L TN Translocator protein (TSPO) DMPCG2L MA Antagonist DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TT37EDJ DMPCG2L TN GABA(A) receptor alpha-3 (GABRA3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTNZPQ1 DMPCG2L TN GABA(A) receptor alpha-5 (GABRA5) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTBMV1G DMPCG2L TN GABA(A) receptor alpha-2 (GABRA2) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTEX6LM DMPCG2L TN GABA(A) receptor gamma-3 (GABRG3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T TI TT0IHXV DMPDW6T TN DNA topoisomerase II (TOP2) DMPDW6T MA Modulator DMPDW6T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPDW6T RU https://www.fda.gov/ DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR TI TTJP4SM DMPDYFR TN Bacterial Penicillin binding protein (Bact PBP) DMPDYFR MA Binder DMPDYFR RN Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/18218742 DMPFN6Y DI DMPFN6Y DMPFN6Y DN Olanzapine DMPFN6Y TI TTEX248 DMPFN6Y TN Dopamine D2 receptor (D2R) DMPFN6Y MA Agonist DMPFN6Y RN Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61. DMPFN6Y RU https://pubmed.ncbi.nlm.nih.gov/11217867 DMPFWO6 DI DMPFWO6 DMPFWO6 DN Halazepam DMPFWO6 TI TTPTXIN DMPFWO6 TN Translocator protein (TSPO) DMPFWO6 MA Modulator DMPFWO6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPFWO6 RU https://www.fda.gov/ DMPGHY8 DI DMPGHY8 DMPGHY8 DN Roflumilast DMPGHY8 TI TTV5CGO DMPGHY8 TN Phosphodiesterase 4 (PDE4) DMPGHY8 MA Modulator DMPGHY8 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMPGHY8 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMPGR1E DI DMPGR1E DMPGR1E DN Clascoterone DMPGR1E TI TTS64P2 DMPGR1E TN Androgen receptor (AR) DMPGR1E MA Antagonist DMPGR1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPGR1E RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF TI TTEX248 DMPGUCF TN Dopamine D2 receptor (D2R) DMPGUCF MA Agonist DMPGUCF RN The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. DMPGUCF RU https://pubmed.ncbi.nlm.nih.gov/17301410 DMPHVQ1 DI DMPHVQ1 DMPHVQ1 DN Human prothrombin complex concentrate DMPHVQ1 TI TT6L509 DMPHVQ1 TN Coagulation factor IIa (F2) DMPHVQ1 MA Modulator DMPHVQ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMPHVQ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMPHWU6 DI DMPHWU6 DMPHWU6 DN Tandospirone DMPHWU6 TI TT85JO3 DMPHWU6 TN 5-HT receptor (5HTR) DMPHWU6 MA Modulator DMPHWU6 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPHWU6 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTN6J5F DMPHXMI TN Bacterial DNA gyrase (Bact gyrase) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTIXTO3 DMPHXMI TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE TI TTG140O DMPHZQE TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMPHZQE MA Blocker DMPHZQE RN Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53. DMPHZQE RU https://pubmed.ncbi.nlm.nih.gov/14998554 DMPI6Z0 DI DMPI6Z0 DMPI6Z0 DN Zopiclone DMPI6Z0 TI TTAN6JD DMPI6Z0 TN Glutamate receptor AMPA (GRIA) DMPI6Z0 MA Binder DMPI6Z0 RN Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453. DMPI6Z0 RU https://pubmed.ncbi.nlm.nih.gov/19300573 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T TI TTTIBOJ DMPI98T TN Histamine H1 receptor (H1R) DMPI98T MA Inhibitor DMPI98T RN Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. DMPI98T RU https://pubmed.ncbi.nlm.nih.gov/17685877 DMPIBJK DI DMPIBJK DMPIBJK DN Propafenone DMPIBJK TI TT05DLS DMPIBJK TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMPIBJK MA Modulator DMPIBJK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPIBJK RU https://www.fda.gov/ DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS TI TTK0943 DMPIHLS TN Prostaglandin G/H synthase (COX) DMPIHLS MA Modulator DMPIHLS RN Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/11221916 DMPL395 DI DMPL395 DMPL395 DN Insulin degludec DMPL395 TI TTZOPHG DMPL395 TN Insulin (INS) DMPL395 MA Modulator DMPL395 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMPL395 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMPLY7B DI DMPLY7B DMPLY7B DN Cefmenoxime DMPLY7B TI TT85JMW DMPLY7B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMPLY7B MA Binder DMPLY7B RN In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701. DMPLY7B RU https://pubmed.ncbi.nlm.nih.gov/3134847 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTEX248 DMPM4SK TN Dopamine D2 receptor (D2R) DMPM4SK MA Agonist DMPM4SK RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/15977970 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTBRKXS DMPM4SK TN Adrenergic receptor alpha-1B (ADRA1B) DMPM4SK MA Antagonist DMPM4SK RN Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/18945553 DMPMYE8 DI DMPMYE8 DMPMYE8 DN Miconazole DMPMYE8 TI TTTSOUD DMPMYE8 TN Candida Cytochrome P450 51 (Candi ERG11) DMPMYE8 MA Modulator DMPMYE8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPMYE8 RU https://www.fda.gov/ DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW TI TT1VOHK DMPN1TW TN Potassium channel unspecific (KC) DMPN1TW MA Modulator DMPN1TW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPN1TW RU https://www.fda.gov/ DMPO0MS DI DMPO0MS DMPO0MS DN Gallamine Triethiodide DMPO0MS TI TTYEG6Q DMPO0MS TN Muscarinic acetylcholine receptor M2 (CHRM2) DMPO0MS MA Antagonist DMPO0MS RN Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24. DMPO0MS RU https://pubmed.ncbi.nlm.nih.gov/11921079 DMPOD47 DI DMPOD47 DMPOD47 DN Ajmalicine DMPOD47 TI TTR6W5O DMPOD47 TN Adrenergic receptor beta-1 (ADRB1) DMPOD47 MA Modulator DMPOD47 RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMPOD47 RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMPOU5H DI DMPOU5H DMPOU5H DN ENASIDENIB MESYLATE DMPOU5H TI TTDTWV0 DMPOU5H TN Isocitrate dehydrogenase (IDH) DMPOU5H MA Inhibitor DMPOU5H RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMPOU5H RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TTTB4UP DMPQAGE TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMPQAGE MA Inhibitor DMPQAGE RN Clinical pipeline report, company report or official report of Roche (2009). DMPQAGE RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TT1ZAVI DMPQAGE TN Prostaglandin E2 receptor EP2 (PTGER2) DMPQAGE MA Modulator DMPQAGE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341). DMPQAGE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341 DMPRBQV DI DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV TI TTL69WB DMPRBQV TN Angiotensin-converting enzyme (ACE) DMPRBQV MA Inhibitor DMPRBQV RN Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. DMPRBQV RU https://pubmed.ncbi.nlm.nih.gov/11862223 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G TI TTKWM86 DMPRI8G TN Opioid receptor mu (MOP) DMPRI8G MA Agonist DMPRI8G RN Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8. DMPRI8G RU https://pubmed.ncbi.nlm.nih.gov/19494155 DMPSB8F DI DMPSB8F DMPSB8F DN MEPTAZINOL DMPSB8F TI TTEB0GD DMPSB8F TN Cholinesterase (BCHE) DMPSB8F MA Inhibitor DMPSB8F RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMPSB8F RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMPT74U DI DMPT74U DMPT74U DN Gramicidin D DMPT74U TI TT4ILYC DMPT74U TN Bacterial Dihydropteroate synthetase (Bact folP) DMPT74U MA Binder DMPT74U RN Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86. DMPT74U RU https://pubmed.ncbi.nlm.nih.gov/11570868 DMPU2WX DI DMPU2WX DMPU2WX DN Omacetaxine mepesuccinate DMPU2WX TI TTA4FIU DMPU2WX TN Ribosome A (hRA) DMPU2WX MA Modulator DMPU2WX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMPU2WX RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMPUKA7 DI DMPUKA7 DMPUKA7 DN Caplacizumab DMPUKA7 TI TT3SZBT DMPUKA7 TN von Willebrand factor (VWF) DMPUKA7 MA Inhibitor DMPUKA7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMPUKA7 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf DMPVRN9 DI DMPVRN9 DMPVRN9 DN Setmelanotide DMPVRN9 TI TTD0CIQ DMPVRN9 TN Melanocortin receptor 4 (MC4R) DMPVRN9 MA Agonist DMPVRN9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPVRN9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf DMPWB7T DI DMPWB7T DMPWB7T DN Maprotiline DMPWB7T TI TTAWNKZ DMPWB7T TN Norepinephrine transporter (NET) DMPWB7T MA Inhibitor DMPWB7T RN Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28. DMPWB7T RU https://pubmed.ncbi.nlm.nih.gov/15900091 DMPWCTH DI DMPWCTH DMPWCTH DN Neocarzinostatin DMPWCTH TI TTUTN1I DMPWCTH TN Human Deoxyribonucleic acid (hDNA) DMPWCTH MA Modulator DMPWCTH RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPWCTH RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPWGBR DI DMPWGBR DMPWGBR DN Triclabendazole DMPWGBR TI TTEAID7 DMPWGBR TN Trypanosoma Cruzipain (Trypano CYSP) DMPWGBR MA Inhibitor DMPWGBR RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMPWGBR RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMPWNDB DI DMPWNDB DMPWNDB DN Balofloxacin DMPWNDB TI TTJP4SM DMPWNDB TN Bacterial Penicillin binding protein (Bact PBP) DMPWNDB MA Inhibitor DMPWNDB RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMPWNDB RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMPWSEM DI DMPWSEM DMPWSEM DN Lercanidipine DMPWSEM TI TTFK1JQ DMPWSEM TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMPWSEM MA Blocker DMPWSEM RN Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. DMPWSEM RU https://pubmed.ncbi.nlm.nih.gov/19619074 DMPXITB DI DMPXITB DMPXITB DN Hetacillin DMPXITB TI TTJP4SM DMPXITB TN Bacterial Penicillin binding protein (Bact PBP) DMPXITB MA Modulator DMPXITB RN JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051. DMPXITB RU https://www.ncbi.nlm.nih.gov/pubmed/23846595 DMPZI3Q DI DMPZI3Q DMPZI3Q DN Ketoconazole DMPZI3Q TI TTTSOUD DMPZI3Q TN Candida Cytochrome P450 51 (Candi ERG11) DMPZI3Q MA Inhibitor DMPZI3Q RN Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. DMPZI3Q RU https://pubmed.ncbi.nlm.nih.gov/19566112 DMPZS7U DI DMPZS7U DMPZS7U DN Oxyphenbutazone DMPZS7U TI TTFNGC9 DMPZS7U TN Serum albumin (ALB) DMPZS7U MA Modulator DMPZS7U RN Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4. DMPZS7U RU https://www.ncbi.nlm.nih.gov/pubmed/7062254 DMQ0C2Z DI DMQ0C2Z DMQ0C2Z DN Prevnar DMQ0C2Z TI TT9GOIR DMQ0C2Z TN Streptococcus Diphtheria protein (Stre DIPP) DMQ0C2Z RN Patent WO2013131983 A1. DMQ0C2Z RU http://www.google.com/patents/WO2013131983A1?cl=en DMQ0RKZ DI DMQ0RKZ DMQ0RKZ DN Nimodipine DMQ0RKZ TI TT5HONZ DMQ0RKZ TN Calcium channel unspecific (CaC) DMQ0RKZ MA Blocker DMQ0RKZ RN Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44. DMQ0RKZ RU https://pubmed.ncbi.nlm.nih.gov/19443934 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TTGKNB4 DMQ2491 TN Epidermal growth factor receptor (EGFR) DMQ2491 MA Activator DMQ2491 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TT23PYC DMQ2491 TN Soluble guanylate cyclase (GCS) DMQ2491 MA Modulator DMQ2491 RN Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/11896472 DMQ2AIJ DI DMQ2AIJ DMQ2AIJ DN Lestaurtinib DMQ2AIJ TI TTGJCWZ DMQ2AIJ TN Fms-like tyrosine kinase 3 (FLT-3) DMQ2AIJ MA Modulator DMQ2AIJ RN Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71. DMQ2AIJ RU https://pubmed.ncbi.nlm.nih.gov/17984313 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTPADOQ DMQ2FKJ TN HMG-CoA reductase (HMGCR) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TT3PQ2Y DMQ2FKJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/10941801 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTLVP78 DMQ2FKJ TN Dihydroorotate dehydrogenase (DHODH) DMQ2FKJ MA Modulator DMQ2FKJ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMQ2FPC DI DMQ2FPC DMQ2FPC DN Vasopressin DMQ2FPC TI TTK8R02 DMQ2FPC TN Vasopressin V2 receptor (V2R) DMQ2FPC MA Agonist DMQ2FPC RN Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9. DMQ2FPC RU https://pubmed.ncbi.nlm.nih.gov/16738530 DMQ2JO5 DI DMQ2JO5 DMQ2JO5 DN Hydrocodone DMQ2JO5 TI TTKWM86 DMQ2JO5 TN Opioid receptor mu (MOP) DMQ2JO5 MA Modulator DMQ2JO5 RN Clinical pipeline report, company report or official report of kempharm. DMQ2JO5 RU http://www.kempharm.com/pages/pipeline/pain.php DMQ314B DI DMQ314B DMQ314B DN Hexobarbital DMQ314B TI TT1MPAY DMQ314B TN GABA(A) receptor alpha-1 (GABRA1) DMQ314B MA Antagonist DMQ314B RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMQ314B RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN TI TTEX248 DMQ4HIN TN Dopamine D2 receptor (D2R) DMQ4HIN MA Agonist DMQ4HIN RN Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7. DMQ4HIN RU https://pubmed.ncbi.nlm.nih.gov/19145338 DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK TI TT2A0DR DMQ4TJK TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMQ4TJK MA Inhibitor DMQ4TJK RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMQ4TJK RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMQ5S6C DI DMQ5S6C DMQ5S6C DN Tebipenem pivoxil DMQ5S6C TI TTJP4SM DMQ5S6C TN Bacterial Penicillin binding protein (Bact PBP) DMQ5S6C MA Binder DMQ5S6C RN In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18. DMQ5S6C RU https://pubmed.ncbi.nlm.nih.gov/30718255 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT6PKBN DMQ8E9R TN Proto-oncogene c-Src (SRC) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT3PJMV DMQ8E9R TN Tyrosine-protein kinase ABL1 (ABL) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TTGKNB4 DMQ8E9R TN Epidermal growth factor receptor (EGFR) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8FR2 DI DMQ8FR2 DMQ8FR2 DN Prednisolone DMQ8FR2 TI TTYRL6O DMQ8FR2 TN Glucocorticoid receptor (NR3C1) DMQ8FR2 MA Modulator DMQ8FR2 RN Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6. DMQ8FR2 RU https://pubmed.ncbi.nlm.nih.gov/11081607 DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTJQOD7 DMQ8HOJ TN 5-HT 2A receptor (HTR2A) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTEX248 DMQ8HOJ TN Dopamine D2 receptor (D2R) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK TI TTS4UGC DMQ8JIK TN Farnesoid X-activated receptor (FXR) DMQ8JIK MA Modulator DMQ8JIK RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DMQ8JIK RU https://pubmed.ncbi.nlm.nih.gov/12052824 DMQ8R4E DI DMQ8R4E DMQ8R4E DN Naftopidil DMQ8R4E TI TTNGILX DMQ8R4E TN Adrenergic receptor alpha-1A (ADRA1A) DMQ8R4E MA Inhibitor DMQ8R4E RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMQ8R4E RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMQ9MVG DI DMQ9MVG DMQ9MVG DN Chlorhexidine DMQ9MVG TI TT4ILYC DMQ9MVG TN Bacterial Dihydropteroate synthetase (Bact folP) DMQ9MVG MA Breaker DMQ9MVG RN The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5. DMQ9MVG RU https://pubmed.ncbi.nlm.nih.gov/1335944 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTQ38E9 DMQCTIH TN Sodium/potassium-transporting ATPase (SPT ATPase) DMQCTIH MA Inhibitor DMQCTIH RN Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/15554746 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTACFNR DMQCTIH TN Organic anion transporter M1 (SLCO4C1) DMQCTIH MA Modulator DMQCTIH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227). DMQCTIH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227 DMQG17S DI DMQG17S DMQG17S DN Tirofiban DMQG17S TI TT38RM1 DMQG17S TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQG17S MA Modulator DMQG17S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQG17S RU https://www.fda.gov/ DMQHM2D DI DMQHM2D DMQHM2D DN Benzylpenicilloyl Polylysine DMQHM2D TI TTDGEC0 DMQHM2D TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMQHM2D MA Binder DMQHM2D RN Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. DMQHM2D RU https://pubmed.ncbi.nlm.nih.gov/7436456 DMQI0FU DI DMQI0FU DMQI0FU DN Insulin-glulisine DMQI0FU TI TTCBFJO DMQI0FU TN Insulin receptor (INSR) DMQI0FU MA Binder DMQI0FU RN Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. DMQI0FU RU https://pubmed.ncbi.nlm.nih.gov/19496630 DMQJHR7 DI DMQJHR7 DMQJHR7 DN Indacaterol DMQJHR7 TI TT2CJVK DMQJHR7 TN Adrenergic receptor beta-2 (ADRB2) DMQJHR7 MA Agonist DMQJHR7 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMQJHR7 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ TI TTUTN1I DMQL8XJ TN Human Deoxyribonucleic acid (hDNA) DMQL8XJ MA Modulator DMQL8XJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMQL8XJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TT2NUT5 DMQLT4N TN Adrenergic receptor alpha-2C (ADRA2C) DMQLT4N MA Modulator DMQLT4N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520). DMQLT4N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TTQ8AFT DMQLT4N TN Adrenergic receptor Alpha-2 (ADRA2) DMQLT4N MA Agonist DMQLT4N RN Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90. DMQLT4N RU https://pubmed.ncbi.nlm.nih.gov/10943881 DMQLX7O DI DMQLX7O DMQLX7O DN Arteether DMQLX7O TI TT9X7H4 DMQLX7O TN Beta-hematin formation (BHF) DMQLX7O MA Modulator DMQLX7O RN Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52. DMQLX7O RU https://pubmed.ncbi.nlm.nih.gov/22354307 DMQM9S0 DI DMQM9S0 DMQM9S0 DN Palivizumab DMQM9S0 TI TT57ID8 DMQM9S0 TN Respiratory syncytial virus protein F (RSV F) DMQM9S0 MA Modulator DMQM9S0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQM9S0 RU https://www.fda.gov/ DMQMBZ1 DI DMQMBZ1 DMQMBZ1 DN Rivaroxaban DMQMBZ1 TI TTCIHJA DMQMBZ1 TN Coagulation factor Xa (F10) DMQMBZ1 MA Modulator DMQMBZ1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMQMBZ1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMQMGXV DI DMQMGXV DMQMGXV DN Loxoprofen gel DMQMGXV TI TTK0943 DMQMGXV TN Prostaglandin G/H synthase (COX) DMQMGXV MA Inhibitor DMQMGXV RN Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9. DMQMGXV RU https://pubmed.ncbi.nlm.nih.gov/24261771 DMQMV1B DI DMQMV1B DMQMV1B DN Adalimumab DMQMV1B TI TTF8CQI DMQMV1B TN Tumor necrosis factor (TNF) DMQMV1B RN Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. DMQMV1B RU https://pubmed.ncbi.nlm.nih.gov/19573024 DMQNI7O DI DMQNI7O DMQNI7O DN OTL-200 DMQNI7O TI TTYQANR DMQNI7O TN Cerebroside-sulfatase (ARSA) DMQNI7O MA Replacement DMQNI7O RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMQNI7O RU https://www.orchard-tx.com/approach/pipeline/ DMQNWRD DI DMQNWRD DMQNWRD DN Oxaliplatin DMQNWRD TI TTUTN1I DMQNWRD TN Human Deoxyribonucleic acid (hDNA) DMQNWRD MA Modulator DMQNWRD RN Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93. DMQNWRD RU https://www.ncbi.nlm.nih.gov/pubmed/23019159 DMQPD1F DI DMQPD1F DMQPD1F DN Panitumumab DMQPD1F TI TTGKNB4 DMQPD1F TN Epidermal growth factor receptor (EGFR) DMQPD1F MA Suppressor DMQPD1F RN Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. DMQPD1F RU https://pubmed.ncbi.nlm.nih.gov/19616446 DMQPTOZ DI DMQPTOZ DMQPTOZ DN Icatibant DMQPTOZ TI TTGY8IW DMQPTOZ TN B2 bradykinin receptor (BDKRB2) DMQPTOZ MA Antagonist DMQPTOZ RN Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41. DMQPTOZ RU https://pubmed.ncbi.nlm.nih.gov/19552510 DMQRPOS DI DMQRPOS DMQRPOS DN Chlorphentermine hydrochloride DMQRPOS TI TT3ROYC DMQRPOS TN Serotonin transporter (SERT) DMQRPOS MA Modulator DMQRPOS RN Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75. DMQRPOS RU https://www.ncbi.nlm.nih.gov/pubmed/10458725 DMQSA2V DI DMQSA2V DMQSA2V DN Valbenazine tosylate DMQSA2V TI TTNZRI3 DMQSA2V TN Synaptic vesicle amine transporter (SLC18A2) DMQSA2V MA Modulator DMQSA2V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQSA2V RU https://www.fda.gov/ DMQSGM0 DI DMQSGM0 DMQSGM0 DN Hydroxyamphetamine Hydrobromide DMQSGM0 TI TTIU98M DMQSGM0 TN Trace amine-associated receptor-1 (TAAR1) DMQSGM0 MA Modulator DMQSGM0 RN Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37. DMQSGM0 RU https://www.ncbi.nlm.nih.gov/pubmed/3884149 DMQTAGO DI DMQTAGO DMQTAGO DN BMS-201038 DMQTAGO TI TTUS1RD DMQTAGO TN Microsomal triglyceride transfer protein (MTTP) DMQTAGO MA Inhibitor DMQTAGO RN Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8. DMQTAGO RU https://pubmed.ncbi.nlm.nih.gov/19276898 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTHQZV7 DMQTFAO TN Mothers against decapentaplegic homolog 3 (SMAD3) DMQTFAO MA Inhibitor DMQTFAO RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTTQR47 DMQTFAO TN Solute carrier family 22 member 8 (SLC22A8) DMQTFAO MA Inhibitor DMQTFAO RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMQTJSX DI DMQTJSX DMQTJSX DN Fluvoxamine DMQTJSX TI TT3ROYC DMQTJSX TN Serotonin transporter (SERT) DMQTJSX MA Inhibitor DMQTJSX RN Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4. DMQTJSX RU https://pubmed.ncbi.nlm.nih.gov/19568609 DMQTREB DI DMQTREB DMQTREB DN Uridine DMQTREB TI TTO0IB8 DMQTREB TN Thymidine phosphorylase (TYMP) DMQTREB MA Inhibitor DMQTREB RN Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell. 2007 Nov;20(4):107-10. DMQTREB RU https://pubmed.ncbi.nlm.nih.gov/17949350 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTUTN1I DMQUSBT TN Human Deoxyribonucleic acid (hDNA) DMQUSBT MA Intercalator DMQUSBT RN 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. DMQUSBT RU https://pubmed.ncbi.nlm.nih.gov/2472832 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTABD5E DMQUSBT TN DNA replication (DNA repli) DMQUSBT MA Modulator DMQUSBT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQUSBT RU https://www.fda.gov/ DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTRHEQ4 DMQVRZH TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMQVRZH MA Inhibitor DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTWNV8U DMQVRZH TN Nicotinic acid receptor (HCAR2) DMQVRZH MA Agonist DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TT06AWU DMQVZJD TN Phosphodiesterase 3A (PDE3A) DMQVZJD MA Inhibitor DMQVZJD RN Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18. DMQVZJD RU https://pubmed.ncbi.nlm.nih.gov/3027339 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TTZCG4L DMQVZJD TN Phosphodiesterase 3 (PDE3) DMQVZJD MA Modulator DMQVZJD RN In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9. DMQVZJD RU https://www.ncbi.nlm.nih.gov/pubmed/12657857 DMQWZ0H DI DMQWZ0H DMQWZ0H DN Benzthiazide DMQWZ0H TI TTANPDJ DMQWZ0H TN Carbonic anhydrase II (CA-II) DMQWZ0H MA Inhibitor DMQWZ0H RN Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4. DMQWZ0H RU https://pubmed.ncbi.nlm.nih.gov/13760527 DMQXI9F DI DMQXI9F DMQXI9F DN L-Phenylalanine DMQXI9F TI TTUHP71 DMQXI9F TN Tyrosine 3-monooxygenase (TH) DMQXI9F MA Binder DMQXI9F RN Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67. DMQXI9F RU https://pubmed.ncbi.nlm.nih.gov/17305546 DMQXLD2 DI DMQXLD2 DMQXLD2 DN Cyproterone DMQXLD2 TI TTS64P2 DMQXLD2 TN Androgen receptor (AR) DMQXLD2 MA Antagonist DMQXLD2 RN Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. DMQXLD2 RU https://pubmed.ncbi.nlm.nih.gov/19463689 DMQXTJS DI DMQXTJS DMQXTJS DN Eptifibatide DMQXTJS TI TT38RM1 DMQXTJS TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQXTJS MA Modulator DMQXTJS RN Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62. DMQXTJS RU https://pubmed.ncbi.nlm.nih.gov/2033037 DMQYJIR DI DMQYJIR DMQYJIR DN Macimorelin DMQYJIR TI TTWDC17 DMQYJIR TN Growth hormone secretagogue receptor 1 (GHSR) DMQYJIR MA Agonist DMQYJIR RN National Cancer Institute Drug Dictionary (drug id 735530). DMQYJIR RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=735530 DMQYUWG DI DMQYUWG DMQYUWG DN Toremifene DMQYUWG TI TTZAYWL DMQYUWG TN Estrogen receptor (ESR) DMQYUWG MA Modulator DMQYUWG RN Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81. DMQYUWG RU https://pubmed.ncbi.nlm.nih.gov/19468285 DMQYV60 DI DMQYV60 DMQYV60 DN Isopropamide iodide DMQYV60 TI TTOXS3C DMQYV60 TN Muscarinic acetylcholine receptor (CHRM) DMQYV60 MA Modulator DMQYV60 RN Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7. DMQYV60 RU https://pubmed.ncbi.nlm.nih.gov/3580704 DMQZ9GF DI DMQZ9GF DMQZ9GF DN Trilostane DMQZ9GF TI TTOM3J0 DMQZ9GF TN Estrogen receptor beta (ESR2) DMQZ9GF MA Modulator DMQZ9GF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQZ9GF RU https://www.fda.gov/ DMQZBXI DI DMQZBXI DMQZBXI DN Calaspargase pegol DMQZBXI TI TT4WT91 DMQZBXI TN Asparaginase (ASRGL1) DMQZBXI MA Inhibitor DMQZBXI RN Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82. DMQZBXI RU https://pubmed.ncbi.nlm.nih.gov/25348002 DMR0TYK DI DMR0TYK DMR0TYK DN Fosdenopterin DMR0TYK TI TT7RJY8 DMR0TYK TN Xanthine dehydrogenase/oxidase (XDH) DMR0TYK MA Cofactor DMR0TYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMR0TYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf DMR27C8 DI DMR27C8 DMR27C8 DN Artesunate DMR27C8 TI TTZVSJ2 DMR27C8 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMR27C8 MA Inhibitor DMR27C8 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMR27C8 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMR2IQ4 DI DMR2IQ4 DMR2IQ4 DN Tizanidine DMR2IQ4 TI TTQ8AFT DMR2IQ4 TN Adrenergic receptor Alpha-2 (ADRA2) DMR2IQ4 MA Agonist DMR2IQ4 RN Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. DMR2IQ4 RU https://pubmed.ncbi.nlm.nih.gov/9074844 DMR2J95 DI DMR2J95 DMR2J95 DN Omadacycline DMR2J95 TI TTOVFH2 DMR2J95 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMR2J95 MA Inhibitor DMR2J95 RN Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204. DMR2J95 RU https://pubmed.ncbi.nlm.nih.gov/30290000 DMR4HIW DI DMR4HIW DMR4HIW DN Insulin-glargine DMR4HIW TI TTZOPHG DMR4HIW TN Insulin (INS) DMR4HIW MA Modulator DMR4HIW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMR4HIW RU https://www.fda.gov/ DMR5QS6 DI DMR5QS6 DMR5QS6 DN Hydroxystilbamidine Isethionate DMR5QS6 TI TTS1W4A DMR5QS6 TN Bacterial Deoxyribonucleic acid (Bact DNA) DMR5QS6 MA Modulator DMR5QS6 RN Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42. DMR5QS6 RU https://www.ncbi.nlm.nih.gov/pubmed/1242363 DMR5ZUP DI DMR5ZUP DMR5ZUP DN Paramethadione DMR5ZUP TI TT729IR DMR5ZUP TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMR5ZUP MA Blocker DMR5ZUP RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DMR5ZUP RU https://pubmed.ncbi.nlm.nih.gov/17291698 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H TI TTP835K DMR6N7H TN ATP-binding cassette transporter C8 (ABCC8) DMR6N7H MA Modulator DMR6N7H RN Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/16249427 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TT3ROYC DMR6QH0 TN Serotonin transporter (SERT) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TTAWNKZ DMR6QH0 TN Norepinephrine transporter (NET) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR7IVC DI DMR7IVC DMR7IVC DN Pimavanserin DMR7IVC TI TTJQOD7 DMR7IVC TN 5-HT 2A receptor (HTR2A) DMR7IVC MA Modulator DMR7IVC RN Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52. DMR7IVC RU https://www.ncbi.nlm.nih.gov/pubmed/22954754 DMR87LC DI DMR87LC DMR87LC DN Ethambutol DMR87LC TI TT1Q8GP DMR87LC TN Mycobacterium Arabinosyltransferase C (MycB embC) DMR87LC MA Inhibitor DMR87LC RN The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46. DMR87LC RU https://pubmed.ncbi.nlm.nih.gov/19596878 DMR8H31 DI DMR8H31 DMR8H31 DN Quinapril DMR8H31 TI TTL69WB DMR8H31 TN Angiotensin-converting enzyme (ACE) DMR8H31 MA Inhibitor DMR8H31 RN An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50. DMR8H31 RU https://pubmed.ncbi.nlm.nih.gov/19270231 DMR8ONJ DI DMR8ONJ DMR8ONJ DN Leflunomide DMR8ONJ TI TT3PQ2Y DMR8ONJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMR8ONJ MA Inhibitor DMR8ONJ RN Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91. DMR8ONJ RU https://pubmed.ncbi.nlm.nih.gov/10583416 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTLP6GN DMR8YD6 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMR8YD6 MA Inhibitor DMR8YD6 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTGTQHC DMR8YD6 TN DNA topoisomerase I (TOP1) DMR8YD6 MA Inhibitor DMR8YD6 RN Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/12027807 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTPOI4B DMR8YD6 TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DMR8YD6 MA Inhibitor DMR8YD6 RN Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/8951505 DMRADYL DI DMRADYL DMRADYL DN Pinacidil DMRADYL TI TT1VOHK DMRADYL TN Potassium channel unspecific (KC) DMRADYL MA Modulator DMRADYL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRADYL RU https://www.fda.gov/ DMRBJNZ DI DMRBJNZ DMRBJNZ DN Forasartan DMRBJNZ TI TT8DBY3 DMRBJNZ TN Angiotensin II receptor type-1 (AGTR1) DMRBJNZ MA Antagonist DMRBJNZ RN Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26. DMRBJNZ RU https://pubmed.ncbi.nlm.nih.gov/12593652 DMRCLZB DI DMRCLZB DMRCLZB DN Pentagastrin DMRCLZB TI TTVFO0U DMRCLZB TN Gastrin/cholecystokinin type B receptor (CCKBR) DMRCLZB MA Agonist DMRCLZB RN Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21. DMRCLZB RU https://pubmed.ncbi.nlm.nih.gov/18580872 DMRCX8K DI DMRCX8K DMRCX8K DN Eloctate DMRCX8K TI TT1290U DMRCX8K TN Coagulation factor VIII (F8) DMRCX8K MA Modulator DMRCX8K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRCX8K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRD1QK DI DMRD1QK DMRD1QK DN Netilmicin DMRD1QK TI TTQ8KVI DMRD1QK TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMRD1QK MA Binder DMRD1QK RN Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6. DMRD1QK RU https://pubmed.ncbi.nlm.nih.gov/6927285 DMRDUC0 DI DMRDUC0 DMRDUC0 DN Elagolix sodium DMRDUC0 TI TT8R70G DMRDUC0 TN Gonadotropin-releasing hormone receptor (GNRHR) DMRDUC0 MA Antagonist DMRDUC0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMRDUC0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMREUQ6 DI DMREUQ6 DMREUQ6 DN Valsartan DMREUQ6 TI TT8DBY3 DMREUQ6 TN Angiotensin II receptor type-1 (AGTR1) DMREUQ6 MA Antagonist DMREUQ6 RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMREUQ6 RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK TI TTLWPVF DMRF9YK TN Sodium/glucose cotransporter 2 (SGLT2) DMRF9YK MA Modulator DMRF9YK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRF9YK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRFWGK DI DMRFWGK DMRFWGK DN Novobiocin DMRFWGK TI TT0IHXV DMRFWGK TN DNA topoisomerase II (TOP2) DMRFWGK MA Inhibitor DMRFWGK RN Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9. DMRFWGK RU https://pubmed.ncbi.nlm.nih.gov/19082504 DMRGZ16 DI DMRGZ16 DMRGZ16 DN Sulfamethazine DMRGZ16 TI TT4ILYC DMRGZ16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMRGZ16 MA Inhibitor DMRGZ16 RN A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80. DMRGZ16 RU https://pubmed.ncbi.nlm.nih.gov/19505691 DMRH0D5 DI DMRH0D5 DMRH0D5 DN PEGylated IFN beta 1-a DMRH0D5 TI TT4TZ8J DMRH0D5 TN Interferon-beta (IFNB1) DMRH0D5 MA Modulator DMRH0D5 RN Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. DMRH0D5 RU https://pubmed.ncbi.nlm.nih.gov/24794721 DMRH7CV DI DMRH7CV DMRH7CV DN Deserpidine DMRH7CV TI TTL69WB DMRH7CV TN Angiotensin-converting enzyme (ACE) DMRH7CV MA Inhibitor DMRH7CV RN Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906. DMRH7CV RU https://pubmed.ncbi.nlm.nih.gov/12651915 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 TI TTUTN1I DMRHGI9 TN Human Deoxyribonucleic acid (hDNA) DMRHGI9 MA Modulator DMRHGI9 RN Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/8533159 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTUTJGQ DMRICNP TN Vascular endothelial growth factor receptor 2 (KDR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TT4DXQT DMRICNP TN Proto-oncogene c-Ret (RET) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTGKNB4 DMRICNP TN Epidermal growth factor receptor (EGFR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRJ3YX DI DMRJ3YX DMRJ3YX DN Alteplase DMRJ3YX TI TTP86E2 DMRJ3YX TN Plasminogen (PLG) DMRJ3YX MA Activator DMRJ3YX RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMRJ3YX RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMRJ7D1 DI DMRJ7D1 DMRJ7D1 DN Nomegestrol acetate DMRJ7D1 TI TTZAYWL DMRJ7D1 TN Estrogen receptor (ESR) DMRJ7D1 MA Modulator DMRJ7D1 RN Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61. DMRJ7D1 RU https://pubmed.ncbi.nlm.nih.gov/2918478 DMRJFN9 DI DMRJFN9 DMRJFN9 DN Theophylline DMRJFN9 TI TTSLI08 DMRJFN9 TN Adenosine receptor (ADOR) DMRJFN9 MA Antagonist DMRJFN9 RN Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92. DMRJFN9 RU https://pubmed.ncbi.nlm.nih.gov/17874974 DMRJLAT DI DMRJLAT DMRJLAT DN Osimertinib DMRJLAT TI TTGKNB4 DMRJLAT TN Epidermal growth factor receptor (EGFR) DMRJLAT MA Inhibitor DMRJLAT RN AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. DMRJLAT RU https://pubmed.ncbi.nlm.nih.gov/24893891 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TT6OEDT DMRJSP8 TN Cannabinoid receptor 1 (CB1) DMRJSP8 MA Inhibitor DMRJSP8 RN Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9. DMRJSP8 RU https://pubmed.ncbi.nlm.nih.gov/18831576 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TTXMY0J DMRJSP8 TN Pancreatic triacylglycerol lipase (PNLIP) DMRJSP8 MA Modulator DMRJSP8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRJSP8 RU https://www.fda.gov/ DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT TI TT8DBY3 DMRK8OT TN Angiotensin II receptor type-1 (AGTR1) DMRK8OT MA Antagonist DMRK8OT RN Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. DMRK8OT RU https://pubmed.ncbi.nlm.nih.gov/19563275 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 TI TTABD5E DMRKE63 TN DNA replication (DNA repli) DMRKE63 MA Intercalator DMRKE63 RN Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23. DMRKE63 RU https://pubmed.ncbi.nlm.nih.gov/19509245 DMRKOS1 DI DMRKOS1 DMRKOS1 DN Oxilofrine DMRKOS1 TI TTVIREA DMRKOS1 TN Adrenergic receptor (ADR) DMRKOS1 MA Modulator DMRKOS1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMRKOS1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMRKXPT DI DMRKXPT DMRKXPT DN Ketoprofen DMRKXPT TI TTVKILB DMRKXPT TN Prostaglandin G/H synthase 2 (COX-2) DMRKXPT MA Inhibitor DMRKXPT RN Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62. DMRKXPT RU https://pubmed.ncbi.nlm.nih.gov/17588732 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB TI TTQHJ1K DMRL3AB TN Histamine H2 receptor (H2R) DMRL3AB MA Antagonist DMRL3AB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMRL3AB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMRM0JV DI DMRM0JV DMRM0JV DN Nalidixic acid DMRM0JV TI TT0IHXV DMRM0JV TN DNA topoisomerase II (TOP2) DMRM0JV MA Inhibitor DMRM0JV RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DMRM0JV RU https://pubmed.ncbi.nlm.nih.gov/2847647 DMRM3AW DI DMRM3AW DMRM3AW DN Acarbose DMRM3AW TI TTXWASR DMRM3AW TN Intestinal maltase-glucoamylase (MGAM) DMRM3AW MA Modulator DMRM3AW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRM3AW RU https://www.fda.gov/ DMRMCXW DI DMRMCXW DMRMCXW DN Zotarolimus DMRMCXW TI TTCJG29 DMRMCXW TN Serine/threonine-protein kinase mTOR (mTOR) DMRMCXW MA Modulator DMRMCXW RN Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516. DMRMCXW RU https://pubmed.ncbi.nlm.nih.gov/18497896 DMRMDWA DI DMRMDWA DMRMDWA DN Estropipate DMRMDWA TI TTZAYWL DMRMDWA TN Estrogen receptor (ESR) DMRMDWA MA Modulator DMRMDWA RN US patent application no. 5,004,651, Stabilizing system for solid dosage forms. DMRMDWA RU http://www.google.com/patents/US5004651 DMRMFP4 DI DMRMFP4 DMRMFP4 DN Inamrinone Lactate DMRMFP4 TI TTZCG4L DMRMFP4 TN Phosphodiesterase 3 (PDE3) DMRMFP4 MA Inhibitor DMRMFP4 RN Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8. DMRMFP4 RU https://pubmed.ncbi.nlm.nih.gov/12076859 DMRMS0L DI DMRMS0L DMRMS0L DN Morphine DMRMS0L TI TTKWM86 DMRMS0L TN Opioid receptor mu (MOP) DMRMS0L MA Modulator DMRMS0L RN Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8. DMRMS0L RU https://www.ncbi.nlm.nih.gov/pubmed/15901793 DMRMS1A DI DMRMS1A DMRMS1A DN Betamethasone Benzoate DMRMS1A TI TTYRL6O DMRMS1A TN Glucocorticoid receptor (NR3C1) DMRMS1A MA Modulator DMRMS1A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRMS1A RU https://www.fda.gov/ DMRQD04 DI DMRQD04 DMRQD04 DN Tramadol DMRQD04 TI TTWJBZ5 DMRQD04 TN 5-HT 2C receptor (HTR2C) DMRQD04 MA Modulator DMRQD04 RN The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. DMRQD04 RU https://pubmed.ncbi.nlm.nih.gov/15105221 DMRSKMZ DI DMRSKMZ DMRSKMZ DN Satumomab Pendetide DMRSKMZ TI TTX35ZM DMRSKMZ TN Tumor-associated glycoprotein 72 (TAG-72) DMRSKMZ MA Binder DMRSKMZ RN Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1. DMRSKMZ RU https://pubmed.ncbi.nlm.nih.gov/9755434 DMRSX53 DI DMRSX53 DMRSX53 DN nusinersen DMRSX53 TI TTSVGQ5 DMRSX53 TN SMN1 messenger RNA (SMN1 mRNA) DMRSX53 MA Modulator DMRSX53 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMRSX53 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMRSZA5 DI DMRSZA5 DMRSZA5 DN Cefacetrile DMRSZA5 TI TTJP4SM DMRSZA5 TN Bacterial Penicillin binding protein (Bact PBP) DMRSZA5 MA Binder DMRSZA5 RN Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42. DMRSZA5 RU https://pubmed.ncbi.nlm.nih.gov/18665871 DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP TI TTRJYB6 DMRTSGP TN Acid-sensing ion channel 1 (ASIC1) DMRTSGP MA Modulator DMRTSGP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRTSGP RU https://www.fda.gov/ DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 TI TTS087L DMRV7H0 TN Solute carrier family 12 member 1 (SLC12A1) DMRV7H0 MA Blocker DMRV7H0 RN Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. DMRV7H0 RU https://pubmed.ncbi.nlm.nih.gov/19141616 DMRVBWU DI DMRVBWU DMRVBWU DN Bentazepam DMRVBWU TI TTEX6LM DMRVBWU TN GABA(A) receptor gamma-3 (GABRG3) DMRVBWU MA Modulator DMRVBWU RN Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96. DMRVBWU RU https://pubmed.ncbi.nlm.nih.gov/20530587 DMS0AFE DI DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE TI TT26PHO DMS0AFE TN Mineralocorticoid receptor (MR) DMS0AFE MA Modulator DMS0AFE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS0AFE RU https://www.fda.gov/ DMS104F DI DMS104F DMS104F DN Temsirolimus DMS104F TI TTCJG29 DMS104F TN Serine/threonine-protein kinase mTOR (mTOR) DMS104F MA Inhibitor DMS104F RN Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. DMS104F RU https://pubmed.ncbi.nlm.nih.gov/25312588 DMS1GYT DI DMS1GYT DMS1GYT DN Mirabegron DMS1GYT TI TTMXGCW DMS1GYT TN Adrenergic receptor beta-3 (ADRB3) DMS1GYT MA Modulator DMS1GYT RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMS1GYT RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMS2IUH DI DMS2IUH DMS2IUH DN Valganciclovir DMS2IUH TI TTIU7X1 DMS2IUH TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMS2IUH MA Inhibitor DMS2IUH RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DMS2IUH RU https://pubmed.ncbi.nlm.nih.gov/19275707 DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TT7MRDV DMS2J0Z TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTX41N9 DMS2J0Z TN Tyrosine-protein kinase Kit (KIT) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTGJCWZ DMS2J0Z TN Fms-like tyrosine kinase 3 (FLT-3) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2M7O DI DMS2M7O DMS2M7O DN Deferiprone DMS2M7O TI TTUDR0C DMS2M7O TN Iron (Fe) DMS2M7O MA Modulator DMS2M7O RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMS2M7O RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMS3508 DI DMS3508 DMS3508 DN Carboprost tromethamine DMS3508 TI TTT2ZAR DMS3508 TN Prostaglandin F2-alpha receptor (PTGFR) DMS3508 MA Modulator DMS3508 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS3508 RU https://www.fda.gov/ DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTYCILE DMS3GVE TN Vasopressin receptor (VR) DMS3GVE MA Modulator DMS3GVE RN Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/10594321 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTL9MHW DMS3GVE TN Vasopressin V1b receptor (V1BR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTK8R02 DMS3GVE TN Vasopressin V2 receptor (V2R) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTSCIUP DMS3GVE TN Oxytocin receptor (OTR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TT4TFGN DMS3GVE TN Vasopressin V1a receptor (V1AR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GX2 DI DMS3GX2 DMS3GX2 DN Telmisartan DMS3GX2 TI TT8DBY3 DMS3GX2 TN Angiotensin II receptor type-1 (AGTR1) DMS3GX2 MA Antagonist DMS3GX2 RN Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35. DMS3GX2 RU https://pubmed.ncbi.nlm.nih.gov/19395110 DMS3YE9 DI DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 TI TTXT3PU DMS3YE9 TN Influenza M2 protein (Influ M) DMS3YE9 MA Inhibitor DMS3YE9 RN Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76. DMS3YE9 RU https://pubmed.ncbi.nlm.nih.gov/19469531 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ TI TTJHKYD DMS4BLQ TN Delta-aminolevulinic acid dehydratase (ALAD) DMS4BLQ MA Inhibitor DMS4BLQ RN Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. DMS4BLQ RU https://pubmed.ncbi.nlm.nih.gov/12665801 DMS51VC DI DMS51VC DMS51VC DN Clomiphene citrate DMS51VC TI TTZAYWL DMS51VC TN Estrogen receptor (ESR) DMS51VC MA Modulator DMS51VC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS51VC RU https://www.fda.gov/ DMS5IEB DI DMS5IEB DMS5IEB DN Docarpamine DMS5IEB TI TTEX248 DMS5IEB TN Dopamine D2 receptor (D2R) DMS5IEB MA Modulator DMS5IEB RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMS5IEB RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTN6J5F DMS60RB TN Bacterial DNA gyrase (Bact gyrase) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTIXTO3 DMS60RB TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS7OU8 DI DMS7OU8 DMS7OU8 DN Elapegademase DMS7OU8 TI TTLP57V DMS7OU8 TN Adenosine deaminase (ADA) DMS7OU8 MA Modulator DMS7OU8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMS7OU8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMS7T13 DI DMS7T13 DMS7T13 DN Meclizine DMS7T13 TI TTRANFM DMS7T13 TN Orphan nuclear receptor NR1I3 (NR1I3) DMS7T13 MA Modulator DMS7T13 RN Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73. DMS7T13 RU https://pubmed.ncbi.nlm.nih.gov/16684648 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTUTJGQ DMS8IFC TN Vascular endothelial growth factor receptor 2 (KDR) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTX41N9 DMS8IFC TN Tyrosine-protein kinase Kit (KIT) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTI7421 DMS8IFC TN Platelet-derived growth factor receptor beta (PDGFRB) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTGKNB4 DMS8IFC TN Epidermal growth factor receptor (EGFR) DMS8IFC MA Inhibitor DMS8IFC RN Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. DMS8IFC RU http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227 DMSA4B3 DI DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 TI TT26PHO DMSA4B3 TN Mineralocorticoid receptor (MR) DMSA4B3 MA Binder DMSA4B3 RN Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. DMSA4B3 RU https://pubmed.ncbi.nlm.nih.gov/6227474 DMSA4HZ DI DMSA4HZ DMSA4HZ DN KU-0058948 DMSA4HZ TI TTVDSZ0 DMSA4HZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSA4HZ MA Inhibitor DMSA4HZ RN Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11. DMSA4HZ RU https://pubmed.ncbi.nlm.nih.gov/19354255 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTFZDNP DMSA8RU TN Activation B7-1 antigen (CD80) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTHGXBU DMSA8RU TN T-lymphocyte activation antigen CD86 (FUN1) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT8J1S3 DMSB068 TN Smoothened homolog (SMO) DMSB068 MA Modulator DMSB068 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMSB068 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT4LXBC DMSB068 TN Hedgehog signaling pathway (HS pathway) DMSB068 MA Inhibitor DMSB068 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSB068 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TTCJG29 DMSB068 TN Serine/threonine-protein kinase mTOR (mTOR) DMSB068 MA Inhibitor DMSB068 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSB068 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMSBRUW DI DMSBRUW DMSBRUW DN Decamethonium DMSBRUW TI TT54JVQ DMSBRUW TN Neuronal acetylcholine receptor alpha-1 (CHRNA1) DMSBRUW MA Modulator DMSBRUW RN Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6. DMSBRUW RU https://www.ncbi.nlm.nih.gov/pubmed/21102480 DMSC4A7 DI DMSC4A7 DMSC4A7 DN Indomethacin DMSC4A7 TI TTVKILB DMSC4A7 TN Prostaglandin G/H synthase 2 (COX-2) DMSC4A7 MA Modulator DMSC4A7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSC4A7 RU https://www.fda.gov/ DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTTX5M8 DMSCDY9 TN Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTV0PE2 DMSCDY9 TN Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCIKZ DI DMSCIKZ DMSCIKZ DN Dopexamine DMSCIKZ TI TTEX248 DMSCIKZ TN Dopamine D2 receptor (D2R) DMSCIKZ MA Modulator DMSCIKZ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMSCIKZ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMSD1UN DI DMSD1UN DMSD1UN DN Bevacizumab DMSD1UN TI TTOHSBA DMSD1UN TN Vascular endothelial growth factor A (VEGFA) DMSD1UN MA Inhibitor DMSD1UN RN FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085. DMSD1UN RU https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085 DMSE3I7 DI DMSE3I7 DMSE3I7 DN Gemcitabine DMSE3I7 TI TTBWDI0 DMSE3I7 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMSE3I7 MA Modulator DMSE3I7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSE3I7 RU https://www.fda.gov/ DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 TI TTT3P91 DMSEPK8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMSEPK8 MA Inhibitor DMSEPK8 RN Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. DMSEPK8 RU https://pubmed.ncbi.nlm.nih.gov/18778117 DMSF4PR DI DMSF4PR DMSF4PR DN Chlormerodrin DMSF4PR TI TTJUWVB DMSF4PR TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMSF4PR MA Modulator DMSF4PR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSF4PR RU https://www.fda.gov/ DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V TI TTCJ2X8 DMSFK9V TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSFK9V MA Inhibitor DMSFK9V RN 2011 Pipeline of Bristol-Myers Squibb. DMSFK9V RU http://www.bms.com/pages/default.aspx DMSFQ8I DI DMSFQ8I DMSFQ8I DN Meclocycline DMSFQ8I TI TTQ8KVI DMSFQ8I TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMSFQ8I MA Binder DMSFQ8I RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMSFQ8I RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMSHPW8 DI DMSHPW8 DMSHPW8 DN Tolterodine DMSHPW8 TI TTQ13Z5 DMSHPW8 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSHPW8 MA Antagonist DMSHPW8 RN Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. DMSHPW8 RU https://pubmed.ncbi.nlm.nih.gov/14769832 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB TI TTKY2NS DMSI5CB TN Duffy antigen chemokine receptor (ACKR1) DMSI5CB MA Modulator DMSI5CB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSI5CB RU https://www.fda.gov/ DMSIMD8 DI DMSIMD8 DMSIMD8 DN Cefuroxime DMSIMD8 TI TTJP4SM DMSIMD8 TN Bacterial Penicillin binding protein (Bact PBP) DMSIMD8 MA Binder DMSIMD8 RN Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. DMSIMD8 RU https://pubmed.ncbi.nlm.nih.gov/12615852 DMSIVND DI DMSIVND DMSIVND DN Hydroxychloroquine DMSIVND TI TTRJ1K4 DMSIVND TN Toll-like receptor 7 (TLR7) DMSIVND MA Antagonist DMSIVND RN TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. DMSIVND RU https://pubmed.ncbi.nlm.nih.gov/18220957 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TT3MOS2 DMSJDTY TN Aldehyde oxidase (AOX1) DMSJDTY MA Inhibitor DMSJDTY RN Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8512597 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TTPFZJ1 DMSJDTY TN Vasopressin V1 receptor (V1R) DMSJDTY MA Agonist DMSJDTY RN Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8738818 DMSJVAM DI DMSJVAM DMSJVAM DN Amisulpride DMSJVAM TI TTEX248 DMSJVAM TN Dopamine D2 receptor (D2R) DMSJVAM MA Antagonist DMSJVAM RN Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. DMSJVAM RU https://pubmed.ncbi.nlm.nih.gov/16696579 DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTN6J5F DMSL679 TN Bacterial DNA gyrase (Bact gyrase) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTIXTO3 DMSL679 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSLJP4 DI DMSLJP4 DMSLJP4 DN Ziconotide DMSLJP4 TI TT4FDG6 DMSLJP4 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMSLJP4 MA Blocker DMSLJP4 RN Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. DMSLJP4 RU https://pubmed.ncbi.nlm.nih.gov/19249984 DMSM2KE DI DMSM2KE DMSM2KE DN Nitrofurazone DMSM2KE TI TTOVFH2 DMSM2KE TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMSM2KE MA Inhibitor DMSM2KE RN The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74. DMSM2KE RU https://pubmed.ncbi.nlm.nih.gov/22941660 DMSNVGB DI DMSNVGB DMSNVGB DN Echothiophate Iodide DMSNVGB TI TT1RS9F DMSNVGB TN Acetylcholinesterase (AChE) DMSNVGB MA Modulator DMSNVGB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSNVGB RU https://www.fda.gov/ DMSOAJ2 DI DMSOAJ2 DMSOAJ2 DN N-0923 DMSOAJ2 TI TTEX248 DMSOAJ2 TN Dopamine D2 receptor (D2R) DMSOAJ2 MA Agonist DMSOAJ2 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMSOAJ2 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMSOQK1 DI DMSOQK1 DMSOQK1 DN Chloroprocaine DMSOQK1 TI TTWK8D0 DMSOQK1 TN Sodium pump subunit alpha-1 (ATP1A1) DMSOQK1 MA Blocker DMSOQK1 RN Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403. DMSOQK1 RU https://pubmed.ncbi.nlm.nih.gov/11352545 DMSOURV DI DMSOURV DMSOURV DN Formoterol DMSOURV TI TT2CJVK DMSOURV TN Adrenergic receptor beta-2 (ADRB2) DMSOURV MA Agonist DMSOURV RN Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104. DMSOURV RU https://pubmed.ncbi.nlm.nih.gov/12137617 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TT3ROYC DMSOX7I TN Serotonin transporter (SERT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTAWNKZ DMSOX7I TN Norepinephrine transporter (NET) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTVBI8W DMSOX7I TN Dopamine transporter (DAT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSP4JX DI DMSP4JX DMSP4JX DN Cetraxate DMSP4JX TI TT5L2VC DMSP4JX TN Kallikrein-related peptidase (KLK) DMSP4JX MA Modulator DMSP4JX RN A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48. DMSP4JX RU https://pubmed.ncbi.nlm.nih.gov/4261023 DMSPJG2 DI DMSPJG2 DMSPJG2 DN Ropivacaine DMSPJG2 TI TT90XZ8 DMSPJG2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMSPJG2 MA Modulator DMSPJG2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSPJG2 RU https://www.fda.gov/ DMSQ1JV DI DMSQ1JV DMSQ1JV DN LAS-34273 DMSQ1JV TI TTQ13Z5 DMSQ1JV TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSQ1JV MA Antagonist DMSQ1JV RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMSQ1JV RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMSQ8MD DI DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD TI TT06AWU DMSQ8MD TN Phosphodiesterase 3A (PDE3A) DMSQ8MD MA Inhibitor DMSQ8MD RN Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. DMSQ8MD RU https://pubmed.ncbi.nlm.nih.gov/16000354 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TTN9VTF DMSQDLE TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMSQDLE MA Blocker DMSQDLE RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMSQDLE RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TT05DLS DMSQDLE TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSQDLE MA Modulator DMSQDLE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQDLE RU https://www.fda.gov/ DMSQVD6 DI DMSQVD6 DMSQVD6 DN Ceforanide DMSQVD6 TI TTJP4SM DMSQVD6 TN Bacterial Penicillin binding protein (Bact PBP) DMSQVD6 MA Binder DMSQVD6 RN The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3. DMSQVD6 RU https://pubmed.ncbi.nlm.nih.gov/12890292 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 TI TTXFI1K DMSQZE2 TN Hyaluronidase (HYAL) DMSQZE2 MA Modulator DMSQZE2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQZE2 RU https://www.fda.gov/ DMSREPX DI DMSREPX DMSREPX DN Levobetaxolol DMSREPX TI TTR6W5O DMSREPX TN Adrenergic receptor beta-1 (ADRB1) DMSREPX MA Antagonist DMSREPX RN Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9. DMSREPX RU https://pubmed.ncbi.nlm.nih.gov/15117564 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO TI TTPHEX3 DMSRZAO TN Ceramide glucosyltransferase (UGCG) DMSRZAO MA Modulator DMSRZAO RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSRZAO RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTVJ1D8 DMSTA36 TN Vascular endothelial growth factor receptor (VEGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTRLW2X DMSTA36 TN Fibroblast growth factor receptor 1 (FGFR1) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTGJCWZ DMSTA36 TN Fms-like tyrosine kinase 3 (FLT-3) DMSTA36 MA Inhibitor DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTI2WET DMSTA36 TN Platelet-derived growth factor receptor (PDGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSUVM1 DI DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 TI TTJP4SM DMSUVM1 TN Bacterial Penicillin binding protein (Bact PBP) DMSUVM1 MA Binder DMSUVM1 RN Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. DMSUVM1 RU https://pubmed.ncbi.nlm.nih.gov/17724158 DMSVOCZ DI DMSVOCZ DMSVOCZ DN Pantoprazole DMSVOCZ TI TTLOKXP DMSVOCZ TN Gastric H(+)/K(+) ATPase (Proton pump) DMSVOCZ MA Modulator DMSVOCZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOCZ RU https://www.fda.gov/ DMSVOZT DI DMSVOZT DMSVOZT DN Nifedipine DMSVOZT TI TTXHYV6 DMSVOZT TN Voltage-gated L-type calcium channel (L-CaC) DMSVOZT MA Modulator DMSVOZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOZT RU https://www.fda.gov/ DMSWNJF DI DMSWNJF DMSWNJF DN Ravulizumab DMSWNJF TI TTKANGO DMSWNJF TN Complement C5 (CO5) DMSWNJF MA Inhibitor DMSWNJF RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSWNJF RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSWUGE DI DMSWUGE DMSWUGE DN Telbivudine DMSWUGE TI TTT4SY6 DMSWUGE TN Hepatitis B virus Polymerase (HBV P) DMSWUGE MA Inhibitor DMSWUGE RN Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. DMSWUGE RU https://pubmed.ncbi.nlm.nih.gov/19187868 DMSWYF5 DI DMSWYF5 DMSWYF5 DN Quinine DMSWYF5 TI TT05DLS DMSWYF5 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSWYF5 MA Modulator DMSWYF5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSWYF5 RU https://www.fda.gov/ DMSXKYG DI DMSXKYG DMSXKYG DN Gamma-homolinolenic acid DMSXKYG TI TT8NGED DMSXKYG TN Prostaglandin G/H synthase 1 (COX-1) DMSXKYG MA Inhibitor DMSXKYG RN Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96. DMSXKYG RU https://pubmed.ncbi.nlm.nih.gov/11939906 DMSY4ZG DI DMSY4ZG DMSY4ZG DN Tenofovir disoproxil fumarate DMSY4ZG TI TT84ETX DMSY4ZG TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSY4ZG MA Modulator DMSY4ZG RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMSY4ZG RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMSYFM8 DI DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 TI TTWF7UG DMSYFM8 TN Somatostatin (SST) DMSYFM8 MA Binder DMSYFM8 RN Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61. DMSYFM8 RU https://pubmed.ncbi.nlm.nih.gov/19595735 DMSYPNW DI DMSYPNW DMSYPNW DN Ranibizumab DMSYPNW TI TTOHSBA DMSYPNW TN Vascular endothelial growth factor A (VEGFA) DMSYPNW RN Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. DMSYPNW RU https://pubmed.ncbi.nlm.nih.gov/17031284 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX TI TT5FNQT DMSYRBX TN Human immunodeficiency virus Protease (HIV PR) DMSYRBX MA Modulator DMSYRBX RN Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9. DMSYRBX RU https://pubmed.ncbi.nlm.nih.gov/11237841 DMSZLJR DI DMSZLJR DMSZLJR DN Avelumab DMSZLJR TI TT8ZLTI DMSZLJR TN Programmed cell death 1 ligand 1 (PD-L1) DMSZLJR RN Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. DMSZLJR RU https://pubmed.ncbi.nlm.nih.gov/26014098 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK TI TTIU98M DMSZQAK TN Trace amine-associated receptor-1 (TAAR1) DMSZQAK MA Modulator DMSZQAK RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMSZQAK RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT9IK2Z DMT1I52 TN N-methyl-D-aspartate receptor (NMDAR) DMT1I52 MA Agonist DMT1I52 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTCS3P1 DMT1I52 TN Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) DMT1I52 MA Inhibitor DMT1I52 RN Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/15302885 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT6TMZU DMT1I52 TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTLD29N DMT1I52 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT2EJP DI DMT2EJP DMT2EJP DN Podofilox DMT2EJP TI TT0IHXV DMT2EJP TN DNA topoisomerase II (TOP2) DMT2EJP MA Modulator DMT2EJP RN Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39. DMT2EJP RU https://pubmed.ncbi.nlm.nih.gov/11102564 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC TI TTAWNKZ DMT2FDC TN Norepinephrine transporter (NET) DMT2FDC MA Inhibitor DMT2FDC RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMT2FDC RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV TI TTA4LDE DMT2KRV TN Calcineurin (PPP3CA) DMT2KRV MA Inhibitor DMT2KRV RN Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45. DMT2KRV RU https://pubmed.ncbi.nlm.nih.gov/17414949 DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTOHSBA DMT3D5I TN Vascular endothelial growth factor A (VEGFA) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTPJQHE DMT3D5I TN Vascular endothelial growth factor B (VEGFB) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TT48I1Y DMT3D5I TN Placenta growth factor (PlGF) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT45MU DI DMT45MU DMT45MU DN Rosiglitazone XR DMT45MU TI TTZMAO3 DMT45MU TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMT45MU MA Agonist DMT45MU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMT45MU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMT57WC DI DMT57WC DMT57WC DN Tetrahydrozoline DMT57WC TI TT2NUT5 DMT57WC TN Adrenergic receptor alpha-2C (ADRA2C) DMT57WC MA Modulator DMT57WC RN Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. DMT57WC RU https://pubmed.ncbi.nlm.nih.gov/18259967 DMT5GNL DI DMT5GNL DMT5GNL DN Romidepsin DMT5GNL TI TT6R7JZ DMT5GNL TN Histone deacetylase 1 (HDAC1) DMT5GNL MA Inhibitor DMT5GNL RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMT5GNL RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMT5HA4 DI DMT5HA4 DMT5HA4 DN Ketamine DMT5HA4 TI TT9IK2Z DMT5HA4 TN N-methyl-D-aspartate receptor (NMDAR) DMT5HA4 MA Antagonist DMT5HA4 RN Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64. DMT5HA4 RU https://pubmed.ncbi.nlm.nih.gov/19583475 DMT5RMB DI DMT5RMB DMT5RMB DN Cyclofenil DMT5RMB TI TTZAYWL DMT5RMB TN Estrogen receptor (ESR) DMT5RMB MA Modulator DMT5RMB RN Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511. DMT5RMB RU https://pubmed.ncbi.nlm.nih.gov/16610793 DMT6AM2 DI DMT6AM2 DMT6AM2 DN Ozanimod DMT6AM2 TI TT9JZCK DMT6AM2 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMT6AM2 MA Agonist DMT6AM2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMT6AM2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf DMT70RC DI DMT70RC DMT70RC DN Piperaquine DMT70RC TI TTZVSJ2 DMT70RC TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMT70RC MA Inhibitor DMT70RC RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMT70RC RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMT73J8 DI DMT73J8 DMT73J8 DN Luliconazole DMT73J8 TI TTTSOUD DMT73J8 TN Candida Cytochrome P450 51 (Candi ERG11) DMT73J8 MA Inhibitor DMT73J8 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMT73J8 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ TI TTS64P2 DMT81LZ TN Androgen receptor (AR) DMT81LZ MA Inhibitor DMT81LZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMT81LZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMT9FH3 DI DMT9FH3 DMT9FH3 DN Terlipressin DMT9FH3 TI TT4TFGN DMT9FH3 TN Vasopressin V1a receptor (V1AR) DMT9FH3 MA Stimulator DMT9FH3 RN Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31. DMT9FH3 RU https://pubmed.ncbi.nlm.nih.gov/19589090 DMT9K8G DI DMT9K8G DMT9K8G DN Raltitrexed DMT9K8G TI TTU6BFZ DMT9K8G TN Candida Thymidylate synthase (Candi TMP1) DMT9K8G MA Inhibitor DMT9K8G RN DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. DMT9K8G RU https://pubmed.ncbi.nlm.nih.gov/18773878 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE TI TTHVCUP DMTA5OE TN DNA [cytosine-5]-methyltransferase (DNMT) DMTA5OE MA Inhibitor DMTA5OE RN The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28. DMTA5OE RU https://pubmed.ncbi.nlm.nih.gov/19194470 DMTAFY4 DI DMTAFY4 DMTAFY4 DN Oxacillin DMTAFY4 TI TTJP4SM DMTAFY4 TN Bacterial Penicillin binding protein (Bact PBP) DMTAFY4 MA Binder DMTAFY4 RN Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8. DMTAFY4 RU https://pubmed.ncbi.nlm.nih.gov/19433567 DMTAJQE DI DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE TI TTQKWA4 DMTAJQE TN Fungal Cell membrane ergosterol (Fung CME) DMTAJQE MA Modulator DMTAJQE RN Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78. DMTAJQE RU https://pubmed.ncbi.nlm.nih.gov/12488039 DMTAREC DI DMTAREC DMTAREC DN Rimexolone DMTAREC TI TTPNQAC DMTAREC TN Estrogen-related receptor-alpha (ESRRA) DMTAREC MA Modulator DMTAREC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMTAREC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMTBGW8 DI DMTBGW8 DMTBGW8 DN Vardenafil DMTBGW8 TI TTJ0IQB DMTBGW8 TN Phosphodiesterase 5A (PDE5A) DMTBGW8 MA Binder DMTBGW8 RN The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12. DMTBGW8 RU https://pubmed.ncbi.nlm.nih.gov/12475462 DMTBKF3 DI DMTBKF3 DMTBKF3 DN Piperacillin DMTBKF3 TI TTJP4SM DMTBKF3 TN Bacterial Penicillin binding protein (Bact PBP) DMTBKF3 MA Binder DMTBKF3 RN In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6. DMTBKF3 RU https://pubmed.ncbi.nlm.nih.gov/15551215 DMTBW2O DI DMTBW2O DMTBW2O DN Propylhexedrine DMTBW2O TI TT2NUT5 DMTBW2O TN Adrenergic receptor alpha-2C (ADRA2C) DMTBW2O MA Modulator DMTBW2O RN Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7. DMTBW2O RU https://pubmed.ncbi.nlm.nih.gov/7533806 DMTGBAX DI DMTGBAX DMTGBAX DN Pomalidomide DMTGBAX TI TTDIBYJ DMTGBAX TN Angiogenesis/myeloma cell growth (AMCG) DMTGBAX MA Modulator DMTGBAX RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMTGBAX RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTPC4TU DMTGDN8 TN 5-HT 3A receptor (HTR3A) DMTGDN8 MA Antagonist DMTGDN8 RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMTGDN8 RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTT3P91 DMTGDN8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMTGDN8 MA Modulator DMTGDN8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTGDN8 RU https://www.fda.gov/ DMTHWBI DI DMTHWBI DMTHWBI DN Nitrous oxide DMTHWBI TI TT9IK2Z DMTHWBI TN N-methyl-D-aspartate receptor (NMDAR) DMTHWBI MA Antagonist DMTHWBI RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMTHWBI RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT3PJMV DMTI8YE TN Tyrosine-protein kinase ABL1 (ABL) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT6PKBN DMTI8YE TN Proto-oncogene c-Src (SRC) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTIGA0 DI DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 TI TTTIBOJ DMTIGA0 TN Histamine H1 receptor (H1R) DMTIGA0 MA Antagonist DMTIGA0 RN Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52. DMTIGA0 RU https://pubmed.ncbi.nlm.nih.gov/10384858 DMTIQF3 DI DMTIQF3 DMTIQF3 DN Treprostinil DMTIQF3 TI TTOFYT1 DMTIQF3 TN Prostacyclin receptor (PTGIR) DMTIQF3 MA Agonist DMTIQF3 RN Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35. DMTIQF3 RU https://pubmed.ncbi.nlm.nih.gov/19332188 DMTIUFA DI DMTIUFA DMTIUFA DN Celtura DMTIUFA TI TT3J5ZI DMTIUFA TN Cell mediated immunity response (CMIR) DMTIUFA RN A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43. DMTIUFA RU https://pubmed.ncbi.nlm.nih.gov/22902681 DMTIVEN DI DMTIVEN DMTIVEN DN Metronidazole DMTIVEN TI TTS1W4A DMTIVEN TN Bacterial Deoxyribonucleic acid (Bact DNA) DMTIVEN MA Modulator DMTIVEN RN DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8. DMTIVEN RU https://www.ncbi.nlm.nih.gov/pubmed/11406179 DMTK234 DI DMTK234 DMTK234 DN Piroxicam DMTK234 TI TT8NGED DMTK234 TN Prostaglandin G/H synthase 1 (COX-1) DMTK234 MA Modulator DMTK234 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTK234 RU https://www.fda.gov/ DMTK4LS DI DMTK4LS DMTK4LS DN Triptorelin DMTK4LS TI TT8R70G DMTK4LS TN Gonadotropin-releasing hormone receptor (GNRHR) DMTK4LS MA Modulator DMTK4LS RN Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44. DMTK4LS RU https://pubmed.ncbi.nlm.nih.gov/17185802 DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TT6EO5L DMTKD7Q TN Erbb2 tyrosine kinase receptor (HER2) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TTGKNB4 DMTKD7Q TN Epidermal growth factor receptor (EGFR) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKU46 DI DMTKU46 DMTKU46 DN Bismuth DMTKU46 TI TTFNGC9 DMTKU46 TN Serum albumin (ALB) DMTKU46 MA Binder DMTKU46 RN Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. DMTKU46 RU https://pubmed.ncbi.nlm.nih.gov/11110794 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TT2CEJG DMTL94F TN C-C chemokine receptor type 5 (CCR5) DMTL94F MA Antagonist DMTL94F RN Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/19501260 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TTJIH8Q DMTL94F TN CCR5 messenger RNA (CCR5 mRNA) DMTL94F MA Antagonist DMTL94F RN Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/16298345 DMTL9IP DI DMTL9IP DMTL9IP DN Meprednisone DMTL9IP TI TTYRL6O DMTL9IP TN Glucocorticoid receptor (NR3C1) DMTL9IP MA Modulator DMTL9IP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTL9IP RU https://www.fda.gov/ DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTL7C8Q DMTM2IK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMTM2IK MA Inhibitor DMTM2IK RN Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/18506437 DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTZFTY4 DMTM2IK TN Amidophosphoribosyltransferase (PPAT) DMTM2IK MA Breaker DMTM2IK RN 6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/19281843 DMTN5XI DI DMTN5XI DMTN5XI DN Chlordiazepoxide DMTN5XI TI TTPTXIN DMTN5XI TN Translocator protein (TSPO) DMTN5XI MA Modulator DMTN5XI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTN5XI RU https://www.fda.gov/ DMTNFCQ DI DMTNFCQ DMTNFCQ DN Levobunolol DMTNFCQ TI TTR6W5O DMTNFCQ TN Adrenergic receptor beta-1 (ADRB1) DMTNFCQ MA Antagonist DMTNFCQ RN Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. DMTNFCQ RU https://pubmed.ncbi.nlm.nih.gov/6147147 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J TI TTNJYV2 DMTO13J TN Gamma-aminobutyric acid receptor (GAR) DMTO13J MA Agonist DMTO13J RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTO13J RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTP1DC DI DMTP1DC DMTP1DC DN Irbesartan DMTP1DC TI TT8DBY3 DMTP1DC TN Angiotensin II receptor type-1 (AGTR1) DMTP1DC MA Antagonist DMTP1DC RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMTP1DC RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMTP2NJ DI DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ TI TTP3UTW DMTP2NJ TN Steroid hormone receptor ERR (ESRR) DMTP2NJ MA Modulator DMTP2NJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTP2NJ RU https://www.fda.gov/ DMTPAM3 DI DMTPAM3 DMTPAM3 DN Metformin arginine-hemisuccinimide DMTPAM3 TI TTCBFJO DMTPAM3 TN Insulin receptor (INSR) DMTPAM3 MA Inhibitor DMTPAM3 RN Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91. DMTPAM3 RU https://pubmed.ncbi.nlm.nih.gov/15135305 DMTPIZC DI DMTPIZC DMTPIZC DN Conjugated estrogens a DMTPIZC TI TTZAYWL DMTPIZC TN Estrogen receptor (ESR) DMTPIZC MA Modulator DMTPIZC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMTPIZC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMTQS9A DI DMTQS9A DMTQS9A DN Metaproterenol sulfate DMTQS9A TI TT2CJVK DMTQS9A TN Adrenergic receptor beta-2 (ADRB2) DMTQS9A MA Modulator DMTQS9A RN Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9. DMTQS9A RU https://pubmed.ncbi.nlm.nih.gov/18037507 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L TI TTU6BFZ DMTS85L TN Candida Thymidylate synthase (Candi TMP1) DMTS85L MA Inhibitor DMTS85L RN UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. DMTS85L RU https://pubmed.ncbi.nlm.nih.gov/15709193 DMTSRI6 DI DMTSRI6 DMTSRI6 DN Oprelvekin DMTSRI6 TI TTZPLJS DMTSRI6 TN Interleukin 11 receptor alpha (IL11RA) DMTSRI6 MA Binder DMTSRI6 RN Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71. DMTSRI6 RU https://pubmed.ncbi.nlm.nih.gov/18020592 DMTUKZH DI DMTUKZH DMTUKZH DN Deferoxamine mesylate DMTUKZH TI TTUDR0C DMTUKZH TN Iron (Fe) DMTUKZH MA Modulator DMTUKZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTUKZH RU https://www.fda.gov/ DMTW3R8 DI DMTW3R8 DMTW3R8 DN Sulfadiazine DMTW3R8 TI TT4ILYC DMTW3R8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMTW3R8 MA Inhibitor DMTW3R8 RN Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. DMTW3R8 RU https://pubmed.ncbi.nlm.nih.gov/18434167 DMTW6IU DI DMTW6IU DMTW6IU DN Methadone DMTW6IU TI TTN4QDT DMTW6IU TN Opioid receptor (OPR) DMTW6IU MA Agonist DMTW6IU RN Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25. DMTW6IU RU https://pubmed.ncbi.nlm.nih.gov/19535889 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTO0FDJ DMTWS9E TN Cyclin-dependent kinase 6 (CDK6) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TT0PG8F DMTWS9E TN Cyclin-dependent kinase 4 (CDK4) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTV5CGO DMTWS9E TN Phosphodiesterase 4 (PDE4) DMTWS9E MA Inhibitor DMTWS9E RN Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. DMTWS9E RU https://pubmed.ncbi.nlm.nih.gov/17352685 DMTWUXR DI DMTWUXR DMTWUXR DN Chlormezanone DMTWUXR TI TTPTXIN DMTWUXR TN Translocator protein (TSPO) DMTWUXR MA Agonist DMTWUXR RN Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8. DMTWUXR RU https://pubmed.ncbi.nlm.nih.gov/7105820 DMTX2BH DI DMTX2BH DMTX2BH DN Cefonicid DMTX2BH TI TTJP4SM DMTX2BH TN Bacterial Penicillin binding protein (Bact PBP) DMTX2BH MA Binder DMTX2BH RN Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6. DMTX2BH RU https://pubmed.ncbi.nlm.nih.gov/6376452 DMTY169 DI DMTY169 DMTY169 DN Norethindrone DMTY169 TI TTUV8G9 DMTY169 TN Progesterone receptor (PGR) DMTY169 MA Agonist DMTY169 RN Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. DMTY169 RU https://pubmed.ncbi.nlm.nih.gov/15189034 DMTY9LU DI DMTY9LU DMTY9LU DN Piperazine DMTY9LU TI TTNJYV2 DMTY9LU TN Gamma-aminobutyric acid receptor (GAR) DMTY9LU MA Antagonist DMTY9LU RN Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31. DMTY9LU RU https://pubmed.ncbi.nlm.nih.gov/13678839 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TTT2ZAR DMTYOPD TN Prostaglandin F2-alpha receptor (PTGFR) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TT1ZAVI DMTYOPD TN Prostaglandin E2 receptor EP2 (PTGER2) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTZC5G DI DMTZC5G DMTZC5G DN Bezlotoxumab DMTZC5G TI TTQH65V DMTZC5G TN Clostridium difficile Toxin B (CD toxB) DMTZC5G MA Modulator DMTZC5G RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMTZC5G RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMTZNQ9 DI DMTZNQ9 DMTZNQ9 DN Interferon alfa-n3 DMTZNQ9 TI TT95SOA DMTZNQ9 TN Interferon alpha (IFNA) DMTZNQ9 MA Modulator DMTZNQ9 RN Clinical pipeline report, company report or official report of Hemispherx Biopharma. DMTZNQ9 RU http://www.hemispherx.net/content/rnd/ DMU0YP6 DI DMU0YP6 DMU0YP6 DN Flumethasone Pivalate DMU0YP6 TI TTP3UTW DMU0YP6 TN Steroid hormone receptor ERR (ESRR) DMU0YP6 MA Modulator DMU0YP6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU0YP6 RU https://www.fda.gov/ DMU1GX0 DI DMU1GX0 DMU1GX0 DN Mitotane DMU1GX0 TI TTZAYWL DMU1GX0 TN Estrogen receptor (ESR) DMU1GX0 MA Binder DMU1GX0 RN Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. DMU1GX0 RU https://pubmed.ncbi.nlm.nih.gov/15898346 DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTF8CQI DMU1XOD TN Tumor necrosis factor (TNF) DMU1XOD RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMU1XOD RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTEMV5X DMU1XOD TN Serine protease unspecific (SP) DMU1XOD MA Inhibitor DMU1XOD RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU1XOD RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU3DNC DI DMU3DNC DMU3DNC DN Pentoxifylline DMU3DNC TI TTF8CQI DMU3DNC TN Tumor necrosis factor (TNF) DMU3DNC RN Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20. DMU3DNC RU https://pubmed.ncbi.nlm.nih.gov/15190511 DMU3FGB DI DMU3FGB DMU3FGB DN Dhaq diacetate DMU3FGB TI TT0IHXV DMU3FGB TN DNA topoisomerase II (TOP2) DMU3FGB MA Inhibitor DMU3FGB RN The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. DMU3FGB RU https://pubmed.ncbi.nlm.nih.gov/19176397 DMU3IET DI DMU3IET DMU3IET DN Thiethylperazine DMU3IET TI TTEX248 DMU3IET TN Dopamine D2 receptor (D2R) DMU3IET MA Antagonist DMU3IET RN Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3. DMU3IET RU https://pubmed.ncbi.nlm.nih.gov/6130555 DMU4D5Y DI DMU4D5Y DMU4D5Y DN Benzquinamide DMU4D5Y TI TT0JLSD DMU4D5Y TN Multidrug resistance protein (MDR) DMU4D5Y MA Inhibitor DMU4D5Y RN Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65. DMU4D5Y RU https://pubmed.ncbi.nlm.nih.gov/1362504 DMU4JLB DI DMU4JLB DMU4JLB DN Penicillin G Procaine DMU4JLB TI TTJP4SM DMU4JLB TN Bacterial Penicillin binding protein (Bact PBP) DMU4JLB MA Modulator DMU4JLB RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMU4JLB RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMU4ORS DI DMU4ORS DMU4ORS DN Magnesium DMU4ORS TI TT9IK2Z DMU4ORS TN N-methyl-D-aspartate receptor (NMDAR) DMU4ORS MA Antagonist DMU4ORS RN Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42. DMU4ORS RU https://pubmed.ncbi.nlm.nih.gov/19249986 DMU54C3 DI DMU54C3 DMU54C3 DN Flutropium bromide DMU54C3 TI TTH18TF DMU54C3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMU54C3 MA Modulator DMU54C3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMU54C3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMU54QB DI DMU54QB DMU54QB DN Treximet DMU54QB TI TTSQIFT DMU54QB TN 5-HT 1A receptor (HTR1A) DMU54QB MA Antagonist DMU54QB RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMU54QB RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMU6OFP DI DMU6OFP DMU6OFP DN Dyclonine DMU6OFP TI TTZOVE0 DMU6OFP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMU6OFP MA Blocker DMU6OFP RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMU6OFP RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMU764S DI DMU764S DMU764S DN Ritonavir DMU764S TI TT5FNQT DMU764S TN Human immunodeficiency virus Protease (HIV PR) DMU764S MA Inhibitor DMU764S RN Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20. DMU764S RU https://pubmed.ncbi.nlm.nih.gov/19108994 DMU7SF8 DI DMU7SF8 DMU7SF8 DN Conjugated estrogens b DMU7SF8 TI TTZAYWL DMU7SF8 TN Estrogen receptor (ESR) DMU7SF8 MA Modulator DMU7SF8 RN Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13. DMU7SF8 RU https://pubmed.ncbi.nlm.nih.gov/326277 DMU7YEL DI DMU7YEL DMU7YEL DN Sufentanil DMU7YEL TI TTN4QDT DMU7YEL TN Opioid receptor (OPR) DMU7YEL MA Antagonist DMU7YEL RN mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96. DMU7YEL RU https://pubmed.ncbi.nlm.nih.gov/19519662 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TT6L509 DMU8ANS TN Coagulation factor IIa (F2) DMU8ANS MA Inhibitor DMU8ANS RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMU8ANS RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TTMQO60 DMU8ANS TN Rho-associated protein kinase (ROCK) DMU8ANS MA Modulator DMU8ANS RN Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. DMU8ANS RU https://www.ncbi.nlm.nih.gov/pubmed/10779382 DMU8JGH DI DMU8JGH DMU8JGH DN Hydralazine DMU8JGH TI TT7HC21 DMU8JGH TN Membrane copper amine oxidase (AOC3) DMU8JGH MA Modulator DMU8JGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8JGH RU https://www.fda.gov/ DMU8KOD DI DMU8KOD DMU8KOD DN Anakinra DMU8KOD TI TTWOTEA DMU8KOD TN Interleukin 1 receptor type 1 (IL1R1) DMU8KOD MA Antagonist DMU8KOD RN IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87. DMU8KOD RU https://pubmed.ncbi.nlm.nih.gov/19541594 DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTN6J5F DMU8V4S TN Bacterial DNA gyrase (Bact gyrase) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTIXTO3 DMU8V4S TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU92F8 DI DMU92F8 DMU92F8 DN Promestriene DMU92F8 TI TTZAYWL DMU92F8 TN Estrogen receptor (ESR) DMU92F8 MA Modulator DMU92F8 RN Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients. Anticancer Drugs. 2013 Nov;24(10):989-98. DMU92F8 RU https://pubmed.ncbi.nlm.nih.gov/24080714 DMU9C8F DI DMU9C8F DMU9C8F DN Bavencio DMU9C8F TI TT8ZLTI DMU9C8F TN Programmed cell death 1 ligand 1 (PD-L1) DMU9C8F MA Inhibitor DMU9C8F RN ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health. DMU9C8F RU https://clinicaltrials.gov/ct2/show/NCT03403777 DMU9D2F DI DMU9D2F DMU9D2F DN Gabexate DMU9D2F TI TTEMV5X DMU9D2F TN Serine protease unspecific (SP) DMU9D2F MA Inhibitor DMU9D2F RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU9D2F RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU9MYJ DI DMU9MYJ DMU9MYJ DN Oxandrolone DMU9MYJ TI TTS64P2 DMU9MYJ TN Androgen receptor (AR) DMU9MYJ MA Agonist DMU9MYJ RN The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4. DMU9MYJ RU https://pubmed.ncbi.nlm.nih.gov/17364004 DMUBP9O DI DMUBP9O DMUBP9O DN Voglibose DMUBP9O TI TTXWASR DMUBP9O TN Intestinal maltase-glucoamylase (MGAM) DMUBP9O MA Inhibitor DMUBP9O RN Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6. DMUBP9O RU https://pubmed.ncbi.nlm.nih.gov/19568704 DMUCWEX DI DMUCWEX DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co DMUCWEX TI TT42M75 DMUCWEX TN Carbamoyl-phosphate synthetase I (CPS1) DMUCWEX MA Modulator DMUCWEX RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMUCWEX RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TT26PHO DMUDIR8 TN Mineralocorticoid receptor (MR) DMUDIR8 MA Agonist DMUDIR8 RN Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/14570856 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TTS64P2 DMUDIR8 TN Androgen receptor (AR) DMUDIR8 MA Inhibitor DMUDIR8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM TI TT5TPI6 DMUDJZM TN Opioid receptor sigma 1 (OPRS1) DMUDJZM MA Agonist DMUDJZM RN Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/15869321 DMUDWP9 DI DMUDWP9 DMUDWP9 DN Mepindolol DMUDWP9 TI TTMXGCW DMUDWP9 TN Adrenergic receptor beta-3 (ADRB3) DMUDWP9 MA Modulator DMUDWP9 RN Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3. DMUDWP9 RU https://pubmed.ncbi.nlm.nih.gov/2873820 DMUFGAY DI DMUFGAY DMUFGAY DN Betazole DMUFGAY TI TTQHJ1K DMUFGAY TN Histamine H2 receptor (H2R) DMUFGAY MA Antagonist DMUFGAY RN Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6. DMUFGAY RU https://pubmed.ncbi.nlm.nih.gov/2892392 DMUHCF1 DI DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 TI TTS64P2 DMUHCF1 TN Androgen receptor (AR) DMUHCF1 MA Agonist DMUHCF1 RN An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. DMUHCF1 RU https://pubmed.ncbi.nlm.nih.gov/17023534 DMUI0CH DI DMUI0CH DMUI0CH DN Tobramycin DMUI0CH TI TTOVFH2 DMUI0CH TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMUI0CH MA Modulator DMUI0CH RN Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81. DMUI0CH RU https://www.ncbi.nlm.nih.gov/pubmed/391568 DMUIASK DI DMUIASK DMUIASK DN Cosyntropin DMUIASK TI TTPWFDX DMUIASK TN Melanocortin receptor 2 (MC2R) DMUIASK MA Antagonist DMUIASK RN Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12. DMUIASK RU https://pubmed.ncbi.nlm.nih.gov/19496914 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTK0943 DMUIE76 TN Prostaglandin G/H synthase (COX) DMUIE76 MA Inhibitor DMUIE76 RN Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/15662292 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTAWNKZ DMUIE76 TN Norepinephrine transporter (NET) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TT3ROYC DMUIE76 TN Serotonin transporter (SERT) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUJGR1 DI DMUJGR1 DMUJGR1 DN Sorivudine DMUJGR1 TI TT84ETX DMUJGR1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUJGR1 MA Modulator DMUJGR1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUJGR1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TT2Q6G1 DMUKC5L TN Vascular endothelial growth factor receptor 1 (FLT-1) DMUKC5L MA Inhibitor DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTDCBX5 DMUKC5L TN Vascular endothelial growth factor receptor 3 (FLT-4) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTUTJGQ DMUKC5L TN Vascular endothelial growth factor receptor 2 (KDR) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUL45H DI DMUL45H DMUL45H DN Naltrexone DMUL45H TI TTN4QDT DMUL45H TN Opioid receptor (OPR) DMUL45H MA Antagonist DMUL45H RN An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. DMUL45H RU https://pubmed.ncbi.nlm.nih.gov/18250251 DMUL5EW DI DMUL5EW DMUL5EW DN Posaconazole DMUL5EW TI TTTSOUD DMUL5EW TN Candida Cytochrome P450 51 (Candi ERG11) DMUL5EW MA Inhibitor DMUL5EW RN A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6. DMUL5EW RU https://pubmed.ncbi.nlm.nih.gov/16961575 DMUL7T1 DI DMUL7T1 DMUL7T1 DN Imidapril DMUL7T1 TI TTL69WB DMUL7T1 TN Angiotensin-converting enzyme (ACE) DMUL7T1 MA Modulator DMUL7T1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUL7T1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMULAI4 DI DMULAI4 DMULAI4 DN Carbimazole DMULAI4 TI TT52XDZ DMULAI4 TN Thyroid peroxidase (TPO) DMULAI4 MA Inhibitor DMULAI4 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DMULAI4 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTU6BFZ DMUM7HZ TN Candida Thymidylate synthase (Candi TMP1) DMUM7HZ MA Inhibitor DMUM7HZ RN The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/14689231 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTZPS91 DMUM7HZ TN Dihydrothymine dehydrogenase (DPYD) DMUM7HZ MA Inhibitor DMUM7HZ RN Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/12044515 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTQY2EJ DMUM7HZ TN TERT messenger RNA (TERT mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTP1UKZ DMUM7HZ TN Thymidylate synthase messenger RNA (TYMS mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUMOEV DI DMUMOEV DMUMOEV DN Ansuvimab DMUMOEV TI TT2F0AU DMUMOEV TN Ebola virus Envelope glycoprotein (EV GP) DMUMOEV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMUMOEV RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTZ9SOR DMUMQZ0 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMUMQZ0 MA Antagonist DMUMQZ0 RN Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/19465630 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTOXS3C DMUMQZ0 TN Muscarinic acetylcholine receptor (CHRM) DMUMQZ0 MA Antagonist DMUMQZ0 RN Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/9454790 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV TI TTJP4SM DMUNSWV TN Bacterial Penicillin binding protein (Bact PBP) DMUNSWV MA Binder DMUNSWV RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMUNSWV RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 TI TTZAYWL DMUNTE3 TN Estrogen receptor (ESR) DMUNTE3 MA Agonist DMUNTE3 RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMUOK4C DI DMUOK4C DMUOK4C DN Lisinopril DMUOK4C TI TTL69WB DMUOK4C TN Angiotensin-converting enzyme (ACE) DMUOK4C MA Inhibitor DMUOK4C RN Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71. DMUOK4C RU https://pubmed.ncbi.nlm.nih.gov/19556720 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTJGNVC DMUOT9V TN Apoptosis regulator Bcl-2 (BCL-2) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTYFKSZ DMUOT9V TN Tubulin beta (TUBB) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUPE07 DI DMUPE07 DMUPE07 DN Nicotinamide DMUPE07 TI TTVDSZ0 DMUPE07 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMUPE07 MA Binder DMUPE07 RN beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59. DMUPE07 RU https://pubmed.ncbi.nlm.nih.gov/19333861 DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI TI TTNZRI3 DMUPFLI TN Synaptic vesicle amine transporter (SLC18A2) DMUPFLI MA Modulator DMUPFLI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUPFLI RU https://www.fda.gov/ DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTFPKRB DMUPOGR TN cAMP-dependent chloride channel F508 deletion (CFTR del F508) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTRLZHP DMUPOGR TN cAMP-dependent chloride channel (CFTR) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUQ0E8 DI DMUQ0E8 DMUQ0E8 DN Tepotinib DMUQ0E8 TI TTNDSF4 DMUQ0E8 TN Proto-oncogene c-Met (MET) DMUQ0E8 MA Modulator DMUQ0E8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMUQ0E8 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf DMUR64T DI DMUR64T DMUR64T DN Lesinurad DMUR64T TI TTA592U DMUR64T TN Urate anion exchanger 1 (URAT1) DMUR64T MA Modulator DMUR64T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031). DMUR64T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031 DMUR94J DI DMUR94J DMUR94J DN Certoparin sodium DMUR94J TI TTCIHJA DMUR94J TN Coagulation factor Xa (F10) DMUR94J MA Modulator DMUR94J RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUR94J RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUSLW3 DI DMUSLW3 DMUSLW3 DN Carbetocin DMUSLW3 TI TTSCIUP DMUSLW3 TN Oxytocin receptor (OTR) DMUSLW3 MA Agonist DMUSLW3 RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMUSLW3 RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMUSZHD DI DMUSZHD DMUSZHD DN Hydrochlorothiazide DMUSZHD TI TTL69WB DMUSZHD TN Angiotensin-converting enzyme (ACE) DMUSZHD MA Modulator DMUSZHD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUSZHD RU https://www.fda.gov/ DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 TI TT1VOHK DMUTEX3 TN Potassium channel unspecific (KC) DMUTEX3 MA Modulator DMUTEX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUTEX3 RU https://www.fda.gov/ DMUTL7O DI DMUTL7O DMUTL7O DN Cloxacillin DMUTL7O TI TTJP4SM DMUTL7O TN Bacterial Penicillin binding protein (Bact PBP) DMUTL7O MA Binder DMUTL7O RN Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303. DMUTL7O RU https://pubmed.ncbi.nlm.nih.gov/17386727 DMUTYR2 DI DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 TI TTOFYT1 DMUTYR2 TN Prostacyclin receptor (PTGIR) DMUTYR2 MA Agonist DMUTYR2 RN Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. DMUTYR2 RU https://pubmed.ncbi.nlm.nih.gov/19302827 DMUTZ8S DI DMUTZ8S DMUTZ8S DN Interferon Alfa-2a, Recombinant DMUTZ8S TI TTGJVQM DMUTZ8S TN Fibroblast growth factor receptor 2 (FGFR2) DMUTZ8S MA Binder DMUTZ8S RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMUTZ8S RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMUV8OR DI DMUV8OR DMUV8OR DN Indecainide DMUV8OR TI TTZOVE0 DMUV8OR TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUV8OR MA Blocker DMUV8OR RN Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21. DMUV8OR RU https://pubmed.ncbi.nlm.nih.gov/6206315 DMUWAM2 DI DMUWAM2 DMUWAM2 DN Pyronaridine DMUWAM2 TI TTZVSJ2 DMUWAM2 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMUWAM2 MA Inhibitor DMUWAM2 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMUWAM2 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMUWBIJ DI DMUWBIJ DMUWBIJ DN Propiverine DMUWBIJ TI TTH18TF DMUWBIJ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMUWBIJ MA Antagonist DMUWBIJ RN Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. DMUWBIJ RU https://pubmed.ncbi.nlm.nih.gov/10374898 DMUXP52 DI DMUXP52 DMUXP52 DN Clobetasol DMUXP52 TI TT9V5JH DMUXP52 TN Phospholipase A2 (PLA2G1B) DMUXP52 MA Inhibitor DMUXP52 RN Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. DMUXP52 RU https://pubmed.ncbi.nlm.nih.gov/6743552 DMUY2OR DI DMUY2OR DMUY2OR DN Cynarin DMUY2OR TI TTLOQ79 DMUY2OR TN Taste receptor (TASR) DMUY2OR MA Modulator DMUY2OR RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMUY2OR RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMUY35B DI DMUY35B DMUY35B DN Progesterone DMUY35B TI TTUV8G9 DMUY35B TN Progesterone receptor (PGR) DMUY35B MA Agonist DMUY35B RN Clinical pipeline report, company report or official report of lipocine. DMUY35B RU http://www.lipocine.com/pipeline/lpcn-1107/ DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI TI TTXT4D5 DMUYNEI TN Bacterial Cell membrane (Bact CM) DMUYNEI MA Modulator DMUYNEI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUYNEI RU https://www.fda.gov/ DMUZNIG DI DMUZNIG DMUZNIG DN Troleandomycin DMUZNIG TI TTUWYEA DMUZNIG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMUZNIG MA Binder DMUZNIG RN Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5. DMUZNIG RU https://pubmed.ncbi.nlm.nih.gov/6972981 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTUPDWN DMUZPJ5 TN Cholinergic receptor unspecific (CHR) DMUZPJ5 MA Antagonist DMUZPJ5 RN Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/9429048 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTF4E0J DMUZPJ5 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUZPJ5 MA Antagonist DMUZPJ5 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMV05SW DI DMV05SW DMV05SW DN As-1670542 DMV05SW TI TTIHYA4 DMV05SW TN Thrombopoietin receptor (MPL) DMV05SW MA Agonist DMV05SW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMV05SW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS TI TTYRL6O DMV0RNS TN Glucocorticoid receptor (NR3C1) DMV0RNS MA Modulator DMV0RNS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV0RNS RU https://www.fda.gov/ DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTAXZ0K DMV23GL TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTLXAKE DMV23GL TN Solute carrier family 29 member 1 (SLC29A1) DMV23GL MA Inhibitor DMV23GL RN Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/17636949 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTRK8B9 DMV23GL TN Sodium channel unspecific (NaC) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TTAWNKZ DMV26S8 TN Norepinephrine transporter (NET) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TT3ROYC DMV26S8 TN Serotonin transporter (SERT) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV2JNY DI DMV2JNY DMV2JNY DN Cephapirin DMV2JNY TI TTJP4SM DMV2JNY TN Bacterial Penicillin binding protein (Bact PBP) DMV2JNY MA Binder DMV2JNY RN The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85. DMV2JNY RU https://pubmed.ncbi.nlm.nih.gov/808545 DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TTLT9XQ DMV3YMX TN Integrin beta-7 (ITGB7) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TT4BT06 DMV3YMX TN Integrin alpha-4 (ITGA4) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV4KOA DI DMV4KOA DMV4KOA DN GW642444 DMV4KOA TI TT2CJVK DMV4KOA TN Adrenergic receptor beta-2 (ADRB2) DMV4KOA MA Agonist DMV4KOA RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMV4KOA RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMV62ED DI DMV62ED DMV62ED DN Fotemustine DMV62ED TI TTR7UJ3 DMV62ED TN Cytoplasmic thioredoxin reductase (TXNRD1) DMV62ED MA Inhibitor DMV62ED RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV62ED RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV67QO DI DMV67QO DMV67QO DN Ibalizumab DMV67QO TI TTN2JFW DMV67QO TN T-cell surface glycoprotein CD4 (CD4) DMV67QO MA Modulator DMV67QO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMV67QO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMV74ZH DI DMV74ZH DMV74ZH DN Pizotyline DMV74ZH TI TT85JO3 DMV74ZH TN 5-HT receptor (5HTR) DMV74ZH MA Modulator DMV74ZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMV74ZH RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMV7IM6 DI DMV7IM6 DMV7IM6 DN Histamine Phosphate DMV7IM6 TI TT7CXIM DMV7IM6 TN Histamine receptor (HR) DMV7IM6 MA Modulator DMV7IM6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV7IM6 RU https://www.fda.gov/ DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT TI TTS64P2 DMV7YFT TN Androgen receptor (AR) DMV7YFT MA Antagonist DMV7YFT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMV7YFT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf DMV96ZH DI DMV96ZH DMV96ZH DN Anapsos DMV96ZH TI TTXL3MF DMV96ZH TN Lymphoid cell adhesion molecule expression (LCDME) DMV96ZH MA Modulator DMV96ZH RN Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90. DMV96ZH RU https://pubmed.ncbi.nlm.nih.gov/12220959 DMV9ADG DI DMV9ADG DMV9ADG DN Pilocarpine DMV9ADG TI TTH18TF DMV9ADG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMV9ADG MA Agonist DMV9ADG RN Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6. DMV9ADG RU https://pubmed.ncbi.nlm.nih.gov/19465517 DMVAIH4 DI DMVAIH4 DMVAIH4 DN Hylenex DMVAIH4 TI TTYTVXF DMVAIH4 TN Hyaluronic acid (HA) DMVAIH4 MA Modulator DMVAIH4 RN Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. DMVAIH4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/ DMVAZP9 DI DMVAZP9 DMVAZP9 DN Tenoxicam DMVAZP9 TI TTVKILB DMVAZP9 TN Prostaglandin G/H synthase 2 (COX-2) DMVAZP9 MA Inhibitor DMVAZP9 RN The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. DMVAZP9 RU https://pubmed.ncbi.nlm.nih.gov/16245223 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK TI TTEX248 DMVE3TK TN Dopamine D2 receptor (D2R) DMVE3TK MA Agonist DMVE3TK RN Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44. DMVE3TK RU https://pubmed.ncbi.nlm.nih.gov/19303749 DMVEK07 DI DMVEK07 DMVEK07 DN Magnesium Sulfate DMVEK07 TI TT9IK2Z DMVEK07 TN N-methyl-D-aspartate receptor (NMDAR) DMVEK07 MA Antagonist DMVEK07 RN Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95. DMVEK07 RU https://pubmed.ncbi.nlm.nih.gov/17720112 DMVGPMX DI DMVGPMX DMVGPMX DN Fosfomycin DMVGPMX TI TTICX3S DMVGPMX TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMVGPMX MA Inhibitor DMVGPMX RN Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005 Feb 4;280(5):3757-63. DMVGPMX RU https://pubmed.ncbi.nlm.nih.gov/15531591 DMVHJLX DI DMVHJLX DMVHJLX DN Perospirone DMVHJLX TI TTYSN63 DMVHJLX TN 5-HT 2 receptor (5HT2R) DMVHJLX MA Modulator DMVHJLX RN Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8. DMVHJLX RU https://pubmed.ncbi.nlm.nih.gov/7690975 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TTVQ6R9 DMVIKJZ TN C1 esterase inhibitor (SERPING1) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TT7LRQH DMVIKJZ TN Complement C1s component (C1S) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVJS2K DI DMVJS2K DMVJS2K DN Monobenzone DMVJS2K TI TTULVH8 DMVJS2K TN Tyrosinase (TYR) DMVJS2K MA Inhibitor DMVJS2K RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DMVJS2K RU https://pubmed.ncbi.nlm.nih.gov/19159217 DMVKA4O DI DMVKA4O DMVKA4O DN Mianserin DMVKA4O TI TTYSN63 DMVKA4O TN 5-HT 2 receptor (5HT2R) DMVKA4O MA Antagonist DMVKA4O RN 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6. DMVKA4O RU https://pubmed.ncbi.nlm.nih.gov/18155835 DMVLHNI DI DMVLHNI DMVLHNI DN Tridihexethyl DMVLHNI TI TTH18TF DMVLHNI TN Muscarinic acetylcholine receptor M5 (CHRM5) DMVLHNI MA Binder DMVLHNI RN Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991 Nov;41(11):1737-41. DMVLHNI RU https://pubmed.ncbi.nlm.nih.gov/1944902 DMVLMW6 DI DMVLMW6 DMVLMW6 DN Ketanserin DMVLMW6 TI TTYSN63 DMVLMW6 TN 5-HT 2 receptor (5HT2R) DMVLMW6 MA Antagonist DMVLMW6 RN Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8. DMVLMW6 RU https://pubmed.ncbi.nlm.nih.gov/14607779 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTZCW3T DMVM6QR TN Dihydropyrimidinase related protein 2 (DPYSL2) DMVM6QR MA Modulator DMVM6QR RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTN9VTF DMVM6QR TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTIG65Q DMVM6QR TN Voltage-gated sodium channel (Nav) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVMQ1L DI DMVMQ1L DMVMQ1L DN Nafronyl DMVMQ1L TI TT85JO3 DMVMQ1L TN 5-HT receptor (5HTR) DMVMQ1L MA Modulator DMVMQ1L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVMQ1L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVMY7K DI DMVMY7K DMVMY7K DN Arepanrix DMVMY7K TI TT3J5ZI DMVMY7K TN Cell mediated immunity response (CMIR) DMVMY7K RN Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57. DMVMY7K RU https://pubmed.ncbi.nlm.nih.gov/25452148 DMVN2E6 DI DMVN2E6 DMVN2E6 DN Vinpocetine DMVN2E6 TI TTHQENC DMVN2E6 TN Phosphodiesterase 1 (PDE1) DMVN2E6 MA Inhibitor DMVN2E6 RN Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401. DMVN2E6 RU https://pubmed.ncbi.nlm.nih.gov/19285714 DMVN5OH DI DMVN5OH DMVN5OH DN Minocycline DMVN5OH TI TTQ8KVI DMVN5OH TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMVN5OH MA Binder DMVN5OH RN Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. DMVN5OH RU https://pubmed.ncbi.nlm.nih.gov/16723578 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB TI TTKWM86 DMVO0UB TN Opioid receptor mu (MOP) DMVO0UB MA Agonist DMVO0UB RN Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87. DMVO0UB RU https://pubmed.ncbi.nlm.nih.gov/11240090 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTANPDJ DMVO4ED TN Carbonic anhydrase II (CA-II) DMVO4ED MA Inhibitor DMVO4ED RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVO4ED RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTHQPL7 DMVO4ED TN Carbonic anhydrase I (CA-I) DMVO4ED MA Modulator DMVO4ED RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVO4ED RU https://www.fda.gov/ DMVOIK1 DI DMVOIK1 DMVOIK1 DN Rosoxacin DMVOIK1 TI TT0IHXV DMVOIK1 TN DNA topoisomerase II (TOP2) DMVOIK1 MA Inhibitor DMVOIK1 RN Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. DMVOIK1 RU https://pubmed.ncbi.nlm.nih.gov/3010848 DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTED8JB DMVONE6 TN Epidermal growth factor (EGF) DMVONE6 MA Modulator DMVONE6 RN Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52. DMVONE6 RU http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTGKNB4 DMVONE6 TN Epidermal growth factor receptor (EGFR) DMVONE6 MA Modulator DMVONE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMVONE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TTQY2EJ DMVP5YE TN TERT messenger RNA (TERT mRNA) DMVP5YE RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMVP5YE RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TT0IHXV DMVP5YE TN DNA topoisomerase II (TOP2) DMVP5YE MA Modulator DMVP5YE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVP5YE RU https://www.fda.gov/ DMVPUQI DI DMVPUQI DMVPUQI DN Hydroflumethiazide DMVPUQI TI TTS087L DMVPUQI TN Solute carrier family 12 member 1 (SLC12A1) DMVPUQI MA Blocker DMVPUQI RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMVPUQI RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMVPWLZ DI DMVPWLZ DMVPWLZ DN Terbutyline DMVPWLZ TI TTVIREA DMVPWLZ TN Adrenergic receptor (ADR) DMVPWLZ MA Modulator DMVPWLZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVPWLZ RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVPZBE DI DMVPZBE DMVPZBE DN Iloprost DMVPZBE TI TT1ZAVI DMVPZBE TN Prostaglandin E2 receptor EP2 (PTGER2) DMVPZBE MA Agonist DMVPZBE RN Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27. DMVPZBE RU https://pubmed.ncbi.nlm.nih.gov/17408863 DMVR628 DI DMVR628 DMVR628 DN Vindesine DMVR628 TI TTYFKSZ DMVR628 TN Tubulin beta (TUBB) DMVR628 MA Binder DMVR628 RN Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. DMVR628 RU https://pubmed.ncbi.nlm.nih.gov/17465195 DMVRH9C DI DMVRH9C DMVRH9C DN Lomefloxacin DMVRH9C TI TT0IHXV DMVRH9C TN DNA topoisomerase II (TOP2) DMVRH9C MA Inhibitor DMVRH9C RN Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22. DMVRH9C RU https://pubmed.ncbi.nlm.nih.gov/12215656 DMVRIC2 DI DMVRIC2 DMVRIC2 DN Zileuton DMVRIC2 TI TT2J34L DMVRIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DMVRIC2 MA Inhibitor DMVRIC2 RN 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52. DMVRIC2 RU https://pubmed.ncbi.nlm.nih.gov/19309543 DMVRLT7 DI DMVRLT7 DMVRLT7 DN Fludarabine DMVRLT7 TI TTLP57V DMVRLT7 TN Adenosine deaminase (ADA) DMVRLT7 MA Inhibitor DMVRLT7 RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DMVRLT7 RU https://pubmed.ncbi.nlm.nih.gov/10887639 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TTMSFAW DMVRYT2 TN Cannabinoid receptor 2 (CB2) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TT6OEDT DMVRYT2 TN Cannabinoid receptor 1 (CB1) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVS9WQ DI DMVS9WQ DMVS9WQ DN Nitisinone DMVS9WQ TI TT8DSFC DMVS9WQ TN Hydroxyphenylpyruvate dioxygenase (HPD) DMVS9WQ MA Inhibitor DMVS9WQ RN Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36. DMVS9WQ RU https://pubmed.ncbi.nlm.nih.gov/18422479 DMVTHER DI DMVTHER DMVTHER DN Lincomycin DMVTHER TI TTUWYEA DMVTHER TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMVTHER MA Inhibitor DMVTHER RN Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. DMVTHER RU https://pubmed.ncbi.nlm.nih.gov/10856379 DMVTHWQ DI DMVTHWQ DMVTHWQ DN Silver sulfadiazine DMVTHWQ TI TT4ILYC DMVTHWQ TN Bacterial Dihydropteroate synthetase (Bact folP) DMVTHWQ MA Binder DMVTHWQ RN Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4. DMVTHWQ RU https://pubmed.ncbi.nlm.nih.gov/16921417 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTIXTO3 DMVTU5Q TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTZ82MR DMVTU5Q TN Plasmodium DNA gyrase (Malaria gyrase) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVWHTG DI DMVWHTG DMVWHTG DN Afamelanotide DMVWHTG TI TT0MV2T DMVWHTG TN Melanocortin receptor 1 (MC1R) DMVWHTG MA Modulator DMVWHTG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMVWHTG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf DMVXFYE DI DMVXFYE DMVXFYE DN Vinorelbine DMVXFYE TI TTML2WA DMVXFYE TN Tubulin (TUB) DMVXFYE MA Inhibitor DMVXFYE RN Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9. DMVXFYE RU https://pubmed.ncbi.nlm.nih.gov/18633246 DMVY4GN DI DMVY4GN DMVY4GN DN Testolactone DMVY4GN TI TTSZLWK DMVY4GN TN Aromatase (CYP19A1) DMVY4GN MA Inhibitor DMVY4GN RN Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9. DMVY4GN RU https://pubmed.ncbi.nlm.nih.gov/11792932 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE TI TTLP6GN DMVYSLE TN Bacterial DD-carboxypeptidase (Bact vanYB) DMVYSLE MA Inhibitor DMVYSLE RN Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/7626623 DMVYXR8 DI DMVYXR8 DMVYXR8 DN Sumatriptan DMVYXR8 TI TT6MSOK DMVYXR8 TN 5-HT 1D receptor (HTR1D) DMVYXR8 MA Agonist DMVYXR8 RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMVYXR8 RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMVZQ2M DI DMVZQ2M DMVZQ2M DN Probucol DMVZQ2M TI TTJW1GN DMVZQ2M TN ATP-binding cassette transporter A1 (ABCA1) DMVZQ2M MA Modulator DMVZQ2M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVZQ2M RU https://www.fda.gov/ DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TT1MPAY DMW1OQ0 TN GABA(A) receptor alpha-1 (GABRA1) DMW1OQ0 MA Antagonist DMW1OQ0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMW1OQ0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TTEX6LM DMW1OQ0 TN GABA(A) receptor gamma-3 (GABRG3) DMW1OQ0 MA Modulator DMW1OQ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW1OQ0 RU https://www.fda.gov/ DMW2GEJ DI DMW2GEJ DMW2GEJ DN Mepolizumab DMW2GEJ TI TTPREZD DMW2GEJ TN Interleukin-5 (IL5) DMW2GEJ MA Modulator DMW2GEJ RN Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30. DMW2GEJ RU https://www.ncbi.nlm.nih.gov/pubmed/18298130 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TT5HONZ DMW4M97 TN Calcium channel unspecific (CaC) DMW4M97 MA Modulator DMW4M97 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TTXHYV6 DMW4M97 TN Voltage-gated L-type calcium channel (L-CaC) DMW4M97 MA Inhibitor DMW4M97 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMW4X37 DI DMW4X37 DMW4X37 DN Diphenylpyraline DMW4X37 TI TTTIBOJ DMW4X37 TN Histamine H1 receptor (H1R) DMW4X37 MA Antagonist DMW4X37 RN Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9. DMW4X37 RU https://pubmed.ncbi.nlm.nih.gov/7920432 DMW51AX DI DMW51AX DMW51AX DN Anisodamine DMW51AX TI TTR6W5O DMW51AX TN Adrenergic receptor beta-1 (ADRB1) DMW51AX MA Modulator DMW51AX RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMW51AX RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMW542E DI DMW542E DMW542E DN Orphenadrine DMW542E TI TT9IK2Z DMW542E TN N-methyl-D-aspartate receptor (NMDAR) DMW542E MA Antagonist DMW542E RN Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. DMW542E RU https://pubmed.ncbi.nlm.nih.gov/19217209 DMW5ML9 DI DMW5ML9 DMW5ML9 DN Tecovirimat DMW5ML9 TI TTG7UOF DMW5ML9 TN Variola virus Envelope phospholipase F13 (VARV p37) DMW5ML9 MA Inhibitor DMW5ML9 RN Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review DMW5ML9 RU https://pubmed.ncbi.nlm.nih.gov/20191435 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TTK8CXU DMW649X TN 5-HT 1B receptor (HTR1B) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TT6MSOK DMW649X TN 5-HT 1D receptor (HTR1D) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW67MU DI DMW67MU DMW67MU DN Botulinum Toxin Type A DMW67MU TI TTYQWA0 DMW67MU TN Synaptosomal-associated protein 25 (SNAP25) DMW67MU MA Inhibitor DMW67MU RN Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71. DMW67MU RU https://pubmed.ncbi.nlm.nih.gov/12381720 DMW6F0S DI DMW6F0S DMW6F0S DN Mizoribine DMW6F0S TI TTL7C8Q DMW6F0S TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMW6F0S MA Inhibitor DMW6F0S RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DMW6F0S RU https://pubmed.ncbi.nlm.nih.gov/11288107 DMW6GVL DI DMW6GVL DMW6GVL DN Nadolol DMW6GVL TI TTR6W5O DMW6GVL TN Adrenergic receptor beta-1 (ADRB1) DMW6GVL MA Modulator DMW6GVL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW6GVL RU https://www.fda.gov/ DMW6ZJI DI DMW6ZJI DMW6ZJI DN Levocetirizine dihydrochloride DMW6ZJI TI TTTIBOJ DMW6ZJI TN Histamine H1 receptor (H1R) DMW6ZJI MA Antagonist DMW6ZJI RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DMW6ZJI RU https://pubmed.ncbi.nlm.nih.gov/19210904 DMW83TP DI DMW83TP DMW83TP DN Pimozide DMW83TP TI TTEX248 DMW83TP TN Dopamine D2 receptor (D2R) DMW83TP MA Antagonist DMW83TP RN [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1. DMW83TP RU https://pubmed.ncbi.nlm.nih.gov/16924461 DMW8KI7 DI DMW8KI7 DMW8KI7 DN Insulin Susp Isophane Recombinant Human DMW8KI7 TI TTZOPHG DMW8KI7 TN Insulin (INS) DMW8KI7 MA Modulator DMW8KI7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW8KI7 RU https://www.fda.gov/ DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TTOHSBA DMW8QNG TN Vascular endothelial growth factor A (VEGFA) DMW8QNG MA Inhibitor DMW8QNG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMW8QNG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TT9HKJA DMW8QNG TN Vascular endothelial growth factor (VEGF) DMW8QNG MA Inhibitor DMW8QNG RN Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000. DMW8QNG RU https://pubmed.ncbi.nlm.nih.gov/31768932 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTGBPJE DMWA24P TN PI3-kinase delta (PIK3CD) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTHBTOP DMWA24P TN PI3-kinase gamma (PIK3CG) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA2DZ DI DMWA2DZ DMWA2DZ DN Berotralstat DMWA2DZ TI TTMF8H9 DMWA2DZ TN Plasma kallikrein (KLKB1) DMWA2DZ MA Inhibitor DMWA2DZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWA2DZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf DMWBHRY DI DMWBHRY DMWBHRY DN Olmesartan medoxomil DMWBHRY TI TT8DBY3 DMWBHRY TN Angiotensin II receptor type-1 (AGTR1) DMWBHRY MA Antagonist DMWBHRY RN Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56. DMWBHRY RU https://pubmed.ncbi.nlm.nih.gov/19528815 DMWBQKU DI DMWBQKU DMWBQKU DN Olprinone DMWBQKU TI TTZCG4L DMWBQKU TN Phosphodiesterase 3 (PDE3) DMWBQKU MA Inhibitor DMWBQKU RN Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74. DMWBQKU RU https://pubmed.ncbi.nlm.nih.gov/12397365 DMWCOSR DI DMWCOSR DMWCOSR DN Quinethazone DMWCOSR TI TTUNARX DMWCOSR TN Carbonic anhydrase (CA) DMWCOSR MA Inhibitor DMWCOSR RN Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. DMWCOSR RU https://pubmed.ncbi.nlm.nih.gov/18374572 DMWCQP4 DI DMWCQP4 DMWCQP4 DN Interferon alfa-2B DMWCQP4 TI TTSIUJ9 DMWCQP4 TN Interferon-alpha 2 (IFNA2) DMWCQP4 MA Modulator DMWCQP4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWCQP4 RU https://www.fda.gov/ DMWCRN1 DI DMWCRN1 DMWCRN1 DN Ispaghula DMWCRN1 TI TTH18TF DMWCRN1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWCRN1 MA Antagonist DMWCRN1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMWCRN1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 TI TTP3UTW DMWE2N4 TN Steroid hormone receptor ERR (ESRR) DMWE2N4 MA Modulator DMWE2N4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWE2N4 RU https://www.fda.gov/ DMWE60C DI DMWE60C DMWE60C DN Rufinamide DMWE60C TI TTRK8B9 DMWE60C TN Sodium channel unspecific (NaC) DMWE60C MA Blocker DMWE60C RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DMWE60C RU https://pubmed.ncbi.nlm.nih.gov/17874969 DMWF5R4 DI DMWF5R4 DMWF5R4 DN Melphalan flufenamide DMWF5R4 TI TTUTN1I DMWF5R4 TN Human Deoxyribonucleic acid (hDNA) DMWF5R4 MA Binder DMWF5R4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWF5R4 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSYVO6 DMWFHMZ TN Cholesterol desmolase (CYP11A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/11161433 DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSZLWK DMWFHMZ TN Aromatase (CYP19A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/17602675 DMWFJTR DI DMWFJTR DMWFJTR DN Linagliptin DMWFJTR TI TTDIGC1 DMWFJTR TN Dipeptidyl peptidase 4 (DPP-4) DMWFJTR MA Inhibitor DMWFJTR RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMWFJTR RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT1ZAVI DMWH7NQ TN Prostaglandin E2 receptor EP2 (PTGER2) DMWH7NQ MA Agonist DMWH7NQ RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT2O84V DMWH7NQ TN Thromboxane A2 receptor (TBXA2R) DMWH7NQ MA Modulator DMWH7NQ RN Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/10509658 DMWH9CN DI DMWH9CN DMWH9CN DN Ridogrel DMWH9CN TI TT2O84V DMWH9CN TN Thromboxane A2 receptor (TBXA2R) DMWH9CN MA Binder DMWH9CN RN Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42. DMWH9CN RU https://pubmed.ncbi.nlm.nih.gov/19337130 DMWIJTN DI DMWIJTN DMWIJTN DN Voclosporin DMWIJTN TI TTA4LDE DMWIJTN TN Calcineurin (PPP3CA) DMWIJTN MA Inhibitor DMWIJTN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWIJTN RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf DMWIX23 DI DMWIX23 DMWIX23 DN Metaraminol DMWIX23 TI TTEX248 DMWIX23 TN Dopamine D2 receptor (D2R) DMWIX23 MA Agonist DMWIX23 RN Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9. DMWIX23 RU https://pubmed.ncbi.nlm.nih.gov/9663612 DMWLC57 DI DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 TI TT2GM5R DMWLC57 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMWLC57 MA Modulator DMWLC57 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMWLC57 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMWLTU2 DI DMWLTU2 DMWLTU2 DN PSMA-11 Ga-68 DMWLTU2 TI TT9G4N0 DMWLTU2 TN Glutamate carboxypeptidase II (GCPII) DMWLTU2 MA Binder DMWLTU2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWLTU2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf DMWMCN0 DI DMWMCN0 DMWMCN0 DN Erenumab DMWMCN0 TI TTY6O0Q DMWMCN0 TN Calcitonin gene-related peptide receptor (CGRPR) DMWMCN0 MA Modulator DMWMCN0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWMCN0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWMPD4 DI DMWMPD4 DMWMPD4 DN Vorinostat DMWMPD4 TI TT6R7JZ DMWMPD4 TN Histone deacetylase 1 (HDAC1) DMWMPD4 MA Inhibitor DMWMPD4 RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DMWMPD4 RU https://pubmed.ncbi.nlm.nih.gov/19721445 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTZOVE0 DMWMPRG TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMWMPRG MA Blocker DMWMPRG RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTRK8B9 DMWMPRG TN Sodium channel unspecific (NaC) DMWMPRG MA Antagonist DMWMPRG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWMPRG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTIG65Q DMWMPRG TN Voltage-gated sodium channel (Nav) DMWMPRG MA Inhibitor DMWMPRG RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMWNHPC DI DMWNHPC DMWNHPC DN Aminolevulinic Acid Hydrochloride DMWNHPC TI TTNFMS9 DMWNHPC TN Protoporphyrinogen oxidase (PPOX) DMWNHPC MA Modulator DMWNHPC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNHPC RU https://www.fda.gov/ DMWNRZT DI DMWNRZT DMWNRZT DN Basiliximab DMWNRZT TI TT10Y9E DMWNRZT TN Interleukin 2 receptor alpha (IL2RA) DMWNRZT MA Modulator DMWNRZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNRZT RU https://www.fda.gov/ DMWO3N6 DI DMWO3N6 DMWO3N6 DN Indeloxazine DMWO3N6 TI TTGP7BY DMWO3N6 TN Monoamine oxidase type B (MAO-B) DMWO3N6 MA Modulator DMWO3N6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMWO3N6 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TTEX6LM DMWOSKJ TN GABA(A) receptor gamma-3 (GABRG3) DMWOSKJ MA Modulator (allosteric modulator) DMWOSKJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMWOSKJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TT1MPAY DMWOSKJ TN GABA(A) receptor alpha-1 (GABRA1) DMWOSKJ MA Modulator DMWOSKJ RN Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7. DMWOSKJ RU https://www.ncbi.nlm.nih.gov/pubmed/17113947 DMWP1BH DI DMWP1BH DMWP1BH DN Tazemetostat DMWP1BH TI TT9MZCQ DMWP1BH TN Enhancer of zeste homolog 2 (EZH2) DMWP1BH MA Inhibitor DMWP1BH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWP1BH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf DMWQ16I DI DMWQ16I DMWQ16I DN Primaquine DMWQ16I TI TT698WO DMWQ16I TN Plasmodium Deoxyribonucleic acid (Malaria DNA) DMWQ16I RN Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107. DMWQ16I RU https://pubmed.ncbi.nlm.nih.gov/17686563 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTGJCWZ DMWQ4MZ TN Fms-like tyrosine kinase 3 (FLT-3) DMWQ4MZ MA Inhibitor DMWQ4MZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWQ4MZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTZPY6J DMWQ4MZ TN Tyrosine-protein kinase UFO (AXL) DMWQ4MZ MA Inhibitor DMWQ4MZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWQ4MZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWS3FH DI DMWS3FH DMWS3FH DN Fondaparinux sodium DMWS3FH TI TTCIHJA DMWS3FH TN Coagulation factor Xa (F10) DMWS3FH MA Inhibitor DMWS3FH RN Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24. DMWS3FH RU https://pubmed.ncbi.nlm.nih.gov/13679646 DMWSA0V DI DMWSA0V DMWSA0V DN Patisiran DMWSA0V TI TTPOYU7 DMWSA0V TN Transthyretin messenger RNA (TTR mRNA) DMWSA0V RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DMWSA0V RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND TI TTQ13Z5 DMWSMND TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWSMND MA Agonist DMWSMND RN Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. DMWSMND RU https://pubmed.ncbi.nlm.nih.gov/18450949 DMWT905 DI DMWT905 DMWT905 DN Mefloquine DMWT905 TI TTT28H3 DMWT905 TN Plasmodium 80S ribosome (Malaria 80S) DMWT905 MA Binder DMWT905 RN An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14. DMWT905 RU https://pubmed.ncbi.nlm.nih.gov/3544894 DMWTAOI DI DMWTAOI DMWTAOI DN Estramustine DMWTAOI TI TTSBFYK DMWTAOI TN Estramustine binding protein (EMBP) DMWTAOI MA Binder DMWTAOI RN Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5. DMWTAOI RU https://pubmed.ncbi.nlm.nih.gov/7703721 DMWTVAN DI DMWTVAN DMWTVAN DN Rauwolfia serpentina root DMWTVAN TI TTZIFHC DMWTVAN TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMWTVAN MA Inhibitor DMWTVAN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMWTVAN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMWU0I2 DI DMWU0I2 DMWU0I2 DN Pralsetinib DMWU0I2 TI TT4DXQT DMWU0I2 TN Proto-oncogene c-Ret (RET) DMWU0I2 MA Inhibitor DMWU0I2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWU0I2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf DMWUFQ4 DI DMWUFQ4 DMWUFQ4 DN Ramucirumab DMWUFQ4 TI TTUTJGQ DMWUFQ4 TN Vascular endothelial growth factor receptor 2 (KDR) DMWUFQ4 MA Modulator DMWUFQ4 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMWUFQ4 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMWUIJE DI DMWUIJE DMWUIJE DN Tolmetin DMWUIJE TI TTVKILB DMWUIJE TN Prostaglandin G/H synthase 2 (COX-2) DMWUIJE MA Inhibitor DMWUIJE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DMWUIJE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DMWUMRL DI DMWUMRL DMWUMRL DN Interferon gamma-1b DMWUMRL TI TT13TL0 DMWUMRL TN Interferon gamma receptor (IFNGR2) DMWUMRL MA Binder DMWUMRL RN Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9. DMWUMRL RU https://pubmed.ncbi.nlm.nih.gov/17251453 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG TI TTJP4SM DMWV2AG TN Bacterial Penicillin binding protein (Bact PBP) DMWV2AG MA Binder DMWV2AG RN Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. DMWV2AG RU https://pubmed.ncbi.nlm.nih.gov/19532086 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TT2A0DR DMWV3TZ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMWV3TZ MA Inhibitor DMWV3TZ RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMWV3TZ RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TTT02K8 DMWV3TZ TN Steroid 5-alpha-reductase 2 (SRD5A2) DMWV3TZ MA Inhibitor DMWV3TZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV3TZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMWVCF3 DI DMWVCF3 DMWVCF3 DN Fusidic acid DMWVCF3 TI TT6HP1T DMWVCF3 TN Streptococcus Elongation factor G (Stre-coc fusA) DMWVCF3 MA Inhibitor DMWVCF3 RN Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. DMWVCF3 RU https://pubmed.ncbi.nlm.nih.gov/19289529 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP TI TTQ38E9 DMWVIGP TN Sodium/potassium-transporting ATPase (SPT ATPase) DMWVIGP MA Inhibitor DMWVIGP RN Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. DMWVIGP RU https://pubmed.ncbi.nlm.nih.gov/11525233 DMWX5CO DI DMWX5CO DMWX5CO DN Nicotine DMWX5CO TI TTJSZTB DMWX5CO TN Nicotinic acetylcholine receptor (nAChR) DMWX5CO MA Antagonist DMWX5CO RN Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91. DMWX5CO RU https://pubmed.ncbi.nlm.nih.gov/19481556 DMWX683 DI DMWX683 DMWX683 DN Mupirocin DMWX683 TI TT6KYJ5 DMWX683 TN Bacterial Isoleucyl-tRNA synthetase (Bact ileS) DMWX683 MA Modulator DMWX683 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWX683 RU https://www.fda.gov/ DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTQ13Z5 DMWXLYZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWXLYZ MA Antagonist DMWXLYZ RN M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/19416629 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTOXS3C DMWXLYZ TN Muscarinic acetylcholine receptor (CHRM) DMWXLYZ MA Antagonist DMWXLYZ RN Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/9029489 DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B TI TT9B4N3 DMX0E5B TN Prostaglandin receptor (PTGR) DMX0E5B MA Modulator DMX0E5B RN Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95. DMX0E5B RU https://pubmed.ncbi.nlm.nih.gov/19274525 DMX0EZJ DI DMX0EZJ DMX0EZJ DN Prothionamide DMX0EZJ TI TTVTX4N DMX0EZJ TN Bacterial Fatty acid synthetase I (Bact inhA) DMX0EZJ MA Inhibitor DMX0EZJ RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DMX0EZJ RU https://pubmed.ncbi.nlm.nih.gov/17227913 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q TI TTTIBOJ DMX0K3Q TN Histamine H1 receptor (H1R) DMX0K3Q MA Antagonist DMX0K3Q RN Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038. DMX0K3Q RU https://pubmed.ncbi.nlm.nih.gov/19381339 DMX2358 DI DMX2358 DMX2358 DN Adapalene DMX2358 TI TTOD7B3 DMX2358 TN Retinoic acid receptor (RAR) DMX2358 MA Binder DMX2358 RN A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4. DMX2358 RU https://pubmed.ncbi.nlm.nih.gov/18848668 DMX38HQ DI DMX38HQ DMX38HQ DN Apomorphine DMX38HQ TI TTEX248 DMX38HQ TN Dopamine D2 receptor (D2R) DMX38HQ MA Agonist DMX38HQ RN Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89. DMX38HQ RU https://pubmed.ncbi.nlm.nih.gov/19173265 DMX4GND DI DMX4GND DMX4GND DN Meperidine DMX4GND TI TTQ8AFT DMX4GND TN Adrenergic receptor Alpha-2 (ADRA2) DMX4GND MA Agonist DMX4GND RN Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7. DMX4GND RU https://pubmed.ncbi.nlm.nih.gov/18234187 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 TI TTWCGQT DMX6OE3 TN Serine/threonine-protein kinase B-raf (BRAF) DMX6OE3 MA Inhibitor DMX6OE3 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). DMX6OE3 RU http://www.gsk.com/ DMX6RTG DI DMX6RTG DMX6RTG DN Trospium DMX6RTG TI TTH18TF DMX6RTG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMX6RTG MA Antagonist DMX6RTG RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX6RTG RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX7A5V DI DMX7A5V DMX7A5V DN Faropenem DMX7A5V TI TT4ILYC DMX7A5V TN Bacterial Dihydropteroate synthetase (Bact folP) DMX7A5V MA Inhibitor DMX7A5V RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMX7A5V RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMX7LKS DI DMX7LKS DMX7LKS DN Isovanillin DMX7LKS TI TT3MOS2 DMX7LKS TN Aldehyde oxidase (AOX1) DMX7LKS MA Inhibitor DMX7LKS RN Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56. DMX7LKS RU https://pubmed.ncbi.nlm.nih.gov/16543721 DMX7V28 DI DMX7V28 DMX7V28 DN Insulin-aspart DMX7V28 TI TTZOPHG DMX7V28 TN Insulin (INS) DMX7V28 MA Modulator DMX7V28 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMX7V28 RU https://www.fda.gov/ DMX8CVY DI DMX8CVY DMX8CVY DN Pivampicillin DMX8CVY TI TTJP4SM DMX8CVY TN Bacterial Penicillin binding protein (Bact PBP) DMX8CVY MA Binder DMX8CVY RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX8CVY RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX8M26 DI DMX8M26 DMX8M26 DN Hyaluronate sodium DMX8M26 TI TTG8DNU DMX8M26 TN Hyaluronic acid receptor (LYVE1) DMX8M26 MA Modulator DMX8M26 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4954). DMX8M26 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954 DMX9K8F DI DMX9K8F DMX9K8F DN Carbachol DMX9K8F TI TTF4E0J DMX9K8F TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMX9K8F MA Antagonist DMX9K8F RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMX9K8F RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMX9PIA DI DMX9PIA DMX9PIA DN Live attenuated influenza vaccine DMX9PIA TI TT3J5ZI DMX9PIA TN Cell mediated immunity response (CMIR) DMX9PIA RN Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84. DMX9PIA RU https://pubmed.ncbi.nlm.nih.gov/18174020 DMXBLMP DI DMXBLMP DMXBLMP DN Riociguat DMXBLMP TI TTWNFC2 DMXBLMP TN Soluble guanylyl cyclase (GUCY2D) DMXBLMP MA Modulator DMXBLMP RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXBLMP RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXBQAM DI DMXBQAM DMXBQAM DN Miglitol DMXBQAM TI TTXWASR DMXBQAM TN Intestinal maltase-glucoamylase (MGAM) DMXBQAM MA Inhibitor DMXBQAM RN Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29. DMXBQAM RU https://pubmed.ncbi.nlm.nih.gov/9951949 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TT3NKIB DMXC1K9 TN Pancreatic elastase 1 (CELA1) DMXC1K9 MA Inhibitor DMXC1K9 RN Elastase inhibitors. J Soc Biol. 2001;195(2):143-50. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/11723826 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TTN9D8E DMXC1K9 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXC1K9 MA Antagonist DMXC1K9 RN NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/19381304 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H TI TTPADOQ DMXCM7H TN HMG-CoA reductase (HMGCR) DMXCM7H MA Inhibitor DMXCM7H RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMXCM7H RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMXDZAQ DI DMXDZAQ DMXDZAQ DN Bepotastine DMXDZAQ TI TTTIBOJ DMXDZAQ TN Histamine H1 receptor (H1R) DMXDZAQ MA Antagonist DMXDZAQ RN Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72. DMXDZAQ RU https://pubmed.ncbi.nlm.nih.gov/18606918 DMXE76K DI DMXE76K DMXE76K DN Delamanid DMXE76K TI TTXT4D5 DMXE76K TN Bacterial Cell membrane (Bact CM) DMXE76K MA Inhibitor DMXE76K RN Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483. DMXE76K RU https://pubmed.ncbi.nlm.nih.gov/33243846 DMXEACF DI DMXEACF DMXEACF DN Idarucizumab DMXEACF TI TTFDXCO DMXEACF TN Dabigatran (Dabi) DMXEACF MA Binder DMXEACF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015 DMXEACF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TTVKILB DMXGDFK TN Prostaglandin G/H synthase 2 (COX-2) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TT8NGED DMXGDFK TN Prostaglandin G/H synthase 1 (COX-1) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGJEI DI DMXGJEI DMXGJEI DN Chlophedianol DMXGJEI TI TTTIBOJ DMXGJEI TN Histamine H1 receptor (H1R) DMXGJEI MA Antagonist DMXGJEI RN Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. DMXGJEI RU https://pubmed.ncbi.nlm.nih.gov/2905706 DMXGQYZ DI DMXGQYZ DMXGQYZ DN Fleroxacin DMXGQYZ TI TT0IHXV DMXGQYZ TN DNA topoisomerase II (TOP2) DMXGQYZ MA Inhibitor DMXGQYZ RN Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. DMXGQYZ RU https://pubmed.ncbi.nlm.nih.gov/8861529 DMXIQYS DI DMXIQYS DMXIQYS DN Iodipamide DMXIQYS TI TTFNGC9 DMXIQYS TN Serum albumin (ALB) DMXIQYS MA Binder DMXIQYS RN Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. DMXIQYS RU https://pubmed.ncbi.nlm.nih.gov/18436441 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTK982E DMXJ7O8 TN Collagen (CO) DMXJ7O8 MA Activator DMXJ7O8 RN Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/19626722 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTOP832 DMXJ7O8 TN Solute carrier family 23 member 2 (SLC23A2) DMXJ7O8 MA Modulator DMXJ7O8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042). DMXJ7O8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TT6XAGK DMXJ7O8 TN Solute carrier family 23 member 1 (SLC23A1) DMXJ7O8 MA Modulator DMXJ7O8 RN Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/11895172 DMXKJ6C DI DMXKJ6C DMXKJ6C DN Torasemide DMXKJ6C TI TTS087L DMXKJ6C TN Solute carrier family 12 member 1 (SLC12A1) DMXKJ6C MA Blocker DMXKJ6C RN Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. DMXKJ6C RU https://pubmed.ncbi.nlm.nih.gov/17460608 DMXKZT3 DI DMXKZT3 DMXKZT3 DN Buclizine DMXKZT3 TI TTTIBOJ DMXKZT3 TN Histamine H1 receptor (H1R) DMXKZT3 MA Antagonist DMXKZT3 RN Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. DMXKZT3 RU https://pubmed.ncbi.nlm.nih.gov/13294975 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTBH0VX DMXLBCQ TN Histone deacetylase (HDAC) DMXLBCQ MA Inhibitor DMXLBCQ RN Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/20583972 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTFJ8Q1 DMXLBCQ TN Protein kinase C alpha (PRKCA) DMXLBCQ MA Modulator DMXLBCQ RN Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/23686835 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TT27RFC DMXLKHV TN Opioid receptor delta (OPRD1) DMXLKHV MA Agonist DMXLKHV RN Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. DMXLKHV RU https://pubmed.ncbi.nlm.nih.gov/17525040 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TTKWM86 DMXLKHV TN Opioid receptor mu (MOP) DMXLKHV MA Modulator DMXLKHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMXLKHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTKWM86 DMXLSH3 TN Opioid receptor mu (MOP) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTAWNKZ DMXLSH3 TN Norepinephrine transporter (NET) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLT8C DI DMXLT8C DMXLT8C DN Sulfisoxazole DMXLT8C TI TT4ILYC DMXLT8C TN Bacterial Dihydropteroate synthetase (Bact folP) DMXLT8C MA Inhibitor DMXLT8C RN Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. DMXLT8C RU https://pubmed.ncbi.nlm.nih.gov/7486915 DMXLVDT DI DMXLVDT DMXLVDT DN Lasmiditan DMXLVDT TI TT0MI3F DMXLVDT TN 5-HT 1F receptor (HTR1F) DMXLVDT MA Agonist DMXLVDT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMXLVDT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf DMXLYQF DI DMXLYQF DMXLYQF DN Belatacept DMXLYQF TI TTQ13FT DMXLYQF TN T-cell-specific surface glycoprotein CD28 (CD28) DMXLYQF MA Inhibitor DMXLYQF RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMXLYQF RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMXNR04 DI DMXNR04 DMXNR04 DN Unoprostone DMXNR04 TI TT9B4N3 DMXNR04 TN Prostaglandin receptor (PTGR) DMXNR04 MA Modulator DMXNR04 RN Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504. DMXNR04 RU https://pubmed.ncbi.nlm.nih.gov/11381053 DMXNZM4 DI DMXNZM4 DMXNZM4 DN Oxazepam DMXNZM4 TI TTPTXIN DMXNZM4 TN Translocator protein (TSPO) DMXNZM4 MA Agonist DMXNZM4 RN Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9. DMXNZM4 RU https://pubmed.ncbi.nlm.nih.gov/18692521 DMXOELT DI DMXOELT DMXOELT DN Midazolam DMXOELT TI TTPTXIN DMXOELT TN Translocator protein (TSPO) DMXOELT MA Modulator DMXOELT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXOELT RU https://www.fda.gov/ DMXQKSL DI DMXQKSL DMXQKSL DN Dinoprost Tromethamine DMXQKSL TI TTOFYT1 DMXQKSL TN Prostacyclin receptor (PTGIR) DMXQKSL MA Antagonist DMXQKSL RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMXQKSL RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMXQS7K DI DMXQS7K DMXQS7K DN Cenestin DMXQS7K TI TTZAYWL DMXQS7K TN Estrogen receptor (ESR) DMXQS7K MA Agonist DMXQS7K RN Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6. DMXQS7K RU https://pubmed.ncbi.nlm.nih.gov/11887204 DMXSVGI DI DMXSVGI DMXSVGI DN Loncastuximab tesirine DMXSVGI TI TTW640A DMXSVGI TN B-lymphocyte surface antigen B4 (CD19) DMXSVGI MA Inhibitor DMXSVGI RN Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645. DMXSVGI RU https://pubmed.ncbi.nlm.nih.gov/33211842 DMXTCVF DI DMXTCVF DMXTCVF DN Radium-223-Dichloride DMXTCVF TI TTUTN1I DMXTCVF TN Human Deoxyribonucleic acid (hDNA) DMXTCVF MA Modulator DMXTCVF RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXTCVF RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ TI TTTIBOJ DMXTMBJ TN Histamine H1 receptor (H1R) DMXTMBJ MA Antagonist DMXTMBJ RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMXTMBJ RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMXVU6D DI DMXVU6D DMXVU6D DN Diphemanil Methylsulfate DMXVU6D TI TTZ9SOR DMXVU6D TN Muscarinic acetylcholine receptor M1 (CHRM1) DMXVU6D MA Modulator DMXVU6D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXVU6D RU https://www.fda.gov/ DMXW92T DI DMXW92T DMXW92T DN Ixekizumab DMXW92T TI TTG0MT6 DMXW92T TN Interleukin-17 (IL17) DMXW92T MA Modulator DMXW92T RN Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. DMXW92T RU https://pubmed.ncbi.nlm.nih.gov/23013312 DMXWOCP DI DMXWOCP DMXWOCP DN Ethotoin DMXWOCP TI TTZOVE0 DMXWOCP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMXWOCP MA Blocker DMXWOCP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXWOCP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O TI TTJ0IQB DMXY30O TN Phosphodiesterase 5A (PDE5A) DMXY30O MA Modulator DMXY30O RN Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46. DMXY30O RU https://www.ncbi.nlm.nih.gov/pubmed/21649691 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C TI TTUTN1I DMXYJ9C TN Human Deoxyribonucleic acid (hDNA) DMXYJ9C MA Modulator DMXYJ9C RN DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/15132775 DMXYJOB DI DMXYJOB DMXYJOB DN Phentolamine DMXYJOB TI TTEX248 DMXYJOB TN Dopamine D2 receptor (D2R) DMXYJOB MA Antagonist DMXYJOB RN Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6. DMXYJOB RU https://pubmed.ncbi.nlm.nih.gov/19474390 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTVBI8W DMXYTN9 TN Dopamine transporter (DAT) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTAWNKZ DMXYTN9 TN Norepinephrine transporter (NET) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXZ84M DI DMXZ84M DMXZ84M DN Malathion DMXZ84M TI TT1RS9F DMXZ84M TN Acetylcholinesterase (AChE) DMXZ84M MA Inhibitor DMXZ84M RN Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40. DMXZ84M RU https://pubmed.ncbi.nlm.nih.gov/19444631 DMXZOCG DI DMXZOCG DMXZOCG DN Phenobarbital DMXZOCG TI TTNJYV2 DMXZOCG TN Gamma-aminobutyric acid receptor (GAR) DMXZOCG MA Antagonist DMXZOCG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMXZOCG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 TI TTUTN1I DMXZRW0 TN Human Deoxyribonucleic acid (hDNA) DMXZRW0 MA Binder DMXZRW0 RN Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62. DMXZRW0 RU https://pubmed.ncbi.nlm.nih.gov/1664221 DMY0EKH DI DMY0EKH DMY0EKH DN Nemonapride DMY0EKH TI TTEX248 DMY0EKH TN Dopamine D2 receptor (D2R) DMY0EKH MA Agonist DMY0EKH RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMY0EKH RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMY0KGJ DI DMY0KGJ DMY0KGJ DN Chlorprothixene DMY0KGJ TI TTEX248 DMY0KGJ TN Dopamine D2 receptor (D2R) DMY0KGJ MA Antagonist DMY0KGJ RN Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. DMY0KGJ RU https://pubmed.ncbi.nlm.nih.gov/19091563 DMY0M8J DI DMY0M8J DMY0M8J DN Sargramostim DMY0M8J TI TT6MP2Z DMY0M8J TN GMCSFR-alpha (CSF2RA) DMY0M8J MA Binder DMY0M8J RN Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9. DMY0M8J RU https://pubmed.ncbi.nlm.nih.gov/12901131 DMY18XK DI DMY18XK DMY18XK DN Penicillin G Sodium DMY18XK TI TTJP4SM DMY18XK TN Bacterial Penicillin binding protein (Bact PBP) DMY18XK MA Modulator DMY18XK RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMY18XK RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMY2KX9 DI DMY2KX9 DMY2KX9 DN Alendronate DMY2KX9 TI TTIKWV4 DMY2KX9 TN Geranyltranstransferase (FDPS) DMY2KX9 MA Modulator DMY2KX9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY2KX9 RU https://www.fda.gov/ DMY4D87 DI DMY4D87 DMY4D87 DN Quazepam DMY4D87 TI TTPTXIN DMY4D87 TN Translocator protein (TSPO) DMY4D87 MA Modulator DMY4D87 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY4D87 RU https://www.fda.gov/ DMY4UMW DI DMY4UMW DMY4UMW DN Atovaquone DMY4UMW TI TT3PQ2Y DMY4UMW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMY4UMW MA Inhibitor DMY4UMW RN Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42. DMY4UMW RU https://pubmed.ncbi.nlm.nih.gov/15044733 DMY5JEP DI DMY5JEP DMY5JEP DN Mezlocillin DMY5JEP TI TT85JMW DMY5JEP TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMY5JEP MA Binder DMY5JEP RN Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302. DMY5JEP RU https://pubmed.ncbi.nlm.nih.gov/2949271 DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 TI TTJP4SM DMY60I8 TN Bacterial Penicillin binding protein (Bact PBP) DMY60I8 MA Binder DMY60I8 RN Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. DMY60I8 RU https://pubmed.ncbi.nlm.nih.gov/19528266 DMY62FC DI DMY62FC DMY62FC DN Tezacaftor And Ivacaftor DMY62FC TI TTRLZHP DMY62FC TN cAMP-dependent chloride channel (CFTR) DMY62FC MA Binder DMY62FC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMY62FC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMY6T31 DI DMY6T31 DMY6T31 DN Isoflurane DMY6T31 TI TTAN6JD DMY6T31 TN Glutamate receptor AMPA (GRIA) DMY6T31 MA Agonist DMY6T31 RN Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5. DMY6T31 RU https://pubmed.ncbi.nlm.nih.gov/15680938 DMY7ESM DI DMY7ESM DMY7ESM DN Recombinant Factor IX DMY7ESM TI TTFEZ5Q DMY7ESM TN Coagulation factor IX (F9) DMY7ESM MA Modulator DMY7ESM RN BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80. DMY7ESM RU https://pubmed.ncbi.nlm.nih.gov/25324957 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED TI TT07C3Y DMY7PED TN 5-HT 4 receptor (HTR4) DMY7PED MA Agonist DMY7PED RN Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90. DMY7PED RU https://pubmed.ncbi.nlm.nih.gov/18948374 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW TI TTZAYWL DMY85QW TN Estrogen receptor (ESR) DMY85QW MA Modulator DMY85QW RN Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15. DMY85QW RU https://pubmed.ncbi.nlm.nih.gov/19543129 DMY9BMK DI DMY9BMK DMY9BMK DN Rocuronium DMY9BMK TI TTF4E0J DMY9BMK TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMY9BMK MA Antagonist DMY9BMK RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMY9BMK RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW TI TTAN6JD DMY9TCW TN Glutamate receptor AMPA (GRIA) DMY9TCW MA Binder DMY9TCW RN Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71. DMY9TCW RU https://pubmed.ncbi.nlm.nih.gov/19099296 DMYBV3G DI DMYBV3G DMYBV3G DN Paricalcitol DMYBV3G TI TTK59TV DMYBV3G TN Vitamin D3 receptor (VDR) DMYBV3G MA Agonist DMYBV3G RN New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226. DMYBV3G RU https://pubmed.ncbi.nlm.nih.gov/19494617 DMYCXKL DI DMYCXKL DMYCXKL DN Capmatinib DMYCXKL TI TTNDSF4 DMYCXKL TN Proto-oncogene c-Met (MET) DMYCXKL MA Modulator DMYCXKL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMYCXKL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf DMYE5LJ DI DMYE5LJ DMYE5LJ DN DEOXYCYTIDINE DMYE5LJ TI TTP3QRF DMYE5LJ TN Thymidine kinase 1 (TK1) DMYE5LJ MA Inhibitor DMYE5LJ RN Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. DMYE5LJ RU https://pubmed.ncbi.nlm.nih.gov/7097717 DMYFBMS DI DMYFBMS DMYFBMS DN 99mTc-fanolesomab DMYFBMS TI TTNV1KZ DMYFBMS TN Fucosyltransferase IV (CD15) DMYFBMS RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMYFBMS RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTSNVHO DMYGHX5 TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTNJYV2 DMYGHX5 TN Gamma-aminobutyric acid receptor (GAR) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTGJCWZ DMYGJQO TN Fms-like tyrosine kinase 3 (FLT-3) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT3PJMV DMYGJQO TN Tyrosine-protein kinase ABL1 (ABL) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTX41N9 DMYGJQO TN Tyrosine-protein kinase Kit (KIT) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT4DXQT DMYGJQO TN Proto-oncogene c-Ret (RET) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYHBKN DI DMYHBKN DMYHBKN DN Exenatide DMYHBKN TI TTVIMDE DMYHBKN TN Glucagon-like peptide 1 receptor (GLP1R) DMYHBKN MA Binder DMYHBKN RN Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9. DMYHBKN RU https://pubmed.ncbi.nlm.nih.gov/19459763 DMYHDCA DI DMYHDCA DMYHDCA DN Pranlukast DMYHDCA TI TTGKOY9 DMYHDCA TN Leukotriene CysLT1 receptor (CYSLTR1) DMYHDCA MA Antagonist DMYHDCA RN Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203. DMYHDCA RU https://pubmed.ncbi.nlm.nih.gov/19610262 DMYHN59 DI DMYHN59 DMYHN59 DN Axicabtagene ciloleucel DMYHN59 TI TTW640A DMYHN59 TN B-lymphocyte surface antigen B4 (CD19) DMYHN59 MA CAR-T-Cell-Therapy DMYHN59 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMYHN59 RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel DMYILBE DI DMYILBE DMYILBE DN Modafinil DMYILBE TI TTVBI8W DMYILBE TN Dopamine transporter (DAT) DMYILBE MA Modulator DMYILBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYILBE RU https://www.fda.gov/ DMYK490 DI DMYK490 DMYK490 DN Nepafenac DMYK490 TI TTK0943 DMYK490 TN Prostaglandin G/H synthase (COX) DMYK490 MA Inhibitor DMYK490 RN Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15. DMYK490 RU https://pubmed.ncbi.nlm.nih.gov/12506103 DMYKUNR DI DMYKUNR DMYKUNR DN Moxalactam Disodium DMYKUNR TI TT85JMW DMYKUNR TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMYKUNR MA Modulator DMYKUNR RN Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12. DMYKUNR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283783 DMYLMU0 DI DMYLMU0 DMYLMU0 DN Isosorbide mononitrate DMYLMU0 TI TT6HPVC DMYLMU0 TN Guanylate cyclase (GC) DMYLMU0 MA Stimulator DMYLMU0 RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMYLMU0 RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTIU7X1 DMYLOVR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMYLOVR MA Modulator DMYLOVR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYLOVR RU https://www.fda.gov/ DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTHPJTK DMYLOVR TN Varicella-zoster virus DNA polymerase (VZV ORF28) DMYLOVR MA Modulator DMYLOVR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYLOVR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 TI TT2CJVK DMYM974 TN Adrenergic receptor beta-2 (ADRB2) DMYM974 MA Agonist DMYM974 RN Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. DMYM974 RU https://pubmed.ncbi.nlm.nih.gov/19271027 DMYN59P DI DMYN59P DMYN59P DN Vildagliptin DMYN59P TI TTDIGC1 DMYN59P TN Dipeptidyl peptidase 4 (DPP-4) DMYN59P MA Inhibitor DMYN59P RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMYN59P RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMYN8MA DI DMYN8MA DMYN8MA DN Tianeptine DMYN8MA TI TT3ROYC DMYN8MA TN Serotonin transporter (SERT) DMYN8MA MA Inhibitor DMYN8MA RN Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. DMYN8MA RU https://pubmed.ncbi.nlm.nih.gov/17109609 DMYNMDP DI DMYNMDP DMYNMDP DN Tocainide DMYNMDP TI TT05DLS DMYNMDP TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMYNMDP MA Modulator DMYNMDP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYNMDP RU https://www.fda.gov/ DMYOAKS DI DMYOAKS DMYOAKS DN Teduglutide DMYOAKS TI TT1YWO5 DMYOAKS TN Glucagon-like peptide 2 receptor (GLP2R) DMYOAKS MA Modulator DMYOAKS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYOAKS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYP4XC DI DMYP4XC DMYP4XC DN Norgestimate DMYP4XC TI TTUV8G9 DMYP4XC TN Progesterone receptor (PGR) DMYP4XC MA Agonist DMYP4XC RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMYP4XC RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMYQCWT DI DMYQCWT DMYQCWT DN Tecartus DMYQCWT TI TTW640A DMYQCWT TN B-lymphocyte surface antigen B4 (CD19) DMYQCWT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMYQCWT RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO TI TTX2N1T DMYQDBO TN Transferase unspecific (TF) DMYQDBO MA Modulator DMYQDBO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2013 DMYQDBO RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf DMYQVGN DI DMYQVGN DMYQVGN DN Premarin/Trimegestone DMYQVGN TI TTZAYWL DMYQVGN TN Estrogen receptor (ESR) DMYQVGN MA Modulator DMYQVGN RN The Haunting of Medical Journals: How Ghostwriting Sold RT PLoS Med. 2010 September; 7(9): e1000335. DMYQVGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935455/ DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTA8PLI DMYRBO1 TN Casein kinase I epsilon (CSNK1E) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTGBPJE DMYRBO1 TN PI3-kinase delta (PIK3CD) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRX8B DI DMYRX8B DMYRX8B DN Ardeparin DMYRX8B TI TT4QPUL DMYRX8B TN Antithrombin-III (ATIII) DMYRX8B MA Modulator DMYRX8B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYRX8B RU https://www.fda.gov/ DMYSCIL DI DMYSCIL DMYSCIL DN Prolastin DMYSCIL TI TTZBFA0 DMYSCIL TN Protease unspecific (PRO) DMYSCIL MA Inhibitor DMYSCIL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYSCIL RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYT0OG DI DMYT0OG DMYT0OG DN Vigabatrin DMYT0OG TI TTT2LD9 DMYT0OG TN GABA transaminase (ABAT) DMYT0OG MA Inhibitor DMYT0OG RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMYT0OG RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMYT2FP DI DMYT2FP DMYT2FP DN Cellulose Sodium Phosphate DMYT2FP TI TT8X5NO DMYT2FP TN Calcium (Ca) DMYT2FP MA Modulator DMYT2FP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYT2FP RU https://www.fda.gov/ DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L TI TT0IHXV DMYTE6L TN DNA topoisomerase II (TOP2) DMYTE6L MA Inhibitor DMYTE6L RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DMYTE6L RU https://pubmed.ncbi.nlm.nih.gov/3282749 DMYTXVR DI DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR TI TTJP4SM DMYTXVR TN Bacterial Penicillin binding protein (Bact PBP) DMYTXVR MA Binder DMYTXVR RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMYTXVR RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMYURI6 DI DMYURI6 DMYURI6 DN Raltegravir DMYURI6 TI TT5FH9Y DMYURI6 TN Human immunodeficiency virus Integrase (HIV IN) DMYURI6 MA Modulator DMYURI6 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMYURI6 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMYVP5G DI DMYVP5G DMYVP5G DN Insulin recombinant DMYVP5G TI TTCBFJO DMYVP5G TN Insulin receptor (INSR) DMYVP5G MA Binder DMYVP5G RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMYVP5G RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMYWQ0O DI DMYWQ0O DMYWQ0O DN Tetrabenazine DMYWQ0O TI TTNZRI3 DMYWQ0O TN Synaptic vesicle amine transporter (SLC18A2) DMYWQ0O MA Blocker DMYWQ0O RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DMYWQ0O RU https://pubmed.ncbi.nlm.nih.gov/19571144 DMYX7NI DI DMYX7NI DMYX7NI DN Acetohydroxamic Acid DMYX7NI TI TTAS2UO DMYX7NI TN Bacterial Urease (Bact ureC) DMYX7NI MA Inhibitor DMYX7NI RN Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121. DMYX7NI RU https://pubmed.ncbi.nlm.nih.gov/18638408 DMYXBV3 DI DMYXBV3 DMYXBV3 DN Dulaglutide DMYXBV3 TI TTVIMDE DMYXBV3 TN Glucagon-like peptide 1 receptor (GLP1R) DMYXBV3 MA Agonist DMYXBV3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMYXBV3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TTKWM86 DMYZ0P1 TN Opioid receptor mu (MOP) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TT27RFC DMYZ0P1 TN Opioid receptor delta (OPRD1) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N TI TTYFKSZ DMYZ57N TN Tubulin beta (TUBB) DMYZ57N MA Binder DMYZ57N RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMYZ57N RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMYZFXN DI DMYZFXN DMYZFXN DN Lornoxicam DMYZFXN TI TTK0943 DMYZFXN TN Prostaglandin G/H synthase (COX) DMYZFXN MA Modulator DMYZFXN RN The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. DMYZFXN RU https://pubmed.ncbi.nlm.nih.gov/10450786 DMYZITL DI DMYZITL DMYZITL DN Cephaloglycin DMYZITL TI TTJP4SM DMYZITL TN Bacterial Penicillin binding protein (Bact PBP) DMYZITL MA Modulator DMYZITL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYZITL RU https://www.fda.gov/ DMZ0P95 DI DMZ0P95 DMZ0P95 DN Ga-68-DOTATOC DMZ0P95 TI TTZ6T9E DMZ0P95 TN Somatostatin receptor type 2 (SSTR2) DMZ0P95 MA Binder DMZ0P95 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMZ0P95 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf DMZ0Q1G DI DMZ0Q1G DMZ0Q1G DN Permethrin DMZ0Q1G TI TTRK8B9 DMZ0Q1G TN Sodium channel unspecific (NaC) DMZ0Q1G MA Blocker DMZ0Q1G RN In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8. DMZ0Q1G RU https://pubmed.ncbi.nlm.nih.gov/14651650 DMZ1WXJ DI DMZ1WXJ DMZ1WXJ DN Vitamin B1 DMZ1WXJ TI TT8RHGB DMZ1WXJ TN Bacterial Pyruvate decarboxylase (Bact aceE) DMZ1WXJ MA Cofactor DMZ1WXJ RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMZ1WXJ RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMZ2WL4 DI DMZ2WL4 DMZ2WL4 DN Cefpiramide DMZ2WL4 TI TTJP4SM DMZ2WL4 TN Bacterial Penicillin binding protein (Bact PBP) DMZ2WL4 MA Binder DMZ2WL4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMZ2WL4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMZ30JT DI DMZ30JT DMZ30JT DN Oxantel pamoate DMZ30JT TI TTHDSE2 DMZ30JT TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMZ30JT MA Inhibitor DMZ30JT RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DMZ30JT RU https://pubmed.ncbi.nlm.nih.gov/11031122 DMZ36RN DI DMZ36RN DMZ36RN DN Mazindol DMZ36RN TI TTAWNKZ DMZ36RN TN Norepinephrine transporter (NET) DMZ36RN MA Modulator DMZ36RN RN Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. DMZ36RN RU https://pubmed.ncbi.nlm.nih.gov/15300361 DMZ4P3A DI DMZ4P3A DMZ4P3A DN Telithromycin DMZ4P3A TI TTUWYEA DMZ4P3A TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMZ4P3A MA Binder DMZ4P3A RN An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47. DMZ4P3A RU https://pubmed.ncbi.nlm.nih.gov/15386111 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TTVKILB DMZ5RGV TN Prostaglandin G/H synthase 2 (COX-2) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TT8NGED DMZ5RGV TN Prostaglandin G/H synthase 1 (COX-1) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ65K8 DI DMZ65K8 DMZ65K8 DN Pilsicainide DMZ65K8 TI TTRK8B9 DMZ65K8 TN Sodium channel unspecific (NaC) DMZ65K8 MA Modulator DMZ65K8 RN A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42. DMZ65K8 RU https://pubmed.ncbi.nlm.nih.gov/21869589 DMZ6VEY DI DMZ6VEY DMZ6VEY DN Sulfacetamide DMZ6VEY TI TT915ZD DMZ6VEY TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMZ6VEY MA Inhibitor DMZ6VEY RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMZ6VEY RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMZ7XNQ DI DMZ7XNQ DMZ7XNQ DN Tacrolimus DMZ7XNQ TI TTA4LDE DMZ7XNQ TN Calcineurin (PPP3CA) DMZ7XNQ MA Inhibitor DMZ7XNQ RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMZ7XNQ RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMZ80SB DI DMZ80SB DMZ80SB DN Azatadine DMZ80SB TI TTTIBOJ DMZ80SB TN Histamine H1 receptor (H1R) DMZ80SB MA Antagonist DMZ80SB RN Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7. DMZ80SB RU https://pubmed.ncbi.nlm.nih.gov/1982614 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTPFZJ1 DMZ905C TN Vasopressin V1 receptor (V1R) DMZ905C MA Antagonist DMZ905C RN Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/1337114 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTL9MHW DMZ905C TN Vasopressin V1b receptor (V1BR) DMZ905C MA Inhibitor DMZ905C RN New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/7241506 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTK8R02 DMZ905C TN Vasopressin V2 receptor (V2R) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TT4TFGN DMZ905C TN Vasopressin V1a receptor (V1AR) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/10376439 DMZ9BMU DI DMZ9BMU DMZ9BMU DN Colistimethate DMZ9BMU TI TT4ILYC DMZ9BMU TN Bacterial Dihydropteroate synthetase (Bact folP) DMZ9BMU MA Binder DMZ9BMU RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMZ9BMU RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMZ9FAO DI DMZ9FAO DMZ9FAO DN Somatomedin-1 DMZ9FAO TI TTHRID2 DMZ9FAO TN Insulin-like growth factor I receptor (IGF1R) DMZ9FAO MA Modulator DMZ9FAO RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMZ9FAO RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMZA017 DI DMZA017 DMZA017 DN Tetracycline DMZA017 TI TTQ8KVI DMZA017 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZA017 MA Binder DMZA017 RN The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. DMZA017 RU https://pubmed.ncbi.nlm.nih.gov/14723559 DMZA5PQ DI DMZA5PQ DMZA5PQ DN Glipizide DMZA5PQ TI TTG140O DMZA5PQ TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMZA5PQ MA Blocker DMZA5PQ RN Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6. DMZA5PQ RU https://pubmed.ncbi.nlm.nih.gov/19233162 DMZAL7W DI DMZAL7W DMZAL7W DN Promazine DMZAL7W TI TTH18TF DMZAL7W TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZAL7W MA Binder DMZAL7W RN Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. DMZAL7W RU https://pubmed.ncbi.nlm.nih.gov/2899826 DMZBU15 DI DMZBU15 DMZBU15 DN Tripelennamine DMZBU15 TI TTTIBOJ DMZBU15 TN Histamine H1 receptor (H1R) DMZBU15 MA Antagonist DMZBU15 RN Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309. DMZBU15 RU https://pubmed.ncbi.nlm.nih.gov/15914334 DMZC1HS DI DMZC1HS DMZC1HS DN Ivacaftor DMZC1HS TI TTRLZHP DMZC1HS TN cAMP-dependent chloride channel (CFTR) DMZC1HS MA Modulator DMZC1HS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMZC1HS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMZC6GT DI DMZC6GT DMZC6GT DN Elliptinium acetate DMZC6GT TI TTABD5E DMZC6GT TN DNA replication (DNA repli) DMZC6GT MA Modulator DMZC6GT RN Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64. DMZC6GT RU https://pubmed.ncbi.nlm.nih.gov/91123 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR TI TTIU7X1 DMZD5QR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMZD5QR MA Inhibitor DMZD5QR RN Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. DMZD5QR RU https://pubmed.ncbi.nlm.nih.gov/19372559 DMZDCS0 DI DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 TI TTJ584C DMZDCS0 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMZDCS0 MA Agonist DMZDCS0 RN Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92. DMZDCS0 RU https://pubmed.ncbi.nlm.nih.gov/19124612 DMZDF0B DI DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B TI TTK0943 DMZDF0B TN Prostaglandin G/H synthase (COX) DMZDF0B MA Modulator DMZDF0B RN Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. DMZDF0B RU https://pubmed.ncbi.nlm.nih.gov/12966366 DMZDN4W DI DMZDN4W DMZDN4W DN L-alanine DMZDN4W TI TTT2LD9 DMZDN4W TN GABA transaminase (ABAT) DMZDN4W MA Inhibitor DMZDN4W RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMZDN4W RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTN6J5F DMZEONG TN Bacterial DNA gyrase (Bact gyrase) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTIXTO3 DMZEONG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEPFJ DI DMZEPFJ DMZEPFJ DN Demeclocycline DMZEPFJ TI TTQ8KVI DMZEPFJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZEPFJ MA Binder DMZEPFJ RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMZEPFJ RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMZFICR DI DMZFICR DMZFICR DN Bevantolol DMZFICR TI TTEX248 DMZFICR TN Dopamine D2 receptor (D2R) DMZFICR MA Antagonist DMZFICR RN Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7. DMZFICR RU https://pubmed.ncbi.nlm.nih.gov/17703743 DMZG5WL DI DMZG5WL DMZG5WL DN Emapalumab DMZG5WL TI TT93WF5 DMZG5WL TN Interferon-gamma (IFNG) DMZG5WL MA Modulator DMZG5WL RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMZG5WL RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMZGXUM DI DMZGXUM DMZGXUM DN Estazolam DMZGXUM TI TTPTXIN DMZGXUM TN Translocator protein (TSPO) DMZGXUM MA Agonist DMZGXUM RN Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9. DMZGXUM RU https://pubmed.ncbi.nlm.nih.gov/15876530 DMZHPNE DI DMZHPNE DMZHPNE DN Cimetropium bromide DMZHPNE TI TTH18TF DMZHPNE TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZHPNE MA Modulator DMZHPNE RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZHPNE RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZHUO5 DI DMZHUO5 DMZHUO5 DN Phenylephrine DMZHUO5 TI TTEX248 DMZHUO5 TN Dopamine D2 receptor (D2R) DMZHUO5 MA Agonist DMZHUO5 RN MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64. DMZHUO5 RU https://pubmed.ncbi.nlm.nih.gov/19482300 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TT4ILYC DMZI2UF TN Bacterial Dihydropteroate synthetase (Bact folP) DMZI2UF MA Binder DMZI2UF RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TTGP7BY DMZI2UF TN Monoamine oxidase type B (MAO-B) DMZI2UF MA Inhibitor DMZI2UF RN Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/11928718 DMZI3WO DI DMZI3WO DMZI3WO DN Etomidate DMZI3WO TI TTEX6LM DMZI3WO TN GABA(A) receptor gamma-3 (GABRG3) DMZI3WO MA Modulator DMZI3WO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZI3WO RU https://www.fda.gov/ DMZJYBW DI DMZJYBW DMZJYBW DN Metocurine Iodide DMZJYBW TI TTL1ATN DMZJYBW TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMZJYBW MA Modulator DMZJYBW RN NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8. DMZJYBW RU https://www.ncbi.nlm.nih.gov/pubmed/17993502 DMZKXB7 DI DMZKXB7 DMZKXB7 DN Butylscopolamine DMZKXB7 TI TTH18TF DMZKXB7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZKXB7 MA Modulator DMZKXB7 RN Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7. DMZKXB7 RU https://pubmed.ncbi.nlm.nih.gov/8036897 DMZKYIV DI DMZKYIV DMZKYIV DN Amsacrine DMZKYIV TI TT0IHXV DMZKYIV TN DNA topoisomerase II (TOP2) DMZKYIV MA Inhibitor DMZKYIV RN Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. DMZKYIV RU https://pubmed.ncbi.nlm.nih.gov/11716434 DMZL3IV DI DMZL3IV DMZL3IV DN Alemtuzumab DMZL3IV TI TTQT5S9 DMZL3IV TN Cambridge pathology 1 antigen (CD52) DMZL3IV RN Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. DMZL3IV RU https://pubmed.ncbi.nlm.nih.gov/19545375 DMZLBUO DI DMZLBUO DMZLBUO DN Lucanthone DMZLBUO TI TT0IHXV DMZLBUO TN DNA topoisomerase II (TOP2) DMZLBUO MA Inhibitor DMZLBUO RN Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45. DMZLBUO RU https://pubmed.ncbi.nlm.nih.gov/15832946 DMZLGRB DI DMZLGRB DMZLGRB DN Pimecrolimus DMZLGRB TI TTA4LDE DMZLGRB TN Calcineurin (PPP3CA) DMZLGRB MA Inhibitor DMZLGRB RN Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8. DMZLGRB RU https://pubmed.ncbi.nlm.nih.gov/19499228 DMZLHKJ DI DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ TI TTUTN1I DMZLHKJ TN Human Deoxyribonucleic acid (hDNA) DMZLHKJ MA Binder DMZLHKJ RN Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410. DMZLHKJ RU https://pubmed.ncbi.nlm.nih.gov/19580332 DMZM84R DI DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R TI TTUV8G9 DMZM84R TN Progesterone receptor (PGR) DMZM84R MA Binder DMZM84R RN Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. DMZM84R RU https://pubmed.ncbi.nlm.nih.gov/858280 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TT06AWU DMZMSCT TN Phosphodiesterase 3A (PDE3A) DMZMSCT MA Inhibitor DMZMSCT RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DMZMSCT RU https://pubmed.ncbi.nlm.nih.gov/2985781 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TTZCG4L DMZMSCT TN Phosphodiesterase 3 (PDE3) DMZMSCT MA Modulator DMZMSCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZMSCT RU https://www.fda.gov/ DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF TI TTS64P2 DMZMSPF TN Androgen receptor (AR) DMZMSPF MA Antagonist DMZMSPF RN Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. DMZMSPF RU https://pubmed.ncbi.nlm.nih.gov/19533338 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI TI TTRK8B9 DMZOLBI TN Sodium channel unspecific (NaC) DMZOLBI MA Modulator DMZOLBI RN Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7. DMZOLBI RU https://pubmed.ncbi.nlm.nih.gov/24319110 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK TI TTP3UTW DMZPHIK TN Steroid hormone receptor ERR (ESRR) DMZPHIK MA Modulator DMZPHIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZPHIK RU https://www.fda.gov/ DMZPXRC DI DMZPXRC DMZPXRC DN Carzinophilin DMZPXRC TI TTY1GPO DMZPXRC TN Human Deoxyribonucleic acid major groove (hDNA maj) DMZPXRC MA Modulator DMZPXRC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZPXRC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZQOUX DI DMZQOUX DMZQOUX DN Trastuzumab DMZQOUX TI TT6EO5L DMZQOUX TN Erbb2 tyrosine kinase receptor (HER2) DMZQOUX RN Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. DMZQOUX RU https://pubmed.ncbi.nlm.nih.gov/15179190 DMZR15V DI DMZR15V DMZR15V DN Selpercatinib DMZR15V TI TT4DXQT DMZR15V TN Proto-oncogene c-Ret (RET) DMZR15V MA Inhibitor DMZR15V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMZR15V RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf DMZR26N DI DMZR26N DMZR26N DN Ciprofloxacin+dexamethasone DMZR26N TI TT0IHXV DMZR26N TN DNA topoisomerase II (TOP2) DMZR26N MA Binder DMZR26N RN Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. DMZR26N RU https://pubmed.ncbi.nlm.nih.gov/16634700 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTRK8B9 DMZREFQ TN Sodium channel unspecific (NaC) DMZREFQ MA Blocker DMZREFQ RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTN9VTF DMZREFQ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTIG65Q DMZREFQ TN Voltage-gated sodium channel (Nav) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZSDGX DI DMZSDGX DMZSDGX DN Dicyclomine DMZSDGX TI TTZ9SOR DMZSDGX TN Muscarinic acetylcholine receptor M1 (CHRM1) DMZSDGX MA Antagonist DMZSDGX RN [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11. DMZSDGX RU https://pubmed.ncbi.nlm.nih.gov/19627722 DMZSWQC DI DMZSWQC DMZSWQC DN Flunisolide DMZSWQC TI TTYRL6O DMZSWQC TN Glucocorticoid receptor (NR3C1) DMZSWQC MA Agonist DMZSWQC RN The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7. DMZSWQC RU https://pubmed.ncbi.nlm.nih.gov/19254810 DMZT2P0 DI DMZT2P0 DMZT2P0 DN Abobotulinum toxin A DMZT2P0 TI TTZJD1B DMZT2P0 TN Acetylcholine release (Ach rele) DMZT2P0 MA Modulator DMZT2P0 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMZT2P0 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMZT4N7 DI DMZT4N7 DMZT4N7 DN Leucovorin/5-fluorouracil DMZT4N7 TI TTU6BFZ DMZT4N7 TN Candida Thymidylate synthase (Candi TMP1) DMZT4N7 MA Inhibitor DMZT4N7 RN Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44. DMZT4N7 RU https://pubmed.ncbi.nlm.nih.gov/19383847 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTD0CIQ DMZTGN2 TN Melanocortin receptor 4 (MC4R) DMZTGN2 MA Agonist DMZTGN2 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTKWM86 DMZTGN2 TN Opioid receptor mu (MOP) DMZTGN2 MA Modulator DMZTGN2 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMZTXCH DI DMZTXCH DMZTXCH DN Remifentanil DMZTXCH TI TTKWM86 DMZTXCH TN Opioid receptor mu (MOP) DMZTXCH MA Agonist DMZTXCH RN The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96. DMZTXCH RU https://pubmed.ncbi.nlm.nih.gov/19058913 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTZPWGN DMZU5JP TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMZU5JP MA Blocker DMZU5JP RN Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/19582593 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTX4QDJ DMZU5JP TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMZU5JP MA Inhibitor DMZU5JP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZUR4N DI DMZUR4N DMZUR4N DN Triclosan DMZUR4N TI TTNX2CS DMZUR4N TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMZUR4N MA Binder DMZUR4N RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMZUR4N RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMZUW6P DI DMZUW6P DMZUW6P DN Factor viia DMZUW6P TI TTF0EGX DMZUW6P TN Coagulation factor VII (F7) DMZUW6P MA Modulator DMZUW6P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMZUW6P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMZV2PJ DI DMZV2PJ DMZV2PJ DN Acetophenazine DMZV2PJ TI TTEX248 DMZV2PJ TN Dopamine D2 receptor (D2R) DMZV2PJ MA Antagonist DMZV2PJ RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMZV2PJ RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMZVMKF DI DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF TI TT34BHT DMZVMKF TN Adrenergic receptor alpha-1D (ADRA1D) DMZVMKF MA Antagonist DMZVMKF RN Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. DMZVMKF RU https://pubmed.ncbi.nlm.nih.gov/11893233 DMZW9HA DI DMZW9HA DMZW9HA DN Olsalazine DMZW9HA TI TTPZ7AG DMZW9HA TN Oxidoreductase unspecific (OR) DMZW9HA MA Modulator DMZW9HA RN Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90. DMZW9HA RU https://pubmed.ncbi.nlm.nih.gov/21203919 DMZYLFC DI DMZYLFC DMZYLFC DN Viomycin sulfate DMZYLFC TI TTIA0J5 DMZYLFC TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMZYLFC MA Modulator DMZYLFC RN The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7. DMZYLFC RU https://www.ncbi.nlm.nih.gov/pubmed/17515906 nan DI nan nan DN nan nan TI TTIHYA4 nan TN Thrombopoietin receptor (MPL) nan MA Agonist nan RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). nan RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM5GFIK DI DM5GFIK DM5GFIK DN Icotinib hydrochloride DM5GFIK TI TTGKNB4 DM5GFIK TN Epidermal growth factor receptor (EGFR) DM5GFIK MA Antagonist DM5GFIK RN Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202. DM5GFIK RU https://pubmed.ncbi.nlm.nih.gov/21144613 DM5GIWZ DI DM5GIWZ DM5GIWZ DN Mirogabalin DM5GIWZ TI TTFK1JQ DM5GIWZ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5GIWZ MA Modulator DM5GIWZ RN Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61. DM5GIWZ RU https://pubmed.ncbi.nlm.nih.gov/25231896 DMBZ27L DI DMBZ27L DMBZ27L DN Favipiravir DMBZ27L TI TT79JGK DMBZ27L TN Mycobacterium RNA polymerase (MycB RNAP) DMBZ27L MA Modulator DMBZ27L RN Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54. DMBZ27L RU https://www.ncbi.nlm.nih.gov/pubmed/24084488 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TT6R7JZ DMDWYUN TN Histone deacetylase 1 (HDAC1) DMDWYUN MA Modulator DMDWYUN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDWYUN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TTBH0VX DMDWYUN TN Histone deacetylase (HDAC) DMDWYUN MA Inhibitor DMDWYUN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDWYUN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRCOU5 DI DMRCOU5 DMRCOU5 DN Dicycloplatin DMRCOU5 TI TTUTN1I DMRCOU5 TN Human Deoxyribonucleic acid (hDNA) DMRCOU5 MA Inhibitor DMRCOU5 RN Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63. DMRCOU5 RU https://pubmed.ncbi.nlm.nih.gov/24403501 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTST7KB DMY67U8 TN Fibroblast growth factor receptor 3 (FGFR3) DMY67U8 MA Inhibitor DMY67U8 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTI2WET DMY67U8 TN Platelet-derived growth factor receptor (PDGFR) DMY67U8 MA Inhibitor DMY67U8 RN Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/18635661 DM2M47Y DI DM2M47Y DM2M47Y DN TKM-ApoB DM2M47Y TI TTN1IE2 DM2M47Y TN APOB messenger RNA (APOB mRNA) DM2M47Y RN Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146. DM2M47Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/ DM2VOQ3 DI DM2VOQ3 DM2VOQ3 DN Mosapride DM2VOQ3 TI TT07C3Y DM2VOQ3 TN 5-HT 4 receptor (HTR4) DM2VOQ3 MA Agonist DM2VOQ3 RN The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37. DM2VOQ3 RU https://pubmed.ncbi.nlm.nih.gov/18415081 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTKPW01 DM3S8XC TN Androgen receptor messenger RNA (AR mRNA) DM3S8XC MA Agonist DM3S8XC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). DM3S8XC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTS64P2 DM3S8XC TN Androgen receptor (AR) DM3S8XC MA Modulator DM3S8XC RN Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501. DM3S8XC RU https://www.ncbi.nlm.nih.gov/pubmed/12089345 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTLD29N DM3YH4I TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTF45NW DM3YH4I TN Strychnine-binding glycine receptor (GLRA1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TTQHWNA DM4OQRD TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM4OQRD MA Inhibitor DM4OQRD RN A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/18974394 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TT0LF7H DM4OQRD TN Fibroblast growth factor receptor (FGFR) DM4OQRD MA Antagonist DM4OQRD RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/11576867 DM4TX7J DI DM4TX7J DM4TX7J DN Talipexole DM4TX7J TI TTEX248 DM4TX7J TN Dopamine D2 receptor (D2R) DM4TX7J MA Agonist DM4TX7J RN Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res Commun Mol Pathol Pharmacol. 1997 Jan;95(1):67-82. DM4TX7J RU https://pubmed.ncbi.nlm.nih.gov/9055350 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTPADOQ DM5FABJ TN HMG-CoA reductase (HMGCR) DM5FABJ MA Inhibitor DM5FABJ RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT2O84V DM5FABJ TN Thromboxane A2 receptor (TBXA2R) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTNVEIR DM5FABJ TN Prostaglandin D2 receptor (PTGDR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTOFYT1 DM5FABJ TN Prostacyclin receptor (PTGIR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTQDMX5 DM5FABJ TN Prostaglandin D2 receptor 2 (PTGDR2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTT2ZAR DM5FABJ TN Prostaglandin F2-alpha receptor (PTGFR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT1ZAVI DM5FABJ TN Prostaglandin E2 receptor EP2 (PTGER2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM6VFO1 DI DM6VFO1 DM6VFO1 DN Pregnenolone DM6VFO1 TI TTPNQAC DM6VFO1 TN Estrogen-related receptor-alpha (ESRRA) DM6VFO1 MA Agonist DM6VFO1 RN Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6. DM6VFO1 RU https://pubmed.ncbi.nlm.nih.gov/16597193 DM8EKSV DI DM8EKSV DM8EKSV DN Anti-MIF antibodies DM8EKSV TI TT2AST1 DM8EKSV TN Macrophage migration inhibitory factor (MIF) DM8EKSV MA Inhibitor DM8EKSV RN Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455. DM8EKSV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293543/ DM8NWFD DI DM8NWFD DM8NWFD DN Hypericum DM8NWFD TI TTAWNKZ DM8NWFD TN Norepinephrine transporter (NET) DM8NWFD MA Inhibitor DM8NWFD RN The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. DM8NWFD RU https://pubmed.ncbi.nlm.nih.gov/10483049 DM92S6N DI DM92S6N DM92S6N DN Levamlodipine DM92S6N TI TTXHYV6 DM92S6N TN Voltage-gated L-type calcium channel (L-CaC) DM92S6N MA Modulator DM92S6N RN Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4. DM92S6N RU https://pubmed.ncbi.nlm.nih.gov/18604992 DMB0FWL DI DMB0FWL DMB0FWL DN Dihydrocodeine DMB0FWL TI TTN4QDT DMB0FWL TN Opioid receptor (OPR) DMB0FWL MA Modulator DMB0FWL RN Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63. DMB0FWL RU https://pubmed.ncbi.nlm.nih.gov/12420793 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TT4TFGN DMB7WYM TN Vasopressin V1a receptor (V1AR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTSCIUP DMB7WYM TN Oxytocin receptor (OTR) DMB7WYM MA Inhibitor DMB7WYM RN Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/16297621 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTL9MHW DMB7WYM TN Vasopressin V1b receptor (V1BR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTK8R02 DMB7WYM TN Vasopressin V2 receptor (V2R) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTQL5VC DMBPN7T TN Platelet-activating factor receptor (PTAFR) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTTIBOJ DMBPN7T TN Histamine H1 receptor (H1R) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMC5Q8X DI DMC5Q8X DMC5Q8X DN Berberine DMC5Q8X TI TTUJFD0 DMC5Q8X TN Telomerase reverse transcriptase (TERT) DMC5Q8X MA Inhibitor DMC5Q8X RN Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103. DMC5Q8X RU https://pubmed.ncbi.nlm.nih.gov/11880232 DMDN4A1 DI DMDN4A1 DMDN4A1 DN Glitazone DMDN4A1 TI TTZMAO3 DMDN4A1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDN4A1 MA Agonist DMDN4A1 RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMDN4A1 RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMF8CJ9 DI DMF8CJ9 DMF8CJ9 DN Pyridine DMF8CJ9 TI TTKNWZ4 DMF8CJ9 TN Thromboxane-A synthase (TBXAS1) DMF8CJ9 MA Inhibitor DMF8CJ9 RN Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55. DMF8CJ9 RU https://pubmed.ncbi.nlm.nih.gov/7199089 DMHEAB1 DI DMHEAB1 DMHEAB1 DN Neupro DMHEAB1 TI TTWFZ1N DMHEAB1 TN Dopamine receptor (DR) DMHEAB1 MA Agonist DMHEAB1 RN Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718. DMHEAB1 RU https://pubmed.ncbi.nlm.nih.gov/31243728 DMIGKA1 DI DMIGKA1 DMIGKA1 DN Ozagrel DMIGKA1 TI TTQBR95 DMIGKA1 TN Stress-activated protein kinase 2a (p38 alpha) DMIGKA1 MA Inhibitor DMIGKA1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMIGKA1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMIV8CT DI DMIV8CT DMIV8CT DN Parecoxib DMIV8CT TI TTSZDQU DMIV8CT TN Lactotransferrin (LTF) DMIV8CT MA Inhibitor DMIV8CT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIV8CT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKV32D DI DMKV32D DMKV32D DN Xylometazoline DMKV32D TI TT2NUT5 DMKV32D TN Adrenergic receptor alpha-2C (ADRA2C) DMKV32D MA Modulator DMKV32D RN Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. DMKV32D RU https://pubmed.ncbi.nlm.nih.gov/20030735 DMN2Q5I DI DMN2Q5I DMN2Q5I DN Diacerein DMN2Q5I TI TTRYK0X DMN2Q5I TN Interleukin-1 beta (IL1B) DMN2Q5I MA Inhibitor DMN2Q5I RN Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86. DMN2Q5I RU https://pubmed.ncbi.nlm.nih.gov/19247594 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTPLTSQ DMOSJD0 TN Neutrophil elastase (NE) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/17874973 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTEMV5X DMOSJD0 TN Serine protease unspecific (SP) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TTAWNKZ DMTV7XH TN Norepinephrine transporter (NET) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TT0K1SC DMTV7XH TN 5-HT 2B receptor (HTR2B) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMVILAD DI DMVILAD DMVILAD DN MOTILIN DMVILAD TI TT953CX DMVILAD TN Motilin receptor (MLNR) DMVILAD MA Inhibitor DMVILAD RN Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7. DMVILAD RU https://pubmed.ncbi.nlm.nih.gov/17125271 DMVPLNC DI DMVPLNC DMVPLNC DN Ingrezza DMVPLNC TI TTNZRI3 DMVPLNC TN Synaptic vesicle amine transporter (SLC18A2) DMVPLNC MA Antagonist DMVPLNC RN VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111. DMVPLNC RU https://pubmed.ncbi.nlm.nih.gov/29680151 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TT8NGED DMVXLOD TN Prostaglandin G/H synthase 1 (COX-1) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TTVKILB DMVXLOD TN Prostaglandin G/H synthase 2 (COX-2) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2AST1 DMVZL26 TN Macrophage migration inhibitory factor (MIF) DMVZL26 MA Inhibitor DMVZL26 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2J34L DMVZL26 TN Arachidonate 5-lipoxygenase (5-LOX) DMVZL26 MA Inhibitor DMVZL26 RN Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/18760329 DMWDEN0 DI DMWDEN0 DMWDEN0 DN Amylin DMWDEN0 TI TTD0CIQ DMWDEN0 TN Melanocortin receptor 4 (MC4R) DMWDEN0 MA Agonist DMWDEN0 RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMWDEN0 RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMWL182 DI DMWL182 DMWL182 DN Beraprost DMWL182 TI TTOFYT1 DMWL182 TN Prostacyclin receptor (PTGIR) DMWL182 MA Agonist DMWL182 RN Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174. DMWL182 RU https://pubmed.ncbi.nlm.nih.gov/25584359 DMXBYQR DI DMXBYQR DMXBYQR DN Silymarin DMXBYQR TI TT2J34L DMXBYQR TN Arachidonate 5-lipoxygenase (5-LOX) DMXBYQR MA Inhibitor DMXBYQR RN Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. DMXBYQR RU https://pubmed.ncbi.nlm.nih.gov/10782486 DMY2AEF DI DMY2AEF DMY2AEF DN PAI-1 DMY2AEF TI TTGY7WI DMY2AEF TN Urokinase-type plasminogen activator (PLAU) DMY2AEF MA Inhibitor DMY2AEF RN Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. DMY2AEF RU https://pubmed.ncbi.nlm.nih.gov/7563153 DMYGEH7 DI DMYGEH7 DMYGEH7 DN Ceftolozane sulfate DMYGEH7 TI TTJP4SM DMYGEH7 TN Bacterial Penicillin binding protein (Bact PBP) DMYGEH7 MA Modulator DMYGEH7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYGEH7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYOC29 DI DMYOC29 DMYOC29 DN Hirudin DMYOC29 TI TT6L509 DMYOC29 TN Coagulation factor IIa (F2) DMYOC29 MA Inhibitor DMYOC29 RN Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69. DMYOC29 RU https://pubmed.ncbi.nlm.nih.gov/12427016 DMZ5Y1P DI DMZ5Y1P DMZ5Y1P DN Dichloroacetate DMZ5Y1P TI TTCZOF2 DMZ5Y1P TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMZ5Y1P MA Inhibitor DMZ5Y1P RN Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. DMZ5Y1P RU https://pubmed.ncbi.nlm.nih.gov/31768777 DMXIRA0 DI DMXIRA0 DMXIRA0 DN RLX030 DMXIRA0 TI TTMAHD1 DMXIRA0 TN Relaxin receptor 1 (RXFP1) DMXIRA0 MA Modulator DMXIRA0 RN Design of the RELAXin in acute heart failure study. Am Heart J. 2012 Feb;163(2):149-55.e1. DMXIRA0 RU https://pubmed.ncbi.nlm.nih.gov/22305830 DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTCGSZ4 DMOML9Q TN Pancreatic alpha-amylase (AMY2A) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TT7MRGU DMOML9Q TN Chymotrypsin (CTR) DMOML9Q MA Modulator DMOML9Q RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMOML9Q RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTXMY0J DMOML9Q TN Pancreatic triacylglycerol lipase (PNLIP) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DM26I8H DI DM26I8H DM26I8H DN TK-DLI DM26I8H TI TTP3QRF DM26I8H TN Thymidine kinase 1 (TK1) DM26I8H MA Modulator DM26I8H RN Company report (Takara Bio) DM26I8H RU http://www.takara-bio.com/news_e/2008/10/07.htm DMBRFUQ DI DMBRFUQ DMBRFUQ DN B-cell lymphoma vaccine DMBRFUQ TI TT6MP2Z DMBRFUQ TN GMCSFR-alpha (CSF2RA) DMBRFUQ RN Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2. DMBRFUQ RU http://meeting.ascopubs.org/cgi/content/abstract/27/18S/2?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Idiotype+vaccine+therapy+(BiovaxID)+in+follicular+lymphoma+&searchid=1&FIRSTINDEX=0&volume=27&issue=18S&resourcetype=HWCIT DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT9W8GU DMF2O4T TN Gamma-secretase (GS) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8JRS7 DMF2O4T TN Beta-secretase (BACE) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTWN3F4 DMF2O4T TN Presenilin 2 (PSEN2) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTVKILB DMF2O4T TN Prostaglandin G/H synthase 2 (COX-2) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8NGED DMF2O4T TN Prostaglandin G/H synthase 1 (COX-1) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTZ3S8C DMF2O4T TN Presenilin 1 (PSEN1) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMLRKJX DI DMLRKJX DMLRKJX DN Neugranin DMLRKJX TI TT5TQ2W DMLRKJX TN Granulocyte colony-stimulating factor (CSF3) DMLRKJX MA Modulator DMLRKJX RN Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840. DMLRKJX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275271/ DMP5O1U DI DMP5O1U DMP5O1U DN GSK2696273 DMP5O1U TI TTLP57V DMP5O1U TN Adenosine deaminase (ADA) DMP5O1U MA Modulator DMP5O1U RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMP5O1U RU https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ DMUY09W DI DMUY09W DMUY09W DN SK-NBP601 DMUY09W TI TT1290U DMUY09W TN Coagulation factor VIII (F8) DMUY09W MA Inhibitor DMUY09W RN Clinical pipeline report, company report or official report of SK Chemicals. DMUY09W RU http://www.skchemicals.com/en/about/rd_result.asp DMXSDJU DI DMXSDJU DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine DMXSDJU TI TTISGCA DMXSDJU TN Toll-like receptor 4 (TLR4) DMXSDJU RN Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006. DMXSDJU RU http://miranda.hemscott.com/ir/agy/ir.jsp?page=news_regulatory&article=36483600159086 DMYA6TR DI DMYA6TR DMYA6TR DN Human coagulation factor X DMYA6TR TI TTCIHJA DMYA6TR TN Coagulation factor Xa (F10) DMYA6TR MA Modulator DMYA6TR RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMYA6TR RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TTRLW2X DM02BVQ TN Fibroblast growth factor receptor 1 (FGFR1) DM02BVQ MA Inhibitor DM02BVQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DM02BVQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TT0LF7H DM02BVQ TN Fibroblast growth factor receptor (FGFR) DM02BVQ MA Antagonist DM02BVQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM02BVQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM06KRC DI DM06KRC DM06KRC DN Oregovomab DM06KRC TI TTC1PS3 DM06KRC TN Ovarian carcinoma antigen CA125 (MUC16) DM06KRC RN MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129. DM06KRC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/ DM0762O DI DM0762O DM0762O DN Fenfluramine DM0762O TI TT85JO3 DM0762O TN 5-HT receptor (5HTR) DM0762O MA Antagonist DM0762O RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM0762O RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM07653 DI DM07653 DM07653 DN SULTHIAME DM07653 TI TTANPDJ DM07653 TN Carbonic anhydrase II (CA-II) DM07653 MA Inhibitor DM07653 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM07653 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM08XIN DI DM08XIN DM08XIN DN EPIANDROSTERONE DM08XIN TI TTKN8W0 DM08XIN TN Glucose-6-phosphate dehydrogenase (G6PD) DM08XIN MA Inhibitor DM08XIN RN Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9. DM08XIN RU https://pubmed.ncbi.nlm.nih.gov/19231202 DM097UP DI DM097UP DM097UP DN CBT-1 DM097UP TI TT3OT40 DM097UP TN Multidrug resistance protein 1 (ABCB1) DM097UP MA Modulator DM097UP RN A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512. DM097UP RU https://www.ncbi.nlm.nih.gov/pubmed/22416063 DM09M3H DI DM09M3H DM09M3H DN BAY 94-9027 DM09M3H TI TT1290U DM09M3H TN Coagulation factor VIII (F8) DM09M3H MA Modulator DM09M3H RN Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96. DM09M3H RU https://pubmed.ncbi.nlm.nih.gov/24843882 DM09RKB DI DM09RKB DM09RKB DN LC-150444 DM09RKB TI TTDIGC1 DM09RKB TN Dipeptidyl peptidase 4 (DPP-4) DM09RKB MA Inhibitor DM09RKB RN Clinical pipeline report, company report or official report of ShangHai APIs Chemical. DM09RKB RU http://www.apischemical.com/APIsproducts4/850649-62-6,Alogliptin(SYR-322).htm DM09TVB DI DM09TVB DM09TVB DN Zimura DM09TVB TI TTKANGO DM09TVB TN Complement C5 (CO5) DM09TVB MA Inhibitor DM09TVB RN C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. DM09TVB RU https://pubmed.ncbi.nlm.nih.gov/32882310 DM0AEDT DI DM0AEDT DM0AEDT DN BIIB067 DM0AEDT TI TT6RVLG DM0AEDT TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DM0AEDT MA Inhibitor DM0AEDT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0AEDT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0DIEZ DI DM0DIEZ DM0DIEZ DN UNI-rhIL-11 DM0DIEZ TI TTZPLJS DM0DIEZ TN Interleukin 11 receptor alpha (IL11RA) DM0DIEZ MA Modulator DM0DIEZ RN Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5. DM0DIEZ RU https://pubmed.ncbi.nlm.nih.gov/12478901 DM0EQ9X DI DM0EQ9X DM0EQ9X DN Av 133 DM0EQ9X TI TTNZRI3 DM0EQ9X TN Synaptic vesicle amine transporter (SLC18A2) DM0EQ9X MA Enhancer DM0EQ9X RN Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952. DM0EQ9X RU https://pubmed.ncbi.nlm.nih.gov/24098749 DM0GUV2 DI DM0GUV2 DM0GUV2 DN DE-766 DM0GUV2 TI TTGKNB4 DM0GUV2 TN Epidermal growth factor receptor (EGFR) DM0GUV2 MA Modulator DM0GUV2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM0GUV2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM0HIU5 DI DM0HIU5 DM0HIU5 DN Solanezumab DM0HIU5 TI TTE4KHA DM0HIU5 TN Amyloid beta A4 protein (APP) DM0HIU5 MA Modulator DM0HIU5 RN Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. DM0HIU5 RU https://pubmed.ncbi.nlm.nih.gov/24450890 DM0JA9N DI DM0JA9N DM0JA9N DN Cyrtominetin DM0JA9N TI TT5FLYB DM0JA9N TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM0JA9N MA Modulator DM0JA9N RN Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8. DM0JA9N RU https://pubmed.ncbi.nlm.nih.gov/23376250 DM0LQ94 DI DM0LQ94 DM0LQ94 DN GnRH DM0LQ94 TI TT8R70G DM0LQ94 TN Gonadotropin-releasing hormone receptor (GNRHR) DM0LQ94 MA Modulator DM0LQ94 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DM0LQ94 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTGKNB4 DM0MI81 TN Epidermal growth factor receptor (EGFR) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTOHSBA DM0MI81 TN Vascular endothelial growth factor A (VEGFA) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0Q6CM DI DM0Q6CM DM0Q6CM DN CIGB-300 DM0Q6CM TI TTZ5NI7 DM0Q6CM TN Casein kinase II (CSNK2) DM0Q6CM MA Modulator DM0Q6CM RN Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944. DM0Q6CM RU https://pubmed.ncbi.nlm.nih.gov/25279177 DM0QNF4 DI DM0QNF4 DM0QNF4 DN TRx0237 DM0QNF4 TI TTS87KH DM0QNF4 TN Microtubule-associated protein tau (MAPT) DM0QNF4 MA Inhibitor DM0QNF4 RN Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296. DM0QNF4 RU https://pubmed.ncbi.nlm.nih.gov/32091331 DM0QV27 DI DM0QV27 DM0QV27 DN NN5401 DM0QV27 TI TTCBFJO DM0QV27 TN Insulin receptor (INSR) DM0QV27 MA Modulator DM0QV27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM0QV27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM0TWCY DI DM0TWCY DM0TWCY DN PF-04950615 DM0TWCY TI TTBRG7E DM0TWCY TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM0TWCY RN Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8. DM0TWCY RU https://pubmed.ncbi.nlm.nih.gov/24316621 DM0ZOGX DI DM0ZOGX DM0ZOGX DN Linopirdine DM0ZOGX TI TTIVDM3 DM0ZOGX TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DM0ZOGX MA Modulator DM0ZOGX RN The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40. DM0ZOGX RU https://pubmed.ncbi.nlm.nih.gov/21099148 DM103O8 DI DM103O8 DM103O8 DN Ligelizumab DM103O8 TI TTYJQTF DM103O8 TN Immunoglobulin E (IgE) DM103O8 MA Inhibitor DM103O8 RN Clinical pipeline report, company report or official report of Novartis. DM103O8 RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=Ligelizumab&field_pipeline_filing_date=All DM13V0P DI DM13V0P DM13V0P DN Rivoceranib DM13V0P TI TTUTJGQ DM13V0P TN Vascular endothelial growth factor receptor 2 (KDR) DM13V0P MA Antagonist DM13V0P RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM13V0P RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUN7MC DM15ZIB TN T-cell surface glycoprotein CD3 (CD3) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUE541 DM15ZIB TN Leukocyte surface antigen Leu-16 (CD20) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM180DM DI DM180DM DM180DM DN ARGX-113 DM180DM TI TTKLPHO DM180DM TN Neonatal Fc receptor (FCGRT) DM180DM MA Antagonist DM180DM RN Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673. DM180DM RU https://pubmed.ncbi.nlm.nih.gov/31118245 DM1874J DI DM1874J DM1874J DN TRC105 DM1874J TI TTB30LE DM1874J TN Endoglin CD105 (ENG) DM1874J MA Modulator DM1874J RN An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. DM1874J RU https://pubmed.ncbi.nlm.nih.gov/25261556 DM18B72 DI DM18B72 DM18B72 DN Rosiglitazone + simvastatin DM18B72 TI TTZMAO3 DM18B72 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM18B72 MA Agonist DM18B72 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM18B72 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TTXHYV6 DM1975O TN Voltage-gated L-type calcium channel (L-CaC) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TT4FDG6 DM1975O TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM19CFZ DI DM19CFZ DM19CFZ DN DIMS-0150 DM19CFZ TI TTKLNRV DM19CFZ TN NFKB messenger RNA (NFKB mRNA) DM19CFZ RN News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013). DM19CFZ RU http://www.nature.com/nrd/journal/v12/n3/full/nrd3963.html DM1ARHT DI DM1ARHT DM1ARHT DN BYM338 DM1ARHT TI TTX2DRI DM1ARHT TN Activin receptor type IIA (ACVR2A) DM1ARHT MA Inhibitor DM1ARHT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ARHT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM1BXMY DI DM1BXMY DM1BXMY DN LY2605541 DM1BXMY TI TTZOPHG DM1BXMY TN Insulin (INS) DM1BXMY MA Modulator DM1BXMY RN LY2605541--a preferential hepato-specific insulin analogue. Diabetes. 2014 Feb;63(2):390-2. DM1BXMY RU https://pubmed.ncbi.nlm.nih.gov/24464715 DM1C95G DI DM1C95G DM1C95G DN DARE-BV1 DM1C95G TI TTUWYEA DM1C95G TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM1C95G RN Characterization of Escherichia coli 50S ribosomal protein L31. FEMS Microbiol Lett. 1999 Nov 15;180(2):345-9. DM1C95G RU https://pubmed.ncbi.nlm.nih.gov/10556732 DM1EO3G DI DM1EO3G DM1EO3G DN Odanacatib DM1EO3G TI TTDZN01 DM1EO3G TN Cathepsin K (CTSK) DM1EO3G MA Inhibitor DM1EO3G RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM1EO3G RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTGPQ0F DM1IZ5D TN Prolyl endopeptidase FAP (FAP) DM1IZ5D MA Inhibitor DM1IZ5D RN Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9. DM1IZ5D RU https://pubmed.ncbi.nlm.nih.gov/18032930 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTJGLZF DM1IZ5D TN Dipeptidyl peptidase 8 (DPP-8) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTNDUL7 DM1IZ5D TN Dipeptidyl peptidase 9 (DPP-9) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1JCW8 DI DM1JCW8 DM1JCW8 DN Xaliproden DM1JCW8 TI TTSQIFT DM1JCW8 TN 5-HT 1A receptor (HTR1A) DM1JCW8 MA Antagonist DM1JCW8 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM1JCW8 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM1K78U DI DM1K78U DM1K78U DN Apricitabine DM1K78U TI TT84ETX DM1K78U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1K78U MA Modulator DM1K78U RN Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. DM1K78U RU https://www.ncbi.nlm.nih.gov/pubmed/18211121 DM1NQDW DI DM1NQDW DM1NQDW DN SGI110 DM1NQDW TI TT6S2FE DM1NQDW TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM1NQDW MA Modulator DM1NQDW RN Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46. DM1NQDW RU https://pubmed.ncbi.nlm.nih.gov/25793777 DM1NTVQ DI DM1NTVQ DM1NTVQ DN Tadekinig alfa DM1NTVQ TI TTRICUF DM1NTVQ TN Interleukin-18 (IL18) DM1NTVQ MA Inhibitor DM1NTVQ RN Clinical pipeline report, company report or official report of AB2 Bio. DM1NTVQ RU http://www.ab2bio.com/en/products.36.html DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTJQOD7 DM1ODMR TN 5-HT 2A receptor (HTR2A) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTWJBZ5 DM1ODMR TN 5-HT 2C receptor (HTR2C) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1PI9G DI DM1PI9G DM1PI9G DN NN8717 DM1PI9G TI TTAXGIP DM1PI9G TN Coagulation factor XIII (F13B) DM1PI9G MA Modulator DM1PI9G RN Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14. DM1PI9G RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786906/ DM1PRT6 DI DM1PRT6 DM1PRT6 DN M710 DM1PRT6 TI TT9HKJA DM1PRT6 TN Vascular endothelial growth factor (VEGF) DM1PRT6 MA Inhibitor DM1PRT6 RN ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health. DM1PRT6 RU https://clinicaltrials.gov/ct2/show/NCT03610646 DM1RMF5 DI DM1RMF5 DM1RMF5 DN Acadesine DM1RMF5 TI TTLAFZV DM1RMF5 TN AMP-activated protein kinase (AMPK) DM1RMF5 MA Modulator DM1RMF5 RN Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44. DM1RMF5 RU https://pubmed.ncbi.nlm.nih.gov/18671468 DM1RWMY DI DM1RWMY DM1RWMY DN Plasma derived factor VIII PEGylated liposomal DM1RWMY TI TT1290U DM1RWMY TN Coagulation factor VIII (F8) DM1RWMY MA Modulator DM1RWMY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM1RWMY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM1SMAI DI DM1SMAI DM1SMAI DN Eperisone DM1SMAI TI TTCRJKY DM1SMAI TN Voltage-gated calcium channel (Cav) DM1SMAI MA Modulator DM1SMAI RN Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305. DM1SMAI RU https://pubmed.ncbi.nlm.nih.gov/2555204 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTGJCWZ DM1T6ZN TN Fms-like tyrosine kinase 3 (FLT-3) DM1T6ZN MA Modulator DM1T6ZN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM1T6ZN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTRMX3V DM1T6ZN TN Janus kinase 2 (JAK-2) DM1T6ZN MA Modulator DM1T6ZN RN National Cancer Institute Drug Dictionary (drug id 609888). DM1T6ZN RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=609888 DM1TJXA DI DM1TJXA DM1TJXA DN Chloride DM1TJXA TI TTTSOUD DM1TJXA TN Candida Cytochrome P450 51 (Candi ERG11) DM1TJXA MA Modulator DM1TJXA RN Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22. DM1TJXA RU https://pubmed.ncbi.nlm.nih.gov/25902926 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTGBPJE DM1WEHC TN PI3-kinase delta (PIK3CD) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTHBTOP DM1WEHC TN PI3-kinase gamma (PIK3CG) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTTHBCA DM1WEHC TN PI3-kinase beta (PIK3CB) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTEUNMR DM1WEHC TN PI3-kinase alpha (PIK3CA) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WMOK DI DM1WMOK DM1WMOK DN Generx DM1WMOK TI TTCEKVZ DM1WMOK TN Fibroblast growth factor-4 (FGF4) DM1WMOK MA Replacement DM1WMOK RN Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. DM1WMOK RU https://pubmed.ncbi.nlm.nih.gov/17825712 DM1WNGJ DI DM1WNGJ DM1WNGJ DN DFP-10917 DM1WNGJ TI TTABD5E DM1WNGJ TN DNA replication (DNA repli) DM1WNGJ MA Inhibitor DM1WNGJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1WNGJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1YVLM DI DM1YVLM DM1YVLM DN FST-201 DM1YVLM TI TTYRL6O DM1YVLM TN Glucocorticoid receptor (NR3C1) DM1YVLM MA Agonist DM1YVLM RN A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83. DM1YVLM RU https://pubmed.ncbi.nlm.nih.gov/19756415 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TTWKB01 DM20KYR TN HUMAN janus kinase 1 (JAK-1) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TT0F5HE DM20KYR TN HUMAN janus kinase 2 (JAK-2) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM23BUP DI DM23BUP DM23BUP DN PF-05280014 DM23BUP TI TT6EO5L DM23BUP TN Erbb2 tyrosine kinase receptor (HER2) DM23BUP MA Antagonist DM23BUP RN Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9. DM23BUP RU https://pubmed.ncbi.nlm.nih.gov/25001079 DM25TMP DI DM25TMP DM25TMP DN Rubraca rucaparib DM25TMP TI TTEBCY8 DM25TMP TN Poly [ADP-ribose] polymerase (PARP) DM25TMP MA Inhibitor DM25TMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25TMP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM29XGY DI DM29XGY DM29XGY DN HMPL-004 DM29XGY TI TTBD054 DM29XGY TN Inflammation pathogenesis (IP) DM29XGY MA Antagonist DM29XGY RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DM29XGY RU http://www.hmplglobal.com/en/hmpl-004/ DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTXWASR DM2ATZB TN Intestinal maltase-glucoamylase (MGAM) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTHCF4J DM2ATZB TN Alpha-glucosidase (GLA) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTLPC70 DM2ATZB TN Lysosomal alpha-glucosidase (GAA) DM2ATZB MA Inhibitor DM2ATZB RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM2EJM3 DI DM2EJM3 DM2EJM3 DN AKB-6548 DM2EJM3 TI TTJQFBG DM2EJM3 TN HIF-prolyl hydroxylase (HPH) DM2EJM3 MA Modulator DM2EJM3 RN DOI: 10.1038/nrd4422 DM2EJM3 RU http://www.nature.com/nrd/journal/v13/n11/fig_tab/nrd4422_T2.html DM2F9YO DI DM2F9YO DM2F9YO DN Anakinra DM2F9YO TI TTT7FOP DM2F9YO TN HUMAN interleukin-1 receptor 1 (IL1R1) DM2F9YO MA Antagonist DM2F9YO RN FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. DM2F9YO RU http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_drug_name DM2FV5N DI DM2FV5N DM2FV5N DN Darunavir + cobicistat DM2FV5N TI TT1D53B DM2FV5N TN COVID-19 3C-like protease (3CLpro) DM2FV5N MA Inhibitor DM2FV5N RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DM2FV5N RU https://pubmed.ncbi.nlm.nih.gov/32205870 DM2GF14 DI DM2GF14 DM2GF14 DN PF-06410293 DM2GF14 TI TTF8CQI DM2GF14 TN Tumor necrosis factor (TNF) DM2GF14 RN Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20. DM2GF14 RU https://pubmed.ncbi.nlm.nih.gov/25114503 DM2GHCR DI DM2GHCR DM2GHCR DN Rebamipide DM2GHCR TI TT5Y4EM DM2GHCR TN N-formyl peptide receptor (FPR1) DM2GHCR MA Antagonist DM2GHCR RN Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94. DM2GHCR RU https://pubmed.ncbi.nlm.nih.gov/11259567 DM2H8FZ DI DM2H8FZ DM2H8FZ DN TAK-700 DM2H8FZ TI TTRA5BZ DM2H8FZ TN Steroid 17-alpha-monooxygenase (S17AH) DM2H8FZ MA Modulator DM2H8FZ RN Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. DM2H8FZ RU https://pubmed.ncbi.nlm.nih.gov/22249003 DM2J4YB DI DM2J4YB DM2J4YB DN ABP 501 DM2J4YB TI TTF8CQI DM2J4YB TN Tumor necrosis factor (TNF) DM2J4YB RN Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30. DM2J4YB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/ DM2OBNW DI DM2OBNW DM2OBNW DN Bococizumab DM2OBNW TI TTBRG7E DM2OBNW TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM2OBNW RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DM2OBNW RU https://pubmed.ncbi.nlm.nih.gov/25323928 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTZ97H5 DM2R15Q TN Phosphodiesterase 4A (PDE4A) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTSKMI8 DM2R15Q TN Phosphodiesterase 4D (PDE4D) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTVIAT9 DM2R15Q TN Phosphodiesterase 4B (PDE4B) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2RTGP DI DM2RTGP DM2RTGP DN Alpha-glucosidase DM2RTGP TI TTXWASR DM2RTGP TN Intestinal maltase-glucoamylase (MGAM) DM2RTGP MA Modulator DM2RTGP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DM2RTGP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DM2TNJ1 DI DM2TNJ1 DM2TNJ1 DN Molgramostim DM2TNJ1 TI TT6MP2Z DM2TNJ1 TN GMCSFR-alpha (CSF2RA) DM2TNJ1 MA Agonist DM2TNJ1 RN Clinical pipeline report, company report or official report of gensci-china. DM2TNJ1 RU http://www.gensci-china.com/gensci/cp1_somatropinAQ.asp?MaxID=3 DM2XSG0 DI DM2XSG0 DM2XSG0 DN GMA105 DM2XSG0 TI TTVIMDE DM2XSG0 TN Glucagon-like peptide 1 receptor (GLP1R) DM2XSG0 MA Inhibitor DM2XSG0 RN Clinical pipeline report, company report or official report of Gmax Biopharm. DM2XSG0 RU http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html DM2YQK8 DI DM2YQK8 DM2YQK8 DN AR-301 DM2YQK8 TI TT5FLYB DM2YQK8 TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM2YQK8 MA Inhibitor DM2YQK8 RN Clinical pipeline report, company report or official report of Aridis Pharmaceuticals. DM2YQK8 RU https://www.aridispharma.com/ar-301/ DM3274D DI DM3274D DM3274D DN Fostamatinib disodium DM3274D TI TTOU65C DM3274D TN Tyrosine-protein kinase SYK (SYK) DM3274D MA Inhibitor DM3274D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3274D RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM34GOF DI DM34GOF DM34GOF DN REL-1017 DM34GOF TI TT9IK2Z DM34GOF TN N-methyl-D-aspartate receptor (NMDAR) DM34GOF MA Antagonist DM34GOF RN N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238. DM34GOF RU https://pubmed.ncbi.nlm.nih.gov/31454827 DM35GBS DI DM35GBS DM35GBS DN Favipiravir DM35GBS TI TTV1095 DM35GBS TN COVID-19 RNA-directed RNA polymerase (RdRp) DM35GBS MA Inhibitor DM35GBS RN Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020. DM35GBS RU https://doi.org/10.1101/2020.03.17.20037432 DM35T1O DI DM35T1O DM35T1O DN Epristeride DM35T1O TI TT2A0DR DM35T1O TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM35T1O MA Inhibitor DM35T1O RN Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8. DM35T1O RU https://pubmed.ncbi.nlm.nih.gov/21094046 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTEX248 DM36C17 TN Dopamine D2 receptor (D2R) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTJQOD7 DM36C17 TN 5-HT 2A receptor (HTR2A) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM376WT DI DM376WT DM376WT DN NKTR 214 DM376WT TI TT9721Y DM376WT TN Interleukin 2 receptor beta (IL2RB) DM376WT MA Agonist DM376WT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM376WT RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3A701 DI DM3A701 DM3A701 DN IDP-122 DM3A701 TI TTP3UTW DM3A701 TN Steroid hormone receptor ERR (ESRR) DM3A701 MA Agonist DM3A701 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3A701 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3BK2Y DI DM3BK2Y DM3BK2Y DN OTL-103 DM3BK2Y TI TTE8T73 DM3BK2Y TN Wiskott-Aldrich syndrome protein (WAS) DM3BK2Y MA Replacement DM3BK2Y RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DM3BK2Y RU https://www.orchard-tx.com/approach/pipeline/ DM3BO8G DI DM3BO8G DM3BO8G DN SUVN-G3031 DM3BO8G TI TT9JNIC DM3BO8G TN Histamine H3 receptor (H3R) DM3BO8G MA Antagonist DM3BO8G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3BO8G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3DG5C DI DM3DG5C DM3DG5C DN THX-TS01 DM3DG5C TI TT94IAG DM3DG5C TN Cannabinoid receptor (CB) DM3DG5C MA Modulator DM3DG5C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3DG5C RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3FIC2 DI DM3FIC2 DM3FIC2 DN ABT-761 DM3FIC2 TI TT2J34L DM3FIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DM3FIC2 MA Inhibitor DM3FIC2 RN Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. DM3FIC2 RU https://pubmed.ncbi.nlm.nih.gov/20190281 DM3FPAQ DI DM3FPAQ DM3FPAQ DN Anifrolumab DM3FPAQ TI TTMQB37 DM3FPAQ TN Interferon alpha/beta receptor 2 (IFNAR2) DM3FPAQ MA Antagonist DM3FPAQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3FPAQ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTISP28 DM3G74J TN Retinoic acid receptor beta (RARB) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTW38KT DM3G74J TN Retinoic acid receptor alpha (RARA) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3GTAL DI DM3GTAL DM3GTAL DN Maribavir DM3GTAL TI TTXQ04B DM3GTAL TN Cytomegalovirus Ganciclovir kinase (CMV UL97) DM3GTAL MA Inhibitor DM3GTAL RN The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14. DM3GTAL RU https://pubmed.ncbi.nlm.nih.gov/12502806 DM3H2U4 DI DM3H2U4 DM3H2U4 DN Patrome DM3H2U4 TI TTN451K DM3H2U4 TN Aromatic-L-amino-acid decarboxylase (DDC) DM3H2U4 MA Modulator DM3H2U4 RN The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72. DM3H2U4 RU https://pubmed.ncbi.nlm.nih.gov/11106255 DM3IWS8 DI DM3IWS8 DM3IWS8 DN Laquinimod DM3IWS8 TI TTSXVID DM3IWS8 TN Nuclear factor NF-kappa-B (NFKB) DM3IWS8 MA Modulator DM3IWS8 RN Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24. DM3IWS8 RU https://pubmed.ncbi.nlm.nih.gov/22766690 DM3L2GT DI DM3L2GT DM3L2GT DN O6-Benzylguanine alkylade DM3L2GT TI TTJ8DV7 DM3L2GT TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DM3L2GT MA Modulator DM3L2GT RN Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. DM3L2GT RU https://pubmed.ncbi.nlm.nih.gov/19204199 DM3MAYQ DI DM3MAYQ DM3MAYQ DN BMS-986205 DM3MAYQ TI TTZJYKH DM3MAYQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM3MAYQ MA Inhibitor DM3MAYQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3MAYQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3MXT8 DI DM3MXT8 DM3MXT8 DN BI 201335 DM3MXT8 TI TT5FNQT DM3MXT8 TN Human immunodeficiency virus Protease (HIV PR) DM3MXT8 MA Inhibitor DM3MXT8 RN 2011 Pipeline of Boehringer Ingelheim Pharma. DM3MXT8 RU http://www.boehringer-ingelheim.com/ DM3OU54 DI DM3OU54 DM3OU54 DN ICI 118,551 DM3OU54 TI TT2CJVK DM3OU54 TN Adrenergic receptor beta-2 (ADRB2) DM3OU54 MA Antagonist DM3OU54 RN Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5. DM3OU54 RU https://pubmed.ncbi.nlm.nih.gov/2907563 DM3PA8H DI DM3PA8H DM3PA8H DN THVD-201 DM3PA8H TI TTOXS3C DM3PA8H TN Muscarinic acetylcholine receptor (CHRM) DM3PA8H MA Agonist DM3PA8H RN Future therapies: Early trials and basic science. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10 Suppl 4): S179-S180. DM3PA8H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919188/ DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TT9HKJA DM3PS2E TN Vascular endothelial growth factor (VEGF) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTGKIED DM3PS2E TN Fibroblast growth factor-2 (FGF2) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTSM78N DM3PS2E TN Platelet-derived growth factor A (PDGFA) DM3PS2E MA Inhibitor DM3PS2E RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PS2E RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM3PSUF DI DM3PSUF DM3PSUF DN MK-3102 DM3PSUF TI TTDIGC1 DM3PSUF TN Dipeptidyl peptidase 4 (DPP-4) DM3PSUF MA Modulator DM3PSUF RN Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. DM3PSUF RU https://pubmed.ncbi.nlm.nih.gov/24660890 DM3QLK2 DI DM3QLK2 DM3QLK2 DN Atamestane + Toremifene DM3QLK2 TI TTSZLWK DM3QLK2 TN Aromatase (CYP19A1) DM3QLK2 MA Modulator DM3QLK2 RN Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. DM3QLK2 RU https://pubmed.ncbi.nlm.nih.gov/17942301 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TT8NGED DM3RWXL TN Prostaglandin G/H synthase 1 (COX-1) DM3RWXL MA Modulator DM3RWXL RN Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37. DM3RWXL RU https://pubmed.ncbi.nlm.nih.gov/15020596 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TTUF2HO DM3RWXL TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM3RWXL MA Inhibitor DM3RWXL RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM3RWXL RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM3UQ9K DI DM3UQ9K DM3UQ9K DN Acolbifene DM3UQ9K TI TTZAYWL DM3UQ9K TN Estrogen receptor (ESR) DM3UQ9K MA Modulator DM3UQ9K RN Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82. DM3UQ9K RU https://pubmed.ncbi.nlm.nih.gov/15720121 DM3WP0N DI DM3WP0N DM3WP0N DN Al3818 DM3WP0N TI TT6PKBN DM3WP0N TN Proto-oncogene c-Src (SRC) DM3WP0N MA Inhibitor DM3WP0N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3WP0N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3YEV0 DI DM3YEV0 DM3YEV0 DN 131I-labelled aCD45 DM3YEV0 TI TTUS45N DM3YEV0 TN Leukocyte common antigen (PTPRC) DM3YEV0 RN 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. DM3YEV0 RU https://pubmed.ncbi.nlm.nih.gov/16254140 DM3YXP8 DI DM3YXP8 DM3YXP8 DN Remacemide DM3YXP8 TI TT9IK2Z DM3YXP8 TN N-methyl-D-aspartate receptor (NMDAR) DM3YXP8 MA Agonist DM3YXP8 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM3YXP8 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM3ZL7D DI DM3ZL7D DM3ZL7D DN Edotecarin DM3ZL7D TI TTGTQHC DM3ZL7D TN DNA topoisomerase I (TOP1) DM3ZL7D MA Inhibitor DM3ZL7D RN Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36. DM3ZL7D RU https://pubmed.ncbi.nlm.nih.gov/15929804 DM407I6 DI DM407I6 DM407I6 DN BAY 853934 DM407I6 TI TTJQFBG DM407I6 TN HIF-prolyl hydroxylase (HPH) DM407I6 MA Inhibitor DM407I6 RN Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003. DM407I6 RU https://pubmed.ncbi.nlm.nih.gov/29485740 DM408GM DI DM408GM DM408GM DN S-474474 DM408GM TI TT8DBY3 DM408GM TN Angiotensin II receptor type-1 (AGTR1) DM408GM MA Blocker DM408GM RN Clinical pipeline report, company report or official report of Shionogi (2011). DM408GM RU http://www.shionogi.co.jp/index_e.html DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TTAWNKZ DM42GP9 TN Norepinephrine transporter (NET) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TT3ROYC DM42GP9 TN Serotonin transporter (SERT) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTRLW2X DM42PFT TN Fibroblast growth factor receptor 1 (FGFR1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTGJVQM DM42PFT TN Fibroblast growth factor receptor 2 (FGFR2) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTUTJGQ DM42PFT TN Vascular endothelial growth factor receptor 2 (KDR) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT8FYO9 DM42PFT TN Platelet-derived growth factor receptor alpha (PDGFRA) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTST7KB DM42PFT TN Fibroblast growth factor receptor 3 (FGFR3) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTDCBX5 DM42PFT TN Vascular endothelial growth factor receptor 3 (FLT-4) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTI7421 DM42PFT TN Platelet-derived growth factor receptor beta (PDGFRB) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT2Q6G1 DM42PFT TN Vascular endothelial growth factor receptor 1 (FLT-1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM45DS8 DI DM45DS8 DM45DS8 DN NKTR-181 DM45DS8 TI TTKWM86 DM45DS8 TN Opioid receptor mu (MOP) DM45DS8 MA Agonist DM45DS8 RN A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418. DM45DS8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411218/ DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTOA6YT DM49IGE TN MERS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTKXI53 DM49IGE TN SARS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTV1095 DM49IGE TN COVID-19 RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TT8JRS7 DM4CGH5 TN Beta-secretase (BACE) DM4CGH5 MA Modulator DM4CGH5 RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DM4CGH5 RU https://pubmed.ncbi.nlm.nih.gov/25621019 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TTJUNZF DM4CGH5 TN Beta-secretase 1 (BACE1) DM4CGH5 MA Inhibitor DM4CGH5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4CGH5 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DM4CSDH DI DM4CSDH DM4CSDH DN CS-8958 DM4CSDH TI TT50QJ3 DM4CSDH TN Influenza Neuraminidase (Influ NA) DM4CSDH MA Inhibitor DM4CSDH RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DM4CSDH RU https://pubmed.ncbi.nlm.nih.gov/19067613 DM4E9PK DI DM4E9PK DM4E9PK DN AM-111 DM4E9PK TI TTR2TXZ DM4E9PK TN Jun N terminal kinase (JNK) DM4E9PK MA Modulator DM4E9PK RN The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985. DM4E9PK RU https://www.ncbi.nlm.nih.gov/pubmed/22427801 DM4EGPN DI DM4EGPN DM4EGPN DN Lanperisone DM4EGPN TI TT84DRB DM4EGPN TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DM4EGPN MA Modulator DM4EGPN RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DM4EGPN RU https://pubmed.ncbi.nlm.nih.gov/16126840 DM4FHQR DI DM4FHQR DM4FHQR DN Canfosfamide DM4FHQR TI TT40K12 DM4FHQR TN Glutathione S-transferase P (GSTP1) DM4FHQR MA Modulator DM4FHQR RN Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78. DM4FHQR RU https://pubmed.ncbi.nlm.nih.gov/24066958 DM4FPM3 DI DM4FPM3 DM4FPM3 DN Amediplase DM4FPM3 TI TTGY7WI DM4FPM3 TN Urokinase-type plasminogen activator (PLAU) DM4FPM3 MA Activator DM4FPM3 RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM4FPM3 RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM4GWL7 DI DM4GWL7 DM4GWL7 DN Gefapixant DM4GWL7 TI TT2THBD DM4GWL7 TN P2X purinoceptor 3 (P2RX3) DM4GWL7 MA Inhibitor DM4GWL7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM4GWL7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM4GXW3 DI DM4GXW3 DM4GXW3 DN Ataluren DM4GXW3 TI TT2TNRM DM4GXW3 TN Dystrophin nonsense mutant (DMD) DM4GXW3 MA Modulator DM4GXW3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341). DM4GXW3 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7341 DM4HK8Z DI DM4HK8Z DM4HK8Z DN ASTX727 DM4HK8Z TI TTHVCUP DM4HK8Z TN DNA [cytosine-5]-methyltransferase (DNMT) DM4HK8Z MA Inhibitor DM4HK8Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4HK8Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4HQ52 DI DM4HQ52 DM4HQ52 DN APL-2 DM4HQ52 TI TTJGY7A DM4HQ52 TN Complement C3 (CO3) DM4HQ52 MA Inhibitor DM4HQ52 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM4HQ52 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM4HYMS DI DM4HYMS DM4HYMS DN ABT-888 DM4HYMS TI TTEBCY8 DM4HYMS TN Poly [ADP-ribose] polymerase (PARP) DM4HYMS MA Modulator DM4HYMS RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4HYMS RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4K9WH DI DM4K9WH DM4K9WH DN R1678 DM4K9WH TI TTHJTF7 DM4K9WH TN Glycine transporter GlyT-1 (SLC6A9) DM4K9WH MA Blocker DM4K9WH RN Clinical pipeline report, company report or official report of Roche (2009). DM4K9WH RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM4N1SP DI DM4N1SP DM4N1SP DN Shigamabs DM4N1SP TI TT1HYOF DM4N1SP TN Bacterial Shiga toxin 2 subunit B (Bact stxII) DM4N1SP MA Modulator DM4N1SP RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DM4N1SP RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DM4NX0C DI DM4NX0C DM4NX0C DN Fevipiprant DM4NX0C TI TTQDMX5 DM4NX0C TN Prostaglandin D2 receptor 2 (PTGDR2) DM4NX0C MA Antagonist DM4NX0C RN Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. DM4NX0C RU https://pubmed.ncbi.nlm.nih.gov/29363343 DM4OAIU DI DM4OAIU DM4OAIU DN LMI070 DM4OAIU TI TT8QL6X DM4OAIU TN Survival motor neuron protein (SMN1) DM4OAIU MA Modulator DM4OAIU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4OAIU RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4OHMP DI DM4OHMP DM4OHMP DN A-3309 DM4OHMP TI TTPI1M5 DM4OHMP TN Ileal sodium/bile acid cotransporter (SLC10A2) DM4OHMP MA Inhibitor DM4OHMP RN Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. DM4OHMP RU https://pubmed.ncbi.nlm.nih.gov/23215781 DM4P5UJ DI DM4P5UJ DM4P5UJ DN VM-501 DM4P5UJ TI TTGUYTR DM4P5UJ TN Interleukin-11 (IL11) DM4P5UJ MA Agonist DM4P5UJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052) DM4P5UJ RU http://adisinsight.springer.com/drugs/800033052 DM4SKYI DI DM4SKYI DM4SKYI DN PAMAQUESIDE DM4SKYI TI TT61VTP DM4SKYI TN Cholesterol uptake (Chole uptake) DM4SKYI MA Modulator DM4SKYI RN Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. J Lipid Res. 1999 Mar;40(3):464-74. DM4SKYI RU https://pubmed.ncbi.nlm.nih.gov/10064735 DM4TOEQ DI DM4TOEQ DM4TOEQ DN Spartalizumab DM4TOEQ TI TTNBFWK DM4TOEQ TN Programmed cell death protein 1 (PD-1) DM4TOEQ RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM4TOEQ RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM4U5NF DI DM4U5NF DM4U5NF DN ISIS-TTR DM4U5NF TI TTPOYU7 DM4U5NF TN Transthyretin messenger RNA (TTR mRNA) DM4U5NF RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DM4U5NF RU http://www.isispharm.com/index.htm DM4VJ5Q DI DM4VJ5Q DM4VJ5Q DN ATG-Fresenius S DM4VJ5Q TI TTXQYT6 DM4VJ5Q TN T-cells (T-cells) DM4VJ5Q RN Clinical pipeline report, company report or official report of Neovii Biotech. DM4VJ5Q RU http://www.neoviibiotech.com/products-and-pipeline/atg-fresenius.html DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT6L509 DM4W8RE TN Coagulation factor IIa (F2) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16460939 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTP86E2 DM4W8RE TN Plasminogen (PLG) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT2WR1T DM4W8RE TN Cationic trypsinogen (PRSS1) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTCIHJA DM4W8RE TN Coagulation factor Xa (F10) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4XBM7 DI DM4XBM7 DM4XBM7 DN DiaPep-277 DM4XBM7 TI TT9HL5R DM4XBM7 TN Mitochondrial matrix protein P1 (HSPD1) DM4XBM7 MA Modulator DM4XBM7 RN Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75. DM4XBM7 RU https://pubmed.ncbi.nlm.nih.gov/17024692 DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TT9ISBX DM4XSQ2 TN HIF-prolyl hydroxylase 2 (HPH-2) DM4XSQ2 MA Inhibitor DM4XSQ2 RN Crystalline forms of a prolyl hydroxylase inhibitor. US9115085. DM4XSQ2 RU http://www.freepatentsonline.com/US9115085.html DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TTMHFRY DM4XSQ2 TN HIF-prolyl hydroxylase 1 (HPH-1) DM4XSQ2 MA Inhibitor DM4XSQ2 RN The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54. DM4XSQ2 RU https://pubmed.ncbi.nlm.nih.gov/18301799 DM4Y1SP DI DM4Y1SP DM4Y1SP DN Carisbamate DM4Y1SP TI TTRK8B9 DM4Y1SP TN Sodium channel unspecific (NaC) DM4Y1SP MA Blocker DM4Y1SP RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DM4Y1SP RU https://pubmed.ncbi.nlm.nih.gov/19008076 DM4Y7WV DI DM4Y7WV DM4Y7WV DN GRASPA DM4Y7WV TI TT4WT91 DM4Y7WV TN Asparaginase (ASRGL1) DM4Y7WV MA Modulator DM4Y7WV RN l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65. DM4Y7WV RU https://pubmed.ncbi.nlm.nih.gov/21332712 DM4YDAJ DI DM4YDAJ DM4YDAJ DN Sildenafil DM4YDAJ TI TTRYFSB DM4YDAJ TN HUMAN phosphodiesterase type 5 (PDE5) DM4YDAJ MA Inhibitor DM4YDAJ RN Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005. DM4YDAJ RU https://pubmed.ncbi.nlm.nih.gov/15650225 DM4YGWA DI DM4YGWA DM4YGWA DN Esonarimod DM4YGWA TI TTGD6BY DM4YGWA TN TNF-alpha/IL-1 beta production (TNFA/IL1B produ) DM4YGWA MA Modulator DM4YGWA RN KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res. 2002;28(5):197-205. DM4YGWA RU https://pubmed.ncbi.nlm.nih.gov/12635495 DM4Z9QI DI DM4Z9QI DM4Z9QI DN Olokizumab DM4Z9QI TI TTT1V78 DM4Z9QI TN Interleukin-6 (IL6) DM4Z9QI MA Modulator DM4Z9QI RN Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615. DM4Z9QI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/ DM50SNX DI DM50SNX DM50SNX DN Bucelipase alfa DM50SNX TI TTTRNQW DM50SNX TN Bile-salt-activated lipase (CEL) DM50SNX MA Modulator DM50SNX RN ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health. DM50SNX RU https://clinicaltrials.gov/ct2/show/NCT00743483 DM51JW4 DI DM51JW4 DM51JW4 DN BIIB037 DM51JW4 TI TTE4KHA DM51JW4 TN Amyloid beta A4 protein (APP) DM51JW4 MA Modulator DM51JW4 RN Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. DM51JW4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/ DM52QEZ DI DM52QEZ DM52QEZ DN Zalutumumab DM52QEZ TI TTGKNB4 DM52QEZ TN Epidermal growth factor receptor (EGFR) DM52QEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM52QEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM53J6B DI DM53J6B DM53J6B DN PDR001 DM53J6B TI TTNBFWK DM53J6B TN Programmed cell death protein 1 (PD-1) DM53J6B MA Antagonist DM53J6B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM53J6B RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM57B9J DI DM57B9J DM57B9J DN Biferonex DM57B9J TI TT4TZ8J DM57B9J TN Interferon-beta (IFNB1) DM57B9J MA Modulator DM57B9J RN Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62. DM57B9J RU https://pubmed.ncbi.nlm.nih.gov/19480465 DM5DAP3 DI DM5DAP3 DM5DAP3 DN PGF2ALPHA-IE DM5DAP3 TI TTT2ZAR DM5DAP3 TN Prostaglandin F2-alpha receptor (PTGFR) DM5DAP3 MA Modulator DM5DAP3 RN Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7. DM5DAP3 RU https://pubmed.ncbi.nlm.nih.gov/7532135 DM5DRMY DI DM5DRMY DM5DRMY DN P1101 DM5DRMY TI TT95SOA DM5DRMY TN Interferon alpha (IFNA) DM5DRMY MA Inhibitor DM5DRMY RN Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94. DM5DRMY RU https://pubmed.ncbi.nlm.nih.gov/25545244 DM5E73H DI DM5E73H DM5E73H DN Revusiran DM5E73H TI TTPOYU7 DM5E73H TN Transthyretin messenger RNA (TTR mRNA) DM5E73H RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DM5E73H RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DM5FZH4 DI DM5FZH4 DM5FZH4 DN ProstaVac DM5FZH4 TI TTS78AZ DM5FZH4 TN Prostate specific antigen (KLK3) DM5FZH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DM5FZH4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTYPXQF DM5H0R9 TN Protein kinase C beta (PRKCB) DM5H0R9 MA Modulator DM5H0R9 RN The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83. DM5H0R9 RU https://pubmed.ncbi.nlm.nih.gov/18452078 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTWTSCV DM5H0R9 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTHBTOP DM5H0R9 TN PI3-kinase gamma (PIK3CG) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5K6J4 DI DM5K6J4 DM5K6J4 DN AJM-300 DM5K6J4 TI TT6S84X DM5K6J4 TN Integrin alpha-4/beta-1 (ITGA4/B1) DM5K6J4 MA Modulator DM5K6J4 RN Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42. DM5K6J4 RU https://pubmed.ncbi.nlm.nih.gov/23623333 DM5KL8E DI DM5KL8E DM5KL8E DN IBI-308 DM5KL8E TI TTNBFWK DM5KL8E TN Programmed cell death protein 1 (PD-1) DM5KL8E RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM5KL8E RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM5L8QT DI DM5L8QT DM5L8QT DN INO-1001 DM5L8QT TI TTEBCY8 DM5L8QT TN Poly [ADP-ribose] polymerase (PARP) DM5L8QT MA Modulator DM5L8QT RN Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12. DM5L8QT RU https://pubmed.ncbi.nlm.nih.gov/20395771 DM5LQHB DI DM5LQHB DM5LQHB DN CCX-168 DM5LQHB TI TTHXFA1 DM5LQHB TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM5LQHB MA Antagonist DM5LQHB RN Clinical pipeline report, company report or official report of ChemoCentryx. DM5LQHB RU http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/ DM5N1OB DI DM5N1OB DM5N1OB DN Asp-2151 DM5N1OB TI TTKCVJR DM5N1OB TN Herpes simplex virus Helicase-primase (HSV UL8) DM5N1OB MA Inhibitor DM5N1OB RN Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4. DM5N1OB RU https://pubmed.ncbi.nlm.nih.gov/22155691 DM5PRLA DI DM5PRLA DM5PRLA DN Fasinumab DM5PRLA TI TTDN3LF DM5PRLA TN Nerve growth factor (NGF) DM5PRLA MA Inhibitor DM5PRLA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5PRLA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5S4DL DI DM5S4DL DM5S4DL DN Forigerimod DM5S4DL TI TTPVYKI DM5S4DL TN Signal transduction unspecific (ST) DM5S4DL MA Modulator DM5S4DL RN Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83. DM5S4DL RU https://pubmed.ncbi.nlm.nih.gov/19035498 DM5S4LX DI DM5S4LX DM5S4LX DN Mirvetuximab soravtansine DM5S4LX TI TTVC37M DM5S4LX TN Folate receptor alpha (FOLR1) DM5S4LX MA Antagonist DM5S4LX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5S4LX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5ST9Z DI DM5ST9Z DM5ST9Z DN Zolbetuximab DM5ST9Z TI TT6PKBX DM5ST9Z TN Claudin-18 (CLDN18) DM5ST9Z RN FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619. DM5ST9Z RU https://pubmed.ncbi.nlm.nih.gov/33610734 DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTHTKNY DM5T4IS TN Serine/threonine PP2A-alpha (PPP2CA) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTLA7IX DM5T4IS TN Protein phosphatase 1A (PPM1A) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5VH6U DI DM5VH6U DM5VH6U DN Serlopitant DM5VH6U TI TTZPO1L DM5VH6U TN Substance-P receptor (TACR1) DM5VH6U MA Antagonist DM5VH6U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5VH6U RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5WCV4 DI DM5WCV4 DM5WCV4 DN JX-594 DM5WCV4 TI TTNYZG2 DM5WCV4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM5WCV4 MA Modulator DM5WCV4 RN Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70. DM5WCV4 RU https://pubmed.ncbi.nlm.nih.gov/16905462 DM5X7DJ DI DM5X7DJ DM5X7DJ DN Chlorpromazine DM5X7DJ TI TTAIY2U DM5X7DJ TN HUMAN clathrin-mediated endocytosis (RME) DM5X7DJ MA Inhibitor DM5X7DJ RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM5X7DJ RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM5X849 DI DM5X849 DM5X849 DN MEDI4736 DM5X849 TI TT8ZLTI DM5X849 TN Programmed cell death 1 ligand 1 (PD-L1) DM5X849 MA Modulator DM5X849 RN National Cancer Institute Drug Dictionary (drug id 740856). DM5X849 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856 DM5XUQL DI DM5XUQL DM5XUQL DN CPI-613 DM5XUQL TI TTH8T6I DM5XUQL TN Alpha-ketoglutarate dehydrogenase (OGDH) DM5XUQL MA Modulator DM5XUQL RN A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. DM5XUQL RU https://pubmed.ncbi.nlm.nih.gov/24612826 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTD16BI DM5Y4Q2 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTZGK1R DM5Y4Q2 TN HUMAN glycosylation of host receptor (GHR) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TT3A1EZ DM5Y4Q2 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DM60TVK DI DM60TVK DM60TVK DN CQA 206-291 DM60TVK TI TTEX248 DM60TVK TN Dopamine D2 receptor (D2R) DM60TVK MA Agonist DM60TVK RN The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9. DM60TVK RU https://pubmed.ncbi.nlm.nih.gov/2565766 DM624TW DI DM624TW DM624TW DN Omecamtiv mecarbil DM624TW TI TT9WOBN DM624TW TN Cardiac myosin (MYBPC3) DM624TW MA Modulator DM624TW RN CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009 Apr;12(4):243-51. DM624TW RU https://pubmed.ncbi.nlm.nih.gov/19350469 DM62E7C DI DM62E7C DM62E7C DN CPL-7075 DM62E7C TI TTF8CQI DM62E7C TN Tumor necrosis factor (TNF) DM62E7C MA Inhibitor DM62E7C RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM62E7C RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM62QTW DI DM62QTW DM62QTW DN RTB101 DM62QTW TI TT4GO0F DM62QTW TN CREB-regulated transcription coactivator 1 (TORC1) DM62QTW MA Inhibitor DM62QTW RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM62QTW RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM64QG9 DI DM64QG9 DM64QG9 DN Diquafosol DM64QG9 TI TTOZHQC DM64QG9 TN P2Y purinoceptor 2 (P2RY2) DM64QG9 MA Agonist DM64QG9 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM64QG9 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM64WYC DI DM64WYC DM64WYC DN Atx-101 DM64WYC TI TTLG1PD DM64WYC TN Proliferating cell nuclear antigen (PCNA) DM64WYC MA Immunomodulator DM64WYC RN Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430. DM64WYC RU https://pubmed.ncbi.nlm.nih.gov/23936203 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTZMAO3 DM67P0F TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTJ584C DM67P0F TN Peroxisome proliferator-activated receptor alpha (PPARA) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM6BU57 DI DM6BU57 DM6BU57 DN Eraxis/Vfend DM6BU57 TI TTZMS1L DM6BU57 TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DM6BU57 MA Inhibitor DM6BU57 RN Pfizer. Product Development Pipeline. March 31 2009. DM6BU57 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TTPLTSQ DM6BZCV TN Neutrophil elastase (NE) DM6BZCV MA Inhibitor DM6BZCV RN Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19169649 DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TT3NKIB DM6BZCV TN Pancreatic elastase 1 (CELA1) DM6BZCV MA Inhibitor DM6BZCV RN Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19487982 DM6CHNJ DI DM6CHNJ DM6CHNJ DN Camptothecin DM6CHNJ TI TTGTQHC DM6CHNJ TN DNA topoisomerase I (TOP1) DM6CHNJ MA Modulator DM6CHNJ RN Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. DM6CHNJ RU https://pubmed.ncbi.nlm.nih.gov/16990856 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TTMPZ7V DM6ENSJ TN Interleukin 13 receptor alpha-2 (IL13RA2) DM6ENSJ MA Modulator DM6ENSJ RN Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94. DM6ENSJ RU https://www.ncbi.nlm.nih.gov/pubmed/24325475 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TT0GVCH DM6ENSJ TN Interleukin-13 (IL13) DM6ENSJ MA Inhibitor DM6ENSJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6ENSJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTWDC17 DM6HXTS TN Growth hormone secretagogue receptor 1 (GHSR) DM6HXTS MA Stimulator DM6HXTS RN Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73. DM6HXTS RU https://pubmed.ncbi.nlm.nih.gov/19196529 DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTHCF4J DM6HXTS TN Alpha-glucosidase (GLA) DM6HXTS MA Modulator DM6HXTS RN Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87. DM6HXTS RU https://www.ncbi.nlm.nih.gov/pubmed/23378626 DM6KRLW DI DM6KRLW DM6KRLW DN BQ788 DM6KRLW TI TT3ZTGU DM6KRLW TN Endothelin B receptor (EDNRB) DM6KRLW MA Antagonist DM6KRLW RN BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71. DM6KRLW RU https://pubmed.ncbi.nlm.nih.gov/10340767 DM6L4ZT DI DM6L4ZT DM6L4ZT DN SB-742457 DM6L4ZT TI TTJS8PY DM6L4ZT TN 5-HT 6 receptor (HTR6) DM6L4ZT MA Antagonist DM6L4ZT RN 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. DM6L4ZT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/ DM6L5ZQ DI DM6L5ZQ DM6L5ZQ DN Vercirnon DM6L5ZQ TI TTIPS8B DM6L5ZQ TN C-C chemokine receptor type 9 (CCR9) DM6L5ZQ MA Modulator DM6L5ZQ RN GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81. DM6L5ZQ RU https://pubmed.ncbi.nlm.nih.gov/20582872 DM6LVCQ DI DM6LVCQ DM6LVCQ DN LY-CoV555 DM6LVCQ TI TTZ3COY DM6LVCQ TN COVID-19 spike glycoprotein (S) DM6LVCQ MA Inhibitor DM6LVCQ RN Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189. DM6LVCQ RU https://pubmed.ncbi.nlm.nih.gov/33378611 DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TTNGILX DM6P8HU TN Adrenergic receptor alpha-1A (ADRA1A) DM6P8HU MA Antagonist DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TT2A0DR DM6P8HU TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM6P8HU MA Inhibitor DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6PMNR DI DM6PMNR DM6PMNR DN Ulocuplumab DM6PMNR TI TTBID49 DM6PMNR TN C-X-C chemokine receptor type 4 (CXCR4) DM6PMNR MA Antagonist DM6PMNR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6PMNR RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTUTJGQ DM6QOVN TN Vascular endothelial growth factor receptor 2 (KDR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTR5TV4 DM6QOVN TN ERBB2 messenger RNA (HER2 mRNA) DM6QOVN MA Inhibitor DM6QOVN RN Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/18077425 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTGKNB4 DM6QOVN TN Epidermal growth factor receptor (EGFR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TT6EO5L DM6QOVN TN Erbb2 tyrosine kinase receptor (HER2) DM6QOVN MA Inhibitor DM6QOVN RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM6QZIA DI DM6QZIA DM6QZIA DN Solithromycin DM6QZIA TI TTUWYEA DM6QZIA TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM6QZIA MA Modulator DM6QZIA RN Company report (cempra) DM6QZIA RU http://www.cempra.com/products/Solithromycin-cem-101/ DM6R2XF DI DM6R2XF DM6R2XF DN FKB238 DM6R2XF TI TT9HKJA DM6R2XF TN Vascular endothelial growth factor (VEGF) DM6R2XF MA Inhibitor DM6R2XF RN Clinical pipeline report, company report or official report of Fujifilm. DM6R2XF RU https://fujifilmkyowakirin-biologics.com/en/pipeline/ DM6RUKX DI DM6RUKX DM6RUKX DN BVT.2733 DM6RUKX TI TTN7BL9 DM6RUKX TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM6RUKX MA Inhibitor DM6RUKX RN Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62. DM6RUKX RU https://pubmed.ncbi.nlm.nih.gov/12960099 DM6RWBN DI DM6RWBN DM6RWBN DN Beperminogene perplasmid DM6RWBN TI TTNDSF4 DM6RWBN TN Proto-oncogene c-Met (MET) DM6RWBN MA Modulator DM6RWBN RN Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56. DM6RWBN RU https://pubmed.ncbi.nlm.nih.gov/25190335 DM6S4R2 DI DM6S4R2 DM6S4R2 DN DA-3031 DM6S4R2 TI TT5TQ2W DM6S4R2 TN Granulocyte colony-stimulating factor (CSF3) DM6S4R2 MA Modulator DM6S4R2 RN A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6. DM6S4R2 RU https://www.ncbi.nlm.nih.gov/pubmed/23677653 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMTWOS DM6V34C TN Matrix metalloproteinase-7 (MMP-7) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMX39J DM6V34C TN Matrix metalloproteinase-1 (MMP-1) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTLM12X DM6V34C TN Matrix metalloproteinase-2 (MMP-2) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6WZG8 DI DM6WZG8 DM6WZG8 DN AXS-05 DM6WZG8 TI TT9IK2Z DM6WZG8 TN N-methyl-D-aspartate receptor (NMDAR) DM6WZG8 MA Antagonist DM6WZG8 RN Clinical pipeline report, company report or official report of Axsome Therapeutics. DM6WZG8 RU https://axsome.com/axs-pipeline/about-axs-05/ DM71CK8 DI DM71CK8 DM71CK8 DN Beloranib DM71CK8 TI TTZL0OI DM71CK8 TN Methionine aminopeptidase 2 (METAP2) DM71CK8 MA Inhibitor DM71CK8 RN 2011 Pipeline of Zafgen. DM71CK8 RU http://www.zafgen.com/approach-pipeline.html DM71GPM DI DM71GPM DM71GPM DN Grippol Plus DM71GPM TI TT3J5ZI DM71GPM TN Cell mediated immunity response (CMIR) DM71GPM RN Clinical pipeline report, company report or official report of Petrovax. DM71GPM RU http://petrovax.com/medication/catalog/grippallplus/ DM71ZL6 DI DM71ZL6 DM71ZL6 DN TZTX-001 DM71ZL6 TI TTZAYWL DM71ZL6 TN Estrogen receptor (ESR) DM71ZL6 MA Modulator DM71ZL6 RN Clinical pipeline report, company report or official report of Pharmabiz. DM71ZL6 RU http://www.pharmabiz.com/PrintArticle.aspx?aid=77569&sid=2 DM735FA DI DM735FA DM735FA DN IMO-2125 DM735FA TI TTSHG0T DM735FA TN Toll-like receptor 9 (TLR9) DM735FA MA Agonist DM735FA RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DM735FA RU http://www.iderapharma.com/ DM76GZ0 DI DM76GZ0 DM76GZ0 DN Angiotensin-(1-7) DM76GZ0 TI TTOISYB DM76GZ0 TN Proto-oncogene Mas (MAS) DM76GZ0 MA Agonist DM76GZ0 RN New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. DM76GZ0 RU https://pubmed.ncbi.nlm.nih.gov/23166114 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTZMAO3 DM7BCWT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTJ584C DM7BCWT TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BSRH DI DM7BSRH DM7BSRH DN Tramiprosate DM7BSRH TI TTE4KHA DM7BSRH TN Amyloid beta A4 protein (APP) DM7BSRH MA Antagonist DM7BSRH RN Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. DM7BSRH RU https://pubmed.ncbi.nlm.nih.gov/16675063 DM7EBH9 DI DM7EBH9 DM7EBH9 DN ALX-0081 DM7EBH9 TI TT3SZBT DM7EBH9 TN von Willebrand factor (VWF) DM7EBH9 MA Binder DM7EBH9 RN Clinical pipeline report, company report or official report of Ablynx DM7EBH9 RU http://hugin.info/137912/R/1338761/319541.pdf DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTKWFB8 DM7EOBQ TN Catechol-O-methyl-transferase (COMT) DM7EOBQ MA Inhibitor DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTEX248 DM7EOBQ TN Dopamine D2 receptor (D2R) DM7EOBQ MA Agonist DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EVUF DI DM7EVUF DM7EVUF DN ABL001 DM7EVUF TI TTS7G69 DM7EVUF TN Fusion protein Bcr-Abl (Bcr-Abl) DM7EVUF MA Inhibitor DM7EVUF RN Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. DM7EVUF RU https://pubmed.ncbi.nlm.nih.gov/31826340 DM7F2VG DI DM7F2VG DM7F2VG DN SA-237 DM7F2VG TI TT0E5SK DM7F2VG TN Interleukin 6 receptor (IL6R) DM7F2VG MA Antagonist DM7F2VG RN IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. DM7F2VG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893229/ DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TT07C3Y DM7HQNX TN 5-HT 4 receptor (HTR4) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TTNXLKE DM7HQNX TN 5-HT 3 receptor (5HT3R) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT3SZBT DM7JFDO TN von Willebrand factor (VWF) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT1290U DM7JFDO TN Coagulation factor VIII (F8) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7KI4E DI DM7KI4E DM7KI4E DN Oblimersen DM7KI4E TI TTJGNVC DM7KI4E TN Apoptosis regulator Bcl-2 (BCL-2) DM7KI4E MA Inhibitor DM7KI4E RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM7KI4E RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM7NJYC DI DM7NJYC DM7NJYC DN BGB-A317 DM7NJYC TI TTNBFWK DM7NJYC TN Programmed cell death protein 1 (PD-1) DM7NJYC MA Inhibitor DM7NJYC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7NJYC RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7NV1I DI DM7NV1I DM7NV1I DN SPD-465 DM7NV1I TI TTIU98M DM7NV1I TN Trace amine-associated receptor-1 (TAAR1) DM7NV1I MA Agonist DM7NV1I RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DM7NV1I RU https://pubmed.ncbi.nlm.nih.gov/24950453 DM7OSHC DI DM7OSHC DM7OSHC DN Pinaverium bromide DM7OSHC TI TTXHYV6 DM7OSHC TN Voltage-gated L-type calcium channel (L-CaC) DM7OSHC MA Blocker DM7OSHC RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM7OSHC RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM7QI29 DI DM7QI29 DM7QI29 DN Crenezumab DM7QI29 TI TTE4KHA DM7QI29 TN Amyloid beta A4 protein (APP) DM7QI29 MA Modulator DM7QI29 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7QI29 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM7R145 DI DM7R145 DM7R145 DN Otesaconazole DM7R145 TI TTTSOUD DM7R145 TN Candida Cytochrome P450 51 (Candi ERG11) DM7R145 MA Inhibitor DM7R145 RN Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73. DM7R145 RU https://pubmed.ncbi.nlm.nih.gov/26124165 DM7R3N5 DI DM7R3N5 DM7R3N5 DN Mirikizumab DM7R3N5 TI TTRTK6Y DM7R3N5 TN Interleukin-12 alpha (IL12A) DM7R3N5 MA Inhibitor DM7R3N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7R3N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7V9LH DI DM7V9LH DM7V9LH DN Blisibimod DM7V9LH TI TTWMIDN DM7V9LH TN B-cell-activating factor (TNFSF13B) DM7V9LH MA Inhibitor DM7V9LH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7V9LH RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM7WORZ DI DM7WORZ DM7WORZ DN LY-686017 DM7WORZ TI TTZPO1L DM7WORZ TN Substance-P receptor (TACR1) DM7WORZ MA Antagonist DM7WORZ RN Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498. DM7WORZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804869/ DM7WYXJ DI DM7WYXJ DM7WYXJ DN P-1101 DM7WYXJ TI TTSIUJ9 DM7WYXJ TN Interferon-alpha 2 (IFNA2) DM7WYXJ MA Modulator DM7WYXJ RN Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8. DM7WYXJ RU https://pubmed.ncbi.nlm.nih.gov/20486736 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TT9B4N3 DM7YNV9 TN Prostaglandin receptor (PTGR) DM7YNV9 MA Modulator DM7YNV9 RN Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. DM7YNV9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/ DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTV8DM2 DM7YNV9 TN Bacterial Dihydrofolate reductase (Bact DHFR) DM7YNV9 MA Modulator DM7YNV9 RN Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44. DM7YNV9 RU https://www.ncbi.nlm.nih.gov/pubmed/19257839 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTYZVDJ DM7YNV9 TN Dihydrofolate reductase (DHFR) DM7YNV9 MA Inhibitor DM7YNV9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7YNV9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTJQOD7 DM7ZFBA TN 5-HT 2A receptor (HTR2A) DM7ZFBA MA Antagonist DM7ZFBA RN Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/11259563 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTQ6VDM DM7ZFBA TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTWJBZ5 DM7ZFBA TN 5-HT 2C receptor (HTR2C) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TT2JWF6 DM7ZOAE TN Peroxisome proliferator-activated receptor delta (PPARD) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TTJ584C DM7ZOAE TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTGA1IV DM803GL TN Matrix metalloproteinase-8 (MMP-8) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTMX39J DM803GL TN Matrix metalloproteinase-1 (MMP-1) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM823WQ DI DM823WQ DM823WQ DN FP-1201 DM823WQ TI TT4TZ8J DM823WQ TN Interferon-beta (IFNB1) DM823WQ MA Modulator DM823WQ RN The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107. DM823WQ RU https://www.ncbi.nlm.nih.gov/pubmed/24503265 DM83EBP DI DM83EBP DM83EBP DN Alisporivir DM83EBP TI TTATDGJ DM83EBP TN Calcium signal-modulating cyclophilin ligand (CAML) DM83EBP MA Inhibitor DM83EBP RN DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687. DM83EBP RU https://pubmed.ncbi.nlm.nih.gov/21060866 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTOHSBA DM83SEB TN Vascular endothelial growth factor A (VEGFA) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTKLQTJ DM83SEB TN Angiopoietin-2 (ANGPT2) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM84AD1 DI DM84AD1 DM84AD1 DN Arofylline DM84AD1 TI TTV5CGO DM84AD1 TN Phosphodiesterase 4 (PDE4) DM84AD1 MA Inhibitor DM84AD1 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM84AD1 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM84LO5 DI DM84LO5 DM84LO5 DN MK-8109 DM84LO5 TI TTVC37M DM84LO5 TN Folate receptor alpha (FOLR1) DM84LO5 MA Modulator DM84LO5 RN A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996. DM84LO5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560517/ DM8D13S DI DM8D13S DM8D13S DN MABp1 DM8D13S TI TTPM6HI DM8D13S TN Interleukin-1 alpha (IL1A) DM8D13S MA Inhibitor DM8D13S RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8D13S RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8E51L DI DM8E51L DM8E51L DN FASORACETAM DM8E51L TI TTAN6JD DM8E51L TN Glutamate receptor AMPA (GRIA) DM8E51L MA Modulator DM8E51L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM8E51L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM8FSPV DI DM8FSPV DM8FSPV DN JTZ-951 DM8FSPV TI TTJQFBG DM8FSPV TN HIF-prolyl hydroxylase (HPH) DM8FSPV MA Modulator DM8FSPV RN DOI: 10.1038/nrneph.2015.82 DM8FSPV RU http://www.nature.com/nrneph/journal/v11/n7/fig_tab/nrneph.2015.82_T1.html DM8GFEV DI DM8GFEV DM8GFEV DN Atacicept DM8GFEV TI TTOI1RM DM8GFEV TN A proliferation-inducing ligand (APRIL) DM8GFEV MA Modulator DM8GFEV RN Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72. DM8GFEV RU https://pubmed.ncbi.nlm.nih.gov/19779889 DM8HCFD DI DM8HCFD DM8HCFD DN Sarilumab DM8HCFD TI TTDVAKP DM8HCFD TN HUMAN interleukin-6 receptor (IL6R) DM8HCFD MA Blocker DM8HCFD RN IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. DM8HCFD RU https://pubmed.ncbi.nlm.nih.gov/25898198 DM8HVNR DI DM8HVNR DM8HVNR DN Recombinant acidic fibroblast growth factor DM8HVNR TI TT5HU6Z DM8HVNR TN Fibroblast growth factor (FGF) DM8HVNR MA Modulator DM8HVNR RN Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79. DM8HVNR RU https://pubmed.ncbi.nlm.nih.gov/1700280 DM8J29L DI DM8J29L DM8J29L DN PF-04965842 DM8J29L TI TTJSQEF DM8J29L TN Tyrosine-protein kinase (PTK) DM8J29L MA Inhibitor DM8J29L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8J29L RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TT6R7JZ DM8JWNA TN Histone deacetylase 1 (HDAC1) DM8JWNA MA Inhibitor DM8JWNA RN NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/12816865 DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TTBH0VX DM8JWNA TN Histone deacetylase (HDAC) DM8JWNA MA Inhibitor DM8JWNA RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM8K5Z6 DI DM8K5Z6 DM8K5Z6 DN Motexafin lutetium DM8K5Z6 TI TTS78AZ DM8K5Z6 TN Prostate specific antigen (KLK3) DM8K5Z6 MA Modulator DM8K5Z6 RN Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76. DM8K5Z6 RU https://pubmed.ncbi.nlm.nih.gov/18676760 DM8L3JU DI DM8L3JU DM8L3JU DN Fosclin DM8L3JU TI TTLH4J3 DM8L3JU TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM8L3JU MA Inhibitor DM8L3JU RN Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8. DM8L3JU RU https://pubmed.ncbi.nlm.nih.gov/14976608 DM8L7JD DI DM8L7JD DM8L7JD DN Zoniporide hydrochloride DM8L7JD TI TTGSEFH DM8L7JD TN Sodium/hydrogen exchanger 1 (SLC9A1) DM8L7JD MA Inhibitor DM8L7JD RN Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. DM8L7JD RU https://pubmed.ncbi.nlm.nih.gov/12595915 DM8M2N3 DI DM8M2N3 DM8M2N3 DN Glycyrrhizin DM8M2N3 TI TTN7BL9 DM8M2N3 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM8M2N3 MA Inhibitor DM8M2N3 RN Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32. DM8M2N3 RU https://pubmed.ncbi.nlm.nih.gov/19574056 DM8QIRN DI DM8QIRN DM8QIRN DN AMT-011 DM8QIRN TI TTOF3WZ DM8QIRN TN Lipoprotein lipase (LPL) DM8QIRN MA Modulator DM8QIRN RN Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70. DM8QIRN RU https://pubmed.ncbi.nlm.nih.gov/23527320 DM8RBHJ DI DM8RBHJ DM8RBHJ DN Esomeprazole magnesium + Aspirin DM8RBHJ TI TTF1QVM DM8RBHJ TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM8RBHJ MA Inhibitor DM8RBHJ RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM8RBHJ RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM8RLJ5 DI DM8RLJ5 DM8RLJ5 DN RAD-1901 DM8RLJ5 TI TTZAYWL DM8RLJ5 TN Estrogen receptor (ESR) DM8RLJ5 MA Modulator DM8RLJ5 RN RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56. DM8RLJ5 RU https://pubmed.ncbi.nlm.nih.gov/26164151 DM8SYTE DI DM8SYTE DM8SYTE DN AIR-insulin DM8SYTE TI TTF89GD DM8SYTE TN Interleukin-2 (IL2) DM8SYTE MA Modulator DM8SYTE RN The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7. DM8SYTE RU https://pubmed.ncbi.nlm.nih.gov/17563303 DM8VO16 DI DM8VO16 DM8VO16 DN KH-902 DM8VO16 TI TTVJ1D8 DM8VO16 TN Vascular endothelial growth factor receptor (VEGFR) DM8VO16 MA Modulator DM8VO16 RN Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. DM8VO16 RU https://pubmed.ncbi.nlm.nih.gov/22340191 DM8Y12A DI DM8Y12A DM8Y12A DN PH-80 DM8Y12A TI TTOASGR DM8Y12A TN Neuroepithelial receptor (NR) DM8Y12A MA Modulator DM8Y12A RN Patents by Assignee Pherin Corporation. DM8Y12A RU http://patents.justia.com/assignee/pherin-corporation DM8Y4JS DI DM8Y4JS DM8Y4JS DN AC220 DM8Y4JS TI TTGJCWZ DM8Y4JS TN Fms-like tyrosine kinase 3 (FLT-3) DM8Y4JS MA Inhibitor DM8Y4JS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8Y4JS RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8Z0I3 DI DM8Z0I3 DM8Z0I3 DN MF-101 DM8Z0I3 TI TTOM3J0 DM8Z0I3 TN Estrogen receptor beta (ESR2) DM8Z0I3 MA Antagonist DM8Z0I3 RN MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. DM8Z0I3 RU https://pubmed.ncbi.nlm.nih.gov/19182698 DM90AG2 DI DM90AG2 DM90AG2 DN Ularitide DM90AG2 TI TTJME02 DM90AG2 TN Atrial natriuretic peptide receptor A (NPR1) DM90AG2 MA Modulator DM90AG2 RN Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23. DM90AG2 RU https://pubmed.ncbi.nlm.nih.gov/25670819 DM91LGU DI DM91LGU DM91LGU DN Abexinostat DM91LGU TI TTBH0VX DM91LGU TN Histone deacetylase (HDAC) DM91LGU MA Modulator DM91LGU RN Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31. DM91LGU RU https://pubmed.ncbi.nlm.nih.gov/25600050 DM936V7 DI DM936V7 DM936V7 DN GS-9674 DM936V7 TI TTS4UGC DM936V7 TN Farnesoid X-activated receptor (FXR) DM936V7 MA Agonist DM936V7 RN The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. DM936V7 RU https://pubmed.ncbi.nlm.nih.gov/30661255 DM942HP DI DM942HP DM942HP DN Brivanib DM942HP TI TTUTJGQ DM942HP TN Vascular endothelial growth factor receptor 2 (KDR) DM942HP MA Modulator DM942HP RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM942HP RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM94Y6O DI DM94Y6O DM94Y6O DN BMN-701 DM94Y6O TI TTLPC70 DM94Y6O TN Lysosomal alpha-glucosidase (GAA) DM94Y6O MA Modulator DM94Y6O RN Clinical pipeline report, company report or official report of BioMarin Pharma. DM94Y6O RU https://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php DM95IPS DI DM95IPS DM95IPS DN Tivanisiran DM95IPS TI TT50OG3 DM95IPS TN TRPV1 messenger RNA (TRPV1 mRNA) DM95IPS MA Inhibitor DM95IPS RN Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. DM95IPS RU https://pubmed.ncbi.nlm.nih.gov/29569947 DM97S10 DI DM97S10 DM97S10 DN DP-b99 DM97S10 TI TT6X50U DM97S10 TN Matrix metalloproteinase-9 (MMP-9) DM97S10 MA Inhibitor DM97S10 RN DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. DM97S10 RU https://pubmed.ncbi.nlm.nih.gov/24918931 DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTOHSBA DM9CEI5 TN Vascular endothelial growth factor A (VEGFA) DM9CEI5 MA Inhibitor DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TT6EO5L DM9CEI5 TN Erbb2 tyrosine kinase receptor (HER2) DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTS4UGC DM9CEI5 TN Farnesoid X-activated receptor (FXR) DM9CEI5 MA Antagonist DM9CEI5 RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DM9CEI5 RU https://pubmed.ncbi.nlm.nih.gov/12052824 DM9CMI3 DI DM9CMI3 DM9CMI3 DN H5N1 influenza vaccine DM9CMI3 TI TT3J5ZI DM9CMI3 TN Cell mediated immunity response (CMIR) DM9CMI3 RN Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008. DM9CMI3 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2008.00066.x/full DM9DEYL DI DM9DEYL DM9DEYL DN SD-6010 DM9DEYL TI TTF10I9 DM9DEYL TN Nitric-oxide synthase inducible (NOS2) DM9DEYL MA Inhibitor DM9DEYL RN A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. DM9DEYL RU https://pubmed.ncbi.nlm.nih.gov/23144445 DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTUE541 DM9EXGI TN Leukocyte surface antigen Leu-16 (CD20) DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTOHSBA DM9EXGI TN Vascular endothelial growth factor A (VEGFA) DM9EXGI MA Inhibitor DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EZM0 DI DM9EZM0 DM9EZM0 DN LNP023 DM9EZM0 TI TTA0P7K DM9EZM0 TN Complement factor B (CFB) DM9EZM0 MA Inhibitor DM9EZM0 RN Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. DM9EZM0 RU https://pubmed.ncbi.nlm.nih.gov/32073845 DM9FAJM DI DM9FAJM DM9FAJM DN D-5519 DM9FAJM TI TTPNQAC DM9FAJM TN Estrogen-related receptor-alpha (ESRRA) DM9FAJM MA Modulator DM9FAJM RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199) DM9FAJM RU http://adisinsight.springer.com/drugs/800007199 DM9G5XD DI DM9G5XD DM9G5XD DN IB-MECA DM9G5XD TI TTJFY5U DM9G5XD TN Adenosine A3 receptor (ADORA3) DM9G5XD MA Agonist DM9G5XD RN A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60. DM9G5XD RU https://pubmed.ncbi.nlm.nih.gov/8262217 DM9GSVQ DI DM9GSVQ DM9GSVQ DN Tasquinimod DM9GSVQ TI TT0TMQG DM9GSVQ TN Calgranulin B (S100A9) DM9GSVQ MA Modulator DM9GSVQ RN Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014; 73(1): 1-8. DM9GSVQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889691/ DM9HUYP DI DM9HUYP DM9HUYP DN ZANOTERONE DM9HUYP TI TTS64P2 DM9HUYP TN Androgen receptor (AR) DM9HUYP MA Inhibitor DM9HUYP RN Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70. DM9HUYP RU https://pubmed.ncbi.nlm.nih.gov/1588549 DM9J0KD DI DM9J0KD DM9J0KD DN K-103-IP DM9J0KD TI TTK0943 DM9J0KD TN Prostaglandin G/H synthase (COX) DM9J0KD MA Modulator DM9J0KD RN ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health. DM9J0KD RU https://clinicaltrials.gov/ct2/show/NCT02089425 DM9J5Q4 DI DM9J5Q4 DM9J5Q4 DN VAL-083 DM9J5Q4 TI TTUTN1I DM9J5Q4 TN Human Deoxyribonucleic acid (hDNA) DM9J5Q4 MA Modulator DM9J5Q4 RN Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3. DM9J5Q4 RU https://pubmed.ncbi.nlm.nih.gov/6487788 DM9K3LM DI DM9K3LM DM9K3LM DN MPDL-3280A DM9K3LM TI TT8ZLTI DM9K3LM TN Programmed cell death 1 ligand 1 (PD-L1) DM9K3LM MA Modulator DM9K3LM RN Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47. DM9K3LM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014795/ DM9L1AC DI DM9L1AC DM9L1AC DN SYR-472 DM9L1AC TI TTDIGC1 DM9L1AC TN Dipeptidyl peptidase 4 (DPP-4) DM9L1AC MA Inhibitor DM9L1AC RN SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. DM9L1AC RU https://pubmed.ncbi.nlm.nih.gov/24622716 DM9LH10 DI DM9LH10 DM9LH10 DN Vadastuximab talirine DM9LH10 TI TTJVYO3 DM9LH10 TN Myeloid cell surface antigen CD33 (CD33) DM9LH10 MA Antagonist DM9LH10 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LH10 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TT4C8EA DM9PVHX TN Dopamine D3 receptor (D3R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTGP7BY DM9PVHX TN Monoamine oxidase type B (MAO-B) DM9PVHX MA Inhibitor DM9PVHX RN Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/17296539 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTEX248 DM9PVHX TN Dopamine D2 receptor (D2R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9QPOU DI DM9QPOU DM9QPOU DN Epoetin zeta DM9QPOU TI TTAUX24 DM9QPOU TN Erythropoietin Receptor (EPOR) DM9QPOU MA Modulator DM9QPOU RN Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28. DM9QPOU RU https://pubmed.ncbi.nlm.nih.gov/18931828 DM9R2SD DI DM9R2SD DM9R2SD DN Alilusem DM9R2SD TI TTYJL7K DM9R2SD TN Sodium/potassium transport (Na/K trans) DM9R2SD MA Modulator DM9R2SD RN US patent application no. 8,067,031, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use. DM9R2SD RU http://www.google.lv/patents/US8067031 DM9R5J6 DI DM9R5J6 DM9R5J6 DN Tezepelumab DM9R5J6 TI TTHMW3T DM9R5J6 TN Thymic stromal lymphopoietin (TSLP) DM9R5J6 RN Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. DM9R5J6 RU https://pubmed.ncbi.nlm.nih.gov/28877011 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTAZ05C DM9SKW8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DM9SKW8 MA Modulator DM9SKW8 RN The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. DM9SKW8 RU https://pubmed.ncbi.nlm.nih.gov/25075128 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTWTSCV DM9SKW8 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM9SKW8 MA Inhibitor DM9SKW8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SKW8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9T8OF DI DM9T8OF DM9T8OF DN RQ-00000004 DM9T8OF TI TTLOKXP DM9T8OF TN Gastric H(+)/K(+) ATPase (Proton pump) DM9T8OF MA Modulator DM9T8OF RN N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9. DM9T8OF RU https://pubmed.ncbi.nlm.nih.gov/18981288 DM9Y3B5 DI DM9Y3B5 DM9Y3B5 DN CMX-001 DM9Y3B5 TI TTATL6Y DM9Y3B5 TN DNA-dependent DNA polymerase (DPOL) DM9Y3B5 MA Inhibitor DM9Y3B5 RN Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797. DM9Y3B5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274371/ DM9Y3EG DI DM9Y3EG DM9Y3EG DN Guadecitabine DM9Y3EG TI TT6S2FE DM9Y3EG TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9Y3EG MA Inhibitor DM9Y3EG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Y3EG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9YI2C DI DM9YI2C DM9YI2C DN ErepoXen DM9YI2C TI TTAUX24 DM9YI2C TN Erythropoietin Receptor (EPOR) DM9YI2C MA Agonist DM9YI2C RN Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83. DM9YI2C RU https://pubmed.ncbi.nlm.nih.gov/16885048 DM9Z4N5 DI DM9Z4N5 DM9Z4N5 DN RA101495 DM9Z4N5 TI TTKANGO DM9Z4N5 TN Complement C5 (CO5) DM9Z4N5 MA Inhibitor DM9Z4N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Z4N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA0WEK DI DMA0WEK DMA0WEK DN Coprexa DMA0WEK TI TT6RVLG DMA0WEK TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMA0WEK MA Inhibitor DMA0WEK RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMA0WEK RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMA16IL DI DMA16IL DMA16IL DN NU-100 DMA16IL TI TT4TZ8J DMA16IL TN Interferon-beta (IFNB1) DMA16IL MA Modulator DMA16IL RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DMA16IL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DMA25NO DI DMA25NO DMA25NO DN MK-4214 DMA25NO TI TT5TQ2W DMA25NO TN Granulocyte colony-stimulating factor (CSF3) DMA25NO MA Modulator DMA25NO RN DOI: 10.1038/nbt0710-636a DMA25NO RU http://www.nature.com/nbt/journal/v28/n7/full/nbt0710-636a.html DMA2NYS DI DMA2NYS DMA2NYS DN Lampalizumab DMA2NYS TI TT8D13I DMA2NYS TN Complement factor D (CFD) DMA2NYS MA Inhibitor DMA2NYS RN In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95. DMA2NYS RU https://pubmed.ncbi.nlm.nih.gov/30444371 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTOHSBA DMA86FL TN Vascular endothelial growth factor A (VEGFA) DMA86FL MA Inhibitor DMA86FL RN Clinical pipeline report, company report or official report of Genentech (2009). DMA86FL RU http://www.gene.com/gene/pipeline/status/ DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT3PQ2Y DMA86FL TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMA86FL MA Inhibitor DMA86FL RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTG8HIM DMA86FL TN Dual specificity protein phosphatase 1 (DUSP1) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT2J34L DMA86FL TN Arachidonate 5-lipoxygenase (5-LOX) DMA86FL MA Inhibitor DMA86FL RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTR0SWN DMA86FL TN M-phase inducer phosphatase 2 (MPIP2) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTZJYKH DMA86FL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMA86FL MA Inhibitor DMA86FL RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTJNTSI DMA86FL TN Rotamase Pin1 (PIN1) DMA86FL MA Inhibitor DMA86FL RN Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/27258148 DMACVEI DI DMACVEI DMACVEI DN SPI-2012 DMACVEI TI TT5TQ2W DMACVEI TN Granulocyte colony-stimulating factor (CSF3) DMACVEI MA Modulator DMACVEI RN Company report (Sppirx) DMACVEI RU http://www.sppirx.com/338-spectrum-products-development-spi2012.html DMACYW6 DI DMACYW6 DMACYW6 DN NKTR-214 DMACYW6 TI TT9721Y DMACYW6 TN Interleukin 2 receptor beta (IL2RB) DMACYW6 MA Agonist DMACYW6 RN Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661. DMACYW6 RU https://pubmed.ncbi.nlm.nih.gov/32005826 DMAD2OZ DI DMAD2OZ DMAD2OZ DN Palovarotene DMAD2OZ TI TT1Q3IE DMAD2OZ TN Retinoic acid receptor gamma (RARG) DMAD2OZ MA Agonist DMAD2OZ RN Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12. DMAD2OZ RU https://pubmed.ncbi.nlm.nih.gov/22282548 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTGP7BY DMAFPHB TN Monoamine oxidase type B (MAO-B) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTJQOD7 DMAFPHB TN 5-HT 2A receptor (HTR2A) DMAFPHB MA Inhibitor DMAFPHB RN Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/3543362 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TT3WG5C DMAFPHB TN Monoamine oxidase type A (MAO-A) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFUIR DI DMAFUIR DMAFUIR DN DWP-431 DMAFUIR TI TTP3IGX DMAFUIR TN Bone morphogenetic protein 2 (BMP2) DMAFUIR MA Modulator DMAFUIR RN Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9. DMAFUIR RU https://pubmed.ncbi.nlm.nih.gov/24412416 DMAJM12 DI DMAJM12 DMAJM12 DN LATIN T1D DMAJM12 TI TTVIMDE DMAJM12 TN Glucagon-like peptide 1 receptor (GLP1R) DMAJM12 MA Agonist DMAJM12 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAJM12 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMALFKX DI DMALFKX DMALFKX DN Savolitinib DMALFKX TI TTNDSF4 DMALFKX TN Proto-oncogene c-Met (MET) DMALFKX MA Inhibitor DMALFKX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMALFKX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAMTGI DI DMAMTGI DMAMTGI DN SD-101 DMAMTGI TI TTSHG0T DMAMTGI TN Toll-like receptor 9 (TLR9) DMAMTGI RN Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829. DMAMTGI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303062/ DMANKTO DI DMANKTO DMANKTO DN Vatreptacog alfa (activated) DMANKTO TI TTF0EGX DMANKTO TN Coagulation factor VII (F7) DMANKTO MA Modulator DMANKTO RN Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. DMANKTO RU https://pubmed.ncbi.nlm.nih.gov/22470921 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTDIGC1 DMAPRWV TN Dipeptidyl peptidase 4 (DPP-4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTN7Y4P DMAPRWV TN Sodium/glucose cotransporter 2 (SLC5A4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAR1YS DI DMAR1YS DMAR1YS DN BMS-986165 DMAR1YS TI TTBYWP2 DMAR1YS TN TYK2 tyrosine kinase (TYK2) DMAR1YS MA Inhibitor DMAR1YS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAR1YS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTVBI8W DMAR9ND TN Dopamine transporter (DAT) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTAWNKZ DMAR9ND TN Norepinephrine transporter (NET) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTN4QDT DMAR9ND TN Opioid receptor (OPR) DMAR9ND MA Antagonist DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT4C8EA DMASPWR TN Dopamine D3 receptor (D3R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT5TPI6 DMASPWR TN Opioid receptor sigma 1 (OPRS1) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTSQIFT DMASPWR TN 5-HT 1A receptor (HTR1A) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTE0A2F DMASPWR TN Dopamine D4 receptor (D4R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMATC14 DI DMATC14 DMATC14 DN Tozadenant DMATC14 TI TTM2AOE DMATC14 TN Adenosine A2a receptor (ADORA2A) DMATC14 MA Antagonist DMATC14 RN Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76. DMATC14 RU https://pubmed.ncbi.nlm.nih.gov/25008546 DMAXTFO DI DMAXTFO DMAXTFO DN H1N1 influenza vaccine DMAXTFO TI TT3J5ZI DMAXTFO TN Cell mediated immunity response (CMIR) DMAXTFO RN Clinical pipeline report, company report or official report of Sanofi Pasteur. DMAXTFO RU http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency.aspx DMAYC76 DI DMAYC76 DMAYC76 DN Levomequitazine DMAYC76 TI TT7CXIM DMAYC76 TN Histamine receptor (HR) DMAYC76 MA Antagonist DMAYC76 RN Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42. DMAYC76 RU https://pubmed.ncbi.nlm.nih.gov/9454781 DMAYO46 DI DMAYO46 DMAYO46 DN AEZS-108 DMAYO46 TI TT8R70G DMAYO46 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAYO46 MA Modulator DMAYO46 RN Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34. DMAYO46 RU https://pubmed.ncbi.nlm.nih.gov/10639165 DMAYTIH DI DMAYTIH DMAYTIH DN S-06911 DMAYTIH TI TTK59TV DMAYTIH TN Vitamin D3 receptor (VDR) DMAYTIH MA Inhibitor DMAYTIH RN Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73. DMAYTIH RU https://pubmed.ncbi.nlm.nih.gov/12520525 DMB06MU DI DMB06MU DMB06MU DN HC-1119 DMB06MU TI TTS64P2 DMB06MU TN Androgen receptor (AR) DMB06MU MA Inhibitor DMB06MU RN Clinical pipeline report, company report or official report of Hinova Pharmaceuticals. DMB06MU RU http://www.hinovapharma.com/en/chanpinxianguan.html DMB147A DI DMB147A DMB147A DN BAX-817 DMB147A TI TTF0EGX DMB147A TN Coagulation factor VII (F7) DMB147A MA Inhibitor DMB147A RN Clinical pipeline report, company report or official report of Baxter. DMB147A RU http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2025563 DMB24H7 DI DMB24H7 DMB24H7 DN Motavizumab DMB24H7 TI TT57ID8 DMB24H7 TN Respiratory syncytial virus protein F (RSV F) DMB24H7 MA Modulator DMB24H7 RN Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. DMB24H7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/ DMB2C0E DI DMB2C0E DMB2C0E DN Elagolix DMB2C0E TI TT8R70G DMB2C0E TN Gonadotropin-releasing hormone receptor (GNRHR) DMB2C0E MA Antagonist DMB2C0E RN Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28. DMB2C0E RU https://pubmed.ncbi.nlm.nih.gov/25581052 DMB34TZ DI DMB34TZ DMB34TZ DN Grippol TC DMB34TZ TI TT3J5ZI DMB34TZ TN Cell mediated immunity response (CMIR) DMB34TZ RN Clinical pipeline report, company report or official report of Petrovax. DMB34TZ RU http://petrovax.com/medication/catalog/grippallplus/ DMB4JPG DI DMB4JPG DMB4JPG DN CNTX-4975 DMB4JPG TI TTMI6F5 DMB4JPG TN Transient receptor potential cation channel V1 (TRPV1) DMB4JPG MA Agonist DMB4JPG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB4JPG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMB9587 DI DMB9587 DMB9587 DN Amocarzine DMB9587 TI TT1RS9F DMB9587 TN Acetylcholinesterase (AChE) DMB9587 MA Inhibitor DMB9587 RN Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211. DMB9587 RU https://pubmed.ncbi.nlm.nih.gov/1359747 DMBD4K3 DI DMBD4K3 DMBD4K3 DN Selinexor DMBD4K3 TI TTCJUR4 DMBD4K3 TN Exportin-1 (XPO1) DMBD4K3 MA Inhibitor DMBD4K3 RN Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73. DMBD4K3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/ DMBEL3Q DI DMBEL3Q DMBEL3Q DN GDC-0853 DMBEL3Q TI TTGM6VW DMBEL3Q TN Tyrosine-protein kinase BTK (ATK) DMBEL3Q MA Inhibitor DMBEL3Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBEL3Q RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMBER0Q DI DMBER0Q DMBER0Q DN Hu5F9-G4 DMBER0Q TI TT28S46 DMBER0Q TN Leukocyte surface antigen CD47 (CD47) DMBER0Q MA Inhibitor DMBER0Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBER0Q RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBFE4K DI DMBFE4K DMBFE4K DN Tirapazamine DMBFE4K TI TT0IHXV DMBFE4K TN DNA topoisomerase II (TOP2) DMBFE4K MA Modulator DMBFE4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBFE4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBH4FL DI DMBH4FL DMBH4FL DN BI 655066 DMBH4FL TI TTC1GLB DMBH4FL TN Interleukin-23 (IL23) DMBH4FL RN Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. DMBH4FL RU https://pubmed.ncbi.nlm.nih.gov/25769911 DMBIZ7H DI DMBIZ7H DMBIZ7H DN ICT-107 DMBIZ7H TI TTMPZ7V DMBIZ7H TN Interleukin 13 receptor alpha-2 (IL13RA2) DMBIZ7H RN Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics. DMBIZ7H RU http://www.imuc.com/pipeline/ict-107 DMBJTVL DI DMBJTVL DMBJTVL DN Isotretinoin DMBJTVL TI TTNHMO8 DMBJTVL TN COVID-19 papain-like proteinase (PL-PRO) DMBJTVL MA Inhibitor DMBJTVL RN ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health. DMBJTVL RU https://clinicaltrials.gov/ct2/show/NCT04361422 DMBKWAF DI DMBKWAF DMBKWAF DN Peg-G-CSF DMBKWAF TI TTC70AJ DMBKWAF TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMBKWAF MA Stimulator DMBKWAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMBKWAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMBPY9Z DI DMBPY9Z DMBPY9Z DN MBG453 DMBPY9Z TI TT1RWL7 DMBPY9Z TN Hepatitis A virus cellular receptor 2 (TIM3) DMBPY9Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBPY9Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBQK0X DI DMBQK0X DMBQK0X DN Algenpantucel-L DMBQK0X TI TTPJ1I3 DMBQK0X TN Galactosyltransferase (GALT) DMBQK0X RN Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer. 2014; 45(2): 190-201. DMBQK0X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024386/ DMBRQF5 DI DMBRQF5 DMBRQF5 DN ApoC-III DMBRQF5 TI TT3GKN5 DMBRQF5 TN Lipase unspecific (LIP) DMBRQF5 MA Inhibitor DMBRQF5 RN An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor Int J Clin Pract. 2008 May;62(5):799-809. DMBRQF5 RU https://pubmed.ncbi.nlm.nih.gov/18201179 DMBS3UG DI DMBS3UG DMBS3UG DN CORT-125134 DMBS3UG TI TTYRL6O DMBS3UG TN Glucocorticoid receptor (NR3C1) DMBS3UG MA Antagonist DMBS3UG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBS3UG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTJX3UE DMBWO5T TN Somatostatin receptor type 3 (SSTR3) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TT2BC4G DMBWO5T TN Somatostatin receptor type 5 (SSTR5) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTZ6T9E DMBWO5T TN Somatostatin receptor type 2 (SSTR2) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTAE1BR DMBWO5T TN Somatostatin receptor type 4 (SSTR4) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTIND6G DMBWO5T TN Somatostatin receptor type 1 (SSTR1) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBXR23 DI DMBXR23 DMBXR23 DN BMN-110 DMBXR23 TI TTT9YPO DMBXR23 TN N-acetylgalactosamine 6 sulfatase (GALNS) DMBXR23 MA Modulator DMBXR23 RN Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90. DMBXR23 RU https://pubmed.ncbi.nlm.nih.gov/24810369 DMBY31K DI DMBY31K DMBY31K DN Rivoglitazone DMBY31K TI TTZMAO3 DMBY31K TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMBY31K MA Agonist DMBY31K RN A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13. DMBY31K RU https://pubmed.ncbi.nlm.nih.gov/21492364 DMBY56U DI DMBY56U DMBY56U DN EXISULIND DMBY56U TI TTJ0IQB DMBY56U TN Phosphodiesterase 5A (PDE5A) DMBY56U MA Modulator DMBY56U RN Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42. DMBY56U RU https://pubmed.ncbi.nlm.nih.gov/10910034 DMC4X7L DI DMC4X7L DMC4X7L DN CMS-024-02 DMC4X7L TI TTBH0VX DMC4X7L TN Histone deacetylase (HDAC) DMC4X7L MA Modulator DMC4X7L RN US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery. DMC4X7L RU http://www.google.com/patents/US20120302505 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTROQ37 DMC7W6R TN MAPK/ERK kinase kinase (MAP3K) DMC7W6R MA Modulator DMC7W6R RN Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59. DMC7W6R RU https://www.ncbi.nlm.nih.gov/pubmed/22569000 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTIDAPM DMC7W6R TN ERK activator kinase 1 (MEK1) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTTW2NY DMC7W6R TN ERK activator kinase 2 (MEK2) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCA6BW DI DMCA6BW DMCA6BW DN Pixykine DMCA6BW TI TT6MP2Z DMCA6BW TN GMCSFR-alpha (CSF2RA) DMCA6BW MA Modulator DMCA6BW RN Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7. DMCA6BW RU https://www.ncbi.nlm.nih.gov/pubmed/9827896 DMCA7FN DI DMCA7FN DMCA7FN DN Exatecan DMCA7FN TI TTGTQHC DMCA7FN TN DNA topoisomerase I (TOP1) DMCA7FN MA Inhibitor DMCA7FN RN Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70. DMCA7FN RU https://pubmed.ncbi.nlm.nih.gov/11751488 DMCDZ15 DI DMCDZ15 DMCDZ15 DN Evacetrapib DMCDZ15 TI TTFQAYR DMCDZ15 TN Cholesteryl ester transfer protein (CETP) DMCDZ15 MA Inhibitor DMCDZ15 RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMCDZ15 RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMCF6SX DI DMCF6SX DMCF6SX DN TAK-491 DMCF6SX TI TT8DBY3 DMCF6SX TN Angiotensin II receptor type-1 (AGTR1) DMCF6SX MA Modulator DMCF6SX RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMCF6SX RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTHPFTS DMCGWBJ TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT7AOUD DMCGWBJ TN Fatty acid synthase (FASN) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT84ETX DMCGWBJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCGWBJ MA Inhibitor DMCGWBJ RN Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11591519 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTBE4IR DMCGWBJ TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTJ4QE7 DMCGWBJ TN Matrix metalloproteinase-14 (MMP-14) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTNX2CS DMCGWBJ TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMCGWBJ MA Inhibitor DMCGWBJ RN Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/17263522 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTLM12X DMCGWBJ TN Matrix metalloproteinase-2 (MMP-2) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTE14XG DMCGWBJ TN Squalene monooxygenase (SQLE) DMCGWBJ MA Inhibitor DMCGWBJ RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTPLTSQ DMCGWBJ TN Neutrophil elastase (NE) DMCGWBJ MA Inhibitor DMCGWBJ RN Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/20004577 DMCHA27 DI DMCHA27 DMCHA27 DN Almonertinib DMCHA27 TI TTGKNB4 DMCHA27 TN Epidermal growth factor receptor (EGFR) DMCHA27 MA Inhibitor DMCHA27 RN Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. DMCHA27 RU https://pubmed.ncbi.nlm.nih.gov/32916310 DMCJRL1 DI DMCJRL1 DMCJRL1 DN MGN-1703 DMCJRL1 TI TTSHG0T DMCJRL1 TN Toll-like receptor 9 (TLR9) DMCJRL1 MA Agonist DMCJRL1 RN Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. DMCJRL1 RU https://pubmed.ncbi.nlm.nih.gov/24816725 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TTJQOD7 DMCJY35 TN 5-HT 2A receptor (HTR2A) DMCJY35 MA Antagonist DMCJY35 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMCJY35 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TT9NXW4 DMCJY35 TN Sigma intracellular receptor 2 (TMEM97) DMCJY35 MA Antagonist DMCJY35 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCJY35 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMCKPG4 DI DMCKPG4 DMCKPG4 DN ABC294640 DMCKPG4 TI TTCN0M9 DMCKPG4 TN Sphingosine kinase 2 (SPHK2) DMCKPG4 MA Modulator DMCKPG4 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMCKPG4 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMCMDVR DI DMCMDVR DMCMDVR DN Triptolide DMCMDVR TI TTSXVID DMCMDVR TN Nuclear factor NF-kappa-B (NFKB) DMCMDVR MA Inhibitor DMCMDVR RN Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18. DMCMDVR RU https://pubmed.ncbi.nlm.nih.gov/11753684 DMCMIJ1 DI DMCMIJ1 DMCMIJ1 DN NT0202 DMCMIJ1 TI TTIU98M DMCMIJ1 TN Trace amine-associated receptor-1 (TAAR1) DMCMIJ1 MA Agonist DMCMIJ1 RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMCMIJ1 RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMCMJRA DI DMCMJRA DMCMJRA DN EGF816 DMCMJRA TI TTGKNB4 DMCMJRA TN Epidermal growth factor receptor (EGFR) DMCMJRA MA Inhibitor DMCMJRA RN Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. DMCMJRA RU https://pubmed.ncbi.nlm.nih.gov/24065731 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TTGTQHC DMCRGY4 TN DNA topoisomerase I (TOP1) DMCRGY4 MA Inhibitor DMCRGY4 RN Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9. DMCRGY4 RU https://pubmed.ncbi.nlm.nih.gov/10692484 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TT2GPK3 DMCRGY4 TN DNA topoisomerase (TOP) DMCRGY4 MA Inhibitor DMCRGY4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCRGY4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCWM03 DI DMCWM03 DMCWM03 DN Unfractionated heparin DMCWM03 TI TT4QPUL DMCWM03 TN Antithrombin-III (ATIII) DMCWM03 MA Modulator DMCWM03 RN Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97. DMCWM03 RU https://pubmed.ncbi.nlm.nih.gov/7164033 DMD1FTP DI DMD1FTP DMD1FTP DN PRO-140 DMD1FTP TI TT2CEJG DMD1FTP TN C-C chemokine receptor type 5 (CCR5) DMD1FTP MA Antagonist DMD1FTP RN Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62. DMD1FTP RU https://pubmed.ncbi.nlm.nih.gov/21389095 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TT50QJ3 DMD2O0L TN Influenza Neuraminidase (Influ NA) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TTQ8J1V DMD2O0L TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD5QRS DI DMD5QRS DMD5QRS DN Ranirestat DMD5QRS TI TTFBNVI DMD5QRS TN Aldose reductase (AKR1B1) DMD5QRS MA Inhibitor DMD5QRS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMD5QRS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMD6AUX DI DMD6AUX DMD6AUX DN Tat-NR2B9c DMD6AUX TI TT9PB26 DMD6AUX TN Presynaptic density protein 95 (DLG4) DMD6AUX MA Inhibitor DMD6AUX RN Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. DMD6AUX RU https://pubmed.ncbi.nlm.nih.gov/22388811 DMD7K9X DI DMD7K9X DMD7K9X DN Davunetide DMD7K9X TI TTS87KH DMD7K9X TN Microtubule-associated protein tau (MAPT) DMD7K9X MA Modulator DMD7K9X RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DMD7K9X RU https://pubmed.ncbi.nlm.nih.gov/21902667 DMD7L48 DI DMD7L48 DMD7L48 DN Plinabulin DMD7L48 TI TTYFKSZ DMD7L48 TN Tubulin beta (TUBB) DMD7L48 MA Modulator DMD7L48 RN NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. DMD7L48 RU https://www.ncbi.nlm.nih.gov/pubmed/16317287 DMD7L48 DI DMD7L48 DMD7L48 DN Plinabulin DMD7L48 TI TTKIGZF DMD7L48 TN Guanine nucleotide exchange factor (GNEF) DMD7L48 MA Stimulator DMD7L48 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD7L48 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMD7XWS DI DMD7XWS DMD7XWS DN AS-013 DMD7XWS TI TTG1QMU DMD7XWS TN Prostaglandin E2 receptor EP1 (PTGER1) DMD7XWS MA Agonist DMD7XWS RN Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7. DMD7XWS RU https://pubmed.ncbi.nlm.nih.gov/9844994 DMD8QTC DI DMD8QTC DMD8QTC DN Apadenoson DMD8QTC TI TTM2AOE DMD8QTC TN Adenosine A2a receptor (ADORA2A) DMD8QTC MA Agonist DMD8QTC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290). DMD8QTC RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290 DMDAN8H DI DMDAN8H DMDAN8H DN BMS-582664 DMDAN8H TI TTST7KB DMDAN8H TN Fibroblast growth factor receptor 3 (FGFR3) DMDAN8H MA Inhibitor DMDAN8H RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMDAN8H RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMDBY30 DI DMDBY30 DMDBY30 DN Nelipepimut S DMDBY30 TI TT6EO5L DMDBY30 TN Erbb2 tyrosine kinase receptor (HER2) DMDBY30 MA Inhibitor DMDBY30 RN The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. DMDBY30 RU https://pubmed.ncbi.nlm.nih.gov/24896623 DMDC7OH DI DMDC7OH DMDC7OH DN PH94B NS DMDC7OH TI TTCI43M DMDC7OH TN GABA(A) receptor (GABAR) DMDC7OH MA Modulator DMDC7OH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDC7OH RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMDCFXJ DI DMDCFXJ DMDCFXJ DN Vaborbactam DMDCFXJ TI TTHI19T DMDCFXJ TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMDCFXJ MA Inhibitor DMDCFXJ RN Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17. DMDCFXJ RU https://pubmed.ncbi.nlm.nih.gov/28848018 DMDCQW0 DI DMDCQW0 DMDCQW0 DN Quinotolast DMDCQW0 TI TT7KY5U DMDCQW0 TN Histamine/peptide leukotriene release (His/p-LT rele) DMDCQW0 MA Modulator DMDCQW0 RN Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol. 1993 Sep;63(1):73-81. DMDCQW0 RU https://pubmed.ncbi.nlm.nih.gov/7505860 DMDEJX9 DI DMDEJX9 DMDEJX9 DN Reproxalap DMDEJX9 TI TTZEX7Y DMDEJX9 TN Malondialdehyde (MDA) DMDEJX9 MA Inhibitor DMDEJX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDEJX9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDGK83 DI DMDGK83 DMDGK83 DN NN1841 DMDGK83 TI TTAXGIP DMDGK83 TN Coagulation factor XIII (F13B) DMDGK83 MA Modulator DMDGK83 RN Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13. DMDGK83 RU https://pubmed.ncbi.nlm.nih.gov/25031548 DMDJLY9 DI DMDJLY9 DMDJLY9 DN NM-702 DMDJLY9 TI TTUST1O DMDJLY9 TN Phosphodiesterase (PDE) DMDJLY9 MA Inhibitor DMDJLY9 RN The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. DMDJLY9 RU https://pubmed.ncbi.nlm.nih.gov/17174195 DMDJLY9 DI DMDJLY9 DMDJLY9 DN NM-702 DMDJLY9 TI TTKNWZ4 DMDJLY9 TN Thromboxane-A synthase (TBXAS1) DMDJLY9 MA Inhibitor DMDJLY9 RN The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. DMDJLY9 RU https://pubmed.ncbi.nlm.nih.gov/17174195 DMDLU4Z DI DMDLU4Z DMDLU4Z DN Desmoteplase DMDLU4Z TI TTP86E2 DMDLU4Z TN Plasminogen (PLG) DMDLU4Z MA Activator DMDLU4Z RN Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43. DMDLU4Z RU https://pubmed.ncbi.nlm.nih.gov/12574572 DMDMAE4 DI DMDMAE4 DMDMAE4 DN SAR438584 DMDMAE4 TI TT57ID8 DMDMAE4 TN Respiratory syncytial virus protein F (RSV F) DMDMAE4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470) DMDMAE4 RU http://adisinsight.springer.com/drugs/800040470 DMDN4ZP DI DMDN4ZP DMDN4ZP DN Lixivaptan DMDN4ZP TI TTV9GOF DMDN4ZP TN Histidine decarboxylase (HDC) DMDN4ZP MA Inhibitor DMDN4ZP RN Clinical pipeline report, company report or official report of Biofrontera (2009). DMDN4ZP RU http://www.biofrontera.com/index.php?id=5 DMDN4ZP DI DMDN4ZP DMDN4ZP DN Lixivaptan DMDN4ZP TI TTK8R02 DMDN4ZP TN Vasopressin V2 receptor (V2R) DMDN4ZP MA Antagonist DMDN4ZP RN Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. DMDN4ZP RU https://pubmed.ncbi.nlm.nih.gov/17355215 DMDTGWQ DI DMDTGWQ DMDTGWQ DN GMI-1271 DMDTGWQ TI TTAU4D6 DMDTGWQ TN E-selectin (SELE) DMDTGWQ MA Inhibitor DMDTGWQ RN Clinical pipeline report, company report or official report of glycomimetics. DMDTGWQ RU http://www.glycomimetics.com/programs-pipeline/gmi-1271/ DMDU5Y2 DI DMDU5Y2 DMDU5Y2 DN QPI-1002 DMDU5Y2 TI TT7SBF5 DMDU5Y2 TN Cellular tumor antigen p53 (TP53) DMDU5Y2 MA Modulator DMDU5Y2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDU5Y2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDV4EP DI DMDV4EP DMDV4EP DN MRTX849 DMDV4EP TI TT3LH46 DMDV4EP TN KRAS G12C mutant (KRAS G12C) DMDV4EP MA Inhibitor DMDV4EP RN Clinical pipeline report, company report or official report of Mirati Therapeutics. DMDV4EP RU https://www.mirati.com/science/pipeline/ DMDVAFP DI DMDVAFP DMDVAFP DN RG7601 DMDVAFP TI TTJGNVC DMDVAFP TN Apoptosis regulator Bcl-2 (BCL-2) DMDVAFP MA Modulator DMDVAFP RN ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DMDVAFP RU https://pubmed.ncbi.nlm.nih.gov/23291630 DMDWU1S DI DMDWU1S DMDWU1S DN Rubitecan DMDWU1S TI TTGTQHC DMDWU1S TN DNA topoisomerase I (TOP1) DMDWU1S MA Inhibitor DMDWU1S RN Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9. DMDWU1S RU https://pubmed.ncbi.nlm.nih.gov/16370935 DMDXE4I DI DMDXE4I DMDXE4I DN ABP959 DMDXE4I TI TTKANGO DMDXE4I TN Complement C5 (CO5) DMDXE4I MA Inhibitor DMDXE4I RN A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74. DMDXE4I RU https://pubmed.ncbi.nlm.nih.gov/32196749 DMDZ6Q3 DI DMDZ6Q3 DMDZ6Q3 DN Napabucasin DMDZ6Q3 TI TTH8FZW DMDZ6Q3 TN Signal transducer and activator of transcription 3 (STAT3) DMDZ6Q3 MA Inhibitor DMDZ6Q3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDZ6Q3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDZW8K DI DMDZW8K DMDZW8K DN RBT-101 DMDZW8K TI TTX4GLS DMDZW8K TN Mammalian target of rapamycin complex 1 (mTORC1) DMDZW8K MA Inhibitor DMDZW8K RN Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533. DMDZW8K RU https://pubmed.ncbi.nlm.nih.gov/30057410 DME5PN3 DI DME5PN3 DME5PN3 DN Satavaptan DME5PN3 TI TTK8R02 DME5PN3 TN Vasopressin V2 receptor (V2R) DME5PN3 MA Antagonist DME5PN3 RN Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17. DME5PN3 RU https://pubmed.ncbi.nlm.nih.gov/19196237 DME617W DI DME617W DME617W DN Neucardin DME617W TI TTEH395 DME617W TN Pro-neuregulin-1 (Pro-NRG1) DME617W MA Modulator DME617W RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DME617W RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DME76AP DI DME76AP DME76AP DN Bis(olanzapine) pamoate monohydrate DME76AP TI TTEX248 DME76AP TN Dopamine D2 receptor (D2R) DME76AP MA Modulator DME76AP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME76AP RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME76AP DI DME76AP DME76AP DN Bis(olanzapine) pamoate monohydrate DME76AP TI TTYSN63 DME76AP TN 5-HT 2 receptor (5HT2R) DME76AP MA Modulator DME76AP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME76AP RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME9QGW DI DME9QGW DME9QGW DN Marizomib DME9QGW TI TTU7ZMG DME9QGW TN Proteasome (PS) DME9QGW MA Inhibitor DME9QGW RN Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. DME9QGW RU https://pubmed.ncbi.nlm.nih.gov/21247382 DMEAOZ0 DI DMEAOZ0 DMEAOZ0 DN Cilengitide DMEAOZ0 TI TT69TQN DMEAOZ0 TN Integrin alpha-V/beta-3 (ITGAV/B3) DMEAOZ0 MA Modulator DMEAOZ0 RN The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449. DMEAOZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/19212436 DMEDSVJ DI DMEDSVJ DMEDSVJ DN Ociperlimab DMEDSVJ TI TTWNL74 DMEDSVJ TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMEDSVJ MA Inhibitor DMEDSVJ RN Clinical pipeline report, company report or official report of BeiGene. DMEDSVJ RU https://www.beigene.com/science-and-product-portfolio/pipeline/ociperlimab DMEFCTP DI DMEFCTP DMEFCTP DN Glufosfamide DMEFCTP TI TTUTN1I DMEFCTP TN Human Deoxyribonucleic acid (hDNA) DMEFCTP MA Modulator DMEFCTP RN A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33. DMEFCTP RU https://www.ncbi.nlm.nih.gov/pubmed/17786181 DMEFCTP DI DMEFCTP DMEFCTP DN Glufosfamide DMEFCTP TI TTUBNVO DMEFCTP TN DNA synthesis (DNA synth) DMEFCTP MA Inhibitor DMEFCTP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFCTP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMEH641 DI DMEH641 DMEH641 DN PRX-302 DMEH641 TI TTS78AZ DMEH641 TN Prostate specific antigen (KLK3) DMEH641 MA Modulator DMEH641 RN Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54. DMEH641 RU https://pubmed.ncbi.nlm.nih.gov/21129846 DMEKAYI DI DMEKAYI DMEKAYI DN Netupitant DMEKAYI TI TTZPO1L DMEKAYI TN Substance-P receptor (TACR1) DMEKAYI MA Antagonist DMEKAYI RN Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44. DMEKAYI RU https://pubmed.ncbi.nlm.nih.gov/24969614 DMENDP6 DI DMENDP6 DMENDP6 DN OBI-1 DMENDP6 TI TT1290U DMENDP6 TN Coagulation factor VIII (F8) DMENDP6 MA Modulator DMENDP6 RN Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70. DMENDP6 RU https://pubmed.ncbi.nlm.nih.gov/25623166 DMER75Y DI DMER75Y DMER75Y DN RG6013 DMER75Y TI TTFEZ5Q DMER75Y TN Coagulation factor IX (F9) DMER75Y RN Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13. DMER75Y RU https://pubmed.ncbi.nlm.nih.gov/24738137 DMESAZK DI DMESAZK DMESAZK DN Peretinoin DMESAZK TI TTOD7B3 DMESAZK TN Retinoic acid receptor (RAR) DMESAZK MA Modulator DMESAZK RN Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191. DMESAZK RU https://pubmed.ncbi.nlm.nih.gov/23587162 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTEYTKG DMEW5Z8 TN Carbonic anhydrase XIV (CA-XIV) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTCFSPE DMEW5Z8 TN Carbonic anhydrase VI (CA-VI) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TT2LVK8 DMEW5Z8 TN Carbonic anhydrase IX (CA-IX) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTSYM0R DMEW5Z8 TN Carbonic anhydrase XII (CA-XII) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTANPDJ DMEW5Z8 TN Carbonic anhydrase II (CA-II) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTUNARX DMEW5Z8 TN Carbonic anhydrase (CA) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTZHA0O DMEW5Z8 TN Carbonic anhydrase IV (CA-IV) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTHQPL7 DMEW5Z8 TN Carbonic anhydrase I (CA-I) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEWRXA DI DMEWRXA DMEWRXA DN SHP647 DMEWRXA TI TTBD6I7 DMEWRXA TN Mucosal addressin cell adhesion molecule 1 (MADCAM1) DMEWRXA MA Inhibitor DMEWRXA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWRXA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEX86V DI DMEX86V DMEX86V DN Epcoritamab DMEX86V TI TTUN7MC DMEX86V TN T-cell surface glycoprotein CD3 (CD3) DMEX86V MA Inhibitor DMEX86V RN Clinical pipeline report, company report or official report of Genmab. DMEX86V RU https://www.genmab.com/pipeline/ DMEX86V DI DMEX86V DMEX86V DN Epcoritamab DMEX86V TI TTUE541 DMEX86V TN Leukocyte surface antigen Leu-16 (CD20) DMEX86V MA Inhibitor DMEX86V RN Clinical pipeline report, company report or official report of Genmab. DMEX86V RU https://www.genmab.com/pipeline/ DMEY1F3 DI DMEY1F3 DMEY1F3 DN Zabofloxacin DMEY1F3 TI TTN6J5F DMEY1F3 TN Bacterial DNA gyrase (Bact gyrase) DMEY1F3 MA Modulator DMEY1F3 RN DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8. DMEY1F3 RU https://www.ncbi.nlm.nih.gov/pubmed/20403681 DMEY1F3 DI DMEY1F3 DMEY1F3 DN Zabofloxacin DMEY1F3 TI TTIXTO3 DMEY1F3 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMEY1F3 MA Modulator DMEY1F3 RN DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8. DMEY1F3 RU https://www.ncbi.nlm.nih.gov/pubmed/20403681 DMEZ0H5 DI DMEZ0H5 DMEZ0H5 DN LY2963016 DMEZ0H5 TI TTZOPHG DMEZ0H5 TN Insulin (INS) DMEZ0H5 MA Agonist DMEZ0H5 RN Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33. DMEZ0H5 RU https://pubmed.ncbi.nlm.nih.gov/25974640 DMF0NA9 DI DMF0NA9 DMF0NA9 DN KX-01 DMF0NA9 TI TT6PKBN DMF0NA9 TN Proto-oncogene c-Src (SRC) DMF0NA9 MA Inhibitor DMF0NA9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF0NA9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMF30HL DI DMF30HL DMF30HL DN Zarnestra DMF30HL TI TTXQKM3 DMF30HL TN Farnesyl protein transferase (Ftase) DMF30HL MA Modulator DMF30HL RN Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500. DMF30HL RU https://www.ncbi.nlm.nih.gov/pubmed/19707379 DMF30HL DI DMF30HL DMF30HL DN Zarnestra DMF30HL TI TTIKWV4 DMF30HL TN Geranyltranstransferase (FDPS) DMF30HL MA Inhibitor DMF30HL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF30HL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TTD16BI DMF3V01 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMF3V01 MA Inhibitor DMF3V01 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TTZGK1R DMF3V01 TN HUMAN glycosylation of host receptor (GHR) DMF3V01 MA Inhibitor DMF3V01 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TT3A1EZ DMF3V01 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMF3V01 MA Inhibitor DMF3V01 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMF50XJ DI DMF50XJ DMF50XJ DN Amitriptyline+ketamine DMF50XJ TI TT9IK2Z DMF50XJ TN N-methyl-D-aspartate receptor (NMDAR) DMF50XJ MA Antagonist DMF50XJ RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMF50XJ RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMF5GZI DI DMF5GZI DMF5GZI DN RG7388 DMF5GZI TI TT08GJW DMF5GZI TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMF5GZI MA Modulator DMF5GZI RN Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21. DMF5GZI RU https://pubmed.ncbi.nlm.nih.gov/25844600 DMF5GZI DI DMF5GZI DMF5GZI DN RG7388 DMF5GZI TI TT0JESD DMF5GZI TN Erbb4 tyrosine kinase receptor (Erbb-4) DMF5GZI MA Inhibitor DMF5GZI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799). DMF5GZI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799 DMF98Q0 DI DMF98Q0 DMF98Q0 DN Momelotinib DMF98Q0 TI TTRMX3V DMF98Q0 TN Janus kinase 2 (JAK-2) DMF98Q0 MA Modulator DMF98Q0 RN Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4. DMF98Q0 RU https://www.ncbi.nlm.nih.gov/pubmed/25322686 DMFBNA3 DI DMFBNA3 DMFBNA3 DN Nicaraven DMFBNA3 TI TTVDSZ0 DMFBNA3 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMFBNA3 MA Modulator DMFBNA3 RN Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7. DMFBNA3 RU https://pubmed.ncbi.nlm.nih.gov/17094462 DMFD249 DI DMFD249 DMFD249 DN Nebracetam DMFD249 TI TTZ9SOR DMFD249 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFD249 MA Agonist DMFD249 RN Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80. DMFD249 RU https://pubmed.ncbi.nlm.nih.gov/2041225 DMFDNT0 DI DMFDNT0 DMFDNT0 DN Tocilizumab DMFDNT0 TI TTDVAKP DMFDNT0 TN HUMAN interleukin-6 receptor (IL6R) DMFDNT0 MA Inhibitor DMFDNT0 RN Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0. DMFDNT0 RU https://pubmed.ncbi.nlm.nih.gov/32247642 DMFIP35 DI DMFIP35 DMFIP35 DN Adhexil DMFIP35 TI TTWODQF DMFIP35 TN Fibrin (FG) DMFIP35 MA Modulator DMFIP35 RN Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci. Fertil Steril. 2010 Mar 1;93(4):1045-51. DMFIP35 RU https://pubmed.ncbi.nlm.nih.gov/19147133 DMFJLB6 DI DMFJLB6 DMFJLB6 DN Lanabecestat DMFJLB6 TI TT8JRS7 DMFJLB6 TN Beta-secretase (BACE) DMFJLB6 MA Inhibitor DMFJLB6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFJLB6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFKOR9 DI DMFKOR9 DMFKOR9 DN Pafuramidine DMFKOR9 TI TTUTN1I DMFKOR9 TN Human Deoxyribonucleic acid (hDNA) DMFKOR9 MA Modulator DMFKOR9 RN DNA Minor Groove Induced Dimerization of Heterocyclic Cations: Compound Structure, Binding Affinity and Specificity for a TTAA Site DMFKOR9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988403 DMFLJHQ DI DMFLJHQ DMFLJHQ DN LCQ908 DMFLJHQ TI TTF8P9I DMFLJHQ TN Diacylglycerol acyltransferase 1 (DGAT1) DMFLJHQ MA Modulator DMFLJHQ RN DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96. DMFLJHQ RU https://pubmed.ncbi.nlm.nih.gov/20597032 DMFLWX1 DI DMFLWX1 DMFLWX1 DN Farletuzumab DMFLWX1 TI TTVC37M DMFLWX1 TN Folate receptor alpha (FOLR1) DMFLWX1 MA Modulator DMFLWX1 RN Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8. DMFLWX1 RU https://www.ncbi.nlm.nih.gov/pubmed/23474348 DMFMWYC DI DMFMWYC DMFMWYC DN Resatorvid DMFMWYC TI TTISGCA DMFMWYC TN Toll-like receptor 4 (TLR4) DMFMWYC MA Antagonist DMFMWYC RN Clinical pipeline report, company report or official report of Takeda (2009). DMFMWYC RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMFQ1WX DI DMFQ1WX DMFQ1WX DN CLS006 DMFQ1WX TI TTL3N71 DMFQ1WX TN Virus Replication (Viru Repli) DMFQ1WX MA Inhibitor DMFQ1WX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFQ1WX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMFSHEM DI DMFSHEM DMFSHEM DN Ragaglitazar DMFSHEM TI TTZMAO3 DMFSHEM TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMFSHEM MA Modulator DMFSHEM RN Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. DMFSHEM RU https://pubmed.ncbi.nlm.nih.gov/14551179 DMFSHEM DI DMFSHEM DMFSHEM DN Ragaglitazar DMFSHEM TI TTJ584C DMFSHEM TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFSHEM MA Modulator DMFSHEM RN Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. DMFSHEM RU https://pubmed.ncbi.nlm.nih.gov/14551179 DMFUOM7 DI DMFUOM7 DMFUOM7 DN ALN-TTRsc DMFUOM7 TI TTC1I86 DMFUOM7 TN Transthyretin (TTR) DMFUOM7 MA Inhibitor DMFUOM7 RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DMFUOM7 RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/ DMFWE9S DI DMFWE9S DMFWE9S DN Mobocertinib DMFWE9S TI TT2M7YX DMFWE9S TN EGFR Exon20ins mutant (EGFR Exon20ins) DMFWE9S MA Inhibitor DMFWE9S RN Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Feb 25;candisc.1683.2020. DMFWE9S RU https://pubmed.ncbi.nlm.nih.gov/33632773 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TT1MPAY DMFWMKZ TN GABA(A) receptor alpha-1 (GABRA1) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TTZA1NY DMFWMKZ TN GABA(A) receptor beta-2 (GABRB2) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TT06RH5 DMFWMKZ TN GABA(A) receptor gamma-2 (GABRG2) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TTNJYV2 DMFWMKZ TN Gamma-aminobutyric acid receptor (GAR) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFZ81T DI DMFZ81T DMFZ81T DN Fidanacogene elaparvovec DMFZ81T TI TTFEZ5Q DMFZ81T TN Coagulation factor IX (F9) DMFZ81T MA Replacement DMFZ81T RN Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218. DMFZ81T RU https://pubmed.ncbi.nlm.nih.gov/33636038 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TT6R7JZ DMFZBNE TN Histone deacetylase 1 (HDAC1) DMFZBNE MA Inhibitor DMFZBNE RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMFZBNE RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TTRMX3V DMFZBNE TN Janus kinase 2 (JAK-2) DMFZBNE MA Inhibitor DMFZBNE RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMFZBNE RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TTBH0VX DMFZBNE TN Histone deacetylase (HDAC) DMFZBNE MA Inhibitor DMFZBNE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFZBNE RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG2QP4 DI DMG2QP4 DMG2QP4 DN SEP-363856 DMG2QP4 TI TTSQIFT DMG2QP4 TN 5-HT 1A receptor (HTR1A) DMG2QP4 MA Agonist DMG2QP4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG2QP4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG2QP4 DI DMG2QP4 DMG2QP4 DN SEP-363856 DMG2QP4 TI TTIU98M DMG2QP4 TN Trace amine-associated receptor-1 (TAAR1) DMG2QP4 MA Agonist DMG2QP4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG2QP4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG324Y DI DMG324Y DMG324Y DN AMG 145 DMG324Y TI TTBRG7E DMG324Y TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMG324Y MA Modulator DMG324Y RN PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40. DMG324Y RU https://pubmed.ncbi.nlm.nih.gov/25282519 DMG3NFZ DI DMG3NFZ DMG3NFZ DN Muraglitazar DMG3NFZ TI TTZMAO3 DMG3NFZ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMG3NFZ MA Modulator DMG3NFZ RN Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. DMG3NFZ RU https://www.ncbi.nlm.nih.gov/pubmed/16199244 DMG3NFZ DI DMG3NFZ DMG3NFZ DN Muraglitazar DMG3NFZ TI TTJ584C DMG3NFZ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG3NFZ MA Modulator DMG3NFZ RN Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. DMG3NFZ RU https://www.ncbi.nlm.nih.gov/pubmed/16199244 DMG4UJ6 DI DMG4UJ6 DMG4UJ6 DN EVK-001 DMG4UJ6 TI TTWFZ1N DMG4UJ6 TN Dopamine receptor (DR) DMG4UJ6 MA Antagonist DMG4UJ6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG4UJ6 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMG5BTD DI DMG5BTD DMG5BTD DN ALZT-OP1 DMG5BTD TI TTE4KHA DMG5BTD TN Amyloid beta A4 protein (APP) DMG5BTD MA Inhibitor DMG5BTD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG5BTD RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMG8U6M DI DMG8U6M DMG8U6M DN DIPROTEVERINE HYDROCHLORIDE DMG8U6M TI TT5HONZ DMG8U6M TN Calcium channel unspecific (CaC) DMG8U6M MA Antagonist DMG8U6M RN Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9. DMG8U6M RU https://pubmed.ncbi.nlm.nih.gov/8998385 DMGF8MZ DI DMGF8MZ DMGF8MZ DN FPL-62064 DMGF8MZ TI TT2J34L DMGF8MZ TN Arachidonate 5-lipoxygenase (5-LOX) DMGF8MZ MA Modulator DMGF8MZ RN FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. DMGF8MZ RU https://pubmed.ncbi.nlm.nih.gov/2117338 DMGFULM DI DMGFULM DMGFULM DN Heparin low molecular weight DMGFULM TI TT4QPUL DMGFULM TN Antithrombin-III (ATIII) DMGFULM MA Modulator DMGFULM RN Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8. DMGFULM RU https://pubmed.ncbi.nlm.nih.gov/8588200 DMGJQVI DI DMGJQVI DMGJQVI DN GS-6615 DMGJQVI TI TT40BO8 DMGJQVI TN Late inward sodium current (LISC) DMGJQVI MA Modulator DMGJQVI RN Clinical pipeline report, company report or official report of Gilead. DMGJQVI RU http://www.gilead.com/news/press-releases/2014/5/gilead-announces-phase-1-data-for-investigational-therapy-gs6615-in-patients-with-long-qt3-syndrome DMGKBZH DI DMGKBZH DMGKBZH DN TD-1792 DMGKBZH TI TTLP6GN DMGKBZH TN Bacterial DD-carboxypeptidase (Bact vanYB) DMGKBZH MA Inhibitor DMGKBZH RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMGKBZH RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMGMNUE DI DMGMNUE DMGMNUE DN AM0010 DMGMNUE TI TTT0Q1F DMGMNUE TN Interleukin-10 (IL10) DMGMNUE MA Modulator DMGMNUE RN Clinical pipeline report, company report or official report of ARMO BioSciences. DMGMNUE RU http://www.armobio.com/drug-development DMGNC6T DI DMGNC6T DMGNC6T DN M-0011 DMGNC6T TI TTT2KE3 DMGNC6T TN Alpha-mannosidase (MANA) DMGNC6T MA Modulator DMGNC6T RN ClinicalTrials.gov (NCT01681953) A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis. U.S. National Institutes of Health. DMGNC6T RU https://clinicaltrials.gov/ct2/show/NCT01681953 DMGNHC2 DI DMGNHC2 DMGNHC2 DN MK-3415A DMGNHC2 TI TTQH65V DMGNHC2 TN Clostridium difficile Toxin B (CD toxB) DMGNHC2 RN ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health. DMGNHC2 RU https://clinicaltrials.gov/ct2/show/NCT01513239 DMGNHC2 DI DMGNHC2 DMGNHC2 DN MK-3415A DMGNHC2 TI TT64H8L DMGNHC2 TN Clostridium difficile Toxin A (CD toxA) DMGNHC2 RN ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health. DMGNHC2 RU https://clinicaltrials.gov/ct2/show/NCT01513239 DMGOTK4 DI DMGOTK4 DMGOTK4 DN Rhumab Beta7 DMGOTK4 TI TTLT9XQ DMGOTK4 TN Integrin beta-7 (ITGB7) DMGOTK4 RN A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30. DMGOTK4 RU https://pubmed.ncbi.nlm.nih.gov/22717454 DMGQ1TV DI DMGQ1TV DMGQ1TV DN ASP1941 DMGQ1TV TI TTLWPVF DMGQ1TV TN Sodium/glucose cotransporter 2 (SGLT2) DMGQ1TV MA Modulator DMGQ1TV RN Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44. DMGQ1TV RU https://www.ncbi.nlm.nih.gov/pubmed/25685284 DMGR98T DI DMGR98T DMGR98T DN SAGE-217 DMGR98T TI TTEX6LM DMGR98T TN GABA(A) receptor gamma-3 (GABRG3) DMGR98T MA Modulator DMGR98T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGR98T RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMGRBN5 DI DMGRBN5 DMGRBN5 DN TESAGLITAZAR DMGRBN5 TI TTZMAO3 DMGRBN5 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGRBN5 MA Modulator DMGRBN5 RN Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32. DMGRBN5 RU https://www.ncbi.nlm.nih.gov/pubmed/22131108 DMGRBN5 DI DMGRBN5 DMGRBN5 DN TESAGLITAZAR DMGRBN5 TI TTJ584C DMGRBN5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGRBN5 MA Modulator DMGRBN5 RN Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32. DMGRBN5 RU https://www.ncbi.nlm.nih.gov/pubmed/22131108 DMGTCI0 DI DMGTCI0 DMGTCI0 DN Rilimogene galvacirepvec DMGTCI0 TI TTS78AZ DMGTCI0 TN Prostate specific antigen (KLK3) DMGTCI0 MA Modulator DMGTCI0 RN Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105. DMGTCI0 RU https://pubmed.ncbi.nlm.nih.gov/20100959 DMGWVLX DI DMGWVLX DMGWVLX DN Itolizumab DMGWVLX TI TTMF6KC DMGWVLX TN T-cell differentiation antigen CD6 (TP120) DMGWVLX RN Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014 Sep;71(3):484-92. DMGWVLX RU https://pubmed.ncbi.nlm.nih.gov/24703722 DMGYK2N DI DMGYK2N DMGYK2N DN Tilsotolimod DMGYK2N TI TTSHG0T DMGYK2N TN Toll-like receptor 9 (TLR9) DMGYK2N MA Agonist DMGYK2N RN Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020. DMGYK2N RU https://pubmed.ncbi.nlm.nih.gov/33707233 DMGZPX6 DI DMGZPX6 DMGZPX6 DN PI-88 DMGZPX6 TI TTDCBX5 DMGZPX6 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMGZPX6 MA Modulator DMGZPX6 RN Company report (Medigen) DMGZPX6 RU http://www.medigen.com.tw/en/muparfostat-pi-88/ DMH2EA1 DI DMH2EA1 DMH2EA1 DN Laromustine DMH2EA1 TI TTUTN1I DMH2EA1 TN Human Deoxyribonucleic acid (hDNA) DMH2EA1 MA Binder DMH2EA1 RN Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6. DMH2EA1 RU https://pubmed.ncbi.nlm.nih.gov/20511167 DMH2FN1 DI DMH2FN1 DMH2FN1 DN Suronacrine maleate DMH2FN1 TI TTAWNKZ DMH2FN1 TN Norepinephrine transporter (NET) DMH2FN1 MA Modulator DMH2FN1 RN Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7. DMH2FN1 RU https://www.ncbi.nlm.nih.gov/pubmed/1776748 DMH2FN1 DI DMH2FN1 DMH2FN1 DN Suronacrine maleate DMH2FN1 TI TT1RS9F DMH2FN1 TN Acetylcholinesterase (AChE) DMH2FN1 MA Modulator DMH2FN1 RN Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7. DMH2FN1 RU https://www.ncbi.nlm.nih.gov/pubmed/1776748 DMH3XDR DI DMH3XDR DMH3XDR DN BI 425809 DMH3XDR TI TTHJTF7 DMH3XDR TN Glycine transporter GlyT-1 (SLC6A9) DMH3XDR MA Inhibitor DMH3XDR RN Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. DMH3XDR RU https://pubmed.ncbi.nlm.nih.gov/33610228 DMH7W9X DI DMH7W9X DMH7W9X DN SNDX-275 DMH7W9X TI TT6R7JZ DMH7W9X TN Histone deacetylase 1 (HDAC1) DMH7W9X MA Inhibitor DMH7W9X RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMH7W9X RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMH7W9X DI DMH7W9X DMH7W9X DN SNDX-275 DMH7W9X TI TTBH0VX DMH7W9X TN Histone deacetylase (HDAC) DMH7W9X MA Inhibitor DMH7W9X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH7W9X RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH8IT5 DI DMH8IT5 DMH8IT5 DN Donaperminogene seltoplasmid DMH8IT5 TI TT4V2JM DMH8IT5 TN Hepatocyte growth factor (HGF) DMH8IT5 MA Replacement DMH8IT5 RN Clinical pipeline report, company report or official report of ViroMed. DMH8IT5 RU http://menu.itooza.com/cmsupload/contdown.php?sn=20190912100403_fd_image_119_65_142__1669.pdf&rsn=ViroMed_May_30_2018.pdf DMH9EUA DI DMH9EUA DMH9EUA DN Nemolizumab DMH9EUA TI TT9HPX0 DMH9EUA TN Interleukin 31 receptor (IL31R) DMH9EUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH9EUA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHDNK0 DI DMHDNK0 DMHDNK0 DN TroVax DMHDNK0 TI TT70MLA DMHDNK0 TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMHDNK0 RN Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47. DMHDNK0 RU https://pubmed.ncbi.nlm.nih.gov/20881001 DMHFBOG DI DMHFBOG DMHFBOG DN SAR231893 DMHFBOG TI TTDWHC3 DMHFBOG TN Interleukin 4 receptor alpha (IL4R) DMHFBOG MA Modulator DMHFBOG RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMHFBOG RU https://pubmed.ncbi.nlm.nih.gov/23688323 DMHJCGV DI DMHJCGV DMHJCGV DN Candoxatril DMHJCGV TI TT5TKPM DMHJCGV TN Neutral endopeptidase (MME) DMHJCGV MA Inhibitor DMHJCGV RN Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13. DMHJCGV RU https://pubmed.ncbi.nlm.nih.gov/18379655 DMHKCIS DI DMHKCIS DMHKCIS DN Aldoxorubicin DMHKCIS TI TT0IHXV DMHKCIS TN DNA topoisomerase II (TOP2) DMHKCIS MA Modulator DMHKCIS RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHKCIS RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHKZLF DI DMHKZLF DMHKZLF DN OSI-906 DMHKZLF TI TTHRID2 DMHKZLF TN Insulin-like growth factor I receptor (IGF1R) DMHKZLF MA Inhibitor DMHKZLF RN Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5. DMHKZLF RU https://pubmed.ncbi.nlm.nih.gov/20346655 DMHN3PG DI DMHN3PG DMHN3PG DN GRT-6005 DMHN3PG TI TTKWM86 DMHN3PG TN Opioid receptor mu (MOP) DMHN3PG MA Modulator DMHN3PG RN Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6. DMHN3PG RU https://pubmed.ncbi.nlm.nih.gov/25248647 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TT2Q6G1 DMHOSCQ TN Vascular endothelial growth factor receptor 1 (FLT-1) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTUTJGQ DMHOSCQ TN Vascular endothelial growth factor receptor 2 (KDR) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTDCBX5 DMHOSCQ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTVJ1D8 DMHOSCQ TN Vascular endothelial growth factor receptor (VEGFR) DMHOSCQ MA Inhibitor DMHOSCQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHOSCQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHQ5GK DI DMHQ5GK DMHQ5GK DN Bapineuzumab DMHQ5GK TI TTE4KHA DMHQ5GK TN Amyloid beta A4 protein (APP) DMHQ5GK RN Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82. DMHQ5GK RU https://pubmed.ncbi.nlm.nih.gov/21091109 DMHQRYE DI DMHQRYE DMHQRYE DN Tenidap DMHQRYE TI TT2J34L DMHQRYE TN Arachidonate 5-lipoxygenase (5-LOX) DMHQRYE MA Modulator DMHQRYE RN The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3. DMHQRYE RU https://pubmed.ncbi.nlm.nih.gov/18475454 DMHTY9W DI DMHTY9W DMHTY9W DN Ublituximab DMHTY9W TI TTUE541 DMHTY9W TN Leukocyte surface antigen Leu-16 (CD20) DMHTY9W RN The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51. DMHTY9W RU https://pubmed.ncbi.nlm.nih.gov/25552707 DMHULRK DI DMHULRK DMHULRK DN GV1001 DMHULRK TI TTUJFD0 DMHULRK TN Telomerase reverse transcriptase (TERT) DMHULRK RN Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82. DMHULRK RU https://pubmed.ncbi.nlm.nih.gov/17060934 DMHXTAQ DI DMHXTAQ DMHXTAQ DN Pazufloxacin DMHXTAQ TI TTN6J5F DMHXTAQ TN Bacterial DNA gyrase (Bact gyrase) DMHXTAQ MA Inhibitor DMHXTAQ RN Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. DMHXTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/11709337 DMHXTAQ DI DMHXTAQ DMHXTAQ DN Pazufloxacin DMHXTAQ TI TTFK8YB DMHXTAQ TN Bacterial DNA topoisomerase 4A (Bact parC) DMHXTAQ MA Inhibitor DMHXTAQ RN Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. DMHXTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/11709337 DMHZBEO DI DMHZBEO DMHZBEO DN Difelikefalin DMHZBEO TI TTQW87Y DMHZBEO TN Opioid receptor kappa (OPRK1) DMHZBEO MA Agonist DMHZBEO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHZBEO RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMI1R5S DI DMI1R5S DMI1R5S DN SAIT101 DMI1R5S TI TTUE541 DMI1R5S TN Leukocyte surface antigen Leu-16 (CD20) DMI1R5S RN Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163. DMI1R5S RU https://pubmed.ncbi.nlm.nih.gov/29915719 DMI1ZXV DI DMI1ZXV DMI1ZXV DN Epratuzumab DMI1ZXV TI TTM6QSK DMI1ZXV TN B-cell receptor CD22 (CD22) DMI1ZXV RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMI1ZXV RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMI3YLK DI DMI3YLK DMI3YLK DN LA-EP2006 DMI3YLK TI TT5TQ2W DMI3YLK TN Granulocyte colony-stimulating factor (CSF3) DMI3YLK MA Modulator DMI3YLK RN National Cancer Institute Drug Dictionary (drug id 724518). DMI3YLK RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724518 DMIC56X DI DMIC56X DMIC56X DN NASVAC DMIC56X TI TTRF7Q8 DMIC56X TN Natural killer cell receptor (NKCR) DMIC56X RN In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7. DMIC56X RU https://pubmed.ncbi.nlm.nih.gov/25193323 DMIC56X DI DMIC56X DMIC56X DN NASVAC DMIC56X TI TT6KSF7 DMIC56X TN Hepatitis B virus Large envelope protein (HBV S) DMIC56X RN In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7. DMIC56X RU https://pubmed.ncbi.nlm.nih.gov/25193323 DMIE1WY DI DMIE1WY DMIE1WY DN AG-881 DMIE1WY TI TTDTWV0 DMIE1WY TN Isocitrate dehydrogenase (IDH) DMIE1WY MA Inhibitor DMIE1WY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIE1WY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTVIAT9 DMIG4OX TN Phosphodiesterase 4B (PDE4B) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTSKMI8 DMIG4OX TN Phosphodiesterase 4D (PDE4D) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTZ97H5 DMIG4OX TN Phosphodiesterase 4A (PDE4A) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DMIGFOR DI DMIGFOR DMIGFOR DN I3C DMIGFOR TI TTSHAEB DMIGFOR TN NF-kappa-B inhibitor alpha (NFKBIA) DMIGFOR MA Inhibitor DMIGFOR RN Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137. DMIGFOR RU https://pubmed.ncbi.nlm.nih.gov/32800927 DMIGX84 DI DMIGX84 DMIGX84 DN Cethromycin DMIGX84 TI TTLFGBV DMIGX84 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMIGX84 MA Inhibitor DMIGX84 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMIGX84 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMIJGT9 DI DMIJGT9 DMIJGT9 DN INCB24360 DMIJGT9 TI TTZJYKH DMIJGT9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIJGT9 MA Inhibitor DMIJGT9 RN Incyte. Product Development Pipeline. DMIJGT9 RU http://www.incyte.com/drugs_product_pipeline.html DMIKDCQ DI DMIKDCQ DMIKDCQ DN Ensartinib DMIKDCQ TI TTPMQSO DMIKDCQ TN ALK tyrosine kinase receptor (ALK) DMIKDCQ MA Inhibitor DMIKDCQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIKDCQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTVKILB DMIKMA9 TN Prostaglandin G/H synthase 2 (COX-2) DMIKMA9 MA Inhibitor DMIKMA9 RN Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/25097102 DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTHQPL7 DMIKMA9 TN Carbonic anhydrase I (CA-I) DMIKMA9 MA Inhibitor DMIKMA9 RN Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/26095375 DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTANPDJ DMIKMA9 TN Carbonic anhydrase II (CA-II) DMIKMA9 MA Inhibitor DMIKMA9 RN Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/26095375 DMIL37Z DI DMIL37Z DMIL37Z DN Losmapimod DMIL37Z TI TTQBR95 DMIL37Z TN Stress-activated protein kinase 2a (p38 alpha) DMIL37Z MA Inhibitor DMIL37Z RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMIL37Z RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMIM5AP DI DMIM5AP DMIM5AP DN TAK-875 DMIM5AP TI TTB8FUC DMIM5AP TN Free fatty acid receptor 1 (GPR40) DMIM5AP MA Modulator DMIM5AP RN Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81. DMIM5AP RU https://pubmed.ncbi.nlm.nih.gov/25787200 DMIPNBG DI DMIPNBG DMIPNBG DN Nemonaxacin DMIPNBG TI TTIXTO3 DMIPNBG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMIPNBG MA Modulator DMIPNBG RN In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9. DMIPNBG RU https://www.ncbi.nlm.nih.gov/pubmed/19833635 DMIQ31Y DI DMIQ31Y DMIQ31Y DN Custirsen DMIQ31Y TI TTRL76H DMIQ31Y TN Clusterin messenger RNA (Clusterin mRNA) DMIQ31Y RN Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54. DMIQ31Y RU https://pubmed.ncbi.nlm.nih.gov/19342222 DMIQCFG DI DMIQCFG DMIQCFG DN Ulinastatin DMIQCFG TI TT2WR1T DMIQCFG TN Cationic trypsinogen (PRSS1) DMIQCFG MA Modulator DMIQCFG RN Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8. DMIQCFG RU https://pubmed.ncbi.nlm.nih.gov/24737258 DMIRYU9 DI DMIRYU9 DMIRYU9 DN Pancopride DMIRYU9 TI TTNXLKE DMIRYU9 TN 5-HT 3 receptor (5HT3R) DMIRYU9 MA Inhibitor DMIRYU9 RN Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64. DMIRYU9 RU https://pubmed.ncbi.nlm.nih.gov/1451737 DMITJAK DI DMITJAK DMITJAK DN Androsterone DMITJAK TI TTNJYV2 DMITJAK TN Gamma-aminobutyric acid receptor (GAR) DMITJAK MA Inhibitor DMITJAK RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMITJAK RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMITJRU DI DMITJRU DMITJRU DN Epothilon DMITJRU TI TTML2WA DMITJRU TN Tubulin (TUB) DMITJRU MA Stablizer DMITJRU RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DMITJRU RU https://pubmed.ncbi.nlm.nih.gov/18764727 DMIWLJE DI DMIWLJE DMIWLJE DN Guanine DMIWLJE TI TTLSWP6 DMIWLJE TN GTP cyclohydrolase-I (GCH1) DMIWLJE MA Inhibitor DMIWLJE RN GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73. DMIWLJE RU https://pubmed.ncbi.nlm.nih.gov/11361142 DMIZJ8M DI DMIZJ8M DMIZJ8M DN Psoralen DMIZJ8M TI TTGP7BY DMIZJ8M TN Monoamine oxidase type B (MAO-B) DMIZJ8M MA Inhibitor DMIZJ8M RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMIZJ8M RU https://pubmed.ncbi.nlm.nih.gov/11169165 DMIZJ8M DI DMIZJ8M DMIZJ8M DN Psoralen DMIZJ8M TI TT3WG5C DMIZJ8M TN Monoamine oxidase type A (MAO-A) DMIZJ8M MA Inhibitor DMIZJ8M RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMIZJ8M RU https://pubmed.ncbi.nlm.nih.gov/11169165 DMJ2KIE DI DMJ2KIE DMJ2KIE DN NI-101 DMJ2KIE TI TTE4KHA DMJ2KIE TN Amyloid beta A4 protein (APP) DMJ2KIE RN Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479. DMJ2KIE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862506/ DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTAU4D6 DMJ432G TN E-selectin (SELE) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TT2IYXF DMJ432G TN L-selectin (SELL) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTE5VG0 DMJ432G TN P-selectin (SELP) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTBGONL DMJ432G TN Selectin (SEL) DMJ432G MA Antagonist DMJ432G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ432G RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJ6F5C DI DMJ6F5C DMJ6F5C DN XL019 DMJ6F5C TI TTRMX3V DMJ6F5C TN Janus kinase 2 (JAK-2) DMJ6F5C MA Inhibitor DMJ6F5C RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMJ6F5C RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMJ7IKW DI DMJ7IKW DMJ7IKW DN PF-4494700 DMJ7IKW TI TTMO9HF DMJ7IKW TN Advanced glycosylation end product receptor (AGER) DMJ7IKW MA Antagonist DMJ7IKW RN Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. DMJ7IKW RU https://pubmed.ncbi.nlm.nih.gov/25586103 DMJ8AUE DI DMJ8AUE DMJ8AUE DN Plitidepsin DMJ8AUE TI TTSQC14 DMJ8AUE TN Palmitoyl-protein thioesterase 1 (PPT1) DMJ8AUE MA Modulator DMJ8AUE RN Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B DMJ8AUE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765 DMJ9ZIY DI DMJ9ZIY DMJ9ZIY DN CK-2017357 DMJ9ZIY TI TTYUMF5 DMJ9ZIY TN Fast skeletal muscle troponin complex (TNNC2) DMJ9ZIY MA Modulator DMJ9ZIY RN Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5. DMJ9ZIY RU https://pubmed.ncbi.nlm.nih.gov/22344294 DMJBHO0 DI DMJBHO0 DMJBHO0 DN PC-DAC:Insulin DMJBHO0 TI TTZOPHG DMJBHO0 TN Insulin (INS) DMJBHO0 MA Modulator DMJBHO0 RN Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539. DMJBHO0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901028/ DMJBU9V DI DMJBU9V DMJBU9V DN Velimogene aliplasmid DMJBU9V TI TTGS10J DMJBU9V TN HLA class I antigen B-7 (HLA-B) DMJBU9V MA Modulator DMJBU9V RN Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51. DMJBU9V RU https://pubmed.ncbi.nlm.nih.gov/20367461 DMJBXO3 DI DMJBXO3 DMJBXO3 DN VX-661 DMJBXO3 TI TTRLZHP DMJBXO3 TN cAMP-dependent chloride channel (CFTR) DMJBXO3 MA Regulator DMJBXO3 RN CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11. DMJBXO3 RU https://pubmed.ncbi.nlm.nih.gov/25083129 DMJCF1O DI DMJCF1O DMJCF1O DN Maralixibat DMJCF1O TI TTPI1M5 DMJCF1O TN Ileal sodium/bile acid cotransporter (SLC10A2) DMJCF1O MA Inhibitor DMJCF1O RN Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689. DMJCF1O RU https://pubmed.ncbi.nlm.nih.gov/32653991 DMJFD2I DI DMJFD2I DMJFD2I DN ABT-492 DMJFD2I TI TTIXTO3 DMJFD2I TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMJFD2I MA Modulator DMJFD2I RN Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus DMJFD2I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028753 DMJFNR9 DI DMJFNR9 DMJFNR9 DN Viramidine DMJFNR9 TI TTL7C8Q DMJFNR9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMJFNR9 MA Inhibitor DMJFNR9 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMJFNR9 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMJKWMA DI DMJKWMA DMJKWMA DN Tanezumab DMJKWMA TI TTDN3LF DMJKWMA TN Nerve growth factor (NGF) DMJKWMA MA Inhibitor DMJKWMA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJKWMA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJNSLU DI DMJNSLU DMJNSLU DN AAV2-hRPE65v2 DMJNSLU TI TTBOH16 DMJNSLU TN Retinal pigment epithelium protein (RPE65) DMJNSLU MA Modulator DMJNSLU RN AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012 Feb 8;4(120):120ra15. DMJNSLU RU https://pubmed.ncbi.nlm.nih.gov/22323828 DMJPGUA DI DMJPGUA DMJPGUA DN Manidipine DMJPGUA TI TTEAID7 DMJPGUA TN Trypanosoma Cruzipain (Trypano CYSP) DMJPGUA MA Inhibitor DMJPGUA RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMJPGUA RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMJRFYB DI DMJRFYB DMJRFYB DN RG7201 DMJRFYB TI TTN7Y4P DMJRFYB TN Sodium/glucose cotransporter 2 (SLC5A4) DMJRFYB MA Modulator DMJRFYB RN Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. DMJRFYB RU https://pubmed.ncbi.nlm.nih.gov/24678906 DMJRQDG DI DMJRQDG DMJRQDG DN AG-SPT201 DMJRQDG TI TTF1QVM DMJRQDG TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMJRQDG MA Modulator DMJRQDG RN Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. DMJRQDG RU https://pubmed.ncbi.nlm.nih.gov/10197495 DMJS8V3 DI DMJS8V3 DMJS8V3 DN Disufenton sodium DMJS8V3 TI TT8E7Z0 DMJS8V3 TN Free radical (FRD) DMJS8V3 MA Modulator DMJS8V3 RN NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8. DMJS8V3 RU https://pubmed.ncbi.nlm.nih.gov/11136936 DMK0QW6 DI DMK0QW6 DMK0QW6 DN Albinterferon alfa-2b DMK0QW6 TI TTSIUJ9 DMK0QW6 TN Interferon-alpha 2 (IFNA2) DMK0QW6 MA Modulator DMK0QW6 RN Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002. DMK0QW6 RU https://pubmed.ncbi.nlm.nih.gov/19275518 DMK1IPV DI DMK1IPV DMK1IPV DN SCY-078 DMK1IPV TI TT0SFXH DMK1IPV TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMK1IPV MA Inhibitor DMK1IPV RN Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. DMK1IPV RU https://pubmed.ncbi.nlm.nih.gov/25512406 DMK2Y4V DI DMK2Y4V DMK2Y4V DN Ancrod DMK2Y4V TI TTZUXYS DMK2Y4V TN Vitamin K-dependent protein C (PROC) DMK2Y4V MA Modulator DMK2Y4V RN Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7. DMK2Y4V RU https://pubmed.ncbi.nlm.nih.gov/2589675 DMK301H DI DMK301H DMK301H DN MK-8742 DMK301H TI TTCJ2X8 DMK301H TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMK301H MA Modulator DMK301H RN Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40. DMK301H RU https://pubmed.ncbi.nlm.nih.gov/24127258 DMK34MZ DI DMK34MZ DMK34MZ DN Xilonix DMK34MZ TI TTPM6HI DMK34MZ TN Interleukin-1 alpha (IL1A) DMK34MZ MA Modulator DMK34MZ RN Clinical pipeline report, company report or official report of xbiotech. DMK34MZ RU http://www.xbiotech.com/clinical/oncology.html DMK38MV DI DMK38MV DMK38MV DN Fulranumab DMK38MV TI TTEDJN4 DMK38MV TN Low-affinity nerve growth factor receptor (NGFR) DMK38MV MA Antagonist DMK38MV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMK38MV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMK56G0 DI DMK56G0 DMK56G0 DN Bexagliflozin DMK56G0 TI TTF8JAT DMK56G0 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMK56G0 MA Inhibitor DMK56G0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK56G0 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK6OFY DI DMK6OFY DMK6OFY DN Peginterferon lambda-1a DMK6OFY TI TTM624L DMK6OFY TN Interleukin-29 (IL29) DMK6OFY MA Agonist DMK6OFY RN Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. DMK6OFY RU https://pubmed.ncbi.nlm.nih.gov/20645873 DMK6QBZ DI DMK6QBZ DMK6QBZ DN OMS721 DMK6QBZ TI TTR01E9 DMK6QBZ TN Mannan-binding lectin serine protease-2 (MASP2) DMK6QBZ MA Inhibitor DMK6QBZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK6QBZ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMK8AQP DI DMK8AQP DMK8AQP DN Sirukumab DMK8AQP TI TT0E5SK DMK8AQP TN Interleukin 6 receptor (IL6R) DMK8AQP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). DMK8AQP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310 DMK8AQP DI DMK8AQP DMK8AQP DN Sirukumab DMK8AQP TI TTT1V78 DMK8AQP TN Interleukin-6 (IL6) DMK8AQP MA Inhibitor DMK8AQP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK8AQP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMK9BP2 DI DMK9BP2 DMK9BP2 DN Mavacamten DMK9BP2 TI TTITSMB DMK9BP2 TN Myosin (MYO) DMK9BP2 MA Inhibitor DMK9BP2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK9BP2 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMKA2PI DI DMKA2PI DMKA2PI DN Efpeglenatide DMKA2PI TI TTVIMDE DMKA2PI TN Glucagon-like peptide 1 receptor (GLP1R) DMKA2PI MA Agonist DMKA2PI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKA2PI RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMKB4ZY DI DMKB4ZY DMKB4ZY DN Zanolimumab DMKB4ZY TI TTN2JFW DMKB4ZY TN T-cell surface glycoprotein CD4 (CD4) DMKB4ZY RN Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62. DMKB4ZY RU https://pubmed.ncbi.nlm.nih.gov/17311990 DMKD2BQ DI DMKD2BQ DMKD2BQ DN Creatine ALS-08 DMKD2BQ TI TTZ1DV7 DMKD2BQ TN Mitochondrial function (MF) DMKD2BQ MA Modulator DMKD2BQ RN The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207. DMKD2BQ RU https://pubmed.ncbi.nlm.nih.gov/16055197 DMKE187 DI DMKE187 DMKE187 DN Telmisartan DMKE187 TI TTPKMXQ DMKE187 TN HUMAN type-1 angiotensin II receptor (AGTR1) DMKE187 MA Blocker DMKE187 RN Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. DMKE187 RU https://pubmed.ncbi.nlm.nih.gov/32246101 DMKHLRT DI DMKHLRT DMKHLRT DN SAND-26 DMKHLRT TI TTDIGC1 DMKHLRT TN Dipeptidyl peptidase 4 (DPP-4) DMKHLRT RN Clinical pipeline report, company report or official report of Siesonline. DMKHLRT RU http://www.siesonline.it/en/wp-content/uploads/2013/05/21.pdf DMKL5AT DI DMKL5AT DMKL5AT DN Flurpiridaz F 18 DMKL5AT TI TTRU1NG DMKL5AT TN Mitochondrial complex I (NDUFA13) DMKL5AT MA Inhibitor DMKL5AT RN The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011 Jul;41(4):305-13. DMKL5AT RU https://pubmed.ncbi.nlm.nih.gov/21624564 DMKL9QO DI DMKL9QO DMKL9QO DN Seocalcitol DMKL9QO TI TTK59TV DMKL9QO TN Vitamin D3 receptor (VDR) DMKL9QO MA Inhibitor DMKL9QO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKL9QO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKLBHX DI DMKLBHX DMKLBHX DN ALO-02 DMKLBHX TI TTN4QDT DMKLBHX TN Opioid receptor (OPR) DMKLBHX MA Modulator DMKLBHX RN Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9. DMKLBHX RU https://pubmed.ncbi.nlm.nih.gov/15943961 DMKMTDG DI DMKMTDG DMKMTDG DN Balovaptan DMKMTDG TI TT4TFGN DMKMTDG TN Vasopressin V1a receptor (V1AR) DMKMTDG MA Antagonist DMKMTDG RN Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525. DMKMTDG RU https://pubmed.ncbi.nlm.nih.gov/31951127 DMKNCVM DI DMKNCVM DMKNCVM DN Dalcetrapib DMKNCVM TI TTFQAYR DMKNCVM TN Cholesteryl ester transfer protein (CETP) DMKNCVM MA Inhibitor DMKNCVM RN Clinical pipeline report, company report or official report of Roche (2009). DMKNCVM RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMKP45D DI DMKP45D DMKP45D DN Naproxcinod DMKP45D TI TTK0943 DMKP45D TN Prostaglandin G/H synthase (COX) DMKP45D MA Modulator DMKP45D RN Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57. DMKP45D RU https://pubmed.ncbi.nlm.nih.gov/19392579 DMKQZ0L DI DMKQZ0L DMKQZ0L DN ERITORAN DMKQZ0L TI TTISGCA DMKQZ0L TN Toll-like receptor 4 (TLR4) DMKQZ0L MA Inhibitor DMKQZ0L RN Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6. DMKQZ0L RU https://pubmed.ncbi.nlm.nih.gov/18828583 DMKSAG1 DI DMKSAG1 DMKSAG1 DN Tabalumab DMKSAG1 TI TTWMIDN DMKSAG1 TN B-cell-activating factor (TNFSF13B) DMKSAG1 MA Modulator DMKSAG1 RN Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8. DMKSAG1 RU https://pubmed.ncbi.nlm.nih.gov/23268367 DMKTS2M DI DMKTS2M DMKTS2M DN Rifaximin DR DMKTS2M TI TTHKJLN DMKTS2M TN DNA-directed RNA polymerase (RNAP) DMKTS2M MA Inhibitor DMKTS2M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKTS2M RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMKUOVP DI DMKUOVP DMKUOVP DN Ublituximab + umbralisib DMKUOVP TI TTUE541 DMKUOVP TN Leukocyte surface antigen Leu-16 (CD20) DMKUOVP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUOVP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKWBJR DI DMKWBJR DMKWBJR DN ISIS-PKK DMKWBJR TI TTN0PCX DMKWBJR TN Plasma kallikrein messenger RNA (KLKB1 mRNA) DMKWBJR RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMKWBJR RU https://www.isispharm.com/pipeline/isis-pkkrx/ DMKWV4B DI DMKWV4B DMKWV4B DN Golnerminogene pradenovac DMKWV4B TI TTF8CQI DMKWV4B TN Tumor necrosis factor (TNF) DMKWV4B MA Modulator DMKWV4B RN TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30. DMKWV4B RU https://pubmed.ncbi.nlm.nih.gov/16132372 DMKZRBP DI DMKZRBP DMKZRBP DN Litoxetine DMKZRBP TI TT3ROYC DMKZRBP TN Serotonin transporter (SERT) DMKZRBP MA Modulator DMKZRBP RN Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. DMKZRBP RU https://www.ncbi.nlm.nih.gov/pubmed/8385615 DMKZRBP DI DMKZRBP DMKZRBP DN Litoxetine DMKZRBP TI TTNXLKE DMKZRBP TN 5-HT 3 receptor (5HT3R) DMKZRBP MA Modulator DMKZRBP RN Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. DMKZRBP RU https://www.ncbi.nlm.nih.gov/pubmed/8385615 DML1KTO DI DML1KTO DML1KTO DN PT2977 DML1KTO TI TTDMLNT DML1KTO TN Hypoxia-inducible factor 2 alpha (HIF-2A) DML1KTO MA Inhibitor DML1KTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML1KTO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML61S4 DI DML61S4 DML61S4 DN ARQ-151 DML61S4 TI TTV5CGO DML61S4 TN Phosphodiesterase 4 (PDE4) DML61S4 MA Inhibitor DML61S4 RN Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239. DML61S4 RU https://pubmed.ncbi.nlm.nih.gov/32668113 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TTJGNVC DML6GAN TN Apoptosis regulator Bcl-2 (BCL-2) DML6GAN MA Modulator DML6GAN RN Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16381626 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TT6EO5L DML6GAN TN Erbb2 tyrosine kinase receptor (HER2) DML6GAN MA Inhibitor DML6GAN RN Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16381626 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TTUTN1I DML6GAN TN Human Deoxyribonucleic acid (hDNA) DML6GAN MA Binder DML6GAN RN Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16782917 DML83IW DI DML83IW DML83IW DN Semagacestat DML83IW TI TT9W8GU DML83IW TN Gamma-secretase (GS) DML83IW MA Modulator DML83IW RN A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. DML83IW RU https://pubmed.ncbi.nlm.nih.gov/23883379 DMLA1ER DI DMLA1ER DMLA1ER DN EC20 DMLA1ER TI TTVC37M DMLA1ER TN Folate receptor alpha (FOLR1) DMLA1ER MA Modulator DMLA1ER RN EP patent application no. 2822386, Folate receptor alpha binding ligands. DMLA1ER RU http://www.google.com/patents/EP2822386A1?cl=en DMLAYTP DI DMLAYTP DMLAYTP DN Soluble ferric pyrophosphate DMLAYTP TI TTUDR0C DMLAYTP TN Iron (Fe) DMLAYTP MA Modulator DMLAYTP RN A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12. DMLAYTP RU https://pubmed.ncbi.nlm.nih.gov/14748943 DMLB3I4 DI DMLB3I4 DMLB3I4 DN Trastuzumab-DM1 DMLB3I4 TI TT6EO5L DMLB3I4 TN Erbb2 tyrosine kinase receptor (HER2) DMLB3I4 RN Clinical pipeline report, company report or official report of Genentech (2009). DMLB3I4 RU http://www.gene.com/gene/pipeline/status/ DMLBYRA DI DMLBYRA DMLBYRA DN ADX N05 DMLBYRA TI TT5TPI6 DMLBYRA TN Opioid receptor sigma 1 (OPRS1) DMLBYRA MA Modulator DMLBYRA RN Clinical pipeline report, company report or official report of SK BioPhamaceuticals. DMLBYRA RU http://www.skbp.com/etc/news_view_14.asp DMLCXPD DI DMLCXPD DMLCXPD DN TG-C DMLCXPD TI TTR9XHZ DMLCXPD TN Transforming growth factor beta 1 (TGFB1) DMLCXPD MA Modulator DMLCXPD RN Clinical pipeline report, company report or official report of Tissue Gene, Inc. DMLCXPD RU http://www.tissuegene.com/products/cartilage.html DMLDB1X DI DMLDB1X DMLDB1X DN Andecaliximab DMLDB1X TI TT6X50U DMLDB1X TN Matrix metalloproteinase-9 (MMP-9) DMLDB1X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDB1X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLG96Z DI DMLG96Z DMLG96Z DN INM-176 DMLG96Z TI TT1RS9F DMLG96Z TN Acetylcholinesterase (AChE) DMLG96Z MA Inhibitor DMLG96Z RN The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Abeta(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012 Sep 28;143(2):611-20. DMLG96Z RU https://pubmed.ncbi.nlm.nih.gov/22846435 DMLHEU7 DI DMLHEU7 DMLHEU7 DN Ridaforolimus DMLHEU7 TI TTCJG29 DMLHEU7 TN Serine/threonine-protein kinase mTOR (mTOR) DMLHEU7 MA Inhibitor DMLHEU7 RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMLHEU7 RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMLIMEA DI DMLIMEA DMLIMEA DN Varespladib methyl DMLIMEA TI TT2XHSJ DMLIMEA TN Secretory phospholipase A2 (sPLA2) DMLIMEA MA Modulator DMLIMEA RN Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43. DMLIMEA RU https://pubmed.ncbi.nlm.nih.gov/21446779 DMLKI2B DI DMLKI2B DMLKI2B DN Trafermin DMLKI2B TI TTGJVQM DMLKI2B TN Fibroblast growth factor receptor 2 (FGFR2) DMLKI2B MA Activator DMLKI2B RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMLKI2B RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMLMN2F DI DMLMN2F DMLMN2F DN CM-AT DMLMN2F TI TT7MRGU DMLMN2F TN Chymotrypsin (CTR) DMLMN2F MA Modulator DMLMN2F RN Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4. DMLMN2F RU https://pubmed.ncbi.nlm.nih.gov/20697394 DMLMS6J DI DMLMS6J DMLMS6J DN OTL-101 DMLMS6J TI TTLP57V DMLMS6J TN Adenosine deaminase (ADA) DMLMS6J MA Replacement DMLMS6J RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMLMS6J RU https://www.orchard-tx.com/approach/pipeline/ DMLO0KD DI DMLO0KD DMLO0KD DN Vicineum DMLO0KD TI TTZ8WH4 DMLO0KD TN Tumor-associated calcium signal transducer 1 (EPCAM) DMLO0KD RN Clinical pipeline report, company report or official report of Sesen Bio. DMLO0KD RU https://sesenbio.com/our-programs/ DMLQO7F DI DMLQO7F DMLQO7F DN EVP-6124 DMLQO7F TI TTLA931 DMLQO7F TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMLQO7F MA Modulator DMLQO7F RN Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24. DMLQO7F RU https://pubmed.ncbi.nlm.nih.gov/24419307 DMLRHM5 DI DMLRHM5 DMLRHM5 DN [3H](R)-(-)-baclofen DMLRHM5 TI TTDCVZW DMLRHM5 TN Gamma-aminobutyric acid B receptor (GABBR) DMLRHM5 MA Agonist DMLRHM5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242). DMLRHM5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTOM3J0 DMLSOB7 TN Estrogen receptor beta (ESR2) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTZAYWL DMLSOB7 TN Estrogen receptor (ESR) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTPADOQ DMLSOB7 TN HMG-CoA reductase (HMGCR) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSV74 DI DMLSV74 DMLSV74 DN Sotorasib DMLSV74 TI TT3LH46 DMLSV74 TN KRAS G12C mutant (KRAS G12C) DMLSV74 MA Inhibitor DMLSV74 RN Clinical pipeline report, company report or official report of Amgen. DMLSV74 RU https://www.amgenpipeline.com/ DMLU8NX DI DMLU8NX DMLU8NX DN Benserazide DMLU8NX TI TTN451K DMLU8NX TN Aromatic-L-amino-acid decarboxylase (DDC) DMLU8NX MA Inhibitor DMLU8NX RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMLU8NX RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMLVNTA DI DMLVNTA DMLVNTA DN Besipirdine DMLVNTA TI TTNGILX DMLVNTA TN Adrenergic receptor alpha-1A (ADRA1A) DMLVNTA MA Antagonist DMLVNTA RN Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46. DMLVNTA RU https://pubmed.ncbi.nlm.nih.gov/9103515 DMLWIU4 DI DMLWIU4 DMLWIU4 DN Cefluprenam DMLWIU4 TI TTJP4SM DMLWIU4 TN Bacterial Penicillin binding protein (Bact PBP) DMLWIU4 MA Inhibitor DMLWIU4 RN Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7. DMLWIU4 RU https://pubmed.ncbi.nlm.nih.gov/1804003 DMLY0H5 DI DMLY0H5 DMLY0H5 DN Astuprotimut-R DMLY0H5 TI TTWSKHD DMLY0H5 TN Melanoma-associated antigen 3 (MAGEA3) DMLY0H5 MA Modulator DMLY0H5 RN National Cancer Institute Drug Dictionary (drug id 600553). DMLY0H5 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600553 DMLY9F1 DI DMLY9F1 DMLY9F1 DN Azetirelin DMLY9F1 TI TT4J8MF DMLY9F1 TN Thyrotropin-releasing hormone receptor (TRHR) DMLY9F1 MA Modulator DMLY9F1 RN Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull. 1995 Jul;18(7):976-9. DMLY9F1 RU https://pubmed.ncbi.nlm.nih.gov/7581253 DMLYGH4 DI DMLYGH4 DMLYGH4 DN MK-4827 DMLYGH4 TI TTEBCY8 DMLYGH4 TN Poly [ADP-ribose] polymerase (PARP) DMLYGH4 MA Modulator DMLYGH4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMLYGH4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMM0HAE DI DMM0HAE DMM0HAE DN DSC-127 DMM0HAE TI TTOISYB DMM0HAE TN Proto-oncogene Mas (MAS) DMM0HAE MA Agonist DMM0HAE RN New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. DMM0HAE RU https://pubmed.ncbi.nlm.nih.gov/23166114 DMM0VO3 DI DMM0VO3 DMM0VO3 DN BSI-201 DMM0VO3 TI TTEBCY8 DMM0VO3 TN Poly [ADP-ribose] polymerase (PARP) DMM0VO3 MA Modulator DMM0VO3 RN Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. DMM0VO3 RU https://pubmed.ncbi.nlm.nih.gov/22291137 DMM1YC4 DI DMM1YC4 DMM1YC4 DN E-101 DMM1YC4 TI TTVCZPI DMM1YC4 TN Myeloperoxidase (MPO) DMM1YC4 MA Modulator DMM1YC4 RN In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42. DMM1YC4 RU https://pubmed.ncbi.nlm.nih.gov/21118915 DMM1Z9G DI DMM1Z9G DMM1Z9G DN Vutrisiran DMM1Z9G TI TTPOYU7 DMM1Z9G TN Transthyretin messenger RNA (TTR mRNA) DMM1Z9G MA Inhibitor DMM1Z9G RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. DMM1Z9G RU https://www.alnylam.com/alnylam-rnai-pipeline/ DMM2JXP DI DMM2JXP DMM2JXP DN VX-787 DMM2JXP TI TT62KQV DMM2JXP TN Influenza Polymerase basic protein 2 (Influ PB2) DMM2JXP MA Inhibitor DMM2JXP RN Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014 Aug 14;57(15):6668-78. DMM2JXP RU https://pubmed.ncbi.nlm.nih.gov/25019388 DMM2LTC DI DMM2LTC DMM2LTC DN KSI-301 DMM2LTC TI TT9HKJA DMM2LTC TN Vascular endothelial growth factor (VEGF) DMM2LTC MA Inhibitor DMM2LTC RN Clinical pipeline report, company report or official report of Kodiak Sciences. DMM2LTC RU https://kodiak.com/our-pipeline/ DMM2OZH DI DMM2OZH DMM2OZH DN Ushercell DMM2OZH TI TTAUG8D DMM2OZH TN Human immunodeficiency virus Transmission (HIV Tran) DMM2OZH MA Modulator DMM2OZH RN Short Communication: Enhancement of HIV Infection by Cellulose Sulfate. AIDS Res Hum Retroviruses. 2008 July; 24(7): 925-929. DMM2OZH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927036/ DMM4C95 DI DMM4C95 DMM4C95 DN PF-06438179 DMM4C95 TI TTF8CQI DMM4C95 TN Tumor necrosis factor (TNF) DMM4C95 MA Inhibitor DMM4C95 RN Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7. DMM4C95 RU https://pubmed.ncbi.nlm.nih.gov/24722561 DMM4FJ3 DI DMM4FJ3 DMM4FJ3 DN Finerenone DMM4FJ3 TI TT26PHO DMM4FJ3 TN Mineralocorticoid receptor (MR) DMM4FJ3 MA Antagonist DMM4FJ3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM4FJ3 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMM5VTA DI DMM5VTA DMM5VTA DN Dutogliptin DMM5VTA TI TTDIGC1 DMM5VTA TN Dipeptidyl peptidase 4 (DPP-4) DMM5VTA MA Inhibitor DMM5VTA RN Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. DMM5VTA RU https://pubmed.ncbi.nlm.nih.gov/20380656 DMM6G5D DI DMM6G5D DMM6G5D DN AZD0914 DMM6G5D TI TTN6J5F DMM6G5D TN Bacterial DNA gyrase (Bact gyrase) DMM6G5D MA Modulator DMM6G5D RN High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.Antimicrob Agents Chemother.2014 Sep;58(9):5585-8. DMM6G5D RU https://www.ncbi.nlm.nih.gov/pubmed/24982070 DMM74PK DI DMM74PK DMM74PK DN Atrasentan DMM74PK TI TTKRD0G DMM74PK TN Endothelin A receptor (EDNRA) DMM74PK MA Antagonist DMM74PK RN Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S. DMM74PK RU https://pubmed.ncbi.nlm.nih.gov/12193124 DMM76GL DI DMM76GL DMM76GL DN Ceftobiprole DMM76GL TI TTJP4SM DMM76GL TN Bacterial Penicillin binding protein (Bact PBP) DMM76GL MA Modulator DMM76GL RN Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. DMM76GL RU https://www.ncbi.nlm.nih.gov/pubmed/17470659 DMM9JEF DI DMM9JEF DMM9JEF DN Imatinib DMM9JEF TI TTE63HY DMM9JEF TN HUMAN fusion protein Bcr-Abl (Bcr-Abl) DMM9JEF MA Inhibitor DMM9JEF RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMM9JEF RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMM9XL2 DI DMM9XL2 DMM9XL2 DN BMN-111 DMM9XL2 TI TTRK0B9 DMM9XL2 TN C-type natriuretic peptide (NPPC) DMM9XL2 MA Modulator DMM9XL2 RN Clinical pipeline report, company report or official report of Biomarin. DMM9XL2 RU https://www.bmrn.com/pipeline/clinical-trials/achondroplasia.php DMMA0C7 DI DMMA0C7 DMMA0C7 DN Laquinamod DMMA0C7 TI TTZF0K2 DMMA0C7 TN C-X-C motif chemokine 2 (CXCL2) DMMA0C7 MA Modulator DMMA0C7 RN Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9. DMMA0C7 RU https://pubmed.ncbi.nlm.nih.gov/18220950 DMMBC5W DI DMMBC5W DMMBC5W DN PDGF-BB DMMBC5W TI TTQA6SX DMMBC5W TN Platelet-derived growth factor B (PDGFB) DMMBC5W MA Modulator DMMBC5W RN Clinical pipeline report, company report or official report of Adocia. DMMBC5W RU http://www.adocia.fr/WP/products/bc-pdgf-bb-en/ DMMBJYC DI DMMBJYC DMMBJYC DN ZYH-1 DMMBJYC TI TTZMAO3 DMMBJYC TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMBJYC MA Modulator DMMBJYC RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DMMBJYC RU https://pubmed.ncbi.nlm.nih.gov/24062180 DMMBJYC DI DMMBJYC DMMBJYC DN ZYH-1 DMMBJYC TI TTJ584C DMMBJYC TN Peroxisome proliferator-activated receptor alpha (PPARA) DMMBJYC MA Modulator DMMBJYC RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DMMBJYC RU https://pubmed.ncbi.nlm.nih.gov/24062180 DMMC3Y8 DI DMMC3Y8 DMMC3Y8 DN NPC-01 DMMC3Y8 TI TTZAYWL DMMC3Y8 TN Estrogen receptor (ESR) DMMC3Y8 MA Modulator DMMC3Y8 RN ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health. DMMC3Y8 RU https://clinicaltrials.gov/ct2/show/NCT01246791 DMMC3Y8 DI DMMC3Y8 DMMC3Y8 DN NPC-01 DMMC3Y8 TI TTUV8G9 DMMC3Y8 TN Progesterone receptor (PGR) DMMC3Y8 MA Agonist DMMC3Y8 RN ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health. DMMC3Y8 RU https://clinicaltrials.gov/ct2/show/NCT01246791 DMMD856 DI DMMD856 DMMD856 DN Sulopenem DMMD856 TI TTJP4SM DMMD856 TN Bacterial Penicillin binding protein (Bact PBP) DMMD856 MA Modulator DMMD856 RN In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37. DMMD856 RU https://pubmed.ncbi.nlm.nih.gov/8786624 DMME6GJ DI DMME6GJ DMME6GJ DN SB12 DMME6GJ TI TTKANGO DMME6GJ TN Complement C5 (CO5) DMME6GJ MA Inhibitor DMME6GJ RN Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. DMME6GJ RU https://pubmed.ncbi.nlm.nih.gov/31324874 DMMEAOL DI DMMEAOL DMMEAOL DN Coversin DMMEAOL TI TTKANGO DMMEAOL TN Complement C5 (CO5) DMMEAOL MA Inhibitor DMMEAOL RN Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258. DMMEAOL RU https://pubmed.ncbi.nlm.nih.gov/29296765 DMMF5K4 DI DMMF5K4 DMMF5K4 DN ABL 001 DMMF5K4 TI TTS7G69 DMMF5K4 TN Fusion protein Bcr-Abl (Bcr-Abl) DMMF5K4 MA Inhibitor DMMF5K4 RN ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125. DMMF5K4 RU https://ash.confex.com/ash/2014/webprogram/Paper76344.html DMMIWCE DI DMMIWCE DMMIWCE DN Sifuvirtide DMMIWCE TI TTG90S6 DMMIWCE TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMMIWCE MA Modulator DMMIWCE RN Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96. DMMIWCE RU https://www.ncbi.nlm.nih.gov/pubmed/22228771 DMMJ63A DI DMMJ63A DMMJ63A DN PT-304 DMMJ63A TI TT84ETX DMMJ63A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMJ63A MA Inhibitor DMMJ63A RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMMJ63A RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMMKE2H DI DMMKE2H DMMKE2H DN Valoctocogene roxaparvovec DMMKE2H TI TT1290U DMMKE2H TN Coagulation factor VIII (F8) DMMKE2H MA Replacement DMMKE2H RN Clinical pipeline report, company report or official report of BioMarin Pharmaceutical. DMMKE2H RU https://www.biomarin.com/our-treatments/pipeline/ DMMKGBP DI DMMKGBP DMMKGBP DN D-Methionine DMMKGBP TI TTZL0OI DMMKGBP TN Methionine aminopeptidase 2 (METAP2) DMMKGBP MA Inhibitor DMMKGBP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMKGBP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMLXA9 DI DMMLXA9 DMMLXA9 DN LX-4211 DMMLXA9 TI TT2UE56 DMMLXA9 TN Sodium/glucose cotransporter 1 (SGLT1) DMMLXA9 MA Modulator DMMLXA9 RN LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. DMMLXA9 RU https://pubmed.ncbi.nlm.nih.gov/22739142 DMMLXA9 DI DMMLXA9 DMMLXA9 DN LX-4211 DMMLXA9 TI TTLWPVF DMMLXA9 TN Sodium/glucose cotransporter 2 (SGLT2) DMMLXA9 MA Modulator DMMLXA9 RN LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. DMMLXA9 RU https://pubmed.ncbi.nlm.nih.gov/22739142 DMMNP2F DI DMMNP2F DMMNP2F DN G17DT DMMNP2F TI TT4LRVO DMMNP2F TN Gastrin (GAST) DMMNP2F RN G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. DMMNP2F RU https://pubmed.ncbi.nlm.nih.gov/17309331 DMMO6P0 DI DMMO6P0 DMMO6P0 DN Tifacogin DMMO6P0 TI TT068JH DMMO6P0 TN Tissue factor pathway inhibitor (TFPI) DMMO6P0 MA Inhibitor DMMO6P0 RN Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47. DMMO6P0 RU https://pubmed.ncbi.nlm.nih.gov/12851279 DMMP51W DI DMMP51W DMMP51W DN sparsentan DMMP51W TI TT8DBY3 DMMP51W TN Angiotensin II receptor type-1 (AGTR1) DMMP51W MA Antagonist DMMP51W RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMMP51W RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMMP51W DI DMMP51W DMMP51W DN sparsentan DMMP51W TI TTKRD0G DMMP51W TN Endothelin A receptor (EDNRA) DMMP51W MA Antagonist DMMP51W RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMMP51W RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMMQ2U9 DI DMMQ2U9 DMMQ2U9 DN VGX-3100 DMMQ2U9 TI TTE2N95 DMMQ2U9 TN Human papillomavirus protein E6 (HPV E6) DMMQ2U9 MA Modulator DMMQ2U9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMQ2U9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMQ2U9 DI DMMQ2U9 DMMQ2U9 DN VGX-3100 DMMQ2U9 TI TT3CPZW DMMQ2U9 TN Human papillomavirus protein E7 (HPV E7) DMMQ2U9 MA Modulator DMMQ2U9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMQ2U9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMQ7BY DI DMMQ7BY DMMQ7BY DN Fitusiran DMMQ7BY TI TTZ4MD5 DMMQ7BY TN SERPINC1 messenger RNA (SERPINC1 mRNA) DMMQ7BY MA Inhibitor DMMQ7BY RN Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828. DMMQ7BY RU https://pubmed.ncbi.nlm.nih.gov/28691885 DMMTKC6 DI DMMTKC6 DMMTKC6 DN TEV-48125 DMMTKC6 TI TTAFORY DMMTKC6 TN Calcitonin gene-related peptide (CALC) DMMTKC6 RN TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8. DMMTKC6 RU https://pubmed.ncbi.nlm.nih.gov/27281531 DMMTW9K DI DMMTW9K DMMTW9K DN Vicriviroc DMMTW9K TI TT2CEJG DMMTW9K TN C-C chemokine receptor type 5 (CCR5) DMMTW9K MA Antagonist DMMTW9K RN HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42. DMMTW9K RU https://pubmed.ncbi.nlm.nih.gov/19532079 DMMWO7V DI DMMWO7V DMMWO7V DN ABBV-951 DMMWO7V TI TTWFZ1N DMMWO7V TN Dopamine receptor (DR) DMMWO7V MA Activator DMMWO7V RN Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61. DMMWO7V RU https://pubmed.ncbi.nlm.nih.gov/33772855 DMMX75K DI DMMX75K DMMX75K DN LEE011 DMMX75K TI TT0PG8F DMMX75K TN Cyclin-dependent kinase 4 (CDK4) DMMX75K MA Modulator DMMX75K RN Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. DMMX75K RU https://pubmed.ncbi.nlm.nih.gov/24045179 DMMX75K DI DMMX75K DMMX75K DN LEE011 DMMX75K TI TTO0FDJ DMMX75K TN Cyclin-dependent kinase 6 (CDK6) DMMX75K MA Modulator DMMX75K RN Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. DMMX75K RU https://pubmed.ncbi.nlm.nih.gov/24045179 DMMZDJ6 DI DMMZDJ6 DMMZDJ6 DN Captopril DMMZDJ6 TI TTGFNPD DMMZDJ6 TN HUMAN angiotensin-converting enzyme (ACE) DMMZDJ6 MA Inhibitor DMMZDJ6 RN Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31. DMMZDJ6 RU https://pubmed.ncbi.nlm.nih.gov/32291526 DMMZS2T DI DMMZS2T DMMZS2T DN 177-Lu-oxodotreotide DMMZS2T TI TTOMNR9 DMMZS2T TN Somatostatin receptor (SSTR) DMMZS2T MA Agonist DMMZS2T RN Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12. DMMZS2T RU https://pubmed.ncbi.nlm.nih.gov/22388631 DMN1ZEU DI DMN1ZEU DMN1ZEU DN Radiosensitizer gene therapy DMN1ZEU TI TTP3QRF DMN1ZEU TN Thymidine kinase 1 (TK1) DMN1ZEU MA Inhibitor DMN1ZEU RN Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8. DMN1ZEU RU https://pubmed.ncbi.nlm.nih.gov/9815600 DMN4E7T DI DMN4E7T DMN4E7T DN Guaiacol DMN4E7T TI TTANPDJ DMN4E7T TN Carbonic anhydrase II (CA-II) DMN4E7T MA Inhibitor DMN4E7T RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMN4E7T RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMN72OM DI DMN72OM DMN72OM DN U300 DMN72OM TI TTZOPHG DMN72OM TN Insulin (INS) DMN72OM MA Modulator DMN72OM RN U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014 Dec;14(12):1849-60. DMN72OM RU https://pubmed.ncbi.nlm.nih.gov/25311556 DMN8DQH DI DMN8DQH DMN8DQH DN Darusentan DMN8DQH TI TTKRD0G DMN8DQH TN Endothelin A receptor (EDNRA) DMN8DQH MA Antagonist DMN8DQH RN Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62. DMN8DQH RU https://pubmed.ncbi.nlm.nih.gov/16633090 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TTD16BI DMN9BO3 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMN9BO3 MA Inhibitor DMN9BO3 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TTZGK1R DMN9BO3 TN HUMAN glycosylation of host receptor (GHR) DMN9BO3 MA Inhibitor DMN9BO3 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TT3A1EZ DMN9BO3 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMN9BO3 MA Inhibitor DMN9BO3 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMN9ETB DI DMN9ETB DMN9ETB DN Contusugene ladenovec DMN9ETB TI TT7SBF5 DMN9ETB TN Cellular tumor antigen p53 (TP53) DMN9ETB MA Modulator DMN9ETB RN A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61. DMN9ETB RU https://pubmed.ncbi.nlm.nih.gov/19169960 DMNAYUJ DI DMNAYUJ DMNAYUJ DN Lu AF35700 DMNAYUJ TI TTEX248 DMNAYUJ TN Dopamine D2 receptor (D2R) DMNAYUJ MA Modulator DMNAYUJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNAYUJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNCY1I DI DMNCY1I DMNCY1I DN (-)-Phenserine DMNCY1I TI TT1RS9F DMNCY1I TN Acetylcholinesterase (AChE) DMNCY1I MA Inhibitor DMNCY1I RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMNCY1I RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMNCY1I DI DMNCY1I DMNCY1I DN (-)-Phenserine DMNCY1I TI TTEB0GD DMNCY1I TN Cholinesterase (BCHE) DMNCY1I MA Inhibitor DMNCY1I RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMNCY1I RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMND3AB DI DMND3AB DMND3AB DN Asimadoline DMND3AB TI TTQW87Y DMND3AB TN Opioid receptor kappa (OPRK1) DMND3AB MA Agonist DMND3AB RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMND3AB RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMNDCFY DI DMNDCFY DMNDCFY DN MPL-S DMNDCFY TI TTF10I9 DMNDCFY TN Nitric-oxide synthase inducible (NOS2) DMNDCFY MA Modulator DMNDCFY RN Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47. DMNDCFY RU https://pubmed.ncbi.nlm.nih.gov/9234781 DMNDGWE DI DMNDGWE DMNDGWE DN IT-101 DMNDGWE TI TTQHWNA DMNDGWE TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMNDGWE MA Inhibitor DMNDGWE RN CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67. DMNDGWE RU https://pubmed.ncbi.nlm.nih.gov/25833208 DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTJGNVC DMNE56X TN Apoptosis regulator Bcl-2 (BCL-2) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTU1E82 DMNE56X TN Apoptosis regulator Bcl-xL (BCL-xL) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTQ79W8 DMNE56X TN Apoptosis regulator Bcl-W (BCL-W) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTFCJ7S DMNE56X TN G1/S-specific cyclin-D1 (CCND1) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNE56X RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TTCGSZ4 DMNF4UH TN Pancreatic alpha-amylase (AMY2A) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TTXMY0J DMNF4UH TN Pancreatic triacylglycerol lipase (PNLIP) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TT7MRGU DMNF4UH TN Chymotrypsin (CTR) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNGCAD DI DMNGCAD DMNGCAD DN Rova-T DMNGCAD TI TT1C9K6 DMNGCAD TN Delta-like protein 3 (DLL3) DMNGCAD MA Inhibitor DMNGCAD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNGCAD RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMNKBEC DI DMNKBEC DMNKBEC DN BGJ398 DMNKBEC TI TTRLW2X DMNKBEC TN Fibroblast growth factor receptor 1 (FGFR1) DMNKBEC MA Modulator DMNKBEC RN Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. DMNKBEC RU https://pubmed.ncbi.nlm.nih.gov/23129509 DMNKBEC DI DMNKBEC DMNKBEC DN BGJ398 DMNKBEC TI TT0LF7H DMNKBEC TN Fibroblast growth factor receptor (FGFR) DMNKBEC MA Inhibitor DMNKBEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNKBEC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNM93X DI DMNM93X DMNM93X DN Linagliptin DMNM93X TI TTF928K DMNM93X TN HUMAN dipeptidyl peptidase 4 (DPP-4) DMNM93X MA Inhibitor DMNM93X RN DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26. DMNM93X RU https://pubmed.ncbi.nlm.nih.gov/32336007 DMNQ869 DI DMNQ869 DMNQ869 DN ABT-267 DMNQ869 TI TTCJ2X8 DMNQ869 TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMNQ869 MA Modulator DMNQ869 RN Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. DMNQ869 RU https://pubmed.ncbi.nlm.nih.gov/24400777 DMNVP8Q DI DMNVP8Q DMNVP8Q DN Tivantinib DMNVP8Q TI TTNDSF4 DMNVP8Q TN Proto-oncogene c-Met (MET) DMNVP8Q MA Inhibitor DMNVP8Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948). DMNVP8Q RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948 DMNY05F DI DMNY05F DMNY05F DN Lopinavir + ritonavir + oseltamivir DMNY05F TI TT1D53B DMNY05F TN COVID-19 3C-like protease (3CLpro) DMNY05F MA Inhibitor DMNY05F RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMNY05F RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMNZOCK DI DMNZOCK DMNZOCK DN PF-05280586 DMNZOCK TI TTUE541 DMNZOCK TN Leukocyte surface antigen Leu-16 (CD20) DMNZOCK MA Antagonist DMNZOCK RN Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81. DMNZOCK RU https://pubmed.ncbi.nlm.nih.gov/24604381 DMO1234 DI DMO1234 DMO1234 DN TNX-102 DMO1234 TI TT2NUT5 DMO1234 TN Adrenergic receptor alpha-2C (ADRA2C) DMO1234 MA Antagonist DMO1234 RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMO1234 RU http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia DMO1234 DI DMO1234 DMO1234 DN TNX-102 DMO1234 TI TTJQOD7 DMO1234 TN 5-HT 2A receptor (HTR2A) DMO1234 MA Antagonist DMO1234 RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMO1234 RU http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia DMO3ITF DI DMO3ITF DMO3ITF DN GASTRAZOLE DMO3ITF TI TTVFO0U DMO3ITF TN Gastrin/cholecystokinin type B receptor (CCKBR) DMO3ITF MA Antagonist DMO3ITF RN Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115. DMO3ITF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/ DMO628K DI DMO628K DMO628K DN Arbaclofen placarbil DMO628K TI TTDCVZW DMO628K TN Gamma-aminobutyric acid B receptor (GABBR) DMO628K MA Modulator DMO628K RN Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21. DMO628K RU https://www.ncbi.nlm.nih.gov/pubmed/19502531 DMO628K DI DMO628K DMO628K DN Arbaclofen placarbil DMO628K TI TTEX6LM DMO628K TN GABA(A) receptor gamma-3 (GABRG3) DMO628K MA Agonist DMO628K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO628K RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMO7BQS DI DMO7BQS DMO7BQS DN DMP-444 DMO7BQS TI TT38RM1 DMO7BQS TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMO7BQS MA Modulator DMO7BQS RN Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4. DMO7BQS RU https://pubmed.ncbi.nlm.nih.gov/12911097 DMO8PT9 DI DMO8PT9 DMO8PT9 DN MLN8237 DMO8PT9 TI TTPS3C0 DMO8PT9 TN Aurora kinase A (AURKA) DMO8PT9 MA Inhibitor DMO8PT9 RN Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553. DMO8PT9 RU http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8553 DMODA2X DI DMODA2X DMODA2X DN Bardoxolone methyl DMODA2X TI TTT2SVW DMODA2X TN PPAR-gamma messenger RNA (PPARG mRNA) DMODA2X MA Antagonist DMODA2X RN A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6. DMODA2X RU https://pubmed.ncbi.nlm.nih.gov/11043571 DMOF0CA DI DMOF0CA DMOF0CA DN Nolatrexed DMOF0CA TI TTU6BFZ DMOF0CA TN Candida Thymidylate synthase (Candi TMP1) DMOF0CA MA Inhibitor DMOF0CA RN A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20. DMOF0CA RU https://pubmed.ncbi.nlm.nih.gov/10070890 DMOFH1M DI DMOFH1M DMOFH1M DN Volasertib DMOFH1M TI TTIYVQP DMOFH1M TN Polo-like kinase 1 (PLK1) DMOFH1M MA Modulator DMOFH1M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168). DMOFH1M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168 DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TTS87KH DMOFIBM TN Microtubule-associated protein tau (MAPT) DMOFIBM MA Inhibitor DMOFIBM RN Clinical pipeline report, company report or official report of TauRx. DMOFIBM RU http://taurx.com/press-releases-announcements.html DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TTZGF8B DMOFIBM TN Tau protein aggregation (TauA) DMOFIBM MA Modulator DMOFIBM RN Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81. DMOFIBM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000701/ DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TT9RZ03 DMOFIBM TN TAR DNA binding protein 43 (TARDBP) DMOFIBM MA Inhibitor DMOFIBM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOFIBM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMOG2X1 DI DMOG2X1 DMOG2X1 DN Trebananib DMOG2X1 TI TTKLQTJ DMOG2X1 TN Angiopoietin-2 (ANGPT2) DMOG2X1 MA Inhibitor DMOG2X1 RN Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. DMOG2X1 RU https://pubmed.ncbi.nlm.nih.gov/28751444 DMOG2X1 DI DMOG2X1 DMOG2X1 DN Trebananib DMOG2X1 TI TTWNQ1T DMOG2X1 TN Angiopoietin-1 (ANGPT1) DMOG2X1 MA Inhibitor DMOG2X1 RN Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. DMOG2X1 RU https://pubmed.ncbi.nlm.nih.gov/28751444 DMOHUR2 DI DMOHUR2 DMOHUR2 DN GLYX-13 DMOHUR2 TI TT9IK2Z DMOHUR2 TN N-methyl-D-aspartate receptor (NMDAR) DMOHUR2 MA Agonist DMOHUR2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOHUR2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMOJQGT DI DMOJQGT DMOJQGT DN ICARIIN DMOJQGT TI TTJ0IQB DMOJQGT TN Phosphodiesterase 5A (PDE5A) DMOJQGT MA Inhibitor DMOJQGT RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMOJQGT RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMOKQV7 DI DMOKQV7 DMOKQV7 DN XOMA 052 DMOKQV7 TI TTRYK0X DMOKQV7 TN Interleukin-1 beta (IL1B) DMOKQV7 RN Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69. DMOKQV7 RU https://pubmed.ncbi.nlm.nih.gov/21154167 DMOKT7Y DI DMOKT7Y DMOKT7Y DN FARGLITAZAR DMOKT7Y TI TTZMAO3 DMOKT7Y TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMOKT7Y MA Modulator DMOKT7Y RN Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84. DMOKT7Y RU https://www.ncbi.nlm.nih.gov/pubmed/10393202 DMOLR5W DI DMOLR5W DMOLR5W DN Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W TI TTBHFYQ DMOLR5W TN Mucin-1 (MUC1) DMOLR5W RN Clinical pipeline report, company report or official report of Immunomedics. DMOLR5W RU http://www.immunomedics.com/clivatuzumab-demo.shtml DMOMDXI DI DMOMDXI DMOMDXI DN Pratosartan DMOMDXI TI TT8DBY3 DMOMDXI TN Angiotensin II receptor type-1 (AGTR1) DMOMDXI MA Antagonist DMOMDXI RN Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7. DMOMDXI RU https://pubmed.ncbi.nlm.nih.gov/18360048 DMOQ9H1 DI DMOQ9H1 DMOQ9H1 DN Tremelimumab DMOQ9H1 TI TTI2S1D DMOQ9H1 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMOQ9H1 MA Modulator DMOQ9H1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). DMOQ9H1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 DMOQKAD DI DMOQKAD DMOQKAD DN SNF472 DMOQKAD TI TTGUHMF DMOQKAD TN Hydroxyapatite (HA) DMOQKAD MA Binder DMOQKAD RN Clinical pipeline report, company report or official report of Sanifit. DMOQKAD RU https://www.sanifit.com/lead-compound-snf472/ DMORSFB DI DMORSFB DMORSFB DN Chloroquine DMORSFB TI TTD16BI DMORSFB TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMORSFB MA Inhibitor DMORSFB RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMORSFB RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMORSFB DI DMORSFB DMORSFB DN Chloroquine DMORSFB TI TTZGK1R DMORSFB TN HUMAN glycosylation of host receptor (GHR) DMORSFB MA Inhibitor DMORSFB RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMORSFB RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMOSTXF DI DMOSTXF DMOSTXF DN Rigosertib DMOSTXF TI TTIYVQP DMOSTXF TN Polo-like kinase 1 (PLK1) DMOSTXF MA Modulator DMOSTXF RN Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. DMOSTXF RU https://pubmed.ncbi.nlm.nih.gov/24493827 DMOSTXF DI DMOSTXF DMOSTXF DN Rigosertib DMOSTXF TI TTHBTOP DMOSTXF TN PI3-kinase gamma (PIK3CG) DMOSTXF MA Modulator DMOSTXF RN Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. DMOSTXF RU https://pubmed.ncbi.nlm.nih.gov/24493827 DMOTCIU DI DMOTCIU DMOTCIU DN Lerisetron DMOTCIU TI TTNXLKE DMOTCIU TN 5-HT 3 receptor (5HT3R) DMOTCIU MA Antagonist DMOTCIU RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMOTCIU RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMOTH6V DI DMOTH6V DMOTH6V DN Interferon alpha 2a DMOTH6V TI TTSIUJ9 DMOTH6V TN Interferon-alpha 2 (IFNA2) DMOTH6V MA Modulator DMOTH6V RN Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60. DMOTH6V RU https://pubmed.ncbi.nlm.nih.gov/2840988 DMOUGX1 DI DMOUGX1 DMOUGX1 DN Diamyd DMOUGX1 TI TT7UY6K DMOUGX1 TN Glutamate decarboxylase 2 (GAD2) DMOUGX1 MA Immunomodulator DMOUGX1 RN Clinical pipeline report, company report or official report of Diamyd Medical. DMOUGX1 RU http://www.diamyd.com/docs/gadProducts.aspx?section=products DMOVEDH DI DMOVEDH DMOVEDH DN SYM-004 DMOVEDH TI TTGKNB4 DMOVEDH TN Epidermal growth factor receptor (EGFR) DMOVEDH RN Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206. DMOVEDH RU https://pubmed.ncbi.nlm.nih.gov/24204198 DMOWINT DI DMOWINT DMOWINT DN Reloxaliase DMOWINT TI TTMDQIJ DMOWINT TN Oxalate absorption (Oxalate absor) DMOWINT MA Replacement DMOWINT RN Clinical pipeline report, company report or official report of Allena Pharmaceuticals. DMOWINT RU https://www.allenapharma.com/reloxaliase DMOWQAF DI DMOWQAF DMOWQAF DN Recombinant human iduronate-2-sulfatase DMOWQAF TI TTNY2AP DMOWQAF TN Iduronate 2-sulfatase (IDS) DMOWQAF MA Modulator DMOWQAF RN The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074. DMOWQAF RU https://pubmed.ncbi.nlm.nih.gov/24454794 DMOYGZF DI DMOYGZF DMOYGZF DN Retosiban DMOYGZF TI TTSCIUP DMOYGZF TN Oxytocin receptor (OTR) DMOYGZF MA Modulator DMOYGZF RN The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6. DMOYGZF RU https://www.ncbi.nlm.nih.gov/pubmed/26207346 DMP0NGX DI DMP0NGX DMP0NGX DN Cilansetron DMP0NGX TI TTPC4TU DMP0NGX TN 5-HT 3A receptor (HTR3A) DMP0NGX MA Modulator DMP0NGX RN Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93. DMP0NGX RU https://www.ncbi.nlm.nih.gov/pubmed/15757394 DMP2BFG DI DMP2BFG DMP2BFG DN Anacetrapib DMP2BFG TI TTFQAYR DMP2BFG TN Cholesteryl ester transfer protein (CETP) DMP2BFG MA Inhibitor DMP2BFG RN Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6. DMP2BFG RU https://pubmed.ncbi.nlm.nih.gov/19552746 DMP2SGN DI DMP2SGN DMP2SGN DN Dabelotine DMP2SGN TI TTVIREA DMP2SGN TN Adrenergic receptor (ADR) DMP2SGN MA Modulator DMP2SGN RN US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation. DMP2SGN RU http://www.google.nl/patents/US20070049576 DMP36KD DI DMP36KD DMP36KD DN MLN4924 DMP36KD TI TTVKOPM DMP36KD TN NEDD8-activating enzyme (NAE) DMP36KD MA Modulator DMP36KD RN Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Cell Death Dis.2012 Sep 6;3:e386. DMP36KD RU https://www.ncbi.nlm.nih.gov/pubmed/22951983 DMP36KD DI DMP36KD DMP36KD DN MLN4924 DMP36KD TI TTNDC4K DMP36KD TN Ubiquitin-like protein Nedd8 (NEDD8) DMP36KD MA Inhibitor DMP36KD RN Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834. DMP36KD RU https://pubmed.ncbi.nlm.nih.gov/28569775 DMP3GI2 DI DMP3GI2 DMP3GI2 DN KW-3357 DMP3GI2 TI TT4QPUL DMP3GI2 TN Antithrombin-III (ATIII) DMP3GI2 MA Modulator DMP3GI2 RN Company report (kyowa-kirin) DMP3GI2 RU http://www.kyowa-kirin.com/news_releases/2014/e20140801_01.html DMP5G1K DI DMP5G1K DMP5G1K DN KPS-0373 DMP5G1K TI TT2Z39D DMP5G1K TN Thyrotropin-releasing hormone (TRH) DMP5G1K MA Modulator DMP5G1K RN DOI: 10.1002/mdc3.12057 DMP5G1K RU http://www.movementdisorders.org/MDS/Journals/Clinical-Practice-E-Journal-Overview/Movement-Disorders-Clinical-Practice-E-Journal-Volume-1-Issue-4/Treatment-Options-in-Degenerative-Cerebellar-Ataxia-A-Systematic-Review.htm DMP5L8S DI DMP5L8S DMP5L8S DN 177Lu-DOTA-octreotate DMP5L8S TI TTOMNR9 DMP5L8S TN Somatostatin receptor (SSTR) DMP5L8S MA Modulator DMP5L8S RN Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25. DMP5L8S RU https://pubmed.ncbi.nlm.nih.gov/24632546 DMP61YB DI DMP61YB DMP61YB DN ISRAPAFANT DMP61YB TI TTQL5VC DMP61YB TN Platelet-activating factor receptor (PTAFR) DMP61YB MA Antagonist DMP61YB RN Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40. DMP61YB RU https://pubmed.ncbi.nlm.nih.gov/20007715 DMP6IMQ DI DMP6IMQ DMP6IMQ DN Rindopepimut DMP6IMQ TI TTGKNB4 DMP6IMQ TN Epidermal growth factor receptor (EGFR) DMP6IMQ MA Modulator DMP6IMQ RN Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. DMP6IMQ RU https://pubmed.ncbi.nlm.nih.gov/21154166 DMP83UZ DI DMP83UZ DMP83UZ DN Fumaric acid DMP83UZ TI TT93WF5 DMP83UZ TN Interferon-gamma (IFNG) DMP83UZ MA Binder DMP83UZ RN Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. DMP83UZ RU https://pubmed.ncbi.nlm.nih.gov/18764723 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTEX248 DMP8ESD TN Dopamine D2 receptor (D2R) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTZFYLI DMP8ESD TN Dopamine D1 receptor (D1R) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTJQOD7 DMP8ESD TN 5-HT 2A receptor (HTR2A) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8MDW DI DMP8MDW DMP8MDW DN GS-5745 DMP8MDW TI TT6X50U DMP8MDW TN Matrix metalloproteinase-9 (MMP-9) DMP8MDW MA Modulator DMP8MDW RN National Cancer Institute Drug Dictionary (drug id 747683). DMP8MDW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747683 DMPBA0D DI DMPBA0D DMPBA0D DN Sofpironium bromide DMPBA0D TI TTUPDWN DMPBA0D TN Cholinergic receptor unspecific (CHR) DMPBA0D MA Antagonist DMPBA0D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPBA0D RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPBJ8W DI DMPBJ8W DMPBJ8W DN Turoctocog alfa DMPBJ8W TI TT1290U DMPBJ8W TN Coagulation factor VIII (F8) DMPBJ8W MA Modulator DMPBJ8W RN The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9. DMPBJ8W RU https://pubmed.ncbi.nlm.nih.gov/25495795 DMPCFXN DI DMPCFXN DMPCFXN DN QAW-039 DMPCFXN TI TTNVEIR DMPCFXN TN Prostaglandin D2 receptor (PTGDR) DMPCFXN MA Antagonist DMPCFXN RN Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015. DMPCFXN RU http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A6361 DMPDQ8T DI DMPDQ8T DMPDQ8T DN AB-103 DMPDQ8T TI TTQ13FT DMPDQ8T TN T-cell-specific surface glycoprotein CD28 (CD28) DMPDQ8T MA Antagonist DMPDQ8T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPDQ8T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPG4OM DI DMPG4OM DMPG4OM DN CAZ AVI DMPG4OM TI TTHI19T DMPG4OM TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMPG4OM MA Modulator DMPG4OM RN NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7. DMPG4OM RU https://pubmed.ncbi.nlm.nih.gov/22587688 DMPGH7N DI DMPGH7N DMPGH7N DN ThermoProfen DMPGH7N TI TT8NGED DMPGH7N TN Prostaglandin G/H synthase 1 (COX-1) DMPGH7N MA Inhibitor DMPGH7N RN Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49. DMPGH7N RU https://pubmed.ncbi.nlm.nih.gov/20210866 DMPGH7N DI DMPGH7N DMPGH7N DN ThermoProfen DMPGH7N TI TTVKILB DMPGH7N TN Prostaglandin G/H synthase 2 (COX-2) DMPGH7N MA Inhibitor DMPGH7N RN Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49. DMPGH7N RU https://pubmed.ncbi.nlm.nih.gov/20210866 DMPH1RK DI DMPH1RK DMPH1RK DN Alferminogene tadenovec DMPH1RK TI TTCEKVZ DMPH1RK TN Fibroblast growth factor-4 (FGF4) DMPH1RK MA Modulator DMPH1RK RN Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93. DMPH1RK RU https://pubmed.ncbi.nlm.nih.gov/18379964 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTZMAO3 DMPIDXT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMPIDXT MA Agonist DMPIDXT RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMPIDXT RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTI2WET DMPIDXT TN Platelet-derived growth factor receptor (PDGFR) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTUTJGQ DMPIDXT TN Vascular endothelial growth factor receptor 2 (KDR) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTPS3C0 DMPIDXT TN Aurora kinase A (AURKA) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTRLW2X DMPIDXT TN Fibroblast growth factor receptor 1 (FGFR1) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TT5LS6T DMPIDXT TN Aurora kinase B (AURKB) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPJTZ1 DI DMPJTZ1 DMPJTZ1 DN RBP-7000 DMPJTZ1 TI TTEX248 DMPJTZ1 TN Dopamine D2 receptor (D2R) DMPJTZ1 MA Modulator DMPJTZ1 RN Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43. DMPJTZ1 RU https://pubmed.ncbi.nlm.nih.gov/24464285 DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TT2Q6G1 DMPOTM4 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTRLW2X DMPOTM4 TN Fibroblast growth factor receptor 1 (FGFR1) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTUTJGQ DMPOTM4 TN Vascular endothelial growth factor receptor 2 (KDR) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTDCBX5 DMPOTM4 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TT7MRDV DMPOTM4 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPOTM4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTVJ1D8 DMPOTM4 TN Vascular endothelial growth factor receptor (VEGFR) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPOTM4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPQR1D DI DMPQR1D DMPQR1D DN Claudiximab DMPQR1D TI TT6PKBX DMPQR1D TN Claudin-18 (CLDN18) DMPQR1D RN Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9. DMPQR1D RU https://pubmed.ncbi.nlm.nih.gov/23900716 DMPRI14 DI DMPRI14 DMPRI14 DN Baricitinib DMPRI14 TI TT0AGBL DMPRI14 TN HUMAN cyclin G-associated kinase (GAK) DMPRI14 MA Inhibitor DMPRI14 RN Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. DMPRI14 RU https://pubmed.ncbi.nlm.nih.gov/32032529 DMPRI14 DI DMPRI14 DMPRI14 DN Baricitinib DMPRI14 TI TTN9A16 DMPRI14 TN HUMAN adaptor-associated kinase 1 (AAK1) DMPRI14 MA Inhibitor DMPRI14 RN Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. DMPRI14 RU https://pubmed.ncbi.nlm.nih.gov/32032529 DMPSG4D DI DMPSG4D DMPSG4D DN Flobufen DMPSG4D TI TT2J34L DMPSG4D TN Arachidonate 5-lipoxygenase (5-LOX) DMPSG4D MA Modulator DMPSG4D RN Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52. DMPSG4D RU https://pubmed.ncbi.nlm.nih.gov/9205780 DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTSHG0T DMPTCYB TN Toll-like receptor 9 (TLR9) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTY7ZHS DMPTCYB TN Toll-like receptor 2 (TLR2) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTISGCA DMPTCYB TN Toll-like receptor 4 (TLR4) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPV6B2 DI DMPV6B2 DMPV6B2 DN BA-058 DMPV6B2 TI TTEPJL5 DMPV6B2 TN Parathyroid hormone receptor (PTH2R) DMPV6B2 MA Modulator DMPV6B2 RN Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul-Sep; 4(3): 147-152. DMPV6B2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952405/ DMPVW6H DI DMPVW6H DMPVW6H DN Morphine-6-glucuronide DMPVW6H TI TTKWM86 DMPVW6H TN Opioid receptor mu (MOP) DMPVW6H MA Agonist DMPVW6H RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DMPVW6H RU https://pubmed.ncbi.nlm.nih.gov/15757410 DMPW5SB DI DMPW5SB DMPW5SB DN Bay 86-9766 DMPW5SB TI TTROQ37 DMPW5SB TN MAPK/ERK kinase kinase (MAP3K) DMPW5SB MA Modulator DMPW5SB RN RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47. DMPW5SB RU https://www.ncbi.nlm.nih.gov/pubmed/19706763 DMPW5UF DI DMPW5UF DMPW5UF DN Avalglucosidase alfa DMPW5UF TI TTLPC70 DMPW5UF TN Lysosomal alpha-glucosidase (GAA) DMPW5UF MA Replacement DMPW5UF RN ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health. DMPW5UF RU https://clinicaltrials.gov/ct2/show/NCT02782741 DMPXOYJ DI DMPXOYJ DMPXOYJ DN CPI-0610 DMPXOYJ TI TTRA6BO DMPXOYJ TN Bromodomain-containing protein 4 (BRD4) DMPXOYJ MA Modulator DMPXOYJ RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMPXOYJ RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMPXOYJ DI DMPXOYJ DMPXOYJ DN CPI-0610 DMPXOYJ TI TTE4BSY DMPXOYJ TN Bromodomain and extraterminal domain protein (BET) DMPXOYJ MA Inhibitor DMPXOYJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXOYJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPYET9 DI DMPYET9 DMPYET9 DN Taspoglutide DMPYET9 TI TTVIMDE DMPYET9 TN Glucagon-like peptide 1 receptor (GLP1R) DMPYET9 MA Agonist DMPYET9 RN Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64. DMPYET9 RU https://pubmed.ncbi.nlm.nih.gov/19929995 DMQ0IZ6 DI DMQ0IZ6 DMQ0IZ6 DN 177Lu-labelled PSMA-617 DMQ0IZ6 TI TT9G4N0 DMQ0IZ6 TN Glutamate carboxypeptidase II (GCPII) DMQ0IZ6 RN [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8. DMQ0IZ6 RU https://pubmed.ncbi.nlm.nih.gov/27350005 DMQ38JZ DI DMQ38JZ DMQ38JZ DN HB-AS02V DMQ38JZ TI TT3J5ZI DMQ38JZ TN Cell mediated immunity response (CMIR) DMQ38JZ RN Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84. DMQ38JZ RU https://pubmed.ncbi.nlm.nih.gov/20523113 DMQ4CSX DI DMQ4CSX DMQ4CSX DN Rezafungin DMQ4CSX TI TT0SFXH DMQ4CSX TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMQ4CSX MA Inhibitor DMQ4CSX RN Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343. DMQ4CSX RU https://pubmed.ncbi.nlm.nih.gov/31292663 DMQ509J DI DMQ509J DMQ509J DN Alicaforsen DMQ509J TI TTA1L39 DMQ509J TN ICAM1 messenger RNA (ICAM1 mRNA) DMQ509J RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMQ509J RU http://www.isispharm.com/Pipeline/index.htm DMQ509J DI DMQ509J DMQ509J DN Alicaforsen DMQ509J TI TTCT6F7 DMQ509J TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMQ509J MA Antagonist DMQ509J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ509J RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQ94CT DI DMQ94CT DMQ94CT DN AT9283 DMQ94CT TI TT5LS6T DMQ94CT TN Aurora kinase B (AURKB) DMQ94CT MA Modulator DMQ94CT RN A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73. DMQ94CT RU https://pubmed.ncbi.nlm.nih.gov/25370467 DMQ94CT DI DMQ94CT DMQ94CT DN AT9283 DMQ94CT TI TTPS3C0 DMQ94CT TN Aurora kinase A (AURKA) DMQ94CT MA Modulator DMQ94CT RN A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73. DMQ94CT RU https://pubmed.ncbi.nlm.nih.gov/25370467 DMQBF7O DI DMQBF7O DMQBF7O DN MK-3222 DMQBF7O TI TTC1GLB DMQBF7O TN Interleukin-23 (IL23) DMQBF7O RN Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. DMQBF7O RU https://pubmed.ncbi.nlm.nih.gov/26042589 DMQCZ4N DI DMQCZ4N DMQCZ4N DN Glyminox DMQCZ4N TI TT84ETX DMQCZ4N TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQCZ4N MA Inhibitor DMQCZ4N RN Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31. DMQCZ4N RU https://pubmed.ncbi.nlm.nih.gov/15043398 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TTULVH8 DMQEC6Z TN Tyrosinase (TYR) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TT8MK59 DMQEC6Z TN Melanocytes lineage-specific antigen GP100 (PMEL) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TT362RB DMQEC6Z TN MART-1 melanoma antigen (MLANA) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQG7ZM DI DMQG7ZM DMQG7ZM DN Belagenpumatucel-L DMQG7ZM TI TTI0KH6 DMQG7ZM TN TGF beta-2 messenger RNA (TGFB2 mRNA) DMQG7ZM RN National Cancer Institute Drug Dictionary (drug id 590662). DMQG7ZM RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=590662 DMQGR45 DI DMQGR45 DMQGR45 DN Pixantrone DMQGR45 TI TT0IHXV DMQGR45 TN DNA topoisomerase II (TOP2) DMQGR45 MA Modulator DMQGR45 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQGR45 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQGV5P DI DMQGV5P DMQGV5P DN VLB-01 DMQGV5P TI TT32JK8 DMQGV5P TN Melatonin receptor type 1B (MTNR1B) DMQGV5P MA Modulator DMQGV5P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQGV5P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQHX1Y DI DMQHX1Y DMQHX1Y DN Etirinotecan pegol DMQHX1Y TI TTGTQHC DMQHX1Y TN DNA topoisomerase I (TOP1) DMQHX1Y MA Inhibitor DMQHX1Y RN Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37. DMQHX1Y RU https://pubmed.ncbi.nlm.nih.gov/25228368 DMQIE7U DI DMQIE7U DMQIE7U DN GMA102 DMQIE7U TI TTVIMDE DMQIE7U TN Glucagon-like peptide 1 receptor (GLP1R) DMQIE7U MA Inhibitor DMQIE7U RN Clinical pipeline report, company report or official report of Gmax Biopharm. DMQIE7U RU http://www.gmaxbiopharm.com/wap_product_detailen/id/2.html DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTN4QDT DMQJXL4 TN Opioid receptor (OPR) DMQJXL4 MA Agonist DMQJXL4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQJXL4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTLA931 DMQJXL4 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMQJXL4 MA Agonist DMQJXL4 RN Clinical pipeline report, company report or official report of Roche (2009). DMQJXL4 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TT9W8GU DMQJXL4 TN Gamma-secretase (GS) DMQJXL4 MA Inhibitor DMQJXL4 RN Clinical pipeline report, company report or official report of Roche (2009). DMQJXL4 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTD0CIQ DMQJXL4 TN Melanocortin receptor 4 (MC4R) DMQJXL4 MA Agonist DMQJXL4 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMQJXL4 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTBW580 DMQJXL4 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMQJXL4 MA Modulator DMQJXL4 RN Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/23334208 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTKLQTJ DMQJXL4 TN Angiopoietin-2 (ANGPT2) DMQJXL4 MA Modulator DMQJXL4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTWNQ1T DMQJXL4 TN Angiopoietin-1 (ANGPT1) DMQJXL4 MA Modulator DMQJXL4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQL0KF DI DMQL0KF DMQL0KF DN Vanadate DMQL0KF TI TTZVSJ2 DMQL0KF TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMQL0KF MA Inhibitor DMQL0KF RN Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7. DMQL0KF RU https://pubmed.ncbi.nlm.nih.gov/11145964 DMQLSMB DI DMQLSMB DMQLSMB DN Dociparstat sodium DMQLSMB TI TT4UGTF DMQLSMB TN Stromal cell-derived factor 1 (CXCL12) DMQLSMB MA Inhibitor DMQLSMB RN Clinical pipeline report, company report or official report of Chimerix. DMQLSMB RU https://www.chimerix.com/our-science/dstat/ DMQLSMB DI DMQLSMB DMQLSMB DN Dociparstat sodium DMQLSMB TI TTSG7Q5 DMQLSMB TN Platelet factor 4 (PF4) DMQLSMB MA Inhibitor DMQLSMB RN Clinical pipeline report, company report or official report of Chimerix. DMQLSMB RU https://www.chimerix.com/our-science/dstat/ DMQM2FH DI DMQM2FH DMQM2FH DN RRx-001 DMQM2FH TI TT8E7Z0 DMQM2FH TN Free radical (FRD) DMQM2FH MA Modulator DMQM2FH RN Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8. DMQM2FH RU https://pubmed.ncbi.nlm.nih.gov/22589277 DMQNMAT DI DMQNMAT DMQNMAT DN Tirzepatide DMQNMAT TI TTVIMDE DMQNMAT TN Glucagon-like peptide 1 receptor (GLP1R) DMQNMAT MA Agonist DMQNMAT RN Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. DMQNMAT RU https://pubmed.ncbi.nlm.nih.gov/33236115 DMQNVR8 DI DMQNVR8 DMQNVR8 DN Lopinavir + ritonavir DMQNVR8 TI TT1D53B DMQNVR8 TN COVID-19 3C-like protease (3CLpro) DMQNVR8 MA Inhibitor DMQNVR8 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMQNVR8 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMQOCD8 DI DMQOCD8 DMQOCD8 DN RUBOXISTAURIN HYDROCHLORIDE DMQOCD8 TI TTYPXQF DMQOCD8 TN Protein kinase C beta (PRKCB) DMQOCD8 MA Modulator DMQOCD8 RN Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9. DMQOCD8 RU https://pubmed.ncbi.nlm.nih.gov/17472415 DMQP0X5 DI DMQP0X5 DMQP0X5 DN Lebrikizumab DMQP0X5 TI TT0GVCH DMQP0X5 TN Interleukin-13 (IL13) DMQP0X5 MA Modulator DMQP0X5 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMQP0X5 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT0JLSD DMQPH29 TN Multidrug resistance protein (MDR) DMQPH29 MA Inhibitor DMQPH29 RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19442032 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTANPDJ DMQPH29 TN Carbonic anhydrase II (CA-II) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTSYM0R DMQPH29 TN Carbonic anhydrase XII (CA-XII) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTCFSPE DMQPH29 TN Carbonic anhydrase VI (CA-VI) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT2LVK8 DMQPH29 TN Carbonic anhydrase IX (CA-IX) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTXV4FI DMQPH29 TN Albendazole monooxygenase (CYP3A4) DMQPH29 MA Inhibitor DMQPH29 RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTF10I9 DMQPH29 TN Nitric-oxide synthase inducible (NOS2) DMQPH29 MA Inhibitor DMQPH29 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTEYTKG DMQPH29 TN Carbonic anhydrase XIV (CA-XIV) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHQPL7 DMQPH29 TN Carbonic anhydrase I (CA-I) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHVCUP DMQPH29 TN DNA [cytosine-5]-methyltransferase (DNMT) DMQPH29 MA Inhibitor DMQPH29 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHY57M DMQPH29 TN Matrix metalloproteinase-13 (MMP-13) DMQPH29 MA Inhibitor DMQPH29 RN High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18358729 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT6VZ78 DMQPH29 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMQPH29 MA Inhibitor DMQPH29 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT7RJY8 DMQPH29 TN Xanthine dehydrogenase/oxidase (XDH) DMQPH29 MA Inhibitor DMQPH29 RN Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19388706 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT8NGED DMQPH29 TN Prostaglandin G/H synthase 1 (COX-1) DMQPH29 MA Inhibitor DMQPH29 RN Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/15780608 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT6X50U DMQPH29 TN Matrix metalloproteinase-9 (MMP-9) DMQPH29 MA Inhibitor DMQPH29 RN Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19128977 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTVKILB DMQPH29 TN Prostaglandin G/H synthase 2 (COX-2) DMQPH29 MA Inhibitor DMQPH29 RN Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/15780608 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTZHA0O DMQPH29 TN Carbonic anhydrase IV (CA-IV) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTE4KHA DMQPH29 TN Amyloid beta A4 protein (APP) DMQPH29 MA Inhibitor DMQPH29 RN Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/17004725 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTUNARX DMQPH29 TN Carbonic anhydrase (CA) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQRL2Y DI DMQRL2Y DMQRL2Y DN AC0010 DMQRL2Y TI TTG96HZ DMQRL2Y TN EGFR messenger RNA (EGFR mRNA) DMQRL2Y MA Inhibitor DMQRL2Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQRL2Y RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQSBX4 DI DMQSBX4 DMQSBX4 DN Clazosentan DMQSBX4 TI TTKRD0G DMQSBX4 TN Endothelin A receptor (EDNRA) DMQSBX4 MA Antagonist DMQSBX4 RN Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. DMQSBX4 RU https://pubmed.ncbi.nlm.nih.gov/17700991 DMQSBX4 DI DMQSBX4 DMQSBX4 DN Clazosentan DMQSBX4 TI TTCV6O0 DMQSBX4 TN Endothelin receptor (EDNR) DMQSBX4 MA Antagonist DMQSBX4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSBX4 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMQTLVB DI DMQTLVB DMQTLVB DN Hebergel DMQTLVB TI TTSIUJ9 DMQTLVB TN Interferon-alpha 2 (IFNA2) DMQTLVB MA Modulator DMQTLVB RN Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7. DMQTLVB RU https://pubmed.ncbi.nlm.nih.gov/16316735 DMQZI7K DI DMQZI7K DMQZI7K DN ISIS 23722 DMQZI7K TI TTTPU1G DMQZI7K TN Apoptosis inhibitor survivin (BIRC5) DMQZI7K MA Modulator DMQZI7K RN Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71. DMQZI7K RU https://www.ncbi.nlm.nih.gov/pubmed/22088485 DMR0EWV DI DMR0EWV DMR0EWV DN SAR342434 DMR0EWV TI TTZOPHG DMR0EWV TN Insulin (INS) DMR0EWV MA Modulator DMR0EWV RN Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451. DMR0EWV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403967/ DMR21Q3 DI DMR21Q3 DMR21Q3 DN Clevudine DMR21Q3 TI TTS5K1M DMR21Q3 TN Hepatitis B virus Reverse transcriptase (HBV RT) DMR21Q3 MA Inhibitor DMR21Q3 RN 2011 Pipeline of Bukwang. DMR21Q3 RU http://bkmedical.en.ecplaza.net/ DMR23M1 DI DMR23M1 DMR23M1 DN Mapracorat DMR23M1 TI TTYRL6O DMR23M1 TN Glucocorticoid receptor (NR3C1) DMR23M1 MA Agonist DMR23M1 RN Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103. DMR23M1 RU https://pubmed.ncbi.nlm.nih.gov/19422381 DMR2JD4 DI DMR2JD4 DMR2JD4 DN Darotropium + 642444 DMR2JD4 TI TTZ9SOR DMR2JD4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMR2JD4 MA Agonist DMR2JD4 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMR2JD4 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMR6YH3 DI DMR6YH3 DMR6YH3 DN GLP-1 DMR6YH3 TI TTVIMDE DMR6YH3 TN Glucagon-like peptide 1 receptor (GLP1R) DMR6YH3 MA Modulator DMR6YH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMR6YH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMR71ST DI DMR71ST DMR71ST DN ASP1929 DMR71ST TI TTGKNB4 DMR71ST TN Epidermal growth factor receptor (EGFR) DMR71ST MA Inhibitor DMR71ST RN ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health. DMR71ST RU https://clinicaltrials.gov/ct2/show/NCT04305795 DMR9TF1 DI DMR9TF1 DMR9TF1 DN Bimekizumab DMR9TF1 TI TT2B6PS DMR9TF1 TN Cytokine ML-1 (IL17F) DMR9TF1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR9TF1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMR9TF1 DI DMR9TF1 DMR9TF1 DN Bimekizumab DMR9TF1 TI TTG0MT6 DMR9TF1 TN Interleukin-17 (IL17) DMR9TF1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR9TF1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMRD5SP DI DMRD5SP DMRD5SP DN Fenretinide DMRD5SP TI TTOD7B3 DMRD5SP TN Retinoic acid receptor (RAR) DMRD5SP MA Modulator DMRD5SP RN National Cancer Institute Drug Dictionary (drug id 39582). DMRD5SP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39582 DMREDYP DI DMREDYP DMREDYP DN ABT-869 DMREDYP TI TTDCBX5 DMREDYP TN Vascular endothelial growth factor receptor 3 (FLT-4) DMREDYP MA Modulator DMREDYP RN Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. DMREDYP RU https://pubmed.ncbi.nlm.nih.gov/16648571 DMRG1X3 DI DMRG1X3 DMRG1X3 DN Pirtobrutinib DMRG1X3 TI TTGM6VW DMRG1X3 TN Tyrosine-protein kinase BTK (ATK) DMRG1X3 MA Inhibitor DMRG1X3 RN Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. DMRG1X3 RU https://pubmed.ncbi.nlm.nih.gov/31028669 DMRH291 DI DMRH291 DMRH291 DN Dexanabinol DMRH291 TI TT9IK2Z DMRH291 TN N-methyl-D-aspartate receptor (NMDAR) DMRH291 MA Antagonist DMRH291 RN Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. DMRH291 RU https://pubmed.ncbi.nlm.nih.gov/19249984 DMRJK3U DI DMRJK3U DMRJK3U DN Avotermin DMRJK3U TI TTWOMY8 DMRJK3U TN Transforming growth factor beta 3 (TGFB3) DMRJK3U MA Modulator DMRJK3U RN Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48. DMRJK3U RU https://pubmed.ncbi.nlm.nih.gov/21793965 DMRKTCP DI DMRKTCP DMRKTCP DN MGA012 DMRKTCP TI TTNBFWK DMRKTCP TN Programmed cell death protein 1 (PD-1) DMRKTCP MA Inhibitor DMRKTCP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRKTCP RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMRLVUD DI DMRLVUD DMRLVUD DN Imagabalin DMRLVUD TI TTFK1JQ DMRLVUD TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMRLVUD MA Agonist DMRLVUD RN Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. DMRLVUD RU https://pubmed.ncbi.nlm.nih.gov/21664606 DMRNGD2 DI DMRNGD2 DMRNGD2 DN GSK1278863 DMRNGD2 TI TTMHFRY DMRNGD2 TN HIF-prolyl hydroxylase 1 (HPH-1) DMRNGD2 MA Inhibitor DMRNGD2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMRNGD2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMRSI1M DI DMRSI1M DMRSI1M DN NAV5001 DMRSI1M TI TTVBI8W DMRSI1M TN Dopamine transporter (DAT) DMRSI1M MA Modulator DMRSI1M RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMRSI1M RU https://pubmed.ncbi.nlm.nih.gov/9593103 DMRSNEU DI DMRSNEU DMRSNEU DN Masitinib DMRSNEU TI TT6PKBN DMRSNEU TN Proto-oncogene c-Src (SRC) DMRSNEU MA Inhibitor DMRSNEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRSNEU RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRSNEU DI DMRSNEU DMRSNEU DN Masitinib DMRSNEU TI TTJSQEF DMRSNEU TN Tyrosine-protein kinase (PTK) DMRSNEU MA Inhibitor DMRSNEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRSNEU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRUEKC DI DMRUEKC DMRUEKC DN Synthetic conjugated estrogen DMRUEKC TI TTZAYWL DMRUEKC TN Estrogen receptor (ESR) DMRUEKC MA Modulator DMRUEKC RN Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol. 2004 Feb;103(2):245-53. DMRUEKC RU https://pubmed.ncbi.nlm.nih.gov/14754691 DMRV4DT DI DMRV4DT DMRV4DT DN AT1001 DMRV4DT TI TTLC8E1 DMRV4DT TN Haptoglobin (HP) DMRV4DT MA Modulator DMRV4DT RN Zonulin, regulation of tight junctions, and autoimmune diseases DMRV4DT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384703 DMS0ZBI DI DMS0ZBI DMS0ZBI DN Ag-221 DMS0ZBI TI TTDTWV0 DMS0ZBI TN Isocitrate dehydrogenase (IDH) DMS0ZBI MA Inhibitor DMS0ZBI RN New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213. DMS0ZBI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323358/ DMS1EQ7 DI DMS1EQ7 DMS1EQ7 DN PF-1228305 DMS1EQ7 TI TTKRD0G DMS1EQ7 TN Endothelin A receptor (EDNRA) DMS1EQ7 MA Antagonist DMS1EQ7 RN Pfizer. Product Development Pipeline. March 31 2009. DMS1EQ7 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TT3ROYC DMS1X67 TN Serotonin transporter (SERT) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928 DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TTVBI8W DMS1X67 TN Dopamine transporter (DAT) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927 DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TTAWNKZ DMS1X67 TN Norepinephrine transporter (NET) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMS2GA1 DI DMS2GA1 DMS2GA1 DN Bindarit DMS2GA1 TI TTNAY0P DMS2GA1 TN Monocyte chemotactic and activating factor (CCL2) DMS2GA1 MA Inhibitor DMS2GA1 RN Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69. DMS2GA1 RU https://pubmed.ncbi.nlm.nih.gov/22189654 DMS2WV3 DI DMS2WV3 DMS2WV3 DN AIDSVAX DMS2WV3 TI TTBYP1X DMS2WV3 TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMS2WV3 RN HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D. 2003;4(4):249-53. DMS2WV3 RU https://pubmed.ncbi.nlm.nih.gov/12848591 DMS57DJ DI DMS57DJ DMS57DJ DN Trimegestone/ethinyl estradiol DMS57DJ TI TTZAYWL DMS57DJ TN Estrogen receptor (ESR) DMS57DJ MA Modulator DMS57DJ RN Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol. 2005 Mar;94(4):361-8. DMS57DJ RU https://pubmed.ncbi.nlm.nih.gov/15857755 DMS9503 DI DMS9503 DMS9503 DN Benzylpenicillin DMS9503 TI TT85JMW DMS9503 TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMS9503 MA Binder DMS9503 RN Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9. DMS9503 RU https://pubmed.ncbi.nlm.nih.gov/11353613 DMS9503 DI DMS9503 DMS9503 DN Benzylpenicillin DMS9503 TI TTTKCMH DMS9503 TN Bacterial Penicillin binding protein 1 (Bact pbp) DMS9503 MA Binder DMS9503 RN Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9. DMS9503 RU https://pubmed.ncbi.nlm.nih.gov/11802794 DMS9GE1 DI DMS9GE1 DMS9GE1 DN MyoCell SDF-1 DMS9GE1 TI TT4UGTF DMS9GE1 TN Stromal cell-derived factor 1 (CXCL12) DMS9GE1 MA Modulator DMS9GE1 RN Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97. DMS9GE1 RU https://pubmed.ncbi.nlm.nih.gov/21219236 DMS9R43 DI DMS9R43 DMS9R43 DN Ecopipam DMS9R43 TI TTZFYLI DMS9R43 TN Dopamine D1 receptor (D1R) DMS9R43 MA Modulator DMS9R43 RN A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30. DMS9R43 RU https://www.ncbi.nlm.nih.gov/pubmed/24434529 DMSCGM8 DI DMSCGM8 DMSCGM8 DN LentiGlobin DMSCGM8 TI TTM6HK1 DMSCGM8 TN Hemoglobin subunit beta (HBB) DMSCGM8 MA Modulator DMSCGM8 RN Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81. DMSCGM8 RU https://pubmed.ncbi.nlm.nih.gov/25429463 DMSDBPG DI DMSDBPG DMSDBPG DN KN046 DMSDBPG TI TTI2S1D DMSDBPG TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMSDBPG MA Inhibitor DMSDBPG RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMSDBPG RU http://www.alphamabonc.com/pipeline/kn046.html DMSDBPG DI DMSDBPG DMSDBPG DN KN046 DMSDBPG TI TT8ZLTI DMSDBPG TN Programmed cell death 1 ligand 1 (PD-L1) DMSDBPG MA Inhibitor DMSDBPG RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMSDBPG RU http://www.alphamabonc.com/pipeline/kn046.html DMSFX75 DI DMSFX75 DMSFX75 DN QVA-149 DMSFX75 TI TT2CJVK DMSFX75 TN Adrenergic receptor beta-2 (ADRB2) DMSFX75 MA Agonist DMSFX75 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMSFX75 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMSMFN2 DI DMSMFN2 DMSMFN2 DN GSK2140944 DMSMFN2 TI TT0IHXV DMSMFN2 TN DNA topoisomerase II (TOP2) DMSMFN2 MA Inhibitor DMSMFN2 RN Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32. DMSMFN2 RU https://pubmed.ncbi.nlm.nih.gov/24759716 DMSO02K DI DMSO02K DMSO02K DN AMT-061 DMSO02K TI TTFEZ5Q DMSO02K TN Coagulation factor IX (F9) DMSO02K RN Clinical pipeline report, company report or official report of uniQure. DMSO02K RU http://uniqure.com/gene-therapy/hemophilia.php DMSP0X8 DI DMSP0X8 DMSP0X8 DN IDAZOXAN HYDROCHLORIDE DMSP0X8 TI TT2NUT5 DMSP0X8 TN Adrenergic receptor alpha-2C (ADRA2C) DMSP0X8 MA Modulator DMSP0X8 RN Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4. DMSP0X8 RU https://pubmed.ncbi.nlm.nih.gov/1354730 DMSPN58 DI DMSPN58 DMSPN58 DN Clomethiazole DMSPN58 TI TTEX6LM DMSPN58 TN GABA(A) receptor gamma-3 (GABRG3) DMSPN58 MA Modulator DMSPN58 RN Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62. DMSPN58 RU https://www.ncbi.nlm.nih.gov/pubmed/12359265 DMSRIT4 DI DMSRIT4 DMSRIT4 DN Lenzilumab DMSRIT4 TI TTPZGYX DMSRIT4 TN HUMAN colony-stimulating factor (GM-CSF) DMSRIT4 MA Inhibitor DMSRIT4 RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DMSRIT4 RU https://pubmed.ncbi.nlm.nih.gov/32317220 DMSW80U DI DMSW80U DMSW80U DN VM-202 DMSW80U TI TT4V2JM DMSW80U TN Hepatocyte growth factor (HGF) DMSW80U MA Modulator DMSW80U RN Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63. DMSW80U RU https://pubmed.ncbi.nlm.nih.gov/18620865 DMSY0NE DI DMSY0NE DMSY0NE DN CS1001 DMSY0NE TI TT8ZLTI DMSY0NE TN Programmed cell death 1 ligand 1 (PD-L1) DMSY0NE RN GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. DMSY0NE RU https://pubmed.ncbi.nlm.nih.gov/33209620 DMSZPR3 DI DMSZPR3 DMSZPR3 DN Rolofylline DMSZPR3 TI TTK25J1 DMSZPR3 TN Adenosine A1 receptor (ADORA1) DMSZPR3 MA Antagonist DMSZPR3 RN Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72. DMSZPR3 RU https://pubmed.ncbi.nlm.nih.gov/19196240 DMT0A3Y DI DMT0A3Y DMT0A3Y DN APD-334 DMT0A3Y TI TT9JZCK DMT0A3Y TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMT0A3Y MA Agonist DMT0A3Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT0A3Y RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMT4K0Z DI DMT4K0Z DMT4K0Z DN L-citrulline DMT4K0Z TI TTI1PRE DMT4K0Z TN G-protein coupled receptor GPCR33 (GPRC6A) DMT4K0Z MA Agonist DMT4K0Z RN Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97. DMT4K0Z RU https://pubmed.ncbi.nlm.nih.gov/15576628 DMT4QHD DI DMT4QHD DMT4QHD DN GDC-0032 DMT4QHD TI TTEUNMR DMT4QHD TN PI3-kinase alpha (PIK3CA) DMT4QHD MA Modulator DMT4QHD RN Company report (BioOncology) DMT4QHD RU http://www.biooncology.com/pipeline-molecules/taselisib-gdc-0032 DMT4QHD DI DMT4QHD DMT4QHD DN GDC-0032 DMT4QHD TI TTHBTOP DMT4QHD TN PI3-kinase gamma (PIK3CG) DMT4QHD MA Inhibitor DMT4QHD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT4QHD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMT67EH DI DMT67EH DMT67EH DN Ibodutant DMT67EH TI TTYO0A3 DMT67EH TN Substance-K receptor (TACR2) DMT67EH MA Antagonist DMT67EH RN Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5. DMT67EH RU https://pubmed.ncbi.nlm.nih.gov/24436990 DMT71EX DI DMT71EX DMT71EX DN SSR-126517E DMT71EX TI TTCIHJA DMT71EX TN Coagulation factor Xa (F10) DMT71EX MA Inhibitor DMT71EX RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMT71EX RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMT8IAJ DI DMT8IAJ DMT8IAJ DN MK-8808 DMT8IAJ TI TTUE541 DMT8IAJ TN Leukocyte surface antigen Leu-16 (CD20) DMT8IAJ MA Agonist DMT8IAJ RN Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68. DMT8IAJ RU https://pubmed.ncbi.nlm.nih.gov/14576843 DMT8J0I DI DMT8J0I DMT8J0I DN GSK1265744 DMT8J0I TI TT5FH9Y DMT8J0I TN Human immunodeficiency virus Integrase (HIV IN) DMT8J0I MA Inhibitor DMT8J0I RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMT8J0I RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMTCR2O DI DMTCR2O DMTCR2O DN Tecarfarin DMTCR2O TI TTEUC8H DMTCR2O TN Vitamin K epoxide reductase complex 1 (VKORC1) DMTCR2O MA Inhibitor DMTCR2O RN Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74. DMTCR2O RU https://pubmed.ncbi.nlm.nih.gov/20622200 DMTD7AB DI DMTD7AB DMTD7AB DN Pracinostat DMTD7AB TI TTBH0VX DMTD7AB TN Histone deacetylase (HDAC) DMTD7AB MA Modulator DMTD7AB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365). DMTD7AB RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8365 DMTGYSO DI DMTGYSO DMTGYSO DN Fasiglifam hemihydrate DMTGYSO TI TTB8FUC DMTGYSO TN Free fatty acid receptor 1 (GPR40) DMTGYSO MA Modulator DMTGYSO RN A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280. DMTGYSO RU https://pubmed.ncbi.nlm.nih.gov/24130766 DMTKRY1 DI DMTKRY1 DMTKRY1 DN Netivudine DMTKRY1 TI TTIU7X1 DMTKRY1 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMTKRY1 MA Modulator DMTKRY1 RN Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206. DMTKRY1 RU https://pubmed.ncbi.nlm.nih.gov/10188760 DMTL5Q0 DI DMTL5Q0 DMTL5Q0 DN Losartan DMTL5Q0 TI TTPKMXQ DMTL5Q0 TN HUMAN type-1 angiotensin II receptor (AGTR1) DMTL5Q0 MA Blocker DMTL5Q0 RN Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. DMTL5Q0 RU https://pubmed.ncbi.nlm.nih.gov/32246101 DMTNQB0 DI DMTNQB0 DMTNQB0 DN CC-486 DMTNQB0 TI TTVDSZ0 DMTNQB0 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTNQB0 MA Inhibitor DMTNQB0 RN Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3. DMTNQB0 RU https://pubmed.ncbi.nlm.nih.gov/12519059 DMTNQB0 DI DMTNQB0 DMTNQB0 DN CC-486 DMTNQB0 TI TT6S2FE DMTNQB0 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMTNQB0 MA Inhibitor DMTNQB0 RN Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96. DMTNQB0 RU https://pubmed.ncbi.nlm.nih.gov/26442612 DMTNUJ8 DI DMTNUJ8 DMTNUJ8 DN E-2609 DMTNUJ8 TI TT8JRS7 DMTNUJ8 TN Beta-secretase (BACE) DMTNUJ8 MA Inhibitor DMTNUJ8 RN Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329. DMTNUJ8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086426/ DMTNUJ8 DI DMTNUJ8 DMTNUJ8 DN E-2609 DMTNUJ8 TI TTJUNZF DMTNUJ8 TN Beta-secretase 1 (BACE1) DMTNUJ8 MA Inhibitor DMTNUJ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTNUJ8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMTQJE0 DI DMTQJE0 DMTQJE0 DN RG3638 DMTQJE0 TI TTNDSF4 DMTQJE0 TN Proto-oncogene c-Met (MET) DMTQJE0 MA Modulator DMTQJE0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMTQJE0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMTSN8L DI DMTSN8L DMTSN8L DN PT005 DMTSN8L TI TT2CJVK DMTSN8L TN Adrenergic receptor beta-2 (ADRB2) DMTSN8L MA Agonist DMTSN8L RN Clinical pipeline report, company report or official report of Pearl Therapeutics. DMTSN8L RU http://www.pearltherapeutics.com/PT005 DMTSONL DI DMTSONL DMTSONL DN Claritin/Singulair DMTSONL TI TTGKOY9 DMTSONL TN Leukotriene CysLT1 receptor (CYSLTR1) DMTSONL MA Modulator DMTSONL RN Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48. DMTSONL RU https://pubmed.ncbi.nlm.nih.gov/11533366 DMTUV7L DI DMTUV7L DMTUV7L DN GED-0301 DMTUV7L TI TT0J32Z DMTUV7L TN Smad7 messenger RNA (Smad7 mRNA) DMTUV7L MA Inhibitor DMTUV7L RN A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7. DMTUV7L RU https://pubmed.ncbi.nlm.nih.gov/22971085 DMTUV7L DI DMTUV7L DMTUV7L DN GED-0301 DMTUV7L TI TTW06P4 DMTUV7L TN Mothers against decapentaplegic homolog 7 (SMAD7) DMTUV7L MA Inhibitor DMTUV7L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTUV7L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTV7ZM DI DMTV7ZM DMTV7ZM DN Eptastigmine DMTV7ZM TI TT1RS9F DMTV7ZM TN Acetylcholinesterase (AChE) DMTV7ZM MA Inhibitor DMTV7ZM RN Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86. DMTV7ZM RU https://pubmed.ncbi.nlm.nih.gov/11830755 DMTV7ZM DI DMTV7ZM DMTV7ZM DN Eptastigmine DMTV7ZM TI TTEB0GD DMTV7ZM TN Cholinesterase (BCHE) DMTV7ZM MA Inhibitor DMTV7ZM RN Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85. DMTV7ZM RU https://pubmed.ncbi.nlm.nih.gov/16570913 DMTZ1A5 DI DMTZ1A5 DMTZ1A5 DN 13-cis-retinoic acid DMTZ1A5 TI TTOD7B3 DMTZ1A5 TN Retinoic acid receptor (RAR) DMTZ1A5 MA Modulator DMTZ1A5 RN 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7. DMTZ1A5 RU https://pubmed.ncbi.nlm.nih.gov/10951254 DMU2J7Y DI DMU2J7Y DMU2J7Y DN Ciltacabtagene autoleucel DMU2J7Y TI TTZ3P4W DMU2J7Y TN B-cell maturation protein (TNFRSF17) DMU2J7Y RN ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health. DMU2J7Y RU https://clinicaltrials.gov/ct2/show/NCT04181827 DMU2ZFK DI DMU2ZFK DMU2ZFK DN CT-2584 DMU2ZFK TI TTUAIKM DMU2ZFK TN Cholinephosphate cytidylyltransferase (PCYT1B) DMU2ZFK MA Modulator DMU2ZFK RN Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13. DMU2ZFK RU https://pubmed.ncbi.nlm.nih.gov/11016649 DMU72KL DI DMU72KL DMU72KL DN ICP-022 DMU72KL TI TTGM6VW DMU72KL TN Tyrosine-protein kinase BTK (ATK) DMU72KL MA Inhibitor DMU72KL RN Clinical pipeline report, company report or official report of InnoCare Pharma. DMU72KL RU https://www.innocarepharma.com/en/pipeline/our-pipeline/ DMUE843 DI DMUE843 DMUE843 DN Hematide DMUE843 TI TTAUX24 DMUE843 TN Erythropoietin Receptor (EPOR) DMUE843 MA Agonist DMUE843 RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMUE843 RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMUES7Y DI DMUES7Y DMUES7Y DN AB154 DMUES7Y TI TTWNL74 DMUES7Y TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMUES7Y MA Inhibitor DMUES7Y RN Clinical pipeline report, company report or official report of Arcus Biosciences. DMUES7Y RU https://arcusbio.com/domvanalimab/ DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTF4E0J DMUF0BJ TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUF0BJ MA Inhibitor DMUF0BJ RN Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16640326 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TT4H1MQ DMUF0BJ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMUF0BJ MA Inhibitor DMUF0BJ RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTTVAFQ DMUF0BJ TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMUF0BJ MA Inhibitor DMUF0BJ RN Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2316-9. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/18356044 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TT5KPZR DMUF0BJ TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMUF0BJ MA Inhibitor DMUF0BJ RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTLA931 DMUF0BJ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMUF0BJ MA Inhibitor DMUF0BJ RN 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16171993 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTJSZTB DMUF0BJ TN Nicotinic acetylcholine receptor (nAChR) DMUF0BJ MA Antagonist DMUF0BJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUF0BJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMUHS5Q DI DMUHS5Q DMUHS5Q DN E-913 DMUHS5Q TI TT2CEJG DMUHS5Q TN C-C chemokine receptor type 5 (CCR5) DMUHS5Q MA Antagonist DMUHS5Q RN Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34. DMUHS5Q RU https://pubmed.ncbi.nlm.nih.gov/17920529 DMUIBV8 DI DMUIBV8 DMUIBV8 DN Azimilide DMUIBV8 TI TT1VOHK DMUIBV8 TN Potassium channel unspecific (KC) DMUIBV8 MA Modulator DMUIBV8 RN Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9. DMUIBV8 RU https://www.ncbi.nlm.nih.gov/pubmed/10730550 DMUNBMA DI DMUNBMA DMUNBMA DN MT-1621 DMUNBMA TI TT7KNZQ DMUNBMA TN Thymidine kinase 2 (Mt-TK2) DMUNBMA MA Replacement DMUNBMA RN Clinical pipeline report, company report or official report of Modis Therapeutics. DMUNBMA RU https://www.modistx.com/product/ DMUNMY0 DI DMUNMY0 DMUNMY0 DN Ralfinamide DMUNMY0 TI TT4FDG6 DMUNMY0 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMUNMY0 MA Blocker DMUNMY0 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMUNMY0 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMUNMY0 DI DMUNMY0 DMUNMY0 DN Ralfinamide DMUNMY0 TI TTRK8B9 DMUNMY0 TN Sodium channel unspecific (NaC) DMUNMY0 MA Blocker DMUNMY0 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMUNMY0 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMUOFAC DI DMUOFAC DMUOFAC DN Balixafortide DMUOFAC TI TTBID49 DMUOFAC TN C-X-C chemokine receptor type 4 (CXCR4) DMUOFAC MA Antagonist DMUOFAC RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMUOFAC RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMUP5Z0 DI DMUP5Z0 DMUP5Z0 DN PF-03084014 DMUP5Z0 TI TT9W8GU DMUP5Z0 TN Gamma-secretase (GS) DMUP5Z0 MA Modulator DMUP5Z0 RN Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77. DMUP5Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/20363853 DMUP5Z0 DI DMUP5Z0 DMUP5Z0 DN PF-03084014 DMUP5Z0 TI TTE4KHA DMUP5Z0 TN Amyloid beta A4 protein (APP) DMUP5Z0 MA Inhibitor DMUP5Z0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUP5Z0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TT3ROYC DMUQ1DO TN Serotonin transporter (SERT) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc. DMUQ1DO RU http://www.intracellulartherapies.com/products-technology/iti-007.html DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TTJQOD7 DMUQ1DO TN 5-HT 2A receptor (HTR2A) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc. DMUQ1DO RU http://www.intracellulartherapies.com/products-technology/iti-007.html DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TT85JO3 DMUQ1DO TN 5-HT receptor (5HTR) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUQ1DO RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMUQ390 DI DMUQ390 DMUQ390 DN Murepavadin DMUQ390 TI TTJZ7GF DMUQ390 TN Pseudomonas LPS-assembly protein LptD (Pseudo lptD) DMUQ390 MA Antagonist DMUQ390 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMUQ390 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMUS1F8 DI DMUS1F8 DMUS1F8 DN Inolimomab DMUS1F8 TI TT10Y9E DMUS1F8 TN Interleukin 2 receptor alpha (IL2RA) DMUS1F8 MA Modulator DMUS1F8 RN Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41. DMUS1F8 RU https://www.ncbi.nlm.nih.gov/pubmed/17085306 DMUVMWZ DI DMUVMWZ DMUVMWZ DN Carebastine DMUVMWZ TI TTTIBOJ DMUVMWZ TN Histamine H1 receptor (H1R) DMUVMWZ MA Antagonist DMUVMWZ RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMUVMWZ RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMUVSG4 DI DMUVSG4 DMUVSG4 DN Sasanlimab DMUVSG4 TI TTNBFWK DMUVSG4 TN Programmed cell death protein 1 (PD-1) DMUVSG4 RN Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. DMUVSG4 RU https://pubmed.ncbi.nlm.nih.gov/32847983 DMUVZAO DI DMUVZAO DMUVZAO DN GSK642444 DMUVZAO TI TT2CJVK DMUVZAO TN Adrenergic receptor beta-2 (ADRB2) DMUVZAO MA Agonist DMUVZAO RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMUVZAO RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMUWXEB DI DMUWXEB DMUWXEB DN QPI-1007 DMUWXEB TI TT12VNG DMUWXEB TN Caspase 2 messenger RNA (CASP2 mRNA) DMUWXEB RN Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66. DMUWXEB RU https://pubmed.ncbi.nlm.nih.gov/25054518 DMUX7Z8 DI DMUX7Z8 DMUX7Z8 DN DE-117 DMUX7Z8 TI TT1ZAVI DMUX7Z8 TN Prostaglandin E2 receptor EP2 (PTGER2) DMUX7Z8 MA Agonist DMUX7Z8 RN Clinical pipeline report, company report or official report of Santen Pharmaceutical. DMUX7Z8 RU http://www.santeninc.com/research/moa/ DMUYOC8 DI DMUYOC8 DMUYOC8 DN AP12009 DMUYOC8 TI TTY9TWO DMUYOC8 TN Transforming growth factor beta 2 (TGFB2) DMUYOC8 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUYOC8 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMV1SOR DI DMV1SOR DMV1SOR DN AVP-786 DMV1SOR TI TT3ROYC DMV1SOR TN Serotonin transporter (SERT) DMV1SOR MA Modulator DMV1SOR RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMV1SOR RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMV1SOR DI DMV1SOR DMV1SOR DN AVP-786 DMV1SOR TI TT5TPI6 DMV1SOR TN Opioid receptor sigma 1 (OPRS1) DMV1SOR MA Modulator DMV1SOR RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMV1SOR RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMV3DHQ DI DMV3DHQ DMV3DHQ DN IDDBCP161883 DMV3DHQ TI TTDIGC1 DMV3DHQ TN Dipeptidyl peptidase 4 (DPP-4) DMV3DHQ MA Inhibitor DMV3DHQ RN Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. DMV3DHQ RU https://pubmed.ncbi.nlm.nih.gov/23671395 DMV574J DI DMV574J DMV574J DN CSL312 DMV574J TI TTMXD0O DMV574J TN Coagulation factor XII (F12) DMV574J MA Inhibitor DMV574J RN Clinical pipeline report, company report or official report of CSL Behring. DMV574J RU https://www.cslbehring.com/r-and-d/product-pipeline DMV7T64 DI DMV7T64 DMV7T64 DN Talactoferrin DMV7T64 TI TTSZDQU DMV7T64 TN Lactotransferrin (LTF) DMV7T64 MA Modulator DMV7T64 RN Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. DMV7T64 RU https://pubmed.ncbi.nlm.nih.gov/17188087 DMV8EXG DI DMV8EXG DMV8EXG DN PolyHeme DMV8EXG TI TTQO71U DMV8EXG TN Hemoglobin (HB) DMV8EXG MA Modulator DMV8EXG RN Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65. DMV8EXG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322929/ DMVA8KU DI DMVA8KU DMVA8KU DN ASP0113 DMVA8KU TI TTK938H DMVA8KU TN Cytomegalovirus Deoxyribonucleic acid (CMV DNA) DMVA8KU RN VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009 Oct;11(5):572-8. DMVA8KU RU https://pubmed.ncbi.nlm.nih.gov/19806506 DMVBA7I DI DMVBA7I DMVBA7I DN Reparixin DMVBA7I TI TT30C9G DMVBA7I TN C-X-C chemokine receptor type 2 (CXCR2) DMVBA7I MA Modulator DMVBA7I RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMVBA7I RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMVBA7I DI DMVBA7I DMVBA7I DN Reparixin DMVBA7I TI TTMWT8Z DMVBA7I TN C-X-C chemokine receptor type 1 (CXCR1) DMVBA7I MA Modulator DMVBA7I RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMVBA7I RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMVDCGZ DI DMVDCGZ DMVDCGZ DN Pyridoxamine DMVDCGZ TI TTMO9HF DMVDCGZ TN Advanced glycosylation end product receptor (AGER) DMVDCGZ MA Inhibitor DMVDCGZ RN Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81. DMVDCGZ RU https://pubmed.ncbi.nlm.nih.gov/20441560 DMVEHM4 DI DMVEHM4 DMVEHM4 DN Phentermine+topiramate DMVEHM4 TI TTNJYV2 DMVEHM4 TN Gamma-aminobutyric acid receptor (GAR) DMVEHM4 MA Modulator DMVEHM4 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMVEHM4 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMVEHM4 DI DMVEHM4 DMVEHM4 DN Phentermine+topiramate DMVEHM4 TI TTUNARX DMVEHM4 TN Carbonic anhydrase (CA) DMVEHM4 MA Inhibitor DMVEHM4 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMVEHM4 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMVHF8G DI DMVHF8G DMVHF8G DN Binodenoson DMVHF8G TI TTM2AOE DMVHF8G TN Adenosine A2a receptor (ADORA2A) DMVHF8G MA Agonist DMVHF8G RN Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12. DMVHF8G RU https://pubmed.ncbi.nlm.nih.gov/17531571 DMVHRL8 DI DMVHRL8 DMVHRL8 DN Alfimeprase DMVHRL8 TI TTWODQF DMVHRL8 TN Fibrin (FG) DMVHRL8 MA Modulator DMVHRL8 RN Disulfide structure of alfimeprase: A recombinant analog of fibrolase. Protein Sci. 2001 June; 10(6): 1264-1267. DMVHRL8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374009/ DMVHZDP DI DMVHZDP DMVHZDP DN PF-06439535 DMVHZDP TI TT9HKJA DMVHZDP TN Vascular endothelial growth factor (VEGF) DMVHZDP RN National Cancer Institute Drug Dictionary (drug id 43234). DMVHZDP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43234 DMVJNFI DI DMVJNFI DMVJNFI DN Spermidine DMVJNFI TI TTR7UJ3 DMVJNFI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVJNFI MA Inhibitor DMVJNFI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVJNFI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTS74QB DMVJW0S TN Inhibitor of apoptosis protein (hIAP) DMVJW0S MA Modulator DMVJW0S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729). DMVJW0S RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7729 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTIRY6K DMVJW0S TN Cellular inhibitor of apoptosis 2 (BIRC3) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTR7B60 DMVJW0S TN X-linked inhibitor of apoptosis protein (XIAP) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTQ5LRD DMVJW0S TN Cellular inhibitor of apoptosis 1 (BIRC2) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVKL3B DI DMVKL3B DMVKL3B DN Ravulizumab DMVKL3B TI TTN0GJ5 DMVKL3B TN HUMAN complement C5 protein (C5) DMVKL3B MA Inhibitor DMVKL3B RN Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. DMVKL3B RU https://pubmed.ncbi.nlm.nih.gov/32327719 DMVLKDX DI DMVLKDX DMVLKDX DN Streptokinase rectal suppository DMVLKDX TI TT2VCLI DMVLKDX TN Streptococcus Streptokinase (Stre-coc skc) DMVLKDX MA Modulator DMVLKDX RN Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 2005 Nov 2;5:5. DMVLKDX RU https://www.ncbi.nlm.nih.gov/pubmed/16262910 DMVLWG7 DI DMVLWG7 DMVLWG7 DN Ad5FGF-4 DMVLWG7 TI TTCEKVZ DMVLWG7 TN Fibroblast growth factor-4 (FGF4) DMVLWG7 MA Modulator DMVLWG7 RN Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N. DMVLWG7 RU https://pubmed.ncbi.nlm.nih.gov/14615023 DMVO1C0 DI DMVO1C0 DMVO1C0 DN NBI-98854 DMVO1C0 TI TTNZRI3 DMVO1C0 TN Synaptic vesicle amine transporter (SLC18A2) DMVO1C0 MA Inhibitor DMVO1C0 RN NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7. DMVO1C0 RU https://pubmed.ncbi.nlm.nih.gov/26346941 DMVO7UW DI DMVO7UW DMVO7UW DN Siltuximab DMVO7UW TI TTJH4Y5 DMVO7UW TN HUMAN interleukin 6 (IL6) DMVO7UW MA Inhibitor DMVO7UW RN Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3. DMVO7UW RU https://pubmed.ncbi.nlm.nih.gov/29999789 DMVOY6B DI DMVOY6B DMVOY6B DN AMD-070 DMVOY6B TI TTBID49 DMVOY6B TN C-X-C chemokine receptor type 4 (CXCR4) DMVOY6B MA Antagonist DMVOY6B RN Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. DMVOY6B RU https://pubmed.ncbi.nlm.nih.gov/18362694 DMVP7HI DI DMVP7HI DMVP7HI DN Nestorone DMVP7HI TI TTUV8G9 DMVP7HI TN Progesterone receptor (PGR) DMVP7HI MA Agonist DMVP7HI RN Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97. DMVP7HI RU https://pubmed.ncbi.nlm.nih.gov/25200475 DMVQ5X1 DI DMVQ5X1 DMVQ5X1 DN Roclatan DMVQ5X1 TI TTAWNKZ DMVQ5X1 TN Norepinephrine transporter (NET) DMVQ5X1 MA Modulator DMVQ5X1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVQ5X1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVQ5X1 DI DMVQ5X1 DMVQ5X1 DN Roclatan DMVQ5X1 TI TTMQO60 DMVQ5X1 TN Rho-associated protein kinase (ROCK) DMVQ5X1 MA Modulator DMVQ5X1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVQ5X1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVSX6O DI DMVSX6O DMVSX6O DN Tebipenem DMVSX6O TI TT6OEDT DMVSX6O TN Cannabinoid receptor 1 (CB1) DMVSX6O MA Antagonist DMVSX6O RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMVSX6O RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMVU687 DI DMVU687 DMVU687 DN Esketamine DMVU687 TI TT9IK2Z DMVU687 TN N-methyl-D-aspartate receptor (NMDAR) DMVU687 MA Antagonist DMVU687 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVU687 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMVU8RW DI DMVU8RW DMVU8RW DN PRT4445 DMVU8RW TI TTCIHJA DMVU8RW TN Coagulation factor Xa (F10) DMVU8RW MA Modulator DMVU8RW RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMVU8RW RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMVXUR0 DI DMVXUR0 DMVXUR0 DN Magrolimab DMVXUR0 TI TTN2JFW DMVXUR0 TN T-cell surface glycoprotein CD4 (CD4) DMVXUR0 MA Inhibitor DMVXUR0 RN Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. DMVXUR0 RU https://pubmed.ncbi.nlm.nih.gov/33423844 DMVY0BU DI DMVY0BU DMVY0BU DN Apaziquone DMVY0BU TI TTUTN1I DMVY0BU TN Human Deoxyribonucleic acid (hDNA) DMVY0BU MA Modulator DMVY0BU RN EO9 (Apaziquone): from the clinic to the laboratory and back again DMVY0BU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569998 DMVZ57G DI DMVZ57G DMVZ57G DN MD1003 DMVZ57G TI TTSXVID DMVZ57G TN Nuclear factor NF-kappa-B (NFKB) DMVZ57G MA Inhibitor DMVZ57G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVZ57G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMW34B1 DI DMW34B1 DMW34B1 DN BL-8040 DMW34B1 TI TTBID49 DMW34B1 TN C-X-C chemokine receptor type 4 (CXCR4) DMW34B1 MA Antagonist DMW34B1 RN The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21). DMW34B1 RU http://www.bloodjournal.org/content/122/21/3939?sso-checked=true DMW5PHL DI DMW5PHL DMW5PHL DN Taberminogene vadenovec DMW5PHL TI TTDCBX5 DMW5PHL TN Vascular endothelial growth factor receptor 3 (FLT-4) DMW5PHL MA Modulator DMW5PHL RN Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. DMW5PHL RU https://pubmed.ncbi.nlm.nih.gov/25312588 DMW63TQ DI DMW63TQ DMW63TQ DN PF-06741086 DMW63TQ TI TT068JH DMW63TQ TN Tissue factor pathway inhibitor (TFPI) DMW63TQ MA Inhibitor DMW63TQ RN Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46. DMW63TQ RU https://pubmed.ncbi.nlm.nih.gov/30927117 DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTSQIFT DMW6C81 TN 5-HT 1A receptor (HTR1A) DMW6C81 MA Agonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTWJBZ5 DMW6C81 TN 5-HT 2C receptor (HTR2C) DMW6C81 MA Antagonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTK8CXU DMW6C81 TN 5-HT 1B receptor (HTR1B) DMW6C81 MA Agonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMWA74Y DI DMWA74Y DMWA74Y DN Radotinib DMWA74Y TI TTS7G69 DMWA74Y TN Fusion protein Bcr-Abl (Bcr-Abl) DMWA74Y MA Modulator DMWA74Y RN Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93. DMWA74Y RU https://www.ncbi.nlm.nih.gov/pubmed/22242557 DMWAHTN DI DMWAHTN DMWAHTN DN Cetilistat DMWAHTN TI TTKYZA9 DMWAHTN TN Gastric triacylglycerol lipase (LIPF) DMWAHTN MA Modulator DMWAHTN RN Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9. DMWAHTN RU https://pubmed.ncbi.nlm.nih.gov/16953261 DMWAL73 DI DMWAL73 DMWAL73 DN Albutropin DMWAL73 TI TTT3YKH DMWAL73 TN Somatotropin (GH1) DMWAL73 MA Modulator DMWAL73 RN Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58. DMWAL73 RU https://pubmed.ncbi.nlm.nih.gov/12450581 DMWBZJD DI DMWBZJD DMWBZJD DN GDC-0068 DMWBZJD TI TTWTSCV DMWBZJD TN RAC-alpha serine/threonine-protein kinase (AKT1) DMWBZJD MA Inhibitor DMWBZJD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWBZJD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TTD16BI DMWD3IV TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMWD3IV MA Inhibitor DMWD3IV RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TTZGK1R DMWD3IV TN HUMAN glycosylation of host receptor (GHR) DMWD3IV MA Inhibitor DMWD3IV RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TT3A1EZ DMWD3IV TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMWD3IV MA Inhibitor DMWD3IV RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMWDEFC DI DMWDEFC DMWDEFC DN Zatosetron maleate DMWDEFC TI TTNXLKE DMWDEFC TN 5-HT 3 receptor (5HT3R) DMWDEFC MA Modulator DMWDEFC RN Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31. DMWDEFC RU https://www.ncbi.nlm.nih.gov/pubmed/10211913 DMWE3SC DI DMWE3SC DMWE3SC DN ASC09 + ritonavir + oseltamivir DMWE3SC TI TT1D53B DMWE3SC TN COVID-19 3C-like protease (3CLpro) DMWE3SC MA Inhibitor DMWE3SC RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMWE3SC RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMWGRQD DI DMWGRQD DMWGRQD DN LU AE58054 DMWGRQD TI TTJS8PY DMWGRQD TN 5-HT 6 receptor (HTR6) DMWGRQD MA Enhancer DMWGRQD RN Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. DMWGRQD RU https://pubmed.ncbi.nlm.nih.gov/20569520 DMWL2XD DI DMWL2XD DMWL2XD DN GSK2402968 DMWL2XD TI TTWLFXU DMWL2XD TN Dystrophin messenger RNA (DMD mRNA) DMWL2XD MA Modulator DMWL2XD RN Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96. DMWL2XD RU https://pubmed.ncbi.nlm.nih.gov/25209738 DMWLF2X DI DMWLF2X DMWLF2X DN Ceftobiprole medocaril DMWLF2X TI TTJP4SM DMWLF2X TN Bacterial Penicillin binding protein (Bact PBP) DMWLF2X MA Binder DMWLF2X RN Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509. DMWLF2X RU https://pubmed.ncbi.nlm.nih.gov/30198789 DMWM4D0 DI DMWM4D0 DMWM4D0 DN TAS-120 DMWM4D0 TI TT0LF7H DMWM4D0 TN Fibroblast growth factor receptor (FGFR) DMWM4D0 MA Antagonist DMWM4D0 RN TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270. DMWM4D0 RU http://mct.aacrjournals.org/content/12/11_Supplement/A270.short DMWM4D0 DI DMWM4D0 DMWM4D0 DN TAS-120 DMWM4D0 TI TT5HU6Z DMWM4D0 TN Fibroblast growth factor (FGF) DMWM4D0 MA Inhibitor DMWM4D0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWM4D0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWMT5N DI DMWMT5N DMWMT5N DN VRS-317 DMWMT5N TI TTT3YKH DMWMT5N TN Somatotropin (GH1) DMWMT5N MA Modulator DMWMT5N RN Company report (Versartis) DMWMT5N RU http://www.versartis.com/content/productpipeline/vrs-317.htm DMWO5ZR DI DMWO5ZR DMWO5ZR DN Cediranib DMWO5ZR TI TTUTJGQ DMWO5ZR TN Vascular endothelial growth factor receptor 2 (KDR) DMWO5ZR MA Inhibitor DMWO5ZR RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMWO5ZR RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMWOF1E DI DMWOF1E DMWOF1E DN SKY59 DMWOF1E TI TTKANGO DMWOF1E TN Complement C5 (CO5) DMWOF1E MA Inhibitor DMWOF1E RN The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. DMWOF1E RU https://pubmed.ncbi.nlm.nih.gov/31978221 DMWPA4L DI DMWPA4L DMWPA4L DN PF-07055480 DMWPA4L TI TT1290U DMWPA4L TN Coagulation factor VIII (F8) DMWPA4L MA Replacement DMWPA4L RN Clinical pipeline report, company report or official report of Pfizer. DMWPA4L RU https://www.pfizer.com/science/rare-diseases/pipeline DMWTPCA DI DMWTPCA DMWTPCA DN L-651582 DMWTPCA TI TTH18TF DMWTPCA TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWTPCA MA Modulator DMWTPCA RN The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther. 1991 Jun;257(3):967-71. DMWTPCA RU https://pubmed.ncbi.nlm.nih.gov/1646332 DMWUN1S DI DMWUN1S DMWUN1S DN Drisapersen DMWUN1S TI TTWLFXU DMWUN1S TN Dystrophin messenger RNA (DMD mRNA) DMWUN1S RN PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther. 2010 Aug;12(4):478-86. DMWUN1S RU https://pubmed.ncbi.nlm.nih.gov/20677099 DMWX90U DI DMWX90U DMWX90U DN Gantenerumab DMWX90U TI TTE4KHA DMWX90U TN Amyloid beta A4 protein (APP) DMWX90U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWX90U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWYPZF DI DMWYPZF DMWYPZF DN BAY-35-3377 DMWYPZF TI TTN6J5F DMWYPZF TN Bacterial DNA gyrase (Bact gyrase) DMWYPZF MA Inhibitor DMWYPZF RN Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013 Oct;66(10):571-91. DMWYPZF RU https://pubmed.ncbi.nlm.nih.gov/24002361 DMWZ2TU DI DMWZ2TU DMWZ2TU DN CO-1686 DMWZ2TU TI TTGKNB4 DMWZ2TU TN Epidermal growth factor receptor (EGFR) DMWZ2TU MA Modulator DMWZ2TU RN Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. DMWZ2TU RU https://pubmed.ncbi.nlm.nih.gov/25923550 DMWZIRJ DI DMWZIRJ DMWZIRJ DN LY404039 DMWZIRJ TI TT8A9EF DMWZIRJ TN Metabotropic glutamate receptor 3 (mGluR3) DMWZIRJ MA Agonist DMWZIRJ RN Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75. DMWZIRJ RU https://pubmed.ncbi.nlm.nih.gov/19552508 DMX04CA DI DMX04CA DMX04CA DN VB-111 DMX04CA TI TTF0RCZ DMX04CA TN Apoptosis mediating surface antigen FAS (FAS) DMX04CA MA Modulator DMX04CA RN Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007. DMX04CA RU https://www.ncbi.nlm.nih.gov/pubmed/23589178 DMX04CA DI DMX04CA DMX04CA DN VB-111 DMX04CA TI TTG043C DMX04CA TN Tumor necrosis factor receptor type I (TNF-R1) DMX04CA MA Modulator DMX04CA RN Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007. DMX04CA RU https://www.ncbi.nlm.nih.gov/pubmed/23589178 DMX0O9U DI DMX0O9U DMX0O9U DN Lopinavir + ritonavir + favipiravir DMX0O9U TI TT1D53B DMX0O9U TN COVID-19 3C-like protease (3CLpro) DMX0O9U MA Inhibitor DMX0O9U RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMX0O9U RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMX0PWV DI DMX0PWV DMX0PWV DN Anti-IL-23 DMX0PWV TI TT6H4QR DMX0PWV TN Interleukin 23 receptor (IL23R) DMX0PWV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). DMX0PWV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293 DMX178V DI DMX178V DMX178V DN 177-Lu-PSMA-617 DMX178V TI TT9G4N0 DMX178V TN Glutamate carboxypeptidase II (GCPII) DMX178V MA Agonist DMX178V RN Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921. DMX178V RU https://pubmed.ncbi.nlm.nih.gov/32760622 DMX36BH DI DMX36BH DMX36BH DN Andolast DMX36BH TI TT1VOHK DMX36BH TN Potassium channel unspecific (KC) DMX36BH MA Opener DMX36BH RN BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46. DMX36BH RU https://pubmed.ncbi.nlm.nih.gov/18473808 DMX7BM4 DI DMX7BM4 DMX7BM4 DN Efaproxyn DMX7BM4 TI TTQO71U DMX7BM4 TN Hemoglobin (HB) DMX7BM4 MA Inhibitor DMX7BM4 RN Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9. DMX7BM4 RU https://pubmed.ncbi.nlm.nih.gov/15817356 DMX9K3W DI DMX9K3W DMX9K3W DN Cetraxal Otic DMX9K3W TI TT1WJCI DMX9K3W TN Streptococcus Topoisomerase IV A (Stre-coc parC) DMX9K3W MA Modulator DMX9K3W RN DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33. DMX9K3W RU https://pubmed.ncbi.nlm.nih.gov/20534341 DMX9K3W DI DMX9K3W DMX9K3W DN Cetraxal Otic DMX9K3W TI TTE72ID DMX9K3W TN Haemophilus influenzae DNA gyrase A (Hae-influ gyrA) DMX9K3W MA Modulator DMX9K3W RN DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33. DMX9K3W RU https://pubmed.ncbi.nlm.nih.gov/20534341 DMX9YLR DI DMX9YLR DMX9YLR DN Pridopidine DMX9YLR TI TTEX248 DMX9YLR TN Dopamine D2 receptor (D2R) DMX9YLR MA Modulator DMX9YLR RN Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. DMX9YLR RU https://pubmed.ncbi.nlm.nih.gov/20616707 DMXAO4J DI DMXAO4J DMXAO4J DN SAR153191 DMXAO4J TI TT0E5SK DMXAO4J TN Interleukin 6 receptor (IL6R) DMXAO4J MA Antagonist DMXAO4J RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMXAO4J RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMXAZ47 DI DMXAZ47 DMXAZ47 DN HGH-CTP DMXAZ47 TI TTT3YKH DMXAZ47 TN Somatotropin (GH1) DMXAZ47 MA Agonist DMXAZ47 RN Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538. DMXAZ47 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122423/ DMXBHR6 DI DMXBHR6 DMXBHR6 DN Balaglitazone DMXBHR6 TI TTZMAO3 DMXBHR6 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMXBHR6 MA Modulator DMXBHR6 RN Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97. DMXBHR6 RU https://www.ncbi.nlm.nih.gov/pubmed/22372600 DMXGE3O DI DMXGE3O DMXGE3O DN SAR408701 DMXGE3O TI TTY6DTE DMXGE3O TN Carcinoembryonic antigen CEA (CD66e) DMXGE3O RN ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. DMXGE3O RU https://clinicaltrials.gov/ct2/show/NCT02187848 DMXHI89 DI DMXHI89 DMXHI89 DN Velac Gel DMXHI89 TI TTOD7B3 DMXHI89 TN Retinoic acid receptor (RAR) DMXHI89 MA Inhibitor DMXHI89 RN Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74. DMXHI89 RU https://pubmed.ncbi.nlm.nih.gov/1652368 DMXJMKF DI DMXJMKF DMXJMKF DN Ganaxolone DMXJMKF TI TTGXH6N DMXJMKF TN GABA(A) receptor delta (GABRD) DMXJMKF MA Modulator DMXJMKF RN Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91. DMXJMKF RU https://www.ncbi.nlm.nih.gov/pubmed/9778270 DMXJMKF DI DMXJMKF DMXJMKF DN Ganaxolone DMXJMKF TI TTEX6LM DMXJMKF TN GABA(A) receptor gamma-3 (GABRG3) DMXJMKF MA Agonist DMXJMKF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXJMKF RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMXLGED DI DMXLGED DMXLGED DN esuberaprost DMXLGED TI TTOFYT1 DMXLGED TN Prostacyclin receptor (PTGIR) DMXLGED MA Agonist DMXLGED RN Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9. DMXLGED RU https://pubmed.ncbi.nlm.nih.gov/2665758 DMXNZQK DI DMXNZQK DMXNZQK DN SUN-101 DMXNZQK TI TTOXS3C DMXNZQK TN Muscarinic acetylcholine receptor (CHRM) DMXNZQK MA Inhibitor DMXNZQK RN Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120. DMXNZQK RU http://breathe.ersjournals.com/content/10/2/110 DMXU4ON DI DMXU4ON DMXU4ON DN Synthetic hypericin DMXU4ON TI TTYVX59 DMXU4ON TN Protein kinase C (PRKC) DMXU4ON MA Inhibitor DMXU4ON RN Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8. DMXU4ON RU https://pubmed.ncbi.nlm.nih.gov/16396605 DMXY34J DI DMXY34J DMXY34J DN S-110 DMXY34J TI TT6S2FE DMXY34J TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMXY34J MA Inhibitor DMXY34J RN S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. DMXY34J RU https://pubmed.ncbi.nlm.nih.gov/20442312 DMXY34J DI DMXY34J DMXY34J DN S-110 DMXY34J TI TTHVCUP DMXY34J TN DNA [cytosine-5]-methyltransferase (DNMT) DMXY34J MA Inhibitor DMXY34J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXY34J RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMXYM1H DI DMXYM1H DMXYM1H DN Visilizumab DMXYM1H TI TTBMAOZ DMXYM1H TN Regulatory protein unspecific (RGP) DMXYM1H RN Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9. DMXYM1H RU https://pubmed.ncbi.nlm.nih.gov/18424236 DMXYRPO DI DMXYRPO DMXYRPO DN Act1 DMXYRPO TI TT4F7SL DMXYRPO TN Gap junction alpha-1 protein (GJA1) DMXYRPO MA Modulator DMXYRPO RN Company report (FirstString Research) DMXYRPO RU http://firststringresearch.com/platform-technology/ DMXZ9T3 DI DMXZ9T3 DMXZ9T3 DN AC-170 DMXZ9T3 TI TTTIBOJ DMXZ9T3 TN Histamine H1 receptor (H1R) DMXZ9T3 MA Antagonist DMXZ9T3 RN Clinical pipeline report, company report or official report of NicOx SA. DMXZ9T3 RU http://www.nicox.com/rd/ac-170/ DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TTD16BI DMXZAL2 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMXZAL2 MA Inhibitor DMXZAL2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TTZGK1R DMXZAL2 TN HUMAN glycosylation of host receptor (GHR) DMXZAL2 MA Inhibitor DMXZAL2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TT3A1EZ DMXZAL2 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMXZAL2 MA Inhibitor DMXZAL2 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMY60DT DI DMY60DT DMY60DT DN N8-GP DMY60DT TI TT1290U DMY60DT TN Coagulation factor VIII (F8) DMY60DT MA Modulator DMY60DT RN Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8. DMY60DT RU https://pubmed.ncbi.nlm.nih.gov/23398640 DMY7WH1 DI DMY7WH1 DMY7WH1 DN Sutimlimab DMY7WH1 TI TT7LRQH DMY7WH1 TN Complement C1s component (C1S) DMY7WH1 MA Inhibitor DMY7WH1 RN Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531. DMY7WH1 RU https://pubmed.ncbi.nlm.nih.gov/31847708 DMY96O3 DI DMY96O3 DMY96O3 DN acelarin DMY96O3 TI TTUBNVO DMY96O3 TN DNA synthesis (DNA synth) DMY96O3 MA Inhibitor DMY96O3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY96O3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYA41S DI DMYA41S DMYA41S DN TNX-355 DMYA41S TI TTN2JFW DMYA41S TN T-cell surface glycoprotein CD4 (CD4) DMYA41S MA Binder DMYA41S RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DMYA41S RU https://pubmed.ncbi.nlm.nih.gov/16182193 DMYHSO2 DI DMYHSO2 DMYHSO2 DN ABT-874 DMYHSO2 TI TTGW72V DMYHSO2 TN Interleukin-12 beta (IL12B) DMYHSO2 MA Modulator DMYHSO2 RN Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20. DMYHSO2 RU https://www.ncbi.nlm.nih.gov/pubmed/22077474 DMYHV17 DI DMYHV17 DMYHV17 DN Sumanirole DMYHV17 TI TTEX248 DMYHV17 TN Dopamine D2 receptor (D2R) DMYHV17 MA Agonist DMYHV17 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMYHV17 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMYJ2QB DI DMYJ2QB DMYJ2QB DN D2A21 DMYJ2QB TI TTXT4D5 DMYJ2QB TN Bacterial Cell membrane (Bact CM) DMYJ2QB MA Modulator DMYJ2QB RN In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41. DMYJ2QB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126975/ DMYLT67 DI DMYLT67 DMYLT67 DN TKI258 DMYLT67 TI TTST7KB DMYLT67 TN Fibroblast growth factor receptor 3 (FGFR3) DMYLT67 MA Inhibitor DMYLT67 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYLT67 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYLT67 DI DMYLT67 DMYLT67 DN TKI258 DMYLT67 TI TTI2WET DMYLT67 TN Platelet-derived growth factor receptor (PDGFR) DMYLT67 MA Inhibitor DMYLT67 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYLT67 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYN391 DI DMYN391 DMYN391 DN Odevixibat DMYN391 TI TTPI1M5 DMYN391 TN Ileal sodium/bile acid cotransporter (SLC10A2) DMYN391 MA Inhibitor DMYN391 RN Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689. DMYN391 RU https://pubmed.ncbi.nlm.nih.gov/32653991 DMYN3IH DI DMYN3IH DMYN3IH DN AGI-1067 DMYN3IH TI TT1AVS7 DMYN3IH TN Second phase insulin secretion (SPI secr) DMYN3IH MA Inhibitor DMYN3IH RN AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55. DMYN3IH RU https://pubmed.ncbi.nlm.nih.gov/20211684 DMYNJHI DI DMYNJHI DMYNJHI DN Arc029 DMYNJHI TI TT7RGTM DMYNJHI TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMYNJHI MA Inhibitor DMYNJHI RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DMYNJHI RU https://pubmed.ncbi.nlm.nih.gov/2552119 DMYNJHI DI DMYNJHI DMYNJHI DN Arc029 DMYNJHI TI TTZIFHC DMYNJHI TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMYNJHI MA Inhibitor DMYNJHI RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DMYNJHI RU https://pubmed.ncbi.nlm.nih.gov/2552119 DMYTC4I DI DMYTC4I DMYTC4I DN NeuVax DMYTC4I TI TT6EO5L DMYTC4I TN Erbb2 tyrosine kinase receptor (HER2) DMYTC4I RN The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. DMYTC4I RU https://pubmed.ncbi.nlm.nih.gov/24896623 DMYVBF6 DI DMYVBF6 DMYVBF6 DN Edasalonexent DMYVBF6 TI TTSXVID DMYVBF6 TN Nuclear factor NF-kappa-B (NFKB) DMYVBF6 MA Inhibitor DMYVBF6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYVBF6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMYX7VI DI DMYX7VI DMYX7VI DN Rintatolimod DMYX7VI TI TTD24Y0 DMYX7VI TN Toll-like receptor 3 (TLR3) DMYX7VI RN A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. DMYX7VI RU https://pubmed.ncbi.nlm.nih.gov/22431963 DMYXOHV DI DMYXOHV DMYXOHV DN Rifalazil DMYXOHV TI TTIJ5EB DMYXOHV TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMYXOHV MA Inhibitor DMYXOHV RN Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. DMYXOHV RU https://pubmed.ncbi.nlm.nih.gov/17691942 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TTT7PJU DMZ1UOI TN Janus kinase 3 (JAK-3) DMZ1UOI MA Inhibitor DMZ1UOI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). DMZ1UOI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TT6DM01 DMZ1UOI TN Janus kinase 1 (JAK-1) DMZ1UOI MA Inhibitor DMZ1UOI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047). DMZ1UOI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TTJSQEF DMZ1UOI TN Tyrosine-protein kinase (PTK) DMZ1UOI MA Inhibitor DMZ1UOI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ1UOI RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ3P6C DI DMZ3P6C DMZ3P6C DN Teplizumab DMZ3P6C TI TTBMAOZ DMZ3P6C TN Regulatory protein unspecific (RGP) DMZ3P6C RN Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901. DMZ3P6C RU https://pubmed.ncbi.nlm.nih.gov/21038470 DMZ3P6C DI DMZ3P6C DMZ3P6C DN Teplizumab DMZ3P6C TI TTV3XPL DMZ3P6C TN T-cell surface glycoprotein CD3 gamma (CD3G) DMZ3P6C MA Inhibitor DMZ3P6C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ3P6C RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZ61IA DI DMZ61IA DMZ61IA DN Setipiprant DMZ61IA TI TTQDMX5 DMZ61IA TN Prostaglandin D2 receptor 2 (PTGDR2) DMZ61IA MA Antagonist DMZ61IA RN Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52. DMZ61IA RU https://pubmed.ncbi.nlm.nih.gov/24964348 DMZ61IA DI DMZ61IA DMZ61IA DN Setipiprant DMZ61IA TI TTNVEIR DMZ61IA TN Prostaglandin D2 receptor (PTGDR) DMZ61IA MA Antagonist DMZ61IA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ61IA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ6VD5 DI DMZ6VD5 DMZ6VD5 DN M-518101 DMZ6VD5 TI TTUST1O DMZ6VD5 TN Phosphodiesterase (PDE) DMZ6VD5 MA Inhibitor DMZ6VD5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6VD5 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ7AMY DI DMZ7AMY DMZ7AMY DN Amivantamab DMZ7AMY TI TTNDSF4 DMZ7AMY TN Proto-oncogene c-Met (MET) DMZ7AMY MA Inhibitor DMZ7AMY RN Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DMZ7AMY RU https://pubmed.ncbi.nlm.nih.gov/32414908 DMZ7AMY DI DMZ7AMY DMZ7AMY DN Amivantamab DMZ7AMY TI TTGKNB4 DMZ7AMY TN Epidermal growth factor receptor (EGFR) DMZ7AMY MA Inhibitor DMZ7AMY RN Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DMZ7AMY RU https://pubmed.ncbi.nlm.nih.gov/32414908 DMZA2K0 DI DMZA2K0 DMZA2K0 DN INCSHR1210 DMZA2K0 TI TTNBFWK DMZA2K0 TN Programmed cell death protein 1 (PD-1) DMZA2K0 MA Inhibitor DMZA2K0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZA2K0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZA47Y DI DMZA47Y DMZA47Y DN Iomab-B DMZA47Y TI TTUS45N DMZA47Y TN Leukocyte common antigen (PTPRC) DMZA47Y RN Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. DMZA47Y RU http://www.actiniumpharma.com/products/pipeline/iomab-b/ DMZARP1 DI DMZARP1 DMZARP1 DN FV-100 DMZARP1 TI TTP3QRF DMZARP1 TN Thymidine kinase 1 (TK1) DMZARP1 MA Inhibitor DMZARP1 RN Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54. DMZARP1 RU https://pubmed.ncbi.nlm.nih.gov/11809847 DMZB9RI DI DMZB9RI DMZB9RI DN Arabaclofen DMZB9RI TI TTDCVZW DMZB9RI TN Gamma-aminobutyric acid B receptor (GABBR) DMZB9RI MA Agonist DMZB9RI RN Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84. DMZB9RI RU https://pubmed.ncbi.nlm.nih.gov/23436129 DMZBGI8 DI DMZBGI8 DMZBGI8 DN Tilarginine acetate DMZBGI8 TI TTCM4B3 DMZBGI8 TN Nitric-oxide synthase endothelial (NOS3) DMZBGI8 MA Modulator DMZBGI8 RN Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66. DMZBGI8 RU https://pubmed.ncbi.nlm.nih.gov/17387132 DMZE2JO DI DMZE2JO DMZE2JO DN SNS-595 DMZE2JO TI TT0IHXV DMZE2JO TN DNA topoisomerase II (TOP2) DMZE2JO MA Modulator DMZE2JO RN A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.Haematologica.2015 Feb;100(2):231-7. DMZE2JO RU https://www.ncbi.nlm.nih.gov/pubmed/25381131 DMZHN5B DI DMZHN5B DMZHN5B DN MIM-D3 DMZHN5B TI TTTDVOJ DMZHN5B TN Tropomyosin-related kinase A (TrkA) DMZHN5B MA Agonist DMZHN5B RN Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285. DMZHN5B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/ DMZIM37 DI DMZIM37 DMZIM37 DN CP-868596 DMZIM37 TI TT8FYO9 DMZIM37 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMZIM37 MA Modulator DMZIM37 RN The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9. DMZIM37 RU https://www.ncbi.nlm.nih.gov/pubmed/25597754 DMZIM37 DI DMZIM37 DMZIM37 DN CP-868596 DMZIM37 TI TT6PKBN DMZIM37 TN Proto-oncogene c-Src (SRC) DMZIM37 MA Inhibitor DMZIM37 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZIM37 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZJGVL DI DMZJGVL DMZJGVL DN CSL-654 DMZJGVL TI TTFEZ5Q DMZJGVL TN Coagulation factor IX (F9) DMZJGVL MA Modulator DMZJGVL RN Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411. DMZJGVL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448255/ DMZKGPV DI DMZKGPV DMZKGPV DN Gemigliptin DMZKGPV TI TTDIGC1 DMZKGPV TN Dipeptidyl peptidase 4 (DPP-4) DMZKGPV MA Inhibitor DMZKGPV RN Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41. DMZKGPV RU https://pubmed.ncbi.nlm.nih.gov/25350224 DMZKTYJ DI DMZKTYJ DMZKTYJ DN Enmetazobactam DMZKTYJ TI TTHI19T DMZKTYJ TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMZKTYJ MA Inhibitor DMZKTYJ RN Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20. DMZKTYJ RU https://pubmed.ncbi.nlm.nih.gov/32253209 DMZL1I8 DI DMZL1I8 DMZL1I8 DN Fidarestat DMZL1I8 TI TTFBNVI DMZL1I8 TN Aldose reductase (AKR1B1) DMZL1I8 MA Inhibitor DMZL1I8 RN Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82. DMZL1I8 RU https://pubmed.ncbi.nlm.nih.gov/11574441 DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TT362RB DMZPEHY TN MART-1 melanoma antigen (MLANA) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TT8MK59 DMZPEHY TN Melanocytes lineage-specific antigen GP100 (PMEL) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TTULVH8 DMZPEHY TN Tyrosinase (TYR) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZS2R7 DI DMZS2R7 DMZS2R7 DN Granexin gel DMZS2R7 TI TT4F7SL DMZS2R7 TN Gap junction alpha-1 protein (GJA1) DMZS2R7 MA Modulator DMZS2R7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZS2R7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0798Z DI DM0798Z DM0798Z DN NLG8189 DM0798Z TI TTZJYKH DM0798Z TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0798Z MA Inhibitor DM0798Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0798Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0ASTP DI DM0ASTP DM0ASTP DN Verapamil DM0ASTP TI TTHQJ2Y DM0ASTP TN HUMAN two pore channel subtype 2 (TPC2) DM0ASTP MA Blocker DM0ASTP RN Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. DM0ASTP RU https://pubmed.ncbi.nlm.nih.gov/32221306 DM0EFQS DI DM0EFQS DM0EFQS DN Plasminogen DM0EFQS TI TTP86E2 DM0EFQS TN Plasminogen (PLG) DM0EFQS MA Modulator DM0EFQS RN Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54. DM0EFQS RU https://pubmed.ncbi.nlm.nih.gov/15841308 DM0JETC DI DM0JETC DM0JETC DN Genistein DM0JETC TI TTOM3J0 DM0JETC TN Estrogen receptor beta (ESR2) DM0JETC MA Modulator DM0JETC RN Company report (Axcentua) DM0JETC RU http://axcentua.com/science/genistein/ DM0NZDT DI DM0NZDT DM0NZDT DN Pactimibe DM0NZDT TI TTMF541 DM0NZDT TN Liver carboxylesterase (CES1) DM0NZDT MA Inhibitor DM0NZDT RN Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33. DM0NZDT RU https://pubmed.ncbi.nlm.nih.gov/18620381 DM12UX6 DI DM12UX6 DM12UX6 DN 131 I-omburtamab DM12UX6 TI TT6CQUM DM12UX6 TN B7 homolog 3 (CD276) DM12UX6 MA Inhibitor DM12UX6 RN IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177. DM12UX6 RU https://pubmed.ncbi.nlm.nih.gov/33047248 DM15VBJ DI DM15VBJ DM15VBJ DN Artemisone DM15VBJ TI TT9X7H4 DM15VBJ TN Beta-hematin formation (BHF) DM15VBJ MA Modulator DM15VBJ RN Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS One. 2013; 8(12): e82962. DM15VBJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877007/ DM1LFUN DI DM1LFUN DM1LFUN DN Ravidasvir DM1LFUN TI TTCJ2X8 DM1LFUN TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM1LFUN MA Inhibitor DM1LFUN RN Clinical pipeline report, company report or official report of Presidio Pharmaceuticals. DM1LFUN RU http://www.presidiopharma.com/ DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTHQPL7 DM1QSM3 TN Carbonic anhydrase I (CA-I) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTZHA0O DM1QSM3 TN Carbonic anhydrase IV (CA-IV) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTUNARX DM1QSM3 TN Carbonic anhydrase (CA) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTSYM0R DM1QSM3 TN Carbonic anhydrase XII (CA-XII) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTANPDJ DM1QSM3 TN Carbonic anhydrase II (CA-II) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTEYTKG DM1QSM3 TN Carbonic anhydrase XIV (CA-XIV) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TT2LVK8 DM1QSM3 TN Carbonic anhydrase IX (CA-IX) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1SV8I DI DM1SV8I DM1SV8I DN PHN-131 DM1SV8I TI TTQW87Y DM1SV8I TN Opioid receptor kappa (OPRK1) DM1SV8I MA Agonist DM1SV8I RN Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. DM1SV8I RU https://pubmed.ncbi.nlm.nih.gov/2826773 DM23ARP DI DM23ARP DM23ARP DN V-710 DM23ARP TI TTE0AHP DM23ARP TN Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB) DM23ARP RN Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013 Apr 3;309(13):1368-78. DM23ARP RU https://pubmed.ncbi.nlm.nih.gov/23549582 DM2U3MX DI DM2U3MX DM2U3MX DN VX-509 DM2U3MX TI TTT7PJU DM2U3MX TN Janus kinase 3 (JAK-3) DM2U3MX MA Inhibitor DM2U3MX RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM2U3MX RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM2YNMI DI DM2YNMI DM2YNMI DN MK-1654 DM2YNMI TI TT57ID8 DM2YNMI TN Respiratory syncytial virus protein F (RSV F) DM2YNMI MA Inhibitor DM2YNMI RN A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153. DM2YNMI RU https://pubmed.ncbi.nlm.nih.gov/31515478 DM30JWZ DI DM30JWZ DM30JWZ DN SM04554 DM30JWZ TI TTFPSHI DM30JWZ TN Wnt signaling pathway (Wnt pathway) DM30JWZ MA Modulator DM30JWZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM30JWZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM31L9K DI DM31L9K DM31L9K DN Sepofarsen DM31L9K TI TT3XBOV DM31L9K TN CEP290 messenger RNA (CEP290 mRNA) DM31L9K MA Inhibitor DM31L9K RN Clinical pipeline report, company report or official report of ProQR Therapeutics. DM31L9K RU https://www.proqr.com/pipeline DM31VZT DI DM31VZT DM31VZT DN CAD-106 DM31VZT TI TTE4KHA DM31VZT TN Amyloid beta A4 protein (APP) DM31VZT RN The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31. DM31VZT RU https://pubmed.ncbi.nlm.nih.gov/21697382 DM32148 DI DM32148 DM32148 DN CD19 CAR T cells DM32148 TI TTW640A DM32148 TN B-lymphocyte surface antigen B4 (CD19) DM32148 MA CAR-T-Cell-Therapy DM32148 RN ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma DM32148 RU https://clinicaltrials.gov/ct2/show/NCT03391726 DM36HBS DI DM36HBS DM36HBS DN ALXN1101 DM36HBS TI TTH13AB DM36HBS TN Cyclic pyranopterin monophosphate synthase (MOCS1) DM36HBS MA Modulator DM36HBS RN ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health. DM36HBS RU https://clinicaltrials.gov/ct2/show/NCT02047461 DM3827C DI DM3827C DM3827C DN AZD4547 DM3827C TI TTRLW2X DM3827C TN Fibroblast growth factor receptor 1 (FGFR1) DM3827C MA Modulator DM3827C RN AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56. DM3827C RU https://pubmed.ncbi.nlm.nih.gov/22369928 DM3827C DI DM3827C DM3827C DN AZD4547 DM3827C TI TT0LF7H DM3827C TN Fibroblast growth factor receptor (FGFR) DM3827C MA Inhibitor DM3827C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3827C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3MJUS DI DM3MJUS DM3MJUS DN NBTX-001 DM3MJUS TI TT9IK2Z DM3MJUS TN N-methyl-D-aspartate receptor (NMDAR) DM3MJUS MA Antagonist DM3MJUS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3MJUS RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM45Z3P DI DM45Z3P DM45Z3P DN CD123/CLL1 CAR-T Cells DM45Z3P TI TTENHJ0 DM45Z3P TN Interleukin 3 receptor alpha (IL3RA) DM45Z3P MA CAR-T-Cell-Therapy(Dual specific) DM45Z3P RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DM45Z3P RU https://clinicaltrials.gov/ct2/show/NCT03631576 DM45Z3P DI DM45Z3P DM45Z3P DN CD123/CLL1 CAR-T Cells DM45Z3P TI TT70N8V DM45Z3P TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM45Z3P MA CAR-T-Cell-Therapy(Dual specific) DM45Z3P RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DM45Z3P RU https://clinicaltrials.gov/ct2/show/NCT03631576 DM4H78P DI DM4H78P DM4H78P DN NT-501 DM4H78P TI TTT2F9E DM4H78P TN Ciliary neurotrophic factor receptor alpha (CNTFR) DM4H78P MA Modulator DM4H78P RN Clinical pipeline report, company report or official report of Neurotech. DM4H78P RU http://www.neurotechusa.com/cntfrenexus.html DM4OYXE DI DM4OYXE DM4OYXE DN LIAROZOLE DM4OYXE TI TTD7Q0R DM4OYXE TN Cytochrome P450 26 (CYP26A1) DM4OYXE MA Inhibitor DM4OYXE RN Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13. DM4OYXE RU https://pubmed.ncbi.nlm.nih.gov/18722776 DM4OYXE DI DM4OYXE DM4OYXE DN LIAROZOLE DM4OYXE TI TTSZLWK DM4OYXE TN Aromatase (CYP19A1) DM4OYXE MA Inhibitor DM4OYXE RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM4OYXE RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM4WQBO DI DM4WQBO DM4WQBO DN VM-1500 DM4WQBO TI TT84ETX DM4WQBO TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4WQBO MA Inhibitor DM4WQBO RN 127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52. DM4WQBO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149639/ DM5G1NT DI DM5G1NT DM5G1NT DN VX-210 DM5G1NT TI TTXEVN8 DM5G1NT TN Transforming protein Rho (RHO) DM5G1NT MA Inhibitor DM5G1NT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5G1NT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5UJ9P DI DM5UJ9P DM5UJ9P DN IMU-838 DM5UJ9P TI TT3UY29 DM5UJ9P TN HUMAN dihydroorotate dehydrogenase (DHODH) DM5UJ9P MA Inhibitor DM5UJ9P RN IMU-838 Targeting DHODH DM5UJ9P RU https://www.immunic-therapeutics.com/imu838/ DM5WQ2U DI DM5WQ2U DM5WQ2U DN SR-123781A DM5WQ2U TI TTCIHJA DM5WQ2U TN Coagulation factor Xa (F10) DM5WQ2U MA Modulator DM5WQ2U RN SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60. DM5WQ2U RU https://pubmed.ncbi.nlm.nih.gov/11372679 DM5WQ2U DI DM5WQ2U DM5WQ2U DN SR-123781A DM5WQ2U TI TT6L509 DM5WQ2U TN Coagulation factor IIa (F2) DM5WQ2U MA Modulator DM5WQ2U RN SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60. DM5WQ2U RU https://pubmed.ncbi.nlm.nih.gov/11372679 DM5YHU2 DI DM5YHU2 DM5YHU2 DN Avoralstat DM5YHU2 TI TTJLNAW DM5YHU2 TN Tissue kallikrein (KLK2) DM5YHU2 MA Inhibitor DM5YHU2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5YHU2 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM5YHU2 DI DM5YHU2 DM5YHU2 DN Avoralstat DM5YHU2 TI TTDJ4MY DM5YHU2 TN Kininogen (KNG1) DM5YHU2 MA Inhibitor DM5YHU2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5YHU2 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM6GTMD DI DM6GTMD DM6GTMD DN ADX-48621 DM6GTMD TI TTHS256 DM6GTMD TN Metabotropic glutamate receptor 5 (mGluR5) DM6GTMD MA Modulator DM6GTMD RN Pipeline of Addex Pharma. Addex Pharma. 2009. DM6GTMD RU http://www.addexpharma.com/pipeline-old/adx48621/ DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTNDSF4 DM752PU TN Proto-oncogene c-Met (MET) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTDCBX5 DM752PU TN Vascular endothelial growth factor receptor 3 (FLT-4) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTUTJGQ DM752PU TN Vascular endothelial growth factor receptor 2 (KDR) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TT4DXQT DM752PU TN Proto-oncogene c-Ret (RET) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTNDSF4 DM752PU TN Proto-oncogene c-Met (MET) DM752PU MA Inhibitor DM752PU RN Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45. DM752PU RU https://pubmed.ncbi.nlm.nih.gov/21242122 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TT4DXQT DM752PU TN Proto-oncogene c-Ret (RET) DM752PU MA Inhibitor DM752PU RN Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45. DM752PU RU https://pubmed.ncbi.nlm.nih.gov/21242122 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTU8W4S DM752PU TN Protein kinase (PK) DM752PU MA Inhibitor DM752PU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM752PU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8D6O2 DI DM8D6O2 DM8D6O2 DN Nafamostat DM8D6O2 TI TTZ3COY DM8D6O2 TN COVID-19 spike glycoprotein (S) DM8D6O2 MA Inhibitor DM8D6O2 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DM8D6O2 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DM8D6O2 DI DM8D6O2 DM8D6O2 DN Nafamostat DM8D6O2 TI TT85VHW DM8D6O2 TN MERS-CoV spike glycoprotein (S) DM8D6O2 MA Inhibitor DM8D6O2 RN Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. DM8D6O2 RU https://pubmed.ncbi.nlm.nih.gov/27550352 DM901ZW DI DM901ZW DM901ZW DN Naptumomab estafenatox DM901ZW TI TT70MLA DM901ZW TN Oncotrophoblast glycoprotein 5T4 (TPBG) DM901ZW MA Immunomodulator DM901ZW RN Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370. DM901ZW RU https://pubmed.ncbi.nlm.nih.gov/24445502 DM948AP DI DM948AP DM948AP DN MAb114 DM948AP TI TT2F0AU DM948AP TN Ebola virus Envelope glycoprotein (EV GP) DM948AP RN Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. DM948AP RU https://pubmed.ncbi.nlm.nih.gov/33751449 DMB8UQ3 DI DMB8UQ3 DMB8UQ3 DN Ramatroban DMB8UQ3 TI TT2O84V DMB8UQ3 TN Thromboxane A2 receptor (TBXA2R) DMB8UQ3 MA Antagonist DMB8UQ3 RN Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7. DMB8UQ3 RU https://pubmed.ncbi.nlm.nih.gov/17761352 DMB8UQ3 DI DMB8UQ3 DMB8UQ3 DN Ramatroban DMB8UQ3 TI TTQDMX5 DMB8UQ3 TN Prostaglandin D2 receptor 2 (PTGDR2) DMB8UQ3 MA Antagonist DMB8UQ3 RN CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. DMB8UQ3 RU https://pubmed.ncbi.nlm.nih.gov/16256979 DMBFOAZ DI DMBFOAZ DMBFOAZ DN AMG520 DMBFOAZ TI TTJUNZF DMBFOAZ TN Beta-secretase 1 (BACE1) DMBFOAZ MA Inhibitor DMBFOAZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBFOAZ RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMBIO6E DI DMBIO6E DMBIO6E DN Meclinertant DMBIO6E TI TTTUMEP DMBIO6E TN Neurotensin receptor type 1 (NTSR1) DMBIO6E MA Antagonist DMBIO6E RN Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23. DMBIO6E RU https://pubmed.ncbi.nlm.nih.gov/19118604 DMBJ15R DI DMBJ15R DMBJ15R DN Pexacerfont DMBJ15R TI TT7EFHR DMBJ15R TN Corticotropin-releasing factor receptor 1 (CRHR1) DMBJ15R MA Antagonist DMBJ15R RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMBJ15R RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMBJ4IZ DI DMBJ4IZ DMBJ4IZ DN LECOZOTAN HYDROCHLORIDE DMBJ4IZ TI TTSQIFT DMBJ4IZ TN 5-HT 1A receptor (HTR1A) DMBJ4IZ MA Antagonist DMBJ4IZ RN A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in... Clin Pharmacol Ther. 2008 Jan;83(1):86-96. DMBJ4IZ RU https://pubmed.ncbi.nlm.nih.gov/17507923 DMC3794 DI DMC3794 DMC3794 DN Indium-111 DMC3794 TI TTGKNB4 DMC3794 TN Epidermal growth factor receptor (EGFR) DMC3794 RN Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. DMC3794 RU https://pubmed.ncbi.nlm.nih.gov/25731184 DMCA2PJ DI DMCA2PJ DMCA2PJ DN ONO-2506 DMCA2PJ TI TTMXGCW DMCA2PJ TN Adrenergic receptor beta-3 (ADRB3) DMCA2PJ MA Agonist DMCA2PJ RN FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12. DMCA2PJ RU https://pubmed.ncbi.nlm.nih.gov/9195306 DMCA2PJ DI DMCA2PJ DMCA2PJ DN ONO-2506 DMCA2PJ TI TTQ0V86 DMCA2PJ TN S100 calcium-binding protein B (S100B) DMCA2PJ MA Modulator DMCA2PJ RN Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42. DMCA2PJ RU https://www.ncbi.nlm.nih.gov/pubmed/15857298 DMCGK6X DI DMCGK6X DMCGK6X DN PRO 140 DMCGK6X TI TT2CEJG DMCGK6X TN C-C chemokine receptor type 5 (CCR5) DMCGK6X MA Inhibitor DMCGK6X RN The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353. DMCGK6X RU https://pubmed.ncbi.nlm.nih.gov/29708899 DMCTRLN DI DMCTRLN DMCTRLN DN OT-101 DMCTRLN TI TTI0KH6 DMCTRLN TN TGF beta-2 messenger RNA (TGFB2 mRNA) DMCTRLN MA Inhibitor DMCTRLN RN Clinical pipeline report, company report or official report of Oncotelic. DMCTRLN RU https://www.oncotelic.com/pipeline/ DMD5AEB DI DMD5AEB DMD5AEB DN NAL-GLU DMD5AEB TI TT0ID4A DMD5AEB TN Leutinizing-hormone-releasing hormone (GNRH1) DMD5AEB RN The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7. DMD5AEB RU https://pubmed.ncbi.nlm.nih.gov/1750480 DMD741P DI DMD741P DMD741P DN Alagebrium chloride DMD741P TI TTMO9HF DMD741P TN Advanced glycosylation end product receptor (AGER) DMD741P MA Breaker DMD741P RN Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58. DMD741P RU https://pubmed.ncbi.nlm.nih.gov/20126491 DMD9ISG DI DMD9ISG DMD9ISG DN SM-88 DMD9ISG TI TT8E7Z0 DMD9ISG TN Free radical (FRD) DMD9ISG MA Stimulator DMD9ISG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD9ISG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDG8Q3 DI DMDG8Q3 DMDG8Q3 DN Varlitinib DMDG8Q3 TI TTGKNB4 DMDG8Q3 TN Epidermal growth factor receptor (EGFR) DMDG8Q3 MA Modulator DMDG8Q3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDG8Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDG8Q3 DI DMDG8Q3 DMDG8Q3 DN Varlitinib DMDG8Q3 TI TT6EO5L DMDG8Q3 TN Erbb2 tyrosine kinase receptor (HER2) DMDG8Q3 MA Modulator DMDG8Q3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDG8Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDLGRO DI DMDLGRO DMDLGRO DN Aramchol DMDLGRO TI TT6RIOV DMDLGRO TN Acyl-CoA desaturase (SCD) DMDLGRO MA Inhibitor DMDLGRO RN The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. DMDLGRO RU https://pubmed.ncbi.nlm.nih.gov/24815326 DMDQOWT DI DMDQOWT DMDQOWT DN MOR-208 DMDQOWT TI TTW640A DMDQOWT TN B-lymphocyte surface antigen B4 (CD19) DMDQOWT RN A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. DMDQOWT RU https://pubmed.ncbi.nlm.nih.gov/25301708 DMEUGZL DI DMEUGZL DMEUGZL DN Legumain-cleavable doxorubicin prodrugs DMEUGZL TI TTPTWV5 DMEUGZL TN Legumain (LGMN) DMEUGZL MA Modulator DMEUGZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2380). DMEUGZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2380 DMFCLT6 DI DMFCLT6 DMFCLT6 DN CE-224535 DMFCLT6 TI TT473XN DMFCLT6 TN P2X purinoceptor 7 (P2RX7) DMFCLT6 MA Antagonist DMFCLT6 RN Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7. DMFCLT6 RU https://pubmed.ncbi.nlm.nih.gov/22382341 DMFE0P1 DI DMFE0P1 DMFE0P1 DN Metformin glycinate DMFE0P1 TI TTCBFJO DMFE0P1 TN Insulin receptor (INSR) DMFE0P1 MA Inhibitor DMFE0P1 RN Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144. DMFE0P1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521136/ DMGC970 DI DMGC970 DMGC970 DN AG-013 DMGC970 TI TTNOJIZ DMGC970 TN Trefoil factor-1 (TFF1) DMGC970 MA Modulator DMGC970 RN AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70. DMGC970 RU https://pubmed.ncbi.nlm.nih.gov/20542722 DMGKRAJ DI DMGKRAJ DMGKRAJ DN VB4-845 DMGKRAJ TI TTZ8WH4 DMGKRAJ TN Tumor-associated calcium signal transducer 1 (EPCAM) DMGKRAJ RN A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249. DMGKRAJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994189/ DMGPJ5U DI DMGPJ5U DMGPJ5U DN JNJ-54861911 DMGPJ5U TI TT8JRS7 DMGPJ5U TN Beta-secretase (BACE) DMGPJ5U MA Inhibitor DMGPJ5U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGPJ5U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMH7CSQ DI DMH7CSQ DMH7CSQ DN Gavilimomab DMH7CSQ TI TT5UJWD DMH7CSQ TN Basigin (BSG) DMH7CSQ RN National Cancer Institute Drug Dictionary (drug id 38221). DMH7CSQ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38221 DMH7IPW DI DMH7IPW DMH7IPW DN Sarizotan DMH7IPW TI TTSQIFT DMH7IPW TN 5-HT 1A receptor (HTR1A) DMH7IPW MA Modulator DMH7IPW RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMH7IPW RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMH7IPW DI DMH7IPW DMH7IPW DN Sarizotan DMH7IPW TI TTEX248 DMH7IPW TN Dopamine D2 receptor (D2R) DMH7IPW MA Modulator DMH7IPW RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMH7IPW RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMH8VMP DI DMH8VMP DMH8VMP DN Emixustat DMH8VMP TI TTBOH16 DMH8VMP TN Retinal pigment epithelium protein (RPE65) DMH8VMP MA Inhibitor DMH8VMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH8VMP RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMHWE5R DI DMHWE5R DMHWE5R DN Batabulin DMHWE5R TI TTYFKSZ DMHWE5R TN Tubulin beta (TUBB) DMHWE5R MA Inhibitor DMHWE5R RN Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605. DMHWE5R RU https://pubmed.ncbi.nlm.nih.gov/11606124 DMHWY2G DI DMHWY2G DMHWY2G DN Pagoclone DMHWY2G TI TTEX6LM DMHWY2G TN GABA(A) receptor gamma-3 (GABRG3) DMHWY2G MA Modulator DMHWY2G RN Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73. DMHWY2G RU https://pubmed.ncbi.nlm.nih.gov/16702891 DMHXJ68 DI DMHXJ68 DMHXJ68 DN WVE-210201 DMHXJ68 TI TT48MP6 DMHXJ68 TN Dystrophin (DMD) DMHXJ68 MA Modulator DMHXJ68 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHXJ68 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMI215P DI DMI215P DMI215P DN Lopinavir + ritonavir + interferon beta-1b DMI215P TI TTWOH4Q DMI215P TN MERS-CoV 3C-like proteinase (3CLpro) DMI215P MA Inhibitor DMI215P RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMI215P RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMIUA3M DI DMIUA3M DMIUA3M DN Imprime PGG DMIUA3M TI TTJGY7A DMIUA3M TN Complement C3 (CO3) DMIUA3M MA Modulator DMIUA3M RN National Cancer Institute Drug Dictionary (drug id 599816). DMIUA3M RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816 DMJQHXD DI DMJQHXD DMJQHXD DN AZD3293 DMJQHXD TI TT8JRS7 DMJQHXD TN Beta-secretase (BACE) DMJQHXD MA Modulator DMJQHXD RN AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008. DMJQHXD RU http://www.neurobiologyofaging.org/article/S0197-4580(08)00131-0/abstract DMJRU3A DI DMJRU3A DMJRU3A DN AMO-02 DMJRU3A TI TTRSMW9 DMJRU3A TN Glycogen synthase kinase-3 beta (GSK-3B) DMJRU3A MA Inhibitor DMJRU3A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJRU3A RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJYTUQ DI DMJYTUQ DMJYTUQ DN CR-845 DMJYTUQ TI TTQW87Y DMJYTUQ TN Opioid receptor kappa (OPRK1) DMJYTUQ MA Agonist DMJYTUQ RN Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322. DMJYTUQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691465/ DMKGQF0 DI DMKGQF0 DMKGQF0 DN Suvodirsen DMKGQF0 TI TTWLFXU DMKGQF0 TN Dystrophin messenger RNA (DMD mRNA) DMKGQF0 MA Inhibitor DMKGQF0 RN Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. DMKGQF0 RU https://pubmed.ncbi.nlm.nih.gov/32782413 DMKMZW2 DI DMKMZW2 DMKMZW2 DN MTC-DOX DMKMZW2 TI TT0IHXV DMKMZW2 TN DNA topoisomerase II (TOP2) DMKMZW2 MA Modulator DMKMZW2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMKMZW2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMKT16N DI DMKT16N DMKT16N DN Bevacizumab DMKT16N TI TT140V6 DMKT16N TN HUMAN vascular endothelial growth factor (VEGF) DMKT16N MA Inhibitor DMKT16N RN ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) DMKT16N RU https://clinicaltrials.gov/ct2/show/NCT04275414 DMKY9GI DI DMKY9GI DMKY9GI DN Activated recombinant FVII-albumin fusion protein DMKY9GI TI TTF0EGX DMKY9GI TN Coagulation factor VII (F7) DMKY9GI MA Modulator DMKY9GI RN ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. DMKY9GI RU https://clinicaltrials.gov/ct2/show/NCT01542619 DMKY9GI DI DMKY9GI DMKY9GI DN Activated recombinant FVII-albumin fusion protein DMKY9GI TI TTFNGC9 DMKY9GI TN Serum albumin (ALB) DMKY9GI MA Modulator DMKY9GI RN ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. DMKY9GI RU https://clinicaltrials.gov/ct2/show/NCT01542619 DML906E DI DML906E DML906E DN CY-1503 DML906E TI TTE5VG0 DML906E TN P-selectin (SELP) DML906E MA Modulator DML906E RN Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9. DML906E RU https://pubmed.ncbi.nlm.nih.gov/7543381 DML906E DI DML906E DML906E DN CY-1503 DML906E TI TTAU4D6 DML906E TN E-selectin (SELE) DML906E MA Modulator DML906E RN Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9. DML906E RU https://pubmed.ncbi.nlm.nih.gov/7543381 DML9FD4 DI DML9FD4 DML9FD4 DN Rinfabate DML9FD4 TI TTHRID2 DML9FD4 TN Insulin-like growth factor I receptor (IGF1R) DML9FD4 MA Modulator DML9FD4 RN Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7. DML9FD4 RU https://pubmed.ncbi.nlm.nih.gov/15777106 DMMHSLC DI DMMHSLC DMMHSLC DN Afq056 DMMHSLC TI TTHS256 DMMHSLC TN Metabotropic glutamate receptor 5 (mGluR5) DMMHSLC MA Modulator DMMHSLC RN Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41. DMMHSLC RU https://pubmed.ncbi.nlm.nih.gov/23775850 DMMTL7V DI DMMTL7V DMMTL7V DN Hemoglobin raffimer DMMTL7V TI TTQO71U DMMTL7V TN Hemoglobin (HB) DMMTL7V MA Modulator DMMTL7V RN Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73. DMMTL7V RU https://pubmed.ncbi.nlm.nih.gov/15814750 DMN6F1W DI DMN6F1W DMN6F1W DN Amiodarone DMN6F1W TI TTHQJ2Y DMN6F1W TN HUMAN two pore channel subtype 2 (TPC2) DMN6F1W MA Blocker DMN6F1W RN Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. DMN6F1W RU https://pubmed.ncbi.nlm.nih.gov/32221306 DMNIYSZ DI DMNIYSZ DMNIYSZ DN RP101 DMNIYSZ TI TTP3QRF DMNIYSZ TN Thymidine kinase 1 (TK1) DMNIYSZ MA Inhibitor DMNIYSZ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMNIYSZ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMNTCV4 DI DMNTCV4 DMNTCV4 DN MBX-8025 DMNTCV4 TI TT2JWF6 DMNTCV4 TN Peroxisome proliferator-activated receptor delta (PPARD) DMNTCV4 MA Agonist DMNTCV4 RN ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008. DMNTCV4 RU https://clinicaltrials.gov/ct2/show/NCT00701883 DMOJLCV DI DMOJLCV DMOJLCV DN SAR164877 DMOJLCV TI TTDN3LF DMOJLCV TN Nerve growth factor (NGF) DMOJLCV MA Modulator DMOJLCV RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DMOJLCV RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DMONWJ4 DI DMONWJ4 DMONWJ4 DN Imetelstat DMONWJ4 TI TTUJFD0 DMONWJ4 TN Telomerase reverse transcriptase (TERT) DMONWJ4 MA Inhibitor DMONWJ4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMONWJ4 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMONYS9 DI DMONYS9 DMONYS9 DN MBX-102 DMONYS9 TI TTZMAO3 DMONYS9 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMONYS9 MA Agonist DMONYS9 RN MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. DMONYS9 RU https://pubmed.ncbi.nlm.nih.gov/19389808 DMP8HW1 DI DMP8HW1 DMP8HW1 DN LY2157299 DMP8HW1 TI TTP4520 DMP8HW1 TN TGF-beta receptor type I (TGFBR1) DMP8HW1 MA Modulator DMP8HW1 RN Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23. DMP8HW1 RU https://pubmed.ncbi.nlm.nih.gov/25488804 DMP8HW1 DI DMP8HW1 DMP8HW1 DN LY2157299 DMP8HW1 TI TTR9XHZ DMP8HW1 TN Transforming growth factor beta 1 (TGFB1) DMP8HW1 MA Inhibitor DMP8HW1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP8HW1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPDA17 DI DMPDA17 DMPDA17 DN Omburtamab I-131 DMPDA17 TI TT6CQUM DMPDA17 TN B7 homolog 3 (CD276) DMPDA17 MA Inhibitor DMPDA17 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPDA17 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPLQ1V DI DMPLQ1V DMPLQ1V DN IFX-1 DMPLQ1V TI TTRJ91Q DMPLQ1V TN HUMAN complement C5 alpha (C5A) DMPLQ1V MA Inhibitor DMPLQ1V RN 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology DMPLQ1V RU https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html DMPWH30 DI DMPWH30 DMPWH30 DN Pimagedine HCl DMPWH30 TI TTF10I9 DMPWH30 TN Nitric-oxide synthase inducible (NOS2) DMPWH30 MA Inhibitor DMPWH30 RN Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49. DMPWH30 RU https://pubmed.ncbi.nlm.nih.gov/18639532 DMQ1FU8 DI DMQ1FU8 DMQ1FU8 DN Montelukast DMQ1FU8 TI TTSB6CA DMQ1FU8 TN HUMAN cysteinyl leukotriene receptor (CysLTR) DMQ1FU8 MA Antagonist DMQ1FU8 RN As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828. DMQ1FU8 RU https://pubmed.ncbi.nlm.nih.gov/32416408 DMRZ1F2 DI DMRZ1F2 DMRZ1F2 DN Padsevonil DMRZ1F2 TI TTT3P91 DMRZ1F2 TN Synaptic vesicle glycoprotein 2A (SV2A) DMRZ1F2 MA Inhibitor DMRZ1F2 RN Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20. DMRZ1F2 RU https://pubmed.ncbi.nlm.nih.gov/31619464 DMRZ1F2 DI DMRZ1F2 DMRZ1F2 DN Padsevonil DMRZ1F2 TI TTCI43M DMRZ1F2 TN GABA(A) receptor (GABAR) DMRZ1F2 MA Inhibitor DMRZ1F2 RN Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20. DMRZ1F2 RU https://pubmed.ncbi.nlm.nih.gov/31619464 DMS8QF9 DI DMS8QF9 DMS8QF9 DN Arimoclomol DMS8QF9 TI TTG91S4 DMS8QF9 TN Heat shock protein (HSP) DMS8QF9 MA Modulator DMS8QF9 RN Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96. DMS8QF9 RU https://pubmed.ncbi.nlm.nih.gov/20582873 DMSR7D2 DI DMSR7D2 DMSR7D2 DN CX-516 DMSR7D2 TI TTAN6JD DMSR7D2 TN Glutamate receptor AMPA (GRIA) DMSR7D2 MA Modulator DMSR7D2 RN Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36. DMSR7D2 RU https://pubmed.ncbi.nlm.nih.gov/16083327 DMST3FM DI DMST3FM DMST3FM DN CART-19 DMST3FM TI TTW640A DMST3FM TN B-lymphocyte surface antigen B4 (CD19) DMST3FM MA CAR-T-Cell-Therapy DMST3FM RN ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL DMST3FM RU https://clinicaltrials.gov/ct2/show/NCT03027739 DMT13UA DI DMT13UA DMT13UA DN Olokizumab DMT13UA TI TTJH4Y5 DMT13UA TN HUMAN interleukin 6 (IL6) DMT13UA MA Inhibitor DMT13UA RN Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82. DMT13UA RU https://pubmed.ncbi.nlm.nih.gov/24670876 DMTIESG DI DMTIESG DMTIESG DN Omburtamab DMTIESG TI TT6CQUM DMTIESG TN B7 homolog 3 (CD276) DMTIESG MA Inhibitor DMTIESG RN Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3. DMTIESG RU https://pubmed.ncbi.nlm.nih.gov/33533945 DMUOMBZ DI DMUOMBZ DMUOMBZ DN CLL1 CAR-T Cell DMUOMBZ TI TT70N8V DMUOMBZ TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMUOMBZ MA CAR-T-Cell-Therapy(Dual specific) DMUOMBZ RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DMUOMBZ RU https://clinicaltrials.gov/ct2/show/NCT03631576 DMUQWRD DI DMUQWRD DMUQWRD DN LYS-SAF302 DMUQWRD TI TTPJ2SH DMUQWRD TN N-sulphoglucosamine sulphohydrolase (SGSH) DMUQWRD MA Replacement DMUQWRD RN Clinical pipeline report, company report or official report of Lysogene. DMUQWRD RU https://www.lysogene.com/lys-saf302/ DMURH4X DI DMURH4X DMURH4X DN Oxypurinol DMURH4X TI TT7RJY8 DMURH4X TN Xanthine dehydrogenase/oxidase (XDH) DMURH4X MA Inhibitor DMURH4X RN Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52. DMURH4X RU https://pubmed.ncbi.nlm.nih.gov/2829916 DMUSJ3D DI DMUSJ3D DMUSJ3D DN BIIB-088 DMUSJ3D TI TTHBDA9 DMUSJ3D TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DMUSJ3D RN ClinicalTrials.gov (NCT04850118) A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health. DMUSJ3D RU https://clinicaltrials.gov/ct2/show/NCT04850118 DMV52CP DI DMV52CP DMV52CP DN Bucindolol DMV52CP TI TT2CJVK DMV52CP TN Adrenergic receptor beta-2 (ADRB2) DMV52CP MA Modulator DMV52CP RN Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9. DMV52CP RU https://www.ncbi.nlm.nih.gov/pubmed/2412063 DMV52CP DI DMV52CP DMV52CP DN Bucindolol DMV52CP TI TTR6W5O DMV52CP TN Adrenergic receptor beta-1 (ADRB1) DMV52CP MA Modulator DMV52CP RN Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9. DMV52CP RU https://www.ncbi.nlm.nih.gov/pubmed/2412063 DMVB4OS DI DMVB4OS DMVB4OS DN AVN 211 DMVB4OS TI TTJS8PY DMVB4OS TN 5-HT 6 receptor (HTR6) DMVB4OS MA Modulator DMVB4OS RN Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. DMVB4OS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/ DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TT7SBF5 DMVDTR2 TN Cellular tumor antigen p53 (TP53) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TTJGNVC DMVDTR2 TN Apoptosis regulator Bcl-2 (BCL-2) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TTQ57WJ DMVDTR2 TN Apoptosis regulator BAX (BAX) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVSIN2 DI DMVSIN2 DMVSIN2 DN Emapalumab DMVSIN2 TI TTR10KI DMVSIN2 TN HUMAN interferon gamma (IFNG) DMVSIN2 MA Inhibitor DMVSIN2 RN Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011. DMVSIN2 RU https://pubmed.ncbi.nlm.nih.gov/15476870 DMW7TZV DI DMW7TZV DMW7TZV DN GS-6207 DMW7TZV TI TTTWS2G DMW7TZV TN Human immunodeficiency virus Capsid p24 (HIV p24) DMW7TZV MA Inhibitor DMW7TZV RN Clinical pipeline report, company report or official report of Gilead Sciences. DMW7TZV RU https://www.gilead.com/science-and-medicine/pipeline DMWE3GB DI DMWE3GB DMWE3GB DN TG-4010 DMWE3GB TI TTBHFYQ DMWE3GB TN Mucin-1 (MUC1) DMWE3GB MA Modulator DMWE3GB RN A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44. DMWE3GB RU https://pubmed.ncbi.nlm.nih.gov/18594319 DMWE3GB DI DMWE3GB DMWE3GB DN TG-4010 DMWE3GB TI TTF89GD DMWE3GB TN Interleukin-2 (IL2) DMWE3GB MA Modulator DMWE3GB RN A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44. DMWE3GB RU https://pubmed.ncbi.nlm.nih.gov/18594319 DMWZ6DK DI DMWZ6DK DMWZ6DK DN Roledumab DMWZ6DK TI TTLCKI8 DMWZ6DK TN Blood group Rh(D) polypeptide (RHD) DMWZ6DK RN Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. Vox Sang. 2012 Oct;103(3):213-22. DMWZ6DK RU https://pubmed.ncbi.nlm.nih.gov/22568808 DMX9V8K DI DMX9V8K DMX9V8K DN Contigoside B DMX9V8K TI TTFBNVI DMX9V8K TN Aldose reductase (AKR1B1) DMX9V8K MA Inhibitor DMX9V8K RN Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5. DMX9V8K RU https://pubmed.ncbi.nlm.nih.gov/8699190 DMX9V8K DI DMX9V8K DMX9V8K DN Contigoside B DMX9V8K TI TTL69WB DMX9V8K TN Angiotensin-converting enzyme (ACE) DMX9V8K MA Inhibitor DMX9V8K RN Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3. DMX9V8K RU https://pubmed.ncbi.nlm.nih.gov/3430165 DMXCD69 DI DMXCD69 DMXCD69 DN CEP1347 DMXCD69 TI TTUNSIX DMXCD69 TN Mixed lineage kinase 1 (MAP3K9) DMXCD69 MA Inhibitor DMXCD69 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMXCD69 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMYFQJL DI DMYFQJL DMYFQJL DN BNV-222 DMYFQJL TI TTFBNVI DMYFQJL TN Aldose reductase (AKR1B1) DMYFQJL MA Inhibitor DMYFQJL RN ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health. DMYFQJL RU https://clinicaltrials.gov/ct2/show/NCT02332005 DMYKNME DI DMYKNME DMYKNME DN PF-06651600 DMYKNME TI TTT7PJU DMYKNME TN Janus kinase 3 (JAK-3) DMYKNME MA Inhibitor DMYKNME RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYKNME RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMYVKM5 DI DMYVKM5 DMYVKM5 DN Darbufelone DMYVKM5 TI TT2J34L DMYVKM5 TN Arachidonate 5-lipoxygenase (5-LOX) DMYVKM5 MA Modulator DMYVKM5 RN Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. DMYVKM5 RU https://pubmed.ncbi.nlm.nih.gov/23517721 DMYVKM5 DI DMYVKM5 DMYVKM5 DN Darbufelone DMYVKM5 TI TTVKILB DMYVKM5 TN Prostaglandin G/H synthase 2 (COX-2) DMYVKM5 MA Modulator DMYVKM5 RN Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. DMYVKM5 RU https://pubmed.ncbi.nlm.nih.gov/23517721 DMZ0T24 DI DMZ0T24 DMZ0T24 DN Abagovomab DMZ0T24 TI TTC1PS3 DMZ0T24 TN Ovarian carcinoma antigen CA125 (MUC16) DMZ0T24 RN Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62. DMZ0T24 RU https://pubmed.ncbi.nlm.nih.gov/21322756 DMZGKXW DI DMZGKXW DMZGKXW DN Atogepant DMZGKXW TI TTQ4ESF DMZGKXW TN Calgranulin D (S100A12) DMZGKXW MA Antagonist DMZGKXW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZGKXW RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZV3SY DI DMZV3SY DMZV3SY DN Denagliptin DMZV3SY TI TTDIGC1 DMZV3SY TN Dipeptidyl peptidase 4 (DPP-4) DMZV3SY MA Inhibitor DMZV3SY RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMZV3SY RU https://pubmed.ncbi.nlm.nih.gov/19149538 DM78DOT DI DM78DOT DM78DOT DN AllerB DM78DOT TI TT9V5JH DM78DOT TN Phospholipase A2 (PLA2G1B) DM78DOT MA Inhibitor DM78DOT RN Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54. DM78DOT RU https://pubmed.ncbi.nlm.nih.gov/9648701 DMEARCM DI DMEARCM DMEARCM DN OrM3 DMEARCM TI TTH18TF DMEARCM TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEARCM MA Antagonist DMEARCM RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMEARCM RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMJM9LZ DI DMJM9LZ DMJM9LZ DN LB80380 DMJM9LZ TI TTS5K1M DMJM9LZ TN Hepatitis B virus Reverse transcriptase (HBV RT) DMJM9LZ MA Inhibitor DMJM9LZ RN 2011 Pipeline of LG Life Sciences. DMJM9LZ RU http://www.lgls.com/ DMOE582 DI DMOE582 DMOE582 DN TZP-101 DMOE582 TI TTWDC17 DMOE582 TN Growth hormone secretagogue receptor 1 (GHSR) DMOE582 MA Agonist DMOE582 RN Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18. DMOE582 RU https://pubmed.ncbi.nlm.nih.gov/19432500 DMXB4NL DI DMXB4NL DMXB4NL DN MEDI4893 DMXB4NL TI TT5FLYB DMXB4NL TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DMXB4NL RN Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. DMXB4NL RU https://pubmed.ncbi.nlm.nih.gov/25210036 DM0TH9A DI DM0TH9A DM0TH9A DN Bimosiamose DM0TH9A TI TTAU4D6 DM0TH9A TN E-selectin (SELE) DM0TH9A MA Inhibitor DM0TH9A RN Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82. DM0TH9A RU https://pubmed.ncbi.nlm.nih.gov/18598003 DMGM1IR DI DMGM1IR DMGM1IR DN RhuDex DMGM1IR TI TTFZDNP DMGM1IR TN Activation B7-1 antigen (CD80) DMGM1IR MA Inhibitor DMGM1IR RN A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. DMGM1IR RU https://pubmed.ncbi.nlm.nih.gov/21447719 DMJBDL0 DI DMJBDL0 DMJBDL0 DN BIIB104 DMJBDL0 TI TTAN6JD DMJBDL0 TN Glutamate receptor AMPA (GRIA) DMJBDL0 MA Activator DMJBDL0 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJBDL0 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMKJDR6 DI DMKJDR6 DMKJDR6 DN VX-702 DMKJDR6 TI TTQBR95 DMKJDR6 TN Stress-activated protein kinase 2a (p38 alpha) DMKJDR6 MA Modulator DMKJDR6 RN Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. DMKJDR6 RU https://pubmed.ncbi.nlm.nih.gov/19404957 DMLQ3PO DI DMLQ3PO DMLQ3PO DN INCB13739 DMLQ3PO TI TTN7BL9 DMLQ3PO TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMLQ3PO MA Inhibitor DMLQ3PO RN Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008. DMLQ3PO RU http://www.medicalnewstoday.com/articles/110647.php DMLQ3PO DI DMLQ3PO DMLQ3PO DN INCB13739 DMLQ3PO TI TTWC6MY DMLQ3PO TN Protein tyrosine phosphatase (PTP) DMLQ3PO MA Inhibitor DMLQ3PO RN Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9. DMLQ3PO RU https://pubmed.ncbi.nlm.nih.gov/9341756 DMMWC6F DI DMMWC6F DMMWC6F DN INCB9471 DMMWC6F TI TT2CEJG DMMWC6F TN C-C chemokine receptor type 5 (CCR5) DMMWC6F MA Antagonist DMMWC6F RN Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34. DMMWC6F RU https://pubmed.ncbi.nlm.nih.gov/17920529 DMR6LXM DI DMR6LXM DMR6LXM DN CAP-232 DMR6LXM TI TT4LOT8 DMR6LXM TN Pyruvate kinase M2 (PKM) DMR6LXM MA Modulator DMR6LXM RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMR6LXM RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSC8YW DI DMSC8YW DMSC8YW DN ANA773 DMSC8YW TI TTRJ1K4 DMSC8YW TN Toll-like receptor 7 (TLR7) DMSC8YW MA Agonist DMSC8YW RN Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011). DMSC8YW RU http://www.anadyspharma.com/ DMUB8WN DI DMUB8WN DMUB8WN DN Aerovant DMUB8WN TI TTDWHC3 DMUB8WN TN Interleukin 4 receptor alpha (IL4R) DMUB8WN MA Antagonist DMUB8WN RN Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009. DMUB8WN RU http://www.news-medical.net/news/2009/03/03/46411.aspx DMYZU6G DI DMYZU6G DMYZU6G DN MEM-1003 DMYZU6G TI TTXHYV6 DMYZU6G TN Voltage-gated L-type calcium channel (L-CaC) DMYZU6G MA Modulator DMYZU6G RN Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73. DMYZU6G RU https://pubmed.ncbi.nlm.nih.gov/16621170 DM0157T DI DM0157T DM0157T DN DM199 DM0157T TI TTGY8IW DM0157T TN B2 bradykinin receptor (BDKRB2) DM0157T MA Activator DM0157T RN Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119. DM0157T RU https://pubmed.ncbi.nlm.nih.gov/26038695 DM01SR6 DI DM01SR6 DM01SR6 DN L-NAME DM01SR6 TI TTCM4B3 DM01SR6 TN Nitric-oxide synthase endothelial (NOS3) DM01SR6 MA Inhibitor DM01SR6 RN Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61. DM01SR6 RU https://pubmed.ncbi.nlm.nih.gov/19586617 DM0298B DI DM0298B DM0298B DN Salvicine DM0298B TI TT0IHXV DM0298B TN DNA topoisomerase II (TOP2) DM0298B MA Modulator DM0298B RN Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. DM0298B RU https://pubmed.ncbi.nlm.nih.gov/17723179 DM03NQS DI DM03NQS DM03NQS DN GTP-200 DM03NQS TI TTWDC17 DM03NQS TN Growth hormone secretagogue receptor 1 (GHSR) DM03NQS MA Agonist DM03NQS RN Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346. DM03NQS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268047/ DM047HI DI DM047HI DM047HI DN VBP15 DM047HI TI TTOZRK6 DM047HI TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM047HI MA Agonist DM047HI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM047HI RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTZ97H5 DM0568C TN Phosphodiesterase 4A (PDE4A) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTVIAT9 DM0568C TN Phosphodiesterase 4B (PDE4B) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTSKMI8 DM0568C TN Phosphodiesterase 4D (PDE4D) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM059CZ DI DM059CZ DM059CZ DN DPK-060 DM059CZ TI TTXT4D5 DM059CZ TN Bacterial Cell membrane (Bact CM) DM059CZ MA Enhancer DM059CZ RN The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29. DM059CZ RU https://pubmed.ncbi.nlm.nih.gov/25614221 DM05TBE DI DM05TBE DM05TBE DN KLS-0611 DM05TBE TI TTHBUXE DM05TBE TN Mucin (MUC) DM05TBE MA Stimulator DM05TBE RN WO patent application no. 2011,1034,23, Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors. DM05TBE RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110825&CC=WO&NR=2011103423A1&KC=A1 DM05WIU DI DM05WIU DM05WIU DN PBI-05204 DM05WIU TI TTQ38E9 DM05WIU TN Sodium/potassium-transporting ATPase (SPT ATPase) DM05WIU MA Inhibitor DM05WIU RN First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf- beta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1204-12. DM05WIU RU https://pubmed.ncbi.nlm.nih.gov/24919855 DM06GDC DI DM06GDC DM06GDC DN T2c-001 DM06GDC TI TTXQYT6 DM06GDC TN T-cells (T-cells) DM06GDC MA Modulator DM06GDC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM06GDC RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM08F12 DI DM08F12 DM08F12 DN KT6-971 DM08F12 TI TTNA5ZS DM08F12 TN Cholesterol absorption (Chole absorp) DM08F12 MA Inhibitor DM08F12 RN Intestinal and Hepatic Niemann-Pick C1-Like 1. Correction in: Diabetes Metab J. 2013 December; 37(6): 486-487. DM08F12 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753488/ DM094UH DI DM094UH DM094UH DN CB-839 DM094UH TI TTCW0KX DM094UH TN Glutaminase (GLS) DM094UH MA Modulator DM094UH RN Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901. DM094UH RU https://pubmed.ncbi.nlm.nih.gov/24523301 DM0AOID DI DM0AOID DM0AOID DN MB-CART19.1 DM0AOID TI TTW640A DM0AOID TN B-lymphocyte surface antigen B4 (CD19) DM0AOID MA CAR-T-Cell-Therapy DM0AOID RN ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL DM0AOID RU https://clinicaltrials.gov/ct2/show/NCT03321123 DM0BFJ5 DI DM0BFJ5 DM0BFJ5 DN RPSGL-Ig DM0BFJ5 TI TTE5VG0 DM0BFJ5 TN P-selectin (SELP) DM0BFJ5 MA Inhibitor DM0BFJ5 RN rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6. DM0BFJ5 RU https://pubmed.ncbi.nlm.nih.gov/25817339 DM0CL4I DI DM0CL4I DM0CL4I DN MCS-110 DM0CL4I TI TT731LW DM0CL4I TN Colony stimulating factor-1 receptor (CSF-1R) DM0CL4I MA Modulator DM0CL4I RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0CL4I RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0DRAZ DI DM0DRAZ DM0DRAZ DN AMG 479 DM0DRAZ TI TTHRID2 DM0DRAZ TN Insulin-like growth factor I receptor (IGF1R) DM0DRAZ MA Inhibitor DM0DRAZ RN Clinical pipeline report, company report or official report of Amgen (2009). DM0DRAZ RU http://www.amgen.com/science/pipe.jsp DM0DT45 DI DM0DT45 DM0DT45 DN CYSTEMUSTINE DM0DT45 TI TTUTN1I DM0DT45 TN Human Deoxyribonucleic acid (hDNA) DM0DT45 MA Binder DM0DT45 RN A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7. DM0DT45 RU https://pubmed.ncbi.nlm.nih.gov/18411412 DM0EDHJ DI DM0EDHJ DM0EDHJ DN CC-90011 DM0EDHJ TI TTNR0UQ DM0EDHJ TN Lysine-specific histone demethylase 1 (LSD) DM0EDHJ MA Inhibitor DM0EDHJ RN Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529. DM0EDHJ RU https://pubmed.ncbi.nlm.nih.gov/33034194 DM0EZWI DI DM0EZWI DM0EZWI DN MDX-1100 DM0EZWI TI TTQOVYA DM0EZWI TN C-X-C motif chemokine 10 (CXCL10) DM0EZWI RN A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9. DM0EZWI RU https://pubmed.ncbi.nlm.nih.gov/22147649 DM0FGDO DI DM0FGDO DM0FGDO DN ACCLAIM DM0FGDO TI TTCM4B3 DM0FGDO TN Nitric-oxide synthase endothelial (NOS3) DM0FGDO MA Stimulator DM0FGDO RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DM0FGDO RU http://www.centerwatch.com/ DM0FJIE DI DM0FJIE DM0FJIE DN Ontuxizumab DM0FJIE TI TTYJWT7 DM0FJIE TN Endosialin (CD248) DM0FJIE MA Inhibitor DM0FJIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0FJIE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM0FXMZ DI DM0FXMZ DM0FXMZ DN APG-101 DM0FXMZ TI TTF0RCZ DM0FXMZ TN Apoptosis mediating surface antigen FAS (FAS) DM0FXMZ MA Inhibitor DM0FXMZ RN Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100. DM0FXMZ RU https://pubmed.ncbi.nlm.nih.gov/22446296 DM0G5O6 DI DM0G5O6 DM0G5O6 DN Flumatinib DM0G5O6 TI TT3PJMV DM0G5O6 TN Tyrosine-protein kinase ABL1 (ABL) DM0G5O6 MA Inhibitor DM0G5O6 RN Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25. DM0G5O6 RU https://pubmed.ncbi.nlm.nih.gov/24205792 DM0GZTD DI DM0GZTD DM0GZTD DN L-ornithine phenylacetate DM0GZTD TI TTSXVID DM0GZTD TN Nuclear factor NF-kappa-B (NFKB) DM0GZTD MA Modulator DM0GZTD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0GZTD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0K8U7 DI DM0K8U7 DM0K8U7 DN YSIL6 DM0K8U7 TI TTT1V78 DM0K8U7 TN Interleukin-6 (IL6) DM0K8U7 MA Inhibitor DM0K8U7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380) DM0K8U7 RU http://adisinsight.springer.com/drugs/800020380 DM0KBML DI DM0KBML DM0KBML DN REGN-COV2 DM0KBML TI TTZ3COY DM0KBML TN COVID-19 spike glycoprotein (S) DM0KBML MA Inhibitor DM0KBML RN REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251. DM0KBML RU https://pubmed.ncbi.nlm.nih.gov/33332778 DM0KJDY DI DM0KJDY DM0KJDY DN LY2801653 DM0KJDY TI TTNDSF4 DM0KJDY TN Proto-oncogene c-Met (MET) DM0KJDY MA Modulator DM0KJDY RN Clinical pipeline report, company report or official report of Eli Lilly. DM0KJDY RU http://www.lillyoncologypipeline.com/met-inhibitor.aspx DM0KJDY DI DM0KJDY DM0KJDY DN LY2801653 DM0KJDY TI TTU8W4S DM0KJDY TN Protein kinase (PK) DM0KJDY MA Inhibitor DM0KJDY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0KJDY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0KRLJ DI DM0KRLJ DM0KRLJ DN PF-885706 DM0KRLJ TI TT07C3Y DM0KRLJ TN 5-HT 4 receptor (HTR4) DM0KRLJ MA Agonist DM0KRLJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025579) DM0KRLJ RU http://adisinsight.springer.com/drugs/800025579 DM0KVJC DI DM0KVJC DM0KVJC DN EC-145 DM0KVJC TI TTVC37M DM0KVJC TN Folate receptor alpha (FOLR1) DM0KVJC MA Modulator DM0KVJC RN Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30. DM0KVJC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645936/ DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TT6S84O DM0LA6E TN Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TTFP96H DM0LA6E TN Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TTRP4JT DM0LA6E TN Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0M7QW DI DM0M7QW DM0M7QW DN AZD-8848 DM0M7QW TI TTRJ1K4 DM0M7QW TN Toll-like receptor 7 (TLR7) DM0M7QW MA Agonist DM0M7QW RN Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53. DM0M7QW RU https://pubmed.ncbi.nlm.nih.gov/22726593 DM0MO8I DI DM0MO8I DM0MO8I DN BQ-123 DM0MO8I TI TTKRD0G DM0MO8I TN Endothelin A receptor (EDNRA) DM0MO8I MA Antagonist DM0MO8I RN Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4. DM0MO8I RU https://pubmed.ncbi.nlm.nih.gov/9068384 DM0MTP8 DI DM0MTP8 DM0MTP8 DN CN-105 DM0MTP8 TI TTKS9CB DM0MTP8 TN Apolipoprotein E (APOE) DM0MTP8 MA Agonist DM0MTP8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0MTP8 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM0NFMS DI DM0NFMS DM0NFMS DN XEN-2174 DM0NFMS TI TTAWNKZ DM0NFMS TN Norepinephrine transporter (NET) DM0NFMS MA Inhibitor DM0NFMS RN Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6. DM0NFMS RU https://pubmed.ncbi.nlm.nih.gov/15661433 DM0NJWG DI DM0NJWG DM0NJWG DN Human interleukin-2 DM0NJWG TI TTF89GD DM0NJWG TN Interleukin-2 (IL2) DM0NJWG MA Modulator DM0NJWG RN Clinical pipeline report, company report or official report of Immunservice. DM0NJWG RU http://www.immunservice.com/index.php?page=regulatory DM0OHX3 DI DM0OHX3 DM0OHX3 DN LB-30870 DM0OHX3 TI TT6L509 DM0OHX3 TN Coagulation factor IIa (F2) DM0OHX3 MA Inhibitor DM0OHX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM0OHX3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTFQI4H DM0OVZ2 TN Tankyrase-2 (TNKS-2) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTVUSO7 DM0OVZ2 TN Tankyrase-1 (TNKS-1) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTVDSZ0 DM0OVZ2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTQ4V96 DM0OVZ2 TN Poly [ADP-ribose] polymerase 2 (PARP2) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OYLQ DI DM0OYLQ DM0OYLQ DN I-vation DM0OYLQ TI TTJL8VG DM0OYLQ TN Corticosteroid-binding globulin (SERPINA6) DM0OYLQ MA Modulator DM0OYLQ RN Cortisol binding in rat skeletal muscle. J Biol Chem. 1975 Feb 25;250(4):1207-11. DM0OYLQ RU https://pubmed.ncbi.nlm.nih.gov/163248 DM0PFNC DI DM0PFNC DM0PFNC DN AZD6738 DM0PFNC TI TT8ZYBQ DM0PFNC TN Serine/threonine-protein kinase ATR (FRP1) DM0PFNC MA Inhibitor DM0PFNC RN National Cancer Institute Drug Dictionary (drug id 754022). DM0PFNC RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754022 DM0POWG DI DM0POWG DM0POWG DN Vidofludimus DM0POWG TI TTLVP78 DM0POWG TN Dihydroorotate dehydrogenase (DHODH) DM0POWG MA Modulator DM0POWG RN Company report (4SC) DM0POWG RU http://www.4sc.de/product-pipeline/clinical/vidofludimus DM0RA8F DI DM0RA8F DM0RA8F DN Oleoyl-estrone DM0RA8F TI TT8A9EF DM0RA8F TN Metabotropic glutamate receptor 3 (mGluR3) DM0RA8F MA Agonist DM0RA8F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0RA8F RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0RA8F DI DM0RA8F DM0RA8F DN Oleoyl-estrone DM0RA8F TI TTXJ47W DM0RA8F TN Metabotropic glutamate receptor 2 (mGluR2) DM0RA8F MA Agonist DM0RA8F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0RA8F RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0RPY5 DI DM0RPY5 DM0RPY5 DN ACH-3102 DM0RPY5 TI TTCJ2X8 DM0RPY5 TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM0RPY5 MA Modulator DM0RPY5 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0RPY5 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0TZEP DI DM0TZEP DM0TZEP DN Bamosiran DM0TZEP TI TTG8ZWP DM0TZEP TN ADRB2 messenger RNA (ADRB2 mRNA) DM0TZEP MA Inhibitor DM0TZEP RN Clinical pipeline report, company report or official report of Sylentis. DM0TZEP RU https://www.sylentis.com/index.php/en/pipeline/bamosiran DM0VGDC DI DM0VGDC DM0VGDC DN ARRY-382 DM0VGDC TI TT731LW DM0VGDC TN Colony stimulating factor-1 receptor (CSF-1R) DM0VGDC MA Modulator DM0VGDC RN Company report (Array) DM0VGDC RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-382/ DM0VGDC DI DM0VGDC DM0VGDC DN ARRY-382 DM0VGDC TI TT7MRDV DM0VGDC TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM0VGDC MA Inhibitor DM0VGDC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0VGDC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0W3R7 DI DM0W3R7 DM0W3R7 DN MCLA-128 DM0W3R7 TI TT6EO5L DM0W3R7 TN Erbb2 tyrosine kinase receptor (HER2) DM0W3R7 MA Antagonist DM0W3R7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0W3R7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0WY3H DI DM0WY3H DM0WY3H DN JNJ-39220675 DM0WY3H TI TT9JNIC DM0WY3H TN Histamine H3 receptor (H3R) DM0WY3H MA Antagonist DM0WY3H RN JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. DM0WY3H RU https://pubmed.ncbi.nlm.nih.gov/21086115 DM0Y8JP DI DM0Y8JP DM0Y8JP DN DAS-181 DM0Y8JP TI TT50QJ3 DM0Y8JP TN Influenza Neuraminidase (Influ NA) DM0Y8JP MA Inhibitor DM0Y8JP RN Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838. DM0Y8JP RU https://pubmed.ncbi.nlm.nih.gov/19893749 DM0YCPL DI DM0YCPL DM0YCPL DN Bemcentinib DM0YCPL TI TTZPY6J DM0YCPL TN Tyrosine-protein kinase UFO (AXL) DM0YCPL MA Inhibitor DM0YCPL RN AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999. DM0YCPL RU https://pubmed.ncbi.nlm.nih.gov/32018052 DM0YO4Q DI DM0YO4Q DM0YO4Q DN Urocortin 2 DM0YO4Q TI TTIY658 DM0YO4Q TN Corticotropin-releasing factor receptor 2 (CRHR2) DM0YO4Q MA Antagonist DM0YO4Q RN Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies. Ann N Y Acad Sci. 2009 Apr;1163:215-20. DM0YO4Q RU https://pubmed.ncbi.nlm.nih.gov/19456342 DM0YWQ4 DI DM0YWQ4 DM0YWQ4 DN VB 1953 DM0YWQ4 TI TTFK8YB DM0YWQ4 TN Bacterial DNA topoisomerase 4A (Bact parC) DM0YWQ4 MA Inhibitor DM0YWQ4 RN Clinical pipeline report, company report or official report of Vyome Therapeutics. DM0YWQ4 RU https://www.vyometx.com/platform-strategy.html DM0YWQ4 DI DM0YWQ4 DM0YWQ4 DN VB 1953 DM0YWQ4 TI TTN6J5F DM0YWQ4 TN Bacterial DNA gyrase (Bact gyrase) DM0YWQ4 MA Inhibitor DM0YWQ4 RN Clinical pipeline report, company report or official report of Vyome Therapeutics. DM0YWQ4 RU https://www.vyometx.com/platform-strategy.html DM0ZIT2 DI DM0ZIT2 DM0ZIT2 DN PTX-200 DM0ZIT2 TI TTWTSCV DM0ZIT2 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM0ZIT2 MA Inhibitor DM0ZIT2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0ZIT2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM104SP DI DM104SP DM104SP DN Vericigiuat DM104SP TI TTLBYH1 DM104SP TN Guanylate cyclase soluble beta-1 (GUCY1B1) DM104SP MA Modulator DM104SP RN Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38. DM104SP RU https://pubmed.ncbi.nlm.nih.gov/25056511 DM129T7 DI DM129T7 DM129T7 DN CROMOGLYCATE LISETIL HYDROCHLORIDE DM129T7 TI TTE87WJ DM129T7 TN Calcium-activated potassium channel KCa1.1 (KCNMA1) DM129T7 MA Modulator DM129T7 RN The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochim Biophys Acta. 2011 Sep;1810(9):867-74. DM129T7 RU https://pubmed.ncbi.nlm.nih.gov/21635937 DM13G5R DI DM13G5R DM13G5R DN TRK-170 DM13G5R TI TT7ZMI1 DM13G5R TN Integrin alpha-4/beta-7 (ITGA4/B7) DM13G5R MA Modulator DM13G5R RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM13G5R RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM13G5R DI DM13G5R DM13G5R DN TRK-170 DM13G5R TI TT6S84X DM13G5R TN Integrin alpha-4/beta-1 (ITGA4/B1) DM13G5R MA Modulator DM13G5R RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM13G5R RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM13OVF DI DM13OVF DM13OVF DN REMD 477 DM13OVF TI TT9O6WS DM13OVF TN Glucagon receptor (GCGR) DM13OVF MA Antagonist DM13OVF RN Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305. DM13OVF RU https://pubmed.ncbi.nlm.nih.gov/29283470 DM157U0 DI DM157U0 DM157U0 DN Sofinicline DM157U0 TI TTL1ATN DM157U0 TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM157U0 MA Modulator DM157U0 RN Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63. DM157U0 RU https://pubmed.ncbi.nlm.nih.gov/24965900 DM15MRZ DI DM15MRZ DM15MRZ DN IMR-687 DM15MRZ TI TTZOEBC DM15MRZ TN Phosphodiesterase 9 (PDE9) DM15MRZ MA Inhibitor DM15MRZ RN Clinical pipeline report, company report or official report of Imara. DM15MRZ RU https://imaratx.com/our-programs/ DM15QL9 DI DM15QL9 DM15QL9 DN ROXINDOLE DM15QL9 TI TTEX248 DM15QL9 TN Dopamine D2 receptor (D2R) DM15QL9 MA Inhibitor DM15QL9 RN Indolebutylamines as selective 5-HT(1A) agonists. J Med Chem. 2004 Sep 9;47(19):4677-83. DM15QL9 RU https://pubmed.ncbi.nlm.nih.gov/15341483 DM15RZO DI DM15RZO DM15RZO DN KYMRIAH DM15RZO TI TTW640A DM15RZO TN B-lymphocyte surface antigen B4 (CD19) DM15RZO MA CAR-T-Cell-Therapy DM15RZO RN ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies DM15RZO RU https://clinicaltrials.gov/ct2/show/NCT03642626 DM16IMT DI DM16IMT DM16IMT DN CRYPTOPHYCIN 52 DM16IMT TI TTML2WA DM16IMT TN Tubulin (TUB) DM16IMT MA Inhibitor DM16IMT RN Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9. DM16IMT RU https://pubmed.ncbi.nlm.nih.gov/12581573 DM16KJ3 DI DM16KJ3 DM16KJ3 DN CNS-5161 DM16KJ3 TI TT9IK2Z DM16KJ3 TN N-methyl-D-aspartate receptor (NMDAR) DM16KJ3 MA Antagonist DM16KJ3 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM16KJ3 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM16RIC DI DM16RIC DM16RIC DN Oprozomib DM16RIC TI TTU7ZMG DM16RIC TN Proteasome (PS) DM16RIC MA Modulator DM16RIC RN A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15. DM16RIC RU https://pubmed.ncbi.nlm.nih.gov/20805366 DM17469 DI DM17469 DM17469 DN ARRY-502 DM17469 TI TTQDMX5 DM17469 TN Prostaglandin D2 receptor 2 (PTGDR2) DM17469 MA Modulator DM17469 RN Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502). DM17469 RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-502/ DM17JSI DI DM17JSI DM17JSI DN CGC-11047 DM17JSI TI TTUTN1I DM17JSI TN Human Deoxyribonucleic acid (hDNA) DM17JSI MA Modulator DM17JSI RN Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75. DM17JSI RU https://pubmed.ncbi.nlm.nih.gov/19487545 DM17OZM DI DM17OZM DM17OZM DN GL-0817 DM17OZM TI TTWSKHD DM17OZM TN Melanoma-associated antigen 3 (MAGEA3) DM17OZM MA Immunomodulator DM17OZM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM17OZM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM180VX DI DM180VX DM180VX DN SC-49483 DM180VX TI TTXWASR DM180VX TN Intestinal maltase-glucoamylase (MGAM) DM180VX MA Inhibitor DM180VX RN Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8. DM180VX RU https://pubmed.ncbi.nlm.nih.gov/8923673 DM1945H DI DM1945H DM1945H DN JTT-251 DM1945H TI TT3UNDH DM1945H TN Pyruvate dehydrogenase kinase (PDHK) DM1945H MA Inhibitor DM1945H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1945H RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM19GUH DI DM19GUH DM19GUH DN TVB-2640 DM19GUH TI TT7AOUD DM19GUH TN Fatty acid synthase (FASN) DM19GUH MA Inhibitor DM19GUH RN Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117. DM19GUH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027139/ DM1AQLW DI DM1AQLW DM1AQLW DN Otilimab DM1AQLW TI TTPZGYX DM1AQLW TN HUMAN colony-stimulating factor (GM-CSF) DM1AQLW MA Inhibitor DM1AQLW RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DM1AQLW RU https://pubmed.ncbi.nlm.nih.gov/32317220 DM1B8IT DI DM1B8IT DM1B8IT DN Apadoline DM1B8IT TI TTQW87Y DM1B8IT TN Opioid receptor kappa (OPRK1) DM1B8IT MA Agonist DM1B8IT RN Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68. DM1B8IT RU https://pubmed.ncbi.nlm.nih.gov/15989506 DM1BYNF DI DM1BYNF DM1BYNF DN THRX-198321 DM1BYNF TI TT2CJVK DM1BYNF TN Adrenergic receptor beta-2 (ADRB2) DM1BYNF MA Modulator DM1BYNF RN THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99. DM1BYNF RU https://pubmed.ncbi.nlm.nih.gov/21139051 DM1C9NQ DI DM1C9NQ DM1C9NQ DN SCY-635 DM1C9NQ TI TTATDGJ DM1C9NQ TN Calcium signal-modulating cyclophilin ligand (CAML) DM1C9NQ MA Modulator DM1C9NQ RN SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. DM1C9NQ RU https://pubmed.ncbi.nlm.nih.gov/19933795 DM1CLKO DI DM1CLKO DM1CLKO DN ASKP-1240 DM1CLKO TI TTN6Y9A DM1CLKO TN CD40L receptor (CD40) DM1CLKO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874). DM1CLKO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874 DM1E4VP DI DM1E4VP DM1E4VP DN IL-21 DM1E4VP TI TT9QEJ6 DM1E4VP TN Interleukin-21 (IL21) DM1E4VP MA Modulator DM1E4VP RN National Cancer Institute Drug Dictionary (drug id 409696). DM1E4VP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=409696 DM1EK5D DI DM1EK5D DM1EK5D DN Ortataxel DM1EK5D TI TT0JLSD DM1EK5D TN Multidrug resistance protein (MDR) DM1EK5D MA Modulator DM1EK5D RN Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009). DM1EK5D RU http://www.spectrumpharm.com/products_Spectrum.html DM1EK5D DI DM1EK5D DM1EK5D DN Ortataxel DM1EK5D TI TTF8CQI DM1EK5D TN Tumor necrosis factor (TNF) DM1EK5D MA Inhibitor DM1EK5D RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DM1EK5D RU https://pubmed.ncbi.nlm.nih.gov/19265486 DM1EPMF DI DM1EPMF DM1EPMF DN GSK1322322 DM1EPMF TI TTICO5G DM1EPMF TN Staphylococcus Peptide deformylase (Stap-coc def) DM1EPMF MA Modulator DM1EPMF RN Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. DM1EPMF RU https://pubmed.ncbi.nlm.nih.gov/25174923 DM1FCDH DI DM1FCDH DM1FCDH DN EV-077 DM1FCDH TI TTKNWZ4 DM1FCDH TN Thromboxane-A synthase (TBXAS1) DM1FCDH MA Modulator DM1FCDH RN Company report (Pharmaceuticalintelligence) DM1FCDH RU http://pharmaceuticalintelligence.com/tag/diabetic-nephropathy/ DM1FJ2B DI DM1FJ2B DM1FJ2B DN AFP464 DM1FJ2B TI TT2QPV9 DM1FJ2B TN Aryl hydrocarbon receptor signaling pathway (AhR pathway) DM1FJ2B MA Suppressor DM1FJ2B RN Clinical pipeline report, company report or official report of AFP464. DM1FJ2B RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afp464 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTSKMI8 DM1FS2W TN Phosphodiesterase 4D (PDE4D) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTVIAT9 DM1FS2W TN Phosphodiesterase 4B (PDE4B) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTZ97H5 DM1FS2W TN Phosphodiesterase 4A (PDE4A) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1G6ME DI DM1G6ME DM1G6ME DN VIS410 DM1G6ME TI TTF4CAM DM1G6ME TN Influenza Hemagglutinin (Influ HA) DM1G6ME MA Inhibitor DM1G6ME RN Clinical pipeline report, company report or official report of Visterra. DM1G6ME RU http://www.visterrainc.com/#pipeline DM1GRCU DI DM1GRCU DM1GRCU DN JNJ-17216498 DM1GRCU TI TT9JNIC DM1GRCU TN Histamine H3 receptor (H3R) DM1GRCU MA Antagonist DM1GRCU RN Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61. DM1GRCU RU https://pubmed.ncbi.nlm.nih.gov/15466448 DM1H7UK DI DM1H7UK DM1H7UK DN Dectrekumab DM1H7UK TI TT0GVCH DM1H7UK TN Interleukin-13 (IL13) DM1H7UK MA Inhibitor DM1H7UK RN Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. DM1H7UK RU https://pubmed.ncbi.nlm.nih.gov/25226850 DM1HC9R DI DM1HC9R DM1HC9R DN MGL-3196 DM1HC9R TI TTGER3L DM1HC9R TN Thyroid hormone receptor beta (THRB) DM1HC9R MA Agonist DM1HC9R RN Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. DM1HC9R RU https://pubmed.ncbi.nlm.nih.gov/24075770 DM1HG3U DI DM1HG3U DM1HG3U DN DM-99 DM1HG3U TI TTCBFJO DM1HG3U TN Insulin receptor (INSR) DM1HG3U MA Agonist DM1HG3U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM1HG3U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM1IBRT DI DM1IBRT DM1IBRT DN OPN-305 DM1IBRT TI TTY7ZHS DM1IBRT TN Toll-like receptor 2 (TLR2) DM1IBRT RN Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. DM1IBRT RU https://pubmed.ncbi.nlm.nih.gov/22354933 DM1JBD8 DI DM1JBD8 DM1JBD8 DN OC-000459 DM1JBD8 TI TTQDMX5 DM1JBD8 TN Prostaglandin D2 receptor 2 (PTGDR2) DM1JBD8 MA Antagonist DM1JBD8 RN Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85. DM1JBD8 RU https://pubmed.ncbi.nlm.nih.gov/23379537 DM1JNDV DI DM1JNDV DM1JNDV DN PRX00933 DM1JNDV TI TTWJBZ5 DM1JNDV TN 5-HT 2C receptor (HTR2C) DM1JNDV MA Agonist DM1JNDV RN 2011 Pipeline of Proximagen Group plc. DM1JNDV RU http://www.proximagen.com/science/pipeline/ DM1KGS7 DI DM1KGS7 DM1KGS7 DN Tesofensine DM1KGS7 TI TTCBFJO DM1KGS7 TN Insulin receptor (INSR) DM1KGS7 MA Inhibitor DM1KGS7 RN The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. DM1KGS7 RU https://pubmed.ncbi.nlm.nih.gov/20385125 DM1LDIP DI DM1LDIP DM1LDIP DN Econail DM1LDIP TI TTTSOUD DM1LDIP TN Candida Cytochrome P450 51 (Candi ERG11) DM1LDIP MA Inhibitor DM1LDIP RN Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45. DM1LDIP RU https://pubmed.ncbi.nlm.nih.gov/20625155 DM1M0PR DI DM1M0PR DM1M0PR DN Saruplase DM1M0PR TI TTGY7WI DM1M0PR TN Urokinase-type plasminogen activator (PLAU) DM1M0PR MA Activator DM1M0PR RN Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4. DM1M0PR RU https://pubmed.ncbi.nlm.nih.gov/7534946 DM1M57I DI DM1M57I DM1M57I DN MK-2578 DM1M57I TI TTQG4NR DM1M57I TN Erythropoietin (EPO) DM1M57I MA Agonist DM1M57I RN Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. DM1M57I RU https://pubmed.ncbi.nlm.nih.gov/20622817 DM1NCUY DI DM1NCUY DM1NCUY DN CMI-392 DM1NCUY TI TT2J34L DM1NCUY TN Arachidonate 5-lipoxygenase (5-LOX) DM1NCUY MA Modulator DM1NCUY RN Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. DM1NCUY RU https://pubmed.ncbi.nlm.nih.gov/11529688 DM1NCUY DI DM1NCUY DM1NCUY DN CMI-392 DM1NCUY TI TTQL5VC DM1NCUY TN Platelet-activating factor receptor (PTAFR) DM1NCUY MA Modulator DM1NCUY RN Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. DM1NCUY RU https://pubmed.ncbi.nlm.nih.gov/11529688 DM1NMGJ DI DM1NMGJ DM1NMGJ DN BI 456906 DM1NMGJ TI TTVIMDE DM1NMGJ TN Glucagon-like peptide 1 receptor (GLP1R) DM1NMGJ MA Agonist DM1NMGJ RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM1NMGJ RU https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi DM1O0DV DI DM1O0DV DM1O0DV DN Pradefovir DM1O0DV TI TTS5K1M DM1O0DV TN Hepatitis B virus Reverse transcriptase (HBV RT) DM1O0DV MA Modulator DM1O0DV RN DOI: 10.1128/AAC.01566-05 DM1O0DV RU http://aac.asm.org/content/50/9/2926.full DM1ODP6 DI DM1ODP6 DM1ODP6 DN VA-106483 DM1ODP6 TI TTK8R02 DM1ODP6 TN Vasopressin V2 receptor (V2R) DM1ODP6 MA Inhibitor DM1ODP6 RN New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34. DM1ODP6 RU https://pubmed.ncbi.nlm.nih.gov/19053774 DM1P60V DI DM1P60V DM1P60V DN NYX-2925 DM1P60V TI TT9IK2Z DM1P60V TN N-methyl-D-aspartate receptor (NMDAR) DM1P60V MA Modulator DM1P60V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1P60V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM1S2FZ DI DM1S2FZ DM1S2FZ DN Cemdisiran DM1S2FZ TI TT2LJRF DM1S2FZ TN C5 messenger RNA (C5 mRNA) DM1S2FZ MA Inhibitor DM1S2FZ RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. DM1S2FZ RU https://www.alnylam.com/alnylam-rnai-pipeline/ DM1S489 DI DM1S489 DM1S489 DN E6005 DM1S489 TI TTV5CGO DM1S489 TN Phosphodiesterase 4 (PDE4) DM1S489 MA Inhibitor DM1S489 RN Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. DM1S489 RU https://pubmed.ncbi.nlm.nih.gov/23674603 DM1SB94 DI DM1SB94 DM1SB94 DN Tiprelestat DM1SB94 TI TT5MLC4 DM1SB94 TN Leukocyte proteinase-3 (PRTN3) DM1SB94 MA Modulator DM1SB94 RN Company report (Proteo Biotech AG) DM1SB94 RU http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html DM1SB94 DI DM1SB94 DM1SB94 DN Tiprelestat DM1SB94 TI TTPLTSQ DM1SB94 TN Neutrophil elastase (NE) DM1SB94 MA Modulator DM1SB94 RN Company report (Proteo Biotech AG) DM1SB94 RU http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html DM1T3KQ DI DM1T3KQ DM1T3KQ DN AMG-714 DM1T3KQ TI TTJFA35 DM1T3KQ TN Interleukin-15 (IL15) DM1T3KQ RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM1T3KQ RU https://pubmed.ncbi.nlm.nih.gov/18321156 DM1TKG4 DI DM1TKG4 DM1TKG4 DN RDEA3170 DM1TKG4 TI TTA592U DM1TKG4 TN Urate anion exchanger 1 (URAT1) DM1TKG4 MA Modulator DM1TKG4 RN The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164. DM1TKG4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750299/ DM1TSHL DI DM1TSHL DM1TSHL DN Taprenepag DM1TSHL TI TT1ZAVI DM1TSHL TN Prostaglandin E2 receptor EP2 (PTGER2) DM1TSHL MA Agonist DM1TSHL RN A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17. DM1TSHL RU https://pubmed.ncbi.nlm.nih.gov/21851167 DM1TWIE DI DM1TWIE DM1TWIE DN CFZ533 DM1TWIE TI TTN6Y9A DM1TWIE TN CD40L receptor (CD40) DM1TWIE MA Inhibitor DM1TWIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1TWIE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM1UO4S DI DM1UO4S DM1UO4S DN Descartes-11 DM1UO4S TI TTZ3P4W DM1UO4S TN B-cell maturation protein (TNFRSF17) DM1UO4S RN Clinical pipeline report, company report or official report of Cartesian Therapeutics. DM1UO4S RU https://www.cartesiantherapeutics.com/clinical-trials/ DM1USXR DI DM1USXR DM1USXR DN AQ-13 DM1USXR TI TTKY2NS DM1USXR TN Duffy antigen chemokine receptor (ACKR1) DM1USXR MA Modulator DM1USXR RN From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420. DM1USXR RU http://www.sciencedirect.com/science/article/pii/S1995764510601010 DM1VITS DI DM1VITS DM1VITS DN APD-403 DM1VITS TI TTEX248 DM1VITS TN Dopamine D2 receptor (D2R) DM1VITS MA Antagonist DM1VITS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DM1VITS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DM1VK96 DI DM1VK96 DM1VK96 DN LANEPITANT DM1VK96 TI TTZPO1L DM1VK96 TN Substance-P receptor (TACR1) DM1VK96 MA Antagonist DM1VK96 RN NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94. DM1VK96 RU https://pubmed.ncbi.nlm.nih.gov/25228541 DM1X3L0 DI DM1X3L0 DM1X3L0 DN BGB-3245 DM1X3L0 TI TTB18GJ DM1X3L0 TN Proto-oncogene c-RAF (c-RAF) DM1X3L0 MA Inhibitor DM1X3L0 RN Clinical pipeline report, company report or official report of BeiGene. DM1X3L0 RU https://www.beigene.com/science-and-product-portfolio/pipeline DM1YAK6 DI DM1YAK6 DM1YAK6 DN GDC0941 DM1YAK6 TI TTHBTOP DM1YAK6 TN PI3-kinase gamma (PIK3CG) DM1YAK6 MA Inhibitor DM1YAK6 RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1YAK6 RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1ZJYS DI DM1ZJYS DM1ZJYS DN Dusigitumab DM1ZJYS TI TTE8WGO DM1ZJYS TN Insulin-like growth factor-II (IGF2) DM1ZJYS MA Inhibitor DM1ZJYS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ZJYS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1ZOCK DI DM1ZOCK DM1ZOCK DN Bryostatin-1 DM1ZOCK TI TTBZ7OD DM1ZOCK TN Protein kinase C epsilon (PRKCE) DM1ZOCK MA Activator DM1ZOCK RN Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. DM1ZOCK RU https://pubmed.ncbi.nlm.nih.gov/11490365 DM1ZQEN DI DM1ZQEN DM1ZQEN DN TRAXOPRODIL MESYLATE DM1ZQEN TI TT9IK2Z DM1ZQEN TN N-methyl-D-aspartate receptor (NMDAR) DM1ZQEN MA Modulator DM1ZQEN RN The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005 Dec;22(12):1428-43. DM1ZQEN RU https://pubmed.ncbi.nlm.nih.gov/16379581 DM20ATW DI DM20ATW DM20ATW DN Diflomotecan DM20ATW TI TTGTQHC DM20ATW TN DNA topoisomerase I (TOP1) DM20ATW MA Inhibitor DM20ATW RN Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75. DM20ATW RU https://pubmed.ncbi.nlm.nih.gov/19053883 DM20CIM DI DM20CIM DM20CIM DN RNF43-721 DM20CIM TI TTD91BL DM20CIM TN RING finger protein 43 (RNF43) DM20CIM MA Modulator DM20CIM RN Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011 Jan-Feb; 2(1): 73-79. DM20CIM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440656/ DM20MDU DI DM20MDU DM20MDU DN Danoprevir DM20MDU TI TT5FNQT DM20MDU TN Human immunodeficiency virus Protease (HIV PR) DM20MDU MA Inhibitor DM20MDU RN 2011 Pipeline of InterMune. DM20MDU RU http://www.intermune.com/pipeline DM219SF DI DM219SF DM219SF DN JNJ-40346527 DM219SF TI TT731LW DM219SF TN Colony stimulating factor-1 receptor (CSF-1R) DM219SF MA Modulator DM219SF RN An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. DM219SF RU https://pubmed.ncbi.nlm.nih.gov/25628399 DM21Z68 DI DM21Z68 DM21Z68 DN Nimacimab DM21Z68 TI TT6OEDT DM21Z68 TN Cannabinoid receptor 1 (CB1) DM21Z68 MA Antagonist DM21Z68 RN Clinical pipeline report, company report or official report of Bird Rock Bio. DM21Z68 RU http://www.birdrockbio.com/our-pipeline/nimacimab/ DM23UQ9 DI DM23UQ9 DM23UQ9 DN ABT-122 DM23UQ9 TI TTF8CQI DM23UQ9 TN Tumor necrosis factor (TNF) DM23UQ9 MA Modulator DM23UQ9 RN DOI: 10.1136/annrheumdis-2015-eular.4042 DM23UQ9 RU http://ard.bmj.com/content/74/Suppl_2/479.2.abstract DM23UQ9 DI DM23UQ9 DM23UQ9 DN ABT-122 DM23UQ9 TI TTG0MT6 DM23UQ9 TN Interleukin-17 (IL17) DM23UQ9 MA Modulator DM23UQ9 RN DOI: 10.1136/annrheumdis-2015-eular.4042 DM23UQ9 RU http://ard.bmj.com/content/74/Suppl_2/479.2.abstract DM23Y6K DI DM23Y6K DM23Y6K DN LYS228 DM23Y6K TI TT85JMW DM23Y6K TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM23Y6K MA Binder DM23Y6K RN Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18. DM23Y6K RU https://pubmed.ncbi.nlm.nih.gov/30061293 DM2458E DI DM2458E DM2458E DN Matuzumab DM2458E TI TTGKNB4 DM2458E TN Epidermal growth factor receptor (EGFR) DM2458E RN Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73. DM2458E RU https://pubmed.ncbi.nlm.nih.gov/18394559 DM24I0N DI DM24I0N DM24I0N DN PF-4878691 DM24I0N TI TTRJ1K4 DM24I0N TN Toll-like receptor 7 (TLR7) DM24I0N MA Agonist DM24I0N RN The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9. DM24I0N RU https://pubmed.ncbi.nlm.nih.gov/21451504 DM24SOL DI DM24SOL DM24SOL DN MLN1202 DM24SOL TI TTFZYTO DM24SOL TN C-C chemokine receptor type 2 (CCR2) DM24SOL MA Antagonist DM24SOL RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM24SOL RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM24SOL DI DM24SOL DM24SOL DN MLN1202 DM24SOL TI TTUPB12 DM24SOL TN Measles virus Fusion glycoprotein (MeV F) DM24SOL MA Inhibitor DM24SOL RN Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. DM24SOL RU https://pubmed.ncbi.nlm.nih.gov/19453286 DM2570B DI DM2570B DM2570B DN Poly-ICLC DM2570B TI TTD24Y0 DM2570B TN Toll-like receptor 3 (TLR3) DM2570B MA Inducer DM2570B RN Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12;5:10. DM2570B RU https://pubmed.ncbi.nlm.nih.gov/17295916 DM25VY8 DI DM25VY8 DM25VY8 DN Mydicar DM25VY8 TI TTE6THL DM25VY8 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) DM25VY8 MA Modulator DM25VY8 RN Clinical pipeline report, company report or official report of Celladon. DM25VY8 RU http://www.celladon.com/mydicar/ DM25YLM DI DM25YLM DM25YLM DN GSK2981278 DM25YLM TI TTGV6LY DM25YLM TN Nuclear receptor ROR-gamma (RORG) DM25YLM MA Agonist DM25YLM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25YLM RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM263RP DI DM263RP DM263RP DN BIIB092 DM263RP TI TTS87KH DM263RP TN Microtubule-associated protein tau (MAPT) DM263RP MA Inhibitor DM263RP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM263RP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM26IH8 DI DM26IH8 DM26IH8 DN S-297995 DM26IH8 TI TTN4QDT DM26IH8 TN Opioid receptor (OPR) DM26IH8 MA Antagonist DM26IH8 RN Clinical pipeline report, company report or official report of Shionogi (2011). DM26IH8 RU http://www.shionogi.co.jp/index_e.html DM26YJ1 DI DM26YJ1 DM26YJ1 DN PEGPH20 DM26YJ1 TI TTXFI1K DM26YJ1 TN Hyaluronidase (HYAL) DM26YJ1 MA Modulator DM26YJ1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM26YJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM276N1 DI DM276N1 DM276N1 DN Piritrexim DM276N1 TI TTYZVDJ DM276N1 TN Dihydrofolate reductase (DHFR) DM276N1 MA Modulator DM276N1 RN Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88. DM276N1 RU https://www.ncbi.nlm.nih.gov/pubmed/15571870 DM27D4J DI DM27D4J DM27D4J DN PD-0325901 DM27D4J TI TTROQ37 DM27D4J TN MAPK/ERK kinase kinase (MAP3K) DM27D4J MA Modulator DM27D4J RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM27D4J RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM27KFY DI DM27KFY DM27KFY DN SB-207266A DM27KFY TI TT07C3Y DM27KFY TN 5-HT 4 receptor (HTR4) DM27KFY MA Antagonist DM27KFY RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DM27KFY RU https://pubmed.ncbi.nlm.nih.gov/11293643 DM28A5D DI DM28A5D DM28A5D DN CAR-T cells targeting CD19 DM28A5D TI TTW640A DM28A5D TN B-lymphocyte surface antigen B4 (CD19) DM28A5D MA CAR-T-Cell-Therapy DM28A5D RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM28A5D RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM28M6I DI DM28M6I DM28M6I DN TV-1102 DM28M6I TI TT2VIZQ DM28M6I TN ITGAV messenger RNA (ITGAV mRNA) DM28M6I RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM28M6I RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM293JT DI DM293JT DM293JT DN BIIB 033 DM293JT TI TTZYQ80 DM293JT TN Leucine-rich repeat neuronal protein 1 (LINGO1) DM293JT RN Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. DM293JT RU https://pubmed.ncbi.nlm.nih.gov/25340070 DM2C1YN DI DM2C1YN DM2C1YN DN MEGF0444A DM2C1YN TI TT7WD0H DM2C1YN TN Epidermal growth factor-like protein 7 (EGFL7) DM2C1YN MA Modulator DM2C1YN RN A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614. DM2C1YN RU http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2614 DM2CJ4O DI DM2CJ4O DM2CJ4O DN Rebmab-100 DM2CJ4O TI TTUPAD7 DM2CJ4O TN Galactoside 3(4)-L-fucosyltransferase (FUT3) DM2CJ4O RN A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015 Aug;138(2):272-7. DM2CJ4O RU https://pubmed.ncbi.nlm.nih.gov/26026738 DM2CJB4 DI DM2CJB4 DM2CJB4 DN MK-0773 DM2CJB4 TI TTS64P2 DM2CJB4 TN Androgen receptor (AR) DM2CJB4 MA Modulator DM2CJB4 RN Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64. DM2CJB4 RU https://pubmed.ncbi.nlm.nih.gov/20356837 DM2CUS0 DI DM2CUS0 DM2CUS0 DN F901318 DM2CUS0 TI TTTSUI2 DM2CUS0 TN Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) DM2CUS0 MA Inhibitor DM2CUS0 RN Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18. DM2CUS0 RU https://pubmed.ncbi.nlm.nih.gov/29891595 DM2HDTM DI DM2HDTM DM2HDTM DN Tosagestin DM2HDTM TI TTUV8G9 DM2HDTM TN Progesterone receptor (PGR) DM2HDTM MA Agonist DM2HDTM RN Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65. DM2HDTM RU https://pubmed.ncbi.nlm.nih.gov/1616875 DM2IFJQ DI DM2IFJQ DM2IFJQ DN GBL-310 DM2IFJQ TI TTVOE6D DM2IFJQ TN Mitogen-activated protein kinase (MAPK) DM2IFJQ MA Inhibitor DM2IFJQ RN WO patent application no. 2010,0456,51, Methods for analyzing drug response. DM2IFJQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045651A1&KC=A1 DM2IFYZ DI DM2IFYZ DM2IFYZ DN CB-10-01 DM2IFYZ TI TTUJFD0 DM2IFYZ TN Telomerase reverse transcriptase (TERT) DM2IFYZ RN Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12. DM2IFYZ RU https://pubmed.ncbi.nlm.nih.gov/17324292 DM2J36F DI DM2J36F DM2J36F DN BILN-2061 DM2J36F TI TTWXB3E DM2J36F TN Hepatitis C virus NS3 helicase (HCV NS3) DM2J36F MA Inhibitor DM2J36F RN Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5. DM2J36F RU https://pubmed.ncbi.nlm.nih.gov/15732092 DM2K5VP DI DM2K5VP DM2K5VP DN Coxsackievirus A21 DM2K5VP TI TT5Z9WY DM2K5VP TN Complement decay-accelerating factor (CD55) DM2K5VP MA Inhibitor DM2K5VP RN Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41. DM2K5VP RU https://pubmed.ncbi.nlm.nih.gov/17391493 DM2KQ71 DI DM2KQ71 DM2KQ71 DN Sutezolid DM2KQ71 TI TT2VX74 DM2KQ71 TN Bacterial Protein synthesis (Bact PROS) DM2KQ71 MA Modulator DM2KQ71 RN Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59. DM2KQ71 RU https://pubmed.ncbi.nlm.nih.gov/20385852 DM2L9CO DI DM2L9CO DM2L9CO DN Ezatiostat DM2L9CO TI TT40K12 DM2L9CO TN Glutathione S-transferase P (GSTP1) DM2L9CO MA Modulator DM2L9CO RN National Cancer Institute Drug Dictionary (drug id 485244). DM2L9CO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=485244 DM2LBC3 DI DM2LBC3 DM2LBC3 DN TEW-7197 DM2LBC3 TI TTP4520 DM2LBC3 TN TGF-beta receptor type I (TGFBR1) DM2LBC3 MA Modulator DM2LBC3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2LBC3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2LBC3 DI DM2LBC3 DM2LBC3 DN TEW-7197 DM2LBC3 TI TTO3HT7 DM2LBC3 TN Transforming growth factor beta (TGFB) DM2LBC3 MA Antagonist DM2LBC3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2LBC3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM2LBHN DI DM2LBHN DM2LBHN DN JTE-051 DM2LBHN TI TT3C80U DM2LBHN TN T-cell-specific kinase (ITK) DM2LBHN MA Inhibitor DM2LBHN RN Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490. DM2LBHN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174519/ DM2LZIY DI DM2LZIY DM2LZIY DN BT-061 DM2LZIY TI TTN2JFW DM2LZIY TN T-cell surface glycoprotein CD4 (CD4) DM2LZIY RN Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2. DM2LZIY RU https://pubmed.ncbi.nlm.nih.gov/25666094 DM2M80G DI DM2M80G DM2M80G DN Z 360 DM2M80G TI TTVFO0U DM2M80G TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2M80G MA Modulator DM2M80G RN Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22. DM2M80G RU https://www.ncbi.nlm.nih.gov/pubmed/20118543 DM2MSGF DI DM2MSGF DM2MSGF DN ASP9831 DM2MSGF TI TTV5CGO DM2MSGF TN Phosphodiesterase 4 (PDE4) DM2MSGF MA Inhibitor DM2MSGF RN Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. DM2MSGF RU https://pubmed.ncbi.nlm.nih.gov/24530600 DM2N0Z3 DI DM2N0Z3 DM2N0Z3 DN KUR-211 DM2N0Z3 TI TTWODQF DM2N0Z3 TN Fibrin (FG) DM2N0Z3 MA Modulator DM2N0Z3 RN Clinical pipeline report, company report or official report of Kuros. DM2N0Z3 RU http://www.kuros.ch/cms/front_content.php?idcat=78 DM2NF6X DI DM2NF6X DM2NF6X DN MIV-210 DM2NF6X TI TTS5K1M DM2NF6X TN Hepatitis B virus Reverse transcriptase (HBV RT) DM2NF6X MA Modulator DM2NF6X RN Emerging antivirals for the treatment of hepatitis B DM2NF6X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069299 DM2NJYC DI DM2NJYC DM2NJYC DN Patidegib DM2NJYC TI TT4LXBC DM2NJYC TN Hedgehog signaling pathway (HS pathway) DM2NJYC MA Inhibitor DM2NJYC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2NJYC RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM2O4MI DI DM2O4MI DM2O4MI DN UK-432097 DM2O4MI TI TTM2AOE DM2O4MI TN Adenosine A2a receptor (ADORA2A) DM2O4MI MA Agonist DM2O4MI RN Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7. DM2O4MI RU https://pubmed.ncbi.nlm.nih.gov/21393508 DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TT6MSOK DM2O7NM TN 5-HT 1D receptor (HTR1D) DM2O7NM MA Agonist DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TTYSN63 DM2O7NM TN 5-HT 2 receptor (5HT2R) DM2O7NM MA Inhibitor DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TTSQIFT DM2O7NM TN 5-HT 1A receptor (HTR1A) DM2O7NM MA Modulator DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2OS51 DI DM2OS51 DM2OS51 DN ABT-126 DM2OS51 TI TTLA931 DM2OS51 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2OS51 MA Modulator DM2OS51 RN A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90. DM2OS51 RU http://www.sciencedirect.com/science/article/pii/S2352873715000104 DM2PEU5 DI DM2PEU5 DM2PEU5 DN CNSB-001 DM2PEU5 TI TTQ29KF DM2PEU5 TN Voltage-gated potassium channel Kv7 (KCNQ) DM2PEU5 MA Agonist DM2PEU5 RN The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72. DM2PEU5 RU https://pubmed.ncbi.nlm.nih.gov/20433607 DM2PEU5 DI DM2PEU5 DM2PEU5 DN CNSB-001 DM2PEU5 TI TTN4QDT DM2PEU5 TN Opioid receptor (OPR) DM2PEU5 MA Agonist DM2PEU5 RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM2PEU5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM2POHA DI DM2POHA DM2POHA DN AGS-16C3F DM2POHA TI TTD4TKP DM2POHA TN Phosphodiesterase I beta (ENPP3) DM2POHA MA Inhibitor DM2POHA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2POHA RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM2Q50G DI DM2Q50G DM2Q50G DN Belnacasan DM2Q50G TI TTCQIBE DM2Q50G TN Caspase-1 (CASP1) DM2Q50G MA Inhibitor DM2Q50G RN (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16. DM2Q50G RU https://pubmed.ncbi.nlm.nih.gov/17289835 DM2QBDS DI DM2QBDS DM2QBDS DN Disitertide DM2QBDS TI TTR9XHZ DM2QBDS TN Transforming growth factor beta 1 (TGFB1) DM2QBDS MA Inhibitor DM2QBDS RN Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94. DM2QBDS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960190/ DM2QIN1 DI DM2QIN1 DM2QIN1 DN HT-100 DM2QIN1 TI TTXYCDZ DM2QIN1 TN Bifunctional aminoacyl-tRNA synthetase (EPRS) DM2QIN1 MA Modulator DM2QIN1 RN Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7. DM2QIN1 RU https://pubmed.ncbi.nlm.nih.gov/22327401 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTHRID2 DM2RJ4D TN Insulin-like growth factor I receptor (IGF1R) DM2RJ4D MA Modulator DM2RJ4D RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DM2RJ4D RU https://pubmed.ncbi.nlm.nih.gov/24282274 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTDC8N2 DM2RJ4D TN Erbb3 tyrosine kinase receptor (Erbb-3) DM2RJ4D MA Modulator DM2RJ4D RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DM2RJ4D RU https://pubmed.ncbi.nlm.nih.gov/24282274 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTCJG29 DM2RJ4D TN Serine/threonine-protein kinase mTOR (mTOR) DM2RJ4D MA Inhibitor DM2RJ4D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2RJ4D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM2RS0V DI DM2RS0V DM2RS0V DN Isofagomine tartrate DM2RS0V TI TT1B5PU DM2RS0V TN Glucosylceramidase (GBA) DM2RS0V MA Inhibitor DM2RS0V RN Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008 Nov 3;9(16):2650-62. DM2RS0V RU https://pubmed.ncbi.nlm.nih.gov/18972510 DM2SWI8 DI DM2SWI8 DM2SWI8 DN RG7888 DM2SWI8 TI TTBW580 DM2SWI8 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DM2SWI8 RN Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105. DM2SWI8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288389/ DM2TSMD DI DM2TSMD DM2TSMD DN 177Lu-labelled NeoBOMB1 DM2TSMD TI TTC1MVT DM2TSMD TN Gastrin-releasing peptide receptor (GRPR) DM2TSMD RN 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299. DM2TSMD RU https://pubmed.ncbi.nlm.nih.gov/27609789 DM2U45Q DI DM2U45Q DM2U45Q DN Danegaptide DM2U45Q TI TTJO6E9 DM2U45Q TN Gap junction protein (GJP) DM2U45Q MA Modulator DM2U45Q RN The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. DM2U45Q RU https://pubmed.ncbi.nlm.nih.gov/19252062 DM2U530 DI DM2U530 DM2U530 DN ALD-401 DM2U530 TI TTFLN4T DM2U530 TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM2U530 MA Modulator DM2U530 RN A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72. DM2U530 RU https://pubmed.ncbi.nlm.nih.gov/21998334 DM2UGT7 DI DM2UGT7 DM2UGT7 DN RG-101 DM2UGT7 TI TTP03CE DM2UGT7 TN Hepatitis C virus microRNA miR-122 (HCV MIR122) DM2UGT7 MA Modulator DM2UGT7 RN Company report (Isis Pharmaceuticals) DM2UGT7 RU https://www.isispharm.com/pipeline/rg-101/ DM2UJ1H DI DM2UJ1H DM2UJ1H DN NW-3509 DM2UJ1H TI TTRK8B9 DM2UJ1H TN Sodium channel unspecific (NaC) DM2UJ1H MA Blocker DM2UJ1H RN Clinical pipeline report, company report or official report of Newron. DM2UJ1H RU http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=52 DM2UKJV DI DM2UKJV DM2UKJV DN SP-333 DM2UKJV TI TTLDPRG DM2UKJV TN Guanylyl cyclase C (GUCY2C) DM2UKJV MA Agonist DM2UKJV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2UKJV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TT6OEDT DM2UOSN TN Cannabinoid receptor 1 (CB1) DM2UOSN MA Agonist DM2UOSN RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM2UOSN RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TTW20TU DM2UOSN TN TRAIL receptor 2 (TRAIL-R2) DM2UOSN MA Agonist DM2UOSN RN Clinical pipeline report, company report or official report of Amgen (2009). DM2UOSN RU http://www.amgen.com/science/pipe.jsp DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TT90XZ8 DM2UOSN TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM2UOSN MA Binder DM2UOSN RN Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12. DM2UOSN RU https://pubmed.ncbi.nlm.nih.gov/10762603 DM2UP6Z DI DM2UP6Z DM2UP6Z DN ARO-AAT DM2UP6Z TI TT2L4TV DM2UP6Z TN SERPINA1 messenger RNA (SERPINA1 mRNA) DM2UP6Z RN Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals. DM2UP6Z RU https://arrowheadpharma.com/pipeline/ DM2USXP DI DM2USXP DM2USXP DN Remlarsen DM2USXP TI TTO60BY DM2USXP TN microRNA hsa-miR-29b (MIR29b) DM2USXP MA Replacement DM2USXP RN A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081. DM2USXP RU https://pubmed.ncbi.nlm.nih.gov/30472058 DM2VO97 DI DM2VO97 DM2VO97 DN RK-023 DM2VO97 TI TT30NW6 DM2VO97 TN Chloride channel protein 2 (CLC-2) DM2VO97 MA Modulator DM2VO97 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2VO97 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2VO9T DI DM2VO9T DM2VO9T DN GBR 830 DM2VO9T TI TTL31H0 DM2VO9T TN OX40L receptor (CD134) DM2VO9T MA Antagonist DM2VO9T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2VO9T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTSKMI8 DM2WP8F TN Phosphodiesterase 4D (PDE4D) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTZ97H5 DM2WP8F TN Phosphodiesterase 4A (PDE4A) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTVIAT9 DM2WP8F TN Phosphodiesterase 4B (PDE4B) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM2X0SP DI DM2X0SP DM2X0SP DN VIR-2218 DM2X0SP TI TTINUYD DM2X0SP TN Hepatitis B virus Large envelope protein (HBV S) DM2X0SP MA Inhibitor DM2X0SP RN Clinical pipeline report, company report or official report of Vir Biotechnology. DM2X0SP RU https://www.vir.bio/pipeline/ DM2XE80 DI DM2XE80 DM2XE80 DN BAY-X-7195 DM2XE80 TI TTGKOY9 DM2XE80 TN Leukotriene CysLT1 receptor (CYSLTR1) DM2XE80 MA Modulator DM2XE80 RN The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85. DM2XE80 RU https://www.ncbi.nlm.nih.gov/pubmed/8838238 DM2XE80 DI DM2XE80 DM2XE80 DN BAY-X-7195 DM2XE80 TI TT0PZR5 DM2XE80 TN Leukotriene CysLT2 receptor (CYSLTR2) DM2XE80 MA Modulator DM2XE80 RN The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85. DM2XE80 RU https://www.ncbi.nlm.nih.gov/pubmed/8838238 DM2YIOE DI DM2YIOE DM2YIOE DN SDZ-MAR-327 DM2YIOE TI TTSQIFT DM2YIOE TN 5-HT 1A receptor (HTR1A) DM2YIOE MA Modulator DM2YIOE RN DOI: 10.1038/sj.mp.4002062 DM2YIOE RU http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html DM2YIOE DI DM2YIOE DM2YIOE DN SDZ-MAR-327 DM2YIOE TI TTEX248 DM2YIOE TN Dopamine D2 receptor (D2R) DM2YIOE MA Modulator DM2YIOE RN DOI: 10.1038/sj.mp.4002062 DM2YIOE RU http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html DM2YIZH DI DM2YIZH DM2YIZH DN NCX-1000 DM2YIZH TI TTZY5KP DM2YIZH TN Caspase (CASP) DM2YIZH MA Modulator DM2YIZH RN Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42. DM2YIZH RU https://pubmed.ncbi.nlm.nih.gov/15345658 DM2ZLWH DI DM2ZLWH DM2ZLWH DN TG-0054 DM2ZLWH TI TTBID49 DM2ZLWH TN C-X-C chemokine receptor type 4 (CXCR4) DM2ZLWH MA Inhibitor DM2ZLWH RN CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28. DM2ZLWH RU https://pubmed.ncbi.nlm.nih.gov/24823505 DM2ZUXK DI DM2ZUXK DM2ZUXK DN Lu-AA34893 DM2ZUXK TI TT3ROYC DM2ZUXK TN Serotonin transporter (SERT) DM2ZUXK MA Modulator DM2ZUXK RN Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105). DM2ZUXK RU https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false DM2ZUXK DI DM2ZUXK DM2ZUXK DN Lu-AA34893 DM2ZUXK TI TT85JO3 DM2ZUXK TN 5-HT receptor (5HTR) DM2ZUXK MA Modulator DM2ZUXK RN Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105). DM2ZUXK RU https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false DM32NWD DI DM32NWD DM32NWD DN LIK-066 DM32NWD TI TT2UE56 DM32NWD TN Sodium/glucose cotransporter 1 (SGLT1) DM32NWD MA Inhibitor DM32NWD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915). DM32NWD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915 DM32NWD DI DM32NWD DM32NWD DN LIK-066 DM32NWD TI TTLWPVF DM32NWD TN Sodium/glucose cotransporter 2 (SGLT2) DM32NWD MA Inhibitor DM32NWD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM32NWD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM32UOC DI DM32UOC DM32UOC DN EDP-938 DM32UOC TI TT25A0I DM32UOC TN Respiratory syncytial virus protein N (RSV N) DM32UOC MA Inhibitor DM32UOC RN EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428. DM32UOC RU https://pubmed.ncbi.nlm.nih.gov/33720995 DM32YTJ DI DM32YTJ DM32YTJ DN APN-301 DM32YTJ TI TTF89GD DM32YTJ TN Interleukin-2 (IL2) DM32YTJ MA Modulator DM32YTJ RN Clinical pipeline report, company report or official report of APEIRON Biologics. DM32YTJ RU http://www.apeiron-biologics.com/index.php/projects/apn301-hu14-18-il2.html DM347TQ DI DM347TQ DM347TQ DN MK-3697 DM347TQ TI TT9N02I DM347TQ TN Orexin receptor type 2 (HCRTR2) DM347TQ MA Modulator DM347TQ RN Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90. DM347TQ RU https://pubmed.ncbi.nlm.nih.gov/25248679 DM34FWR DI DM34FWR DM34FWR DN Lu-AA39959 DM34FWR TI TTM7WCE DM34FWR TN Ion channel unspecific (IC) DM34FWR MA Modulator DM34FWR RN Lundbeck: leading the way in the treatment of CNS disorders. DM34FWR RU http://onlinelibrary.wiley.com/doi/10.1002/fps.78/pdf DM35KDA DI DM35KDA DM35KDA DN Ataciguat DM35KDA TI TTJME02 DM35KDA TN Atrial natriuretic peptide receptor A (NPR1) DM35KDA MA Activator DM35KDA RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM35KDA RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM35S2I DI DM35S2I DM35S2I DN ASM-024 DM35S2I TI TTJSZTB DM35S2I TN Nicotinic acetylcholine receptor (nAChR) DM35S2I MA Agonist DM35S2I RN Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4. DM35S2I RU https://pubmed.ncbi.nlm.nih.gov/26252534 DM37CX4 DI DM37CX4 DM37CX4 DN IC14 DM37CX4 TI TTCLGZ8 DM37CX4 TN HUAMN monocyte differentiation antigen CD14 (CD14) DM37CX4 MA Inhibitor DM37CX4 RN IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19) DM37CX4 RU https://clinicaltrials.gov/ct2/show/NCT04391309 DM3816P DI DM3816P DM3816P DN PAC-14028 DM3816P TI TTMI6F5 DM3816P TN Transient receptor potential cation channel V1 (TRPV1) DM3816P MA Antagonist DM3816P RN Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6. DM3816P RU https://pubmed.ncbi.nlm.nih.gov/22477184 DM38ARE DI DM38ARE DM38ARE DN Gp100:209-217(210M) peptide vaccine DM38ARE TI TT8MK59 DM38ARE TN Melanocytes lineage-specific antigen GP100 (PMEL) DM38ARE RN National Cancer Institute Drug Dictionary (drug id 476335). DM38ARE RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=476335 DM39RXO DI DM39RXO DM39RXO DN SiG12D-LODER DM39RXO TI TT9TVNM DM39RXO TN KRAS G12D mutant messenger RNA (KRAS mRNA) DM39RXO MA Inhibitor DM39RXO RN Clinical pipeline report, company report or official report of Silenseed. DM39RXO RU https://www.silenseed.com/kras-loder-for-pancreatic-cancer/ DM3AIF7 DI DM3AIF7 DM3AIF7 DN TNF alpha kinoid DM3AIF7 TI TTF8CQI DM3AIF7 TN Tumor necrosis factor (TNF) DM3AIF7 RN Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703. DM3AIF7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346328/ DM3BN4W DI DM3BN4W DM3BN4W DN CFI-400945 DM3BN4W TI TTGPNZQ DM3BN4W TN Polo-like kinase 4 (PLK4) DM3BN4W MA Inhibitor DM3BN4W RN Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76. DM3BN4W RU https://pubmed.ncbi.nlm.nih.gov/25043604 DM3C8GQ DI DM3C8GQ DM3C8GQ DN PF-489791 DM3C8GQ TI TTJ0IQB DM3C8GQ TN Phosphodiesterase 5A (PDE5A) DM3C8GQ MA Inhibitor DM3C8GQ RN Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358. DM3C8GQ RU https://www.smr.org.uk/smr/archive/pastmeetings/Downloads/SMR_Dec_09_Report.pdf DM3C9F8 DI DM3C9F8 DM3C9F8 DN RVT-505 DM3C9F8 TI TT037IE DM3C9F8 TN Aryl hydrocarbon receptor (AHR) DM3C9F8 MA Modulator DM3C9F8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3C9F8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM3C9NV DI DM3C9NV DM3C9NV DN TD-8954 DM3C9NV TI TT07C3Y DM3C9NV TN 5-HT 4 receptor (HTR4) DM3C9NV MA Modulator DM3C9NV RN The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25. DM3C9NV RU https://pubmed.ncbi.nlm.nih.gov/21687517 DM3CVHQ DI DM3CVHQ DM3CVHQ DN FE-202158 DM3CVHQ TI TT4TFGN DM3CVHQ TN Vasopressin V1a receptor (V1AR) DM3CVHQ MA Agonist DM3CVHQ RN The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014 Jul;42(7):e525-33. DM3CVHQ RU https://pubmed.ncbi.nlm.nih.gov/24674922 DM3D52L DI DM3D52L DM3D52L DN TAS-114 DM3D52L TI TTH6MBO DM3D52L TN dUTP pyrophosphatase (DUT) DM3D52L MA Inhibitor DM3D52L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3D52L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3DQXG DI DM3DQXG DM3DQXG DN NPSP-795 DM3DQXG TI TTEPJL5 DM3DQXG TN Parathyroid hormone receptor (PTH2R) DM3DQXG MA Modulator DM3DQXG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332). DM3DQXG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332 DM3DWKN DI DM3DWKN DM3DWKN DN PF-4191834 DM3DWKN TI TT2J34L DM3DWKN TN Arachidonate 5-lipoxygenase (5-LOX) DM3DWKN MA Inhibitor DM3DWKN RN Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. DM3DWKN RU https://pubmed.ncbi.nlm.nih.gov/20378715 DM3FS1G DI DM3FS1G DM3FS1G DN RT-001 DM3FS1G TI TTB52WU DM3FS1G TN Bacterial Botulinum toxin A (Bact botA) DM3FS1G MA Modulator DM3FS1G RN Clinical pipeline report, company report or official report of Revance Therapeutics. DM3FS1G RU http://www.revance.com/mechanism-of-action-rt001/ DM3GEHC DI DM3GEHC DM3GEHC DN CX-8998 DM3GEHC TI TTT6NKW DM3GEHC TN Voltage-gated T-type calcium channel (T-CaC) DM3GEHC MA Modulator DM3GEHC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3GEHC RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3GRKY DI DM3GRKY DM3GRKY DN S-707106 DM3GRKY TI TTCBFJO DM3GRKY TN Insulin receptor (INSR) DM3GRKY MA Modulator DM3GRKY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM3GRKY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM3H0IX DI DM3H0IX DM3H0IX DN AMG 890 DM3H0IX TI TTU9LGY DM3H0IX TN Apolipoprotein A messenger RNA (LPA mRNA) DM3H0IX MA Inhibitor DM3H0IX RN Clinical pipeline report, company report or official report of Amgen. DM3H0IX RU https://www.amgenpipeline.com/ DM3H82Q DI DM3H82Q DM3H82Q DN NS-7 DM3H82Q TI TTRK8B9 DM3H82Q TN Sodium channel unspecific (NaC) DM3H82Q MA Modulator DM3H82Q RN Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9. DM3H82Q RU https://pubmed.ncbi.nlm.nih.gov/10773024 DM3I71U DI DM3I71U DM3I71U DN MKT-077 DM3I71U TI TTMTPG3 DM3I71U TN Mortalin (HSPA9) DM3I71U MA Modulator DM3I71U RN Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21. DM3I71U RU https://pubmed.ncbi.nlm.nih.gov/11156371 DM3ICO6 DI DM3ICO6 DM3ICO6 DN JNJ-74494550 DM3ICO6 TI TTNCIE0 DM3ICO6 TN CD70 antigen (CD27-L) DM3ICO6 RN Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467. DM3ICO6 RU https://pubmed.ncbi.nlm.nih.gov/32601337 DM3ICYL DI DM3ICYL DM3ICYL DN AP-301-IH DM3ICYL TI TTF8CQI DM3ICYL TN Tumor necrosis factor (TNF) DM3ICYL MA Inhibitor DM3ICYL RN AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63. DM3ICYL RU https://pubmed.ncbi.nlm.nih.gov/23313096 DM3IEHP DI DM3IEHP DM3IEHP DN NN8555 DM3IEHP TI TTLRN4A DM3IEHP TN NKG2 D activating NK receptor (KLRK1) DM3IEHP MA Antagonist DM3IEHP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3IEHP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3JFZ2 DI DM3JFZ2 DM3JFZ2 DN CXL DM3JFZ2 TI TTHI19T DM3JFZ2 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM3JFZ2 MA Modulator DM3JFZ2 RN Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215. DM3JFZ2 RU http://www.mdpi.com/2079-6382/3/2/193 DM3JNXS DI DM3JNXS DM3JNXS DN AN-1792 DM3JNXS TI TTE4KHA DM3JNXS TN Amyloid beta A4 protein (APP) DM3JNXS MA Inhibitor DM3JNXS RN Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63. DM3JNXS RU https://pubmed.ncbi.nlm.nih.gov/16936277 DM3JSFK DI DM3JSFK DM3JSFK DN AZD-5069 DM3JSFK TI TT30C9G DM3JSFK TN C-X-C chemokine receptor type 2 (CXCR2) DM3JSFK MA Inhibitor DM3JSFK RN Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50. DM3JSFK RU https://pubmed.ncbi.nlm.nih.gov/25736418 DM3L51O DI DM3L51O DM3L51O DN Rilopirox DM3L51O TI TT2J34L DM3L51O TN Arachidonate 5-lipoxygenase (5-LOX) DM3L51O MA Inhibitor DM3L51O RN Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34 Suppl 1:91-3. DM3L51O RU https://pubmed.ncbi.nlm.nih.gov/1840158 DM3ORVD DI DM3ORVD DM3ORVD DN Neramexane DM3ORVD TI TT9IK2Z DM3ORVD TN N-methyl-D-aspartate receptor (NMDAR) DM3ORVD MA Antagonist DM3ORVD RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DM3ORVD RU https://pubmed.ncbi.nlm.nih.gov/15757410 DM3P91Z DI DM3P91Z DM3P91Z DN Alacizumab pegol DM3P91Z TI TTUTJGQ DM3P91Z TN Vascular endothelial growth factor receptor 2 (KDR) DM3P91Z RN Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. DM3P91Z RU https://pubmed.ncbi.nlm.nih.gov/18056191 DM3POT6 DI DM3POT6 DM3POT6 DN ATL1102 DM3POT6 TI TTJMF9P DM3POT6 TN ITGA4 messenger RNA (ITGA4 mRNA) DM3POT6 MA Modulator DM3POT6 RN CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8. DM3POT6 RU https://www.ncbi.nlm.nih.gov/pubmed/25239835 DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TTULVH8 DM3QDA6 TN Tyrosinase (TYR) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TTWSKHD DM3QDA6 TN Melanoma-associated antigen 3 (MAGEA3) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TT362RB DM3QDA6 TN MART-1 melanoma antigen (MLANA) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3RBJW DI DM3RBJW DM3RBJW DN MB-11055 DM3RBJW TI TTLAFZV DM3RBJW TN AMP-activated protein kinase (AMPK) DM3RBJW MA Modulator DM3RBJW RN Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72. DM3RBJW RU https://www.ncbi.nlm.nih.gov/pubmed/17429005 DM3RU0A DI DM3RU0A DM3RU0A DN CAR-T cells targeting CD20 DM3RU0A TI TTUE541 DM3RU0A TN Leukocyte surface antigen Leu-16 (CD20) DM3RU0A MA CAR-T-Cell-Therapy DM3RU0A RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM3RU0A RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM3SYOK DI DM3SYOK DM3SYOK DN CTP-543 DM3SYOK TI TTRMX3V DM3SYOK TN Janus kinase 2 (JAK-2) DM3SYOK MA Inhibitor DM3SYOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3SYOK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3SYOK DI DM3SYOK DM3SYOK DN CTP-543 DM3SYOK TI TT6DM01 DM3SYOK TN Janus kinase 1 (JAK-1) DM3SYOK MA Inhibitor DM3SYOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3SYOK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3TN1A DI DM3TN1A DM3TN1A DN ASP7991 DM3TN1A TI TTBUYHA DM3TN1A TN Extracellular calcium-sensing receptor (CASR) DM3TN1A MA Agonist DM3TN1A RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616) DM3TN1A RU http://adisinsight.springer.com/drugs/800035616 DM3TRF7 DI DM3TRF7 DM3TRF7 DN Brasofensine DM3TRF7 TI TT3ROYC DM3TRF7 TN Serotonin transporter (SERT) DM3TRF7 MA Modulator DM3TRF7 RN Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7. DM3TRF7 RU https://pubmed.ncbi.nlm.nih.gov/11249705 DM3TUBR DI DM3TUBR DM3TUBR DN Acalabrutinib DM3TUBR TI TTOWPER DM3TUBR TN HUMAN bruton tyrosine kinase (BTK) DM3TUBR MA Inhibitor DM3TUBR RN AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 DM3TUBR RU https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html DM3U9BY DI DM3U9BY DM3U9BY DN RO-5126766 DM3U9BY TI TTROQ37 DM3U9BY TN MAPK/ERK kinase kinase (MAP3K) DM3U9BY MA Modulator DM3U9BY RN The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217. DM3U9BY RU https://www.ncbi.nlm.nih.gov/pubmed/25422890 DM3U9BY DI DM3U9BY DM3U9BY DN RO-5126766 DM3U9BY TI TTQ9K3Y DM3U9BY TN Serine/threonine-protein kinase Raf (RAF) DM3U9BY MA Modulator DM3U9BY RN The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217. DM3U9BY RU https://www.ncbi.nlm.nih.gov/pubmed/25422890 DM3V7QO DI DM3V7QO DM3V7QO DN Vatelizumab DM3V7QO TI TTMSB0A DM3V7QO TN Integrin alpha-2/beta-1 (ITGA2/B1) DM3V7QO RN Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146. DM3V7QO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/ DM3VP19 DI DM3VP19 DM3VP19 DN APC-8015F DM3VP19 TI TTCT6F7 DM3VP19 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM3VP19 MA Modulator DM3VP19 RN National Cancer Institute Drug Dictionary (drug id 561410). DM3VP19 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561410 DM3WCL4 DI DM3WCL4 DM3WCL4 DN Baltaleucel-T DM3WCL4 TI TTXQYT6 DM3WCL4 TN T-cells (T-cells) DM3WCL4 MA Immunomodulator DM3WCL4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3WCL4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3WDZ5 DI DM3WDZ5 DM3WDZ5 DN MK-1775 DM3WDZ5 TI TTJFOAL DM3WDZ5 TN Wee1-like protein kinase (WEE1) DM3WDZ5 MA Inhibitor DM3WDZ5 RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM3WDZ5 RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM3WSDR DI DM3WSDR DM3WSDR DN IXT-m200 DM3WSDR TI TT3UEY0 DM3WSDR TN Methamphetamine (Meth) DM3WSDR MA Antagonist DM3WSDR RN Clinical pipeline report, company report or official report of InterveXion Therapeutics. DM3WSDR RU http://intervexion.com/research-development/anti-methamphetamine-products/ DM3WSL2 DI DM3WSL2 DM3WSL2 DN HPH-116 DM3WSL2 TI TT8Z1OP DM3WSL2 TN Human immunodeficiency virus Nucleocapsid p7 (HIV p7) DM3WSL2 MA Modulator DM3WSL2 RN Clinical pipeline report, company report or official report of H-Phar. DM3WSL2 RU http://www.h-phar.com/Projects_Projet_1.php DM3WX0K DI DM3WX0K DM3WX0K DN HQK-1004 DM3WX0K TI TTP3QRF DM3WX0K TN Thymidine kinase 1 (TK1) DM3WX0K MA Modulator DM3WX0K RN Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7. DM3WX0K RU https://pubmed.ncbi.nlm.nih.gov/11555713 DM3WY0B DI DM3WY0B DM3WY0B DN LAS-41002 DM3WY0B TI TTYRL6O DM3WY0B TN Glucocorticoid receptor (NR3C1) DM3WY0B MA Modulator DM3WY0B RN Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134. DM3WY0B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432345/ DM3XRUH DI DM3XRUH DM3XRUH DN LJN452 DM3XRUH TI TTS4UGC DM3XRUH TN Farnesoid X-activated receptor (FXR) DM3XRUH MA Agonist DM3XRUH RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DM3XRUH RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DM3XT5V DI DM3XT5V DM3XT5V DN APD371 DM3XT5V TI TTMSFAW DM3XT5V TN Cannabinoid receptor 2 (CB2) DM3XT5V MA Agonist DM3XT5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3XT5V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3YB2C DI DM3YB2C DM3YB2C DN CDP-6038 DM3YB2C TI TTT1V78 DM3YB2C TN Interleukin-6 (IL6) DM3YB2C MA Modulator DM3YB2C RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM3YB2C RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM3YIKR DI DM3YIKR DM3YIKR DN PF-4523655 DM3YIKR TI TTVEOY6 DM3YIKR TN RTP801 messenger RNA (RTP801 mRNA) DM3YIKR RN DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010 DM3YIKR RU http://www.nature.com/scibx/journal/v3/n20/full/scibx.2010.629.html DM3YVKQ DI DM3YVKQ DM3YVKQ DN YT-146 DM3YVKQ TI TTNE7KG DM3YVKQ TN Adenosine A2b receptor (ADORA2B) DM3YVKQ MA Agonist DM3YVKQ RN Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10. DM3YVKQ RU https://pubmed.ncbi.nlm.nih.gov/8135838 DM3Z6IQ DI DM3Z6IQ DM3Z6IQ DN CLR-3001 DM3Z6IQ TI TTEX248 DM3Z6IQ TN Dopamine D2 receptor (D2R) DM3Z6IQ MA Modulator DM3Z6IQ RN Clinical pipeline report, company report or official report of Clera Inc. DM3Z6IQ RU http://clera.com/cognition/ DM3Z6IQ DI DM3Z6IQ DM3Z6IQ DN CLR-3001 DM3Z6IQ TI TT3ROYC DM3Z6IQ TN Serotonin transporter (SERT) DM3Z6IQ MA Inhibitor DM3Z6IQ RN Clinical pipeline report, company report or official report of Clera Inc. DM3Z6IQ RU http://clera.com/cognition/ DM3ZEYL DI DM3ZEYL DM3ZEYL DN Piboserod DM3ZEYL TI TT07C3Y DM3ZEYL TN 5-HT 4 receptor (HTR4) DM3ZEYL MA Antagonist DM3ZEYL RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DM3ZEYL RU https://pubmed.ncbi.nlm.nih.gov/11293643 DM3ZL2O DI DM3ZL2O DM3ZL2O DN GSK-557296 DM3ZL2O TI TTSCIUP DM3ZL2O TN Oxytocin receptor (OTR) DM3ZL2O MA Antagonist DM3ZL2O RN Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85. DM3ZL2O RU https://pubmed.ncbi.nlm.nih.gov/23530818 DM40HOY DI DM40HOY DM40HOY DN KLH-2109 DM40HOY TI TT8R70G DM40HOY TN Gonadotropin-releasing hormone receptor (GNRHR) DM40HOY MA Agonist DM40HOY RN Clinical pipeline report, company report or official report of Avarx. DM40HOY RU http://www.avarx.com/AvaRx/SubDomains/bucket2705902527756613996/Listings/bucket5664821816690947691/Public.Listing.display.html DM42B0C DI DM42B0C DM42B0C DN BMS-986253 DM42B0C TI TTCTE1G DM42B0C TN Interleukin-8 (IL8) DM42B0C MA Inhibitor DM42B0C RN Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240. DM42B0C RU https://pubmed.ncbi.nlm.nih.gov/31488216 DM43O9N DI DM43O9N DM43O9N DN LY-334370 DM43O9N TI TT0MI3F DM43O9N TN 5-HT 1F receptor (HTR1F) DM43O9N MA Modulator DM43O9N RN Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4. DM43O9N RU https://www.ncbi.nlm.nih.gov/pubmed/11675061 DM450XS DI DM450XS DM450XS DN BAY 2253651 DM450XS TI TTGR91N DM450XS TN TWIK-related acid-sensitive potassium channel 1 (TASK1) DM450XS MA Inhibitor DM450XS RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM450XS RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM452RF DI DM452RF DM452RF DN RG7880 DM452RF TI TTLDX4N DM452RF TN Interleukin-22 (IL22) DM452RF MA Modulator DM452RF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM452RF RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM457XO DI DM457XO DM457XO DN IW-1701 DM457XO TI TT6HPVC DM457XO TN Guanylate cyclase (GC) DM457XO MA Stimulator DM457XO RN Clinical pipeline report, company report or official report of Cyclerion Therapeutics. DM457XO RU https://www.cyclerion.com/other-clinical-assets/ DM489FT DI DM489FT DM489FT DN GW-870086-X DM489FT TI TTYRL6O DM489FT TN Glucocorticoid receptor (NR3C1) DM489FT MA Agonist DM489FT RN Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7. DM489FT RU https://pubmed.ncbi.nlm.nih.gov/23462748 DM48DPS DI DM48DPS DM48DPS DN AB-729 DM48DPS TI TT43YWN DM48DPS TN Hepatitis B virus messenger RNA (HBV mRNA) DM48DPS MA Inhibitor DM48DPS RN Clinical pipeline report, company report or official report of Arbutus Biopharma. DM48DPS RU http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php DM4AC2F DI DM4AC2F DM4AC2F DN RGI-2001 DM4AC2F TI TT7AKW1 DM4AC2F TN T-cell receptor (TCR) DM4AC2F MA Modulator DM4AC2F RN Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68. DM4AC2F RU https://pubmed.ncbi.nlm.nih.gov/21145405 DM4BLJM DI DM4BLJM DM4BLJM DN Thymoctonan DM4BLJM TI TTF89GD DM4BLJM TN Interleukin-2 (IL2) DM4BLJM MA Modulator DM4BLJM RN Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7. DM4BLJM RU https://pubmed.ncbi.nlm.nih.gov/8530805 DM4BTH8 DI DM4BTH8 DM4BTH8 DN GSK2330672 DM4BTH8 TI TTPI1M5 DM4BTH8 TN Ileal sodium/bile acid cotransporter (SLC10A2) DM4BTH8 MA Modulator DM4BTH8 RN Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. DM4BTH8 RU https://pubmed.ncbi.nlm.nih.gov/23678871 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTV9A7R DM4C7E6 TN Lactoylglutathione lyase (GLO1) DM4C7E6 MA Inhibitor DM4C7E6 RN Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/18258440 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTF8CQI DM4C7E6 TN Tumor necrosis factor (TNF) DM4C7E6 MA Inhibitor DM4C7E6 RN Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/20850306 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT7RJY8 DM4C7E6 TN Xanthine dehydrogenase/oxidase (XDH) DM4C7E6 MA Inhibitor DM4C7E6 RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT2IYXF DM4C7E6 TN L-selectin (SELL) DM4C7E6 MA Inhibitor DM4C7E6 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTNGKET DM4C7E6 TN Prolyl endopeptidase (PREP) DM4C7E6 MA Inhibitor DM4C7E6 RN Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/18650094 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTE5VG0 DM4C7E6 TN P-selectin (SELP) DM4C7E6 MA Inhibitor DM4C7E6 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT2J34L DM4C7E6 TN Arachidonate 5-lipoxygenase (5-LOX) DM4C7E6 MA Inhibitor DM4C7E6 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM4CIKA DI DM4CIKA DM4CIKA DN RDP58 DM4CIKA TI TTF8CQI DM4CIKA TN Tumor necrosis factor (TNF) DM4CIKA MA Inhibitor DM4CIKA RN RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31. DM4CIKA RU https://pubmed.ncbi.nlm.nih.gov/12540016 DM4CJNE DI DM4CJNE DM4CJNE DN AYX-1 DM4CJNE TI TTUQREN DM4CJNE TN Early growth response protein 1 (EGR-1) DM4CJNE MA Inhibitor DM4CJNE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4CJNE RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4EF9Y DI DM4EF9Y DM4EF9Y DN LY-2608204 DM4EF9Y TI TTDLNGZ DM4EF9Y TN Glucokinase (GCK) DM4EF9Y MA Activator DM4EF9Y RN Clinical pipeline report, company report or official report of Eli Lilly. DM4EF9Y RU http://www.lillytrials.com/initiated/initiated.html DM4EHVB DI DM4EHVB DM4EHVB DN PPI-668 DM4EHVB TI TTCJ2X8 DM4EHVB TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM4EHVB MA Modulator DM4EHVB RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EHVB RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4EP6Y DI DM4EP6Y DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE DM4EP6Y TI TTUTN1I DM4EP6Y TN Human Deoxyribonucleic acid (hDNA) DM4EP6Y MA Modulator DM4EP6Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4EP6Y DI DM4EP6Y DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE DM4EP6Y TI TT0IHXV DM4EP6Y TN DNA topoisomerase II (TOP2) DM4EP6Y MA Modulator DM4EP6Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4FBUH DI DM4FBUH DM4FBUH DN EXC 001 DM4FBUH TI TTCJVNE DM4FBUH TN CTGF messenger RNA (CTGF mRNA) DM4FBUH RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DM4FBUH RU http://www.isispharm.com/index.htm DM4FIWC DI DM4FIWC DM4FIWC DN PI-88/Taxotere DM4FIWC TI TTJGNVC DM4FIWC TN Apoptosis regulator Bcl-2 (BCL-2) DM4FIWC MA Modulator DM4FIWC RN Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7. DM4FIWC RU https://pubmed.ncbi.nlm.nih.gov/19917571 DM4FIWC DI DM4FIWC DM4FIWC DN PI-88/Taxotere DM4FIWC TI TT63KYR DM4FIWC TN Tubulin beta-1 chain (TUBB1) DM4FIWC MA Modulator DM4FIWC RN Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7. DM4FIWC RU https://pubmed.ncbi.nlm.nih.gov/19917571 DM4H8EZ DI DM4H8EZ DM4H8EZ DN IFN-alpha DM4H8EZ TI TT95SOA DM4H8EZ TN Interferon alpha (IFNA) DM4H8EZ MA Modulator DM4H8EZ RN WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. DM4H8EZ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2 DM4I6XK DI DM4I6XK DM4I6XK DN TB-402 DM4I6XK TI TT1290U DM4I6XK TN Coagulation factor VIII (F8) DM4I6XK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM4I6XK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM4JFMZ DI DM4JFMZ DM4JFMZ DN T-82 DM4JFMZ TI TT1RS9F DM4JFMZ TN Acetylcholinesterase (AChE) DM4JFMZ MA Inhibitor DM4JFMZ RN Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103. DM4JFMZ RU https://pubmed.ncbi.nlm.nih.gov/12650838 DM4JGNH DI DM4JGNH DM4JGNH DN BAY 1067197 DM4JGNH TI TTK25J1 DM4JGNH TN Adenosine A1 receptor (ADORA1) DM4JGNH MA Modulator DM4JGNH RN Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619. DM4JGNH RU http://www.pnas.org/content/111/12/4614 DM4KOAC DI DM4KOAC DM4KOAC DN AGN-241751 DM4KOAC TI TT9IK2Z DM4KOAC TN N-methyl-D-aspartate receptor (NMDAR) DM4KOAC MA Modulator DM4KOAC RN Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799-808. DM4KOAC RU https://pubmed.ncbi.nlm.nih.gov/33059355 DM4KTN6 DI DM4KTN6 DM4KTN6 DN ASP-3652 DM4KTN6 TI TTMXGCW DM4KTN6 TN Adrenergic receptor beta-3 (ADRB3) DM4KTN6 MA Agonist DM4KTN6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029610) DM4KTN6 RU http://adisinsight.springer.com/drugs/800029610 DM4KWEF DI DM4KWEF DM4KWEF DN S-0509 DM4KWEF TI TTVFO0U DM4KWEF TN Gastrin/cholecystokinin type B receptor (CCKBR) DM4KWEF MA Antagonist DM4KWEF RN Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88. DM4KWEF RU https://pubmed.ncbi.nlm.nih.gov/10759628 DM4L5VJ DI DM4L5VJ DM4L5VJ DN R-phenserine DM4L5VJ TI TT1RS9F DM4L5VJ TN Acetylcholinesterase (AChE) DM4L5VJ MA Inhibitor DM4L5VJ RN An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90. DM4L5VJ RU https://pubmed.ncbi.nlm.nih.gov/15974893 DM4LJH8 DI DM4LJH8 DM4LJH8 DN CYT003 DM4LJH8 TI TTSHG0T DM4LJH8 TN Toll-like receptor 9 (TLR9) DM4LJH8 MA Agonist DM4LJH8 RN CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8. DM4LJH8 RU https://pubmed.ncbi.nlm.nih.gov/26042362 DM4LKFO DI DM4LKFO DM4LKFO DN NELOTANSERIN DM4LKFO TI TTJQOD7 DM4LKFO TN 5-HT 2A receptor (HTR2A) DM4LKFO MA Modulator DM4LKFO RN Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90. DM4LKFO RU https://www.ncbi.nlm.nih.gov/pubmed/19841476 DM4MF9V DI DM4MF9V DM4MF9V DN proglumide DM4MF9V TI TTCG0AL DM4MF9V TN Cholecystokinin receptor type A (CCKAR) DM4MF9V MA Antagonist DM4MF9V RN Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. DM4MF9V RU https://pubmed.ncbi.nlm.nih.gov/3440035 DM4MSLY DI DM4MSLY DM4MSLY DN ZN-c3 DM4MSLY TI TTJFOAL DM4MSLY TN Wee1-like protein kinase (WEE1) DM4MSLY MA Inhibitor DM4MSLY RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DM4MSLY RU https://zentalis.com/our-pipeline/pipeline/ DM4N2O0 DI DM4N2O0 DM4N2O0 DN Apilimod dimesylate DM4N2O0 TI TTA4M1N DM4N2O0 TN Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) DM4N2O0 MA Inhibitor DM4N2O0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4N2O0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4N6EK DI DM4N6EK DM4N6EK DN LY293558 DM4N6EK TI TT0MYE2 DM4N6EK TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM4N6EK MA Modulator DM4N6EK RN Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60. DM4N6EK RU https://pubmed.ncbi.nlm.nih.gov/20942817 DM4N6PF DI DM4N6PF DM4N6PF DN RP-49356 DM4N6PF TI TT1VOHK DM4N6PF TN Potassium channel unspecific (KC) DM4N6PF MA Opener DM4N6PF RN Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92. DM4N6PF RU https://pubmed.ncbi.nlm.nih.gov/2158844 DM4NXWE DI DM4NXWE DM4NXWE DN UB-311 DM4NXWE TI TTE4KHA DM4NXWE TN Amyloid beta A4 protein (APP) DM4NXWE MA Modulator DM4NXWE RN Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7. DM4NXWE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979042/ DM4NY58 DI DM4NY58 DM4NY58 DN SB-623 DM4NY58 TI TT6R7JZ DM4NY58 TN Histone deacetylase 1 (HDAC1) DM4NY58 MA Inhibitor DM4NY58 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM4NY58 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM4O17U DI DM4O17U DM4O17U DN VLTS-589 DM4O17U TI TT69TQN DM4O17U TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4O17U MA Modulator DM4O17U RN AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35. DM4O17U RU http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1914/html DM4OT29 DI DM4OT29 DM4OT29 DN POL-6326 DM4OT29 TI TTBID49 DM4OT29 TN C-X-C chemokine receptor type 4 (CXCR4) DM4OT29 MA Antagonist DM4OT29 RN CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64. DM4OT29 RU https://pubmed.ncbi.nlm.nih.gov/22376154 DM4QHZS DI DM4QHZS DM4QHZS DN BMS-986177 DM4QHZS TI TTDM4ZU DM4QHZS TN Factor XI messenger RNA (F11 mRNA) DM4QHZS MA Inhibitor DM4QHZS RN Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205. DM4QHZS RU https://pubmed.ncbi.nlm.nih.gov/28952381 DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TTQW87Y DM4R23C TN Opioid receptor kappa (OPRK1) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TT27RFC DM4R23C TN Opioid receptor delta (OPRD1) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TTKWM86 DM4R23C TN Opioid receptor mu (MOP) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4RXDQ DI DM4RXDQ DM4RXDQ DN ISIS-HBV DM4RXDQ TI TT43YWN DM4RXDQ TN Hepatitis B virus messenger RNA (HBV mRNA) DM4RXDQ RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM4RXDQ RU https://www.isispharm.com/pipeline/isis-hbvrx/ DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTN7BL9 DM4SOAW TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM4SOAW MA Inhibitor DM4SOAW RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/20100662 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TT9V5JH DM4SOAW TN Phospholipase A2 (PLA2G1B) DM4SOAW MA Inhibitor DM4SOAW RN Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/15993585 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTIU7X1 DM4SOAW TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM4SOAW MA Inhibitor DM4SOAW RN DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/10654412 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTZHY6R DM4SOAW TN Glycogen phosphorylase muscle form (GP) DM4SOAW MA Inhibitor DM4SOAW RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/19642687 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTELIN2 DM4SOAW TN PTPN1 messenger RNA (PTPN1 mRNA) DM4SOAW MA Inhibitor DM4SOAW RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/19836230 DM4T9RS DI DM4T9RS DM4T9RS DN ATN-161 DM4T9RS TI TT69TQN DM4T9RS TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4T9RS MA Antagonist DM4T9RS RN A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80. DM4T9RS RU https://pubmed.ncbi.nlm.nih.gov/16985061 DM4T9RS DI DM4T9RS DM4T9RS DN ATN-161 DM4T9RS TI TTH4QIS DM4T9RS TN Integrin alpha-5/beta-1 (ITGA5/B1) DM4T9RS MA Antagonist DM4T9RS RN A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80. DM4T9RS RU https://pubmed.ncbi.nlm.nih.gov/16985061 DM4V8WF DI DM4V8WF DM4V8WF DN Cenicriviroc DM4V8WF TI TT2CEJG DM4V8WF TN C-C chemokine receptor type 5 (CCR5) DM4V8WF MA Modulator DM4V8WF RN The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6. DM4V8WF RU https://pubmed.ncbi.nlm.nih.gov/25433008 DM4V8WF DI DM4V8WF DM4V8WF DN Cenicriviroc DM4V8WF TI TTFZYTO DM4V8WF TN C-C chemokine receptor type 2 (CCR2) DM4V8WF MA Antagonist DM4V8WF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4V8WF RU http://phrma-docs.phrma.org/files/dmfile/2017-HIV-AIDS-MID-Drug-List.pdf DM4VWXI DI DM4VWXI DM4VWXI DN [131I]-Metuximab DM4VWXI TI TT5UJWD DM4VWXI TN Basigin (BSG) DM4VWXI RN Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44. DM4VWXI RU https://pubmed.ncbi.nlm.nih.gov/16690431 DM4W28K DI DM4W28K DM4W28K DN NCX 1022 DM4W28K TI TTK0943 DM4W28K TN Prostaglandin G/H synthase (COX) DM4W28K MA Modulator DM4W28K RN Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. DM4W28K RU https://pubmed.ncbi.nlm.nih.gov/15313880 DM4WHOS DI DM4WHOS DM4WHOS DN KPP203 DM4WHOS TI TT7BQRM DM4WHOS TN Sphingosine-1 phosphate receptor (S1PR) DM4WHOS MA Agonist DM4WHOS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WHOS RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM4XMF7 DI DM4XMF7 DM4XMF7 DN LY2606368 DM4XMF7 TI TTTU902 DM4XMF7 TN Checkpoint kinase-1 (CHK1) DM4XMF7 MA Inhibitor DM4XMF7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4XMF7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4ZIDH DI DM4ZIDH DM4ZIDH DN Xentuzumab DM4ZIDH TI TTT6LOU DM4ZIDH TN Insulin-like growth factor-I (IGF1) DM4ZIDH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZIDH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4ZIDH DI DM4ZIDH DM4ZIDH DN Xentuzumab DM4ZIDH TI TTE8WGO DM4ZIDH TN Insulin-like growth factor-II (IGF2) DM4ZIDH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZIDH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4ZLTY DI DM4ZLTY DM4ZLTY DN ABBV-2222 DM4ZLTY TI TTRLZHP DM4ZLTY TN cAMP-dependent chloride channel (CFTR) DM4ZLTY MA Modulator DM4ZLTY RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM4ZLTY RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM50M2R DI DM50M2R DM50M2R DN JTT-654 DM50M2R TI TTN7BL9 DM50M2R TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM50M2R MA Inhibitor DM50M2R RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DM50M2R RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DM50Z4U DI DM50Z4U DM50Z4U DN Milataxel DM50Z4U TI TTML2WA DM50Z4U TN Tubulin (TUB) DM50Z4U MA Inhibitor DM50Z4U RN J Clin Oncol 28, 2010 (suppl; abstr e13075). DM50Z4U RU http://meetinglibrary.asco.org/content/54296-74 DM51LTG DI DM51LTG DM51LTG DN BMS-708163 DM51LTG TI TT9W8GU DM51LTG TN Gamma-secretase (GS) DM51LTG MA Modulator DM51LTG RN Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40. DM51LTG RU https://pubmed.ncbi.nlm.nih.gov/22892585 DM524GR DI DM524GR DM524GR DN ICP-192 DM524GR TI TT0LF7H DM524GR TN Fibroblast growth factor receptor (FGFR) DM524GR MA Inhibitor DM524GR RN Clinical pipeline report, company report or official report of InnoCare Pharma. DM524GR RU https://www.innocarepharma.com/en/pipeline/our-pipeline/ DM52HUD DI DM52HUD DM52HUD DN Dexloxiglumide DM52HUD TI TTVFO0U DM52HUD TN Gastrin/cholecystokinin type B receptor (CCKBR) DM52HUD MA Inhibitor DM52HUD RN Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7. DM52HUD RU https://pubmed.ncbi.nlm.nih.gov/9341915 DM52HUD DI DM52HUD DM52HUD DN Dexloxiglumide DM52HUD TI TTCG0AL DM52HUD TN Cholecystokinin receptor type A (CCKAR) DM52HUD MA Inhibitor DM52HUD RN Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9. DM52HUD RU https://pubmed.ncbi.nlm.nih.gov/2464062 DM548TK DI DM548TK DM548TK DN KD025 DM548TK TI TTGWKQJ DM548TK TN Rho-associated protein kinase 2 (ROCK2) DM548TK MA Inhibitor DM548TK RN Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. DM548TK RU https://pubmed.ncbi.nlm.nih.gov/25385601 DM54MAJ DI DM54MAJ DM54MAJ DN YF-476 DM54MAJ TI TTVFO0U DM54MAJ TN Gastrin/cholecystokinin type B receptor (CCKBR) DM54MAJ MA Inhibitor DM54MAJ RN CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90. DM54MAJ RU https://pubmed.ncbi.nlm.nih.gov/15513388 DM563NC DI DM563NC DM563NC DN Fasitibant chloride DM563NC TI TTGY8IW DM563NC TN B2 bradykinin receptor (BDKRB2) DM563NC MA Antagonist DM563NC RN Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10. DM563NC RU https://pubmed.ncbi.nlm.nih.gov/22251015 DM57TY3 DI DM57TY3 DM57TY3 DN 9-ING-41 DM57TY3 TI TTRSMW9 DM57TY3 TN Glycogen synthase kinase-3 beta (GSK-3B) DM57TY3 MA Inhibitor DM57TY3 RN 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. DM57TY3 RU https://pubmed.ncbi.nlm.nih.gov/31882719 DM58HR7 DI DM58HR7 DM58HR7 DN SC-75416 DM58HR7 TI TTVKILB DM58HR7 TN Prostaglandin G/H synthase 2 (COX-2) DM58HR7 MA Inhibitor DM58HR7 RN Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66. DM58HR7 RU https://pubmed.ncbi.nlm.nih.gov/17882158 DM59OJ2 DI DM59OJ2 DM59OJ2 DN Abicipar pegol DM59OJ2 TI TTOHSBA DM59OJ2 TN Vascular endothelial growth factor A (VEGFA) DM59OJ2 MA Inhibitor DM59OJ2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM59OJ2 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM5BL4C DI DM5BL4C DM5BL4C DN Veltuzumab DM5BL4C TI TTUE541 DM5BL4C TN Leukocyte surface antigen Leu-16 (CD20) DM5BL4C MA Modulator DM5BL4C RN Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7. DM5BL4C RU https://pubmed.ncbi.nlm.nih.gov/19330725 DM5C70M DI DM5C70M DM5C70M DN T-607 DM5C70M TI TTYFKSZ DM5C70M TN Tubulin beta (TUBB) DM5C70M MA Inhibitor DM5C70M RN Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476. DM5C70M RU http://www.sciencedirect.com/science/article/pii/0040402072880293 DM5CB8U DI DM5CB8U DM5CB8U DN DELTIBANT DM5CB8U TI TTGY8IW DM5CB8U TN B2 bradykinin receptor (BDKRB2) DM5CB8U MA Modulator DM5CB8U RN CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20. DM5CB8U RU https://pubmed.ncbi.nlm.nih.gov/1462875 DM5D6Y7 DI DM5D6Y7 DM5D6Y7 DN OBI-3424 DM5D6Y7 TI TTUTN1I DM5D6Y7 TN Human Deoxyribonucleic acid (hDNA) DM5D6Y7 RN OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. DM5D6Y7 RU https://pubmed.ncbi.nlm.nih.gov/31015346 DM5DSGJ DI DM5DSGJ DM5DSGJ DN MD-0727 DM5DSGJ TI TTNA5ZS DM5DSGJ TN Cholesterol absorption (Chole absorp) DM5DSGJ MA Modulator DM5DSGJ RN Th-P16:297 Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects. Atherosclerosis Supplements Volume 7, Issue 3, 2006, Pages 558-559. DM5DSGJ RU http://www.sciencedirect.com/science/article/pii/S1567568806822555 DM5EFXZ DI DM5EFXZ DM5EFXZ DN Alpha-1 antitrypsin DM5EFXZ TI TT2WR1T DM5EFXZ TN Cationic trypsinogen (PRSS1) DM5EFXZ MA Modulator DM5EFXZ RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM5EFXZ RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM5F0QY DI DM5F0QY DM5F0QY DN IONIS-416858 DM5F0QY TI TTDM4ZU DM5F0QY TN Factor XI messenger RNA (F11 mRNA) DM5F0QY MA Inhibitor DM5F0QY RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM5F0QY RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM5GAC4 DI DM5GAC4 DM5GAC4 DN SRD-441 DM5GAC4 TI TTZBFA0 DM5GAC4 TN Protease unspecific (PRO) DM5GAC4 MA Inhibitor DM5GAC4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807) DM5GAC4 RU http://adisinsight.springer.com/drugs/800029807 DM5GKYD DI DM5GKYD DM5GKYD DN CDX-3379 DM5GKYD TI TTDC8N2 DM5GKYD TN Erbb3 tyrosine kinase receptor (Erbb-3) DM5GKYD MA Antagonist DM5GKYD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5GKYD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM5GQD7 DI DM5GQD7 DM5GQD7 DN Metoprine DM5GQD7 TI TT9SL3Q DM5GQD7 TN Polypeptide deformylase (PDF) DM5GQD7 MA Inhibitor DM5GQD7 RN Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. DM5GQD7 RU https://pubmed.ncbi.nlm.nih.gov/16612649 DM5GQD7 DI DM5GQD7 DM5GQD7 DN Metoprine DM5GQD7 TI TT2B6EV DM5GQD7 TN Histamine N-methyltransferase (HNMT) DM5GQD7 MA Inhibitor DM5GQD7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5GQD7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5H8V1 DI DM5H8V1 DM5H8V1 DN PF-06826647 DM5H8V1 TI TTBYWP2 DM5H8V1 TN TYK2 tyrosine kinase (TYK2) DM5H8V1 MA Inhibitor DM5H8V1 RN Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577. DM5H8V1 RU https://pubmed.ncbi.nlm.nih.gov/32787094 DM5HMTB DI DM5HMTB DM5HMTB DN Porphobilinogen DM5HMTB TI TTJHKYD DM5HMTB TN Delta-aminolevulinic acid dehydratase (ALAD) DM5HMTB MA Inhibitor DM5HMTB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5HMTB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5HPZU DI DM5HPZU DM5HPZU DN NOX-H94 DM5HPZU TI TTPCG5T DM5HPZU TN Hepcidin (HAMP) DM5HPZU MA Inhibitor DM5HPZU RN The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5. DM5HPZU RU https://pubmed.ncbi.nlm.nih.gov/23349391 DM5IX9M DI DM5IX9M DM5IX9M DN LY-156735 DM5IX9M TI TT0WAIE DM5IX9M TN Melatonin receptor type 1A (MTNR1A) DM5IX9M MA Agonist DM5IX9M RN Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25. DM5IX9M RU https://pubmed.ncbi.nlm.nih.gov/16183237 DM5LM3O DI DM5LM3O DM5LM3O DN IONIS-DNM2-2.5Rx DM5LM3O TI TTVRA5G DM5LM3O TN DNM2 messenger RNA (DNM2 mRNA) DM5LM3O MA Inhibitor DM5LM3O RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM5LM3O RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM5LQEI DI DM5LQEI DM5LQEI DN Leuvectin DM5LQEI TI TTF89GD DM5LQEI TN Interleukin-2 (IL2) DM5LQEI MA Modulator DM5LQEI RN Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6. DM5LQEI RU https://pubmed.ncbi.nlm.nih.gov/10854152 DM5N4OA DI DM5N4OA DM5N4OA DN KVD824 DM5N4OA TI TTMF8H9 DM5N4OA TN Plasma kallikrein (KLKB1) DM5N4OA MA Inhibitor DM5N4OA RN Clinical pipeline report, company report or official report of KalVista Pharmaceuticals. DM5N4OA RU https://www.kalvista.com/products-pipeline/kvd824-hae DM5NC39 DI DM5NC39 DM5NC39 DN SAGE-324 DM5NC39 TI TTCI43M DM5NC39 TN GABA(A) receptor (GABAR) DM5NC39 MA Modulator DM5NC39 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM5NC39 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM5O6GC DI DM5O6GC DM5O6GC DN ONO-9054 DM5O6GC TI TTT2ZAR DM5O6GC TN Prostaglandin F2-alpha receptor (PTGFR) DM5O6GC MA Modulator DM5O6GC RN IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52. DM5O6GC RU https://pubmed.ncbi.nlm.nih.gov/25788650 DM5O6GC DI DM5O6GC DM5O6GC DN ONO-9054 DM5O6GC TI TTPNGDE DM5O6GC TN Prostaglandin E2 receptor EP3 (PTGER3) DM5O6GC MA Modulator DM5O6GC RN IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52. DM5O6GC RU https://pubmed.ncbi.nlm.nih.gov/25788650 DM5OU2W DI DM5OU2W DM5OU2W DN BMS-986253 DM5OU2W TI TT3JF7X DM5OU2W TN HUMAN interleukin 8 (IL8) DM5OU2W MA Inhibitor DM5OU2W RN ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health. DM5OU2W RU https://clinicaltrials.gov/ct2/show/NCT04347226 DM5PBLM DI DM5PBLM DM5PBLM DN EYP001 DM5PBLM TI TTS4UGC DM5PBLM TN Farnesoid X-activated receptor (FXR) DM5PBLM MA Agonist DM5PBLM RN Clinical pipeline report, company report or official report of ENYO Pharma. DM5PBLM RU http://www.enyopharma.com/pipeline/eyp001-in-nash/ DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTVIAT9 DM5Q9RY TN Phosphodiesterase 4B (PDE4B) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTSKMI8 DM5Q9RY TN Phosphodiesterase 4D (PDE4D) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTZ97H5 DM5Q9RY TN Phosphodiesterase 4A (PDE4A) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5R89X DI DM5R89X DM5R89X DN SARIPIDEM DM5R89X TI TTEX6LM DM5R89X TN GABA(A) receptor gamma-3 (GABRG3) DM5R89X MA Modulator DM5R89X RN Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol. 1995 Mar;6(2):116-126. DM5R89X RU https://pubmed.ncbi.nlm.nih.gov/11224318 DM5RAB9 DI DM5RAB9 DM5RAB9 DN RG-7234 DM5RAB9 TI TT9H85R DM5RAB9 TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DM5RAB9 MA Inhibitor DM5RAB9 RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DM5RAB9 RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DM5TC43 DI DM5TC43 DM5TC43 DN AR-12286 DM5TC43 TI TTMQO60 DM5TC43 TN Rho-associated protein kinase (ROCK) DM5TC43 MA Modulator DM5TC43 RN Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1. DM5TC43 RU https://pubmed.ncbi.nlm.nih.gov/21794845 DM5TMYC DI DM5TMYC DM5TMYC DN iOWH032 DM5TMYC TI TTRLZHP DM5TMYC TN cAMP-dependent chloride channel (CFTR) DM5TMYC MA Inhibitor DM5TMYC RN Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25. DM5TMYC RU https://pubmed.ncbi.nlm.nih.gov/21859305 DM5UFRO DI DM5UFRO DM5UFRO DN Itriglumide DM5UFRO TI TTVFO0U DM5UFRO TN Gastrin/cholecystokinin type B receptor (CCKBR) DM5UFRO MA Antagonist DM5UFRO RN Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231. DM5UFRO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718729/ DM5WK0J DI DM5WK0J DM5WK0J DN ARQ 092 DM5WK0J TI TTAZ05C DM5WK0J TN RAC-gamma serine/threonine-protein kinase (AKT3) DM5WK0J MA Modulator DM5WK0J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5WK0J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5WK0J DI DM5WK0J DM5WK0J DN ARQ 092 DM5WK0J TI TTWTSCV DM5WK0J TN RAC-alpha serine/threonine-protein kinase (AKT1) DM5WK0J MA Inhibitor DM5WK0J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5WK0J RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM5WZ0O DI DM5WZ0O DM5WZ0O DN EDP-420 DM5WZ0O TI TTLFGBV DM5WZ0O TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM5WZ0O MA Inhibitor DM5WZ0O RN EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670. DM5WZ0O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855536/ DM5XRMA DI DM5XRMA DM5XRMA DN Tipapkinogene sovacivec DM5XRMA TI TTE2N95 DM5XRMA TN Human papillomavirus protein E6 (HPV E6) DM5XRMA MA Modulator DM5XRMA RN Immune therapy for human papillomaviruses-related cancers DM5XRMA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927 DM5XRMA DI DM5XRMA DM5XRMA DN Tipapkinogene sovacivec DM5XRMA TI TT3CPZW DM5XRMA TN Human papillomavirus protein E7 (HPV E7) DM5XRMA MA Modulator DM5XRMA RN Immune therapy for human papillomaviruses-related cancers DM5XRMA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927 DM5XT3G DI DM5XT3G DM5XT3G DN DE-098 DM5XT3G TI TTF0RCZ DM5XT3G TN Apoptosis mediating surface antigen FAS (FAS) DM5XT3G RN ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221. DM5XT3G RU http://www.biomedcentral.com/1471-2474/11/221 DM5XYFH DI DM5XYFH DM5XYFH DN SGS742 DM5XYFH TI TTDCVZW DM5XYFH TN Gamma-aminobutyric acid B receptor (GABBR) DM5XYFH MA Modulator DM5XYFH RN SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87. DM5XYFH RU https://pubmed.ncbi.nlm.nih.gov/15451390 DM5Z34K DI DM5Z34K DM5Z34K DN UCB-35440 DM5Z34K TI TT2J34L DM5Z34K TN Arachidonate 5-lipoxygenase (5-LOX) DM5Z34K MA Modulator DM5Z34K RN The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71. DM5Z34K RU https://pubmed.ncbi.nlm.nih.gov/15627437 DM5Z34K DI DM5Z34K DM5Z34K DN UCB-35440 DM5Z34K TI TTTIBOJ DM5Z34K TN Histamine H1 receptor (H1R) DM5Z34K MA Modulator DM5Z34K RN The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71. DM5Z34K RU https://pubmed.ncbi.nlm.nih.gov/15627437 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TTV3XPL DM5Z3VP TN T-cell surface glycoprotein CD3 gamma (CD3G) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TTZAT79 DM5Z3VP TN T-cell surface glycoprotein CD3 epsilon (CD3E) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TT6EO5L DM5Z3VP TN Erbb2 tyrosine kinase receptor (HER2) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5ZTE4 DI DM5ZTE4 DM5ZTE4 DN PRO-001 DM5ZTE4 TI TT2EDHU DM5ZTE4 TN Insulin-degrading enzyme (IDE) DM5ZTE4 MA Modulator DM5ZTE4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2371). DM5ZTE4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2371 DM60G5O DI DM60G5O DM60G5O DN KB002/003 DM60G5O TI TTNYZG2 DM60G5O TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM60G5O MA Modulator DM60G5O RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM60G5O RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM63P1W DI DM63P1W DM63P1W DN Descartes-08 DM63P1W TI TTZ3P4W DM63P1W TN B-cell maturation protein (TNFRSF17) DM63P1W MA CAR-T-Cell-Therapy DM63P1W RN ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma DM63P1W RU https://clinicaltrials.gov/ct2/show/NCT03448978 DM63QY0 DI DM63QY0 DM63QY0 DN SAR292833 DM63QY0 TI TT946IA DM63QY0 TN Transient receptor potential cation channel V3 (TRPV3) DM63QY0 MA Modulator DM63QY0 RN Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44. DM63QY0 RU https://pubmed.ncbi.nlm.nih.gov/23848361 DM64NYP DI DM64NYP DM64NYP DN TRN-157 DM64NYP TI TTQ13Z5 DM64NYP TN Muscarinic acetylcholine receptor M3 (CHRM3) DM64NYP MA Antagonist DM64NYP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15). DM64NYP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15 DM64ZYM DI DM64ZYM DM64ZYM DN GPI-1485 DM64ZYM TI TTMW94E DM64ZYM TN FK506-binding protein 1A (FKBP1A) DM64ZYM MA Binder DM64ZYM RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DM64ZYM RU https://pubmed.ncbi.nlm.nih.gov/18991661 DM652CM DI DM652CM DM652CM DN RV-568 DM652CM TI TTU8W4S DM652CM TN Protein kinase (PK) DM652CM MA Inhibitor DM652CM RN Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DM652CM RU https://pubmed.ncbi.nlm.nih.gov/25599809 DM65PTO DI DM65PTO DM65PTO DN AMG 232 DM65PTO TI TT08GJW DM65PTO TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM65PTO MA Modulator DM65PTO RN Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41. DM65PTO RU https://pubmed.ncbi.nlm.nih.gov/24967612 DM67EMK DI DM67EMK DM67EMK DN SCH-900776 DM67EMK TI TTTU902 DM67EMK TN Checkpoint kinase-1 (CHK1) DM67EMK MA Inhibitor DM67EMK RN Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. DM67EMK RU https://pubmed.ncbi.nlm.nih.gov/21321066 DM68K39 DI DM68K39 DM68K39 DN ETIPREDNOL DICLOACETATE DM68K39 TI TTYRL6O DM68K39 TN Glucocorticoid receptor (NR3C1) DM68K39 MA Modulator DM68K39 RN Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.Int J Inflam.2012;2012:789623. DM68K39 RU https://www.ncbi.nlm.nih.gov/pubmed/22536546 DM69NF1 DI DM69NF1 DM69NF1 DN EP-101 DM69NF1 TI TTOXS3C DM69NF1 TN Muscarinic acetylcholine receptor (CHRM) DM69NF1 MA Antagonist DM69NF1 RN Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17. DM69NF1 RU https://pubmed.ncbi.nlm.nih.gov/23274274 DM6ABD9 DI DM6ABD9 DM6ABD9 DN ATHX-105 DM6ABD9 TI TTWJBZ5 DM6ABD9 TN 5-HT 2C receptor (HTR2C) DM6ABD9 MA Agonist DM6ABD9 RN Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60. DM6ABD9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/ DM6AI9N DI DM6AI9N DM6AI9N DN AZD-2927 DM6AI9N TI TTM7WCE DM6AI9N TN Ion channel unspecific (IC) DM6AI9N MA Modulator DM6AI9N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704). DM6AI9N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7704 DM6AJKC DI DM6AJKC DM6AJKC DN AFN-1720 DM6AJKC TI TTVTX4N DM6AJKC TN Bacterial Fatty acid synthetase I (Bact inhA) DM6AJKC MA Inhibitor DM6AJKC RN Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM. DM6AJKC RU http://www.virtualizationconference.com/node/2779672 DM6B9HP DI DM6B9HP DM6B9HP DN Apomine DM6B9HP TI TTS4UGC DM6B9HP TN Farnesoid X-activated receptor (FXR) DM6B9HP MA Agonist DM6B9HP RN The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59. DM6B9HP RU https://pubmed.ncbi.nlm.nih.gov/11254888 DM6BKG2 DI DM6BKG2 DM6BKG2 DN VVP-808 DM6BKG2 TI TTCBFJO DM6BKG2 TN Insulin receptor (INSR) DM6BKG2 MA Modulator DM6BKG2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM6BKG2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM6CNFW DI DM6CNFW DM6CNFW DN RG7686 DM6CNFW TI TTJTSX4 DM6CNFW TN Glypican-3 (GPC3) DM6CNFW RN First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8. DM6CNFW RU https://pubmed.ncbi.nlm.nih.gov/23362325 DM6CVZ5 DI DM6CVZ5 DM6CVZ5 DN Bavisant DM6CVZ5 TI TT9JNIC DM6CVZ5 TN Histamine H3 receptor (H3R) DM6CVZ5 MA Antagonist DM6CVZ5 RN Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34. DM6CVZ5 RU https://pubmed.ncbi.nlm.nih.gov/22519922 DM6DK9A DI DM6DK9A DM6DK9A DN PVX-410 DM6DK9A TI TT7ILZ1 DM6DK9A TN SLAM family member 7 SLAMF7 (CS1) DM6DK9A MA Modulator DM6DK9A RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DM6DK9A RU https://pubmed.ncbi.nlm.nih.gov/25764988 DM6DKF9 DI DM6DKF9 DM6DKF9 DN GSK961081 DM6DKF9 TI TT2CJVK DM6DKF9 TN Adrenergic receptor beta-2 (ADRB2) DM6DKF9 MA Modulator DM6DKF9 RN Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and 2-adrenoceptor agonist properties.J Pharmacol Exp Ther.2014 Oct;351(1):190-9. DM6DKF9 RU https://www.ncbi.nlm.nih.gov/pubmed/25100753 DM6DL5K DI DM6DL5K DM6DL5K DN Leridistim DM6DL5K TI TTPYS82 DM6DL5K TN Interleukin 3 receptor (CSF2RB) DM6DL5K MA Agonist DM6DL5K RN Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33. DM6DL5K RU https://pubmed.ncbi.nlm.nih.gov/11713344 DM6EIZG DI DM6EIZG DM6EIZG DN BIM23A760 DM6EIZG TI TT2J34L DM6EIZG TN Arachidonate 5-lipoxygenase (5-LOX) DM6EIZG MA Inhibitor DM6EIZG RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DM6EIZG RU https://pubmed.ncbi.nlm.nih.gov/10940813 DM6EIZG DI DM6EIZG DM6EIZG DN BIM23A760 DM6EIZG TI TTEX248 DM6EIZG TN Dopamine D2 receptor (D2R) DM6EIZG MA Modulator DM6EIZG RN BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. DM6EIZG RU https://pubmed.ncbi.nlm.nih.gov/16625841 DM6F5EV DI DM6F5EV DM6F5EV DN PD-360324 DM6F5EV TI TT731LW DM6F5EV TN Colony stimulating factor-1 receptor (CSF-1R) DM6F5EV MA Modulator DM6F5EV RN Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70. DM6F5EV RU https://www.ncbi.nlm.nih.gov/pubmed/26376111 DM6HBGN DI DM6HBGN DM6HBGN DN GSK-1399686 DM6HBGN TI TTUWYEA DM6HBGN TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM6HBGN MA Modulator DM6HBGN RN Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015 March; 8(2): 66-82. DM6HBGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314302/ DM6HJ3V DI DM6HJ3V DM6HJ3V DN ASP0819 DM6HJ3V TI TT7M9I6 DM6HJ3V TN Calcium-activated potassium channel KCa3.1 (KCNN4) DM6HJ3V MA Activator DM6HJ3V RN Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369. DM6HJ3V RU https://pubmed.ncbi.nlm.nih.gov/33328761 DM6IQ3V DI DM6IQ3V DM6IQ3V DN IMO-2055 DM6IQ3V TI TTSHG0T DM6IQ3V TN Toll-like receptor 9 (TLR9) DM6IQ3V MA Agonist DM6IQ3V RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DM6IQ3V RU http://www.iderapharma.com/ DM6JTSZ DI DM6JTSZ DM6JTSZ DN MB-07811 DM6JTSZ TI TTGER3L DM6JTSZ TN Thyroid hormone receptor beta (THRB) DM6JTSZ MA Modulator DM6JTSZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589). DM6JTSZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589 DM6L5TR DI DM6L5TR DM6L5TR DN EGEN-001 DM6L5TR TI TTGW72V DM6L5TR TN Interleukin-12 beta (IL12B) DM6L5TR MA Modulator DM6L5TR RN National Cancer Institute Drug Dictionary (drug id 454593). DM6L5TR RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=454593 DM6MUCX DI DM6MUCX DM6MUCX DN CpG-10101 DM6MUCX TI TTSHG0T DM6MUCX TN Toll-like receptor 9 (TLR9) DM6MUCX MA Agonist DM6MUCX RN Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51. DM6MUCX RU https://pubmed.ncbi.nlm.nih.gov/17713157 DM6N05H DI DM6N05H DM6N05H DN BIO-11006 DM6N05H TI TTHRM39 DM6N05H TN Myristoylated alanine-rich C-kinase substrate (MARCKS) DM6N05H MA Inhibitor DM6N05H RN Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation. Exp Lung Res. 2010 Mar;36(2):75-84. DM6N05H RU https://pubmed.ncbi.nlm.nih.gov/20205598 DM6OC53 DI DM6OC53 DM6OC53 DN PDX-101 DM6OC53 TI TTBH0VX DM6OC53 TN Histone deacetylase (HDAC) DM6OC53 MA Modulator DM6OC53 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM6OC53 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM6OFJ8 DI DM6OFJ8 DM6OFJ8 DN Indibulin DM6OFJ8 TI TTML2WA DM6OFJ8 TN Tubulin (TUB) DM6OFJ8 MA Stablizer DM6OFJ8 RN 2011 Pipeline of ZioPharm. DM6OFJ8 RU http://www.ziopharm.com/clinical_dev.php DM6OLGC DI DM6OLGC DM6OLGC DN MK-3207 DM6OLGC TI TTY6O0Q DM6OLGC TN Calcitonin gene-related peptide receptor (CGRPR) DM6OLGC MA Antagonist DM6OLGC RN Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. DM6OLGC RU https://pubmed.ncbi.nlm.nih.gov/20065019 DM6P91T DI DM6P91T DM6P91T DN INGN-241 DM6P91T TI TT1EPXZ DM6P91T TN Interleukin-24 (IL24) DM6P91T MA Inhibitor DM6P91T RN Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan;11(1):160-72. DM6P91T RU https://pubmed.ncbi.nlm.nih.gov/15585417 DM6PBUM DI DM6PBUM DM6PBUM DN Birinapant DM6PBUM TI TTR7B60 DM6PBUM TN X-linked inhibitor of apoptosis protein (XIAP) DM6PBUM MA Modulator DM6PBUM RN cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. DM6PBUM RU https://pubmed.ncbi.nlm.nih.gov/24497535 DM6PBUM DI DM6PBUM DM6PBUM DN Birinapant DM6PBUM TI TTQ5LRD DM6PBUM TN Cellular inhibitor of apoptosis 1 (BIRC2) DM6PBUM MA Modulator DM6PBUM RN cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. DM6PBUM RU https://pubmed.ncbi.nlm.nih.gov/24497535 DM6PDX2 DI DM6PDX2 DM6PDX2 DN IONIS-C9Rx DM6PDX2 TI TTA4SHR DM6PDX2 TN C9orf72 messenger RNA (C9orf72 mRNA) DM6PDX2 MA Inhibitor DM6PDX2 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM6PDX2 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM6PTIX DI DM6PTIX DM6PTIX DN ABT-981 DM6PTIX TI TTPM6HI DM6PTIX TN Interleukin-1 alpha (IL1A) DM6PTIX MA Modulator DM6PTIX RN Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19. DM6PTIX RU https://pubmed.ncbi.nlm.nih.gov/25764208 DM6PTIX DI DM6PTIX DM6PTIX DN ABT-981 DM6PTIX TI TTRYK0X DM6PTIX TN Interleukin-1 beta (IL1B) DM6PTIX MA Modulator DM6PTIX RN Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19. DM6PTIX RU https://pubmed.ncbi.nlm.nih.gov/25764208 DM6Q295 DI DM6Q295 DM6Q295 DN SAR566658 DM6Q295 TI TTCFSPE DM6Q295 TN Carbonic anhydrase VI (CA-VI) DM6Q295 MA Inhibitor DM6Q295 RN An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669. DM6Q295 RU https://pubmed.ncbi.nlm.nih.gov/32451330 DM6RBYT DI DM6RBYT DM6RBYT DN ALD-403 DM6RBYT TI TTAFORY DM6RBYT TN Calcitonin gene-related peptide (CALC) DM6RBYT MA Modulator DM6RBYT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM6RBYT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM6RKG3 DI DM6RKG3 DM6RKG3 DN Fadolmidine DM6RKG3 TI TT2NUT5 DM6RKG3 TN Adrenergic receptor alpha-2C (ADRA2C) DM6RKG3 MA Agonist DM6RKG3 RN Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26. DM6RKG3 RU https://pubmed.ncbi.nlm.nih.gov/15179442 DM6RKG3 DI DM6RKG3 DM6RKG3 DN Fadolmidine DM6RKG3 TI TTQ8AFT DM6RKG3 TN Adrenergic receptor Alpha-2 (ADRA2) DM6RKG3 MA Agonist DM6RKG3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RKG3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM6RQXB DI DM6RQXB DM6RQXB DN CNTO-6785 DM6RQXB TI TTG0MT6 DM6RQXB TN Interleukin-17 (IL17) DM6RQXB RN Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. DM6RQXB RU https://pubmed.ncbi.nlm.nih.gov/25549584 DM6RQXB DI DM6RQXB DM6RQXB DN CNTO-6785 DM6RQXB TI TT69OHW DM6RQXB TN Interleukin 17 receptor (IL17R) DM6RQXB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RQXB RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM6RTVG DI DM6RTVG DM6RTVG DN Urelumab DM6RTVG TI TTPW9LJ DM6RTVG TN Co-stimulatory molecule 4-1BB (CD137) DM6RTVG MA Agonist DM6RTVG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RTVG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6S83X DI DM6S83X DM6S83X DN NDDP DM6S83X TI TTUTN1I DM6S83X TN Human Deoxyribonucleic acid (hDNA) DM6S83X MA Binder DM6S83X RN Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6. DM6S83X RU https://pubmed.ncbi.nlm.nih.gov/8017841 DM6SANW DI DM6SANW DM6SANW DN TD-5108 DM6SANW TI TT07C3Y DM6SANW TN 5-HT 4 receptor (HTR4) DM6SANW MA Agonist DM6SANW RN The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37. DM6SANW RU https://pubmed.ncbi.nlm.nih.gov/18415081 DM6TAFE DI DM6TAFE DM6TAFE DN TTAC-0001 DM6TAFE TI TTUTJGQ DM6TAFE TN Vascular endothelial growth factor receptor 2 (KDR) DM6TAFE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM6TAFE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM6UGHA DI DM6UGHA DM6UGHA DN DSP-6952 DM6UGHA TI TT07C3Y DM6UGHA TN 5-HT 4 receptor (HTR4) DM6UGHA MA Agonist DM6UGHA RN DSP-6952, a high affinity serotonin (5-HT4) receptor partial agonist. Sumitomo Dainippon Pharma Co. Ltd. DM6UGHA RU http://www.biocentury.com/products/dsp-6952 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TTI3NXG DM6UQNW TN Human immunodeficiency virus Matrix p17 (HIV MA) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TT84ETX DM6UQNW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TT4NXYM DM6UQNW TN Human immunodeficiency virus Negative factor (HIV nef) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TTTWS2G DM6UQNW TN Human immunodeficiency virus Capsid p24 (HIV p24) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6VPIO DI DM6VPIO DM6VPIO DN MM36 DM6VPIO TI TT0JLSD DM6VPIO TN Multidrug resistance protein (MDR) DM6VPIO MA Inhibitor DM6VPIO RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DM6VPIO RU https://pubmed.ncbi.nlm.nih.gov/19442032 DM6VQTF DI DM6VQTF DM6VQTF DN ZEN-3694 DM6VQTF TI TTE4BSY DM6VQTF TN Bromodomain and extraterminal domain protein (BET) DM6VQTF MA Inhibitor DM6VQTF RN Clinical pipeline report, company report or official report of Zenith Epigenetics. DM6VQTF RU https://www.zenithepigenetics.com/programs/pipeline DM6WN2D DI DM6WN2D DM6WN2D DN ABT-308 DM6WN2D TI TTMPZ7V DM6WN2D TN Interleukin 13 receptor alpha-2 (IL13RA2) DM6WN2D MA Antagonist DM6WN2D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6WN2D RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM6X70G DI DM6X70G DM6X70G DN ABI-H2158 DM6X70G TI TTM42UJ DM6X70G TN Hepatitis B virus Capsid protein (HBV C) DM6X70G MA Inhibitor DM6X70G RN Clinical pipeline report, company report or official report of Assembly Biosciences. DM6X70G RU https://www.assemblybio.com/pipeline/ DM6XJ9S DI DM6XJ9S DM6XJ9S DN SB-743921 DM6XJ9S TI TTTRP0H DM6XJ9S TN Kinesin-like protein KIF11 (KIF11) DM6XJ9S MA Inhibitor DM6XJ9S RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. DM6XJ9S RU https://pubmed.ncbi.nlm.nih.gov/19357798 DM6XN4C DI DM6XN4C DM6XN4C DN CAR-T cells targeting CD22 DM6XN4C TI TTM6QSK DM6XN4C TN B-cell receptor CD22 (CD22) DM6XN4C MA CAR-T-Cell-Therapy DM6XN4C RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM6XN4C RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM6YI5T DI DM6YI5T DM6YI5T DN Tegobuvir DM6YI5T TI TTMVBWH DM6YI5T TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM6YI5T MA Inhibitor DM6YI5T RN Clinical pipeline report, company report or official report of Gilead (2011). DM6YI5T RU http://www.gilead.com/ DM6Z9BV DI DM6Z9BV DM6Z9BV DN CeaVac DM6Z9BV TI TTY6DTE DM6Z9BV TN Carcinoembryonic antigen CEA (CD66e) DM6Z9BV RN Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5. DM6Z9BV RU https://pubmed.ncbi.nlm.nih.gov/10561367 DM6ZIES DI DM6ZIES DM6ZIES DN A-6 DM6ZIES TI TTWFBT7 DM6ZIES TN Extracellular matrix receptor III (CD44) DM6ZIES MA Modulator DM6ZIES RN Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135. DM6ZIES RU https://www.ncbi.nlm.nih.gov/pubmed/25870596 DM6ZOUV DI DM6ZOUV DM6ZOUV DN Clazakizumab DM6ZOUV TI TTJH4Y5 DM6ZOUV TN HUMAN interleukin 6 (IL6) DM6ZOUV MA Inhibitor DM6ZOUV RN Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452. DM6ZOUV RU https://pubmed.ncbi.nlm.nih.gov/32291137 DM7063I DI DM7063I DM7063I DN LADIRUBICIN DM7063I TI TTUTN1I DM7063I TN Human Deoxyribonucleic acid (hDNA) DM7063I MA Binder DM7063I RN The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81. DM7063I RU https://pubmed.ncbi.nlm.nih.gov/16036566 DM71BZV DI DM71BZV DM71BZV DN Etamicastat DM71BZV TI TTYIP79 DM71BZV TN Dopamine beta hydroxylase (DBH) DM71BZV MA Inhibitor DM71BZV RN Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42. DM71BZV RU https://pubmed.ncbi.nlm.nih.gov/21171669 DM71HVW DI DM71HVW DM71HVW DN PH-794428 DM71HVW TI TTKMAZ6 DM71HVW TN Growth hormone receptor (GHR) DM71HVW MA Modulator DM71HVW RN PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51. DM71HVW RU https://www.ncbi.nlm.nih.gov/pubmed/18802875 DM725UG DI DM725UG DM725UG DN DN24-02 DM725UG TI TT6EO5L DM725UG TN Erbb2 tyrosine kinase receptor (HER2) DM725UG MA Modulator DM725UG RN Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7. DM725UG RU https://pubmed.ncbi.nlm.nih.gov/17704416 DM726HX DI DM726HX DM726HX DN MGCD-0103 DM726HX TI TT6R7JZ DM726HX TN Histone deacetylase 1 (HDAC1) DM726HX MA Inhibitor DM726HX RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DM726HX RU https://pubmed.ncbi.nlm.nih.gov/19721445 DM726HX DI DM726HX DM726HX DN MGCD-0103 DM726HX TI TTBH0VX DM726HX TN Histone deacetylase (HDAC) DM726HX MA Inhibitor DM726HX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM726HX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM72GZO DI DM72GZO DM72GZO DN JNJ-42165279 DM72GZO TI TTDP1UC DM72GZO TN Fatty acid amide hydrolase (FAAH) DM72GZO MA Inhibitor DM72GZO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM72GZO RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM72O6F DI DM72O6F DM72O6F DN GI-6207 DM72O6F TI TTY6DTE DM72O6F TN Carcinoembryonic antigen CEA (CD66e) DM72O6F MA Modulator DM72O6F RN Clinical pipeline report, company report or official report of GlobeImmune. DM72O6F RU https://www.globeimmune.com/cancer/gi-6207/ DM73UTG DI DM73UTG DM73UTG DN PRALNACASAN DM73UTG TI TTCQIBE DM73UTG TN Caspase-1 (CASP1) DM73UTG MA Modulator DM73UTG RN Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46. DM73UTG RU https://pubmed.ncbi.nlm.nih.gov/13129693 DM73XNG DI DM73XNG DM73XNG DN EVT302 DM73XNG TI TTGP7BY DM73XNG TN Monoamine oxidase type B (MAO-B) DM73XNG MA Inhibitor DM73XNG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM73XNG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM740BS DI DM740BS DM740BS DN BI 1358894 DM740BS TI TT32NQ1 DM740BS TN Short transient receptor potential channel 5 (TRPC5) DM740BS MA Inhibitor DM740BS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM740BS RU https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop DM740BS DI DM740BS DM740BS DN BI 1358894 DM740BS TI TTX0H5W DM740BS TN Short transient receptor potential channel 4 (TRPC4) DM740BS MA Inhibitor DM740BS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM740BS RU https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop DM740LV DI DM740LV DM740LV DN YKP-GI DM740LV TI TT07C3Y DM740LV TN 5-HT 4 receptor (HTR4) DM740LV MA Agonist DM740LV RN A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1. DM740LV RU https://pubmed.ncbi.nlm.nih.gov/25148765 DM74KIM DI DM74KIM DM74KIM DN KB-003 DM74KIM TI TTNYZG2 DM74KIM TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM74KIM RN US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. DM74KIM RU https://www.google.com/patents/US20100158905 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TT5HONZ DM74ZKN TN Calcium channel unspecific (CaC) DM74ZKN MA Blocker DM74ZKN RN Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/20980921 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TT1VOHK DM74ZKN TN Potassium channel unspecific (KC) DM74ZKN MA Blocker DM74ZKN RN Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/20980921 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TTRK8B9 DM74ZKN TN Sodium channel unspecific (NaC) DM74ZKN MA Inhibitor DM74ZKN RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM753H8 DI DM753H8 DM753H8 DN EB8018 DM753H8 TI TTTCRU2 DM753H8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM753H8 MA Inhibitor DM753H8 RN Clinical pipeline report, company report or official report of Enterome Biosciences. DM753H8 RU https://www.enterome.com/#pipeline DM756GE DI DM756GE DM756GE DN APH-0812 DM756GE TI TTYVX59 DM756GE TN Protein kinase C (PRKC) DM756GE MA Inhibitor DM756GE RN Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. DM756GE RU https://pubmed.ncbi.nlm.nih.gov/17585335 DM756GE DI DM756GE DM756GE DN APH-0812 DM756GE TI TTBH0VX DM756GE TN Histone deacetylase (HDAC) DM756GE MA Inhibitor DM756GE RN Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. DM756GE RU https://pubmed.ncbi.nlm.nih.gov/17585335 DM7583A DI DM7583A DM7583A DN Beta-caryophyllene DM7583A TI TTMSFAW DM7583A TN Cannabinoid receptor 2 (CB2) DM7583A MA Agonist DM7583A RN The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20. DM7583A RU https://pubmed.ncbi.nlm.nih.gov/24210682 DM7586F DI DM7586F DM7586F DN Bafetinib DM7586F TI TT1RWNJ DM7586F TN Tyrosine-protein kinase Lyn (JTK8) DM7586F MA Modulator DM7586F RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7586F RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7586F DI DM7586F DM7586F DN Bafetinib DM7586F TI TTS7G69 DM7586F TN Fusion protein Bcr-Abl (Bcr-Abl) DM7586F MA Modulator DM7586F RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7586F RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM75RFJ DI DM75RFJ DM75RFJ DN Siplizumab DM75RFJ TI TTJDUNO DM75RFJ TN T-cell surface antigen CD2 (CD2) DM75RFJ RN Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52. DM75RFJ RU https://pubmed.ncbi.nlm.nih.gov/15757402 DM79YAS DI DM79YAS DM79YAS DN Racotumomab DM79YAS TI TTSFNKW DM79YAS TN Tumor antigen NGcGM3 (NGcGM3) DM79YAS MA Modulator DM79YAS RN Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012; 2: 150. DM79YAS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478665/ DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TT27RFC DM7ADGX TN Opioid receptor delta (OPRD1) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TTQW87Y DM7ADGX TN Opioid receptor kappa (OPRK1) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TTKWM86 DM7ADGX TN Opioid receptor mu (MOP) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7AFJ8 DI DM7AFJ8 DM7AFJ8 DN Diannexin DM7AFJ8 TI TT2Z83I DM7AFJ8 TN Annexin A5 (ANXA5) DM7AFJ8 MA Modulator DM7AFJ8 RN Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000 Nov;30(4):305-12. DM7AFJ8 RU https://pubmed.ncbi.nlm.nih.gov/11065275 DM7B1AR DI DM7B1AR DM7B1AR DN AZD-1446 DM7B1AR TI TTL1ATN DM7B1AR TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM7B1AR MA Modulator DM7B1AR RN A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. DM7B1AR RU https://www.ncbi.nlm.nih.gov/pubmed/23640072 DM7BN5W DI DM7BN5W DM7BN5W DN LPN023 DM7BN5W TI TTA0P7K DM7BN5W TN Complement factor B (CFB) DM7BN5W MA Inhibitor DM7BN5W RN Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166. DM7BN5W RU https://pubmed.ncbi.nlm.nih.gov/31611870 DM7EJ8S DI DM7EJ8S DM7EJ8S DN PF-06882961 DM7EJ8S TI TTVIMDE DM7EJ8S TN Glucagon-like peptide 1 receptor (GLP1R) DM7EJ8S MA Agonist DM7EJ8S RN Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5;80(3):485-500.e7. DM7EJ8S RU https://pubmed.ncbi.nlm.nih.gov/33027691 DM7G4Y9 DI DM7G4Y9 DM7G4Y9 DN Ralinepag DM7G4Y9 TI TTOFYT1 DM7G4Y9 TN Prostacyclin receptor (PTGIR) DM7G4Y9 MA Agonist DM7G4Y9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7G4Y9 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM7GELO DI DM7GELO DM7GELO DN CMVpp65-A0201 DM7GELO TI TTNDHVE DM7GELO TN Cytomegalovirus 65kDa phosphoprotein (HCV UL83) DM7GELO RN National Cancer Institute Drug Dictionary (drug id 599982). DM7GELO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599982 DM7GPMB DI DM7GPMB DM7GPMB DN Depatuxizumab DM7GPMB TI TTGKNB4 DM7GPMB TN Epidermal growth factor receptor (EGFR) DM7GPMB MA Antagonist DM7GPMB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7GPMB RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7HNFV DI DM7HNFV DM7HNFV DN GSK2982772 DM7HNFV TI TTAIQSN DM7HNFV TN Receptor-interacting protein 1 (RIPK1) DM7HNFV MA Inhibitor DM7HNFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7HNFV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM7I0MT DI DM7I0MT DM7I0MT DN MT203 DM7I0MT TI TTNYZG2 DM7I0MT TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM7I0MT MA Modulator DM7I0MT RN GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. DM7I0MT RU https://pubmed.ncbi.nlm.nih.gov/25748625 DM7I56B DI DM7I56B DM7I56B DN ATM AVI DM7I56B TI TTUE541 DM7I56B TN Leukocyte surface antigen Leu-16 (CD20) DM7I56B MA Modulator DM7I56B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM7I56B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM7IFNB DI DM7IFNB DM7IFNB DN LY3202626 DM7IFNB TI TT8JRS7 DM7IFNB TN Beta-secretase (BACE) DM7IFNB MA Inhibitor DM7IFNB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IFNB RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7IGO9 DI DM7IGO9 DM7IGO9 DN Apimostinel DM7IGO9 TI TT9IK2Z DM7IGO9 TN N-methyl-D-aspartate receptor (NMDAR) DM7IGO9 MA Partial agonist DM7IGO9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IGO9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM7IH48 DI DM7IH48 DM7IH48 DN Dapansutrile DM7IH48 TI TT4EN8X DM7IH48 TN Caterpiller protein 1.1 (NLRP3) DM7IH48 MA Inhibitor DM7IH48 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IH48 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7K4YR DI DM7K4YR DM7K4YR DN MIS-416 DM7K4YR TI TTSHG0T DM7K4YR TN Toll-like receptor 9 (TLR9) DM7K4YR MA Modulator DM7K4YR RN DOI: 10.1371/journal.pone.0087712 DM7K4YR RU http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712 DM7K4YR DI DM7K4YR DM7K4YR DN MIS-416 DM7K4YR TI TTYPUHA DM7K4YR TN Pattern recognition receptor NOD2 (NOD2) DM7K4YR MA Modulator DM7K4YR RN DOI: 10.1371/journal.pone.0087712 DM7K4YR RU http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712 DM7KR4C DI DM7KR4C DM7KR4C DN YM-934 DM7KR4C TI TT1VOHK DM7KR4C TN Potassium channel unspecific (KC) DM7KR4C MA Blocker DM7KR4C RN Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83. DM7KR4C RU https://pubmed.ncbi.nlm.nih.gov/7524979 DM7MBV6 DI DM7MBV6 DM7MBV6 DN Lancovutide DM7MBV6 TI TTCYAXN DM7MBV6 TN Chloride channel unspecific (ClC) DM7MBV6 MA Modulator DM7MBV6 RN Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59. DM7MBV6 RU https://pubmed.ncbi.nlm.nih.gov/21156814 DM7NHLC DI DM7NHLC DM7NHLC DN BAY-85-3934 DM7NHLC TI TTMHFRY DM7NHLC TN HIF-prolyl hydroxylase 1 (HPH-1) DM7NHLC MA Inhibitor DM7NHLC RN Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838. DM7NHLC RU https://pubmed.ncbi.nlm.nih.gov/25392999 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTVBI8W DM7NJWY TN Dopamine transporter (DAT) DM7NJWY MA Inhibitor DM7NJWY RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTAWNKZ DM7NJWY TN Norepinephrine transporter (NET) DM7NJWY MA Inhibitor DM7NJWY RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTVFO0U DM7NJWY TN Gastrin/cholecystokinin type B receptor (CCKBR) DM7NJWY MA Antagonist DM7NJWY RN Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/8791971 DM7OTQS DI DM7OTQS DM7OTQS DN JNJ-10311795 DM7OTQS TI TT8VUE0 DM7OTQS TN Chymase (CYM) DM7OTQS MA Inhibitor DM7OTQS RN Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30. DM7OTQS RU https://pubmed.ncbi.nlm.nih.gov/17361995 DM7OTQS DI DM7OTQS DM7OTQS DN JNJ-10311795 DM7OTQS TI TTQAJF1 DM7OTQS TN Cathepsin G (CTSG) DM7OTQS MA Inhibitor DM7OTQS RN Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30. DM7OTQS RU https://pubmed.ncbi.nlm.nih.gov/17361995 DM7P0WR DI DM7P0WR DM7P0WR DN NAI-acne DM7P0WR TI TTYQIFM DM7P0WR TN Staphylococcus Elongation factor Tu (Stap-coc tuf) DM7P0WR MA Modulator DM7P0WR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031008) DM7P0WR RU http://adisinsight.springer.com/drugs/800031008 DM7PCLY DI DM7PCLY DM7PCLY DN ARC1779 DM7PCLY TI TT3SZBT DM7PCLY TN von Willebrand factor (VWF) DM7PCLY MA Inhibitor DM7PCLY RN Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037. DM7PCLY RU https://pubmed.ncbi.nlm.nih.gov/31315441 DM7PT8R DI DM7PT8R DM7PT8R DN BioE-743 DM7PT8R TI TT8XK6L DM7PT8R TN Quinone reductase 1 (NQO1) DM7PT8R MA Modulator DM7PT8R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7PT8R RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7QUN0 DI DM7QUN0 DM7QUN0 DN HQK-1001 DM7QUN0 TI TTQO71U DM7QUN0 TN Hemoglobin (HB) DM7QUN0 MA Inducer DM7QUN0 RN A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8. DM7QUN0 RU https://pubmed.ncbi.nlm.nih.gov/24224649 DM7RYL4 DI DM7RYL4 DM7RYL4 DN FG-2216 DM7RYL4 TI TTJQFBG DM7RYL4 TN HIF-prolyl hydroxylase (HPH) DM7RYL4 MA Modulator DM7RYL4 RN Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD DM7RYL4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014028 DM7USVA DI DM7USVA DM7USVA DN Duvelisib DM7USVA TI TTK5FVJ DM7USVA TN HUMAN PI3-kinase delta (PIK3CD) DM7USVA MA Inhibitor DM7USVA RN ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. DM7USVA RU https://clinicaltrials.gov/ct2/show/NCT04372602 DM7USVA DI DM7USVA DM7USVA DN Duvelisib DM7USVA TI TTHXGLJ DM7USVA TN HUMAN PI3-kinase gamma (PIK3CG) DM7USVA MA Inhibitor DM7USVA RN ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. DM7USVA RU https://clinicaltrials.gov/ct2/show/NCT04372602 DM7V96W DI DM7V96W DM7V96W DN GSK2798745 DM7V96W TI TTKP2SU DM7V96W TN Transient receptor potential cation channel V4 (TRPV4) DM7V96W MA Antagonist DM7V96W RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM7V96W RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM7VG8L DI DM7VG8L DM7VG8L DN MTC-896 DM7VG8L TI TT6QAJ3 DM7VG8L TN Melanocortin receptor 5 (MC5R) DM7VG8L MA Antagonist DM7VG8L RN Clinical pipeline report, company report or official report of Avarx. DM7VG8L RU http://www.avarx.com/AvaRx/SubDomains/Company231/Listings/231/Public.Listing.display.html DM7VJE1 DI DM7VJE1 DM7VJE1 DN IONIS-TMPRSS6-LRx DM7VJE1 TI TTNIUKC DM7VJE1 TN TMPRSS6 messenger RNA (TMPRSS6 mRNA) DM7VJE1 MA Inhibitor DM7VJE1 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM7VJE1 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM7W0JE DI DM7W0JE DM7W0JE DN LEO 124249 DM7W0JE TI TTJSQEF DM7W0JE TN Tyrosine-protein kinase (PTK) DM7W0JE MA Inhibitor DM7W0JE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7W0JE RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7X54F DI DM7X54F DM7X54F DN ABT-288 DM7X54F TI TT9JNIC DM7X54F TN Histamine H3 receptor (H3R) DM7X54F MA Modulator DM7X54F RN A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71. DM7X54F RU https://www.ncbi.nlm.nih.gov/pubmed/25024314 DM7XIAJ DI DM7XIAJ DM7XIAJ DN ID-93/GLA-SE DM7XIAJ TI TTVH0YQ DM7XIAJ TN Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens) DM7XIAJ MA Modulator DM7XIAJ RN US patent application no. US20150182612 A1. DM7XIAJ RU https://www.google.co.in/patents/US20150182612 DM7XV4R DI DM7XV4R DM7XV4R DN BMS-954561 DM7XV4R TI TTJSZTB DM7XV4R TN Nicotinic acetylcholine receptor (nAChR) DM7XV4R MA Modulator DM7XV4R RN EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders. DM7XV4R RU http://www.google.com/patents/EP2774991A1?cl=en DM7XZY5 DI DM7XZY5 DM7XZY5 DN Triapine DM7XZY5 TI TTBWDI0 DM7XZY5 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DM7XZY5 MA Modulator DM7XZY5 RN PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9. DM7XZY5 RU https://pubmed.ncbi.nlm.nih.gov/19433896 DM7Y60I DI DM7Y60I DM7Y60I DN Plevitrexed DM7Y60I TI TTU6BFZ DM7Y60I TN Candida Thymidylate synthase (Candi TMP1) DM7Y60I MA Inhibitor DM7Y60I RN Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30. DM7Y60I RU https://pubmed.ncbi.nlm.nih.gov/17297914 DM7YWVT DI DM7YWVT DM7YWVT DN PRX-321 DM7YWVT TI TTDWHC3 DM7YWVT TN Interleukin 4 receptor alpha (IL4R) DM7YWVT MA Agonist DM7YWVT RN Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5. DM7YWVT RU https://pubmed.ncbi.nlm.nih.gov/19478131 DM7ZM1H DI DM7ZM1H DM7ZM1H DN BHT-3009 DM7ZM1H TI TT2RY5P DM7ZM1H TN Myelin basic protein (MBP) DM7ZM1H RN BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70. DM7ZM1H RU https://pubmed.ncbi.nlm.nih.gov/19649992 DM7ZQAT DI DM7ZQAT DM7ZQAT DN ALZ-801 DM7ZQAT TI TTE4KHA DM7ZQAT TN Amyloid beta A4 protein (APP) DM7ZQAT MA Inhibitor DM7ZQAT RN Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012. DM7ZQAT RU http://www.alzheon.com/?page_id=280 DM80HOV DI DM80HOV DM80HOV DN SDF-1 DM80HOV TI TT4UGTF DM80HOV TN Stromal cell-derived factor 1 (CXCL12) DM80HOV MA Inhibitor DM80HOV RN SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7. DM80HOV RU https://pubmed.ncbi.nlm.nih.gov/22673496 DM819CO DI DM819CO DM819CO DN ADMVA DM819CO TI TTFBNVI DM819CO TN Aldose reductase (AKR1B1) DM819CO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DM819CO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DM81D4I DI DM81D4I DM81D4I DN PF-4447943 DM81D4I TI TTZOEBC DM81D4I TN Phosphodiesterase 9 (PDE9) DM81D4I MA Inhibitor DM81D4I RN A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21. DM81D4I RU https://pubmed.ncbi.nlm.nih.gov/24801218 DM81SDB DI DM81SDB DM81SDB DN Niravoline DM81SDB TI TTQW87Y DM81SDB TN Opioid receptor kappa (OPRK1) DM81SDB MA Modulator DM81SDB RN Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema. Acta Neurochir (Wien). 1999;141(7):771-8. DM81SDB RU https://www.ncbi.nlm.nih.gov/pubmed/10481790 DM81UAZ DI DM81UAZ DM81UAZ DN TAK-272 DM81UAZ TI TTB2MXP DM81UAZ TN Angiotensinogenase renin (REN) DM81UAZ MA Modulator DM81UAZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033655) DM81UAZ RU http://adisinsight.springer.com/drugs/800033655 DM81UJW DI DM81UJW DM81UJW DN LY-2590443 DM81UJW TI TTZPO1L DM81UJW TN Substance-P receptor (TACR1) DM81UJW MA Antagonist DM81UJW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DM81UJW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DM821BS DI DM821BS DM821BS DN Adipiplon DM821BS TI TT37EDJ DM821BS TN GABA(A) receptor alpha-3 (GABRA3) DM821BS MA Modulator DM821BS RN Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3. DM821BS RU https://pubmed.ncbi.nlm.nih.gov/21762686 DM826SW DI DM826SW DM826SW DN PF-04236921 DM826SW TI TTF6I40 DM826SW TN Interleukin (IL) DM826SW MA Inhibitor DM826SW RN US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. DM826SW RU https://www.google.com/patents/US20100158905 DM826SW DI DM826SW DM826SW DN PF-04236921 DM826SW TI TTT1V78 DM826SW TN Interleukin-6 (IL6) DM826SW MA Inhibitor DM826SW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM826SW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM83IYE DI DM83IYE DM83IYE DN BAY1193397 DM83IYE TI TT2NUT5 DM83IYE TN Adrenergic receptor alpha-2C (ADRA2C) DM83IYE MA Antagonist DM83IYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM83IYE RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TT0PG8F DM83QCL TN Cyclin-dependent kinase 4 (CDK4) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TT7HF4W DM83QCL TN Cyclin-dependent kinase 2 (CDK2) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TTH6V3D DM83QCL TN Cyclin-dependent kinase 1 (CDK1) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM85WID DI DM85WID DM85WID DN Crobenetine DM85WID TI TTRK8B9 DM85WID TN Sodium channel unspecific (NaC) DM85WID MA Antagonist DM85WID RN Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8. DM85WID RU https://pubmed.ncbi.nlm.nih.gov/11739251 DM867BJ DI DM867BJ DM867BJ DN SLV320 DM867BJ TI TTK25J1 DM867BJ TN Adenosine A1 receptor (ADORA1) DM867BJ MA Antagonist DM867BJ RN Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64. DM867BJ RU https://pubmed.ncbi.nlm.nih.gov/19196241 DM89ASO DI DM89ASO DM89ASO DN JCAR015 DM89ASO TI TTW640A DM89ASO TN B-lymphocyte surface antigen B4 (CD19) DM89ASO MA CAR-T-Cell-Therapy DM89ASO RN ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL). DM89ASO RU https://clinicaltrials.gov/ct2/show/NCT02535364 DM89D6C DI DM89D6C DM89D6C DN DNL758 DM89D6C TI TTAIQSN DM89D6C TN Receptor-interacting protein 1 (RIPK1) DM89D6C MA Inhibitor DM89D6C RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DM89D6C RU https://pubmed.ncbi.nlm.nih.gov/32669658 DM89QXT DI DM89QXT DM89QXT DN MET409 DM89QXT TI TTS4UGC DM89QXT TN Farnesoid X-activated receptor (FXR) DM89QXT MA Agonist DM89QXT RN Clinical pipeline report, company report or official report of Metacrine. DM89QXT RU https://www.metacrine.com/programs/ DM8A120 DI DM8A120 DM8A120 DN RO7121661 DM8A120 TI TTNBFWK DM8A120 TN Programmed cell death protein 1 (PD-1) DM8A120 MA Inhibitor DM8A120 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM8A120 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM8A120 DI DM8A120 DM8A120 DN RO7121661 DM8A120 TI TT1RWL7 DM8A120 TN Hepatitis A virus cellular receptor 2 (TIM3) DM8A120 MA Inhibitor DM8A120 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM8A120 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM8A71F DI DM8A71F DM8A71F DN AR-67 DM8A71F TI TTGTQHC DM8A71F TN DNA topoisomerase I (TOP1) DM8A71F MA Inhibitor DM8A71F RN Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54. DM8A71F RU https://pubmed.ncbi.nlm.nih.gov/24807458 DM8AM60 DI DM8AM60 DM8AM60 DN TC-5214 DM8AM60 TI TT35UGH DM8AM60 TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DM8AM60 MA Antagonist DM8AM60 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8AM60 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8AM60 DI DM8AM60 DM8AM60 DN TC-5214 DM8AM60 TI TT5KPZR DM8AM60 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM8AM60 MA Antagonist DM8AM60 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8AM60 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8ARQW DI DM8ARQW DM8ARQW DN ORM-12741 DM8ARQW TI TT2NUT5 DM8ARQW TN Adrenergic receptor alpha-2C (ADRA2C) DM8ARQW MA Antagonist DM8ARQW RN A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014 May;53(5):948-52. DM8ARQW RU https://pubmed.ncbi.nlm.nih.gov/24489014 DM8C1H4 DI DM8C1H4 DM8C1H4 DN PF-06823859 DM8C1H4 TI TT4TZ8J DM8C1H4 TN Interferon-beta (IFNB1) DM8C1H4 MA Blocker DM8C1H4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8C1H4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8CWL0 DI DM8CWL0 DM8CWL0 DN BVT.28949 DM8CWL0 TI TTJQOD7 DM8CWL0 TN 5-HT 2A receptor (HTR2A) DM8CWL0 MA Antagonist DM8CWL0 RN Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. DM8CWL0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/ DM8DVC9 DI DM8DVC9 DM8DVC9 DN RT-400 DM8DVC9 TI TTIY658 DM8DVC9 TN Corticotropin-releasing factor receptor 2 (CRHR2) DM8DVC9 MA Agonist DM8DVC9 RN Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020 Jun;19(6):389-413. DM8DVC9 RU https://pubmed.ncbi.nlm.nih.gov/32494050 DM8DZKI DI DM8DZKI DM8DZKI DN TNP-2092 DM8DZKI TI TTN6J5F DM8DZKI TN Bacterial DNA gyrase (Bact gyrase) DM8DZKI MA Inhibitor DM8DZKI RN Clinical pipeline report, company report or official report of TenNor Therapeutics. DM8DZKI RU http://www.tennorx.com/en/h-col-158.html DM8DZKI DI DM8DZKI DM8DZKI DN TNP-2092 DM8DZKI TI TTFK8YB DM8DZKI TN Bacterial DNA topoisomerase 4A (Bact parC) DM8DZKI MA Inhibitor DM8DZKI RN Clinical pipeline report, company report or official report of TenNor Therapeutics. DM8DZKI RU http://www.tennorx.com/en/h-col-158.html DM8FZOG DI DM8FZOG DM8FZOG DN AZD-2327 DM8FZOG TI TT27RFC DM8FZOG TN Opioid receptor delta (OPRD1) DM8FZOG MA Agonist DM8FZOG RN Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204. DM8FZOG RU https://pubmed.ncbi.nlm.nih.gov/21444630 DM8GHIX DI DM8GHIX DM8GHIX DN ADC-3680 DM8GHIX TI TTQDMX5 DM8GHIX TN Prostaglandin D2 receptor 2 (PTGDR2) DM8GHIX MA Antagonist DM8GHIX RN Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. DM8GHIX RU https://pubmed.ncbi.nlm.nih.gov/24073896 DM8H7OA DI DM8H7OA DM8H7OA DN Netoglitazone DM8H7OA TI TTZMAO3 DM8H7OA TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM8H7OA MA Modulator DM8H7OA RN Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84. DM8H7OA RU https://www.ncbi.nlm.nih.gov/pubmed/16137931 DM8HBUI DI DM8HBUI DM8HBUI DN ADU-S100 DM8HBUI TI TTT402Y DM8HBUI TN Stimulator of interferon genes protein (TMEM173) DM8HBUI MA Activator DM8HBUI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8HBUI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8J9DC DI DM8J9DC DM8J9DC DN RG7221 DM8J9DC TI TTOHSBA DM8J9DC TN Vascular endothelial growth factor A (VEGFA) DM8J9DC MA Modulator DM8J9DC RN Bispecific antibodies and their applications DM8J9DC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327 DM8J9DC DI DM8J9DC DM8J9DC DN RG7221 DM8J9DC TI TTKLQTJ DM8J9DC TN Angiopoietin-2 (ANGPT2) DM8J9DC MA Modulator DM8J9DC RN Company report (Roche pipeline: July 27, 2017) DM8J9DC RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM8JMNL DI DM8JMNL DM8JMNL DN RG7155 DM8JMNL TI TT731LW DM8JMNL TN Colony stimulating factor-1 receptor (CSF-1R) DM8JMNL MA Modulator DM8JMNL RN Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59. DM8JMNL RU https://pubmed.ncbi.nlm.nih.gov/24898549 DM8JMNL DI DM8JMNL DM8JMNL DN RG7155 DM8JMNL TI TT0IQER DM8JMNL TN Macrophage colony-stimulating factor 1 (CSF1) DM8JMNL MA Antagonist DM8JMNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8JMNL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TTJFA35 DM8JQZC TN Interleukin-15 (IL15) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TTF89GD DM8JQZC TN Interleukin-2 (IL2) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TT0JTFD DM8JQZC TN Interleukin-9 (IL9) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JVIB DI DM8JVIB DM8JVIB DN 18F-LMI-1195 DM8JVIB TI TTAWNKZ DM8JVIB TN Norepinephrine transporter (NET) DM8JVIB MA Enhancer DM8JVIB RN Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6. DM8JVIB RU https://pubmed.ncbi.nlm.nih.gov/23670901 DM8K5IF DI DM8K5IF DM8K5IF DN E7850 DM8K5IF TI TT9ABMF DM8K5IF TN Serine/threonine-protein kinase Chk2 (RAD53) DM8K5IF MA Modulator DM8K5IF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1988). DM8K5IF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1988 DM8LBUK DI DM8LBUK DM8LBUK DN UNI-PH (1-34) DM8LBUK TI TTEPJL5 DM8LBUK TN Parathyroid hormone receptor (PTH2R) DM8LBUK MA Modulator DM8LBUK RN Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006 July 4; 175(1): 52-59. DM8LBUK RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482742/ DM8LBYT DI DM8LBYT DM8LBYT DN NIS793 DM8LBYT TI TTO3HT7 DM8LBYT TN Transforming growth factor beta (TGFB) DM8LBYT MA Inhibitor DM8LBYT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8LBYT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8MJ3F DI DM8MJ3F DM8MJ3F DN PB1046 DM8MJ3F TI TT4O5P0 DM8MJ3F TN Helodermin-preferring VIP receptor (VIPR2) DM8MJ3F MA Agonist DM8MJ3F RN Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals. DM8MJ3F RU http://phasebio.com/clinical-development-pipeline/vasomera/ DM8N3OQ DI DM8N3OQ DM8N3OQ DN GT-AADC DM8N3OQ TI TTN451K DM8N3OQ TN Aromatic-L-amino-acid decarboxylase (DDC) DM8N3OQ MA Replacement DM8N3OQ RN Clinical pipeline report, company report or official report of PTC Therapeutics. DM8N3OQ RU https://www.ptcbio.com/our-pipeline/areas-of-interest/additional-areas/ DM8N3ZQ DI DM8N3ZQ DM8N3ZQ DN XP-21279 DM8N3ZQ TI TTEX248 DM8N3ZQ TN Dopamine D2 receptor (D2R) DM8N3ZQ MA Agonist DM8N3ZQ RN Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82. DM8N3ZQ RU https://pubmed.ncbi.nlm.nih.gov/24339234 DM8NLDI DI DM8NLDI DM8NLDI DN Endostatin DM8NLDI TI TTBPXMA DM8NLDI TN Prolactin receptor (PRLR) DM8NLDI MA Modulator DM8NLDI RN Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604. DM8NLDI RU https://pubmed.ncbi.nlm.nih.gov/12839947 DM8NODR DI DM8NODR DM8NODR DN ATI-502 DM8NODR TI TTT7PJU DM8NODR TN Janus kinase 3 (JAK-3) DM8NODR MA Inhibitor DM8NODR RN ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. DM8NODR RU https://clinicaltrials.gov/ct2/show/NCT03759340 DM8NODR DI DM8NODR DM8NODR DN ATI-502 DM8NODR TI TT6DM01 DM8NODR TN Janus kinase 1 (JAK-1) DM8NODR MA Inhibitor DM8NODR RN ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. DM8NODR RU https://clinicaltrials.gov/ct2/show/NCT03759340 DM8OG0J DI DM8OG0J DM8OG0J DN LY-517717 DM8OG0J TI TTCIHJA DM8OG0J TN Coagulation factor Xa (F10) DM8OG0J MA Inhibitor DM8OG0J RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM8OG0J RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM8QGPE DI DM8QGPE DM8QGPE DN HepaStem DM8QGPE TI TTGSVH2 DM8QGPE TN Phenylalanine hydroxylase (PAH) DM8QGPE MA Modulator DM8QGPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240). DM8QGPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240 DM8QXEY DI DM8QXEY DM8QXEY DN Evt201 DM8QXEY TI TTCI43M DM8QXEY TN GABA(A) receptor (GABAR) DM8QXEY MA Modulator DM8QXEY RN The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64. DM8QXEY RU https://pubmed.ncbi.nlm.nih.gov/19345644 DM8R71T DI DM8R71T DM8R71T DN BL-22 DM8R71T TI TTM6QSK DM8R71T TN B-cell receptor CD22 (CD22) DM8R71T RN Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903. DM8R71T RU https://pubmed.ncbi.nlm.nih.gov/20215554 DM8SNEM DI DM8SNEM DM8SNEM DN BAY 11-42524 DM8SNEM TI TT8VUE0 DM8SNEM TN Chymase (CYM) DM8SNEM MA Inhibitor DM8SNEM RN ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction. DM8SNEM RU https://clinicaltrials.gov/ct2/show/NCT02452515 DM8SVIY DI DM8SVIY DM8SVIY DN AZD4635 DM8SVIY TI TTM2AOE DM8SVIY TN Adenosine A2a receptor (ADORA2A) DM8SVIY MA Antagonist DM8SVIY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8SVIY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8T6KQ DI DM8T6KQ DM8T6KQ DN PF-232798 DM8T6KQ TI TT2CEJG DM8T6KQ TN C-C chemokine receptor type 5 (CCR5) DM8T6KQ MA Antagonist DM8T6KQ RN An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77. DM8T6KQ RU https://pubmed.ncbi.nlm.nih.gov/21128663 DM8TDBY DI DM8TDBY DM8TDBY DN OCFENTANIL DM8TDBY TI TTN4QDT DM8TDBY TN Opioid receptor (OPR) DM8TDBY MA Modulator DM8TDBY RN Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6. DM8TDBY RU https://pubmed.ncbi.nlm.nih.gov/1952145 DM8TKG5 DI DM8TKG5 DM8TKG5 DN SB-265610 DM8TKG5 TI TT30C9G DM8TKG5 TN C-X-C chemokine receptor type 2 (CXCR2) DM8TKG5 MA Antagonist DM8TKG5 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM8TKG5 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM8TOS0 DI DM8TOS0 DM8TOS0 DN HER-2 Protein AutoVac DM8TOS0 TI TT6EO5L DM8TOS0 TN Erbb2 tyrosine kinase receptor (HER2) DM8TOS0 MA Inhibitor DM8TOS0 RN Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. DM8TOS0 RU https://pubmed.ncbi.nlm.nih.gov/22124364 DM8UCNK DI DM8UCNK DM8UCNK DN Telisotuzumab vedotin DM8UCNK TI TTNDSF4 DM8UCNK TN Proto-oncogene c-Met (MET) DM8UCNK RN Clinical pipeline report, company report or official report of AbbVie. DM8UCNK RU https://www.abbvie.com/our-science/pipeline/abbv-399.html DM8UQJG DI DM8UQJG DM8UQJG DN CDX-1307 DM8UQJG TI TTUH273 DM8UQJG TN Choriogonadotropin beta (CG-beta) DM8UQJG RN CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733-42. DM8UQJG RU https://pubmed.ncbi.nlm.nih.gov/21692696 DM8VWPH DI DM8VWPH DM8VWPH DN Doxorubicin-eluting beads DM8VWPH TI TT0IHXV DM8VWPH TN DNA topoisomerase II (TOP2) DM8VWPH MA Modulator DM8VWPH RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8VWPH RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TTMX39J DM8W4N9 TN Matrix metalloproteinase-1 (MMP-1) DM8W4N9 MA Inhibitor DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TTHY57M DM8W4N9 TN Matrix metalloproteinase-13 (MMP-13) DM8W4N9 MA Modulator DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TT6AZXG DM8W4N9 TN TNF alpha converting enzyme (ADAM17) DM8W4N9 MA Modulator DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8WU3O DI DM8WU3O DM8WU3O DN Drug 2862277 DM8WU3O TI TTG043C DM8WU3O TN Tumor necrosis factor receptor type I (TNF-R1) DM8WU3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DM8WU3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DM8X5Q1 DI DM8X5Q1 DM8X5Q1 DN CP101 DM8X5Q1 TI TT9IK2Z DM8X5Q1 TN N-methyl-D-aspartate receptor (NMDAR) DM8X5Q1 MA Antagonist DM8X5Q1 RN The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17. DM8X5Q1 RU https://pubmed.ncbi.nlm.nih.gov/9219855 DM8XH3S DI DM8XH3S DM8XH3S DN H-1152 DM8XH3S TI TTZN7RP DM8XH3S TN Rho-associated protein kinase 1 (ROCK1) DM8XH3S MA Inhibitor DM8XH3S RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DM8XH3S RU https://pubmed.ncbi.nlm.nih.gov/17064221 DM8YF01 DI DM8YF01 DM8YF01 DN Interferon-alpha lozenge DM8YF01 TI TT95SOA DM8YF01 TN Interferon alpha (IFNA) DM8YF01 MA Modulator DM8YF01 RN Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7. DM8YF01 RU https://pubmed.ncbi.nlm.nih.gov/12090541 DM8ZTW7 DI DM8ZTW7 DM8ZTW7 DN MK-1029 DM8ZTW7 TI TTNVEIR DM8ZTW7 TN Prostaglandin D2 receptor (PTGDR) DM8ZTW7 MA Inhibitor DM8ZTW7 RN Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. DM8ZTW7 RU https://pubmed.ncbi.nlm.nih.gov/24073896 DM90DTM DI DM90DTM DM90DTM DN Sirukumab DM90DTM TI TTJH4Y5 DM90DTM TN HUMAN interleukin 6 (IL6) DM90DTM MA Inhibitor DM90DTM RN Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90. DM90DTM RU https://pubmed.ncbi.nlm.nih.gov/27913990 DM91U0R DI DM91U0R DM91U0R DN ABX-EGF DM91U0R TI TTGKNB4 DM91U0R TN Epidermal growth factor receptor (EGFR) DM91U0R RN Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. DM91U0R RU https://pubmed.ncbi.nlm.nih.gov/11920518 DM92X7N DI DM92X7N DM92X7N DN ASN002 DM92X7N TI TT2HUPM DM92X7N TN SYK messenger RNA (SYK mRNA) DM92X7N MA Inhibitor DM92X7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM92X7N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM93CTQ DI DM93CTQ DM93CTQ DN AR08 DM93CTQ TI TTVIREA DM93CTQ TN Adrenergic receptor (ADR) DM93CTQ MA Modulator DM93CTQ RN Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594. DM93CTQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287224/ DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TTPS3C0 DM93YKJ TN Aurora kinase A (AURKA) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TT860QF DM93YKJ TN LCK tyrosine protein kinase (LCK) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TT5LS6T DM93YKJ TN Aurora kinase B (AURKB) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM94NBE DI DM94NBE DM94NBE DN PF-04991532 DM94NBE TI TTDLNGZ DM94NBE TN Glucokinase (GCK) DM94NBE MA Activator DM94NBE RN The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139. DM94NBE RU https://pubmed.ncbi.nlm.nih.gov/24858947 DM95FR3 DI DM95FR3 DM95FR3 DN Tarextumab DM95FR3 TI TTVX7IA DM95FR3 TN Notch-3 receptor (NOTCH3) DM95FR3 MA Modulator DM95FR3 RN Company report (OncoMed Pharmaceuticals) DM95FR3 RU http://www.oncomed.com/Pipeline.html DM95FR3 DI DM95FR3 DM95FR3 DN Tarextumab DM95FR3 TI TT82FVD DM95FR3 TN Notch-2 receptor (NOTCH2) DM95FR3 MA Modulator DM95FR3 RN Company report (OncoMed Pharmaceuticals) DM95FR3 RU http://www.oncomed.com/Pipeline.html DM96NCR DI DM96NCR DM96NCR DN Eniluracil DM96NCR TI TTZPS91 DM96NCR TN Dihydrothymine dehydrogenase (DPYD) DM96NCR MA Modulator DM96NCR RN Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49. DM96NCR RU https://pubmed.ncbi.nlm.nih.gov/11060767 DM96NHM DI DM96NHM DM96NHM DN Dimiracetam DM96NHM TI TT9IK2Z DM96NHM TN N-methyl-D-aspartate receptor (NMDAR) DM96NHM MA Antagonist DM96NHM RN Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94. DM96NHM RU https://pubmed.ncbi.nlm.nih.gov/24486381 DM96VWD DI DM96VWD DM96VWD DN PINOCEMBRIN DM96VWD TI TTI84H7 DM96VWD TN Cytochrome P450 1B1 (CYP1B1) DM96VWD MA Inhibitor DM96VWD RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM96VWD RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM973N4 DI DM973N4 DM973N4 DN AMG 853 DM973N4 TI TTQDMX5 DM973N4 TN Prostaglandin D2 receptor 2 (PTGDR2) DM973N4 MA Modulator DM973N4 RN Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45. DM973N4 RU https://www.ncbi.nlm.nih.gov/pubmed/23174659 DM973N4 DI DM973N4 DM973N4 DN AMG 853 DM973N4 TI TTNVEIR DM973N4 TN Prostaglandin D2 receptor (PTGDR) DM973N4 MA Modulator DM973N4 RN Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45. DM973N4 RU https://www.ncbi.nlm.nih.gov/pubmed/23174659 DM98RW0 DI DM98RW0 DM98RW0 DN Cirmtuzumab DM98RW0 TI TTDEJAU DM98RW0 TN Neurotrophic tyrosine kinase ROR1 (ROR1) DM98RW0 MA Antagonist DM98RW0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM98RW0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9AWSO DI DM9AWSO DM9AWSO DN Telapristone DM9AWSO TI TTUV8G9 DM9AWSO TN Progesterone receptor (PGR) DM9AWSO MA Antagonist DM9AWSO RN In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. DM9AWSO RU https://pubmed.ncbi.nlm.nih.gov/15120421 DM9BREJ DI DM9BREJ DM9BREJ DN MYK-491 DM9BREJ TI TTITSMB DM9BREJ TN Myosin (MYO) DM9BREJ MA Activator DM9BREJ RN Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658. DM9BREJ RU https://pubmed.ncbi.nlm.nih.gov/32558989 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TT1LVF2 DM9DJL2 TN Cyclin-dependent kinase 9 (CDK9) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TTH6V3D DM9DJL2 TN Cyclin-dependent kinase 1 (CDK1) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TT0PG8F DM9DJL2 TN Cyclin-dependent kinase 4 (CDK4) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9EFH0 DI DM9EFH0 DM9EFH0 DN NS 1209 DM9EFH0 TI TT0MYE2 DM9EFH0 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM9EFH0 MA Modulator DM9EFH0 RN The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9. DM9EFH0 RU https://pubmed.ncbi.nlm.nih.gov/19299805 DM9FHV8 DI DM9FHV8 DM9FHV8 DN CK-2127107 DM9FHV8 TI TTYUMF5 DM9FHV8 TN Fast skeletal muscle troponin complex (TNNC2) DM9FHV8 MA Modulator DM9FHV8 RN Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5. DM9FHV8 RU https://pubmed.ncbi.nlm.nih.gov/22344294 DM9FXU7 DI DM9FXU7 DM9FXU7 DN MDL-27192 DM9FXU7 TI TT9IK2Z DM9FXU7 TN N-methyl-D-aspartate receptor (NMDAR) DM9FXU7 MA Modulator DM9FXU7 RN Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54. DM9FXU7 RU https://pubmed.ncbi.nlm.nih.gov/9169290 DM9FZYT DI DM9FZYT DM9FZYT DN BI-655130 DM9FZYT TI TTUS18T DM9FZYT TN IL-1 receptor-like 2 (IL1RL2) DM9FZYT MA Antagonist DM9FZYT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FZYT RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM9GRTK DI DM9GRTK DM9GRTK DN ACYLINE DM9GRTK TI TT8R70G DM9GRTK TN Gonadotropin-releasing hormone receptor (GNRHR) DM9GRTK MA Inhibitor DM9GRTK RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM9GRTK RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM9GZW6 DI DM9GZW6 DM9GZW6 DN Vabicaserin DM9GZW6 TI TT0K1SC DM9GZW6 TN 5-HT 2B receptor (HTR2B) DM9GZW6 MA Modulator DM9GZW6 RN Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111. DM9GZW6 RU https://www.ncbi.nlm.nih.gov/pubmed/24759548 DM9GZW6 DI DM9GZW6 DM9GZW6 DN Vabicaserin DM9GZW6 TI TTWJBZ5 DM9GZW6 TN 5-HT 2C receptor (HTR2C) DM9GZW6 MA Modulator DM9GZW6 RN Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111. DM9GZW6 RU https://www.ncbi.nlm.nih.gov/pubmed/24759548 DM9IMEZ DI DM9IMEZ DM9IMEZ DN Seviteronel DM9IMEZ TI TTRA5BZ DM9IMEZ TN Steroid 17-alpha-monooxygenase (S17AH) DM9IMEZ MA Inhibitor DM9IMEZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9IMEZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9JGTQ DI DM9JGTQ DM9JGTQ DN PH10 nasal spray DM9JGTQ TI TT3FOGT DM9JGTQ TN Chemosensory receptor (CheR) DM9JGTQ MA Modulator DM9JGTQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9JGTQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM9KB7A DI DM9KB7A DM9KB7A DN ZGN-1061 DM9KB7A TI TTZL0OI DM9KB7A TN Methionine aminopeptidase 2 (METAP2) DM9KB7A MA Inhibitor DM9KB7A RN The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219. DM9KB7A RU https://pubmed.ncbi.nlm.nih.gov/32077231 DM9KL7P DI DM9KL7P DM9KL7P DN ALT-801 DM9KL7P TI TT7SBF5 DM9KL7P TN Cellular tumor antigen p53 (TP53) DM9KL7P MA Immunomodulator (Immunostimulant) DM9KL7P RN Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. DM9KL7P RU https://pubmed.ncbi.nlm.nih.gov/21994418 DM9KNJT DI DM9KNJT DM9KNJT DN Vobarilizumab DM9KNJT TI TTFNGC9 DM9KNJT TN Serum albumin (ALB) DM9KNJT MA Inhibitor DM9KNJT RN Clinical pipeline report, company report or official report of Ablynx. DM9KNJT RU https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf DM9KNJT DI DM9KNJT DM9KNJT DN Vobarilizumab DM9KNJT TI TT0E5SK DM9KNJT TN Interleukin 6 receptor (IL6R) DM9KNJT MA Inhibitor DM9KNJT RN Clinical pipeline report, company report or official report of Ablynx. DM9KNJT RU https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf DM9KTSG DI DM9KTSG DM9KTSG DN S-1360 DM9KTSG TI TT5FH9Y DM9KTSG TN Human immunodeficiency virus Integrase (HIV IN) DM9KTSG MA Inhibitor DM9KTSG RN HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68. DM9KTSG RU https://pubmed.ncbi.nlm.nih.gov/17472411 DM9L15R DI DM9L15R DM9L15R DN Dextofisopam DM9L15R TI TTPTXIN DM9L15R TN Translocator protein (TSPO) DM9L15R MA Agonist DM9L15R RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM9L15R RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM9L15R DI DM9L15R DM9L15R DN Dextofisopam DM9L15R TI TTNJYV2 DM9L15R TN Gamma-aminobutyric acid receptor (GAR) DM9L15R MA Agonist DM9L15R RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM9L15R RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM9LKYP DI DM9LKYP DM9LKYP DN AZ-40140 DM9LKYP TI TTMXGCW DM9LKYP TN Adrenergic receptor beta-3 (ADRB3) DM9LKYP MA Agonist DM9LKYP RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM9LKYP RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TTRHEQ4 DM9LNXS TN Diacylglycerol O-acyltransferase 2 (DGAT2) DM9LNXS MA Inhibitor DM9LNXS RN 2011 Pipeline of Arisaph Pharmaceuticals. DM9LNXS RU http://www.arisaph.com/ DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TTWNV8U DM9LNXS TN Nicotinic acid receptor (HCAR2) DM9LNXS MA Agonist DM9LNXS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LNXS RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TT8WFXV DM9LNXS TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM9LNXS MA Agonist DM9LNXS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LNXS RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM9LZ0M DI DM9LZ0M DM9LZ0M DN APD-515 DM9LZ0M TI TTOXS3C DM9LZ0M TN Muscarinic acetylcholine receptor (CHRM) DM9LZ0M MA Agonist DM9LZ0M RN Clinical pipeline report, company report or official report of Acacia Pharma. DM9LZ0M RU http://www.acaciapharma.com/pipeline/apd515 DM9M5WV DI DM9M5WV DM9M5WV DN MRG-201 DM9M5WV TI TTK982E DM9M5WV TN Collagen (CO) DM9M5WV MA Modulator DM9M5WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9M5WV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9M5WV DI DM9M5WV DM9M5WV DN MRG-201 DM9M5WV TI TT1GNRQ DM9M5WV TN microRNA hsa-miR-155 (MIR155) DM9M5WV MA Modulator DM9M5WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9M5WV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9MKQ5 DI DM9MKQ5 DM9MKQ5 DN Hu3F8 mAb DM9MKQ5 TI TT80ARU DM9MKQ5 TN Ganglioside GD2 (GD2) DM9MKQ5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9MKQ5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9OPK3 DI DM9OPK3 DM9OPK3 DN SPD-556 DM9OPK3 TI TTK8R02 DM9OPK3 TN Vasopressin V2 receptor (V2R) DM9OPK3 MA Antagonist DM9OPK3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). DM9OPK3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368 DM9ORUW DI DM9ORUW DM9ORUW DN FRM-0962 DM9ORUW TI TTE4KHA DM9ORUW TN Amyloid beta A4 protein (APP) DM9ORUW MA Modulator DM9ORUW RN Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014 DM9ORUW RU http://www.nature.com/scibx/journal/v7/n40/full/scibx.2014.1175.html DM9OXEJ DI DM9OXEJ DM9OXEJ DN BIIB 023 DM9OXEJ TI TTBTDM1 DM9OXEJ TN TNF-related weak inducer of apoptosis (TWEAK) DM9OXEJ MA Modulator DM9OXEJ RN ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. DM9OXEJ RU https://clinicaltrials.gov/ct2/show/NCT00771329 DM9OZU5 DI DM9OZU5 DM9OZU5 DN Heat shock protein vaccine DM9OZU5 TI TTG91S4 DM9OZU5 TN Heat shock protein (HSP) DM9OZU5 RN Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 2012 Nov 1;12(9):1183-97. DM9OZU5 RU https://pubmed.ncbi.nlm.nih.gov/22804241 DM9PVNJ DI DM9PVNJ DM9PVNJ DN TCN-032 DM9PVNJ TI TTXT3PU DM9PVNJ TN Influenza M2 protein (Influ M) DM9PVNJ RN Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663. DM9PVNJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906546/ DM9Q2B6 DI DM9Q2B6 DM9Q2B6 DN GS-9876 DM9Q2B6 TI TTOU65C DM9Q2B6 TN Tyrosine-protein kinase SYK (SYK) DM9Q2B6 MA Inhibitor DM9Q2B6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Q2B6 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9QF65 DI DM9QF65 DM9QF65 DN GR-MD-02 DM9QF65 TI TTFPQV7 DM9QF65 TN Galectin-3 (LGALS3) DM9QF65 MA Inhibitor DM9QF65 RN Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481. DM9QF65 RU https://pubmed.ncbi.nlm.nih.gov/24367597 DM9QFW2 DI DM9QFW2 DM9QFW2 DN Tau-binding PET tracer DM9QFW2 TI TTS87KH DM9QFW2 TN Microtubule-associated protein tau (MAPT) DM9QFW2 MA Modulator DM9QFW2 RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DM9QFW2 RU https://pubmed.ncbi.nlm.nih.gov/21902667 DM9RC7D DI DM9RC7D DM9RC7D DN SAGE-718 DM9RC7D TI TT9IK2Z DM9RC7D TN N-methyl-D-aspartate receptor (NMDAR) DM9RC7D MA Modulator DM9RC7D RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM9RC7D RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM9REBL DI DM9REBL DM9REBL DN DDP-225 DM9REBL TI TTNXLKE DM9REBL TN 5-HT 3 receptor (5HT3R) DM9REBL MA Modulator DM9REBL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM9REBL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM9RW6H DI DM9RW6H DM9RW6H DN JNJ-56136379 DM9RW6H TI TTM42UJ DM9RW6H TN Hepatitis B virus Capsid protein (HBV C) DM9RW6H MA Inhibitor DM9RW6H RN JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9. DM9RW6H RU https://pubmed.ncbi.nlm.nih.gov/32343960 DM9S3P7 DI DM9S3P7 DM9S3P7 DN PF-06473871 DM9S3P7 TI TTIL516 DM9S3P7 TN CCN2 messenger RNA (CCN2 mRNA) DM9S3P7 MA Inhibitor DM9S3P7 RN A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861. DM9S3P7 RU https://pubmed.ncbi.nlm.nih.gov/30349773 DM9SX6Y DI DM9SX6Y DM9SX6Y DN Indisulam DM9SX6Y TI TT2LVK8 DM9SX6Y TN Carbonic anhydrase IX (CA-IX) DM9SX6Y MA Modulator DM9SX6Y RN Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. DM9SX6Y RU https://www.ncbi.nlm.nih.gov/pubmed/14684331 DM9T8A2 DI DM9T8A2 DM9T8A2 DN LGD-4665 DM9T8A2 TI TTIHYA4 DM9T8A2 TN Thrombopoietin receptor (MPL) DM9T8A2 MA Agonist DM9T8A2 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DM9T8A2 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DM9UMIO DI DM9UMIO DM9UMIO DN JNJ-38518168 DM9UMIO TI TTXJ178 DM9UMIO TN Histamine H4 receptor (H4R) DM9UMIO MA Antagonist DM9UMIO RN The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65. DM9UMIO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379874/ DM9UMSJ DI DM9UMSJ DM9UMSJ DN AM001 DM9UMSJ TI TTOE7I0 DM9UMSJ TN Rap guanine nucleotide exchange factor 3 (RAPGEF3) DM9UMSJ MA Inhibitor DM9UMSJ RN Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Cardiovasc Res. 2019 Oct 1;115(12):1766-1777. DM9UMSJ RU https://pubmed.ncbi.nlm.nih.gov/30873562 DM9VEAL DI DM9VEAL DM9VEAL DN NPC-1C DM9VEAL TI TT34I9F DM9VEAL TN Neoplasm antigen (NA) DM9VEAL RN National Cancer Institute Drug Dictionary (drug id 663436). DM9VEAL RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436 DM9XKJU DI DM9XKJU DM9XKJU DN J 591 Lu-177 DM9XKJU TI TT9G4N0 DM9XKJU TN Glutamate carboxypeptidase II (GCPII) DM9XKJU MA Modulator DM9XKJU RN Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91. DM9XKJU RU https://pubmed.ncbi.nlm.nih.gov/23714732 DM9Y1XB DI DM9Y1XB DM9Y1XB DN ABT-RTA-408 DM9Y1XB TI TTA6ZN2 DM9Y1XB TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9Y1XB MA Modulator DM9Y1XB RN National Cancer Institute Drug Dictionary (drug id 756624). DM9Y1XB RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756624 DM9ZHRS DI DM9ZHRS DM9ZHRS DN LIM-0705 DM9ZHRS TI TTK8XD6 DM9ZHRS TN ATP-binding cassette transporter (ABCA) DM9ZHRS MA Activator DM9ZHRS RN WO patent application no. 2010,0428,86, Pyrone analogs for therapeutic treatment. DM9ZHRS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100415&CC=WO&NR=2010042886A2&KC=A2 DMA04DE DI DMA04DE DMA04DE DN Topiroxostat DMA04DE TI TT7RJY8 DMA04DE TN Xanthine dehydrogenase/oxidase (XDH) DMA04DE MA Inhibitor DMA04DE RN QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52. DMA04DE RU https://pubmed.ncbi.nlm.nih.gov/24214189 DMA0DSJ DI DMA0DSJ DMA0DSJ DN L-694,458 DMA0DSJ TI TTPLTSQ DMA0DSJ TN Neutrophil elastase (NE) DMA0DSJ MA Inhibitor DMA0DSJ RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMA0DSJ RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMA0QZH DI DMA0QZH DMA0QZH DN SSR-180575 DMA0QZH TI TTPTXIN DMA0QZH TN Translocator protein (TSPO) DMA0QZH MA Inhibitor DMA0QZH RN SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J PharmacolExp Ther. 2002 Jun;301(3):1067-78. DMA0QZH RU https://pubmed.ncbi.nlm.nih.gov/12023539 DMA0RI9 DI DMA0RI9 DMA0RI9 DN LIDORESTAT DMA0RI9 TI TTFBNVI DMA0RI9 TN Aldose reductase (AKR1B1) DMA0RI9 MA Inhibitor DMA0RI9 RN Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52. DMA0RI9 RU https://pubmed.ncbi.nlm.nih.gov/15857120 DMA12HB DI DMA12HB DMA12HB DN SEP--4199 DMA12HB TI TTEX248 DMA12HB TN Dopamine D2 receptor (D2R) DMA12HB MA Antagonist DMA12HB RN ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health. DMA12HB RU https://clinicaltrials.gov/ct2/show/NCT03543410 DMA12HB DI DMA12HB DMA12HB DN SEP--4199 DMA12HB TI TT85JO3 DMA12HB TN 5-HT receptor (5HTR) DMA12HB MA Antagonist DMA12HB RN ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health. DMA12HB RU https://clinicaltrials.gov/ct2/show/NCT03543410 DMA2IXQ DI DMA2IXQ DMA2IXQ DN GSK2586184 DMA2IXQ TI TT6DM01 DMA2IXQ TN Janus kinase 1 (JAK-1) DMA2IXQ MA Modulator DMA2IXQ RN DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9. DMA2IXQ RU https://pubmed.ncbi.nlm.nih.gov/25724932 DMA2UYE DI DMA2UYE DMA2UYE DN Ro-24-7429 DMA2UYE TI TTT3ZC9 DMA2UYE TN Human immunodeficiency virus Tat protein (HIV tat) DMA2UYE MA Modulator DMA2UYE RN A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52. DMA2UYE RU https://pubmed.ncbi.nlm.nih.gov/7594660 DMA42BV DI DMA42BV DMA42BV DN AVE-2268 DMA42BV TI TTLWPVF DMA42BV TN Sodium/glucose cotransporter 2 (SGLT2) DMA42BV MA Modulator DMA42BV RN Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. DMA42BV RU https://pubmed.ncbi.nlm.nih.gov/19137908 DMA4LNE DI DMA4LNE DMA4LNE DN SGN-LIV1A DMA4LNE TI TTZN1CF DMA4LNE TN Solute carrier family 39 member 6 (SLC39A6) DMA4LNE RN SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. DMA4LNE RU https://pubmed.ncbi.nlm.nih.gov/25253783 DMA4OGL DI DMA4OGL DMA4OGL DN OMS824 DMA4OGL TI TTJW4LU DMA4OGL TN Phosphodiesterase 10A (PDE10) DMA4OGL MA Inhibitor DMA4OGL RN New Drugs/Drug News. P T. 2013 November; 38(11): 667-672. DMA4OGL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875261/ DMA5D6T DI DMA5D6T DMA5D6T DN CX1789 DMA5D6T TI TTAN6JD DMA5D6T TN Glutamate receptor AMPA (GRIA) DMA5D6T MA Agonist DMA5D6T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA5D6T RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA6HQJ DI DMA6HQJ DMA6HQJ DN HO/03/03 DMA6HQJ TI TTYVX59 DMA6HQJ TN Protein kinase C (PRKC) DMA6HQJ MA Modulator DMA6HQJ RN WO patent application no. 2014,0853,81, Pharmaceutical combinations. DMA6HQJ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140605&CC=WO&NR=2014085381A1&KC=A1 DMA6RBF DI DMA6RBF DMA6RBF DN GSK1325756 DMA6RBF TI TT30C9G DMA6RBF TN C-X-C chemokine receptor type 2 (CXCR2) DMA6RBF MA Modulator DMA6RBF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA6RBF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA75FG DI DMA75FG DMA75FG DN BAY 794980 DMA75FG TI TT1290U DMA75FG TN Coagulation factor VIII (F8) DMA75FG MA Modulator DMA75FG RN Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost. 2012 Nov;108(5):913-22. DMA75FG RU https://pubmed.ncbi.nlm.nih.gov/23014711 DMA7ISF DI DMA7ISF DMA7ISF DN Tarloxotinib DMA7ISF TI TT6EO5L DMA7ISF TN Erbb2 tyrosine kinase receptor (HER2) DMA7ISF MA Inhibitor DMA7ISF RN Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. DMA7ISF RU https://pubmed.ncbi.nlm.nih.gov/33355298 DMA7ISF DI DMA7ISF DMA7ISF DN Tarloxotinib DMA7ISF TI TTGKNB4 DMA7ISF TN Epidermal growth factor receptor (EGFR) DMA7ISF MA Inhibitor DMA7ISF RN Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. DMA7ISF RU https://pubmed.ncbi.nlm.nih.gov/33355298 DMA9238 DI DMA9238 DMA9238 DN BTRX-246040 DMA9238 TI TTNT7K8 DMA9238 TN Nociceptin receptor (OPRL1) DMA9238 MA Antagonist DMA9238 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA9238 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMA9FKY DI DMA9FKY DMA9FKY DN AG140699 DMA9FKY TI TTVDSZ0 DMA9FKY TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA9FKY MA Inhibitor DMA9FKY RN Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. DMA9FKY RU https://pubmed.ncbi.nlm.nih.gov/15864271 DMA9MBR DI DMA9MBR DMA9MBR DN PF-04523655 DMA9MBR TI TT0AWFK DMA9MBR TN HIF-1 responsive protein RTP801 (DDIT4) DMA9MBR RN Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. DMA9MBR RU https://pubmed.ncbi.nlm.nih.gov/19568274 DMA9SEY DI DMA9SEY DMA9SEY DN GDC-0084 DMA9SEY TI TTHBTOP DMA9SEY TN PI3-kinase gamma (PIK3CG) DMA9SEY MA Inhibitor DMA9SEY RN Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829. DMA9SEY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379803/ DMA9VGW DI DMA9VGW DMA9VGW DN Sitafloxacin DMA9VGW TI TTN6J5F DMA9VGW TN Bacterial DNA gyrase (Bact gyrase) DMA9VGW MA Inhibitor DMA9VGW RN Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DMA9VGW RU https://pubmed.ncbi.nlm.nih.gov/18390884 DMA9VGW DI DMA9VGW DMA9VGW DN Sitafloxacin DMA9VGW TI TTFK8YB DMA9VGW TN Bacterial DNA topoisomerase 4A (Bact parC) DMA9VGW MA Inhibitor DMA9VGW RN Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DMA9VGW RU https://pubmed.ncbi.nlm.nih.gov/18390884 DMABRXY DI DMABRXY DMABRXY DN IDM-2101 DMABRXY TI TTY6DTE DMABRXY TN Carcinoembryonic antigen CEA (CD66e) DMABRXY RN Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. DMABRXY RU https://pubmed.ncbi.nlm.nih.gov/18802154 DMABRXY DI DMABRXY DMABRXY DN IDM-2101 DMABRXY TI TTWSKHD DMABRXY TN Melanoma-associated antigen 3 (MAGEA3) DMABRXY RN Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. DMABRXY RU https://pubmed.ncbi.nlm.nih.gov/18802154 DMAC457 DI DMAC457 DMAC457 DN LY3127804 DMAC457 TI TT0APVH DMAC457 TN HUMAN angiopoietin-2 (ANG-2) DMAC457 MA Inhibitor DMAC457 RN Updates: Lilly's Global COVID-19 Response DMAC457 RU https://www.lilly.com/news/stories/coronavirus-covid19-global-response DMACTBM DI DMACTBM DMACTBM DN DAC-060 DMACTBM TI TTBH0VX DMACTBM TN Histone deacetylase (HDAC) DMACTBM MA Inhibitor DMACTBM RN Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369. DMACTBM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341130/ DMAEB9O DI DMAEB9O DMAEB9O DN Valomaciclovir stearate DMAEB9O TI TTIU7X1 DMAEB9O TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMAEB9O MA Modulator DMAEB9O RN Progress in the Development of New Therapies for Herpesvirus Infections. Curr Opin Virol. 2011 December 1; 1(6): 548-554. DMAEB9O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230035/ DMAEWS1 DI DMAEWS1 DMAEWS1 DN GAM-501 DMAEWS1 TI TTQA6SX DMAEWS1 TN Platelet-derived growth factor B (PDGFB) DMAEWS1 MA Modulator DMAEWS1 RN Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9. DMAEWS1 RU https://pubmed.ncbi.nlm.nih.gov/19821960 DMAFUHK DI DMAFUHK DMAFUHK DN QGC-001 DMAFUHK TI TT9PBIL DMAFUHK TN Glutamyl aminopeptidase (ENPEP) DMAFUHK MA Inhibitor DMAFUHK RN Clinical pipeline report, company report or official report of Quantum Genomics. DMAFUHK RU http://www.quantum-genomics.com/www/en/science/programme-qgc001/ DMAFUHK DI DMAFUHK DMAFUHK DN QGC-001 DMAFUHK TI TTGMFY7 DMAFUHK TN Aspartyl aminopeptidase (DNPEP) DMAFUHK MA Inhibitor DMAFUHK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAFUHK RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMAFZ84 DI DMAFZ84 DMAFZ84 DN PIKAMILONE DMAFZ84 TI TTNJYV2 DMAFZ84 TN Gamma-aminobutyric acid receptor (GAR) DMAFZ84 MA Modulator DMAFZ84 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMAFZ84 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMAG4SX DI DMAG4SX DMAG4SX DN BILR-355 DMAG4SX TI TT84ETX DMAG4SX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMAG4SX MA Inhibitor DMAG4SX RN Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8. DMAG4SX RU https://pubmed.ncbi.nlm.nih.gov/21128991 DMAHGKE DI DMAHGKE DMAHGKE DN E7016 DMAHGKE TI TTEBCY8 DMAHGKE TN Poly [ADP-ribose] polymerase (PARP) DMAHGKE MA Modulator DMAHGKE RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMAHGKE RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMAHOEP DI DMAHOEP DMAHOEP DN GRNVAC1 DMAHOEP TI TTUJFD0 DMAHOEP TN Telomerase reverse transcriptase (TERT) DMAHOEP RN Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42. DMAHOEP RU https://pubmed.ncbi.nlm.nih.gov/21332640 DMAIGTE DI DMAIGTE DMAIGTE DN SurVaxM DMAIGTE TI TTTPU1G DMAIGTE TN Apoptosis inhibitor survivin (BIRC5) DMAIGTE MA Inhibitor DMAIGTE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAIGTE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAIW6C DI DMAIW6C DMAIW6C DN Clazakizumab DMAIW6C TI TTT1V78 DMAIW6C TN Interleukin-6 (IL6) DMAIW6C MA Inhibitor DMAIW6C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAIW6C RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAJ6YL DI DMAJ6YL DMAJ6YL DN TNX-1300 DMAJ6YL TI TTX7ZJ3 DMAJ6YL TN Cocaine (Coca) DMAJ6YL MA Degrader DMAJ6YL RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMAJ6YL RU https://www.tonixpharma.com/pipeline/overview DMAJ85O DI DMAJ85O DMAJ85O DN VDA-1102 DMAJ85O TI TTK02H8 DMAJ85O TN Hexokinase-2 (HK2) DMAJ85O MA Modulator DMAJ85O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAJ85O RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAJ85O DI DMAJ85O DMAJ85O DN VDA-1102 DMAJ85O TI TTAMKGB DMAJ85O TN Voltage-dependent anion-selective channel 1 (VDAC1) DMAJ85O MA Modulator DMAJ85O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAJ85O RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAJH75 DI DMAJH75 DMAJH75 DN RSV-604 DMAJH75 TI TT25A0I DMAJH75 TN Respiratory syncytial virus protein N (RSV N) DMAJH75 MA Inhibitor DMAJH75 RN Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. DMAJH75 RU https://pubmed.ncbi.nlm.nih.gov/25451060 DMAKSMX DI DMAKSMX DMAKSMX DN Camicinal DMAKSMX TI TT953CX DMAKSMX TN Motilin receptor (MLNR) DMAKSMX MA Modulator DMAKSMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DMAKSMX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DMANC59 DI DMANC59 DMANC59 DN AZD-3241 DMANC59 TI TTVCZPI DMANC59 TN Myeloperoxidase (MPO) DMANC59 MA Inhibitor DMANC59 RN Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. DMANC59 RU https://pubmed.ncbi.nlm.nih.gov/26137956 DMANRGW DI DMANRGW DMANRGW DN IP10 C8 DMANRGW TI TTDIGC1 DMANRGW TN Dipeptidyl peptidase 4 (DPP-4) DMANRGW MA Modulator DMANRGW RN Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. DMANRGW RU https://pubmed.ncbi.nlm.nih.gov/19327105 DMANRGW DI DMANRGW DMANRGW DN IP10 C8 DMANRGW TI TTPHMWB DMANRGW TN Aminopeptidase N (ANPEP) DMANRGW MA Modulator DMANRGW RN Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. DMANRGW RU https://pubmed.ncbi.nlm.nih.gov/19327105 DMAOUZV DI DMAOUZV DMAOUZV DN Nivatrotamab DMAOUZV TI TTUN7MC DMAOUZV TN T-cell surface glycoprotein CD3 (CD3) DMAOUZV MA Inhibitor DMAOUZV RN Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. DMAOUZV RU https://ymabs.com/research-development/pipeline/ DMAOUZV DI DMAOUZV DMAOUZV DN Nivatrotamab DMAOUZV TI TT80ARU DMAOUZV TN Ganglioside GD2 (GD2) DMAOUZV MA Inhibitor DMAOUZV RN Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. DMAOUZV RU https://ymabs.com/research-development/pipeline/ DMAQW9M DI DMAQW9M DMAQW9M DN SFX-01 DMAQW9M TI TTA6ZN2 DMAQW9M TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAQW9M MA Activator DMAQW9M RN Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. DMAQW9M RU https://pubmed.ncbi.nlm.nih.gov/30610225 DMARIQK DI DMARIQK DMARIQK DN AT-527 DMARIQK TI TTSUKYD DMARIQK TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMARIQK MA Inhibitor DMARIQK RN AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02479-20. DMARIQK RU https://pubmed.ncbi.nlm.nih.gov/33558299 DMARQ0H DI DMARQ0H DMARQ0H DN JKB-122 DMARQ0H TI TTN4QDT DMARQ0H TN Opioid receptor (OPR) DMARQ0H MA Modulator DMARQ0H RN WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase. DMARQ0H RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20111110&CC=WO&NR=2011140190A1&KC=A1 DMARVFG DI DMARVFG DMARVFG DN Talacotuzumab DMARVFG TI TTENHJ0 DMARVFG TN Interleukin 3 receptor alpha (IL3RA) DMARVFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMARVFG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMASRP3 DI DMASRP3 DMASRP3 DN AVA-101 DMASRP3 TI TT9HKJA DMASRP3 TN Vascular endothelial growth factor (VEGF) DMASRP3 MA Modulator DMASRP3 RN Clinical pipeline report, company report or official report of Avalanche Biotechnologies. DMASRP3 RU http://www.avalanchebiotech.com/ DMAUN15 DI DMAUN15 DMAUN15 DN Carlumab DMAUN15 TI TTNAY0P DMAUN15 TN Monocyte chemotactic and activating factor (CCL2) DMAUN15 RN Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23. DMAUN15 RU https://pubmed.ncbi.nlm.nih.gov/24928772 DMAV426 DI DMAV426 DMAV426 DN (S)-oxybutynin DMAV426 TI TTZ9SOR DMAV426 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMAV426 MA Antagonist DMAV426 RN Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7. DMAV426 RU https://pubmed.ncbi.nlm.nih.gov/1993995 DMAVM2E DI DMAVM2E DMAVM2E DN NYX-783 DMAVM2E TI TT9IK2Z DMAVM2E TN N-methyl-D-aspartate receptor (NMDAR) DMAVM2E MA Modulator DMAVM2E RN Clinical pipeline report, company report or official report of Aptinyx. DMAVM2E RU https://www.aptinyx.com/pipeline/ DMAVQR1 DI DMAVQR1 DMAVQR1 DN THR-184 DMAVQR1 TI TTKOBRA DMAVQR1 TN Bone morphogenetic protein 7 (BMP7) DMAVQR1 MA Agonist DMAVQR1 RN Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018 Feb;29(2):670-679. DMAVQR1 RU https://pubmed.ncbi.nlm.nih.gov/29203473 DMAW4EL DI DMAW4EL DMAW4EL DN CLR-1404 DMAW4EL TI TTHBTOP DMAW4EL TN PI3-kinase gamma (PIK3CG) DMAW4EL MA Inhibitor DMAW4EL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMAW4EL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMAWKSM DI DMAWKSM DMAWKSM DN CetuGEX DMAWKSM TI TTGKNB4 DMAWKSM TN Epidermal growth factor receptor (EGFR) DMAWKSM RN Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92. DMAWKSM RU https://pubmed.ncbi.nlm.nih.gov/21293176 DMAWLVB DI DMAWLVB DMAWLVB DN TPI ASM8 DMAWLVB TI TTPYS82 DMAWLVB TN Interleukin 3 receptor (CSF2RB) DMAWLVB MA Modulator DMAWLVB RN Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95. DMAWLVB RU https://www.ncbi.nlm.nih.gov/pubmed/22989709 DMAWXJT DI DMAWXJT DMAWXJT DN ORG-13011 DMAWXJT TI TTSQIFT DMAWXJT TN 5-HT 1A receptor (HTR1A) DMAWXJT MA Antagonist DMAWXJT RN Antagonism of the 5-HT1A receptor stimulus in a conditioned taste aversion procedure. Eur Neuropsychopharmacol. 1999 Jun;9(4):345-9. DMAWXJT RU https://pubmed.ncbi.nlm.nih.gov/10422896 DMAX632 DI DMAX632 DMAX632 DN HDV-interferon DMAX632 TI TTV2CN0 DMAX632 TN Interferon receptor (IFNR) DMAX632 MA Modulator DMAX632 RN Interferon in HDV infection. Antiviral Res. 1994 Jul;24(2-3):165-74. DMAX632 RU https://pubmed.ncbi.nlm.nih.gov/7979316 DMAYWXD DI DMAYWXD DMAYWXD DN VA-111913 DMAYWXD TI TT4TFGN DMAYWXD TN Vasopressin V1a receptor (V1AR) DMAYWXD MA Antagonist DMAYWXD RN Clinical pipeline report, company report or official report of Avarx. DMAYWXD RU http://www.avarx.com/AvaRx/SubDomains/bucket304f365f4d5c821c892abf2b5eb4/Listings/bucket3e0f28b94cc197c9e1c49f1451ad/Public.Listing.display.html DMAZ2L6 DI DMAZ2L6 DMAZ2L6 DN TROXACITABINE DMAZ2L6 TI TTUTN1I DMAZ2L6 TN Human Deoxyribonucleic acid (hDNA) DMAZ2L6 MA Binder DMAZ2L6 RN Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8. DMAZ2L6 RU https://pubmed.ncbi.nlm.nih.gov/15171046 DMAZ460 DI DMAZ460 DMAZ460 DN Pankomab-GEX DMAZ460 TI TTBHFYQ DMAZ460 TN Mucin-1 (MUC1) DMAZ460 RN Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44. DMAZ460 RU https://pubmed.ncbi.nlm.nih.gov/23275306 DMAZHT0 DI DMAZHT0 DMAZHT0 DN TA-8995 DMAZHT0 TI TTFQAYR DMAZHT0 TN Cholesteryl ester transfer protein (CETP) DMAZHT0 MA Inhibitor DMAZHT0 RN Amgen To Acquire Privately-Held Dezima Pharma DMAZHT0 RU http://www.amgen.com/media/media_pr_detail.jsp?releaseID=2088272 DMAZIND DI DMAZIND DMAZIND DN Otlertuzumab DMAZIND TI TTFCW29 DMAZIND TN Leukocyte antigen CD37 (CD37) DMAZIND MA Inhibitor DMAZIND RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAZIND RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAZNVX DI DMAZNVX DMAZNVX DN YM-264 DMAZNVX TI TTQL5VC DMAZNVX TN Platelet-activating factor receptor (PTAFR) DMAZNVX MA Antagonist DMAZNVX RN Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5. DMAZNVX RU https://pubmed.ncbi.nlm.nih.gov/2025290 DMB0CXT DI DMB0CXT DMB0CXT DN GSK2330811 DMB0CXT TI TTIVXSE DMB0CXT TN Oncostatin-M (OSM) DMB0CXT MA Inhibitor DMB0CXT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0CXT RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMB0TNL DI DMB0TNL DMB0TNL DN AC-201 DMB0TNL TI TTRYK0X DMB0TNL TN Interleukin-1 beta (IL1B) DMB0TNL MA Inhibitor DMB0TNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0TNL RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMB0TNL DI DMB0TNL DMB0TNL DN AC-201 DMB0TNL TI TTCQIBE DMB0TNL TN Caspase-1 (CASP1) DMB0TNL MA Inhibitor DMB0TNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0TNL RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMB0UF9 DI DMB0UF9 DMB0UF9 DN Bb2121 DMB0UF9 TI TTZ3P4W DMB0UF9 TN B-cell maturation protein (TNFRSF17) DMB0UF9 MA Immunomodulator DMB0UF9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0UF9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMB1UYV DI DMB1UYV DMB1UYV DN IC-485 DMB1UYV TI TTV5CGO DMB1UYV TN Phosphodiesterase 4 (PDE4) DMB1UYV MA Inhibitor DMB1UYV RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMB1UYV RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMB1WF3 DI DMB1WF3 DMB1WF3 DN OPC-14523 DMB1WF3 TI TT5TPI6 DMB1WF3 TN Opioid receptor sigma 1 (OPRS1) DMB1WF3 MA Modulator DMB1WF3 RN Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. DMB1WF3 RU https://www.ncbi.nlm.nih.gov/pubmed/11747902 DMB1WF3 DI DMB1WF3 DMB1WF3 DN OPC-14523 DMB1WF3 TI TTSQIFT DMB1WF3 TN 5-HT 1A receptor (HTR1A) DMB1WF3 MA Modulator DMB1WF3 RN Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. DMB1WF3 RU https://www.ncbi.nlm.nih.gov/pubmed/11747902 DMB38KH DI DMB38KH DMB38KH DN Elisidepsin DMB38KH TI TTDC8N2 DMB38KH TN Erbb3 tyrosine kinase receptor (Erbb-3) DMB38KH MA Inhibitor DMB38KH RN Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64. DMB38KH RU https://pubmed.ncbi.nlm.nih.gov/19346126 DMB4A8I DI DMB4A8I DMB4A8I DN MANOALIDE DMB4A8I TI TT9V5JH DMB4A8I TN Phospholipase A2 (PLA2G1B) DMB4A8I MA Modulator DMB4A8I RN Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7. DMB4A8I RU https://www.ncbi.nlm.nih.gov/pubmed/9804280 DMB4GD9 DI DMB4GD9 DMB4GD9 DN IONIS-GCGR-Rx DMB4GD9 TI TTLMJSC DMB4GD9 TN Glucagon receptor messenger RNA (GCGR mRNA) DMB4GD9 MA Inhibitor DMB4GD9 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMB4GD9 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMB4HCY DI DMB4HCY DMB4HCY DN KUR-212 DMB4HCY TI TTWODQF DMB4HCY TN Fibrin (FG) DMB4HCY MA Modulator DMB4HCY RN Clinical pipeline report, company report or official report of Kuros. DMB4HCY RU http://www.kuros.ch/cms/front_content.php?idcat=80 DMB4M6O DI DMB4M6O DMB4M6O DN RG7314 DMB4M6O TI TT4TFGN DMB4M6O TN Vasopressin V1a receptor (V1AR) DMB4M6O MA Modulator DMB4M6O RN Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30. DMB4M6O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/ DMB5L6Q DI DMB5L6Q DMB5L6Q DN LY-2940094 DMB5L6Q TI TTNT7K8 DMB5L6Q TN Nociceptin receptor (OPRL1) DMB5L6Q MA Modulator DMB5L6Q RN Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97. DMB5L6Q RU http://www.sciencedirect.com/science/article/pii/S0006295215001562 DMB7CPG DI DMB7CPG DMB7CPG DN Elsiglutide DMB7CPG TI TT1YWO5 DMB7CPG TN Glucagon-like peptide 2 receptor (GLP2R) DMB7CPG MA Modulator DMB7CPG RN Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014. DMB7CPG RU http://onlinelibrary.wiley.com/doi/10.1111/ajco.12305/abstract DMB7WT1 DI DMB7WT1 DMB7WT1 DN L-697,661 DMB7WT1 TI TT84ETX DMB7WT1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB7WT1 MA Modulator DMB7WT1 RN Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8. DMB7WT1 RU https://www.ncbi.nlm.nih.gov/pubmed/7532595 DMB87M3 DI DMB87M3 DMB87M3 DN AZD9668 DMB87M3 TI TTPLTSQ DMB87M3 TN Neutrophil elastase (NE) DMB87M3 MA Inhibitor DMB87M3 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMB87M3 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMB9ADM DI DMB9ADM DMB9ADM DN FolateImmune DMB9ADM TI TTVC37M DMB9ADM TN Folate receptor alpha (FOLR1) DMB9ADM MA Modulator DMB9ADM RN Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91. DMB9ADM RU https://pubmed.ncbi.nlm.nih.gov/19738218 DMB9LRJ DI DMB9LRJ DMB9LRJ DN Bintrafusp alfa DMB9LRJ TI TTO3HT7 DMB9LRJ TN Transforming growth factor beta (TGFB) DMB9LRJ RN Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. DMB9LRJ RU https://pubmed.ncbi.nlm.nih.gov/32173464 DMB9LRJ DI DMB9LRJ DMB9LRJ DN Bintrafusp alfa DMB9LRJ TI TT8ZLTI DMB9LRJ TN Programmed cell death 1 ligand 1 (PD-L1) DMB9LRJ RN Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. DMB9LRJ RU https://pubmed.ncbi.nlm.nih.gov/32173464 DMBADQV DI DMBADQV DMBADQV DN ASP-3291 DMBADQV TI TTEOSZT DMBADQV TN Melanocortin receptor (MCR) DMBADQV MA Modulator DMBADQV RN Clinical pipeline report, company report or official report of Drais Pharmaceuticals. DMBADQV RU http://www.draispharma.com/press.php DMBC7HZ DI DMBC7HZ DMBC7HZ DN DM-CHOC-PEN DMBC7HZ TI TTUTN1I DMBC7HZ TN Human Deoxyribonucleic acid (hDNA) DMBC7HZ MA Modulator DMBC7HZ RN Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835. DMBC7HZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717391/ DMBDFN7 DI DMBDFN7 DMBDFN7 DN GS-4977 DMBDFN7 TI TTOQCD8 DMBDFN7 TN Apoptosis signal-regulating kinase 1 (MAP3K5) DMBDFN7 MA Inhibitor DMBDFN7 RN Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. DMBDFN7 RU https://pubmed.ncbi.nlm.nih.gov/25531162 DMBFPO1 DI DMBFPO1 DMBFPO1 DN F-8-IL-10 fusion protein DMBFPO1 TI TTT0Q1F DMBFPO1 TN Interleukin-10 (IL10) DMBFPO1 MA Modulator DMBFPO1 RN Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142. DMBFPO1 RU https://pubmed.ncbi.nlm.nih.gov/19781067 DMBFZET DI DMBFZET DMBFZET DN DX-890 DMBFZET TI TTPLTSQ DMBFZET TN Neutrophil elastase (NE) DMBFZET MA Inhibitor DMBFZET RN Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. DMBFZET RU https://pubmed.ncbi.nlm.nih.gov/17874973 DMBFZSX DI DMBFZSX DMBFZSX DN RALURIDINE DMBFZSX TI TT84ETX DMBFZSX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBFZSX MA Inhibitor DMBFZSX RN 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603. DMBFZSX RU https://pubmed.ncbi.nlm.nih.gov/7526782 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTK25J1 DMBH316 TN Adenosine A1 receptor (ADORA1) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTNE7KG DMBH316 TN Adenosine A2b receptor (ADORA2B) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTM2AOE DMBH316 TN Adenosine A2a receptor (ADORA2A) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTJFY5U DMBH316 TN Adenosine A3 receptor (ADORA3) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH7XI DI DMBH7XI DMBH7XI DN Pramiconazole DMBH7XI TI TTTSOUD DMBH7XI TN Candida Cytochrome P450 51 (Candi ERG11) DMBH7XI MA Modulator DMBH7XI RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBH7XI RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBHN4K DI DMBHN4K DMBHN4K DN RQ-00000005 DMBHN4K TI TTWDC17 DMBHN4K TN Growth hormone secretagogue receptor 1 (GHSR) DMBHN4K MA Agonist DMBHN4K RN Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86. DMBHN4K RU https://pubmed.ncbi.nlm.nih.gov/24670149 DMBHP56 DI DMBHP56 DMBHP56 DN Efungumab DMBHP56 TI TT78R5H DMBHP56 TN Heat shock protein 90 alpha (HSP90A) DMBHP56 RN Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. DMBHP56 RU https://pubmed.ncbi.nlm.nih.gov/19773528 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TTRK8B9 DMBHPDW TN Sodium channel unspecific (NaC) DMBHPDW MA Blocker DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TTNJYV2 DMBHPDW TN Gamma-aminobutyric acid receptor (GAR) DMBHPDW MA Agonist DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TT6R7JZ DMBHPDW TN Histone deacetylase 1 (HDAC1) DMBHPDW MA Inhibitor DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBJ3GL DI DMBJ3GL DMBJ3GL DN Nerenone DMBJ3GL TI TT26PHO DMBJ3GL TN Mineralocorticoid receptor (MR) DMBJ3GL MA Antagonist DMBJ3GL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMBJ3GL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMBJMZC DI DMBJMZC DMBJMZC DN GSK239512 DMBJMZC TI TT9JNIC DMBJMZC TN Histamine H3 receptor (H3R) DMBJMZC MA Antagonist DMBJMZC RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMBJMZC RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMBJN19 DI DMBJN19 DMBJN19 DN Rontalizumab DMBJN19 TI TT95SOA DMBJN19 TN Interferon alpha (IFNA) DMBJN19 RN Clinical pipeline report, company report or official report of Genentech (2011). DMBJN19 RU http://www.gene.com/gene/index.jsp DMBJU2G DI DMBJU2G DMBJU2G DN SAR-260093 DMBJU2G TI TT7QNVC DMBJU2G TN Glucose-dependent insulinotropic receptor (GPR119) DMBJU2G MA Agonist DMBJU2G RN GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59. DMBJU2G RU https://pubmed.ncbi.nlm.nih.gov/19780700 DMBJY1Z DI DMBJY1Z DMBJY1Z DN SCH-900271 DMBJY1Z TI TTWNV8U DMBJY1Z TN Nicotinic acid receptor (HCAR2) DMBJY1Z MA Modulator DMBJY1Z RN Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8. DMBJY1Z RU https://pubmed.ncbi.nlm.nih.gov/24900372 DMBKQSZ DI DMBKQSZ DMBKQSZ DN TTP399 DMBKQSZ TI TTDLNGZ DMBKQSZ TN Glucokinase (GCK) DMBKQSZ MA Activator DMBKQSZ RN Clinical pipeline report, company report or official report of vTv Therapeutics. DMBKQSZ RU https://vtvtherapeutics.com/pipeline/ttp399/ DMBL3VD DI DMBL3VD DMBL3VD DN PF-05212384 DMBL3VD TI TTCJG29 DMBL3VD TN Serine/threonine-protein kinase mTOR (mTOR) DMBL3VD MA Modulator DMBL3VD RN First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. DMBL3VD RU https://pubmed.ncbi.nlm.nih.gov/25652454 DMBL3VD DI DMBL3VD DMBL3VD DN PF-05212384 DMBL3VD TI TTHBTOP DMBL3VD TN PI3-kinase gamma (PIK3CG) DMBL3VD MA Modulator DMBL3VD RN First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. DMBL3VD RU https://pubmed.ncbi.nlm.nih.gov/25652454 DMBLHGP DI DMBLHGP DMBLHGP DN Saracatinib DMBLHGP TI TT6PKBN DMBLHGP TN Proto-oncogene c-Src (SRC) DMBLHGP MA Modulator DMBLHGP RN Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45. DMBLHGP RU https://www.ncbi.nlm.nih.gov/pubmed/20557276 DMBLHGP DI DMBLHGP DMBLHGP DN Saracatinib DMBLHGP TI TT3PJMV DMBLHGP TN Tyrosine-protein kinase ABL1 (ABL) DMBLHGP MA Modulator DMBLHGP RN Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45. DMBLHGP RU https://www.ncbi.nlm.nih.gov/pubmed/20557276 DMBM2I9 DI DMBM2I9 DMBM2I9 DN LY-518674 DMBM2I9 TI TTJ584C DMBM2I9 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMBM2I9 MA Agonist DMBM2I9 RN Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6. DMBM2I9 RU https://pubmed.ncbi.nlm.nih.gov/18988892 DMBM47Z DI DMBM47Z DMBM47Z DN Oxazolidinones DMBM47Z TI TTLFGBV DMBM47Z TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMBM47Z MA Inhibitor DMBM47Z RN Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. DMBM47Z RU https://pubmed.ncbi.nlm.nih.gov/10411137 DMBM47Z DI DMBM47Z DMBM47Z DN Oxazolidinones DMBM47Z TI TT38DW5 DMBM47Z TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMBM47Z MA Inhibitor DMBM47Z RN Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. DMBM47Z RU https://pubmed.ncbi.nlm.nih.gov/10411137 DMBNU1W DI DMBNU1W DMBNU1W DN TTP-054 DMBNU1W TI TTVIMDE DMBNU1W TN Glucagon-like peptide 1 receptor (GLP1R) DMBNU1W MA Modulator DMBNU1W RN Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor. Exp Diabetes Res. 2012; 2012: 709893. DMBNU1W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352573/ DMBO021 DI DMBO021 DMBO021 DN THR-18 DMBO021 TI TTTO43N DMBO021 TN Endothelial plasminogen activator inhibitor (SERPINE1) DMBO021 MA Activator DMBO021 RN THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models. Neurol Res. 2011 Nov;33(9):983-90. DMBO021 RU https://pubmed.ncbi.nlm.nih.gov/22081002 DMBOL4K DI DMBOL4K DMBOL4K DN 264W94 DMBOL4K TI TTPI1M5 DMBOL4K TN Ileal sodium/bile acid cotransporter (SLC10A2) DMBOL4K MA Modulator DMBOL4K RN Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. DMBOL4K RU https://pubmed.ncbi.nlm.nih.gov/21934041 DMBOZPH DI DMBOZPH DMBOZPH DN RX-5902 DMBOZPH TI TTOTSW1 DMBOZPH TN ATP-dependent RNA helicase DDX5 (DDX5) DMBOZPH MA Modulator DMBOZPH RN Company report (Rexahn) DMBOZPH RU http://investors.rexahn.com/releasedetail.cfm?releaseid=895381 DMBOZPH DI DMBOZPH DMBOZPH DN RX-5902 DMBOZPH TI TTZKPVC DMBOZPH TN Phosphorylated p68 RNA helicase (pDDX5) DMBOZPH MA Inhibitor DMBOZPH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBOZPH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBPJ9U DI DMBPJ9U DMBPJ9U DN PEGylated pitrakinra DMBPJ9U TI TTLGTKB DMBPJ9U TN Interleukin-4 (IL4) DMBPJ9U MA Modulator DMBPJ9U RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMBPJ9U RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMBPJ9U DI DMBPJ9U DMBPJ9U DN PEGylated pitrakinra DMBPJ9U TI TT0GVCH DMBPJ9U TN Interleukin-13 (IL13) DMBPJ9U MA Modulator DMBPJ9U RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMBPJ9U RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMBQC3L DI DMBQC3L DMBQC3L DN Verubulin DMBQC3L TI TTYFKSZ DMBQC3L TN Tubulin beta (TUBB) DMBQC3L MA Modulator DMBQC3L RN Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54. DMBQC3L RU https://www.ncbi.nlm.nih.gov/pubmed/24678059 DMBQD9H DI DMBQD9H DMBQD9H DN TAK-906 DMBQD9H TI TT4C8EA DMBQD9H TN Dopamine D3 receptor (D3R) DMBQD9H MA Inhibitor DMBQD9H RN Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18. DMBQD9H RU https://pubmed.ncbi.nlm.nih.gov/33462988 DMBQD9H DI DMBQD9H DMBQD9H DN TAK-906 DMBQD9H TI TTEX248 DMBQD9H TN Dopamine D2 receptor (D2R) DMBQD9H MA Inhibitor DMBQD9H RN Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18. DMBQD9H RU https://pubmed.ncbi.nlm.nih.gov/33462988 DMBR0QK DI DMBR0QK DMBR0QK DN Atorvastatin DMBR0QK TI TTDJB68 DMBR0QK TN HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) DMBR0QK MA Inhibitor DMBR0QK RN Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042. DMBR0QK RU https://pubmed.ncbi.nlm.nih.gov/32347925 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TT0EOB8 DMBR8NF TN B-Raf messenger RNA (BRAF mRNA) DMBR8NF MA Inhibitor DMBR8NF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). DMBR8NF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TTAN5W2 DMBR8NF TN Raf messenger RNA (Raf mRNA) DMBR8NF MA Inhibitor DMBR8NF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). DMBR8NF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TTQ9K3Y DMBR8NF TN Serine/threonine-protein kinase Raf (RAF) DMBR8NF MA Inhibitor DMBR8NF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBR8NF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBRKZ7 DI DMBRKZ7 DMBRKZ7 DN CT1812 DMBRKZ7 TI TT9NXW4 DMBRKZ7 TN Sigma intracellular receptor 2 (TMEM97) DMBRKZ7 MA Antagonist DMBRKZ7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBRKZ7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMBRL19 DI DMBRL19 DMBRL19 DN Bimakalim DMBRL19 TI TT1VOHK DMBRL19 TN Potassium channel unspecific (KC) DMBRL19 MA Agonist DMBRL19 RN Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46. DMBRL19 RU https://pubmed.ncbi.nlm.nih.gov/15115902 DMBSXR9 DI DMBSXR9 DMBSXR9 DN rhACE2 DMBSXR9 TI TTYRG7F DMBSXR9 TN HUMAN angiotensin-converting enzyme 2 (ACE2) DMBSXR9 MA Inhibitor DMBSXR9 RN ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 DMBSXR9 RU https://clinicaltrials.gov/ct2/show/NCT04346797 DMBT46Y DI DMBT46Y DMBT46Y DN CTP-543 DMBT46Y TI TTRMX3V DMBT46Y TN Janus kinase 2 (JAK-2) DMBT46Y MA Inhibitor DMBT46Y RN Clinical pipeline report, company report or official report of Concert Pharmaceuticals. DMBT46Y RU https://www.concertpharma.com/product-pipeline/ctp-543/ DMBT46Y DI DMBT46Y DMBT46Y DN CTP-543 DMBT46Y TI TT6DM01 DMBT46Y TN Janus kinase 1 (JAK-1) DMBT46Y MA Inhibitor DMBT46Y RN Clinical pipeline report, company report or official report of Concert Pharmaceuticals. DMBT46Y RU https://www.concertpharma.com/product-pipeline/ctp-543/ DMBTVFE DI DMBTVFE DMBTVFE DN MEDI-551 DMBTVFE TI TTW640A DMBTVFE TN B-lymphocyte surface antigen B4 (CD19) DMBTVFE RN Clinical pipeline report, company report or official report of MedImmune (2011). DMBTVFE RU http://www.medimmune.com/research_pipeline.aspx DMBUSNL DI DMBUSNL DMBUSNL DN Pumosetrag DMBUSNL TI TTNXLKE DMBUSNL TN 5-HT 3 receptor (5HT3R) DMBUSNL MA Modulator DMBUSNL RN Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.Neurogastroenterol Motil.2014 Jan;26(1):13-20. DMBUSNL RU https://www.ncbi.nlm.nih.gov/pubmed/24001105 DMBVI6E DI DMBVI6E DMBVI6E DN Ostabolin-C DMBVI6E TI TT6F7GZ DMBVI6E TN Parathyroid hormone (PTH) DMBVI6E MA Modulator DMBVI6E RN ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs. 2008 Nov;11(11):827-40. DMBVI6E RU https://www.ncbi.nlm.nih.gov/pubmed/18988128 DMBWNX5 DI DMBWNX5 DMBWNX5 DN AMA-76 DMBWNX5 TI TTMQO60 DMBWNX5 TN Rho-associated protein kinase (ROCK) DMBWNX5 MA Modulator DMBWNX5 RN AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16. DMBWNX5 RU https://pubmed.ncbi.nlm.nih.gov/24474276 DMBWPZJ DI DMBWPZJ DMBWPZJ DN GSK2245035 DMBWPZJ TI TTRJ1K4 DMBWPZJ TN Toll-like receptor 7 (TLR7) DMBWPZJ MA Modulator DMBWPZJ RN Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80. DMBWPZJ RU https://pubmed.ncbi.nlm.nih.gov/26044169 DMBX2RE DI DMBX2RE DMBX2RE DN MN-221 DMBX2RE TI TT2CJVK DMBX2RE TN Adrenergic receptor beta-2 (ADRB2) DMBX2RE MA Agonist DMBX2RE RN Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13. DMBX2RE RU https://pubmed.ncbi.nlm.nih.gov/19527375 DMBX9C0 DI DMBX9C0 DMBX9C0 DN GW-427353 DMBX9C0 TI TTMXGCW DMBX9C0 TN Adrenergic receptor beta-3 (ADRB3) DMBX9C0 MA Agonist DMBX9C0 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMBX9C0 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMBXEG9 DI DMBXEG9 DMBXEG9 DN Intetumumab DMBXEG9 TI TT69TQN DMBXEG9 TN Integrin alpha-V/beta-3 (ITGAV/B3) DMBXEG9 MA Modulator DMBXEG9 RN A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52. DMBXEG9 RU https://pubmed.ncbi.nlm.nih.gov/21750555 DMBXWJ5 DI DMBXWJ5 DMBXWJ5 DN JNJ 63723283 DMBXWJ5 TI TTNBFWK DMBXWJ5 TN Programmed cell death protein 1 (PD-1) DMBXWJ5 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMBXWJ5 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMBYDNE DI DMBYDNE DMBYDNE DN Managlinat dialanetil DMBYDNE TI TTWHDVK DMBYDNE TN Fructose-1,6-bisphosphatase (FBP) DMBYDNE MA Modulator DMBYDNE RN MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5. DMBYDNE RU https://pubmed.ncbi.nlm.nih.gov/15911772 DMBYJ92 DI DMBYJ92 DMBYJ92 DN Dilmapimod DMBYJ92 TI TTQBR95 DMBYJ92 TN Stress-activated protein kinase 2a (p38 alpha) DMBYJ92 MA Inhibitor DMBYJ92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMBYJ92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMBZ6CP DI DMBZ6CP DMBZ6CP DN PRN1008 DMBZ6CP TI TTGM6VW DMBZ6CP TN Tyrosine-protein kinase BTK (ATK) DMBZ6CP MA Inhibitor DMBZ6CP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBZ6CP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMBZK3P DI DMBZK3P DMBZK3P DN ISF35 DMBZK3P TI TTIJP3Q DMBZK3P TN TNF related activation protein (CD40LG) DMBZK3P MA Binder DMBZK3P RN Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25. DMBZK3P RU https://pubmed.ncbi.nlm.nih.gov/25382101 DMBZO8N DI DMBZO8N DMBZO8N DN Sabarubicin DMBZO8N TI TT0IHXV DMBZO8N TN DNA topoisomerase II (TOP2) DMBZO8N MA Modulator DMBZO8N RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBZO8N RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBZQS7 DI DMBZQS7 DMBZQS7 DN ASP-8477 DMBZQS7 TI TTVJ1D8 DMBZQS7 TN Vascular endothelial growth factor receptor (VEGFR) DMBZQS7 MA Modulator DMBZQS7 RN ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. DMBZQS7 RU https://clinicaltrials.gov/ct2/show/NCT02065349 DMC04SR DI DMC04SR DMC04SR DN LB-100 DMC04SR TI TTHTKNY DMC04SR TN Serine/threonine PP2A-alpha (PPP2CA) DMC04SR MA Inhibitor DMC04SR RN Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72. DMC04SR RU https://pubmed.ncbi.nlm.nih.gov/24867249 DMC04SR DI DMC04SR DMC04SR DN LB-100 DMC04SR TI TTRKDL6 DMC04SR TN Serine/threonine PP2A (PP2A) DMC04SR MA Inhibitor DMC04SR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC04SR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC13BQ DI DMC13BQ DMC13BQ DN ICO-25 DMC13BQ TI TTBHFYQ DMC13BQ TN Mucin-1 (MUC1) DMC13BQ RN The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5. DMC13BQ RU https://pubmed.ncbi.nlm.nih.gov/12534220 DMC1F2T DI DMC1F2T DMC1F2T DN FP-1097 DMC1F2T TI TTZ9SOR DMC1F2T TN Muscarinic acetylcholine receptor M1 (CHRM1) DMC1F2T MA Antagonist DMC1F2T RN Clinical pipeline report, company report or official report of FemmePharma. DMC1F2T RU http://femmepharma.com/ DMC1F2T DI DMC1F2T DMC1F2T DN FP-1097 DMC1F2T TI TTYEG6Q DMC1F2T TN Muscarinic acetylcholine receptor M2 (CHRM2) DMC1F2T MA Antagonist DMC1F2T RN Clinical pipeline report, company report or official report of FemmePharma. DMC1F2T RU http://femmepharma.com/ DMC1I56 DI DMC1I56 DMC1I56 DN Exherin DMC1I56 TI TT1WS0T DMC1I56 TN Neural cadherin (CDH2) DMC1I56 MA Binder DMC1I56 RN Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5. DMC1I56 RU https://pubmed.ncbi.nlm.nih.gov/19190075 DMC2FAL DI DMC2FAL DMC2FAL DN PF-3893787 DMC2FAL TI TTXJ178 DMC2FAL TN Histamine H4 receptor (H4R) DMC2FAL MA Antagonist DMC2FAL RN Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. DMC2FAL RU https://pubmed.ncbi.nlm.nih.gov/21920751 DMC3P45 DI DMC3P45 DMC3P45 DN Terameprocol DMC3P45 TI TTZEP6S DMC3P45 TN Transcription factor Sp1 (SP1) DMC3P45 MA Modulator DMC3P45 RN Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14. DMC3P45 RU https://pubmed.ncbi.nlm.nih.gov/18311658 DMC3PJS DI DMC3PJS DMC3PJS DN Oxytrex DMC3PJS TI TTN4QDT DMC3PJS TN Opioid receptor (OPR) DMC3PJS MA Modulator DMC3PJS RN Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. DMC3PJS RU https://pubmed.ncbi.nlm.nih.gov/17685875 DMC3T2S DI DMC3T2S DMC3T2S DN PIRODOMAST DMC3T2S TI TTTWGIX DMC3T2S TN Leukotriene receptor (LTR) DMC3T2S MA Modulator DMC3T2S RN Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003. DMC3T2S RU https://pubmed.ncbi.nlm.nih.gov/2462630 DMC48SP DI DMC48SP DMC48SP DN AZD-7268 DMC48SP TI TTN4QDT DMC48SP TN Opioid receptor (OPR) DMC48SP MA Modulator DMC48SP RN EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders. DMC48SP RU http://www.google.com/patents/EP2774991A1?cl=en DMC56T4 DI DMC56T4 DMC56T4 DN RAF265 DMC56T4 TI TTUTJGQ DMC56T4 TN Vascular endothelial growth factor receptor 2 (KDR) DMC56T4 MA Modulator DMC56T4 RN RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. DMC56T4 RU https://pubmed.ncbi.nlm.nih.gov/22773056 DMC5MQD DI DMC5MQD DMC5MQD DN M2951 DMC5MQD TI TTGM6VW DMC5MQD TN Tyrosine-protein kinase BTK (ATK) DMC5MQD MA Inhibitor DMC5MQD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC5MQD RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMC5PB2 DI DMC5PB2 DMC5PB2 DN E-4716 DMC5PB2 TI TTTIBOJ DMC5PB2 TN Histamine H1 receptor (H1R) DMC5PB2 MA Modulator DMC5PB2 RN Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol. 2005 Jan;59(1):43-53. DMC5PB2 RU https://pubmed.ncbi.nlm.nih.gov/15606439 DMC5TV6 DI DMC5TV6 DMC5TV6 DN TPI-287 DMC5TV6 TI TT1WDO0 DMC5TV6 TN Microtubule (MicroTu) DMC5TV6 MA Stabilizer DMC5TV6 RN TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012 Sep;11(9):1959-67. DMC5TV6 RU https://pubmed.ncbi.nlm.nih.gov/22622283 DMC8NAO DI DMC8NAO DMC8NAO DN ADXS-HPV DMC8NAO TI TT3CPZW DMC8NAO TN Human papillomavirus protein E7 (HPV E7) DMC8NAO RN ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231. DMC8NAO RU http://www.immunotherapyofcancer.org/content/1/S1/P231 DMCA8G1 DI DMCA8G1 DMCA8G1 DN VTP-43742 DMCA8G1 TI TTGV6LY DMCA8G1 TN Nuclear receptor ROR-gamma (RORG) DMCA8G1 MA Inhibitor DMCA8G1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCA8G1 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCAFVN DI DMCAFVN DMCAFVN DN IRT-102 DMCAFVN TI TT6IEYX DMCAFVN TN Opioid receptor zeta (OGFR) DMCAFVN MA Modulator DMCAFVN RN The opiate receptor binding interactions of 3H-methionine enkephalin, an opioid peptide. Eur J Pharmacol. 1978 Feb 1;47(3):319-31. DMCAFVN RU https://pubmed.ncbi.nlm.nih.gov/204498 DMCAFXM DI DMCAFXM DMCAFXM DN ALX-101 DMCAFXM TI TTM1EQF DMCAFXM TN Oxysterols receptor LXR (NR1H) DMCAFXM MA Agonist DMCAFXM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCAFXM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCATH2 DI DMCATH2 DMCATH2 DN Dilpacimab DMCATH2 TI TTV23LH DMCATH2 TN Delta-like protein 4 (DLL4) DMCATH2 RN Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35. DMCATH2 RU https://pubmed.ncbi.nlm.nih.gov/21473903 DMCATH2 DI DMCATH2 DMCATH2 DN Dilpacimab DMCATH2 TI TT9HKJA DMCATH2 TN Vascular endothelial growth factor (VEGF) DMCATH2 RN Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35. DMCATH2 RU https://pubmed.ncbi.nlm.nih.gov/21473903 DMCBEYH DI DMCBEYH DMCBEYH DN P54 DMCBEYH TI TTUIZKC DMCBEYH TN DNA-binding factor KBF1 (p105) DMCBEYH MA Modulator DMCBEYH RN Identification of p54(nrb) and the 14-3-3 Protein HS1 as TNF-alpha-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol. 2005 Jul 31;38(4):447-56. DMCBEYH RU https://pubmed.ncbi.nlm.nih.gov/16053712 DMCD6G1 DI DMCD6G1 DMCD6G1 DN SMT-C1100 DMCD6G1 TI TTNO1VA DMCD6G1 TN Utrophin (UTRN) DMCD6G1 MA Regulator (upregulator) DMCD6G1 RN Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol.2015 Jun;55(6):698-707. DMCD6G1 RU https://pubmed.ncbi.nlm.nih.gov/25651188 DMCDAVK DI DMCDAVK DMCDAVK DN GSK3036656 DMCDAVK TI TT46T5G DMCDAVK TN Mycobacterium Leucine-tRNA ligase (MycB leuS) DMCDAVK MA Inhibitor DMCDAVK RN Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem. 2017 Oct 12;60(19):8011-8026. DMCDAVK RU https://pubmed.ncbi.nlm.nih.gov/28953378 DMCDMFP DI DMCDMFP DMCDMFP DN TT-223 DMCDMFP TI TTVFO0U DMCDMFP TN Gastrin/cholecystokinin type B receptor (CCKBR) DMCDMFP MA Modulator DMCDMFP RN The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98. DMCDMFP RU https://pubmed.ncbi.nlm.nih.gov/10757621 DMCDON3 DI DMCDON3 DMCDON3 DN SLV 306 DMCDON3 TI TT5TKPM DMCDON3 TN Neutral endopeptidase (MME) DMCDON3 MA Modulator DMCDON3 RN The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. DMCDON3 RU https://pubmed.ncbi.nlm.nih.gov/22480515 DMCDON3 DI DMCDON3 DMCDON3 DN SLV 306 DMCDON3 TI TT1BGDH DMCDON3 TN Endothelin-converting enzyme (ECE) DMCDON3 MA Modulator DMCDON3 RN The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. DMCDON3 RU https://pubmed.ncbi.nlm.nih.gov/22480515 DMCEPUA DI DMCEPUA DMCEPUA DN ERB-041 DMCEPUA TI TTOM3J0 DMCEPUA TN Estrogen receptor beta (ESR2) DMCEPUA MA Agonist DMCEPUA RN Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98. DMCEPUA RU https://pubmed.ncbi.nlm.nih.gov/24217507 DMCEUOH DI DMCEUOH DMCEUOH DN Fluoropeptide vaccine DMCEUOH TI TTN2JFW DMCEUOH TN T-cell surface glycoprotein CD4 (CD4) DMCEUOH RN A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402. DMCEUOH RU https://pubmed.ncbi.nlm.nih.gov/24928790 DMCEUOH DI DMCEUOH DMCEUOH DN Fluoropeptide vaccine DMCEUOH TI TTMHA6L DMCEUOH TN T-cell surface glycoprotein CD8 (CD8) DMCEUOH RN A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402. DMCEUOH RU https://pubmed.ncbi.nlm.nih.gov/24928790 DMCF5E0 DI DMCF5E0 DMCF5E0 DN Vaniprevir DMCF5E0 TI TT5FNQT DMCF5E0 TN Human immunodeficiency virus Protease (HIV PR) DMCF5E0 MA Inhibitor DMCF5E0 RN Clinical pipeline report, company report or official report of Merck (2011). DMCF5E0 RU http://www.merck.com/index.html DMCFGP3 DI DMCFGP3 DMCFGP3 DN LKA651 DMCFGP3 TI TTQG4NR DMCFGP3 TN Erythropoietin (EPO) DMCFGP3 RN Clinical pipeline report, company report or official report of Novartis. DMCFGP3 RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=LKA651&field_pipeline_filing_date=All DMCFLRH DI DMCFLRH DMCFLRH DN Cibinetide DMCFLRH TI TTAUX24 DMCFLRH TN Erythropoietin Receptor (EPOR) DMCFLRH MA Agonist DMCFLRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCFLRH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCFPBE DI DMCFPBE DMCFPBE DN NN8765 DMCFPBE TI TTC4IMS DMCFPBE TN NKG2-A/B-activating NK receptor (NKG2A) DMCFPBE MA Modulator DMCFPBE RN Handbook of Therapeutic Antibodies. 2014. 1. Page(1098). DMCFPBE RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA2173&lpg=PA2173&dq=%22NN-8765%22+++drug&source=bl&ots=OSgek3Ubee&sig=uPqJzQ0sfWmrddc5W83GKlUI4JQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI3cTx8NTGyAIVTgWOCh29iQZt DMCGK9H DI DMCGK9H DMCGK9H DN VT-1129 DMCGK9H TI TT3C1VN DMCGK9H TN Enzyme unspecific (Enz) DMCGK9H MA Inhibitor DMCGK9H RN The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7. DMCGK9H RU https://pubmed.ncbi.nlm.nih.gov/25224009 DMCGK9H DI DMCGK9H DMCGK9H DN VT-1129 DMCGK9H TI TT67TDP DMCGK9H TN Lanosterol 14-alpha demethylase (CYP51A1) DMCGK9H MA Inhibitor DMCGK9H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCGK9H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCGNJ6 DI DMCGNJ6 DMCGNJ6 DN CDX-1401 DMCGNJ6 TI TTE5ITK DMCGNJ6 TN Cancer/testis antigen 1 (NY-ESO-1) DMCGNJ6 MA Modulator DMCGNJ6 RN National Cancer Institute Drug Dictionary (drug id 651880). DMCGNJ6 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=651880 DMCH3G5 DI DMCH3G5 DMCH3G5 DN AQX-1125 DMCH3G5 TI TTTP2Z1 DMCH3G5 TN SH2 domain inositol 5'-phosphatase 1 (INPP5D) DMCH3G5 MA Agonist DMCH3G5 RN Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol. 2013 Mar;168(6):1519-29. DMCH3G5 RU https://pubmed.ncbi.nlm.nih.gov/23121409 DMCHFB0 DI DMCHFB0 DMCHFB0 DN YH-4808 DMCHFB0 TI TTLOKXP DMCHFB0 TN Gastric H(+)/K(+) ATPase (Proton pump) DMCHFB0 MA Modulator DMCHFB0 RN Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704. DMCHFB0 RU https://www.ncbi.nlm.nih.gov/pubmed/22783985 DMCHWX1 DI DMCHWX1 DMCHWX1 DN DCR-PHXC DMCHWX1 TI TTW76JE DMCHWX1 TN LDHA messenger RNA (LDHA mRNA) DMCHWX1 MA Inhibitor DMCHWX1 RN Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. DMCHWX1 RU https://pubmed.ncbi.nlm.nih.gov/33912759 DMCHZAN DI DMCHZAN DMCHZAN DN RGH-896 DMCHZAN TI TTN9D8E DMCHZAN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMCHZAN MA Antagonist DMCHZAN RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMCHZAN RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMCIGRB DI DMCIGRB DMCIGRB DN Fialuridine DMCIGRB TI TTIU7X1 DMCIGRB TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMCIGRB MA Modulator DMCIGRB RN Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7. DMCIGRB RU https://pubmed.ncbi.nlm.nih.gov/8622980 DMCIGRW DI DMCIGRW DMCIGRW DN GSK2838232 DMCIGRW TI TT5TOX7 DMCIGRW TN Human immunodeficiency virus Maturation (HIV Mat) DMCIGRW MA Modulator DMCIGRW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762) DMCIGRW RU http://adisinsight.springer.com/drugs/800037762 DMCJX79 DI DMCJX79 DMCJX79 DN ITV-1 DMCJX79 TI TTG90S6 DMCJX79 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMCJX79 RN Clinical pipeline report, company report or official report of Immunotech Laboratories. DMCJX79 RU http://www.immunotechlab.com/ipf/ DMCK8SX DI DMCK8SX DMCK8SX DN MDX-1097 DMCK8SX TI TT1HM0R DMCK8SX TN Kappa myeloma antigen (KMA) DMCK8SX RN MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43. DMCK8SX RU https://pubmed.ncbi.nlm.nih.gov/25653020 DMCKNBA DI DMCKNBA DMCKNBA DN Lufironil DMCKNBA TI TTNH25W DMCKNBA TN Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) DMCKNBA MA Modulator DMCKNBA RN Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994Jul;32(7):515-20. DMCKNBA RU https://pubmed.ncbi.nlm.nih.gov/7981331 DMCLEXM DI DMCLEXM DMCLEXM DN SAR-110894 DMCLEXM TI TT9JNIC DMCLEXM TN Histamine H3 receptor (H3R) DMCLEXM MA Antagonist DMCLEXM RN SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. DMCLEXM RU https://pubmed.ncbi.nlm.nih.gov/22542742 DMCLT2F DI DMCLT2F DMCLT2F DN Emepepimut-S DMCLT2F TI TTBHFYQ DMCLT2F TN Mucin-1 (MUC1) DMCLT2F RN Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7. DMCLT2F RU https://pubmed.ncbi.nlm.nih.gov/21689064 DMCLWDJ DI DMCLWDJ DMCLWDJ DN Lumacaftor DMCLWDJ TI TTRLZHP DMCLWDJ TN cAMP-dependent chloride channel (CFTR) DMCLWDJ MA Regulator DMCLWDJ RN A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38. DMCLWDJ RU https://pubmed.ncbi.nlm.nih.gov/24973281 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTL9MHW DMCMD93 TN Vasopressin V1b receptor (V1BR) DMCMD93 MA Antagonist DMCMD93 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTK8R02 DMCMD93 TN Vasopressin V2 receptor (V2R) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTSCIUP DMCMD93 TN Oxytocin receptor (OTR) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TT4TFGN DMCMD93 TN Vasopressin V1a receptor (V1AR) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCN4H6 DI DMCN4H6 DMCN4H6 DN Flezelastine DMCN4H6 TI TTEWNM1 DMCN4H6 TN IL-1 synthesis/release (IL-1 synth/rele) DMCN4H6 MA Modulator DMCN4H6 RN Effects of flezelastine and its enantiomers on LPS-induced IL-1 beta generation in vitro and LPS-induced pyrexia in vivo. Agents Actions. 1994 Mar;41(1-2):99-100. DMCN4H6 RU https://pubmed.ncbi.nlm.nih.gov/7915872 DMCN9GX DI DMCN9GX DMCN9GX DN CVX-045 DMCN9GX TI TTKI0H1 DMCN9GX TN Thrombospondin-1 (THBS1) DMCN9GX MA Agonist DMCN9GX RN Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl Oncol. 2011 Aug;4(4):249-57. DMCN9GX RU https://pubmed.ncbi.nlm.nih.gov/21804921 DMCNL7Z DI DMCNL7Z DMCNL7Z DN MT-3724 DMCNL7Z TI TTUE541 DMCNL7Z TN Leukocyte surface antigen Leu-16 (CD20) DMCNL7Z MA Inhibitor DMCNL7Z RN Clinical pipeline report, company report or official report of Molecular Templates. DMCNL7Z RU https://www.mtem.com/pipeline/mt-3724 DMCNTFW DI DMCNTFW DMCNTFW DN Ad-RTS-hIL-12 DMCNTFW TI TTG68FB DMCNTFW TN Interleukine 12 (IL-12) DMCNTFW MA Replacement DMCNTFW RN Clinical pipeline report, company report or official report of Ziopharm Oncology. DMCNTFW RU https://ziopharm.com/controlled-il-12/ DMCO8UZ DI DMCO8UZ DMCO8UZ DN KP-496 DMCO8UZ TI TTGKOY9 DMCO8UZ TN Leukotriene CysLT1 receptor (CYSLTR1) DMCO8UZ MA Modulator DMCO8UZ RN Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10. DMCO8UZ RU https://pubmed.ncbi.nlm.nih.gov/17130683 DMCO8UZ DI DMCO8UZ DMCO8UZ DN KP-496 DMCO8UZ TI TT2O84V DMCO8UZ TN Thromboxane A2 receptor (TBXA2R) DMCO8UZ MA Modulator DMCO8UZ RN Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10. DMCO8UZ RU https://pubmed.ncbi.nlm.nih.gov/17130683 DMCPUKG DI DMCPUKG DMCPUKG DN BAY 85-8501 DMCPUKG TI TTPLTSQ DMCPUKG TN Neutrophil elastase (NE) DMCPUKG MA Modulator DMCPUKG RN Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73. DMCPUKG RU https://pubmed.ncbi.nlm.nih.gov/26083237 DMCQARM DI DMCQARM DMCQARM DN TTP889 DMCQARM TI TTFEZ5Q DMCQARM TN Coagulation factor IX (F9) DMCQARM MA Inhibitor DMCQARM RN Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63. DMCQARM RU https://pubmed.ncbi.nlm.nih.gov/18088349 DMCQARM DI DMCQARM DMCQARM DN TTP889 DMCQARM TI TTUPB12 DMCQARM TN Measles virus Fusion glycoprotein (MeV F) DMCQARM MA Inhibitor DMCQARM RN Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. DMCQARM RU https://pubmed.ncbi.nlm.nih.gov/19453286 DMCQBFT DI DMCQBFT DMCQBFT DN Parthenolide DMCQBFT TI TTJ3E9X DMCQBFT TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMCQBFT MA Inhibitor DMCQBFT RN The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66. DMCQBFT RU https://pubmed.ncbi.nlm.nih.gov/11514225 DMCQBFT DI DMCQBFT DMCQBFT DN Parthenolide DMCQBFT TI TTSXVID DMCQBFT TN Nuclear factor NF-kappa-B (NFKB) DMCQBFT MA Inhibitor DMCQBFT RN Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15. DMCQBFT RU https://pubmed.ncbi.nlm.nih.gov/15630139 DMCQL5I DI DMCQL5I DMCQL5I DN DE-110 DMCQL5I TI TTYRL6O DMCQL5I TN Glucocorticoid receptor (NR3C1) DMCQL5I MA Agonist DMCQL5I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031667) DMCQL5I RU http://adisinsight.springer.com/drugs/800031667 DMCSGJ2 DI DMCSGJ2 DMCSGJ2 DN BAY1163877 DMCSGJ2 TI TT0LF7H DMCSGJ2 TN Fibroblast growth factor receptor (FGFR) DMCSGJ2 MA Antagonist DMCSGJ2 RN Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739. DMCSGJ2 RU http://cancerres.aacrjournals.org/content/74/19_Supplement/1739 DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTWPA54 DMCSN69 TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMCSN69 MA Inhibitor DMCSN69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSN69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTSN6QU DMCSN69 TN HIF1-alpha messenger RNA (HIF1A mRNA) DMCSN69 MA Inhibitor DMCSN69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSN69 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTDMLNT DMCSN69 TN Hypoxia-inducible factor 2 alpha (HIF-2A) DMCSN69 MA Inhibitor DMCSN69 RN Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236. DMCSN69 RU https://pubmed.ncbi.nlm.nih.gov/30089425 DMCSR8I DI DMCSR8I DMCSR8I DN Recoflavone DMCSR8I TI TTSXVID DMCSR8I TN Nuclear factor NF-kappa-B (NFKB) DMCSR8I MA Modulator DMCSR8I RN DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91. DMCSR8I RU https://pubmed.ncbi.nlm.nih.gov/18222973 DMCSXI4 DI DMCSXI4 DMCSXI4 DN Elezanumab DMCSXI4 TI TTURJV4 DMCSXI4 TN Repulsive guidance molecule A (RGMA) DMCSXI4 MA Inhibitor DMCSXI4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSXI4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCT08V DI DMCT08V DMCT08V DN Domagrozumab DMCT08V TI TTSWPH8 DMCT08V TN Growth/differentiation factor 8 (GDF-8) DMCT08V MA Inhibitor DMCT08V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCT08V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCT1RQ DI DMCT1RQ DMCT1RQ DN LFG-316 DMCT1RQ TI TTKANGO DMCT1RQ TN Complement C5 (CO5) DMCT1RQ RN Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29. DMCT1RQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/ DMCT8EY DI DMCT8EY DMCT8EY DN Cenderitide DMCT8EY TI TTJME02 DMCT8EY TN Atrial natriuretic peptide receptor A (NPR1) DMCT8EY MA Agonist DMCT8EY RN 2011 Pipeline of Nile Therapeutics. DMCT8EY RU http://www.nilethera.com/pipeline.html DMCTWIB DI DMCTWIB DMCTWIB DN AL102 DMCTWIB TI TT9W8GU DMCTWIB TN Gamma-secretase (GS) DMCTWIB MA Inhibitor DMCTWIB RN Clinical pipeline report, company report or official report of Ayala Pharmaceuticals. DMCTWIB RU https://www.ayalapharma.com/pipeline/investigational-therapies-al101-and-al102 DMCU74R DI DMCU74R DMCU74R DN Daporinad DMCU74R TI TTD1WIG DMCU74R TN Nicotinamide phosphoribosyltransferase (NAMPT) DMCU74R MA Inhibitor DMCU74R RN Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. DMCU74R RU https://pubmed.ncbi.nlm.nih.gov/18201551 DMCUGI8 DI DMCUGI8 DMCUGI8 DN ONO-AE1-437 DMCUGI8 TI TT79WV3 DMCUGI8 TN Prostaglandin E2 receptor EP4 (PTGER4) DMCUGI8 MA Agonist DMCUGI8 RN An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90. DMCUGI8 RU https://pubmed.ncbi.nlm.nih.gov/15295094 DMCV602 DI DMCV602 DMCV602 DN LY2523355 DMCV602 TI TTTRP0H DMCV602 TN Kinesin-like protein KIF11 (KIF11) DMCV602 MA Modulator DMCV602 RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMCV602 RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMCXNIP DI DMCXNIP DMCXNIP DN MORAb-009 DMCXNIP TI TT4RXME DMCXNIP TN Mesothelin (MSLN) DMCXNIP RN Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. DMCXNIP RU https://pubmed.ncbi.nlm.nih.gov/25231400 DMCXRZF DI DMCXRZF DMCXRZF DN LY2603618 DMCXRZF TI TTTU902 DMCXRZF TN Checkpoint kinase-1 (CHK1) DMCXRZF MA Modulator DMCXRZF RN Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. DMCXRZF RU https://pubmed.ncbi.nlm.nih.gov/24114124 DMCY785 DI DMCY785 DMCY785 DN SB-656933 DMCY785 TI TT30C9G DMCY785 TN C-X-C chemokine receptor type 2 (CXCR2) DMCY785 MA Antagonist DMCY785 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMCY785 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMCY9PO DI DMCY9PO DMCY9PO DN Itarnafloxin DMCY9PO TI TTCSZH7 DMCY9PO TN Nucleolin (NCL) DMCY9PO MA Inhibitor DMCY9PO RN Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275. DMCY9PO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119469/ DMCZFMS DI DMCZFMS DMCZFMS DN ABX-IL8 DMCZFMS TI TTCTE1G DMCZFMS TN Interleukin-8 (IL8) DMCZFMS RN Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34. DMCZFMS RU https://pubmed.ncbi.nlm.nih.gov/12107097 DMCZH5B DI DMCZH5B DMCZH5B DN GS-9256 DMCZH5B TI TT5FNQT DMCZH5B TN Human immunodeficiency virus Protease (HIV PR) DMCZH5B MA Inhibitor DMCZH5B RN Clinical pipeline report, company report or official report of Gilead (2011). DMCZH5B RU http://www.gilead.com/ DMD09CT DI DMD09CT DMD09CT DN LY-362884 DMD09CT TI TTMXGCW DMD09CT TN Adrenergic receptor beta-3 (ADRB3) DMD09CT MA Agonist DMD09CT RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMD09CT RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMD0E8U DI DMD0E8U DMD0E8U DN Naveglitazar DMD0E8U TI TTZMAO3 DMD0E8U TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMD0E8U MA Modulator DMD0E8U RN The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61. DMD0E8U RU https://pubmed.ncbi.nlm.nih.gov/17012539 DMD0E8U DI DMD0E8U DMD0E8U DN Naveglitazar DMD0E8U TI TTJ584C DMD0E8U TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD0E8U MA Modulator DMD0E8U RN The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61. DMD0E8U RU https://pubmed.ncbi.nlm.nih.gov/17012539 DMD0I29 DI DMD0I29 DMD0I29 DN ATL-104 DMD0I29 TI TTDB5IS DMD0I29 TN Receptor unspecific (Rec) DMD0I29 MA Modulator DMD0I29 RN Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9. DMD0I29 RU https://pubmed.ncbi.nlm.nih.gov/18997832 DMD275X DI DMD275X DMD275X DN Pardoprunox DMD275X TI TTEX248 DMD275X TN Dopamine D2 receptor (D2R) DMD275X MA Agonist DMD275X RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMD275X RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMD2RFO DI DMD2RFO DMD2RFO DN AQW-051 DMD2RFO TI TTLA931 DMD2RFO TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMD2RFO MA Agonist DMD2RFO RN AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. DMD2RFO RU https://pubmed.ncbi.nlm.nih.gov/25172125 DMD3RU8 DI DMD3RU8 DMD3RU8 DN GFT14 DMD3RU8 TI TTJ584C DMD3RU8 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD3RU8 MA Agonist DMD3RU8 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296) DMD3RU8 RU http://adisinsight.springer.com/drugs/800024296 DMD3WNP DI DMD3WNP DMD3WNP DN RO5520985 DMD3WNP TI TTOHSBA DMD3WNP TN Vascular endothelial growth factor A (VEGFA) DMD3WNP MA Modulator DMD3WNP RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMD3WNP RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMD3WNP DI DMD3WNP DMD3WNP DN RO5520985 DMD3WNP TI TTKLQTJ DMD3WNP TN Angiopoietin-2 (ANGPT2) DMD3WNP MA Modulator DMD3WNP RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMD3WNP RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMD3XMG DI DMD3XMG DMD3XMG DN AFTVac DMD3XMG TI TT6MP2Z DMD3XMG TN GMCSFR-alpha (CSF2RA) DMD3XMG RN Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. DMD3XMG RU https://pubmed.ncbi.nlm.nih.gov/15014006 DMD3XMG DI DMD3XMG DMD3XMG DN AFTVac DMD3XMG TI TT9721Y DMD3XMG TN Interleukin 2 receptor beta (IL2RB) DMD3XMG RN Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. DMD3XMG RU https://pubmed.ncbi.nlm.nih.gov/15014006 DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTVIAT9 DMD4KAU TN Phosphodiesterase 4B (PDE4B) DMD4KAU MA Inhibitor DMD4KAU RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMD4KAU RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTSKMI8 DMD4KAU TN Phosphodiesterase 4D (PDE4D) DMD4KAU MA Inhibitor DMD4KAU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMD4KAU RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTZ97H5 DMD4KAU TN Phosphodiesterase 4A (PDE4A) DMD4KAU MA Inhibitor DMD4KAU RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMD4KAU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMD4OK0 DI DMD4OK0 DMD4OK0 DN K-134 DMD4OK0 TI TTZCG4L DMD4OK0 TN Phosphodiesterase 3 (PDE3) DMD4OK0 MA Modulator DMD4OK0 RN A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1. DMD4OK0 RU https://pubmed.ncbi.nlm.nih.gov/22119244 DMD4YRG DI DMD4YRG DMD4YRG DN EQ-917 DMD4YRG TI TTGTQHC DMD4YRG TN DNA topoisomerase I (TOP1) DMD4YRG MA Inhibitor DMD4YRG RN The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200. DMD4YRG RU https://pubmed.ncbi.nlm.nih.gov/20566426 DMD51RN DI DMD51RN DMD51RN DN TAK-448 DMD51RN TI TTU2O6T DMD51RN TN Metastasis-suppressor KiSS-1 (KISS1) DMD51RN MA Modulator DMD51RN RN Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.Eur J Pharmacol.2014 Jul 15;735:77-85. DMD51RN RU https://www.ncbi.nlm.nih.gov/pubmed/24747751 DMD6E5W DI DMD6E5W DMD6E5W DN MK-8342 DMD6E5W TI TTUV8G9 DMD6E5W TN Progesterone receptor (PGR) DMD6E5W MA Agonist DMD6E5W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMD6E5W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMD72F4 DI DMD72F4 DMD72F4 DN T-817MA DMD72F4 TI TTV0YFR DMD72F4 TN Lipid peroxidation (LPO) DMD72F4 MA Modulator DMD72F4 RN A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60. DMD72F4 RU https://pubmed.ncbi.nlm.nih.gov/18573265 DMD72F4 DI DMD72F4 DMD72F4 DN T-817MA DMD72F4 TI TTE4KHA DMD72F4 TN Amyloid beta A4 protein (APP) DMD72F4 MA Inhibitor DMD72F4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD72F4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMD74BJ DI DMD74BJ DMD74BJ DN PF-05089771 DMD74BJ TI TT4G2JS DMD74BJ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMD74BJ MA Blocker DMD74BJ RN Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127. DMD74BJ RU https://pubmed.ncbi.nlm.nih.gov/26419464 DMD8GNB DI DMD8GNB DMD8GNB DN BXT-51072 DMD8GNB TI TTF10I9 DMD8GNB TN Nitric-oxide synthase inducible (NOS2) DMD8GNB MA Modulator DMD8GNB RN Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8. DMD8GNB RU https://pubmed.ncbi.nlm.nih.gov/11078703 DMD8RU0 DI DMD8RU0 DMD8RU0 DN SEphB4-HSA DMD8RU0 TI TTKPV6O DMD8RU0 TN Ephrin type-B receptor 2 (EPHB2) DMD8RU0 MA Inhibitor DMD8RU0 RN National Cancer Institute Drug Dictionary (drug name SEphB4-HSA). DMD8RU0 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-ephb4-hsa-fusion-protein DMD8XOY DI DMD8XOY DMD8XOY DN S-38093 DMD8XOY TI TT9JNIC DMD8XOY TN Histamine H3 receptor (H3R) DMD8XOY MA Antagonist DMD8XOY RN Histamine H3 Receptors and Sleep-Wake Regulation. JPET January 2011 vol. 336 no. 1 17-23. DMD8XOY RU http://jpet.aspetjournals.org/content/336/1/17.full DMD9KYF DI DMD9KYF DMD9KYF DN LY3023414 DMD9KYF TI TTCJG29 DMD9KYF TN Serine/threonine-protein kinase mTOR (mTOR) DMD9KYF MA Modulator DMD9KYF RN Company report (Lilly) DMD9KYF RU http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx DMD9KYF DI DMD9KYF DMD9KYF DN LY3023414 DMD9KYF TI TTEUNMR DMD9KYF TN PI3-kinase alpha (PIK3CA) DMD9KYF MA Modulator DMD9KYF RN Company report (Lilly) DMD9KYF RU http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx DMD9RV3 DI DMD9RV3 DMD9RV3 DN INCB039110 DMD9RV3 TI TTRMX3V DMD9RV3 TN Janus kinase 2 (JAK-2) DMD9RV3 MA Inhibitor DMD9RV3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DMD9RV3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DMD9RV3 DI DMD9RV3 DMD9RV3 DN INCB039110 DMD9RV3 TI TT6DM01 DMD9RV3 TN Janus kinase 1 (JAK-1) DMD9RV3 MA Inhibitor DMD9RV3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047). DMD9RV3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047 DMDAHL6 DI DMDAHL6 DMDAHL6 DN GS-5806 DMDAHL6 TI TT57ID8 DMDAHL6 TN Respiratory syncytial virus protein F (RSV F) DMDAHL6 MA Inhibitor DMDAHL6 RN Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43. DMDAHL6 RU https://pubmed.ncbi.nlm.nih.gov/25574686 DMDAKZW DI DMDAKZW DMDAKZW DN Vacc-4x DMDAKZW TI TTTWS2G DMDAKZW TN Human immunodeficiency virus Capsid p24 (HIV p24) DMDAKZW RN Clinical pipeline report, company report or official report of Bionor Pharma. DMDAKZW RU http://www.bionorpharma.com/en/News/2011/Scientific/Vacc-4x+results+presented+in+Bangkok.b7C_wljS1c.ips DMDB4EJ DI DMDB4EJ DMDB4EJ DN Tarafenacin DMDB4EJ TI TTQ13Z5 DMDB4EJ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMDB4EJ MA Antagonist DMDB4EJ RN In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. DMDB4EJ RU https://pubmed.ncbi.nlm.nih.gov/19222482 DMDEL3F DI DMDEL3F DMDEL3F DN EMZ701 DMDEL3F TI TTSYFMA DMDEL3F TN Interferon alpha/beta receptor 1 (IFNAR1) DMDEL3F MA Modulator DMDEL3F RN Patent EP2766021 A1. DMDEL3F RU http://www.google.com/patents/EP2766021A1?cl=en DMDF7XB DI DMDF7XB DMDF7XB DN SYN120 DMDF7XB TI TTJS8PY DMDF7XB TN 5-HT 6 receptor (HTR6) DMDF7XB MA Antagonist DMDF7XB RN Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822. DMDF7XB RU https://pubmed.ncbi.nlm.nih.gov/30262889 DMDF7XB DI DMDF7XB DMDF7XB DN SYN120 DMDF7XB TI TTJQOD7 DMDF7XB TN 5-HT 2A receptor (HTR2A) DMDF7XB MA Antagonist DMDF7XB RN Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822. DMDF7XB RU https://pubmed.ncbi.nlm.nih.gov/30262889 DMDFZK8 DI DMDFZK8 DMDFZK8 DN LY3113593 DMDFZK8 TI TT07RIB DMDFZK8 TN Bone morphogenetic protein 6 (BMP6) DMDFZK8 MA Inhibitor DMDFZK8 RN Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948. DMDFZK8 RU https://pubmed.ncbi.nlm.nih.gov/30677788 DMDGPKS DI DMDGPKS DMDGPKS DN RG7625 DMDGPKS TI TTUMQVO DMDGPKS TN Cathepsin S (CTSS) DMDGPKS MA Antagonist DMDGPKS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDGPKS RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMDGZ1C DI DMDGZ1C DMDGZ1C DN FE-202767 DMDGZ1C TI TTSCIUP DMDGZ1C TN Oxytocin receptor (OTR) DMDGZ1C MA Agonist DMDGZ1C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMDGZ1C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMDI43Y DI DMDI43Y DMDI43Y DN BGB-324 DMDI43Y TI TTZPY6J DMDI43Y TN Tyrosine-protein kinase UFO (AXL) DMDI43Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835). DMDI43Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835 DMDJRU1 DI DMDJRU1 DMDJRU1 DN MM-121 DMDJRU1 TI TTDC8N2 DMDJRU1 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDJRU1 MA Modulator DMDJRU1 RN Company report (Merrimack) DMDJRU1 RU http://investors.merrimack.com/releasedetail.cfm?releaseid=897168 DMDJUWG DI DMDJUWG DMDJUWG DN DLX-105 DMDJUWG TI TTF8CQI DMDJUWG TN Tumor necrosis factor (TNF) DMDJUWG RN Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8. DMDJUWG RU https://pubmed.ncbi.nlm.nih.gov/12606779 DMDK0HX DI DMDK0HX DMDK0HX DN INCB54707 DMDK0HX TI TT6DM01 DMDK0HX TN Janus kinase 1 (JAK-1) DMDK0HX MA Inhibitor DMDK0HX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDK0HX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTSKMI8 DMDK7CL TN Phosphodiesterase 4D (PDE4D) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTVIAT9 DMDK7CL TN Phosphodiesterase 4B (PDE4B) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTZ97H5 DMDK7CL TN Phosphodiesterase 4A (PDE4A) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDKRS3 DI DMDKRS3 DMDKRS3 DN Antistasin DMDKRS3 TI TTCIHJA DMDKRS3 TN Coagulation factor Xa (F10) DMDKRS3 MA Inhibitor DMDKRS3 RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DMDKRS3 RU https://pubmed.ncbi.nlm.nih.gov/11804648 DMDKWA3 DI DMDKWA3 DMDKWA3 DN Vx-001 DMDKWA3 TI TTUJFD0 DMDKWA3 TN Telomerase reverse transcriptase (TERT) DMDKWA3 RN Clinical pipeline report, company report or official report of Vaxon-biotech. DMDKWA3 RU http://vaxon-biotech.com/ DMDL9WU DI DMDL9WU DMDL9WU DN AV-201 DMDL9WU TI TTN451K DMDL9WU TN Aromatic-L-amino-acid decarboxylase (DDC) DMDL9WU MA Modulator DMDL9WU RN UCSF report DMDL9WU RU http://pdcenter.neurology.ucsf.edu/research/learn-about-closed-studies/gene-therapy-aadc-phase-i DMDLOBZ DI DMDLOBZ DMDLOBZ DN Selinexor oral DMDLOBZ TI TTCJUR4 DMDLOBZ TN Exportin-1 (XPO1) DMDLOBZ MA Inhibitor DMDLOBZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDLOBZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMDMQW0 DI DMDMQW0 DMDMQW0 DN SAR-100842 DMDMQW0 TI TTQ6S1K DMDMQW0 TN Lysophosphatidic acid receptor 1 (LPAR1) DMDMQW0 MA Modulator DMDMQW0 RN Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11. DMDMQW0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/ DMDMQW0 DI DMDMQW0 DMDMQW0 DN SAR-100842 DMDMQW0 TI TTE2YJR DMDMQW0 TN Lysophosphatidate-3 receptor (LPAR3) DMDMQW0 MA Modulator DMDMQW0 RN Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11. DMDMQW0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/ DMDMXKQ DI DMDMXKQ DMDMXKQ DN GSK1292263 DMDMXKQ TI TT7QNVC DMDMXKQ TN Glucose-dependent insulinotropic receptor (GPR119) DMDMXKQ MA Modulator DMDMXKQ RN Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494. DMDMXKQ RU https://www.ncbi.nlm.nih.gov/pubmed/24699248 DMDN6FO DI DMDN6FO DMDN6FO DN MVI-816 DMDN6FO TI TTBRZQS DMDN6FO TN Prostatic acid phosphatase (ACPP) DMDN6FO MA Modulator DMDN6FO RN Company report (Madisonvaccine) DMDN6FO RU http://www.madisonvaccinesinc.com/Home/News DMDNHRA DI DMDNHRA DMDNHRA DN Ilodecakin DMDNHRA TI TTT0Q1F DMDNHRA TN Interleukin-10 (IL10) DMDNHRA MA Modulator DMDNHRA RN Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58. DMDNHRA RU https://pubmed.ncbi.nlm.nih.gov/16118714 DMDNJ18 DI DMDNJ18 DMDNJ18 DN F-627 DMDNJ18 TI TT5TQ2W DMDNJ18 TN Granulocyte colony-stimulating factor (CSF3) DMDNJ18 MA Modulator DMDNJ18 RN Clinical pipeline report, company report or official report of Generon (Shanghai) Corporation Ltd. DMDNJ18 RU http://www.generonbiomed.com/html/en/index.php?ac=article&at=list&tid=29 DMDNRU1 DI DMDNRU1 DMDNRU1 DN RNS-60 DMDNRU1 TI TTO7FVG DMDNRU1 TN Heat shock protein 90 (HSP90) DMDNRU1 MA Modulator DMDNRU1 RN Clinical pipeline report, company report or official report of Revalesio. DMDNRU1 RU http://revalesio.com/about-our-technology/ DMDPBMH DI DMDPBMH DMDPBMH DN TB-403 DMDPBMH TI TT48I1Y DMDPBMH TN Placenta growth factor (PlGF) DMDPBMH MA Inhibitor DMDPBMH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDPBMH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDPFTB DI DMDPFTB DMDPFTB DN V-101 DMDPFTB TI TT2NUT5 DMDPFTB TN Adrenergic receptor alpha-2C (ADRA2C) DMDPFTB MA Agonist DMDPFTB RN Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4. DMDPFTB RU https://pubmed.ncbi.nlm.nih.gov/23223767 DMDPLEM DI DMDPLEM DMDPLEM DN BMS-184476 DMDPLEM TI TTML2WA DMDPLEM TN Tubulin (TUB) DMDPLEM MA Inhibitor DMDPLEM RN Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218. DMDPLEM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/ DMDPNCJ DI DMDPNCJ DMDPNCJ DN IMO-8400 DMDPNCJ TI TTOK0LR DMDPNCJ TN Toll-like receptor (TLR) DMDPNCJ MA Antagonist DMDPNCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDPNCJ RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMDPQV5 DI DMDPQV5 DMDPQV5 DN BMS-599626 DMDPQV5 TI TTGKNB4 DMDPQV5 TN Epidermal growth factor receptor (EGFR) DMDPQV5 MA Inhibitor DMDPQV5 RN AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. DMDPQV5 RU https://pubmed.ncbi.nlm.nih.gov/20119866 DMDPQV5 DI DMDPQV5 DMDPQV5 DN BMS-599626 DMDPQV5 TI TT6EO5L DMDPQV5 TN Erbb2 tyrosine kinase receptor (HER2) DMDPQV5 MA Inhibitor DMDPQV5 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMDPQV5 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMDQH9A DI DMDQH9A DMDQH9A DN ADL-5859 DMDQH9A TI TT27RFC DMDQH9A TN Opioid receptor delta (OPRD1) DMDQH9A MA Agonist DMDQH9A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMDQH9A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMDQS4W DI DMDQS4W DMDQS4W DN ASC-J9 DMDQS4W TI TTS64P2 DMDQS4W TN Androgen receptor (AR) DMDQS4W MA Inhibitor DMDQS4W RN New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73. DMDQS4W RU https://pubmed.ncbi.nlm.nih.gov/23219429 DMDR2SZ DI DMDR2SZ DMDR2SZ DN MCT-125 DMDR2SZ TI TTAWNKZ DMDR2SZ TN Norepinephrine transporter (NET) DMDR2SZ MA Inhibitor DMDR2SZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMDR2SZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMDS20X DI DMDS20X DMDS20X DN Enoblituzumab DMDS20X TI TT6CQUM DMDS20X TN B7 homolog 3 (CD276) DMDS20X MA Inhibitor DMDS20X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDS20X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDSNIR DI DMDSNIR DMDSNIR DN BBI503 DMDSNIR TI TTPV9O1 DMDSNIR TN Cancer stemness kinase (CSK) DMDSNIR MA Inhibitor DMDSNIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDSNIR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDSNIR DI DMDSNIR DMDSNIR DN BBI503 DMDSNIR TI TTPMIQ9 DMDSNIR TN Serine/threonine-protein kinase (STK) DMDSNIR MA Inhibitor DMDSNIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDSNIR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDTI0L DI DMDTI0L DMDTI0L DN Masilukast DMDTI0L TI TTGKOY9 DMDTI0L TN Leukotriene CysLT1 receptor (CYSLTR1) DMDTI0L MA Modulator DMDTI0L RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDTI0L RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDTNOS DI DMDTNOS DMDTNOS DN NNC-0123-0000-0338 DMDTNOS TI TTZOPHG DMDTNOS TN Insulin (INS) DMDTNOS MA Modulator DMDTNOS RN ClinicalTrials.gov (NCT01334034) Safety of NNC 0123-0000-0338 in Healthy Subjects. U.S. National Institutes of Health. DMDTNOS RU https://clinicaltrials.gov/ct2/show/NCT01334034 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTML2WA DMDUV1S TN Tubulin (TUB) DMDUV1S MA Inhibitor DMDUV1S RN Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/9554885 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTYFKSZ DMDUV1S TN Tubulin beta (TUBB) DMDUV1S MA Inhibitor DMDUV1S RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTJ2PTI DMDUV1S TN Tubulin beta-2 chain (TUBB2) DMDUV1S MA Inhibitor DMDUV1S RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTVWAGF DMDUVCZ TN MHC class I NK cell receptor 2DS1 (CD158h) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TT4UXPE DMDUVCZ TN MHC class I NK cell receptor 2DL1 (CD158A) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTU0P73 DMDUVCZ TN MHC class I NK cell receptor 2DL2 (CD158b1) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTEX3SI DMDUVCZ TN MHC class I NK cell receptor 2DL3 (CD158b2) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTV3CFI DMDUVCZ TN MHC class I NK cell receptor 2DS2 (CD158j) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDV8MK DI DMDV8MK DMDV8MK DN CALDARET HYDRATE DMDV8MK TI TT619TC DMDV8MK TN Sodium/calcium exchanger (SLC) DMDV8MK MA Modulator DMDV8MK RN Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33. DMDV8MK RU https://pubmed.ncbi.nlm.nih.gov/17299242 DMDW5ZC DI DMDW5ZC DMDW5ZC DN SER-100 DMDW5ZC TI TTNT7K8 DMDW5ZC TN Nociceptin receptor (OPRL1) DMDW5ZC MA Agonist DMDW5ZC RN Clinical pipeline report, company report or official report of Serodus ASA. DMDW5ZC RU http://www.serodus.com/Pipeline/SER100TRISH DMDWG36 DI DMDWG36 DMDWG36 DN Codrituzumab DMDWG36 TI TTJTSX4 DMDWG36 TN Glypican-3 (GPC3) DMDWG36 MA Inhibitor DMDWG36 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDWG36 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDWP0U DI DMDWP0U DMDWP0U DN BTA-798 DMDWP0U TI TT8R3VP DMDWP0U TN Rhinovirus Capsid protein (HRV VP) DMDWP0U MA Inhibitor DMDWP0U RN Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012 Jan 15;83(2):185-92. DMDWP0U RU https://pubmed.ncbi.nlm.nih.gov/21889497 DMDWYZS DI DMDWYZS DMDWYZS DN GTx-758 DMDWYZS TI TTZAYWL DMDWYZS TN Estrogen receptor (ESR) DMDWYZS MA Modulator DMDWYZS RN Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41. DMDWYZS RU https://pubmed.ncbi.nlm.nih.gov/24968970 DMDY01J DI DMDY01J DMDY01J DN NHS-IL2-LT DMDY01J TI TTUTN1I DMDY01J TN Human Deoxyribonucleic acid (hDNA) DMDY01J MA Modulator DMDY01J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDY01J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDYVN8 DI DMDYVN8 DMDYVN8 DN MEDI-528 DMDYVN8 TI TT0JTFD DMDYVN8 TN Interleukin-9 (IL9) DMDYVN8 MA Inhibitor DMDYVN8 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMDYVN8 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMDYWM8 DI DMDYWM8 DMDYWM8 DN E-10030 DMDYWM8 TI TTQA6SX DMDYWM8 TN Platelet-derived growth factor B (PDGFB) DMDYWM8 MA Antagonist DMDYWM8 RN Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50. DMDYWM8 RU https://pubmed.ncbi.nlm.nih.gov/20592747 DMDYZRS DI DMDYZRS DMDYZRS DN BPS-804 DMDYZRS TI TTYRO4F DMDYZRS TN Sclerostin (SOST) DMDYZRS RN WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery. DMDYZRS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100910&CC=WO&NR=2010100179A2&KC=A2 DMDZ4R2 DI DMDZ4R2 DMDZ4R2 DN Org-30029 DMDZ4R2 TI TTZCG4L DMDZ4R2 TN Phosphodiesterase 3 (PDE3) DMDZ4R2 MA Modulator DMDZ4R2 RN Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606. DMDZ4R2 RU https://pubmed.ncbi.nlm.nih.gov/8431987 DMDZE3B DI DMDZE3B DMDZE3B DN HGT-1111 DMDZE3B TI TTYQANR DMDZE3B TN Cerebroside-sulfatase (ARSA) DMDZE3B MA Modulator DMDZE3B RN ClinicalTrials.gov (NCT00681811) Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD. U.S. National Institutes of Health. DMDZE3B RU https://clinicaltrials.gov/ct2/show/NCT00681811 DMDZWPL DI DMDZWPL DMDZWPL DN ITCA-638 DMDZWPL TI TTS2TGF DMDZWPL TN Interferon-omega (IFNW1) DMDZWPL MA Modulator DMDZWPL RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMDZWPL RU https://pubmed.ncbi.nlm.nih.gov/19319841 DME01HT DI DME01HT DME01HT DN Fluciclatide F-18 DME01HT TI TT69TQN DME01HT TN Integrin alpha-V/beta-3 (ITGAV/B3) DME01HT MA Modulator DME01HT RN Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22. DME01HT RU https://www.ncbi.nlm.nih.gov/pubmed/19091899 DME0JMV DI DME0JMV DME0JMV DN AZX-100 DME0JMV TI TT5IP87 DME0JMV TN Heat shock protein 20 (HSP20) DME0JMV MA Modulator DME0JMV RN Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21. DME0JMV RU https://pubmed.ncbi.nlm.nih.gov/20140957 DME1WV2 DI DME1WV2 DME1WV2 DN KD-7040 DME1WV2 TI TTF10I9 DME1WV2 TN Nitric-oxide synthase inducible (NOS2) DME1WV2 MA Inhibitor DME1WV2 RN WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration. DME1WV2 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140206&CC=WO&NR=2014021408A1&KC=A1 DME1YMX DI DME1YMX DME1YMX DN RG7935 DME1YMX TI TT08OSU DME1YMX TN Synuclein alpha (SNCA) DME1YMX RN alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399. DME1YMX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281589/ DME25TI DI DME25TI DME25TI DN Prosaptide TX14(A) DME25TI TI TTDB5IS DME25TI TN Receptor unspecific (Rec) DME25TI MA Modulator DME25TI RN Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81. DME25TI RU http://www.sciencedirect.com/science/article/pii/S1090380107000584 DME26RS DI DME26RS DME26RS DN LTB4 DME26RS TI TTN53ZF DME26RS TN Leukotriene B4 receptor 1 (LTB4R) DME26RS MA Agonist DME26RS RN LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47. DME26RS RU https://pubmed.ncbi.nlm.nih.gov/25706874 DME26RS DI DME26RS DME26RS DN LTB4 DME26RS TI TTVJX54 DME26RS TN Leukotriene B4 receptor 2 (LTB4R2) DME26RS MA Inhibitor DME26RS RN Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993). DME26RS RU http://www.sciencedirect.com/science/article/pii/S0960894X01810003 DME2S4D DI DME2S4D DME2S4D DN JNJ-61393215 DME2S4D TI TT60Q8D DME2S4D TN Orexin receptor type 1 (HCRTR1) DME2S4D MA Antagonist DME2S4D RN Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308. DME2S4D RU https://pubmed.ncbi.nlm.nih.gov/32895369 DME321B DI DME321B DME321B DN VX-944 DME321B TI TTCAQMW DME321B TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DME321B MA Inhibitor DME321B RN Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96. DME321B RU https://pubmed.ncbi.nlm.nih.gov/15940263 DME321B DI DME321B DME321B DN VX-944 DME321B TI TTL7C8Q DME321B TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DME321B MA Inhibitor DME321B RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DME321B RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DME384W DI DME384W DME384W DN AdPEDR DME384W TI TTR59S1 DME384W TN Pigment epithelium-derived factor (SERPINF1) DME384W MA Inhibitor DME384W RN Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. DME384W RU https://pubmed.ncbi.nlm.nih.gov/15757408 DME3POC DI DME3POC DME3POC DN Imisopasem manganese DME3POC TI TT9O4C5 DME3POC TN Superoxide dismutase Mn (SOD Mn) DME3POC MA Modulator DME3POC RN The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40. DME3POC RU https://pubmed.ncbi.nlm.nih.gov/20298121 DME3ZYC DI DME3ZYC DME3ZYC DN ALKS 4230 DME3ZYC TI TTAJU0S DME3ZYC TN Interleukin 2 receptor (IL2R) DME3ZYC MA Agonist DME3ZYC RN ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. DME3ZYC RU https://pubmed.ncbi.nlm.nih.gov/32317293 DME4LA1 DI DME4LA1 DME4LA1 DN Tideglusib DME4LA1 TI TTRSMW9 DME4LA1 TN Glycogen synthase kinase-3 beta (GSK-3B) DME4LA1 MA Inhibitor DME4LA1 RN Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904. DME4LA1 RU https://pubmed.ncbi.nlm.nih.gov/22102280 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TT8QL1J DME53YS TN Protein kinase C theta (PRKCQ) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TTYPXQF DME53YS TN Protein kinase C beta (PRKCB) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TTFJ8Q1 DME53YS TN Protein kinase C alpha (PRKCA) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME5CSV DI DME5CSV DME5CSV DN Mibampator DME5CSV TI TTAN6JD DME5CSV TN Glutamate receptor AMPA (GRIA) DME5CSV MA Agonist DME5CSV RN Mibampator (LY451395) Randomized Clinical Trial for Agitation/Aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5): 707-719. DME5CSV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938603/ DME6I03 DI DME6I03 DME6I03 DN VDA-1102 DME6I03 TI TTJLNAW DME6I03 TN Tissue kallikrein (KLK2) DME6I03 MA Modulator DME6I03 RN Clinical pipeline report, company report or official report of Vidac Pharma. DME6I03 RU http://www.vidacpharma.com/vda-1102-iv-vidac-pharma DME6I03 DI DME6I03 DME6I03 DN VDA-1102 DME6I03 TI TTPZI04 DME6I03 TN Voltage-dependent anion channel (VDAC) DME6I03 MA Modulator DME6I03 RN Clinical pipeline report, company report or official report of Vidac Pharma. DME6I03 RU http://www.vidacpharma.com/vda-1102-iv-vidac-pharma DME6KAF DI DME6KAF DME6KAF DN NPC-15199 DME6KAF TI TTW6MKR DME6KAF TN Calcium release (Ca rele) DME6KAF MA Modulator DME6KAF RN NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33. DME6KAF RU https://pubmed.ncbi.nlm.nih.gov/10857466 DME6QH1 DI DME6QH1 DME6QH1 DN AMG 557 DME6QH1 TI TTB9Z8R DME6QH1 TN B7-related protein 1 (B7RP1) DME6QH1 MA Modulator DME6QH1 RN Administration Of AMG 557, A Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. San Diego, CA October 25-30, 2013 DME6QH1 RU http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109110 DME6X27 DI DME6X27 DME6X27 DN UR-63325 DME6X27 TI TTXJ178 DME6X27 TN Histamine H4 receptor (H4R) DME6X27 MA Antagonist DME6X27 RN Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87. DME6X27 RU https://pubmed.ncbi.nlm.nih.gov/22202103 DME71WA DI DME71WA DME71WA DN Q301 DME71WA TI TT2J34L DME71WA TN Arachidonate 5-lipoxygenase (5-LOX) DME71WA MA Inhibitor DME71WA RN Clinical pipeline report, company report or official report of Qurient. DME71WA RU http://www.qurient.com/bbs/content.php?co_id=q301 DME7VZD DI DME7VZD DME7VZD DN Vilaprisan DME7VZD TI TTUV8G9 DME7VZD TN Progesterone receptor (PGR) DME7VZD MA Antagonist DME7VZD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939) DME7VZD RU http://adisinsight.springer.com/drugs/800033939 DME8ARP DI DME8ARP DME8ARP DN RX-3117 DME8ARP TI TT6S2FE DME8ARP TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DME8ARP MA Inhibitor DME8ARP RN Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57. DME8ARP RU https://pubmed.ncbi.nlm.nih.gov/24048768 DME8IFQ DI DME8IFQ DME8IFQ DN Noberastine DME8IFQ TI TTTIBOJ DME8IFQ TN Histamine H1 receptor (H1R) DME8IFQ MA Antagonist DME8IFQ RN A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare. Eur J Clin Pharmacol. 1991;40(1):83-5. DME8IFQ RU https://pubmed.ncbi.nlm.nih.gov/1676366 DME8O5K DI DME8O5K DME8O5K DN LOU064 DME8O5K TI TTGM6VW DME8O5K TN Tyrosine-protein kinase BTK (ATK) DME8O5K MA Inhibitor DME8O5K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME8O5K RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DME8PFQ DI DME8PFQ DME8PFQ DN TMX-049 DME8PFQ TI TT7RJY8 DME8PFQ TN Xanthine dehydrogenase/oxidase (XDH) DME8PFQ MA Inhibitor DME8PFQ RN Clinical pipeline report, company report or official report of Teijin Pharma. DME8PFQ RU https://www.teijin.com/news/2019/20190920_3737.html DME8XD7 DI DME8XD7 DME8XD7 DN ASP-1707 DME8XD7 TI TT8R70G DME8XD7 TN Gonadotropin-releasing hormone receptor (GNRHR) DME8XD7 MA Antagonist DME8XD7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032657) DME8XD7 RU http://adisinsight.springer.com/drugs/800032657 DME8Z5M DI DME8Z5M DME8Z5M DN AZD-3199 DME8Z5M TI TT2CJVK DME8Z5M TN Adrenergic receptor beta-2 (ADRB2) DME8Z5M MA Agonist DME8Z5M RN Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762. DME8Z5M RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/ DMEB3T9 DI DMEB3T9 DMEB3T9 DN Amdoxovir DMEB3T9 TI TT84ETX DMEB3T9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEB3T9 MA Modulator DMEB3T9 RN Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23. DMEB3T9 RU https://www.ncbi.nlm.nih.gov/pubmed/16964830 DMED5J6 DI DMED5J6 DMED5J6 DN JTT-851 DMED5J6 TI TTB8FUC DMED5J6 TN Free fatty acid receptor 1 (GPR40) DMED5J6 MA Agonist DMED5J6 RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DMED5J6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DMEDITW DI DMEDITW DMEDITW DN MK-1454 DMEDITW TI TTT402Y DMEDITW TN Stimulator of interferon genes protein (TMEM173) DMEDITW MA Agonist DMEDITW RN National Cancer Institute Drug Dictionary (drug name MK1454). DMEDITW RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-1454 DMEFD0B DI DMEFD0B DMEFD0B DN RG6100 DMEFD0B TI TTS87KH DMEFD0B TN Microtubule-associated protein tau (MAPT) DMEFD0B MA Inhibitor DMEFD0B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFD0B RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMEFW3G DI DMEFW3G DMEFW3G DN KD019 DMEFW3G TI TTI4ZX2 DMEFW3G TN Ephrin type-B receptor 4 (EPHB4) DMEFW3G MA Modulator DMEFW3G RN XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26. DMEFW3G RU https://pubmed.ncbi.nlm.nih.gov/22011666 DMEFW3G DI DMEFW3G DMEFW3G DN KD019 DMEFW3G TI TTJSQEF DMEFW3G TN Tyrosine-protein kinase (PTK) DMEFW3G MA Inhibitor DMEFW3G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFW3G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMEG4TC DI DMEG4TC DMEG4TC DN Stannsoporfin DMEG4TC TI TTI6V2A DMEG4TC TN Heme oxygenase 1 (HMOX1) DMEG4TC MA Inhibitor DMEG4TC RN Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. 2004 Oct;28(5):365-8. DMEG4TC RU https://pubmed.ncbi.nlm.nih.gov/15686268 DMEGDWA DI DMEGDWA DMEGDWA DN BNC-210 DMEGDWA TI TTNJYV2 DMEGDWA TN Gamma-aminobutyric acid receptor (GAR) DMEGDWA MA Modulator DMEGDWA RN 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. DMEGDWA RU https://pubmed.ncbi.nlm.nih.gov/23989795 DMEGNHZ DI DMEGNHZ DMEGNHZ DN SAR279356 DMEGNHZ TI TTAFD3Y DMEGNHZ TN Poly-N-acetyl glucosamine (PNAG) DMEGNHZ MA Modulator DMEGNHZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMEGNHZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMEGTH1 DI DMEGTH1 DMEGTH1 DN Ozarelix DMEGTH1 TI TT8R70G DMEGTH1 TN Gonadotropin-releasing hormone receptor (GNRHR) DMEGTH1 MA Modulator DMEGTH1 RN Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9. DMEGTH1 RU https://pubmed.ncbi.nlm.nih.gov/20623634 DMEHOI1 DI DMEHOI1 DMEHOI1 DN Novaferon DMEHOI1 TI TTSIUJ9 DMEHOI1 TN Interferon-alpha 2 (IFNA2) DMEHOI1 MA Modulator DMEHOI1 RN Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8. DMEHOI1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/ DMEJICQ DI DMEJICQ DMEJICQ DN Aprocitentan DMEJICQ TI TTCV6O0 DMEJICQ TN Endothelin receptor (EDNR) DMEJICQ MA Antagonist DMEJICQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEJICQ RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMEK580 DI DMEK580 DMEK580 DN CD19 CAR T cells DMEK580 TI TTW640A DMEK580 TN B-lymphocyte surface antigen B4 (CD19) DMEK580 MA CAR-T-Cell-Therapy DMEK580 RN ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies DMEK580 RU https://clinicaltrials.gov/ct2/show/NCT02846584 DMEL15U DI DMEL15U DMEL15U DN FK-143 DMEL15U TI TT2A0DR DMEL15U TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMEL15U MA Modulator DMEL15U RN FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63. DMEL15U RU https://www.ncbi.nlm.nih.gov/pubmed/7734404 DMEL5SV DI DMEL5SV DMEL5SV DN FR139317 DMEL5SV TI TTZPO1L DMEL5SV TN Substance-P receptor (TACR1) DMEL5SV MA Antagonist DMEL5SV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEL5SV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMEL5SV DI DMEL5SV DMEL5SV DN FR139317 DMEL5SV TI TTKRD0G DMEL5SV TN Endothelin A receptor (EDNRA) DMEL5SV MA Antagonist DMEL5SV RN Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505. DMEL5SV RU https://pubmed.ncbi.nlm.nih.gov/12147302 DMELUAK DI DMELUAK DMELUAK DN MP470 DMELUAK TI TT8FYO9 DMELUAK TN Platelet-derived growth factor receptor alpha (PDGFRA) DMELUAK MA Modulator DMELUAK RN Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. DMELUAK RU https://pubmed.ncbi.nlm.nih.gov/24849582 DMELUAK DI DMELUAK DMELUAK DN MP470 DMELUAK TI TTX41N9 DMELUAK TN Tyrosine-protein kinase Kit (KIT) DMELUAK MA Modulator DMELUAK RN Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. DMELUAK RU https://pubmed.ncbi.nlm.nih.gov/24849582 DMELUYN DI DMELUYN DMELUYN DN XP-23829 DMELUYN TI TTSXVID DMELUYN TN Nuclear factor NF-kappa-B (NFKB) DMELUYN MA Inhibitor DMELUYN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491) DMELUYN RU http://adisinsight.springer.com/drugs/800036491 DMEN5KA DI DMEN5KA DMEN5KA DN GTS-21 DMEN5KA TI TTLA931 DMEN5KA TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMEN5KA MA Agonist DMEN5KA RN The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81. DMEN5KA RU https://pubmed.ncbi.nlm.nih.gov/10942043 DMEO9Y7 DI DMEO9Y7 DMEO9Y7 DN INGAP peptide DMEO9Y7 TI TTGMYVE DMEO9Y7 TN Phosphofructokinase 2 (PFK2) DMEO9Y7 MA Modulator DMEO9Y7 RN A Pentadecapeptide Fragment of Islet Neogenesis-Associated Protein Increases Beta-Cell Mass and Reverses Diabetes in C57BL/6J Mice. Ann Surg. 2004 November; 240(5): 875-884. DMEO9Y7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356495/ DMER82Z DI DMER82Z DMER82Z DN COR-1 DMER82Z TI TTR6W5O DMER82Z TN Adrenergic receptor beta-1 (ADRB1) DMER82Z MA Antagonist DMER82Z RN Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9. DMER82Z RU https://pubmed.ncbi.nlm.nih.gov/22968742 DMESMHU DI DMESMHU DMESMHU DN AVE-0657 DMESMHU TI TTFZVPO DMESMHU TN Sodium/hydrogen exchanger 3 (SLC9A3) DMESMHU MA Inhibitor DMESMHU RN Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53. DMESMHU RU https://pubmed.ncbi.nlm.nih.gov/24384423 DMEVARK DI DMEVARK DMEVARK DN GSK561679 DMEVARK TI TT7EFHR DMEVARK TN Corticotropin-releasing factor receptor 1 (CRHR1) DMEVARK MA Antagonist DMEVARK RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEVARK RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMEVXS1 DI DMEVXS1 DMEVXS1 DN PRX-3140 DMEVXS1 TI TT07C3Y DMEVXS1 TN 5-HT 4 receptor (HTR4) DMEVXS1 MA Modulator DMEVXS1 RN Clinical pipeline report, company report or official report of Nanotherapeutics. DMEVXS1 RU http://www.nanotherapeutics.com/prx-3140/ DMEW3K9 DI DMEW3K9 DMEW3K9 DN AZD7624 DMEW3K9 TI TTWELHI DMEW3K9 TN Stress-activated protein kinase (p38) DMEW3K9 MA Inhibitor DMEW3K9 RN Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DMEW3K9 RU https://pubmed.ncbi.nlm.nih.gov/25599809 DMEW62S DI DMEW62S DMEW62S DN AB-106 DMEW62S TI TTSZ6Y3 DMEW62S TN Proto-oncogene c-Ros (ROS1) DMEW62S MA Inhibitor DMEW62S RN Clinical pipeline report, company report or official report of AnHeart Therapeutics. DMEW62S RU https://anhearttherapeutics.com/pipeline/ DMEW62S DI DMEW62S DMEW62S DN AB-106 DMEW62S TI TTJOCTY DMEW62S TN Tropomyosin receptor kinase (Trk) DMEW62S MA Inhibitor DMEW62S RN Clinical pipeline report, company report or official report of AnHeart Therapeutics. DMEW62S RU https://anhearttherapeutics.com/pipeline/ DMEWQ4X DI DMEWQ4X DMEWQ4X DN ABT-639 DMEWQ4X TI TTZPWGN DMEWQ4X TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMEWQ4X MA Modulator DMEWQ4X RN Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83. DMEWQ4X RU https://pubmed.ncbi.nlm.nih.gov/26035253 DMEXKF4 DI DMEXKF4 DMEXKF4 DN GSK3196165 DMEXKF4 TI TTNYZG2 DMEXKF4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMEXKF4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEXKF4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEXMV5 DI DMEXMV5 DMEXMV5 DN Virexxa DMEXMV5 TI TTUV8G9 DMEXMV5 TN Progesterone receptor (PGR) DMEXMV5 MA Inducer DMEXMV5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMEXMV5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMEXN7V DI DMEXN7V DMEXN7V DN APN401 DMEXN7V TI TTHRAIJ DMEXN7V TN CBLB messenger RNA (CBLB mRNA) DMEXN7V MA Inhibitor DMEXN7V RN Clinical pipeline report, company report or official report of Apeiron Biologics. DMEXN7V RU https://www.apeiron-biologics.com/science/#apn401 DMEYIVW DI DMEYIVW DMEYIVW DN CAP1-6D DMEYIVW TI TTY6DTE DMEYIVW TN Carcinoembryonic antigen CEA (CD66e) DMEYIVW MA Modulator DMEYIVW RN Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7. DMEYIVW RU https://pubmed.ncbi.nlm.nih.gov/9377571 DMEYKRN DI DMEYKRN DMEYKRN DN TAK-379 DMEYKRN TI TTCBFJO DMEYKRN TN Insulin receptor (INSR) DMEYKRN MA Modulator DMEYKRN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMEYKRN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMEYMTX DI DMEYMTX DMEYMTX DN CP-461 DMEYMTX TI TTJGW1Z DMEYMTX TN Phosphodiesterase 2A (PDE2A) DMEYMTX MA Inhibitor DMEYMTX RN Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83. DMEYMTX RU https://pubmed.ncbi.nlm.nih.gov/11569947 DMEYNQA DI DMEYNQA DMEYNQA DN ALN-RSV01 DMEYNQA TI TTWSF5D DMEYNQA TN HRSV Nucleoprotein messenger RNA (HRSV N mRNA) DMEYNQA MA Inhibitor DMEYNQA RN Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31. DMEYNQA RU https://pubmed.ncbi.nlm.nih.gov/18242722 DMEYQPN DI DMEYQPN DMEYQPN DN P-1736 DMEYQPN TI TTB8FUC DMEYQPN TN Free fatty acid receptor 1 (GPR40) DMEYQPN MA Modulator DMEYQPN RN Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946. DMEYQPN RU https://pubmed.ncbi.nlm.nih.gov/24194903 DMEZLFT DI DMEZLFT DMEZLFT DN Camsirubicin DMEZLFT TI TTCGY2K DMEZLFT TN DNA topoisomerase II alpha (TOP2A) DMEZLFT MA Inhibitor DMEZLFT RN Clinical pipeline report, company report or official report of Monopar Therapeutics. DMEZLFT RU https://www.monopartx.com/pipeline/Camsirubicin DMF34UY DI DMF34UY DMF34UY DN AZD-2423 DMF34UY TI TTFZYTO DMF34UY TN C-C chemokine receptor type 2 (CCR2) DMF34UY MA Antagonist DMF34UY RN CA patent application no. 841416, Method of selecting therapeutic indications. DMF34UY RU http://www.google.com/patents/CA2841416A1?cl=en DMF3MV1 DI DMF3MV1 DMF3MV1 DN GDC-0980/RG7422 DMF3MV1 TI TTCJG29 DMF3MV1 TN Serine/threonine-protein kinase mTOR (mTOR) DMF3MV1 MA Modulator DMF3MV1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMF3MV1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMF3MV1 DI DMF3MV1 DMF3MV1 DN GDC-0980/RG7422 DMF3MV1 TI TTHBTOP DMF3MV1 TN PI3-kinase gamma (PIK3CG) DMF3MV1 MA Modulator DMF3MV1 RN GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. DMF3MV1 RU https://pubmed.ncbi.nlm.nih.gov/21998291 DMF3QN1 DI DMF3QN1 DMF3QN1 DN ALKS33 DMF3QN1 TI TTKWM86 DMF3QN1 TN Opioid receptor mu (MOP) DMF3QN1 MA Inhibitor DMF3QN1 RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMF3QN1 RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMF46PD DI DMF46PD DMF46PD DN BMS-911543 DMF46PD TI TTRMX3V DMF46PD TN Janus kinase 2 (JAK-2) DMF46PD MA Modulator DMF46PD RN Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. DMF46PD RU https://pubmed.ncbi.nlm.nih.gov/22015772 DMF4MX9 DI DMF4MX9 DMF4MX9 DN Cobomarsen DMF4MX9 TI TT1GNRQ DMF4MX9 TN microRNA hsa-miR-155 (MIR155) DMF4MX9 MA Inhibitor DMF4MX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF4MX9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF5YEN DI DMF5YEN DMF5YEN DN PG-102 DMF5YEN TI TTIJP3Q DMF5YEN TN TNF related activation protein (CD40LG) DMF5YEN MA Modulator DMF5YEN RN Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27. DMF5YEN RU https://www.ncbi.nlm.nih.gov/pubmed/25795759 DMF61ML DI DMF61ML DMF61ML DN TF0023 DMF61ML TI TT6L509 DMF61ML TN Coagulation factor IIa (F2) DMF61ML MA Inhibitor DMF61ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF61ML RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMF6CTI DI DMF6CTI DMF6CTI DN KHK-6188 DMF6CTI TI TTMSFAW DMF6CTI TN Cannabinoid receptor 2 (CB2) DMF6CTI MA Agonist DMF6CTI RN Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2). DMF6CTI RU http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands DMF7J6D DI DMF7J6D DMF7J6D DN INGN-225 DMF7J6D TI TT7SBF5 DMF7J6D TN Cellular tumor antigen p53 (TP53) DMF7J6D RN INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. DMF7J6D RU https://pubmed.ncbi.nlm.nih.gov/20420527 DMF86P2 DI DMF86P2 DMF86P2 DN BI 655064 DMF86P2 TI TTIJP3Q DMF86P2 TN TNF related activation protein (CD40LG) DMF86P2 RN FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study DMF86P2 RU http://ard.bmj.com/content/74/Suppl_2/483.3.abstract DMF86P2 DI DMF86P2 DMF86P2 DN BI 655064 DMF86P2 TI TTN6Y9A DMF86P2 TN CD40L receptor (CD40) DMF86P2 MA Inhibitor DMF86P2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF86P2 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMF910Q DI DMF910Q DMF910Q DN GS-9451 DMF910Q TI TTWXB3E DMF910Q TN Hepatitis C virus NS3 helicase (HCV NS3) DMF910Q MA Modulator DMF910Q RN Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295. DMF910Q RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457362/ DMF93RQ DI DMF93RQ DMF93RQ DN INS-37217 DMF93RQ TI TTOZHQC DMF93RQ TN P2Y purinoceptor 2 (P2RY2) DMF93RQ MA Agonist DMF93RQ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMF93RQ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMF95KD DI DMF95KD DMF95KD DN SAR-407899 DMF95KD TI TTZN7RP DMF95KD TN Rho-associated protein kinase 1 (ROCK1) DMF95KD MA Inhibitor DMF95KD RN The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9. DMF95KD RU https://pubmed.ncbi.nlm.nih.gov/22388233 DMF9RB4 DI DMF9RB4 DMF9RB4 DN Procysteine DMF9RB4 TI TTULV0X DMF9RB4 TN Reactive oxygen species (ROS) DMF9RB4 MA Modulator DMF9RB4 RN Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10. DMF9RB4 RU https://pubmed.ncbi.nlm.nih.gov/23681269 DMF9Z2T DI DMF9Z2T DMF9Z2T DN T-2007 DMF9Z2T TI TTEX6LM DMF9Z2T TN GABA(A) receptor gamma-3 (GABRG3) DMF9Z2T MA Agonist DMF9Z2T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMF9Z2T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMFAKGR DI DMFAKGR DMFAKGR DN CG-400549 DMFAKGR TI TTZBRVL DMFAKGR TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMFAKGR MA Inhibitor DMFAKGR RN In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. DMFAKGR RU https://pubmed.ncbi.nlm.nih.gov/17420210 DMFAO5G DI DMFAO5G DMFAO5G DN S-PRAnt DMFAO5G TI TTUV8G9 DMFAO5G TN Progesterone receptor (PGR) DMFAO5G MA Antagonist DMFAO5G RN BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64. DMFAO5G RU https://pubmed.ncbi.nlm.nih.gov/23739217 DMFAU3Z DI DMFAU3Z DMFAU3Z DN GSK249320 DMFAU3Z TI TT9XFON DMFAU3Z TN Myelin-associated glycoprotein (MAG) DMFAU3Z RN First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. DMFAU3Z RU https://pubmed.ncbi.nlm.nih.gov/23267856 DMFCIKN DI DMFCIKN DMFCIKN DN Polivy DMFCIKN TI TTBN5I7 DMFCIKN TN B-cell-specific glycoprotein B29 (CD79B) DMFCIKN MA Agonist DMFCIKN RN Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475. DMFCIKN RU https://pubmed.ncbi.nlm.nih.gov/31352604 DMFDA4Y DI DMFDA4Y DMFDA4Y DN SR-2640 DMFDA4Y TI TTTWGIX DMFDA4Y TN Leukotriene receptor (LTR) DMFDA4Y MA Modulator DMFDA4Y RN Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4. DMFDA4Y RU https://pubmed.ncbi.nlm.nih.gov/1677467 DMFG8TI DI DMFG8TI DMFG8TI DN INCB00928 DMFG8TI TI TTJNBQA DMFG8TI TN Activin receptor-like kinase 2 (ALK-2) DMFG8TI MA Inhibitor DMFG8TI RN Clinical pipeline report, company report or official report of Incyte. DMFG8TI RU https://www.incyte.com/what-we-do/pharmaceutical-portfolio DMFGNB4 DI DMFGNB4 DMFGNB4 DN LY-2623091 DMFGNB4 TI TT26PHO DMFGNB4 TN Mineralocorticoid receptor (MR) DMFGNB4 MA Antagonist DMFGNB4 RN Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. DMFGNB4 RU https://pubmed.ncbi.nlm.nih.gov/26083526 DMFI5J4 DI DMFI5J4 DMFI5J4 DN Dextromethorphan+quinidine DMFI5J4 TI TTSZLWK DMFI5J4 TN Aromatase (CYP19A1) DMFI5J4 MA Inhibitor DMFI5J4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMFI5J4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMFI5J4 DI DMFI5J4 DMFI5J4 DN Dextromethorphan+quinidine DMFI5J4 TI TT9IK2Z DMFI5J4 TN N-methyl-D-aspartate receptor (NMDAR) DMFI5J4 MA Antagonist DMFI5J4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMFI5J4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TT9W8GU DMFIVSR TN Gamma-secretase (GS) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TT8JRS7 DMFIVSR TN Beta-secretase (BACE) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TTWN3F4 DMFIVSR TN Presenilin 2 (PSEN2) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TTZ3S8C DMFIVSR TN Presenilin 1 (PSEN1) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFL96Z DI DMFL96Z DMFL96Z DN Pegamotecan DMFL96Z TI TTGTQHC DMFL96Z TN DNA topoisomerase I (TOP1) DMFL96Z MA Inhibitor DMFL96Z RN A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. DMFL96Z RU https://pubmed.ncbi.nlm.nih.gov/18398613 DMFLCW4 DI DMFLCW4 DMFLCW4 DN AZD8931 DMFLCW4 TI TT6EO5L DMFLCW4 TN Erbb2 tyrosine kinase receptor (HER2) DMFLCW4 MA Inhibitor DMFLCW4 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMFLCW4 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMFLZPC DI DMFLZPC DMFLZPC DN VER 50589 DMFLZPC TI TT78R5H DMFLZPC TN Heat shock protein 90 alpha (HSP90A) DMFLZPC MA Inhibitor DMFLZPC RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMFLZPC RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMFM6OU DI DMFM6OU DMFM6OU DN PerioPatch DMFM6OU TI TTHS7CM DMFM6OU TN Beta-glucuronidase (GUSB) DMFM6OU MA Modulator DMFM6OU RN Clinical pipeline report, company report or official report of Izun Pharmaceuticals. DMFM6OU RU http://izunpharma.com/products/periopatch/ DMFMKQ3 DI DMFMKQ3 DMFMKQ3 DN LY3015014 DMFMKQ3 TI TTBRG7E DMFMKQ3 TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMFMKQ3 RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMFMKQ3 RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMFNDBC DI DMFNDBC DMFNDBC DN Otelixizumab DMFNDBC TI TTUN7MC DMFNDBC TN T-cell surface glycoprotein CD3 (CD3) DMFNDBC MA Modulator DMFNDBC RN Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54. DMFNDBC RU https://www.ncbi.nlm.nih.gov/pubmed/25011949 DMFNZPY DI DMFNZPY DMFNZPY DN SSR-240612 DMFNZPY TI TTG5QIA DMFNZPY TN B1 bradykinin receptor (BDKRB1) DMFNZPY MA Antagonist DMFNZPY RN The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287. DMFNZPY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978253/ DMFO2G5 DI DMFO2G5 DMFO2G5 DN Afabicin DMFO2G5 TI TTZBRVL DMFO2G5 TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMFO2G5 MA Inhibitor DMFO2G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFO2G5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMFO6MH DI DMFO6MH DMFO6MH DN Kevetrin DMFO6MH TI TT7SBF5 DMFO6MH TN Cellular tumor antigen p53 (TP53) DMFO6MH MA Stimulator DMFO6MH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFO6MH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFORDT DI DMFORDT DMFORDT DN Afimoxifene DMFORDT TI TTZAYWL DMFORDT TN Estrogen receptor (ESR) DMFORDT MA Modulator DMFORDT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMFORDT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMFT5D6 DI DMFT5D6 DMFT5D6 DN Telcagepant DMFT5D6 TI TTY6O0Q DMFT5D6 TN Calcitonin gene-related peptide receptor (CGRPR) DMFT5D6 MA Antagonist DMFT5D6 RN CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5. DMFT5D6 RU https://pubmed.ncbi.nlm.nih.gov/19469188 DMFU0JY DI DMFU0JY DMFU0JY DN TH-302 DMFU0JY TI TTUTN1I DMFU0JY TN Human Deoxyribonucleic acid (hDNA) DMFU0JY MA Modulator DMFU0JY RN Company report (Threshold Pharmaceuticals) DMFU0JY RU http://www.thresholdpharm.com/what-is-th-302 DMFVL5J DI DMFVL5J DMFVL5J DN AZD-4877 DMFVL5J TI TTTRP0H DMFVL5J TN Kinesin-like protein KIF11 (KIF11) DMFVL5J MA Inhibitor DMFVL5J RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMFVL5J RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMFVNSB DI DMFVNSB DMFVNSB DN WY-50295-tromethamine DMFVNSB TI TT2J34L DMFVNSB TN Arachidonate 5-lipoxygenase (5-LOX) DMFVNSB MA Inhibitor DMFVNSB RN WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41. DMFVNSB RU https://pubmed.ncbi.nlm.nih.gov/10319915 DMFW860 DI DMFW860 DMFW860 DN ABT-450 DMFW860 TI TT5FNQT DMFW860 TN Human immunodeficiency virus Protease (HIV PR) DMFW860 MA Inhibitor DMFW860 RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DMFW860 RU http://www.abbott.com/index2.htm DMFWZ2U DI DMFWZ2U DMFWZ2U DN Valopicitabine dihydrochloride DMFWZ2U TI TTMVBWH DMFWZ2U TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMFWZ2U MA Modulator DMFWZ2U RN Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8. DMFWZ2U RU https://pubmed.ncbi.nlm.nih.gov/17328231 DMFX3P1 DI DMFX3P1 DMFX3P1 DN ONO-5129 DMFX3P1 TI TTZMAO3 DMFX3P1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMFX3P1 MA Modulator DMFX3P1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFX3P1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFX3P1 DI DMFX3P1 DMFX3P1 DN ONO-5129 DMFX3P1 TI TTJ584C DMFX3P1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFX3P1 MA Modulator DMFX3P1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFX3P1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFXN2T DI DMFXN2T DMFXN2T DN AMG 745 DMFXN2T TI TTSWPH8 DMFXN2T TN Growth/differentiation factor 8 (GDF-8) DMFXN2T MA Antagonist DMFXN2T RN The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151. DMFXN2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177043/ DMFYABR DI DMFYABR DMFYABR DN PRO-044 DMFYABR TI TTWLFXU DMFYABR TN Dystrophin messenger RNA (DMD mRNA) DMFYABR RN Update on neuromuscular disorders in pediatric orthopaedics: Duchenne muscular dystrophy, myelomeningocele, and cerebral palsy. J Pediatr Orthop. 2014 Oct-Nov;34 Suppl 1:S44-8. DMFYABR RU https://pubmed.ncbi.nlm.nih.gov/25207736 DMFZ084 DI DMFZ084 DMFZ084 DN Fresolimumab DMFZ084 TI TTO3HT7 DMFZ084 TN Transforming growth factor beta (TGFB) DMFZ084 MA Inhibitor DMFZ084 RN Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504. DMFZ084 RU https://pubmed.ncbi.nlm.nih.gov/29476019 DMFZULI DI DMFZULI DMFZULI DN Upamostat DMFZULI TI TTGY7WI DMFZULI TN Urokinase-type plasminogen activator (PLAU) DMFZULI MA Inhibitor DMFZULI RN Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70. DMFZULI RU https://pubmed.ncbi.nlm.nih.gov/23412098 DMG1LVA DI DMG1LVA DMG1LVA DN BLZ-945 DMG1LVA TI TTC70AJ DMG1LVA TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMG1LVA MA Inhibitor DMG1LVA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMG1LVA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMG1LVA DI DMG1LVA DMG1LVA DN BLZ-945 DMG1LVA TI TT7MRDV DMG1LVA TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMG1LVA MA Antagonist DMG1LVA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG1LVA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG1VXR DI DMG1VXR DMG1VXR DN SBC-014 DMG1VXR TI TTC70AJ DMG1VXR TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMG1VXR MA Modulator DMG1VXR RN A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2. DMG1VXR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639539/ DMG3O2Z DI DMG3O2Z DMG3O2Z DN Girentuximab I-124 DMG3O2Z TI TT2LVK8 DMG3O2Z TN Carbonic anhydrase IX (CA-IX) DMG3O2Z MA Enhancer DMG3O2Z RN Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407. DMG3O2Z RU https://pubmed.ncbi.nlm.nih.gov/23204838 DMG3ON2 DI DMG3ON2 DMG3ON2 DN BIA 3-202 DMG3ON2 TI TTKWFB8 DMG3ON2 TN Catechol-O-methyl-transferase (COMT) DMG3ON2 MA Inhibitor DMG3ON2 RN Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8. DMG3ON2 RU https://pubmed.ncbi.nlm.nih.gov/12236793 DMG439E DI DMG439E DMG439E DN Fipamezole DMG439E TI TTQ8AFT DMG439E TN Adrenergic receptor Alpha-2 (ADRA2) DMG439E MA Antagonist DMG439E RN Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. DMG439E RU https://pubmed.ncbi.nlm.nih.gov/16939381 DMG5C8D DI DMG5C8D DMG5C8D DN GS-9620 DMG5C8D TI TTRJ1K4 DMG5C8D TN Toll-like receptor 7 (TLR7) DMG5C8D MA Modulator DMG5C8D RN Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105. DMG5C8D RU https://pubmed.ncbi.nlm.nih.gov/24133297 DMG5Q7F DI DMG5Q7F DMG5Q7F DN IPI-549 DMG5Q7F TI TTHBTOP DMG5Q7F TN PI3-kinase gamma (PIK3CG) DMG5Q7F MA Inhibitor DMG5Q7F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG5Q7F RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG65WH DI DMG65WH DMG65WH DN Ficlatuzumab DMG65WH TI TT4V2JM DMG65WH TN Hepatocyte growth factor (HGF) DMG65WH MA Inhibitor DMG65WH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG65WH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG6KXB DI DMG6KXB DMG6KXB DN MK-8245 DMG6KXB TI TT6RIOV DMG6KXB TN Acyl-CoA desaturase (SCD) DMG6KXB MA Inhibitor DMG6KXB RN Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96. DMG6KXB RU https://pubmed.ncbi.nlm.nih.gov/21661758 DMG7IEN DI DMG7IEN DMG7IEN DN Anatibant DMG7IEN TI TTGY8IW DMG7IEN TN B2 bradykinin receptor (BDKRB2) DMG7IEN MA Antagonist DMG7IEN RN Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34. DMG7IEN RU https://pubmed.ncbi.nlm.nih.gov/19487935 DMG7PDY DI DMG7PDY DMG7PDY DN XEN-D0501 DMG7PDY TI TTMI6F5 DMG7PDY TN Transient receptor potential cation channel V1 (TRPV1) DMG7PDY MA Antagonist DMG7PDY RN An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31. DMG7PDY RU https://pubmed.ncbi.nlm.nih.gov/21676011 DMG7RAV DI DMG7RAV DMG7RAV DN LMB-2 DMG7RAV TI TT10Y9E DMG7RAV TN Interleukin 2 receptor alpha (IL2RA) DMG7RAV MA Modulator DMG7RAV RN Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36. DMG7RAV RU https://pubmed.ncbi.nlm.nih.gov/10764422 DMG7XOC DI DMG7XOC DMG7XOC DN NIC5-15 DMG7XOC TI TTE4KHA DMG7XOC TN Amyloid beta A4 protein (APP) DMG7XOC MA Inhibitor DMG7XOC RN Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20. DMG7XOC RU https://pubmed.ncbi.nlm.nih.gov/25325702 DMG7YI9 DI DMG7YI9 DMG7YI9 DN ZYH7 DMG7YI9 TI TTJ584C DMG7YI9 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG7YI9 MA Agonist DMG7YI9 RN Clinical pipeline report, company report or official report of Zydus Cadila. DMG7YI9 RU https://zyduscadila.com/public/pdf/investorpresentation/Investor_Presentation_February_2020.pdf DMG7YQL DI DMG7YQL DMG7YQL DN GSK2245840 DMG7YQL TI TTUF2HO DMG7YQL TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMG7YQL MA Modulator DMG7YQL RN Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. DMG7YQL RU https://pubmed.ncbi.nlm.nih.gov/25574479 DMG8NLI DI DMG8NLI DMG8NLI DN P-9808 DMG8NLI TI TTT0HW3 DMG8NLI TN Porphobilinogen deaminase (HMBS) DMG8NLI MA Modulator DMG8NLI RN Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. DMG8NLI RU https://pubmed.ncbi.nlm.nih.gov/17375984 DMG9MN2 DI DMG9MN2 DMG9MN2 DN SAR97276 DMG9MN2 TI TTQ2GJ0 DMG9MN2 TN Plasmodial phospholipid metabolism (PPP metab) DMG9MN2 MA Antagonist DMG9MN2 RN Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276. DMG9MN2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437492/ DMGBLI3 DI DMGBLI3 DMGBLI3 DN VS-6063 DMGBLI3 TI TTON5IT DMGBLI3 TN Focal adhesion kinase 1 (FAK) DMGBLI3 MA Inhibitor DMGBLI3 RN Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. DMGBLI3 RU https://pubmed.ncbi.nlm.nih.gov/24062525 DMGBPME DI DMGBPME DMGBPME DN 2-Methoxyestradiol DMGBPME TI TTQHWNA DMGBPME TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMGBPME MA Modulator DMGBPME RN 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73. DMGBPME RU https://www.ncbi.nlm.nih.gov/pubmed/15623651 DMGCRKY DI DMGCRKY DMGCRKY DN Midismase DMGCRKY TI TT6RVLG DMGCRKY TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMGCRKY MA Modulator DMGCRKY RN A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis DMGCRKY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364 DMGCTX5 DI DMGCTX5 DMGCTX5 DN Combined PR1/WT1 vaccine DMGCTX5 TI TT5MLC4 DMGCTX5 TN Leukocyte proteinase-3 (PRTN3) DMGCTX5 RN Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. DMGCTX5 RU https://pubmed.ncbi.nlm.nih.gov/17875804 DMGCTX5 DI DMGCTX5 DMGCTX5 DN Combined PR1/WT1 vaccine DMGCTX5 TI TTZ8UT4 DMGCTX5 TN Wilms tumor protein (WT1) DMGCTX5 RN Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. DMGCTX5 RU https://pubmed.ncbi.nlm.nih.gov/17875804 DMGD1YP DI DMGD1YP DMGD1YP DN MEDI9929 DMGD1YP TI TTHMW3T DMGD1YP TN Thymic stromal lymphopoietin (TSLP) DMGD1YP MA Modulator DMGD1YP RN Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929). European medicines agency science medicines health (EMEA-001613-PIP01-14). European Union. 2015. DMGD1YP RU http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001613-PIP01-14/pip_001268.jsp&mid=WC0b01ac058001d129 DMGD3XT DI DMGD3XT DMGD3XT DN DRL-17822 DMGD3XT TI TTFQAYR DMGD3XT TN Cholesteryl ester transfer protein (CETP) DMGD3XT MA Inhibitor DMGD3XT RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMGD3XT RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMGDB21 DI DMGDB21 DMGDB21 DN VX-150 DMGDB21 TI TT90XZ8 DMGDB21 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMGDB21 MA Inhibitor DMGDB21 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGDB21 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMGDF2X DI DMGDF2X DMGDF2X DN ASP-7147 DMGDF2X TI TTC1MVT DMGDF2X TN Gastrin-releasing peptide receptor (GRPR) DMGDF2X MA Antagonist DMGDF2X RN Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion DMGDF2X RU http://www.astellas.com/en/corporate/news/detail/astellas-and-drais-partner-to-.html DMGE058 DI DMGE058 DMGE058 DN Cabiralizumab DMGE058 TI TT7MRDV DMGE058 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMGE058 MA Antagonist DMGE058 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE058 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGE058 DI DMGE058 DMGE058 DN Cabiralizumab DMGE058 TI TTNYZG2 DMGE058 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMGE058 MA Antagonist DMGE058 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE058 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGE8FK DI DMGE8FK DMGE8FK DN AMR-001 DMGE8FK TI TTZAVYN DMGE8FK TN Hematopoietic progenitor cell antigen CD34 (CD34) DMGE8FK MA Modulator DMGE8FK RN National Cancer Institute Drug Dictionary (drug id 743421). DMGE8FK RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=743421 DMGEAM6 DI DMGEAM6 DMGEAM6 DN Cinaciguat DMGEAM6 TI TTLBYH1 DMGEAM6 TN Guanylate cyclase soluble beta-1 (GUCY1B1) DMGEAM6 MA Activator DMGEAM6 RN Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 Jun 2;119(21):2781-8. DMGEAM6 RU https://pubmed.ncbi.nlm.nih.gov/19451356 DMGFZOL DI DMGFZOL DMGFZOL DN Enadoline DMGFZOL TI TTQW87Y DMGFZOL TN Opioid receptor kappa (OPRK1) DMGFZOL MA Agonist DMGFZOL RN Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9. DMGFZOL RU https://pubmed.ncbi.nlm.nih.gov/10204752 DMGHQ37 DI DMGHQ37 DMGHQ37 DN Icaritin DMGHQ37 TI TTZAYWL DMGHQ37 TN Estrogen receptor (ESR) DMGHQ37 MA Modulator DMGHQ37 RN A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER protein.Carcinogenesis.2012 May;33(5):1089-97. DMGHQ37 RU https://www.ncbi.nlm.nih.gov/pubmed/22345291 DMGIRM1 DI DMGIRM1 DMGIRM1 DN SH-529 DMGIRM1 TI TT470F3 DMGIRM1 TN TNF alpha production (TNFA produ) DMGIRM1 MA Modulator DMGIRM1 RN Particulate beta-glucan induces TNF-alpha production in wound macrophages via a redox-sensitive NF- beta-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9. DMGIRM1 RU https://pubmed.ncbi.nlm.nih.gov/21518092 DMGJ1X2 DI DMGJ1X2 DMGJ1X2 DN Aplindore fumarate DMGJ1X2 TI TTEX248 DMGJ1X2 TN Dopamine D2 receptor (D2R) DMGJ1X2 MA Agonist DMGJ1X2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMGJ1X2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMGJ71F DI DMGJ71F DMGJ71F DN ALT-836 DMGJ71F TI TT38MDJ DMGJ71F TN Tissue factor (F3) DMGJ71F MA Inhibitor DMGJ71F RN ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303. DMGJ71F RU https://pubmed.ncbi.nlm.nih.gov/25801992 DMGJEB8 DI DMGJEB8 DMGJEB8 DN SSR125543 DMGJEB8 TI TT7EFHR DMGJEB8 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMGJEB8 MA Antagonist DMGJEB8 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMGJEB8 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMGJYZ8 DI DMGJYZ8 DMGJYZ8 DN EDP-305 DMGJYZ8 TI TTS4UGC DMGJYZ8 TN Farnesoid X-activated receptor (FXR) DMGJYZ8 MA Agonist DMGJYZ8 RN A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669. DMGJYZ8 RU https://pubmed.ncbi.nlm.nih.gov/32329946 DMGK1JE DI DMGK1JE DMGK1JE DN MORAb-004 DMGK1JE TI TTYJWT7 DMGK1JE TN Endosialin (CD248) DMGK1JE MA Modulator DMGK1JE RN A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8. DMGK1JE RU https://pubmed.ncbi.nlm.nih.gov/25398449 DMGLCVU DI DMGLCVU DMGLCVU DN R-salbutamol sulphate DMGLCVU TI TT2CJVK DMGLCVU TN Adrenergic receptor beta-2 (ADRB2) DMGLCVU MA Agonist DMGLCVU RN Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52. DMGLCVU RU https://pubmed.ncbi.nlm.nih.gov/9404370 DMGLVBI DI DMGLVBI DMGLVBI DN JTT-302 DMGLVBI TI TTFQAYR DMGLVBI TN Cholesteryl ester transfer protein (CETP) DMGLVBI MA Inhibitor DMGLVBI RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMGLVBI RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMGMC8H DI DMGMC8H DMGMC8H DN LY333531 DMGMC8H TI TT9SL3Q DMGMC8H TN Polypeptide deformylase (PDF) DMGMC8H MA Inhibitor DMGMC8H RN Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23. DMGMC8H RU https://pubmed.ncbi.nlm.nih.gov/10623528 DMGMC8H DI DMGMC8H DMGMC8H DN LY333531 DMGMC8H TI TTYPXQF DMGMC8H TN Protein kinase C beta (PRKCB) DMGMC8H MA Inhibitor DMGMC8H RN Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8. DMGMC8H RU https://pubmed.ncbi.nlm.nih.gov/12540629 DMGNFBC DI DMGNFBC DMGNFBC DN APN301 DMGNFBC TI TT80ARU DMGNFBC TN Ganglioside GD2 (GD2) DMGNFBC MA Inhibitor DMGNFBC RN Clinical pipeline report, company report or official report of Apeiron Biologics. DMGNFBC RU https://www.apeiron-biologics.com/childrens-oncology-group-and-apeiron-to-jointly-conduct-phase-ii-study-in-neuroblastoma-with-hu14-18-il2-apn301/ DMGNK67 DI DMGNK67 DMGNK67 DN TETRAPLATIN TETRANITRATE DMGNK67 TI TTUTN1I DMGNK67 TN Human Deoxyribonucleic acid (hDNA) DMGNK67 MA Binder DMGNK67 RN Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8. DMGNK67 RU https://pubmed.ncbi.nlm.nih.gov/8490203 DMGO45I DI DMGO45I DMGO45I DN FR-146687 DMGO45I TI TTTU72V DMGO45I TN Steroid 5-alpha-reductase 1 (SRD5A1) DMGO45I MA Inhibitor DMGO45I RN Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94. DMGO45I RU https://pubmed.ncbi.nlm.nih.gov/12236849 DMGO7QT DI DMGO7QT DMGO7QT DN INK128 DMGO7QT TI TTCJG29 DMGO7QT TN Serine/threonine-protein kinase mTOR (mTOR) DMGO7QT MA Inhibitor DMGO7QT RN 2011 Pipeline of Intellikine. DMGO7QT RU http://www.intellikine.com/pipeline/ DMGOFL3 DI DMGOFL3 DMGOFL3 DN AMG 151 DMGOFL3 TI TTDLNGZ DMGOFL3 TN Glucokinase (GCK) DMGOFL3 MA Inhibitor DMGOFL3 RN This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009 DMGOFL3 RU http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf DMGP9VN DI DMGP9VN DMGP9VN DN PDC-1421 DMGP9VN TI TTAWNKZ DMGP9VN TN Norepinephrine transporter (NET) DMGP9VN MA Inhibitor DMGP9VN RN Clinical pipeline report, company report or official report of BioInvent. DMGP9VN RU https://www.biolite.com.tw/tw/medicine/bli1005.html DMGQ175 DI DMGQ175 DMGQ175 DN Mapatumumab DMGQ175 TI TT5WLRX DMGQ175 TN TRAIL receptor 1 (TRAIL-R1) DMGQ175 MA Modulator DMGQ175 RN National Cancer Institute Drug Dictionary (drug id 486626). DMGQ175 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=486626 DMGQSVX DI DMGQSVX DMGQSVX DN AZD-2115 DMGQSVX TI TTOXS3C DMGQSVX TN Muscarinic acetylcholine receptor (CHRM) DMGQSVX MA Agonist DMGQSVX RN Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. DMGQSVX RU https://pubmed.ncbi.nlm.nih.gov/22917191 DMGQSVX DI DMGQSVX DMGQSVX DN AZD-2115 DMGQSVX TI TT2CJVK DMGQSVX TN Adrenergic receptor beta-2 (ADRB2) DMGQSVX MA Agonist DMGQSVX RN Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. DMGQSVX RU https://pubmed.ncbi.nlm.nih.gov/22917191 DMGROQP DI DMGROQP DMGROQP DN FK-505 DMGROQP TI TTFH2RS DMGROQP TN FK506-binding protein (FKBP) DMGROQP MA Modulator DMGROQP RN Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632. DMGROQP RU http://circres.ahajournals.org/content/84/6/623.full.html DMGTB2Q DI DMGTB2Q DMGTB2Q DN SSR411298 DMGTB2Q TI TTDP1UC DMGTB2Q TN Fatty acid amide hydrolase (FAAH) DMGTB2Q MA Inhibitor DMGTB2Q RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMGTB2Q RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMGTJUP DI DMGTJUP DMGTJUP DN IONIS-PTP1BRX DMGTJUP TI TTMS7KP DMGTJUP TN Protein-tyrosine phosphatase 1B (PTP1B) DMGTJUP MA Inhibitor DMGTJUP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGTJUP RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMGU05N DI DMGU05N DMGU05N DN GSK598809 DMGU05N TI TT4C8EA DMGU05N TN Dopamine D3 receptor (D3R) DMGU05N MA Antagonist DMGU05N RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMGU05N RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMGUI51 DI DMGUI51 DMGUI51 DN MSDC-0602 DMGUI51 TI TTCBFJO DMGUI51 TN Insulin receptor (INSR) DMGUI51 MA Modulator DMGUI51 RN Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. DMGUI51 RU https://pubmed.ncbi.nlm.nih.gov/22621923 DMGUTPN DI DMGUTPN DMGUTPN DN ABT-414 DMGUTPN TI TTGKNB4 DMGUTPN TN Epidermal growth factor receptor (EGFR) DMGUTPN RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DMGUTPN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DMGVKHQ DI DMGVKHQ DMGVKHQ DN ADX10059 DMGVKHQ TI TTHS256 DMGVKHQ TN Metabotropic glutamate receptor 5 (mGluR5) DMGVKHQ MA Modulator DMGVKHQ RN A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9. DMGVKHQ RU https://pubmed.ncbi.nlm.nih.gov/19460767 DMGVQI8 DI DMGVQI8 DMGVQI8 DN AM-001 DMGVQI8 TI TTRLW2X DMGVQI8 TN Fibroblast growth factor receptor 1 (FGFR1) DMGVQI8 MA Antagonist DMGVQI8 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917) DMGVQI8 RU http://adisinsight.springer.com/drugs/800029917 DMGWE4H DI DMGWE4H DMGWE4H DN TGFK09SD DMGWE4H TI TTSQIFT DMGWE4H TN 5-HT 1A receptor (HTR1A) DMGWE4H MA Modulator DMGWE4H RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032503) DMGWE4H RU http://adisinsight.springer.com/drugs/800032503 DMGWNCJ DI DMGWNCJ DMGWNCJ DN Ifabotuzumab DMGWNCJ TI TTHS2LR DMGWNCJ TN Ephrin type-A receptor 3 (EPHA3) DMGWNCJ MA Antagonist DMGWNCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGWNCJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGWP8L DI DMGWP8L DMGWP8L DN TLC-388 DMGWP8L TI TTGTQHC DMGWP8L TN DNA topoisomerase I (TOP1) DMGWP8L MA Inhibitor DMGWP8L RN Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12. DMGWP8L RU https://pubmed.ncbi.nlm.nih.gov/9885371 DMGWZ93 DI DMGWZ93 DMGWZ93 DN Lulizumab pegol DMGWZ93 TI TTQ13FT DMGWZ93 TN T-cell-specific surface glycoprotein CD28 (CD28) DMGWZ93 MA Modulator DMGWZ93 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGWZ93 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMGXTOP DI DMGXTOP DMGXTOP DN JTX-2011 DMGXTOP TI TTE5VP6 DMGXTOP TN Inducible T-cell costimulator (ICOS) DMGXTOP MA Agonist DMGXTOP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGXTOP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGY5JC DI DMGY5JC DMGY5JC DN Pentacea DMGY5JC TI TTY6DTE DMGY5JC TN Carcinoembryonic antigen CEA (CD66e) DMGY5JC RN Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83. DMGY5JC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828581/ DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TTLYXIT DMGYBZI TN Aurora kinase C (AURKC) DMGYBZI MA Inhibitor DMGYBZI RN Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/15828847 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TT9RTBL DMGYBZI TN Aurora B messenger RNA (AURKB mRNA) DMGYBZI MA Inhibitor DMGYBZI RN Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/15828847 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TT5LS6T DMGYBZI TN Aurora kinase B (AURKB) DMGYBZI MA Inhibitor DMGYBZI RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TTPS3C0 DMGYBZI TN Aurora kinase A (AURKA) DMGYBZI MA Inhibitor DMGYBZI RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMGYSZ0 DI DMGYSZ0 DMGYSZ0 DN TVI-Kidney-1 DMGYSZ0 TI TTXQYT6 DMGYSZ0 TN T-cells (T-cells) DMGYSZ0 RN Clinical pipeline report, company report or official report of TVAX Biomedical. DMGYSZ0 RU http://www.tvaxbiomedical.com/tvi-kidney.shtml DMGYXFP DI DMGYXFP DMGYXFP DN BMS-582949 DMGYXFP TI TTGFK5X DMGYXFP TN Protein kinase unspecific (PK) DMGYXFP MA Modulator DMGYXFP RN Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. DMGYXFP RU https://pubmed.ncbi.nlm.nih.gov/23578688 DMGYXFP DI DMGYXFP DMGYXFP DN BMS-582949 DMGYXFP TI TTWELHI DMGYXFP TN Stress-activated protein kinase (p38) DMGYXFP MA Inhibitor DMGYXFP RN Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. DMGYXFP RU https://pubmed.ncbi.nlm.nih.gov/23578688 DMH0C8J DI DMH0C8J DMH0C8J DN GW-813893 DMH0C8J TI TTCIHJA DMH0C8J TN Coagulation factor Xa (F10) DMH0C8J MA Inhibitor DMH0C8J RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMH0C8J RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMH0LM2 DI DMH0LM2 DMH0LM2 DN POT-4 DMH0LM2 TI TTJGY7A DMH0LM2 TN Complement C3 (CO3) DMH0LM2 MA Inhibitor DMH0LM2 RN Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292. DMH0LM2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700864/ DMH1DYU DI DMH1DYU DMH1DYU DN MSC1936369B DMH1DYU TI TTROQ37 DMH1DYU TN MAPK/ERK kinase kinase (MAP3K) DMH1DYU MA Modulator DMH1DYU RN Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101. DMH1DYU RU https://pubmed.ncbi.nlm.nih.gov/23629727 DMH2VS0 DI DMH2VS0 DMH2VS0 DN CLP-1001 DMH2VS0 TI TTWN7KV DMH2VS0 TN Na-K-Cl cotransporter (NKCC) DMH2VS0 MA Modulator DMH2VS0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446) DMH2VS0 RU http://adisinsight.springer.com/drugs/800034446 DMH3YKJ DI DMH3YKJ DMH3YKJ DN LY2382770 DMH3YKJ TI TTO3HT7 DMH3YKJ TN Transforming growth factor beta (TGFB) DMH3YKJ MA Inhibitor DMH3YKJ RN A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31. DMH3YKJ RU https://pubmed.ncbi.nlm.nih.gov/25270361 DMH4BFD DI DMH4BFD DMH4BFD DN TN-871 DMH4BFD TI TTTD45S DMH4BFD TN Neurotransmitter release (NT rele) DMH4BFD MA Modulator DMH4BFD RN Effects of an indene-derivative, TN-871, on synaptic transmission in a sympathetic ganglion: presynaptic actions on neurotransmitter release. Bull Tokyo Med Dent Univ. 1995 Mar;42(1):19-29. DMH4BFD RU https://pubmed.ncbi.nlm.nih.gov/7895315 DMH4C3M DI DMH4C3M DMH4C3M DN STA-5326 DMH4C3M TI TTRTK6Y DMH4C3M TN Interleukin-12 alpha (IL12A) DMH4C3M MA Inhibitor DMH4C3M RN Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. DMH4C3M RU https://pubmed.ncbi.nlm.nih.gov/18847496 DMH5CAL DI DMH5CAL DMH5CAL DN ARQ 761 DMH5CAL TI TT8XK6L DMH5CAL TN Quinone reductase 1 (NQO1) DMH5CAL MA Inhibitor DMH5CAL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH5CAL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH5GQU DI DMH5GQU DMH5GQU DN CO-101 DMH5GQU TI TTUTN1I DMH5GQU TN Human Deoxyribonucleic acid (hDNA) DMH5GQU MA Inhibitor DMH5GQU RN Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12. DMH5GQU RU https://pubmed.ncbi.nlm.nih.gov/16807468 DMH5GQU DI DMH5GQU DMH5GQU DN CO-101 DMH5GQU TI TTBWDI0 DMH5GQU TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMH5GQU MA Inhibitor DMH5GQU RN Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12. DMH5GQU RU https://pubmed.ncbi.nlm.nih.gov/16807468 DMH5LFR DI DMH5LFR DMH5LFR DN ALXN6000 DMH5LFR TI TT0BE68 DMH5LFR TN Membrane glycoprotein OX2 (CD200) DMH5LFR RN American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103. DMH5LFR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086088/ DMH5MVE DI DMH5MVE DMH5MVE DN Sodium stibogluconate DMH5MVE TI TTNJKC3 DMH5MVE TN Leishmania DNA topoisomerase I (Leishm TOP1) DMH5MVE MA Modulator DMH5MVE RN Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62. DMH5MVE RU https://pubmed.ncbi.nlm.nih.gov/15562618 DMH6XJG DI DMH6XJG DMH6XJG DN WCK-2349 DMH6XJG TI TTIXTO3 DMH6XJG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMH6XJG MA Modulator DMH6XJG RN DOI: 10.1038/ja.2013.86 DMH6XJG RU http://www.nature.com/ja/journal/v66/n10/fig_tab/ja201386t3.html DMH7Q4E DI DMH7Q4E DMH7Q4E DN Bimagrumab DMH7Q4E TI TTRG4QN DMH7Q4E TN Activin receptor type II (ACVR2) DMH7Q4E MA Inhibitor DMH7Q4E RN Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919. DMH7Q4E RU https://pubmed.ncbi.nlm.nih.gov/29566437 DMH7RJ1 DI DMH7RJ1 DMH7RJ1 DN BIIB014 DMH7RJ1 TI TTM2AOE DMH7RJ1 TN Adenosine A2a receptor (ADORA2A) DMH7RJ1 MA Antagonist DMH7RJ1 RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DMH7RJ1 RU https://pubmed.ncbi.nlm.nih.gov/17016425 DMH85M0 DI DMH85M0 DMH85M0 DN ZD-6126 DMH85M0 TI TTYFKSZ DMH85M0 TN Tubulin beta (TUBB) DMH85M0 MA Inhibitor DMH85M0 RN Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67. DMH85M0 RU https://pubmed.ncbi.nlm.nih.gov/18219445 DMH96JW DI DMH96JW DMH96JW DN Dersalazine DMH96JW TI TTQL5VC DMH96JW TN Platelet-activating factor receptor (PTAFR) DMH96JW MA Inhibitor DMH96JW RN The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740. DMH96JW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315044/ DMH97XA DI DMH97XA DMH97XA DN Igmesine DMH97XA TI TTA7UJC DMH97XA TN Alpha-1-antitrypsin (SERPINA1) DMH97XA MA Modulator DMH97XA RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMH97XA RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMH97XA DI DMH97XA DMH97XA DN Igmesine DMH97XA TI TT5TPI6 DMH97XA TN Opioid receptor sigma 1 (OPRS1) DMH97XA MA Agonist DMH97XA RN Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19. DMH97XA RU https://pubmed.ncbi.nlm.nih.gov/16551835 DMH9JFZ DI DMH9JFZ DMH9JFZ DN NBI-5788 DMH9JFZ TI TT2RY5P DMH9JFZ TN Myelin basic protein (MBP) DMH9JFZ MA Binder DMH9JFZ RN NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65. DMH9JFZ RU https://pubmed.ncbi.nlm.nih.gov/11079539 DMH9RTV DI DMH9RTV DMH9RTV DN Omigapil DMH9RTV TI TTUGSWA DMH9RTV TN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DMH9RTV MA Modulator DMH9RTV RN Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3887-9. DMH9RTV RU https://pubmed.ncbi.nlm.nih.gov/16505364 DMHBN8X DI DMHBN8X DMHBN8X DN 60P002 DMHBN8X TI TTQL5VC DMHBN8X TN Platelet-activating factor receptor (PTAFR) DMHBN8X MA Antagonist DMHBN8X RN Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals. DMHBN8X RU https://60degreespharma.com/research-development/clinical-pipeline/ DMHBOUX DI DMHBOUX DMHBOUX DN CORT125281 DMHBOUX TI TTOZRK6 DMHBOUX TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMHBOUX MA Antagonist DMHBOUX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBOUX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHC2AW DI DMHC2AW DMHC2AW DN SPI-205 DMHC2AW TI TTEDJN4 DMHC2AW TN Low-affinity nerve growth factor receptor (NGFR) DMHC2AW MA Modulator DMHC2AW RN AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9. DMHC2AW RU https://www.ncbi.nlm.nih.gov/pubmed/18465624 DMHET8R DI DMHET8R DMHET8R DN VRC-HIVDNA016-00-VP DMHET8R TI TTUIFO6 DMHET8R TN Human immunodeficiency virus Adenovector Ad35 (HIV Ad35) DMHET8R RN ClinicalTrials.gov (NCT00123968) Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults. U.S. National Institutes of Health. DMHET8R RU https://clinicaltrials.gov/ct2/show/NCT00123968 DMHETPI DI DMHETPI DMHETPI DN ISIS-FXI DMHETPI TI TTDM4ZU DMHETPI TN Factor XI messenger RNA (F11 mRNA) DMHETPI RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMHETPI RU http://www.isispharm.com/index.htm DMHEWT7 DI DMHEWT7 DMHEWT7 DN TRU-015 DMHEWT7 TI TTUE541 DMHEWT7 TN Leukocyte surface antigen Leu-16 (CD20) DMHEWT7 MA Antagonist DMHEWT7 RN TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32. DMHEWT7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061958/ DMHFUJT DI DMHFUJT DMHFUJT DN AZ-01, PEGylated interferon-beta DMHFUJT TI TT4TZ8J DMHFUJT TN Interferon-beta (IFNB1) DMHFUJT MA Modulator DMHFUJT RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DMHFUJT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DMHG3UR DI DMHG3UR DMHG3UR DN NOX-E36 DMHG3UR TI TTNAY0P DMHG3UR TN Monocyte chemotactic and activating factor (CCL2) DMHG3UR MA Inhibitor DMHG3UR RN Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923. DMHG3UR RU https://pubmed.ncbi.nlm.nih.gov/25901662 DMHI36A DI DMHI36A DMHI36A DN IFX-1 DMHI36A TI TTKANGO DMHI36A TN Complement C5 (CO5) DMHI36A MA Inhibitor DMHI36A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHI36A RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHI6GE DI DMHI6GE DMHI6GE DN Pirsidomine DMHI6GE TI TT6HPVC DMHI6GE TN Guanylate cyclase (GC) DMHI6GE MA Modulator DMHI6GE RN Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12. DMHI6GE RU https://pubmed.ncbi.nlm.nih.gov/9658207 DMHJEZS DI DMHJEZS DMHJEZS DN CR-3294 DMHJEZS TI TTF10I9 DMHJEZS TN Nitric-oxide synthase inducible (NOS2) DMHJEZS MA Inhibitor DMHJEZS RN Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827. DMHJEZS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926937/ DMHJTR2 DI DMHJTR2 DMHJTR2 DN XL880 DMHJTR2 TI TTUTJGQ DMHJTR2 TN Vascular endothelial growth factor receptor 2 (KDR) DMHJTR2 MA Modulator DMHJTR2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHJTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHJTR2 DI DMHJTR2 DMHJTR2 DN XL880 DMHJTR2 TI TTNDSF4 DMHJTR2 TN Proto-oncogene c-Met (MET) DMHJTR2 MA Modulator DMHJTR2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHJTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHKIOF DI DMHKIOF DMHKIOF DN OT551 DMHKIOF TI TTA6ZN2 DMHKIOF TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMHKIOF MA Activator DMHKIOF RN Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. DMHKIOF RU https://pubmed.ncbi.nlm.nih.gov/26594225 DMHKTGX DI DMHKTGX DMHKTGX DN BAY 1142524 DMHKTGX TI TT8VUE0 DMHKTGX TN Chymase (CYM) DMHKTGX MA Inhibitor DMHKTGX RN Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479. DMHKTGX RU https://pubmed.ncbi.nlm.nih.gov/29878583 DMHLXUY DI DMHLXUY DMHLXUY DN ASP8273 DMHLXUY TI TTGKNB4 DMHLXUY TN Epidermal growth factor receptor (EGFR) DMHLXUY MA Inhibitor DMHLXUY RN Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083. DMHLXUY RU http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8083 DMHMV6E DI DMHMV6E DMHMV6E DN BMS-986020 DMHMV6E TI TTQ6S1K DMHMV6E TN Lysophosphatidic acid receptor 1 (LPAR1) DMHMV6E MA Antagonist DMHMV6E RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHMV6E RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMHNIGB DI DMHNIGB DMHNIGB DN GPX-150D DMHNIGB TI TT0IHXV DMHNIGB TN DNA topoisomerase II (TOP2) DMHNIGB MA Modulator DMHNIGB RN Company report (Gem pharmaceuticals) DMHNIGB RU http://www.gempharmaceuticals.com/targeted-therapy-approach.shtml DMHNYWP DI DMHNYWP DMHNYWP DN ISIS-GCGR DMHNYWP TI TTLMJSC DMHNYWP TN Glucagon receptor messenger RNA (GCGR mRNA) DMHNYWP RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMHNYWP RU http://www.isispharm.com/index.htm DMHOF7T DI DMHOF7T DMHOF7T DN MEHD-7945A DMHOF7T TI TTGKNB4 DMHOF7T TN Epidermal growth factor receptor (EGFR) DMHOF7T MA Modulator DMHOF7T RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHOF7T RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHOF7T DI DMHOF7T DMHOF7T DN MEHD-7945A DMHOF7T TI TTDC8N2 DMHOF7T TN Erbb3 tyrosine kinase receptor (Erbb-3) DMHOF7T MA Modulator DMHOF7T RN Company report (Biooncology) DMHOF7T RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMHOJ8W DI DMHOJ8W DMHOJ8W DN Isatoribine DMHOJ8W TI TTRJ1K4 DMHOJ8W TN Toll-like receptor 7 (TLR7) DMHOJ8W MA Agonist DMHOJ8W RN Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40. DMHOJ8W RU https://pubmed.ncbi.nlm.nih.gov/18066870 DMHOLB7 DI DMHOLB7 DMHOLB7 DN A-85380 DMHOLB7 TI TTJSZTB DMHOLB7 TN Nicotinic acetylcholine receptor (nAChR) DMHOLB7 MA Agonist DMHOLB7 RN The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30. DMHOLB7 RU https://pubmed.ncbi.nlm.nih.gov/11772288 DMHPEFS DI DMHPEFS DMHPEFS DN TAK-128 DMHPEFS TI TT2O84V DMHPEFS TN Thromboxane A2 receptor (TBXA2R) DMHPEFS MA Modulator DMHPEFS RN ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health. DMHPEFS RU https://clinicaltrials.gov/ct2/show/NCT00229437 DMHQKN6 DI DMHQKN6 DMHQKN6 DN CART-19 DMHQKN6 TI TTW640A DMHQKN6 TN B-lymphocyte surface antigen B4 (CD19) DMHQKN6 MA CAR-T-Cell-Therapy DMHQKN6 RN ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy DMHQKN6 RU https://clinicaltrials.gov/ct2/show/NCT01029366 DMHQV6R DI DMHQV6R DMHQV6R DN GS-4059 DMHQV6R TI TTGM6VW DMHQV6R TN Tyrosine-protein kinase BTK (ATK) DMHQV6R MA Inhibitor DMHQV6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHQV6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHSL87 DI DMHSL87 DMHSL87 DN Methoxyestradiol DMHSL87 TI TT6RVLG DMHSL87 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMHSL87 MA Inhibitor DMHSL87 RN Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. DMHSL87 RU https://pubmed.ncbi.nlm.nih.gov/12409296 DMHTIGU DI DMHTIGU DMHTIGU DN MK-5442 DMHTIGU TI TTBUYHA DMHTIGU TN Extracellular calcium-sensing receptor (CASR) DMHTIGU MA Modulator DMHTIGU RN Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93. DMHTIGU RU https://pubmed.ncbi.nlm.nih.gov/21187599 DMHU8SJ DI DMHU8SJ DMHU8SJ DN MB07803 DMHU8SJ TI TTWHDVK DMHU8SJ TN Fructose-1,6-bisphosphatase (FBP) DMHU8SJ MA Modulator DMHU8SJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHU8SJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHUCQS DI DMHUCQS DMHUCQS DN PL-3994 DMHUCQS TI TTJME02 DMHUCQS TN Atrial natriuretic peptide receptor A (NPR1) DMHUCQS MA Agonist DMHUCQS RN In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238. DMHUCQS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070431/ DMHVEGJ DI DMHVEGJ DMHVEGJ DN CC-930 DMHVEGJ TI TTR2TXZ DMHVEGJ TN Jun N terminal kinase (JNK) DMHVEGJ MA Modulator DMHVEGJ RN In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80. DMHVEGJ RU https://pubmed.ncbi.nlm.nih.gov/25475995 DMHVJZ6 DI DMHVJZ6 DMHVJZ6 DN SAM-531 DMHVJZ6 TI TTJS8PY DMHVJZ6 TN 5-HT 6 receptor (HTR6) DMHVJZ6 MA Antagonist DMHVJZ6 RN Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9. DMHVJZ6 RU https://pubmed.ncbi.nlm.nih.gov/23336058 DMHVZ27 DI DMHVZ27 DMHVZ27 DN Anti-CD137 DMHVZ27 TI TTPW9LJ DMHVZ27 TN Co-stimulatory molecule 4-1BB (CD137) DMHVZ27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878). DMHVZ27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878 DMHYZEK DI DMHYZEK DMHYZEK DN BIBH 1 DMHYZEK TI TTGPQ0F DMHYZEK TN Prolyl endopeptidase FAP (FAP) DMHYZEK RN A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. DMHYZEK RU https://pubmed.ncbi.nlm.nih.gov/12738716 DMHZ4JI DI DMHZ4JI DMHZ4JI DN HGT-1410 DMHZ4JI TI TTPJ2SH DMHZ4JI TN N-sulphoglucosamine sulphohydrolase (SGSH) DMHZ4JI MA Modulator DMHZ4JI RN ClinicalTrials.gov (NCT01155778) Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients. U.S. National Institutes of Health. DMHZ4JI RU https://clinicaltrials.gov/ct2/show/NCT01155778 DMHZIFJ DI DMHZIFJ DMHZIFJ DN PS-938285 DMHZIFJ TI TT30C9G DMHZIFJ TN C-X-C chemokine receptor type 2 (CXCR2) DMHZIFJ MA Antagonist DMHZIFJ RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMHZIFJ RU http://www.centerwatch.com/ DMI2GSK DI DMI2GSK DMI2GSK DN Coluracetam DMI2GSK TI TTAN6JD DMI2GSK TN Glutamate receptor AMPA (GRIA) DMI2GSK MA Modulator DMI2GSK RN MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm. 2008 Jul;115(7):1027-35. DMI2GSK RU https://pubmed.ncbi.nlm.nih.gov/18446264 DMI2XP1 DI DMI2XP1 DMI2XP1 DN L19-IL-2 fusion protein DMI2XP1 TI TTF89GD DMI2XP1 TN Interleukin-2 (IL2) DMI2XP1 RN National Cancer Institute Drug Dictionary (drug id 665656). DMI2XP1 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=665656 DMI3WFG DI DMI3WFG DMI3WFG DN AMG 334 DMI3WFG TI TTY6O0Q DMI3WFG TN Calcitonin gene-related peptide receptor (CGRPR) DMI3WFG MA Modulator DMI3WFG RN EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43. DMI3WFG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182181/ DMI4C90 DI DMI4C90 DMI4C90 DN HF-0220 DMI4C90 TI TTCYE56 DMI4C90 TN Glutathione-dependent PGD synthase (HPGDS) DMI4C90 MA Stimulator DMI4C90 RN US patent application no. 2009,0062,529, Multi-cyclic compounds. DMI4C90 RU http://www.google.st/patents/US20090062529 DMI4E9K DI DMI4E9K DMI4E9K DN MLN0264 DMI4E9K TI TTLDPRG DMI4E9K TN Guanylyl cyclase C (GUCY2C) DMI4E9K MA Modulator DMI4E9K RN J Clin Oncol 31, 2013 (suppl; abstr TPS3646). DMI4E9K RU http://meetinglibrary.asco.org/content/111779-132 DMI57ZA DI DMI57ZA DMI57ZA DN TGWOOAA DMI57ZA TI TTYSN63 DMI57ZA TN 5-HT 2 receptor (5HT2R) DMI57ZA MA Antagonist DMI57ZA RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMI57ZA RU http://www.fabrekramer.com/?page_id=70 DMI57ZA DI DMI57ZA DMI57ZA DN TGWOOAA DMI57ZA TI TTSQIFT DMI57ZA TN 5-HT 1A receptor (HTR1A) DMI57ZA MA Antagonist DMI57ZA RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMI57ZA RU http://www.fabrekramer.com/?page_id=70 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TTVBI8W DMI5HFU TN Dopamine transporter (DAT) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TTAWNKZ DMI5HFU TN Norepinephrine transporter (NET) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TT3ROYC DMI5HFU TN Serotonin transporter (SERT) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5TXZ DI DMI5TXZ DMI5TXZ DN AEM-28 DMI5TXZ TI TTKS9CB DMI5TXZ TN Apolipoprotein E (APOE) DMI5TXZ MA Modulator DMI5TXZ RN Clinical pipeline report, company report or official report of LipimetiX. DMI5TXZ RU http://www.lipimetix.com/technology.html DMI69E5 DI DMI69E5 DMI69E5 DN DS-3201b DMI69E5 TI TTNJA0C DMI69E5 TN Enhancer of zeste homolog 1 (EZH1) DMI69E5 MA Inhibitor DMI69E5 RN Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. DMI69E5 RU https://pubmed.ncbi.nlm.nih.gov/30658046 DMI69E5 DI DMI69E5 DMI69E5 DN DS-3201b DMI69E5 TI TT9MZCQ DMI69E5 TN Enhancer of zeste homolog 2 (EZH2) DMI69E5 MA Inhibitor DMI69E5 RN Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. DMI69E5 RU https://pubmed.ncbi.nlm.nih.gov/30658046 DMI874B DI DMI874B DMI874B DN Iratumumab DMI874B TI TT2GM5R DMI874B TN Lymphocyte activation antigen CD30 (TNFRSF8) DMI874B RN Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2. DMI874B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337265/ DMI9WVM DI DMI9WVM DMI9WVM DN MEDI-575 DMI9WVM TI TT8FYO9 DMI9WVM TN Platelet-derived growth factor receptor alpha (PDGFRA) DMI9WVM RN Clinical pipeline report, company report or official report of MedImmune (2011). DMI9WVM RU http://www.medimmune.com/research_pipeline.aspx DMIAZ13 DI DMIAZ13 DMIAZ13 DN Ponezumab DMIAZ13 TI TTE4KHA DMIAZ13 TN Amyloid beta A4 protein (APP) DMIAZ13 RN Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. DMIAZ13 RU https://pubmed.ncbi.nlm.nih.gov/22197375 DMIBXK0 DI DMIBXK0 DMIBXK0 DN AZD-7009 DMIBXK0 TI TT1VOHK DMIBXK0 TN Potassium channel unspecific (KC) DMIBXK0 MA Modulator DMIBXK0 RN Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23. DMIBXK0 RU https://pubmed.ncbi.nlm.nih.gov/24508473 DMICMNU DI DMICMNU DMICMNU DN ISIS-GCCR DMICMNU TI TTOZRK6 DMICMNU TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMICMNU RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMICMNU RU http://www.isispharm.com/index.htm DMICMXE DI DMICMXE DMICMXE DN Ferroquine DMICMXE TI TT0OV9N DMICMXE TN Haematin (HA) DMICMXE MA Inhibitor DMICMXE RN Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005 May-Jun;2(3):185-93. DMICMXE RU https://www.ncbi.nlm.nih.gov/pubmed/15934779 DMIEPJG DI DMIEPJG DMIEPJG DN BTT-1023 DMIEPJG TI TT7HC21 DMIEPJG TN Membrane copper amine oxidase (AOC3) DMIEPJG RN Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9. DMIEPJG RU https://pubmed.ncbi.nlm.nih.gov/23847292 DMIERPK DI DMIERPK DMIERPK DN UE-2343 DMIERPK TI TTN7BL9 DMIERPK TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMIERPK MA Inhibitor DMIERPK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIERPK RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMIEXUM DI DMIEXUM DMIEXUM DN GSK768974 DMIEXUM TI TTEPJL5 DMIEXUM TN Parathyroid hormone receptor (PTH2R) DMIEXUM MA Agonist DMIEXUM RN Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone. 2000 Oct;27(4):471-8. DMIEXUM RU https://pubmed.ncbi.nlm.nih.gov/11033441 DMIEZUB DI DMIEZUB DMIEZUB DN L-DOS47 DMIEZUB TI TTUTJGQ DMIEZUB TN Vascular endothelial growth factor receptor 2 (KDR) DMIEZUB RN Clinical pipeline report, company report or official report of Helix BioPharma. DMIEZUB RU https://www.helixbiopharma.com/pipeline/ DMIFA0L DI DMIFA0L DMIFA0L DN APG-115 DMIFA0L TI TT08GJW DMIFA0L TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMIFA0L MA Inhibitor DMIFA0L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFA0L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFA0L DI DMIFA0L DMIFA0L DN APG-115 DMIFA0L TI TT7SBF5 DMIFA0L TN Cellular tumor antigen p53 (TP53) DMIFA0L MA Inhibitor DMIFA0L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFA0L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFGLY DI DMIFGLY DMIFGLY DN Leukemia cancer vaccine DMIFGLY TI TT6MP2Z DMIFGLY TN GMCSFR-alpha (CSF2RA) DMIFGLY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMIFGLY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMIG98L DI DMIG98L DMIG98L DN RC-3095 DMIG98L TI TTC1MVT DMIG98L TN Gastrin-releasing peptide receptor (GRPR) DMIG98L MA Inhibitor DMIG98L RN Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8. DMIG98L RU https://pubmed.ncbi.nlm.nih.gov/15940257 DMIHQ5G DI DMIHQ5G DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine DMIHQ5G TI TTF89GD DMIHQ5G TN Interleukin-2 (IL2) DMIHQ5G RN Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41. DMIHQ5G RU https://pubmed.ncbi.nlm.nih.gov/16249392 DMIHQ5G DI DMIHQ5G DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine DMIHQ5G TI TTIJP3Q DMIHQ5G TN TNF related activation protein (CD40LG) DMIHQ5G RN Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41. DMIHQ5G RU https://pubmed.ncbi.nlm.nih.gov/16249392 DMIJNLG DI DMIJNLG DMIJNLG DN Semapimod DMIJNLG TI TTB18GJ DMIJNLG TN Proto-oncogene c-RAF (c-RAF) DMIJNLG MA Modulator DMIJNLG RN Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300. DMIJNLG RU https://pubmed.ncbi.nlm.nih.gov/16081798 DMIK2AD DI DMIK2AD DMIK2AD DN OPC-64005 DMIK2AD TI TT8G3Z7 DMIK2AD TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMIK2AD MA Inhibitor DMIK2AD RN Clinical pipeline report, company report or official report of Otsuka Pharmaceutical. DMIK2AD RU https://www.otsuka.co.jp/en/research-and-development/pipeline/ DMIKH67 DI DMIKH67 DMIKH67 DN Valetizumab DMIKH67 TI TTMSB0A DMIKH67 TN Integrin alpha-2/beta-1 (ITGA2/B1) DMIKH67 RN Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146. DMIKH67 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/ DMIM1U9 DI DMIM1U9 DMIM1U9 DN Vorolanib DMIM1U9 TI TTVJ1D8 DMIM1U9 TN Vascular endothelial growth factor receptor (VEGFR) DMIM1U9 MA Inhibitor DMIM1U9 RN Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. DMIM1U9 RU https://pubmed.ncbi.nlm.nih.gov/33707933 DMIM1U9 DI DMIM1U9 DMIM1U9 DN Vorolanib DMIM1U9 TI TTI2WET DMIM1U9 TN Platelet-derived growth factor receptor (PDGFR) DMIM1U9 MA Inhibitor DMIM1U9 RN Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. DMIM1U9 RU https://pubmed.ncbi.nlm.nih.gov/33707933 DMIN0SV DI DMIN0SV DMIN0SV DN GSK2269557 DMIN0SV TI TTWELHI DMIN0SV TN Stress-activated protein kinase (p38) DMIN0SV MA Inhibitor DMIN0SV RN Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70. DMIN0SV RU https://pubmed.ncbi.nlm.nih.gov/22765651 DMINQP1 DI DMINQP1 DMINQP1 DN NEUROPEPTIDE-Y DMINQP1 TI TTRK9JT DMINQP1 TN Neuropeptide Y receptor type 1 (NPY1R) DMINQP1 MA Inhibitor DMINQP1 RN 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6. DMINQP1 RU https://pubmed.ncbi.nlm.nih.gov/19916528 DMINQP1 DI DMINQP1 DMINQP1 DN NEUROPEPTIDE-Y DMINQP1 TI TTJ6WK9 DMINQP1 TN Neuropeptide Y receptor type 2 (NPY2R) DMINQP1 MA Inhibitor DMINQP1 RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMINQP1 RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMIO59F DI DMIO59F DMIO59F DN ORG-34517 DMIO59F TI TTYRL6O DMIO59F TN Glucocorticoid receptor (NR3C1) DMIO59F MA Antagonist DMIO59F RN Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann N Y Acad Sci. 2008 Dec;1148:536-41. DMIO59F RU https://pubmed.ncbi.nlm.nih.gov/19120154 DMIOGZM DI DMIOGZM DMIOGZM DN ELIPRODIL DMIOGZM TI TTLD29N DMIOGZM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMIOGZM MA Inhibitor DMIOGZM RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMIOGZM RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMIOGZM DI DMIOGZM DMIOGZM DN ELIPRODIL DMIOGZM TI TTN9D8E DMIOGZM TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMIOGZM MA Inhibitor DMIOGZM RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMIOGZM RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMIOUEY DI DMIOUEY DMIOUEY DN AMG 337 DMIOUEY TI TTNDSF4 DMIOUEY TN Proto-oncogene c-Met (MET) DMIOUEY MA Modulator DMIOUEY RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2508). DMIOUEY RU http://meetinglibrary.asco.org/content/127112-144 DMIQB13 DI DMIQB13 DMIQB13 DN SHAPE DMIQB13 TI TTBH0VX DMIQB13 TN Histone deacetylase (HDAC) DMIQB13 MA Inhibitor DMIQB13 RN Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals. DMIQB13 RU http://tetralogicpharma.com/shape/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TTSQIFT DMIQDFW TN 5-HT 1A receptor (HTR1A) DMIQDFW MA Agonist DMIQDFW RN Clinical pipeline report, company report or official report of Neurim Pharmaceuticals. DMIQDFW RU http://www.neurim.com/products/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TT6MSOK DMIQDFW TN 5-HT 1D receptor (HTR1D) DMIQDFW MA Agonist DMIQDFW RN Clinical pipeline report, company report or official report of Neurim Pharmaceuticals. DMIQDFW RU http://www.neurim.com/products/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TT0WAIE DMIQDFW TN Melatonin receptor type 1A (MTNR1A) DMIQDFW MA Agonist DMIQDFW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288). DMIQDFW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288 DMIRPSA DI DMIRPSA DMIRPSA DN Mitoglitazone DMIRPSA TI TTCBFJO DMIRPSA TN Insulin receptor (INSR) DMIRPSA MA Modulator DMIRPSA RN An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73. DMIRPSA RU https://pubmed.ncbi.nlm.nih.gov/24931567 DMIRPSA DI DMIRPSA DMIRPSA DN Mitoglitazone DMIRPSA TI TTSJH2W DMIRPSA TN Mitochondrial protein unspecific (MP) DMIRPSA MA Modulator DMIRPSA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIRPSA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMIRSWE DI DMIRSWE DMIRSWE DN CYT-006-AngQb DMIRSWE TI TTGN1ZA DMIRSWE TN Angiotensin II receptor (AGTR) DMIRSWE RN CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75. DMIRSWE RU https://pubmed.ncbi.nlm.nih.gov/19333885 DMISETH DI DMISETH DMISETH DN HER2/neu peptide vaccine DMISETH TI TT6EO5L DMISETH TN Erbb2 tyrosine kinase receptor (HER2) DMISETH RN N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35. DMISETH RU https://pubmed.ncbi.nlm.nih.gov/19596910 DMISQOZ DI DMISQOZ DMISQOZ DN AP-761 DMISQOZ TI TTQDMX5 DMISQOZ TN Prostaglandin D2 receptor 2 (PTGDR2) DMISQOZ MA Antagonist DMISQOZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464) DMISQOZ RU http://adisinsight.springer.com/drugs/800028464 DMIU19E DI DMIU19E DMIU19E DN CP-101,606 DMIU19E TI TTN9D8E DMIU19E TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMIU19E MA Antagonist DMIU19E RN NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8. DMIU19E RU https://pubmed.ncbi.nlm.nih.gov/11698028 DMIUC3M DI DMIUC3M DMIUC3M DN IMGN901 DMIUC3M TI TTUBJQ3 DMIUC3M TN Neural cell adhesion molecule (NCAM) DMIUC3M MA Modulator DMIUC3M RN Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. DMIUC3M RU https://pubmed.ncbi.nlm.nih.gov/24492307 DMIUS5X DI DMIUS5X DMIUS5X DN R1507 DMIUS5X TI TTHRID2 DMIUS5X TN Insulin-like growth factor I receptor (IGF1R) DMIUS5X MA Inhibitor DMIUS5X RN Clinical pipeline report, company report or official report of Roche (2009). DMIUS5X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMIV9ZE DI DMIV9ZE DMIV9ZE DN LOXORIBINE DMIV9ZE TI TTRJ1K4 DMIV9ZE TN Toll-like receptor 7 (TLR7) DMIV9ZE MA Agonist DMIV9ZE RN The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97. DMIV9ZE RU https://pubmed.ncbi.nlm.nih.gov/14579267 DMIVR9K DI DMIVR9K DMIVR9K DN MER-3001 DMIVR9K TI TTZOPHG DMIVR9K TN Insulin (INS) DMIVR9K MA Modulator DMIVR9K RN Clinical pipeline report, company report or official report of Mercia Pharma Inc. DMIVR9K RU http://merciapharma.com/?page_id=81 DMIVUFL DI DMIVUFL DMIVUFL DN ACH-1625 DMIVUFL TI TT5FNQT DMIVUFL TN Human immunodeficiency virus Protease (HIV PR) DMIVUFL MA Inhibitor DMIVUFL RN Clinical pipeline report, company report or official report of Achillion (2011). DMIVUFL RU http://www.achillion.com/main.aspx?pn=ProductPipeline&fl=l DMIVZ3M DI DMIVZ3M DMIVZ3M DN AME-133v DMIVZ3M TI TTUE541 DMIVZ3M TN Leukocyte surface antigen Leu-16 (CD20) DMIVZ3M RN Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. DMIVZ3M RU https://pubmed.ncbi.nlm.nih.gov/22223529 DMIW453 DI DMIW453 DMIW453 DN Pelitinib DMIW453 TI TTGKNB4 DMIW453 TN Epidermal growth factor receptor (EGFR) DMIW453 MA Modulator DMIW453 RN EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12. DMIW453 RU https://www.ncbi.nlm.nih.gov/pubmed/23379415 DMIXT2Y DI DMIXT2Y DMIXT2Y DN MGAH22 DMIXT2Y TI TT6EO5L DMIXT2Y TN Erbb2 tyrosine kinase receptor (HER2) DMIXT2Y MA Modulator DMIXT2Y RN Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123. DMIXT2Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/ DMIYFWA DI DMIYFWA DMIYFWA DN Dapirolizumab pegol DMIYFWA TI TTIJP3Q DMIYFWA TN TNF related activation protein (CD40LG) DMIYFWA MA Inhibitor DMIYFWA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIYFWA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMIZKEC DI DMIZKEC DMIZKEC DN BMS-986036 DMIZKEC TI TTQ916P DMIZKEC TN Fibroblast growth factor-21 (FGF21) DMIZKEC MA Agonist DMIZKEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIZKEC RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMIZYV1 DI DMIZYV1 DMIZYV1 DN QAV-680 DMIZYV1 TI TTQDMX5 DMIZYV1 TN Prostaglandin D2 receptor 2 (PTGDR2) DMIZYV1 MA Antagonist DMIZYV1 RN Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91. DMIZYV1 RU https://pubmed.ncbi.nlm.nih.gov/24021582 DMJ1DIB DI DMJ1DIB DMJ1DIB DN S-tenatoprazole DMJ1DIB TI TTLOKXP DMJ1DIB TN Gastric H(+)/K(+) ATPase (Proton pump) DMJ1DIB MA Modulator DMJ1DIB RN Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62. DMJ1DIB RU https://www.ncbi.nlm.nih.gov/pubmed/15023167 DMJ1FXL DI DMJ1FXL DMJ1FXL DN JNJ-53718678 DMJ1FXL TI TT57ID8 DMJ1FXL TN Respiratory syncytial virus protein F (RSV F) DMJ1FXL MA Inhibitor DMJ1FXL RN Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756. DMJ1FXL RU https://pubmed.ncbi.nlm.nih.gov/29684148 DMJ2763 DI DMJ2763 DMJ2763 DN IONIS-FB-LRx DMJ2763 TI TT3SGK7 DMJ2763 TN CFB messenger RNA (CFB mRNA) DMJ2763 MA Inhibitor DMJ2763 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMJ2763 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMJ2FTU DI DMJ2FTU DMJ2FTU DN TGBA01AD DMJ2FTU TI TT6MSOK DMJ2FTU TN 5-HT 1D receptor (HTR1D) DMJ2FTU MA Modulator DMJ2FTU RN Company report (Fabrekramer) DMJ2FTU RU http://www.fabrekramer.com/?page_id=66 DMJ2FTU DI DMJ2FTU DMJ2FTU DN TGBA01AD DMJ2FTU TI TTSQIFT DMJ2FTU TN 5-HT 1A receptor (HTR1A) DMJ2FTU MA Modulator DMJ2FTU RN Company report (Fabrekramer) DMJ2FTU RU http://www.fabrekramer.com/?page_id=66 DMJ2REU DI DMJ2REU DMJ2REU DN Berubicin DMJ2REU TI TT0IHXV DMJ2REU TN DNA topoisomerase II (TOP2) DMJ2REU MA Modulator DMJ2REU RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJ2REU RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJ34G6 DI DMJ34G6 DMJ34G6 DN SAR-125844 DMJ34G6 TI TTNDSF4 DMJ34G6 TN Proto-oncogene c-Met (MET) DMJ34G6 MA Inhibitor DMJ34G6 RN The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94. DMJ34G6 RU https://pubmed.ncbi.nlm.nih.gov/25504634 DMJ37UX DI DMJ37UX DMJ37UX DN Revacept DMJ37UX TI TTTJUVZ DMJ37UX TN Platelet glycoprotein VI (GP6) DMJ37UX MA Inhibitor DMJ37UX RN Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9. DMJ37UX RU https://pubmed.ncbi.nlm.nih.gov/21502572 DMJ3KPO DI DMJ3KPO DMJ3KPO DN TD-101 DMJ3KPO TI TT2FX8W DMJ3KPO TN Keratin 6A messenger RNA (KRT6A mRNA) DMJ3KPO RN First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb;18(2):442-6. DMJ3KPO RU https://pubmed.ncbi.nlm.nih.gov/19935778 DMJ48AB DI DMJ48AB DMJ48AB DN ARRY-797 DMJ48AB TI TTYT93M DMJ48AB TN MAP kinase p38 (MAPK12) DMJ48AB MA Inhibitor DMJ48AB RN Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs DMJ48AB RU http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1720505&highlight= DMJ48AB DI DMJ48AB DMJ48AB DN ARRY-797 DMJ48AB TI TTWELHI DMJ48AB TN Stress-activated protein kinase (p38) DMJ48AB MA Inhibitor DMJ48AB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ48AB RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJ4BKT DI DMJ4BKT DMJ4BKT DN F-16-IL-2 fusion protein DMJ4BKT TI TTUCPMY DMJ4BKT TN Tenascin (TNC) DMJ4BKT MA Modulator DMJ4BKT RN National Cancer Institute Drug Dictionary (drug id 674718). DMJ4BKT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674718 DMJ4GPR DI DMJ4GPR DMJ4GPR DN AMP-579 DMJ4GPR TI TTM2AOE DMJ4GPR TN Adenosine A2a receptor (ADORA2A) DMJ4GPR MA Modulator DMJ4GPR RN Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53. DMJ4GPR RU https://pubmed.ncbi.nlm.nih.gov/15271662 DMJ4GPR DI DMJ4GPR DMJ4GPR DN AMP-579 DMJ4GPR TI TTK25J1 DMJ4GPR TN Adenosine A1 receptor (ADORA1) DMJ4GPR MA Modulator DMJ4GPR RN Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53. DMJ4GPR RU https://pubmed.ncbi.nlm.nih.gov/15271662 DMJ7QP8 DI DMJ7QP8 DMJ7QP8 DN AN-019 DMJ7QP8 TI TTS7G69 DMJ7QP8 TN Fusion protein Bcr-Abl (Bcr-Abl) DMJ7QP8 MA Inhibitor DMJ7QP8 RN Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78. DMJ7QP8 RU https://pubmed.ncbi.nlm.nih.gov/23151973 DMJ8V3K DI DMJ8V3K DMJ8V3K DN AZD5312 DMJ8V3K TI TTS64P2 DMJ8V3K TN Androgen receptor (AR) DMJ8V3K MA Modulator DMJ8V3K RN Company report (Astrazeneca) DMJ8V3K RU https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html DMJ94L0 DI DMJ94L0 DMJ94L0 DN ZK-91587 DMJ94L0 TI TT26PHO DMJ94L0 TN Mineralocorticoid receptor (MR) DMJ94L0 MA Antagonist DMJ94L0 RN ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43. DMJ94L0 RU https://pubmed.ncbi.nlm.nih.gov/3193846 DMJ9M5D DI DMJ9M5D DMJ9M5D DN SGN-30 DMJ9M5D TI TT2GM5R DMJ9M5D TN Lymphocyte activation antigen CD30 (TNFRSF8) DMJ9M5D RN The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42. DMJ9M5D RU https://pubmed.ncbi.nlm.nih.gov/12097283 DMJ9RN8 DI DMJ9RN8 DMJ9RN8 DN SAR-339658 DMJ9RN8 TI TTMSB0A DMJ9RN8 TN Integrin alpha-2/beta-1 (ITGA2/B1) DMJ9RN8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578). DMJ9RN8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578 DMJ9XCO DI DMJ9XCO DMJ9XCO DN CCX-140 DMJ9XCO TI TTFZYTO DMJ9XCO TN C-C chemokine receptor type 2 (CCR2) DMJ9XCO MA Antagonist DMJ9XCO RN Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348. DMJ9XCO RU https://pubmed.ncbi.nlm.nih.gov/25945357 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TTYT93M DMJAEG6 TN MAP kinase p38 (MAPK12) DMJAEG6 MA Inhibitor DMJAEG6 RN P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/19055838 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TTQBR95 DMJAEG6 TN Stress-activated protein kinase 2a (p38 alpha) DMJAEG6 MA Inhibitor DMJAEG6 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TT73U6C DMJAEG6 TN Stress-activated protein kinase 2b (p38 beta) DMJAEG6 MA Inhibitor DMJAEG6 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMJC8DR DI DMJC8DR DMJC8DR DN BNC-105 DMJC8DR TI TTYFKSZ DMJC8DR TN Tubulin beta (TUBB) DMJC8DR MA Modulator DMJC8DR RN The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60. DMJC8DR RU https://www.ncbi.nlm.nih.gov/pubmed/25482941 DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TTO3HT7 DMJCULI TN Transforming growth factor beta (TGFB) DMJCULI MA Inhibitor DMJCULI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCULI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TT8ZLTI DMJCULI TN Programmed cell death 1 ligand 1 (PD-L1) DMJCULI MA Inhibitor DMJCULI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCULI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TTNBFWK DMJCULI TN Programmed cell death protein 1 (PD-1) DMJCULI RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMJCULI RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMJD7H4 DI DMJD7H4 DMJD7H4 DN CX-1739 DMJD7H4 TI TTAN6JD DMJD7H4 TN Glutamate receptor AMPA (GRIA) DMJD7H4 MA Agonist DMJD7H4 RN AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82. DMJD7H4 RU https://pubmed.ncbi.nlm.nih.gov/22801296 DMJFDS0 DI DMJFDS0 DMJFDS0 DN BI-409306 DMJFDS0 TI TTZOEBC DMJFDS0 TN Phosphodiesterase 9 (PDE9) DMJFDS0 MA Inhibitor DMJFDS0 RN Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline. DMJFDS0 RU https://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html DMJFLBC DI DMJFLBC DMJFLBC DN AVN 101 DMJFLBC TI TTJS8PY DMJFLBC TN 5-HT 6 receptor (HTR6) DMJFLBC MA Modulator DMJFLBC RN Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. DMJFLBC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/ DMJGL72 DI DMJGL72 DMJGL72 DN KW-2478 DMJGL72 TI TT78R5H DMJGL72 TN Heat shock protein 90 alpha (HSP90A) DMJGL72 MA Modulator DMJGL72 RN Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68. DMJGL72 RU https://pubmed.ncbi.nlm.nih.gov/22829970 DMJGVXT DI DMJGVXT DMJGVXT DN ISIS-PTP1Brx DMJGVXT TI TTELIN2 DMJGVXT TN PTPN1 messenger RNA (PTPN1 mRNA) DMJGVXT MA Modulator DMJGVXT RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMJGVXT RU https://www.isispharm.com/pipeline/isis-ptp1brx/ DMJGYPK DI DMJGYPK DMJGYPK DN AZD9056 DMJGYPK TI TT473XN DMJGYPK TN P2X purinoceptor 7 (P2RX7) DMJGYPK MA Antagonist DMJGYPK RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJGYPK RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJH2AC DI DMJH2AC DMJH2AC DN SPD-557 DMJH2AC TI TT07C3Y DMJH2AC TN 5-HT 4 receptor (HTR4) DMJH2AC MA Agonist DMJH2AC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMJH2AC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMJH3U0 DI DMJH3U0 DMJH3U0 DN TAK-659 DMJH3U0 TI TTOU65C DMJH3U0 TN Tyrosine-protein kinase SYK (SYK) DMJH3U0 MA Inhibitor DMJH3U0 RN J Clin Oncol 32:5s, 2014 (suppl; abstr 8580). DMJH3U0 RU http://meetinglibrary.asco.org/content/134551-144 DMJH3U0 DI DMJH3U0 DMJH3U0 DN TAK-659 DMJH3U0 TI TTGJCWZ DMJH3U0 TN Fms-like tyrosine kinase 3 (FLT-3) DMJH3U0 MA Inhibitor DMJH3U0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJH3U0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJH6EL DI DMJH6EL DMJH6EL DN Selurampanel DMJH6EL TI TTAN6JD DMJH6EL TN Glutamate receptor AMPA (GRIA) DMJH6EL MA Antagonist DMJH6EL RN BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13. DMJH6EL RU https://pubmed.ncbi.nlm.nih.gov/24147649 DMJHA6Q DI DMJHA6Q DMJHA6Q DN Ar9281 DMJHA6Q TI TT7WVHI DMJHA6Q TN Soluble epoxide hydrolase (EPHX2) DMJHA6Q MA Inhibitor DMJHA6Q RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMJHA6Q RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMJHVZC DI DMJHVZC DMJHVZC DN MLN-591RL DMJHVZC TI TT9G4N0 DMJHVZC TN Glutamate carboxypeptidase II (GCPII) DMJHVZC RN Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28. DMJHVZC RU https://pubmed.ncbi.nlm.nih.gov/25984435 DMJIB89 DI DMJIB89 DMJIB89 DN Remetinostat DMJIB89 TI TTBH0VX DMJIB89 TN Histone deacetylase (HDAC) DMJIB89 MA Inhibitor DMJIB89 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJIB89 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJIBSG DI DMJIBSG DMJIBSG DN OBE-101 DMJIBSG TI TTTIBOJ DMJIBSG TN Histamine H1 receptor (H1R) DMJIBSG MA Modulator DMJIBSG RN Betahistine in the treatment of M ni re's disease. Neuropsychiatr Dis Treat. 2007 August; 3(4): 429-440. DMJIBSG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655085/ DMJIMXH DI DMJIMXH DMJIMXH DN Puerarin DMJIMXH TI TTWJBZ5 DMJIMXH TN 5-HT 2C receptor (HTR2C) DMJIMXH MA Modulator DMJIMXH RN NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav. 2003 Jun;75(3):619-25. DMJIMXH RU https://www.ncbi.nlm.nih.gov/pubmed/12895679 DMJK5CT DI DMJK5CT DMJK5CT DN STX-140 DMJK5CT TI TTHM0R1 DMJK5CT TN Steryl-sulfatase (STS) DMJK5CT MA Inhibitor DMJK5CT RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMJK5CT RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMJK5CT DI DMJK5CT DMJK5CT DN STX-140 DMJK5CT TI TTANPDJ DMJK5CT TN Carbonic anhydrase II (CA-II) DMJK5CT MA Inhibitor DMJK5CT RN Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308. DMJK5CT RU https://pubmed.ncbi.nlm.nih.gov/18260615 DMJK8L1 DI DMJK8L1 DMJK8L1 DN MRG002 DMJK8L1 TI TT6EO5L DMJK8L1 TN Erbb2 tyrosine kinase receptor (HER2) DMJK8L1 RN ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health. DMJK8L1 RU https://clinicaltrials.gov/ct2/show/NCT04839510 DMJKBAY DI DMJKBAY DMJKBAY DN NGX-267 DMJKBAY TI TTZ9SOR DMJKBAY TN Muscarinic acetylcholine receptor M1 (CHRM1) DMJKBAY MA Agonist DMJKBAY RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMJKBAY RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMJKHVX DI DMJKHVX DMJKHVX DN Mazapertine succinate DMJKHVX TI TTSQIFT DMJKHVX TN 5-HT 1A receptor (HTR1A) DMJKHVX MA Modulator DMJKHVX RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMJKHVX RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMJKHVX DI DMJKHVX DMJKHVX DN Mazapertine succinate DMJKHVX TI TTEX248 DMJKHVX TN Dopamine D2 receptor (D2R) DMJKHVX MA Modulator DMJKHVX RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMJKHVX RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMJKLHU DI DMJKLHU DMJKLHU DN CAP-7.1 DMJKLHU TI TT0IHXV DMJKLHU TN DNA topoisomerase II (TOP2) DMJKLHU MA Modulator DMJKLHU RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJKLHU RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJL4A7 DI DMJL4A7 DMJL4A7 DN O-desulfated heparin DMJL4A7 TI TT4QPUL DMJL4A7 TN Antithrombin-III (ATIII) DMJL4A7 MA Modulator DMJL4A7 RN Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8. DMJL4A7 RU https://pubmed.ncbi.nlm.nih.gov/6778897 DMJLNZQ DI DMJLNZQ DMJLNZQ DN K-828-AB DMJLNZQ TI TTT2LD9 DMJLNZQ TN GABA transaminase (ABAT) DMJLNZQ MA Inhibitor DMJLNZQ RN Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd. DMJLNZQ RU http://www.biocentury.com/products/k-828-ab DMJN09S DI DMJN09S DMJN09S DN GEN-1 DMJN09S TI TTG68FB DMJN09S TN Interleukine 12 (IL-12) DMJN09S MA Replacement DMJN09S RN Clinical pipeline report, company report or official report of Celsion. DMJN09S RU https://celsion.com/gen-1/ DMJN3BA DI DMJN3BA DMJN3BA DN Zalospirone DMJN3BA TI TTSQIFT DMJN3BA TN 5-HT 1A receptor (HTR1A) DMJN3BA MA Agonist DMJN3BA RN The serotonin 5-HT receptor agonist tandospirone improves executive function in common marmosets. Behav Brain Res. 2015 Jul 1;287:120-6. DMJN3BA RU https://pubmed.ncbi.nlm.nih.gov/25804359 DMJN9PU DI DMJN9PU DMJN9PU DN INCB86550 DMJN9PU TI TT8ZLTI DMJN9PU TN Programmed cell death 1 ligand 1 (PD-L1) DMJN9PU MA Inhibitor DMJN9PU RN National Cancer Institute Drug Dictionary (drug name INCB086550). DMJN9PU RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pd-l1-inhibitor-incb086550 DMJNO3D DI DMJNO3D DMJNO3D DN Follicle stimulating hormone DMJNO3D TI TT13GFV DMJNO3D TN Follicle stimulating hormone (FSHB) DMJNO3D MA Modulator DMJNO3D RN Company report (Glycotope) DMJNO3D RU http://www.glycotope.com/glycotopes-fully-human-and-glycooptimized-recombinant-fsh-gextm-showed-superior-activity-and-excellent-tolerability-in-a-phase-ii-clinical-trial-for-in-vitro-fertilisation DMJO402 DI DMJO402 DMJO402 DN Anti-LAG3 DMJO402 TI TTNVXAW DMJO402 TN Lymphocyte activation gene 3 protein (LAG3) DMJO402 MA Inhibitor DMJO402 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJO402 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMJOM5L DI DMJOM5L DMJOM5L DN Talampanel DMJOM5L TI TTAN6JD DMJOM5L TN Glutamate receptor AMPA (GRIA) DMJOM5L MA Antagonist DMJOM5L RN Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009 Apr;50(4):694-701. DMJOM5L RU https://pubmed.ncbi.nlm.nih.gov/19220413 DMJOYNZ DI DMJOYNZ DMJOYNZ DN Lu AF11167 DMJOYNZ TI TTJW4LU DMJOYNZ TN Phosphodiesterase 10A (PDE10) DMJOYNZ MA Inhibitor DMJOYNZ RN PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178. DMJOYNZ RU https://pubmed.ncbi.nlm.nih.gov/33551724 DMJPE61 DI DMJPE61 DMJPE61 DN PF-02545920 DMJPE61 TI TTJW4LU DMJPE61 TN Phosphodiesterase 10A (PDE10) DMJPE61 MA Inhibitor DMJPE61 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJPE61 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJPV5X DI DMJPV5X DMJPV5X DN Alovudine DMJPV5X TI TT84ETX DMJPV5X TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJPV5X MA Modulator DMJPV5X RN Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. DMJPV5X RU https://www.ncbi.nlm.nih.gov/pubmed/18211121 DMJPZDC DI DMJPZDC DMJPZDC DN Anti-PSCA mab DMJPZDC TI TT9T4AV DMJPZDC TN Prostate stem cell antigen (PSCA) DMJPZDC MA Modulator DMJPZDC RN Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. DMJPZDC RU https://pubmed.ncbi.nlm.nih.gov/22020316 DMJR9H0 DI DMJR9H0 DMJR9H0 DN CC-292 DMJR9H0 TI TTGM6VW DMJR9H0 TN Tyrosine-protein kinase BTK (ATK) DMJR9H0 MA Modulator DMJR9H0 RN Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. DMJR9H0 RU https://pubmed.ncbi.nlm.nih.gov/23709115 DMJRD7A DI DMJRD7A DMJRD7A DN GSK3326595 DMJRD7A TI TTR1D7X DMJRD7A TN Protein arginine methyltransferase 5 (PRMT5) DMJRD7A MA Inhibitor DMJRD7A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJRD7A RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJRK6D DI DMJRK6D DMJRK6D DN SB-9200 DMJRK6D TI TTVB0O3 DMJRK6D TN Retinoic acid-inducible gene-1 (RIG-1) DMJRK6D MA Modulator DMJRK6D RN Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200) DMJRK6D RU http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/ DMJRK6D DI DMJRK6D DMJRK6D DN SB-9200 DMJRK6D TI TTYPUHA DMJRK6D TN Pattern recognition receptor NOD2 (NOD2) DMJRK6D MA Modulator DMJRK6D RN Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200) DMJRK6D RU http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/ DMJSADP DI DMJSADP DMJSADP DN BI 2536 DMJSADP TI TTIYVQP DMJSADP TN Polo-like kinase 1 (PLK1) DMJSADP MA Inhibitor DMJSADP RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMJSADP RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMJSD5W DI DMJSD5W DMJSD5W DN FK-070 DMJSD5W TI TT2O84V DMJSD5W TN Thromboxane A2 receptor (TBXA2R) DMJSD5W MA Modulator DMJSD5W RN Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. DMJSD5W RU https://pubmed.ncbi.nlm.nih.gov/8794987 DMJSD5W DI DMJSD5W DMJSD5W DN FK-070 DMJSD5W TI TTKNWZ4 DMJSD5W TN Thromboxane-A synthase (TBXAS1) DMJSD5W MA Modulator DMJSD5W RN Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. DMJSD5W RU https://pubmed.ncbi.nlm.nih.gov/8794987 DMJSVRL DI DMJSVRL DMJSVRL DN JM216 DMJSVRL TI TTUTN1I DMJSVRL TN Human Deoxyribonucleic acid (hDNA) DMJSVRL MA Modulator DMJSVRL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJSVRL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJSWXL DI DMJSWXL DMJSWXL DN Ad-p53 DMJSWXL TI TT7SBF5 DMJSWXL TN Cellular tumor antigen p53 (TP53) DMJSWXL MA Modulator DMJSWXL RN Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. DMJSWXL RU https://pubmed.ncbi.nlm.nih.gov/12637944 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TTGP7BY DMJSY3Q TN Monoamine oxidase type B (MAO-B) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TT3WG5C DMJSY3Q TN Monoamine oxidase type A (MAO-A) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TT1RS9F DMJSY3Q TN Acetylcholinesterase (AChE) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJTU8D DI DMJTU8D DMJTU8D DN OGX-427 DMJTU8D TI TTMG98T DMJTU8D TN Heat shock protein 27 (HSP27) DMJTU8D MA Modulator DMJTU8D RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJTU8D RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJTYO4 DI DMJTYO4 DMJTYO4 DN PGL-2 DMJTYO4 TI TTHM0R1 DMJTYO4 TN Steryl-sulfatase (STS) DMJTYO4 MA Inhibitor DMJTYO4 RN Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65. DMJTYO4 RU https://pubmed.ncbi.nlm.nih.gov/24604234 DMJUSM8 DI DMJUSM8 DMJUSM8 DN VX-759 DMJUSM8 TI TTMVBWH DMJUSM8 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMJUSM8 MA Inhibitor DMJUSM8 RN 2011 Pipeline of Vertex. DMJUSM8 RU http://www.vrtx.com/current-projects.html DMJUV6C DI DMJUV6C DMJUV6C DN BMS-223131 DMJUV6C TI TT1AQ50 DMJUV6C TN Charybdotoxin receptor beta-4 (BKbeta4) DMJUV6C MA Modulator DMJUV6C RN Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7. DMJUV6C RU https://pubmed.ncbi.nlm.nih.gov/15701710 DMJV3AX DI DMJV3AX DMJV3AX DN IVA337 DMJV3AX TI TTRMIZ7 DMJV3AX TN Peroxisome proliferator-activated receptor (PPAR) DMJV3AX MA Agonist DMJV3AX RN Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940. DMJV3AX RU https://pubmed.ncbi.nlm.nih.gov/28801346 DMJVN89 DI DMJVN89 DMJVN89 DN AEB07 DMJVN89 TI TTYVX59 DMJVN89 TN Protein kinase C (PRKC) DMJVN89 MA Inhibitor DMJVN89 RN What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81. DMJVN89 RU https://pubmed.ncbi.nlm.nih.gov/18828764 DMJVU7Y DI DMJVU7Y DMJVU7Y DN MBL-HCV1 DMJVU7Y TI TTDBG95 DMJVU7Y TN Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) DMJVU7Y MA Modulator DMJVU7Y RN Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-54. DMJVU7Y RU https://pubmed.ncbi.nlm.nih.gov/23356386 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTLU5FO DMJWD62 TN Calcium-activated potassium channel KCa4.2 (KCNT2) DMJWD62 MA Inhibitor (gating inhibitor) DMJWD62 RN Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/16687497 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTKP2SU DMJWD62 TN Transient receptor potential cation channel V4 (TRPV4) DMJWD62 MA Activator DMJWD62 RN Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/11827975 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTGJFK1 DMJWD62 TN Calcium-activated potassium channel KCa4.1 (KCNT1) DMJWD62 MA Activator DMJWD62 RN Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/16687497 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTEO25X DMJWD62 TN Inward rectifier potassium channel Kir3.4 (KCNJ5) DMJWD62 MA Inhibitor (gating inhibitor) DMJWD62 RN Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1087-92. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/14732702 DMJWE3I DI DMJWE3I DMJWE3I DN Gossypol DMJWE3I TI TTJGNVC DMJWE3I TN Apoptosis regulator Bcl-2 (BCL-2) DMJWE3I MA Regulator DMJWE3I RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMJWE3I RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMJX2P4 DI DMJX2P4 DMJX2P4 DN Fezakinumab DMJX2P4 TI TTLDX4N DMJX2P4 TN Interleukin-22 (IL22) DMJX2P4 RN Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. DMJX2P4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/ DMJX3O8 DI DMJX3O8 DMJX3O8 DN OSI-027 DMJX3O8 TI TTCJG29 DMJX3O8 TN Serine/threonine-protein kinase mTOR (mTOR) DMJX3O8 MA Inhibitor DMJX3O8 RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DMJX3O8 RU https://pubmed.ncbi.nlm.nih.gov/19644473 DMJY2TM DI DMJY2TM DMJY2TM DN Gabapentin enacarbil DMJY2TM TI TT61XTV DMJY2TM TN Sodium-dependent multivitamin transporter (SLC5A6) DMJY2TM MA Modulator DMJY2TM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJY2TM RU https://www.fda.gov/ DMJZVPB DI DMJZVPB DMJZVPB DN ENMD-2076 DMJZVPB TI TTPS3C0 DMJZVPB TN Aurora kinase A (AURKA) DMJZVPB MA Inhibitor DMJZVPB RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJZVPB RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJZVPB DI DMJZVPB DMJZVPB DN ENMD-2076 DMJZVPB TI TTU8W4S DMJZVPB TN Protein kinase (PK) DMJZVPB MA Inhibitor DMJZVPB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJZVPB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK0MJP DI DMK0MJP DMK0MJP DN Odelepran DMK0MJP TI TTN4QDT DMK0MJP TN Opioid receptor (OPR) DMK0MJP MA Antagonist DMK0MJP RN A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20. DMK0MJP RU https://pubmed.ncbi.nlm.nih.gov/24010675 DMK0NGB DI DMK0NGB DMK0NGB DN Rozanolixizumab DMK0NGB TI TTPY4SE DMK0NGB TN Immunoglobulin Fc receptor (FCR) DMK0NGB MA Antagonist DMK0NGB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK0NGB RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMK10ZC DI DMK10ZC DMK10ZC DN PLECONARIL DMK10ZC TI TT87Q2D DMK10ZC TN Picornavirus Capsid protein VP1 (PicVir VP1) DMK10ZC MA Modulator DMK10ZC RN Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9. DMK10ZC RU https://pubmed.ncbi.nlm.nih.gov/16251287 DMK2E0N DI DMK2E0N DMK2E0N DN RAXOFELAST DMK2E0N TI TTV0YFR DMK2E0N TN Lipid peroxidation (LPO) DMK2E0N MA Modulator DMK2E0N RN Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91. DMK2E0N RU https://pubmed.ncbi.nlm.nih.gov/15988325 DMK2LGM DI DMK2LGM DMK2LGM DN AVN 322 DMK2LGM TI TTJS8PY DMK2LGM TN 5-HT 6 receptor (HTR6) DMK2LGM MA Modulator DMK2LGM RN 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. DMK2LGM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/ DMK2T7J DI DMK2T7J DMK2T7J DN IW-1973 DMK2T7J TI TT23PYC DMK2T7J TN Soluble guanylate cyclase (GCS) DMK2T7J MA Agonist DMK2T7J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK2T7J RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMK3RL8 DI DMK3RL8 DMK3RL8 DN Somatropin intranasal rhGH DMK3RL8 TI TTT3YKH DMK3RL8 TN Somatotropin (GH1) DMK3RL8 MA Modulator DMK3RL8 RN Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20. DMK3RL8 RU https://www.ncbi.nlm.nih.gov/pubmed/15871547 DMK3U1X DI DMK3U1X DMK3U1X DN ALT-803 DMK3U1X TI TTGN89I DMK3U1X TN Interleukin 15 receptor alpha (IL15RA) DMK3U1X MA Agonist DMK3U1X RN Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86. DMK3U1X RU https://pubmed.ncbi.nlm.nih.gov/23644531 DMK3VYU DI DMK3VYU DMK3VYU DN ATI-502 DMK3VYU TI TTJSQEF DMK3VYU TN Tyrosine-protein kinase (PTK) DMK3VYU MA Inhibitor DMK3VYU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK3VYU RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMK4FRU DI DMK4FRU DMK4FRU DN CBLB-502 DMK4FRU TI TTCXP8J DMK4FRU TN Toll-like receptor 5 (TLR5) DMK4FRU MA Agonist DMK4FRU RN Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One. 2014 May 30;9(5):e96165. DMK4FRU RU https://pubmed.ncbi.nlm.nih.gov/24879439 DMK4VOU DI DMK4VOU DMK4VOU DN KVD001 DMK4VOU TI TTMF8H9 DMK4VOU TN Plasma kallikrein (KLKB1) DMK4VOU MA Inhibitor DMK4VOU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK4VOU RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK5PYS DI DMK5PYS DMK5PYS DN RG7745 DMK5PYS TI TTF4CAM DMK5PYS TN Influenza Hemagglutinin (Influ HA) DMK5PYS RN Clinical pipeline report, company report or official report of Roche. DMK5PYS RU http://www.roche.com/irp2q13e-annex.pdf DMK6FYR DI DMK6FYR DMK6FYR DN DiabeCell DMK6FYR TI TTXQYT6 DMK6FYR TN T-cells (T-cells) DMK6FYR MA Modulator DMK6FYR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMK6FYR RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMK7CYX DI DMK7CYX DMK7CYX DN Vadimezan DMK7CYX TI TTSXVID DMK7CYX TN Nuclear factor NF-kappa-B (NFKB) DMK7CYX MA Modulator DMK7CYX RN Auckland Cancer Society Research Centre report DMK7CYX RU https://www.fmhs.auckland.ac.nz/en/sms/about/our-departments/oncology/cancer-trials-nz/trials-and-research-projects/closed/asa404.html DMK7DFM DI DMK7DFM DMK7DFM DN CPX-POM DMK7DFM TI TTX09M4 DMK7DFM TN Ribonucleotide reductase (RIR) DMK7DFM MA Inhibitor DMK7DFM RN Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. DMK7DFM RU https://pubmed.ncbi.nlm.nih.gov/31113837 DMK7OHI DI DMK7OHI DMK7OHI DN INCAGN01949 DMK7OHI TI TTL31H0 DMK7OHI TN OX40L receptor (CD134) DMK7OHI MA Agonist DMK7OHI RN Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655. DMK7OHI RU https://pubmed.ncbi.nlm.nih.gov/33083509 DMK8PTH DI DMK8PTH DMK8PTH DN PRM-151 DMK8PTH TI TTNJ5A6 DMK8PTH TN Neuronal pentraxin-2 (NPTX2) DMK8PTH MA Modulator DMK8PTH RN PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15. DMK8PTH RU https://pubmed.ncbi.nlm.nih.gov/20603654 DMK8SY6 DI DMK8SY6 DMK8SY6 DN E2027 DMK8SY6 TI TTZOEBC DMK8SY6 TN Phosphodiesterase 9 (PDE9) DMK8SY6 MA Antagonist DMK8SY6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK8SY6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMK9NQI DI DMK9NQI DMK9NQI DN CPP-115 DMK9NQI TI TTT2LD9 DMK9NQI TN GABA transaminase (ABAT) DMK9NQI MA Inhibitor DMK9NQI RN Clinical pipeline report, company report or official report of Catalyst Pharma. DMK9NQI RU http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588 DMKA705 DI DMKA705 DMKA705 DN PGL-2001 DMKA705 TI TTHM0R1 DMKA705 TN Steryl-sulfatase (STS) DMKA705 MA Inhibitor DMKA705 RN Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65. DMKA705 RU https://pubmed.ncbi.nlm.nih.gov/24604234 DMKAUM9 DI DMKAUM9 DMKAUM9 DN Eculizumab DMKAUM9 TI TTN0GJ5 DMKAUM9 TN HUMAN complement C5 protein (C5) DMKAUM9 MA Inhibitor DMKAUM9 RN Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. DMKAUM9 RU https://pubmed.ncbi.nlm.nih.gov/32327719 DMKBIPR DI DMKBIPR DMKBIPR DN Actimab-A DMKBIPR TI TTJVYO3 DMKBIPR TN Myeloid cell surface antigen CD33 (CD33) DMKBIPR MA Inhibitor DMKBIPR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKBIPR RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMKBRDL DI DMKBRDL DMKBRDL DN BEZ235 DMKBRDL TI TTCJG29 DMKBRDL TN Serine/threonine-protein kinase mTOR (mTOR) DMKBRDL MA Modulator DMKBRDL RN The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43. DMKBRDL RU https://www.ncbi.nlm.nih.gov/pubmed/22355272 DMKBRDL DI DMKBRDL DMKBRDL DN BEZ235 DMKBRDL TI TTHBTOP DMKBRDL TN PI3-kinase gamma (PIK3CG) DMKBRDL MA Modulator DMKBRDL RN The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43. DMKBRDL RU https://www.ncbi.nlm.nih.gov/pubmed/22355272 DMKCBSM DI DMKCBSM DMKCBSM DN SOM3355 DMKCBSM TI TTNZRI3 DMKCBSM TN Synaptic vesicle amine transporter (SLC18A2) DMKCBSM MA Inhibitor DMKCBSM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKCBSM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKD5ZO DI DMKD5ZO DMKD5ZO DN NN-8226 DMKD5ZO TI TTNZMY2 DMKD5ZO TN Interleukin-20 (IL20) DMKD5ZO RN Handbook of Therapeutic Antibodies. 2014. 1. Page(995). DMKD5ZO RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false DMKDGI8 DI DMKDGI8 DMKDGI8 DN BP-100-1-01 DMKDGI8 TI TTEYRJ9 DMKDGI8 TN GRB2 messenger RNA (GRB2 mRNA) DMKDGI8 MA Modulator DMKDGI8 RN ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health. DMKDGI8 RU https://clinicaltrials.gov/ct2/show/NCT01159028 DMKDN1C DI DMKDN1C DMKDN1C DN MVA-85A DMKDN1C TI TTZYJ8U DMKDN1C TN Mycobacterium Antigen complex 85A (MycB fbpA) DMKDN1C RN MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010 Feb;12(1):124-34. DMKDN1C RU https://pubmed.ncbi.nlm.nih.gov/20140824 DMKDP57 DI DMKDP57 DMKDP57 DN Safotibant DMKDP57 TI TTG5QIA DMKDP57 TN B1 bradykinin receptor (BDKRB1) DMKDP57 MA Modulator DMKDP57 RN The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38. DMKDP57 RU http://www.sciencedirect.com/science/article/pii/S030438351300829X DMKEV7N DI DMKEV7N DMKEV7N DN PK1 DMKEV7N TI TTCGY2K DMKEV7N TN DNA topoisomerase II alpha (TOP2A) DMKEV7N MA Modulator DMKEV7N RN Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36. DMKEV7N RU https://pubmed.ncbi.nlm.nih.gov/19424581 DMKFJXP DI DMKFJXP DMKFJXP DN BDB001 DMKFJXP TI TTOK0LR DMKFJXP TN Toll-like receptor (TLR) DMKFJXP MA Agonist DMKFJXP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKFJXP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKGM42 DI DMKGM42 DMKGM42 DN BREQUINAR DMKGM42 TI TTLVP78 DMKGM42 TN Dihydroorotate dehydrogenase (DHODH) DMKGM42 MA Modulator DMKGM42 RN DOI: 10.1203/00006450-198807000-00137 DMKGM42 RU http://www.nature.com/pr/journal/v24/n1/abs/pr1988506a.html DMKH4PI DI DMKH4PI DMKH4PI DN BMS 791325 DMKH4PI TI TTMVBWH DMKH4PI TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMKH4PI MA Inhibitor DMKH4PI RN 2011 Pipeline of Bristol-Myers Squibb. DMKH4PI RU http://www.bms.com/pages/default.aspx DMKHNXA DI DMKHNXA DMKHNXA DN G100 DMKHNXA TI TTISGCA DMKHNXA TN Toll-like receptor 4 (TLR4) DMKHNXA MA Antagonist DMKHNXA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKHNXA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKICA3 DI DMKICA3 DMKICA3 DN BIO-1211 DMKICA3 TI TT4BT06 DMKICA3 TN Integrin alpha-4 (ITGA4) DMKICA3 MA Antagonist DMKICA3 RN A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11. DMKICA3 RU https://pubmed.ncbi.nlm.nih.gov/10934094 DMKIE9C DI DMKIE9C DMKIE9C DN JNJ-26481585 DMKIE9C TI TTBH0VX DMKIE9C TN Histone deacetylase (HDAC) DMKIE9C MA Modulator DMKIE9C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503). DMKIE9C RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503 DMKIZAL DI DMKIZAL DMKIZAL DN ONO-1603 DMKIZAL TI TTNGKET DMKIZAL TN Prolyl endopeptidase (PREP) DMKIZAL MA Modulator DMKIZAL RN ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4. DMKIZAL RU https://pubmed.ncbi.nlm.nih.gov/8878106 DMKJ9LU DI DMKJ9LU DMKJ9LU DN SPD602 DMKJ9LU TI TTUDR0C DMKJ9LU TN Iron (Fe) DMKJ9LU MA Modulator DMKJ9LU RN ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health. DMKJ9LU RU https://clinicaltrials.gov/ct2/show/NCT01604941 DMKJF6H DI DMKJF6H DMKJF6H DN YM-430 DMKJF6H TI TTMXGCW DMKJF6H TN Adrenergic receptor beta-3 (ADRB3) DMKJF6H MA Modulator DMKJF6H RN Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6. DMKJF6H RU https://pubmed.ncbi.nlm.nih.gov/9084878 DMKJFDM DI DMKJFDM DMKJFDM DN CP-601927 DMKJFDM TI TTL1ATN DMKJFDM TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMKJFDM MA Modulator DMKJFDM RN Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32. DMKJFDM RU https://pubmed.ncbi.nlm.nih.gov/21594972 DMKJIDU DI DMKJIDU DMKJIDU DN TZI-41078 DMKJIDU TI TTG3K2U DMKJIDU TN Lipoxygenase (ALOX) DMKJIDU MA Modulator DMKJIDU RN Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. DMKJIDU RU https://pubmed.ncbi.nlm.nih.gov/8581424 DMKJIDU DI DMKJIDU DMKJIDU DN TZI-41078 DMKJIDU TI TTK0943 DMKJIDU TN Prostaglandin G/H synthase (COX) DMKJIDU MA Modulator DMKJIDU RN Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. DMKJIDU RU https://pubmed.ncbi.nlm.nih.gov/8581424 DMKLJMI DI DMKLJMI DMKLJMI DN NIC-002 DMKLJMI TI TTJSZTB DMKLJMI TN Nicotinic acetylcholine receptor (nAChR) DMKLJMI RN Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106. DMKLJMI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513862/ DMKLMG6 DI DMKLMG6 DMKLMG6 DN KN035 DMKLMG6 TI TT8ZLTI DMKLMG6 TN Programmed cell death 1 ligand 1 (PD-L1) DMKLMG6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMKLMG6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMKM7EW DI DMKM7EW DMKM7EW DN PF-06463922 DMKM7EW TI TTPMQSO DMKM7EW TN ALK tyrosine kinase receptor (ALK) DMKM7EW MA Inhibitor DMKM7EW RN PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81. DMKM7EW RU https://pubmed.ncbi.nlm.nih.gov/26144315 DMKMSC4 DI DMKMSC4 DMKMSC4 DN MDX-1342 DMKMSC4 TI TTW640A DMKMSC4 TN B-lymphocyte surface antigen B4 (CD19) DMKMSC4 RN A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. DMKMSC4 RU https://pubmed.ncbi.nlm.nih.gov/19657637 DMKNIVG DI DMKNIVG DMKNIVG DN Sodium butyrate DMKNIVG TI TT6R7JZ DMKNIVG TN Histone deacetylase 1 (HDAC1) DMKNIVG MA Inhibitor DMKNIVG RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMKNIVG RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMKNRYH DI DMKNRYH DMKNRYH DN AKB-9778 DMKNRYH TI TT64I9Q DMKNRYH TN Protein tyrosine phosphatase beta (PTPRB) DMKNRYH MA Modulator DMKNRYH RN Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201. DMKNRYH RU https://www.ncbi.nlm.nih.gov/pubmed/23899555 DMKNRYH DI DMKNRYH DMKNRYH DN AKB-9778 DMKNRYH TI TT9VGXW DMKNRYH TN Angiopoietin 1 receptor (TEK) DMKNRYH MA Activator DMKNRYH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKNRYH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMKO0BQ DI DMKO0BQ DMKO0BQ DN BLD-2660 DMKO0BQ TI TT45V0U DMKO0BQ TN HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1) DMKO0BQ MA Inhibitor DMKO0BQ RN ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health. DMKO0BQ RU https://clinicaltrials.gov/ct2/show/NCT04334460 DMKO0BQ DI DMKO0BQ DMKO0BQ DN BLD-2660 DMKO0BQ TI TTO361H DMKO0BQ TN HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1) DMKO0BQ MA Inhibitor DMKO0BQ RN ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health. DMKO0BQ RU https://clinicaltrials.gov/ct2/show/NCT04334460 DMKOTUJ DI DMKOTUJ DMKOTUJ DN SRX246 DMKOTUJ TI TT4TFGN DMKOTUJ TN Vasopressin V1a receptor (V1AR) DMKOTUJ MA Antagonist DMKOTUJ RN Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682. DMKOTUJ RU https://pubmed.ncbi.nlm.nih.gov/33207828 DMKP3SJ DI DMKP3SJ DMKP3SJ DN F-351 DMKP3SJ TI TTRAXK5 DMKP3SJ TN Aminotransferase (AT) DMKP3SJ MA Inhibitor DMKP3SJ RN Expansion of the clavulanic acid gene cluster: identification and in vivo functional analysis of three new genes required for biosynthesis of clavulanic acid by Streptomyces clavuligerus. J Bacteriol. 2000 Jul;182(14):4087-95. DMKP3SJ RU https://pubmed.ncbi.nlm.nih.gov/10869089 DMKPZ0Q DI DMKPZ0Q DMKPZ0Q DN Mitoquinone DMKPZ0Q TI TTULV0X DMKPZ0Q TN Reactive oxygen species (ROS) DMKPZ0Q MA Inhibitor DMKPZ0Q RN Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192. DMKPZ0Q RU https://pubmed.ncbi.nlm.nih.gov/32867213 DMKQ3MC DI DMKQ3MC DMKQ3MC DN Human interferon alpha oral DMKQ3MC TI TT95SOA DMKQ3MC TN Interferon alpha (IFNA) DMKQ3MC MA Modulator DMKQ3MC RN Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9. DMKQ3MC RU https://pubmed.ncbi.nlm.nih.gov/1388878 DMKQXDB DI DMKQXDB DMKQXDB DN Rostafuroxin DMKQXDB TI TTQ38E9 DMKQXDB TN Sodium/potassium-transporting ATPase (SPT ATPase) DMKQXDB MA Modulator DMKQXDB RN Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35. DMKQXDB RU https://pubmed.ncbi.nlm.nih.gov/16467500 DMKRFCO DI DMKRFCO DMKRFCO DN CDX-301 DMKRFCO TI TTGJCWZ DMKRFCO TN Fms-like tyrosine kinase 3 (FLT-3) DMKRFCO MA Inhibitor DMKRFCO RN Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30. DMKRFCO RU https://pubmed.ncbi.nlm.nih.gov/25915810 DMKRGVJ DI DMKRGVJ DMKRGVJ DN INS-1 DMKRGVJ TI TTZ7WFL DMKRGVJ TN Glucose metabolism (Glucose metab) DMKRGVJ MA Modulator DMKRGVJ RN Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and beta-cells. Am J Physiol Endocrinol Metab. 2012 April 15; 302(8): E932-E940. DMKRGVJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330724/ DMKS7RJ DI DMKS7RJ DMKS7RJ DN CGS-15873A DMKS7RJ TI TTEX248 DMKS7RJ TN Dopamine D2 receptor (D2R) DMKS7RJ MA Modulator DMKS7RJ RN Biochemical and pharmacological characterization of the putative dopamine autoreceptor agonist benzopyranopyridine, CGS 15873A. Article first published online: 5 OCT 2004. DMKS7RJ RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430180303/abstract DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TTMBO1Z DMKSUOI TN Cyclin-dependent kinase (CDK) DMKSUOI MA Inhibitor DMKSUOI RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMKSUOI RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TT31JXP DMKSUOI TN Myophosphorylase (PYGM) DMKSUOI MA Inhibitor DMKSUOI RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMKSUOI RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TT1LVF2 DMKSUOI TN Cyclin-dependent kinase 9 (CDK9) DMKSUOI MA Inhibitor DMKSUOI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKSUOI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKTLSD DI DMKTLSD DMKTLSD DN S-15535 DMKTLSD TI TTSQIFT DMKTLSD TN 5-HT 1A receptor (HTR1A) DMKTLSD MA Antagonist DMKTLSD RN S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14. DMKTLSD RU https://pubmed.ncbi.nlm.nih.gov/10578133 DMKTP8E DI DMKTP8E DMKTP8E DN PRX002 DMKTP8E TI TT08OSU DMKTP8E TN Synuclein alpha (SNCA) DMKTP8E MA Inhibitor DMKTP8E RN Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214. DMKTP8E RU https://pubmed.ncbi.nlm.nih.gov/29913017 DMKU6MW DI DMKU6MW DMKU6MW DN JB991 DMKU6MW TI TT9B4N3 DMKU6MW TN Prostaglandin receptor (PTGR) DMKU6MW MA Agonist DMKU6MW RN US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis. DMKU6MW RU http://www.google.com/patents/US20060041016 DMKU93J DI DMKU93J DMKU93J DN VAS-203 DMKU93J TI TTCM4B3 DMKU93J TN Nitric-oxide synthase endothelial (NOS3) DMKU93J MA Inhibitor DMKU93J RN Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606. DMKU93J RU https://pubmed.ncbi.nlm.nih.gov/24831445 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTSQIFT DMKUE8O TN 5-HT 1A receptor (HTR1A) DMKUE8O MA Antagonist DMKUE8O RN Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 DMKUE8O RU http://link.springer.com/article/10.1007%2Fs40290-014-0070-6 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTEX248 DMKUE8O TN Dopamine D2 receptor (D2R) DMKUE8O MA Antagonist DMKUE8O RN Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 DMKUE8O RU http://link.springer.com/article/10.1007%2Fs40290-014-0070-6 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TT4C8EA DMKUE8O TN Dopamine D3 receptor (D3R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTE0A2F DMKUE8O TN Dopamine D4 receptor (D4R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTJQOD7 DMKUE8O TN 5-HT 2A receptor (HTR2A) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TT8G3Z7 DMKUE8O TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTTIBOJ DMKUE8O TN Histamine H1 receptor (H1R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTO9X1H DMKUE8O TN 5-HT 7 receptor (HTR7) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKV5UM DI DMKV5UM DMKV5UM DN TM-601 DMKV5UM TI TTCYAXN DMKV5UM TN Chloride channel unspecific (ClC) DMKV5UM MA Inhibitor DMKV5UM RN NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21. DMKV5UM RU https://pubmed.ncbi.nlm.nih.gov/7819188 DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTVDSZ0 DMKVBL8 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTFQI4H DMKVBL8 TN Tankyrase-2 (TNKS-2) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTVUSO7 DMKVBL8 TN Tankyrase-1 (TNKS-1) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTQ4V96 DMKVBL8 TN Poly [ADP-ribose] polymerase 2 (PARP2) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVIWM DI DMKVIWM DMKVIWM DN QR-333 DMKVIWM TI TTFBNVI DMKVIWM TN Aldose reductase (AKR1B1) DMKVIWM MA Inhibitor DMKVIWM RN A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53. DMKVIWM RU https://pubmed.ncbi.nlm.nih.gov/16112498 DMKVP7E DI DMKVP7E DMKVP7E DN Apolizumab DMKVP7E TI TTYA75N DMKVP7E TN MHC class II antigen DR (HLA-DR) DMKVP7E MA Modulator DMKVP7E RN A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. DMKVP7E RU https://www.ncbi.nlm.nih.gov/pubmed/17071489 DMKVXYS DI DMKVXYS DMKVXYS DN FK-409 DMKVXYS TI TTWNFC2 DMKVXYS TN Soluble guanylyl cyclase (GUCY2D) DMKVXYS MA Modulator DMKVXYS RN Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993 Aug 15;246(3):205-12. DMKVXYS RU https://www.ncbi.nlm.nih.gov/pubmed/7901040 DMKWCTR DI DMKWCTR DMKWCTR DN GS-9973 DMKWCTR TI TTOU65C DMKWCTR TN Tyrosine-protein kinase SYK (SYK) DMKWCTR MA Modulator DMKWCTR RN An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. DMKWCTR RU https://pubmed.ncbi.nlm.nih.gov/25696919 DMKWGS1 DI DMKWGS1 DMKWGS1 DN PBT-2 DMKWGS1 TI TTS87KH DMKWGS1 TN Microtubule-associated protein tau (MAPT) DMKWGS1 MA Modulator DMKWGS1 RN PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16. DMKWGS1 RU https://pubmed.ncbi.nlm.nih.gov/20164561 DMKY638 DI DMKY638 DMKY638 DN BMS-813160 DMKY638 TI TTFZYTO DMKY638 TN C-C chemokine receptor type 2 (CCR2) DMKY638 MA Modulator DMKY638 RN A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. DMKY638 RU https://pubmed.ncbi.nlm.nih.gov/21936726 DMKY638 DI DMKY638 DMKY638 DN BMS-813160 DMKY638 TI TT2CEJG DMKY638 TN C-C chemokine receptor type 5 (CCR5) DMKY638 MA Modulator DMKY638 RN A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. DMKY638 RU https://pubmed.ncbi.nlm.nih.gov/21936726 DMKYMS2 DI DMKYMS2 DMKYMS2 DN LY-2428757 DMKYMS2 TI TTVIMDE DMKYMS2 TN Glucagon-like peptide 1 receptor (GLP1R) DMKYMS2 MA Stimulator DMKYMS2 RN Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes. 2009; 2: 37-49. DMKYMS2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818016/ DMKZN3A DI DMKZN3A DMKZN3A DN Golotimod DMKZN3A TI TTH8FZW DMKZN3A TN Signal transducer and activator of transcription 3 (STAT3) DMKZN3A MA Inhibitor DMKZN3A RN National Cancer Institute Drug Dictionary (drug id 617379). DMKZN3A RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=617379 DMKZUVC DI DMKZUVC DMKZUVC DN INS-50589 DMKZUVC TI TTZ1DT0 DMKZUVC TN P2Y purinoceptor 12 (P2RY12) DMKZUVC MA Modulator DMKZUVC RN Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56. DMKZUVC RU https://pubmed.ncbi.nlm.nih.gov/17654304 DML0I2Z DI DML0I2Z DML0I2Z DN M118 DML0I2Z TI TT4QPUL DML0I2Z TN Antithrombin-III (ATIII) DML0I2Z MA Inhibitor DML0I2Z RN Clinical pipeline report, company report or official report of Momentapharma. DML0I2Z RU http://www.momentapharma.com/pipeline/adomiparin.php DML0KWM DI DML0KWM DML0KWM DN CAR-T cells targeting CD30 DML0KWM TI TT2GM5R DML0KWM TN Lymphocyte activation antigen CD30 (TNFRSF8) DML0KWM MA CAR-T-Cell-Therapy DML0KWM RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DML0KWM RU https://clinicaltrials.gov/ct2/show/NCT03196830 DML10K3 DI DML10K3 DML10K3 DN SF1126 DML10K3 TI TTHBTOP DML10K3 TN PI3-kinase gamma (PIK3CG) DML10K3 MA Modulator DML10K3 RN An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81. DML10K3 RU https://www.ncbi.nlm.nih.gov/pubmed/23355037 DML10K3 DI DML10K3 DML10K3 DN SF1126 DML10K3 TI TTCJG29 DML10K3 TN Serine/threonine-protein kinase mTOR (mTOR) DML10K3 MA Inhibitor DML10K3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML10K3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML1CK2 DI DML1CK2 DML1CK2 DN BMS-188797 DML1CK2 TI TTML2WA DML1CK2 TN Tubulin (TUB) DML1CK2 MA Inhibitor DML1CK2 RN Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94. DML1CK2 RU https://pubmed.ncbi.nlm.nih.gov/14613998 DML27AE DI DML27AE DML27AE DN Arverapamil DML27AE TI TT5HONZ DML27AE TN Calcium channel unspecific (CaC) DML27AE MA Modulator DML27AE RN BJMP 2010;3(4):a342 DML27AE RU http://bjmp.org/files/2010-3-4/bjmp-2010-3-4-a342.pdf DML2CPW DI DML2CPW DML2CPW DN VAY736 DML2CPW TI TT7NJSE DML2CPW TN B-cell-activating factor receptor (TNFRSF13C) DML2CPW RN National Cancer Institute Drug Dictionary (drug id 762784). DML2CPW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762784 DML2D30 DI DML2D30 DML2D30 DN S-16924 DML2D30 TI TTSQIFT DML2D30 TN 5-HT 1A receptor (HTR1A) DML2D30 MA Modulator DML2D30 RN S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55. DML2D30 RU https://pubmed.ncbi.nlm.nih.gov/9732398 DML2D8Q DI DML2D8Q DML2D8Q DN Bevirimat DML2D8Q TI TTFGZB6 DML2D8Q TN Human immunodeficiency virus GAG protein (HIV gag) DML2D8Q MA Inhibitor DML2D8Q RN Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65. DML2D8Q RU https://pubmed.ncbi.nlm.nih.gov/23399723 DML2ZWR DI DML2ZWR DML2ZWR DN Solubilized type 1 native bovine collagen DML2ZWR TI TTUABC1 DML2ZWR TN Collagen I (COL1A2) DML2ZWR MA Modulator DML2ZWR RN Company report (Argentisrx) DML2ZWR RU http://www.argentisrx.com/arg201-development-to-date.html DML38VU DI DML38VU DML38VU DN PF-446687 DML38VU TI TTD0CIQ DML38VU TN Melanocortin receptor 4 (MC4R) DML38VU MA Modulator DML38VU RN Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65. DML38VU RU https://pubmed.ncbi.nlm.nih.gov/25652247 DML3PJF DI DML3PJF DML3PJF DN ARN-810 DML3PJF TI TTZAYWL DML3PJF TN Estrogen receptor (ESR) DML3PJF MA Modulator DML3PJF RN Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem.2015 Jun 25;58(12):4888-904. DML3PJF RU https://pubmed.ncbi.nlm.nih.gov/25879485 DML4GU1 DI DML4GU1 DML4GU1 DN 99mTc-MIP-1404 DML4GU1 TI TT9G4N0 DML4GU1 TN Glutamate carboxypeptidase II (GCPII) DML4GU1 MA Modulator DML4GU1 RN 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76. DML4GU1 RU https://pubmed.ncbi.nlm.nih.gov/23733925 DML4PMG DI DML4PMG DML4PMG DN Dendritic cell vaccine DML4PMG TI TTUJFD0 DML4PMG TN Telomerase reverse transcriptase (TERT) DML4PMG RN In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8. DML4PMG RU https://pubmed.ncbi.nlm.nih.gov/19908943 DML4RCG DI DML4RCG DML4RCG DN HS-110 DML4RCG TI TTFZDNP DML4RCG TN Activation B7-1 antigen (CD80) DML4RCG RN Clinical pipeline report, company report or official report of Heat Biologics. DML4RCG RU http://www.heatbio.com/product-pipeline/hs-110 DML4RCG DI DML4RCG DML4RCG DN HS-110 DML4RCG TI TTFPKXQ DML4RCG TN Endoplasmin (HSP90B1) DML4RCG RN Clinical pipeline report, company report or official report of Heat Biologics. DML4RCG RU http://www.heatbio.com/product-pipeline/hs-110 DML5AE4 DI DML5AE4 DML5AE4 DN FK-3311 DML5AE4 TI TTVKILB DML5AE4 TN Prostaglandin G/H synthase 2 (COX-2) DML5AE4 MA Modulator DML5AE4 RN Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80. DML5AE4 RU https://pubmed.ncbi.nlm.nih.gov/17613692 DML5S71 DI DML5S71 DML5S71 DN Nexopamil DML5S71 TI TT5HONZ DML5S71 TN Calcium channel unspecific (CaC) DML5S71 MA Blocker DML5S71 RN Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. DML5S71 RU https://pubmed.ncbi.nlm.nih.gov/7506319 DML5S71 DI DML5S71 DML5S71 DN Nexopamil DML5S71 TI TTYSN63 DML5S71 TN 5-HT 2 receptor (5HT2R) DML5S71 MA Modulator DML5S71 RN Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. DML5S71 RU https://pubmed.ncbi.nlm.nih.gov/7506319 DML6PO5 DI DML6PO5 DML6PO5 DN GM-CSF cancer vaccine DML6PO5 TI TT6MP2Z DML6PO5 TN GMCSFR-alpha (CSF2RA) DML6PO5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DML6PO5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DML6TAS DI DML6TAS DML6TAS DN OPI-1002 DML6TAS TI TT12KOD DML6TAS TN P53 messenger RNA (TP53 mRNA) DML6TAS RN 2011 Pipeline of Quark Pharm. DML6TAS RU http://www.quarkpharma.com/qbi-en/home/homepage/ DML6XSP DI DML6XSP DML6XSP DN Resiquimod DML6XSP TI TTRJ1K4 DML6XSP TN Toll-like receptor 7 (TLR7) DML6XSP MA Modulator DML6XSP RN TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70. DML6XSP RU https://www.ncbi.nlm.nih.gov/pubmed/16081189 DML6XSP DI DML6XSP DML6XSP DN Resiquimod DML6XSP TI TT8CWFK DML6XSP TN Toll-like receptor 8 (TLR8) DML6XSP MA Modulator DML6XSP RN TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70. DML6XSP RU https://www.ncbi.nlm.nih.gov/pubmed/16081189 DML6XWR DI DML6XWR DML6XWR DN LY2944876 DML6XWR TI TTVIMDE DML6XWR TN Glucagon-like peptide 1 receptor (GLP1R) DML6XWR MA Modulator DML6XWR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML6XWR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML6XWR DI DML6XWR DML6XWR DN LY2944876 DML6XWR TI TT9O6WS DML6XWR TN Glucagon receptor (GCGR) DML6XWR MA Modulator DML6XWR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML6XWR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML7N4B DI DML7N4B DML7N4B DN MUC1-Poly-ICLC DML7N4B TI TTBHFYQ DML7N4B TN Mucin-1 (MUC1) DML7N4B RN Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429. DML7N4B RU https://pubmed.ncbi.nlm.nih.gov/23802084 DML7WP0 DI DML7WP0 DML7WP0 DN Eldacimibe DML7WP0 TI TTMF541 DML7WP0 TN Liver carboxylesterase (CES1) DML7WP0 MA Modulator DML7WP0 RN Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46. DML7WP0 RU https://pubmed.ncbi.nlm.nih.gov/7621974 DML84CN DI DML84CN DML84CN DN ISIS-CRPRx DML84CN TI TTWRN6M DML84CN TN CRP messenger RNA (CRP mRNA) DML84CN MA Modulator DML84CN RN Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):49-60. DML84CN RU https://pubmed.ncbi.nlm.nih.gov/24211663 DML8N3Y DI DML8N3Y DML8N3Y DN Recifercept DML8N3Y TI TTST7KB DML8N3Y TN Fibroblast growth factor receptor 3 (FGFR3) DML8N3Y RN In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368. DML8N3Y RU https://pubmed.ncbi.nlm.nih.gov/33370388 DML97KB DI DML97KB DML97KB DN TAS-106 DML97KB TI TT79JGK DML97KB TN Mycobacterium RNA polymerase (MycB RNAP) DML97KB MA Modulator DML97KB RN Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26. DML97KB RU https://www.ncbi.nlm.nih.gov/pubmed/20839029 DML9AVG DI DML9AVG DML9AVG DN IMG-7289 DML9AVG TI TTNR0UQ DML9AVG TN Lysine-specific histone demethylase 1 (LSD) DML9AVG MA Inhibitor DML9AVG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML9AVG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML9M5S DI DML9M5S DML9M5S DN AZD-4017 DML9M5S TI TTN7BL9 DML9M5S TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DML9M5S MA Inhibitor DML9M5S RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DML9M5S RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMLA8H3 DI DMLA8H3 DMLA8H3 DN LX2931 DMLA8H3 TI TT618Q2 DMLA8H3 TN Sphingosine-1-phosphate lyase 1 (SGPL1) DMLA8H3 MA Inhibitor DMLA8H3 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMLA8H3 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMLAOHX DI DMLAOHX DMLAOHX DN Avdoralimab DMLAOHX TI TTQLO2H DMLAOHX TN HUMAN C5a receptor (C5aR) DMLAOHX MA Inhibitor DMLAOHX RN Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77. DMLAOHX RU https://pubmed.ncbi.nlm.nih.gov/29691378 DMLBD5I DI DMLBD5I DMLBD5I DN LXE408 DMLBD5I TI TTSVQWU DMLBD5I TN Leishmania major Proteasome (Leishm Proteasome) DMLBD5I MA Inhibitor DMLBD5I RN Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781. DMLBD5I RU https://pubmed.ncbi.nlm.nih.gov/32667203 DMLBWT1 DI DMLBWT1 DMLBWT1 DN ALRN-6924 DMLBWT1 TI TT08GJW DMLBWT1 TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMLBWT1 MA Antagonist DMLBWT1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLBWT1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLBWT1 DI DMLBWT1 DMLBWT1 DN ALRN-6924 DMLBWT1 TI TT9OUDQ DMLBWT1 TN p53-binding protein Mdm4 (MDM4) DMLBWT1 MA Inhibitor DMLBWT1 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMLBWT1 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTVIAT9 DMLCUAS TN Phosphodiesterase 4B (PDE4B) DMLCUAS MA Inhibitor DMLCUAS RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMLCUAS RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTSKMI8 DMLCUAS TN Phosphodiesterase 4D (PDE4D) DMLCUAS MA Inhibitor DMLCUAS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMLCUAS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTZ97H5 DMLCUAS TN Phosphodiesterase 4A (PDE4A) DMLCUAS MA Inhibitor DMLCUAS RN GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. DMLCUAS RU https://pubmed.ncbi.nlm.nih.gov/21205923 DMLD4VQ DI DMLD4VQ DMLD4VQ DN RPL-554 DMLD4VQ TI TTZCG4L DMLD4VQ TN Phosphodiesterase 3 (PDE3) DMLD4VQ MA Modulator DMLD4VQ RN Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27. DMLD4VQ RU https://www.ncbi.nlm.nih.gov/pubmed/24429275 DMLD80M DI DMLD80M DMLD80M DN Brivoligide DMLD80M TI TTE8LGD DMLD80M TN EGR1 messenger RNA (EGR1 mRNA) DMLD80M MA Inhibitor DMLD80M RN ClinicalTrials.gov (NCT04104919) Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores. U.S. National Institutes of Health. DMLD80M RU https://clinicaltrials.gov/ct2/show/NCT04104919 DMLDBQ5 DI DMLDBQ5 DMLDBQ5 DN SEN-196 DMLDBQ5 TI TTUF2HO DMLDBQ5 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMLDBQ5 MA Inhibitor DMLDBQ5 RN Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69. DMLDBQ5 RU https://pubmed.ncbi.nlm.nih.gov/22086720 DMLEO2Z DI DMLEO2Z DMLEO2Z DN ABT-652 DMLEO2Z TI TT9JNIC DMLEO2Z TN Histamine H3 receptor (H3R) DMLEO2Z MA Modulator DMLEO2Z RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225) DMLEO2Z RU http://adisinsight.springer.com/drugs/800032225 DMLEX1D DI DMLEX1D DMLEX1D DN Lexibulin DMLEX1D TI TTYFKSZ DMLEX1D TN Tubulin beta (TUBB) DMLEX1D MA Inhibitor DMLEX1D RN National Cancer Institute Drug Dictionary (drug id 598799). DMLEX1D RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=598799 DMLFGHX DI DMLFGHX DMLFGHX DN BRL 35135 DMLFGHX TI TTR6W5O DMLFGHX TN Adrenergic receptor beta-1 (ADRB1) DMLFGHX MA Agonist DMLFGHX RN Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300. DMLFGHX RU https://pubmed.ncbi.nlm.nih.gov/8877018 DMLFI7Q DI DMLFI7Q DMLFI7Q DN GSK-2251052 DMLFI7Q TI TT37GL6 DMLFI7Q TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DMLFI7Q MA Inhibitor DMLFI7Q RN Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. DMLFI7Q RU https://pubmed.ncbi.nlm.nih.gov/25348524 DMLFSMX DI DMLFSMX DMLFSMX DN GK1-399 DMLFSMX TI TTDLNGZ DMLFSMX TN Glucokinase (GCK) DMLFSMX MA Inhibitor DMLFSMX RN Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260. DMLFSMX RU http://vtvtherapeutics.com/pipeline/ttp399 DMLHPVW DI DMLHPVW DMLHPVW DN L1-79 DMLHPVW TI TTUHP71 DMLHPVW TN Tyrosine 3-monooxygenase (TH) DMLHPVW MA Inhibitor DMLHPVW RN Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981. DMLHPVW RU https://pubmed.ncbi.nlm.nih.gov/31492568 DMLIPY1 DI DMLIPY1 DMLIPY1 DN Xmab 5871 DMLIPY1 TI TT5RWKQ DMLIPY1 TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMLIPY1 MA Modulator DMLIPY1 RN CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. DMLIPY1 RU https://pubmed.ncbi.nlm.nih.gov/22820352 DMLIPY1 DI DMLIPY1 DMLIPY1 DN Xmab 5871 DMLIPY1 TI TTW640A DMLIPY1 TN B-lymphocyte surface antigen B4 (CD19) DMLIPY1 MA Modulator DMLIPY1 RN Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64. DMLIPY1 RU https://www.ncbi.nlm.nih.gov/pubmed/24782179 DMLK59M DI DMLK59M DMLK59M DN AZD1480 DMLK59M TI TTRMX3V DMLK59M TN Janus kinase 2 (JAK-2) DMLK59M MA Modulator DMLK59M RN The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97. DMLK59M RU https://pubmed.ncbi.nlm.nih.gov/19962667 DMLMNFX DI DMLMNFX DMLMNFX DN Omaveloxolone DMLMNFX TI TTA6ZN2 DMLMNFX TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMLMNFX MA Activator DMLMNFX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLMNFX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMLMV0O DI DMLMV0O DMLMV0O DN MK-7655 DMLMV0O TI TTHI19T DMLMV0O TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMLMV0O MA Inhibitor DMLMV0O RN Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5. DMLMV0O RU https://pubmed.ncbi.nlm.nih.gov/24433862 DMLMZ6Q DI DMLMZ6Q DMLMZ6Q DN NP-2 DMLMZ6Q TI TTN4QDT DMLMZ6Q TN Opioid receptor (OPR) DMLMZ6Q MA Antagonist DMLMZ6Q RN Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94. DMLMZ6Q RU https://pubmed.ncbi.nlm.nih.gov/11278319 DMLNKX7 DI DMLNKX7 DMLNKX7 DN STX-107 DMLNKX7 TI TTHS256 DMLNKX7 TN Metabotropic glutamate receptor 5 (mGluR5) DMLNKX7 MA Antagonist DMLNKX7 RN Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30. DMLNKX7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/ DMLO18H DI DMLO18H DMLO18H DN BAY-Y-5959 DMLO18H TI TTXHYV6 DMLO18H TN Voltage-gated L-type calcium channel (L-CaC) DMLO18H MA Modulator DMLO18H RN Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6. DMLO18H RU https://pubmed.ncbi.nlm.nih.gov/9694931 DMLPEZS DI DMLPEZS DMLPEZS DN Venglustat DMLPEZS TI TTPHEX3 DMLPEZS TN Ceramide glucosyltransferase (UGCG) DMLPEZS MA Inhibitor DMLPEZS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPEZS RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMLPNVS DI DMLPNVS DMLPNVS DN MB-102 DMLPNVS TI TTENHJ0 DMLPNVS TN Interleukin 3 receptor alpha (IL3RA) DMLPNVS MA CAR-T-Cell-Therapy DMLPNVS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPNVS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLPRZJ DI DMLPRZJ DMLPRZJ DN Ensaculin hydrochloride DMLPRZJ TI TTSQIFT DMLPRZJ TN 5-HT 1A receptor (HTR1A) DMLPRZJ MA Modulator DMLPRZJ RN Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. DMLPRZJ RU https://pubmed.ncbi.nlm.nih.gov/12177685 DMLQ3OK DI DMLQ3OK DMLQ3OK DN PF-05175157 DMLQ3OK TI TTY84UG DMLQ3OK TN Acetyl-CoA carboxylase 2 (ACACB) DMLQ3OK MA Inhibitor DMLQ3OK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264). DMLQ3OK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264 DMLQDBH DI DMLQDBH DMLQDBH DN HM-5016504 DMLQDBH TI TTNDSF4 DMLQDBH TN Proto-oncogene c-Met (MET) DMLQDBH MA Inhibitor DMLQDBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMLQDBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMLQK6E DI DMLQK6E DMLQK6E DN PYM-50028 DMLQK6E TI TTSMLOH DMLQK6E TN Brain-derived neurotrophic factor (BDNF) DMLQK6E MA Agonist DMLQK6E RN PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97. DMLQK6E RU https://pubmed.ncbi.nlm.nih.gov/18364399 DMLQRFO DI DMLQRFO DMLQRFO DN AGN-2979 DMLQRFO TI TTZSJHV DMLQRFO TN Tryptophan 5-hydroxylase 1 (TPH1) DMLQRFO MA Modulator DMLQRFO RN Antidepressant-like action of AGN 2979, a tryptophan hydroxylase activation inhibitor, in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol. 2001 Oct;11(5):351-7. DMLQRFO RU https://pubmed.ncbi.nlm.nih.gov/11597821 DMLQRYH DI DMLQRYH DMLQRYH DN CH-4051 DMLQRYH TI TTYZVDJ DMLQRYH TN Dihydrofolate reductase (DHFR) DMLQRYH MA Inhibitor DMLQRYH RN CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67. DMLQRYH RU https://pubmed.ncbi.nlm.nih.gov/20721827 DMLRTN1 DI DMLRTN1 DMLRTN1 DN CI-1012 DMLRTN1 TI TT3NH7G DMLRTN1 TN Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) DMLRTN1 MA Inhibitor DMLRTN1 RN WO patent application no. 2006,0835,53, Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase. DMLRTN1 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060810&CC=WO&NR=2006083553A2&KC=A2 DMLRU9I DI DMLRU9I DMLRU9I DN Lunacalcipol DMLRU9I TI TT82UI1 DMLRU9I TN Cytochrome P450 24 (CYP24A1) DMLRU9I MA Inhibitor DMLRU9I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679) DMLRU9I RU http://adisinsight.springer.com/drugs/800022679 DMLS269 DI DMLS269 DMLS269 DN E-1224 DMLS269 TI TTTSOUD DMLS269 TN Candida Cytochrome P450 51 (Candi ERG11) DMLS269 MA Inhibitor DMLS269 RN Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242. DMLS269 RU https://pubmed.ncbi.nlm.nih.gov/23277882 DMLSK01 DI DMLSK01 DMLSK01 DN Altrakincept DMLSK01 TI TTDWHC3 DMLSK01 TN Interleukin 4 receptor alpha (IL4R) DMLSK01 MA Modulator DMLSK01 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMLSK01 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMLT7JV DI DMLT7JV DMLT7JV DN CNV-2197944 DMLT7JV TI TT4FDG6 DMLT7JV TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMLT7JV MA Blocker DMLT7JV RN Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd. DMLT7JV RU http://www.convergencepharma.com/index.asp?page_id=30 DMLT94F DI DMLT94F DMLT94F DN VLS-101 DMLT94F TI TTDEJAU DMLT94F TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMLT94F RN Clinical pipeline report, company report or official report of VelosBio. DMLT94F RU https://velosbio.com/our-science/pipeline DMLTAES DI DMLTAES DMLTAES DN MK-0752 DMLTAES TI TT9W8GU DMLTAES TN Gamma-secretase (GS) DMLTAES MA Modulator DMLTAES RN Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52. DMLTAES RU https://pubmed.ncbi.nlm.nih.gov/20702149 DMLTI39 DI DMLTI39 DMLTI39 DN Lumiliximab DMLTI39 TI TTCH6MU DMLTI39 TN Lymphocyte IgE receptor (CD23) DMLTI39 RN Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8. DMLTI39 RU https://pubmed.ncbi.nlm.nih.gov/16210051 DMLTSDC DI DMLTSDC DMLTSDC DN LY-2456302 DMLTSDC TI TTQW87Y DMLTSDC TN Opioid receptor kappa (OPRK1) DMLTSDC MA Antagonist DMLTSDC RN LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. DMLTSDC RU https://pubmed.ncbi.nlm.nih.gov/24071566 DMLUM3Y DI DMLUM3Y DMLUM3Y DN ONO-4641 DMLUM3Y TI TT9JZCK DMLUM3Y TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMLUM3Y MA Agonist DMLUM3Y RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMLUM3Y RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMLV1ET DI DMLV1ET DMLV1ET DN BIIB074 DMLV1ET TI TT4G2JS DMLV1ET TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMLV1ET MA Inhibitor DMLV1ET RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMLV1ET RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMLV9GS DI DMLV9GS DMLV9GS DN AD04 DMLV9GS TI TTNXLKE DMLV9GS TN 5-HT 3 receptor (5HT3R) DMLV9GS MA Antagonist DMLV9GS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLV9GS RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLVCZR DI DMLVCZR DMLVCZR DN ACH-4471 DMLVCZR TI TT8D13I DMLVCZR TN Complement factor D (CFD) DMLVCZR MA Inhibitor DMLVCZR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVCZR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMLVHAJ DI DMLVHAJ DMLVHAJ DN PX-12 DMLVHAJ TI TTZJ5U9 DMLVHAJ TN Thioredoxin (TXN) DMLVHAJ MA Inhibitor DMLVHAJ RN 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51. DMLVHAJ RU https://pubmed.ncbi.nlm.nih.gov/18202017 DMLVQKF DI DMLVQKF DMLVQKF DN MRX-6 DMLVQKF TI TT9V5JH DMLVQKF TN Phospholipase A2 (PLA2G1B) DMLVQKF MA Inhibitor DMLVQKF RN A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5. DMLVQKF RU https://pubmed.ncbi.nlm.nih.gov/17346444 DMLWKZ7 DI DMLWKZ7 DMLWKZ7 DN GO-203-2c DMLWKZ7 TI TTBHFYQ DMLWKZ7 TN Mucin-1 (MUC1) DMLWKZ7 MA Inhibitor DMLWKZ7 RN Clinical pipeline report, company report or official report of Genus Oncology. DMLWKZ7 RU http://www.genusoncology.com/phase-1-trial-GO-203-2c.php DMLWM4G DI DMLWM4G DMLWM4G DN VX-15 DMLWM4G TI TT5UT28 DMLWM4G TN Semaphorin-4D (SEMA4D) DMLWM4G RN Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36. DMLWM4G RU https://pubmed.ncbi.nlm.nih.gov/26446947 DMLWM4G DI DMLWM4G DMLWM4G DN VX-15 DMLWM4G TI TT5TKPM DMLWM4G TN Neutral endopeptidase (MME) DMLWM4G MA Inhibitor DMLWM4G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLWM4G RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLXFM6 DI DMLXFM6 DMLXFM6 DN AZD-8683 DMLXFM6 TI TTOXS3C DMLXFM6 TN Muscarinic acetylcholine receptor (CHRM) DMLXFM6 MA Antagonist DMLXFM6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17). DMLXFM6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17 DMLYIPA DI DMLYIPA DMLYIPA DN SGT-53 DMLYIPA TI TT7SBF5 DMLYIPA TN Cellular tumor antigen p53 (TP53) DMLYIPA MA Stimulator DMLYIPA RN Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. DMLYIPA RU https://pubmed.ncbi.nlm.nih.gov/23470564 DMM02VJ DI DMM02VJ DMM02VJ DN JI-101 DMM02VJ TI TT0JESD DMM02VJ TN Erbb4 tyrosine kinase receptor (Erbb-4) DMM02VJ MA Modulator DMM02VJ RN A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24. DMM02VJ RU https://www.ncbi.nlm.nih.gov/pubmed/26365907 DMM0N1F DI DMM0N1F DMM0N1F DN AZD-0865 DMM0N1F TI TTLOKXP DMM0N1F TN Gastric H(+)/K(+) ATPase (Proton pump) DMM0N1F MA Modulator DMM0N1F RN Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205. DMM0N1F RU https://pubmed.ncbi.nlm.nih.gov/17081503 DMM15RI DI DMM15RI DMM15RI DN Ranpirnase DMM15RI TI TTRBUYN DMM15RI TN Ribonuclease (RNase) DMM15RI MA Modulator DMM15RI RN Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27. DMM15RI RU https://pubmed.ncbi.nlm.nih.gov/18476793 DMM3AI8 DI DMM3AI8 DMM3AI8 DN SLx-4090 DMM3AI8 TI TTUS1RD DMM3AI8 TN Microsomal triglyceride transfer protein (MTTP) DMM3AI8 MA Modulator DMM3AI8 RN A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. DMM3AI8 RU https://pubmed.ncbi.nlm.nih.gov/21406547 DMM3BPL DI DMM3BPL DMM3BPL DN DAS-431 DMM3BPL TI TTZFYLI DMM3BPL TN Dopamine D1 receptor (D1R) DMM3BPL MA Agonist DMM3BPL RN Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16. DMM3BPL RU https://pubmed.ncbi.nlm.nih.gov/11607045 DMM4EJI DI DMM4EJI DMM4EJI DN Resten-NG DMM4EJI TI TTNQ5ZP DMM4EJI TN Myc messenger RNA (MYC mRNA) DMM4EJI RN Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. DMM4EJI RU https://pubmed.ncbi.nlm.nih.gov/11590694 DMM549D DI DMM549D DMM549D DN IMO-3100 DMM549D TI TTSHG0T DMM549D TN Toll-like receptor 9 (TLR9) DMM549D MA Modulator DMM549D RN Company report (Iderapharma) DMM549D RU http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887 DMM549D DI DMM549D DMM549D DN IMO-3100 DMM549D TI TTRJ1K4 DMM549D TN Toll-like receptor 7 (TLR7) DMM549D MA Modulator DMM549D RN Company report (Iderapharma) DMM549D RU http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887 DMM5BVG DI DMM5BVG DMM5BVG DN TBR-760 DMM5BVG TI TTZ6T9E DMM5BVG TN Somatostatin receptor type 2 (SSTR2) DMM5BVG MA Agonist DMM5BVG RN TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. DMM5BVG RU https://pubmed.ncbi.nlm.nih.gov/32591776 DMM5BVG DI DMM5BVG DMM5BVG DN TBR-760 DMM5BVG TI TTEX248 DMM5BVG TN Dopamine D2 receptor (D2R) DMM5BVG MA Agonist DMM5BVG RN TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. DMM5BVG RU https://pubmed.ncbi.nlm.nih.gov/32591776 DMM5JAN DI DMM5JAN DMM5JAN DN LY2495655 DMM5JAN TI TTSWPH8 DMM5JAN TN Growth/differentiation factor 8 (GDF-8) DMM5JAN MA Modulator DMM5JAN RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMM5JAN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TT4C8EA DMM5SCF TN Dopamine D3 receptor (D3R) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TTWFZ1N DMM5SCF TN Dopamine receptor (DR) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TTEX248 DMM5SCF TN Dopamine D2 receptor (D2R) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMM65W1 DI DMM65W1 DMM65W1 DN CX-717 DMM65W1 TI TTAN6JD DMM65W1 TN Glutamate receptor AMPA (GRIA) DMM65W1 MA Modulator DMM65W1 RN Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol. 2012 Aug;26(8):1047-57. DMM65W1 RU https://pubmed.ncbi.nlm.nih.gov/21940760 DMM6B2Y DI DMM6B2Y DMM6B2Y DN ADU- S100 DMM6B2Y TI TTT402Y DMM6B2Y TN Stimulator of interferon genes protein (TMEM173) DMM6B2Y MA Agonist DMM6B2Y RN Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. DMM6B2Y RU https://pubmed.ncbi.nlm.nih.gov/30540940 DMM6J5Z DI DMM6J5Z DMM6J5Z DN PQ-912 DMM6J5Z TI TTJ7YTV DMM6J5Z TN Glutaminyl cyclase (QPCT) DMM6J5Z MA Inhibitor DMM6J5Z RN Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498. DMM6J5Z RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763757/ DMM6KZR DI DMM6KZR DMM6KZR DN Mutant ras vaccine DMM6KZR TI TTW2R9X DMM6KZR TN GTPase NRas (NRAS) DMM6KZR RN The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55. DMM6KZR RU https://pubmed.ncbi.nlm.nih.gov/24565030 DMM7F1E DI DMM7F1E DMM7F1E DN PRUVANSERIN DMM7F1E TI TTJQOD7 DMM7F1E TN 5-HT 2A receptor (HTR2A) DMM7F1E MA Modulator DMM7F1E RN 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76. DMM7F1E RU https://www.ncbi.nlm.nih.gov/pubmed/18673166 DMM7Q68 DI DMM7Q68 DMM7Q68 DN BAY-2253651 DMM7Q68 TI TTGR91N DMM7Q68 TN TWIK-related acid-sensitive potassium channel 1 (TASK1) DMM7Q68 MA Inhibitor DMM7Q68 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMM7Q68 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMM7Z6K DI DMM7Z6K DMM7Z6K DN CXA10 DMM7Z6K TI TT3Z6Y9 DMM7Z6K TN Cysteines of Keap1 (KEAP1 Cysteines) DMM7Z6K MA Inactivator DMM7Z6K RN The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. DMM7Z6K RU https://pubmed.ncbi.nlm.nih.gov/28510041 DMM7Z6K DI DMM7Z6K DMM7Z6K DN CXA10 DMM7Z6K TI TTA6ZN2 DMM7Z6K TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMM7Z6K MA Activator DMM7Z6K RN The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. DMM7Z6K RU https://pubmed.ncbi.nlm.nih.gov/28510041 DMM8IAQ DI DMM8IAQ DMM8IAQ DN PNU-142731A DMM8IAQ TI TT26HJ8 DMM8IAQ TN Eosinophil/lymphocyte-rich accumulation (ELR accum) DMM8IAQ MA Modulator DMM8IAQ RN Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma. J Pharmacol Exp Ther. 1999 Jul;290(1):188-95. DMM8IAQ RU https://pubmed.ncbi.nlm.nih.gov/10381775 DMM8Z3Q DI DMM8Z3Q DMM8Z3Q DN Encequidar DMM8Z3Q TI TTJUXV6 DMM8Z3Q TN Multidrug resistance protein 3 (ABCB4) DMM8Z3Q MA Inhibitor DMM8Z3Q RN Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem. 2021 Apr 8;64(7):3677-3693. DMM8Z3Q RU https://pubmed.ncbi.nlm.nih.gov/33729781 DMM9F25 DI DMM9F25 DMM9F25 DN LDE225 DMM9F25 TI TT8J1S3 DMM9F25 TN Smoothened homolog (SMO) DMM9F25 MA Modulator DMM9F25 RN Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79. DMM9F25 RU https://pubmed.ncbi.nlm.nih.gov/25093491 DMMAIY2 DI DMMAIY2 DMMAIY2 DN GSK-256073 DMMAIY2 TI TTWNV8U DMMAIY2 TN Nicotinic acid receptor (HCAR2) DMMAIY2 MA Agonist DMMAIY2 RN GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21. DMMAIY2 RU https://pubmed.ncbi.nlm.nih.gov/23701262 DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TTK8CXU DMMBAIH TN 5-HT 1B receptor (HTR1B) DMMBAIH MA Modulator DMMBAIH RN Company report (NeurAxon) DMMBAIH RU http://www.neuraxon.com/103110.html DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TT6MSOK DMMBAIH TN 5-HT 1D receptor (HTR1D) DMMBAIH MA Modulator DMMBAIH RN Company report (NeurAxon) DMMBAIH RU http://www.neuraxon.com/103110.html DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TTZUFI5 DMMBAIH TN Nitric-oxide synthase brain (NOS1) DMMBAIH MA Inhibitor DMMBAIH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMBAIH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMMBVCJ DI DMMBVCJ DMMBVCJ DN ASCJ-9 DMMBVCJ TI TTS64P2 DMMBVCJ TN Androgen receptor (AR) DMMBVCJ MA Enhancer DMMBVCJ RN Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764. DMMBVCJ RU https://pubmed.ncbi.nlm.nih.gov/23928703 DMMC3XR DI DMMC3XR DMMC3XR DN DPV-001 DMMC3XR TI TTOK0LR DMMC3XR TN Toll-like receptor (TLR) DMMC3XR MA Modulator DMMC3XR RN UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013. DMMC3XR RU http://ubivac.com/zap/?page_id=2668 DMMCA9V DI DMMCA9V DMMCA9V DN SAR-113945 DMMCA9V TI TTJ3E9X DMMCA9V TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMMCA9V MA Inhibitor DMMCA9V RN The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653. DMMCA9V RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248209/ DMMCL9F DI DMMCL9F DMMCL9F DN AZD1981 DMMCL9F TI TTQDMX5 DMMCL9F TN Prostaglandin D2 receptor 2 (PTGDR2) DMMCL9F MA Antagonist DMMCL9F RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMMCL9F RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTCJG29 DMMCYZ8 TN Serine/threonine-protein kinase mTOR (mTOR) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTHBTOP DMMCYZ8 TN PI3-kinase gamma (PIK3CG) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTTHBCA DMMCYZ8 TN PI3-kinase beta (PIK3CB) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154 DMMEAGO DI DMMEAGO DMMEAGO DN BMS-955176 DMMEAGO TI TT5TOX7 DMMEAGO TN Human immunodeficiency virus Maturation (HIV Mat) DMMEAGO MA Inhibitor DMMEAGO RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMMEAGO RU http://news.bms.com/press-release/study-next-generation-investigational-hiv-1-maturation-inhibitor-shows-positive-result DMMEL6B DI DMMEL6B DMMEL6B DN PRO22 DMMEL6B TI TTSXVID DMMEL6B TN Nuclear factor NF-kappa-B (NFKB) DMMEL6B MA Inhibitor DMMEL6B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMEL6B RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMFLXN DI DMMFLXN DMMFLXN DN AD-452 DMMFLXN TI TTXM6JN DMMFLXN TN Cytokine receptor unspecific (CRF) DMMFLXN MA Modulator DMMFLXN RN Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9. DMMFLXN RU http://www.sciencedirect.com/science/article/pii/S1672293011500017 DMMG61B DI DMMG61B DMMG61B DN ACT-GRO-777 DMMG61B TI TTCSZH7 DMMG61B TN Nucleolin (NCL) DMMG61B RN Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890. DMMG61B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104705/ DMMGAUK DI DMMGAUK DMMGAUK DN AGN-XX/YY DMMGAUK TI TT2NUT5 DMMGAUK TN Adrenergic receptor alpha-2C (ADRA2C) DMMGAUK MA Agonist DMMGAUK RN Patent WO2008058220 A2. DMMGAUK RU http://www.google.com/patents/WO2008058220A2?cl=en DMMGSFV DI DMMGSFV DMMGSFV DN PF-06700841 DMMGSFV TI TT6DM01 DMMGSFV TN Janus kinase 1 (JAK-1) DMMGSFV MA Inhibitor DMMGSFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMGSFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMGSFV DI DMMGSFV DMMGSFV DN PF-06700841 DMMGSFV TI TTBYWP2 DMMGSFV TN TYK2 tyrosine kinase (TYK2) DMMGSFV MA Inhibitor DMMGSFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMGSFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TT8FYO9 DMMHX9K TN Platelet-derived growth factor receptor alpha (PDGFRA) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTX41N9 DMMHX9K TN Tyrosine-protein kinase Kit (KIT) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTVJ1D8 DMMHX9K TN Vascular endothelial growth factor receptor (VEGFR) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTI7421 DMMHX9K TN Platelet-derived growth factor receptor beta (PDGFRB) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMI0RH DI DMMI0RH DMMI0RH DN LY-2599506 DMMI0RH TI TTDLNGZ DMMI0RH TN Glucokinase (GCK) DMMI0RH MA Inhibitor DMMI0RH RN This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009 DMMI0RH RU http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf DMMI84K DI DMMI84K DMMI84K DN Beta-lapachone DMMI84K TI TTGTQHC DMMI84K TN DNA topoisomerase I (TOP1) DMMI84K MA Modulator DMMI84K RN Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42. DMMI84K RU https://pubmed.ncbi.nlm.nih.gov/12188909 DMMIHSO DI DMMIHSO DMMIHSO DN ENERGI-F701 DMMIHSO TI TTLAFZV DMMIHSO TN AMP-activated protein kinase (AMPK) DMMIHSO MA Activator DMMIHSO RN Clinical pipeline report, company report or official report of Energenesis Biomedical. DMMIHSO RU https://www.energenesis-biomedical.com/_en/tech_detail.php?id=186 DMMIYZ7 DI DMMIYZ7 DMMIYZ7 DN Palifosfamide DMMIYZ7 TI TT6S2FE DMMIYZ7 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMMIYZ7 MA Inhibitor DMMIYZ7 RN Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. DMMIYZ7 RU https://pubmed.ncbi.nlm.nih.gov/22027537 DMMJUHD DI DMMJUHD DMMJUHD DN P-276 DMMJUHD TI TT0PG8F DMMJUHD TN Cyclin-dependent kinase 4 (CDK4) DMMJUHD MA Inhibitor DMMJUHD RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMMJUHD RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMMJUHD DI DMMJUHD DMMJUHD DN P-276 DMMJUHD TI TTH6V3D DMMJUHD TN Cyclin-dependent kinase 1 (CDK1) DMMJUHD MA Inhibitor DMMJUHD RN P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34. DMMJUHD RU https://pubmed.ncbi.nlm.nih.gov/17363487 DMMK6IT DI DMMK6IT DMMK6IT DN Testogen TDS DMMK6IT TI TTS64P2 DMMK6IT TN Androgen receptor (AR) DMMK6IT MA Modulator DMMK6IT RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DMMK6IT RU https://pubmed.ncbi.nlm.nih.gov/2912689 DMMKASG DI DMMKASG DMMKASG DN AGTC-0106 DMMKASG TI TTA7UJC DMMKASG TN Alpha-1-antitrypsin (SERPINA1) DMMKASG MA Modulator DMMKASG RN First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9. DMMKASG RU https://pubmed.ncbi.nlm.nih.gov/22965030 DMMKCJ6 DI DMMKCJ6 DMMKCJ6 DN BC-7013 DMMKCJ6 TI TTUWYEA DMMKCJ6 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMMKCJ6 MA Modulator DMMKCJ6 RN Company report (briva) DMMKCJ6 RU http://www.nabriva.com/fileadmin/content/ICAAC_2009/F1-1521_In_vitro_antibacterial_spectrum_of_BC-7013.pdf DMMKOPX DI DMMKOPX DMMKOPX DN PM-00104 DMMKOPX TI TTUTN1I DMMKOPX TN Human Deoxyribonucleic acid (hDNA) DMMKOPX MA Modulator DMMKOPX RN Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95. DMMKOPX RU https://pubmed.ncbi.nlm.nih.gov/21330323 DMMKW8L DI DMMKW8L DMMKW8L DN ASTX660 DMMKW8L TI TTK3WBU DMMKW8L TN XIAP messenger RNA (XIAP mRNA) DMMKW8L MA Inhibitor DMMKW8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMKW8L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMML7BE DI DMML7BE DMML7BE DN Xl147 DMML7BE TI TTHBTOP DMML7BE TN PI3-kinase gamma (PIK3CG) DMML7BE MA Modulator DMML7BE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). DMML7BE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156 DMMN21R DI DMMN21R DMMN21R DN Cenersen DMMN21R TI TT12KOD DMMN21R TN P53 messenger RNA (TP53 mRNA) DMMN21R RN Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. DMMN21R RU https://pubmed.ncbi.nlm.nih.gov/21717444 DMMNTOW DI DMMNTOW DMMNTOW DN TTP435 DMMNTOW TI TT4DE1O DMMNTOW TN Agouti-related protein (AGRP) DMMNTOW MA Inhibitor DMMNTOW RN Clinical pipeline report, company report or official report of TransTech Pharma (2011). DMMNTOW RU http://www.ttpharma.com/ DMMNXIW DI DMMNXIW DMMNXIW DN TS-022 DMMNXIW TI TTNVEIR DMMNXIW TN Prostaglandin D2 receptor (PTGDR) DMMNXIW MA Agonist DMMNXIW RN Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14. DMMNXIW RU https://pubmed.ncbi.nlm.nih.gov/17141215 DMMO46E DI DMMO46E DMMO46E DN Pidilizumab DMMO46E TI TT8ZLTI DMMO46E TN Programmed cell death 1 ligand 1 (PD-L1) DMMO46E RN PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. DMMO46E RU https://pubmed.ncbi.nlm.nih.gov/21577144 DMMOHUA DI DMMOHUA DMMOHUA DN Contezolid acefosamil DMMOHUA TI TTLIZBJ DMMOHUA TN Protein synthesis (hPRO synth) DMMOHUA MA Inhibitor DMMOHUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMOHUA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMOWT9 DI DMMOWT9 DMMOWT9 DN GSK3640254 DMMOWT9 TI TT5TOX7 DMMOWT9 TN Human immunodeficiency virus Maturation (HIV Mat) DMMOWT9 MA Inhibitor DMMOWT9 RN Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671. DMMOWT9 RU https://pubmed.ncbi.nlm.nih.gov/33200887 DMMPC6W DI DMMPC6W DMMPC6W DN CTL019 DMMPC6W TI TTW640A DMMPC6W TN B-lymphocyte surface antigen B4 (CD19) DMMPC6W MA CAR-T-Cell-Therapy DMMPC6W RN ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. DMMPC6W RU https://clinicaltrials.gov/ct2/show/NCT02445248 DMMQ1YU DI DMMQ1YU DMMQ1YU DN FLUASTERONE DMMQ1YU TI TT3V81G DMMQ1YU TN Nuclear receptor unspecific (NR) DMMQ1YU MA Modulator DMMQ1YU RN Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002 Jun 14;277(24):21379-88. DMMQ1YU RU https://pubmed.ncbi.nlm.nih.gov/11934890 DMMQ6VT DI DMMQ6VT DMMQ6VT DN Leronlimab DMMQ6VT TI TTH91NV DMMQ6VT TN HUMAN C-C chemokine receptor 5 (CCR5) DMMQ6VT MA Inhibitor DMMQ6VT RN Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 DMMQ6VT RU https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full.pdf DMMQFG2 DI DMMQFG2 DMMQFG2 DN Imeglimin DMMQFG2 TI TTLAFZV DMMQFG2 TN AMP-activated protein kinase (AMPK) DMMQFG2 MA Modulator DMMQFG2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542) DMMQFG2 RU http://adisinsight.springer.com/drugs/800032542 DMMQY0O DI DMMQY0O DMMQY0O DN GED-0507-34-Levo DMMQY0O TI TTZMAO3 DMMQY0O TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMQY0O MA Agonist DMMQY0O RN PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7. DMMQY0O RU https://pubmed.ncbi.nlm.nih.gov/23651165 DMMQYF6 DI DMMQYF6 DMMQYF6 DN TRO-19622 DMMQYF6 TI TTAN6JD DMMQYF6 TN Glutamate receptor AMPA (GRIA) DMMQYF6 MA Antagonist DMMQYF6 RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMMQYF6 RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMMQZ3I DI DMMQZ3I DMMQZ3I DN HMR59 DMMQZ3I TI TTBGTEJ DMMQZ3I TN Membrane inhibitor of reactive lysis (CD59) DMMQZ3I MA Replacement DMMQZ3I RN Clinical pipeline report, company report or official report of Hemera Biosciences. DMMQZ3I RU https://www.hemerabiosciences.com/hmr59/ DMMRKPF DI DMMRKPF DMMRKPF DN CHS-131 DMMRKPF TI TTZMAO3 DMMRKPF TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMRKPF MA Modulator DMMRKPF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMRKPF RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMMRYEK DI DMMRYEK DMMRYEK DN MPSK3169A DMMRYEK TI TTNIZ2B DMMRYEK TN PCSK9 messenger RNA (PCSK9 mRNA) DMMRYEK MA Modulator DMMRYEK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388). DMMRYEK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2388 DMMSBW5 DI DMMSBW5 DMMSBW5 DN LY-545694 DMMSBW5 TI TTDXZ24 DMMSBW5 TN Glutamate receptor ionotropic (GRI) DMMSBW5 MA Antagonist DMMSBW5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019739) DMMSBW5 RU http://adisinsight.springer.com/drugs/800019739 DMMSGAT DI DMMSGAT DMMSGAT DN BI 207127 DMMSGAT TI TTMVBWH DMMSGAT TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMMSGAT MA Inhibitor DMMSGAT RN 2011 Pipeline of Boehringer Ingelheim Pharma. DMMSGAT RU http://www.boehringer-ingelheim.com/ DMMSIG7 DI DMMSIG7 DMMSIG7 DN DM-71 DMMSIG7 TI TTCBFJO DMMSIG7 TN Insulin receptor (INSR) DMMSIG7 MA Modulator DMMSIG7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMMSIG7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMMSTCF DI DMMSTCF DMMSTCF DN K-832 DMMSTCF TI TTSD92E DMMSTCF TN Interleukin-1 (IL1) DMMSTCF MA Inhibitor DMMSTCF RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMMSTCF RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMMU41F DI DMMU41F DMMU41F DN SRX-246 DMMU41F TI TT4TFGN DMMU41F TN Vasopressin V1a receptor (V1AR) DMMU41F MA Antagonist DMMU41F RN Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43. DMMU41F RU https://pubmed.ncbi.nlm.nih.gov/23471831 DMMUPTN DI DMMUPTN DMMUPTN DN ADL-5747 DMMUPTN TI TT27RFC DMMUPTN TN Opioid receptor delta (OPRD1) DMMUPTN MA Agonist DMMUPTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMMUPTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMMUR6V DI DMMUR6V DMMUR6V DN NS-2710 DMMUR6V TI TT37EDJ DMMUR6V TN GABA(A) receptor alpha-3 (GABRA3) DMMUR6V MA Modulator DMMUR6V RN GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202. DMMUR6V RU https://pubmed.ncbi.nlm.nih.gov/21050172 DMMVFRC DI DMMVFRC DMMVFRC DN Mavrilimumab DMMVFRC TI TT6MP2Z DMMVFRC TN GMCSFR-alpha (CSF2RA) DMMVFRC RN Clinical pipeline report, company report or official report of MedImmune (2011). DMMVFRC RU http://www.medimmune.com/research_pipeline.aspx DMMVFRC DI DMMVFRC DMMVFRC DN Mavrilimumab DMMVFRC TI TTNYZG2 DMMVFRC TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMMVFRC MA Antagonist DMMVFRC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMVFRC RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMMWCZS DI DMMWCZS DMMWCZS DN SCH 420814 DMMWCZS TI TTM2AOE DMMWCZS TN Adenosine A2a receptor (ADORA2A) DMMWCZS MA Antagonist DMMWCZS RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DMMWCZS RU https://pubmed.ncbi.nlm.nih.gov/17016425 DMMWIHC DI DMMWIHC DMMWIHC DN CYT 99007 DMMWIHC TI TTAWI51 DMMWIHC TN Interleukin 7 receptor alpha (IL7R) DMMWIHC MA Binder DMMWIHC RN Perspectives on interleukin-7 therapy in HIV infection. Curr Opin HIV AIDS. 2007 May;2(3):228-33. DMMWIHC RU https://pubmed.ncbi.nlm.nih.gov/19372891 DMMWPSQ DI DMMWPSQ DMMWPSQ DN TA-2005 DMMWPSQ TI TT2CJVK DMMWPSQ TN Adrenergic receptor beta-2 (ADRB2) DMMWPSQ MA Agonist DMMWPSQ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMMWPSQ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMMX1EJ DI DMMX1EJ DMMX1EJ DN AS-1402 DMMX1EJ TI TTBHFYQ DMMX1EJ TN Mucin-1 (MUC1) DMMX1EJ RN Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73. DMMX1EJ RU https://pubmed.ncbi.nlm.nih.gov/19811637 DMMYTRU DI DMMYTRU DMMYTRU DN RQ-00000007 (oral) DMMYTRU TI TT79WV3 DMMYTRU TN Prostaglandin E2 receptor EP4 (PTGER4) DMMYTRU MA Antagonist DMMYTRU RN Clinical pipeline report, company report or official report of Avarx. DMMYTRU RU http://www.avarx.com/AvaRx/SubDomains/bucket5733245651167129819/Listings/bucket2137138075456035728/Public.Listing.display.html DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TTLYXIT DMMZOYN TN Aurora kinase C (AURKC) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TTPS3C0 DMMZOYN TN Aurora kinase A (AURKA) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TT5LS6T DMMZOYN TN Aurora kinase B (AURKB) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZQ7V DI DMMZQ7V DMMZQ7V DN Granotapide DMMZQ7V TI TTUS1RD DMMZQ7V TN Microsomal triglyceride transfer protein (MTTP) DMMZQ7V MA Inhibitor DMMZQ7V RN JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther. 2011 Mar;336(3):850-6. DMMZQ7V RU https://pubmed.ncbi.nlm.nih.gov/21139060 DMN0VS2 DI DMN0VS2 DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b DMN0VS2 TI TT1D53B DMN0VS2 TN COVID-19 3C-like protease (3CLpro) DMN0VS2 MA Inhibitor DMN0VS2 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMN0VS2 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMN0VS2 DI DMN0VS2 DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b DMN0VS2 TI TTV1095 DMN0VS2 TN COVID-19 RNA-directed RNA polymerase (RdRp) DMN0VS2 MA Inhibitor DMN0VS2 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMN0VS2 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMN1EFR DI DMN1EFR DMN1EFR DN RhGDF-5 DMN1EFR TI TT37XV9 DMN1EFR TN Growth/differentiation factor 5 (GDF-5) DMN1EFR MA Modulator DMN1EFR RN Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90. DMN1EFR RU https://pubmed.ncbi.nlm.nih.gov/16945037 DMN1SWB DI DMN1SWB DMN1SWB DN EGS-21 DMN1SWB TI TTCBFJO DMN1SWB TN Insulin receptor (INSR) DMN1SWB MA Modulator DMN1SWB RN Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 2014 Jan 10;289(2):723-34. DMN1SWB RU https://pubmed.ncbi.nlm.nih.gov/24214972 DMN28WK DI DMN28WK DMN28WK DN BMS-919373 DMN28WK TI TTW0CMT DMN28WK TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMN28WK MA Inhibitor DMN28WK RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504) DMN28WK RU http://adisinsight.springer.com/drugs/800035504 DMN3S1B DI DMN3S1B DMN3S1B DN ABT-229 DMN3S1B TI TTQ6VDM DMN3S1B TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMN3S1B MA Inhibitor DMN3S1B RN 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8. DMN3S1B RU https://pubmed.ncbi.nlm.nih.gov/20869254 DMN45IC DI DMN45IC DMN45IC DN AFM13 DMN45IC TI TTIFOC0 DMN45IC TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMN45IC RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMN45IC RU https://www.affimed.com/rock-platform/pipeline/ DMN45IC DI DMN45IC DMN45IC DN AFM13 DMN45IC TI TT2GM5R DMN45IC TN Lymphocyte activation antigen CD30 (TNFRSF8) DMN45IC RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMN45IC RU https://www.affimed.com/rock-platform/pipeline/ DMN45RI DI DMN45RI DMN45RI DN MIJ821 DMN45RI TI TTN9D8E DMN45RI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMN45RI MA Modulator DMN45RI RN Clinical pipeline report, company report or official report of Cadent Therapeutics. DMN45RI RU https://www.cipherbio.com/data-viz/organization/Cadent%2BTherapeutics/products DMN5JCX DI DMN5JCX DMN5JCX DN Carboxyamidotriazole orotate DMN5JCX TI TTF89GD DMN5JCX TN Interleukin-2 (IL2) DMN5JCX MA Inhibitor DMN5JCX RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2071). DMN5JCX RU http://meetinglibrary.asco.org/content/132006-144 DMN68ZL DI DMN68ZL DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine DMN68ZL TI TT8MK59 DMN68ZL TN Melanocytes lineage-specific antigen GP100 (PMEL) DMN68ZL RN ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. DMN68ZL RU https://clinicaltrials.gov/ct2/show/NCT00003362 DMN68ZL DI DMN68ZL DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine DMN68ZL TI TTULVH8 DMN68ZL TN Tyrosinase (TYR) DMN68ZL RN ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. DMN68ZL RU https://clinicaltrials.gov/ct2/show/NCT00003362 DMN6IDO DI DMN6IDO DMN6IDO DN GTP-010 DMN6IDO TI TTVIMDE DMN6IDO TN Glucagon-like peptide 1 receptor (GLP1R) DMN6IDO MA Agonist DMN6IDO RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMN6IDO RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMN6J18 DI DMN6J18 DMN6J18 DN Vupanorsen DMN6J18 TI TT59GO7 DMN6J18 TN ANGPTL3 messenger RNA (ANGPTL3 mRNA) DMN6J18 MA Inhibitor DMN6J18 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMN6J18 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMN6TKI DI DMN6TKI DMN6TKI DN Carmoterol DMN6TKI TI TT2CJVK DMN6TKI TN Adrenergic receptor beta-2 (ADRB2) DMN6TKI MA Agonist DMN6TKI RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMN6TKI RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMN7EUO DI DMN7EUO DMN7EUO DN N6022 DMN7EUO TI TTVG0SN DMN7EUO TN S-nitrosoglutathione reductase (CBR1) DMN7EUO MA Inhibitor DMN7EUO RN Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012 Mar 13;51(10):2157-68. DMN7EUO RU https://pubmed.ncbi.nlm.nih.gov/22335564 DMN7VK1 DI DMN7VK1 DMN7VK1 DN AV-101 DMN7VK1 TI TT9IK2Z DMN7VK1 TN N-methyl-D-aspartate receptor (NMDAR) DMN7VK1 MA Antagonist DMN7VK1 RN Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc. DMN7VK1 RU http://www.vistagen.com/?page_id=198 DMN94QM DI DMN94QM DMN94QM DN PF-06291874 DMN94QM TI TT9O6WS DMN94QM TN Glucagon receptor (GCGR) DMN94QM MA Antagonist DMN94QM RN Clinical pipeline report, company report or official report of pfizer. DMN94QM RU http://www.pfizer.com/sites/default/files/product-pipeline/110614_Pipeline_Update.pdf DMNABMU DI DMNABMU DMNABMU DN GS-4997 DMNABMU TI TTOQCD8 DMNABMU TN Apoptosis signal-regulating kinase 1 (MAP3K5) DMNABMU MA Inhibitor DMNABMU RN Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. DMNABMU RU https://pubmed.ncbi.nlm.nih.gov/25531162 DMNAECP DI DMNAECP DMNAECP DN SR-147778 DMNAECP TI TT6OEDT DMNAECP TN Cannabinoid receptor 1 (CB1) DMNAECP MA Modulator DMNAECP RN Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77. DMNAECP RU https://www.ncbi.nlm.nih.gov/pubmed/23278647 DMNAU1V DI DMNAU1V DMNAU1V DN ABT-436 DMNAU1V TI TTL9MHW DMNAU1V TN Vasopressin V1b receptor (V1BR) DMNAU1V MA Modulator DMNAU1V RN The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115. DMNAU1V RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016603/ DMNB4P1 DI DMNB4P1 DMNB4P1 DN TAK-653 DMNB4P1 TI TTAN6JD DMNB4P1 TN Glutamate receptor AMPA (GRIA) DMNB4P1 MA Activator DMNB4P1 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNB4P1 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TT1MG9E DMNB4XK TN Extracellular signal-regulated kinase 1 (ERK1) DMNB4XK MA Modulator DMNB4XK RN DOI: 10.1158/1538-7445.AM2015-4693 DMNB4XK RU http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TT4TQBX DMNB4XK TN Extracellular signal-regulated kinase 2 (ERK2) DMNB4XK MA Modulator DMNB4XK RN DOI: 10.1158/1538-7445.AM2015-4693 DMNB4XK RU http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TTKPV6O DMNB4XK TN Ephrin type-B receptor 2 (EPHB2) DMNB4XK MA Inhibitor DMNB4XK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNB4XK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNC1AF DI DMNC1AF DMNC1AF DN CR-665 DMNC1AF TI TTQW87Y DMNC1AF TN Opioid receptor kappa (OPRK1) DMNC1AF MA Agonist DMNC1AF RN Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24. DMNC1AF RU https://pubmed.ncbi.nlm.nih.gov/19672186 DMNC76I DI DMNC76I DMNC76I DN COL-1077 DMNC76I TI TTRK8B9 DMNC76I TN Sodium channel unspecific (NaC) DMNC76I MA Antagonist DMNC76I RN Clinical pipeline report, company report or official report of Columbia Laboratories. DMNC76I RU http://companies.einnews.com/news/columbia-laboratories-news DMNE1FR DI DMNE1FR DMNE1FR DN Resminostat DMNE1FR TI TT6R7JZ DMNE1FR TN Histone deacetylase 1 (HDAC1) DMNE1FR MA Inhibitor DMNE1FR RN 2011 Pipeline of 4SC AG. DMNE1FR RU http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html DMNE7L3 DI DMNE7L3 DMNE7L3 DN CC-220 DMNE7L3 TI TTDKGTC DMNE7L3 TN Protein cereblon (CRBN) DMNE7L3 MA Inhibitor DMNE7L3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNE7L3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNEHY1 DI DMNEHY1 DMNEHY1 DN OI338GT DMNEHY1 TI TTVIMDE DMNEHY1 TN Glucagon-like peptide 1 receptor (GLP1R) DMNEHY1 MA Modulator DMNEHY1 RN Clinical pipeline report, company report or official report of Novo Nordisk A/S. DMNEHY1 RU http://www.novonordisk.com/bin/getPDF.1781915.pdf DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TTPNGDE DMNF38S TN Prostaglandin E2 receptor EP3 (PTGER3) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TT1ZAVI DMNF38S TN Prostaglandin E2 receptor EP2 (PTGER2) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TT79WV3 DMNF38S TN Prostaglandin E2 receptor EP4 (PTGER4) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNFADH DI DMNFADH DMNFADH DN APR-246 DMNFADH TI TT7SBF5 DMNFADH TN Cellular tumor antigen p53 (TP53) DMNFADH MA Stimulator DMNFADH RN APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. DMNFADH RU https://pubmed.ncbi.nlm.nih.gov/24157875 DMNFKVW DI DMNFKVW DMNFKVW DN BR-4628 DMNFKVW TI TT26PHO DMNFKVW TN Mineralocorticoid receptor (MR) DMNFKVW MA Antagonist DMNFKVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMNFKVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMNFP21 DI DMNFP21 DMNFP21 DN TC-6987 DMNFP21 TI TTLA931 DMNFP21 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMNFP21 MA Modulator DMNFP21 RN ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. DMNFP21 RU https://clinicaltrials.gov/ct2/show/NCT01293669 DMNFVKC DI DMNFVKC DMNFVKC DN Vapitadine DMNFVKC TI TTTIBOJ DMNFVKC TN Histamine H1 receptor (H1R) DMNFVKC MA Antagonist DMNFVKC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) DMNFVKC RU http://adisinsight.springer.com/drugs/800020866 DMNFZYE DI DMNFZYE DMNFZYE DN WT1-targeted autologous dendritic cell vaccine DMNFZYE TI TTZ8UT4 DMNFZYE TN Wilms tumor protein (WT1) DMNFZYE RN ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health. DMNFZYE RU https://clinicaltrials.gov/ct2/show/NCT01686334 DMNG35S DI DMNG35S DMNG35S DN ABT-751 DMNG35S TI TTYFKSZ DMNG35S TN Tubulin beta (TUBB) DMNG35S MA Modulator DMNG35S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNG35S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNGT89 DI DMNGT89 DMNGT89 DN Lirilumab DMNGT89 TI TTAZF9M DMNGT89 TN RAS-like protein KIR (GEM) DMNGT89 MA Modulator DMNGT89 RN Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40. DMNGT89 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/ DMNJ491 DI DMNJ491 DMNJ491 DN IMGN529 DMNJ491 TI TTFCW29 DMNJ491 TN Leukocyte antigen CD37 (CD37) DMNJ491 RN The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10. DMNJ491 RU https://pubmed.ncbi.nlm.nih.gov/24445867 DMNKAFQ DI DMNKAFQ DMNKAFQ DN Instiladrin DMNKAFQ TI TTSIUJ9 DMNKAFQ TN Interferon-alpha 2 (IFNA2) DMNKAFQ MA Modulator DMNKAFQ RN ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health. DMNKAFQ RU https://clinicaltrials.gov/ct2/show/NCT01687244 DMNL9HO DI DMNL9HO DMNL9HO DN Tabimorelin DMNL9HO TI TTWDC17 DMNL9HO TN Growth hormone secretagogue receptor 1 (GHSR) DMNL9HO MA Modulator DMNL9HO RN Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9. DMNL9HO RU https://pubmed.ncbi.nlm.nih.gov/10427162 DMNLH9W DI DMNLH9W DMNLH9W DN KN026 DMNLH9W TI TT6EO5L DMNLH9W TN Erbb2 tyrosine kinase receptor (HER2) DMNLH9W MA Inhibitor DMNLH9W RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMNLH9W RU http://www.alphamabonc.com/pipeline/kn026.html DMNLQHK DI DMNLQHK DMNLQHK DN Tanespimycin DMNLQHK TI TT78R5H DMNLQHK TN Heat shock protein 90 alpha (HSP90A) DMNLQHK MA Inhibitor DMNLQHK RN Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. DMNLQHK RU https://pubmed.ncbi.nlm.nih.gov/19466875 DMNM4CK DI DMNM4CK DMNM4CK DN PF-00734200 DMNM4CK TI TTDIGC1 DMNM4CK TN Dipeptidyl peptidase 4 (DPP-4) DMNM4CK MA Modulator DMNM4CK RN Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9. DMNM4CK RU https://www.ncbi.nlm.nih.gov/pubmed/21392067 DMNM9DZ DI DMNM9DZ DMNM9DZ DN Nepicastat oral DMNM9DZ TI TTYIP79 DMNM9DZ TN Dopamine beta hydroxylase (DBH) DMNM9DZ MA Inhibitor DMNM9DZ RN Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9. DMNM9DZ RU https://pubmed.ncbi.nlm.nih.gov/9283721 DMNO5UE DI DMNO5UE DMNO5UE DN Labetuzumab I-131 DMNO5UE TI TTY6DTE DMNO5UE TN Carcinoembryonic antigen CEA (CD66e) DMNO5UE RN National Cancer Institute Drug Dictionary (drug id 692828). DMNO5UE RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=692828 DMNO7BC DI DMNO7BC DMNO7BC DN AeroLEF DMNO7BC TI TTN4QDT DMNO7BC TN Opioid receptor (OPR) DMNO7BC MA Agonist DMNO7BC RN Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246. DMNO7BC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371376/ DMNOMV2 DI DMNOMV2 DMNOMV2 DN HP-184 DMNOMV2 TI TTQ6VDM DMNOMV2 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMNOMV2 MA Blocker DMNOMV2 RN Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. DMNOMV2 RU https://pubmed.ncbi.nlm.nih.gov/18321149 DMNOMV2 DI DMNOMV2 DMNOMV2 DN HP-184 DMNOMV2 TI TTN9VTF DMNOMV2 TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMNOMV2 MA Blocker DMNOMV2 RN Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. DMNOMV2 RU https://pubmed.ncbi.nlm.nih.gov/18321149 DMNPRMC DI DMNPRMC DMNPRMC DN SPI-1620 DMNPRMC TI TT3ZTGU DMNPRMC TN Endothelin B receptor (EDNRB) DMNPRMC MA Agonist DMNPRMC RN Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009). DMNPRMC RU http://www.spectrumpharm.com/products_Spectrum.html DMNQ5T2 DI DMNQ5T2 DMNQ5T2 DN AG-858 DMNQ5T2 TI TTHYBIX DMNQ5T2 TN Heat shock protein 70 (HSP70) DMNQ5T2 RN Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265. DMNQ5T2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088345/ DMNQ7DV DI DMNQ7DV DMNQ7DV DN APD-209 DMNQ7DV TI TT2CJVK DMNQ7DV TN Adrenergic receptor beta-2 (ADRB2) DMNQ7DV MA Agonist DMNQ7DV RN Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385. DMNQ7DV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746778/ DMNQG24 DI DMNQG24 DMNQG24 DN Volociximab DMNQG24 TI TTH4QIS DMNQG24 TN Integrin alpha-5/beta-1 (ITGA5/B1) DMNQG24 RN Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. DMNQG24 RU https://pubmed.ncbi.nlm.nih.gov/17024968 DMNRHMX DI DMNRHMX DMNRHMX DN SKF-110679 DMNRHMX TI TTKMAZ6 DMNRHMX TN Growth hormone receptor (GHR) DMNRHMX MA Modulator DMNRHMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093). DMNRHMX RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093 DMNRYPF DI DMNRYPF DMNRYPF DN Cixutumumab DMNRYPF TI TTHRID2 DMNRYPF TN Insulin-like growth factor I receptor (IGF1R) DMNRYPF MA Modulator DMNRYPF RN Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64. DMNRYPF RU https://pubmed.ncbi.nlm.nih.gov/25858498 DMNSRY7 DI DMNSRY7 DMNSRY7 DN PXL-770 DMNSRY7 TI TTLAFZV DMNSRY7 TN AMP-activated protein kinase (AMPK) DMNSRY7 MA Activator DMNSRY7 RN Clinical pipeline report, company report or official report of Poxel SA. DMNSRY7 RU https://www.poxelpharma.com/en_us/product-pipeline/pxl770 DMNST69 DI DMNST69 DMNST69 DN Metaiodobenzylguanidine I-131 DMNST69 TI TTAWNKZ DMNST69 TN Norepinephrine transporter (NET) DMNST69 MA Modulator DMNST69 RN Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91. DMNST69 RU https://pubmed.ncbi.nlm.nih.gov/24573553 DMNSYXB DI DMNSYXB DMNSYXB DN Filibuvir DMNSYXB TI TTMVBWH DMNSYXB TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMNSYXB MA Inhibitor DMNSYXB RN Clinical pipeline report, company report or official report of Pfizer (2011). DMNSYXB RU http://www.pfizer.com/home/ DMNTC7O DI DMNTC7O DMNTC7O DN RO-4995819 DMNTC7O TI TT8A9EF DMNTC7O TN Metabotropic glutamate receptor 3 (mGluR3) DMNTC7O MA Modulator DMNTC7O RN Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112. DMNTC7O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/ DMNTC7O DI DMNTC7O DMNTC7O DN RO-4995819 DMNTC7O TI TTXJ47W DMNTC7O TN Metabotropic glutamate receptor 2 (mGluR2) DMNTC7O MA Modulator DMNTC7O RN Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112. DMNTC7O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/ DMNU48O DI DMNU48O DMNU48O DN Peptide YY 3-36 DMNU48O TI TTVFJLX DMNU48O TN Peptide tyrosine tyrosine PYY (PYY) DMNU48O MA Modulator DMNU48O RN Clinical pipeline report, company report or official report of Emisphere. DMNU48O RU http://ir.emisphere.com/releasedetail.cfm?releaseid=356364 DMNUXKA DI DMNUXKA DMNUXKA DN INCAGN01876 DMNUXKA TI TTG6LA7 DMNUXKA TN Activation-inducible TNFR family receptor (TNFRSF18) DMNUXKA MA Agonist DMNUXKA RN Clinical pipeline report, company report or official report of Agenus. DMNUXKA RU https://agenusbio.com/pipeline/ DMNVFZA DI DMNVFZA DMNVFZA DN AC-1202 DMNVFZA TI TTNHYJL DMNVFZA TN Ketogenesis (KG) DMNVFZA MA Modulator DMNVFZA RN Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31. DMNVFZA RU https://pubmed.ncbi.nlm.nih.gov/19664276 DMNVU28 DI DMNVU28 DMNVU28 DN ASB17061 DMNVU28 TI TT8VUE0 DMNVU28 TN Chymase (CYM) DMNVU28 MA Modulator DMNVU28 RN Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82. DMNVU28 RU https://pubmed.ncbi.nlm.nih.gov/23889510 DMNVZDT DI DMNVZDT DMNVZDT DN ISIS-FGFR4 DMNVZDT TI TT1KX2S DMNVZDT TN FGFR4 messenger RNA (FGFR4 mRNA) DMNVZDT RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMNVZDT RU http://www.isispharm.com/index.htm DMNW0DG DI DMNW0DG DMNW0DG DN Iodine-131-tositumomab DMNW0DG TI TTUE541 DMNW0DG TN Leukocyte surface antigen Leu-16 (CD20) DMNW0DG RN Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5. DMNW0DG RU https://pubmed.ncbi.nlm.nih.gov/18502830 DMNW5I9 DI DMNW5I9 DMNW5I9 DN CERE-110 DMNW5I9 TI TTDN3LF DMNW5I9 TN Nerve growth factor (NGF) DMNW5I9 MA Modulator DMNW5I9 RN CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7. DMNW5I9 RU https://pubmed.ncbi.nlm.nih.gov/20373268 DMNWYHD DI DMNWYHD DMNWYHD DN RDEA-684 DMNWYHD TI TTA592U DMNWYHD TN Urate anion exchanger 1 (URAT1) DMNWYHD MA Inhibitor DMNWYHD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031). DMNWYHD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031 DMNXJ5B DI DMNXJ5B DMNXJ5B DN TGFK08AA DMNXJ5B TI TTSQIFT DMNXJ5B TN 5-HT 1A receptor (HTR1A) DMNXJ5B MA Modulator DMNXJ5B RN 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. DMNXJ5B RU https://pubmed.ncbi.nlm.nih.gov/23989795 DMNY3J0 DI DMNY3J0 DMNY3J0 DN VTB-38543 DMNY3J0 TI TTXA6PH DMNY3J0 TN Oxysterols receptor LXR-beta (NR1H2) DMNY3J0 MA Agonist DMNY3J0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNY3J0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMNZ35F DI DMNZ35F DMNZ35F DN HP-228 DMNZ35F TI TTF10I9 DMNZ35F TN Nitric-oxide synthase inducible (NOS2) DMNZ35F MA Modulator DMNZ35F RN HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91. DMNZ35F RU https://pubmed.ncbi.nlm.nih.gov/7473142 DMO02LU DI DMO02LU DMO02LU DN PF-3463275 DMO02LU TI TTHJTF7 DMO02LU TN Glycine transporter GlyT-1 (SLC6A9) DMO02LU MA Inhibitor DMO02LU RN Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. DMO02LU RU https://pubmed.ncbi.nlm.nih.gov/24172334 DMO0C5R DI DMO0C5R DMO0C5R DN NU300 DMO0C5R TI TTC6JZQ DMO0C5R TN Haemophilus influenzae CRM197 (Hae-influ CRM197) DMO0C5R MA Modulator DMO0C5R RN ClinicalTrials.gov (NCT02140047) Exploratory Clinical Study of MT-2301. U.S. National Institutes of Health. DMO0C5R RU https://clinicaltrials.gov/ct2/show/NCT02140047 DMO0VGH DI DMO0VGH DMO0VGH DN Coenzyme Q10 analog DMO0VGH TI TT8XK6L DMO0VGH TN Quinone reductase 1 (NQO1) DMO0VGH MA Modulator DMO0VGH RN Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135. DMO0VGH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204556/ DMO10JI DI DMO10JI DMO10JI DN HibTITER DMO10JI TI TTC6JZQ DMO10JI TN Haemophilus influenzae CRM197 (Hae-influ CRM197) DMO10JI RN Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. J Microbiol Immunol Infect. 1998 Sep;31(3):180-6. DMO10JI RU https://pubmed.ncbi.nlm.nih.gov/10496155 DMO1VHC DI DMO1VHC DMO1VHC DN ALX-0061 DMO1VHC TI TT0E5SK DMO1VHC TN Interleukin 6 receptor (IL6R) DMO1VHC RN The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135. DMO1VHC RU https://pubmed.ncbi.nlm.nih.gov/25994180 DMO1XUK DI DMO1XUK DMO1XUK DN Myeloma cancer vaccine DMO1XUK TI TT6MP2Z DMO1XUK TN GMCSFR-alpha (CSF2RA) DMO1XUK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMO1XUK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMO1ZGX DI DMO1ZGX DMO1ZGX DN CRILVASTATIN DMO1ZGX TI TTPADOQ DMO1ZGX TN HMG-CoA reductase (HMGCR) DMO1ZGX MA Inhibitor DMO1ZGX RN Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8. DMO1ZGX RU https://pubmed.ncbi.nlm.nih.gov/8842455 DMO2TYL DI DMO2TYL DMO2TYL DN Ramipril DMO2TYL TI TTGFNPD DMO2TYL TN HUMAN angiotensin-converting enzyme (ACE) DMO2TYL MA Inhibitor DMO2TYL RN Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31. DMO2TYL RU https://pubmed.ncbi.nlm.nih.gov/32291526 DMO3U4W DI DMO3U4W DMO3U4W DN VX-222 DMO3U4W TI TTMVBWH DMO3U4W TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMO3U4W MA Inhibitor DMO3U4W RN 2011 Pipeline of Vertex. DMO3U4W RU http://www.vrtx.com/current-projects.html DMO4EYX DI DMO4EYX DMO4EYX DN Soblidotin DMO4EYX TI TTML2WA DMO4EYX TN Tubulin (TUB) DMO4EYX MA Modulator DMO4EYX RN Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81. DMO4EYX RU https://pubmed.ncbi.nlm.nih.gov/16827132 DMO4I61 DI DMO4I61 DMO4I61 DN H5N1 influenza vaccine DMO4I61 TI TT3J5ZI DMO4I61 TN Cell mediated immunity response (CMIR) DMO4I61 RN Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80. DMO4I61 RU https://pubmed.ncbi.nlm.nih.gov/20941447 DMO4MNQ DI DMO4MNQ DMO4MNQ DN BGS-649 DMO4MNQ TI TTSZLWK DMO4MNQ TN Aromatase (CYP19A1) DMO4MNQ MA Inhibitor DMO4MNQ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111) DMO4MNQ RU http://adisinsight.springer.com/drugs/800032111 DMO5JS3 DI DMO5JS3 DMO5JS3 DN GSK3389404 DMO5JS3 TI TTSJVOI DMO5JS3 TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMO5JS3 MA Inhibitor DMO5JS3 RN A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. DMO5JS3 RU https://pubmed.ncbi.nlm.nih.gov/30861337 DMO72IF DI DMO72IF DMO72IF DN AMG 301 DMO72IF TI TT5OREU DMO72IF TN PACAP type I receptor (PAC1R) DMO72IF MA Inhibitor DMO72IF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO72IF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMO7MBS DI DMO7MBS DMO7MBS DN MM-111 DMO7MBS TI TT6EO5L DMO7MBS TN Erbb2 tyrosine kinase receptor (HER2) DMO7MBS MA Modulator DMO7MBS RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMO7MBS RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMO84TL DI DMO84TL DMO84TL DN ME-3407 DMO84TL TI TT18ETS DMO84TL TN Myosin light kinase (MYLK) DMO84TL MA Inhibitor DMO84TL RN ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34. DMO84TL RU https://pubmed.ncbi.nlm.nih.gov/9176222 DMO8IEZ DI DMO8IEZ DMO8IEZ DN LY-2828360 DMO8IEZ TI TTMSFAW DMO8IEZ TN Cannabinoid receptor 2 (CB2) DMO8IEZ MA Agonist DMO8IEZ RN Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2). DMO8IEZ RU http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands DMO9LBE DI DMO9LBE DMO9LBE DN SUN N4057 DMO9LBE TI TTSQIFT DMO9LBE TN 5-HT 1A receptor (HTR1A) DMO9LBE MA Agonist DMO9LBE RN Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia. No To Shinkei. 2001 Sep;53(9):853-8. DMO9LBE RU https://pubmed.ncbi.nlm.nih.gov/11596480 DMO9QB8 DI DMO9QB8 DMO9QB8 DN R-IFN-1a DMO9QB8 TI TTSYFMA DMO9QB8 TN Interferon alpha/beta receptor 1 (IFNAR1) DMO9QB8 MA Modulator DMO9QB8 RN Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6. DMO9QB8 RU https://pubmed.ncbi.nlm.nih.gov/10526196 DMOB01U DI DMOB01U DMOB01U DN Amsilarotene DMOB01U TI TTOD7B3 DMOB01U TN Retinoic acid receptor (RAR) DMOB01U MA Antagonist DMOB01U RN Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32. DMOB01U RU https://pubmed.ncbi.nlm.nih.gov/12177113 DMOB1EM DI DMOB1EM DMOB1EM DN Plasmin DMOB1EM TI TTWODQF DMOB1EM TN Fibrin (FG) DMOB1EM MA Modulator DMOB1EM RN ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health. DMOB1EM RU https://clinicaltrials.gov/ct2/show/NCT01014975 DMOCID7 DI DMOCID7 DMOCID7 DN Etazolate DMOCID7 TI TTEX6LM DMOCID7 TN GABA(A) receptor gamma-3 (GABRG3) DMOCID7 MA Modulator DMOCID7 RN Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008 Jul;106(1):392-404. DMOCID7 RU https://pubmed.ncbi.nlm.nih.gov/18397369 DMOCRYB DI DMOCRYB DMOCRYB DN GLPG-1837 DMOCRYB TI TTRLZHP DMOCRYB TN cAMP-dependent chloride channel (CFTR) DMOCRYB MA Enhancer DMOCRYB RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMOCRYB RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMODJTX DI DMODJTX DMODJTX DN AMG-181 DMODJTX TI TTLT9XQ DMODJTX TN Integrin beta-7 (ITGB7) DMODJTX RN Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68. DMODJTX RU https://pubmed.ncbi.nlm.nih.gov/23425116 DMODJTX DI DMODJTX DMODJTX DN AMG-181 DMODJTX TI TT4BT06 DMODJTX TN Integrin alpha-4 (ITGA4) DMODJTX MA Inhibitor DMODJTX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMODJTX RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMODLN7 DI DMODLN7 DMODLN7 DN IRX-2 DMODLN7 TI TTXM6JN DMODLN7 TN Cytokine receptor unspecific (CRF) DMODLN7 MA Modulator DMODLN7 RN Clinical pipeline report, company report or official report of IRX Therapeutics. DMODLN7 RU http://www.irxtherapeutics.com/prod_irx2.html DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTCJG29 DMOEARH TN Serine/threonine-protein kinase mTOR (mTOR) DMOEARH MA Inhibitor DMOEARH RN Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. DMOEARH RU https://pubmed.ncbi.nlm.nih.gov/24309100 DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTX4GLS DMOEARH TN Mammalian target of rapamycin complex 1 (mTORC1) DMOEARH MA Inhibitor DMOEARH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOEARH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTWDKCL DMOEARH TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMOEARH MA Inhibitor DMOEARH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOEARH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOFTRE DI DMOFTRE DMOFTRE DN Cizolirtine DMOFTRE TI TTVSFJW DMOFTRE TN Calcitonin gene-related peptide 1 (CALCA) DMOFTRE MA Inhibitor DMOFTRE RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMOFTRE RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMOGDCQ DI DMOGDCQ DMOGDCQ DN Ab-01 DMOGDCQ TI TTZO9B0 DMOGDCQ TN Interleukin 21 receptor (IL21R) DMOGDCQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2304). DMOGDCQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2304 DMOGFNI DI DMOGFNI DMOGFNI DN AVN-101 DMOGFNI TI TTO9X1H DMOGFNI TN 5-HT 7 receptor (HTR7) DMOGFNI MA Antagonist DMOGFNI RN AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. DMOGFNI RU https://pubmed.ncbi.nlm.nih.gov/27232215 DMOGYQ0 DI DMOGYQ0 DMOGYQ0 DN ONO-2952 DMOGYQ0 TI TTPTXIN DMOGYQ0 TN Translocator protein (TSPO) DMOGYQ0 MA Antagonist DMOGYQ0 RN Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Jul 17;99:51-66. DMOGYQ0 RU https://pubmed.ncbi.nlm.nih.gov/26189762 DMOH8LD DI DMOH8LD DMOH8LD DN Senktide DMOH8LD TI TTBPGLU DMOH8LD TN Neuromedin-K receptor (TACR3) DMOH8LD MA Agonist DMOH8LD RN Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63. DMOH8LD RU https://pubmed.ncbi.nlm.nih.gov/12598409 DMOH8LD DI DMOH8LD DMOH8LD DN Senktide DMOH8LD TI TT4BT06 DMOH8LD TN Integrin alpha-4 (ITGA4) DMOH8LD MA Inhibitor DMOH8LD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOH8LD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMOHAS2 DI DMOHAS2 DMOHAS2 DN GPC-3298306 DMOHAS2 TI TTJTSX4 DMOHAS2 TN Glypican-3 (GPC3) DMOHAS2 RN Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91. DMOHAS2 RU https://pubmed.ncbi.nlm.nih.gov/18974622 DMOHT5V DI DMOHT5V DMOHT5V DN DKN-01 DMOHT5V TI TTE3RAC DMOHT5V TN Dickkopf-related protein 1 (DKK1) DMOHT5V MA Inhibitor DMOHT5V RN The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644. DMOHT5V RU https://pubmed.ncbi.nlm.nih.gov/32408777 DMOI9EL DI DMOI9EL DMOI9EL DN Radezolid DMOI9EL TI TT2VX74 DMOI9EL TN Bacterial Protein synthesis (Bact PROS) DMOI9EL MA Inhibitor DMOI9EL RN Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo). 2011 Jun;64(6):413-25. DMOI9EL RU https://pubmed.ncbi.nlm.nih.gov/21587262 DMOJ7QA DI DMOJ7QA DMOJ7QA DN Mitemcinal fumarate DMOJ7QA TI TT953CX DMOJ7QA TN Motilin receptor (MLNR) DMOJ7QA MA Agonist DMOJ7QA RN Clinical pipeline report, company report or official report of Roche (2009). DMOJ7QA RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMOJA5G DI DMOJA5G DMOJA5G DN Nuplazid DMOJA5G TI TTJQOD7 DMOJA5G TN 5-HT 2A receptor (HTR2A) DMOJA5G MA Agonist DMOJA5G RN The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. DMOJA5G RU https://pubmed.ncbi.nlm.nih.gov/30288594 DMOJA5G DI DMOJA5G DMOJA5G DN Nuplazid DMOJA5G TI TTWJBZ5 DMOJA5G TN 5-HT 2C receptor (HTR2C) DMOJA5G MA Agonist DMOJA5G RN The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. DMOJA5G RU https://pubmed.ncbi.nlm.nih.gov/30288594 DMOKUA5 DI DMOKUA5 DMOKUA5 DN XR-5000 DMOKUA5 TI TTGTQHC DMOKUA5 TN DNA topoisomerase I (TOP1) DMOKUA5 MA Modulator DMOKUA5 RN Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. DMOKUA5 RU https://pubmed.ncbi.nlm.nih.gov/12075748 DMOKUA5 DI DMOKUA5 DMOKUA5 DN XR-5000 DMOKUA5 TI TT0IHXV DMOKUA5 TN DNA topoisomerase II (TOP2) DMOKUA5 MA Modulator DMOKUA5 RN Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. DMOKUA5 RU https://pubmed.ncbi.nlm.nih.gov/12075748 DMOLTAD DI DMOLTAD DMOLTAD DN SM-04690 DMOLTAD TI TTFPSHI DMOLTAD TN Wnt signaling pathway (Wnt pathway) DMOLTAD MA Modulator DMOLTAD RN Clinical pipeline report, company report or official report of Phrma.org Arthritis 2014. DMOLTAD RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-arthritis.pdf DMOMDA4 DI DMOMDA4 DMOMDA4 DN B-701 DMOMDA4 TI TTST7KB DMOMDA4 TN Fibroblast growth factor receptor 3 (FGFR3) DMOMDA4 MA Antagonist DMOMDA4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOMDA4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMOMI97 DI DMOMI97 DMOMI97 DN UNI-rE-4 DMOMI97 TI TTVIMDE DMOMI97 TN Glucagon-like peptide 1 receptor (GLP1R) DMOMI97 MA Modulator DMOMI97 RN Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. DMOMI97 RU https://pubmed.ncbi.nlm.nih.gov/19748064 DMOMS7R DI DMOMS7R DMOMS7R DN GI-6301 DMOMS7R TI TTBXAHS DMOMS7R TN T-box transcription factor T (TBXT) DMOMS7R RN Clinical pipeline report, company report or official report of GlobeImmune. DMOMS7R RU https://www.globeimmune.com/cancer/gi-6301/ DMOPWSX DI DMOPWSX DMOPWSX DN Ibrolipim DMOPWSX TI TTOF3WZ DMOPWSX TN Lipoprotein lipase (LPL) DMOPWSX MA Modulator DMOPWSX RN NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92. DMOPWSX RU https://pubmed.ncbi.nlm.nih.gov/16311090 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTVIAT9 DMOQ7YI TN Phosphodiesterase 4B (PDE4B) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTSKMI8 DMOQ7YI TN Phosphodiesterase 4D (PDE4D) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTZ97H5 DMOQ7YI TN Phosphodiesterase 4A (PDE4A) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOR8SY DI DMOR8SY DMOR8SY DN CNT0-1959 DMOR8SY TI TTC1GLB DMOR8SY TN Interleukin-23 (IL23) DMOR8SY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMOR8SY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DMORFZD DI DMORFZD DMORFZD DN Tolamba DMORFZD TI TTSHG0T DMORFZD TN Toll-like receptor 9 (TLR9) DMORFZD RN Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291. DMORFZD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747261/ DMORJD4 DI DMORJD4 DMORJD4 DN AVB-500 DMORJD4 TI TT69QD2 DMORJD4 TN AXL receptor tyrosine kinase ligand (GAS6) DMORJD4 MA Inhibitor DMORJD4 RN Clinical pipeline report, company report or official report of Aravive. DMORJD4 RU https://aravive.com/pipeline/ DMORNVB DI DMORNVB DMORNVB DN NU-172 DMORNVB TI TT6L509 DMORNVB TN Coagulation factor IIa (F2) DMORNVB MA Inhibitor DMORNVB RN Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214. DMORNVB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260938/ DMOS5JZ DI DMOS5JZ DMOS5JZ DN Lexatumumab DMOS5JZ TI TTW20TU DMOS5JZ TN TRAIL receptor 2 (TRAIL-R2) DMOS5JZ RN National Cancer Institute Drug Dictionary (drug id 528015). DMOS5JZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=528015 DMOSCBF DI DMOSCBF DMOSCBF DN SAR-3419 DMOSCBF TI TTW640A DMOSCBF TN B-lymphocyte surface antigen B4 (CD19) DMOSCBF RN A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. DMOSCBF RU https://pubmed.ncbi.nlm.nih.gov/24132920 DMOSL9P DI DMOSL9P DMOSL9P DN E6201 DMOSL9P TI TTROQ37 DMOSL9P TN MAPK/ERK kinase kinase (MAP3K) DMOSL9P MA Modulator DMOSL9P RN E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31. DMOSL9P RU https://pubmed.ncbi.nlm.nih.gov/20627998 DMOT0M7 DI DMOT0M7 DMOT0M7 DN JTX-4014 DMOT0M7 TI TTNBFWK DMOT0M7 TN Programmed cell death protein 1 (PD-1) DMOT0M7 MA Inhibitor DMOT0M7 RN Clinical pipeline report, company report or official report of Jounce Therapeutics. DMOT0M7 RU https://jouncetx.com/our-pipeline/ DMOT0WR DI DMOT0WR DMOT0WR DN ONO-2333Ms DMOT0WR TI TT7EFHR DMOT0WR TN Corticotropin-releasing factor receptor 1 (CRHR1) DMOT0WR MA Antagonist DMOT0WR RN Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86. DMOT0WR RU https://pubmed.ncbi.nlm.nih.gov/23294766 DMOV0AP DI DMOV0AP DMOV0AP DN 842166X DMOV0AP TI TTMSFAW DMOV0AP TN Cannabinoid receptor 2 (CB2) DMOV0AP MA Agonist DMOV0AP RN The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49. DMOV0AP RU https://pubmed.ncbi.nlm.nih.gov/24358778 DMOVB3Y DI DMOVB3Y DMOVB3Y DN GKT-137831 DMOVB3Y TI TTQRBSJ DMOVB3Y TN NADPH oxidase 4 (NOX4) DMOVB3Y MA Modulator DMOVB3Y RN Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327. DMOVB3Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/ DMOVB3Y DI DMOVB3Y DMOVB3Y DN GKT-137831 DMOVB3Y TI TTFQVUT DMOVB3Y TN NADPH oxidase (NOX) DMOVB3Y MA Modulator DMOVB3Y RN Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327. DMOVB3Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/ DMOVQP8 DI DMOVQP8 DMOVQP8 DN SPP-600 DMOVQP8 TI TTB2MXP DMOVQP8 TN Angiotensinogenase renin (REN) DMOVQP8 MA Inhibitor DMOVQP8 RN Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2012 Jan;94(1):146-9. DMOVQP8 RU https://pubmed.ncbi.nlm.nih.gov/22173206 DMOW9X2 DI DMOW9X2 DMOW9X2 DN KRP-203 DMOW9X2 TI TT9JZCK DMOW9X2 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMOW9X2 MA Agonist DMOW9X2 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMOW9X2 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMOX1CU DI DMOX1CU DMOX1CU DN NCX-4016 DMOX1CU TI TTK0943 DMOX1CU TN Prostaglandin G/H synthase (COX) DMOX1CU MA Inhibitor DMOX1CU RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMOX1CU RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMOXKIC DI DMOXKIC DMOXKIC DN MEDI3902 DMOXKIC TI TTLK9NJ DMOXKIC TN Pseudomonas PcrV protein type III (Pseudo pcrV) DMOXKIC RN A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155. DMOXKIC RU https://pubmed.ncbi.nlm.nih.gov/25391481 DMOXKIC DI DMOXKIC DMOXKIC DN MEDI3902 DMOXKIC TI TTTPDRC DMOXKIC TN Pseudomonas Psl exopolysaccharide (Pseudo pslG) DMOXKIC RN A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155. DMOXKIC RU https://pubmed.ncbi.nlm.nih.gov/25391481 DMOYS8A DI DMOYS8A DMOYS8A DN PTG-300 DMOYS8A TI TTPCG5T DMOYS8A TN Hepcidin (HAMP) DMOYS8A MA Replacement DMOYS8A RN Clinical pipeline report, company report or official report of Protagonist Therapeutics. DMOYS8A RU https://www.protagonist-inc.com/pipeline/#overview DMOZ04X DI DMOZ04X DMOZ04X DN AZD-5213 DMOZ04X TI TT9JNIC DMOZ04X TN Histamine H3 receptor (H3R) DMOZ04X MA Antagonist DMOZ04X RN SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. DMOZ04X RU https://pubmed.ncbi.nlm.nih.gov/22542742 DMOZAMN DI DMOZAMN DMOZAMN DN TAK-935 DMOZAMN TI TT4EB85 DMOZAMN TN Cholesterol 24-hydroxylase (CYP46A1) DMOZAMN MA Inhibitor DMOZAMN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040983) DMOZAMN RU http://adisinsight.springer.com/drugs/800040983 DMOZW4C DI DMOZW4C DMOZW4C DN Neublastin DMOZW4C TI TT63XRS DMOZW4C TN GDNF receptor alpha-3 (GFRA3) DMOZW4C MA Modulator DMOZW4C RN First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoSOne. 2015 May 11;10(5):e0125034. DMOZW4C RU https://pubmed.ncbi.nlm.nih.gov/25962165 DMP05GL DI DMP05GL DMP05GL DN LYC-30937 DMP05GL TI TT5WKM8 DMP05GL TN ATP phosphatase (ATPase) DMP05GL MA Modulator DMP05GL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP05GL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMP0LST DI DMP0LST DMP0LST DN APL-101 DMP0LST TI TTNDSF4 DMP0LST TN Proto-oncogene c-Met (MET) DMP0LST MA Inhibitor DMP0LST RN Clinical pipeline report, company report or official report of Apollomics. DMP0LST RU https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-101/ DMP1873 DI DMP1873 DMP1873 DN TAK-063 DMP1873 TI TTJW4LU DMP1873 TN Phosphodiesterase 10A (PDE10) DMP1873 MA Inhibitor DMP1873 RN Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197. DMP1873 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/ DMP1W9Z DI DMP1W9Z DMP1W9Z DN NP-01 DMP1W9Z TI TTCBFJO DMP1W9Z TN Insulin receptor (INSR) DMP1W9Z MA Agonist DMP1W9Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMP1W9Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMP2BWX DI DMP2BWX DMP2BWX DN Ispinesib DMP2BWX TI TTTRP0H DMP2BWX TN Kinesin-like protein KIF11 (KIF11) DMP2BWX MA Inhibitor DMP2BWX RN Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. DMP2BWX RU https://pubmed.ncbi.nlm.nih.gov/19554570 DMP2DNS DI DMP2DNS DMP2DNS DN Rambazole DMP2DNS TI TTD7Q0R DMP2DNS TN Cytochrome P450 26 (CYP26A1) DMP2DNS MA Inhibitor DMP2DNS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DMP2DNS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DMP2DNS DI DMP2DNS DMP2DNS DN Rambazole DMP2DNS TI TTYO0A3 DMP2DNS TN Substance-K receptor (TACR2) DMP2DNS MA Antagonist DMP2DNS RN Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11. DMP2DNS RU https://pubmed.ncbi.nlm.nih.gov/15925360 DMP30SA DI DMP30SA DMP30SA DN TVB-2640 DMP30SA TI TT7AOUD DMP30SA TN Fatty acid synthase (FASN) DMP30SA MA Inhibitor DMP30SA RN Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118. DMP30SA RU https://pubmed.ncbi.nlm.nih.gov/31630414 DMP42W1 DI DMP42W1 DMP42W1 DN IW-6118 DMP42W1 TI TTDP1UC DMP42W1 TN Fatty acid amide hydrolase (FAAH) DMP42W1 MA Modulator DMP42W1 RN The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685. DMP42W1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581/ DMP56WJ DI DMP56WJ DMP56WJ DN CF102 DMP56WJ TI TTJFY5U DMP56WJ TN Adenosine A3 receptor (ADORA3) DMP56WJ MA Agonist DMP56WJ RN 2011 Pipeline of Can-Fite BioPharm. DMP56WJ RU http://www.canfite.com/pipeline.html DMP5Y1A DI DMP5Y1A DMP5Y1A DN AGN-199981 DMP5Y1A TI TTWM4TY DMP5Y1A TN Adrenergic receptor alpha-2B (ADRA2B) DMP5Y1A MA Agonist DMP5Y1A RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMP5Y1A RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMP5Z9N DI DMP5Z9N DMP5Z9N DN SAN-300 DMP5Z9N TI TTPERWV DMP5Z9N TN Integrin alpha-1 (VLA-1) DMP5Z9N MA Antagonist DMP5Z9N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP5Z9N RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMP62L5 DI DMP62L5 DMP62L5 DN Resiniferatoxin DMP62L5 TI TTMI6F5 DMP62L5 TN Transient receptor potential cation channel V1 (TRPV1) DMP62L5 MA Activator DMP62L5 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMP62L5 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTSECX1 DMP6B59 TN Connective tissue growth factor (CTGF) DMP6B59 MA Inhibitor DMP6B59 RN Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/17979604 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTJQOD7 DMP6B59 TN 5-HT 2A receptor (HTR2A) DMP6B59 MA Modulator DMP6B59 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTEX248 DMP6B59 TN Dopamine D2 receptor (D2R) DMP6B59 MA Modulator DMP6B59 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMP6MH9 DI DMP6MH9 DMP6MH9 DN DA-8031 DMP6MH9 TI TT3ROYC DMP6MH9 TN Serotonin transporter (SERT) DMP6MH9 MA Inhibitor DMP6MH9 RN Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior. Int J Urol. 2014 Mar;21(3):325-9. DMP6MH9 RU https://pubmed.ncbi.nlm.nih.gov/23968141 DMP7J0S DI DMP7J0S DMP7J0S DN R411 DMP7J0S TI TT6S84X DMP7J0S TN Integrin alpha-4/beta-1 (ITGA4/B1) DMP7J0S MA Modulator DMP7J0S RN Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20. DMP7J0S RU https://pubmed.ncbi.nlm.nih.gov/20885411 DMP925B DI DMP925B DMP925B DN ICA-105665 DMP925B TI TTIVDM3 DMP925B TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMP925B MA Activator DMP925B RN New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. DMP925B RU https://pubmed.ncbi.nlm.nih.gov/18590620 DMP9TKE DI DMP9TKE DMP9TKE DN PTC299 DMP9TKE TI TT2J34L DMP9TKE TN Arachidonate 5-lipoxygenase (5-LOX) DMP9TKE MA Inhibitor DMP9TKE RN Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42. DMP9TKE RU https://pubmed.ncbi.nlm.nih.gov/2124522 DMP9TKE DI DMP9TKE DMP9TKE DN PTC299 DMP9TKE TI TTOHSBA DMP9TKE TN Vascular endothelial growth factor A (VEGFA) DMP9TKE MA Modulator DMP9TKE RN Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24. DMP9TKE RU https://www.ncbi.nlm.nih.gov/pubmed/25407389 DMPAJ41 DI DMPAJ41 DMPAJ41 DN BIIB-021 DMPAJ41 TI TT78R5H DMPAJ41 TN Heat shock protein 90 alpha (HSP90A) DMPAJ41 MA Inhibitor DMPAJ41 RN BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9. DMPAJ41 RU https://pubmed.ncbi.nlm.nih.gov/19372565 DMPBK8N DI DMPBK8N DMPBK8N DN GSK3228836 DMPBK8N TI TTSJVOI DMPBK8N TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMPBK8N MA Inhibitor DMPBK8N RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMPBK8N RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMPBKUZ DI DMPBKUZ DMPBKUZ DN SCH-900978 DMPBKUZ TI TTZPO1L DMPBKUZ TN Substance-P receptor (TACR1) DMPBKUZ MA Antagonist DMPBKUZ RN Clinical pipeline report, company report or official report of OPKO Health, Inc. DMPBKUZ RU http://investor.opko.com/secfiling.cfm?filingID=950123-10-54487&CIK=944809 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TTU0P73 DMPBR0D TN MHC class I NK cell receptor 2DL2 (CD158b1) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TTEX3SI DMPBR0D TN MHC class I NK cell receptor 2DL3 (CD158b2) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TT4UXPE DMPBR0D TN MHC class I NK cell receptor 2DL1 (CD158A) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBTVK DI DMPBTVK DMPBTVK DN MGB-BP-3 DMPBTVK TI TTS1W4A DMPBTVK TN Bacterial Deoxyribonucleic acid (Bact DNA) DMPBTVK MA Binder DMPBTVK RN Clinical pipeline report, company report or official report of MGB Biopharma. DMPBTVK RU https://www.mgb-biopharma.com/wp-content/uploads/SMi-MGB-Biopharma-Presentation.pdf DMPBV9D DI DMPBV9D DMPBV9D DN Flupirtine DMPBV9D TI TTQ29KF DMPBV9D TN Voltage-gated potassium channel Kv7 (KCNQ) DMPBV9D MA Modulator DMPBV9D RN Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249. DMPBV9D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743843/ DMPC4EK DI DMPC4EK DMPC4EK DN EP-217609 DMPC4EK TI TTCIHJA DMPC4EK TN Coagulation factor Xa (F10) DMPC4EK MA Modulator DMPC4EK RN Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95. DMPC4EK RU https://www.ncbi.nlm.nih.gov/pubmed/22144183 DMPC4EK DI DMPC4EK DMPC4EK DN EP-217609 DMPC4EK TI TT6L509 DMPC4EK TN Coagulation factor IIa (F2) DMPC4EK MA Modulator DMPC4EK RN Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95. DMPC4EK RU https://www.ncbi.nlm.nih.gov/pubmed/22144183 DMPD3X6 DI DMPD3X6 DMPD3X6 DN Pegmusirudin DMPD3X6 TI TT6L509 DMPD3X6 TN Coagulation factor IIa (F2) DMPD3X6 MA Modulator DMPD3X6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMPD3X6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMPDVM8 DI DMPDVM8 DMPDVM8 DN ABT-510 DMPDVM8 TI TTKI0H1 DMPDVM8 TN Thrombospondin-1 (THBS1) DMPDVM8 MA Modulator DMPDVM8 RN A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9. DMPDVM8 RU https://pubmed.ncbi.nlm.nih.gov/17551310 DMPE2B9 DI DMPE2B9 DMPE2B9 DN ZD-7288 DMPE2B9 TI TTKLW9S DMPE2B9 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DMPE2B9 MA Modulator DMPE2B9 RN ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats. World J Gastroenterol. 2014 Feb 28;20(8):2091-7. DMPE2B9 RU https://pubmed.ncbi.nlm.nih.gov/24587682 DMPER4A DI DMPER4A DMPER4A DN NIR178 DMPER4A TI TTSLI08 DMPER4A TN Adenosine receptor (ADOR) DMPER4A MA Antagonist DMPER4A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPER4A RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTJGNVC DMPF9ZM TN Apoptosis regulator Bcl-2 (BCL-2) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTU1E82 DMPF9ZM TN Apoptosis regulator Bcl-xL (BCL-xL) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTL53M6 DMPF9ZM TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPFG7H DI DMPFG7H DMPFG7H DN JNJ-16269110 DMPFG7H TI TTUS1RD DMPFG7H TN Microsomal triglyceride transfer protein (MTTP) DMPFG7H MA Inhibitor DMPFG7H RN ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health. DMPFG7H RU https://clinicaltrials.gov/ct2/show/NCT00672386 DMPFVJB DI DMPFVJB DMPFVJB DN 5-hydroxymethyl-2-furfural DMPFVJB TI TTQO71U DMPFVJB TN Hemoglobin (HB) DMPFVJB MA Modulator DMPFVJB RN 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61. DMPFVJB RU https://pubmed.ncbi.nlm.nih.gov/15686467 DMPH1AG DI DMPH1AG DMPH1AG DN TG100801 DMPH1AG TI TT9HKJA DMPH1AG TN Vascular endothelial growth factor (VEGF) DMPH1AG MA Inhibitor DMPH1AG RN Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37. DMPH1AG RU https://pubmed.ncbi.nlm.nih.gov/18330892 DMPHCDL DI DMPHCDL DMPHCDL DN GLPG-0634 DMPHCDL TI TT6DM01 DMPHCDL TN Janus kinase 1 (JAK-1) DMPHCDL MA Modulator DMPHCDL RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMPHCDL RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMPI6N0 DI DMPI6N0 DMPI6N0 DN XZK-monascus DMPI6N0 TI TTPADOQ DMPI6N0 TN HMG-CoA reductase (HMGCR) DMPI6N0 MA Modulator DMPI6N0 RN NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med. 2012 Mar 22;7:8. DMPI6N0 RU https://pubmed.ncbi.nlm.nih.gov/22439629 DMPJQZG DI DMPJQZG DMPJQZG DN NSC-645809 DMPJQZG TI TTJLP0R DMPJQZG TN Quinone reductase 2 (NQO2) DMPJQZG MA Inhibitor DMPJQZG RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMPJQZG RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMPK34E DI DMPK34E DMPK34E DN Sun13834 DMPK34E TI TTV5CGO DMPK34E TN Phosphodiesterase 4 (PDE4) DMPK34E MA Inhibitor DMPK34E RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DMPK34E RU https://pubmed.ncbi.nlm.nih.gov/7925603 DMPK34E DI DMPK34E DMPK34E DN Sun13834 DMPK34E TI TT8VUE0 DMPK34E TN Chymase (CYM) DMPK34E MA Modulator DMPK34E RN Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91. DMPK34E RU https://www.ncbi.nlm.nih.gov/pubmed/18996112 DMPKWR3 DI DMPKWR3 DMPKWR3 DN MEDI-546 DMPKWR3 TI TTSYFMA DMPKWR3 TN Interferon alpha/beta receptor 1 (IFNAR1) DMPKWR3 MA Modulator DMPKWR3 RN Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39. DMPKWR3 RU https://pubmed.ncbi.nlm.nih.gov/25606664 DMPL9KG DI DMPL9KG DMPL9KG DN LGD-6972 DMPL9KG TI TT9O6WS DMPL9KG TN Glucagon receptor (GCGR) DMPL9KG MA Antagonist DMPL9KG RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DMPL9KG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DMPLKAH DI DMPLKAH DMPLKAH DN GSK-706769 DMPLKAH TI TT2CEJG DMPLKAH TN C-C chemokine receptor type 5 (CCR5) DMPLKAH MA Antagonist DMPLKAH RN Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40. DMPLKAH RU https://pubmed.ncbi.nlm.nih.gov/19483700 DMPMO6G DI DMPMO6G DMPMO6G DN CC-401 DMPMO6G TI TTR2TXZ DMPMO6G TN Jun N terminal kinase (JNK) DMPMO6G MA Modulator DMPMO6G RN Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49. DMPMO6G RU https://www.ncbi.nlm.nih.gov/pubmed/19629069 DMPMU38 DI DMPMU38 DMPMU38 DN JVRS-100 DMPMU38 TI TTSHG0T DMPMU38 TN Toll-like receptor 9 (TLR9) DMPMU38 RN Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820. DMPMU38 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690618/ DMPN314 DI DMPN314 DMPN314 DN SNA-120 DMPN314 TI TTTDVOJ DMPN314 TN Tropomyosin-related kinase A (TrkA) DMPN314 MA Inhibitor DMPN314 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPN314 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPNDYU DI DMPNDYU DMPNDYU DN MEM-3454 DMPNDYU TI TTLA931 DMPNDYU TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMPNDYU MA Antagonist DMPNDYU RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMPNDYU RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMPNYXQ DI DMPNYXQ DMPNYXQ DN BIO-11006 DMPNYXQ TI TTHRM39 DMPNYXQ TN Myristoylated alanine-rich C-kinase substrate (MARCKS) DMPNYXQ MA Inhibitor DMPNYXQ RN An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol. 2016 Nov;55(5):617-622. DMPNYXQ RU https://pubmed.ncbi.nlm.nih.gov/27556883 DMPO4M1 DI DMPO4M1 DMPO4M1 DN Paquinimod DMPO4M1 TI TT0TMQG DMPO4M1 TN Calgranulin B (S100A9) DMPO4M1 MA Inhibitor DMPO4M1 RN Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8. DMPO4M1 RU https://pubmed.ncbi.nlm.nih.gov/25969431 DMPO7UG DI DMPO7UG DMPO7UG DN AGEN2034 DMPO7UG TI TTNBFWK DMPO7UG TN Programmed cell death protein 1 (PD-1) DMPO7UG MA Inhibitor DMPO7UG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPO7UG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPQHOR DI DMPQHOR DMPQHOR DN AMG 208 DMPQHOR TI TTNDSF4 DMPQHOR TN Proto-oncogene c-Met (MET) DMPQHOR MA Modulator DMPQHOR RN A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706. DMPQHOR RU https://pubmed.ncbi.nlm.nih.gov/26155941 DMPR8E9 DI DMPR8E9 DMPR8E9 DN ACP-001 DMPR8E9 TI TTT3YKH DMPR8E9 TN Somatotropin (GH1) DMPR8E9 MA Modulator DMPR8E9 RN ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health. DMPR8E9 RU https://clinicaltrials.gov/ct2/show/NCT01947907 DMPRIHK DI DMPRIHK DMPRIHK DN Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells DMPRIHK TI TT6EO5L DMPRIHK TN Erbb2 tyrosine kinase receptor (HER2) DMPRIHK RN Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60. DMPRIHK RU https://pubmed.ncbi.nlm.nih.gov/11359672 DMPRYU1 DI DMPRYU1 DMPRYU1 DN PF-04457845 DMPRYU1 TI TTDP1UC DMPRYU1 TN Fatty acid amide hydrolase (FAAH) DMPRYU1 MA Inhibitor DMPRYU1 RN Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96. DMPRYU1 RU https://pubmed.ncbi.nlm.nih.gov/21666860 DMPRZX4 DI DMPRZX4 DMPRZX4 DN LAS 100977 DMPRZX4 TI TT2CJVK DMPRZX4 TN Adrenergic receptor beta-2 (ADRB2) DMPRZX4 MA Agonist DMPRZX4 RN Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509. DMPRZX4 RU https://pubmed.ncbi.nlm.nih.gov/22588259 DMPSBTL DI DMPSBTL DMPSBTL DN VY-AADC DMPSBTL TI TTN451K DMPSBTL TN Aromatic-L-amino-acid decarboxylase (DDC) DMPSBTL MA Replacement DMPSBTL RN Clinical pipeline report, company report or official report of Voyager Therapeutics. DMPSBTL RU https://www.voyagertherapeutics.com/our-approach-programs/clinical-trials/ DMPSCVY DI DMPSCVY DMPSCVY DN CMX-2043 DMPSCVY TI TTWTSCV DMPSCVY TN RAC-alpha serine/threonine-protein kinase (AKT1) DMPSCVY MA Modulator DMPSCVY RN Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64. DMPSCVY RU https://pubmed.ncbi.nlm.nih.gov/24751172 DMPSCVY DI DMPSCVY DMPSCVY DN CMX-2043 DMPSCVY TI TTNDSF4 DMPSCVY TN Proto-oncogene c-Met (MET) DMPSCVY MA Modulator DMPSCVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPSCVY RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TTBD6I7 DMPUAOE TN Mucosal addressin cell adhesion molecule 1 (MADCAM1) DMPUAOE RN Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. DMPUAOE RU https://pubmed.ncbi.nlm.nih.gov/17355213 DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TT30C9G DMPUAOE TN C-X-C chemokine receptor type 2 (CXCR2) DMPUAOE MA Modulator DMPUAOE RN CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11. DMPUAOE RU https://www.ncbi.nlm.nih.gov/pubmed/25695403 DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TTMWT8Z DMPUAOE TN C-X-C chemokine receptor type 1 (CXCR1) DMPUAOE MA Antagonist DMPUAOE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPUAOE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPVAUT DI DMPVAUT DMPVAUT DN CCX872 DMPVAUT TI TTFZYTO DMPVAUT TN C-C chemokine receptor type 2 (CCR2) DMPVAUT MA Inhibitor DMPVAUT RN Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78. DMPVAUT RU http://www.sciencedirect.com/science/article/pii/S014067361460341X DMPVQYR DI DMPVQYR DMPVQYR DN PF-05212377 DMPVQYR TI TTJS8PY DMPVQYR TN 5-HT 6 receptor (HTR6) DMPVQYR MA Antagonist DMPVQYR RN PF-05212377 Alzheimer's Disease (Phase 2). Pfizer. DMPVQYR RU http://www.alzforum.org/therapeutics/pf-05212377 DMPW0UL DI DMPW0UL DMPW0UL DN SYN-120 DMPW0UL TI TTJS8PY DMPW0UL TN 5-HT 6 receptor (HTR6) DMPW0UL MA Antagonist DMPW0UL RN The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168. DMPW0UL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268149/ DMPW28M DI DMPW28M DMPW28M DN PD-200390 DMPW28M TI TT729IR DMPW28M TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMPW28M MA Modulator DMPW28M RN Pfizer. Product Development Pipeline. March 31 2009. DMPW28M RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMPWSBL DI DMPWSBL DMPWSBL DN ALD-518 DMPWSBL TI TTT1V78 DMPWSBL TN Interleukin-6 (IL6) DMPWSBL MA Modulator DMPWSBL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMPWSBL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMPXH7N DI DMPXH7N DMPXH7N DN FKW00GA DMPXH7N TI TTJQOD7 DMPXH7N TN 5-HT 2A receptor (HTR2A) DMPXH7N MA Antagonist DMPXH7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXH7N RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMPXH7N DI DMPXH7N DMPXH7N DN FKW00GA DMPXH7N TI TTSQIFT DMPXH7N TN 5-HT 1A receptor (HTR1A) DMPXH7N MA Antagonist DMPXH7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXH7N RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMPXK27 DI DMPXK27 DMPXK27 DN PBI-4050 DMPXK27 TI TTB8FUC DMPXK27 TN Free fatty acid receptor 1 (GPR40) DMPXK27 MA Agonist DMPXK27 RN Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663. DMPXK27 RU https://pubmed.ncbi.nlm.nih.gov/30578394 DMPXK27 DI DMPXK27 DMPXK27 DN PBI-4050 DMPXK27 TI TTG0MQD DMPXK27 TN Inflammation-related GPCR EX33 (GPR84) DMPXK27 MA Antagonist DMPXK27 RN Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663. DMPXK27 RU https://pubmed.ncbi.nlm.nih.gov/30578394 DMPZ67G DI DMPZ67G DMPZ67G DN SDZ-281-240 DMPZ67G TI TTMW94E DMPZ67G TN FK506-binding protein 1A (FKBP1A) DMPZ67G MA Modulator DMPZ67G RN Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10. DMPZ67G RU https://pubmed.ncbi.nlm.nih.gov/8618008 DMPZ97S DI DMPZ97S DMPZ97S DN NNZ-2566 DMPZ97S TI TT9RTYG DMPZ97S TN Neuropeptide receptor (NPR) DMPZ97S MA Modulator DMPZ97S RN NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. DMPZ97S RU https://pubmed.ncbi.nlm.nih.gov/19656406 DMQ08AJ DI DMQ08AJ DMQ08AJ DN Edotreotide DMQ08AJ TI TTOMNR9 DMQ08AJ TN Somatostatin receptor (SSTR) DMQ08AJ MA Modulator DMQ08AJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQ08AJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQ0XZE DI DMQ0XZE DMQ0XZE DN GI-4000 + gemcitabine DMQ0XZE TI TTRHMTC DMQ0XZE TN Mutated KRAS (mKRAS) DMQ0XZE MA Modulator DMQ0XZE RN Clinical pipeline report, company report or official report of GlobeImmune. DMQ0XZE RU https://www.globeimmune.com/cancer/gi-4000/ DMQ1GH4 DI DMQ1GH4 DMQ1GH4 DN AEF0117 DMQ1GH4 TI TT6OEDT DMQ1GH4 TN Cannabinoid receptor 1 (CB1) DMQ1GH4 MA Antagonist DMQ1GH4 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMQ1GH4 RU https://brain.labex.u-bordeaux.fr/Actions/Focus/CannaPreg-i6901.html DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TTGP7BY DMQ2O8V TN Monoamine oxidase type B (MAO-B) DMQ2O8V MA Inhibitor DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TT9IK2Z DMQ2O8V TN N-methyl-D-aspartate receptor (NMDAR) DMQ2O8V MA Antagonist DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TT3WG5C DMQ2O8V TN Monoamine oxidase type A (MAO-A) DMQ2O8V MA Inhibitor DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ30X2 DI DMQ30X2 DMQ30X2 DN HQP1351 DMQ30X2 TI TTS7G69 DMQ30X2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMQ30X2 MA Inhibitor DMQ30X2 RN Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88. DMQ30X2 RU https://pubmed.ncbi.nlm.nih.gov/31673329 DMQ3C05 DI DMQ3C05 DMQ3C05 DN ISIS-APO(a) DMQ3C05 TI TTU9LGY DMQ3C05 TN Apolipoprotein A messenger RNA (LPA mRNA) DMQ3C05 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMQ3C05 RU https://www.isispharm.com/pipeline/isis-apoarx/ DMQ3RWN DI DMQ3RWN DMQ3RWN DN Iralukast DMQ3RWN TI TTGKOY9 DMQ3RWN TN Leukotriene CysLT1 receptor (CYSLTR1) DMQ3RWN MA Modulator DMQ3RWN RN Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8. DMQ3RWN RU https://pubmed.ncbi.nlm.nih.gov/9504401 DMQ47U6 DI DMQ47U6 DMQ47U6 DN CR8020 DMQ47U6 TI TTF4CAM DMQ47U6 TN Influenza Hemagglutinin (Influ HA) DMQ47U6 RN Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92. DMQ47U6 RU https://pubmed.ncbi.nlm.nih.gov/25210195 DMQ58YH DI DMQ58YH DMQ58YH DN Anti-LT alpha DMQ58YH TI TTP73TM DMQ58YH TN Lymphotoxin-alpha (LTA) DMQ58YH RN Clinical pipeline report, company report or official report of Genentech (2011). DMQ58YH RU http://www.gene.com/gene/index.jsp DMQ6ANE DI DMQ6ANE DMQ6ANE DN TGOF02N DMQ6ANE TI TTYSN63 DMQ6ANE TN 5-HT 2 receptor (5HT2R) DMQ6ANE MA Modulator DMQ6ANE RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMQ6ANE RU http://www.fabrekramer.com/?page_id=76 DMQ6KZM DI DMQ6KZM DMQ6KZM DN ABI-009 DMQ6KZM TI TTCJG29 DMQ6KZM TN Serine/threonine-protein kinase mTOR (mTOR) DMQ6KZM MA Inhibitor DMQ6KZM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ6KZM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ73AY DI DMQ73AY DMQ73AY DN Reovirus DMQ73AY TI TTW2R9X DMQ73AY TN GTPase NRas (NRAS) DMQ73AY MA Modulator DMQ73AY RN Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors. DMQ73AY RU http://cancerres.aacrjournals.org/content/72/8_Supplement/2488.short DMQ7UL8 DI DMQ7UL8 DMQ7UL8 DN Camostat DMQ7UL8 TI TTEMV5X DMQ7UL8 TN Serine protease unspecific (SP) DMQ7UL8 MA Inhibitor DMQ7UL8 RN Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9. DMQ7UL8 RU https://pubmed.ncbi.nlm.nih.gov/19145783 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTVIAT9 DMQ874W TN Phosphodiesterase 4B (PDE4B) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTSKMI8 DMQ874W TN Phosphodiesterase 4D (PDE4D) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTZ97H5 DMQ874W TN Phosphodiesterase 4A (PDE4A) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ8J0U DI DMQ8J0U DMQ8J0U DN Basmisanil DMQ8J0U TI TTNZPQ1 DMQ8J0U TN GABA(A) receptor alpha-5 (GABRA5) DMQ8J0U MA Modulator DMQ8J0U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ8J0U RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQ8K93 DI DMQ8K93 DMQ8K93 DN RFT-5.dgA DMQ8K93 TI TT10Y9E DMQ8K93 TN Interleukin 2 receptor alpha (IL2RA) DMQ8K93 MA Modulator DMQ8K93 RN Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36. DMQ8K93 RU https://www.ncbi.nlm.nih.gov/pubmed/12702527 DMQA3MV DI DMQA3MV DMQA3MV DN MNX-100 DMQA3MV TI TT2MN5K DMQA3MV TN Phosphorylated protein kinase B (pAKT) DMQA3MV MA Modulator DMQA3MV RN Clinical pipeline report, company report or official report of MetronomX. DMQA3MV RU http://www.metronomxgroup.com/mnx-100.php DMQBP7R DI DMQBP7R DMQBP7R DN CAT 1004 DMQBP7R TI TTUIZKC DMQBP7R TN DNA-binding factor KBF1 (p105) DMQBP7R MA Inhibitor DMQBP7R RN Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc. DMQBP7R RU http://www.catabasis.com/clinical-trials-cat-1004-movedmd.php DMQBP7R DI DMQBP7R DMQBP7R DN CAT 1004 DMQBP7R TI TTSXVID DMQBP7R TN Nuclear factor NF-kappa-B (NFKB) DMQBP7R MA Inhibitor DMQBP7R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBP7R RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMQCFSM DI DMQCFSM DMQCFSM DN BGB-3112 DMQCFSM TI TTGM6VW DMQCFSM TN Tyrosine-protein kinase BTK (ATK) DMQCFSM MA Inhibitor DMQCFSM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQCFSM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQD1GN DI DMQD1GN DMQD1GN DN JNJ-32729463 DMQD1GN TI TTN6J5F DMQD1GN TN Bacterial DNA gyrase (Bact gyrase) DMQD1GN MA Inhibitor DMQD1GN RN Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. DMQD1GN RU https://pubmed.ncbi.nlm.nih.gov/21911562 DMQD1GN DI DMQD1GN DMQD1GN DN JNJ-32729463 DMQD1GN TI TTFK8YB DMQD1GN TN Bacterial DNA topoisomerase 4A (Bact parC) DMQD1GN MA Inhibitor DMQD1GN RN Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. DMQD1GN RU https://pubmed.ncbi.nlm.nih.gov/21911562 DMQD5NA DI DMQD5NA DMQD5NA DN TD-9855 DMQD5NA TI TTAWNKZ DMQD5NA TN Norepinephrine transporter (NET) DMQD5NA MA Modulator DMQD5NA RN Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. DMQD5NA RU https://pubmed.ncbi.nlm.nih.gov/25522383 DMQD5NA DI DMQD5NA DMQD5NA DN TD-9855 DMQD5NA TI TT3ROYC DMQD5NA TN Serotonin transporter (SERT) DMQD5NA MA Modulator DMQD5NA RN Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. DMQD5NA RU https://pubmed.ncbi.nlm.nih.gov/25522383 DMQD753 DI DMQD753 DMQD753 DN SUVN-502 DMQD753 TI TTJS8PY DMQD753 TN 5-HT 6 receptor (HTR6) DMQD753 MA Antagonist DMQD753 RN Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344. DMQD753 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007800/ DMQDLVW DI DMQDLVW DMQDLVW DN KRP-104 DMQDLVW TI TTDIGC1 DMQDLVW TN Dipeptidyl peptidase 4 (DPP-4) DMQDLVW MA Modulator DMQDLVW RN Clinical pipeline report, company report or official report of Activx. DMQDLVW RU http://www.activx.com/press/news_20080821.html DMQEC9P DI DMQEC9P DMQEC9P DN GW-870086-X DMQEC9P TI TTYRL6O DMQEC9P TN Glucocorticoid receptor (NR3C1) DMQEC9P MA Agonist DMQEC9P RN Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7. DMQEC9P RU https://pubmed.ncbi.nlm.nih.gov/23462748 DMQERC6 DI DMQERC6 DMQERC6 DN E5555 DMQERC6 TI TTL935N DMQERC6 TN Proteinase activated receptor 1 (F2R) DMQERC6 MA Antagonist DMQERC6 RN Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53. DMQERC6 RU https://pubmed.ncbi.nlm.nih.gov/21502577 DMQFU1R DI DMQFU1R DMQFU1R DN Anti-M1 prime DMQFU1R TI TTA5LWY DMQFU1R TN M1-prime segment of membrane-expressed IgE (M1 IgE) DMQFU1R RN Clinical pipeline report, company report or official report of Genentech (2011). DMQFU1R RU http://www.gene.com/gene/index.jsp DMQGBM1 DI DMQGBM1 DMQGBM1 DN EVT-201 DMQGBM1 TI TTEX6LM DMQGBM1 TN GABA(A) receptor gamma-3 (GABRG3) DMQGBM1 MA Modulator DMQGBM1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMQGBM1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMQGBM1 DI DMQGBM1 DMQGBM1 DN EVT-201 DMQGBM1 TI TT1MPAY DMQGBM1 TN GABA(A) receptor alpha-1 (GABRA1) DMQGBM1 MA Modulator DMQGBM1 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMQGBM1 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMQGI73 DI DMQGI73 DMQGI73 DN AVI-4557 DMQGI73 TI TTWP7HQ DMQGI73 TN CYP3A4 messenger RNA (CYP3A4 mRNA) DMQGI73 RN Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002 Jul;30(7):757-62. DMQGI73 RU https://pubmed.ncbi.nlm.nih.gov/12065433 DMQGI8R DI DMQGI8R DMQGI8R DN CD20 CAR T cells DMQGI8R TI TTUE541 DMQGI8R TN Leukocyte surface antigen Leu-16 (CD20) DMQGI8R MA CAR-T-Cell-Therapy DMQGI8R RN ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies DMQGI8R RU https://clinicaltrials.gov/ct2/show/NCT02846584 DMQGO74 DI DMQGO74 DMQGO74 DN ONO-3307 DMQGO74 TI TTZBFA0 DMQGO74 TN Protease unspecific (PRO) DMQGO74 MA Modulator DMQGO74 RN Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. DMQGO74 RU https://pubmed.ncbi.nlm.nih.gov/2515329 DMQGPLO DI DMQGPLO DMQGPLO DN GSK-1070806 DMQGPLO TI TTRICUF DMQGPLO TN Interleukin-18 (IL18) DMQGPLO RN Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220. DMQGPLO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059231/ DMQH1NV DI DMQH1NV DMQH1NV DN Emivirine DMQH1NV TI TT84ETX DMQH1NV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQH1NV MA Modulator DMQH1NV RN Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704. DMQH1NV RU https://www.ncbi.nlm.nih.gov/pubmed/19446143 DMQH2SF DI DMQH2SF DMQH2SF DN IPH4102 DMQH2SF TI TTQH3N0 DMQH2SF TN MHC class I NK cell receptor 3DL2 (CD158k) DMQH2SF MA Antagonist DMQH2SF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQH2SF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQHBSX DI DMQHBSX DMQHBSX DN NITD609 DMQHBSX TI TTJFY5U DMQHBSX TN Adenosine A3 receptor (ADORA3) DMQHBSX MA Inhibitor DMQHBSX RN Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80. DMQHBSX RU https://pubmed.ncbi.nlm.nih.gov/20813948 DMQHBSX DI DMQHBSX DMQHBSX DN NITD609 DMQHBSX TI TTQ6VDM DMQHBSX TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMQHBSX MA Inhibitor DMQHBSX RN Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80. DMQHBSX RU https://pubmed.ncbi.nlm.nih.gov/20813948 DMQHS6B DI DMQHS6B DMQHS6B DN MK-866 DMQHS6B TI TT2J34L DMQHS6B TN Arachidonate 5-lipoxygenase (5-LOX) DMQHS6B MA Modulator DMQHS6B RN Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats DMQHS6B RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574003 DMQI43G DI DMQI43G DMQI43G DN BMS 650032 DMQI43G TI TT5FNQT DMQI43G TN Human immunodeficiency virus Protease (HIV PR) DMQI43G MA Inhibitor DMQI43G RN 2011 Pipeline of Bristol-Myers Squibb. DMQI43G RU http://www.bms.com/pages/default.aspx DMQJ5DV DI DMQJ5DV DMQJ5DV DN ATN-224 DMQJ5DV TI TT6RVLG DMQJ5DV TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMQJ5DV MA Inhibitor DMQJ5DV RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMQJ5DV RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMQJBUK DI DMQJBUK DMQJBUK DN CD19-targeting CAR T cells DMQJBUK TI TTW640A DMQJBUK TN B-lymphocyte surface antigen B4 (CD19) DMQJBUK MA CAR-T-Cell-Therapy DMQJBUK RN ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. DMQJBUK RU https://clinicaltrials.gov/ct2/show/NCT02132624 DMQKSGI DI DMQKSGI DMQKSGI DN Myo-inositol DMQKSGI TI TTI0TCK DMQKSGI TN Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) DMQKSGI MA Inhibitor DMQKSGI RN Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50. DMQKSGI RU https://pubmed.ncbi.nlm.nih.gov/9989274 DMQKSGI DI DMQKSGI DMQKSGI DN Myo-inositol DMQKSGI TI TTE4KHA DMQKSGI TN Amyloid beta A4 protein (APP) DMQKSGI MA Inhibitor DMQKSGI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQKSGI RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQKU2F DI DMQKU2F DMQKU2F DN DWP-05195 DMQKU2F TI TTMI6F5 DMQKU2F TN Transient receptor potential cation channel V1 (TRPV1) DMQKU2F MA Antagonist DMQKU2F RN TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 . DMQKU2F RU http://benthamopen.com/contents/pdf/TOPAINJ/TOPAINJ-6-108.pdf DMQKZDT DI DMQKZDT DMQKZDT DN Talnetant DMQKZDT TI TTBPGLU DMQKZDT TN Neuromedin-K receptor (TACR3) DMQKZDT MA Antagonist DMQKZDT RN Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67. DMQKZDT RU https://pubmed.ncbi.nlm.nih.gov/19540857 DMQL3VS DI DMQL3VS DMQL3VS DN BMS-275183 DMQL3VS TI TTML2WA DMQL3VS TN Tubulin (TUB) DMQL3VS MA Inhibitor DMQL3VS RN A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31. DMQL3VS RU https://pubmed.ncbi.nlm.nih.gov/20680660 DMQLZOF DI DMQLZOF DMQLZOF DN PF-06252616 DMQLZOF TI TTSWPH8 DMQLZOF TN Growth/differentiation factor 8 (GDF-8) DMQLZOF RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMQLZOF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMQM3IX DI DMQM3IX DMQM3IX DN SELODENOSON DMQM3IX TI TTK25J1 DMQM3IX TN Adenosine A1 receptor (ADORA1) DMQM3IX MA Agonist DMQM3IX RN Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. DMQM3IX RU https://pubmed.ncbi.nlm.nih.gov/21185259 DMQM7IL DI DMQM7IL DMQM7IL DN SAR245409 DMQM7IL TI TTHBTOP DMQM7IL TN PI3-kinase gamma (PIK3CG) DMQM7IL MA Inhibitor DMQM7IL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). DMQM7IL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156 DMQM7IL DI DMQM7IL DMQM7IL DN SAR245409 DMQM7IL TI TTCJG29 DMQM7IL TN Serine/threonine-protein kinase mTOR (mTOR) DMQM7IL MA Inhibitor DMQM7IL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMQM7IL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMQMF4O DI DMQMF4O DMQMF4O DN PF-04937319 DMQMF4O TI TTDLNGZ DMQMF4O TN Glucokinase (GCK) DMQMF4O MA Modulator DMQMF4O RN Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. DMQMF4O RU https://pubmed.ncbi.nlm.nih.gov/25885172 DMQMTO1 DI DMQMTO1 DMQMTO1 DN MBX-2044 DMQMTO1 TI TTZMAO3 DMQMTO1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMQMTO1 MA Agonist DMQMTO1 RN MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. DMQMTO1 RU https://pubmed.ncbi.nlm.nih.gov/19389808 DMQMV9F DI DMQMV9F DMQMV9F DN Apaxifylline DMQMV9F TI TTK25J1 DMQMV9F TN Adenosine A1 receptor (ADORA1) DMQMV9F MA Antagonist DMQMV9F RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779) DMQMV9F RU http://adisinsight.springer.com/drugs/800004779 DMQMYP5 DI DMQMYP5 DMQMYP5 DN VOFOPITANT HYDROCHLORIDE DMQMYP5 TI TTZPO1L DMQMYP5 TN Substance-P receptor (TACR1) DMQMYP5 MA Antagonist DMQMYP5 RN Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58. DMQMYP5 RU https://pubmed.ncbi.nlm.nih.gov/19428297 DMQO2IT DI DMQO2IT DMQO2IT DN G1T38 DMQO2IT TI TT0PG8F DMQO2IT TN Cyclin-dependent kinase 4 (CDK4) DMQO2IT MA Inhibitor DMQO2IT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO2IT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQO2IT DI DMQO2IT DMQO2IT DN G1T38 DMQO2IT TI TTO0FDJ DMQO2IT TN Cyclin-dependent kinase 6 (CDK6) DMQO2IT MA Inhibitor DMQO2IT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO2IT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TTU0P73 DMQOBH4 TN MHC class I NK cell receptor 2DL2 (CD158b1) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TT4UXPE DMQOBH4 TN MHC class I NK cell receptor 2DL1 (CD158A) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TTEX3SI DMQOBH4 TN MHC class I NK cell receptor 2DL3 (CD158b2) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOTHP DI DMQOTHP DMQOTHP DN AZD9833 DMQOTHP TI TTZAYWL DMQOTHP TN Estrogen receptor (ESR) DMQOTHP MA Degrader DMQOTHP RN Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. J Med Chem. 2020 Dec 10;63(23):14530-14559. DMQOTHP RU https://pubmed.ncbi.nlm.nih.gov/32910656 DMQOXNL DI DMQOXNL DMQOXNL DN LMB763 DMQOXNL TI TTS4UGC DMQOXNL TN Farnesoid X-activated receptor (FXR) DMQOXNL MA Agonist DMQOXNL RN Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880. DMQOXNL RU https://pubmed.ncbi.nlm.nih.gov/31940200 DMQR23W DI DMQR23W DMQR23W DN MRE-0094 DMQR23W TI TTM2AOE DMQR23W TN Adenosine A2a receptor (ADORA2A) DMQR23W MA Agonist DMQR23W RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMQR23W RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMQR9I8 DI DMQR9I8 DMQR9I8 DN G-202 DMQR9I8 TI TT9G4N0 DMQR9I8 TN Glutamate carboxypeptidase II (GCPII) DMQR9I8 MA Inhibitor DMQR9I8 RN National Cancer Institute Drug Dictionary (drug id 666090). DMQR9I8 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=666090 DMQRCX5 DI DMQRCX5 DMQRCX5 DN DCDS-4501A DMQRCX5 TI TTBN5I7 DMQRCX5 TN B-cell-specific glycoprotein B29 (CD79B) DMQRCX5 RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DMQRCX5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DMQSA7H DI DMQSA7H DMQSA7H DN Interferon beta 1a DMQSA7H TI TT4TZ8J DMQSA7H TN Interferon-beta (IFNB1) DMQSA7H MA Modulator DMQSA7H RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQSA7H RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQSC5O DI DMQSC5O DMQSC5O DN Varlilumab DMQSC5O TI TTDO1MV DMQSC5O TN T-cell activation antigen CD27 (CD27) DMQSC5O MA Inhibitor DMQSC5O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSC5O RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMQSIY1 DI DMQSIY1 DMQSIY1 DN CLS003 DMQSIY1 TI TTL3N71 DMQSIY1 TN Virus Replication (Viru Repli) DMQSIY1 MA Inhibitor DMQSIY1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSIY1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQSN7B DI DMQSN7B DMQSN7B DN SR-31747 DMQSN7B TI TT4VQZX DMQSN7B TN Cholestenol delta-isomerase (EBP) DMQSN7B MA Modulator DMQSN7B RN Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302. DMQSN7B RU https://pubmed.ncbi.nlm.nih.gov/9618436 DMQSO4L DI DMQSO4L DMQSO4L DN ML-04 DMQSO4L TI TT2O4W9 DMQSO4L TN Luteinizing hormone receptor (LHCGR) DMQSO4L MA Modulator DMQSO4L RN Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007 Jan;34(1):55-70. DMQSO4L RU https://pubmed.ncbi.nlm.nih.gov/17210462 DMQTREC DI DMQTREC DMQTREC DN Her2-targeted autologous T-cell therapy DMQTREC TI TT6EO5L DMQTREC TN Erbb2 tyrosine kinase receptor (HER2) DMQTREC MA Inhibitor DMQTREC RN A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545. DMQTREC RU https://pubmed.ncbi.nlm.nih.gov/25009822 DMQUWXY DI DMQUWXY DMQUWXY DN CRLX101 DMQUWXY TI TTGTQHC DMQUWXY TN DNA topoisomerase I (TOP1) DMQUWXY MA Modulator DMQUWXY RN Company report (Ceruleanrx) DMQUWXY RU http://ceruleanrx.com/platform-pipeline/crlx101.php DMQV1OU DI DMQV1OU DMQV1OU DN LY-2875358 DMQV1OU TI TTNDSF4 DMQV1OU TN Proto-oncogene c-Met (MET) DMQV1OU RN Clinical pipeline report, company report or official report of Eli Lilly. DMQV1OU RU http://www.lillyoncologypipeline.com/met-antibody.aspx DMQVC3E DI DMQVC3E DMQVC3E DN Salvianolic acid B DMQVC3E TI TTZHNQA DMQVC3E TN Insulin-like growth factor-binding protein 3 (IGFBP3) DMQVC3E MA Inhibitor DMQVC3E RN Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020 Feb;139:98-112. DMQVC3E RU https://pubmed.ncbi.nlm.nih.gov/31982427 DMQVN6P DI DMQVN6P DMQVN6P DN K-604 DMQVN6P TI TTMF541 DMQVN6P TN Liver carboxylesterase (CES1) DMQVN6P MA Inhibitor DMQVN6P RN A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7. DMQVN6P RU https://pubmed.ncbi.nlm.nih.gov/16820149 DMQX5UA DI DMQX5UA DMQX5UA DN FLX-787 DMQX5UA TI TTFRV98 DMQX5UA TN Melanoma antigen gp75 (TYRP1) DMQX5UA MA Activator DMQX5UA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQX5UA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQX5UA DI DMQX5UA DMQX5UA DN FLX-787 DMQX5UA TI TT79AOF DMQX5UA TN Transient receptor potential channel (TRP channel) DMQX5UA MA Agonist DMQX5UA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQX5UA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQXL1T DI DMQXL1T DMQXL1T DN CT 327 DMQXL1T TI TTTDVOJ DMQXL1T TN Tropomyosin-related kinase A (TrkA) DMQXL1T MA Inhibitor DMQXL1T RN Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8. DMQXL1T RU https://pubmed.ncbi.nlm.nih.gov/25594427 DMQXYRG DI DMQXYRG DMQXYRG DN 9-AMINOCAMPTOTHECIN DMQXYRG TI TTGTQHC DMQXYRG TN DNA topoisomerase I (TOP1) DMQXYRG MA Inhibitor DMQXYRG RN Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87. DMQXYRG RU https://pubmed.ncbi.nlm.nih.gov/11193893 DMQZ5HF DI DMQZ5HF DMQZ5HF DN KNI-272 DMQZ5HF TI TT5FNQT DMQZ5HF TN Human immunodeficiency virus Protease (HIV PR) DMQZ5HF MA Modulator DMQZ5HF RN Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activit... Antimicrob Agents Chemother. 2002 Feb;46(2):402-8. DMQZ5HF RU https://www.ncbi.nlm.nih.gov/pubmed/11796349 DMQZJNA DI DMQZJNA DMQZJNA DN LCAR-B38M CAR-T Cell DMQZJNA TI TTZ3P4W DMQZJNA TN B-cell maturation protein (TNFRSF17) DMQZJNA MA CAR-T-Cell-Therapy DMQZJNA RN ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma DMQZJNA RU https://clinicaltrials.gov/ct2/show/NCT03758417 DMQZWYE DI DMQZWYE DMQZWYE DN MRX-4 DMQZWYE TI TT9V5JH DMQZWYE TN Phospholipase A2 (PLA2G1B) DMQZWYE MA Inhibitor DMQZWYE RN Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008 DMQZWYE RU http://www.nature.com/scibx/journal/v1/n41/full/scibx.2008.999.html DMQZXDW DI DMQZXDW DMQZXDW DN Lum001 DMQZXDW TI TTPI1M5 DMQZXDW TN Ileal sodium/bile acid cotransporter (SLC10A2) DMQZXDW MA Inhibitor DMQZXDW RN Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6. DMQZXDW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322589/ DMQZXDW DI DMQZXDW DMQZXDW DN Lum001 DMQZXDW TI TTWZRY5 DMQZXDW TN Sodium/bile acid cotransporter (SLC10A1) DMQZXDW MA Inhibitor DMQZXDW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQZXDW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMR09IH DI DMR09IH DMR09IH DN SRP-9001 DMR09IH TI TT48MP6 DMR09IH TN Dystrophin (DMD) DMR09IH MA Replacement DMR09IH RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMR09IH RU https://www.sarepta.com/products-pipeline/pipeline DMR0N74 DI DMR0N74 DMR0N74 DN LAM-002 DMR0N74 TI TTA4M1N DMR0N74 TN Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) DMR0N74 MA Inhibitor DMR0N74 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR0N74 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR1MIV DI DMR1MIV DMR1MIV DN ASP8062 DMR1MIV TI TTDCVZW DMR1MIV TN Gamma-aminobutyric acid B receptor (GABBR) DMR1MIV MA Modulator DMR1MIV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR1MIV RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMR1MQW DI DMR1MQW DMR1MQW DN Lenzilumab DMR1MQW TI TTNYZG2 DMR1MQW TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMR1MQW MA Antagonist DMR1MQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR1MQW RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMR2YPF DI DMR2YPF DMR2YPF DN ALG-1001 DMR2YPF TI TT9HKJA DMR2YPF TN Vascular endothelial growth factor (VEGF) DMR2YPF MA Modulator DMR2YPF RN Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070. DMR2YPF RU https://pubmed.ncbi.nlm.nih.gov/25802751 DMR37X8 DI DMR37X8 DMR37X8 DN TTP-448 DMR37X8 TI TTMO9HF DMR37X8 TN Advanced glycosylation end product receptor (AGER) DMR37X8 MA Modulator DMR37X8 RN Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. DMR37X8 RU https://pubmed.ncbi.nlm.nih.gov/25586103 DMR3952 DI DMR3952 DMR3952 DN FBS-0701 DMR3952 TI TTQO71U DMR3952 TN Hemoglobin (HB) DMR3952 MA Modulator DMR3952 RN A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52. DMR3952 RU https://pubmed.ncbi.nlm.nih.gov/22919029 DMR3P98 DI DMR3P98 DMR3P98 DN ORG 34517/34850 DMR3P98 TI TTYRL6O DMR3P98 TN Glucocorticoid receptor (NR3C1) DMR3P98 MA Antagonist DMR3P98 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMR3P98 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMR3P98 DI DMR3P98 DMR3P98 DN ORG 34517/34850 DMR3P98 TI TTBFROQ DMR3P98 TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMR3P98 MA Inhibitor DMR3P98 RN A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601. DMR3P98 RU https://pubmed.ncbi.nlm.nih.gov/10944598 DMR4YEG DI DMR4YEG DMR4YEG DN Tesidolumab DMR4YEG TI TTKANGO DMR4YEG TN Complement C5 (CO5) DMR4YEG MA Inhibitor DMR4YEG RN Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 Sep;20(9):2581-2588. DMR4YEG RU https://pubmed.ncbi.nlm.nih.gov/32301258 DMR50I7 DI DMR50I7 DMR50I7 DN Elsamitrucin DMR50I7 TI TT0IHXV DMR50I7 TN DNA topoisomerase II (TOP2) DMR50I7 MA Modulator DMR50I7 RN Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72. DMR50I7 RU https://pubmed.ncbi.nlm.nih.gov/15474012 DMR59I4 DI DMR59I4 DMR59I4 DN BBI-5000 DMR59I4 TI TTQDMX5 DMR59I4 TN Prostaglandin D2 receptor 2 (PTGDR2) DMR59I4 MA Antagonist DMR59I4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR59I4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMR5GSB DI DMR5GSB DMR5GSB DN Tetrahydrouridine DMR5GSB TI TTQ12RK DMR5GSB TN Cytidine deaminase (CDA) DMR5GSB MA Modulator DMR5GSB RN Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424. DMR5GSB RU https://pubmed.ncbi.nlm.nih.gov/22616006 DMR5J6K DI DMR5J6K DMR5J6K DN DAPITANT DMR5J6K TI TTZPO1L DMR5J6K TN Substance-P receptor (TACR1) DMR5J6K MA Antagonist DMR5J6K RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225) DMR5J6K RU http://adisinsight.springer.com/drugs/800004225 DMR69CG DI DMR69CG DMR69CG DN XEN-402 DMR69CG TI TT4G2JS DMR69CG TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMR69CG MA Inhibitor DMR69CG RN Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5. DMR69CG RU https://pubmed.ncbi.nlm.nih.gov/22035805 DMR6USG DI DMR6USG DMR6USG DN PELITREXOL DMR6USG TI TTEXB9Z DMR6USG TN Glycinamide ribonucleotide formyltransferase (GART) DMR6USG MA Inhibitor DMR6USG RN Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075. DMR6USG RU http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3075 DMR7H2V DI DMR7H2V DMR7H2V DN PRX-08066 DMR7H2V TI TT0K1SC DMR7H2V TN 5-HT 2B receptor (HTR2B) DMR7H2V MA Antagonist DMR7H2V RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DMR7H2V RU https://pubmed.ncbi.nlm.nih.gov/17064221 DMR8W7Y DI DMR8W7Y DMR8W7Y DN AKCEA-ANGPTL3-LRX DMR8W7Y TI TTUO98L DMR8W7Y TN Angiopoietin-related protein 3 (ANGPTL3) DMR8W7Y MA Inhibitor DMR8W7Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR8W7Y RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMR8Y4F DI DMR8Y4F DMR8Y4F DN Troplasminogen alfa DMR8Y4F TI TTP86E2 DMR8Y4F TN Plasminogen (PLG) DMR8Y4F MA Modulator DMR8Y4F RN V-10153 (Vernalis). Curr Opin Investig Drugs. 2005 Sep;6(9):951-5. DMR8Y4F RU https://pubmed.ncbi.nlm.nih.gov/16187695 DMR9COG DI DMR9COG DMR9COG DN STX-100 DMR9COG TI TTIQSVM DMR9COG TN Integrin alpha-V/beta-6 (ITGAV/B6) DMR9COG MA Antagonist DMR9COG RN Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896. DMR9COG RU http://www.sciencedirect.com/science/article/pii/S0925443912002281 DMRA3T2 DI DMRA3T2 DMRA3T2 DN GSK2339345 DMRA3T2 TI TTRK8B9 DMRA3T2 TN Sodium channel unspecific (NaC) DMRA3T2 MA Modulator DMRA3T2 RN ClinicalTrials.gov (NCT01494636) The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects. U.S. National Institutes of Health. DMRA3T2 RU https://clinicaltrials.gov/ct2/show/NCT01494636 DMRAFBK DI DMRAFBK DMRAFBK DN PF-04958242 DMRAFBK TI TTAN6JD DMRAFBK TN Glutamate receptor AMPA (GRIA) DMRAFBK MA Activator DMRAFBK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRAFBK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRC0EQ DI DMRC0EQ DMRC0EQ DN Bertilimumab DMRC0EQ TI TTCF05Y DMRC0EQ TN Small-inducible cytokine A11 (CCL11) DMRC0EQ MA Modulator DMRC0EQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRC0EQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRDEKZ DI DMRDEKZ DMRDEKZ DN LY2928057 DMRDEKZ TI TT6Y1PG DMRDEKZ TN Solute carrier family 40 member 1 (SLC40A1) DMRDEKZ MA Modulator DMRDEKZ RN Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400. DMRDEKZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653431/ DMRFK0B DI DMRFK0B DMRFK0B DN SAGE-217b DMRFK0B TI TTGXH6N DMRFK0B TN GABA(A) receptor delta (GABRD) DMRFK0B MA Immunostimulant DMRFK0B RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRFK0B RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRFO34 DI DMRFO34 DMRFO34 DN SR 16234 DMRFO34 TI TTZAYWL DMRFO34 TN Estrogen receptor (ESR) DMRFO34 MA Modulator DMRFO34 RN National Cancer Institute Drug Dictionary (drug id 599816). DMRFO34 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816 DMRFY7I DI DMRFY7I DMRFY7I DN ICA-17043 DMRFY7I TI TTMNI76 DMRFY7I TN Calcium-activated potassium channel (KCN) DMRFY7I MA Inhibitor DMRFY7I RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMRFY7I RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMRFY7I DI DMRFY7I DMRFY7I DN ICA-17043 DMRFY7I TI TT7M9I6 DMRFY7I TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMRFY7I MA Modulator DMRFY7I RN Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9. DMRFY7I RU https://www.ncbi.nlm.nih.gov/pubmed/19236269 DMRG0A3 DI DMRG0A3 DMRG0A3 DN ARQ 531 DMRG0A3 TI TTGM6VW DMRG0A3 TN Tyrosine-protein kinase BTK (ATK) DMRG0A3 MA Inhibitor DMRG0A3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRG0A3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRGQVZ DI DMRGQVZ DMRGQVZ DN Antroquinonol DMRGQVZ TI TT6S2FE DMRGQVZ TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMRGQVZ MA Inhibitor DMRGQVZ RN Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35. DMRGQVZ RU https://pubmed.ncbi.nlm.nih.gov/24784321 DMRGTZ2 DI DMRGTZ2 DMRGTZ2 DN SSTarbaclofen DMRGTZ2 TI TTDCVZW DMRGTZ2 TN Gamma-aminobutyric acid B receptor (GABBR) DMRGTZ2 MA Modulator DMRGTZ2 RN Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128. DMRGTZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/22993295 DMRHD6B DI DMRHD6B DMRHD6B DN SKL-NP DMRHD6B TI TTKLW9S DMRHD6B TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DMRHD6B MA Modulator DMRHD6B RN A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons. Korean J Physiol Pharmacol. 2012 Aug;16(4):237-41. DMRHD6B RU https://pubmed.ncbi.nlm.nih.gov/22915988 DMRIO6D DI DMRIO6D DMRIO6D DN ORMD-0901 DMRIO6D TI TTVIMDE DMRIO6D TN Glucagon-like peptide 1 receptor (GLP1R) DMRIO6D MA Agonist DMRIO6D RN Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23. DMRIO6D RU https://pubmed.ncbi.nlm.nih.gov/21129350 DMRJ5LP DI DMRJ5LP DMRJ5LP DN Vasoactive intestinal peptide DMRJ5LP TI TTCL30I DMRJ5LP TN Vasoactive intestinal polypeptide receptor 1 (VIPR1) DMRJ5LP MA Antagonist DMRJ5LP RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DMRJ5LP RU https://pubmed.ncbi.nlm.nih.gov/17064221 DMRN543 DI DMRN543 DMRN543 DN ISIS-EIF4E DMRN543 TI TTNBTCW DMRN543 TN eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) DMRN543 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMRN543 RU http://www.isispharm.com/index.htm DMRO6XT DI DMRO6XT DMRO6XT DN BGB-290 DMRO6XT TI TTKSAQZ DMRO6XT TN Tankyrase (TNKS) DMRO6XT MA Modulator DMRO6XT RN National Cancer Institute Drug Dictionary (drug id 769217). DMRO6XT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=769217 DMRO6XT DI DMRO6XT DMRO6XT DN BGB-290 DMRO6XT TI TTEBCY8 DMRO6XT TN Poly [ADP-ribose] polymerase (PARP) DMRO6XT MA Inhibitor DMRO6XT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRO6XT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRP3CV DI DMRP3CV DMRP3CV DN Phenylalanine hydroxylase DMRP3CV TI TTGSVH2 DMRP3CV TN Phenylalanine hydroxylase (PAH) DMRP3CV MA Modulator DMRP3CV RN Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44. DMRP3CV RU https://pubmed.ncbi.nlm.nih.gov/24743000 DMRPCF2 DI DMRPCF2 DMRPCF2 DN MGCD265 DMRPCF2 TI TTZPY6J DMRPCF2 TN Tyrosine-protein kinase UFO (AXL) DMRPCF2 MA Modulator DMRPCF2 RN Company report (Mirati Therapeutics: formerly MethylGene) DMRPCF2 RU http://www.mirati.com/programs/mgcd265/ DMRPCF2 DI DMRPCF2 DMRPCF2 DN MGCD265 DMRPCF2 TI TTU8W4S DMRPCF2 TN Protein kinase (PK) DMRPCF2 MA Inhibitor DMRPCF2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRPCF2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRQ0SA DI DMRQ0SA DMRQ0SA DN TT-401 DMRQ0SA TI TTVIMDE DMRQ0SA TN Glucagon-like peptide 1 receptor (GLP1R) DMRQ0SA MA Modulator DMRQ0SA RN Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83. DMRQ0SA RU https://pubmed.ncbi.nlm.nih.gov/24083687 DMRQ0SA DI DMRQ0SA DMRQ0SA DN TT-401 DMRQ0SA TI TT9O6WS DMRQ0SA TN Glucagon receptor (GCGR) DMRQ0SA MA Agonist DMRQ0SA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ0SA RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRQGMZ DI DMRQGMZ DMRQGMZ DN HD-003 DMRQGMZ TI TT20DOQ DMRQGMZ TN Hydroxy radical elimination (HYRE) DMRQGMZ MA Modulator DMRQGMZ RN Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. DMRQGMZ RU https://pubmed.ncbi.nlm.nih.gov/22466296 DMRQUH4 DI DMRQUH4 DMRQUH4 DN NI-0801 DMRQUH4 TI TTQOVYA DMRQUH4 TN C-X-C motif chemokine 10 (CXCL10) DMRQUH4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267) DMRQUH4 RU http://adisinsight.springer.com/drugs/800029267 DMRSG31 DI DMRSG31 DMRSG31 DN BCX-3408 DMRSG31 TI TTMCF1Y DMRSG31 TN Purine nucleoside phosphorylase (PNP) DMRSG31 MA Inhibitor DMRSG31 RN BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008. DMRSG31 RU http://ash.confex.com/ash/2008/webprogram/Paper7315.html DMRSK2I DI DMRSK2I DMRSK2I DN MGCD290 DMRSK2I TI TTVO9RI DMRSK2I TN Fungal Probable histone deacetylase HOS2 (Fung HOS2) DMRSK2I MA Inhibitor DMRSK2I RN Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009 Dec;47(12):3797-804. DMRSK2I RU https://pubmed.ncbi.nlm.nih.gov/19794038 DMRSN2C DI DMRSN2C DMRSN2C DN MB-12066 DMRSN2C TI TTUF2HO DMRSN2C TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMRSN2C MA Modulator DMRSN2C RN Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953. DMRSN2C RU https://www.ncbi.nlm.nih.gov/pubmed/23762270 DMRSU4X DI DMRSU4X DMRSU4X DN Salirasib DMRSU4X TI TTW2R9X DMRSU4X TN GTPase NRas (NRAS) DMRSU4X MA Antagonist DMRSU4X RN The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89. DMRSU4X RU https://pubmed.ncbi.nlm.nih.gov/18374183 DMRSU4X DI DMRSU4X DMRSU4X DN Salirasib DMRSU4X TI TTCJG29 DMRSU4X TN Serine/threonine-protein kinase mTOR (mTOR) DMRSU4X MA Modulator DMRSU4X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMRSU4X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMRT28X DI DMRT28X DMRT28X DN ONO-6126 DMRT28X TI TTV5CGO DMRT28X TN Phosphodiesterase 4 (PDE4) DMRT28X MA Inhibitor DMRT28X RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMRT28X RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMRT8K4 DI DMRT8K4 DMRT8K4 DN MK-0812 DMRT8K4 TI TTFZYTO DMRT8K4 TN C-C chemokine receptor type 2 (CCR2) DMRT8K4 MA Antagonist DMRT8K4 RN Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10. DMRT8K4 RU https://pubmed.ncbi.nlm.nih.gov/19913021 DMRTD7I DI DMRTD7I DMRTD7I DN PLX8394 DMRTD7I TI TTWCGQT DMRTD7I TN Serine/threonine-protein kinase B-raf (BRAF) DMRTD7I MA Inhibitor DMRTD7I RN Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62. DMRTD7I RU https://pubmed.ncbi.nlm.nih.gov/24283590 DMRVEHY DI DMRVEHY DMRVEHY DN LY3012212 DMRVEHY TI TT2Q6G1 DMRVEHY TN Vascular endothelial growth factor receptor 1 (FLT-1) DMRVEHY MA Modulator DMRVEHY RN Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11. DMRVEHY RU https://pubmed.ncbi.nlm.nih.gov/23903897 DMRWE5D DI DMRWE5D DMRWE5D DN SB-728-T DMRWE5D TI TT2CEJG DMRWE5D TN C-C chemokine receptor type 5 (CCR5) DMRWE5D MA Modulator DMRWE5D RN Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910. DMRWE5D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084652/ DMRWG8B DI DMRWG8B DMRWG8B DN BNT321 DMRWG8B TI TTD9I12 DMRWG8B TN Carbohydrate antigen 19-9 (CA 19-9) DMRWG8B MA Inhibitor DMRWG8B RN Clinical pipeline report, company report or official report of BioNTech. DMRWG8B RU https://biontech.de/science/pipeline DMRXCUQ DI DMRXCUQ DMRXCUQ DN SPL-108 DMRXCUQ TI TTWFBT7 DMRXCUQ TN Extracellular matrix receptor III (CD44) DMRXCUQ MA Inhibitor DMRXCUQ RN Clinical pipeline report, company report or official report of Splash Pharmaceuticals. DMRXCUQ RU http://www.splashpharma.com/new-page DMRYH3M DI DMRYH3M DMRYH3M DN ADP-A2M4 DMRYH3M TI TT9EQUY DMRYH3M TN Melanoma-associated antigen 4 (MAGEA4) DMRYH3M RN Clinical pipeline report, company report or official report of Adaptimmune. DMRYH3M RU https://www.adaptimmune.com/pipeline/adp-a2m4 DMRYHWI DI DMRYHWI DMRYHWI DN SB-705498 DMRYHWI TI TTMI6F5 DMRYHWI TN Transient receptor potential cation channel V1 (TRPV1) DMRYHWI MA Blocker DMRYHWI RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMRYHWI RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMRYLBW DI DMRYLBW DMRYLBW DN NTO-1151 DMRYLBW TI TTRBUYN DMRYLBW TN Ribonuclease (RNase) DMRYLBW MA Modulator DMRYLBW RN Clinical pipeline report, company report or official report of Nanotherapeutics. DMRYLBW RU http://www.nanotherapeutics.com/triapine/ DMRZA6G DI DMRZA6G DMRZA6G DN S-8921 DMRZA6G TI TTPI1M5 DMRZA6G TN Ileal sodium/bile acid cotransporter (SLC10A2) DMRZA6G MA Inhibitor DMRZA6G RN Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11. DMRZA6G RU https://pubmed.ncbi.nlm.nih.gov/9714138 DMRZBPI DI DMRZBPI DMRZBPI DN YM-543 DMRZBPI TI TTLWPVF DMRZBPI TN Sodium/glucose cotransporter 2 (SGLT2) DMRZBPI MA Modulator DMRZBPI RN Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183. DMRZBPI RU https://www.ncbi.nlm.nih.gov/pubmed/23374077 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTUV8G9 DMRZLU4 TN Progesterone receptor (PGR) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTYRL6O DMRZLU4 TN Glucocorticoid receptor (NR3C1) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTKPW01 DMRZLU4 TN Androgen receptor messenger RNA (AR mRNA) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTHL6YX DMRZLU4 TN Progesterone (PG) DMRZLU4 MA Antagonist DMRZLU4 RN Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/23788750 DMS01AX DI DMS01AX DMS01AX DN CERE-120 DMS01AX TI TTWFC4G DMS01AX TN Netrin (NET) DMS01AX MA Modulator DMS01AX RN Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007 Jan;15(1):62-8. DMS01AX RU https://pubmed.ncbi.nlm.nih.gov/17164776 DMS0GA6 DI DMS0GA6 DMS0GA6 DN AMY-101 DMS0GA6 TI TTJGY7A DMS0GA6 TN Complement C3 (CO3) DMS0GA6 MA Inhibitor DMS0GA6 RN The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450. DMS0GA6 RU https://pubmed.ncbi.nlm.nih.gov/32360516 DMS1YPZ DI DMS1YPZ DMS1YPZ DN SAR391786 DMS1YPZ TI TTSWPH8 DMS1YPZ TN Growth/differentiation factor 8 (GDF-8) DMS1YPZ RN Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63. DMS1YPZ RU https://pubmed.ncbi.nlm.nih.gov/20190380 DMS2MQ5 DI DMS2MQ5 DMS2MQ5 DN BGC-20-1531 DMS2MQ5 TI TT79WV3 DMS2MQ5 TN Prostaglandin E2 receptor EP4 (PTGER4) DMS2MQ5 MA Antagonist DMS2MQ5 RN BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327. DMS2MQ5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697835/ DMS2Q9G DI DMS2Q9G DMS2Q9G DN PHA848125 DMS2Q9G TI TT7HF4W DMS2Q9G TN Cyclin-dependent kinase 2 (CDK2) DMS2Q9G MA Inhibitor DMS2Q9G RN Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63. DMS2Q9G RU https://pubmed.ncbi.nlm.nih.gov/19603809 DMS2WB5 DI DMS2WB5 DMS2WB5 DN CX157 DMS2WB5 TI TT3WG5C DMS2WB5 TN Monoamine oxidase type A (MAO-A) DMS2WB5 MA Inhibitor DMS2WB5 RN Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31. DMS2WB5 RU https://pubmed.ncbi.nlm.nih.gov/19890267 DMS2WIN DI DMS2WIN DMS2WIN DN Delphinidin DMS2WIN TI TTUTJGQ DMS2WIN TN Vascular endothelial growth factor receptor 2 (KDR) DMS2WIN MA Modulator DMS2WIN RN Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis. 2006 May;27(5):989-96. DMS2WIN RU https://pubmed.ncbi.nlm.nih.gov/16308314 DMS34YO DI DMS34YO DMS34YO DN PM184 DMS34YO TI TTHVQ4N DMS34YO TN Tubulin polymerization (TubP) DMS34YO MA Inhibitor DMS34YO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS34YO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS4XFI DI DMS4XFI DMS4XFI DN OPT-302 DMS4XFI TI TT0QUFV DMS4XFI TN Vascular endothelial growth factor C (VEGFC) DMS4XFI MA Inhibitor DMS4XFI RN Clinical pipeline report, company report or official report of Opthea. DMS4XFI RU https://opthea.com/ DMS4XFI DI DMS4XFI DMS4XFI DN OPT-302 DMS4XFI TI TTOM5H4 DMS4XFI TN Vascular endothelial growth factor D (VEGFD) DMS4XFI MA Inhibitor DMS4XFI RN Clinical pipeline report, company report or official report of Opthea. DMS4XFI RU https://opthea.com/ DMS610L DI DMS610L DMS610L DN PF-04691502 DMS610L TI TTCJG29 DMS610L TN Serine/threonine-protein kinase mTOR (mTOR) DMS610L MA Modulator DMS610L RN PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99. DMS610L RU https://www.ncbi.nlm.nih.gov/pubmed/21750219 DMS610L DI DMS610L DMS610L DN PF-04691502 DMS610L TI TTHBTOP DMS610L TN PI3-kinase gamma (PIK3CG) DMS610L MA Modulator DMS610L RN PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99. DMS610L RU https://www.ncbi.nlm.nih.gov/pubmed/21750219 DMS6E9J DI DMS6E9J DMS6E9J DN Lefitolimod DMS6E9J TI TTSHG0T DMS6E9J TN Toll-like receptor 9 (TLR9) DMS6E9J MA Agonist DMS6E9J RN Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096. DMS6E9J RU https://pubmed.ncbi.nlm.nih.gov/31741757 DMS6ZA0 DI DMS6ZA0 DMS6ZA0 DN BTD-001 DMS6ZA0 TI TTCI43M DMS6ZA0 TN GABA(A) receptor (GABAR) DMS6ZA0 MA Antagonist DMS6ZA0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS6ZA0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMS7609 DI DMS7609 DMS7609 DN YM-358 DMS7609 TI TT8DBY3 DMS7609 TN Angiotensin II receptor type-1 (AGTR1) DMS7609 MA Antagonist DMS7609 RN Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. DMS7609 RU https://pubmed.ncbi.nlm.nih.gov/10706380 DMS7FRI DI DMS7FRI DMS7FRI DN Methanesulfonyl fluoride DMS7FRI TI TT1RS9F DMS7FRI TN Acetylcholinesterase (AChE) DMS7FRI MA Inhibitor DMS7FRI RN A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. Br J Clin Pharmacol. 2013 May;75(5):1231-9. DMS7FRI RU https://pubmed.ncbi.nlm.nih.gov/23116458 DMS8Q7A DI DMS8Q7A DMS8Q7A DN Ontazolast DMS8Q7A TI TTTWGIX DMS8Q7A TN Leukotriene receptor (LTR) DMS8Q7A MA Modulator DMS8Q7A RN Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64. DMS8Q7A RU https://pubmed.ncbi.nlm.nih.gov/9110922 DMS9BDQ DI DMS9BDQ DMS9BDQ DN Tipelukast DMS9BDQ TI TT2J34L DMS9BDQ TN Arachidonate 5-lipoxygenase (5-LOX) DMS9BDQ MA Modulator DMS9BDQ RN Company report (MediciNova) DMS9BDQ RU http://medicinova.com/clinical-development/core/mn-001-nash/ DMS9BDQ DI DMS9BDQ DMS9BDQ DN Tipelukast DMS9BDQ TI TTZCG4L DMS9BDQ TN Phosphodiesterase 3 (PDE3) DMS9BDQ MA Modulator DMS9BDQ RN Company report (MediciNova) DMS9BDQ RU http://medicinova.com/clinical-development/core/mn-001-nash/ DMS9Y1T DI DMS9Y1T DMS9Y1T DN DG-17 DMS9Y1T TI TT5FNQT DMS9Y1T TN Human immunodeficiency virus Protease (HIV PR) DMS9Y1T MA Inhibitor DMS9Y1T RN Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999 April 16; 13(6): 661-667. DMS9Y1T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566777/ DMSA2LZ DI DMSA2LZ DMSA2LZ DN TPI-1020 DMSA2LZ TI TTYRL6O DMSA2LZ TN Glucocorticoid receptor (NR3C1) DMSA2LZ MA Antagonist DMSA2LZ RN Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br J Pharmacol. 2012 Oct;167(3):515-26. DMSA2LZ RU https://pubmed.ncbi.nlm.nih.gov/22563753 DMSABRI DI DMSABRI DMSABRI DN CERC-301 DMSABRI TI TTN9D8E DMSABRI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMSABRI MA Antagonist DMSABRI RN Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8. DMSABRI RU https://pubmed.ncbi.nlm.nih.gov/26325093 DMSBLOU DI DMSBLOU DMSBLOU DN AEG-33773 DMSBLOU TI TTHYBIX DMSBLOU TN Heat shock protein 70 (HSP70) DMSBLOU MA Inhibitor DMSBLOU RN Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009 DMSBLOU RU http://www.nature.com/scibx/journal/v2/n11/full/scibx.2009.462.html DMSBNTZ DI DMSBNTZ DMSBNTZ DN CBX-129801 DMSBNTZ TI TTKF4WV DMSBNTZ TN Connecting peptide (C-peptide) DMSBNTZ MA Modulator DMSBNTZ RN ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health. DMSBNTZ RU https://clinicaltrials.gov/ct2/show/NCT01681290 DMSBPJI DI DMSBPJI DMSBPJI DN BL-7040 DMSBPJI TI TTSHG0T DMSBPJI TN Toll-like receptor 9 (TLR9) DMSBPJI MA Activator DMSBPJI RN Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14. DMSBPJI RU https://pubmed.ncbi.nlm.nih.gov/26003847 DMSC7TN DI DMSC7TN DMSC7TN DN Rimacalib DMSC7TN TI TTFYL58 DMSC7TN TN CaM-kinase II (CAMK2) DMSC7TN MA Modulator DMSC7TN RN Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci. 2009 Sep;1173:706-11. DMSC7TN RU https://pubmed.ncbi.nlm.nih.gov/19758219 DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTRMX3V DMSCR2H TN Janus kinase 2 (JAK-2) DMSCR2H MA Modulator DMSCR2H RN Company report (Portola Pharmaceuticals) DMSCR2H RU https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/ DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTOU65C DMSCR2H TN Tyrosine-protein kinase SYK (SYK) DMSCR2H MA Modulator DMSCR2H RN Company report (Portola Pharmaceuticals) DMSCR2H RU https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/ DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTT7PJU DMSCR2H TN Janus kinase 3 (JAK-3) DMSCR2H MA Inhibitor DMSCR2H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSCR2H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TT6DM01 DMSCR2H TN Janus kinase 1 (JAK-1) DMSCR2H MA Inhibitor DMSCR2H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSCR2H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSE9TH DI DMSE9TH DMSE9TH DN MT-1303 DMSE9TH TI TT9JZCK DMSE9TH TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMSE9TH MA Modulator DMSE9TH RN Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75. DMSE9TH RU https://pubmed.ncbi.nlm.nih.gov/26239599 DMSEVBH DI DMSEVBH DMSEVBH DN Lersivirine DMSEVBH TI TT84ETX DMSEVBH TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSEVBH MA Inhibitor DMSEVBH RN Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95. DMSEVBH RU https://pubmed.ncbi.nlm.nih.gov/21095483 DMSF10P DI DMSF10P DMSF10P DN RGN-259 DMSF10P TI TTH5WZF DMSF10P TN Actin (ACT) DMSF10P MA Modulator DMSF10P RN Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6. DMSF10P RU https://pubmed.ncbi.nlm.nih.gov/25826322 DMSF7WJ DI DMSF7WJ DMSF7WJ DN CL-329167 DMSF7WJ TI TT8DBY3 DMSF7WJ TN Angiotensin II receptor type-1 (AGTR1) DMSF7WJ MA Antagonist DMSF7WJ RN Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52. DMSF7WJ RU https://pubmed.ncbi.nlm.nih.gov/8067441 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TT8FYO9 DMSFWT7 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTGJCWZ DMSFWT7 TN Fms-like tyrosine kinase 3 (FLT-3) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTX41N9 DMSFWT7 TN Tyrosine-protein kinase Kit (KIT) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTI7421 DMSFWT7 TN Platelet-derived growth factor receptor beta (PDGFRB) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TT2Q6G1 DMSFWT7 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTDCBX5 DMSFWT7 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTUTJGQ DMSFWT7 TN Vascular endothelial growth factor receptor 2 (KDR) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSGFOY DI DMSGFOY DMSGFOY DN Coltuximab ravtansine DMSGFOY TI TTW640A DMSGFOY TN B-lymphocyte surface antigen B4 (CD19) DMSGFOY MA Inhibitor DMSGFOY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSGFOY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TT7HF4W DMSH108 TN Cyclin-dependent kinase 2 (CDK2) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTQYF7G DMSH108 TN Cyclin-dependent kinase 7 (CDK7) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTH6V3D DMSH108 TN Cyclin-dependent kinase 1 (CDK1) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTMBO1Z DMSH108 TN Cyclin-dependent kinase (CDK) DMSH108 MA Inhibitor DMSH108 RN Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19470731 DMSHE70 DI DMSHE70 DMSHE70 DN GSK2141795 DMSHE70 TI TTAZ05C DMSHE70 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMSHE70 MA Modulator DMSHE70 RN Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7. DMSHE70 RU https://pubmed.ncbi.nlm.nih.gov/21572779 DMSHGWN DI DMSHGWN DMSHGWN DN Lintopride DMSHGWN TI TT07C3Y DMSHGWN TN 5-HT 4 receptor (HTR4) DMSHGWN MA Modulator DMSHGWN RN The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. DMSHGWN RU https://pubmed.ncbi.nlm.nih.gov/8580279 DMSHGWN DI DMSHGWN DMSHGWN DN Lintopride DMSHGWN TI TTNXLKE DMSHGWN TN 5-HT 3 receptor (5HT3R) DMSHGWN MA Modulator DMSHGWN RN The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. DMSHGWN RU https://pubmed.ncbi.nlm.nih.gov/8580279 DMSHV9C DI DMSHV9C DMSHV9C DN CCX-354 DMSHV9C TI TTC24WT DMSHV9C TN C-C chemokine receptor type 1 (CCR1) DMSHV9C MA Antagonist DMSHV9C RN Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44. DMSHV9C RU https://pubmed.ncbi.nlm.nih.gov/22589376 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TT6EO5L DMSI8N3 TN Erbb2 tyrosine kinase receptor (HER2) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TT0JESD DMSI8N3 TN Erbb4 tyrosine kinase receptor (Erbb-4) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TTGKNB4 DMSI8N3 TN Epidermal growth factor receptor (EGFR) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TTWTSCV DMSI8N3 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSIGAB DI DMSIGAB DMSIGAB DN L-alanosine DMSIGAB TI TTEWTCR DMSIGAB TN Adenine synthesis (Adeni synth) DMSIGAB MA Modulator DMSIGAB RN Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006 Feb;5(2):337-46. DMSIGAB RU https://pubmed.ncbi.nlm.nih.gov/16505107 DMSIXG4 DI DMSIXG4 DMSIXG4 DN TT-173 DMSIXG4 TI TT38MDJ DMSIXG4 TN Tissue factor (F3) DMSIXG4 MA Modulator DMSIXG4 RN TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63. DMSIXG4 RU https://pubmed.ncbi.nlm.nih.gov/26374745 DMSJ3Z5 DI DMSJ3Z5 DMSJ3Z5 DN REGN1979 DMSJ3Z5 TI TTUE541 DMSJ3Z5 TN Leukocyte surface antigen Leu-16 (CD20) DMSJ3Z5 MA Inhibitor DMSJ3Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJ3Z5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSJOE3 DI DMSJOE3 DMSJOE3 DN LM-030 DMSJOE3 TI TT5L2VC DMSJOE3 TN Kallikrein-related peptidase (KLK) DMSJOE3 MA Inhibitor DMSJOE3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJOE3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSJU5B DI DMSJU5B DMSJU5B DN RP-L102 DMSJU5B TI TTV5HJS DMSJU5B TN Fanconi anemia group A protein (FANCA) DMSJU5B MA Replacement DMSJU5B RN Clinical pipeline report, company report or official report of Rocket Pharmaceuticals. DMSJU5B RU https://rocketpharma.com/our-disease-focus/ DMSKMET DI DMSKMET DMSKMET DN Gimatecan DMSKMET TI TTGTQHC DMSKMET TN DNA topoisomerase I (TOP1) DMSKMET MA Inhibitor DMSKMET RN Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol. 2013 May 15;85(10):1433-40. DMSKMET RU https://pubmed.ncbi.nlm.nih.gov/23466420 DMSL3DX DI DMSL3DX DMSL3DX DN GS-5885 DMSL3DX TI TTCJ2X8 DMSL3DX TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSL3DX MA Modulator DMSL3DX RN Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46. DMSL3DX RU https://pubmed.ncbi.nlm.nih.gov/24320933 DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TTSQIFT DMSLIW6 TN 5-HT 1A receptor (HTR1A) DMSLIW6 MA Antagonist DMSLIW6 RN Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015. DMSLIW6 RU http://minervaneurosciences.com/ DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TT3ROYC DMSLIW6 TN Serotonin transporter (SERT) DMSLIW6 MA Inhibitor DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TTVBI8W DMSLIW6 TN Dopamine transporter (DAT) DMSLIW6 MA Inhibitor DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TT85JO3 DMSLIW6 TN 5-HT receptor (5HTR) DMSLIW6 MA Antagonist DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLMY7 DI DMSLMY7 DMSLMY7 DN 11C-PBR-28 DMSLMY7 TI TTPTXIN DMSLMY7 TN Translocator protein (TSPO) DMSLMY7 MA Binder DMSLMY7 RN PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett. 2007 Jan 16;411(3):200-5. DMSLMY7 RU https://pubmed.ncbi.nlm.nih.gov/17127001 DMSMCXN DI DMSMCXN DMSMCXN DN HBV vaccine DMSMCXN TI TT3J5ZI DMSMCXN TN Cell mediated immunity response (CMIR) DMSMCXN RN ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health. DMSMCXN RU https://clinicaltrials.gov/ct2/show/NCT00508833 DMSO846 DI DMSO846 DMSO846 DN Orvepitant DMSO846 TI TTZPO1L DMSO846 TN Substance-P receptor (TACR1) DMSO846 MA Antagonist DMSO846 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMSO846 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMSOPAU DI DMSOPAU DMSOPAU DN Pyrazoloacridine DMSOPAU TI TT0IHXV DMSOPAU TN DNA topoisomerase II (TOP2) DMSOPAU MA Modulator DMSOPAU RN Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91. DMSOPAU RU https://pubmed.ncbi.nlm.nih.gov/9533538 DMSPWX6 DI DMSPWX6 DMSPWX6 DN MK-5172 DMSPWX6 TI TT5FNQT DMSPWX6 TN Human immunodeficiency virus Protease (HIV PR) DMSPWX6 MA Inhibitor DMSPWX6 RN Clinical pipeline report, company report or official report of Merck (2011). DMSPWX6 RU http://www.merck.com/index.html DMSRC5D DI DMSRC5D DMSRC5D DN IDX899 DMSRC5D TI TT84ETX DMSRC5D TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSRC5D MA Modulator DMSRC5D RN Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78. DMSRC5D RU https://www.ncbi.nlm.nih.gov/pubmed/24158593 DMSROM4 DI DMSROM4 DMSROM4 DN BHQ880 DMSROM4 TI TTE3RAC DMSROM4 TN Dickkopf-related protein 1 (DKK1) DMSROM4 MA Inhibitor DMSROM4 RN Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9. DMSROM4 RU https://pubmed.ncbi.nlm.nih.gov/19417213 DMSRVXO DI DMSRVXO DMSRVXO DN BMS-986263 DMSRVXO TI TTPSWQG DMSRVXO TN SERPINH1 messenger RNA (SERPINH1 mRNA) DMSRVXO MA Inhibitor DMSRVXO RN A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. AAPS J. 2019 Jul 22;21(5):92. DMSRVXO RU https://pubmed.ncbi.nlm.nih.gov/31332587 DMST4OR DI DMST4OR DMST4OR DN Selgantolimod DMST4OR TI TT8CWFK DMST4OR TN Toll-like receptor 8 (TLR8) DMST4OR MA Agonist DMST4OR RN Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203. DMST4OR RU https://pubmed.ncbi.nlm.nih.gov/32407112 DMSTH01 DI DMSTH01 DMSTH01 DN Rocilinostat DMSTH01 TI TTBH0VX DMSTH01 TN Histone deacetylase (HDAC) DMSTH01 MA Inhibitor DMSTH01 RN National Cancer Institute Drug Dictionary (drug id 698408). DMSTH01 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=698408 DMSTHG1 DI DMSTHG1 DMSTHG1 DN VX-371 DMSTHG1 TI TTQM7TE DMSTHG1 TN Amiloride-sensitive sodium channel (ENaC) DMSTHG1 MA Inhibitor DMSTHG1 RN The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652. DMSTHG1 RU https://pubmed.ncbi.nlm.nih.gov/29599187 DMSTJ6Q DI DMSTJ6Q DMSTJ6Q DN INX-189 DMSTJ6Q TI TTMVBWH DMSTJ6Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMSTJ6Q MA Inhibitor DMSTJ6Q RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMSTJ6Q RU http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa DMSUB64 DI DMSUB64 DMSUB64 DN BAY 57-1293 DMSUB64 TI TTKCVJR DMSUB64 TN Herpes simplex virus Helicase-primase (HSV UL8) DMSUB64 MA Inhibitor DMSUB64 RN Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40. DMSUB64 RU https://pubmed.ncbi.nlm.nih.gov/15266895 DMSUQFJ DI DMSUQFJ DMSUQFJ DN SBI-087 DMSUQFJ TI TTUE541 DMSUQFJ TN Leukocyte surface antigen Leu-16 (CD20) DMSUQFJ MA Inhibitor DMSUQFJ RN Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208. DMSUQFJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730845/ DMSV60C DI DMSV60C DMSV60C DN MEDI0382 DMSV60C TI TT0NUFM DMSV60C TN Glucagon (GCG) DMSV60C MA Agonist DMSV60C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSV60C RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMSVWI7 DI DMSVWI7 DMSVWI7 DN Neladenoson bialanate DMSVWI7 TI TT92EIB DMSVWI7 TN ADORA1 messenger RNA (ADORA1 mRNA) DMSVWI7 MA Agonist DMSVWI7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSVWI7 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMSW5XJ DI DMSW5XJ DMSW5XJ DN RV521 DMSW5XJ TI TT57ID8 DMSW5XJ TN Respiratory syncytial virus protein F (RSV F) DMSW5XJ MA Inhibitor DMSW5XJ RN Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676. DMSW5XJ RU https://pubmed.ncbi.nlm.nih.gov/33729773 DMSWLM5 DI DMSWLM5 DMSWLM5 DN CP-122721 DMSWLM5 TI TTZPO1L DMSWLM5 TN Substance-P receptor (TACR1) DMSWLM5 MA Antagonist DMSWLM5 RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMSWLM5 RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMSWPA6 DI DMSWPA6 DMSWPA6 DN Superoxide dismutase DMSWPA6 TI TT6RVLG DMSWPA6 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMSWPA6 MA Modulator DMSWPA6 RN Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36. DMSWPA6 RU https://www.ncbi.nlm.nih.gov/pubmed/21574914 DMSWUNX DI DMSWUNX DMSWUNX DN Naratuximab emtansine DMSWUNX TI TTFCW29 DMSWUNX TN Leukocyte antigen CD37 (CD37) DMSWUNX MA Inhibitor DMSWUNX RN Clinical pipeline report, company report or official report of Debiopharm. DMSWUNX RU https://www.debiopharm.com/drug-development/pipeline/debio-1562/ DMSZFTP DI DMSZFTP DMSZFTP DN Met-enkephalin DMSZFTP TI TT27RFC DMSZFTP TN Opioid receptor delta (OPRD1) DMSZFTP MA Agonist DMSZFTP RN Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9. DMSZFTP RU https://pubmed.ncbi.nlm.nih.gov/7813576 DMSZFTP DI DMSZFTP DMSZFTP DN Met-enkephalin DMSZFTP TI TTKWM86 DMSZFTP TN Opioid receptor mu (MOP) DMSZFTP MA Inhibitor DMSZFTP RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMSZFTP RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMSZOXQ DI DMSZOXQ DMSZOXQ DN Baminercept DMSZOXQ TI TTFO0PM DMSZOXQ TN Lymphotoxin beta receptor (LTBR) DMSZOXQ MA Antagonist DMSZOXQ RN ClinicalTrials.gov (NCT01552681) Baminercept in Sj ren's Syndrome. U.S. National Institutes of Health. DMSZOXQ RU https://clinicaltrials.gov/ct2/show/NCT01552681 DMSZQHX DI DMSZQHX DMSZQHX DN BI-505 DMSZQHX TI TTCT6F7 DMSZQHX TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMSZQHX RN A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. DMSZQHX RU https://pubmed.ncbi.nlm.nih.gov/23597564 DMSZQHX DI DMSZQHX DMSZQHX DN BI-505 DMSZQHX TI TTZPY6J DMSZQHX TN Tyrosine-protein kinase UFO (AXL) DMSZQHX MA Inhibitor DMSZQHX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSZQHX RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMT0K4F DI DMT0K4F DMT0K4F DN MTR105 DMT0K4F TI TTCM4B3 DMT0K4F TN Nitric-oxide synthase endothelial (NOS3) DMT0K4F MA Inhibitor DMT0K4F RN Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7. DMT0K4F RU https://pubmed.ncbi.nlm.nih.gov/18434722 DMT1OZ6 DI DMT1OZ6 DMT1OZ6 DN MK-2206 DMT1OZ6 TI TTAZ05C DMT1OZ6 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMT1OZ6 MA Modulator DMT1OZ6 RN First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95. DMT1OZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/22025163 DMT1OZ6 DI DMT1OZ6 DMT1OZ6 DN MK-2206 DMT1OZ6 TI TT0A1R8 DMT1OZ6 TN E2 ubiquitin-conjugating enzyme T (UBE2T) DMT1OZ6 MA Inhibitor DMT1OZ6 RN UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72. DMT1OZ6 RU https://pubmed.ncbi.nlm.nih.gov/26943030 DMT1ZX0 DI DMT1ZX0 DMT1ZX0 DN RG1577 DMT1ZX0 TI TTGP7BY DMT1ZX0 TN Monoamine oxidase type B (MAO-B) DMT1ZX0 MA Modulator DMT1ZX0 RN Sembragiline Alzheimer's Disease (Phase 2). Evotech AG, Roche. DMT1ZX0 RU http://www.alzforum.org/therapeutics/sembragiline DMT3KB4 DI DMT3KB4 DMT3KB4 DN Lobeline DMT3KB4 TI TTNZRI3 DMT3KB4 TN Synaptic vesicle amine transporter (SLC18A2) DMT3KB4 MA Inhibitor DMT3KB4 RN Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27. DMT3KB4 RU https://pubmed.ncbi.nlm.nih.gov/21050177 DMT3ORQ DI DMT3ORQ DMT3ORQ DN CP-80794 DMT3ORQ TI TTB2MXP DMT3ORQ TN Angiotensinogenase renin (REN) DMT3ORQ MA Inhibitor DMT3ORQ RN Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1992 Jul;20(1):75-82. DMT3ORQ RU https://pubmed.ncbi.nlm.nih.gov/1383634 DMT3S10 DI DMT3S10 DMT3S10 DN AN0128 DMT3S10 TI TTF8CQI DMT3S10 TN Tumor necrosis factor (TNF) DMT3S10 MA Inhibitor DMT3S10 RN Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52. DMT3S10 RU https://pubmed.ncbi.nlm.nih.gov/18218841 DMT4FI5 DI DMT4FI5 DMT4FI5 DN SAR-566658 DMT4FI5 TI TTBHFYQ DMT4FI5 TN Mucin-1 (MUC1) DMT4FI5 RN Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73. DMT4FI5 RU http://mct.aacrjournals.org/content/12/11_Supplement/A73.short DMT4MKF DI DMT4MKF DMT4MKF DN Emibetuzumab DMT4MKF TI TTNDSF4 DMT4MKF TN Proto-oncogene c-Met (MET) DMT4MKF MA Inhibitor DMT4MKF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT4MKF RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMT4OPL DI DMT4OPL DMT4OPL DN Tonabersat DMT4OPL TI TT6MSOK DMT4OPL TN 5-HT 1D receptor (HTR1D) DMT4OPL MA Agonist DMT4OPL RN The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia. 2000 Jul;20(6):538-45. DMT4OPL RU https://pubmed.ncbi.nlm.nih.gov/11075836 DMT4QRD DI DMT4QRD DMT4QRD DN RG-4929 DMT4QRD TI TTN7BL9 DMT4QRD TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMT4QRD MA Inhibitor DMT4QRD RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMT4QRD RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMT4UC1 DI DMT4UC1 DMT4UC1 DN Sibrotuzumab DMT4UC1 TI TTGPQ0F DMT4UC1 TN Prolyl endopeptidase FAP (FAP) DMT4UC1 MA Inhibitor DMT4UC1 RN A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. DMT4UC1 RU https://pubmed.ncbi.nlm.nih.gov/12738716 DMT5QSD DI DMT5QSD DMT5QSD DN Resimmune DMT5QSD TI TTZAT79 DMT5QSD TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMT5QSD MA Modulator DMT5QSD RN Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800. DMT5QSD RU https://www.ncbi.nlm.nih.gov/pubmed/25795722 DMT5QYJ DI DMT5QYJ DMT5QYJ DN ATI-2173 DMT5QYJ TI TTT4SY6 DMT5QYJ TN Hepatitis B virus Polymerase (HBV P) DMT5QYJ MA Inhibitor DMT5QYJ RN ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20. DMT5QYJ RU https://pubmed.ncbi.nlm.nih.gov/32540975 DMT5YK7 DI DMT5YK7 DMT5YK7 DN GSK2890457 DMT5YK7 TI TTF5WCR DMT5YK7 TN Endogenous gut peptide (EGP) DMT5YK7 MA Modulator DMT5YK7 RN Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014 Aug;23(8):1055-66. DMT5YK7 RU https://pubmed.ncbi.nlm.nih.gov/25000213 DMT6E5N DI DMT6E5N DMT6E5N DN Onapristone DMT6E5N TI TTUV8G9 DMT6E5N TN Progesterone receptor (PGR) DMT6E5N MA Modulator DMT6E5N RN Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8. DMT6E5N RU https://www.ncbi.nlm.nih.gov/pubmed/10448262 DMT6H3J DI DMT6H3J DMT6H3J DN AbGn-168 DMT6H3J TI TTS5K8U DMT6H3J TN P-selectin glycoprotein ligand 1 (SELPLG) DMT6H3J RN Clinical pipeline report, company report or official report of Avarx. DMT6H3J RU http://www.avarx.com/AvaRx/SubDomains/bucket3739906636580370793/Listings/bucket460336945731305549/Public.Listing.display.html DMT6O2E DI DMT6O2E DMT6O2E DN NC318 DMT6O2E TI TTBSZPF DMT6O2E TN Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15) DMT6O2E MA Inhibitor DMT6O2E RN Clinical pipeline report, company report or official report of NextCure. DMT6O2E RU http://www.nextcure.com/pipeline/ DMT8GVU DI DMT8GVU DMT8GVU DN 177Lu-DOTATATE DMT8GVU TI TTOMNR9 DMT8GVU TN Somatostatin receptor (SSTR) DMT8GVU MA Modulator DMT8GVU RN Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25. DMT8GVU RU https://pubmed.ncbi.nlm.nih.gov/24632546 DMT8GVU DI DMT8GVU DMT8GVU DN 177Lu-DOTATATE DMT8GVU TI TTAE1BR DMT8GVU TN Somatostatin receptor type 4 (SSTR4) DMT8GVU MA Inhibitor DMT8GVU RN New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors DMT8GVU RU https://www.cancercommons.org/tag/177lu-dotatate/ DMT8L6P DI DMT8L6P DMT8L6P DN BMS-817399 DMT8L6P TI TTC24WT DMT8L6P TN C-C chemokine receptor type 1 (CCR1) DMT8L6P MA Modulator DMT8L6P RN Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64. DMT8L6P RU https://pubmed.ncbi.nlm.nih.gov/25101488 DMT8SMO DI DMT8SMO DMT8SMO DN TKA-731 DMT8SMO TI TTZPO1L DMT8SMO TN Substance-P receptor (TACR1) DMT8SMO MA Antagonist DMT8SMO RN The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71. DMT8SMO RU https://pubmed.ncbi.nlm.nih.gov/16199188 DMT9QI2 DI DMT9QI2 DMT9QI2 DN OCV-101 DMT9QI2 TI TT2Q6G1 DMT9QI2 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMT9QI2 MA Modulator DMT9QI2 RN Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104. DMT9QI2 RU https://www.ncbi.nlm.nih.gov/pubmed/23020774 DMTAEMB DI DMTAEMB DMTAEMB DN AX-200 DMTAEMB TI TTC70AJ DMTAEMB TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMTAEMB MA Modulator DMTAEMB RN Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7. DMTAEMB RU https://pubmed.ncbi.nlm.nih.gov/23963331 DMTAX8B DI DMTAX8B DMTAX8B DN S-2150 DMTAX8B TI TT5HONZ DMTAX8B TN Calcium channel unspecific (CaC) DMTAX8B MA Modulator DMTAX8B RN Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80. DMTAX8B RU https://pubmed.ncbi.nlm.nih.gov/10757414 DMTB63Q DI DMTB63Q DMTB63Q DN Estetrol DMTB63Q TI TTZAYWL DMTB63Q TN Estrogen receptor (ESR) DMTB63Q MA Modulator DMTB63Q RN Clinical pipeline report, company report or official report of Pantarhei Bioscience. DMTB63Q RU http://pantarheibio.com/pipeline/estetrol.htm DMTBAV3 DI DMTBAV3 DMTBAV3 DN RX-0201 DMTBAV3 TI TTWTSCV DMTBAV3 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMTBAV3 MA Inhibitor DMTBAV3 RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMTBAV3 RU http://www.centerwatch.com/ DMTBFE4 DI DMTBFE4 DMTBFE4 DN LY2090314 DMTBFE4 TI TTRZQE3 DMTBFE4 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMTBFE4 MA Modulator DMTBFE4 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMTBFE4 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMTBFE4 DI DMTBFE4 DMTBFE4 DN LY2090314 DMTBFE4 TI TTRSMW9 DMTBFE4 TN Glycogen synthase kinase-3 beta (GSK-3B) DMTBFE4 MA Modulator DMTBFE4 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMTBFE4 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMTBFXW DI DMTBFXW DMTBFXW DN CART 19 DMTBFXW TI TTW640A DMTBFXW TN B-lymphocyte surface antigen B4 (CD19) DMTBFXW MA CAR-T-Cell-Therapy DMTBFXW RN ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL DMTBFXW RU https://clinicaltrials.gov/ct2/show/NCT02935543 DMTBRPO DI DMTBRPO DMTBRPO DN REGN910-3 DMTBRPO TI TTKLQTJ DMTBRPO TN Angiopoietin-2 (ANGPT2) DMTBRPO MA Inhibitor DMTBRPO RN ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health. DMTBRPO RU https://clinicaltrials.gov/ct2/show/NCT02713204 DMTCXSG DI DMTCXSG DMTCXSG DN Abituzumab DMTCXSG TI TTT1R2L DMTCXSG TN Integrin alpha-V (ITGAV) DMTCXSG RN Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40. DMTCXSG RU https://pubmed.ncbi.nlm.nih.gov/25319061 DMTDANB DI DMTDANB DMTDANB DN Pegsunercept DMTDANB TI TTF8CQI DMTDANB TN Tumor necrosis factor (TNF) DMTDANB MA Inhibitor DMTDANB RN Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8. DMTDANB RU https://pubmed.ncbi.nlm.nih.gov/18403591 DMTE071 DI DMTE071 DMTE071 DN CHF-5074 DMTE071 TI TT9W8GU DMTE071 TN Gamma-secretase (GS) DMTE071 MA Modulator DMTE071 RN CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93. DMTE071 RU https://www.ncbi.nlm.nih.gov/pubmed/19239474 DMTE8DC DI DMTE8DC DMTE8DC DN Pozelimab DMTE8DC TI TTKANGO DMTE8DC TN Complement C5 (CO5) DMTE8DC MA Inhibitor DMTE8DC RN Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892. DMTE8DC RU https://pubmed.ncbi.nlm.nih.gov/32384086 DMTF24A DI DMTF24A DMTF24A DN ASP-7035 DMTF24A TI TTK8R02 DMTF24A TN Vasopressin V2 receptor (V2R) DMTF24A MA Agonist DMTF24A RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285) DMTF24A RU http://adisinsight.springer.com/drugs/800030285 DMTFE9Y DI DMTFE9Y DMTFE9Y DN AFN-1252 DMTFE9Y TI TTZBRVL DMTFE9Y TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMTFE9Y MA Inhibitor DMTFE9Y RN Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5. DMTFE9Y RU https://pubmed.ncbi.nlm.nih.gov/23433442 DMTG2O0 DI DMTG2O0 DMTG2O0 DN Anrukinzumab DMTG2O0 TI TT0GVCH DMTG2O0 TN Interleukin-13 (IL13) DMTG2O0 MA Modulator DMTG2O0 RN Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900. DMTG2O0 RU https://www.ncbi.nlm.nih.gov/pubmed/25567115 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTJW4LU DMTGNWU TN Phosphodiesterase 10A (PDE10) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTZCG4L DMTGNWU TN Phosphodiesterase 3 (PDE3) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTZ97H5 DMTGNWU TN Phosphodiesterase 4A (PDE4A) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTJGW1Z DMTGNWU TN Phosphodiesterase 2A (PDE2A) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGR25 DI DMTGR25 DMTGR25 DN L-745,870 DMTGR25 TI TTE0A2F DMTGR25 TN Dopamine D4 receptor (D4R) DMTGR25 MA Antagonist DMTGR25 RN Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77. DMTGR25 RU https://pubmed.ncbi.nlm.nih.gov/18604600 DMTGU6K DI DMTGU6K DMTGU6K DN REN-1654 DMTGU6K TI TT7KPH1 DMTGU6K TN MAPK/ERK signaling pathway (MAPK pathway) DMTGU6K MA Modulator DMTGU6K RN US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. DMTGU6K RU http://www.google.com/patents/US20060270742 DMTGU6K DI DMTGU6K DMTGU6K DN REN-1654 DMTGU6K TI TTX1JEN DMTGU6K TN JNK signaling pathway (JNK pathway) DMTGU6K MA Modulator DMTGU6K RN US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. DMTGU6K RU http://www.google.com/patents/US20060270742 DMTHR4U DI DMTHR4U DMTHR4U DN ASM8 DMTHR4U TI TTU3Y87 DMTHR4U TN CCR3 messenger RNA (CCR3 mRNA) DMTHR4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60). DMTHR4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60 DMTIED1 DI DMTIED1 DMTIED1 DN 131I-TM-601 DMTIED1 TI TTCYAXN DMTIED1 TN Chloride channel unspecific (ClC) DMTIED1 MA Inhibitor DMTIED1 RN Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6. DMTIED1 RU https://pubmed.ncbi.nlm.nih.gov/15809479 DMTJMK5 DI DMTJMK5 DMTJMK5 DN TD-1211 DMTJMK5 TI TTKWM86 DMTJMK5 TN Opioid receptor mu (MOP) DMTJMK5 MA Modulator DMTJMK5 RN The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. DMTJMK5 RU https://pubmed.ncbi.nlm.nih.gov/23549670 DMTJOEL DI DMTJOEL DMTJOEL DN DIADENOSINE TETRAPHOSPHATE DMTJOEL TI TTSLI08 DMTJOEL TN Adenosine receptor (ADOR) DMTJOEL MA Modulator DMTJOEL RN Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44. DMTJOEL RU https://pubmed.ncbi.nlm.nih.gov/8922729 DMTJOQX DI DMTJOQX DMTJOQX DN SMP-986 DMTJOQX TI TTRK8B9 DMTJOQX TN Sodium channel unspecific (NaC) DMTJOQX MA Antagonist DMTJOQX RN DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129. DMTJOQX RU http://www.sciencedirect.com/science/article/pii/S0022534708603717 DMTJOQX DI DMTJOQX DMTJOQX DN SMP-986 DMTJOQX TI TTOXS3C DMTJOQX TN Muscarinic acetylcholine receptor (CHRM) DMTJOQX MA Antagonist DMTJOQX RN DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129. DMTJOQX RU http://www.sciencedirect.com/science/article/pii/S0022534708603717 DMTJWNE DI DMTJWNE DMTJWNE DN PF-03446962 DMTJWNE TI TTGYPTC DMTJWNE TN Activin receptor-like kinase-1 (ACVRL1) DMTJWNE MA Modulator DMTJWNE RN ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006. DMTJWNE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143549/ DMTKDIP DI DMTKDIP DMTKDIP DN BMS-986141 DMTKDIP TI TT3I4WV DMTKDIP TN Prostate apoptosis response-4 (PAWR) DMTKDIP MA Antagonist DMTKDIP RN Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. Eur J Med Chem. 2021 Jan 1;209:112893. DMTKDIP RU https://pubmed.ncbi.nlm.nih.gov/33049608 DMTKSVA DI DMTKSVA DMTKSVA DN CIMICOXIB DMTKSVA TI TTVKILB DMTKSVA TN Prostaglandin G/H synthase 2 (COX-2) DMTKSVA MA Modulator DMTKSVA RN Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81. DMTKSVA RU https://www.ncbi.nlm.nih.gov/pubmed/24461644 DMTL39C DI DMTL39C DMTL39C DN Plevitrexed (R)-isomer DMTL39C TI TTU6BFZ DMTL39C TN Candida Thymidylate synthase (Candi TMP1) DMTL39C MA Inhibitor DMTL39C RN Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30. DMTL39C RU https://pubmed.ncbi.nlm.nih.gov/17297914 DMTL39C DI DMTL39C DMTL39C DN Plevitrexed (R)-isomer DMTL39C TI TT5FOMZ DMTL39C TN Thymidylate synthase (TYMS) DMTL39C MA Inhibitor DMTL39C RN Differential effect of 1,10-phenanthroline on mammalian, yeast, and parasite glycosylphosphatidylinositol anchor synthesis. Biochem Biophys Res Commun. 2001 Nov 16;288(5):1112-8. DMTL39C RU https://pubmed.ncbi.nlm.nih.gov/11700026 DMTLB92 DI DMTLB92 DMTLB92 DN DI-Leu16-IL2 DMTLB92 TI TTUE541 DMTLB92 TN Leukocyte surface antigen Leu-16 (CD20) DMTLB92 MA Modulator DMTLB92 RN National Cancer Institute Drug Dictionary (drug id 599668). DMTLB92 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599668 DMTLR6Y DI DMTLR6Y DMTLR6Y DN 3K3A-APC DMTLR6Y TI TTZUXYS DMTLR6Y TN Vitamin K-dependent protein C (PROC) DMTLR6Y MA Modulator DMTLR6Y RN Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22. DMTLR6Y RU https://pubmed.ncbi.nlm.nih.gov/22632606 DMTM4QA DI DMTM4QA DMTM4QA DN LCL161 DMTM4QA TI TTS74QB DMTM4QA TN Inhibitor of apoptosis protein (hIAP) DMTM4QA MA Modulator DMTM4QA RN National Cancer Institute Drug Dictionary (drug id 670651). DMTM4QA RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670651 DMTMCPZ DI DMTMCPZ DMTMCPZ DN KB001A DMTMCPZ TI TTLK9NJ DMTMCPZ TN Pseudomonas PcrV protein type III (Pseudo pcrV) DMTMCPZ MA Inhibitor DMTMCPZ RN KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491. DMTMCPZ RU https://pubmed.ncbi.nlm.nih.gov/29292092 DMTN16K DI DMTN16K DMTN16K DN Implitapide DMTN16K TI TTUS1RD DMTN16K TN Microsomal triglyceride transfer protein (MTTP) DMTN16K MA Inhibitor DMTN16K RN Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70. DMTN16K RU https://pubmed.ncbi.nlm.nih.gov/19080731 DMTNDM2 DI DMTNDM2 DMTNDM2 DN Setrobuvir DMTNDM2 TI TTMVBWH DMTNDM2 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMTNDM2 MA Inhibitor DMTNDM2 RN Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011). DMTNDM2 RU http://www.anadyspharma.com/ DMTNOXQ DI DMTNOXQ DMTNOXQ DN OT-551 DMTNOXQ TI TTA6ZN2 DMTNOXQ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTNOXQ MA Inhibitor DMTNOXQ RN New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. DMTNOXQ RU https://pubmed.ncbi.nlm.nih.gov/23812264 DMTOCIV DI DMTOCIV DMTOCIV DN SR-43845 DMTOCIV TI TTB2MXP DMTOCIV TN Angiotensinogenase renin (REN) DMTOCIV MA Inhibitor DMTOCIV RN Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens Suppl. 1989 Apr;7(2):S33-5. DMTOCIV RU https://pubmed.ncbi.nlm.nih.gov/2666612 DMTOI7S DI DMTOI7S DMTOI7S DN ARRY-520 DMTOI7S TI TTTRP0H DMTOI7S TN Kinesin-like protein KIF11 (KIF11) DMTOI7S MA Inhibitor DMTOI7S RN Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct;23(10):1755-62. DMTOI7S RU https://pubmed.ncbi.nlm.nih.gov/19458629 DMTPQUA DI DMTPQUA DMTPQUA DN LY-2624803 DMTPQUA TI TTTIBOJ DMTPQUA TN Histamine H1 receptor (H1R) DMTPQUA MA Modulator DMTPQUA RN Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. DMTPQUA RU https://pubmed.ncbi.nlm.nih.gov/25423562 DMTQ1Y3 DI DMTQ1Y3 DMTQ1Y3 DN AXL-1717 DMTQ1Y3 TI TTHRID2 DMTQ1Y3 TN Insulin-like growth factor I receptor (IGF1R) DMTQ1Y3 MA Inhibitor DMTQ1Y3 RN Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7. DMTQ1Y3 RU https://pubmed.ncbi.nlm.nih.gov/20698809 DMTQ2K0 DI DMTQ2K0 DMTQ2K0 DN SelG1 DMTQ2K0 TI TTE5VG0 DMTQ2K0 TN P-selectin (SELP) DMTQ2K0 RN Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011). DMTQ2K0 RU http://www.selexys.com/product_pipeline.asp DMTRONK DI DMTRONK DMTRONK DN BZL-101 DMTRONK TI TT34ECM DMTRONK TN Cell cycle (CC) DMTRONK MA Inhibitor DMTRONK RN BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405. DMTRONK RU https://www.ncbi.nlm.nih.gov/pubmed/20574166 DMTROUI DI DMTROUI DMTROUI DN Vazegepant DMTROUI TI TT67OLB DMTROUI TN HUMAN calcitonin gene-related peptide type 1 receptor (CALCRL) DMTROUI MA Inhibitor DMTROUI RN Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen DMTROUI RU https://clinicaltrials.gov/ct2/show/NCT04346615 DMTSVJM DI DMTSVJM DMTSVJM DN CJM112 DMTSVJM TI TTG0MT6 DMTSVJM TN Interleukin-17 (IL17) DMTSVJM MA Inhibitor DMTSVJM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTSVJM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTUMYX DI DMTUMYX DMTUMYX DN AS-902330 DMTUMYX TI TT6ICRA DMTUMYX TN Fibroblast growth factor-18 (FGF18) DMTUMYX MA Modulator DMTUMYX RN Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014 Jul;66(7):1820-31. DMTUMYX RU https://pubmed.ncbi.nlm.nih.gov/24740822 DMTVGMZ DI DMTVGMZ DMTVGMZ DN NKP 608 DMTVGMZ TI TTZPO1L DMTVGMZ TN Substance-P receptor (TACR1) DMTVGMZ MA Antagonist DMTVGMZ RN Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther.2012 Feb;35(3):360-7. DMTVGMZ RU https://pubmed.ncbi.nlm.nih.gov/22221140 DMTVGY7 DI DMTVGY7 DMTVGY7 DN BMS-770767 DMTVGY7 TI TTN7BL9 DMTVGY7 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTVGY7 MA Modulator DMTVGY7 RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMTVGY7 RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMTVS3A DI DMTVS3A DMTVS3A DN Somatoprim DMTVS3A TI TTOMNR9 DMTVS3A TN Somatostatin receptor (SSTR) DMTVS3A MA Modulator DMTVS3A RN DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34. DMTVS3A RU https://www.ncbi.nlm.nih.gov/pubmed/22065857 DMTVU2Q DI DMTVU2Q DMTVU2Q DN LY2541546 DMTVU2Q TI TTYRO4F DMTVU2Q TN Sclerostin (SOST) DMTVU2Q RN Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DMTVU2Q RU https://pubmed.ncbi.nlm.nih.gov/22106037 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT06RH5 DMTW79H TN GABA(A) receptor gamma-2 (GABRG2) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTDCVZW DMTW79H TN Gamma-aminobutyric acid B receptor (GABBR) DMTW79H MA Inhibitor DMTW79H RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT8RXO5 DMTW79H TN GABA transporter-3 (SLC6A11) DMTW79H MA Inhibitor DMTW79H RN Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/6268788 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTBMV1G DMTW79H TN GABA(A) receptor alpha-2 (GABRA2) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT37EDJ DMTW79H TN GABA(A) receptor alpha-3 (GABRA3) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTNJYV2 DMTW79H TN Gamma-aminobutyric acid receptor (GAR) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTZA1NY DMTW79H TN GABA(A) receptor beta-2 (GABRB2) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT1MPAY DMTW79H TN GABA(A) receptor alpha-1 (GABRA1) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTNZPQ1 DMTW79H TN GABA(A) receptor alpha-5 (GABRA5) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTPRKM0 DMTW79H TN GABA transporter GAT-1 (SLC6A1) DMTW79H MA Inhibitor DMTW79H RN Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/15509161 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT4BT06 DMTW79H TN Integrin alpha-4 (ITGA4) DMTW79H MA Binder DMTW79H RN Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/17355213 DMTX8IZ DI DMTX8IZ DMTX8IZ DN Endoxifen DMTX8IZ TI TTZAYWL DMTX8IZ TN Estrogen receptor (ESR) DMTX8IZ MA Modulator DMTX8IZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMTX8IZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMTXCUS DI DMTXCUS DMTXCUS DN Galiximab DMTXCUS TI TTFZDNP DMTXCUS TN Activation B7-1 antigen (CD80) DMTXCUS RN Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8. DMTXCUS RU https://pubmed.ncbi.nlm.nih.gov/15994148 DMTXHJ9 DI DMTXHJ9 DMTXHJ9 DN Sirolimus DMTXHJ9 TI TT7HQAF DMTXHJ9 TN HUMAN mammalian target of rapamycin (mTOR) DMTXHJ9 MA Inhibitor DMTXHJ9 RN Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14. DMTXHJ9 RU https://pubmed.ncbi.nlm.nih.gov/32194980 DMTXNZK DI DMTXNZK DMTXNZK DN Icofungipen DMTXNZK TI TT2GPK3 DMTXNZK TN DNA topoisomerase (TOP) DMTXNZK MA Inhibitor DMTXNZK RN Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9. DMTXNZK RU https://pubmed.ncbi.nlm.nih.gov/12527422 DMTXNZK DI DMTXNZK DMTXNZK DN Icofungipen DMTXNZK TI TTBZHDM DMTXNZK TN Fungal Isoleucyl t-RNA synthetase (Fung ILS1) DMTXNZK MA Modulator DMTXNZK RN Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92. DMTXNZK RU https://pubmed.ncbi.nlm.nih.gov/15855534 DMTY4KN DI DMTY4KN DMTY4KN DN Dexefaroxan DMTY4KN TI TTM2AOE DMTY4KN TN Adenosine A2a receptor (ADORA2A) DMTY4KN MA Agonist DMTY4KN RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTY4KN RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTY4KN DI DMTY4KN DMTY4KN DN Dexefaroxan DMTY4KN TI TTJSZTB DMTY4KN TN Nicotinic acetylcholine receptor (nAChR) DMTY4KN MA Agonist DMTY4KN RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTY4KN RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTY4PG DI DMTY4PG DMTY4PG DN GI-4000 DMTY4PG TI TTW2R9X DMTY4PG TN GTPase NRas (NRAS) DMTY4PG RN Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10. DMTY4PG RU https://pubmed.ncbi.nlm.nih.gov/25044103 DMTY6OF DI DMTY6OF DMTY6OF DN ATI-501 DMTY6OF TI TTT7PJU DMTY6OF TN Janus kinase 3 (JAK-3) DMTY6OF MA Inhibitor DMTY6OF RN Clinical pipeline report, company report or official report of Aclaris Therapeutics. DMTY6OF RU https://www.aclaristx.com/pipeline/ DMTY6OF DI DMTY6OF DMTY6OF DN ATI-501 DMTY6OF TI TT6DM01 DMTY6OF TN Janus kinase 1 (JAK-1) DMTY6OF MA Inhibitor DMTY6OF RN Clinical pipeline report, company report or official report of Aclaris Therapeutics. DMTY6OF RU https://www.aclaristx.com/pipeline/ DMTYD8Q DI DMTYD8Q DMTYD8Q DN ZD2079 DMTYD8Q TI TTMXGCW DMTYD8Q TN Adrenergic receptor beta-3 (ADRB3) DMTYD8Q MA Agonist DMTYD8Q RN Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. DMTYD8Q RU https://pubmed.ncbi.nlm.nih.gov/10207980 DMTYXQF DI DMTYXQF DMTYXQF DN NVP-AUY922 DMTYXQF TI TT78R5H DMTYXQF TN Heat shock protein 90 alpha (HSP90A) DMTYXQF MA Inhibitor DMTYXQF RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMTYXQF RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMU0812 DI DMU0812 DMU0812 DN PAZ-320 DMU0812 TI TTXWASR DMU0812 TN Intestinal maltase-glucoamylase (MGAM) DMU0812 MA Modulator DMU0812 RN Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022. DMU0812 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455361/ DMU1MR9 DI DMU1MR9 DMU1MR9 DN IMD-1041 DMU1MR9 TI TTJ3E9X DMU1MR9 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMU1MR9 MA Inhibitor DMU1MR9 RN Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45. DMU1MR9 RU https://pubmed.ncbi.nlm.nih.gov/23042949 DMU1XZD DI DMU1XZD DMU1XZD DN Erteberel DMU1XZD TI TTOM3J0 DMU1XZD TN Estrogen receptor beta (ESR2) DMU1XZD MA Agonist DMU1XZD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986) DMU1XZD RU http://adisinsight.springer.com/drugs/800031986 DMU2GP4 DI DMU2GP4 DMU2GP4 DN DT-1687 DMU2GP4 TI TTICZ1O DMU2GP4 TN Metabotropic glutamate receptor 4 (mGluR4) DMU2GP4 MA Modulator DMU2GP4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292). DMU2GP4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292 DMU3KOH DI DMU3KOH DMU3KOH DN NNC-0151-0000-0000 DMU3KOH TI TTKANGO DMU3KOH TN Complement C5 (CO5) DMU3KOH RN Complement-targeted therapeutics. Nat Biotechnol. 2007 Nov;25(11):1265-75. DMU3KOH RU https://pubmed.ncbi.nlm.nih.gov/17989689 DMU3P1K DI DMU3P1K DMU3P1K DN Cenerimod DMU3P1K TI TT2DLFI DMU3P1K TN Lysosphingolipid receptor (LSPR) DMU3P1K MA Agonist DMU3P1K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU3P1K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMU3XJP DI DMU3XJP DMU3XJP DN Pascolizumab DMU3XJP TI TTLGTKB DMU3XJP TN Interleukin-4 (IL4) DMU3XJP MA Modulator DMU3XJP RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMU3XJP RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMU4CS8 DI DMU4CS8 DMU4CS8 DN MEDI6012 DMU4CS8 TI TTGZ91P DMU4CS8 TN Lecithin-cholesterol acyltransferase (LCAT) DMU4CS8 MA Modulator DMU4CS8 RN Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria. J Nephropathol. 2015 January; 4(1): 25-28. DMU4CS8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316582/ DMU5EVR DI DMU5EVR DMU5EVR DN GSK2586881 DMU5EVR TI TTUI5H7 DMU5EVR TN Angiotensin-converting enzyme 2 (ACE2) DMU5EVR MA Modulator DMU5EVR RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMU5EVR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMU5H3A DI DMU5H3A DMU5H3A DN PZ-128 DMU5H3A TI TTL935N DMU5H3A TN Proteinase activated receptor 1 (F2R) DMU5H3A MA Antagonist DMU5H3A RN PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003. DMU5H3A RU https://pubmed.ncbi.nlm.nih.gov/33028101 DMU5SZP DI DMU5SZP DMU5SZP DN Inecalcitol oral DMU5SZP TI TTK59TV DMU5SZP TN Vitamin D3 receptor (VDR) DMU5SZP MA Agonist DMU5SZP RN Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013 Mar 1;12(5):743-52. DMU5SZP RU https://pubmed.ncbi.nlm.nih.gov/23388458 DMU62I8 DI DMU62I8 DMU62I8 DN CX2009 DMU62I8 TI TT2AFT6 DMU62I8 TN Activated leukocyte cell adhesionmolecule (ALCAM) DMU62I8 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMU62I8 RU https://cytomx.com/pipeline/ DMU6NBO DI DMU6NBO DMU6NBO DN APX3330 DMU6NBO TI TTHGL48 DMU6NBO TN AP endonuclease 1 (APEX1) DMU6NBO MA Inhibitor DMU6NBO RN Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19. DMU6NBO RU https://pubmed.ncbi.nlm.nih.gov/28825044 DMU6R3O DI DMU6R3O DMU6R3O DN CLG561 DMU6R3O TI TTLA0VS DMU6R3O TN Complement factor P (CFP) DMU6R3O MA Inhibitor DMU6R3O RN Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342. DMU6R3O RU https://pubmed.ncbi.nlm.nih.gov/30686077 DMU7ZMH DI DMU7ZMH DMU7ZMH DN S-364735 DMU7ZMH TI TT5FH9Y DMU7ZMH TN Human immunodeficiency virus Integrase (HIV IN) DMU7ZMH MA Inhibitor DMU7ZMH RN The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8. DMU7ZMH RU https://pubmed.ncbi.nlm.nih.gov/18160521 DMU81BH DI DMU81BH DMU81BH DN LY-2189102 DMU81BH TI TTRYK0X DMU81BH TN Interleukin-1 beta (IL1B) DMU81BH RN Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46. DMU81BH RU https://pubmed.ncbi.nlm.nih.gov/23514733 DMUA0XC DI DMUA0XC DMUA0XC DN ALF-5755 DMUA0XC TI TTL4H8N DMUA0XC TN Regenerating human pro-islet peptide (REG3A) DMUA0XC MA Modulator DMUA0XC RN HIP/PAP prevents excitotoxic neuronal death and promotes plasticity. Ann Clin Transl Neurol. 2014 October; 1(10): 739-754. DMUA0XC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241802/ DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTBWX8P DMUAOFM TN Staphylococcus Manganese transporter C (Stap-coc MntC) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTE6QWF DMUAOFM TN Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TT4SVB7 DMUAOFM TN Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTWGZ64 DMUAOFM TN Staphylococcus Clumping factor A (Stap-coc ClfA) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAXS5 DI DMUAXS5 DMUAXS5 DN FP-1039 DMUAXS5 TI TTRLW2X DMUAXS5 TN Fibroblast growth factor receptor 1 (FGFR1) DMUAXS5 MA Antagonist DMUAXS5 RN FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927. DMUAXS5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514973/ DMUB3OY DI DMUB3OY DMUB3OY DN RO-5323441 DMUB3OY TI TT48I1Y DMUB3OY TN Placenta growth factor (PlGF) DMUB3OY MA Inhibitor DMUB3OY RN RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011. DMUB3OY RU http://cancerres.aacrjournals.org/content/70/8_Supplement/1370.abstract DMUDMHA DI DMUDMHA DMUDMHA DN CZEN-002 DMUDMHA TI TTSXVID DMUDMHA TN Nuclear factor NF-kappa-B (NFKB) DMUDMHA MA Modulator DMUDMHA RN US patent application no. US20100278784 A1. DMUDMHA RU https://www.google.com.ar/patents/US20100278784 DMUE0AK DI DMUE0AK DMUE0AK DN Saratin DMUE0AK TI TTE5Q4N DMUE0AK TN VWF-dependent platelet-collagen conversion (VDDPCC) DMUE0AK MA Inhibitor DMUE0AK RN Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200. DMUE0AK RU https://pubmed.ncbi.nlm.nih.gov/15213861 DMUE90I DI DMUE90I DMUE90I DN AZD1656 DMUE90I TI TTDLNGZ DMUE90I TN Glucokinase (GCK) DMUE90I MA Activator DMUE90I RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMUE90I RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMUFCQG DI DMUFCQG DMUFCQG DN IC14 DMUFCQG TI TT6I7DC DMUFCQG TN Monocyte differentiation antigen CD14 (CD14) DMUFCQG RN IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4. DMUFCQG RU https://pubmed.ncbi.nlm.nih.gov/11717588 DMUFY4K DI DMUFY4K DMUFY4K DN BCT303 DMUFY4K TI TTTSEPU DMUFY4K TN Thyroid hormone receptor alpha (THRA) DMUFY4K MA Modulator DMUFY4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUFY4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUFY4K DI DMUFY4K DMUFY4K DN BCT303 DMUFY4K TI TTGER3L DMUFY4K TN Thyroid hormone receptor beta (THRB) DMUFY4K MA Modulator DMUFY4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUFY4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUGBQK DI DMUGBQK DMUGBQK DN DVC1-0101 DMUGBQK TI TTGKIED DMUGBQK TN Fibroblast growth factor-2 (FGF2) DMUGBQK MA Modulator DMUGBQK RN DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14. DMUGBQK RU https://pubmed.ncbi.nlm.nih.gov/23319060 DMUGN4B DI DMUGN4B DMUGN4B DN MN-305 DMUGN4B TI TTSQIFT DMUGN4B TN 5-HT 1A receptor (HTR1A) DMUGN4B MA Agonist DMUGN4B RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMUGN4B RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMUHDX3 DI DMUHDX3 DMUHDX3 DN PC-SOD DMUHDX3 TI TT6RVLG DMUHDX3 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMUHDX3 MA Modulator DMUHDX3 RN A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis DMUHDX3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364 DMUI5PA DI DMUI5PA DMUI5PA DN Brostallicin DMUI5PA TI TTOVXHF DMUI5PA TN Human Deoxyribonucleic acid minor groove (hDNA min) DMUI5PA MA Inhibitor DMUI5PA RN Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46. DMUI5PA RU https://pubmed.ncbi.nlm.nih.gov/19938904 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TTDWHC3 DMUICJD TN Interleukin 4 receptor alpha (IL4R) DMUICJD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697). DMUICJD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TTLGTKB DMUICJD TN Interleukin-4 (IL4) DMUICJD MA Modulator DMUICJD RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMUICJD RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TT0GVCH DMUICJD TN Interleukin-13 (IL13) DMUICJD MA Modulator DMUICJD RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMUICJD RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMUJ0W7 DI DMUJ0W7 DMUJ0W7 DN CP-724714 DMUJ0W7 TI TT6EO5L DMUJ0W7 TN Erbb2 tyrosine kinase receptor (HER2) DMUJ0W7 MA Inhibitor DMUJ0W7 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMUJ0W7 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TT8MK59 DMUJ1WV TN Melanocytes lineage-specific antigen GP100 (PMEL) DMUJ1WV MA Modulator DMUJ1WV RN Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors DMUJ1WV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624013 DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TTV3XPL DMUJ1WV TN T-cell surface glycoprotein CD3 gamma (CD3G) DMUJ1WV MA Inhibitor DMUJ1WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUJ1WV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TT7AKW1 DMUJ1WV TN T-cell receptor (TCR) DMUJ1WV MA Modulator DMUJ1WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUJ1WV RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMUK6HC DI DMUK6HC DMUK6HC DN N-5984 DMUK6HC TI TTMXGCW DMUK6HC TN Adrenergic receptor beta-3 (ADRB3) DMUK6HC MA Agonist DMUK6HC RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMUK6HC RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMUL6GY DI DMUL6GY DMUL6GY DN BEMORADAN DMUL6GY TI TT06AWU DMUL6GY TN Phosphodiesterase 3A (PDE3A) DMUL6GY MA Inhibitor DMUL6GY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMUL6GY RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMULZ4W DI DMULZ4W DMULZ4W DN CHR-2797 DMULZ4W TI TT371QC DMULZ4W TN Puromycin-sensitive aminopeptidase (NPEPPS) DMULZ4W MA Inhibitor DMULZ4W RN CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79. DMULZ4W RU https://pubmed.ncbi.nlm.nih.gov/18701491 DMULZ4W DI DMULZ4W DMULZ4W DN CHR-2797 DMULZ4W TI TTWLEZV DMULZ4W TN Aminopeptidase (AMP) DMULZ4W MA Inhibitor DMULZ4W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMULZ4W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUM2KA DI DMUM2KA DMUM2KA DN BN82451 DMUM2KA TI TTRK8B9 DMUM2KA TN Sodium channel unspecific (NaC) DMUM2KA MA Blocker DMUM2KA RN Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. DMUM2KA RU https://pubmed.ncbi.nlm.nih.gov/19453283 DMUM2KA DI DMUM2KA DMUM2KA DN BN82451 DMUM2KA TI TTK0943 DMUM2KA TN Prostaglandin G/H synthase (COX) DMUM2KA MA Inhibitor DMUM2KA RN Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. DMUM2KA RU https://pubmed.ncbi.nlm.nih.gov/19453283 DMUM370 DI DMUM370 DMUM370 DN MSH-1001 DMUM370 TI TT1VOHK DMUM370 TN Potassium channel unspecific (KC) DMUM370 MA Opener DMUM370 RN KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7. DMUM370 RU https://pubmed.ncbi.nlm.nih.gov/19372634 DMUMCB9 DI DMUMCB9 DMUMCB9 DN Amelubant DMUMCB9 TI TTN53ZF DMUMCB9 TN Leukotriene B4 receptor 1 (LTB4R) DMUMCB9 MA Antagonist DMUMCB9 RN Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63. DMUMCB9 RU https://pubmed.ncbi.nlm.nih.gov/16356023 DMUMCWS DI DMUMCWS DMUMCWS DN MEMP1972A DMUMCWS TI TTYJQTF DMUMCWS TN Immunoglobulin E (IgE) DMUMCWS RN International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011 DMUMCWS RU http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf DMUNJZB DI DMUNJZB DMUNJZB DN UCN-01 DMUNJZB TI TTTU902 DMUNJZB TN Checkpoint kinase-1 (CHK1) DMUNJZB MA Inhibitor DMUNJZB RN Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30. DMUNJZB RU https://pubmed.ncbi.nlm.nih.gov/19473860 DMUOEKM DI DMUOEKM DMUOEKM DN JNJ-39393406 DMUOEKM TI TTLA931 DMUOEKM TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMUOEKM MA Modulator DMUOEKM RN Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204. DMUOEKM RU https://pubmed.ncbi.nlm.nih.gov/22766391 DMUOYQR DI DMUOYQR DMUOYQR DN AVI-5126 DMUOYQR TI TTNQ5ZP DMUOYQR TN Myc messenger RNA (MYC mRNA) DMUOYQR RN Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. DMUOYQR RU https://pubmed.ncbi.nlm.nih.gov/22149555 DMUPD4G DI DMUPD4G DMUPD4G DN ISIS 113715 DMUPD4G TI TTELIN2 DMUPD4G TN PTPN1 messenger RNA (PTPN1 mRNA) DMUPD4G RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMUPD4G RU http://www.isispharm.com/Pipeline/index.htm DMUPJWH DI DMUPJWH DMUPJWH DN YM-598 DMUPJWH TI TTKRD0G DMUPJWH TN Endothelin A receptor (EDNRA) DMUPJWH MA Antagonist DMUPJWH RN Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233. DMUPJWH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087127/ DMUPZFO DI DMUPZFO DMUPZFO DN Neihulizumab DMUPZFO TI TTS5K8U DMUPZFO TN P-selectin glycoprotein ligand 1 (SELPLG) DMUPZFO MA Inhibitor DMUPZFO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUPZFO RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMUQH78 DI DMUQH78 DMUQH78 DN Tempol DMUQH78 TI TT6RVLG DMUQH78 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMUQH78 MA Modulator DMUQH78 RN The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34. DMUQH78 RU https://www.ncbi.nlm.nih.gov/pubmed/15943756 DMUQZT4 DI DMUQZT4 DMUQZT4 DN VPI-2690B DMUQZT4 TI TTHRID2 DMUQZT4 TN Insulin-like growth factor I receptor (IGF1R) DMUQZT4 MA Antagonist DMUQZT4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUQZT4 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMURX4B DI DMURX4B DMURX4B DN Recombinant batroxobin DMURX4B TI TTWODQF DMURX4B TN Fibrin (FG) DMURX4B MA Modulator DMURX4B RN Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 2004 Jul 30;571(1-3):67-73. DMURX4B RU https://pubmed.ncbi.nlm.nih.gov/15280019 DMURXMJ DI DMURXMJ DMURXMJ DN HTI-101 DMURXMJ TI TT3C1VN DMURXMJ TN Enzyme unspecific (Enz) DMURXMJ MA Antagonist DMURXMJ RN Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006. DMURXMJ RU http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-new-studies-from-hti-101-presented-at-proteoglycan-research-conference-56000982.html DMUT9OE DI DMUT9OE DMUT9OE DN Zadaxin/lamivudine DMUT9OE TI TTSYFMA DMUT9OE TN Interferon alpha/beta receptor 1 (IFNAR1) DMUT9OE MA Modulator DMUT9OE RN Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7. DMUT9OE RU https://pubmed.ncbi.nlm.nih.gov/15992078 DMUT9OE DI DMUT9OE DMUT9OE DN Zadaxin/lamivudine DMUT9OE TI TTSHG0T DMUT9OE TN Toll-like receptor 9 (TLR9) DMUT9OE MA Modulator DMUT9OE RN Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7. DMUT9OE RU https://pubmed.ncbi.nlm.nih.gov/15992078 DMUTS1W DI DMUTS1W DMUTS1W DN BMS-936557 DMUTS1W TI TTQOVYA DMUTS1W TN C-X-C motif chemokine 10 (CXCL10) DMUTS1W RN Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50. DMUTS1W RU https://pubmed.ncbi.nlm.nih.gov/23461895 DMUVMY9 DI DMUVMY9 DMUVMY9 DN BI-836858 DMUVMY9 TI TTJVYO3 DMUVMY9 TN Myeloid cell surface antigen CD33 (CD33) DMUVMY9 RN The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53. DMUVMY9 RU https://pubmed.ncbi.nlm.nih.gov/24809231 DMUVON0 DI DMUVON0 DMUVON0 DN PNT-2258 DMUVON0 TI TTFOUV4 DMUVON0 TN BCL-2 messenger RNA (BCL2 mRNA) DMUVON0 RN Clinical pipeline report, company report or official report of ProNAi. DMUVON0 RU http://pronai.com/pnt2258-targeting-bcl2/ DMUWFI7 DI DMUWFI7 DMUWFI7 DN QAX-576 DMUWFI7 TI TT0GVCH DMUWFI7 TN Interleukin-13 (IL13) DMUWFI7 MA Modulator DMUWFI7 RN Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. DMUWFI7 RU https://pubmed.ncbi.nlm.nih.gov/25226850 DMUWJI4 DI DMUWJI4 DMUWJI4 DN E-6700 DMUWJI4 TI TT2J34L DMUWJI4 TN Arachidonate 5-lipoxygenase (5-LOX) DMUWJI4 MA Modulator DMUWJI4 RN Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. DMUWJI4 RU https://pubmed.ncbi.nlm.nih.gov/8759636 DMUWJI4 DI DMUWJI4 DMUWJI4 DN E-6700 DMUWJI4 TI TTKNWZ4 DMUWJI4 TN Thromboxane-A synthase (TBXAS1) DMUWJI4 MA Modulator DMUWJI4 RN Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. DMUWJI4 RU https://pubmed.ncbi.nlm.nih.gov/8759636 DMUX8JZ DI DMUX8JZ DMUX8JZ DN Nivocasan DMUX8JZ TI TTCQIBE DMUX8JZ TN Caspase-1 (CASP1) DMUX8JZ MA Modulator DMUX8JZ RN Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91. DMUX8JZ RU https://pubmed.ncbi.nlm.nih.gov/24045874 DMUXDGZ DI DMUXDGZ DMUXDGZ DN EPX-300 DMUXDGZ TI TT85JO3 DMUXDGZ TN 5-HT receptor (5HTR) DMUXDGZ MA Modulator DMUXDGZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUXDGZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMUXIRM DI DMUXIRM DMUXIRM DN DS-8500 DMUXIRM TI TT7QNVC DMUXIRM TN Glucose-dependent insulinotropic receptor (GPR119) DMUXIRM MA Modulator DMUXIRM RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DMUXIRM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DMV0A28 DI DMV0A28 DMV0A28 DN Recombinant RGD-hirudin DMV0A28 TI TT6L509 DMV0A28 TN Coagulation factor IIa (F2) DMV0A28 MA Modulator DMV0A28 RN The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8. DMV0A28 RU https://pubmed.ncbi.nlm.nih.gov/17585879 DMV0MZ3 DI DMV0MZ3 DMV0MZ3 DN FK-962 DMV0MZ3 TI TTOMNR9 DMV0MZ3 TN Somatostatin receptor (SSTR) DMV0MZ3 MA Modulator DMV0MZ3 RN FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7. DMV0MZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/11172755 DMV14LM DI DMV14LM DMV14LM DN LY2886721 DMV14LM TI TT8JRS7 DMV14LM TN Beta-secretase (BACE) DMV14LM MA Modulator DMV14LM RN Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9. DMV14LM RU https://www.ncbi.nlm.nih.gov/pubmed/24530026 DMV17HK DI DMV17HK DMV17HK DN PTI-125 DMV17HK TI TTSTRZY DMV17HK TN Filamin A (FLNA) DMV17HK MA Inhibitor DMV17HK RN Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84. DMV17HK RU https://pubmed.ncbi.nlm.nih.gov/22815492 DMV1T59 DI DMV1T59 DMV1T59 DN JNJ-18038683 DMV1T59 TI TTO9X1H DMV1T59 TN 5-HT 7 receptor (HTR7) DMV1T59 MA Antagonist DMV1T59 RN Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453. DMV1T59 RU https://pubmed.ncbi.nlm.nih.gov/25642174 DMV27SP DI DMV27SP DMV27SP DN Panobacumab DMV27SP TI TT4ESMB DMV27SP TN Pseudomonas Lipopolysaccharide (Pseudo LPS) DMV27SP MA Modulator DMV27SP RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMV27SP RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMV2YDK DI DMV2YDK DMV2YDK DN LEISH-F1 DMV2YDK TI TT3J5ZI DMV2YDK TN Cell mediated immunity response (CMIR) DMV2YDK RN A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7. DMV2YDK RU https://pubmed.ncbi.nlm.nih.gov/21414377 DMV319J DI DMV319J DMV319J DN RO-4905417 DMV319J TI TTS5K8U DMV319J TN P-selectin glycoprotein ligand 1 (SELPLG) DMV319J RN WO patent application no. 2013,0144,05, Methods. DMV319J RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130131&CC=WO&NR=2013014405A2&KC=A2 DMV3TO4 DI DMV3TO4 DMV3TO4 DN GSK3810109 DMV3TO4 TI TT2ISQT DMV3TO4 TN Human immunodeficiency virus Attachment (HIV att) DMV3TO4 MA Inhibitor DMV3TO4 RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMV3TO4 RU https://viivhealthcare.com/en-us/medicines-in-development/ DMV41P5 DI DMV41P5 DMV41P5 DN JNJ-37822681 DMV41P5 TI TTEX248 DMV41P5 TN Dopamine D2 receptor (D2R) DMV41P5 MA Agonist DMV41P5 RN Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15. DMV41P5 RU https://pubmed.ncbi.nlm.nih.gov/23754735 DMV50R1 DI DMV50R1 DMV50R1 DN HE3235 DMV50R1 TI TTYA7V2 DMV50R1 TN Prostate cance cell (PCC) DMV50R1 MA Inhibitor DMV50R1 RN 17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78. DMV50R1 RU https://pubmed.ncbi.nlm.nih.gov/20814732 DMV6SNU DI DMV6SNU DMV6SNU DN GSK4069889 DMV6SNU TI TT1RWL7 DMV6SNU TN Hepatitis A virus cellular receptor 2 (TIM3) DMV6SNU MA Inhibitor DMV6SNU RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMV6SNU RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMV7ZU0 DI DMV7ZU0 DMV7ZU0 DN GS-6624 DMV7ZU0 TI TTFSUHX DMV7ZU0 TN Lysyl oxidase homolog 2 (LOXL2) DMV7ZU0 RN National Cancer Institute Drug Dictionary (drug id 681814). DMV7ZU0 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681814 DMV84OK DI DMV84OK DMV84OK DN DTI-0009 DMV84OK TI TTK25J1 DMV84OK TN Adenosine A1 receptor (ADORA1) DMV84OK MA Agonist DMV84OK RN Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. DMV84OK RU https://pubmed.ncbi.nlm.nih.gov/21185259 DMV86DY DI DMV86DY DMV86DY DN [131I]-BC8 DMV86DY TI TTUS45N DMV86DY TN Leukocyte common antigen (PTPRC) DMV86DY RN Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31. DMV86DY RU https://pubmed.ncbi.nlm.nih.gov/7849300 DMV8WU9 DI DMV8WU9 DMV8WU9 DN LYC-55716 DMV8WU9 TI TTGV6LY DMV8WU9 TN Nuclear receptor ROR-gamma (RORG) DMV8WU9 MA Agonist DMV8WU9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV8WU9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMV934L DI DMV934L DMV934L DN ALX-40-4C DMV934L TI TTT3ZC9 DMV934L TN Human immunodeficiency virus Tat protein (HIV tat) DMV934L MA Modulator DMV934L RN Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31. DMV934L RU https://pubmed.ncbi.nlm.nih.gov/8627756 DMV96BY DI DMV96BY DMV96BY DN ETS-6218 DMV96BY TI TT7CXIM DMV96BY TN Histamine receptor (HR) DMV96BY MA Modulator DMV96BY RN Clinical pipeline report, company report or official report of e-Therapeutics. DMV96BY RU http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTI2WET DMVA5NS TN Platelet-derived growth factor receptor (PDGFR) DMVA5NS MA Inhibitor DMVA5NS RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMVA5NS RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTUTJGQ DMVA5NS TN Vascular endothelial growth factor receptor 2 (KDR) DMVA5NS MA Inhibitor DMVA5NS RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMVA5NS RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTVJ1D8 DMVA5NS TN Vascular endothelial growth factor receptor (VEGFR) DMVA5NS MA Inhibitor DMVA5NS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVA5NS RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMVACTU DI DMVACTU DMVACTU DN Interferon alpha-2b DMVACTU TI TTSIUJ9 DMVACTU TN Interferon-alpha 2 (IFNA2) DMVACTU MA Modulator DMVACTU RN Clinical pipeline report, company report or official report of Avarx. DMVACTU RU http://www.avarx.com/AvaRx/SubDomains/Company271/Listings/bucketc9a4f99040669fa206037a416235/Public.Listing.display.html DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTVIAT9 DMVADGZ TN Phosphodiesterase 4B (PDE4B) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTSKMI8 DMVADGZ TN Phosphodiesterase 4D (PDE4D) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTZ97H5 DMVADGZ TN Phosphodiesterase 4A (PDE4A) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVB8EO DI DMVB8EO DMVB8EO DN XLCART001 DMVB8EO TI TTW640A DMVB8EO TN B-lymphocyte surface antigen B4 (CD19) DMVB8EO MA CAR-T-Cell-Therapy DMVB8EO RN ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects DMVB8EO RU https://clinicaltrials.gov/ct2/show/NCT03598179 DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTZ97H5 DMVC90W TN Phosphodiesterase 4A (PDE4A) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTVIAT9 DMVC90W TN Phosphodiesterase 4B (PDE4B) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTSKMI8 DMVC90W TN Phosphodiesterase 4D (PDE4D) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVCXZK DI DMVCXZK DMVCXZK DN Rupintrivir DMVCXZK TI TTGW0DV DMVCXZK TN Rhinovirus Protease 3C (HRV P3C) DMVCXZK MA Modulator DMVCXZK RN Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011 Oct;85(19):10319-31. DMVCXZK RU https://pubmed.ncbi.nlm.nih.gov/21795339 DMVDO93 DI DMVDO93 DMVDO93 DN BL-1020 DMVDO93 TI TTEX248 DMVDO93 TN Dopamine D2 receptor (D2R) DMVDO93 MA Antagonist DMVDO93 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMVDO93 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMVDO93 DI DMVDO93 DMVDO93 DN BL-1020 DMVDO93 TI TTNJYV2 DMVDO93 TN Gamma-aminobutyric acid receptor (GAR) DMVDO93 MA Agonist DMVDO93 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMVDO93 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMVIRN3 DI DMVIRN3 DMVIRN3 DN N-DESMETHYLCLOZAPINE DMVIRN3 TI TTZ9SOR DMVIRN3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMVIRN3 MA Modulator DMVIRN3 RN N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95. DMVIRN3 RU https://www.ncbi.nlm.nih.gov/pubmed/15900318 DMVIWNK DI DMVIWNK DMVIWNK DN SFV IL-12 gene therapy DMVIWNK TI TTGW72V DMVIWNK TN Interleukin-12 beta (IL12B) DMVIWNK MA Modulator DMVIWNK RN Clinical pipeline report, company report or official report of Trademarkia. DMVIWNK RU http://www.trademarkia.com/lipovil-12-79009798.html DMVJ6WS DI DMVJ6WS DMVJ6WS DN Melogliptin DMVJ6WS TI TTDIGC1 DMVJ6WS TN Dipeptidyl peptidase 4 (DPP-4) DMVJ6WS MA Inhibitor DMVJ6WS RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMVJ6WS RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMVJB09 DI DMVJB09 DMVJB09 DN MK-1903 DMVJB09 TI TTWNV8U DMVJB09 TN Nicotinic acid receptor (HCAR2) DMVJB09 MA Agonist DMVJB09 RN Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115. DMVJB09 RU https://pubmed.ncbi.nlm.nih.gov/22914621 DMVJD2W DI DMVJD2W DMVJD2W DN Pazopanib + Tyverb/Tykerb DMVJD2W TI TTGKNB4 DMVJD2W TN Epidermal growth factor receptor (EGFR) DMVJD2W MA Inhibitor DMVJD2W RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMVJD2W RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMVJD2W DI DMVJD2W DMVJD2W DN Pazopanib + Tyverb/Tykerb DMVJD2W TI TT6EO5L DMVJD2W TN Erbb2 tyrosine kinase receptor (HER2) DMVJD2W MA Inhibitor DMVJD2W RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMVJD2W RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMVJWPR DI DMVJWPR DMVJWPR DN TOK-001 DMVJWPR TI TTS64P2 DMVJWPR TN Androgen receptor (AR) DMVJWPR MA Inhibitor DMVJWPR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638). DMVJWPR RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638 DMVJXOH DI DMVJXOH DMVJXOH DN BMS-986012 DMVJXOH TI TTW7KYV DMVJXOH TN Fucosyl GM1 (FucGM1) DMVJXOH MA Inhibitor DMVJXOH RN A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. DMVJXOH RU https://pubmed.ncbi.nlm.nih.gov/30021910 DMVKPEZ DI DMVKPEZ DMVKPEZ DN AZD-9164 DMVKPEZ TI TTOXS3C DMVKPEZ TN Muscarinic acetylcholine receptor (CHRM) DMVKPEZ MA Antagonist DMVKPEZ RN The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6. DMVKPEZ RU https://pubmed.ncbi.nlm.nih.gov/22047691 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTZHA0O DMVKW0N TN Carbonic anhydrase IV (CA-IV) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTUNARX DMVKW0N TN Carbonic anhydrase (CA) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTHQPL7 DMVKW0N TN Carbonic anhydrase I (CA-I) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTEYTKG DMVKW0N TN Carbonic anhydrase XIV (CA-XIV) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TT2LVK8 DMVKW0N TN Carbonic anhydrase IX (CA-IX) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTCFSPE DMVKW0N TN Carbonic anhydrase VI (CA-VI) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTHM0R1 DMVKW0N TN Steryl-sulfatase (STS) DMVKW0N MA Inhibitor DMVKW0N RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/20148564 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTSYM0R DMVKW0N TN Carbonic anhydrase XII (CA-XII) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTSZLWK DMVKW0N TN Aromatase (CYP19A1) DMVKW0N MA Inhibitor DMVKW0N RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/20148564 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTANPDJ DMVKW0N TN Carbonic anhydrase II (CA-II) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVLXMG DI DMVLXMG DMVLXMG DN Camostat mesylate DMVLXMG TI TT3FDB1 DMVLXMG TN HUMAN transmembrane protease serine 2 (TMPRSS2) DMVLXMG MA Inhibitor DMVLXMG RN SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. DMVLXMG RU https://pubmed.ncbi.nlm.nih.gov/32142651 DMVM13R DI DMVM13R DMVM13R DN LJPC-401 DMVM13R TI TTPCG5T DMVM13R TN Hepcidin (HAMP) DMVM13R MA Agonist DMVM13R RN ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health. DMVM13R RU https://clinicaltrials.gov/ct2/show/NCT03395704 DMVNAYE DI DMVNAYE DMVNAYE DN MK-8521 DMVNAYE TI TT0NUFM DMVNAYE TN Glucagon (GCG) DMVNAYE MA Co-agonist DMVNAYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVNAYE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVNAYE DI DMVNAYE DMVNAYE DN MK-8521 DMVNAYE TI TT9O6WS DMVNAYE TN Glucagon receptor (GCGR) DMVNAYE MA Co-agonist DMVNAYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVNAYE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVO5DR DI DMVO5DR DMVO5DR DN CP-331684 DMVO5DR TI TTMXGCW DMVO5DR TN Adrenergic receptor beta-3 (ADRB3) DMVO5DR MA Agonist DMVO5DR RN CN patent application no. 1717230, Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor. DMVO5DR RU https://www.google.com/patents/CN1717230A?cl=en DMVQARP DI DMVQARP DMVQARP DN WCK-771 DMVQARP TI TTN6J5F DMVQARP TN Bacterial DNA gyrase (Bact gyrase) DMVQARP MA Modulator DMVQARP RN Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models DMVQARP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196 DMVQARP DI DMVQARP DMVQARP DN WCK-771 DMVQARP TI TTIXTO3 DMVQARP TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVQARP MA Modulator DMVQARP RN Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models DMVQARP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196 DMVQHBK DI DMVQHBK DMVQHBK DN Anti-GD2 CART DMVQHBK TI TT80ARU DMVQHBK TN Ganglioside GD2 (GD2) DMVQHBK MA CAR-T-Cell-Therapy DMVQHBK RN ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma DMVQHBK RU https://clinicaltrials.gov/ct2/show/NCT02765243 DMVR6OM DI DMVR6OM DMVR6OM DN Flotetuzumab DMVR6OM TI TTENHJ0 DMVR6OM TN Interleukin 3 receptor alpha (IL3RA) DMVR6OM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVR6OM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMVRNAO DI DMVRNAO DMVRNAO DN Anti-IP10 DMVRNAO TI TTQOVYA DMVRNAO TN C-X-C motif chemokine 10 (CXCL10) DMVRNAO RN Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50. DMVRNAO RU https://pubmed.ncbi.nlm.nih.gov/23461895 DMVS61L DI DMVS61L DMVS61L DN Tepoxalin DMVS61L TI TTLGTKB DMVS61L TN Interleukin-4 (IL4) DMVS61L MA Inhibitor DMVS61L RN Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30. DMVS61L RU https://pubmed.ncbi.nlm.nih.gov/7575347 DMVS61L DI DMVS61L DMVS61L DN Tepoxalin DMVS61L TI TT2J34L DMVS61L TN Arachidonate 5-lipoxygenase (5-LOX) DMVS61L MA Inhibitor DMVS61L RN Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48. DMVS61L RU https://pubmed.ncbi.nlm.nih.gov/8812216 DMVSUH1 DI DMVSUH1 DMVSUH1 DN JNJ-64565111 DMVSUH1 TI TT0NUFM DMVSUH1 TN Glucagon (GCG) DMVSUH1 MA Agonist DMVSUH1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVSUH1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVU1R9 DI DMVU1R9 DMVU1R9 DN RM-1929 DMVU1R9 TI TTGKNB4 DMVU1R9 TN Epidermal growth factor receptor (EGFR) DMVU1R9 MA Antagonist DMVU1R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVU1R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVUGF7 DI DMVUGF7 DMVUGF7 DN PUR-0110 DMVUGF7 TI TT4EWFY DMVUGF7 TN TNF/IL-10 release (TNF/IL10 rele) DMVUGF7 MA Modulator DMVUGF7 RN PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production. Clin Exp Immunol. 2004 Mar;135(3):440-7. DMVUGF7 RU https://pubmed.ncbi.nlm.nih.gov/15008976 DMVUX1C DI DMVUX1C DMVUX1C DN BFH-772 DMVUX1C TI TTVJ1D8 DMVUX1C TN Vascular endothelial growth factor receptor (VEGFR) DMVUX1C MA Agonist DMVUX1C RN CA patent application no. 841416, Method of selecting therapeutic indications. DMVUX1C RU http://www.google.com/patents/CA2841416A1?cl=en DMVW5KR DI DMVW5KR DMVW5KR DN Olcegepant DMVW5KR TI TTY6O0Q DMVW5KR TN Calcitonin gene-related peptide receptor (CGRPR) DMVW5KR MA Modulator DMVW5KR RN Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74. DMVW5KR RU https://www.ncbi.nlm.nih.gov/pubmed/17665333 DMVX6H0 DI DMVX6H0 DMVX6H0 DN TRV027 DMVX6H0 TI TT8DBY3 DMVX6H0 TN Angiotensin II receptor type-1 (AGTR1) DMVX6H0 MA Antagonist DMVX6H0 RN First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9. DMVX6H0 RU https://pubmed.ncbi.nlm.nih.gov/23813302 DMVXGU0 DI DMVXGU0 DMVXGU0 DN RG7596 DMVXGU0 TI TTBN5I7 DMVXGU0 TN B-cell-specific glycoprotein B29 (CD79B) DMVXGU0 MA Modulator DMVXGU0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852). DMVXGU0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852 DMVXLQ7 DI DMVXLQ7 DMVXLQ7 DN TLN-4601 DMVXLQ7 TI TTPTXIN DMVXLQ7 TN Translocator protein (TSPO) DMVXLQ7 MA Modulator DMVXLQ7 RN TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation.Biochem Pharmacol.2010 Nov 15;80(10):1572-9. DMVXLQ7 RU https://www.ncbi.nlm.nih.gov/pubmed/20655882 DMVXZC4 DI DMVXZC4 DMVXZC4 DN OBP-601 DMVXZC4 TI TT84ETX DMVXZC4 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMVXZC4 MA Inhibitor DMVXZC4 RN Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. DMVXZC4 RU https://pubmed.ncbi.nlm.nih.gov/22733071 DMVXZJ4 DI DMVXZJ4 DMVXZJ4 DN RetinoStat DMVXZJ4 TI TT63DI9 DMVXZJ4 TN Endostatin (COL18A1) DMVXZJ4 MA Modulator DMVXZJ4 RN Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91. DMVXZJ4 RU https://pubmed.ncbi.nlm.nih.gov/22716662 DMVXZJ4 DI DMVXZJ4 DMVXZJ4 DN RetinoStat DMVXZJ4 TI TTP86E2 DMVXZJ4 TN Plasminogen (PLG) DMVXZJ4 MA Modulator DMVXZJ4 RN Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91. DMVXZJ4 RU https://pubmed.ncbi.nlm.nih.gov/22716662 DMVZ01T DI DMVZ01T DMVZ01T DN SSR240600 DMVZ01T TI TTZPO1L DMVZ01T TN Substance-P receptor (TACR1) DMVZ01T MA Antagonist DMVZ01T RN SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. DMVZ01T RU https://pubmed.ncbi.nlm.nih.gov/12438541 DMVZT2I DI DMVZT2I DMVZT2I DN CX-072 DMVZT2I TI TT8ZLTI DMVZT2I TN Programmed cell death 1 ligand 1 (PD-L1) DMVZT2I MA Inhibitor DMVZT2I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVZT2I RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMW03YD DI DMW03YD DMW03YD DN BAN2401 DMW03YD TI TTE4KHA DMW03YD TN Amyloid beta A4 protein (APP) DMW03YD MA Modulator DMW03YD RN The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88. DMW03YD RU https://pubmed.ncbi.nlm.nih.gov/25096615 DMW145U DI DMW145U DMW145U DN TMC-310911 DMW145U TI TT5FNQT DMW145U TN Human immunodeficiency virus Protease (HIV PR) DMW145U MA Inhibitor DMW145U RN Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology Volume 21, Issue 9, 18 September 2014, Pages 1115-1142. DMW145U RU http://www.sciencedirect.com/science/article/pii/S1074552114002890 DMW17KS DI DMW17KS DMW17KS DN TOL-3021 DMW17KS TI TTUTN1I DMW17KS TN Human Deoxyribonucleic acid (hDNA) DMW17KS MA Modulator DMW17KS RN Clinical pipeline report, company report or official report of Tolerion. DMW17KS RU http://www.tolerioninc.com/TOL-3021_press_release.html DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TTI2WET DMW1NKO TN Platelet-derived growth factor receptor (PDGFR) DMW1NKO MA Modulator DMW1NKO RN National Cancer Institute Drug Dictionary (drug id 695817). DMW1NKO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817 DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TT2Q6G1 DMW1NKO TN Vascular endothelial growth factor receptor 1 (FLT-1) DMW1NKO MA Modulator DMW1NKO RN National Cancer Institute Drug Dictionary (drug id 695817). DMW1NKO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817 DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TTVJ1D8 DMW1NKO TN Vascular endothelial growth factor receptor (VEGFR) DMW1NKO MA Inhibitor DMW1NKO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW1NKO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW1OI6 DI DMW1OI6 DMW1OI6 DN P32/98 DMW1OI6 TI TTDIGC1 DMW1OI6 TN Dipeptidyl peptidase 4 (DPP-4) DMW1OI6 MA Inhibitor DMW1OI6 RN Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50. DMW1OI6 RU https://pubmed.ncbi.nlm.nih.gov/11916911 DMW2IF9 DI DMW2IF9 DMW2IF9 DN IR502 DMW2IF9 TI TT7AKW1 DMW2IF9 TN T-cell receptor (TCR) DMW2IF9 MA Modulator DMW2IF9 RN WO patent application no. 2004,0677,06, Production of multimeric proteins. DMW2IF9 RU http://www.google.com/patents/WO2004067706A2?cl=en DMW2QYT DI DMW2QYT DMW2QYT DN Firategrast DMW2QYT TI TT6S84X DMW2QYT TN Integrin alpha-4/beta-1 (ITGA4/B1) DMW2QYT MA Modulator DMW2QYT RN Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9. DMW2QYT RU https://www.ncbi.nlm.nih.gov/pubmed/22226929 DMW4LTI DI DMW4LTI DMW4LTI DN Votucalis DMW4LTI TI TT7CXIM DMW4LTI TN Histamine receptor (HR) DMW4LTI MA Antagonist DMW4LTI RN CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils. DMW4LTI RU http://www.google.com.ar/patents/CA2520580A1?cl=en DMW4YK1 DI DMW4YK1 DMW4YK1 DN Remogliflozin etabonate DMW4YK1 TI TTN7Y4P DMW4YK1 TN Sodium/glucose cotransporter 2 (SLC5A4) DMW4YK1 MA Blocker DMW4YK1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW4YK1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW4YK1 DI DMW4YK1 DMW4YK1 DN Remogliflozin etabonate DMW4YK1 TI TTLWPVF DMW4YK1 TN Sodium/glucose cotransporter 2 (SGLT2) DMW4YK1 MA Inhibitor DMW4YK1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW4YK1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMW50NF DI DMW50NF DMW50NF DN LE-SN38 DMW50NF TI TTGTQHC DMW50NF TN DNA topoisomerase I (TOP1) DMW50NF MA Inhibitor DMW50NF RN Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012 Nov;32(11):4823-32. DMW50NF RU https://pubmed.ncbi.nlm.nih.gov/23155248 DMW6NMP DI DMW6NMP DMW6NMP DN L19-TNF-alpha DMW6NMP TI TTPJ921 DMW6NMP TN Fibronectin (FN1) DMW6NMP RN National Cancer Institute Drug Dictionary (drug id 686947). DMW6NMP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=686947 DMW6UA3 DI DMW6UA3 DMW6UA3 DN SR-46559A DMW6UA3 TI TTZ9SOR DMW6UA3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMW6UA3 MA Agonist DMW6UA3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMW6UA3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMW6VA0 DI DMW6VA0 DMW6VA0 DN LM-1507.NA DMW6VA0 TI TTGKOY9 DMW6VA0 TN Leukotriene CysLT1 receptor (CYSLTR1) DMW6VA0 MA Antagonist DMW6VA0 RN Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46. DMW6VA0 RU https://pubmed.ncbi.nlm.nih.gov/11996896 DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TT2LBCR DMW7L0Y TN HUMAN toll-like receptor 9 (TLR9) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TTAVUMS DMW7L0Y TN HUMAN toll-like receptor 2 (TLR2) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TTLSU52 DMW7L0Y TN HUMAN toll-like receptor 6 (TLR6) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7PFS DI DMW7PFS DMW7PFS DN Turosteride DMW7PFS TI TT2A0DR DMW7PFS TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMW7PFS MA Inhibitor DMW7PFS RN Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55. DMW7PFS RU https://pubmed.ncbi.nlm.nih.gov/8240976 DMW8X05 DI DMW8X05 DMW8X05 DN THR-149 DMW8X05 TI TTMF8H9 DMW8X05 TN Plasma kallikrein (KLKB1) DMW8X05 MA Inhibitor DMW8X05 RN Clinical pipeline report, company report or official report of Oxurion. DMW8X05 RU https://www.oxurion.com/product/thr-149-pkal-inhibitor DMW9F1G DI DMW9F1G DMW9F1G DN CKD602 DMW9F1G TI TTGTQHC DMW9F1G TN DNA topoisomerase I (TOP1) DMW9F1G MA Inhibitor DMW9F1G RN Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998 Oct;21(5):581-90. DMW9F1G RU https://pubmed.ncbi.nlm.nih.gov/9875499 DMWAD93 DI DMWAD93 DMWAD93 DN Leniolisib DMWAD93 TI TTGBPJE DMWAD93 TN PI3-kinase delta (PIK3CD) DMWAD93 MA Inhibitor DMWAD93 RN Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316. DMWAD93 RU https://pubmed.ncbi.nlm.nih.gov/28972011 DMWB94K DI DMWB94K DMWB94K DN Evenamide DMWB94K TI TTIG65Q DMWB94K TN Voltage-gated sodium channel (Nav) DMWB94K MA Blocker DMWB94K RN Clinical pipeline report, company report or official report of Newron Pharmaceuticals. DMWB94K RU https://www.newron.com/science#evenamide DMWC36Y DI DMWC36Y DMWC36Y DN OMS405 DMWC36Y TI TTZMAO3 DMWC36Y TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMWC36Y MA Agonist DMWC36Y RN Clinical pipeline report, company report or official report of Avarx. DMWC36Y RU http://www.avarx.com/AvaRx/SubDomains/bucket4984694478449561395/Listings/bucket4040741479008611375/Public.Listing.display.html DMWCBY7 DI DMWCBY7 DMWCBY7 DN Odiparcil DMWCBY7 TI TT6L509 DMWCBY7 TN Coagulation factor IIa (F2) DMWCBY7 MA Inhibitor DMWCBY7 RN A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. DMWCBY7 RU https://pubmed.ncbi.nlm.nih.gov/16961606 DMWDJ15 DI DMWDJ15 DMWDJ15 DN UFT/leucovorin calcium DMWDJ15 TI TTU6BFZ DMWDJ15 TN Candida Thymidylate synthase (Candi TMP1) DMWDJ15 MA Modulator DMWDJ15 RN Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008-12. DMWDJ15 RU https://pubmed.ncbi.nlm.nih.gov/2521810 DMWE7B9 DI DMWE7B9 DMWE7B9 DN CX-4945 DMWE7B9 TI TTZ5NI7 DMWE7B9 TN Casein kinase II (CSNK2) DMWE7B9 MA Modulator DMWE7B9 RN CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6. DMWE7B9 RU https://pubmed.ncbi.nlm.nih.gov/23900138 DMWE7B9 DI DMWE7B9 DMWE7B9 DN CX-4945 DMWE7B9 TI TTER6YH DMWE7B9 TN Casein kinase II alpha (CSNK2A1) DMWE7B9 MA Inhibitor DMWE7B9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWE7B9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWEB07 DI DMWEB07 DMWEB07 DN XOMA-629 DMWEB07 TI TTXCSDR DMWEB07 TN Protein bactericidal permeability-increasing (BPI) DMWEB07 MA Inhibitor DMWEB07 RN Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54. DMWEB07 RU https://pubmed.ncbi.nlm.nih.gov/22421877 DMWFTRJ DI DMWFTRJ DMWFTRJ DN MK-0354 DMWFTRJ TI TTWNV8U DMWFTRJ TN Nicotinic acid receptor (HCAR2) DMWFTRJ MA Inhibitor DMWFTRJ RN GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. DMWFTRJ RU https://pubmed.ncbi.nlm.nih.gov/20615702 DMWH7Z5 DI DMWH7Z5 DMWH7Z5 DN BI-836826 DMWH7Z5 TI TTFCW29 DMWH7Z5 TN Leukocyte antigen CD37 (CD37) DMWH7Z5 RN Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61. DMWH7Z5 RU https://pubmed.ncbi.nlm.nih.gov/24555705 DMWI0X3 DI DMWI0X3 DMWI0X3 DN Barusiban DMWI0X3 TI TTSCIUP DMWI0X3 TN Oxytocin receptor (OTR) DMWI0X3 MA Antagonist DMWI0X3 RN The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10. DMWI0X3 RU https://pubmed.ncbi.nlm.nih.gov/19306963 DMWJMFZ DI DMWJMFZ DMWJMFZ DN Miravirsen DMWJMFZ TI TTP03CE DMWJMFZ TN Hepatitis C virus microRNA miR-122 (HCV MIR122) DMWJMFZ MA Modulator DMWJMFZ RN Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic Acids Res.2014 Jan;42(1):609-21. DMWJMFZ RU https://www.ncbi.nlm.nih.gov/pubmed/24068553 DMWK26Q DI DMWK26Q DMWK26Q DN EPX-200 DMWK26Q TI TT85JO3 DMWK26Q TN 5-HT receptor (5HTR) DMWK26Q MA Modulator DMWK26Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWK26Q RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWK9BX DI DMWK9BX DMWK9BX DN SQ-109 DMWK9BX TI TTTLB3R DMWK9BX TN Mycobacterium Membrane protein mmpL3 (MycB mmpL3) DMWK9BX MA Modulator DMWK9BX RN SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809. DMWK9BX RU https://pubmed.ncbi.nlm.nih.gov/22252828 DMWLIPJ DI DMWLIPJ DMWLIPJ DN MAXY-G34 DMWLIPJ TI TTC70AJ DMWLIPJ TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMWLIPJ MA Agonist DMWLIPJ RN Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38. DMWLIPJ RU https://pubmed.ncbi.nlm.nih.gov/24276547 DMWN2EC DI DMWN2EC DMWN2EC DN ORG-25935 DMWN2EC TI TTHJTF7 DMWN2EC TN Glycine transporter GlyT-1 (SLC6A9) DMWN2EC MA Inhibitor DMWN2EC RN The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8. DMWN2EC RU https://pubmed.ncbi.nlm.nih.gov/24525661 DMWNYIE DI DMWNYIE DMWNYIE DN Bemarituzumab DMWNYIE TI TTGKIED DMWNYIE TN Fibroblast growth factor-2 (FGF2) DMWNYIE MA Antagonist DMWNYIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWNYIE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TTM7WCE DMWP59B TN Ion channel unspecific (IC) DMWP59B MA Antagonist DMWP59B RN A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9. DMWP59B RU https://pubmed.ncbi.nlm.nih.gov/22205496 DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TTRK8B9 DMWP59B TN Sodium channel unspecific (NaC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TT5HONZ DMWP59B TN Calcium channel unspecific (CaC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TT1VOHK DMWP59B TN Potassium channel unspecific (KC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWPDUZ DI DMWPDUZ DMWPDUZ DN BTRX-335140 DMWPDUZ TI TTQW87Y DMWPDUZ TN Opioid receptor kappa (OPRK1) DMWPDUZ MA Antagonist DMWPDUZ RN Clinical pipeline report, company report or official report of BlackThorn Therapeutics. DMWPDUZ RU https://www.blackthornrx.com/btrx-335140-kappa-opioid-receptor-antagonist/ DMWPGB8 DI DMWPGB8 DMWPGB8 DN Amg 747 DMWPGB8 TI TTHJTF7 DMWPGB8 TN Glycine transporter GlyT-1 (SLC6A9) DMWPGB8 MA Modulator DMWPGB8 RN Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. DMWPGB8 RU https://pubmed.ncbi.nlm.nih.gov/24172334 DMWPGLS DI DMWPGLS DMWPGLS DN ASN100 DMWPGLS TI TTKE96O DMWPGLS TN Staphylococcus Five leukocidin toxins (Stap-coc lukF) DMWPGLS MA Modulator DMWPGLS RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMWPGLS RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMWPGLS DI DMWPGLS DMWPGLS DN ASN100 DMWPGLS TI TT5FLYB DMWPGLS TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DMWPGLS MA Modulator DMWPGLS RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMWPGLS RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMWPI2U DI DMWPI2U DMWPI2U DN TC-6499-12 DMWPI2U TI TTL1ATN DMWPI2U TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMWPI2U MA Modulator DMWPI2U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWPI2U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWPSJR DI DMWPSJR DMWPSJR DN TAK-831 DMWPSJR TI TT7Y3EJ DMWPSJR TN D-amino acid oxidase (DAO) DMWPSJR MA Inhibitor DMWPSJR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWPSJR RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMWT73D DI DMWT73D DMWT73D DN PMX-60056 DMWT73D TI TT4QPUL DMWT73D TN Antithrombin-III (ATIII) DMWT73D MA Antagonist DMWT73D RN Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721. DMWT73D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070/ DMWU41P DI DMWU41P DMWU41P DN TRIDMAC DMWU41P TI TTJSZTB DMWU41P TN Nicotinic acetylcholine receptor (nAChR) DMWU41P MA Antagonist DMWU41P RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMWU41P RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMWUQI9 DI DMWUQI9 DMWUQI9 DN CER-001 DMWUQI9 TI TT7GN3U DMWUQI9 TN Apolipoprotein A-I (APOA1) DMWUQI9 MA Modulator DMWUQI9 RN Clinical pipeline report, company report or official report of Cerenis. DMWUQI9 RU http://www.cerenis.com/en/our-therapies/cer-001 DMWV2N1 DI DMWV2N1 DMWV2N1 DN IONIS-GCCRRX DMWV2N1 TI TTYRL6O DMWV2N1 TN Glucocorticoid receptor (NR3C1) DMWV2N1 MA Antagonist DMWV2N1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV2N1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMWVBS2 DI DMWVBS2 DMWVBS2 DN NXN-462 DMWVBS2 TI TTZUFI5 DMWVBS2 TN Nitric-oxide synthase brain (NOS1) DMWVBS2 MA Inhibitor DMWVBS2 RN ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health. DMWVBS2 RU https://clinicaltrials.gov/ct2/show/NCT01748877 DMWVBTQ DI DMWVBTQ DMWVBTQ DN PD-145065 DMWVBTQ TI TTKRD0G DMWVBTQ TN Endothelin A receptor (EDNRA) DMWVBTQ MA Modulator DMWVBTQ RN Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13. DMWVBTQ RU https://pubmed.ncbi.nlm.nih.gov/8032643 DMWVBTQ DI DMWVBTQ DMWVBTQ DN PD-145065 DMWVBTQ TI TT3ZTGU DMWVBTQ TN Endothelin B receptor (EDNRB) DMWVBTQ MA Modulator DMWVBTQ RN Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13. DMWVBTQ RU https://pubmed.ncbi.nlm.nih.gov/8032643 DMWVPO0 DI DMWVPO0 DMWVPO0 DN BPN14770 DMWVPO0 TI TTSKMI8 DMWVPO0 TN Phosphodiesterase 4D (PDE4D) DMWVPO0 MA Inhibitor DMWVPO0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWVPO0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWXJSZ DI DMWXJSZ DMWXJSZ DN GRC-15300 DMWXJSZ TI TTMI6F5 DMWXJSZ TN Transient receptor potential cation channel V1 (TRPV1) DMWXJSZ MA Antagonist DMWXJSZ RN The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759. DMWXJSZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966322/ DMWY0V1 DI DMWY0V1 DMWY0V1 DN LIPO-5 DMWY0V1 TI TTFGZB6 DMWY0V1 TN Human immunodeficiency virus GAG protein (HIV gag) DMWY0V1 RN HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. DMWY0V1 RU https://pubmed.ncbi.nlm.nih.gov/25839103 DMWY0V1 DI DMWY0V1 DMWY0V1 DN LIPO-5 DMWY0V1 TI TT4NXYM DMWY0V1 TN Human immunodeficiency virus Negative factor (HIV nef) DMWY0V1 RN HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. DMWY0V1 RU https://pubmed.ncbi.nlm.nih.gov/25839103 DMWY609 DI DMWY609 DMWY609 DN CG201 DMWY609 TI TT0ID4A DMWY609 TN Leutinizing-hormone-releasing hormone (GNRH1) DMWY609 MA Modulator DMWY609 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWY609 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWYMJN DI DMWYMJN DMWYMJN DN ALN-CC5 DMWYMJN TI TT2LJRF DMWYMJN TN C5 messenger RNA (C5 mRNA) DMWYMJN MA Inhibitor DMWYMJN RN Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492. DMWYMJN RU https://pubmed.ncbi.nlm.nih.gov/31193726 DMX04O8 DI DMX04O8 DMX04O8 DN NYX-2925 DMX04O8 TI TT9IK2Z DMX04O8 TN N-methyl-D-aspartate receptor (NMDAR) DMX04O8 MA Modulator DMX04O8 RN NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther. 2018 Sep;366(3):485-497. DMX04O8 RU https://pubmed.ncbi.nlm.nih.gov/29986951 DMX054A DI DMX054A DMX054A DN CP-547632 DMX054A TI TTUTJGQ DMX054A TN Vascular endothelial growth factor receptor 2 (KDR) DMX054A MA Inhibitor DMX054A RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMX054A RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMX1KDM DI DMX1KDM DMX1KDM DN ABI-H0731 DMX1KDM TI TTM42UJ DMX1KDM TN Hepatitis B virus Capsid protein (HBV C) DMX1KDM MA Inhibitor DMX1KDM RN Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. DMX1KDM RU https://pubmed.ncbi.nlm.nih.gov/31711752 DMX27IT DI DMX27IT DMX27IT DN DTRM-555 DMX27IT TI TTGM6VW DMX27IT TN Tyrosine-protein kinase BTK (ATK) DMX27IT MA Inhibitor DMX27IT RN ClinicalTrials.gov (NCT04305444) Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas. U.S. National Institutes of Health. DMX27IT RU https://clinicaltrials.gov/ct2/show/NCT04305444 DMX27Q1 DI DMX27Q1 DMX27Q1 DN GSK933776A DMX27Q1 TI TTE4KHA DMX27Q1 TN Amyloid beta A4 protein (APP) DMX27Q1 MA Modulator DMX27Q1 RN Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569. DMX27Q1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832388/ DMX2LO3 DI DMX2LO3 DMX2LO3 DN 99mTc-RP-128 DMX2LO3 TI TTYG378 DMX2LO3 TN Tuftsin receptor (TR) DMX2LO3 MA Modulator DMX2LO3 RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMX2LO3 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMX2P5G DI DMX2P5G DMX2P5G DN APX005M DMX2P5G TI TTN6Y9A DMX2P5G TN CD40L receptor (CD40) DMX2P5G MA Agonist DMX2P5G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX2P5G RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTUTJGQ DMX302C TN Vascular endothelial growth factor receptor 2 (KDR) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTGKNB4 DMX302C TN Epidermal growth factor receptor (EGFR) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTR5TV4 DMX302C TN ERBB2 messenger RNA (HER2 mRNA) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTGJCWZ DMX302C TN Fms-like tyrosine kinase 3 (FLT-3) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX4DQH DI DMX4DQH DMX4DQH DN Delanzomib DMX4DQH TI TTU7ZMG DMX4DQH TN Proteasome (PS) DMX4DQH MA Modulator DMX4DQH RN Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70. DMX4DQH RU https://pubmed.ncbi.nlm.nih.gov/22178195 DMX4MVP DI DMX4MVP DMX4MVP DN ONO-4053 DMX4MVP TI TTNVEIR DMX4MVP TN Prostaglandin D2 receptor (PTGDR) DMX4MVP MA Antagonist DMX4MVP RN Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219. DMX4MVP RU http://www.sciencedirect.com/science/article/pii/S0091674914034332 DMX4RSD DI DMX4RSD DMX4RSD DN EFEGATRAN SULFATE HYDRATE DMX4RSD TI TT6L509 DMX4RSD TN Coagulation factor IIa (F2) DMX4RSD MA Inhibitor DMX4RSD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMX4RSD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMX4U0B DI DMX4U0B DMX4U0B DN MCS-18 DMX4U0B TI TTY7ZHS DMX4U0B TN Toll-like receptor 2 (TLR2) DMX4U0B MA Modulator DMX4U0B RN The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31. DMX4U0B RU https://pubmed.ncbi.nlm.nih.gov/18507149 DMX5SG7 DI DMX5SG7 DMX5SG7 DN AZD1772//RDX5791 DMX5SG7 TI TTFZVPO DMX5SG7 TN Sodium/hydrogen exchanger 3 (SLC9A3) DMX5SG7 MA Modulator DMX5SG7 RN RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99. DMX5SG7 RU http://www.gastrojournal.org/article/S0016-5085(11)60405-8/pdf DMX6B95 DI DMX6B95 DMX6B95 DN HER1-VSSP vaccine DMX6B95 TI TTGKNB4 DMX6B95 TN Epidermal growth factor receptor (EGFR) DMX6B95 RN Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9. DMX6B95 RU https://pubmed.ncbi.nlm.nih.gov/16841332 DMX6RZG DI DMX6RZG DMX6RZG DN EFT508 DMX6RZG TI TTEZAUX DMX6RZG TN MAPK signal-integrating kinase 1 (MKNK1) DMX6RZG MA Inhibitor DMX6RZG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX6RZG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX6RZG DI DMX6RZG DMX6RZG DN EFT508 DMX6RZG TI TTRECN3 DMX6RZG TN MAP kinase signal-integrating kinase 2 (MKNK2) DMX6RZG MA Inhibitor DMX6RZG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX6RZG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX8C6J DI DMX8C6J DMX8C6J DN HCB1019 DMX8C6J TI TT4F7SL DMX8C6J TN Gap junction alpha-1 protein (GJA1) DMX8C6J MA Inhibitor DMX8C6J RN Clinical pipeline report, company report or official report of OcuNexus Therapeutics. DMX8C6J RU https://ocunexus.com/ophthalmic DMX8JYN DI DMX8JYN DMX8JYN DN RG-7090 DMX8JYN TI TTHS256 DMX8JYN TN Metabotropic glutamate receptor 5 (mGluR5) DMX8JYN MA Antagonist DMX8JYN RN The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250. DMX8JYN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932172/ DMX8ZAQ DI DMX8ZAQ DMX8ZAQ DN Paliroden DMX8ZAQ TI TT9HLZ0 DMX8ZAQ TN Glutamate receptor AMPA 2 (GRIA2) DMX8ZAQ MA Modulator DMX8ZAQ RN Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44. DMX8ZAQ RU https://www.ncbi.nlm.nih.gov/pubmed/23402301 DMX9MSL DI DMX9MSL DMX9MSL DN 2X-121 DMX9MSL TI TTEBCY8 DMX9MSL TN Poly [ADP-ribose] polymerase (PARP) DMX9MSL MA Inhibitor DMX9MSL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX9MSL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX9MSL DI DMX9MSL DMX9MSL DN 2X-121 DMX9MSL TI TTKSAQZ DMX9MSL TN Tankyrase (TNKS) DMX9MSL MA Inhibitor DMX9MSL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX9MSL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTWG9A4 DMX9Y7V TN Adrenergic receptor alpha-2A (ADRA2A) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTBRKXS DMX9Y7V TN Adrenergic receptor alpha-1B (ADRA1B) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TT34BHT DMX9Y7V TN Adrenergic receptor alpha-1D (ADRA1D) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTWM4TY DMX9Y7V TN Adrenergic receptor alpha-2B (ADRA2B) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTNGILX DMX9Y7V TN Adrenergic receptor alpha-1A (ADRA1A) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TT2NUT5 DMX9Y7V TN Adrenergic receptor alpha-2C (ADRA2C) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9ZM4 DI DMX9ZM4 DMX9ZM4 DN PEG-SN38 DMX9ZM4 TI TTGTQHC DMX9ZM4 TN DNA topoisomerase I (TOP1) DMX9ZM4 MA Inhibitor DMX9ZM4 RN EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7(9):e45248. DMX9ZM4 RU https://pubmed.ncbi.nlm.nih.gov/23028879 DMXA6B3 DI DMXA6B3 DMXA6B3 DN RO-4929097 DMXA6B3 TI TT9W8GU DMXA6B3 TN Gamma-secretase (GS) DMXA6B3 MA Modulator DMXA6B3 RN Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53. DMXA6B3 RU https://pubmed.ncbi.nlm.nih.gov/22529266 DMXAH4G DI DMXAH4G DMXAH4G DN PD-143188 DMXAH4G TI TTEX248 DMXAH4G TN Dopamine D2 receptor (D2R) DMXAH4G MA Modulator DMXAH4G RN Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 1998;62(7):649-63. DMXAH4G RU https://pubmed.ncbi.nlm.nih.gov/9472724 DMXB6KG DI DMXB6KG DMXB6KG DN FAD-104 DMXB6KG TI TTUTN1I DMXB6KG TN Human Deoxyribonucleic acid (hDNA) DMXB6KG MA Binder DMXB6KG RN Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65. DMXB6KG RU https://pubmed.ncbi.nlm.nih.gov/1694165 DMXB9RS DI DMXB9RS DMXB9RS DN ROTIGAPTIDE DMXB9RS TI TTJO6E9 DMXB9RS TN Gap junction protein (GJP) DMXB9RS MA Modulator DMXB9RS RN The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95. DMXB9RS RU https://pubmed.ncbi.nlm.nih.gov/16415913 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTL69WB DMXBR27 TN Angiotensin-converting enzyme (ACE) DMXBR27 MA Inhibitor DMXBR27 RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TT5TKPM DMXBR27 TN Neutral endopeptidase (MME) DMXBR27 MA Inhibitor DMXBR27 RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTE6THL DMXBR27 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) DMXBR27 MA Inhibitor DMXBR27 RN Interaction of D-600 with the transmembrane domain of the sarcoplasmic reticulum Ca(2+)-ATPase. Am J Physiol Cell Physiol. 2000 Jul;279(1):C166-72. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/10898728 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTXHYV6 DMXBR27 TN Voltage-gated L-type calcium channel (L-CaC) DMXBR27 MA Blocker DMXBR27 RN Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/18258561 DMXCJKY DI DMXCJKY DMXCJKY DN SLV-334 DMXCJKY TI TT5TKPM DMXCJKY TN Neutral endopeptidase (MME) DMXCJKY MA Modulator DMXCJKY RN Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26. DMXCJKY RU https://www.ncbi.nlm.nih.gov/pubmed/20129503 DMXCJKY DI DMXCJKY DMXCJKY DN SLV-334 DMXCJKY TI TT1BGDH DMXCJKY TN Endothelin-converting enzyme (ECE) DMXCJKY MA Modulator DMXCJKY RN Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26. DMXCJKY RU https://www.ncbi.nlm.nih.gov/pubmed/20129503 DMXDVNZ DI DMXDVNZ DMXDVNZ DN S-555739 DMXDVNZ TI TTNVEIR DMXDVNZ TN Prostaglandin D2 receptor (PTGDR) DMXDVNZ MA Antagonist DMXDVNZ RN Clinical pipeline report, company report or official report of Shionogi (2011). DMXDVNZ RU http://www.shionogi.co.jp/index_e.html DMXEQ0R DI DMXEQ0R DMXEQ0R DN LTX-109 DMXEQ0R TI TTXT4D5 DMXEQ0R TN Bacterial Cell membrane (Bact CM) DMXEQ0R MA Modulator DMXEQ0R RN A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95. DMXEQ0R RU https://pubmed.ncbi.nlm.nih.gov/21732630 DMXF26Y DI DMXF26Y DMXF26Y DN AZD7325 DMXF26Y TI TTAN6JD DMXF26Y TN Glutamate receptor AMPA (GRIA) DMXF26Y MA Agonist DMXF26Y RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMXF26Y RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMXG5WU DI DMXG5WU DMXG5WU DN Xanomeline tartrate DMXG5WU TI TTZ9SOR DMXG5WU TN Muscarinic acetylcholine receptor M1 (CHRM1) DMXG5WU MA Agonist DMXG5WU RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMXG5WU RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMXG9ES DI DMXG9ES DMXG9ES DN RXI-109 DMXG9ES TI TTIL516 DMXG9ES TN CCN2 messenger RNA (CCN2 mRNA) DMXG9ES MA Inhibitor DMXG9ES RN The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446. DMXG9ES RU https://pubmed.ncbi.nlm.nih.gov/30846871 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTSC2YM DMXH1KC TN Mitochondrial uncoupling protein 2 (UCP2) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTMXGCW DMXH1KC TN Adrenergic receptor beta-3 (ADRB3) DMXH1KC MA Agonist DMXH1KC RN Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/11472270 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTI12YJ DMXH1KC TN Mitochondrial uncoupling protein 1 (UCP1) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TT12RJK DMXH1KC TN Mitochondrial uncoupling protein 3 (UCP3) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXI9BP DI DMXI9BP DMXI9BP DN Brilacidin DMXI9BP TI TTXT4D5 DMXI9BP TN Bacterial Cell membrane (Bact CM) DMXI9BP MA Enhancer DMXI9BP RN Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45. DMXI9BP RU https://pubmed.ncbi.nlm.nih.gov/24936592 DMXJ8Z4 DI DMXJ8Z4 DMXJ8Z4 DN AK104 DMXJ8Z4 TI TTI2S1D DMXJ8Z4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMXJ8Z4 MA Inhibitor DMXJ8Z4 RN Clinical pipeline report, company report or official report of Akeso Biopharma. DMXJ8Z4 RU https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/ DMXJ8Z4 DI DMXJ8Z4 DMXJ8Z4 DN AK104 DMXJ8Z4 TI TTNBFWK DMXJ8Z4 TN Programmed cell death protein 1 (PD-1) DMXJ8Z4 MA Inhibitor DMXJ8Z4 RN Clinical pipeline report, company report or official report of Akeso Biopharma. DMXJ8Z4 RU https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/ DMXJWNS DI DMXJWNS DMXJWNS DN MM-093 DMXJWNS TI TTCFEA1 DMXJWNS TN Alpha-fetoprotein (AFP) DMXJWNS MA Modulator DMXJWNS RN MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007 Dec;9(6):603-10. DMXJWNS RU https://pubmed.ncbi.nlm.nih.gov/18041671 DMXKOW6 DI DMXKOW6 DMXKOW6 DN MKC-1106-MT DMXKOW6 TI TT362RB DMXKOW6 TN MART-1 melanoma antigen (MLANA) DMXKOW6 MA Modulator DMXKOW6 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXKOW6 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXKOW6 DI DMXKOW6 DMXKOW6 DN MKC-1106-MT DMXKOW6 TI TTULVH8 DMXKOW6 TN Tyrosinase (TYR) DMXKOW6 MA Modulator DMXKOW6 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXKOW6 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXL7HO DI DMXL7HO DMXL7HO DN OLX10010 DMXL7HO TI TTIL516 DMXL7HO TN CCN2 messenger RNA (CCN2 mRNA) DMXL7HO MA Inhibitor DMXL7HO RN Clinical pipeline report, company report or official report of Olix Pharmaceuticals. DMXL7HO RU https://www.olixpharma.com/eng/rnd/rnd03_olx101a.php DMXLAPF DI DMXLAPF DMXLAPF DN UCB-11056 DMXLAPF TI TT0QZ8R DMXLAPF TN cAMP formation (cAMP form) DMXLAPF MA Modulator DMXLAPF RN ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61. DMXLAPF RU https://pubmed.ncbi.nlm.nih.gov/8245976 DMXLE71 DI DMXLE71 DMXLE71 DN SYL-040012 DMXLE71 TI TTG8ZWP DMXLE71 TN ADRB2 messenger RNA (ADRB2 mRNA) DMXLE71 RN In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91. DMXLE71 RU https://pubmed.ncbi.nlm.nih.gov/24025749 DMXM34I DI DMXM34I DMXM34I DN O-304 DMXM34I TI TTLAFZV DMXM34I TN AMP-activated protein kinase (AMPK) DMXM34I MA Activator DMXM34I RN Clinical pipeline report, company report or official report of Betagenon. DMXM34I RU https://betagenon.com/research-development/o304-our-ampk-activator DMXMC8I DI DMXMC8I DMXMC8I DN FGF-1 DMXMC8I TI TTRLW2X DMXMC8I TN Fibroblast growth factor receptor 1 (FGFR1) DMXMC8I MA Binder DMXMC8I RN Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70. DMXMC8I RU https://pubmed.ncbi.nlm.nih.gov/12085177 DMXO4T8 DI DMXO4T8 DMXO4T8 DN GLPG0974 DMXO4T8 TI TT0FYAN DMXO4T8 TN Free fatty acid receptor 2 (FFAR2) DMXO4T8 MA Antagonist DMXO4T8 RN Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57. DMXO4T8 RU https://pubmed.ncbi.nlm.nih.gov/25380412 DMXOTMP DI DMXOTMP DMXOTMP DN FPI-01 DMXOTMP TI TTZ8UT4 DMXOTMP TN Wilms tumor protein (WT1) DMXOTMP RN Clinical pipeline report, company report or official report of Formula Pharmaceuticals. DMXOTMP RU http://www.formulapharma.com/fp1_01/default.asp DMXR8WN DI DMXR8WN DMXR8WN DN CYCLOPLATAM DMXR8WN TI TTYVX59 DMXR8WN TN Protein kinase C (PRKC) DMXR8WN MA Inhibitor DMXR8WN RN Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73. DMXR8WN RU https://pubmed.ncbi.nlm.nih.gov/9011234 DMXROM7 DI DMXROM7 DMXROM7 DN Polyglutamate camptothecin DMXROM7 TI TTGTQHC DMXROM7 TN DNA topoisomerase I (TOP1) DMXROM7 MA Inhibitor DMXROM7 RN Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. DMXROM7 RU https://pubmed.ncbi.nlm.nih.gov/16990856 DMXSFA0 DI DMXSFA0 DMXSFA0 DN ALV-003 DMXSFA0 TI TTNGKET DMXSFA0 TN Prolyl endopeptidase (PREP) DMXSFA0 MA Modulator DMXSFA0 RN The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95. DMXSFA0 RU https://pubmed.ncbi.nlm.nih.gov/19942485 DMXSZA4 DI DMXSZA4 DMXSZA4 DN MT-3995 DMXSZA4 TI TT26PHO DMXSZA4 TN Mineralocorticoid receptor (MR) DMXSZA4 MA Antagonist DMXSZA4 RN Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. DMXSZA4 RU https://pubmed.ncbi.nlm.nih.gov/26083526 DMXTKCR DI DMXTKCR DMXTKCR DN JT02 DMXTKCR TI TTQOVYA DMXTKCR TN C-X-C motif chemokine 10 (CXCL10) DMXTKCR MA Inhibitor DMXTKCR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXTKCR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMXTOVE DI DMXTOVE DMXTOVE DN Sampatrilat DMXTOVE TI TT5TKPM DMXTOVE TN Neutral endopeptidase (MME) DMXTOVE MA Modulator DMXTOVE RN Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71. DMXTOVE RU https://pubmed.ncbi.nlm.nih.gov/10371365 DMXU5LZ DI DMXU5LZ DMXU5LZ DN CRS-207 DMXU5LZ TI TT4RXME DMXU5LZ TN Mesothelin (MSLN) DMXU5LZ RN Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. DMXU5LZ RU https://pubmed.ncbi.nlm.nih.gov/25584002 DMXUCG3 DI DMXUCG3 DMXUCG3 DN GSK233705 DMXUCG3 TI TTH18TF DMXUCG3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMXUCG3 MA Antagonist DMXUCG3 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMXUCG3 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMXY0H2 DI DMXY0H2 DMXY0H2 DN QAX-028 DMXY0H2 TI TTOXS3C DMXY0H2 TN Muscarinic acetylcholine receptor (CHRM) DMXY0H2 MA Antagonist DMXY0H2 RN EP patent application no. 2398798, Triazolopyridine derivatives as p38 map kinase inhibitors. DMXY0H2 RU http://www.google.com/patents/EP2398798A1?cl=en DMXYLTI DI DMXYLTI DMXYLTI DN CDP323 DMXYLTI TI TT6S84X DMXYLTI TN Integrin alpha-4/beta-1 (ITGA4/B1) DMXYLTI MA Modulator DMXYLTI RN Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438. DMXYLTI RU https://www.ncbi.nlm.nih.gov/pubmed/23472197 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTDCBX5 DMY0UEQ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMY0UEQ MA Inhibitor DMY0UEQ RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTGKNB4 DMY0UEQ TN Epidermal growth factor receptor (EGFR) DMY0UEQ MA Inhibitor DMY0UEQ RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/17416531 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTUTJGQ DMY0UEQ TN Vascular endothelial growth factor receptor 2 (KDR) DMY0UEQ MA Inhibitor DMY0UEQ RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/17416531 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TT1VAUK DMY0UEQ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMY0UEQ MA Inhibitor DMY0UEQ RN Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/16460936 DMY1UGV DI DMY1UGV DMY1UGV DN Bc-3781 intravenous DMY1UGV TI TT2VX74 DMY1UGV TN Bacterial Protein synthesis (Bact PROS) DMY1UGV MA Modulator DMY1UGV RN Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. DMY1UGV RU https://pubmed.ncbi.nlm.nih.gov/23836172 DMY1XJH DI DMY1XJH DMY1XJH DN AMG 570 DMY1XJH TI TTWMIDN DMY1XJH TN B-cell-activating factor (TNFSF13B) DMY1XJH MA Inhibitor DMY1XJH RN Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914. DMY1XJH RU https://pubmed.ncbi.nlm.nih.gov/30789152 DMY1XJH DI DMY1XJH DMY1XJH DN AMG 570 DMY1XJH TI TTB9Z8R DMY1XJH TN B7-related protein 1 (B7RP1) DMY1XJH MA Inhibitor DMY1XJH RN Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914. DMY1XJH RU https://pubmed.ncbi.nlm.nih.gov/30789152 DMY2L7V DI DMY2L7V DMY2L7V DN Lucatumumab DMY2L7V TI TTIJP3Q DMY2L7V TN TNF related activation protein (CD40LG) DMY2L7V MA Modulator DMY2L7V RN Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42. DMY2L7V RU https://www.ncbi.nlm.nih.gov/pubmed/22475052 DMY3KSU DI DMY3KSU DMY3KSU DN GW-42004 DMY3KSU TI TTMSFAW DMY3KSU TN Cannabinoid receptor 2 (CB2) DMY3KSU MA Modulator DMY3KSU RN Company report (Gwpharm) DMY3KSU RU http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx DMY3KSU DI DMY3KSU DMY3KSU DN GW-42004 DMY3KSU TI TT6OEDT DMY3KSU TN Cannabinoid receptor 1 (CB1) DMY3KSU MA Modulator DMY3KSU RN Company report (Gwpharm) DMY3KSU RU http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx DMY4IWC DI DMY4IWC DMY4IWC DN LCB-2183 DMY4IWC TI TT7CXIM DMY4IWC TN Histamine receptor (HR) DMY4IWC MA Modulator DMY4IWC RN LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83. DMY4IWC RU https://pubmed.ncbi.nlm.nih.gov/7989136 DMY4OMS DI DMY4OMS DMY4OMS DN Carabersat DMY4OMS TI TTSB7ZR DMY4OMS TN Trigeminal ganglion stimulation-induced response (TGSR) DMY4OMS MA Modulator DMY4OMS RN Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001 April; 132(7): 1549-1557. DMY4OMS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572685/ DMY53PL DI DMY53PL DMY53PL DN GW 597599 DMY53PL TI TTZPO1L DMY53PL TN Substance-P receptor (TACR1) DMY53PL MA Antagonist DMY53PL RN Application of LC-NMR to the identification of bulk drug impurities in NK1 antagonist GW597599 (vestipitant). Magn Reson Chem. 2010 Jul;48(7):523-30. DMY53PL RU https://pubmed.ncbi.nlm.nih.gov/20535779 DMY5IX4 DI DMY5IX4 DMY5IX4 DN BTL-TML-001 DMY5IX4 TI TTL3N71 DMY5IX4 TN Virus Replication (Viru Repli) DMY5IX4 MA Inhibitor DMY5IX4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY5IX4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMY5NUR DI DMY5NUR DMY5NUR DN VK-2809 DMY5NUR TI TTGER3L DMY5NUR TN Thyroid hormone receptor beta (THRB) DMY5NUR MA Agonist DMY5NUR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY5NUR RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMY61TJ DI DMY61TJ DMY61TJ DN FK-614 DMY61TJ TI TTZMAO3 DMY61TJ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMY61TJ MA Agonist DMY61TJ RN FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8. DMY61TJ RU https://pubmed.ncbi.nlm.nih.gov/16125538 DMY6WUV DI DMY6WUV DMY6WUV DN GDC-0077 DMY6WUV TI TTHBTOP DMY6WUV TN PI3-kinase gamma (PIK3CG) DMY6WUV MA Inhibitor DMY6WUV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY6WUV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY7Q3I DI DMY7Q3I DMY7Q3I DN JNJ-10229570 DMY7Q3I TI TT6QAJ3 DMY7Q3I TN Melanocortin receptor 5 (MC5R) DMY7Q3I MA Antagonist DMY7Q3I RN A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32. DMY7Q3I RU https://pubmed.ncbi.nlm.nih.gov/21602033 DMY89BN DI DMY89BN DMY89BN DN URC102 DMY89BN TI TTA592U DMY89BN TN Urate anion exchanger 1 (URAT1) DMY89BN MA Inhibitor DMY89BN RN Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013). DMY89BN RU http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html DMY9ZGN DI DMY9ZGN DMY9ZGN DN VT-111a DMY9ZGN TI TTEMV5X DMY9ZGN TN Serine protease unspecific (SP) DMY9ZGN MA Modulator DMY9ZGN RN Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329. DMY9ZGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558843/ DMYAQV2 DI DMYAQV2 DMYAQV2 DN ATL101 DMYAQV2 TI TT9G4N0 DMYAQV2 TN Glutamate carboxypeptidase II (GCPII) DMYAQV2 MA Modulator DMYAQV2 RN Clinical pipeline report, company report or official report of Atlab pharma. DMYAQV2 RU http://www.atlab-pharma.com/pipeline_atl101.html DMYAXNM DI DMYAXNM DMYAXNM DN SRK-015 DMYAXNM TI TTM8I2X DMYAXNM TN Myostatin (MSTN) DMYAXNM MA Inhibitor DMYAXNM RN Clinical pipeline report, company report or official report of Scholar Rock. DMYAXNM RU https://scholarrock.com/our-pipeline/spinal-muscular-atrophy/ DMYBIFS DI DMYBIFS DMYBIFS DN Parsaclisib DMYBIFS TI TTGBPJE DMYBIFS TN PI3-kinase delta (PIK3CD) DMYBIFS MA Inhibitor DMYBIFS RN Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752. DMYBIFS RU https://pubmed.ncbi.nlm.nih.gov/30803990 DMYBQEF DI DMYBQEF DMYBQEF DN AP26113 DMYBQEF TI TTPMQSO DMYBQEF TN ALK tyrosine kinase receptor (ALK) DMYBQEF MA Modulator DMYBQEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYBQEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYC2LE DI DMYC2LE DMYC2LE DN Disufenton DMYC2LE TI TTLQTHB DMYC2LE TN Extracellular sulfatase Sulf-2 (SULF2) DMYC2LE MA Inhibitor DMYC2LE RN The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. DMYC2LE RU https://pubmed.ncbi.nlm.nih.gov/23109092 DMYCITZ DI DMYCITZ DMYCITZ DN MP-101 DMYCITZ TI TT8A9EF DMYCITZ TN Metabotropic glutamate receptor 3 (mGluR3) DMYCITZ MA Agonist DMYCITZ RN ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health. DMYCITZ RU https://clinicaltrials.gov/ct2/show/NCT03044249 DMYCITZ DI DMYCITZ DMYCITZ DN MP-101 DMYCITZ TI TTXJ47W DMYCITZ TN Metabotropic glutamate receptor 2 (mGluR2) DMYCITZ MA Agonist DMYCITZ RN ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health. DMYCITZ RU https://clinicaltrials.gov/ct2/show/NCT03044249 DMYDM68 DI DMYDM68 DMYDM68 DN BGP-15 DMYDM68 TI TTEBCY8 DMYDM68 TN Poly [ADP-ribose] polymerase (PARP) DMYDM68 MA Modulator DMYDM68 RN BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37. DMYDM68 RU https://pubmed.ncbi.nlm.nih.gov/22350755 DMYDM68 DI DMYDM68 DMYDM68 DN BGP-15 DMYDM68 TI TTR2TXZ DMYDM68 TN Jun N terminal kinase (JNK) DMYDM68 MA Inhibitor DMYDM68 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYDM68 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYEGRH DI DMYEGRH DMYEGRH DN IL-4R DMYEGRH TI TTLGTKB DMYEGRH TN Interleukin-4 (IL4) DMYEGRH MA Inhibitor DMYEGRH RN Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70. DMYEGRH RU https://pubmed.ncbi.nlm.nih.gov/11398072 DMYEIOH DI DMYEIOH DMYEIOH DN ARQ-154 DMYEIOH TI TTV5CGO DMYEIOH TN Phosphodiesterase 4 (PDE4) DMYEIOH MA Inhibitor DMYEIOH RN Clinical pipeline report, company report or official report of Arcutis Biotherapeutics. DMYEIOH RU https://arcutis.com/trial/arq-154/ DMYEZ5J DI DMYEZ5J DMYEZ5J DN Romilkimab DMYEZ5J TI TTLGTKB DMYEZ5J TN Interleukin-4 (IL4) DMYEZ5J MA Inhibitor DMYEZ5J RN A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. DMYEZ5J RU https://pubmed.ncbi.nlm.nih.gov/32963047 DMYEZ5J DI DMYEZ5J DMYEZ5J DN Romilkimab DMYEZ5J TI TT0GVCH DMYEZ5J TN Interleukin-13 (IL13) DMYEZ5J MA Inhibitor DMYEZ5J RN A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. DMYEZ5J RU https://pubmed.ncbi.nlm.nih.gov/32963047 DMYFRTB DI DMYFRTB DMYFRTB DN PCM-075 DMYFRTB TI TTIYVQP DMYFRTB TN Polo-like kinase 1 (PLK1) DMYFRTB MA Inhibitor DMYFRTB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYFRTB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYG1ZQ DI DMYG1ZQ DMYG1ZQ DN OPNT001 DMYG1ZQ TI TTKWM86 DMYG1ZQ TN Opioid receptor mu (MOP) DMYG1ZQ MA Antagonist DMYG1ZQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYG1ZQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMYILGK DI DMYILGK DMYILGK DN RP6530 DMYILGK TI TTGBPJE DMYILGK TN PI3-kinase delta (PIK3CD) DMYILGK MA Inhibitor DMYILGK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYILGK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYISJK DI DMYISJK DMYISJK DN PX-866 DMYISJK TI TTHBTOP DMYISJK TN PI3-kinase gamma (PIK3CG) DMYISJK MA Inhibitor DMYISJK RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DMYISJK RU https://pubmed.ncbi.nlm.nih.gov/19644473 DMYK1DR DI DMYK1DR DMYK1DR DN BLI-1005 DMYK1DR TI TTAWNKZ DMYK1DR TN Norepinephrine transporter (NET) DMYK1DR MA Inhibitor DMYK1DR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYK1DR RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMYK1JU DI DMYK1JU DMYK1JU DN ASP8232 DMYK1JU TI TT7HC21 DMYK1JU TN Membrane copper amine oxidase (AOC3) DMYK1JU MA Inhibitor DMYK1JU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYK1JU RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTZ97H5 DMYL7VR TN Phosphodiesterase 4A (PDE4A) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTSKMI8 DMYL7VR TN Phosphodiesterase 4D (PDE4D) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTVIAT9 DMYL7VR TN Phosphodiesterase 4B (PDE4B) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYLBOU DI DMYLBOU DMYLBOU DN SB-649868 DMYLBOU TI TT60Q8D DMYLBOU TN Orexin receptor type 1 (HCRTR1) DMYLBOU MA Antagonist DMYLBOU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMYLBOU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMYNTQV DI DMYNTQV DMYNTQV DN CGP-28014 DMYNTQV TI TTKWFB8 DMYNTQV TN Catechol-O-methyl-transferase (COMT) DMYNTQV MA Modulator DMYNTQV RN CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11. DMYNTQV RU https://pubmed.ncbi.nlm.nih.gov/1980718 DMYO185 DI DMYO185 DMYO185 DN BT-062 DMYO185 TI TTYDSVG DMYO185 TN Syndecan-1 (SDC1) DMYO185 RN The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. DMYO185 RU https://pubmed.ncbi.nlm.nih.gov/19509164 DMYOUB6 DI DMYOUB6 DMYOUB6 DN EMA-401 DMYOUB6 TI TTQVOEI DMYOUB6 TN Angiotensin II receptor type-2 (AGTR2) DMYOUB6 MA Antagonist DMYOUB6 RN Clinical pipeline report, company report or official report of Spinifex. DMYOUB6 RU http://www.spinifexpharma.com/EMA401-DEVELOPMENT.html DMYP7TO DI DMYP7TO DMYP7TO DN Trametinib + 2141795 DMYP7TO TI TTWTSCV DMYP7TO TN RAC-alpha serine/threonine-protein kinase (AKT1) DMYP7TO MA Modulator DMYP7TO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMYP7TO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMYPXQ2 DI DMYPXQ2 DMYPXQ2 DN CVBT-141H DMYPXQ2 TI TTMY81X DMYPXQ2 TN Heparin-binding growth factor 1 (FGF1) DMYPXQ2 MA Modulator DMYPXQ2 RN Clinical pipeline report, company report or official report of CVBT. DMYPXQ2 RU http://cvbt.com/index.php?pr=Severe_CHD DMYRIHZ DI DMYRIHZ DMYRIHZ DN PCL-016 DMYRIHZ TI TT3J1EK DMYRIHZ TN Zinc finger protein (ZNF) DMYRIHZ MA Modulator DMYRIHZ RN US patent application no. 2005,0239,723, Compositions and methods useful for treatment of acne. DMYRIHZ RU http://www.google.com/patents/US20050239723 DMYS6MW DI DMYS6MW DMYS6MW DN GCS-100 DMYS6MW TI TTX1OI0 DMYS6MW TN Galectin (LGALS) DMYS6MW MA Modulator DMYS6MW RN GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48. DMYS6MW RU https://pubmed.ncbi.nlm.nih.gov/20190189 DMYSQMW DI DMYSQMW DMYSQMW DN BAY-1902607 DMYSQMW TI TT2THBD DMYSQMW TN P2X purinoceptor 3 (P2RX3) DMYSQMW MA Inhibitor DMYSQMW RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMYSQMW RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMYT470 DI DMYT470 DMYT470 DN Seribantumab DMYT470 TI TTDC8N2 DMYT470 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMYT470 MA Antagonist DMYT470 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYT470 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMYTKF5 DI DMYTKF5 DMYTKF5 DN Interferon DMYTKF5 TI TT6ONYI DMYTKF5 TN Interferon (IFN) DMYTKF5 MA Modulator DMYTKF5 RN Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses. 2013 Sep;7(5):854-62. DMYTKF5 RU https://pubmed.ncbi.nlm.nih.gov/23398960 DMYU6P5 DI DMYU6P5 DMYU6P5 DN GS-9857 DMYU6P5 TI TTWXB3E DMYU6P5 TN Hepatitis C virus NS3 helicase (HCV NS3) DMYU6P5 MA Inhibitor DMYU6P5 RN Clinical pipeline report, company report or official report of Gilead. DMYU6P5 RU http://www.gilead.com/research/pipeline DMYUNXP DI DMYUNXP DMYUNXP DN AZD2811 DMYUNXP TI TTCY4SB DMYUNXP TN Aurora kinase (AURK) DMYUNXP MA Inhibitor DMYUNXP RN Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17. DMYUNXP RU https://pubmed.ncbi.nlm.nih.gov/26865565 DMYUO6B DI DMYUO6B DMYUO6B DN PlaMavax DMYUO6B TI TTDUK07 DMYUO6B TN Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP) DMYUO6B RN Lipid kinase enters the malaria stage. SciBX 6(48); doi:10.1038/scibx.2013.1373. Dec. 19 2013 DMYUO6B RU http://www.nature.com/scibx/journal/v6/n48/full/scibx.2013.1373.html DMYWA0Z DI DMYWA0Z DMYWA0Z DN GORALATIDE DMYWA0Z TI TTLK6DR DMYWA0Z TN Cyclin D1 synthesis (CCND1 synthesis) DMYWA0Z MA Modulator DMYWA0Z RN Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP. Br J Haematol. 1997 Dec;99(3):692-8. DMYWA0Z RU https://pubmed.ncbi.nlm.nih.gov/9401086 DMYWO62 DI DMYWO62 DMYWO62 DN Capadenoson DMYWO62 TI TTK25J1 DMYWO62 TN Adenosine A1 receptor (ADORA1) DMYWO62 MA Agonist DMYWO62 RN A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10. DMYWO62 RU https://pubmed.ncbi.nlm.nih.gov/19012505 DMYXOU2 DI DMYXOU2 DMYXOU2 DN NRX-4204 DMYXOU2 TI TTH029C DMYXOU2 TN Retinoic acid receptor RXR-gamma (RXRG) DMYXOU2 MA Modulator DMYXOU2 RN DOI: 10.1038/scibx.2010.766 DMYXOU2 RU http://www.nature.com/scibx/journal/v3/n25/full/scibx.2010.766.html DMYZWDC DI DMYZWDC DMYZWDC DN ESBA-105 DMYZWDC TI TTF8CQI DMYZWDC TN Tumor necrosis factor (TNF) DMYZWDC RN Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8. DMYZWDC RU https://pubmed.ncbi.nlm.nih.gov/18757508 DMZ0DMY DI DMZ0DMY DMZ0DMY DN LY2874455 DMZ0DMY TI TTGJVQM DMZ0DMY TN Fibroblast growth factor receptor 2 (FGFR2) DMZ0DMY MA Modulator DMZ0DMY RN Company report (Eli Lilly) (drug: LY2874455) DMZ0DMY RU http://www.lillyoncologypipeline.com/fgfr-inhibitor.aspx DMZ0F65 DI DMZ0F65 DMZ0F65 DN Contezolid DMZ0F65 TI TTLIZBJ DMZ0F65 TN Protein synthesis (hPRO synth) DMZ0F65 MA Inhibitor DMZ0F65 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ0F65 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ2XAP DI DMZ2XAP DMZ2XAP DN LX-1031 DMZ2XAP TI TT7ZK9C DMZ2XAP TN Tryptophan 5-hydroxylase (TPH) DMZ2XAP MA Inhibitor DMZ2XAP RN LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8. DMZ2XAP RU https://pubmed.ncbi.nlm.nih.gov/21154152 DMZ2YBE DI DMZ2YBE DMZ2YBE DN Lexipafant DMZ2YBE TI TT84ETX DMZ2YBE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMZ2YBE MA Inhibitor DMZ2YBE RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMZ2YBE RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMZ2YBE DI DMZ2YBE DMZ2YBE DN Lexipafant DMZ2YBE TI TTQL5VC DMZ2YBE TN Platelet-activating factor receptor (PTAFR) DMZ2YBE MA Modulator DMZ2YBE RN Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9. DMZ2YBE RU https://www.ncbi.nlm.nih.gov/pubmed/12440758 DMZ3BER DI DMZ3BER DMZ3BER DN HM-78136B DMZ3BER TI TT6EO5L DMZ3BER TN Erbb2 tyrosine kinase receptor (HER2) DMZ3BER MA Inhibitor DMZ3BER RN Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. DMZ3BER RU https://pubmed.ncbi.nlm.nih.gov/21732342 DMZ3BER DI DMZ3BER DMZ3BER DN HM-78136B DMZ3BER TI TTGKNB4 DMZ3BER TN Epidermal growth factor receptor (EGFR) DMZ3BER MA Inhibitor DMZ3BER RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ3BER RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ3FE8 DI DMZ3FE8 DMZ3FE8 DN VX-135 DMZ3FE8 TI TTMVBWH DMZ3FE8 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMZ3FE8 MA Inhibitor DMZ3FE8 RN All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. DMZ3FE8 RU https://pubmed.ncbi.nlm.nih.gov/23722330 DMZ3OU6 DI DMZ3OU6 DMZ3OU6 DN Lithium DMZ3OU6 TI TTRSMW9 DMZ3OU6 TN Glycogen synthase kinase-3 beta (GSK-3B) DMZ3OU6 MA Inhibitor DMZ3OU6 RN The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874. DMZ3OU6 RU https://pubmed.ncbi.nlm.nih.gov/29212798 DMZ3OU6 DI DMZ3OU6 DMZ3OU6 DN Lithium DMZ3OU6 TI TTRZQE3 DMZ3OU6 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMZ3OU6 MA Inhibitor DMZ3OU6 RN The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874. DMZ3OU6 RU https://pubmed.ncbi.nlm.nih.gov/29212798 DMZ4MCG DI DMZ4MCG DMZ4MCG DN KB-6806 DMZ4MCG TI TTNXLKE DMZ4MCG TN 5-HT 3 receptor (5HT3R) DMZ4MCG MA Antagonist DMZ4MCG RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMZ4MCG RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMZ571Y DI DMZ571Y DMZ571Y DN TG-2349 DMZ571Y TI TTRHUKY DMZ571Y TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMZ571Y MA Modulator DMZ571Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZ571Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZ67Q0 DI DMZ67Q0 DMZ67Q0 DN WT1 peptide vaccine DMZ67Q0 TI TTZ8UT4 DMZ67Q0 TN Wilms tumor protein (WT1) DMZ67Q0 RN Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22. DMZ67Q0 RU https://pubmed.ncbi.nlm.nih.gov/21898091 DMZ6RG2 DI DMZ6RG2 DMZ6RG2 DN TTP273 DMZ6RG2 TI TTVIMDE DMZ6RG2 TN Glucagon-like peptide 1 receptor (GLP1R) DMZ6RG2 MA Agonist DMZ6RG2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6RG2 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZ6Y0T DI DMZ6Y0T DMZ6Y0T DN LEO-32731 DMZ6Y0T TI TTV5CGO DMZ6Y0T TN Phosphodiesterase 4 (PDE4) DMZ6Y0T MA Inhibitor DMZ6Y0T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6Y0T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ70GE DI DMZ70GE DMZ70GE DN BOS-228 DMZ70GE TI TTJP4SM DMZ70GE TN Bacterial Penicillin binding protein (Bact PBP) DMZ70GE MA Inhibitor DMZ70GE RN Clinical pipeline report, company report or official report of Boston Pharmaceuticals. DMZ70GE RU https://www.bostonpharmaceuticals.com/infectious-disease DMZ7I51 DI DMZ7I51 DMZ7I51 DN TA-270 DMZ7I51 TI TT2J34L DMZ7I51 TN Arachidonate 5-lipoxygenase (5-LOX) DMZ7I51 MA Inhibitor DMZ7I51 RN TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE... J Pharmacol Exp Ther. 2003 Nov;307(2):583-8. DMZ7I51 RU https://pubmed.ncbi.nlm.nih.gov/12970384 DMZ7YX3 DI DMZ7YX3 DMZ7YX3 DN M-16209 DMZ7YX3 TI TTFBNVI DMZ7YX3 TN Aldose reductase (AKR1B1) DMZ7YX3 MA Inhibitor DMZ7YX3 RN Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. DMZ7YX3 RU https://pubmed.ncbi.nlm.nih.gov/1828768 DMZ8PY0 DI DMZ8PY0 DMZ8PY0 DN ACE-031 DMZ8PY0 TI TTSWPH8 DMZ8PY0 TN Growth/differentiation factor 8 (GDF-8) DMZ8PY0 MA Inhibitor DMZ8PY0 RN A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. DMZ8PY0 RU https://pubmed.ncbi.nlm.nih.gov/23169607 DMZASMP DI DMZASMP DMZASMP DN LY2784544 DMZASMP TI TTRMX3V DMZASMP TN Janus kinase 2 (JAK-2) DMZASMP MA Modulator DMZASMP RN Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109. DMZASMP RU https://pubmed.ncbi.nlm.nih.gov/23584399 DMZB8AJ DI DMZB8AJ DMZB8AJ DN BMS-986142 DMZB8AJ TI TTGM6VW DMZB8AJ TN Tyrosine-protein kinase BTK (ATK) DMZB8AJ MA Inhibitor DMZB8AJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZB8AJ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZC4V0 DI DMZC4V0 DMZC4V0 DN Buproprion+zonisamide DMZC4V0 TI TTTQR47 DMZC4V0 TN Solute carrier family 22 member 8 (SLC22A8) DMZC4V0 MA Blocker DMZC4V0 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMZC4V0 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMZCA0K DI DMZCA0K DMZCA0K DN TBC-3711 DMZCA0K TI TTKRD0G DMZCA0K TN Endothelin A receptor (EDNRA) DMZCA0K MA Antagonist DMZCA0K RN TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res. 2001 Sep;50(3):374-83. DMZCA0K RU https://pubmed.ncbi.nlm.nih.gov/11518825 DMZCG91 DI DMZCG91 DMZCG91 DN CSL-112 DMZCG91 TI TT7GN3U DMZCG91 TN Apolipoprotein A-I (APOA1) DMZCG91 MA Modulator DMZCG91 RN CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014 Jan;232(1):110-8. DMZCG91 RU https://pubmed.ncbi.nlm.nih.gov/24401224 DMZCI04 DI DMZCI04 DMZCI04 DN PB-1023 DMZCI04 TI TTVIMDE DMZCI04 TN Glucagon-like peptide 1 receptor (GLP1R) DMZCI04 MA Modulator DMZCI04 RN On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice. Toxicol Pathol February 2013 vol. 41 no. 2 303-309. DMZCI04 RU http://tpx.sagepub.com/content/41/2/303.full DMZCI04 DI DMZCI04 DMZCI04 DN PB-1023 DMZCI04 TI TT0NUFM DMZCI04 TN Glucagon (GCG) DMZCI04 MA Agonist DMZCI04 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZCI04 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZCU7I DI DMZCU7I DMZCU7I DN LY-377604 DMZCU7I TI TTMXGCW DMZCU7I TN Adrenergic receptor beta-3 (ADRB3) DMZCU7I MA Agonist DMZCU7I RN Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Med Chem Lett. 2011 August 11; 2(8): 583-586. DMZCU7I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018109/ DMZCVD7 DI DMZCVD7 DMZCVD7 DN K-201 DMZCVD7 TI TT1VOHK DMZCVD7 TN Potassium channel unspecific (KC) DMZCVD7 MA Modulator DMZCVD7 RN Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy DMZCVD7 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340112 DMZE6Y9 DI DMZE6Y9 DMZE6Y9 DN TT-100 DMZE6Y9 TI TTGKNB4 DMZE6Y9 TN Epidermal growth factor receptor (EGFR) DMZE6Y9 MA Inhibitor DMZE6Y9 RN BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. DMZE6Y9 RU http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html DMZE6Y9 DI DMZE6Y9 DMZE6Y9 DN TT-100 DMZE6Y9 TI TTHRID2 DMZE6Y9 TN Insulin-like growth factor I receptor (IGF1R) DMZE6Y9 MA Inhibitor DMZE6Y9 RN BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. DMZE6Y9 RU http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html DMZEJLB DI DMZEJLB DMZEJLB DN CP-533536 DMZEJLB TI TT1ZAVI DMZEJLB TN Prostaglandin E2 receptor EP2 (PTGER2) DMZEJLB MA Agonist DMZEJLB RN Pfizer. Product Development Pipeline. March 31 2009. DMZEJLB RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMZEU6M DI DMZEU6M DMZEU6M DN TAK-831 DMZEU6M TI TT7Y3EJ DMZEU6M TN D-amino acid oxidase (DAO) DMZEU6M MA Inhibitor DMZEU6M RN Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice. Pharm Res. 2020 Aug 5;37(8):164. DMZEU6M RU https://pubmed.ncbi.nlm.nih.gov/32901384 DMZF68E DI DMZF68E DMZF68E DN Ascrolimus DMZF68E TI TTFH2RS DMZF68E TN FK506-binding protein (FKBP) DMZF68E MA Modulator DMZF68E RN Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91. DMZF68E RU https://pubmed.ncbi.nlm.nih.gov/8588225 DMZFV3E DI DMZFV3E DMZFV3E DN Remogli ozin-etabonate DMZFV3E TI TTN7Y4P DMZFV3E TN Sodium/glucose cotransporter 2 (SLC5A4) DMZFV3E MA Modulator DMZFV3E RN Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25. DMZFV3E RU https://pubmed.ncbi.nlm.nih.gov/23631443 DMZFW8V DI DMZFW8V DMZFW8V DN MIN-202 DMZFW8V TI TT9N02I DMZFW8V TN Orexin receptor type 2 (HCRTR2) DMZFW8V MA Antagonist DMZFW8V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFW8V RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMZGNOJ DI DMZGNOJ DMZGNOJ DN S-777469 DMZGNOJ TI TTMSFAW DMZGNOJ TN Cannabinoid receptor 2 (CB2) DMZGNOJ MA Agonist DMZGNOJ RN Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79. DMZGNOJ RU https://pubmed.ncbi.nlm.nih.gov/19216704 DMZHB37 DI DMZHB37 DMZHB37 DN GSK2110183 DMZHB37 TI TTWTSCV DMZHB37 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMZHB37 MA Modulator DMZHB37 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMZHB37 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMZIC4Q DI DMZIC4Q DMZIC4Q DN SPN-812 DMZIC4Q TI TTAWNKZ DMZIC4Q TN Norepinephrine transporter (NET) DMZIC4Q MA Inhibitor DMZIC4Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZIC4Q RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMZIQ8G DI DMZIQ8G DMZIQ8G DN Prolarix DMZIQ8G TI TTJLP0R DMZIQ8G TN Quinone reductase 2 (NQO2) DMZIQ8G MA Inhibitor DMZIQ8G RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMZIQ8G RU http://www.centerwatch.com/ DMZJP2T DI DMZJP2T DMZJP2T DN INCB50465 DMZJP2T TI TTGBPJE DMZJP2T TN PI3-kinase delta (PIK3CD) DMZJP2T MA Inhibitor DMZJP2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZJP2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZJREM DI DMZJREM DMZJREM DN RO-4998452 DMZJREM TI TTLWPVF DMZJREM TN Sodium/glucose cotransporter 2 (SGLT2) DMZJREM MA Modulator DMZJREM RN A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Diabetes Obes Metab.2015 Oct;17(10):984-93. DMZJREM RU https://www.ncbi.nlm.nih.gov/pubmed/26179482 DMZKBMG DI DMZKBMG DMZKBMG DN Lenapenem hydrochloride hydrate DMZKBMG TI TTJP4SM DMZKBMG TN Bacterial Penicillin binding protein (Bact PBP) DMZKBMG MA Inhibitor DMZKBMG RN Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42. DMZKBMG RU https://pubmed.ncbi.nlm.nih.gov/9099223 DMZKPI8 DI DMZKPI8 DMZKPI8 DN TAK-715 DMZKPI8 TI TTWELHI DMZKPI8 TN Stress-activated protein kinase (p38) DMZKPI8 MA Inhibitor DMZKPI8 RN Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94. DMZKPI8 RU https://pubmed.ncbi.nlm.nih.gov/21513885 DMZKYNO DI DMZKYNO DMZKYNO DN Juvidex DMZKYNO TI TTPNE41 DMZKYNO TN CI Man-6-P receptor (IGF2R) DMZKYNO MA Modulator DMZKYNO RN Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125. DMZKYNO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022978/ DMZL48U DI DMZL48U DMZL48U DN KUR-111 DMZL48U TI TT6F7GZ DMZL48U TN Parathyroid hormone (PTH) DMZL48U MA Modulator DMZL48U RN Company report (Cytos) DMZL48U RU http://www.cytos.com/kur-111/ DMZLBAW DI DMZLBAW DMZLBAW DN Fucoxanthin DMZLBAW TI TTSHAEB DMZLBAW TN NF-kappa-B inhibitor alpha (NFKBIA) DMZLBAW MA Inhibitor DMZLBAW RN Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75. DMZLBAW RU https://pubmed.ncbi.nlm.nih.gov/20868674 DMZLGQV DI DMZLGQV DMZLGQV DN AZD2624 DMZLGQV TI TTBPGLU DMZLGQV TN Neuromedin-K receptor (TACR3) DMZLGQV MA Modulator DMZLGQV RN The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204. DMZLGQV RU https://www.ncbi.nlm.nih.gov/pubmed/24525659 DMZMCB1 DI DMZMCB1 DMZMCB1 DN GW274150 DMZMCB1 TI TTF10I9 DMZMCB1 TN Nitric-oxide synthase inducible (NOS2) DMZMCB1 MA Modulator DMZMCB1 RN GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65. DMZMCB1 RU https://www.ncbi.nlm.nih.gov/pubmed/12631066 DMZMSQJ DI DMZMSQJ DMZMSQJ DN AUS-131 DMZMSQJ TI TTOM3J0 DMZMSQJ TN Estrogen receptor beta (ESR2) DMZMSQJ MA Agonist DMZMSQJ RN S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. DMZMSQJ RU https://pubmed.ncbi.nlm.nih.gov/15883431 DMZMUIL DI DMZMUIL DMZMUIL DN PF-04518600 DMZMUIL TI TTL31H0 DMZMUIL TN OX40L receptor (CD134) DMZMUIL MA Agonist DMZMUIL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZMUIL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZO2SY DI DMZO2SY DMZO2SY DN BIIB054 DMZO2SY TI TT08OSU DMZO2SY TN Synuclein alpha (SNCA) DMZO2SY MA Inhibitor DMZO2SY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZO2SY RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZOA2L DI DMZOA2L DMZOA2L DN ETX-9101 DMZOA2L TI TT7CXIM DMZOA2L TN Histamine receptor (HR) DMZOA2L MA Modulator DMZOA2L RN Clinical pipeline report, company report or official report of e-Therapeutics. DMZOA2L RU http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf DMZOIP4 DI DMZOIP4 DMZOIP4 DN LY-2409021 DMZOIP4 TI TT9O6WS DMZOIP4 TN Glucagon receptor (GCGR) DMZOIP4 MA Antagonist DMZOIP4 RN Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22. DMZOIP4 RU https://pubmed.ncbi.nlm.nih.gov/25656305 DMZP84Y DI DMZP84Y DMZP84Y DN Ifetroban sodium DMZP84Y TI TT2O84V DMZP84Y TN Thromboxane A2 receptor (TBXA2R) DMZP84Y MA Antagonist DMZP84Y RN AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. DMZP84Y RU https://pubmed.ncbi.nlm.nih.gov/15613065 DMZQBCL DI DMZQBCL DMZQBCL DN LR3001 DMZQBCL TI TT8V13P DMZQBCL TN Myb messenger RNA (MYB mRNA) DMZQBCL RN Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005. DMZQBCL RU http://www.drugs.com/news/genta-obtains-orphan-designation-c-myb-antisense-lr3001-chronic-myelocytic-leukemia-3031.html DMZR9OU DI DMZR9OU DMZR9OU DN BI-44370 DMZR9OU TI TTY6O0Q DMZR9OU TN Calcitonin gene-related peptide receptor (CGRPR) DMZR9OU MA Antagonist DMZR9OU RN BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84. DMZR9OU RU https://pubmed.ncbi.nlm.nih.gov/21172952 DMZRXTL DI DMZRXTL DMZRXTL DN E7820 DMZRXTL TI TTSJ542 DMZRXTL TN Integrin alpha-2 (ITGA2) DMZRXTL MA Inhibitor DMZRXTL RN Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200. DMZRXTL RU https://pubmed.ncbi.nlm.nih.gov/21208908 DMZT7EP DI DMZT7EP DMZT7EP DN EPI 589 DMZT7EP TI TTIB5LO DMZT7EP TN Quinone reductase (NQO) DMZT7EP MA Modulator DMZT7EP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZT7EP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZT8FS DI DMZT8FS DMZT8FS DN Preverex DMZT8FS TI TTU5CF1 DMZT8FS TN Actin polymerization (Actin poly) DMZT8FS MA Modulator DMZT8FS RN Chronic hypoxia differentially up-regulates protein kinase C-mediated ovine uterine arterial contraction via actin polymerization signaling in pregnancy. Biol Reprod. 2012 Dec 21;87(6):142. DMZT8FS RU https://pubmed.ncbi.nlm.nih.gov/23136295 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTSKMI8 DMZTAJL TN Phosphodiesterase 4D (PDE4D) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTVIAT9 DMZTAJL TN Phosphodiesterase 4B (PDE4B) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTZ97H5 DMZTAJL TN Phosphodiesterase 4A (PDE4A) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTOJ6 DI DMZTOJ6 DMZTOJ6 DN TBA-7371 DMZTOJ6 TI TTLOHU4 DMZTOJ6 TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DMZTOJ6 MA Inhibitor DMZTOJ6 RN Clinical pipeline report, company report or official report of TB Alliance. DMZTOJ6 RU https://www.tballiance.org/portfolio/trial/12010 DMZUAH2 DI DMZUAH2 DMZUAH2 DN ASP-4901 DMZUAH2 TI TTZOEBC DMZUAH2 TN Phosphodiesterase 9 (PDE9) DMZUAH2 MA Inhibitor DMZUAH2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070) DMZUAH2 RU http://adisinsight.springer.com/drugs/800033070 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTNT7K8 DMZUAJ4 TN Nociceptin receptor (OPRL1) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTD0CIQ DMZUAJ4 TN Melanocortin receptor 4 (MC4R) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTXV4FI DMZUAJ4 TN Albendazole monooxygenase (CYP3A4) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTYO0A3 DMZUAJ4 TN Substance-K receptor (TACR2) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TT4TFGN DMZUAJ4 TN Vasopressin V1a receptor (V1AR) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTHXFA1 DMZUAJ4 TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMZUAJ4 MA Modulator DMZUAJ4 RN Company report (Arana Therapeutics) DMZUAJ4 RU http://www.asx.com.au/asxpdf/20090219/pdf/31g4hr7254nxxr.pdf DMZUV7T DI DMZUV7T DMZUV7T DN CART-19 cells DMZUV7T TI TTW640A DMZUV7T TN B-lymphocyte surface antigen B4 (CD19) DMZUV7T MA CAR-T-Cell-Therapy DMZUV7T RN ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol DMZUV7T RU https://clinicaltrials.gov/ct2/show/NCT01551043 DMZV27P DI DMZV27P DMZV27P DN SXC-2023 DMZV27P TI TTBZMIO DMZV27P TN Cystine/glutamate transporter (SLC7A11) DMZV27P MA Activator DMZV27P RN Clinical pipeline report, company report or official report of Promentis Pharmaceuticals. DMZV27P RU https://promentispharma.com/technology/sxc-2023/ DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TT0LF7H DMZW50O TN Fibroblast growth factor receptor (FGFR) DMZW50O MA Modulator DMZW50O RN The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58. DMZW50O RU https://pubmed.ncbi.nlm.nih.gov/25169980 DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTRLW2X DMZW50O TN Fibroblast growth factor receptor 1 (FGFR1) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTGJVQM DMZW50O TN Fibroblast growth factor receptor 2 (FGFR2) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTST7KB DMZW50O TN Fibroblast growth factor receptor 3 (FGFR3) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZWNQF DI DMZWNQF DMZWNQF DN 2'3'-Dideoxyinosine DMZWNQF TI TTMCF1Y DMZWNQF TN Purine nucleoside phosphorylase (PNP) DMZWNQF MA Inhibitor DMZWNQF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZWNQF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZX0VF DI DMZX0VF DMZX0VF DN Tavokinogene telseplasmid DMZX0VF TI TTG68FB DMZX0VF TN Interleukine 12 (IL-12) DMZX0VF MA Replacement DMZX0VF RN Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540. DMZX0VF RU https://pubmed.ncbi.nlm.nih.gov/32147213 DM824EG DI DM824EG DM824EG DN COVA322 DM824EG TI TTF8CQI DM824EG TN Tumor necrosis factor (TNF) DM824EG MA Modulator DM824EG RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM824EG RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM824EG DI DM824EG DM824EG DN COVA322 DM824EG TI TTG0MT6 DM824EG TN Interleukin-17 (IL17) DM824EG MA Modulator DM824EG RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM824EG RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJ1NG4 DI DMJ1NG4 DMJ1NG4 DN Dalazatide DMJ1NG4 TI TTY3UE6 DMJ1NG4 TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMJ1NG4 MA Inhibitor DMJ1NG4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ1NG4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTXBUV DI DMTXBUV DMTXBUV DN BT1718 DMTXBUV TI TTJ4QE7 DMTXBUV TN Matrix metalloproteinase-14 (MMP-14) DMTXBUV MA Inhibitor DMTXBUV RN ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health. DMTXBUV RU https://clinicaltrials.gov/ct2/show/NCT03486730 DMV401D DI DMV401D DMV401D DN Debio-0824 DMV401D TI TTY3UE6 DMV401D TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMV401D MA Inhibitor DMV401D RN Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653. DMV401D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422530/ DM03GDJ DI DM03GDJ DM03GDJ DN Pepinemab DM03GDJ TI TT5UT28 DM03GDJ TN Semaphorin-4D (SEMA4D) DM03GDJ MA Inhibitor DM03GDJ RN Clinical pipeline report, company report or official report of Vaccinex. DM03GDJ RU https://vaccinex.com/pipeline/pepinemab-immuno-oncology/ DM03LWZ DI DM03LWZ DM03LWZ DN CVX-060 DM03LWZ TI TTKLQTJ DM03LWZ TN Angiopoietin-2 (ANGPT2) DM03LWZ RN Clinical pipeline report, company report or official report of CovX (2011). DM03LWZ RU http://www.covx.com/pipeline.html DM04HNB DI DM04HNB DM04HNB DN Anti-CD19 CAR-T DM04HNB TI TTW640A DM04HNB TN B-lymphocyte surface antigen B4 (CD19) DM04HNB MA CAR-T-Cell-Therapy DM04HNB RN ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma DM04HNB RU https://clinicaltrials.gov/ct2/show/NCT02685670 DM059OH DI DM059OH DM059OH DN GSK3145095 DM059OH TI TTAIQSN DM059OH TN Receptor-interacting protein 1 (RIPK1) DM059OH MA Inhibitor DM059OH RN Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862. DM059OH RU https://pubmed.ncbi.nlm.nih.gov/31223438 DM08TH3 DI DM08TH3 DM08TH3 DN ITI-214 DM08TH3 TI TTHQENC DM08TH3 TN Phosphodiesterase 1 (PDE1) DM08TH3 MA Inhibitor DM08TH3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM08TH3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM095HQ DI DM095HQ DM095HQ DN LM11A-31 DM095HQ TI TTEDJN4 DM095HQ TN Low-affinity nerve growth factor receptor (NGFR) DM095HQ MA Modulator DM095HQ RN Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. DM095HQ RU https://pubmed.ncbi.nlm.nih.gov/31073629 DM09JOZ DI DM09JOZ DM09JOZ DN ImMucin DM09JOZ TI TTBHFYQ DM09JOZ TN Mucin-1 (MUC1) DM09JOZ RN Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56. DM09JOZ RU https://pubmed.ncbi.nlm.nih.gov/25496030 DM0C1IX DI DM0C1IX DM0C1IX DN Anti-MUC1 CAR T Cells DM0C1IX TI TTBHFYQ DM0C1IX TN Mucin-1 (MUC1) DM0C1IX MA CAR-T-Cell-Therapy DM0C1IX RN ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor DM0C1IX RU https://clinicaltrials.gov/ct2/show/NCT02587689 DM0C5MV DI DM0C5MV DM0C5MV DN HH2710 DM0C5MV TI TT1MG9E DM0C5MV TN Extracellular signal-regulated kinase 1 (ERK1) DM0C5MV MA Inhibitor DM0C5MV RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DM0C5MV RU https://www.haihepharma.com/en/research DM0C5MV DI DM0C5MV DM0C5MV DN HH2710 DM0C5MV TI TT4TQBX DM0C5MV TN Extracellular signal-regulated kinase 2 (ERK2) DM0C5MV MA Inhibitor DM0C5MV RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DM0C5MV RU https://www.haihepharma.com/en/research DM0CJAN DI DM0CJAN DM0CJAN DN AAV-CNGB3 DM0CJAN TI TT0LJCG DM0CJAN TN Cyclic nucleotide-gated channel beta-3 (CNGB3) DM0CJAN RN Clinical pipeline report, company report or official report of MeiraGTx. DM0CJAN RU https://meiragtx.com/research-development/pipeline/ DM0F9CD DI DM0F9CD DM0F9CD DN CCT301-59 (targeting ROR2) DM0F9CD TI TTUDPCI DM0F9CD TN Neurotrophic tyrosine kinase ROR2 (ROR2) DM0F9CD MA CAR-T-Cell-Therapy DM0F9CD RN ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma DM0F9CD RU https://clinicaltrials.gov/ct2/show/NCT03393936 DM0HSJK DI DM0HSJK DM0HSJK DN FF-10501-01 DM0HSJK TI TTF63Z1 DM0HSJK TN Cell differentiation (CD) DM0HSJK MA Stimulator DM0HSJK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0HSJK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0HTEF DI DM0HTEF DM0HTEF DN PRI-724 DM0HTEF TI TTFRCTK DM0HTEF TN CREB-binding protein (CREBBP) DM0HTEF MA Modulator DM0HTEF RN Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14. DM0HTEF RU https://pubmed.ncbi.nlm.nih.gov/20660310 DM0I5LM DI DM0I5LM DM0I5LM DN DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells DM0I5LM TI TTJIH8Q DM0I5LM TN CCR5 messenger RNA (CCR5 mRNA) DM0I5LM RN Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980. DM0I5LM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418169/ DM0MCTJ DI DM0MCTJ DM0MCTJ DN CART-123 cells DM0MCTJ TI TTENHJ0 DM0MCTJ TN Interleukin 3 receptor alpha (IL3RA) DM0MCTJ MA CAR-T-Cell-Therapy DM0MCTJ RN ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML DM0MCTJ RU https://clinicaltrials.gov/ct2/show/NCT03556982 DM0NZYC DI DM0NZYC DM0NZYC DN KO-539 DM0NZYC TI TT0CZBQ DM0NZYC TN Menin-MLL1 interaction (MEN1-KMT2A PPI) DM0NZYC MA Inhibitor DM0NZYC RN Clinical pipeline report, company report or official report of Kura Oncology. DM0NZYC RU https://kuraoncology.com/pipeline/#ko539 DM0PWX2 DI DM0PWX2 DM0PWX2 DN AUTO2 DM0PWX2 TI TTL9OD4 DM0PWX2 TN Transmembrane activator and CAML interactor (TNFRSF13B) DM0PWX2 MA CAR-T-Cell-Therapy(Dual specific) DM0PWX2 RN ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma DM0PWX2 RU https://clinicaltrials.gov/ct2/show/NCT03287804 DM0PWX2 DI DM0PWX2 DM0PWX2 DN AUTO2 DM0PWX2 TI TTZ3P4W DM0PWX2 TN B-cell maturation protein (TNFRSF17) DM0PWX2 MA CAR-T-Cell-Therapy(Dual specific) DM0PWX2 RN ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma DM0PWX2 RU https://clinicaltrials.gov/ct2/show/NCT03287804 DM0S24D DI DM0S24D DM0S24D DN GTU-TB vaccine DM0S24D TI TTUTN1I DM0S24D TN Human Deoxyribonucleic acid (hDNA) DM0S24D RN Clinical pipeline report, company report or official report of hightechfinland. DM0S24D RU http://www.hightechfinland.com/wwwdata/pdf/2013/Fitbiotech.pdf DM0USBX DI DM0USBX DM0USBX DN CD38 CAR-T Cell DM0USBX TI TTPURFN DM0USBX TN Cyclic ADP-ribose hydrolase 1 (CD38) DM0USBX MA CAR-T-Cell-Therapy DM0USBX RN ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy DM0USBX RU https://clinicaltrials.gov/ct2/show/NCT03754764 DM0VXIM DI DM0VXIM DM0VXIM DN TJ003234 DM0VXIM TI TTPZGYX DM0VXIM TN HUMAN colony-stimulating factor (GM-CSF) DM0VXIM MA Inhibitor DM0VXIM RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DM0VXIM RU https://pubmed.ncbi.nlm.nih.gov/32317220 DM0Y6WU DI DM0Y6WU DM0Y6WU DN REGN5678 DM0Y6WU TI TTQ13FT DM0Y6WU TN T-cell-specific surface glycoprotein CD28 (CD28) DM0Y6WU MA Inhibitor DM0Y6WU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0Y6WU RU https://www.regeneron.com/science/pipeline DM0Y6WU DI DM0Y6WU DM0Y6WU DN REGN5678 DM0Y6WU TI TT9G4N0 DM0Y6WU TN Glutamate carboxypeptidase II (GCPII) DM0Y6WU MA Inhibitor DM0Y6WU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0Y6WU RU https://www.regeneron.com/science/pipeline DM129VT DI DM129VT DM129VT DN 514G3 DM129VT TI TTOWKQ9 DM129VT TN Staphylococcus IgG binding protein A (Stap-coc SpA) DM129VT MA Inhibitor DM129VT RN A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018 Jan 24;13(1):e0190537. DM129VT RU https://pubmed.ncbi.nlm.nih.gov/29364906 DM13AH8 DI DM13AH8 DM13AH8 DN TAS-0728 DM13AH8 TI TT6EO5L DM13AH8 TN Erbb2 tyrosine kinase receptor (HER2) DM13AH8 MA Inhibitor DM13AH8 RN TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742. DM13AH8 RU https://pubmed.ncbi.nlm.nih.gov/30787176 DM148HX DI DM148HX DM148HX DN XToll DM148HX TI TTWYMFE DM148HX TN Mitochondrial 10kDa heat shock protein (HSPE1) DM148HX MA Modulator DM148HX RN XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr Opin Investig Drugs. 2008 May;9(5):523-33. DM148HX RU https://pubmed.ncbi.nlm.nih.gov/18465663 DM18ZLW DI DM18ZLW DM18ZLW DN IMP-321 DM18ZLW TI TTNVXAW DM18ZLW TN Lymphocyte activation gene 3 protein (LAG3) DM18ZLW MA Immunomodulator DM18ZLW RN A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11. DM18ZLW RU https://pubmed.ncbi.nlm.nih.gov/17785860 DM1AB4L DI DM1AB4L DM1AB4L DN Talotrexin DM1AB4L TI TTVC37M DM1AB4L TN Folate receptor alpha (FOLR1) DM1AB4L MA Antagonist DM1AB4L RN Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301. DM1AB4L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033035/ DM1CG47 DI DM1CG47 DM1CG47 DN IL-2 XL DM1CG47 TI TTF89GD DM1CG47 TN Interleukin-2 (IL2) DM1CG47 MA Modulator DM1CG47 RN Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558. DM1CG47 RU http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2558 DM1D6BT DI DM1D6BT DM1D6BT DN PEGylated hyaluronidase (human recombinant) DM1D6BT TI TTXFI1K DM1D6BT TN Hyaluronidase (HYAL) DM1D6BT MA Modulator DM1D6BT RN Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. DM1D6BT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/ DM1DHPO DI DM1DHPO DM1DHPO DN BCMA CAR-T DM1DHPO TI TTZ3P4W DM1DHPO TN B-cell maturation protein (TNFRSF17) DM1DHPO MA CAR-T-Cell-Therapy DM1DHPO RN ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma DM1DHPO RU https://clinicaltrials.gov/ct2/show/NCT03322735 DM1EH9D DI DM1EH9D DM1EH9D DN Anti-CD19 CAR-T cells DM1EH9D TI TTW640A DM1EH9D TN B-lymphocyte surface antigen B4 (CD19) DM1EH9D MA CAR-T-Cell-Therapy DM1EH9D RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM1EH9D RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM1FJW6 DI DM1FJW6 DM1FJW6 DN BT8009 DM1FJW6 TI TTPO9EG DM1FJW6 TN Nectin cell adhesion molecule 4 (NECTIN4) DM1FJW6 RN Clinical pipeline report, company report or official report of Bicycle Therapeutics. DM1FJW6 RU https://www.bicycletherapeutics.com/wp-content/uploads/BT8009-AACR-4479-Rigby.pdf DM1FY97 DI DM1FY97 DM1FY97 DN T3D-959 DM1FY97 TI TT2JWF6 DM1FY97 TN Peroxisome proliferator-activated receptor delta (PPARD) DM1FY97 MA Modulator DM1FY97 RN Phrma report (2013 Alzheimers disease) DM1FY97 RU http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf DM1FY97 DI DM1FY97 DM1FY97 DN T3D-959 DM1FY97 TI TTZMAO3 DM1FY97 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM1FY97 MA Modulator DM1FY97 RN Phrma report (2013 Alzheimers disease) DM1FY97 RU http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf DM1GE67 DI DM1GE67 DM1GE67 DN GS-4224 DM1GE67 TI TT8ZLTI DM1GE67 TN Programmed cell death 1 ligand 1 (PD-L1) DM1GE67 MA Inhibitor DM1GE67 RN Clinical pipeline report, company report or official report of Gilead Sciences. DM1GE67 RU https://www.gilead.com/science-and-medicine/pipeline DM1KZW0 DI DM1KZW0 DM1KZW0 DN MGC018 DM1KZW0 TI TT6CQUM DM1KZW0 TN B7 homolog 3 (CD276) DM1KZW0 RN Clinical pipeline report, company report or official report of MacroGenics. DM1KZW0 RU https://www.macrogenics.com/mgc018-b7-h3/ DM1LO8K DI DM1LO8K DM1LO8K DN RVX-208 DM1LO8K TI TTRA6BO DM1LO8K TN Bromodomain-containing protein 4 (BRD4) DM1LO8K MA Modulator DM1LO8K RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DM1LO8K RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DM1PQJO DI DM1PQJO DM1PQJO DN Enapotamab vedotin DM1PQJO TI TTZPY6J DM1PQJO TN Tyrosine-protein kinase UFO (AXL) DM1PQJO MA Inhibitor DM1PQJO RN Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199. DM1PQJO RU https://pubmed.ncbi.nlm.nih.gov/31600169 DM1U6VX DI DM1U6VX DM1U6VX DN HER-2-targeting CAR T Cells DM1U6VX TI TT6EO5L DM1U6VX TN Erbb2 tyrosine kinase receptor (HER2) DM1U6VX MA CAR-T-Cell-Therapy DM1U6VX RN ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer DM1U6VX RU https://clinicaltrials.gov/ct2/show/NCT02547961 DM1W7LV DI DM1W7LV DM1W7LV DN CAR-T cells targeting MAGE-A1 DM1W7LV TI TT63M7Q DM1W7LV TN Melanoma-associated antigen 1 (MAGEA1) DM1W7LV MA CAR-T-Cell-Therapy DM1W7LV RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DM1W7LV RU https://clinicaltrials.gov/ct2/show/NCT03356808 DM1WB8H DI DM1WB8H DM1WB8H DN Anti-CD19-CAR PBL DM1WB8H TI TTW640A DM1WB8H TN B-lymphocyte surface antigen B4 (CD19) DM1WB8H MA CAR-T-Cell-Therapy DM1WB8H RN ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma DM1WB8H RU https://clinicaltrials.gov/ct2/show/NCT00924326 DM1WD8F DI DM1WD8F DM1WD8F DN ISB 1302 DM1WD8F TI TT6EO5L DM1WD8F TN Erbb2 tyrosine kinase receptor (HER2) DM1WD8F MA Inhibitor DM1WD8F RN Clinical pipeline report, company report or official report of Ichnos Sciences. DM1WD8F RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DM1WD8F DI DM1WD8F DM1WD8F DN ISB 1302 DM1WD8F TI TTUN7MC DM1WD8F TN T-cell surface glycoprotein CD3 (CD3) DM1WD8F MA Inhibitor DM1WD8F RN Clinical pipeline report, company report or official report of Ichnos Sciences. DM1WD8F RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DM1XIMU DI DM1XIMU DM1XIMU DN FF-10101 DM1XIMU TI TTGJCWZ DM1XIMU TN Fms-like tyrosine kinase 3 (FLT-3) DM1XIMU MA Inhibitor DM1XIMU RN A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018 Jan 25;131(4):426-438. DM1XIMU RU https://pubmed.ncbi.nlm.nih.gov/29187377 DM1ZGUX DI DM1ZGUX DM1ZGUX DN CPHPC DM1ZGUX TI TTB7VAT DM1ZGUX TN Serum amyloid P-component (APCS) DM1ZGUX MA Modulator DM1ZGUX RN Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).Acta Crystallogr D Biol Crystallogr.2014 Aug;70(Pt 8):2232-40. DM1ZGUX RU https://www.ncbi.nlm.nih.gov/pubmed/25084341 DM1ZHML DI DM1ZHML DM1ZHML DN HPN328 DM1ZHML TI TT1C9K6 DM1ZHML TN Delta-like protein 3 (DLL3) DM1ZHML RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DM1ZHML RU https://www.harpoontx.com/pipeline/ DM1ZK4W DI DM1ZK4W DM1ZK4W DN TRBC1 DM1ZK4W TI TT1DHW2 DM1ZK4W TN T-cell receptor beta constant 1 (TRBC1) DM1ZK4W MA CAR-T-Cell-Therapy DM1ZK4W RN ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma DM1ZK4W RU https://clinicaltrials.gov/ct2/show/NCT03590574 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTDCBX5 DM21WBH TN Vascular endothelial growth factor receptor 3 (FLT-4) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTO7LKR DM21WBH TN Tyrosine-protein kinase Mer (MERTK) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTGJCWZ DM21WBH TN Fms-like tyrosine kinase 3 (FLT-3) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTNDSF4 DM21WBH TN Proto-oncogene c-Met (MET) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTRLW2X DM21WBH TN Fibroblast growth factor receptor 1 (FGFR1) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTI7421 DM21WBH TN Platelet-derived growth factor receptor beta (PDGFRB) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTUTJGQ DM21WBH TN Vascular endothelial growth factor receptor 2 (KDR) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TT1VAUK DM21WBH TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTST7KB DM21WBH TN Fibroblast growth factor receptor 3 (FGFR3) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTXABCW DM21WBH TN NT-3 growth factor receptor (TrkC) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTKN7QR DM21WBH TN BDNF/NT-3 growth factors receptor (TrkB) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTGJVQM DM21WBH TN Fibroblast growth factor receptor 2 (FGFR2) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTBQ3OC DM21WBH TN Macrophage-stimulating protein receptor (RON) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM25QKC DI DM25QKC DM25QKC DN MK-1308 DM25QKC TI TTI2S1D DM25QKC TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM25QKC MA Inhibitor DM25QKC RN Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403. DM25QKC RU https://pubmed.ncbi.nlm.nih.gov/33276076 DM26VCZ DI DM26VCZ DM26VCZ DN Anti-NY-ESO-1 CAR-T cells DM26VCZ TI TTE5ITK DM26VCZ TN Cancer/testis antigen 1 (NY-ESO-1) DM26VCZ MA CAR-T-Cell-Therapy DM26VCZ RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM26VCZ RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM276Y8 DI DM276Y8 DM276Y8 DN ARV-471 DM276Y8 TI TTS64P2 DM276Y8 TN Androgen receptor (AR) DM276Y8 MA Degrader DM276Y8 RN Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689. DM276Y8 RU https://pubmed.ncbi.nlm.nih.gov/32829249 DM27RXS DI DM27RXS DM27RXS DN ORIN1001 DM27RXS TI TTOJ9QL DM27RXS TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM27RXS MA Inhibitor DM27RXS RN Clinical pipeline report, company report or official report of Orinove. DM27RXS RU http://www.orinove.com/about261.html DM2910G DI DM2910G DM2910G DN Anti-VEGFR2 CD8 cell therapy DM2910G TI TTUTJGQ DM2910G TN Vascular endothelial growth factor receptor 2 (KDR) DM2910G MA Modulator DM2910G RN Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. DM2910G RU https://pubmed.ncbi.nlm.nih.gov/23045683 DM2910G DI DM2910G DM2910G DN Anti-VEGFR2 CD8 cell therapy DM2910G TI TTMHA6L DM2910G TN T-cell surface glycoprotein CD8 (CD8) DM2910G MA Modulator DM2910G RN Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. DM2910G RU https://pubmed.ncbi.nlm.nih.gov/23045683 DM2B1V0 DI DM2B1V0 DM2B1V0 DN CCT301-38 (targeting ROR2) DM2B1V0 TI TTUDPCI DM2B1V0 TN Neurotrophic tyrosine kinase ROR2 (ROR2) DM2B1V0 MA CAR-T-Cell-Therapy DM2B1V0 RN ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma DM2B1V0 RU https://clinicaltrials.gov/ct2/show/NCT03393936 DM2BXDU DI DM2BXDU DM2BXDU DN CFG920 DM2BXDU TI TTRA5BZ DM2BXDU TN Steroid 17-alpha-monooxygenase (S17AH) DM2BXDU MA Inhibitor DM2BXDU RN Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78. DM2BXDU RU https://pubmed.ncbi.nlm.nih.gov/23880851 DM2CDLS DI DM2CDLS DM2CDLS DN QLT-091568 DM2CDLS TI TTMXGCW DM2CDLS TN Adrenergic receptor beta-3 (ADRB3) DM2CDLS MA Antagonist DM2CDLS RN Clinical pipeline report, company report or official report of QLT Inc. DM2CDLS RU http://www.qltinc.com/newsCenter/2009/091230.htm DM2DHJS DI DM2DHJS DM2DHJS DN ONC1-13B DM2DHJS TI TTS64P2 DM2DHJS TN Androgen receptor (AR) DM2DHJS MA Antagonist DM2DHJS RN Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42. DM2DHJS RU https://pubmed.ncbi.nlm.nih.gov/24494031 DM2FSM5 DI DM2FSM5 DM2FSM5 DN CLR-1401 DM2FSM5 TI TTHBTOP DM2FSM5 TN PI3-kinase gamma (PIK3CG) DM2FSM5 MA Inhibitor DM2FSM5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DM2FSM5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DM2HRYD DI DM2HRYD DM2HRYD DN AEG35156 DM2HRYD TI TTK3WBU DM2HRYD TN XIAP messenger RNA (XIAP mRNA) DM2HRYD RN Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. DM2HRYD RU https://pubmed.ncbi.nlm.nih.gov/19568274 DM2LU8M DI DM2LU8M DM2LU8M DN AP1903 DM2LU8M TI TTMW94E DM2LU8M TN FK506-binding protein 1A (FKBP1A) DM2LU8M MA Modulator DM2LU8M RN Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64. DM2LU8M RU https://pubmed.ncbi.nlm.nih.gov/18356813 DM2LYIN DI DM2LYIN DM2LYIN DN LX-7101 DM2LYIN TI TTU8W4S DM2LYIN TN Protein kinase (PK) DM2LYIN MA Inhibitor DM2LYIN RN Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10. DM2LYIN RU https://pubmed.ncbi.nlm.nih.gov/26233434 DM2LZ8F DI DM2LZ8F DM2LZ8F DN Taurocholic acid DM2LZ8F TI TTPI1M5 DM2LZ8F TN Ileal sodium/bile acid cotransporter (SLC10A2) DM2LZ8F MA Modulator DM2LZ8F RN Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. DM2LZ8F RU https://pubmed.ncbi.nlm.nih.gov/9458785 DM2LZ8F DI DM2LZ8F DM2LZ8F DN Taurocholic acid DM2LZ8F TI TTTRNQW DM2LZ8F TN Bile-salt-activated lipase (CEL) DM2LZ8F MA Inhibitor DM2LZ8F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2LZ8F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2X3BR DI DM2X3BR DM2X3BR DN SNN-0031 DM2X3BR TI TTI7421 DM2X3BR TN Platelet-derived growth factor receptor beta (PDGFRB) DM2X3BR MA Modulator DM2X3BR RN Company report (Neuronova) DM2X3BR RU http://www.neuronova.com/index.php?option=com_content&task=view&id=41 DM2YTGQ DI DM2YTGQ DM2YTGQ DN Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes DM2YTGQ TI TTW640A DM2YTGQ TN B-lymphocyte surface antigen B4 (CD19) DM2YTGQ MA CAR-T-Cell-Therapy DM2YTGQ RN ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia DM2YTGQ RU https://clinicaltrials.gov/ct2/show/NCT01865617 DM31NJU DI DM31NJU DM31NJU DN ABY-025 DM31NJU TI TT6EO5L DM31NJU TN Erbb2 tyrosine kinase receptor (HER2) DM31NJU MA Enhancer DM31NJU RN Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8. DM31NJU RU https://pubmed.ncbi.nlm.nih.gov/20554729 DM32AKH DI DM32AKH DM32AKH DN G-207 virus construct DM32AKH TI TTX09M4 DM32AKH TN Ribonucleotide reductase (RIR) DM32AKH MA Inhibitor DM32AKH RN Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011 Dec;30(12):831-41. DM32AKH RU https://pubmed.ncbi.nlm.nih.gov/22059912 DM35XCT DI DM35XCT DM35XCT DN CD56-specific gene-engineered T cells DM35XCT TI TTVXPHT DM35XCT TN Neural cell adhesion molecule 1 (NCAM1) DM35XCT MA CAR-T-Cell-Therapy DM35XCT RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DM35XCT RU https://clinicaltrials.gov/ct2/show/NCT03222674 DM35YFC DI DM35YFC DM35YFC DN MS-1819 DM35YFC TI TTXMY0J DM35YFC TN Pancreatic triacylglycerol lipase (PNLIP) DM35YFC MA Modulator DM35YFC RN Clinical pipeline report, company report or official report of AzurRx. DM35YFC RU http://www.azurrx.com/news-events/press-releases/10-news-2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit DM3FIMD DI DM3FIMD DM3FIMD DN WT-4869 DM3FIMD TI TTZ8UT4 DM3FIMD TN Wilms tumor protein (WT1) DM3FIMD MA Modulator DM3FIMD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385) DM3FIMD RU http://adisinsight.springer.com/drugs/800033385 DM3GO0J DI DM3GO0J DM3GO0J DN Sodium taurocholate DM3GO0J TI TTSDVTR DM3GO0J TN G-protein coupled bile acid receptor 1 (GPBAR1) DM3GO0J MA Modulator DM3GO0J RN Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157. DM3GO0J RU http://www.sciencedirect.com/science/article/pii/S2211383514001300 DM3I267 DI DM3I267 DM3I267 DN CART-EGFR DM3I267 TI TTGKNB4 DM3I267 TN Epidermal growth factor receptor (EGFR) DM3I267 MA CAR-T-Cell-Therapy DM3I267 RN ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) DM3I267 RU https://clinicaltrials.gov/ct2/show/NCT01869166 DM3KXMG DI DM3KXMG DM3KXMG DN IZONSTERIDE DM3KXMG TI TT2A0DR DM3KXMG TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM3KXMG MA Modulator DM3KXMG RN Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9. DM3KXMG RU https://www.ncbi.nlm.nih.gov/pubmed/14751361 DM3XWJ8 DI DM3XWJ8 DM3XWJ8 DN CPI-1205 DM3XWJ8 TI TT9MZCQ DM3XWJ8 TN Enhancer of zeste homolog 2 (EZH2) DM3XWJ8 MA Inhibitor DM3XWJ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3XWJ8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3ZN6Y DI DM3ZN6Y DM3ZN6Y DN FPA-008 DM3ZN6Y TI TT731LW DM3ZN6Y TN Colony stimulating factor-1 receptor (CSF-1R) DM3ZN6Y MA Modulator DM3ZN6Y RN Company report (Five Prime Therapeutics) DM3ZN6Y RU http://www.fiveprime.com/pipeline/fpa008 DM3ZN6Y DI DM3ZN6Y DM3ZN6Y DN FPA-008 DM3ZN6Y TI TT7MRDV DM3ZN6Y TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM3ZN6Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ZN6Y RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM40NEB DI DM40NEB DM40NEB DN CD22 CAR-T DM40NEB TI TTM6QSK DM40NEB TN B-cell receptor CD22 (CD22) DM40NEB MA CAR-T-Cell-Therapy DM40NEB RN ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies DM40NEB RU https://clinicaltrials.gov/ct2/show/NCT02794961 DM43ICH DI DM43ICH DM43ICH DN IMSA101 DM43ICH TI TTT402Y DM43ICH TN Stimulator of interferon genes protein (TMEM173) DM43ICH MA Agonist DM43ICH RN Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics. DM43ICH RU http://www.immunesensor.com/ DM471ZH DI DM471ZH DM471ZH DN ORE-1001 DM471ZH TI TTUI5H7 DM471ZH TN Angiotensin-converting enzyme 2 (ACE2) DM471ZH MA Inhibitor DM471ZH RN Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27. DM471ZH RU https://pubmed.ncbi.nlm.nih.gov/19517214 DM49BX1 DI DM49BX1 DM49BX1 DN F-16-131I DM49BX1 TI TTUCPMY DM49BX1 TN Tenascin (TNC) DM49BX1 RN Tumor-Associated Fibroblasts and their Matrix. Springer. Margareta M. Mueller,Norbert E. Fusenig, 2011. Page(775). DM49BX1 RU https://books.google.com.hk/books?id=NthWAAAAcAAJ&pg=PA775&lpg=PA775&dq=%22F-16-131I%22&source=bl&ots=lx9eNOrJ9J&sig=TSJZ44F1Vb9V3iKhqn2bmzR0H4E&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIgayw4crGyAIVDEiOCh1b7Q2U#v=onepage&q=%22F-16-131I%22&f=false DM4D3YF DI DM4D3YF DM4D3YF DN Anti-BCMA CAR-T cells DM4D3YF TI TTZ3P4W DM4D3YF TN B-cell maturation protein (TNFRSF17) DM4D3YF MA CAR-T-Cell-Therapy DM4D3YF RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM4D3YF RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM4H7UY DI DM4H7UY DM4H7UY DN Milatuzumab DM4H7UY TI TTCMYP9 DM4H7UY TN HLA-DR antigens-associated invariant (CD74) DM4H7UY RN Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. DM4H7UY RU https://pubmed.ncbi.nlm.nih.gov/21228331 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TT84ETX DM4L28K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TTFGZB6 DM4L28K TN Human immunodeficiency virus GAG protein (HIV gag) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TT4NXYM DM4L28K TN Human immunodeficiency virus Negative factor (HIV nef) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4MBUI DI DM4MBUI DM4MBUI DN CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells DM4MBUI TI TTM6QSK DM4MBUI TN B-cell receptor CD22 (CD22) DM4MBUI MA CAR-T-Cell-Therapy(Dual specific) DM4MBUI RN ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy DM4MBUI RU https://clinicaltrials.gov/ct2/show/NCT02903810 DM4MBUI DI DM4MBUI DM4MBUI DN CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells DM4MBUI TI TTW640A DM4MBUI TN B-lymphocyte surface antigen B4 (CD19) DM4MBUI MA CAR-T-Cell-Therapy(Dual specific) DM4MBUI RN ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy DM4MBUI RU https://clinicaltrials.gov/ct2/show/NCT02903810 DM4NK3J DI DM4NK3J DM4NK3J DN SF0166 DM4NK3J TI TT69TQN DM4NK3J TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4NK3J MA Antagonist DM4NK3J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4NK3J RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM4NMBW DI DM4NMBW DM4NMBW DN Anti-Mesothelin CAR-T cells DM4NMBW TI TT4RXME DM4NMBW TN Mesothelin (MSLN) DM4NMBW MA CAR-T-Cell-Therapy DM4NMBW RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM4NMBW RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM4WEZL DI DM4WEZL DM4WEZL DN Anti-CD20 CAR-T cells DM4WEZL TI TTUE541 DM4WEZL TN Leukocyte surface antigen Leu-16 (CD20) DM4WEZL MA CAR-T-Cell-Therapy(Dual specific) DM4WEZL RN ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) DM4WEZL RU https://clinicaltrials.gov/ct2/show/NCT02737085 DM4WEZL DI DM4WEZL DM4WEZL DN Anti-CD20 CAR-T cells DM4WEZL TI TTW640A DM4WEZL TN B-lymphocyte surface antigen B4 (CD19) DM4WEZL MA CAR-T-Cell-Therapy(Dual specific) DM4WEZL RN ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) DM4WEZL RU https://clinicaltrials.gov/ct2/show/NCT02737085 DM581CS DI DM581CS DM581CS DN CD19 and CD22 CAR-T Cells DM581CS TI TTM6QSK DM581CS TN B-cell receptor CD22 (CD22) DM581CS MA CAR-T-Cell-Therapy(Dual specific) DM581CS RN ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma DM581CS RU https://clinicaltrials.gov/ct2/show/NCT03468153 DM581CS DI DM581CS DM581CS DN CD19 and CD22 CAR-T Cells DM581CS TI TTW640A DM581CS TN B-lymphocyte surface antigen B4 (CD19) DM581CS MA CAR-T-Cell-Therapy(Dual specific) DM581CS RN ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma DM581CS RU https://clinicaltrials.gov/ct2/show/NCT03468153 DM5AIKR DI DM5AIKR DM5AIKR DN RGX-104 DM5AIKR TI TTM1EQF DM5AIKR TN Oxysterols receptor LXR (NR1H) DM5AIKR MA Agonist DM5AIKR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5AIKR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5DZEL DI DM5DZEL DM5DZEL DN PLX9486 DM5DZEL TI TTX41N9 DM5DZEL TN Tyrosine-protein kinase Kit (KIT) DM5DZEL MA Inhibitor DM5DZEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5DZEL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5FCO4 DI DM5FCO4 DM5FCO4 DN Elpamotide DM5FCO4 TI TTUTJGQ DM5FCO4 TN Vascular endothelial growth factor receptor 2 (KDR) DM5FCO4 RN Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8. DM5FCO4 RU https://pubmed.ncbi.nlm.nih.gov/22957712 DM5FKU1 DI DM5FKU1 DM5FKU1 DN CAR-T cells targeting Muc1 DM5FKU1 TI TTBHFYQ DM5FKU1 TN Mucin-1 (MUC1) DM5FKU1 MA CAR-T-Cell-Therapy DM5FKU1 RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DM5FKU1 RU https://clinicaltrials.gov/ct2/show/NCT03356795 DM5HUY8 DI DM5HUY8 DM5HUY8 DN BMS-863233 DM5HUY8 TI TTSMTDI DM5HUY8 TN CDC7-related kinase (CDC7) DM5HUY8 MA Modulator DM5HUY8 RN Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. DM5HUY8 RU https://pubmed.ncbi.nlm.nih.gov/22560567 DM5MFHO DI DM5MFHO DM5MFHO DN REIC gene therapy DM5MFHO TI TTY2ZV6 DM5MFHO TN Dickkopf-related protein 3 (DKK3) DM5MFHO MA Modulator DM5MFHO RN Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. J Gastroenterol Hepatol. 2014 May;29(5):973-83. DM5MFHO RU https://pubmed.ncbi.nlm.nih.gov/24372695 DM5N04G DI DM5N04G DM5N04G DN LT-1951 DM5N04G TI TTF10I9 DM5N04G TN Nitric-oxide synthase inducible (NOS2) DM5N04G MA Modulator DM5N04G RN Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14. DM5N04G RU https://pubmed.ncbi.nlm.nih.gov/12742995 DM5NICF DI DM5NICF DM5NICF DN TBI-1501 DM5NICF TI TTW640A DM5NICF TN B-lymphocyte surface antigen B4 (CD19) DM5NICF MA CAR-T-Cell-Therapy DM5NICF RN ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia DM5NICF RU https://clinicaltrials.gov/ct2/show/NCT03155191 DM5O4GR DI DM5O4GR DM5O4GR DN NB1011 DM5O4GR TI TTU6BFZ DM5O4GR TN Candida Thymidylate synthase (Candi TMP1) DM5O4GR MA Binder DM5O4GR RN Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300. DM5O4GR RU https://pubmed.ncbi.nlm.nih.gov/12859954 DM5U3IF DI DM5U3IF DM5U3IF DN KB-004 DM5U3IF TI TTHS2LR DM5U3IF TN Ephrin type-A receptor 3 (EPHA3) DM5U3IF RN Clinical pipeline report, company report or official report of Kalobios. DM5U3IF RU http://kalobios.com/kb004 DM5VF04 DI DM5VF04 DM5VF04 DN GD2-CART01 DM5VF04 TI TT80ARU DM5VF04 TN Ganglioside GD2 (GD2) DM5VF04 MA CAR-T-Cell-Therapy DM5VF04 RN ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma DM5VF04 RU https://clinicaltrials.gov/ct2/show/NCT03373097 DM5VG6S DI DM5VG6S DM5VG6S DN BGB-A333 DM5VG6S TI TT8ZLTI DM5VG6S TN Programmed cell death 1 ligand 1 (PD-L1) DM5VG6S RN Clinical pipeline report, company report or official report of BeiGene. DM5VG6S RU https://www.beigene.com/science-and-product-portfolio/pipeline DM5YDSU DI DM5YDSU DM5YDSU DN ACI-24 DM5YDSU TI TTE4KHA DM5YDSU TN Amyloid beta A4 protein (APP) DM5YDSU RN Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36. DM5YDSU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015631/ DM6078F DI DM6078F DM6078F DN CT84.66 DM6078F TI TTY6DTE DM6078F TN Carcinoembryonic antigen CEA (CD66e) DM6078F RN Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5. DM6078F RU https://pubmed.ncbi.nlm.nih.gov/15011786 DM614BA DI DM614BA DM614BA DN Re-188-P-2045 DM614BA TI TTZ6T9E DM614BA TN Somatostatin receptor type 2 (SSTR2) DM614BA MA Modulator DM614BA RN The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5. DM614BA RU https://pubmed.ncbi.nlm.nih.gov/25359879 DM61MBG DI DM61MBG DM61MBG DN CD22-Targeted CAR-T cells DM61MBG TI TTM6QSK DM61MBG TN B-cell receptor CD22 (CD22) DM61MBG MA CAR-T-Cell-Therapy DM61MBG RN ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies DM61MBG RU https://clinicaltrials.gov/ct2/show/NCT02935153 DM64FY7 DI DM64FY7 DM64FY7 DN CLR457 DM64FY7 TI TTHBTOP DM64FY7 TN PI3-kinase gamma (PIK3CG) DM64FY7 MA Modulator DM64FY7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM64FY7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM64PM7 DI DM64PM7 DM64PM7 DN EXO-230 DM64PM7 TI TT8NGED DM64PM7 TN Prostaglandin G/H synthase 1 (COX-1) DM64PM7 MA Agonist DM64PM7 RN Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083. DM64PM7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831899/ DM65MEL DI DM65MEL DM65MEL DN LXS196 DM65MEL TI TTYVX59 DM65MEL TN Protein kinase C (PRKC) DM65MEL MA Inhibitor DM65MEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM65MEL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM69A1W DI DM69A1W DM69A1W DN CD19 CART DM69A1W TI TTW640A DM69A1W TN B-lymphocyte surface antigen B4 (CD19) DM69A1W MA CAR-T-Cell-Therapy DM69A1W RN ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL DM69A1W RU https://clinicaltrials.gov/ct2/show/NCT03232619 DM6AXV9 DI DM6AXV9 DM6AXV9 DN TOL-101 DM6AXV9 TI TT7AKW1 DM6AXV9 TN T-cell receptor (TCR) DM6AXV9 RN First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355. DM6AXV9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404309/ DM6H1MQ DI DM6H1MQ DM6H1MQ DN CAR-T cells targeting GPC3 DM6H1MQ TI TTJTSX4 DM6H1MQ TN Glypican-3 (GPC3) DM6H1MQ MA CAR-T-Cell-Therapy DM6H1MQ RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DM6H1MQ RU https://clinicaltrials.gov/ct2/show/NCT02959151 DM6H3YS DI DM6H3YS DM6H3YS DN MAGE-A10 TCR DM6H3YS TI TT7AKW1 DM6H3YS TN T-cell receptor (TCR) DM6H3YS MA Immunomodulator DM6H3YS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6H3YS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6HPEC DI DM6HPEC DM6HPEC DN USL311 DM6HPEC TI TTBID49 DM6HPEC TN C-X-C chemokine receptor type 4 (CXCR4) DM6HPEC MA Antagonist DM6HPEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6HPEC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6JLNT DI DM6JLNT DM6JLNT DN 177-Lu-NeoB DM6JLNT TI TTC1MVT DM6JLNT TN Gastrin-releasing peptide receptor (GRPR) DM6JLNT MA Antagonist DM6JLNT RN 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299. DM6JLNT RU https://pubmed.ncbi.nlm.nih.gov/27609789 DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTCJG29 DM6JN19 TN Serine/threonine-protein kinase mTOR (mTOR) DM6JN19 MA Inhibitor DM6JN19 RN National Cancer Institute Drug Dictionary (drug id 728650). DM6JN19 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=728650 DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTX4GLS DM6JN19 TN Mammalian target of rapamycin complex 1 (mTORC1) DM6JN19 MA Inhibitor DM6JN19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6JN19 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTWDKCL DM6JN19 TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DM6JN19 MA Inhibitor DM6JN19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6JN19 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6LDI4 DI DM6LDI4 DM6LDI4 DN BMS-986158 DM6LDI4 TI TTE4BSY DM6LDI4 TN Bromodomain and extraterminal domain protein (BET) DM6LDI4 MA Inhibitor DM6LDI4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6LDI4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6M8O4 DI DM6M8O4 DM6M8O4 DN SAR440234 DM6M8O4 TI TTUN7MC DM6M8O4 TN T-cell surface glycoprotein CD3 (CD3) DM6M8O4 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM6M8O4 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM6M8O4 DI DM6M8O4 DM6M8O4 DN SAR440234 DM6M8O4 TI TTENHJ0 DM6M8O4 TN Interleukin 3 receptor alpha (IL3RA) DM6M8O4 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM6M8O4 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM6V5OB DI DM6V5OB DM6V5OB DN P-552-02 DM6V5OB TI TTRK8B9 DM6V5OB TN Sodium channel unspecific (NaC) DM6V5OB MA Blocker DM6V5OB RN US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion. DM6V5OB RU https://www.google.com/patents/US20140221286 DM6VCPX DI DM6VCPX DM6VCPX DN CAR-T cells targeting CEA DM6VCPX TI TTY6DTE DM6VCPX TN Carcinoembryonic antigen CEA (CD66e) DM6VCPX MA CAR-T-Cell-Therapy DM6VCPX RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DM6VCPX RU https://clinicaltrials.gov/ct2/show/NCT02959151 DM6VGO3 DI DM6VGO3 DM6VGO3 DN OPB-31121 DM6VGO3 TI TTH8FZW DM6VGO3 TN Signal transducer and activator of transcription 3 (STAT3) DM6VGO3 MA Inhibitor DM6VGO3 RN OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52. DM6VGO3 RU https://pubmed.ncbi.nlm.nih.gov/23402820 DM6ZXWY DI DM6ZXWY DM6ZXWY DN CAR.CD30 cells DM6ZXWY TI TT2GM5R DM6ZXWY TN Lymphocyte activation antigen CD30 (TNFRSF8) DM6ZXWY MA CAR-T-Cell-Therapy DM6ZXWY RN ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas DM6ZXWY RU https://clinicaltrials.gov/ct2/show/NCT02663297 DM71BFM DI DM71BFM DM71BFM DN DNA-Ad DM71BFM TI TTQZW34 DM71BFM TN Plasmodium Apical membrane protein (Malaria AMA-1) DM71BFM RN Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241. DM71BFM RU https://pubmed.ncbi.nlm.nih.gov/25211344 DM71I53 DI DM71I53 DM71I53 DN APC-100 DM71I53 TI TTS64P2 DM71I53 TN Androgen receptor (AR) DM71I53 MA Inhibitor DM71I53 RN 2011 Pipeline of Adamis Pharmaceuticals. DM71I53 RU http://www.adamispharmaceuticals.com/ DM72DU3 DI DM72DU3 DM72DU3 DN DZD9008 DM72DU3 TI TT2M7YX DM72DU3 TN EGFR Exon20ins mutant (EGFR Exon20ins) DM72DU3 MA Inhibitor DM72DU3 RN Clinical pipeline report, company report or official report of Dizal Pharmaceuticals. DM72DU3 RU http://www.dizalpharma.com/innovation/science DM72JE4 DI DM72JE4 DM72JE4 DN FF-10502 DM72JE4 TI TTA0XPV DM72JE4 TN DNA polymerase beta (POLB) DM72JE4 MA Inhibitor DM72JE4 RN FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. DM72JE4 RU https://pubmed.ncbi.nlm.nih.gov/29653962 DM75QY9 DI DM75QY9 DM75QY9 DN ATL-313 DM75QY9 TI TTM2AOE DM75QY9 TN Adenosine A2a receptor (ADORA2A) DM75QY9 MA Agonist DM75QY9 RN Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12. DM75QY9 RU https://pubmed.ncbi.nlm.nih.gov/16622196 DM76S3X DI DM76S3X DM76S3X DN ARO-HBV DM76S3X TI TT43YWN DM76S3X TN Hepatitis B virus messenger RNA (HBV mRNA) DM76S3X MA Inhibitor DM76S3X RN Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals. DM76S3X RU https://arrowheadpharma.com/pipeline/ DM78KMT DI DM78KMT DM78KMT DN NPB-001-056 DM78KMT TI TTS7G69 DM78KMT TN Fusion protein Bcr-Abl (Bcr-Abl) DM78KMT MA Inhibitor DM78KMT RN NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88. DM78KMT RU https://pubmed.ncbi.nlm.nih.gov/21622134 DM79GPF DI DM79GPF DM79GPF DN CD19.CAR T Cells DM79GPF TI TTW640A DM79GPF TN B-lymphocyte surface antigen B4 (CD19) DM79GPF MA CAR-T-Cell-Therapy DM79GPF RN ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR DM79GPF RU https://clinicaltrials.gov/ct2/show/NCT03676504 DM7C1AJ DI DM7C1AJ DM7C1AJ DN HT-2157 DM7C1AJ TI TTOPAY7 DM7C1AJ TN Galanin receptor (GAL-R) DM7C1AJ MA Antagonist DM7C1AJ RN Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94. DM7C1AJ RU https://pubmed.ncbi.nlm.nih.gov/16287967 DM7CLEZ DI DM7CLEZ DM7CLEZ DN Eltanexor oral DM7CLEZ TI TTCJUR4 DM7CLEZ TN Exportin-1 (XPO1) DM7CLEZ MA Inhibitor DM7CLEZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7CLEZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7DWLY DI DM7DWLY DM7DWLY DN GLR2007 DM7DWLY TI TT0PG8F DM7DWLY TN Cyclin-dependent kinase 4 (CDK4) DM7DWLY MA Inhibitor DM7DWLY RN Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals. DM7DWLY RU http://www.ganlee.com/en/index.php?optionid=681&auto_id=68 DM7DWLY DI DM7DWLY DM7DWLY DN GLR2007 DM7DWLY TI TTO0FDJ DM7DWLY TN Cyclin-dependent kinase 6 (CDK6) DM7DWLY MA Inhibitor DM7DWLY RN Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals. DM7DWLY RU http://www.ganlee.com/en/index.php?optionid=681&auto_id=68 DM7IWTF DI DM7IWTF DM7IWTF DN ACP-319 DM7IWTF TI TTGM6VW DM7IWTF TN Tyrosine-protein kinase BTK (ATK) DM7IWTF MA Inhibitor DM7IWTF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DM7IWTF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DM7LOSK DI DM7LOSK DM7LOSK DN REGN4018 DM7LOSK TI TTC1PS3 DM7LOSK TN Ovarian carcinoma antigen CA125 (MUC16) DM7LOSK MA Inhibitor DM7LOSK RN A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. DM7LOSK RU https://pubmed.ncbi.nlm.nih.gov/31217340 DM7LOSK DI DM7LOSK DM7LOSK DN REGN4018 DM7LOSK TI TTUN7MC DM7LOSK TN T-cell surface glycoprotein CD3 (CD3) DM7LOSK MA Inhibitor DM7LOSK RN A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. DM7LOSK RU https://pubmed.ncbi.nlm.nih.gov/31217340 DM7NKWQ DI DM7NKWQ DM7NKWQ DN PBCAR20A DM7NKWQ TI TTUE541 DM7NKWQ TN Leukocyte surface antigen Leu-16 (CD20) DM7NKWQ RN Clinical pipeline report, company report or official report of Precision Biosciences. DM7NKWQ RU https://precisionbiosciences.com/pipeline/ DM7O29W DI DM7O29W DM7O29W DN AVX901 DM7O29W TI TT6EO5L DM7O29W TN Erbb2 tyrosine kinase receptor (HER2) DM7O29W MA Inhibitor DM7O29W RN ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health. DM7O29W RU https://clinicaltrials.gov/ct2/show/NCT01526473 DM7O89Q DI DM7O89Q DM7O89Q DN AT-777 DM7O89Q TI TTMVBWH DM7O89Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7O89Q MA Inhibitor DM7O89Q RN Clinical pipeline report, company report or official report of Atea Pharmaceuticals. DM7O89Q RU https://ateapharma.com/about-us/hepatitis-c/ DM7OE3X DI DM7OE3X DM7OE3X DN INCAGN1949 DM7OE3X TI TTL31H0 DM7OE3X TN OX40L receptor (CD134) DM7OE3X MA Agonist DM7OE3X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7OE3X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7RNKM DI DM7RNKM DM7RNKM DN AMT-060 DM7RNKM TI TTFEZ5Q DM7RNKM TN Coagulation factor IX (F9) DM7RNKM MA Modulator DM7RNKM RN Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V. DM7RNKM RU http://www.biocentury.com/products/amt-060 DM7SMNJ DI DM7SMNJ DM7SMNJ DN NKTR-255 DM7SMNJ TI TTGN89I DM7SMNJ TN Interleukin 15 receptor alpha (IL15RA) DM7SMNJ MA Agonist DM7SMNJ RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DM7SMNJ RU https://www.nektar.com/pipeline/rd-pipeline/nktr-255 DM7T1CR DI DM7T1CR DM7T1CR DN LY3016859 DM7T1CR TI TTTLQFR DM7T1CR TN Transforming growth factor alpha (TGFA) DM7T1CR MA Modulator DM7T1CR RN Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43. DM7T1CR RU https://pubmed.ncbi.nlm.nih.gov/24518034 DM7T1CR DI DM7T1CR DM7T1CR DN LY3016859 DM7T1CR TI TTYSB89 DM7T1CR TN Epiregulin (EREG) DM7T1CR MA Modulator DM7T1CR RN Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43. DM7T1CR RU https://pubmed.ncbi.nlm.nih.gov/24518034 DM7TF49 DI DM7TF49 DM7TF49 DN AAV-RPGR DM7TF49 TI TTHBDA9 DM7TF49 TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DM7TF49 RN Clinical pipeline report, company report or official report of MeiraGTx. DM7TF49 RU https://meiragtx.com/research-development/pipeline/ DM7TZL0 DI DM7TZL0 DM7TZL0 DN INCB054329 DM7TZL0 TI TTE4BSY DM7TZL0 TN Bromodomain and extraterminal domain protein (BET) DM7TZL0 MA Inhibitor DM7TZL0 RN The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311. DM7TZL0 RU https://pubmed.ncbi.nlm.nih.gov/30206163 DM7U458 DI DM7U458 DM7U458 DN IDX-184 DM7U458 TI TTE3PC9 DM7U458 TN Hepatitis C virus Non-structural 5 (HCV NS5) DM7U458 MA Inhibitor DM7U458 RN Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrob Agents Chemother. 2012 June; 56(6): 3359-3368. DM7U458 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370800/ DM7WK6N DI DM7WK6N DM7WK6N DN DSP-0509 DM7WK6N TI TTRJ1K4 DM7WK6N TN Toll-like receptor 7 (TLR7) DM7WK6N MA Agonist DM7WK6N RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DM7WK6N RU https://www.ds-pharma.com/rd/clinical/pipeline.html DM8124R DI DM8124R DM8124R DN INCB01158 DM8124R TI TTSANDR DM8124R TN Arginase (ARG) DM8124R MA Inhibitor DM8124R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8124R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8139V DI DM8139V DM8139V DN Anti-CD30 CAR T cells DM8139V TI TT2GM5R DM8139V TN Lymphocyte activation antigen CD30 (TNFRSF8) DM8139V MA CAR-T-Cell-Therapy DM8139V RN ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) DM8139V RU https://clinicaltrials.gov/ct2/show/NCT02274584 DM81JIT DI DM81JIT DM81JIT DN CART33 cells DM81JIT TI TTJVYO3 DM81JIT TN Myeloid cell surface antigen CD33 (CD33) DM81JIT MA CAR-T-Cell-Therapy DM81JIT RN ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 DM81JIT RU https://clinicaltrials.gov/ct2/show/NCT01864902 DM84YEC DI DM84YEC DM84YEC DN Atiprimod DM84YEC TI TTH8FZW DM84YEC TN Signal transducer and activator of transcription 3 (STAT3) DM84YEC MA Inhibitor DM84YEC RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM84YEC RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM86OJ0 DI DM86OJ0 DM86OJ0 DN HPN536 DM86OJ0 TI TT4RXME DM86OJ0 TN Mesothelin (MSLN) DM86OJ0 RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DM86OJ0 RU https://www.harpoontx.com/pipeline/ DM87H0S DI DM87H0S DM87H0S DN ADG106 DM87H0S TI TTPW9LJ DM87H0S TN Co-stimulatory molecule 4-1BB (CD137) DM87H0S MA Inhibitor DM87H0S RN Clinical pipeline report, company report or official report of Adagene. DM87H0S RU https://www.adagene.com/pipeline/adg106/ DM8A5E0 DI DM8A5E0 DM8A5E0 DN Vecabrutinib DM8A5E0 TI TTGM6VW DM8A5E0 TN Tyrosine-protein kinase BTK (ATK) DM8A5E0 MA Inhibitor DM8A5E0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8A5E0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8CMUW DI DM8CMUW DM8CMUW DN 4SCAR19 and 4SCAR22 DM8CMUW TI TTM6QSK DM8CMUW TN B-cell receptor CD22 (CD22) DM8CMUW MA CAR-T-Cell-Therapy(Dual specific) DM8CMUW RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DM8CMUW RU https://clinicaltrials.gov/ct2/show/NCT03125577 DM8CMUW DI DM8CMUW DM8CMUW DN 4SCAR19 and 4SCAR22 DM8CMUW TI TTW640A DM8CMUW TN B-lymphocyte surface antigen B4 (CD19) DM8CMUW MA CAR-T-Cell-Therapy(Dual specific) DM8CMUW RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DM8CMUW RU https://clinicaltrials.gov/ct2/show/NCT03125577 DM8D2LC DI DM8D2LC DM8D2LC DN Tractinostat DM8D2LC TI TTBH0VX DM8D2LC TN Histone deacetylase (HDAC) DM8D2LC MA Inhibitor DM8D2LC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8D2LC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8E3N6 DI DM8E3N6 DM8E3N6 DN IPP-204106 DM8E3N6 TI TTHBS98 DM8E3N6 TN Nucleophosmin (NPM1) DM8E3N6 MA Modulator DM8E3N6 RN Company report (ImmuPharma) DM8E3N6 RU http://www.immupharma.org/cancer-treatment DM8E3N6 DI DM8E3N6 DM8E3N6 DN IPP-204106 DM8E3N6 TI TTCSZH7 DM8E3N6 TN Nucleolin (NCL) DM8E3N6 MA Modulator DM8E3N6 RN Company report (ImmuPharma) DM8E3N6 RU http://www.immupharma.org/cancer-treatment DM8EAGV DI DM8EAGV DM8EAGV DN Anti-EGFR V III CAR-T cells DM8EAGV TI TTZ6B2I DM8EAGV TN Epidermal growth factor receptor variant III (EGFR vIII) DM8EAGV MA CAR-T-Cell-Therapy DM8EAGV RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM8EAGV RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM8ENKS DI DM8ENKS DM8ENKS DN Anti-Factor D DM8ENKS TI TT8D13I DM8ENKS TN Complement factor D (CFD) DM8ENKS RN Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9. DM8ENKS RU https://pubmed.ncbi.nlm.nih.gov/20582862 DM8IC5H DI DM8IC5H DM8IC5H DN Triciribine DM8IC5H TI TT84ETX DM8IC5H TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8IC5H MA Inhibitor DM8IC5H RN Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51. DM8IC5H RU https://pubmed.ncbi.nlm.nih.gov/15916436 DM8J5H1 DI DM8J5H1 DM8J5H1 DN PRLX93936 DM8J5H1 TI TTT48SQ DM8J5H1 TN Voltage-dependent anion-selective channel 3 (VDAC3) DM8J5H1 MA Modulator DM8J5H1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8J5H1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8K0PR DI DM8K0PR DM8K0PR DN DSP-107 DM8K0PR TI TT28S46 DM8K0PR TN Leukocyte surface antigen CD47 (CD47) DM8K0PR RN Clinical pipeline report, company report or official report of KAHR Medical. DM8K0PR RU https://kahrbio.com/technology/#pipeline DM8K7CN DI DM8K7CN DM8K7CN DN SPK-8011 DM8K7CN TI TT1290U DM8K7CN TN Coagulation factor VIII (F8) DM8K7CN MA Replacement DM8K7CN RN Clinical pipeline report, company report or official report of Spark Therapeutics. DM8K7CN RU https://sparktx.com/scientific-platform-programs/ DM8KESD DI DM8KESD DM8KESD DN CD19 CAR-T lymphocytes DM8KESD TI TTW640A DM8KESD TN B-lymphocyte surface antigen B4 (CD19) DM8KESD MA CAR-T-Cell-Therapy DM8KESD RN ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL DM8KESD RU https://clinicaltrials.gov/ct2/show/NCT03467256 DM8M71U DI DM8M71U DM8M71U DN DTX301 DM8M71U TI TT5KIO9 DM8M71U TN Ornithine transcarbamylase (OTC) DM8M71U MA Replacement DM8M71U RN Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical. DM8M71U RU https://www.ultragenyx.com/pipeline/dtx-301-for-otc/ DM8O3R9 DI DM8O3R9 DM8O3R9 DN APG-1252 DM8O3R9 TI TTJGNVC DM8O3R9 TN Apoptosis regulator Bcl-2 (BCL-2) DM8O3R9 MA Inhibitor DM8O3R9 RN Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. DM8O3R9 RU https://pubmed.ncbi.nlm.nih.gov/32346976 DM8O3R9 DI DM8O3R9 DM8O3R9 DN APG-1252 DM8O3R9 TI TTU1E82 DM8O3R9 TN Apoptosis regulator Bcl-xL (BCL-xL) DM8O3R9 MA Inhibitor DM8O3R9 RN Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. DM8O3R9 RU https://pubmed.ncbi.nlm.nih.gov/32346976 DM8P7FC DI DM8P7FC DM8P7FC DN JCARH125 DM8P7FC TI TTZ3P4W DM8P7FC TN B-cell maturation protein (TNFRSF17) DM8P7FC MA CAR-T-Cell-Therapy DM8P7FC RN ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product DM8P7FC RU https://clinicaltrials.gov/ct2/show/NCT03436771 DM8RJTB DI DM8RJTB DM8RJTB DN LY3295668 DM8RJTB TI TTPS3C0 DM8RJTB TN Aurora kinase A (AURKA) DM8RJTB MA Inhibitor DM8RJTB RN Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219. DM8RJTB RU https://pubmed.ncbi.nlm.nih.gov/31530649 DM8RXFB DI DM8RXFB DM8RXFB DN CD19 targeted chimeric antigen receptor T cells DM8RXFB TI TTW640A DM8RXFB TN B-lymphocyte surface antigen B4 (CD19) DM8RXFB MA CAR-T-Cell-Therapy DM8RXFB RN ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma DM8RXFB RU https://clinicaltrials.gov/ct2/show/NCT03118180 DM8V0UL DI DM8V0UL DM8V0UL DN ASP-9521 DM8V0UL TI TT5ZWB6 DM8V0UL TN Dihydrodiol dehydrogenase type I (AKR1C3) DM8V0UL MA Modulator DM8V0UL RN Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004. DM8V0UL RU https://pubmed.ncbi.nlm.nih.gov/24771350 DM8XN4A DI DM8XN4A DM8XN4A DN INCAGN1876 DM8XN4A TI TTG6LA7 DM8XN4A TN Activation-inducible TNFR family receptor (TNFRSF18) DM8XN4A MA Agonist DM8XN4A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8XN4A RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM90BUD DI DM90BUD DM90BUD DN ChronSeal DM90BUD TI TTNDSF4 DM90BUD TN Proto-oncogene c-Met (MET) DM90BUD MA Inhibitor DM90BUD RN Clinical pipeline report, company report or official report of Kringle Pharma. DM90BUD RU http://www.kringle-pharma.com/en/news.html DM90XQC DI DM90XQC DM90XQC DN CTX001 DM90XQC TI TTR61MW DM90XQC TN B-cell lymphoma/leukemia 11A (BCL11A) DM90XQC RN Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. DM90XQC RU https://pubmed.ncbi.nlm.nih.gov/31900462 DM92CUG DI DM92CUG DM92CUG DN Anti-CD19 CAR-T cells DM92CUG TI TTW640A DM92CUG TN B-lymphocyte surface antigen B4 (CD19) DM92CUG MA CAR-T-Cell-Therapy DM92CUG RN ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies DM92CUG RU https://clinicaltrials.gov/ct2/show/NCT03366324 DM95XR8 DI DM95XR8 DM95XR8 DN CTCE-9908 DM95XR8 TI TTBID49 DM95XR8 TN C-X-C chemokine receptor type 4 (CXCR4) DM95XR8 MA Modulator DM95XR8 RN A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6. DM95XR8 RU https://pubmed.ncbi.nlm.nih.gov/19482312 DM98YFK DI DM98YFK DM98YFK DN SB-913 DM98YFK TI TTNY2AP DM98YFK TN Iduronate 2-sulfatase (IDS) DM98YFK MA Replacement DM98YFK RN ClinicalTrials.gov (NCT03041324) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II. U.S. National Institutes of Health. DM98YFK RU https://clinicaltrials.gov/ct2/show/NCT03041324 DM9B7Z5 DI DM9B7Z5 DM9B7Z5 DN Sym015 DM9B7Z5 TI TTNDSF4 DM9B7Z5 TN Proto-oncogene c-Met (MET) DM9B7Z5 MA Inhibitor DM9B7Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9B7Z5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9B7Z5 DI DM9B7Z5 DM9B7Z5 DN Sym015 DM9B7Z5 TI TTGKNB4 DM9B7Z5 TN Epidermal growth factor receptor (EGFR) DM9B7Z5 MA Antagonist DM9B7Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9B7Z5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9DR13 DI DM9DR13 DM9DR13 DN PCAR-019 DM9DR13 TI TTW640A DM9DR13 TN B-lymphocyte surface antigen B4 (CD19) DM9DR13 MA CAR-T-Cell-Therapy DM9DR13 RN ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma DM9DR13 RU https://clinicaltrials.gov/ct2/show/NCT02819583 DM9EM5G DI DM9EM5G DM9EM5G DN ASTX295 DM9EM5G TI TT08GJW DM9EM5G TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM9EM5G MA Antagonist DM9EM5G RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DM9EM5G RU https://astx.com/research-development/clinical-pipeline/astx295-oral-murine-double-minute-2-mdm2-antagonist-solid-tumors/ DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTTDVOJ DM9FB2T TN Tropomyosin-related kinase A (TrkA) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTPMQSO DM9FB2T TN ALK tyrosine kinase receptor (ALK) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTSZ6Y3 DM9FB2T TN Proto-oncogene c-Ros (ROS1) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FNC8 DI DM9FNC8 DM9FNC8 DN RP-3500 DM9FNC8 TI TT8ZYBQ DM9FNC8 TN Serine/threonine-protein kinase ATR (FRP1) DM9FNC8 MA Inhibitor DM9FNC8 RN Clinical pipeline report, company report or official report of Repare Therapeutics. DM9FNC8 RU https://www.reparerx.com/pipeline/ DM9IQ4A DI DM9IQ4A DM9IQ4A DN TRU-016 DM9IQ4A TI TTFCW29 DM9IQ4A TN Leukocyte antigen CD37 (CD37) DM9IQ4A MA Modulator DM9IQ4A RN TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90. DM9IQ4A RU https://pubmed.ncbi.nlm.nih.gov/19943209 DM9MF08 DI DM9MF08 DM9MF08 DN OBP-301 DM9MF08 TI TTUJFD0 DM9MF08 TN Telomerase reverse transcriptase (TERT) DM9MF08 MA Inhibitor DM9MF08 RN Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92. DM9MF08 RU https://pubmed.ncbi.nlm.nih.gov/14734481 DM9NPF6 DI DM9NPF6 DM9NPF6 DN Anti-CD33 CAR-T cells DM9NPF6 TI TTJVYO3 DM9NPF6 TN Myeloid cell surface antigen CD33 (CD33) DM9NPF6 MA CAR-T-Cell-Therapy DM9NPF6 RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM9NPF6 RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM9PJZT DI DM9PJZT DM9PJZT DN Ipamorelin DM9PJZT TI TTWDC17 DM9PJZT TN Growth hormone secretagogue receptor 1 (GHSR) DM9PJZT MA Modulator DM9PJZT RN Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6. DM9PJZT RU https://www.ncbi.nlm.nih.gov/pubmed/19289567 DM9S5I1 DI DM9S5I1 DM9S5I1 DN TC-210 DM9S5I1 TI TT4RXME DM9S5I1 TN Mesothelin (MSLN) DM9S5I1 RN Clinical pipeline report, company report or official report of TCR2 Therapeutics. DM9S5I1 RU https://www.tcr2.com/solid-tumors#tc210 DM9UZM1 DI DM9UZM1 DM9UZM1 DN CCS1477 DM9UZM1 TI TTFRCTK DM9UZM1 TN CREB-binding protein (CREBBP) DM9UZM1 MA Inhibitor DM9UZM1 RN Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. DM9UZM1 RU https://pubmed.ncbi.nlm.nih.gov/33431496 DM9UZM1 DI DM9UZM1 DM9UZM1 DN CCS1477 DM9UZM1 TI TTGH73N DM9UZM1 TN Histone acetyltransferase p300 (EP300) DM9UZM1 MA Inhibitor DM9UZM1 RN Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. DM9UZM1 RU https://pubmed.ncbi.nlm.nih.gov/33431496 DMA1CSR DI DMA1CSR DMA1CSR DN LY3499446 DMA1CSR TI TT3LH46 DMA1CSR TN KRAS G12C mutant (KRAS G12C) DMA1CSR MA Inhibitor DMA1CSR RN KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070. DMA1CSR RU https://pubmed.ncbi.nlm.nih.gov/32711246 DMA41DO DI DMA41DO DMA41DO DN Isunakinra DMA41DO TI TT5BFT0 DMA41DO TN Interleukin-1 receptor (IL1R) DMA41DO MA Inhibitor DMA41DO RN Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2017 Sep;43(5):287-296. DMA41DO RU https://pubmed.ncbi.nlm.nih.gov/27466718 DMA5B1S DI DMA5B1S DMA5B1S DN KRN-330 DMA5B1S TI TT96HUR DMA5B1S TN Cell surface A33 antigen (GPA33) DMA5B1S RN Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90. DMA5B1S RU https://pubmed.ncbi.nlm.nih.gov/24691674 DMA8Z4N DI DMA8Z4N DMA8Z4N DN SB-318 DMA8Z4N TI TT0IUKX DMA8Z4N TN Alpha-L-iduronidase (IDUA) DMA8Z4N MA Replacement DMA8Z4N RN ClinicalTrials.gov (NCT02702115) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I. U.S. National Institutes of Health. DMA8Z4N RU https://clinicaltrials.gov/ct2/show/NCT02702115 DMA9MP5 DI DMA9MP5 DMA9MP5 DN BN-2629 DMA9MP5 TI TTUTN1I DMA9MP5 TN Human Deoxyribonucleic acid (hDNA) DMA9MP5 MA Binder DMA9MP5 RN Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226. DMA9MP5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2620844/ DMACPQO DI DMACPQO DMACPQO DN Dihydrexidine DMACPQO TI TTZFYLI DMACPQO TN Dopamine D1 receptor (D1R) DMACPQO MA Inhibitor DMACPQO RN trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57. DMACPQO RU https://pubmed.ncbi.nlm.nih.gov/17154515 DMADEHZ DI DMADEHZ DMADEHZ DN LY2880070 DMADEHZ TI TTTU902 DMADEHZ TN Checkpoint kinase-1 (CHK1) DMADEHZ MA Inhibitor DMADEHZ RN A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581. DMADEHZ RU https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3581 DMADNY3 DI DMADNY3 DMADNY3 DN SHR-1314 DMADNY3 TI TTG0MT6 DMADNY3 TN Interleukin-17 (IL17) DMADNY3 MA Inhibitor DMADNY3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMADNY3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAGE91 DI DMAGE91 DMAGE91 DN RG7800 DMAGE91 TI TT8QL6X DMAGE91 TN Survival motor neuron protein (SMN1) DMAGE91 MA Modulator DMAGE91 RN Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy. Assay Drug Dev Technol. 2014 August 1; 12(6): 315-341. DMAGE91 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142828/ DMAGX0Q DI DMAGX0Q DMAGX0Q DN REGN5458 DMAGX0Q TI TTUN7MC DMAGX0Q TN T-cell surface glycoprotein CD3 (CD3) DMAGX0Q MA Inhibitor DMAGX0Q RN A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304. DMAGX0Q RU https://pubmed.ncbi.nlm.nih.gov/33651100 DMAGX0Q DI DMAGX0Q DMAGX0Q DN REGN5458 DMAGX0Q TI TTZ3P4W DMAGX0Q TN B-cell maturation protein (TNFRSF17) DMAGX0Q MA Inhibitor DMAGX0Q RN A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304. DMAGX0Q RU https://pubmed.ncbi.nlm.nih.gov/33651100 DMAH6UJ DI DMAH6UJ DMAH6UJ DN AAV-RPE65 DMAH6UJ TI TTBOH16 DMAH6UJ TN Retinal pigment epithelium protein (RPE65) DMAH6UJ RN Clinical pipeline report, company report or official report of MeiraGTx. DMAH6UJ RU https://meiragtx.com/research-development/pipeline/ DMAHWLR DI DMAHWLR DMAHWLR DN MGD007 DMAHWLR TI TTV3XPL DMAHWLR TN T-cell surface glycoprotein CD3 gamma (CD3G) DMAHWLR MA Modulator DMAHWLR RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMAHWLR RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMAHWLR DI DMAHWLR DMAHWLR DN MGD007 DMAHWLR TI TT96HUR DMAHWLR TN Cell surface A33 antigen (GPA33) DMAHWLR MA Modulator DMAHWLR RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMAHWLR RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMAMIU4 DI DMAMIU4 DMAMIU4 DN VIR-201 DMAMIU4 TI TT93WF5 DMAMIU4 TN Interferon-gamma (IFNG) DMAMIU4 MA Modulator DMAMIU4 RN EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents. DMAMIU4 RU http://www.google.com.ar/patents/EP1778251B1?cl=en DMAN21O DI DMAN21O DMAN21O DN VG-101 DMAN21O TI TTOM3J0 DMAN21O TN Estrogen receptor beta (ESR2) DMAN21O MA Agonist DMAN21O RN Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536. DMAN21O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218114/ DMAO04B DI DMAO04B DMAO04B DN CEP-32496 DMAO04B TI TTWCGQT DMAO04B TN Serine/threonine-protein kinase B-raf (BRAF) DMAO04B MA Inhibitor DMAO04B RN Clinical pipeline report, company report or official report of Ambit Biosciences. DMAO04B RU http://www.ambitbio.com/CEP32496 DMAO04B DI DMAO04B DMAO04B DN CEP-32496 DMAO04B TI TT4DXQT DMAO04B TN Proto-oncogene c-Ret (RET) DMAO04B MA Inhibitor DMAO04B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAO04B RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAP5B4 DI DMAP5B4 DMAP5B4 DN AGEN1884 DMAP5B4 TI TTI2S1D DMAP5B4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMAP5B4 MA Antagonist DMAP5B4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAP5B4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMAPUZY DI DMAPUZY DMAPUZY DN AAV1-FS344 DMAPUZY TI TTM8I2X DMAPUZY TN Myostatin (MSTN) DMAPUZY MA Modulator DMAPUZY RN Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med. 2009 November 11; 1(6): 6ra15. DMAPUZY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852878/ DMB19IO DI DMB19IO DMB19IO DN Ad-IL-12 DNA therapeutic DMB19IO TI TTGW72V DMB19IO TN Interleukin-12 beta (IL12B) DMB19IO MA Modulator DMB19IO RN National Cancer Institute Drug Dictionary (drug id 710508). DMB19IO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710508 DMB2NP8 DI DMB2NP8 DMB2NP8 DN T-1249 DMB2NP8 TI TTG90S6 DMB2NP8 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMB2NP8 MA Inhibitor DMB2NP8 RN HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8. DMB2NP8 RU https://pubmed.ncbi.nlm.nih.gov/12324253 DMB4HEW DI DMB4HEW DMB4HEW DN CART-138 cells DMB4HEW TI TTYDSVG DMB4HEW TN Syndecan-1 (SDC1) DMB4HEW MA CAR-T-Cell-Therapy DMB4HEW RN ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma DMB4HEW RU https://clinicaltrials.gov/ct2/show/NCT03196414 DMB5KRA DI DMB5KRA DMB5KRA DN CFI-402411 DMB5KRA TI TTSHWUP DMB5KRA TN MEK kinase kinase 1 (MAP4K1) DMB5KRA MA Inhibitor DMB5KRA RN Clinical pipeline report, company report or official report of Treadwell Therapeutics. DMB5KRA RU https://treadwelltx.com/pipeline/ DMB5X7Z DI DMB5X7Z DMB5X7Z DN ATG002 DMB5X7Z TI TTJSZTB DMB5X7Z TN Nicotinic acetylcholine receptor (nAChR) DMB5X7Z MA Agonist DMB5X7Z RN Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006. DMB5X7Z RU http://www.prnewswire.com/news-releases/athenagen-advances-angiogenesis-drug-to-clinical-testing-56212977.html DMBCIXL DI DMBCIXL DMBCIXL DN Stamulumab DMBCIXL TI TTSWPH8 DMBCIXL TN Growth/differentiation factor 8 (GDF-8) DMBCIXL RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMBCIXL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMBEQ08 DI DMBEQ08 DMBEQ08 DN L-377202 DMBEQ08 TI TT0IHXV DMBEQ08 TN DNA topoisomerase II (TOP2) DMBEQ08 MA Modulator DMBEQ08 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBEQ08 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBFUOI DI DMBFUOI DMBFUOI DN SECTA belomycin DMBFUOI TI TTUTN1I DMBFUOI TN Human Deoxyribonucleic acid (hDNA) DMBFUOI MA Binder DMBFUOI RN Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13. DMBFUOI RU https://pubmed.ncbi.nlm.nih.gov/14624648 DMBGA35 DI DMBGA35 DMBGA35 DN AP-1030 DMBGA35 TI TT0MV2T DMBGA35 TN Melanocortin receptor 1 (MC1R) DMBGA35 MA Modulator DMBGA35 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBGA35 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBGA35 DI DMBGA35 DMBGA35 DN AP-1030 DMBGA35 TI TTD0CIQ DMBGA35 TN Melanocortin receptor 4 (MC4R) DMBGA35 MA Modulator DMBGA35 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBGA35 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBGU7V DI DMBGU7V DMBGU7V DN INCB57643 DMBGU7V TI TTRA6BO DMBGU7V TN Bromodomain-containing protein 4 (BRD4) DMBGU7V MA Inhibitor DMBGU7V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBGU7V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBGXH5 DI DMBGXH5 DMBGXH5 DN AdCh63-MSP1 DMBGXH5 TI TT68ZYJ DMBGXH5 TN Plasmodium Merozoite surface protein 1 (Malaria MSP-1) DMBGXH5 RN Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014 Apr;141(4):628-44. DMBGXH5 RU https://pubmed.ncbi.nlm.nih.gov/24303947 DMBN1XS DI DMBN1XS DMBN1XS DN Triciribine prodrug DMBN1XS TI TTWTSCV DMBN1XS TN RAC-alpha serine/threonine-protein kinase (AKT1) DMBN1XS MA Inhibitor DMBN1XS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMBN1XS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMBPN4K DI DMBPN4K DMBPN4K DN CAR-T cells targeting MucI DMBPN4K TI TTBHFYQ DMBPN4K TN Mucin-1 (MUC1) DMBPN4K MA CAR-T-Cell-Therapy DMBPN4K RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMBPN4K RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMBQRGV DI DMBQRGV DMBQRGV DN NT-501 CNTF DMBQRGV TI TTGEM5Q DMBQRGV TN Ciliary neurotrophic factor (CNTF) DMBQRGV MA Modulator DMBQRGV RN Clinical pipeline report, company report or official report of Neurotech. DMBQRGV RU http://www.neurotechusa.com/cntfrenexus.html DMBUJVX DI DMBUJVX DMBUJVX DN Phenoxodiol DMBUJVX TI TTR7B60 DMBUJVX TN X-linked inhibitor of apoptosis protein (XIAP) DMBUJVX MA Modulator DMBUJVX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBUJVX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBUJVX DI DMBUJVX DMBUJVX DN Phenoxodiol DMBUJVX TI TTOHFIY DMBUJVX TN Sphingosine kinase 1 (SPHK1) DMBUJVX MA Modulator DMBUJVX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBUJVX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBUYIK DI DMBUYIK DMBUYIK DN CWP232291 DMBUYIK TI TTFPSHI DMBUYIK TN Wnt signaling pathway (Wnt pathway) DMBUYIK MA Inhibitor DMBUYIK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBUYIK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBZ68C DI DMBZ68C DMBZ68C DN MALP-2S DMBZ68C TI TTWRI8V DMBZ68C TN Toll-like receptor 6 (TLR6) DMBZ68C MA Modulator DMBZ68C RN Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8. DMBZ68C RU https://pubmed.ncbi.nlm.nih.gov/21172450 DMBZ68C DI DMBZ68C DMBZ68C DN MALP-2S DMBZ68C TI TTY7ZHS DMBZ68C TN Toll-like receptor 2 (TLR2) DMBZ68C MA Modulator DMBZ68C RN Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8. DMBZ68C RU https://pubmed.ncbi.nlm.nih.gov/21172450 DMC1XHK DI DMC1XHK DMC1XHK DN AVR-RD-01 DMC1XHK TI TTIS03D DMC1XHK TN Alpha-galactosidase A (GLA) DMC1XHK RN Clinical pipeline report, company report or official report of Avrobio. DMC1XHK RU https://www.avrobio.com/our-pipeline/ DMC284G DI DMC284G DMC284G DN EGFRvIII CAR DMC284G TI TTZ6B2I DMC284G TN Epidermal growth factor receptor variant III (EGFR vIII) DMC284G MA Modulator DMC284G RN EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84. DMC284G RU https://pubmed.ncbi.nlm.nih.gov/24352643 DMC4ZQD DI DMC4ZQD DMC4ZQD DN ACHM-CNGB3 DMC4ZQD TI TT0LJCG DMC4ZQD TN Cyclic nucleotide-gated channel beta-3 (CNGB3) DMC4ZQD RN Clinical pipeline report, company report or official report of Applied Genetic Technologies. DMC4ZQD RU https://agtc.com/programs/achromatopsia/ DMC5NSO DI DMC5NSO DMC5NSO DN AUTO3 DMC5NSO TI TTM6QSK DMC5NSO TN B-cell receptor CD22 (CD22) DMC5NSO MA CAR-T-Cell-Therapy(Dual specific) DMC5NSO RN ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL DMC5NSO RU https://clinicaltrials.gov/ct2/show/NCT03289455 DMC5NSO DI DMC5NSO DMC5NSO DN AUTO3 DMC5NSO TI TTW640A DMC5NSO TN B-lymphocyte surface antigen B4 (CD19) DMC5NSO MA CAR-T-Cell-Therapy(Dual specific) DMC5NSO RN ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL DMC5NSO RU https://clinicaltrials.gov/ct2/show/NCT03289455 DMC5SAW DI DMC5SAW DMC5SAW DN LY3039478 DMC5SAW TI TTXDIK2 DMC5SAW TN Notch-4 receptor (NOTCH4) DMC5SAW MA Inhibitor DMC5SAW RN J Clin Oncol 33, 2015 (suppl; abstr 2533). DMC5SAW RU http://meetinglibrary.asco.org/content/144588-156 DMC5SAW DI DMC5SAW DMC5SAW DN LY3039478 DMC5SAW TI TTB1STW DMC5SAW TN Notch-1 receptor (NOTCH1) DMC5SAW MA Inhibitor DMC5SAW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC5SAW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCAUKW DI DMCAUKW DMCAUKW DN EMB-01 DMCAUKW TI TTGKNB4 DMCAUKW TN Epidermal growth factor receptor (EGFR) DMCAUKW MA Inhibitor DMCAUKW RN Clinical pipeline report, company report or official report of EpimAb Biotherapeutics. DMCAUKW RU https://www.epimab.com/en/pipeline/1 DMCBQTF DI DMCBQTF DMCBQTF DN S-3304 DMCBQTF TI TT1GHVO DMCBQTF TN Matrix metalloproteinase (MMP) DMCBQTF MA Inhibitor DMCBQTF RN Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93. DMCBQTF RU https://pubmed.ncbi.nlm.nih.gov/15968885 DMCDQX0 DI DMCDQX0 DMCDQX0 DN ND-0801 DMCDQX0 TI TTJSZTB DMCDQX0 TN Nicotinic acetylcholine receptor (nAChR) DMCDQX0 MA Modulator DMCDQX0 RN Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248. DMCDQX0 RU http://link.springer.com/article/10.1007/s40290-013-0026-2 DMCDUJY DI DMCDUJY DMCDUJY DN Anti-CD20-CAR vector-transduced autologous T cells DMCDUJY TI TTUE541 DMCDUJY TN Leukocyte surface antigen Leu-16 (CD20) DMCDUJY MA CAR-T-Cell-Therapy DMCDUJY RN ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy DMCDUJY RU https://clinicaltrials.gov/ct2/show/NCT01735604 DMCEGP2 DI DMCEGP2 DMCEGP2 DN BrevaRex DMCEGP2 TI TTBHFYQ DMCEGP2 TN Mucin-1 (MUC1) DMCEGP2 RN Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33. DMCEGP2 RU https://pubmed.ncbi.nlm.nih.gov/15550589 DMCFSZ5 DI DMCFSZ5 DMCFSZ5 DN TAI-GPC3-CART cells DMCFSZ5 TI TTJTSX4 DMCFSZ5 TN Glypican-3 (GPC3) DMCFSZ5 MA CAR-T-Cell-Therapy DMCFSZ5 RN ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC DMCFSZ5 RU https://clinicaltrials.gov/ct2/show/NCT02715362 DMCGX9Y DI DMCGX9Y DMCGX9Y DN SNDX-5613 DMCGX9Y TI TT0CZBQ DMCGX9Y TN Menin-MLL1 interaction (MEN1-KMT2A PPI) DMCGX9Y MA Inhibitor DMCGX9Y RN Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. DMCGX9Y RU https://syndax.com/pipeline/sndx-5613/ DMCH98G DI DMCH98G DMCH98G DN CD38-specific gene-engineered T cells DMCH98G TI TTPURFN DMCH98G TN Cyclic ADP-ribose hydrolase 1 (CD38) DMCH98G MA CAR-T-Cell-Therapy DMCH98G RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMCH98G RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMCJ10K DI DMCJ10K DMCJ10K DN LM11A-31 DMCJ10K TI TTEDJN4 DMCJ10K TN Low-affinity nerve growth factor receptor (NGFR) DMCJ10K MA Modulator DMCJ10K RN Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63. DMCJ10K RU https://www.ncbi.nlm.nih.gov/pubmed/23545424 DMCLKA4 DI DMCLKA4 DMCLKA4 DN 2-hydroxyoleic acid DMCLKA4 TI TTBOE28 DMCLKA4 TN Sphingomyelin synthase (SMS) DMCLKA4 MA Modulator DMCLKA4 RN Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19569-74. DMCLKA4 RU https://pubmed.ncbi.nlm.nih.gov/22106271 DMCMT4V DI DMCMT4V DMCMT4V DN Dexamethasone palmitate DMCMT4V TI TTPNQAC DMCMT4V TN Estrogen-related receptor-alpha (ESRRA) DMCMT4V MA Agonist DMCMT4V RN Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8. DMCMT4V RU https://pubmed.ncbi.nlm.nih.gov/12133656 DMCP8F3 DI DMCP8F3 DMCP8F3 DN SPK-8016 DMCP8F3 TI TT1290U DMCP8F3 TN Coagulation factor VIII (F8) DMCP8F3 MA Replacement DMCP8F3 RN Clinical pipeline report, company report or official report of Spark Therapeutics. DMCP8F3 RU https://sparktx.com/scientific-platform-programs/ DMCPM92 DI DMCPM92 DMCPM92 DN CAR-T cells targeting CLL1 DMCPM92 TI TT70N8V DMCPM92 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMCPM92 MA CAR-T-Cell-Therapy DMCPM92 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMCPM92 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TT70MLA DMCPZYT TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTKGUEB DMCPZYT TN Melanoma-associated antigen C2 (MAGEC2) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTTPU1G DMCPZYT TN Apoptosis inhibitor survivin (BIRC5) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TT9M6NA DMCPZYT TN Cancer/testis antigen MAGE-C1/CT7 (MAGEC1) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTE5ITK DMCPZYT TN Cancer/testis antigen 1 (NY-ESO-1) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCR7EF DI DMCR7EF DMCR7EF DN CEQ-508 DMCR7EF TI TTRPKQG DMCR7EF TN Beta-catenin (CTNNB1) DMCR7EF RN Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146. DMCR7EF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/ DMCSGNU DI DMCSGNU DMCSGNU DN CD138 CAR T cells DMCSGNU TI TTYDSVG DMCSGNU TN Syndecan-1 (SDC1) DMCSGNU MA CAR-T-Cell-Therapy DMCSGNU RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMCSGNU RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMCT917 DI DMCT917 DMCT917 DN CLL1-specific gene-engineered T cells DMCT917 TI TT70N8V DMCT917 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMCT917 MA CAR-T-Cell-Therapy DMCT917 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMCT917 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMCT9NG DI DMCT9NG DMCT9NG DN GB1275 DMCT9NG TI TTB69FJ DMCT9NG TN Integrin alpha-M (ITGAM) DMCT9NG MA Agonist DMCT9NG RN National Cancer Institute Drug Dictionary (drug name GB1275). DMCT9NG RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cd11b-agonist-gb1275 DMCVBQD DI DMCVBQD DMCVBQD DN MLN1117 DMCVBQD TI TTEUNMR DMCVBQD TN PI3-kinase alpha (PIK3CA) DMCVBQD MA Inhibitor DMCVBQD RN National Cancer Institute Drug Dictionary (drug id 714372). DMCVBQD RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714372 DMCVMUL DI DMCVMUL DMCVMUL DN MGD013 DMCVMUL TI TTNBFWK DMCVMUL TN Programmed cell death protein 1 (PD-1) DMCVMUL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMCVMUL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMCWVPU DI DMCWVPU DMCWVPU DN CBP-501 DMCWVPU TI TT3DCYJ DMCWVPU TN Microtubule affinity regulating kinase 3 (MARK3) DMCWVPU MA Inhibitor DMCWVPU RN National Cancer Institute Drug Dictionary (drug id 577812). DMCWVPU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812 DMCWVPU DI DMCWVPU DMCWVPU DN CBP-501 DMCWVPU TI TTMUG9D DMCWVPU TN MAPK-activated protein kinase 2 (MAPKAPK2) DMCWVPU MA Inhibitor DMCWVPU RN National Cancer Institute Drug Dictionary (drug id 577812). DMCWVPU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812 DMD1V7I DI DMD1V7I DMD1V7I DN Celgosivir DMD1V7I TI TTXWASR DMD1V7I TN Intestinal maltase-glucoamylase (MGAM) DMD1V7I MA Modulator DMD1V7I RN Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70. DMD1V7I RU https://www.ncbi.nlm.nih.gov/pubmed/19649930 DMD20YH DI DMD20YH DMD20YH DN SAR-650984 DMD20YH TI TTPURFN DMD20YH TN Cyclic ADP-ribose hydrolase 1 (CD38) DMD20YH RN Clinical pipeline report, company report or official report of Sanofi-Aventis. DMD20YH RU https://www.sanofioncology.com/m/pipeline/SAR650984.aspx DMD2L1U DI DMD2L1U DMD2L1U DN OBI-888 DMD2L1U TI TT4UXTG DMD2L1U TN Globohexaosylceramide (Globo H) DMD2L1U RN Clinical pipeline report, company report or official report of OBI Pharma. DMD2L1U RU https://www.obipharma.com/obi-888-mab/ DMD37Q5 DI DMD37Q5 DMD37Q5 DN SEL24 DMD37Q5 TI TTA7WGU DMD37Q5 TN Serine/threonine-protein kinase pim (PIM) DMD37Q5 MA Inhibitor DMD37Q5 RN A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. DMD37Q5 RU https://pubmed.ncbi.nlm.nih.gov/29682194 DMD37Q5 DI DMD37Q5 DMD37Q5 DN SEL24 DMD37Q5 TI TTGJCWZ DMD37Q5 TN Fms-like tyrosine kinase 3 (FLT-3) DMD37Q5 MA Inhibitor DMD37Q5 RN A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. DMD37Q5 RU https://pubmed.ncbi.nlm.nih.gov/29682194 DMD3XMW DI DMD3XMW DMD3XMW DN Cethrin DMD3XMW TI TTMQO60 DMD3XMW TN Rho-associated protein kinase (ROCK) DMD3XMW MA Modulator DMD3XMW RN A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96. DMD3XMW RU https://pubmed.ncbi.nlm.nih.gov/21381984 DMD8RLY DI DMD8RLY DMD8RLY DN GEN3009 DMD8RLY TI TTFCW29 DMD8RLY TN Leukocyte antigen CD37 (CD37) DMD8RLY RN Clinical pipeline report, company report or official report of AbbVie. DMD8RLY RU https://www.abbvie.com/our-science/pipeline/gen-3009.html DMD9X6U DI DMD9X6U DMD9X6U DN JNJ-68284528 DMD9X6U TI TTZ3P4W DMD9X6U TN B-cell maturation protein (TNFRSF17) DMD9X6U MA CAR-T-Cell-Therapy DMD9X6U RN ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma DMD9X6U RU https://clinicaltrials.gov/ct2/show/NCT03548207 DMD9Y5T DI DMD9Y5T DMD9Y5T DN AZD7648 DMD9Y5T TI TTK3PY9 DMD9Y5T TN DNA-dependent protein kinase catalytic (PRKDC) DMD9Y5T MA Inhibitor DMD9Y5T RN AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065. DMD9Y5T RU https://pubmed.ncbi.nlm.nih.gov/31699977 DMDASRW DI DMDASRW DMDASRW DN Norleucine DMDASRW TI TT01M3K DMDASRW TN Hepatocyte nuclear factor 1-alpha (HNF1A) DMDASRW MA Inhibitor DMDASRW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMDASRW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMDCHM7 DI DMDCHM7 DMDCHM7 DN BMS-986016 DMDCHM7 TI TTNVXAW DMDCHM7 TN Lymphocyte activation gene 3 protein (LAG3) DMDCHM7 MA Modulator DMDCHM7 RN Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96. DMDCHM7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216/ DMDFG1O DI DMDFG1O DMDFG1O DN HLF 1-11 DMDFG1O TI TTSZDQU DMDFG1O TN Lactotransferrin (LTF) DMDFG1O MA Modulator DMDFG1O RN The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21. DMDFG1O RU https://pubmed.ncbi.nlm.nih.gov/15561882 DMDHJNV DI DMDHJNV DMDHJNV DN Annamycin DMDHJNV TI TTCGY2K DMDHJNV TN DNA topoisomerase II alpha (TOP2A) DMDHJNV RN Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8. DMDHJNV RU https://pubmed.ncbi.nlm.nih.gov/17557149 DMDHKN1 DI DMDHKN1 DMDHKN1 DN Anti-MUC1 CAR T Cells DMDHKN1 TI TTBHFYQ DMDHKN1 TN Mucin-1 (MUC1) DMDHKN1 MA CAR-T-Cell-Therapy DMDHKN1 RN ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC DMDHKN1 RU https://clinicaltrials.gov/ct2/show/NCT03525782 DMDJLX7 DI DMDJLX7 DMDJLX7 DN Timcodar dimesilate DMDJLX7 TI TTFH2RS DMDJLX7 TN FK506-binding protein (FKBP) DMDJLX7 MA Modulator DMDJLX7 RN Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076. DMDJLX7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186452/ DMDJSOH DI DMDJSOH DMDJSOH DN ZK-001 DMDJSOH TI TTVB0Q9 DMDJSOH TN Platelet glycoprotein Ib alpha (CD42b) DMDJSOH MA Modulator DMDJSOH RN Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014 Feb;111(2):279-89. DMDJSOH RU https://pubmed.ncbi.nlm.nih.gov/24172860 DMDKTYU DI DMDKTYU DMDKTYU DN Anti-EGFRvIII CAR transduced PBL DMDKTYU TI TTZ6B2I DMDKTYU TN Epidermal growth factor receptor variant III (EGFR vIII) DMDKTYU MA CAR-T-Cell-Therapy DMDKTYU RN ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health. DMDKTYU RU https://clinicaltrials.gov/ct2/show/NCT01454596 DMDNJP5 DI DMDNJP5 DMDNJP5 DN NM21-1480 DMDNJP5 TI TTPW9LJ DMDNJP5 TN Co-stimulatory molecule 4-1BB (CD137) DMDNJP5 MA Modulator DMDNJP5 RN Clinical pipeline report, company report or official report of Numab Therapeutics. DMDNJP5 RU https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf DMDNJP5 DI DMDNJP5 DMDNJP5 DN NM21-1480 DMDNJP5 TI TT8ZLTI DMDNJP5 TN Programmed cell death 1 ligand 1 (PD-L1) DMDNJP5 MA Modulator DMDNJP5 RN Clinical pipeline report, company report or official report of Numab Therapeutics. DMDNJP5 RU https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf DMDO6J1 DI DMDO6J1 DMDO6J1 DN Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs DMDO6J1 TI TTJTSX4 DMDO6J1 TN Glypican-3 (GPC3) DMDO6J1 MA CAR-T-Cell-Therapy DMDO6J1 RN ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) DMDO6J1 RU https://clinicaltrials.gov/ct2/show/NCT03084380 DMDOXMN DI DMDOXMN DMDOXMN DN AB928 DMDOXMN TI TTM2AOE DMDOXMN TN Adenosine A2a receptor (ADORA2A) DMDOXMN MA Antagonist DMDOXMN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDOXMN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDOXMN DI DMDOXMN DMDOXMN DN AB928 DMDOXMN TI TTNE7KG DMDOXMN TN Adenosine A2b receptor (ADORA2B) DMDOXMN MA Antagonist DMDOXMN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDOXMN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDQO0S DI DMDQO0S DMDQO0S DN BMS-753493 DMDQO0S TI TTVC37M DMDQO0S TN Folate receptor alpha (FOLR1) DMDQO0S MA Modulator DMDQO0S RN A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31. DMDQO0S RU https://pubmed.ncbi.nlm.nih.gov/25380635 DMDRYZK DI DMDRYZK DMDRYZK DN Anti-CD19 CAR-T cells DMDRYZK TI TTW640A DMDRYZK TN B-lymphocyte surface antigen B4 (CD19) DMDRYZK MA CAR-T-Cell-Therapy DMDRYZK RN ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma DMDRYZK RU https://clinicaltrials.gov/ct2/show/NCT02851589 DMDSKR2 DI DMDSKR2 DMDSKR2 DN CAR-T cells targeting Glypican-3 (GPC3) DMDSKR2 TI TTJTSX4 DMDSKR2 TN Glypican-3 (GPC3) DMDSKR2 MA CAR-T-Cell-Therapy DMDSKR2 RN ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3 DMDSKR2 RU https://clinicaltrials.gov/ct2/show/NCT02723942 DMDTNFB DI DMDTNFB DMDTNFB DN ISIS-STAT3 DMDTNFB TI TTHJT3X DMDTNFB TN STAT3 messenger RNA (STAT3 mRNA) DMDTNFB RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMDTNFB RU http://www.isispharm.com/index.htm DMDWCOF DI DMDWCOF DMDWCOF DN EGFR CART DMDWCOF TI TTGKNB4 DMDWCOF TN Epidermal growth factor receptor (EGFR) DMDWCOF MA CAR-T-Cell-Therapy DMDWCOF RN ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer DMDWCOF RU https://clinicaltrials.gov/ct2/show/NCT03152435 DME2W4T DI DME2W4T DME2W4T DN Forodesine DME2W4T TI TTMCF1Y DME2W4T TN Purine nucleoside phosphorylase (PNP) DME2W4T MA Inhibitor DME2W4T RN Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75. DME2W4T RU https://pubmed.ncbi.nlm.nih.gov/19541822 DME6NMJ DI DME6NMJ DME6NMJ DN CYT-0851 DME6NMJ TI TTC0G1L DME6NMJ TN DNA repair protein RAD51 homolog 1 (RAD51) DME6NMJ MA Inhibitor DME6NMJ RN National Cancer Institute Drug Dictionary (drug name CYT0851). DME6NMJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rad51-inhibitor-cyt-0851 DME6PB0 DI DME6PB0 DME6PB0 DN MG7-CART DME6PB0 TI TTPXOQN DME6PB0 TN Gastric carcinoma-associated antigen MG7 (MG7) DME6PB0 MA CAR-T-Cell-Therapy DME6PB0 RN ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART) DME6PB0 RU https://clinicaltrials.gov/ct2/show/NCT02862704 DME6PB0 DI DME6PB0 DME6PB0 DN MG7-CART DME6PB0 TI TTPW9LJ DME6PB0 TN Co-stimulatory molecule 4-1BB (CD137) DME6PB0 MA CAR-T-Cell-Therapy DME6PB0 RN ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART) DME6PB0 RU https://clinicaltrials.gov/ct2/show/NCT02862704 DME7PBN DI DME7PBN DME7PBN DN mRNA-3704 DME7PBN TI TTCQ21Y DME7PBN TN Methylmalonyl-CoA mutase (MMUT) DME7PBN MA Replacement DME7PBN RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DME7PBN RU https://www.modernatx.com/mrna-3705 DME8JW1 DI DME8JW1 DME8JW1 DN KTE-C19 CAR DME8JW1 TI TTW640A DME8JW1 TN B-lymphocyte surface antigen B4 (CD19) DME8JW1 MA Inhibitor DME8JW1 RN Clinical pipeline report, company report or official report of Kite Pharma. DME8JW1 RU http://ir.kitepharma.com/releasedetail.cfm?releaseid=867609 DMECGKO DI DMECGKO DMECGKO DN CD19 CAR-T Cells DMECGKO TI TTW640A DMECGKO TN B-lymphocyte surface antigen B4 (CD19) DMECGKO MA CAR-T-Cell-Therapy DMECGKO RN ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. DMECGKO RU https://clinicaltrials.gov/ct2/show/NCT03263208 DMED9QV DI DMED9QV DMED9QV DN INCB40093 DMED9QV TI TTGBPJE DMED9QV TN PI3-kinase delta (PIK3CD) DMED9QV MA Inhibitor DMED9QV RN INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors. DMED9QV RU http://cancerres.aacrjournals.org/content/74/19_Supplement/4531.short DMEF4L5 DI DMEF4L5 DMEF4L5 DN AMG888/U3-1287 DMEF4L5 TI TTDC8N2 DMEF4L5 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMEF4L5 MA Modulator DMEF4L5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DMEF4L5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DMEGPSW DI DMEGPSW DMEGPSW DN AdCh63 AMA1 DMEGPSW TI TTQZW34 DMEGPSW TN Plasmodium Apical membrane protein (Malaria AMA-1) DMEGPSW RN ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health. DMEGPSW RU https://clinicaltrials.gov/ct2/show/NCT01142765 DMEGSU5 DI DMEGSU5 DMEGSU5 DN 4SCAR-GD2 DMEGSU5 TI TT80ARU DMEGSU5 TN Ganglioside GD2 (GD2) DMEGSU5 MA CAR-T-Cell-Therapy DMEGSU5 RN ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2 DMEGSU5 RU https://clinicaltrials.gov/ct2/show/NCT02992210 DMEJT5Z DI DMEJT5Z DMEJT5Z DN SN-32793 DMEJT5Z TI TTGKNB4 DMEJT5Z TN Epidermal growth factor receptor (EGFR) DMEJT5Z MA Inhibitor DMEJT5Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMEJT5Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMELJDI DI DMELJDI DMELJDI DN KAI-9803 DMELJDI TI TT9WJ8U DMELJDI TN Protein kinase C delta (PRKCD) DMELJDI MA Inhibitor DMELJDI RN PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101. DMELJDI RU https://pubmed.ncbi.nlm.nih.gov/19519579 DMELJIV DI DMELJIV DMELJIV DN OPA-6566 DMELJIV TI TTM2AOE DMELJIV TN Adenosine A2a receptor (ADORA2A) DMELJIV MA Agonist DMELJIV RN Clinical pipeline report, company report or official report of Acucela. DMELJIV RU http://www.acucela.com/Read-About-Us/Press-Releases/Acucela-and-Otsuka-Pharmaceutical-Announce-the-(1) DMEMRW0 DI DMEMRW0 DMEMRW0 DN Lipoteichoic acid DMEMRW0 TI TTY7ZHS DMEMRW0 TN Toll-like receptor 2 (TLR2) DMEMRW0 MA Modulator DMEMRW0 RN Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94. DMEMRW0 RU https://pubmed.ncbi.nlm.nih.gov/12594207 DMEN2L7 DI DMEN2L7 DMEN2L7 DN AG019 DMEN2L7 TI TTT0Q1F DMEN2L7 TN Interleukin-10 (IL10) DMEN2L7 RN ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health. DMEN2L7 RU https://clinicaltrials.gov/ct2/show/NCT03751007 DMENF5K DI DMENF5K DMENF5K DN Liatermin DMENF5K TI TTF23ML DMENF5K TN Glial cell line-derived neurotrophic factor (GDNF) DMENF5K MA Modulator DMENF5K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMENF5K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMENFD6 DI DMENFD6 DMENFD6 DN Metelimumab DMENFD6 TI TTP4520 DMENFD6 TN TGF-beta receptor type I (TGFBR1) DMENFD6 RN Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. DMENFD6 RU https://pubmed.ncbi.nlm.nih.gov/15573100 DMENIQ7 DI DMENIQ7 DMENIQ7 DN CAR-T cells targeting BCMA DMENIQ7 TI TTZ3P4W DMENIQ7 TN B-cell maturation protein (TNFRSF17) DMENIQ7 MA CAR-T-Cell-Therapy DMENIQ7 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMENIQ7 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMEOLVP DI DMEOLVP DMEOLVP DN NI-0401 DMEOLVP TI TTBMAOZ DMEOLVP TN Regulatory protein unspecific (RGP) DMEOLVP RN Clinical pipeline report, company report or official report of NovImmune. DMEOLVP RU http://www.novimmune.com/pipeline/ni-0401.html DMEOS5K DI DMEOS5K DMEOS5K DN AEE-788 DMEOS5K TI TTGJVQM DMEOS5K TN Fibroblast growth factor receptor 2 (FGFR2) DMEOS5K MA Inhibitor DMEOS5K RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMEOS5K RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMEOS5K DI DMEOS5K DMEOS5K DN AEE-788 DMEOS5K TI TTST7KB DMEOS5K TN Fibroblast growth factor receptor 3 (FGFR3) DMEOS5K MA Inhibitor DMEOS5K RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMEOS5K RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMEU86T DI DMEU86T DMEU86T DN ACT017 DMEU86T TI TTTJUVZ DMEU86T TN Platelet glycoprotein VI (GP6) DMEU86T MA Inhibitor DMEU86T RN Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. DMEU86T RU https://pubmed.ncbi.nlm.nih.gov/31017822 DMEVGI9 DI DMEVGI9 DMEVGI9 DN SPK-7001 DMEVGI9 TI TTOA18V DMEVGI9 TN Rab proteins geranylgeranyltransferase component A 1 (CHM) DMEVGI9 MA Replacement DMEVGI9 RN Clinical pipeline report, company report or official report of Spark Therapeutics. DMEVGI9 RU https://sparktx.com/scientific-platform-programs/ DMEWXFK DI DMEWXFK DMEWXFK DN C 82 DMEWXFK TI TTFRCTK DMEWXFK TN CREB-binding protein (CREBBP) DMEWXFK MA Inhibitor DMEWXFK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWXFK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEWXFK DI DMEWXFK DMEWXFK DN C 82 DMEWXFK TI TTRPKQG DMEWXFK TN Beta-catenin (CTNNB1) DMEWXFK MA Inhibitor DMEWXFK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWXFK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMF4AOE DI DMF4AOE DMF4AOE DN 177-Lu-PSMA-R2 DMF4AOE TI TT9G4N0 DMF4AOE TN Glutamate carboxypeptidase II (GCPII) DMF4AOE MA Agonist DMF4AOE RN National Cancer Institute Drug Dictionary (drug name Lu-177-PSMA-R2). DMF4AOE RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-psma-r2 DMF7EX8 DI DMF7EX8 DMF7EX8 DN EGFR antisense DNA DMF7EX8 TI TTG96HZ DMF7EX8 TN EGFR messenger RNA (EGFR mRNA) DMF7EX8 RN Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352. DMF7EX8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684443/ DMFA4CK DI DMFA4CK DMFA4CK DN BAY 1902607 DMFA4CK TI TT2THBD DMFA4CK TN P2X purinoceptor 3 (P2RX3) DMFA4CK MA Antagonist DMFA4CK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFA4CK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFAMNH DI DMFAMNH DMFAMNH DN 99mTc-rBitistatin DMFAMNH TI TT38RM1 DMFAMNH TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMFAMNH MA Modulator DMFAMNH RN Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63. DMFAMNH RU https://pubmed.ncbi.nlm.nih.gov/17921036 DMFCPG0 DI DMFCPG0 DMFCPG0 DN CAR-T cells targeting GD2 DMFCPG0 TI TT80ARU DMFCPG0 TN Ganglioside GD2 (GD2) DMFCPG0 MA CAR-T-Cell-Therapy DMFCPG0 RN ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients DMFCPG0 RU https://clinicaltrials.gov/ct2/show/NCT03252171 DMFHV9L DI DMFHV9L DMFHV9L DN Leber's congenital amaurosis gene therapy DMFHV9L TI TTBOH16 DMFHV9L TN Retinal pigment epithelium protein (RPE65) DMFHV9L MA Modulator DMFHV9L RN ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health. DMFHV9L RU https://clinicaltrials.gov/ct2/show/NCT00749957 DMFJB35 DI DMFJB35 DMFJB35 DN ABO-102 DMFJB35 TI TTPJ2SH DMFJB35 TN N-sulphoglucosamine sulphohydrolase (SGSH) DMFJB35 RN Clinical pipeline report, company report or official report of Abeona Therapeutics. DMFJB35 RU https://www.abeonatherapeutics.com/science DMFK5IX DI DMFK5IX DMFK5IX DN MAK683 DMFK5IX TI TTFNJ4R DMFK5IX TN Embryonic ectoderm development protein (EED) DMFK5IX MA Inhibitor DMFK5IX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFK5IX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TTCYAXN DMFKA4G TN Chloride channel unspecific (ClC) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TT1GHVO DMFKA4G TN Matrix metalloproteinase (MMP) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TT6X50U DMFKA4G TN Matrix metalloproteinase-9 (MMP-9) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFOR9Y DI DMFOR9Y DMFOR9Y DN TSR-011 DMFOR9Y TI TTPMQSO DMFOR9Y TN ALK tyrosine kinase receptor (ALK) DMFOR9Y MA Inhibitor DMFOR9Y RN Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4. DMFOR9Y RU https://pubmed.ncbi.nlm.nih.gov/23020724 DMFTZX0 DI DMFTZX0 DMFTZX0 DN AFM24 DMFTZX0 TI TTIFOC0 DMFTZX0 TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMFTZX0 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMFTZX0 RU https://www.affimed.com/rock-platform/pipeline/ DMFTZX0 DI DMFTZX0 DMFTZX0 DN AFM24 DMFTZX0 TI TTGKNB4 DMFTZX0 TN Epidermal growth factor receptor (EGFR) DMFTZX0 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMFTZX0 RU https://www.affimed.com/rock-platform/pipeline/ DMFUDHM DI DMFUDHM DMFUDHM DN MUC-1 CART cell immunotherapy DMFUDHM TI TTBHFYQ DMFUDHM TN Mucin-1 (MUC1) DMFUDHM MA CAR-T-Cell-Therapy DMFUDHM RN ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma DMFUDHM RU https://clinicaltrials.gov/ct2/show/NCT03633773 DMFV6TY DI DMFV6TY DMFV6TY DN Anti-CD123-CAR-transduced T cells DMFV6TY TI TTENHJ0 DMFV6TY TN Interleukin 3 receptor alpha (IL3RA) DMFV6TY MA CAR-T-Cell-Therapy DMFV6TY RN ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies DMFV6TY RU https://clinicaltrials.gov/ct2/show/NCT02937103 DMFVTSG DI DMFVTSG DMFVTSG DN 4SCAR19 and 4SCAR20 DMFVTSG TI TTUE541 DMFVTSG TN Leukocyte surface antigen Leu-16 (CD20) DMFVTSG MA CAR-T-Cell-Therapy(Dual specific) DMFVTSG RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMFVTSG RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMFVTSG DI DMFVTSG DMFVTSG DN 4SCAR19 and 4SCAR20 DMFVTSG TI TTW640A DMFVTSG TN B-lymphocyte surface antigen B4 (CD19) DMFVTSG MA CAR-T-Cell-Therapy(Dual specific) DMFVTSG RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMFVTSG RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMFZS8A DI DMFZS8A DMFZS8A DN CD38 and BCMA CAR-T Cells DMFZS8A TI TTZ3P4W DMFZS8A TN B-cell maturation protein (TNFRSF17) DMFZS8A MA CAR-T-Cell-Therapy(Dual specific) DMFZS8A RN ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma DMFZS8A RU https://clinicaltrials.gov/ct2/show/NCT03767751 DMFZS8A DI DMFZS8A DMFZS8A DN CD38 and BCMA CAR-T Cells DMFZS8A TI TTPURFN DMFZS8A TN Cyclic ADP-ribose hydrolase 1 (CD38) DMFZS8A MA CAR-T-Cell-Therapy(Dual specific) DMFZS8A RN ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma DMFZS8A RU https://clinicaltrials.gov/ct2/show/NCT03767751 DMG107N DI DMG107N DMG107N DN ISB 1342 DMG107N TI TTPURFN DMG107N TN Cyclic ADP-ribose hydrolase 1 (CD38) DMG107N MA Inhibitor DMG107N RN Clinical pipeline report, company report or official report of Ichnos Sciences. DMG107N RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DMG107N DI DMG107N DMG107N DN ISB 1342 DMG107N TI TTUN7MC DMG107N TN T-cell surface glycoprotein CD3 (CD3) DMG107N MA Inhibitor DMG107N RN Clinical pipeline report, company report or official report of Ichnos Sciences. DMG107N RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DMG48WN DI DMG48WN DMG48WN DN G0-203-2c DMG48WN TI TTBHFYQ DMG48WN TN Mucin-1 (MUC1) DMG48WN MA Modulator DMG48WN RN Clinical pipeline report, company report or official report of Genus Oncology. DMG48WN RU http://www.genusoncology.com/phase-1-trial-GO-203-2c.php DMG65CV DI DMG65CV DMG65CV DN INCB057643 DMG65CV TI TTE4BSY DMG65CV TN Bromodomain and extraterminal domain protein (BET) DMG65CV MA Inhibitor DMG65CV RN Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257. DMG65CV RU https://pubmed.ncbi.nlm.nih.gov/31527168 DMG7XHE DI DMG7XHE DMG7XHE DN Monalizumab DMG7XHE TI TTC4IMS DMG7XHE TN NKG2-A/B-activating NK receptor (NKG2A) DMG7XHE MA Antagonist DMG7XHE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG7XHE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG8JLC DI DMG8JLC DMG8JLC DN SRP-9003 DMG8JLC TI TTEDCQ0 DMG8JLC TN Beta-sarcoglycan (SGCB) DMG8JLC MA Replacement DMG8JLC RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMG8JLC RU https://www.sarepta.com/products-pipeline/pipeline DMG9OAV DI DMG9OAV DMG9OAV DN AUTO1 DMG9OAV TI TTW640A DMG9OAV TN B-lymphocyte surface antigen B4 (CD19) DMG9OAV RN Clinical pipeline report, company report or official report of Autolus Therapeutics. DMG9OAV RU https://www.autolus.com/pipeline/ DMGC96P DI DMGC96P DMGC96P DN MLN-2704 DMGC96P TI TT9G4N0 DMGC96P TN Glutamate carboxypeptidase II (GCPII) DMGC96P RN Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 1;26(13):2147-54. DMGC96P RU https://pubmed.ncbi.nlm.nih.gov/18362364 DMGDK9C DI DMGDK9C DMGDK9C DN CD19 specific CAR T cells DMGDK9C TI TTW640A DMGDK9C TN B-lymphocyte surface antigen B4 (CD19) DMGDK9C MA CAR-T-Cell-Therapy DMGDK9C RN ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia DMGDK9C RU https://clinicaltrials.gov/ct2/show/NCT02028455 DMGEZVF DI DMGEZVF DMGEZVF DN JS016 DMGEZVF TI TTZ3COY DMGEZVF TN COVID-19 spike glycoprotein (S) DMGEZVF MA Inhibitor DMGEZVF RN Clinical pipeline report, company report or official report of Lilly. DMGEZVF RU https://www.lilly.com/discovery/clinical-development-pipeline# DMGF2PU DI DMGF2PU DMGF2PU DN BNT411 DMGF2PU TI TTRJ1K4 DMGF2PU TN Toll-like receptor 7 (TLR7) DMGF2PU MA Agonist DMGF2PU RN Clinical pipeline report, company report or official report of BioNTech. DMGF2PU RU https://biontech.de/science/pipeline DMGFPQ0 DI DMGFPQ0 DMGFPQ0 DN PBF509 DMGFPQ0 TI TTM2AOE DMGFPQ0 TN Adenosine A2a receptor (ADORA2A) DMGFPQ0 MA Antagonist DMGFPQ0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGFPQ0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGIN7J DI DMGIN7J DMGIN7J DN Onyvax-105 DMGIN7J TI TT5Z9WY DMGIN7J TN Complement decay-accelerating factor (CD55) DMGIN7J RN Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72. DMGIN7J RU https://pubmed.ncbi.nlm.nih.gov/14755894 DMGM7QD DI DMGM7QD DMGM7QD DN BMS-777607 DMGM7QD TI TTNDSF4 DMGM7QD TN Proto-oncogene c-Met (MET) DMGM7QD MA Inhibitor DMGM7QD RN Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4. DMGM7QD RU https://pubmed.ncbi.nlm.nih.gov/19260711 DMGN679 DI DMGN679 DMGN679 DN GPC3-CART cells DMGN679 TI TTJTSX4 DMGN679 TN Glypican-3 (GPC3) DMGN679 MA CAR-T-Cell-Therapy DMGN679 RN ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) DMGN679 RU https://clinicaltrials.gov/ct2/show/NCT03130712 DMGQX0U DI DMGQX0U DMGQX0U DN ALX148 DMGQX0U TI TT28S46 DMGQX0U TN Leukocyte surface antigen CD47 (CD47) DMGQX0U MA Inhibitor DMGQX0U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGQX0U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGTB5N DI DMGTB5N DMGTB5N DN LJM716 DMGTB5N TI TTDC8N2 DMGTB5N TN Erbb3 tyrosine kinase receptor (Erbb-3) DMGTB5N RN An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35. DMGTB5N RU https://pubmed.ncbi.nlm.nih.gov/23928993 DMGTOIX DI DMGTOIX DMGTOIX DN A166 DMGTOIX TI TT6EO5L DMGTOIX TN Erbb2 tyrosine kinase receptor (HER2) DMGTOIX RN Clinical pipeline report, company report or official report of KLUS Pharma. DMGTOIX RU https://www.kluspharma.com/pipeline DMH064K DI DMH064K DMH064K DN SEL-24 DMH064K TI TTTN5QW DMH064K TN Serine/threonine-protein kinase pim-1 (PIM1) DMH064K MA Inhibitor DMH064K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158). DMH064K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158 DMH064K DI DMH064K DMH064K DN SEL-24 DMH064K TI TTGJCWZ DMH064K TN Fms-like tyrosine kinase 3 (FLT-3) DMH064K MA Inhibitor DMH064K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH064K RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH0ROP DI DMH0ROP DMH0ROP DN Maltose DMH0ROP TI TTXWASR DMH0ROP TN Intestinal maltase-glucoamylase (MGAM) DMH0ROP MA Inhibitor DMH0ROP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMH0ROP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMH0ROP DI DMH0ROP DMH0ROP DN Maltose DMH0ROP TI TTHCF4J DMH0ROP TN Alpha-glucosidase (GLA) DMH0ROP MA Inhibitor DMH0ROP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMH0ROP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMH2NKD DI DMH2NKD DMH2NKD DN EB-101 DMH2NKD TI TTE4KHA DMH2NKD TN Amyloid beta A4 protein (APP) DMH2NKD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMH2NKD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMH32LC DI DMH32LC DMH32LC DN ISIS-DMPK DMH32LC TI TTZQTY2 DMH32LC TN DMPK messenger RNA (DMPK mRNA) DMH32LC RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMH32LC RU https://www.isispharm.com/pipeline/isis-dmpkrx/ DMH70A9 DI DMH70A9 DMH70A9 DN BCMA CAR T cells DMH70A9 TI TTZ3P4W DMH70A9 TN B-cell maturation protein (TNFRSF17) DMH70A9 MA CAR-T-Cell-Therapy DMH70A9 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMH70A9 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMH9RGV DI DMH9RGV DMH9RGV DN TTP-814 DMH9RGV TI TTMS7KP DMH9RGV TN Protein-tyrosine phosphatase 1B (PTP1B) DMH9RGV MA Inhibitor DMH9RGV RN Protein tyrosine phosphatase 1B (PTP-1B; PTPN1). SciBX 5(7); doi:10.1038/scibx.2012.176. Feb. 16 2012 DMH9RGV RU http://www.nature.com/scibx/journal/v5/n7/full/scibx.2012.176.html DMHIQDC DI DMHIQDC DMHIQDC DN CUDC-907 DMHIQDC TI TTHBTOP DMHIQDC TN PI3-kinase gamma (PIK3CG) DMHIQDC MA Modulator DMHIQDC RN Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res.2012 Aug 1;18(15):4104-13. DMHIQDC RU https://www.ncbi.nlm.nih.gov/pubmed/22693356 DMHIQDC DI DMHIQDC DMHIQDC DN CUDC-907 DMHIQDC TI TTBH0VX DMHIQDC TN Histone deacetylase (HDAC) DMHIQDC MA Inhibitor DMHIQDC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHIQDC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHMC19 DI DMHMC19 DMHMC19 DN CD137 CAR-T Cell DMHMC19 TI TTPW9LJ DMHMC19 TN Co-stimulatory molecule 4-1BB (CD137) DMHMC19 MA CAR-T-Cell-Therapy DMHMC19 RN ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies DMHMC19 RU https://clinicaltrials.gov/ct2/show/NCT02965092 DMHNFXR DI DMHNFXR DMHNFXR DN Chimeric Antigen Receptor Modified T cells Targeting CD19 DMHNFXR TI TTW640A DMHNFXR TN B-lymphocyte surface antigen B4 (CD19) DMHNFXR MA CAR-T-Cell-Therapy DMHNFXR RN ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma DMHNFXR RU https://clinicaltrials.gov/ct2/show/NCT02349698 DMHOWU5 DI DMHOWU5 DMHOWU5 DN CD123-specific gene-engineered T cells DMHOWU5 TI TTENHJ0 DMHOWU5 TN Interleukin 3 receptor alpha (IL3RA) DMHOWU5 MA CAR-T-Cell-Therapy DMHOWU5 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMHOWU5 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMHPZ8G DI DMHPZ8G DMHPZ8G DN CD20-Specific CAR T Cells DMHPZ8G TI TTUE541 DMHPZ8G TN Leukocyte surface antigen Leu-16 (CD20) DMHPZ8G MA CAR-T-Cell-Therapy DMHPZ8G RN ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas DMHPZ8G RU https://clinicaltrials.gov/ct2/show/NCT03277729 DMHQ2U8 DI DMHQ2U8 DMHQ2U8 DN IMC-F106C DMHQ2U8 TI TTPH7T0 DMHQ2U8 TN Tumor expressed melanoma antigen (PRAME) DMHQ2U8 RN Clinical pipeline report, company report or official report of Immunocore. DMHQ2U8 RU https://www.immunocore.com/news/immunocore-announces-dosing-first-patient-fourth-immtac DMHRCQI DI DMHRCQI DMHRCQI DN eFT226 DMHRCQI TI TTIGYVZ DMHRCQI TN HUMAN eukaryotic initiation factor-4A (eIF4A) DMHRCQI MA Inhibitor DMHRCQI RN Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020 Jun 11;63(11):5879-5955. DMHRCQI RU https://pubmed.ncbi.nlm.nih.gov/32470302 DMHSLVJ DI DMHSLVJ DMHSLVJ DN Anti-CD19 CAR transduced T cells DMHSLVJ TI TTW640A DMHSLVJ TN B-lymphocyte surface antigen B4 (CD19) DMHSLVJ MA CAR-T-Cell-Therapy DMHSLVJ RN ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies DMHSLVJ RU https://clinicaltrials.gov/ct2/show/NCT03191773 DMHTG8P DI DMHTG8P DMHTG8P DN TP-0903 DMHTG8P TI TTZPY6J DMHTG8P TN Tyrosine-protein kinase UFO (AXL) DMHTG8P MA Inhibitor DMHTG8P RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHTG8P RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHW289 DI DMHW289 DMHW289 DN DCC-3014 DMHW289 TI TT7MRDV DMHW289 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMHW289 MA Inhibitor DMHW289 RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMHW289 RU https://www.deciphera.com/pipeline/dcc-3014/ DMHXTNW DI DMHXTNW DMHXTNW DN LY-2228820 DMHXTNW TI TTWELHI DMHXTNW TN Stress-activated protein kinase (p38) DMHXTNW MA Inhibitor DMHXTNW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959). DMHXTNW RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959 DMHZUF8 DI DMHZUF8 DMHZUF8 DN AGN-208397 DMHZUF8 TI TT6EO5L DMHZUF8 TN Erbb2 tyrosine kinase receptor (HER2) DMHZUF8 MA Inhibitor DMHZUF8 RN New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. DMHZUF8 RU https://pubmed.ncbi.nlm.nih.gov/23812264 DMI0H3B DI DMI0H3B DMI0H3B DN UshStat DMI0H3B TI TTNIMDP DMI0H3B TN Myosin-7 (MYH7) DMI0H3B MA Modulator DMI0H3B RN EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One. 2014 Apr 4;9(4):e94272. DMI0H3B RU https://pubmed.ncbi.nlm.nih.gov/24705452 DMI17NX DI DMI17NX DMI17NX DN ART621 DMI17NX TI TTF8CQI DMI17NX TN Tumor necrosis factor (TNF) DMI17NX MA Inhibitor DMI17NX RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DMI17NX RU https://pubmed.ncbi.nlm.nih.gov/19249988 DMI27RF DI DMI27RF DMI27RF DN AAV-AQP1 DMI27RF TI TTSF1KH DMI27RF TN Aquaporin-1 (AQP1) DMI27RF RN Clinical pipeline report, company report or official report of MeiraGTx. DMI27RF RU https://meiragtx.com/research-development/pipeline/ DMI2OVA DI DMI2OVA DMI2OVA DN CD19-targeting CAR T Cells DMI2OVA TI TTW640A DMI2OVA TN B-lymphocyte surface antigen B4 (CD19) DMI2OVA MA CAR-T-Cell-Therapy DMI2OVA RN ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma DMI2OVA RU https://clinicaltrials.gov/ct2/show/NCT02547948 DMI42Q0 DI DMI42Q0 DMI42Q0 DN BGB-A425 DMI42Q0 TI TT1RWL7 DMI42Q0 TN Hepatitis A virus cellular receptor 2 (TIM3) DMI42Q0 RN Clinical pipeline report, company report or official report of BeiGene. DMI42Q0 RU https://www.beigene.com/science-and-product-portfolio/pipeline DMI71FN DI DMI71FN DMI71FN DN EDO-S101 DMI71FN TI TTBH0VX DMI71FN TN Histone deacetylase (HDAC) DMI71FN MA Inhibitor DMI71FN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI71FN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI7S39 DI DMI7S39 DMI7S39 DN FLX475 DMI7S39 TI TT7HQD0 DMI7S39 TN C-C chemokine receptor type 4 (CCR4) DMI7S39 MA Antagonist DMI7S39 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI7S39 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTRA6BO DMI8RG1 TN Bromodomain-containing protein 4 (BRD4) DMI8RG1 MA Modulator DMI8RG1 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMI8RG1 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTDP48B DMI8RG1 TN Bromodomain-containing protein 2 (BRD2) DMI8RG1 MA Modulator DMI8RG1 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMI8RG1 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTE4BSY DMI8RG1 TN Bromodomain and extraterminal domain protein (BET) DMI8RG1 MA Inhibitor DMI8RG1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI8RG1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI8TW3 DI DMI8TW3 DMI8TW3 DN 4SCAR19/22 T cells DMI8TW3 TI TTM6QSK DMI8TW3 TN B-cell receptor CD22 (CD22) DMI8TW3 MA CAR-T-Cell-Therapy(Dual specific) DMI8TW3 RN ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies DMI8TW3 RU https://clinicaltrials.gov/ct2/show/NCT03098355 DMI8TW3 DI DMI8TW3 DMI8TW3 DN 4SCAR19/22 T cells DMI8TW3 TI TTW640A DMI8TW3 TN B-lymphocyte surface antigen B4 (CD19) DMI8TW3 MA CAR-T-Cell-Therapy(Dual specific) DMI8TW3 RN ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies DMI8TW3 RU https://clinicaltrials.gov/ct2/show/NCT03098355 DMI9FXE DI DMI9FXE DMI9FXE DN KBP-5074 DMI9FXE TI TT26PHO DMI9FXE TN Mineralocorticoid receptor (MR) DMI9FXE MA Antagonist DMI9FXE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI9FXE RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMIA9JD DI DMIA9JD DMIA9JD DN YSCMA DMIA9JD TI TTDIGC1 DMIA9JD TN Dipeptidyl peptidase 4 (DPP-4) DMIA9JD RN Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30. DMIA9JD RU https://pubmed.ncbi.nlm.nih.gov/24502396 DMIFCY2 DI DMIFCY2 DMIFCY2 DN H3B-6545 DMIFCY2 TI TTZAYWL DMIFCY2 TN Estrogen receptor (ESR) DMIFCY2 MA Antagonist DMIFCY2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFCY2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIM9TZ DI DMIM9TZ DMIM9TZ DN CAR-T cells targeting CD19 DMIM9TZ TI TTW640A DMIM9TZ TN B-lymphocyte surface antigen B4 (CD19) DMIM9TZ MA CAR-T-Cell-Therapy DMIM9TZ RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMIM9TZ RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMIMA4V DI DMIMA4V DMIMA4V DN BPX-501 DMIMA4V TI TTXQYT6 DMIMA4V TN T-cells (T-cells) DMIMA4V MA Immunomodulator DMIMA4V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIMA4V RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMIOUFK DI DMIOUFK DMIOUFK DN Emfilermin DMIOUFK TI TTID542 DMIOUFK TN Leukemia inhibitory factor receptor (LIFR) DMIOUFK MA Inhibitor DMIOUFK RN Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol. 2004 May; 57(5): 576-585. DMIOUFK RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884498/ DMIREUZ DI DMIREUZ DMIREUZ DN Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy DMIREUZ TI TTLP57V DMIREUZ TN Adenosine deaminase (ADA) DMIREUZ MA Modulator DMIREUZ RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMIREUZ RU https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ DMIRG15 DI DMIRG15 DMIRG15 DN MaC46/M87o DMIRG15 TI TTG90S6 DMIRG15 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMIRG15 MA Modulator DMIRG15 RN DOI: 10.1038/mt.sj.6300124 DMIRG15 RU http://www.nature.com/mt/journal/v15/n5/full/6300124a.html DMIRGTZ DI DMIRGTZ DMIRGTZ DN ACHM-CNGA3 DMIRGTZ TI TTW0QOV DMIRGTZ TN Cyclic nucleotide-gated channel alpha-3 (CNGA3) DMIRGTZ RN Clinical pipeline report, company report or official report of Applied Genetic Technologies. DMIRGTZ RU https://agtc.com/programs/achromatopsia/ DMIS75V DI DMIS75V DMIS75V DN MTL-CEPBA DMIS75V TI TT5LWG1 DMIS75V TN CEBPA messenger RNA (CEBPA mRNA) DMIS75V MA Activator DMIS75V RN MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. DMIS75V RU https://pubmed.ncbi.nlm.nih.gov/32357963 DMIU0VP DI DMIU0VP DMIU0VP DN SNX-5422 DMIU0VP TI TT78R5H DMIU0VP TN Heat shock protein 90 alpha (HSP90A) DMIU0VP MA Inhibitor DMIU0VP RN SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55. DMIU0VP RU https://pubmed.ncbi.nlm.nih.gov/18948577 DMIU0VP DI DMIU0VP DMIU0VP DN SNX-5422 DMIU0VP TI TTH5YN2 DMIU0VP TN Heat shock protein 90 beta (HSP90B) DMIU0VP MA Inhibitor DMIU0VP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIU0VP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIU1HY DI DMIU1HY DMIU1HY DN HuM-195-Ac-225 DMIU1HY TI TTJVYO3 DMIU1HY TN Myeloid cell surface antigen CD33 (CD33) DMIU1HY MA Inhibitor DMIU1HY RN J Clin Oncol 29: 2011 (suppl; abstr 6516). DMIU1HY RU http://meetinglibrary.asco.org/content/77232-102 DMIU26T DI DMIU26T DMIU26T DN OP-1250 DMIU26T TI TTZAYWL DMIU26T TN Estrogen receptor (ESR) DMIU26T MA Antagonist DMIU26T RN Clinical pipeline report, company report or official report of Olema Pharmaceuticals. DMIU26T RU https://olema.com/pipeline/ DMIVE67 DI DMIVE67 DMIVE67 DN TPX-0046 DMIVE67 TI TT4DXQT DMIVE67 TN Proto-oncogene c-Ret (RET) DMIVE67 MA Inhibitor DMIVE67 RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMIVE67 RU https://tptherapeutics.com/pipeline/tpx-0046/ DMIVE67 DI DMIVE67 DMIVE67 DN TPX-0046 DMIVE67 TI TT6PKBN DMIVE67 TN Proto-oncogene c-Src (SRC) DMIVE67 MA Inhibitor DMIVE67 RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMIVE67 RU https://tptherapeutics.com/pipeline/tpx-0046/ DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TTSHTOI DMIXPNG TN Histone deacetylase 2 (HDAC2) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TT6R7JZ DMIXPNG TN Histone deacetylase 1 (HDAC1) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TT4YWTO DMIXPNG TN Histone deacetylase 3 (HDAC3) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIY1ZB DI DMIY1ZB DMIY1ZB DN 4SCAR19 cells DMIY1ZB TI TTW640A DMIY1ZB TN B-lymphocyte surface antigen B4 (CD19) DMIY1ZB MA CAR-T-Cell-Therapy DMIY1ZB RN ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies DMIY1ZB RU https://clinicaltrials.gov/ct2/show/NCT03050190 DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTLSWP6 DMJ42E6 TN GTP cyclohydrolase-I (GCH1) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTN451K DMJ42E6 TN Aromatic-L-amino-acid decarboxylase (DDC) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTUHP71 DMJ42E6 TN Tyrosine 3-monooxygenase (TH) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ5MPG DI DMJ5MPG DMJ5MPG DN BDC-1001 DMJ5MPG TI TTY6DTE DMJ5MPG TN Carcinoembryonic antigen CEA (CD66e) DMJ5MPG RN Clinical pipeline report, company report or official report of Bolt Biotherapeutics. DMJ5MPG RU https://www.boltbio.com/pipeline/ DMJ7LP0 DI DMJ7LP0 DMJ7LP0 DN CTX110 DMJ7LP0 TI TTQO71U DMJ7LP0 TN Hemoglobin (HB) DMJ7LP0 RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DMJ7LP0 RU http://www.crisprtx.com/programs/pipeline DMJ9CY4 DI DMJ9CY4 DMJ9CY4 DN IL-2/gene-modified lymphocytes DMJ9CY4 TI TTF89GD DMJ9CY4 TN Interleukin-2 (IL2) DMJ9CY4 MA Modulator DMJ9CY4 RN Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 November; 97(11): 1622-1631. DMJ9CY4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487433/ DMJBQ96 DI DMJBQ96 DMJBQ96 DN Cetrelimab DMJBQ96 TI TTNBFWK DMJBQ96 TN Programmed cell death protein 1 (PD-1) DMJBQ96 RN Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924. DMJBQ96 RU https://pubmed.ncbi.nlm.nih.gov/30544512 DMJC2RU DI DMJC2RU DMJC2RU DN PBCAR0191 DMJC2RU TI TTW640A DMJC2RU TN B-lymphocyte surface antigen B4 (CD19) DMJC2RU MA CAR-T-Cell-Therapy DMJC2RU RN ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL DMJC2RU RU https://clinicaltrials.gov/ct2/show/NCT03666000 DMJDV0K DI DMJDV0K DMJDV0K DN SPR720 DMJDV0K TI TTS7LWX DMJDV0K TN Bacterial DNA gyrase B (Bact gyrB) DMJDV0K MA Inhibitor DMJDV0K RN Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331. DMJDV0K RU https://pubmed.ncbi.nlm.nih.gov/32183511 DMJDVCW DI DMJDVCW DMJDVCW DN HL-085 DMJDVCW TI TTZCRP3 DMJDVCW TN ERK activator kinase (MEK) DMJDVCW MA Inhibitor DMJDVCW RN Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551. DMJDVCW RU https://pubmed.ncbi.nlm.nih.gov/28954413 DMJEXLI DI DMJEXLI DMJEXLI DN CPI-0209 DMJEXLI TI TT9MZCQ DMJEXLI TN Enhancer of zeste homolog 2 (EZH2) DMJEXLI MA Inhibitor DMJEXLI RN ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health. DMJEXLI RU https://clinicaltrials.gov/ct2/show/NCT04104776 DMJKFNU DI DMJKFNU DMJKFNU DN DCC-2036 DMJKFNU TI TT3PJMV DMJKFNU TN Tyrosine-protein kinase ABL1 (ABL) DMJKFNU MA Modulator DMJKFNU RN Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications) DMJKFNU RU http://www.deciphera.com/pipeline DMJKFNU DI DMJKFNU DMJKFNU DN DCC-2036 DMJKFNU TI TT9VGXW DMJKFNU TN Angiopoietin 1 receptor (TEK) DMJKFNU MA Inhibitor DMJKFNU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJKFNU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJLMEF DI DMJLMEF DMJLMEF DN AP-30663 DMJLMEF TI TTKU9YD DMJLMEF TN Calcium-activated potassium channel KCa2 (KCNN) DMJLMEF MA Inhibitor DMJLMEF RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJLMEF RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJPSIL DI DMJPSIL DMJPSIL DN Dapivirine DMJPSIL TI TT84ETX DMJPSIL TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJPSIL MA Inhibitor DMJPSIL RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMJPSIL RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMJSQXT DI DMJSQXT DMJSQXT DN TAK-007 DMJSQXT TI TTW640A DMJSQXT TN B-lymphocyte surface antigen B4 (CD19) DMJSQXT RN Clinical pipeline report, company report or official report of Takeda. DMJSQXT RU https://www.takeda.com/newsroom/newsreleases/2020/takeda-opens-new-rd-cell-therapy-manufacturing-facility-to--support-expansion-of-next-generation-clinical-programs/ DMJV2IF DI DMJV2IF DMJV2IF DN JCAR017 DMJV2IF TI TTW640A DMJV2IF TN B-lymphocyte surface antigen B4 (CD19) DMJV2IF MA CAR-T-Cell-Therapy DMJV2IF RN ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product DMJV2IF RU https://clinicaltrials.gov/ct2/show/NCT03436771 DMJVENR DI DMJVENR DMJVENR DN CAR-T cells targeting CD2 DMJVENR TI TT80ARU DMJVENR TN Ganglioside GD2 (GD2) DMJVENR MA CAR-T-Cell-Therapy DMJVENR RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DMJVENR RU https://clinicaltrials.gov/ct2/show/NCT03356795 DMJVFK7 DI DMJVFK7 DMJVFK7 DN Meplazumab DMJVFK7 TI TTG21IS DMJVFK7 TN HUMAN basigin (BSG) DMJVFK7 MA Inhibitor DMJVFK7 RN Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial DMJVFK7 RU https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1 DMJVGIH DI DMJVGIH DMJVGIH DN AIGIV DMJVGIH TI TTRLPUB DMJVGIH TN Bacillus anthracis Protective antigen (Anthrax PA) DMJVGIH MA Modulator DMJVGIH RN Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. DMJVGIH RU https://pubmed.ncbi.nlm.nih.gov/23979731 DMK095Z DI DMK095Z DMK095Z DN SRP-9004 DMK095Z TI TTS9Q5V DMK095Z TN Sarcoglycan alpha (SGCA) DMK095Z MA Replacement DMK095Z RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMK095Z RU https://www.sarepta.com/products-pipeline/pipeline DMK2L38 DI DMK2L38 DMK2L38 DN M3814 DMK2L38 TI TTK3PY9 DMK2L38 TN DNA-dependent protein kinase catalytic (PRKDC) DMK2L38 MA Inhibitor DMK2L38 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK2L38 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK2RIB DI DMK2RIB DMK2RIB DN GTB-3550 DMK2RIB TI TTJVYO3 DMK2RIB TN Myeloid cell surface antigen CD33 (CD33) DMK2RIB MA Inhibitor DMK2RIB RN Clinical pipeline report, company report or official report of GT Biopharma. DMK2RIB RU https://www.gtbiopharma.com/product-pipeline/gtb-3550 DMK2RIB DI DMK2RIB DMK2RIB DN GTB-3550 DMK2RIB TI TT7KTSR DMK2RIB TN Immunoglobulin gamma Fc receptor III (FCGR3) DMK2RIB MA Inhibitor DMK2RIB RN Clinical pipeline report, company report or official report of GT Biopharma. DMK2RIB RU https://www.gtbiopharma.com/product-pipeline/gtb-3550 DMK4VY9 DI DMK4VY9 DMK4VY9 DN DS-7300 DMK4VY9 TI TTGTQHC DMK4VY9 TN DNA topoisomerase I (TOP1) DMK4VY9 MA Inhibitor DMK4VY9 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMK4VY9 RU https://www.daiichisankyo.com/rd/pipeline/ DMK4VY9 DI DMK4VY9 DMK4VY9 DN DS-7300 DMK4VY9 TI TT6CQUM DMK4VY9 TN B7 homolog 3 (CD276) DMK4VY9 MA Inhibitor DMK4VY9 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMK4VY9 RU https://www.daiichisankyo.com/rd/pipeline/ DMKC8F9 DI DMKC8F9 DMKC8F9 DN 4SCAR19 and 4SCAR70 DMKC8F9 TI TTW640A DMKC8F9 TN B-lymphocyte surface antigen B4 (CD19) DMKC8F9 MA CAR-T-Cell-Therapy(Dual specific) DMKC8F9 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMKC8F9 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMKC8F9 DI DMKC8F9 DMKC8F9 DN 4SCAR19 and 4SCAR70 DMKC8F9 TI TTNCIE0 DMKC8F9 TN CD70 antigen (CD27-L) DMKC8F9 MA CAR-T-Cell-Therapy(Dual specific) DMKC8F9 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMKC8F9 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMKCJ75 DI DMKCJ75 DMKCJ75 DN CBL0102 DMKCJ75 TI TTETDKQ DMKCJ75 TN Facilitates chromatin transcription complex (FACT) DMKCJ75 MA Modulator DMKCJ75 RN Company report (Incuron) DMKCJ75 RU http://www.incuron.ru/en/news-en/item/2-incuron-announce-cbl0102-orphan-drug-status-for-hepatocellular-carcinoma DMKGU5F DI DMKGU5F DMKGU5F DN CART20 DMKGU5F TI TTUE541 DMKGU5F TN Leukocyte surface antigen Leu-16 (CD20) DMKGU5F MA CAR-T-Cell-Therapy DMKGU5F RN ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma DMKGU5F RU https://clinicaltrials.gov/ct2/show/NCT02965157 DMKMSP2 DI DMKMSP2 DMKMSP2 DN INCB53914 DMKMSP2 TI TTA7WGU DMKMSP2 TN Serine/threonine-protein kinase pim (PIM) DMKMSP2 MA Inhibitor DMKMSP2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKMSP2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKNA94 DI DMKNA94 DMKNA94 DN INO-8875 DMKNA94 TI TTK25J1 DMKNA94 TN Adenosine A1 receptor (ADORA1) DMKNA94 MA Agonist DMKNA94 RN INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67. DMKNA94 RU https://pubmed.ncbi.nlm.nih.gov/23055540 DMKQRUJ DI DMKQRUJ DMKQRUJ DN CD19-directed CAR-T cells DMKQRUJ TI TTW640A DMKQRUJ TN B-lymphocyte surface antigen B4 (CD19) DMKQRUJ MA CAR-T-Cell-Therapy DMKQRUJ RN ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy DMKQRUJ RU https://clinicaltrials.gov/ct2/show/NCT02537977 DMKV5D6 DI DMKV5D6 DMKV5D6 DN IM19 CAR-T DMKV5D6 TI TTW640A DMKV5D6 TN B-lymphocyte surface antigen B4 (CD19) DMKV5D6 MA CAR-T-Cell-Therapy DMKV5D6 RN ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells DMKV5D6 RU https://clinicaltrials.gov/ct2/show/NCT03142646 DMKVMWO DI DMKVMWO DMKVMWO DN RP-L201 DMKVMWO TI TTIJWR7 DMKVMWO TN Integrin beta-2 (ITGB2) DMKVMWO MA Replacement DMKVMWO RN Clinical pipeline report, company report or official report of Rocket Pharmaceuticals. DMKVMWO RU https://rocketpharma.com/our-disease-focus/ DML0GIU DI DML0GIU DML0GIU DN AIV001 DML0GIU TI TTVJ1D8 DML0GIU TN Vascular endothelial growth factor receptor (VEGFR) DML0GIU MA Inhibitor DML0GIU RN Clinical pipeline report, company report or official report of AiViva BioPharma. DML0GIU RU https://aiviva.com/aiv001 DML29RF DI DML29RF DML29RF DN KP-100 DML29RF TI TTWC6MY DML29RF TN Protein tyrosine phosphatase (PTP) DML29RF MA Inhibitor DML29RF RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010512) DML29RF RU http://adisinsight.springer.com/drugs/800010512 DML54PD DI DML54PD DML54PD DN TriCAR-T-CD19 DML54PD TI TTW640A DML54PD TN B-lymphocyte surface antigen B4 (CD19) DML54PD MA CAR-T-Cell-Therapy DML54PD RN ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 DML54PD RU https://clinicaltrials.gov/ct2/show/NCT03497533 DML6EVJ DI DML6EVJ DML6EVJ DN F-14512 DML6EVJ TI TT0IHXV DML6EVJ TN DNA topoisomerase II (TOP2) DML6EVJ MA Modulator DML6EVJ RN Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.Apoptosis.2012 Apr;17(4):364-76. DML6EVJ RU https://www.ncbi.nlm.nih.gov/pubmed/22127645 DML8US9 DI DML8US9 DML8US9 DN CLIC-1901 DML8US9 TI TTW640A DML8US9 TN B-lymphocyte surface antigen B4 (CD19) DML8US9 MA CAR-T-Cell-Therapy DML8US9 RN ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies DML8US9 RU https://clinicaltrials.gov/ct2/show/NCT03765177 DMLAKPI DI DMLAKPI DMLAKPI DN AU101 DMLAKPI TI TTQ13FT DMLAKPI TN T-cell-specific surface glycoprotein CD28 (CD28) DMLAKPI MA Immunomodulator DMLAKPI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLAKPI RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLE8T9 DI DMLE8T9 DMLE8T9 DN CART30 DMLE8T9 TI TT2GM5R DMLE8T9 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMLE8T9 MA CAR-T-Cell-Therapy DMLE8T9 RN ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas DMLE8T9 RU https://clinicaltrials.gov/ct2/show/NCT02259556 DMLEVFW DI DMLEVFW DMLEVFW DN IFN alpha kinoid DMLEVFW TI TT95SOA DMLEVFW TN Interferon alpha (IFNA) DMLEVFW MA Modulator DMLEVFW RN Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56. DMLEVFW RU https://pubmed.ncbi.nlm.nih.gov/23203821 DMLFB25 DI DMLFB25 DMLFB25 DN Anti-CD19 and Anti-CD20 CAR-T Cells DMLFB25 TI TTUE541 DMLFB25 TN Leukocyte surface antigen Leu-16 (CD20) DMLFB25 MA CAR-T-Cell-Therapy(Dual specific) DMLFB25 RN ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma DMLFB25 RU https://clinicaltrials.gov/ct2/show/NCT03207178 DMLFB25 DI DMLFB25 DMLFB25 DN Anti-CD19 and Anti-CD20 CAR-T Cells DMLFB25 TI TTW640A DMLFB25 TN B-lymphocyte surface antigen B4 (CD19) DMLFB25 MA CAR-T-Cell-Therapy(Dual specific) DMLFB25 RN ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma DMLFB25 RU https://clinicaltrials.gov/ct2/show/NCT03207178 DMLOGI4 DI DMLOGI4 DMLOGI4 DN Autologous CD19-targeting CAR T cells DMLOGI4 TI TTW640A DMLOGI4 TN B-lymphocyte surface antigen B4 (CD19) DMLOGI4 MA CAR-T-Cell-Therapy DMLOGI4 RN ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy DMLOGI4 RU https://clinicaltrials.gov/ct2/show/NCT02963038 DMLPTOF DI DMLPTOF DMLPTOF DN PEN-866 DMLPTOF TI TTGTQHC DMLPTOF TN DNA topoisomerase I (TOP1) DMLPTOF MA Inhibitor DMLPTOF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPTOF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLROMP DI DMLROMP DMLROMP DN TKM-PLK1 DMLROMP TI TTH4IP0 DMLROMP TN PLK1 messenger RNA (PLK1 mRNA) DMLROMP RN Clinical pipeline report, company report or official report of Arbutus Biopharma. DMLROMP RU http://arbutusbio.com/portfolio/tkm-plk1.php DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTTHBCA DMLSYJQ TN PI3-kinase beta (PIK3CB) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTGBPJE DMLSYJQ TN PI3-kinase delta (PIK3CD) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTEUNMR DMLSYJQ TN PI3-kinase alpha (PIK3CA) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTHBTOP DMLSYJQ TN PI3-kinase gamma (PIK3CG) DMLSYJQ MA Modulator DMLSYJQ RN Company report (Chugai-pharm) DMLSYJQ RU http://www.chugai-pharm.co.jp/html/meeting/pdf/140424ePresentation.pdf DMLV4U1 DI DMLV4U1 DMLV4U1 DN ZN-e4 DMLV4U1 TI TTGKNB4 DMLV4U1 TN Epidermal growth factor receptor (EGFR) DMLV4U1 MA Inhibitor DMLV4U1 RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DMLV4U1 RU https://zentalis.com/our-pipeline/pipeline/ DMM10J4 DI DMM10J4 DMM10J4 DN BMS-986288 DMM10J4 TI TTI2S1D DMM10J4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMM10J4 MA Inhibitor DMM10J4 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMM10J4 RU https://cytomx.com/pipeline/ DMM35D2 DI DMM35D2 DMM35D2 DN CD33-specific gene-engineered T cells DMM35D2 TI TTJVYO3 DMM35D2 TN Myeloid cell surface antigen CD33 (CD33) DMM35D2 MA CAR-T-Cell-Therapy DMM35D2 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMM35D2 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMM8J5W DI DMM8J5W DMM8J5W DN 4SCAR-PSMA DMM8J5W TI TT9G4N0 DMM8J5W TN Glutamate carboxypeptidase II (GCPII) DMM8J5W MA CAR-T-Cell-Therapy DMM8J5W RN ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T DMM8J5W RU https://clinicaltrials.gov/ct2/show/NCT03185468 DMM9L1R DI DMM9L1R DMM9L1R DN PEP-223/CoVaccine HT DMM9L1R TI TT8R70G DMM9L1R TN Gonadotropin-releasing hormone receptor (GNRHR) DMM9L1R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DMM9L1R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DMMAQJ7 DI DMMAQJ7 DMMAQJ7 DN CAR-T cells targeting Mesothelin DMMAQJ7 TI TT4RXME DMMAQJ7 TN Mesothelin (MSLN) DMMAQJ7 MA CAR-T-Cell-Therapy DMMAQJ7 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMMAQJ7 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMMAUOK DI DMMAUOK DMMAUOK DN PEN-221 DMMAUOK TI TTZ6T9E DMMAUOK TN Somatostatin receptor type 2 (SSTR2) DMMAUOK MA Modulator DMMAUOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMAUOK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMB5CV DI DMMB5CV DMMB5CV DN Medusa IL-2 DMMB5CV TI TTF89GD DMMB5CV TN Interleukin-2 (IL2) DMMB5CV MA Modulator DMMB5CV RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMB5CV RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMD10S DI DMMD10S DMMD10S DN EMD 55900 DMMD10S TI TTGKNB4 DMMD10S TN Epidermal growth factor receptor (EGFR) DMMD10S RN Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. DMMD10S RU https://pubmed.ncbi.nlm.nih.gov/11920518 DMMHLJQ DI DMMHLJQ DMMHLJQ DN CD19 CAR T cells DMMHLJQ TI TTW640A DMMHLJQ TN B-lymphocyte surface antigen B4 (CD19) DMMHLJQ MA CAR-T-Cell-Therapy DMMHLJQ RN ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies DMMHLJQ RU https://clinicaltrials.gov/ct2/show/NCT02772198 DMMNIBY DI DMMNIBY DMMNIBY DN Aflunov DMMNIBY TI TT3J5ZI DMMNIBY TN Cell mediated immunity response (CMIR) DMMNIBY RN Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57. DMMNIBY RU https://pubmed.ncbi.nlm.nih.gov/22309663 DMMOA2X DI DMMOA2X DMMOA2X DN Nikkomycin Z DMMOA2X TI TTBGVF1 DMMOA2X TN Candida Chitin synthase 3 (Candi CHS3) DMMOA2X MA Modulator DMMOA2X RN Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans. Yeast. 2002 Mar 15;19(4):341-9. DMMOA2X RU https://pubmed.ncbi.nlm.nih.gov/11870857 DMMQGPE DI DMMQGPE DMMQGPE DN Zenocutuzomab DMMQGPE TI TT6EO5L DMMQGPE TN Erbb2 tyrosine kinase receptor (HER2) DMMQGPE MA Inhibitor DMMQGPE RN Clinical pipeline report, company report or official report of Merus. DMMQGPE RU https://merus.nl/pipeline/ DMMQGPE DI DMMQGPE DMMQGPE DN Zenocutuzomab DMMQGPE TI TTDC8N2 DMMQGPE TN Erbb3 tyrosine kinase receptor (Erbb-3) DMMQGPE MA Inhibitor DMMQGPE RN Clinical pipeline report, company report or official report of Merus. DMMQGPE RU https://merus.nl/pipeline/ DMMQYL9 DI DMMQYL9 DMMQYL9 DN CC-223 DMMQYL9 TI TTCJG29 DMMQYL9 TN Serine/threonine-protein kinase mTOR (mTOR) DMMQYL9 MA Modulator DMMQYL9 RN CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305. DMMQYL9 RU https://pubmed.ncbi.nlm.nih.gov/25855786 DMMTDK1 DI DMMTDK1 DMMTDK1 DN CART-HER-2 DMMTDK1 TI TT6EO5L DMMTDK1 TN Erbb2 tyrosine kinase receptor (HER2) DMMTDK1 MA CAR-T-Cell-Therapy DMMTDK1 RN ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors DMMTDK1 RU https://clinicaltrials.gov/ct2/show/NCT01935843 DMMUCH0 DI DMMUCH0 DMMUCH0 DN SHR2554 DMMUCH0 TI TT9MZCQ DMMUCH0 TN Enhancer of zeste homolog 2 (EZH2) DMMUCH0 MA Inhibitor DMMUCH0 RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMMUCH0 RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMMUSHR DI DMMUSHR DMMUSHR DN Anti-CD19/22-CAR vector-transduced T cells DMMUSHR TI TTM6QSK DMMUSHR TN B-cell receptor CD22 (CD22) DMMUSHR MA CAR-T-Cell-Therapy(Dual specific) DMMUSHR RN ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 DMMUSHR RU https://clinicaltrials.gov/ct2/show/NCT03185494 DMMUSHR DI DMMUSHR DMMUSHR DN Anti-CD19/22-CAR vector-transduced T cells DMMUSHR TI TTW640A DMMUSHR TN B-lymphocyte surface antigen B4 (CD19) DMMUSHR MA CAR-T-Cell-Therapy(Dual specific) DMMUSHR RN ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 DMMUSHR RU https://clinicaltrials.gov/ct2/show/NCT03185494 DMMVWSY DI DMMVWSY DMMVWSY DN CK-101 DMMVWSY TI TTG96HZ DMMVWSY TN EGFR messenger RNA (EGFR mRNA) DMMVWSY MA Inhibitor DMMVWSY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMVWSY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMZSIB DI DMMZSIB DMMZSIB DN Interferon alpha 5 DMMZSIB TI TTLHGSF DMMZSIB TN Interferon-alpha 5 (IFNA5) DMMZSIB MA Modulator DMMZSIB RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMMZSIB RU https://pubmed.ncbi.nlm.nih.gov/19319841 DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TT8NGED DMN0EMP TN Prostaglandin G/H synthase 1 (COX-1) DMN0EMP MA Inhibitor DMN0EMP RN Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82. DMN0EMP RU https://pubmed.ncbi.nlm.nih.gov/15568761 DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TTPZ7AG DMN0EMP TN Oxidoreductase unspecific (OR) DMN0EMP MA Modulator DMN0EMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMN0EMP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TTSJH2W DMN0EMP TN Mitochondrial protein unspecific (MP) DMN0EMP MA Modulator DMN0EMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMN0EMP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMN0ZQ5 DI DMN0ZQ5 DMN0ZQ5 DN OTSGC-A24 DMN0ZQ5 TI TT2Q6G1 DMN0ZQ5 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMN0ZQ5 RN J Clin Oncol 33, 2015 (suppl 3; abstr 65). DMN0ZQ5 RU http://meetinglibrary.asco.org/content/140443-158 DMN0ZQ5 DI DMN0ZQ5 DMN0ZQ5 DN OTSGC-A24 DMN0ZQ5 TI TTUTJGQ DMN0ZQ5 TN Vascular endothelial growth factor receptor 2 (KDR) DMN0ZQ5 RN J Clin Oncol 33, 2015 (suppl 3; abstr 65). DMN0ZQ5 RU http://meetinglibrary.asco.org/content/140443-158 DMN2FS3 DI DMN2FS3 DMN2FS3 DN EPZ-5676 DMN2FS3 TI TTSZ8T1 DMN2FS3 TN Histone-lysine N-methyltransferase (HLNM) DMN2FS3 MA Modulator DMN2FS3 RN Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 August 8; 122(6): 1017-1025. DMN2FS3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739029/ DMN3C2I DI DMN3C2I DMN3C2I DN CAR-T cells targeting EphA2 DMN3C2I TI TTRJB2G DMN3C2I TN Ephrin type-A receptor 2 (EPHA2) DMN3C2I MA CAR-T-Cell-Therapy DMN3C2I RN ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients DMN3C2I RU https://clinicaltrials.gov/ct2/show/NCT02575261 DMN62MP DI DMN62MP DMN62MP DN WASP gene therapy DMN62MP TI TTE8T73 DMN62MP TN Wiskott-Aldrich syndrome protein (WAS) DMN62MP MA Modulator DMN62MP RN ClinicalTrials.gov (NCT01347242) Gene Therapy for Wiskott-Aldrich Syndrome (WAS). U.S. National Institutes of Health. DMN62MP RU https://clinicaltrials.gov/ct2/show/NCT01347242 DMN7QBE DI DMN7QBE DMN7QBE DN GANTACURIUM CHLORIDE DMN7QBE TI TTJSZTB DMN7QBE TN Nicotinic acetylcholine receptor (nAChR) DMN7QBE MA Modulator DMN7QBE RN Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 April; 112(4): 892-899. DMN7QBE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854830/ DMNHE43 DI DMNHE43 DMNHE43 DN HTU-PA DMNHE43 TI TTGY7WI DMNHE43 TN Urokinase-type plasminogen activator (PLAU) DMNHE43 MA Activator DMNHE43 RN Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7. DMNHE43 RU https://pubmed.ncbi.nlm.nih.gov/2936742 DMNHZS4 DI DMNHZS4 DMNHZS4 DN IMX-110 DMNHZS4 TI TTH8FZW DMNHZS4 TN Signal transducer and activator of transcription 3 (STAT3) DMNHZS4 MA Inhibitor DMNHZS4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNHZS4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNKLZM DI DMNKLZM DMNKLZM DN TgAAG76 DMNKLZM TI TTBOH16 DMNKLZM TN Retinal pigment epithelium protein (RPE65) DMNKLZM MA Modulator DMNKLZM RN tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7. DMNKLZM RU https://pubmed.ncbi.nlm.nih.gov/20677098 DMNMV0D DI DMNMV0D DMNMV0D DN JAB-3312 DMNMV0D TI TT7WUAV DMNMV0D TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMNMV0D MA Inhibitor DMNMV0D RN Clinical pipeline report, company report or official report of AbbVie. DMNMV0D RU https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html DMNTP23 DI DMNTP23 DMNTP23 DN Anti-CD19-CAR-T cells DMNTP23 TI TTW640A DMNTP23 TN B-lymphocyte surface antigen B4 (CD19) DMNTP23 MA CAR-T-Cell-Therapy DMNTP23 RN ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia DMNTP23 RU https://clinicaltrials.gov/ct2/show/NCT02672501 DMNV8SY DI DMNV8SY DMNV8SY DN SNN-0029 DMNV8SY TI TTOHSBA DMNV8SY TN Vascular endothelial growth factor A (VEGFA) DMNV8SY MA Modulator DMNV8SY RN Clinical pipeline report, company report or official report of Neuronova. DMNV8SY RU http://www.neuronova.com/index.php?option=com_content&task=view&id=40&Itemid=71 DMNXLOT DI DMNXLOT DMNXLOT DN ALAMIFOVIR DMNXLOT TI TTMR83K DMNXLOT TN Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS) DMNXLOT MA Modulator DMNXLOT RN Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine. Correction in: Antimicrob Agents Chemother. 2013 November; 57(11): 5788. DMNXLOT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754288/ DMNZ6VA DI DMNZ6VA DMNZ6VA DN Erythropoietin-transfected autologous cell therapy DMNZ6VA TI TTQG4NR DMNZ6VA TN Erythropoietin (EPO) DMNZ6VA MA Modulator DMNZ6VA RN Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. DMNZ6VA RU https://pubmed.ncbi.nlm.nih.gov/19088705 DMNZ7F2 DI DMNZ7F2 DMNZ7F2 DN CD19.CAR-T cells DMNZ7F2 TI TTW640A DMNZ7F2 TN B-lymphocyte surface antigen B4 (CD19) DMNZ7F2 MA CAR-T-Cell-Therapy DMNZ7F2 RN ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma DMNZ7F2 RU https://clinicaltrials.gov/ct2/show/NCT02652910 DMNZJAE DI DMNZJAE DMNZJAE DN AAV-CNGA3 DMNZJAE TI TTW0QOV DMNZJAE TN Cyclic nucleotide-gated channel alpha-3 (CNGA3) DMNZJAE RN Clinical pipeline report, company report or official report of MeiraGTx. DMNZJAE RU https://meiragtx.com/research-development/pipeline/ DMOCHVE DI DMOCHVE DMOCHVE DN SL-401 DMOCHVE TI TTPYS82 DMOCHVE TN Interleukin 3 receptor (CSF2RB) DMOCHVE MA Inhibitor DMOCHVE RN Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. DMOCHVE RU https://pubmed.ncbi.nlm.nih.gov/24859366 DMODTX5 DI DMODTX5 DMODTX5 DN BDTX-189 DMODTX5 TI TT6EO5L DMODTX5 TN Erbb2 tyrosine kinase receptor (HER2) DMODTX5 MA Inhibitor DMODTX5 RN Clinical pipeline report, company report or official report of Black Diamond Therapeutics. DMODTX5 RU https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/ DMODTX5 DI DMODTX5 DMODTX5 DN BDTX-189 DMODTX5 TI TTGKNB4 DMODTX5 TN Epidermal growth factor receptor (EGFR) DMODTX5 MA Inhibitor DMODTX5 RN Clinical pipeline report, company report or official report of Black Diamond Therapeutics. DMODTX5 RU https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/ DMOI5PB DI DMOI5PB DMOI5PB DN CARCIK-CD19 DMOI5PB TI TTW640A DMOI5PB TN B-lymphocyte surface antigen B4 (CD19) DMOI5PB MA CAR-T-Cell-Therapy DMOI5PB RN ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT DMOI5PB RU https://clinicaltrials.gov/ct2/show/NCT03389035 DMOKVJD DI DMOKVJD DMOKVJD DN ODM-207 DMOKVJD TI TTE4BSY DMOKVJD TN Bromodomain and extraterminal domain protein (BET) DMOKVJD MA Inhibitor DMOKVJD RN First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736. DMOKVJD RU https://pubmed.ncbi.nlm.nih.gov/32989226 DMON4IL DI DMON4IL DMON4IL DN TG100-115 DMON4IL TI TTHBTOP DMON4IL TN PI3-kinase gamma (PIK3CG) DMON4IL MA Inhibitor DMON4IL RN Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. DMON4IL RU https://pubmed.ncbi.nlm.nih.gov/19056934 DMOPVET DI DMOPVET DMOPVET DN ADXS-PSA DMOPVET TI TTS78AZ DMOPVET TN Prostate specific antigen (KLK3) DMOPVET MA Modulator DMOPVET RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DMOPVET RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DMOPVIQ DI DMOPVIQ DMOPVIQ DN AVX701 DMOPVIQ TI TTY6DTE DMOPVIQ TN Carcinoembryonic antigen CEA (CD66e) DMOPVIQ MA Modulator DMOPVIQ RN Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71. DMOPVIQ RU https://pubmed.ncbi.nlm.nih.gov/21952287 DMOUW65 DI DMOUW65 DMOUW65 DN PRX-102 DMOUW65 TI TTIS03D DMOUW65 TN Alpha-galactosidase A (GLA) DMOUW65 MA Modulator DMOUW65 RN Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67. DMOUW65 RU https://pubmed.ncbi.nlm.nih.gov/25155442 DMOVF6E DI DMOVF6E DMOVF6E DN Humanized CD19 CAR-T cells DMOVF6E TI TTW640A DMOVF6E TN B-lymphocyte surface antigen B4 (CD19) DMOVF6E MA CAR-T-Cell-Therapy DMOVF6E RN ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia DMOVF6E RU https://clinicaltrials.gov/ct2/show/NCT03275493 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTADRX7 DMOYS1N TN Insulin receptor substrate-1 (IRS1) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTH8FZW DMOYS1N TN Signal transducer and activator of transcription 3 (STAT3) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTF95B8 DMOYS1N TN Insulin receptor substrate 2 (IRS2) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMPAZ3U DI DMPAZ3U DMPAZ3U DN AU105 DMPAZ3U TI TT6EO5L DMPAZ3U TN Erbb2 tyrosine kinase receptor (HER2) DMPAZ3U MA Immunomodulator DMPAZ3U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPAZ3U RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPB9OD DI DMPB9OD DMPB9OD DN OBI-999 DMPB9OD TI TT4UXTG DMPB9OD TN Globohexaosylceramide (Globo H) DMPB9OD RN Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132. DMPB9OD RU https://pubmed.ncbi.nlm.nih.gov/33722855 DMPFGL8 DI DMPFGL8 DMPFGL8 DN BAL-101553 DMPFGL8 TI TTYFKSZ DMPFGL8 TN Tubulin beta (TUBB) DMPFGL8 MA Inhibitor DMPFGL8 RN Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. DMPFGL8 RU https://pubmed.ncbi.nlm.nih.gov/25407467 DMPFGL8 DI DMPFGL8 DMPFGL8 DN BAL-101553 DMPFGL8 TI TTML2WA DMPFGL8 TN Tubulin (TUB) DMPFGL8 MA Inhibitor DMPFGL8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPFGL8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPJLS4 DI DMPJLS4 DMPJLS4 DN CAD-1883 DMPJLS4 TI TTKU9YD DMPJLS4 TN Calcium-activated potassium channel KCa2 (KCNN) DMPJLS4 MA Activator DMPJLS4 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMPJLS4 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMPK35H DI DMPK35H DMPK35H DN CAR-T cells targeting mesothelin DMPK35H TI TT4RXME DMPK35H TN Mesothelin (MSLN) DMPK35H MA CAR-T-Cell-Therapy DMPK35H RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DMPK35H RU https://clinicaltrials.gov/ct2/show/NCT02959151 DMPLBDF DI DMPLBDF DMPLBDF DN Omburtamab I-124 DMPLBDF TI TT6CQUM DMPLBDF TN B7 homolog 3 (CD276) DMPLBDF MA Inhibitor DMPLBDF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPLBDF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPMF6L DI DMPMF6L DMPMF6L DN Nepadutant DMPMF6L TI TTYO0A3 DMPMF6L TN Substance-K receptor (TACR2) DMPMF6L MA Antagonist DMPMF6L RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DMPMF6L RU https://pubmed.ncbi.nlm.nih.gov/17979603 DMPNR0J DI DMPNR0J DMPNR0J DN Muc1-specific gene-engineered T cells DMPNR0J TI TTBHFYQ DMPNR0J TN Mucin-1 (MUC1) DMPNR0J MA CAR-T-Cell-Therapy DMPNR0J RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMPNR0J RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMPS3I6 DI DMPS3I6 DMPS3I6 DN CD38 CAR T cells DMPS3I6 TI TTPURFN DMPS3I6 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMPS3I6 MA CAR-T-Cell-Therapy DMPS3I6 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMPS3I6 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMPWBM2 DI DMPWBM2 DMPWBM2 DN APG-2575 DMPWBM2 TI TTJGNVC DMPWBM2 TN Apoptosis regulator Bcl-2 (BCL-2) DMPWBM2 MA Inhibitor DMPWBM2 RN A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344. DMPWBM2 RU https://pubmed.ncbi.nlm.nih.gov/32093809 DMPWHU6 DI DMPWHU6 DMPWHU6 DN V81444 DMPWHU6 TI TTM2AOE DMPWHU6 TN Adenosine A2a receptor (ADORA2A) DMPWHU6 MA Antagonist DMPWHU6 RN Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74. DMPWHU6 RU https://pubmed.ncbi.nlm.nih.gov/24687255 DMPXOGD DI DMPXOGD DMPXOGD DN SAR-161271 DMPXOGD TI TTZOPHG DMPXOGD TN Insulin (INS) DMPXOGD MA Modulator DMPXOGD RN Clinical pipeline report, company report or official report of sanofi-aventis. DMPXOGD RU http://en.sanofi.com/img/content/study/TDU10987_summary.pdf DMPYW28 DI DMPYW28 DMPYW28 DN CG-806 DMPYW28 TI TTGM6VW DMPYW28 TN Tyrosine-protein kinase BTK (ATK) DMPYW28 MA Inhibitor DMPYW28 RN Clinical pipeline report, company report or official report of Aptose Biosciences. DMPYW28 RU https://www.aptose.com/product-pipeline/cg-806-for-b-cell DMPZE2G DI DMPZE2G DMPZE2G DN ZPL521 DMPZE2G TI TTT1JVS DMPZE2G TN Cytosolic phospholipase A2 (GIVA cPLA2) DMPZE2G MA Inhibitor DMPZE2G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPZE2G RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQ5EYJ DI DMQ5EYJ DMQ5EYJ DN ISA-P53-01 DMQ5EYJ TI TT7SBF5 DMQ5EYJ TN Cellular tumor antigen p53 (TP53) DMQ5EYJ RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMQ5EYJ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMQ8VUW DI DMQ8VUW DMQ8VUW DN FCN-437 DMQ8VUW TI TT0PG8F DMQ8VUW TN Cyclin-dependent kinase 4 (CDK4) DMQ8VUW MA Inhibitor DMQ8VUW RN Clinical pipeline report, company report or official report of Fochon Pharmaceuticals. DMQ8VUW RU http://fochon.com/what-we-do/fcn-411/ DMQ8VUW DI DMQ8VUW DMQ8VUW DN FCN-437 DMQ8VUW TI TTO0FDJ DMQ8VUW TN Cyclin-dependent kinase 6 (CDK6) DMQ8VUW MA Inhibitor DMQ8VUW RN Clinical pipeline report, company report or official report of Fochon Pharmaceuticals. DMQ8VUW RU http://fochon.com/what-we-do/fcn-411/ DMQB7SZ DI DMQB7SZ DMQB7SZ DN CD19 and CD22 CAR-T Cells DMQB7SZ TI TTM6QSK DMQB7SZ TN B-cell receptor CD22 (CD22) DMQB7SZ MA CAR-T-Cell-Therapy(Dual specific) DMQB7SZ RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMQB7SZ RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMQB7SZ DI DMQB7SZ DMQB7SZ DN CD19 and CD22 CAR-T Cells DMQB7SZ TI TTW640A DMQB7SZ TN B-lymphocyte surface antigen B4 (CD19) DMQB7SZ MA CAR-T-Cell-Therapy(Dual specific) DMQB7SZ RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMQB7SZ RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMQD6B9 DI DMQD6B9 DMQD6B9 DN Anti-HER2 CAR-T DMQD6B9 TI TT6EO5L DMQD6B9 TN Erbb2 tyrosine kinase receptor (HER2) DMQD6B9 MA CAR-T-Cell-Therapy DMQD6B9 RN ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer DMQD6B9 RU https://clinicaltrials.gov/ct2/show/NCT02713984 DMQE7TW DI DMQE7TW DMQE7TW DN CD19-CAR T cell DMQE7TW TI TTW640A DMQE7TW TN B-lymphocyte surface antigen B4 (CD19) DMQE7TW MA CAR-T-Cell-Therapy DMQE7TW RN ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL DMQE7TW RU https://clinicaltrials.gov/ct2/show/NCT03373071 DMQJ6YL DI DMQJ6YL DMQJ6YL DN CD19 CAR Gene Transduced T Lymphocytes DMQJ6YL TI TTW640A DMQJ6YL TN B-lymphocyte surface antigen B4 (CD19) DMQJ6YL MA CAR-T-Cell-Therapy DMQJ6YL RN ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes DMQJ6YL RU https://clinicaltrials.gov/ct2/show/NCT02134262 DMQN9ME DI DMQN9ME DMQN9ME DN LGH-447 DMQN9ME TI TT69J2Z DMQN9ME TN Serine/threonine-protein kinase pim-2 (PIM2) DMQN9ME MA Modulator DMQN9ME RN Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014 Apr 1;20(7):1834-45. DMQN9ME RU https://pubmed.ncbi.nlm.nih.gov/24474669 DMQO5UF DI DMQO5UF DMQO5UF DN INCB62079 DMQO5UF TI TT5BR7T DMQO5UF TN Fibroblast growth factor receptor 4 (FGFR4) DMQO5UF MA Inhibitor DMQO5UF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO5UF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQOW0H DI DMQOW0H DMQOW0H DN PP-1420 DMQOW0H TI TTIB95A DMQOW0H TN Pancreatic hormone (PH) DMQOW0H MA Modulator DMQOW0H RN Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9. DMQOW0H RU https://pubmed.ncbi.nlm.nih.gov/21834938 DMQS5DY DI DMQS5DY DMQS5DY DN TRX-518 DMQS5DY TI TTG6LA7 DMQS5DY TN Activation-inducible TNFR family receptor (TNFRSF18) DMQS5DY RN Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5. DMQS5DY RU https://pubmed.ncbi.nlm.nih.gov/26153987 DMQSF5C DI DMQSF5C DMQSF5C DN FBT-A05 DMQSF5C TI TTUE541 DMQSF5C TN Leukocyte surface antigen Leu-16 (CD20) DMQSF5C RN Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160. DMQSF5C RU https://pubmed.ncbi.nlm.nih.gov/23815981 DMQU4EI DI DMQU4EI DMQU4EI DN Galnobax DMQU4EI TI TTR6W5O DMQU4EI TN Adrenergic receptor beta-1 (ADRB1) DMQU4EI MA Agonist DMQU4EI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQU4EI RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMQWI7V DI DMQWI7V DMQWI7V DN Hematopoietic stem cell gene therapy DMQWI7V TI TTE8T73 DMQWI7V TN Wiskott-Aldrich syndrome protein (WAS) DMQWI7V MA Modulator DMQWI7V RN Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5. DMQWI7V RU https://pubmed.ncbi.nlm.nih.gov/17078381 DMQXU4C DI DMQXU4C DMQXU4C DN Anti-CD19-CAR vector-transduced T cells DMQXU4C TI TTW640A DMQXU4C TN B-lymphocyte surface antigen B4 (CD19) DMQXU4C MA CAR-T-Cell-Therapy DMQXU4C RN ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma DMQXU4C RU https://clinicaltrials.gov/ct2/show/NCT02081937 DMQZJ3B DI DMQZJ3B DMQZJ3B DN Anti-HIV ribozyme therapy DMQZJ3B TI TTT3ZC9 DMQZJ3B TN Human immunodeficiency virus Tat protein (HIV tat) DMQZJ3B MA Modulator DMQZJ3B RN Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98. DMQZJ3B RU https://pubmed.ncbi.nlm.nih.gov/15017082 DMR3VCY DI DMR3VCY DMR3VCY DN MP0250 DMR3VCY TI TTOHSBA DMR3VCY TN Vascular endothelial growth factor A (VEGFA) DMR3VCY MA Inhibitor DMR3VCY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3VCY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR3VCY DI DMR3VCY DMR3VCY DN MP0250 DMR3VCY TI TT4V2JM DMR3VCY TN Hepatocyte growth factor (HGF) DMR3VCY MA Inhibitor DMR3VCY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3VCY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR65X7 DI DMR65X7 DMR65X7 DN TC-110 DMR65X7 TI TTW640A DMR65X7 TN B-lymphocyte surface antigen B4 (CD19) DMR65X7 RN Clinical pipeline report, company report or official report of TCR2 Therapeutics. DMR65X7 RU https://www.tcr2.com/hematological-malignancies#tc110 DMR8AHJ DI DMR8AHJ DMR8AHJ DN MOR-202 DMR8AHJ TI TTPURFN DMR8AHJ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMR8AHJ RN Clinical pipeline report, company report or official report of MorphoSys. DMR8AHJ RU https://www.morphosys.com/pipeline/proprietary-product-portfolio/mor202 DMR8EPF DI DMR8EPF DMR8EPF DN BIIB-087 DMR8EPF TI TTT2CZY DMR8EPF TN Retinoschisin (RS1) DMR8EPF RN ClinicalTrials.gov (NCT02416622) Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS). U.S. National Institutes of Health. DMR8EPF RU https://clinicaltrials.gov/ct2/show/NCT02416622 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTVDSZ0 DMR9H6B TN Poly [ADP-ribose] polymerase 1 (PARP1) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTQ4V96 DMR9H6B TN Poly [ADP-ribose] polymerase 2 (PARP2) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTU1SOM DMR9H6B TN Microtubule polymerization (MicroTu poly) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMRABOS DI DMRABOS DMRABOS DN WX-554 DMRABOS TI TTROQ37 DMRABOS TN MAPK/ERK kinase kinase (MAP3K) DMRABOS MA Modulator DMRABOS RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMRABOS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMRC7PI DI DMRC7PI DMRC7PI DN SGN-CD33A DMRC7PI TI TTJVYO3 DMRC7PI TN Myeloid cell surface antigen CD33 (CD33) DMRC7PI RN SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63. DMRC7PI RU https://pubmed.ncbi.nlm.nih.gov/23770776 DMRE0LU DI DMRE0LU DMRE0LU DN REGN5459 DMRE0LU TI TTUN7MC DMRE0LU TN T-cell surface glycoprotein CD3 (CD3) DMRE0LU MA Inhibitor DMRE0LU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DMRE0LU RU https://www.regeneron.com/science/pipeline DMRE0LU DI DMRE0LU DMRE0LU DN REGN5459 DMRE0LU TI TTZ3P4W DMRE0LU TN B-cell maturation protein (TNFRSF17) DMRE0LU MA Inhibitor DMRE0LU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DMRE0LU RU https://www.regeneron.com/science/pipeline DMREQCF DI DMREQCF DMREQCF DN CAR-T Cells targeting EpCAM DMREQCF TI TTZ8WH4 DMREQCF TN Tumor-associated calcium signal transducer 1 (EPCAM) DMREQCF MA CAR-T-Cell-Therapy DMREQCF RN ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer DMREQCF RU https://clinicaltrials.gov/ct2/show/NCT03013712 DMRET3H DI DMRET3H DMRET3H DN AG-013958 DMRET3H TI TTVJ1D8 DMRET3H TN Vascular endothelial growth factor receptor (VEGFR) DMRET3H MA Inhibitor DMRET3H RN Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933. DMRET3H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995411/ DMRHOFB DI DMRHOFB DMRHOFB DN Ferritarg P DMRHOFB TI TT975ZT DMRHOFB TN Ferritin (FTH1) DMRHOFB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019964) DMRHOFB RU http://adisinsight.springer.com/drugs/800019964 DMRJ3ND DI DMRJ3ND DMRJ3ND DN CD19 and CD20 CAR-T Cells DMRJ3ND TI TTUE541 DMRJ3ND TN Leukocyte surface antigen Leu-16 (CD20) DMRJ3ND MA CAR-T-Cell-Therapy(Dual specific) DMRJ3ND RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMRJ3ND RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMRJ3ND DI DMRJ3ND DMRJ3ND DN CD19 and CD20 CAR-T Cells DMRJ3ND TI TTW640A DMRJ3ND TN B-lymphocyte surface antigen B4 (CD19) DMRJ3ND MA CAR-T-Cell-Therapy(Dual specific) DMRJ3ND RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMRJ3ND RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMRJK26 DI DMRJK26 DMRJK26 DN UCART019 DMRJK26 TI TTW640A DMRJK26 TN B-lymphocyte surface antigen B4 (CD19) DMRJK26 MA CAR-T-Cell-Therapy DMRJK26 RN ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma DMRJK26 RU https://clinicaltrials.gov/ct2/show/NCT03166878 DMRLV7G DI DMRLV7G DMRLV7G DN INCB59872 DMRLV7G TI TTNR0UQ DMRLV7G TN Lysine-specific histone demethylase 1 (LSD) DMRLV7G MA Inhibitor DMRLV7G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLV7G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRS58M DI DMRS58M DMRS58M DN Avrina DMRS58M TI TTSXVID DMRS58M TN Nuclear factor NF-kappa-B (NFKB) DMRS58M MA Modulator DMRS58M RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRS58M RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRSI1O DI DMRSI1O DMRSI1O DN ChronVac-C hepatitis C DNA vaccine DMRSI1O TI TTZYW5V DMRSI1O TN Hepatitis C virus Deoxyribonucleic acid (HCV DNA) DMRSI1O RN Clinical pipeline report, company report or official report of Inovio Pharmaceuticals. DMRSI1O RU http://ir.inovio.com/news/news-releases/news-releases-details/2013/Inovio-Collaborator-ChronTech-Reports-Interim-Phase-II-Clinical-Study-Results-from-ChronVac-C-Vaccine-for-Hepatitis-C-Infection/default.aspx DMRXQCL DI DMRXQCL DMRXQCL DN DT388IL-3 DMRXQCL TI TTPYS82 DMRXQCL TN Interleukin 3 receptor (CSF2RB) DMRXQCL MA Inhibitor DMRXQCL RN Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806. DMRXQCL RU https://pubmed.ncbi.nlm.nih.gov/15614527 DMS0L6J DI DMS0L6J DMS0L6J DN NY-ESO-TCR DMS0L6J TI TT7AKW1 DMS0L6J TN T-cell receptor (TCR) DMS0L6J MA CAR-T-Cell-Therapy DMS0L6J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS0L6J RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMS19IH DI DMS19IH DMS19IH DN MBO7133 DMS19IH TI TTUTN1I DMS19IH TN Human Deoxyribonucleic acid (hDNA) DMS19IH MA Binder DMS19IH RN Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004. DMS19IH RU http://www.dtic.mil/get-tr-doc/pdf?AD=ADA431390 DMS1NMO DI DMS1NMO DMS1NMO DN SCRI-huCAR19v1 DMS1NMO TI TTW640A DMS1NMO TN B-lymphocyte surface antigen B4 (CD19) DMS1NMO MA CAR-T-Cell-Therapy DMS1NMO RN ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma DMS1NMO RU https://clinicaltrials.gov/ct2/show/NCT03684889 DMS326R DI DMS326R DMS326R DN Anti-CD19 CAR T cells DMS326R TI TTW640A DMS326R TN B-lymphocyte surface antigen B4 (CD19) DMS326R MA CAR-T-Cell-Therapy DMS326R RN ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma DMS326R RU https://clinicaltrials.gov/ct2/show/NCT02842138 DMS5OL0 DI DMS5OL0 DMS5OL0 DN CD56 CAR T cells DMS5OL0 TI TTVXPHT DMS5OL0 TN Neural cell adhesion molecule 1 (NCAM1) DMS5OL0 MA CAR-T-Cell-Therapy DMS5OL0 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMS5OL0 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMSDZ8U DI DMSDZ8U DMSDZ8U DN Rintatolimod DMSDZ8U TI TT1CN09 DMSDZ8U TN HUMAN toll-like receptor 3 (TLR3) DMSDZ8U MA Agonist DMSDZ8U RN Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. DMSDZ8U RU https://pubmed.ncbi.nlm.nih.gov/27045557 DMSFEOC DI DMSFEOC DMSFEOC DN Anti-CD19 CAR-T cells DMSFEOC TI TTW640A DMSFEOC TN B-lymphocyte surface antigen B4 (CD19) DMSFEOC MA CAR-T-Cell-Therapy DMSFEOC RN ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy DMSFEOC RU https://clinicaltrials.gov/ct2/show/NCT02782351 DMSGM2L DI DMSGM2L DMSGM2L DN PBCAR269A DMSGM2L TI TTZ3P4W DMSGM2L TN B-cell maturation protein (TNFRSF17) DMSGM2L RN Clinical pipeline report, company report or official report of Precision Biosciences. DMSGM2L RU https://precisionbiosciences.com/pipeline/ DMSJ54W DI DMSJ54W DMSJ54W DN PC14586 DMSJ54W TI TTJC50M DMSJ54W TN P53 Y220C mutant (TP53 Y220C) DMSJ54W MA Reactivator DMSJ54W RN Clinical pipeline report, company report or official report of PMV Pharmaceuticals. DMSJ54W RU https://www.pmvpharma.com/pipeline/ DMSOQ6E DI DMSOQ6E DMSOQ6E DN AT-342 DMSOQ6E TI TT34ZAF DMSOQ6E TN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMSOQ6E MA Replacement DMSOQ6E RN ClinicalTrials.gov (NCT03223194) Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS). U.S. National Institutes of Health. DMSOQ6E RU https://clinicaltrials.gov/ct2/show/NCT03223194 DMSOX57 DI DMSOX57 DMSOX57 DN SJCAR19 DMSOX57 TI TTW640A DMSOX57 TN B-lymphocyte surface antigen B4 (CD19) DMSOX57 MA CAR-T-Cell-Therapy DMSOX57 RN ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia DMSOX57 RU https://clinicaltrials.gov/ct2/show/NCT03573700 DMST6A3 DI DMST6A3 DMST6A3 DN Sodium pyruvate DMST6A3 TI TTULV0X DMST6A3 TN Reactive oxygen species (ROS) DMST6A3 MA Antagonist DMST6A3 RN A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. DMST6A3 RU https://pubmed.ncbi.nlm.nih.gov/16766717 DMST6A3 DI DMST6A3 DMST6A3 DN Sodium pyruvate DMST6A3 TI TTZHA0O DMST6A3 TN Carbonic anhydrase IV (CA-IV) DMST6A3 MA Inhibitor DMST6A3 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8. DMST6A3 RU https://pubmed.ncbi.nlm.nih.gov/15664815 DMSTEFK DI DMSTEFK DMSTEFK DN SKB264 DMSTEFK TI TTP2HE5 DMSTEFK TN Tumor associated calcium signal transducer 2 (TACSTD2) DMSTEFK RN ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health. DMSTEFK RU https://clinicaltrials.gov/ct2/show/NCT04152499 DMT17XU DI DMT17XU DMT17XU DN 131I-radretumab DMT17XU TI TTBVIQC DMT17XU TN Integrin beta-1 (ITGB1) DMT17XU RN Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43. DMT17XU RU https://pubmed.ncbi.nlm.nih.gov/24777501 DMT2FAP DI DMT2FAP DMT2FAP DN AZD-2836 DMT2FAP TI TTCJ2X8 DMT2FAP TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMT2FAP MA Modulator DMT2FAP RN TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711. DMT2FAP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/ DMT89K2 DI DMT89K2 DMT89K2 DN CAR-T cells targeting GD2 DMT89K2 TI TT80ARU DMT89K2 TN Ganglioside GD2 (GD2) DMT89K2 MA CAR-T-Cell-Therapy DMT89K2 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMT89K2 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMTAODR DI DMTAODR DMTAODR DN NBE-002 DMTAODR TI TTDEJAU DMTAODR TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMTAODR RN Clinical pipeline report, company report or official report of NBE-Therapeutics. DMTAODR RU https://www.nbe-therapeutics.com/technology/overview DMTCADJ DI DMTCADJ DMTCADJ DN McN3377 DMTCADJ TI TTHS256 DMTCADJ TN Metabotropic glutamate receptor 5 (mGluR5) DMTCADJ MA Modulator DMTCADJ RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTCADJ RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTEY1L DI DMTEY1L DMTEY1L DN BMS-986315 DMTEY1L TI TTC4IMS DMTEY1L TN NKG2-A/B-activating NK receptor (NKG2A) DMTEY1L MA Inhibitor DMTEY1L RN ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. DMTEY1L RU https://clinicaltrials.gov/ct2/show/NCT04349267 DMTH75R DI DMTH75R DMTH75R DN OXY-111A DMTH75R TI TTQO71U DMTH75R TN Hemoglobin (HB) DMTH75R MA Enhancer DMTH75R RN Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71. DMTH75R RU https://pubmed.ncbi.nlm.nih.gov/9753039 DMTJQ8S DI DMTJQ8S DMTJQ8S DN GS-9219 DMTJQ8S TI TTIU7X1 DMTJQ8S TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMTJQ8S MA Inhibitor DMTJQ8S RN GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32. DMTJQ8S RU https://pubmed.ncbi.nlm.nih.gov/18451250 DMTJWIQ DI DMTJWIQ DMTJWIQ DN LY2940680 DMTJWIQ TI TT8J1S3 DMTJWIQ TN Smoothened homolog (SMO) DMTJWIQ MA Modulator DMTJWIQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTJWIQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTMVEW DI DMTMVEW DMTMVEW DN JCAR014 DMTMVEW TI TTW640A DMTMVEW TN B-lymphocyte surface antigen B4 (CD19) DMTMVEW MA CAR-T-Cell-Therapy DMTMVEW RN ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma DMTMVEW RU https://clinicaltrials.gov/ct2/show/NCT02706405 DMTO9VF DI DMTO9VF DMTO9VF DN Anti-CD22-CAR-transduced T cells DMTO9VF TI TTM6QSK DMTO9VF TN B-cell receptor CD22 (CD22) DMTO9VF MA CAR-T-Cell-Therapy DMTO9VF RN ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies DMTO9VF RU https://clinicaltrials.gov/ct2/show/NCT03262298 DMTOMWB DI DMTOMWB DMTOMWB DN BI 1206 DMTOMWB TI TT5RWKQ DMTOMWB TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMTOMWB RN Clinical pipeline report, company report or official report of BioInvent. DMTOMWB RU https://www.bioinvent.com/pipeline/bi-1206-in-solid-tumors/ DMTQIB2 DI DMTQIB2 DMTQIB2 DN Anti-MUC1 CAR-T cells DMTQIB2 TI TTBHFYQ DMTQIB2 TN Mucin-1 (MUC1) DMTQIB2 MA CAR-T-Cell-Therapy DMTQIB2 RN ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor DMTQIB2 RU https://clinicaltrials.gov/ct2/show/NCT02617134 DMTS51C DI DMTS51C DMTS51C DN AGTC-501 DMTS51C TI TTHBDA9 DMTS51C TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DMTS51C RN ClinicalTrials.gov (NCT03316560) Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health. DMTS51C RU https://clinicaltrials.gov/ct2/show/NCT03316560 DMTV42K DI DMTV42K DMTV42K DN G1 DMTV42K TI TTDSB34 DMTV42K TN G-protein coupled estrogen receptor 1 (GPER1) DMTV42K MA Agonist DMTV42K RN Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12. DMTV42K RU https://pubmed.ncbi.nlm.nih.gov/16520733 DMTV4L7 DI DMTV4L7 DMTV4L7 DN CHS-828 DMTV4L7 TI TTD1WIG DMTV4L7 TN Nicotinamide phosphoribosyltransferase (NAMPT) DMTV4L7 MA Inhibitor DMTV4L7 RN Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. DMTV4L7 RU https://pubmed.ncbi.nlm.nih.gov/18201551 DMTVXBY DI DMTVXBY DMTVXBY DN Anti-CD38 CAR-T cells DMTVXBY TI TTPURFN DMTVXBY TN Cyclic ADP-ribose hydrolase 1 (CD38) DMTVXBY MA CAR-T-Cell-Therapy DMTVXBY RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMTVXBY RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMTY96S DI DMTY96S DMTY96S DN Eptacog beta DMTY96S TI TTLPJWH DMTY96S TN Thioredoxin reductase (PRDX5) DMTY96S MA Inhibitor DMTY96S RN APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. DMTY96S RU https://pubmed.ncbi.nlm.nih.gov/24157875 DMTZSPJ DI DMTZSPJ DMTZSPJ DN Anti-CD30-CAR-transduced T cells DMTZSPJ TI TT2GM5R DMTZSPJ TN Lymphocyte activation antigen CD30 (TNFRSF8) DMTZSPJ MA CAR-T-Cell-Therapy DMTZSPJ RN ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies DMTZSPJ RU https://clinicaltrials.gov/ct2/show/NCT02958410 DMU348C DI DMU348C DMU348C DN CD19 CART DMU348C TI TTW640A DMU348C TN B-lymphocyte surface antigen B4 (CD19) DMU348C MA CAR-T-Cell-Therapy DMU348C RN ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. DMU348C RU https://clinicaltrials.gov/ct2/show/NCT03146533 DMU3PD7 DI DMU3PD7 DMU3PD7 DN RGX-121 DMU3PD7 TI TTNY2AP DMU3PD7 TN Iduronate 2-sulfatase (IDS) DMU3PD7 MA Replacement DMU3PD7 RN Clinical pipeline report, company report or official report of REGENXBIO. DMU3PD7 RU https://www.regenxbio.com/rgx-121/ DMU6MJ1 DI DMU6MJ1 DMU6MJ1 DN NAHE-001 DMU6MJ1 TI TTLHGSF DMU6MJ1 TN Interferon-alpha 5 (IFNA5) DMU6MJ1 MA Modulator DMU6MJ1 RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMU6MJ1 RU https://pubmed.ncbi.nlm.nih.gov/19319841 DMU6TG7 DI DMU6TG7 DMU6TG7 DN XMT-1592 DMU6TG7 TI TTQPZTM DMU6TG7 TN Sodium/phosphate cotransporter 2B (SLC34A2) DMU6TG7 RN Clinical pipeline report, company report or official report of Mersana Therapeutics. DMU6TG7 RU https://www.mersana.com/pipeline/xmt-1592/ DMU9BCD DI DMU9BCD DMU9BCD DN NS-018 DMU9BCD TI TTRMX3V DMU9BCD TN Janus kinase 2 (JAK-2) DMU9BCD MA Modulator DMU9BCD RN Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174. DMU9BCD RU https://pubmed.ncbi.nlm.nih.gov/24413068 DMUARWH DI DMUARWH DMUARWH DN CD19 CAR T Cells DMUARWH TI TTW640A DMUARWH TN B-lymphocyte surface antigen B4 (CD19) DMUARWH MA CAR-T-Cell-Therapy DMUARWH RN ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant DMUARWH RU https://clinicaltrials.gov/ct2/show/NCT01475058 DMUBEX4 DI DMUBEX4 DMUBEX4 DN CAR-T cells targeting MAGE-A4 DMUBEX4 TI TT9EQUY DMUBEX4 TN Melanoma-associated antigen 4 (MAGEA4) DMUBEX4 MA CAR-T-Cell-Therapy DMUBEX4 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMUBEX4 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMUBLC3 DI DMUBLC3 DMUBLC3 DN ABO-101 DMUBLC3 TI TTDM6HZ DMUBLC3 TN Alpha-N-acetylglucosaminidase (NAGLU) DMUBLC3 RN Clinical pipeline report, company report or official report of Abeona Therapeutics. DMUBLC3 RU https://www.abeonatherapeutics.com/science DMUGHWR DI DMUGHWR DMUGHWR DN WP-1066 DMUGHWR TI TTKAWRQ DMUGHWR TN JAK-STAT signaling pathway (JAK-STAT pathway) DMUGHWR MA Inhibitor DMUGHWR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7972). DMUGHWR RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7972 DMUGHWR DI DMUGHWR DMUGHWR DN WP-1066 DMUGHWR TI TTH8FZW DMUGHWR TN Signal transducer and activator of transcription 3 (STAT3) DMUGHWR MA Inhibitor DMUGHWR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUGHWR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUGMFN DI DMUGMFN DMUGMFN DN CXB-909 DMUGMFN TI TTDN3LF DMUGMFN TN Nerve growth factor (NGF) DMUGMFN MA Modulator DMUGMFN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUGMFN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUNM4D DI DMUNM4D DMUNM4D DN ESR0114 DMUNM4D TI TTGV6LY DMUNM4D TN Nuclear receptor ROR-gamma (RORG) DMUNM4D MA Inhibitor DMUNM4D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUNM4D RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMUP52Y DI DMUP52Y DMUP52Y DN SB-FIX DMUP52Y TI TTFEZ5Q DMUP52Y TN Coagulation factor IX (F9) DMUP52Y MA Replacement DMUP52Y RN ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health. DMUP52Y RU https://clinicaltrials.gov/ct2/show/NCT02695160 DMUS79V DI DMUS79V DMUS79V DN CART-138 cells DMUS79V TI TTYDSVG DMUS79V TN Syndecan-1 (SDC1) DMUS79V MA CAR-T-Cell-Therapy DMUS79V RN ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 DMUS79V RU https://clinicaltrials.gov/ct2/show/NCT01886976 DMUYFS1 DI DMUYFS1 DMUYFS1 DN 4SCAR19 and 4SCAR30 DMUYFS1 TI TT2GM5R DMUYFS1 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMUYFS1 MA CAR-T-Cell-Therapy(Dual specific) DMUYFS1 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMUYFS1 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMUYFS1 DI DMUYFS1 DMUYFS1 DN 4SCAR19 and 4SCAR30 DMUYFS1 TI TTW640A DMUYFS1 TN B-lymphocyte surface antigen B4 (CD19) DMUYFS1 MA CAR-T-Cell-Therapy(Dual specific) DMUYFS1 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMUYFS1 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMUZIRY DI DMUZIRY DMUZIRY DN Cal-1 DMUZIRY TI TT2CEJG DMUZIRY TN C-C chemokine receptor type 5 (CCR5) DMUZIRY MA Modulator DMUZIRY RN Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. DMUZIRY RU https://pubmed.ncbi.nlm.nih.gov/26015947 DMV1EA9 DI DMV1EA9 DMV1EA9 DN BIL010t DMV1EA9 TI TT473XN DMV1EA9 TN P2X purinoceptor 7 (P2RX7) DMV1EA9 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMV1EA9 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMV1SDA DI DMV1SDA DMV1SDA DN HM43239 DMV1SDA TI TTOU65C DMV1SDA TN Tyrosine-protein kinase SYK (SYK) DMV1SDA MA Inhibitor DMV1SDA RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DMV1SDA RU https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD DMV1SDA DI DMV1SDA DMV1SDA DN HM43239 DMV1SDA TI TTGJCWZ DMV1SDA TN Fms-like tyrosine kinase 3 (FLT-3) DMV1SDA MA Inhibitor DMV1SDA RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DMV1SDA RU https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD DMV5H0S DI DMV5H0S DMV5H0S DN Anti-C-met CAR-T cells DMV5H0S TI TTNDSF4 DMV5H0S TN Proto-oncogene c-Met (MET) DMV5H0S MA CAR-T-Cell-Therapy DMV5H0S RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMV5H0S RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMV6GX7 DI DMV6GX7 DMV6GX7 DN ONO-7475 DMV6GX7 TI TTO7LKR DMV6GX7 TN Tyrosine-protein kinase Mer (MERTK) DMV6GX7 MA Inhibitor DMV6GX7 RN Clinical pipeline report, company report or official report of Ono Pharmaceutical. DMV6GX7 RU https://www.ono-pharma.com/ir/library/pipeline.html DMV6GX7 DI DMV6GX7 DMV6GX7 DN ONO-7475 DMV6GX7 TI TTZPY6J DMV6GX7 TN Tyrosine-protein kinase UFO (AXL) DMV6GX7 MA Inhibitor DMV6GX7 RN Clinical pipeline report, company report or official report of Ono Pharmaceutical. DMV6GX7 RU https://www.ono-pharma.com/ir/library/pipeline.html DMV7Q6X DI DMV7Q6X DMV7Q6X DN APN-201 DMV7Q6X TI TT6RVLG DMV7Q6X TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMV7Q6X MA Modulator DMV7Q6X RN Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. DMV7Q6X RU https://pubmed.ncbi.nlm.nih.gov/18650828 DMV9QGW DI DMV9QGW DMV9QGW DN BPX-601 DMV9QGW TI TT9T4AV DMV9QGW TN Prostate stem cell antigen (PSCA) DMV9QGW MA CAR-T-Cell-Therapy DMV9QGW RN ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors DMV9QGW RU https://clinicaltrials.gov/ct2/show/NCT02744287 DMVFHL9 DI DMVFHL9 DMVFHL9 DN CAR-T cells targeting CD22 DMVFHL9 TI TTM6QSK DMVFHL9 TN B-cell receptor CD22 (CD22) DMVFHL9 MA CAR-T-Cell-Therapy DMVFHL9 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMVFHL9 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMVG4OC DI DMVG4OC DMVG4OC DN ZN-c5 DMVG4OC TI TTZAYWL DMVG4OC TN Estrogen receptor (ESR) DMVG4OC MA Degrader DMVG4OC RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DMVG4OC RU https://zentalis.com/our-pipeline/pipeline/ DMVKQT8 DI DMVKQT8 DMVKQT8 DN SALACINOL DMVKQT8 TI TTXWASR DMVKQT8 TN Intestinal maltase-glucoamylase (MGAM) DMVKQT8 MA Inhibitor DMVKQT8 RN Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8. DMVKQT8 RU https://pubmed.ncbi.nlm.nih.gov/20970346 DMVKQT8 DI DMVKQT8 DMVKQT8 DN SALACINOL DMVKQT8 TI TTLPC70 DMVKQT8 TN Lysosomal alpha-glucosidase (GAA) DMVKQT8 MA Inhibitor DMVKQT8 RN Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4. DMVKQT8 RU https://pubmed.ncbi.nlm.nih.gov/18547114 DMVNCSK DI DMVNCSK DMVNCSK DN ASC-101 DMVNCSK TI TT3C1VN DMVNCSK TN Enzyme unspecific (Enz) DMVNCSK MA Modulator DMVNCSK RN ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health. DMVNCSK RU https://clinicaltrials.gov/ct2/show/NCT01983761 DMVW1GY DI DMVW1GY DMVW1GY DN CART-19/BCMA DMVW1GY TI TTZ3P4W DMVW1GY TN B-cell maturation protein (TNFRSF17) DMVW1GY MA CAR-T-Cell-Therapy(Dual specific) DMVW1GY RN ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT DMVW1GY RU https://clinicaltrials.gov/ct2/show/NCT03455972 DMVW1GY DI DMVW1GY DMVW1GY DN CART-19/BCMA DMVW1GY TI TTW640A DMVW1GY TN B-lymphocyte surface antigen B4 (CD19) DMVW1GY MA CAR-T-Cell-Therapy(Dual specific) DMVW1GY RN ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT DMVW1GY RU https://clinicaltrials.gov/ct2/show/NCT03455972 DMVYTG7 DI DMVYTG7 DMVYTG7 DN BGB-283 DMVYTG7 TI TTWCGQT DMVYTG7 TN Serine/threonine-protein kinase B-raf (BRAF) DMVYTG7 MA Inhibitor DMVYTG7 RN BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97. DMVYTG7 RU https://pubmed.ncbi.nlm.nih.gov/26208524 DMVZ9XL DI DMVZ9XL DMVZ9XL DN 177Lu-labelled DOTA-JR11 DMVZ9XL TI TTOMNR9 DMVZ9XL TN Somatostatin receptor (SSTR) DMVZ9XL RN Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398. DMVZ9XL RU https://pubmed.ncbi.nlm.nih.gov/32859703 DMVZXIA DI DMVZXIA DMVZXIA DN ASTX029 DMVZXIA TI TT1MG9E DMVZXIA TN Extracellular signal-regulated kinase 1 (ERK1) DMVZXIA MA Inhibitor DMVZXIA RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMVZXIA RU https://astx.com/research-development/clinical-pipeline/ DMVZXIA DI DMVZXIA DMVZXIA DN ASTX029 DMVZXIA TI TT4TQBX DMVZXIA TN Extracellular signal-regulated kinase 2 (ERK2) DMVZXIA MA Inhibitor DMVZXIA RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMVZXIA RU https://astx.com/research-development/clinical-pipeline/ DMW340V DI DMW340V DMW340V DN CAR-T cells targeting PSMA DMW340V TI TT9G4N0 DMW340V TN Glutamate carboxypeptidase II (GCPII) DMW340V MA CAR-T-Cell-Therapy DMW340V RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DMW340V RU https://clinicaltrials.gov/ct2/show/NCT03356795 DMWCJ1F DI DMWCJ1F DMWCJ1F DN OT-58 DMWCJ1F TI TTVZJ7G DMWCJ1F TN Cystathionine beta-synthase (CBS) DMWCJ1F MA Replacement DMWCJ1F RN Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020 Jun;173:48-56. DMWCJ1F RU https://pubmed.ncbi.nlm.nih.gov/31857119 DMWE205 DI DMWE205 DMWE205 DN DCR-MYC DMWE205 TI TTVW4XU DMWE205 TN MYCBP messenger RNA (MYCBP mRNA) DMWE205 RN National Cancer Institute Drug Dictionary (drug id 759983). DMWE205 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=759983 DMWEJ0C DI DMWEJ0C DMWEJ0C DN FGF401 DMWEJ0C TI TT1KX2S DMWEJ0C TN FGFR4 messenger RNA (FGFR4 mRNA) DMWEJ0C MA Antagonist DMWEJ0C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWEJ0C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWIH59 DI DMWIH59 DMWIH59 DN T2c-003 DMWIH59 TI TTFBNVI DMWIH59 TN Aldose reductase (AKR1B1) DMWIH59 MA Modulator DMWIH59 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMWIH59 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMWLZI6 DI DMWLZI6 DMWLZI6 DN AZD0466 DMWLZI6 TI TTJGNVC DMWLZI6 TN Apoptosis regulator Bcl-2 (BCL-2) DMWLZI6 MA Inhibitor DMWLZI6 RN Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. DMWLZI6 RU https://pubmed.ncbi.nlm.nih.gov/33495510 DMWLZI6 DI DMWLZI6 DMWLZI6 DN AZD0466 DMWLZI6 TI TTU1E82 DMWLZI6 TN Apoptosis regulator Bcl-xL (BCL-xL) DMWLZI6 MA Inhibitor DMWLZI6 RN Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. DMWLZI6 RU https://pubmed.ncbi.nlm.nih.gov/33495510 DMWOYNT DI DMWOYNT DMWOYNT DN CART-BCMA cells DMWOYNT TI TTZ3P4W DMWOYNT TN B-cell maturation protein (TNFRSF17) DMWOYNT MA CAR-T-Cell-Therapy DMWOYNT RN ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma DMWOYNT RU https://clinicaltrials.gov/ct2/show/NCT03196414 DMWPD7N DI DMWPD7N DMWPD7N DN 177Lu-labelled PSMA-R2 DMWPD7N TI TT9G4N0 DMWPD7N TN Glutamate carboxypeptidase II (GCPII) DMWPD7N RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMWPD7N RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMWSGZU DI DMWSGZU DMWSGZU DN Epithalon DMWSGZU TI TTUJFD0 DMWSGZU TN Telomerase reverse transcriptase (TERT) DMWSGZU MA Modulator DMWSGZU RN Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2. DMWSGZU RU https://pubmed.ncbi.nlm.nih.gov/12937682 DMWYT4K DI DMWYT4K DMWYT4K DN CART-19 cells DMWYT4K TI TTW640A DMWYT4K TN B-lymphocyte surface antigen B4 (CD19) DMWYT4K MA CAR-T-Cell-Therapy DMWYT4K RN ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL DMWYT4K RU https://clinicaltrials.gov/ct2/show/NCT03544021 DMWZOD7 DI DMWZOD7 DMWZOD7 DN CNVN-202 DMWZOD7 TI TTJ8O14 DMWZOD7 TN Tumor suppressor candidate 2 (TUSC2) DMWZOD7 MA Suppressor DMWZOD7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766) DMWZOD7 RU http://adisinsight.springer.com/drugs/800018766 DMX0R1E DI DMX0R1E DMX0R1E DN CART-19/22 DMX0R1E TI TTM6QSK DMX0R1E TN B-cell receptor CD22 (CD22) DMX0R1E MA CAR-T-Cell-Therapy(Dual specific) DMX0R1E RN ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. DMX0R1E RU https://clinicaltrials.gov/ct2/show/NCT03614858 DMX0R1E DI DMX0R1E DMX0R1E DN CART-19/22 DMX0R1E TI TTW640A DMX0R1E TN B-lymphocyte surface antigen B4 (CD19) DMX0R1E MA CAR-T-Cell-Therapy(Dual specific) DMX0R1E RN ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. DMX0R1E RU https://clinicaltrials.gov/ct2/show/NCT03614858 DMX168L DI DMX168L DMX168L DN PLX2853 DMX168L TI TTRA6BO DMX168L TN Bromodomain-containing protein 4 (BRD4) DMX168L MA Inhibitor DMX168L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX168L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX3CNS DI DMX3CNS DMX3CNS DN Stargen DMX3CNS TI TTLB52K DMX3CNS TN ATP-binding cassette transporter A4 (ABCA4) DMX3CNS MA Modulator DMX3CNS RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMX3CNS RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-positive-dsmb-review-of-ongoing-retinostat-r-and-stargen-clinical-studies/ DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTLSWP6 DMXF9DM TN GTP cyclohydrolase-I (GCH1) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTN451K DMXF9DM TN Aromatic-L-amino-acid decarboxylase (DDC) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTUHP71 DMXF9DM TN Tyrosine 3-monooxygenase (TH) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXI03L DI DMXI03L DMXI03L DN Anti-mesothelin CAR transduced PBL DMXI03L TI TT4RXME DMXI03L TN Mesothelin (MSLN) DMXI03L MA CAR-T-Cell-Therapy DMXI03L RN ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer DMXI03L RU https://clinicaltrials.gov/ct2/show/NCT01583686 DMXI8CD DI DMXI8CD DMXI8CD DN TRC-253 DMXI8CD TI TTKPW01 DMXI8CD TN Androgen receptor messenger RNA (AR mRNA) DMXI8CD MA Antagonist DMXI8CD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXI8CD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXJ683 DI DMXJ683 DMXJ683 DN KY1044 DMXJ683 TI TTE5VP6 DMXJ683 TN Inducible T-cell costimulator (ICOS) DMXJ683 MA Inhibitor DMXJ683 RN Clinical pipeline report, company report or official report of Kymab. DMXJ683 RU https://www.kymab.com/pipeline/ky1044/ DMXKDUL DI DMXKDUL DMXKDUL DN BGT226 DMXKDUL TI TTCJG29 DMXKDUL TN Serine/threonine-protein kinase mTOR (mTOR) DMXKDUL MA Modulator DMXKDUL RN Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8. DMXKDUL RU https://pubmed.ncbi.nlm.nih.gov/21959532 DMXKDUL DI DMXKDUL DMXKDUL DN BGT226 DMXKDUL TI TTHBTOP DMXKDUL TN PI3-kinase gamma (PIK3CG) DMXKDUL MA Modulator DMXKDUL RN Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8. DMXKDUL RU https://pubmed.ncbi.nlm.nih.gov/21959532 DMXKOUC DI DMXKOUC DMXKOUC DN Neu-120 DMXKOUC TI TTRSMW9 DMXKOUC TN Glycogen synthase kinase-3 beta (GSK-3B) DMXKOUC MA Modulator DMXKOUC RN Company report (Neurim Pharmaceuticals) DMXKOUC RU http://www.neurim.com/products/ DMXKOUC DI DMXKOUC DMXKOUC DN Neu-120 DMXKOUC TI TTGP7BY DMXKOUC TN Monoamine oxidase type B (MAO-B) DMXKOUC MA Modulator DMXKOUC RN Company report (Neurim Pharmaceuticals) DMXKOUC RU http://www.neurim.com/products/ DMXLPYE DI DMXLPYE DMXLPYE DN ONO-7579 DMXLPYE TI TTTDVOJ DMXLPYE TN Tropomyosin-related kinase A (TrkA) DMXLPYE MA Inhibitor DMXLPYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXLPYE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXMK30 DI DMXMK30 DMXMK30 DN Anti-CD20-CAR-transduced T cells DMXMK30 TI TTUE541 DMXMK30 TN Leukocyte surface antigen Leu-16 (CD20) DMXMK30 MA CAR-T-Cell-Therapy DMXMK30 RN ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies DMXMK30 RU https://clinicaltrials.gov/ct2/show/NCT02710149 DMXNTR7 DI DMXNTR7 DMXNTR7 DN SOBI003 DMXNTR7 TI TTPJ2SH DMXNTR7 TN N-sulphoglucosamine sulphohydrolase (SGSH) DMXNTR7 MA Replacement DMXNTR7 RN Clinical pipeline report, company report or official report of Swedish Orphan Biovitrum. DMXNTR7 RU https://www.sobi.com/en/press-releases/fda-accepts-investigational-new-drug-application-and-grants-fast-track-status DMXSEHF DI DMXSEHF DMXSEHF DN Y-39983 DMXSEHF TI TTMQO60 DMXSEHF TN Rho-associated protein kinase (ROCK) DMXSEHF MA Modulator DMXSEHF RN Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70. DMXSEHF RU https://www.ncbi.nlm.nih.gov/pubmed/21950703 DMXU7P6 DI DMXU7P6 DMXU7P6 DN MB-CART20.1 DMXU7P6 TI TTUE541 DMXU7P6 TN Leukocyte surface antigen Leu-16 (CD20) DMXU7P6 MA CAR-T-Cell-Therapy DMXU7P6 RN ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma DMXU7P6 RU https://clinicaltrials.gov/ct2/show/NCT03664635 DMXU98C DI DMXU98C DMXU98C DN AO-176 DMXU98C TI TT28S46 DMXU98C TN Leukocyte surface antigen CD47 (CD47) DMXU98C MA Inhibitor DMXU98C RN Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. DMXU98C RU https://pubmed.ncbi.nlm.nih.gov/31879362 DMXV6YP DI DMXV6YP DMXV6YP DN Fus-1 tumor suppressor gene therapy DMXV6YP TI TTJ8O14 DMXV6YP TN Tumor suppressor candidate 2 (TUSC2) DMXV6YP MA Suppressor DMXV6YP RN INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87. DMXV6YP RU https://pubmed.ncbi.nlm.nih.gov/17472413 DMXVIQN DI DMXVIQN DMXVIQN DN MOR-103 DMXVIQN TI TT6MP2Z DMXVIQN TN GMCSFR-alpha (CSF2RA) DMXVIQN RN MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64. DMXVIQN RU https://pubmed.ncbi.nlm.nih.gov/24534756 DMXVRI0 DI DMXVRI0 DMXVRI0 DN Beclanorsen DMXVRI0 TI TTFOUV4 DMXVRI0 TN BCL-2 messenger RNA (BCL2 mRNA) DMXVRI0 RN Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8. DMXVRI0 RU https://pubmed.ncbi.nlm.nih.gov/25589916 DMXYHC7 DI DMXYHC7 DMXYHC7 DN RU-101 DMXYHC7 TI TTFNGC9 DMXYHC7 TN Serum albumin (ALB) DMXYHC7 MA Modulator DMXYHC7 RN Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283. DMXYHC7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920766/ DMXYOTP DI DMXYOTP DMXYOTP DN Anti-MUC1 CAR-T cells DMXYOTP TI TTBHFYQ DMXYOTP TN Mucin-1 (MUC1) DMXYOTP MA CAR-T-Cell-Therapy DMXYOTP RN ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer DMXYOTP RU https://clinicaltrials.gov/ct2/show/NCT03706326 DMY1CP9 DI DMY1CP9 DMY1CP9 DN GLG-801 DMY1CP9 TI TTH8FZW DMY1CP9 TN Signal transducer and activator of transcription 3 (STAT3) DMY1CP9 MA Inhibitor DMY1CP9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY1CP9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY3TAD DI DMY3TAD DMY3TAD DN Recombinant factor VIIa PEGylated liposomal DMY3TAD TI TTF0EGX DMY3TAD TN Coagulation factor VII (F7) DMY3TAD MA Modulator DMY3TAD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMY3TAD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMY6U8R DI DMY6U8R DMY6U8R DN Anti-CD22 CAR-T cells DMY6U8R TI TTM6QSK DMY6U8R TN B-cell receptor CD22 (CD22) DMY6U8R MA CAR-T-Cell-Therapy DMY6U8R RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMY6U8R RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMY8NUF DI DMY8NUF DMY8NUF DN CEP-9722 DMY8NUF TI TTEBCY8 DMY8NUF TN Poly [ADP-ribose] polymerase (PARP) DMY8NUF MA Modulator DMY8NUF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMY8NUF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYBKMV DI DMYBKMV DMYBKMV DN BT5528 DMYBKMV TI TTRJB2G DMYBKMV TN Ephrin type-A receptor 2 (EPHA2) DMYBKMV RN MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394. DMYBKMV RU https://pubmed.ncbi.nlm.nih.gov/32398269 DMYCID5 DI DMYCID5 DMYCID5 DN ARV-110 DMYCID5 TI TTS64P2 DMYCID5 TN Androgen receptor (AR) DMYCID5 MA Degrader DMYCID5 RN Clinical pipeline report, company report or official report of Arvinas. DMYCID5 RU https://www.arvinas.com/pipeline-programs/androgen-receptor DMYEAB1 DI DMYEAB1 DMYEAB1 DN PIPERINE DMYEAB1 TI TT3WG5C DMYEAB1 TN Monoamine oxidase type A (MAO-A) DMYEAB1 MA Inhibitor DMYEAB1 RN Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. DMYEAB1 RU https://pubmed.ncbi.nlm.nih.gov/19969454 DMYEAB1 DI DMYEAB1 DMYEAB1 DN PIPERINE DMYEAB1 TI TTGP7BY DMYEAB1 TN Monoamine oxidase type B (MAO-B) DMYEAB1 MA Inhibitor DMYEAB1 RN Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. DMYEAB1 RU https://pubmed.ncbi.nlm.nih.gov/19969454 DMYGK1D DI DMYGK1D DMYGK1D DN OTL-300 DMYGK1D TI TTM6HK1 DMYGK1D TN Hemoglobin subunit beta (HBB) DMYGK1D RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMYGK1D RU https://www.orchard-tx.com/approach/pipeline/ DMYGNDI DI DMYGNDI DMYGNDI DN LMP1-CAR-T cells DMYGNDI TI TT0BI4Q DMYGNDI TN Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) DMYGNDI MA CAR-T-Cell-Therapy DMYGNDI RN ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application DMYGNDI RU https://clinicaltrials.gov/ct2/show/NCT02980315 DMYKZB3 DI DMYKZB3 DMYKZB3 DN Anti-DR5 cells DMYKZB3 TI TTW20TU DMYKZB3 TN TRAIL receptor 2 (TRAIL-R2) DMYKZB3 MA CAR-T-Cell-Therapy DMYKZB3 RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMYKZB3 RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMYOMSC DI DMYOMSC DMYOMSC DN Aderbasib DMYOMSC TI TTOMWSY DMYOMSC TN Mammalian disintegrin-metalloprotease (ADAM10) DMYOMSC MA Modulator DMYOMSC RN Company report (Incyte) DMYOMSC RU http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQwNjgzfENoaWxkSUQ9NDYyNTAzfFR5cGU9MQ==&t=1 DMYOMSC DI DMYOMSC DMYOMSC DN Aderbasib DMYOMSC TI TT6AZXG DMYOMSC TN TNF alpha converting enzyme (ADAM17) DMYOMSC MA Modulator DMYOMSC RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYOMSC RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYPQT4 DI DMYPQT4 DMYPQT4 DN 4SCAR19 and 4SCAR123 DMYPQT4 TI TTENHJ0 DMYPQT4 TN Interleukin 3 receptor alpha (IL3RA) DMYPQT4 MA CAR-T-Cell-Therapy(Dual specific) DMYPQT4 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMYPQT4 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMYPQT4 DI DMYPQT4 DMYPQT4 DN 4SCAR19 and 4SCAR123 DMYPQT4 TI TTW640A DMYPQT4 TN B-lymphocyte surface antigen B4 (CD19) DMYPQT4 MA CAR-T-Cell-Therapy(Dual specific) DMYPQT4 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMYPQT4 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMYR8LF DI DMYR8LF DMYR8LF DN NKTR-262 DMYR8LF TI TTRJ1K4 DMYR8LF TN Toll-like receptor 7 (TLR7) DMYR8LF MA Agonist DMYR8LF RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DMYR8LF RU https://www.nektar.com/pipeline/rd-pipeline/nktr-262 DMYR8LF DI DMYR8LF DMYR8LF DN NKTR-262 DMYR8LF TI TT8CWFK DMYR8LF TN Toll-like receptor 8 (TLR8) DMYR8LF MA Agonist DMYR8LF RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DMYR8LF RU https://www.nektar.com/pipeline/rd-pipeline/nktr-262 DMZ18IO DI DMZ18IO DMZ18IO DN Anti-BCMA-CAR-transduced T cells DMZ18IO TI TTZ3P4W DMZ18IO TN B-cell maturation protein (TNFRSF17) DMZ18IO MA CAR-T-Cell-Therapy DMZ18IO RN ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies DMZ18IO RU https://clinicaltrials.gov/ct2/show/NCT02954445 DMZ416B DI DMZ416B DMZ416B DN KD020 DMZ416B TI TTUS1RD DMZ416B TN Microsomal triglyceride transfer protein (MTTP) DMZ416B MA Modulator DMZ416B RN Clinical pipeline report, company report or official report of Kadmon Pharmaceuticals. DMZ416B RU http://kadmon.com/press/kadmon-corporation-presents-encouraging-nonclinical-data-on-tesevatinib-kd019-at-aacr-annual-meeting/ DMZ9VCF DI DMZ9VCF DMZ9VCF DN X-396 DMZ9VCF TI TTPMQSO DMZ9VCF TN ALK tyrosine kinase receptor (ALK) DMZ9VCF MA Inhibitor DMZ9VCF RN Clinical pipeline report, company report or official report of Xcovery. DMZ9VCF RU http://www.xcovery.com/our-science/alk-inhibitor/ DMZABYH DI DMZABYH DMZABYH DN GEN3013 DMZABYH TI TTUN7MC DMZABYH TN T-cell surface glycoprotein CD3 (CD3) DMZABYH RN DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625. DMZABYH RU https://pubmed.ncbi.nlm.nih.gov/31981978 DMZABYH DI DMZABYH DMZABYH DN GEN3013 DMZABYH TI TTUE541 DMZABYH TN Leukocyte surface antigen Leu-16 (CD20) DMZABYH RN DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625. DMZABYH RU https://pubmed.ncbi.nlm.nih.gov/31981978 DMZB6LO DI DMZB6LO DMZB6LO DN OPC-167832 DMZB6LO TI TTLOHU4 DMZB6LO TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DMZB6LO MA Inhibitor DMZB6LO RN OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19. DMZB6LO RU https://pubmed.ncbi.nlm.nih.gov/32229496 DMZD7OA DI DMZD7OA DMZD7OA DN Quaratusugene ozeplasmid DMZD7OA TI TTJ8O14 DMZD7OA TN Tumor suppressor candidate 2 (TUSC2) DMZD7OA RN Clinical pipeline report, company report or official report of Genprex. DMZD7OA RU https://www.genprex.com/technology/reqorsa/ DMZEA9X DI DMZEA9X DMZEA9X DN BIW-8962 DMZEA9X TI TTGOFW6 DMZEA9X TN Ganglioside GM2 activator (GM2A) DMZEA9X RN Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63. DMZEA9X RU https://pubmed.ncbi.nlm.nih.gov/21895875 DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TT7HF4W DMZFIGQ TN Cyclin-dependent kinase 2 (CDK2) DMZFIGQ MA Modulator DMZFIGQ RN Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42. DMZFIGQ RU https://pubmed.ncbi.nlm.nih.gov/22372550 DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TTMBO1Z DMZFIGQ TN Cyclin-dependent kinase (CDK) DMZFIGQ MA Inhibitor DMZFIGQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFIGQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TTU8W4S DMZFIGQ TN Protein kinase (PK) DMZFIGQ MA Inhibitor DMZFIGQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFIGQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZHJV8 DI DMZHJV8 DMZHJV8 DN CAR-T cells targeting CD30 DMZHJV8 TI TT2GM5R DMZHJV8 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMZHJV8 MA CAR-T-Cell-Therapy DMZHJV8 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMZHJV8 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMZK7IT DI DMZK7IT DMZK7IT DN BCT-100 DMZK7IT TI TTSANDR DMZK7IT TN Arginase (ARG) DMZK7IT MA Modulator DMZK7IT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZK7IT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZKFJO DI DMZKFJO DMZKFJO DN PAT-SC1 DMZKFJO TI TT5Z9WY DMZKFJO TN Complement decay-accelerating factor (CD55) DMZKFJO RN Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep. 2014 Mar;31(3):1059-66. DMZKFJO RU https://pubmed.ncbi.nlm.nih.gov/24452482 DMZKFU7 DI DMZKFU7 DMZKFU7 DN 4SCAR19 and 4SCAR38 DMZKFU7 TI TTW640A DMZKFU7 TN B-lymphocyte surface antigen B4 (CD19) DMZKFU7 MA CAR-T-Cell-Therapy(Dual specific) DMZKFU7 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMZKFU7 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMZKFU7 DI DMZKFU7 DMZKFU7 DN 4SCAR19 and 4SCAR38 DMZKFU7 TI TTPURFN DMZKFU7 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMZKFU7 MA CAR-T-Cell-Therapy(Dual specific) DMZKFU7 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMZKFU7 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TT6EO5L DMZM6I2 TN Erbb2 tyrosine kinase receptor (HER2) DMZM6I2 MA Inhibitor DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TTGKNB4 DMZM6I2 TN Epidermal growth factor receptor (EGFR) DMZM6I2 MA Antagonist DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TTDC8N2 DMZM6I2 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMZM6I2 MA Inhibitor DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZSIV1 DI DMZSIV1 DMZSIV1 DN NC410 DMZSIV1 TI TTSI7A8 DMZSIV1 TN Leukocyte-associated Ig-like receptor 1 (LAIR1) DMZSIV1 MA Inhibitor DMZSIV1 RN Clinical pipeline report, company report or official report of NextCure. DMZSIV1 RU http://www.nextcure.com/pipeline/ DMZTQD8 DI DMZTQD8 DMZTQD8 DN Sirna-027 DMZTQD8 TI TT1VAUK DMZTQD8 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMZTQD8 RN 2011 Pipeline of Sirna Therapeutics. DMZTQD8 RU http://www.sirna.com/ DM459Q7 DI DM459Q7 DM459Q7 DN BMS-833923 DM459Q7 TI TT8J1S3 DM459Q7 TN Smoothened homolog (SMO) DM459Q7 MA Inhibitor DM459Q7 RN Clinical pipeline report, company report or official report of Exelixis (2011). DM459Q7 RU http://www.exelixis.com/pipeline DMNCOE1 DI DMNCOE1 DMNCOE1 DN FRM-6308 DMNCOE1 TI TTJW4LU DMNCOE1 TN Phosphodiesterase 10A (PDE10) DMNCOE1 MA Inhibitor DMNCOE1 RN Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2. DMNCOE1 RU https://pubmed.ncbi.nlm.nih.gov/25131831 DMQGH76 DI DMQGH76 DMQGH76 DN S-222611 DMQGH76 TI TT6EO5L DMQGH76 TN Erbb2 tyrosine kinase receptor (HER2) DMQGH76 MA Inhibitor DMQGH76 RN Clinical pipeline report, company report or official report of Shionogi (2011). DMQGH76 RU http://www.shionogi.co.jp/index_e.html DMQGH76 DI DMQGH76 DMQGH76 DN S-222611 DMQGH76 TI TTGKNB4 DMQGH76 TN Epidermal growth factor receptor (EGFR) DMQGH76 MA Inhibitor DMQGH76 RN Clinical pipeline report, company report or official report of Shionogi (2011). DMQGH76 RU http://www.shionogi.co.jp/index_e.html DMVWYOU DI DMVWYOU DMVWYOU DN GGF DMVWYOU TI TTEH395 DMVWYOU TN Pro-neuregulin-1 (Pro-NRG1) DMVWYOU MA Modulator DMVWYOU RN Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol. 2001 Mar 19;152(6):1289-99. DMVWYOU RU https://pubmed.ncbi.nlm.nih.gov/11257128 DM01JU8 DI DM01JU8 DM01JU8 DN JTE-451 DM01JU8 TI TTGV6LY DM01JU8 TN Nuclear receptor ROR-gamma (RORG) DM01JU8 MA Antagonist DM01JU8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM01JU8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM029TQ DI DM029TQ DM029TQ DN DS-1150b DM029TQ TI TTP6MT5 DM029TQ TN Glucose transporter type 4 (SLC2A4) DM029TQ MA Modulator DM029TQ RN Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014 DM029TQ RU http://www.nature.com/scibx/journal/v7/n22/full/scibx.2014.633.html DM0351T DI DM0351T DM0351T DN 5-FP DM0351T TI TTUTN1I DM0351T TN Human Deoxyribonucleic acid (hDNA) DM0351T MA Binder DM0351T RN Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9. DM0351T RU https://pubmed.ncbi.nlm.nih.gov/12684389 DM035LO DI DM035LO DM035LO DN GP-3269 DM035LO TI TTL732K DM035LO TN Adenosine kinase (ADK) DM035LO MA Inhibitor DM035LO RN Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20. DM035LO RU https://pubmed.ncbi.nlm.nih.gov/16302820 DM03O8T DI DM03O8T DM03O8T DN PSMA-VRP DM03O8T TI TT9G4N0 DM03O8T TN Glutamate carboxypeptidase II (GCPII) DM03O8T RN A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013 Jan 30;31(6):943-9. DM03O8T RU https://pubmed.ncbi.nlm.nih.gov/23246260 DM049IX DI DM049IX DM049IX DN CDRI-97/78 DM049IX TI TTQ2GJ0 DM049IX TN Plasmodial phospholipid metabolism (PPP metab) DM049IX MA Modulator DM049IX RN Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521. DM049IX RU https://pubmed.ncbi.nlm.nih.gov/24800100 DM056JD DI DM056JD DM056JD DN PF-06648671 DM056JD TI TT9W8GU DM056JD TN Gamma-secretase (GS) DM056JD MA Modulator DM056JD RN Pharmacokinetic and Pharmacodynamic Effects of a -Secretase Modulator, PF-06648671, on CSF Amyloid- Peptides in Randomized Phase I Studies. Clin Pharmacol Ther. 2020 Jan;107(1):211-220. DM056JD RU https://pubmed.ncbi.nlm.nih.gov/31314925 DM05R4C DI DM05R4C DM05R4C DN CLN-081 DM05R4C TI TTGKNB4 DM05R4C TN Epidermal growth factor receptor (EGFR) DM05R4C MA Inhibitor DM05R4C RN TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. DM05R4C RU https://pubmed.ncbi.nlm.nih.gov/29748209 DM09SW6 DI DM09SW6 DM09SW6 DN CD4CAR DM09SW6 TI TTN2JFW DM09SW6 TN T-cell surface glycoprotein CD4 (CD4) DM09SW6 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM09SW6 RU https://icellgene.com/our-pipeline.html DM0A6N9 DI DM0A6N9 DM0A6N9 DN PTI-80 DM0A6N9 TI TTS87KH DM0A6N9 TN Microtubule-associated protein tau (MAPT) DM0A6N9 MA Inhibitor DM0A6N9 RN Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014. DM0A6N9 RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf DM0BNLC DI DM0BNLC DM0BNLC DN PENNVAX-6 DM0BNLC TI TTEC2T3 DM0BNLC TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DM0BNLC MA Modulator DM0BNLC RN Company report (Inovio) DM0BNLC RU http://www.inovio.com/products/infectious-disease-vaccines/hiv/pennvax-g/ DM0DJPE DI DM0DJPE DM0DJPE DN Drug 2838232 DM0DJPE TI TTMCA52 DM0DJPE TN Viral Maturation (VM) DM0DJPE MA Modulator DM0DJPE RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762) DM0DJPE RU http://adisinsight.springer.com/drugs/800037762 DM0E37K DI DM0E37K DM0E37K DN Pegdinetanib DM0E37K TI TTUTJGQ DM0E37K TN Vascular endothelial growth factor receptor 2 (KDR) DM0E37K MA Modulator DM0E37K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM0E37K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM0E3ZG DI DM0E3ZG DM0E3ZG DN REGN3048 DM0E3ZG TI TTZ3COY DM0E3ZG TN COVID-19 spike glycoprotein (S) DM0E3ZG MA Inhibitor DM0E3ZG RN Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71. DM0E3ZG RU https://pubmed.ncbi.nlm.nih.gov/29885377 DM0EKUQ DI DM0EKUQ DM0EKUQ DN NY-ESO-1 vaccine DM0EKUQ TI TTE5ITK DM0EKUQ TN Cancer/testis antigen 1 (NY-ESO-1) DM0EKUQ RN Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822. DM0EKUQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151653/ DM0EWMT DI DM0EWMT DM0EWMT DN SRK-181 DM0EWMT TI TTR9XHZ DM0EWMT TN Transforming growth factor beta 1 (TGFB1) DM0EWMT MA Inhibitor DM0EWMT RN Clinical pipeline report, company report or official report of Scholar Rock. DM0EWMT RU https://scholarrock.com/our-pipeline/oncology/ DM0EZ69 DI DM0EZ69 DM0EZ69 DN SYN004 DM0EZ69 TI TTGKNB4 DM0EZ69 TN Epidermal growth factor receptor (EGFR) DM0EZ69 MA Inhibitor DM0EZ69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0EZ69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM0H5JD DI DM0H5JD DM0H5JD DN MEDI3617 DM0H5JD TI TTKLQTJ DM0H5JD TN Angiopoietin-2 (ANGPT2) DM0H5JD MA Inhibitor DM0H5JD RN Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15;24(12):2749-2757. DM0H5JD RU https://pubmed.ncbi.nlm.nih.gov/29559563 DM0HKU7 DI DM0HKU7 DM0HKU7 DN Macozinone DM0HKU7 TI TTLOHU4 DM0HKU7 TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DM0HKU7 MA Inhibitor DM0HKU7 RN Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351. DM0HKU7 RU https://pubmed.ncbi.nlm.nih.gov/30891138 DM0I8RZ DI DM0I8RZ DM0I8RZ DN Affitope AD-01 DM0I8RZ TI TTE4KHA DM0I8RZ TN Amyloid beta A4 protein (APP) DM0I8RZ RN Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808. DM0I8RZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313573/ DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TTTDVOJ DM0IVGU TN Tropomyosin-related kinase A (TrkA) DM0IVGU MA Inhibitor DM0IVGU RN National Cancer Institute Drug Dictionary (drug id 747694). DM0IVGU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694 DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TTC70AJ DM0IVGU TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM0IVGU MA Inhibitor DM0IVGU RN National Cancer Institute Drug Dictionary (drug id 747694). DM0IVGU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694 DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TT7MRDV DM0IVGU TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM0IVGU MA Inhibitor DM0IVGU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0IVGU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0J7UR DI DM0J7UR DM0J7UR DN MEDI9197 DM0J7UR TI TTRJ1K4 DM0J7UR TN Toll-like receptor 7 (TLR7) DM0J7UR MA Agonist DM0J7UR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0J7UR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0J7UR DI DM0J7UR DM0J7UR DN MEDI9197 DM0J7UR TI TT8CWFK DM0J7UR TN Toll-like receptor 8 (TLR8) DM0J7UR MA Agonist DM0J7UR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0J7UR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0JT9C DI DM0JT9C DM0JT9C DN DN1508052 DM0JT9C TI TT8CWFK DM0JT9C TN Toll-like receptor 8 (TLR8) DM0JT9C MA Agonist DM0JT9C RN Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech. DM0JT9C RU http://www.denovo-sh.com/En/technology.aspx?BaseInfoCateID=48&CateID=48 DM0LKHV DI DM0LKHV DM0LKHV DN B7-2/GM-CSF DM0LKHV TI TTZ9SOR DM0LKHV TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0LKHV MA Agonist DM0LKHV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0LKHV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0LKHV DI DM0LKHV DM0LKHV DN B7-2/GM-CSF DM0LKHV TI TTQWUPT DM0LKHV TN Thyroid hormone receptor (THR) DM0LKHV MA Agonist DM0LKHV RN Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010 Mar;15(2):177-82. DM0LKHV RU https://pubmed.ncbi.nlm.nih.gov/19002578 DM0O2N4 DI DM0O2N4 DM0O2N4 DN pbi-shRNA EWS-FLI-Type 1 DM0O2N4 TI TTHOM2S DM0O2N4 TN EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA) DM0O2N4 MA Inhibitor DM0O2N4 RN National Cancer Institute Drug Dictionary (drug id 780967). DM0O2N4 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/780967 DM0P729 DI DM0P729 DM0P729 DN GSK461364 DM0P729 TI TTIYVQP DM0P729 TN Polo-like kinase 1 (PLK1) DM0P729 MA Inhibitor DM0P729 RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DM0P729 RU https://pubmed.ncbi.nlm.nih.gov/19474163 DM0PYEQ DI DM0PYEQ DM0PYEQ DN NIP-004 DM0PYEQ TI TTIHYA4 DM0PYEQ TN Thrombopoietin receptor (MPL) DM0PYEQ MA Agonist DM0PYEQ RN A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7. DM0PYEQ RU https://pubmed.ncbi.nlm.nih.gov/16484588 DM0Q7NO DI DM0Q7NO DM0Q7NO DN AMG 176 DM0Q7NO TI TTL53M6 DM0Q7NO TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM0Q7NO MA Inhibitor DM0Q7NO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0Q7NO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0QH9K DI DM0QH9K DM0QH9K DN FS118 DM0QH9K TI TTNVXAW DM0QH9K TN Lymphocyte activation gene 3 protein (LAG3) DM0QH9K RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0QH9K RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0QH9K DI DM0QH9K DM0QH9K DN FS118 DM0QH9K TI TT8ZLTI DM0QH9K TN Programmed cell death 1 ligand 1 (PD-L1) DM0QH9K RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0QH9K RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0QZJX DI DM0QZJX DM0QZJX DN JNJ-55308942 DM0QZJX TI TT473XN DM0QZJX TN P2X purinoceptor 7 (P2RX7) DM0QZJX MA Inhibitor DM0QZJX RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0QZJX RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0RD4F DI DM0RD4F DM0RD4F DN DS-6051 DM0RD4F TI TTTDVOJ DM0RD4F TN Tropomyosin-related kinase A (TrkA) DM0RD4F MA Inhibitor DM0RD4F RN National Cancer Institute Drug Dictionary (drug id 766123). DM0RD4F RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123 DM0RD4F DI DM0RD4F DM0RD4F DN DS-6051 DM0RD4F TI TTSZ6Y3 DM0RD4F TN Proto-oncogene c-Ros (ROS1) DM0RD4F MA Inhibitor DM0RD4F RN National Cancer Institute Drug Dictionary (drug id 766123). DM0RD4F RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123 DM0RIQF DI DM0RIQF DM0RIQF DN MDX-1203 DM0RIQF TI TTNCIE0 DM0RIQF TN CD70 antigen (CD27-L) DM0RIQF RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2558). DM0RIQF RU http://meetinglibrary.asco.org/content/130447-144 DM0S9OT DI DM0S9OT DM0S9OT DN VRC07-523LS DM0S9OT TI TTN2JFW DM0S9OT TN T-cell surface glycoprotein CD4 (CD4) DM0S9OT RN Clinical pipeline report, company report or official report of TaiMed Biologics. DM0S9OT RU http://www.taimedbiologics.com/pipeline/44 DM0SRAN DI DM0SRAN DM0SRAN DN CC-122 DM0SRAN TI TTDKGTC DM0SRAN TN Protein cereblon (CRBN) DM0SRAN MA Modulator DM0SRAN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0SRAN RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0UL47 DI DM0UL47 DM0UL47 DN Anti-PD-L1 DM0UL47 TI TT8ZLTI DM0UL47 TN Programmed cell death 1 ligand 1 (PD-L1) DM0UL47 RN Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. DM0UL47 RU https://pubmed.ncbi.nlm.nih.gov/22658128 DM0UOA9 DI DM0UOA9 DM0UOA9 DN NV-52 DM0UOA9 TI TTKNWZ4 DM0UOA9 TN Thromboxane-A synthase (TBXAS1) DM0UOA9 MA Inhibitor DM0UOA9 RN Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66. DM0UOA9 RU https://pubmed.ncbi.nlm.nih.gov/18457468 DM0W275 DI DM0W275 DM0W275 DN Human CD19 targeted T Cells DM0W275 TI TTW640A DM0W275 TN B-lymphocyte surface antigen B4 (CD19) DM0W275 MA CAR-T-Cell-Therapy DM0W275 RN ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. DM0W275 RU https://clinicaltrials.gov/ct2/show/NCT03720457 DM0WCR4 DI DM0WCR4 DM0WCR4 DN AZD-6088 DM0WCR4 TI TTZ9SOR DM0WCR4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0WCR4 MA Agonist DM0WCR4 RN Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints. AAPS J. 2012 December; 14(4): 657-663. DM0WCR4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475849/ DM0WTMD DI DM0WTMD DM0WTMD DN DSP-2230 DM0WTMD TI TT4G2JS DM0WTMD TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0WTMD MA Inhibitor DM0WTMD RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0WTMD RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0WTMD DI DM0WTMD DM0WTMD DN DSP-2230 DM0WTMD TI TT90XZ8 DM0WTMD TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM0WTMD MA Inhibitor DM0WTMD RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0WTMD RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0XDYT DI DM0XDYT DM0XDYT DN CD10-CART DM0XDYT TI TT5TKPM DM0XDYT TN Neutral endopeptidase (MME) DM0XDYT MA CAR-T-Cell-Therapy(Dual specific) DM0XDYT RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DM0XDYT RU https://clinicaltrials.gov/ct2/show/NCT03407859 DM0YCG3 DI DM0YCG3 DM0YCG3 DN RVT-103+RVT-104 DM0YCG3 TI TTEB0GD DM0YCG3 TN Cholinesterase (BCHE) DM0YCG3 MA Inhibitor DM0YCG3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0YCG3 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DM0Z3JS DI DM0Z3JS DM0Z3JS DN ASG-22ME DM0Z3JS TI TTPO9EG DM0Z3JS TN Nectin cell adhesion molecule 4 (NECTIN4) DM0Z3JS RN 2011 Pipeline of Seattle Genetics. DM0Z3JS RU http://www.seagen.com/product_pipeline.php DM0ZDJ5 DI DM0ZDJ5 DM0ZDJ5 DN Anti-EGFL7 DM0ZDJ5 TI TT7WD0H DM0ZDJ5 TN Epidermal growth factor-like protein 7 (EGFL7) DM0ZDJ5 RN Clinical pipeline report, company report or official report of Genentech (2009). DM0ZDJ5 RU http://www.gene.com/gene/pipeline/status/ DM0ZMNI DI DM0ZMNI DM0ZMNI DN REGN6569 DM0ZMNI TI TTG6LA7 DM0ZMNI TN Activation-inducible TNFR family receptor (TNFRSF18) DM0ZMNI MA Inhibitor DM0ZMNI RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0ZMNI RU https://www.regeneron.com/science/pipeline DM0ZNAR DI DM0ZNAR DM0ZNAR DN Belvarafenib DM0ZNAR TI TTB18GJ DM0ZNAR TN Proto-oncogene c-RAF (c-RAF) DM0ZNAR MA Inhibitor DM0ZNAR RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DM0ZNAR RU https://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline DM0ZQ48 DI DM0ZQ48 DM0ZQ48 DN GPI-16072 DM0ZQ48 TI TT9G4N0 DM0ZQ48 TN Glutamate carboxypeptidase II (GCPII) DM0ZQ48 MA Inhibitor DM0ZQ48 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM0ZQ48 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM0ZQ7J DI DM0ZQ7J DM0ZQ7J DN TAK-041 DM0ZQ7J TI TTOL9B0 DM0ZQ7J TN G-protein-coupled receptor PGR3 (GPR139) DM0ZQ7J MA Agonist DM0ZQ7J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0ZQ7J RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM12GN7 DI DM12GN7 DM12GN7 DN CB-5083 DM12GN7 TI TTHNLSB DM12GN7 TN Valosin-containing protein p97 (VCP) DM12GN7 MA Inhibitor DM12GN7 RN Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479. DM12GN7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479320/ DM132EG DI DM132EG DM132EG DN M802 DM132EG TI TT6EO5L DM132EG TN Erbb2 tyrosine kinase receptor (HER2) DM132EG MA Inhibitor DM132EG RN A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355. DM132EG RU https://pubmed.ncbi.nlm.nih.gov/31412896 DM132EG DI DM132EG DM132EG DN M802 DM132EG TI TTUN7MC DM132EG TN T-cell surface glycoprotein CD3 (CD3) DM132EG MA Inhibitor DM132EG RN A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355. DM132EG RU https://pubmed.ncbi.nlm.nih.gov/31412896 DM13YK0 DI DM13YK0 DM13YK0 DN Ferroportin mab DM13YK0 TI TT6Y1PG DM13YK0 TN Solute carrier family 40 member 1 (SLC40A1) DM13YK0 RN The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. DM13YK0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/ DM14XQN DI DM14XQN DM14XQN DN BAY 79-4620 DM14XQN TI TT2LVK8 DM14XQN TN Carbonic anhydrase IX (CA-IX) DM14XQN RN Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9. DM14XQN RU https://pubmed.ncbi.nlm.nih.gov/22147747 DM15PG9 DI DM15PG9 DM15PG9 DN SAR351034 DM15PG9 TI TT2JWF6 DM15PG9 TN Peroxisome proliferator-activated receptor delta (PPARD) DM15PG9 MA Modulator DM15PG9 RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DM15PG9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DM16IX2 DI DM16IX2 DM16IX2 DN LY-2979165 DM16IX2 TI TTXJ47W DM16IX2 TN Metabotropic glutamate receptor 2 (mGluR2) DM16IX2 MA Modulator DM16IX2 RN Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78). DM16IX2 RU https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=Annual+Reports+in+Medicinal+Chemistry++LY-2979165&source=bl&ots=oPRAtBeGRL&sig=la4YgUxL9zkXRln2i4EVFFFVzUg&hl=zh-CN&sa=X&ved=0CB4Q6AEwAGoVChMIsbb8qP3FyAIVC1iOCh3bcgiX#v=onepage&q=Annual%20Reports%20in%20Medicinal%20Chemistry%20%20LY-2979165&f=false DM16QSG DI DM16QSG DM16QSG DN Adaphostin DM16QSG TI TTS7G69 DM16QSG TN Fusion protein Bcr-Abl (Bcr-Abl) DM16QSG MA Inhibitor DM16QSG RN Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71. DM16QSG RU https://pubmed.ncbi.nlm.nih.gov/11781252 DM195JA DI DM195JA DM195JA DN BAY-86-7548 DM195JA TI TTHYDUM DM195JA TN Bombesin receptor (BS) DM195JA MA Enhancer DM195JA RN Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72. DM195JA RU https://pubmed.ncbi.nlm.nih.gov/23564761 DM19UTO DI DM19UTO DM19UTO DN Acebilustat DM19UTO TI TTXZEAJ DM19UTO TN Leukotriene A-4 hydrolase (LTA4H) DM19UTO MA Inhibitor DM19UTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM19UTO RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM1AKNI DI DM1AKNI DM1AKNI DN TAK-252 DM1AKNI TI TTL31H0 DM1AKNI TN OX40L receptor (CD134) DM1AKNI MA Agonist DM1AKNI RN Clinical pipeline report, company report or official report of Shattuck Labs. DM1AKNI RU https://www.shattucklabs.com/pipeline/overview/ DM1AKNI DI DM1AKNI DM1AKNI DN TAK-252 DM1AKNI TI TT8ZLTI DM1AKNI TN Programmed cell death 1 ligand 1 (PD-L1) DM1AKNI MA Agonist DM1AKNI RN Clinical pipeline report, company report or official report of Shattuck Labs. DM1AKNI RU https://www.shattucklabs.com/pipeline/overview/ DM1ALHT DI DM1ALHT DM1ALHT DN MEDl-551 DM1ALHT TI TTW640A DM1ALHT TN B-lymphocyte surface antigen B4 (CD19) DM1ALHT RN CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. DM1ALHT RU https://pubmed.ncbi.nlm.nih.gov/22820352 DM1ALY9 DI DM1ALY9 DM1ALY9 DN TAK-931 DM1ALY9 TI TTSMTDI DM1ALY9 TN CDC7-related kinase (CDC7) DM1ALY9 MA Inhibitor DM1ALY9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ALY9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1B3UM DI DM1B3UM DM1B3UM DN GDC-0152 DM1B3UM TI TTR7B60 DM1B3UM TN X-linked inhibitor of apoptosis protein (XIAP) DM1B3UM MA Modulator DM1B3UM RN Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13. DM1B3UM RU https://pubmed.ncbi.nlm.nih.gov/22413863 DM1B4CQ DI DM1B4CQ DM1B4CQ DN RTL-1000 DM1B4CQ TI TTXQYT6 DM1B4CQ TN T-cells (T-cells) DM1B4CQ MA Binder DM1B4CQ RN RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14. DM1B4CQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026883/ DM1C4UM DI DM1C4UM DM1C4UM DN LAMB3-transduced autologous epidermal stem cells DM1C4UM TI TT2WOUQ DM1C4UM TN Laminin beta-3 chain (LAMB3) DM1C4UM MA Modulator DM1C4UM RN Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006 Dec;12(12):1397-402. DM1C4UM RU https://pubmed.ncbi.nlm.nih.gov/17115047 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TT7CPI5 DM1CZSJ TN Bromodomain testis-specific protein (BRDT) DM1CZSJ MA Inhibitor DM1CZSJ RN Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17;150(4):673-84. DM1CZSJ RU https://pubmed.ncbi.nlm.nih.gov/22901802 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TTRA6BO DM1CZSJ TN Bromodomain-containing protein 4 (BRD4) DM1CZSJ MA Inhibitor DM1CZSJ RN Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. DM1CZSJ RU https://pubmed.ncbi.nlm.nih.gov/20871596 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TTE4BSY DM1CZSJ TN Bromodomain and extraterminal domain protein (BET) DM1CZSJ MA Inhibitor DM1CZSJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1CZSJ RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM1D2O0 DI DM1D2O0 DM1D2O0 DN KML-001 DM1D2O0 TI TTUJFD0 DM1D2O0 TN Telomerase reverse transcriptase (TERT) DM1D2O0 MA Inhibitor DM1D2O0 RN National Cancer Institute Drug Dictionary (drug id 672554). DM1D2O0 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=672554 DM1DISM DI DM1DISM DM1DISM DN MDAM (y-methylene-10-deazaaminopterin) DM1DISM TI TTYZVDJ DM1DISM TN Dihydrofolate reductase (DHFR) DM1DISM MA Inhibitor DM1DISM RN Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37. DM1DISM RU https://pubmed.ncbi.nlm.nih.gov/3275776 DM1DIVY DI DM1DIVY DM1DIVY DN TRemelimumab + MEDI0562 DM1DIVY TI TTI2S1D DM1DIVY TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM1DIVY MA Agonist DM1DIVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1DIVY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1DIVY DI DM1DIVY DM1DIVY DN TRemelimumab + MEDI0562 DM1DIVY TI TTL31H0 DM1DIVY TN OX40L receptor (CD134) DM1DIVY MA Agonist DM1DIVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1DIVY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1EBRK DI DM1EBRK DM1EBRK DN FPA144 DM1EBRK TI TTGKIED DM1EBRK TN Fibroblast growth factor-2 (FGF2) DM1EBRK MA Antagonist DM1EBRK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1EBRK RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1F50I DI DM1F50I DM1F50I DN ABT-110 DM1F50I TI TTDN3LF DM1F50I TN Nerve growth factor (NGF) DM1F50I MA Modulator DM1F50I RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DM1F50I RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DM1FJ9C DI DM1FJ9C DM1FJ9C DN AMG 876 DM1FJ9C TI TTUPB12 DM1FJ9C TN Measles virus Fusion glycoprotein (MeV F) DM1FJ9C MA Modulator DM1FJ9C RN Clinical pipeline report, company report or official report of Amgen. DM1FJ9C RU http://www.amgenpipeline.com/pipeline/ DM1FLXD DI DM1FLXD DM1FLXD DN CAN04 DM1FLXD TI TTWS50K DM1FLXD TN Interleukin 1 receptor accessory protein (IL1RAP) DM1FLXD MA Inhibitor DM1FLXD RN A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) DM1FLXD RU https://clinicaltrials.gov/ct2/show/NCT03267316 DM1FTEC DI DM1FTEC DM1FTEC DN ARQ-171 DM1FTEC TI TTVJDNB DM1FTEC TN E2F transcription factor 1 (E2F1) DM1FTEC MA Modulator DM1FTEC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396) DM1FTEC RU http://adisinsight.springer.com/drugs/800025396 DM1FUAR DI DM1FUAR DM1FUAR DN MV-CEA DM1FUAR TI TTY6DTE DM1FUAR TN Carcinoembryonic antigen CEA (CD66e) DM1FUAR MA Modulator DM1FUAR RN Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1;70(3):875-82. DM1FUAR RU https://pubmed.ncbi.nlm.nih.gov/20103634 DM1FW0C DI DM1FW0C DM1FW0C DN AZD7762 DM1FW0C TI TTTU902 DM1FW0C TN Checkpoint kinase-1 (CHK1) DM1FW0C MA Inhibitor DM1FW0C RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1FW0C RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1FX09 DI DM1FX09 DM1FX09 DN DT-TX-30 DM1FX09 TI TT2O84V DM1FX09 TN Thromboxane A2 receptor (TBXA2R) DM1FX09 MA Antagonist DM1FX09 RN DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90. DM1FX09 RU https://pubmed.ncbi.nlm.nih.gov/9226103 DM1GV6O DI DM1GV6O DM1GV6O DN CC-90011 DM1GV6O TI TTNR0UQ DM1GV6O TN Lysine-specific histone demethylase 1 (LSD) DM1GV6O MA Inhibitor DM1GV6O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1GV6O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1H75D DI DM1H75D DM1H75D DN Z-100 DM1H75D TI TTV2CN0 DM1H75D TN Interferon receptor (IFNR) DM1H75D MA Modulator DM1H75D RN Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol. 2004 Sep;85(Pt 9):2603-13. DM1H75D RU https://pubmed.ncbi.nlm.nih.gov/15302954 DM1HUA3 DI DM1HUA3 DM1HUA3 DN RHIgM12B7 DM1HUA3 TI TTYOVWN DM1HUA3 TN Programmed cell death protein 2 (PD-2) DM1HUA3 RN National Cancer Institute Drug Dictionary (drug id 593681). DM1HUA3 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=593681 DM1ITDN DI DM1ITDN DM1ITDN DN NsG-0202 DM1ITDN TI TTDN3LF DM1ITDN TN Nerve growth factor (NGF) DM1ITDN MA Modulator DM1ITDN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1ITDN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTGTQHC DM1KD7U TN DNA topoisomerase I (TOP1) DM1KD7U MA Modulator DM1KD7U RN Company report (Indena) DM1KD7U RU http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/ DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTYFKSZ DM1KD7U TN Tubulin beta (TUBB) DM1KD7U MA Modulator DM1KD7U RN Company report (Indena) DM1KD7U RU http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/ DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTOHSBA DM1KD7U TN Vascular endothelial growth factor A (VEGFA) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTB8Y9K DM1KD7U TN Angiogenesis (AGG) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TT4V2JM DM1KD7U TN Hepatocyte growth factor (HGF) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1M4B8 DI DM1M4B8 DM1M4B8 DN CC-93269 DM1M4B8 TI TTZ3P4W DM1M4B8 TN B-cell maturation protein (TNFRSF17) DM1M4B8 RN T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081. DM1M4B8 RU https://pubmed.ncbi.nlm.nih.gov/33227097 DM1MY26 DI DM1MY26 DM1MY26 DN IGN523 DM1MY26 TI TT5CZSM DM1MY26 TN Lymphocyte activation antigen 4F2 (SLC3A2) DM1MY26 RN Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20. DM1MY26 RU https://pubmed.ncbi.nlm.nih.gov/25556716 DM1N8PZ DI DM1N8PZ DM1N8PZ DN rAAV1.tMCK.human-alpha-sarcoglycan DM1N8PZ TI TTS9Q5V DM1N8PZ TN Sarcoglycan alpha (SGCA) DM1N8PZ MA Modulator DM1N8PZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1N8PZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1N9YS DI DM1N9YS DM1N9YS DN MSX-122 DM1N9YS TI TTBID49 DM1N9YS TN C-X-C chemokine receptor type 4 (CXCR4) DM1N9YS MA Antagonist DM1N9YS RN Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85. DM1N9YS RU https://pubmed.ncbi.nlm.nih.gov/14597730 DM1NHEA DI DM1NHEA DM1NHEA DN RG7450 DM1NHEA TI TT9E64S DM1NHEA TN Metalloreductase STEAP1 (STEAP1) DM1NHEA MA Modulator DM1NHEA RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DM1NHEA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DM1O2X6 DI DM1O2X6 DM1O2X6 DN KPG-818 DM1O2X6 TI TTEZQ39 DM1O2X6 TN Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) DM1O2X6 MA Modulator DM1O2X6 RN Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals. DM1O2X6 RU https://www.kangpugroup.com/research_development/pipeline.html DM1PK0T DI DM1PK0T DM1PK0T DN GLYCAR T cells DM1PK0T TI TTJTSX4 DM1PK0T TN Glypican-3 (GPC3) DM1PK0T MA CAR-T-Cell-Therapy DM1PK0T RN ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) DM1PK0T RU https://clinicaltrials.gov/ct2/show/NCT02905188 DM1R4MQ DI DM1R4MQ DM1R4MQ DN RG7893 DM1R4MQ TI TT4G2JS DM1R4MQ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM1R4MQ MA Inhibitor DM1R4MQ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740) DM1R4MQ RU http://adisinsight.springer.com/drugs/800041740 DM1R8P4 DI DM1R8P4 DM1R8P4 DN CART-19 DM1R8P4 TI TTW640A DM1R8P4 TN B-lymphocyte surface antigen B4 (CD19) DM1R8P4 MA CAR-T-Cell-Therapy DM1R8P4 RN ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma DM1R8P4 RU https://clinicaltrials.gov/ct2/show/NCT03101709 DM1RBT8 DI DM1RBT8 DM1RBT8 DN NN-9926 DM1RBT8 TI TTVIMDE DM1RBT8 TN Glucagon-like peptide 1 receptor (GLP1R) DM1RBT8 MA Agonist DM1RBT8 RN Clinical pipeline report, company report or official report of Addex Pharmaceuticals. DM1RBT8 RU https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&ved=0CEkQFjAFahUKEwiqkvGZp7nIAhWRBo4KHcHbD4U&url=http%3a%2f%2fwww%2eedisoninvestmentresearch%2ecom%2f%3fACT%3d18%26ID%3d6480&usg=AFQjCNHEg3ua1DahAa3uYwDK0pG0MPee7Q DM1RD0T DI DM1RD0T DM1RD0T DN ASP-4058 DM1RD0T TI TT9JZCK DM1RD0T TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM1RD0T MA Modulator DM1RD0T RN ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819. DM1RD0T RU https://pubmed.ncbi.nlm.nih.gov/25347187 DM1RD0T DI DM1RD0T DM1RD0T DN ASP-4058 DM1RD0T TI TTDZCKV DM1RD0T TN Sphingosine-1-phosphate receptor 5 (S1PR5) DM1RD0T MA Modulator DM1RD0T RN ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819. DM1RD0T RU https://pubmed.ncbi.nlm.nih.gov/25347187 DM1RNT7 DI DM1RNT7 DM1RNT7 DN IDR-1018 DM1RNT7 TI TTXT4D5 DM1RNT7 TN Bacterial Cell membrane (Bact CM) DM1RNT7 MA Regulator DM1RNT7 RN Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373. DM1RNT7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412849/ DM1T8KN DI DM1T8KN DM1T8KN DN JCAR020 DM1T8KN TI TTC1PS3 DM1T8KN TN Ovarian carcinoma antigen CA125 (MUC16) DM1T8KN MA Immunomodulator DM1T8KN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1T8KN RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1UEBR DI DM1UEBR DM1UEBR DN CC-99712 DM1UEBR TI TTZ3P4W DM1UEBR TN B-cell maturation protein (TNFRSF17) DM1UEBR RN ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health. DM1UEBR RU https://clinicaltrials.gov/ct2/show/NCT04036461 DM1UIOA DI DM1UIOA DM1UIOA DN XB-947 DM1UIOA TI TT4NVEM DM1UIOA TN DNA topoisomerase II beta (TOP2B) DM1UIOA MA Modulator DM1UIOA RN XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173. DM1UIOA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC18430/ DM1UIQP DI DM1UIQP DM1UIQP DN SAFIRONIL DM1UIQP TI TTNH25W DM1UIQP TN Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) DM1UIQP MA Modulator DM1UIQP RN Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001 Aug;1(2):227-40. DM1UIQP RU https://pubmed.ncbi.nlm.nih.gov/12455417 DM1UQ4Y DI DM1UQ4Y DM1UQ4Y DN GSK3845097 DM1UQ4Y TI TTE5ITK DM1UQ4Y TN Cancer/testis antigen 1 (NY-ESO-1) DM1UQ4Y RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM1UQ4Y RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DM1V9YG DI DM1V9YG DM1V9YG DN BRL-52656 DM1V9YG TI TTQW87Y DM1V9YG TN Opioid receptor kappa (OPRK1) DM1V9YG MA Agonist DM1V9YG RN Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat. J Pharm Pharmacol. 1999 Nov;51(11):1251-6. DM1V9YG RU https://pubmed.ncbi.nlm.nih.gov/10632082 DM1XOZK DI DM1XOZK DM1XOZK DN ZYT-1 DM1XOZK TI TTGER3L DM1XOZK TN Thyroid hormone receptor beta (THRB) DM1XOZK MA Modulator DM1XOZK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1XOZK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1YSMD DI DM1YSMD DM1YSMD DN MEDI6383 DM1YSMD TI TTBW580 DM1YSMD TN TAX transcriptionally-activated glycoprotein 1 (OX40) DM1YSMD RN J Clin Oncol 33, 2015 (suppl; abstr 3056). DM1YSMD RU http://meetinglibrary.asco.org/content/150554-156 DM1ZY6M DI DM1ZY6M DM1ZY6M DN 227Th-labelled MSLN-TTC DM1ZY6M TI TT4RXME DM1ZY6M TN Mesothelin (MSLN) DM1ZY6M RN Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. DM1ZY6M RU https://pubmed.ncbi.nlm.nih.gov/31064781 DM20HS7 DI DM20HS7 DM20HS7 DN GTP-004 DM20HS7 TI TT1RS9F DM20HS7 TN Acetylcholinesterase (AChE) DM20HS7 MA Inhibitor DM20HS7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM20HS7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM23K45 DI DM23K45 DM23K45 DN Pc4 DM23K45 TI TTJGNVC DM23K45 TN Apoptosis regulator Bcl-2 (BCL-2) DM23K45 MA Agonist DM23K45 RN Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8. DM23K45 RU https://pubmed.ncbi.nlm.nih.gov/12929741 DM2594H DI DM2594H DM2594H DN PS-178990 DM2594H TI TTS64P2 DM2594H TN Androgen receptor (AR) DM2594H MA Binder DM2594H RN Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010. DM2594H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602589/ DM25CBW DI DM25CBW DM25CBW DN A-348441 DM25CBW TI TTOZRK6 DM25CBW TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM25CBW MA Inhibitor DM25CBW RN Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90. DM25CBW RU https://pubmed.ncbi.nlm.nih.gov/16987661 DM25GIA DI DM25GIA DM25GIA DN REC-01 DM25GIA TI TTDIGC1 DM25GIA TN Dipeptidyl peptidase 4 (DPP-4) DM25GIA MA Inhibitor DM25GIA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25GIA RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM27J3D DI DM27J3D DM27J3D DN BLU-554 DM27J3D TI TT1KX2S DM27J3D TN FGFR4 messenger RNA (FGFR4 mRNA) DM27J3D MA Inhibitor DM27J3D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM27J3D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM289Z4 DI DM289Z4 DM289Z4 DN LY2624587 DM289Z4 TI TTBID49 DM289Z4 TN C-X-C chemokine receptor type 4 (CXCR4) DM289Z4 MA Antagonist DM289Z4 RN Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585. DM289Z4 RU https://pubmed.ncbi.nlm.nih.gov/26954567 DM2AHXW DI DM2AHXW DM2AHXW DN CD171 specific CAR T cells expressing EGFRt DM2AHXW TI TTC9D3K DM2AHXW TN Neural cell adhesion molecule L1 (L1CAM) DM2AHXW MA CAR-T-Cell-Therapy DM2AHXW RN ClinicalTrials.gov (NCT02311621) Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 DM2AHXW RU https://clinicaltrials.gov/ct2/show/NCT02311621 DM2B0TJ DI DM2B0TJ DM2B0TJ DN Leukocyte interleukin DM2B0TJ TI TT9721Y DM2B0TJ TN Interleukin 2 receptor beta (IL2RB) DM2B0TJ MA Modulator DM2B0TJ RN Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64. DM2B0TJ RU https://pubmed.ncbi.nlm.nih.gov/7650289 DM2B9E0 DI DM2B9E0 DM2B9E0 DN AT13387 DM2B9E0 TI TT78R5H DM2B9E0 TN Heat shock protein 90 alpha (HSP90A) DM2B9E0 MA Inhibitor DM2B9E0 RN Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008. DM2B9E0 RU http://www.drugs.com/clinical_trials/astex-presents-updates-at13387-hsp90-inhibitor-at9283-multi-targeted-kinase-inhibitor-eortc-nci-5775.html DM2BYWI DI DM2BYWI DM2BYWI DN MGD019 DM2BYWI TI TTI2S1D DM2BYWI TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM2BYWI MA Inhibitor DM2BYWI RN Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DM2BYWI RU https://pubmed.ncbi.nlm.nih.gov/33377134 DM2BYWI DI DM2BYWI DM2BYWI DN MGD019 DM2BYWI TI TTNBFWK DM2BYWI TN Programmed cell death protein 1 (PD-1) DM2BYWI MA Inhibitor DM2BYWI RN Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DM2BYWI RU https://pubmed.ncbi.nlm.nih.gov/33377134 DM2D7Z0 DI DM2D7Z0 DM2D7Z0 DN PPC-5650 DM2D7Z0 TI TTRJYB6 DM2D7Z0 TN Acid-sensing ion channel 1 (ASIC1) DM2D7Z0 MA Modulator DM2D7Z0 RN ClinicalTrials.gov (NCT01449487) Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid. U.S. National Institutes of Health. DM2D7Z0 RU https://clinicaltrials.gov/ct2/show/NCT01449487 DM2E5Z7 DI DM2E5Z7 DM2E5Z7 DN RG7882 DM2E5Z7 TI TT4RXME DM2E5Z7 TN Mesothelin (MSLN) DM2E5Z7 RN Molecular Imaging As a Tool for Drug Development and Trial Design. JCO July 13, 2015 JCO.2015.61.6425 DM2E5Z7 RU http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6425.full DM2FH10 DI DM2FH10 DM2FH10 DN INBRX-105 DM2FH10 TI TTPW9LJ DM2FH10 TN Co-stimulatory molecule 4-1BB (CD137) DM2FH10 MA Agonist DM2FH10 RN Clinical pipeline report, company report or official report of Inhibrx. DM2FH10 RU https://inhibrx.com/inbrx-105/ DM2FH10 DI DM2FH10 DM2FH10 DN INBRX-105 DM2FH10 TI TT8ZLTI DM2FH10 TN Programmed cell death 1 ligand 1 (PD-L1) DM2FH10 MA Inhibitor DM2FH10 RN Clinical pipeline report, company report or official report of Inhibrx. DM2FH10 RU https://inhibrx.com/inbrx-105/ DM2GHIP DI DM2GHIP DM2GHIP DN FFC-14A DM2GHIP TI TTUTN1I DM2GHIP TN Human Deoxyribonucleic acid (hDNA) DM2GHIP MA Binder DM2GHIP RN The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21. DM2GHIP RU https://pubmed.ncbi.nlm.nih.gov/16039951 DM2HES0 DI DM2HES0 DM2HES0 DN CTCE-0214 DM2HES0 TI TTBID49 DM2HES0 TN C-X-C chemokine receptor type 4 (CXCR4) DM2HES0 MA Agonist DM2HES0 RN Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. DM2HES0 RU https://pubmed.ncbi.nlm.nih.gov/21274742 DM2IDQ9 DI DM2IDQ9 DM2IDQ9 DN RG-7103 DM2IDQ9 TI TT4O5P0 DM2IDQ9 TN Helodermin-preferring VIP receptor (VIPR2) DM2IDQ9 MA Agonist DM2IDQ9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027925) DM2IDQ9 RU http://adisinsight.springer.com/drugs/800027925 DM2IEB7 DI DM2IEB7 DM2IEB7 DN Anti-CD30-CAR T cells DM2IEB7 TI TT2GM5R DM2IEB7 TN Lymphocyte activation antigen CD30 (TNFRSF8) DM2IEB7 MA CAR-T-Cell-Therapy DM2IEB7 RN ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas DM2IEB7 RU https://clinicaltrials.gov/ct2/show/NCT03049449 DM2KCIP DI DM2KCIP DM2KCIP DN GSK3179106 DM2KCIP TI TT4DXQT DM2KCIP TN Proto-oncogene c-Ret (RET) DM2KCIP MA Inhibitor DM2KCIP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2KCIP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM2KVM0 DI DM2KVM0 DM2KVM0 DN BI-44847 DM2KVM0 TI TTLWPVF DM2KVM0 TN Sodium/glucose cotransporter 2 (SGLT2) DM2KVM0 MA Modulator DM2KVM0 RN Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes DM2KVM0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437808 DM2L7TH DI DM2L7TH DM2L7TH DN GSK1521498 DM2L7TH TI TTKWM86 DM2L7TH TN Opioid receptor mu (MOP) DM2L7TH MA Agonist DM2L7TH RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM2L7TH RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM2LHPU DI DM2LHPU DM2LHPU DN ZK-200775 DM2LHPU TI TTAN6JD DM2LHPU TN Glutamate receptor AMPA (GRIA) DM2LHPU MA Inhibitor DM2LHPU RN Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10. DM2LHPU RU https://pubmed.ncbi.nlm.nih.gov/11354378 DM2MILF DI DM2MILF DM2MILF DN GPA-TriMAR-T cells DM2MILF TI TT9VL2N DM2MILF TN Gp100[209-217] peptide (PMEL) DM2MILF MA CAR-T-Cell-Therapy DM2MILF RN ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy DM2MILF RU https://clinicaltrials.gov/ct2/show/NCT03649529 DM2NBC7 DI DM2NBC7 DM2NBC7 DN EZN-2968 DM2NBC7 TI TTQHWNA DM2NBC7 TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM2NBC7 MA Modulator DM2NBC7 RN Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8. DM2NBC7 RU https://www.ncbi.nlm.nih.gov/pubmed/24292632 DM2NTBL DI DM2NTBL DM2NTBL DN PF-05241328 DM2NTBL TI TT4G2JS DM2NTBL TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM2NTBL MA Inhibitor DM2NTBL RN Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. DM2NTBL RU https://pubmed.ncbi.nlm.nih.gov/25060923 DM2OB6S DI DM2OB6S DM2OB6S DN CI-8993 DM2OB6S TI TT51SK8 DM2OB6S TN V-set immunoregulatory receptor (VSIR) DM2OB6S MA Antagonist DM2OB6S RN Clinical pipeline report, company report or official report of Curis. DM2OB6S RU https://www.curis.com/pipeline/ci-8993/ DM2OEQ9 DI DM2OEQ9 DM2OEQ9 DN CD19-directed CAR-T cells DM2OEQ9 TI TTW640A DM2OEQ9 TN B-lymphocyte surface antigen B4 (CD19) DM2OEQ9 MA CAR-T-Cell-Therapy DM2OEQ9 RN ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects DM2OEQ9 RU https://clinicaltrials.gov/ct2/show/NCT03483688 DM2POGY DI DM2POGY DM2POGY DN AMG 509 DM2POGY TI TT9E64S DM2POGY TN Metalloreductase STEAP1 (STEAP1) DM2POGY MA Inhibitor DM2POGY RN Clinical pipeline report, company report or official report of Amgen. DM2POGY RU https://www.amgenpipeline.com/ DM2PVLH DI DM2PVLH DM2PVLH DN MGA271 DM2PVLH TI TT6CQUM DM2PVLH TN B7 homolog 3 (CD276) DM2PVLH MA Modulator DM2PVLH RN T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236. DM2PVLH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107447/ DM2PYE0 DI DM2PYE0 DM2PYE0 DN DSP-8658 DM2PYE0 TI TTZMAO3 DM2PYE0 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM2PYE0 MA Modulator DM2PYE0 RN Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9. DM2PYE0 RU https://pubmed.ncbi.nlm.nih.gov/26011171 DM2QBMI DI DM2QBMI DM2QBMI DN CLP-1004 DM2QBMI TI TT1VOHK DM2QBMI TN Potassium channel unspecific (KC) DM2QBMI MA Binder DM2QBMI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783) DM2QBMI RU http://adisinsight.springer.com/drugs/800036783 DM2S04R DI DM2S04R DM2S04R DN Zemab DM2S04R TI TT6EO5L DM2S04R TN Erbb2 tyrosine kinase receptor (HER2) DM2S04R RN Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883. DM2S04R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202854/ DM2SALJ DI DM2SALJ DM2SALJ DN Flanvotumab DM2SALJ TI TTFRV98 DM2SALJ TN Melanoma antigen gp75 (TYRP1) DM2SALJ RN National Cancer Institute Drug Dictionary (drug id 675217). DM2SALJ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=675217 DM2SQBF DI DM2SQBF DM2SQBF DN 225Ac-labelled aCD33 DM2SQBF TI TTJVYO3 DM2SQBF TN Myeloid cell surface antigen CD33 (CD33) DM2SQBF RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DM2SQBF RU https://pubmed.ncbi.nlm.nih.gov/32728208 DM2TAUR DI DM2TAUR DM2TAUR DN MK-0731 DM2TAUR TI TTTRP0H DM2TAUR TN Kinesin-like protein KIF11 (KIF11) DM2TAUR MA Inhibitor DM2TAUR RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DM2TAUR RU https://pubmed.ncbi.nlm.nih.gov/22825217 DM2TFUD DI DM2TFUD DM2TFUD DN Anti-BCMA CAR-T cells DM2TFUD TI TTZ3P4W DM2TFUD TN B-cell maturation protein (TNFRSF17) DM2TFUD MA CAR-T-Cell-Therapy DM2TFUD RN ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma DM2TFUD RU https://clinicaltrials.gov/ct2/show/NCT03093168 DM2THBX DI DM2THBX DM2THBX DN OM-174 DM2THBX TI TTISGCA DM2THBX TN Toll-like receptor 4 (TLR4) DM2THBX MA Modulator DM2THBX RN Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. DM2THBX RU https://pubmed.ncbi.nlm.nih.gov/23547558 DM2THBX DI DM2THBX DM2THBX DN OM-174 DM2THBX TI TTY7ZHS DM2THBX TN Toll-like receptor 2 (TLR2) DM2THBX MA Modulator DM2THBX RN Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. DM2THBX RU https://pubmed.ncbi.nlm.nih.gov/23547558 DM2UMGE DI DM2UMGE DM2UMGE DN Ad5-TRAIL DM2UMGE TI TTA5MS9 DM2UMGE TN TNF related apoptosis inducing ligand (TNFSF10) DM2UMGE MA Modulator DM2UMGE RN Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006 Jun;13(6):628-32. DM2UMGE RU https://pubmed.ncbi.nlm.nih.gov/16456549 DM2V4EO DI DM2V4EO DM2V4EO DN BCMA CART and huCART19 DM2V4EO TI TTZ3P4W DM2V4EO TN B-cell maturation protein (TNFRSF17) DM2V4EO MA CAR-T-Cell-Therapy(Dual specific) DM2V4EO RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DM2V4EO RU https://clinicaltrials.gov/ct2/show/NCT03549442 DM2V4EO DI DM2V4EO DM2V4EO DN BCMA CART and huCART19 DM2V4EO TI TTW640A DM2V4EO TN B-lymphocyte surface antigen B4 (CD19) DM2V4EO MA CAR-T-Cell-Therapy(Dual specific) DM2V4EO RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DM2V4EO RU https://clinicaltrials.gov/ct2/show/NCT03549442 DM2WMJ7 DI DM2WMJ7 DM2WMJ7 DN BMS-816336 DM2WMJ7 TI TTN7BL9 DM2WMJ7 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM2WMJ7 MA Inhibitor DM2WMJ7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027626) DM2WMJ7 RU http://adisinsight.springer.com/drugs/800027626 DM2WZ86 DI DM2WZ86 DM2WZ86 DN TRV250 DM2WZ86 TI TT27RFC DM2WZ86 TN Opioid receptor delta (OPRD1) DM2WZ86 MA Modulator DM2WZ86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2WZ86 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM2XIRW DI DM2XIRW DM2XIRW DN NMS-03305293 DM2XIRW TI TTVDSZ0 DM2XIRW TN Poly [ADP-ribose] polymerase 1 (PARP1) DM2XIRW MA Inhibitor DM2XIRW RN NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843. DM2XIRW RU https://cancerres.aacrjournals.org/content/78/13_Supplement/4843 DM2Y4D7 DI DM2Y4D7 DM2Y4D7 DN UCARTCS1 DM2Y4D7 TI TT7ILZ1 DM2Y4D7 TN SLAM family member 7 SLAMF7 (CS1) DM2Y4D7 RN ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health. DM2Y4D7 RU https://clinicaltrials.gov/ct2/show/NCT04142619 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TT7HF4W DM2Y4FG TN Cyclin-dependent kinase 2 (CDK2) DM2Y4FG MA Inhibitor DM2Y4FG RN A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21368575 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TT0PG8F DM2Y4FG TN Cyclin-dependent kinase 4 (CDK4) DM2Y4FG MA Inhibitor DM2Y4FG RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21253554 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TTH6V3D DM2Y4FG TN Cyclin-dependent kinase 1 (CDK1) DM2Y4FG MA Inhibitor DM2Y4FG RN A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21368575 DM2Z4YQ DI DM2Z4YQ DM2Z4YQ DN BI 907828 DM2Z4YQ TI TT08GJW DM2Z4YQ TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM2Z4YQ MA Inhibitor DM2Z4YQ RN MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874. DM2Z4YQ RU https://pubmed.ncbi.nlm.nih.gov/32651541 DM2ZJ1C DI DM2ZJ1C DM2ZJ1C DN PF-06747143 DM2ZJ1C TI TTBID49 DM2ZJ1C TN C-X-C chemokine receptor type 4 (CXCR4) DM2ZJ1C MA Antagonist DM2ZJ1C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2ZJ1C RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM31FOP DI DM31FOP DM31FOP DN NI-0101 DM31FOP TI TTISGCA DM31FOP TN Toll-like receptor 4 (TLR4) DM31FOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DM31FOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DM31RQS DI DM31RQS DM31RQS DN BAY 86-8050 DM31RQS TI TTYCILE DM31RQS TN Vasopressin receptor (VR) DM31RQS MA Modulator DM31RQS RN WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists. DM31RQS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20150319&CC=WO&NR=2015036563A1&KC=A1 DM31VNC DI DM31VNC DM31VNC DN DS-8895 DM31VNC TI TTRJB2G DM31VNC TN Ephrin type-A receptor 2 (EPHA2) DM31VNC RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DM31VNC RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM324RM DI DM324RM DM324RM DN JCAR023 DM324RM TI TTC9D3K DM324RM TN Neural cell adhesion molecule L1 (L1CAM) DM324RM MA CAR-T-Cell-Therapy DM324RM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM324RM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM32TFO DI DM32TFO DM32TFO DN CP-870,893 DM32TFO TI TTN6Y9A DM32TFO TN CD40L receptor (CD40) DM32TFO MA Agonist DM32TFO RN Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83. DM32TFO RU https://pubmed.ncbi.nlm.nih.gov/17327609 DM32VKQ DI DM32VKQ DM32VKQ DN NI-0701 DM32VKQ TI TT9DWLC DM32VKQ TN T-cell-specific protein RANTES (CCL5) DM32VKQ MA Inhibitor DM32VKQ RN Handbook of Therapeutic Antibodies. Stefan D bel, Janice M. Reichert, 2014. Page(1021). DM32VKQ RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA1021&lpg=PA1021&dq=%E2%80%9CNI-0701%E2%80%9D++RANTES&source=bl&ots=OSgek1U9gk&sig=gMuc7gZ8ZO4IH9EIdhuDhOrHTaU&hl=zh-CN&sa=X&ved=0CC8Q6AEwA2oVChMItuDj3InGyAIVzQmOCh0QPQ3H#v=onepage&q=%E2%80%9CNI-0701%E2%80%9D%20%20RANTES&f=false DM3402P DI DM3402P DM3402P DN MDX-1411 DM3402P TI TTNCIE0 DM3402P TN CD70 antigen (CD27-L) DM3402P RN Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3. DM3402P RU https://pubmed.ncbi.nlm.nih.gov/19741612 DM3415L DI DM3415L DM3415L DN BAX-499 DM3415L TI TT068JH DM3415L TN Tissue factor pathway inhibitor (TFPI) DM3415L MA Inhibitor DM3415L RN Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45. DM3415L RU https://pubmed.ncbi.nlm.nih.gov/23528042 DM3427C DI DM3427C DM3427C DN PF-4427429 DM3427C TI TTAFORY DM3427C TN Calcitonin gene-related peptide (CALC) DM3427C MA Modulator DM3427C RN Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints DM3427C RU http://www.tevapharm.com/news/teva_announces_positive_results_for_tev_48125_in_phase_iib_chronic_migraine_study_meeting_primary_and_secondary_endpoints_02_15.aspx DM36EY7 DI DM36EY7 DM36EY7 DN AZD4721 DM36EY7 TI TT30C9G DM36EY7 TN C-X-C chemokine receptor type 2 (CXCR2) DM36EY7 MA Antagonist DM36EY7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038326) DM36EY7 RU http://adisinsight.springer.com/drugs/800038326 DM36FOG DI DM36FOG DM36FOG DN APD-597 DM36FOG TI TT7QNVC DM36FOG TN Glucose-dependent insulinotropic receptor (GPR119) DM36FOG MA Agonist DM36FOG RN Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5. DM36FOG RU https://pubmed.ncbi.nlm.nih.gov/22264481 DM36ONA DI DM36ONA DM36ONA DN Turofexorate isopropyl DM36ONA TI TTS4UGC DM36ONA TN Farnesoid X-activated receptor (FXR) DM36ONA MA Modulator DM36ONA RN A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. DM36ONA RU https://pubmed.ncbi.nlm.nih.gov/19136377 DM36PKZ DI DM36PKZ DM36PKZ DN PF-3758309 DM36PKZ TI TT7Y3BZ DM36PKZ TN PAK-4 protein kinase (PAK4) DM36PKZ MA Inhibitor DM36PKZ RN Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. DM36PKZ RU https://pubmed.ncbi.nlm.nih.gov/20439741 DM36WTQ DI DM36WTQ DM36WTQ DN AC-262271 DM36WTQ TI TTZ9SOR DM36WTQ TN Muscarinic acetylcholine receptor M1 (CHRM1) DM36WTQ MA Agonist DM36WTQ RN Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals. DM36WTQ RU http://www.biocentury.com/products/ac-262271 DM3720L DI DM3720L DM3720L DN REGN5093 DM3720L TI TTNDSF4 DM3720L TN Proto-oncogene c-Met (MET) DM3720L MA Inhibitor DM3720L RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM3720L RU https://www.regeneron.com/science/pipeline DM37OJN DI DM37OJN DM37OJN DN CD20-CAR-T Cells DM37OJN TI TTUE541 DM37OJN TN Leukocyte surface antigen Leu-16 (CD20) DM37OJN MA CAR-T-Cell-Therapy DM37OJN RN ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma DM37OJN RU https://clinicaltrials.gov/ct2/show/NCT03576807 DM38F50 DI DM38F50 DM38F50 DN PTX-35 DM38F50 TI TTDV6BQ DM38F50 TN Tumor necrosis factor receptor member 25 (TNFRSF25) DM38F50 MA Agonist DM38F50 RN Clinical pipeline report, company report or official report of Pelican Therapeutics. DM38F50 RU https://www.pelicantherapeutics.com/products DM38JZU DI DM38JZU DM38JZU DN EMD-1204831 DM38JZU TI TTNDSF4 DM38JZU TN Proto-oncogene c-Met (MET) DM38JZU MA Inhibitor DM38JZU RN 2012 ASCO Annual Meeting. DM38JZU RU http://meetinglibrary.asco.org/subcategories/2012%20ASCO%20Annual%20Meeting DM39LPN DI DM39LPN DM39LPN DN CarVAC DM39LPN TI TTW640A DM39LPN TN B-lymphocyte surface antigen B4 (CD19) DM39LPN RN ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health. DM39LPN RU https://clinicaltrials.gov/ct2/show/NCT04156243 DM39PSZ DI DM39PSZ DM39PSZ DN ME1100 DM39PSZ TI TTOVFH2 DM39PSZ TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM39PSZ MA Inhibitor DM39PSZ RN ClinicalTrials.gov (NCT01961830) Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers. U.S. National Institutes of Health. DM39PSZ RU https://clinicaltrials.gov/ct2/show/NCT01961830 DM39QWN DI DM39QWN DM39QWN DN ANS-6637 DM39QWN TI TTFLN4T DM39QWN TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM39QWN MA Inhibitor DM39QWN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM39QWN RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM3AD65 DI DM3AD65 DM3AD65 DN EGFR806-specific CAR T cell DM3AD65 TI TTGKNB4 DM3AD65 TN Epidermal growth factor receptor (EGFR) DM3AD65 MA CAR-T-Cell-Therapy DM3AD65 RN ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors DM3AD65 RU https://clinicaltrials.gov/ct2/show/NCT03638167 DM3AHNX DI DM3AHNX DM3AHNX DN CAR-T Cells targeting CD19 DM3AHNX TI TTW640A DM3AHNX TN B-lymphocyte surface antigen B4 (CD19) DM3AHNX MA CAR-T-Cell-Therapy DM3AHNX RN ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia DM3AHNX RU https://clinicaltrials.gov/ct2/show/NCT03186118 DM3DUHL DI DM3DUHL DM3DUHL DN TESTOSTERONE BUCICLATE DM3DUHL TI TTS64P2 DM3DUHL TN Androgen receptor (AR) DM3DUHL MA Agonist DM3DUHL RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DM3DUHL RU https://pubmed.ncbi.nlm.nih.gov/2912689 DM3E20L DI DM3E20L DM3E20L DN Nagrestipen DM3E20L TI TT8I4WB DM3E20L TN Macrophage inflammatory protein 1-alpha (CCL3) DM3E20L MA Modulator DM3E20L RN Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. Cancer Res. 2014 Sep 15;74(18):5070-8. DM3E20L RU https://pubmed.ncbi.nlm.nih.gov/25038226 DM3E2IY DI DM3E2IY DM3E2IY DN 225Ac-labelled aCD38 DM3E2IY TI TTPURFN DM3E2IY TN Cyclic ADP-ribose hydrolase 1 (CD38) DM3E2IY RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DM3E2IY RU https://pubmed.ncbi.nlm.nih.gov/32728208 DM3EWUX DI DM3EWUX DM3EWUX DN AZD8701 DM3EWUX TI TT1X3QF DM3EWUX TN FOXP3 messenger RNA (FOXP3 mRNA) DM3EWUX MA Inhibitor DM3EWUX RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM3EWUX RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM3GSB2 DI DM3GSB2 DM3GSB2 DN TPST-1495 DM3GSB2 TI TT79WV3 DM3GSB2 TN Prostaglandin E2 receptor EP4 (PTGER4) DM3GSB2 MA Antagonist DM3GSB2 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DM3GSB2 RU https://www.tempesttx.com/pipeline/ DM3GSB2 DI DM3GSB2 DM3GSB2 DN TPST-1495 DM3GSB2 TI TT1ZAVI DM3GSB2 TN Prostaglandin E2 receptor EP2 (PTGER2) DM3GSB2 MA Antagonist DM3GSB2 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DM3GSB2 RU https://www.tempesttx.com/pipeline/ DM3GSPR DI DM3GSPR DM3GSPR DN GEM3PSCA DM3GSPR TI TT9T4AV DM3GSPR TN Prostate stem cell antigen (PSCA) DM3GSPR MA Inhibitor DM3GSPR RN Clinical pipeline report, company report or official report of Gemoab. DM3GSPR RU https://www.gemoab.com/gem3psca DM3H6YC DI DM3H6YC DM3H6YC DN G-619 DM3H6YC TI TT2O84V DM3H6YC TN Thromboxane A2 receptor (TBXA2R) DM3H6YC MA Modulator DM3H6YC RN G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9. DM3H6YC RU https://pubmed.ncbi.nlm.nih.gov/8566149 DM3H6YC DI DM3H6YC DM3H6YC DN G-619 DM3H6YC TI TTKNWZ4 DM3H6YC TN Thromboxane-A synthase (TBXAS1) DM3H6YC MA Modulator DM3H6YC RN G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9. DM3H6YC RU https://pubmed.ncbi.nlm.nih.gov/8566149 DM3HOUX DI DM3HOUX DM3HOUX DN OPL-CCL2-LPM DM3HOUX TI TTFZYTO DM3HOUX TN C-C chemokine receptor type 2 (CCR2) DM3HOUX MA Modulator DM3HOUX RN Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303. DM3HOUX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675261/ DM3IJQ5 DI DM3IJQ5 DM3IJQ5 DN MEDI5117 DM3IJQ5 TI TTT1V78 DM3IJQ5 TN Interleukin-6 (IL6) DM3IJQ5 MA Modulator DM3IJQ5 RN Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. DM3IJQ5 RU https://pubmed.ncbi.nlm.nih.gov/21723291 DM3IPSX DI DM3IPSX DM3IPSX DN ATLCAR.CD30.CCR4 cells DM3IPSX TI TT2GM5R DM3IPSX TN Lymphocyte activation antigen CD30 (TNFRSF8) DM3IPSX MA CAR-T-Cell-Therapy(Dual specific) DM3IPSX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DM3IPSX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DM3IPSX DI DM3IPSX DM3IPSX DN ATLCAR.CD30.CCR4 cells DM3IPSX TI TT7HQD0 DM3IPSX TN C-C chemokine receptor type 4 (CCR4) DM3IPSX MA CAR-T-Cell-Therapy(Dual specific) DM3IPSX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DM3IPSX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DM3IT6R DI DM3IT6R DM3IT6R DN N9-GP DM3IT6R TI TTFEZ5Q DM3IT6R TN Coagulation factor IX (F9) DM3IT6R MA Modulator DM3IT6R RN Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011 Sep 8;118(10):2695-701. DM3IT6R RU https://pubmed.ncbi.nlm.nih.gov/21555744 DM3J1T9 DI DM3J1T9 DM3J1T9 DN CPC-212 DM3J1T9 TI TT1RS9F DM3J1T9 TN Acetylcholinesterase (AChE) DM3J1T9 MA Inhibitor DM3J1T9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3J1T9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3JOIX DI DM3JOIX DM3JOIX DN BI-754091 DM3JOIX TI TTNBFWK DM3JOIX TN Programmed cell death protein 1 (PD-1) DM3JOIX RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM3JOIX RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM3JUXW DI DM3JUXW DM3JUXW DN MVA HER-2 AutoVac DM3JUXW TI TT6EO5L DM3JUXW TN Erbb2 tyrosine kinase receptor (HER2) DM3JUXW RN Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8. DM3JUXW RU https://pubmed.ncbi.nlm.nih.gov/23585514 DM3K4FY DI DM3K4FY DM3K4FY DN TG-1801 DM3K4FY TI TTW640A DM3K4FY TN B-lymphocyte surface antigen B4 (CD19) DM3K4FY RN Clinical pipeline report, company report or official report of TG Theraputics. DM3K4FY RU https://www.tgtherapeutics.com/our-pipeline/tg-1801/ DM3K4FY DI DM3K4FY DM3K4FY DN TG-1801 DM3K4FY TI TT28S46 DM3K4FY TN Leukocyte surface antigen CD47 (CD47) DM3K4FY RN Clinical pipeline report, company report or official report of TG Theraputics. DM3K4FY RU https://www.tgtherapeutics.com/our-pipeline/tg-1801/ DM3K8VM DI DM3K8VM DM3K8VM DN BMS-908662 DM3K8VM TI TTWCGQT DM3K8VM TN Serine/threonine-protein kinase B-raf (BRAF) DM3K8VM MA Inhibitor DM3K8VM RN Clinical pipeline report, company report or official report of Exelixis (2011). DM3K8VM RU http://www.exelixis.com/pipeline DM3KARJ DI DM3KARJ DM3KARJ DN GSK2647544 DM3KARJ TI TTDNFMT DM3KARJ TN Platelet-activating factor acetylhydrolase (PLA2G7) DM3KARJ MA Modulator DM3KARJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432). DM3KARJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432 DM3KYO4 DI DM3KYO4 DM3KYO4 DN ZD-9379 DM3KYO4 TI TTZ8EM9 DM3KYO4 TN Glycine receptor (GlyR) DM3KYO4 MA Modulator DM3KYO4 RN Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26. DM3KYO4 RU https://pubmed.ncbi.nlm.nih.gov/12829411 DM3LOF1 DI DM3LOF1 DM3LOF1 DN E 7974 DM3LOF1 TI TTML2WA DM3LOF1 TN Tubulin (TUB) DM3LOF1 MA Inhibitor DM3LOF1 RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DM3LOF1 RU https://pubmed.ncbi.nlm.nih.gov/18764727 DM3LRAC DI DM3LRAC DM3LRAC DN XL092 DM3LRAC TI TTVJ1D8 DM3LRAC TN Vascular endothelial growth factor receptor (VEGFR) DM3LRAC MA Inhibitor DM3LRAC RN Clinical pipeline report, company report or official report of Exelixis. DM3LRAC RU https://www.exelixis.com/pipeline/ DM3LRAC DI DM3LRAC DM3LRAC DN XL092 DM3LRAC TI TTNDSF4 DM3LRAC TN Proto-oncogene c-Met (MET) DM3LRAC MA Inhibitor DM3LRAC RN Clinical pipeline report, company report or official report of Exelixis. DM3LRAC RU https://www.exelixis.com/pipeline/ DM3LRAF DI DM3LRAF DM3LRAF DN CD19CAT-41BBZ CAR T-cells DM3LRAF TI TTW640A DM3LRAF TN B-lymphocyte surface antigen B4 (CD19) DM3LRAF MA CAR-T-Cell-Therapy DM3LRAF RN ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19 DM3LRAF RU https://clinicaltrials.gov/ct2/show/NCT02935257 DM3O52N DI DM3O52N DM3O52N DN RLY-4008 DM3O52N TI TTGJVQM DM3O52N TN Fibroblast growth factor receptor 2 (FGFR2) DM3O52N MA Inhibitor DM3O52N RN Clinical pipeline report, company report or official report of Relay Therapeutics. DM3O52N RU https://relaytx.com/pipeline/ DM3OFZC DI DM3OFZC DM3OFZC DN Anti-BCMA CAR T cells DM3OFZC TI TTZ3P4W DM3OFZC TN B-cell maturation protein (TNFRSF17) DM3OFZC MA CAR-T-Cell-Therapy DM3OFZC RN ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma DM3OFZC RU https://clinicaltrials.gov/ct2/show/NCT03559764 DM3OP41 DI DM3OP41 DM3OP41 DN LXR 623 DM3OP41 TI TTM1EQF DM3OP41 TN Oxysterols receptor LXR (NR1H) DM3OP41 MA Modulator DM3OP41 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DM3OP41 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DM3P0H1 DI DM3P0H1 DM3P0H1 DN Duvortuxizumab DM3P0H1 TI TTW640A DM3P0H1 TN B-lymphocyte surface antigen B4 (CD19) DM3P0H1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3P0H1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3PC0J DI DM3PC0J DM3PC0J DN N-8295 DM3PC0J TI TTSHG0T DM3PC0J TN Toll-like receptor 9 (TLR9) DM3PC0J RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019871) DM3PC0J RU http://adisinsight.springer.com/drugs/800019871 DM3PJSE DI DM3PJSE DM3PJSE DN TP-271 DM3PJSE TI TTOVFH2 DM3PJSE TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM3PJSE MA Inhibitor DM3PJSE RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DM3PJSE RU https://www.tphase.com/products/pipeline/ DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTWTSCV DM3PVBJ TN RAC-alpha serine/threonine-protein kinase (AKT1) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTAZ05C DM3PVBJ TN RAC-gamma serine/threonine-protein kinase (AKT3) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTG0U4H DM3PVBJ TN Ribosomal protein S6 kinase beta-1 (S6K1) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3RSMF DI DM3RSMF DM3RSMF DN Sgx523 DM3RSMF TI TTNDSF4 DM3RSMF TN Proto-oncogene c-Met (MET) DM3RSMF MA Inhibitor DM3RSMF RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DM3RSMF RU http://www.centerwatch.com/ DM3U2VY DI DM3U2VY DM3U2VY DN CG-200745 DM3U2VY TI TTBH0VX DM3U2VY TN Histone deacetylase (HDAC) DM3U2VY MA Inhibitor DM3U2VY RN Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. DM3U2VY RU https://pubmed.ncbi.nlm.nih.gov/25781604 DM3VC6T DI DM3VC6T DM3VC6T DN EW-A-401 DM3VC6T TI TT2Q6G1 DM3VC6T TN Vascular endothelial growth factor receptor 1 (FLT-1) DM3VC6T MA Modulator DM3VC6T RN DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007 DM3VC6T RU http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(14)00160-6 DM3WP70 DI DM3WP70 DM3WP70 DN MEDI-547 DM3WP70 TI TTRJB2G DM3WP70 TN Ephrin type-A receptor 2 (EPHA2) DM3WP70 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822). DM3WP70 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1822 DM3YZCV DI DM3YZCV DM3YZCV DN ICAR30 T cells DM3YZCV TI TT2GM5R DM3YZCV TN Lymphocyte activation antigen CD30 (TNFRSF8) DM3YZCV MA CAR-T-Cell-Therapy DM3YZCV RN ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas DM3YZCV RU https://clinicaltrials.gov/ct2/show/NCT03383965 DM3Z07E DI DM3Z07E DM3Z07E DN TP-1287 DM3Z07E TI TT1LVF2 DM3Z07E TN Cyclin-dependent kinase 9 (CDK9) DM3Z07E MA Inhibitor DM3Z07E RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DM3Z07E RU https://www.sdponcology.com/pipeline/ DM3Z2JB DI DM3Z2JB DM3Z2JB DN GDC-0349 DM3Z2JB TI TTCJG29 DM3Z2JB TN Serine/threonine-protein kinase mTOR (mTOR) DM3Z2JB MA Inhibitor DM3Z2JB RN Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. DM3Z2JB RU https://pubmed.ncbi.nlm.nih.gov/24900569 DM3ZW6A DI DM3ZW6A DM3ZW6A DN VAN-10-4-eluting stent DM3ZW6A TI TT4TQBX DM3ZW6A TN Extracellular signal-regulated kinase 2 (ERK2) DM3ZW6A MA Inhibitor DM3ZW6A RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DM3ZW6A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DM3ZW6A DI DM3ZW6A DM3ZW6A DN VAN-10-4-eluting stent DM3ZW6A TI TT1MG9E DM3ZW6A TN Extracellular signal-regulated kinase 1 (ERK1) DM3ZW6A MA Inhibitor DM3ZW6A RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DM3ZW6A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DM42KZW DI DM42KZW DM42KZW DN DS-1093 DM42KZW TI TTJQFBG DM42KZW TN HIF-prolyl hydroxylase (HPH) DM42KZW MA Modulator DM42KZW RN Company report (Daiichisankyo) DM42KZW RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM43GPX DI DM43GPX DM43GPX DN BVI-007 DM43GPX TI TTIHYA4 DM43GPX TN Thrombopoietin receptor (MPL) DM43GPX MA Antagonist DM43GPX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DM43GPX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM43GPX DI DM43GPX DM43GPX DN BVI-007 DM43GPX TI TTCG5PE DM43GPX TN Thrombopoietin (THPO) DM43GPX MA Inhibitor DM43GPX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM43GPX RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM43RV5 DI DM43RV5 DM43RV5 DN BM-ca DM43RV5 TI TTUE541 DM43RV5 TN Leukocyte surface antigen Leu-16 (CD20) DM43RV5 RN BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44. DM43RV5 RU https://pubmed.ncbi.nlm.nih.gov/21152859 DM43X0Q DI DM43X0Q DM43X0Q DN IM19 DM43X0Q TI TTW640A DM43X0Q TN B-lymphocyte surface antigen B4 (CD19) DM43X0Q MA CAR-T-Cell-Therapy DM43X0Q RN ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients DM43X0Q RU https://clinicaltrials.gov/ct2/show/NCT03528421 DM4581B DI DM4581B DM4581B DN CC-94676 DM4581B TI TTS64P2 DM4581B TN Androgen receptor (AR) DM4581B MA Degrader DM4581B RN ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health. DM4581B RU https://clinicaltrials.gov/ct2/show/NCT04428788 DM45BHM DI DM45BHM DM45BHM DN CEA CAR-T DM45BHM TI TTY6DTE DM45BHM TN Carcinoembryonic antigen CEA (CD66e) DM45BHM RN Clinical pipeline report, company report or official report of Sorrento Therapeutics. DM45BHM RU https://sorrentotherapeutics.com/research/immuno-oncology/car-t/ DM45HT6 DI DM45HT6 DM45HT6 DN RG6062 DM45HT6 TI TTUE541 DM45HT6 TN Leukocyte surface antigen Leu-16 (CD20) DM45HT6 MA Modulator DM45HT6 RN Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. DM45HT6 RU https://pubmed.ncbi.nlm.nih.gov/33739857 DM45MR0 DI DM45MR0 DM45MR0 DN HIP-2B DM45MR0 TI TTL4H8N DM45MR0 TN Regenerating human pro-islet peptide (REG3A) DM45MR0 MA Modulator DM45MR0 RN Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33. DM45MR0 RU https://pubmed.ncbi.nlm.nih.gov/10550309 DM45SGE DI DM45SGE DM45SGE DN JNJ-39439335 DM45SGE TI TTMI6F5 DM45SGE TN Transient receptor potential cation channel V1 (TRPV1) DM45SGE MA Antagonist DM45SGE RN Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74. DM45SGE RU https://pubmed.ncbi.nlm.nih.gov/25850459 DM491NI DI DM491NI DM491NI DN SM04755 DM491NI TI TTFPSHI DM491NI TN Wnt signaling pathway (Wnt pathway) DM491NI MA Modulator DM491NI RN A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. DM491NI RU https://clinicaltrials.gov/ct2/show/NCT02191761?term=NCT02191761&rank=1 DM4953W DI DM4953W DM4953W DN KOS-2187 DM4953W TI TT953CX DM4953W TN Motilin receptor (MLNR) DM4953W MA Agonist DM4953W RN Kosan Announces Selection of KOS-2187 As Motilide Clinical Candidate at World Congress of Gastroenterology Meeting. Kosan. 2006. DM4953W RU http://www.redorbit.com/news/health/237602/kosan_announces_selection_of_kos2187_as_motilide_clinical_candidate_at/ DM49O6Y DI DM49O6Y DM49O6Y DN ABBV-323 DM49O6Y TI TTN6Y9A DM49O6Y TN CD40L receptor (CD40) DM49O6Y MA Antagonist DM49O6Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM49O6Y RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM49RAT DI DM49RAT DM49RAT DN CD19 Redirected Autologous T Cells DM49RAT TI TTW640A DM49RAT TN B-lymphocyte surface antigen B4 (CD19) DM49RAT MA CAR-T-Cell-Therapy DM49RAT RN ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) DM49RAT RU https://clinicaltrials.gov/ct2/show/NCT03030976 DM49RI7 DI DM49RI7 DM49RI7 DN EP-51216 DM49RI7 TI TTKMAZ6 DM49RI7 TN Growth hormone receptor (GHR) DM49RI7 MA Agonist DM49RI7 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM49RI7 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM49VWQ DI DM49VWQ DM49VWQ DN JNJ-3534 DM49VWQ TI TTGV6LY DM49VWQ TN Nuclear receptor ROR-gamma (RORG) DM49VWQ MA Modulator DM49VWQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM49VWQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM4A3U7 DI DM4A3U7 DM4A3U7 DN DAVLB-HYDRAZIDE DM4A3U7 TI TTYFKSZ DM4A3U7 TN Tubulin beta (TUBB) DM4A3U7 MA Modulator DM4A3U7 RN An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971. DM4A3U7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/ DM4AU8K DI DM4AU8K DM4AU8K DN PX-478 DM4AU8K TI TTQHWNA DM4AU8K TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM4AU8K MA Inhibitor DM4AU8K RN The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58. DM4AU8K RU https://pubmed.ncbi.nlm.nih.gov/19372568 DM4AXPT DI DM4AXPT DM4AXPT DN VMD-928 DM4AXPT TI TTTDVOJ DM4AXPT TN Tropomyosin-related kinase A (TrkA) DM4AXPT MA Inhibitor DM4AXPT RN ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health. DM4AXPT RU https://clinicaltrials.gov/ct2/show/NCT03556228 DM4BD5U DI DM4BD5U DM4BD5U DN E2730 DM4BD5U TI TTPW8EF DM4BD5U TN Synaptic transmission (ST) DM4BD5U MA Modulator DM4BD5U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4BD5U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4CXE2 DI DM4CXE2 DM4CXE2 DN CAR-20/19-T Cells DM4CXE2 TI TTUE541 DM4CXE2 TN Leukocyte surface antigen Leu-16 (CD20) DM4CXE2 MA CAR-T-Cell-Therapy(Dual specific) DM4CXE2 RN ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells DM4CXE2 RU https://clinicaltrials.gov/ct2/show/NCT03375619 DM4CXE2 DI DM4CXE2 DM4CXE2 DN CAR-20/19-T Cells DM4CXE2 TI TTW640A DM4CXE2 TN B-lymphocyte surface antigen B4 (CD19) DM4CXE2 MA CAR-T-Cell-Therapy(Dual specific) DM4CXE2 RN ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells DM4CXE2 RU https://clinicaltrials.gov/ct2/show/NCT03375619 DM4CY2G DI DM4CY2G DM4CY2G DN PEDF gene therapy DM4CY2G TI TTR59S1 DM4CY2G TN Pigment epithelium-derived factor (SERPINF1) DM4CY2G MA Inhibitor DM4CY2G RN Adenovector pigment epithelium-derived factor (AdPEDF) delivery for wet age-related macular degeneration. Retina. 2005 Dec;25(8 Suppl):S48-S49. DM4CY2G RU https://pubmed.ncbi.nlm.nih.gov/16374334 DM4CZ2Y DI DM4CZ2Y DM4CZ2Y DN ARX-424 DM4CZ2Y TI TT4TZ8J DM4CZ2Y TN Interferon-beta (IFNB1) DM4CZ2Y MA Modulator DM4CZ2Y RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DM4CZ2Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DM4D85V DI DM4D85V DM4D85V DN ARN-6039 DM4D85V TI TTGV6LY DM4D85V TN Nuclear receptor ROR-gamma (RORG) DM4D85V MA Agonist DM4D85V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4D85V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4F8AU DI DM4F8AU DM4F8AU DN HuCART-meso cells DM4F8AU TI TT4RXME DM4F8AU TN Mesothelin (MSLN) DM4F8AU MA CAR-T-Cell-Therapy DM4F8AU RN ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer DM4F8AU RU https://clinicaltrials.gov/ct2/show/NCT03323944 DM4FOX0 DI DM4FOX0 DM4FOX0 DN AK107 DM4FOX0 TI TTV8N19 DM4FOX0 TN Immune checkpoint (ICH) DM4FOX0 MA Inhibitor DM4FOX0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4FOX0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4FW2E DI DM4FW2E DM4FW2E DN LMP400 DM4FW2E TI TTGTQHC DM4FW2E TN DNA topoisomerase I (TOP1) DM4FW2E MA Inhibitor DM4FW2E RN Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. DM4FW2E RU https://pubmed.ncbi.nlm.nih.gov/31227499 DM4G1SP DI DM4G1SP DM4G1SP DN AMG 596 DM4G1SP TI TTUN7MC DM4G1SP TN T-cell surface glycoprotein CD3 (CD3) DM4G1SP MA Inhibitor DM4G1SP RN Clinical pipeline report, company report or official report of Amgen. DM4G1SP RU https://www.amgenpipeline.com/ DM4G1SP DI DM4G1SP DM4G1SP DN AMG 596 DM4G1SP TI TTZ6B2I DM4G1SP TN Epidermal growth factor receptor variant III (EGFR vIII) DM4G1SP MA Inhibitor DM4G1SP RN Clinical pipeline report, company report or official report of Amgen. DM4G1SP RU https://www.amgenpipeline.com/ DM4GJ50 DI DM4GJ50 DM4GJ50 DN CXR-1002 DM4GJ50 TI TTTN5QW DM4GJ50 TN Serine/threonine-protein kinase pim-1 (PIM1) DM4GJ50 MA Inhibitor DM4GJ50 RN 123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46. DM4GJ50 RU http://www.researchgate.net/publication/251668212_123_Antitumor_activity_of_CXR1002_a_novel_anti-cancer_clinical_phase_compound_that_induces_ER_stress_and_inhibits_PIM_kinases_Human_tumor_xenograft_efficacy_and_in_vitro_mode_of_action DM4GKV2 DI DM4GKV2 DM4GKV2 DN TAK-243 DM4GKV2 TI TTU8HT1 DM4GKV2 TN Ubiquitin-activating enzyme (UBA) DM4GKV2 MA Inhibitor DM4GKV2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4GKV2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4I02O DI DM4I02O DM4I02O DN NJA-730 DM4I02O TI TT1ERKL DM4I02O TN CD40 messenger RNA (CD40 mRNA) DM4I02O MA Inhibitor DM4I02O RN Clinical pipeline report, company report or official report of NapaJen Pharma. DM4I02O RU https://www.napajen.com/en/study/nja-730/ DM4I92Z DI DM4I92Z DM4I92Z DN SKI-G-801 DM4I92Z TI TTGJCWZ DM4I92Z TN Fms-like tyrosine kinase 3 (FLT-3) DM4I92Z MA Inhibitor DM4I92Z RN Clinical pipeline report, company report or official report of Genosco. DM4I92Z RU http://genosco.com/pipeline/ski-g-801/ DM4IG16 DI DM4IG16 DM4IG16 DN ZYGK-1 DM4IG16 TI TTDLNGZ DM4IG16 TN Glucokinase (GCK) DM4IG16 MA Activator DM4IG16 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DM4IG16 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DM4JG0B DI DM4JG0B DM4JG0B DN DA-3607 DM4JG0B TI TTA5MS9 DM4JG0B TN TNF related apoptosis inducing ligand (TNFSF10) DM4JG0B MA Binder DM4JG0B RN Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 2006 Feb;13(4):330-8. DM4JG0B RU https://pubmed.ncbi.nlm.nih.gov/16195699 DM4KLNA DI DM4KLNA DM4KLNA DN SM08502 DM4KLNA TI TTFPSHI DM4KLNA TN Wnt signaling pathway (Wnt pathway) DM4KLNA MA Inhibitor DM4KLNA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4KLNA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4KPV0 DI DM4KPV0 DM4KPV0 DN ABT-413 DM4KPV0 TI TTS9BDA DM4KPV0 TN Spectrin non-erythroid beta chain 1 (SPTBN1) DM4KPV0 RN The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. International Journal of Medicinal Chemistry Volume 2011 (2011), Article ID 424535, Page(8). DM4KPV0 RU http://www.hindawi.com/journals/ijmc/2011/424535/ DM4LR0Y DI DM4LR0Y DM4LR0Y DN GSK-958108 DM4LR0Y TI TTSQIFT DM4LR0Y TN 5-HT 1A receptor (HTR1A) DM4LR0Y MA Antagonist DM4LR0Y RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM4LR0Y RU https://gsk.sylogent.com/files/24664.pdf DM4MDCH DI DM4MDCH DM4MDCH DN XMT-1001 DM4MDCH TI TTGTQHC DM4MDCH TN DNA topoisomerase I (TOP1) DM4MDCH MA Inhibitor DM4MDCH RN Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res. 2012 May 1;18(9):2591-602. DM4MDCH RU https://pubmed.ncbi.nlm.nih.gov/22392910 DM4MY9C DI DM4MY9C DM4MY9C DN IM156 DM4MY9C TI TTLAFZV DM4MY9C TN AMP-activated protein kinase (AMPK) DM4MY9C MA Inhibitor DM4MY9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4MY9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4O07Q DI DM4O07Q DM4O07Q DN RWJ-68023 DM4O07Q TI TT953CX DM4O07Q TN Motilin receptor (MLNR) DM4O07Q MA Antagonist DM4O07Q RN Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol. 2004 Apr;57(4):393-401. DM4O07Q RU https://pubmed.ncbi.nlm.nih.gov/15025736 DM4OTWL DI DM4OTWL DM4OTWL DN DA-1229 DM4OTWL TI TTDIGC1 DM4OTWL TN Dipeptidyl peptidase 4 (DPP-4) DM4OTWL MA Inhibitor DM4OTWL RN DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9. DM4OTWL RU https://pubmed.ncbi.nlm.nih.gov/22056373 DM4OWJ8 DI DM4OWJ8 DM4OWJ8 DN CART-ddBCMA DM4OWJ8 TI TTZ3P4W DM4OWJ8 TN B-cell maturation protein (TNFRSF17) DM4OWJ8 RN Clinical pipeline report, company report or official report of Arcellx. DM4OWJ8 RU https://arcellx.com/pipeline/overview/ DM4PWNU DI DM4PWNU DM4PWNU DN CD19 CAR T DM4PWNU TI TTW640A DM4PWNU TN B-lymphocyte surface antigen B4 (CD19) DM4PWNU MA CAR-T-Cell-Therapy DM4PWNU RN ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies DM4PWNU RU https://clinicaltrials.gov/ct2/show/NCT03559439 DM4QIOH DI DM4QIOH DM4QIOH DN JSM 6427 DM4QIOH TI TTHIZP9 DM4QIOH TN Integrin alpha-5 (ITGA5) DM4QIOH MA Antagonist DM4QIOH RN An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. DM4QIOH RU https://pubmed.ncbi.nlm.nih.gov/18804537 DM4QIOH DI DM4QIOH DM4QIOH DN JSM 6427 DM4QIOH TI TTBVIQC DM4QIOH TN Integrin beta-1 (ITGB1) DM4QIOH MA Antagonist DM4QIOH RN An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. DM4QIOH RU https://pubmed.ncbi.nlm.nih.gov/18804537 DM4QPT0 DI DM4QPT0 DM4QPT0 DN PF-05105679 DM4QPT0 TI TTXDKTO DM4QPT0 TN Long transient receptor potential channel 8 (TRPM8) DM4QPT0 MA Modulator DM4QPT0 RN Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69. DM4QPT0 RU https://pubmed.ncbi.nlm.nih.gov/25125580 DM4QV8Y DI DM4QV8Y DM4QV8Y DN TT-301 DM4QV8Y TI TTRYK0X DM4QV8Y TN Interleukin-1 beta (IL1B) DM4QV8Y MA Inhibitor DM4QV8Y RN A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176. DM4QV8Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220427/ DM4R6UV DI DM4R6UV DM4R6UV DN Bradykinin DM4R6UV TI TTGY8IW DM4R6UV TN B2 bradykinin receptor (BDKRB2) DM4R6UV MA Inhibitor DM4R6UV RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DM4R6UV RU https://pubmed.ncbi.nlm.nih.gov/10882364 DM4RHM5 DI DM4RHM5 DM4RHM5 DN Allogeneic CART-33 DM4RHM5 TI TTJVYO3 DM4RHM5 TN Myeloid cell surface antigen CD33 (CD33) DM4RHM5 MA CAR-T-Cell-Therapy DM4RHM5 RN ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML DM4RHM5 RU https://clinicaltrials.gov/ct2/show/NCT02799680 DM4RK6P DI DM4RK6P DM4RK6P DN AR-12 DM4RK6P TI TT9QBI6 DM4RK6P TN Phosphoinositide dependent protein kinase-1 (PDPK1) DM4RK6P MA Modulator DM4RK6P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4RK6P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4SNK8 DI DM4SNK8 DM4SNK8 DN CARD-024 DM4SNK8 TI TTB2MXP DM4SNK8 TN Angiotensinogenase renin (REN) DM4SNK8 MA Agonist DM4SNK8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413). DM4SNK8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TTIU7X1 DM4T5LH TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TT1U2YM DM4T5LH TN Cytomegalovirus DNA polymerase (CMV UL54) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TTMCF1Y DM4T5LH TN Purine nucleoside phosphorylase (PNP) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T916 DI DM4T916 DM4T916 DN BI-836845 DM4T916 TI TTT6LOU DM4T916 TN Insulin-like growth factor-I (IGF1) DM4T916 MA Modulator DM4T916 RN Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409. DM4T916 RU https://www.ncbi.nlm.nih.gov/pubmed/24296829 DM4TN6W DI DM4TN6W DM4TN6W DN ABI-H3733 DM4TN6W TI TTM42UJ DM4TN6W TN Hepatitis B virus Capsid protein (HBV C) DM4TN6W MA Inhibitor DM4TN6W RN Clinical pipeline report, company report or official report of Assembly Biosciences. DM4TN6W RU https://www.assemblybio.com/pipeline/ DM4UAPD DI DM4UAPD DM4UAPD DN Clemizole DM4UAPD TI TTALKDS DM4UAPD TN Hepatitis C virus Non-structural 4B (HCV NS4B) DM4UAPD MA Modulator DM4UAPD RN The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74. DM4UAPD RU https://pubmed.ncbi.nlm.nih.gov/20486856 DM4UOY5 DI DM4UOY5 DM4UOY5 DN TEN010 DM4UOY5 TI TTRA6BO DM4UOY5 TN Bromodomain-containing protein 4 (BRD4) DM4UOY5 MA Modulator DM4UOY5 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DM4UOY5 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DM4UVTO DI DM4UVTO DM4UVTO DN SYN125 DM4UVTO TI TTNBFWK DM4UVTO TN Programmed cell death protein 1 (PD-1) DM4UVTO RN Clinical pipeline report, company report or official report of Symphogen. DM4UVTO RU https://www.synermore.com/pipeline DM4VCJA DI DM4VCJA DM4VCJA DN CD30 CAR T Cells DM4VCJA TI TT2GM5R DM4VCJA TN Lymphocyte activation antigen CD30 (TNFRSF8) DM4VCJA MA CAR-T-Cell-Therapy DM4VCJA RN ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) DM4VCJA RU https://clinicaltrials.gov/ct2/show/NCT02917083 DM4VTX6 DI DM4VTX6 DM4VTX6 DN RASV-Sp DM4VTX6 TI TTHI19T DM4VTX6 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM4VTX6 RN WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae. DM4VTX6 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045620A1&KC=A1 DM4W7Z0 DI DM4W7Z0 DM4W7Z0 DN Emactuzumab DM4W7Z0 TI TT0IQER DM4W7Z0 TN Macrophage colony-stimulating factor 1 (CSF1) DM4W7Z0 MA Antagonist DM4W7Z0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4W7Z0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4W92J DI DM4W92J DM4W92J DN TC-2216 DM4W92J TI TTL1ATN DM4W92J TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM4W92J MA Modulator DM4W92J RN TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77. DM4W92J RU https://www.ncbi.nlm.nih.gov/pubmed/19040552 DM4WAC2 DI DM4WAC2 DM4WAC2 DN APL-501 DM4WAC2 TI TTNBFWK DM4WAC2 TN Programmed cell death protein 1 (PD-1) DM4WAC2 MA Inhibitor DM4WAC2 RN Clinical pipeline report, company report or official report of Apollomics. DM4WAC2 RU https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-501/ DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTWG9A4 DM4WSHG TN Adrenergic receptor alpha-2A (ADRA2A) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTJQOD7 DM4WSHG TN 5-HT 2A receptor (HTR2A) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTEX248 DM4WSHG TN Dopamine D2 receptor (D2R) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4XETK DI DM4XETK DM4XETK DN RX108 DM4XETK TI TTQ38E9 DM4XETK TN Sodium/potassium-transporting ATPase (SPT ATPase) DM4XETK MA Inhibitor DM4XETK RN ClinicalTrials.gov (NCT03646071) A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. DM4XETK RU https://clinicaltrials.gov/ct2/show/NCT03646071 DM4XT15 DI DM4XT15 DM4XT15 DN CART22-65s cells DM4XT15 TI TTM6QSK DM4XT15 TN B-cell receptor CD22 (CD22) DM4XT15 MA CAR-T-Cell-Therapy DM4XT15 RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DM4XT15 RU https://clinicaltrials.gov/ct2/show/NCT03620058 DM4XZY9 DI DM4XZY9 DM4XZY9 DN DWP-09031 DM4XZY9 TI TTE4KHA DM4XZY9 TN Amyloid beta A4 protein (APP) DM4XZY9 MA Inhibitor DM4XZY9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM4XZY9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM4YA0D DI DM4YA0D DM4YA0D DN LBR-101 DM4YA0D TI TTY6O0Q DM4YA0D TN Calcitonin gene-related peptide receptor (CGRPR) DM4YA0D RN Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492. DM4YA0D RU https://pubmed.ncbi.nlm.nih.gov/24366980 DM4YIWK DI DM4YIWK DM4YIWK DN VBY-129 DM4YIWK TI TTUMQVO DM4YIWK TN Cathepsin S (CTSS) DM4YIWK MA Inhibitor DM4YIWK RN Clinical pipeline report, company report or official report of ViroBay. DM4YIWK RU http://www.virobayinc.com/VBY-129.php DM4Z1CH DI DM4Z1CH DM4Z1CH DN 4-aminosalicylate sodium DM4Z1CH TI TTK0943 DM4Z1CH TN Prostaglandin G/H synthase (COX) DM4Z1CH MA Modulator DM4Z1CH RN 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202. DM4Z1CH RU https://pubmed.ncbi.nlm.nih.gov/22493349 DM4ZCY0 DI DM4ZCY0 DM4ZCY0 DN DSP-0337 DM4ZCY0 TI TTH8FZW DM4ZCY0 TN Signal transducer and activator of transcription 3 (STAT3) DM4ZCY0 MA Inhibitor DM4ZCY0 RN Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289. DM4ZCY0 RU https://pubmed.ncbi.nlm.nih.gov/31277685 DM4ZDOE DI DM4ZDOE DM4ZDOE DN DpC DM4ZDOE TI TTUDR0C DM4ZDOE TN Iron (Fe) DM4ZDOE MA Chelator DM4ZDOE RN Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082. DM4ZDOE RU https://pubmed.ncbi.nlm.nih.gov/29334758 DM4ZIRK DI DM4ZIRK DM4ZIRK DN VTX-1463 DM4ZIRK TI TT8CWFK DM4ZIRK TN Toll-like receptor 8 (TLR8) DM4ZIRK MA Agonist DM4ZIRK RN VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6. DM4ZIRK RU https://pubmed.ncbi.nlm.nih.gov/21548830 DM4ZK6G DI DM4ZK6G DM4ZK6G DN GSK3050002 DM4ZK6G TI TT2XAZY DM4ZK6G TN Liver and activation-regulated chemokine (CCL20) DM4ZK6G MA Inhibitor DM4ZK6G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZK6G RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM4ZN8M DI DM4ZN8M DM4ZN8M DN N-803 DM4ZN8M TI TTJFA35 DM4ZN8M TN Interleukin-15 (IL15) DM4ZN8M MA Agonist DM4ZN8M RN The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. DM4ZN8M RU https://pubmed.ncbi.nlm.nih.gov/32163523 DM51MSD DI DM51MSD DM51MSD DN BPX-101 DM51MSD TI TTIJP3Q DM51MSD TN TNF related activation protein (CD40LG) DM51MSD RN Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363. DM51MSD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/ DM529QO DI DM529QO DM529QO DN pbi-shRNA STMN1 DM529QO TI TT7W5OT DM529QO TN STMN1 messenger RNA (STMN1 mRNA) DM529QO MA Inhibitor DM529QO RN Clinical pipeline report, company report or official report of Gradalis. DM529QO RU https://www.gradalisinc.com/product/development-pipeline DM52O7W DI DM52O7W DM52O7W DN GBR1302 DM52O7W TI TT6EO5L DM52O7W TN Erbb2 tyrosine kinase receptor (HER2) DM52O7W MA Inhibitor DM52O7W RN Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals. DM52O7W RU https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf DM52O7W DI DM52O7W DM52O7W DN GBR1302 DM52O7W TI TTUN7MC DM52O7W TN T-cell surface glycoprotein CD3 (CD3) DM52O7W MA Inhibitor DM52O7W RN Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals. DM52O7W RU https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TTVIMDE DM53IPE TN Glucagon-like peptide 1 receptor (GLP1R) DM53IPE MA Modulator DM53IPE RN Company report (Sanofi) (drug: LIXisenatide) DM53IPE RU http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TT9O6WS DM53IPE TN Glucagon receptor (GCGR) DM53IPE MA Modulator DM53IPE RN Company report (Sanofi) (drug: LIXisenatide) DM53IPE RU http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TT0NUFM DM53IPE TN Glucagon (GCG) DM53IPE MA Agonist DM53IPE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM53IPE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM56PFL DI DM56PFL DM56PFL DN TSR-042 DM56PFL TI TTNBFWK DM56PFL TN Programmed cell death protein 1 (PD-1) DM56PFL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM56PFL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM56VG2 DI DM56VG2 DM56VG2 DN AVE0897 DM56VG2 TI TTJ584C DM56VG2 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM56VG2 MA Agonist DM56VG2 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM56VG2 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM572ZL DI DM572ZL DM572ZL DN BBP-398 DM572ZL TI TT7WUAV DM572ZL TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DM572ZL MA Inhibitor DM572ZL RN ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. DM572ZL RU https://clinicaltrials.gov/ct2/show/NCT04528836 DM57FHW DI DM57FHW DM57FHW DN WF-11605 DM57FHW TI TTTWGIX DM57FHW TN Leukotriene receptor (LTR) DM57FHW MA Modulator DM57FHW RN WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8. DM57FHW RU https://pubmed.ncbi.nlm.nih.gov/1320602 DM58J7E DI DM58J7E DM58J7E DN Tedalinab DM58J7E TI TTMSFAW DM58J7E TN Cannabinoid receptor 2 (CB2) DM58J7E MA Agonist DM58J7E RN Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010 DM58J7E RU http://www.nature.com/scibx/journal/v3/n46/full/scibx.2010.1384.html DM59EUY DI DM59EUY DM59EUY DN ADCI DM59EUY TI TT9IK2Z DM59EUY TN N-methyl-D-aspartate receptor (NMDAR) DM59EUY MA Modulator DM59EUY RN The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. DM59EUY RU https://pubmed.ncbi.nlm.nih.gov/10714396 DM59EUY DI DM59EUY DM59EUY DN ADCI DM59EUY TI TTRK8B9 DM59EUY TN Sodium channel unspecific (NaC) DM59EUY MA Modulator DM59EUY RN The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. DM59EUY RU https://pubmed.ncbi.nlm.nih.gov/10714396 DM59TI2 DI DM59TI2 DM59TI2 DN M9831 DM59TI2 TI TTK3PY9 DM59TI2 TN DNA-dependent protein kinase catalytic (PRKDC) DM59TI2 MA Inhibitor DM59TI2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM59TI2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM59ZDN DI DM59ZDN DM59ZDN DN Nesvacumab DM59ZDN TI TTKLQTJ DM59ZDN TN Angiopoietin-2 (ANGPT2) DM59ZDN MA Inhibitor DM59ZDN RN Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. DM59ZDN RU https://pubmed.ncbi.nlm.nih.gov/31513439 DM5AGKV DI DM5AGKV DM5AGKV DN DTRMWXHS-12 DM5AGKV TI TTGM6VW DM5AGKV TN Tyrosine-protein kinase BTK (ATK) DM5AGKV MA Inhibitor DM5AGKV RN ClinicalTrials.gov (NCT02900716) Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas. U.S. National Institutes of Health. DM5AGKV RU https://clinicaltrials.gov/ct2/show/NCT02900716 DM5AW7J DI DM5AW7J DM5AW7J DN BIIB 015 DM5AW7J TI TTN7HMG DM5AW7J TN Teratocarcinoma-derived growth factor 1 (TDGF1) DM5AW7J RN An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46. DM5AW7J RU https://pubmed.ncbi.nlm.nih.gov/21458984 DM5AWK1 DI DM5AWK1 DM5AWK1 DN NKP-1339 DM5AWK1 TI TTW26OG DM5AWK1 TN Endoplasmic reticulum chaperone BiP (HSPA5) DM5AWK1 MA Inhibitor DM5AWK1 RN NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82. DM5AWK1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/ DM5AWK1 DI DM5AWK1 DM5AWK1 DN NKP-1339 DM5AWK1 TI TT0K6EO DM5AWK1 TN Stress-activated protein kinase JNK1 (JNK1) DM5AWK1 MA Inhibitor DM5AWK1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496). DM5AWK1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1496 DM5BIM1 DI DM5BIM1 DM5BIM1 DN Anti-mesothelin CAR T Cells DM5BIM1 TI TT4RXME DM5BIM1 TN Mesothelin (MSLN) DM5BIM1 MA CAR-T-Cell-Therapy DM5BIM1 RN ClinicalTrials.gov (NCT02930993) Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors DM5BIM1 RU https://clinicaltrials.gov/ct2/show/NCT02930993 DM5BMIO DI DM5BMIO DM5BMIO DN YTB323 DM5BMIO TI TTW640A DM5BMIO TN B-lymphocyte surface antigen B4 (CD19) DM5BMIO RN Clinical pipeline report, company report or official report of Novartis. DM5BMIO RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=YTB323&field_pipeline_filing_date=All DM5BQK3 DI DM5BQK3 DM5BQK3 DN NBI-34041 DM5BQK3 TI TTIY658 DM5BQK3 TN Corticotropin-releasing factor receptor 2 (CRHR2) DM5BQK3 MA Antagonist DM5BQK3 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM5BQK3 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM5E9LX DI DM5E9LX DM5E9LX DN GSK586529 DM5E9LX TI TT7EFHR DM5E9LX TN Corticotropin-releasing factor receptor 1 (CRHR1) DM5E9LX MA Antagonist DM5E9LX RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM5E9LX RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM5EFPS DI DM5EFPS DM5EFPS DN MK-3134 DM5EFPS TI TT9JNIC DM5EFPS TN Histamine H3 receptor (H3R) DM5EFPS MA Agonist DM5EFPS RN Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24. DM5EFPS RU https://pubmed.ncbi.nlm.nih.gov/21644059 DM5EM04 DI DM5EM04 DM5EM04 DN CLL1-CD33 cCART cell therapy DM5EM04 TI TTJVYO3 DM5EM04 TN Myeloid cell surface antigen CD33 (CD33) DM5EM04 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM5EM04 RU http://icellgene.com/our-pipeline.html DM5EM04 DI DM5EM04 DM5EM04 DN CLL1-CD33 cCART cell therapy DM5EM04 TI TT70N8V DM5EM04 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM5EM04 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM5EM04 RU http://icellgene.com/our-pipeline.html DM5EUIY DI DM5EUIY DM5EUIY DN ROR1 CAR-specific Autologous T-Lymphocytes DM5EUIY TI TTDEJAU DM5EUIY TN Neurotrophic tyrosine kinase ROR1 (ROR1) DM5EUIY MA CAR-T-Cell-Therapy DM5EUIY RN ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies DM5EUIY RU https://clinicaltrials.gov/ct2/show/NCT02706392 DM5EXJV DI DM5EXJV DM5EXJV DN LY-2881835 DM5EXJV TI TTB8FUC DM5EXJV TN Free fatty acid receptor 1 (GPR40) DM5EXJV MA Modulator DM5EXJV RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DM5EXJV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DM5INE7 DI DM5INE7 DM5INE7 DN NM-3 DM5INE7 TI TT9HKJA DM5INE7 TN Vascular endothelial growth factor (VEGF) DM5INE7 MA Inhibitor DM5INE7 RN 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42. DM5INE7 RU https://pubmed.ncbi.nlm.nih.gov/16644677 DM5INZP DI DM5INZP DM5INZP DN LEQ-506 DM5INZP TI TT8J1S3 DM5INZP TN Smoothened homolog (SMO) DM5INZP MA Inhibitor DM5INZP RN Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5. DM5INZP RU https://pubmed.ncbi.nlm.nih.gov/23821351 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTEX248 DM5IPHE TN Dopamine D2 receptor (D2R) DM5IPHE MA Antagonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTSQIFT DM5IPHE TN 5-HT 1A receptor (HTR1A) DM5IPHE MA Agonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTJQOD7 DM5IPHE TN 5-HT 2A receptor (HTR2A) DM5IPHE MA Antagonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPUS DI DM5IPUS DM5IPUS DN SPI-014 DM5IPUS TI TT9W8GU DM5IPUS TN Gamma-secretase (GS) DM5IPUS MA Modulator DM5IPUS RN Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756. DM5IPUS RU https://pubmed.ncbi.nlm.nih.gov/23320246 DM5KBDY DI DM5KBDY DM5KBDY DN PF-06263507 DM5KBDY TI TT70MLA DM5KBDY TN Oncotrophoblast glycoprotein 5T4 (TPBG) DM5KBDY RN National Cancer Institute Drug Dictionary (drug id 751006). DM5KBDY RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751006 DM5KDGI DI DM5KDGI DM5KDGI DN TAK-901 DM5KDGI TI TT5LS6T DM5KDGI TN Aurora kinase B (AURKB) DM5KDGI MA Inhibitor DM5KDGI RN Clinical pipeline report, company report or official report of Takeda (2009). DM5KDGI RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM5KI6X DI DM5KI6X DM5KI6X DN PRX003 DM5KI6X TI TTD26RC DM5KI6X TN Cell adhesion molecule (CADM) DM5KI6X MA Inhibitor DM5KI6X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5KI6X RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM5KMYQ DI DM5KMYQ DM5KMYQ DN Actimab-M DM5KMYQ TI TTJVYO3 DM5KMYQ TN Myeloid cell surface antigen CD33 (CD33) DM5KMYQ MA Inhibitor DM5KMYQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5KMYQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM5KU30 DI DM5KU30 DM5KU30 DN BAL-30072 DM5KU30 TI TTJP4SM DM5KU30 TN Bacterial Penicillin binding protein (Bact PBP) DM5KU30 MA Inhibitor DM5KU30 RN In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302. DM5KU30 RU https://pubmed.ncbi.nlm.nih.gov/20308379 DM5M48F DI DM5M48F DM5M48F DN BMS214662 DM5M48F TI TTXQKM3 DM5M48F TN Farnesyl protein transferase (Ftase) DM5M48F MA Modulator DM5M48F RN Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604. DM5M48F RU https://www.ncbi.nlm.nih.gov/pubmed/15356656 DM5OP86 DI DM5OP86 DM5OP86 DN LY3127804 DM5OP86 TI TTKLQTJ DM5OP86 TN Angiopoietin-2 (ANGPT2) DM5OP86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OP86 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5OTGR DI DM5OTGR DM5OTGR DN RG7461 DM5OTGR TI TTGPQ0F DM5OTGR TN Prolyl endopeptidase FAP (FAP) DM5OTGR MA Antagonist DM5OTGR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OTGR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5OWXA DI DM5OWXA DM5OWXA DN NBM-BMX DM5OWXA TI TTT6LFV DM5OWXA TN Histone deacetylase 8 (HDAC8) DM5OWXA MA Inhibitor DM5OWXA RN Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals. DM5OWXA RU https://www.naturewise.com.tw/#_index2 DM5OXPZ DI DM5OXPZ DM5OXPZ DN RPI-MN DM5OXPZ TI TTJSZTB DM5OXPZ TN Nicotinic acetylcholine receptor (nAChR) DM5OXPZ MA Antagonist DM5OXPZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OXPZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5PUO0 DI DM5PUO0 DM5PUO0 DN PF-00337210 DM5PUO0 TI TTUTJGQ DM5PUO0 TN Vascular endothelial growth factor receptor 2 (KDR) DM5PUO0 MA Modulator DM5PUO0 RN Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function. Diabetes. 2013 August; 62(8): 2870-2878. DM5PUO0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717875/ DM5QHID DI DM5QHID DM5QHID DN NSD-788 DM5QHID TI TTEX6LM DM5QHID TN GABA(A) receptor gamma-3 (GABRG3) DM5QHID MA Modulator DM5QHID RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DM5QHID RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DM5QO1A DI DM5QO1A DM5QO1A DN LY3415244 DM5QO1A TI TT1RWL7 DM5QO1A TN Hepatitis A virus cellular receptor 2 (TIM3) DM5QO1A MA Inhibitor DM5QO1A RN Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. DM5QO1A RU https://pubmed.ncbi.nlm.nih.gov/33441294 DM5QO1A DI DM5QO1A DM5QO1A DN LY3415244 DM5QO1A TI TT8ZLTI DM5QO1A TN Programmed cell death 1 ligand 1 (PD-L1) DM5QO1A MA Inhibitor DM5QO1A RN Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. DM5QO1A RU https://pubmed.ncbi.nlm.nih.gov/33441294 DM5R7VI DI DM5R7VI DM5R7VI DN ARN-6039 DM5R7VI TI TTGV6LY DM5R7VI TN Nuclear receptor ROR-gamma (RORG) DM5R7VI MA Agonist DM5R7VI RN Clinical pipeline report, company report or official report of Arrien Pharmaceuticals. DM5R7VI RU https://www.arrienpharma.com/arn-6039.html DM5RIT8 DI DM5RIT8 DM5RIT8 DN TP-6076 DM5RIT8 TI TTOVFH2 DM5RIT8 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM5RIT8 RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DM5RIT8 RU https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf DM5RLM4 DI DM5RLM4 DM5RLM4 DN 4SCAR19 cells DM5RLM4 TI TTW640A DM5RLM4 TN B-lymphocyte surface antigen B4 (CD19) DM5RLM4 MA CAR-T-Cell-Therapy DM5RLM4 RN ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia DM5RLM4 RU https://clinicaltrials.gov/ct2/show/NCT02968472 DM5SJO9 DI DM5SJO9 DM5SJO9 DN ACHN-975 DM5SJO9 TI TT2D1J6 DM5SJO9 TN Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC) DM5SJO9 MA Modulator DM5SJO9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5SJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5SN0A DI DM5SN0A DM5SN0A DN MT-5111 DM5SN0A TI TT6EO5L DM5SN0A TN Erbb2 tyrosine kinase receptor (HER2) DM5SN0A MA Inhibitor DM5SN0A RN Clinical pipeline report, company report or official report of Molecular Templates. DM5SN0A RU https://www.mtem.com/pipeline/mt-5111 DM5SO1T DI DM5SO1T DM5SO1T DN INCAGN2390 DM5SO1T TI TT1RWL7 DM5SO1T TN Hepatitis A virus cellular receptor 2 (TIM3) DM5SO1T MA Inhibitor DM5SO1T RN Clinical pipeline report, company report or official report of Agenus. DM5SO1T RU https://agenusbio.com/pipeline/ DM5SZAK DI DM5SZAK DM5SZAK DN JNJ-63709178 DM5SZAK TI TTUN7MC DM5SZAK TN T-cell surface glycoprotein CD3 (CD3) DM5SZAK MA Inhibitor DM5SZAK RN Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145. DM5SZAK RU https://pubmed.ncbi.nlm.nih.gov/29206680 DM5SZAK DI DM5SZAK DM5SZAK DN JNJ-63709178 DM5SZAK TI TTENHJ0 DM5SZAK TN Interleukin 3 receptor alpha (IL3RA) DM5SZAK MA Inhibitor DM5SZAK RN Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145. DM5SZAK RU https://pubmed.ncbi.nlm.nih.gov/29206680 DM5TB76 DI DM5TB76 DM5TB76 DN DACRA 089 DM5TB76 TI TTAT87F DM5TB76 TN Amylin receptor (IAPPR) DM5TB76 MA Agonist DM5TB76 RN A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602. DM5TB76 RU https://pubmed.ncbi.nlm.nih.gov/28109166 DM5TB76 DI DM5TB76 DM5TB76 DN DACRA 089 DM5TB76 TI TTLWS2O DM5TB76 TN Calcitonin receptor (CALCR) DM5TB76 MA Agonist DM5TB76 RN A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602. DM5TB76 RU https://pubmed.ncbi.nlm.nih.gov/28109166 DM5TLAP DI DM5TLAP DM5TLAP DN PRX-07034 DM5TLAP TI TTJS8PY DM5TLAP TN 5-HT 6 receptor (HTR6) DM5TLAP MA Antagonist DM5TLAP RN Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects. Can J Physiol Pharmacol. 2015 Jan;93(1):13-21. DM5TLAP RU https://pubmed.ncbi.nlm.nih.gov/25429515 DM5UQA9 DI DM5UQA9 DM5UQA9 DN Anti-meso-CAR vector transduced T cells DM5UQA9 TI TT4RXME DM5UQA9 TN Mesothelin (MSLN) DM5UQA9 MA CAR-T-Cell-Therapy DM5UQA9 RN ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso DM5UQA9 RU https://clinicaltrials.gov/ct2/show/NCT02580747 DM5UXAB DI DM5UXAB DM5UXAB DN SAR442085 DM5UXAB TI TTPURFN DM5UXAB TN Cyclic ADP-ribose hydrolase 1 (CD38) DM5UXAB MA Inhibitor DM5UXAB RN Clinical pipeline report, company report or official report of Sanofi. DM5UXAB RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DM5VEN9 DI DM5VEN9 DM5VEN9 DN Minnelide 001 DM5VEN9 TI TTHYBIX DM5VEN9 TN Heat shock protein 70 (HSP70) DM5VEN9 MA Modulator DM5VEN9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5VEN9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5VS7B DI DM5VS7B DM5VS7B DN GSK-2241658A DM5VS7B TI TTE5ITK DM5VS7B TN Cancer/testis antigen 1 (NY-ESO-1) DM5VS7B RN ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health. DM5VS7B RU https://clinicaltrials.gov/ct2/show/NCT01213472 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TTLYXIT DM5VSZR TN Aurora kinase C (AURKC) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TTPS3C0 DM5VSZR TN Aurora kinase A (AURKA) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TT5LS6T DM5VSZR TN Aurora kinase B (AURKB) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VXWO DI DM5VXWO DM5VXWO DN MP-157 DM5VXWO TI TTQVOEI DM5VXWO TN Angiotensin II receptor type-2 (AGTR2) DM5VXWO MA Agonist DM5VXWO RN As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard DM5VXWO RU http://blogs.nature.com/spoonful/2014/02/as-drug-target-reemerges-the-question-is-to-block-or-stimulate-it.html DM5VY23 DI DM5VY23 DM5VY23 DN ONC206 DM5VY23 TI TTEX248 DM5VY23 TN Dopamine D2 receptor (D2R) DM5VY23 MA Antagonist DM5VY23 RN ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro. Front Oncol. 2020 Oct 20;10:577141. DM5VY23 RU https://pubmed.ncbi.nlm.nih.gov/33194693 DM5WCBM DI DM5WCBM DM5WCBM DN ING-1 DM5WCBM TI TTZ8WH4 DM5WCBM TN Tumor-associated calcium signal transducer 1 (EPCAM) DM5WCBM RN ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65. DM5WCBM RU https://pubmed.ncbi.nlm.nih.gov/15569986 DM5WDKY DI DM5WDKY DM5WDKY DN TAS-103 DM5WDKY TI TT0IHXV DM5WDKY TN DNA topoisomerase II (TOP2) DM5WDKY MA Modulator DM5WDKY RN Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother Pharmacol. 2000;45(1):78-84. DM5WDKY RU https://www.ncbi.nlm.nih.gov/pubmed/10647506 DM5WKU1 DI DM5WKU1 DM5WKU1 DN Cardiotrophin-1 DM5WKU1 TI TTXGTZU DM5WKU1 TN Cardiotrophin-1 (CTF1) DM5WKU1 MA Stimulator DM5WKU1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5WKU1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5XCRQ DI DM5XCRQ DM5XCRQ DN R552 DM5XCRQ TI TTAIQSN DM5XCRQ TN Receptor-interacting protein 1 (RIPK1) DM5XCRQ MA Inhibitor DM5XCRQ RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DM5XCRQ RU https://pubmed.ncbi.nlm.nih.gov/32669658 DM5XMHB DI DM5XMHB DM5XMHB DN UC-781 DM5XMHB TI TT84ETX DM5XMHB TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM5XMHB MA Inhibitor DM5XMHB RN The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86. DM5XMHB RU https://pubmed.ncbi.nlm.nih.gov/16103169 DM5YUOM DI DM5YUOM DM5YUOM DN Irofulven/Taxotere DM5YUOM TI TT63KYR DM5YUOM TN Tubulin beta-1 chain (TUBB1) DM5YUOM MA Modulator DM5YUOM RN Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. DM5YUOM RU https://pubmed.ncbi.nlm.nih.gov/14991863 DM5YUOM DI DM5YUOM DM5YUOM DN Irofulven/Taxotere DM5YUOM TI TTJGNVC DM5YUOM TN Apoptosis regulator Bcl-2 (BCL-2) DM5YUOM MA Modulator DM5YUOM RN Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. DM5YUOM RU https://pubmed.ncbi.nlm.nih.gov/14991863 DM5ZC0E DI DM5ZC0E DM5ZC0E DN 124I-8H9 DM5ZC0E TI TT6CQUM DM5ZC0E TN B7 homolog 3 (CD276) DM5ZC0E RN National Cancer Institute Drug Dictionary (drug id 722029). DM5ZC0E RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=722029 DM5ZR4Q DI DM5ZR4Q DM5ZR4Q DN PSI-938 DM5ZR4Q TI TTMVBWH DM5ZR4Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5ZR4Q MA Inhibitor DM5ZR4Q RN 2011 Pipeline of Pharmasset. DM5ZR4Q RU http://www.pharmasset.com/pipeline/default.aspx DM601GL DI DM601GL DM601GL DN INNO-105 DM601GL TI TT6IEYX DM601GL TN Opioid receptor zeta (OGFR) DM601GL MA Modulator DM601GL RN National Cancer Institute Drug Dictionary (drug id 428488). DM601GL RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=428488 DM61JH5 DI DM61JH5 DM61JH5 DN BIWA 4 DM61JH5 TI TTWFBT7 DM61JH5 TN Extracellular matrix receptor III (CD44) DM61JH5 RN A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. DM61JH5 RU https://pubmed.ncbi.nlm.nih.gov/17062682 DM64LVS DI DM64LVS DM64LVS DN ICT-121 DM64LVS TI TTXMZ81 DM64LVS TN Prominin-1 (PROM1) DM64LVS RN Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59. DM64LVS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322523/ DM64U1Y DI DM64U1Y DM64U1Y DN R-1663 DM64U1Y TI TTCIHJA DM64U1Y TN Coagulation factor Xa (F10) DM64U1Y MA Inhibitor DM64U1Y RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM64U1Y RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM65B7G DI DM65B7G DM65B7G DN MCP-202 DM65B7G TI TT27RFC DM65B7G TN Opioid receptor delta (OPRD1) DM65B7G MA Agonist DM65B7G RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018026) DM65B7G RU http://adisinsight.springer.com/drugs/800018026 DM674MP DI DM674MP DM674MP DN CLT030 DM674MP TI TT70N8V DM674MP TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM674MP RN Clinical pipeline report, company report or official report of Cellerant Therapeutics. DM674MP RU https://www.cellerant.com/programs/clt030/ DM67OU4 DI DM67OU4 DM67OU4 DN ANAVEX 2-73 DM67OU4 TI TT5TPI6 DM67OU4 TN Opioid receptor sigma 1 (OPRS1) DM67OU4 MA Agonist DM67OU4 RN 2011 Pipeline of Anavex. DM67OU4 RU http://anavex.com/pipeline.html DM67OU4 DI DM67OU4 DM67OU4 DN ANAVEX 2-73 DM67OU4 TI TTZ9SOR DM67OU4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM67OU4 MA Agonist DM67OU4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM67OU4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM68D3O DI DM68D3O DM68D3O DN PG-545 DM68D3O TI TTR7GJO DM68D3O TN Heparanase (HPSE) DM68D3O MA Modulator DM68D3O RN PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42. DM68D3O RU https://pubmed.ncbi.nlm.nih.gov/21285983 DM68I93 DI DM68I93 DM68I93 DN CTS-21166 DM68I93 TI TT8JRS7 DM68I93 TN Beta-secretase (BACE) DM68I93 MA Inhibitor DM68I93 RN ClinicalTrials.gov (NCT00621010) Safety Study of CTS21166 to Treat Alzheimer Disease. U. S. National Institutes of Health. 2008. DM68I93 RU https://clinicaltrials.gov/ct2/show/NCT00621010 DM695QT DI DM695QT DM695QT DN HMR-1031 DM695QT TI TT6S84X DM695QT TN Integrin alpha-4/beta-1 (ITGA4/B1) DM695QT MA Modulator DM695QT RN Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13. DM695QT RU https://pubmed.ncbi.nlm.nih.gov/14999362 DM69YM1 DI DM69YM1 DM69YM1 DN CC-98633 DM69YM1 TI TTZ3P4W DM69YM1 TN B-cell maturation protein (TNFRSF17) DM69YM1 RN ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. DM69YM1 RU https://clinicaltrials.gov/ct2/show/NCT04394650 DM69ZBU DI DM69ZBU DM69ZBU DN DST-2970 DM69ZBU TI TTRA5BZ DM69ZBU TN Steroid 17-alpha-monooxygenase (S17AH) DM69ZBU MA Inhibitor DM69ZBU RN Clinical pipeline report, company report or official report of DisperSol Technologies. DM69ZBU RU https://www.dispersoltech.com/pipeline/ DM6ADMG DI DM6ADMG DM6ADMG DN MEDI-557 DM6ADMG TI TT57ID8 DM6ADMG TN Respiratory syncytial virus protein F (RSV F) DM6ADMG RN Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. DM6ADMG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/ DM6AMKZ DI DM6AMKZ DM6AMKZ DN Embeconazole DM6AMKZ TI TTTSOUD DM6AMKZ TN Candida Cytochrome P450 51 (Candi ERG11) DM6AMKZ MA Inhibitor DM6AMKZ RN CS-758. Antifungal lanosterol 14alpha-demethylase inhibitor, 003, vol28, no3, 217-223. DM6AMKZ RU http://cat.inist.fr/?aModele=afficheN&cpsidt=14796964 DM6DULC DI DM6DULC DM6DULC DN CAR-T Cells targeting Mesothelin DM6DULC TI TT4RXME DM6DULC TN Mesothelin (MSLN) DM6DULC MA CAR-T-Cell-Therapy DM6DULC RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DM6DULC RU https://clinicaltrials.gov/ct2/show/NCT03267173 DM6ER9L DI DM6ER9L DM6ER9L DN Pfizer 10 DM6ER9L TI TT4C8EA DM6ER9L TN Dopamine D3 receptor (D3R) DM6ER9L MA Agonist DM6ER9L RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DM6ER9L RU https://pubmed.ncbi.nlm.nih.gov/17826689 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTO9X1H DM6GKMU TN 5-HT 7 receptor (HTR7) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTEX248 DM6GKMU TN Dopamine D2 receptor (D2R) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTJQOD7 DM6GKMU TN 5-HT 2A receptor (HTR2A) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKYF DI DM6GKYF DM6GKYF DN TTX-080 DM6GKYF TI TTLKFB3 DM6GKYF TN MHC class I antigen G (HLA-G) DM6GKYF MA Inhibitor DM6GKYF RN Clinical pipeline report, company report or official report of Tizona Therapeutics. DM6GKYF RU https://www.tizonatx.com/science/ DM6GNDP DI DM6GNDP DM6GNDP DN CD19 CAR-T cells DM6GNDP TI TTW640A DM6GNDP TN B-lymphocyte surface antigen B4 (CD19) DM6GNDP MA CAR-T-Cell-Therapy DM6GNDP RN ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. DM6GNDP RU https://clinicaltrials.gov/ct2/show/NCT03671460 DM6GRNC DI DM6GRNC DM6GRNC DN CAR-T cells targeting MUC1 DM6GRNC TI TTBHFYQ DM6GRNC TN Mucin-1 (MUC1) DM6GRNC MA CAR-T-Cell-Therapy DM6GRNC RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DM6GRNC RU https://clinicaltrials.gov/ct2/show/NCT03198052 DM6IT3M DI DM6IT3M DM6IT3M DN AMG 701 DM6IT3M TI TTUN7MC DM6IT3M TN T-cell surface glycoprotein CD3 (CD3) DM6IT3M MA Inhibitor DM6IT3M RN Clinical pipeline report, company report or official report of Amgen. DM6IT3M RU https://www.amgenpipeline.com/ DM6IT3M DI DM6IT3M DM6IT3M DN AMG 701 DM6IT3M TI TTZ3P4W DM6IT3M TN B-cell maturation protein (TNFRSF17) DM6IT3M MA Inhibitor DM6IT3M RN Clinical pipeline report, company report or official report of Amgen. DM6IT3M RU https://www.amgenpipeline.com/ DM6J085 DI DM6J085 DM6J085 DN M6223 DM6J085 TI TTWNL74 DM6J085 TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DM6J085 MA Inhibitor DM6J085 RN ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health. DM6J085 RU https://clinicaltrials.gov/ct2/show/NCT04457778 DM6K3JQ DI DM6K3JQ DM6K3JQ DN COTI-2 DM6K3JQ TI TT7SBF5 DM6K3JQ TN Cellular tumor antigen p53 (TP53) DM6K3JQ MA Modulator DM6K3JQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6K3JQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6K47B DI DM6K47B DM6K47B DN DC/I540/KLH vaccine DM6K47B TI TTUJFD0 DM6K47B TN Telomerase reverse transcriptase (TERT) DM6K47B RN Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1;10(3):828-39. DM6K47B RU https://pubmed.ncbi.nlm.nih.gov/14871958 DM6KE4G DI DM6KE4G DM6KE4G DN GSK2849330 DM6KE4G TI TTDC8N2 DM6KE4G TN Erbb3 tyrosine kinase receptor (Erbb-3) DM6KE4G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DM6KE4G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DM6KOBZ DI DM6KOBZ DM6KOBZ DN TAK-285 DM6KOBZ TI TT6EO5L DM6KOBZ TN Erbb2 tyrosine kinase receptor (HER2) DM6KOBZ MA Inhibitor DM6KOBZ RN Clinical pipeline report, company report or official report of Takeda (2009). DM6KOBZ RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM6KU93 DI DM6KU93 DM6KU93 DN Alvespimycin hydrochloride DM6KU93 TI TT78R5H DM6KU93 TN Heat shock protein 90 alpha (HSP90A) DM6KU93 MA Inhibitor DM6KU93 RN Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. DM6KU93 RU https://pubmed.ncbi.nlm.nih.gov/18260120 DM6L5IP DI DM6L5IP DM6L5IP DN Axitirome DM6L5IP TI TTGER3L DM6L5IP TN Thyroid hormone receptor beta (THRB) DM6L5IP MA Modulator DM6L5IP RN Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253. DM6L5IP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642162/ DM6LQIU DI DM6LQIU DM6LQIU DN VIR-2482 DM6LQIU TI TTF4CAM DM6LQIU TN Influenza Hemagglutinin (Influ HA) DM6LQIU RN Clinical pipeline report, company report or official report of Vir Biotechnology. DM6LQIU RU https://www.vir.bio/pipeline/ DM6NG3C DI DM6NG3C DM6NG3C DN CMV glycoprotein B subunit vaccine DM6NG3C TI TTUR18Y DM6NG3C TN Cytomegalovirus Glycoprotein B (CMV gB) DM6NG3C RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM6NG3C RU http://www.gsk-clinicalstudyregister.com/study/108890#ps DM6NUCA DI DM6NUCA DM6NUCA DN ADR-851 DM6NUCA TI TTNXLKE DM6NUCA TN 5-HT 3 receptor (5HT3R) DM6NUCA MA Modulator DM6NUCA RN Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9. DM6NUCA RU https://pubmed.ncbi.nlm.nih.gov/1804661 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTNDSF4 DM6NVTR TN Proto-oncogene c-Met (MET) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTO7LKR DM6NVTR TN Tyrosine-protein kinase Mer (MERTK) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTZPY6J DM6NVTR TN Tyrosine-protein kinase UFO (AXL) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTIEMFN DM6NVTR TN TYRO3 tyrosine kinase receptor (TYRO3) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6O0TM DI DM6O0TM DM6O0TM DN ATA2271 DM6O0TM TI TT4RXME DM6O0TM TN Mesothelin (MSLN) DM6O0TM RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DM6O0TM RU https://www.atarabio.com/pipeline/ata2271-ata3271/ DM6OJI1 DI DM6OJI1 DM6OJI1 DN DIAPLASININ DM6OJI1 TI TTTO43N DM6OJI1 TN Endothelial plasminogen activator inhibitor (SERPINE1) DM6OJI1 MA Inhibitor DM6OJI1 RN Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9. DM6OJI1 RU https://pubmed.ncbi.nlm.nih.gov/20345708 DM6OKH4 DI DM6OKH4 DM6OKH4 DN TAK-020 DM6OKH4 TI TTGM6VW DM6OKH4 TN Tyrosine-protein kinase BTK (ATK) DM6OKH4 MA Inhibitor DM6OKH4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6OKH4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM6P93J DI DM6P93J DM6P93J DN API-023 DM6P93J TI TTF1QVM DM6P93J TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM6P93J MA Inhibitor DM6P93J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DM6P93J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DM6PFCN DI DM6PFCN DM6PFCN DN LY3009120 DM6PFCN TI TTQ9K3Y DM6PFCN TN Serine/threonine-protein kinase Raf (RAF) DM6PFCN MA Modulator DM6PFCN RN Company report (eli lily) DM6PFCN RU http://www.lillyoncologypipeline.com/pan-raf-inhibitor.aspx DM6PI5B DI DM6PI5B DM6PI5B DN M3258 DM6PI5B TI TTEAD9J DM6PI5B TN Proteasome beta-8 (PS beta-8) DM6PI5B MA Inhibitor DM6PI5B RN Clinical pipeline report, company report or official report of EMD Serono. DM6PI5B RU https://medical.emdserono.com/en_US/home/oncology/m3258.html DM6PN4H DI DM6PN4H DM6PN4H DN AjvW2 DM6PN4H TI TT38RM1 DM6PN4H TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM6PN4H RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DM6PN4H RU https://pubmed.ncbi.nlm.nih.gov/11804648 DM6PN4H DI DM6PN4H DM6PN4H DN AjvW2 DM6PN4H TI TT0IHXV DM6PN4H TN DNA topoisomerase II (TOP2) DM6PN4H MA Inhibitor DM6PN4H RN The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82. DM6PN4H RU https://pubmed.ncbi.nlm.nih.gov/12423680 DM6QENU DI DM6QENU DM6QENU DN Anti-FGFR3 DM6QENU TI TTST7KB DM6QENU TN Fibroblast growth factor receptor 3 (FGFR3) DM6QENU RN Clinical pipeline report, company report or official report of Genentech (2011). DM6QENU RU http://www.gene.com/gene/index.jsp DM6R4DO DI DM6R4DO DM6R4DO DN GC-1008 DM6R4DO TI TT5BDCY DM6R4DO TN TGF-beta receptor (TGFBR) DM6R4DO MA Modulator DM6R4DO RN Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.PLoS One.2014 Mar 11;9(3):e90353. DM6R4DO RU https://www.ncbi.nlm.nih.gov/pubmed/24618589 DM6SCUK DI DM6SCUK DM6SCUK DN CI-959 DM6SCUK TI TT4IN7L DM6SCUK TN Histamine release (His rele) DM6SCUK MA Modulator DM6SCUK RN Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33. DM6SCUK RU https://pubmed.ncbi.nlm.nih.gov/7557089 DM6TLPD DI DM6TLPD DM6TLPD DN RG6115 DM6TLPD TI TTRJ1K4 DM6TLPD TN Toll-like receptor 7 (TLR7) DM6TLPD MA Agonist DM6TLPD RN Clinical pipeline report, company report or official report of Roche. DM6TLPD RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM6UN42 DI DM6UN42 DM6UN42 DN SAR444245 DM6UN42 TI TTF89GD DM6UN42 TN Interleukin-2 (IL2) DM6UN42 RN Clinical pipeline report, company report or official report of Sanofi. DM6UN42 RU https://www.sanofi.com/en/media-room/press-releases/2020/2020-10-29-07-00-00 DM6UOXF DI DM6UOXF DM6UOXF DN AZD1419 DM6UOXF TI TTSHG0T DM6UOXF TN Toll-like receptor 9 (TLR9) DM6UOXF MA Agonist DM6UOXF RN Clinical pipeline report, company report or official report of dynavax. DM6UOXF RU http://investors.dynavax.com/releasedetail.cfm?releaseid=611310 DM6URNJ DI DM6URNJ DM6URNJ DN JNJ-67856633 DM6URNJ TI TTCI81G DM6URNJ TN MALT lymphoma-associated translocation (MALT1) DM6URNJ MA Inhibitor DM6URNJ RN National Cancer Institute Drug Dictionary (drug name JNJ67856633). DM6URNJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/malt1-inhibitor-jnj-67856633 DM6V0KY DI DM6V0KY DM6V0KY DN Xmab-2513 DM6V0KY TI TT2GM5R DM6V0KY TN Lymphocyte activation antigen CD30 (TNFRSF8) DM6V0KY RN Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531. DM6V0KY RU http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8531 DM6VR13 DI DM6VR13 DM6VR13 DN JNJ-69086420 DM6VR13 TI TTJLNAW DM6VR13 TN Tissue kallikrein (KLK2) DM6VR13 MA Inhibitor DM6VR13 RN ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health. DM6VR13 RU https://clinicaltrials.gov/ct2/show/NCT04644770 DM6WN9X DI DM6WN9X DM6WN9X DN DS-3801 DM6WN9X TI TT953CX DM6WN9X TN Motilin receptor (MLNR) DM6WN9X MA Agonist DM6WN9X RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DM6WN9X RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM6X82R DI DM6X82R DM6X82R DN CART22 cells DM6X82R TI TTM6QSK DM6X82R TN B-cell receptor CD22 (CD22) DM6X82R MA CAR-T-Cell-Therapy DM6X82R RN ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia DM6X82R RU https://clinicaltrials.gov/ct2/show/NCT02588456 DM6XC8H DI DM6XC8H DM6XC8H DN MSC110 DM6XC8H TI TT0IQER DM6XC8H TN Macrophage colony-stimulating factor 1 (CSF1) DM6XC8H MA Inhibitor DM6XC8H RN Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. DM6XC8H RU https://pubmed.ncbi.nlm.nih.gov/30894455 DM6XTZL DI DM6XTZL DM6XTZL DN MSC-1 DM6XTZL TI TTGZ5WN DM6XTZL TN Leukemia inhibitory factor (LIF) DM6XTZL RN National Cancer Institute Drug Dictionary (drug name MSC-1). DM6XTZL RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-lif-monoclonal-antibody-msc-1 DM6XVCO DI DM6XVCO DM6XVCO DN RG7116 DM6XVCO TI TTDC8N2 DM6XVCO TN Erbb3 tyrosine kinase receptor (Erbb-3) DM6XVCO MA Modulator DM6XVCO RN RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013 Aug 15;73(16):5183-94. DM6XVCO RU https://pubmed.ncbi.nlm.nih.gov/23780344 DM6XWV4 DI DM6XWV4 DM6XWV4 DN EGFRvIII CAR T cells DM6XWV4 TI TTZ6B2I DM6XWV4 TN Epidermal growth factor receptor variant III (EGFR vIII) DM6XWV4 MA CAR-T-Cell-Therapy DM6XWV4 RN ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma DM6XWV4 RU https://clinicaltrials.gov/ct2/show/NCT02664363 DM6XZRL DI DM6XZRL DM6XZRL DN SA-5845 DM6XZRL TI TT5TPI6 DM6XZRL TN Opioid receptor sigma 1 (OPRS1) DM6XZRL MA Binder DM6XZRL RN Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45. DM6XZRL RU https://pubmed.ncbi.nlm.nih.gov/15534066 DM6YAGE DI DM6YAGE DM6YAGE DN RWJ-67657 DM6YAGE TI TTVKILB DM6YAGE TN Prostaglandin G/H synthase 2 (COX-2) DM6YAGE MA Inhibitor DM6YAGE RN Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43. DM6YAGE RU https://pubmed.ncbi.nlm.nih.gov/11876759 DM6Z7AD DI DM6Z7AD DM6Z7AD DN CAR-T cells targeting CD80/86 DM6Z7AD TI TTFZDNP DM6Z7AD TN Activation B7-1 antigen (CD80) DM6Z7AD MA CAR-T-Cell-Therapy DM6Z7AD RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DM6Z7AD RU https://clinicaltrials.gov/ct2/show/NCT03198052 DM6ZOD2 DI DM6ZOD2 DM6ZOD2 DN SUVN-D4010 DM6ZOD2 TI TT07C3Y DM6ZOD2 TN 5-HT 4 receptor (HTR4) DM6ZOD2 MA Agonist DM6ZOD2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6ZOD2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM70DYV DI DM70DYV DM70DYV DN GSK311739 DM70DYV TI TTBH0VX DM70DYV TN Histone deacetylase (HDAC) DM70DYV MA Modulator DM70DYV RN Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014. DM70DYV RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf DM71HLX DI DM71HLX DM71HLX DN FAZ053 DM71HLX TI TT8ZLTI DM71HLX TN Programmed cell death 1 ligand 1 (PD-L1) DM71HLX MA Inhibitor DM71HLX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM71HLX RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM71Q69 DI DM71Q69 DM71Q69 DN ABBV-184 DM71Q69 TI TTUN7MC DM71Q69 TN T-cell surface glycoprotein CD3 (CD3) DM71Q69 RN Clinical pipeline report, company report or official report of AbbVie. DM71Q69 RU https://www.abbvie.com/our-science/pipeline/abbv-184.html DM72FOD DI DM72FOD DM72FOD DN Azd-3839 DM72FOD TI TT8JRS7 DM72FOD TN Beta-secretase (BACE) DM72FOD MA Inhibitor DM72FOD RN Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57. DM72FOD RU https://pubmed.ncbi.nlm.nih.gov/23048024 DM72GZV DI DM72GZV DM72GZV DN ZEN003694 DM72GZV TI TTE4BSY DM72GZV TN Bromodomain and extraterminal domain protein (BET) DM72GZV MA Inhibitor DM72GZV RN Clinical pipeline report, company report or official report of Zenith Epigenetics. DM72GZV RU https://www.zenithepigenetics.com/programs/pipeline DM73920 DI DM73920 DM73920 DN Anti-EGFRvIII CAR T cells DM73920 TI TTZ6B2I DM73920 TN Epidermal growth factor receptor variant III (EGFR vIII) DM73920 MA CAR-T-Cell-Therapy DM73920 RN ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme DM73920 RU https://clinicaltrials.gov/ct2/show/NCT02844062 DM73YG5 DI DM73YG5 DM73YG5 DN SM09419 DM73YG5 TI TT6K9BV DM73YG5 TN Cdc-like kinase (CLK) DM73YG5 MA Inhibitor DM73YG5 RN SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models. Blood; 2019,134 (Supplement_1):1377. DM73YG5 RU https://doi.org/10.1182/blood-2019-130500 DM74YO8 DI DM74YO8 DM74YO8 DN PDC-41 DM74YO8 TI TTT2ZAR DM74YO8 TN Prostaglandin F2-alpha receptor (PTGFR) DM74YO8 MA Antagonist DM74YO8 RN THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97. DM74YO8 RU https://pubmed.ncbi.nlm.nih.gov/12537309 DM75FWO DI DM75FWO DM75FWO DN PSI-697 DM75FWO TI TTE5VG0 DM75FWO TN P-selectin (SELP) DM75FWO MA Inhibitor DM75FWO RN Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007. DM75FWO RU https://pubmed.ncbi.nlm.nih.gov/23525448 DM760FA DI DM760FA DM760FA DN OPB-51602 DM760FA TI TTH8FZW DM760FA TN Signal transducer and activator of transcription 3 (STAT3) DM760FA MA Inhibitor DM760FA RN Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005. DM760FA RU https://pubmed.ncbi.nlm.nih.gov/25609248 DM796RI DI DM796RI DM796RI DN ZYAN1 DM796RI TI TTJQFBG DM796RI TN HIF-prolyl hydroxylase (HPH) DM796RI MA Inhibitor DM796RI RN Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12. DM796RI RU https://pubmed.ncbi.nlm.nih.gov/26367279 DM79W8K DI DM79W8K DM79W8K DN ICo-007 DM79W8K TI TTAN5W2 DM79W8K TN Raf messenger RNA (Raf mRNA) DM79W8K RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DM79W8K RU http://www.isispharm.com/Pipeline/index.htm DM79XGM DI DM79XGM DM79XGM DN BIBX-1382 DM79XGM TI TTGKNB4 DM79XGM TN Epidermal growth factor receptor (EGFR) DM79XGM MA Antagonist DM79XGM RN Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. DM79XGM RU https://pubmed.ncbi.nlm.nih.gov/12008195 DM7A6R5 DI DM7A6R5 DM7A6R5 DN SCH-900117 DM7A6R5 TI TTG0MT6 DM7A6R5 TN Interleukin-17 (IL17) DM7A6R5 MA Modulator DM7A6R5 RN Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. DM7A6R5 RU https://pubmed.ncbi.nlm.nih.gov/23023676 DM7B2JC DI DM7B2JC DM7B2JC DN PF-05190457 DM7B2JC TI TTWDC17 DM7B2JC TN Growth hormone secretagogue receptor 1 (GHSR) DM7B2JC MA Modulator DM7B2JC RN A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014 DM7B2JC RU http://www.nature.com/scibx/journal/v7/n6/full/scibx.2014.160.html DM7B650 DI DM7B650 DM7B650 DN RG-2833 DM7B650 TI TT6R7JZ DM7B650 TN Histone deacetylase 1 (HDAC1) DM7B650 MA Modulator DM7B650 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7B650 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TT7HF4W DM7BMD6 TN Cyclin-dependent kinase 2 (CDK2) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TTGJCWZ DM7BMD6 TN Fms-like tyrosine kinase 3 (FLT-3) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TT0PG8F DM7BMD6 TN Cyclin-dependent kinase 4 (CDK4) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TTO0FDJ DM7BMD6 TN Cyclin-dependent kinase 6 (CDK6) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BOFR DI DM7BOFR DM7BOFR DN PF-06939999 DM7BOFR TI TTR1D7X DM7BOFR TN Protein arginine methyltransferase 5 (PRMT5) DM7BOFR MA Inhibitor DM7BOFR RN National Cancer Institute Drug Dictionary (drug name PF-06939999). DM7BOFR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/protein-arginine-methyltransferase-5-inhibitor-pf-06939999 DM7C062 DI DM7C062 DM7C062 DN RTA-901 DM7C062 TI TT78R5H DM7C062 TN Heat shock protein 90 alpha (HSP90A) DM7C062 MA Modulator DM7C062 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7C062 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7C4U9 DI DM7C4U9 DM7C4U9 DN DS-7309 DM7C4U9 TI TTDLNGZ DM7C4U9 TN Glucokinase (GCK) DM7C4U9 MA Inhibitor DM7C4U9 RN Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013 DM7C4U9 RU http://www.nature.com/scibx/journal/v6/n45/full/scibx.2013.1279.html DM7C68W DI DM7C68W DM7C68W DN AST-008 DM7C68W TI TTSHG0T DM7C68W TN Toll-like receptor 9 (TLR9) DM7C68W MA Agonist DM7C68W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7C68W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7CD8Z DI DM7CD8Z DM7CD8Z DN AMAP-102 DM7CD8Z TI TTYSN63 DM7CD8Z TN 5-HT 2 receptor (5HT2R) DM7CD8Z MA Antagonist DM7CD8Z RN Clinical pipeline report, company report or official report of Anamar. DM7CD8Z RU http://anamar.com/rd/project-amap102/ DM7CHZ2 DI DM7CHZ2 DM7CHZ2 DN TTC-352 DM7CHZ2 TI TTZAYWL DM7CHZ2 TN Estrogen receptor (ESR) DM7CHZ2 MA Agonist DM7CHZ2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7CHZ2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7CIN4 DI DM7CIN4 DM7CIN4 DN GSK-625433 DM7CIN4 TI TTMVBWH DM7CIN4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7CIN4 MA Inhibitor DM7CIN4 RN Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552. DM7CIN4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687230/ DM7CNTG DI DM7CNTG DM7CNTG DN AMG 397 DM7CNTG TI TTL53M6 DM7CNTG TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM7CNTG MA Inhibitor DM7CNTG RN Clinical pipeline report, company report or official report of Amgen. DM7CNTG RU https://www.amgenpipeline.com/ DM7DAKX DI DM7DAKX DM7DAKX DN SRT2379 DM7DAKX TI TTUF2HO DM7DAKX TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM7DAKX MA Modulator DM7DAKX RN SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8. DM7DAKX RU http://www.ccforum.com/content/17/S4/P8 DM7DFBL DI DM7DFBL DM7DFBL DN TAK-441 DM7DFBL TI TT8J1S3 DM7DFBL TN Smoothened homolog (SMO) DM7DFBL MA Modulator DM7DFBL RN TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66. DM7DFBL RU https://pubmed.ncbi.nlm.nih.gov/23564295 DM7E1W0 DI DM7E1W0 DM7E1W0 DN CC-95251 DM7E1W0 TI TTBRJS9 DM7E1W0 TN Inhibitory receptor SHPS-1 (SIRPA) DM7E1W0 RN ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health. DM7E1W0 RU https://clinicaltrials.gov/ct2/show/NCT03783403 DM7E6V2 DI DM7E6V2 DM7E6V2 DN TTC-352 DM7E6V2 TI TTZAYWL DM7E6V2 TN Estrogen receptor (ESR) DM7E6V2 MA Agonist DM7E6V2 RN Clinical pipeline report, company report or official report of TTC Oncology. DM7E6V2 RU https://ttconcology.com/our-product/ DM7EAG8 DI DM7EAG8 DM7EAG8 DN Cilobradine DM7EAG8 TI TTKLW9S DM7EAG8 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DM7EAG8 MA Modulator DM7EAG8 RN Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003 Oct 8;478(2-3):161-71. DM7EAG8 RU https://pubmed.ncbi.nlm.nih.gov/14575801 DM7ER9J DI DM7ER9J DM7ER9J DN MS-553 DM7ER9J TI TTYPXQF DM7ER9J TN Protein kinase C beta (PRKCB) DM7ER9J MA Inhibitor DM7ER9J RN ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health. DM7ER9J RU https://clinicaltrials.gov/ct2/show/NCT03492125 DM7FN12 DI DM7FN12 DM7FN12 DN GSK2256294 DM7FN12 TI TT7WVHI DM7FN12 TN Soluble epoxide hydrolase (EPHX2) DM7FN12 MA Modulator DM7FN12 RN In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. DM7FN12 RU https://pubmed.ncbi.nlm.nih.gov/23434473 DM7GSZL DI DM7GSZL DM7GSZL DN PF-05230907 DM7GSZL TI TTGKNB4 DM7GSZL TN Epidermal growth factor receptor (EGFR) DM7GSZL MA Inhibitor DM7GSZL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7GSZL RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM7GUH3 DI DM7GUH3 DM7GUH3 DN SEA-TGT DM7GUH3 TI TTWNL74 DM7GUH3 TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DM7GUH3 MA Inhibitor DM7GUH3 RN Clinical pipeline report, company report or official report of Seagen. DM7GUH3 RU https://www.seagen.com/science/pipeline DM7H6XI DI DM7H6XI DM7H6XI DN RO6870810 DM7H6XI TI TTE4BSY DM7H6XI TN Bromodomain and extraterminal domain protein (BET) DM7H6XI MA Inhibitor DM7H6XI RN A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 Feb;124(4):744-753. DM7H6XI RU https://pubmed.ncbi.nlm.nih.gov/33311588 DM7I1AQ DI DM7I1AQ DM7I1AQ DN GSK1614235 DM7I1AQ TI TT2UE56 DM7I1AQ TN Sodium/glucose cotransporter 1 (SGLT1) DM7I1AQ MA Blocker DM7I1AQ RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM7I1AQ RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM7I39W DI DM7I39W DM7I39W DN CSL-362-AML DM7I39W TI TTENHJ0 DM7I39W TN Interleukin 3 receptor alpha (IL3RA) DM7I39W RN Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. DM7I39W RU https://pubmed.ncbi.nlm.nih.gov/24363400 DM7JNHU DI DM7JNHU DM7JNHU DN LAM-001 DM7JNHU TI TTCJG29 DM7JNHU TN Serine/threonine-protein kinase mTOR (mTOR) DM7JNHU MA Inhibitor DM7JNHU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7JNHU RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM7JW0B DI DM7JW0B DM7JW0B DN BMS-903452 DM7JW0B TI TT7QNVC DM7JW0B TN Glucose-dependent insulinotropic receptor (GPR119) DM7JW0B MA Modulator DM7JW0B RN Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508. DM7JW0B RU https://pubmed.ncbi.nlm.nih.gov/25208139 DM7L45S DI DM7L45S DM7L45S DN 227Th-labelled PSMA-TTC DM7L45S TI TT9G4N0 DM7L45S TN Glutamate carboxypeptidase II (GCPII) DM7L45S RN Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. Clin Cancer Res. 2021 May 25. DM7L45S RU https://pubmed.ncbi.nlm.nih.gov/34035067 DM7L91K DI DM7L91K DM7L91K DN BAY1179470 DM7L91K TI TTGJVQM DM7L91K TN Fibroblast growth factor receptor 2 (FGFR2) DM7L91K MA Antagonist DM7L91K RN National Cancer Institute Drug Dictionary (drug id 751593). DM7L91K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751593 DM7LIV2 DI DM7LIV2 DM7LIV2 DN REGN3051 DM7LIV2 TI TTZ3COY DM7LIV2 TN COVID-19 spike glycoprotein (S) DM7LIV2 MA Inhibitor DM7LIV2 RN Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71. DM7LIV2 RU https://pubmed.ncbi.nlm.nih.gov/29885377 DM7MS10 DI DM7MS10 DM7MS10 DN WVT078 DM7MS10 TI TTUN7MC DM7MS10 TN T-cell surface glycoprotein CD3 (CD3) DM7MS10 RN ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health. DM7MS10 RU https://clinicaltrials.gov/ct2/show/NCT04123418 DM7MS10 DI DM7MS10 DM7MS10 DN WVT078 DM7MS10 TI TTZ3P4W DM7MS10 TN B-cell maturation protein (TNFRSF17) DM7MS10 RN ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health. DM7MS10 RU https://clinicaltrials.gov/ct2/show/NCT04123418 DM7MWX0 DI DM7MWX0 DM7MWX0 DN ARQ 751 DM7MWX0 TI TTWTSCV DM7MWX0 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM7MWX0 MA Inhibitor DM7MWX0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7MWX0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7OC9K DI DM7OC9K DM7OC9K DN PF-05230905 DM7OC9K TI TTF8CQI DM7OC9K TN Tumor necrosis factor (TNF) DM7OC9K MA Inhibitor DM7OC9K RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033173) DM7OC9K RU http://adisinsight.springer.com/drugs/800033173 DM7PLMJ DI DM7PLMJ DM7PLMJ DN AG-707 DM7PLMJ TI TTHYBIX DM7PLMJ TN Heat shock protein 70 (HSP70) DM7PLMJ MA Modulator DM7PLMJ RN A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41. DM7PLMJ RU https://pubmed.ncbi.nlm.nih.gov/21767588 DM7Q4EX DI DM7Q4EX DM7Q4EX DN Temanogrel DM7Q4EX TI TTJQOD7 DM7Q4EX TN 5-HT 2A receptor (HTR2A) DM7Q4EX MA Agonist DM7Q4EX RN Clinical pipeline report, company report or official report of Arena Pharmaceuticals. DM7Q4EX RU http://www.arenapharm.com/temanogrel DM7QGHO DI DM7QGHO DM7QGHO DN AZD5991 DM7QGHO TI TTL53M6 DM7QGHO TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM7QGHO MA Inhibitor DM7QGHO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QGHO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7QO05 DI DM7QO05 DM7QO05 DN SAR438335 DM7QO05 TI TTVIMDE DM7QO05 TN Glucagon-like peptide 1 receptor (GLP1R) DM7QO05 MA Agonist DM7QO05 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QO05 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM7QO05 DI DM7QO05 DM7QO05 DN SAR438335 DM7QO05 TI TTYMKBE DM7QO05 TN Gastric inhibitory polypeptide receptor (GIPR) DM7QO05 MA Agonist DM7QO05 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QO05 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM7QTIC DI DM7QTIC DM7QTIC DN BGB-11417 DM7QTIC TI TTJGNVC DM7QTIC TN Apoptosis regulator Bcl-2 (BCL-2) DM7QTIC MA Inhibitor DM7QTIC RN Clinical pipeline report, company report or official report of BeiGene. DM7QTIC RU https://www.beigenemedical.com/CongressDocuments/Hu%20BGB-11417%20AACR%20Poster%202020.pdf DM7RPSG DI DM7RPSG DM7RPSG DN BF-1 DM7RPSG TI TT85JO3 DM7RPSG TN 5-HT receptor (5HTR) DM7RPSG MA Modulator DM7RPSG RN Serotonin (5-HT2B) receptor. SciBX 4(19); doi:10.1038/scibx.2011.534. May 12 2011 DM7RPSG RU http://www.nature.com/scibx/journal/v4/n19/full/scibx.2011.534.html DM7TOWX DI DM7TOWX DM7TOWX DN ABT-333 DM7TOWX TI TTMVBWH DM7TOWX TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7TOWX MA Inhibitor DM7TOWX RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DM7TOWX RU http://www.abbott.com/index2.htm DM7UJ6E DI DM7UJ6E DM7UJ6E DN HER2-specific T cells DM7UJ6E TI TT6EO5L DM7UJ6E TN Erbb2 tyrosine kinase receptor (HER2) DM7UJ6E MA CAR-T-Cell-Therapy DM7UJ6E RN ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma DM7UJ6E RU https://clinicaltrials.gov/ct2/show/NCT02442297 DM7V2OM DI DM7V2OM DM7V2OM DN D-3263 DM7V2OM TI TTXDKTO DM7V2OM TN Long transient receptor potential channel 8 (TRPM8) DM7V2OM MA Modulator DM7V2OM RN Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107. DM7V2OM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/ DM7W5N2 DI DM7W5N2 DM7W5N2 DN BI 894999 DM7W5N2 TI TTE4BSY DM7W5N2 TN Bromodomain and extraterminal domain protein (BET) DM7W5N2 MA Inhibitor DM7W5N2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7W5N2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7WKTM DI DM7WKTM DM7WKTM DN SLV-338 DM7WKTM TI TT5TKPM DM7WKTM TN Neutral endopeptidase (MME) DM7WKTM MA Modulator DM7WKTM RN Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. DM7WKTM RU https://pubmed.ncbi.nlm.nih.gov/21888014 DM7WKTM DI DM7WKTM DM7WKTM DN SLV-338 DM7WKTM TI TT1BGDH DM7WKTM TN Endothelin-converting enzyme (ECE) DM7WKTM MA Modulator DM7WKTM RN Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. DM7WKTM RU https://pubmed.ncbi.nlm.nih.gov/21888014 DM7X2HK DI DM7X2HK DM7X2HK DN AE-08 DM7X2HK TI TT8MK59 DM7X2HK TN Melanocytes lineage-specific antigen GP100 (PMEL) DM7X2HK RN Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. DM7X2HK RU https://pubmed.ncbi.nlm.nih.gov/20355185 DM7XAV1 DI DM7XAV1 DM7XAV1 DN JBH492 DM7XAV1 TI TT2GIDQ DM7XAV1 TN C-C chemokine receptor type 7 (CCR7) DM7XAV1 RN ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health. DM7XAV1 RU https://clinicaltrials.gov/ct2/show/NCT04240704 DM7XES6 DI DM7XES6 DM7XES6 DN ANX-042 DM7XES6 TI TTWVLS6 DM7XES6 TN Natriuretic peptide receptor (NPR3) DM7XES6 MA Modulator DM7XES6 RN Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation: Novel Therapeutic Concepts to Combat Heart Failure. Circ Heart Fail. 2013 May; 6(3): 594-605. DM7XES6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981104/ DM7YFW5 DI DM7YFW5 DM7YFW5 DN OPB-111077 DM7YFW5 TI TTH8FZW DM7YFW5 TN Signal transducer and activator of transcription 3 (STAT3) DM7YFW5 MA Inhibitor DM7YFW5 RN Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518. DM7YFW5 RU https://pubmed.ncbi.nlm.nih.gov/29898591 DM7YX8G DI DM7YX8G DM7YX8G DN Pennvax-G DM7YX8G TI TTUTN1I DM7YX8G TN Human Deoxyribonucleic acid (hDNA) DM7YX8G RN Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601. DM7YX8G RU https://pubmed.ncbi.nlm.nih.gov/25531694 DM7Z8NP DI DM7Z8NP DM7Z8NP DN AM-461 DM7Z8NP TI TTQDMX5 DM7Z8NP TN Prostaglandin D2 receptor 2 (PTGDR2) DM7Z8NP MA Antagonist DM7Z8NP RN A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011 Dec;21(12):1931-6. DM7Z8NP RU https://pubmed.ncbi.nlm.nih.gov/22082220 DM7ZU3B DI DM7ZU3B DM7ZU3B DN AXT-914 DM7ZU3B TI TTBUYHA DM7ZU3B TN Extracellular calcium-sensing receptor (CASR) DM7ZU3B MA Antagonist DM7ZU3B RN AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10. DM7ZU3B RU https://pubmed.ncbi.nlm.nih.gov/24769332 DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTVIAT9 DM82KWY TN Phosphodiesterase 4B (PDE4B) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTSKMI8 DM82KWY TN Phosphodiesterase 4D (PDE4D) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTZ97H5 DM82KWY TN Phosphodiesterase 4A (PDE4A) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82OS7 DI DM82OS7 DM82OS7 DN Anti-CD123 CAR-T treatment DM82OS7 TI TTENHJ0 DM82OS7 TN Interleukin 3 receptor alpha (IL3RA) DM82OS7 MA CAR-T-Cell-Therapy DM82OS7 RN ClinicalTrials.gov (NCT03672851) Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia DM82OS7 RU https://clinicaltrials.gov/ct2/show/NCT03672851 DM830EN DI DM830EN DM830EN DN NEO-201 DM830EN TI TTY6DTE DM830EN TN Carcinoembryonic antigen CEA (CD66e) DM830EN MA Inhibitor DM830EN RN The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198. DM830EN RU https://pubmed.ncbi.nlm.nih.gov/31928422 DM830EN DI DM830EN DM830EN DN NEO-201 DM830EN TI TTA9CK4 DM830EN TN Biliary glycoprotein 1 (CEACAM1) DM830EN MA Inhibitor DM830EN RN The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198. DM830EN RU https://pubmed.ncbi.nlm.nih.gov/31928422 DM83E5B DI DM83E5B DM83E5B DN Synthetic neutrophil inhibitor peptide DM83E5B TI TTHQGFL DM83E5B TN PMN apoptosis and chemotaxis (PMNAC) DM83E5B MA Inhibitor DM83E5B RN Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide. Am J Respir Crit Care Med. 2001 Apr;163(5):1198-205. DM83E5B RU https://pubmed.ncbi.nlm.nih.gov/11316659 DM84LXE DI DM84LXE DM84LXE DN BGB-10188 DM84LXE TI TTGBPJE DM84LXE TN PI3-kinase delta (PIK3CD) DM84LXE MA Inhibitor DM84LXE RN ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health. DM84LXE RU https://clinicaltrials.gov/ct2/show/NCT04282018 DM84WXZ DI DM84WXZ DM84WXZ DN AZD-7295 DM84WXZ TI TTCJ2X8 DM84WXZ TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM84WXZ MA Modulator DM84WXZ RN TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711. DM84WXZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/ DM85AXS DI DM85AXS DM85AXS DN MBS301 DM85AXS TI TT6EO5L DM85AXS TN Erbb2 tyrosine kinase receptor (HER2) DM85AXS MA Inhibitor DM85AXS RN Clinical pipeline report, company report or official report of Beijing Mabworks Biotech. DM85AXS RU http://www.mab-works.com/product/5.html DM86CZJ DI DM86CZJ DM86CZJ DN C-CAR011 DM86CZJ TI TTW640A DM86CZJ TN B-lymphocyte surface antigen B4 (CD19) DM86CZJ MA CAR-T-Cell-Therapy DM86CZJ RN ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL DM86CZJ RU https://clinicaltrials.gov/ct2/show/NCT03299738 DM87SM9 DI DM87SM9 DM87SM9 DN ABBV-467 DM87SM9 TI TTL53M6 DM87SM9 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM87SM9 MA Inhibitor DM87SM9 RN Clinical pipeline report, company report or official report of AbbVie. DM87SM9 RU https://www.abbvie.com/our-science/pipeline/abbv-467.html DM89DHO DI DM89DHO DM89DHO DN ALN-VSP DM89DHO TI TTBGTCW DM89DHO TN Kinesin spindle messenger RNA (KIF11 mRNA) DM89DHO RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011). DM89DHO RU http://www.alnylam.com/Programs-and-Pipeline/index.php DM89NML DI DM89NML DM89NML DN XL652/XL014 DM89NML TI TTM1EQF DM89NML TN Oxysterols receptor LXR (NR1H) DM89NML MA Modulator DM89NML RN Clinical pipeline report, company report or official report of Exelixis (2011). DM89NML RU http://www.exelixis.com/pipeline DM8ANIM DI DM8ANIM DM8ANIM DN Lactermin DM8ANIM TI TTDB5IS DM8ANIM TN Receptor unspecific (Rec) DM8ANIM MA Modulator DM8ANIM RN Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75. DM8ANIM RU https://pubmed.ncbi.nlm.nih.gov/16261254 DM8B2WQ DI DM8B2WQ DM8B2WQ DN AN-2718 DM8B2WQ TI TT37GL6 DM8B2WQ TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DM8B2WQ MA Inhibitor DM8B2WQ RN Metalloid compounds as drugs. Res Pharm Sci. 2013 Jul-Sep; 8(3): 145-158. DM8B2WQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764666/ DM8B40M DI DM8B40M DM8B40M DN ONC-392 DM8B40M TI TTI2S1D DM8B40M TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM8B40M MA Inhibitor DM8B40M RN Clinical pipeline report, company report or official report of OncoImmune. DM8B40M RU https://www.oncoc4.com/index.php/product-development/onc-392 DM8BG0M DI DM8BG0M DM8BG0M DN FP-253-GDEPT DM8BG0M TI TTVYIH7 DM8BG0M TN Schistosoma Purine nucleoside phosphorylase (sch PNP) DM8BG0M MA Modulator DM8BG0M RN Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57. DM8BG0M RU https://pubmed.ncbi.nlm.nih.gov/15493036 DM8BXDI DI DM8BXDI DM8BXDI DN MEDI7814 DM8BXDI TI TTKANGO DM8BXDI TN Complement C5 (CO5) DM8BXDI MA Modulator DM8BXDI RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8BXDI RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8CGUV DI DM8CGUV DM8CGUV DN MCLA-145 DM8CGUV TI TTPW9LJ DM8CGUV TN Co-stimulatory molecule 4-1BB (CD137) DM8CGUV MA Agonist DM8CGUV RN Clinical pipeline report, company report or official report of Merus. DM8CGUV RU https://merus.nl/publication-category/mcla-145/ DM8CGUV DI DM8CGUV DM8CGUV DN MCLA-145 DM8CGUV TI TT8ZLTI DM8CGUV TN Programmed cell death 1 ligand 1 (PD-L1) DM8CGUV MA Agonist DM8CGUV RN Clinical pipeline report, company report or official report of Merus. DM8CGUV RU https://merus.nl/pipeline/ DM8CYJ1 DI DM8CYJ1 DM8CYJ1 DN AVP-13358 DM8CYJ1 TI TTYJQTF DM8CYJ1 TN Immunoglobulin E (IgE) DM8CYJ1 MA Inhibitor DM8CYJ1 RN Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. DM8CYJ1 RU https://pubmed.ncbi.nlm.nih.gov/15588078 DM8DBT6 DI DM8DBT6 DM8DBT6 DN ASP-0777 DM8DBT6 TI TT9IK2Z DM8DBT6 TN N-methyl-D-aspartate receptor (NMDAR) DM8DBT6 MA Modulator DM8DBT6 RN US patent application no. 2011,0262,442, Compositions for treating cns disorders. DM8DBT6 RU https://www.google.com/patents/US20110262442 DM8DMI0 DI DM8DMI0 DM8DMI0 DN AZD-8165 DM8DMI0 TI TT6L509 DM8DMI0 TN Coagulation factor IIa (F2) DM8DMI0 MA Inhibitor DM8DMI0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DM8DMI0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DM8DWOL DI DM8DWOL DM8DWOL DN CDNA vaccine DM8DWOL TI TTNYZG2 DM8DWOL TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM8DWOL MA Modulator DM8DWOL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8DWOL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8FQPX DI DM8FQPX DM8FQPX DN KTN3379 DM8FQPX TI TTDC8N2 DM8FQPX TN Erbb3 tyrosine kinase receptor (Erbb-3) DM8FQPX RN A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750. DM8FQPX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455348/ DM8GC65 DI DM8GC65 DM8GC65 DN RG3039 DM8GC65 TI TTLSW9V DM8GC65 TN Scavenger decapping enzyme DcpS (DCPS) DM8GC65 MA Inhibitor DM8GC65 RN 2011 Pipeline of Repligen. DM8GC65 RU http://www.repligen.com/products/pipeline DM8H2AG DI DM8H2AG DM8H2AG DN TTX-030 DM8H2AG TI TTYM8DJ DM8H2AG TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DM8H2AG MA Inhibitor DM8H2AG RN Clinical pipeline report, company report or official report of AbbVie. DM8H2AG RU https://www.abbvie.com/our-science/pipeline/ttx-030.html DM8I4G0 DI DM8I4G0 DM8I4G0 DN AEB701 DM8I4G0 TI TTYVX59 DM8I4G0 TN Protein kinase C (PRKC) DM8I4G0 MA Inhibitor DM8I4G0 RN Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253. DM8I4G0 RU http://synapse.koreamed.org/DOIx.php?id=10.4285/jkstn.2012.26.4.248 DM8J3WE DI DM8J3WE DM8J3WE DN Nibentan DM8J3WE TI TT1VOHK DM8J3WE TN Potassium channel unspecific (KC) DM8J3WE MA Blocker DM8J3WE RN Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23. DM8J3WE RU https://pubmed.ncbi.nlm.nih.gov/15821703 DM8KRA3 DI DM8KRA3 DM8KRA3 DN EDP-514 DM8KRA3 TI TTM42UJ DM8KRA3 TN Hepatitis B virus Capsid protein (HBV C) DM8KRA3 MA Inhibitor DM8KRA3 RN Clinical pipeline report, company report or official report of Enanta Pharmaceuticals. DM8KRA3 RU https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Clinical-Trial-Progress-for-EDP-514-its-Lead-Core-Inhibitor-for-Hepatitis-B-Virus/default.aspx DM8L1GJ DI DM8L1GJ DM8L1GJ DN SNA-125 DM8L1GJ TI TTT7PJU DM8L1GJ TN Janus kinase 3 (JAK-3) DM8L1GJ MA Inhibitor DM8L1GJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8L1GJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8L36X DI DM8L36X DM8L36X DN CNTO-3649 DM8L36X TI TTVIMDE DM8L36X TN Glucagon-like peptide 1 receptor (GLP1R) DM8L36X MA Agonist DM8L36X RN GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7(11):e49152. DM8L36X RU https://pubmed.ncbi.nlm.nih.gov/23133675 DM8LG2I DI DM8LG2I DM8LG2I DN AF-130 DM8LG2I TI TT2THBD DM8LG2I TN P2X purinoceptor 3 (P2RX3) DM8LG2I MA Antagonist DM8LG2I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8LG2I RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM8LGWR DI DM8LGWR DM8LGWR DN LY-2811376 DM8LGWR TI TT8JRS7 DM8LGWR TN Beta-secretase (BACE) DM8LGWR MA Inhibitor DM8LGWR RN Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012). DM8LGWR RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM8MGSH DI DM8MGSH DM8MGSH DN GPRC5D CAR-T cell therapy DM8MGSH TI TTHRAPJ DM8MGSH TN G-protein coupled receptor C 5D (GPRC5D) DM8MGSH RN GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. DM8MGSH RU https://pubmed.ncbi.nlm.nih.gov/30918115 DM8NLPI DI DM8NLPI DM8NLPI DN CAR CD30 T cells DM8NLPI TI TT2GM5R DM8NLPI TN Lymphocyte activation antigen CD30 (TNFRSF8) DM8NLPI MA CAR-T-Cell-Therapy DM8NLPI RN ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) DM8NLPI RU https://clinicaltrials.gov/ct2/show/NCT01316146 DM8O2AQ DI DM8O2AQ DM8O2AQ DN SPN-803 DM8O2AQ TI TTAN5W2 DM8O2AQ TN Raf messenger RNA (Raf mRNA) DM8O2AQ MA Inhibitor DM8O2AQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). DM8O2AQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184 DM8O2AQ DI DM8O2AQ DM8O2AQ DN SPN-803 DM8O2AQ TI TT0EOB8 DM8O2AQ TN B-Raf messenger RNA (BRAF mRNA) DM8O2AQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). DM8O2AQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943 DM8P3N5 DI DM8P3N5 DM8P3N5 DN ISIS-AR DM8P3N5 TI TTKPW01 DM8P3N5 TN Androgen receptor messenger RNA (AR mRNA) DM8P3N5 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM8P3N5 RU https://www.isispharm.com/pipeline/isis-arrx/ DM8R2ZX DI DM8R2ZX DM8R2ZX DN CART-19 DM8R2ZX TI TTW640A DM8R2ZX TN B-lymphocyte surface antigen B4 (CD19) DM8R2ZX MA CAR-T-Cell-Therapy DM8R2ZX RN ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia DM8R2ZX RU https://clinicaltrials.gov/ct2/show/NCT02810223 DM8RD4T DI DM8RD4T DM8RD4T DN EC0489 DM8RD4T TI TTVC37M DM8RD4T TN Folate receptor alpha (FOLR1) DM8RD4T MA Modulator DM8RD4T RN National Cancer Institute Drug Dictionary (drug id 638649). DM8RD4T RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=638649 DM8RNSB DI DM8RNSB DM8RNSB DN WP1220 DM8RNSB TI TTH8FZW DM8RNSB TN Signal transducer and activator of transcription 3 (STAT3) DM8RNSB MA Inhibitor DM8RNSB RN Clinical pipeline report, company report or official report of Moleculin Biotech. DM8RNSB RU https://www.moleculin.com/technology/wp1220/ DM8SINB DI DM8SINB DM8SINB DN SDZ-LAV-694 DM8SINB TI TTML2WA DM8SINB TN Tubulin (TUB) DM8SINB MA Inhibitor DM8SINB RN Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers. Recent Patents on Anti-Infective Drug Discovery 12/2009; 4(3):164-82. DM8SINB RU http://www.researchgate.net/profile/Harish_Joshi/publication/26735183_Recent_patents_reveal_microtubules_as_persistent_promising_target_for_novel_drug_development_for_cancers/links/0deec5192b302d6e79000000.pdf DM8T2KA DI DM8T2KA DM8T2KA DN CI-966 DM8T2KA TI TTPRKM0 DM8T2KA TN GABA transporter GAT-1 (SLC6A1) DM8T2KA MA Modulator DM8T2KA RN Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24. DM8T2KA RU https://pubmed.ncbi.nlm.nih.gov/7851497 DM8TU5R DI DM8TU5R DM8TU5R DN E7766 DM8TU5R TI TTT402Y DM8TU5R TN Stimulator of interferon genes protein (TMEM173) DM8TU5R MA Agonist DM8TU5R RN E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743. DM8TU5R RU https://pubmed.ncbi.nlm.nih.gov/33522135 DM8U23L DI DM8U23L DM8U23L DN GGTI-2418 DM8U23L TI TTXQKM3 DM8U23L TN Farnesyl protein transferase (Ftase) DM8U23L MA Modulator DM8U23L RN Company report (Prescient) DM8U23L RU http://prescienttherapeutics.com/ptx-100/ DM8U2IE DI DM8U2IE DM8U2IE DN FGI-101-1A6 DM8U2IE TI TTHU7JA DM8U2IE TN Tumor susceptibility gene protein 101 (TSG101) DM8U2IE RN ClinicalTrials.gov (NCT01299142) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6). U.S. National Institutes of Health. DM8U2IE RU https://clinicaltrials.gov/ct2/show/NCT01299142 DM8U3Q2 DI DM8U3Q2 DM8U3Q2 DN BAY-1075553 DM8U3Q2 TI TT9G4N0 DM8U3Q2 TN Glutamate carboxypeptidase II (GCPII) DM8U3Q2 MA Modulator DM8U3Q2 RN Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101. DM8U3Q2 RU https://pubmed.ncbi.nlm.nih.gov/23955632 DM8UTPJ DI DM8UTPJ DM8UTPJ DN VX-500 DM8UTPJ TI TT5FNQT DM8UTPJ TN Human immunodeficiency virus Protease (HIV PR) DM8UTPJ MA Inhibitor DM8UTPJ RN 2011 Pipeline of Vertex. DM8UTPJ RU http://www.vrtx.com/current-projects.html DM8V62T DI DM8V62T DM8V62T DN BAY1834845 DM8V62T TI TTKFVXR DM8V62T TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM8V62T MA Inhibitor DM8V62T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8V62T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8VGRX DI DM8VGRX DM8VGRX DN RGX-202 DM8VGRX TI TTYUHB5 DM8VGRX TN Solute carrier family 6 member 8 (SLC6A8) DM8VGRX MA Inhibitor DM8VGRX RN Clinical pipeline report, company report or official report of Rgenix. DM8VGRX RU https://rgenix.com/rgx-202/ DM8VQ1S DI DM8VQ1S DM8VQ1S DN AD-337 DM8VQ1S TI TT3ROYC DM8VQ1S TN Serotonin transporter (SERT) DM8VQ1S MA Modulator DM8VQ1S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8VQ1S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8WBNF DI DM8WBNF DM8WBNF DN DTX401 DM8WBNF TI TTBQMJ8 DM8WBNF TN Glucose-6-phosphatase (G6PC) DM8WBNF MA Replacement DM8WBNF RN Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical. DM8WBNF RU https://www.ultragenyx.com/pipeline/dtx-401-for-gsd1a/ DM8XM72 DI DM8XM72 DM8XM72 DN CIGB-500 DM8XM72 TI TTSTYLU DM8XM72 TN Growth hormone secretion (GH secr) DM8XM72 MA Modulator DM8XM72 RN Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 1993 Nov;77(5):1393-7. DM8XM72 RU https://pubmed.ncbi.nlm.nih.gov/8077339 DM8XMPT DI DM8XMPT DM8XMPT DN 4SC-203 DM8XMPT TI TTGJCWZ DM8XMPT TN Fms-like tyrosine kinase 3 (FLT-3) DM8XMPT MA Modulator DM8XMPT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8XMPT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8Y1M9 DI DM8Y1M9 DM8Y1M9 DN PSMA CAR-T cell therapy DM8Y1M9 TI TT9G4N0 DM8Y1M9 TN Glutamate carboxypeptidase II (GCPII) DM8Y1M9 RN Clinical pipeline report, company report or official report of Tmunity. DM8Y1M9 RU https://www.tmunity.com/pipeline DM8YNI6 DI DM8YNI6 DM8YNI6 DN SKL-PSY DM8YNI6 TI TTSQIFT DM8YNI6 TN 5-HT 1A receptor (HTR1A) DM8YNI6 MA Modulator DM8YNI6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1). DM8YNI6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1 DM8ZROW DI DM8ZROW DM8ZROW DN SNDX-6352 DM8ZROW TI TT7MRDV DM8ZROW TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM8ZROW MA Antagonist DM8ZROW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8ZROW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8ZS7T DI DM8ZS7T DM8ZS7T DN LX2761 DM8ZS7T TI TT2UE56 DM8ZS7T TN Sodium/glucose cotransporter 1 (SGLT1) DM8ZS7T MA Inhibitor DM8ZS7T RN Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals. DM8ZS7T RU https://www.lexpharma.com/pipeline/lx2761 DM90EO3 DI DM90EO3 DM90EO3 DN ABBV-621 DM90EO3 TI TTA5MS9 DM90EO3 TN TNF related apoptosis inducing ligand (TNFSF10) DM90EO3 MA Agonist DM90EO3 RN Clinical pipeline report, company report or official report of AbbVie. DM90EO3 RU https://www.abbvie.com/our-science/pipeline/abbv-621.html DM90P1K DI DM90P1K DM90P1K DN INO-3401 DM90P1K TI TTUTN1I DM90P1K TN Human Deoxyribonucleic acid (hDNA) DM90P1K RN ClinicalTrials.gov (NCT01403155) A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001. U.S. National Institutes of Health. DM90P1K RU https://clinicaltrials.gov/ct2/show/NCT01403155 DM90QPK DI DM90QPK DM90QPK DN CART-meso cells DM90QPK TI TT4RXME DM90QPK TN Mesothelin (MSLN) DM90QPK MA CAR-T-Cell-Therapy DM90QPK RN ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers DM90QPK RU https://clinicaltrials.gov/ct2/show/NCT02159716 DM926CH DI DM926CH DM926CH DN CTX130 DM926CH TI TTNCIE0 DM926CH TN CD70 antigen (CD27-L) DM926CH RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DM926CH RU http://www.crisprtx.com/programs/pipeline DM92RQT DI DM92RQT DM92RQT DN AAB-003/PF-05236812 DM92RQT TI TTE4KHA DM92RQT TN Amyloid beta A4 protein (APP) DM92RQT MA Modulator DM92RQT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM92RQT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM92YWD DI DM92YWD DM92YWD DN AMG 282 DM92YWD TI TT5MD4P DM92YWD TN Interleukin-33 (IL33) DM92YWD RN Clinical pipeline report, company report or official report of Amgen. DM92YWD RU http://www.amgenpipeline.com/pipeline/ DM93AJW DI DM93AJW DM93AJW DN LY2780301 DM93AJW TI TT7M3PI DM93AJW TN Ribosomal protein S6 kinase (S6K) DM93AJW MA Modulator DM93AJW RN A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. DM93AJW RU https://pubmed.ncbi.nlm.nih.gov/25902900 DM93AJW DI DM93AJW DM93AJW DN LY2780301 DM93AJW TI TTAZ05C DM93AJW TN RAC-gamma serine/threonine-protein kinase (AKT3) DM93AJW MA Modulator DM93AJW RN A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. DM93AJW RU https://pubmed.ncbi.nlm.nih.gov/25902900 DM93LMS DI DM93LMS DM93LMS DN PF-01247324 DM93LMS TI TT90XZ8 DM93LMS TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM93LMS MA Blocker DM93LMS RN Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067. DM93LMS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352054/ DM93QP2 DI DM93QP2 DM93QP2 DN Insulin transdermal DM93QP2 TI TTCBFJO DM93QP2 TN Insulin receptor (INSR) DM93QP2 MA Modulator DM93QP2 RN Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461-74. DM93QP2 RU https://pubmed.ncbi.nlm.nih.gov/12739984 DM94E6W DI DM94E6W DM94E6W DN LTT462 DM94E6W TI TTVOE6D DM94E6W TN Mitogen-activated protein kinase (MAPK) DM94E6W MA Inhibitor DM94E6W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM94E6W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM95F8B DI DM95F8B DM95F8B DN RO-14 DM95F8B TI TT4QPUL DM95F8B TN Antithrombin-III (ATIII) DM95F8B MA Modulator DM95F8B RN Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10. DM95F8B RU https://pubmed.ncbi.nlm.nih.gov/24647152 DM96JTX DI DM96JTX DM96JTX DN ATEVIRDINE DM96JTX TI TT84ETX DM96JTX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM96JTX MA Modulator DM96JTX RN Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89. DM96JTX RU https://pubmed.ncbi.nlm.nih.gov/8809165 DM98EP5 DI DM98EP5 DM98EP5 DN BAY 2701439 DM98EP5 TI TT6EO5L DM98EP5 TN Erbb2 tyrosine kinase receptor (HER2) DM98EP5 MA Inhibitor DM98EP5 RN National Cancer Institute Drug Dictionary (drug name BAY2701439). DM98EP5 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-anti-her2-monoclonal-antibody-bay2701439 DM9B68S DI DM9B68S DM9B68S DN POL-6014 DM9B68S TI TTPLTSQ DM9B68S TN Neutrophil elastase (NE) DM9B68S MA Inhibitor DM9B68S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358). DM9B68S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358 DM9BJ3G DI DM9BJ3G DM9BJ3G DN ENMD-1198 DM9BJ3G TI TTQHWNA DM9BJ3G TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM9BJ3G MA Inhibitor DM9BJ3G RN ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18. DM9BJ3G RU https://pubmed.ncbi.nlm.nih.gov/20442304 DM9CDPO DI DM9CDPO DM9CDPO DN TBC-M4 DM9CDPO TI TTEC2T3 DM9CDPO TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DM9CDPO RN A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. DM9CDPO RU https://pubmed.ncbi.nlm.nih.gov/19943789 DM9CDPO DI DM9CDPO DM9CDPO DN TBC-M4 DM9CDPO TI TTFGZB6 DM9CDPO TN Human immunodeficiency virus GAG protein (HIV gag) DM9CDPO RN A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. DM9CDPO RU https://pubmed.ncbi.nlm.nih.gov/19943789 DM9ERH1 DI DM9ERH1 DM9ERH1 DN Capravirine DM9ERH1 TI TT84ETX DM9ERH1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9ERH1 MA Inhibitor DM9ERH1 RN Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98. DM9ERH1 RU https://pubmed.ncbi.nlm.nih.gov/15205383 DM9F15C DI DM9F15C DM9F15C DN MAU868 DM9F15C TI TT09JLE DM9F15C TN BV virus Major capsid protein VP1 (BKV VP1) DM9F15C MA Inhibitor DM9F15C RN Clinical pipeline report, company report or official report of Amplyx Pharmaceuticals. DM9F15C RU https://amplyx.com/our-pipeline/ DM9GC4R DI DM9GC4R DM9GC4R DN VGX-100 DM9GC4R TI TT0QUFV DM9GC4R TN Vascular endothelial growth factor C (VEGFC) DM9GC4R MA Modulator DM9GC4R RN National Cancer Institute Drug Dictionary (drug id 724066). DM9GC4R RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724066 DM9GLHO DI DM9GLHO DM9GLHO DN Ad-OC-hsvTK/valacyclovir DM9GLHO TI TTP3QRF DM9GLHO TN Thymidine kinase 1 (TK1) DM9GLHO MA Inhibitor DM9GLHO RN Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41. DM9GLHO RU https://pubmed.ncbi.nlm.nih.gov/12639303 DM9IDUH DI DM9IDUH DM9IDUH DN TRX518 DM9IDUH TI TTG6LA7 DM9IDUH TN Activation-inducible TNFR family receptor (TNFRSF18) DM9IDUH RN Clinical pipeline report, company report or official report of Leap Therapeutics. DM9IDUH RU https://www.leaptx.com/our-pipeline DM9JU8L DI DM9JU8L DM9JU8L DN AKP-501 DM9JU8L TI TT13GFV DM9JU8L TN Follicle stimulating hormone (FSHB) DM9JU8L MA Modulator DM9JU8L RN AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009 Apr;82(4):247-54. DM9JU8L RU https://pubmed.ncbi.nlm.nih.gov/19183407 DM9JV80 DI DM9JV80 DM9JV80 DN Gp41 HIV-1 vaccine DM9JV80 TI TTG90S6 DM9JV80 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM9JV80 MA Modulator DM9JV80 RN Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. DM9JV80 RU https://pubmed.ncbi.nlm.nih.gov/20111582 DM9JXMD DI DM9JXMD DM9JXMD DN KPT-9274 DM9JXMD TI TT7Y3BZ DM9JXMD TN PAK-4 protein kinase (PAK4) DM9JXMD MA Inhibitor DM9JXMD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9JXMD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9KS1A DI DM9KS1A DM9KS1A DN DA-727 DM9KS1A TI TTGN1ZA DM9KS1A TN Angiotensin II receptor (AGTR) DM9KS1A MA Modulator DM9KS1A RN WO patent application no. 2009,0880,06, Combined pharmaceutical agent. DM9KS1A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090716&CC=WO&NR=2009088006A1&KC=A1 DM9L0D8 DI DM9L0D8 DM9L0D8 DN BOS172738 DM9L0D8 TI TT4DXQT DM9L0D8 TN Proto-oncogene c-Ret (RET) DM9L0D8 MA Inhibitor DM9L0D8 RN National Cancer Institute Drug Dictionary (drug name Zeteletinib). DM9L0D8 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zeteletinib DM9LYXQ DI DM9LYXQ DM9LYXQ DN Leflunomide DM9LYXQ TI TT3UY29 DM9LYXQ TN HUMAN dihydroorotate dehydrogenase (DHODH) DM9LYXQ MA Inhibitor DM9LYXQ RN On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w. DM9LYXQ RU https://pubmed.ncbi.nlm.nih.gov/23452331 DM9NYHT DI DM9NYHT DM9NYHT DN LY2787106 DM9NYHT TI TTPCG5T DM9NYHT TN Hepcidin (HAMP) DM9NYHT MA Inhibitor DM9NYHT RN A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73. DM9NYHT RU https://www.ncbi.nlm.nih.gov/pubmed/28327200 DM9O3RY DI DM9O3RY DM9O3RY DN Rosmantuzumab DM9O3RY TI TT7HJTF DM9O3RY TN R-spondin-3 (RSPO3) DM9O3RY MA Inhibitor DM9O3RY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9O3RY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9OA35 DI DM9OA35 DM9OA35 DN Long-acting erythropoietin conjugate DM9OA35 TI TTQG4NR DM9OA35 TN Erythropoietin (EPO) DM9OA35 MA Modulator DM9OA35 RN Company report (Pharmexcil) DM9OA35 RU http://www.pharmexcil.com/v1/docs/KoreanCompanies/hanmi.pdf DM9ODT6 DI DM9ODT6 DM9ODT6 DN CYC065 DM9ODT6 TI TT1LVF2 DM9ODT6 TN Cyclin-dependent kinase 9 (CDK9) DM9ODT6 MA Inhibitor DM9ODT6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9ODT6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9ODT6 DI DM9ODT6 DM9ODT6 DN CYC065 DM9ODT6 TI TT7HF4W DM9ODT6 TN Cyclin-dependent kinase 2 (CDK2) DM9ODT6 MA Inhibitor DM9ODT6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9ODT6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9P0NA DI DM9P0NA DM9P0NA DN AMG 319 DM9P0NA TI TTGBPJE DM9P0NA TN PI3-kinase delta (PIK3CD) DM9P0NA MA Inhibitor DM9P0NA RN National Cancer Institute Drug Dictionary (drug id 696292). DM9P0NA RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=696292 DM9PNR6 DI DM9PNR6 DM9PNR6 DN WST-057 DM9PNR6 TI TTZ9SOR DM9PNR6 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM9PNR6 MA Antagonist DM9PNR6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9PNR6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM9PQ2N DI DM9PQ2N DM9PQ2N DN RO-23-7553 DM9PQ2N TI TTK59TV DM9PQ2N TN Vitamin D3 receptor (VDR) DM9PQ2N MA Agonist DM9PQ2N RN Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331-8. DM9PQ2N RU https://pubmed.ncbi.nlm.nih.gov/9815816 DM9QNMB DI DM9QNMB DM9QNMB DN RG6084 DM9QNMB TI TTFAOU7 DM9QNMB TN CD274 messenger RNA (CD274 mRNA) DM9QNMB MA Inhibitor DM9QNMB RN Clinical pipeline report, company report or official report of Roche. DM9QNMB RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM9R0VA DI DM9R0VA DM9R0VA DN Belerofon DM9R0VA TI TTSYFMA DM9R0VA TN Interferon alpha/beta receptor 1 (IFNAR1) DM9R0VA MA Modulator DM9R0VA RN WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. DM9R0VA RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2 DM9RTXM DI DM9RTXM DM9RTXM DN LY3164530 DM9RTXM TI TTGKNB4 DM9RTXM TN Epidermal growth factor receptor (EGFR) DM9RTXM MA Modulator DM9RTXM RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM9RTXM RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM9RTXM DI DM9RTXM DM9RTXM DN LY3164530 DM9RTXM TI TTNDSF4 DM9RTXM TN Proto-oncogene c-Met (MET) DM9RTXM MA Modulator DM9RTXM RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM9RTXM RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM9SCME DI DM9SCME DM9SCME DN IRX4204 DM9SCME TI TTH029C DM9SCME TN Retinoic acid receptor RXR-gamma (RXRG) DM9SCME MA Modulator DM9SCME RN Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79. DM9SCME RU https://www.ncbi.nlm.nih.gov/pubmed/26862735 DM9SCME DI DM9SCME DM9SCME DN IRX4204 DM9SCME TI TTP7WQM DM9SCME TN Retinoic acid receptor RXR (RXR) DM9SCME MA Agonist DM9SCME RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SCME RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9SYVJ DI DM9SYVJ DM9SYVJ DN ABX-1431 DM9SYVJ TI TTZ963I DM9SYVJ TN Monoglyceride lipase (MAGL) DM9SYVJ MA Inhibitor DM9SYVJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SYVJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM9TD2N DI DM9TD2N DM9TD2N DN GD2 T cells DM9TD2N TI TT80ARU DM9TD2N TN Ganglioside GD2 (GD2) DM9TD2N MA CAR-T-Cell-Therapy DM9TD2N RN ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma DM9TD2N RU https://clinicaltrials.gov/ct2/show/NCT01953900 DM9UZTO DI DM9UZTO DM9UZTO DN PF-06444752 DM9UZTO TI TTYJQTF DM9UZTO TN Immunoglobulin E (IgE) DM9UZTO MA Modulator DM9UZTO RN ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health. DM9UZTO RU https://clinicaltrials.gov/ct2/show/NCT01723254 DM9VB4I DI DM9VB4I DM9VB4I DN Hu-CART meso cells DM9VB4I TI TT4RXME DM9VB4I TN Mesothelin (MSLN) DM9VB4I MA CAR-T-Cell-Therapy DM9VB4I RN ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers DM9VB4I RU https://clinicaltrials.gov/ct2/show/NCT03054298 DM9W0B6 DI DM9W0B6 DM9W0B6 DN VTR-297 DM9W0B6 TI TTBH0VX DM9W0B6 TN Histone deacetylase (HDAC) DM9W0B6 MA Inhibitor DM9W0B6 RN Clinical pipeline report, company report or official report of Vanda Pharmaceuticals. DM9W0B6 RU https://vandapharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/vanda-pharmaceuticals-reports-third-quarter-2019-financial DM9W1BS DI DM9W1BS DM9W1BS DN Anti-CD19 CAR-T DM9W1BS TI TTW640A DM9W1BS TN B-lymphocyte surface antigen B4 (CD19) DM9W1BS MA CAR-T-Cell-Therapy DM9W1BS RN ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma DM9W1BS RU https://clinicaltrials.gov/ct2/show/NCT03110640 DM9X20P DI DM9X20P DM9X20P DN AZD-8418 DM9X20P TI TTAN6JD DM9X20P TN Glutamate receptor AMPA (GRIA) DM9X20P MA Modulator DM9X20P RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031633) DM9X20P RU http://adisinsight.springer.com/drugs/800031633 DM9Y51T DI DM9Y51T DM9Y51T DN ISIS-ANGPTL3 DM9Y51T TI TT59GO7 DM9Y51T TN ANGPTL3 messenger RNA (ANGPTL3 mRNA) DM9Y51T RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM9Y51T RU https://www.isispharm.com/pipeline/isis-angptl3rx/ DM9YNTO DI DM9YNTO DM9YNTO DN ERY974 DM9YNTO TI TTJTSX4 DM9YNTO TN Glypican-3 (GPC3) DM9YNTO MA Inhibitor DM9YNTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9YNTO RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9ZOMD DI DM9ZOMD DM9ZOMD DN CUDC-101 DM9ZOMD TI TTGKNB4 DM9ZOMD TN Epidermal growth factor receptor (EGFR) DM9ZOMD MA Modulator DM9ZOMD RN A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. DM9ZOMD RU https://pubmed.ncbi.nlm.nih.gov/25573383 DM9ZOMD DI DM9ZOMD DM9ZOMD DN CUDC-101 DM9ZOMD TI TT6EO5L DM9ZOMD TN Erbb2 tyrosine kinase receptor (HER2) DM9ZOMD MA Modulator DM9ZOMD RN A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. DM9ZOMD RU https://pubmed.ncbi.nlm.nih.gov/25573383 DMA1EDN DI DMA1EDN DMA1EDN DN MK-8033 DMA1EDN TI TTNDSF4 DMA1EDN TN Proto-oncogene c-Met (MET) DMA1EDN MA Inhibitor DMA1EDN RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMA1EDN RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMA1I04 DI DMA1I04 DMA1I04 DN AMG 211 DMA1I04 TI TTY6DTE DMA1I04 TN Carcinoembryonic antigen CEA (CD66e) DMA1I04 MA Immunomodulator DMA1I04 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA1I04 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTVIAT9 DMA1KQV TN Phosphodiesterase 4B (PDE4B) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTSKMI8 DMA1KQV TN Phosphodiesterase 4D (PDE4D) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTZ97H5 DMA1KQV TN Phosphodiesterase 4A (PDE4A) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1QUC DI DMA1QUC DMA1QUC DN CAD-1833 DMA1QUC TI TTKU9YD DMA1QUC TN Calcium-activated potassium channel KCa2 (KCNN) DMA1QUC MA Modulator DMA1QUC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA1QUC RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA2B5Y DI DMA2B5Y DMA2B5Y DN DS-3032 DMA2B5Y TI TT08GJW DMA2B5Y TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMA2B5Y MA Inhibitor DMA2B5Y RN Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. DMA2B5Y RU https://pubmed.ncbi.nlm.nih.gov/24577402 DMA368V DI DMA368V DMA368V DN MGD010 DMA368V TI TT5RWKQ DMA368V TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMA368V MA Modulator DMA368V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA368V RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMA368V DI DMA368V DMA368V DN MGD010 DMA368V TI TTBN5I7 DMA368V TN B-cell-specific glycoprotein B29 (CD79B) DMA368V MA Modulator DMA368V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA368V RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMA3B9T DI DMA3B9T DMA3B9T DN AMG 673 DMA3B9T TI TTJVYO3 DMA3B9T TN Myeloid cell surface antigen CD33 (CD33) DMA3B9T MA Inhibitor DMA3B9T RN Clinical pipeline report, company report or official report of Amgen. DMA3B9T RU https://www.amgenpipeline.com/ DMA3B9T DI DMA3B9T DMA3B9T DN AMG 673 DMA3B9T TI TTUN7MC DMA3B9T TN T-cell surface glycoprotein CD3 (CD3) DMA3B9T MA Inhibitor DMA3B9T RN Clinical pipeline report, company report or official report of Amgen. DMA3B9T RU https://www.amgenpipeline.com/ DMA41JD DI DMA41JD DMA41JD DN GSK-1827771 DMA41JD TI TT51DEV DMA41JD TN Interleukin 1 receptor type 2 (IL1R2) DMA41JD RN WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne. DMA41JD RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130117&CC=WO&NR=2013007763A1&KC=A1 DMA46DO DI DMA46DO DMA46DO DN INS-117548 DMA46DO TI TTGWKQJ DMA46DO TN Rho-associated protein kinase 2 (ROCK2) DMA46DO MA Modulator DMA46DO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA46DO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA46DO DI DMA46DO DMA46DO DN INS-117548 DMA46DO TI TTZN7RP DMA46DO TN Rho-associated protein kinase 1 (ROCK1) DMA46DO MA Modulator DMA46DO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA46DO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA46RN DI DMA46RN DMA46RN DN EGFRvIII-CARs DMA46RN TI TTZ6B2I DMA46RN TN Epidermal growth factor receptor variant III (EGFR vIII) DMA46RN MA CAR-T-Cell-Therapy DMA46RN RN ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM DMA46RN RU https://clinicaltrials.gov/ct2/show/NCT03283631 DMA4BRV DI DMA4BRV DMA4BRV DN Elinogrel DMA4BRV TI TTZ1DT0 DMA4BRV TN P2Y purinoceptor 12 (P2RY12) DMA4BRV MA Antagonist DMA4BRV RN Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8. DMA4BRV RU https://pubmed.ncbi.nlm.nih.gov/20178048 DMA4WEO DI DMA4WEO DMA4WEO DN ABSK021 DMA4WEO TI TT7MRDV DMA4WEO TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMA4WEO MA Inhibitor DMA4WEO RN Clinical pipeline report, company report or official report of Abbisko Therapeutics. DMA4WEO RU http://www.abbisko.com/page104?_l=en DMA6JME DI DMA6JME DMA6JME DN RTA 901 DMA6JME TI TTO7FVG DMA6JME TN Heat shock protein 90 (HSP90) DMA6JME MA Inhibitor DMA6JME RN Clinical pipeline report, company report or official report of Reata Pharmaceuticals. DMA6JME RU https://www.reatapharma.com/our-science/default.aspx DMA6O9R DI DMA6O9R DMA6O9R DN SAR-389644 DMA6O9R TI TTNVEIR DMA6O9R TN Prostaglandin D2 receptor (PTGDR) DMA6O9R MA Antagonist DMA6O9R RN US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders. DMA6O9R RU http://www.google.com/patents/US20080300217 DMA71OL DI DMA71OL DMA71OL DN ASP8374 DMA71OL TI TTWNL74 DMA71OL TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMA71OL MA Antagonist DMA71OL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA71OL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMA7L3O DI DMA7L3O DMA7L3O DN Anti-CEA CAR-T cells DMA7L3O TI TTY6DTE DMA7L3O TN Carcinoembryonic antigen CEA (CD66e) DMA7L3O MA CAR-T-Cell-Therapy DMA7L3O RN ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases DMA7L3O RU https://clinicaltrials.gov/ct2/show/NCT02416466 DMA7PWX DI DMA7PWX DMA7PWX DN Combotox DMA7PWX TI TTM6QSK DMA7PWX TN B-cell receptor CD22 (CD22) DMA7PWX MA Modulator DMA7PWX RN A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. DMA7PWX RU https://www.ncbi.nlm.nih.gov/pubmed/21732928 DMA7PWX DI DMA7PWX DMA7PWX DN Combotox DMA7PWX TI TTW640A DMA7PWX TN B-lymphocyte surface antigen B4 (CD19) DMA7PWX MA Modulator DMA7PWX RN A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. DMA7PWX RU https://www.ncbi.nlm.nih.gov/pubmed/21732928 DMA9M81 DI DMA9M81 DMA9M81 DN CAR138 T Cells DMA9M81 TI TTYDSVG DMA9M81 TN Syndecan-1 (SDC1) DMA9M81 MA CAR-T-Cell-Therapy DMA9M81 RN ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma DMA9M81 RU https://clinicaltrials.gov/ct2/show/NCT03672318 DMA9UX2 DI DMA9UX2 DMA9UX2 DN Gerilimzumab DMA9UX2 TI TTT1V78 DMA9UX2 TN Interleukin-6 (IL6) DMA9UX2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA9UX2 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TTLYXIT DMAC5F2 TN Aurora kinase C (AURKC) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TTPS3C0 DMAC5F2 TN Aurora kinase A (AURKA) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TT5LS6T DMAC5F2 TN Aurora kinase B (AURKB) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMACLIH DI DMACLIH DMACLIH DN RG7813 DMACLIH TI TTY6DTE DMACLIH TN Carcinoembryonic antigen CEA (CD66e) DMACLIH MA Inhibitor DMACLIH RN Clinical pipeline report, company report or official report of Roche. DMACLIH RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMAD6HS DI DMAD6HS DMAD6HS DN SPC4955 DMAD6HS TI TT2718H DMAD6HS TN Apolipoprotein B-100 (APOB) DMAD6HS MA Inhibitor DMAD6HS RN 2011 Pipeline of Santaris Pharma. DMAD6HS RU http://www.santaris.com/product-pipeline DMAE9I0 DI DMAE9I0 DMAE9I0 DN Dexpirronium DMAE9I0 TI TTH18TF DMAE9I0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMAE9I0 MA Antagonist DMAE9I0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMAE9I0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMAEK3L DI DMAEK3L DMAEK3L DN PF-05082566 DMAEK3L TI TTPW9LJ DMAEK3L TN Co-stimulatory molecule 4-1BB (CD137) DMAEK3L MA Modulator DMAEK3L RN Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. DMAEK3L RU https://pubmed.ncbi.nlm.nih.gov/22406983 DMAESIY DI DMAESIY DMAESIY DN ANX005 DMAESIY TI TT7LRQH DMAESIY TN Complement C1s component (C1S) DMAESIY MA Inhibitor DMAESIY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAESIY RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMAESQI DI DMAESQI DMAESQI DN MCY-M11 DMAESQI TI TT4RXME DMAESQI TN Mesothelin (MSLN) DMAESQI RN Clinical pipeline report, company report or official report of MaxCyte. DMAESQI RU https://maxcyte.com/carma-cell-therapies-expands-phase-i-trial-of-anti-mesothelin-mrna-car-pbmc-cell-therapy-mcy-m11/ DMAG6BV DI DMAG6BV DMAG6BV DN LGK974 DMAG6BV TI TTNFBTO DMAG6BV TN Protein-serine O-palmitoleoyltransferase porcupine (PORCN) DMAG6BV MA Inhibitor DMAG6BV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAG6BV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAGCHE DI DMAGCHE DMAGCHE DN Multi-envelope HIV vaccine DMAGCHE TI TTBYP1X DMAGCHE TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMAGCHE RN An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428. DMAGCHE RU https://pubmed.ncbi.nlm.nih.gov/18826331 DMAGCHE DI DMAGCHE DMAGCHE DN Multi-envelope HIV vaccine DMAGCHE TI TTG90S6 DMAGCHE TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMAGCHE RN An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428. DMAGCHE RU https://pubmed.ncbi.nlm.nih.gov/18826331 DMAH12E DI DMAH12E DMAH12E DN F-15845 DMAH12E TI TTZOVE0 DMAH12E TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMAH12E MA Inhibitor DMAH12E RN Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91. DMAH12E RU https://pubmed.ncbi.nlm.nih.gov/20718741 DMAI0SH DI DMAI0SH DMAI0SH DN TNB-383B DMAI0SH TI TTUN7MC DMAI0SH TN T-cell surface glycoprotein CD3 (CD3) DMAI0SH RN Clinical pipeline report, company report or official report of AbbVie. DMAI0SH RU https://www.abbvie.com/our-science/pipeline/tnb-383b.html DMAI0SH DI DMAI0SH DMAI0SH DN TNB-383B DMAI0SH TI TTZ3P4W DMAI0SH TN B-cell maturation protein (TNFRSF17) DMAI0SH RN Clinical pipeline report, company report or official report of AbbVie. DMAI0SH RU https://www.abbvie.com/our-science/pipeline/tnb-383b.html DMAJ2T4 DI DMAJ2T4 DMAJ2T4 DN VX-916 DMAJ2T4 TI TTMVBWH DMAJ2T4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAJ2T4 MA Inhibitor DMAJ2T4 RN 2011 Pipeline of Vertex. DMAJ2T4 RU http://www.vrtx.com/current-projects.html DMAJPOX DI DMAJPOX DMAJPOX DN Balapiravir DMAJPOX TI TTMVBWH DMAJPOX TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAJPOX MA Inhibitor DMAJPOX RN R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49. DMAJPOX RU https://pubmed.ncbi.nlm.nih.gov/18828074 DMAK89L DI DMAK89L DMAK89L DN GSK2661380 DMAK89L TI TTNBFWK DMAK89L TN Programmed cell death protein 1 (PD-1) DMAK89L MA Inhibitor DMAK89L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760). DMAK89L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760 DMAKD0I DI DMAKD0I DMAKD0I DN AVX-470 DMAKD0I TI TTG043C DMAKD0I TN Tumor necrosis factor receptor type I (TNF-R1) DMAKD0I RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMAKD0I RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMAKD0I DI DMAKD0I DMAKD0I DN AVX-470 DMAKD0I TI TTF8CQI DMAKD0I TN Tumor necrosis factor (TNF) DMAKD0I MA Inhibitor DMAKD0I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAKD0I RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAKWQD DI DMAKWQD DMAKWQD DN EVT100 DMAKWQD TI TTN9D8E DMAKWQD TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMAKWQD MA Antagonist DMAKWQD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAKWQD RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMAKZTW DI DMAKZTW DMAKZTW DN CART-117 cells DMAKZTW TI TTX41N9 DMAKZTW TN Tyrosine-protein kinase Kit (KIT) DMAKZTW MA CAR-T-Cell-Therapy DMAKZTW RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMAKZTW RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMALK7F DI DMALK7F DMALK7F DN KW-5092 DMALK7F TI TT1RS9F DMALK7F TN Acetylcholinesterase (AChE) DMALK7F MA Inhibitor DMALK7F RN Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8. DMALK7F RU https://pubmed.ncbi.nlm.nih.gov/9143009 DMAOJBX DI DMAOJBX DMAOJBX DN Tetrandrine DMAOJBX TI TT5HONZ DMAOJBX TN Calcium channel unspecific (CaC) DMAOJBX MA Antagonist DMAOJBX RN Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31. DMAOJBX RU https://pubmed.ncbi.nlm.nih.gov/1787886 DMAOV7M DI DMAOV7M DMAOV7M DN TMC649128 DMAOV7M TI TTMVBWH DMAOV7M TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAOV7M MA Inhibitor DMAOV7M RN Clinical pipeline report, company report or official report of Medivir (2011). DMAOV7M RU http://www.medivir.se/v4/en/ DMAP6CS DI DMAP6CS DMAP6CS DN RBN-2397 DMAP6CS TI TT2FRAN DMAP6CS TN Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) DMAP6CS MA Inhibitor DMAP6CS RN Clinical pipeline report, company report or official report of Ribon Therapeutics. DMAP6CS RU https://ribontx.com/rbn-2397/ DMAQ24G DI DMAQ24G DMAQ24G DN MDCO-216 DMAQ24G TI TT7GN3U DMAQ24G TN Apolipoprotein A-I (APOA1) DMAQ24G MA Modulator DMAQ24G RN MDCO-216 (Apo A-I Milano/POPC Complex) Administered to Cynomolgus Monkeys Induces Pronounced Changes in Plasma Lipids and Apolipoproteins. Circulation. 2011; 124: A10978. DMAQ24G RU https://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A10978 DMAQJHO DI DMAQJHO DMAQJHO DN Monohydroxyethylrutoside DMAQJHO TI TTUDR0C DMAQJHO TN Iron (Fe) DMAQJHO MA Modulator DMAQJHO RN Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54. DMAQJHO RU https://pubmed.ncbi.nlm.nih.gov/9815559 DMAQYRL DI DMAQYRL DMAQYRL DN Eptacog alfa DMAQYRL TI TTF0EGX DMAQYRL TN Coagulation factor VII (F7) DMAQYRL MA Modulator DMAQYRL RN Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36. DMAQYRL RU https://pubmed.ncbi.nlm.nih.gov/18345709 DMARHU4 DI DMARHU4 DMARHU4 DN UCART-22 DMARHU4 TI TTM6QSK DMARHU4 TN B-cell receptor CD22 (CD22) DMARHU4 RN Clinical pipeline report, company report or official report of Cellectis. DMARHU4 RU https://www.cellectis.com/en/products/product-candidates/ DMARYFK DI DMARYFK DMARYFK DN Autologous melanoma cell vaccine DMARYFK TI TTNYZG2 DMARYFK TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMARYFK MA Modulator DMARYFK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMARYFK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMAS1RB DI DMAS1RB DMAS1RB DN MK-8776 DMAS1RB TI TTTU902 DMAS1RB TN Checkpoint kinase-1 (CHK1) DMAS1RB MA Inhibitor DMAS1RB RN Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095. DMAS1RB RU https://pubmed.ncbi.nlm.nih.gov/31443367 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TTLYXIT DMASGXJ TN Aurora kinase C (AURKC) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TT5LS6T DMASGXJ TN Aurora kinase B (AURKB) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TTPS3C0 DMASGXJ TN Aurora kinase A (AURKA) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASKX9 DI DMASKX9 DMASKX9 DN PF-06342674 DMASKX9 TI TTAWI51 DMASKX9 TN Interleukin 7 receptor alpha (IL7R) DMASKX9 MA Antagonist DMASKX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMASKX9 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMATJL9 DI DMATJL9 DMATJL9 DN SGN-B6A DMATJL9 TI TTKQSXZ DMATJL9 TN Integrin beta-6 (ITGB6) DMATJL9 RN Clinical pipeline report, company report or official report of Seagen. DMATJL9 RU https://www.seagen.com/science/pipeline DMAU8L9 DI DMAU8L9 DMAU8L9 DN ZW49 DMAU8L9 TI TT6EO5L DMAU8L9 TN Erbb2 tyrosine kinase receptor (HER2) DMAU8L9 MA Inhibitor DMAU8L9 RN Clinical pipeline report, company report or official report of Zymeworks. DMAU8L9 RU https://www.zymeworks.com/pipeline#zw49 DMAV86R DI DMAV86R DMAV86R DN CTT1403 DMAV86R TI TT9G4N0 DMAV86R TN Glutamate carboxypeptidase II (GCPII) DMAV86R MA Inhibitor DMAV86R RN 177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017 Apr 27;7(7):1928-1939. DMAV86R RU https://pubmed.ncbi.nlm.nih.gov/28638478 DMAWO5I DI DMAWO5I DMAWO5I DN PTX-100 DMAWO5I TI TT4P2VW DMAWO5I TN Geranylgeranyl transferase (GGTase) DMAWO5I MA Inhibitor DMAWO5I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAWO5I RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAWVTX DI DMAWVTX DMAWVTX DN Cyclopentenylcytosine DMAWVTX TI TTN12BZ DMAWVTX TN CTP synthase (CTPS1) DMAWVTX MA Inhibitor DMAWVTX RN Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. DMAWVTX RU https://pubmed.ncbi.nlm.nih.gov/8250543 DMAXHC0 DI DMAXHC0 DMAXHC0 DN AZD9567 DMAXHC0 TI TTOZRK6 DMAXHC0 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMAXHC0 MA Modulator DMAXHC0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAXHC0 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAXVZ1 DI DMAXVZ1 DMAXVZ1 DN AGEN2373 DMAXVZ1 TI TTPW9LJ DMAXVZ1 TN Co-stimulatory molecule 4-1BB (CD137) DMAXVZ1 MA Activator DMAXVZ1 RN Clinical pipeline report, company report or official report of Agenus. DMAXVZ1 RU https://agenusbio.com/agen2373-alpha-cd137/ DMAY6X2 DI DMAY6X2 DMAY6X2 DN CZ-48 DMAY6X2 TI TTGTQHC DMAY6X2 TN DNA topoisomerase I (TOP1) DMAY6X2 MA Inhibitor DMAY6X2 RN Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23. DMAY6X2 RU https://pubmed.ncbi.nlm.nih.gov/11193897 DMAY8I4 DI DMAY8I4 DMAY8I4 DN CGTG-102 DMAY8I4 TI TTNYZG2 DMAY8I4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMAY8I4 MA Modulator DMAY8I4 RN Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1;135(3):720-30. DMAY8I4 RU https://pubmed.ncbi.nlm.nih.gov/24374597 DMAYD7O DI DMAYD7O DMAYD7O DN IT-141 DMAYD7O TI TTGTQHC DMAYD7O TN DNA topoisomerase I (TOP1) DMAYD7O MA Inhibitor DMAYD7O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAYD7O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAYHT4 DI DMAYHT4 DMAYHT4 DN CC-31244 DMAYHT4 TI TTMVBWH DMAYHT4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAYHT4 MA Inhibitor DMAYHT4 RN Clinical pipeline report, company report or official report of Cocrystal Pharma. DMAYHT4 RU https://www.cocrystalpharma.com/development-pipeline/hepatitis-c/cc-31244 DMAYSFK DI DMAYSFK DMAYSFK DN BL-1021 DMAYSFK TI TTAWNKZ DMAYSFK TN Norepinephrine transporter (NET) DMAYSFK MA Modulator DMAYSFK RN Company report (BioLineRx) DMAYSFK RU http://www.biolinerx.com/default.asp?pageid=13&itemid=13 DMAYSFK DI DMAYSFK DMAYSFK DN BL-1021 DMAYSFK TI TT3ROYC DMAYSFK TN Serotonin transporter (SERT) DMAYSFK MA Modulator DMAYSFK RN Company report (BioLineRx) DMAYSFK RU http://www.biolinerx.com/default.asp?pageid=13&itemid=13 DMAYTRK DI DMAYTRK DMAYTRK DN H3B-6527 DMAYTRK TI TT1KX2S DMAYTRK TN FGFR4 messenger RNA (FGFR4 mRNA) DMAYTRK MA Inhibitor DMAYTRK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAYTRK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMB01L5 DI DMB01L5 DMB01L5 DN ABBV-3067 DMB01L5 TI TTRLZHP DMB01L5 TN cAMP-dependent chloride channel (CFTR) DMB01L5 MA Modulator DMB01L5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMB01L5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMB1MZS DI DMB1MZS DMB1MZS DN SCO-120 DMB1MZS TI TTZAYWL DMB1MZS TN Estrogen receptor (ESR) DMB1MZS MA Degrader DMB1MZS RN Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company. DMB1MZS RU https://www.sparc.life/research-programs/sco-120 DMB2MKU DI DMB2MKU DMB2MKU DN CIGB-128 DMB2MKU TI TTSIUJ9 DMB2MKU TN Interferon-alpha 2 (IFNA2) DMB2MKU MA Modulator DMB2MKU RN Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. DMB2MKU RU https://www.ncbi.nlm.nih.gov/pubmed/23272809 DMB2MKU DI DMB2MKU DMB2MKU DN CIGB-128 DMB2MKU TI TT93WF5 DMB2MKU TN Interferon-gamma (IFNG) DMB2MKU MA Modulator DMB2MKU RN Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. DMB2MKU RU https://www.ncbi.nlm.nih.gov/pubmed/23272809 DMB3I04 DI DMB3I04 DMB3I04 DN VM-206 DMB3I04 TI TT6EO5L DMB3I04 TN Erbb2 tyrosine kinase receptor (HER2) DMB3I04 RN WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer. DMB3I04 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140918&CC=WO&NR=2014144121A2&KC=A2 DMB3LQU DI DMB3LQU DMB3LQU DN HuA33 DMB3LQU TI TT96HUR DMB3LQU TN Cell surface A33 antigen (GPA33) DMB3LQU RN (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. DMB3LQU RU https://pubmed.ncbi.nlm.nih.gov/21764796 DMB3WJF DI DMB3WJF DMB3WJF DN Solulin DMB3WJF TI TT6L509 DMB3WJF TN Coagulation factor IIa (F2) DMB3WJF MA Modulator DMB3WJF RN The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82. DMB3WJF RU https://pubmed.ncbi.nlm.nih.gov/21645225 DMB3YZJ DI DMB3YZJ DMB3YZJ DN Sonepcizumab DMB3YZJ TI TT9JZCK DMB3YZJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMB3YZJ RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMB3YZJ RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMB51K2 DI DMB51K2 DMB51K2 DN LY3405105 DMB51K2 TI TTQYF7G DMB51K2 TN Cyclin-dependent kinase 7 (CDK7) DMB51K2 MA Inhibitor DMB51K2 RN CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. DMB51K2 RU https://pubmed.ncbi.nlm.nih.gov/32385714 DMB5A63 DI DMB5A63 DMB5A63 DN AC0058TA DMB5A63 TI TTGM6VW DMB5A63 TN Tyrosine-protein kinase BTK (ATK) DMB5A63 MA Inhibitor DMB5A63 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB5A63 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMB5JWX DI DMB5JWX DMB5JWX DN Pegadricase DMB5JWX TI TTZ1SWF DMB5JWX TN Uric acid (URA) DMB5JWX MA Modulator DMB5JWX RN Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9. DMB5JWX RU https://pubmed.ncbi.nlm.nih.gov/12233890 DMB6FMH DI DMB6FMH DMB6FMH DN BMTP-11 DMB6FMH TI TTZPLJS DMB6FMH TN Interleukin 11 receptor alpha (IL11RA) DMB6FMH MA Modulator DMB6FMH RN Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51. DMB6FMH RU https://pubmed.ncbi.nlm.nih.gov/25779950 DMB6M1P DI DMB6M1P DMB6M1P DN PT-112 DMB6M1P TI TT84ETX DMB6M1P TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB6M1P MA Inhibitor DMB6M1P RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMB6M1P RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMB6Q19 DI DMB6Q19 DMB6Q19 DN AMG 820 DMB6Q19 TI TT731LW DMB6Q19 TN Colony stimulating factor-1 receptor (CSF-1R) DMB6Q19 MA Modulator DMB6Q19 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMB6Q19 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMB6Q19 DI DMB6Q19 DMB6Q19 DN AMG 820 DMB6Q19 TI TTC70AJ DMB6Q19 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMB6Q19 MA Inhibitor DMB6Q19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB6Q19 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMB83V4 DI DMB83V4 DMB83V4 DN IBI318 DMB83V4 TI TTNBFWK DMB83V4 TN Programmed cell death protein 1 (PD-1) DMB83V4 MA Inhibitor DMB83V4 RN Clinical pipeline report, company report or official report of Innovent. DMB83V4 RU http://innoventbio.com/#/news/208 DMB83V4 DI DMB83V4 DMB83V4 DN IBI318 DMB83V4 TI TT8ZLTI DMB83V4 TN Programmed cell death 1 ligand 1 (PD-L1) DMB83V4 MA Inhibitor DMB83V4 RN Clinical pipeline report, company report or official report of Innovent. DMB83V4 RU http://innoventbio.com/#/news/208 DMB8RI6 DI DMB8RI6 DMB8RI6 DN CD19 CAR T cells DMB8RI6 TI TTW640A DMB8RI6 TN B-lymphocyte surface antigen B4 (CD19) DMB8RI6 MA CAR-T-Cell-Therapy DMB8RI6 RN ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia DMB8RI6 RU https://clinicaltrials.gov/ct2/show/NCT02975687 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TTDNFMT DMB9861 TN Platelet-activating factor acetylhydrolase (PLA2G7) DMB9861 MA Inhibitor DMB9861 RN Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009 Aug;20(4):327-32. DMB9861 RU https://pubmed.ncbi.nlm.nih.gov/19550325 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TTP3QRF DMB9861 TN Thymidine kinase 1 (TK1) DMB9861 MA Inhibitor DMB9861 RN Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22. DMB9861 RU https://pubmed.ncbi.nlm.nih.gov/9693096 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TT9V5JH DMB9861 TN Phospholipase A2 (PLA2G1B) DMB9861 MA Modulator DMB9861 RN Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.J Am Coll Cardiol.2014 Jan 7-14;63(1):86-8. DMB9861 RU https://www.ncbi.nlm.nih.gov/pubmed/23973698 DMB9N4J DI DMB9N4J DMB9N4J DN ABT-957 DMB9N4J TI TTG5QB7 DMB9N4J TN Calpain-2 (CAPN2) DMB9N4J MA Modulator DMB9N4J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMB9N4J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBCATZ DI DMBCATZ DMBCATZ DN ATR-107 DMBCATZ TI TTZO9B0 DMBCATZ TN Interleukin 21 receptor (IL21R) DMBCATZ RN Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22. DMBCATZ RU https://pubmed.ncbi.nlm.nih.gov/23913720 DMBCJW6 DI DMBCJW6 DMBCJW6 DN CT053 DMBCJW6 TI TTZ3P4W DMBCJW6 TN B-cell maturation protein (TNFRSF17) DMBCJW6 RN ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health. DMBCJW6 RU https://clinicaltrials.gov/ct2/show/NCT03915184 DMBDW93 DI DMBDW93 DMBDW93 DN GW-695634 DMBDW93 TI TT84ETX DMBDW93 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBDW93 MA Inhibitor DMBDW93 RN Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. DMBDW93 RU https://pubmed.ncbi.nlm.nih.gov/16499282 DMBEA6V DI DMBEA6V DMBEA6V DN AZD1208 DMBEA6V TI TT69J2Z DMBEA6V TN Serine/threonine-protein kinase pim-2 (PIM2) DMBEA6V MA Modulator DMBEA6V RN AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. DMBEA6V RU https://pubmed.ncbi.nlm.nih.gov/24363397 DMBFYSR DI DMBFYSR DMBFYSR DN Hepcidin mab DMBFYSR TI TTPCG5T DMBFYSR TN Hepcidin (HAMP) DMBFYSR RN The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. DMBFYSR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/ DMBG534 DI DMBG534 DMBG534 DN Org-25435 DMBG534 TI TTEX6LM DMBG534 TN GABA(A) receptor gamma-3 (GABRG3) DMBG534 MA Modulator DMBG534 RN First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiol. 2010 Jun 29;10:10. DMBG534 RU https://pubmed.ncbi.nlm.nih.gov/20587019 DMBG9HI DI DMBG9HI DMBG9HI DN AB023 DMBG9HI TI TTJCPUT DMBG9HI TN Coagulation factor XI (F11) DMBG9HI MA Inhibitor DMBG9HI RN Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809. DMBG9HI RU https://pubmed.ncbi.nlm.nih.gov/30700130 DMBGI74 DI DMBGI74 DMBGI74 DN ALX-0141 DMBGI74 TI TT9E8HR DMBGI74 TN Osteoclast differentiation factor (ODF) DMBGI74 MA Inhibitor DMBGI74 RN Clinical pipeline report, company report or official report of Ablynx. DMBGI74 RU http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0141/ DMBGUDR DI DMBGUDR DMBGUDR DN Safingol DMBGUDR TI TTYVX59 DMBGUDR TN Protein kinase C (PRKC) DMBGUDR MA Inhibitor DMBGUDR RN The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71. DMBGUDR RU https://pubmed.ncbi.nlm.nih.gov/19885570 DMBHCSL DI DMBHCSL DMBHCSL DN CART-33 cells DMBHCSL TI TTJVYO3 DMBHCSL TN Myeloid cell surface antigen CD33 (CD33) DMBHCSL MA CAR-T-Cell-Therapy DMBHCSL RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMBHCSL RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMBI4EN DI DMBI4EN DMBI4EN DN MEDI4212 DMBI4EN TI TTYJQTF DMBI4EN TN Immunoglobulin E (IgE) DMBI4EN MA Modulator DMBI4EN RN A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64. DMBI4EN RU https://pubmed.ncbi.nlm.nih.gov/24583620 DMBIPQL DI DMBIPQL DMBIPQL DN Enavatuzumab DMBIPQL TI TTKPS7V DMBIPQL TN TNF superfamily receptor 12A (TNFRSF12A) DMBIPQL RN Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25. DMBIPQL RU https://pubmed.ncbi.nlm.nih.gov/23073510 DMBK9AM DI DMBK9AM DMBK9AM DN PLX-4720 DMBK9AM TI TT0EOB8 DMBK9AM TN B-Raf messenger RNA (BRAF mRNA) DMBK9AM MA Inhibitor DMBK9AM RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DMBK9AM RU https://pubmed.ncbi.nlm.nih.gov/22037378 DMBK9AM DI DMBK9AM DMBK9AM DN PLX-4720 DMBK9AM TI TTUTJGQ DMBK9AM TN Vascular endothelial growth factor receptor 2 (KDR) DMBK9AM MA Inhibitor DMBK9AM RN In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. DMBK9AM RU https://pubmed.ncbi.nlm.nih.gov/12538485 DMBKL6O DI DMBKL6O DMBKL6O DN SOR-C13 DMBKL6O TI TTBK14N DMBKL6O TN Transient receptor potential cation channel V6 (TRPV6) DMBKL6O MA Inhibitor DMBKL6O RN In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866. DMBKL6O RU https://pubmed.ncbi.nlm.nih.gov/23554944 DMBKO2W DI DMBKO2W DMBKO2W DN ATI-355 DMBKO2W TI TT7GXMU DMBKO2W TN Reticulon-4 (RTN4) DMBKO2W RN Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818. DMBKO2W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589918/ DMBL7CW DI DMBL7CW DMBL7CW DN PRT-062607 DMBL7CW TI TTOU65C DMBL7CW TN Tyrosine-protein kinase SYK (SYK) DMBL7CW MA Inhibitor DMBL7CW RN Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243. DMBL7CW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/ DMBOXA1 DI DMBOXA1 DMBOXA1 DN [3H]fenobam DMBOXA1 TI TTHS256 DMBOXA1 TN Metabotropic glutamate receptor 5 (mGluR5) DMBOXA1 MA Modulator (allosteric modulator) DMBOXA1 RN Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. DMBOXA1 RU https://pubmed.ncbi.nlm.nih.gov/16040814 DMBPV9W DI DMBPV9W DMBPV9W DN IT-139 DMBPV9W TI TTW26OG DMBPV9W TN Endoplasmic reticulum chaperone BiP (HSPA5) DMBPV9W MA Inhibitor DMBPV9W RN NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82. DMBPV9W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/ DMBQ2TF DI DMBQ2TF DMBQ2TF DN AZD-5438 DMBQ2TF TI TT7HF4W DMBQ2TF TN Cyclin-dependent kinase 2 (CDK2) DMBQ2TF MA Modulator DMBQ2TF RN AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14. DMBQ2TF RU https://www.ncbi.nlm.nih.gov/pubmed/22795803 DMBQ6XY DI DMBQ6XY DMBQ6XY DN TP-3654 DMBQ6XY TI TTA7WGU DMBQ6XY TN Serine/threonine-protein kinase pim (PIM) DMBQ6XY MA Inhibitor DMBQ6XY RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMBQ6XY RU https://www.sdponcology.com/pipeline/ DMBQWVR DI DMBQWVR DMBQWVR DN ARQ-751 DMBQWVR TI TTQ7UAP DMBQWVR TN RAC serine/threonine-protein kinase (AKT) DMBQWVR MA Inhibitor DMBQWVR RN Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479. DMBQWVR RU https://pubmed.ncbi.nlm.nih.gov/26469692 DMBRN2G DI DMBRN2G DMBRN2G DN DA-697b DMBRN2G TI TT3SZBT DMBRN2G TN von Willebrand factor (VWF) DMBRN2G MA Inhibitor DMBRN2G RN A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12. DMBRN2G RU https://pubmed.ncbi.nlm.nih.gov/20062928 DMBRYZ7 DI DMBRYZ7 DMBRYZ7 DN RG6292 DMBRYZ7 TI TT10Y9E DMBRYZ7 TN Interleukin 2 receptor alpha (IL2RA) DMBRYZ7 MA Inhibitor DMBRYZ7 RN Clinical pipeline report, company report or official report of Roche. DMBRYZ7 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMBSI6Y DI DMBSI6Y DMBSI6Y DN KITE-718 DMBSI6Y TI TTWSKHD DMBSI6Y TN Melanoma-associated antigen 3 (MAGEA3) DMBSI6Y RN ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health. DMBSI6Y RU https://clinicaltrials.gov/ct2/show/NCT03139370 DMBSI6Y DI DMBSI6Y DMBSI6Y DN KITE-718 DMBSI6Y TI TTJIWMO DMBSI6Y TN Melanoma-associated antigen 6 (MAGEA6) DMBSI6Y RN ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health. DMBSI6Y RU https://clinicaltrials.gov/ct2/show/NCT03139370 DMBSQH9 DI DMBSQH9 DMBSQH9 DN PBF-999 DMBSQH9 TI TTM2AOE DMBSQH9 TN Adenosine A2a receptor (ADORA2A) DMBSQH9 MA Antagonist DMBSQH9 RN Clinical pipeline report, company report or official report of Palobiofarma. DMBSQH9 RU https://www.palobiofarma.com/pipeline-2/ DMBSQH9 DI DMBSQH9 DMBSQH9 DN PBF-999 DMBSQH9 TI TTJW4LU DMBSQH9 TN Phosphodiesterase 10A (PDE10) DMBSQH9 MA Inhibitor DMBSQH9 RN Clinical pipeline report, company report or official report of Palobiofarma. DMBSQH9 RU https://www.palobiofarma.com/pipeline-2/ DMBSXZ1 DI DMBSXZ1 DMBSXZ1 DN MK-7162 DMBSXZ1 TI TTZJYKH DMBSXZ1 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBSXZ1 MA Inhibitor DMBSXZ1 RN ClinicalTrials.gov (NCT03364049) Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002). U.S. National Institutes of Health. DMBSXZ1 RU https://clinicaltrials.gov/ct2/show/NCT03364049 DMBTL2M DI DMBTL2M DMBTL2M DN TP-1454 DMBTL2M TI TT4LOT8 DMBTL2M TN Pyruvate kinase M2 (PKM) DMBTL2M MA Activator DMBTL2M RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMBTL2M RU https://www.ds-pharma.com/rd/clinical/pipeline.html DMBTSZD DI DMBTSZD DMBTSZD DN BIMU-1 DMBTSZD TI TT07C3Y DMBTSZD TN 5-HT 4 receptor (HTR4) DMBTSZD MA Modulator DMBTSZD RN Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. DMBTSZD RU https://pubmed.ncbi.nlm.nih.gov/8058105 DMBTSZD DI DMBTSZD DMBTSZD DN BIMU-1 DMBTSZD TI TTNXLKE DMBTSZD TN 5-HT 3 receptor (5HT3R) DMBTSZD MA Modulator DMBTSZD RN Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. DMBTSZD RU https://pubmed.ncbi.nlm.nih.gov/8058105 DMBUI2A DI DMBUI2A DMBUI2A DN BETULINIC ACID DMBUI2A TI TTIU7X1 DMBUI2A TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMBUI2A MA Inhibitor DMBUI2A RN DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3. DMBUI2A RU https://pubmed.ncbi.nlm.nih.gov/10654414 DMBUOX4 DI DMBUOX4 DMBUOX4 DN ADX71149 DMBUOX4 TI TTXJ47W DMBUOX4 TN Metabotropic glutamate receptor 2 (mGluR2) DMBUOX4 MA Modulator DMBUOX4 RN MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1). DMBUOX4 RU http://www.researchgate.net/publication/260023632_MGlu2_receptor-mediated_modulation_of_conditioned_avoidance_behavior_in_rats DMBV3P8 DI DMBV3P8 DMBV3P8 DN JNJ-54728518 DMBV3P8 TI TTVIMDE DMBV3P8 TN Glucagon-like peptide 1 receptor (GLP1R) DMBV3P8 MA Agonist DMBV3P8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBV3P8 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMBVM1Q DI DMBVM1Q DMBVM1Q DN AlphaMedix DMBVM1Q TI TTOMNR9 DMBVM1Q TN Somatostatin receptor (SSTR) DMBVM1Q MA Activator DMBVM1Q RN Clinical pipeline report, company report or official report of Orano Med. DMBVM1Q RU https://www.oranomed.com/en/pipeline DMBVUFL DI DMBVUFL DMBVUFL DN Anti-GD2 T-cells (1RG-CART) DMBVUFL TI TT80ARU DMBVUFL TN Ganglioside GD2 (GD2) DMBVUFL MA CAR-T-Cell-Therapy DMBVUFL RN ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) DMBVUFL RU https://clinicaltrials.gov/ct2/show/NCT02761915 DMBVZND DI DMBVZND DMBVZND DN ONYX-015 DMBVZND TI TT7SBF5 DMBVZND TN Cellular tumor antigen p53 (TP53) DMBVZND MA Modulator DMBVZND RN Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. DMBVZND RU https://pubmed.ncbi.nlm.nih.gov/15607965 DMBZ2QT DI DMBZ2QT DMBZ2QT DN PHE885 DMBZ2QT TI TTZ3P4W DMBZ2QT TN B-cell maturation protein (TNFRSF17) DMBZ2QT RN ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. DMBZ2QT RU https://clinicaltrials.gov/ct2/show/NCT04318327 DMC0VJF DI DMC0VJF DMC0VJF DN Laevo-Bambuterol DMC0VJF TI TTMXGCW DMC0VJF TN Adrenergic receptor beta-3 (ADRB3) DMC0VJF MA Modulator DMC0VJF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29). DMC0VJF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29 DMC14KV DI DMC14KV DMC14KV DN GSK1995057 DMC14KV TI TTG043C DMC14KV TN Tumor necrosis factor receptor type I (TNF-R1) DMC14KV RN Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203. DMC14KV RU https://pubmed.ncbi.nlm.nih.gov/23832582 DMC1AZP DI DMC1AZP DMC1AZP DN SAR-405838 DMC1AZP TI TT7SBF5 DMC1AZP TN Cellular tumor antigen p53 (TP53) DMC1AZP MA Modulator DMC1AZP RN SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. DMC1AZP RU https://pubmed.ncbi.nlm.nih.gov/25145672 DMC1BXV DI DMC1BXV DMC1BXV DN AZD-3514 DMC1BXV TI TTS64P2 DMC1BXV TN Androgen receptor (AR) DMC1BXV MA Antagonist DMC1BXV RN AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. DMC1BXV RU https://pubmed.ncbi.nlm.nih.gov/23861347 DMC1HRA DI DMC1HRA DMC1HRA DN Thiarabine DMC1HRA TI TTUTN1I DMC1HRA TN Human Deoxyribonucleic acid (hDNA) DMC1HRA MA Inhibitor DMC1HRA RN Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev. 2009 July; 109(7): 2880-2893. DMC1HRA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827868/ DMC29LV DI DMC29LV DMC29LV DN ONO-4059 DMC29LV TI TTGM6VW DMC29LV TN Tyrosine-protein kinase BTK (ATK) DMC29LV MA Modulator DMC29LV RN ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model. Cancer Research. 08/2013; 73(8 Supplement):2452-2452. DMC29LV RU http://cancerres.aacrjournals.org/content/73/8_Supplement/2452 DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TT7MRDV DMC2IJN TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TTNDSF4 DMC2IJN TN Proto-oncogene c-Met (MET) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TT6PKBN DMC2IJN TN Proto-oncogene c-Src (SRC) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC3G2E DI DMC3G2E DMC3G2E DN AMG 330 DMC3G2E TI TTJVYO3 DMC3G2E TN Myeloid cell surface antigen CD33 (CD33) DMC3G2E MA Inhibitor DMC3G2E RN Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. DMC3G2E RU https://pubmed.ncbi.nlm.nih.gov/24674885 DMC3G2E DI DMC3G2E DMC3G2E DN AMG 330 DMC3G2E TI TTUN7MC DMC3G2E TN T-cell surface glycoprotein CD3 (CD3) DMC3G2E MA Inhibitor DMC3G2E RN Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. DMC3G2E RU https://pubmed.ncbi.nlm.nih.gov/24674885 DMC47M9 DI DMC47M9 DMC47M9 DN GSK2831781 DMC47M9 TI TTNVXAW DMC47M9 TN Lymphocyte activation gene 3 protein (LAG3) DMC47M9 MA Inhibitor DMC47M9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC47M9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMC4RNA DI DMC4RNA DMC4RNA DN TAK-733 DMC4RNA TI TTROQ37 DMC4RNA TN MAPK/ERK kinase kinase (MAP3K) DMC4RNA MA Modulator DMC4RNA RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMC4RNA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMC5HXI DI DMC5HXI DMC5HXI DN STRO-002 DMC5HXI TI TTVC37M DMC5HXI TN Folate receptor alpha (FOLR1) DMC5HXI RN Clinical pipeline report, company report or official report of Sutro Biopharma. DMC5HXI RU https://www.sutrobio.com/pipeline/ DMC60S8 DI DMC60S8 DMC60S8 DN MDL-27531 DMC60S8 TI TTZ8EM9 DMC60S8 TN Glycine receptor (GlyR) DMC60S8 MA Modulator DMC60S8 RN MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5. DMC60S8 RU https://pubmed.ncbi.nlm.nih.gov/1480315 DMC6PKJ DI DMC6PKJ DMC6PKJ DN CYC140 DMC6PKJ TI TTIYVQP DMC6PKJ TN Polo-like kinase 1 (PLK1) DMC6PKJ MA Inhibitor DMC6PKJ RN Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals. DMC6PKJ RU https://cyclacel.com/research_programs_oncology_cyc140.shtml DMC6QE4 DI DMC6QE4 DMC6QE4 DN GSK1795091 DMC6QE4 TI TTISGCA DMC6QE4 TN Toll-like receptor 4 (TLR4) DMC6QE4 MA Agonist DMC6QE4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC6QE4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC7Y5F DI DMC7Y5F DMC7Y5F DN CAR-T cells recognizing EpCAM DMC7Y5F TI TTZ8WH4 DMC7Y5F TN Tumor-associated calcium signal transducer 1 (EPCAM) DMC7Y5F MA CAR-T-Cell-Therapy DMC7Y5F RN ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer DMC7Y5F RU https://clinicaltrials.gov/ct2/show/NCT02915445 DMC80LV DI DMC80LV DMC80LV DN ASP1948 DMC80LV TI TTIPJCB DMC80LV TN Neuropilin-1 (NRP1) DMC80LV MA Inhibitor DMC80LV RN National Cancer Institute Drug Dictionary (drug name ASP1948). DMC80LV RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-nrp1-antibody-asp1948 DMC84Y9 DI DMC84Y9 DMC84Y9 DN Tepoditamab DMC84Y9 TI TTUN7MC DMC84Y9 TN T-cell surface glycoprotein CD3 (CD3) DMC84Y9 RN MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. DMC84Y9 RU https://pubmed.ncbi.nlm.nih.gov/31286786 DMC84Y9 DI DMC84Y9 DMC84Y9 DN Tepoditamab DMC84Y9 TI TT70N8V DMC84Y9 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMC84Y9 RN MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. DMC84Y9 RU https://pubmed.ncbi.nlm.nih.gov/31286786 DMC8J0G DI DMC8J0G DMC8J0G DN VX-128 DMC8J0G TI TT90XZ8 DMC8J0G TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMC8J0G MA Inhibitor DMC8J0G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC8J0G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TTFQEMX DMC8XHQ TN Casein kinase I alpha (CSNK1A1) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TT1LVF2 DMC8XHQ TN Cyclin-dependent kinase 9 (CDK9) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TTQYF7G DMC8XHQ TN Cyclin-dependent kinase 7 (CDK7) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC9N7D DI DMC9N7D DMC9N7D DN VYR 006 DMC9N7D TI TTYZVDJ DMC9N7D TN Dihydrofolate reductase (DHFR) DMC9N7D MA Inhibitor DMC9N7D RN Clinical pipeline report, company report or official report of Vyera Pharmaceuticals. DMC9N7D RU https://www.vyera.com/news-center/vyera-pharmaceuticals-has-initiated-a-phase-1-study-of-a-new-dihydrofolate-reductase-inhibitor-designed-as-a-potential-treatment-for-toxoplasmosis DMCA1NX DI DMCA1NX DMCA1NX DN MK-4280 DMCA1NX TI TTNVXAW DMCA1NX TN Lymphocyte activation gene 3 protein (LAG3) DMCA1NX MA Inhibitor DMCA1NX RN Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14. DMCA1NX RU https://pubmed.ncbi.nlm.nih.gov/29427592 DMCABUR DI DMCABUR DMCABUR DN Anti-CD19 anti-CD20 Bispecific CAR-T DMCABUR TI TTUE541 DMCABUR TN Leukocyte surface antigen Leu-16 (CD20) DMCABUR MA CAR-T-Cell-Therapy(Dual specific) DMCABUR RN ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL DMCABUR RU https://clinicaltrials.gov/ct2/show/NCT03271515 DMCABUR DI DMCABUR DMCABUR DN Anti-CD19 anti-CD20 Bispecific CAR-T DMCABUR TI TTW640A DMCABUR TN B-lymphocyte surface antigen B4 (CD19) DMCABUR MA CAR-T-Cell-Therapy(Dual specific) DMCABUR RN ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL DMCABUR RU https://clinicaltrials.gov/ct2/show/NCT03271515 DMCBGLW DI DMCBGLW DMCBGLW DN GSK2636771 DMCBGLW TI TTTHBCA DMCBGLW TN PI3-kinase beta (PIK3CB) DMCBGLW MA Inhibitor DMCBGLW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967). DMCBGLW RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7967 DMCBV20 DI DMCBV20 DMCBV20 DN LY-2334737 DMCBV20 TI TTBWDI0 DMCBV20 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMCBV20 MA Modulator DMCBV20 RN Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. DMCBV20 RU https://pubmed.ncbi.nlm.nih.gov/23616084 DMCBV20 DI DMCBV20 DMCBV20 DN LY-2334737 DMCBV20 TI TTUTN1I DMCBV20 TN Human Deoxyribonucleic acid (hDNA) DMCBV20 MA Modulator DMCBV20 RN Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. DMCBV20 RU https://pubmed.ncbi.nlm.nih.gov/23616084 DMCDMPW DI DMCDMPW DMCDMPW DN ASP9801 DMCDMPW TI TT8FRMO DMCDMPW TN Interleukin-7 (IL7) DMCDMPW RN Clinical pipeline report, company report or official report of Astellas Pharma. DMCDMPW RU https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf DMCDMPW DI DMCDMPW DMCDMPW DN ASP9801 DMCDMPW TI TTF89GD DMCDMPW TN Interleukin-2 (IL2) DMCDMPW RN Clinical pipeline report, company report or official report of Astellas Pharma. DMCDMPW RU https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf DMCE08M DI DMCE08M DMCE08M DN AT7519 DMCE08M TI TT7HF4W DMCE08M TN Cyclin-dependent kinase 2 (CDK2) DMCE08M MA Inhibitor DMCE08M RN Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32. DMCE08M RU https://pubmed.ncbi.nlm.nih.gov/19174555 DMCED9U DI DMCED9U DMCED9U DN IRX-5183 DMCED9U TI TTW38KT DMCED9U TN Retinoic acid receptor alpha (RARA) DMCED9U MA Agonist DMCED9U RN Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25. DMCED9U RU https://pubmed.ncbi.nlm.nih.gov/14712350 DMCED9U DI DMCED9U DMCED9U DN IRX-5183 DMCED9U TI TTP7WQM DMCED9U TN Retinoic acid receptor RXR (RXR) DMCED9U MA Agonist DMCED9U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCED9U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCFGD4 DI DMCFGD4 DMCFGD4 DN TM38837 DMCFGD4 TI TT6OEDT DMCFGD4 TN Cannabinoid receptor 1 (CB1) DMCFGD4 MA Antagonist DMCFGD4 RN 2011 Pipeline of 7TM Pharma. DMCFGD4 RU http://www.7tm.com/Pipeline.aspx DMCFJM3 DI DMCFJM3 DMCFJM3 DN DS-7423 DMCFJM3 TI TTCJG29 DMCFJM3 TN Serine/threonine-protein kinase mTOR (mTOR) DMCFJM3 MA Modulator DMCFJM3 RN Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220. DMCFJM3 RU https://pubmed.ncbi.nlm.nih.gov/24504419 DMCFJM3 DI DMCFJM3 DMCFJM3 DN DS-7423 DMCFJM3 TI TTHBTOP DMCFJM3 TN PI3-kinase gamma (PIK3CG) DMCFJM3 MA Modulator DMCFJM3 RN Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220. DMCFJM3 RU https://pubmed.ncbi.nlm.nih.gov/24504419 DMCFMHR DI DMCFMHR DMCFMHR DN CCR5 mab DMCFMHR TI TT2CEJG DMCFMHR TN C-C chemokine receptor type 5 (CCR5) DMCFMHR RN CCR5 Monoclonal Antibodies for HIV-1 Therapy. Curr Opin HIV AIDS. 2009 March; 4(2): 104-111. DMCFMHR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/ DMCFPX8 DI DMCFPX8 DMCFPX8 DN 123-Iodine-labeled MFE-23 DMCFPX8 TI TTY6DTE DMCFPX8 TN Carcinoembryonic antigen CEA (CD66e) DMCFPX8 RN Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts.. Biochem J. 2000 March 1; 346(Pt 2): 519-528. DMCFPX8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220881/ DMCG01R DI DMCG01R DMCG01R DN TTP-4000 DMCG01R TI TTMO9HF DMCG01R TN Advanced glycosylation end product receptor (AGER) DMCG01R MA Inhibitor DMCG01R RN Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177. DMCG01R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709862/ DMCG7XL DI DMCG7XL DMCG7XL DN AMG 910 DMCG7XL TI TTUN7MC DMCG7XL TN T-cell surface glycoprotein CD3 (CD3) DMCG7XL MA Inhibitor DMCG7XL RN Clinical pipeline report, company report or official report of Amgen. DMCG7XL RU https://www.amgenpipeline.com/ DMCG7XL DI DMCG7XL DMCG7XL DN AMG 910 DMCG7XL TI TT6PKBX DMCG7XL TN Claudin-18 (CLDN18) DMCG7XL MA Inhibitor DMCG7XL RN Clinical pipeline report, company report or official report of Amgen. DMCG7XL RU https://www.amgenpipeline.com/ DMCGPU8 DI DMCGPU8 DMCGPU8 DN SNX281 DMCGPU8 TI TTT402Y DMCGPU8 TN Stimulator of interferon genes protein (TMEM173) DMCGPU8 MA Inhibitor DMCGPU8 RN Clinical pipeline report, company report or official report of Silicon Therapeutics. DMCGPU8 RU https://silicontx.com/therapeutics-and-pipeline/targets/sting-agonist/ DMCJFLS DI DMCJFLS DMCJFLS DN MEDI-570 DMCJFLS TI TTE5VP6 DMCJFLS TN Inducible T-cell costimulator (ICOS) DMCJFLS MA Modulator DMCJFLS RN B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4. DMCJFLS RU https://pubmed.ncbi.nlm.nih.gov/23566679 DMCJNRL DI DMCJNRL DMCJNRL DN BAY1251152 DMCJNRL TI TTQ7ABG DMCJNRL TN Positive transcription elongation factor b (P-TEFb) DMCJNRL MA Inhibitor DMCJNRL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCJNRL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCJUI9 DI DMCJUI9 DMCJUI9 DN GSK1070916A DMCJUI9 TI TT5LS6T DMCJUI9 TN Aurora kinase B (AURKB) DMCJUI9 MA Modulator DMCJUI9 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMCJUI9 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMCJUI9 DI DMCJUI9 DMCJUI9 DN GSK1070916A DMCJUI9 TI TTLYXIT DMCJUI9 TN Aurora kinase C (AURKC) DMCJUI9 MA Modulator DMCJUI9 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMCJUI9 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMCK2YR DI DMCK2YR DMCK2YR DN Sym022 DMCK2YR TI TTNVXAW DMCK2YR TN Lymphocyte activation gene 3 protein (LAG3) DMCK2YR MA Inhibitor DMCK2YR RN Clinical pipeline report, company report or official report of Symphogen. DMCK2YR RU http://www.symphogen.com/pipeline/products/sym022/ DMCK3OI DI DMCK3OI DMCK3OI DN FT-7051 DMCK3OI TI TTFRCTK DMCK3OI TN CREB-binding protein (CREBBP) DMCK3OI MA Inhibitor DMCK3OI RN Clinical pipeline report, company report or official report of FORMA Therapeutics. DMCK3OI RU https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/ DMCK3OI DI DMCK3OI DMCK3OI DN FT-7051 DMCK3OI TI TTGH73N DMCK3OI TN Histone acetyltransferase p300 (EP300) DMCK3OI MA Inhibitor DMCK3OI RN Clinical pipeline report, company report or official report of FORMA Therapeutics. DMCK3OI RU https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/ DMCKE90 DI DMCKE90 DMCKE90 DN Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules DMCKE90 TI TT1D53B DMCKE90 TN COVID-19 3C-like protease (3CLpro) DMCKE90 MA Inhibitor DMCKE90 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMCKE90 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMCKF5J DI DMCKF5J DMCKF5J DN TAK-676 DMCKF5J TI TTT402Y DMCKF5J TN Stimulator of interferon genes protein (TMEM173) DMCKF5J MA Agonist DMCKF5J RN National Cancer Institute Drug Dictionary (drug name TAK676). DMCKF5J RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-tak-676 DMCKNJX DI DMCKNJX DMCKNJX DN GSK3052230 DMCKNJX TI TT5HU6Z DMCKNJX TN Fibroblast growth factor (FGF) DMCKNJX MA Inhibitor DMCKNJX RN National Cancer Institute Drug Dictionary (drug id 599037). DMCKNJX RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599037 DMCKZUT DI DMCKZUT DMCKZUT DN GlyT1 PET radiotracers DMCKZUT TI TTHJTF7 DMCKZUT TN Glycine transporter GlyT-1 (SLC6A9) DMCKZUT MA Modulator DMCKZUT RN Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19. DMCKZUT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023951/ DMCM0K6 DI DMCM0K6 DMCM0K6 DN YPEG-Somatropin DMCM0K6 TI TTT3YKH DMCM0K6 TN Somatotropin (GH1) DMCM0K6 MA Modulator DMCM0K6 RN Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60. DMCM0K6 RU https://pubmed.ncbi.nlm.nih.gov/16026111 DMCMYPX DI DMCMYPX DMCMYPX DN MEDI-2338 DMCMYPX TI TTRICUF DMCMYPX TN Interleukin-18 (IL18) DMCMYPX MA Modulator DMCMYPX RN Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412. DMCMYPX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010626/ DMCN7WI DI DMCN7WI DMCN7WI DN AST-005 DMCN7WI TI TTF8CQI DMCN7WI TN Tumor necrosis factor (TNF) DMCN7WI MA Inhibitor DMCN7WI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCN7WI RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCNFZG DI DMCNFZG DMCNFZG DN Anti-GD2-CAR engineered T cells DMCNFZG TI TT80ARU DMCNFZG TN Ganglioside GD2 (GD2) DMCNFZG MA CAR-T-Cell-Therapy DMCNFZG RN ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors DMCNFZG RU https://clinicaltrials.gov/ct2/show/NCT02107963 DMCNV0M DI DMCNV0M DMCNV0M DN ARRY-380 DMCNV0M TI TT6EO5L DMCNV0M TN Erbb2 tyrosine kinase receptor (HER2) DMCNV0M MA Modulator DMCNV0M RN ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice DMCNV0M RU http://arraybiopharma.com/publications/arry-380-potent-small-molecule-inhibitor-erbb2-increases-survival-intracranial-erbb2-xenograft-models-mice/ DMCOJM7 DI DMCOJM7 DMCOJM7 DN CNTX-6970 DMCOJM7 TI TTFZYTO DMCOJM7 TN C-C chemokine receptor type 2 (CCR2) DMCOJM7 MA Antagonist DMCOJM7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCOJM7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCOUHT DI DMCOUHT DMCOUHT DN PF-2413873 DMCOUHT TI TTUV8G9 DMCOUHT TN Progesterone receptor (PGR) DMCOUHT MA Antagonist DMCOUHT RN Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873. Journal of Labelled Compounds. 08/2009; 52(10):435 - 442. DMCOUHT RU http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1657/abstract DMCP7SD DI DMCP7SD DMCP7SD DN Seclidemstat DMCP7SD TI TTNR0UQ DMCP7SD TN Lysine-specific histone demethylase 1 (LSD) DMCP7SD MA Inhibitor DMCP7SD RN Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196. DMCP7SD RU https://pubmed.ncbi.nlm.nih.gov/33042135 DMCPF90 DI DMCPF90 DMCPF90 DN Mivebresib DMCPF90 TI TTE4BSY DMCPF90 TN Bromodomain and extraterminal domain protein (BET) DMCPF90 MA Inhibitor DMCPF90 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCPF90 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCQEL6 DI DMCQEL6 DMCQEL6 DN BAY 94-9343 DMCQEL6 TI TT4RXME DMCQEL6 TN Mesothelin (MSLN) DMCQEL6 MA Modulator DMCQEL6 RN National Cancer Institute Drug Dictionary (drug id 712853). DMCQEL6 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=712853 DMCQTLG DI DMCQTLG DMCQTLG DN INB03 DMCQTLG TI TTF8CQI DMCQTLG TN Tumor necrosis factor (TNF) DMCQTLG MA Inhibitor DMCQTLG RN Clinical pipeline report, company report or official report of INmune Bio. DMCQTLG RU https://inmunebio.com/index.php/en/science/inb03/overview DMCRLQZ DI DMCRLQZ DMCRLQZ DN ARQ 621 DMCRLQZ TI TTTRP0H DMCRLQZ TN Kinesin-like protein KIF11 (KIF11) DMCRLQZ MA Modulator DMCRLQZ RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMCRLQZ RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMCSEUY DI DMCSEUY DMCSEUY DN ALN-TTR01 DMCSEUY TI TTPOYU7 DMCSEUY TN Transthyretin messenger RNA (TTR mRNA) DMCSEUY MA Inhibitor DMCSEUY RN Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29. DMCSEUY RU https://pubmed.ncbi.nlm.nih.gov/23984729 DMCT37W DI DMCT37W DMCT37W DN MK-4830 DMCT37W TI TTHC6XU DMCT37W TN Leukocyte immunoglobulin-like receptor B2 (LILRB2) DMCT37W MA Inhibitor DMCT37W RN National Cancer Institute Drug Dictionary (drug name MK4830). DMCT37W RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ilt4-monoclonal-antibody-mk-4830 DMCT4BA DI DMCT4BA DMCT4BA DN DMUC-5754A DMCT4BA TI TTC1PS3 DMCT4BA TN Ovarian carcinoma antigen CA125 (MUC16) DMCT4BA RN Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32. DMCT4BA RU https://pubmed.ncbi.nlm.nih.gov/23629491 DMCU54M DI DMCU54M DMCU54M DN Posiphen R-phenserine DMCU54M TI TT08OSU DMCU54M TN Synuclein alpha (SNCA) DMCU54M MA Modulator DMCU54M RN The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13). DMCU54M RU http://www.hindawi.com/journals/pd/2012/142372/ DMCUBFR DI DMCUBFR DMCUBFR DN CD19 CAR T Cells DMCUBFR TI TTW640A DMCUBFR TN B-lymphocyte surface antigen B4 (CD19) DMCUBFR MA CAR-T-Cell-Therapy DMCUBFR RN ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) DMCUBFR RU https://clinicaltrials.gov/ct2/show/NCT01853631 DMCUBZO DI DMCUBZO DMCUBZO DN RG7828 DMCUBZO TI TTUE541 DMCUBZO TN Leukocyte surface antigen Leu-16 (CD20) DMCUBZO MA Stimulator DMCUBZO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCUBZO RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMCUE71 DI DMCUE71 DMCUE71 DN PRGN-3005 DMCUE71 TI TTC1PS3 DMCUE71 TN Ovarian carcinoma antigen CA125 (MUC16) DMCUE71 RN Clinical pipeline report, company report or official report of Precigen. DMCUE71 RU https://precigen.com/pipeline/ DMCVO2Y DI DMCVO2Y DMCVO2Y DN MLN-576 DMCVO2Y TI TTGTQHC DMCVO2Y TN DNA topoisomerase I (TOP1) DMCVO2Y MA Modulator DMCVO2Y RN In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. DMCVO2Y RU https://pubmed.ncbi.nlm.nih.gov/11914637 DMCVO2Y DI DMCVO2Y DMCVO2Y DN MLN-576 DMCVO2Y TI TT0IHXV DMCVO2Y TN DNA topoisomerase II (TOP2) DMCVO2Y MA Modulator DMCVO2Y RN In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. DMCVO2Y RU https://pubmed.ncbi.nlm.nih.gov/11914637 DMCW71N DI DMCW71N DMCW71N DN BMS-830216 DMCW71N TI TTX4RTB DMCW71N TN Melanin-concentrating hormone receptor 1 (MCHR1) DMCW71N MA Antagonist DMCW71N RN 2011 Pipeline of Bristol-Myers Squibb. DMCW71N RU http://www.bms.com/pages/default.aspx DMCWVS7 DI DMCWVS7 DMCWVS7 DN CCX-025 DMCWVS7 TI TTIPS8B DMCWVS7 TN C-C chemokine receptor type 9 (CCR9) DMCWVS7 MA Antagonist DMCWVS7 RN Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29. DMCWVS7 RU https://pubmed.ncbi.nlm.nih.gov/22946654 DMCX0H7 DI DMCX0H7 DMCX0H7 DN BMS-820132 DMCX0H7 TI TTDLNGZ DMCX0H7 TN Glucokinase (GCK) DMCX0H7 MA Inhibitor DMCX0H7 RN Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37. DMCX0H7 RU https://pubmed.ncbi.nlm.nih.gov/26085543 DMCYV26 DI DMCYV26 DMCYV26 DN Allogeneic CART-19 DMCYV26 TI TTW640A DMCYV26 TN B-lymphocyte surface antigen B4 (CD19) DMCYV26 MA CAR-T-Cell-Therapy DMCYV26 RN ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL DMCYV26 RU https://clinicaltrials.gov/ct2/show/NCT02799550 DMCZ3A2 DI DMCZ3A2 DMCZ3A2 DN CD19-targeted CART cells DMCZ3A2 TI TTW640A DMCZ3A2 TN B-lymphocyte surface antigen B4 (CD19) DMCZ3A2 MA CAR-T-Cell-Therapy DMCZ3A2 RN ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia DMCZ3A2 RU https://clinicaltrials.gov/ct2/show/NCT03599375 DMCZI8L DI DMCZI8L DMCZI8L DN ABBV-257 DMCZI8L TI TTF8CQI DMCZI8L TN Tumor necrosis factor (TNF) DMCZI8L MA Inhibitor DMCZI8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCZI8L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCZI8L DI DMCZI8L DMCZI8L DN ABBV-257 DMCZI8L TI TTG0MT6 DMCZI8L TN Interleukin-17 (IL17) DMCZI8L MA Inhibitor DMCZI8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCZI8L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCZQNJ DI DMCZQNJ DMCZQNJ DN IMC-EB10 DMCZQNJ TI TTGJCWZ DMCZQNJ TN Fms-like tyrosine kinase 3 (FLT-3) DMCZQNJ RN IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51. DMCZQNJ RU https://pubmed.ncbi.nlm.nih.gov/16651440 DMD0BMN DI DMD0BMN DMD0BMN DN ASG-5ME DMD0BMN TI TT0NYDG DMD0BMN TN Choline transporter-like protein 4 (SLC44A4) DMD0BMN RN 2011 Pipeline of Seattle Genetics. DMD0BMN RU http://www.seagen.com/product_pipeline.php DMD0NA1 DI DMD0NA1 DMD0NA1 DN TP 6076 DMD0NA1 TI TTOVFH2 DMD0NA1 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMD0NA1 MA Inhibitor DMD0NA1 RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DMD0NA1 RU https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf DMD0XWR DI DMD0XWR DMD0XWR DN CART123 cells DMD0XWR TI TTENHJ0 DMD0XWR TN Interleukin 3 receptor alpha (IL3RA) DMD0XWR MA CAR-T-Cell-Therapy DMD0XWR RN ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML DMD0XWR RU https://clinicaltrials.gov/ct2/show/NCT03766126 DMD16JK DI DMD16JK DMD16JK DN RG-7816 DMD16JK TI TTNZPQ1 DMD16JK TN GABA(A) receptor alpha-5 (GABRA5) DMD16JK MA Modulator DMD16JK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMD16JK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMD23AX DI DMD23AX DMD23AX DN Systebryl DMD23AX TI TTE4KHA DMD23AX TN Amyloid beta A4 protein (APP) DMD23AX MA Inhibitor DMD23AX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMD23AX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMD2BIT DI DMD2BIT DMD2BIT DN AT001/r84 DMD2BIT TI TTOHSBA DMD2BIT TN Vascular endothelial growth factor A (VEGFA) DMD2BIT RN Clinical pipeline report, company report or official report of Affitech (2011). DMD2BIT RU http://www.affitech.com/ DMD2GKF DI DMD2GKF DMD2GKF DN SFLT-01 DMD2GKF TI TTOHSBA DMD2GKF TN Vascular endothelial growth factor A (VEGFA) DMD2GKF MA Modulator DMD2GKF RN sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15. DMD2GKF RU https://pubmed.ncbi.nlm.nih.gov/21252283 DMD2GKF DI DMD2GKF DMD2GKF DN SFLT-01 DMD2GKF TI TT48I1Y DMD2GKF TN Placenta growth factor (PlGF) DMD2GKF MA Modulator DMD2GKF RN sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15. DMD2GKF RU https://pubmed.ncbi.nlm.nih.gov/21252283 DMD2VRY DI DMD2VRY DMD2VRY DN SAR-115740 DMD2VRY TI TTMI6F5 DMD2VRY TN Transient receptor potential cation channel V1 (TRPV1) DMD2VRY MA Antagonist DMD2VRY RN Clinical pipeline report, company report or official report of Sanofi. DMD2VRY RU https://ncats.nih.gov/files/SAR115740.pdf DMD51GC DI DMD51GC DMD51GC DN LY3321367 DMD51GC TI TT1RWL7 DMD51GC TN Hepatitis A virus cellular receptor 2 (TIM3) DMD51GC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD51GC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMD6H8B DI DMD6H8B DMD6H8B DN GMZ-2 DMD6H8B TI TT3J5ZI DMD6H8B TN Cell mediated immunity response (CMIR) DMD6H8B RN Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359. DMD6H8B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265551/ DMD751X DI DMD751X DMD751X DN 1614235 + 2330672 DMD751X TI TT2UE56 DMD751X TN Sodium/glucose cotransporter 1 (SGLT1) DMD751X MA Modulator DMD751X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915). DMD751X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915 DMD751X DI DMD751X DMD751X DN 1614235 + 2330672 DMD751X TI TTPI1M5 DMD751X TN Ileal sodium/bile acid cotransporter (SLC10A2) DMD751X MA Modulator DMD751X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960). DMD751X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=960 DMD79TX DI DMD79TX DMD79TX DN TAK-102 DMD79TX TI TTJTSX4 DMD79TX TN Glypican-3 (GPC3) DMD79TX RN ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health. DMD79TX RU https://clinicaltrials.gov/ct2/show/NCT04405778 DMD7LHM DI DMD7LHM DMD7LHM DN ION 224 DMD7LHM TI TT8N5V1 DMD7LHM TN DGAT2 messenger RNA (DGAT2 mRNA) DMD7LHM MA Inhibitor DMD7LHM RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMD7LHM RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMD83WO DI DMD83WO DMD83WO DN AST-1306 DMD83WO TI TTGKNB4 DMD83WO TN Epidermal growth factor receptor (EGFR) DMD83WO MA Modulator DMD83WO RN AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. DMD83WO RU https://pubmed.ncbi.nlm.nih.gov/21789172 DMD9N12 DI DMD9N12 DMD9N12 DN BAY 2416964 DMD9N12 TI TT037IE DMD9N12 TN Aryl hydrocarbon receptor (AHR) DMD9N12 MA Antagonist DMD9N12 RN ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health. DMD9N12 RU https://clinicaltrials.gov/ct2/show/NCT04069026 DMD9OVI DI DMD9OVI DMD9OVI DN MEDI1191 DMD9OVI TI TTG68FB DMD9OVI TN Interleukine 12 (IL-12) DMD9OVI MA Replacement DMD9OVI RN Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. DMD9OVI RU https://pubmed.ncbi.nlm.nih.gov/32817076 DMD9U5Q DI DMD9U5Q DMD9U5Q DN IMA 203 DMD9U5Q TI TTPH7T0 DMD9U5Q TN Tumor expressed melanoma antigen (PRAME) DMD9U5Q RN Clinical pipeline report, company report or official report of Immatics. DMD9U5Q RU https://immatics.com/our-pipeline/ DMDA1UB DI DMDA1UB DMDA1UB DN AI-850 DMDA1UB TI TTJGNVC DMDA1UB TN Apoptosis regulator Bcl-2 (BCL-2) DMDA1UB MA Modulator DMDA1UB RN Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. DMDA1UB RU https://pubmed.ncbi.nlm.nih.gov/15835739 DMDA1UB DI DMDA1UB DMDA1UB DN AI-850 DMDA1UB TI TT63KYR DMDA1UB TN Tubulin beta-1 chain (TUBB1) DMDA1UB MA Modulator DMDA1UB RN Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. DMDA1UB RU https://pubmed.ncbi.nlm.nih.gov/15835739 DMDAHEL DI DMDAHEL DMDAHEL DN SGM-1019 DMDAHEL TI TT473XN DMDAHEL TN P2X purinoceptor 7 (P2RX7) DMDAHEL MA Modulator DMDAHEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDAHEL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMDB3OK DI DMDB3OK DMDB3OK DN MLN-3126 DMDB3OK TI TTIPS8B DMDB3OK TN C-C chemokine receptor type 9 (CCR9) DMDB3OK MA Antagonist DMDB3OK RN Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29. DMDB3OK RU https://pubmed.ncbi.nlm.nih.gov/22946654 DMDB7KU DI DMDB7KU DMDB7KU DN ISO-1 DMDB7KU TI TT2AST1 DMDB7KU TN Macrophage migration inhibitory factor (MIF) DMDB7KU MA Inhibitor DMDB7KU RN The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. DMDB7KU RU https://pubmed.ncbi.nlm.nih.gov/11997397 DMDBW2N DI DMDBW2N DMDBW2N DN JNJ-64619178 DMDBW2N TI TTR1D7X DMDBW2N TN Protein arginine methyltransferase 5 (PRMT5) DMDBW2N MA Inhibitor DMDBW2N RN A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114. DMDBW2N RU https://pubmed.ncbi.nlm.nih.gov/30640571 DMDC9TB DI DMDC9TB DMDC9TB DN P-BCMA-101 CAR-T cells DMDC9TB TI TTZ3P4W DMDC9TB TN B-cell maturation protein (TNFRSF17) DMDC9TB MA CAR-T-Cell-Therapy DMDC9TB RN ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) DMDC9TB RU https://clinicaltrials.gov/ct2/show/NCT03288493 DMDE9I6 DI DMDE9I6 DMDE9I6 DN PF-06801591 DMDE9I6 TI TTNBFWK DMDE9I6 TN Programmed cell death protein 1 (PD-1) DMDE9I6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMDE9I6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMDER9S DI DMDER9S DMDER9S DN Minnelide DMDER9S TI TTHYBIX DMDER9S TN Heat shock protein 70 (HSP70) DMDER9S MA Inhibitor DMDER9S RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDER9S RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDF29A DI DMDF29A DMDF29A DN STM 434 DMDF29A TI TTMQO60 DMDF29A TN Rho-associated protein kinase (ROCK) DMDF29A MA Inhibitor DMDF29A RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMDF29A RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMDF29A DI DMDF29A DMDF29A DN STM 434 DMDF29A TI TT9RV4P DMDF29A TN Activin (ACT) DMDF29A MA Inhibitor DMDF29A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDF29A RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMDFA3E DI DMDFA3E DMDFA3E DN 349U85.HCL DMDFA3E TI TTZCG4L DMDFA3E TN Phosphodiesterase 3 (PDE3) DMDFA3E MA Modulator DMDFA3E RN Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63. DMDFA3E RU https://pubmed.ncbi.nlm.nih.gov/8299318 DMDFC2Y DI DMDFC2Y DMDFC2Y DN VIC-1911 DMDFC2Y TI TTPS3C0 DMDFC2Y TN Aurora kinase A (AURKA) DMDFC2Y MA Inhibitor DMDFC2Y RN Clinical pipeline report, company report or official report of VITRAC Therapeutics. DMDFC2Y RU https://vitractherapeutics.com/ DMDFY1R DI DMDFY1R DMDFY1R DN CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells DMDFY1R TI TTENHJ0 DMDFY1R TN Interleukin 3 receptor alpha (IL3RA) DMDFY1R MA CAR-T-Cell-Therapy DMDFY1R RN ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT DMDFY1R RU https://clinicaltrials.gov/ct2/show/NCT03114670 DMDG30Q DI DMDG30Q DMDG30Q DN VOB560 DMDG30Q TI TTJGNVC DMDG30Q TN Apoptosis regulator Bcl-2 (BCL-2) DMDG30Q MA Inhibitor DMDG30Q RN Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287. DMDG30Q RU https://pubmed.ncbi.nlm.nih.gov/32455818 DMDGCHR DI DMDGCHR DMDGCHR DN NN-1218 DMDGCHR TI TTCBFJO DMDGCHR TN Insulin receptor (INSR) DMDGCHR MA Modulator DMDGCHR RN Ultrafast-Acting Insulins: State of the Art. J Diabetes Sci Technol. 2012 July; 6(4): 728-742. DMDGCHR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440142/ DMDHQYA DI DMDHQYA DMDHQYA DN SAM-6 DMDHQYA TI TTW26OG DMDHQYA TN Endoplasmic reticulum chaperone BiP (HSPA5) DMDHQYA RN A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86. DMDHQYA RU https://pubmed.ncbi.nlm.nih.gov/18268478 DMDIPW8 DI DMDIPW8 DMDIPW8 DN JNJ-38877605 DMDIPW8 TI TTNDSF4 DMDIPW8 TN Proto-oncogene c-Met (MET) DMDIPW8 MA Inhibitor DMDIPW8 RN The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304. DMDIPW8 RU https://pubmed.ncbi.nlm.nih.gov/25745036 DMDK4MG DI DMDK4MG DMDK4MG DN M7583 DMDK4MG TI TTGM6VW DMDK4MG TN Tyrosine-protein kinase BTK (ATK) DMDK4MG MA Inhibitor DMDK4MG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDK4MG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDKAIC DI DMDKAIC DMDKAIC DN ISIS-SGLT2 DMDKAIC TI TTF8JAT DMDKAIC TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMDKAIC RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMDKAIC RU http://www.isispharm.com/index.htm DMDLJM1 DI DMDLJM1 DMDLJM1 DN NKR-2 CAR-T Cells DMDLJM1 TI TTLRN4A DMDLJM1 TN NKG2 D activating NK receptor (KLRK1) DMDLJM1 MA CAR-T-Cell-Therapy DMDLJM1 RN ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 DMDLJM1 RU https://clinicaltrials.gov/ct2/show/NCT03612739 DMDLTCU DI DMDLTCU DMDLTCU DN Lotilibcin DMDLTCU TI TTXT4D5 DMDLTCU TN Bacterial Cell membrane (Bact CM) DMDLTCU MA Modulator DMDLTCU RN Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287. DMDLTCU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468324/ DMDM85L DI DMDM85L DMDM85L DN RH 1 DMDM85L TI TTUTN1I DMDM85L TN Human Deoxyribonucleic acid (hDNA) DMDM85L MA Modulator DMDM85L RN Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1 DMDM85L RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612562 DMDMKVL DI DMDMKVL DMDMKVL DN GEM333 DMDMKVL TI TTJVYO3 DMDMKVL TN Myeloid cell surface antigen CD33 (CD33) DMDMKVL MA Inhibitor DMDMKVL RN Clinical pipeline report, company report or official report of Gemoab. DMDMKVL RU https://www.gemoab.com/gem333 DMDMKVL DI DMDMKVL DMDMKVL DN GEM333 DMDMKVL TI TTUN7MC DMDMKVL TN T-cell surface glycoprotein CD3 (CD3) DMDMKVL MA Inhibitor DMDMKVL RN Clinical pipeline report, company report or official report of Gemoab. DMDMKVL RU https://www.gemoab.com/gem333 DMDMNJ6 DI DMDMNJ6 DMDMNJ6 DN Anti-HER3/EGFR DAF DMDMNJ6 TI TTGKNB4 DMDMNJ6 TN Epidermal growth factor receptor (EGFR) DMDMNJ6 MA Modulator DMDMNJ6 RN Company report (Biooncology) DMDMNJ6 RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMDMNJ6 DI DMDMNJ6 DMDMNJ6 DN Anti-HER3/EGFR DAF DMDMNJ6 TI TTDC8N2 DMDMNJ6 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDMNJ6 MA Modulator DMDMNJ6 RN Company report (Biooncology) DMDMNJ6 RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMDMPKC DI DMDMPKC DMDMPKC DN GGF-2 DMDMPKC TI TTEH395 DMDMPKC TN Pro-neuregulin-1 (Pro-NRG1) DMDMPKC MA Modulator DMDMPKC RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDMPKC RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDNPAV DI DMDNPAV DMDNPAV DN TTI-621 DMDNPAV TI TT28S46 DMDNPAV TN Leukocyte surface antigen CD47 (CD47) DMDNPAV MA Inhibitor DMDNPAV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDNPAV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDOCNW DI DMDOCNW DMDOCNW DN E-7050 DMDOCNW TI TTUTJGQ DMDOCNW TN Vascular endothelial growth factor receptor 2 (KDR) DMDOCNW MA Modulator DMDOCNW RN E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. DMDOCNW RU https://pubmed.ncbi.nlm.nih.gov/19832844 DMDOCNW DI DMDOCNW DMDOCNW DN E-7050 DMDOCNW TI TTNDSF4 DMDOCNW TN Proto-oncogene c-Met (MET) DMDOCNW MA Modulator DMDOCNW RN E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. DMDOCNW RU https://pubmed.ncbi.nlm.nih.gov/19832844 DMDOSL0 DI DMDOSL0 DMDOSL0 DN SUN-N8075 DMDOSL0 TI TTC0BEN DMDOSL0 TN Oxidative stress (OS) DMDOSL0 MA Inhibitor DMDOSL0 RN Protective effect of SUN N8075, a free radical scavenger, against excessive light-induced retinal damage in mice. Biol Pharm Bull. 2014;37(3):424-30. DMDOSL0 RU https://pubmed.ncbi.nlm.nih.gov/24583861 DMDP6UF DI DMDP6UF DMDP6UF DN SCH-721015 DMDP6UF TI TTSIUJ9 DMDP6UF TN Interferon-alpha 2 (IFNA2) DMDP6UF MA Modulator DMDP6UF RN Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51. DMDP6UF RU https://pubmed.ncbi.nlm.nih.gov/21900961 DMDPGCS DI DMDPGCS DMDPGCS DN EGT-0001474 DMDPGCS TI TTLWPVF DMDPGCS TN Sodium/glucose cotransporter 2 (SGLT2) DMDPGCS MA Modulator DMDPGCS RN PhRMA report DMDPGCS RU http://www.phrma.org/sites/default/files/pdf/diabetes2012.pdf DMDQG4Y DI DMDQG4Y DMDQG4Y DN CPC-250 DMDQG4Y TI TT1RS9F DMDQG4Y TN Acetylcholinesterase (AChE) DMDQG4Y MA Inhibitor DMDQG4Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDQG4Y RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMDQJEZ DI DMDQJEZ DMDQJEZ DN PF-06952229 DMDQJEZ TI TTP4520 DMDQJEZ TN TGF-beta receptor type I (TGFBR1) DMDQJEZ MA Inhibitor DMDQJEZ RN Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. DMDQJEZ RU https://pubmed.ncbi.nlm.nih.gov/25444759 DMDQRWT DI DMDQRWT DMDQRWT DN S-265744 LAP DMDQRWT TI TT5FH9Y DMDQRWT TN Human immunodeficiency virus Integrase (HIV IN) DMDQRWT MA Inhibitor DMDQRWT RN Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014 DMDQRWT RU http://www.nature.com/news/long-acting-shot-prevents-infection-with-hiv-analogue-1.14819 DMDRBNJ DI DMDRBNJ DMDRBNJ DN ROCICLOVIR DMDRBNJ TI TTIU7X1 DMDRBNJ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMDRBNJ MA Modulator DMDRBNJ RN Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405-11. DMDRBNJ RU https://pubmed.ncbi.nlm.nih.gov/2540193 DMDSC63 DI DMDSC63 DMDSC63 DN VEL-0230 DMDSC63 TI TTDZN01 DMDSC63 TN Cathepsin K (CTSK) DMDSC63 MA Inhibitor DMDSC63 RN Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4. DMDSC63 RU https://pubmed.ncbi.nlm.nih.gov/11677133 DMDSCQG DI DMDSCQG DMDSCQG DN PF-04840082 DMDSCQG TI TTE3RAC DMDSCQG TN Dickkopf-related protein 1 (DKK1) DMDSCQG MA Modulator DMDSCQG RN The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13. DMDSCQG RU https://pubmed.ncbi.nlm.nih.gov/20089807 DMDSF0Q DI DMDSF0Q DMDSF0Q DN TROVIRDINE HYDROCHLORIDE DMDSF0Q TI TT84ETX DMDSF0Q TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMDSF0Q MA Modulator DMDSF0Q RN Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives tr... Antiviral Res. 1995 Dec;28(4):331-42. DMDSF0Q RU https://www.ncbi.nlm.nih.gov/pubmed/8669892 DMDSFEB DI DMDSFEB DMDSFEB DN SI-B001 DMDSFEB TI TTGKNB4 DMDSFEB TN Epidermal growth factor receptor (EGFR) DMDSFEB RN Clinical pipeline report, company report or official report of SystImmune. DMDSFEB RU https://systimmune.com/pipeline.html DMDSFEB DI DMDSFEB DMDSFEB DN SI-B001 DMDSFEB TI TTDC8N2 DMDSFEB TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDSFEB RN Clinical pipeline report, company report or official report of SystImmune. DMDSFEB RU https://systimmune.com/pipeline.html DMDSVRP DI DMDSVRP DMDSVRP DN DV-1179 DMDSVRP TI TTSHG0T DMDSVRP TN Toll-like receptor 9 (TLR9) DMDSVRP MA Modulator DMDSVRP RN Company report (Dynavax) DMDSVRP RU http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/ DMDSVRP DI DMDSVRP DMDSVRP DN DV-1179 DMDSVRP TI TTRJ1K4 DMDSVRP TN Toll-like receptor 7 (TLR7) DMDSVRP MA Modulator DMDSVRP RN Company report (Dynavax) DMDSVRP RU http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/ DMDSZNC DI DMDSZNC DMDSZNC DN INCAGN2385 DMDSZNC TI TTNVXAW DMDSZNC TN Lymphocyte activation gene 3 protein (LAG3) DMDSZNC MA Inhibitor DMDSZNC RN Clinical pipeline report, company report or official report of Agenus. DMDSZNC RU https://agenusbio.com/pipeline/ DMDU54Y DI DMDU54Y DMDU54Y DN IK-175 DMDU54Y TI TT037IE DMDU54Y TN Aryl hydrocarbon receptor (AHR) DMDU54Y MA Antagonist DMDU54Y RN Clinical pipeline report, company report or official report of Ikena Oncology. DMDU54Y RU https://ikenaoncology.com/pipeline/immunotherapy/ahr-antagonist-program/ DMDUIO4 DI DMDUIO4 DMDUIO4 DN AGS-348 DMDUIO4 TI TTABNSJ DMDUIO4 TN Pyruvate kinase (PK) DMDUIO4 MA Modulator DMDUIO4 RN Clinical pipeline report, company report or official report of Agios Pharmaceuticals. DMDUIO4 RU http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=1919588 DMDXFBJ DI DMDXFBJ DMDXFBJ DN LOXO-195 DMDXFBJ TI TTTDVOJ DMDXFBJ TN Tropomyosin-related kinase A (TrkA) DMDXFBJ MA Inhibitor DMDXFBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDXFBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDY08K DI DMDY08K DMDY08K DN GDC-0623 DMDY08K TI TTZCRP3 DMDY08K TN ERK activator kinase (MEK) DMDY08K MA Inhibitor DMDY08K RN Clinical pipeline report, company report or official report of Genentech (2011). DMDY08K RU http://www.gene.com/gene/index.jsp DMDZ26X DI DMDZ26X DMDZ26X DN GDC-0425 DMDZ26X TI TTTU902 DMDZ26X TN Checkpoint kinase-1 (CHK1) DMDZ26X MA Modulator DMDZ26X RN Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199). DMDZ26X RU http://cancerres.aacrjournals.org/content/75/15_Supplement/6 DMDZBTY DI DMDZBTY DMDZBTY DN HuM195/rGel DMDZBTY TI TTJVYO3 DMDZBTY TN Myeloid cell surface antigen CD33 (CD33) DMDZBTY RN Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21. DMDZBTY RU https://pubmed.ncbi.nlm.nih.gov/22875630 DMDZQ23 DI DMDZQ23 DMDZQ23 DN HF-0299 DMDZQ23 TI TTHRID2 DMDZQ23 TN Insulin-like growth factor I receptor (IGF1R) DMDZQ23 MA Modulator DMDZQ23 RN A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11. DMDZQ23 RU https://pubmed.ncbi.nlm.nih.gov/11162926 DMDZR0V DI DMDZR0V DMDZR0V DN Anti-CEA CAR-T cells DMDZR0V TI TTY6DTE DMDZR0V TN Carcinoembryonic antigen CEA (CD66e) DMDZR0V MA CAR-T-Cell-Therapy DMDZR0V RN ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) DMDZR0V RU https://clinicaltrials.gov/ct2/show/NCT03682744 DME0CJ9 DI DME0CJ9 DME0CJ9 DN R763 DME0CJ9 TI TT5LS6T DME0CJ9 TN Aurora kinase B (AURKB) DME0CJ9 MA Inhibitor DME0CJ9 RN Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. DME0CJ9 RU https://pubmed.ncbi.nlm.nih.gov/19609559 DME0CJ9 DI DME0CJ9 DME0CJ9 DN R763 DME0CJ9 TI TTPS3C0 DME0CJ9 TN Aurora kinase A (AURKA) DME0CJ9 MA Inhibitor DME0CJ9 RN Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. DME0CJ9 RU https://pubmed.ncbi.nlm.nih.gov/19609559 DME0F5W DI DME0F5W DME0F5W DN XL418 DME0F5W TI TT7M3PI DME0F5W TN Ribosomal protein S6 kinase (S6K) DME0F5W MA Modulator DME0F5W RN Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer DME0F5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564 DME0F5W DI DME0F5W DME0F5W DN XL418 DME0F5W TI TTAZ05C DME0F5W TN RAC-gamma serine/threonine-protein kinase (AKT3) DME0F5W MA Modulator DME0F5W RN Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer DME0F5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564 DME0WX2 DI DME0WX2 DME0WX2 DN Org-43902 DME0WX2 TI TT2O4W9 DME0WX2 TN Luteinizing hormone receptor (LHCGR) DME0WX2 MA Agonist DME0WX2 RN First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. J Clin Endocrinol Metab. 2013 Apr;98(4):1558-66. DME0WX2 RU https://pubmed.ncbi.nlm.nih.gov/23515453 DME18UM DI DME18UM DME18UM DN MER-102 DME18UM TI TT4QPUL DME18UM TN Antithrombin-III (ATIII) DME18UM MA Inhibitor DME18UM RN Clinical pipeline report, company report or official report of Merrion's GIPET technology. DME18UM RU http://www.merrionpharma.com/content/portfolio/mer102.asp DME1Y9W DI DME1Y9W DME1Y9W DN Protexia DME1Y9W TI TTEB0GD DME1Y9W TN Cholinesterase (BCHE) DME1Y9W MA Modulator DME1Y9W RN In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5. DME1Y9W RU https://pubmed.ncbi.nlm.nih.gov/16429486 DME1ZAH DI DME1ZAH DME1ZAH DN MK-1496 DME1ZAH TI TTIYVQP DME1ZAH TN Polo-like kinase 1 (PLK1) DME1ZAH MA Inhibitor DME1ZAH RN J Clin Oncol 29: 2011 (suppl; abstr 3012). DME1ZAH RU http://meetinglibrary.asco.org/content/73894-102 DME2QUZ DI DME2QUZ DME2QUZ DN NOV1501 DME2QUZ TI TTV23LH DME2QUZ TN Delta-like protein 4 (DLL4) DME2QUZ MA Inhibitor DME2QUZ RN Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538. DME2QUZ RU https://pubmed.ncbi.nlm.nih.gov/32580836 DME2QUZ DI DME2QUZ DME2QUZ DN NOV1501 DME2QUZ TI TT9HKJA DME2QUZ TN Vascular endothelial growth factor (VEGF) DME2QUZ MA Inhibitor DME2QUZ RN Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538. DME2QUZ RU https://pubmed.ncbi.nlm.nih.gov/32580836 DME3BJL DI DME3BJL DME3BJL DN PF-07062119 DME3BJL TI TTUN7MC DME3BJL TN T-cell surface glycoprotein CD3 (CD3) DME3BJL MA Inhibitor DME3BJL RN Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395. DME3BJL RU https://pubmed.ncbi.nlm.nih.gov/33459147 DME3BJL DI DME3BJL DME3BJL DN PF-07062119 DME3BJL TI TTLDPRG DME3BJL TN Guanylyl cyclase C (GUCY2C) DME3BJL MA Inhibitor DME3BJL RN Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395. DME3BJL RU https://pubmed.ncbi.nlm.nih.gov/33459147 DME3VU8 DI DME3VU8 DME3VU8 DN REGN1400 DME3VU8 TI TTDC8N2 DME3VU8 TN Erbb3 tyrosine kinase receptor (Erbb-3) DME3VU8 RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2516). DME3VU8 RU http://meetinglibrary.asco.org/content/131992-144 DME4B8I DI DME4B8I DME4B8I DN MGD009 DME4B8I TI TT6CQUM DME4B8I TN B7 homolog 3 (CD276) DME4B8I MA Immunomodulator DME4B8I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME4B8I RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DME4D7H DI DME4D7H DME4D7H DN HM71224 DME4D7H TI TTGM6VW DME4D7H TN Tyrosine-protein kinase BTK (ATK) DME4D7H MA Inhibitor DME4D7H RN HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211. DME4D7H RU https://pubmed.ncbi.nlm.nih.gov/28950886 DME630T DI DME630T DME630T DN AV4025 DME630T TI TTCJ2X8 DME630T TN Hepatitis C virus Non-structural 5A (HCV NS5A) DME630T MA Modulator DME630T RN Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014 Sep 25;57(18):7716-30. DME630T RU https://pubmed.ncbi.nlm.nih.gov/25148100 DME63VK DI DME63VK DME63VK DN ONO-4578 DME63VK TI TT79WV3 DME63VK TN Prostaglandin E2 receptor EP4 (PTGER4) DME63VK MA Antagonist DME63VK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME63VK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DME6UNO DI DME6UNO DME6UNO DN M012 DME6UNO TI TT6Y1PG DME6UNO TN Solute carrier family 40 member 1 (SLC40A1) DME6UNO MA Agonist DME6UNO RN Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. DME6UNO RU https://pubmed.ncbi.nlm.nih.gov/29523504 DME6VX4 DI DME6VX4 DME6VX4 DN GZ402668 DME6VX4 TI TTQT5S9 DME6VX4 TN Cambridge pathology 1 antigen (CD52) DME6VX4 RN Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14. DME6VX4 RU http://www.neurology.org/content/84/14_Supplement/S20.006 DME7BMT DI DME7BMT DME7BMT DN MEDI4920 DME7BMT TI TTIJP3Q DME7BMT TN TNF related activation protein (CD40LG) DME7BMT MA Inhibitor DME7BMT RN ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health. DME7BMT RU https://clinicaltrials.gov/ct2/show/NCT02151110 DME7IVL DI DME7IVL DME7IVL DN Xmab-7195 DME7IVL TI TTYJQTF DME7IVL TN Immunoglobulin E (IgE) DME7IVL MA Inhibitor DME7IVL RN Clinical pipeline report, company report or official report of Xencor. DME7IVL RU http://www.xencor.com/pipeline/xmab7195/ DME7JFM DI DME7JFM DME7JFM DN MR1-1 DME7JFM TI TTGKNB4 DME7JFM TN Epidermal growth factor receptor (EGFR) DME7JFM MA Modulator DME7JFM RN A Phase I Study of Immunotoxin, MR1-1. Duke University report. DME7JFM RU http://www.cancer.duke.edu/btc/modules/ClinicalTrials4/index.php?id=72 DME8DUV DI DME8DUV DME8DUV DN KM-023 DME8DUV TI TT84ETX DME8DUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DME8DUV MA Inhibitor DME8DUV RN Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9. DME8DUV RU https://pubmed.ncbi.nlm.nih.gov/25302016 DME9NYV DI DME9NYV DME9NYV DN BI 905711 DME9NYV TI TTW20TU DME9NYV TN TRAIL receptor 2 (TRAIL-R2) DME9NYV MA Activator DME9NYV RN Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108. DME9NYV RU https://pubmed.ncbi.nlm.nih.gov/33037135 DME9UTO DI DME9UTO DME9UTO DN RP4010 DME9UTO TI TTE76YK DME9UTO TN Calcium-release activated calcium channel (CRACM) DME9UTO MA Inhibitor DME9UTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME9UTO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMECVP9 DI DMECVP9 DMECVP9 DN OP-0595 DMECVP9 TI TTHI19T DMECVP9 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMECVP9 MA Inhibitor DMECVP9 RN OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86. DMECVP9 RU https://pubmed.ncbi.nlm.nih.gov/26089439 DMED2WN DI DMED2WN DMED2WN DN PLX73086 DMED2WN TI TT0IQER DMED2WN TN Macrophage colony-stimulating factor 1 (CSF1) DMED2WN MA Antagonist DMED2WN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMED2WN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMED4AJ DI DMED4AJ DMED4AJ DN BGC-20-1259 DMED4AJ TI TT3ROYC DMED4AJ TN Serotonin transporter (SERT) DMED4AJ MA Modulator DMED4AJ RN Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86. DMED4AJ RU https://www.ncbi.nlm.nih.gov/pubmed/21521422 DMEFUSJ DI DMEFUSJ DMEFUSJ DN RG6296 DMEFUSJ TI TTIFOC0 DMEFUSJ TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMEFUSJ MA Inhibitor DMEFUSJ RN Clinical pipeline report, company report or official report of Genentech. DMEFUSJ RU https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html DMEFUSJ DI DMEFUSJ DMEFUSJ DN RG6296 DMEFUSJ TI TTZ3P4W DMEFUSJ TN B-cell maturation protein (TNFRSF17) DMEFUSJ MA Inhibitor DMEFUSJ RN Clinical pipeline report, company report or official report of Genentech. DMEFUSJ RU https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html DMEGN5I DI DMEGN5I DMEGN5I DN HMPL-689 DMEGN5I TI TTGBPJE DMEGN5I TN PI3-kinase delta (PIK3CD) DMEGN5I MA Inhibitor DMEGN5I RN Clinical pipeline report, company report or official report of Hutchison MediPharma. DMEGN5I RU https://www.hutch-med.com/pipeline-and-products/our-pipeline/ DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT1LVF2 DMEGOQP TN Cyclin-dependent kinase 9 (CDK9) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TTMYWL7 DMEGOQP TN Cyclin-dependent kinase 3 (CDK3) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TTH6V3D DMEGOQP TN Cyclin-dependent kinase 1 (CDK1) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT7HF4W DMEGOQP TN Cyclin-dependent kinase 2 (CDK2) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT0PG8F DMEGOQP TN Cyclin-dependent kinase 4 (CDK4) DMEGOQP MA Inhibitor DMEGOQP RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMEHOVF DI DMEHOVF DMEHOVF DN AMG-139 DMEHOVF TI TTC1GLB DMEHOVF TN Interleukin-23 (IL23) DMEHOVF RN Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72. DMEHOVF RU https://pubmed.ncbi.nlm.nih.gov/25205227 DMEHWPC DI DMEHWPC DMEHWPC DN IMO-9200 DMEHWPC TI TTOK0LR DMEHWPC TN Toll-like receptor (TLR) DMEHWPC MA Antagonist DMEHWPC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEHWPC RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEIM5G DI DMEIM5G DMEIM5G DN IPI-940 DMEIM5G TI TTDP1UC DMEIM5G TN Fatty acid amide hydrolase (FAAH) DMEIM5G MA Inhibitor DMEIM5G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400). DMEIM5G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400 DMEIMBP DI DMEIMBP DMEIMBP DN AMG 811 DMEIMBP TI TT93WF5 DMEIMBP TN Interferon-gamma (IFNG) DMEIMBP MA Modulator DMEIMBP RN Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53. DMEIMBP RU https://pubmed.ncbi.nlm.nih.gov/25213774 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TT1LVF2 DMEITAS TN Cyclin-dependent kinase 9 (CDK9) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TT7HF4W DMEITAS TN Cyclin-dependent kinase 2 (CDK2) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TTQYF7G DMEITAS TN Cyclin-dependent kinase 7 (CDK7) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEJ4B7 DI DMEJ4B7 DMEJ4B7 DN ISIS 325568 DMEJ4B7 TI TTLMJSC DMEJ4B7 TN Glucagon receptor messenger RNA (GCGR mRNA) DMEJ4B7 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMEJ4B7 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMEJ4C1 DI DMEJ4C1 DMEJ4C1 DN MVT-5873 DMEJ4C1 TI TT80ARU DMEJ4C1 TN Ganglioside GD2 (GD2) DMEJ4C1 MA Modulator DMEJ4C1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEJ4C1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMEJMTR DI DMEJMTR DMEJMTR DN GSK1440115 DMEJMTR TI TTW5UDX DMEJMTR TN Urotensin II receptor (UTS2R) DMEJMTR MA Antagonist DMEJMTR RN Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. Front Pharmacol. 2013; 4: 54. DMEJMTR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638148/ DMEMQ5J DI DMEMQ5J DMEMQ5J DN ME-1071 DMEMQ5J TI TTHI19T DMEMQ5J TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMEMQ5J MA Inhibitor DMEMQ5J RN Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38. DMEMQ5J RU https://pubmed.ncbi.nlm.nih.gov/23489027 DMEN6YF DI DMEN6YF DMEN6YF DN CART-123 cells DMEN6YF TI TTENHJ0 DMEN6YF TN Interleukin 3 receptor alpha (IL3RA) DMEN6YF MA CAR-T-Cell-Therapy DMEN6YF RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMEN6YF RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMEOJUN DI DMEOJUN DMEOJUN DN PPI-383 DMEOJUN TI TTMVBWH DMEOJUN TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMEOJUN MA Inhibitor DMEOJUN RN 1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES. Journal of Hepatology Volume 56, Supplement 2, April 2012, Pages S464. DMEOJUN RU http://www.sciencedirect.com/science/article/pii/S0168827812611854 DMEP321 DI DMEP321 DMEP321 DN BVT-74316 DMEP321 TI TTJS8PY DMEP321 TN 5-HT 6 receptor (HTR6) DMEP321 MA Antagonist DMEP321 RN Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60. DMEP321 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/ DMEP7HO DI DMEP7HO DMEP7HO DN MSH-372 DMEP7HO TI TT84ETX DMEP7HO TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEP7HO MA Inhibitor DMEP7HO RN WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors. DMEP7HO RU http://www.google.com/patents/WO2004029042A1?cl=en DMEPHMR DI DMEPHMR DMEPHMR DN BCMA-CS1 cCAR DMEPHMR TI TTZ3P4W DMEPHMR TN B-cell maturation protein (TNFRSF17) DMEPHMR RN ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. DMEPHMR RU https://clinicaltrials.gov/ct2/show/NCT04156269 DMEPHMR DI DMEPHMR DMEPHMR DN BCMA-CS1 cCAR DMEPHMR TI TT7ILZ1 DMEPHMR TN SLAM family member 7 SLAMF7 (CS1) DMEPHMR RN ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. DMEPHMR RU https://clinicaltrials.gov/ct2/show/NCT04156269 DMEPJ7C DI DMEPJ7C DMEPJ7C DN BI 905677 DMEPJ7C TI TTSXOWE DMEPJ7C TN LDL receptor related protein-6 (LRP-6) DMEPJ7C MA Antagonist DMEPJ7C RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMEPJ7C RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMEPJ7C DI DMEPJ7C DMEPJ7C DN BI 905677 DMEPJ7C TI TT7VMG4 DMEPJ7C TN Low-density lipoprotein receptor-related protein 5 (LRP5) DMEPJ7C MA Antagonist DMEPJ7C RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMEPJ7C RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMEQY4Z DI DMEQY4Z DMEQY4Z DN DZD1516 DMEQY4Z TI TT6EO5L DMEQY4Z TN Erbb2 tyrosine kinase receptor (HER2) DMEQY4Z MA Inhibitor DMEQY4Z RN ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health. DMEQY4Z RU https://clinicaltrials.gov/ct2/show/NCT04509596 DMERDMV DI DMERDMV DMERDMV DN OI362GT DMERDMV TI TTZOPHG DMERDMV TN Insulin (INS) DMERDMV MA Modulator DMERDMV RN Novo Nordisk increased operating profit in local currencies by 15% in the first quarter of 2014 DMERDMV RU https://www.novonordisk.com/bin/getPDF.1781915.pdf DMERJ6V DI DMERJ6V DMERJ6V DN PHX-1766 DMERJ6V TI TTRHUKY DMERJ6V TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMERJ6V MA Modulator DMERJ6V RN Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antivir Ther. 2012;17(2):365-75. DMERJ6V RU https://pubmed.ncbi.nlm.nih.gov/22293533 DMESZQU DI DMESZQU DMESZQU DN Litenimod DMESZQU TI TTSHG0T DMESZQU TN Toll-like receptor 9 (TLR9) DMESZQU MA Modulator DMESZQU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DMESZQU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DMET0H4 DI DMET0H4 DMET0H4 DN IQB-9302 DMET0H4 TI TTW0CMT DMET0H4 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMET0H4 MA Opener DMET0H4 RN Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92. DMET0H4 RU https://pubmed.ncbi.nlm.nih.gov/11159686 DMETGAQ DI DMETGAQ DMETGAQ DN CD19-directed CAR-T cells DMETGAQ TI TTW640A DMETGAQ TN B-lymphocyte surface antigen B4 (CD19) DMETGAQ MA CAR-T-Cell-Therapy DMETGAQ RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMETGAQ RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMETIBD DI DMETIBD DMETIBD DN MK-8719 DMETIBD TI TT2I6UX DMETIBD TN Beta-N-acetylhexosaminidase (OGA) DMETIBD MA Inhibitor DMETIBD RN Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097. DMETIBD RU https://pubmed.ncbi.nlm.nih.gov/31487175 DMEWRNZ DI DMEWRNZ DMEWRNZ DN GEN1046 DMEWRNZ TI TTPW9LJ DMEWRNZ TN Co-stimulatory molecule 4-1BB (CD137) DMEWRNZ MA Agonist DMEWRNZ RN Clinical pipeline report, company report or official report of Genmab. DMEWRNZ RU https://www.genmab.com/pipeline/ DMEWRNZ DI DMEWRNZ DMEWRNZ DN GEN1046 DMEWRNZ TI TT8ZLTI DMEWRNZ TN Programmed cell death 1 ligand 1 (PD-L1) DMEWRNZ MA Agonist DMEWRNZ RN Clinical pipeline report, company report or official report of Genmab. DMEWRNZ RU https://www.genmab.com/pipeline/ DMEXT97 DI DMEXT97 DMEXT97 DN ADG116 DMEXT97 TI TTI2S1D DMEXT97 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMEXT97 MA Inhibitor DMEXT97 RN Clinical pipeline report, company report or official report of Adagene. DMEXT97 RU https://www.adagene.com/pipeline/adg116/ DMEY2LK DI DMEY2LK DMEY2LK DN LCAR-B4822M CAR-T Cell DMEY2LK TI TTZ3P4W DMEY2LK TN B-cell maturation protein (TNFRSF17) DMEY2LK MA CAR-T-Cell-Therapy DMEY2LK RN ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma DMEY2LK RU https://clinicaltrials.gov/ct2/show/NCT03674463 DMF0O3X DI DMF0O3X DMF0O3X DN MCLA-158 DMF0O3X TI TTTSGRH DMF0O3X TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMF0O3X MA Inhibitor DMF0O3X RN Clinical pipeline report, company report or official report of Merus. DMF0O3X RU https://merus.nl/pipeline/ DMF0O3X DI DMF0O3X DMF0O3X DN MCLA-158 DMF0O3X TI TTGKNB4 DMF0O3X TN Epidermal growth factor receptor (EGFR) DMF0O3X MA Inhibitor DMF0O3X RN Clinical pipeline report, company report or official report of Merus. DMF0O3X RU https://merus.nl/pipeline/ DMF21XQ DI DMF21XQ DMF21XQ DN NGM120 DMF21XQ TI TTE61UB DMF21XQ TN GDNF family receptor alpha-like (GFRAL) DMF21XQ MA Antagonist DMF21XQ RN Clinical pipeline report, company report or official report of NGM Biopharmaceuticals. DMF21XQ RU https://www.ngmbio.com/pipeline/ DMF2CZ9 DI DMF2CZ9 DMF2CZ9 DN OSI-930 DMF2CZ9 TI TTUTJGQ DMF2CZ9 TN Vascular endothelial growth factor receptor 2 (KDR) DMF2CZ9 MA Modulator DMF2CZ9 RN OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74. DMF2CZ9 RU https://pubmed.ncbi.nlm.nih.gov/22750060 DMF2CZ9 DI DMF2CZ9 DMF2CZ9 DN OSI-930 DMF2CZ9 TI TTX41N9 DMF2CZ9 TN Tyrosine-protein kinase Kit (KIT) DMF2CZ9 MA Modulator DMF2CZ9 RN OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74. DMF2CZ9 RU https://pubmed.ncbi.nlm.nih.gov/22750060 DMF3IBC DI DMF3IBC DMF3IBC DN Plasma derived human butyrylcholinesterase DMF3IBC TI TTEB0GD DMF3IBC TN Cholinesterase (BCHE) DMF3IBC MA Modulator DMF3IBC RN Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8. DMF3IBC RU https://pubmed.ncbi.nlm.nih.gov/26121420 DMF3MN1 DI DMF3MN1 DMF3MN1 DN NBXT-001+Nobilis inhalation device DMF3MN1 TI TT9IK2Z DMF3MN1 TN N-methyl-D-aspartate receptor (NMDAR) DMF3MN1 MA Antagonist DMF3MN1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF3MN1 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMF5KNO DI DMF5KNO DMF5KNO DN OTSSP167 DMF5KNO TI TTBZOTY DMF5KNO TN Tyrosine-protein kinase MELK (MELK) DMF5KNO MA Inhibitor DMF5KNO RN Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec;3(12):1629-40. DMF5KNO RU https://pubmed.ncbi.nlm.nih.gov/23283305 DMF5KNO DI DMF5KNO DMF5KNO DN OTSSP167 DMF5KNO TI TT5MN2U DMF5KNO TN Maternal embryonic leucine zipper kinase (MELK) DMF5KNO MA Inhibitor DMF5KNO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF5KNO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF89ZT DI DMF89ZT DMF89ZT DN SEP-228432 DMF89ZT TI TT3ROYC DMF89ZT TN Serotonin transporter (SERT) DMF89ZT MA Inhibitor DMF89ZT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028715) DMF89ZT RU http://adisinsight.springer.com/drugs/800028715 DMF8WAT DI DMF8WAT DMF8WAT DN CNTO-5825 DMF8WAT TI TT0GVCH DMF8WAT TN Interleukin-13 (IL13) DMF8WAT RN Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98. DMF8WAT RU https://pubmed.ncbi.nlm.nih.gov/23043368 DMF93T2 DI DMF93T2 DMF93T2 DN Anti-CD19/BCMA CAR-T cells DMF93T2 TI TTZ3P4W DMF93T2 TN B-cell maturation protein (TNFRSF17) DMF93T2 MA CAR-T-Cell-Therapy(Dual specific) DMF93T2 RN ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM DMF93T2 RU https://clinicaltrials.gov/ct2/show/NCT03706547 DMF93T2 DI DMF93T2 DMF93T2 DN Anti-CD19/BCMA CAR-T cells DMF93T2 TI TTW640A DMF93T2 TN B-lymphocyte surface antigen B4 (CD19) DMF93T2 MA CAR-T-Cell-Therapy(Dual specific) DMF93T2 RN ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM DMF93T2 RU https://clinicaltrials.gov/ct2/show/NCT03706547 DMF9ALP DI DMF9ALP DMF9ALP DN BAY 1817080 DMF9ALP TI TT2THBD DMF9ALP TN P2X purinoceptor 3 (P2RX3) DMF9ALP MA Antagonist DMF9ALP RN Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240. DMF9ALP RU https://pubmed.ncbi.nlm.nih.gov/33986030 DMFA2XQ DI DMFA2XQ DMFA2XQ DN GQ1001 DMFA2XQ TI TT6EO5L DMFA2XQ TN Erbb2 tyrosine kinase receptor (HER2) DMFA2XQ RN Clinical pipeline report, company report or official report of GeneQuantum Healthcare. DMFA2XQ RU http://www.genequantum.com/#/common/product?pid=12&id=13&type=7 DMFBMU7 DI DMFBMU7 DMFBMU7 DN Axatilamab DMFBMU7 TI TT7MRDV DMFBMU7 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMFBMU7 MA Antagonist DMFBMU7 RN Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. DMFBMU7 RU https://syndax.com/pipeline/axatilimab/ DMFBOQ7 DI DMFBOQ7 DMFBOQ7 DN Xanthine DMFBOQ7 TI TTNE7KG DMFBOQ7 TN Adenosine A2b receptor (ADORA2B) DMFBOQ7 MA Antagonist DMFBOQ7 RN Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6. DMFBOQ7 RU https://pubmed.ncbi.nlm.nih.gov/11542498 DMFC2OY DI DMFC2OY DMFC2OY DN GDC-0994 DMFC2OY TI TT1MG9E DMFC2OY TN Extracellular signal-regulated kinase 1 (ERK1) DMFC2OY MA Modulator DMFC2OY RN ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors DMFC2OY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142 DMFC2OY DI DMFC2OY DMFC2OY DN GDC-0994 DMFC2OY TI TT4TQBX DMFC2OY TN Extracellular signal-regulated kinase 2 (ERK2) DMFC2OY MA Modulator DMFC2OY RN ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors DMFC2OY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142 DMFDAY7 DI DMFDAY7 DMFDAY7 DN LY3214996 DMFDAY7 TI TT4TQBX DMFDAY7 TN Extracellular signal-regulated kinase 2 (ERK2) DMFDAY7 MA Inhibitor DMFDAY7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFDAY7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFDBV5 DI DMFDBV5 DMFDBV5 DN NPT200-11 DMFDBV5 TI TT08OSU DMFDBV5 TN Synuclein alpha (SNCA) DMFDBV5 MA Inhibitor DMFDBV5 RN The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165. DMFDBV5 RU https://pubmed.ncbi.nlm.nih.gov/30385782 DMFDKS7 DI DMFDKS7 DMFDKS7 DN RG-7348 DMFDKS7 TI TTMVBWH DMFDKS7 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMFDKS7 MA Modulator DMFDKS7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFDKS7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFEI6T DI DMFEI6T DMFEI6T DN IPH5201 DMFEI6T TI TTYM8DJ DMFEI6T TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMFEI6T MA Inhibitor DMFEI6T RN ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health. DMFEI6T RU https://clinicaltrials.gov/ct2/show/NCT04261075 DMFELMQ DI DMFELMQ DMFELMQ DN AMEP DMFELMQ TI TT69TQN DMFELMQ TN Integrin alpha-V/beta-3 (ITGAV/B3) DMFELMQ MA Modulator DMFELMQ RN Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90. DMFELMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25781650 DMFELMQ DI DMFELMQ DMFELMQ DN AMEP DMFELMQ TI TTH4QIS DMFELMQ TN Integrin alpha-5/beta-1 (ITGA5/B1) DMFELMQ MA Modulator DMFELMQ RN Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90. DMFELMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25781650 DMFEORD DI DMFEORD DMFEORD DN DNL201 DMFEORD TI TTK0FEA DMFEORD TN Leucine-rich repeat kinase 2 (LRRK2) DMFEORD MA Inhibitor DMFEORD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFEORD RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFG1YA DI DMFG1YA DMFG1YA DN 177Lu-AMBA DMFG1YA TI TTC1MVT DMFG1YA TN Gastrin-releasing peptide receptor (GRPR) DMFG1YA MA Agonist DMFG1YA RN Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48. DMFG1YA RU https://pubmed.ncbi.nlm.nih.gov/21036718 DMFG6ML DI DMFG6ML DMFG6ML DN TAS3681 DMFG6ML TI TTS64P2 DMFG6ML TN Androgen receptor (AR) DMFG6ML MA Antagonist DMFG6ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFG6ML RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFGQXB DI DMFGQXB DMFGQXB DN CD28 and CD137 CAR-T Cells DMFGQXB TI TTQ13FT DMFGQXB TN T-cell-specific surface glycoprotein CD28 (CD28) DMFGQXB MA CAR-T-Cell-Therapy(Dual specific) DMFGQXB RN ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia DMFGQXB RU https://clinicaltrials.gov/ct2/show/NCT02186860 DMFGQXB DI DMFGQXB DMFGQXB DN CD28 and CD137 CAR-T Cells DMFGQXB TI TTPW9LJ DMFGQXB TN Co-stimulatory molecule 4-1BB (CD137) DMFGQXB MA CAR-T-Cell-Therapy(Dual specific) DMFGQXB RN ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia DMFGQXB RU https://clinicaltrials.gov/ct2/show/NCT02186860 DMFGR98 DI DMFGR98 DMFGR98 DN RG-7351 DMFGR98 TI TTIU98M DMFGR98 TN Trace amine-associated receptor-1 (TAAR1) DMFGR98 MA Agonist DMFGR98 RN Clinical pipeline report, company report or official report of Roche. DMFGR98 RU http://www.roche.com/roche_group_pipeline_2010-02-18.pdf DMFGYKS DI DMFGYKS DMFGYKS DN MK-5108 DMFGYKS TI TT5LS6T DMFGYKS TN Aurora kinase B (AURKB) DMFGYKS MA Inhibitor DMFGYKS RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMFGYKS RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMFGYKS DI DMFGYKS DMFGYKS DN MK-5108 DMFGYKS TI TTPS3C0 DMFGYKS TN Aurora kinase A (AURKA) DMFGYKS MA Inhibitor DMFGYKS RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMFGYKS RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMFH3JM DI DMFH3JM DMFH3JM DN ABT-767 DMFH3JM TI TTEBCY8 DMFH3JM TN Poly [ADP-ribose] polymerase (PARP) DMFH3JM MA Modulator DMFH3JM RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFH3JM RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFIS4D DI DMFIS4D DMFIS4D DN MCD-386 DMFIS4D TI TTZ9SOR DMFIS4D TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFIS4D MA Agonist DMFIS4D RN The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5. DMFIS4D RU https://pubmed.ncbi.nlm.nih.gov/16041192 DMFJGUL DI DMFJGUL DMFJGUL DN BI 3011441 DMFJGUL TI TTZCRP3 DMFJGUL TN ERK activator kinase (MEK) DMFJGUL MA Inhibitor DMFJGUL RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMFJGUL RU https://www.inoncology.com/ourpipeline/mek-inhibitor DMFJXDZ DI DMFJXDZ DMFJXDZ DN IGM-8444 DMFJXDZ TI TTW20TU DMFJXDZ TN TRAIL receptor 2 (TRAIL-R2) DMFJXDZ MA Agonist DMFJXDZ RN Clinical pipeline report, company report or official report of IGM Biosciences. DMFJXDZ RU https://igmbio.com/pipeline/death-receptor-5/ DMFJZK3 DI DMFJZK3 DMFJZK3 DN Arecoline DMFJZK3 TI TTZ9SOR DMFJZK3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFJZK3 MA Inhibitor DMFJZK3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFJZK3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFK7UR DI DMFK7UR DMFK7UR DN Simotaxel DMFK7UR TI TTYFKSZ DMFK7UR TN Tubulin beta (TUBB) DMFK7UR MA Inhibitor DMFK7UR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMFK7UR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMFKEVO DI DMFKEVO DMFKEVO DN KA2237 DMFKEVO TI TTHBTOP DMFKEVO TN PI3-kinase gamma (PIK3CG) DMFKEVO MA Inhibitor DMFKEVO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFKEVO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFLP21 DI DMFLP21 DMFLP21 DN MK 8719 DMFLP21 TI TT2I6UX DMFLP21 TN Beta-N-acetylhexosaminidase (OGA) DMFLP21 MA Inhibitor DMFLP21 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFLP21 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFMGZR DI DMFMGZR DMFMGZR DN CPL207-280CA DMFMGZR TI TTB8FUC DMFMGZR TN Free fatty acid receptor 1 (GPR40) DMFMGZR MA Agonist DMFMGZR RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMFMGZR RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMFMW5C DI DMFMW5C DMFMW5C DN MVA-BN Breast DMFMW5C TI TTS78AZ DMFMW5C TN Prostate specific antigen (KLK3) DMFMW5C MA Antagonist DMFMW5C RN Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44. DMFMW5C RU https://pubmed.ncbi.nlm.nih.gov/21670078 DMFMWLQ DI DMFMWLQ DMFMWLQ DN JS004 DMFMWLQ TI TTER58P DMFMWLQ TN B- and T-lymphocyte attenuator (BTLA) DMFMWLQ MA Inhibitor DMFMWLQ RN Clinical pipeline report, company report or official report of Junshi Biosciences. DMFMWLQ RU https://www.junshipharma.com/en/Treatment.html DMFNSHM DI DMFNSHM DMFNSHM DN LHF-535 DMFNSHM TI TTD2IK3 DMFNSHM TN Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC) DMFNSHM MA Inhibitor DMFNSHM RN A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439. DMFNSHM RU https://pubmed.ncbi.nlm.nih.gov/30576397 DMFNYQ9 DI DMFNYQ9 DMFNYQ9 DN ME-401 DMFNYQ9 TI TTGBPJE DMFNYQ9 TN PI3-kinase delta (PIK3CD) DMFNYQ9 MA Inhibitor DMFNYQ9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFNYQ9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TT3PJMV DMFO7RP TN Tyrosine-protein kinase ABL1 (ABL) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TTGJCWZ DMFO7RP TN Fms-like tyrosine kinase 3 (FLT-3) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TTRLW2X DMFO7RP TN Fibroblast growth factor receptor 1 (FGFR1) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFOXGB DI DMFOXGB DMFOXGB DN INCB81776 DMFOXGB TI TTO7LKR DMFOXGB TN Tyrosine-protein kinase Mer (MERTK) DMFOXGB MA Inhibitor DMFOXGB RN A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477. DMFOXGB RU https://pubmed.ncbi.nlm.nih.gov/33425754 DMFOXGB DI DMFOXGB DMFOXGB DN INCB81776 DMFOXGB TI TTZPY6J DMFOXGB TN Tyrosine-protein kinase UFO (AXL) DMFOXGB MA Inhibitor DMFOXGB RN A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477. DMFOXGB RU https://pubmed.ncbi.nlm.nih.gov/33425754 DMFRM15 DI DMFRM15 DMFRM15 DN HX-100 DMFRM15 TI TTELV3W DMFRM15 TN Transformation-sensitive protein p120 (TRPA1) DMFRM15 MA Inhibitor DMFRM15 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFRM15 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFSMCB DI DMFSMCB DMFSMCB DN Patritumab DMFSMCB TI TTDC8N2 DMFSMCB TN Erbb3 tyrosine kinase receptor (Erbb-3) DMFSMCB RN Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6. DMFSMCB RU https://pubmed.ncbi.nlm.nih.gov/24442032 DMFTAWU DI DMFTAWU DMFTAWU DN mRNA-2416 DMFTAWU TI TTBW580 DMFTAWU TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMFTAWU MA Replacement DMFTAWU RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMFTAWU RU https://www.modernatx.com/mrna-2416 DMFTGHX DI DMFTGHX DMFTGHX DN Ad5CMV-NIS DMFTGHX TI TTW7HI9 DMFTGHX TN Sodium/iodide cotransporter (SLC5A5) DMFTGHX MA Modulator DMFTGHX RN Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter. Mol Ther. 2009 December; 17(12): 2041-2048. DMFTGHX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810133/ DMFU0H5 DI DMFU0H5 DMFU0H5 DN LY3410738 DMFU0H5 TI TTV2A1R DMFU0H5 TN Oxalosuccinate decarboxylase (IDH1) DMFU0H5 MA Inhibitor DMFU0H5 RN LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML). Cancer Res 2020;80(16 Suppl):Abstract nr 6417. DMFU0H5 RU https://cancerres.aacrjournals.org/content/80/16_Supplement/6417 DMFU58V DI DMFU58V DMFU58V DN AG2034 DMFU58V TI TTCSJBZ DMFU58V TN GAR transformylase (GART) DMFU58V MA Modulator DMFU58V RN Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7. DMFU58V RU https://pubmed.ncbi.nlm.nih.gov/10803927 DMFVT43 DI DMFVT43 DMFVT43 DN E7046 DMFVT43 TI TT79WV3 DMFVT43 TN Prostaglandin E2 receptor EP4 (PTGER4) DMFVT43 MA Antagonist DMFVT43 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFVT43 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFWPLQ DI DMFWPLQ DMFWPLQ DN MEDI-565 DMFWPLQ TI TTV3XPL DMFWPLQ TN T-cell surface glycoprotein CD3 gamma (CD3G) DMFWPLQ MA Modulator DMFWPLQ RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMFWPLQ RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMFYKDX DI DMFYKDX DMFYKDX DN UK-396082 DMFYKDX TI TTP18AY DMFYKDX TN Carboxypeptidase B2 (CPB2) DMFYKDX MA Inhibitor DMFYKDX RN Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6. DMFYKDX RU https://pubmed.ncbi.nlm.nih.gov/19954973 DMFZ52G DI DMFZ52G DMFZ52G DN Anti-OX40 mab DMFZ52G TI TTL31H0 DMFZ52G TN OX40L receptor (CD134) DMFZ52G MA Modulator DMFZ52G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873). DMFZ52G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873 DMG0Q27 DI DMG0Q27 DMG0Q27 DN MK-3281 DMG0Q27 TI TTMVBWH DMG0Q27 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMG0Q27 MA Inhibitor DMG0Q27 RN Clinical pipeline report, company report or official report of Merck (2011). DMG0Q27 RU http://www.merck.com/index.html DMG0SPO DI DMG0SPO DMG0SPO DN CS-0777 DMG0SPO TI TT9JZCK DMG0SPO TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMG0SPO MA Modulator DMG0SPO RN Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. DMG0SPO RU https://pubmed.ncbi.nlm.nih.gov/24900318 DMG0SWE DI DMG0SWE DMG0SWE DN NBF-006 DMG0SWE TI TT48Z3K DMG0SWE TN GSTP1 messenger RNA (GSTP1 mRNA) DMG0SWE MA Inhibitor DMG0SWE RN Clinical pipeline report, company report or official report of Nitto Biopharma. DMG0SWE RU https://www.nittobiopharma.com/index.php DMG2IE5 DI DMG2IE5 DMG2IE5 DN PF-3732010 DMG2IE5 TI TTARMD9 DMG2IE5 TN Placental cadherin (CDH3) DMG2IE5 RN National Cancer Institute Drug Dictionary (drug id 580366). DMG2IE5 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=580366 DMG3J6C DI DMG3J6C DMG3J6C DN BMS-933043 DMG3J6C TI TTLA931 DMG3J6C TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMG3J6C MA Modulator DMG3J6C RN Clinical pipeline report, company report or official report of Phrma.org Alzheimers 2012. DMG3J6C RU http://phrma.org/sites/default/files/pdf/alzheimers2012.pdf DMG4H9Y DI DMG4H9Y DMG4H9Y DN ABT-072 DMG4H9Y TI TTMVBWH DMG4H9Y TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMG4H9Y MA Inhibitor DMG4H9Y RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DMG4H9Y RU http://www.abbott.com/index2.htm DMG4QDT DI DMG4QDT DMG4QDT DN MUC-1 dendritic cancer vaccine DMG4QDT TI TTBHFYQ DMG4QDT TN Mucin-1 (MUC1) DMG4QDT RN Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003 Oct;12(4):493-502. DMG4QDT RU https://pubmed.ncbi.nlm.nih.gov/12964025 DMG4RK0 DI DMG4RK0 DMG4RK0 DN AAD-2004 DMG4RK0 TI TTYLQ8V DMG4RK0 TN Prostaglandin E synthase (PTGES) DMG4RK0 MA Inhibitor DMG4RK0 RN Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61. DMG4RK0 RU https://pubmed.ncbi.nlm.nih.gov/22537108 DMG4U32 DI DMG4U32 DMG4U32 DN TPST-1120 DMG4U32 TI TTJ584C DMG4U32 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG4U32 MA Antagonist DMG4U32 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DMG4U32 RU https://www.tempesttx.com/pipeline/ DMG64PE DI DMG64PE DMG64PE DN AMG 506 DMG64PE TI TTGPQ0F DMG64PE TN Prolyl endopeptidase FAP (FAP) DMG64PE MA Inhibitor DMG64PE RN Clinical pipeline report, company report or official report of Amgen. DMG64PE RU https://www.amgenpipeline.com/ DMG64PE DI DMG64PE DMG64PE DN AMG 506 DMG64PE TI TTPW9LJ DMG64PE TN Co-stimulatory molecule 4-1BB (CD137) DMG64PE MA Inhibitor DMG64PE RN Clinical pipeline report, company report or official report of Amgen. DMG64PE RU https://www.amgenpipeline.com/ DMG6HLE DI DMG6HLE DMG6HLE DN LY3303560 DMG6HLE TI TTS87KH DMG6HLE TN Microtubule-associated protein tau (MAPT) DMG6HLE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG6HLE RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMG6NI8 DI DMG6NI8 DMG6NI8 DN SSR-125329A DMG6NI8 TI TT5TPI6 DMG6NI8 TN Opioid receptor sigma 1 (OPRS1) DMG6NI8 MA Binder DMG6NI8 RN SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31. DMG6NI8 RU https://pubmed.ncbi.nlm.nih.gov/12450578 DMG6S8U DI DMG6S8U DMG6S8U DN INNO-305 DMG6S8U TI TTZ8UT4 DMG6S8U TN Wilms tumor protein (WT1) DMG6S8U MA Modulator DMG6S8U RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753) DMG6S8U RU http://adisinsight.springer.com/drugs/800023753 DMG74BY DI DMG74BY DMG74BY DN (-)-3PPP, Maryland DMG74BY TI TTEX248 DMG74BY TN Dopamine D2 receptor (D2R) DMG74BY MA Agonist DMG74BY RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMG74BY RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMG75P3 DI DMG75P3 DMG75P3 DN 4SC-205 DMG75P3 TI TTTRP0H DMG75P3 TN Kinesin-like protein KIF11 (KIF11) DMG75P3 MA Inhibitor DMG75P3 RN 2011 Pipeline of 4SC AG. DMG75P3 RU http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html DMG7FLI DI DMG7FLI DMG7FLI DN UCART123 DMG7FLI TI TTENHJ0 DMG7FLI TN Interleukin 3 receptor alpha (IL3RA) DMG7FLI MA CAR-T-Cell-Therapy DMG7FLI RN ClinicalTrials.gov (NCT03190278) Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia DMG7FLI RU https://clinicaltrials.gov/ct2/show/NCT03190278 DMG7I5J DI DMG7I5J DMG7I5J DN DS-3078 DMG7I5J TI TTCJG29 DMG7I5J TN Serine/threonine-protein kinase mTOR (mTOR) DMG7I5J MA Modulator DMG7I5J RN A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173. DMG7I5J RU http://mct.aacrjournals.org/content/12/11_Supplement/C173.abstract DMG7XKP DI DMG7XKP DMG7XKP DN SKF-105494 DMG7XKP TI TTYCILE DMG7XKP TN Vasopressin receptor (VR) DMG7XKP MA Modulator DMG7XKP RN Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6. DMG7XKP RU https://pubmed.ncbi.nlm.nih.gov/1659234 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TT84ETX DMG82ZA TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTEC2T3 DMG82ZA TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TT4NXYM DMG82ZA TN Human immunodeficiency virus Negative factor (HIV nef) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTF7I5O DMG82ZA TN Human immunodeficiency virus Rev protein (HIV rev) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTFGZB6 DMG82ZA TN Human immunodeficiency virus GAG protein (HIV gag) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG98QO DI DMG98QO DMG98QO DN M3541 DMG98QO TI TTKBM7V DMG98QO TN ATM serine/threonine kinase (ATM) DMG98QO MA Inhibitor DMG98QO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG98QO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTOA6YT DMG9C4I TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMG9C4I MA Inhibitor DMG9C4I RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMG9C4I RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTKXI53 DMG9C4I TN SARS-CoV RNA-directed RNA polymerase (RdRp) DMG9C4I MA Inhibitor DMG9C4I RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMG9C4I RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTV1095 DMG9C4I TN COVID-19 RNA-directed RNA polymerase (RdRp) DMG9C4I MA Blocker DMG9C4I RN BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 DMG9C4I RU https://www.biospace.com/article/releases/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid-19/ DMGA1DS DI DMGA1DS DMGA1DS DN D-0502 DMGA1DS TI TTZAYWL DMGA1DS TN Estrogen receptor (ESR) DMGA1DS MA Degrader DMGA1DS RN Clinical pipeline report, company report or official report of InventisBio. DMGA1DS RU http://www.inventisbio.com/en/product.html?id=1 DMGAKR9 DI DMGAKR9 DMGAKR9 DN AVL-3288 DMGAKR9 TI TTLA931 DMGAKR9 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMGAKR9 MA Modulator DMGAKR9 RN Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014. DMGAKR9 RU https://pubmed.ncbi.nlm.nih.gov/22096516 DMGAP53 DI DMGAP53 DMGAP53 DN BDD-10103 DMGAP53 TI TTRK8B9 DMGAP53 TN Sodium channel unspecific (NaC) DMGAP53 MA Modulator DMGAP53 RN Clinical pipeline report, company report or official report of Birds Pharma AG. DMGAP53 RU http://www.birdspharma.com/projects/bdd_10103/ DMGAR9Y DI DMGAR9Y DMGAR9Y DN BIT225 DMGAR9Y TI TT5FNQT DMGAR9Y TN Human immunodeficiency virus Protease (HIV PR) DMGAR9Y MA Inhibitor DMGAR9Y RN 2011 Pipeline of Biotron. DMGAR9Y RU http://www.biotron.com.au/ DMGAW0H DI DMGAW0H DMGAW0H DN CER-522 DMGAW0H TI TT7GN3U DMGAW0H TN Apolipoprotein A-I (APOA1) DMGAW0H MA Modulator DMGAW0H RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033541) DMGAW0H RU http://adisinsight.springer.com/drugs/800033541 DMGB32Z DI DMGB32Z DMGB32Z DN PF-06427878 DMGB32Z TI TTRHEQ4 DMGB32Z TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMGB32Z MA Inhibitor DMGB32Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGB32Z RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMGBKCJ DI DMGBKCJ DMGBKCJ DN ONO-7475 DMGBKCJ TI TTO7LKR DMGBKCJ TN Tyrosine-protein kinase Mer (MERTK) DMGBKCJ MA Inhibitor DMGBKCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGBKCJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGBKCJ DI DMGBKCJ DMGBKCJ DN ONO-7475 DMGBKCJ TI TTZPY6J DMGBKCJ TN Tyrosine-protein kinase UFO (AXL) DMGBKCJ MA Inhibitor DMGBKCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGBKCJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGC2AT DI DMGC2AT DMGC2AT DN TR1801-ADC DMGC2AT TI TTNDSF4 DMGC2AT TN Proto-oncogene c-Met (MET) DMGC2AT RN TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. DMGC2AT RU https://pubmed.ncbi.nlm.nih.gov/31736230 DMGDARN DI DMGDARN DMGDARN DN AP32788 DMGDARN TI TTGKNB4 DMGDARN TN Epidermal growth factor receptor (EGFR) DMGDARN MA Inhibitor DMGDARN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGDARN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGDJQR DI DMGDJQR DMGDJQR DN BMS-394136 DMGDJQR TI TTW0CMT DMGDJQR TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMGDJQR MA Modulator DMGDJQR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMGDJQR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMGE3DY DI DMGE3DY DMGE3DY DN 18-MC DMGE3DY TI TT35UGH DMGE3DY TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DMGE3DY MA Antagonist DMGE3DY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE3DY RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMGF71W DI DMGF71W DMGF71W DN GRN163 DMGF71W TI TTUJFD0 DMGF71W TN Telomerase reverse transcriptase (TERT) DMGF71W MA Inhibitor DMGF71W RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMGF71W RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMGFABM DI DMGFABM DMGFABM DN BC-3205 DMGFABM TI TTUWYEA DMGFABM TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMGFABM MA Modulator DMGFABM RN Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. J Clin Microbiol. 2012 October; 50(10): 3361-3364. DMGFABM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457460/ DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT0EOB8 DMGFAVQ TN B-Raf messenger RNA (BRAF mRNA) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT5TURO DMGFAVQ TN A-Raf messenger RNA (ARAF mRNA) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTROQ37 DMGFAVQ TN MAPK/ERK kinase kinase (MAP3K) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTAN5W2 DMGFAVQ TN Raf messenger RNA (Raf mRNA) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTZCRP3 DMGFAVQ TN ERK activator kinase (MEK) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT1EDJZ DMGFAVQ TN Microtubule-associated protein (MAP) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFH7T DI DMGFH7T DMGFH7T DN BI-836880 DMGFH7T TI TT9HKJA DMGFH7T TN Vascular endothelial growth factor (VEGF) DMGFH7T MA Inhibitor DMGFH7T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGFH7T RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGFTAI DI DMGFTAI DMGFTAI DN SHR0534 DMGFTAI TI TTB8FUC DMGFTAI TN Free fatty acid receptor 1 (GPR40) DMGFTAI MA Agonist DMGFTAI RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMGFTAI RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMGFTAI DI DMGFTAI DMGFTAI DN SHR0534 DMGFTAI TI TTG0MQD DMGFTAI TN Inflammation-related GPCR EX33 (GPR84) DMGFTAI MA Agonist DMGFTAI RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMGFTAI RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMGFVYL DI DMGFVYL DMGFVYL DN ALO-1567 DMGFVYL TI TTFBNVI DMGFVYL TN Aldose reductase (AKR1B1) DMGFVYL MA Inhibitor DMGFVYL RN Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol. 1991 Aug;32(2):221-7. DMGFVYL RU https://pubmed.ncbi.nlm.nih.gov/1931471 DMGHN98 DI DMGHN98 DMGHN98 DN GS-9901 DMGHN98 TI TTGBPJE DMGHN98 TN PI3-kinase delta (PIK3CD) DMGHN98 MA Inhibitor DMGHN98 RN Clinical pipeline report, company report or official report of Gilead. DMGHN98 RU http://www.gilead.com/research/pipeline DMGI58S DI DMGI58S DMGI58S DN CAR-T cells targeting Lewis-Y DMGI58S TI TTV75BJ DMGI58S TN Carbohydrate antigen Lewis-Y (Lewis-Y) DMGI58S MA CAR-T-Cell-Therapy DMGI58S RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMGI58S RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMGIAND DI DMGIAND DMGIAND DN ALLO-501 DMGIAND TI TTW640A DMGIAND TN B-lymphocyte surface antigen B4 (CD19) DMGIAND RN Clinical pipeline report, company report or official report of Allogene Therapeutics. DMGIAND RU https://www.allogene.com/pipeline#all0-501/501A DMGJ7A4 DI DMGJ7A4 DMGJ7A4 DN A/Anhui/05 DMGJ7A4 TI TTF4CAM DMGJ7A4 TN Influenza Hemagglutinin (Influ HA) DMGJ7A4 RN A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989. DMGJ7A4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302345/ DMGJCDR DI DMGJCDR DMGJCDR DN Teneligliptin DMGJCDR TI TTDIGC1 DMGJCDR TN Dipeptidyl peptidase 4 (DPP-4) DMGJCDR MA Modulator DMGJCDR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMGJCDR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMGJNTQ DI DMGJNTQ DMGJNTQ DN FT-819 DMGJNTQ TI TTW640A DMGJNTQ TN B-lymphocyte surface antigen B4 (CD19) DMGJNTQ RN Clinical pipeline report, company report or official report of Fate Therapeutics. DMGJNTQ RU https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft819/ DMGLEM1 DI DMGLEM1 DMGLEM1 DN PF9601N DMGLEM1 TI TTGP7BY DMGLEM1 TN Monoamine oxidase type B (MAO-B) DMGLEM1 MA Inhibitor DMGLEM1 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMGLEM1 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMGLHYU DI DMGLHYU DMGLHYU DN Enkastim-ev DMGLHYU TI TTHYBIX DMGLHYU TN Heat shock protein 70 (HSP70) DMGLHYU MA Modulator DMGLHYU RN Company report (Multimmune) DMGLHYU RU http://www.multimmune.com/mi-THERAPEUTICS-PIPELINE/ DMGLTE2 DI DMGLTE2 DMGLTE2 DN LY2922470 DMGLTE2 TI TTB8FUC DMGLTE2 TN Free fatty acid receptor 1 (GPR40) DMGLTE2 MA Agonist DMGLTE2 RN The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916. DMGLTE2 RU https://pubmed.ncbi.nlm.nih.gov/27749056 DMGLXQ9 DI DMGLXQ9 DMGLXQ9 DN RG7854 DMGLXQ9 TI TTRJ1K4 DMGLXQ9 TN Toll-like receptor 7 (TLR7) DMGLXQ9 MA Agonist DMGLXQ9 RN Clinical pipeline report, company report or official report of Roche. DMGLXQ9 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGMEH7 DI DMGMEH7 DMGMEH7 DN VGX-3400 DMGMEH7 TI TTF4CAM DMGMEH7 TN Influenza Hemagglutinin (Influ HA) DMGMEH7 RN Clinical pipeline report, company report or official report of Inovio Pharmaceuticals. DMGMEH7 RU http://www.inovio.com/products/infectious-disease-vaccines/influenza/pandemic/ DMGMFXJ DI DMGMFXJ DMGMFXJ DN BI 1701963 DMGMFXJ TI TTB1RA4 DMGMFXJ TN GTPase KRas (KRAS) DMGMFXJ MA Inhibitor DMGMFXJ RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMGMFXJ RU https://www.boehringer-ingelheim.com/press-release/first-pan-kras-inhibitor-advances-clinical-testing DMGMI8P DI DMGMI8P DMGMI8P DN CMP-001 DMGMI8P TI TTSHG0T DMGMI8P TN Toll-like receptor 9 (TLR9) DMGMI8P MA Agonist DMGMI8P RN Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals. DMGMI8P RU https://checkmatepharma.com/pipeline/ DMGN96R DI DMGN96R DMGN96R DN Ipafricept DMGN96R TI TTVZ87F DMGN96R TN Wnt protein (WNT) DMGN96R MA Modulator DMGN96R RN Clinical pipeline report, company report or official report of OncoMed Pharmaceuticals. DMGN96R RU http://www.oncomed.com/Pipeline.html DMGO4XJ DI DMGO4XJ DMGO4XJ DN DFP-14927 DMGO4XJ TI TTATL6Y DMGO4XJ TN DNA-dependent DNA polymerase (DPOL) DMGO4XJ MA Inhibitor DMGO4XJ RN National Cancer Institute Drug Dictionary (drug name DFP14927). DMGO4XJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927 DMGO4XJ DI DMGO4XJ DMGO4XJ DN DFP-14927 DMGO4XJ TI TTUTN1I DMGO4XJ TN Human Deoxyribonucleic acid (hDNA) DMGO4XJ MA Inhibitor DMGO4XJ RN National Cancer Institute Drug Dictionary (drug name DFP14927). DMGO4XJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927 DMGO6M1 DI DMGO6M1 DMGO6M1 DN GZ402666 DMGO6M1 TI TTLPC70 DMGO6M1 TN Lysosomal alpha-glucosidase (GAA) DMGO6M1 MA Modulator DMGO6M1 RN ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health. DMGO6M1 RU https://clinicaltrials.gov/ct2/show/NCT01898364 DMGONUE DI DMGONUE DMGONUE DN AB680 DMGONUE TI TTK0O6Y DMGONUE TN Ecto-5'-nucleotidase (CD73) DMGONUE MA Inhibitor DMGONUE RN Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468. DMGONUE RU https://pubmed.ncbi.nlm.nih.gov/32614585 DMGPIV0 DI DMGPIV0 DMGPIV0 DN STA-5312 DMGPIV0 TI TTYFKSZ DMGPIV0 TN Tubulin beta (TUBB) DMGPIV0 MA Inhibitor DMGPIV0 RN Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 11/2006; 16(19):5164-8. DMGPIV0 RU http://pubs.acs.org/doi/abs/10.1021/op6002852 DMGPR1C DI DMGPR1C DMGPR1C DN CART-EGFRvIII T cells DMGPR1C TI TTZ6B2I DMGPR1C TN Epidermal growth factor receptor variant III (EGFR vIII) DMGPR1C MA CAR-T-Cell-Therapy DMGPR1C RN ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma DMGPR1C RU https://clinicaltrials.gov/ct2/show/NCT02209376 DMGSDPL DI DMGSDPL DMGSDPL DN NK-314 DMGSDPL TI TT0IHXV DMGSDPL TN DNA topoisomerase II (TOP2) DMGSDPL MA Modulator DMGSDPL RN NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. DMGSDPL RU https://pubmed.ncbi.nlm.nih.gov/18596031 DMGSEB0 DI DMGSEB0 DMGSEB0 DN CKD-516 DMGSEB0 TI TTYFKSZ DMGSEB0 TN Tubulin beta (TUBB) DMGSEB0 MA Inhibitor DMGSEB0 RN CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11. DMGSEB0 RU https://pubmed.ncbi.nlm.nih.gov/24202729 DMGTL8Z DI DMGTL8Z DMGTL8Z DN ZP-1848 DMGTL8Z TI TT1YWO5 DMGTL8Z TN Glucagon-like peptide 2 receptor (GLP2R) DMGTL8Z MA Modulator DMGTL8Z RN US patent application no. 8,580,918, Peptidic glp-2 agonists. DMGTL8Z RU http://www.google.com/patents/US8580918 DMGUKRN DI DMGUKRN DMGUKRN DN PF-06648671 DMGUKRN TI TT9W8GU DMGUKRN TN Gamma-secretase (GS) DMGUKRN MA Modulator DMGUKRN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGUKRN RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMGUM90 DI DMGUM90 DMGUM90 DN Anti-CD133-CAR vector-transduced T cells DMGUM90 TI TTXMZ81 DMGUM90 TN Prominin-1 (PROM1) DMGUM90 MA CAR-T-Cell-Therapy DMGUM90 RN ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 DMGUM90 RU https://clinicaltrials.gov/ct2/show/NCT02541370 DMGUQ8V DI DMGUQ8V DMGUQ8V DN CD19+ CAR T Cells DMGUQ8V TI TTW640A DMGUQ8V TN B-lymphocyte surface antigen B4 (CD19) DMGUQ8V MA CAR-T-Cell-Therapy DMGUQ8V RN ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies DMGUQ8V RU https://clinicaltrials.gov/ct2/show/NCT02529813 DMGWC86 DI DMGWC86 DMGWC86 DN OMP-52M51 DMGWC86 TI TTB1STW DMGWC86 TN Notch-1 receptor (NOTCH1) DMGWC86 RN National Cancer Institute Drug Dictionary (drug id 741867). DMGWC86 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741867 DMGXS8L DI DMGXS8L DMGXS8L DN CD20Bi aATC DMGXS8L TI TTUN7MC DMGXS8L TN T-cell surface glycoprotein CD3 (CD3) DMGXS8L MA Modulator DMGXS8L RN CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. DMGXS8L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/ DMGXS8L DI DMGXS8L DMGXS8L DN CD20Bi aATC DMGXS8L TI TTUE541 DMGXS8L TN Leukocyte surface antigen Leu-16 (CD20) DMGXS8L MA Modulator DMGXS8L RN CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. DMGXS8L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/ DMH0D5M DI DMH0D5M DMH0D5M DN OI287GT DMH0D5M TI TTZOPHG DMH0D5M TN Insulin (INS) DMH0D5M MA Modulator DMH0D5M RN Company report (Novonordisk) DMH0D5M RU http://www.novonordisk.com/bin/getPDF.1698237.pdf DMH1NXO DI DMH1NXO DMH1NXO DN FP-025 DMH1NXO TI TTXZ0KQ DMH1NXO TN Matrix metalloproteinase-12 (MMP-12) DMH1NXO MA Inhibitor DMH1NXO RN Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7. DMH1NXO RU https://www.ncbi.nlm.nih.gov/pubmed/26174966 DMH3E5C DI DMH3E5C DMH3E5C DN TMB-365 DMH3E5C TI TTN2JFW DMH3E5C TN T-cell surface glycoprotein CD4 (CD4) DMH3E5C RN Clinical pipeline report, company report or official report of TaiMed Biologics. DMH3E5C RU http://www.taimedbiologics.com/pipeline/36 DMH6SNO DI DMH6SNO DMH6SNO DN OP-R003 DMH6SNO TI TTT1V78 DMH6SNO TN Interleukin-6 (IL6) DMH6SNO MA Modulator DMH6SNO RN A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma DMH6SNO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787636 DMH701Q DI DMH701Q DMH701Q DN CFI-402257 DMH701Q TI TTP7EGM DMH701Q TN Dual specificity protein kinase TTK (MPS1) DMH701Q MA Inhibitor DMH701Q RN Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. DMH701Q RU https://pubmed.ncbi.nlm.nih.gov/28270606 DMH76KD DI DMH76KD DMH76KD DN Syntropin DMH76KD TI TTKMAZ6 DMH76KD TN Growth hormone receptor (GHR) DMH76KD MA Modulator DMH76KD RN Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83. DMH76KD RU https://pubmed.ncbi.nlm.nih.gov/9695137 DMH789J DI DMH789J DMH789J DN AntiCD19 CART DMH789J TI TTW640A DMH789J TN B-lymphocyte surface antigen B4 (CD19) DMH789J MA CAR-T-Cell-Therapy DMH789J RN ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma DMH789J RU https://clinicaltrials.gov/ct2/show/NCT03434769 DMH86KO DI DMH86KO DMH86KO DN PCSK9 Adnectin DMH86KO TI TTBRG7E DMH86KO TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMH86KO MA Modulator DMH86KO RN Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412-24. DMH86KO RU https://pubmed.ncbi.nlm.nih.gov/24917546 DMH8UF0 DI DMH8UF0 DMH8UF0 DN SY-1425 DMH8UF0 TI TTW38KT DMH8UF0 TN Retinoic acid receptor alpha (RARA) DMH8UF0 MA Agonist DMH8UF0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH8UF0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH8VXE DI DMH8VXE DMH8VXE DN MSB2311 DMH8VXE TI TT8ZLTI DMH8VXE TN Programmed cell death 1 ligand 1 (PD-L1) DMH8VXE RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMH8VXE RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMH8Z9W DI DMH8Z9W DMH8Z9W DN ADVAX DMH8Z9W TI TTRPO9Z DMH8Z9W TN TNF-alpha signaling pathway (TNFA pathway) DMH8Z9W MA Modulator DMH8Z9W RN Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. DMH8Z9W RU https://pubmed.ncbi.nlm.nih.gov/20111582 DMH9M62 DI DMH9M62 DMH9M62 DN AMP-224 DMH9M62 TI TTNBFWK DMH9M62 TN Programmed cell death protein 1 (PD-1) DMH9M62 MA Modulator DMH9M62 RN National Cancer Institute Drug Dictionary (drug id 700595). DMH9M62 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=700595 DMHARE7 DI DMHARE7 DMHARE7 DN NP-500 DMHARE7 TI TTZOPHG DMHARE7 TN Insulin (INS) DMHARE7 MA Modulator DMHARE7 RN Napo Receives Commitments for a Private Placement of Common Shares and Enters into Binding Letter of Intent for Intellectual Property License. Napo. JANUARY 08, 2007 DMHARE7 RU http://www.prnewswire.com/news-releases/napo-receives-commitments-for-a-private-placement-of-common-shares-and-enters-into-binding-letter-of-intent-for-intellectual-property-license-53349492.html DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTV9A7R DMHAZLM TN Lactoylglutathione lyase (GLO1) DMHAZLM MA Inhibitor DMHAZLM RN Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/18258440 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTOM3J0 DMHAZLM TN Estrogen receptor beta (ESR2) DMHAZLM MA Inhibitor DMHAZLM RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTI84H7 DMHAZLM TN Cytochrome P450 1B1 (CYP1B1) DMHAZLM MA Inhibitor DMHAZLM RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTSZLWK DMHAZLM TN Aromatase (CYP19A1) DMHAZLM MA Inhibitor DMHAZLM RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTIWB6L DMHAZLM TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMHAZLM MA Inhibitor DMHAZLM RN Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/18533708 DMHBD3T DI DMHBD3T DMHBD3T DN SBT6050 DMHBD3T TI TT6EO5L DMHBD3T TN Erbb2 tyrosine kinase receptor (HER2) DMHBD3T RN Clinical pipeline report, company report or official report of Silverback Therapeutics. DMHBD3T RU https://silverbacktx.com/pipeline/#sbt6050 DMHBD3T DI DMHBD3T DMHBD3T DN SBT6050 DMHBD3T TI TT8CWFK DMHBD3T TN Toll-like receptor 8 (TLR8) DMHBD3T MA Agonist DMHBD3T RN Clinical pipeline report, company report or official report of Silverback Therapeutics. DMHBD3T RU https://silverbacktx.com/pipeline/#sbt6050 DMHBEKM DI DMHBEKM DMHBEKM DN AZD0284 DMHBEKM TI TTGV6LY DMHBEKM TN Nuclear receptor ROR-gamma (RORG) DMHBEKM MA Agonist DMHBEKM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBEKM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHBK6L DI DMHBK6L DMHBK6L DN CTAP-201 DMHBK6L TI TTK59TV DMHBK6L TN Vitamin D3 receptor (VDR) DMHBK6L MA Agonist DMHBK6L RN Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009 April; 156(8): 1267-1278. DMHBK6L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697742/ DMHBNKP DI DMHBNKP DMHBNKP DN C-Met/PD-L1 CAR-T Cell DMHBNKP TI TTNDSF4 DMHBNKP TN Proto-oncogene c-Met (MET) DMHBNKP MA CAR-T-Cell-Therapy(Dual specific) DMHBNKP RN ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC DMHBNKP RU https://clinicaltrials.gov/ct2/show/NCT03672305 DMHBNKP DI DMHBNKP DMHBNKP DN C-Met/PD-L1 CAR-T Cell DMHBNKP TI TT8ZLTI DMHBNKP TN Programmed cell death 1 ligand 1 (PD-L1) DMHBNKP MA CAR-T-Cell-Therapy(Dual specific) DMHBNKP RN ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC DMHBNKP RU https://clinicaltrials.gov/ct2/show/NCT03672305 DMHBUMZ DI DMHBUMZ DMHBUMZ DN AFP TCR DMHBUMZ TI TT7AKW1 DMHBUMZ TN T-cell receptor (TCR) DMHBUMZ MA Immunomodulator DMHBUMZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBUMZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMHCBI0 DI DMHCBI0 DMHCBI0 DN AIP-303 DMHCBI0 TI TT6EO5L DMHCBI0 TN Erbb2 tyrosine kinase receptor (HER2) DMHCBI0 RN Clinical pipeline report, company report or official report of Adagene. DMHCBI0 RU https://www.advancedinnovativepartners.com/technology DMHCUZV DI DMHCUZV DMHCUZV DN SEL120 DMHCUZV TI TTBJR4L DMHCUZV TN Cyclin-dependent kinase 8 (CDK8) DMHCUZV MA Inhibitor DMHCUZV RN Clinical pipeline report, company report or official report of Ryvu Therapeutics. DMHCUZV RU https://ryvu.com/pipeline/ DMHCUZV DI DMHCUZV DMHCUZV DN SEL120 DMHCUZV TI TTNABU9 DMHCUZV TN Cyclin-dependent kinase 19 (CDK19) DMHCUZV MA Inhibitor DMHCUZV RN Clinical pipeline report, company report or official report of Ryvu Therapeutics. DMHCUZV RU https://ryvu.com/pipeline/ DMHD615 DI DMHD615 DMHD615 DN ALB-109564(a) DMHD615 TI TTYFKSZ DMHD615 TN Tubulin beta (TUBB) DMHD615 MA Modulator DMHD615 RN 2010 ASCO Annual Meeting DMHD615 RU http://meetinglibrary.asco.org/content/41250-74 DMHD6PA DI DMHD6PA DMHD6PA DN TnMUC-1 CAR-T cell therapy DMHD6PA TI TTBHFYQ DMHD6PA TN Mucin-1 (MUC1) DMHD6PA MA Inhibitor DMHD6PA RN ClinicalTrials.gov (NCT04025216) A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers. U.S. National Institutes of Health. DMHD6PA RU https://clinicaltrials.gov/ct2/show/NCT04025216 DMHD8CF DI DMHD8CF DMHD8CF DN TRV734 DMHD8CF TI TTKWM86 DMHD8CF TN Opioid receptor mu (MOP) DMHD8CF MA Agonist DMHD8CF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHD8CF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMHDCSL DI DMHDCSL DMHDCSL DN LZM009 DMHDCSL TI TTNBFWK DMHDCSL TN Programmed cell death protein 1 (PD-1) DMHDCSL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMHDCSL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMHDSYF DI DMHDSYF DMHDSYF DN CRX-675 DMHDSYF TI TTISGCA DMHDSYF TN Toll-like receptor 4 (TLR4) DMHDSYF MA Agonist DMHDSYF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DMHDSYF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DMHE3MD DI DMHE3MD DMHE3MD DN ALLO-715 DMHE3MD TI TTZ3P4W DMHE3MD TN B-cell maturation protein (TNFRSF17) DMHE3MD RN Clinical pipeline report, company report or official report of Allogene Therapeutics. DMHE3MD RU https://www.allogene.com/pipeline#all0-501/501A DMHELFU DI DMHELFU DMHELFU DN BF-389 DMHELFU TI TT2J34L DMHELFU TN Arachidonate 5-lipoxygenase (5-LOX) DMHELFU MA Modulator DMHELFU RN Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. DMHELFU RU https://pubmed.ncbi.nlm.nih.gov/1456184 DMHG4Q9 DI DMHG4Q9 DMHG4Q9 DN ICAR19 CAR-T cells DMHG4Q9 TI TTW640A DMHG4Q9 TN B-lymphocyte surface antigen B4 (CD19) DMHG4Q9 MA CAR-T-Cell-Therapy DMHG4Q9 RN ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia DMHG4Q9 RU https://clinicaltrials.gov/ct2/show/NCT03383952 DMHG7DZ DI DMHG7DZ DMHG7DZ DN UltraCD40L DMHG7DZ TI TTIJP3Q DMHG7DZ TN TNF related activation protein (CD40LG) DMHG7DZ MA Modulator DMHG7DZ RN CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357. DMHG7DZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569584/ DMHI8RS DI DMHI8RS DMHI8RS DN HCBE-11 DMHI8RS TI TTFO0PM DMHI8RS TN Lymphotoxin beta receptor (LTBR) DMHI8RS RN Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33. DMHI8RS RU https://pubmed.ncbi.nlm.nih.gov/22357629 DMHIA7Y DI DMHIA7Y DMHIA7Y DN TAS-1440 DMHIA7Y TI TTNR0UQ DMHIA7Y TN Lysine-specific histone demethylase 1 (LSD) DMHIA7Y MA Inhibitor DMHIA7Y RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMHIA7Y RU https://astx.com/tas1440-oral-lsd1-inhibitor-hematological-malignancies/ DMHIPF5 DI DMHIPF5 DMHIPF5 DN ADV-1002401 DMHIPF5 TI TTDLNGZ DMHIPF5 TN Glucokinase (GCK) DMHIPF5 MA Inhibitor DMHIPF5 RN The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats. PLoS One. 2014; 9(5): e97139. DMHIPF5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032240/ DMHIS3M DI DMHIS3M DMHIS3M DN PRAX-330 DMHIS3M TI TT54ERL DMHIS3M TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMHIS3M MA Inhibitor DMHIS3M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHIS3M RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMHJLB6 DI DMHJLB6 DMHJLB6 DN CC-90006 DMHJLB6 TI TTNBFWK DMHJLB6 TN Programmed cell death protein 1 (PD-1) DMHJLB6 MA Antagonist DMHJLB6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHJLB6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHK9WR DI DMHK9WR DMHK9WR DN CTX-101 DMHK9WR TI TTW640A DMHK9WR TN B-lymphocyte surface antigen B4 (CD19) DMHK9WR RN Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. DMHK9WR RU https://pubmed.ncbi.nlm.nih.gov/31900462 DMHMDC0 DI DMHMDC0 DMHMDC0 DN JWCAR029 DMHMDC0 TI TTW640A DMHMDC0 TN B-lymphocyte surface antigen B4 (CD19) DMHMDC0 MA CAR-T-Cell-Therapy DMHMDC0 RN ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma DMHMDC0 RU https://clinicaltrials.gov/ct2/show/NCT03344367 DMHMG6X DI DMHMG6X DMHMG6X DN SX-682 DMHMG6X TI TTMWT8Z DMHMG6X TN C-X-C chemokine receptor type 1 (CXCR1) DMHMG6X MA Inhibitor DMHMG6X RN Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. DMHMG6X RU https://pubmed.ncbi.nlm.nih.gov/31848188 DMHMG6X DI DMHMG6X DMHMG6X DN SX-682 DMHMG6X TI TT30C9G DMHMG6X TN C-X-C chemokine receptor type 2 (CXCR2) DMHMG6X MA Inhibitor DMHMG6X RN Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. DMHMG6X RU https://pubmed.ncbi.nlm.nih.gov/31848188 DMHMPK1 DI DMHMPK1 DMHMPK1 DN CD22-CART DMHMPK1 TI TTM6QSK DMHMPK1 TN B-cell receptor CD22 (CD22) DMHMPK1 MA CAR-T-Cell-Therapy(Dual specific) DMHMPK1 RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DMHMPK1 RU https://clinicaltrials.gov/ct2/show/NCT03407859 DMHMZC7 DI DMHMZC7 DMHMZC7 DN GCC-4401 DMHMZC7 TI TTCIHJA DMHMZC7 TN Coagulation factor Xa (F10) DMHMZC7 MA Inhibitor DMHMZC7 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMHMZC7 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMHNZ3U DI DMHNZ3U DMHNZ3U DN PRT543 DMHNZ3U TI TTR1D7X DMHNZ3U TN Protein arginine methyltransferase 5 (PRMT5) DMHNZ3U MA Inhibitor DMHNZ3U RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMHNZ3U RU https://preludetx.com/science/prmt5/prt543/ DMHO6XP DI DMHO6XP DMHO6XP DN MyoDys DMHO6XP TI TT48MP6 DMHO6XP TN Dystrophin (DMD) DMHO6XP MA Modulator DMHO6XP RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280) DMHO6XP RU http://adisinsight.springer.com/drugs/800009280 DMHP71R DI DMHP71R DMHP71R DN IQ-DAA DMHP71R TI TT3YGCD DMHP71R TN Bacterial Protective antigen (Bact pagA) DMHP71R MA Modulator DMHP71R RN Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43. DMHP71R RU https://www.ncbi.nlm.nih.gov/pubmed/19207098 DMHP71R DI DMHP71R DMHP71R DN IQ-DAA DMHP71R TI TTIQSC1 DMHP71R TN Bacterial Lethal factor (Bact lef) DMHP71R MA Modulator DMHP71R RN Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43. DMHP71R RU https://www.ncbi.nlm.nih.gov/pubmed/19207098 DMHR7D4 DI DMHR7D4 DMHR7D4 DN REGN-910 DMHR7D4 TI TTKLQTJ DMHR7D4 TN Angiopoietin-2 (ANGPT2) DMHR7D4 RN Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18. DMHR7D4 RU https://pubmed.ncbi.nlm.nih.gov/23149917 DMHRY8A DI DMHRY8A DMHRY8A DN THR-687 DMHRY8A TI TTQFP08 DMHRY8A TN Integrin (ITG) DMHRY8A MA Antagonist DMHRY8A RN The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019 Mar;180:43-52. DMHRY8A RU https://pubmed.ncbi.nlm.nih.gov/30472075 DMHS29U DI DMHS29U DMHS29U DN Iboctadekin DMHS29U TI TTRICUF DMHS29U TN Interleukin-18 (IL18) DMHS29U MA Modulator DMHS29U RN Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78. DMHS29U RU https://pubmed.ncbi.nlm.nih.gov/24777679 DMHS79I DI DMHS79I DMHS79I DN MK-1092 DMHS79I TI TTNVEIR DMHS79I TN Prostaglandin D2 receptor (PTGDR) DMHS79I MA Antagonist DMHS79I RN The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. DMHS79I RU https://pubmed.ncbi.nlm.nih.gov/30528099 DMHT3CB DI DMHT3CB DMHT3CB DN LC-350189 DMHT3CB TI TT7RJY8 DMHT3CB TN Xanthine dehydrogenase/oxidase (XDH) DMHT3CB MA Inhibitor DMHT3CB RN Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. DMHT3CB RU https://pubmed.ncbi.nlm.nih.gov/26357467 DMHT5XV DI DMHT5XV DMHT5XV DN REC-02 DMHT5XV TI TT4UGTF DMHT5XV TN Stromal cell-derived factor 1 (CXCL12) DMHT5XV MA Modulator DMHT5XV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHT5XV RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMHTEZ8 DI DMHTEZ8 DMHTEZ8 DN BMS-986249 DMHTEZ8 TI TTI2S1D DMHTEZ8 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMHTEZ8 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMHTEZ8 RU https://cytomx.com/pipeline/ DMHTNLJ DI DMHTNLJ DMHTNLJ DN CD7.CAR/28zeta CAR T cells DMHTNLJ TI TTP6B8O DMHTNLJ TN T-cell antigen CD7 (CD7) DMHTNLJ MA CAR-T-Cell-Therapy DMHTNLJ RN ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells DMHTNLJ RU https://clinicaltrials.gov/ct2/show/NCT03690011 DMHTWBL DI DMHTWBL DMHTWBL DN MK-8504 DMHTWBL TI TT84ETX DMHTWBL TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMHTWBL MA Inhibitor DMHTWBL RN ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health. DMHTWBL RU https://clinicaltrials.gov/ct2/show/NCT03188523 DMHV58T DI DMHV58T DMHV58T DN Peldesine DMHV58T TI TTMCF1Y DMHV58T TN Purine nucleoside phosphorylase (PNP) DMHV58T MA Inhibitor DMHV58T RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHV58T RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHVIZC DI DMHVIZC DMHVIZC DN NN-7415 DMHVIZC TI TT068JH DMHVIZC TN Tissue factor pathway inhibitor (TFPI) DMHVIZC MA Modulator DMHVIZC RN Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54. DMHVIZC RU https://www.ncbi.nlm.nih.gov/pubmed/25641556 DMHW1LI DI DMHW1LI DMHW1LI DN Iptakalim DMHW1LI TI TT1VOHK DMHW1LI TN Potassium channel unspecific (KC) DMHW1LI MA Opener DMHW1LI RN Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4. DMHW1LI RU https://pubmed.ncbi.nlm.nih.gov/22368410 DMHWVY1 DI DMHWVY1 DMHWVY1 DN CART-19 cells DMHWVY1 TI TTW640A DMHWVY1 TN B-lymphocyte surface antigen B4 (CD19) DMHWVY1 MA CAR-T-Cell-Therapy DMHWVY1 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMHWVY1 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMHXA79 DI DMHXA79 DMHXA79 DN Mesothelin-targeted T cells DMHXA79 TI TT4RXME DMHXA79 TN Mesothelin (MSLN) DMHXA79 MA CAR-T-Cell-Therapy DMHXA79 RN ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer DMHXA79 RU https://clinicaltrials.gov/ct2/show/NCT02792114 DMHYO38 DI DMHYO38 DMHYO38 DN AT-787 DMHYO38 TI TTMVBWH DMHYO38 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMHYO38 MA Inhibitor DMHYO38 RN Clinical pipeline report, company report or official report of Atea Pharmaceuticals. DMHYO38 RU https://ateapharma.com/about-us/hepatitis-c/ DMHZ24N DI DMHZ24N DMHZ24N DN RP-A501 DMHZ24N TI TTULDG7 DMHZ24N TN Lysosome-associated membrane glycoprotein 2 (LAMP2) DMHZ24N MA Replacement DMHZ24N RN ClinicalTrials.gov (NCT03882437) Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B. U.S. National Institutes of Health. DMHZ24N RU https://clinicaltrials.gov/ct2/show/NCT03882437 DMI0KQW DI DMI0KQW DMI0KQW DN HPN217 DMI0KQW TI TTZ3P4W DMI0KQW TN B-cell maturation protein (TNFRSF17) DMI0KQW RN Clinical pipeline report, company report or official report of AbbVie. DMI0KQW RU https://www.abbvie.com/our-science/pipeline/hpn-217.html DMI24RF DI DMI24RF DMI24RF DN OT-82 DMI24RF TI TTD1WIG DMI24RF TN Nicotinamide phosphoribosyltransferase (NAMPT) DMI24RF MA Inhibitor DMI24RF RN OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828-1839. DMI24RF RU https://pubmed.ncbi.nlm.nih.gov/31896781 DMI319T DI DMI319T DMI319T DN GS 9667 DMI319T TI TTK25J1 DMI319T TN Adenosine A1 receptor (ADORA1) DMI319T MA Agonist DMI319T RN Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92. DMI319T RU https://pubmed.ncbi.nlm.nih.gov/23427000 DMI3FU6 DI DMI3FU6 DMI3FU6 DN GSK4074386 DMI3FU6 TI TTNVXAW DMI3FU6 TN Lymphocyte activation gene 3 protein (LAG3) DMI3FU6 MA Inhibitor DMI3FU6 RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMI3FU6 RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMI4O92 DI DMI4O92 DMI4O92 DN LFA-102 DMI4O92 TI TTBPXMA DMI4O92 TN Prolactin receptor (PRLR) DMI4O92 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721). DMI4O92 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1721 DMI4TEC DI DMI4TEC DMI4TEC DN HTI-1090 DMI4TEC TI TTXNCBV DMI4TEC TN Tryptophan 2,3-dioxygenase (TDO) DMI4TEC MA Inhibitor DMI4TEC RN Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263. DMI4TEC RU https://pubmed.ncbi.nlm.nih.gov/30734612 DMI4TEC DI DMI4TEC DMI4TEC DN HTI-1090 DMI4TEC TI TTZJYKH DMI4TEC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI4TEC MA Inhibitor DMI4TEC RN Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263. DMI4TEC RU https://pubmed.ncbi.nlm.nih.gov/30734612 DMI4UY3 DI DMI4UY3 DMI4UY3 DN BNC375 DMI4UY3 TI TTLA931 DMI4UY3 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMI4UY3 MA Modulator DMI4UY3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI4UY3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMI5UEB DI DMI5UEB DMI5UEB DN Unacylated ghrelin DMI5UEB TI TT1OCL0 DMI5UEB TN Ghrelin (GHRL) DMI5UEB MA Inhibitor DMI5UEB RN Alize Pharma signs research collaboration and license option agreement with Lilly. Lyon, France, January 25, 2010. DMI5UEB RU http://www.alz-pharma.com/actualite/alize-pharma-signs-research-collaboration-and-license-option-agreement-with-lilly DMI6EUB DI DMI6EUB DMI6EUB DN Cyclolignan picropodophyllin DMI6EUB TI TTHRID2 DMI6EUB TN Insulin-like growth factor I receptor (IGF1R) DMI6EUB MA Inhibitor DMI6EUB RN The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007 Jul;46(1):108-15. DMI6EUB RU https://pubmed.ncbi.nlm.nih.gov/17606126 DMI7JO6 DI DMI7JO6 DMI7JO6 DN AMG 427 DMI7JO6 TI TTUN7MC DMI7JO6 TN T-cell surface glycoprotein CD3 (CD3) DMI7JO6 MA Inhibitor DMI7JO6 RN Clinical pipeline report, company report or official report of Amgen. DMI7JO6 RU https://www.amgenpipeline.com/ DMI7JO6 DI DMI7JO6 DMI7JO6 DN AMG 427 DMI7JO6 TI TTGJCWZ DMI7JO6 TN Fms-like tyrosine kinase 3 (FLT-3) DMI7JO6 MA Inhibitor DMI7JO6 RN Clinical pipeline report, company report or official report of Amgen. DMI7JO6 RU https://www.amgenpipeline.com/ DMI7XMU DI DMI7XMU DMI7XMU DN CT 868 DMI7XMU TI TTVIMDE DMI7XMU TN Glucagon-like peptide 1 receptor (GLP1R) DMI7XMU MA Modulator DMI7XMU RN Clinical pipeline report, company report or official report of Carmot Therapeutics. DMI7XMU RU http://carmot-therapeutics.us/pipeline/ DMI7XMU DI DMI7XMU DMI7XMU DN CT 868 DMI7XMU TI TTYMKBE DMI7XMU TN Gastric inhibitory polypeptide receptor (GIPR) DMI7XMU MA Modulator DMI7XMU RN Clinical pipeline report, company report or official report of Carmot Therapeutics. DMI7XMU RU http://carmot-therapeutics.us/pipeline/ DMI7ZK3 DI DMI7ZK3 DMI7ZK3 DN NKTT-120 DMI7ZK3 TI TTA6ZER DMI7ZK3 TN Immunoglobulin G1k (IgG1k) DMI7ZK3 RN Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42. DMI7ZK3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374518/ DMI826O DI DMI826O DMI826O DN BP1002 DMI826O TI TTFOUV4 DMI826O TN BCL-2 messenger RNA (BCL2 mRNA) DMI826O MA Inhibitor DMI826O RN Clinical pipeline report, company report or official report of Bio-Path Holdings. DMI826O RU http://dnabilize.com/bp1002/ DMI8795 DI DMI8795 DMI8795 DN UK-371800 DMI8795 TI TTJ0IQB DMI8795 TN Phosphodiesterase 5A (PDE5A) DMI8795 MA Inhibitor DMI8795 RN Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6. DMI8795 RU https://pubmed.ncbi.nlm.nih.gov/18951784 DMI8QNB DI DMI8QNB DMI8QNB DN DFP 13318 DMI8QNB TI TTGTQHC DMI8QNB TN DNA topoisomerase I (TOP1) DMI8QNB MA Inhibitor DMI8QNB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI8QNB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI9A1Z DI DMI9A1Z DMI9A1Z DN FPI-1434 DMI9A1Z TI TTHRID2 DMI9A1Z TN Insulin-like growth factor I receptor (IGF1R) DMI9A1Z RN Clinical pipeline report, company report or official report of Fusion Pharmaceuticals. DMI9A1Z RU https://fusionpharma.com/fusion-pipeline/ DMIAK9P DI DMIAK9P DMIAK9P DN ROR1R-CAR-T Cell DMIAK9P TI TTDEJAU DMIAK9P TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMIAK9P MA CAR-T-Cell-Therapy DMIAK9P RN ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) DMIAK9P RU https://clinicaltrials.gov/ct2/show/NCT02194374 DMIAOU6 DI DMIAOU6 DMIAOU6 DN SLN124 DMIAOU6 TI TTNIUKC DMIAOU6 TN TMPRSS6 messenger RNA (TMPRSS6 mRNA) DMIAOU6 MA Inhibitor DMIAOU6 RN SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301. DMIAOU6 RU https://pubmed.ncbi.nlm.nih.gov/31976476 DMIAVBL DI DMIAVBL DMIAVBL DN Ki23819 DMIAVBL TI TTGJCWZ DMIAVBL TN Fms-like tyrosine kinase 3 (FLT-3) DMIAVBL MA Inhibitor DMIAVBL RN Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia. 2005 Jun;19(6):930-5. DMIAVBL RU https://pubmed.ncbi.nlm.nih.gov/15815726 DMICUPT DI DMICUPT DMICUPT DN 11C-6-Me-BTA-1 DMICUPT TI TTE4KHA DMICUPT TN Amyloid beta A4 protein (APP) DMICUPT MA Modulator DMICUPT RN Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80. DMICUPT RU https://pubmed.ncbi.nlm.nih.gov/18084683 DMICW7D DI DMICW7D DMICW7D DN AZD-3161 DMICW7D TI TTRK8B9 DMICW7D TN Sodium channel unspecific (NaC) DMICW7D MA Modulator DMICW7D RN Recent progress in sodium channel modulators for pain.Bioorganic & Medicinal Chemistry Letters Volume 24, Issue 16, 15 August 2014, Pages 3690-3699. DMICW7D RU http://www.sciencedirect.com/science/article/pii/S0960894X14006660 DMIDEKB DI DMIDEKB DMIDEKB DN AAV2-hFIX16 DMIDEKB TI TTFEZ5Q DMIDEKB TN Coagulation factor IX (F9) DMIDEKB MA Modulator DMIDEKB RN Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739. DMIDEKB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069673/ DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTSKMI8 DMIEAMU TN Phosphodiesterase 4D (PDE4D) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTVIAT9 DMIEAMU TN Phosphodiesterase 4B (PDE4B) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTZ97H5 DMIEAMU TN Phosphodiesterase 4A (PDE4A) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEJ0W DI DMIEJ0W DMIEJ0W DN Radiolabelled-huA33 DMIEJ0W TI TT96HUR DMIEJ0W TN Cell surface A33 antigen (GPA33) DMIEJ0W RN (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. DMIEJ0W RU https://pubmed.ncbi.nlm.nih.gov/21764796 DMIEKTF DI DMIEKTF DMIEKTF DN Alofanib DMIEKTF TI TTGJVQM DMIEKTF TN Fibroblast growth factor receptor 2 (FGFR2) DMIEKTF MA Inhibitor DMIEKTF RN Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156. DMIEKTF RU https://pubmed.ncbi.nlm.nih.gov/27919550 DMIF8RY DI DMIF8RY DMIF8RY DN SUN-K0706 DMIF8RY TI TT6PKBN DMIF8RY TN Proto-oncogene c-Src (SRC) DMIF8RY MA Inhibitor DMIF8RY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIF8RY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIF9DZ DI DMIF9DZ DMIF9DZ DN BGB-3113 DMIF9DZ TI TTGM6VW DMIF9DZ TN Tyrosine-protein kinase BTK (ATK) DMIF9DZ MA Inhibitor DMIF9DZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIF9DZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFJZD DI DMIFJZD DMIFJZD DN AFM11 DMIFJZD TI TTW640A DMIFJZD TN B-lymphocyte surface antigen B4 (CD19) DMIFJZD MA Inhibitor DMIFJZD RN A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604. DMIFJZD RU https://pubmed.ncbi.nlm.nih.gov/25875246 DMIFJZD DI DMIFJZD DMIFJZD DN AFM11 DMIFJZD TI TTUN7MC DMIFJZD TN T-cell surface glycoprotein CD3 (CD3) DMIFJZD MA Inhibitor DMIFJZD RN A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604. DMIFJZD RU https://pubmed.ncbi.nlm.nih.gov/25875246 DMIFSN2 DI DMIFSN2 DMIFSN2 DN GMX1777 DMIFSN2 TI TTD1WIG DMIFSN2 TN Nicotinamide phosphoribosyltransferase (NAMPT) DMIFSN2 MA Modulator DMIFSN2 RN The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88. DMIFSN2 RU https://pubmed.ncbi.nlm.nih.gov/19703994 DMIHC4R DI DMIHC4R DMIHC4R DN RG6146 DMIHC4R TI TTE4BSY DMIHC4R TN Bromodomain and extraterminal domain protein (BET) DMIHC4R MA Inhibitor DMIHC4R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIHC4R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIJSDO DI DMIJSDO DMIJSDO DN AVI-6003 DMIJSDO TI TT3Z102 DMIJSDO TN Ebola virus VP35 messenger RNA (EV VP35 mRNA) DMIJSDO MA Modulator DMIJSDO RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMIJSDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMIJSDO DI DMIJSDO DMIJSDO DN AVI-6003 DMIJSDO TI TTDJLWQ DMIJSDO TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMIJSDO MA Modulator DMIJSDO RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMIJSDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMIKE0O DI DMIKE0O DMIKE0O DN PRT1419 DMIKE0O TI TTL53M6 DMIKE0O TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMIKE0O MA Inhibitor DMIKE0O RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMIKE0O RU https://preludetx.com/science/mcl1/prt1419/ DMIKV9W DI DMIKV9W DMIKV9W DN Utomilumab DMIKV9W TI TTPW9LJ DMIKV9W TN Co-stimulatory molecule 4-1BB (CD137) DMIKV9W MA Agonist DMIKV9W RN First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. DMIKV9W RU https://pubmed.ncbi.nlm.nih.gov/32144134 DMIKX01 DI DMIKX01 DMIKX01 DN CTP-298 DMIKX01 TI TT5FNQT DMIKX01 TN Human immunodeficiency virus Protease (HIV PR) DMIKX01 MA Inhibitor DMIKX01 RN Avanir Licenses Concert's Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal. Vol 2012 Issue 3 Page(38). DMIKX01 RU http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1696/html DMILHMC DI DMILHMC DMILHMC DN CC8464 DMILHMC TI TT4G2JS DMILHMC TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMILHMC MA Inhibitor DMILHMC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMILHMC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMIMH8L DI DMIMH8L DMIMH8L DN ATD transdermal gel DMIMH8L TI TTZAYWL DMIMH8L TN Estrogen receptor (ESR) DMIMH8L MA Inhibitor DMIMH8L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMIMH8L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMIMK84 DI DMIMK84 DMIMK84 DN D2C7 DMIMK84 TI TTGKNB4 DMIMK84 TN Epidermal growth factor receptor (EGFR) DMIMK84 RN Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142. DMIMK84 RU https://pubmed.ncbi.nlm.nih.gov/31142380 DMIMK84 DI DMIMK84 DMIMK84 DN D2C7 DMIMK84 TI TTZ6B2I DMIMK84 TN Epidermal growth factor receptor variant III (EGFR vIII) DMIMK84 RN Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142. DMIMK84 RU https://pubmed.ncbi.nlm.nih.gov/31142380 DMIMVEX DI DMIMVEX DMIMVEX DN MMI-0100 DMIMVEX TI TTMUG9D DMIMVEX TN MAPK-activated protein kinase 2 (MAPKAPK2) DMIMVEX MA Inhibitor DMIMVEX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094). DMIMVEX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2094 DMIQXDJ DI DMIQXDJ DMIQXDJ DN ABBV-151 DMIQXDJ TI TTR9XHZ DMIQXDJ TN Transforming growth factor beta 1 (TGFB1) DMIQXDJ MA Inhibitor DMIQXDJ RN Clinical pipeline report, company report or official report of AbbVie. DMIQXDJ RU https://www.abbvie.com/our-science/pipeline/abbv-151.html DMIR21F DI DMIR21F DMIR21F DN PFK-158 DMIR21F TI TTTHMQJ DMIR21F TN Renal carcinoma antigen NY-REN-56 (PFKFB3) DMIR21F MA Inhibitor DMIR21F RN Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14. DMIR21F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072985/ DMIRX3Z DI DMIRX3Z DMIRX3Z DN BM-212 DMIRX3Z TI TTTLB3R DMIRX3Z TN Mycobacterium Membrane protein mmpL3 (MycB mmpL3) DMIRX3Z MA Modulator DMIRX3Z RN MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. DMIRX3Z RU https://pubmed.ncbi.nlm.nih.gov/22024828 DMIRYM8 DI DMIRYM8 DMIRYM8 DN ALX-0651 DMIRYM8 TI TTBID49 DMIRYM8 TN C-X-C chemokine receptor type 4 (CXCR4) DMIRYM8 MA Inhibitor DMIRYM8 RN Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606. DMIRYM8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011214/ DMIS8BV DI DMIS8BV DMIS8BV DN PMD-026 DMIS8BV TI TTMVQXO DMIS8BV TN Ribosomal protein S6 kinase beta-2 (RPS6KB2) DMIS8BV MA Inhibitor DMIS8BV RN ClinicalTrials.gov (NCT04115306) Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health. DMIS8BV RU https://clinicaltrials.gov/ct2/show/NCT04115306 DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTQOVYA DMITVHM TN C-X-C motif chemokine 10 (CXCL10) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TT95SOA DMITVHM TN Interferon alpha (IFNA) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTGPQ0F DMITVHM TN Prolyl endopeptidase FAP (FAP) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTWE5PB DMITVHM TN C-X-C motif chemokine 9 (CXCL9) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMIV04R DI DMIV04R DMIV04R DN Elpetrigine DMIV04R TI TT5HONZ DMIV04R TN Calcium channel unspecific (CaC) DMIV04R MA Blocker DMIV04R RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMIV04R RU http://www.jazzpharma.com/products/ DMIVGYK DI DMIVGYK DMIVGYK DN SL-801 DMIVGYK TI TTCJUR4 DMIVGYK TN Exportin-1 (XPO1) DMIVGYK MA Inhibitor DMIVGYK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIVGYK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIVHDN DI DMIVHDN DMIVHDN DN GSK2618960 DMIVHDN TI TT8FRMO DMIVHDN TN Interleukin-7 (IL7) DMIVHDN MA Modulator DMIVHDN RN ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health. DMIVHDN RU https://clinicaltrials.gov/ct2/show/NCT02293161 DMIVUX1 DI DMIVUX1 DMIVUX1 DN Anti-EGFR CAR T DMIVUX1 TI TTGKNB4 DMIVUX1 TN Epidermal growth factor receptor (EGFR) DMIVUX1 MA CAR-T-Cell-Therapy DMIVUX1 RN ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR DMIVUX1 RU https://clinicaltrials.gov/ct2/show/NCT02331693 DMIW5NG DI DMIW5NG DMIW5NG DN RG7342 DMIW5NG TI TTHS256 DMIW5NG TN Metabotropic glutamate receptor 5 (mGluR5) DMIW5NG MA Agonist DMIW5NG RN Clinical pipeline report, company report or official report of Roche. DMIW5NG RU http://www.roche.com/irp2q14e-annex.pdf DMIX5HF DI DMIX5HF DMIX5HF DN AAV2/8-LSPhGAA DMIX5HF TI TTHCF4J DMIX5HF TN Alpha-glucosidase (GLA) DMIX5HF RN ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health. DMIX5HF RU https://clinicaltrials.gov/ct2/show/NCT03533673 DMIXABW DI DMIXABW DMIXABW DN Genz-644282 DMIXABW TI TTGTQHC DMIXABW TN DNA topoisomerase I (TOP1) DMIXABW MA Inhibitor DMIXABW RN Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87. DMIXABW RU https://pubmed.ncbi.nlm.nih.gov/21415217 DMIXMQE DI DMIXMQE DMIXMQE DN GAP T cells DMIXMQE TI TTJTSX4 DMIXMQE TN Glypican-3 (GPC3) DMIXMQE MA CAR-T-Cell-Therapy DMIXMQE RN ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) DMIXMQE RU https://clinicaltrials.gov/ct2/show/NCT02932956 DMIYHAW DI DMIYHAW DMIYHAW DN PU-H71 DMIYHAW TI TTH5YN2 DMIYHAW TN Heat shock protein 90 beta (HSP90B) DMIYHAW MA Inhibitor DMIYHAW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIYHAW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIYQEM DI DMIYQEM DMIYQEM DN P-7170 DMIYQEM TI TTHBTOP DMIYQEM TN PI3-kinase gamma (PIK3CG) DMIYQEM MA Inhibitor DMIYQEM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMIYQEM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMJ0Y86 DI DMJ0Y86 DMJ0Y86 DN DV281 DMJ0Y86 TI TTSHG0T DMJ0Y86 TN Toll-like receptor 9 (TLR9) DMJ0Y86 MA Agonist DMJ0Y86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ0Y86 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJ1E24 DI DMJ1E24 DMJ1E24 DN MEDI5752 DMJ1E24 TI TTI2S1D DMJ1E24 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJ1E24 MA Inhibitor DMJ1E24 RN Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. DMJ1E24 RU https://pubmed.ncbi.nlm.nih.gov/33947716 DMJ1E24 DI DMJ1E24 DMJ1E24 DN MEDI5752 DMJ1E24 TI TTNBFWK DMJ1E24 TN Programmed cell death protein 1 (PD-1) DMJ1E24 MA Inhibitor DMJ1E24 RN Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. DMJ1E24 RU https://pubmed.ncbi.nlm.nih.gov/33947716 DMJ1SQY DI DMJ1SQY DMJ1SQY DN 19-28z T CELLS DMJ1SQY TI TTW640A DMJ1SQY TN B-lymphocyte surface antigen B4 (CD19) DMJ1SQY MA CAR-T-Cell-Therapy DMJ1SQY RN ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma DMJ1SQY RU https://clinicaltrials.gov/ct2/show/NCT01840566 DMJ2Q6H DI DMJ2Q6H DMJ2Q6H DN MK-7288 DMJ2Q6H TI TT9JNIC DMJ2Q6H TN Histamine H3 receptor (H3R) DMJ2Q6H MA Agonist DMJ2Q6H RN Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. J Clin Pharmacol. 2013 Dec;53(12):1294-302. DMJ2Q6H RU https://pubmed.ncbi.nlm.nih.gov/24122944 DMJ2R69 DI DMJ2R69 DMJ2R69 DN W-198 DMJ2R69 TI TT3OT40 DMJ2R69 TN Multidrug resistance protein 1 (ABCB1) DMJ2R69 MA Modulator DMJ2R69 RN Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63. DMJ2R69 RU https://pubmed.ncbi.nlm.nih.gov/22739155 DMJ36YH DI DMJ36YH DMJ36YH DN ACE-011 DMJ36YH TI TTO3HT7 DMJ36YH TN Transforming growth factor beta (TGFB) DMJ36YH MA Inhibitor DMJ36YH RN Clinical pipeline report, company report or official report of Acceleron Pharma (2011). DMJ36YH RU http://www.acceleronpharma.com/ DMJ37LH DI DMJ37LH DMJ37LH DN BCMA CART DMJ37LH TI TTZ3P4W DMJ37LH TN B-cell maturation protein (TNFRSF17) DMJ37LH MA CAR-T-Cell-Therapy DMJ37LH RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DMJ37LH RU https://clinicaltrials.gov/ct2/show/NCT03549442 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TTKWM86 DMJ3HQY TN Opioid receptor mu (MOP) DMJ3HQY MA Inhibitor DMJ3HQY RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TT27RFC DMJ3HQY TN Opioid receptor delta (OPRD1) DMJ3HQY MA Inhibitor DMJ3HQY RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TTQW87Y DMJ3HQY TN Opioid receptor kappa (OPRK1) DMJ3HQY MA Inhibitor DMJ3HQY RN Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem. 2008 Mar 27;51(6):1824-30. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18293909 DMJ3PNS DI DMJ3PNS DMJ3PNS DN P-2745 DMJ3PNS TI TTP4520 DMJ3PNS TN TGF-beta receptor type I (TGFBR1) DMJ3PNS MA Modulator DMJ3PNS RN Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822. DMJ3PNS RU http://cancerres.aacrjournals.org/content/72/8_Supplement/1822.short DMJ4W5V DI DMJ4W5V DMJ4W5V DN BCMA CAR-T Cells DMJ4W5V TI TTZ3P4W DMJ4W5V TN B-cell maturation protein (TNFRSF17) DMJ4W5V MA CAR-T-Cell-Therapy DMJ4W5V RN ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma DMJ4W5V RU https://clinicaltrials.gov/ct2/show/NCT03661554 DMJ52F9 DI DMJ52F9 DMJ52F9 DN HER2p63-71 peptide vaccine DMJ52F9 TI TT6EO5L DMJ52F9 TN Erbb2 tyrosine kinase receptor (HER2) DMJ52F9 RN Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82. DMJ52F9 RU https://pubmed.ncbi.nlm.nih.gov/10950153 DMJ56MS DI DMJ56MS DMJ56MS DN BUTYLATEDHYDROXYTOLUENE DMJ56MS TI TTANPDJ DMJ56MS TN Carbonic anhydrase II (CA-II) DMJ56MS MA Inhibitor DMJ56MS RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMJ56MS RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMJ7WRI DI DMJ7WRI DMJ7WRI DN GCC-1290K DMJ7WRI TI TTCRJKY DMJ7WRI TN Voltage-gated calcium channel (Cav) DMJ7WRI MA Modulator DMJ7WRI RN Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34. DMJ7WRI RU https://pubmed.ncbi.nlm.nih.gov/19428798 DMJ7WRI DI DMJ7WRI DMJ7WRI DN GCC-1290K DMJ7WRI TI TTYVX59 DMJ7WRI TN Protein kinase C (PRKC) DMJ7WRI MA Modulator DMJ7WRI RN Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34. DMJ7WRI RU https://pubmed.ncbi.nlm.nih.gov/19428798 DMJ83Z7 DI DMJ83Z7 DMJ83Z7 DN CYT-609 DMJ83Z7 TI TTF8CQI DMJ83Z7 TN Tumor necrosis factor (TNF) DMJ83Z7 MA Modulator DMJ83Z7 RN Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149. DMJ83Z7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004980/ DMJ8ACF DI DMJ8ACF DMJ8ACF DN ALX-0761 DMJ8ACF TI TTG0MT6 DMJ8ACF TN Interleukin-17 (IL17) DMJ8ACF MA Modulator DMJ8ACF RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMJ8ACF RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJ8ACF DI DMJ8ACF DMJ8ACF DN ALX-0761 DMJ8ACF TI TTVMO5W DMJ8ACF TN Interleukin-25 (IL25) DMJ8ACF MA Modulator DMJ8ACF RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMJ8ACF RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJA27W DI DMJA27W DMJA27W DN GDC-5573 DMJA27W TI TTB18GJ DMJA27W TN Proto-oncogene c-RAF (c-RAF) DMJA27W MA Inhibitor DMJA27W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJA27W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJA3H1 DI DMJA3H1 DMJA3H1 DN Anti-CEA-CAR T DMJA3H1 TI TTY6DTE DMJA3H1 TN Carcinoembryonic antigen CEA (CD66e) DMJA3H1 MA CAR-T-Cell-Therapy DMJA3H1 RN ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer DMJA3H1 RU https://clinicaltrials.gov/ct2/show/NCT02349724 DMJAPRK DI DMJAPRK DMJAPRK DN STX 64 DMJAPRK TI TTHM0R1 DMJAPRK TN Steryl-sulfatase (STS) DMJAPRK MA Inhibitor DMJAPRK RN Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006 Mar 1;12(5):1585-92. DMJAPRK RU https://pubmed.ncbi.nlm.nih.gov/16533785 DMJAVN7 DI DMJAVN7 DMJAVN7 DN GSK3186899 DMJAVN7 TI TTJ21A9 DMJAVN7 TN Cyclin-dependent kinase 12 (CDK12) DMJAVN7 MA Inhibitor DMJAVN7 RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMJAVN7 RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMJB6E2 DI DMJB6E2 DMJB6E2 DN 99mTc-MIP-1405 DMJB6E2 TI TT9G4N0 DMJB6E2 TN Glutamate carboxypeptidase II (GCPII) DMJB6E2 MA Modulator DMJB6E2 RN 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76. DMJB6E2 RU https://pubmed.ncbi.nlm.nih.gov/23733925 DMJCIGN DI DMJCIGN DMJCIGN DN CC-95775 DMJCIGN TI TTE4BSY DMJCIGN TN Bromodomain and extraterminal domain protein (BET) DMJCIGN MA Inhibitor DMJCIGN RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMJCIGN RU https://www.bms.com/researchers-and-partners/in-the-pipeline.html DMJCQKA DI DMJCQKA DMJCQKA DN Sphingosine-1-Phosphate DMJCQKA TI TT9JZCK DMJCQKA TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMJCQKA MA Inhibitor DMJCQKA RN Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4. DMJCQKA RU https://pubmed.ncbi.nlm.nih.gov/20304639 DMJCT6Q DI DMJCT6Q DMJCT6Q DN CD19 CAR T-cells DMJCT6Q TI TTW640A DMJCT6Q TN B-lymphocyte surface antigen B4 (CD19) DMJCT6Q MA CAR-T-Cell-Therapy DMJCT6Q RN ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies DMJCT6Q RU https://clinicaltrials.gov/ct2/show/NCT02443831 DMJCX6D DI DMJCX6D DMJCX6D DN ASN003 DMJCX6D TI TTWCGQT DMJCX6D TN Serine/threonine-protein kinase B-raf (BRAF) DMJCX6D MA Inhibitor DMJCX6D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCX6D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJDP0E DI DMJDP0E DMJDP0E DN DSP-1053 DMJDP0E TI TTSQIFT DMJDP0E TN 5-HT 1A receptor (HTR1A) DMJDP0E MA Antagonist DMJDP0E RN DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect. 2015 Jun;3(3):e00142. DMJDP0E RU https://pubmed.ncbi.nlm.nih.gov/26171224 DMJDVW4 DI DMJDVW4 DMJDVW4 DN GSK2816126 DMJDVW4 TI TT9MZCQ DMJDVW4 TN Enhancer of zeste homolog 2 (EZH2) DMJDVW4 MA Modulator DMJDVW4 RN National Cancer Institute Drug Dictionary (drug id 756211). DMJDVW4 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756211 DMJEACT DI DMJEACT DMJEACT DN LC-1 DMJEACT TI TTSXVID DMJEACT TN Nuclear factor NF-kappa-B (NFKB) DMJEACT MA Inhibitor DMJEACT RN A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494. DMJEACT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982935/ DMJEBK8 DI DMJEBK8 DMJEBK8 DN TCD-717 DMJEBK8 TI TT10AWB DMJEBK8 TN Choline kinase (CHKA) DMJEBK8 MA Inhibitor DMJEBK8 RN National Cancer Institute Drug Dictionary (drug id 687183). DMJEBK8 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=687183 DMJFK6X DI DMJFK6X DMJFK6X DN JNJ-63898081 DMJFK6X TI TT9G4N0 DMJFK6X TN Glutamate carboxypeptidase II (GCPII) DMJFK6X MA Inhibitor DMJFK6X RN Clinical pipeline report, company report or official report of Genmab. DMJFK6X RU https://www.genmab.com/pipeline/ DMJFKW3 DI DMJFKW3 DMJFKW3 DN AMG 595 DMJFKW3 TI TTGKNB4 DMJFKW3 TN Epidermal growth factor receptor (EGFR) DMJFKW3 MA Modulator DMJFKW3 RN AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24. DMJFKW3 RU https://pubmed.ncbi.nlm.nih.gov/25931519 DMJFM3O DI DMJFM3O DMJFM3O DN RG6139 DMJFM3O TI TTNBFWK DMJFM3O TN Programmed cell death protein 1 (PD-1) DMJFM3O MA Inhibitor DMJFM3O RN Clinical pipeline report, company report or official report of Genentech. DMJFM3O RU https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html DMJFM3O DI DMJFM3O DMJFM3O DN RG6139 DMJFM3O TI TTNVXAW DMJFM3O TN Lymphocyte activation gene 3 protein (LAG3) DMJFM3O MA Inhibitor DMJFM3O RN Clinical pipeline report, company report or official report of Genentech. DMJFM3O RU https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html DMJFPK6 DI DMJFPK6 DMJFPK6 DN CIGB-228 DMJFPK6 TI TT3CPZW DMJFPK6 TN Human papillomavirus protein E7 (HPV E7) DMJFPK6 RN Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951. DMJFPK6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/ DMJFWPR DI DMJFWPR DMJFWPR DN ABT-102 DMJFWPR TI TTMI6F5 DMJFWPR TN Transient receptor potential cation channel V1 (TRPV1) DMJFWPR MA Blocker DMJFWPR RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMJFWPR RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMJG7AY DI DMJG7AY DMJG7AY DN TD-1473 DMJG7AY TI TTJSQEF DMJG7AY TN Tyrosine-protein kinase (PTK) DMJG7AY MA Inhibitor DMJG7AY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJG7AY RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMJIH83 DI DMJIH83 DMJIH83 DN XmAb20717 DMJIH83 TI TTI2S1D DMJIH83 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJIH83 RN Clinical pipeline report, company report or official report of Xencor. DMJIH83 RU https://xencor.com/pipeline/xmab20717/ DMJIH83 DI DMJIH83 DMJIH83 DN XmAb20717 DMJIH83 TI TTNBFWK DMJIH83 TN Programmed cell death protein 1 (PD-1) DMJIH83 RN Clinical pipeline report, company report or official report of Xencor. DMJIH83 RU https://xencor.com/pipeline/xmab20717/ DMJIW5Z DI DMJIW5Z DMJIW5Z DN CD19-CAR-T Cells DMJIW5Z TI TTW640A DMJIW5Z TN B-lymphocyte surface antigen B4 (CD19) DMJIW5Z MA CAR-T-Cell-Therapy DMJIW5Z RN ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL DMJIW5Z RU https://clinicaltrials.gov/ct2/show/NCT03574168 DMJK1R0 DI DMJK1R0 DMJK1R0 DN CAR-T cells targeting CD19 DMJK1R0 TI TTW640A DMJK1R0 TN B-lymphocyte surface antigen B4 (CD19) DMJK1R0 MA CAR-T-Cell-Therapy DMJK1R0 RN ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma DMJK1R0 RU https://clinicaltrials.gov/ct2/show/NCT03086954 DMJK7V0 DI DMJK7V0 DMJK7V0 DN Ge2270a DMJK7V0 TI TTG45NU DMJK7V0 TN Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) DMJK7V0 MA Inhibitor DMJK7V0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJK7V0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJKBWO DI DMJKBWO DMJKBWO DN HER2-specific CAR T cell DMJKBWO TI TT6EO5L DMJKBWO TN Erbb2 tyrosine kinase receptor (HER2) DMJKBWO MA CAR-T-Cell-Therapy DMJKBWO RN ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors DMJKBWO RU https://clinicaltrials.gov/ct2/show/NCT03500991 DMJLIQ2 DI DMJLIQ2 DMJLIQ2 DN GALAMUSTINE HYDROCHLORIDE DMJLIQ2 TI TTUTN1I DMJLIQ2 TN Human Deoxyribonucleic acid (hDNA) DMJLIQ2 MA Antagonist DMJLIQ2 RN 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9. DMJLIQ2 RU https://pubmed.ncbi.nlm.nih.gov/3802075 DMJLNEF DI DMJLNEF DMJLNEF DN Cipatinib DMJLNEF TI TTGKNB4 DMJLNEF TN Epidermal growth factor receptor (EGFR) DMJLNEF MA Modulator DMJLNEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJLNEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJLNEF DI DMJLNEF DMJLNEF DN Cipatinib DMJLNEF TI TT6EO5L DMJLNEF TN Erbb2 tyrosine kinase receptor (HER2) DMJLNEF MA Modulator DMJLNEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJLNEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJLZ8T DI DMJLZ8T DMJLZ8T DN CHT-25 DMJLZ8T TI TT10Y9E DMJLZ8T TN Interleukin 2 receptor alpha (IL2RA) DMJLZ8T MA Modulator DMJLZ8T RN A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710. DMJLZ8T RU https://pubmed.ncbi.nlm.nih.gov/20008855 DMJNFI2 DI DMJNFI2 DMJNFI2 DN BMEC-1217B DMJNFI2 TI TTFTSHD DMJNFI2 TN Cytokine unspecific (CYK) DMJNFI2 MA Regulator DMJNFI2 RN ClinicalTrials.gov (NCT00425971) Safety Study of Anti-Asthma Agent BMEC-1217B. U.S. National Institutes of Health. DMJNFI2 RU https://clinicaltrials.gov/ct2/show/NCT00425971 DMJO0BP DI DMJO0BP DMJO0BP DN PU3 DMJO0BP TI TT78R5H DMJO0BP TN Heat shock protein 90 alpha (HSP90A) DMJO0BP MA Inhibitor DMJO0BP RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMJO0BP RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMJOMD4 DI DMJOMD4 DMJOMD4 DN MP-0112 DMJOMD4 TI TTOHSBA DMJOMD4 TN Vascular endothelial growth factor A (VEGFA) DMJOMD4 MA Inhibitor DMJOMD4 RN Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2. DMJOMD4 RU https://pubmed.ncbi.nlm.nih.gov/24907435 DMJP83V DI DMJP83V DMJP83V DN Gene therapy, IFN-b DMJP83V TI TT4TZ8J DMJP83V TN Interferon-beta (IFNB1) DMJP83V MA Modulator DMJP83V RN Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65. DMJP83V RU https://pubmed.ncbi.nlm.nih.gov/15546502 DMJPCHK DI DMJPCHK DMJPCHK DN LY309887 DMJPCHK TI TTEXB9Z DMJPCHK TN Glycinamide ribonucleotide formyltransferase (GART) DMJPCHK MA Inhibitor DMJPCHK RN New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7. DMJPCHK RU https://pubmed.ncbi.nlm.nih.gov/9717984 DMJPEVA DI DMJPEVA DMJPEVA DN CNTX-0290 DMJPEVA TI TTAE1BR DMJPEVA TN Somatostatin receptor type 4 (SSTR4) DMJPEVA MA Agonist DMJPEVA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJPEVA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJPUDW DI DMJPUDW DMJPUDW DN DS-8273 DMJPUDW TI TTW20TU DMJPUDW TN TRAIL receptor 2 (TRAIL-R2) DMJPUDW MA Agonist DMJPUDW RN First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306. DMJPUDW RU https://pubmed.ncbi.nlm.nih.gov/28050790 DMJPXZ4 DI DMJPXZ4 DMJPXZ4 DN GSK618334 DMJPXZ4 TI TT4C8EA DMJPXZ4 TN Dopamine D3 receptor (D3R) DMJPXZ4 MA Antagonist DMJPXZ4 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMJPXZ4 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMJPXZ4 DI DMJPXZ4 DMJPXZ4 DN GSK618334 DMJPXZ4 TI TTOHFIY DMJPXZ4 TN Sphingosine kinase 1 (SPHK1) DMJPXZ4 MA Inhibitor DMJPXZ4 RN Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. DMJPXZ4 RU https://pubmed.ncbi.nlm.nih.gov/27811359 DMJQDUC DI DMJQDUC DMJQDUC DN Aminoguanidine DMJQDUC TI TTFZYTO DMJQDUC TN C-C chemokine receptor type 2 (CCR2) DMJQDUC MA Antagonist DMJQDUC RN Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005. DMJQDUC RU http://www.aegis.com/news/bw/2005/BW050801.html DMJQDUC DI DMJQDUC DMJQDUC DN Aminoguanidine DMJQDUC TI TTF10I9 DMJQDUC TN Nitric-oxide synthase inducible (NOS2) DMJQDUC MA Inhibitor DMJQDUC RN Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800. DMJQDUC RU https://pubmed.ncbi.nlm.nih.gov/19572977 DMJQG25 DI DMJQG25 DMJQG25 DN CLX-0921 DMJQG25 TI TTZMAO3 DMJQG25 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJQG25 MA Agonist DMJQG25 RN A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. DMJQG25 RU https://pubmed.ncbi.nlm.nih.gov/12898466 DMJQHTN DI DMJQHTN DMJQHTN DN WCK-1152 DMJQHTN TI TTIXTO3 DMJQHTN TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMJQHTN MA Modulator DMJQHTN RN DOI: 10.1093/jac/dki361 DMJQHTN RU http://jac.oxfordjournals.org/content/56/6/1130.full.pdf DMJR6TC DI DMJR6TC DMJR6TC DN 90Y-cG250 DMJR6TC TI TT2LVK8 DMJR6TC TN Carbonic anhydrase IX (CA-IX) DMJR6TC RN Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23. DMJR6TC RU https://pubmed.ncbi.nlm.nih.gov/23759990 DMJRALD DI DMJRALD DMJRALD DN LIPO-4 DMJRALD TI TTN2JFW DMJRALD TN T-cell surface glycoprotein CD4 (CD4) DMJRALD RN Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15. DMJRALD RU https://pubmed.ncbi.nlm.nih.gov/23850610 DMJRALD DI DMJRALD DMJRALD DN LIPO-4 DMJRALD TI TTMHA6L DMJRALD TN T-cell surface glycoprotein CD8 (CD8) DMJRALD RN Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15. DMJRALD RU https://pubmed.ncbi.nlm.nih.gov/23850610 DMJSFTX DI DMJSFTX DMJSFTX DN CPI-006 DMJSFTX TI TTK0O6Y DMJSFTX TN Ecto-5'-nucleotidase (CD73) DMJSFTX RN Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. DMJSFTX RU https://www.corvuspharma.com/our-science/our-pipeline/ DMJSX9N DI DMJSX9N DMJSX9N DN V-24343 DMJSX9N TI TT6OEDT DMJSX9N TN Cannabinoid receptor 1 (CB1) DMJSX9N MA Antagonist DMJSX9N RN Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65. DMJSX9N RU https://pubmed.ncbi.nlm.nih.gov/19249987 DMJVCS1 DI DMJVCS1 DMJVCS1 DN RWJ-671818 DMJVCS1 TI TT6L509 DMJVCS1 TN Coagulation factor IIa (F2) DMJVCS1 MA Modulator DMJVCS1 RN Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56. DMJVCS1 RU https://pubmed.ncbi.nlm.nih.gov/20102150 DMJVL57 DI DMJVL57 DMJVL57 DN XEN1101 DMJVL57 TI TTIVDM3 DMJVL57 TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMJVL57 MA Activator DMJVL57 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJVL57 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJVZBC DI DMJVZBC DMJVZBC DN TP-0184 DMJVZBC TI TTJNBQA DMJVZBC TN Activin receptor-like kinase 2 (ALK-2) DMJVZBC MA Inhibitor DMJVZBC RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMJVZBC RU https://www.sdponcology.com/pipeline/ DMJVZBC DI DMJVZBC DMJVZBC DN TP-0184 DMJVZBC TI TTP4520 DMJVZBC TN TGF-beta receptor type I (TGFBR1) DMJVZBC MA Inhibitor DMJVZBC RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMJVZBC RU https://www.sdponcology.com/pipeline/ DMJW4TP DI DMJW4TP DMJW4TP DN Autologous ET1402L1-CART cells DMJW4TP TI TT3WAD0 DMJW4TP TN HLA-A02/AFP complex (HLA-A02/AFP) DMJW4TP MA CAR-T-Cell-Therapy DMJW4TP RN ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma DMJW4TP RU https://clinicaltrials.gov/ct2/show/NCT03349255 DMJW5R0 DI DMJW5R0 DMJW5R0 DN SI-B003 DMJW5R0 TI TTI2S1D DMJW5R0 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJW5R0 RN Clinical pipeline report, company report or official report of SystImmune. DMJW5R0 RU https://systimmune.com/pipeline.html DMJW5R0 DI DMJW5R0 DMJW5R0 DN SI-B003 DMJW5R0 TI TTNBFWK DMJW5R0 TN Programmed cell death protein 1 (PD-1) DMJW5R0 RN Clinical pipeline report, company report or official report of SystImmune. DMJW5R0 RU https://systimmune.com/pipeline.html DMJX6SM DI DMJX6SM DMJX6SM DN CKD-712 DMJX6SM TI TTKAWRQ DMJX6SM TN JAK-STAT signaling pathway (JAK-STAT pathway) DMJX6SM MA Inhibitor DMJX6SM RN HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008 Oct;20(10):1839-47. DMJX6SM RU https://pubmed.ncbi.nlm.nih.gov/18634870 DMJXBVP DI DMJXBVP DMJXBVP DN TAS-119 DMJXBVP TI TTPS3C0 DMJXBVP TN Aurora kinase A (AURKA) DMJXBVP MA Inhibitor DMJXBVP RN TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268. DMJXBVP RU http://mct.aacrjournals.org/content/12/11_Supplement/A268.short DMJY15D DI DMJY15D DMJY15D DN PWT-33597 DMJY15D TI TTCJG29 DMJY15D TN Serine/threonine-protein kinase mTOR (mTOR) DMJY15D MA Modulator DMJY15D RN PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials DMJY15D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862 DMJY15D DI DMJY15D DMJY15D DN PWT-33597 DMJY15D TI TTEUNMR DMJY15D TN PI3-kinase alpha (PIK3CA) DMJY15D MA Modulator DMJY15D RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJY15D RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJY35M DI DMJY35M DMJY35M DN AVE1701 DMJY35M TI TTC24WT DMJY35M TN C-C chemokine receptor type 1 (CCR1) DMJY35M MA Antagonist DMJY35M RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMJY35M RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMJY9TW DI DMJY9TW DMJY9TW DN DRF-1042 DMJY9TW TI TTGTQHC DMJY9TW TN DNA topoisomerase I (TOP1) DMJY9TW MA Inhibitor DMJY9TW RN Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. DMJY9TW RU https://pubmed.ncbi.nlm.nih.gov/15778426 DMK09D4 DI DMK09D4 DMK09D4 DN ASC09 + ritonavir DMK09D4 TI TT1D53B DMK09D4 TN COVID-19 3C-like protease (3CLpro) DMK09D4 MA Inhibitor DMK09D4 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMK09D4 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMK0AW6 DI DMK0AW6 DMK0AW6 DN XOMA-3AB DMK0AW6 TI TTB52WU DMK0AW6 TN Bacterial Botulinum toxin A (Bact botA) DMK0AW6 RN Clinical pipeline report, company report or official report of XOMA. DMK0AW6 RU http://www.xoma.com/content/pipeline/biodefense.htm DMK0BTN DI DMK0BTN DMK0BTN DN KQ-791 DMK0BTN TI TTMS7KP DMK0BTN TN Protein-tyrosine phosphatase 1B (PTP1B) DMK0BTN MA Antagonist DMK0BTN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK0BTN RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK0QDO DI DMK0QDO DMK0QDO DN CC-90002 DMK0QDO TI TT28S46 DMK0QDO TN Leukocyte surface antigen CD47 (CD47) DMK0QDO MA Inhibitor DMK0QDO RN National Cancer Institute Drug Dictionary (drug name CC 90002). DMK0QDO RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd47-monoclonal-antibody-cc-90002 DMK19V6 DI DMK19V6 DMK19V6 DN PF-06671008 DMK19V6 TI TTARMD9 DMK19V6 TN Placental cadherin (CDH3) DMK19V6 MA Immunomodulator DMK19V6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK19V6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMK25QD DI DMK25QD DMK25QD DN Anti-BCMA CAR-T cells DMK25QD TI TTZ3P4W DMK25QD TN B-cell maturation protein (TNFRSF17) DMK25QD MA CAR-T-Cell-Therapy DMK25QD RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMK25QD RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMK3S9J DI DMK3S9J DMK3S9J DN GSK1144814 DMK3S9J TI TTBPGLU DMK3S9J TN Neuromedin-K receptor (TACR3) DMK3S9J MA Modulator DMK3S9J RN Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39. DMK3S9J RU https://www.ncbi.nlm.nih.gov/pubmed/23067311 DMK3S9J DI DMK3S9J DMK3S9J DN GSK1144814 DMK3S9J TI TTZPO1L DMK3S9J TN Substance-P receptor (TACR1) DMK3S9J MA Modulator DMK3S9J RN Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39. DMK3S9J RU https://www.ncbi.nlm.nih.gov/pubmed/23067311 DMK48PM DI DMK48PM DMK48PM DN SY-1365 DMK48PM TI TTQYF7G DMK48PM TN Cyclin-dependent kinase 7 (CDK7) DMK48PM MA Inhibitor DMK48PM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK48PM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK4GIS DI DMK4GIS DMK4GIS DN Anti-hCD70 CAR transduced PBL DMK4GIS TI TTNCIE0 DMK4GIS TN CD70 antigen (CD27-L) DMK4GIS MA CAR-T-Cell-Therapy DMK4GIS RN ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers DMK4GIS RU https://clinicaltrials.gov/ct2/show/NCT02830724 DMK4PWM DI DMK4PWM DMK4PWM DN PLX-5622 DMK4PWM TI TTC70AJ DMK4PWM TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMK4PWM MA Inhibitor DMK4PWM RN Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527. DMK4PWM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356419/ DMK6P9J DI DMK6P9J DMK6P9J DN RG7741 DMK6P9J TI TTTU902 DMK6P9J TN Checkpoint kinase-1 (CHK1) DMK6P9J MA Modulator DMK6P9J RN National Cancer Institute Drug Dictionary (drug id 730054). DMK6P9J RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=730054 DMK7BND DI DMK7BND DMK7BND DN Briciclib DMK7BND TI TTFCJ7S DMK7BND TN G1/S-specific cyclin-D1 (CCND1) DMK7BND MA Inhibitor DMK7BND RN Clinical pipeline report, company report or official report of Onconova. DMK7BND RU http://www.onconova.com/product-pipeline/briciclib.php DMK7UNL DI DMK7UNL DMK7UNL DN M-0004 DMK7UNL TI TT07C3Y DMK7UNL TN 5-HT 4 receptor (HTR4) DMK7UNL MA Agonist DMK7UNL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMK7UNL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMK96CE DI DMK96CE DMK96CE DN GC-1113 DMK96CE TI TTQG4NR DMK96CE TN Erythropoietin (EPO) DMK96CE MA Modulator DMK96CE RN A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9. DMK96CE RU https://pubmed.ncbi.nlm.nih.gov/22644842 DMK9XUQ DI DMK9XUQ DMK9XUQ DN XmAb23104 DMK9XUQ TI TTNBFWK DMK9XUQ TN Programmed cell death protein 1 (PD-1) DMK9XUQ RN Clinical pipeline report, company report or official report of Xencor. DMK9XUQ RU https://xencor.com/pipeline/xmab23104/ DMK9XUQ DI DMK9XUQ DMK9XUQ DN XmAb23104 DMK9XUQ TI TTE5VP6 DMK9XUQ TN Inducible T-cell costimulator (ICOS) DMK9XUQ RN Clinical pipeline report, company report or official report of Xencor. DMK9XUQ RU https://xencor.com/pipeline/xmab23104/ DMK9Y71 DI DMK9Y71 DMK9Y71 DN Recombinant human Erbb3 fragment therapeutic tumor vaccine DMK9Y71 TI TTDC8N2 DMK9Y71 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMK9Y71 RN Clinical pipeline report, company report or official report of Zensun. DMK9Y71 RU http://www.zensunusa.com/research/ DMK9Y71 DI DMK9Y71 DMK9Y71 DN Recombinant human Erbb3 fragment therapeutic tumor vaccine DMK9Y71 TI TT6EO5L DMK9Y71 TN Erbb2 tyrosine kinase receptor (HER2) DMK9Y71 RN Clinical pipeline report, company report or official report of Zensun. DMK9Y71 RU http://www.zensunusa.com/research/ DMKA2FL DI DMKA2FL DMKA2FL DN CD19/CD22 CAR T-Cells DMKA2FL TI TTM6QSK DMKA2FL TN B-cell receptor CD22 (CD22) DMKA2FL MA CAR-T-Cell-Therapy(Dual specific) DMKA2FL RN ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies DMKA2FL RU https://clinicaltrials.gov/ct2/show/NCT03448393 DMKA2FL DI DMKA2FL DMKA2FL DN CD19/CD22 CAR T-Cells DMKA2FL TI TTW640A DMKA2FL TN B-lymphocyte surface antigen B4 (CD19) DMKA2FL MA CAR-T-Cell-Therapy(Dual specific) DMKA2FL RN ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies DMKA2FL RU https://clinicaltrials.gov/ct2/show/NCT03448393 DMKCRMD DI DMKCRMD DMKCRMD DN AVB-S6-500 DMKCRMD TI TTZPY6J DMKCRMD TN Tyrosine-protein kinase UFO (AXL) DMKCRMD MA Inhibitor DMKCRMD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKCRMD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKF1O2 DI DMKF1O2 DMKF1O2 DN AMG 119 DMKF1O2 TI TT1C9K6 DMKF1O2 TN Delta-like protein 3 (DLL3) DMKF1O2 MA Inhibitor DMKF1O2 RN Clinical pipeline report, company report or official report of Amgen. DMKF1O2 RU https://www.amgenpipeline.com/ DMKFVX5 DI DMKFVX5 DMKFVX5 DN KUL-7211 DMKFVX5 TI TT2CJVK DMKFVX5 TN Adrenergic receptor beta-2 (ADRB2) DMKFVX5 MA Modulator DMKFVX5 RN The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14. DMKFVX5 RU https://www.ncbi.nlm.nih.gov/pubmed/16133579 DMKFVX5 DI DMKFVX5 DMKFVX5 DN KUL-7211 DMKFVX5 TI TTMXGCW DMKFVX5 TN Adrenergic receptor beta-3 (ADRB3) DMKFVX5 MA Modulator DMKFVX5 RN The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14. DMKFVX5 RU https://www.ncbi.nlm.nih.gov/pubmed/16133579 DMKH3Z9 DI DMKH3Z9 DMKH3Z9 DN CC-90010 DMKH3Z9 TI TTE4BSY DMKH3Z9 TN Bromodomain and extraterminal domain protein (BET) DMKH3Z9 MA Inhibitor DMKH3Z9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKH3Z9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKHM7O DI DMKHM7O DMKHM7O DN SAR-126119 DMKHM7O TI TTP18AY DMKHM7O TN Carboxypeptidase B2 (CPB2) DMKHM7O MA Inhibitor DMKHM7O RN TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6. DMKHM7O RU https://pubmed.ncbi.nlm.nih.gov/18600565 DMKHVNE DI DMKHVNE DMKHVNE DN YKP-1358 DMKHVNE TI TTJQOD7 DMKHVNE TN 5-HT 2A receptor (HTR2A) DMKHVNE MA Modulator DMKHVNE RN Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8. DMKHVNE RU https://pubmed.ncbi.nlm.nih.gov/17259948 DMKHVNE DI DMKHVNE DMKHVNE DN YKP-1358 DMKHVNE TI TTEX248 DMKHVNE TN Dopamine D2 receptor (D2R) DMKHVNE MA Modulator DMKHVNE RN Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8. DMKHVNE RU https://pubmed.ncbi.nlm.nih.gov/17259948 DMKJRQS DI DMKJRQS DMKJRQS DN NCX-1015 DMKJRQS TI TTYRL6O DMKJRQS TN Glucocorticoid receptor (NR3C1) DMKJRQS MA Modulator DMKJRQS RN Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol. 2003 Sep 15;171(6):3245-52. DMKJRQS RU https://pubmed.ncbi.nlm.nih.gov/12960354 DMKL92E DI DMKL92E DMKL92E DN Anti-CD22 CAR-T cells DMKL92E TI TTM6QSK DMKL92E TN B-cell receptor CD22 (CD22) DMKL92E MA CAR-T-Cell-Therapy DMKL92E RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMKL92E RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMKMN5R DI DMKMN5R DMKMN5R DN KUR-501 DMKMN5R TI TT80ARU DMKMN5R TN Ganglioside GD2 (GD2) DMKMN5R RN Clinical pipeline report, company report or official report of Kuur Therapeutics. DMKMN5R RU https://kuurtx.com/product-overview/ DMKMR2X DI DMKMR2X DMKMR2X DN ERB-257 DMKMR2X TI TTOM3J0 DMKMR2X TN Estrogen receptor beta (ESR2) DMKMR2X MA Agonist DMKMR2X RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030075) DMKMR2X RU http://adisinsight.springer.com/drugs/800030075 DMKMU2S DI DMKMU2S DMKMU2S DN GNX102 DMKMU2S TI TTZUFEL DMKMU2S TN Tumor-associated glycan antigen (TAGA) DMKMU2S RN Clinical pipeline report, company report or official report of GlycoNex. DMKMU2S RU http://www.glyconex.com.tw/index.php/en-us/product-pipeline-us DMKN8XD DI DMKN8XD DMKN8XD DN CART-38 cells DMKN8XD TI TTPURFN DMKN8XD TN Cyclic ADP-ribose hydrolase 1 (CD38) DMKN8XD MA CAR-T-Cell-Therapy DMKN8XD RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMKN8XD RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMKNH8B DI DMKNH8B DMKNH8B DN MK-2118 DMKNH8B TI TTT402Y DMKNH8B TN Stimulator of interferon genes protein (TMEM173) DMKNH8B MA Agonist DMKNH8B RN National Cancer Institute Drug Dictionary (drug name ML2118). DMKNH8B RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-2118 DMKNMAE DI DMKNMAE DMKNMAE DN Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 DMKNMAE TI TTZ3P4W DMKNMAE TN B-cell maturation protein (TNFRSF17) DMKNMAE MA CAR-T-Cell-Therapy DMKNMAE RN ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma DMKNMAE RU https://clinicaltrials.gov/ct2/show/NCT03338972 DMKO7EA DI DMKO7EA DMKO7EA DN ISF-402 DMKO7EA TI TTCBFJO DMKO7EA TN Insulin receptor (INSR) DMKO7EA MA Modulator DMKO7EA RN Ability of GHTD-amide and analogs to enhance insulin activity through zinc chelation and dispersal of insulin oligomers. Peptides. 2009 Jun;30(6):1088-97. DMKO7EA RU https://pubmed.ncbi.nlm.nih.gov/19463741 DMKOE84 DI DMKOE84 DMKOE84 DN PF-4603629 DMKOE84 TI TTVIMDE DMKOE84 TN Glucagon-like peptide 1 receptor (GLP1R) DMKOE84 MA Modulator DMKOE84 RN Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. DMKOE84 RU https://pubmed.ncbi.nlm.nih.gov/19748064 DMKPAOD DI DMKPAOD DMKPAOD DN DA-6886 DMKPAOD TI TT07C3Y DMKPAOD TN 5-HT 4 receptor (HTR4) DMKPAOD MA Agonist DMKPAOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMKPAOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMKPBVX DI DMKPBVX DMKPBVX DN Englitazone sodium DMKPBVX TI TTZMAO3 DMKPBVX TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMKPBVX MA Agonist DMKPBVX RN PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61. DMKPBVX RU https://pubmed.ncbi.nlm.nih.gov/12586994 DMKQHE5 DI DMKQHE5 DMKQHE5 DN BI-11634 DMKQHE5 TI TTCIHJA DMKQHE5 TN Coagulation factor Xa (F10) DMKQHE5 MA Inhibitor DMKQHE5 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMKQHE5 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMKR3GD DI DMKR3GD DMKR3GD DN EP-42675 DMKR3GD TI TTCIHJA DMKR3GD TN Coagulation factor Xa (F10) DMKR3GD MA Modulator DMKR3GD RN EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. DMKR3GD RU https://pubmed.ncbi.nlm.nih.gov/24237610 DMKR3GD DI DMKR3GD DMKR3GD DN EP-42675 DMKR3GD TI TT6L509 DMKR3GD TN Coagulation factor IIa (F2) DMKR3GD MA Modulator DMKR3GD RN EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. DMKR3GD RU https://pubmed.ncbi.nlm.nih.gov/24237610 DMKR8S1 DI DMKR8S1 DMKR8S1 DN BMS-779788 DMKR8S1 TI TTM1EQF DMKR8S1 TN Oxysterols receptor LXR (NR1H) DMKR8S1 MA Modulator DMKR8S1 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMKR8S1 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMKSU35 DI DMKSU35 DMKSU35 DN PU-AD DMKSU35 TI TT78R5H DMKSU35 TN Heat shock protein 90 alpha (HSP90A) DMKSU35 MA Inhibitor DMKSU35 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKSU35 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKUT08 DI DMKUT08 DMKUT08 DN TAK-071 DMKUT08 TI TTZ9SOR DMKUT08 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMKUT08 MA Modulator DMKUT08 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUT08 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKUXB5 DI DMKUXB5 DMKUXB5 DN CDT-fenofibrate DMKUXB5 TI TTJ584C DMKUXB5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMKUXB5 MA Agonist DMKUXB5 RN Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93. DMKUXB5 RU https://pubmed.ncbi.nlm.nih.gov/9808609 DMKVE8X DI DMKVE8X DMKVE8X DN Acriflavine DMKVE8X TI TT5FH9Y DMKVE8X TN Human immunodeficiency virus Integrase (HIV IN) DMKVE8X MA Modulator DMKVE8X RN Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6. DMKVE8X RU https://pubmed.ncbi.nlm.nih.gov/10665342 DMKVIS5 DI DMKVIS5 DMKVIS5 DN RG7907 DMKVIS5 TI TTM42UJ DMKVIS5 TN Hepatitis B virus Capsid protein (HBV C) DMKVIS5 MA Inhibitor DMKVIS5 RN Clinical pipeline report, company report or official report of Roche. DMKVIS5 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMKW10G DI DMKW10G DMKW10G DN SGN-CD30C DMKW10G TI TT2GM5R DMKW10G TN Lymphocyte activation antigen CD30 (TNFRSF8) DMKW10G RN Clinical pipeline report, company report or official report of Seagen. DMKW10G RU https://www.seagen.com/science/pipeline DMKW27X DI DMKW27X DMKW27X DN CART-19 cells DMKW27X TI TTW640A DMKW27X TN B-lymphocyte surface antigen B4 (CD19) DMKW27X MA CAR-T-Cell-Therapy DMKW27X RN ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). DMKW27X RU https://clinicaltrials.gov/ct2/show/NCT02924753 DMKW4AJ DI DMKW4AJ DMKW4AJ DN Tasidotin hydrochloride DMKW4AJ TI TTYFKSZ DMKW4AJ TN Tubulin beta (TUBB) DMKW4AJ MA Binder DMKW4AJ RN Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. DMKW4AJ RU https://pubmed.ncbi.nlm.nih.gov/18927208 DMKWSFI DI DMKWSFI DMKWSFI DN CR-002 DMKWSFI TI TTQA6SX DMKWSFI TN Platelet-derived growth factor B (PDGFB) DMKWSFI MA Modulator DMKWSFI RN A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44. DMKWSFI RU https://www.ncbi.nlm.nih.gov/pubmed/18538109 DMKX174 DI DMKX174 DMKX174 DN FOR46 DMKX174 TI TTMS7DF DMKX174 TN Membrane cofactor protein (CD46) DMKX174 RN Clinical pipeline report, company report or official report of Fortis Therapeutics. DMKX174 RU https://fortistx.com/for46-pipeline/ DMKY1L4 DI DMKY1L4 DMKY1L4 DN Glucose-6-phosphate DMKY1L4 TI TTC67I0 DMKY1L4 TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMKY1L4 MA Inhibitor DMKY1L4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKY1L4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKZVLH DI DMKZVLH DMKZVLH DN Lefradafiban DMKZVLH TI TT38RM1 DMKZVLH TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMKZVLH MA Modulator DMKZVLH RN Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. DMKZVLH RU https://pubmed.ncbi.nlm.nih.gov/11250974 DML028U DI DML028U DML028U DN G1T28-1 DML028U TI TT0PG8F DML028U TN Cyclin-dependent kinase 4 (CDK4) DML028U MA Modulator DML028U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML028U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML028U DI DML028U DML028U DN G1T28-1 DML028U TI TTO0FDJ DML028U TN Cyclin-dependent kinase 6 (CDK6) DML028U MA Modulator DML028U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML028U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML07UZ DI DML07UZ DML07UZ DN CD19-CAR-T2 Cells DML07UZ TI TTW640A DML07UZ TN B-lymphocyte surface antigen B4 (CD19) DML07UZ MA CAR-T-Cell-Therapy DML07UZ RN ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia DML07UZ RU https://clinicaltrials.gov/ct2/show/NCT02822326 DML0OCD DI DML0OCD DML0OCD DN PF-3864086 DML0OCD TI TTMI6F5 DML0OCD TN Transient receptor potential cation channel V1 (TRPV1) DML0OCD MA Antagonist DML0OCD RN Clinical pipeline report, company report or official report of pfizer. DML0OCD RU https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf DML1KSA DI DML1KSA DML1KSA DN GMI-1359 DML1KSA TI TTAU4D6 DML1KSA TN E-selectin (SELE) DML1KSA MA Antagonist DML1KSA RN Clinical pipeline report, company report or official report of GlycoMimetics. DML1KSA RU http://glycomimetics.com/pipeline/programs/gmi-1359/ DML1KSA DI DML1KSA DML1KSA DN GMI-1359 DML1KSA TI TTBID49 DML1KSA TN C-X-C chemokine receptor type 4 (CXCR4) DML1KSA MA Antagonist DML1KSA RN Clinical pipeline report, company report or official report of GlycoMimetics. DML1KSA RU http://glycomimetics.com/pipeline/programs/gmi-1359/ DML3K9N DI DML3K9N DML3K9N DN XTL-6865 DML3K9N TI TTDBG95 DML3K9N TN Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) DML3K9N MA Modulator DML3K9N RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML3K9N RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML3M0O DI DML3M0O DML3M0O DN TAK-701 DML3M0O TI TT4V2JM DML3M0O TN Hepatocyte growth factor (HGF) DML3M0O MA Modulator DML3M0O RN Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103. DML3M0O RU https://www.ncbi.nlm.nih.gov/pubmed/22270953 DML3WT6 DI DML3WT6 DML3WT6 DN PF-06821497 DML3WT6 TI TT9MZCQ DML3WT6 TN Enhancer of zeste homolog 2 (EZH2) DML3WT6 MA Inhibitor DML3WT6 RN Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665. DML3WT6 RU https://pubmed.ncbi.nlm.nih.gov/29211475 DML4C3Q DI DML4C3Q DML4C3Q DN RO-5212054 DML4C3Q TI TTWCGQT DML4C3Q TN Serine/threonine-protein kinase B-raf (BRAF) DML4C3Q MA Inhibitor DML4C3Q RN National Cancer Institute Drug Dictionary (drug id 680347). DML4C3Q RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=680347 DML4H05 DI DML4H05 DML4H05 DN KX2-361 DML4H05 TI TT6PKBN DML4H05 TN Proto-oncogene c-Src (SRC) DML4H05 MA Inhibitor DML4H05 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206). DML4H05 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206 DML4JXZ DI DML4JXZ DML4JXZ DN F-7TG DML4JXZ TI TTF0EGX DML4JXZ TN Coagulation factor VII (F7) DML4JXZ MA Modulator DML4JXZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DML4JXZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DML4SIE DI DML4SIE DML4SIE DN Atu-027 DML4SIE TI TTW3P4R DML4SIE TN Protein kinase N3 (PKN3) DML4SIE MA Modulator DML4SIE RN Company report (Silence Therapeutics) DML4SIE RU http://www.silence-therapeutics.com/pipeline/?doing_wp_cron=1455613779.0401461124420166015625#AboutAtu027 DML5FX2 DI DML5FX2 DML5FX2 DN MDX-018 DML5FX2 TI TTCTE1G DML5FX2 TN Interleukin-8 (IL8) DML5FX2 MA Modulator DML5FX2 RN Company report (Genmab) DML5FX2 RU http://www.genmab.com/product-pipeline/products-in-development/humax-il8 DML5O7T DI DML5O7T DML5O7T DN IM23 DML5O7T TI TTENHJ0 DML5O7T TN Interleukin 3 receptor alpha (IL3RA) DML5O7T MA CAR-T-Cell-Therapy DML5O7T RN ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) DML5O7T RU https://clinicaltrials.gov/ct2/show/NCT03585517 DML5V76 DI DML5V76 DML5V76 DN MK-4166 DML5V76 TI TTG6LA7 DML5V76 TN Activation-inducible TNFR family receptor (TNFRSF18) DML5V76 RN Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5. DML5V76 RU https://pubmed.ncbi.nlm.nih.gov/26153987 DML6QJN DI DML6QJN DML6QJN DN SDZ-MKS-492 DML6QJN TI TTZCG4L DML6QJN TN Phosphodiesterase 3 (PDE3) DML6QJN MA Modulator DML6QJN RN Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5. DML6QJN RU https://pubmed.ncbi.nlm.nih.gov/8250732 DML781M DI DML781M DML781M DN BAY1895344 DML781M TI TT8ZYBQ DML781M TN Serine/threonine-protein kinase ATR (FRP1) DML781M MA Inhibitor DML781M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML781M RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML79KE DI DML79KE DML79KE DN AGT-182 DML79KE TI TTCBFJO DML79KE TN Insulin receptor (INSR) DML79KE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DML79KE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DML8M3B DI DML8M3B DML8M3B DN LY-2584702 DML8M3B TI TT7M3PI DML8M3B TN Ribosomal protein S6 kinase (S6K) DML8M3B MA Modulator DML8M3B RN A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84. DML8M3B RU https://www.ncbi.nlm.nih.gov/pubmed/24456794 DMLA1QD DI DMLA1QD DMLA1QD DN MB-101 DMLA1QD TI TTMPZ7V DMLA1QD TN Interleukin 13 receptor alpha-2 (IL13RA2) DMLA1QD MA Immunomodulator DMLA1QD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLA1QD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLAP8F DI DMLAP8F DMLAP8F DN AMG 424 DMLAP8F TI TTPURFN DMLAP8F TN Cyclic ADP-ribose hydrolase 1 (CD38) DMLAP8F MA Inhibitor DMLAP8F RN Clinical pipeline report, company report or official report of Amgen. DMLAP8F RU https://www.amgenpipeline.com/ DMLAP8F DI DMLAP8F DMLAP8F DN AMG 424 DMLAP8F TI TTUN7MC DMLAP8F TN T-cell surface glycoprotein CD3 (CD3) DMLAP8F MA Inhibitor DMLAP8F RN Clinical pipeline report, company report or official report of Amgen. DMLAP8F RU https://www.amgenpipeline.com/ DMLBKZV DI DMLBKZV DMLBKZV DN CER-002 DMLBKZV TI TT2JWF6 DMLBKZV TN Peroxisome proliferator-activated receptor delta (PPARD) DMLBKZV MA Agonist DMLBKZV RN Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899. DMLBKZV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997800/ DMLCTI5 DI DMLCTI5 DMLCTI5 DN MK-8353 DMLCTI5 TI TTKPV6O DMLCTI5 TN Ephrin type-B receptor 2 (EPHB2) DMLCTI5 MA Inhibitor DMLCTI5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLCTI5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLDSX8 DI DMLDSX8 DMLDSX8 DN TT-30 DMLDSX8 TI TT0HUN7 DMLDSX8 TN Complement receptor type 2 (CD21) DMLDSX8 MA Modulator DMLDSX8 RN The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16. DMLDSX8 RU https://pubmed.ncbi.nlm.nih.gov/22577173 DMLDSX8 DI DMLDSX8 DMLDSX8 DN TT-30 DMLDSX8 TI TTUW6OP DMLDSX8 TN Complement factor H (CFH) DMLDSX8 MA Modulator DMLDSX8 RN The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16. DMLDSX8 RU https://pubmed.ncbi.nlm.nih.gov/22577173 DMLDZX1 DI DMLDZX1 DMLDZX1 DN PfAMA-1 DMLDZX1 TI TTQZW34 DMLDZX1 TN Plasmodium Apical membrane protein (Malaria AMA-1) DMLDZX1 RN Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite devel... J Cell Sci. 2003 Sep 15;116(Pt 18):3825-34. DMLDZX1 RU https://pubmed.ncbi.nlm.nih.gov/12902400 DMLEKUY DI DMLEKUY DMLEKUY DN APG-1387 DMLEKUY TI TTS74QB DMLEKUY TN Inhibitor of apoptosis protein (hIAP) DMLEKUY MA Inhibitor DMLEKUY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLEKUY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLEKUY DI DMLEKUY DMLEKUY DN APG-1387 DMLEKUY TI TTR7B60 DMLEKUY TN X-linked inhibitor of apoptosis protein (XIAP) DMLEKUY MA Antagonist DMLEKUY RN XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510. DMLEKUY RU https://pubmed.ncbi.nlm.nih.gov/29556337 DMLGD0V DI DMLGD0V DMLGD0V DN PF-04776548 DMLGD0V TI TT5FNQT DMLGD0V TN Human immunodeficiency virus Protease (HIV PR) DMLGD0V MA Modulator DMLGD0V RN ClinicalTrials.gov (NCT01045317) A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body. U.S. National Institutes of Health. DMLGD0V RU https://clinicaltrials.gov/ct2/show/NCT01045317 DMLGJKE DI DMLGJKE DMLGJKE DN CART-22 cells DMLGJKE TI TTM6QSK DMLGJKE TN B-cell receptor CD22 (CD22) DMLGJKE MA CAR-T-Cell-Therapy DMLGJKE RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMLGJKE RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMLH2Q6 DI DMLH2Q6 DMLH2Q6 DN Figopitant DMLH2Q6 TI TTZPO1L DMLH2Q6 TN Substance-P receptor (TACR1) DMLH2Q6 MA Antagonist DMLH2Q6 RN Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos. 2012 Mar;40(3):419-25. DMLH2Q6 RU https://pubmed.ncbi.nlm.nih.gov/22184457 DMLHIMO DI DMLHIMO DMLHIMO DN REV-576 DMLHIMO TI TTKANGO DMLHIMO TN Complement C5 (CO5) DMLHIMO MA Inhibitor DMLHIMO RN Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct;23(12):1324-6. DMLHIMO RU https://pubmed.ncbi.nlm.nih.gov/25228739 DMLI5VG DI DMLI5VG DMLI5VG DN CAR-T cells targeting HER2 DMLI5VG TI TT6EO5L DMLI5VG TN Erbb2 tyrosine kinase receptor (HER2) DMLI5VG MA CAR-T-Cell-Therapy DMLI5VG RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMLI5VG RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMLI9U6 DI DMLI9U6 DMLI9U6 DN AVI-7537 DMLI9U6 TI TTDJLWQ DMLI9U6 TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMLI9U6 RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMLI9U6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMLJHM2 DI DMLJHM2 DMLJHM2 DN PD-L1 t-haNK DMLJHM2 TI TT8ZLTI DMLJHM2 TN Programmed cell death 1 ligand 1 (PD-L1) DMLJHM2 RN ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health. DMLJHM2 RU https://clinicaltrials.gov/ct2/show/NCT04050709 DMLJOAF DI DMLJOAF DMLJOAF DN BI-135585 DMLJOAF TI TTN7BL9 DMLJOAF TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMLJOAF MA Modulator DMLJOAF RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMLJOAF RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMLJWPN DI DMLJWPN DMLJWPN DN Alx-5407 DMLJWPN TI TTHJTF7 DMLJWPN TN Glycine transporter GlyT-1 (SLC6A9) DMLJWPN MA Blocker DMLJWPN RN ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20. DMLJWPN RU https://pubmed.ncbi.nlm.nih.gov/11723250 DMLKF3H DI DMLKF3H DMLKF3H DN Prolanta DMLKF3H TI TTBPXMA DMLKF3H TN Prolactin receptor (PRLR) DMLKF3H MA Antagonist DMLKF3H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLKF3H RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLKS7W DI DMLKS7W DMLKS7W DN NV-5138 DMLKS7W TI TTX4GLS DMLKS7W TN Mammalian target of rapamycin complex 1 (mTORC1) DMLKS7W MA Activator DMLKS7W RN Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554. DMLKS7W RU https://pubmed.ncbi.nlm.nih.gov/30990795 DMLONJG DI DMLONJG DMLONJG DN CC-97540 DMLONJG TI TTW640A DMLONJG TN B-lymphocyte surface antigen B4 (CD19) DMLONJG RN A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma DMLONJG RU https://clinicaltrials.gov/ct2/show/NCT04231747 DMLPB0X DI DMLPB0X DMLPB0X DN SB-436811 DMLPB0X TI TTW5UDX DMLPB0X TN Urotensin II receptor (UTS2R) DMLPB0X MA Inhibitor DMLPB0X RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DMLPB0X RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMLPBVF DI DMLPBVF DMLPBVF DN SUVN-911 DMLPBVF TI TT5KPZR DMLPBVF TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMLPBVF MA Antagonist DMLPBVF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPBVF RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLQJ5P DI DMLQJ5P DMLQJ5P DN AMG 228 DMLQJ5P TI TTG6LA7 DMLQJ5P TN Activation-inducible TNFR family receptor (TNFRSF18) DMLQJ5P MA Agonist DMLQJ5P RN Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93. DMLQJ5P RU https://pubmed.ncbi.nlm.nih.gov/30253804 DMLQOF1 DI DMLQOF1 DMLQOF1 DN MK-7246 DMLQOF1 TI TTQDMX5 DMLQOF1 TN Prostaglandin D2 receptor 2 (PTGDR2) DMLQOF1 MA Modulator DMLQOF1 RN Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. DMLQOF1 RU https://pubmed.ncbi.nlm.nih.gov/21106375 DMLQYVD DI DMLQYVD DMLQYVD DN ELND-004 DMLQYVD TI TT4BT06 DMLQYVD TN Integrin alpha-4 (ITGA4) DMLQYVD MA Inhibitor DMLQYVD RN Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8. DMLQYVD RU https://pubmed.ncbi.nlm.nih.gov/12794117 DMLRGX1 DI DMLRGX1 DMLRGX1 DN BAY 1082439 DMLRGX1 TI TTTHBCA DMLRGX1 TN PI3-kinase beta (PIK3CB) DMLRGX1 MA Modulator DMLRGX1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMLRGX1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMLSUQ8 DI DMLSUQ8 DMLSUQ8 DN KHK2455 DMLSUQ8 TI TTZJYKH DMLSUQ8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMLSUQ8 MA Inhibitor DMLSUQ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLSUQ8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLUOVS DI DMLUOVS DMLUOVS DN TJC4 DMLUOVS TI TT28S46 DMLUOVS TN Leukocyte surface antigen CD47 (CD47) DMLUOVS RN Clinical pipeline report, company report or official report of I-MAB Biopharma. DMLUOVS RU https://i-mabbiopharma.com/en/Pipeline.aspx DMLUYAJ DI DMLUYAJ DMLUYAJ DN OPK-0018 DMLUYAJ TI TT4QPUL DMLUYAJ TN Antithrombin-III (ATIII) DMLUYAJ MA Antagonist DMLUYAJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DMLUYAJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DMLVG9D DI DMLVG9D DMLVG9D DN DCC-3014 DMLVG9D TI TT7MRDV DMLVG9D TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMLVG9D MA Inhibitor DMLVG9D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVG9D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLVNWO DI DMLVNWO DMLVNWO DN Oleclumab DMLVNWO TI TTK0O6Y DMLVNWO TN Ecto-5'-nucleotidase (CD73) DMLVNWO MA Inhibitor DMLVNWO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVNWO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLXGAI DI DMLXGAI DMLXGAI DN LYS-6KAKT1 DMLXGAI TI TT7M3PI DMLXGAI TN Ribosomal protein S6 kinase (S6K) DMLXGAI MA Modulator DMLXGAI RN DOI: 10.1016/S1359-6349(10)71767-5 DMLXGAI RU https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer DMLXGAI DI DMLXGAI DMLXGAI DN LYS-6KAKT1 DMLXGAI TI TTAZ05C DMLXGAI TN RAC-gamma serine/threonine-protein kinase (AKT3) DMLXGAI MA Modulator DMLXGAI RN DOI: 10.1016/S1359-6349(10)71767-5 DMLXGAI RU https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer DMLYAGD DI DMLYAGD DMLYAGD DN JNJ-64264681 DMLYAGD TI TTGM6VW DMLYAGD TN Tyrosine-protein kinase BTK (ATK) DMLYAGD MA Inhibitor DMLYAGD RN A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia DMLYAGD RU https://clinicaltrials.gov/ct2/show/NCT04657224 DMLYP2N DI DMLYP2N DMLYP2N DN AMG 757 DMLYP2N TI TTUN7MC DMLYP2N TN T-cell surface glycoprotein CD3 (CD3) DMLYP2N MA Inhibitor DMLYP2N RN Clinical pipeline report, company report or official report of Amgen. DMLYP2N RU https://www.amgenpipeline.com/ DMLYP2N DI DMLYP2N DMLYP2N DN AMG 757 DMLYP2N TI TT1C9K6 DMLYP2N TN Delta-like protein 3 (DLL3) DMLYP2N MA Inhibitor DMLYP2N RN Clinical pipeline report, company report or official report of Amgen. DMLYP2N RU https://www.amgenpipeline.com/ DMLZDVR DI DMLZDVR DMLZDVR DN HPN424 DMLZDVR TI TT9G4N0 DMLZDVR TN Glutamate carboxypeptidase II (GCPII) DMLZDVR RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DMLZDVR RU https://www.harpoontx.com/pipeline/ DMM0HNF DI DMM0HNF DMM0HNF DN AMG 160 DMM0HNF TI TTUN7MC DMM0HNF TN T-cell surface glycoprotein CD3 (CD3) DMM0HNF MA Inhibitor DMM0HNF RN Clinical pipeline report, company report or official report of Amgen. DMM0HNF RU https://www.amgenpipeline.com/ DMM0HNF DI DMM0HNF DMM0HNF DN AMG 160 DMM0HNF TI TT9G4N0 DMM0HNF TN Glutamate carboxypeptidase II (GCPII) DMM0HNF MA Inhibitor DMM0HNF RN Clinical pipeline report, company report or official report of Amgen. DMM0HNF RU https://www.amgenpipeline.com/ DMM0VBU DI DMM0VBU DMM0VBU DN BCA101 DMM0VBU TI TTO3HT7 DMM0VBU TN Transforming growth factor beta (TGFB) DMM0VBU MA Inhibitor DMM0VBU RN ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health. DMM0VBU RU https://clinicaltrials.gov/ct2/show/NCT04429542 DMM0VBU DI DMM0VBU DMM0VBU DN BCA101 DMM0VBU TI TTGKNB4 DMM0VBU TN Epidermal growth factor receptor (EGFR) DMM0VBU MA Inhibitor DMM0VBU RN ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health. DMM0VBU RU https://clinicaltrials.gov/ct2/show/NCT04429542 DMM1N5C DI DMM1N5C DMM1N5C DN VGX-1027 DMM1N5C TI TTXT2VN DMM1N5C TN NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway) DMM1N5C MA Inhibitor DMM1N5C RN Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155(5):722-30. DMM1N5C RU https://pubmed.ncbi.nlm.nih.gov/18776919 DMM1RB6 DI DMM1RB6 DMM1RB6 DN GW-328267 DMM1RB6 TI TTM2AOE DMM1RB6 TN Adenosine A2a receptor (ADORA2A) DMM1RB6 MA Modulator DMM1RB6 RN ADENOSINE RECEPTORS AS TARGETS FOR THERAPEUTIC INTERVENTION IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE DMM1RB6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778268 DMM1Y8F DI DMM1Y8F DMM1Y8F DN NGD 94-1 DMM1Y8F TI TTE0A2F DMM1Y8F TN Dopamine D4 receptor (D4R) DMM1Y8F MA Antagonist DMM1Y8F RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM1Y8F RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM1Y8F DI DMM1Y8F DMM1Y8F DN NGD 94-1 DMM1Y8F TI TT729IR DMM1Y8F TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMM1Y8F MA Blocker DMM1Y8F RN Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. DMM1Y8F RU https://pubmed.ncbi.nlm.nih.gov/11784784 DMM2EZW DI DMM2EZW DMM2EZW DN BHV-5000 DMM2EZW TI TT9IK2Z DMM2EZW TN N-methyl-D-aspartate receptor (NMDAR) DMM2EZW MA Antagonist DMM2EZW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM2EZW RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM2SNG DI DMM2SNG DMM2SNG DN NC-4016 DMM2SNG TI TTUTN1I DMM2SNG TN Human Deoxyribonucleic acid (hDNA) DMM2SNG MA Inhibitor DMM2SNG RN Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209. DMM2SNG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224659/ DMM2V74 DI DMM2V74 DMM2V74 DN 177Lu-labelled CTT-1403 DMM2V74 TI TT9G4N0 DMM2V74 TN Glutamate carboxypeptidase II (GCPII) DMM2V74 RN Clinical pipeline report, company report or official report of Cancer Targeted Technologies. DMM2V74 RU https://www.cancertargetedtechnology.com/pipeline/ctt1403/ DMM3DBU DI DMM3DBU DMM3DBU DN BMS-986301 DMM3DBU TI TTT402Y DMM3DBU TN Stimulator of interferon genes protein (TMEM173) DMM3DBU MA Agonist DMM3DBU RN Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323. DMM3DBU RU https://pubmed.ncbi.nlm.nih.gov/33081170 DMM3U2Q DI DMM3U2Q DMM3U2Q DN TJ4309 DMM3U2Q TI TTK0O6Y DMM3U2Q TN Ecto-5'-nucleotidase (CD73) DMM3U2Q RN ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health. DMM3U2Q RU https://clinicaltrials.gov/ct2/show/NCT04322006 DMM45P9 DI DMM45P9 DMM45P9 DN Ad-IFN-alpha DMM45P9 TI TT95SOA DMM45P9 TN Interferon alpha (IFNA) DMM45P9 MA Modulator DMM45P9 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMM45P9 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMM57CS DI DMM57CS DMM57CS DN Drug 2849330 DMM57CS TI TTDC8N2 DMM57CS TN Erbb3 tyrosine kinase receptor (Erbb-3) DMM57CS RN National Cancer Institute Drug Dictionary (drug id 754219). DMM57CS RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754219 DMM5N8P DI DMM5N8P DMM5N8P DN MRX-2843 DMM5N8P TI TTO7LKR DMM5N8P TN Tyrosine-protein kinase Mer (MERTK) DMM5N8P MA Inhibitor DMM5N8P RN The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. DMM5N8P RU https://pubmed.ncbi.nlm.nih.gov/27158668 DMM5N8P DI DMM5N8P DMM5N8P DN MRX-2843 DMM5N8P TI TTGJCWZ DMM5N8P TN Fms-like tyrosine kinase 3 (FLT-3) DMM5N8P MA Inhibitor DMM5N8P RN The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. DMM5N8P RU https://pubmed.ncbi.nlm.nih.gov/27158668 DMM7RC5 DI DMM7RC5 DMM7RC5 DN NCX-6560 DMM7RC5 TI TTPADOQ DMM7RC5 TN HMG-CoA reductase (HMGCR) DMM7RC5 MA Inhibitor DMM7RC5 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMM7RC5 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMM7TBO DI DMM7TBO DMM7TBO DN MORAb-022 DMM7TBO TI TTNYZG2 DMM7TBO TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMM7TBO RN Clinical pipeline report, company report or official report of Morphotek. DMM7TBO RU http://www.morphotek.com/pipeline/MORAb-022.aspx DMM7TBO DI DMM7TBO DMM7TBO DN MORAb-022 DMM7TBO TI TT0T5HK DMM7TBO TN Immunoglobulin gamma-1 heavy NIE (NIE) DMM7TBO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM7TBO RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMM7VOB DI DMM7VOB DMM7VOB DN Hepapoietin DMM7VOB TI TTNDSF4 DMM7VOB TN Proto-oncogene c-Met (MET) DMM7VOB MA Inhibitor DMM7VOB RN Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002. DMM7VOB RU http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2002.01110.x/full DMM7ZXR DI DMM7ZXR DMM7ZXR DN GSK2126458 DMM7ZXR TI TTHBTOP DMM7ZXR TN PI3-kinase gamma (PIK3CG) DMM7ZXR MA Modulator DMM7ZXR RN Company report (GSK) DMM7ZXR RU http://www.gsk-clinicalstudyregister.com/study/113794#ps DMM86OH DI DMM86OH DMM86OH DN DSP-6745 DMM86OH TI TT85JO3 DMM86OH TN 5-HT receptor (5HTR) DMM86OH MA Antagonist DMM86OH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM86OH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM8GZT DI DMM8GZT DMM8GZT DN DL-017 DMM8GZT TI TT34BHT DMM8GZT TN Adrenergic receptor alpha-1D (ADRA1D) DMM8GZT MA Modulator DMM8GZT RN Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9. DMM8GZT RU https://pubmed.ncbi.nlm.nih.gov/11707693 DMM95XS DI DMM95XS DMM95XS DN CART19 cell DMM95XS TI TTW640A DMM95XS TN B-lymphocyte surface antigen B4 (CD19) DMM95XS MA CAR-T-Cell-Therapy DMM95XS RN ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT DMM95XS RU https://clinicaltrials.gov/ct2/show/NCT03685786 DMM9ORD DI DMM9ORD DMM9ORD DN ASG-15ME DMM9ORD TI TTTVEKI DMM9ORD TN SLIT and NTRK-like family member 6 (SLITRK6) DMM9ORD RN Clinical pipeline report, company report or official report of Seattle Genetics. DMM9ORD RU http://www.seattlegenetics.com/asg15me DMM9S51 DI DMM9S51 DMM9S51 DN ELND-002 DMM9S51 TI TT4BT06 DMM9S51 TN Integrin alpha-4 (ITGA4) DMM9S51 MA Antagonist DMM9S51 RN Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8. DMM9S51 RU https://pubmed.ncbi.nlm.nih.gov/12794117 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTANPDJ DMMAS3K TN Carbonic anhydrase II (CA-II) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TT2LVK8 DMMAS3K TN Carbonic anhydrase IX (CA-IX) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15664814 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTHQPL7 DMMAS3K TN Carbonic anhydrase I (CA-I) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTZHA0O DMMAS3K TN Carbonic anhydrase IV (CA-IV) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTUNARX DMMAS3K TN Carbonic anhydrase (CA) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMMBQ20 DI DMMBQ20 DMMBQ20 DN CPI-818 DMMBQ20 TI TT3C80U DMMBQ20 TN T-cell-specific kinase (ITK) DMMBQ20 MA Inhibitor DMMBQ20 RN Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. DMMBQ20 RU https://www.corvuspharma.com/our-science/our-pipeline/ DMMBQV3 DI DMMBQV3 DMMBQV3 DN Ad5-ENVA-48 DMMBQV3 TI TTEC2T3 DMMBQV3 TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMMBQV3 RN ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health. DMMBQV3 RU https://clinicaltrials.gov/ct2/show/NCT00695877 DMMC6YR DI DMMC6YR DMMC6YR DN CM2489 DMMC6YR TI TT5HONZ DMMC6YR TN Calcium channel unspecific (CaC) DMMC6YR MA Modulator DMMC6YR RN Molecular pharmacology of store-operated CRAC channels DMMC6YR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913763 DMME5P8 DI DMME5P8 DMME5P8 DN Pfizer 4 DMME5P8 TI TT5TKPM DMME5P8 TN Neutral endopeptidase (MME) DMME5P8 MA Inhibitor DMME5P8 RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DMME5P8 RU https://pubmed.ncbi.nlm.nih.gov/17826689 DMMEFO0 DI DMMEFO0 DMMEFO0 DN COH29 DMMEFO0 TI TTX09M4 DMMEFO0 TN Ribonucleotide reductase (RIR) DMMEFO0 MA Inhibitor DMMEFO0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMEFO0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMEPKR DI DMMEPKR DMMEPKR DN PEG-Interferon lambda (IL-29) DMMEPKR TI TTM624L DMMEPKR TN Interleukin-29 (IL29) DMMEPKR MA Agonist DMMEPKR RN Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. DMMEPKR RU https://pubmed.ncbi.nlm.nih.gov/20645873 DMMETU8 DI DMMETU8 DMMETU8 DN PF-4418948 DMMETU8 TI TT1ZAVI DMMETU8 TN Prostaglandin E2 receptor EP2 (PTGER2) DMMETU8 MA Antagonist DMMETU8 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMMETU8 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMMF0J3 DI DMMF0J3 DMMF0J3 DN CMX-157 DMMF0J3 TI TT84ETX DMMF0J3 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMF0J3 MA Inhibitor DMMF0J3 RN Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193. DMMF0J3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612025/ DMMF6UB DI DMMF6UB DMMF6UB DN GE-1170A DMMF6UB TI TTYQIFM DMMF6UB TN Staphylococcus Elongation factor Tu (Stap-coc tuf) DMMF6UB MA Inhibitor DMMF6UB RN GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005. DMMF6UB RU https://pubmed.ncbi.nlm.nih.gov/11124042 DMMFL2P DI DMMFL2P DMMFL2P DN Anti-CD7 CAR-T cells DMMFL2P TI TTP6B8O DMMFL2P TN T-cell antigen CD7 (CD7) DMMFL2P MA CAR-T-Cell-Therapy DMMFL2P RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMMFL2P RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMMI4XR DI DMMI4XR DMMI4XR DN JNJ-17305600 DMMI4XR TI TTHJTF7 DMMI4XR TN Glycine transporter GlyT-1 (SLC6A9) DMMI4XR MA Inhibitor DMMI4XR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMMI4XR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMMJ1PO DI DMMJ1PO DMMJ1PO DN SGN-CD70A DMMJ1PO TI TTNCIE0 DMMJ1PO TN CD70 antigen (CD27-L) DMMJ1PO RN SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647. DMMJ1PO RU http://cancerres.aacrjournals.org/content/74/19_Supplement/2647 DMMJXAR DI DMMJXAR DMMJXAR DN Entolimod DMMJXAR TI TTCXP8J DMMJXAR TN Toll-like receptor 5 (TLR5) DMMJXAR MA Agonist DMMJXAR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMJXAR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMJZ2E DI DMMJZ2E DMMJZ2E DN PF-07104091 DMMJZ2E TI TT7HF4W DMMJZ2E TN Cyclin-dependent kinase 2 (CDK2) DMMJZ2E MA Inhibitor DMMJZ2E RN ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health. DMMJZ2E RU https://clinicaltrials.gov/ct2/show/NCT04553133 DMMKN4Q DI DMMKN4Q DMMKN4Q DN NOX-A12 DMMKN4Q TI TT4UGTF DMMKN4Q TN Stromal cell-derived factor 1 (CXCL12) DMMKN4Q MA Inhibitor DMMKN4Q RN SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. Transpl Int. 2015 Dec;28(12):1426-35. DMMKN4Q RU https://pubmed.ncbi.nlm.nih.gov/26265085 DMMKUOZ DI DMMKUOZ DMMKUOZ DN VCH-286 DMMKUOZ TI TT2CEJG DMMKUOZ TN C-C chemokine receptor type 5 (CCR5) DMMKUOZ MA Antagonist DMMKUOZ RN The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int. 2012;2012:401965. DMMKUOZ RU https://pubmed.ncbi.nlm.nih.gov/22848825 DMMKZYV DI DMMKZYV DMMKZYV DN Namitecan DMMKZYV TI TTGTQHC DMMKZYV TN DNA topoisomerase I (TOP1) DMMKZYV MA Inhibitor DMMKZYV RN Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501. DMMKZYV RU https://pubmed.ncbi.nlm.nih.gov/22680917 DMMO2EJ DI DMMO2EJ DMMO2EJ DN CD19.CAR-aNKT cells DMMO2EJ TI TTW640A DMMO2EJ TN B-lymphocyte surface antigen B4 (CD19) DMMO2EJ MA CAR-T-Cell-Therapy DMMO2EJ RN ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) DMMO2EJ RU https://clinicaltrials.gov/ct2/show/NCT03774654 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTCJG29 DMMO3G5 TN Serine/threonine-protein kinase mTOR (mTOR) DMMO3G5 MA Modulator DMMO3G5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMMO3G5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTHBTOP DMMO3G5 TN PI3-kinase gamma (PIK3CG) DMMO3G5 MA Modulator DMMO3G5 RN VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. DMMO3G5 RU https://pubmed.ncbi.nlm.nih.gov/23270925 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTX4GLS DMMO3G5 TN Mammalian target of rapamycin complex 1 (mTORC1) DMMO3G5 MA Inhibitor DMMO3G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMO3G5 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTWDKCL DMMO3G5 TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMMO3G5 MA Inhibitor DMMO3G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMO3G5 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMMP7XG DI DMMP7XG DMMP7XG DN MAXY-4 DMMP7XG TI TTHGXBU DMMP7XG TN T-lymphocyte activation antigen CD86 (FUN1) DMMP7XG MA Inhibitor DMMP7XG RN Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3. DMMP7XG RU https://pubmed.ncbi.nlm.nih.gov/21474713 DMMP7XG DI DMMP7XG DMMP7XG DN MAXY-4 DMMP7XG TI TTFZDNP DMMP7XG TN Activation B7-1 antigen (CD80) DMMP7XG MA Inhibitor DMMP7XG RN Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3. DMMP7XG RU https://pubmed.ncbi.nlm.nih.gov/21474713 DMMPFZO DI DMMPFZO DMMPFZO DN IC9.GD2.CAR.IL-15 T-cells DMMPFZO TI TT80ARU DMMPFZO TN Ganglioside GD2 (GD2) DMMPFZO MA CAR-T-Cell-Therapy DMMPFZO RN ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma DMMPFZO RU https://clinicaltrials.gov/ct2/show/NCT03721068 DMMPINS DI DMMPINS DMMPINS DN IGM-2323 DMMPINS TI TTUN7MC DMMPINS TN T-cell surface glycoprotein CD3 (CD3) DMMPINS MA Inhibitor DMMPINS RN Clinical pipeline report, company report or official report of IGM Biosciences. DMMPINS RU https://igmbio.com/pipeline/cd20-x-dc3/ DMMPINS DI DMMPINS DMMPINS DN IGM-2323 DMMPINS TI TTUE541 DMMPINS TN Leukocyte surface antigen Leu-16 (CD20) DMMPINS MA Inhibitor DMMPINS RN Clinical pipeline report, company report or official report of IGM Biosciences. DMMPINS RU https://igmbio.com/pipeline/cd20-x-dc3/ DMMPKN3 DI DMMPKN3 DMMPKN3 DN CTX-471 DMMPKN3 TI TTPW9LJ DMMPKN3 TN Co-stimulatory molecule 4-1BB (CD137) DMMPKN3 MA Agonist DMMPKN3 RN Clinical pipeline report, company report or official report of Compass Therapeutics. DMMPKN3 RU https://www.compasstherapeutics.com/candidates/ctx-471-cd137-agonist/ DMMPTCK DI DMMPTCK DMMPTCK DN ARRY-300 DMMPTCK TI TTROQ37 DMMPTCK TN MAPK/ERK kinase kinase (MAP3K) DMMPTCK MA Modulator DMMPTCK RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. DMMPTCK RU https://pubmed.ncbi.nlm.nih.gov/23587417 DMMQ12N DI DMMQ12N DMMQ12N DN BI 860585 DMMQ12N TI TTCJG29 DMMQ12N TN Serine/threonine-protein kinase mTOR (mTOR) DMMQ12N MA Inhibitor DMMQ12N RN Clinical pipeline report, company report or official report of tatcongress. DMMQ12N RU http://tatcongress.org/wp-content/uploads/2014/05/tat2014-abstracts-poster-session-6_140217.pdf DMMR4E7 DI DMMR4E7 DMMR4E7 DN PBSVax DMMR4E7 TI TT3NH7G DMMR4E7 TN Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) DMMR4E7 MA Modulator DMMR4E7 RN ClinicalTrials.gov (NCT01578889) Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults. U.S. National Institutes of Health. DMMR4E7 RU https://clinicaltrials.gov/ct2/show/NCT01578889 DMMR7CH DI DMMR7CH DMMR7CH DN Insulin oral sublingual DMMR7CH TI TTCBFJO DMMR7CH TN Insulin receptor (INSR) DMMR7CH MA Modulator DMMR7CH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMMR7CH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMMRANJ DI DMMRANJ DMMRANJ DN Anti-CD19-CAR T DMMRANJ TI TTW640A DMMRANJ TN B-lymphocyte surface antigen B4 (CD19) DMMRANJ MA CAR-T-Cell-Therapy DMMRANJ RN ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL DMMRANJ RU https://clinicaltrials.gov/ct2/show/NCT02546739 DMMRDUN DI DMMRDUN DMMRDUN DN TrasGEX DMMRDUN TI TT6EO5L DMMRDUN TN Erbb2 tyrosine kinase receptor (HER2) DMMRDUN RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2515). DMMRDUN RU http://meetinglibrary.asco.org/content/131582-144 DMMVXGR DI DMMVXGR DMMVXGR DN H3B-8800 DMMVXGR TI TTXR78S DMMVXGR TN SF3b complex (SF3b) DMMVXGR MA Modulator DMMVXGR RN Clinical pipeline report, company report or official report of H3 Biomedicine. DMMVXGR RU https://www.h3biomedicine.com/science/ DMMW72C DI DMMW72C DMMW72C DN AZD-1152-HQPA DMMW72C TI TT5LS6T DMMW72C TN Aurora kinase B (AURKB) DMMW72C MA Modulator DMMW72C RN Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80. DMMW72C RU https://www.ncbi.nlm.nih.gov/pubmed/22661287 DMMWEH6 DI DMMWEH6 DMMWEH6 DN AVP-21D9 DMMWEH6 TI TT3YGCD DMMWEH6 TN Bacterial Protective antigen (Bact pagA) DMMWEH6 RN Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625. DMMWEH6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068543/ DMMWNQP DI DMMWNQP DMMWNQP DN TAK-329 DMMWNQP TI TTDLNGZ DMMWNQP TN Glucokinase (GCK) DMMWNQP MA Inhibitor DMMWNQP RN Clinical pipeline report, company report or official report of Takeda. DMMWNQP RU https://www.takeda.com/csr/reports/pdf/index/ar2011_16_en.pdf DMMWS3O DI DMMWS3O DMMWS3O DN RG-7010 DMMWS3O TI TTHRID2 DMMWS3O TN Insulin-like growth factor I receptor (IGF1R) DMMWS3O MA Modulator DMMWS3O RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031207) DMMWS3O RU http://adisinsight.springer.com/drugs/800031207 DMMYRHV DI DMMYRHV DMMYRHV DN NOX-700 DMMYRHV TI TTUO9SZ DMMYRHV TN Nitric oxide elimination (NOE) DMMYRHV MA Modulator DMMYRHV RN Inhibition of nitrosylation, nitration, lymphocyte proliferation, and gene expression in acute and delayed cardiac allograft rejection by an orally active dithiocarbamate. J Cardiovasc Pharmacol. 2004 Apr;43(4):522-30. DMMYRHV RU https://pubmed.ncbi.nlm.nih.gov/15085063 DMN3D72 DI DMN3D72 DMN3D72 DN SL-172154 DMN3D72 TI TTN6Y9A DMN3D72 TN CD40L receptor (CD40) DMN3D72 MA Inhibitor DMN3D72 RN Clinical pipeline report, company report or official report of Shattuck Labs. DMN3D72 RU https://www.shattucklabs.com/pipeline/overview/ DMN3D72 DI DMN3D72 DMN3D72 DN SL-172154 DMN3D72 TI TT28S46 DMN3D72 TN Leukocyte surface antigen CD47 (CD47) DMN3D72 MA Inhibitor DMN3D72 RN Clinical pipeline report, company report or official report of Shattuck Labs. DMN3D72 RU https://www.shattucklabs.com/pipeline/overview/ DMN40DU DI DMN40DU DMN40DU DN MK-4621 DMN40DU TI TTVB0O3 DMN40DU TN Retinoic acid-inducible gene-1 (RIG-1) DMN40DU MA Agonist DMN40DU RN National Cancer Institute Drug Dictionary (drug name RGT100). DMN40DU RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rig-i-selective-ligand-rgt100 DMN4D3A DI DMN4D3A DMN4D3A DN ARI-2243 DMN4D3A TI TTDIGC1 DMN4D3A TN Dipeptidyl peptidase 4 (DPP-4) DMN4D3A MA Modulator DMN4D3A RN Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37. DMN4D3A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996165/ DMN4I7P DI DMN4I7P DMN4I7P DN GSK3901961 DMN4I7P TI TTE5ITK DMN4I7P TN Cancer/testis antigen 1 (NY-ESO-1) DMN4I7P RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMN4I7P RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMN4LMT DI DMN4LMT DMN4LMT DN Oxeglitazar DMN4LMT TI TTZMAO3 DMN4LMT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMN4LMT MA Modulator DMN4LMT RN Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. DMN4LMT RU https://pubmed.ncbi.nlm.nih.gov/20653327 DMN4LMT DI DMN4LMT DMN4LMT DN Oxeglitazar DMN4LMT TI TTJ584C DMN4LMT TN Peroxisome proliferator-activated receptor alpha (PPARA) DMN4LMT MA Modulator DMN4LMT RN Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. DMN4LMT RU https://pubmed.ncbi.nlm.nih.gov/20653327 DMN4OGH DI DMN4OGH DMN4OGH DN TAK-960 DMN4OGH TI TTIYVQP DMN4OGH TN Polo-like kinase 1 (PLK1) DMN4OGH MA Modulator DMN4OGH RN TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9. DMN4OGH RU https://pubmed.ncbi.nlm.nih.gov/22188812 DMN8I5Q DI DMN8I5Q DMN8I5Q DN CDP-7657 DMN8I5Q TI TTIJP3Q DMN8I5Q TN TNF related activation protein (CD40LG) DMN8I5Q RN CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234. DMN8I5Q RU https://pubmed.ncbi.nlm.nih.gov/26335795 DMN9JCD DI DMN9JCD DMN9JCD DN VS-4718 DMN9JCD TI TTON5IT DMN9JCD TN Focal adhesion kinase 1 (FAK) DMN9JCD MA Inhibitor DMN9JCD RN FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61. DMN9JCD RU https://pubmed.ncbi.nlm.nih.gov/24899686 DMN9MPX DI DMN9MPX DMN9MPX DN 212Pb-labelled DOTAMTATE DMN9MPX TI TTOMNR9 DMN9MPX TN Somatostatin receptor (SSTR) DMN9MPX RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMN9MPX RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMNAR29 DI DMNAR29 DMNAR29 DN HuCART19 DMNAR29 TI TTW640A DMNAR29 TN B-lymphocyte surface antigen B4 (CD19) DMNAR29 MA CAR-T-Cell-Therapy DMNAR29 RN ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy DMNAR29 RU https://clinicaltrials.gov/ct2/show/NCT02374333 DMNBPKS DI DMNBPKS DMNBPKS DN Iofolastat I-124 DMNBPKS TI TT9G4N0 DMNBPKS TN Glutamate carboxypeptidase II (GCPII) DMNBPKS MA Inhibitor DMNBPKS RN 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011 Jul;52(7):1087-93. DMNBPKS RU https://pubmed.ncbi.nlm.nih.gov/21680691 DMNCBIU DI DMNCBIU DMNCBIU DN IC9-CAR19 T cells DMNCBIU TI TTW640A DMNCBIU TN B-lymphocyte surface antigen B4 (CD19) DMNCBIU MA CAR-T-Cell-Therapy DMNCBIU RN ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma DMNCBIU RU https://clinicaltrials.gov/ct2/show/NCT03696784 DMNDACU DI DMNDACU DMNDACU DN CD19 CAR-T cells DMNDACU TI TTW640A DMNDACU TN B-lymphocyte surface antigen B4 (CD19) DMNDACU MA CAR-T-Cell-Therapy DMNDACU RN ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia DMNDACU RU https://clinicaltrials.gov/ct2/show/NCT03064269 DMNDGPT DI DMNDGPT DMNDGPT DN DS-2969 DMNDGPT TI TTPBZUO DMNDGPT TN Clostridium difficile DNA gyrase (CD gyr) DMNDGPT MA Inhibitor DMNDGPT RN In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17. DMNDGPT RU https://pubmed.ncbi.nlm.nih.gov/29439962 DMNDHKL DI DMNDHKL DMNDHKL DN TG-1701 DMNDHKL TI TTGM6VW DMNDHKL TN Tyrosine-protein kinase BTK (ATK) DMNDHKL MA Inhibitor DMNDHKL RN Clinical pipeline report, company report or official report of TG Therapeutics. DMNDHKL RU https://www.tgtherapeutics.com/our-pipeline/tg-1701/ DMNE9Z0 DI DMNE9Z0 DMNE9Z0 DN T-0128 DMNE9Z0 TI TTUTN1I DMNE9Z0 TN Human Deoxyribonucleic acid (hDNA) DMNE9Z0 MA Inhibitor DMNE9Z0 RN Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95. DMNE9Z0 RU https://pubmed.ncbi.nlm.nih.gov/10850447 DMNEFQ6 DI DMNEFQ6 DMNEFQ6 DN AMG 529 DMNEFQ6 TI TTYM94H DMNEFQ6 TN Asialoglycoprotein receptor 1 (ASGR1) DMNEFQ6 MA Inhibitor DMNEFQ6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNEFQ6 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMNEVKA DI DMNEVKA DMNEVKA DN E2012 DMNEVKA TI TT9W8GU DMNEVKA TN Gamma-secretase (GS) DMNEVKA MA Modulator DMNEVKA RN Chemical Biology, Molecular Mechanism and Clinical Perspective of -Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol.2011 Dec;9(4):598-622. DMNEVKA RU https://www.ncbi.nlm.nih.gov/pubmed/22798753 DMNF09S DI DMNF09S DMNF09S DN NV-04 DMNF09S TI TTXPQW1 DMNF09S TN Hormone unspecific (HOM) DMNF09S MA Modulator DMNF09S RN US patent application no. 2011,0201,626, 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase. DMNF09S RU https://www.google.com/patents/US20110201626 DMNF3GW DI DMNF3GW DMNF3GW DN Afeletecan DMNF3GW TI TTGTQHC DMNF3GW TN DNA topoisomerase I (TOP1) DMNF3GW MA Inhibitor DMNF3GW RN The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Invest New Drugs. 2012 June; 30(3): 1208-1210. DMNF3GW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/ DMNFDYE DI DMNFDYE DMNFDYE DN KD3010 DMNFDYE TI TT2JWF6 DMNFDYE TN Peroxisome proliferator-activated receptor delta (PPARD) DMNFDYE MA Agonist DMNFDYE RN Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007. DMNFDYE RU http://www.newsrx.com/newsletters/Health-Business-Week/2006-10-27/102320063331046HBW.html DMNFEC6 DI DMNFEC6 DMNFEC6 DN Drug 2878175 DMNFEC6 TI TTMVBWH DMNFEC6 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMNFEC6 MA Inhibitor DMNFEC6 RN P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY. Journal of Hepatology Volume 60, Issue 1, Supplement, April 2014, Pages S496. DMNFEC6 RU http://www.sciencedirect.com/science/article/pii/S0168827814613842 DMNFO2B DI DMNFO2B DMNFO2B DN Anti-BCMA CAR T cells DMNFO2B TI TTZ3P4W DMNFO2B TN B-cell maturation protein (TNFRSF17) DMNFO2B MA CAR-T-Cell-Therapy DMNFO2B RN ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma DMNFO2B RU https://clinicaltrials.gov/ct2/show/NCT02215967 DMNFZOT DI DMNFZOT DMNFZOT DN TAK-593 DMNFZOT TI TTUTJGQ DMNFZOT TN Vascular endothelial growth factor receptor 2 (KDR) DMNFZOT MA Modulator DMNFZOT RN Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. DMNFZOT RU https://www.ncbi.nlm.nih.gov/pubmed/21182308 DMNFZOT DI DMNFZOT DMNFZOT DN TAK-593 DMNFZOT TI TTI7421 DMNFZOT TN Platelet-derived growth factor receptor beta (PDGFRB) DMNFZOT MA Modulator DMNFZOT RN Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. DMNFZOT RU https://www.ncbi.nlm.nih.gov/pubmed/21182308 DMNH1Y5 DI DMNH1Y5 DMNH1Y5 DN CAR-T Cells targeting MUCI DMNH1Y5 TI TTBHFYQ DMNH1Y5 TN Mucin-1 (MUC1) DMNH1Y5 MA CAR-T-Cell-Therapy DMNH1Y5 RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMNH1Y5 RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMNHBMC DI DMNHBMC DMNHBMC DN AIC-292 DMNHBMC TI TT84ETX DMNHBMC TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMNHBMC MA Inhibitor DMNHBMC RN In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. DMNHBMC RU https://pubmed.ncbi.nlm.nih.gov/23959304 DMNHPOT DI DMNHPOT DMNHPOT DN LErafAON DMNHPOT TI TTAN5W2 DMNHPOT TN Raf messenger RNA (Raf mRNA) DMNHPOT RN Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53. DMNHPOT RU https://pubmed.ncbi.nlm.nih.gov/15014358 DMNHSI8 DI DMNHSI8 DMNHSI8 DN PCO371 DMNHSI8 TI TTFPD47 DMNHSI8 TN Parathyroid hormone 1 receptor (PTH1R) DMNHSI8 MA Agonist DMNHSI8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNHSI8 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMNI60O DI DMNI60O DMNI60O DN MEDI4276 DMNI60O TI TT6EO5L DMNI60O TN Erbb2 tyrosine kinase receptor (HER2) DMNI60O MA Modulator DMNI60O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNI60O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNICD4 DI DMNICD4 DMNICD4 DN CYT-013-IL1bQb DMNICD4 TI TTRYK0X DMNICD4 TN Interleukin-1 beta (IL1B) DMNICD4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623). DMNICD4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623 DMNIVFJ DI DMNIVFJ DMNIVFJ DN AVN-322 DMNIVFJ TI TTJS8PY DMNIVFJ TN 5-HT 6 receptor (HTR6) DMNIVFJ MA Antagonist DMNIVFJ RN AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Curr Alzheimer Res. 2017;14(3):268-294. DMNIVFJ RU https://pubmed.ncbi.nlm.nih.gov/27829340 DMNJTLC DI DMNJTLC DMNJTLC DN Neu-2000 DMNJTLC TI TTN9D8E DMNJTLC TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMNJTLC MA Antagonist DMNJTLC RN Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56. DMNJTLC RU https://pubmed.ncbi.nlm.nih.gov/21152450 DMNKV3O DI DMNKV3O DMNKV3O DN XEN007 DMNKV3O TI TTX4QDJ DMNKV3O TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMNKV3O MA Inhibitor DMNKV3O RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNKV3O RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNL5G7 DI DMNL5G7 DMNL5G7 DN BAY-1817080 DMNL5G7 TI TT2THBD DMNL5G7 TN P2X purinoceptor 3 (P2RX3) DMNL5G7 MA Inhibitor DMNL5G7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNL5G7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNL8MO DI DMNL8MO DMNL8MO DN MEDI-573 DMNL8MO TI TTT6LOU DMNL8MO TN Insulin-like growth factor-I (IGF1) DMNL8MO MA Modulator DMNL8MO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNL8MO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNLK5Y DI DMNLK5Y DMNLK5Y DN PF-06647020 DMNLK5Y TI TTXH2ZN DMNLK5Y TN Inactive tyrosine-protein kinase 7 (PTK7) DMNLK5Y MA Inhibitor DMNLK5Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLK5Y RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMNLY9R DI DMNLY9R DMNLY9R DN YM-16151-4 DMNLY9R TI TTR6W5O DMNLY9R TN Adrenergic receptor beta-1 (ADRB1) DMNLY9R MA Modulator DMNLY9R RN Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. DMNLY9R RU https://pubmed.ncbi.nlm.nih.gov/7685438 DMNLY9R DI DMNLY9R DMNLY9R DN YM-16151-4 DMNLY9R TI TT5HONZ DMNLY9R TN Calcium channel unspecific (CaC) DMNLY9R MA Modulator DMNLY9R RN Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. DMNLY9R RU https://pubmed.ncbi.nlm.nih.gov/7685438 DMNO91Q DI DMNO91Q DMNO91Q DN PTI-202 DMNO91Q TI TTN4QDT DMNO91Q TN Opioid receptor (OPR) DMNO91Q MA Modulator DMNO91Q RN Clinical pipeline report, company report or official report of Pain Therapeutics, Inc. DMNO91Q RU http://www.paintrials.com/pti-202.html DMNOSYW DI DMNOSYW DMNOSYW DN BI-853520 DMNOSYW TI TTON5IT DMNOSYW TN Focal adhesion kinase 1 (FAK) DMNOSYW MA Modulator DMNOSYW RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNOSYW RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNP6T3 DI DMNP6T3 DMNP6T3 DN GEN1042 DMNP6T3 TI TTN6Y9A DMNP6T3 TN CD40L receptor (CD40) DMNP6T3 MA Agonist DMNP6T3 RN Clinical pipeline report, company report or official report of Genmab. DMNP6T3 RU https://www.genmab.com/pipeline/ DMNP6T3 DI DMNP6T3 DMNP6T3 DN GEN1042 DMNP6T3 TI TTPW9LJ DMNP6T3 TN Co-stimulatory molecule 4-1BB (CD137) DMNP6T3 MA Agonist DMNP6T3 RN Clinical pipeline report, company report or official report of Genmab. DMNP6T3 RU https://www.genmab.com/pipeline/ DMNPS59 DI DMNPS59 DMNPS59 DN EZN-4176 DMNPS59 TI TTKPW01 DMNPS59 TN Androgen receptor messenger RNA (AR mRNA) DMNPS59 RN 2011 Pipeline of Santaris Pharma. DMNPS59 RU http://www.santaris.com/product-pipeline DMNSC0O DI DMNSC0O DMNSC0O DN DNL747 DMNSC0O TI TTAIQSN DMNSC0O TN Receptor-interacting protein 1 (RIPK1) DMNSC0O MA Inhibitor DMNSC0O RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DMNSC0O RU https://pubmed.ncbi.nlm.nih.gov/32669658 DMNSJ3C DI DMNSJ3C DMNSJ3C DN JNJ-26854165 DMNSJ3C TI TT08GJW DMNSJ3C TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMNSJ3C MA Modulator DMNSJ3C RN Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741. DMNSJ3C RU https://pubmed.ncbi.nlm.nih.gov/24040331 DMNTVUK DI DMNTVUK DMNTVUK DN TS01 DMNTVUK TI TT7LRQH DMNTVUK TN Complement C1s component (C1S) DMNTVUK MA Modulator DMNTVUK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNTVUK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNUY32 DI DMNUY32 DMNUY32 DN BI-811283 DMNUY32 TI TT5LS6T DMNUY32 TN Aurora kinase B (AURKB) DMNUY32 MA Inhibitor DMNUY32 RN Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32. DMNUY32 RU https://pubmed.ncbi.nlm.nih.gov/22350019 DMNVDI2 DI DMNVDI2 DMNVDI2 DN RAD-140 DMNVDI2 TI TTS64P2 DMNVDI2 TN Androgen receptor (AR) DMNVDI2 MA Modulator DMNVDI2 RN Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. DMNVDI2 RU https://pubmed.ncbi.nlm.nih.gov/24900290 DMNVPI1 DI DMNVPI1 DMNVPI1 DN BAY 1905254 DMNVPI1 TI TT0R2QD DMNVPI1 TN Ig-like domain-containing receptor 2 (ILDR2) DMNVPI1 MA Inhibitor DMNVPI1 RN Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911. DMNVPI1 RU https://pubmed.ncbi.nlm.nih.gov/32312711 DMNW3LH DI DMNW3LH DMNW3LH DN SY-5609 DMNW3LH TI TTQYF7G DMNW3LH TN Cyclin-dependent kinase 7 (CDK7) DMNW3LH MA Inhibitor DMNW3LH RN Clinical pipeline report, company report or official report of Syros Pharmaceuticals. DMNW3LH RU https://www.syros.com/programs/sy-5609 DMNWPMO DI DMNWPMO DMNWPMO DN IDH305 DMNWPMO TI TTV2A1R DMNWPMO TN Oxalosuccinate decarboxylase (IDH1) DMNWPMO MA Inhibitor DMNWPMO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNWPMO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNX0V7 DI DMNX0V7 DMNX0V7 DN CD38 CAR-T DMNX0V7 TI TTPURFN DMNX0V7 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMNX0V7 RN Clinical pipeline report, company report or official report of Sorrento Therapeutics. DMNX0V7 RU https://sorrentotherapeutics.com/research/pipeline/ DMNX3US DI DMNX3US DMNX3US DN GS-9820 DMNX3US TI TTGBPJE DMNX3US TN PI3-kinase delta (PIK3CD) DMNX3US MA Inhibitor DMNX3US RN National Cancer Institute Drug Dictionary (drug id 741949). DMNX3US RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741949 DMNY0U5 DI DMNY0U5 DMNY0U5 DN BPI-9016 M DMNY0U5 TI TTNDSF4 DMNY0U5 TN Proto-oncogene c-Met (MET) DMNY0U5 MA Inhibitor DMNY0U5 RN First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6. DMNY0U5 RU https://pubmed.ncbi.nlm.nih.gov/31948451 DMNY0U5 DI DMNY0U5 DMNY0U5 DN BPI-9016 M DMNY0U5 TI TTZPY6J DMNY0U5 TN Tyrosine-protein kinase UFO (AXL) DMNY0U5 MA Inhibitor DMNY0U5 RN First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6. DMNY0U5 RU https://pubmed.ncbi.nlm.nih.gov/31948451 DMNYGB8 DI DMNYGB8 DMNYGB8 DN GSK-1322888 DMNYGB8 TI TT953CX DMNYGB8 TN Motilin receptor (MLNR) DMNYGB8 MA Agonist DMNYGB8 RN ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health. DMNYGB8 RU https://clinicaltrials.gov/ct2/show/NCT01294566 DMNZ6XH DI DMNZ6XH DMNZ6XH DN VNRX-5133 DMNZ6XH TI TTHI19T DMNZ6XH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMNZ6XH MA Inhibitor DMNZ6XH RN Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801. DMNZ6XH RU https://pubmed.ncbi.nlm.nih.gov/31765155 DMNZQU5 DI DMNZQU5 DMNZQU5 DN P-7435 DMNZQU5 TI TTF8P9I DMNZQU5 TN Diacylglycerol acyltransferase 1 (DGAT1) DMNZQU5 MA Inhibitor DMNZQU5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033014) DMNZQU5 RU http://adisinsight.springer.com/drugs/800033014 DMO0AJE DI DMO0AJE DMO0AJE DN CC-90010 DMO0AJE TI TTE4BSY DMO0AJE TN Bromodomain and extraterminal domain protein (BET) DMO0AJE MA Inhibitor DMO0AJE RN Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Ann Oncol. 2020 Jun;31(6):780-788. DMO0AJE RU https://pubmed.ncbi.nlm.nih.gov/32240793 DMO0CA8 DI DMO0CA8 DMO0CA8 DN SHP616 DMO0CA8 TI TT7LRQH DMO0CA8 TN Complement C1s component (C1S) DMO0CA8 MA Inhibitor DMO0CA8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO0CA8 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMO0JP1 DI DMO0JP1 DMO0JP1 DN OMS527 DMO0JP1 TI TT1APCZ DMO0JP1 TN Phosphodiesterase 7 (PDE7) DMO0JP1 MA Inhibitor DMO0JP1 RN Clinical pipeline report, company report or official report of Omeros. DMO0JP1 RU https://www.omeros.com/pipeline/ DMO1FTI DI DMO1FTI DMO1FTI DN Sphingosine DMO1FTI TI TTUAIKM DMO1FTI TN Cholinephosphate cytidylyltransferase (PCYT1B) DMO1FTI MA Inhibitor DMO1FTI RN Sphingosine inhibits the activity of rat liver CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1990 Jul 15;265(20):11746-50. DMO1FTI RU https://pubmed.ncbi.nlm.nih.gov/2164014 DMO1N8A DI DMO1N8A DMO1N8A DN SRX-251 DMO1N8A TI TT4TFGN DMO1N8A TN Vasopressin V1a receptor (V1AR) DMO1N8A MA Antagonist DMO1N8A RN Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006 Feb;83(2):169-74. DMO1N8A RU https://pubmed.ncbi.nlm.nih.gov/16504276 DMO23R0 DI DMO23R0 DMO23R0 DN CVX 096 DMO23R0 TI TTVIMDE DMO23R0 TN Glucagon-like peptide 1 receptor (GLP1R) DMO23R0 MA Modulator DMO23R0 RN Chemically programmed antibodies. Trends Biotechnol. 2014 April; 32(4): 186-197. DMO23R0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978777/ DMO2WYX DI DMO2WYX DMO2WYX DN ZT-1 DMO2WYX TI TT1RS9F DMO2WYX TN Acetylcholinesterase (AChE) DMO2WYX MA Inhibitor DMO2WYX RN A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651-6. DMO2WYX RU https://pubmed.ncbi.nlm.nih.gov/15052575 DMO4SD2 DI DMO4SD2 DMO4SD2 DN ONO-4232 DMO4SD2 TI TT79WV3 DMO4SD2 TN Prostaglandin E2 receptor EP4 (PTGER4) DMO4SD2 MA Agonist DMO4SD2 RN ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345. DMO4SD2 RU http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A15345 DMO53AD DI DMO53AD DMO53AD DN Cavrotolimod DMO53AD TI TTSHG0T DMO53AD TN Toll-like receptor 9 (TLR9) DMO53AD MA Agonist DMO53AD RN Clinical pipeline report, company report or official report of Exicure. DMO53AD RU https://www.exicuretx.com/pipeline/index.php DMO548K DI DMO548K DMO548K DN LX9211 DMO548K TI TT0Z32T DMO548K TN Adaptor-associated kinase 1 (AAK1) DMO548K MA Inhibitor DMO548K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO548K RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMO5760 DI DMO5760 DMO5760 DN SR13668 DMO5760 TI TTAZ05C DMO5760 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMO5760 MA Modulator DMO5760 RN Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. DMO5760 RU https://pubmed.ncbi.nlm.nih.gov/21372034 DMO7TES DI DMO7TES DMO7TES DN CCX507 DMO7TES TI TTIPS8B DMO7TES TN C-C chemokine receptor type 9 (CCR9) DMO7TES MA Antagonist DMO7TES RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO7TES RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMO87YS DI DMO87YS DMO87YS DN GSK065 DMO87YS TI TTIY56R DMO87YS TN Kynurenine 3-hydroxylase (KMO) DMO87YS MA Inhibitor DMO87YS RN Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827. DMO87YS RU https://pubmed.ncbi.nlm.nih.gov/28604669 DMO8L6T DI DMO8L6T DMO8L6T DN TD-0714 DMO8L6T TI TT5TKPM DMO8L6T TN Neutral endopeptidase (MME) DMO8L6T MA Inhibitor DMO8L6T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO8L6T RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMO8QY1 DI DMO8QY1 DMO8QY1 DN SAR-21609 DMO8QY1 TI TTSHG0T DMO8QY1 TN Toll-like receptor 9 (TLR9) DMO8QY1 MA Agonist DMO8QY1 RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMO8QY1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMO8SGD DI DMO8SGD DMO8SGD DN Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy DMO8SGD TI TTP3QRF DMO8SGD TN Thymidine kinase 1 (TK1) DMO8SGD MA Modulator DMO8SGD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMO8SGD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMO8Z1D DI DMO8Z1D DMO8Z1D DN UK-66914 DMO8Z1D TI TT1VOHK DMO8Z1D TN Potassium channel unspecific (KC) DMO8Z1D MA Blocker DMO8Z1D RN Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85. DMO8Z1D RU https://pubmed.ncbi.nlm.nih.gov/1711597 DMO97RV DI DMO97RV DMO97RV DN CSL-362 DMO97RV TI TTPYS82 DMO97RV TN Interleukin 3 receptor (CSF2RB) DMO97RV RN Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. DMO97RV RU https://pubmed.ncbi.nlm.nih.gov/24363400 DMO9BGI DI DMO9BGI DMO9BGI DN RG6076 DMO9BGI TI TTPW9LJ DMO9BGI TN Co-stimulatory molecule 4-1BB (CD137) DMO9BGI RN Clinical pipeline report, company report or official report of Roche. DMO9BGI RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMO9KZE DI DMO9KZE DMO9KZE DN XR-5944 DMO9KZE TI TT0IHXV DMO9KZE TN DNA topoisomerase II (TOP2) DMO9KZE MA Modulator DMO9KZE RN Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67. DMO9KZE RU https://pubmed.ncbi.nlm.nih.gov/11335793 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TTV3XPL DMOAET3 TN T-cell surface glycoprotein CD3 gamma (CD3G) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TTZAT79 DMOAET3 TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TT9G4N0 DMOAET3 TN Glutamate carboxypeptidase II (GCPII) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOCQ4K DI DMOCQ4K DMOCQ4K DN TTI-622 DMOCQ4K TI TT28S46 DMOCQ4K TN Leukocyte surface antigen CD47 (CD47) DMOCQ4K MA Blocker DMOCQ4K RN Clinical pipeline report, company report or official report of Trillium Therapeutics. DMOCQ4K RU https://trilliumtherapeutics.com/pipeline/ DMODGJU DI DMODGJU DMODGJU DN KRN633 DMODGJU TI TTUTJGQ DMODGJU TN Vascular endothelial growth factor receptor 2 (KDR) DMODGJU MA Inhibitor DMODGJU RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMODGJU RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMOE5NQ DI DMOE5NQ DMOE5NQ DN RG7347 DMOE5NQ TI TTIPJCB DMOE5NQ TN Neuropilin-1 (NRP1) DMOE5NQ MA Modulator DMOE5NQ RN Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Front Oncol. 2015; 5: 125. DMOE5NQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453476/ DMOE5SZ DI DMOE5SZ DMOE5SZ DN GW-409544 DMOE5SZ TI TTZMAO3 DMOE5SZ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMOE5SZ MA Modulator DMOE5SZ RN Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. DMOE5SZ RU https://pubmed.ncbi.nlm.nih.gov/22685582 DMOE5SZ DI DMOE5SZ DMOE5SZ DN GW-409544 DMOE5SZ TI TTJ584C DMOE5SZ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMOE5SZ MA Modulator DMOE5SZ RN Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. DMOE5SZ RU https://pubmed.ncbi.nlm.nih.gov/22685582 DMOFSLE DI DMOFSLE DMOFSLE DN IMD-0354 DMOFSLE TI TTJ3E9X DMOFSLE TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMOFSLE MA Inhibitor DMOFSLE RN I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15. DMOFSLE RU https://pubmed.ncbi.nlm.nih.gov/20573155 DMOFT1V DI DMOFT1V DMOFT1V DN C-2507 DMOFT1V TI TT5FH9Y DMOFT1V TN Human immunodeficiency virus Integrase (HIV IN) DMOFT1V MA Inhibitor DMOFT1V RN Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85. DMOFT1V RU https://pubmed.ncbi.nlm.nih.gov/19843978 DMOG8IE DI DMOG8IE DMOG8IE DN EVT 401 DMOG8IE TI TT473XN DMOG8IE TN P2X purinoceptor 7 (P2RX7) DMOG8IE MA Antagonist DMOG8IE RN Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417. DMOG8IE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360091/ DMOHACZ DI DMOHACZ DMOHACZ DN CD19-TriCAR-T DMOHACZ TI TTW640A DMOHACZ TN B-lymphocyte surface antigen B4 (CD19) DMOHACZ MA CAR-T-Cell-Therapy DMOHACZ RN ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy DMOHACZ RU https://clinicaltrials.gov/ct2/show/NCT03720496 DMOIE05 DI DMOIE05 DMOIE05 DN 609A DMOIE05 TI TTNBFWK DMOIE05 TN Programmed cell death protein 1 (PD-1) DMOIE05 MA Inhibitor DMOIE05 RN Clinical pipeline report, company report or official report of 3SBio. DMOIE05 RU http://www.3sbio.com/en/news/details.aspx?id=111 DMOJ1AH DI DMOJ1AH DMOJ1AH DN CART22-65s cells and huCART19 Cells DMOJ1AH TI TTM6QSK DMOJ1AH TN B-cell receptor CD22 (CD22) DMOJ1AH MA CAR-T-Cell-Therapy(Dual specific) DMOJ1AH RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DMOJ1AH RU https://clinicaltrials.gov/ct2/show/NCT03620058 DMOJ1AH DI DMOJ1AH DMOJ1AH DN CART22-65s cells and huCART19 Cells DMOJ1AH TI TTW640A DMOJ1AH TN B-lymphocyte surface antigen B4 (CD19) DMOJ1AH MA CAR-T-Cell-Therapy(Dual specific) DMOJ1AH RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DMOJ1AH RU https://clinicaltrials.gov/ct2/show/NCT03620058 DMOJA7N DI DMOJA7N DMOJA7N DN SSR-128428 DMOJA7N TI TTCIHJA DMOJA7N TN Coagulation factor Xa (F10) DMOJA7N MA Modulator DMOJA7N RN Company report (Sanofi) (drug: FY2008) DMOJA7N RU http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf DMOJA7N DI DMOJA7N DMOJA7N DN SSR-128428 DMOJA7N TI TT6L509 DMOJA7N TN Coagulation factor IIa (F2) DMOJA7N MA Modulator DMOJA7N RN Company report (Sanofi) (drug: FY2008) DMOJA7N RU http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf DMOJEXG DI DMOJEXG DMOJEXG DN CART-Muc1 cells DMOJEXG TI TTBHFYQ DMOJEXG TN Mucin-1 (MUC1) DMOJEXG MA CAR-T-Cell-Therapy DMOJEXG RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMOJEXG RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMOJZUE DI DMOJZUE DMOJZUE DN BI-831266 DMOJZUE TI TT5LS6T DMOJZUE TN Aurora kinase B (AURKB) DMOJZUE MA Modulator DMOJZUE RN A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22. DMOJZUE RU https://pubmed.ncbi.nlm.nih.gov/25529193 DMOL9JR DI DMOL9JR DMOL9JR DN JNJ-42491293 DMOL9JR TI TTXJ47W DMOL9JR TN Metabotropic glutamate receptor 2 (mGluR2) DMOL9JR MA Binder DMOL9JR RN Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708. DMOL9JR RU https://pubmed.ncbi.nlm.nih.gov/25176435 DMOLFAU DI DMOLFAU DMOLFAU DN Thiopilocarpine DMOLFAU TI TTZ9SOR DMOLFAU TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLFAU MA Agonist DMOLFAU RN SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992 Nov 3;222(1):21-5. DMOLFAU RU https://pubmed.ncbi.nlm.nih.gov/1468496 DMONZ1L DI DMONZ1L DMONZ1L DN LY3381916 DMONZ1L TI TTZJYKH DMONZ1L TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMONZ1L MA Inhibitor DMONZ1L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMONZ1L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOPGXM DI DMOPGXM DMOPGXM DN PBF-1129 DMOPGXM TI TTNE7KG DMOPGXM TN Adenosine A2b receptor (ADORA2B) DMOPGXM MA Antagonist DMOPGXM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOPGXM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOQ2GB DI DMOQ2GB DMOQ2GB DN BR6819 DMOQ2GB TI TTYCILE DMOQ2GB TN Vasopressin receptor (VR) DMOQ2GB MA Antagonist DMOQ2GB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOQ2GB RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMORN60 DI DMORN60 DMORN60 DN CBL0137 DMORN60 TI TTETDKQ DMORN60 TN Facilitates chromatin transcription complex (FACT) DMORN60 MA Modulator DMORN60 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMORN60 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMOSCQ9 DI DMOSCQ9 DMOSCQ9 DN DNL104 DMOSCQ9 TI TTAIQSN DMOSCQ9 TN Receptor-interacting protein 1 (RIPK1) DMOSCQ9 MA Inhibitor DMOSCQ9 RN DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414. DMOSCQ9 RU https://pubmed.ncbi.nlm.nih.gov/31437302 DMOSRFZ DI DMOSRFZ DMOSRFZ DN OC-10X DMOSRFZ TI TT9K83W DMOSRFZ TN Tubulin receptor (TUBR) DMOSRFZ MA Inhibitor DMOSRFZ RN ClinicalTrials.gov (NCT01869933) Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X. U.S. National Institutes of Health. DMOSRFZ RU https://clinicaltrials.gov/ct2/show/NCT01869933 DMOTLN4 DI DMOTLN4 DMOTLN4 DN CBT-101 DMOTLN4 TI TTNDSF4 DMOTLN4 TN Proto-oncogene c-Met (MET) DMOTLN4 MA Inhibitor DMOTLN4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOTLN4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOUHR4 DI DMOUHR4 DMOUHR4 DN CA-170 DMOUHR4 TI TT8ZLTI DMOUHR4 TN Programmed cell death 1 ligand 1 (PD-L1) DMOUHR4 MA Inhibitor DMOUHR4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOUHR4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOUHR4 DI DMOUHR4 DMOUHR4 DN CA-170 DMOUHR4 TI TT51SK8 DMOUHR4 TN V-set immunoregulatory receptor (VSIR) DMOUHR4 MA Inhibitor DMOUHR4 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMOUHR4 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMOUVE7 DI DMOUVE7 DMOUVE7 DN BAY-85-8102 DMOUVE7 TI TTPTXIN DMOUVE7 TN Translocator protein (TSPO) DMOUVE7 MA Agonist DMOUVE7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMOUVE7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMOV2ML DI DMOV2ML DMOV2ML DN LY3300054 DMOV2ML TI TT8ZLTI DMOV2ML TN Programmed cell death 1 ligand 1 (PD-L1) DMOV2ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOV2ML RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOV2ZD DI DMOV2ZD DMOV2ZD DN C188-9 DMOV2ZD TI TTHJT3X DMOV2ZD TN STAT3 messenger RNA (STAT3 mRNA) DMOV2ZD MA Inhibitor DMOV2ZD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOV2ZD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOWTRL DI DMOWTRL DMOWTRL DN GSK-2315698 DMOWTRL TI TTB7VAT DMOWTRL TN Serum amyloid P-component (APCS) DMOWTRL RN Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15. DMOWTRL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/ DMOWYKS DI DMOWYKS DMOWYKS DN RG6346 DMOWYKS TI TTSJVOI DMOWYKS TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMOWYKS MA Inhibitor DMOWYKS RN Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals. DMOWYKS RU https://dicerna.com/pipeline/rg6346/ DMOX6EJ DI DMOX6EJ DMOX6EJ DN PF-06840003 DMOX6EJ TI TTZJYKH DMOX6EJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOX6EJ MA Inhibitor DMOX6EJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOX6EJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMOXDIY DI DMOXDIY DMOXDIY DN CB-5339 DMOXDIY TI TTHNLSB DMOXDIY TN Valosin-containing protein p97 (VCP) DMOXDIY MA Inhibitor DMOXDIY RN Clinical pipeline report, company report or official report of Cleave Therapeutics. DMOXDIY RU https://www.casipharmaceuticals.com/product-pipeline/cb-5339/ DMOYPTK DI DMOYPTK DMOYPTK DN AZD4573 DMOYPTK TI TT1LVF2 DMOYPTK TN Cyclin-dependent kinase 9 (CDK9) DMOYPTK MA Inhibitor DMOYPTK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOYPTK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOYUPM DI DMOYUPM DMOYUPM DN PPL-100 DMOYUPM TI TT5FNQT DMOYUPM TN Human immunodeficiency virus Protease (HIV PR) DMOYUPM MA Inhibitor DMOYUPM RN Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res. 2006 Jun;70(2):17-20. DMOYUPM RU https://pubmed.ncbi.nlm.nih.gov/16473417 DMOYX6W DI DMOYX6W DMOYX6W DN PSMA-targeted tubulysin B conjugates DMOYX6W TI TT9G4N0 DMOYX6W TN Glutamate carboxypeptidase II (GCPII) DMOYX6W MA Modulator DMOYX6W RN Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm. 2009 May-Jun;6(3):780-9. DMOYX6W RU https://pubmed.ncbi.nlm.nih.gov/19361233 DMOZ3AT DI DMOZ3AT DMOZ3AT DN ACT-178882 DMOZ3AT TI TTB2MXP DMOZ3AT TN Angiotensinogenase renin (REN) DMOZ3AT MA Inhibitor DMOZ3AT RN Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Clin Drug Investig. 2013 Mar;33(3):207-13. DMOZ3AT RU https://pubmed.ncbi.nlm.nih.gov/23381958 DMP1ZF8 DI DMP1ZF8 DMP1ZF8 DN IC9-CAR19 cells DMP1ZF8 TI TTW640A DMP1ZF8 TN B-lymphocyte surface antigen B4 (CD19) DMP1ZF8 MA CAR-T-Cell-Therapy DMP1ZF8 RN ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia DMP1ZF8 RU https://clinicaltrials.gov/ct2/show/NCT03016377 DMP3QSA DI DMP3QSA DMP3QSA DN Quinazoline derivative 9 DMP3QSA TI TTQFRP0 DMP3QSA TN MEK kinase kinase 2 (MAP4K2) DMP3QSA MA Inhibitor DMP3QSA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP3QSA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP3QSA DI DMP3QSA DMP3QSA DN Quinazoline derivative 9 DMP3QSA TI TTRHJA3 DMP3QSA TN SPS1/STE20-related protein kinase YSK4 (YSK4) DMP3QSA MA Inhibitor DMP3QSA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP3QSA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP5CLY DI DMP5CLY DMP5CLY DN PRT6207 DMP5CLY TI TTOU65C DMP5CLY TN Tyrosine-protein kinase SYK (SYK) DMP5CLY MA Modulator DMP5CLY RN Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243. DMP5CLY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/ DMP5V83 DI DMP5V83 DMP5V83 DN CD22-specific CAR T-cells also expressing an EGFRt DMP5V83 TI TTM6QSK DMP5V83 TN B-cell receptor CD22 (CD22) DMP5V83 MA CAR-T-Cell-Therapy DMP5V83 RN ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma DMP5V83 RU https://clinicaltrials.gov/ct2/show/NCT03244306 DMP6I9T DI DMP6I9T DMP6I9T DN INO-3510 DMP6I9T TI TTUTN1I DMP6I9T TN Human Deoxyribonucleic acid (hDNA) DMP6I9T RN Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine. Inovio. March 26, 2012. DMP6I9T RU http://www.prnewswire.com/news-releases/inovio-receives-us-patent-for-syncon-h1n1-influenza-universal-vaccine-144185625.html DMP70FI DI DMP70FI DMP70FI DN BIBT986 DMP70FI TI TTCIHJA DMP70FI TN Coagulation factor Xa (F10) DMP70FI MA Inhibitor DMP70FI RN Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9. DMP70FI RU https://pubmed.ncbi.nlm.nih.gov/16839346 DMP8QY2 DI DMP8QY2 DMP8QY2 DN M1774 DMP8QY2 TI TT8ZYBQ DMP8QY2 TN Serine/threonine-protein kinase ATR (FRP1) DMP8QY2 MA Inhibitor DMP8QY2 RN National Cancer Institute Drug Dictionary (drug name M1774). DMP8QY2 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-m1774 DMP9J5V DI DMP9J5V DMP9J5V DN NLG802 DMP9J5V TI TTZJYKH DMP9J5V TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMP9J5V MA Inhibitor DMP9J5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP9J5V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMP9UO0 DI DMP9UO0 DMP9UO0 DN Lu-AE04621 DMP9UO0 TI TTEX248 DMP9UO0 TN Dopamine D2 receptor (D2R) DMP9UO0 MA Modulator DMP9UO0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031909) DMP9UO0 RU http://adisinsight.springer.com/drugs/800031909 DMP9VXQ DI DMP9VXQ DMP9VXQ DN ALPHA-FMH DMP9VXQ TI TTV9GOF DMP9VXQ TN Histidine decarboxylase (HDC) DMP9VXQ MA Modulator DMP9VXQ RN Alpha-Fluoromethylhistidine. Kinetics of uptake and inhibition of histamine synthesis in basophil (2H3) cell cultures. Mol Pharmacol. 1985 Aug;28(2):191-9. DMP9VXQ RU https://pubmed.ncbi.nlm.nih.gov/2410770 DMP9ZT1 DI DMP9ZT1 DMP9ZT1 DN ARQ 736 DMP9ZT1 TI TTWCGQT DMP9ZT1 TN Serine/threonine-protein kinase B-raf (BRAF) DMP9ZT1 MA Modulator DMP9ZT1 RN National Cancer Institute Drug Dictionary (drug id 688029). DMP9ZT1 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688029 DMPADR1 DI DMPADR1 DMPADR1 DN CD19/CD22 Chimeric Antigen Receptor T Cells DMPADR1 TI TTM6QSK DMPADR1 TN B-cell receptor CD22 (CD22) DMPADR1 MA CAR-T-Cell-Therapy(Dual specific) DMPADR1 RN ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia DMPADR1 RU https://clinicaltrials.gov/ct2/show/NCT03233854 DMPADR1 DI DMPADR1 DMPADR1 DN CD19/CD22 Chimeric Antigen Receptor T Cells DMPADR1 TI TTW640A DMPADR1 TN B-lymphocyte surface antigen B4 (CD19) DMPADR1 MA CAR-T-Cell-Therapy(Dual specific) DMPADR1 RN ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia DMPADR1 RU https://clinicaltrials.gov/ct2/show/NCT03233854 DMPAWBN DI DMPAWBN DMPAWBN DN GSK525762 DMPAWBN TI TTRA6BO DMPAWBN TN Bromodomain-containing protein 4 (BRD4) DMPAWBN MA Modulator DMPAWBN RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMPAWBN RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMPAWBN DI DMPAWBN DMPAWBN DN GSK525762 DMPAWBN TI TTE4BSY DMPAWBN TN Bromodomain and extraterminal domain protein (BET) DMPAWBN MA Inhibitor DMPAWBN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPAWBN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTV3XPL DMPCUN5 TN T-cell surface glycoprotein CD3 gamma (CD3G) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTZAT79 DMPCUN5 TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTZ8WH4 DMPCUN5 TN Tumor-associated calcium signal transducer 1 (EPCAM) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPD0KL DI DMPD0KL DMPD0KL DN ABBV-428 DMPD0KL TI TTIJP3Q DMPD0KL TN TNF related activation protein (CD40LG) DMPD0KL MA Stimulator DMPD0KL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPD0KL RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPE0KD DI DMPE0KD DMPE0KD DN MB-110 DMPE0KD TI TTCJ2X8 DMPE0KD TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMPE0KD MA Inhibitor DMPE0KD RN Clinical pipeline report, company report or official report of Microbio. DMPE0KD RU https://www.microbio.com.tw/home_03.php?p=7&a=15 DMPENAL DI DMPENAL DMPENAL DN FSI-189 DMPENAL TI TTBRJS9 DMPENAL TN Inhibitory receptor SHPS-1 (SIRPA) DMPENAL RN T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391. DMPENAL RU https://pubmed.ncbi.nlm.nih.gov/32265560 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTLD29N DMPHZI5 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TT0MYE2 DMPHZI5 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMPHZI5 MA Inhibitor DMPHZI5 RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTAN6JD DMPHZI5 TN Glutamate receptor AMPA (GRIA) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil r... J Med Chem. 2007 Apr 5;50(7):1558-70. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/17348638 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTKJEMQ DMPHZI5 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTVPQTF DMPHZI5 TN Glutamate receptor AMPA 1 (GRIA1) DMPHZI5 MA Inhibitor DMPHZI5 RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/17004715 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTN9D8E DMPHZI5 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPJA64 DI DMPJA64 DMPJA64 DN DA-1241 DMPJA64 TI TT7QNVC DMPJA64 TN Glucose-dependent insulinotropic receptor (GPR119) DMPJA64 MA Agonist DMPJA64 RN ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health. DMPJA64 RU https://clinicaltrials.gov/ct2/show/NCT03646721 DMPJBCR DI DMPJBCR DMPJBCR DN APO-010 DMPJBCR TI TTF0RCZ DMPJBCR TN Apoptosis mediating surface antigen FAS (FAS) DMPJBCR MA Binder DMPJBCR RN APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64. DMPJBCR RU https://pubmed.ncbi.nlm.nih.gov/21183510 DMPJMB7 DI DMPJMB7 DMPJMB7 DN NLX-101 DMPJMB7 TI TTSQIFT DMPJMB7 TN 5-HT 1A receptor (HTR1A) DMPJMB7 MA Modulator DMPJMB7 RN In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.Psychopharmacology (Berl).2012 May;221(2):261-72. DMPJMB7 RU https://www.ncbi.nlm.nih.gov/pubmed/22147258 DMPK32V DI DMPK32V DMPK32V DN BMS-754807 DMPK32V TI TTWTSCV DMPK32V TN RAC-alpha serine/threonine-protein kinase (AKT1) DMPK32V MA Inhibitor DMPK32V RN Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3. DMPK32V RU https://pubmed.ncbi.nlm.nih.gov/19778024 DMPKH6Y DI DMPKH6Y DMPKH6Y DN IPL 550,260 DMPKH6Y TI TTO0YVN DMPKH6Y TN Leukocyte (WBC) DMPKH6Y MA Modulator DMPKH6Y RN WO patent application no. 2005,0792,17, Oligonucleotide decoys and methods of use. DMPKH6Y RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050901&CC=WO&NR=2005079217A2&KC=A2 DMPKO84 DI DMPKO84 DMPKO84 DN PF-07220060 DMPKO84 TI TT0PG8F DMPKO84 TN Cyclin-dependent kinase 4 (CDK4) DMPKO84 MA Inhibitor DMPKO84 RN ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health. DMPKO84 RU https://clinicaltrials.gov/ct2/show/NCT04557449 DMPLFBV DI DMPLFBV DMPLFBV DN MEDI0680 DMPLFBV TI TTNBFWK DMPLFBV TN Programmed cell death protein 1 (PD-1) DMPLFBV RN A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73. DMPLFBV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/ DMPLHBI DI DMPLHBI DMPLHBI DN ARI-0001 cells DMPLHBI TI TTW640A DMPLHBI TN B-lymphocyte surface antigen B4 (CD19) DMPLHBI MA CAR-T-Cell-Therapy DMPLHBI RN ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy DMPLHBI RU https://clinicaltrials.gov/ct2/show/NCT03144583 DMPLV9G DI DMPLV9G DMPLV9G DN OBP-801 DMPLV9G TI TT6R7JZ DMPLV9G TN Histone deacetylase 1 (HDAC1) DMPLV9G MA Inhibitor DMPLV9G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2658). DMPLV9G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2658 DMPLV9G DI DMPLV9G DMPLV9G DN OBP-801 DMPLV9G TI TTBH0VX DMPLV9G TN Histone deacetylase (HDAC) DMPLV9G MA Inhibitor DMPLV9G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPLV9G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPMDTH DI DMPMDTH DMPMDTH DN Azd9496 DMPMDTH TI TTZAYWL DMPMDTH TN Estrogen receptor (ESR) DMPMDTH MA Antagonist DMPMDTH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPMDTH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPNBJ1 DI DMPNBJ1 DMPNBJ1 DN BAY1436032 DMPNBJ1 TI TTXDKHT DMPNBJ1 TN Mutated oxalosuccinate decarboxylase (mIDH1) DMPNBJ1 MA Inhibitor DMPNBJ1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPNBJ1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPQ1TM DI DMPQ1TM DMPQ1TM DN CA-011 DMPQ1TM TI TTMI6F5 DMPQ1TM TN Transient receptor potential cation channel V1 (TRPV1) DMPQ1TM MA Agonist DMPQ1TM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPQ1TM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMPQ5XC DI DMPQ5XC DMPQ5XC DN BMS-824383 DMPQ5XC TI TTCJ2X8 DMPQ5XC TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMPQ5XC MA Inhibitor DMPQ5XC RN 2011 Pipeline of Bristol-Myers Squibb. DMPQ5XC RU http://www.bms.com/pages/default.aspx DMPQE2S DI DMPQE2S DMPQE2S DN LVGN6051 DMPQE2S TI TTPW9LJ DMPQE2S TN Co-stimulatory molecule 4-1BB (CD137) DMPQE2S MA Activator DMPQE2S RN Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141. DMPQE2S RU https://pubmed.ncbi.nlm.nih.gov/31105267 DMPR3A6 DI DMPR3A6 DMPR3A6 DN DS-1055 DMPR3A6 TI TT0FAYT DMPR3A6 TN Transforming growth factor beta activator LRRC32 (LRRC32) DMPR3A6 MA Inhibitor DMPR3A6 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMPR3A6 RU https://www.daiichisankyo.com/media/press_release/detail/index_4081.html DMPS6U9 DI DMPS6U9 DMPS6U9 DN AC430 DMPS6U9 TI TTRMX3V DMPS6U9 TN Janus kinase 2 (JAK-2) DMPS6U9 MA Modulator DMPS6U9 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMPS6U9 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMPTYE6 DI DMPTYE6 DMPTYE6 DN CCW702 DMPTYE6 TI TTUN7MC DMPTYE6 TN T-cell surface glycoprotein CD3 (CD3) DMPTYE6 RN Clinical pipeline report, company report or official report of AbbVie. DMPTYE6 RU https://www.abbvie.com/our-science/pipeline/ccw702.html DMPTYE6 DI DMPTYE6 DMPTYE6 DN CCW702 DMPTYE6 TI TT9G4N0 DMPTYE6 TN Glutamate carboxypeptidase II (GCPII) DMPTYE6 RN Clinical pipeline report, company report or official report of AbbVie. DMPTYE6 RU https://www.abbvie.com/our-science/pipeline/ccw702.html DMPVUGE DI DMPVUGE DMPVUGE DN CDX-1127 DMPVUGE TI TTDO1MV DMPVUGE TN T-cell activation antigen CD27 (CD27) DMPVUGE MA Modulator DMPVUGE RN Clinical pipeline report, company report or official report of Celldex Therapeutics. DMPVUGE RU http://www.celldex.com/pipeline/cdx-1127.php DMPW21Z DI DMPW21Z DMPW21Z DN MEDI-578 DMPW21Z TI TTDN3LF DMPW21Z TN Nerve growth factor (NGF) DMPW21Z MA Modulator DMPW21Z RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DMPW21Z RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DMPWOH9 DI DMPWOH9 DMPWOH9 DN DKY709 DMPWOH9 TI TTKT5NV DMPWOH9 TN Zinc finger protein Helios (IKZF2) DMPWOH9 MA Degrader DMPWOH9 RN Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021 Apr;20(4):247-250. DMPWOH9 RU https://pubmed.ncbi.nlm.nih.gov/33737725 DMPXDL6 DI DMPXDL6 DMPXDL6 DN ABBV-CLS-579 DMPXDL6 TI TTY8PUS DMPXDL6 TN Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) DMPXDL6 MA Inhibitor DMPXDL6 RN Clinical pipeline report, company report or official report of Calico Life Sciences. DMPXDL6 RU https://www.calicolabs.com/press/calico-and-abbvie-share-update-on-early-stage-clinical-programs DMPXLMB DI DMPXLMB DMPXLMB DN Demobesin DMPXLMB TI TTHYDUM DMPXLMB TN Bombesin receptor (BS) DMPXLMB MA Antagonist DMPXLMB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38). DMPXLMB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38 DMPXOVA DI DMPXOVA DMPXOVA DN IN10018 DMPXOVA TI TTON5IT DMPXOVA TN Focal adhesion kinase 1 (FAK) DMPXOVA MA Inhibitor DMPXOVA RN Clinical pipeline report, company report or official report of InxMed. DMPXOVA RU http://en.inxmed.com/intro/3.html DMQ01MP DI DMQ01MP DMQ01MP DN ILV-095 DMQ01MP TI TTLDX4N DMQ01MP TN Interleukin-22 (IL22) DMQ01MP RN Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. DMQ01MP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/ DMQ0F5P DI DMQ0F5P DMQ0F5P DN NUC-3373 DMQ0F5P TI TT5FOMZ DMQ0F5P TN Thymidylate synthase (TYMS) DMQ0F5P MA Inhibitor DMQ0F5P RN Clinical pipeline report, company report or official report of NuCana. DMQ0F5P RU http://www.nucana.com/nuc3373.html DMQ0K95 DI DMQ0K95 DMQ0K95 DN Lu-02-750 DMQ0K95 TI TTEX248 DMQ0K95 TN Dopamine D2 receptor (D2R) DMQ0K95 MA Agonist DMQ0K95 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031195) DMQ0K95 RU http://adisinsight.springer.com/drugs/800031195 DMQ0N5Z DI DMQ0N5Z DMQ0N5Z DN AMG 562 DMQ0N5Z TI TTW640A DMQ0N5Z TN B-lymphocyte surface antigen B4 (CD19) DMQ0N5Z MA Inhibitor DMQ0N5Z RN Clinical pipeline report, company report or official report of Amgen. DMQ0N5Z RU https://www.amgenpipeline.com/ DMQ0RXA DI DMQ0RXA DMQ0RXA DN 11C-GSK-215083 DMQ0RXA TI TTJS8PY DMQ0RXA TN 5-HT 6 receptor (HTR6) DMQ0RXA MA Antagonist DMQ0RXA RN Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 Feb;53(2):295-303. DMQ0RXA RU https://pubmed.ncbi.nlm.nih.gov/22223878 DMQ1OX4 DI DMQ1OX4 DMQ1OX4 DN AZD1979 DMQ1OX4 TI TTX4RTB DMQ1OX4 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQ1OX4 MA Modulator DMQ1OX4 RN Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc DMQ1OX4 RU http://www.biocentury.com/products/azd1979 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTJFY5U DMQ2K1V TN Adenosine A3 receptor (ADORA3) DMQ2K1V MA Inhibitor DMQ2K1V RN Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/20801028 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTM2AOE DMQ2K1V TN Adenosine A2a receptor (ADORA2A) DMQ2K1V MA Inhibitor DMQ2K1V RN Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/11087559 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTK25J1 DMQ2K1V TN Adenosine A1 receptor (ADORA1) DMQ2K1V MA Inhibitor DMQ2K1V RN Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/11087559 DMQ2OP0 DI DMQ2OP0 DMQ2OP0 DN CA-170 DMQ2OP0 TI TT8ZLTI DMQ2OP0 TN Programmed cell death 1 ligand 1 (PD-L1) DMQ2OP0 MA Inhibitor DMQ2OP0 RN CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804. DMQ2OP0 RU https://pubmed.ncbi.nlm.nih.gov/31374878 DMQ2Y1J DI DMQ2Y1J DMQ2Y1J DN CAR-T cells targeting EpCAM DMQ2Y1J TI TTZ8WH4 DMQ2Y1J TN Tumor-associated calcium signal transducer 1 (EPCAM) DMQ2Y1J MA CAR-T-Cell-Therapy DMQ2Y1J RN ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) DMQ2Y1J RU https://clinicaltrials.gov/ct2/show/NCT03563326 DMQ3O1U DI DMQ3O1U DMQ3O1U DN ABT-165 DMQ3O1U TI TTV23LH DMQ3O1U TN Delta-like protein 4 (DLL4) DMQ3O1U MA Inhibitor DMQ3O1U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ3O1U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ3O1U DI DMQ3O1U DMQ3O1U DN ABT-165 DMQ3O1U TI TT9HKJA DMQ3O1U TN Vascular endothelial growth factor (VEGF) DMQ3O1U MA Inhibitor DMQ3O1U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ3O1U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ46DN DI DMQ46DN DMQ46DN DN GW-796406 DMQ46DN TI TT5TKPM DMQ46DN TN Neutral endopeptidase (MME) DMQ46DN MA Modulator DMQ46DN RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMQ46DN RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMQ46DN DI DMQ46DN DMQ46DN DN GW-796406 DMQ46DN TI TTL69WB DMQ46DN TN Angiotensin-converting enzyme (ACE) DMQ46DN MA Modulator DMQ46DN RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMQ46DN RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMQ4UJ6 DI DMQ4UJ6 DMQ4UJ6 DN CART-10 cells DMQ4UJ6 TI TT5TKPM DMQ4UJ6 TN Neutral endopeptidase (MME) DMQ4UJ6 MA CAR-T-Cell-Therapy DMQ4UJ6 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMQ4UJ6 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMQ4Z1P DI DMQ4Z1P DMQ4Z1P DN Peginterferon beta DMQ4Z1P TI TTRMX3V DMQ4Z1P TN Janus kinase 2 (JAK-2) DMQ4Z1P MA Inhibitor DMQ4Z1P RN Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34. DMQ4Z1P RU https://pubmed.ncbi.nlm.nih.gov/18528425 DMQ5ZND DI DMQ5ZND DMQ5ZND DN Anti-MUC1 mab DMQ5ZND TI TTBHFYQ DMQ5ZND TN Mucin-1 (MUC1) DMQ5ZND MA Modulator DMQ5ZND RN Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics. 2001;20(5-6):313-24. DMQ5ZND RU https://pubmed.ncbi.nlm.nih.gov/11839249 DMQ5ZVK DI DMQ5ZVK DMQ5ZVK DN JNJ-54175446 DMQ5ZVK TI TT473XN DMQ5ZVK TN P2X purinoceptor 7 (P2RX7) DMQ5ZVK MA Antagonist DMQ5ZVK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ5ZVK RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQ65YW DI DMQ65YW DMQ65YW DN RO-09-4889 DMQ65YW TI TTZPS91 DMQ65YW TN Dihydrothymine dehydrogenase (DPYD) DMQ65YW MA Modulator DMQ65YW RN Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35. DMQ65YW RU https://pubmed.ncbi.nlm.nih.gov/15073108 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTK25J1 DMQ6DLZ TN Adenosine A1 receptor (ADORA1) DMQ6DLZ MA Inhibitor DMQ6DLZ RN 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/11170626 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTM2AOE DMQ6DLZ TN Adenosine A2a receptor (ADORA2A) DMQ6DLZ MA Inhibitor DMQ6DLZ RN Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/8246243 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTNE7KG DMQ6DLZ TN Adenosine A2b receptor (ADORA2B) DMQ6DLZ MA Inhibitor DMQ6DLZ RN Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/8246243 DMQ6GUY DI DMQ6GUY DMQ6GUY DN EOS100850 DMQ6GUY TI TTM2AOE DMQ6GUY TN Adenosine A2a receptor (ADORA2A) DMQ6GUY MA Antagonist DMQ6GUY RN National Cancer Institute Drug Dictionary (drug name EOS100850). DMQ6GUY RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a2a-receptor-antagonist-eos100850 DMQ6YAZ DI DMQ6YAZ DMQ6YAZ DN EMD-534085 DMQ6YAZ TI TTBGTCW DMQ6YAZ TN Kinesin spindle messenger RNA (KIF11 mRNA) DMQ6YAZ MA Inhibitor DMQ6YAZ RN The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5. DMQ6YAZ RU https://pubmed.ncbi.nlm.nih.gov/20149654 DMQ76B4 DI DMQ76B4 DMQ76B4 DN BCL11a shRNA DMQ76B4 TI TTPLHYK DMQ76B4 TN BCL11A messenger RNA (BCL11A mRNA) DMQ76B4 MA Inhibitor DMQ76B4 RN Clinical pipeline report, company report or official report of bluebird bio. DMQ76B4 RU https://www.bluebirdbio.com/our-science/pipeline DMQ789Z DI DMQ789Z DMQ789Z DN 8H9 DMQ789Z TI TTUCPMY DMQ789Z TN Tenascin (TNC) DMQ789Z RN In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24. DMQ789Z RU https://pubmed.ncbi.nlm.nih.gov/14973056 DMQ7UN6 DI DMQ7UN6 DMQ7UN6 DN Trodusquemine DMQ7UN6 TI TTMS7KP DMQ7UN6 TN Protein-tyrosine phosphatase 1B (PTP1B) DMQ7UN6 MA Inhibitor DMQ7UN6 RN Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring). 2010 Aug;18(8):1516-23. DMQ7UN6 RU https://pubmed.ncbi.nlm.nih.gov/20075852 DMQ7WJI DI DMQ7WJI DMQ7WJI DN CAF-01 DMQ7WJI TI TT3J5ZI DMQ7WJI TN Cell mediated immunity response (CMIR) DMQ7WJI MA Modulator DMQ7WJI RN Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114. DMQ7WJI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655441/ DMQ82SH DI DMQ82SH DMQ82SH DN PMZ-2123 DMQ82SH TI TTKRD0G DMQ82SH TN Endothelin A receptor (EDNRA) DMQ82SH MA Antagonist DMQ82SH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ82SH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMQ8ACY DI DMQ8ACY DMQ8ACY DN DCCCyB DMQ8ACY TI TTHJTF7 DMQ8ACY TN Glycine transporter GlyT-1 (SLC6A9) DMQ8ACY MA Modulator DMQ8ACY RN Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354. DMQ8ACY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007840/ DMQ8NTZ DI DMQ8NTZ DMQ8NTZ DN 192C86 DMQ8NTZ TI TTNVEIR DMQ8NTZ TN Prostaglandin D2 receptor (PTGDR) DMQ8NTZ MA Modulator DMQ8NTZ RN Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145. DMQ8NTZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795261/ DMQ8YKR DI DMQ8YKR DMQ8YKR DN TAK-648 DMQ8YKR TI TTV5CGO DMQ8YKR TN Phosphodiesterase 4 (PDE4) DMQ8YKR MA Inhibitor DMQ8YKR RN Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction. Clin Transl Sci. 2017 May;10(3):185-193. DMQ8YKR RU https://pubmed.ncbi.nlm.nih.gov/28088839 DMQ9317 DI DMQ9317 DMQ9317 DN GEN1044 DMQ9317 TI TT70MLA DMQ9317 TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMQ9317 RN Clinical pipeline report, company report or official report of AbbVie. DMQ9317 RU https://www.abbvie.com/our-science/pipeline/gen-1044.html DMQ9317 DI DMQ9317 DMQ9317 DN GEN1044 DMQ9317 TI TTUN7MC DMQ9317 TN T-cell surface glycoprotein CD3 (CD3) DMQ9317 RN Clinical pipeline report, company report or official report of AbbVie. DMQ9317 RU https://www.abbvie.com/our-science/pipeline/gen-1044.html DMQ98MW DI DMQ98MW DMQ98MW DN SAR164653 DMQ98MW TI TT5NILS DMQ98MW TN Cathepsin A (CTSA) DMQ98MW MA Modulator DMQ98MW RN Tolerability, safety and pharmacokinetics of the novel Cathepsin A inhibitor SAR164653 in healthy subjects.Clinical Pharmacology in Drug Development 05/2015. DMQ98MW RU http://www.researchgate.net/publication/276150796_Tolerability_safety_and_pharmacokinetics_of_the_novel_Cathepsin_A_inhibitor_SAR164653_in_healthy_subjects DMQ9KZW DI DMQ9KZW DMQ9KZW DN Biomed 101 DMQ9KZW TI TTN53ZF DMQ9KZW TN Leukotriene B4 receptor 1 (LTB4R) DMQ9KZW MA Binder DMQ9KZW RN Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003. DMQ9KZW RU http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101740 DMQ9KZW DI DMQ9KZW DMQ9KZW DN Biomed 101 DMQ9KZW TI TTVJX54 DMQ9KZW TN Leukotriene B4 receptor 2 (LTB4R2) DMQ9KZW MA Inhibitor DMQ9KZW RN Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993). DMQ9KZW RU http://www.sciencedirect.com/science/article/pii/S0960894X01810003 DMQ9ZY0 DI DMQ9ZY0 DMQ9ZY0 DN SAR-104772 DMQ9ZY0 TI TTP18AY DMQ9ZY0 TN Carboxypeptidase B2 (CPB2) DMQ9ZY0 MA Inhibitor DMQ9ZY0 RN Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009. DMQ9ZY0 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03596.x/full DMQA1VT DI DMQA1VT DMQA1VT DN Autologous cell based gene therapy DMQA1VT TI TTCM4B3 DMQA1VT TN Nitric-oxide synthase endothelial (NOS3) DMQA1VT MA Modulator DMQA1VT RN Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8. DMQA1VT RU https://pubmed.ncbi.nlm.nih.gov/12231180 DMQAIU1 DI DMQAIU1 DMQAIU1 DN RGLS4326 DMQAIU1 TI TTMGJ19 DMQAIU1 TN microRNA hsa-miR-17 (MIR17) DMQAIU1 MA Inhibitor DMQAIU1 RN Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. DMQAIU1 RU https://pubmed.ncbi.nlm.nih.gov/31515477 DMQB3HD DI DMQB3HD DMQB3HD DN XmAb22841 DMQB3HD TI TTI2S1D DMQB3HD TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMQB3HD RN Clinical pipeline report, company report or official report of Xencor. DMQB3HD RU https://xencor.com/pipeline/xmab22841/ DMQB3HD DI DMQB3HD DMQB3HD DN XmAb22841 DMQB3HD TI TTNVXAW DMQB3HD TN Lymphocyte activation gene 3 protein (LAG3) DMQB3HD RN Clinical pipeline report, company report or official report of Xencor. DMQB3HD RU https://xencor.com/pipeline/xmab22841/ DMQB4VN DI DMQB4VN DMQB4VN DN MGD006 DMQB4VN TI TTUN7MC DMQB4VN TN T-cell surface glycoprotein CD3 (CD3) DMQB4VN MA Modulator DMQB4VN RN A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. DMQB4VN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288763/ DMQB4VN DI DMQB4VN DMQB4VN DN MGD006 DMQB4VN TI TTENHJ0 DMQB4VN TN Interleukin 3 receptor alpha (IL3RA) DMQB4VN MA Modulator DMQB4VN RN A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82. DMQB4VN RU https://www.ncbi.nlm.nih.gov/pubmed/26019218 DMQBEYV DI DMQBEYV DMQBEYV DN GC021109 DMQBEYV TI TTNVSKA DMQBEYV TN P2Y purinoceptor 6 (P2RY6) DMQBEYV MA Agonist DMQBEYV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBEYV RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQBO3V DI DMQBO3V DMQBO3V DN M4344 DMQBO3V TI TT8ZYBQ DMQBO3V TN Serine/threonine-protein kinase ATR (FRP1) DMQBO3V MA Inhibitor DMQBO3V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBO3V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQCHU3 DI DMQCHU3 DMQCHU3 DN CPP -15 DMQCHU3 TI TTT2LD9 DMQCHU3 TN GABA transaminase (ABAT) DMQCHU3 MA Modulator DMQCHU3 RN Clinical pipeline report, company report or official report of Catalyst Pharma. DMQCHU3 RU http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588 DMQDBSU DI DMQDBSU DMQDBSU DN MEDI1341 DMQDBSU TI TT08OSU DMQDBSU TN Synuclein alpha (SNCA) DMQDBSU MA Inhibitor DMQDBSU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQDBSU RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQDKYV DI DMQDKYV DMQDKYV DN E-2212 DMQDKYV TI TT9W8GU DMQDKYV TN Gamma-secretase (GS) DMQDKYV MA Modulator DMQDKYV RN Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry. 2013 May 14;52(19):3197-216. DMQDKYV RU https://pubmed.ncbi.nlm.nih.gov/23614767 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TTWRN6M DMQDUG4 TN CRP messenger RNA (CRP mRNA) DMQDUG4 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMQDUG4 RU http://www.isispharm.com/Pipeline/index.htm DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT6TH8V DMQDUG4 TN Tyrosine-protein kinase BRK (PTK6) DMQDUG4 MA Inhibitor DMQDUG4 RN Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/15073106 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT860QF DMQDUG4 TN LCK tyrosine protein kinase (LCK) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT3PJMV DMQDUG4 TN Tyrosine-protein kinase ABL1 (ABL) DMQDUG4 MA Inhibitor DMQDUG4 RN Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/18257513 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT6PKBN DMQDUG4 TN Proto-oncogene c-Src (SRC) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TTCQ2E5 DMQDUG4 TN RIP2 messenger RNA (RIP2 mRNA) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQE4IX DI DMQE4IX DMQE4IX DN MG-1102 DMQE4IX TI TTGUMYS DMQE4IX TN Apolipoprotein(a) (LPA) DMQE4IX MA Modulator DMQE4IX RN Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia. 2012 Apr;14(4):335-43. DMQE4IX RU https://pubmed.ncbi.nlm.nih.gov/22577348 DMQE9PS DI DMQE9PS DMQE9PS DN LXH254 DMQE9PS TI TTAN5W2 DMQE9PS TN Raf messenger RNA (Raf mRNA) DMQE9PS MA Inhibitor DMQE9PS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQE9PS RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQEO4V DI DMQEO4V DMQEO4V DN AZD-5122 DMQEO4V TI TT30C9G DMQEO4V TN C-X-C chemokine receptor type 2 (CXCR2) DMQEO4V MA Modulator DMQEO4V RN Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589. DMQEO4V RU http://www.mdpi.com/1424-8247/4/4/567 DMQEOD6 DI DMQEOD6 DMQEOD6 DN VTP-27999 DMQEOD6 TI TTB2MXP DMQEOD6 TN Angiotensinogenase renin (REN) DMQEOD6 MA Inhibitor DMQEOD6 RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMQEOD6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMQF982 DI DMQF982 DMQF982 DN AEW-541 DMQF982 TI TTHRID2 DMQF982 TN Insulin-like growth factor I receptor (IGF1R) DMQF982 MA Inhibitor DMQF982 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMQF982 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMQF982 DI DMQF982 DMQF982 DN AEW-541 DMQF982 TI TTCBFJO DMQF982 TN Insulin receptor (INSR) DMQF982 MA Inhibitor DMQF982 RN Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009 Aug 27;52(16):4981-5004. DMQF982 RU https://pubmed.ncbi.nlm.nih.gov/19610618 DMQFX8R DI DMQFX8R DMQFX8R DN DN1406131 DMQFX8R TI TTXNCBV DMQFX8R TN Tryptophan 2,3-dioxygenase (TDO) DMQFX8R MA Inhibitor DMQFX8R RN ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health. DMQFX8R RU https://clinicaltrials.gov/ct2/show/NCT03641794 DMQFX8R DI DMQFX8R DMQFX8R DN DN1406131 DMQFX8R TI TTZJYKH DMQFX8R TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQFX8R MA Inhibitor DMQFX8R RN ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health. DMQFX8R RU https://clinicaltrials.gov/ct2/show/NCT03641794 DMQGPRE DI DMQGPRE DMQGPRE DN ABBV-399 DMQGPRE TI TTNDSF4 DMQGPRE TN Proto-oncogene c-Met (MET) DMQGPRE MA Inhibitor DMQGPRE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQGPRE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMQH2DK DI DMQH2DK DMQH2DK DN CAR-GPC3 T Cells DMQH2DK TI TTJTSX4 DMQH2DK TN Glypican-3 (GPC3) DMQH2DK MA CAR-T-Cell-Therapy DMQH2DK RN ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma DMQH2DK RU https://clinicaltrials.gov/ct2/show/NCT02876978 DMQHPME DI DMQHPME DMQHPME DN MK-8583 DMQHPME TI TT84ETX DMQHPME TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQHPME MA Inhibitor DMQHPME RN ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health. DMQHPME RU https://clinicaltrials.gov/ct2/show/NCT03552536 DMQHWMJ DI DMQHWMJ DMQHWMJ DN LAM-003 DMQHWMJ TI TTO7FVG DMQHWMJ TN Heat shock protein 90 (HSP90) DMQHWMJ MA Inhibitor DMQHWMJ RN LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673. DMQHWMJ RU https://pubmed.ncbi.nlm.nih.gov/31751472 DMQI970 DI DMQI970 DMQI970 DN Lumoxiti DMQI970 TI TTM6QSK DMQI970 TN B-cell receptor CD22 (CD22) DMQI970 MA Inhibitor DMQI970 RN Clinical pipeline report, company report or official report of Innate Pharma. DMQI970 RU https://www.innate-pharma.com/fr/produits/lumoxiti DMQIE58 DI DMQIE58 DMQIE58 DN HH2853 DMQIE58 TI TTNJA0C DMQIE58 TN Enhancer of zeste homolog 1 (EZH1) DMQIE58 MA Inhibitor DMQIE58 RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DMQIE58 RU https://www.haihepharma.com/en/news/details/215 DMQIE58 DI DMQIE58 DMQIE58 DN HH2853 DMQIE58 TI TT9MZCQ DMQIE58 TN Enhancer of zeste homolog 2 (EZH2) DMQIE58 MA Inhibitor DMQIE58 RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DMQIE58 RU https://www.haihepharma.com/en/news/details/215 DMQIEFB DI DMQIEFB DMQIEFB DN Debio 0827 DMQIEFB TI TT5TKPM DMQIEFB TN Neutral endopeptidase (MME) DMQIEFB MA Inhibitor DMQIEFB RN Clinical pipeline report, company report or official report of Debiopharm (2011). DMQIEFB RU http://www.debiopharm.com/our-business/pipeline.html DMQIKZG DI DMQIKZG DMQIKZG DN BAY 1834942 DMQIKZG TI TTIGH2W DMQIKZG TN Normal cross-reacting antigen (CD66c) DMQIKZG MA Blocker DMQIKZG RN ClinicalTrials.gov (NCT03596372) Study of BAY1834942 in Patients With Solid Tumors. U.S. National Institutes of Health. DMQIKZG RU https://clinicaltrials.gov/ct2/show/NCT03596372 DMQK5ET DI DMQK5ET DMQK5ET DN NG-350A DMQK5ET TI TTN6Y9A DMQK5ET TN CD40L receptor (CD40) DMQK5ET MA Agonist DMQK5ET RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMQK5ET RU https://psioxus.com/technology-products/ng-350a/ DMQKDJZ DI DMQKDJZ DMQKDJZ DN DWJ-208 DMQKDJZ TI TT4G2JS DMQKDJZ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMQKDJZ MA Antagonist DMQKDJZ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMQKDJZ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMQLODU DI DMQLODU DMQLODU DN Citarinostat DMQLODU TI TT5ZKDI DMQLODU TN Histone deacetylase 6 (HDAC6) DMQLODU MA Inhibitor DMQLODU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQLODU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQMEDH DI DMQMEDH DMQMEDH DN BGB-A445 DMQMEDH TI TTL31H0 DMQMEDH TN OX40L receptor (CD134) DMQMEDH RN Clinical pipeline report, company report or official report of BeiGene. DMQMEDH RU https://www.beigene.com/science-and-product-portfolio/pipeline DMQMO4N DI DMQMO4N DMQMO4N DN SRF388 DMQMO4N TI TTC5LTG DMQMO4N TN Interleukin-27 (IL27) DMQMO4N RN Clinical pipeline report, company report or official report of Surface oncology. DMQMO4N RU https://www.surfaceoncology.com/pipeline-programs/ DMQNRGE DI DMQNRGE DMQNRGE DN PTG-100 DMQNRGE TI TTLT9XQ DMQNRGE TN Integrin beta-7 (ITGB7) DMQNRGE MA Antagonist DMQNRGE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNRGE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQNRGE DI DMQNRGE DMQNRGE DN PTG-100 DMQNRGE TI TT4BT06 DMQNRGE TN Integrin alpha-4 (ITGA4) DMQNRGE MA Antagonist DMQNRGE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNRGE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQNS51 DI DMQNS51 DMQNS51 DN PRN2246 DMQNS51 TI TTGM6VW DMQNS51 TN Tyrosine-protein kinase BTK (ATK) DMQNS51 MA Inhibitor DMQNS51 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNS51 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQOHRA DI DMQOHRA DMQOHRA DN JNJ-67571244 DMQOHRA TI TTJVYO3 DMQOHRA TN Myeloid cell surface antigen CD33 (CD33) DMQOHRA MA Inhibitor DMQOHRA RN Clinical pipeline report, company report or official report of Genmab. DMQOHRA RU https://www.genmab.com/pipeline/ DMQOM5V DI DMQOM5V DMQOM5V DN GSK2646264 DMQOM5V TI TTOU65C DMQOM5V TN Tyrosine-protein kinase SYK (SYK) DMQOM5V MA Inhibitor DMQOM5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQOM5V RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQP6VB DI DMQP6VB DMQP6VB DN LY3200882 DMQP6VB TI TTP4520 DMQP6VB TN TGF-beta receptor type I (TGFBR1) DMQP6VB MA Inhibitor DMQP6VB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQP6VB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQPI4V DI DMQPI4V DMQPI4V DN ELOMOTECAN HYDROCHLORIDE DMQPI4V TI TTGTQHC DMQPI4V TN DNA topoisomerase I (TOP1) DMQPI4V MA Modulator DMQPI4V RN The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci. 2000;922:303-5. DMQPI4V RU https://www.ncbi.nlm.nih.gov/pubmed/11193907 DMQR4HA DI DMQR4HA DMQR4HA DN DABIS MALEATE DMQR4HA TI TTUTN1I DMQR4HA TN Human Deoxyribonucleic acid (hDNA) DMQR4HA MA Binder DMQR4HA RN DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9. DMQR4HA RU https://pubmed.ncbi.nlm.nih.gov/2393411 DMQRKXP DI DMQRKXP DMQRKXP DN AEA-35p DMQRKXP TI TTYA75N DMQRKXP TN MHC class II antigen DR (HLA-DR) DMQRKXP RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMQRKXP RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMQRNTG DI DMQRNTG DMQRNTG DN MP-124 DMQRNTG TI TTEBCY8 DMQRNTG TN Poly [ADP-ribose] polymerase (PARP) DMQRNTG MA Modulator DMQRNTG RN Company report (Mitsubishi Tanabe Pharma) DMQRNTG RU http://www.mt-pharma-america.com/development.php DMQSJ9T DI DMQSJ9T DMQSJ9T DN Meso-CART DMQSJ9T TI TT4RXME DMQSJ9T TN Mesothelin (MSLN) DMQSJ9T MA CAR-T-Cell-Therapy DMQSJ9T RN ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma DMQSJ9T RU https://clinicaltrials.gov/ct2/show/NCT02706782 DMQTOBF DI DMQTOBF DMQTOBF DN CART-56 cells DMQTOBF TI TTVXPHT DMQTOBF TN Neural cell adhesion molecule 1 (NCAM1) DMQTOBF MA CAR-T-Cell-Therapy DMQTOBF RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMQTOBF RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMQTUH8 DI DMQTUH8 DMQTUH8 DN Calanolide A DMQTUH8 TI TT84ETX DMQTUH8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQTUH8 MA Inhibitor DMQTUH8 RN Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9. DMQTUH8 RU https://pubmed.ncbi.nlm.nih.gov/11366704 DMQUFNY DI DMQUFNY DMQUFNY DN ARM210 DMQUFNY TI TT9YXM1 DMQUFNY TN Ryanodine receptor (RYR) DMQUFNY MA Modulator DMQUFNY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQUFNY RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMQUNRW DI DMQUNRW DMQUNRW DN PF-06763809 DMQUNRW TI TTRX125 DMQUNRW TN Transcription factor unspecific (TF) DMQUNRW MA Inhibitor DMQUNRW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQUNRW RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQVEZB DI DMQVEZB DMQVEZB DN Adjustable basal insulin DMQVEZB TI TTZOPHG DMQVEZB TN Insulin (INS) DMQVEZB MA Modulator DMQVEZB RN The future of basal insulin supplementation. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8. DMQVEZB RU https://pubmed.ncbi.nlm.nih.gov/21568722 DMQYBSH DI DMQYBSH DMQYBSH DN PF-05231023 DMQYBSH TI TTQ916P DMQYBSH TN Fibroblast growth factor-21 (FGF21) DMQYBSH RN Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11. DMQYBSH RU https://pubmed.ncbi.nlm.nih.gov/25805881 DMQZSXD DI DMQZSXD DMQZSXD DN GSK3117391 DMQZSXD TI TTBH0VX DMQZSXD TN Histone deacetylase (HDAC) DMQZSXD MA Modulator DMQZSXD RN The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42. DMQZSXD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215088/ DMR0S8U DI DMR0S8U DMR0S8U DN C326 DMR0S8U TI TTT1V78 DMR0S8U TN Interleukin-6 (IL6) DMR0S8U MA Inhibitor DMR0S8U RN The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009 Jul 9;114(2):437-43. DMR0S8U RU https://pubmed.ncbi.nlm.nih.gov/19383972 DMR0U4V DI DMR0U4V DMR0U4V DN XEN-D0103 DMR0U4V TI TTW0CMT DMR0U4V TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMR0U4V MA Inhibitor DMR0U4V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542). DMR0U4V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542 DMR0Z65 DI DMR0Z65 DMR0Z65 DN CART-20 cells DMR0Z65 TI TTUE541 DMR0Z65 TN Leukocyte surface antigen Leu-16 (CD20) DMR0Z65 MA CAR-T-Cell-Therapy DMR0Z65 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMR0Z65 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMR12S0 DI DMR12S0 DMR12S0 DN ORIC-101 DMR12S0 TI TTOZRK6 DMR12S0 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMR12S0 MA Antagonist DMR12S0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR12S0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR14VE DI DMR14VE DMR14VE DN KH-901 DMR14VE TI TT6MP2Z DMR14VE TN GMCSFR-alpha (CSF2RA) DMR14VE RN Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90. DMR14VE RU https://pubmed.ncbi.nlm.nih.gov/17593813 DMR17YI DI DMR17YI DMR17YI DN Isoquine DMR17YI TI TTQ6VDM DMR17YI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMR17YI MA Inhibitor DMR17YI RN Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. DMR17YI RU https://pubmed.ncbi.nlm.nih.gov/19222165 DMR17YI DI DMR17YI DMR17YI DN Isoquine DMR17YI TI TTVG215 DMR17YI TN Debrisoquine 4-hydroxylase (CYP2D6) DMR17YI MA Inhibitor DMR17YI RN Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. DMR17YI RU https://pubmed.ncbi.nlm.nih.gov/19222165 DMR24MI DI DMR24MI DMR24MI DN GSK-2256098 DMR24MI TI TTON5IT DMR24MI TN Focal adhesion kinase 1 (FAK) DMR24MI MA Inhibitor DMR24MI RN A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9. DMR24MI RU https://pubmed.ncbi.nlm.nih.gov/25486573 DMR35U4 DI DMR35U4 DMR35U4 DN AMXT1501 DMR35U4 TI TTJR4Z5 DMR35U4 TN Polyamine transport (Poly trans) DMR35U4 MA Inhibitor DMR35U4 RN AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. 2013 Sep 15;133(6):1323-33. DMR35U4 RU https://pubmed.ncbi.nlm.nih.gov/23457004 DMR38M4 DI DMR38M4 DMR38M4 DN UNBS-1450 DMR38M4 TI TTWK8D0 DMR38M4 TN Sodium pump subunit alpha-1 (ATP1A1) DMR38M4 MA Inhibitor DMR38M4 RN Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 2015 Jun 11;6:e1782. DMR38M4 RU https://pubmed.ncbi.nlm.nih.gov/26068790 DMR3E4L DI DMR3E4L DMR3E4L DN Irdabisant DMR3E4L TI TT9JNIC DMR3E4L TN Histamine H3 receptor (H3R) DMR3E4L MA Antagonist DMR3E4L RN CEP-26401 (irdabisant), a potent and selective histamine H receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33. DMR3E4L RU https://pubmed.ncbi.nlm.nih.gov/22001260 DMR3SO5 DI DMR3SO5 DMR3SO5 DN JCAR018 DMR3SO5 TI TTM6QSK DMR3SO5 TN B-cell receptor CD22 (CD22) DMR3SO5 MA Immunomodulator DMR3SO5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3SO5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMR5ATX DI DMR5ATX DMR5ATX DN NKR-2 cells DMR5ATX TI TTLRN4A DMR5ATX TN NKG2 D activating NK receptor (KLRK1) DMR5ATX MA CAR-T-Cell-Therapy DMR5ATX RN ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases DMR5ATX RU https://clinicaltrials.gov/ct2/show/NCT03310008 DMR6T8L DI DMR6T8L DMR6T8L DN COM902 DMR6T8L TI TTWNL74 DMR6T8L TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMR6T8L RN COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26. DMR6T8L RU https://pubmed.ncbi.nlm.nih.gov/33903974 DMR7BAO DI DMR7BAO DMR7BAO DN PRN1371 DMR7BAO TI TT0LF7H DMR7BAO TN Fibroblast growth factor receptor (FGFR) DMR7BAO MA Inhibitor DMR7BAO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR7BAO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR7EF6 DI DMR7EF6 DMR7EF6 DN KHK-2866 DMR7EF6 TI TT15SL0 DMR7EF6 TN Proheparin-binding EGF-like growth factor (HBEGF) DMR7EF6 RN ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health. DMR7EF6 RU https://clinicaltrials.gov/ct2/show/NCT01279291 DMR7LKC DI DMR7LKC DMR7LKC DN LM-CD45 DMR7LKC TI TTUS45N DMR7LKC TN Leukocyte common antigen (PTPRC) DMR7LKC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932) DMR7LKC RU http://adisinsight.springer.com/drugs/800002932 DMR7OGL DI DMR7OGL DMR7OGL DN ABT-239 DMR7OGL TI TT9JNIC DMR7OGL TN Histamine H3 receptor (H3R) DMR7OGL MA Antagonist DMR7OGL RN Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol. 2009 May;157(1):139-49. DMR7OGL RU https://pubmed.ncbi.nlm.nih.gov/19413577 DMR8OG2 DI DMR8OG2 DMR8OG2 DN IMGN-853 DMR8OG2 TI TTVC37M DMR8OG2 TN Folate receptor alpha (FOLR1) DMR8OG2 MA Inhibitor DMR8OG2 RN Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92. DMR8OG2 RU https://pubmed.ncbi.nlm.nih.gov/19891424 DMR93S5 DI DMR93S5 DMR93S5 DN ATL1103 DMR93S5 TI TTHJWYD DMR93S5 TN GHR messenger RNA (GHR mRNA) DMR93S5 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMR93S5 RU http://www.isispharm.com/Pipeline/index.htm DMR9PCT DI DMR9PCT DMR9PCT DN VX-970 DMR9PCT TI TT8ZYBQ DMR9PCT TN Serine/threonine-protein kinase ATR (FRP1) DMR9PCT MA Inhibitor DMR9PCT RN ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79. DMR9PCT RU https://pubmed.ncbi.nlm.nih.gov/25269479 DMRAWGC DI DMRAWGC DMRAWGC DN KM-819 DMRAWGC TI TTSKL3G DMRAWGC TN FAS-associated factor 1 (FAF1) DMRAWGC MA Inhibitor DMRAWGC RN A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022. DMRAWGC RU https://pubmed.ncbi.nlm.nih.gov/30992659 DMRAXFH DI DMRAXFH DMRAXFH DN SRT3025 DMRAXFH TI TTUF2HO DMRAXFH TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMRAXFH MA Modulator DMRAXFH RN The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. DMRAXFH RU https://pubmed.ncbi.nlm.nih.gov/26226624 DMRBVHE DI DMRBVHE DMRBVHE DN GSK690693 DMRBVHE TI TTAZ05C DMRBVHE TN RAC-gamma serine/threonine-protein kinase (AKT3) DMRBVHE MA Modulator DMRBVHE RN Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74. DMRBVHE RU https://www.ncbi.nlm.nih.gov/pubmed/18381444 DMRCHOU DI DMRCHOU DMRCHOU DN H-103 DMRCHOU TI TTHYBIX DMRCHOU TN Heat shock protein 70 (HSP70) DMRCHOU MA Modulator DMRCHOU RN A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82. DMRCHOU RU https://pubmed.ncbi.nlm.nih.gov/19092859 DMRD1IW DI DMRD1IW DMRD1IW DN SCO-088 DMRD1IW TI TTS7G69 DMRD1IW TN Fusion protein Bcr-Abl (Bcr-Abl) DMRD1IW MA Inhibitor DMRD1IW RN Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company. DMRD1IW RU https://www.sparc.life/research-programs/sco-088 DMRD2B0 DI DMRD2B0 DMRD2B0 DN CXD-101 DMRD2B0 TI TTBH0VX DMRD2B0 TN Histone deacetylase (HDAC) DMRD2B0 MA Inhibitor DMRD2B0 RN Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7. DMRD2B0 RU https://pubmed.ncbi.nlm.nih.gov/20002107 DMRDNPC DI DMRDNPC DMRDNPC DN GS-6620 DMRDNPC TI TTMVBWH DMRDNPC TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMRDNPC MA Inhibitor DMRDNPC RN Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42. DMRDNPC RU https://pubmed.ncbi.nlm.nih.gov/24419349 DMRDY0G DI DMRDY0G DMRDY0G DN ACV-1 DMRDY0G TI TTJ49OM DMRDY0G TN Neuronal acetylcholine receptor alpha-10 (CHRNA10) DMRDY0G MA Modulator DMRDY0G RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRDY0G RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRE6UT DI DMRE6UT DMRE6UT DN IBC-VS01 DMRE6UT TI TTZOPHG DMRE6UT TN Insulin (INS) DMRE6UT MA Modulator DMRE6UT RN Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine. Ther Adv Endocrinol Metab. 2011 February; 2(1): 9-16. DMRE6UT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474625/ DMRGF9Q DI DMRGF9Q DMRGF9Q DN APD-916 DMRGF9Q TI TT9JNIC DMRGF9Q TN Histamine H3 receptor (H3R) DMRGF9Q MA Antagonist DMRGF9Q RN Identification of biaryl sulfone derivatives as antagonists of the histamine H receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916). Bioorg Med Chem Lett. 2012 Jan 1;22(1):71-5. DMRGF9Q RU https://pubmed.ncbi.nlm.nih.gov/22172695 DMRGHKN DI DMRGHKN DMRGHKN DN RG7827 DMRGHKN TI TTPW9LJ DMRGHKN TN Co-stimulatory molecule 4-1BB (CD137) DMRGHKN MA Agonist DMRGHKN RN Clinical pipeline report, company report or official report of Roche. DMRGHKN RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMRGP72 DI DMRGP72 DMRGP72 DN G1T-48 DMRGP72 TI TTZAYWL DMRGP72 TN Estrogen receptor (ESR) DMRGP72 MA Degrader DMRGP72 RN G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646. DMRGP72 RU https://pubmed.ncbi.nlm.nih.gov/32130619 DMRGVT9 DI DMRGVT9 DMRGVT9 DN PF-06826647 DMRGVT9 TI TTBYWP2 DMRGVT9 TN TYK2 tyrosine kinase (TYK2) DMRGVT9 MA Inhibitor DMRGVT9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRGVT9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMRGWDB DI DMRGWDB DMRGWDB DN PZ01 CAR-T cells DMRGWDB TI TTW640A DMRGWDB TN B-lymphocyte surface antigen B4 (CD19) DMRGWDB MA CAR-T-Cell-Therapy DMRGWDB RN ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma DMRGWDB RU https://clinicaltrials.gov/ct2/show/NCT03281551 DMRH740 DI DMRH740 DMRH740 DN CS-8080 DMRH740 TI TTM1EQF DMRH740 TN Oxysterols receptor LXR (NR1H) DMRH740 MA Modulator DMRH740 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMRH740 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMRHQTU DI DMRHQTU DMRHQTU DN PSMA subunit vaccine DMRHQTU TI TT9G4N0 DMRHQTU TN Glutamate carboxypeptidase II (GCPII) DMRHQTU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMRHQTU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMRI6YT DI DMRI6YT DMRI6YT DN BI 836880 DMRI6YT TI TTKLQTJ DMRI6YT TN Angiopoietin-2 (ANGPT2) DMRI6YT MA Blocker DMRI6YT RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMRI6YT RU https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor DMRI6YT DI DMRI6YT DMRI6YT DN BI 836880 DMRI6YT TI TT9HKJA DMRI6YT TN Vascular endothelial growth factor (VEGF) DMRI6YT MA Blocker DMRI6YT RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMRI6YT RU https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor DMRIH0S DI DMRIH0S DMRIH0S DN SAR113244 DMRIH0S TI TTIW59R DMRIH0S TN C-X-C chemokine receptor type 5 (CXCR5) DMRIH0S MA Modulator DMRIH0S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRIH0S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRINBJ DI DMRINBJ DMRINBJ DN TAK-169 DMRINBJ TI TTPURFN DMRINBJ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMRINBJ MA Inhibitor DMRINBJ RN Clinical pipeline report, company report or official report of Molecular Templates. DMRINBJ RU https://www.mtem.com/pipeline/tak-169 DMRJEXM DI DMRJEXM DMRJEXM DN NN-414 DMRJEXM TI TTP835K DMRJEXM TN ATP-binding cassette transporter C8 (ABCC8) DMRJEXM MA Modulator DMRJEXM RN Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7. DMRJEXM RU https://www.ncbi.nlm.nih.gov/pubmed/15045689 DMRJF2Q DI DMRJF2Q DMRJF2Q DN Citatuzumab bogatox DMRJF2Q TI TTZ8WH4 DMRJF2Q TN Tumor-associated calcium signal transducer 1 (EPCAM) DMRJF2Q RN Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92. DMRJF2Q RU https://pubmed.ncbi.nlm.nih.gov/22856424 DMRL6W5 DI DMRL6W5 DMRL6W5 DN BAY2402234 DMRL6W5 TI TTLVP78 DMRL6W5 TN Dihydroorotate dehydrogenase (DHODH) DMRL6W5 MA Inhibitor DMRL6W5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRL6W5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRLPFG DI DMRLPFG DMRLPFG DN DS-3201 DMRLPFG TI TTNJA0C DMRLPFG TN Enhancer of zeste homolog 1 (EZH1) DMRLPFG MA Inhibitor DMRLPFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLPFG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRLPFG DI DMRLPFG DMRLPFG DN DS-3201 DMRLPFG TI TT9MZCQ DMRLPFG TN Enhancer of zeste homolog 2 (EZH2) DMRLPFG MA Inhibitor DMRLPFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLPFG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRMC7U DI DMRMC7U DMRMC7U DN AMG 579 DMRMC7U TI TTJW4LU DMRMC7U TN Phosphodiesterase 10A (PDE10) DMRMC7U MA Inhibitor DMRMC7U RN Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41. DMRMC7U RU https://pubmed.ncbi.nlm.nih.gov/25062128 DMRNIB9 DI DMRNIB9 DMRNIB9 DN CART-34 cells DMRNIB9 TI TTZAVYN DMRNIB9 TN Hematopoietic progenitor cell antigen CD34 (CD34) DMRNIB9 MA CAR-T-Cell-Therapy DMRNIB9 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMRNIB9 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMRP3N8 DI DMRP3N8 DMRP3N8 DN AZD4831 DMRP3N8 TI TTVCZPI DMRP3N8 TN Myeloperoxidase (MPO) DMRP3N8 MA Modulator DMRP3N8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRP3N8 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMRP4BM DI DMRP4BM DMRP4BM DN MB-104 DMRP4BM TI TT7ILZ1 DMRP4BM TN SLAM family member 7 SLAMF7 (CS1) DMRP4BM RN Clinical pipeline report, company report or official report of Mustang Bio. DMRP4BM RU https://www.mustangbio.com/pipeline/ DMRP9YF DI DMRP9YF DMRP9YF DN XEN901 DMRP9YF TI TT54ERL DMRP9YF TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMRP9YF MA Inhibitor DMRP9YF RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRP9YF RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRQ32K DI DMRQ32K DMRQ32K DN AX-024 DMRQ32K TI TTXQYT6 DMRQ32K TN T-cells (T-cells) DMRQ32K MA Inhibitor DMRQ32K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ32K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRQ32K DI DMRQ32K DMRQ32K DN AX-024 DMRQ32K TI TTMA3VF DMRQ32K TN NCK adaptor protein 1 (NCK1) DMRQ32K MA Modulator DMRQ32K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ32K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRQ4L6 DI DMRQ4L6 DMRQ4L6 DN HHCYH33 DMRQ4L6 TI TTEUNMR DMRQ4L6 TN PI3-kinase alpha (PIK3CA) DMRQ4L6 MA Inhibitor DMRQ4L6 RN Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85. DMRQ4L6 RU https://pubmed.ncbi.nlm.nih.gov/33446653 DMRQ5YT DI DMRQ5YT DMRQ5YT DN PTH(7-34) liposomal cream DMRQ5YT TI TTEPJL5 DMRQ5YT TN Parathyroid hormone receptor (PTH2R) DMRQ5YT MA Modulator DMRQ5YT RN Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008 Dec;43(6):1022-30. DMRQ5YT RU https://pubmed.ncbi.nlm.nih.gov/18761112 DMRQX9H DI DMRQX9H DMRQX9H DN CJ-12255 DMRQX9H TI TTZPO1L DMRQX9H TN Substance-P receptor (TACR1) DMRQX9H MA Antagonist DMRQX9H RN Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype. Life Sci. 2013 Aug 6;93(4):169-77. DMRQX9H RU https://pubmed.ncbi.nlm.nih.gov/23792204 DMRSG04 DI DMRSG04 DMRSG04 DN CAR-T cells targeting EGFRviii DMRSG04 TI TTZ6B2I DMRSG04 TN Epidermal growth factor receptor variant III (EGFR vIII) DMRSG04 MA CAR-T-Cell-Therapy DMRSG04 RN ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme DMRSG04 RU https://clinicaltrials.gov/ct2/show/NCT03170141 DMRU4YV DI DMRU4YV DMRU4YV DN GSK-2018682 DMRU4YV TI TT9JZCK DMRU4YV TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMRU4YV MA Agonist DMRU4YV RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMRU4YV RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TTVIMDE DMRVDUM TN Glucagon-like peptide 1 receptor (GLP1R) DMRVDUM MA Modulator DMRVDUM RN Company report (Zealandpharma) DMRVDUM RU http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TT9O6WS DMRVDUM TN Glucagon receptor (GCGR) DMRVDUM MA Modulator DMRVDUM RN Company report (Zealandpharma) DMRVDUM RU http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TT0NUFM DMRVDUM TN Glucagon (GCG) DMRVDUM MA Agonist DMRVDUM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRVDUM RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRWI7E DI DMRWI7E DMRWI7E DN Anti-N3pG-Abeta antibody DMRWI7E TI TTE4KHA DMRWI7E TN Amyloid beta A4 protein (APP) DMRWI7E RN LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co. DMRWI7E RU http://www.alzforum.org/therapeutics/ly3002813 DMRWTFG DI DMRWTFG DMRWTFG DN A-337 DMRWTFG TI TTZ8WH4 DMRWTFG TN Tumor-associated calcium signal transducer 1 (EPCAM) DMRWTFG MA Inhibitor DMRWTFG RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMRWTFG RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMRWTFG DI DMRWTFG DMRWTFG DN A-337 DMRWTFG TI TTUN7MC DMRWTFG TN T-cell surface glycoprotein CD3 (CD3) DMRWTFG MA Inhibitor DMRWTFG RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMRWTFG RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMRX530 DI DMRX530 DMRX530 DN TAS-116 DMRX530 TI TTH5YN2 DMRX530 TN Heat shock protein 90 beta (HSP90B) DMRX530 MA Inhibitor DMRX530 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRX530 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRXDN3 DI DMRXDN3 DMRXDN3 DN BCI-838 DMRXDN3 TI TTXJ47W DMRXDN3 TN Metabotropic glutamate receptor 2 (mGluR2) DMRXDN3 MA Modulator DMRXDN3 RN Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010 DMRXDN3 RU http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html DMRXDN3 DI DMRXDN3 DMRXDN3 DN BCI-838 DMRXDN3 TI TT8A9EF DMRXDN3 TN Metabotropic glutamate receptor 3 (mGluR3) DMRXDN3 MA Modulator DMRXDN3 RN Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010 DMRXDN3 RU http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html DMRXW9P DI DMRXW9P DMRXW9P DN GSK-2130579A DMRXW9P TI TTZ8UT4 DMRXW9P TN Wilms tumor protein (WT1) DMRXW9P RN Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012. DMRXW9P RU http://science.thomsonreuters.com.cn/media/spotlight_on_report_Q22012.pdf DMRYHWA DI DMRYHWA DMRYHWA DN IC9-GD2-CD28-OX40 DMRYHWA TI TT80ARU DMRYHWA TN Ganglioside GD2 (GD2) DMRYHWA MA CAR-T-Cell-Therapy DMRYHWA RN ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN DMRYHWA RU https://clinicaltrials.gov/ct2/show/NCT01822652 DMRYM03 DI DMRYM03 DMRYM03 DN HMS5552 DMRYM03 TI TTDLNGZ DMRYM03 TN Glucokinase (GCK) DMRYM03 MA Activator DMRYM03 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRYM03 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRYNJD DI DMRYNJD DMRYNJD DN GSK3745417 DMRYNJD TI TTT402Y DMRYNJD TN Stimulator of interferon genes protein (TMEM173) DMRYNJD MA Agonist DMRYNJD RN National Cancer Institute Drug Dictionary (drug name GSK3745417). DMRYNJD RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417 DMRZHV6 DI DMRZHV6 DMRZHV6 DN PF-06873600 DMRZHV6 TI TTMBO1Z DMRZHV6 TN Cyclin-dependent kinase (CDK) DMRZHV6 MA Inhibitor DMRZHV6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRZHV6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS0P5O DI DMS0P5O DMS0P5O DN MB-103 DMS0P5O TI TT6EO5L DMS0P5O TN Erbb2 tyrosine kinase receptor (HER2) DMS0P5O RN Clinical pipeline report, company report or official report of Mustang Bio. DMS0P5O RU https://www.mustangbio.com/pipeline/ DMS1HR3 DI DMS1HR3 DMS1HR3 DN ABM-1310 DMS1HR3 TI TTWCGQT DMS1HR3 TN Serine/threonine-protein kinase B-raf (BRAF) DMS1HR3 MA Inhibitor DMS1HR3 RN Clinical pipeline report, company report or official report of ABM Therapeutics. DMS1HR3 RU http://www.abmtx.com/site/development3 DMS1NC8 DI DMS1NC8 DMS1NC8 DN DZ-2640 DMS1NC8 TI TTJP4SM DMS1NC8 TN Bacterial Penicillin binding protein (Bact PBP) DMS1NC8 MA Modulator DMS1NC8 RN In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8. DMS1NC8 RU https://pubmed.ncbi.nlm.nih.gov/10882697 DMS1O56 DI DMS1O56 DMS1O56 DN FF-10101-01 DMS1O56 TI TTGJCWZ DMS1O56 TN Fms-like tyrosine kinase 3 (FLT-3) DMS1O56 MA Inhibitor DMS1O56 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS1O56 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS20X6 DI DMS20X6 DMS20X6 DN CDX-1135 DMS20X6 TI TTEA8OW DMS20X6 TN Complement receptor type 1 (CR1) DMS20X6 MA Modulator DMS20X6 RN Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013 Nov;56(1-2):91-7. DMS20X6 RU https://pubmed.ncbi.nlm.nih.gov/23685261 DMS25DL DI DMS25DL DMS25DL DN GS-1423 DMS25DL TI TTO3HT7 DMS25DL TN Transforming growth factor beta (TGFB) DMS25DL RN Clinical pipeline report, company report or official report of Agenus. DMS25DL RU https://agenusbio.com/pipeline/ DMS25DL DI DMS25DL DMS25DL DN GS-1423 DMS25DL TI TTK0O6Y DMS25DL TN Ecto-5'-nucleotidase (CD73) DMS25DL RN Clinical pipeline report, company report or official report of Agenus. DMS25DL RU https://agenusbio.com/pipeline/ DMS31YW DI DMS31YW DMS31YW DN YM-57158 DMS31YW TI TTGKOY9 DMS31YW TN Leukotriene CysLT1 receptor (CYSLTR1) DMS31YW MA Modulator DMS31YW RN In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9. DMS31YW RU https://pubmed.ncbi.nlm.nih.gov/9808690 DMS31YW DI DMS31YW DMS31YW DN YM-57158 DMS31YW TI TT2O84V DMS31YW TN Thromboxane A2 receptor (TBXA2R) DMS31YW MA Modulator DMS31YW RN In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9. DMS31YW RU https://pubmed.ncbi.nlm.nih.gov/9808690 DMS3915 DI DMS3915 DMS3915 DN AC 165198 DMS3915 TI TTUPB12 DMS3915 TN Measles virus Fusion glycoprotein (MeV F) DMS3915 MA Modulator DMS3915 RN WO patent application no. 2013,1306,83, Xten conjugate compositions and methods of making same. DMS3915 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130906&CC=WO&NR=2013130683A2&KC=A2 DMS436I DI DMS436I DMS436I DN ETX201 DMS436I TI TTZXH48 DMS436I TN TNF receptor (TNFR) DMS436I MA Antagonist DMS436I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS436I RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMS4H1J DI DMS4H1J DMS4H1J DN BMS-936564 DMS4H1J TI TTBID49 DMS4H1J TN C-X-C chemokine receptor type 4 (CXCR4) DMS4H1J MA Modulator DMS4H1J RN BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. DMS4H1J RU https://pubmed.ncbi.nlm.nih.gov/23213054 DMS4H30 DI DMS4H30 DMS4H30 DN BT-063 DMS4H30 TI TTDB5IS DMS4H30 TN Receptor unspecific (Rec) DMS4H30 RN Clinical pipeline report, company report or official report of Biotest. DMS4H30 RU http://www.biotest.com/de/en/r_d/pipeline/bt063.cfm DMS4P6K DI DMS4P6K DMS4P6K DN Biostrophin DMS4P6K TI TT48MP6 DMS4P6K TN Dystrophin (DMD) DMS4P6K MA Modulator DMS4P6K RN Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8. DMS4P6K RU https://pubmed.ncbi.nlm.nih.gov/23609411 DMS6DPF DI DMS6DPF DMS6DPF DN ADPT01 DMS6DPF TI TTNBFWK DMS6DPF TN Programmed cell death protein 1 (PD-1) DMS6DPF MA Inhibitor DMS6DPF RN Clinical pipeline report, company report or official report of Novartis. DMS6DPF RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All DMS6DPF DI DMS6DPF DMS6DPF DN ADPT01 DMS6DPF TI TTNVXAW DMS6DPF TN Lymphocyte activation gene 3 protein (LAG3) DMS6DPF MA Inhibitor DMS6DPF RN Clinical pipeline report, company report or official report of Novartis. DMS6DPF RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All DMS72GN DI DMS72GN DMS72GN DN AMG 172 DMS72GN TI TTNCIE0 DMS72GN TN CD70 antigen (CD27-L) DMS72GN MA Modulator DMS72GN RN National Cancer Institute Drug Dictionary (drug id 721679). DMS72GN RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=721679 DMS8NM5 DI DMS8NM5 DMS8NM5 DN OS2966 DMS8NM5 TI TTBVIQC DMS8NM5 TN Integrin beta-1 (ITGB1) DMS8NM5 MA Inhibitor DMS8NM5 RN Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40. DMS8NM5 RU https://pubmed.ncbi.nlm.nih.gov/33396712 DMS9EKG DI DMS9EKG DMS9EKG DN VCL-1M01 DMS9EKG TI TTF89GD DMS9EKG TN Interleukin-2 (IL2) DMS9EKG MA Modulator DMS9EKG RN Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995 Mar;2(2):164-7. DMS9EKG RU https://pubmed.ncbi.nlm.nih.gov/7719933 DMS9I6A DI DMS9I6A DMS9I6A DN AZD7687 DMS9I6A TI TTF8P9I DMS9I6A TN Diacylglycerol acyltransferase 1 (DGAT1) DMS9I6A MA Inhibitor DMS9I6A RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMS9I6A RU http://www.astrazeneca.com/Home DMS9LVC DI DMS9LVC DMS9LVC DN KUR-502 DMS9LVC TI TTW640A DMS9LVC TN B-lymphocyte surface antigen B4 (CD19) DMS9LVC RN Clinical pipeline report, company report or official report of Kuur Therapeutics. DMS9LVC RU https://kuurtx.com/product-overview/ DMS9WXG DI DMS9WXG DMS9WXG DN HGS-1029 DMS9WXG TI TTR7B60 DMS9WXG TN X-linked inhibitor of apoptosis protein (XIAP) DMS9WXG MA Antagonist DMS9WXG RN Clinical pipeline report, company report or official report of Aegera Therapeutics Inc. DMS9WXG RU http://www.aegera.com/aeg40826.php DMSA27Z DI DMSA27Z DMSA27Z DN MK-6186 DMSA27Z TI TT84ETX DMSA27Z TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSA27Z MA Inhibitor DMSA27Z RN Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. DMSA27Z RU https://pubmed.ncbi.nlm.nih.gov/22391531 DMSAQBC DI DMSAQBC DMSAQBC DN PPI-2458 DMSAQBC TI TTZL0OI DMSAQBC TN Methionine aminopeptidase 2 (METAP2) DMSAQBC MA Inhibitor DMSAQBC RN Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26. DMSAQBC RU https://pubmed.ncbi.nlm.nih.gov/23355637 DMSBM6A DI DMSBM6A DMSBM6A DN BNC-101 DMSBM6A TI TTTSGRH DMSBM6A TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMSBM6A MA Inhibitor DMSBM6A RN Clinical pipeline report, company report or official report of Bionomics. DMSBM6A RU https://www.bionomics.com.au/research-development/pipeline/oncology DMSBWAQ DI DMSBWAQ DMSBWAQ DN Bb21217 DMSBWAQ TI TTZ3P4W DMSBWAQ TN B-cell maturation protein (TNFRSF17) DMSBWAQ MA CAR-T-Cell-Therapy DMSBWAQ RN ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma DMSBWAQ RU https://clinicaltrials.gov/ct2/show/NCT03274219 DMSCV02 DI DMSCV02 DMSCV02 DN [N-methyl-3H(3)]AZ-10419369 DMSCV02 TI TTK8CXU DMSCV02 TN 5-HT 1B receptor (HTR1B) DMSCV02 MA Antagonist DMSCV02 RN 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43. DMSCV02 RU https://pubmed.ncbi.nlm.nih.gov/25841787 DMSCXB7 DI DMSCXB7 DMSCXB7 DN UK-240455 DMSCXB7 TI TTZ8EM9 DMSCXB7 TN Glycine receptor (GlyR) DMSCXB7 MA Modulator DMSCXB7 RN UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9. DMSCXB7 RU https://pubmed.ncbi.nlm.nih.gov/11892937 DMSDNU1 DI DMSDNU1 DMSDNU1 DN CHF 5407 DMSDNU1 TI TTQ13Z5 DMSDNU1 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSDNU1 MA Modulator DMSDNU1 RN Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyc... J Pharmacol Exp Ther. 2010 Dec;335(3):622-35. DMSDNU1 RU https://www.ncbi.nlm.nih.gov/pubmed/20805306 DMSE19U DI DMSE19U DMSE19U DN GDC0134 DMSE19U TI TTF4AVB DMSE19U TN Protein delta homolog 1 (DLK1) DMSE19U MA Inhibitor DMSE19U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSE19U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMSENTW DI DMSENTW DMSENTW DN NJH395 DMSENTW TI TT6EO5L DMSENTW TN Erbb2 tyrosine kinase receptor (HER2) DMSENTW RN ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health. DMSENTW RU https://clinicaltrials.gov/ct2/show/NCT03696771 DMSGEU6 DI DMSGEU6 DMSGEU6 DN JAB-3068 DMSGEU6 TI TT7WUAV DMSGEU6 TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMSGEU6 MA Inhibitor DMSGEU6 RN Clinical pipeline report, company report or official report of AbbVie. DMSGEU6 RU https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html DMSGNVK DI DMSGNVK DMSGNVK DN GSK2793660 DMSGNVK TI TT4H0V2 DMSGNVK TN Dipeptidyl peptidase I (CTSC) DMSGNVK MA Modulator DMSGNVK RN ClinicalTrials.gov (NCT02058407) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects. U.S. National Institutes of Health. DMSGNVK RU https://clinicaltrials.gov/ct2/show/NCT02058407 DMSGRA7 DI DMSGRA7 DMSGRA7 DN CIGB-M3 DMSGRA7 TI TTY6DTE DMSGRA7 TN Carcinoembryonic antigen CEA (CD66e) DMSGRA7 RN Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353-63. DMSGRA7 RU https://pubmed.ncbi.nlm.nih.gov/21711100 DMSHK23 DI DMSHK23 DMSHK23 DN AMG-191 DMSHK23 TI TTX41N9 DMSHK23 TN Tyrosine-protein kinase Kit (KIT) DMSHK23 MA Inhibitor DMSHK23 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029529) DMSHK23 RU http://adisinsight.springer.com/drugs/800029529 DMSJBUZ DI DMSJBUZ DMSJBUZ DN CD20-CART DMSJBUZ TI TTUE541 DMSJBUZ TN Leukocyte surface antigen Leu-16 (CD20) DMSJBUZ MA CAR-T-Cell-Therapy(Dual specific) DMSJBUZ RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DMSJBUZ RU https://clinicaltrials.gov/ct2/show/NCT03407859 DMSJOTL DI DMSJOTL DMSJOTL DN PF-06817024 DMSJOTL TI TTFTSHD DMSJOTL TN Cytokine unspecific (CYK) DMSJOTL MA Modulator DMSJOTL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJOTL RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSJVX3 DI DMSJVX3 DMSJVX3 DN CM3.1-AC100 DMSJVX3 TI TTVIMDE DMSJVX3 TN Glucagon-like peptide 1 receptor (GLP1R) DMSJVX3 MA Agonist DMSJVX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMSJVX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMSJWTE DI DMSJWTE DMSJWTE DN OKI 179 DMSJWTE TI TTBH0VX DMSJWTE TN Histone deacetylase (HDAC) DMSJWTE MA Inhibitor DMSJWTE RN Clinical pipeline report, company report or official report of OnKure Therapeutics. DMSJWTE RU http://onkuretherapeutics.com/pipeline/ DMSKF29 DI DMSKF29 DMSKF29 DN TNT009 DMSKF29 TI TT7LRQH DMSKF29 TN Complement C1s component (C1S) DMSKF29 MA Inhibitor DMSKF29 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSKF29 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMSKHIC DI DMSKHIC DMSKHIC DN R4996 DMSKHIC TI TTLA931 DMSKHIC TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMSKHIC MA Agonist DMSKHIC RN Clinical pipeline report, company report or official report of Roche (2009). DMSKHIC RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMSKI8W DI DMSKI8W DMSKI8W DN KPG-121 DMSKI8W TI TTEZQ39 DMSKI8W TN Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) DMSKI8W MA Modulator DMSKI8W RN Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals. DMSKI8W RU https://www.kangpugroup.com/research_development/pipeline.html DMSLDHG DI DMSLDHG DMSLDHG DN HPP-854 DMSLDHG TI TT8JRS7 DMSLDHG TN Beta-secretase (BACE) DMSLDHG MA Modulator DMSLDHG RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DMSLDHG RU https://pubmed.ncbi.nlm.nih.gov/25621019 DMSLE03 DI DMSLE03 DMSLE03 DN PF-562271 DMSLE03 TI TTON5IT DMSLE03 TN Focal adhesion kinase 1 (FAK) DMSLE03 MA Inhibitor DMSLE03 RN Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45. DMSLE03 RU https://pubmed.ncbi.nlm.nih.gov/21903606 DMSLPTO DI DMSLPTO DMSLPTO DN ZY01 DMSLPTO TI TT6OEDT DMSLPTO TN Cannabinoid receptor 1 (CB1) DMSLPTO MA Antagonist DMSLPTO RN 2011 Pipeline of Zydus Cadila Group. DMSLPTO RU http://www.zyduscadila.com/ DMSLQW2 DI DMSLQW2 DMSLQW2 DN TRPH-222 DMSLQW2 TI TTM6QSK DMSLQW2 TN B-cell receptor CD22 (CD22) DMSLQW2 RN Clinical pipeline report, company report or official report of Triphase Accelerator. DMSLQW2 RU http://triphaseco.com/trph-222/ DMSM0IJ DI DMSM0IJ DMSM0IJ DN RG6279 DMSM0IJ TI TTNBFWK DMSM0IJ TN Programmed cell death protein 1 (PD-1) DMSM0IJ RN Clinical pipeline report, company report or official report of Roche. DMSM0IJ RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMSM42V DI DMSM42V DMSM42V DN CYAD-101 DMSM42V TI TTLRN4A DMSM42V TN NKG2 D activating NK receptor (KLRK1) DMSM42V MA CAR-T-Cell-Therapy DMSM42V RN ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells DMSM42V RU https://clinicaltrials.gov/ct2/show/NCT03692429 DMSMNRQ DI DMSMNRQ DMSMNRQ DN PF-07265807 DMSMNRQ TI TTO7LKR DMSMNRQ TN Tyrosine-protein kinase Mer (MERTK) DMSMNRQ MA Inhibitor DMSMNRQ RN National Cancer Institute Drug Dictionary (drug name PF-07265807). DMSMNRQ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807 DMSMNRQ DI DMSMNRQ DMSMNRQ DN PF-07265807 DMSMNRQ TI TTZPY6J DMSMNRQ TN Tyrosine-protein kinase UFO (AXL) DMSMNRQ MA Inhibitor DMSMNRQ RN National Cancer Institute Drug Dictionary (drug name PF-07265807). DMSMNRQ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807 DMSMRC1 DI DMSMRC1 DMSMRC1 DN 1069C DMSMRC1 TI TTYFKSZ DMSMRC1 TN Tubulin beta (TUBB) DMSMRC1 MA Modulator DMSMRC1 RN Patent WO2005108424 A1. DMSMRC1 RU http://www.google.com/patents/WO2005108424A1?cl=en DMSO3JA DI DMSO3JA DMSO3JA DN C7R-GD2.CART cells DMSO3JA TI TT80ARU DMSO3JA TN Ganglioside GD2 (GD2) DMSO3JA MA CAR-T-Cell-Therapy DMSO3JA RN ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N) DMSO3JA RU https://clinicaltrials.gov/ct2/show/NCT03635632 DMSOB5D DI DMSOB5D DMSOB5D DN Chi Lob 7/4 DMSOB5D TI TTIJP3Q DMSOB5D TN TNF related activation protein (CD40LG) DMSOB5D MA Modulator DMSOB5D RN Agonistic CD40 antibodies and cancer therapy DMSOB5D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590838 DMSPBOW DI DMSPBOW DMSPBOW DN AIC100 DMSPBOW TI TTCT6F7 DMSPBOW TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMSPBOW RN Clinical pipeline report, company report or official report of AffyImmune Therapeutics. DMSPBOW RU https://affyimmune.com/pipeline/ DMSPQDM DI DMSPQDM DMSPQDM DN JNJ-61610588 DMSPQDM TI TT51SK8 DMSPQDM TN V-set immunoregulatory receptor (VSIR) DMSPQDM MA Inhibitor DMSPQDM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSPQDM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT1RWNJ DMSQ3AZ TN Tyrosine-protein kinase Lyn (JTK8) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TTGKNB4 DMSQ3AZ TN Epidermal growth factor receptor (EGFR) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TTDCBX5 DMSQ3AZ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT2B9KF DMSQ3AZ TN Fyn tyrosine protein kinase (FYN) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT6EO5L DMSQ3AZ TN Erbb2 tyrosine kinase receptor (HER2) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT860QF DMSQ3AZ TN LCK tyrosine protein kinase (LCK) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT0SQ8J DMSQ3AZ TN Yes tyrosine kinase (YES) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT0JESD DMSQ3AZ TN Erbb4 tyrosine kinase receptor (Erbb-4) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQZEP DI DMSQZEP DMSQZEP DN TAR-200 DMSQZEP TI TTUBNVO DMSQZEP TN DNA synthesis (DNA synth) DMSQZEP MA Inhibitor DMSQZEP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSQZEP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMSR5HD DI DMSR5HD DMSR5HD DN GSI-136 DMSR5HD TI TT9W8GU DMSR5HD TN Gamma-secretase (GS) DMSR5HD MA Modulator DMSR5HD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMSR5HD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSR91U DI DMSR91U DMSR91U DN AVE0118 DMSR91U TI TT1VOHK DMSR91U TN Potassium channel unspecific (KC) DMSR91U MA Modulator DMSR91U RN Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20. DMSR91U RU https://www.ncbi.nlm.nih.gov/pubmed/24629214 DMSRICG DI DMSRICG DMSRICG DN TNB-486 DMSRICG TI TTW640A DMSRICG TN B-lymphocyte surface antigen B4 (CD19) DMSRICG RN Clinical pipeline report, company report or official report of Teneobio. DMSRICG RU https://teneobio.com/our-pipeline/ DMSRICG DI DMSRICG DMSRICG DN TNB-486 DMSRICG TI TTUN7MC DMSRICG TN T-cell surface glycoprotein CD3 (CD3) DMSRICG RN Clinical pipeline report, company report or official report of Teneobio. DMSRICG RU https://teneobio.com/our-pipeline/ DMSUFW6 DI DMSUFW6 DMSUFW6 DN SSR-125047 DMSUFW6 TI TT5TPI6 DMSUFW6 TN Opioid receptor sigma 1 (OPRS1) DMSUFW6 MA Binder DMSUFW6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMSUFW6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMSUFW6 DI DMSUFW6 DMSUFW6 DN SSR-125047 DMSUFW6 TI TTFBNVI DMSUFW6 TN Aldose reductase (AKR1B1) DMSUFW6 MA Inhibitor DMSUFW6 RN Aldose reductase inhibitors: an update. Ann Pharmacother. 1993 Jun;27(6):751-4. DMSUFW6 RU https://pubmed.ncbi.nlm.nih.gov/8329799 DMSVD2R DI DMSVD2R DMSVD2R DN SGN-CD228A DMSVD2R TI TT8OBT3 DMSVD2R TN Melanotransferrin (MELTF) DMSVD2R RN Clinical pipeline report, company report or official report of Seagen. DMSVD2R RU https://www.seagen.com/science/pipeline DMSVO92 DI DMSVO92 DMSVO92 DN Tigapotide DMSVO92 TI TTYH1ZK DMSVO92 TN Beta-microseminoprotein (MSMB) DMSVO92 MA Inhibitor DMSVO92 RN National Cancer Institute Drug Dictionary (drug id 600185). DMSVO92 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600185 DMSWJ6D DI DMSWJ6D DMSWJ6D DN NU-206 DMSWJ6D TI TTI9HL4 DMSWJ6D TN Roof plate-specific spondin-1 (RSPO1) DMSWJ6D MA Modulator DMSWJ6D RN R-spondin1 and FOXL2 act into two distinct cellular types during goat ovarian differentiation.BMC Dev Biol.2008 Apr 2;8:36. DMSWJ6D RU https://www.ncbi.nlm.nih.gov/pubmed/18384673 DMSX24U DI DMSX24U DMSX24U DN AFO-18 DMSX24U TI TT3J5ZI DMSX24U TN Cell mediated immunity response (CMIR) DMSX24U RN ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health. DMSX24U RU https://clinicaltrials.gov/ct2/show/NCT01009762 DMSX5NJ DI DMSX5NJ DMSX5NJ DN RG6330 DMSX5NJ TI TT3LH46 DMSX5NJ TN KRAS G12C mutant (KRAS G12C) DMSX5NJ MA Inhibitor DMSX5NJ RN Clinical pipeline report, company report or official report of Roche. DMSX5NJ RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMSYB83 DI DMSYB83 DMSYB83 DN IMGN-388 DMSYB83 TI TTT1R2L DMSYB83 TN Integrin alpha-V (ITGAV) DMSYB83 RN Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9. DMSYB83 RU https://pubmed.ncbi.nlm.nih.gov/20841470 DMSZ8HT DI DMSZ8HT DMSZ8HT DN MazF gene therapy DMSZ8HT TI TTRBUYN DMSZ8HT TN Ribonuclease (RNase) DMSZ8HT MA Modulator DMSZ8HT RN Clinical pipeline report, company report or official report of Takara Bio. DMSZ8HT RU http://www.takara-bio.com/medi_e/ DMSZIP5 DI DMSZIP5 DMSZIP5 DN SB-639 DMSZIP5 TI TT6R7JZ DMSZIP5 TN Histone deacetylase 1 (HDAC1) DMSZIP5 MA Inhibitor DMSZIP5 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMSZIP5 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMT0EBU DI DMT0EBU DMT0EBU DN MT-112 DMT0EBU TI TT9G4N0 DMT0EBU TN Glutamate carboxypeptidase II (GCPII) DMT0EBU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMT0EBU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMT27PA DI DMT27PA DMT27PA DN AMV564 DMT27PA TI TTJVYO3 DMT27PA TN Myeloid cell surface antigen CD33 (CD33) DMT27PA MA Modulator DMT27PA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT27PA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMT35N2 DI DMT35N2 DMT35N2 DN C-CAR088 DMT35N2 TI TTZ3P4W DMT35N2 TN B-cell maturation protein (TNFRSF17) DMT35N2 MA CAR-T-Cell-Therapy DMT35N2 RN ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma DMT35N2 RU https://clinicaltrials.gov/ct2/show/NCT03751293 DMT3HKZ DI DMT3HKZ DMT3HKZ DN HL-018 DMT3HKZ TI TT0FYAN DMT3HKZ TN Free fatty acid receptor 2 (FFAR2) DMT3HKZ MA Inhibitor DMT3HKZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226). DMT3HKZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226 DMT3V2W DI DMT3V2W DMT3V2W DN GSK2879552 DMT3V2W TI TTNR0UQ DMT3V2W TN Lysine-specific histone demethylase 1 (LSD) DMT3V2W MA Inhibitor DMT3V2W RN A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69. DMT3V2W RU https://pubmed.ncbi.nlm.nih.gov/26175415 DMT4Z5B DI DMT4Z5B DMT4Z5B DN CALAA-01 DMT4Z5B TI TTBWDI0 DMT4Z5B TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMT4Z5B MA Modulator DMT4Z5B RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT4Z5B RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT4Z5B DI DMT4Z5B DMT4Z5B DN CALAA-01 DMT4Z5B TI TTV5YEH DMT4Z5B TN Transferrin (TF) DMT4Z5B MA Modulator DMT4Z5B RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT4Z5B RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT5AEF DI DMT5AEF DMT5AEF DN TST-10088 DMT5AEF TI TTJ073B DMT5AEF TN Ribosome (hRBS) DMT5AEF MA Immunomodulator (Immunostimulant) DMT5AEF RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. DMT5AEF RU https://pubmed.ncbi.nlm.nih.gov/20094643 DMT5Z84 DI DMT5Z84 DMT5Z84 DN ATI-0917 DMT5Z84 TI TTF7I5O DMT5Z84 TN Human immunodeficiency virus Rev protein (HIV rev) DMT5Z84 MA Inhibitor DMT5Z84 RN Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53. DMT5Z84 RU https://pubmed.ncbi.nlm.nih.gov/19335283 DMT7L30 DI DMT7L30 DMT7L30 DN CR-3465 DMT7L30 TI TTGKOY9 DMT7L30 TN Leukotriene CysLT1 receptor (CYSLTR1) DMT7L30 MA Modulator DMT7L30 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT7L30 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT7YOU DI DMT7YOU DMT7YOU DN CD19t-haNK DMT7YOU TI TTW640A DMT7YOU TN B-lymphocyte surface antigen B4 (CD19) DMT7YOU RN ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health. DMT7YOU RU https://clinicaltrials.gov/ct2/show/NCT04052061 DMT9MHE DI DMT9MHE DMT9MHE DN IMGN289 DMT9MHE TI TTGKNB4 DMT9MHE TN Epidermal growth factor receptor (EGFR) DMT9MHE MA Inhibitor DMT9MHE RN World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29. DMT9MHE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/ DMTAOPC DI DMTAOPC DMTAOPC DN SAR442720 DMTAOPC TI TT7WUAV DMTAOPC TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMTAOPC MA Inhibitor DMTAOPC RN Clinical pipeline report, company report or official report of Revolution Medicines. DMTAOPC RU https://www.revmed.com/pipeline/rmc-4630 DMTB4R8 DI DMTB4R8 DMTB4R8 DN BAY1125976 DMTB4R8 TI TTAZ05C DMTB4R8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMTB4R8 MA Modulator DMTB4R8 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTB4R8 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTCB8I DI DMTCB8I DMTCB8I DN CART-19 T cells DMTCB8I TI TTW640A DMTCB8I TN B-lymphocyte surface antigen B4 (CD19) DMTCB8I MA CAR-T-Cell-Therapy DMTCB8I RN ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma DMTCB8I RU https://clinicaltrials.gov/ct2/show/NCT02135406 DMTCLM3 DI DMTCLM3 DMTCLM3 DN CGM097 DMTCLM3 TI TT7SBF5 DMTCLM3 TN Cellular tumor antigen p53 (TP53) DMTCLM3 MA Modulator DMTCLM3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTCLM3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTD4EF DI DMTD4EF DMTD4EF DN ALPN-202 DMTD4EF TI TTI2S1D DMTD4EF TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMTD4EF MA Inhibitor DMTD4EF RN Clinical pipeline report, company report or official report of Alpine Immune Sciences. DMTD4EF RU https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf DMTD4EF DI DMTD4EF DMTD4EF DN ALPN-202 DMTD4EF TI TT8ZLTI DMTD4EF TN Programmed cell death 1 ligand 1 (PD-L1) DMTD4EF MA Inhibitor DMTD4EF RN Clinical pipeline report, company report or official report of Alpine Immune Sciences. DMTD4EF RU https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf DMTD57A DI DMTD57A DMTD57A DN AZD8329 DMTD57A TI TTN7BL9 DMTD57A TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTD57A MA Inhibitor DMTD57A RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMTD57A RU http://www.astrazeneca.com/Home DMTDWIE DI DMTDWIE DMTDWIE DN BRX-005 DMTDWIE TI TTHYBIX DMTDWIE TN Heat shock protein 70 (HSP70) DMTDWIE MA Modulator DMTDWIE RN Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9. DMTDWIE RU https://pubmed.ncbi.nlm.nih.gov/11021362 DMTE18G DI DMTE18G DMTE18G DN CHF-4227 DMTE18G TI TTZAYWL DMTE18G TN Estrogen receptor (ESR) DMTE18G MA Modulator DMTE18G RN Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. J Pharmacol Exp Ther. 2002 Oct;303(1):196-203. DMTE18G RU https://pubmed.ncbi.nlm.nih.gov/12235251 DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTRA6BO DMTEA9C TN Bromodomain-containing protein 4 (BRD4) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTHE657 DMTEA9C TN Bromodomain-containing protein 3 (BRD3) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTDP48B DMTEA9C TN Bromodomain-containing protein 2 (BRD2) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEG6B DI DMTEG6B DMTEG6B DN PENCLOMEDINE DMTEG6B TI TTUTN1I DMTEG6B TN Human Deoxyribonucleic acid (hDNA) DMTEG6B MA Modulator DMTEG6B RN The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest New Drugs. 2003 Aug;21(3):269-79. DMTEG6B RU https://www.ncbi.nlm.nih.gov/pubmed/14578677 DMTFAGU DI DMTFAGU DMTFAGU DN SAR228810 DMTFAGU TI TTE4KHA DMTFAGU TN Amyloid beta A4 protein (APP) DMTFAGU RN SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809. DMTFAGU RU http://www.sciencedirect.com/science/article/pii/S1552526013023352 DMTFU8Q DI DMTFU8Q DMTFU8Q DN OMP-131R10 DMTFU8Q TI TT7HJTF DMTFU8Q TN R-spondin-3 (RSPO3) DMTFU8Q RN Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. DMTFU8Q RU https://pubmed.ncbi.nlm.nih.gov/32160239 DMTFUM4 DI DMTFUM4 DMTFUM4 DN IMMU-114 DMTFUM4 TI TTYA75N DMTFUM4 TN MHC class II antigen DR (HLA-DR) DMTFUM4 RN The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant. 2012 Jul;47(7):967-80. DMTFUM4 RU https://pubmed.ncbi.nlm.nih.gov/22020022 DMTFWLE DI DMTFWLE DMTFWLE DN KUC-7483 DMTFWLE TI TTMXGCW DMTFWLE TN Adrenergic receptor beta-3 (ADRB3) DMTFWLE MA Agonist DMTFWLE RN Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8. DMTFWLE RU https://pubmed.ncbi.nlm.nih.gov/22511202 DMTG9EV DI DMTG9EV DMTG9EV DN ATRC-101 DMTG9EV TI TTHC8EF DMTG9EV TN Polyadenylate-binding protein 1 (PABPC1) DMTG9EV RN Clinical pipeline report, company report or official report of Atreca. DMTG9EV RU https://www.atreca.com/pipeline/ DMTG9WM DI DMTG9WM DMTG9WM DN BBI-6000 DMTG9WM TI TTGV6LY DMTG9WM TN Nuclear receptor ROR-gamma (RORG) DMTG9WM MA Inhibitor DMTG9WM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTG9WM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMTGLOY DI DMTGLOY DMTGLOY DN TK216 DMTGLOY TI TT9AH0M DMTGLOY TN Protein C-ets-2 (ETS2) DMTGLOY MA Inhibitor DMTGLOY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTGLOY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTGZN8 DI DMTGZN8 DMTGZN8 DN AMG 780 DMTGZN8 TI TTWNQ1T DMTGZN8 TN Angiopoietin-1 (ANGPT1) DMTGZN8 MA Modulator DMTGZN8 RN Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022. DMTGZN8 RU http://cancerres.aacrjournals.org/content/74/19_Supplement/1022 DMTK1BV DI DMTK1BV DMTK1BV DN SRF617 DMTK1BV TI TTYM8DJ DMTK1BV TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMTK1BV RN Clinical pipeline report, company report or official report of Surface oncology. DMTK1BV RU https://www.surfaceoncology.com/pipeline-programs/ DMTK78L DI DMTK78L DMTK78L DN Anti-CD30 CAR-T cells DMTK78L TI TT2GM5R DMTK78L TN Lymphocyte activation antigen CD30 (TNFRSF8) DMTK78L MA CAR-T-Cell-Therapy DMTK78L RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMTK78L RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMTKPH4 DI DMTKPH4 DMTKPH4 DN VBY- 891 DMTKPH4 TI TTUMQVO DMTKPH4 TN Cathepsin S (CTSS) DMTKPH4 MA Modulator DMTKPH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DMTKPH4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DMTKZ1Q DI DMTKZ1Q DMTKZ1Q DN DS-6157 DMTKZ1Q TI TTGTQHC DMTKZ1Q TN DNA topoisomerase I (TOP1) DMTKZ1Q MA Inhibitor DMTKZ1Q RN Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. DMTKZ1Q RU https://pubmed.ncbi.nlm.nih.gov/33579785 DMTKZ1Q DI DMTKZ1Q DMTKZ1Q DN DS-6157 DMTKZ1Q TI TT26C7Z DMTKZ1Q TN G-protein coupled receptor 20 (GPR20) DMTKZ1Q MA Inhibitor DMTKZ1Q RN Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. DMTKZ1Q RU https://pubmed.ncbi.nlm.nih.gov/33579785 DMTLNGV DI DMTLNGV DMTLNGV DN Umespirone DMTLNGV TI TTEX248 DMTLNGV TN Dopamine D2 receptor (D2R) DMTLNGV MA Antagonist DMTLNGV RN The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96. DMTLNGV RU https://pubmed.ncbi.nlm.nih.gov/1685786 DMTLNGV DI DMTLNGV DMTLNGV DN Umespirone DMTLNGV TI TTSQIFT DMTLNGV TN 5-HT 1A receptor (HTR1A) DMTLNGV MA Antagonist DMTLNGV RN The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96. DMTLNGV RU https://pubmed.ncbi.nlm.nih.gov/1685786 DMTLP1N DI DMTLP1N DMTLP1N DN Combinectin DMTLP1N TI TTG90S6 DMTLP1N TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMTLP1N MA Inhibitor DMTLP1N RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMTLP1N RU https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf DMTLP1N DI DMTLP1N DMTLP1N DN Combinectin DMTLP1N TI TTN2JFW DMTLP1N TN T-cell surface glycoprotein CD4 (CD4) DMTLP1N MA Inhibitor DMTLP1N RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMTLP1N RU https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf DMTLU37 DI DMTLU37 DMTLU37 DN Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 DMTLU37 TI TT4RXME DMTLU37 TN Mesothelin (MSLN) DMTLU37 MA CAR-T-Cell-Therapy DMTLU37 RN ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer DMTLU37 RU https://clinicaltrials.gov/ct2/show/NCT01897415 DMTMUWJ DI DMTMUWJ DMTMUWJ DN BMS-986299 DMTMUWJ TI TT4EN8X DMTMUWJ TN Caterpiller protein 1.1 (NLRP3) DMTMUWJ MA Agonist DMTMUWJ RN National Cancer Institute Drug Dictionary (drug name BMS-986299). DMTMUWJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nlrp3-agonist-bms-986299 DMTNUA4 DI DMTNUA4 DMTNUA4 DN ZL-1201 DMTNUA4 TI TT28S46 DMTNUA4 TN Leukocyte surface antigen CD47 (CD47) DMTNUA4 RN Clinical pipeline report, company report or official report of ZAI Lab. DMTNUA4 RU http://www.zailaboratory.com/pipeline/list.aspx DMTNYIB DI DMTNYIB DMTNYIB DN IM21 CART DMTNYIB TI TTZ3P4W DMTNYIB TN B-cell maturation protein (TNFRSF17) DMTNYIB MA CAR-T-Cell-Therapy DMTNYIB RN ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma DMTNYIB RU https://clinicaltrials.gov/ct2/show/NCT03711864 DMTOLI5 DI DMTOLI5 DMTOLI5 DN Pomaglumetad DMTOLI5 TI TT8A9EF DMTOLI5 TN Metabotropic glutamate receptor 3 (mGluR3) DMTOLI5 MA Modulator DMTOLI5 RN LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45. DMTOLI5 RU https://pubmed.ncbi.nlm.nih.gov/20571979 DMTOLI5 DI DMTOLI5 DMTOLI5 DN Pomaglumetad DMTOLI5 TI TTXJ47W DMTOLI5 TN Metabotropic glutamate receptor 2 (mGluR2) DMTOLI5 MA Modulator DMTOLI5 RN LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45. DMTOLI5 RU https://pubmed.ncbi.nlm.nih.gov/20571979 DMTOUY9 DI DMTOUY9 DMTOUY9 DN Suramin DMTOUY9 TI TTZFDBT DMTOUY9 TN Follicle-stimulating hormone receptor (FSHR) DMTOUY9 MA Antagonist DMTOUY9 RN Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008 Nov;8(13):1384-94. DMTOUY9 RU https://pubmed.ncbi.nlm.nih.gov/18991754 DMTOUY9 DI DMTOUY9 DMTOUY9 DN Suramin DMTOUY9 TI TTR7GJO DMTOUY9 TN Heparanase (HPSE) DMTOUY9 MA Inhibitor DMTOUY9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1728). DMTOUY9 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 DMTOXLG DI DMTOXLG DMTOXLG DN PPI-461 DMTOXLG TI TTCJ2X8 DMTOXLG TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMTOXLG MA Modulator DMTOXLG RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTOXLG RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTP9ER DI DMTP9ER DMTP9ER DN D-20133 DMTP9ER TI TT1UZQH DMTP9ER TN Phospholipase C (PLC) DMTP9ER MA Inhibitor DMTP9ER RN Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Curr Med Chem. 2011; 18(18): 2727-2742. DMTP9ER RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091980/ DMTQ4PN DI DMTQ4PN DMTQ4PN DN Metastat DMTQ4PN TI TTLM12X DMTQ4PN TN Matrix metalloproteinase-2 (MMP-2) DMTQ4PN MA Inhibitor DMTQ4PN RN Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. DMTQ4PN RU https://pubmed.ncbi.nlm.nih.gov/12209155 DMTR7EH DI DMTR7EH DMTR7EH DN Desoxypeganine DMTR7EH TI TT1RS9F DMTR7EH TN Acetylcholinesterase (AChE) DMTR7EH MA Modulator DMTR7EH RN Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7. DMTR7EH RU https://pubmed.ncbi.nlm.nih.gov/18560630 DMTR7EH DI DMTR7EH DMTR7EH DN Desoxypeganine DMTR7EH TI TT3WG5C DMTR7EH TN Monoamine oxidase type A (MAO-A) DMTR7EH MA Modulator DMTR7EH RN Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7. DMTR7EH RU https://pubmed.ncbi.nlm.nih.gov/18560630 DMTRF71 DI DMTRF71 DMTRF71 DN BIIB 028 DMTRF71 TI TT78R5H DMTRF71 TN Heat shock protein 90 alpha (HSP90A) DMTRF71 MA Inhibitor DMTRF71 RN Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. DMTRF71 RU https://pubmed.ncbi.nlm.nih.gov/23873691 DMTS5VF DI DMTS5VF DMTS5VF DN MGN-1706 DMTS5VF TI TTSHG0T DMTS5VF TN Toll-like receptor 9 (TLR9) DMTS5VF MA Agonist DMTS5VF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DMTS5VF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DMTSIYZ DI DMTSIYZ DMTSIYZ DN CVN058 DMTSIYZ TI TTNXLKE DMTSIYZ TN 5-HT 3 receptor (5HT3R) DMTSIYZ MA Antagonist DMTSIYZ RN Clinical pipeline report, company report or official report of Cerevance. DMTSIYZ RU https://cerevance.com/pipeline/ DMTSKXR DI DMTSKXR DMTSKXR DN SKI-O-703 DMTSKXR TI TTOU65C DMTSKXR TN Tyrosine-protein kinase SYK (SYK) DMTSKXR MA Inhibitor DMTSKXR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTSKXR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTUKW9 DI DMTUKW9 DMTUKW9 DN MORAb-066 DMTUKW9 TI TT38MDJ DMTUKW9 TN Tissue factor (F3) DMTUKW9 RN Clinical pipeline report, company report or official report of Morphotek. DMTUKW9 RU http://www.morphotek.com/pipeline/MORAb-066.aspx DMTULGS DI DMTULGS DMTULGS DN Demogastrin DMTULGS TI TTVFO0U DMTULGS TN Gastrin/cholecystokinin type B receptor (CCKBR) DMTULGS MA Modulator DMTULGS RN Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy. Regul Pept. 1999 Oct 22;84(1-3):81-9. DMTULGS RU https://pubmed.ncbi.nlm.nih.gov/10535412 DMTUVCG DI DMTUVCG DMTUVCG DN MIK665 DMTUVCG TI TTL53M6 DMTUVCG TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMTUVCG MA Inhibitor DMTUVCG RN MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443. DMTUVCG RU https://pubmed.ncbi.nlm.nih.gov/32513939 DMTV09A DI DMTV09A DMTV09A DN Cyt-1010 DMTV09A TI TTKWM86 DMTV09A TN Opioid receptor mu (MOP) DMTV09A MA Agonist DMTV09A RN Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188. DMTV09A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400840/ DMTVQH2 DI DMTVQH2 DMTVQH2 DN NGP 555 DMTVQH2 TI TT9W8GU DMTVQH2 TN Gamma-secretase (GS) DMTVQH2 MA Modulator DMTVQH2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTVQH2 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMTWNLY DI DMTWNLY DMTWNLY DN GZ402674 DMTWNLY TI TTGTQHC DMTWNLY TN DNA topoisomerase I (TOP1) DMTWNLY MA Modulator DMTWNLY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMTWNLY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMTWSM2 DI DMTWSM2 DMTWSM2 DN RG7129 DMTWSM2 TI TT8JRS7 DMTWSM2 TN Beta-secretase (BACE) DMTWSM2 MA Modulator DMTWSM2 RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DMTWSM2 RU https://pubmed.ncbi.nlm.nih.gov/25621019 DMTXE19 DI DMTXE19 DMTXE19 DN TAK-114 DMTXE19 TI TTH8FZW DMTXE19 TN Signal transducer and activator of transcription 3 (STAT3) DMTXE19 MA Modulator DMTXE19 RN Clinical pipeline report, company report or official report of Gastroenterology. DMTXE19 RU https://www.takeda.com/siteassets/system/investors/report/quarterlyannouncements/fy2014/takeda-ir-event--a-global-leader-in-gastroenterology-held-on-march-9-2015/qr2014_q3_p_en.pdf DMTXIZ1 DI DMTXIZ1 DMTXIZ1 DN MBX-700 DMTXIZ1 TI TTMVBWH DMTXIZ1 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMTXIZ1 MA Inhibitor DMTXIZ1 RN Clinical pipeline report, company report or official report of Microbiotix Inc. DMTXIZ1 RU http://www.microbiotix.com/therapeutic-programs-hcv.htm DMTYGWV DI DMTYGWV DMTYGWV DN NSC-639829 DMTYGWV TI TTYFKSZ DMTYGWV TN Tubulin beta (TUBB) DMTYGWV MA Modulator DMTYGWV RN Solubilization of NSC-639829. Int J Pharm. 2001 Aug 28;225(1-2):41-7. DMTYGWV RU https://pubmed.ncbi.nlm.nih.gov/11489553 DMTYNRB DI DMTYNRB DMTYNRB DN KD033 DMTYNRB TI TT8ZLTI DMTYNRB TN Programmed cell death 1 ligand 1 (PD-L1) DMTYNRB MA Inhibitor DMTYNRB RN Clinical pipeline report, company report or official report of Kadmon. DMTYNRB RU https://kadmon.com/clinical-pipeline/pipeline/kd033/ DMTZ3A6 DI DMTZ3A6 DMTZ3A6 DN BMS-196085 DMTZ3A6 TI TTMXGCW DMTZ3A6 TN Adrenergic receptor beta-3 (ADRB3) DMTZ3A6 MA Inhibitor DMTZ3A6 RN Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6. DMTZ3A6 RU https://pubmed.ncbi.nlm.nih.gov/17533126 DMTZ983 DI DMTZ983 DMTZ983 DN SER-101 DMTZ983 TI TT07C3Y DMTZ983 TN 5-HT 4 receptor (HTR4) DMTZ983 MA Antagonist DMTZ983 RN Phase I clinical trail of SER101 (RO1160367) for treating heart failure leukemia. Roche. DMTZ983 RU http://www.biocentury.com/products/ser101 DMTZADW DI DMTZADW DMTZADW DN CAR-T cells targeting BCMA DMTZADW TI TTZ3P4W DMTZADW TN B-cell maturation protein (TNFRSF17) DMTZADW MA CAR-T-Cell-Therapy DMTZADW RN ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma DMTZADW RU https://clinicaltrials.gov/ct2/show/NCT03672253 DMTZXSO DI DMTZXSO DMTZXSO DN CAR-T cells targeting Mesothelin DMTZXSO TI TT4RXME DMTZXSO TN Mesothelin (MSLN) DMTZXSO MA CAR-T-Cell-Therapy DMTZXSO RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMTZXSO RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMU03WD DI DMU03WD DMU03WD DN IO-202 DMU03WD TI TTREOKA DMU03WD TN Leukocyte immunoglobulin-like receptor B4 (LILRB4) DMU03WD MA Inhibitor DMU03WD RN Clinical pipeline report, company report or official report of Immune-Onc Therapeutics. DMU03WD RU https://www.immune-onc.com/news/2020-09-16-io-202-fpi DMU0Q6L DI DMU0Q6L DMU0Q6L DN SDX-7320 DMU0Q6L TI TTZL0OI DMU0Q6L TN Methionine aminopeptidase 2 (METAP2) DMU0Q6L MA Inhibitor DMU0Q6L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU0Q6L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU0V45 DI DMU0V45 DMU0V45 DN XEN-D0101 DMU0V45 TI TTW0CMT DMU0V45 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMU0V45 MA Modulator DMU0V45 RN Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15. DMU0V45 RU https://pubmed.ncbi.nlm.nih.gov/23364608 DMU1X8K DI DMU1X8K DMU1X8K DN GSK2820151 DMU1X8K TI TTE4BSY DMU1X8K TN Bromodomain and extraterminal domain protein (BET) DMU1X8K MA Inhibitor DMU1X8K RN ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health. DMU1X8K RU https://clinicaltrials.gov/ct2/show/NCT02630251 DMU21JF DI DMU21JF DMU21JF DN AGS-009 DMU21JF TI TT95SOA DMU21JF TN Interferon alpha (IFNA) DMU21JF RN Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221. DMU21JF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358492/ DMU263R DI DMU263R DMU263R DN VBY-376 DMU263R TI TTWXB3E DMU263R TN Hepatitis C virus NS3 helicase (HCV NS3) DMU263R MA Inhibitor DMU263R RN Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765. DMU263R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185733/ DMU26OE DI DMU26OE DMU26OE DN PIM447 DMU26OE TI TTA7WGU DMU26OE TN Serine/threonine-protein kinase pim (PIM) DMU26OE MA Inhibitor DMU26OE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU26OE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU2A6D DI DMU2A6D DMU2A6D DN PF-4217903 DMU2A6D TI TTNDSF4 DMU2A6D TN Proto-oncogene c-Met (MET) DMU2A6D MA Inhibitor DMU2A6D RN Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. DMU2A6D RU https://pubmed.ncbi.nlm.nih.gov/22389468 DMU2D0B DI DMU2D0B DMU2D0B DN ZYDPLA 1 DMU2D0B TI TTDIGC1 DMU2D0B TN Dipeptidyl peptidase 4 (DPP-4) DMU2D0B MA Inhibitor DMU2D0B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU2D0B RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMU4G9J DI DMU4G9J DMU4G9J DN CAR-T cells targeting PSCA DMU4G9J TI TT9T4AV DMU4G9J TN Prostate stem cell antigen (PSCA) DMU4G9J MA CAR-T-Cell-Therapy DMU4G9J RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMU4G9J RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMU67HD DI DMU67HD DMU67HD DN ATR-01 DMU67HD TI TTK3C21 DMU67HD TN Acetoacetyl-CoA thiolase (ACAT1) DMU67HD MA Inhibitor DMU67HD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU67HD RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMU6CQ7 DI DMU6CQ7 DMU6CQ7 DN NHS-IL 12 DMU6CQ7 TI TTGW72V DMU6CQ7 TN Interleukin-12 beta (IL12B) DMU6CQ7 MA Modulator DMU6CQ7 RN The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84. DMU6CQ7 RU https://pubmed.ncbi.nlm.nih.gov/24681847 DMU6K37 DI DMU6K37 DMU6K37 DN ABBV-2737 DMU6K37 TI TTRLZHP DMU6K37 TN cAMP-dependent chloride channel (CFTR) DMU6K37 MA Modulator DMU6K37 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMU6K37 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMU6ZMX DI DMU6ZMX DMU6ZMX DN Carmoxirole DMU6ZMX TI TTEX248 DMU6ZMX TN Dopamine D2 receptor (D2R) DMU6ZMX MA Agonist DMU6ZMX RN Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. Cardiovasc Drugs Ther. 1998 Sep;12(4):387-94. DMU6ZMX RU https://pubmed.ncbi.nlm.nih.gov/9825185 DMU790L DI DMU790L DMU790L DN BOS172722 DMU790L TI TTP7EGM DMU790L TN Dual specificity protein kinase TTK (MPS1) DMU790L MA Inhibitor DMU790L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU790L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU87HW DI DMU87HW DMU87HW DN RGX-111 DMU87HW TI TT0IUKX DMU87HW TN Alpha-L-iduronidase (IDUA) DMU87HW MA Replacement DMU87HW RN Clinical pipeline report, company report or official report of REGENXBIO. DMU87HW RU https://regenxbio.com/rgx-111/ DMU8OCN DI DMU8OCN DMU8OCN DN CS1-CAR T Therapy DMU8OCN TI TT7ILZ1 DMU8OCN TN SLAM family member 7 SLAMF7 (CS1) DMU8OCN MA CAR-T-Cell-Therapy DMU8OCN RN ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma DMU8OCN RU https://clinicaltrials.gov/ct2/show/NCT03710421 DMU8QD2 DI DMU8QD2 DMU8QD2 DN Apramycin DMU8QD2 TI TT38DW5 DMU8QD2 TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMU8QD2 MA Inhibitor DMU8QD2 RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMU8QD2 RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMU901D DI DMU901D DMU901D DN L-MDAM DMU901D TI TTYZVDJ DMU901D TN Dihydrofolate reductase (DHFR) DMU901D MA Inhibitor DMU901D RN Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12. DMU901D RU https://pubmed.ncbi.nlm.nih.gov/9816221 DMU9VDS DI DMU9VDS DMU9VDS DN Mibefradil DMU9VDS TI TTZPWGN DMU9VDS TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMU9VDS MA Inhibitor DMU9VDS RN Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8. DMU9VDS RU https://pubmed.ncbi.nlm.nih.gov/10991994 DMU9ZGN DI DMU9ZGN DMU9ZGN DN SDZ-GPI-562 DMU9ZGN TI TT38RM1 DMU9ZGN TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMU9ZGN MA Modulator DMU9ZGN RN Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75. DMU9ZGN RU https://www.ncbi.nlm.nih.gov/pubmed/10357155 DMUAJZD DI DMUAJZD DMUAJZD DN SAR247799 DMUAJZD TI TT9JZCK DMUAJZD TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMUAJZD MA Agonist DMUAJZD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUAJZD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMUAMZY DI DMUAMZY DMUAMZY DN APVO436 DMUAMZY TI TTUN7MC DMUAMZY TN T-cell surface glycoprotein CD3 (CD3) DMUAMZY MA Inhibitor DMUAMZY RN Clinical pipeline report, company report or official report of Aptevo. DMUAMZY RU https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/ DMUAMZY DI DMUAMZY DMUAMZY DN APVO436 DMUAMZY TI TTENHJ0 DMUAMZY TN Interleukin 3 receptor alpha (IL3RA) DMUAMZY MA Inhibitor DMUAMZY RN Clinical pipeline report, company report or official report of Aptevo. DMUAMZY RU https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/ DMUANF3 DI DMUANF3 DMUANF3 DN MLN8054 DMUANF3 TI TTPS3C0 DMUANF3 TN Aurora kinase A (AURKA) DMUANF3 MA Inhibitor DMUANF3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMUANF3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMUANF9 DI DMUANF9 DMUANF9 DN PHE-377 DMUANF9 TI TTMI6F5 DMUANF9 TN Transient receptor potential cation channel V1 (TRPV1) DMUANF9 MA Antagonist DMUANF9 RN Clinical pipeline report, company report or official report of Pharmeste. DMUANF9 RU http://www.pharmeste.com/home.asp?op=interna&id=1 DMUB3H9 DI DMUB3H9 DMUB3H9 DN KITE-439 DMUB3H9 TI TT3CPZW DMUB3H9 TN Human papillomavirus protein E7 (HPV E7) DMUB3H9 MA Inhibitor DMUB3H9 RN ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health. DMUB3H9 RU https://clinicaltrials.gov/ct2/show/NCT03912831 DMUBMN5 DI DMUBMN5 DMUBMN5 DN BIBV 308 DMUBMN5 TI TT2O84V DMUBMN5 TN Thromboxane A2 receptor (TBXA2R) DMUBMN5 MA Antagonist DMUBMN5 RN AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. DMUBMN5 RU https://pubmed.ncbi.nlm.nih.gov/15613065 DMUBP0V DI DMUBP0V DMUBP0V DN CNTO888 DMUBP0V TI TTNAY0P DMUBP0V TN Monocyte chemotactic and activating factor (CCL2) DMUBP0V RN CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62. DMUBP0V RU https://pubmed.ncbi.nlm.nih.gov/17710158 DMUBTC6 DI DMUBTC6 DMUBTC6 DN ND7001 DMUBTC6 TI TTJGW1Z DMUBTC6 TN Phosphodiesterase 2A (PDE2A) DMUBTC6 MA Modulator DMUBTC6 RN Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212. DMUBTC6 RU https://pubmed.ncbi.nlm.nih.gov/22947663 DMUBYFM DI DMUBYFM DMUBYFM DN ACE-041 DMUBYFM TI TTAP4T1 DMUBYFM TN Growth/differentiation factor 2 (GDF2) DMUBYFM MA Modulator DMUBYFM RN Company report (Acceleron Pharma) DMUBYFM RU http://www.acceleronpharma.com/products/dalantercept/ DMUC6EP DI DMUC6EP DMUC6EP DN BIIB095 DMUC6EP TI TT4G2JS DMUC6EP TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUC6EP MA Inhibitor DMUC6EP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUC6EP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUCF9L DI DMUCF9L DMUCF9L DN ABBV-2451 DMUCF9L TI TTRLZHP DMUCF9L TN cAMP-dependent chloride channel (CFTR) DMUCF9L MA Modulator DMUCF9L RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUCF9L RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUCQYW DI DMUCQYW DMUCQYW DN LMP744 DMUCQYW TI TTGTQHC DMUCQYW TN DNA topoisomerase I (TOP1) DMUCQYW MA Inhibitor DMUCQYW RN Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. DMUCQYW RU https://pubmed.ncbi.nlm.nih.gov/31227499 DMUETI2 DI DMUETI2 DMUETI2 DN AMG 167 DMUETI2 TI TTYRO4F DMUETI2 TN Sclerostin (SOST) DMUETI2 MA Modulator DMUETI2 RN Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448. DMUETI2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/ DMUEZ7V DI DMUEZ7V DMUEZ7V DN HPP404 DMUEZ7V TI TT9JNIC DMUEZ7V TN Histamine H3 receptor (H3R) DMUEZ7V MA Antagonist DMUEZ7V RN Clinical pipeline report, company report or official report of TransTech Pharma (2011). DMUEZ7V RU http://www.ttpharma.com/ DMUF6W9 DI DMUF6W9 DMUF6W9 DN PF-05186462 DMUF6W9 TI TT4G2JS DMUF6W9 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUF6W9 MA Inhibitor DMUF6W9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875) DMUF6W9 RU http://adisinsight.springer.com/drugs/800026875 DMUFN29 DI DMUFN29 DMUFN29 DN EPI-7386 DMUFN29 TI TTS64P2 DMUFN29 TN Androgen receptor (AR) DMUFN29 MA Inhibitor DMUFN29 RN Clinical pipeline report, company report or official report of ESSA Pharma. DMUFN29 RU https://www.essapharma.com/pipeline/ DMUFRDK DI DMUFRDK DMUFRDK DN Anti-CD22 DMUFRDK TI TTM6QSK DMUFRDK TN B-cell receptor CD22 (CD22) DMUFRDK RN 2011 Pipeline of Seattle Genetics. DMUFRDK RU http://www.seagen.com/product_pipeline.php DMUGN0J DI DMUGN0J DMUGN0J DN CDX-1140 DMUGN0J TI TTN6Y9A DMUGN0J TN CD40L receptor (CD40) DMUGN0J MA Agonist DMUGN0J RN Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. DMUGN0J RU https://pubmed.ncbi.nlm.nih.gov/30382327 DMUHOJP DI DMUHOJP DMUHOJP DN MK-2637 DMUHOJP TI TTHJTF7 DMUHOJP TN Glycine transporter GlyT-1 (SLC6A9) DMUHOJP MA Modulator DMUHOJP RN Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015 Jan;69(1):33-40. DMUHOJP RU https://pubmed.ncbi.nlm.nih.gov/25196464 DMUI8F3 DI DMUI8F3 DMUI8F3 DN Friulimicin DMUI8F3 TI TTXT4D5 DMUI8F3 TN Bacterial Cell membrane (Bact CM) DMUI8F3 MA Inhibitor DMUI8F3 RN Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60. DMUI8F3 RU https://pubmed.ncbi.nlm.nih.gov/21306875 DMUJ1EL DI DMUJ1EL DMUJ1EL DN BI 113823 DMUJ1EL TI TTG5QIA DMUJ1EL TN B1 bradykinin receptor (BDKRB1) DMUJ1EL MA Modulator DMUJ1EL RN The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42. DMUJ1EL RU https://pubmed.ncbi.nlm.nih.gov/25088373 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTUTJGQ DMUJCBT TN Vascular endothelial growth factor receptor 2 (KDR) DMUJCBT MA Antagonist DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TT9VGXW DMUJCBT TN Angiopoietin 1 receptor (TEK) DMUJCBT MA Inhibitor DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTNDSF4 DMUJCBT TN Proto-oncogene c-Met (MET) DMUJCBT MA Inhibitor DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTTDVOJ DMUJCBT TN Tropomyosin-related kinase A (TrkA) DMUJCBT MA Inhibitor DMUJCBT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMUJCBT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTXABCW DMUJCBT TN NT-3 growth factor receptor (TrkC) DMUJCBT MA Inhibitor DMUJCBT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMUJCBT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUJF9T DI DMUJF9T DMUJF9T DN CD123-CD33 Ccar DMUJF9T TI TTJVYO3 DMUJF9T TN Myeloid cell surface antigen CD33 (CD33) DMUJF9T RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUJF9T RU http://icellgene.com/our-pipeline.html DMUJF9T DI DMUJF9T DMUJF9T DN CD123-CD33 Ccar DMUJF9T TI TTENHJ0 DMUJF9T TN Interleukin 3 receptor alpha (IL3RA) DMUJF9T RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUJF9T RU http://icellgene.com/our-pipeline.html DMUK6YM DI DMUK6YM DMUK6YM DN BAY1161909 DMUK6YM TI TTP7EGM DMUK6YM TN Dual specificity protein kinase TTK (MPS1) DMUK6YM MA Inhibitor DMUK6YM RN National Cancer Institute Drug Dictionary (drug id 761238). DMUK6YM RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761238 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TTC1GLB DMUKBI2 TN Interleukin-23 (IL23) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TTBW580 DMUKBI2 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TT8SLDN DMUKBI2 TN Interleukin-36 gamma (IL36G) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKFCG DI DMUKFCG DMUKFCG DN Anti-Mesothelin CAR-T cells DMUKFCG TI TT4RXME DMUKFCG TN Mesothelin (MSLN) DMUKFCG MA CAR-T-Cell-Therapy DMUKFCG RN ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. DMUKFCG RU https://clinicaltrials.gov/ct2/show/NCT03545815 DMUKNDO DI DMUKNDO DMUKNDO DN Anti-BCMA CART Cells DMUKNDO TI TTZ3P4W DMUKNDO TN B-cell maturation protein (TNFRSF17) DMUKNDO MA CAR-T-Cell-Therapy DMUKNDO RN ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma DMUKNDO RU https://clinicaltrials.gov/ct2/show/NCT03767725 DMULBZM DI DMULBZM DMULBZM DN Cosibelimab DMULBZM TI TT8ZLTI DMULBZM TN Programmed cell death 1 ligand 1 (PD-L1) DMULBZM RN Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers DMULBZM RU https://clinicaltrials.gov/ct2/show/NCT03212404 DMULRYC DI DMULRYC DMULRYC DN VBY- 036 DMULRYC TI TTUMQVO DMULRYC TN Cathepsin S (CTSS) DMULRYC MA Inhibitor DMULRYC RN Clinical pipeline report, company report or official report of ViroBay. DMULRYC RU http://virobayinc.com/VBY-036.php DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TT5LS6T DMUMHXT TN Aurora kinase B (AURKB) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TTUTJGQ DMUMHXT TN Vascular endothelial growth factor receptor 2 (KDR) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TTPS3C0 DMUMHXT TN Aurora kinase A (AURKA) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMVXK DI DMUMVXK DMUMVXK DN ATR-101 DMUMVXK TI TT4V7ST DMUMVXK TN Sterol O-acyltransferase (SOAT) DMUMVXK MA Modulator DMUMVXK RN Company report (Atterocor) DMUMVXK RU http://atterocor.com/pdf/Atterocor-ENDO-PR-61214.pdf DMUMWFK DI DMUMWFK DMUMWFK DN Anti-GPC3 CAR T DMUMWFK TI TTJTSX4 DMUMWFK TN Glypican-3 (GPC3) DMUMWFK MA CAR-T-Cell-Therapy DMUMWFK RN ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC DMUMWFK RU https://clinicaltrials.gov/ct2/show/NCT02395250 DMUN7EQ DI DMUN7EQ DMUN7EQ DN SKF-105809 DMUN7EQ TI TTK0943 DMUN7EQ TN Prostaglandin G/H synthase (COX) DMUN7EQ MA Modulator DMUN7EQ RN Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. DMUN7EQ RU https://pubmed.ncbi.nlm.nih.gov/1906235 DMUN7EQ DI DMUN7EQ DMUN7EQ DN SKF-105809 DMUN7EQ TI TT2J34L DMUN7EQ TN Arachidonate 5-lipoxygenase (5-LOX) DMUN7EQ MA Inhibitor DMUN7EQ RN Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. DMUN7EQ RU https://pubmed.ncbi.nlm.nih.gov/1906235 DMUNFEP DI DMUNFEP DMUNFEP DN GDC0310 DMUNFEP TI TT4G2JS DMUNFEP TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUNFEP MA Inhibitor DMUNFEP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUNFEP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMUNSPI DI DMUNSPI DMUNSPI DN INBRX-109 DMUNSPI TI TTW20TU DMUNSPI TN TRAIL receptor 2 (TRAIL-R2) DMUNSPI RN Clinical pipeline report, company report or official report of Inhibrx. DMUNSPI RU https://inhibrx.com/inbrx-109/ DMUNVXR DI DMUNVXR DMUNVXR DN GSK-2239633 DMUNVXR TI TT7HQD0 DMUNVXR TN C-C chemokine receptor type 4 (CCR4) DMUNVXR MA Antagonist DMUNVXR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61). DMUNVXR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61 DMUP6M5 DI DMUP6M5 DMUP6M5 DN BGB-15025 DMUP6M5 TI TTSHWUP DMUP6M5 TN MEK kinase kinase 1 (MAP4K1) DMUP6M5 MA Inhibitor DMUP6M5 RN ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. DMUP6M5 RU https://clinicaltrials.gov/ct2/show/NCT04649385 DMUPA7C DI DMUPA7C DMUPA7C DN NOCICEPTIN DMUPA7C TI TTKWM86 DMUPA7C TN Opioid receptor mu (MOP) DMUPA7C MA Inhibitor DMUPA7C RN Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem. 2008 Feb 28;51(4):1058-62. DMUPA7C RU https://pubmed.ncbi.nlm.nih.gov/18232652 DMUPA7C DI DMUPA7C DMUPA7C DN NOCICEPTIN DMUPA7C TI TTNT7K8 DMUPA7C TN Nociceptin receptor (OPRL1) DMUPA7C MA Inhibitor DMUPA7C RN Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41. DMUPA7C RU https://pubmed.ncbi.nlm.nih.gov/9353393 DMUPQ70 DI DMUPQ70 DMUPQ70 DN SPC5001 DMUPQ70 TI TTBRG7E DMUPQ70 TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMUPQ70 MA Inhibitor DMUPQ70 RN 2011 Pipeline of Santaris Pharma. DMUPQ70 RU http://www.santaris.com/product-pipeline DMUQ3C1 DI DMUQ3C1 DMUQ3C1 DN Anti-CD19 CAR-T cells DMUQ3C1 TI TTW640A DMUQ3C1 TN B-lymphocyte surface antigen B4 (CD19) DMUQ3C1 MA CAR-T-Cell-Therapy DMUQ3C1 RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMUQ3C1 RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMUR1MN DI DMUR1MN DMUR1MN DN CD19-CAR and CD28-CAR T Cells DMUR1MN TI TTQ13FT DMUR1MN TN T-cell-specific surface glycoprotein CD28 (CD28) DMUR1MN MA CAR-T-Cell-Therapy(Dual specific) DMUR1MN RN ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia DMUR1MN RU https://clinicaltrials.gov/ct2/show/NCT02146924 DMUR1MN DI DMUR1MN DMUR1MN DN CD19-CAR and CD28-CAR T Cells DMUR1MN TI TTW640A DMUR1MN TN B-lymphocyte surface antigen B4 (CD19) DMUR1MN MA CAR-T-Cell-Therapy(Dual specific) DMUR1MN RN ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia DMUR1MN RU https://clinicaltrials.gov/ct2/show/NCT02146924 DMUR49N DI DMUR49N DMUR49N DN Begacestat DMUR49N TI TT9W8GU DMUR49N TN Gamma-secretase (GS) DMUR49N MA Modulator DMUR49N RN Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. DMUR49N RU https://pubmed.ncbi.nlm.nih.gov/19671883 DMURO94 DI DMURO94 DMURO94 DN GNE Lipoplex DMURO94 TI TT4DP5S DMURO94 TN N-acetylmannosamine kinase (GNE) DMURO94 MA Inhibitor DMURO94 RN Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther. 2011 Nov;22(11):1331-41. DMURO94 RU https://pubmed.ncbi.nlm.nih.gov/21517694 DMURVPF DI DMURVPF DMURVPF DN Dendritic cell vaccine DMURVPF TI TT7SBF5 DMURVPF TN Cellular tumor antigen p53 (TP53) DMURVPF RN Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. DMURVPF RU https://pubmed.ncbi.nlm.nih.gov/14985857 DMUSOM9 DI DMUSOM9 DMUSOM9 DN ABBV-CX-2029 DMUSOM9 TI TT8MG4S DMUSOM9 TN Transferrin receptor protein 1 (TFRC) DMUSOM9 RN Clinical pipeline report, company report or official report of AbbVie. DMUSOM9 RU https://www.abbvie.com/our-science/pipeline/abbv-2029.html DMUSPW5 DI DMUSPW5 DMUSPW5 DN NCO-48 DMUSPW5 TI TTT4SY6 DMUSPW5 TN Hepatitis B virus Polymerase (HBV P) DMUSPW5 MA Inhibitor DMUSPW5 RN Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects DMUSPW5 RU https://clinicaltrials.gov/ct2/show/NCT04309526 DMUT4YZ DI DMUT4YZ DMUT4YZ DN RLY-1971 DMUT4YZ TI TT7WUAV DMUT4YZ TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMUT4YZ MA Inhibitor DMUT4YZ RN Clinical pipeline report, company report or official report of Relay Therapeutics. DMUT4YZ RU https://relaytx.com/pipeline/ DMUTISK DI DMUTISK DMUTISK DN Pennvax-B DMUTISK TI TTUTN1I DMUTISK TN Human Deoxyribonucleic acid (hDNA) DMUTISK RN Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601. DMUTISK RU https://pubmed.ncbi.nlm.nih.gov/25531694 DMUVGMS DI DMUVGMS DMUVGMS DN MRG-110 DMUVGMS TI TTIXJ2S DMUVGMS TN microRNA hsa-miR-92 (MIR92) DMUVGMS MA Inhibitor DMUVGMS RN Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 2020 Dec;30(6):335-345. DMUVGMS RU https://pubmed.ncbi.nlm.nih.gov/32707001 DMUVLC4 DI DMUVLC4 DMUVLC4 DN IMGC936 DMUVLC4 TI TTTYQNS DMUVLC4 TN Cellular disintegrin-related protein (ADAM9) DMUVLC4 MA Inhibitor DMUVLC4 RN Clinical pipeline report, company report or official report of ImmunoGen. DMUVLC4 RU https://www.immunogen.com/category/imgc936/ DMUVYC5 DI DMUVYC5 DMUVYC5 DN Anti-CD19 EBV CTL therapy DMUVYC5 TI TTW640A DMUVYC5 TN B-lymphocyte surface antigen B4 (CD19) DMUVYC5 RN Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia. 2010 May;24(5):1080-4. DMUVYC5 RU https://pubmed.ncbi.nlm.nih.gov/20220773 DMUXAP1 DI DMUXAP1 DMUXAP1 DN TAK-573 DMUXAP1 TI TTPURFN DMUXAP1 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMUXAP1 RN Clinical pipeline report, company report or official report of Takeda. DMUXAP1 RU https://www.takeda.com/what-we-do/research-and-development/our-pipeline/ DMUYN26 DI DMUYN26 DMUYN26 DN IMC-CS4 DMUYN26 TI TT731LW DMUYN26 TN Colony stimulating factor-1 receptor (CSF-1R) DMUYN26 MA Modulator DMUYN26 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUYN26 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUYTW3 DI DMUYTW3 DMUYTW3 DN CD20-CD19 cCAR DMUYTW3 TI TTW640A DMUYTW3 TN B-lymphocyte surface antigen B4 (CD19) DMUYTW3 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUYTW3 RU http://icellgene.com/our-pipeline.html DMUYTW3 DI DMUYTW3 DMUYTW3 DN CD20-CD19 cCAR DMUYTW3 TI TTUE541 DMUYTW3 TN Leukocyte surface antigen Leu-16 (CD20) DMUYTW3 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUYTW3 RU http://icellgene.com/our-pipeline.html DMUZFVH DI DMUZFVH DMUZFVH DN ONT-10 DMUZFVH TI TTBHFYQ DMUZFVH TN Mucin-1 (MUC1) DMUZFVH RN Clinical pipeline report, company report or official report of Oncothyreon. DMUZFVH RU http://www.oncothyreon.com/product_pipeline/ont-10.html DMV0AH8 DI DMV0AH8 DMV0AH8 DN TCN-P DMV0AH8 TI TTAZ05C DMV0AH8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMV0AH8 MA Modulator DMV0AH8 RN Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9. DMV0AH8 RU https://www.ncbi.nlm.nih.gov/pubmed/20644979 DMV0MHI DI DMV0MHI DMV0MHI DN EP-7041 DMV0MHI TI TTJCPUT DMV0MHI TN Coagulation factor XI (F11) DMV0MHI MA Inhibitor DMV0MHI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV0MHI RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMV1BTP DI DMV1BTP DMV1BTP DN ISIS-SOD1 DMV1BTP TI TTP9K3Q DMV1BTP TN SOD1 messenger RNA (SOD1 mRNA) DMV1BTP RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMV1BTP RU http://www.isispharm.com/index.htm DMV3L62 DI DMV3L62 DMV3L62 DN Sym023 DMV3L62 TI TT1RWL7 DMV3L62 TN Hepatitis A virus cellular receptor 2 (TIM3) DMV3L62 MA Inhibitor DMV3L62 RN Clinical pipeline report, company report or official report of Symphogen. DMV3L62 RU http://www.symphogen.com/pipeline/products/sym023/ DMV5LGJ DI DMV5LGJ DMV5LGJ DN Tedatioxetine DMV5LGJ TI TTNXLKE DMV5LGJ TN 5-HT 3 receptor (5HT3R) DMV5LGJ MA Modulator DMV5LGJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV5LGJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV5LGJ DI DMV5LGJ DMV5LGJ DN Tedatioxetine DMV5LGJ TI TTWJBZ5 DMV5LGJ TN 5-HT 2C receptor (HTR2C) DMV5LGJ MA Modulator DMV5LGJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV5LGJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV5PEK DI DMV5PEK DMV5PEK DN ARO-HIF2 DMV5PEK TI TTWPA54 DMV5PEK TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMV5PEK MA Inhibitor DMV5PEK RN National Cancer Institute Drug Dictionary (drug name ARO-HIF2). DMV5PEK RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hif2a-rnai-aro-hif2 DMV5X8M DI DMV5X8M DMV5X8M DN PTI-125 DMV5X8M TI TTSTRZY DMV5X8M TN Filamin A (FLNA) DMV5X8M MA Inhibitor DMV5X8M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV5X8M RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMV632P DI DMV632P DMV632P DN CEP-37440 DMV632P TI TTON5IT DMV632P TN Focal adhesion kinase 1 (FAK) DMV632P MA Modulator DMV632P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV632P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV6DF3 DI DMV6DF3 DMV6DF3 DN AZD5658 DMV6DF3 TI TTDLNGZ DMV6DF3 TN Glucokinase (GCK) DMV6DF3 MA Activator DMV6DF3 RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMV6DF3 RU http://www.astrazeneca.com/Home DMV6JFK DI DMV6JFK DMV6JFK DN AGEN1181 DMV6JFK TI TTI2S1D DMV6JFK TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMV6JFK MA Inhibitor DMV6JFK RN Clinical pipeline report, company report or official report of Agenus. DMV6JFK RU https://agenusbio.com/agen1181-second-generation-anti-ctla-4/ DMV74JC DI DMV74JC DMV74JC DN CVX-241 DMV74JC TI TTKLQTJ DMV74JC TN Angiopoietin-2 (ANGPT2) DMV74JC MA Modulator DMV74JC RN Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616. DMV74JC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012461/ DMV80DP DI DMV80DP DMV80DP DN LAS-186323 DMV80DP TI TTLVP78 DMV80DP TN Dihydroorotate dehydrogenase (DHODH) DMV80DP MA Inhibitor DMV80DP RN Clinical pipeline report, company report or official report of Aslanpharma. DMV80DP RU http://www.aslanpharma.com/download/Press%20Release%20-%20Almirall-ASLAN%20Licensing.pdf DMV84ZR DI DMV84ZR DMV84ZR DN CARTmeso/19 DMV84ZR TI TTW640A DMV84ZR TN B-lymphocyte surface antigen B4 (CD19) DMV84ZR MA CAR-T-Cell-Therapy(Dual specific) DMV84ZR RN ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer DMV84ZR RU https://clinicaltrials.gov/ct2/show/NCT03497819 DMV84ZR DI DMV84ZR DMV84ZR DN CARTmeso/19 DMV84ZR TI TT4RXME DMV84ZR TN Mesothelin (MSLN) DMV84ZR MA CAR-T-Cell-Therapy(Dual specific) DMV84ZR RN ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer DMV84ZR RU https://clinicaltrials.gov/ct2/show/NCT03497819 DMV8BI4 DI DMV8BI4 DMV8BI4 DN MK-6325 DMV8BI4 TI TTRHUKY DMV8BI4 TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMV8BI4 MA Modulator DMV8BI4 RN Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6. DMV8BI4 RU https://pubmed.ncbi.nlm.nih.gov/25754231 DMV8IQW DI DMV8IQW DMV8IQW DN Tafluposide DMV8IQW TI TTGTQHC DMV8IQW TN DNA topoisomerase I (TOP1) DMV8IQW MA Modulator DMV8IQW RN Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. DMV8IQW RU https://pubmed.ncbi.nlm.nih.gov/12853890 DMV8IQW DI DMV8IQW DMV8IQW DN Tafluposide DMV8IQW TI TT0IHXV DMV8IQW TN DNA topoisomerase II (TOP2) DMV8IQW MA Modulator DMV8IQW RN Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. DMV8IQW RU https://pubmed.ncbi.nlm.nih.gov/12853890 DMV8IWJ DI DMV8IWJ DMV8IWJ DN GEN1029 DMV8IWJ TI TTW20TU DMV8IWJ TN TRAIL receptor 2 (TRAIL-R2) DMV8IWJ MA Agonist DMV8IWJ RN National Cancer Institute Drug Dictionary (drug name Tilogotamab). DMV8IWJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tilogotamab DMV9FTH DI DMV9FTH DMV9FTH DN FP-045 DMV9FTH TI TTFLN4T DMV9FTH TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMV9FTH MA Agonist DMV9FTH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV9FTH RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMVA186 DI DMVA186 DMVA186 DN R7334 DMVA186 TI TT48I1Y DMVA186 TN Placenta growth factor (PlGF) DMVA186 RN Clinical pipeline report, company report or official report of Roche (2009). DMVA186 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMVBQ2L DI DMVBQ2L DMVBQ2L DN SGN LIV1A DMVBQ2L TI TTZN1CF DMVBQ2L TN Solute carrier family 39 member 6 (SLC39A6) DMVBQ2L RN SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. DMVBQ2L RU https://pubmed.ncbi.nlm.nih.gov/25253783 DMVD327 DI DMVD327 DMVD327 DN AVI-7288 DMVD327 TI TT1E5A4 DMVD327 TN Marburg virus NP messenger RNA (MV NP mRNA) DMVD327 RN AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med. 2015 Jul 23;373(4):339-48. DMVD327 RU https://pubmed.ncbi.nlm.nih.gov/26200980 DMVDIWO DI DMVDIWO DMVDIWO DN CDX-527 DMVDIWO TI TTNBFWK DMVDIWO TN Programmed cell death protein 1 (PD-1) DMVDIWO MA Inhibitor DMVDIWO RN Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. DMVDIWO RU https://pubmed.ncbi.nlm.nih.gov/32451681 DMVDIWO DI DMVDIWO DMVDIWO DN CDX-527 DMVDIWO TI TTDO1MV DMVDIWO TN T-cell activation antigen CD27 (CD27) DMVDIWO MA Activator DMVDIWO RN Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. DMVDIWO RU https://pubmed.ncbi.nlm.nih.gov/32451681 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TTRJ1K4 DMVDYTG TN Toll-like receptor 7 (TLR7) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TTSHG0T DMVDYTG TN Toll-like receptor 9 (TLR9) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TT8CWFK DMVDYTG TN Toll-like receptor 8 (TLR8) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVEGND DI DMVEGND DMVEGND DN GSK3368715 DMVEGND TI TTVOJAI DMVEGND TN Protein arginine methyltransferase 1 (PRMT1) DMVEGND MA Inhibitor DMVEGND RN National Cancer Institute Drug Dictionary (drug name GSK6097608). DMVEGND RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt1-inhibitor-gsk3368715 DMVGBA1 DI DMVGBA1 DMVGBA1 DN HuMNC2-CAR44 T cells DMVGBA1 TI TTBHFYQ DMVGBA1 TN Mucin-1 (MUC1) DMVGBA1 RN Clinical pipeline report, company report or official report of Minerva Biotechnologies. DMVGBA1 RU https://www.minervabio.com/minervabio.com/pipeline/ DMVGN42 DI DMVGN42 DMVGN42 DN TRX-818 DMVGN42 TI TTB8Y9K DMVGN42 TN Angiogenesis (AGG) DMVGN42 MA Inhibitor DMVGN42 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVGN42 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVGTP6 DI DMVGTP6 DMVGTP6 DN MB-105 DMVGTP6 TI TT9T4AV DMVGTP6 TN Prostate stem cell antigen (PSCA) DMVGTP6 RN Clinical pipeline report, company report or official report of Mustang Bio. DMVGTP6 RU https://www.mustangbio.com/pipeline/ DMVHPOX DI DMVHPOX DMVHPOX DN AGN-242266 DMVHPOX TI TTS4UGC DMVHPOX TN Farnesoid X-activated receptor (FXR) DMVHPOX MA Agonist DMVHPOX RN Clinical pipeline report, company report or official report of AbbVie. DMVHPOX RU https://www.abbvie.com/our-science/pipeline/agn-242266-fxr-agonist.html DMVIMQX DI DMVIMQX DMVIMQX DN ZSTK474 DMVIMQX TI TTHBTOP DMVIMQX TN PI3-kinase gamma (PIK3CG) DMVIMQX MA Modulator DMVIMQX RN Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct;15(10):1172-83. DMVIMQX RU https://pubmed.ncbi.nlm.nih.gov/24204196 DMVJMF1 DI DMVJMF1 DMVJMF1 DN RGD-891 DMVJMF1 TI TT38RM1 DMVJMF1 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMVJMF1 MA Modulator DMVJMF1 RN Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56. DMVJMF1 RU https://pubmed.ncbi.nlm.nih.gov/11075310 DMVJWBS DI DMVJWBS DMVJWBS DN JSI-1187 DMVJWBS TI TT1MG9E DMVJWBS TN Extracellular signal-regulated kinase 1 (ERK1) DMVJWBS MA Inhibitor DMVJWBS RN National Cancer Institute Drug Dictionary (drug name JSI1187). DMVJWBS RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187 DMVJWBS DI DMVJWBS DMVJWBS DN JSI-1187 DMVJWBS TI TT4TQBX DMVJWBS TN Extracellular signal-regulated kinase 2 (ERK2) DMVJWBS MA Inhibitor DMVJWBS RN National Cancer Institute Drug Dictionary (drug name JSI1187). DMVJWBS RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187 DMVK3M2 DI DMVK3M2 DMVK3M2 DN CART-BCMA DMVK3M2 TI TTZ3P4W DMVK3M2 TN B-cell maturation protein (TNFRSF17) DMVK3M2 MA CAR-T-Cell-Therapy DMVK3M2 RN ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma DMVK3M2 RU https://clinicaltrials.gov/ct2/show/NCT02546167 DMVL87N DI DMVL87N DMVL87N DN AV-965 DMVL87N TI TTSQIFT DMVL87N TN 5-HT 1A receptor (HTR1A) DMVL87N MA Antagonist DMVL87N RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025412) DMVL87N RU http://adisinsight.springer.com/drugs/800025412 DMVLPRT DI DMVLPRT DMVLPRT DN ABT-700 DMVLPRT TI TTNDSF4 DMVLPRT TN Proto-oncogene c-Met (MET) DMVLPRT MA Modulator DMVLPRT RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2507). DMVLPRT RU http://meetinglibrary.asco.org/content/134301-144 DMVMIBY DI DMVMIBY DMVMIBY DN AGG-523 DMVMIBY TI TTXSU2Y DMVMIBY TN Aggrecanase (ADAMTS5) DMVMIBY MA Inhibitor DMVMIBY RN Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23. DMVMIBY RU https://pubmed.ncbi.nlm.nih.gov/21163358 DMVNLGW DI DMVNLGW DMVNLGW DN MR-1817 DMVNLGW TI TTMI6F5 DMVNLGW TN Transient receptor potential cation channel V1 (TRPV1) DMVNLGW MA Antagonist DMVNLGW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030745) DMVNLGW RU http://adisinsight.springer.com/drugs/800030745 DMVONF0 DI DMVONF0 DMVONF0 DN CD19/CD22 CAR T cells DMVONF0 TI TTM6QSK DMVONF0 TN B-cell receptor CD22 (CD22) DMVONF0 MA CAR-T-Cell-Therapy(Dual specific) DMVONF0 RN ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia DMVONF0 RU https://clinicaltrials.gov/ct2/show/NCT03241940 DMVONF0 DI DMVONF0 DMVONF0 DN CD19/CD22 CAR T cells DMVONF0 TI TTW640A DMVONF0 TN B-lymphocyte surface antigen B4 (CD19) DMVONF0 MA CAR-T-Cell-Therapy(Dual specific) DMVONF0 RN ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia DMVONF0 RU https://clinicaltrials.gov/ct2/show/NCT03241940 DMVPAZ7 DI DMVPAZ7 DMVPAZ7 DN BAY1143572 DMVPAZ7 TI TTQ7ABG DMVPAZ7 TN Positive transcription elongation factor b (P-TEFb) DMVPAZ7 MA Modulator DMVPAZ7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVPAZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVQAEK DI DMVQAEK DMVQAEK DN ND-1.1 DMVQAEK TI TTF4CAM DMVQAEK TN Influenza Hemagglutinin (Influ HA) DMVQAEK RN An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94. DMVQAEK RU https://pubmed.ncbi.nlm.nih.gov/23155123 DMVQJOS DI DMVQJOS DMVQJOS DN PXS-25 DMVQJOS TI TTPNE41 DMVQJOS TN CI Man-6-P receptor (IGF2R) DMVQJOS MA Inhibitor DMVQJOS RN Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93. DMVQJOS RU https://pubmed.ncbi.nlm.nih.gov/21478477 DMVQX5K DI DMVQX5K DMVQX5K DN AMG 404 DMVQX5K TI TTNBFWK DMVQX5K TN Programmed cell death protein 1 (PD-1) DMVQX5K MA Inhibitor DMVQX5K RN ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health. DMVQX5K RU https://clinicaltrials.gov/ct2/show/NCT03853109 DMVRTCW DI DMVRTCW DMVRTCW DN HDM201 DMVRTCW TI TT7SBF5 DMVRTCW TN Cellular tumor antigen p53 (TP53) DMVRTCW MA Inhibitor DMVRTCW RN National Cancer Institute Drug Dictionary (drug id 761551). DMVRTCW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761551 DMVRTCW DI DMVRTCW DMVRTCW DN HDM201 DMVRTCW TI TT08GJW DMVRTCW TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMVRTCW MA Inhibitor DMVRTCW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVRTCW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVS87W DI DMVS87W DMVS87W DN BIIB068 DMVS87W TI TTGM6VW DMVS87W TN Tyrosine-protein kinase BTK (ATK) DMVS87W MA Inhibitor DMVS87W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVS87W RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMVSPZM DI DMVSPZM DMVSPZM DN Anti-CD38 CAR-T cells DMVSPZM TI TTPURFN DMVSPZM TN Cyclic ADP-ribose hydrolase 1 (CD38) DMVSPZM MA CAR-T-Cell-Therapy DMVSPZM RN ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients DMVSPZM RU https://clinicaltrials.gov/ct2/show/NCT03464916 DMVUL1H DI DMVUL1H DMVUL1H DN Sleeping Beauty CAR-TCR DMVUL1H TI TTW640A DMVUL1H TN B-lymphocyte surface antigen B4 (CD19) DMVUL1H RN Clinical pipeline report, company report or official report of Ziopharm Oncology. DMVUL1H RU https://ziopharm.com/pipeline/ DMVUW8A DI DMVUW8A DMVUW8A DN AVI-6002 DMVUW8A TI TT3Z102 DMVUW8A TN Ebola virus VP35 messenger RNA (EV VP35 mRNA) DMVUW8A MA Modulator DMVUW8A RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMVUW8A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMVUW8A DI DMVUW8A DMVUW8A DN AVI-6002 DMVUW8A TI TTDJLWQ DMVUW8A TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMVUW8A MA Modulator DMVUW8A RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMVUW8A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMVWHS1 DI DMVWHS1 DMVWHS1 DN GPC3 targeting CAR-T cells DMVWHS1 TI TTJTSX4 DMVWHS1 TN Glypican-3 (GPC3) DMVWHS1 MA CAR-T-Cell-Therapy DMVWHS1 RN ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression DMVWHS1 RU https://clinicaltrials.gov/ct2/show/NCT03198546 DMVWMUK DI DMVWMUK DMVWMUK DN AZD4785 DMVWMUK TI TTB1RA4 DMVWMUK TN GTPase KRas (KRAS) DMVWMUK MA Inhibitor DMVWMUK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVWMUK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVXLS5 DI DMVXLS5 DMVXLS5 DN Sym021 DMVXLS5 TI TTNBFWK DMVXLS5 TN Programmed cell death protein 1 (PD-1) DMVXLS5 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMVXLS5 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMVXQ5W DI DMVXQ5W DMVXQ5W DN RO-5458640 DMVXQ5W TI TTBTDM1 DMVXQ5W TN TNF-related weak inducer of apoptosis (TWEAK) DMVXQ5W MA Modulator DMVXQ5W RN A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308. DMVXQ5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929451/ DMVXRYC DI DMVXRYC DMVXRYC DN AM-211 DMVXRYC TI TTQDMX5 DMVXRYC TN Prostaglandin D2 receptor 2 (PTGDR2) DMVXRYC MA Antagonist DMVXRYC RN Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 Jul;338(1):290-301. DMVXRYC RU https://pubmed.ncbi.nlm.nih.gov/21487069 DMVYEFZ DI DMVYEFZ DMVYEFZ DN TAK-202 DMVYEFZ TI TTFZYTO DMVYEFZ TN C-C chemokine receptor type 2 (CCR2) DMVYEFZ MA Antagonist DMVYEFZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVYEFZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVYO41 DI DMVYO41 DMVYO41 DN XK-469 DMVYO41 TI TT4NVEM DMVYO41 TN DNA topoisomerase II beta (TOP2B) DMVYO41 MA Modulator DMVYO41 RN A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32. DMVYO41 RU https://www.ncbi.nlm.nih.gov/pubmed/24300566 DMVYRH2 DI DMVYRH2 DMVYRH2 DN Perifosine DMVYRH2 TI TTHBTOP DMVYRH2 TN PI3-kinase gamma (PIK3CG) DMVYRH2 MA Modulator DMVYRH2 RN Company report (Aezsinc) DMVYRH2 RU http://www.aezsinc.com/en/page.php?p=60&q=504 DMW0H9Y DI DMW0H9Y DMW0H9Y DN KA2507 DMW0H9Y TI TT5ZKDI DMW0H9Y TN Histone deacetylase 6 (HDAC6) DMW0H9Y MA Inhibitor DMW0H9Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW0H9Y RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW0ZDF DI DMW0ZDF DMW0ZDF DN BCMA-specific CAR-expressing T Lymphocytes DMW0ZDF TI TTZ3P4W DMW0ZDF TN B-cell maturation protein (TNFRSF17) DMW0ZDF MA CAR-T-Cell-Therapy DMW0ZDF RN ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma DMW0ZDF RU https://clinicaltrials.gov/ct2/show/NCT03502577 DMW10HM DI DMW10HM DMW10HM DN Tak-220 DMW10HM TI TT2CEJG DMW10HM TN C-C chemokine receptor type 5 (CCR5) DMW10HM MA Binder DMW10HM RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DMW10HM RU https://pubmed.ncbi.nlm.nih.gov/16182193 DMW16VR DI DMW16VR DMW16VR DN CT-200 DMW16VR TI TTBH0VX DMW16VR TN Histone deacetylase (HDAC) DMW16VR MA Inhibitor DMW16VR RN Clinical pipeline report, company report or official report of Celleron. DMW16VR RU http://cellerontherapeutics.com/ DMW1OKT DI DMW1OKT DMW1OKT DN CBT-501 DMW1OKT TI TTNBFWK DMW1OKT TN Programmed cell death protein 1 (PD-1) DMW1OKT MA Modulator DMW1OKT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW1OKT RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMW1ZAM DI DMW1ZAM DMW1ZAM DN Iboctadekin + Doxil DMW1ZAM TI TT0IHXV DMW1ZAM TN DNA topoisomerase II (TOP2) DMW1ZAM MA Inhibitor DMW1ZAM RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW1ZAM RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW1ZAM DI DMW1ZAM DMW1ZAM DN Iboctadekin + Doxil DMW1ZAM TI TTRICUF DMW1ZAM TN Interleukin-18 (IL18) DMW1ZAM MA Modulator DMW1ZAM RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW1ZAM RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW2HS8 DI DMW2HS8 DMW2HS8 DN YM-116 DMW2HS8 TI TTC8NQ2 DMW2HS8 TN Lyase unspecific (LYA) DMW2HS8 MA Inhibitor DMW2HS8 RN YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79(2):213-20. DMW2HS8 RU https://pubmed.ncbi.nlm.nih.gov/10202857 DMW2O5D DI DMW2O5D DMW2O5D DN MK-3328 DMW2O5D TI TTHS256 DMW2O5D TN Metabotropic glutamate receptor 5 (mGluR5) DMW2O5D MA Modulator DMW2O5D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMW2O5D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMW3MCX DI DMW3MCX DMW3MCX DN PRT811 DMW3MCX TI TTR1D7X DMW3MCX TN Protein arginine methyltransferase 5 (PRMT5) DMW3MCX MA Inhibitor DMW3MCX RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMW3MCX RU https://preludetx.com/science/prmt5/prt811/ DMW43DL DI DMW43DL DMW43DL DN TAK-828 DMW43DL TI TTGV6LY DMW43DL TN Nuclear receptor ROR-gamma (RORG) DMW43DL MA Agonist DMW43DL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW43DL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMW4GM2 DI DMW4GM2 DMW4GM2 DN AZD5153 DMW4GM2 TI TTRA6BO DMW4GM2 TN Bromodomain-containing protein 4 (BRD4) DMW4GM2 MA Inhibitor DMW4GM2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW4GM2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW4JRY DI DMW4JRY DMW4JRY DN OBT076 DMW4JRY TI TTG180Q DMW4JRY TN Lymphocyte antigen 75 (LY75) DMW4JRY RN MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. DMW4JRY RU https://pubmed.ncbi.nlm.nih.gov/31227646 DMW4VQF DI DMW4VQF DMW4VQF DN AZD6423 DMW4VQF TI TT9IK2Z DMW4VQF TN N-methyl-D-aspartate receptor (NMDAR) DMW4VQF MA Antagonist DMW4VQF RN Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009. DMW4VQF RU http://www.ncbi.nlm.nih.gov/books/NBK5283/ DMW549Y DI DMW549Y DMW549Y DN Anti-CD19 CART Cells DMW549Y TI TTW640A DMW549Y TN B-lymphocyte surface antigen B4 (CD19) DMW549Y MA CAR-T-Cell-Therapy DMW549Y RN ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma DMW549Y RU https://clinicaltrials.gov/ct2/show/NCT03767725 DMW5J9B DI DMW5J9B DMW5J9B DN JX-929 DMW5J9B TI TTKRTP6 DMW5J9B TN Cytosine deaminase (AICDA) DMW5J9B MA Modulator DMW5J9B RN Micromanaging oncolytic viruses. SciBX 1(42); doi:10.1038/scibx.2008.1014. Nov. 20 2008 DMW5J9B RU http://www.nature.com/scibx/journal/v1/n42/full/scibx.2008.1014.html DMW64UZ DI DMW64UZ DMW64UZ DN SKL-10406 DMW64UZ TI TTEX248 DMW64UZ TN Dopamine D2 receptor (D2R) DMW64UZ MA Binder DMW64UZ RN Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793. DMW64UZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/ DMW64UZ DI DMW64UZ DMW64UZ DN SKL-10406 DMW64UZ TI TTJQOD7 DMW64UZ TN 5-HT 2A receptor (HTR2A) DMW64UZ MA Binder DMW64UZ RN Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793. DMW64UZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/ DMW6X0O DI DMW6X0O DMW6X0O DN ACH-2684 DMW6X0O TI TTWXB3E DMW6X0O TN Hepatitis C virus NS3 helicase (HCV NS3) DMW6X0O MA Modulator DMW6X0O RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMW6X0O RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMW72NJ DI DMW72NJ DMW72NJ DN ASP3026 DMW72NJ TI TTPMQSO DMW72NJ TN ALK tyrosine kinase receptor (ALK) DMW72NJ MA Modulator DMW72NJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740). DMW72NJ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7740 DMW739O DI DMW739O DMW739O DN EP-51389 DMW739O TI TTKMAZ6 DMW739O TN Growth hormone receptor (GHR) DMW739O MA Agonist DMW739O RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMW739O RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMW7CLY DI DMW7CLY DMW7CLY DN INCB15050 DMW7CLY TI TT2CEJG DMW7CLY TN C-C chemokine receptor type 5 (CCR5) DMW7CLY MA Antagonist DMW7CLY RN Incyte. Product Development Pipeline. DMW7CLY RU http://www.incyte.com/drugs_product_pipeline.html DMW7K39 DI DMW7K39 DMW7K39 DN Pyrotinib DMW7K39 TI TTG96HZ DMW7K39 TN EGFR messenger RNA (EGFR mRNA) DMW7K39 MA Inhibitor DMW7K39 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW7K39 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW7VGZ DI DMW7VGZ DMW7VGZ DN PegCNTF DMW7VGZ TI TTT2F9E DMW7VGZ TN Ciliary neurotrophic factor receptor alpha (CNTFR) DMW7VGZ MA Agonist DMW7VGZ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMW7VGZ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMW7VGZ DI DMW7VGZ DMW7VGZ DN PegCNTF DMW7VGZ TI TTQL5VC DMW7VGZ TN Platelet-activating factor receptor (PTAFR) DMW7VGZ MA Modulator DMW7VGZ RN Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21. DMW7VGZ RU https://pubmed.ncbi.nlm.nih.gov/1793070 DMW8VEH DI DMW8VEH DMW8VEH DN BMY-43748 DMW8VEH TI TT0IHXV DMW8VEH TN DNA topoisomerase II (TOP2) DMW8VEH MA Modulator DMW8VEH RN Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503. DMW8VEH RU https://pubmed.ncbi.nlm.nih.gov/20732241 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TT27RFC DMW9YOJ TN Opioid receptor delta (OPRD1) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TTKWM86 DMW9YOJ TN Opioid receptor mu (MOP) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TTQW87Y DMW9YOJ TN Opioid receptor kappa (OPRK1) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TTKWM86 DMW9ZFS TN Opioid receptor mu (MOP) DMW9ZFS MA Antagonist DMW9ZFS RN Clinical pipeline report, company report or official report of signaturerx. DMW9ZFS RU http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TT27RFC DMW9ZFS TN Opioid receptor delta (OPRD1) DMW9ZFS MA Inhibitor DMW9ZFS RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMW9ZFS RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TTQW87Y DMW9ZFS TN Opioid receptor kappa (OPRK1) DMW9ZFS MA Inhibitor DMW9ZFS RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMW9ZFS RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMWAMNT DI DMWAMNT DMWAMNT DN CAR-T Cells targeting EGFRvIII DMWAMNT TI TTZ6B2I DMWAMNT TN Epidermal growth factor receptor variant III (EGFR vIII) DMWAMNT MA CAR-T-Cell-Therapy DMWAMNT RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMWAMNT RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMWBA1S DI DMWBA1S DMWBA1S DN PT-302 DMWBA1S TI TT84ETX DMWBA1S TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMWBA1S MA Inhibitor DMWBA1S RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMWBA1S RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMWBQ2Z DI DMWBQ2Z DMWBQ2Z DN TGF-BR2 mab DMWBQ2Z TI TTZE3P7 DMWBQ2Z TN TGF-beta receptor type II (TGFBR2) DMWBQ2Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1795). DMWBQ2Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1795 DMWCJEU DI DMWCJEU DMWCJEU DN AZD0156 DMWCJEU TI TTKBM7V DMWCJEU TN ATM serine/threonine kinase (ATM) DMWCJEU MA Inhibitor DMWCJEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWCJEU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWDQOV DI DMWDQOV DMWDQOV DN GSK1482160 DMWDQOV TI TT473XN DMWDQOV TN P2X purinoceptor 7 (P2RX7) DMWDQOV MA Antagonist DMWDQOV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMWDQOV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMWG2K6 DI DMWG2K6 DMWG2K6 DN AMG 199 DMWG2K6 TI TTUN7MC DMWG2K6 TN T-cell surface glycoprotein CD3 (CD3) DMWG2K6 MA Inhibitor DMWG2K6 RN Clinical pipeline report, company report or official report of Amgen. DMWG2K6 RU https://www.amgenpipeline.com/ DMWG2K6 DI DMWG2K6 DMWG2K6 DN AMG 199 DMWG2K6 TI TTVO0JU DMWG2K6 TN Mucin-17 (MUC17) DMWG2K6 MA Inhibitor DMWG2K6 RN Clinical pipeline report, company report or official report of Amgen. DMWG2K6 RU https://www.amgenpipeline.com/ DMWGKHZ DI DMWGKHZ DMWGKHZ DN ATF-936 DMWGKHZ TI TTBUYHA DMWGKHZ TN Extracellular calcium-sensing receptor (CASR) DMWGKHZ MA Antagonist DMWGKHZ RN ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41. DMWGKHZ RU https://pubmed.ncbi.nlm.nih.gov/21514409 DMWHZEG DI DMWHZEG DMWHZEG DN OMN-54 DMWHZEG TI TTPVYKI DMWHZEG TN Signal transduction unspecific (ST) DMWHZEG MA Inhibitor DMWHZEG RN Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar;8(2):311-22. DMWHZEG RU https://pubmed.ncbi.nlm.nih.gov/24388358 DMWHZFS DI DMWHZFS DMWHZFS DN BI 754091 DMWHZFS TI TTNBFWK DMWHZFS TN Programmed cell death protein 1 (PD-1) DMWHZFS MA Inhibitor DMWHZFS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMWHZFS RU https://www.inoncology.com/ourpipeline/pd1-inhibitor DMWI0AL DI DMWI0AL DMWI0AL DN GSK6097608 DMWI0AL TI TT83C4X DMWI0AL TN T-cell surface protein tactile (CD96) DMWI0AL MA Antagonist DMWI0AL RN National Cancer Institute Drug Dictionary (drug name GSK6097608). DMWI0AL RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd96-monoclonal-antibody-gsk6097608 DMWIEC1 DI DMWIEC1 DMWIEC1 DN OTSA-101-DTPA-90Y DMWIEC1 TI TTP1S2F DMWIEC1 TN Frizzled-10 (FZD10) DMWIEC1 RN A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646. DMWIEC1 RU https://pubmed.ncbi.nlm.nih.gov/29884132 DMWIJL1 DI DMWIJL1 DMWIJL1 DN Anti-PD-L1 CSR T cells DMWIJL1 TI TT8ZLTI DMWIJL1 TN Programmed cell death 1 ligand 1 (PD-L1) DMWIJL1 MA CAR-T-Cell-Therapy DMWIJL1 RN ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme DMWIJL1 RU https://clinicaltrials.gov/ct2/show/NCT02937844 DMWIXLC DI DMWIXLC DMWIXLC DN CAR-T Cells targeting PSCA DMWIXLC TI TT9T4AV DMWIXLC TN Prostate stem cell antigen (PSCA) DMWIXLC MA CAR-T-Cell-Therapy DMWIXLC RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMWIXLC RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMWJ0IH DI DMWJ0IH DMWJ0IH DN REGN-421 DMWJ0IH TI TTV23LH DMWJ0IH TN Delta-like protein 4 (DLL4) DMWJ0IH RN J Clin Oncol 31, 2013 (suppl; abstr 2502). DMWJ0IH RU http://meetinglibrary.asco.org/content/113836-132 DMWK679 DI DMWK679 DMWK679 DN OMP-18R5 DMWK679 TI TTUQMO5 DMWK679 TN Frizzled-7 receptor (FZD7) DMWK679 MA Inhibitor DMWK679 RN Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. DMWK679 RU https://pubmed.ncbi.nlm.nih.gov/22753465 DMWK951 DI DMWK951 DMWK951 DN MLN7243 DMWK951 TI TTU8HT1 DMWK951 TN Ubiquitin-activating enzyme (UBA) DMWK951 MA Modulator DMWK951 RN National Cancer Institute Drug Dictionary (drug id 757275). DMWK951 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=757275 DMWKDOQ DI DMWKDOQ DMWKDOQ DN MRX34 DMWKDOQ TI TT96IGO DMWKDOQ TN microRNA hsa-miR-34 (MIR34) DMWKDOQ MA Modulator DMWKDOQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWKDOQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWKYSM DI DMWKYSM DMWKYSM DN Anti-CD19-CAR DMWKYSM TI TTW640A DMWKYSM TN B-lymphocyte surface antigen B4 (CD19) DMWKYSM MA CAR-T-Cell-Therapy DMWKYSM RN ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma DMWKYSM RU https://clinicaltrials.gov/ct2/show/NCT01593696 DMWN2FP DI DMWN2FP DMWN2FP DN NZV930 DMWN2FP TI TTK0O6Y DMWN2FP TN Ecto-5'-nucleotidase (CD73) DMWN2FP MA Inhibitor DMWN2FP RN Clinical pipeline report, company report or official report of Surface oncology. DMWN2FP RU https://www.surfaceoncology.com/pipeline/the-srf373-nzv930-program/ DMWN7D3 DI DMWN7D3 DMWN7D3 DN ABT-354 DMWN7D3 TI TTJS8PY DMWN7D3 TN 5-HT 6 receptor (HTR6) DMWN7D3 MA Modulator DMWN7D3 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035134) DMWN7D3 RU http://adisinsight.springer.com/drugs/800035134 DMWOE62 DI DMWOE62 DMWOE62 DN U3-1565 DMWOE62 TI TT15SL0 DMWOE62 TN Proheparin-binding EGF-like growth factor (HBEGF) DMWOE62 MA Modulator DMWOE62 RN J Clin Oncol 31, 2013 (suppl; abstr 2519). DMWOE62 RU http://meetinglibrary.asco.org/content/111447-132 DMWP3G1 DI DMWP3G1 DMWP3G1 DN Debio 0932 DMWP3G1 TI TT78R5H DMWP3G1 TN Heat shock protein 90 alpha (HSP90A) DMWP3G1 MA Inhibitor DMWP3G1 RN Clinical pipeline report, company report or official report of Debiopharm (2011). DMWP3G1 RU http://www.debiopharm.com/our-business/pipeline.html DMWR93D DI DMWR93D DMWR93D DN Genaconazole DMWR93D TI TTTSOUD DMWR93D TN Candida Cytochrome P450 51 (Candi ERG11) DMWR93D MA Modulator DMWR93D RN New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47. DMWR93D RU https://pubmed.ncbi.nlm.nih.gov/11204162 DMWS40H DI DMWS40H DMWS40H DN CTX120 DMWS40H TI TTZ3P4W DMWS40H TN B-cell maturation protein (TNFRSF17) DMWS40H RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DMWS40H RU http://www.crisprtx.com/programs/pipeline DMWSC5L DI DMWSC5L DMWSC5L DN L-778123 DMWSC5L TI TTXQKM3 DMWSC5L TN Farnesyl protein transferase (Ftase) DMWSC5L MA Modulator DMWSC5L RN Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58. DMWSC5L RU https://www.ncbi.nlm.nih.gov/pubmed/12479371 DMWSC5L DI DMWSC5L DMWSC5L DN L-778123 DMWSC5L TI TTX20QP DMWSC5L TN Geranylgeranyl transferase I (GGTase-I) DMWSC5L MA Modulator DMWSC5L RN Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58. DMWSC5L RU https://www.ncbi.nlm.nih.gov/pubmed/12479371 DMWSI04 DI DMWSI04 DMWSI04 DN IMC-002 DMWSI04 TI TT28S46 DMWSI04 TN Leukocyte surface antigen CD47 (CD47) DMWSI04 MA Blocker DMWSI04 RN Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics. DMWSI04 RU http://www.immuneoncia.com/immun/index.php/pipeline/ DMWT5RS DI DMWT5RS DMWT5RS DN Daniquidone DMWT5RS TI TTGTQHC DMWT5RS TN DNA topoisomerase I (TOP1) DMWT5RS MA Modulator DMWT5RS RN Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23. DMWT5RS RU https://www.ncbi.nlm.nih.gov/pubmed/23912694 DMWT5RS DI DMWT5RS DMWT5RS DN Daniquidone DMWT5RS TI TT0IHXV DMWT5RS TN DNA topoisomerase II (TOP2) DMWT5RS MA Modulator DMWT5RS RN Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23. DMWT5RS RU https://www.ncbi.nlm.nih.gov/pubmed/23912694 DMWT8RI DI DMWT8RI DMWT8RI DN PRX-105 DMWT8RI TI TT1RS9F DMWT8RI TN Acetylcholinesterase (AChE) DMWT8RI MA Inhibitor DMWT8RI RN Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):202-9. DMWT8RI RU https://pubmed.ncbi.nlm.nih.gov/26051873 DMWTVM1 DI DMWTVM1 DMWTVM1 DN EDP-322 DMWTVM1 TI TT3OT40 DMWTVM1 TN Multidrug resistance protein 1 (ABCB1) DMWTVM1 MA Inhibitor DMWTVM1 RN In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7. DMWTVM1 RU https://pubmed.ncbi.nlm.nih.gov/25182063 DMWU682 DI DMWU682 DMWU682 DN PX-102 DMWU682 TI TTS4UGC DMWU682 TN Farnesoid X-activated receptor (FXR) DMWU682 MA Agonist DMWU682 RN An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology. 2018 Oct;155(4):1012-1016. DMWU682 RU https://pubmed.ncbi.nlm.nih.gov/29928896 DMWU71N DI DMWU71N DMWU71N DN SAN-134 DMWU71N TI TT1YWO5 DMWU71N TN Glucagon-like peptide 2 receptor (GLP2R) DMWU71N MA Inhibitor DMWU71N RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865) DMWU71N RU http://adisinsight.springer.com/drugs/800020865 DMWV8C6 DI DMWV8C6 DMWV8C6 DN CA-4948 DMWV8C6 TI TTKFVXR DMWV8C6 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMWV8C6 MA Inhibitor DMWV8C6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV8C6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWXQC9 DI DMWXQC9 DMWXQC9 DN Drug 2881078 DMWXQC9 TI TTS64P2 DMWXQC9 TN Androgen receptor (AR) DMWXQC9 MA Modulator DMWXQC9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743) DMWXQC9 RU http://adisinsight.springer.com/drugs/800039743 DMWYEDX DI DMWYEDX DMWYEDX DN ON-01210.Na DMWYEDX TI TTGQUFK DMWYEDX TN PI3K/AKT/mTOR pathway (PAm pathway) DMWYEDX MA Inhibitor DMWYEDX RN ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. DMWYEDX RU https://pubmed.ncbi.nlm.nih.gov/23505494 DMWYF1H DI DMWYF1H DMWYF1H DN AZD8186 DMWYF1H TI TTTHBCA DMWYF1H TN PI3-kinase beta (PIK3CB) DMWYF1H MA Inhibitor DMWYF1H RN National Cancer Institute Drug Dictionary (drug id 751594). DMWYF1H RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751594 DMWYF1H DI DMWYF1H DMWYF1H DN AZD8186 DMWYF1H TI TTHBTOP DMWYF1H TN PI3-kinase gamma (PIK3CG) DMWYF1H MA Inhibitor DMWYF1H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWYF1H RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWYHXG DI DMWYHXG DMWYHXG DN AZD-9819 DMWYHXG TI TTPLTSQ DMWYHXG TN Neutrophil elastase (NE) DMWYHXG MA Inhibitor DMWYHXG RN Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9. DMWYHXG RU https://pubmed.ncbi.nlm.nih.gov/26203069 DMX05W8 DI DMX05W8 DMX05W8 DN SYN-1001 DMX05W8 TI TTN4QDT DMX05W8 TN Opioid receptor (OPR) DMX05W8 MA Agonist DMX05W8 RN Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther. 2005 May;313(2):712-9. DMX05W8 RU https://pubmed.ncbi.nlm.nih.gov/15647327 DMX0DUH DI DMX0DUH DMX0DUH DN MEDI2228 DMX0DUH TI TTZ3P4W DMX0DUH TN B-cell maturation protein (TNFRSF17) DMX0DUH MA Inhibitor DMX0DUH RN A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162. DMX0DUH RU https://pubmed.ncbi.nlm.nih.gov/32060401 DMX0JLI DI DMX0JLI DMX0JLI DN A-837093 DMX0JLI TI TTMVBWH DMX0JLI TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMX0JLI MA Inhibitor DMX0JLI RN Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. DMX0JLI RU https://pubmed.ncbi.nlm.nih.gov/18321145 DMX1D0S DI DMX1D0S DMX1D0S DN OMP-21M18 DMX1D0S TI TTV23LH DMX1D0S TN Delta-like protein 4 (DLL4) DMX1D0S MA Modulator DMX1D0S RN National Cancer Institute Drug Dictionary (drug id 614677). DMX1D0S RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=614677 DMX2J57 DI DMX2J57 DMX2J57 DN GT103 DMX2J57 TI TTUW6OP DMX2J57 TN Complement factor H (CFH) DMX2J57 MA Inhibitor DMX2J57 RN Clinical pipeline report, company report or official report of Grid Therapeutics. DMX2J57 RU https://gridtherapeutics.com/research-development/gt103/ DMX3FN4 DI DMX3FN4 DMX3FN4 DN ISIS-APOCIII DMX3FN4 TI TTXOZQ1 DMX3FN4 TN ApoC-III messenger RNA (APOC3 mRNA) DMX3FN4 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMX3FN4 RU http://www.isispharm.com/index.htm DMX4PWV DI DMX4PWV DMX4PWV DN ASP1951 DMX4PWV TI TTG6LA7 DMX4PWV TN Activation-inducible TNFR family receptor (TNFRSF18) DMX4PWV MA Agonist DMX4PWV RN ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. DMX4PWV RU https://clinicaltrials.gov/ct2/show/NCT03799003 DMX4ZDY DI DMX4ZDY DMX4ZDY DN CAR-T Cells targeting CEA DMX4ZDY TI TTY6DTE DMX4ZDY TN Carcinoembryonic antigen CEA (CD66e) DMX4ZDY MA CAR-T-Cell-Therapy DMX4ZDY RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMX4ZDY RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMX5290 DI DMX5290 DMX5290 DN FF-10502-01 DMX5290 TI TTUBNVO DMX5290 TN DNA synthesis (DNA synth) DMX5290 MA Inhibitor DMX5290 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX5290 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX5LB7 DI DMX5LB7 DMX5LB7 DN PUR0200 DMX5LB7 TI TTOXS3C DMX5LB7 TN Muscarinic acetylcholine receptor (CHRM) DMX5LB7 MA Modulator DMX5LB7 RN Clinical pipeline report, company report or official report of pulmatrix pipeline. DMX5LB7 RU http://pulmatrix.com/pipeline.html DMX6AJ8 DI DMX6AJ8 DMX6AJ8 DN ZM-H1505R DMX6AJ8 TI TTM42UJ DMX6AJ8 TN Hepatitis B virus Capsid protein (HBV C) DMX6AJ8 MA Inhibitor DMX6AJ8 RN Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma. DMX6AJ8 RU http://www.core-biopharma.com/pipeline.html DMX6V1L DI DMX6V1L DMX6V1L DN ST-1141 DMX6V1L TI TTWDC17 DMX6V1L TN Growth hormone secretagogue receptor 1 (GHSR) DMX6V1L MA Agonist DMX6V1L RN The Prokinetic Face of Ghrelin. International Journal of Peptides Volume 2010 (2010), Article ID 493614, Page(11). DMX6V1L RU http://www.hindawi.com/journals/ijpep/2010/493614/ DMX8LY4 DI DMX8LY4 DMX8LY4 DN NS-8 DMX8LY4 TI TT1VOHK DMX8LY4 TN Potassium channel unspecific (KC) DMX8LY4 MA Agonist DMX8LY4 RN Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76. DMX8LY4 RU https://pubmed.ncbi.nlm.nih.gov/24747752 DMX8YO1 DI DMX8YO1 DMX8YO1 DN RG6125 DMX8YO1 TI TTRGWZC DMX8YO1 TN Osteoblast cadherin (CDH11) DMX8YO1 MA Inhibitor DMX8YO1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX8YO1 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMX94YF DI DMX94YF DMX94YF DN SEA-CD70 DMX94YF TI TTNCIE0 DMX94YF TN CD70 antigen (CD27-L) DMX94YF MA Inhibitor DMX94YF RN Clinical pipeline report, company report or official report of Seagen. DMX94YF RU https://www.seagen.com/science/pipeline DMX9AK6 DI DMX9AK6 DMX9AK6 DN PACAP38 DMX9AK6 TI TTW4LYC DMX9AK6 TN Pituitary adenylate cyclase-activating 38 (PACAP-38) DMX9AK6 MA Modulator DMX9AK6 RN Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expr... Ann N Y Acad Sci. 1996 Dec 26;805:204-16; discussion 217-8. DMX9AK6 RU https://pubmed.ncbi.nlm.nih.gov/8993404 DMX9EA0 DI DMX9EA0 DMX9EA0 DN TAK-058 DMX9EA0 TI TTNXLKE DMX9EA0 TN 5-HT 3 receptor (5HT3R) DMX9EA0 MA Antagonist DMX9EA0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805) DMX9EA0 RU http://adisinsight.springer.com/drugs/800040805 DMX9ER7 DI DMX9ER7 DMX9ER7 DN BIZELESIN DMX9ER7 TI TTUTN1I DMX9ER7 TN Human Deoxyribonucleic acid (hDNA) DMX9ER7 MA Inhibitor DMX9ER7 RN Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30. DMX9ER7 RU https://pubmed.ncbi.nlm.nih.gov/8180230 DMXA7W9 DI DMXA7W9 DMXA7W9 DN SGN-70 DMXA7W9 TI TTNCIE0 DMXA7W9 TN CD70 antigen (CD27-L) DMXA7W9 RN 2011 Pipeline of Seattle Genetics. DMXA7W9 RU http://www.seagen.com/product_pipeline.php DMXAUB7 DI DMXAUB7 DMXAUB7 DN EI1071 DMXAUB7 TI TT7MRDV DMXAUB7 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMXAUB7 MA Inhibitor DMXAUB7 RN Clinical pipeline report, company report or official report of Elixiron Immunotherapeutics. DMXAUB7 RU https://www.elixiron.com/ DMXBS6U DI DMXBS6U DMXBS6U DN RG7775 DMXBS6U TI TT08GJW DMXBS6U TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMXBS6U MA Inhibitor DMXBS6U RN Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche. DMXBS6U RU http://www.biocentury.com/products/rg7775 DMXCJP8 DI DMXCJP8 DMXCJP8 DN STP1002 DMXCJP8 TI TTKSAQZ DMXCJP8 TN Tankyrase (TNKS) DMXCJP8 MA Inhibitor DMXCJP8 RN Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171. DMXCJP8 RU https://cancerres.aacrjournals.org/content/77/13_Supplement/5171 DMXCN37 DI DMXCN37 DMXCN37 DN DS-1040 DMXCN37 TI TTP18AY DMXCN37 TN Carboxypeptidase B2 (CPB2) DMXCN37 MA Modulator DMXCN37 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMXCN37 RU http://www.daiichisankyo.com/rd/pipeline/development_pipeline/index.html#details01 DMXD4TC DI DMXD4TC DMXD4TC DN CAR19 T cells carrying cytoplasmic activated PD-1 DMXD4TC TI TTW640A DMXD4TC TN B-lymphocyte surface antigen B4 (CD19) DMXD4TC MA CAR-T-Cell-Therapy DMXD4TC RN ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma DMXD4TC RU https://clinicaltrials.gov/ct2/show/NCT03540303 DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTPURFN DMXD5QP TN Cyclic ADP-ribose hydrolase 1 (CD38) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTUN7MC DMXD5QP TN T-cell surface glycoprotein CD3 (CD3) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTQ13FT DMXD5QP TN T-cell-specific surface glycoprotein CD28 (CD28) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXDMH5 DI DMXDMH5 DMXDMH5 DN APVO414 DMXDMH5 TI TT9G4N0 DMXDMH5 TN Glutamate carboxypeptidase II (GCPII) DMXDMH5 MA Inhibitor DMXDMH5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXDMH5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXETUQ DI DMXETUQ DMXETUQ DN HER-2/HER-1 vaccine DMXETUQ TI TTGKNB4 DMXETUQ TN Epidermal growth factor receptor (EGFR) DMXETUQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMXETUQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMXFY18 DI DMXFY18 DMXFY18 DN EZN-3042 DMXFY18 TI TTTPU1G DMXFY18 TN Apoptosis inhibitor survivin (BIRC5) DMXFY18 MA Modulator DMXFY18 RN SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45. DMXFY18 RU https://www.ncbi.nlm.nih.gov/pubmed/18790754 DMXFYN0 DI DMXFYN0 DMXFYN0 DN AZD-3043 DMXFYN0 TI TTEX6LM DMXFYN0 TN GABA(A) receptor gamma-3 (GABRG3) DMXFYN0 MA Modulator DMXFYN0 RN AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77. DMXFYN0 RU https://pubmed.ncbi.nlm.nih.gov/22531340 DMXG3T1 DI DMXG3T1 DMXG3T1 DN GS-6637 DMXG3T1 TI TTFLN4T DMXG3T1 TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMXG3T1 MA Inhibitor DMXG3T1 RN Clinical pipeline report, company report or official report of Gilead. DMXG3T1 RU http://www.gilead.com/~/media/Files/pdfs/other/Gilead_Sciences_Company_Overview_FactSheet_080514.pdf DMXHKYJ DI DMXHKYJ DMXHKYJ DN P1446A-05 DMXHKYJ TI TT0PG8F DMXHKYJ TN Cyclin-dependent kinase 4 (CDK4) DMXHKYJ MA Inhibitor DMXHKYJ RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMXHKYJ RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMXI5ON DI DMXI5ON DMXI5ON DN IMC-3C5 DMXI5ON TI TTDCBX5 DMXI5ON TN Vascular endothelial growth factor receptor 3 (FLT-4) DMXI5ON MA Modulator DMXI5ON RN Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414. DMXI5ON RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464486/ DMXI9P4 DI DMXI9P4 DMXI9P4 DN EPX-100 DMXI9P4 TI TT85JO3 DMXI9P4 TN 5-HT receptor (5HTR) DMXI9P4 MA Modulator DMXI9P4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXI9P4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMXIDWE DI DMXIDWE DMXIDWE DN BAY-60-5521 DMXIDWE TI TTFQAYR DMXIDWE TN Cholesteryl ester transfer protein (CETP) DMXIDWE MA Inhibitor DMXIDWE RN Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8. DMXIDWE RU https://pubmed.ncbi.nlm.nih.gov/21838789 DMXIKYR DI DMXIKYR DMXIKYR DN APTO-253 DMXIKYR TI TTTI53X DMXIKYR TN Kruppel like factor 4 (KLF4) DMXIKYR MA Inhibitor DMXIKYR RN Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. DMXIKYR RU https://pubmed.ncbi.nlm.nih.gov/26268924 DMXIMQT DI DMXIMQT DMXIMQT DN APX-3330 DMXIMQT TI TTHGL48 DMXIMQT TN AP endonuclease 1 (APEX1) DMXIMQT MA Inhibitor DMXIMQT RN Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100. DMXIMQT RU https://pubmed.ncbi.nlm.nih.gov/20937296 DMXKFOQ DI DMXKFOQ DMXKFOQ DN RPI-78M DMXKFOQ TI TTJSZTB DMXKFOQ TN Nicotinic acetylcholine receptor (nAChR) DMXKFOQ MA Antagonist DMXKFOQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXKFOQ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMXKO1L DI DMXKO1L DMXKO1L DN L-796568 DMXKO1L TI TT2CJVK DMXKO1L TN Adrenergic receptor beta-2 (ADRB2) DMXKO1L MA Inhibitor DMXKO1L RN Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. DMXKO1L RU https://pubmed.ncbi.nlm.nih.gov/20181479 DMXKO1L DI DMXKO1L DMXKO1L DN L-796568 DMXKO1L TI TTR6W5O DMXKO1L TN Adrenergic receptor beta-1 (ADRB1) DMXKO1L MA Inhibitor DMXKO1L RN Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. DMXKO1L RU https://pubmed.ncbi.nlm.nih.gov/20181479 DMXLHVW DI DMXLHVW DMXLHVW DN PLX51107 DMXLHVW TI TTE4BSY DMXLHVW TN Bromodomain and extraterminal domain protein (BET) DMXLHVW MA Inhibitor DMXLHVW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXLHVW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXMK5S DI DMXMK5S DMXMK5S DN Alfa-interferon DMXMK5S TI TTMQB37 DMXMK5S TN Interferon alpha/beta receptor 2 (IFNAR2) DMXMK5S MA Stimulator DMXMK5S RN New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. DMXMK5S RU https://pubmed.ncbi.nlm.nih.gov/18616415 DMXO3PV DI DMXO3PV DMXO3PV DN BI 905681 DMXO3PV TI TT7VMG4 DMXO3PV TN Low-density lipoprotein receptor-related protein 5 (LRP5) DMXO3PV MA Antagonist DMXO3PV RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMXO3PV RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMXPLMN DI DMXPLMN DMXPLMN DN INTOPLICINE DMXPLMN TI TTGTQHC DMXPLMN TN DNA topoisomerase I (TOP1) DMXPLMN MA Modulator DMXPLMN RN Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74. DMXPLMN RU https://www.ncbi.nlm.nih.gov/pubmed/8232227 DMXQ4NO DI DMXQ4NO DMXQ4NO DN Palomid-529 DMXQ4NO TI TTX4GLS DMXQ4NO TN Mammalian target of rapamycin complex 1 (mTORC1) DMXQ4NO MA Inhibitor DMXQ4NO RN Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. DMXQ4NO RU https://pubmed.ncbi.nlm.nih.gov/23436212 DMXQ4NO DI DMXQ4NO DMXQ4NO DN Palomid-529 DMXQ4NO TI TTWDKCL DMXQ4NO TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMXQ4NO MA Inhibitor DMXQ4NO RN Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. DMXQ4NO RU https://pubmed.ncbi.nlm.nih.gov/23436212 DMXQF1T DI DMXQF1T DMXQF1T DN SSR-181507 DMXQF1T TI TTSQIFT DMXQF1T TN 5-HT 1A receptor (HTR1A) DMXQF1T MA Modulator DMXQF1T RN SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35. DMXQF1T RU https://www.ncbi.nlm.nih.gov/pubmed/20920519 DMXQF1T DI DMXQF1T DMXQF1T DN SSR-181507 DMXQF1T TI TTEX248 DMXQF1T TN Dopamine D2 receptor (D2R) DMXQF1T MA Modulator DMXQF1T RN SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35. DMXQF1T RU https://www.ncbi.nlm.nih.gov/pubmed/20920519 DMXQGKL DI DMXQGKL DMXQGKL DN CB-813 DMXQGKL TI TTF0EGX DMXQGKL TN Coagulation factor VII (F7) DMXQGKL MA Modulator DMXQGKL RN Clinical pipeline report, company report or official report of Catalyst Biosciences. DMXQGKL RU http://www.catalystbiosciences.com/news/15-06-24/ DMXQHZC DI DMXQHZC DMXQHZC DN MM-151 DMXQHZC TI TTDC8N2 DMXQHZC TN Erbb3 tyrosine kinase receptor (Erbb-3) DMXQHZC MA Modulator DMXQHZC RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DMXQHZC RU https://pubmed.ncbi.nlm.nih.gov/24282274 DMXQHZC DI DMXQHZC DMXQHZC DN MM-151 DMXQHZC TI TTGKNB4 DMXQHZC TN Epidermal growth factor receptor (EGFR) DMXQHZC MA Antagonist DMXQHZC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXQHZC RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXQOHV DI DMXQOHV DMXQOHV DN COM701 DMXQOHV TI TTOGCNT DMXQOHV TN Transmembrane protein PVRIG (PVRIG) DMXQOHV RN Clinical pipeline report, company report or official report of Compugen. DMXQOHV RU https://cgen.com/pipeline/com701-pvrig/ DMXR6HI DI DMXR6HI DMXR6HI DN KITE-585 DMXR6HI TI TTZ3P4W DMXR6HI TN B-cell maturation protein (TNFRSF17) DMXR6HI MA CAR-T-Cell-Therapy DMXR6HI RN ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma DMXR6HI RU https://clinicaltrials.gov/ct2/show/NCT03318861 DMXRPT6 DI DMXRPT6 DMXRPT6 DN GSK1070916 DMXRPT6 TI TT5LS6T DMXRPT6 TN Aurora kinase B (AURKB) DMXRPT6 MA Modulator DMXRPT6 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMXRPT6 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMXRPT6 DI DMXRPT6 DMXRPT6 DN GSK1070916 DMXRPT6 TI TTLYXIT DMXRPT6 TN Aurora kinase C (AURKC) DMXRPT6 MA Modulator DMXRPT6 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMXRPT6 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMXSMF9 DI DMXSMF9 DMXSMF9 DN IMP-701 DMXSMF9 TI TTNVXAW DMXSMF9 TN Lymphocyte activation gene 3 protein (LAG3) DMXSMF9 RN IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5. DMXSMF9 RU https://pubmed.ncbi.nlm.nih.gov/17394654 DMXST9F DI DMXST9F DMXST9F DN DS-1205 DMXST9F TI TTZPY6J DMXST9F TN Tyrosine-protein kinase UFO (AXL) DMXST9F MA Inhibitor DMXST9F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXST9F RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXTKYR DI DMXTKYR DMXTKYR DN SB-1578 DMXTKYR TI TTRMX3V DMXTKYR TN Janus kinase 2 (JAK-2) DMXTKYR MA Inhibitor DMXTKYR RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMXTKYR RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMXTOCE DI DMXTOCE DMXTOCE DN XmAb13676 DMXTOCE TI TTUE541 DMXTOCE TN Leukocyte surface antigen Leu-16 (CD20) DMXTOCE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXTOCE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TT6X50U DMXTYWJ TN Matrix metalloproteinase-9 (MMP-9) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TTXZ0KQ DMXTYWJ TN Matrix metalloproteinase-12 (MMP-12) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TTLM12X DMXTYWJ TN Matrix metalloproteinase-2 (MMP-2) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXU2GS DI DMXU2GS DMXU2GS DN SBS-1000 DMXU2GS TI TTZOPHG DMXU2GS TN Insulin (INS) DMXU2GS MA Modulator DMXU2GS RN Synergistic antihyperglycemic effects between plant-derived oleanolic acid and insulin in streptozotocin-induced diabetic rats. Ren Fail. 2010;32(7):832-9. DMXU2GS RU https://pubmed.ncbi.nlm.nih.gov/20662697 DMXU5FK DI DMXU5FK DMXU5FK DN BMS-986189 DMXU5FK TI TT8ZLTI DMXU5FK TN Programmed cell death 1 ligand 1 (PD-L1) DMXU5FK MA Inhibitor DMXU5FK RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMXU5FK RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMXUJ1P DI DMXUJ1P DMXUJ1P DN IBI188 DMXUJ1P TI TT28S46 DMXUJ1P TN Leukocyte surface antigen CD47 (CD47) DMXUJ1P MA Blocker DMXUJ1P RN Clinical pipeline report, company report or official report of Innovent Biologics. DMXUJ1P RU https://www.innoventbio.com/ScienceAndProducts/Pipeline/ProductRAndD DMXUT3Z DI DMXUT3Z DMXUT3Z DN CC-8490 DMXUT3Z TI TTZAYWL DMXUT3Z TN Estrogen receptor (ESR) DMXUT3Z MA Modulator DMXUT3Z RN Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23. DMXUT3Z RU https://pubmed.ncbi.nlm.nih.gov/15604281 DMXW07J DI DMXW07J DMXW07J DN EDP-239 DMXW07J TI TTCJ2X8 DMXW07J TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMXW07J MA Modulator DMXW07J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXW07J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXYCZV DI DMXYCZV DMXYCZV DN AMG 256 DMXYCZV TI TTZO9B0 DMXYCZV TN Interleukin 21 receptor (IL21R) DMXYCZV MA Agonist DMXYCZV RN Clinical pipeline report, company report or official report of Amgen. DMXYCZV RU https://www.amgenpipeline.com/ DMXYN1H DI DMXYN1H DMXYN1H DN KAR5585 DMXYN1H TI TTZSJHV DMXYN1H TN Tryptophan 5-hydroxylase 1 (TPH1) DMXYN1H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXYN1H RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMXZ1A8 DI DMXZ1A8 DMXZ1A8 DN HMPL-523 DMXZ1A8 TI TTOU65C DMXZ1A8 TN Tyrosine-protein kinase SYK (SYK) DMXZ1A8 MA Inhibitor DMXZ1A8 RN Clinical pipeline report, company report or official report of Hutchison MediPharma. DMXZ1A8 RU https://www.hutch-med.com/pipeline-and-products/our-pipeline/ DMXZ6A0 DI DMXZ6A0 DMXZ6A0 DN DP-4088 DMXZ6A0 TI TT6L509 DMXZ6A0 TN Coagulation factor IIa (F2) DMXZ6A0 MA Inhibitor DMXZ6A0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMXZ6A0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMXZOI0 DI DMXZOI0 DMXZOI0 DN P11187 DMXZOI0 TI TTB8FUC DMXZOI0 TN Free fatty acid receptor 1 (GPR40) DMXZOI0 MA Modulator DMXZOI0 RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DMXZOI0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DMY0DPM DI DMY0DPM DMY0DPM DN ARC-1905 DMY0DPM TI TTKANGO DMY0DPM TN Complement C5 (CO5) DMY0DPM RN ClinicalTrials.gov (NCT00950638) A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. U.S. National Institutes of Health. DMY0DPM RU https://clinicaltrials.gov/ct2/show/NCT00950638 DMY0HU6 DI DMY0HU6 DMY0HU6 DN ETC-1922159 DMY0HU6 TI TTNFBTO DMY0HU6 TN Protein-serine O-palmitoleoyltransferase porcupine (PORCN) DMY0HU6 MA Inhibitor DMY0HU6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY0HU6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY0QL7 DI DMY0QL7 DMY0QL7 DN Iomab-ACT DMY0QL7 TI TTUS45N DMY0QL7 TN Leukocyte common antigen (PTPRC) DMY0QL7 MA Inhibitor DMY0QL7 RN Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. DMY0QL7 RU https://www.actiniumpharma.com/product-pipeline/iomab-b DMY1AFS DI DMY1AFS DMY1AFS DN LY294002 DMY1AFS TI TTHBTOP DMY1AFS TN PI3-kinase gamma (PIK3CG) DMY1AFS MA Inhibitor DMY1AFS RN Clinical pipeline report, company report or official report of Genentech (2009). DMY1AFS RU http://www.gene.com/gene/pipeline/status/ DMY1DFK DI DMY1DFK DMY1DFK DN ITASETRON DMY1DFK TI TTNXLKE DMY1DFK TN 5-HT 3 receptor (5HT3R) DMY1DFK MA Modulator DMY1DFK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMY1DFK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMY218P DI DMY218P DMY218P DN CART-19 autologous T-cells DMY218P TI TTW640A DMY218P TN B-lymphocyte surface antigen B4 (CD19) DMY218P MA CAR-T-Cell-Therapy DMY218P RN ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP DMY218P RU https://clinicaltrials.gov/ct2/show/NCT02476734 DMY2GDQ DI DMY2GDQ DMY2GDQ DN P-PSMA-101 DMY2GDQ TI TTZ3P4W DMY2GDQ TN B-cell maturation protein (TNFRSF17) DMY2GDQ RN Clinical pipeline report, company report or official report of Poseida Therapeutics. DMY2GDQ RU https://poseida.com/science/pipeline/#cart-therapies DMY2MO4 DI DMY2MO4 DMY2MO4 DN Anti-meso-CAR T cells DMY2MO4 TI TT4RXME DMY2MO4 TN Mesothelin (MSLN) DMY2MO4 MA CAR-T-Cell-Therapy DMY2MO4 RN ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso DMY2MO4 RU https://clinicaltrials.gov/ct2/show/NCT02580747 DMY3NWK DI DMY3NWK DMY3NWK DN CART22 cells expressing anti-CD22 scFv TCRz:41BB DMY3NWK TI TTM6QSK DMY3NWK TN B-cell receptor CD22 (CD22) DMY3NWK MA CAR-T-Cell-Therapy DMY3NWK RN ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL DMY3NWK RU https://clinicaltrials.gov/ct2/show/NCT02650414 DMY4B6J DI DMY4B6J DMY4B6J DN BI-847325 DMY4B6J TI TTROQ37 DMY4B6J TN MAPK/ERK kinase kinase (MAP3K) DMY4B6J MA Modulator DMY4B6J RN doi: 10.1158/1535-7163.TARG-13-B281 DMY4B6J RU http://mct.aacrjournals.org/content/12/11_Supplement/B281.short DMY4B6J DI DMY4B6J DMY4B6J DN BI-847325 DMY4B6J TI TT5LS6T DMY4B6J TN Aurora kinase B (AURKB) DMY4B6J MA Modulator DMY4B6J RN doi: 10.1158/1535-7163.TARG-13-B281 DMY4B6J RU http://mct.aacrjournals.org/content/12/11_Supplement/B281.short DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TT7HF4W DMY4WVK TN Cyclin-dependent kinase 2 (CDK2) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TT0PG8F DMY4WVK TN Cyclin-dependent kinase 4 (CDK4) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TTH6V3D DMY4WVK TN Cyclin-dependent kinase 1 (CDK1) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY5IM2 DI DMY5IM2 DMY5IM2 DN ARL-67085 DMY5IM2 TI TTZ1DT0 DMY5IM2 TN P2Y purinoceptor 12 (P2RY12) DMY5IM2 MA Agonist DMY5IM2 RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DMY5IM2 RU https://pubmed.ncbi.nlm.nih.gov/10578132 DMY5V4U DI DMY5V4U DMY5V4U DN CM-CS1 T-cell DMY5V4U TI TTLRN4A DMY5V4U TN NKG2 D activating NK receptor (KLRK1) DMY5V4U MA CAR-T-Cell-Therapy DMY5V4U RN ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands DMY5V4U RU https://clinicaltrials.gov/ct2/show/NCT02203825 DMY61GX DI DMY61GX DMY61GX DN FGLL DMY61GX TI TTUBJQ3 DMY61GX TN Neural cell adhesion molecule (NCAM) DMY61GX MA Modulator DMY61GX RN An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18. DMY61GX RU https://pubmed.ncbi.nlm.nih.gov/23076631 DMY6QFH DI DMY6QFH DMY6QFH DN DFP-11207 DMY6QFH TI TTU6BFZ DMY6QFH TN Candida Thymidylate synthase (Candi TMP1) DMY6QFH MA Inhibitor DMY6QFH RN National Cancer Institute Drug Dictionary (drug id 762603). DMY6QFH RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762603 DMY6V5T DI DMY6V5T DMY6V5T DN ICasp9M28z T cell DMY6V5T TI TT4RXME DMY6V5T TN Mesothelin (MSLN) DMY6V5T MA CAR-T-Cell-Therapy DMY6V5T RN ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin DMY6V5T RU https://clinicaltrials.gov/ct2/show/NCT02414269 DMY7CW1 DI DMY7CW1 DMY7CW1 DN JNJ-74699157 DMY7CW1 TI TT3LH46 DMY7CW1 TN KRAS G12C mutant (KRAS G12C) DMY7CW1 MA Inhibitor DMY7CW1 RN KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070. DMY7CW1 RU https://pubmed.ncbi.nlm.nih.gov/32711246 DMY84TW DI DMY84TW DMY84TW DN CVT-6883 DMY84TW TI TTNE7KG DMY84TW TN Adenosine A2b receptor (ADORA2B) DMY84TW MA Modulator DMY84TW RN GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95. DMY84TW RU https://pubmed.ncbi.nlm.nih.gov/22923737 DMY8D5O DI DMY8D5O DMY8D5O DN RTI-336 DMY8D5O TI TTVBI8W DMY8D5O TN Dopamine transporter (DAT) DMY8D5O MA Modulator DMY8D5O RN Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.AAPS J.2006 Mar 24;8(1):E196-203. DMY8D5O RU https://www.ncbi.nlm.nih.gov/pubmed/16584128 DMY8W3S DI DMY8W3S DMY8W3S DN LY3484356 DMY8W3S TI TTZAYWL DMY8W3S TN Estrogen receptor (ESR) DMY8W3S MA Degrader DMY8W3S RN ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health. DMY8W3S RU https://clinicaltrials.gov/ct2/show/NCT04647487 DMY93SW DI DMY93SW DMY93SW DN XL550 DMY93SW TI TT26PHO DMY93SW TN Mineralocorticoid receptor (MR) DMY93SW MA Antagonist DMY93SW RN Clinical pipeline report, company report or official report of Exelixis (2011). DMY93SW RU http://www.exelixis.com/pipeline DMY95MZ DI DMY95MZ DMY95MZ DN DSP-0565 DMY95MZ TI TT5HONZ DMY95MZ TN Calcium channel unspecific (CaC) DMY95MZ MA Modulator DMY95MZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035668) DMY95MZ RU http://adisinsight.springer.com/drugs/800035668 DMY9L4C DI DMY9L4C DMY9L4C DN BXCL702 DMY9L4C TI TT3C1VN DMY9L4C TN Enzyme unspecific (Enz) DMY9L4C MA Inhibitor DMY9L4C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY9L4C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY9LG1 DI DMY9LG1 DMY9LG1 DN PAN-90806 DMY9LG1 TI TT9HKJA DMY9LG1 TN Vascular endothelial growth factor (VEGF) DMY9LG1 MA Inhibitor DMY9LG1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY9LG1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMY9XWB DI DMY9XWB DMY9XWB DN PMI-005 DMY9XWB TI TTF8CQI DMY9XWB TN Tumor necrosis factor (TNF) DMY9XWB MA Inhibitor DMY9XWB RN US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases. DMY9XWB RU https://www.google.com.ar/patents/US20080269123 DMY9ZAS DI DMY9ZAS DMY9ZAS DN EUK-189 DMY9ZAS TI TTPS279 DMY9ZAS TN Catalase (CAT) DMY9ZAS MA Modulator DMY9ZAS RN Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90. DMY9ZAS RU https://pubmed.ncbi.nlm.nih.gov/18569084 DMY9ZAS DI DMY9ZAS DMY9ZAS DN EUK-189 DMY9ZAS TI TT6RVLG DMY9ZAS TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMY9ZAS MA Modulator DMY9ZAS RN Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90. DMY9ZAS RU https://pubmed.ncbi.nlm.nih.gov/18569084 DMYAIUB DI DMYAIUB DMYAIUB DN Valortim DMYAIUB TI TT3YGCD DMYAIUB TN Bacterial Protective antigen (Bact pagA) DMYAIUB RN Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142. DMYAIUB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232684/ DMYBELW DI DMYBELW DMYBELW DN REGN1193 DMYBELW TI TT9O6WS DMYBELW TN Glucagon receptor (GCGR) DMYBELW MA Blocker DMYBELW RN A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. DMYBELW RU https://pubmed.ncbi.nlm.nih.gov/28755409 DMYBHER DI DMYBHER DMYBHER DN KPL-716 DMYBHER TI TT1RJXK DMYBHER TN Interleukin-31 (IL31) DMYBHER MA Inhibitor DMYBHER RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBHER RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMYBHIR DI DMYBHIR DMYBHIR DN IBI-20089 DMYBHIR TI TTYRL6O DMYBHIR TN Glucocorticoid receptor (NR3C1) DMYBHIR MA Agonist DMYBHIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBHIR RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYBX4N DI DMYBX4N DMYBX4N DN AZD1390 DMYBX4N TI TTKBM7V DMYBX4N TN ATM serine/threonine kinase (ATM) DMYBX4N MA Inhibitor DMYBX4N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBX4N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYCMNR DI DMYCMNR DMYCMNR DN CAR-T Cells targeting HER2 DMYCMNR TI TT6EO5L DMYCMNR TN Erbb2 tyrosine kinase receptor (HER2) DMYCMNR MA CAR-T-Cell-Therapy DMYCMNR RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMYCMNR RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMYD31U DI DMYD31U DMYD31U DN CD33-CAR-T Cell DMYD31U TI TTJVYO3 DMYD31U TN Myeloid cell surface antigen CD33 (CD33) DMYD31U MA CAR-T-Cell-Therapy DMYD31U RN ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia DMYD31U RU https://clinicaltrials.gov/ct2/show/NCT03126864 DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TTVB0O3 DMYD37G TN Retinoic acid-inducible gene-1 (RIG-1) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TTRJ1K4 DMYD37G TN Toll-like receptor 7 (TLR7) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TT8CWFK DMYD37G TN Toll-like receptor 8 (TLR8) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYDNQ2 DI DMYDNQ2 DMYDNQ2 DN CA102N DMYDNQ2 TI TTVKILB DMYDNQ2 TN Prostaglandin G/H synthase 2 (COX-2) DMYDNQ2 MA Inhibitor DMYDNQ2 RN National Cancer Institute Drug Dictionary (drug name CA102N). DMYDNQ2 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nimesulide-hyaluronic-acid-conjugate-ca102n DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TTUTJGQ DMYDTJ6 TN Vascular endothelial growth factor receptor 2 (KDR) DMYDTJ6 MA Inhibitor DMYDTJ6 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYDTJ6 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TT9VGXW DMYDTJ6 TN Angiopoietin 1 receptor (TEK) DMYDTJ6 MA Modulator DMYDTJ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842). DMYDTJ6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842 DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TT2Q6G1 DMYDTJ6 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMYDTJ6 MA Modulator DMYDTJ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189). DMYDTJ6 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8189 DMYEALO DI DMYEALO DMYEALO DN TMC-647055 DMYEALO TI TTMVBWH DMYEALO TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMYEALO MA Inhibitor DMYEALO RN WO patent application no. 2014,1522,75, Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055. DMYEALO RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014152275A1&KC=A1 DMYERSD DI DMYERSD DMYERSD DN BPX-701 DMYERSD TI TT7AKW1 DMYERSD TN T-cell receptor (TCR) DMYERSD MA Immunomodulator DMYERSD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYERSD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMYFB10 DI DMYFB10 DMYFB10 DN Abaperidone DMYFB10 TI TTJQOD7 DMYFB10 TN 5-HT 2A receptor (HTR2A) DMYFB10 MA Modulator DMYFB10 RN 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9. DMYFB10 RU https://www.ncbi.nlm.nih.gov/pubmed/9876110 DMYFB10 DI DMYFB10 DMYFB10 DN Abaperidone DMYFB10 TI TTEX248 DMYFB10 TN Dopamine D2 receptor (D2R) DMYFB10 MA Modulator DMYFB10 RN 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9. DMYFB10 RU https://www.ncbi.nlm.nih.gov/pubmed/9876110 DMYFOJQ DI DMYFOJQ DMYFOJQ DN DT-200 DMYFOJQ TI TTS64P2 DMYFOJQ TN Androgen receptor (AR) DMYFOJQ MA Modulator DMYFOJQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYFOJQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMYFUOP DI DMYFUOP DMYFUOP DN TTP-547 DMYFUOP TI TTDLNGZ DMYFUOP TN Glucokinase (GCK) DMYFUOP MA Activator DMYFUOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DMYFUOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DMYFWQT DI DMYFWQT DMYFWQT DN CD19 CAR T-cells DMYFWQT TI TTW640A DMYFWQT TN B-lymphocyte surface antigen B4 (CD19) DMYFWQT MA CAR-T-Cell-Therapy DMYFWQT RN ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma DMYFWQT RU https://clinicaltrials.gov/ct2/show/NCT03298828 DMYFZLA DI DMYFZLA DMYFZLA DN AMG 420 DMYFZLA TI TTZ3P4W DMYFZLA TN B-cell maturation protein (TNFRSF17) DMYFZLA MA Inhibitor DMYFZLA RN Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783. DMYFZLA RU https://pubmed.ncbi.nlm.nih.gov/31895611 DMYG3PZ DI DMYG3PZ DMYG3PZ DN IDX-189 DMYG3PZ TI TTMVBWH DMYG3PZ TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMYG3PZ MA Inhibitor DMYG3PZ RN Clinical pipeline report, company report or official report of Idenix (2011). DMYG3PZ RU http://www.idenix.com/ DMYG704 DI DMYG704 DMYG704 DN TAK-137 DMYG704 TI TTAN6JD DMYG704 TN Glutamate receptor AMPA (GRIA) DMYG704 MA Modulator DMYG704 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYG704 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYHEUA DI DMYHEUA DMYHEUA DN ASN007 DMYHEUA TI TT1MG9E DMYHEUA TN Extracellular signal-regulated kinase 1 (ERK1) DMYHEUA MA Inhibitor DMYHEUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYHEUA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYHIAR DI DMYHIAR DMYHIAR DN AdRTVP-1 DMYHIAR TI TTEQF1O DMYHIAR TN Glioma pathogenesis-related protein 1 (GLIPR1) DMYHIAR MA Modulator DMYHIAR RN Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63. DMYHIAR RU https://pubmed.ncbi.nlm.nih.gov/16485011 DMYHNV3 DI DMYHNV3 DMYHNV3 DN BLY719 DMYHNV3 TI TTEUNMR DMYHNV3 TN PI3-kinase alpha (PIK3CA) DMYHNV3 MA Inhibitor DMYHNV3 RN In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82. DMYHNV3 RU https://pubmed.ncbi.nlm.nih.gov/25550549 DMYHU24 DI DMYHU24 DMYHU24 DN DSP-3905 DMYHU24 TI TT4G2JS DMYHU24 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMYHU24 MA Inhibitor DMYHU24 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMYHU24 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMYIBFM DI DMYIBFM DMYIBFM DN BMS-936561 DMYIBFM TI TTNCIE0 DMYIBFM TN CD70 antigen (CD27-L) DMYIBFM MA Modulator DMYIBFM RN Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106. DMYIBFM RU https://pubmed.ncbi.nlm.nih.gov/25869904 DMYIPKJ DI DMYIPKJ DMYIPKJ DN AT13148 DMYIPKJ TI TTMQO60 DMYIPKJ TN Rho-associated protein kinase (ROCK) DMYIPKJ MA Modulator DMYIPKJ RN Company report (Astex) DMYIPKJ RU http://www.astx.com/pipeline/products/clinical DMYIXQZ DI DMYIXQZ DMYIXQZ DN LP-108 DMYIXQZ TI TTJGNVC DMYIXQZ TN Apoptosis regulator Bcl-2 (BCL-2) DMYIXQZ RN National Cancer Institute Drug Dictionary (drug name LP-108). DMYIXQZ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-lp-108 DMYIZFW DI DMYIZFW DMYIZFW DN Anti-CD123 CAR-T cells DMYIZFW TI TTENHJ0 DMYIZFW TN Interleukin 3 receptor alpha (IL3RA) DMYIZFW MA CAR-T-Cell-Therapy DMYIZFW RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMYIZFW RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMYJCUP DI DMYJCUP DMYJCUP DN JNJ-64417184 DMYJCUP TI TT6275O DMYJCUP TN HRSV RNA-directed RNA polymerase L (HRSV L) DMYJCUP MA Inhibitor DMYJCUP RN Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. DMYJCUP RU https://pubmed.ncbi.nlm.nih.gov/30974127 DMYK52O DI DMYK52O DMYK52O DN LHC165 DMYK52O TI TTRJ1K4 DMYK52O TN Toll-like receptor 7 (TLR7) DMYK52O MA Agonist DMYK52O RN Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238. DMYK52O RU https://pubmed.ncbi.nlm.nih.gov/32203790 DMYKPXJ DI DMYKPXJ DMYKPXJ DN 9cUAB-30 DMYKPXJ TI TTH029C DMYKPXJ TN Retinoic acid receptor RXR-gamma (RXRG) DMYKPXJ MA Modulator DMYKPXJ RN In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64. DMYKPXJ RU https://pubmed.ncbi.nlm.nih.gov/17446266 DMYLFQR DI DMYLFQR DMYLFQR DN BMS-986120 DMYLFQR TI TT3I4WV DMYLFQR TN Prostate apoptosis response-4 (PAWR) DMYLFQR MA Antagonist DMYLFQR RN PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. DMYLFQR RU https://pubmed.ncbi.nlm.nih.gov/29269513 DMYNSRH DI DMYNSRH DMYNSRH DN NGM313 DMYNSRH TI TTARBVH DMYNSRH TN Beta-klotho (KLB) DMYNSRH MA Modulator DMYNSRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYNSRH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYNSRH DI DMYNSRH DMYNSRH DN NGM313 DMYNSRH TI TTRLW2X DMYNSRH TN Fibroblast growth factor receptor 1 (FGFR1) DMYNSRH MA Modulator DMYNSRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYNSRH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYP9WR DI DMYP9WR DMYP9WR DN PF-06940434 DMYP9WR TI TT7B3HE DMYP9WR TN Integrin alpha-V/beta-8 (ITGAV/B8) DMYP9WR MA Antagonist DMYP9WR RN ClinicalTrials.gov (NCT04152018) Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health. DMYP9WR RU https://clinicaltrials.gov/ct2/show/NCT04152018 DMYPU8V DI DMYPU8V DMYPU8V DN BAY 1238097 DMYPU8V TI TTE4BSY DMYPU8V TN Bromodomain and extraterminal domain protein (BET) DMYPU8V MA Inhibitor DMYPU8V RN Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. DMYPU8V RU https://pubmed.ncbi.nlm.nih.gov/28653353 DMYPWHD DI DMYPWHD DMYPWHD DN NLG919 DMYPWHD TI TTV8N19 DMYPWHD TN Immune checkpoint (ICH) DMYPWHD MA Modulator DMYPWHD RN Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov. 2014 Dec;13(12):879. DMYPWHD RU https://pubmed.ncbi.nlm.nih.gov/25435209 DMYQFCN DI DMYQFCN DMYQFCN DN Anti-CD19-CAR T cells DMYQFCN TI TTW640A DMYQFCN TN B-lymphocyte surface antigen B4 (CD19) DMYQFCN MA CAR-T-Cell-Therapy DMYQFCN RN ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies DMYQFCN RU https://clinicaltrials.gov/ct2/show/NCT02659943 DMYQUIP DI DMYQUIP DMYQUIP DN PAC1 DMYQUIP TI TTPF2QI DMYQUIP TN Caspase-3 (CASP3) DMYQUIP MA Activator DMYQUIP RN Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50. DMYQUIP RU https://pubmed.ncbi.nlm.nih.gov/16936720 DMYR1K8 DI DMYR1K8 DMYR1K8 DN S-17092-1 DMYR1K8 TI TTNGKET DMYR1K8 TN Prolyl endopeptidase (PREP) DMYR1K8 MA Inhibitor DMYR1K8 RN Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29. DMYR1K8 RU https://pubmed.ncbi.nlm.nih.gov/12603817 DMYR3IE DI DMYR3IE DMYR3IE DN JES-9501 DMYR3IE TI TTEB0GD DMYR3IE TN Cholinesterase (BCHE) DMYR3IE MA Modulator DMYR3IE RN Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5. DMYR3IE RU https://pubmed.ncbi.nlm.nih.gov/11226396 DMYR7XP DI DMYR7XP DMYR7XP DN PF-4455242 DMYR7XP TI TTQW87Y DMYR7XP TN Opioid receptor kappa (OPRK1) DMYR7XP MA Modulator DMYR7XP RN Design and discovery of a selective small molecule opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem. 2011 Aug 25;54(16):5868-77. DMYR7XP RU https://pubmed.ncbi.nlm.nih.gov/21744827 DMYRPBI DI DMYRPBI DMYRPBI DN SR-4554 DMYRPBI TI TT5XVD6 DMYRPBI TN Intracellular nitroreductase (INR) DMYRPBI MA Modulator DMYRPBI RN A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res. 2003 Nov 1;9(14):5101-12. DMYRPBI RU https://pubmed.ncbi.nlm.nih.gov/14613987 DMYRPC8 DI DMYRPC8 DMYRPC8 DN RVSVIN HIV-1 gag vaccine DMYRPC8 TI TTFGZB6 DMYRPC8 TN Human immunodeficiency virus GAG protein (HIV gag) DMYRPC8 RN Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81. DMYRPC8 RU https://pubmed.ncbi.nlm.nih.gov/21987744 DMYS13R DI DMYS13R DMYS13R DN XL999 DMYS13R TI TTUTJGQ DMYS13R TN Vascular endothelial growth factor receptor 2 (KDR) DMYS13R MA Inhibitor DMYS13R RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. DMYS13R RU https://pubmed.ncbi.nlm.nih.gov/17440629 DMYSJTR DI DMYSJTR DMYSJTR DN MM-302 DMYSJTR TI TT6EO5L DMYSJTR TN Erbb2 tyrosine kinase receptor (HER2) DMYSJTR MA Modulator DMYSJTR RN Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24. DMYSJTR RU https://pubmed.ncbi.nlm.nih.gov/25918676 DMYSQHT DI DMYSQHT DMYSQHT DN XL-041 DMYSQHT TI TTM1EQF DMYSQHT TN Oxysterols receptor LXR (NR1H) DMYSQHT MA Modulator DMYSQHT RN Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30. DMYSQHT RU https://pubmed.ncbi.nlm.nih.gov/25523004 DMYTIP4 DI DMYTIP4 DMYTIP4 DN Aleplasinin DMYTIP4 TI TT5QA2I DMYTIP4 TN Plasminogen activator inhibitor (PAI) DMYTIP4 MA Inhibitor DMYTIP4 RN CN patent application no. 102046168, Pai-1 expression and activity inhibitors for the treatment of ocular disorders. DMYTIP4 RU http://www.google.com/patents/CN102046168A?cl=en DMYTJG7 DI DMYTJG7 DMYTJG7 DN AG-270 DMYTJG7 TI TTSMPXQ DMYTJG7 TN S-adenosylmethionine synthase type-2 (MAT2A) DMYTJG7 MA Inhibitor DMYTJG7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYTJG7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYVBU6 DI DMYVBU6 DMYVBU6 DN MEDI0562 DMYVBU6 TI TTL31H0 DMYVBU6 TN OX40L receptor (CD134) DMYVBU6 MA Agonist DMYVBU6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYVBU6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYVDXW DI DMYVDXW DMYVDXW DN 11C-AZD-2184 DMYVDXW TI TTE4KHA DMYVDXW TN Amyloid beta A4 protein (APP) DMYVDXW MA Binder DMYVDXW RN Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593. DMYVDXW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590405/ DMYWDT4 DI DMYWDT4 DMYWDT4 DN GNKG-168 DMYWDT4 TI TTSHG0T DMYWDT4 TN Toll-like receptor 9 (TLR9) DMYWDT4 MA Modulator DMYWDT4 RN National Cancer Institute Drug Dictionary (drug id 662816). DMYWDT4 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=662816 DMYX4NP DI DMYX4NP DMYX4NP DN RG7203 DMYX4NP TI TTJW4LU DMYX4NP TN Phosphodiesterase 10A (PDE10) DMYX4NP MA Inhibitor DMYX4NP RN Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013 DMYX4NP RU http://www.nature.com/scibx/journal/v6/n41/pdf/scibx.2013.1153.pdf?WT.ec_id=SCIBX-20131024 DMYXDB9 DI DMYXDB9 DMYXDB9 DN NN-8828 DMYXDB9 TI TT9QEJ6 DMYXDB9 TN Interleukin-21 (IL21) DMYXDB9 RN Handbook of Therapeutic Antibodies. 2014. 1. Page(995). DMYXDB9 RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false DMYXQBF DI DMYXQBF DMYXQBF DN CEP-37251 DMYXQBF TI TT9E8HR DMYXQBF TN Osteoclast differentiation factor (ODF) DMYXQBF MA Inhibitor DMYXQBF RN This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010 DMYXQBF RU http://www.nature.com/scibx/journal/v3/n40/pdf/scibx.2010.1202.pdf DMZ0D3V DI DMZ0D3V DMZ0D3V DN GRC-6211 DMZ0D3V TI TTMI6F5 DMZ0D3V TN Transient receptor potential cation channel V1 (TRPV1) DMZ0D3V MA Antagonist DMZ0D3V RN GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86. DMZ0D3V RU https://pubmed.ncbi.nlm.nih.gov/19010489 DMZ0D3V DI DMZ0D3V DMZ0D3V DN GRC-6211 DMZ0D3V TI TT0IHXV DMZ0D3V TN DNA topoisomerase II (TOP2) DMZ0D3V MA Inhibitor DMZ0D3V RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DMZ0D3V RU https://pubmed.ncbi.nlm.nih.gov/2847647 DMZ13WQ DI DMZ13WQ DMZ13WQ DN BCMA-CD19 cCAR DMZ13WQ TI TTW640A DMZ13WQ TN B-lymphocyte surface antigen B4 (CD19) DMZ13WQ RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMZ13WQ RU https://icellgene.com/our-pipeline.html DMZ13WQ DI DMZ13WQ DMZ13WQ DN BCMA-CD19 cCAR DMZ13WQ TI TTZ3P4W DMZ13WQ TN B-cell maturation protein (TNFRSF17) DMZ13WQ RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMZ13WQ RU https://icellgene.com/our-pipeline.html DMZ1V0E DI DMZ1V0E DMZ1V0E DN BIIB 022 DMZ1V0E TI TTHRID2 DMZ1V0E TN Insulin-like growth factor I receptor (IGF1R) DMZ1V0E MA Antagonist DMZ1V0E RN A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25. DMZ1V0E RU https://pubmed.ncbi.nlm.nih.gov/24458261 DMZ1XR5 DI DMZ1XR5 DMZ1XR5 DN SAR-114137 DMZ1XR5 TI TTUMQVO DMZ1XR5 TN Cathepsin S (CTSS) DMZ1XR5 MA Inhibitor DMZ1XR5 RN From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48. DMZ1XR5 RU https://pubmed.ncbi.nlm.nih.gov/23201054 DMZ1XR5 DI DMZ1XR5 DMZ1XR5 DN SAR-114137 DMZ1XR5 TI TTDZN01 DMZ1XR5 TN Cathepsin K (CTSK) DMZ1XR5 MA Inhibitor DMZ1XR5 RN From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48. DMZ1XR5 RU https://pubmed.ncbi.nlm.nih.gov/23201054 DMZ2D0G DI DMZ2D0G DMZ2D0G DN Anti-CD45 mabs DMZ2D0G TI TTUS45N DMZ2D0G TN Leukocyte common antigen (PTPRC) DMZ2D0G RN CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94. DMZ2D0G RU https://pubmed.ncbi.nlm.nih.gov/16818275 DMZ2G69 DI DMZ2G69 DMZ2G69 DN Navicixizumab DMZ2G69 TI TTOHSBA DMZ2G69 TN Vascular endothelial growth factor A (VEGFA) DMZ2G69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ2G69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZ2G69 DI DMZ2G69 DMZ2G69 DN Navicixizumab DMZ2G69 TI TTV23LH DMZ2G69 TN Delta-like protein 4 (DLL4) DMZ2G69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ2G69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZ39T6 DI DMZ39T6 DMZ39T6 DN AVID200 DMZ39T6 TI TTO3HT7 DMZ39T6 TN Transforming growth factor beta (TGFB) DMZ39T6 MA Inhibitor DMZ39T6 RN TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826. DMZ39T6 RU https://pubmed.ncbi.nlm.nih.gov/31211692 DMZ4I03 DI DMZ4I03 DMZ4I03 DN CART-meso-19 T cells DMZ4I03 TI TTW640A DMZ4I03 TN B-lymphocyte surface antigen B4 (CD19) DMZ4I03 MA CAR-T-Cell-Therapy(Dual specific) DMZ4I03 RN ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMZ4I03 RU https://clinicaltrials.gov/ct2/show/NCT02465983 DMZ4I03 DI DMZ4I03 DMZ4I03 DN CART-meso-19 T cells DMZ4I03 TI TT4RXME DMZ4I03 TN Mesothelin (MSLN) DMZ4I03 MA CAR-T-Cell-Therapy(Dual specific) DMZ4I03 RN ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMZ4I03 RU https://clinicaltrials.gov/ct2/show/NCT02465983 DMZ4WMT DI DMZ4WMT DMZ4WMT DN BMS-986104 DMZ4WMT TI TT9JZCK DMZ4WMT TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMZ4WMT MA Modulator DMZ4WMT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ4WMT RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ51EX DI DMZ51EX DMZ51EX DN BCL201 DMZ51EX TI TTJGNVC DMZ51EX TN Apoptosis regulator Bcl-2 (BCL-2) DMZ51EX MA Inhibitor DMZ51EX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ51EX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ5A6D DI DMZ5A6D DMZ5A6D DN GSK2398852 DMZ5A6D TI TTB7VAT DMZ5A6D TN Serum amyloid P-component (APCS) DMZ5A6D RN ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health. DMZ5A6D RU https://clinicaltrials.gov/ct2/show/NCT01777243 DMZ5YMX DI DMZ5YMX DMZ5YMX DN 18F-FEDAA-1106 DMZ5YMX TI TTPTXIN DMZ5YMX TN Translocator protein (TSPO) DMZ5YMX MA Modulator DMZ5YMX RN Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther. 2003 Sep;306(3):828-37. DMZ5YMX RU https://pubmed.ncbi.nlm.nih.gov/12928523 DMZ6042 DI DMZ6042 DMZ6042 DN ZYOG1 DMZ6042 TI TTVIMDE DMZ6042 TN Glucagon-like peptide 1 receptor (GLP1R) DMZ6042 MA Agonist DMZ6042 RN 2011 Pipeline of Zydus Cadila Group. DMZ6042 RU http://www.zyduscadila.com/ DMZ60X4 DI DMZ60X4 DMZ60X4 DN TNO155 DMZ60X4 TI TT7WUAV DMZ60X4 TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMZ60X4 MA Inhibitor DMZ60X4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ60X4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ72BD DI DMZ72BD DMZ72BD DN NP-G2-044 DMZ72BD TI TTTRS9B DMZ72BD TN Fascin (FSCN1) DMZ72BD MA Inhibitor DMZ72BD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ72BD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ763A DI DMZ763A DMZ763A DN Autologous T Cells Expressing MET scFv CAR DMZ763A TI TTNDSF4 DMZ763A TN Proto-oncogene c-Met (MET) DMZ763A MA CAR-T-Cell-Therapy DMZ763A RN ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) DMZ763A RU https://clinicaltrials.gov/ct2/show/NCT03060356 DMZ8QRI DI DMZ8QRI DMZ8QRI DN PF-04995274 DMZ8QRI TI TT07C3Y DMZ8QRI TN 5-HT 4 receptor (HTR4) DMZ8QRI MA Agonist DMZ8QRI RN Pharmacokinetics, safety and tolerability of PF04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease. Alzheimer's and Dementia. DMZ8QRI RU http://www.alzheimersanddementia.com/article/S1552-5260(11)02414-9/abstract DMZ8WAQ DI DMZ8WAQ DMZ8WAQ DN Retroviral vector-transduced autologous T cells to express CD22-specific CARs DMZ8WAQ TI TTM6QSK DMZ8WAQ TN B-cell receptor CD22 (CD22) DMZ8WAQ MA CAR-T-Cell-Therapy DMZ8WAQ RN ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients DMZ8WAQ RU https://clinicaltrials.gov/ct2/show/NCT02721407 DMZ9EMO DI DMZ9EMO DMZ9EMO DN TST001 DMZ9EMO TI TT6PKBX DMZ9EMO TN Claudin-18 (CLDN18) DMZ9EMO RN Clinical pipeline report, company report or official report of Transcenta. DMZ9EMO RU http://www.transcenta.com/pipeline DMZ9NVP DI DMZ9NVP DMZ9NVP DN M8891 DMZ9NVP TI TTZL0OI DMZ9NVP TN Methionine aminopeptidase 2 (METAP2) DMZ9NVP MA Inhibitor DMZ9NVP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ9NVP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ9YWG DI DMZ9YWG DMZ9YWG DN SB 11285 DMZ9YWG TI TTT402Y DMZ9YWG TN Stimulator of interferon genes protein (TMEM173) DMZ9YWG MA Agonist DMZ9YWG RN Clinical pipeline report, company report or official report of F-star Therapeutics. DMZ9YWG RU https://www.f-star.com/pipeline/sb-11285/ DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TT3ROYC DMZC9XU TN Serotonin transporter (SERT) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TTAWNKZ DMZC9XU TN Norepinephrine transporter (NET) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TTVBI8W DMZC9XU TN Dopamine transporter (DAT) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTRICUF DMZCBMS TN Interleukin-18 (IL18) DMZCBMS MA Modulator DMZCBMS RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMZCBMS RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTUE541 DMZCBMS TN Leukocyte surface antigen Leu-16 (CD20) DMZCBMS RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMZCBMS RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTN9VTF DMZCBMS TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZCBMS MA Blocker DMZCBMS RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMZCBMS RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMZDLHV DI DMZDLHV DMZDLHV DN BCMA nanobody CAR-T cells DMZDLHV TI TTZ3P4W DMZDLHV TN B-cell maturation protein (TNFRSF17) DMZDLHV MA CAR-T-Cell-Therapy DMZDLHV RN ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma DMZDLHV RU https://clinicaltrials.gov/ct2/show/NCT03664661 DMZG9U0 DI DMZG9U0 DMZG9U0 DN TeloB-Vax DMZG9U0 TI TTUJFD0 DMZG9U0 TN Telomerase reverse transcriptase (TERT) DMZG9U0 MA Modulator DMZG9U0 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZG9U0 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZI4UX DI DMZI4UX DMZI4UX DN ATLCAR.CD30 cells DMZI4UX TI TT2GM5R DMZI4UX TN Lymphocyte activation antigen CD30 (TNFRSF8) DMZI4UX MA CAR-T-Cell-Therapy DMZI4UX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DMZI4UX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DMZIK8R DI DMZIK8R DMZIK8R DN TXA709 DMZIK8R TI TT4W1VJ DMZIK8R TN Bacterial Celldivision protein FtsZ (Bact ftsZ) DMZIK8R MA Inhibitor DMZIK8R RN Clinical pipeline report, company report or official report of TAXIS Pharmaceuticals. DMZIK8R RU https://www.taxispharma.com/research-development/our-pipeline/ DMZJH23 DI DMZJH23 DMZJH23 DN REP8839 DMZJH23 TI TTOJ46K DMZJH23 TN Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) DMZJH23 MA Inhibitor DMZJH23 RN Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52. DMZJH23 RU https://pubmed.ncbi.nlm.nih.gov/16189105 DMZJNHM DI DMZJNHM DMZJNHM DN SYNB1891 DMZJNHM TI TTT402Y DMZJNHM TN Stimulator of interferon genes protein (TMEM173) DMZJNHM MA Agonist DMZJNHM RN Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739. DMZJNHM RU https://pubmed.ncbi.nlm.nih.gov/32483165 DMZK1GW DI DMZK1GW DMZK1GW DN OG987SC DMZK1GW TI TTVIMDE DMZK1GW TN Glucagon-like peptide 1 receptor (GLP1R) DMZK1GW MA Modulator DMZK1GW RN Clinical pipeline report, company report or official report of Novo Nordisk A/S. DMZK1GW RU http://www.novonordisk.com/bin/getPDF.1866957.pdf DMZK7N8 DI DMZK7N8 DMZK7N8 DN Keratinocyte growth factor DMZK7N8 TI TTFY134 DMZK7N8 TN Keratinocyte growth factor (FGF7) DMZK7N8 MA Modulator DMZK7N8 RN Keratinocyte growth factor.Cell Biol Int.1995 May;19(5):399-411. DMZK7N8 RU https://www.ncbi.nlm.nih.gov/pubmed/7640656 DMZLCTD DI DMZLCTD DMZLCTD DN AV-203 DMZLCTD TI TTDC8N2 DMZLCTD TN Erbb3 tyrosine kinase receptor (Erbb-3) DMZLCTD RN Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14. DMZLCTD RU https://pubmed.ncbi.nlm.nih.gov/25542901 DMZLIWX DI DMZLIWX DMZLIWX DN LY3475070 DMZLIWX TI TTK0O6Y DMZLIWX TN Ecto-5'-nucleotidase (CD73) DMZLIWX MA Inhibitor DMZLIWX RN CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508. DMZLIWX RU https://pubmed.ncbi.nlm.nih.gov/32351498 DMZM0T8 DI DMZM0T8 DMZM0T8 DN ABBV-838 DMZM0T8 TI TT7ILZ1 DMZM0T8 TN SLAM family member 7 SLAMF7 (CS1) DMZM0T8 MA Inhibitor DMZM0T8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM0T8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZMAOW DI DMZMAOW DMZMAOW DN BI 765063 DMZMAOW TI TTBRJS9 DMZMAOW TN Inhibitory receptor SHPS-1 (SIRPA) DMZMAOW MA Antagonist DMZMAOW RN Clinical pipeline report, company report or official report of OSE Immunotherapeutics. DMZMAOW RU https://ose-immuno.com/en/ose-product/ose-172/ DMZMSBI DI DMZMSBI DMZMSBI DN KO-947 DMZMSBI TI TTKPV6O DMZMSBI TN Ephrin type-B receptor 2 (EPHB2) DMZMSBI MA Inhibitor DMZMSBI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZMSBI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZN35T DI DMZN35T DMZN35T DN EGFRt/19-28z/4-1BBL CAR T cells DMZN35T TI TTW640A DMZN35T TN B-lymphocyte surface antigen B4 (CD19) DMZN35T MA CAR-T-Cell-Therapy DMZN35T RN ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies DMZN35T RU https://clinicaltrials.gov/ct2/show/NCT03085173 DMZN5QX DI DMZN5QX DMZN5QX DN MGD014 DMZN5QX TI TTEC2T3 DMZN5QX TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMZN5QX MA Inhibitor DMZN5QX RN Clinical pipeline report, company report or official report of MacroGenics. DMZN5QX RU https://www.macrogenics.com/mgd014/ DMZN5QX DI DMZN5QX DMZN5QX DN MGD014 DMZN5QX TI TTUN7MC DMZN5QX TN T-cell surface glycoprotein CD3 (CD3) DMZN5QX MA Inhibitor DMZN5QX RN Clinical pipeline report, company report or official report of MacroGenics. DMZN5QX RU https://www.macrogenics.com/mgd014/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTSKMI8 DMZNTHJ TN Phosphodiesterase 4D (PDE4D) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTVIAT9 DMZNTHJ TN Phosphodiesterase 4B (PDE4B) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTZ97H5 DMZNTHJ TN Phosphodiesterase 4A (PDE4A) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZOAT3 DI DMZOAT3 DMZOAT3 DN FT-1101 DMZOAT3 TI TTE4BSY DMZOAT3 TN Bromodomain and extraterminal domain protein (BET) DMZOAT3 MA Inhibitor DMZOAT3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZOAT3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZP671 DI DMZP671 DMZP671 DN SUVN 911 DMZP671 TI TTL1ATN DMZP671 TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMZP671 MA Antagonist DMZP671 RN Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853. DMZP671 RU https://pubmed.ncbi.nlm.nih.gov/32026697 DMZQ2DK DI DMZQ2DK DMZQ2DK DN AMG 986 DMZQ2DK TI TTJ8E43 DMZQ2DK TN Apelin receptor (APLNR) DMZQ2DK MA Agonist DMZQ2DK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZQ2DK RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMZQEDY DI DMZQEDY DMZQEDY DN AZD-2551 DMZQEDY TI TTZBFA0 DMZQEDY TN Protease unspecific (PRO) DMZQEDY MA Inhibitor DMZQEDY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854) DMZQEDY RU http://adisinsight.springer.com/drugs/800029854 DMZQP7N DI DMZQP7N DMZQP7N DN ZD7114 DMZQP7N TI TTMXGCW DMZQP7N TN Adrenergic receptor beta-3 (ADRB3) DMZQP7N MA Agonist DMZQP7N RN Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. DMZQP7N RU https://pubmed.ncbi.nlm.nih.gov/10207980 DMZS1D2 DI DMZS1D2 DMZS1D2 DN BMS-852927 DMZS1D2 TI TTM1EQF DMZS1D2 TN Oxysterols receptor LXR (NR1H) DMZS1D2 MA Modulator DMZS1D2 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMZS1D2 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMZS350 DI DMZS350 DMZS350 DN Donor-derived CD19/22 bispecific CAR-T cells DMZS350 TI TTM6QSK DMZS350 TN B-cell receptor CD22 (CD22) DMZS350 MA CAR-T-Cell-Therapy(Dual specific) DMZS350 RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMZS350 RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMZS350 DI DMZS350 DMZS350 DN Donor-derived CD19/22 bispecific CAR-T cells DMZS350 TI TTW640A DMZS350 TN B-lymphocyte surface antigen B4 (CD19) DMZS350 MA CAR-T-Cell-Therapy(Dual specific) DMZS350 RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMZS350 RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMZSD3T DI DMZSD3T DMZSD3T DN Patient-derived CD19- and CD22 specific CAR DMZSD3T TI TTM6QSK DMZSD3T TN B-cell receptor CD22 (CD22) DMZSD3T MA CAR-T-Cell-Therapy(Dual specific) DMZSD3T RN ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma DMZSD3T RU https://clinicaltrials.gov/ct2/show/NCT03330691 DMZSD3T DI DMZSD3T DMZSD3T DN Patient-derived CD19- and CD22 specific CAR DMZSD3T TI TTW640A DMZSD3T TN B-lymphocyte surface antigen B4 (CD19) DMZSD3T MA CAR-T-Cell-Therapy(Dual specific) DMZSD3T RN ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma DMZSD3T RU https://clinicaltrials.gov/ct2/show/NCT03330691 DMZT89C DI DMZT89C DMZT89C DN DNL151 DMZT89C TI TTK0FEA DMZT89C TN Leucine-rich repeat kinase 2 (LRRK2) DMZT89C MA Inhibitor DMZT89C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZT89C RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZTMEJ DI DMZTMEJ DMZTMEJ DN AG-270 DMZTMEJ TI TTSMPXQ DMZTMEJ TN S-adenosylmethionine synthase type-2 (MAT2A) DMZTMEJ MA Inhibitor DMZTMEJ RN Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449. DMZTMEJ RU https://pubmed.ncbi.nlm.nih.gov/33829783 DMZU2G1 DI DMZU2G1 DMZU2G1 DN LMP-1/LMP-2 CTLs DMZU2G1 TI TTBK351 DMZU2G1 TN Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) DMZU2G1 MA Modulator DMZU2G1 RN In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42. DMZU2G1 RU https://pubmed.ncbi.nlm.nih.gov/16753867 DMZU2G1 DI DMZU2G1 DMZU2G1 DN LMP-1/LMP-2 CTLs DMZU2G1 TI TT0BI4Q DMZU2G1 TN Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) DMZU2G1 MA Modulator DMZU2G1 RN In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42. DMZU2G1 RU https://pubmed.ncbi.nlm.nih.gov/16753867 DMZUA5C DI DMZUA5C DMZUA5C DN MK-6302 DMZUA5C TI TTC70AJ DMZUA5C TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMZUA5C MA Modulator DMZUA5C RN Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. DMZUA5C RU https://pubmed.ncbi.nlm.nih.gov/20622817 DMZUM67 DI DMZUM67 DMZUM67 DN M9241 DMZUM67 TI TTG68FB DMZUM67 TN Interleukine 12 (IL-12) DMZUM67 MA Replacement DMZUM67 RN Clinical pipeline report, company report or official report of EMD Serono. DMZUM67 RU https://medical.emdserono.com/content/healthcare/biopharma/usmi/en_US/home/immuno-oncology/m9241--nhs-il12--.html DMZVFOQ DI DMZVFOQ DMZVFOQ DN GS-5829 DMZVFOQ TI TTE4BSY DMZVFOQ TN Bromodomain and extraterminal domain protein (BET) DMZVFOQ MA Inhibitor DMZVFOQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZVFOQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZWFKQ DI DMZWFKQ DMZWFKQ DN OPC-14117 DMZWFKQ TI TTAD7UL DMZWFKQ TN Superoxide anion (SPA) DMZWFKQ MA Modulator DMZWFKQ RN Evaluation of superoxide scavenging activity of OPC-14117 by electron spin resonance technique. Free Radic Res Commun. 1991;15(4):223-30. DMZWFKQ RU https://pubmed.ncbi.nlm.nih.gov/1667773 DMZXDBN DI DMZXDBN DMZXDBN DN HER2-CAR T Cells DMZXDBN TI TT6EO5L DMZXDBN TN Erbb2 tyrosine kinase receptor (HER2) DMZXDBN MA CAR-T-Cell-Therapy DMZXDBN RN ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases DMZXDBN RU https://clinicaltrials.gov/ct2/show/NCT03696030 DMZXG7Q DI DMZXG7Q DMZXG7Q DN HPP971 DMZXG7Q TI TTA6ZN2 DMZXG7Q TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMZXG7Q MA Activator DMZXG7Q RN Clinical pipeline report, company report or official report of vTv Therapeutics. DMZXG7Q RU https://vtvtherapeutics.com/pipeline/nrf2-bach1-program/ DMZYCWT DI DMZYCWT DMZYCWT DN BCI-632 DMZYCWT TI TTXJ47W DMZYCWT TN Metabotropic glutamate receptor 2 (mGluR2) DMZYCWT MA Antagonist DMZYCWT RN Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87. DMZYCWT RU https://pubmed.ncbi.nlm.nih.gov/15317467 DMZYCWT DI DMZYCWT DMZYCWT DN BCI-632 DMZYCWT TI TT8A9EF DMZYCWT TN Metabotropic glutamate receptor 3 (mGluR3) DMZYCWT MA Modulator DMZYCWT RN Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87. DMZYCWT RU https://pubmed.ncbi.nlm.nih.gov/15317467 DM0RX5E DI DM0RX5E DM0RX5E DN CAR-GPC3 T cells DM0RX5E TI TTJTSX4 DM0RX5E TN Glypican-3 (GPC3) DM0RX5E MA CAR-T-Cell-Therapy DM0RX5E RN ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma DM0RX5E RU https://clinicaltrials.gov/ct2/show/NCT03146234 DM21Y8J DI DM21Y8J DM21Y8J DN isatin sulfonamide 34 DM21Y8J TI TTM7Y45 DM21Y8J TN Caspase-7 (CASP7) DM21Y8J MA Inhibitor DM21Y8J RN Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26. DM21Y8J RU https://pubmed.ncbi.nlm.nih.gov/11384246 DM21Y8J DI DM21Y8J DM21Y8J DN isatin sulfonamide 34 DM21Y8J TI TTB6T7O DM21Y8J TN Caspase-9 (CASP9) DM21Y8J MA Inhibitor DM21Y8J RN Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26. DM21Y8J RU https://pubmed.ncbi.nlm.nih.gov/11384246 DM2N653 DI DM2N653 DM2N653 DN example 98 (WO2011020806) DM2N653 TI TT69DB8 DM2N653 TN Beta-site APP-cleaving enzyme 2 (BACE2) DM2N653 MA Inhibitor DM2N653 RN BACE2 as a new diabetes target: a patent review (2010 - 2012). Expert Opin Ther Pat. 2013 May;23(5):649-63. DM2N653 RU https://pubmed.ncbi.nlm.nih.gov/23506624 DM2NZ6K DI DM2NZ6K DM2NZ6K DN KGP94 DM2NZ6K TI TT36ETB DM2NZ6K TN Cathepsin L (CTSL) DM2NZ6K MA Inhibitor DM2NZ6K RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DM2NZ6K RU https://pubmed.ncbi.nlm.nih.gov/20933415 DM2V6R7 DI DM2V6R7 DM2V6R7 DN CD19-CAR T Cells DM2V6R7 TI TTW640A DM2V6R7 TN B-lymphocyte surface antigen B4 (CD19) DM2V6R7 MA CAR-T-Cell-Therapy DM2V6R7 RN ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation DM2V6R7 RU https://clinicaltrials.gov/ct2/show/NCT03423706 DM3ADQW DI DM3ADQW DM3ADQW DN NIA-114 DM3ADQW TI TTWNV8U DM3ADQW TN Nicotinic acid receptor (HCAR2) DM3ADQW MA Agonist DM3ADQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ADQW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3ADQW DI DM3ADQW DM3ADQW DN NIA-114 DM3ADQW TI TT8WFXV DM3ADQW TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM3ADQW MA Agonist DM3ADQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ADQW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3M9OY DI DM3M9OY DM3M9OY DN Anti-CD19/20-CAR vector-transduced T cells DM3M9OY TI TTUE541 DM3M9OY TN Leukocyte surface antigen Leu-16 (CD20) DM3M9OY MA CAR-T-Cell-Therapy(Dual specific) DM3M9OY RN ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 DM3M9OY RU https://clinicaltrials.gov/ct2/show/NCT03097770 DM3M9OY DI DM3M9OY DM3M9OY DN Anti-CD19/20-CAR vector-transduced T cells DM3M9OY TI TTW640A DM3M9OY TN B-lymphocyte surface antigen B4 (CD19) DM3M9OY MA CAR-T-Cell-Therapy(Dual specific) DM3M9OY RN ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 DM3M9OY RU https://clinicaltrials.gov/ct2/show/NCT03097770 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTT2ZAR DM4XAU7 TN Prostaglandin F2-alpha receptor (PTGFR) DM4XAU7 MA Agonist DM4XAU7 RN Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/12519077 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTQDMX5 DM4XAU7 TN Prostaglandin D2 receptor 2 (PTGDR2) DM4XAU7 MA Agonist DM4XAU7 RN Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/12721327 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT2O84V DM4XAU7 TN Thromboxane A2 receptor (TBXA2R) DM4XAU7 MA Agonist DM4XAU7 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTG1QMU DM4XAU7 TN Prostaglandin E2 receptor EP1 (PTGER1) DM4XAU7 MA Agonist DM4XAU7 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTPNGDE DM4XAU7 TN Prostaglandin E2 receptor EP3 (PTGER3) DM4XAU7 MA Agonist DM4XAU7 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT1ZAVI DM4XAU7 TN Prostaglandin E2 receptor EP2 (PTGER2) DM4XAU7 MA Agonist DM4XAU7 RN Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10462542 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT79WV3 DM4XAU7 TN Prostaglandin E2 receptor EP4 (PTGER4) DM4XAU7 MA Agonist DM4XAU7 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTNVEIR DM4XAU7 TN Prostaglandin D2 receptor (PTGDR) DM4XAU7 MA Agonist DM4XAU7 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM531SA DI DM531SA DM531SA DN bimatoprost (free acid form) DM531SA TI TTT2ZAR DM531SA TN Prostaglandin F2-alpha receptor (PTGFR) DM531SA MA Agonist DM531SA RN Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000 Aug;130(8):1933-43. DM531SA RU https://pubmed.ncbi.nlm.nih.gov/10952685 DM5I2HL DI DM5I2HL DM5I2HL DN GSK269962A DM5I2HL TI TTGWKQJ DM5I2HL TN Rho-associated protein kinase 2 (ROCK2) DM5I2HL MA Inhibitor DM5I2HL RN Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. DM5I2HL RU https://pubmed.ncbi.nlm.nih.gov/17018693 DM5I2HL DI DM5I2HL DM5I2HL DN GSK269962A DM5I2HL TI TTZN7RP DM5I2HL TN Rho-associated protein kinase 1 (ROCK1) DM5I2HL MA Inhibitor DM5I2HL RN Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. DM5I2HL RU https://pubmed.ncbi.nlm.nih.gov/17018693 DM5UWH3 DI DM5UWH3 DM5UWH3 DN PMID22911925C2 DM5UWH3 TI TT8JRS7 DM5UWH3 TN Beta-secretase (BACE) DM5UWH3 MA Inhibitor DM5UWH3 RN Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7. DM5UWH3 RU https://pubmed.ncbi.nlm.nih.gov/22911925 DM6NVPT DI DM6NVPT DM6NVPT DN Anti-CD19 Chimeric Antigen Receptor T Cells DM6NVPT TI TTW640A DM6NVPT TN B-lymphocyte surface antigen B4 (CD19) DM6NVPT MA CAR-T-Cell-Therapy DM6NVPT RN ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies DM6NVPT RU https://clinicaltrials.gov/ct2/show/NCT03624686 DM6ZHTV DI DM6ZHTV DM6ZHTV DN CAR-CLD18 T cell DM6ZHTV TI TT6PKBX DM6ZHTV TN Claudin-18 (CLDN18) DM6ZHTV MA CAR-T-Cell-Therapy DM6ZHTV RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DM6ZHTV RU https://clinicaltrials.gov/ct2/show/NCT03302403 DM7W6YN DI DM7W6YN DM7W6YN DN GR148672X DM7W6YN TI TTMF541 DM7W6YN TN Liver carboxylesterase (CES1) DM7W6YN MA Inhibitor DM7W6YN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592). DM7W6YN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592 DM87BTM DI DM87BTM DM87BTM DN GD2-targeted CAR-T cells DM87BTM TI TT80ARU DM87BTM TN Ganglioside GD2 (GD2) DM87BTM MA CAR-T-Cell-Therapy DM87BTM RN ClinicalTrials.gov (NCT02919046) Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children DM87BTM RU https://clinicaltrials.gov/ct2/show/NCT02919046 DM8VTF2 DI DM8VTF2 DM8VTF2 DN CD19-UCART DM8VTF2 TI TTW640A DM8VTF2 TN B-lymphocyte surface antigen B4 (CD19) DM8VTF2 MA CAR-T-Cell-Therapy DM8VTF2 RN ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART DM8VTF2 RU https://clinicaltrials.gov/ct2/show/NCT03229876 DMAK1ME DI DMAK1ME DMAK1ME DN CAR-T cells targeting CD56 DMAK1ME TI TTVXPHT DMAK1ME TN Neural cell adhesion molecule 1 (NCAM1) DMAK1ME MA CAR-T-Cell-Therapy DMAK1ME RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMAK1ME RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMAPV6J DI DMAPV6J DMAPV6J DN MK-0249 DMAPV6J TI TT9JNIC DMAPV6J TN Histamine H3 receptor (H3R) DMAPV6J MA Agonist DMAPV6J RN Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem. 2008 Aug 14;51(15):4780-9. DMAPV6J RU https://pubmed.ncbi.nlm.nih.gov/18598020 DMBDT3V DI DMBDT3V DMBDT3V DN CAR-GPC3 T cell DMBDT3V TI TTJTSX4 DMBDT3V TN Glypican-3 (GPC3) DMBDT3V MA CAR-T-Cell-Therapy DMBDT3V RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMBDT3V RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMCEPKM DI DMCEPKM DMCEPKM DN BCMA-CART DMCEPKM TI TTZ3P4W DMCEPKM TN B-cell maturation protein (TNFRSF17) DMCEPKM MA CAR-T-Cell-Therapy DMCEPKM RN ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma DMCEPKM RU https://clinicaltrials.gov/ct2/show/NCT03492268 DMCM5GK DI DMCM5GK DMCM5GK DN TAK-070 DMCM5GK TI TT8JRS7 DMCM5GK TN Beta-secretase (BACE) DMCM5GK MA Inhibitor DMCM5GK RN A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66. DMCM5GK RU https://pubmed.ncbi.nlm.nih.gov/20720123 DMCV5ND DI DMCV5ND DMCV5ND DN GSK-264220A DMCV5ND TI TTHSZXO DMCV5ND TN Endothelial lipase (LIPG) DMCV5ND MA Inhibitor DMCV5ND RN Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30. DMCV5ND RU https://pubmed.ncbi.nlm.nih.gov/19058966 DMDU6GN DI DMDU6GN DMDU6GN DN JNJ-479655 DMDU6GN TI TT473XN DMDU6GN TN P2X purinoceptor 7 (P2RX7) DMDU6GN MA Antagonist DMDU6GN RN Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40. DMDU6GN RU https://pubmed.ncbi.nlm.nih.gov/23889535 DMF936G DI DMF936G DMF936G DN CD19CART DMF936G TI TTW640A DMF936G TN B-lymphocyte surface antigen B4 (CD19) DMF936G MA CAR-T-Cell-Therapy DMF936G RN ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies DMF936G RU https://clinicaltrials.gov/ct2/show/NCT02813837 DMGANIC DI DMGANIC DMGANIC DN tamatinib DMGANIC TI TTOU65C DMGANIC TN Tyrosine-protein kinase SYK (SYK) DMGANIC MA Inhibitor DMGANIC RN Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9. DMGANIC RU https://pubmed.ncbi.nlm.nih.gov/19254842 DMGANIC DI DMGANIC DMGANIC DN tamatinib DMGANIC TI TT4DXQT DMGANIC TN Proto-oncogene c-Ret (RET) DMGANIC MA Inhibitor DMGANIC RN Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6. DMGANIC RU https://pubmed.ncbi.nlm.nih.gov/19107952 DMGPTFL DI DMGPTFL DMGPTFL DN AZ-4217 DMGPTFL TI TT8JRS7 DMGPTFL TN Beta-secretase (BACE) DMGPTFL MA Inhibitor DMGPTFL RN AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci. 2013 Jun 12;33(24):10075-84. DMGPTFL RU https://pubmed.ncbi.nlm.nih.gov/23761903 DMGW10M DI DMGW10M DMGW10M DN CAR-T cells targeting BCMA DMGW10M TI TTZ3P4W DMGW10M TN B-cell maturation protein (TNFRSF17) DMGW10M MA CAR-T-Cell-Therapy DMGW10M RN ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma DMGW10M RU https://clinicaltrials.gov/ct2/show/NCT03473496 DMH5C37 DI DMH5C37 DMH5C37 DN CAR-T cells targeting CD38 DMH5C37 TI TTPURFN DMH5C37 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMH5C37 MA CAR-T-Cell-Therapy DMH5C37 RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMH5C37 RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMHBQYU DI DMHBQYU DMHBQYU DN CAR-T cells targeting CD138 DMHBQYU TI TTYDSVG DMHBQYU TN Syndecan-1 (SDC1) DMHBQYU MA CAR-T-Cell-Therapy DMHBQYU RN ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma DMHBQYU RU https://clinicaltrials.gov/ct2/show/NCT03473496 DMHPME3 DI DMHPME3 DMHPME3 DN PMID18163548C4 DMHPME3 TI TTGY7WI DMHPME3 TN Urokinase-type plasminogen activator (PLAU) DMHPME3 MA Inhibitor DMHPME3 RN Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6. DMHPME3 RU https://pubmed.ncbi.nlm.nih.gov/18163548 DMJGFLD DI DMJGFLD DMJGFLD DN PMID15026062C41 DMJGFLD TI TTLUQ8E DMJGFLD TN Hormone sensitive lipase (LIPE) DMJGFLD MA Inhibitor DMJGFLD RN Carbazates as potent inhibitors of hormone-sensitive lipase. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1741-4. DMJGFLD RU https://pubmed.ncbi.nlm.nih.gov/15026062 DMLF2UY DI DMLF2UY DMLF2UY DN CAR-BCMA T cell DMLF2UY TI TTZ3P4W DMLF2UY TN B-cell maturation protein (TNFRSF17) DMLF2UY MA CAR-T-Cell-Therapy DMLF2UY RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMLF2UY RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMLPAFG DI DMLPAFG DMLPAFG DN CD19-targeted CAR-T cells DMLPAFG TI TTW640A DMLPAFG TN B-lymphocyte surface antigen B4 (CD19) DMLPAFG MA CAR-T-Cell-Therapy DMLPAFG RN ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation DMLPAFG RU https://clinicaltrials.gov/ct2/show/NCT03564977 DMN2EI1 DI DMN2EI1 DMN2EI1 DN bis-triazole derivative 10 DMN2EI1 TI TTP86E2 DMN2EI1 TN Plasminogen (PLG) DMN2EI1 MA Inhibitor DMN2EI1 RN A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem. 2012 Feb 9;55(3):1171-80. DMN2EI1 RU https://pubmed.ncbi.nlm.nih.gov/22276953 DMN2I3P DI DMN2I3P DMN2I3P DN alpha-ketothiazole analogue 36 DMN2I3P TI TTDM4ZU DMN2I3P TN Factor XI messenger RNA (F11 mRNA) DMN2I3P MA Inhibitor DMN2I3P RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMN2I3P RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMO0892 DI DMO0892 DMO0892 DN PF-4708671 DMO0892 TI TTG0U4H DMO0892 TN Ribosomal protein S6 kinase beta-1 (S6K1) DMO0892 MA Inhibitor DMO0892 RN Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55. DMO0892 RU https://pubmed.ncbi.nlm.nih.gov/20704563 DMO1IHL DI DMO1IHL DMO1IHL DN PMID17935984C1 DMO1IHL TI TTHY57M DMO1IHL TN Matrix metalloproteinase-13 (MMP-13) DMO1IHL MA Inhibitor DMO1IHL RN Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34. DMO1IHL RU https://pubmed.ncbi.nlm.nih.gov/17935984 DMOI0TN DI DMOI0TN DMOI0TN DN VU0364739 DMOI0TN TI TTRLMKF DMOI0TN TN Phospholipase D2 (PLD2) DMOI0TN MA Inhibitor DMOI0TN RN Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem. 2010 Sep 23;53(18):6706-19. DMOI0TN RU https://pubmed.ncbi.nlm.nih.gov/20735042 DMR1NYF DI DMR1NYF DMR1NYF DN KH064 DMR1NYF TI TTO8QRU DMR1NYF TN Group IIA phospholipase A2 (GIIA sPLA2) DMR1NYF MA Inhibitor DMR1NYF RN D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5. DMR1NYF RU https://pubmed.ncbi.nlm.nih.gov/12616631 DMS87UT DI DMS87UT DMS87UT DN CD19-targeted CAR-T cells DMS87UT TI TTW640A DMS87UT TN B-lymphocyte surface antigen B4 (CD19) DMS87UT MA CAR-T-Cell-Therapy DMS87UT RN ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma DMS87UT RU https://clinicaltrials.gov/ct2/show/NCT02728882 DMSRK2A DI DMSRK2A DMSRK2A DN UK-356202 DMSRK2A TI TTGY7WI DMSRK2A TN Urokinase-type plasminogen activator (PLAU) DMSRK2A MA Inhibitor DMSRK2A RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMSRK2A RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMUEQ6C DI DMUEQ6C DMUEQ6C DN CART-meso cells DMUEQ6C TI TT4RXME DMUEQ6C TN Mesothelin (MSLN) DMUEQ6C MA CAR-T-Cell-Therapy DMUEQ6C RN ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMUEQ6C RU https://clinicaltrials.gov/ct2/show/NCT03638193 DMV6RMB DI DMV6RMB DMV6RMB DN EPCAM-targeted CAR-T cells DMV6RMB TI TTZ8WH4 DMV6RMB TN Tumor-associated calcium signal transducer 1 (EPCAM) DMV6RMB MA CAR-T-Cell-Therapy DMV6RMB RN ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer DMV6RMB RU https://clinicaltrials.gov/ct2/show/NCT02725125 DMW15TC DI DMW15TC DMW15TC DN methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate DMW15TC TI TTRJSMV DMW15TC TN Factor XII messenger RNA (FA12 mRNA) DMW15TC MA Inhibitor DMW15TC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2361). DMW15TC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2361 DMWA5XP DI DMWA5XP DMWA5XP DN KU-60019 DMWA5XP TI TTKBM7V DMWA5XP TN ATM serine/threonine kinase (ATM) DMWA5XP MA Inhibitor DMWA5XP RN Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902. DMWA5XP RU https://pubmed.ncbi.nlm.nih.gov/19808981 DMWXGRQ DI DMWXGRQ DMWXGRQ DN BCMA-UCART DMWXGRQ TI TTZ3P4W DMWXGRQ TN B-cell maturation protein (TNFRSF17) DMWXGRQ MA CAR-T-Cell-Therapy DMWXGRQ RN ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART DMWXGRQ RU https://clinicaltrials.gov/ct2/show/NCT03752541 DMX1IZ9 DI DMX1IZ9 DMX1IZ9 DN PMID23981898C11d DMX1IZ9 TI TT8JRS7 DMX1IZ9 TN Beta-secretase (BACE) DMX1IZ9 MA Inhibitor DMX1IZ9 RN Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective beta-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid beta-peptides. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6. DMX1IZ9 RU https://pubmed.ncbi.nlm.nih.gov/23981898 DMX1ZQV DI DMX1ZQV DMX1ZQV DN (S)-DRF-1042 DMX1ZQV TI TTGTQHC DMX1ZQV TN DNA topoisomerase I (TOP1) DMX1ZQV MA Inhibitor DMX1ZQV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMX1ZQV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMXE0F2 DI DMXE0F2 DMXE0F2 DN PMID10498202C1 DMXE0F2 TI TTPT2QI DMXE0F2 TN Cathepsin D (CTSD) DMXE0F2 MA Inhibitor DMXE0F2 RN Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6. DMXE0F2 RU https://pubmed.ncbi.nlm.nih.gov/10498202 DMXFI90 DI DMXFI90 DMXFI90 DN oxazine 89 DMXFI90 TI TT8JRS7 DMXFI90 TN Beta-secretase (BACE) DMXFI90 MA Inhibitor DMXFI90 RN beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013 May 23;56(10):3980-95. DMXFI90 RU https://pubmed.ncbi.nlm.nih.gov/23590342 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT8SJGB DMXM19W TN Cyclic nucleotide-gated channel alpha-2 (CNGA2) DMXM19W MA Blocker (channel blocker) DMXM19W RN State-dependent block of CNG channels by dequalinium. J Gen Physiol. 2004 Mar;123(3):295-304. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/14981138 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TTHIQMC DMXM19W TN Cyclic nucleotide-gated channel alpha-1 (CNGA1) DMXM19W MA Blocker (channel blocker) DMXM19W RN Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/12508052 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT9R6BE DMXM19W TN Calcium-activated potassium channel KCa2.1 (KCNN1) DMXM19W MA Blocker (channel blocker) DMXM19W RN Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/10696100 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT9JH25 DMXM19W TN Calcium-activated potassium channel KCa2.3 (KCNN3) DMXM19W MA Blocker (channel blocker) DMXM19W RN Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/11369031 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT2T5M0 DMXM19W TN Calcium-activated potassium channel KCa2.2 (KCNN2) DMXM19W MA Blocker (channel blocker) DMXM19W RN Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/10915830 DMXU2D1 DI DMXU2D1 DMXU2D1 DN CAR-CD19 T cell DMXU2D1 TI TTW640A DMXU2D1 TN B-lymphocyte surface antigen B4 (CD19) DMXU2D1 MA CAR-T-Cell-Therapy DMXU2D1 RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMXU2D1 RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMZO6CV DI DMZO6CV DMZO6CV DN tiratricol DMZO6CV TI TTTSEPU DMZO6CV TN Thyroid hormone receptor alpha (THRA) DMZO6CV MA Agonist DMZO6CV RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMZO6CV RU https://pubmed.ncbi.nlm.nih.gov/2158622 DMZO6CV DI DMZO6CV DMZO6CV DN tiratricol DMZO6CV TI TTGER3L DMZO6CV TN Thyroid hormone receptor beta (THRB) DMZO6CV MA Agonist DMZO6CV RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMZO6CV RU https://pubmed.ncbi.nlm.nih.gov/2158622 DM01DG4 DI DM01DG4 DM01DG4 DN Isoxazoline derivative 4 DM01DG4 TI TTDP1UC DM01DG4 TN Fatty acid amide hydrolase (FAAH) DM01DG4 MA Inhibitor DM01DG4 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM01DG4 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM01FD3 DI DM01FD3 DM01FD3 DN Isoxazole-based bicyclic compound 19 DM01FD3 TI TTE4BSY DM01FD3 TN Bromodomain and extraterminal domain protein (BET) DM01FD3 MA Inhibitor DM01FD3 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM01FD3 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM01GEB DI DM01GEB DM01GEB DN Pyrrolidinyl urea derivative 6 DM01GEB TI TTTDVOJ DM01GEB TN Tropomyosin-related kinase A (TrkA) DM01GEB MA Inhibitor DM01GEB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM01GEB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM01GVE DI DM01GVE DM01GVE DN PMID26651364-Compound-5a DM01GVE TI TTTCRU2 DM01GVE TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM01GVE MA Antagonist DM01GVE RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM01GVE RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM01IWV DI DM01IWV DM01IWV DN PMID26651364-Compound-109 DM01IWV TI TTTCRU2 DM01IWV TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM01IWV MA Antagonist DM01IWV RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM01IWV RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM01RXU DI DM01RXU DM01RXU DN Imidazo bicyclic iminium derivative 1 DM01RXU TI TTJOMH6 DM01RXU TN Zinc finger protein GLI1 (Gli1) DM01RXU MA Inhibitor DM01RXU RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM01RXU RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM02D1B DI DM02D1B DM02D1B DN PMID25666693-Compound-29 DM02D1B TI TTMI6F5 DM02D1B TN Transient receptor potential cation channel V1 (TRPV1) DM02D1B MA Antagonist DM02D1B RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM02D1B RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM02J8N DI DM02J8N DM02J8N DN Spiroimidazolone derivative 3 DM02J8N TI TT9O6WS DM02J8N TN Glucagon receptor (GCGR) DM02J8N MA Antagonist DM02J8N RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM02J8N RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM02O5V DI DM02O5V DM02O5V DN PMID25666693-Compound-113 DM02O5V TI TTMI6F5 DM02O5V TN Transient receptor potential cation channel V1 (TRPV1) DM02O5V MA Antagonist DM02O5V RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM02O5V RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM02RQ4 DI DM02RQ4 DM02RQ4 DN N-acylpiperidine ether derivative 2 DM02RQ4 TI TTTDVOJ DM02RQ4 TN Tropomyosin-related kinase A (TrkA) DM02RQ4 MA Inhibitor DM02RQ4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM02RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTCY4SB DM02V5Q TN Aurora kinase (AURK) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTIDAPM DM02V5Q TN ERK activator kinase 1 (MEK1) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTTU902 DM02V5Q TN Checkpoint kinase-1 (CHK1) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TT7HF4W DM02V5Q TN Cyclin-dependent kinase 2 (CDK2) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02ZM4 DI DM02ZM4 DM02ZM4 DN Urea and carbamate bioisostere derivative 5 DM02ZM4 TI TTL7C8Q DM02ZM4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM02ZM4 MA Inhibitor DM02ZM4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM02ZM4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM031RU DI DM031RU DM031RU DN Resorcinol compound 7 DM031RU TI TTULVH8 DM031RU TN Tyrosinase (TYR) DM031RU MA Inhibitor DM031RU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM031RU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM031YW DI DM031YW DM031YW DN Quinoxaline derivative 2 DM031YW TI TTSXVID DM031YW TN Nuclear factor NF-kappa-B (NFKB) DM031YW MA Inhibitor DM031YW RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM031YW RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM03UK2 DI DM03UK2 DM03UK2 DN PMID25482888-Compound-6 DM03UK2 TI TTDIGC1 DM03UK2 TN Dipeptidyl peptidase 4 (DPP-4) DM03UK2 MA Inhibitor DM03UK2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM03UK2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM048C1 DI DM048C1 DM048C1 DN PMID25747044-Compound-miRNA DM048C1 TI TTLUW5B DM048C1 TN Laminin receptor 37/67kDa (LRP/LR) DM048C1 MA Inhibitor DM048C1 RN Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease.Expert Opin Ther Pat. 2015 May;25(5):567-82. DM048C1 RU https://www.ncbi.nlm.nih.gov/pubmed/25747044 DM04ZJ2 DI DM04ZJ2 DM04ZJ2 DN Alkyl mannoside derivative 5 DM04ZJ2 TI TTTCRU2 DM04ZJ2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM04ZJ2 MA Antagonist DM04ZJ2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM04ZJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM05D48 DI DM05D48 DM05D48 DN PMID25666693-Compound-77 DM05D48 TI TTMI6F5 DM05D48 TN Transient receptor potential cation channel V1 (TRPV1) DM05D48 MA Antagonist DM05D48 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM05D48 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM05S2X DI DM05S2X DM05S2X DN Pyrazole and benzimidazole derivative 1 DM05S2X TI TTRZQE3 DM05S2X TN Glycogen synthase kinase-3 alpha (GSK-3A) DM05S2X MA Inhibitor DM05S2X RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM05S2X RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM05V8Q DI DM05V8Q DM05V8Q DN 4-aryl quinol derivative 3 DM05V8Q TI TTR7UJ3 DM05V8Q TN Cytoplasmic thioredoxin reductase (TXNRD1) DM05V8Q MA Inhibitor DM05V8Q RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM05V8Q RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM05VO6 DI DM05VO6 DM05VO6 DN Thiazolidine derivative 1 DM05VO6 TI TTULVH8 DM05VO6 TN Tyrosinase (TYR) DM05VO6 MA Inhibitor DM05VO6 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM05VO6 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTXNCBV DM05WXD TN Tryptophan 2,3-dioxygenase (TDO) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTALN9W DM05WXD TN Indoleamine 2,3-dioxygenase 2 (IDO2) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTZJYKH DM05WXD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM067UC DI DM067UC DM067UC DN Piperazine carbamate/urea derivative 7 DM067UC TI TT9JNIC DM067UC TN Histamine H3 receptor (H3R) DM067UC MA Ligand DM067UC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM067UC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM06IWA DI DM06IWA DM06IWA DN PMID25666693-Compound-161 DM06IWA TI TTMI6F5 DM06IWA TN Transient receptor potential cation channel V1 (TRPV1) DM06IWA MA Antagonist DM06IWA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM06IWA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM06LDV DI DM06LDV DM06LDV DN PMID25656651-Compound-28a DM06LDV TI TT3PJMV DM06LDV TN Tyrosine-protein kinase ABL1 (ABL) DM06LDV MA Inhibitor DM06LDV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM06LDV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM06MJH DI DM06MJH DM06MJH DN Diaryl amine derivative 1 DM06MJH TI TT1LVF2 DM06MJH TN Cyclin-dependent kinase 9 (CDK9) DM06MJH MA Inhibitor DM06MJH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06MJH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06MJH DI DM06MJH DM06MJH DN Diaryl amine derivative 1 DM06MJH TI TT7HF4W DM06MJH TN Cyclin-dependent kinase 2 (CDK2) DM06MJH MA Inhibitor DM06MJH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06MJH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06PX4 DI DM06PX4 DM06PX4 DN PMID30074415-Compound-19 DM06PX4 TI TTUNARX DM06PX4 TN Carbonic anhydrase (CA) DM06PX4 MA Inhibitor DM06PX4 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM06PX4 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM06U3J DI DM06U3J DM06U3J DN Alkyl sulfone derivative 1 DM06U3J TI TT1LVF2 DM06U3J TN Cyclin-dependent kinase 9 (CDK9) DM06U3J MA Inhibitor DM06U3J RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06U3J RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06U3J DI DM06U3J DM06U3J DN Alkyl sulfone derivative 1 DM06U3J TI TT7HF4W DM06U3J TN Cyclin-dependent kinase 2 (CDK2) DM06U3J MA Inhibitor DM06U3J RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06U3J RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM07C1I DI DM07C1I DM07C1I DN Phthalazine ketone derivative 2 DM07C1I TI TTVDSZ0 DM07C1I TN Poly [ADP-ribose] polymerase 1 (PARP1) DM07C1I MA Inhibitor DM07C1I RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM07C1I RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM07DC6 DI DM07DC6 DM07DC6 DN PMID26004420-Compound-US20140142115B DM07DC6 TI TTJ13ST DM07DC6 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM07DC6 MA Inhibitor DM07DC6 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM07DC6 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM07GEK DI DM07GEK DM07GEK DN Pyrazolo[1,5-a]pyrimidine derivative 10 DM07GEK TI TT6OEDT DM07GEK TN Cannabinoid receptor 1 (CB1) DM07GEK MA Antagonist DM07GEK RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM07GEK RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTRQ6UD DM07U5R TN Diacylglycerol lipase alpha (DAGLA) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTDP1UC DM07U5R TN Fatty acid amide hydrolase (FAAH) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTZ963I DM07U5R TN Monoglyceride lipase (MAGL) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM08CBJ DI DM08CBJ DM08CBJ DN PMID30107136-Compound-Example51 DM08CBJ TI TT23XQV DM08CBJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM08CBJ MA Inhibitor DM08CBJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM08CBJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM08OV7 DI DM08OV7 DM08OV7 DN PMID29671355-Compound-72b DM08OV7 TI TTTQGH8 DM08OV7 TN Histone deacetylase 4 (HDAC4) DM08OV7 MA Inhibitor DM08OV7 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM08OV7 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM09FOQ DI DM09FOQ DM09FOQ DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 4 DM09FOQ TI TTV8CRH DM09FOQ TN Lysine-specific demethylase 4C (KDM4C) DM09FOQ MA Inhibitor DM09FOQ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM09FOQ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM09LY3 DI DM09LY3 DM09LY3 DN Cycloalkyl acid derivative 2 DM09LY3 TI TTA592U DM09LY3 TN Urate anion exchanger 1 (URAT1) DM09LY3 MA Inhibitor DM09LY3 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM09LY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM0B578 DI DM0B578 DM0B578 DN PMID25666693-Compound-61 DM0B578 TI TTMI6F5 DM0B578 TN Transient receptor potential cation channel V1 (TRPV1) DM0B578 MA Antagonist DM0B578 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0B578 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0B9SP DI DM0B9SP DM0B9SP DN Aryl urea derivative 1 DM0B9SP TI TTDP1UC DM0B9SP TN Fatty acid amide hydrolase (FAAH) DM0B9SP MA Inhibitor DM0B9SP RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0B9SP RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0BRNU DI DM0BRNU DM0BRNU DN Polyhydroxy benzamide derivative 2 DM0BRNU TI TTULVH8 DM0BRNU TN Tyrosinase (TYR) DM0BRNU MA Inhibitor DM0BRNU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM0BRNU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM0BTH8 DI DM0BTH8 DM0BTH8 DN Metal complex derivative 2 DM0BTH8 TI TTR7UJ3 DM0BTH8 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM0BTH8 MA Inhibitor DM0BTH8 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM0BTH8 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM0C1ZO DI DM0C1ZO DM0C1ZO DN Aryl cyclopropylamine derivative 4 DM0C1ZO TI TTNR0UQ DM0C1ZO TN Lysine-specific histone demethylase 1 (LSD) DM0C1ZO MA Inhibitor DM0C1ZO RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM0C1ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM0C48S DI DM0C48S DM0C48S DN Azetidinyl-piperazine derivative 2 DM0C48S TI TTZ963I DM0C48S TN Monoglyceride lipase (MAGL) DM0C48S MA Inhibitor DM0C48S RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM0C48S RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM0C9YL DI DM0C9YL DM0C9YL DN PMID25656651-Compound-15a DM0C9YL TI TTS7G69 DM0C9YL TN Fusion protein Bcr-Abl (Bcr-Abl) DM0C9YL MA Inhibitor DM0C9YL RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0C9YL RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0CEJM DI DM0CEJM DM0CEJM DN Antibodie derivative 8 DM0CEJM TI TTOHSBA DM0CEJM TN Vascular endothelial growth factor A (VEGFA) DM0CEJM MA Disrupter DM0CEJM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM0CEJM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM0D3HU DI DM0D3HU DM0D3HU DN Dihydrothieno [2,3-e]indazole derivative 2 DM0D3HU TI TTRPDBG DM0D3HU TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM0D3HU MA Inhibitor DM0D3HU RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM0D3HU RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM0DAR1 DI DM0DAR1 DM0DAR1 DN PMID29324067-Compound-25 DM0DAR1 TI TT3WG5C DM0DAR1 TN Monoamine oxidase type A (MAO-A) DM0DAR1 MA Inhibitor DM0DAR1 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM0DAR1 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM0DYAU DI DM0DYAU DM0DYAU DN 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine DM0DYAU TI TT42OGM DM0DYAU TN Hematopoietic cell kinase (HCK) DM0DYAU MA Inhibitor DM0DYAU RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DM0DYAU RU http://www.freepatentsonline.com/US9765037.html DM0E38G DI DM0E38G DM0E38G DN Flavonoid derivative 6 DM0E38G TI TTV8CRH DM0E38G TN Lysine-specific demethylase 4C (KDM4C) DM0E38G MA Inhibitor DM0E38G RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM0E38G RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM0E8YF DI DM0E8YF DM0E8YF DN Azole benzene derivative 1 DM0E8YF TI TT7RJY8 DM0E8YF TN Xanthine dehydrogenase/oxidase (XDH) DM0E8YF MA Inhibitor DM0E8YF RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM0E8YF RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM0EBS8 DI DM0EBS8 DM0EBS8 DN Carbamoyl oxime derivative 1 DM0EBS8 TI TTGX13H DM0EBS8 TN Fatty-acid amide hydrolase 1 (FAAH1) DM0EBS8 MA Inhibitor DM0EBS8 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0EBS8 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0ECWR DI DM0ECWR DM0ECWR DN Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1 DM0ECWR TI TTSCIM2 DM0ECWR TN Extracellular lysophospholipase D (E-NPP2) DM0ECWR MA Inhibitor DM0ECWR RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM0ECWR RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM0ENF3 DI DM0ENF3 DM0ENF3 DN Oxindole derivative 3 DM0ENF3 TI TT6AXLY DM0ENF3 TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DM0ENF3 MA Inhibitor DM0ENF3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM0ENF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM0ENF3 DI DM0ENF3 DM0ENF3 DN Oxindole derivative 3 DM0ENF3 TI TTK0FEA DM0ENF3 TN Leucine-rich repeat kinase 2 (LRRK2) DM0ENF3 MA Inhibitor DM0ENF3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM0ENF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM0EYON DI DM0EYON DM0EYON DN PMID25666693-Compound-148 DM0EYON TI TTMI6F5 DM0EYON TN Transient receptor potential cation channel V1 (TRPV1) DM0EYON MA Antagonist DM0EYON RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0EYON RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0F6VU DI DM0F6VU DM0F6VU DN PMID27607364-Compound-162 DM0F6VU TI TTPTXIN DM0F6VU TN Translocator protein (TSPO) DM0F6VU MA Ligand DM0F6VU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM0F6VU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM0FPMV DI DM0FPMV DM0FPMV DN Pyrazolo[1,5-a]pyrimidine derivative 1 DM0FPMV TI TT6OEDT DM0FPMV TN Cannabinoid receptor 1 (CB1) DM0FPMV MA Antagonist DM0FPMV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0FPMV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0FSPQ DI DM0FSPQ DM0FSPQ DN Aryl mannoside derivative 17 DM0FSPQ TI TTTCRU2 DM0FSPQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0FSPQ MA Antagonist DM0FSPQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0FSPQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0G8XP DI DM0G8XP DM0G8XP DN Beta-phe compound 3 DM0G8XP TI TTDIGC1 DM0G8XP TN Dipeptidyl peptidase 4 (DPP-4) DM0G8XP MA Inhibitor DM0G8XP RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM0G8XP RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM0GCTY DI DM0GCTY DM0GCTY DN Piperidine derivative 6 DM0GCTY TI TT9NXW4 DM0GCTY TN Sigma intracellular receptor 2 (TMEM97) DM0GCTY MA Ligand DM0GCTY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0GCTY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0GCTY DI DM0GCTY DM0GCTY DN Piperidine derivative 6 DM0GCTY TI TT5TPI6 DM0GCTY TN Opioid receptor sigma 1 (OPRS1) DM0GCTY MA Ligand DM0GCTY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0GCTY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0GOCZ DI DM0GOCZ DM0GOCZ DN US9340511, 2 DM0GOCZ TI TT9ISBX DM0GOCZ TN HIF-prolyl hydroxylase 2 (HPH-2) DM0GOCZ MA Inhibitor DM0GOCZ RN Process for making isoquinoline compounds. US9708269. DM0GOCZ RU http://www.freepatentsonline.com/US9708269.html DM0GTUH DI DM0GTUH DM0GTUH DN Six-membered heterocyclic benzamide derivative 5 DM0GTUH TI TTTDVOJ DM0GTUH TN Tropomyosin-related kinase A (TrkA) DM0GTUH MA Inhibitor DM0GTUH RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM0GTUH RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM0HIQU DI DM0HIQU DM0HIQU DN 1,2-diamino cyclopentane-based derivative 23 DM0HIQU TI TT9N02I DM0HIQU TN Orexin receptor type 2 (HCRTR2) DM0HIQU MA Antagonist DM0HIQU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM0HIQU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM0HIQU DI DM0HIQU DM0HIQU DN 1,2-diamino cyclopentane-based derivative 23 DM0HIQU TI TT60Q8D DM0HIQU TN Orexin receptor type 1 (HCRTR1) DM0HIQU MA Antagonist DM0HIQU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM0HIQU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM0HOJW DI DM0HOJW DM0HOJW DN Aryl urea derivative 4 DM0HOJW TI TTDP1UC DM0HOJW TN Fatty acid amide hydrolase (FAAH) DM0HOJW MA Inhibitor DM0HOJW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0HOJW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TTH6V3D DM0HU5O TN Cyclin-dependent kinase 1 (CDK1) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TT7HF4W DM0HU5O TN Cyclin-dependent kinase 2 (CDK2) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TT0PG8F DM0HU5O TN Cyclin-dependent kinase 4 (CDK4) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0I72B DI DM0I72B DM0I72B DN PMID25666693-Compound-44 DM0I72B TI TTMI6F5 DM0I72B TN Transient receptor potential cation channel V1 (TRPV1) DM0I72B MA Antagonist DM0I72B RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0I72B RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0IJYQ DI DM0IJYQ DM0IJYQ DN Azetidinyl-piperidine derivative 1 DM0IJYQ TI TTZ963I DM0IJYQ TN Monoglyceride lipase (MAGL) DM0IJYQ MA Inhibitor DM0IJYQ RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM0IJYQ RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM0IRPO DI DM0IRPO DM0IRPO DN Carbamide derivative 23 DM0IRPO TI TTOHSBA DM0IRPO TN Vascular endothelial growth factor A (VEGFA) DM0IRPO MA Inhibitor DM0IRPO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM0IRPO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM0IZW8 DI DM0IZW8 DM0IZW8 DN Cyclopropyl-spiro piperidine derivative 3 DM0IZW8 TI TT4G2JS DM0IZW8 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0IZW8 MA Blocker DM0IZW8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM0IZW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM0J2TE DI DM0J2TE DM0J2TE DN Piperidinyl triazole derivative 3 DM0J2TE TI TTTJZ4M DM0J2TE TN Prolylcarboxypeptidase (PRCP) DM0J2TE MA Inhibitor DM0J2TE RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM0J2TE RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM0JSOZ DI DM0JSOZ DM0JSOZ DN PMID26924192-Compound-32 DM0JSOZ TI TTRA6BO DM0JSOZ TN Bromodomain-containing protein 4 (BRD4) DM0JSOZ MA Inhibitor DM0JSOZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0JSOZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0JSOZ DI DM0JSOZ DM0JSOZ DN PMID26924192-Compound-32 DM0JSOZ TI TTU6FSC DM0JSOZ TN Extracellular signal-regulated kinase 5 (ERK5) DM0JSOZ MA Inhibitor DM0JSOZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0JSOZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0JYWT DI DM0JYWT DM0JYWT DN Tricyclic pyrrolidine derivative 4 DM0JYWT TI TTWJBZ5 DM0JYWT TN 5-HT 2C receptor (HTR2C) DM0JYWT MA Agonist DM0JYWT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM0JYWT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM0K4XE DI DM0K4XE DM0K4XE DN PMID25399762-Compound-Figure1-Chukrasone B DM0K4XE TI TT3WG5C DM0K4XE TN Monoamine oxidase type A (MAO-A) DM0K4XE MA Inhibitor DM0K4XE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM0K4XE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM0K5Q1 DI DM0K5Q1 DM0K5Q1 DN Peptide analog 15 DM0K5Q1 TI TTSJMN8 DM0K5Q1 TN Immunoproteasome complex (IP) DM0K5Q1 MA Inhibitor DM0K5Q1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0K5Q1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0K62M DI DM0K62M DM0K62M DN Cyclic hydroxamate derivative 1 DM0K62M TI TTZJYKH DM0K62M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0K62M MA Inhibitor DM0K62M RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM0K62M RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM0KPQ9 DI DM0KPQ9 DM0KPQ9 DN PMID28394193-Compound-51 DM0KPQ9 TI TT9MZCQ DM0KPQ9 TN Enhancer of zeste homolog 2 (EZH2) DM0KPQ9 MA Inhibitor DM0KPQ9 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM0KPQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM0KR8E DI DM0KR8E DM0KR8E DN PMID27841045-Compound-136 DM0KR8E TI TT7RJY8 DM0KR8E TN Xanthine dehydrogenase/oxidase (XDH) DM0KR8E MA Inhibitor DM0KR8E RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM0KR8E RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM0L68P DI DM0L68P DM0L68P DN PMID27215781-Compound-37 DM0L68P TI TTMSFAW DM0L68P TN Cannabinoid receptor 2 (CB2) DM0L68P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM0L68P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM0L68P DI DM0L68P DM0L68P DN PMID27215781-Compound-37 DM0L68P TI TT6OEDT DM0L68P TN Cannabinoid receptor 1 (CB1) DM0L68P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM0L68P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM0LB21 DI DM0LB21 DM0LB21 DN PMID27977313-Compound-39 DM0LB21 TI TTR7UJ3 DM0LB21 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM0LB21 MA Inhibitor DM0LB21 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM0LB21 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM0LGTY DI DM0LGTY DM0LGTY DN PMID27998201-Compound-6 DM0LGTY TI TT36ETB DM0LGTY TN Cathepsin L (CTSL) DM0LGTY MA Inhibitor DM0LGTY RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM0LGTY RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM0LGTY DI DM0LGTY DM0LGTY DN PMID27998201-Compound-6 DM0LGTY TI TTUMQVO DM0LGTY TN Cathepsin S (CTSS) DM0LGTY MA Inhibitor DM0LGTY RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM0LGTY RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TTOUSTQ DM0LXT2 TN Proteasome beta-9 (PS beta-9) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TT8EPLT DM0LXT2 TN Proteasome beta-1 (PS beta-1) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TT68GPI DM0LXT2 TN Proteasome beta-5 (PS beta-5) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TTEAD9J DM0LXT2 TN Proteasome beta-8 (PS beta-8) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0MEXT DI DM0MEXT DM0MEXT DN PMID25666693-Compound-46 DM0MEXT TI TTMI6F5 DM0MEXT TN Transient receptor potential cation channel V1 (TRPV1) DM0MEXT MA Antagonist DM0MEXT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0MEXT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0MLI9 DI DM0MLI9 DM0MLI9 DN Quinoline derivative 19 DM0MLI9 TI TTSCO7R DM0MLI9 TN NAD-dependent deacetylase sirtuin (SIRT) DM0MLI9 MA Inhibitor DM0MLI9 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM0MLI9 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTU1E82 DM0NEVC TN Apoptosis regulator Bcl-xL (BCL-xL) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTJGNVC DM0NEVC TN Apoptosis regulator Bcl-2 (BCL-2) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTL53M6 DM0NEVC TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NIB5 DI DM0NIB5 DM0NIB5 DN US9359293, TM DM0NIB5 TI TTLKF5M DM0NIB5 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM0NIB5 MA Inhibitor DM0NIB5 RN Methods of treatment using modulators of SIRT2. US9359293. DM0NIB5 RU http://www.freepatentsonline.com/US9359293.html DM0NJFZ DI DM0NJFZ DM0NJFZ DN Aminocyclopentenone compound 6 DM0NJFZ TI TTRA6BO DM0NJFZ TN Bromodomain-containing protein 4 (BRD4) DM0NJFZ MA Inhibitor DM0NJFZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0NJFZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0NM1Y DI DM0NM1Y DM0NM1Y DN PMID26666989-Compound-Figure9left01 DM0NM1Y TI TT8BUGW DM0NM1Y TN Glycogen phosphorylase (PYG) DM0NM1Y MA Inhibitor DM0NM1Y RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM0NM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM0NYK3 DI DM0NYK3 DM0NYK3 DN PMID27321640-Compound-58 DM0NYK3 TI TTJW4LU DM0NYK3 TN Phosphodiesterase 10A (PDE10) DM0NYK3 MA Inhibitor DM0NYK3 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM0NYK3 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM0NYK3 DI DM0NYK3 DM0NYK3 DN PMID27321640-Compound-58 DM0NYK3 TI TTJGW1Z DM0NYK3 TN Phosphodiesterase 2A (PDE2A) DM0NYK3 MA Inhibitor DM0NYK3 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM0NYK3 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM0O18N DI DM0O18N DM0O18N DN PMID28766366-Compound-Scheme9EHT5372 DM0O18N TI TTYGQ8A DM0O18N TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM0O18N MA Inhibitor DM0O18N RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM0O18N RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM0O18N DI DM0O18N DM0O18N DN PMID28766366-Compound-Scheme9EHT5372 DM0O18N TI TTSBVFO DM0O18N TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM0O18N MA Inhibitor DM0O18N RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM0O18N RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM0O4WR DI DM0O4WR DM0O4WR DN Pyrazolo[1,5-a]pyrimidine derivative 11 DM0O4WR TI TT6OEDT DM0O4WR TN Cannabinoid receptor 1 (CB1) DM0O4WR MA Antagonist DM0O4WR RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0O4WR RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0O8WS DI DM0O8WS DM0O8WS DN US8987457, 198 DM0O8WS TI TTCGOIN DM0O8WS TN PIM-3 protein kinase (PIM3) DM0O8WS MA Inhibitor DM0O8WS RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DM0O8WS RU http://www.freepatentsonline.com/US8987457.html DM0OBAW DI DM0OBAW DM0OBAW DN PMID25470667-Compound-PF-04620110 DM0OBAW TI TTF8P9I DM0OBAW TN Diacylglycerol acyltransferase 1 (DGAT1) DM0OBAW MA Inhibitor DM0OBAW RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM0OBAW RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TTT7PJU DM0OMAL TN Janus kinase 3 (JAK-3) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TT6DM01 DM0OMAL TN Janus kinase 1 (JAK-1) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TTRMX3V DM0OMAL TN Janus kinase 2 (JAK-2) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMBW DI DM0OMBW DM0OMBW DN Cyclopropane 1-carboxylic acid derivative 6 DM0OMBW TI TTIY56R DM0OMBW TN Kynurenine 3-hydroxylase (KMO) DM0OMBW MA Inhibitor DM0OMBW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM0OMBW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM0ON7S DI DM0ON7S DM0ON7S DN Macrolactam derivative 1 DM0ON7S TI TTKFVXR DM0ON7S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM0ON7S MA Inhibitor DM0ON7S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM0ON7S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM0OY5D DI DM0OY5D DM0OY5D DN PMID25666693-Compound-102 DM0OY5D TI TTMI6F5 DM0OY5D TN Transient receptor potential cation channel V1 (TRPV1) DM0OY5D MA Antagonist DM0OY5D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0OY5D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0OYCX DI DM0OYCX DM0OYCX DN Bicyclic heteroaryl amide derivative 3 DM0OYCX TI TT473XN DM0OYCX TN P2X purinoceptor 7 (P2RX7) DM0OYCX MA Antagonist DM0OYCX RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM0OYCX RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM0P2U3 DI DM0P2U3 DM0P2U3 DN AKOS003197197 DM0P2U3 TI TTLQUZS DM0P2U3 TN Cystathionine gamma-lyase (CTH) DM0P2U3 MA Inhibitor DM0P2U3 RN Cystathionine--lyase (CSE) inhibitors. US9725426. DM0P2U3 RU http://www.freepatentsonline.com/US9725426.html DM0P4F3 DI DM0P4F3 DM0P4F3 DN PMID25656651-Compound-37a DM0P4F3 TI TTIV39N DM0P4F3 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM0P4F3 MA Inhibitor DM0P4F3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0P4F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0P4F3 DI DM0P4F3 DM0P4F3 DN PMID25656651-Compound-37a DM0P4F3 TI TTS7G69 DM0P4F3 TN Fusion protein Bcr-Abl (Bcr-Abl) DM0P4F3 MA Inhibitor DM0P4F3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0P4F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0P4TA DI DM0P4TA DM0P4TA DN PMID26004420-Compound-US20140309213B DM0P4TA TI TTJ13ST DM0P4TA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM0P4TA MA Inhibitor DM0P4TA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM0P4TA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM0PBJT DI DM0PBJT DM0PBJT DN Phenoxypiperidine derivative 1 DM0PBJT TI TT9JNIC DM0PBJT TN Histamine H3 receptor (H3R) DM0PBJT RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM0PBJT RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM0Q37R DI DM0Q37R DM0Q37R DN PMID25991433-Compound-H1 DM0Q37R TI TT0K6EO DM0Q37R TN Stress-activated protein kinase JNK1 (JNK1) DM0Q37R MA Inhibitor DM0Q37R RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM0Q37R RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM0Q3HF DI DM0Q3HF DM0Q3HF DN Thiazole carboxamide derivative 11 DM0Q3HF TI TTCZOF2 DM0Q3HF TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM0Q3HF MA Inhibitor DM0Q3HF RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM0Q3HF RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM0Q9VY DI DM0Q9VY DM0Q9VY DN Triazolo-pyridine derivative 1 DM0Q9VY TI TT6DM01 DM0Q9VY TN Janus kinase 1 (JAK-1) DM0Q9VY MA Inhibitor DM0Q9VY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM0Q9VY RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM0Q9VY DI DM0Q9VY DM0Q9VY DN Triazolo-pyridine derivative 1 DM0Q9VY TI TTRMX3V DM0Q9VY TN Janus kinase 2 (JAK-2) DM0Q9VY MA Inhibitor DM0Q9VY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM0Q9VY RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTXABCW DM0QHLK TN NT-3 growth factor receptor (TrkC) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTTDVOJ DM0QHLK TN Tropomyosin-related kinase A (TrkA) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTKN7QR DM0QHLK TN BDNF/NT-3 growth factors receptor (TrkB) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0R5Y8 DI DM0R5Y8 DM0R5Y8 DN PMID27109571-Compound-21 DM0R5Y8 TI TTNT2S6 DM0R5Y8 TN Fatty acid-binding protein 5 (FABP5) DM0R5Y8 MA Inhibitor DM0R5Y8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM0R5Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM0R5Y8 DI DM0R5Y8 DM0R5Y8 DN PMID27109571-Compound-21 DM0R5Y8 TI TTHWMFZ DM0R5Y8 TN Fatty acid-binding protein 4 (FABP4) DM0R5Y8 MA Inhibitor DM0R5Y8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM0R5Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM0R653 DI DM0R653 DM0R653 DN Phenylpropylamine derivative 4 DM0R653 TI TT5TPI6 DM0R653 TN Opioid receptor sigma 1 (OPRS1) DM0R653 MA Ligand DM0R653 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0R653 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0RAC6 DI DM0RAC6 DM0RAC6 DN Benzo[d]oxazole derivative 4 DM0RAC6 TI TTA6ZN2 DM0RAC6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM0RAC6 MA Inhibitor DM0RAC6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM0RAC6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM0RAPC DI DM0RAPC DM0RAPC DN US10030004, Compound 19 DM0RAPC TI TTPKHTZ DM0RAPC TN Activin receptor type IB (ACVR1B) DM0RAPC MA Inhibitor DM0RAPC RN Compounds and methods of use. US10030004. DM0RAPC RU http://www.freepatentsonline.com/US10030004.html DM0RC1Z DI DM0RC1Z DM0RC1Z DN Pyrrole derivative 1 DM0RC1Z TI TT6OEDT DM0RC1Z TN Cannabinoid receptor 1 (CB1) DM0RC1Z MA Antagonist DM0RC1Z RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0RC1Z RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0RI7F DI DM0RI7F DM0RI7F DN Palbociclib/ribociclib analog 1 DM0RI7F TI TT7HF4W DM0RI7F TN Cyclin-dependent kinase 2 (CDK2) DM0RI7F MA Inhibitor DM0RI7F RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0RI7F RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0RI7F DI DM0RI7F DM0RI7F DN Palbociclib/ribociclib analog 1 DM0RI7F TI TT0PG8F DM0RI7F TN Cyclin-dependent kinase 4 (CDK4) DM0RI7F MA Inhibitor DM0RI7F RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0RI7F RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0S2UK DI DM0S2UK DM0S2UK DN US9422240, 1-286 DM0S2UK TI TT9ISBX DM0S2UK TN HIF-prolyl hydroxylase 2 (HPH-2) DM0S2UK MA Inhibitor DM0S2UK RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DM0S2UK RU http://www.freepatentsonline.com/US9422240.html DM0SOKJ DI DM0SOKJ DM0SOKJ DN Imidazole benzamide derivative 1 DM0SOKJ TI TTYLQ8V DM0SOKJ TN Prostaglandin E synthase (PTGES) DM0SOKJ MA Inhibitor DM0SOKJ RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM0SOKJ RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM0SY7Q DI DM0SY7Q DM0SY7Q DN PMID29649907-Compound-30 DM0SY7Q TI TTS4UGC DM0SY7Q TN Farnesoid X-activated receptor (FXR) DM0SY7Q MA Agonist DM0SY7Q RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM0SY7Q RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM0TKP2 DI DM0TKP2 DM0TKP2 DN Benzene sulfonamide derivative 7 DM0TKP2 TI TTIY56R DM0TKP2 TN Kynurenine 3-hydroxylase (KMO) DM0TKP2 MA Inhibitor DM0TKP2 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM0TKP2 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM0TURE DI DM0TURE DM0TURE DN Indandione derivative 3 DM0TURE TI TTV1C0Z DM0TURE TN Neuropeptide S receptor (NPSR) DM0TURE MA Antagonist DM0TURE RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM0TURE RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM0U7P9 DI DM0U7P9 DM0U7P9 DN Mannoside derivative 13 DM0U7P9 TI TTTCRU2 DM0U7P9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0U7P9 MA Antagonist DM0U7P9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0U7P9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0UWNY DI DM0UWNY DM0UWNY DN Benzamide derivative 2 DM0UWNY TI TT9NXW4 DM0UWNY TN Sigma intracellular receptor 2 (TMEM97) DM0UWNY MA Ligand DM0UWNY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0UWNY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT5ZKDI DM0VBMI TN Histone deacetylase 6 (HDAC6) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTT6LFV DM0VBMI TN Histone deacetylase 8 (HDAC8) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTTQGH8 DM0VBMI TN Histone deacetylase 4 (HDAC4) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT6R7JZ DM0VBMI TN Histone deacetylase 1 (HDAC1) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTYHPU6 DM0VBMI TN Histone deacetylase 10 (HDAC10) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTMUEK1 DM0VBMI TN Histone deacetylase 7 (HDAC7) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTSHTOI DM0VBMI TN Histone deacetylase 2 (HDAC2) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT4YWTO DM0VBMI TN Histone deacetylase 3 (HDAC3) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VEBI DI DM0VEBI DM0VEBI DN 6,6-fused nitrogenous heterocyclic compound 1 DM0VEBI TI TT3PJMV DM0VEBI TN Tyrosine-protein kinase ABL1 (ABL) DM0VEBI MA Inhibitor DM0VEBI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0VEBI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0VOY9 DI DM0VOY9 DM0VOY9 DN Pyridotriazolopyrimidine derivative 2 DM0VOY9 TI TT6OEDT DM0VOY9 TN Cannabinoid receptor 1 (CB1) DM0VOY9 MA Antagonist DM0VOY9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0VOY9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0VR23 DI DM0VR23 DM0VR23 DN Biphenyl mannoside derivative 4 DM0VR23 TI TTTCRU2 DM0VR23 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0VR23 MA Antagonist DM0VR23 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0VR23 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0W5UA DI DM0W5UA DM0W5UA DN PMID25482888-Compound-18 DM0W5UA TI TTDIGC1 DM0W5UA TN Dipeptidyl peptidase 4 (DPP-4) DM0W5UA MA Inhibitor DM0W5UA RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM0W5UA RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM0WBM3 DI DM0WBM3 DM0WBM3 DN 3-(phenoxymethyl) benzylamine derivative 6 DM0WBM3 TI TTULVH8 DM0WBM3 TN Tyrosinase (TYR) DM0WBM3 MA Inhibitor DM0WBM3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM0WBM3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM0XA3D DI DM0XA3D DM0XA3D DN PMID29338548-Compound-18 DM0XA3D TI TTHJTF7 DM0XA3D TN Glycine transporter GlyT-1 (SLC6A9) DM0XA3D MA Inhibitor DM0XA3D RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM0XA3D RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM0XVQY DI DM0XVQY DM0XVQY DN Quinazolinone derivative 2 DM0XVQY TI TTL7C8Q DM0XVQY TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM0XVQY MA Inhibitor DM0XVQY RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM0XVQY RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM0Y4X8 DI DM0Y4X8 DM0Y4X8 DN Imidazo bicyclic iminium derivative 7 DM0Y4X8 TI TT8J1S3 DM0Y4X8 TN Smoothened homolog (SMO) DM0Y4X8 MA Inhibitor DM0Y4X8 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM0Y4X8 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM0Y5NU DI DM0Y5NU DM0Y5NU DN PMID27539678-Compound-9 DM0Y5NU TI TTOHFIY DM0Y5NU TN Sphingosine kinase 1 (SPHK1) DM0Y5NU MA Inhibitor DM0Y5NU RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM0Y5NU RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM0YD3Z DI DM0YD3Z DM0YD3Z DN US8598172, 1 DM0YD3Z TI TT976FS DM0YD3Z TN Polo-like kinase 2 (PLK2) DM0YD3Z MA Inhibitor DM0YD3Z RN Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors. US8598172. DM0YD3Z RU http://www.freepatentsonline.com/US8598172.html DM0YTGS DI DM0YTGS DM0YTGS DN Cyclopropyl-spiro piperidine derivative 1 DM0YTGS TI TT4G2JS DM0YTGS TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0YTGS MA Blocker DM0YTGS RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM0YTGS RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM0YUBR DI DM0YUBR DM0YUBR DN Aryl mannoside derivative 18 DM0YUBR TI TTTCRU2 DM0YUBR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0YUBR MA Antagonist DM0YUBR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0YUBR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0ZDL3 DI DM0ZDL3 DM0ZDL3 DN US9475795, 80 DM0ZDL3 TI TTB9CIL DM0ZDL3 TN Prokineticin receptor-1 (PROKR1) DM0ZDL3 MA Inhibitor DM0ZDL3 RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DM0ZDL3 RU http://www.freepatentsonline.com/US9475795.html DM0ZJX7 DI DM0ZJX7 DM0ZJX7 DN N-(phenylpyrazolyl)benzamide derivative 1 DM0ZJX7 TI TTTDVOJ DM0ZJX7 TN Tropomyosin-related kinase A (TrkA) DM0ZJX7 MA Inhibitor DM0ZJX7 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM0ZJX7 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM0ZRI9 DI DM0ZRI9 DM0ZRI9 DN PMID29130358-Compound-Figure16(9c) DM0ZRI9 TI TTHY57M DM0ZRI9 TN Matrix metalloproteinase-13 (MMP-13) DM0ZRI9 MA Inhibitor DM0ZRI9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM0ZRI9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM0ZRI9 DI DM0ZRI9 DM0ZRI9 DN PMID29130358-Compound-Figure16(9c) DM0ZRI9 TI TTLM12X DM0ZRI9 TN Matrix metalloproteinase-2 (MMP-2) DM0ZRI9 MA Inhibitor DM0ZRI9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM0ZRI9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM106SU DI DM106SU DM106SU DN N-oxalyl-D-tyrosine derivative 6 DM106SU TI TTWAQBO DM106SU TN Lysine-specific demethylase 4E (KDM4E) DM106SU MA Inhibitor DM106SU RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM106SU RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM10CGB DI DM10CGB DM10CGB DN Fused heterocyclic compound 5 DM10CGB TI TT7RJY8 DM10CGB TN Xanthine dehydrogenase/oxidase (XDH) DM10CGB MA Inhibitor DM10CGB RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM10CGB RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM10UX4 DI DM10UX4 DM10UX4 DN 1,2-diamino cyclopentane-based derivative 13 DM10UX4 TI TT9N02I DM10UX4 TN Orexin receptor type 2 (HCRTR2) DM10UX4 MA Antagonist DM10UX4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM10UX4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM10UX4 DI DM10UX4 DM10UX4 DN 1,2-diamino cyclopentane-based derivative 13 DM10UX4 TI TT60Q8D DM10UX4 TN Orexin receptor type 1 (HCRTR1) DM10UX4 MA Antagonist DM10UX4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM10UX4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM12QO7 DI DM12QO7 DM12QO7 DN PMID25435285-Compound-10 DM12QO7 TI TTXJ47W DM12QO7 TN Metabotropic glutamate receptor 2 (mGluR2) DM12QO7 MA Antagonist DM12QO7 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM12QO7 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM12VO9 DI DM12VO9 DM12VO9 DN Peptide analog 40 DM12VO9 TI TTSJMN8 DM12VO9 TN Immunoproteasome complex (IP) DM12VO9 MA Inhibitor DM12VO9 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM12VO9 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM12X0P DI DM12X0P DM12X0P DN PMID27967267-Compound-43 DM12X0P TI TT1RS9F DM12X0P TN Acetylcholinesterase (AChE) DM12X0P MA Inhibitor DM12X0P RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM12X0P RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM13K8R DI DM13K8R DM13K8R DN N-oxalyl-D-tyrosine derivative 7 DM13K8R TI TTWAQBO DM13K8R TN Lysine-specific demethylase 4E (KDM4E) DM13K8R MA Inhibitor DM13K8R RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM13K8R RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM14029 DI DM14029 DM14029 DN Quinoline carboxamide derivative 5 DM14029 TI TTPTXIN DM14029 TN Translocator protein (TSPO) DM14029 MA Ligand DM14029 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM14029 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM142HI DI DM142HI DM142HI DN Imidazo triazine derivative 3 DM142HI TI TTJGW1Z DM142HI TN Phosphodiesterase 2A (PDE2A) DM142HI MA Inhibitor DM142HI RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM142HI RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM143OK DI DM143OK DM143OK DN 1,2-diamino cyclopentane-based derivative 3 DM143OK TI TT9N02I DM143OK TN Orexin receptor type 2 (HCRTR2) DM143OK MA Antagonist DM143OK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM143OK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM143OK DI DM143OK DM143OK DN 1,2-diamino cyclopentane-based derivative 3 DM143OK TI TT60Q8D DM143OK TN Orexin receptor type 1 (HCRTR1) DM143OK MA Antagonist DM143OK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM143OK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TT4G2JS DM146TA TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TTZOVE0 DM146TA TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TTAXZ0K DM146TA TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM149WN DI DM149WN DM149WN DN Carboxamide derivative 5 DM149WN TI TTG5QB7 DM149WN TN Calpain-2 (CAPN2) DM149WN MA Inhibitor DM149WN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM149WN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM14KHX DI DM14KHX DM14KHX DN Imidazole derivative 1 DM14KHX TI TT6OEDT DM14KHX TN Cannabinoid receptor 1 (CB1) DM14KHX MA Antagonist DM14KHX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM14KHX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM15AFI DI DM15AFI DM15AFI DN Six-membered heterocyclic benzamide derivative 7 DM15AFI TI TTTDVOJ DM15AFI TN Tropomyosin-related kinase A (TrkA) DM15AFI MA Inhibitor DM15AFI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM15AFI RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM15OKA DI DM15OKA DM15OKA DN PMID28621580-Compound-WO2013112959C68 DM15OKA TI TTOHSBA DM15OKA TN Vascular endothelial growth factor A (VEGFA) DM15OKA MA Inhibitor DM15OKA RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM15OKA RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM15TMH DI DM15TMH DM15TMH DN Peptidomimetic analog 7 DM15TMH TI TTUX68I DM15TMH TN Hypoxia-inducible factor 1 (HIF-1) DM15TMH MA Inhibitor DM15TMH RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM15TMH RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM16ANH DI DM16ANH DM16ANH DN PMID26651364-Compound-10b DM16ANH TI TTTCRU2 DM16ANH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM16ANH MA Antagonist DM16ANH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM16ANH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM16E95 DI DM16E95 DM16E95 DN PMID28092474-Compound-33i DM16E95 TI TT6R7JZ DM16E95 TN Histone deacetylase 1 (HDAC1) DM16E95 MA Inhibitor DM16E95 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM16E95 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM16E95 DI DM16E95 DM16E95 DN PMID28092474-Compound-33i DM16E95 TI TT5ZKDI DM16E95 TN Histone deacetylase 6 (HDAC6) DM16E95 MA Inhibitor DM16E95 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM16E95 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM16M4A DI DM16M4A DM16M4A DN Dihydropyridine compound 1 DM16M4A TI TT4DXQT DM16M4A TN Proto-oncogene c-Ret (RET) DM16M4A MA Inhibitor DM16M4A RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM16M4A RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM16URY DI DM16URY DM16URY DN PMID28270021-Compound-WO2015042088Example11 DM16URY TI TTTDVOJ DM16URY TN Tropomyosin-related kinase A (TrkA) DM16URY MA Inhibitor DM16URY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM16URY RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM17D30 DI DM17D30 DM17D30 DN 3-phenyl propanoic derivative 2 DM17D30 TI TTA6ZN2 DM17D30 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM17D30 MA Inhibitor DM17D30 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM17D30 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM17D30 DI DM17D30 DM17D30 DN 3-phenyl propanoic derivative 2 DM17D30 TI TTHQJI6 DM17D30 TN Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE) DM17D30 MA Modulator DM17D30 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM17D30 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM17FKL DI DM17FKL DM17FKL DN PMID25416646-Compound-Figure5-C DM17FKL TI TT2JWF6 DM17FKL TN Peroxisome proliferator-activated receptor delta (PPARD) DM17FKL MA Agonist DM17FKL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM17FKL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM17FKL DI DM17FKL DM17FKL DN PMID25416646-Compound-Figure5-C DM17FKL TI TTZMAO3 DM17FKL TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM17FKL MA Agonist DM17FKL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM17FKL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM17KL2 DI DM17KL2 DM17KL2 DN PMID27454349-Compound-95 DM17KL2 TI TTK59TV DM17KL2 TN Vitamin D3 receptor (VDR) DM17KL2 MA Agonist DM17KL2 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DM17KL2 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TTHS0U8 DM17P3F TN Stress-activated protein kinase JNK2 (JNK2) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TT0K6EO DM17P3F TN Stress-activated protein kinase JNK1 (JNK1) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TT056SO DM17P3F TN Stress-activated protein kinase JNK3 (JNK3) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17YHP DI DM17YHP DM17YHP DN US9132129, Cpd047 DM17YHP TI TTH9LDP DM17YHP TN PC4 and SFRS1-interacting protein (PSIP1) DM17YHP MA Inhibitor DM17YHP RN Antiviral compounds. US9132129. DM17YHP RU http://www.freepatentsonline.com/US9132129.html DM189D7 DI DM189D7 DM189D7 DN Lazabemide analog 1 DM189D7 TI TTGP7BY DM189D7 TN Monoamine oxidase type B (MAO-B) DM189D7 MA Inhibitor DM189D7 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM189D7 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM18DY6 DI DM18DY6 DM18DY6 DN PMID28092474-Compound-33g DM18DY6 TI TT5ZKDI DM18DY6 TN Histone deacetylase 6 (HDAC6) DM18DY6 MA Inhibitor DM18DY6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM18DY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM18DY6 DI DM18DY6 DM18DY6 DN PMID28092474-Compound-33g DM18DY6 TI TT6R7JZ DM18DY6 TN Histone deacetylase 1 (HDAC1) DM18DY6 MA Inhibitor DM18DY6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM18DY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM18FP4 DI DM18FP4 DM18FP4 DN PMID25399762-Compound-Table 5-O-methyl-M30 DM18FP4 TI TT3WG5C DM18FP4 TN Monoamine oxidase type A (MAO-A) DM18FP4 MA Inhibitor DM18FP4 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM18FP4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM18LO7 DI DM18LO7 DM18LO7 DN PMID28074661-Compound-US20100022547C83 DM18LO7 TI TTL7C8Q DM18LO7 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM18LO7 MA Inhibitor DM18LO7 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM18LO7 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM18P4N DI DM18P4N DM18P4N DN Imidazo triazine derivative 5 DM18P4N TI TTJGW1Z DM18P4N TN Phosphodiesterase 2A (PDE2A) DM18P4N MA Inhibitor DM18P4N RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM18P4N RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM18PRU DI DM18PRU DM18PRU DN PMID28074661-Compound-US20120264760C82 DM18PRU TI TTL7C8Q DM18PRU TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM18PRU MA Inhibitor DM18PRU RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM18PRU RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTL53M6 DM18UA5 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTU1E82 DM18UA5 TN Apoptosis regulator Bcl-xL (BCL-xL) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTJGNVC DM18UA5 TN Apoptosis regulator Bcl-2 (BCL-2) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM198BY DI DM198BY DM198BY DN Palmarumycin derivative 3 DM198BY TI TTR7UJ3 DM198BY TN Cytoplasmic thioredoxin reductase (TXNRD1) DM198BY MA Inhibitor DM198BY RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM198BY RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM19BQ6 DI DM19BQ6 DM19BQ6 DN PMID28048944-Compound-20 DM19BQ6 TI TTZN7RP DM19BQ6 TN Rho-associated protein kinase 1 (ROCK1) DM19BQ6 MA Inhibitor DM19BQ6 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM19BQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM19GAY DI DM19GAY DM19GAY DN STK696827 DM19GAY TI TT1NFO3 DM19GAY TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM19GAY MA Inhibitor DM19GAY RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM19GAY RU http://www.freepatentsonline.com/US8785499.html DM1A0GT DI DM1A0GT DM1A0GT DN PMID25666693-Compound-65 DM1A0GT TI TTMI6F5 DM1A0GT TN Transient receptor potential cation channel V1 (TRPV1) DM1A0GT MA Antagonist DM1A0GT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1A0GT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TTRMX3V DM1A0VB TN Janus kinase 2 (JAK-2) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TTT7PJU DM1A0VB TN Janus kinase 3 (JAK-3) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TT6DM01 DM1A0VB TN Janus kinase 1 (JAK-1) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0WU DI DM1A0WU DM1A0WU DN Cyclohexane carboxamide derivative 2 DM1A0WU TI TTTJZ4M DM1A0WU TN Prolylcarboxypeptidase (PRCP) DM1A0WU MA Inhibitor DM1A0WU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM1A0WU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM1AGSD DI DM1AGSD DM1AGSD DN Tetrazole derivative 1 DM1AGSD TI TT473XN DM1AGSD TN P2X purinoceptor 7 (P2RX7) DM1AGSD MA Antagonist DM1AGSD RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1AGSD RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1B74D DI DM1B74D DM1B74D DN Oxazolo[3,4-a]pyrazine derivative 4 DM1B74D TI TTV1C0Z DM1B74D TN Neuropeptide S receptor (NPSR) DM1B74D MA Antagonist DM1B74D RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM1B74D RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM1BIY4 DI DM1BIY4 DM1BIY4 DN Phenylmethanesulfonamide derivative 1 DM1BIY4 TI TTJOW1I DM1BIY4 TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DM1BIY4 MA Inhibitor DM1BIY4 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM1BIY4 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM1BN74 DI DM1BN74 DM1BN74 DN PMID28048944-Compound-3 DM1BN74 TI TTZN7RP DM1BN74 TN Rho-associated protein kinase 1 (ROCK1) DM1BN74 MA Inhibitor DM1BN74 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM1BN74 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM1BN74 DI DM1BN74 DM1BN74 DN PMID28048944-Compound-3 DM1BN74 TI TTGWKQJ DM1BN74 TN Rho-associated protein kinase 2 (ROCK2) DM1BN74 MA Inhibitor DM1BN74 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM1BN74 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM1C8MA DI DM1C8MA DM1C8MA DN Thieno[3,2-c]pyridine-7-carboxamide derivative 1 DM1C8MA TI TTCZOF2 DM1C8MA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM1C8MA MA Inhibitor DM1C8MA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM1C8MA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTT7PJU DM1CM7S TN Janus kinase 3 (JAK-3) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTRMX3V DM1CM7S TN Janus kinase 2 (JAK-2) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTBYWP2 DM1CM7S TN TYK2 tyrosine kinase (TYK2) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TT6DM01 DM1CM7S TN Janus kinase 1 (JAK-1) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CNRH DI DM1CNRH DM1CNRH DN Indole-based analog 12 DM1CNRH TI TTMBO1Z DM1CNRH TN Cyclin-dependent kinase (CDK) DM1CNRH MA Inhibitor DM1CNRH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM1CNRH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM1CWU7 DI DM1CWU7 DM1CWU7 DN Heteroaryl-carboxamide derivative 11 DM1CWU7 TI TT5L2VC DM1CWU7 TN Kallikrein-related peptidase (KLK) DM1CWU7 MA Inhibitor DM1CWU7 RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM1CWU7 RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TT0K1SC DM1D2AS TN 5-HT 2B receptor (HTR2B) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TTWJBZ5 DM1D2AS TN 5-HT 2C receptor (HTR2C) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TTJQOD7 DM1D2AS TN 5-HT 2A receptor (HTR2A) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D7CE DI DM1D7CE DM1D7CE DN Peptide analog 51 DM1D7CE TI TTDIGC1 DM1D7CE TN Dipeptidyl peptidase 4 (DPP-4) DM1D7CE MA Inhibitor DM1D7CE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM1D7CE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM1DN6V DI DM1DN6V DM1DN6V DN PMID28092474-Compound-33h DM1DN6V TI TT5ZKDI DM1DN6V TN Histone deacetylase 6 (HDAC6) DM1DN6V MA Inhibitor DM1DN6V RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM1DN6V RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM1DN6V DI DM1DN6V DM1DN6V DN PMID28092474-Compound-33h DM1DN6V TI TT6R7JZ DM1DN6V TN Histone deacetylase 1 (HDAC1) DM1DN6V MA Inhibitor DM1DN6V RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM1DN6V RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM1DN94 DI DM1DN94 DM1DN94 DN Carboxamide derivative 11 DM1DN94 TI TTG5QB7 DM1DN94 TN Calpain-2 (CAPN2) DM1DN94 MA Inhibitor DM1DN94 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM1DN94 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM1DXME DI DM1DXME DM1DXME DN Benzimidazole derivative 17 DM1DXME TI TTYLQ8V DM1DXME TN Prostaglandin E synthase (PTGES) DM1DXME MA Inhibitor DM1DXME RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM1DXME RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM1EU06 DI DM1EU06 DM1EU06 DN PMID25980951-Compound-45 DM1EU06 TI TTR7B60 DM1EU06 TN X-linked inhibitor of apoptosis protein (XIAP) DM1EU06 MA Antagonist DM1EU06 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM1EU06 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM1FTV6 DI DM1FTV6 DM1FTV6 DN PMID25666693-Compound-153 DM1FTV6 TI TTMI6F5 DM1FTV6 TN Transient receptor potential cation channel V1 (TRPV1) DM1FTV6 MA Antagonist DM1FTV6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1FTV6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1FUOY DI DM1FUOY DM1FUOY DN amidepsines DM1FUOY TI TTF8P9I DM1FUOY TN Diacylglycerol acyltransferase 1 (DGAT1) DM1FUOY MA Inhibitor DM1FUOY RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM1FUOY RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM1G2J5 DI DM1G2J5 DM1G2J5 DN Peptide analog 64 DM1G2J5 TI TTPLTSQ DM1G2J5 TN Neutrophil elastase (NE) DM1G2J5 MA Inhibitor DM1G2J5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM1G2J5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM1G6AE DI DM1G6AE DM1G6AE DN PMID25666693-Compound-15 DM1G6AE TI TTMI6F5 DM1G6AE TN Transient receptor potential cation channel V1 (TRPV1) DM1G6AE MA Antagonist DM1G6AE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1G6AE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1G7KI DI DM1G7KI DM1G7KI DN Aryl urea derivative 3 DM1G7KI TI TTDP1UC DM1G7KI TN Fatty acid amide hydrolase (FAAH) DM1G7KI MA Inhibitor DM1G7KI RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM1G7KI RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM1G8SM DI DM1G8SM DM1G8SM DN Isoxazole-based bicyclic compound 11 DM1G8SM TI TTE4BSY DM1G8SM TN Bromodomain and extraterminal domain protein (BET) DM1G8SM MA Inhibitor DM1G8SM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM1G8SM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM1GYZQ DI DM1GYZQ DM1GYZQ DN Pyrrolo[2,3-d]pyrimidine derivative 16 DM1GYZQ TI TTGM6VW DM1GYZQ TN Tyrosine-protein kinase BTK (ATK) DM1GYZQ MA Inhibitor DM1GYZQ RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM1GYZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM1HAGJ DI DM1HAGJ DM1HAGJ DN PMID26815044-Compound-122 DM1HAGJ TI TTULVH8 DM1HAGJ TN Tyrosinase (TYR) DM1HAGJ MA Inhibitor DM1HAGJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM1HAGJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM1HI8Q DI DM1HI8Q DM1HI8Q DN Hydrazide derivative 4 DM1HI8Q TI TTK0FEA DM1HI8Q TN Leucine-rich repeat kinase 2 (LRRK2) DM1HI8Q MA Inhibitor DM1HI8Q RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM1HI8Q RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM1HIEZ DI DM1HIEZ DM1HIEZ DN PMID26394986-Compound-43 DM1HIEZ TI TTH8FZW DM1HIEZ TN Signal transducer and activator of transcription 3 (STAT3) DM1HIEZ MA Inhibitor DM1HIEZ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM1HIEZ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM1HPY7 DI DM1HPY7 DM1HPY7 DN PMID27841036-Compound-XI DM1HPY7 TI TTEBCY8 DM1HPY7 TN Poly [ADP-ribose] polymerase (PARP) DM1HPY7 MA Inhibitor DM1HPY7 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1HPY7 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1HYW4 DI DM1HYW4 DM1HYW4 DN Phenylsulfonyl derivative 4 DM1HYW4 TI TT9JNIC DM1HYW4 TN Histamine H3 receptor (H3R) DM1HYW4 MA Inhibitor DM1HYW4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM1HYW4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM1I7Z6 DI DM1I7Z6 DM1I7Z6 DN Pyrimidinone derivative 1 DM1I7Z6 TI TTCZOF2 DM1I7Z6 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM1I7Z6 MA Inhibitor DM1I7Z6 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM1I7Z6 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM1I9JC DI DM1I9JC DM1I9JC DN PMID28454500-Compound-60 DM1I9JC TI TTA6ZN2 DM1I9JC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1I9JC MA Inhibitor DM1I9JC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1I9JC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1I9JC DI DM1I9JC DM1I9JC DN PMID28454500-Compound-60 DM1I9JC TI TTGIZLN DM1I9JC TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DM1I9JC MA Modulator DM1I9JC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1I9JC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1J2V8 DI DM1J2V8 DM1J2V8 DN PMID27539678-Compound-13 DM1J2V8 TI TTOHFIY DM1J2V8 TN Sphingosine kinase 1 (SPHK1) DM1J2V8 MA Inhibitor DM1J2V8 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM1J2V8 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM1J3LE DI DM1J3LE DM1J3LE DN PMID25980951-Compound-16 DM1J3LE TI TTQ5LRD DM1J3LE TN Cellular inhibitor of apoptosis 1 (BIRC2) DM1J3LE MA Antagonist DM1J3LE RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM1J3LE RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM1JAFV DI DM1JAFV DM1JAFV DN PMID25522065-Compound-35 DM1JAFV TI TTX4RTB DM1JAFV TN Melanin-concentrating hormone receptor 1 (MCHR1) DM1JAFV MA Antagonist DM1JAFV RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM1JAFV RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTDZN01 DM1JOZN TN Cathepsin K (CTSK) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TT36ETB DM1JOZN TN Cathepsin L (CTSL) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTF2LRI DM1JOZN TN Cathepsin B (CTSB) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTUMQVO DM1JOZN TN Cathepsin S (CTSS) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JXKY DI DM1JXKY DM1JXKY DN Imidazo isoindole derivative 1 DM1JXKY TI TTZJYKH DM1JXKY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1JXKY MA Inhibitor DM1JXKY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1JXKY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1JYNW DI DM1JYNW DM1JYNW DN Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW TI TTTDVOJ DM1JYNW TN Tropomyosin-related kinase A (TrkA) DM1JYNW MA Inhibitor DM1JYNW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1JYNW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1JYNW DI DM1JYNW DM1JYNW DN Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW TI TTSZ6Y3 DM1JYNW TN Proto-oncogene c-Ros (ROS1) DM1JYNW MA Inhibitor DM1JYNW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1JYNW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1K5HS DI DM1K5HS DM1K5HS DN US8592431, 185 DM1K5HS TI TTLJKZ0 DM1K5HS TN Acetyl-CoA transporter (SLC33A1) DM1K5HS MA Inhibitor DM1K5HS RN Fused ring compound and use thereof. US8592431. DM1K5HS RU http://www.freepatentsonline.com/US8592431.html DM1K5T0 DI DM1K5T0 DM1K5T0 DN US9156852, 83 DM1K5T0 TI TTI1FPZ DM1K5T0 TN Epithelial discoidin domain receptor 1 (DDR1) DM1K5T0 MA Inhibitor DM1K5T0 RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DM1K5T0 RU http://www.freepatentsonline.com/US9156852.html DM1KBSV DI DM1KBSV DM1KBSV DN Macrocycle derivative 13 DM1KBSV TI TTKN7QR DM1KBSV TN BDNF/NT-3 growth factors receptor (TrkB) DM1KBSV MA Inhibitor DM1KBSV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1KBSV RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1KHGY DI DM1KHGY DM1KHGY DN Triazolo-pyrazinone derivative 1 DM1KHGY TI TT473XN DM1KHGY TN P2X purinoceptor 7 (P2RX7) DM1KHGY MA Antagonist DM1KHGY RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1KHGY RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1KJAQ DI DM1KJAQ DM1KJAQ DN PMID27841036-Compound-38 DM1KJAQ TI TTEBCY8 DM1KJAQ TN Poly [ADP-ribose] polymerase (PARP) DM1KJAQ MA Inhibitor DM1KJAQ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1KJAQ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1KT4I DI DM1KT4I DM1KT4I DN Hexahydro naphthalene derivative 3 DM1KT4I TI TTPADOQ DM1KT4I TN HMG-CoA reductase (HMGCR) DM1KT4I MA Inhibitor DM1KT4I RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM1KT4I RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM1KVTZ DI DM1KVTZ DM1KVTZ DN Bicarboxylic and tricarboxylic ethynyl derivative 3 DM1KVTZ TI TTHS256 DM1KVTZ TN Metabotropic glutamate receptor 5 (mGluR5) DM1KVTZ MA Modulator DM1KVTZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM1KVTZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM1L3ZA DI DM1L3ZA DM1L3ZA DN Thiadiazolidindione derivative 1 DM1L3ZA TI TTRZQE3 DM1L3ZA TN Glycogen synthase kinase-3 alpha (GSK-3A) DM1L3ZA MA Inhibitor DM1L3ZA RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM1L3ZA RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM1LIRP DI DM1LIRP DM1LIRP DN PMID26651364-Compound-112 DM1LIRP TI TTTCRU2 DM1LIRP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1LIRP MA Antagonist DM1LIRP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1LIRP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1LPKH DI DM1LPKH DM1LPKH DN Oxazolo[3,4-a]pyrazine derivative 3 DM1LPKH TI TTV1C0Z DM1LPKH TN Neuropeptide S receptor (NPSR) DM1LPKH MA Antagonist DM1LPKH RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM1LPKH RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM1M3WF DI DM1M3WF DM1M3WF DN PMID26651364-Compound-8a DM1M3WF TI TTTCRU2 DM1M3WF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1M3WF MA Antagonist DM1M3WF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1M3WF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1MQ7J DI DM1MQ7J DM1MQ7J DN US8710232, 8 DM1MQ7J TI TT4UJX5 DM1MQ7J TN Carboxypeptidase B1 (CPB1) DM1MQ7J MA Inhibitor DM1MQ7J RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DM1MQ7J RU http://www.freepatentsonline.com/US8710232.html DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TTJUALD DM1MVQD TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TT6VZ78 DM1MVQD TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TT6S2FE DM1MVQD TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MZ70 DI DM1MZ70 DM1MZ70 DN PMID25666693-Compound-82 DM1MZ70 TI TTMI6F5 DM1MZ70 TN Transient receptor potential cation channel V1 (TRPV1) DM1MZ70 MA Antagonist DM1MZ70 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1MZ70 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1N5UH DI DM1N5UH DM1N5UH DN PMID25522065-Compound-22 DM1N5UH TI TTX4RTB DM1N5UH TN Melanin-concentrating hormone receptor 1 (MCHR1) DM1N5UH MA Antagonist DM1N5UH RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM1N5UH RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM1N74R DI DM1N74R DM1N74R DN US8586571, 6 DM1N74R TI TT0C8BY DM1N74R TN Plasma retinol-binding protein (RBP4) DM1N74R MA Inhibitor DM1N74R RN Heterocyclic compound. US8586571. DM1N74R RU http://www.freepatentsonline.com/US8586571.html DM1NJ3U DI DM1NJ3U DM1NJ3U DN PMID29338548-Compound-49 DM1NJ3U TI TTHJTF7 DM1NJ3U TN Glycine transporter GlyT-1 (SLC6A9) DM1NJ3U MA Inhibitor DM1NJ3U RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM1NJ3U RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM1NMR6 DI DM1NMR6 DM1NMR6 DN Peptide analog 29 DM1NMR6 TI TTSJMN8 DM1NMR6 TN Immunoproteasome complex (IP) DM1NMR6 MA Inhibitor DM1NMR6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM1NMR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM1PU37 DI DM1PU37 DM1PU37 DN BDBM50173330 DM1PU37 TI TTTCXO0 DM1PU37 TN G protein-coupled receptor kinase 5 (GRK5) DM1PU37 MA Inhibitor DM1PU37 RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DM1PU37 RU http://www.freepatentsonline.com/US10023564.html DM1Q7AL DI DM1Q7AL DM1Q7AL DN Biaryl mannoside derivative 9 DM1Q7AL TI TTTCRU2 DM1Q7AL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1Q7AL MA Antagonist DM1Q7AL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1Q7AL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1QH8Z DI DM1QH8Z DM1QH8Z DN Five-membered heteroaromatic compound 2 DM1QH8Z TI TTZJYKH DM1QH8Z TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1QH8Z MA Inhibitor DM1QH8Z RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1QH8Z RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1QHV0 DI DM1QHV0 DM1QHV0 DN PMID28870136-Compound-45 DM1QHV0 TI TTK0O6Y DM1QHV0 TN Ecto-5'-nucleotidase (CD73) DM1QHV0 MA Inhibitor DM1QHV0 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM1QHV0 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM1QUN0 DI DM1QUN0 DM1QUN0 DN PMID28074661-Compound-US20158969342C84 DM1QUN0 TI TTL7C8Q DM1QUN0 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM1QUN0 MA Inhibitor DM1QUN0 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM1QUN0 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM1R0FJ DI DM1R0FJ DM1R0FJ DN Dihydrodiazepinocarbazolone derivative 2 DM1R0FJ TI TTEBCY8 DM1R0FJ TN Poly [ADP-ribose] polymerase (PARP) DM1R0FJ MA Inhibitor DM1R0FJ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1R0FJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1R205 DI DM1R205 DM1R205 DN Triazolo-pyridine derivative 5 DM1R205 TI TTJW4LU DM1R205 TN Phosphodiesterase 10A (PDE10) DM1R205 MA Inhibitor DM1R205 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM1R205 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM1R205 DI DM1R205 DM1R205 DN Triazolo-pyridine derivative 5 DM1R205 TI TTJGW1Z DM1R205 TN Phosphodiesterase 2A (PDE2A) DM1R205 MA Inhibitor DM1R205 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM1R205 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM1R6GA DI DM1R6GA DM1R6GA DN PMID27019002-Compound-28 DM1R6GA TI TTNR0UQ DM1R6GA TN Lysine-specific histone demethylase 1 (LSD) DM1R6GA MA Inhibitor DM1R6GA RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM1R6GA RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM1RN89 DI DM1RN89 DM1RN89 DN PMID28051882-Compound-XIV DM1RN89 TI TT9NXW4 DM1RN89 TN Sigma intracellular receptor 2 (TMEM97) DM1RN89 MA Ligand DM1RN89 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM1RN89 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM1RN89 DI DM1RN89 DM1RN89 DN PMID28051882-Compound-XIV DM1RN89 TI TT5TPI6 DM1RN89 TN Opioid receptor sigma 1 (OPRS1) DM1RN89 MA Ligand DM1RN89 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM1RN89 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTSHTOI DM1RPL4 TN Histone deacetylase 2 (HDAC2) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT4YWTO DM1RPL4 TN Histone deacetylase 3 (HDAC3) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT5ZKDI DM1RPL4 TN Histone deacetylase 6 (HDAC6) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT6R7JZ DM1RPL4 TN Histone deacetylase 1 (HDAC1) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTTQGH8 DM1RPL4 TN Histone deacetylase 4 (HDAC4) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTMUEK1 DM1RPL4 TN Histone deacetylase 7 (HDAC7) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTUELN5 DM1RPL4 TN Histone deacetylase 5 (HDAC5) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTT6LFV DM1RPL4 TN Histone deacetylase 8 (HDAC8) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RQIU DI DM1RQIU DM1RQIU DN Aminobenzoxazole analog 1 DM1RQIU TI TT473XN DM1RQIU TN P2X purinoceptor 7 (P2RX7) DM1RQIU MA Antagonist DM1RQIU RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1RQIU RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1RS4X DI DM1RS4X DM1RS4X DN PMID28454500-Compound-92 DM1RS4X TI TTA6ZN2 DM1RS4X TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1RS4X MA Inhibitor DM1RS4X RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1RS4X RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1SH5R DI DM1SH5R DM1SH5R DN Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R TI TTDZN01 DM1SH5R TN Cathepsin K (CTSK) DM1SH5R MA Inhibitor DM1SH5R RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1SH5R RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1SH5R DI DM1SH5R DM1SH5R DN Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R TI TTUMQVO DM1SH5R TN Cathepsin S (CTSS) DM1SH5R MA Inhibitor DM1SH5R RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1SH5R RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTWFZ1N DM1STAD TN Dopamine receptor (DR) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTJQOD7 DM1STAD TN 5-HT 2A receptor (HTR2A) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTEX248 DM1STAD TN Dopamine D2 receptor (D2R) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1SWYU DI DM1SWYU DM1SWYU DN PMID29334795-Compound-28 DM1SWYU TI TT9JNIC DM1SWYU TN Histamine H3 receptor (H3R) DM1SWYU RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM1SWYU RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM1TCBQ DI DM1TCBQ DM1TCBQ DN PMID30107136-Compound-Example47 DM1TCBQ TI TT23XQV DM1TCBQ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM1TCBQ MA Inhibitor DM1TCBQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM1TCBQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM1TV6F DI DM1TV6F DM1TV6F DN Aryl mannoside derivative 1 DM1TV6F TI TTTCRU2 DM1TV6F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1TV6F MA Antagonist DM1TV6F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1TV6F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1U6H2 DI DM1U6H2 DM1U6H2 DN PMID29865878-Compound-64 DM1U6H2 TI TTEAD9J DM1U6H2 TN Proteasome beta-8 (PS beta-8) DM1U6H2 MA Inhibitor DM1U6H2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM1U6H2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM1VHYX DI DM1VHYX DM1VHYX DN PMID25991433-Compound-E4 DM1VHYX TI TT0K6EO DM1VHYX TN Stress-activated protein kinase JNK1 (JNK1) DM1VHYX MA Inhibitor DM1VHYX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM1VHYX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM1VOPH DI DM1VOPH DM1VOPH DN PMID27774824-Compound-Figure8Example99 DM1VOPH TI TTRMX3V DM1VOPH TN Janus kinase 2 (JAK-2) DM1VOPH MA Inhibitor DM1VOPH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1VOPH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1VPLU DI DM1VPLU DM1VPLU DN US10150740, Example 9 DM1VPLU TI TTQFZWR DM1VPLU TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DM1VPLU MA Inhibitor DM1VPLU RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DM1VPLU RU http://www.freepatentsonline.com/US10150740.html DM1VYZ9 DI DM1VYZ9 DM1VYZ9 DN Biphenyl 1,2-diamine derivative 1 DM1VYZ9 TI TTZJYKH DM1VYZ9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1VYZ9 MA Modulator DM1VYZ9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1VYZ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1W02D DI DM1W02D DM1W02D DN Tricyclic heterocycle derivative 2 DM1W02D TI TTRMX3V DM1W02D TN Janus kinase 2 (JAK-2) DM1W02D MA Inhibitor DM1W02D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1W02D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1W02D DI DM1W02D DM1W02D DN Tricyclic heterocycle derivative 2 DM1W02D TI TTT7PJU DM1W02D TN Janus kinase 3 (JAK-3) DM1W02D MA Inhibitor DM1W02D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1W02D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1XUVB DI DM1XUVB DM1XUVB DN Piperazine derivative 8 DM1XUVB TI TTSCIM2 DM1XUVB TN Extracellular lysophospholipase D (E-NPP2) DM1XUVB RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM1XUVB RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM1Y8OM DI DM1Y8OM DM1Y8OM DN Biaryl mannoside derivative 13 DM1Y8OM TI TTTCRU2 DM1Y8OM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1Y8OM MA Antagonist DM1Y8OM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1Y8OM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1ZFC9 DI DM1ZFC9 DM1ZFC9 DN PMID28454500-Compound-11 DM1ZFC9 TI TTA6ZN2 DM1ZFC9 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1ZFC9 MA Activator DM1ZFC9 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1ZFC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1ZFC9 DI DM1ZFC9 DM1ZFC9 DN PMID28454500-Compound-11 DM1ZFC9 TI TT3Z6Y9 DM1ZFC9 TN Cysteines of Keap1 (KEAP1 Cysteines) DM1ZFC9 MA Modulator DM1ZFC9 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1ZFC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1ZIPN DI DM1ZIPN DM1ZIPN DN Cyclic octapeptide derivative 1 DM1ZIPN TI TTUX68I DM1ZIPN TN Hypoxia-inducible factor 1 (HIF-1) DM1ZIPN MA Inhibitor DM1ZIPN RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM1ZIPN RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM1ZK7E DI DM1ZK7E DM1ZK7E DN Ketoheterocycle derivative 1 DM1ZK7E TI TTDP1UC DM1ZK7E TN Fatty acid amide hydrolase (FAAH) DM1ZK7E MA Inhibitor DM1ZK7E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM1ZK7E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM1ZSEI DI DM1ZSEI DM1ZSEI DN PMID26560530-Compound-15 DM1ZSEI TI TT2F4OL DM1ZSEI TN Tissue transglutaminase (TG2) DM1ZSEI MA Inhibitor DM1ZSEI RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM1ZSEI RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM20YBJ DI DM20YBJ DM20YBJ DN Indoline derivative 3 DM20YBJ TI TT5OU0D DM20YBJ TN PRKR-like endoplasmic reticulum kinase (PERK) DM20YBJ MA Inhibitor DM20YBJ RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM20YBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TTQBR95 DM2135Y TN Stress-activated protein kinase 2a (p38 alpha) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TT3ZIJL DM2135Y TN JNK-interacting protein peptide (pepJIP) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TT0K6EO DM2135Y TN Stress-activated protein kinase JNK1 (JNK1) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM214WA DI DM214WA DM214WA DN PMID27744724-Compound-19 DM214WA TI TTL53M6 DM214WA TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM214WA MA Inhibitor DM214WA RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM214WA RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM21J83 DI DM21J83 DM21J83 DN Tetra-hydro-oxazolopyridine derivative 4 DM21J83 TI TTHS256 DM21J83 TN Metabotropic glutamate receptor 5 (mGluR5) DM21J83 MA Modulator DM21J83 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM21J83 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM21QCE DI DM21QCE DM21QCE DN PMID29473428-Compound-16 DM21QCE TI TTZJYKH DM21QCE TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM21QCE RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM21QCE RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM21S5G DI DM21S5G DM21S5G DN Piperidinyl pyrazole derivative 2 DM21S5G TI TTTJZ4M DM21S5G TN Prolylcarboxypeptidase (PRCP) DM21S5G MA Inhibitor DM21S5G RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM21S5G RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM231WS DI DM231WS DM231WS DN P-coumaric acid derivative 1 DM231WS TI TTULVH8 DM231WS TN Tyrosinase (TYR) DM231WS MA Inhibitor DM231WS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM231WS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM23NEX DI DM23NEX DM23NEX DN PMID25399762-Compound-Figure1-Aphanamixoid A DM23NEX TI TT3WG5C DM23NEX TN Monoamine oxidase type A (MAO-A) DM23NEX MA Inhibitor DM23NEX RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM23NEX RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM23XQL DI DM23XQL DM23XQL DN Di-substituted piperidine derivative 2 DM23XQL TI TTEB0GD DM23XQL TN Cholinesterase (BCHE) DM23XQL MA Inhibitor DM23XQL RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM23XQL RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM23XQL DI DM23XQL DM23XQL DN Di-substituted piperidine derivative 2 DM23XQL TI TT1RS9F DM23XQL TN Acetylcholinesterase (AChE) DM23XQL MA Inhibitor DM23XQL RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM23XQL RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM249KU DI DM249KU DM249KU DN Benzodihydroisofuran derivative 1 DM249KU TI TTTJZ4M DM249KU TN Prolylcarboxypeptidase (PRCP) DM249KU MA Inhibitor DM249KU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM249KU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM24FSP DI DM24FSP DM24FSP DN PMID27109571-Compound-30 DM24FSP TI TTNT2S6 DM24FSP TN Fatty acid-binding protein 5 (FABP5) DM24FSP MA Inhibitor DM24FSP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM24FSP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM24FSP DI DM24FSP DM24FSP DN PMID27109571-Compound-30 DM24FSP TI TTHWMFZ DM24FSP TN Fatty acid-binding protein 4 (FABP4) DM24FSP MA Inhibitor DM24FSP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM24FSP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM24NZG DI DM24NZG DM24NZG DN Benzothiazepine analog 3 DM24NZG TI TTPTXIN DM24NZG TN Translocator protein (TSPO) DM24NZG MA Ligand DM24NZG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM24NZG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM251GL DI DM251GL DM251GL DN Aryl mannoside derivative 10 DM251GL TI TTTCRU2 DM251GL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM251GL MA Antagonist DM251GL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM251GL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM25BNZ DI DM25BNZ DM25BNZ DN PMID27998201-Compound-24 DM25BNZ TI TTF2LRI DM25BNZ TN Cathepsin B (CTSB) DM25BNZ MA Inhibitor DM25BNZ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM25BNZ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM25IMA DI DM25IMA DM25IMA DN Fused heterocyclic compound 9 DM25IMA TI TT7RJY8 DM25IMA TN Xanthine dehydrogenase/oxidase (XDH) DM25IMA MA Inhibitor DM25IMA RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM25IMA RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM25M8D DI DM25M8D DM25M8D DN Pyridine-carboximide derivative 1 DM25M8D TI TTF8P9I DM25M8D TN Diacylglycerol acyltransferase 1 (DGAT1) DM25M8D MA Inhibitor DM25M8D RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM25M8D RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM25PMQ DI DM25PMQ DM25PMQ DN PMID28394193-Compound-38 DM25PMQ TI TT9MZCQ DM25PMQ TN Enhancer of zeste homolog 2 (EZH2) DM25PMQ MA Inhibitor DM25PMQ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM25PMQ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM25WGP DI DM25WGP DM25WGP DN PMID26815044-Compound-124 DM25WGP TI TTULVH8 DM25WGP TN Tyrosinase (TYR) DM25WGP MA Inhibitor DM25WGP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM25WGP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM25ZY4 DI DM25ZY4 DM25ZY4 DN Benzothiazepine analog 7 DM25ZY4 TI TTPTXIN DM25ZY4 TN Translocator protein (TSPO) DM25ZY4 MA Ligand DM25ZY4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM25ZY4 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM26IRH DI DM26IRH DM26IRH DN PMID29649907-Compound-41 DM26IRH TI TTS4UGC DM26IRH TN Farnesoid X-activated receptor (FXR) DM26IRH MA Agonist DM26IRH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM26IRH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM26NQE DI DM26NQE DM26NQE DN PMID25666693-Compound-90 DM26NQE TI TTMI6F5 DM26NQE TN Transient receptor potential cation channel V1 (TRPV1) DM26NQE MA Antagonist DM26NQE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM26NQE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM26WNY DI DM26WNY DM26WNY DN PMID28870136-Compound-63 DM26WNY TI TTK0O6Y DM26WNY TN Ecto-5'-nucleotidase (CD73) DM26WNY MA Inhibitor DM26WNY RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM26WNY RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM27154 DI DM27154 DM27154 DN PMID25666693-Compound-152 DM27154 TI TTMI6F5 DM27154 TN Transient receptor potential cation channel V1 (TRPV1) DM27154 MA Antagonist DM27154 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM27154 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM27DQP DI DM27DQP DM27DQP DN PMID25726713-Compound-46 DM27DQP TI TT8J1S3 DM27DQP TN Smoothened homolog (SMO) DM27DQP MA Inhibitor DM27DQP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM27DQP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM27SFD DI DM27SFD DM27SFD DN US10034861, Example 164 DM27SFD TI TT3ZS42 DM27SFD TN Phosphodiesterase 1B (PDE1B) DM27SFD MA Inhibitor DM27SFD RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DM27SFD RU http://www.freepatentsonline.com/US10034861.html DM27U1F DI DM27U1F DM27U1F DN PMID25435285-Compound-22 DM27U1F TI TT8A9EF DM27U1F TN Metabotropic glutamate receptor 3 (mGluR3) DM27U1F MA Antagonist DM27U1F RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM27U1F RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM27U1F DI DM27U1F DM27U1F DN PMID25435285-Compound-22 DM27U1F TI TTXJ47W DM27U1F TN Metabotropic glutamate receptor 2 (mGluR2) DM27U1F MA Antagonist DM27U1F RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM27U1F RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM28E0A DI DM28E0A DM28E0A DN Oxazolo[3,4-a]pyrazine derivative 2 DM28E0A TI TTV1C0Z DM28E0A TN Neuropeptide S receptor (NPSR) DM28E0A MA Antagonist DM28E0A RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM28E0A RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM28NK0 DI DM28NK0 DM28NK0 DN Peptide analog 62 DM28NK0 TI TTQAJF1 DM28NK0 TN Cathepsin G (CTSG) DM28NK0 MA Inhibitor DM28NK0 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM28NK0 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM28NK0 DI DM28NK0 DM28NK0 DN Peptide analog 62 DM28NK0 TI TTPLTSQ DM28NK0 TN Neutrophil elastase (NE) DM28NK0 MA Inhibitor DM28NK0 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM28NK0 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM28XHN DI DM28XHN DM28XHN DN US10035778, Example 1 DM28XHN TI TTIF29E DM28XHN TN Integrin beta-8 (ITGB8) DM28XHN MA Inhibitor DM28XHN RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DM28XHN RU http://www.freepatentsonline.com/US10035778.html DM29KS1 DI DM29KS1 DM29KS1 DN US8592431, 181 DM29KS1 TI TTLJKZ0 DM29KS1 TN Acetyl-CoA transporter (SLC33A1) DM29KS1 MA Inhibitor DM29KS1 RN Fused ring compound and use thereof. US8592431. DM29KS1 RU http://www.freepatentsonline.com/US8592431.html DM2A75P DI DM2A75P DM2A75P DN PMID28454500-Compound-96 DM2A75P TI TTA6ZN2 DM2A75P TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM2A75P MA Inhibitor DM2A75P RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2A75P RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2ANJ7 DI DM2ANJ7 DM2ANJ7 DN PMID26666989-Compound-Figure9middle02 DM2ANJ7 TI TT8BUGW DM2ANJ7 TN Glycogen phosphorylase (PYG) DM2ANJ7 MA Inhibitor DM2ANJ7 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM2ANJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM2AVEG DI DM2AVEG DM2AVEG DN PMID27841045-Compound-130 DM2AVEG TI TT7RJY8 DM2AVEG TN Xanthine dehydrogenase/oxidase (XDH) DM2AVEG MA Inhibitor DM2AVEG RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2AVEG RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2BLJ6 DI DM2BLJ6 DM2BLJ6 DN Central azetidine derivative 2 DM2BLJ6 TI TTHS256 DM2BLJ6 TN Metabotropic glutamate receptor 5 (mGluR5) DM2BLJ6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2BLJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2BM1L DI DM2BM1L DM2BM1L DN Heteroaryl-substituted urea derivative 1 DM2BM1L TI TTDP1UC DM2BM1L TN Fatty acid amide hydrolase (FAAH) DM2BM1L MA Inhibitor DM2BM1L RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2BM1L RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2BTCU DI DM2BTCU DM2BTCU DN PMID25666693-Compound-158 DM2BTCU TI TTMI6F5 DM2BTCU TN Transient receptor potential cation channel V1 (TRPV1) DM2BTCU MA Antagonist DM2BTCU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2BTCU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2BZI0 DI DM2BZI0 DM2BZI0 DN Cyclic cyanoethypypazole derivative 1 DM2BZI0 TI TTRMX3V DM2BZI0 TN Janus kinase 2 (JAK-2) DM2BZI0 MA Inhibitor DM2BZI0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2BZI0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2BZI0 DI DM2BZI0 DM2BZI0 DN Cyclic cyanoethypypazole derivative 1 DM2BZI0 TI TT6DM01 DM2BZI0 TN Janus kinase 1 (JAK-1) DM2BZI0 MA Inhibitor DM2BZI0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2BZI0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2C58A DI DM2C58A DM2C58A DN PMID25666693-Compound-60 DM2C58A TI TTMI6F5 DM2C58A TN Transient receptor potential cation channel V1 (TRPV1) DM2C58A MA Antagonist DM2C58A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2C58A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2C6ZF DI DM2C6ZF DM2C6ZF DN PMID29671355-Compound-16 DM2C6ZF TI TT5ZKDI DM2C6ZF TN Histone deacetylase 6 (HDAC6) DM2C6ZF MA Inhibitor DM2C6ZF RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2C6ZF RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TT0PG8F DM2CT4G TN Cyclin-dependent kinase 4 (CDK4) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TTO0FDJ DM2CT4G TN Cyclin-dependent kinase 6 (CDK6) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TT8J1S3 DM2CT4G TN Smoothened homolog (SMO) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TTCJG29 DM2CT4G TN Serine/threonine-protein kinase mTOR (mTOR) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2D4WQ DI DM2D4WQ DM2D4WQ DN Tetrazolyl urea derivative 1 DM2D4WQ TI TTDP1UC DM2D4WQ TN Fatty acid amide hydrolase (FAAH) DM2D4WQ MA Inhibitor DM2D4WQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2D4WQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2DEOA DI DM2DEOA DM2DEOA DN US10100051, Compound 11 DM2DEOA TI TT9ISBX DM2DEOA TN HIF-prolyl hydroxylase 2 (HPH-2) DM2DEOA MA Inhibitor DM2DEOA RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DM2DEOA RU http://www.freepatentsonline.com/US10100051.html DM2DK1E DI DM2DK1E DM2DK1E DN Pyrazole derivative 4 DM2DK1E TI TT6OEDT DM2DK1E TN Cannabinoid receptor 1 (CB1) DM2DK1E MA Antagonist DM2DK1E RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2DK1E RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2DL4I DI DM2DL4I DM2DL4I DN Imidazo[1,2-b]pyridazine derivative 4 DM2DL4I TI TTTDVOJ DM2DL4I TN Tropomyosin-related kinase A (TrkA) DM2DL4I MA Inhibitor DM2DL4I RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2DL4I RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2DT6L DI DM2DT6L DM2DT6L DN BB 0223767 DM2DT6L TI TTOJ9QL DM2DT6L TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM2DT6L MA Inhibitor DM2DT6L RN IRE-1 inhibitors. US8614253. DM2DT6L RU http://www.freepatentsonline.com/US8614253.html DM2DU7R DI DM2DU7R DM2DU7R DN US20160326143, 50 DM2DU7R TI TTW7OTG DM2DU7R TN Leukotriene C4 synthase (LTC4S) DM2DU7R MA Inhibitor DM2DU7R RN Compounds and uses. US9657001. DM2DU7R RU http://www.freepatentsonline.com/US9657001.html DM2DYMS DI DM2DYMS DM2DYMS DN Diphenyl purine derivative 1 DM2DYMS TI TT6OEDT DM2DYMS TN Cannabinoid receptor 1 (CB1) DM2DYMS MA Antagonist DM2DYMS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2DYMS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2E6M7 DI DM2E6M7 DM2E6M7 DN PMID26394986-Compound-42 DM2E6M7 TI TTH8FZW DM2E6M7 TN Signal transducer and activator of transcription 3 (STAT3) DM2E6M7 MA Inhibitor DM2E6M7 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM2E6M7 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM2E7DJ DI DM2E7DJ DM2E7DJ DN Pyrrolo[2,3-d]pyrimidine derivative 20 DM2E7DJ TI TTGM6VW DM2E7DJ TN Tyrosine-protein kinase BTK (ATK) DM2E7DJ MA Inhibitor DM2E7DJ RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM2E7DJ RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM2EDOM DI DM2EDOM DM2EDOM DN Azaindole derivative 3 DM2EDOM TI TT7RJY8 DM2EDOM TN Xanthine dehydrogenase/oxidase (XDH) DM2EDOM MA Inhibitor DM2EDOM RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2EDOM RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2EVJR DI DM2EVJR DM2EVJR DN Pyrrolo-pyridinone derivative 4 DM2EVJR TI TT4DXQT DM2EVJR TN Proto-oncogene c-Ret (RET) DM2EVJR MA Inhibitor DM2EVJR RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM2EVJR RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TT4YWTO DM2F0CQ TN Histone deacetylase 3 (HDAC3) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TTSHTOI DM2F0CQ TN Histone deacetylase 2 (HDAC2) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TT6R7JZ DM2F0CQ TN Histone deacetylase 1 (HDAC1) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F1T0 DI DM2F1T0 DM2F1T0 DN PMID25435179-Compound-WO2012106509CAY10602 DM2F1T0 TI TTUF2HO DM2F1T0 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM2F1T0 MA Inhibitor DM2F1T0 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM2F1T0 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM2FDCT DI DM2FDCT DM2FDCT DN PMID26004420-Compound-WO2014150132C DM2FDCT TI TTJ13ST DM2FDCT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM2FDCT MA Inhibitor DM2FDCT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM2FDCT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM2FPHZ DI DM2FPHZ DM2FPHZ DN PMID28394193-Compound-55 DM2FPHZ TI TTJW2UQ DM2FPHZ TN EZH2 Y641N mutant (EZH2 Y641N) DM2FPHZ MA Inhibitor DM2FPHZ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2FPHZ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2FPHZ DI DM2FPHZ DM2FPHZ DN PMID28394193-Compound-55 DM2FPHZ TI TT9MZCQ DM2FPHZ TN Enhancer of zeste homolog 2 (EZH2) DM2FPHZ MA Inhibitor DM2FPHZ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2FPHZ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2FUIB DI DM2FUIB DM2FUIB DN Acyl piperidine derivative 2 DM2FUIB TI TT2F4OL DM2FUIB TN Tissue transglutaminase (TG2) DM2FUIB MA Inhibitor DM2FUIB RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2FUIB RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2FZPE DI DM2FZPE DM2FZPE DN Piperidinyl triazole derivative 2 DM2FZPE TI TTTJZ4M DM2FZPE TN Prolylcarboxypeptidase (PRCP) DM2FZPE MA Inhibitor DM2FZPE RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM2FZPE RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTJQOD7 DM2G3VE TN 5-HT 2A receptor (HTR2A) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTJS8PY DM2G3VE TN 5-HT 6 receptor (HTR6) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTO9X1H DM2G3VE TN 5-HT 7 receptor (HTR7) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTEX248 DM2G3VE TN Dopamine D2 receptor (D2R) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTSQIFT DM2G3VE TN 5-HT 1A receptor (HTR1A) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G83R DI DM2G83R DM2G83R DN Benzimidazole and imadazopyridine carboximidamide compound 1 DM2G83R TI TTZJYKH DM2G83R TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM2G83R MA Inhibitor DM2G83R RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM2G83R RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM2G8DN DI DM2G8DN DM2G8DN DN PMID30074415-Compound-GS3 DM2G8DN TI TT2LVK8 DM2G8DN TN Carbonic anhydrase IX (CA-IX) DM2G8DN MA Inhibitor DM2G8DN RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM2G8DN RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM2GDXH DI DM2GDXH DM2GDXH DN PMID27744724-Compound-29 DM2GDXH TI TTL53M6 DM2GDXH TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM2GDXH MA Inhibitor DM2GDXH RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM2GDXH RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM2GL47 DI DM2GL47 DM2GL47 DN Isoflavone derivative 5 DM2GL47 TI TTJOMH6 DM2GL47 TN Zinc finger protein GLI1 (Gli1) DM2GL47 MA Inhibitor DM2GL47 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2GL47 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2GL47 DI DM2GL47 DM2GL47 DN Isoflavone derivative 5 DM2GL47 TI TT8J1S3 DM2GL47 TN Smoothened homolog (SMO) DM2GL47 MA Inhibitor DM2GL47 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2GL47 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2GON6 DI DM2GON6 DM2GON6 DN PMID26815044-Compound-117 DM2GON6 TI TTULVH8 DM2GON6 TN Tyrosinase (TYR) DM2GON6 MA Inhibitor DM2GON6 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2GON6 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2GPLQ DI DM2GPLQ DM2GPLQ DN Urea and carbamate bioisostere derivative 7 DM2GPLQ TI TTL7C8Q DM2GPLQ TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM2GPLQ MA Inhibitor DM2GPLQ RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM2GPLQ RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM2GR5Q DI DM2GR5Q DM2GR5Q DN Pyridinone compound 1 DM2GR5Q TI TTZCRP3 DM2GR5Q TN ERK activator kinase (MEK) DM2GR5Q MA Inhibitor DM2GR5Q RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM2GR5Q RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM2GZ5Y DI DM2GZ5Y DM2GZ5Y DN Biphenyl mannoside derivative 18 DM2GZ5Y TI TTTCRU2 DM2GZ5Y TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2GZ5Y MA Antagonist DM2GZ5Y RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2GZ5Y RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2H95E DI DM2H95E DM2H95E DN Thiazole carboxamide derivative 5 DM2H95E TI TTCZOF2 DM2H95E TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM2H95E MA Inhibitor DM2H95E RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM2H95E RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM2HG9U DI DM2HG9U DM2HG9U DN PMID25468267-Compound-49 DM2HG9U TI TT0RGE9 DM2HG9U TN Lysine-specific demethylase 4 (KDM4) DM2HG9U MA Inhibitor DM2HG9U RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM2HG9U RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM2HLGC DI DM2HLGC DM2HLGC DN DZ9 DM2HLGC TI TT1NFO3 DM2HLGC TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM2HLGC MA Inhibitor DM2HLGC RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM2HLGC RU http://www.freepatentsonline.com/US8785499.html DM2HO1S DI DM2HO1S DM2HO1S DN Pyrazole derivative 20 DM2HO1S TI TT6OEDT DM2HO1S TN Cannabinoid receptor 1 (CB1) DM2HO1S MA Antagonist DM2HO1S RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2HO1S RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2I1QZ DI DM2I1QZ DM2I1QZ DN PMID26651364-Compound-126b DM2I1QZ TI TTTCRU2 DM2I1QZ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2I1QZ MA Antagonist DM2I1QZ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2I1QZ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2I9HY DI DM2I9HY DM2I9HY DN PMID28394193-Compound-52 DM2I9HY TI TT9MZCQ DM2I9HY TN Enhancer of zeste homolog 2 (EZH2) DM2I9HY MA Inhibitor DM2I9HY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2I9HY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2IBX9 DI DM2IBX9 DM2IBX9 DN Di-substituted piperidine derivative 3 DM2IBX9 TI TTEB0GD DM2IBX9 TN Cholinesterase (BCHE) DM2IBX9 MA Inhibitor DM2IBX9 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM2IBX9 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM2IKDL DI DM2IKDL DM2IKDL DN Resorcinol compound 24 DM2IKDL TI TTULVH8 DM2IKDL TN Tyrosinase (TYR) DM2IKDL MA Inhibitor DM2IKDL RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2IKDL RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2ISDH DI DM2ISDH DM2ISDH DN PMID25991433-Compound-A7 DM2ISDH TI TTHS0U8 DM2ISDH TN Stress-activated protein kinase JNK2 (JNK2) DM2ISDH MA Inhibitor DM2ISDH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2ISDH DI DM2ISDH DM2ISDH DN PMID25991433-Compound-A7 DM2ISDH TI TT0K6EO DM2ISDH TN Stress-activated protein kinase JNK1 (JNK1) DM2ISDH MA Inhibitor DM2ISDH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2J8IS DI DM2J8IS DM2J8IS DN US8772478, 1 DM2J8IS TI TTQICM2 DM2J8IS TN ADAM metallopeptidase 33 (ADAM33) DM2J8IS MA Inhibitor DM2J8IS RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DM2J8IS RU http://www.freepatentsonline.com/US8772478.html DM2JF0T DI DM2JF0T DM2JF0T DN PMID28092474-Compound-32t DM2JF0T TI TT6R7JZ DM2JF0T TN Histone deacetylase 1 (HDAC1) DM2JF0T MA Inhibitor DM2JF0T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM2JF0T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM2JF0T DI DM2JF0T DM2JF0T DN PMID28092474-Compound-32t DM2JF0T TI TT5ZKDI DM2JF0T TN Histone deacetylase 6 (HDAC6) DM2JF0T MA Inhibitor DM2JF0T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM2JF0T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM2K54D DI DM2K54D DM2K54D DN PMID27967267-Compound-stenine DM2K54D TI TT1RS9F DM2K54D TN Acetylcholinesterase (AChE) DM2K54D MA Inhibitor DM2K54D RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM2K54D RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM2K6YU DI DM2K6YU DM2K6YU DN US8546370, 11 DM2K6YU TI TTUMHT8 DM2K6YU TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DM2K6YU MA Inhibitor DM2K6YU RN Compounds and compositions as kinase inhibitors. US8546370. DM2K6YU RU http://www.freepatentsonline.com/US8546370.html DM2KTAB DI DM2KTAB DM2KTAB DN PMID25666693-Compound-160 DM2KTAB TI TTMI6F5 DM2KTAB TN Transient receptor potential cation channel V1 (TRPV1) DM2KTAB MA Antagonist DM2KTAB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2KTAB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2KVDH DI DM2KVDH DM2KVDH DN PMID28394193-Compound-27 DM2KVDH TI TT9MZCQ DM2KVDH TN Enhancer of zeste homolog 2 (EZH2) DM2KVDH MA Inhibitor DM2KVDH RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2KVDH RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2KVMT DI DM2KVMT DM2KVMT DN Heterocycle-containing compound 2 DM2KVMT TI TT9O6WS DM2KVMT TN Glucagon receptor (GCGR) DM2KVMT MA Antagonist DM2KVMT RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM2KVMT RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM2L7ES DI DM2L7ES DM2L7ES DN PMID29338548-Compound-41 DM2L7ES TI TTHJTF7 DM2L7ES TN Glycine transporter GlyT-1 (SLC6A9) DM2L7ES MA Inhibitor DM2L7ES RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM2L7ES RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM2L83Y DI DM2L83Y DM2L83Y DN AGGGWZCOULSEER-PYUWXLGESA-N DM2L83Y TI TT5U49F DM2L83Y TN PRKACA messenger RNA (PRKACA mRNA) DM2L83Y MA Inhibitor DM2L83Y RN Purine derivatives. US8846696. DM2L83Y RU http://www.freepatentsonline.com/US8846696.html DM2L9KI DI DM2L9KI DM2L9KI DN Peptide analog 20 DM2L9KI TI TTSJMN8 DM2L9KI TN Immunoproteasome complex (IP) DM2L9KI MA Inhibitor DM2L9KI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2L9KI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2LQXY DI DM2LQXY DM2LQXY DN Ketoheterocycle derivative 4 DM2LQXY TI TTDP1UC DM2LQXY TN Fatty acid amide hydrolase (FAAH) DM2LQXY MA Inhibitor DM2LQXY RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2LQXY RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2MPN0 DI DM2MPN0 DM2MPN0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2 DM2MPN0 TI TT6OEDT DM2MPN0 TN Cannabinoid receptor 1 (CB1) DM2MPN0 MA Antagonist DM2MPN0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2MPN0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2MQD0 DI DM2MQD0 DM2MQD0 DN SB19065 DM2MQD0 TI TT42OGM DM2MQD0 TN Hematopoietic cell kinase (HCK) DM2MQD0 MA Inhibitor DM2MQD0 RN Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066. DM2MQD0 RU http://www.freepatentsonline.com/US9062066.html DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TTQ6VDM DM2MYL9 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TT5TPI6 DM2MYL9 TN Opioid receptor sigma 1 (OPRS1) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TT9NXW4 DM2MYL9 TN Sigma intracellular receptor 2 (TMEM97) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2NS5T DI DM2NS5T DM2NS5T DN PMID28394193-Compound-39 DM2NS5T TI TT9MZCQ DM2NS5T TN Enhancer of zeste homolog 2 (EZH2) DM2NS5T MA Inhibitor DM2NS5T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2NS5T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2NVLZ DI DM2NVLZ DM2NVLZ DN PMID25514969-Compound-8 DM2NVLZ TI TT4EB85 DM2NVLZ TN Cholesterol 24-hydroxylase (CYP46A1) DM2NVLZ MA Inhibitor DM2NVLZ RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DM2NVLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DM2OM4Z DI DM2OM4Z DM2OM4Z DN PMID28454500-Compound-35 DM2OM4Z TI TTA6ZN2 DM2OM4Z TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM2OM4Z MA Activator DM2OM4Z RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2OM4Z RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2OM4Z DI DM2OM4Z DM2OM4Z DN PMID28454500-Compound-35 DM2OM4Z TI TT3Z6Y9 DM2OM4Z TN Cysteines of Keap1 (KEAP1 Cysteines) DM2OM4Z MA Modulator DM2OM4Z RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2OM4Z RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2OTJS DI DM2OTJS DM2OTJS DN Dipeptide analog 1 DM2OTJS TI TTOUSTQ DM2OTJS TN Proteasome beta-9 (PS beta-9) DM2OTJS MA Inhibitor DM2OTJS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2OTJS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2OTJS DI DM2OTJS DM2OTJS DN Dipeptide analog 1 DM2OTJS TI TTEAD9J DM2OTJS TN Proteasome beta-8 (PS beta-8) DM2OTJS MA Inhibitor DM2OTJS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2OTJS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2OXW3 DI DM2OXW3 DM2OXW3 DN Peptide analog 69 DM2OXW3 TI TTPLTSQ DM2OXW3 TN Neutrophil elastase (NE) DM2OXW3 MA Inhibitor DM2OXW3 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM2OXW3 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM2P05S DI DM2P05S DM2P05S DN PMID29053063-Compound-5 DM2P05S TI TTZ963I DM2P05S TN Monoglyceride lipase (MAGL) DM2P05S MA Inhibitor DM2P05S RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM2P05S RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM2P509 DI DM2P509 DM2P509 DN N-oxalyl-D-tyrosine derivative 1 DM2P509 TI TTWAQBO DM2P509 TN Lysine-specific demethylase 4E (KDM4E) DM2P509 MA Inhibitor DM2P509 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM2P509 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM2P5J9 DI DM2P5J9 DM2P5J9 DN PMID27321640-Compound-75 DM2P5J9 TI TTJGW1Z DM2P5J9 TN Phosphodiesterase 2A (PDE2A) DM2P5J9 MA Inhibitor DM2P5J9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM2P5J9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM2PUBI DI DM2PUBI DM2PUBI DN PMID26099857-Compound-WO2011037610Formula(I) DM2PUBI TI TTKVTQO DM2PUBI TN Prostaglandin transporter (SLC21A2) DM2PUBI MA Inhibitor DM2PUBI RN Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1.Expert Opin Ther Pat. 2015;25(9):1069-77. DM2PUBI RU https://www.ncbi.nlm.nih.gov/pubmed/26099857 DM2QCBF DI DM2QCBF DM2QCBF DN Heterocyclic derivative 2 DM2QCBF TI TTHS256 DM2QCBF TN Metabotropic glutamate receptor 5 (mGluR5) DM2QCBF MA Modulator DM2QCBF RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2QCBF RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2QNMC DI DM2QNMC DM2QNMC DN Bidentate ligands of Markush derivative 2 DM2QNMC TI TTK0FEA DM2QNMC TN Leucine-rich repeat kinase 2 (LRRK2) DM2QNMC MA Inhibitor DM2QNMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM2QNMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM2QNMC DI DM2QNMC DM2QNMC DN Bidentate ligands of Markush derivative 2 DM2QNMC TI TTVOE6D DM2QNMC TN Mitogen-activated protein kinase (MAPK) DM2QNMC MA Inhibitor DM2QNMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM2QNMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM2QRIW DI DM2QRIW DM2QRIW DN PMID29130358-Compound-Figure17(13) DM2QRIW TI TT6X50U DM2QRIW TN Matrix metalloproteinase-9 (MMP-9) DM2QRIW MA Inhibitor DM2QRIW RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM2QRIW RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM2QVHY DI DM2QVHY DM2QVHY DN Fused heterocyclic compound 3 DM2QVHY TI TT7RJY8 DM2QVHY TN Xanthine dehydrogenase/oxidase (XDH) DM2QVHY MA Inhibitor DM2QVHY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2QVHY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2QWXF DI DM2QWXF DM2QWXF DN PMID26560530-Compound-32 DM2QWXF TI TT2F4OL DM2QWXF TN Tissue transglutaminase (TG2) DM2QWXF MA Inhibitor DM2QWXF RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2QWXF RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2QXVW DI DM2QXVW DM2QXVW DN Furopyridine derivative 1 DM2QXVW TI TT6OEDT DM2QXVW TN Cannabinoid receptor 1 (CB1) DM2QXVW MA Antagonist DM2QXVW RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2QXVW RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2R468 DI DM2R468 DM2R468 DN Piperazine carbamate/urea derivative 3 DM2R468 TI TT9JNIC DM2R468 TN Histamine H3 receptor (H3R) DM2R468 MA Ligand DM2R468 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM2R468 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM2RE91 DI DM2RE91 DM2RE91 DN US9586945, 1 DM2RE91 TI TTYJRN5 DM2RE91 TN N-acetylglucosaminyltransferase I (NAGAT1) DM2RE91 MA Inhibitor DM2RE91 RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DM2RE91 RU http://www.freepatentsonline.com/US9586945.html DM2RPYB DI DM2RPYB DM2RPYB DN Resorcinol compound 32 DM2RPYB TI TTULVH8 DM2RPYB TN Tyrosinase (TYR) DM2RPYB MA Inhibitor DM2RPYB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2RPYB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2RZL8 DI DM2RZL8 DM2RZL8 DN Sulfonamide derivative 9 DM2RZL8 TI TT2F4OL DM2RZL8 TN Tissue transglutaminase (TG2) DM2RZL8 MA Inhibitor DM2RZL8 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2RZL8 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2SUCK DI DM2SUCK DM2SUCK DN Isoxazole-based bicyclic compound 17 DM2SUCK TI TTE4BSY DM2SUCK TN Bromodomain and extraterminal domain protein (BET) DM2SUCK MA Inhibitor DM2SUCK RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM2SUCK RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM2SZ0B DI DM2SZ0B DM2SZ0B DN PMID26651364-Compound-7e DM2SZ0B TI TTTCRU2 DM2SZ0B TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2SZ0B MA Antagonist DM2SZ0B RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2SZ0B RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2TDXW DI DM2TDXW DM2TDXW DN Carbamide derivative 15 DM2TDXW TI TTOHSBA DM2TDXW TN Vascular endothelial growth factor A (VEGFA) DM2TDXW MA Inhibitor DM2TDXW RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM2TDXW RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM2TF64 DI DM2TF64 DM2TF64 DN Aminopyrimidine derivative 10 DM2TF64 TI TTH5TC2 DM2TF64 TN NF-kappa-B-activating kinase (TBK1) DM2TF64 MA Inhibitor DM2TF64 RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM2TF64 RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM2TNH4 DI DM2TNH4 DM2TNH4 DN PMID27599163-Compound-77 DM2TNH4 TI TTPTXIN DM2TNH4 TN Translocator protein (TSPO) DM2TNH4 MA Ligand DM2TNH4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM2TNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM2U1QH DI DM2U1QH DM2U1QH DN Diazepinone derivative 5 DM2U1QH TI TTHS256 DM2U1QH TN Metabotropic glutamate receptor 5 (mGluR5) DM2U1QH MA Modulator DM2U1QH RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2U1QH RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2UDV8 DI DM2UDV8 DM2UDV8 DN Azetidinyl-piperidine derivative 3 DM2UDV8 TI TTZ963I DM2UDV8 TN Monoglyceride lipase (MAGL) DM2UDV8 MA Inhibitor DM2UDV8 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM2UDV8 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM2UGK3 DI DM2UGK3 DM2UGK3 DN Azetidine-1-carboxamide derivative 3 DM2UGK3 TI TT6OEDT DM2UGK3 TN Cannabinoid receptor 1 (CB1) DM2UGK3 MA Antagonist DM2UGK3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2UGK3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2ULB8 DI DM2ULB8 DM2ULB8 DN US9187437, 38 DM2ULB8 TI TTDYP7I DM2ULB8 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM2ULB8 MA Inhibitor DM2ULB8 RN Substituted oxadiazole compounds. US9187437. DM2ULB8 RU http://www.freepatentsonline.com/US9187437.html DM2URPE DI DM2URPE DM2URPE DN Cyclohexyl carbamate derivative 7 DM2URPE TI TTULVH8 DM2URPE TN Tyrosinase (TYR) DM2URPE MA Inhibitor DM2URPE RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2URPE RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2UWSX DI DM2UWSX DM2UWSX DN Amidine compound 2 DM2UWSX TI TTQR74A DM2UWSX TN Proteinase activated receptor 2 (PAR2) DM2UWSX MA Antagonist DM2UWSX RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM2UWSX RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM2V31C DI DM2V31C DM2V31C DN Ampicidin analog 1 DM2V31C TI TTBH0VX DM2V31C TN Histone deacetylase (HDAC) DM2V31C MA Inhibitor DM2V31C RN Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30. DM2V31C RU https://www.ncbi.nlm.nih.gov/pubmed/26566576 DM2VHJ7 DI DM2VHJ7 DM2VHJ7 DN PMID26666989-Compound-Figure12bottommiddle02 DM2VHJ7 TI TT8BUGW DM2VHJ7 TN Glycogen phosphorylase (PYG) DM2VHJ7 MA Inhibitor DM2VHJ7 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM2VHJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTT7PJU DM2VQ4P TN Janus kinase 3 (JAK-3) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTBYWP2 DM2VQ4P TN TYK2 tyrosine kinase (TYK2) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTRMX3V DM2VQ4P TN Janus kinase 2 (JAK-2) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TT6DM01 DM2VQ4P TN Janus kinase 1 (JAK-1) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VZG6 DI DM2VZG6 DM2VZG6 DN PMID25435285-Compound-51 DM2VZG6 TI TTXJ47W DM2VZG6 TN Metabotropic glutamate receptor 2 (mGluR2) DM2VZG6 MA Antagonist DM2VZG6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM2VZG6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM2W7JE DI DM2W7JE DM2W7JE DN Aryl mannoside derivative 13 DM2W7JE TI TTTCRU2 DM2W7JE TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2W7JE MA Antagonist DM2W7JE RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2W7JE RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2W9AP DI DM2W9AP DM2W9AP DN PMID25482888-Compound-21 DM2W9AP TI TTDIGC1 DM2W9AP TN Dipeptidyl peptidase 4 (DPP-4) DM2W9AP MA Inhibitor DM2W9AP RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM2W9AP RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM2WDXV DI DM2WDXV DM2WDXV DN Thiazole derivative 1 DM2WDXV TI TTULVH8 DM2WDXV TN Tyrosinase (TYR) DM2WDXV MA Inhibitor DM2WDXV RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2WDXV RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2WJKR DI DM2WJKR DM2WJKR DN PMID25666693-Compound-134 DM2WJKR TI TTMI6F5 DM2WJKR TN Transient receptor potential cation channel V1 (TRPV1) DM2WJKR MA Antagonist DM2WJKR RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2WJKR RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2WMGO DI DM2WMGO DM2WMGO DN Antibodie derivative 4 DM2WMGO TI TTOHSBA DM2WMGO TN Vascular endothelial growth factor A (VEGFA) DM2WMGO MA Inhibitor DM2WMGO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM2WMGO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM2X4R0 DI DM2X4R0 DM2X4R0 DN PMID26560530-Compound-54 DM2X4R0 TI TT2F4OL DM2X4R0 TN Tissue transglutaminase (TG2) DM2X4R0 MA Inhibitor DM2X4R0 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2X4R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2XGNY DI DM2XGNY DM2XGNY DN Piperazine derivative 4 DM2XGNY TI TTJQOD7 DM2XGNY TN 5-HT 2A receptor (HTR2A) DM2XGNY MA Antagonist DM2XGNY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM2XGNY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM2XKTB DI DM2XKTB DM2XKTB DN PMID28270021-Compound-WO2013161919Example85-117 DM2XKTB TI TTTDVOJ DM2XKTB TN Tropomyosin-related kinase A (TrkA) DM2XKTB MA Inhibitor DM2XKTB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM2XKTB RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM2Y64W DI DM2Y64W DM2Y64W DN PMID26004420-Compound-WO2012058116C DM2Y64W TI TTJ13ST DM2Y64W TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM2Y64W MA Inhibitor DM2Y64W RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM2Y64W RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTTDVOJ DM2YAPJ TN Tropomyosin-related kinase A (TrkA) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTXABCW DM2YAPJ TN NT-3 growth factor receptor (TrkC) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTKN7QR DM2YAPJ TN BDNF/NT-3 growth factors receptor (TrkB) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YPLF DI DM2YPLF DM2YPLF DN PMID27774822-Compound-Figure2Example1-1right DM2YPLF TI TTT7PJU DM2YPLF TN Janus kinase 3 (JAK-3) DM2YPLF MA Inhibitor DM2YPLF RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2YPLF RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2YPLF DI DM2YPLF DM2YPLF DN PMID27774822-Compound-Figure2Example1-1right DM2YPLF TI TTRMX3V DM2YPLF TN Janus kinase 2 (JAK-2) DM2YPLF MA Inhibitor DM2YPLF RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2YPLF RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2YVGH DI DM2YVGH DM2YVGH DN Biaryl mannoside derivative 23 DM2YVGH TI TTTCRU2 DM2YVGH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2YVGH MA Antagonist DM2YVGH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2YVGH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2Z43I DI DM2Z43I DM2Z43I DN US9073931, E1 DM2Z43I TI TTECBXN DM2Z43I TN Oxysterols receptor LXR-alpha (NR1H3) DM2Z43I MA Inhibitor DM2Z43I RN Liver X receptor modulators. US9073931. DM2Z43I RU http://www.freepatentsonline.com/US9073931.html DM2ZCTW DI DM2ZCTW DM2ZCTW DN PMID25991433-Compound-E5 DM2ZCTW TI TT0K6EO DM2ZCTW TN Stress-activated protein kinase JNK1 (JNK1) DM2ZCTW MA Inhibitor DM2ZCTW RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ZCTW RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2ZR8M DI DM2ZR8M DM2ZR8M DN PMID25666693-Compound-98 DM2ZR8M TI TTMI6F5 DM2ZR8M TN Transient receptor potential cation channel V1 (TRPV1) DM2ZR8M MA Antagonist DM2ZR8M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2ZR8M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2ZUVH DI DM2ZUVH DM2ZUVH DN PMID25399762-Compound-Table1-C18 DM2ZUVH TI TTGP7BY DM2ZUVH TN Monoamine oxidase type B (MAO-B) DM2ZUVH MA Inhibitor DM2ZUVH RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM2ZUVH RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM2ZVXD DI DM2ZVXD DM2ZVXD DN PMID25666693-Compound-83 DM2ZVXD TI TTMI6F5 DM2ZVXD TN Transient receptor potential cation channel V1 (TRPV1) DM2ZVXD MA Antagonist DM2ZVXD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2ZVXD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2ZWSM DI DM2ZWSM DM2ZWSM DN Cyclopropyl-spiro piperidine derivative 4 DM2ZWSM TI TT4G2JS DM2ZWSM TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM2ZWSM MA Blocker DM2ZWSM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM2ZWSM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM2ZYVL DI DM2ZYVL DM2ZYVL DN Isoflavone derivative 6 DM2ZYVL TI TTJOMH6 DM2ZYVL TN Zinc finger protein GLI1 (Gli1) DM2ZYVL MA Inhibitor DM2ZYVL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2ZYVL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2ZYVL DI DM2ZYVL DM2ZYVL DN Isoflavone derivative 6 DM2ZYVL TI TT8J1S3 DM2ZYVL TN Smoothened homolog (SMO) DM2ZYVL MA Inhibitor DM2ZYVL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2ZYVL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM305UL DI DM305UL DM305UL DN N-(pyridin-2-yl)pyridine methylsulfone derivative 1 DM305UL TI TT7HF4W DM305UL TN Cyclin-dependent kinase 2 (CDK2) DM305UL MA Inhibitor DM305UL RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM305UL RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM305UL DI DM305UL DM305UL DN N-(pyridin-2-yl)pyridine methylsulfone derivative 1 DM305UL TI TT1LVF2 DM305UL TN Cyclin-dependent kinase 9 (CDK9) DM305UL MA Inhibitor DM305UL RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM305UL RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTT7PJU DM30Y8M TN Janus kinase 3 (JAK-3) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTBYWP2 DM30Y8M TN TYK2 tyrosine kinase (TYK2) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTRMX3V DM30Y8M TN Janus kinase 2 (JAK-2) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TT6DM01 DM30Y8M TN Janus kinase 1 (JAK-1) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM310ES DI DM310ES DM310ES DN N-(naphthylamino)-benzoate derivative 1 DM310ES TI TT5ZWB6 DM310ES TN Dihydrodiol dehydrogenase type I (AKR1C3) DM310ES MA Inhibitor; Antagonist; Blocker DM310ES RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM310ES RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM316FB DI DM316FB DM316FB DN US9434725, 315 DM316FB TI TTCGOIN DM316FB TN PIM-3 protein kinase (PIM3) DM316FB MA Inhibitor DM316FB RN 5-azaindazole compounds and methods of use. US9434725. DM316FB RU http://www.freepatentsonline.com/US9434725.html DM31BMP DI DM31BMP DM31BMP DN Metal complex derivative 3 DM31BMP TI TTR7UJ3 DM31BMP TN Cytoplasmic thioredoxin reductase (TXNRD1) DM31BMP MA Inhibitor DM31BMP RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM31BMP RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM32N7D DI DM32N7D DM32N7D DN Pyrimidopyridazinone derivative 1 DM32N7D TI TTRMX3V DM32N7D TN Janus kinase 2 (JAK-2) DM32N7D MA Inhibitor DM32N7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM32N7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM32N7D DI DM32N7D DM32N7D DN Pyrimidopyridazinone derivative 1 DM32N7D TI TTOU65C DM32N7D TN Tyrosine-protein kinase SYK (SYK) DM32N7D MA Inhibitor DM32N7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM32N7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTRA6BO DM346EU TN Bromodomain-containing protein 4 (BRD4) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTHE657 DM346EU TN Bromodomain-containing protein 3 (BRD3) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTDP48B DM346EU TN Bromodomain-containing protein 2 (BRD2) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TT7CPI5 DM346EU TN Bromodomain testis-specific protein (BRDT) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM34KXF DI DM34KXF DM34KXF DN US8921389, 1 DM34KXF TI TT9ISBX DM34KXF TN HIF-prolyl hydroxylase 2 (HPH-2) DM34KXF MA Inhibitor DM34KXF RN Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170. DM34KXF RU http://www.freepatentsonline.com/US9695170.html DM34MCP DI DM34MCP DM34MCP DN Triazolo[4,3-b]pyridazine derivative 1 DM34MCP TI TTSCO7R DM34MCP TN NAD-dependent deacetylase sirtuin (SIRT) DM34MCP MA Inhibitor DM34MCP RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM34MCP RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM34NZ8 DI DM34NZ8 DM34NZ8 DN Imatinib and nilotinib derivative 2 DM34NZ8 TI TTUNARX DM34NZ8 TN Carbonic anhydrase (CA) DM34NZ8 MA Inhibitor DM34NZ8 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM34NZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM34ZCG DI DM34ZCG DM34ZCG DN Imidazo cyclohexylamine derivative 1 DM34ZCG TI TTDIGC1 DM34ZCG TN Dipeptidyl peptidase 4 (DPP-4) DM34ZCG MA Inhibitor DM34ZCG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM34ZCG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM361J8 DI DM361J8 DM361J8 DN Fused heterocyclic compound 2 DM361J8 TI TT7RJY8 DM361J8 TN Xanthine dehydrogenase/oxidase (XDH) DM361J8 MA Inhibitor DM361J8 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM361J8 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM36P7T DI DM36P7T DM36P7T DN PMID28627961-Compound-22 DM36P7T TI TTYLQ8V DM36P7T TN Prostaglandin E synthase (PTGES) DM36P7T MA Inhibitor DM36P7T RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM36P7T RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM36QM5 DI DM36QM5 DM36QM5 DN Azole derivative 5 DM36QM5 TI TTDP1UC DM36QM5 TN Fatty acid amide hydrolase (FAAH) DM36QM5 MA Inhibitor DM36QM5 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM36QM5 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM36R21 DI DM36R21 DM36R21 DN US8481733, 95 DM36R21 TI TTIET93 DM36R21 TN Activated CDC42 kinase 1 (ACK-1) DM36R21 MA Inhibitor DM36R21 RN Substituted imidazopyr- and imidazotri-azines. US8481733. DM36R21 RU http://www.freepatentsonline.com/US8481733.html DM37FDV DI DM37FDV DM37FDV DN PMID25684022-Compound-WO2010127754 DM37FDV TI TTCZOF2 DM37FDV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM37FDV MA Inhibitor DM37FDV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM37FDV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM37GMQ DI DM37GMQ DM37GMQ DN PMID26004420-Compound-WO2010129379A DM37GMQ TI TTJ13ST DM37GMQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM37GMQ MA Inhibitor DM37GMQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM37GMQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM37MCN DI DM37MCN DM37MCN DN Epoxysuccinate derivative 5 DM37MCN TI TTG5QB7 DM37MCN TN Calpain-2 (CAPN2) DM37MCN MA Inhibitor DM37MCN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM37MCN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TTQBR95 DM37VIQ TN Stress-activated protein kinase 2a (p38 alpha) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TT0K6EO DM37VIQ TN Stress-activated protein kinase JNK1 (JNK1) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TTHS0U8 DM37VIQ TN Stress-activated protein kinase JNK2 (JNK2) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TT056SO DM37VIQ TN Stress-activated protein kinase JNK3 (JNK3) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM389YD DI DM389YD DM389YD DN Diazepinone derivative 4 DM389YD TI TTHS256 DM389YD TN Metabotropic glutamate receptor 5 (mGluR5) DM389YD MA Modulator DM389YD RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM389YD RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM394WH DI DM394WH DM394WH DN PMID29671355-Compound-70 DM394WH TI TTTQGH8 DM394WH TN Histone deacetylase 4 (HDAC4) DM394WH MA Inhibitor DM394WH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM394WH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM39FDV DI DM39FDV DM39FDV DN PMID30107136-Compound-Example53 DM39FDV TI TT23XQV DM39FDV TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM39FDV MA Inhibitor DM39FDV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM39FDV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM39H1F DI DM39H1F DM39H1F DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3 DM39H1F TI TTPTXIN DM39H1F TN Translocator protein (TSPO) DM39H1F MA Ligand DM39H1F RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM39H1F RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM39HCU DI DM39HCU DM39HCU DN PMID29649907-Compound-33 DM39HCU TI TTS4UGC DM39HCU TN Farnesoid X-activated receptor (FXR) DM39HCU MA Agonist DM39HCU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM39HCU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM39NBT DI DM39NBT DM39NBT DN PMID25991433-Compound-A10 DM39NBT TI TTHS0U8 DM39NBT TN Stress-activated protein kinase JNK2 (JNK2) DM39NBT MA Inhibitor DM39NBT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM39NBT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM39NBT DI DM39NBT DM39NBT DN PMID25991433-Compound-A10 DM39NBT TI TT0K6EO DM39NBT TN Stress-activated protein kinase JNK1 (JNK1) DM39NBT MA Inhibitor DM39NBT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM39NBT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM39QU8 DI DM39QU8 DM39QU8 DN PMID28870136-Compound-60 DM39QU8 TI TTK0O6Y DM39QU8 TN Ecto-5'-nucleotidase (CD73) DM39QU8 MA Inhibitor DM39QU8 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM39QU8 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM3AUZS DI DM3AUZS DM3AUZS DN PMID27109571-Compound-44 DM3AUZS TI TTMY6L1 DM3AUZS TN Fatty acid-binding protein (FABP) DM3AUZS MA Inhibitor DM3AUZS RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM3AUZS RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM3AY9K DI DM3AY9K DM3AY9K DN PMID30107136-Compound-Example58 DM3AY9K TI TT23XQV DM3AY9K TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM3AY9K MA Inhibitor DM3AY9K RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM3AY9K RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM3B5RS DI DM3B5RS DM3B5RS DN Carbazole-3-carboxamide analog 1 DM3B5RS TI TTMSFAW DM3B5RS TN Cannabinoid receptor 2 (CB2) DM3B5RS MA Agonist DM3B5RS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM3B5RS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM3B5RS DI DM3B5RS DM3B5RS DN Carbazole-3-carboxamide analog 1 DM3B5RS TI TT6OEDT DM3B5RS TN Cannabinoid receptor 1 (CB1) DM3B5RS MA Agonist DM3B5RS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM3B5RS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM3BA1L DI DM3BA1L DM3BA1L DN PMID28766366-Compound-Scheme12-2 DM3BA1L TI TTSBVFO DM3BA1L TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM3BA1L MA Inhibitor DM3BA1L RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM3BA1L RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TT0PG8F DM3BDFV TN Cyclin-dependent kinase 4 (CDK4) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TTO0FDJ DM3BDFV TN Cyclin-dependent kinase 6 (CDK6) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TT8J1S3 DM3BDFV TN Smoothened homolog (SMO) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TTCJG29 DM3BDFV TN Serine/threonine-protein kinase mTOR (mTOR) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDHN DI DM3BDHN DM3BDHN DN US10081632, Compound 25 DM3BDHN TI TT3KYWB DM3BDHN TN Ribosomal protein S6 kinase alpha-6 (RSK6) DM3BDHN MA Inhibitor DM3BDHN RN Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366. DM3BDHN RU http://www.freepatentsonline.com/US9771366.html DM3BGEN DI DM3BGEN DM3BGEN DN Benzazepine derivative 3 DM3BGEN TI TTWJBZ5 DM3BGEN TN 5-HT 2C receptor (HTR2C) DM3BGEN MA Agonist DM3BGEN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3BGEN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3BOZP DI DM3BOZP DM3BOZP DN PMID25726713-Compound-16 DM3BOZP TI TT8J1S3 DM3BOZP TN Smoothened homolog (SMO) DM3BOZP MA Inhibitor DM3BOZP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BOZP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3CF91 DI DM3CF91 DM3CF91 DN Carbamate derivative 11 DM3CF91 TI TTZ963I DM3CF91 TN Monoglyceride lipase (MAGL) DM3CF91 MA Inhibitor DM3CF91 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM3CF91 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM3CPJQ DI DM3CPJQ DM3CPJQ DN PMID27967267-Compound-neotuberostemonine DM3CPJQ TI TT1RS9F DM3CPJQ TN Acetylcholinesterase (AChE) DM3CPJQ MA Inhibitor DM3CPJQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM3CPJQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM3CVWU DI DM3CVWU DM3CVWU DN Aryl pyrimidine derivative 1 DM3CVWU TI TT1LVF2 DM3CVWU TN Cyclin-dependent kinase 9 (CDK9) DM3CVWU MA Inhibitor DM3CVWU RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM3CVWU RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTT7PJU DM3D1L6 TN Janus kinase 3 (JAK-3) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTBYWP2 DM3D1L6 TN TYK2 tyrosine kinase (TYK2) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTRMX3V DM3D1L6 TN Janus kinase 2 (JAK-2) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TT6DM01 DM3D1L6 TN Janus kinase 1 (JAK-1) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D4RI DI DM3D4RI DM3D4RI DN PMID25666693-Compound-14 DM3D4RI TI TTMI6F5 DM3D4RI TN Transient receptor potential cation channel V1 (TRPV1) DM3D4RI MA Antagonist DM3D4RI RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3D4RI RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3DIW9 DI DM3DIW9 DM3DIW9 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 2 DM3DIW9 TI TTJW4LU DM3DIW9 TN Phosphodiesterase 10A (PDE10) DM3DIW9 MA Inhibitor DM3DIW9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM3DIW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM3DIW9 DI DM3DIW9 DM3DIW9 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 2 DM3DIW9 TI TTJGW1Z DM3DIW9 TN Phosphodiesterase 2A (PDE2A) DM3DIW9 MA Inhibitor DM3DIW9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM3DIW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM3E5V6 DI DM3E5V6 DM3E5V6 DN Indomethacin analog 1 DM3E5V6 TI TT5ZWB6 DM3E5V6 TN Dihydrodiol dehydrogenase type I (AKR1C3) DM3E5V6 MA Inhibitor; Antagonist; Blocker DM3E5V6 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM3E5V6 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM3E75P DI DM3E75P DM3E75P DN Aromatic bicyclic compound 4 DM3E75P TI TTRMX3V DM3E75P TN Janus kinase 2 (JAK-2) DM3E75P MA Inhibitor DM3E75P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3E75P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3E75P DI DM3E75P DM3E75P DN Aromatic bicyclic compound 4 DM3E75P TI TT6PKBN DM3E75P TN Proto-oncogene c-Src (SRC) DM3E75P MA Inhibitor DM3E75P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3E75P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3EAHB DI DM3EAHB DM3EAHB DN Spiroimidazolone derivative 2 DM3EAHB TI TT9O6WS DM3EAHB TN Glucagon receptor (GCGR) DM3EAHB MA Antagonist DM3EAHB RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM3EAHB RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM3EHSN DI DM3EHSN DM3EHSN DN 4-Carboxamido-isoindolinone derivative 2 DM3EHSN TI TTVDSZ0 DM3EHSN TN Poly [ADP-ribose] polymerase 1 (PARP1) DM3EHSN MA Inhibitor DM3EHSN RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3EHSN RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3F4KS DI DM3F4KS DM3F4KS DN Pyridinone carboxamide derivative 1 DM3F4KS TI TTCZOF2 DM3F4KS TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM3F4KS MA Inhibitor DM3F4KS RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM3F4KS RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM3FAIS DI DM3FAIS DM3FAIS DN PMID27841036-Compound-V DM3FAIS TI TTEBCY8 DM3FAIS TN Poly [ADP-ribose] polymerase (PARP) DM3FAIS MA Inhibitor DM3FAIS RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3FAIS RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3FY85 DI DM3FY85 DM3FY85 DN PMID27774822-Compound-Figure6Example3 DM3FY85 TI TTT7PJU DM3FY85 TN Janus kinase 3 (JAK-3) DM3FY85 MA Inhibitor DM3FY85 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3FY85 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3G21F DI DM3G21F DM3G21F DN PMID27828716-Compound-15 DM3G21F TI TTRZQE3 DM3G21F TN Glycogen synthase kinase-3 alpha (GSK-3A) DM3G21F MA Inhibitor DM3G21F RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM3G21F RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM3G6YV DI DM3G6YV DM3G6YV DN PMID27019002-Compound-45 DM3G6YV TI TTNR0UQ DM3G6YV TN Lysine-specific histone demethylase 1 (LSD) DM3G6YV MA Inhibitor DM3G6YV RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3G6YV RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3GU7K DI DM3GU7K DM3GU7K DN Pyridic ketone derivative 1 DM3GU7K TI TTTW2NY DM3GU7K TN ERK activator kinase 2 (MEK2) DM3GU7K MA Inhibitor DM3GU7K RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3GU7K RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3GU7K DI DM3GU7K DM3GU7K DN Pyridic ketone derivative 1 DM3GU7K TI TTIDAPM DM3GU7K TN ERK activator kinase 1 (MEK1) DM3GU7K MA Inhibitor DM3GU7K RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3GU7K RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3GYPD DI DM3GYPD DM3GYPD DN Pyrimidine derivative 16 DM3GYPD TI TTNR0UQ DM3GYPD TN Lysine-specific histone demethylase 1 (LSD) DM3GYPD MA Inhibitor DM3GYPD RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3GYPD RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTMUEK1 DM3H78D TN Histone deacetylase 7 (HDAC7) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT8M4E1 DM3H78D TN Histone deacetylase 9 (HDAC9) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTT6LFV DM3H78D TN Histone deacetylase 8 (HDAC8) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTTQGH8 DM3H78D TN Histone deacetylase 4 (HDAC4) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTUELN5 DM3H78D TN Histone deacetylase 5 (HDAC5) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT5ZKDI DM3H78D TN Histone deacetylase 6 (HDAC6) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTSHTOI DM3H78D TN Histone deacetylase 2 (HDAC2) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT4YWTO DM3H78D TN Histone deacetylase 3 (HDAC3) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT6R7JZ DM3H78D TN Histone deacetylase 1 (HDAC1) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3HR7F DI DM3HR7F DM3HR7F DN PMID28454500-Compound-9 DM3HR7F TI TTA6ZN2 DM3HR7F TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM3HR7F MA Activator DM3HR7F RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM3HR7F RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM3HR7F DI DM3HR7F DM3HR7F DN PMID28454500-Compound-9 DM3HR7F TI TT3Z6Y9 DM3HR7F TN Cysteines of Keap1 (KEAP1 Cysteines) DM3HR7F MA Modulator DM3HR7F RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM3HR7F RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM3HVCZ DI DM3HVCZ DM3HVCZ DN Tetra-hydro-pyrazolopyrazine derivative 1 DM3HVCZ TI TTHS256 DM3HVCZ TN Metabotropic glutamate receptor 5 (mGluR5) DM3HVCZ MA Modulator DM3HVCZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM3HVCZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM3I6OF DI DM3I6OF DM3I6OF DN PMID25522065-Compound-2 DM3I6OF TI TTX4RTB DM3I6OF TN Melanin-concentrating hormone receptor 1 (MCHR1) DM3I6OF MA Antagonist DM3I6OF RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM3I6OF RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM3I90D DI DM3I90D DM3I90D DN PMID25666693-Compound-20 DM3I90D TI TTMI6F5 DM3I90D TN Transient receptor potential cation channel V1 (TRPV1) DM3I90D MA Antagonist DM3I90D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3I90D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3IV7K DI DM3IV7K DM3IV7K DN Isoxazole-based bicyclic compound 8 DM3IV7K TI TTE4BSY DM3IV7K TN Bromodomain and extraterminal domain protein (BET) DM3IV7K MA Inhibitor DM3IV7K RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3IV7K RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3IXYL DI DM3IXYL DM3IXYL DN Quinoline carboxamide derivative 8 DM3IXYL TI TTPTXIN DM3IXYL TN Translocator protein (TSPO) DM3IXYL MA Ligand DM3IXYL RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM3IXYL RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM3IZ0H DI DM3IZ0H DM3IZ0H DN PMID25684022-Compound-WO2011137219 35(1-11) DM3IZ0H TI TTCZOF2 DM3IZ0H TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM3IZ0H MA Inhibitor DM3IZ0H RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM3IZ0H RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM3K25J DI DM3K25J DM3K25J DN Benzoheterocyclic compound 1 DM3K25J TI TTZCRP3 DM3K25J TN ERK activator kinase (MEK) DM3K25J MA Inhibitor DM3K25J RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3K25J RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3K7IM DI DM3K7IM DM3K7IM DN Piperazine urea derivative 4 DM3K7IM TI TTQR74A DM3K7IM TN Proteinase activated receptor 2 (PAR2) DM3K7IM MA Antagonist DM3K7IM RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM3K7IM RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM3KSV9 DI DM3KSV9 DM3KSV9 DN PMID25666693-Compound-51 DM3KSV9 TI TTMI6F5 DM3KSV9 TN Transient receptor potential cation channel V1 (TRPV1) DM3KSV9 MA Antagonist DM3KSV9 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3KSV9 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3KW2A DI DM3KW2A DM3KW2A DN Ketoheterocycle derivative 2 DM3KW2A TI TTDP1UC DM3KW2A TN Fatty acid amide hydrolase (FAAH) DM3KW2A MA Inhibitor DM3KW2A RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM3KW2A RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM3KWFQ DI DM3KWFQ DM3KWFQ DN PMID25991433-Compound-C1 DM3KWFQ TI TTHS0U8 DM3KWFQ TN Stress-activated protein kinase JNK2 (JNK2) DM3KWFQ MA Inhibitor DM3KWFQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3KWFQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LCIM DI DM3LCIM DM3LCIM DN PMID26651364-Compound-7b DM3LCIM TI TTTCRU2 DM3LCIM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM3LCIM MA Antagonist DM3LCIM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM3LCIM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM3LKTE DI DM3LKTE DM3LKTE DN Piperazinyl norbenzomorphane compound 1 DM3LKTE TI TT9NXW4 DM3LKTE TN Sigma intracellular receptor 2 (TMEM97) DM3LKTE MA Ligand DM3LKTE RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM3LKTE RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM3LNQG DI DM3LNQG DM3LNQG DN Aminoazetidine derivative 7 DM3LNQG TI TT6OEDT DM3LNQG TN Cannabinoid receptor 1 (CB1) DM3LNQG MA Antagonist DM3LNQG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3LNQG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TT3ZIJL DM3LWUR TN JNK-interacting protein peptide (pepJIP) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TTVOE6D DM3LWUR TN Mitogen-activated protein kinase (MAPK) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TTQBR95 DM3LWUR TN Stress-activated protein kinase 2a (p38 alpha) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3M169 DI DM3M169 DM3M169 DN Cyclopropane 1-carboxylic acid derivative 10 DM3M169 TI TTIY56R DM3M169 TN Kynurenine 3-hydroxylase (KMO) DM3M169 MA Inhibitor DM3M169 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM3M169 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM3M1NB DI DM3M1NB DM3M1NB DN PMID26004420-Compound-US20140031349B DM3M1NB TI TTJ13ST DM3M1NB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM3M1NB MA Inhibitor DM3M1NB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM3M1NB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM3M6SE DI DM3M6SE DM3M6SE DN PMID27774822-Compound-Figure10CompoundA DM3M6SE TI TTJSQEF DM3M6SE TN Tyrosine-protein kinase (PTK) DM3M6SE MA Inhibitor DM3M6SE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3M6SE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3MRD9 DI DM3MRD9 DM3MRD9 DN BDBM50061608 DM3MRD9 TI TTCGOIN DM3MRD9 TN PIM-3 protein kinase (PIM3) DM3MRD9 MA Inhibitor DM3MRD9 RN Azole compounds as PIM inhibitors. US9321756. DM3MRD9 RU http://www.freepatentsonline.com/US9321756.html DM3MVW1 DI DM3MVW1 DM3MVW1 DN PMID28350212-Compound-23 DM3MVW1 TI TTZS04O DM3MVW1 TN Gamma-secretase subunit APH-1A/1B (APH-1) DM3MVW1 MA Inhibitor DM3MVW1 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DM3MVW1 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DM3NE8J DI DM3NE8J DM3NE8J DN US9206139, 4 DM3NE8J TI TTYG6BU DM3NE8J TN Aggrecanase-1 (ADAMTS4) DM3NE8J MA Inhibitor DM3NE8J RN Aggrecanase inhibitors. US9206139. DM3NE8J RU http://www.freepatentsonline.com/US9206139.html DM3NPOU DI DM3NPOU DM3NPOU DN PMID30074415-Compound-21 DM3NPOU TI TTUNARX DM3NPOU TN Carbonic anhydrase (CA) DM3NPOU MA Inhibitor DM3NPOU RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM3NPOU RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM3NXP8 DI DM3NXP8 DM3NXP8 DN PMID26924192-Compound-57 DM3NXP8 TI TTE4BSY DM3NXP8 TN Bromodomain and extraterminal domain protein (BET) DM3NXP8 MA Inhibitor DM3NXP8 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3NXP8 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3O7UG DI DM3O7UG DM3O7UG DN Heteroaryl-azepine derivative 6 DM3O7UG TI TTWJBZ5 DM3O7UG TN 5-HT 2C receptor (HTR2C) DM3O7UG MA Agonist DM3O7UG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3O7UG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3OB4T DI DM3OB4T DM3OB4T DN SCHEMBL16322760 DM3OB4T TI TT78309 DM3OB4T TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DM3OB4T MA Inhibitor DM3OB4T RN Substituted benzylpyrazoles. US9765058. DM3OB4T RU http://www.freepatentsonline.com/US9765058.html DM3OCXI DI DM3OCXI DM3OCXI DN Di-substituted piperidine derivative 1 DM3OCXI TI TTEB0GD DM3OCXI TN Cholinesterase (BCHE) DM3OCXI MA Inhibitor DM3OCXI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM3OCXI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM3OPBR DI DM3OPBR DM3OPBR DN ZNFTXQFGUIKQQE-UHFFFAOYSA-N DM3OPBR TI TTDYP7I DM3OPBR TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3OPBR MA Inhibitor DM3OPBR RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DM3OPBR RU http://www.freepatentsonline.com/US9150519.html DM3OZ0F DI DM3OZ0F DM3OZ0F DN Salicylic acid derivative 5 DM3OZ0F TI TTH8FZW DM3OZ0F TN Signal transducer and activator of transcription 3 (STAT3) DM3OZ0F MA Inhibitor DM3OZ0F RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3OZ0F RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3PEUN DI DM3PEUN DM3PEUN DN Dihydropyrido pyrazinone compound 3 DM3PEUN TI TTIYVQP DM3PEUN TN Polo-like kinase 1 (PLK1) DM3PEUN MA Inhibitor DM3PEUN RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3PEUN RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3PF60 DI DM3PF60 DM3PF60 DN Monoamine derivative 5 DM3PF60 TI TTULVH8 DM3PF60 TN Tyrosinase (TYR) DM3PF60 MA Inhibitor DM3PF60 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM3PF60 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM3PU57 DI DM3PU57 DM3PU57 DN US8940736, 23 DM3PU57 TI TTR93NU DM3PU57 TN Casein kinase II alpha prime (CSNK2A2) DM3PU57 MA Inhibitor DM3PU57 RN Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736. DM3PU57 RU http://www.freepatentsonline.com/US8940736.html DM3Q1FT DI DM3Q1FT DM3Q1FT DN PMID28766366-Compound-Scheme27LeucettamineB DM3Q1FT TI TTSBVFO DM3Q1FT TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM3Q1FT MA Inhibitor DM3Q1FT RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM3Q1FT RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM3Q9OX DI DM3Q9OX DM3Q9OX DN Deuterated 3-cyanoquinoline derivative 1 DM3Q9OX TI TTS7G69 DM3Q9OX TN Fusion protein Bcr-Abl (Bcr-Abl) DM3Q9OX MA Inhibitor DM3Q9OX RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM3Q9OX RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM3Q9OX DI DM3Q9OX DM3Q9OX DN Deuterated 3-cyanoquinoline derivative 1 DM3Q9OX TI TT6PKBN DM3Q9OX TN Proto-oncogene c-Src (SRC) DM3Q9OX MA Inhibitor DM3Q9OX RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM3Q9OX RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM3QIF4 DI DM3QIF4 DM3QIF4 DN US9181182, 40 DM3QIF4 TI TTDYP7I DM3QIF4 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3QIF4 MA Inhibitor DM3QIF4 RN S1P receptors modulators. US9181182. DM3QIF4 RU http://www.freepatentsonline.com/US9181182.html DM3QMA0 DI DM3QMA0 DM3QMA0 DN Bicyclic heteroaryl carboxamide analog 3 DM3QMA0 TI TTHS256 DM3QMA0 TN Metabotropic glutamate receptor 5 (mGluR5) DM3QMA0 MA Modulator DM3QMA0 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM3QMA0 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM3QO5R DI DM3QO5R DM3QO5R DN PMID26004420-Compound-WO2014015495D DM3QO5R TI TTJ13ST DM3QO5R TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM3QO5R MA Inhibitor DM3QO5R RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM3QO5R RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM3QU80 DI DM3QU80 DM3QU80 DN PMID25726713-Compound-29 DM3QU80 TI TT8J1S3 DM3QU80 TN Smoothened homolog (SMO) DM3QU80 MA Inhibitor DM3QU80 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3QU80 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTVIREA DM3QX0R TN Adrenergic receptor (ADR) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTEX248 DM3QX0R TN Dopamine D2 receptor (D2R) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTSQIFT DM3QX0R TN 5-HT 1A receptor (HTR1A) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3R7BT DI DM3R7BT DM3R7BT DN US9127005, P2B DM3R7BT TI TT3T17P DM3R7BT TN Phospholipase D1 (PLD1) DM3R7BT MA Inhibitor DM3R7BT RN Isoform selective phospholipase D inhibitors. US9127005. DM3R7BT RU http://www.freepatentsonline.com/US9127005.html DM3R9PL DI DM3R9PL DM3R9PL DN Pyrazole derivative 1 DM3R9PL TI TT6OEDT DM3R9PL TN Cannabinoid receptor 1 (CB1) DM3R9PL MA Antagonist DM3R9PL RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3R9PL RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3RAU4 DI DM3RAU4 DM3RAU4 DN Pyrazine carboxamide derivative 1 DM3RAU4 TI TTF8P9I DM3RAU4 TN Diacylglycerol acyltransferase 1 (DGAT1) DM3RAU4 MA Inhibitor DM3RAU4 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM3RAU4 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM3REN5 DI DM3REN5 DM3REN5 DN Pyrimido-indole derivative 2 DM3REN5 TI TTE4BSY DM3REN5 TN Bromodomain and extraterminal domain protein (BET) DM3REN5 MA Inhibitor DM3REN5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3REN5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3RK0S DI DM3RK0S DM3RK0S DN Cycloalkyl nitrile pyrazole carboxamide derivative 1 DM3RK0S TI TTRMX3V DM3RK0S TN Janus kinase 2 (JAK-2) DM3RK0S MA Inhibitor DM3RK0S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3RK0S RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3RK0S DI DM3RK0S DM3RK0S DN Cycloalkyl nitrile pyrazole carboxamide derivative 1 DM3RK0S TI TT6DM01 DM3RK0S TN Janus kinase 1 (JAK-1) DM3RK0S MA Inhibitor DM3RK0S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3RK0S RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3S0LI DI DM3S0LI DM3S0LI DN Azaindazole derivative 1 DM3S0LI TI TTK0FEA DM3S0LI TN Leucine-rich repeat kinase 2 (LRRK2) DM3S0LI MA Inhibitor DM3S0LI RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3S0LI RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3SQUD DI DM3SQUD DM3SQUD DN Urea and carbamate bioisostere derivative 15 DM3SQUD TI TTL7C8Q DM3SQUD TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM3SQUD MA Inhibitor DM3SQUD RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM3SQUD RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM3T840 DI DM3T840 DM3T840 DN Isoxazole-based bicyclic compound 7 DM3T840 TI TTE4BSY DM3T840 TN Bromodomain and extraterminal domain protein (BET) DM3T840 MA Inhibitor DM3T840 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3T840 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3TVI6 DI DM3TVI6 DM3TVI6 DN Quinazolinedione derivative 2 DM3TVI6 TI TTVDSZ0 DM3TVI6 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM3TVI6 MA Inhibitor DM3TVI6 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3TVI6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3U58I DI DM3U58I DM3U58I DN Oxindole derivative 4 DM3U58I TI TT6AXLY DM3U58I TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DM3U58I MA Inhibitor DM3U58I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U58I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U58I DI DM3U58I DM3U58I DN Oxindole derivative 4 DM3U58I TI TTK0FEA DM3U58I TN Leucine-rich repeat kinase 2 (LRRK2) DM3U58I MA Inhibitor DM3U58I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U58I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U79M DI DM3U79M DM3U79M DN Hydrazide derivative 3 DM3U79M TI TTK0FEA DM3U79M TN Leucine-rich repeat kinase 2 (LRRK2) DM3U79M MA Inhibitor DM3U79M RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U79M RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U7RN DI DM3U7RN DM3U7RN DN PMID27376512-Compound-PG-11048 DM3U7RN TI TTBH0VX DM3U7RN TN Histone deacetylase (HDAC) DM3U7RN MA Inhibitor DM3U7RN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM3U7RN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM3U7RN DI DM3U7RN DM3U7RN DN PMID27376512-Compound-PG-11048 DM3U7RN TI TTHVCUP DM3U7RN TN DNA [cytosine-5]-methyltransferase (DNMT) DM3U7RN MA Inhibitor DM3U7RN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM3U7RN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM3UBG2 DI DM3UBG2 DM3UBG2 DN Pyrazolo[1,5-a]pyrimidine derivative 5 DM3UBG2 TI TT6OEDT DM3UBG2 TN Cannabinoid receptor 1 (CB1) DM3UBG2 MA Antagonist DM3UBG2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3UBG2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3VA8P DI DM3VA8P DM3VA8P DN Pyrrolidine derivative 13 DM3VA8P TI TT4TFGN DM3VA8P TN Vasopressin V1a receptor (V1AR) DM3VA8P MA Antagonist DM3VA8P RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DM3VA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DM3VA8P DI DM3VA8P DM3VA8P DN Pyrrolidine derivative 13 DM3VA8P TI TTSCIUP DM3VA8P TN Oxytocin receptor (OTR) DM3VA8P MA Antagonist DM3VA8P RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DM3VA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DM3VB6G DI DM3VB6G DM3VB6G DN 3-phenyl pyrazole derivative 1 DM3VB6G TI TTJQOD7 DM3VB6G TN 5-HT 2A receptor (HTR2A) DM3VB6G MA Antagonist DM3VB6G RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3VB6G RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3VL64 DI DM3VL64 DM3VL64 DN PMID29334795-Compound-23 DM3VL64 TI TT9JNIC DM3VL64 TN Histamine H3 receptor (H3R) DM3VL64 MA Inverse agonist DM3VL64 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3VL64 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3VL82 DI DM3VL82 DM3VL82 DN Pyrrolidinyl urea derivative 13 DM3VL82 TI TTTDVOJ DM3VL82 TN Tropomyosin-related kinase A (TrkA) DM3VL82 MA Inhibitor DM3VL82 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM3VL82 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM3VNK0 DI DM3VNK0 DM3VNK0 DN BDBM50080563 DM3VNK0 TI TTDYP7I DM3VNK0 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3VNK0 MA Inhibitor DM3VNK0 RN Pyridin-4-yl derivatives. US9617250. DM3VNK0 RU http://www.freepatentsonline.com/US9617250.html DM3VQ1Y DI DM3VQ1Y DM3VQ1Y DN PMID29865878-Compound-57 DM3VQ1Y TI TTEAD9J DM3VQ1Y TN Proteasome beta-8 (PS beta-8) DM3VQ1Y MA Inhibitor DM3VQ1Y RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM3VQ1Y RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM3W5SM DI DM3W5SM DM3W5SM DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1 DM3W5SM TI TTXJ47W DM3W5SM TN Metabotropic glutamate receptor 2 (mGluR2) DM3W5SM MA Antagonist DM3W5SM RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM3W5SM RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM3WHL2 DI DM3WHL2 DM3WHL2 DN Azetidinyl-piperazine derivative 3 DM3WHL2 TI TTZ963I DM3WHL2 TN Monoglyceride lipase (MAGL) DM3WHL2 MA Inhibitor DM3WHL2 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM3WHL2 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM3WQNY DI DM3WQNY DM3WQNY DN 4-Hydroxybenzoicacid DM3WQNY TI TTGP7BY DM3WQNY TN Monoamine oxidase type B (MAO-B) DM3WQNY MA Inhibitor DM3WQNY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM3WQNY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM3X4PJ DI DM3X4PJ DM3X4PJ DN Cyclopropylamine derivative 7 DM3X4PJ TI TTNR0UQ DM3X4PJ TN Lysine-specific histone demethylase 1 (LSD) DM3X4PJ MA Inhibitor DM3X4PJ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3X4PJ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3XWMO DI DM3XWMO DM3XWMO DN US8598210, Table XV, 4 DM3XWMO TI TT9ISBX DM3XWMO TN HIF-prolyl hydroxylase 2 (HPH-2) DM3XWMO MA Inhibitor DM3XWMO RN Prolyl hydroxylase inhibitors and methods of use. US8598210. DM3XWMO RU http://www.freepatentsonline.com/US8598210.html DM3YMHP DI DM3YMHP DM3YMHP DN Imidazo pyridine derivative 4 DM3YMHP TI TTV1C0Z DM3YMHP TN Neuropeptide S receptor (NPSR) DM3YMHP MA Antagonist DM3YMHP RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM3YMHP RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM3YPX1 DI DM3YPX1 DM3YPX1 DN Indoline derivative 21 DM3YPX1 TI TTOHSBA DM3YPX1 TN Vascular endothelial growth factor A (VEGFA) DM3YPX1 MA Inhibitor DM3YPX1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM3YPX1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM3Z5UQ DI DM3Z5UQ DM3Z5UQ DN Benzo[d]oxazol-2(3H)-one derivative 3 DM3Z5UQ TI TT9JNIC DM3Z5UQ TN Histamine H3 receptor (H3R) DM3Z5UQ MA Inhibitor DM3Z5UQ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3Z5UQ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3Z5UQ DI DM3Z5UQ DM3Z5UQ DN Benzo[d]oxazol-2(3H)-one derivative 3 DM3Z5UQ TI TTEX248 DM3Z5UQ TN Dopamine D2 receptor (D2R) DM3Z5UQ MA Ligand DM3Z5UQ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3Z5UQ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3ZF95 DI DM3ZF95 DM3ZF95 DN 1,2-diamino cyclopentane-based derivative 10 DM3ZF95 TI TT9N02I DM3ZF95 TN Orexin receptor type 2 (HCRTR2) DM3ZF95 MA Antagonist DM3ZF95 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM3ZF95 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM3ZF95 DI DM3ZF95 DM3ZF95 DN 1,2-diamino cyclopentane-based derivative 10 DM3ZF95 TI TT60Q8D DM3ZF95 TN Orexin receptor type 1 (HCRTR1) DM3ZF95 MA Antagonist DM3ZF95 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM3ZF95 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM3ZGBH DI DM3ZGBH DM3ZGBH DN Coumaricacid DM3ZGBH TI TTGP7BY DM3ZGBH TN Monoamine oxidase type B (MAO-B) DM3ZGBH MA Inhibitor DM3ZGBH RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM3ZGBH RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM40FVN DI DM40FVN DM40FVN DN PMID25684022-Compound-US20130053382 36(3-5) DM40FVN TI TTCZOF2 DM40FVN TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM40FVN MA Inhibitor DM40FVN RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM40FVN RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM40KU8 DI DM40KU8 DM40KU8 DN US10023583, Example 8 DM40KU8 TI TTY2KP7 DM40KU8 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DM40KU8 MA Inhibitor DM40KU8 RN Bicyclic pyridine compound. US10023583. DM40KU8 RU http://www.freepatentsonline.com/US10023583.html DM40LIN DI DM40LIN DM40LIN DN PMID27321640-Compound-76 DM40LIN TI TTJGW1Z DM40LIN TN Phosphodiesterase 2A (PDE2A) DM40LIN MA Inhibitor DM40LIN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM40LIN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM410Z6 DI DM410Z6 DM410Z6 DN PMID25522065-Compound-11 DM410Z6 TI TTX4RTB DM410Z6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM410Z6 MA Antagonist DM410Z6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM410Z6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM417XY DI DM417XY DM417XY DN Aryl alkanolamine derivative 1 DM417XY TI TT5TPI6 DM417XY TN Opioid receptor sigma 1 (OPRS1) DM417XY MA Antagonist DM417XY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM417XY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM4192V DI DM4192V DM4192V DN Pyrimidine derivative 34 DM4192V TI TTPLTSQ DM4192V TN Neutrophil elastase (NE) DM4192V MA Inhibitor DM4192V RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM4192V RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM4198Z DI DM4198Z DM4198Z DN Benzofurans derivative 1 DM4198Z TI TTA592U DM4198Z TN Urate anion exchanger 1 (URAT1) DM4198Z MA Inhibitor DM4198Z RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM4198Z RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM41B5O DI DM41B5O DM41B5O DN PMID27321640-Compound-59 DM41B5O TI TTJW4LU DM41B5O TN Phosphodiesterase 10A (PDE10) DM41B5O MA Inhibitor DM41B5O RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM41B5O RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM41B5O DI DM41B5O DM41B5O DN PMID27321640-Compound-59 DM41B5O TI TTJGW1Z DM41B5O TN Phosphodiesterase 2A (PDE2A) DM41B5O MA Inhibitor DM41B5O RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM41B5O RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM41ZW9 DI DM41ZW9 DM41ZW9 DN Ruxolitinib derivative 1 DM41ZW9 TI TTJSQEF DM41ZW9 TN Tyrosine-protein kinase (PTK) DM41ZW9 MA Inhibitor DM41ZW9 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM41ZW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM42BU9 DI DM42BU9 DM42BU9 DN Benzoic acid linked peptide analog 3 DM42BU9 TI TTULVH8 DM42BU9 TN Tyrosinase (TYR) DM42BU9 MA Inhibitor DM42BU9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM42BU9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM42EST DI DM42EST DM42EST DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 DM42EST TI TTJGW1Z DM42EST TN Phosphodiesterase 2A (PDE2A) DM42EST MA Inhibitor DM42EST RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM42EST RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM42EST DI DM42EST DM42EST DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 DM42EST TI TTJW4LU DM42EST TN Phosphodiesterase 10A (PDE10) DM42EST MA Inhibitor DM42EST RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM42EST RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM42OYU DI DM42OYU DM42OYU DN PMID28870136-Compound-50 DM42OYU TI TTK0O6Y DM42OYU TN Ecto-5'-nucleotidase (CD73) DM42OYU MA Inhibitor DM42OYU RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM42OYU RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM42VUQ DI DM42VUQ DM42VUQ DN PMID27019002-Compound-42a DM42VUQ TI TTNR0UQ DM42VUQ TN Lysine-specific histone demethylase 1 (LSD) DM42VUQ MA Inhibitor DM42VUQ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM42VUQ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM42XWO DI DM42XWO DM42XWO DN US10053465, 8 DM42XWO TI TTIEMFN DM42XWO TN TYRO3 tyrosine kinase receptor (TYRO3) DM42XWO MA Inhibitor DM42XWO RN Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465. DM42XWO RU http://www.freepatentsonline.com/US10053465.html DM435GR DI DM435GR DM435GR DN PMID27109571-Compound-25 DM435GR TI TTNT2S6 DM435GR TN Fatty acid-binding protein 5 (FABP5) DM435GR MA Inhibitor DM435GR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM435GR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM435GR DI DM435GR DM435GR DN PMID27109571-Compound-25 DM435GR TI TTHWMFZ DM435GR TN Fatty acid-binding protein 4 (FABP4) DM435GR MA Inhibitor DM435GR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM435GR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM437ZC DI DM437ZC DM437ZC DN PMID28270021-Compound-WO2010077680 103 DM437ZC TI TTTDVOJ DM437ZC TN Tropomyosin-related kinase A (TrkA) DM437ZC MA Antagonist DM437ZC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM437ZC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM43APD DI DM43APD DM43APD DN Aromatic ring compound 3 DM43APD TI TT9O6WS DM43APD TN Glucagon receptor (GCGR) DM43APD MA Antagonist DM43APD RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM43APD RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM43EKN DI DM43EKN DM43EKN DN 3-(phenoxymethyl) benzylamine derivative 3 DM43EKN TI TTULVH8 DM43EKN TN Tyrosinase (TYR) DM43EKN MA Inhibitor DM43EKN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM43EKN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM43YA0 DI DM43YA0 DM43YA0 DN 4-Carboxamido-isoindolinone derivative 3 DM43YA0 TI TTVDSZ0 DM43YA0 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM43YA0 MA Inhibitor DM43YA0 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM43YA0 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM43Z1G DI DM43Z1G DM43Z1G DN PMID26394986-Compound-22 DM43Z1G TI TTH8FZW DM43Z1G TN Signal transducer and activator of transcription 3 (STAT3) DM43Z1G MA Inhibitor DM43Z1G RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM43Z1G RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM45COR DI DM45COR DM45COR DN Chalcone derivative 4 DM45COR TI TTA6ZN2 DM45COR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM45COR MA Activator DM45COR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM45COR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM45COR DI DM45COR DM45COR DN Chalcone derivative 4 DM45COR TI TT3Z6Y9 DM45COR TN Cysteines of Keap1 (KEAP1 Cysteines) DM45COR MA Modulator DM45COR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM45COR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM45JMT DI DM45JMT DM45JMT DN Peptide analog 61 DM45JMT TI TTQAJF1 DM45JMT TN Cathepsin G (CTSG) DM45JMT MA Inhibitor DM45JMT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM45JMT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM45JMT DI DM45JMT DM45JMT DN Peptide analog 61 DM45JMT TI TTPLTSQ DM45JMT TN Neutrophil elastase (NE) DM45JMT MA Inhibitor DM45JMT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM45JMT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM45QW1 DI DM45QW1 DM45QW1 DN PMID29865878-Compound-56 DM45QW1 TI TTSJMN8 DM45QW1 TN Immunoproteasome complex (IP) DM45QW1 MA Inhibitor DM45QW1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM45QW1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM460D1 DI DM460D1 DM460D1 DN PMID27336223-Compound-8 DM460D1 TI TTISP28 DM460D1 TN Retinoic acid receptor beta (RARB) DM460D1 MA Agonist DM460D1 RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM460D1 RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM462XZ DI DM462XZ DM462XZ DN PMID29865878-Compound-45 DM462XZ TI TTSJMN8 DM462XZ TN Immunoproteasome complex (IP) DM462XZ MA Inhibitor DM462XZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM462XZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM46NRV DI DM46NRV DM46NRV DN Biphenyl mannoside derivative 7 DM46NRV TI TTTCRU2 DM46NRV TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM46NRV MA Antagonist DM46NRV RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM46NRV RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM46UPM DI DM46UPM DM46UPM DN BDBM50363780 DM46UPM TI TTLKF5M DM46UPM TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM46UPM MA Inhibitor DM46UPM RN Aroyl thiourea derivatives. US9365508. DM46UPM RU http://www.freepatentsonline.com/US9365508.html DM4765M DI DM4765M DM4765M DN Curcumin analog 1 DM4765M TI TTH8FZW DM4765M TN Signal transducer and activator of transcription 3 (STAT3) DM4765M MA Inhibitor DM4765M RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4765M RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4765M DI DM4765M DM4765M DN Curcumin analog 1 DM4765M TI TTRMX3V DM4765M TN Janus kinase 2 (JAK-2) DM4765M MA Inhibitor DM4765M RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4765M RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM47FNS DI DM47FNS DM47FNS DN PMID28270021-Compound-WO2010077680 811 DM47FNS TI TTTDVOJ DM47FNS TN Tropomyosin-related kinase A (TrkA) DM47FNS MA Antagonist DM47FNS RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM47FNS RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM47KWB DI DM47KWB DM47KWB DN Benzo[d]oxazol-2(3H)-one derivative 2 DM47KWB TI TT9JNIC DM47KWB TN Histamine H3 receptor (H3R) DM47KWB MA Inhibitor DM47KWB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM47KWB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM47KWB DI DM47KWB DM47KWB DN Benzo[d]oxazol-2(3H)-one derivative 2 DM47KWB TI TTEX248 DM47KWB TN Dopamine D2 receptor (D2R) DM47KWB MA Ligand DM47KWB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM47KWB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM47L9Q DI DM47L9Q DM47L9Q DN Mycophenolic acid/nucleotide derivative 12 DM47L9Q TI TTL7C8Q DM47L9Q TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM47L9Q MA Inhibitor DM47L9Q RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM47L9Q RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM47M2U DI DM47M2U DM47M2U DN PMID29865878-Compound-52 DM47M2U TI TTSJMN8 DM47M2U TN Immunoproteasome complex (IP) DM47M2U MA Inhibitor DM47M2U RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM47M2U RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM47V3I DI DM47V3I DM47V3I DN Aryl oxyanilide derivative 2 DM47V3I TI TTPTXIN DM47V3I TN Translocator protein (TSPO) DM47V3I MA Ligand DM47V3I RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM47V3I RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM48PIO DI DM48PIO DM48PIO DN Azetidine urea derivative 3 DM48PIO TI TTDP1UC DM48PIO TN Fatty acid amide hydrolase (FAAH) DM48PIO MA Inhibitor DM48PIO RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM48PIO RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM48YKE DI DM48YKE DM48YKE DN PMID25772215-Compound-EP2149552diaminopyrimidines DM48YKE TI TT1ZAVI DM48YKE TN Prostaglandin E2 receptor EP2 (PTGER2) DM48YKE MA Antagonist DM48YKE RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM48YKE RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM49FU0 DI DM49FU0 DM49FU0 DN Epoxysuccinate derivative 9 DM49FU0 TI TTG5QB7 DM49FU0 TN Calpain-2 (CAPN2) DM49FU0 MA Inhibitor DM49FU0 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM49FU0 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM49V8G DI DM49V8G DM49V8G DN PMID26651364-Compound-9c DM49V8G TI TTTCRU2 DM49V8G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM49V8G MA Antagonist DM49V8G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM49V8G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM49YTU DI DM49YTU DM49YTU DN PMID29671355-Compound-74 DM49YTU TI TT5ZKDI DM49YTU TN Histone deacetylase 6 (HDAC6) DM49YTU MA Inhibitor DM49YTU RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM49YTU RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM49YTU DI DM49YTU DM49YTU DN PMID29671355-Compound-74 DM49YTU TI TTSHTOI DM49YTU TN Histone deacetylase 2 (HDAC2) DM49YTU MA Inhibitor DM49YTU RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM49YTU RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM4AFHY DI DM4AFHY DM4AFHY DN PMID26161698-Compound-25 DM4AFHY TI TT7HF4W DM4AFHY TN Cyclin-dependent kinase 2 (CDK2) DM4AFHY MA Inhibitor DM4AFHY RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM4AFHY RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM4AFHY DI DM4AFHY DM4AFHY DN PMID26161698-Compound-25 DM4AFHY TI TT1LVF2 DM4AFHY TN Cyclin-dependent kinase 9 (CDK9) DM4AFHY MA Inhibitor DM4AFHY RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM4AFHY RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM4AM1E DI DM4AM1E DM4AM1E DN Aromatic hydrazine carboxyimidoamide derivative 5 DM4AM1E TI TTULVH8 DM4AM1E TN Tyrosinase (TYR) DM4AM1E MA Inhibitor DM4AM1E RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM4AM1E RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM4AOIR DI DM4AOIR DM4AOIR DN PMID29473428-Compound-41 DM4AOIR TI TTZJYKH DM4AOIR TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM4AOIR MA Antagonist DM4AOIR RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM4AOIR RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM4C5QY DI DM4C5QY DM4C5QY DN Biaryl mannoside derivative 14 DM4C5QY TI TTTCRU2 DM4C5QY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4C5QY MA Antagonist DM4C5QY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4C5QY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4CN9K DI DM4CN9K DM4CN9K DN PMID30107136-Compound-Example13 DM4CN9K TI TT23XQV DM4CN9K TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4CN9K MA Inhibitor DM4CN9K RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4CN9K RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTJW4LU DM4CSBD TN Phosphodiesterase 10A (PDE10) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTQ6VDM DM4CSBD TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTJGW1Z DM4CSBD TN Phosphodiesterase 2A (PDE2A) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4D1WK DI DM4D1WK DM4D1WK DN PMID30107136-Compound-Example49 DM4D1WK TI TT23XQV DM4D1WK TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4D1WK MA Inhibitor DM4D1WK RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4D1WK RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4D75L DI DM4D75L DM4D75L DN PMID27019002-Compound-50 DM4D75L TI TTNR0UQ DM4D75L TN Lysine-specific histone demethylase 1 (LSD) DM4D75L MA Inhibitor DM4D75L RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM4D75L RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM4DJA7 DI DM4DJA7 DM4DJA7 DN QCPOIDRINIAUKU-SRBBEKPSSA-N DM4DJA7 TI TTXHWA7 DM4DJA7 TN Ubiquitin-activating enzyme E1 (UBAE1) DM4DJA7 MA Inhibitor DM4DJA7 RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DM4DJA7 RU http://www.freepatentsonline.com/US10202389.html DM4DOUB DI DM4DOUB DM4DOUB DN PMID28460551-Compound-2 DM4DOUB TI TTI7421 DM4DOUB TN Platelet-derived growth factor receptor beta (PDGFRB) DM4DOUB MA Inhibitor DM4DOUB RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DM4DOUB RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DM4EFRL DI DM4EFRL DM4EFRL DN PMID27977313-Compound-48 DM4EFRL TI TTR7UJ3 DM4EFRL TN Cytoplasmic thioredoxin reductase (TXNRD1) DM4EFRL MA Inhibitor DM4EFRL RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM4EFRL RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM4EUFL DI DM4EUFL DM4EUFL DN Fused aromatic compound 1 DM4EUFL TI TTZMAO3 DM4EUFL TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM4EUFL MA Agonist DM4EUFL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4EUFL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4FD7C DI DM4FD7C DM4FD7C DN PMID28870136-Compound-46 DM4FD7C TI TTK0O6Y DM4FD7C TN Ecto-5'-nucleotidase (CD73) DM4FD7C MA Inhibitor DM4FD7C RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM4FD7C RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM4FHTG DI DM4FHTG DM4FHTG DN Benzoxazinone derivative 2 DM4FHTG TI TT5L2VC DM4FHTG TN Kallikrein-related peptidase (KLK) DM4FHTG MA Inhibitor DM4FHTG RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM4FHTG RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM4FHTG DI DM4FHTG DM4FHTG DN Benzoxazinone derivative 2 DM4FHTG TI TT4319X DM4FHTG TN Kallikrein-4 (KLK4) DM4FHTG MA Inhibitor DM4FHTG RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM4FHTG RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM4G3OC DI DM4G3OC DM4G3OC DN US8669361, 102 DM4G3OC TI TTCGOIN DM4G3OC TN PIM-3 protein kinase (PIM3) DM4G3OC MA Inhibitor DM4G3OC RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9573943. DM4G3OC RU http://www.freepatentsonline.com/US9573943.html DM4GF58 DI DM4GF58 DM4GF58 DN Pyrazolo[3,4-d]pyrimidine derivative 7 DM4GF58 TI TT4DXQT DM4GF58 TN Proto-oncogene c-Ret (RET) DM4GF58 MA Inhibitor DM4GF58 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM4GF58 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM4GQJH DI DM4GQJH DM4GQJH DN PMID25553724-Compound-EP20132578214 2 DM4GQJH TI TTSXVID DM4GQJH TN Nuclear factor NF-kappa-B (NFKB) DM4GQJH MA Inhibitor DM4GQJH RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM4GQJH RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM4GR2C DI DM4GR2C DM4GR2C DN 1,3,4-oxadiazole derivative 4 DM4GR2C TI TT23XQV DM4GR2C TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4GR2C MA Inhibitor DM4GR2C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4GR2C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4GUZO DI DM4GUZO DM4GUZO DN PMID25666693-Compound-50 DM4GUZO TI TTMI6F5 DM4GUZO TN Transient receptor potential cation channel V1 (TRPV1) DM4GUZO MA Antagonist DM4GUZO RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4GUZO RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4GZBI DI DM4GZBI DM4GZBI DN Indolizine derivative 1 DM4GZBI TI TTN9T81 DM4GZBI TN Arachidonate 15-lipoxygenase (15-LOX) DM4GZBI MA Inhibitor DM4GZBI RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DM4GZBI RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DM4GZBI DI DM4GZBI DM4GZBI DN Indolizine derivative 1 DM4GZBI TI TTDNFMT DM4GZBI TN Platelet-activating factor acetylhydrolase (PLA2G7) DM4GZBI MA Inhibitor DM4GZBI RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DM4GZBI RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DM4HBWU DI DM4HBWU DM4HBWU DN Tricyclic indole compound 1 DM4HBWU TI TTPTXIN DM4HBWU TN Translocator protein (TSPO) DM4HBWU MA Ligand DM4HBWU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM4HBWU RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM4I75L DI DM4I75L DM4I75L DN Monoamine derivative 3 DM4I75L TI TTULVH8 DM4I75L TN Tyrosinase (TYR) DM4I75L MA Inhibitor DM4I75L RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM4I75L RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM4I829 DI DM4I829 DM4I829 DN BDBM50080408 DM4I829 TI TTI1FPZ DM4I829 TN Epithelial discoidin domain receptor 1 (DDR1) DM4I829 MA Inhibitor DM4I829 RN Quinazolinedione derivative. US9567304. DM4I829 RU http://www.freepatentsonline.com/US9567304.html DM4ILAK DI DM4ILAK DM4ILAK DN PMID30280939-Compound-WO2015035128 DM4ILAK TI TTOK0LR DM4ILAK TN Toll-like receptor (TLR) DM4ILAK MA Agonist DM4ILAK RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM4ILAK RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM4IS6Q DI DM4IS6Q DM4IS6Q DN PMID27109571-Compound-32 DM4IS6Q TI TTMY6L1 DM4IS6Q TN Fatty acid-binding protein (FABP) DM4IS6Q MA Inhibitor DM4IS6Q RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4IS6Q RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4ISCQ DI DM4ISCQ DM4ISCQ DN Carbamide derivative 3 DM4ISCQ TI TTF8P9I DM4ISCQ TN Diacylglycerol acyltransferase 1 (DGAT1) DM4ISCQ MA Inhibitor DM4ISCQ RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM4ISCQ RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM4IZUH DI DM4IZUH DM4IZUH DN PMID27551786-Compound-138 DM4IZUH TI TT26PHO DM4IZUH TN Mineralocorticoid receptor (MR) DM4IZUH MA Antagonist DM4IZUH RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM4IZUH RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM4J2SM DI DM4J2SM DM4J2SM DN PMID25399762-Compound-Table 7-Veratraldehyde DM4J2SM TI TTGP7BY DM4J2SM TN Monoamine oxidase type B (MAO-B) DM4J2SM MA Inhibitor DM4J2SM RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4J2SM RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4JDHO DI DM4JDHO DM4JDHO DN Aminopiperidine derivative 2 DM4JDHO TI TTDIGC1 DM4JDHO TN Dipeptidyl peptidase 4 (DPP-4) DM4JDHO MA Inhibitor DM4JDHO RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM4JDHO RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM4JNLQ DI DM4JNLQ DM4JNLQ DN Indoline derivative 20 DM4JNLQ TI TTOHSBA DM4JNLQ TN Vascular endothelial growth factor A (VEGFA) DM4JNLQ MA Inhibitor DM4JNLQ RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM4JNLQ RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM4JZ2T DI DM4JZ2T DM4JZ2T DN Piperazine derivative 2 DM4JZ2T TI TT6OEDT DM4JZ2T TN Cannabinoid receptor 1 (CB1) DM4JZ2T MA Antagonist DM4JZ2T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM4JZ2T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM4K3AU DI DM4K3AU DM4K3AU DN PMID25435285-Compound-44 DM4K3AU TI TTXJ47W DM4K3AU TN Metabotropic glutamate receptor 2 (mGluR2) DM4K3AU MA Antagonist DM4K3AU RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM4K3AU RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTT7PJU DM4KBZQ TN Janus kinase 3 (JAK-3) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TT6DM01 DM4KBZQ TN Janus kinase 1 (JAK-1) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTBYWP2 DM4KBZQ TN TYK2 tyrosine kinase (TYK2) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTKAWRQ DM4KBZQ TN JAK-STAT signaling pathway (JAK-STAT pathway) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTJSQEF DM4KBZQ TN Tyrosine-protein kinase (PTK) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KWVF DI DM4KWVF DM4KWVF DN PMID28594589-Compound-TABLE3C14 DM4KWVF TI TTZCRP3 DM4KWVF TN ERK activator kinase (MEK) DM4KWVF MA Inhibitor DM4KWVF RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM4KWVF RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM4LF0X DI DM4LF0X DM4LF0X DN PMID26651364-Compound-6e DM4LF0X TI TTTCRU2 DM4LF0X TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4LF0X MA Antagonist DM4LF0X RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4LF0X RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4M2TU DI DM4M2TU DM4M2TU DN PMID26004420-Compound-US20140336177D DM4M2TU TI TTJ13ST DM4M2TU TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM4M2TU MA Inhibitor DM4M2TU RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM4M2TU RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM4MA2X DI DM4MA2X DM4MA2X DN PMID26666989-Compound-Figure9middle01 DM4MA2X TI TT8BUGW DM4MA2X TN Glycogen phosphorylase (PYG) DM4MA2X MA Inhibitor DM4MA2X RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM4MA2X RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM4MAHK DI DM4MAHK DM4MAHK DN Salicylic acid derivative 4 DM4MAHK TI TTH8FZW DM4MAHK TN Signal transducer and activator of transcription 3 (STAT3) DM4MAHK MA Inhibitor DM4MAHK RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4MAHK RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4MJ3U DI DM4MJ3U DM4MJ3U DN US9493447, 1001 DM4MJ3U TI TTIS4OW DM4MJ3U TN Phosphodiesterase 8 (PDE8) DM4MJ3U MA Inhibitor DM4MJ3U RN Optically active PDE10 inhibitor. US9493447. DM4MJ3U RU http://www.freepatentsonline.com/US9493447.html DM4MRP9 DI DM4MRP9 DM4MRP9 DN US8987457, 117 DM4MRP9 TI TTCGOIN DM4MRP9 TN PIM-3 protein kinase (PIM3) DM4MRP9 MA Inhibitor DM4MRP9 RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DM4MRP9 RU http://www.freepatentsonline.com/US8987457.html DM4MZ29 DI DM4MZ29 DM4MZ29 DN PMID26924192-Compound-21 DM4MZ29 TI TTRA6BO DM4MZ29 TN Bromodomain-containing protein 4 (BRD4) DM4MZ29 MA Inhibitor DM4MZ29 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM4MZ29 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM4NVTB DI DM4NVTB DM4NVTB DN PMID28394193-Compound-50 DM4NVTB TI TT9MZCQ DM4NVTB TN Enhancer of zeste homolog 2 (EZH2) DM4NVTB MA Inhibitor DM4NVTB RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4NVTB RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4NXBK DI DM4NXBK DM4NXBK DN PMID25684022-Compound-WO2011137219 38(5-7) DM4NXBK TI TTCZOF2 DM4NXBK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM4NXBK MA Inhibitor DM4NXBK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM4NXBK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM4O3DW DI DM4O3DW DM4O3DW DN 3,4-Dihydroxybenzaldehyde DM4O3DW TI TTGP7BY DM4O3DW TN Monoamine oxidase type B (MAO-B) DM4O3DW MA Inhibitor DM4O3DW RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4O3DW RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4O9T3 DI DM4O9T3 DM4O9T3 DN Flavonoid derivative 8 DM4O9T3 TI TTZMAO3 DM4O9T3 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM4O9T3 MA Agonist DM4O9T3 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4O9T3 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4O9T3 DI DM4O9T3 DM4O9T3 DN Flavonoid derivative 8 DM4O9T3 TI TTJ584C DM4O9T3 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM4O9T3 MA Agonist DM4O9T3 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4O9T3 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4OGKH DI DM4OGKH DM4OGKH DN Salicylic acid derivative 3 DM4OGKH TI TTH8FZW DM4OGKH TN Signal transducer and activator of transcription 3 (STAT3) DM4OGKH MA Inhibitor DM4OGKH RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4OGKH RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4OHB5 DI DM4OHB5 DM4OHB5 DN US9181182, 47 DM4OHB5 TI TTDYP7I DM4OHB5 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM4OHB5 MA Inhibitor DM4OHB5 RN S1P receptors modulators. US9181182. DM4OHB5 RU http://www.freepatentsonline.com/US9181182.html DM4P9HL DI DM4P9HL DM4P9HL DN Cyclopropane 1-carboxylic acid derivative 8 DM4P9HL TI TTIY56R DM4P9HL TN Kynurenine 3-hydroxylase (KMO) DM4P9HL MA Inhibitor DM4P9HL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM4P9HL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM4Q5SW DI DM4Q5SW DM4Q5SW DN PMID29338548-Compound-33 DM4Q5SW TI TTHJTF7 DM4Q5SW TN Glycine transporter GlyT-1 (SLC6A9) DM4Q5SW MA Inhibitor DM4Q5SW RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM4Q5SW RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM4Q6XZ DI DM4Q6XZ DM4Q6XZ DN PMID27376512-Compound-Table1Example5 DM4Q6XZ TI TT6S2FE DM4Q6XZ TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM4Q6XZ MA Inhibitor DM4Q6XZ RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM4Q6XZ RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM4QA6X DI DM4QA6X DM4QA6X DN PMID27788040-Compound-6a DM4QA6X TI TTV1C0Z DM4QA6X TN Neuropeptide S receptor (NPSR) DM4QA6X MA Antagonist DM4QA6X RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM4QA6X RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM4QUY0 DI DM4QUY0 DM4QUY0 DN Mannoside derivative 12 DM4QUY0 TI TTTCRU2 DM4QUY0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4QUY0 MA Antagonist DM4QUY0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4QUY0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4QVD0 DI DM4QVD0 DM4QVD0 DN Piperidinyl triazole derivative 5 DM4QVD0 TI TTTJZ4M DM4QVD0 TN Prolylcarboxypeptidase (PRCP) DM4QVD0 MA Inhibitor DM4QVD0 RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM4QVD0 RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM4QYIJ DI DM4QYIJ DM4QYIJ DN PMID25666693-Compound-84 DM4QYIJ TI TTMI6F5 DM4QYIJ TN Transient receptor potential cation channel V1 (TRPV1) DM4QYIJ MA Antagonist DM4QYIJ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4QYIJ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4R1MK DI DM4R1MK DM4R1MK DN Isoquinoline derivative 3 DM4R1MK TI TTMSFAW DM4R1MK TN Cannabinoid receptor 2 (CB2) DM4R1MK RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM4R1MK RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM4R7OQ DI DM4R7OQ DM4R7OQ DN Spirocyclic diamine urea derivative 1 DM4R7OQ TI TTDP1UC DM4R7OQ TN Fatty acid amide hydrolase (FAAH) DM4R7OQ MA Inhibitor DM4R7OQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM4R7OQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM4RTMO DI DM4RTMO DM4RTMO DN Cyclopropane 1-carboxylic acid derivative 7 DM4RTMO TI TTIY56R DM4RTMO TN Kynurenine 3-hydroxylase (KMO) DM4RTMO MA Inhibitor DM4RTMO RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM4RTMO RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM4S2U5 DI DM4S2U5 DM4S2U5 DN Aryl mannoside derivative 2 DM4S2U5 TI TTTCRU2 DM4S2U5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4S2U5 MA Antagonist DM4S2U5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4S2U5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4S5DF DI DM4S5DF DM4S5DF DN US8975409, Comparative compound B DM4S5DF TI TTVSMOH DM4S5DF TN Sphingosine-1-phosphate receptor 2 (S1PR2) DM4S5DF MA Inhibitor DM4S5DF RN Phenyl derivative. US8975409. DM4S5DF RU http://www.freepatentsonline.com/US8975409.html DM4S5ME DI DM4S5ME DM4S5ME DN PMID27109571-Compound-18 DM4S5ME TI TTNT2S6 DM4S5ME TN Fatty acid-binding protein 5 (FABP5) DM4S5ME MA Inhibitor DM4S5ME RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4S5ME RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4S5ME DI DM4S5ME DM4S5ME DN PMID27109571-Compound-18 DM4S5ME TI TTHWMFZ DM4S5ME TN Fatty acid-binding protein 4 (FABP4) DM4S5ME MA Inhibitor DM4S5ME RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4S5ME RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4S5PB DI DM4S5PB DM4S5PB DN PMID26651364-Compound-47 DM4S5PB TI TTTCRU2 DM4S5PB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4S5PB MA Antagonist DM4S5PB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4S5PB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4TOGU DI DM4TOGU DM4TOGU DN Benzanilide compound 1 DM4TOGU TI TTUX68I DM4TOGU TN Hypoxia-inducible factor 1 (HIF-1) DM4TOGU MA Inhibitor DM4TOGU RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM4TOGU RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM4U63E DI DM4U63E DM4U63E DN Five membered heterocyclic benzamide derivative 2 DM4U63E TI TTTDVOJ DM4U63E TN Tropomyosin-related kinase A (TrkA) DM4U63E MA Inhibitor DM4U63E RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM4U63E RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM4UM03 DI DM4UM03 DM4UM03 DN PMID25399762-Compound-Table 6-10 DM4UM03 TI TTGP7BY DM4UM03 TN Monoamine oxidase type B (MAO-B) DM4UM03 MA Inhibitor DM4UM03 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4UM03 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4UM03 DI DM4UM03 DM4UM03 DN PMID25399762-Compound-Table 6-10 DM4UM03 TI TTNR0UQ DM4UM03 TN Lysine-specific histone demethylase 1 (LSD) DM4UM03 MA Inhibitor DM4UM03 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4UM03 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4V3AY DI DM4V3AY DM4V3AY DN PMID28766366-Compound-Scheme12-3 DM4V3AY TI TTSBVFO DM4V3AY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM4V3AY MA Inhibitor DM4V3AY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM4V3AY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM4V3Y5 DI DM4V3Y5 DM4V3Y5 DN Benzamide derivative 11 DM4V3Y5 TI TT9NXW4 DM4V3Y5 TN Sigma intracellular receptor 2 (TMEM97) DM4V3Y5 MA Ligand DM4V3Y5 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM4V3Y5 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM4V3Y5 DI DM4V3Y5 DM4V3Y5 DN Benzamide derivative 11 DM4V3Y5 TI TT5TPI6 DM4V3Y5 TN Opioid receptor sigma 1 (OPRS1) DM4V3Y5 MA Ligand DM4V3Y5 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM4V3Y5 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM4VAQ3 DI DM4VAQ3 DM4VAQ3 DN PMID25666693-Compound-71 DM4VAQ3 TI TTMI6F5 DM4VAQ3 TN Transient receptor potential cation channel V1 (TRPV1) DM4VAQ3 MA Antagonist DM4VAQ3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4VAQ3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4VNWX DI DM4VNWX DM4VNWX DN Hexahydro quinoline derivative 1 DM4VNWX TI TTZJYKH DM4VNWX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM4VNWX MA Inhibitor DM4VNWX RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM4VNWX RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM4VXY1 DI DM4VXY1 DM4VXY1 DN Benzo(b)carbazol-11-one compound 1 DM4VXY1 TI TT4DXQT DM4VXY1 TN Proto-oncogene c-Ret (RET) DM4VXY1 MA Inhibitor DM4VXY1 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM4VXY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM4W0BX DI DM4W0BX DM4W0BX DN PMID26651364-Compound-128 DM4W0BX TI TTTCRU2 DM4W0BX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4W0BX MA Antagonist DM4W0BX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4W0BX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4W72V DI DM4W72V DM4W72V DN PMID27724045-Compound-17 DM4W72V TI TT473XN DM4W72V TN P2X purinoceptor 7 (P2RX7) DM4W72V MA Antagonist DM4W72V RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM4W72V RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM4XAGS DI DM4XAGS DM4XAGS DN Pyridine-2,4-dicarboxylic acid analog 3 DM4XAGS TI TTWAQBO DM4XAGS TN Lysine-specific demethylase 4E (KDM4E) DM4XAGS MA Inhibitor DM4XAGS RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM4XAGS RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM4XJST DI DM4XJST DM4XJST DN PMID25726713-Compound-38 DM4XJST TI TT8J1S3 DM4XJST TN Smoothened homolog (SMO) DM4XJST MA Inhibitor DM4XJST RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM4XJST RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM4Y3US DI DM4Y3US DM4Y3US DN PMID28394193-Compound-57 DM4Y3US TI TTJW2UQ DM4Y3US TN EZH2 Y641N mutant (EZH2 Y641N) DM4Y3US MA Inhibitor DM4Y3US RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4Y3US RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4Y3US DI DM4Y3US DM4Y3US DN PMID28394193-Compound-57 DM4Y3US TI TT9MZCQ DM4Y3US TN Enhancer of zeste homolog 2 (EZH2) DM4Y3US MA Inhibitor DM4Y3US RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4Y3US RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4YE8W DI DM4YE8W DM4YE8W DN PMID25553724-Compound-WO2011127048 34 DM4YE8W TI TTSXVID DM4YE8W TN Nuclear factor NF-kappa-B (NFKB) DM4YE8W MA Modulator DM4YE8W RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM4YE8W RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM4Z2KY DI DM4Z2KY DM4Z2KY DN PMID30280939-Compound-WO2013148427 DM4Z2KY TI TTOK0LR DM4Z2KY TN Toll-like receptor (TLR) DM4Z2KY MA Agonist DM4Z2KY RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM4Z2KY RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM4Z72S DI DM4Z72S DM4Z72S DN Fused triazoloamino-phenyl analog 1 DM4Z72S TI TT473XN DM4Z72S TN P2X purinoceptor 7 (P2RX7) DM4Z72S MA Antagonist DM4Z72S RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM4Z72S RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM4ZAE8 DI DM4ZAE8 DM4ZAE8 DN PMID28394193-Compound-19 DM4ZAE8 TI TT9MZCQ DM4ZAE8 TN Enhancer of zeste homolog 2 (EZH2) DM4ZAE8 MA Inhibitor DM4ZAE8 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4ZAE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4ZG0Q DI DM4ZG0Q DM4ZG0Q DN PMID26651364-Compound-121 DM4ZG0Q TI TTTCRU2 DM4ZG0Q TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4ZG0Q MA Antagonist DM4ZG0Q RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4ZG0Q RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4ZO21 DI DM4ZO21 DM4ZO21 DN PMID28092474-Compound-32p DM4ZO21 TI TT6R7JZ DM4ZO21 TN Histone deacetylase 1 (HDAC1) DM4ZO21 MA Inhibitor DM4ZO21 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM4ZO21 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM4ZO21 DI DM4ZO21 DM4ZO21 DN PMID28092474-Compound-32p DM4ZO21 TI TT5ZKDI DM4ZO21 TN Histone deacetylase 6 (HDAC6) DM4ZO21 MA Inhibitor DM4ZO21 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM4ZO21 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM4ZUDY DI DM4ZUDY DM4ZUDY DN Benzimidazole derivative 2 DM4ZUDY TI TT6OEDT DM4ZUDY TN Cannabinoid receptor 1 (CB1) DM4ZUDY MA Antagonist DM4ZUDY RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM4ZUDY RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM50E4Y DI DM50E4Y DM50E4Y DN Aminoazetidine derivative 4 DM50E4Y TI TT6OEDT DM50E4Y TN Cannabinoid receptor 1 (CB1) DM50E4Y MA Antagonist DM50E4Y RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM50E4Y RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM51JP6 DI DM51JP6 DM51JP6 DN PMID28092474-Compound-33c DM51JP6 TI TT6R7JZ DM51JP6 TN Histone deacetylase 1 (HDAC1) DM51JP6 MA Inhibitor DM51JP6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM51JP6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM51JP6 DI DM51JP6 DM51JP6 DN PMID28092474-Compound-33c DM51JP6 TI TT5ZKDI DM51JP6 TN Histone deacetylase 6 (HDAC6) DM51JP6 MA Inhibitor DM51JP6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM51JP6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TT0K1SC DM51MFS TN 5-HT 2B receptor (HTR2B) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TTWJBZ5 DM51MFS TN 5-HT 2C receptor (HTR2C) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TTJQOD7 DM51MFS TN 5-HT 2A receptor (HTR2A) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM52683 DI DM52683 DM52683 DN Tetrazole acetic acid derivative 1 DM52683 TI TTA592U DM52683 TN Urate anion exchanger 1 (URAT1) DM52683 MA Inhibitor DM52683 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM52683 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM52IQF DI DM52IQF DM52IQF DN BDBM50177012 DM52IQF TI TTECBXN DM52IQF TN Oxysterols receptor LXR-alpha (NR1H3) DM52IQF MA Inhibitor DM52IQF RN Piperazine derivatives as liver X receptor modulators. US10144715. DM52IQF RU http://www.freepatentsonline.com/US10144715.html DM52MIK DI DM52MIK DM52MIK DN PMID26560530-Compound-14 DM52MIK TI TT2F4OL DM52MIK TN Tissue transglutaminase (TG2) DM52MIK MA Inhibitor DM52MIK RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM52MIK RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM52MKV DI DM52MKV DM52MKV DN PMID30273516-Compound-1 DM52MKV TI TTCW0KX DM52MKV TN Glutaminase (GLS) DM52MKV MA Inhibitor DM52MKV RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM52MKV RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM536FO DI DM536FO DM536FO DN US8703720, Reference Compound 2 DM536FO TI TTO3NYT DM536FO TN Galectin-1 (LGALS1) DM536FO MA Inhibitor DM536FO RN Galactoside inhibitors of galectins. US8703720. DM536FO RU http://www.freepatentsonline.com/US8703720.html DM536JN DI DM536JN DM536JN DN PMID25991433-Compound-Eb DM536JN TI TT0K6EO DM536JN TN Stress-activated protein kinase JNK1 (JNK1) DM536JN MA Inhibitor DM536JN RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM536JN RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM53JXE DI DM53JXE DM53JXE DN Indomethacin analog 3 DM53JXE TI TT5ZWB6 DM53JXE TN Dihydrodiol dehydrogenase type I (AKR1C3) DM53JXE MA Inhibitor; Antagonist; Blocker DM53JXE RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM53JXE RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM53LGD DI DM53LGD DM53LGD DN Pyrimido-indole derivative 3 DM53LGD TI TTE4BSY DM53LGD TN Bromodomain and extraterminal domain protein (BET) DM53LGD MA Inhibitor DM53LGD RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM53LGD RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM53O9Y DI DM53O9Y DM53O9Y DN Pyrimidinyl compound 4 DM53O9Y TI TTH5TC2 DM53O9Y TN NF-kappa-B-activating kinase (TBK1) DM53O9Y MA Inhibitor DM53O9Y RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM53O9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM53PBG DI DM53PBG DM53PBG DN PMID25666693-Compound-5 DM53PBG TI TTMI6F5 DM53PBG TN Transient receptor potential cation channel V1 (TRPV1) DM53PBG MA Antagonist DM53PBG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM53PBG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM53Z4I DI DM53Z4I DM53Z4I DN US9040714, 7 DM53Z4I TI TTOJ9QL DM53Z4I TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM53Z4I MA Inhibitor DM53Z4I RN IRE-1 inhibitors. US9040714. DM53Z4I RU http://www.freepatentsonline.com/US9040714.html DM53ZPE DI DM53ZPE DM53ZPE DN Ethynyl compound 5 DM53ZPE TI TTHS256 DM53ZPE TN Metabotropic glutamate receptor 5 (mGluR5) DM53ZPE MA Modulator DM53ZPE RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM53ZPE RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM541QW DI DM541QW DM541QW DN N-(benzimidazolylcarbonyl)-piperidine derivative 1 DM541QW TI TT5ZWB6 DM541QW TN Dihydrodiol dehydrogenase type I (AKR1C3) DM541QW MA Inhibitor DM541QW RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM541QW RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM54DXT DI DM54DXT DM54DXT DN PMID25522065-Compound-3 DM54DXT TI TTX4RTB DM54DXT TN Melanin-concentrating hormone receptor 1 (MCHR1) DM54DXT MA Antagonist DM54DXT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM54DXT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM54EFD DI DM54EFD DM54EFD DN Terpyridineplatinum(II) complexe 3 DM54EFD TI TTEP6RV DM54EFD TN Glutathione reductase (GR) DM54EFD MA Inhibitor DM54EFD RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM54EFD RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM54EFD DI DM54EFD DM54EFD DN Terpyridineplatinum(II) complexe 3 DM54EFD TI TTR7UJ3 DM54EFD TN Cytoplasmic thioredoxin reductase (TXNRD1) DM54EFD MA Inhibitor DM54EFD RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM54EFD RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM54EV2 DI DM54EV2 DM54EV2 DN Bicyclic heteroaryl benzamide derivative 3 DM54EV2 TI TTTDVOJ DM54EV2 TN Tropomyosin-related kinase A (TrkA) DM54EV2 MA Inhibitor DM54EV2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM54EV2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM54V1R DI DM54V1R DM54V1R DN Aryl urea derivative 5 DM54V1R TI TTDP1UC DM54V1R TN Fatty acid amide hydrolase (FAAH) DM54V1R MA Inhibitor DM54V1R RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM54V1R RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM568TX DI DM568TX DM568TX DN N-alkylamide derivative 2 DM568TX TI TTHS256 DM568TX TN Metabotropic glutamate receptor 5 (mGluR5) DM568TX MA Modulator DM568TX RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM568TX RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM56I8H DI DM56I8H DM56I8H DN Quinoline derivative 7 DM56I8H TI TTXJ47W DM56I8H TN Metabotropic glutamate receptor 2 (mGluR2) DM56I8H MA Antagonist DM56I8H RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM56I8H RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM56T1P DI DM56T1P DM56T1P DN Heterocyclic derivative 26 DM56T1P TI TTIXKA4 DM56T1P TN Ribosomal protein S6 kinase alpha-1 (RSK1) DM56T1P MA Inhibitor DM56T1P RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DM56T1P RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DM571JP DI DM571JP DM571JP DN PMID29473428-Compound-15 DM571JP TI TTZJYKH DM571JP TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM571JP MA Inhibitor DM571JP RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM571JP RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM57N3Y DI DM57N3Y DM57N3Y DN PMID29671355-Compound-57 DM57N3Y TI TT4YWTO DM57N3Y TN Histone deacetylase 3 (HDAC3) DM57N3Y MA Inhibitor DM57N3Y RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM57N3Y RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM57N3Y DI DM57N3Y DM57N3Y DN PMID29671355-Compound-57 DM57N3Y TI TT6R7JZ DM57N3Y TN Histone deacetylase 1 (HDAC1) DM57N3Y MA Inhibitor DM57N3Y RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM57N3Y RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM57W29 DI DM57W29 DM57W29 DN Pyrrolo[2,3-d]pyrimidine derivative 30 DM57W29 TI TTGM6VW DM57W29 TN Tyrosine-protein kinase BTK (ATK) DM57W29 MA Inhibitor DM57W29 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM57W29 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM584EP DI DM584EP DM584EP DN PMID27607364-Compound-60 DM584EP TI TTPTXIN DM584EP TN Translocator protein (TSPO) DM584EP MA Ligand DM584EP RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM584EP RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM58QW1 DI DM58QW1 DM58QW1 DN PMID25666693-Compound-40 DM58QW1 TI TTMI6F5 DM58QW1 TN Transient receptor potential cation channel V1 (TRPV1) DM58QW1 MA Antagonist DM58QW1 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM58QW1 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TTQBR95 DM58UO9 TN Stress-activated protein kinase 2a (p38 alpha) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TT3ZIJL DM58UO9 TN JNK-interacting protein peptide (pepJIP) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TTVOE6D DM58UO9 TN Mitogen-activated protein kinase (MAPK) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58X6N DI DM58X6N DM58X6N DN 3-(phenoxymethyl) benzylamine derivative 4 DM58X6N TI TTULVH8 DM58X6N TN Tyrosinase (TYR) DM58X6N MA Inhibitor DM58X6N RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM58X6N RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM58Z4M DI DM58Z4M DM58Z4M DN PMID25666693-Compound-32 DM58Z4M TI TTMI6F5 DM58Z4M TN Transient receptor potential cation channel V1 (TRPV1) DM58Z4M MA Antagonist DM58Z4M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM58Z4M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM59INV DI DM59INV DM59INV DN PMID26004420-Compound-WO2014126944A DM59INV TI TTJ13ST DM59INV TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM59INV MA Inhibitor DM59INV RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM59INV RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM5A4TP DI DM5A4TP DM5A4TP DN Spiroimidazolone derivative 7 DM5A4TP TI TT9O6WS DM5A4TP TN Glucagon receptor (GCGR) DM5A4TP MA Antagonist DM5A4TP RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM5A4TP RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM5A62X DI DM5A62X DM5A62X DN Spiroimidazolone derivative 5 DM5A62X TI TT9O6WS DM5A62X TN Glucagon receptor (GCGR) DM5A62X MA Antagonist DM5A62X RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM5A62X RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM5A8F3 DI DM5A8F3 DM5A8F3 DN Pyrazole derivative 16 DM5A8F3 TI TT6OEDT DM5A8F3 TN Cannabinoid receptor 1 (CB1) DM5A8F3 MA Antagonist DM5A8F3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5A8F3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5ATIV DI DM5ATIV DM5ATIV DN PMID25553724-Compound-WO2011127048 31 DM5ATIV TI TTSXVID DM5ATIV TN Nuclear factor NF-kappa-B (NFKB) DM5ATIV MA Modulator DM5ATIV RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM5ATIV RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM5AUL0 DI DM5AUL0 DM5AUL0 DN Thiadiazolidindione derivative 2 DM5AUL0 TI TTRZQE3 DM5AUL0 TN Glycogen synthase kinase-3 alpha (GSK-3A) DM5AUL0 MA Inhibitor DM5AUL0 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM5AUL0 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM5AXHF DI DM5AXHF DM5AXHF DN Macrolactam derivative 4 DM5AXHF TI TTKFVXR DM5AXHF TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5AXHF MA Inhibitor DM5AXHF RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5AXHF RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5B0F3 DI DM5B0F3 DM5B0F3 DN Diaminopyridine analog 5 DM5B0F3 TI TTKFVXR DM5B0F3 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5B0F3 MA Inhibitor DM5B0F3 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5B0F3 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5B92W DI DM5B92W DM5B92W DN Tricyclic indole compound 3 DM5B92W TI TTPTXIN DM5B92W TN Translocator protein (TSPO) DM5B92W MA Ligand DM5B92W RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5B92W RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5BCGD DI DM5BCGD DM5BCGD DN Cyclopropylamine derivative 5 DM5BCGD TI TTNR0UQ DM5BCGD TN Lysine-specific histone demethylase 1 (LSD) DM5BCGD MA Inhibitor DM5BCGD RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM5BCGD RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM5BF6H DI DM5BF6H DM5BF6H DN Heteroaryl-azepine derivative 11 DM5BF6H TI TTWJBZ5 DM5BF6H TN 5-HT 2C receptor (HTR2C) DM5BF6H MA Agonist DM5BF6H RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5BF6H RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5BFJO DI DM5BFJO DM5BFJO DN CS-W011402 DM5BFJO TI TT6A59G DM5BFJO TN Phosphodiesterase 4C (PDE4C) DM5BFJO MA Inhibitor DM5BFJO RN Imidazopyridazine compounds. US9598421. DM5BFJO RU http://www.freepatentsonline.com/US9598421.html DM5BG6L DI DM5BG6L DM5BG6L DN PMID28766366-Compound-Scheme12-4 DM5BG6L TI TTSBVFO DM5BG6L TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM5BG6L MA Inhibitor DM5BG6L RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM5BG6L RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM5BVCS DI DM5BVCS DM5BVCS DN Galantamine analog 1 DM5BVCS TI TT1RS9F DM5BVCS TN Acetylcholinesterase (AChE) DM5BVCS MA Inhibitor DM5BVCS RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM5BVCS RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TT1RS9F DM5CKVF TN Acetylcholinesterase (AChE) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TTGP7BY DM5CKVF TN Monoamine oxidase type B (MAO-B) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TT3WG5C DM5CKVF TN Monoamine oxidase type A (MAO-A) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TTEB0GD DM5CKVF TN Cholinesterase (BCHE) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CULA DI DM5CULA DM5CULA DN US8609715, A-1 DM5CULA TI TTXL0GC DM5CULA TN Enteropeptidase (TMPRSS15) DM5CULA MA Inhibitor DM5CULA RN Heteroarylcarboxylic acid ester derivative. US8609715. DM5CULA RU http://www.freepatentsonline.com/US8609715.html DM5CUSJ DI DM5CUSJ DM5CUSJ DN Sulfonamide derivative 15 DM5CUSJ TI TTZS04O DM5CUSJ TN Gamma-secretase subunit APH-1A/1B (APH-1) DM5CUSJ MA Inhibitor DM5CUSJ RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DM5CUSJ RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DM5CXQT DI DM5CXQT DM5CXQT DN Isoxazole-based bicyclic compound 1 DM5CXQT TI TTE4BSY DM5CXQT TN Bromodomain and extraterminal domain protein (BET) DM5CXQT MA Inhibitor DM5CXQT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM5CXQT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM5CY86 DI DM5CY86 DM5CY86 DN PMID25666693-Compound-151 DM5CY86 TI TTMI6F5 DM5CY86 TN Transient receptor potential cation channel V1 (TRPV1) DM5CY86 MA Antagonist DM5CY86 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM5CY86 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM5DC9A DI DM5DC9A DM5DC9A DN Oxazolo[3,4-a]pyrazine derivative 6 DM5DC9A TI TTV1C0Z DM5DC9A TN Neuropeptide S receptor (NPSR) DM5DC9A MA Antagonist DM5DC9A RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM5DC9A RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM5E1KS DI DM5E1KS DM5E1KS DN Pyrazolo[1,5-a]pyrimidine derivative 6 DM5E1KS TI TT6OEDT DM5E1KS TN Cannabinoid receptor 1 (CB1) DM5E1KS MA Antagonist DM5E1KS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5E1KS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5E1ZJ DI DM5E1ZJ DM5E1ZJ DN Pyrazole derivative 77 DM5E1ZJ TI TTXJ47W DM5E1ZJ TN Metabotropic glutamate receptor 2 (mGluR2) DM5E1ZJ MA Antagonist DM5E1ZJ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM5E1ZJ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM5E2B3 DI DM5E2B3 DM5E2B3 DN PMID25726713-Compound-42 DM5E2B3 TI TT8J1S3 DM5E2B3 TN Smoothened homolog (SMO) DM5E2B3 MA Inhibitor DM5E2B3 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM5E2B3 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM5E9RH DI DM5E9RH DM5E9RH DN US9340574, 7 DM5E9RH TI TTWMKXP DM5E9RH TN Protein-tyrosine phosphatase eta (HPTP) DM5E9RH MA Inhibitor DM5E9RH RN Inhibitors of protein tyrosine phosphatases. US9340574. DM5E9RH RU http://www.freepatentsonline.com/US9340574.html DM5ECH2 DI DM5ECH2 DM5ECH2 DN PMID25656651-Compound-11a DM5ECH2 TI TTS7G69 DM5ECH2 TN Fusion protein Bcr-Abl (Bcr-Abl) DM5ECH2 MA Inhibitor DM5ECH2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5ECH2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5EGBY DI DM5EGBY DM5EGBY DN Aryl piperazine derivative 10 DM5EGBY TI TTWJBZ5 DM5EGBY TN 5-HT 2C receptor (HTR2C) DM5EGBY MA Agonist DM5EGBY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5EGBY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5EHK2 DI DM5EHK2 DM5EHK2 DN PMID25656651-Compound-16b DM5EHK2 TI TTS7G69 DM5EHK2 TN Fusion protein Bcr-Abl (Bcr-Abl) DM5EHK2 MA Inhibitor DM5EHK2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5EHK2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5F1LR DI DM5F1LR DM5F1LR DN Imidazopyridazine derivative 6 DM5F1LR TI TTQR74A DM5F1LR TN Proteinase activated receptor 2 (PAR2) DM5F1LR MA Antagonist DM5F1LR RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM5F1LR RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM5F8J1 DI DM5F8J1 DM5F8J1 DN Indol-5-ol derivative 1 DM5F8J1 TI TT3PJMV DM5F8J1 TN Tyrosine-protein kinase ABL1 (ABL) DM5F8J1 MA Inhibitor DM5F8J1 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5F8J1 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5FVH0 DI DM5FVH0 DM5FVH0 DN 1,2-diamino cyclopentane-based derivative 29 DM5FVH0 TI TT9N02I DM5FVH0 TN Orexin receptor type 2 (HCRTR2) DM5FVH0 MA Antagonist DM5FVH0 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5FVH0 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5FVH0 DI DM5FVH0 DM5FVH0 DN 1,2-diamino cyclopentane-based derivative 29 DM5FVH0 TI TT60Q8D DM5FVH0 TN Orexin receptor type 1 (HCRTR1) DM5FVH0 MA Antagonist DM5FVH0 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5FVH0 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5G3CN DI DM5G3CN DM5G3CN DN Poly-substituted azoles statin lactone derivative 2 DM5G3CN TI TTPADOQ DM5G3CN TN HMG-CoA reductase (HMGCR) DM5G3CN MA Inhibitor DM5G3CN RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM5G3CN RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM5G67X DI DM5G67X DM5G67X DN Pyrrolo-pyridinone derivative 2 DM5G67X TI TT4DXQT DM5G67X TN Proto-oncogene c-Ret (RET) DM5G67X MA Inhibitor DM5G67X RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM5G67X RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM5GCUR DI DM5GCUR DM5GCUR DN N-acylpiperidine ether derivative 1 DM5GCUR TI TTTDVOJ DM5GCUR TN Tropomyosin-related kinase A (TrkA) DM5GCUR MA Inhibitor DM5GCUR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM5GCUR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM5GEBH DI DM5GEBH DM5GEBH DN Carboxamide derivative 1 DM5GEBH TI TT6OEDT DM5GEBH TN Cannabinoid receptor 1 (CB1) DM5GEBH MA Antagonist DM5GEBH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5GEBH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5GHJA DI DM5GHJA DM5GHJA DN PMID26651364-Compound-114 DM5GHJA TI TTTCRU2 DM5GHJA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5GHJA MA Antagonist DM5GHJA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5GHJA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5GKS6 DI DM5GKS6 DM5GKS6 DN 3-phenyl propanoic derivative 3 DM5GKS6 TI TTA6ZN2 DM5GKS6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5GKS6 MA Inhibitor DM5GKS6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5GKS6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5GKS6 DI DM5GKS6 DM5GKS6 DN 3-phenyl propanoic derivative 3 DM5GKS6 TI TTGIZLN DM5GKS6 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DM5GKS6 MA Modulator DM5GKS6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5GKS6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5GZNS DI DM5GZNS DM5GZNS DN Urea and carbamate bioisostere derivative 4 DM5GZNS TI TTL7C8Q DM5GZNS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5GZNS MA Inhibitor DM5GZNS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5GZNS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5H3R8 DI DM5H3R8 DM5H3R8 DN PhyllanthoidA DM5H3R8 TI TT3WG5C DM5H3R8 TN Monoamine oxidase type A (MAO-A) DM5H3R8 MA Inhibitor DM5H3R8 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM5H3R8 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM5H3YA DI DM5H3YA DM5H3YA DN PMID25522065-Compound-32 DM5H3YA TI TTX4RTB DM5H3YA TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5H3YA MA Antagonist DM5H3YA RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM5H3YA RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM5HUCR DI DM5HUCR DM5HUCR DN PMID27019002-Compound-44 DM5HUCR TI TTNR0UQ DM5HUCR TN Lysine-specific histone demethylase 1 (LSD) DM5HUCR MA Inhibitor DM5HUCR RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM5HUCR RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM5I1QV DI DM5I1QV DM5I1QV DN PMID29671355-Compound-47a DM5I1QV TI TTTQGH8 DM5I1QV TN Histone deacetylase 4 (HDAC4) DM5I1QV MA Inhibitor DM5I1QV RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5I1QV RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5I4CA DI DM5I4CA DM5I4CA DN Fused aryl carbocycle derivative 3 DM5I4CA TI TT9NXW4 DM5I4CA TN Sigma intracellular receptor 2 (TMEM97) DM5I4CA MA Ligand DM5I4CA RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM5I4CA RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM5IFBV DI DM5IFBV DM5IFBV DN PMID29757691-Compound-8a DM5IFBV TI TTEB0GD DM5IFBV TN Cholinesterase (BCHE) DM5IFBV MA Inhibitor DM5IFBV RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5IFBV RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5IFBV DI DM5IFBV DM5IFBV DN PMID29757691-Compound-8a DM5IFBV TI TT1RS9F DM5IFBV TN Acetylcholinesterase (AChE) DM5IFBV MA Inhibitor DM5IFBV RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5IFBV RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5IH2O DI DM5IH2O DM5IH2O DN Benzodihydroisofuran derivative 4 DM5IH2O TI TTTJZ4M DM5IH2O TN Prolylcarboxypeptidase (PRCP) DM5IH2O MA Inhibitor DM5IH2O RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM5IH2O RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM5IWX2 DI DM5IWX2 DM5IWX2 DN 4-aryl quinol derivative 4 DM5IWX2 TI TTR7UJ3 DM5IWX2 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5IWX2 MA Inhibitor DM5IWX2 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5IWX2 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5IZKD DI DM5IZKD DM5IZKD DN PMID28627961-Compound-32 DM5IZKD TI TTYLQ8V DM5IZKD TN Prostaglandin E synthase (PTGES) DM5IZKD MA Inhibitor DM5IZKD RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM5IZKD RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM5J09E DI DM5J09E DM5J09E DN Imidazo[1,2-b]pyridazine acetamide derivative 4 DM5J09E TI TTPTXIN DM5J09E TN Translocator protein (TSPO) DM5J09E MA Ligand DM5J09E RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM5J09E RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM5JSI3 DI DM5JSI3 DM5JSI3 DN PMID27977313-Compound-19 DM5JSI3 TI TTR7UJ3 DM5JSI3 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5JSI3 MA Inhibitor DM5JSI3 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5JSI3 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5JUR2 DI DM5JUR2 DM5JUR2 DN Indole-based analog 5 DM5JUR2 TI TTPTXIN DM5JUR2 TN Translocator protein (TSPO) DM5JUR2 MA Ligand DM5JUR2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5JUR2 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5K3DF DI DM5K3DF DM5K3DF DN PMID30280939-Compound-WO2015091734 DM5K3DF TI TTOK0LR DM5K3DF TN Toll-like receptor (TLR) DM5K3DF MA Agonist DM5K3DF RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM5K3DF RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM5K4YF DI DM5K4YF DM5K4YF DN PMID27376512-Compound-PG-11047 DM5K4YF TI TTBH0VX DM5K4YF TN Histone deacetylase (HDAC) DM5K4YF MA Inhibitor DM5K4YF RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5K4YF RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5K4YF DI DM5K4YF DM5K4YF DN PMID27376512-Compound-PG-11047 DM5K4YF TI TTHVCUP DM5K4YF TN DNA [cytosine-5]-methyltransferase (DNMT) DM5K4YF MA Inhibitor DM5K4YF RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5K4YF RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5K6MG DI DM5K6MG DM5K6MG DN PMID29671355-Compound-26 DM5K6MG TI TT6R7JZ DM5K6MG TN Histone deacetylase 1 (HDAC1) DM5K6MG MA Inhibitor DM5K6MG RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5K6MG RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5K6MG DI DM5K6MG DM5K6MG DN PMID29671355-Compound-26 DM5K6MG TI TT5ZKDI DM5K6MG TN Histone deacetylase 6 (HDAC6) DM5K6MG MA Inhibitor DM5K6MG RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5K6MG RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5KARO DI DM5KARO DM5KARO DN PMID27599163-Compound-52 DM5KARO TI TTPTXIN DM5KARO TN Translocator protein (TSPO) DM5KARO MA Ligand DM5KARO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5KARO RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5KEVG DI DM5KEVG DM5KEVG DN Peptide analog 4 DM5KEVG TI TT23XQV DM5KEVG TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM5KEVG MA Inhibitor DM5KEVG RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5KEVG RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5KTDY DI DM5KTDY DM5KTDY DN Beta-naphthylacetic acids derivative 1 DM5KTDY TI TT5ZWB6 DM5KTDY TN Dihydrodiol dehydrogenase type I (AKR1C3) DM5KTDY MA Inhibitor; Antagonist; Blocker DM5KTDY RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM5KTDY RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM5LK6O DI DM5LK6O DM5LK6O DN US10023583, Example 24 DM5LK6O TI TTY2KP7 DM5LK6O TN Leucyl-cysteinyl aminopeptidase (LNPEP) DM5LK6O MA Inhibitor DM5LK6O RN Bicyclic pyridine compound. US10023583. DM5LK6O RU http://www.freepatentsonline.com/US10023583.html DM5LOST DI DM5LOST DM5LOST DN PMID27454349-Compound-100 DM5LOST TI TTK59TV DM5LOST TN Vitamin D3 receptor (VDR) DM5LOST MA Agonist DM5LOST RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DM5LOST RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DM5LQJW DI DM5LQJW DM5LQJW DN 1,2-diamino cyclopentane-based derivative 27 DM5LQJW TI TT9N02I DM5LQJW TN Orexin receptor type 2 (HCRTR2) DM5LQJW MA Antagonist DM5LQJW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5LQJW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5LQJW DI DM5LQJW DM5LQJW DN 1,2-diamino cyclopentane-based derivative 27 DM5LQJW TI TT60Q8D DM5LQJW TN Orexin receptor type 1 (HCRTR1) DM5LQJW MA Antagonist DM5LQJW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5LQJW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTTQGH8 DM5LYKR TN Histone deacetylase 4 (HDAC4) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TT8M4E1 DM5LYKR TN Histone deacetylase 9 (HDAC9) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTMUEK1 DM5LYKR TN Histone deacetylase 7 (HDAC7) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTUELN5 DM5LYKR TN Histone deacetylase 5 (HDAC5) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5MIEC DI DM5MIEC DM5MIEC DN Aryl mannoside derivative 6 DM5MIEC TI TTTCRU2 DM5MIEC TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5MIEC MA Antagonist DM5MIEC RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5MIEC RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TTWJBZ5 DM5MLQU TN 5-HT 2C receptor (HTR2C) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TT0K1SC DM5MLQU TN 5-HT 2B receptor (HTR2B) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TTJQOD7 DM5MLQU TN 5-HT 2A receptor (HTR2A) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MT4R DI DM5MT4R DM5MT4R DN Bicyclic heteroaryl benzamide derivative 2 DM5MT4R TI TTTDVOJ DM5MT4R TN Tropomyosin-related kinase A (TrkA) DM5MT4R MA Inhibitor DM5MT4R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM5MT4R RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTJQOD7 DM5MUNG TN 5-HT 2A receptor (HTR2A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTNGILX DM5MUNG TN Adrenergic receptor alpha-1A (ADRA1A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TT34BHT DM5MUNG TN Adrenergic receptor alpha-1D (ADRA1D) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTSQIFT DM5MUNG TN 5-HT 1A receptor (HTR1A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MVLG DI DM5MVLG DM5MVLG DN Tetra-hydro-carboline derivative 1 DM5MVLG TI TTSCIM2 DM5MVLG TN Extracellular lysophospholipase D (E-NPP2) DM5MVLG MA Inhibitor DM5MVLG RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM5MVLG RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM5MXFK DI DM5MXFK DM5MXFK DN PMID29473428-Compound-11 DM5MXFK TI TTZJYKH DM5MXFK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5MXFK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM5MXFK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM5N8YJ DI DM5N8YJ DM5N8YJ DN PMID30273516-Compound-40 DM5N8YJ TI TTCW0KX DM5N8YJ TN Glutaminase (GLS) DM5N8YJ MA Inhibitor DM5N8YJ RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM5N8YJ RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM5N9M4 DI DM5N9M4 DM5N9M4 DN PMID26004420-Compound-WO2013062900A DM5N9M4 TI TTJ13ST DM5N9M4 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM5N9M4 MA Inhibitor DM5N9M4 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM5N9M4 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM5NEQ2 DI DM5NEQ2 DM5NEQ2 DN Imidazo[1,2-a]pyridine derivative 1 DM5NEQ2 TI TTHS256 DM5NEQ2 TN Metabotropic glutamate receptor 5 (mGluR5) DM5NEQ2 MA Modulator DM5NEQ2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5NEQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5NJDK DI DM5NJDK DM5NJDK DN PMID28454500-Compound-49 DM5NJDK TI TTA6ZN2 DM5NJDK TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5NJDK MA Activator DM5NJDK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5NJDK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5NJDK DI DM5NJDK DM5NJDK DN PMID28454500-Compound-49 DM5NJDK TI TT3Z6Y9 DM5NJDK TN Cysteines of Keap1 (KEAP1 Cysteines) DM5NJDK MA Modulator DM5NJDK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5NJDK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5NKXO DI DM5NKXO DM5NKXO DN Pyrrolidine derivative 5 DM5NKXO TI TTHS256 DM5NKXO TN Metabotropic glutamate receptor 5 (mGluR5) DM5NKXO RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5NKXO RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTALN9W DM5O8K0 TN Indoleamine 2,3-dioxygenase 2 (IDO2) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTZJYKH DM5O8K0 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTXNCBV DM5O8K0 TN Tryptophan 2,3-dioxygenase (TDO) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5OCM7 DI DM5OCM7 DM5OCM7 DN Piperazine urea derivative 2 DM5OCM7 TI TTGX13H DM5OCM7 TN Fatty-acid amide hydrolase 1 (FAAH1) DM5OCM7 MA Inhibitor DM5OCM7 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM5OCM7 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM5OEQZ DI DM5OEQZ DM5OEQZ DN Macrocycle derivative 2 DM5OEQZ TI TT5YPJF DM5OEQZ TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DM5OEQZ MA Inhibitor DM5OEQZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5OEQZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5OEQZ DI DM5OEQZ DM5OEQZ DN Macrocycle derivative 2 DM5OEQZ TI TT23XQV DM5OEQZ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM5OEQZ MA Inhibitor DM5OEQZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5OEQZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5OH8D DI DM5OH8D DM5OH8D DN Pyrazolopyridine derivative 6 DM5OH8D TI TTRMX3V DM5OH8D TN Janus kinase 2 (JAK-2) DM5OH8D MA Inhibitor DM5OH8D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM5OH8D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM5OH8D DI DM5OH8D DM5OH8D DN Pyrazolopyridine derivative 6 DM5OH8D TI TTT7PJU DM5OH8D TN Janus kinase 3 (JAK-3) DM5OH8D MA Inhibitor DM5OH8D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM5OH8D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM5OQBR DI DM5OQBR DM5OQBR DN PMID27551786-Compound-106 DM5OQBR TI TT26PHO DM5OQBR TN Mineralocorticoid receptor (MR) DM5OQBR MA Antagonist DM5OQBR RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM5OQBR RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM5OXUK DI DM5OXUK DM5OXUK DN PMID27109571-Compound-34 DM5OXUK TI TTMY6L1 DM5OXUK TN Fatty acid-binding protein (FABP) DM5OXUK MA Inhibitor DM5OXUK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM5OXUK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM5OZPV DI DM5OZPV DM5OZPV DN Aminopyrimidine derivative 5 DM5OZPV TI TTBYWP2 DM5OZPV TN TYK2 tyrosine kinase (TYK2) DM5OZPV MA Inhibitor DM5OZPV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM5OZPV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM5P04R DI DM5P04R DM5P04R DN Thiazole carboxamide derivative 9 DM5P04R TI TTCZOF2 DM5P04R TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM5P04R MA Inhibitor DM5P04R RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM5P04R RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM5PS6K DI DM5PS6K DM5PS6K DN Methyl-piperidine compound 1 DM5PS6K TI TTYLQ8V DM5PS6K TN Prostaglandin E synthase (PTGES) DM5PS6K MA Inhibitor DM5PS6K RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM5PS6K RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM5Q4T2 DI DM5Q4T2 DM5Q4T2 DN Biphenyl mannoside derivative 26 DM5Q4T2 TI TTTCRU2 DM5Q4T2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5Q4T2 MA Antagonist DM5Q4T2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5Q4T2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5Q93Y DI DM5Q93Y DM5Q93Y DN XHPNYYOUZWOWNT-PYUWXLGESA-N DM5Q93Y TI TT5U49F DM5Q93Y TN PRKACA messenger RNA (PRKACA mRNA) DM5Q93Y MA Inhibitor DM5Q93Y RN Purine derivatives. US8846696. DM5Q93Y RU http://www.freepatentsonline.com/US8846696.html DM5Q962 DI DM5Q962 DM5Q962 DN PMID28454500-Compound-94 DM5Q962 TI TTA6ZN2 DM5Q962 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5Q962 MA Inhibitor DM5Q962 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5Q962 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5QAKR DI DM5QAKR DM5QAKR DN Hydroxyqunoline analog 5 DM5QAKR TI TTWAQBO DM5QAKR TN Lysine-specific demethylase 4E (KDM4E) DM5QAKR MA Inhibitor DM5QAKR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM5QAKR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM5QH4C DI DM5QH4C DM5QH4C DN PMID27998201-Compound-1 DM5QH4C TI TT36ETB DM5QH4C TN Cathepsin L (CTSL) DM5QH4C MA Inhibitor DM5QH4C RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM5QH4C RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM5RBFC DI DM5RBFC DM5RBFC DN PMID27607364-Compound-10 DM5RBFC TI TTPTXIN DM5RBFC TN Translocator protein (TSPO) DM5RBFC MA Ligand DM5RBFC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM5RBFC RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM5RCBV DI DM5RCBV DM5RCBV DN PMID28048944-Compound-6 DM5RCBV TI TTZN7RP DM5RCBV TN Rho-associated protein kinase 1 (ROCK1) DM5RCBV MA Inhibitor DM5RCBV RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM5RCBV RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM5RCBV DI DM5RCBV DM5RCBV DN PMID28048944-Compound-6 DM5RCBV TI TTGWKQJ DM5RCBV TN Rho-associated protein kinase 2 (ROCK2) DM5RCBV MA Inhibitor DM5RCBV RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM5RCBV RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM5RCW8 DI DM5RCW8 DM5RCW8 DN Pyrrolo[1,2-c]pyrazole derivative 1 DM5RCW8 TI TTZJYKH DM5RCW8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5RCW8 MA Inhibitor DM5RCW8 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM5RCW8 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM5RX9D DI DM5RX9D DM5RX9D DN PMID27376512-Compound-Table1Example30 DM5RX9D TI TT6S2FE DM5RX9D TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM5RX9D MA Inhibitor DM5RX9D RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5RX9D RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5RZWG DI DM5RZWG DM5RZWG DN PMID28454500-Compound-36 DM5RZWG TI TTA6ZN2 DM5RZWG TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5RZWG MA Activator DM5RZWG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5RZWG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5RZWG DI DM5RZWG DM5RZWG DN PMID28454500-Compound-36 DM5RZWG TI TT3Z6Y9 DM5RZWG TN Cysteines of Keap1 (KEAP1 Cysteines) DM5RZWG MA Modulator DM5RZWG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5RZWG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5S3L0 DI DM5S3L0 DM5S3L0 DN Pyrazole derivative 13 DM5S3L0 TI TT6OEDT DM5S3L0 TN Cannabinoid receptor 1 (CB1) DM5S3L0 MA Antagonist DM5S3L0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5S3L0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTBJR4L DM5SD9E TN Cyclin-dependent kinase 8 (CDK8) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTL4Q97 DM5SD9E TN Cyclin-dependent kinase 5 (CDK5) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TT1LVF2 DM5SD9E TN Cyclin-dependent kinase 9 (CDK9) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTH6V3D DM5SD9E TN Cyclin-dependent kinase 1 (CDK1) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTQYF7G DM5SD9E TN Cyclin-dependent kinase 7 (CDK7) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SX8T DI DM5SX8T DM5SX8T DN Uracil derivative 1 DM5SX8T TI TTPLTSQ DM5SX8T TN Neutrophil elastase (NE) DM5SX8T MA Inhibitor DM5SX8T RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM5SX8T RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM5T29W DI DM5T29W DM5T29W DN Biaryl mannoside derivative 12 DM5T29W TI TTTCRU2 DM5T29W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5T29W MA Antagonist DM5T29W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5T29W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5TIFH DI DM5TIFH DM5TIFH DN N-substituted pyrazole derivative 3 DM5TIFH TI TTXJ47W DM5TIFH TN Metabotropic glutamate receptor 2 (mGluR2) DM5TIFH MA Antagonist DM5TIFH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM5TIFH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM5TILQ DI DM5TILQ DM5TILQ DN Triazole gold complexe 3 DM5TILQ TI TTR7UJ3 DM5TILQ TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5TILQ MA Inhibitor DM5TILQ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5TILQ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5U36G DI DM5U36G DM5U36G DN Sterol derivative 1 DM5U36G TI TTPADOQ DM5U36G TN HMG-CoA reductase (HMGCR) DM5U36G MA Inhibitor DM5U36G RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM5U36G RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM5U8WT DI DM5U8WT DM5U8WT DN PMID25991433-Compound-L DM5U8WT TI TTVOE6D DM5U8WT TN Mitogen-activated protein kinase (MAPK) DM5U8WT MA Inhibitor DM5U8WT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5U8WT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5UBMJ DI DM5UBMJ DM5UBMJ DN PMID30273516-Compound-41 DM5UBMJ TI TTCW0KX DM5UBMJ TN Glutaminase (GLS) DM5UBMJ MA Inhibitor DM5UBMJ RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM5UBMJ RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM5UI73 DI DM5UI73 DM5UI73 DN Tihotungstate derivative 1 DM5UI73 TI TTSXVID DM5UI73 TN Nuclear factor NF-kappa-B (NFKB) DM5UI73 MA Inhibitor DM5UI73 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM5UI73 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM5UM8I DI DM5UM8I DM5UM8I DN EEA DM5UM8I TI TTXLEG7 DM5UM8I TN Matrix metalloproteinase-10 (MMP-10) DM5UM8I MA Inhibitor DM5UM8I RN Pseudodipeptides as MMP inhibitors. US8691753. DM5UM8I RU http://www.freepatentsonline.com/US8691753.html DM5UPGZ DI DM5UPGZ DM5UPGZ DN Dihydroisoquinoline carboxamide analog 1 DM5UPGZ TI TT473XN DM5UPGZ TN P2X purinoceptor 7 (P2RX7) DM5UPGZ MA Antagonist DM5UPGZ RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM5UPGZ RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM5UQK6 DI DM5UQK6 DM5UQK6 DN Thiazole derivative 4 DM5UQK6 TI TTTDVOJ DM5UQK6 TN Tropomyosin-related kinase A (TrkA) DM5UQK6 MA Inhibitor DM5UQK6 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM5UQK6 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM5UX7B DI DM5UX7B DM5UX7B DN Mycophenolic acid/nucleotide derivative 3 DM5UX7B TI TTL7C8Q DM5UX7B TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5UX7B MA Inhibitor DM5UX7B RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5UX7B RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5V2D9 DI DM5V2D9 DM5V2D9 DN Carbamide derivative 4 DM5V2D9 TI TTL7C8Q DM5V2D9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5V2D9 MA Inhibitor DM5V2D9 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5V2D9 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5VCQP DI DM5VCQP DM5VCQP DN Quinoline and quinazoline derivative 4 DM5VCQP TI TTOHSBA DM5VCQP TN Vascular endothelial growth factor A (VEGFA) DM5VCQP MA Inhibitor DM5VCQP RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM5VCQP RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM5VRXW DI DM5VRXW DM5VRXW DN Aminopyrimidine derivative 9 DM5VRXW TI TTH5TC2 DM5VRXW TN NF-kappa-B-activating kinase (TBK1) DM5VRXW MA Inhibitor DM5VRXW RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM5VRXW RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM5W0A2 DI DM5W0A2 DM5W0A2 DN US8481586, 5 DM5W0A2 TI TTCGOIN DM5W0A2 TN PIM-3 protein kinase (PIM3) DM5W0A2 MA Inhibitor DM5W0A2 RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DM5W0A2 RU http://www.freepatentsonline.com/US8481586.html DM5WA29 DI DM5WA29 DM5WA29 DN Pyrrolidine derivative 2 DM5WA29 TI TTHS256 DM5WA29 TN Metabotropic glutamate receptor 5 (mGluR5) DM5WA29 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5WA29 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5WAGC DI DM5WAGC DM5WAGC DN Binuclear gold(I) compound 2 DM5WAGC TI TTR7UJ3 DM5WAGC TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5WAGC MA Inhibitor DM5WAGC RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5WAGC RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5WIX3 DI DM5WIX3 DM5WIX3 DN PMID25980951-Compound-29 DM5WIX3 TI TTR7B60 DM5WIX3 TN X-linked inhibitor of apoptosis protein (XIAP) DM5WIX3 MA Antagonist DM5WIX3 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM5WIX3 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM5WMO9 DI DM5WMO9 DM5WMO9 DN Carboxamide derivative 10 DM5WMO9 TI TTG5QB7 DM5WMO9 TN Calpain-2 (CAPN2) DM5WMO9 MA Inhibitor DM5WMO9 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM5WMO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM5WN0U DI DM5WN0U DM5WN0U DN Binuclear gold(I) compound 1 DM5WN0U TI TTR7UJ3 DM5WN0U TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5WN0U MA Inhibitor DM5WN0U RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5WN0U RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5WQP3 DI DM5WQP3 DM5WQP3 DN P-coumaric acid derivative 4 DM5WQP3 TI TTULVH8 DM5WQP3 TN Tyrosinase (TYR) DM5WQP3 MA Inhibitor DM5WQP3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM5WQP3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM5X160 DI DM5X160 DM5X160 DN Imidazopyridazine derivative 7 DM5X160 TI TTQR74A DM5X160 TN Proteinase activated receptor 2 (PAR2) DM5X160 MA Antagonist DM5X160 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM5X160 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM5X92S DI DM5X92S DM5X92S DN Amidopyrazole derivative 1 DM5X92S TI TTKFVXR DM5X92S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5X92S MA Inhibitor DM5X92S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5X92S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5Y13R DI DM5Y13R DM5Y13R DN Dihydropyrimidinone derivative 2 DM5Y13R TI TTPLTSQ DM5Y13R TN Neutrophil elastase (NE) DM5Y13R MA Inhibitor DM5Y13R RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM5Y13R RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM5Y1DC DI DM5Y1DC DM5Y1DC DN 1,2-diamino cyclopentane-based derivative 21 DM5Y1DC TI TT9N02I DM5Y1DC TN Orexin receptor type 2 (HCRTR2) DM5Y1DC MA Antagonist DM5Y1DC RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5Y1DC RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5Y1DC DI DM5Y1DC DM5Y1DC DN 1,2-diamino cyclopentane-based derivative 21 DM5Y1DC TI TT60Q8D DM5Y1DC TN Orexin receptor type 1 (HCRTR1) DM5Y1DC MA Antagonist DM5Y1DC RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5Y1DC RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5YD1K DI DM5YD1K DM5YD1K DN PMID25991433-Compound-A5 DM5YD1K TI TTHS0U8 DM5YD1K TN Stress-activated protein kinase JNK2 (JNK2) DM5YD1K MA Inhibitor DM5YD1K RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5YD1K RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5YD1K DI DM5YD1K DM5YD1K DN PMID25991433-Compound-A5 DM5YD1K TI TT0K6EO DM5YD1K TN Stress-activated protein kinase JNK1 (JNK1) DM5YD1K MA Inhibitor DM5YD1K RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5YD1K RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5YD4W DI DM5YD4W DM5YD4W DN Heteroaromatic ring derivative 2 DM5YD4W TI TTSCIM2 DM5YD4W TN Extracellular lysophospholipase D (E-NPP2) DM5YD4W MA Inhibitor DM5YD4W RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM5YD4W RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM5YMQH DI DM5YMQH DM5YMQH DN PMID25522065-Compound-39 DM5YMQH TI TTX4RTB DM5YMQH TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5YMQH MA Antagonist DM5YMQH RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM5YMQH RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM5YNTM DI DM5YNTM DM5YNTM DN Benzamide derivative 19 DM5YNTM TI TTF8P9I DM5YNTM TN Diacylglycerol acyltransferase 1 (DGAT1) DM5YNTM MA Inhibitor DM5YNTM RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM5YNTM RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM5YSTU DI DM5YSTU DM5YSTU DN Tetra-hydro-naphthyridine derivative 1 DM5YSTU TI TTDP1UC DM5YSTU TN Fatty acid amide hydrolase (FAAH) DM5YSTU MA Inhibitor DM5YSTU RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM5YSTU RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM5ZELW DI DM5ZELW DM5ZELW DN PMID25666693-Compound-81 DM5ZELW TI TTMI6F5 DM5ZELW TN Transient receptor potential cation channel V1 (TRPV1) DM5ZELW MA Antagonist DM5ZELW RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM5ZELW RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM5ZGK3 DI DM5ZGK3 DM5ZGK3 DN US8829193, 3 DM5ZGK3 TI TTCGOIN DM5ZGK3 TN PIM-3 protein kinase (PIM3) DM5ZGK3 MA Inhibitor DM5ZGK3 RN PIM kinase inhibitors and methods of their use. US8829193. DM5ZGK3 RU http://www.freepatentsonline.com/US8829193.html DM5ZGNK DI DM5ZGNK DM5ZGNK DN Benzodiazepine derivative 2 DM5ZGNK TI TTJGW1Z DM5ZGNK TN Phosphodiesterase 2A (PDE2A) DM5ZGNK MA Inhibitor DM5ZGNK RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZGNK RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM5ZKR2 DI DM5ZKR2 DM5ZKR2 DN Benzoic acid derivative 1 DM5ZKR2 TI TTA592U DM5ZKR2 TN Urate anion exchanger 1 (URAT1) DM5ZKR2 MA Inhibitor DM5ZKR2 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM5ZKR2 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM5ZQKS DI DM5ZQKS DM5ZQKS DN Triazolo-pyridine derivative 4 DM5ZQKS TI TTJW4LU DM5ZQKS TN Phosphodiesterase 10A (PDE10) DM5ZQKS MA Inhibitor DM5ZQKS RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZQKS RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM5ZQKS DI DM5ZQKS DM5ZQKS DN Triazolo-pyridine derivative 4 DM5ZQKS TI TTJGW1Z DM5ZQKS TN Phosphodiesterase 2A (PDE2A) DM5ZQKS MA Inhibitor DM5ZQKS RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZQKS RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM614F8 DI DM614F8 DM614F8 DN Isoxazole-based bicyclic compound 16 DM614F8 TI TTE4BSY DM614F8 TN Bromodomain and extraterminal domain protein (BET) DM614F8 MA Inhibitor DM614F8 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM614F8 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM61NOP DI DM61NOP DM61NOP DN PMID26882240-Compound-6 DM61NOP TI TTUX68I DM61NOP TN Hypoxia-inducible factor 1 (HIF-1) DM61NOP MA Inhibitor DM61NOP RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM61NOP RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM61SR0 DI DM61SR0 DM61SR0 DN PMID27539678-Compound-10 DM61SR0 TI TTOHFIY DM61SR0 TN Sphingosine kinase 1 (SPHK1) DM61SR0 MA Inhibitor DM61SR0 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM61SR0 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM628MP DI DM628MP DM628MP DN PMID28394193-Compound-32 DM628MP TI TT9MZCQ DM628MP TN Enhancer of zeste homolog 2 (EZH2) DM628MP MA Inhibitor DM628MP RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM628MP RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6293C DI DM6293C DM6293C DN AC1MOZOL DM6293C TI TT3ZS42 DM6293C TN Phosphodiesterase 1B (PDE1B) DM6293C MA Inhibitor DM6293C RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DM6293C RU http://www.freepatentsonline.com/US9173884.html DM62A1H DI DM62A1H DM62A1H DN PMID26004420-Compound-WO2010129379B DM62A1H TI TTJ13ST DM62A1H TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM62A1H MA Inhibitor DM62A1H RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM62A1H RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM62K40 DI DM62K40 DM62K40 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 DM62K40 TI TTJGW1Z DM62K40 TN Phosphodiesterase 2A (PDE2A) DM62K40 MA Inhibitor DM62K40 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM62K40 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM62K40 DI DM62K40 DM62K40 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 DM62K40 TI TTJW4LU DM62K40 TN Phosphodiesterase 10A (PDE10) DM62K40 MA Inhibitor DM62K40 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM62K40 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM62XNE DI DM62XNE DM62XNE DN PMID25991433-Compound-E3 DM62XNE TI TT0K6EO DM62XNE TN Stress-activated protein kinase JNK1 (JNK1) DM62XNE MA Inhibitor DM62XNE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM62XNE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM63128 DI DM63128 DM63128 DN Phenylsulfonyl derivative 2 DM63128 TI TT9JNIC DM63128 TN Histamine H3 receptor (H3R) DM63128 MA Inhibitor DM63128 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM63128 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM637IC DI DM637IC DM637IC DN PMID25980951-Compound-14 DM637IC TI TTR7B60 DM637IC TN X-linked inhibitor of apoptosis protein (XIAP) DM637IC MA Antagonist DM637IC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM637IC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM63NX5 DI DM63NX5 DM63NX5 DN 1,3-dihydroxy phenyl derivative 2 DM63NX5 TI TT23XQV DM63NX5 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM63NX5 MA Inhibitor DM63NX5 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM63NX5 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM63UM8 DI DM63UM8 DM63UM8 DN PMID25666693-Compound-19 DM63UM8 TI TTMI6F5 DM63UM8 TN Transient receptor potential cation channel V1 (TRPV1) DM63UM8 MA Antagonist DM63UM8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM63UM8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM63XHT DI DM63XHT DM63XHT DN Aryl piperazine derivative 16 DM63XHT TI TTWT5K7 DM63XHT TN 5-HT 1 receptor (5HT1R) DM63XHT MA Agonist DM63XHT RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM63XHT RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM63XHT DI DM63XHT DM63XHT DN Aryl piperazine derivative 16 DM63XHT TI TTSQIFT DM63XHT TN 5-HT 1A receptor (HTR1A) DM63XHT MA Agonist DM63XHT RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM63XHT RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM64QNL DI DM64QNL DM64QNL DN PMID28074661-Compound-WO2009018344C79 DM64QNL TI TTL7C8Q DM64QNL TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM64QNL MA Inhibitor DM64QNL RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM64QNL RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM64R2K DI DM64R2K DM64R2K DN Resorcinol compound 18 DM64R2K TI TTULVH8 DM64R2K TN Tyrosinase (TYR) DM64R2K MA Inhibitor DM64R2K RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM64R2K RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM654Z0 DI DM654Z0 DM654Z0 DN Imidazo[1,2-b]pyridazine acetamide derivative 1 DM654Z0 TI TTPTXIN DM654Z0 TN Translocator protein (TSPO) DM654Z0 MA Ligand DM654Z0 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM654Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM658HJ DI DM658HJ DM658HJ DN PMID28394193-Compound-36 DM658HJ TI TT9MZCQ DM658HJ TN Enhancer of zeste homolog 2 (EZH2) DM658HJ MA Inhibitor DM658HJ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM658HJ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM65NBS DI DM65NBS DM65NBS DN Sulfonylated piperazine derivative 5 DM65NBS TI TT6OEDT DM65NBS TN Cannabinoid receptor 1 (CB1) DM65NBS MA Antagonist DM65NBS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM65NBS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM673GR DI DM673GR DM673GR DN N-oxalyl-D-tyrosine derivative 5 DM673GR TI TTWAQBO DM673GR TN Lysine-specific demethylase 4E (KDM4E) DM673GR MA Inhibitor DM673GR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM673GR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM675SX DI DM675SX DM675SX DN PMID27841045-Compound-155 DM675SX TI TT7RJY8 DM675SX TN Xanthine dehydrogenase/oxidase (XDH) DM675SX MA Inhibitor DM675SX RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM675SX RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM67DEG DI DM67DEG DM67DEG DN PMID25666693-Compound-49 DM67DEG TI TTMI6F5 DM67DEG TN Transient receptor potential cation channel V1 (TRPV1) DM67DEG MA Antagonist DM67DEG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM67DEG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM67NBI DI DM67NBI DM67NBI DN PMID27977313-Compound-28 DM67NBI TI TTR7UJ3 DM67NBI TN Cytoplasmic thioredoxin reductase (TXNRD1) DM67NBI MA Inhibitor DM67NBI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM67NBI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM67RMX DI DM67RMX DM67RMX DN PMID27998201-Compound-19 DM67RMX TI TT36ETB DM67RMX TN Cathepsin L (CTSL) DM67RMX MA Inhibitor DM67RMX RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM67RMX RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM67VNW DI DM67VNW DM67VNW DN PMID27376512-Compound-miR-155-5p DM67VNW TI TT6S2FE DM67VNW TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM67VNW MA Inhibitor DM67VNW RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM67VNW RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM67WM4 DI DM67WM4 DM67WM4 DN PMID25726713-Compound-15 DM67WM4 TI TT8J1S3 DM67WM4 TN Smoothened homolog (SMO) DM67WM4 MA Inhibitor DM67WM4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM67WM4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM67XSL DI DM67XSL DM67XSL DN PMID28870136-Compound-38 DM67XSL TI TTK0O6Y DM67XSL TN Ecto-5'-nucleotidase (CD73) DM67XSL MA Inhibitor DM67XSL RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM67XSL RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM6803W DI DM6803W DM6803W DN Biphenyl carboxamidopropanoic acid derivative 1 DM6803W TI TT9O6WS DM6803W TN Glucagon receptor (GCGR) DM6803W MA Antagonist DM6803W RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6803W RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM683R7 DI DM683R7 DM683R7 DN 1,2,4-oxadiazole derivative 5 DM683R7 TI TT23XQV DM683R7 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM683R7 MA Inhibitor DM683R7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM683R7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM684IK DI DM684IK DM684IK DN PMID25656651-Compound-37c DM684IK TI TTIV39N DM684IK TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM684IK MA Inhibitor DM684IK RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM684IK RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM684IK DI DM684IK DM684IK DN PMID25656651-Compound-37c DM684IK TI TTS7G69 DM684IK TN Fusion protein Bcr-Abl (Bcr-Abl) DM684IK MA Inhibitor DM684IK RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM684IK RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM68B1R DI DM68B1R DM68B1R DN PMID28117607-Compound-6 DM68B1R TI TTK0FEA DM68B1R TN Leucine-rich repeat kinase 2 (LRRK2) DM68B1R MA Inhibitor DM68B1R RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM68B1R RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM68KPS DI DM68KPS DM68KPS DN PMID27967267-Compound-42 DM68KPS TI TT1RS9F DM68KPS TN Acetylcholinesterase (AChE) DM68KPS MA Inhibitor DM68KPS RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM68KPS RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM68M0G DI DM68M0G DM68M0G DN Peptide analog 6 DM68M0G TI TT23XQV DM68M0G TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM68M0G MA Inhibitor DM68M0G RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM68M0G RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM69A05 DI DM69A05 DM69A05 DN PMID29324067-Compound-40 DM69A05 TI TTGP7BY DM69A05 TN Monoamine oxidase type B (MAO-B) DM69A05 MA Inhibitor DM69A05 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM69A05 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM69HL5 DI DM69HL5 DM69HL5 DN Bicyclic heteroaryl amide derivative 2 DM69HL5 TI TT473XN DM69HL5 TN P2X purinoceptor 7 (P2RX7) DM69HL5 MA Antagonist DM69HL5 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM69HL5 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM69Y7R DI DM69Y7R DM69Y7R DN PMID29338548-Compound-39 DM69Y7R TI TTHJTF7 DM69Y7R TN Glycine transporter GlyT-1 (SLC6A9) DM69Y7R MA Inhibitor DM69Y7R RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM69Y7R RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6A8TS DI DM6A8TS DM6A8TS DN PMID25726713-Compound-64 DM6A8TS TI TT8J1S3 DM6A8TS TN Smoothened homolog (SMO) DM6A8TS MA Inhibitor DM6A8TS RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM6A8TS RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM6A8XJ DI DM6A8XJ DM6A8XJ DN US9586945, 5 DM6A8XJ TI TTYJRN5 DM6A8XJ TN N-acetylglucosaminyltransferase I (NAGAT1) DM6A8XJ MA Inhibitor DM6A8XJ RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DM6A8XJ RU http://www.freepatentsonline.com/US9586945.html DM6A9UR DI DM6A9UR DM6A9UR DN Flavonoid derivative 7 DM6A9UR TI TTL4Q97 DM6A9UR TN Cyclin-dependent kinase 5 (CDK5) DM6A9UR MA Inhibitor DM6A9UR RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6A9UR RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6BJEW DI DM6BJEW DM6BJEW DN Urea and carbamate bioisostere derivative 13 DM6BJEW TI TTL7C8Q DM6BJEW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM6BJEW MA Inhibitor DM6BJEW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM6BJEW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM6BKQ8 DI DM6BKQ8 DM6BKQ8 DN PMID29338548-Compound-38 DM6BKQ8 TI TTHJTF7 DM6BKQ8 TN Glycine transporter GlyT-1 (SLC6A9) DM6BKQ8 MA Inhibitor DM6BKQ8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM6BKQ8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6BQFA DI DM6BQFA DM6BQFA DN PMID28454500-Compound-8 DM6BQFA TI TTA6ZN2 DM6BQFA TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6BQFA MA Activator DM6BQFA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6BQFA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6BQFA DI DM6BQFA DM6BQFA DN PMID28454500-Compound-8 DM6BQFA TI TT3Z6Y9 DM6BQFA TN Cysteines of Keap1 (KEAP1 Cysteines) DM6BQFA MA Modulator DM6BQFA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6BQFA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6BTMX DI DM6BTMX DM6BTMX DN Pyrrolo[2,3-d]pyrimidine derivative 33 DM6BTMX TI TTGM6VW DM6BTMX TN Tyrosine-protein kinase BTK (ATK) DM6BTMX MA Inhibitor DM6BTMX RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM6BTMX RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM6C45G DI DM6C45G DM6C45G DN PMID26609882-Compound-83 DM6C45G TI TTWJBZ5 DM6C45G TN 5-HT 2C receptor (HTR2C) DM6C45G MA Agonist DM6C45G RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6C45G RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6C5DR DI DM6C5DR DM6C5DR DN Piperidine derivative 4 DM6C5DR TI TT5TPI6 DM6C5DR TN Opioid receptor sigma 1 (OPRS1) DM6C5DR MA Ligand DM6C5DR RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM6C5DR RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM6CK7J DI DM6CK7J DM6CK7J DN Aryl cyclopropylamine derivative 5 DM6CK7J TI TTNR0UQ DM6CK7J TN Lysine-specific histone demethylase 1 (LSD) DM6CK7J MA Inhibitor DM6CK7J RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6CK7J RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6D1XR DI DM6D1XR DM6D1XR DN Pyrido[3,2-d]pyrimidine derivative 3 DM6D1XR TI TTTDVOJ DM6D1XR TN Tropomyosin-related kinase A (TrkA) DM6D1XR MA Inhibitor DM6D1XR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6D1XR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6DFAK DI DM6DFAK DM6DFAK DN PMID25666693-Compound-63 DM6DFAK TI TTMI6F5 DM6DFAK TN Transient receptor potential cation channel V1 (TRPV1) DM6DFAK MA Antagonist DM6DFAK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6DFAK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6DFTX DI DM6DFTX DM6DFTX DN BDBM50434164 DM6DFTX TI TTOYT5L DM6DFTX TN Dipeptidyl-peptidase 7 (DPP7) DM6DFTX MA Inhibitor DM6DFTX RN FAP inhibitors. US9346814. DM6DFTX RU http://www.freepatentsonline.com/US9346814.html DM6DJZ7 DI DM6DJZ7 DM6DJZ7 DN PMID28092474-Compound-33o DM6DJZ7 TI TT5ZKDI DM6DJZ7 TN Histone deacetylase 6 (HDAC6) DM6DJZ7 MA Inhibitor DM6DJZ7 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6DJZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6DJZ7 DI DM6DJZ7 DM6DJZ7 DN PMID28092474-Compound-33o DM6DJZ7 TI TT6R7JZ DM6DJZ7 TN Histone deacetylase 1 (HDAC1) DM6DJZ7 MA Inhibitor DM6DJZ7 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6DJZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6E1N4 DI DM6E1N4 DM6E1N4 DN Quinoline and quinazoline derivative 10 DM6E1N4 TI TTOHSBA DM6E1N4 TN Vascular endothelial growth factor A (VEGFA) DM6E1N4 MA Inhibitor DM6E1N4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM6E1N4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM6E50A DI DM6E50A DM6E50A DN PMID27336223-Compound-5 DM6E50A TI TTW38KT DM6E50A TN Retinoic acid receptor alpha (RARA) DM6E50A MA Agonist DM6E50A RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM6E50A RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM6E9L4 DI DM6E9L4 DM6E9L4 DN Cyclopropylamine derivative 3 DM6E9L4 TI TTNR0UQ DM6E9L4 TN Lysine-specific histone demethylase 1 (LSD) DM6E9L4 MA Inhibitor DM6E9L4 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6E9L4 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6EFIN DI DM6EFIN DM6EFIN DN PMID26815044-Compound-125 DM6EFIN TI TTULVH8 DM6EFIN TN Tyrosinase (TYR) DM6EFIN MA Inhibitor DM6EFIN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6EFIN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6EJ93 DI DM6EJ93 DM6EJ93 DN PMID29671355-Compound-39 DM6EJ93 TI TT6R7JZ DM6EJ93 TN Histone deacetylase 1 (HDAC1) DM6EJ93 MA Inhibitor DM6EJ93 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM6EJ93 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM6EJ93 DI DM6EJ93 DM6EJ93 DN PMID29671355-Compound-39 DM6EJ93 TI TT5ZKDI DM6EJ93 TN Histone deacetylase 6 (HDAC6) DM6EJ93 MA Inhibitor DM6EJ93 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM6EJ93 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM6EKIV DI DM6EKIV DM6EKIV DN PMID30107136-Compound-Example16 DM6EKIV TI TTNBFWK DM6EKIV TN Programmed cell death protein 1 (PD-1) DM6EKIV MA Inhibitor DM6EKIV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6EKIV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6EMYB DI DM6EMYB DM6EMYB DN US8937193-compound-6b DM6EMYB TI TTGT9C7 DM6EMYB TN Bcl-2-related protein A1 (BCL2A1) DM6EMYB MA Inhibitor DM6EMYB RN Apogossypolone derivatives as anticancer agents. US8937193. DM6EMYB RU http://www.freepatentsonline.com/US8937193.html DM6EN54 DI DM6EN54 DM6EN54 DN PMID25470667-Compound-AZD3988 DM6EN54 TI TTF8P9I DM6EN54 TN Diacylglycerol acyltransferase 1 (DGAT1) DM6EN54 MA Inhibitor DM6EN54 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM6EN54 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM6EQVT DI DM6EQVT DM6EQVT DN US9682983, 1 DM6EQVT TI TTPKHTZ DM6EQVT TN Activin receptor type IB (ACVR1B) DM6EQVT MA Inhibitor DM6EQVT RN BMP inhibitors and methods of use thereof. US9682983. DM6EQVT RU http://www.freepatentsonline.com/US9682983.html DM6EY5Z DI DM6EY5Z DM6EY5Z DN Heterocycle-containing compound 5 DM6EY5Z TI TT9O6WS DM6EY5Z TN Glucagon receptor (GCGR) DM6EY5Z MA Antagonist DM6EY5Z RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6EY5Z RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM6F7M2 DI DM6F7M2 DM6F7M2 DN US9623028, Compound 101 DM6F7M2 TI TTV298Y DM6F7M2 TN Calmodulin-dependent kinase II (CAMKK2) DM6F7M2 MA Inhibitor DM6F7M2 RN Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028. DM6F7M2 RU http://www.freepatentsonline.com/US9623028.html DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TT056SO DM6FCS9 TN Stress-activated protein kinase JNK3 (JNK3) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TTHS0U8 DM6FCS9 TN Stress-activated protein kinase JNK2 (JNK2) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TT0K6EO DM6FCS9 TN Stress-activated protein kinase JNK1 (JNK1) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FQ8L DI DM6FQ8L DM6FQ8L DN Aryl carboxamide derivative 3 DM6FQ8L TI TTZOVE0 DM6FQ8L TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM6FQ8L MA Inhibitor DM6FQ8L RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM6FQ8L RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM6G2WJ DI DM6G2WJ DM6G2WJ DN PMID26560530-Compound-5 DM6G2WJ TI TT2F4OL DM6G2WJ TN Tissue transglutaminase (TG2) DM6G2WJ MA Inhibitor DM6G2WJ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM6G2WJ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM6GFYR DI DM6GFYR DM6GFYR DN PMID26651364-Compound-50 DM6GFYR TI TTTCRU2 DM6GFYR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6GFYR MA Antagonist DM6GFYR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6GFYR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6GSCV DI DM6GSCV DM6GSCV DN Quinoline derivative 10 DM6GSCV TI TT473XN DM6GSCV TN P2X purinoceptor 7 (P2RX7) DM6GSCV MA Antagonist DM6GSCV RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM6GSCV RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM6GTDM DI DM6GTDM DM6GTDM DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 DM6GTDM TI TT6OEDT DM6GTDM TN Cannabinoid receptor 1 (CB1) DM6GTDM MA Agonist DM6GTDM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM6GTDM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM6GTDM DI DM6GTDM DM6GTDM DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 DM6GTDM TI TTMSFAW DM6GTDM TN Cannabinoid receptor 2 (CB2) DM6GTDM MA Agonist DM6GTDM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM6GTDM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM6GZW4 DI DM6GZW4 DM6GZW4 DN Carboxamide derivative 6 DM6GZW4 TI TTG5QB7 DM6GZW4 TN Calpain-2 (CAPN2) DM6GZW4 MA Inhibitor DM6GZW4 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM6GZW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM6HI34 DI DM6HI34 DM6HI34 DN Carboxamide derivative 8 DM6HI34 TI TTG5QB7 DM6HI34 TN Calpain-2 (CAPN2) DM6HI34 MA Inhibitor DM6HI34 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM6HI34 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM6HOES DI DM6HOES DM6HOES DN PMID28870136-Compound-54 DM6HOES TI TTK0O6Y DM6HOES TN Ecto-5'-nucleotidase (CD73) DM6HOES MA Inhibitor DM6HOES RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM6HOES RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM6HTU0 DI DM6HTU0 DM6HTU0 DN PMID26651364-Compound-9b DM6HTU0 TI TTTCRU2 DM6HTU0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6HTU0 MA Antagonist DM6HTU0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6HTU0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6HWBK DI DM6HWBK DM6HWBK DN PMID27109571-Compound-12 DM6HWBK TI TTNT2S6 DM6HWBK TN Fatty acid-binding protein 5 (FABP5) DM6HWBK MA Inhibitor DM6HWBK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM6HWBK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM6HWBK DI DM6HWBK DM6HWBK DN PMID27109571-Compound-12 DM6HWBK TI TTHWMFZ DM6HWBK TN Fatty acid-binding protein 4 (FABP4) DM6HWBK MA Inhibitor DM6HWBK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM6HWBK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM6HWN3 DI DM6HWN3 DM6HWN3 DN Heterocyclic derivative 6 DM6HWN3 TI TTCZOF2 DM6HWN3 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6HWN3 MA Inhibitor DM6HWN3 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6HWN3 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6I49E DI DM6I49E DM6I49E DN PMID25666693-Compound-42 DM6I49E TI TTMI6F5 DM6I49E TN Transient receptor potential cation channel V1 (TRPV1) DM6I49E MA Antagonist DM6I49E RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6I49E RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6IJRG DI DM6IJRG DM6IJRG DN Pyrrolo[2,3-d]pyrimidine derivative 29 DM6IJRG TI TTGM6VW DM6IJRG TN Tyrosine-protein kinase BTK (ATK) DM6IJRG MA Inhibitor DM6IJRG RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM6IJRG RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM6IQWE DI DM6IQWE DM6IQWE DN Peptide analog 57 DM6IQWE TI TTQAJF1 DM6IQWE TN Cathepsin G (CTSG) DM6IQWE MA Inhibitor DM6IQWE RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM6IQWE RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM6IQWE DI DM6IQWE DM6IQWE DN Peptide analog 57 DM6IQWE TI TTPLTSQ DM6IQWE TN Neutrophil elastase (NE) DM6IQWE MA Inhibitor DM6IQWE RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM6IQWE RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM6IRJL DI DM6IRJL DM6IRJL DN Heterocycle-containing compound 4 DM6IRJL TI TT9O6WS DM6IRJL TN Glucagon receptor (GCGR) DM6IRJL MA Antagonist DM6IRJL RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6IRJL RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM6IYAT DI DM6IYAT DM6IYAT DN PMID28270010-Compound-Figure21-b DM6IYAT TI TTPMQSO DM6IYAT TN ALK tyrosine kinase receptor (ALK) DM6IYAT MA Inhibitor DM6IYAT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6IYAT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6IYAT DI DM6IYAT DM6IYAT DN PMID28270010-Compound-Figure21-b DM6IYAT TI TTSZ6Y3 DM6IYAT TN Proto-oncogene c-Ros (ROS1) DM6IYAT MA Inhibitor DM6IYAT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6IYAT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6J0Z8 DI DM6J0Z8 DM6J0Z8 DN PMID29338548-Compound-15 DM6J0Z8 TI TTHJTF7 DM6J0Z8 TN Glycine transporter GlyT-1 (SLC6A9) DM6J0Z8 MA Inhibitor DM6J0Z8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM6J0Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6JR3X DI DM6JR3X DM6JR3X DN Indoline derivative 11 DM6JR3X TI TT5OU0D DM6JR3X TN PRKR-like endoplasmic reticulum kinase (PERK) DM6JR3X MA Inhibitor DM6JR3X RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM6JR3X RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM6JRCW DI DM6JRCW DM6JRCW DN PMID28092474-Compound-34 DM6JRCW TI TTBH0VX DM6JRCW TN Histone deacetylase (HDAC) DM6JRCW MA Inhibitor DM6JRCW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6JRCW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TT8EPLT DM6JV1W TN Proteasome beta-1 (PS beta-1) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TT68GPI DM6JV1W TN Proteasome beta-5 (PS beta-5) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TTOUSTQ DM6JV1W TN Proteasome beta-9 (PS beta-9) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TTEAD9J DM6JV1W TN Proteasome beta-8 (PS beta-8) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JVR5 DI DM6JVR5 DM6JVR5 DN PMID26161698-Compound-18 DM6JVR5 TI TTRSMW9 DM6JVR5 TN Glycogen synthase kinase-3 beta (GSK-3B) DM6JVR5 MA Inhibitor DM6JVR5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6JVR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6JVR5 DI DM6JVR5 DM6JVR5 DN PMID26161698-Compound-18 DM6JVR5 TI TTL4Q97 DM6JVR5 TN Cyclin-dependent kinase 5 (CDK5) DM6JVR5 MA Inhibitor DM6JVR5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6JVR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6K29H DI DM6K29H DM6K29H DN Aryl mannoside derivative 19 DM6K29H TI TTTCRU2 DM6K29H TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6K29H MA Antagonist DM6K29H RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6K29H RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6K59I DI DM6K59I DM6K59I DN Cyclopropane 1-carboxylic acid derivative 3 DM6K59I TI TTIY56R DM6K59I TN Kynurenine 3-hydroxylase (KMO) DM6K59I MA Inhibitor DM6K59I RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM6K59I RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM6KGUB DI DM6KGUB DM6KGUB DN Bipyrazole derivative 1 DM6KGUB TI TT6DM01 DM6KGUB TN Janus kinase 1 (JAK-1) DM6KGUB MA Inhibitor DM6KGUB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM6KGUB RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM6KJLG DI DM6KJLG DM6KJLG DN Trepenoid derivative 1 DM6KJLG TI TTA6ZN2 DM6KJLG TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6KJLG MA Activator DM6KJLG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6KJLG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6KJLG DI DM6KJLG DM6KJLG DN Trepenoid derivative 1 DM6KJLG TI TT3Z6Y9 DM6KJLG TN Cysteines of Keap1 (KEAP1 Cysteines) DM6KJLG MA Modulator DM6KJLG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6KJLG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6KPYL DI DM6KPYL DM6KPYL DN STK296197 DM6KPYL TI TT3RMNA DM6KPYL TN Chymotrypsin-C (CLCR) DM6KPYL MA Inhibitor DM6KPYL RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DM6KPYL RU http://www.freepatentsonline.com/US9695194.html DM6KROX DI DM6KROX DM6KROX DN Pyrazole derivative 35 DM6KROX TI TT6OEDT DM6KROX TN Cannabinoid receptor 1 (CB1) DM6KROX MA Antagonist DM6KROX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM6KROX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTKN7QR DM6KXOQ TN BDNF/NT-3 growth factors receptor (TrkB) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTXABCW DM6KXOQ TN NT-3 growth factor receptor (TrkC) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTTDVOJ DM6KXOQ TN Tropomyosin-related kinase A (TrkA) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6LR42 DI DM6LR42 DM6LR42 DN PMID25399762-Compound-Table 6-13 DM6LR42 TI TTGP7BY DM6LR42 TN Monoamine oxidase type B (MAO-B) DM6LR42 MA Inhibitor DM6LR42 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6LR42 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM6LR42 DI DM6LR42 DM6LR42 DN PMID25399762-Compound-Table 6-13 DM6LR42 TI TTNR0UQ DM6LR42 TN Lysine-specific histone demethylase 1 (LSD) DM6LR42 MA Inhibitor DM6LR42 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6LR42 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM6LXHS DI DM6LXHS DM6LXHS DN PMID26651364-Compound-117a DM6LXHS TI TTTCRU2 DM6LXHS TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6LXHS MA Antagonist DM6LXHS RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6LXHS RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6MCBU DI DM6MCBU DM6MCBU DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4 DM6MCBU TI TTV1C0Z DM6MCBU TN Neuropeptide S receptor (NPSR) DM6MCBU MA Antagonist DM6MCBU RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM6MCBU RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM6N8T3 DI DM6N8T3 DM6N8T3 DN Pyridine derivative 4 DM6N8T3 TI TTOHSBA DM6N8T3 TN Vascular endothelial growth factor A (VEGFA) DM6N8T3 MA Inhibitor DM6N8T3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM6N8T3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM6NJV7 DI DM6NJV7 DM6NJV7 DN Heterocyclic derivative 16 DM6NJV7 TI TTCZOF2 DM6NJV7 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6NJV7 MA Inhibitor DM6NJV7 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6NJV7 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6NR9Y DI DM6NR9Y DM6NR9Y DN Diarylamine and arylheteroarylamine pyrazole derivative 2 DM6NR9Y TI TTJQOD7 DM6NR9Y TN 5-HT 2A receptor (HTR2A) DM6NR9Y MA Agonist DM6NR9Y RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6NR9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6O2Q9 DI DM6O2Q9 DM6O2Q9 DN Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 DM6O2Q9 TI TTG0U4H DM6O2Q9 TN Ribosomal protein S6 kinase beta-1 (S6K1) DM6O2Q9 MA Inhibitor DM6O2Q9 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DM6O2Q9 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DM6O78C DI DM6O78C DM6O78C DN PMID29649907-Compound-26 DM6O78C TI TTS4UGC DM6O78C TN Farnesoid X-activated receptor (FXR) DM6O78C MA Agonist DM6O78C RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM6O78C RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM6OCSJ DI DM6OCSJ DM6OCSJ DN PMID27774824-Compound-Figure8Example22 DM6OCSJ TI TTRMX3V DM6OCSJ TN Janus kinase 2 (JAK-2) DM6OCSJ MA Inhibitor DM6OCSJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM6OCSJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM6ODU7 DI DM6ODU7 DM6ODU7 DN PMID25666693-Compound-124 DM6ODU7 TI TTMI6F5 DM6ODU7 TN Transient receptor potential cation channel V1 (TRPV1) DM6ODU7 MA Antagonist DM6ODU7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6ODU7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6OEHK DI DM6OEHK DM6OEHK DN PMID25980951-Compound-22 DM6OEHK TI TTR7B60 DM6OEHK TN X-linked inhibitor of apoptosis protein (XIAP) DM6OEHK MA Antagonist DM6OEHK RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM6OEHK RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM6OEHK DI DM6OEHK DM6OEHK DN PMID25980951-Compound-22 DM6OEHK TI TTQ5LRD DM6OEHK TN Cellular inhibitor of apoptosis 1 (BIRC2) DM6OEHK MA Antagonist DM6OEHK RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM6OEHK RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM6OG2Y DI DM6OG2Y DM6OG2Y DN N-phenyl-pyridine-2-carboxamide derivative 2 DM6OG2Y TI TT23XQV DM6OG2Y TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6OG2Y MA Inhibitor DM6OG2Y RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6OG2Y RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6ON31 DI DM6ON31 DM6ON31 DN Disulfide compound 2 DM6ON31 TI TTR7UJ3 DM6ON31 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM6ON31 MA Inhibitor DM6ON31 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM6ON31 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM6OQKM DI DM6OQKM DM6OQKM DN PMID26651364-Compound-113 DM6OQKM TI TTTCRU2 DM6OQKM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6OQKM MA Antagonist DM6OQKM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6OQKM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6ORB9 DI DM6ORB9 DM6ORB9 DN PMID25726713-Compound-14 DM6ORB9 TI TT8J1S3 DM6ORB9 TN Smoothened homolog (SMO) DM6ORB9 MA Inhibitor DM6ORB9 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM6ORB9 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM6PDEH DI DM6PDEH DM6PDEH DN PMID29757691-Compound-8d DM6PDEH TI TT1RS9F DM6PDEH TN Acetylcholinesterase (AChE) DM6PDEH MA Inhibitor DM6PDEH RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM6PDEH RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM6PDEH DI DM6PDEH DM6PDEH DN PMID29757691-Compound-8d DM6PDEH TI TTEB0GD DM6PDEH TN Cholinesterase (BCHE) DM6PDEH MA Inhibitor DM6PDEH RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM6PDEH RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM6PMZC DI DM6PMZC DM6PMZC DN Benzenamine derivative 1 DM6PMZC TI TTNR0UQ DM6PMZC TN Lysine-specific histone demethylase 1 (LSD) DM6PMZC MA Inhibitor DM6PMZC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6PMZC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6PTOX DI DM6PTOX DM6PTOX DN Benzyl phenyl ether derivative 1 DM6PTOX TI TT23XQV DM6PTOX TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6PTOX MA Inhibitor DM6PTOX RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6PTOX RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6QBV2 DI DM6QBV2 DM6QBV2 DN Polyhydroxy benzamide derivative 4 DM6QBV2 TI TTULVH8 DM6QBV2 TN Tyrosinase (TYR) DM6QBV2 MA Inhibitor DM6QBV2 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6QBV2 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6QHGV DI DM6QHGV DM6QHGV DN PMID25666693-Compound-128 DM6QHGV TI TTMI6F5 DM6QHGV TN Transient receptor potential cation channel V1 (TRPV1) DM6QHGV MA Antagonist DM6QHGV RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6QHGV RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6QHO0 DI DM6QHO0 DM6QHO0 DN Tihoacetate derivative 1 DM6QHO0 TI TTA592U DM6QHO0 TN Urate anion exchanger 1 (URAT1) DM6QHO0 MA Inhibitor DM6QHO0 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM6QHO0 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM6QSND DI DM6QSND DM6QSND DN Tricyclic isoxazoloquinazoline derivative 1 DM6QSND TI TT5OU0D DM6QSND TN PRKR-like endoplasmic reticulum kinase (PERK) DM6QSND MA Inhibitor DM6QSND RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM6QSND RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM6R1YP DI DM6R1YP DM6R1YP DN US9682983, 33 DM6R1YP TI TTPKHTZ DM6R1YP TN Activin receptor type IB (ACVR1B) DM6R1YP MA Inhibitor DM6R1YP RN BMP inhibitors and methods of use thereof. US9682983. DM6R1YP RU http://www.freepatentsonline.com/US9682983.html DM6R34M DI DM6R34M DM6R34M DN N-{4 DM6R34M TI TTCGOIN DM6R34M TN PIM-3 protein kinase (PIM3) DM6R34M MA Inhibitor DM6R34M RN Kinase inhibitors and methods of their use. US8592455. DM6R34M RU http://www.freepatentsonline.com/US8592455.html DM6RGOY DI DM6RGOY DM6RGOY DN Dihydropyridine compound 2 DM6RGOY TI TT4DXQT DM6RGOY TN Proto-oncogene c-Ret (RET) DM6RGOY MA Inhibitor DM6RGOY RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM6RGOY RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM6RLTV DI DM6RLTV DM6RLTV DN Dipeptide analog 3 DM6RLTV TI TT2F4OL DM6RLTV TN Tissue transglutaminase (TG2) DM6RLTV MA Inhibitor DM6RLTV RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM6RLTV RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM6RLVB DI DM6RLVB DM6RLVB DN Hydrazide derivative 5 DM6RLVB TI TTK0FEA DM6RLVB TN Leucine-rich repeat kinase 2 (LRRK2) DM6RLVB MA Inhibitor DM6RLVB RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM6RLVB RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM6RQKH DI DM6RQKH DM6RQKH DN PMID25666693-Compound-89 DM6RQKH TI TTMI6F5 DM6RQKH TN Transient receptor potential cation channel V1 (TRPV1) DM6RQKH MA Antagonist DM6RQKH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6RQKH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6SL9D DI DM6SL9D DM6SL9D DN PMID25666693-Compound-16 DM6SL9D TI TTMI6F5 DM6SL9D TN Transient receptor potential cation channel V1 (TRPV1) DM6SL9D MA Antagonist DM6SL9D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6SL9D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6SPTJ DI DM6SPTJ DM6SPTJ DN Bidentate pyrazolopyrimidine acetamide analog 2 DM6SPTJ TI TTPTXIN DM6SPTJ TN Translocator protein (TSPO) DM6SPTJ MA Ligand DM6SPTJ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM6SPTJ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM6T2FM DI DM6T2FM DM6T2FM DN PMID28394193-Compound-14 DM6T2FM TI TT9MZCQ DM6T2FM TN Enhancer of zeste homolog 2 (EZH2) DM6T2FM MA Inhibitor DM6T2FM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM6T2FM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6T2FM DI DM6T2FM DM6T2FM DN PMID28394193-Compound-14 DM6T2FM TI TTJBYRU DM6T2FM TN EZH2 Y641F mutant (EZH2 Y641F) DM6T2FM MA Inhibitor DM6T2FM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM6T2FM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6TB4Z DI DM6TB4Z DM6TB4Z DN Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z TI TTKFVXR DM6TB4Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM6TB4Z MA Inhibitor DM6TB4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM6TB4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM6TB4Z DI DM6TB4Z DM6TB4Z DN Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z TI TTXAJWN DM6TB4Z TN IL-1 receptor-associated kinase 1 (IRAK1) DM6TB4Z MA Inhibitor DM6TB4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM6TB4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM6TGUR DI DM6TGUR DM6TGUR DN PMID25656651-Compound-31b DM6TGUR TI TTIV39N DM6TGUR TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM6TGUR MA Inhibitor DM6TGUR RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM6TGUR RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM6TJU0 DI DM6TJU0 DM6TJU0 DN PMID28270021-Compound-WO2010077680 803 DM6TJU0 TI TTTDVOJ DM6TJU0 TN Tropomyosin-related kinase A (TrkA) DM6TJU0 MA Antagonist DM6TJU0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6TJU0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6TMXL DI DM6TMXL DM6TMXL DN N-containing heterocyclic derivative 1 DM6TMXL TI TTJOW1I DM6TMXL TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DM6TMXL MA Inhibitor DM6TMXL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM6TMXL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM6TXF4 DI DM6TXF4 DM6TXF4 DN Biphenyl carboxylic acid derivative 2 DM6TXF4 TI TTL53M6 DM6TXF4 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM6TXF4 MA Inhibitor DM6TXF4 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM6TXF4 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM6TYM0 DI DM6TYM0 DM6TYM0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 DM6TYM0 TI TT6OEDT DM6TYM0 TN Cannabinoid receptor 1 (CB1) DM6TYM0 MA Antagonist DM6TYM0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM6TYM0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM6U3ZR DI DM6U3ZR DM6U3ZR DN US8481586, 40 DM6U3ZR TI TTCGOIN DM6U3ZR TN PIM-3 protein kinase (PIM3) DM6U3ZR MA Inhibitor DM6U3ZR RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DM6U3ZR RU http://www.freepatentsonline.com/US8481586.html DM6UTAQ DI DM6UTAQ DM6UTAQ DN PMID27744724-Compound-5 DM6UTAQ TI TTL53M6 DM6UTAQ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM6UTAQ MA Inhibitor DM6UTAQ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM6UTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM6UXZK DI DM6UXZK DM6UXZK DN US9522888, 575 DM6UXZK TI TTDYP7I DM6UXZK TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM6UXZK MA Inhibitor DM6UXZK RN Substituted bicyclic compounds. US9522888. DM6UXZK RU http://www.freepatentsonline.com/US9522888.html DM6V13W DI DM6V13W DM6V13W DN PMID27336223-Compound-9 DM6V13W TI TT1Q3IE DM6V13W TN Retinoic acid receptor gamma (RARG) DM6V13W MA Agonist DM6V13W RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM6V13W RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM6VAS2 DI DM6VAS2 DM6VAS2 DN PMID28270021-Compound-WO2010077680 481 DM6VAS2 TI TTTDVOJ DM6VAS2 TN Tropomyosin-related kinase A (TrkA) DM6VAS2 MA Antagonist DM6VAS2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6VAS2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6VER5 DI DM6VER5 DM6VER5 DN PMID26651364-Compound-124 DM6VER5 TI TTTCRU2 DM6VER5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6VER5 MA Antagonist DM6VER5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6VER5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6VP5K DI DM6VP5K DM6VP5K DN PMID30280939-Compound-WO2005070959 DM6VP5K TI TTOK0LR DM6VP5K TN Toll-like receptor (TLR) DM6VP5K MA Immune response agent DM6VP5K RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM6VP5K RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM6VPIR DI DM6VPIR DM6VPIR DN Cyclohexyl carbamate derivative 2 DM6VPIR TI TTULVH8 DM6VPIR TN Tyrosinase (TYR) DM6VPIR MA Inhibitor DM6VPIR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6VPIR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6W0TM DI DM6W0TM DM6W0TM DN Benzamide derivative 5 DM6W0TM TI TTA6ZN2 DM6W0TM TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6W0TM MA Inhibitor DM6W0TM RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6W0TM RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6WTR2 DI DM6WTR2 DM6WTR2 DN Thiazole carboxamide derivative 22 DM6WTR2 TI TTCZOF2 DM6WTR2 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6WTR2 MA Inhibitor DM6WTR2 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6WTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6X2CO DI DM6X2CO DM6X2CO DN PMID28092474-Compound-34b DM6X2CO TI TT5ZKDI DM6X2CO TN Histone deacetylase 6 (HDAC6) DM6X2CO MA Inhibitor DM6X2CO RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6X2CO RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6X2CO DI DM6X2CO DM6X2CO DN PMID28092474-Compound-34b DM6X2CO TI TT6R7JZ DM6X2CO TN Histone deacetylase 1 (HDAC1) DM6X2CO MA Inhibitor DM6X2CO RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6X2CO RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6XFA5 DI DM6XFA5 DM6XFA5 DN Resorcinol compound 14 DM6XFA5 TI TTULVH8 DM6XFA5 TN Tyrosinase (TYR) DM6XFA5 MA Inhibitor DM6XFA5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6XFA5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6XRDH DI DM6XRDH DM6XRDH DN Benzazepine derivative 5 DM6XRDH TI TTWJBZ5 DM6XRDH TN 5-HT 2C receptor (HTR2C) DM6XRDH MA Agonist DM6XRDH RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6XRDH RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6XWL9 DI DM6XWL9 DM6XWL9 DN PMID30107136-Compound-Example59 DM6XWL9 TI TT23XQV DM6XWL9 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6XWL9 MA Inhibitor DM6XWL9 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6XWL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6XYFB DI DM6XYFB DM6XYFB DN PMID29053063-Compound-7e DM6XYFB TI TTZ963I DM6XYFB TN Monoglyceride lipase (MAGL) DM6XYFB MA Inhibitor DM6XYFB RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM6XYFB RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM6Y27J DI DM6Y27J DM6Y27J DN Pyrazole derivative 76 DM6Y27J TI TTXJ47W DM6Y27J TN Metabotropic glutamate receptor 2 (mGluR2) DM6Y27J MA Antagonist DM6Y27J RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM6Y27J RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM6YBTR DI DM6YBTR DM6YBTR DN Tacrine-coumarin hybrid derivative 1 DM6YBTR TI TT3WG5C DM6YBTR TN Monoamine oxidase type A (MAO-A) DM6YBTR RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM6YBTR RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM6YBTR DI DM6YBTR DM6YBTR DN Tacrine-coumarin hybrid derivative 1 DM6YBTR TI TTGP7BY DM6YBTR TN Monoamine oxidase type B (MAO-B) DM6YBTR RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM6YBTR RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM6YGLT DI DM6YGLT DM6YGLT DN PMID26924192-Compound-56 DM6YGLT TI TTE4BSY DM6YGLT TN Bromodomain and extraterminal domain protein (BET) DM6YGLT MA Inhibitor DM6YGLT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM6YGLT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM6YLMB DI DM6YLMB DM6YLMB DN PMID28270010-Compound-Figure16-b-2 DM6YLMB TI TTTDVOJ DM6YLMB TN Tropomyosin-related kinase A (TrkA) DM6YLMB MA Inhibitor DM6YLMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6YLMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6YQO3 DI DM6YQO3 DM6YQO3 DN BK3 DM6YQO3 TI TT42OGM DM6YQO3 TN Hematopoietic cell kinase (HCK) DM6YQO3 MA Inhibitor DM6YQO3 RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DM6YQO3 RU http://www.freepatentsonline.com/US9765037.html DM6YV3O DI DM6YV3O DM6YV3O DN N-(2-phenylcyclopropyl) amino acid derivative 2 DM6YV3O TI TT32XQJ DM6YV3O TN Monoamine oxidase (MAO) DM6YV3O MA Inhibitor DM6YV3O RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6YV3O RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6YV3O DI DM6YV3O DM6YV3O DN N-(2-phenylcyclopropyl) amino acid derivative 2 DM6YV3O TI TTNR0UQ DM6YV3O TN Lysine-specific histone demethylase 1 (LSD) DM6YV3O MA Inhibitor DM6YV3O RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6YV3O RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6Z01B DI DM6Z01B DM6Z01B DN US9434725, 285 DM6Z01B TI TTCGOIN DM6Z01B TN PIM-3 protein kinase (PIM3) DM6Z01B MA Inhibitor DM6Z01B RN 5-azaindazole compounds and methods of use. US9434725. DM6Z01B RU http://www.freepatentsonline.com/US9434725.html DM6ZRV4 DI DM6ZRV4 DM6ZRV4 DN PMID26651364-Compound-118 DM6ZRV4 TI TTTCRU2 DM6ZRV4 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6ZRV4 MA Antagonist DM6ZRV4 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6ZRV4 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6ZYMC DI DM6ZYMC DM6ZYMC DN Oxindole derivative 2 DM6ZYMC TI TTK0FEA DM6ZYMC TN Leucine-rich repeat kinase 2 (LRRK2) DM6ZYMC MA Inhibitor DM6ZYMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM6ZYMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM70CTE DI DM70CTE DM70CTE DN PMID27376512-Compound-MTC-434 DM70CTE TI TTHVCUP DM70CTE TN DNA [cytosine-5]-methyltransferase (DNMT) DM70CTE MA Inhibitor DM70CTE RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM70CTE RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM70QPF DI DM70QPF DM70QPF DN Pyrazole derivative 74 DM70QPF TI TTJQOD7 DM70QPF TN 5-HT 2A receptor (HTR2A) DM70QPF MA Antagonist DM70QPF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM70QPF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM712Y0 DI DM712Y0 DM712Y0 DN Benzo[d]oxazole derivative 3 DM712Y0 TI TTA6ZN2 DM712Y0 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM712Y0 MA Inhibitor DM712Y0 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM712Y0 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM715E8 DI DM715E8 DM715E8 DN Biphenyl carboxamidopropanoic acid derivative 4 DM715E8 TI TT9O6WS DM715E8 TN Glucagon receptor (GCGR) DM715E8 MA Antagonist DM715E8 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM715E8 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM71LVY DI DM71LVY DM71LVY DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3 DM71LVY TI TTXJ47W DM71LVY TN Metabotropic glutamate receptor 2 (mGluR2) DM71LVY MA Antagonist DM71LVY RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM71LVY RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM71R3T DI DM71R3T DM71R3T DN Resorcinol compound 27 DM71R3T TI TTULVH8 DM71R3T TN Tyrosinase (TYR) DM71R3T MA Inhibitor DM71R3T RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM71R3T RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM71UYI DI DM71UYI DM71UYI DN Pyridotriazolopyrimidine derivative 1 DM71UYI TI TT6OEDT DM71UYI TN Cannabinoid receptor 1 (CB1) DM71UYI MA Antagonist DM71UYI RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM71UYI RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM72MDA DI DM72MDA DM72MDA DN Tetra-hydro-oxazolopyridine derivative 1 DM72MDA TI TTGP7BY DM72MDA TN Monoamine oxidase type B (MAO-B) DM72MDA MA Modulator DM72MDA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM72MDA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM72MDA DI DM72MDA DM72MDA DN Tetra-hydro-oxazolopyridine derivative 1 DM72MDA TI TTHS256 DM72MDA TN Metabotropic glutamate receptor 5 (mGluR5) DM72MDA MA Modulator DM72MDA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM72MDA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM72T58 DI DM72T58 DM72T58 DN Pyrimidinyl pyrazolamine derivative 1 DM72T58 TI TTS7G69 DM72T58 TN Fusion protein Bcr-Abl (Bcr-Abl) DM72T58 MA Inhibitor DM72T58 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM72T58 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM72TBJ DI DM72TBJ DM72TBJ DN PMID27019002-Compound-43c DM72TBJ TI TTNR0UQ DM72TBJ TN Lysine-specific histone demethylase 1 (LSD) DM72TBJ MA Inhibitor DM72TBJ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM72TBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM73CA5 DI DM73CA5 DM73CA5 DN PMID28394193-Compound-37 DM73CA5 TI TT9MZCQ DM73CA5 TN Enhancer of zeste homolog 2 (EZH2) DM73CA5 MA Inhibitor DM73CA5 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM73CA5 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM73ESA DI DM73ESA DM73ESA DN Imidazo[1,2-b]pyridazine acetamide derivative 6 DM73ESA TI TTPTXIN DM73ESA TN Translocator protein (TSPO) DM73ESA MA Ligand DM73ESA RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM73ESA RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM73GNJ DI DM73GNJ DM73GNJ DN Thiazolidine derivative 2 DM73GNJ TI TTULVH8 DM73GNJ TN Tyrosinase (TYR) DM73GNJ MA Inhibitor DM73GNJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM73GNJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTJGNVC DM73S2C TN Apoptosis regulator Bcl-2 (BCL-2) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTU1E82 DM73S2C TN Apoptosis regulator Bcl-xL (BCL-xL) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTQ79W8 DM73S2C TN Apoptosis regulator Bcl-W (BCL-W) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTL53M6 DM73S2C TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM745TN DI DM745TN DM745TN DN Aminocyclopentenone compound 4 DM745TN TI TTRA6BO DM745TN TN Bromodomain-containing protein 4 (BRD4) DM745TN MA Inhibitor DM745TN RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM745TN RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM74GUB DI DM74GUB DM74GUB DN PMID26560530-Compound-31 DM74GUB TI TT2F4OL DM74GUB TN Tissue transglutaminase (TG2) DM74GUB MA Inhibitor DM74GUB RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM74GUB RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM74NBY DI DM74NBY DM74NBY DN PMID25666693-Compound-129 DM74NBY TI TTMI6F5 DM74NBY TN Transient receptor potential cation channel V1 (TRPV1) DM74NBY MA Antagonist DM74NBY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM74NBY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM74OGS DI DM74OGS DM74OGS DN PMID25666693-Compound-159 DM74OGS TI TTMI6F5 DM74OGS TN Transient receptor potential cation channel V1 (TRPV1) DM74OGS MA Antagonist DM74OGS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM74OGS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM74T5L DI DM74T5L DM74T5L DN Oligooxopiperazine derivative 1 DM74T5L TI TTUX68I DM74T5L TN Hypoxia-inducible factor 1 (HIF-1) DM74T5L MA Inhibitor DM74T5L RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM74T5L RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM74UP5 DI DM74UP5 DM74UP5 DN Mycophenolic acid/nucleotide derivative 5 DM74UP5 TI TTL7C8Q DM74UP5 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM74UP5 MA Inhibitor DM74UP5 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM74UP5 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM74WSJ DI DM74WSJ DM74WSJ DN PMID25435285-Compound-45 DM74WSJ TI TTXJ47W DM74WSJ TN Metabotropic glutamate receptor 2 (mGluR2) DM74WSJ MA Antagonist DM74WSJ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM74WSJ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM759MJ DI DM759MJ DM759MJ DN PMID25399762-Compound-Table 7-Vanillyl alcohol DM759MJ TI TTGP7BY DM759MJ TN Monoamine oxidase type B (MAO-B) DM759MJ MA Inhibitor DM759MJ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM759MJ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM75J4T DI DM75J4T DM75J4T DN Piperazine carbamate/urea derivative 4 DM75J4T TI TT9JNIC DM75J4T TN Histamine H3 receptor (H3R) DM75J4T MA Ligand DM75J4T RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM75J4T RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM75QVW DI DM75QVW DM75QVW DN PMID28074661-Compound-US20120264760C80 DM75QVW TI TTL7C8Q DM75QVW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM75QVW MA Inhibitor DM75QVW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM75QVW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM76HXA DI DM76HXA DM76HXA DN Azole derivative 1 DM76HXA TI TTDP1UC DM76HXA TN Fatty acid amide hydrolase (FAAH) DM76HXA MA Inhibitor DM76HXA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM76HXA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM76Q10 DI DM76Q10 DM76Q10 DN Crystalline anhydrous toluene derivative 1 DM76Q10 TI TTZMAO3 DM76Q10 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM76Q10 MA Agonist DM76Q10 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM76Q10 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM76WBP DI DM76WBP DM76WBP DN PMID26651364-Compound-11c DM76WBP TI TTTCRU2 DM76WBP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM76WBP MA Antagonist DM76WBP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM76WBP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM76XH4 DI DM76XH4 DM76XH4 DN Azepan-4-one derivative 1 DM76XH4 TI TTZC0KV DM76XH4 TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM76XH4 MA Inhibitor DM76XH4 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM76XH4 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM786OD DI DM786OD DM786OD DN Beta-phe compound 2 DM786OD TI TTDIGC1 DM786OD TN Dipeptidyl peptidase 4 (DPP-4) DM786OD MA Inhibitor DM786OD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM786OD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM78IN5 DI DM78IN5 DM78IN5 DN PMID30259754-Compound-Px-102 DM78IN5 TI TTS4UGC DM78IN5 TN Farnesoid X-activated receptor (FXR) DM78IN5 MA Agonist DM78IN5 RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DM78IN5 RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TTGP7BY DM78NOU TN Monoamine oxidase type B (MAO-B) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TT3WG5C DM78NOU TN Monoamine oxidase type A (MAO-A) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TTNR0UQ DM78NOU TN Lysine-specific histone demethylase 1 (LSD) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7960M DI DM7960M DM7960M DN PMID25399762-Compound-Table1-C14 DM7960M TI TTGP7BY DM7960M TN Monoamine oxidase type B (MAO-B) DM7960M MA Inhibitor DM7960M RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7960M RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM79BFU DI DM79BFU DM79BFU DN PMID25435179-Compound-WO2012149608USYDS1 DM79BFU TI TTSCO7R DM79BFU TN NAD-dependent deacetylase sirtuin (SIRT) DM79BFU MA Inhibitor DM79BFU RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM79BFU RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM79KEX DI DM79KEX DM79KEX DN Triazolo-benzodiazepine derivative 1 DM79KEX TI TT9JNIC DM79KEX TN Histamine H3 receptor (H3R) DM79KEX MA Ligand DM79KEX RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM79KEX RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM79WI1 DI DM79WI1 DM79WI1 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1 DM79WI1 TI TTULVH8 DM79WI1 TN Tyrosinase (TYR) DM79WI1 MA Inhibitor DM79WI1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM79WI1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM7AHQE DI DM7AHQE DM7AHQE DN US9216972, 61 DM7AHQE TI TTDYP7I DM7AHQE TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM7AHQE MA Inhibitor DM7AHQE RN Tricyclic heterocyclic compounds. US9216972. DM7AHQE RU http://www.freepatentsonline.com/US9216972.html DM7ATLP DI DM7ATLP DM7ATLP DN PMID28627961-Compound-44 DM7ATLP TI TTYLQ8V DM7ATLP TN Prostaglandin E synthase (PTGES) DM7ATLP MA Inhibitor DM7ATLP RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM7ATLP RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM7AXSM DI DM7AXSM DM7AXSM DN Apogossypolone DM7AXSM TI TTGT9C7 DM7AXSM TN Bcl-2-related protein A1 (BCL2A1) DM7AXSM MA Inhibitor DM7AXSM RN Apogossypolone derivatives as anticancer agents. US8937193. DM7AXSM RU http://www.freepatentsonline.com/US8937193.html DM7B2XG DI DM7B2XG DM7B2XG DN Pyrimidine derivative 14 DM7B2XG TI TTUTJGQ DM7B2XG TN Vascular endothelial growth factor receptor 2 (KDR) DM7B2XG MA Inhibitor DM7B2XG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM7B2XG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM7B81V DI DM7B81V DM7B81V DN 4-(thiazol-5-yl)-pyrimidine derivative 1 DM7B81V TI TT7HF4W DM7B81V TN Cyclin-dependent kinase 2 (CDK2) DM7B81V MA Inhibitor DM7B81V RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM7B81V RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM7B81V DI DM7B81V DM7B81V DN 4-(thiazol-5-yl)-pyrimidine derivative 1 DM7B81V TI TT1LVF2 DM7B81V TN Cyclin-dependent kinase 9 (CDK9) DM7B81V MA Inhibitor DM7B81V RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM7B81V RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM7BRIT DI DM7BRIT DM7BRIT DN Aryl piperazine derivative 8 DM7BRIT TI TTWJBZ5 DM7BRIT TN 5-HT 2C receptor (HTR2C) DM7BRIT MA Agonist DM7BRIT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM7BRIT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM7BRPI DI DM7BRPI DM7BRPI DN PMID29473428-Compound-34 DM7BRPI TI TTZJYKH DM7BRPI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7BRPI MA Inhibitor DM7BRPI RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7BRPI RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7C0R8 DI DM7C0R8 DM7C0R8 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5 DM7C0R8 TI TTXJ47W DM7C0R8 TN Metabotropic glutamate receptor 2 (mGluR2) DM7C0R8 MA Antagonist DM7C0R8 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM7C0R8 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM7CMV6 DI DM7CMV6 DM7CMV6 DN Pyrazole derivative 40 DM7CMV6 TI TT6OEDT DM7CMV6 TN Cannabinoid receptor 1 (CB1) DM7CMV6 MA Antagonist DM7CMV6 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7CMV6 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7CWZ4 DI DM7CWZ4 DM7CWZ4 DN PMID27967267-Compound-36 DM7CWZ4 TI TT1RS9F DM7CWZ4 TN Acetylcholinesterase (AChE) DM7CWZ4 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7CWZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7D0CT DI DM7D0CT DM7D0CT DN PMID25828189-Compound-21 DM7D0CT TI TT9O6WS DM7D0CT TN Glucagon receptor (GCGR) DM7D0CT MA Antagonist DM7D0CT RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM7D0CT RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM7D12Y DI DM7D12Y DM7D12Y DN PMID25514969-Compound-Figure3 DM7D12Y TI TT4EB85 DM7D12Y TN Cholesterol 24-hydroxylase (CYP46A1) DM7D12Y MA Inhibitor DM7D12Y RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DM7D12Y RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DM7DF6Z DI DM7DF6Z DM7DF6Z DN Pyrrolidinyl urea derivative 1 DM7DF6Z TI TTDP1UC DM7DF6Z TN Fatty acid amide hydrolase (FAAH) DM7DF6Z MA Inhibitor DM7DF6Z RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM7DF6Z RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM7DG0M DI DM7DG0M DM7DG0M DN PMID30280939-Compound-WO2008009652 DM7DG0M TI TTOK0LR DM7DG0M TN Toll-like receptor (TLR) DM7DG0M MA Agonist DM7DG0M RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM7DG0M RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM7DTYS DI DM7DTYS DM7DTYS DN Pyrazole derivative 29 DM7DTYS TI TT6OEDT DM7DTYS TN Cannabinoid receptor 1 (CB1) DM7DTYS MA Antagonist DM7DTYS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7DTYS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7DU9P DI DM7DU9P DM7DU9P DN Pyrrolo[1,2-f]triazine derivative 2 DM7DU9P TI TTDIGC1 DM7DU9P TN Dipeptidyl peptidase 4 (DPP-4) DM7DU9P MA Inhibitor DM7DU9P RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM7DU9P RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM7E9HA DI DM7E9HA DM7E9HA DN PMID29649907-Compound-32 DM7E9HA TI TTS4UGC DM7E9HA TN Farnesoid X-activated receptor (FXR) DM7E9HA MA Agonist DM7E9HA RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM7E9HA RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM7EKZ6 DI DM7EKZ6 DM7EKZ6 DN PMID25772215-Compound-US02014179750M1 DM7EKZ6 TI TT1ZAVI DM7EKZ6 TN Prostaglandin E2 receptor EP2 (PTGER2) DM7EKZ6 MA Antagonist DM7EKZ6 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM7EKZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM7EOG4 DI DM7EOG4 DM7EOG4 DN Acrylamide compound 2 DM7EOG4 TI TT9JNIC DM7EOG4 TN Histamine H3 receptor (H3R) DM7EOG4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM7EOG4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM7EW5U DI DM7EW5U DM7EW5U DN PMID29473428-Compound-10 DM7EW5U TI TTZJYKH DM7EW5U TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7EW5U RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7EW5U RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7EXNI DI DM7EXNI DM7EXNI DN PMID27841045-Compound-157 DM7EXNI TI TT7RJY8 DM7EXNI TN Xanthine dehydrogenase/oxidase (XDH) DM7EXNI MA Inhibitor DM7EXNI RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM7EXNI RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM7F9V4 DI DM7F9V4 DM7F9V4 DN Pyrazole derivative 17 DM7F9V4 TI TT6OEDT DM7F9V4 TN Cannabinoid receptor 1 (CB1) DM7F9V4 MA Antagonist DM7F9V4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7F9V4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7G51M DI DM7G51M DM7G51M DN PMID25435285-Compound-49 DM7G51M TI TTXJ47W DM7G51M TN Metabotropic glutamate receptor 2 (mGluR2) DM7G51M MA Antagonist DM7G51M RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM7G51M RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM7GH4Y DI DM7GH4Y DM7GH4Y DN PMID28092474-Compound-33a DM7GH4Y TI TT5ZKDI DM7GH4Y TN Histone deacetylase 6 (HDAC6) DM7GH4Y MA Inhibitor DM7GH4Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM7GH4Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM7GH4Y DI DM7GH4Y DM7GH4Y DN PMID28092474-Compound-33a DM7GH4Y TI TT6R7JZ DM7GH4Y TN Histone deacetylase 1 (HDAC1) DM7GH4Y MA Inhibitor DM7GH4Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM7GH4Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM7HD0T DI DM7HD0T DM7HD0T DN Quinoline derivative 15 DM7HD0T TI TTRZQE3 DM7HD0T TN Glycogen synthase kinase-3 alpha (GSK-3A) DM7HD0T MA Inhibitor DM7HD0T RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM7HD0T RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM7I8ZV DI DM7I8ZV DM7I8ZV DN 1,2-diamino cyclopentane-based derivative 9 DM7I8ZV TI TT9N02I DM7I8ZV TN Orexin receptor type 2 (HCRTR2) DM7I8ZV MA Antagonist DM7I8ZV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7I8ZV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7I8ZV DI DM7I8ZV DM7I8ZV DN 1,2-diamino cyclopentane-based derivative 9 DM7I8ZV TI TT60Q8D DM7I8ZV TN Orexin receptor type 1 (HCRTR1) DM7I8ZV MA Antagonist DM7I8ZV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7I8ZV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7IB8L DI DM7IB8L DM7IB8L DN PMID27551786-Compound-IV DM7IB8L TI TT26PHO DM7IB8L TN Mineralocorticoid receptor (MR) DM7IB8L MA Antagonist DM7IB8L RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM7IB8L RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM7INA1 DI DM7INA1 DM7INA1 DN Central azetidine derivative 1 DM7INA1 TI TTHS256 DM7INA1 TN Metabotropic glutamate receptor 5 (mGluR5) DM7INA1 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7INA1 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7IPWB DI DM7IPWB DM7IPWB DN Pyrrolo[2,3-b]pyridine derivative 2 DM7IPWB TI TTTDVOJ DM7IPWB TN Tropomyosin-related kinase A (TrkA) DM7IPWB MA Inhibitor DM7IPWB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM7IPWB RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM7IYRM DI DM7IYRM DM7IYRM DN PMID27215781-Compound-32 DM7IYRM TI TTMSFAW DM7IYRM TN Cannabinoid receptor 2 (CB2) DM7IYRM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7IYRM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7JARB DI DM7JARB DM7JARB DN Acrylamide compound 3 DM7JARB TI TT9JNIC DM7JARB TN Histamine H3 receptor (H3R) DM7JARB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM7JARB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM7JASU DI DM7JASU DM7JASU DN PMID27019002-Compound-17 DM7JASU TI TT32XQJ DM7JASU TN Monoamine oxidase (MAO) DM7JASU MA Inhibitor DM7JASU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7JASU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7JASU DI DM7JASU DM7JASU DN PMID27019002-Compound-17 DM7JASU TI TTNR0UQ DM7JASU TN Lysine-specific histone demethylase 1 (LSD) DM7JASU MA Inhibitor DM7JASU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7JASU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7JCM6 DI DM7JCM6 DM7JCM6 DN Pyridine derivative 14 DM7JCM6 TI TTHS256 DM7JCM6 TN Metabotropic glutamate receptor 5 (mGluR5) DM7JCM6 MA Modulator DM7JCM6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7JCM6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7JIF0 DI DM7JIF0 DM7JIF0 DN PMID27967267-Compound-3 DM7JIF0 TI TT1RS9F DM7JIF0 TN Acetylcholinesterase (AChE) DM7JIF0 MA Inhibitor DM7JIF0 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7JIF0 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7JX8U DI DM7JX8U DM7JX8U DN 1,2-diamino cyclopentane-based derivative 8 DM7JX8U TI TT9N02I DM7JX8U TN Orexin receptor type 2 (HCRTR2) DM7JX8U MA Antagonist DM7JX8U RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7JX8U RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7JX8U DI DM7JX8U DM7JX8U DN 1,2-diamino cyclopentane-based derivative 8 DM7JX8U TI TT60Q8D DM7JX8U TN Orexin receptor type 1 (HCRTR1) DM7JX8U MA Antagonist DM7JX8U RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7JX8U RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7K256 DI DM7K256 DM7K256 DN Ac-YVAD-FMK DM7K256 TI TTCQIBE DM7K256 TN Caspase-1 (CASP1) DM7K256 MA Inhibitor DM7K256 RN Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59. DM7K256 RU https://www.ncbi.nlm.nih.gov/pubmed/28885866 DM7K3A0 DI DM7K3A0 DM7K3A0 DN PMID30074415-Compound-12 DM7K3A0 TI TT2LVK8 DM7K3A0 TN Carbonic anhydrase IX (CA-IX) DM7K3A0 MA Inhibitor DM7K3A0 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM7K3A0 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM7KNXH DI DM7KNXH DM7KNXH DN Triazole derivative 2 DM7KNXH TI TT473XN DM7KNXH TN P2X purinoceptor 7 (P2RX7) DM7KNXH MA Antagonist DM7KNXH RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM7KNXH RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM7L6WS DI DM7L6WS DM7L6WS DN PMID26666989-Compound-Figure9left02 DM7L6WS TI TT8BUGW DM7L6WS TN Glycogen phosphorylase (PYG) DM7L6WS MA Inhibitor DM7L6WS RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM7L6WS RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM7L8T5 DI DM7L8T5 DM7L8T5 DN Biphenyl mannoside derivative 17 DM7L8T5 TI TTTCRU2 DM7L8T5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM7L8T5 MA Antagonist DM7L8T5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM7L8T5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM7LFNG DI DM7LFNG DM7LFNG DN Pyrazole derivative 12 DM7LFNG TI TT6OEDT DM7LFNG TN Cannabinoid receptor 1 (CB1) DM7LFNG MA Antagonist DM7LFNG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7LFNG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7MNE2 DI DM7MNE2 DM7MNE2 DN US10092575, Example 158 DM7MNE2 TI TT3ZS42 DM7MNE2 TN Phosphodiesterase 1B (PDE1B) DM7MNE2 MA Inhibitor DM7MNE2 RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DM7MNE2 RU http://www.freepatentsonline.com/US10092575.html DM7NTO9 DI DM7NTO9 DM7NTO9 DN Tri-substituted purine derivative 1 DM7NTO9 TI TTH8FZW DM7NTO9 TN Signal transducer and activator of transcription 3 (STAT3) DM7NTO9 MA Inhibitor DM7NTO9 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7NTO9 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7NUT2 DI DM7NUT2 DM7NUT2 DN PMID25399762-Compound-Figure3-Lycojaponicumin C DM7NUT2 TI TT3WG5C DM7NUT2 TN Monoamine oxidase type A (MAO-A) DM7NUT2 MA Inhibitor DM7NUT2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7NUT2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM7O0MD DI DM7O0MD DM7O0MD DN Azepan-4-one derivative 2 DM7O0MD TI TTZC0KV DM7O0MD TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM7O0MD MA Inhibitor DM7O0MD RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM7O0MD RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM7OA9E DI DM7OA9E DM7OA9E DN Aryl pyrimidine derivative 8 DM7OA9E TI TTIY56R DM7OA9E TN Kynurenine 3-hydroxylase (KMO) DM7OA9E MA Inhibitor DM7OA9E RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM7OA9E RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM7OBVT DI DM7OBVT DM7OBVT DN Isoxazole-based bicyclic compound 13 DM7OBVT TI TTE4BSY DM7OBVT TN Bromodomain and extraterminal domain protein (BET) DM7OBVT MA Inhibitor DM7OBVT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM7OBVT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM7OGWH DI DM7OGWH DM7OGWH DN PMID28766366-Compound-Scheme25-2 DM7OGWH TI TTYGQ8A DM7OGWH TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM7OGWH MA Inhibitor DM7OGWH RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7OGWH RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7OGWH DI DM7OGWH DM7OGWH DN PMID28766366-Compound-Scheme25-2 DM7OGWH TI TTSBVFO DM7OGWH TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM7OGWH MA Inhibitor DM7OGWH RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7OGWH RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7OS5E DI DM7OS5E DM7OS5E DN PMID27376512-Compound-MTC-433 DM7OS5E TI TT6S2FE DM7OS5E TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM7OS5E MA Inhibitor DM7OS5E RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM7OS5E RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM7PSB1 DI DM7PSB1 DM7PSB1 DN Urea and carbamate bioisostere derivative 18 DM7PSB1 TI TTL7C8Q DM7PSB1 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM7PSB1 MA Inhibitor DM7PSB1 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM7PSB1 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM7QIMN DI DM7QIMN DM7QIMN DN PMID25776143-Compound-7 DM7QIMN TI TT4TFGN DM7QIMN TN Vasopressin V1a receptor (V1AR) DM7QIMN MA Antagonist DM7QIMN RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DM7QIMN RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DM7QLX8 DI DM7QLX8 DM7QLX8 DN PMID28270010-Compound-Figure17-2 DM7QLX8 TI TTTDVOJ DM7QLX8 TN Tropomyosin-related kinase A (TrkA) DM7QLX8 MA Inhibitor DM7QLX8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM7QLX8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM7R2X0 DI DM7R2X0 DM7R2X0 DN PMID25656651-Compound-20a DM7R2X0 TI TTS7G69 DM7R2X0 TN Fusion protein Bcr-Abl (Bcr-Abl) DM7R2X0 MA Inhibitor DM7R2X0 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM7R2X0 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM7RG5I DI DM7RG5I DM7RG5I DN 1,2-diamino cyclopentane-based derivative 2 DM7RG5I TI TT9N02I DM7RG5I TN Orexin receptor type 2 (HCRTR2) DM7RG5I MA Antagonist DM7RG5I RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7RG5I RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7RG5I DI DM7RG5I DM7RG5I DN 1,2-diamino cyclopentane-based derivative 2 DM7RG5I TI TT60Q8D DM7RG5I TN Orexin receptor type 1 (HCRTR1) DM7RG5I MA Antagonist DM7RG5I RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7RG5I RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7RPKM DI DM7RPKM DM7RPKM DN PMID28766366-Compound-Scheme9EHT9851 DM7RPKM TI TTYGQ8A DM7RPKM TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM7RPKM MA Inhibitor DM7RPKM RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7RPKM RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7RPKM DI DM7RPKM DM7RPKM DN PMID28766366-Compound-Scheme9EHT9851 DM7RPKM TI TTSBVFO DM7RPKM TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM7RPKM MA Inhibitor DM7RPKM RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7RPKM RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7RQ2G DI DM7RQ2G DM7RQ2G DN Quinoline and quinazoline derivative 5 DM7RQ2G TI TTOHSBA DM7RQ2G TN Vascular endothelial growth factor A (VEGFA) DM7RQ2G MA Inhibitor DM7RQ2G RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM7RQ2G RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM7RTQP DI DM7RTQP DM7RTQP DN BDBM50173323 DM7RTQP TI TTTCXO0 DM7RTQP TN G protein-coupled receptor kinase 5 (GRK5) DM7RTQP MA Inhibitor DM7RTQP RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DM7RTQP RU http://www.freepatentsonline.com/US10023564.html DM7SIVA DI DM7SIVA DM7SIVA DN PMID28454500-Compound-13 DM7SIVA TI TTA6ZN2 DM7SIVA TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM7SIVA MA Activator DM7SIVA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM7SIVA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM7SIVA DI DM7SIVA DM7SIVA DN PMID28454500-Compound-13 DM7SIVA TI TT3Z6Y9 DM7SIVA TN Cysteines of Keap1 (KEAP1 Cysteines) DM7SIVA MA Modulator DM7SIVA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM7SIVA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TTRMX3V DM7SK5Q TN Janus kinase 2 (JAK-2) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TTT7PJU DM7SK5Q TN Janus kinase 3 (JAK-3) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TT6DM01 DM7SK5Q TN Janus kinase 1 (JAK-1) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SOZN DI DM7SOZN DM7SOZN DN Chromene derivative 1 DM7SOZN TI TTWJBZ5 DM7SOZN TN 5-HT 2C receptor (HTR2C) DM7SOZN MA Agonist DM7SOZN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM7SOZN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM7SQKD DI DM7SQKD DM7SQKD DN US9682991, 7 DM7SQKD TI TTCGOIN DM7SQKD TN PIM-3 protein kinase (PIM3) DM7SQKD MA Inhibitor DM7SQKD RN Tricyclic compounds for use as kinase inhibitors. US9682991. DM7SQKD RU http://www.freepatentsonline.com/US9682991.html DM7SUFJ DI DM7SUFJ DM7SUFJ DN Hydroxy amidine derivative 2 DM7SUFJ TI TTZJYKH DM7SUFJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7SUFJ MA Inhibitor DM7SUFJ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7SUFJ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7T962 DI DM7T962 DM7T962 DN PMID25666693-Compound-28 DM7T962 TI TTMI6F5 DM7T962 TN Transient receptor potential cation channel V1 (TRPV1) DM7T962 MA Antagonist DM7T962 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM7T962 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM7TASJ DI DM7TASJ DM7TASJ DN BDBM50363773 DM7TASJ TI TTLKF5M DM7TASJ TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM7TASJ MA Inhibitor DM7TASJ RN Aroyl thiourea derivatives. US9365508. DM7TASJ RU http://www.freepatentsonline.com/US9365508.html DM7TLDW DI DM7TLDW DM7TLDW DN PMID27967267-Compound-neostenine DM7TLDW TI TT1RS9F DM7TLDW TN Acetylcholinesterase (AChE) DM7TLDW MA Inhibitor DM7TLDW RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7TLDW RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7TPBF DI DM7TPBF DM7TPBF DN PMID29757691-Compound-7 DM7TPBF TI TT1RS9F DM7TPBF TN Acetylcholinesterase (AChE) DM7TPBF MA Inhibitor DM7TPBF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM7TPBF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM7TPBF DI DM7TPBF DM7TPBF DN PMID29757691-Compound-7 DM7TPBF TI TTEB0GD DM7TPBF TN Cholinesterase (BCHE) DM7TPBF MA Inhibitor DM7TPBF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM7TPBF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM7TW5Z DI DM7TW5Z DM7TW5Z DN 4-aryl quinol derivative 2 DM7TW5Z TI TTR7UJ3 DM7TW5Z TN Cytoplasmic thioredoxin reductase (TXNRD1) DM7TW5Z MA Inhibitor DM7TW5Z RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM7TW5Z RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM7U20W DI DM7U20W DM7U20W DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9 DM7U20W TI TTULVH8 DM7U20W TN Tyrosinase (TYR) DM7U20W MA Inhibitor DM7U20W RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM7U20W RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM7U8WD DI DM7U8WD DM7U8WD DN Peptide analog 47 DM7U8WD TI TTDIGC1 DM7U8WD TN Dipeptidyl peptidase 4 (DPP-4) DM7U8WD MA Inhibitor DM7U8WD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM7U8WD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM7UAKH DI DM7UAKH DM7UAKH DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 DM7UAKH TI TTJW4LU DM7UAKH TN Phosphodiesterase 10A (PDE10) DM7UAKH MA Inhibitor DM7UAKH RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM7UAKH RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM7UAKH DI DM7UAKH DM7UAKH DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 DM7UAKH TI TTJGW1Z DM7UAKH TN Phosphodiesterase 2A (PDE2A) DM7UAKH MA Inhibitor DM7UAKH RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM7UAKH RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM7UDIM DI DM7UDIM DM7UDIM DN PMID28394193-Compound-47 DM7UDIM TI TT9MZCQ DM7UDIM TN Enhancer of zeste homolog 2 (EZH2) DM7UDIM MA Inhibitor DM7UDIM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM7UDIM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM7UEJT DI DM7UEJT DM7UEJT DN Benzamide derivative 7 DM7UEJT TI TT9NXW4 DM7UEJT TN Sigma intracellular receptor 2 (TMEM97) DM7UEJT MA Ligand DM7UEJT RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7UEJT RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7UEJT DI DM7UEJT DM7UEJT DN Benzamide derivative 7 DM7UEJT TI TT5TPI6 DM7UEJT TN Opioid receptor sigma 1 (OPRS1) DM7UEJT MA Ligand DM7UEJT RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7UEJT RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7UK5E DI DM7UK5E DM7UK5E DN KadcoccitoneA DM7UK5E TI TT3WG5C DM7UK5E TN Monoamine oxidase type A (MAO-A) DM7UK5E MA Inhibitor DM7UK5E RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7UK5E RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM7ULWD DI DM7ULWD DM7ULWD DN PMID28350212-Compound-36 DM7ULWD TI TTZS04O DM7ULWD TN Gamma-secretase subunit APH-1A/1B (APH-1) DM7ULWD MA Inhibitor DM7ULWD RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DM7ULWD RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DM7UMW2 DI DM7UMW2 DM7UMW2 DN Imidazoleisoindoles derivative 1 DM7UMW2 TI TTZJYKH DM7UMW2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7UMW2 MA Inhibitor DM7UMW2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7UMW2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7USO9 DI DM7USO9 DM7USO9 DN PMID27215781-Compound-30 DM7USO9 TI TTMSFAW DM7USO9 TN Cannabinoid receptor 2 (CB2) DM7USO9 MA Agonist DM7USO9 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7USO9 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7V6E0 DI DM7V6E0 DM7V6E0 DN PMID25684022-Compound-US20120277229 41(1.3) DM7V6E0 TI TTCZOF2 DM7V6E0 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM7V6E0 MA Inhibitor DM7V6E0 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM7V6E0 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM7VP8M DI DM7VP8M DM7VP8M DN Heterocyclic derivative 4 DM7VP8M TI TTCZOF2 DM7VP8M TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM7VP8M MA Inhibitor DM7VP8M RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM7VP8M RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM7WOD9 DI DM7WOD9 DM7WOD9 DN Piperazinyl methyl quinazolinone derivative 1 DM7WOD9 TI TT9NXW4 DM7WOD9 TN Sigma intracellular receptor 2 (TMEM97) DM7WOD9 MA Ligand DM7WOD9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7WOD9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7WXJ9 DI DM7WXJ9 DM7WXJ9 DN PMID29130358-Compound-Figure18(14) DM7WXJ9 TI TTHY57M DM7WXJ9 TN Matrix metalloproteinase-13 (MMP-13) DM7WXJ9 MA Inhibitor DM7WXJ9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM7WXJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM7WXJ9 DI DM7WXJ9 DM7WXJ9 DN PMID29130358-Compound-Figure18(14) DM7WXJ9 TI TTLM12X DM7WXJ9 TN Matrix metalloproteinase-2 (MMP-2) DM7WXJ9 MA Inhibitor DM7WXJ9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM7WXJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM7X62M DI DM7X62M DM7X62M DN Peptide analog 58 DM7X62M TI TTQAJF1 DM7X62M TN Cathepsin G (CTSG) DM7X62M MA Inhibitor DM7X62M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM7X62M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM7X62M DI DM7X62M DM7X62M DN Peptide analog 58 DM7X62M TI TTPLTSQ DM7X62M TN Neutrophil elastase (NE) DM7X62M MA Inhibitor DM7X62M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM7X62M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM7X6HR DI DM7X6HR DM7X6HR DN PMID25522065-Compound-17 DM7X6HR TI TTX4RTB DM7X6HR TN Melanin-concentrating hormone receptor 1 (MCHR1) DM7X6HR MA Antagonist DM7X6HR RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM7X6HR RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM7XQ18 DI DM7XQ18 DM7XQ18 DN Benzothiazepine analog 12 DM7XQ18 TI TTRA6BO DM7XQ18 TN Bromodomain-containing protein 4 (BRD4) DM7XQ18 MA Inhibitor DM7XQ18 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM7XQ18 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM7XQUT DI DM7XQUT DM7XQUT DN PMID25656651-Compound-46 DM7XQUT TI TT3PJMV DM7XQUT TN Tyrosine-protein kinase ABL1 (ABL) DM7XQUT MA Inhibitor DM7XQUT RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM7XQUT RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM7XS9G DI DM7XS9G DM7XS9G DN N-oxalyl-D-tyrosine derivative 3 DM7XS9G TI TTWAQBO DM7XS9G TN Lysine-specific demethylase 4E (KDM4E) DM7XS9G MA Inhibitor DM7XS9G RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM7XS9G RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM7XSHK DI DM7XSHK DM7XSHK DN Pyrazolopyrimidine derivative 4 DM7XSHK TI TTHS256 DM7XSHK TN Metabotropic glutamate receptor 5 (mGluR5) DM7XSHK MA Modulator DM7XSHK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7XSHK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7XYRA DI DM7XYRA DM7XYRA DN Eptastatin derivative 1 DM7XYRA TI TTPADOQ DM7XYRA TN HMG-CoA reductase (HMGCR) DM7XYRA MA Inhibitor DM7XYRA RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM7XYRA RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM7Y2RL DI DM7Y2RL DM7Y2RL DN Oxazole derivative 1 DM7Y2RL TI TTN7R6K DM7Y2RL TN Signal transducer and activator of transcription 1 (STAT1) DM7Y2RL MA Inhibitor DM7Y2RL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7Y2RL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7Y2RL DI DM7Y2RL DM7Y2RL DN Oxazole derivative 1 DM7Y2RL TI TTH8FZW DM7Y2RL TN Signal transducer and activator of transcription 3 (STAT3) DM7Y2RL MA Inhibitor DM7Y2RL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7Y2RL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7YA9Z DI DM7YA9Z DM7YA9Z DN Pyrimidine derivative 17 DM7YA9Z TI TTNR0UQ DM7YA9Z TN Lysine-specific histone demethylase 1 (LSD) DM7YA9Z MA Inhibitor DM7YA9Z RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7YA9Z RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7YFBT DI DM7YFBT DM7YFBT DN Quinoline carboxamide derivative 9 DM7YFBT TI TTPTXIN DM7YFBT TN Translocator protein (TSPO) DM7YFBT MA Ligand DM7YFBT RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM7YFBT RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM7YJ4L DI DM7YJ4L DM7YJ4L DN PMID25435179-Compound-WO2013059587(VI, 2nd set) DM7YJ4L TI TTSCO7R DM7YJ4L TN NAD-dependent deacetylase sirtuin (SIRT) DM7YJ4L MA Inhibitor DM7YJ4L RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM7YJ4L RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TTSHTOI DM7YQJK TN Histone deacetylase 2 (HDAC2) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TTYHPU6 DM7YQJK TN Histone deacetylase 10 (HDAC10) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT4YWTO DM7YQJK TN Histone deacetylase 3 (HDAC3) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT6R7JZ DM7YQJK TN Histone deacetylase 1 (HDAC1) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT5ZKDI DM7YQJK TN Histone deacetylase 6 (HDAC6) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YVQL DI DM7YVQL DM7YVQL DN Tricyclic phytocannabinoid derivative 2 DM7YVQL TI TTMSFAW DM7YVQL TN Cannabinoid receptor 2 (CB2) DM7YVQL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7YVQL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7YVQL DI DM7YVQL DM7YVQL DN Tricyclic phytocannabinoid derivative 2 DM7YVQL TI TT6OEDT DM7YVQL TN Cannabinoid receptor 1 (CB1) DM7YVQL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7YVQL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM804T5 DI DM804T5 DM804T5 DN US9694002, 59 DM804T5 TI TTANOZH DM804T5 TN SCN1A messenger RNA (SCN1A mRNA) DM804T5 MA Inhibitor DM804T5 RN Substituted benzamides and methods of use thereof. US9694002. DM804T5 RU http://www.freepatentsonline.com/US9694002.html DM805ZN DI DM805ZN DM805ZN DN PMID28092474-Compound-32u DM805ZN TI TT6R7JZ DM805ZN TN Histone deacetylase 1 (HDAC1) DM805ZN MA Inhibitor DM805ZN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM805ZN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM805ZN DI DM805ZN DM805ZN DN PMID28092474-Compound-32u DM805ZN TI TT5ZKDI DM805ZN TN Histone deacetylase 6 (HDAC6) DM805ZN MA Inhibitor DM805ZN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM805ZN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM809AX DI DM809AX DM809AX DN PMID25684022-Compound-WO2004087707 DM809AX TI TTCZOF2 DM809AX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM809AX MA Inhibitor DM809AX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM809AX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM809YH DI DM809YH DM809YH DN Resorcinol compound 6 DM809YH TI TTULVH8 DM809YH TN Tyrosinase (TYR) DM809YH MA Inhibitor DM809YH RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM809YH RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT4YWTO DM80A3V TN Histone deacetylase 3 (HDAC3) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT5ZKDI DM80A3V TN Histone deacetylase 6 (HDAC6) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTT6LFV DM80A3V TN Histone deacetylase 8 (HDAC8) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTSHTOI DM80A3V TN Histone deacetylase 2 (HDAC2) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT6R7JZ DM80A3V TN Histone deacetylase 1 (HDAC1) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTYHPU6 DM80A3V TN Histone deacetylase 10 (HDAC10) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT8K17W DM80A3V TN Histone deacetylase 11 (HDAC11) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80E3F DI DM80E3F DM80E3F DN PMID25666693-Compound-74 DM80E3F TI TTMI6F5 DM80E3F TN Transient receptor potential cation channel V1 (TRPV1) DM80E3F MA Antagonist DM80E3F RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM80E3F RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM80PI1 DI DM80PI1 DM80PI1 DN PMID26651364-Compound-126c DM80PI1 TI TTTCRU2 DM80PI1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM80PI1 MA Antagonist DM80PI1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM80PI1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM80TDC DI DM80TDC DM80TDC DN Benzamide derivative 6 DM80TDC TI TTA6ZN2 DM80TDC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM80TDC MA Inhibitor DM80TDC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM80TDC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM80XRM DI DM80XRM DM80XRM DN Piperidine derivative 3 DM80XRM TI TTQR74A DM80XRM TN Proteinase activated receptor 2 (PAR2) DM80XRM MA Antagonist DM80XRM RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM80XRM RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM81A50 DI DM81A50 DM81A50 DN PMID27967267-Compound-48 DM81A50 TI TT1RS9F DM81A50 TN Acetylcholinesterase (AChE) DM81A50 MA Reactivator DM81A50 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM81A50 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM81MV6 DI DM81MV6 DM81MV6 DN US9567304, Compound F-54 DM81MV6 TI TTI1FPZ DM81MV6 TN Epithelial discoidin domain receptor 1 (DDR1) DM81MV6 MA Inhibitor DM81MV6 RN Quinazolinedione derivative. US9567304. DM81MV6 RU http://www.freepatentsonline.com/US9567304.html DM81RIY DI DM81RIY DM81RIY DN Biphenyl mannoside derivative 30 DM81RIY TI TTTCRU2 DM81RIY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM81RIY MA Antagonist DM81RIY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM81RIY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM81SYN DI DM81SYN DM81SYN DN Cannabinoid quinone derivative 1 DM81SYN TI TTZMAO3 DM81SYN TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM81SYN MA Ligand DM81SYN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM81SYN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM826JW DI DM826JW DM826JW DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 DM826JW TI TTJGW1Z DM826JW TN Phosphodiesterase 2A (PDE2A) DM826JW MA Inhibitor DM826JW RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM826JW RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM826JW DI DM826JW DM826JW DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 DM826JW TI TTJW4LU DM826JW TN Phosphodiesterase 10A (PDE10) DM826JW MA Inhibitor DM826JW RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM826JW RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM82BAM DI DM82BAM DM82BAM DN PMID25666693-Compound-56 DM82BAM TI TTMI6F5 DM82BAM TN Transient receptor potential cation channel V1 (TRPV1) DM82BAM MA Antagonist DM82BAM RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM82BAM RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM839NQ DI DM839NQ DM839NQ DN PMID29338548-Compound-34 DM839NQ TI TTHJTF7 DM839NQ TN Glycine transporter GlyT-1 (SLC6A9) DM839NQ MA Inhibitor DM839NQ RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM839NQ RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM83LTH DI DM83LTH DM83LTH DN Biphenyl mannoside derivative 13 DM83LTH TI TTTCRU2 DM83LTH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM83LTH MA Antagonist DM83LTH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM83LTH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM83LWC DI DM83LWC DM83LWC DN PMID29338548-Compound-25 DM83LWC TI TTHJTF7 DM83LWC TN Glycine transporter GlyT-1 (SLC6A9) DM83LWC MA Inhibitor DM83LWC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM83LWC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM83P6H DI DM83P6H DM83P6H DN PMID28454500-Compound-37 DM83P6H TI TTA6ZN2 DM83P6H TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM83P6H MA Activator DM83P6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM83P6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM83P6H DI DM83P6H DM83P6H DN PMID28454500-Compound-37 DM83P6H TI TT3Z6Y9 DM83P6H TN Cysteines of Keap1 (KEAP1 Cysteines) DM83P6H MA Modulator DM83P6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM83P6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM847I2 DI DM847I2 DM847I2 DN Imidazolyl urea derivative 1 DM847I2 TI TTDP1UC DM847I2 TN Fatty acid amide hydrolase (FAAH) DM847I2 MA Inhibitor DM847I2 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM847I2 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM84HG2 DI DM84HG2 DM84HG2 DN 3-(phenoxymethyl) benzylamine derivative 5 DM84HG2 TI TTULVH8 DM84HG2 TN Tyrosinase (TYR) DM84HG2 MA Inhibitor DM84HG2 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM84HG2 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM84RES DI DM84RES DM84RES DN PMID27215781-Compound-1 DM84RES TI TT6OEDT DM84RES TN Cannabinoid receptor 1 (CB1) DM84RES MA Agonist DM84RES RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM84RES RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM84U7F DI DM84U7F DM84U7F DN PMID25522065-Compound-4 DM84U7F TI TTX4RTB DM84U7F TN Melanin-concentrating hormone receptor 1 (MCHR1) DM84U7F MA Antagonist DM84U7F RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM84U7F RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM853Y7 DI DM853Y7 DM853Y7 DN PMID25666693-Compound-31 DM853Y7 TI TTMI6F5 DM853Y7 TN Transient receptor potential cation channel V1 (TRPV1) DM853Y7 MA Antagonist DM853Y7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM853Y7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM859ZQ DI DM859ZQ DM859ZQ DN Palmarumycin derivative 1 DM859ZQ TI TTR7UJ3 DM859ZQ TN Cytoplasmic thioredoxin reductase (TXNRD1) DM859ZQ MA Inhibitor DM859ZQ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM859ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM85ETX DI DM85ETX DM85ETX DN PMID29130358-Compound-Figure15(7) DM85ETX TI TTXPTJE DM85ETX TN Gelatinase (GEL) DM85ETX MA Inhibitor DM85ETX RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM85ETX RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM85VQR DI DM85VQR DM85VQR DN Dihydrothieno [2,3-e]indazole derivative 3 DM85VQR TI TTRPDBG DM85VQR TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM85VQR MA Inhibitor DM85VQR RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM85VQR RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM85XKT DI DM85XKT DM85XKT DN PMID28074661-Compound-US20120264760C87 DM85XKT TI TTL7C8Q DM85XKT TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM85XKT MA Inhibitor DM85XKT RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM85XKT RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM86BDS DI DM86BDS DM86BDS DN T8361 DM86BDS TI TTOJ9QL DM86BDS TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM86BDS MA Inhibitor DM86BDS RN IRE-1 inhibitors. US8614253. DM86BDS RU http://www.freepatentsonline.com/US8614253.html DM86E2P DI DM86E2P DM86E2P DN Carboxylic acid derivative 1 DM86E2P TI TTYLQ8V DM86E2P TN Prostaglandin E synthase (PTGES) DM86E2P MA Inhibitor DM86E2P RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM86E2P RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM86HU3 DI DM86HU3 DM86HU3 DN Thiazoline derivative 1 DM86HU3 TI TTULVH8 DM86HU3 TN Tyrosinase (TYR) DM86HU3 MA Inhibitor DM86HU3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM86HU3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM86M7D DI DM86M7D DM86M7D DN PMID27774822-Compound-Figure2Example1-1left DM86M7D TI TTT7PJU DM86M7D TN Janus kinase 3 (JAK-3) DM86M7D MA Inhibitor DM86M7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM86M7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM86M7D DI DM86M7D DM86M7D DN PMID27774822-Compound-Figure2Example1-1left DM86M7D TI TTRMX3V DM86M7D TN Janus kinase 2 (JAK-2) DM86M7D MA Inhibitor DM86M7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM86M7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM875RE DI DM875RE DM875RE DN Pyrrole derivative 6 DM875RE TI TT6OEDT DM875RE TN Cannabinoid receptor 1 (CB1) DM875RE MA Antagonist DM875RE RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM875RE RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM87DOX DI DM87DOX DM87DOX DN Ethinyl-pyrazole derivative 3 DM87DOX TI TTXJ47W DM87DOX TN Metabotropic glutamate receptor 2 (mGluR2) DM87DOX MA Antagonist DM87DOX RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM87DOX RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM87HTO DI DM87HTO DM87HTO DN PMID25666693-Compound-68 DM87HTO TI TTMI6F5 DM87HTO TN Transient receptor potential cation channel V1 (TRPV1) DM87HTO MA Antagonist DM87HTO RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM87HTO RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM89GKE DI DM89GKE DM89GKE DN Pyrazolo[3,4-d]pyrimidine derivative 8 DM89GKE TI TT4DXQT DM89GKE TN Proto-oncogene c-Ret (RET) DM89GKE MA Inhibitor DM89GKE RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM89GKE RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTH6V3D DM89LF0 TN Cyclin-dependent kinase 1 (CDK1) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT0PG8F DM89LF0 TN Cyclin-dependent kinase 4 (CDK4) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT7HF4W DM89LF0 TN Cyclin-dependent kinase 2 (CDK2) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT056SO DM89LF0 TN Stress-activated protein kinase JNK3 (JNK3) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTHS0U8 DM89LF0 TN Stress-activated protein kinase JNK2 (JNK2) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT0K6EO DM89LF0 TN Stress-activated protein kinase JNK1 (JNK1) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTQBR95 DM89LF0 TN Stress-activated protein kinase 2a (p38 alpha) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LKQ DI DM89LKQ DM89LKQ DN US9617250, Example 1 Example 204 of D1 DM89LKQ TI TTDYP7I DM89LKQ TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM89LKQ MA Inhibitor DM89LKQ RN Pyridin-4-yl derivatives. US9617250. DM89LKQ RU http://www.freepatentsonline.com/US9617250.html DM89VQT DI DM89VQT DM89VQT DN PMID26651364-Compound-7d DM89VQT TI TTTCRU2 DM89VQT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM89VQT MA Antagonist DM89VQT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM89VQT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8A4B5 DI DM8A4B5 DM8A4B5 DN PMID25666693-Compound-9 DM8A4B5 TI TTMI6F5 DM8A4B5 TN Transient receptor potential cation channel V1 (TRPV1) DM8A4B5 MA Antagonist DM8A4B5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM8A4B5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM8AG0Z DI DM8AG0Z DM8AG0Z DN Quinoline carboxamide derivative 7 DM8AG0Z TI TTPTXIN DM8AG0Z TN Translocator protein (TSPO) DM8AG0Z MA Ligand DM8AG0Z RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8AG0Z RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8B13I DI DM8B13I DM8B13I DN Peptide analog 5 DM8B13I TI TT23XQV DM8B13I TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM8B13I MA Inhibitor DM8B13I RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM8B13I RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM8B1Q4 DI DM8B1Q4 DM8B1Q4 DN US8889672, 252-036-001 DM8B1Q4 TI TTUWGRA DM8B1Q4 TN Protein kinase C zeta (PRKCZ) DM8B1Q4 MA Inhibitor DM8B1Q4 RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DM8B1Q4 RU http://www.freepatentsonline.com/US8889672.html DM8D3FG DI DM8D3FG DM8D3FG DN Beta-phe compound 1 DM8D3FG TI TTDIGC1 DM8D3FG TN Dipeptidyl peptidase 4 (DPP-4) DM8D3FG MA Inhibitor DM8D3FG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM8D3FG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM8DHRN DI DM8DHRN DM8DHRN DN Indoline derivative 14 DM8DHRN TI TTOHSBA DM8DHRN TN Vascular endothelial growth factor A (VEGFA) DM8DHRN MA Inhibitor DM8DHRN RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8DHRN RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8DHZ4 DI DM8DHZ4 DM8DHZ4 DN Thiazole carboxamide derivative 26 DM8DHZ4 TI TTCZOF2 DM8DHZ4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM8DHZ4 MA Inhibitor DM8DHZ4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM8DHZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM8DZA6 DI DM8DZA6 DM8DZA6 DN PMID25666693-Compound-103 DM8DZA6 TI TTMI6F5 DM8DZA6 TN Transient receptor potential cation channel V1 (TRPV1) DM8DZA6 MA Antagonist DM8DZA6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM8DZA6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM8E702 DI DM8E702 DM8E702 DN PMID28074661-Compound-US20100022547C87 DM8E702 TI TTL7C8Q DM8E702 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM8E702 MA Inhibitor DM8E702 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM8E702 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM8EB57 DI DM8EB57 DM8EB57 DN Imidazopyridine derivative 1 DM8EB57 TI TTPTXIN DM8EB57 TN Translocator protein (TSPO) DM8EB57 MA Ligand DM8EB57 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8EB57 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8EQPJ DI DM8EQPJ DM8EQPJ DN Resorcinol compound 21 DM8EQPJ TI TTULVH8 DM8EQPJ TN Tyrosinase (TYR) DM8EQPJ MA Inhibitor DM8EQPJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8EQPJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8EY2G DI DM8EY2G DM8EY2G DN Quinoxaline derivative 5 DM8EY2G TI TTSXVID DM8EY2G TN Nuclear factor NF-kappa-B (NFKB) DM8EY2G MA Inhibitor DM8EY2G RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM8EY2G RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM8F4QP DI DM8F4QP DM8F4QP DN 4-(2-cyclohexylethoxy) aniline derivative 2 DM8F4QP TI TTA6ZN2 DM8F4QP TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM8F4QP MA Inhibitor DM8F4QP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM8F4QP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM8FAW3 DI DM8FAW3 DM8FAW3 DN Aryl pyrimidine derivative 7 DM8FAW3 TI TTIY56R DM8FAW3 TN Kynurenine 3-hydroxylase (KMO) DM8FAW3 MA Inhibitor DM8FAW3 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM8FAW3 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM8FGZB DI DM8FGZB DM8FGZB DN Peptide analog 26 DM8FGZB TI TTSJMN8 DM8FGZB TN Immunoproteasome complex (IP) DM8FGZB MA Inhibitor DM8FGZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM8FGZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM8FQJB DI DM8FQJB DM8FQJB DN PMID26004420-Compound-U2014S0288042A DM8FQJB TI TTJ13ST DM8FQJB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM8FQJB MA Inhibitor DM8FQJB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM8FQJB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM8GCVO DI DM8GCVO DM8GCVO DN Imidazole derivative 2 DM8GCVO TI TT6OEDT DM8GCVO TN Cannabinoid receptor 1 (CB1) DM8GCVO MA Antagonist DM8GCVO RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM8GCVO RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM8GJA7 DI DM8GJA7 DM8GJA7 DN N-(arylamino)sulfonamide derivative 1 DM8GJA7 TI TTZCRP3 DM8GJA7 TN ERK activator kinase (MEK) DM8GJA7 MA Inhibitor DM8GJA7 RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM8GJA7 RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM8GOH3 DI DM8GOH3 DM8GOH3 DN PMID27744724-Compound-26 DM8GOH3 TI TTU1E82 DM8GOH3 TN Apoptosis regulator Bcl-xL (BCL-xL) DM8GOH3 MA Inhibitor DM8GOH3 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM8GOH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM8GOH3 DI DM8GOH3 DM8GOH3 DN PMID27744724-Compound-26 DM8GOH3 TI TTL53M6 DM8GOH3 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM8GOH3 MA Inhibitor DM8GOH3 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM8GOH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM8GW54 DI DM8GW54 DM8GW54 DN US9241942, 32-12 DM8GW54 TI TTOJ9QL DM8GW54 TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM8GW54 MA Inhibitor DM8GW54 RN IRE-1 inhibitors. US9493435. DM8GW54 RU http://www.freepatentsonline.com/US9493435.html DM8GYCD DI DM8GYCD DM8GYCD DN PMID27109571-Compound-7 DM8GYCD TI TTHWMFZ DM8GYCD TN Fatty acid-binding protein 4 (FABP4) DM8GYCD MA Inhibitor DM8GYCD RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM8GYCD RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM8HAJ3 DI DM8HAJ3 DM8HAJ3 DN PMID26651364-Compound-6a DM8HAJ3 TI TTTCRU2 DM8HAJ3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM8HAJ3 MA Antagonist DM8HAJ3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM8HAJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8HDQT DI DM8HDQT DM8HDQT DN Aromatic hydrazine carboxyimidoamide derivative 6 DM8HDQT TI TTULVH8 DM8HDQT TN Tyrosinase (TYR) DM8HDQT MA Inhibitor DM8HDQT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8HDQT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8I051 DI DM8I051 DM8I051 DN Mannoside derivative 11 DM8I051 TI TTTCRU2 DM8I051 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM8I051 MA Antagonist DM8I051 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM8I051 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8IL6Y DI DM8IL6Y DM8IL6Y DN PMID25772215-Compound-US02014179750TG8-15 DM8IL6Y TI TT1ZAVI DM8IL6Y TN Prostaglandin E2 receptor EP2 (PTGER2) DM8IL6Y MA Antagonist DM8IL6Y RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM8IL6Y RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM8IU1G DI DM8IU1G DM8IU1G DN Piperazine carbamic compound 3 DM8IU1G TI TTZ963I DM8IU1G TN Monoglyceride lipase (MAGL) DM8IU1G MA Inhibitor DM8IU1G RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8IU1G RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8JIDR DI DM8JIDR DM8JIDR DN PMID25482888-Compound-12 DM8JIDR TI TTDIGC1 DM8JIDR TN Dipeptidyl peptidase 4 (DPP-4) DM8JIDR MA Inhibitor DM8JIDR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM8JIDR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM8JK2D DI DM8JK2D DM8JK2D DN PMID29338548-Compound-30 DM8JK2D TI TTHJTF7 DM8JK2D TN Glycine transporter GlyT-1 (SLC6A9) DM8JK2D MA Inhibitor DM8JK2D RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM8JK2D RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM8K6IS DI DM8K6IS DM8K6IS DN Pyrimidine derivative 4 DM8K6IS TI TTUTJGQ DM8K6IS TN Vascular endothelial growth factor receptor 2 (KDR) DM8K6IS MA Inhibitor DM8K6IS RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8K6IS RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8KAIY DI DM8KAIY DM8KAIY DN PMID30107136-Compound-Example44 DM8KAIY TI TT23XQV DM8KAIY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM8KAIY MA Inhibitor DM8KAIY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM8KAIY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM8KBHX DI DM8KBHX DM8KBHX DN Pyridine derivative 12 DM8KBHX TI TTHS256 DM8KBHX TN Metabotropic glutamate receptor 5 (mGluR5) DM8KBHX MA Modulator DM8KBHX RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM8KBHX RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM8KF15 DI DM8KF15 DM8KF15 DN PMID26666989-Compound-Figure9middle08 DM8KF15 TI TT8BUGW DM8KF15 TN Glycogen phosphorylase (PYG) DM8KF15 MA Inhibitor DM8KF15 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM8KF15 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM8KWQ9 DI DM8KWQ9 DM8KWQ9 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2 DM8KWQ9 TI TTJGW1Z DM8KWQ9 TN Phosphodiesterase 2A (PDE2A) DM8KWQ9 MA Inhibitor DM8KWQ9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM8KWQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM8L0MN DI DM8L0MN DM8L0MN DN 3-acylidene-2-oxoindole derivative 1 DM8L0MN TI TT2F4OL DM8L0MN TN Tissue transglutaminase (TG2) DM8L0MN MA Inhibitor DM8L0MN RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8L0MN RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8L3KM DI DM8L3KM DM8L3KM DN Aromatic bicyclic compound 6 DM8L3KM TI TTRMX3V DM8L3KM TN Janus kinase 2 (JAK-2) DM8L3KM MA Inhibitor DM8L3KM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8L3KM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8L3KM DI DM8L3KM DM8L3KM DN Aromatic bicyclic compound 6 DM8L3KM TI TT6PKBN DM8L3KM TN Proto-oncogene c-Src (SRC) DM8L3KM MA Inhibitor DM8L3KM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8L3KM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8L5JR DI DM8L5JR DM8L5JR DN PMID25684022-Compound-WO2008107444 DM8L5JR TI TTCZOF2 DM8L5JR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM8L5JR MA Inhibitor DM8L5JR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM8L5JR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM8LFGS DI DM8LFGS DM8LFGS DN Triazole propanedioic acid derivative 1 DM8LFGS TI TTA592U DM8LFGS TN Urate anion exchanger 1 (URAT1) DM8LFGS MA Inhibitor DM8LFGS RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM8LFGS RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM8LNXQ DI DM8LNXQ DM8LNXQ DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2 DM8LNXQ TI TTPTXIN DM8LNXQ TN Translocator protein (TSPO) DM8LNXQ MA Ligand DM8LNXQ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8LNXQ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8LZ60 DI DM8LZ60 DM8LZ60 DN PMID25726713-Compound-13 DM8LZ60 TI TT8J1S3 DM8LZ60 TN Smoothened homolog (SMO) DM8LZ60 MA Inhibitor DM8LZ60 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM8LZ60 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM8MZR6 DI DM8MZR6 DM8MZR6 DN Piperazine derivative 3 DM8MZR6 TI TTJQOD7 DM8MZR6 TN 5-HT 2A receptor (HTR2A) DM8MZR6 MA Antagonist DM8MZR6 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM8MZR6 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM8N10A DI DM8N10A DM8N10A DN PMID29334795-Compound-22 DM8N10A TI TT9JNIC DM8N10A TN Histamine H3 receptor (H3R) DM8N10A MA Agonis; Inverse agonist DM8N10A RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM8N10A RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM8NBJV DI DM8NBJV DM8NBJV DN PMID30273516-Compound-37 DM8NBJV TI TTCW0KX DM8NBJV TN Glutaminase (GLS) DM8NBJV MA Inhibitor DM8NBJV RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM8NBJV RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM8NBM0 DI DM8NBM0 DM8NBM0 DN Pyridine derivative 6 DM8NBM0 TI TTOHSBA DM8NBM0 TN Vascular endothelial growth factor A (VEGFA) DM8NBM0 MA Inhibitor DM8NBM0 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8NBM0 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8NE12 DI DM8NE12 DM8NE12 DN US8921389, 123 DM8NE12 TI TT9ISBX DM8NE12 TN HIF-prolyl hydroxylase 2 (HPH-2) DM8NE12 MA Inhibitor DM8NE12 RN Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389. DM8NE12 RU http://www.freepatentsonline.com/US8921389.html DM8NHQS DI DM8NHQS DM8NHQS DN PMID28092474-Compound-32e DM8NHQS TI TT6R7JZ DM8NHQS TN Histone deacetylase 1 (HDAC1) DM8NHQS MA Inhibitor DM8NHQS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM8NHQS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM8NHQS DI DM8NHQS DM8NHQS DN PMID28092474-Compound-32e DM8NHQS TI TT5ZKDI DM8NHQS TN Histone deacetylase 6 (HDAC6) DM8NHQS MA Inhibitor DM8NHQS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM8NHQS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM8OLYQ DI DM8OLYQ DM8OLYQ DN PMID26609882-Compound-35 DM8OLYQ TI TTJQOD7 DM8OLYQ TN 5-HT 2A receptor (HTR2A) DM8OLYQ MA Antagonist DM8OLYQ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM8OLYQ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM8ONCL DI DM8ONCL DM8ONCL DN Carbamide derivative 25 DM8ONCL TI TTDP1UC DM8ONCL TN Fatty acid amide hydrolase (FAAH) DM8ONCL MA Inhibitor DM8ONCL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8ONCL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8ONCL DI DM8ONCL DM8ONCL DN Carbamide derivative 25 DM8ONCL TI TTZ963I DM8ONCL TN Monoglyceride lipase (MAGL) DM8ONCL MA Inhibitor DM8ONCL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8ONCL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTLRFIH DM8OYI4 TN Signal transducer and activator of transcription 5 (STAT5) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTN7R6K DM8OYI4 TN Signal transducer and activator of transcription 1 (STAT1) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTH8FZW DM8OYI4 TN Signal transducer and activator of transcription 3 (STAT3) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8PET6 DI DM8PET6 DM8PET6 DN PMID28447479-Compound-21 DM8PET6 TI TTSCIM2 DM8PET6 TN Extracellular lysophospholipase D (E-NPP2) DM8PET6 MA Inhibitor DM8PET6 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM8PET6 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM8PHBG DI DM8PHBG DM8PHBG DN Heterocycle-containing compound 1 DM8PHBG TI TT9O6WS DM8PHBG TN Glucagon receptor (GCGR) DM8PHBG MA Antagonist DM8PHBG RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM8PHBG RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM8PJ3F DI DM8PJ3F DM8PJ3F DN PMID28394193-Compound-22 DM8PJ3F TI TT9MZCQ DM8PJ3F TN Enhancer of zeste homolog 2 (EZH2) DM8PJ3F MA Inhibitor DM8PJ3F RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM8PJ3F RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM8POGS DI DM8POGS DM8POGS DN PMID25656651-Compound-10 DM8POGS TI TTS7G69 DM8POGS TN Fusion protein Bcr-Abl (Bcr-Abl) DM8POGS MA Inhibitor DM8POGS RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM8POGS RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM8PVN3 DI DM8PVN3 DM8PVN3 DN Cyclopropane 1-carboxylic acid derivative 4 DM8PVN3 TI TTIY56R DM8PVN3 TN Kynurenine 3-hydroxylase (KMO) DM8PVN3 MA Inhibitor DM8PVN3 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM8PVN3 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM8PZ46 DI DM8PZ46 DM8PZ46 DN PMID29473428-Compound-76 DM8PZ46 TI TTXNCBV DM8PZ46 TN Tryptophan 2,3-dioxygenase (TDO) DM8PZ46 MA Inhibitor DM8PZ46 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8PZ46 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8PZ46 DI DM8PZ46 DM8PZ46 DN PMID29473428-Compound-76 DM8PZ46 TI TTZJYKH DM8PZ46 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM8PZ46 MA Inhibitor DM8PZ46 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8PZ46 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8Q19H DI DM8Q19H DM8Q19H DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4 DM8Q19H TI TTVDSZ0 DM8Q19H TN Poly [ADP-ribose] polymerase 1 (PARP1) DM8Q19H MA Inhibitor DM8Q19H RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM8Q19H RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTDZN01 DM8QZNC TN Cathepsin K (CTSK) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TT36ETB DM8QZNC TN Cathepsin L (CTSL) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTF2LRI DM8QZNC TN Cathepsin B (CTSB) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTUMQVO DM8QZNC TN Cathepsin S (CTSS) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTJOKD1 DM8QZNC TN Cathepsin F (CTSF) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTSD9T1 DM8QZNC TN Cathepsin V (CTSV) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8RAK0 DI DM8RAK0 DM8RAK0 DN PMID29053063-Compound-4 DM8RAK0 TI TTZ963I DM8RAK0 TN Monoglyceride lipase (MAGL) DM8RAK0 MA Inhibitor DM8RAK0 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8RAK0 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8RJTQ DI DM8RJTQ DM8RJTQ DN PMID26004420-Compound-U2014S0288042C DM8RJTQ TI TTJ13ST DM8RJTQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM8RJTQ MA Inhibitor DM8RJTQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM8RJTQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM8S7NQ DI DM8S7NQ DM8S7NQ DN Dihydropyrido pyrazinone compound 1 DM8S7NQ TI TTE4BSY DM8S7NQ TN Bromodomain and extraterminal domain protein (BET) DM8S7NQ MA Inhibitor DM8S7NQ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8S7NQ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8STUQ DI DM8STUQ DM8STUQ DN Amidine oxime derivative 1 DM8STUQ TI TT1RS9F DM8STUQ TN Acetylcholinesterase (AChE) DM8STUQ MA Reactivator DM8STUQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM8STUQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM8SWHO DI DM8SWHO DM8SWHO DN PMID26815044-Compound-115 DM8SWHO TI TTULVH8 DM8SWHO TN Tyrosinase (TYR) DM8SWHO MA Inhibitor DM8SWHO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8SWHO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8SZKU DI DM8SZKU DM8SZKU DN Pyrrolidinyl urea derivative 4 DM8SZKU TI TTTDVOJ DM8SZKU TN Tropomyosin-related kinase A (TrkA) DM8SZKU MA Inhibitor DM8SZKU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM8SZKU RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM8T2LV DI DM8T2LV DM8T2LV DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2 DM8T2LV TI TT6OEDT DM8T2LV TN Cannabinoid receptor 1 (CB1) DM8T2LV MA Antagonist DM8T2LV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM8T2LV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM8TQS4 DI DM8TQS4 DM8TQS4 DN Carboxamide derivative 7 DM8TQS4 TI TTG5QB7 DM8TQS4 TN Calpain-2 (CAPN2) DM8TQS4 MA Inhibitor DM8TQS4 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM8TQS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM8UI4Z DI DM8UI4Z DM8UI4Z DN PMID26560530-Compound-16 DM8UI4Z TI TT2F4OL DM8UI4Z TN Tissue transglutaminase (TG2) DM8UI4Z MA Inhibitor DM8UI4Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8UI4Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8UMQH DI DM8UMQH DM8UMQH DN PMID29671355-Compound-14 DM8UMQH TI TT5ZKDI DM8UMQH TN Histone deacetylase 6 (HDAC6) DM8UMQH MA Inhibitor DM8UMQH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM8UMQH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM8UOKE DI DM8UOKE DM8UOKE DN US9096594, 3 DM8UOKE TI TTFQEMX DM8UOKE TN Casein kinase I alpha (CSNK1A1) DM8UOKE MA Inhibitor DM8UOKE RN Kinase inhibitors and methods of use thereof. US9096594. DM8UOKE RU http://www.freepatentsonline.com/US9096594.html DM8UOY6 DI DM8UOY6 DM8UOY6 DN MHHFJYABEVJNEG-UHFFFAOYSA-N DM8UOY6 TI TTDYP7I DM8UOY6 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM8UOY6 MA Inhibitor DM8UOY6 RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DM8UOY6 RU http://www.freepatentsonline.com/US9150519.html DM8UPO3 DI DM8UPO3 DM8UPO3 DN PMID26161698-Compound-44 DM8UPO3 TI TTMBO1Z DM8UPO3 TN Cyclin-dependent kinase (CDK) DM8UPO3 MA Inhibitor DM8UPO3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM8UPO3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM8UPO3 DI DM8UPO3 DM8UPO3 DN PMID26161698-Compound-44 DM8UPO3 TI TTSMTDI DM8UPO3 TN CDC7-related kinase (CDC7) DM8UPO3 MA Inhibitor DM8UPO3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM8UPO3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM8UXZ3 DI DM8UXZ3 DM8UXZ3 DN Benzenamine derivative 3 DM8UXZ3 TI TTNR0UQ DM8UXZ3 TN Lysine-specific histone demethylase 1 (LSD) DM8UXZ3 MA Inhibitor DM8UXZ3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM8UXZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM8V7QH DI DM8V7QH DM8V7QH DN PMID27828716-Compound-19 DM8V7QH TI TTRZQE3 DM8V7QH TN Glycogen synthase kinase-3 alpha (GSK-3A) DM8V7QH MA Inhibitor DM8V7QH RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM8V7QH RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM8VBU2 DI DM8VBU2 DM8VBU2 DN PMID29473428-Compound-80 DM8VBU2 TI TTZJYKH DM8VBU2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM8VBU2 MA Inhibitor DM8VBU2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8VBU2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8VG4Q DI DM8VG4Q DM8VG4Q DN PMID29671355-Compound-71b DM8VG4Q TI TTTQGH8 DM8VG4Q TN Histone deacetylase 4 (HDAC4) DM8VG4Q MA Inhibitor DM8VG4Q RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM8VG4Q RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM8VIM4 DI DM8VIM4 DM8VIM4 DN Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 TI TTP7EGM DM8VIM4 TN Dual specificity protein kinase TTK (MPS1) DM8VIM4 MA Inhibitor DM8VIM4 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM8VIM4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM8VIM4 DI DM8VIM4 DM8VIM4 DN Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 TI TT5OU0D DM8VIM4 TN PRKR-like endoplasmic reticulum kinase (PERK) DM8VIM4 MA Inhibitor DM8VIM4 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM8VIM4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM8VYMA DI DM8VYMA DM8VYMA DN Pyrrolo-pyrrolone derivative 2 DM8VYMA TI TTRA6BO DM8VYMA TN Bromodomain-containing protein 4 (BRD4) DM8VYMA MA Inhibitor DM8VYMA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8VYMA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8WH97 DI DM8WH97 DM8WH97 DN Quinazolinone derivative 4 DM8WH97 TI TTE4BSY DM8WH97 TN Bromodomain and extraterminal domain protein (BET) DM8WH97 MA Inhibitor DM8WH97 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8WH97 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8WKYT DI DM8WKYT DM8WKYT DN PMID29649907-Compound-37 DM8WKYT TI TTS4UGC DM8WKYT TN Farnesoid X-activated receptor (FXR) DM8WKYT MA Agonist DM8WKYT RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM8WKYT RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM8WP3D DI DM8WP3D DM8WP3D DN PMID26560530-Compound-27 DM8WP3D TI TT2F4OL DM8WP3D TN Tissue transglutaminase (TG2) DM8WP3D MA Inhibitor DM8WP3D RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8WP3D RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8X5GP DI DM8X5GP DM8X5GP DN 7-azaindole derivative 6 DM8X5GP TI TT056SO DM8X5GP TN Stress-activated protein kinase JNK3 (JNK3) DM8X5GP MA Inhibitor DM8X5GP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM8X5GP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM8XESD DI DM8XESD DM8XESD DN PMID25980951-Compound-42 DM8XESD TI TTR7B60 DM8XESD TN X-linked inhibitor of apoptosis protein (XIAP) DM8XESD MA Antagonist DM8XESD RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM8XESD RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM8XESD DI DM8XESD DM8XESD DN PMID25980951-Compound-42 DM8XESD TI TTQ5LRD DM8XESD TN Cellular inhibitor of apoptosis 1 (BIRC2) DM8XESD MA Antagonist DM8XESD RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM8XESD RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM8XJTH DI DM8XJTH DM8XJTH DN SPHINX scaffold, 3 DM8XJTH TI TTU3WV6 DM8XJTH TN SRSF protein kinase 1 (SRPK1) DM8XJTH MA Inhibitor DM8XJTH RN Piperazine derivatives for treating disorders. US9695160. DM8XJTH RU http://www.freepatentsonline.com/US9695160.html DM8YR1V DI DM8YR1V DM8YR1V DN PMID25991433-Compound-E2 DM8YR1V TI TT0K6EO DM8YR1V TN Stress-activated protein kinase JNK1 (JNK1) DM8YR1V MA Inhibitor DM8YR1V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM8YR1V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM8ZRXE DI DM8ZRXE DM8ZRXE DN Bicyclo-heptan-2-amine derivative 3 DM8ZRXE TI TT9NXW4 DM8ZRXE TN Sigma intracellular receptor 2 (TMEM97) DM8ZRXE MA Ligand DM8ZRXE RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM8ZRXE RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM8ZXBS DI DM8ZXBS DM8ZXBS DN Thiazole derivative 2 DM8ZXBS TI TTA6ZN2 DM8ZXBS TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM8ZXBS MA Inhibitor DM8ZXBS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM8ZXBS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM904T7 DI DM904T7 DM904T7 DN Peptide analog 24 DM904T7 TI TTSJMN8 DM904T7 TN Immunoproteasome complex (IP) DM904T7 MA Inhibitor DM904T7 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM904T7 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TT0K1SC DM90WKN TN 5-HT 2B receptor (HTR2B) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TTWJBZ5 DM90WKN TN 5-HT 2C receptor (HTR2C) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TTJQOD7 DM90WKN TN 5-HT 2A receptor (HTR2A) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM913KS DI DM913KS DM913KS DN Piperazinyl methyl quinazolinone derivative 2 DM913KS TI TT9NXW4 DM913KS TN Sigma intracellular receptor 2 (TMEM97) DM913KS MA Ligand DM913KS RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM913KS RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM91Z8B DI DM91Z8B DM91Z8B DN 1,2,4-triazole derivative 2 DM91Z8B TI TT6OEDT DM91Z8B TN Cannabinoid receptor 1 (CB1) DM91Z8B MA Antagonist DM91Z8B RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM91Z8B RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM92F1C DI DM92F1C DM92F1C DN PMID25435285-Compound-47 DM92F1C TI TTXJ47W DM92F1C TN Metabotropic glutamate receptor 2 (mGluR2) DM92F1C MA Antagonist DM92F1C RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM92F1C RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM92HZG DI DM92HZG DM92HZG DN PMID25522065-Compound-13 DM92HZG TI TTX4RTB DM92HZG TN Melanin-concentrating hormone receptor 1 (MCHR1) DM92HZG MA Antagonist DM92HZG RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM92HZG RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM92OT0 DI DM92OT0 DM92OT0 DN PMID26560530-Compound-3 DM92OT0 TI TT2F4OL DM92OT0 TN Tissue transglutaminase (TG2) DM92OT0 MA Inhibitor DM92OT0 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM92OT0 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM92SWJ DI DM92SWJ DM92SWJ DN Purin-6-one derivative 1 DM92SWJ TI TTJGW1Z DM92SWJ TN Phosphodiesterase 2A (PDE2A) DM92SWJ MA Inhibitor DM92SWJ RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM92SWJ RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9358G DI DM9358G DM9358G DN PMID25666693-Compound-123 DM9358G TI TTMI6F5 DM9358G TN Transient receptor potential cation channel V1 (TRPV1) DM9358G MA Antagonist DM9358G RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9358G RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM93VEB DI DM93VEB DM93VEB DN Biphenyl mannoside derivative 6 DM93VEB TI TTTCRU2 DM93VEB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM93VEB MA Antagonist DM93VEB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM93VEB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM94MT3 DI DM94MT3 DM94MT3 DN PMID28074661-Compound-US20100022547C82 DM94MT3 TI TTL7C8Q DM94MT3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM94MT3 MA Inhibitor DM94MT3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM94MT3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM94NZF DI DM94NZF DM94NZF DN Tricyclic phytocannabinoid derivative 1 DM94NZF TI TT6OEDT DM94NZF TN Cannabinoid receptor 1 (CB1) DM94NZF RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM94NZF RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM94NZF DI DM94NZF DM94NZF DN Tricyclic phytocannabinoid derivative 1 DM94NZF TI TTMSFAW DM94NZF TN Cannabinoid receptor 2 (CB2) DM94NZF RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM94NZF RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM94TKW DI DM94TKW DM94TKW DN Binuclear gold(I) compound 3 DM94TKW TI TTR7UJ3 DM94TKW TN Cytoplasmic thioredoxin reductase (TXNRD1) DM94TKW MA Inhibitor DM94TKW RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM94TKW RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM951HL DI DM951HL DM951HL DN Carbamide derivative 5 DM951HL TI TTL7C8Q DM951HL TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM951HL MA Inhibitor DM951HL RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM951HL RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM953EV DI DM953EV DM953EV DN Peptide analog 9 DM953EV TI TTSJMN8 DM953EV TN Immunoproteasome complex (IP) DM953EV MA Inhibitor DM953EV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM953EV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM954C8 DI DM954C8 DM954C8 DN PMID27019002-Compound-28a DM954C8 TI TTNR0UQ DM954C8 TN Lysine-specific histone demethylase 1 (LSD) DM954C8 MA Inhibitor DM954C8 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM954C8 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM95FIN DI DM95FIN DM95FIN DN PMID30107136-Compound-Example42 DM95FIN TI TT23XQV DM95FIN TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM95FIN MA Inhibitor DM95FIN RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM95FIN RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM95YLX DI DM95YLX DM95YLX DN US10071110, Compound cCDV DM95YLX TI TT5DOVB DM95YLX TN Cytomegalovirus Protease (CMV UL80) DM95YLX MA Inhibitor DM95YLX RN Phosphonate compounds. US10071110. DM95YLX RU http://www.freepatentsonline.com/US10071110.html DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT8EPLT DM96KXE TN Proteasome beta-1 (PS beta-1) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TTOUSTQ DM96KXE TN Proteasome beta-9 (PS beta-9) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT49BVC DM96KXE TN Proteasome beta-2 (PS beta-2) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TTEAD9J DM96KXE TN Proteasome beta-8 (PS beta-8) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT68GPI DM96KXE TN Proteasome beta-5 (PS beta-5) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM97BIQ DI DM97BIQ DM97BIQ DN Biphenyl mannoside derivative 15 DM97BIQ TI TTTCRU2 DM97BIQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM97BIQ MA Antagonist DM97BIQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM97BIQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM982GD DI DM982GD DM982GD DN Indoline derivative 13 DM982GD TI TTOHSBA DM982GD TN Vascular endothelial growth factor A (VEGFA) DM982GD MA Inhibitor DM982GD RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM982GD RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM983CY DI DM983CY DM983CY DN Pyrrolo[2,3-d]pyrimidine derivative 11 DM983CY TI TTRMX3V DM983CY TN Janus kinase 2 (JAK-2) DM983CY MA Inhibitor DM983CY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM983CY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM983CY DI DM983CY DM983CY DN Pyrrolo[2,3-d]pyrimidine derivative 11 DM983CY TI TT6DM01 DM983CY TN Janus kinase 1 (JAK-1) DM983CY MA Inhibitor DM983CY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM983CY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM987MK DI DM987MK DM987MK DN Thiazole carboxamide derivative 18 DM987MK TI TTCZOF2 DM987MK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM987MK MA Inhibitor DM987MK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM987MK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM9A8L5 DI DM9A8L5 DM9A8L5 DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1 DM9A8L5 TI TT6OEDT DM9A8L5 TN Cannabinoid receptor 1 (CB1) DM9A8L5 MA Antagonist DM9A8L5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM9A8L5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM9A8PN DI DM9A8PN DM9A8PN DN PMID26077642-Compound-Figure3G DM9A8PN TI TTZC0KV DM9A8PN TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM9A8PN MA Inhibitor DM9A8PN RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM9A8PN RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM9ADSN DI DM9ADSN DM9ADSN DN PMID28270021-Compound-WO2016054807Example82 DM9ADSN TI TTTDVOJ DM9ADSN TN Tropomyosin-related kinase A (TrkA) DM9ADSN MA Inhibitor DM9ADSN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM9ADSN RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM9AGBT DI DM9AGBT DM9AGBT DN Indoline derivative 16 DM9AGBT TI TTOHSBA DM9AGBT TN Vascular endothelial growth factor A (VEGFA) DM9AGBT MA Inhibitor DM9AGBT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM9AGBT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM9AJVK DI DM9AJVK DM9AJVK DN PMID26004420-Compound-WO2012058134C DM9AJVK TI TTJ13ST DM9AJVK TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM9AJVK MA Inhibitor DM9AJVK RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM9AJVK RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM9BYJ0 DI DM9BYJ0 DM9BYJ0 DN Methyl 2-amino-4-phenylthiophene-3-carboxylate DM9BYJ0 TI TTUWGRA DM9BYJ0 TN Protein kinase C zeta (PRKCZ) DM9BYJ0 MA Inhibitor DM9BYJ0 RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DM9BYJ0 RU http://www.freepatentsonline.com/US8889672.html DM9C4XH DI DM9C4XH DM9C4XH DN PMID27537201-Compound-Figure11 DM9C4XH TI TTPADOQ DM9C4XH TN HMG-CoA reductase (HMGCR) DM9C4XH MA Inhibitor DM9C4XH RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM9C4XH RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM9C5Z8 DI DM9C5Z8 DM9C5Z8 DN Selenium compound 1 DM9C5Z8 TI TTZHPB8 DM9C5Z8 TN Lysine-specific demethylase 4A (KDM4A) DM9C5Z8 MA Inhibitor DM9C5Z8 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM9C5Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM9DC3U DI DM9DC3U DM9DC3U DN Fused heterocyclic compound 6 DM9DC3U TI TT7RJY8 DM9DC3U TN Xanthine dehydrogenase/oxidase (XDH) DM9DC3U MA Inhibitor DM9DC3U RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM9DC3U RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTEX248 DM9DJGU TN Dopamine D2 receptor (D2R) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTSQIFT DM9DJGU TN 5-HT 1A receptor (HTR1A) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTJQOD7 DM9DJGU TN 5-HT 2A receptor (HTR2A) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TT4C8EA DM9DJGU TN Dopamine D3 receptor (D3R) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DL1E DI DM9DL1E DM9DL1E DN PMID30107136-Compound-Example54 DM9DL1E TI TT23XQV DM9DL1E TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM9DL1E MA Inhibitor DM9DL1E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM9DL1E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM9E0ZD DI DM9E0ZD DM9E0ZD DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 DM9E0ZD TI TTJGW1Z DM9E0ZD TN Phosphodiesterase 2A (PDE2A) DM9E0ZD MA Inhibitor DM9E0ZD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM9E0ZD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9E0ZD DI DM9E0ZD DM9E0ZD DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 DM9E0ZD TI TTJW4LU DM9E0ZD TN Phosphodiesterase 10A (PDE10) DM9E0ZD MA Inhibitor DM9E0ZD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM9E0ZD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9EGVN DI DM9EGVN DM9EGVN DN Amidine compound 4 DM9EGVN TI TTQR74A DM9EGVN TN Proteinase activated receptor 2 (PAR2) DM9EGVN MA Antagonist DM9EGVN RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM9EGVN RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM9ESPR DI DM9ESPR DM9ESPR DN A1-10436 DM9ESPR TI TT0C8BY DM9ESPR TN Plasma retinol-binding protein (RBP4) DM9ESPR MA Inhibitor DM9ESPR RN Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215. DM9ESPR RU http://www.freepatentsonline.com/US8853215.html DM9FIKD DI DM9FIKD DM9FIKD DN PMID26651364-Compound-9e DM9FIKD TI TTTCRU2 DM9FIKD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9FIKD MA Antagonist DM9FIKD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9FIKD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9FJXS DI DM9FJXS DM9FJXS DN Peptide analog 53 DM9FJXS TI TT2F4OL DM9FJXS TN Tissue transglutaminase (TG2) DM9FJXS MA Inhibitor DM9FJXS RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM9FJXS RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TT49BVC DM9FL81 TN Proteasome beta-2 (PS beta-2) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TT68GPI DM9FL81 TN Proteasome beta-5 (PS beta-5) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TTPNACM DM9FL81 TN Proteasome beta-10 (PS beta-10) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FPK1 DI DM9FPK1 DM9FPK1 DN Benzothiazepine analog 1 DM9FPK1 TI TTPTXIN DM9FPK1 TN Translocator protein (TSPO) DM9FPK1 MA Ligand DM9FPK1 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9FPK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9FRN6 DI DM9FRN6 DM9FRN6 DN 2-hydroxybenzamide derivative 2 DM9FRN6 TI TTA6ZN2 DM9FRN6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9FRN6 MA Activator DM9FRN6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9FRN6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9FRN6 DI DM9FRN6 DM9FRN6 DN 2-hydroxybenzamide derivative 2 DM9FRN6 TI TT3Z6Y9 DM9FRN6 TN Cysteines of Keap1 (KEAP1 Cysteines) DM9FRN6 MA Modulator DM9FRN6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9FRN6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9FRV7 DI DM9FRV7 DM9FRV7 DN Imidazopyridine derivative 2 DM9FRV7 TI TTPTXIN DM9FRV7 TN Translocator protein (TSPO) DM9FRV7 MA Ligand DM9FRV7 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9FRV7 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9FXE7 DI DM9FXE7 DM9FXE7 DN Quinoline derivative 12 DM9FXE7 TI TT473XN DM9FXE7 TN P2X purinoceptor 7 (P2RX7) DM9FXE7 MA Antagonist DM9FXE7 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM9FXE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM9FXE7 DI DM9FXE7 DM9FXE7 DN Quinoline derivative 12 DM9FXE7 TI TTQ6VDM DM9FXE7 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM9FXE7 MA Antagonist DM9FXE7 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM9FXE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM9GLQB DI DM9GLQB DM9GLQB DN BDBM50444058 DM9GLQB TI TTIEMFN DM9GLQB TN TYRO3 tyrosine kinase receptor (TYRO3) DM9GLQB MA Inhibitor DM9GLQB RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DM9GLQB RU http://www.freepatentsonline.com/US9649309.html DM9GPKR DI DM9GPKR DM9GPKR DN 3-Hydroxy-2-butanone DM9GPKR TI TTGP7BY DM9GPKR TN Monoamine oxidase type B (MAO-B) DM9GPKR MA Inhibitor DM9GPKR RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9GPKR RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9GX0F DI DM9GX0F DM9GX0F DN PMID30185082-Compound-53 DM9GX0F TI TT9NXW4 DM9GX0F TN Sigma intracellular receptor 2 (TMEM97) DM9GX0F MA Ligand DM9GX0F RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9GX0F RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9H0Q3 DI DM9H0Q3 DM9H0Q3 DN Biphenyl mannoside derivative 29 DM9H0Q3 TI TTTCRU2 DM9H0Q3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9H0Q3 MA Antagonist DM9H0Q3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9H0Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TT9JNIC DM9H3LI TN Histamine H3 receptor (H3R) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TTTIBOJ DM9H3LI TN Histamine H1 receptor (H1R) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TT3ROYC DM9H3LI TN Serotonin transporter (SERT) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9HMB4 DI DM9HMB4 DM9HMB4 DN PMID30107136-Compound-Example2 DM9HMB4 TI TT8ZLTI DM9HMB4 TN Programmed cell death 1 ligand 1 (PD-L1) DM9HMB4 MA Inhibitor DM9HMB4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM9HMB4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM9HOM6 DI DM9HOM6 DM9HOM6 DN PMID25666693-Compound-11 DM9HOM6 TI TTMI6F5 DM9HOM6 TN Transient receptor potential cation channel V1 (TRPV1) DM9HOM6 MA Antagonist DM9HOM6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9HOM6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM9HQXC DI DM9HQXC DM9HQXC DN US9434727, 63 DM9HQXC TI TT0C8BY DM9HQXC TN Plasma retinol-binding protein (RBP4) DM9HQXC MA Inhibitor DM9HQXC RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DM9HQXC RU http://www.freepatentsonline.com/US9434727.html DM9HRZJ DI DM9HRZJ DM9HRZJ DN PMID26924192-Compound-106 DM9HRZJ TI TTDP48B DM9HRZJ TN Bromodomain-containing protein 2 (BRD2) DM9HRZJ MA Inhibitor DM9HRZJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9HRZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9HZ03 DI DM9HZ03 DM9HZ03 DN US9650366, 2 DM9HZ03 TI TTXEZJ4 DM9HZ03 TN Tyrosine-protein kinase EIF2AK2 (p68) DM9HZ03 MA Inhibitor DM9HZ03 RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DM9HZ03 RU http://www.freepatentsonline.com/US9650366.html DM9I4EV DI DM9I4EV DM9I4EV DN PMID25772215-Compound-US02014179750TG7-74 DM9I4EV TI TT1ZAVI DM9I4EV TN Prostaglandin E2 receptor EP2 (PTGER2) DM9I4EV MA Antagonist DM9I4EV RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM9I4EV RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM9IL5Q DI DM9IL5Q DM9IL5Q DN Heteroaromatic ring derivative 4 DM9IL5Q TI TTSCIM2 DM9IL5Q TN Extracellular lysophospholipase D (E-NPP2) DM9IL5Q MA Inhibitor DM9IL5Q RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM9IL5Q RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM9IPDU DI DM9IPDU DM9IPDU DN Heteroaryl-carboxamide derivative 6 DM9IPDU TI TTCZOF2 DM9IPDU TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM9IPDU MA Inhibitor DM9IPDU RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM9IPDU RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM9J57W DI DM9J57W DM9J57W DN PMID26651364-Compound-6d DM9J57W TI TTTCRU2 DM9J57W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9J57W MA Antagonist DM9J57W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9J57W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9JCL2 DI DM9JCL2 DM9JCL2 DN US9670220, 33 DM9JCL2 TI TTDYP7I DM9JCL2 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM9JCL2 MA Inhibitor DM9JCL2 RN Fused heterocyclic derivatives as S1P modulators. US9670220. DM9JCL2 RU http://www.freepatentsonline.com/US9670220.html DM9JHYL DI DM9JHYL DM9JHYL DN Pyrazole derivative 79 DM9JHYL TI TTXJ47W DM9JHYL TN Metabotropic glutamate receptor 2 (mGluR2) DM9JHYL MA Antagonist DM9JHYL RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM9JHYL RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM9K5BZ DI DM9K5BZ DM9K5BZ DN PMID27841036-Compound-XVII DM9K5BZ TI TTEBCY8 DM9K5BZ TN Poly [ADP-ribose] polymerase (PARP) DM9K5BZ MA Inhibitor DM9K5BZ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM9K5BZ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM9K5CI DI DM9K5CI DM9K5CI DN Pyrrolo-pyridine derivative 1 DM9K5CI TI TTK0FEA DM9K5CI TN Leucine-rich repeat kinase 2 (LRRK2) DM9K5CI MA Inhibitor DM9K5CI RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM9K5CI RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM9K7P0 DI DM9K7P0 DM9K7P0 DN Tricyclic compound 3 DM9K7P0 TI TT6DM01 DM9K7P0 TN Janus kinase 1 (JAK-1) DM9K7P0 MA Inhibitor DM9K7P0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM9K7P0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM9KAF1 DI DM9KAF1 DM9KAF1 DN PMID25553724-Compound-US2012810604610 DM9KAF1 TI TTSXVID DM9KAF1 TN Nuclear factor NF-kappa-B (NFKB) DM9KAF1 MA Inhibitor DM9KAF1 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM9KAF1 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM9KOYX DI DM9KOYX DM9KOYX DN Pyridine-amide derivative 1 DM9KOYX TI TTF8P9I DM9KOYX TN Diacylglycerol acyltransferase 1 (DGAT1) DM9KOYX MA Inhibitor DM9KOYX RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM9KOYX RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM9KSVI DI DM9KSVI DM9KSVI DN US8940736, 7 DM9KSVI TI TTR93NU DM9KSVI TN Casein kinase II alpha prime (CSNK2A2) DM9KSVI MA Inhibitor DM9KSVI RN Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736. DM9KSVI RU http://www.freepatentsonline.com/US8940736.html DM9KTRA DI DM9KTRA DM9KTRA DN PMID25399762-Compound-Figure3-Fluevirosine A DM9KTRA TI TT3WG5C DM9KTRA TN Monoamine oxidase type A (MAO-A) DM9KTRA MA Inhibitor DM9KTRA RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9KTRA RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9KVOD DI DM9KVOD DM9KVOD DN PMID29473428-Compound-4 DM9KVOD TI TTZJYKH DM9KVOD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM9KVOD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM9KVOD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM9L2VR DI DM9L2VR DM9L2VR DN PMID28454500-Compound-95 DM9L2VR TI TTA6ZN2 DM9L2VR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9L2VR MA Inhibitor DM9L2VR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9L2VR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9L5KO DI DM9L5KO DM9L5KO DN 4-Hydroxy-2,5-dimethyl-3(2H)-furanone DM9L5KO TI TTGP7BY DM9L5KO TN Monoamine oxidase type B (MAO-B) DM9L5KO MA Inhibitor DM9L5KO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9L5KO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9LMNB DI DM9LMNB DM9LMNB DN PMID29671355-Compound-19 DM9LMNB TI TT6R7JZ DM9LMNB TN Histone deacetylase 1 (HDAC1) DM9LMNB MA Inhibitor DM9LMNB RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM9LMNB RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM9LMNB DI DM9LMNB DM9LMNB DN PMID29671355-Compound-19 DM9LMNB TI TT5ZKDI DM9LMNB TN Histone deacetylase 6 (HDAC6) DM9LMNB MA Inhibitor DM9LMNB RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM9LMNB RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM9LQCH DI DM9LQCH DM9LQCH DN Heteroaryl-pyrazole derivative 1 DM9LQCH TI TTXJ47W DM9LQCH TN Metabotropic glutamate receptor 2 (mGluR2) DM9LQCH MA Antagonist DM9LQCH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM9LQCH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM9LZJ5 DI DM9LZJ5 DM9LZJ5 DN PMID25666693-Compound-73 DM9LZJ5 TI TTMI6F5 DM9LZJ5 TN Transient receptor potential cation channel V1 (TRPV1) DM9LZJ5 MA Antagonist DM9LZJ5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9LZJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM9MFDH DI DM9MFDH DM9MFDH DN Carbamate derivative 4 DM9MFDH TI TTGX13H DM9MFDH TN Fatty-acid amide hydrolase 1 (FAAH1) DM9MFDH MA Inhibitor DM9MFDH RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM9MFDH RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM9MFUN DI DM9MFUN DM9MFUN DN PMID25726713-Compound-17 DM9MFUN TI TTW6JVU DM9MFUN TN Smoothened D473H mutant (SMO D473H) DM9MFUN MA Antagonist DM9MFUN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM9MFUN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM9MFUN DI DM9MFUN DM9MFUN DN PMID25726713-Compound-17 DM9MFUN TI TT8J1S3 DM9MFUN TN Smoothened homolog (SMO) DM9MFUN MA Antagonist DM9MFUN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM9MFUN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM9MLQ6 DI DM9MLQ6 DM9MLQ6 DN PMID25522065-Compound-24 DM9MLQ6 TI TTX4RTB DM9MLQ6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM9MLQ6 MA Antagonist DM9MLQ6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM9MLQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM9NE5T DI DM9NE5T DM9NE5T DN Heteroaryl-cyclopropylamine derivative 2 DM9NE5T TI TTNR0UQ DM9NE5T TN Lysine-specific histone demethylase 1 (LSD) DM9NE5T MA Inhibitor DM9NE5T RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM9NE5T RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM9NEFG DI DM9NEFG DM9NEFG DN PMID27607364-Compound-65 DM9NEFG TI TTPTXIN DM9NEFG TN Translocator protein (TSPO) DM9NEFG MA Ligand DM9NEFG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9NEFG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9NGDI DI DM9NGDI DM9NGDI DN PMID25553724-Compound-US20130237529 36 DM9NGDI TI TTBP3XA DM9NGDI TN Polyubiquitin-C (UBC) DM9NGDI MA Inhibitor DM9NGDI RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM9NGDI RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM9NMHS DI DM9NMHS DM9NMHS DN Fused benzoheterocycle amide derivative 2 DM9NMHS TI TTKFVXR DM9NMHS TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM9NMHS MA Inhibitor DM9NMHS RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM9NMHS RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM9NOP3 DI DM9NOP3 DM9NOP3 DN Phenylsulfonyl derivative 1 DM9NOP3 TI TT9JNIC DM9NOP3 TN Histamine H3 receptor (H3R) DM9NOP3 MA Inhibitor DM9NOP3 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9NOP3 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9NWXM DI DM9NWXM DM9NWXM DN PMID26924192-Compound-33 DM9NWXM TI TTRA6BO DM9NWXM TN Bromodomain-containing protein 4 (BRD4) DM9NWXM MA Inhibitor DM9NWXM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9NWXM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9NWXM DI DM9NWXM DM9NWXM DN PMID26924192-Compound-33 DM9NWXM TI TTU6FSC DM9NWXM TN Extracellular signal-regulated kinase 5 (ERK5) DM9NWXM MA Inhibitor DM9NWXM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9NWXM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9O56W DI DM9O56W DM9O56W DN Carbamide derivative 10 DM9O56W TI TTL7C8Q DM9O56W TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM9O56W MA Inhibitor DM9O56W RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM9O56W RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM9OHAN DI DM9OHAN DM9OHAN DN PMID25416646-Compound-Figure5-A DM9OHAN TI TTZMAO3 DM9OHAN TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM9OHAN MA Agonist DM9OHAN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM9OHAN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM9OHAN DI DM9OHAN DM9OHAN DN PMID25416646-Compound-Figure5-A DM9OHAN TI TTJ584C DM9OHAN TN Peroxisome proliferator-activated receptor alpha (PPARA) DM9OHAN MA Agonist DM9OHAN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM9OHAN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM9OXAB DI DM9OXAB DM9OXAB DN Pyrazolo[1,5-a]pyrimidine derivative 27 DM9OXAB TI TTTDVOJ DM9OXAB TN Tropomyosin-related kinase A (TrkA) DM9OXAB MA Inhibitor DM9OXAB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM9OXAB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM9PHIK DI DM9PHIK DM9PHIK DN 1,2-diamino cyclopentane-based derivative 20 DM9PHIK TI TT9N02I DM9PHIK TN Orexin receptor type 2 (HCRTR2) DM9PHIK MA Antagonist DM9PHIK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM9PHIK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM9PHIK DI DM9PHIK DM9PHIK DN 1,2-diamino cyclopentane-based derivative 20 DM9PHIK TI TT60Q8D DM9PHIK TN Orexin receptor type 1 (HCRTR1) DM9PHIK MA Antagonist DM9PHIK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM9PHIK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM9PKU2 DI DM9PKU2 DM9PKU2 DN Benzamide derivative 10 DM9PKU2 TI TT9NXW4 DM9PKU2 TN Sigma intracellular receptor 2 (TMEM97) DM9PKU2 MA Ligand DM9PKU2 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9PKU2 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9PKU2 DI DM9PKU2 DM9PKU2 DN Benzamide derivative 10 DM9PKU2 TI TT5TPI6 DM9PKU2 TN Opioid receptor sigma 1 (OPRS1) DM9PKU2 MA Ligand DM9PKU2 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9PKU2 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9PL3F DI DM9PL3F DM9PL3F DN Benzimidazole derivative 4 DM9PL3F TI TTULVH8 DM9PL3F TN Tyrosinase (TYR) DM9PL3F MA Inhibitor DM9PL3F RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM9PL3F RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM9PNTF DI DM9PNTF DM9PNTF DN Pyrazole derivative 54 DM9PNTF TI TT6OEDT DM9PNTF TN Cannabinoid receptor 1 (CB1) DM9PNTF MA Antagonist DM9PNTF RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM9PNTF RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM9PSI3 DI DM9PSI3 DM9PSI3 DN Quinoline and quinazoline derivative 2 DM9PSI3 TI TTOHSBA DM9PSI3 TN Vascular endothelial growth factor A (VEGFA) DM9PSI3 MA Inhibitor DM9PSI3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM9PSI3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM9Q0EC DI DM9Q0EC DM9Q0EC DN AC1LJNG0 DM9Q0EC TI TT1NFO3 DM9Q0EC TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM9Q0EC MA Inhibitor DM9Q0EC RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM9Q0EC RU http://www.freepatentsonline.com/US8785499.html DM9Q0JS DI DM9Q0JS DM9Q0JS DN Peptidomimetic analog 4 DM9Q0JS TI TTH8FZW DM9Q0JS TN Signal transducer and activator of transcription 3 (STAT3) DM9Q0JS MA Inhibitor DM9Q0JS RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9Q0JS RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9QB2S DI DM9QB2S DM9QB2S DN Triazole derivative 1 DM9QB2S TI TT2F4OL DM9QB2S TN Tissue transglutaminase (TG2) DM9QB2S MA Inhibitor DM9QB2S RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM9QB2S RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM9QCTJ DI DM9QCTJ DM9QCTJ DN US10065972, Example 560 DM9QCTJ TI TTT3IXG DM9QCTJ TN Kynurenine oxoglutarate transaminase II (AADAT) DM9QCTJ MA Inhibitor DM9QCTJ RN Bicyclic or tricyclic heterocyclic compound. US10065972. DM9QCTJ RU http://www.freepatentsonline.com/US10065972.html DM9QEIV DI DM9QEIV DM9QEIV DN PMID27376512-Compound-asCEBP-2HPE DM9QEIV TI TT6S2FE DM9QEIV TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9QEIV MA Inhibitor DM9QEIV RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9QEIV RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9QM6I DI DM9QM6I DM9QM6I DN PMID27336223-Compound-7 DM9QM6I TI TTISP28 DM9QM6I TN Retinoic acid receptor beta (RARB) DM9QM6I MA Agonist DM9QM6I RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM9QM6I RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM9RIF4 DI DM9RIF4 DM9RIF4 DN US9132129, Cpd002 DM9RIF4 TI TTH9LDP DM9RIF4 TN PC4 and SFRS1-interacting protein (PSIP1) DM9RIF4 MA Inhibitor DM9RIF4 RN Antiviral compounds. US9132129. DM9RIF4 RU http://www.freepatentsonline.com/US9132129.html DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TTJUALD DM9RSDX TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TT6VZ78 DM9RSDX TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TT6S2FE DM9RSDX TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RZSH DI DM9RZSH DM9RZSH DN PMID25980951-Compound-4 DM9RZSH TI TTR7B60 DM9RZSH TN X-linked inhibitor of apoptosis protein (XIAP) DM9RZSH MA Antagonist DM9RZSH RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM9RZSH RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM9RZSH DI DM9RZSH DM9RZSH DN PMID25980951-Compound-4 DM9RZSH TI TTQ5LRD DM9RZSH TN Cellular inhibitor of apoptosis 1 (BIRC2) DM9RZSH MA Antagonist DM9RZSH RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM9RZSH RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM9S07A DI DM9S07A DM9S07A DN Pyrrolo[2,3-d]pyrimidine derivative 21 DM9S07A TI TTGM6VW DM9S07A TN Tyrosine-protein kinase BTK (ATK) DM9S07A MA Inhibitor DM9S07A RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM9S07A RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM9S2UP DI DM9S2UP DM9S2UP DN PMID27977313-Compound-44 DM9S2UP TI TTR7UJ3 DM9S2UP TN Cytoplasmic thioredoxin reductase (TXNRD1) DM9S2UP MA Inhibitor DM9S2UP RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM9S2UP RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM9SXYH DI DM9SXYH DM9SXYH DN Imidazopyridazine derivative 5 DM9SXYH TI TTQR74A DM9SXYH TN Proteinase activated receptor 2 (PAR2) DM9SXYH MA Antagonist DM9SXYH RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM9SXYH RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM9TJR5 DI DM9TJR5 DM9TJR5 DN PMID26651364-Compound-5e DM9TJR5 TI TTTCRU2 DM9TJR5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9TJR5 MA Antagonist DM9TJR5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9TJR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9TVWJ DI DM9TVWJ DM9TVWJ DN PMID28454500-Compound-40 DM9TVWJ TI TTA6ZN2 DM9TVWJ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9TVWJ MA Activator DM9TVWJ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9TVWJ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9TVWJ DI DM9TVWJ DM9TVWJ DN PMID28454500-Compound-40 DM9TVWJ TI TT3Z6Y9 DM9TVWJ TN Cysteines of Keap1 (KEAP1 Cysteines) DM9TVWJ MA Modulator DM9TVWJ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9TVWJ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9TW5O DI DM9TW5O DM9TW5O DN Pyrimidinyl compound 2 DM9TW5O TI TTH5TC2 DM9TW5O TN NF-kappa-B-activating kinase (TBK1) DM9TW5O MA Inhibitor DM9TW5O RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM9TW5O RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM9U4OZ DI DM9U4OZ DM9U4OZ DN Gold-complexed thiosaccharide derivative 2 DM9U4OZ TI TTH8FZW DM9U4OZ TN Signal transducer and activator of transcription 3 (STAT3) DM9U4OZ MA Inhibitor DM9U4OZ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9U4OZ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9V13U DI DM9V13U DM9V13U DN PMID26560362-Compound-90 DM9V13U TI TTN9T81 DM9V13U TN Arachidonate 15-lipoxygenase (15-LOX) DM9V13U MA Inhibitor DM9V13U RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DM9V13U RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DM9VMJ3 DI DM9VMJ3 DM9VMJ3 DN PMID27841036-Compound-24 DM9VMJ3 TI TTEBCY8 DM9VMJ3 TN Poly [ADP-ribose] polymerase (PARP) DM9VMJ3 MA Inhibitor DM9VMJ3 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM9VMJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM9VXY7 DI DM9VXY7 DM9VXY7 DN PMID27828716-Compound-16 DM9VXY7 TI TTRZQE3 DM9VXY7 TN Glycogen synthase kinase-3 alpha (GSK-3A) DM9VXY7 MA Inhibitor DM9VXY7 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM9VXY7 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM9W1FO DI DM9W1FO DM9W1FO DN Beta-cyclodextrin conjugate derivative 2 DM9W1FO TI TTTCRU2 DM9W1FO TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9W1FO MA Antagonist DM9W1FO RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9W1FO RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9WMJ1 DI DM9WMJ1 DM9WMJ1 DN Ethylvanillin DM9WMJ1 TI TTGP7BY DM9WMJ1 TN Monoamine oxidase type B (MAO-B) DM9WMJ1 MA Inhibitor DM9WMJ1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9WMJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9WUH5 DI DM9WUH5 DM9WUH5 DN Bicyclo-heptan-2-amine derivative 2 DM9WUH5 TI TT9NXW4 DM9WUH5 TN Sigma intracellular receptor 2 (TMEM97) DM9WUH5 MA Ligand DM9WUH5 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9WUH5 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9XBL4 DI DM9XBL4 DM9XBL4 DN Tricyclic heterocycle derivative 4 DM9XBL4 TI TTVSYP9 DM9XBL4 TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DM9XBL4 MA Inhibitor DM9XBL4 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM9XBL4 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM9XQBG DI DM9XQBG DM9XQBG DN Quinoline carboxamide derivative 2 DM9XQBG TI TTH8FZW DM9XQBG TN Signal transducer and activator of transcription 3 (STAT3) DM9XQBG MA Inhibitor DM9XQBG RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9XQBG RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9XRYU DI DM9XRYU DM9XRYU DN PMID25656651-Compound-16a DM9XRYU TI TTS7G69 DM9XRYU TN Fusion protein Bcr-Abl (Bcr-Abl) DM9XRYU MA Inhibitor DM9XRYU RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM9XRYU RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM9XUYM DI DM9XUYM DM9XUYM DN 2,2-dimethylbenzopyran derivative 2 DM9XUYM TI TTUX68I DM9XUYM TN Hypoxia-inducible factor 1 (HIF-1) DM9XUYM MA Inhibitor DM9XUYM RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM9XUYM RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM9Y4ZV DI DM9Y4ZV DM9Y4ZV DN Piperazine derivative 7 DM9Y4ZV TI TT9NXW4 DM9Y4ZV TN Sigma intracellular receptor 2 (TMEM97) DM9Y4ZV MA Ligand DM9Y4ZV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9Y4ZV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9Y4ZV DI DM9Y4ZV DM9Y4ZV DN Piperazine derivative 7 DM9Y4ZV TI TT5TPI6 DM9Y4ZV TN Opioid receptor sigma 1 (OPRS1) DM9Y4ZV MA Ligand DM9Y4ZV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9Y4ZV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9YD0Q DI DM9YD0Q DM9YD0Q DN Diazepinone derivative 1 DM9YD0Q TI TTHS256 DM9YD0Q TN Metabotropic glutamate receptor 5 (mGluR5) DM9YD0Q MA Modulator DM9YD0Q RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM9YD0Q RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM9YI3K DI DM9YI3K DM9YI3K DN US8598210, Table XV, 1 DM9YI3K TI TT9ISBX DM9YI3K TN HIF-prolyl hydroxylase 2 (HPH-2) DM9YI3K MA Inhibitor DM9YI3K RN Prolyl hydroxylase inhibitors and methods of use. US8598210. DM9YI3K RU http://www.freepatentsonline.com/US8598210.html DM9YJWU DI DM9YJWU DM9YJWU DN 3-(phenoxymethyl) benzylamine derivative 1 DM9YJWU TI TTULVH8 DM9YJWU TN Tyrosinase (TYR) DM9YJWU MA Inhibitor DM9YJWU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM9YJWU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM9YS40 DI DM9YS40 DM9YS40 DN Aryl mannoside derivative 7 DM9YS40 TI TTTCRU2 DM9YS40 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9YS40 MA Antagonist DM9YS40 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9YS40 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9ZF3P DI DM9ZF3P DM9ZF3P DN PMID27215781-Compound-28 DM9ZF3P TI TTMSFAW DM9ZF3P TN Cannabinoid receptor 2 (CB2) DM9ZF3P MA Agonist DM9ZF3P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM9ZF3P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM9ZXOP DI DM9ZXOP DM9ZXOP DN PMID28048944-Compound-2 DM9ZXOP TI TTZN7RP DM9ZXOP TN Rho-associated protein kinase 1 (ROCK1) DM9ZXOP MA Inhibitor DM9ZXOP RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM9ZXOP RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM9ZXOP DI DM9ZXOP DM9ZXOP DN PMID28048944-Compound-2 DM9ZXOP TI TTGWKQJ DM9ZXOP TN Rho-associated protein kinase 2 (ROCK2) DM9ZXOP MA Inhibitor DM9ZXOP RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM9ZXOP RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMA02ED DI DMA02ED DMA02ED DN PMID26666989-Compound-Figure9middle07 DMA02ED TI TT8BUGW DMA02ED TN Glycogen phosphorylase (PYG) DMA02ED MA Inhibitor DMA02ED RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMA02ED RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMA04P6 DI DMA04P6 DMA04P6 DN PMID28270021-Compound-WO2014152663 701 DMA04P6 TI TTTDVOJ DMA04P6 TN Tropomyosin-related kinase A (TrkA) DMA04P6 MA Inhibitor DMA04P6 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMA04P6 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMA0RI8 DI DMA0RI8 DMA0RI8 DN PMID29649907-Compound-INT767 DMA0RI8 TI TTS4UGC DMA0RI8 TN Farnesoid X-activated receptor (FXR) DMA0RI8 MA Agonist DMA0RI8 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA0RI8 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA0RI8 DI DMA0RI8 DMA0RI8 DN PMID29649907-Compound-INT767 DMA0RI8 TI TTSDVTR DMA0RI8 TN G-protein coupled bile acid receptor 1 (GPBAR1) DMA0RI8 MA Agonist DMA0RI8 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA0RI8 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA0V4F DI DMA0V4F DMA0V4F DN Imidazopyridine derivative 6 DMA0V4F TI TTYLQ8V DMA0V4F TN Prostaglandin E synthase (PTGES) DMA0V4F MA Inhibitor DMA0V4F RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMA0V4F RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMA1FRM DI DMA1FRM DMA1FRM DN PMID28460551-Compound-3 DMA1FRM TI TTFJ8Q1 DMA1FRM TN Protein kinase C alpha (PRKCA) DMA1FRM MA Inhibitor DMA1FRM RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMA1FRM RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMA1OEF DI DMA1OEF DMA1OEF DN Phthalazine derivative 3 DMA1OEF TI TTVDSZ0 DMA1OEF TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA1OEF MA Inhibitor DMA1OEF RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMA1OEF RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMA1RP9 DI DMA1RP9 DMA1RP9 DN PMID28350212-Compound-16 DMA1RP9 TI TTZS04O DMA1RP9 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMA1RP9 MA Inhibitor DMA1RP9 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMA1RP9 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMA1RVN DI DMA1RVN DMA1RVN DN Ac-YVAD-cmk DMA1RVN TI TTCQIBE DMA1RVN TN Caspase-1 (CASP1) DMA1RVN MA Inhibitor DMA1RVN RN Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59. DMA1RVN RU https://www.ncbi.nlm.nih.gov/pubmed/28885866 DMA1S6Q DI DMA1S6Q DMA1S6Q DN Dihydropyrimidinone derivative 3 DMA1S6Q TI TTJOW1I DMA1S6Q TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMA1S6Q MA Inhibitor DMA1S6Q RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMA1S6Q RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMA25XH DI DMA25XH DMA25XH DN Dihydropyrimidinone derivative 1 DMA25XH TI TTPLTSQ DMA25XH TN Neutrophil elastase (NE) DMA25XH MA Inhibitor DMA25XH RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMA25XH RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMA2IMQ DI DMA2IMQ DMA2IMQ DN PMID25623274-Compound-WO2014132220C1 DMA2IMQ TI TTI2WET DMA2IMQ TN Platelet-derived growth factor receptor (PDGFR) DMA2IMQ MA Inhibitor DMA2IMQ RN Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9. DMA2IMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25623274 DMA2JGU DI DMA2JGU DMA2JGU DN Azaindole derivative 7 DMA2JGU TI TT7RJY8 DMA2JGU TN Xanthine dehydrogenase/oxidase (XDH) DMA2JGU MA Inhibitor DMA2JGU RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMA2JGU RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMA32GJ DI DMA32GJ DMA32GJ DN Sulfonamide derivative 10 DMA32GJ TI TTA592U DMA32GJ TN Urate anion exchanger 1 (URAT1) DMA32GJ MA Inhibitor DMA32GJ RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMA32GJ RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMA360M DI DMA360M DMA360M DN PMID28092474-Compound-33f DMA360M TI TT5ZKDI DMA360M TN Histone deacetylase 6 (HDAC6) DMA360M MA Inhibitor DMA360M RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMA360M RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMA360M DI DMA360M DMA360M DN PMID28092474-Compound-33f DMA360M TI TT6R7JZ DMA360M TN Histone deacetylase 1 (HDAC1) DMA360M MA Inhibitor DMA360M RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMA360M RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMA3BCU DI DMA3BCU DMA3BCU DN Benzazepine derivative 1 DMA3BCU TI TTWJBZ5 DMA3BCU TN 5-HT 2C receptor (HTR2C) DMA3BCU MA Agonist DMA3BCU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMA3BCU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMA3OI4 DI DMA3OI4 DMA3OI4 DN US9359293, TA DMA3OI4 TI TTLKF5M DMA3OI4 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMA3OI4 MA Inhibitor DMA3OI4 RN Methods of treatment using modulators of SIRT2. US9359293. DMA3OI4 RU http://www.freepatentsonline.com/US9359293.html DMA3PE7 DI DMA3PE7 DMA3PE7 DN Ethinyl-pyrazole derivative 2 DMA3PE7 TI TTXJ47W DMA3PE7 TN Metabotropic glutamate receptor 2 (mGluR2) DMA3PE7 MA Antagonist DMA3PE7 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMA3PE7 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMA423P DI DMA423P DMA423P DN PMID28766366-Compound-Scheme15-3 DMA423P TI TTSBVFO DMA423P TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMA423P MA Inhibitor DMA423P RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMA423P RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMA42SB DI DMA42SB DMA42SB DN 1,2,4-oxadiazole derivative 2 DMA42SB TI TTNBFWK DMA42SB TN Programmed cell death protein 1 (PD-1) DMA42SB MA Inhibitor DMA42SB RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMA42SB RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMA430E DI DMA430E DMA430E DN Azetidine-benzoxazin-3(4H)-one derivative 3 DMA430E TI TTZ963I DMA430E TN Monoglyceride lipase (MAGL) DMA430E MA Inhibitor DMA430E RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMA430E RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMA59QF DI DMA59QF DMA59QF DN PMID26666989-Compound-Figure11topright DMA59QF TI TT8BUGW DMA59QF TN Glycogen phosphorylase (PYG) DMA59QF MA Inhibitor DMA59QF RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMA59QF RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMA6BCH DI DMA6BCH DMA6BCH DN Indandione derivative 1 DMA6BCH TI TTV1C0Z DMA6BCH TN Neuropeptide S receptor (NPSR) DMA6BCH MA Antagonist DMA6BCH RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMA6BCH RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMA6H4W DI DMA6H4W DMA6H4W DN PMID29649907-Compound-9 DMA6H4W TI TTS4UGC DMA6H4W TN Farnesoid X-activated receptor (FXR) DMA6H4W MA Agonist DMA6H4W RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA6H4W RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA749P DI DMA749P DMA749P DN 3-phenyl isoquinolin-1(2H) derivative 2 DMA749P TI TTVDSZ0 DMA749P TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA749P MA Inhibitor DMA749P RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMA749P RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMA78MD DI DMA78MD DMA78MD DN Isoflavone derivative 9 DMA78MD TI TTJOMH6 DMA78MD TN Zinc finger protein GLI1 (Gli1) DMA78MD MA Inhibitor DMA78MD RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA78MD RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA78MD DI DMA78MD DMA78MD DN Isoflavone derivative 9 DMA78MD TI TT8J1S3 DMA78MD TN Smoothened homolog (SMO) DMA78MD MA Inhibitor DMA78MD RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA78MD RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA7D3K DI DMA7D3K DMA7D3K DN PMID26651364-Compound-108 DMA7D3K TI TTTCRU2 DMA7D3K TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMA7D3K MA Antagonist DMA7D3K RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMA7D3K RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMA7DI6 DI DMA7DI6 DMA7DI6 DN Imidazo bicyclic iminium derivative 2 DMA7DI6 TI TTJOMH6 DMA7DI6 TN Zinc finger protein GLI1 (Gli1) DMA7DI6 MA Inhibitor DMA7DI6 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA7DI6 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA7H63 DI DMA7H63 DMA7H63 DN PMID27551786-Compound-I DMA7H63 TI TT26PHO DMA7H63 TN Mineralocorticoid receptor (MR) DMA7H63 MA Antagonist DMA7H63 RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMA7H63 RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMA7H9T DI DMA7H9T DMA7H9T DN PMID28394193-Compound-12 DMA7H9T TI TT9MZCQ DMA7H9T TN Enhancer of zeste homolog 2 (EZH2) DMA7H9T MA Inhibitor DMA7H9T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMA7H9T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMA7H9T DI DMA7H9T DMA7H9T DN PMID28394193-Compound-12 DMA7H9T TI TTJBYRU DMA7H9T TN EZH2 Y641F mutant (EZH2 Y641F) DMA7H9T MA Inhibitor DMA7H9T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMA7H9T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMA7JB6 DI DMA7JB6 DMA7JB6 DN BDBM50054344 DMA7JB6 TI TT369M5 DMA7JB6 TN Protein-tyrosine phosphatase SHP-1 (PTPN6) DMA7JB6 MA Inhibitor DMA7JB6 RN Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). US9522881. DMA7JB6 RU http://www.freepatentsonline.com/US9522881.html DMA7OEF DI DMA7OEF DMA7OEF DN PMID28447479-Compound-10 DMA7OEF TI TTSCIM2 DMA7OEF TN Extracellular lysophospholipase D (E-NPP2) DMA7OEF MA Inhibitor DMA7OEF RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMA7OEF RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMA83QK DI DMA83QK DMA83QK DN Triazole derivative 5 DMA83QK TI TTSCIUP DMA83QK TN Oxytocin receptor (OTR) DMA83QK MA Antagonist DMA83QK RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMA83QK RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMA85UD DI DMA85UD DMA85UD DN N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1 DMA85UD TI TT5ZWB6 DMA85UD TN Dihydrodiol dehydrogenase type I (AKR1C3) DMA85UD MA Inhibitor DMA85UD RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMA85UD RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMA89WQ DI DMA89WQ DMA89WQ DN Cyclopropylamine derivative 8 DMA89WQ TI TTNR0UQ DMA89WQ TN Lysine-specific histone demethylase 1 (LSD) DMA89WQ MA Inhibitor DMA89WQ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMA89WQ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMA8BLZ DI DMA8BLZ DMA8BLZ DN MyriberineA DMA8BLZ TI TT3WG5C DMA8BLZ TN Monoamine oxidase type A (MAO-A) DMA8BLZ MA Inhibitor DMA8BLZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMA8BLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMA8G6B DI DMA8G6B DMA8G6B DN PMID25522065-Compound-5 DMA8G6B TI TTX4RTB DMA8G6B TN Melanin-concentrating hormone receptor 1 (MCHR1) DMA8G6B MA Antagonist DMA8G6B RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMA8G6B RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMA8JGP DI DMA8JGP DMA8JGP DN PMID26560530-Compound-12 DMA8JGP TI TT2F4OL DMA8JGP TN Tissue transglutaminase (TG2) DMA8JGP MA Inhibitor DMA8JGP RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMA8JGP RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMA91FM DI DMA91FM DMA91FM DN YYDJCLCSBYCSCO-UHFFFAOYSA-N DMA91FM TI TTDYP7I DMA91FM TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMA91FM MA Inhibitor DMA91FM RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DMA91FM RU http://www.freepatentsonline.com/US9150519.html DMA91IJ DI DMA91IJ DMA91IJ DN Heterocyclic-carboxamide derivative 1 DMA91IJ TI TTCZOF2 DMA91IJ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMA91IJ MA Inhibitor DMA91IJ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMA91IJ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMA91X2 DI DMA91X2 DMA91X2 DN PMID28447479-Compound-14 DMA91X2 TI TTSCIM2 DMA91X2 TN Extracellular lysophospholipase D (E-NPP2) DMA91X2 MA Inhibitor DMA91X2 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMA91X2 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMA9B0V DI DMA9B0V DMA9B0V DN Aryl azepine derivative 1 DMA9B0V TI TT9NXW4 DMA9B0V TN Sigma intracellular receptor 2 (TMEM97) DMA9B0V MA Ligand DMA9B0V RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMA9B0V RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMA9PM4 DI DMA9PM4 DMA9PM4 DN Pyrrolo[2,3-d]pyrimidine derivative 31 DMA9PM4 TI TTGM6VW DMA9PM4 TN Tyrosine-protein kinase BTK (ATK) DMA9PM4 MA Inhibitor DMA9PM4 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMA9PM4 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMA9YDK DI DMA9YDK DMA9YDK DN PMID25666693-Compound-114 DMA9YDK TI TTMI6F5 DMA9YDK TN Transient receptor potential cation channel V1 (TRPV1) DMA9YDK MA Antagonist DMA9YDK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMA9YDK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMAB2EN DI DMAB2EN DMAB2EN DN Pyrazole derivative 75 DMAB2EN TI TTJQOD7 DMAB2EN TN 5-HT 2A receptor (HTR2A) DMAB2EN MA Antagonist DMAB2EN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMAB2EN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMAB3YG DI DMAB3YG DMAB3YG DN Pyrazoline derivative 11 DMAB3YG TI TT6OEDT DMAB3YG TN Cannabinoid receptor 1 (CB1) DMAB3YG MA Antagonist DMAB3YG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMAB3YG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMAB8QF DI DMAB8QF DMAB8QF DN 1,3,4-thiadiazole derivative 1 DMAB8QF TI TT23XQV DMAB8QF TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMAB8QF MA Inhibitor DMAB8QF RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMAB8QF RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAB987 DI DMAB987 DMAB987 DN PMID28048944-Compound-5 DMAB987 TI TTZN7RP DMAB987 TN Rho-associated protein kinase 1 (ROCK1) DMAB987 MA Inhibitor DMAB987 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMAB987 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMAB987 DI DMAB987 DMAB987 DN PMID28048944-Compound-5 DMAB987 TI TTGWKQJ DMAB987 TN Rho-associated protein kinase 2 (ROCK2) DMAB987 MA Inhibitor DMAB987 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMAB987 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMACWQY DI DMACWQY DMACWQY DN PMID25991433-Compound-G4 DMACWQY TI TT0K6EO DMACWQY TN Stress-activated protein kinase JNK1 (JNK1) DMACWQY MA Inhibitor DMACWQY RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMACWQY RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAD3VL DI DMAD3VL DMAD3VL DN US9695118, 8 DMAD3VL TI TTI1FPZ DMAD3VL TN Epithelial discoidin domain receptor 1 (DDR1) DMAD3VL MA Inhibitor DMAD3VL RN Benzamide derivative. US9695118. DMAD3VL RU http://www.freepatentsonline.com/US9695118.html DMADMWB DI DMADMWB DMADMWB DN PMID28092474-Compound-32m DMADMWB TI TT6R7JZ DMADMWB TN Histone deacetylase 1 (HDAC1) DMADMWB MA Inhibitor DMADMWB RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMADMWB RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMADMWB DI DMADMWB DMADMWB DN PMID28092474-Compound-32m DMADMWB TI TT5ZKDI DMADMWB TN Histone deacetylase 6 (HDAC6) DMADMWB MA Inhibitor DMADMWB RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMADMWB RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMAE6CK DI DMAE6CK DMAE6CK DN US20160326143, 28 DMAE6CK TI TTW7OTG DMAE6CK TN Leukotriene C4 synthase (LTC4S) DMAE6CK MA Inhibitor DMAE6CK RN COMPOUNDS AND USES. US20160326143. DMAE6CK RU http://www.freepatentsonline.com/US20160326143.html DMAEBJ4 DI DMAEBJ4 DMAEBJ4 DN Benzamide derivative 15 DMAEBJ4 TI TTYLQ8V DMAEBJ4 TN Prostaglandin E synthase (PTGES) DMAEBJ4 MA Inhibitor DMAEBJ4 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMAEBJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMAEHCP DI DMAEHCP DMAEHCP DN US8791257, 38 DMAEHCP TI TTR93NU DMAEHCP TN Casein kinase II alpha prime (CSNK2A2) DMAEHCP MA Inhibitor DMAEHCP RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMAEHCP RU http://www.freepatentsonline.com/US8791257.html DMAEPD4 DI DMAEPD4 DMAEPD4 DN PMID29671355-Compound-15 DMAEPD4 TI TT5ZKDI DMAEPD4 TN Histone deacetylase 6 (HDAC6) DMAEPD4 MA Inhibitor DMAEPD4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMAEPD4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAEQ0I DI DMAEQ0I DMAEQ0I DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2 DMAEQ0I TI TTULVH8 DMAEQ0I TN Tyrosinase (TYR) DMAEQ0I MA Inhibitor DMAEQ0I RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAEQ0I RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAEYNT DI DMAEYNT DMAEYNT DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 DMAEYNT TI TTJW4LU DMAEYNT TN Phosphodiesterase 10A (PDE10) DMAEYNT MA Inhibitor DMAEYNT RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMAEYNT RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMAEYNT DI DMAEYNT DMAEYNT DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 DMAEYNT TI TTJGW1Z DMAEYNT TN Phosphodiesterase 2A (PDE2A) DMAEYNT MA Inhibitor DMAEYNT RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMAEYNT RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMAEZB1 DI DMAEZB1 DMAEZB1 DN PMID25514969-Compound-9 DMAEZB1 TI TT4EB85 DMAEZB1 TN Cholesterol 24-hydroxylase (CYP46A1) DMAEZB1 MA Inhibitor DMAEZB1 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMAEZB1 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMAFE5R DI DMAFE5R DMAFE5R DN Thiazolopyridine derivative 1 DMAFE5R TI TTBYWP2 DMAFE5R TN TYK2 tyrosine kinase (TYK2) DMAFE5R MA Inhibitor DMAFE5R RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAFE5R RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAFZLP DI DMAFZLP DMAFZLP DN PMID25991433-Compound-P3 DMAFZLP TI TTVOE6D DMAFZLP TN Mitogen-activated protein kinase (MAPK) DMAFZLP MA Inhibitor DMAFZLP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMAFZLP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAGKNJ DI DMAGKNJ DMAGKNJ DN PMID27774824-Compound-Figure12Example1 DMAGKNJ TI TTGM6VW DMAGKNJ TN Tyrosine-protein kinase BTK (ATK) DMAGKNJ MA Inhibitor DMAGKNJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMAGKNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMAGKNJ DI DMAGKNJ DMAGKNJ DN PMID27774824-Compound-Figure12Example1 DMAGKNJ TI TTT7PJU DMAGKNJ TN Janus kinase 3 (JAK-3) DMAGKNJ MA Inhibitor DMAGKNJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMAGKNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMAGNEH DI DMAGNEH DMAGNEH DN US8987457, 15 DMAGNEH TI TTCGOIN DMAGNEH TN PIM-3 protein kinase (PIM3) DMAGNEH MA Inhibitor DMAGNEH RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DMAGNEH RU http://www.freepatentsonline.com/US8987457.html DMAGVHX DI DMAGVHX DMAGVHX DN PMID28454500-Compound-3 DMAGVHX TI TTA6ZN2 DMAGVHX TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAGVHX MA Activator DMAGVHX RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAGVHX RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAGVHX DI DMAGVHX DMAGVHX DN PMID28454500-Compound-3 DMAGVHX TI TT3Z6Y9 DMAGVHX TN Cysteines of Keap1 (KEAP1 Cysteines) DMAGVHX MA Modulator DMAGVHX RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAGVHX RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAH1EP DI DMAH1EP DMAH1EP DN Dihydroxyfumaric acid derivative 1 DMAH1EP TI TTULVH8 DMAH1EP TN Tyrosinase (TYR) DMAH1EP MA Inhibitor DMAH1EP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAH1EP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAH1G7 DI DMAH1G7 DMAH1G7 DN PMID25468267-Compound-52 DMAH1G7 TI TT0RGE9 DMAH1G7 TN Lysine-specific demethylase 4 (KDM4) DMAH1G7 MA Inhibitor DMAH1G7 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAH1G7 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAH435 DI DMAH435 DMAH435 DN Quinazoline derivative 11 DMAH435 TI TTQR74A DMAH435 TN Proteinase activated receptor 2 (PAR2) DMAH435 MA Antagonist DMAH435 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMAH435 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMAH4P8 DI DMAH4P8 DMAH4P8 DN Quinoline derivative 13 DMAH4P8 TI TT473XN DMAH4P8 TN P2X purinoceptor 7 (P2RX7) DMAH4P8 MA Antagonist DMAH4P8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAH4P8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAH4P8 DI DMAH4P8 DMAH4P8 DN Quinoline derivative 13 DMAH4P8 TI TTQ6VDM DMAH4P8 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMAH4P8 MA Antagonist DMAH4P8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAH4P8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAH982 DI DMAH982 DMAH982 DN PMID29671355-Compound-47c DMAH982 TI TTTQGH8 DMAH982 TN Histone deacetylase 4 (HDAC4) DMAH982 MA Inhibitor DMAH982 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMAH982 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTT7PJU DMAHFXV TN Janus kinase 3 (JAK-3) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTRMX3V DMAHFXV TN Janus kinase 2 (JAK-2) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TT6DM01 DMAHFXV TN Janus kinase 1 (JAK-1) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTBYWP2 DMAHFXV TN TYK2 tyrosine kinase (TYK2) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAI19Z DI DMAI19Z DMAI19Z DN PMID25468267-Compound-56 DMAI19Z TI TTV8CRH DMAI19Z TN Lysine-specific demethylase 4C (KDM4C) DMAI19Z MA Inhibitor DMAI19Z RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAI19Z RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAI95U DI DMAI95U DMAI95U DN PMID25656651-Compound-5 DMAI95U TI TTS7G69 DMAI95U TN Fusion protein Bcr-Abl (Bcr-Abl) DMAI95U MA Inhibitor DMAI95U RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAI95U RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAIGJP DI DMAIGJP DMAIGJP DN PMID28454500-Compound-32 DMAIGJP TI TTA6ZN2 DMAIGJP TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAIGJP MA Activator DMAIGJP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAIGJP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAIGJP DI DMAIGJP DMAIGJP DN PMID28454500-Compound-32 DMAIGJP TI TT3Z6Y9 DMAIGJP TN Cysteines of Keap1 (KEAP1 Cysteines) DMAIGJP MA Modulator DMAIGJP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAIGJP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAIJHC DI DMAIJHC DMAIJHC DN Benzamide derivative 8 DMAIJHC TI TT9NXW4 DMAIJHC TN Sigma intracellular receptor 2 (TMEM97) DMAIJHC MA Ligand DMAIJHC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAIJHC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAIJHC DI DMAIJHC DMAIJHC DN Benzamide derivative 8 DMAIJHC TI TT5TPI6 DMAIJHC TN Opioid receptor sigma 1 (OPRS1) DMAIJHC MA Ligand DMAIJHC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAIJHC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAIKJV DI DMAIKJV DMAIKJV DN PMID25991433-Compound-Q2 DMAIKJV TI TTVOE6D DMAIKJV TN Mitogen-activated protein kinase (MAPK) DMAIKJV MA Inhibitor DMAIKJV RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMAIKJV RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAIRL2 DI DMAIRL2 DMAIRL2 DN PMID28270010-Compound-Figure16-b-1 DMAIRL2 TI TTTDVOJ DMAIRL2 TN Tropomyosin-related kinase A (TrkA) DMAIRL2 MA Inhibitor DMAIRL2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMAIRL2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMAITK3 DI DMAITK3 DMAITK3 DN Biaryl mannoside derivative 3 DMAITK3 TI TTTCRU2 DMAITK3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAITK3 MA Antagonist DMAITK3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAITK3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAIVEN DI DMAIVEN DMAIVEN DN PMID25656651-Compound-18 DMAIVEN TI TTS7G69 DMAIVEN TN Fusion protein Bcr-Abl (Bcr-Abl) DMAIVEN MA Inhibitor DMAIVEN RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAIVEN RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAJ74C DI DMAJ74C DMAJ74C DN Bicyclic pyrimidine derivative 1 DMAJ74C TI TTJOW1I DMAJ74C TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMAJ74C MA Inhibitor DMAJ74C RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMAJ74C RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMAJFDT DI DMAJFDT DMAJFDT DN Hydroxyqunoline analog 1 DMAJFDT TI TTWAQBO DMAJFDT TN Lysine-specific demethylase 4E (KDM4E) DMAJFDT MA Inhibitor DMAJFDT RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAJFDT RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAJLM1 DI DMAJLM1 DMAJLM1 DN Peptide analog 65 DMAJLM1 TI TTPLTSQ DMAJLM1 TN Neutrophil elastase (NE) DMAJLM1 MA Inhibitor DMAJLM1 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMAJLM1 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMAJRP1 DI DMAJRP1 DMAJRP1 DN PMID27841045-Compound-145 DMAJRP1 TI TT7RJY8 DMAJRP1 TN Xanthine dehydrogenase/oxidase (XDH) DMAJRP1 MA Inhibitor DMAJRP1 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMAJRP1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMALDZ6 DI DMALDZ6 DMALDZ6 DN Fused heterocyclic compound 10 DMALDZ6 TI TT7RJY8 DMALDZ6 TN Xanthine dehydrogenase/oxidase (XDH) DMALDZ6 MA Inhibitor DMALDZ6 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMALDZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMALF06 DI DMALF06 DMALF06 DN Aromatic bicyclic compound 5 DMALF06 TI TT6PKBN DMALF06 TN Proto-oncogene c-Src (SRC) DMALF06 MA Inhibitor DMALF06 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMALF06 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMALF06 DI DMALF06 DMALF06 DN Aromatic bicyclic compound 5 DMALF06 TI TTRMX3V DMALF06 TN Janus kinase 2 (JAK-2) DMALF06 MA Inhibitor DMALF06 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMALF06 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMALOEW DI DMALOEW DMALOEW DN PMID29649907-Compound-25 DMALOEW TI TTS4UGC DMALOEW TN Farnesoid X-activated receptor (FXR) DMALOEW MA Agonist DMALOEW RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMALOEW RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TT6R7JZ DMALXYR TN Histone deacetylase 1 (HDAC1) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TT5ZKDI DMALXYR TN Histone deacetylase 6 (HDAC6) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TTT6LFV DMALXYR TN Histone deacetylase 8 (HDAC8) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAM0US DI DMAM0US DMAM0US DN PMID29338548-Compound-37 DMAM0US TI TTHJTF7 DMAM0US TN Glycine transporter GlyT-1 (SLC6A9) DMAM0US MA Inhibitor DMAM0US RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMAM0US RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMAM50X DI DMAM50X DMAM50X DN Piperidinone derivative 1 DMAM50X TI TT473XN DMAM50X TN P2X purinoceptor 7 (P2RX7) DMAM50X MA Antagonist DMAM50X RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAM50X RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAM51Z DI DMAM51Z DMAM51Z DN US8536181, C35 DMAM51Z TI TT9ISBX DMAM51Z TN HIF-prolyl hydroxylase 2 (HPH-2) DMAM51Z MA Inhibitor DMAM51Z RN Prolyl hydroxylase inhibitors. US8536181. DMAM51Z RU http://www.freepatentsonline.com/US8536181.html DMAM6YC DI DMAM6YC DMAM6YC DN Indole-based analog 10 DMAM6YC TI TTPTXIN DMAM6YC TN Translocator protein (TSPO) DMAM6YC MA Ligand DMAM6YC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMAM6YC RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMAM7Y2 DI DMAM7Y2 DMAM7Y2 DN Tetra-hydro-pyrazolopyrazine derivative 5 DMAM7Y2 TI TTHS256 DMAM7Y2 TN Metabotropic glutamate receptor 5 (mGluR5) DMAM7Y2 MA Modulator DMAM7Y2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMAM7Y2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMAMRPW DI DMAMRPW DMAMRPW DN PMID25522065-Compound-9 DMAMRPW TI TTX4RTB DMAMRPW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAMRPW MA Antagonist DMAMRPW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAMRPW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAN3BT DI DMAN3BT DMAN3BT DN PMID25522065-Compound-16 DMAN3BT TI TTX4RTB DMAN3BT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAN3BT MA Antagonist DMAN3BT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAN3BT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAN71J DI DMAN71J DMAN71J DN PMID27967267-Compound-7 DMAN71J TI TT1RS9F DMAN71J TN Acetylcholinesterase (AChE) DMAN71J MA Inhibitor DMAN71J RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMAN71J RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMAN7CG DI DMAN7CG DMAN7CG DN PMID27454349-Compound-91 DMAN7CG TI TTK59TV DMAN7CG TN Vitamin D3 receptor (VDR) DMAN7CG MA Agonist DMAN7CG RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMAN7CG RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMANFK8 DI DMANFK8 DMANFK8 DN US9024044, 4 DMANFK8 TI TTXL0GC DMANFK8 TN Enteropeptidase (TMPRSS15) DMANFK8 MA Inhibitor DMANFK8 RN Heteroarylcarboxylic acid ester derivative. US9655879. DMANFK8 RU http://www.freepatentsonline.com/US9655879.html DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT7MRDV DMAOF0W TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT8FYO9 DMAOF0W TN Platelet-derived growth factor receptor alpha (PDGFRA) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TTX41N9 DMAOF0W TN Tyrosine-protein kinase Kit (KIT) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT4DXQT DMAOF0W TN Proto-oncogene c-Ret (RET) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAP1DN DI DMAP1DN DMAP1DN DN US10087167, Compound 4001 DMAP1DN TI TTQFZWR DMAP1DN TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMAP1DN MA Inhibitor DMAP1DN RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMAP1DN RU http://www.freepatentsonline.com/US10087167.html DMAP6YS DI DMAP6YS DMAP6YS DN Urea and carbamate bioisostere derivative 11 DMAP6YS TI TTL7C8Q DMAP6YS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMAP6YS MA Inhibitor DMAP6YS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMAP6YS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMAPGBF DI DMAPGBF DMAPGBF DN US8592431, 457 DMAPGBF TI TTLJKZ0 DMAPGBF TN Acetyl-CoA transporter (SLC33A1) DMAPGBF MA Inhibitor DMAPGBF RN Fused ring compound and use thereof. US8592431. DMAPGBF RU http://www.freepatentsonline.com/US8592431.html DMAPMG2 DI DMAPMG2 DMAPMG2 DN PMID28870136-Compound-37 DMAPMG2 TI TTK0O6Y DMAPMG2 TN Ecto-5'-nucleotidase (CD73) DMAPMG2 MA Inhibitor DMAPMG2 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMAPMG2 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMAQBJP DI DMAQBJP DMAQBJP DN Fused aryl carbocycle derivative 2 DMAQBJP TI TT9NXW4 DMAQBJP TN Sigma intracellular receptor 2 (TMEM97) DMAQBJP MA Ligand DMAQBJP RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAQBJP RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAQHI5 DI DMAQHI5 DMAQHI5 DN PMID25684022-Compound-WO2011137219 36(3-5) DMAQHI5 TI TTCZOF2 DMAQHI5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMAQHI5 MA Inhibitor DMAQHI5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMAQHI5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMAR2OX DI DMAR2OX DMAR2OX DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1 DMAR2OX TI TTVDSZ0 DMAR2OX TN Poly [ADP-ribose] polymerase 1 (PARP1) DMAR2OX MA Inhibitor DMAR2OX RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMAR2OX RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMARHJ9 DI DMARHJ9 DMARHJ9 DN N-(indolylcarbonyl)-piperidine derivative 1 DMARHJ9 TI TT5ZWB6 DMARHJ9 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMARHJ9 MA Inhibitor DMARHJ9 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMARHJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMARLZ6 DI DMARLZ6 DMARLZ6 DN Imidazo[1,2-b]pyridazine acetamide derivative 3 DMARLZ6 TI TTPTXIN DMARLZ6 TN Translocator protein (TSPO) DMARLZ6 MA Ligand DMARLZ6 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMARLZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMARU0E DI DMARU0E DMARU0E DN Macrocycle derivative 9 DMARU0E TI TT23XQV DMARU0E TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMARU0E MA Inhibitor DMARU0E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMARU0E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMARU0E DI DMARU0E DMARU0E DN Macrocycle derivative 9 DMARU0E TI TT5YPJF DMARU0E TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMARU0E MA Inhibitor DMARU0E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMARU0E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAS01P DI DMAS01P DMAS01P DN N-acylpiperidine ether derivative 6 DMAS01P TI TTTDVOJ DMAS01P TN Tropomyosin-related kinase A (TrkA) DMAS01P MA Inhibitor DMAS01P RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMAS01P RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMASGR1 DI DMASGR1 DMASGR1 DN Pyrimidine derivative 13 DMASGR1 TI TTUTJGQ DMASGR1 TN Vascular endothelial growth factor receptor 2 (KDR) DMASGR1 MA Inhibitor DMASGR1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMASGR1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMASV8I DI DMASV8I DMASV8I DN PMID28394193-Compound-43 DMASV8I TI TT9MZCQ DMASV8I TN Enhancer of zeste homolog 2 (EZH2) DMASV8I MA Inhibitor DMASV8I RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMASV8I RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMASXR5 DI DMASXR5 DMASXR5 DN Indoline derivative 2 DMASXR5 TI TT5OU0D DMASXR5 TN PRKR-like endoplasmic reticulum kinase (PERK) DMASXR5 MA Inhibitor DMASXR5 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMASXR5 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMAT9NE DI DMAT9NE DMAT9NE DN Mycophenolic acid/nucleotide derivative 2 DMAT9NE TI TTL7C8Q DMAT9NE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMAT9NE MA Inhibitor DMAT9NE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMAT9NE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMATBZW DI DMATBZW DMATBZW DN Benzene sulfonamide derivative 16 DMATBZW TI TTA592U DMATBZW TN Urate anion exchanger 1 (URAT1) DMATBZW MA Inhibitor DMATBZW RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMATBZW RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMATU1X DI DMATU1X DMATU1X DN Benzene sulfonamide derivative 8 DMATU1X TI TTUX68I DMATU1X TN Hypoxia-inducible factor 1 (HIF-1) DMATU1X MA Inhibitor DMATU1X RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMATU1X RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMAUFS7 DI DMAUFS7 DMAUFS7 DN PMID30107136-Compound-Example14 DMAUFS7 TI TT23XQV DMAUFS7 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMAUFS7 MA Inhibitor DMAUFS7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMAUFS7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAUO6C DI DMAUO6C DMAUO6C DN PMID25522065-Compound-42 DMAUO6C TI TTX4RTB DMAUO6C TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAUO6C MA Antagonist DMAUO6C RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAUO6C RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAV4XY DI DMAV4XY DMAV4XY DN PMID25666693-Compound-87 DMAV4XY TI TTMI6F5 DMAV4XY TN Transient receptor potential cation channel V1 (TRPV1) DMAV4XY MA Antagonist DMAV4XY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMAV4XY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMAV8LM DI DMAV8LM DMAV8LM DN N-phenyl-pyrimidin-4-amine derivative 1 DMAV8LM TI TT7HF4W DMAV8LM TN Cyclin-dependent kinase 2 (CDK2) DMAV8LM MA Inhibitor DMAV8LM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMAV8LM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMAV8LM DI DMAV8LM DMAV8LM DN N-phenyl-pyrimidin-4-amine derivative 1 DMAV8LM TI TT1LVF2 DMAV8LM TN Cyclin-dependent kinase 9 (CDK9) DMAV8LM MA Inhibitor DMAV8LM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMAV8LM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTT7PJU DMAW6KU TN Janus kinase 3 (JAK-3) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTBYWP2 DMAW6KU TN TYK2 tyrosine kinase (TYK2) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTRMX3V DMAW6KU TN Janus kinase 2 (JAK-2) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TT6DM01 DMAW6KU TN Janus kinase 1 (JAK-1) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTRA6BO DMAWLGI TN Bromodomain-containing protein 4 (BRD4) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTHE657 DMAWLGI TN Bromodomain-containing protein 3 (BRD3) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTDP48B DMAWLGI TN Bromodomain-containing protein 2 (BRD2) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TT7CPI5 DMAWLGI TN Bromodomain testis-specific protein (BRDT) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWY4L DI DMAWY4L DMAWY4L DN Tetra-hydro-quinoline derivative 3 DMAWY4L TI TTE4BSY DMAWY4L TN Bromodomain and extraterminal domain protein (BET) DMAWY4L MA Inhibitor DMAWY4L RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWY4L RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAXDV5 DI DMAXDV5 DMAXDV5 DN Benzothiazepine analog 8 DMAXDV5 TI TTPTXIN DMAXDV5 TN Translocator protein (TSPO) DMAXDV5 MA Ligand DMAXDV5 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMAXDV5 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMAXKPC DI DMAXKPC DMAXKPC DN Monoaryl-1,2-diamine derivative 3 DMAXKPC TI TTZJYKH DMAXKPC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMAXKPC MA Modulator DMAXKPC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMAXKPC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMAXS57 DI DMAXS57 DMAXS57 DN PMID28117607-Compound-20 DMAXS57 TI TTK0FEA DMAXS57 TN Leucine-rich repeat kinase 2 (LRRK2) DMAXS57 MA Inhibitor DMAXS57 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMAXS57 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMAXWPS DI DMAXWPS DMAXWPS DN PMID26651364-Compound-9a DMAXWPS TI TTTCRU2 DMAXWPS TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAXWPS MA Antagonist DMAXWPS RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAXWPS RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAY4G1 DI DMAY4G1 DMAY4G1 DN 7-azaindole derivative 9 DMAY4G1 TI TTEBCY8 DMAY4G1 TN Poly [ADP-ribose] polymerase (PARP) DMAY4G1 MA Inhibitor DMAY4G1 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMAY4G1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMAYHNI DI DMAYHNI DMAYHNI DN Aminocyclopentenone compound 2 DMAYHNI TI TTRA6BO DMAYHNI TN Bromodomain-containing protein 4 (BRD4) DMAYHNI MA Inhibitor DMAYHNI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAYHNI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAYINQ DI DMAYINQ DMAYINQ DN PMID25656651-Compound-11c DMAYINQ TI TTS7G69 DMAYINQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMAYINQ MA Inhibitor DMAYINQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAYINQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAYKZ9 DI DMAYKZ9 DMAYKZ9 DN Isoxazole-based bicyclic compound 10 DMAYKZ9 TI TTE4BSY DMAYKZ9 TN Bromodomain and extraterminal domain protein (BET) DMAYKZ9 MA Inhibitor DMAYKZ9 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAYKZ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAYSNQ DI DMAYSNQ DMAYSNQ DN PMID25656651-Compound-25 DMAYSNQ TI TTS7G69 DMAYSNQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMAYSNQ MA Inhibitor DMAYSNQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAYSNQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAYT2E DI DMAYT2E DMAYT2E DN PMID29473428-Compound-48 DMAYT2E TI TTZJYKH DMAYT2E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMAYT2E MA Inhibitor DMAYT2E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMAYT2E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMAZ6DI DI DMAZ6DI DMAZ6DI DN Monoamine derivative 2 DMAZ6DI TI TTULVH8 DMAZ6DI TN Tyrosinase (TYR) DMAZ6DI MA Inhibitor DMAZ6DI RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAZ6DI RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAZI3D DI DMAZI3D DMAZI3D DN Pyrazolo[1,5-a]pyrimidine derivative 15 DMAZI3D TI TTTDVOJ DMAZI3D TN Tropomyosin-related kinase A (TrkA) DMAZI3D MA Inhibitor DMAZI3D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMAZI3D RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMAZIY6 DI DMAZIY6 DMAZIY6 DN PMID26651364-Compound-5f DMAZIY6 TI TTTCRU2 DMAZIY6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAZIY6 MA Antagonist DMAZIY6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAZIY6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAZOH4 DI DMAZOH4 DMAZOH4 DN Diterpenoid derivative 1 DMAZOH4 TI TTA6ZN2 DMAZOH4 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAZOH4 MA Activator DMAZOH4 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAZOH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAZOH4 DI DMAZOH4 DMAZOH4 DN Diterpenoid derivative 1 DMAZOH4 TI TT3Z6Y9 DMAZOH4 TN Cysteines of Keap1 (KEAP1 Cysteines) DMAZOH4 MA Modulator DMAZOH4 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAZOH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TT36ETB DMAZVHJ TN Cathepsin L (CTSL) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TTF2LRI DMAZVHJ TN Cathepsin B (CTSB) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TTUMQVO DMAZVHJ TN Cathepsin S (CTSS) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMB018S DI DMB018S DMB018S DN PMID27744724-Compound-28 DMB018S TI TTL53M6 DMB018S TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMB018S MA Inhibitor DMB018S RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMB018S RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMB08D3 DI DMB08D3 DMB08D3 DN Bidentate ligands of Markush derivative 1 DMB08D3 TI TTK0FEA DMB08D3 TN Leucine-rich repeat kinase 2 (LRRK2) DMB08D3 MA Inhibitor DMB08D3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMB08D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMB08D3 DI DMB08D3 DMB08D3 DN Bidentate ligands of Markush derivative 1 DMB08D3 TI TTVOE6D DMB08D3 TN Mitogen-activated protein kinase (MAPK) DMB08D3 MA Inhibitor DMB08D3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMB08D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMB0D1H DI DMB0D1H DMB0D1H DN Six-membered heterocyclic benzamide derivative 4 DMB0D1H TI TTTDVOJ DMB0D1H TN Tropomyosin-related kinase A (TrkA) DMB0D1H MA Inhibitor DMB0D1H RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMB0D1H RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMB0DS5 DI DMB0DS5 DMB0DS5 DN PMID25726713-Compound-21 DMB0DS5 TI TT8J1S3 DMB0DS5 TN Smoothened homolog (SMO) DMB0DS5 MA Inhibitor DMB0DS5 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMB0DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMB0NVQ DI DMB0NVQ DMB0NVQ DN Steroid derivative 1 DMB0NVQ TI TTUX68I DMB0NVQ TN Hypoxia-inducible factor 1 (HIF-1) DMB0NVQ MA Inhibitor DMB0NVQ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMB0NVQ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMB0S52 DI DMB0S52 DMB0S52 DN PMID27019002-Compound-7 DMB0S52 TI TTNR0UQ DMB0S52 TN Lysine-specific histone demethylase 1 (LSD) DMB0S52 MA Inhibitor DMB0S52 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMB0S52 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMB18V5 DI DMB18V5 DMB18V5 DN PMID27774824-Compound-Figure6Example6 DMB18V5 TI TT6DM01 DMB18V5 TN Janus kinase 1 (JAK-1) DMB18V5 MA Inhibitor DMB18V5 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMB18V5 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMB18V5 DI DMB18V5 DMB18V5 DN PMID27774824-Compound-Figure6Example6 DMB18V5 TI TTRMX3V DMB18V5 TN Janus kinase 2 (JAK-2) DMB18V5 MA Inhibitor DMB18V5 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMB18V5 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMB1EAW DI DMB1EAW DMB1EAW DN 6,6-fused nitrogenous heterocyclic compound 2 DMB1EAW TI TT3PJMV DMB1EAW TN Tyrosine-protein kinase ABL1 (ABL) DMB1EAW MA Inhibitor DMB1EAW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMB1EAW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMB1JG2 DI DMB1JG2 DMB1JG2 DN 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1 DMB1JG2 TI TTOHSBA DMB1JG2 TN Vascular endothelial growth factor A (VEGFA) DMB1JG2 MA Inhibitor DMB1JG2 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMB1JG2 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMB1L32 DI DMB1L32 DMB1L32 DN Benzimidazole carboxamide derivative 1 DMB1L32 TI TTVDSZ0 DMB1L32 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMB1L32 MA Inhibitor DMB1L32 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB1L32 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB1T6S DI DMB1T6S DMB1T6S DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2 DMB1T6S TI TTXJ47W DMB1T6S TN Metabotropic glutamate receptor 2 (mGluR2) DMB1T6S MA Antagonist DMB1T6S RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMB1T6S RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMB1WQZ DI DMB1WQZ DMB1WQZ DN 7-azaindole derivative 7 DMB1WQZ TI TT056SO DMB1WQZ TN Stress-activated protein kinase JNK3 (JNK3) DMB1WQZ MA Inhibitor DMB1WQZ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMB1WQZ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMB2INX DI DMB2INX DMB2INX DN Geminally-substituted cyanoethylpypazolo pyridone derivative 2 DMB2INX TI TTRMX3V DMB2INX TN Janus kinase 2 (JAK-2) DMB2INX MA Inhibitor DMB2INX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMB2INX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMB2INX DI DMB2INX DMB2INX DN Geminally-substituted cyanoethylpypazolo pyridone derivative 2 DMB2INX TI TT6DM01 DMB2INX TN Janus kinase 1 (JAK-1) DMB2INX MA Inhibitor DMB2INX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMB2INX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMB2MH3 DI DMB2MH3 DMB2MH3 DN PMID26924192-Compound-51 DMB2MH3 TI TTE4BSY DMB2MH3 TN Bromodomain and extraterminal domain protein (BET) DMB2MH3 MA Inhibitor DMB2MH3 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMB2MH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMB2MIT DI DMB2MIT DMB2MIT DN PMID25980951-Compound-15 DMB2MIT TI TTR7B60 DMB2MIT TN X-linked inhibitor of apoptosis protein (XIAP) DMB2MIT MA Antagonist DMB2MIT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB2MIT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB2RKC DI DMB2RKC DMB2RKC DN Cyclopropylamine derivative 6 DMB2RKC TI TTNR0UQ DMB2RKC TN Lysine-specific histone demethylase 1 (LSD) DMB2RKC MA Inhibitor DMB2RKC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMB2RKC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMB2RML DI DMB2RML DMB2RML DN PMID25666693-Compound-107 DMB2RML TI TTMI6F5 DMB2RML TN Transient receptor potential cation channel V1 (TRPV1) DMB2RML MA Antagonist DMB2RML RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMB2RML RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMB3806 DI DMB3806 DMB3806 DN 3-substituted-1,2,4-oxadiazole derivative 2 DMB3806 TI TT23XQV DMB3806 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMB3806 MA Inhibitor DMB3806 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMB3806 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMB3DMR DI DMB3DMR DMB3DMR DN PMID25482888-Compound-56 DMB3DMR TI TTDIGC1 DMB3DMR TN Dipeptidyl peptidase 4 (DPP-4) DMB3DMR MA Inhibitor DMB3DMR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMB3DMR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMB3IZT DI DMB3IZT DMB3IZT DN PMID25980951-Compound-5 DMB3IZT TI TTR7B60 DMB3IZT TN X-linked inhibitor of apoptosis protein (XIAP) DMB3IZT MA Antagonist DMB3IZT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB3IZT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB3IZT DI DMB3IZT DMB3IZT DN PMID25980951-Compound-5 DMB3IZT TI TTQ5LRD DMB3IZT TN Cellular inhibitor of apoptosis 1 (BIRC2) DMB3IZT MA Antagonist DMB3IZT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB3IZT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTQ4V96 DMB40HC TN Poly [ADP-ribose] polymerase 2 (PARP2) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTD8MEH DMB40HC TN Poly [ADP-ribose] polymerase 3 (PARP3) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTVDSZ0 DMB40HC TN Poly [ADP-ribose] polymerase 1 (PARP1) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB4JS7 DI DMB4JS7 DMB4JS7 DN US9206139, 5 DMB4JS7 TI TTYG6BU DMB4JS7 TN Aggrecanase-1 (ADAMTS4) DMB4JS7 MA Inhibitor DMB4JS7 RN Aggrecanase inhibitors. US9206139. DMB4JS7 RU http://www.freepatentsonline.com/US9206139.html DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TT49BVC DMB4LNI TN Proteasome beta-2 (PS beta-2) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TTPNACM DMB4LNI TN Proteasome beta-10 (PS beta-10) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TT68GPI DMB4LNI TN Proteasome beta-5 (PS beta-5) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4MJ0 DI DMB4MJ0 DMB4MJ0 DN US9353089, 327 DMB4MJ0 TI TTXMNHO DMB4MJ0 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMB4MJ0 MA Inhibitor DMB4MJ0 RN Compositions and methods for the treatment of malaria. US9353089. DMB4MJ0 RU http://www.freepatentsonline.com/US9353089.html DMB4SH8 DI DMB4SH8 DMB4SH8 DN PMID26666989-Compound-Figure9middle10 DMB4SH8 TI TT8BUGW DMB4SH8 TN Glycogen phosphorylase (PYG) DMB4SH8 MA Inhibitor DMB4SH8 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMB4SH8 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMB56LS DI DMB56LS DMB56LS DN PMID25666693-Compound-80 DMB56LS TI TTMI6F5 DMB56LS TN Transient receptor potential cation channel V1 (TRPV1) DMB56LS MA Antagonist DMB56LS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMB56LS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMB5F8Q DI DMB5F8Q DMB5F8Q DN Isoquinoline derivative 4 DMB5F8Q TI TTMQO60 DMB5F8Q TN Rho-associated protein kinase (ROCK) DMB5F8Q MA Inhibitor DMB5F8Q RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMB5F8Q RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMB5KLD DI DMB5KLD DMB5KLD DN Benzothiazepine analog 6 DMB5KLD TI TTPTXIN DMB5KLD TN Translocator protein (TSPO) DMB5KLD MA Ligand DMB5KLD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMB5KLD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMB5UF7 DI DMB5UF7 DMB5UF7 DN Pyrimido-indole derivative 1 DMB5UF7 TI TTE4BSY DMB5UF7 TN Bromodomain and extraterminal domain protein (BET) DMB5UF7 MA Inhibitor DMB5UF7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMB5UF7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMB5XDM DI DMB5XDM DMB5XDM DN Bicyclic heteroaryl carboxamide analog 1 DMB5XDM TI TTHS256 DMB5XDM TN Metabotropic glutamate receptor 5 (mGluR5) DMB5XDM MA Modulator DMB5XDM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMB5XDM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMB65TO DI DMB65TO DMB65TO DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 DMB65TO TI TT6OEDT DMB65TO TN Cannabinoid receptor 1 (CB1) DMB65TO RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMB65TO RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMB65TO DI DMB65TO DMB65TO DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 DMB65TO TI TTMSFAW DMB65TO TN Cannabinoid receptor 2 (CB2) DMB65TO RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMB65TO RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMB65Z4 DI DMB65Z4 DMB65Z4 DN Purine derivative 1 DMB65Z4 TI TT6OEDT DMB65Z4 TN Cannabinoid receptor 1 (CB1) DMB65Z4 MA Antagonist DMB65Z4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMB65Z4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMB6EFV DI DMB6EFV DMB6EFV DN Pyrazolo[1,5-a]pyrimidine derivative 14 DMB6EFV TI TTTDVOJ DMB6EFV TN Tropomyosin-related kinase A (TrkA) DMB6EFV MA Inhibitor DMB6EFV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMB6EFV RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMB6KS9 DI DMB6KS9 DMB6KS9 DN PMID29130358-Compound-Figure14(5) DMB6KS9 TI TTXPTJE DMB6KS9 TN Gelatinase (GEL) DMB6KS9 MA Inhibitor DMB6KS9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMB6KS9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMB6M3Y DI DMB6M3Y DMB6M3Y DN 3-benzyloxyphenyloxoacetic acid derivative 1 DMB6M3Y TI TTA592U DMB6M3Y TN Urate anion exchanger 1 (URAT1) DMB6M3Y MA Inhibitor DMB6M3Y RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMB6M3Y RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMB74LZ DI DMB74LZ DMB74LZ DN Benzonaphthyridine derivative 2 DMB74LZ TI TTCZOF2 DMB74LZ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMB74LZ MA Inhibitor DMB74LZ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMB74LZ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMB79QJ DI DMB79QJ DMB79QJ DN Salicylic acid derivative 1 DMB79QJ TI TTH8FZW DMB79QJ TN Signal transducer and activator of transcription 3 (STAT3) DMB79QJ MA Inhibitor DMB79QJ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMB79QJ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMB7WNP DI DMB7WNP DMB7WNP DN PMID28394193-Compound-34 DMB7WNP TI TT9MZCQ DMB7WNP TN Enhancer of zeste homolog 2 (EZH2) DMB7WNP MA Inhibitor DMB7WNP RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMB7WNP RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMB8673 DI DMB8673 DMB8673 DN Indirubin derivative 1 DMB8673 TI TTLRFIH DMB8673 TN Signal transducer and activator of transcription 5 (STAT5) DMB8673 MA Inhibitor DMB8673 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMB8673 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMB87WZ DI DMB87WZ DMB87WZ DN PMID25772215-Compound-US02014179750TG7-112-2 DMB87WZ TI TT1ZAVI DMB87WZ TN Prostaglandin E2 receptor EP2 (PTGER2) DMB87WZ MA Antagonist DMB87WZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMB87WZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMB8AJP DI DMB8AJP DMB8AJP DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 DMB8AJP TI TTJW4LU DMB8AJP TN Phosphodiesterase 10A (PDE10) DMB8AJP MA Inhibitor DMB8AJP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMB8AJP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMB8AJP DI DMB8AJP DMB8AJP DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 DMB8AJP TI TTJGW1Z DMB8AJP TN Phosphodiesterase 2A (PDE2A) DMB8AJP MA Inhibitor DMB8AJP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMB8AJP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMB8GHJ DI DMB8GHJ DMB8GHJ DN PMID29334795-Compound-58 DMB8GHJ TI TT9JNIC DMB8GHJ TN Histamine H3 receptor (H3R) DMB8GHJ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMB8GHJ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTH6V3D DMB8MNU TN Cyclin-dependent kinase 1 (CDK1) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTRSMW9 DMB8MNU TN Glycogen synthase kinase-3 beta (GSK-3B) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TT4TQBX DMB8MNU TN Extracellular signal-regulated kinase 2 (ERK2) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTRZQE3 DMB8MNU TN Glycogen synthase kinase-3 alpha (GSK-3A) DMB8MNU MA Inhibitor DMB8MNU RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMB8MNU RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMB92RA DI DMB92RA DMB92RA DN PMID26161698-Compound-17 DMB92RA TI TTMYWL7 DMB92RA TN Cyclin-dependent kinase 3 (CDK3) DMB92RA MA Inhibitor DMB92RA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMB92RA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMB92RA DI DMB92RA DMB92RA DN PMID26161698-Compound-17 DMB92RA TI TT0PG8F DMB92RA TN Cyclin-dependent kinase 4 (CDK4) DMB92RA MA Inhibitor DMB92RA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMB92RA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMB93QU DI DMB93QU DMB93QU DN PMID25522065-Compound-28 DMB93QU TI TTX4RTB DMB93QU TN Melanin-concentrating hormone receptor 1 (MCHR1) DMB93QU MA Antagonist DMB93QU RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMB93QU RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMB9DEO DI DMB9DEO DMB9DEO DN Cyclohexyl carbamate derivative 8 DMB9DEO TI TTULVH8 DMB9DEO TN Tyrosinase (TYR) DMB9DEO MA Inhibitor DMB9DEO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMB9DEO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMB9VEH DI DMB9VEH DMB9VEH DN Benzene sulfonamide derivative 1 DMB9VEH TI TTIY56R DMB9VEH TN Kynurenine 3-hydroxylase (KMO) DMB9VEH MA Inhibitor DMB9VEH RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMB9VEH RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBA2S3 DI DMBA2S3 DMBA2S3 DN PMID29649907-Compound-44 DMBA2S3 TI TTS4UGC DMBA2S3 TN Farnesoid X-activated receptor (FXR) DMBA2S3 MA Antagonist DMBA2S3 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBA2S3 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBAHYO DI DMBAHYO DMBAHYO DN Pyrimidine derivative 6 DMBAHYO TI TTOHSBA DMBAHYO TN Vascular endothelial growth factor A (VEGFA) DMBAHYO MA Inhibitor DMBAHYO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBAHYO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBANT7 DI DMBANT7 DMBANT7 DN Cyclic sulfonamide derivative 3 DMBANT7 TI TT8J1S3 DMBANT7 TN Smoothened homolog (SMO) DMBANT7 MA Inhibitor DMBANT7 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBANT7 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBC48K DI DMBC48K DMBC48K DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5 DMBC48K TI TTULVH8 DMBC48K TN Tyrosinase (TYR) DMBC48K MA Inhibitor DMBC48K RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMBC48K RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMBC9UK DI DMBC9UK DMBC9UK DN 1,2-diamino cyclopentane-based derivative 17 DMBC9UK TI TT9N02I DMBC9UK TN Orexin receptor type 2 (HCRTR2) DMBC9UK MA Antagonist DMBC9UK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBC9UK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBC9UK DI DMBC9UK DMBC9UK DN 1,2-diamino cyclopentane-based derivative 17 DMBC9UK TI TT60Q8D DMBC9UK TN Orexin receptor type 1 (HCRTR1) DMBC9UK MA Antagonist DMBC9UK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBC9UK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBCFJU DI DMBCFJU DMBCFJU DN Peptide analog 56 DMBCFJU TI TTQAJF1 DMBCFJU TN Cathepsin G (CTSG) DMBCFJU MA Inhibitor DMBCFJU RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBCFJU RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBCFJU DI DMBCFJU DMBCFJU DN Peptide analog 56 DMBCFJU TI TTPLTSQ DMBCFJU TN Neutrophil elastase (NE) DMBCFJU MA Inhibitor DMBCFJU RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBCFJU RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBD4K9 DI DMBD4K9 DMBD4K9 DN PMID25980951-Compound-36 DMBD4K9 TI TTR7B60 DMBD4K9 TN X-linked inhibitor of apoptosis protein (XIAP) DMBD4K9 MA Antagonist DMBD4K9 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMBD4K9 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMBD4K9 DI DMBD4K9 DMBD4K9 DN PMID25980951-Compound-36 DMBD4K9 TI TTQ5LRD DMBD4K9 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMBD4K9 MA Antagonist DMBD4K9 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMBD4K9 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMBD706 DI DMBD706 DMBD706 DN PMID25656651-Compound-34b DMBD706 TI TT3PJMV DMBD706 TN Tyrosine-protein kinase ABL1 (ABL) DMBD706 MA Inhibitor DMBD706 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMBD706 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMBD95S DI DMBD95S DMBD95S DN US10059720, Example 80 DMBD95S TI TTY2KP7 DMBD95S TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMBD95S MA Inhibitor DMBD95S RN Pyridine derivative. US10059720. DMBD95S RU http://www.freepatentsonline.com/US10059720.html DMBD9S5 DI DMBD9S5 DMBD9S5 DN PMID25666693-Compound-4 DMBD9S5 TI TTMI6F5 DMBD9S5 TN Transient receptor potential cation channel V1 (TRPV1) DMBD9S5 MA Antagonist DMBD9S5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBD9S5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBE0R2 DI DMBE0R2 DMBE0R2 DN PMID25399762-Compound-Table1-C22 DMBE0R2 TI TTGP7BY DMBE0R2 TN Monoamine oxidase type B (MAO-B) DMBE0R2 MA Inhibitor DMBE0R2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBE0R2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBETU6 DI DMBETU6 DMBETU6 DN PMID27109571-Compound-17 DMBETU6 TI TTNT2S6 DMBETU6 TN Fatty acid-binding protein 5 (FABP5) DMBETU6 MA Inhibitor DMBETU6 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBETU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBETU6 DI DMBETU6 DMBETU6 DN PMID27109571-Compound-17 DMBETU6 TI TTHWMFZ DMBETU6 TN Fatty acid-binding protein 4 (FABP4) DMBETU6 MA Inhibitor DMBETU6 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBETU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBEYD1 DI DMBEYD1 DMBEYD1 DN Aryl pyrimidine derivative 9 DMBEYD1 TI TTIY56R DMBEYD1 TN Kynurenine 3-hydroxylase (KMO) DMBEYD1 MA Inhibitor DMBEYD1 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBEYD1 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBEZUY DI DMBEZUY DMBEZUY DN Pyrimidine derivative 10 DMBEZUY TI TTOHSBA DMBEZUY TN Vascular endothelial growth factor A (VEGFA) DMBEZUY MA Inhibitor DMBEZUY RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBEZUY RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBF1C0 DI DMBF1C0 DMBF1C0 DN US9006244, E1 DMBF1C0 TI TTECBXN DMBF1C0 TN Oxysterols receptor LXR-alpha (NR1H3) DMBF1C0 MA Inhibitor DMBF1C0 RN Liver X receptor modulators. US9006244. DMBF1C0 RU http://www.freepatentsonline.com/US9006244.html DMBF1OG DI DMBF1OG DMBF1OG DN PMID25726713-Compound-59 DMBF1OG TI TT8J1S3 DMBF1OG TN Smoothened homolog (SMO) DMBF1OG MA Inhibitor DMBF1OG RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBF1OG RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBF3ZE DI DMBF3ZE DMBF3ZE DN PMID30273516-Compound-39 DMBF3ZE TI TTCW0KX DMBF3ZE TN Glutaminase (GLS) DMBF3ZE MA Inhibitor DMBF3ZE RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMBF3ZE RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMBFUTL DI DMBFUTL DMBFUTL DN PMID27376512-Compound-CROs DMBFUTL TI TTHVCUP DMBFUTL TN DNA [cytosine-5]-methyltransferase (DNMT) DMBFUTL MA Inhibitor DMBFUTL RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMBFUTL RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMBGTNM DI DMBGTNM DMBGTNM DN Heteroaryl-carboxamide derivative 3 DMBGTNM TI TTCZOF2 DMBGTNM TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMBGTNM MA Inhibitor DMBGTNM RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMBGTNM RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMBH97R DI DMBH97R DMBH97R DN PMID25522065-Compound-46 DMBH97R TI TTX4RTB DMBH97R TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBH97R MA Antagonist DMBH97R RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBH97R RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBHIL2 DI DMBHIL2 DMBHIL2 DN Hydroxy amidine derivative 1 DMBHIL2 TI TTZJYKH DMBHIL2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBHIL2 MA Inhibitor DMBHIL2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBHIL2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBHJDR DI DMBHJDR DMBHJDR DN PMID27109571-Compound-39 DMBHJDR TI TTMY6L1 DMBHJDR TN Fatty acid-binding protein (FABP) DMBHJDR MA Inhibitor DMBHJDR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBHJDR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBHRUP DI DMBHRUP DMBHRUP DN PMID28270010-Compound-Figure16-a DMBHRUP TI TTTDVOJ DMBHRUP TN Tropomyosin-related kinase A (TrkA) DMBHRUP MA Inhibitor DMBHRUP RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMBHRUP RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMBHT2E DI DMBHT2E DMBHT2E DN PMID29649907-Compound-12 DMBHT2E TI TTS4UGC DMBHT2E TN Farnesoid X-activated receptor (FXR) DMBHT2E MA Agonist DMBHT2E RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBHT2E RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBIAQD DI DMBIAQD DMBIAQD DN US8829193, 2 DMBIAQD TI TTCGOIN DMBIAQD TN PIM-3 protein kinase (PIM3) DMBIAQD MA Inhibitor DMBIAQD RN PIM kinase inhibitors and methods of their use. US8829193. DMBIAQD RU http://www.freepatentsonline.com/US8829193.html DMBIK28 DI DMBIK28 DMBIK28 DN PMID30107136-Compound-Example8 DMBIK28 TI TT23XQV DMBIK28 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMBIK28 MA Inhibitor DMBIK28 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMBIK28 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMBINOJ DI DMBINOJ DMBINOJ DN PMID26651364-Compound-6b DMBINOJ TI TTTCRU2 DMBINOJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBINOJ MA Antagonist DMBINOJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBINOJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBINQ9 DI DMBINQ9 DMBINQ9 DN PMID26815044-Compound-31 DMBINQ9 TI TTULVH8 DMBINQ9 TN Tyrosinase (TYR) DMBINQ9 MA Inhibitor DMBINQ9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMBINQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMBIQMS DI DMBIQMS DMBIQMS DN PMID25666693-Compound-118 DMBIQMS TI TTMI6F5 DMBIQMS TN Transient receptor potential cation channel V1 (TRPV1) DMBIQMS MA Antagonist DMBIQMS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBIQMS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBIRMA DI DMBIRMA DMBIRMA DN 2-pyrazinone derivative 5 DMBIRMA TI TTPLTSQ DMBIRMA TN Neutrophil elastase (NE) DMBIRMA MA Inhibitor DMBIRMA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBIRMA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBJH8N DI DMBJH8N DMBJH8N DN Heteroaryl-azepine derivative 8 DMBJH8N TI TTWJBZ5 DMBJH8N TN 5-HT 2C receptor (HTR2C) DMBJH8N MA Agonist DMBJH8N RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMBJH8N RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMBKIR0 DI DMBKIR0 DMBKIR0 DN Amide derivative 2 DMBKIR0 TI TTZJYKH DMBKIR0 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBKIR0 MA Inhibitor DMBKIR0 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBKIR0 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBKNDE DI DMBKNDE DMBKNDE DN PMID27539678-Compound-6 DMBKNDE TI TTOHFIY DMBKNDE TN Sphingosine kinase 1 (SPHK1) DMBKNDE MA Inhibitor DMBKNDE RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMBKNDE RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMBKRY7 DI DMBKRY7 DMBKRY7 DN PMID25656651-Compound-29b DMBKRY7 TI TTS7G69 DMBKRY7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMBKRY7 MA Inhibitor DMBKRY7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMBKRY7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMBKSVH DI DMBKSVH DMBKSVH DN PMID28870136-Compound-64 DMBKSVH TI TTK0O6Y DMBKSVH TN Ecto-5'-nucleotidase (CD73) DMBKSVH MA Inhibitor DMBKSVH RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMBKSVH RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMBL5J9 DI DMBL5J9 DMBL5J9 DN PMID27977313-Compound-31 DMBL5J9 TI TTR7UJ3 DMBL5J9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMBL5J9 MA Inhibitor DMBL5J9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMBL5J9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMBL86O DI DMBL86O DMBL86O DN Quinoline and quinazoline derivative 9 DMBL86O TI TTOHSBA DMBL86O TN Vascular endothelial growth factor A (VEGFA) DMBL86O MA Inhibitor DMBL86O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBL86O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBLSH1 DI DMBLSH1 DMBLSH1 DN Alkyl mannoside derivative 7 DMBLSH1 TI TTTCRU2 DMBLSH1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBLSH1 MA Antagonist DMBLSH1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBLSH1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBMFPC DI DMBMFPC DMBMFPC DN Imidazo bicyclic iminium derivative 8 DMBMFPC TI TT8J1S3 DMBMFPC TN Smoothened homolog (SMO) DMBMFPC MA Inhibitor DMBMFPC RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBMFPC RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBMG1S DI DMBMG1S DMBMG1S DN Hydroxamate analog 2 DMBMG1S TI TT0RGE9 DMBMG1S TN Lysine-specific demethylase 4 (KDM4) DMBMG1S MA Inhibitor DMBMG1S RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMBMG1S RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMBMTUV DI DMBMTUV DMBMTUV DN PMID29473428-Compound-29 DMBMTUV TI TTZJYKH DMBMTUV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBMTUV MA Inhibitor DMBMTUV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBMTUV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBN3X4 DI DMBN3X4 DMBN3X4 DN PMID28766366-Compound-Scheme11 DMBN3X4 TI TTSBVFO DMBN3X4 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBN3X4 MA Inhibitor DMBN3X4 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBN3X4 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBN6KU DI DMBN6KU DMBN6KU DN PMID27336223-Compound-11 DMBN6KU TI TT1Q3IE DMBN6KU TN Retinoic acid receptor gamma (RARG) DMBN6KU MA Agonist DMBN6KU RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMBN6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMBN6W2 DI DMBN6W2 DMBN6W2 DN US10035778, Example 12 DMBN6W2 TI TTIF29E DMBN6W2 TN Integrin beta-8 (ITGB8) DMBN6W2 MA Inhibitor DMBN6W2 RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DMBN6W2 RU http://www.freepatentsonline.com/US10035778.html DMBNAK9 DI DMBNAK9 DMBNAK9 DN PMID25522065-Compound-29 DMBNAK9 TI TTX4RTB DMBNAK9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBNAK9 MA Antagonist DMBNAK9 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBNAK9 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBNHI7 DI DMBNHI7 DMBNHI7 DN PMID27967267-Compound-12 DMBNHI7 TI TT1RS9F DMBNHI7 TN Acetylcholinesterase (AChE) DMBNHI7 MA Inhibitor DMBNHI7 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMBNHI7 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMBOLSU DI DMBOLSU DMBOLSU DN 1,2-diamino cyclopentane-based derivative 33 DMBOLSU TI TT9N02I DMBOLSU TN Orexin receptor type 2 (HCRTR2) DMBOLSU MA Antagonist DMBOLSU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBOLSU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBOLSU DI DMBOLSU DMBOLSU DN 1,2-diamino cyclopentane-based derivative 33 DMBOLSU TI TT60Q8D DMBOLSU TN Orexin receptor type 1 (HCRTR1) DMBOLSU MA Antagonist DMBOLSU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBOLSU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBOX0K DI DMBOX0K DMBOX0K DN PMID27215781-Compound-2 DMBOX0K TI TT6OEDT DMBOX0K TN Cannabinoid receptor 1 (CB1) DMBOX0K MA Agonist DMBOX0K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMBOX0K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMBOX0K DI DMBOX0K DMBOX0K DN PMID27215781-Compound-2 DMBOX0K TI TTMSFAW DMBOX0K TN Cannabinoid receptor 2 (CB2) DMBOX0K MA Agonist DMBOX0K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMBOX0K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMBPT9Z DI DMBPT9Z DMBPT9Z DN PMID25468267-Compound-48 DMBPT9Z TI TT0RGE9 DMBPT9Z TN Lysine-specific demethylase 4 (KDM4) DMBPT9Z MA Inhibitor DMBPT9Z RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMBPT9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TT84OS6 DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TTYGQ8A DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TTSBVFO DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ21J DI DMBQ21J DMBQ21J DN PMID28766366-Compound-Scheme18 DMBQ21J TI TTSBVFO DMBQ21J TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBQ21J MA Inhibitor DMBQ21J RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ21J RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ981 DI DMBQ981 DMBQ981 DN PMID27551786-Compound-III DMBQ981 TI TT26PHO DMBQ981 TN Mineralocorticoid receptor (MR) DMBQ981 MA Antagonist DMBQ981 RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMBQ981 RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMBQOW4 DI DMBQOW4 DMBQOW4 DN PMID29671355-Compound-12 DMBQOW4 TI TTTQGH8 DMBQOW4 TN Histone deacetylase 4 (HDAC4) DMBQOW4 MA Inhibitor DMBQOW4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMBQOW4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMBR2Y9 DI DMBR2Y9 DMBR2Y9 DN 1,5-diphenylpyrrolidin-2-one derivative 2 DMBR2Y9 TI TT6OEDT DMBR2Y9 TN Cannabinoid receptor 1 (CB1) DMBR2Y9 MA Antagonist DMBR2Y9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMBR2Y9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMBR72X DI DMBR72X DMBR72X DN PMID29053063-Compound-14 DMBR72X TI TTDP1UC DMBR72X TN Fatty acid amide hydrolase (FAAH) DMBR72X MA Inhibitor DMBR72X RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMBR72X RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMBR72X DI DMBR72X DMBR72X DN PMID29053063-Compound-14 DMBR72X TI TTZ963I DMBR72X TN Monoglyceride lipase (MAGL) DMBR72X MA Inhibitor DMBR72X RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMBR72X RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMBRQP1 DI DMBRQP1 DMBRQP1 DN PMID29757691-Compound-2a-i DMBRQP1 TI TT1RS9F DMBRQP1 TN Acetylcholinesterase (AChE) DMBRQP1 MA Inhibitor DMBRQP1 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMBRQP1 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMBRQP1 DI DMBRQP1 DMBRQP1 DN PMID29757691-Compound-2a-i DMBRQP1 TI TTEB0GD DMBRQP1 TN Cholinesterase (BCHE) DMBRQP1 MA Inhibitor DMBRQP1 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMBRQP1 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMBRX8D DI DMBRX8D DMBRX8D DN Quinoxaline derivative 6 DMBRX8D TI TTSXVID DMBRX8D TN Nuclear factor NF-kappa-B (NFKB) DMBRX8D MA Inhibitor DMBRX8D RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMBRX8D RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMBS2FT DI DMBS2FT DMBS2FT DN PMID25482888-Compound-13 DMBS2FT TI TTDIGC1 DMBS2FT TN Dipeptidyl peptidase 4 (DPP-4) DMBS2FT MA Inhibitor DMBS2FT RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMBS2FT RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMBS4LE DI DMBS4LE DMBS4LE DN PMID25991433-Compound-K2 DMBS4LE TI TT0K6EO DMBS4LE TN Stress-activated protein kinase JNK1 (JNK1) DMBS4LE MA Inhibitor DMBS4LE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMBS4LE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMBS50K DI DMBS50K DMBS50K DN US10149841, Compound 5 DMBS50K TI TT9ISBX DMBS50K TN HIF-prolyl hydroxylase 2 (HPH-2) DMBS50K MA Inhibitor DMBS50K RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMBS50K RU http://www.freepatentsonline.com/US10149841.html DMBSOED DI DMBSOED DMBSOED DN PMID25435179-Compound-WO2012106509Tenovin-6 DMBSOED TI TTUF2HO DMBSOED TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMBSOED MA Inhibitor DMBSOED RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMBSOED RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMBSP1G DI DMBSP1G DMBSP1G DN PMID25399762-Compound-Figure3-Lycojaponicumin A DMBSP1G TI TT3WG5C DMBSP1G TN Monoamine oxidase type A (MAO-A) DMBSP1G MA Inhibitor DMBSP1G RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBSP1G RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBT4RJ DI DMBT4RJ DMBT4RJ DN 1,2,4-oxadiazole derivative 7 DMBT4RJ TI TT23XQV DMBT4RJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMBT4RJ MA Inhibitor DMBT4RJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMBT4RJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMBTZ8I DI DMBTZ8I DMBTZ8I DN PMID28621580-Compound-WO2013036866C66 DMBTZ8I TI TTOHSBA DMBTZ8I TN Vascular endothelial growth factor A (VEGFA) DMBTZ8I MA Inhibitor DMBTZ8I RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBTZ8I RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBUJ39 DI DMBUJ39 DMBUJ39 DN PMID29671355-Compound-47b DMBUJ39 TI TTTQGH8 DMBUJ39 TN Histone deacetylase 4 (HDAC4) DMBUJ39 MA Inhibitor DMBUJ39 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMBUJ39 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMBUQDR DI DMBUQDR DMBUQDR DN N-acylpiperidine ether derivative 4 DMBUQDR TI TTTDVOJ DMBUQDR TN Tropomyosin-related kinase A (TrkA) DMBUQDR MA Inhibitor DMBUQDR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMBUQDR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMBURAZ DI DMBURAZ DMBURAZ DN IncarviatoneA DMBURAZ TI TT3WG5C DMBURAZ TN Monoamine oxidase type A (MAO-A) DMBURAZ MA Inhibitor DMBURAZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBURAZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBUZHO DI DMBUZHO DMBUZHO DN PMID26394986-Compound-13 DMBUZHO TI TTH8FZW DMBUZHO TN Signal transducer and activator of transcription 3 (STAT3) DMBUZHO MA Inhibitor DMBUZHO RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMBUZHO RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMBV5Z0 DI DMBV5Z0 DMBV5Z0 DN CRWCYVOHVXAEMF-LBPRGKRZSA-N DMBV5Z0 TI TTOYT5L DMBV5Z0 TN Dipeptidyl-peptidase 7 (DPP7) DMBV5Z0 MA Inhibitor DMBV5Z0 RN FAP inhibitors. US9346814. DMBV5Z0 RU http://www.freepatentsonline.com/US9346814.html DMBVDHK DI DMBVDHK DMBVDHK DN Isoxazoline derivative 3 DMBVDHK TI TTDP1UC DMBVDHK TN Fatty acid amide hydrolase (FAAH) DMBVDHK MA Inhibitor DMBVDHK RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMBVDHK RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMBVI7L DI DMBVI7L DMBVI7L DN PMID28394193-Compound-29 DMBVI7L TI TT9MZCQ DMBVI7L TN Enhancer of zeste homolog 2 (EZH2) DMBVI7L MA Inhibitor DMBVI7L RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMBVI7L RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMBVOZK DI DMBVOZK DMBVOZK DN PMID29649907-Compound-18 DMBVOZK TI TTS4UGC DMBVOZK TN Farnesoid X-activated receptor (FXR) DMBVOZK MA Agonist DMBVOZK RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBVOZK RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBW208 DI DMBW208 DMBW208 DN Pyrrolo-pyrrolone derivative 6 DMBW208 TI TTFRCTK DMBW208 TN CREB-binding protein (CREBBP) DMBW208 MA Inhibitor DMBW208 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMBW208 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMBW36Y DI DMBW36Y DMBW36Y DN PMID25666693-Compound-38 DMBW36Y TI TTMI6F5 DMBW36Y TN Transient receptor potential cation channel V1 (TRPV1) DMBW36Y MA Antagonist DMBW36Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBW36Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBWA0V DI DMBWA0V DMBWA0V DN PMID25522065-Compound-50 DMBWA0V TI TTX4RTB DMBWA0V TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBWA0V MA Antagonist DMBWA0V RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBWA0V RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBWAV7 DI DMBWAV7 DMBWAV7 DN PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole DMBWAV7 TI TTSBVFO DMBWAV7 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBWAV7 MA Inhibitor DMBWAV7 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBWAV7 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBWH3O DI DMBWH3O DMBWH3O DN Aryl methoxyacrylate derivative 1 DMBWH3O TI TTUX68I DMBWH3O TN Hypoxia-inducible factor 1 (HIF-1) DMBWH3O MA Inhibitor DMBWH3O RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMBWH3O RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMBWJK4 DI DMBWJK4 DMBWJK4 DN US10065972, Example 281 DMBWJK4 TI TTT3IXG DMBWJK4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMBWJK4 MA Inhibitor DMBWJK4 RN Bicyclic or tricyclic heterocyclic compound. US10065972. DMBWJK4 RU http://www.freepatentsonline.com/US10065972.html DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTXNCBV DMBWLSA TN Tryptophan 2,3-dioxygenase (TDO) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTALN9W DMBWLSA TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTZJYKH DMBWLSA TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWQ8L DI DMBWQ8L DMBWQ8L DN Biphenyl mannoside derivative 25 DMBWQ8L TI TTTCRU2 DMBWQ8L TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBWQ8L MA Antagonist DMBWQ8L RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBWQ8L RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBY65W DI DMBY65W DMBY65W DN 1,2-diamino cyclopentane-based derivative 15 DMBY65W TI TT9N02I DMBY65W TN Orexin receptor type 2 (HCRTR2) DMBY65W MA Antagonist DMBY65W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBY65W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBY65W DI DMBY65W DMBY65W DN 1,2-diamino cyclopentane-based derivative 15 DMBY65W TI TT60Q8D DMBY65W TN Orexin receptor type 1 (HCRTR1) DMBY65W MA Antagonist DMBY65W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBY65W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBYTSI DI DMBYTSI DMBYTSI DN PMID26609882-Compound-34 DMBYTSI TI TTJQOD7 DMBYTSI TN 5-HT 2A receptor (HTR2A) DMBYTSI MA Antagonist DMBYTSI RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMBYTSI RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMBYWJI DI DMBYWJI DMBYWJI DN Pyrazole derivative 66 DMBYWJI TI TTH8FZW DMBYWJI TN Signal transducer and activator of transcription 3 (STAT3) DMBYWJI MA Inhibitor DMBYWJI RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMBYWJI RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT7MRDV DMBZMYT TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT8FYO9 DMBZMYT TN Platelet-derived growth factor receptor alpha (PDGFRA) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTX41N9 DMBZMYT TN Tyrosine-protein kinase Kit (KIT) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTI7421 DMBZMYT TN Platelet-derived growth factor receptor beta (PDGFRB) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT4DXQT DMBZMYT TN Proto-oncogene c-Ret (RET) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTGJCWZ DMBZMYT TN Fms-like tyrosine kinase 3 (FLT-3) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTUTJGQ DMBZMYT TN Vascular endothelial growth factor receptor 2 (KDR) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT6PKBN DMBZMYT TN Proto-oncogene c-Src (SRC) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMC075A DI DMC075A DMC075A DN PMID30107136-Compound-Example45 DMC075A TI TT23XQV DMC075A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMC075A MA Inhibitor DMC075A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMC075A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMC0PUI DI DMC0PUI DMC0PUI DN US9340511, 7 DMC0PUI TI TT9ISBX DMC0PUI TN HIF-prolyl hydroxylase 2 (HPH-2) DMC0PUI MA Inhibitor DMC0PUI RN Process for making isoquinoline compounds. US9708269. DMC0PUI RU http://www.freepatentsonline.com/US9708269.html DMC1QDB DI DMC1QDB DMC1QDB DN PMID25666693-Compound-121 DMC1QDB TI TTMI6F5 DMC1QDB TN Transient receptor potential cation channel V1 (TRPV1) DMC1QDB MA Antagonist DMC1QDB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC1QDB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC1Y2T DI DMC1Y2T DMC1Y2T DN PMID25980951-Compound-31 DMC1Y2T TI TTR7B60 DMC1Y2T TN X-linked inhibitor of apoptosis protein (XIAP) DMC1Y2T MA Antagonist DMC1Y2T RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMC1Y2T RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMC1YR5 DI DMC1YR5 DMC1YR5 DN US9493490, C DMC1YR5 TI TTAZ3MN DMC1YR5 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMC1YR5 MA Inhibitor DMC1YR5 RN Boron-containing small molecules. US9493490. DMC1YR5 RU http://www.freepatentsonline.com/US9493490.html DMC1ZIX DI DMC1ZIX DMC1ZIX DN Hexahydro azepinone derivative 1 DMC1ZIX TI TTMQO60 DMC1ZIX TN Rho-associated protein kinase (ROCK) DMC1ZIX MA Inhibitor DMC1ZIX RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMC1ZIX RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMC24OL DI DMC24OL DMC24OL DN PMID28394193-Compound-28 DMC24OL TI TT9MZCQ DMC24OL TN Enhancer of zeste homolog 2 (EZH2) DMC24OL MA Inhibitor DMC24OL RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMC24OL RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMC26MT DI DMC26MT DMC26MT DN 1,2-diamino cyclopentane-based derivative 24 DMC26MT TI TT9N02I DMC26MT TN Orexin receptor type 2 (HCRTR2) DMC26MT MA Antagonist DMC26MT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMC26MT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMC26MT DI DMC26MT DMC26MT DN 1,2-diamino cyclopentane-based derivative 24 DMC26MT TI TT60Q8D DMC26MT TN Orexin receptor type 1 (HCRTR1) DMC26MT MA Antagonist DMC26MT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMC26MT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMC27TO DI DMC27TO DMC27TO DN Mycophenolic acid/nucleotide derivative 7 DMC27TO TI TTL7C8Q DMC27TO TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMC27TO MA Inhibitor DMC27TO RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMC27TO RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMC28VB DI DMC28VB DMC28VB DN PMID26815044-Compound-118 DMC28VB TI TTULVH8 DMC28VB TN Tyrosinase (TYR) DMC28VB MA Inhibitor DMC28VB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMC28VB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMC2O0Q DI DMC2O0Q DMC2O0Q DN PMID25828189-Compound-22 DMC2O0Q TI TT9O6WS DMC2O0Q TN Glucagon receptor (GCGR) DMC2O0Q MA Antagonist DMC2O0Q RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMC2O0Q RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMC2T4H DI DMC2T4H DMC2T4H DN Diphenyl purine derivative 5 DMC2T4H TI TT6OEDT DMC2T4H TN Cannabinoid receptor 1 (CB1) DMC2T4H MA Antagonist DMC2T4H RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMC2T4H RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMC3DT7 DI DMC3DT7 DMC3DT7 DN PMID25666693-Compound-30 DMC3DT7 TI TTMI6F5 DMC3DT7 TN Transient receptor potential cation channel V1 (TRPV1) DMC3DT7 MA Antagonist DMC3DT7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC3DT7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC3E8M DI DMC3E8M DMC3E8M DN Pyrimidine derivative 3 DMC3E8M TI TTCZOF2 DMC3E8M TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMC3E8M MA Inhibitor DMC3E8M RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMC3E8M RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMC3IN2 DI DMC3IN2 DMC3IN2 DN Dihydrodiazepinocarbazolone derivative 1 DMC3IN2 TI TTVDSZ0 DMC3IN2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMC3IN2 MA Inhibitor DMC3IN2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMC3IN2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMC3IN2 DI DMC3IN2 DMC3IN2 DN Dihydrodiazepinocarbazolone derivative 1 DMC3IN2 TI TTQ4V96 DMC3IN2 TN Poly [ADP-ribose] polymerase 2 (PARP2) DMC3IN2 MA Inhibitor DMC3IN2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMC3IN2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMC3KTB DI DMC3KTB DMC3KTB DN 4-aryl quinol derivative 7 DMC3KTB TI TTR7UJ3 DMC3KTB TN Cytoplasmic thioredoxin reductase (TXNRD1) DMC3KTB MA Inhibitor DMC3KTB RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMC3KTB RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMC3NHJ DI DMC3NHJ DMC3NHJ DN PMID25980951-Compound-18 DMC3NHJ TI TTQ5LRD DMC3NHJ TN Cellular inhibitor of apoptosis 1 (BIRC2) DMC3NHJ MA Antagonist DMC3NHJ RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMC3NHJ RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMC3Q9O DI DMC3Q9O DMC3Q9O DN US9656955, Example 540 DMC3Q9O TI TTYJRN5 DMC3Q9O TN N-acetylglucosaminyltransferase I (NAGAT1) DMC3Q9O MA Inhibitor DMC3Q9O RN Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955. DMC3Q9O RU http://www.freepatentsonline.com/US9656955.html DMC3TJI DI DMC3TJI DMC3TJI DN Carbamide derivative 22 DMC3TJI TI TTOHSBA DMC3TJI TN Vascular endothelial growth factor A (VEGFA) DMC3TJI MA Inhibitor DMC3TJI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMC3TJI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMC41MA DI DMC41MA DMC41MA DN PMID27336223-Compound-14 DMC41MA TI TT1Q3IE DMC41MA TN Retinoic acid receptor gamma (RARG) DMC41MA MA Agonist DMC41MA RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMC41MA RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMC41TK DI DMC41TK DMC41TK DN Dihydropyridine compound 5 DMC41TK TI TT4DXQT DMC41TK TN Proto-oncogene c-Ret (RET) DMC41TK MA Inhibitor DMC41TK RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMC41TK RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMC48AX DI DMC48AX DMC48AX DN Peptide analog 46 DMC48AX TI TTDIGC1 DMC48AX TN Dipeptidyl peptidase 4 (DPP-4) DMC48AX MA Inhibitor DMC48AX RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC48AX RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC49SV DI DMC49SV DMC49SV DN Imidazo pyridine derivative 2 DMC49SV TI TTDIGC1 DMC49SV TN Dipeptidyl peptidase 4 (DPP-4) DMC49SV MA Inhibitor DMC49SV RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC49SV RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC4TQL DI DMC4TQL DMC4TQL DN PMID28092474-Compound-32 DMC4TQL TI TTBH0VX DMC4TQL TN Histone deacetylase (HDAC) DMC4TQL MA Inhibitor DMC4TQL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMC4TQL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMC50F3 DI DMC50F3 DMC50F3 DN PMID25772215-Compound-US02014179750M2 DMC50F3 TI TT1ZAVI DMC50F3 TN Prostaglandin E2 receptor EP2 (PTGER2) DMC50F3 MA Antagonist DMC50F3 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMC50F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMC52VP DI DMC52VP DMC52VP DN PMID27109571-Compound-22 DMC52VP TI TTHWMFZ DMC52VP TN Fatty acid-binding protein 4 (FABP4) DMC52VP MA Inhibitor DMC52VP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMC52VP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMC52VP DI DMC52VP DMC52VP DN PMID27109571-Compound-22 DMC52VP TI TTNT2S6 DMC52VP TN Fatty acid-binding protein 5 (FABP5) DMC52VP MA Inhibitor DMC52VP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMC52VP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMC5F3H DI DMC5F3H DMC5F3H DN Isoquinoline sulfonyl derivative 1 DMC5F3H TI TTMQO60 DMC5F3H TN Rho-associated protein kinase (ROCK) DMC5F3H MA Inhibitor DMC5F3H RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMC5F3H RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMC5G76 DI DMC5G76 DMC5G76 DN Oxazolo[3,4-a]pyrazine derivative 5 DMC5G76 TI TTV1C0Z DMC5G76 TN Neuropeptide S receptor (NPSR) DMC5G76 MA Antagonist DMC5G76 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMC5G76 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMC5G8P DI DMC5G8P DMC5G8P DN Phenoxypiperidine derivative 2 DMC5G8P TI TT9JNIC DMC5G8P TN Histamine H3 receptor (H3R) DMC5G8P RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC5G8P RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC5NR0 DI DMC5NR0 DMC5NR0 DN PMID28394193-Compound-20 DMC5NR0 TI TT9MZCQ DMC5NR0 TN Enhancer of zeste homolog 2 (EZH2) DMC5NR0 MA Inhibitor DMC5NR0 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMC5NR0 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMC5W1Y DI DMC5W1Y DMC5W1Y DN PMID25666693-Compound-6 DMC5W1Y TI TTMI6F5 DMC5W1Y TN Transient receptor potential cation channel V1 (TRPV1) DMC5W1Y MA Antagonist DMC5W1Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC5W1Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC64XQ DI DMC64XQ DMC64XQ DN PMID29130358-Compound-SB-3CT DMC64XQ TI TTLM12X DMC64XQ TN Matrix metalloproteinase-2 (MMP-2) DMC64XQ MA Inhibitor DMC64XQ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMC64XQ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMC64XQ DI DMC64XQ DMC64XQ DN PMID29130358-Compound-SB-3CT DMC64XQ TI TT6X50U DMC64XQ TN Matrix metalloproteinase-9 (MMP-9) DMC64XQ MA Inhibitor DMC64XQ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMC64XQ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMC67G4 DI DMC67G4 DMC67G4 DN US8669361, 103 DMC67G4 TI TTCGOIN DMC67G4 TN PIM-3 protein kinase (PIM3) DMC67G4 MA Inhibitor DMC67G4 RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMC67G4 RU http://www.freepatentsonline.com/US8669361.html DMC6AF2 DI DMC6AF2 DMC6AF2 DN PMID27019002-Compound-21a DMC6AF2 TI TTNR0UQ DMC6AF2 TN Lysine-specific histone demethylase 1 (LSD) DMC6AF2 MA Inhibitor DMC6AF2 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMC6AF2 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMC6HPV DI DMC6HPV DMC6HPV DN PMID25435285-Compound-46 DMC6HPV TI TTXJ47W DMC6HPV TN Metabotropic glutamate receptor 2 (mGluR2) DMC6HPV MA Antagonist DMC6HPV RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMC6HPV RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMC6S0W DI DMC6S0W DMC6S0W DN PMID25514969-Compound-Figure2-2 DMC6S0W TI TT4EB85 DMC6S0W TN Cholesterol 24-hydroxylase (CYP46A1) DMC6S0W MA Inhibitor DMC6S0W RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMC6S0W RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMC7AXQ DI DMC7AXQ DMC7AXQ DN PMID26560530-Compound-2 DMC7AXQ TI TT2F4OL DMC7AXQ TN Tissue transglutaminase (TG2) DMC7AXQ MA Inhibitor DMC7AXQ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMC7AXQ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMC7PTY DI DMC7PTY DMC7PTY DN SCHEMBL17766424 DMC7PTY TI TT78309 DMC7PTY TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMC7PTY MA Inhibitor DMC7PTY RN Substituted benzylpyrazoles. US9765058. DMC7PTY RU http://www.freepatentsonline.com/US9765058.html DMC7UHT DI DMC7UHT DMC7UHT DN Bidentate pyrazolopyrimidine acetamide analog 3 DMC7UHT TI TTPTXIN DMC7UHT TN Translocator protein (TSPO) DMC7UHT MA Ligand DMC7UHT RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMC7UHT RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMC812I DI DMC812I DMC812I DN US9434727, 153 DMC812I TI TT0C8BY DMC812I TN Plasma retinol-binding protein (RBP4) DMC812I MA Inhibitor DMC812I RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DMC812I RU http://www.freepatentsonline.com/US9434727.html DMC82UR DI DMC82UR DMC82UR DN PMID25482888-Compound-14 DMC82UR TI TTDIGC1 DMC82UR TN Dipeptidyl peptidase 4 (DPP-4) DMC82UR MA Inhibitor DMC82UR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC82UR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTJW4LU DMC8935 TN Phosphodiesterase 10A (PDE10) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTQ6VDM DMC8935 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTJGW1Z DMC8935 TN Phosphodiesterase 2A (PDE2A) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8OVU DI DMC8OVU DMC8OVU DN Biphenyl mannoside derivative 23 DMC8OVU TI TTTCRU2 DMC8OVU TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMC8OVU MA Antagonist DMC8OVU RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMC8OVU RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMC95N7 DI DMC95N7 DMC95N7 DN PMID29334795-Compound-67 DMC95N7 TI TT9JNIC DMC95N7 TN Histamine H3 receptor (H3R) DMC95N7 MA Inhibitor DMC95N7 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC95N7 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC95N7 DI DMC95N7 DMC95N7 DN PMID29334795-Compound-67 DMC95N7 TI TTEX248 DMC95N7 TN Dopamine D2 receptor (D2R) DMC95N7 MA Ligand DMC95N7 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC95N7 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC9TGM DI DMC9TGM DMC9TGM DN Pyrrolo[2,3-d]pyrimidine derivative 19 DMC9TGM TI TTGM6VW DMC9TGM TN Tyrosine-protein kinase BTK (ATK) DMC9TGM MA Inhibitor DMC9TGM RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMC9TGM RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMCAD64 DI DMCAD64 DMCAD64 DN Carbamide derivative 13 DMCAD64 TI TTZJYKH DMCAD64 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCAD64 MA Inhibitor DMCAD64 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCAD64 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCAS85 DI DMCAS85 DMCAS85 DN Quinoline carboxamide derivative 3 DMCAS85 TI TTH8FZW DMCAS85 TN Signal transducer and activator of transcription 3 (STAT3) DMCAS85 MA Inhibitor DMCAS85 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMCAS85 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMCAVF0 DI DMCAVF0 DMCAVF0 DN Pyrazolo[1,5-a]pyrimidine derivative 4 DMCAVF0 TI TT6OEDT DMCAVF0 TN Cannabinoid receptor 1 (CB1) DMCAVF0 MA Antagonist DMCAVF0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCAVF0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCB0D6 DI DMCB0D6 DMCB0D6 DN PMID29473428-Compound-14 DMCB0D6 TI TTZJYKH DMCB0D6 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCB0D6 MA Inhibitor DMCB0D6 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCB0D6 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCBPI4 DI DMCBPI4 DMCBPI4 DN 1,2-diamino cyclopentane-based derivative 19 DMCBPI4 TI TT9N02I DMCBPI4 TN Orexin receptor type 2 (HCRTR2) DMCBPI4 MA Antagonist DMCBPI4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCBPI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCBPI4 DI DMCBPI4 DMCBPI4 DN 1,2-diamino cyclopentane-based derivative 19 DMCBPI4 TI TT60Q8D DMCBPI4 TN Orexin receptor type 1 (HCRTR1) DMCBPI4 MA Antagonist DMCBPI4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCBPI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCD0MS DI DMCD0MS DMCD0MS DN Heterocyclic derivative 3 DMCD0MS TI TTHS256 DMCD0MS TN Metabotropic glutamate receptor 5 (mGluR5) DMCD0MS MA Modulator DMCD0MS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMCD0MS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMCD19T DI DMCD19T DMCD19T DN PMID27774822-Compound-Figure6Example2 DMCD19T TI TTT7PJU DMCD19T TN Janus kinase 3 (JAK-3) DMCD19T MA Inhibitor DMCD19T RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCD19T RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTRMX3V DMCDFLQ TN Janus kinase 2 (JAK-2) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT6DM01 DMCDFLQ TN Janus kinase 1 (JAK-1) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTBYWP2 DMCDFLQ TN TYK2 tyrosine kinase (TYK2) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT3C80U DMCDFLQ TN T-cell-specific kinase (ITK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTNDSC3 DMCDFLQ TN B lymphocyte kinase (BLK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT1ZV49 DMCDFLQ TN Tyrosine-protein kinase Tec (PSCTK4) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTGM6VW DMCDFLQ TN Tyrosine-protein kinase BTK (ATK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTT7PJU DMCDFLQ TN Janus kinase 3 (JAK-3) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDHZT DI DMCDHZT DMCDHZT DN PMID25553724-Compound-US2011803494010 DMCDHZT TI TTSXVID DMCDHZT TN Nuclear factor NF-kappa-B (NFKB) DMCDHZT MA Inhibitor DMCDHZT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMCDHZT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMCE3J0 DI DMCE3J0 DMCE3J0 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6 DMCE3J0 TI TTXJ47W DMCE3J0 TN Metabotropic glutamate receptor 2 (mGluR2) DMCE3J0 MA Antagonist DMCE3J0 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMCE3J0 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMCE6MB DI DMCE6MB DMCE6MB DN PMID25666693-Compound-127 DMCE6MB TI TTMI6F5 DMCE6MB TN Transient receptor potential cation channel V1 (TRPV1) DMCE6MB MA Antagonist DMCE6MB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMCE6MB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMCEST4 DI DMCEST4 DMCEST4 DN PMID25656651-Compound-29a DMCEST4 TI TTS7G69 DMCEST4 TN Fusion protein Bcr-Abl (Bcr-Abl) DMCEST4 MA Inhibitor DMCEST4 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCEST4 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCF2G7 DI DMCF2G7 DMCF2G7 DN PMID25470667-Compound-roselipins DMCF2G7 TI TTRHEQ4 DMCF2G7 TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMCF2G7 MA Inhibitor DMCF2G7 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMCF2G7 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMCF6M8 DI DMCF6M8 DMCF6M8 DN Epoxysuccinate derivative 4 DMCF6M8 TI TTG5QB7 DMCF6M8 TN Calpain-2 (CAPN2) DMCF6M8 MA Inhibitor DMCF6M8 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMCF6M8 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMCFEAS DI DMCFEAS DMCFEAS DN Triazole derivative 4 DMCFEAS TI TTSCIUP DMCFEAS TN Oxytocin receptor (OTR) DMCFEAS MA Antagonist DMCFEAS RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMCFEAS RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMCFOXP DI DMCFOXP DMCFOXP DN PMID27744724-Compound-13 DMCFOXP TI TTL53M6 DMCFOXP TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMCFOXP MA Inhibitor DMCFOXP RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMCFOXP RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMCG6BE DI DMCG6BE DMCG6BE DN Piperazine carbamate/urea derivative 2 DMCG6BE TI TT9JNIC DMCG6BE TN Histamine H3 receptor (H3R) DMCG6BE MA Ligand DMCG6BE RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMCG6BE RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMCGUNB DI DMCGUNB DMCGUNB DN US9567304, Compound N-9 DMCGUNB TI TTI1FPZ DMCGUNB TN Epithelial discoidin domain receptor 1 (DDR1) DMCGUNB MA Inhibitor DMCGUNB RN Quinazolinedione derivative. US9567304. DMCGUNB RU http://www.freepatentsonline.com/US9567304.html DMCGX5S DI DMCGX5S DMCGX5S DN Benzazepine derivative 6 DMCGX5S TI TTWJBZ5 DMCGX5S TN 5-HT 2C receptor (HTR2C) DMCGX5S MA Agonist DMCGX5S RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMCGX5S RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMCH1DL DI DMCH1DL DMCH1DL DN Thiazole carboxamide derivative 15 DMCH1DL TI TTCZOF2 DMCH1DL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMCH1DL MA Inhibitor DMCH1DL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMCH1DL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMCH1WX DI DMCH1WX DMCH1WX DN Benzothiazepine analog 5 DMCH1WX TI TTPTXIN DMCH1WX TN Translocator protein (TSPO) DMCH1WX MA Ligand DMCH1WX RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMCH1WX RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMCHLAN DI DMCHLAN DMCHLAN DN Resorcinol compound 28 DMCHLAN TI TTULVH8 DMCHLAN TN Tyrosinase (TYR) DMCHLAN MA Inhibitor DMCHLAN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCHLAN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCHWSF DI DMCHWSF DMCHWSF DN PMID25399762-Compound-Table 6-15 DMCHWSF TI TTGP7BY DMCHWSF TN Monoamine oxidase type B (MAO-B) DMCHWSF MA Inhibitor DMCHWSF RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCHWSF RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCHWSF DI DMCHWSF DMCHWSF DN PMID25399762-Compound-Table 6-15 DMCHWSF TI TTNR0UQ DMCHWSF TN Lysine-specific histone demethylase 1 (LSD) DMCHWSF MA Inhibitor DMCHWSF RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCHWSF RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCI6YH DI DMCI6YH DMCI6YH DN Monoaryl-1,2-diamine derivative 1 DMCI6YH TI TTZJYKH DMCI6YH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCI6YH MA Inhibitor DMCI6YH RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCI6YH RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCIGJ1 DI DMCIGJ1 DMCIGJ1 DN PMID29671355-Compound-24 DMCIGJ1 TI TT6R7JZ DMCIGJ1 TN Histone deacetylase 1 (HDAC1) DMCIGJ1 MA Inhibitor DMCIGJ1 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCIGJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCIGJ1 DI DMCIGJ1 DMCIGJ1 DN PMID29671355-Compound-24 DMCIGJ1 TI TT5ZKDI DMCIGJ1 TN Histone deacetylase 6 (HDAC6) DMCIGJ1 MA Inhibitor DMCIGJ1 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCIGJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCIKR3 DI DMCIKR3 DMCIKR3 DN Quinolinyl pyrazinyl urea derivative 1 DMCIKR3 TI TTRZQE3 DMCIKR3 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCIKR3 MA Inhibitor DMCIKR3 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMCIKR3 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMCIQ01 DI DMCIQ01 DMCIQ01 DN PMID25522065-Compound-40 DMCIQ01 TI TTX4RTB DMCIQ01 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMCIQ01 MA Antagonist DMCIQ01 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMCIQ01 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMCISHW DI DMCISHW DMCISHW DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1 DMCISHW TI TTV1C0Z DMCISHW TN Neuropeptide S receptor (NPSR) DMCISHW MA Antagonist DMCISHW RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMCISHW RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMCIT5A DI DMCIT5A DMCIT5A DN PMID27019002-Compound-37b DMCIT5A TI TTNR0UQ DMCIT5A TN Lysine-specific histone demethylase 1 (LSD) DMCIT5A MA Inhibitor DMCIT5A RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMCIT5A RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMCIV32 DI DMCIV32 DMCIV32 DN Alkyl mannoside derivative 6 DMCIV32 TI TTTCRU2 DMCIV32 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCIV32 MA Antagonist DMCIV32 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCIV32 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCIXD4 DI DMCIXD4 DMCIXD4 DN Piperazine carbamate/urea derivative 1 DMCIXD4 TI TT9JNIC DMCIXD4 TN Histamine H3 receptor (H3R) DMCIXD4 MA Ligand DMCIXD4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMCIXD4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMCJ48G DI DMCJ48G DMCJ48G DN PMID27109571-Compound-36 DMCJ48G TI TTMY6L1 DMCJ48G TN Fatty acid-binding protein (FABP) DMCJ48G MA Inhibitor DMCJ48G RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMCJ48G RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMCJG8Z DI DMCJG8Z DMCJG8Z DN US9434727, 93 DMCJG8Z TI TT0C8BY DMCJG8Z TN Plasma retinol-binding protein (RBP4) DMCJG8Z MA Inhibitor DMCJG8Z RN Substituted 4-phenylpiperidines, their preparation and use. US10072016. DMCJG8Z RU http://www.freepatentsonline.com/US10072016.html DMCJH4F DI DMCJH4F DMCJH4F DN US8524917, 10 DMCJH4F TI TTDYP7I DMCJH4F TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMCJH4F MA Inhibitor DMCJH4F RN 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917. DMCJH4F RU http://www.freepatentsonline.com/US8524917.html DMCJHK2 DI DMCJHK2 DMCJHK2 DN 3ts4 DMCJHK2 TI TTXLEG7 DMCJHK2 TN Matrix metalloproteinase-10 (MMP-10) DMCJHK2 MA Inhibitor DMCJHK2 RN Pseudodipeptides as MMP inhibitors. US8691753. DMCJHK2 RU http://www.freepatentsonline.com/US8691753.html DMCJO0R DI DMCJO0R DMCJO0R DN Resorcinol compound 9 DMCJO0R TI TTULVH8 DMCJO0R TN Tyrosinase (TYR) DMCJO0R MA Inhibitor DMCJO0R RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCJO0R RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCJR4N DI DMCJR4N DMCJR4N DN N-acylpiperidine ether derivative 7 DMCJR4N TI TTTDVOJ DMCJR4N TN Tropomyosin-related kinase A (TrkA) DMCJR4N MA Inhibitor DMCJR4N RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCJR4N RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCJTU1 DI DMCJTU1 DMCJTU1 DN PMID25416646-Compound-Figure5-H DMCJTU1 TI TTZMAO3 DMCJTU1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMCJTU1 MA Agonist DMCJTU1 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMCJTU1 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMCJTU1 DI DMCJTU1 DMCJTU1 DN PMID25416646-Compound-Figure5-H DMCJTU1 TI TTJ584C DMCJTU1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMCJTU1 MA Agonist DMCJTU1 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMCJTU1 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMCJVLR DI DMCJVLR DMCJVLR DN Pyrazolopyridine derivative 2 DMCJVLR TI TTT7PJU DMCJVLR TN Janus kinase 3 (JAK-3) DMCJVLR MA Inhibitor DMCJVLR RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCJVLR RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTS7G69 DMCKAON TN Fusion protein Bcr-Abl (Bcr-Abl) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTX41N9 DMCKAON TN Tyrosine-protein kinase Kit (KIT) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTI7421 DMCKAON TN Platelet-derived growth factor receptor beta (PDGFRB) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKBGM DI DMCKBGM DMCKBGM DN Pyrimidinyl compound 5 DMCKBGM TI TTH5TC2 DMCKBGM TN NF-kappa-B-activating kinase (TBK1) DMCKBGM MA Inhibitor DMCKBGM RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMCKBGM RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMCKSJ8 DI DMCKSJ8 DMCKSJ8 DN Azaindole derivative 4 DMCKSJ8 TI TT7RJY8 DMCKSJ8 TN Xanthine dehydrogenase/oxidase (XDH) DMCKSJ8 MA Inhibitor DMCKSJ8 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMCKSJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TTT7PJU DMCL19N TN Janus kinase 3 (JAK-3) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TTRMX3V DMCL19N TN Janus kinase 2 (JAK-2) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TT6DM01 DMCL19N TN Janus kinase 1 (JAK-1) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCLB5D DI DMCLB5D DMCLB5D DN Boswellia acid derivative 1 DMCLB5D TI TTYLQ8V DMCLB5D TN Prostaglandin E synthase (PTGES) DMCLB5D MA Inhibitor DMCLB5D RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMCLB5D RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMCLHX5 DI DMCLHX5 DMCLHX5 DN US9200020, Table 3 compound 8 DMCLHX5 TI TTBL49X DMCLHX5 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMCLHX5 MA Inhibitor DMCLHX5 RN 6-oxopurine phosphoribosyltransferase inhibitors. US9200020. DMCLHX5 RU http://www.freepatentsonline.com/US9200020.html DMCLJ0M DI DMCLJ0M DMCLJ0M DN PMID29473428-Compound-47 DMCLJ0M TI TTZJYKH DMCLJ0M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCLJ0M MA Inhibitor DMCLJ0M RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCLJ0M RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCLKBY DI DMCLKBY DMCLKBY DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 3 DMCLKBY TI TTV8CRH DMCLKBY TN Lysine-specific demethylase 4C (KDM4C) DMCLKBY MA Inhibitor DMCLKBY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCLKBY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCLTY3 DI DMCLTY3 DMCLTY3 DN Biaryl mannoside derivative 29 DMCLTY3 TI TTTCRU2 DMCLTY3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCLTY3 MA Antagonist DMCLTY3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCLTY3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCLZWS DI DMCLZWS DMCLZWS DN Polyhydroxy benzamide derivative 3 DMCLZWS TI TTULVH8 DMCLZWS TN Tyrosinase (TYR) DMCLZWS MA Inhibitor DMCLZWS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCLZWS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCM3NW DI DMCM3NW DMCM3NW DN Mannoside derivative 6 DMCM3NW TI TTTCRU2 DMCM3NW TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCM3NW MA Antagonist DMCM3NW RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCM3NW RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCMKIL DI DMCMKIL DMCMKIL DN Hydroxyqunoline analog 3 DMCMKIL TI TTWAQBO DMCMKIL TN Lysine-specific demethylase 4E (KDM4E) DMCMKIL MA Inhibitor DMCMKIL RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCMKIL RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCNAM9 DI DMCNAM9 DMCNAM9 DN US8710232, 1 DMCNAM9 TI TT4UJX5 DMCNAM9 TN Carboxypeptidase B1 (CPB1) DMCNAM9 MA Inhibitor DMCNAM9 RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DMCNAM9 RU http://www.freepatentsonline.com/US8710232.html DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT8M4E1 DMCNF36 TN Histone deacetylase 9 (HDAC9) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT5ZKDI DMCNF36 TN Histone deacetylase 6 (HDAC6) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT6R7JZ DMCNF36 TN Histone deacetylase 1 (HDAC1) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNQAF DI DMCNQAF DMCNQAF DN 1,2-diamino cyclopentane-based derivative 18 DMCNQAF TI TT9N02I DMCNQAF TN Orexin receptor type 2 (HCRTR2) DMCNQAF MA Antagonist DMCNQAF RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCNQAF RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCNQAF DI DMCNQAF DMCNQAF DN 1,2-diamino cyclopentane-based derivative 18 DMCNQAF TI TT60Q8D DMCNQAF TN Orexin receptor type 1 (HCRTR1) DMCNQAF MA Antagonist DMCNQAF RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCNQAF RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCNS9T DI DMCNS9T DMCNS9T DN US8710232, 7 DMCNS9T TI TT4UJX5 DMCNS9T TN Carboxypeptidase B1 (CPB1) DMCNS9T MA Inhibitor DMCNS9T RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DMCNS9T RU http://www.freepatentsonline.com/US8710232.html DMCNSZD DI DMCNSZD DMCNSZD DN PMID29473428-Compound-22 DMCNSZD TI TTZJYKH DMCNSZD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCNSZD MA Inhibitor DMCNSZD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCNSZD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCNWPI DI DMCNWPI DMCNWPI DN Pyridine-2,4-dicarboxylic acid analog 2 DMCNWPI TI TTWAQBO DMCNWPI TN Lysine-specific demethylase 4E (KDM4E) DMCNWPI MA Inhibitor DMCNWPI RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCNWPI RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCO0ZS DI DMCO0ZS DMCO0ZS DN Benzotriazole derivative 1 DMCO0ZS TI TT2F4OL DMCO0ZS TN Tissue transglutaminase (TG2) DMCO0ZS MA Inhibitor DMCO0ZS RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMCO0ZS RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMCO8JD DI DMCO8JD DMCO8JD DN Sulfonylated piperazine derivative 1 DMCO8JD TI TT6OEDT DMCO8JD TN Cannabinoid receptor 1 (CB1) DMCO8JD MA Antagonist DMCO8JD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCO8JD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCORT3 DI DMCORT3 DMCORT3 DN Indoline derivative 9 DMCORT3 TI TT5OU0D DMCORT3 TN PRKR-like endoplasmic reticulum kinase (PERK) DMCORT3 MA Inhibitor DMCORT3 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMCORT3 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMCP0WF DI DMCP0WF DMCP0WF DN PMID26004420-Compound-WO2013028474B DMCP0WF TI TTJ13ST DMCP0WF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMCP0WF MA Inhibitor DMCP0WF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMCP0WF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMCP15K DI DMCP15K DMCP15K DN 1,2-diamino cyclopentane-based derivative 5 DMCP15K TI TT9N02I DMCP15K TN Orexin receptor type 2 (HCRTR2) DMCP15K MA Antagonist DMCP15K RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCP15K RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCP15K DI DMCP15K DMCP15K DN 1,2-diamino cyclopentane-based derivative 5 DMCP15K TI TT60Q8D DMCP15K TN Orexin receptor type 1 (HCRTR1) DMCP15K MA Antagonist DMCP15K RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCP15K RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCPV0D DI DMCPV0D DMCPV0D DN Thiazole-fused cycloalkyl carboxamide derivative 1 DMCPV0D TI TT473XN DMCPV0D TN P2X purinoceptor 7 (P2RX7) DMCPV0D MA Antagonist DMCPV0D RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMCPV0D RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMCPVRU DI DMCPVRU DMCPVRU DN Spiroimidazolone derivative 1 DMCPVRU TI TT9O6WS DMCPVRU TN Glucagon receptor (GCGR) DMCPVRU MA Antagonist DMCPVRU RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMCPVRU RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMCQB93 DI DMCQB93 DMCQB93 DN PMID27841045-Compound-132 DMCQB93 TI TT7RJY8 DMCQB93 TN Xanthine dehydrogenase/oxidase (XDH) DMCQB93 MA Inhibitor DMCQB93 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMCQB93 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMCQBZK DI DMCQBZK DMCQBZK DN Imidazo cyclohexylamine derivative 3 DMCQBZK TI TTDIGC1 DMCQBZK TN Dipeptidyl peptidase 4 (DPP-4) DMCQBZK MA Inhibitor DMCQBZK RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMCQBZK RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMCQLJY DI DMCQLJY DMCQLJY DN Benzene sulfonamide derivative 3 DMCQLJY TI TTIY56R DMCQLJY TN Kynurenine 3-hydroxylase (KMO) DMCQLJY MA Inhibitor DMCQLJY RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCQLJY RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCQN5M DI DMCQN5M DMCQN5M DN Pyrrolidine derivative 10 DMCQN5M TI TTSCIUP DMCQN5M TN Oxytocin receptor (OTR) DMCQN5M MA Antagonist DMCQN5M RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMCQN5M RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMCQP0B DI DMCQP0B DMCQP0B DN Flavonoid derivative 1 DMCQP0B TI TTH8FZW DMCQP0B TN Signal transducer and activator of transcription 3 (STAT3) DMCQP0B MA Inhibitor DMCQP0B RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMCQP0B RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMCRA2U DI DMCRA2U DMCRA2U DN PMID25656651-Compound-33a DMCRA2U TI TT3PJMV DMCRA2U TN Tyrosine-protein kinase ABL1 (ABL) DMCRA2U MA Inhibitor DMCRA2U RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCRA2U RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCRJO1 DI DMCRJO1 DMCRJO1 DN PMID26004420-Compound-US20140336177E DMCRJO1 TI TTJ13ST DMCRJO1 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMCRJO1 MA Inhibitor DMCRJO1 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMCRJO1 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMCRNWA DI DMCRNWA DMCRNWA DN PMID26651364-Compound-10c DMCRNWA TI TTTCRU2 DMCRNWA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCRNWA MA Antagonist DMCRNWA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCRNWA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCRVO5 DI DMCRVO5 DMCRVO5 DN Thiazole carboxamide derivative 29 DMCRVO5 TI TTCZOF2 DMCRVO5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMCRVO5 MA Inhibitor DMCRVO5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMCRVO5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMCRWV3 DI DMCRWV3 DMCRWV3 DN PMID29671355-Compound-53 DMCRWV3 TI TTBH0VX DMCRWV3 TN Histone deacetylase (HDAC) DMCRWV3 MA Inhibitor DMCRWV3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCRWV3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCS08K DI DMCS08K DMCS08K DN Pyrazole derivative 22 DMCS08K TI TT6OEDT DMCS08K TN Cannabinoid receptor 1 (CB1) DMCS08K MA Antagonist DMCS08K RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCS08K RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCSIYG DI DMCSIYG DMCSIYG DN Cyclopropane 1-carboxylic acid derivative 5 DMCSIYG TI TTIY56R DMCSIYG TN Kynurenine 3-hydroxylase (KMO) DMCSIYG MA Inhibitor DMCSIYG RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCSIYG RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCT6QW DI DMCT6QW DMCT6QW DN Pyrazolo[1,5-a]pyrimidine derivative 29 DMCT6QW TI TTF8P9I DMCT6QW TN Diacylglycerol acyltransferase 1 (DGAT1) DMCT6QW MA Inhibitor DMCT6QW RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMCT6QW RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMCTMB1 DI DMCTMB1 DMCTMB1 DN PMID27454349-Compound-93 DMCTMB1 TI TTK59TV DMCTMB1 TN Vitamin D3 receptor (VDR) DMCTMB1 MA Agonist DMCTMB1 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMCTMB1 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMCTQ9O DI DMCTQ9O DMCTQ9O DN Pyrazolopyridine derivative 7 DMCTQ9O TI TTT7PJU DMCTQ9O TN Janus kinase 3 (JAK-3) DMCTQ9O MA Inhibitor DMCTQ9O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCTQ9O RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCTQ9O DI DMCTQ9O DMCTQ9O DN Pyrazolopyridine derivative 7 DMCTQ9O TI TTRMX3V DMCTQ9O TN Janus kinase 2 (JAK-2) DMCTQ9O MA Inhibitor DMCTQ9O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCTQ9O RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCTWVY DI DMCTWVY DMCTWVY DN Pyrazolo[3,4-d]pyrimidine derivative 6 DMCTWVY TI TT4DXQT DMCTWVY TN Proto-oncogene c-Ret (RET) DMCTWVY MA Inhibitor DMCTWVY RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMCTWVY RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTRMX3V DMCTXPQ TN Janus kinase 2 (JAK-2) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTT7PJU DMCTXPQ TN Janus kinase 3 (JAK-3) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTJSQEF DMCTXPQ TN Tyrosine-protein kinase (PTK) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCUAO9 DI DMCUAO9 DMCUAO9 DN PMID27977313-Compound-6 DMCUAO9 TI TTR7UJ3 DMCUAO9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMCUAO9 MA Inhibitor DMCUAO9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMCUAO9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMCULI1 DI DMCULI1 DMCULI1 DN PMID25776143-Compound-3 DMCULI1 TI TT4TFGN DMCULI1 TN Vasopressin V1a receptor (V1AR) DMCULI1 MA Inhibitor DMCULI1 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMCULI1 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMCULK7 DI DMCULK7 DMCULK7 DN Lazabemide DMCULK7 TI TTGP7BY DMCULK7 TN Monoamine oxidase type B (MAO-B) DMCULK7 MA Inhibitor DMCULK7 RN The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37. DMCULK7 RU https://pubmed.ncbi.nlm.nih.gov/9489509 DMCULK7 DI DMCULK7 DMCULK7 DN Lazabemide DMCULK7 TI TT32XQJ DMCULK7 TN Monoamine oxidase (MAO) DMCULK7 MA Inhibitor DMCULK7 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCULK7 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCUMSV DI DMCUMSV DMCUMSV DN PMID25553724-Compound-US2012830453910 DMCUMSV TI TTSXVID DMCUMSV TN Nuclear factor NF-kappa-B (NFKB) DMCUMSV MA Inhibitor DMCUMSV RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMCUMSV RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMCUP4L DI DMCUP4L DMCUP4L DN Pyridine-2,4-dicarboxylic acid derivative 3 DMCUP4L TI TT0RGE9 DMCUP4L TN Lysine-specific demethylase 4 (KDM4) DMCUP4L MA Inhibitor DMCUP4L RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCUP4L RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCUQFG DI DMCUQFG DMCUQFG DN Pyrimidine derivative 32 DMCUQFG TI TTDIGC1 DMCUQFG TN Dipeptidyl peptidase 4 (DPP-4) DMCUQFG MA Inhibitor DMCUQFG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMCUQFG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMCUX42 DI DMCUX42 DMCUX42 DN PMID28067079-Compound-97 DMCUX42 TI TTHS256 DMCUX42 TN Metabotropic glutamate receptor 5 (mGluR5) DMCUX42 MA Modulator DMCUX42 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMCUX42 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMCVBPF DI DMCVBPF DMCVBPF DN N-naphtyl-N-benzylurea derivative 1 DMCVBPF TI TTRZQE3 DMCVBPF TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCVBPF MA Inhibitor DMCVBPF RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMCVBPF RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMCWES7 DI DMCWES7 DMCWES7 DN Triazole gold complexe 1 DMCWES7 TI TTR7UJ3 DMCWES7 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMCWES7 MA Inhibitor DMCWES7 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMCWES7 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMCWFU1 DI DMCWFU1 DMCWFU1 DN Isoxazoles and isoxazoline derivative 5 DMCWFU1 TI TTIY56R DMCWFU1 TN Kynurenine 3-hydroxylase (KMO) DMCWFU1 MA Inhibitor DMCWFU1 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCWFU1 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCXDKS DI DMCXDKS DMCXDKS DN PMID25726713-Compound-34 DMCXDKS TI TT8J1S3 DMCXDKS TN Smoothened homolog (SMO) DMCXDKS MA Inhibitor DMCXDKS RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMCXDKS RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMCXELD DI DMCXELD DMCXELD DN PMID25666693-Compound-144 DMCXELD TI TTMI6F5 DMCXELD TN Transient receptor potential cation channel V1 (TRPV1) DMCXELD MA Antagonist DMCXELD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMCXELD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMCXHGW DI DMCXHGW DMCXHGW DN Imidazo pyridine derivative 1 DMCXHGW TI TTTDVOJ DMCXHGW TN Tropomyosin-related kinase A (TrkA) DMCXHGW MA Inhibitor DMCXHGW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCXHGW RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCY5M7 DI DMCY5M7 DMCY5M7 DN Benzimidazole derivative 14 DMCY5M7 TI TTYLQ8V DMCY5M7 TN Prostaglandin E synthase (PTGES) DMCY5M7 MA Inhibitor DMCY5M7 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMCY5M7 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMCYM8P DI DMCYM8P DMCYM8P DN US9073931, E3 DMCYM8P TI TTECBXN DMCYM8P TN Oxysterols receptor LXR-alpha (NR1H3) DMCYM8P MA Inhibitor DMCYM8P RN Liver X receptor modulators. US9073931. DMCYM8P RU http://www.freepatentsonline.com/US9073931.html DMCYOL7 DI DMCYOL7 DMCYOL7 DN Pyrrolo[2,3-b]pyridine derivative 3 DMCYOL7 TI TTTDVOJ DMCYOL7 TN Tropomyosin-related kinase A (TrkA) DMCYOL7 MA Inhibitor DMCYOL7 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCYOL7 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCZ3SH DI DMCZ3SH DMCZ3SH DN PMID29865878-Compound-38 DMCZ3SH TI TTSJMN8 DMCZ3SH TN Immunoproteasome complex (IP) DMCZ3SH MA Inhibitor DMCZ3SH RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMCZ3SH RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMCZ8UV DI DMCZ8UV DMCZ8UV DN Pyrrolo-pyridone derivative 2 DMCZ8UV TI TTRMX3V DMCZ8UV TN Janus kinase 2 (JAK-2) DMCZ8UV MA Inhibitor DMCZ8UV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCZ8UV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCZ8UV DI DMCZ8UV DMCZ8UV DN Pyrrolo-pyridone derivative 2 DMCZ8UV TI TT6DM01 DMCZ8UV TN Janus kinase 1 (JAK-1) DMCZ8UV MA Inhibitor DMCZ8UV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCZ8UV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TT1RS9F DMCZA45 TN Acetylcholinesterase (AChE) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TTGP7BY DMCZA45 TN Monoamine oxidase type B (MAO-B) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TT3WG5C DMCZA45 TN Monoamine oxidase type A (MAO-A) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TTEB0GD DMCZA45 TN Cholinesterase (BCHE) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZJ1W DI DMCZJ1W DMCZJ1W DN Pyrrolo[2,3-d]pyrimidine derivative 27 DMCZJ1W TI TTGM6VW DMCZJ1W TN Tyrosine-protein kinase BTK (ATK) DMCZJ1W MA Inhibitor DMCZJ1W RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMCZJ1W RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMCZORA DI DMCZORA DMCZORA DN Pyrazoline derivative 10 DMCZORA TI TT6OEDT DMCZORA TN Cannabinoid receptor 1 (CB1) DMCZORA MA Antagonist DMCZORA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCZORA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMD03J5 DI DMD03J5 DMD03J5 DN Carbamide derivative 21 DMD03J5 TI TTOHSBA DMD03J5 TN Vascular endothelial growth factor A (VEGFA) DMD03J5 MA Inhibitor DMD03J5 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMD03J5 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMD0GN6 DI DMD0GN6 DMD0GN6 DN US10030004, Compound 33 DMD0GN6 TI TTPKHTZ DMD0GN6 TN Activin receptor type IB (ACVR1B) DMD0GN6 MA Inhibitor DMD0GN6 RN Compounds and methods of use. US10030004. DMD0GN6 RU http://www.freepatentsonline.com/US10030004.html DMD0HAT DI DMD0HAT DMD0HAT DN PMID27019002-Compound-13 DMD0HAT TI TTNR0UQ DMD0HAT TN Lysine-specific histone demethylase 1 (LSD) DMD0HAT MA Inhibitor DMD0HAT RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMD0HAT RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMD0T6S DI DMD0T6S DMD0T6S DN PMID27744724-Compound-20 DMD0T6S TI TTL53M6 DMD0T6S TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMD0T6S MA Inhibitor DMD0T6S RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMD0T6S RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMD0WIA DI DMD0WIA DMD0WIA DN PMID25666693-Compound-119 DMD0WIA TI TTMI6F5 DMD0WIA TN Transient receptor potential cation channel V1 (TRPV1) DMD0WIA MA Antagonist DMD0WIA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMD0WIA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMD0XIL DI DMD0XIL DMD0XIL DN Lactam derivative 3 DMD0XIL TI TTF8P9I DMD0XIL TN Diacylglycerol acyltransferase 1 (DGAT1) DMD0XIL MA Inhibitor DMD0XIL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMD0XIL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMD13OS DI DMD13OS DMD13OS DN PMID25666693-Compound-66 DMD13OS TI TTMI6F5 DMD13OS TN Transient receptor potential cation channel V1 (TRPV1) DMD13OS MA Antagonist DMD13OS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMD13OS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMD198F DI DMD198F DMD198F DN Cyanomethyl pypazole carboxamide derivative 1 DMD198F TI TTRMX3V DMD198F TN Janus kinase 2 (JAK-2) DMD198F MA Inhibitor DMD198F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD198F RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD198F DI DMD198F DMD198F DN Cyanomethyl pypazole carboxamide derivative 1 DMD198F TI TT6DM01 DMD198F TN Janus kinase 1 (JAK-1) DMD198F MA Inhibitor DMD198F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD198F RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TTQ6VDM DMD19QC TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TT5TPI6 DMD19QC TN Opioid receptor sigma 1 (OPRS1) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TT9NXW4 DMD19QC TN Sigma intracellular receptor 2 (TMEM97) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTL4Q97 DMD1G3Z TN Cyclin-dependent kinase 5 (CDK5) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TT1LVF2 DMD1G3Z TN Cyclin-dependent kinase 9 (CDK9) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTH6V3D DMD1G3Z TN Cyclin-dependent kinase 1 (CDK1) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTQYF7G DMD1G3Z TN Cyclin-dependent kinase 7 (CDK7) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TT7HF4W DMD1G3Z TN Cyclin-dependent kinase 2 (CDK2) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1K7E DI DMD1K7E DMD1K7E DN Heterocyclic derivative 17 DMD1K7E TI TTCZOF2 DMD1K7E TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMD1K7E MA Inhibitor DMD1K7E RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMD1K7E RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTOU65C DMD1RT0 TN Tyrosine-protein kinase SYK (SYK) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTT7PJU DMD1RT0 TN Janus kinase 3 (JAK-3) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TT6DM01 DMD1RT0 TN Janus kinase 1 (JAK-1) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTRMX3V DMD1RT0 TN Janus kinase 2 (JAK-2) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1S92 DI DMD1S92 DMD1S92 DN Pyrrolo-pyrazine derivative 4 DMD1S92 TI TTOU65C DMD1S92 TN Tyrosine-protein kinase SYK (SYK) DMD1S92 MA Inhibitor DMD1S92 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD1S92 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD1S92 DI DMD1S92 DMD1S92 DN Pyrrolo-pyrazine derivative 4 DMD1S92 TI TTT7PJU DMD1S92 TN Janus kinase 3 (JAK-3) DMD1S92 MA Inhibitor DMD1S92 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD1S92 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD2BL3 DI DMD2BL3 DMD2BL3 DN Azaindole derivative 5 DMD2BL3 TI TT7RJY8 DMD2BL3 TN Xanthine dehydrogenase/oxidase (XDH) DMD2BL3 MA Inhibitor DMD2BL3 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMD2BL3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMD2CX1 DI DMD2CX1 DMD2CX1 DN Piperazinyl norbenzomorphane compound 2 DMD2CX1 TI TT9NXW4 DMD2CX1 TN Sigma intracellular receptor 2 (TMEM97) DMD2CX1 MA Ligand DMD2CX1 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD2CX1 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTALN9W DMD2KRW TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTZJYKH DMD2KRW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTXNCBV DMD2KRW TN Tryptophan 2,3-dioxygenase (TDO) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2R1H DI DMD2R1H DMD2R1H DN Phthalazine ketone derivative 1 DMD2R1H TI TTVDSZ0 DMD2R1H TN Poly [ADP-ribose] polymerase 1 (PARP1) DMD2R1H MA Inhibitor DMD2R1H RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMD2R1H RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMD3AHN DI DMD3AHN DMD3AHN DN PMID25726713-Compound-12 DMD3AHN TI TT8J1S3 DMD3AHN TN Smoothened homolog (SMO) DMD3AHN MA Inhibitor DMD3AHN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMD3AHN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMD3CB4 DI DMD3CB4 DMD3CB4 DN PMID25772215-Compound-WO2012177618M4 DMD3CB4 TI TT1ZAVI DMD3CB4 TN Prostaglandin E2 receptor EP2 (PTGER2) DMD3CB4 MA Antagonist DMD3CB4 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMD3CB4 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMD3LK1 DI DMD3LK1 DMD3LK1 DN Cycloalkyl nitrile pyrazolo pyridone derivative 1 DMD3LK1 TI TTRMX3V DMD3LK1 TN Janus kinase 2 (JAK-2) DMD3LK1 MA Inhibitor DMD3LK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD3LK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD3LK1 DI DMD3LK1 DMD3LK1 DN Cycloalkyl nitrile pyrazolo pyridone derivative 1 DMD3LK1 TI TT6DM01 DMD3LK1 TN Janus kinase 1 (JAK-1) DMD3LK1 MA Inhibitor DMD3LK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD3LK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD3T1Q DI DMD3T1Q DMD3T1Q DN PMID26609882-Compound-58 DMD3T1Q TI TTWJBZ5 DMD3T1Q TN 5-HT 2C receptor (HTR2C) DMD3T1Q MA Antagonist DMD3T1Q RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMD3T1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMD3U96 DI DMD3U96 DMD3U96 DN PMID27788040-Compound-6b DMD3U96 TI TTV1C0Z DMD3U96 TN Neuropeptide S receptor (NPSR) DMD3U96 MA Antagonist DMD3U96 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMD3U96 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMD41UF DI DMD41UF DMD41UF DN PMID26004420-Compound-WO2012058116B DMD41UF TI TTJ13ST DMD41UF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMD41UF MA Inhibitor DMD41UF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMD41UF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMD4CIU DI DMD4CIU DMD4CIU DN PMID27387065-Compound-6 DMD4CIU TI TTK25J1 DMD4CIU TN Adenosine A1 receptor (ADORA1) DMD4CIU MA Agonist DMD4CIU RN Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).Expert Opin Ther Pat. 2016 Aug;26(8):947-56. DMD4CIU RU https://www.ncbi.nlm.nih.gov/pubmed/27387065 DMD4CU5 DI DMD4CU5 DMD4CU5 DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 DMD4CU5 TI TT6OEDT DMD4CU5 TN Cannabinoid receptor 1 (CB1) DMD4CU5 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD4CU5 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD4CU5 DI DMD4CU5 DMD4CU5 DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 DMD4CU5 TI TTMSFAW DMD4CU5 TN Cannabinoid receptor 2 (CB2) DMD4CU5 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD4CU5 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD4UMP DI DMD4UMP DMD4UMP DN Benzene sulfonamide derivative 6 DMD4UMP TI TTIY56R DMD4UMP TN Kynurenine 3-hydroxylase (KMO) DMD4UMP MA Inhibitor DMD4UMP RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD4UMP RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD51AV DI DMD51AV DMD51AV DN Sulfonamide derivative 6 DMD51AV TI TTZJYKH DMD51AV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD51AV MA Inhibitor DMD51AV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMD51AV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMD51HM DI DMD51HM DMD51HM DN Pyrazole and thiophene derivative 2 DMD51HM TI TTRA6BO DMD51HM TN Bromodomain-containing protein 4 (BRD4) DMD51HM MA Inhibitor DMD51HM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMD51HM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMD59C2 DI DMD59C2 DMD59C2 DN PMID25991433-Compound-A11 DMD59C2 TI TTHS0U8 DMD59C2 TN Stress-activated protein kinase JNK2 (JNK2) DMD59C2 MA Inhibitor DMD59C2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD59C2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD59C2 DI DMD59C2 DMD59C2 DN PMID25991433-Compound-A11 DMD59C2 TI TT0K6EO DMD59C2 TN Stress-activated protein kinase JNK1 (JNK1) DMD59C2 MA Inhibitor DMD59C2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD59C2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTKN7QR DMD5QEL TN BDNF/NT-3 growth factors receptor (TrkB) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTXABCW DMD5QEL TN NT-3 growth factor receptor (TrkC) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTTDVOJ DMD5QEL TN Tropomyosin-related kinase A (TrkA) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD65GU DI DMD65GU DMD65GU DN PMID30107136-Compound-Example11 DMD65GU TI TT23XQV DMD65GU TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMD65GU MA Inhibitor DMD65GU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMD65GU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMD65GU DI DMD65GU DMD65GU DN PMID30107136-Compound-Example11 DMD65GU TI TT5YPJF DMD65GU TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMD65GU MA Inhibitor DMD65GU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMD65GU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMD6GNO DI DMD6GNO DMD6GNO DN Pyrimidine benzenesulfonamide derivative 1 DMD6GNO TI TTIY56R DMD6GNO TN Kynurenine 3-hydroxylase (KMO) DMD6GNO MA Inhibitor DMD6GNO RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD6GNO RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD6Y73 DI DMD6Y73 DMD6Y73 DN Carbamide derivative 24 DMD6Y73 TI TTDP1UC DMD6Y73 TN Fatty acid amide hydrolase (FAAH) DMD6Y73 MA Inhibitor DMD6Y73 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMD6Y73 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMD6Y73 DI DMD6Y73 DMD6Y73 DN Carbamide derivative 24 DMD6Y73 TI TTZ963I DMD6Y73 TN Monoglyceride lipase (MAGL) DMD6Y73 MA Inhibitor DMD6Y73 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMD6Y73 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMD7053 DI DMD7053 DMD7053 DN Biaryl mannoside derivative 7 DMD7053 TI TTTCRU2 DMD7053 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMD7053 MA Antagonist DMD7053 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMD7053 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMD7640 DI DMD7640 DMD7640 DN Benzamide derivative 18 DMD7640 TI TTYLQ8V DMD7640 TN Prostaglandin E synthase (PTGES) DMD7640 MA Inhibitor DMD7640 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMD7640 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMD7AU3 DI DMD7AU3 DMD7AU3 DN PMID28074661-Compound-US20120264760C83 DMD7AU3 TI TTL7C8Q DMD7AU3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMD7AU3 MA Inhibitor DMD7AU3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMD7AU3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMD7OW0 DI DMD7OW0 DMD7OW0 DN Nitrogen/sulfur-substituted estrene derivative 1 DMD7OW0 TI TT5ZWB6 DMD7OW0 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMD7OW0 MA Inhibitor DMD7OW0 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMD7OW0 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMD7Z3H DI DMD7Z3H DMD7Z3H DN Benzylcinnamate DMD7Z3H TI TTGP7BY DMD7Z3H TN Monoamine oxidase type B (MAO-B) DMD7Z3H MA Inhibitor DMD7Z3H RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMD7Z3H RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMD803F DI DMD803F DMD803F DN US9216972, 132 DMD803F TI TTDYP7I DMD803F TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMD803F MA Inhibitor DMD803F RN Tricyclic heterocyclic compounds. US9216972. DMD803F RU http://www.freepatentsonline.com/US9216972.html DMD80Q6 DI DMD80Q6 DMD80Q6 DN PMID25399762-Compound-Table1-C13 DMD80Q6 TI TTGP7BY DMD80Q6 TN Monoamine oxidase type B (MAO-B) DMD80Q6 MA Inhibitor DMD80Q6 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMD80Q6 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMD8AKH DI DMD8AKH DMD8AKH DN Monoaryl-1,2-diamine derivative 4 DMD8AKH TI TTZJYKH DMD8AKH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD8AKH MA Modulator DMD8AKH RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMD8AKH RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TTHS0U8 DMD8AX6 TN Stress-activated protein kinase JNK2 (JNK2) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TT056SO DMD8AX6 TN Stress-activated protein kinase JNK3 (JNK3) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TT0K6EO DMD8AX6 TN Stress-activated protein kinase JNK1 (JNK1) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8C9S DI DMD8C9S DMD8C9S DN Salicylic acid derivative 2 DMD8C9S TI TTH8FZW DMD8C9S TN Signal transducer and activator of transcription 3 (STAT3) DMD8C9S MA Inhibitor DMD8C9S RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMD8C9S RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMD8FS5 DI DMD8FS5 DMD8FS5 DN US10034861, Example 165 DMD8FS5 TI TT3ZS42 DMD8FS5 TN Phosphodiesterase 1B (PDE1B) DMD8FS5 MA Inhibitor DMD8FS5 RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DMD8FS5 RU http://www.freepatentsonline.com/US10034861.html DMD8N5O DI DMD8N5O DMD8N5O DN PMID28766366-Compound-Scheme22Middle DMD8N5O TI TTXZCO0 DMD8N5O TN Microtubule-associated protein tau phosphorylation (MAPT p) DMD8N5O MA Inhibitor DMD8N5O RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMD8N5O RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMD94MP DI DMD94MP DMD94MP DN Adamantyl derivative 1 DMD94MP TI TTMSFAW DMD94MP TN Cannabinoid receptor 2 (CB2) DMD94MP MA Agonist DMD94MP RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD94MP RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD965S DI DMD965S DMD965S DN Quinazoline derivative 15 DMD965S TI TTUTJGQ DMD965S TN Vascular endothelial growth factor receptor 2 (KDR) DMD965S MA Inhibitor DMD965S RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMD965S RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMD965S DI DMD965S DMD965S DN Quinazoline derivative 15 DMD965S TI TT4DXQT DMD965S TN Proto-oncogene c-Ret (RET) DMD965S MA Inhibitor DMD965S RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMD965S RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMD9PZQ DI DMD9PZQ DMD9PZQ DN Ethynyl compound 3 DMD9PZQ TI TTHS256 DMD9PZQ TN Metabotropic glutamate receptor 5 (mGluR5) DMD9PZQ MA Modulator DMD9PZQ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMD9PZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMD9QW2 DI DMD9QW2 DMD9QW2 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 1 DMD9QW2 TI TTJW4LU DMD9QW2 TN Phosphodiesterase 10A (PDE10) DMD9QW2 MA Inhibitor DMD9QW2 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMD9QW2 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMD9QW2 DI DMD9QW2 DMD9QW2 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 1 DMD9QW2 TI TTJGW1Z DMD9QW2 TN Phosphodiesterase 2A (PDE2A) DMD9QW2 MA Inhibitor DMD9QW2 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMD9QW2 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMD9VC1 DI DMD9VC1 DMD9VC1 DN Benzimidazolone acetamide derivative 2 DMD9VC1 TI TTPTXIN DMD9VC1 TN Translocator protein (TSPO) DMD9VC1 MA Ligand DMD9VC1 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMD9VC1 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMD9W6H DI DMD9W6H DMD9W6H DN PMID28454500-Compound-10 DMD9W6H TI TTA6ZN2 DMD9W6H TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMD9W6H MA Activator DMD9W6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMD9W6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMD9W6H DI DMD9W6H DMD9W6H DN PMID28454500-Compound-10 DMD9W6H TI TT3Z6Y9 DMD9W6H TN Cysteines of Keap1 (KEAP1 Cysteines) DMD9W6H MA Modulator DMD9W6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMD9W6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMD9WRS DI DMD9WRS DMD9WRS DN PMID26815044-Compound-49 DMD9WRS TI TTULVH8 DMD9WRS TN Tyrosinase (TYR) DMD9WRS MA Inhibitor DMD9WRS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMD9WRS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDA3PN DI DMDA3PN DMDA3PN DN PMID27828716-Compound-20 DMDA3PN TI TTRZQE3 DMDA3PN TN Glycogen synthase kinase-3 alpha (GSK-3A) DMDA3PN MA Inhibitor DMDA3PN RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMDA3PN RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMDB5FH DI DMDB5FH DMDB5FH DN Pyrazole derivative 27 DMDB5FH TI TT6OEDT DMDB5FH TN Cannabinoid receptor 1 (CB1) DMDB5FH MA Antagonist DMDB5FH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDB5FH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDBK6O DI DMDBK6O DMDBK6O DN Isochroman-4-ketone derivative 1 DMDBK6O TI TTEB0GD DMDBK6O TN Cholinesterase (BCHE) DMDBK6O MA Inhibitor DMDBK6O RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDBK6O RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDBK6O DI DMDBK6O DMDBK6O DN Isochroman-4-ketone derivative 1 DMDBK6O TI TT1RS9F DMDBK6O TN Acetylcholinesterase (AChE) DMDBK6O MA Inhibitor DMDBK6O RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDBK6O RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDCN43 DI DMDCN43 DMDCN43 DN PMID30107136-Compound-Example3 DMDCN43 TI TT23XQV DMDCN43 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMDCN43 MA Inhibitor DMDCN43 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMDCN43 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMDCZVI DI DMDCZVI DMDCZVI DN PMID25772215-Compound-WO2012177618M6 DMDCZVI TI TT1ZAVI DMDCZVI TN Prostaglandin E2 receptor EP2 (PTGER2) DMDCZVI MA Antagonist DMDCZVI RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMDCZVI RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMDEHYR DI DMDEHYR DMDEHYR DN PMID28454500-Compound-58 DMDEHYR TI TTA6ZN2 DMDEHYR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMDEHYR MA Inhibitor DMDEHYR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMDEHYR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMDEHYR DI DMDEHYR DMDEHYR DN PMID28454500-Compound-58 DMDEHYR TI TTGIZLN DMDEHYR TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMDEHYR MA Modulator DMDEHYR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMDEHYR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMDELNU DI DMDELNU DMDELNU DN US9040714, 155 DMDELNU TI TTOJ9QL DMDELNU TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMDELNU MA Inhibitor DMDELNU RN IRE-1 inhibitors. US9040714. DMDELNU RU http://www.freepatentsonline.com/US9040714.html DMDETKY DI DMDETKY DMDETKY DN Pyrazole and thiophene derivative 4 DMDETKY TI TTRA6BO DMDETKY TN Bromodomain-containing protein 4 (BRD4) DMDETKY MA Inhibitor DMDETKY RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDETKY RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDFL6B DI DMDFL6B DMDFL6B DN Heteroaryl-azepine derivative 2 DMDFL6B TI TTWJBZ5 DMDFL6B TN 5-HT 2C receptor (HTR2C) DMDFL6B MA Agonist DMDFL6B RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMDFL6B RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMDFPIO DI DMDFPIO DMDFPIO DN PMID29130358-Compound-Figure13(4) DMDFPIO TI TTLM12X DMDFPIO TN Matrix metalloproteinase-2 (MMP-2) DMDFPIO MA Inhibitor DMDFPIO RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMDFPIO RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMDFPIO DI DMDFPIO DMDFPIO DN PMID29130358-Compound-Figure13(4) DMDFPIO TI TT6X50U DMDFPIO TN Matrix metalloproteinase-9 (MMP-9) DMDFPIO MA Inhibitor DMDFPIO RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMDFPIO RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMDFUBH DI DMDFUBH DMDFUBH DN Piperazine derivative 5 DMDFUBH TI TTQR74A DMDFUBH TN Proteinase activated receptor 2 (PAR2) DMDFUBH MA Antagonist DMDFUBH RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMDFUBH RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMDG5T9 DI DMDG5T9 DMDG5T9 DN Peptide analog 52 DMDG5T9 TI TT2F4OL DMDG5T9 TN Tissue transglutaminase (TG2) DMDG5T9 MA Inhibitor DMDG5T9 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMDG5T9 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMDGSKH DI DMDGSKH DMDGSKH DN Pyrazole derivative 5 DMDGSKH TI TT6OEDT DMDGSKH TN Cannabinoid receptor 1 (CB1) DMDGSKH MA Antagonist DMDGSKH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDGSKH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTT7PJU DMDHGPN TN Janus kinase 3 (JAK-3) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTRMX3V DMDHGPN TN Janus kinase 2 (JAK-2) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TT6DM01 DMDHGPN TN Janus kinase 1 (JAK-1) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTBYWP2 DMDHGPN TN TYK2 tyrosine kinase (TYK2) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHJMU DI DMDHJMU DMDHJMU DN PMID25684022-Compound-US20130053382 35(1-11) DMDHJMU TI TTCZOF2 DMDHJMU TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDHJMU MA Inhibitor DMDHJMU RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDHJMU RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMDIYJ1 DI DMDIYJ1 DMDIYJ1 DN Biphenyl mannoside derivative 20 DMDIYJ1 TI TTTCRU2 DMDIYJ1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMDIYJ1 MA Antagonist DMDIYJ1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMDIYJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMDJ6O8 DI DMDJ6O8 DMDJ6O8 DN PMID29053063-Compound-7b DMDJ6O8 TI TTZ963I DMDJ6O8 TN Monoglyceride lipase (MAGL) DMDJ6O8 MA Inhibitor DMDJ6O8 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDJ6O8 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDJC96 DI DMDJC96 DMDJC96 DN N-oxalylglycine derivative 2 DMDJC96 TI TT0RGE9 DMDJC96 TN Lysine-specific demethylase 4 (KDM4) DMDJC96 MA Inhibitor DMDJC96 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMDJC96 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMDJFUX DI DMDJFUX DMDJFUX DN PMID29338548-Compound-13 DMDJFUX TI TTHJTF7 DMDJFUX TN Glycine transporter GlyT-1 (SLC6A9) DMDJFUX MA Inhibitor DMDJFUX RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMDJFUX RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMDJGPC DI DMDJGPC DMDJGPC DN PMID25656651-Compound-31c DMDJGPC TI TTIV39N DMDJGPC TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMDJGPC MA Inhibitor DMDJGPC RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMDJGPC RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMDJM1Y DI DMDJM1Y DMDJM1Y DN PMID27215781-Compound-29 DMDJM1Y TI TTMSFAW DMDJM1Y TN Cannabinoid receptor 2 (CB2) DMDJM1Y MA Agonist DMDJM1Y RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMDJM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TT6DM01 DMDK4RI TN Janus kinase 1 (JAK-1) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTBYWP2 DMDK4RI TN TYK2 tyrosine kinase (TYK2) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTRMX3V DMDK4RI TN Janus kinase 2 (JAK-2) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTT7PJU DMDK4RI TN Janus kinase 3 (JAK-3) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK7LQ DI DMDK7LQ DMDK7LQ DN Bicarboxylic and tricarboxylic ethynyl derivative 1 DMDK7LQ TI TTHS256 DMDK7LQ TN Metabotropic glutamate receptor 5 (mGluR5) DMDK7LQ MA Modulator DMDK7LQ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMDK7LQ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMDK98P DI DMDK98P DMDK98P DN US8598210, Table XV, 2 DMDK98P TI TT9ISBX DMDK98P TN HIF-prolyl hydroxylase 2 (HPH-2) DMDK98P MA Inhibitor DMDK98P RN Prolyl hydroxylase inhibitors and methods of use. US9598370. DMDK98P RU http://www.freepatentsonline.com/US9598370.html DMDKSJQ DI DMDKSJQ DMDKSJQ DN PMID30259754-Compound-WAY-362450 DMDKSJQ TI TTS4UGC DMDKSJQ TN Farnesoid X-activated receptor (FXR) DMDKSJQ MA Agonist DMDKSJQ RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DMDKSJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DMDKT9X DI DMDKT9X DMDKT9X DN PMID29649907-Compound-1 DMDKT9X TI TTS4UGC DMDKT9X TN Farnesoid X-activated receptor (FXR) DMDKT9X MA Agonist DMDKT9X RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMDKT9X RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMDL3A5 DI DMDL3A5 DMDL3A5 DN Piperazine derivative 6 DMDL3A5 TI TT473XN DMDL3A5 TN P2X purinoceptor 7 (P2RX7) DMDL3A5 MA Antagonist DMDL3A5 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMDL3A5 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMDL6TG DI DMDL6TG DMDL6TG DN PMID25399762-Compound-Figure1-Sarcaboside B DMDL6TG TI TT3WG5C DMDL6TG TN Monoamine oxidase type A (MAO-A) DMDL6TG MA Inhibitor DMDL6TG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDL6TG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDLPB7 DI DMDLPB7 DMDLPB7 DN PMID25482888-Compound-52 DMDLPB7 TI TTDIGC1 DMDLPB7 TN Dipeptidyl peptidase 4 (DPP-4) DMDLPB7 MA Inhibitor DMDLPB7 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMDLPB7 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMDLS54 DI DMDLS54 DMDLS54 DN Poly-substituted azoles statin lactone derivative 1 DMDLS54 TI TTPADOQ DMDLS54 TN HMG-CoA reductase (HMGCR) DMDLS54 MA Inhibitor DMDLS54 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMDLS54 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMDLVXU DI DMDLVXU DMDLVXU DN PMID26666989-Compound-Figure12bottomright DMDLVXU TI TT8BUGW DMDLVXU TN Glycogen phosphorylase (PYG) DMDLVXU MA Inhibitor DMDLVXU RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMDLVXU RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMDLY38 DI DMDLY38 DMDLY38 DN Benzothiazole analog 3 DMDLY38 TI TTULVH8 DMDLY38 TN Tyrosinase (TYR) DMDLY38 MA Inhibitor DMDLY38 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMDLY38 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDM806 DI DMDM806 DMDM806 DN Benzanilide compound 2 DMDM806 TI TTUX68I DMDM806 TN Hypoxia-inducible factor 1 (HIF-1) DMDM806 MA Inhibitor DMDM806 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMDM806 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMDMEHQ DI DMDMEHQ DMDMEHQ DN PMID27109571-Compound-29 DMDMEHQ TI TTNT2S6 DMDMEHQ TN Fatty acid-binding protein 5 (FABP5) DMDMEHQ MA Inhibitor DMDMEHQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDMEHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDMEHQ DI DMDMEHQ DMDMEHQ DN PMID27109571-Compound-29 DMDMEHQ TI TTHWMFZ DMDMEHQ TN Fatty acid-binding protein 4 (FABP4) DMDMEHQ MA Inhibitor DMDMEHQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDMEHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDMFJG DI DMDMFJG DMDMFJG DN PMID25666693-Compound-62 DMDMFJG TI TTMI6F5 DMDMFJG TN Transient receptor potential cation channel V1 (TRPV1) DMDMFJG MA Antagonist DMDMFJG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMDMFJG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMDMJYL DI DMDMJYL DMDMJYL DN PMID25684022-Compound-WO2008005457 DMDMJYL TI TTCZOF2 DMDMJYL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDMJYL MA Inhibitor DMDMJYL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDMJYL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMDN4KP DI DMDN4KP DMDN4KP DN PMID29166791-Compound-AMPCP DMDN4KP TI TTK0O6Y DMDN4KP TN Ecto-5'-nucleotidase (CD73) DMDN4KP MA Inhibitor DMDN4KP RN Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.Expert Opin Ther Pat. 2018 Feb;28(2):167-171. DMDN4KP RU https://www.ncbi.nlm.nih.gov/pubmed/29166791 DMDN5Q4 DI DMDN5Q4 DMDN5Q4 DN PMID26924192-Compound-24 DMDN5Q4 TI TTRA6BO DMDN5Q4 TN Bromodomain-containing protein 4 (BRD4) DMDN5Q4 MA Inhibitor DMDN5Q4 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDN5Q4 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDN8P1 DI DMDN8P1 DMDN8P1 DN US8877733, 27 DMDN8P1 TI TTQFZWR DMDN8P1 TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMDN8P1 MA Inhibitor DMDN8P1 RN 1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733. DMDN8P1 RU http://www.freepatentsonline.com/US8877733.html DMDOB20 DI DMDOB20 DMDOB20 DN Diaryl piperazine derivative 2 DMDOB20 TI TT6OEDT DMDOB20 TN Cannabinoid receptor 1 (CB1) DMDOB20 MA Antagonist DMDOB20 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDOB20 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDOCTB DI DMDOCTB DMDOCTB DN Benzamide derivative 1 DMDOCTB TI TT9NXW4 DMDOCTB TN Sigma intracellular receptor 2 (TMEM97) DMDOCTB MA Ligand DMDOCTB RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMDOCTB RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMDOEFC DI DMDOEFC DMDOEFC DN Ethynyl compound 6 DMDOEFC TI TTHS256 DMDOEFC TN Metabotropic glutamate receptor 5 (mGluR5) DMDOEFC MA Modulator DMDOEFC RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMDOEFC RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMDOQKY DI DMDOQKY DMDOQKY DN Heteroaryl-azepine derivative 1 DMDOQKY TI TTWJBZ5 DMDOQKY TN 5-HT 2C receptor (HTR2C) DMDOQKY MA Agonist DMDOQKY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMDOQKY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMDOVIZ DI DMDOVIZ DMDOVIZ DN PMID28447479-Compound-24 DMDOVIZ TI TTSCIM2 DMDOVIZ TN Extracellular lysophospholipase D (E-NPP2) DMDOVIZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMDOVIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMDP09N DI DMDP09N DMDP09N DN Urea and carbamate bioisostere derivative 14 DMDP09N TI TTL7C8Q DMDP09N TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMDP09N MA Inhibitor DMDP09N RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMDP09N RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMDP4GY DI DMDP4GY DMDP4GY DN Aminopyrimidine derivative 3 DMDP4GY TI TTS7G69 DMDP4GY TN Fusion protein Bcr-Abl (Bcr-Abl) DMDP4GY MA Inhibitor DMDP4GY RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMDP4GY RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMDP87V DI DMDP87V DMDP87V DN US8563594, 152 DMDP87V TI TTDYP7I DMDP87V TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMDP87V MA Inhibitor DMDP87V RN S1P3 receptor inhibitors for treating pain. US8563594. DMDP87V RU http://www.freepatentsonline.com/US8563594.html DMDP8J0 DI DMDP8J0 DMDP8J0 DN PMID26004420-Compound-US20140031349C DMDP8J0 TI TTJ13ST DMDP8J0 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMDP8J0 MA Inhibitor DMDP8J0 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMDP8J0 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMDPHT1 DI DMDPHT1 DMDPHT1 DN Azole benzene derivative 4 DMDPHT1 TI TT7RJY8 DMDPHT1 TN Xanthine dehydrogenase/oxidase (XDH) DMDPHT1 MA Inhibitor DMDPHT1 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMDPHT1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMDQ6H7 DI DMDQ6H7 DMDQ6H7 DN PMID25553724-Compound-US2012820715110 DMDQ6H7 TI TTSXVID DMDQ6H7 TN Nuclear factor NF-kappa-B (NFKB) DMDQ6H7 MA Inhibitor DMDQ6H7 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMDQ6H7 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMDQLUP DI DMDQLUP DMDQLUP DN Imidazo[1,2-b]pyridazine derivative 7 DMDQLUP TI TTTDVOJ DMDQLUP TN Tropomyosin-related kinase A (TrkA) DMDQLUP MA Inhibitor DMDQLUP RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMDQLUP RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMDQMZT DI DMDQMZT DMDQMZT DN PMID27410995-Compound-Figure3c DMDQMZT TI TTG0U4H DMDQMZT TN Ribosomal protein S6 kinase beta-1 (S6K1) DMDQMZT MA Inhibitor DMDQMZT RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMDQMZT RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMDQNKW DI DMDQNKW DMDQNKW DN Pyrimidinone derivative 4 DMDQNKW TI TTPLTSQ DMDQNKW TN Neutrophil elastase (NE) DMDQNKW MA Inhibitor DMDQNKW RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMDQNKW RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMDQTA2 DI DMDQTA2 DMDQTA2 DN PMID26651364-Compound-5c DMDQTA2 TI TTTCRU2 DMDQTA2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMDQTA2 MA Antagonist DMDQTA2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMDQTA2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMDQYJ1 DI DMDQYJ1 DMDQYJ1 DN Hydroxamate analog 3 DMDQYJ1 TI TT0RGE9 DMDQYJ1 TN Lysine-specific demethylase 4 (KDM4) DMDQYJ1 MA Inhibitor DMDQYJ1 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMDQYJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMDRIZF DI DMDRIZF DMDRIZF DN Quinazolinone derivative 3 DMDRIZF TI TTE4BSY DMDRIZF TN Bromodomain and extraterminal domain protein (BET) DMDRIZF MA Inhibitor DMDRIZF RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDRIZF RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDRJ31 DI DMDRJ31 DMDRJ31 DN Antibodie derivative 9 DMDRJ31 TI TTOHSBA DMDRJ31 TN Vascular endothelial growth factor A (VEGFA) DMDRJ31 MA Stablizer DMDRJ31 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMDRJ31 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMDRJHO DI DMDRJHO DMDRJHO DN PMID29338548-Compound-48 DMDRJHO TI TTHJTF7 DMDRJHO TN Glycine transporter GlyT-1 (SLC6A9) DMDRJHO MA Inhibitor DMDRJHO RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMDRJHO RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTDP1UC DMDRK68 TN Fatty acid amide hydrolase (FAAH) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTZ963I DMDRK68 TN Monoglyceride lipase (MAGL) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTSINOV DMDRK68 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDS2CU DI DMDS2CU DMDS2CU DN PMID26560530-Compound-23 DMDS2CU TI TT2F4OL DMDS2CU TN Tissue transglutaminase (TG2) DMDS2CU MA Inhibitor DMDS2CU RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMDS2CU RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMDSUGF DI DMDSUGF DMDSUGF DN Aniline derivative 1 DMDSUGF TI TT7HF4W DMDSUGF TN Cyclin-dependent kinase 2 (CDK2) DMDSUGF MA Inhibitor DMDSUGF RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMDSUGF RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMDSUGF DI DMDSUGF DMDSUGF DN Aniline derivative 1 DMDSUGF TI TTBH0VX DMDSUGF TN Histone deacetylase (HDAC) DMDSUGF MA Inhibitor DMDSUGF RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMDSUGF RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMDT5JI DI DMDT5JI DMDT5JI DN Phenylpyridine derivative 3 DMDT5JI TI TTQVOEI DMDT5JI TN Angiotensin II receptor type-2 (AGTR2) DMDT5JI MA Agonist DMDT5JI RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMDT5JI RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMDT5JI DI DMDT5JI DMDT5JI DN Phenylpyridine derivative 3 DMDT5JI TI TTZMAO3 DMDT5JI TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDT5JI MA Agonist DMDT5JI RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMDT5JI RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMDTQCG DI DMDTQCG DMDTQCG DN Pyrazole derivative 31 DMDTQCG TI TT6OEDT DMDTQCG TN Cannabinoid receptor 1 (CB1) DMDTQCG MA Antagonist DMDTQCG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDTQCG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDTYJ9 DI DMDTYJ9 DMDTYJ9 DN BDBM50434165 DMDTYJ9 TI TTOYT5L DMDTYJ9 TN Dipeptidyl-peptidase 7 (DPP7) DMDTYJ9 MA Inhibitor DMDTYJ9 RN FAP inhibitors. US9346814. DMDTYJ9 RU http://www.freepatentsonline.com/US9346814.html DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTEAD9J DMDU21R TN Proteasome beta-8 (PS beta-8) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT68GPI DMDU21R TN Proteasome beta-5 (PS beta-5) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTOUSTQ DMDU21R TN Proteasome beta-9 (PS beta-9) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT8EPLT DMDU21R TN Proteasome beta-1 (PS beta-1) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTPNACM DMDU21R TN Proteasome beta-10 (PS beta-10) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT49BVC DMDU21R TN Proteasome beta-2 (PS beta-2) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU9XF DI DMDU9XF DMDU9XF DN Carbamide derivative 26 DMDU9XF TI TTDP1UC DMDU9XF TN Fatty acid amide hydrolase (FAAH) DMDU9XF MA Inhibitor DMDU9XF RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDU9XF RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDU9XF DI DMDU9XF DMDU9XF DN Carbamide derivative 26 DMDU9XF TI TTZ963I DMDU9XF TN Monoglyceride lipase (MAGL) DMDU9XF MA Inhibitor DMDU9XF RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDU9XF RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDUSN5 DI DMDUSN5 DMDUSN5 DN PMID28766366-Compound-Scheme8NCGC-00185981 DMDUSN5 TI TTSBVFO DMDUSN5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMDUSN5 MA Inhibitor DMDUSN5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDUSN5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDUXRT DI DMDUXRT DMDUXRT DN PMID26815044-Compound-116 DMDUXRT TI TTULVH8 DMDUXRT TN Tyrosinase (TYR) DMDUXRT MA Inhibitor DMDUXRT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMDUXRT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TT1RS9F DMDV0MP TN Acetylcholinesterase (AChE) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TTGP7BY DMDV0MP TN Monoamine oxidase type B (MAO-B) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TT3WG5C DMDV0MP TN Monoamine oxidase type A (MAO-A) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TTEB0GD DMDV0MP TN Cholinesterase (BCHE) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV6EY DI DMDV6EY DMDV6EY DN Quinoline derivative 3 DMDV6EY TI TTXJ47W DMDV6EY TN Metabotropic glutamate receptor 2 (mGluR2) DMDV6EY MA Antagonist DMDV6EY RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMDV6EY RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMDWH8T DI DMDWH8T DMDWH8T DN PMID25666693-Compound-64 DMDWH8T TI TTMI6F5 DMDWH8T TN Transient receptor potential cation channel V1 (TRPV1) DMDWH8T MA Antagonist DMDWH8T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMDWH8T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMDWIPG DI DMDWIPG DMDWIPG DN PMID25399762-Compound-Table 6-9 DMDWIPG TI TTGP7BY DMDWIPG TN Monoamine oxidase type B (MAO-B) DMDWIPG MA Inhibitor DMDWIPG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDWIPG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDWIPG DI DMDWIPG DMDWIPG DN PMID25399762-Compound-Table 6-9 DMDWIPG TI TTNR0UQ DMDWIPG TN Lysine-specific histone demethylase 1 (LSD) DMDWIPG MA Inhibitor DMDWIPG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDWIPG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDWSIE DI DMDWSIE DMDWSIE DN PMID29649907-Compound-5 DMDWSIE TI TTS4UGC DMDWSIE TN Farnesoid X-activated receptor (FXR) DMDWSIE MA Agonist DMDWSIE RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMDWSIE RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMDX1MK DI DMDX1MK DMDX1MK DN PMID25399762-Compound-Figure1-Eryngiolide A DMDX1MK TI TT3WG5C DMDX1MK TN Monoamine oxidase type A (MAO-A) DMDX1MK MA Inhibitor DMDX1MK RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDX1MK RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDXIU9 DI DMDXIU9 DMDXIU9 DN PMID28766366-Compound-Scheme4Bottom DMDXIU9 TI TTYGQ8A DMDXIU9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMDXIU9 MA Inhibitor DMDXIU9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDXIU9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDXIU9 DI DMDXIU9 DMDXIU9 DN PMID28766366-Compound-Scheme4Bottom DMDXIU9 TI TTSBVFO DMDXIU9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMDXIU9 MA Inhibitor DMDXIU9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDXIU9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDXMH9 DI DMDXMH9 DMDXMH9 DN PMID27109571-Compound-3 DMDXMH9 TI TTMY6L1 DMDXMH9 TN Fatty acid-binding protein (FABP) DMDXMH9 MA Inhibitor DMDXMH9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDXMH9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDYKPC DI DMDYKPC DMDYKPC DN Lactam derivative 1 DMDYKPC TI TTF8P9I DMDYKPC TN Diacylglycerol acyltransferase 1 (DGAT1) DMDYKPC MA Inhibitor DMDYKPC RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMDYKPC RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTALN9W DMDYXKT TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTZJYKH DMDYXKT TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTXNCBV DMDYXKT TN Tryptophan 2,3-dioxygenase (TDO) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDZ7QS DI DMDZ7QS DMDZ7QS DN Benzenamine derivative 2 DMDZ7QS TI TTNR0UQ DMDZ7QS TN Lysine-specific histone demethylase 1 (LSD) DMDZ7QS MA Inhibitor DMDZ7QS RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMDZ7QS RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMDZHAB DI DMDZHAB DMDZHAB DN PMID26004420-Compound-WO2013062900C DMDZHAB TI TTJ13ST DMDZHAB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMDZHAB MA Inhibitor DMDZHAB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMDZHAB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMDZKXC DI DMDZKXC DMDZKXC DN PMID27774824-Compound-Figure5Example13 DMDZKXC TI TTT7PJU DMDZKXC TN Janus kinase 3 (JAK-3) DMDZKXC MA Inhibitor DMDZKXC RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDZKXC RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDZT7Y DI DMDZT7Y DMDZT7Y DN PMID25684022-Compound-EP20041486488 DMDZT7Y TI TTCZOF2 DMDZT7Y TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDZT7Y MA Inhibitor DMDZT7Y RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDZT7Y RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DME0RJ2 DI DME0RJ2 DME0RJ2 DN PMID30259754-Compound-INT-767 DME0RJ2 TI TTS4UGC DME0RJ2 TN Farnesoid X-activated receptor (FXR) DME0RJ2 MA Agonist DME0RJ2 RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DME0RJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DME0TUJ DI DME0TUJ DME0TUJ DN PMID28270010-Compound-Figure17-3 DME0TUJ TI TTTDVOJ DME0TUJ TN Tropomyosin-related kinase A (TrkA) DME0TUJ MA Inhibitor DME0TUJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DME0TUJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTXABCW DME0WSR TN NT-3 growth factor receptor (TrkC) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTTDVOJ DME0WSR TN Tropomyosin-related kinase A (TrkA) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTKN7QR DME0WSR TN BDNF/NT-3 growth factors receptor (TrkB) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0XS4 DI DME0XS4 DME0XS4 DN PMID25514969-Compound-10 DME0XS4 TI TT4EB85 DME0XS4 TN Cholesterol 24-hydroxylase (CYP46A1) DME0XS4 MA Inhibitor DME0XS4 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DME0XS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DME1A80 DI DME1A80 DME1A80 DN US8921389, 210 DME1A80 TI TT9ISBX DME1A80 TN HIF-prolyl hydroxylase 2 (HPH-2) DME1A80 MA Inhibitor DME1A80 RN Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170. DME1A80 RU http://www.freepatentsonline.com/US9695170.html DME1B23 DI DME1B23 DME1B23 DN Sterol derivative 2 DME1B23 TI TTPADOQ DME1B23 TN HMG-CoA reductase (HMGCR) DME1B23 MA Inhibitor DME1B23 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DME1B23 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DME1Q3W DI DME1Q3W DME1Q3W DN Pyrrolo-pyridinone derivative 3 DME1Q3W TI TT4DXQT DME1Q3W TN Proto-oncogene c-Ret (RET) DME1Q3W MA Inhibitor DME1Q3W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DME1Q3W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DME1WHT DI DME1WHT DME1WHT DN PMID28092474-Compound-32h DME1WHT TI TT6R7JZ DME1WHT TN Histone deacetylase 1 (HDAC1) DME1WHT MA Inhibitor DME1WHT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DME1WHT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DME1WHT DI DME1WHT DME1WHT DN PMID28092474-Compound-32h DME1WHT TI TT5ZKDI DME1WHT TN Histone deacetylase 6 (HDAC6) DME1WHT MA Inhibitor DME1WHT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DME1WHT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DME24BI DI DME24BI DME24BI DN Quinazolines and azaquinazoline derivative 1 DME24BI TI TTZCRP3 DME24BI TN ERK activator kinase (MEK) DME24BI MA Inhibitor DME24BI RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DME24BI RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DME26SY DI DME26SY DME26SY DN Piperonal DME26SY TI TTGP7BY DME26SY TN Monoamine oxidase type B (MAO-B) DME26SY MA Inhibitor DME26SY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DME26SY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DME2AZG DI DME2AZG DME2AZG DN US10150740, Example 1 DME2AZG TI TTQFZWR DME2AZG TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DME2AZG MA Inhibitor DME2AZG RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DME2AZG RU http://www.freepatentsonline.com/US10150740.html DME2IHD DI DME2IHD DME2IHD DN PMID27841045-Compound-129 DME2IHD TI TT7RJY8 DME2IHD TN Xanthine dehydrogenase/oxidase (XDH) DME2IHD MA Inhibitor DME2IHD RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DME2IHD RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DME30O6 DI DME30O6 DME30O6 DN 4-(2-cyclohexylethoxy) aniline derivative 1 DME30O6 TI TTA6ZN2 DME30O6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DME30O6 MA Inhibitor DME30O6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DME30O6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DME3HLC DI DME3HLC DME3HLC DN PMID28870136-Compound-57 DME3HLC TI TTK0O6Y DME3HLC TN Ecto-5'-nucleotidase (CD73) DME3HLC MA Inhibitor DME3HLC RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DME3HLC RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DME3NTB DI DME3NTB DME3NTB DN PMID25666693-Compound-96 DME3NTB TI TTMI6F5 DME3NTB TN Transient receptor potential cation channel V1 (TRPV1) DME3NTB MA Antagonist DME3NTB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DME3NTB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TT6DM01 DME3TMS TN Janus kinase 1 (JAK-1) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTRMX3V DME3TMS TN Janus kinase 2 (JAK-2) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TT3PJMV DME3TMS TN Tyrosine-protein kinase ABL1 (ABL) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTBYWP2 DME3TMS TN TYK2 tyrosine kinase (TYK2) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTT7PJU DME3TMS TN Janus kinase 3 (JAK-3) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3YRI DI DME3YRI DME3YRI DN PMID28870136-Compound-67 DME3YRI TI TTK0O6Y DME3YRI TN Ecto-5'-nucleotidase (CD73) DME3YRI MA Inhibitor DME3YRI RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DME3YRI RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DME3ZJO DI DME3ZJO DME3ZJO DN PMID25980951-Compound-10 DME3ZJO TI TTR7B60 DME3ZJO TN X-linked inhibitor of apoptosis protein (XIAP) DME3ZJO MA Antagonist DME3ZJO RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DME3ZJO RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DME40TS DI DME40TS DME40TS DN PMID25470667-Compound-GO-CoA-Tat DME40TS TI TTSYOWR DME40TS TN Ghrelin O acyltransferase (GOAT) DME40TS MA Inhibitor DME40TS RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DME40TS RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DME4OGJ DI DME4OGJ DME4OGJ DN Resorcinol compound 20 DME4OGJ TI TTULVH8 DME4OGJ TN Tyrosinase (TYR) DME4OGJ MA Inhibitor DME4OGJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DME4OGJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DME57SJ DI DME57SJ DME57SJ DN P-toluenesulfonate derivative 1 DME57SJ TI TTZCRP3 DME57SJ TN ERK activator kinase (MEK) DME57SJ MA Inhibitor DME57SJ RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DME57SJ RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DME5WLD DI DME5WLD DME5WLD DN 2-pyrazinone derivative 3 DME5WLD TI TTPLTSQ DME5WLD TN Neutrophil elastase (NE) DME5WLD MA Inhibitor DME5WLD RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DME5WLD RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DME60LY DI DME60LY DME60LY DN PMID26924192-Compound-23 DME60LY TI TTRA6BO DME60LY TN Bromodomain-containing protein 4 (BRD4) DME60LY MA Inhibitor DME60LY RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DME60LY RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DME6FLN DI DME6FLN DME6FLN DN Phenylsulfonyl derivative 3 DME6FLN TI TT9JNIC DME6FLN TN Histamine H3 receptor (H3R) DME6FLN MA Inhibitor DME6FLN RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DME6FLN RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DME6FWY DI DME6FWY DME6FWY DN PMID28394193-Compound-44 DME6FWY TI TT9MZCQ DME6FWY TN Enhancer of zeste homolog 2 (EZH2) DME6FWY MA Inhibitor DME6FWY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DME6FWY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DME6H8Q DI DME6H8Q DME6H8Q DN PMID29649907-Compound-31 DME6H8Q TI TTS4UGC DME6H8Q TN Farnesoid X-activated receptor (FXR) DME6H8Q MA Agonist DME6H8Q RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DME6H8Q RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DME6P7T DI DME6P7T DME6P7T DN Quinolone derivative 1 DME6P7T TI TTL7C8Q DME6P7T TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DME6P7T MA Inhibitor DME6P7T RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DME6P7T RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DME72VA DI DME72VA DME72VA DN Macrolactam derivative 2 DME72VA TI TTKFVXR DME72VA TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DME72VA MA Inhibitor DME72VA RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DME72VA RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DME72ZH DI DME72ZH DME72ZH DN PMID28350212-Compound-12 DME72ZH TI TTZS04O DME72ZH TN Gamma-secretase subunit APH-1A/1B (APH-1) DME72ZH MA Inhibitor DME72ZH RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DME72ZH RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DME7M5R DI DME7M5R DME7M5R DN Imidazopyridine acetamide analog 6 DME7M5R TI TTPTXIN DME7M5R TN Translocator protein (TSPO) DME7M5R MA Ligand DME7M5R RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DME7M5R RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DME7UNT DI DME7UNT DME7UNT DN PMID26651364-Compound-8c DME7UNT TI TTTCRU2 DME7UNT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DME7UNT MA Antagonist DME7UNT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DME7UNT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DME84S5 DI DME84S5 DME84S5 DN Tricyclic compound 7 DME84S5 TI TTGWKQJ DME84S5 TN Rho-associated protein kinase 2 (ROCK2) DME84S5 MA Inhibitor DME84S5 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DME84S5 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DME86DP DI DME86DP DME86DP DN Heteroaryl-azepine derivative 13 DME86DP TI TTWJBZ5 DME86DP TN 5-HT 2C receptor (HTR2C) DME86DP MA Agonist DME86DP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DME86DP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DME8CQA DI DME8CQA DME8CQA DN Isoxazole-based bicyclic compound 18 DME8CQA TI TTE4BSY DME8CQA TN Bromodomain and extraterminal domain protein (BET) DME8CQA MA Inhibitor DME8CQA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DME8CQA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DME8DQ0 DI DME8DQ0 DME8DQ0 DN Biaryl mannoside derivative 19 DME8DQ0 TI TTTCRU2 DME8DQ0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DME8DQ0 MA Antagonist DME8DQ0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DME8DQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DME8JTW DI DME8JTW DME8JTW DN Indazole derivative 1 DME8JTW TI TTCZOF2 DME8JTW TN Pyruvate dehydrogenase kinase 1 (PDHK1) DME8JTW MA Inhibitor DME8JTW RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DME8JTW RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DME8LUY DI DME8LUY DME8LUY DN PMID25666693-Compound-157 DME8LUY TI TTMI6F5 DME8LUY TN Transient receptor potential cation channel V1 (TRPV1) DME8LUY MA Antagonist DME8LUY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DME8LUY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DME8MN1 DI DME8MN1 DME8MN1 DN 1,2,4-triazole derivative 1 DME8MN1 TI TT6OEDT DME8MN1 TN Cannabinoid receptor 1 (CB1) DME8MN1 MA Antagonist DME8MN1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DME8MN1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DME8Q0F DI DME8Q0F DME8Q0F DN Pyrazole derivative 84 DME8Q0F TI TTDP1UC DME8Q0F TN Fatty acid amide hydrolase (FAAH) DME8Q0F MA Inhibitor DME8Q0F RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DME8Q0F RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DME8Q0F DI DME8Q0F DME8Q0F DN Pyrazole derivative 84 DME8Q0F TI TTZ963I DME8Q0F TN Monoglyceride lipase (MAGL) DME8Q0F MA Inhibitor DME8Q0F RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DME8Q0F RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DME9QCM DI DME9QCM DME9QCM DN PMID25726713-Compound-43 DME9QCM TI TT8J1S3 DME9QCM TN Smoothened homolog (SMO) DME9QCM MA Inhibitor DME9QCM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DME9QCM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEAO42 DI DMEAO42 DMEAO42 DN Carbamate derivative 8 DMEAO42 TI TTDP1UC DMEAO42 TN Fatty acid amide hydrolase (FAAH) DMEAO42 MA Inhibitor DMEAO42 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEAO42 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEARS2 DI DMEARS2 DMEARS2 DN US9200020, Table 3, Compound 1B DMEARS2 TI TTBL49X DMEARS2 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMEARS2 MA Inhibitor DMEARS2 RN 6-oxopurine phosphoribosyltransferase inhibitors. US9200020. DMEARS2 RU http://www.freepatentsonline.com/US9200020.html DMEASZY DI DMEASZY DMEASZY DN PMID28092474-Compound-32q DMEASZY TI TT6R7JZ DMEASZY TN Histone deacetylase 1 (HDAC1) DMEASZY MA Inhibitor DMEASZY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEASZY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEASZY DI DMEASZY DMEASZY DN PMID28092474-Compound-32q DMEASZY TI TT5ZKDI DMEASZY TN Histone deacetylase 6 (HDAC6) DMEASZY MA Inhibitor DMEASZY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEASZY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEAUJT DI DMEAUJT DMEAUJT DN US8901295, F609 DMEAUJT TI TTNAFOU DMEAUJT TN Rotamase D (PPID) DMEAUJT MA Inhibitor DMEAUJT RN Inhibitors of cyclophilins and uses thereof. US8901295. DMEAUJT RU http://www.freepatentsonline.com/US8901295.html DMEB59T DI DMEB59T DMEB59T DN US9714230, 12 DMEB59T TI TTIG67W DMEB59T TN Lysine-specific demethylase 5A (KDM5A) DMEB59T MA Inhibitor DMEB59T RN Histone demethylase inhibitors. US9714230. DMEB59T RU http://www.freepatentsonline.com/US9714230.html DMEBGZJ DI DMEBGZJ DMEBGZJ DN Tetra-hydro-naphthalene derivative 2 DMEBGZJ TI TTDP1UC DMEBGZJ TN Fatty acid amide hydrolase (FAAH) DMEBGZJ MA Inhibitor DMEBGZJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEBGZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEC1TR DI DMEC1TR DMEC1TR DN PMID25828189-Compound-19 DMEC1TR TI TT9O6WS DMEC1TR TN Glucagon receptor (GCGR) DMEC1TR MA Antagonist DMEC1TR RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMEC1TR RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMECJDM DI DMECJDM DMECJDM DN Imidazolidine derivative 1 DMECJDM TI TT473XN DMECJDM TN P2X purinoceptor 7 (P2RX7) DMECJDM MA Antagonist DMECJDM RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMECJDM RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMECOY7 DI DMECOY7 DMECOY7 DN PMID25656651-Compound-38 DMECOY7 TI TTS7G69 DMECOY7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMECOY7 MA Inhibitor DMECOY7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMECOY7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMECU90 DI DMECU90 DMECU90 DN PMID28906174-Compound-figure1g DMECU90 TI TT4TFGN DMECU90 TN Vasopressin V1a receptor (V1AR) DMECU90 MA Antagonist DMECU90 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMECU90 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMECU90 DI DMECU90 DMECU90 DN PMID28906174-Compound-figure1g DMECU90 TI TTSCIUP DMECU90 TN Oxytocin receptor (OTR) DMECU90 MA Antagonist DMECU90 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMECU90 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMECZVG DI DMECZVG DMECZVG DN Biphenyl mannoside derivative 16 DMECZVG TI TTTCRU2 DMECZVG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMECZVG MA Antagonist DMECZVG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMECZVG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMED71P DI DMED71P DMED71P DN PMID29865878-Compound-54 DMED71P TI TTSJMN8 DMED71P TN Immunoproteasome complex (IP) DMED71P MA Inhibitor DMED71P RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMED71P RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTALN9W DMEDFNC TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTZJYKH DMEDFNC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTXNCBV DMEDFNC TN Tryptophan 2,3-dioxygenase (TDO) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDNTJ DI DMEDNTJ DMEDNTJ DN Secondary and tertiary (hetero)arylamide derivative 1 DMEDNTJ TI TTGP7BY DMEDNTJ TN Monoamine oxidase type B (MAO-B) DMEDNTJ MA Inhibitor DMEDNTJ RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMEDNTJ RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMEDXW9 DI DMEDXW9 DMEDXW9 DN Pyrazole derivative 14 DMEDXW9 TI TT6OEDT DMEDXW9 TN Cannabinoid receptor 1 (CB1) DMEDXW9 MA Antagonist DMEDXW9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEDXW9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEFA20 DI DMEFA20 DMEFA20 DN PMID25726713-Compound-44 DMEFA20 TI TT8J1S3 DMEFA20 TN Smoothened homolog (SMO) DMEFA20 MA Inhibitor DMEFA20 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEFA20 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEFQND DI DMEFQND DMEFQND DN Maleimides derivative 3 DMEFQND TI TTRZQE3 DMEFQND TN Glycogen synthase kinase-3 alpha (GSK-3A) DMEFQND MA Inhibitor DMEFQND RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMEFQND RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMEG5YO DI DMEG5YO DMEG5YO DN Tetra-substituted urea derivative 1 DMEG5YO TI TTDP1UC DMEG5YO TN Fatty acid amide hydrolase (FAAH) DMEG5YO MA Inhibitor DMEG5YO RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEG5YO RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEG8CB DI DMEG8CB DMEG8CB DN PMID25666693-Compound-106 DMEG8CB TI TTMI6F5 DMEG8CB TN Transient receptor potential cation channel V1 (TRPV1) DMEG8CB MA Antagonist DMEG8CB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEG8CB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEGBHP DI DMEGBHP DMEGBHP DN PMID26394986-Compound-Figure17 DMEGBHP TI TTH8FZW DMEGBHP TN Signal transducer and activator of transcription 3 (STAT3) DMEGBHP MA Inhibitor DMEGBHP RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMEGBHP RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMEGJ73 DI DMEGJ73 DMEGJ73 DN PMID25435285-Compound-43 DMEGJ73 TI TTXJ47W DMEGJ73 TN Metabotropic glutamate receptor 2 (mGluR2) DMEGJ73 MA Antagonist DMEGJ73 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMEGJ73 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMEGK3Q DI DMEGK3Q DMEGK3Q DN Heterocyclic-fused piperazine derivative 1 DMEGK3Q TI TT473XN DMEGK3Q TN P2X purinoceptor 7 (P2RX7) DMEGK3Q MA Antagonist DMEGK3Q RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMEGK3Q RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMEGRMX DI DMEGRMX DMEGRMX DN PMID27454349-Compound-102 DMEGRMX TI TTK59TV DMEGRMX TN Vitamin D3 receptor (VDR) DMEGRMX MA Agonist DMEGRMX RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMEGRMX RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMEGS7U DI DMEGS7U DMEGS7U DN PMID25991433-Compound-P2 DMEGS7U TI TTVOE6D DMEGS7U TN Mitogen-activated protein kinase (MAPK) DMEGS7U MA Inhibitor DMEGS7U RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEGS7U RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEGS9U DI DMEGS9U DMEGS9U DN Pyrazoline derivative 5 DMEGS9U TI TT6OEDT DMEGS9U TN Cannabinoid receptor 1 (CB1) DMEGS9U MA Antagonist DMEGS9U RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEGS9U RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEGVD4 DI DMEGVD4 DMEGVD4 DN Six-membered heterocyclic benzamide derivative 3 DMEGVD4 TI TTTDVOJ DMEGVD4 TN Tropomyosin-related kinase A (TrkA) DMEGVD4 MA Inhibitor DMEGVD4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMEGVD4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMEH0RC DI DMEH0RC DMEH0RC DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3 DMEH0RC TI TT6OEDT DMEH0RC TN Cannabinoid receptor 1 (CB1) DMEH0RC MA Antagonist DMEH0RC RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEH0RC RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEHIS4 DI DMEHIS4 DMEHIS4 DN PMID27774822-Compound-Figure2Example4-3 DMEHIS4 TI TTT7PJU DMEHIS4 TN Janus kinase 3 (JAK-3) DMEHIS4 MA Inhibitor DMEHIS4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMEHIS4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMEHMKY DI DMEHMKY DMEHMKY DN Mycophenolic acid/nucleotide derivative 4 DMEHMKY TI TTL7C8Q DMEHMKY TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEHMKY MA Inhibitor DMEHMKY RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEHMKY RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMEHSR7 DI DMEHSR7 DMEHSR7 DN US9187437, 8 DMEHSR7 TI TTDYP7I DMEHSR7 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMEHSR7 MA Inhibitor DMEHSR7 RN Substituted oxadiazole compounds. US9187437. DMEHSR7 RU http://www.freepatentsonline.com/US9187437.html DMEHYBJ DI DMEHYBJ DMEHYBJ DN Pyrrolo-pyrimidine derivative 2 DMEHYBJ TI TT4DXQT DMEHYBJ TN Proto-oncogene c-Ret (RET) DMEHYBJ MA Inhibitor DMEHYBJ RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMEHYBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMEIA6Y DI DMEIA6Y DMEIA6Y DN PMID25684022-Compound-US20120277229 45(1.5) DMEIA6Y TI TTCZOF2 DMEIA6Y TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMEIA6Y MA Inhibitor DMEIA6Y RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMEIA6Y RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMEIDC0 DI DMEIDC0 DMEIDC0 DN Pyrrolo-pyrimidine derivative 11 DMEIDC0 TI TTK0FEA DMEIDC0 TN Leucine-rich repeat kinase 2 (LRRK2) DMEIDC0 MA Inhibitor DMEIDC0 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEIDC0 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEIG16 DI DMEIG16 DMEIG16 DN Tricyclic compound 4 DMEIG16 TI TTGWKQJ DMEIG16 TN Rho-associated protein kinase 2 (ROCK2) DMEIG16 MA Inhibitor DMEIG16 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMEIG16 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMEIH73 DI DMEIH73 DMEIH73 DN Quinazoline derivative 5 DMEIH73 TI TTPTXIN DMEIH73 TN Translocator protein (TSPO) DMEIH73 MA Ligand DMEIH73 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMEIH73 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMEIZ6Y DI DMEIZ6Y DMEIZ6Y DN PMID28092474-Compound-32f DMEIZ6Y TI TT6R7JZ DMEIZ6Y TN Histone deacetylase 1 (HDAC1) DMEIZ6Y MA Inhibitor DMEIZ6Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEIZ6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEIZ6Y DI DMEIZ6Y DMEIZ6Y DN PMID28092474-Compound-32f DMEIZ6Y TI TT5ZKDI DMEIZ6Y TN Histone deacetylase 6 (HDAC6) DMEIZ6Y MA Inhibitor DMEIZ6Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEIZ6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTRA6BO DMEJ107 TN Bromodomain-containing protein 4 (BRD4) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTHE657 DMEJ107 TN Bromodomain-containing protein 3 (BRD3) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTDP48B DMEJ107 TN Bromodomain-containing protein 2 (BRD2) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TT7CPI5 DMEJ107 TN Bromodomain testis-specific protein (BRDT) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ4LW DI DMEJ4LW DMEJ4LW DN PMID28074661-Compound-US20128202889C90 DMEJ4LW TI TTL7C8Q DMEJ4LW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEJ4LW MA Inhibitor DMEJ4LW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEJ4LW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMEJMPD DI DMEJMPD DMEJMPD DN PMID25656651-Compound-30b DMEJMPD TI TTS7G69 DMEJMPD TN Fusion protein Bcr-Abl (Bcr-Abl) DMEJMPD MA Inhibitor DMEJMPD RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMEJMPD RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMEJNUG DI DMEJNUG DMEJNUG DN PMID25399762-Compound-Table1-C5 DMEJNUG TI TTGP7BY DMEJNUG TN Monoamine oxidase type B (MAO-B) DMEJNUG MA Inhibitor DMEJNUG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMEJNUG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMEJOPL DI DMEJOPL DMEJOPL DN 2,2-bipyridyl derivative 5 DMEJOPL TI TT0RGE9 DMEJOPL TN Lysine-specific demethylase 4 (KDM4) DMEJOPL MA Inhibitor DMEJOPL RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMEJOPL RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TTNR0UQ DMEJR2F TN Lysine-specific histone demethylase 1 (LSD) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TT8VP2T DMEJR2F TN Lysine-specific histone demethylase 1B (KDM1B) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TTGP7BY DMEJR2F TN Monoamine oxidase type B (MAO-B) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TT3WG5C DMEJR2F TN Monoamine oxidase type A (MAO-A) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEKBOG DI DMEKBOG DMEKBOG DN PMID26815044-Compound-64 DMEKBOG TI TTULVH8 DMEKBOG TN Tyrosinase (TYR) DMEKBOG MA Inhibitor DMEKBOG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEKBOG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMEKO71 DI DMEKO71 DMEKO71 DN Tetra-hydro-quinoline derivative 2 DMEKO71 TI TTE4BSY DMEKO71 TN Bromodomain and extraterminal domain protein (BET) DMEKO71 MA Inhibitor DMEKO71 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEKO71 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEL1WX DI DMEL1WX DMEL1WX DN PMID25666693-Compound-1 DMEL1WX TI TTMI6F5 DMEL1WX TN Transient receptor potential cation channel V1 (TRPV1) DMEL1WX MA Antagonist DMEL1WX RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEL1WX RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEL28G DI DMEL28G DMEL28G DN BDBM50177019 DMEL28G TI TTECBXN DMEL28G TN Oxysterols receptor LXR-alpha (NR1H3) DMEL28G MA Inhibitor DMEL28G RN Piperazine derivatives as liver X receptor modulators. US10144715. DMEL28G RU http://www.freepatentsonline.com/US10144715.html DMEL7XA DI DMEL7XA DMEL7XA DN PMID26924192-Compound-25 DMEL7XA TI TTRA6BO DMEL7XA TN Bromodomain-containing protein 4 (BRD4) DMEL7XA MA Inhibitor DMEL7XA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEL7XA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMELA2F DI DMELA2F DMELA2F DN Pyrimidine derivative 21 DMELA2F TI TT8J1S3 DMELA2F TN Smoothened homolog (SMO) DMELA2F MA Inhibitor DMELA2F RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMELA2F RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEM2I8 DI DMEM2I8 DMEM2I8 DN PMID29865878-Compound-63 DMEM2I8 TI TTEAD9J DMEM2I8 TN Proteasome beta-8 (PS beta-8) DMEM2I8 MA Inhibitor DMEM2I8 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMEM2I8 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMEMBOW DI DMEMBOW DMEMBOW DN PMID25522065-Compound-31 DMEMBOW TI TTX4RTB DMEMBOW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMEMBOW MA Antagonist DMEMBOW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMEMBOW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMEMSB2 DI DMEMSB2 DMEMSB2 DN PMID25991433-Compound-Q1 DMEMSB2 TI TTR2TXZ DMEMSB2 TN Jun N terminal kinase (JNK) DMEMSB2 MA Inhibitor DMEMSB2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEMSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEMSB2 DI DMEMSB2 DMEMSB2 DN PMID25991433-Compound-Q1 DMEMSB2 TI TTVOE6D DMEMSB2 TN Mitogen-activated protein kinase (MAPK) DMEMSB2 MA Inhibitor DMEMSB2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEMSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEMT3I DI DMEMT3I DMEMT3I DN Resorcinol compound 12 DMEMT3I TI TTULVH8 DMEMT3I TN Tyrosinase (TYR) DMEMT3I MA Inhibitor DMEMT3I RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEMT3I RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMEMYDZ DI DMEMYDZ DMEMYDZ DN 4-aryl quinol derivative 1 DMEMYDZ TI TTR7UJ3 DMEMYDZ TN Cytoplasmic thioredoxin reductase (TXNRD1) DMEMYDZ MA Inhibitor DMEMYDZ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMEMYDZ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMEN8RA DI DMEN8RA DMEN8RA DN PMID26651364-Compound-127 DMEN8RA TI TTTCRU2 DMEN8RA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMEN8RA MA Antagonist DMEN8RA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMEN8RA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMENQ5O DI DMENQ5O DMENQ5O DN Quinoxaline derivative 1 DMENQ5O TI TTSXVID DMENQ5O TN Nuclear factor NF-kappa-B (NFKB) DMENQ5O MA Inhibitor DMENQ5O RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMENQ5O RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMENX90 DI DMENX90 DMENX90 DN PMID26077642-Compound-Figure3A DMENX90 TI TTVSYP9 DMENX90 TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DMENX90 MA Inhibitor DMENX90 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMENX90 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMENX90 DI DMENX90 DMENX90 DN PMID26077642-Compound-Figure3A DMENX90 TI TTSX29Z DMENX90 TN Ubiquitin C-terminal hydrolase UCH37 (UCHL5) DMENX90 MA Inhibitor DMENX90 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMENX90 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMENYZ0 DI DMENYZ0 DMENYZ0 DN Imidazo bicyclic iminium derivative 3 DMENYZ0 TI TT8J1S3 DMENYZ0 TN Smoothened homolog (SMO) DMENYZ0 MA Inhibitor DMENYZ0 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMENYZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMENZPR DI DMENZPR DMENZPR DN Quinolinyl compound 1 DMENZPR TI TT9O6WS DMENZPR TN Glucagon receptor (GCGR) DMENZPR MA Antagonist DMENZPR RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMENZPR RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMEO9QB DI DMEO9QB DMEO9QB DN Phenylate derivative 1 DMEO9QB TI TT23XQV DMEO9QB TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMEO9QB MA Inhibitor DMEO9QB RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMEO9QB RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMEOHX2 DI DMEOHX2 DMEOHX2 DN PMID28394193-Compound-33 DMEOHX2 TI TT9MZCQ DMEOHX2 TN Enhancer of zeste homolog 2 (EZH2) DMEOHX2 MA Inhibitor DMEOHX2 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMEOHX2 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMEOKCB DI DMEOKCB DMEOKCB DN Thiazole carboxamide derivative 30 DMEOKCB TI TTCZOF2 DMEOKCB TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMEOKCB MA Inhibitor DMEOKCB RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMEOKCB RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMEOZKF DI DMEOZKF DMEOZKF DN PMID29757691-Compound-8b DMEOZKF TI TT1RS9F DMEOZKF TN Acetylcholinesterase (AChE) DMEOZKF MA Inhibitor DMEOZKF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEOZKF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEOZKF DI DMEOZKF DMEOZKF DN PMID29757691-Compound-8b DMEOZKF TI TTEB0GD DMEOZKF TN Cholinesterase (BCHE) DMEOZKF MA Inhibitor DMEOZKF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEOZKF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEP5MJ DI DMEP5MJ DMEP5MJ DN Imidazo bicyclic iminium derivative 6 DMEP5MJ TI TT8J1S3 DMEP5MJ TN Smoothened homolog (SMO) DMEP5MJ MA Inhibitor DMEP5MJ RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEP5MJ RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEP9O8 DI DMEP9O8 DMEP9O8 DN Aryl pyrimidine derivative 5 DMEP9O8 TI TTIY56R DMEP9O8 TN Kynurenine 3-hydroxylase (KMO) DMEP9O8 MA Inhibitor DMEP9O8 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEP9O8 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEPWGH DI DMEPWGH DMEPWGH DN PMID28092474-Compound-32z DMEPWGH TI TT6R7JZ DMEPWGH TN Histone deacetylase 1 (HDAC1) DMEPWGH MA Inhibitor DMEPWGH RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEPWGH RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEPWGH DI DMEPWGH DMEPWGH DN PMID28092474-Compound-32z DMEPWGH TI TT5ZKDI DMEPWGH TN Histone deacetylase 6 (HDAC6) DMEPWGH MA Inhibitor DMEPWGH RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEPWGH RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEPYGQ DI DMEPYGQ DMEPYGQ DN PMID25666693-Compound-70 DMEPYGQ TI TTMI6F5 DMEPYGQ TN Transient receptor potential cation channel V1 (TRPV1) DMEPYGQ MA Antagonist DMEPYGQ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEPYGQ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEQ3RD DI DMEQ3RD DMEQ3RD DN Tri-substituted benzene derivative 1 DMEQ3RD TI TTN9T81 DMEQ3RD TN Arachidonate 15-lipoxygenase (15-LOX) DMEQ3RD MA Inhibitor DMEQ3RD RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMEQ3RD RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMEQ9BN DI DMEQ9BN DMEQ9BN DN PMID25726713-Compound-33 DMEQ9BN TI TT8J1S3 DMEQ9BN TN Smoothened homolog (SMO) DMEQ9BN MA Inhibitor DMEQ9BN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEQ9BN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEQBTO DI DMEQBTO DMEQBTO DN Hydrazinoacetic acid DMEQBTO TI TTLQUZS DMEQBTO TN Cystathionine gamma-lyase (CTH) DMEQBTO MA Inhibitor DMEQBTO RN Cystathionine--lyase (CSE) inhibitors. US9725426. DMEQBTO RU http://www.freepatentsonline.com/US9725426.html DMEQFXZ DI DMEQFXZ DMEQFXZ DN Urea and carbamate bioisostere derivative 1 DMEQFXZ TI TTTB4UP DMEQFXZ TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMEQFXZ MA Inhibitor DMEQFXZ RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEQFXZ RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMER2ZQ DI DMER2ZQ DMER2ZQ DN 2-hydroxybenzamide derivative 1 DMER2ZQ TI TTA6ZN2 DMER2ZQ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMER2ZQ MA Activator DMER2ZQ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMER2ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMER2ZQ DI DMER2ZQ DMER2ZQ DN 2-hydroxybenzamide derivative 1 DMER2ZQ TI TT3Z6Y9 DMER2ZQ TN Cysteines of Keap1 (KEAP1 Cysteines) DMER2ZQ MA Modulator DMER2ZQ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMER2ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMER7QX DI DMER7QX DMER7QX DN JCXGHZCWAHCYGY-UHFFFAOYSA-N DMER7QX TI TTDYP7I DMER7QX TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMER7QX MA Inhibitor DMER7QX RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DMER7QX RU http://www.freepatentsonline.com/US9150519.html DMERD39 DI DMERD39 DMERD39 DN PMID25666693-Compound-2 DMERD39 TI TTMI6F5 DMERD39 TN Transient receptor potential cation channel V1 (TRPV1) DMERD39 MA Antagonist DMERD39 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMERD39 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMERQ7V DI DMERQ7V DMERQ7V DN Diaryl piperazine derivative 1 DMERQ7V TI TT6OEDT DMERQ7V TN Cannabinoid receptor 1 (CB1) DMERQ7V MA Antagonist DMERQ7V RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMERQ7V RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMERWUQ DI DMERWUQ DMERWUQ DN US9586942, 16 DMERWUQ TI TTYJRN5 DMERWUQ TN N-acetylglucosaminyltransferase I (NAGAT1) DMERWUQ MA Inhibitor DMERWUQ RN Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942. DMERWUQ RU http://www.freepatentsonline.com/US9586942.html DMES0UY DI DMES0UY DMES0UY DN PMID29649907-Compound-21 DMES0UY TI TTS4UGC DMES0UY TN Farnesoid X-activated receptor (FXR) DMES0UY MA Agonist DMES0UY RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMES0UY RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMES41R DI DMES41R DMES41R DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 DMES41R TI TTULVH8 DMES41R TN Tyrosinase (TYR) DMES41R MA Inhibitor DMES41R RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMES41R RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMESAUL DI DMESAUL DMESAUL DN Thiazole derivative 5 DMESAUL TI TT473XN DMESAUL TN P2X purinoceptor 7 (P2RX7) DMESAUL MA Antagonist DMESAUL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMESAUL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMESKY1 DI DMESKY1 DMESKY1 DN Benzene sulfonamide derivative 12 DMESKY1 TI TT4G2JS DMESKY1 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMESKY1 MA Inhibitor DMESKY1 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMESKY1 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMESOA8 DI DMESOA8 DMESOA8 DN 1,2,4-oxadiazole derivative 1 DMESOA8 TI TTNBFWK DMESOA8 TN Programmed cell death protein 1 (PD-1) DMESOA8 MA Inhibitor DMESOA8 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMESOA8 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTZ963I DMETCI3 TN Monoglyceride lipase (MAGL) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTDP1UC DMETCI3 TN Fatty acid amide hydrolase (FAAH) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTSINOV DMETCI3 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETIKC DI DMETIKC DMETIKC DN Steroid derivative 3 DMETIKC TI TTUX68I DMETIKC TN Hypoxia-inducible factor 1 (HIF-1) DMETIKC MA Inhibitor DMETIKC RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMETIKC RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMETY0U DI DMETY0U DMETY0U DN US8524917, 11 DMETY0U TI TTDYP7I DMETY0U TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMETY0U MA Inhibitor DMETY0U RN S1P3 receptor inhibitors for treating pain. US8563594. DMETY0U RU http://www.freepatentsonline.com/US8563594.html DMEU12W DI DMEU12W DMEU12W DN NCGC00381656-01 DMEU12W TI TTIG67W DMEU12W TN Lysine-specific demethylase 5A (KDM5A) DMEU12W MA Inhibitor DMEU12W RN Histone demethylase inhibitors. US9738637. DMEU12W RU http://www.freepatentsonline.com/US9738637.html DMEU3J9 DI DMEU3J9 DMEU3J9 DN Furopyridine derivative 2 DMEU3J9 TI TT6OEDT DMEU3J9 TN Cannabinoid receptor 1 (CB1) DMEU3J9 MA Antagonist DMEU3J9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEU3J9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEU48I DI DMEU48I DMEU48I DN PMID25522065-Compound-51 DMEU48I TI TTX4RTB DMEU48I TN Melanin-concentrating hormone receptor 1 (MCHR1) DMEU48I MA Antagonist DMEU48I RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMEU48I RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMEU4Y1 DI DMEU4Y1 DMEU4Y1 DN PMID28394193-Compound-49 DMEU4Y1 TI TT9MZCQ DMEU4Y1 TN Enhancer of zeste homolog 2 (EZH2) DMEU4Y1 MA Inhibitor DMEU4Y1 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMEU4Y1 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMEU5ST DI DMEU5ST DMEU5ST DN US8598210, Table XV, 5 DMEU5ST TI TT9ISBX DMEU5ST TN HIF-prolyl hydroxylase 2 (HPH-2) DMEU5ST MA Inhibitor DMEU5ST RN Prolyl hydroxylase inhibitors and method of use. US8722895. DMEU5ST RU http://www.freepatentsonline.com/US8722895.html DMEUBDA DI DMEUBDA DMEUBDA DN PMID25980951-Compound-38 DMEUBDA TI TTR7B60 DMEUBDA TN X-linked inhibitor of apoptosis protein (XIAP) DMEUBDA MA Antagonist DMEUBDA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEUBDA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEUBDA DI DMEUBDA DMEUBDA DN PMID25980951-Compound-38 DMEUBDA TI TTQ5LRD DMEUBDA TN Cellular inhibitor of apoptosis 1 (BIRC2) DMEUBDA MA Antagonist DMEUBDA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEUBDA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEUC04 DI DMEUC04 DMEUC04 DN PMID29757691-Compound-2a DMEUC04 TI TT1RS9F DMEUC04 TN Acetylcholinesterase (AChE) DMEUC04 MA Inhibitor DMEUC04 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEUC04 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEUC04 DI DMEUC04 DMEUC04 DN PMID29757691-Compound-2a DMEUC04 TI TTEB0GD DMEUC04 TN Cholinesterase (BCHE) DMEUC04 MA Inhibitor DMEUC04 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEUC04 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEUHCD DI DMEUHCD DMEUHCD DN Aza-phenalene-3-ketone derivative 1 DMEUHCD TI TTEBCY8 DMEUHCD TN Poly [ADP-ribose] polymerase (PARP) DMEUHCD MA Inhibitor DMEUHCD RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMEUHCD RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMEUO8G DI DMEUO8G DMEUO8G DN 1,5-di-substituted pyridine derivative 1 DMEUO8G TI TT1LVF2 DMEUO8G TN Cyclin-dependent kinase 9 (CDK9) DMEUO8G MA Inhibitor DMEUO8G RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMEUO8G RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMEUO8G DI DMEUO8G DMEUO8G DN 1,5-di-substituted pyridine derivative 1 DMEUO8G TI TT7HF4W DMEUO8G TN Cyclin-dependent kinase 2 (CDK2) DMEUO8G MA Inhibitor DMEUO8G RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMEUO8G RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMEUSGR DI DMEUSGR DMEUSGR DN PMID26666989-Compound-Figure12topmiddile DMEUSGR TI TT8BUGW DMEUSGR TN Glycogen phosphorylase (PYG) DMEUSGR MA Inhibitor DMEUSGR RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMEUSGR RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMEUZM3 DI DMEUZM3 DMEUZM3 DN PMID29671355-Compound-52 DMEUZM3 TI TTTQGH8 DMEUZM3 TN Histone deacetylase 4 (HDAC4) DMEUZM3 MA Inhibitor DMEUZM3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMEUZM3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMEV9O3 DI DMEV9O3 DMEV9O3 DN Epoxysuccinate derivative 2 DMEV9O3 TI TTG5QB7 DMEV9O3 TN Calpain-2 (CAPN2) DMEV9O3 MA Inhibitor DMEV9O3 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMEV9O3 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMEVBZW DI DMEVBZW DMEVBZW DN AC1LFXA6 DMEVBZW TI TT25MVL DMEVBZW TN Serine protease hepsin (HPN) DMEVBZW MA Inhibitor DMEVBZW RN Hepsin inhibitors. US9182402. DMEVBZW RU http://www.freepatentsonline.com/US9182402.html DMEVGR6 DI DMEVGR6 DMEVGR6 DN US10149841, Compound 1 DMEVGR6 TI TT9ISBX DMEVGR6 TN HIF-prolyl hydroxylase 2 (HPH-2) DMEVGR6 MA Inhibitor DMEVGR6 RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMEVGR6 RU http://www.freepatentsonline.com/US10149841.html DMEVL0S DI DMEVL0S DMEVL0S DN PMID25666693-Compound-48 DMEVL0S TI TTMI6F5 DMEVL0S TN Transient receptor potential cation channel V1 (TRPV1) DMEVL0S MA Antagonist DMEVL0S RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEVL0S RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEVMU9 DI DMEVMU9 DMEVMU9 DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2 DMEVMU9 TI TTVDSZ0 DMEVMU9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMEVMU9 MA Inhibitor DMEVMU9 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMEVMU9 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMEVXT0 DI DMEVXT0 DMEVXT0 DN Pyrrolo-pyrimidine derivative 1 DMEVXT0 TI TTK0FEA DMEVXT0 TN Leucine-rich repeat kinase 2 (LRRK2) DMEVXT0 MA Inhibitor DMEVXT0 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEVXT0 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEVZIK DI DMEVZIK DMEVZIK DN PMID29649907-Compound-29 DMEVZIK TI TTS4UGC DMEVZIK TN Farnesoid X-activated receptor (FXR) DMEVZIK MA Agonist DMEVZIK RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMEVZIK RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMEW0AT DI DMEW0AT DMEW0AT DN 1,2-diamino cyclopentane-based derivative 25 DMEW0AT TI TT9N02I DMEW0AT TN Orexin receptor type 2 (HCRTR2) DMEW0AT MA Antagonist DMEW0AT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMEW0AT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMEW0AT DI DMEW0AT DMEW0AT DN 1,2-diamino cyclopentane-based derivative 25 DMEW0AT TI TT60Q8D DMEW0AT TN Orexin receptor type 1 (HCRTR1) DMEW0AT MA Antagonist DMEW0AT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMEW0AT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMEW46T DI DMEW46T DMEW46T DN PMID27967267-Compound-15 DMEW46T TI TT1RS9F DMEW46T TN Acetylcholinesterase (AChE) DMEW46T MA Inhibitor DMEW46T RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMEW46T RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMEW5LD DI DMEW5LD DMEW5LD DN AC1M1SP5 DMEW5LD TI TTIS4OW DMEW5LD TN Phosphodiesterase 8 (PDE8) DMEW5LD MA Inhibitor DMEW5LD RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DMEW5LD RU http://www.freepatentsonline.com/US9173884.html DMEWA7U DI DMEWA7U DMEWA7U DN Biaryl mannoside derivative 6 DMEWA7U TI TTTCRU2 DMEWA7U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMEWA7U MA Antagonist DMEWA7U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMEWA7U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMEWAQ9 DI DMEWAQ9 DMEWAQ9 DN Piperazine urea derivative 1 DMEWAQ9 TI TTDP1UC DMEWAQ9 TN Fatty acid amide hydrolase (FAAH) DMEWAQ9 MA Inhibitor DMEWAQ9 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWAQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TTVKILB DMEWPQ6 TN Prostaglandin G/H synthase 2 (COX-2) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TTGX13H DMEWPQ6 TN Fatty-acid amide hydrolase 1 (FAAH1) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TT8NGED DMEWPQ6 TN Prostaglandin G/H synthase 1 (COX-1) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEX5VK DI DMEX5VK DMEX5VK DN Oxazolo[3,4-a]pyrazine derivative 7 DMEX5VK TI TTV1C0Z DMEX5VK TN Neuropeptide S receptor (NPSR) DMEX5VK MA Antagonist DMEX5VK RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMEX5VK RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMEX7PV DI DMEX7PV DMEX7PV DN Heterocyclic-substituted 3-alkyl azetidine derivative 2 DMEX7PV TI TT6OEDT DMEX7PV TN Cannabinoid receptor 1 (CB1) DMEX7PV MA Antagonist DMEX7PV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEX7PV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEXATH DI DMEXATH DMEXATH DN PMID27967267-Compound-47 DMEXATH TI TT1RS9F DMEXATH TN Acetylcholinesterase (AChE) DMEXATH MA Reactivator DMEXATH RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMEXATH RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMEXNOP DI DMEXNOP DMEXNOP DN PMID25726713-Compound-23 DMEXNOP TI TT8J1S3 DMEXNOP TN Smoothened homolog (SMO) DMEXNOP MA Inhibitor DMEXNOP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEXNOP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEXPAU DI DMEXPAU DMEXPAU DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 DMEXPAU TI TTMSFAW DMEXPAU TN Cannabinoid receptor 2 (CB2) DMEXPAU RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMEXPAU RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMEXT6J DI DMEXT6J DMEXT6J DN Dihydropyridine compound 6 DMEXT6J TI TT4DXQT DMEXT6J TN Proto-oncogene c-Ret (RET) DMEXT6J MA Inhibitor DMEXT6J RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMEXT6J RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMEXV6L DI DMEXV6L DMEXV6L DN PMID27454349-Compound-97 DMEXV6L TI TTK59TV DMEXV6L TN Vitamin D3 receptor (VDR) DMEXV6L MA Agonist DMEXV6L RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMEXV6L RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMEY6L8 DI DMEY6L8 DMEY6L8 DN Imidazopyridazine derivative 1 DMEY6L8 TI TT6DM01 DMEY6L8 TN Janus kinase 1 (JAK-1) DMEY6L8 MA Inhibitor DMEY6L8 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMEY6L8 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMEY6L8 DI DMEY6L8 DMEY6L8 DN Imidazopyridazine derivative 1 DMEY6L8 TI TTT7PJU DMEY6L8 TN Janus kinase 3 (JAK-3) DMEY6L8 MA Inhibitor DMEY6L8 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMEY6L8 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMEYLM2 DI DMEYLM2 DMEYLM2 DN PMID25482888-Compound-70 DMEYLM2 TI TTDIGC1 DMEYLM2 TN Dipeptidyl peptidase 4 (DPP-4) DMEYLM2 MA Inhibitor DMEYLM2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMEYLM2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMEYS3V DI DMEYS3V DMEYS3V DN Azaindazole derivative 2 DMEYS3V TI TTK0FEA DMEYS3V TN Leucine-rich repeat kinase 2 (LRRK2) DMEYS3V MA Inhibitor DMEYS3V RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEYS3V RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEZ3QV DI DMEZ3QV DMEZ3QV DN PMID25980951-Compound-39 DMEZ3QV TI TTR7B60 DMEZ3QV TN X-linked inhibitor of apoptosis protein (XIAP) DMEZ3QV MA Antagonist DMEZ3QV RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEZ3QV RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEZDQ4 DI DMEZDQ4 DMEZDQ4 DN Alkynyl-heteroaromatic ring compound 1 DMEZDQ4 TI TTIV39N DMEZDQ4 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMEZDQ4 MA Inhibitor DMEZDQ4 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMEZDQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMEZLBQ DI DMEZLBQ DMEZLBQ DN PMID26560530-Compound-4 DMEZLBQ TI TT2F4OL DMEZLBQ TN Tissue transglutaminase (TG2) DMEZLBQ MA Inhibitor DMEZLBQ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMEZLBQ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMEZQ29 DI DMEZQ29 DMEZQ29 DN Tricyclic indole compound 12 DMEZQ29 TI TTPTXIN DMEZQ29 TN Translocator protein (TSPO) DMEZQ29 MA Ligand DMEZQ29 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMEZQ29 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMEZUN7 DI DMEZUN7 DMEZUN7 DN Resorcinol compound 25 DMEZUN7 TI TTULVH8 DMEZUN7 TN Tyrosinase (TYR) DMEZUN7 MA Inhibitor DMEZUN7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEZUN7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMF01AR DI DMF01AR DMF01AR DN Benzisoselenazolone difluorocytidine derivative 1 DMF01AR TI TTR7UJ3 DMF01AR TN Cytoplasmic thioredoxin reductase (TXNRD1) DMF01AR MA Inhibitor DMF01AR RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMF01AR RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMF05GL DI DMF05GL DMF05GL DN Quinazoline derivative 3 DMF05GL TI TTPTXIN DMF05GL TN Translocator protein (TSPO) DMF05GL MA Ligand DMF05GL RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMF05GL RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMF0DE2 DI DMF0DE2 DMF0DE2 DN Peptidomimetic analog 5 DMF0DE2 TI TTH8FZW DMF0DE2 TN Signal transducer and activator of transcription 3 (STAT3) DMF0DE2 MA Inhibitor DMF0DE2 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF0DE2 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF0DE2 DI DMF0DE2 DMF0DE2 DN Peptidomimetic analog 5 DMF0DE2 TI TTN7R6K DMF0DE2 TN Signal transducer and activator of transcription 1 (STAT1) DMF0DE2 MA Inhibitor DMF0DE2 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF0DE2 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF0L3E DI DMF0L3E DMF0L3E DN PMID26651364-Compound-9d DMF0L3E TI TTTCRU2 DMF0L3E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF0L3E MA Antagonist DMF0L3E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF0L3E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TT0PG8F DMF0OW4 TN Cyclin-dependent kinase 4 (CDK4) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TTO0FDJ DMF0OW4 TN Cyclin-dependent kinase 6 (CDK6) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TT8J1S3 DMF0OW4 TN Smoothened homolog (SMO) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TTCJG29 DMF0OW4 TN Serine/threonine-protein kinase mTOR (mTOR) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0XI3 DI DMF0XI3 DMF0XI3 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 1 DMF0XI3 TI TTV8CRH DMF0XI3 TN Lysine-specific demethylase 4C (KDM4C) DMF0XI3 MA Inhibitor DMF0XI3 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMF0XI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMF1MV6 DI DMF1MV6 DMF1MV6 DN PMID26651364-Compound-9f DMF1MV6 TI TTTCRU2 DMF1MV6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF1MV6 MA Antagonist DMF1MV6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF1MV6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF1MZ4 DI DMF1MZ4 DMF1MZ4 DN Peptide analog 42 DMF1MZ4 TI TTSJMN8 DMF1MZ4 TN Immunoproteasome complex (IP) DMF1MZ4 MA Inhibitor DMF1MZ4 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMF1MZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMF1TR6 DI DMF1TR6 DMF1TR6 DN Peptide analog 18 DMF1TR6 TI TTSJMN8 DMF1TR6 TN Immunoproteasome complex (IP) DMF1TR6 MA Inhibitor DMF1TR6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMF1TR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMF1ZJ3 DI DMF1ZJ3 DMF1ZJ3 DN PMID28350212-Compound-30 DMF1ZJ3 TI TTZS04O DMF1ZJ3 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMF1ZJ3 MA Inhibitor DMF1ZJ3 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMF1ZJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMF2ZNT DI DMF2ZNT DMF2ZNT DN PMID28092474-Compound-33k DMF2ZNT TI TT6R7JZ DMF2ZNT TN Histone deacetylase 1 (HDAC1) DMF2ZNT MA Inhibitor DMF2ZNT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMF2ZNT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMF2ZNT DI DMF2ZNT DMF2ZNT DN PMID28092474-Compound-33k DMF2ZNT TI TT5ZKDI DMF2ZNT TN Histone deacetylase 6 (HDAC6) DMF2ZNT MA Inhibitor DMF2ZNT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMF2ZNT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT7MRDV DMF3907 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT8FYO9 DMF3907 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TTX41N9 DMF3907 TN Tyrosine-protein kinase Kit (KIT) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT4DXQT DMF3907 TN Proto-oncogene c-Ret (RET) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3LIX DI DMF3LIX DMF3LIX DN Peptide analog 1 DMF3LIX TI TT23XQV DMF3LIX TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMF3LIX MA Inhibitor DMF3LIX RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMF3LIX RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMF3NCO DI DMF3NCO DMF3NCO DN Phenylpyrrolidinone derivative 2 DMF3NCO TI TT5OU0D DMF3NCO TN PRKR-like endoplasmic reticulum kinase (PERK) DMF3NCO MA Inhibitor DMF3NCO RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMF3NCO RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TT84OS6 DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTYGQ8A DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTSBVFO DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTV4EX0 DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF4YGC DI DMF4YGC DMF4YGC DN P-coumaric acid derivative 6 DMF4YGC TI TTULVH8 DMF4YGC TN Tyrosinase (TYR) DMF4YGC MA Inhibitor DMF4YGC RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMF4YGC RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMF5E6U DI DMF5E6U DMF5E6U DN Tricyclic compound 9 DMF5E6U TI TTAIQSN DMF5E6U TN Receptor-interacting protein 1 (RIPK1) DMF5E6U MA Inhibitor DMF5E6U RN Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256. DMF5E6U RU https://www.ncbi.nlm.nih.gov/pubmed/27568917 DMF5IWB DI DMF5IWB DMF5IWB DN PMID27774822-Compound-Figure7Example63 DMF5IWB TI TTRMX3V DMF5IWB TN Janus kinase 2 (JAK-2) DMF5IWB MA Inhibitor DMF5IWB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMF5IWB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMF5IWB DI DMF5IWB DMF5IWB DN PMID27774822-Compound-Figure7Example63 DMF5IWB TI TT6DM01 DMF5IWB TN Janus kinase 1 (JAK-1) DMF5IWB MA Inhibitor DMF5IWB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMF5IWB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMF5K9J DI DMF5K9J DMF5K9J DN PMID28870136-Compound-65 DMF5K9J TI TTK0O6Y DMF5K9J TN Ecto-5'-nucleotidase (CD73) DMF5K9J MA Inhibitor DMF5K9J RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMF5K9J RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMF5LNK DI DMF5LNK DMF5LNK DN PMID26666989-Compound-Figure12left DMF5LNK TI TT8BUGW DMF5LNK TN Glycogen phosphorylase (PYG) DMF5LNK MA Inhibitor DMF5LNK RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMF5LNK RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMF5ODZ DI DMF5ODZ DMF5ODZ DN PMID25666693-Compound-115 DMF5ODZ TI TTMI6F5 DMF5ODZ TN Transient receptor potential cation channel V1 (TRPV1) DMF5ODZ MA Antagonist DMF5ODZ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMF5ODZ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMF5TB4 DI DMF5TB4 DMF5TB4 DN Biaryl mannoside derivative 24 DMF5TB4 TI TTTCRU2 DMF5TB4 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF5TB4 MA Antagonist DMF5TB4 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF5TB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF5XU8 DI DMF5XU8 DMF5XU8 DN Aryl mannoside derivative 3 DMF5XU8 TI TTTCRU2 DMF5XU8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF5XU8 MA Antagonist DMF5XU8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF5XU8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF6B1I DI DMF6B1I DMF6B1I DN Benzodihydroisofuran derivative 3 DMF6B1I TI TTTJZ4M DMF6B1I TN Prolylcarboxypeptidase (PRCP) DMF6B1I MA Inhibitor DMF6B1I RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMF6B1I RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMF6DUT DI DMF6DUT DMF6DUT DN Pyrimidine derivative 7 DMF6DUT TI TTOHSBA DMF6DUT TN Vascular endothelial growth factor A (VEGFA) DMF6DUT MA Inhibitor DMF6DUT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF6DUT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF6N7Z DI DMF6N7Z DMF6N7Z DN Amidopyrazole derivative 4 DMF6N7Z TI TTKFVXR DMF6N7Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMF6N7Z MA Inhibitor DMF6N7Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMF6N7Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMF6W2Y DI DMF6W2Y DMF6W2Y DN 1,6-naphyridine-4-ketone fused heterocyclic derivative 1 DMF6W2Y TI TTOHSBA DMF6W2Y TN Vascular endothelial growth factor A (VEGFA) DMF6W2Y MA Inhibitor DMF6W2Y RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF6W2Y RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF6Z5I DI DMF6Z5I DMF6Z5I DN PMID26651364-Compound-5d DMF6Z5I TI TTTCRU2 DMF6Z5I TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF6Z5I MA Antagonist DMF6Z5I RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF6Z5I RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF7MEB DI DMF7MEB DMF7MEB DN Pyridazinone derivative 1 DMF7MEB TI TT473XN DMF7MEB TN P2X purinoceptor 7 (P2RX7) DMF7MEB MA Antagonist DMF7MEB RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMF7MEB RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMF7NXJ DI DMF7NXJ DMF7NXJ DN Imidazopyridazine derivative 8 DMF7NXJ TI TTQR74A DMF7NXJ TN Proteinase activated receptor 2 (PAR2) DMF7NXJ MA Antagonist DMF7NXJ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMF7NXJ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMF89PY DI DMF89PY DMF89PY DN PMID25399762-Compound-Table1-C23 DMF89PY TI TTGP7BY DMF89PY TN Monoamine oxidase type B (MAO-B) DMF89PY MA Inhibitor DMF89PY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMF89PY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMF8MIB DI DMF8MIB DMF8MIB DN US8669361, 107 DMF8MIB TI TTCGOIN DMF8MIB TN PIM-3 protein kinase (PIM3) DMF8MIB MA Inhibitor DMF8MIB RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMF8MIB RU http://www.freepatentsonline.com/US8669361.html DMF8V5J DI DMF8V5J DMF8V5J DN PMID25980951-Compound-7 DMF8V5J TI TTQ5LRD DMF8V5J TN Cellular inhibitor of apoptosis 1 (BIRC2) DMF8V5J MA Antagonist DMF8V5J RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMF8V5J RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMF8V5J DI DMF8V5J DMF8V5J DN PMID25980951-Compound-7 DMF8V5J TI TTR7B60 DMF8V5J TN X-linked inhibitor of apoptosis protein (XIAP) DMF8V5J MA Antagonist DMF8V5J RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMF8V5J RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMF9C4I DI DMF9C4I DMF9C4I DN PMID26161824-Compound-68 DMF9C4I TI TT6OEDT DMF9C4I TN Cannabinoid receptor 1 (CB1) DMF9C4I MA Antagonist DMF9C4I RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMF9C4I RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMF9J0Y DI DMF9J0Y DMF9J0Y DN PMID26394986-Compound-20 DMF9J0Y TI TTH8FZW DMF9J0Y TN Signal transducer and activator of transcription 3 (STAT3) DMF9J0Y MA Inhibitor DMF9J0Y RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF9J0Y RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF9LNO DI DMF9LNO DMF9LNO DN US8536181, A41 DMF9LNO TI TT9ISBX DMF9LNO TN HIF-prolyl hydroxylase 2 (HPH-2) DMF9LNO MA Inhibitor DMF9LNO RN Prolyl hydroxylase inhibitors. US8536181. DMF9LNO RU http://www.freepatentsonline.com/US8536181.html DMF9VMW DI DMF9VMW DMF9VMW DN Pyridine derivative 11 DMF9VMW TI TTOHSBA DMF9VMW TN Vascular endothelial growth factor A (VEGFA) DMF9VMW MA Inhibitor DMF9VMW RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF9VMW RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF9X6P DI DMF9X6P DMF9X6P DN PMID25399762-Compound-Table1-C12 DMF9X6P TI TTGP7BY DMF9X6P TN Monoamine oxidase type B (MAO-B) DMF9X6P MA Inhibitor DMF9X6P RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMF9X6P RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMFAGOZ DI DMFAGOZ DMFAGOZ DN PMID27774822-Compound-Figure10Compound12 DMFAGOZ TI TTRMX3V DMFAGOZ TN Janus kinase 2 (JAK-2) DMFAGOZ MA Inhibitor DMFAGOZ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFAGOZ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFAGOZ DI DMFAGOZ DMFAGOZ DN PMID27774822-Compound-Figure10Compound12 DMFAGOZ TI TTJNBQA DMFAGOZ TN Activin receptor-like kinase 2 (ALK-2) DMFAGOZ MA Inhibitor DMFAGOZ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFAGOZ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFALQN DI DMFALQN DMFALQN DN Pyridine derivative 3 DMFALQN TI TTOHSBA DMFALQN TN Vascular endothelial growth factor A (VEGFA) DMFALQN MA Inhibitor DMFALQN RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMFALQN RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMFAM8B DI DMFAM8B DMFAM8B DN Fused aryl carbocycle derivative 1 DMFAM8B TI TT9NXW4 DMFAM8B TN Sigma intracellular receptor 2 (TMEM97) DMFAM8B MA Ligand DMFAM8B RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMFAM8B RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMFARIK DI DMFARIK DMFARIK DN Pyrazole derivative 73 DMFARIK TI TTJQOD7 DMFARIK TN 5-HT 2A receptor (HTR2A) DMFARIK MA Antagonist DMFARIK RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFARIK RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFBHAC DI DMFBHAC DMFBHAC DN PMID25726713-Compound-30 DMFBHAC TI TT8J1S3 DMFBHAC TN Smoothened homolog (SMO) DMFBHAC MA Inhibitor DMFBHAC RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMFBHAC RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMFBPSX DI DMFBPSX DMFBPSX DN 1,2-diamino cyclopentane-based derivative 4 DMFBPSX TI TT9N02I DMFBPSX TN Orexin receptor type 2 (HCRTR2) DMFBPSX MA Antagonist DMFBPSX RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMFBPSX RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMFBPSX DI DMFBPSX DMFBPSX DN 1,2-diamino cyclopentane-based derivative 4 DMFBPSX TI TT60Q8D DMFBPSX TN Orexin receptor type 1 (HCRTR1) DMFBPSX MA Antagonist DMFBPSX RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMFBPSX RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMFBQHZ DI DMFBQHZ DMFBQHZ DN Peptide analog 25 DMFBQHZ TI TT68GPI DMFBQHZ TN Proteasome beta-5 (PS beta-5) DMFBQHZ MA Inhibitor DMFBQHZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMFBQHZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMFBQHZ DI DMFBQHZ DMFBQHZ DN Peptide analog 25 DMFBQHZ TI TTEAD9J DMFBQHZ TN Proteasome beta-8 (PS beta-8) DMFBQHZ MA Inhibitor DMFBQHZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMFBQHZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TT3WG5C DMFBRSL TN Monoamine oxidase type A (MAO-A) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TTGP7BY DMFBRSL TN Monoamine oxidase type B (MAO-B) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TTNR0UQ DMFBRSL TN Lysine-specific histone demethylase 1 (LSD) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFCE51 DI DMFCE51 DMFCE51 DN PMID25553724-Compound-US2012832440110 DMFCE51 TI TTSXVID DMFCE51 TN Nuclear factor NF-kappa-B (NFKB) DMFCE51 MA Inhibitor DMFCE51 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMFCE51 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMFCIGE DI DMFCIGE DMFCIGE DN US9493490, E DMFCIGE TI TTAZ3MN DMFCIGE TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMFCIGE MA Inhibitor DMFCIGE RN Boron-containing small molecules. US9493490. DMFCIGE RU http://www.freepatentsonline.com/US9493490.html DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TT3WG5C DMFD9UZ TN Monoamine oxidase type A (MAO-A) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TTGP7BY DMFD9UZ TN Monoamine oxidase type B (MAO-B) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TT1RS9F DMFD9UZ TN Acetylcholinesterase (AChE) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFDERP DI DMFDERP DMFDERP DN PMID28870136-Compound-52 DMFDERP TI TTK0O6Y DMFDERP TN Ecto-5'-nucleotidase (CD73) DMFDERP MA Inhibitor DMFDERP RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFDERP RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFDLHN DI DMFDLHN DMFDLHN DN Pyrrolidinyl urea derivative 3 DMFDLHN TI TTTDVOJ DMFDLHN TN Tropomyosin-related kinase A (TrkA) DMFDLHN MA Inhibitor DMFDLHN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMFDLHN RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTRMX3V DMFDRJT TN Janus kinase 2 (JAK-2) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTT7PJU DMFDRJT TN Janus kinase 3 (JAK-3) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TT6DM01 DMFDRJT TN Janus kinase 1 (JAK-1) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTBYWP2 DMFDRJT TN TYK2 tyrosine kinase (TYK2) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTKAWRQ DMFDRJT TN JAK-STAT signaling pathway (JAK-STAT pathway) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTJSQEF DMFDRJT TN Tyrosine-protein kinase (PTK) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTXABCW DMFDURZ TN NT-3 growth factor receptor (TrkC) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTKN7QR DMFDURZ TN BDNF/NT-3 growth factors receptor (TrkB) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTTDVOJ DMFDURZ TN Tropomyosin-related kinase A (TrkA) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDXBJ DI DMFDXBJ DMFDXBJ DN Resorcinol compound 16 DMFDXBJ TI TTULVH8 DMFDXBJ TN Tyrosinase (TYR) DMFDXBJ MA Inhibitor DMFDXBJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFDXBJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFE4IY DI DMFE4IY DMFE4IY DN P-coumaric acid derivative 3 DMFE4IY TI TTULVH8 DMFE4IY TN Tyrosinase (TYR) DMFE4IY MA Inhibitor DMFE4IY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFE4IY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFEQD2 DI DMFEQD2 DMFEQD2 DN Mannoside derivative 2 DMFEQD2 TI TTTCRU2 DMFEQD2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMFEQD2 MA Antagonist DMFEQD2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMFEQD2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMFEUMZ DI DMFEUMZ DMFEUMZ DN US8481586, 15 DMFEUMZ TI TTCGOIN DMFEUMZ TN PIM-3 protein kinase (PIM3) DMFEUMZ MA Inhibitor DMFEUMZ RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DMFEUMZ RU http://www.freepatentsonline.com/US8481586.html DMFG2KT DI DMFG2KT DMFG2KT DN Peptide analog 68 DMFG2KT TI TTPLTSQ DMFG2KT TN Neutrophil elastase (NE) DMFG2KT MA Inhibitor DMFG2KT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMFG2KT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMFG7A8 DI DMFG7A8 DMFG7A8 DN Peptide analog 8 DMFG7A8 TI TTN7R6K DMFG7A8 TN Signal transducer and activator of transcription 1 (STAT1) DMFG7A8 MA Inhibitor DMFG7A8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMFG7A8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMFG9HP DI DMFG9HP DMFG9HP DN Hexahydro naphthalene derivative 2 DMFG9HP TI TTPADOQ DMFG9HP TN HMG-CoA reductase (HMGCR) DMFG9HP MA Inhibitor DMFG9HP RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMFG9HP RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMFGIPR DI DMFGIPR DMFGIPR DN US8703720, Reference Compound 1 DMFGIPR TI TTO3NYT DMFGIPR TN Galectin-1 (LGALS1) DMFGIPR MA Inhibitor DMFGIPR RN Galactoside inhibitors of galectins. US8703720. DMFGIPR RU http://www.freepatentsonline.com/US8703720.html DMFHC0O DI DMFHC0O DMFHC0O DN GypensapogeninA DMFHC0O TI TT3WG5C DMFHC0O TN Monoamine oxidase type A (MAO-A) DMFHC0O MA Inhibitor DMFHC0O RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMFHC0O RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMFHD05 DI DMFHD05 DMFHD05 DN Ketoheterocycle derivative 3 DMFHD05 TI TTDP1UC DMFHD05 TN Fatty acid amide hydrolase (FAAH) DMFHD05 MA Inhibitor DMFHD05 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMFHD05 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMFI2H6 DI DMFI2H6 DMFI2H6 DN Indole-based analog 9 DMFI2H6 TI TTPTXIN DMFI2H6 TN Translocator protein (TSPO) DMFI2H6 MA Ligand DMFI2H6 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMFI2H6 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMFIG8C DI DMFIG8C DMFIG8C DN Hydoxyamidine derivative 1 DMFIG8C TI TTZJYKH DMFIG8C TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMFIG8C MA Inhibitor DMFIG8C RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMFIG8C RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMFIP0D DI DMFIP0D DMFIP0D DN Imidazo[1,5-a]pyridine derivative 1 DMFIP0D TI TTZJYKH DMFIP0D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMFIP0D MA Inhibitor DMFIP0D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMFIP0D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTT7PJU DMFIXW4 TN Janus kinase 3 (JAK-3) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTBYWP2 DMFIXW4 TN TYK2 tyrosine kinase (TYK2) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTRMX3V DMFIXW4 TN Janus kinase 2 (JAK-2) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TT6DM01 DMFIXW4 TN Janus kinase 1 (JAK-1) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFJBZI DI DMFJBZI DMFJBZI DN Pyrrolo-pyrrolone derivative 4 DMFJBZI TI TTRA6BO DMFJBZI TN Bromodomain-containing protein 4 (BRD4) DMFJBZI MA Inhibitor DMFJBZI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFJBZI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFJD5L DI DMFJD5L DMFJD5L DN US8772478, 2 DMFJD5L TI TTQICM2 DMFJD5L TN ADAM metallopeptidase 33 (ADAM33) DMFJD5L MA Inhibitor DMFJD5L RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMFJD5L RU http://www.freepatentsonline.com/US8772478.html DMFJG7P DI DMFJG7P DMFJG7P DN PMID27376512-Compound-Table1Example4 DMFJG7P TI TT6S2FE DMFJG7P TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMFJG7P MA Inhibitor DMFJG7P RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMFJG7P RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMFJTE9 DI DMFJTE9 DMFJTE9 DN Benzene sulfonamide derivative 15 DMFJTE9 TI TT4G2JS DMFJTE9 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMFJTE9 MA Blocker DMFJTE9 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMFJTE9 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMFK7EL DI DMFK7EL DMFK7EL DN Benzyl amine derivative 2 DMFK7EL TI TT5L2VC DMFK7EL TN Kallikrein-related peptidase (KLK) DMFK7EL MA Inhibitor DMFK7EL RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMFK7EL RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMFKGZ7 DI DMFKGZ7 DMFKGZ7 DN P-coumaric acid derivative 5 DMFKGZ7 TI TTULVH8 DMFKGZ7 TN Tyrosinase (TYR) DMFKGZ7 MA Inhibitor DMFKGZ7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFKGZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFKN1O DI DMFKN1O DMFKN1O DN PMID25666693-Compound-142 DMFKN1O TI TTMI6F5 DMFKN1O TN Transient receptor potential cation channel V1 (TRPV1) DMFKN1O MA Antagonist DMFKN1O RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFKN1O RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTU1E82 DMFKS2P TN Apoptosis regulator Bcl-xL (BCL-xL) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTJGNVC DMFKS2P TN Apoptosis regulator Bcl-2 (BCL-2) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTL53M6 DMFKS2P TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKTBM DI DMFKTBM DMFKTBM DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2 DMFKTBM TI TTHS256 DMFKTBM TN Metabotropic glutamate receptor 5 (mGluR5) DMFKTBM MA Modulator DMFKTBM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMFKTBM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMFKTJL DI DMFKTJL DMFKTJL DN Aminopiperidine derivative 1 DMFKTJL TI TTDIGC1 DMFKTJL TN Dipeptidyl peptidase 4 (DPP-4) DMFKTJL MA Inhibitor DMFKTJL RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMFKTJL RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMFKX1M DI DMFKX1M DMFKX1M DN Benzoyl-piperidine derivative 2 DMFKX1M TI TTJQOD7 DMFKX1M TN 5-HT 2A receptor (HTR2A) DMFKX1M MA Antagonist DMFKX1M RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFKX1M RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFL38V DI DMFL38V DMFL38V DN PMID29649907-Compound-19 DMFL38V TI TTS4UGC DMFL38V TN Farnesoid X-activated receptor (FXR) DMFL38V MA Agonist DMFL38V RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMFL38V RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMFMJIN DI DMFMJIN DMFMJIN DN PMID29130358-Compound-Figure14(6) DMFMJIN TI TTXPTJE DMFMJIN TN Gelatinase (GEL) DMFMJIN MA Inhibitor DMFMJIN RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFMJIN RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFMZCW DI DMFMZCW DMFMZCW DN Terpyridineplatinum(II) complexe 1 DMFMZCW TI TTR7UJ3 DMFMZCW TN Cytoplasmic thioredoxin reductase (TXNRD1) DMFMZCW MA Inhibitor DMFMZCW RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMFMZCW RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMFN1AR DI DMFN1AR DMFN1AR DN PMID26924192-Compound-53 DMFN1AR TI TTE4BSY DMFN1AR TN Bromodomain and extraterminal domain protein (BET) DMFN1AR MA Inhibitor DMFN1AR RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFN1AR RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFNB1T DI DMFNB1T DMFNB1T DN PMID25666693-Compound-95 DMFNB1T TI TTMI6F5 DMFNB1T TN Transient receptor potential cation channel V1 (TRPV1) DMFNB1T MA Antagonist DMFNB1T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFNB1T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFNGUV DI DMFNGUV DMFNGUV DN Macrolactam derivative 3 DMFNGUV TI TTKFVXR DMFNGUV TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMFNGUV MA Inhibitor DMFNGUV RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFNGUV RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFNK0L DI DMFNK0L DMFNK0L DN Amidine compound 6 DMFNK0L TI TTQR74A DMFNK0L TN Proteinase activated receptor 2 (PAR2) DMFNK0L MA Antagonist DMFNK0L RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMFNK0L RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMFNU9D DI DMFNU9D DMFNU9D DN PMID28870136-Compound-61 DMFNU9D TI TTK0O6Y DMFNU9D TN Ecto-5'-nucleotidase (CD73) DMFNU9D MA Inhibitor DMFNU9D RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFNU9D RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFOBM9 DI DMFOBM9 DMFOBM9 DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3 DMFOBM9 TI TTV1C0Z DMFOBM9 TN Neuropeptide S receptor (NPSR) DMFOBM9 MA Antagonist DMFOBM9 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMFOBM9 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMFOKRW DI DMFOKRW DMFOKRW DN Tacrine heterodimer derivative 1 DMFOKRW TI TT1RS9F DMFOKRW TN Acetylcholinesterase (AChE) DMFOKRW MA Inhibitor DMFOKRW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFOKRW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFOKRW DI DMFOKRW DMFOKRW DN Tacrine heterodimer derivative 1 DMFOKRW TI TTEB0GD DMFOKRW TN Cholinesterase (BCHE) DMFOKRW MA Inhibitor DMFOKRW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFOKRW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFORUW DI DMFORUW DMFORUW DN PMID28074661-Compound-WO2009018344C78 DMFORUW TI TTL7C8Q DMFORUW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMFORUW MA Inhibitor DMFORUW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMFORUW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMFOVPT DI DMFOVPT DMFOVPT DN Bicyclic heteroaryl benzamide derivative 5 DMFOVPT TI TTTDVOJ DMFOVPT TN Tropomyosin-related kinase A (TrkA) DMFOVPT MA Inhibitor DMFOVPT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFOVPT RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFQERG DI DMFQERG DMFQERG DN US9340511, 5 DMFQERG TI TT9ISBX DMFQERG TN HIF-prolyl hydroxylase 2 (HPH-2) DMFQERG MA Inhibitor DMFQERG RN Process for making isoquinoline compounds. US9708269. DMFQERG RU http://www.freepatentsonline.com/US9708269.html DMFQSU8 DI DMFQSU8 DMFQSU8 DN Tricyclic indole compound 7 DMFQSU8 TI TTPTXIN DMFQSU8 TN Translocator protein (TSPO) DMFQSU8 MA Ligand DMFQSU8 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMFQSU8 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMFR23C DI DMFR23C DMFR23C DN 1,2,3-triazole derivative 2 DMFR23C TI TT6OEDT DMFR23C TN Cannabinoid receptor 1 (CB1) DMFR23C MA Antagonist DMFR23C RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFR23C RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFR4S0 DI DMFR4S0 DMFR4S0 DN Resorcinol compound 17 DMFR4S0 TI TTULVH8 DMFR4S0 TN Tyrosinase (TYR) DMFR4S0 MA Inhibitor DMFR4S0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFR4S0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFS2YL DI DMFS2YL DMFS2YL DN PMID25991433-Compound-F1 DMFS2YL TI TTVOE6D DMFS2YL TN Mitogen-activated protein kinase (MAPK) DMFS2YL MA Inhibitor DMFS2YL RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFS2YL RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFS7C3 DI DMFS7C3 DMFS7C3 DN Chalcone derivative 3 DMFS7C3 TI TTA6ZN2 DMFS7C3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMFS7C3 MA Activator DMFS7C3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMFS7C3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMFS7C3 DI DMFS7C3 DMFS7C3 DN Chalcone derivative 3 DMFS7C3 TI TT3Z6Y9 DMFS7C3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMFS7C3 MA Modulator DMFS7C3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMFS7C3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMFSB9Y DI DMFSB9Y DMFSB9Y DN PMID25991433-Compound-A6 DMFSB9Y TI TTHS0U8 DMFSB9Y TN Stress-activated protein kinase JNK2 (JNK2) DMFSB9Y MA Inhibitor DMFSB9Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFSB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFSB9Y DI DMFSB9Y DMFSB9Y DN PMID25991433-Compound-A6 DMFSB9Y TI TT0K6EO DMFSB9Y TN Stress-activated protein kinase JNK1 (JNK1) DMFSB9Y MA Inhibitor DMFSB9Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFSB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFSOQY DI DMFSOQY DMFSOQY DN US9156852, 38 DMFSOQY TI TTU98HG DMFSOQY TN Discoidin domain-containing receptor 2 (DDR2) DMFSOQY MA Inhibitor DMFSOQY RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DMFSOQY RU http://www.freepatentsonline.com/US9156852.html DMFT3RM DI DMFT3RM DMFT3RM DN PMID26609882-Compound-36 DMFT3RM TI TTJQOD7 DMFT3RM TN 5-HT 2A receptor (HTR2A) DMFT3RM MA Antagonist DMFT3RM RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFT3RM RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFTE3Y DI DMFTE3Y DMFTE3Y DN PMID26815044-Compound-123 DMFTE3Y TI TTULVH8 DMFTE3Y TN Tyrosinase (TYR) DMFTE3Y MA Inhibitor DMFTE3Y RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFTE3Y RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFTGZC DI DMFTGZC DMFTGZC DN PMID28350212-Compound-21 DMFTGZC TI TTZS04O DMFTGZC TN Gamma-secretase subunit APH-1A/1B (APH-1) DMFTGZC MA Inhibitor DMFTGZC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMFTGZC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMFTM8X DI DMFTM8X DMFTM8X DN PMID28870136-Compound-68 DMFTM8X TI TTK0O6Y DMFTM8X TN Ecto-5'-nucleotidase (CD73) DMFTM8X MA Inhibitor DMFTM8X RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFTM8X RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFTZBY DI DMFTZBY DMFTZBY DN P-coumaric acid derivative 2 DMFTZBY TI TTULVH8 DMFTZBY TN Tyrosinase (TYR) DMFTZBY MA Inhibitor DMFTZBY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFTZBY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFU6JR DI DMFU6JR DMFU6JR DN PMID26924192-Compound-52 DMFU6JR TI TTE4BSY DMFU6JR TN Bromodomain and extraterminal domain protein (BET) DMFU6JR MA Inhibitor DMFU6JR RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFU6JR RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFU6OD DI DMFU6OD DMFU6OD DN Quinazoline derivative 13 DMFU6OD TI TTQR74A DMFU6OD TN Proteinase activated receptor 2 (PAR2) DMFU6OD MA Antagonist DMFU6OD RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMFU6OD RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMFUEDL DI DMFUEDL DMFUEDL DN Heterocyclic derivative 18 DMFUEDL TI TTCZOF2 DMFUEDL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMFUEDL MA Inhibitor DMFUEDL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMFUEDL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMFUNH4 DI DMFUNH4 DMFUNH4 DN Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 TI TTKFVXR DMFUNH4 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMFUNH4 MA Inhibitor DMFUNH4 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFUNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFUNH4 DI DMFUNH4 DMFUNH4 DN Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 TI TTXAJWN DMFUNH4 TN IL-1 receptor-associated kinase 1 (IRAK1) DMFUNH4 MA Inhibitor DMFUNH4 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFUNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFUSPR DI DMFUSPR DMFUSPR DN Pyrazolo[1,5-a]pyrimidine derivative 7 DMFUSPR TI TT6OEDT DMFUSPR TN Cannabinoid receptor 1 (CB1) DMFUSPR MA Antagonist DMFUSPR RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFUSPR RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFV36A DI DMFV36A DMFV36A DN Pyrazolo[1,5-a]pyrimidine derivative 19 DMFV36A TI TTTDVOJ DMFV36A TN Tropomyosin-related kinase A (TrkA) DMFV36A MA Inhibitor DMFV36A RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMFV36A RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMFV64B DI DMFV64B DMFV64B DN Pyrrole derivative 3 DMFV64B TI TT6OEDT DMFV64B TN Cannabinoid receptor 1 (CB1) DMFV64B MA Antagonist DMFV64B RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFV64B RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTMX39J DMFWXPS TN Matrix metalloproteinase-1 (MMP-1) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTLM12X DMFWXPS TN Matrix metalloproteinase-2 (MMP-2) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTUZ2L5 DMFWXPS TN Matrix metalloproteinase-3 (MMP-3) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWYKE DI DMFWYKE DMFWYKE DN AC1LCOK0 DMFWYKE TI TT3RMNA DMFWYKE TN Chymotrypsin-C (CLCR) DMFWYKE MA Inhibitor DMFWYKE RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMFWYKE RU http://www.freepatentsonline.com/US9695194.html DMFXC5L DI DMFXC5L DMFXC5L DN Benzodiazepine derivative 1 DMFXC5L TI TTPTXIN DMFXC5L TN Translocator protein (TSPO) DMFXC5L MA Ligand DMFXC5L RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMFXC5L RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMFXCPQ DI DMFXCPQ DMFXCPQ DN PMID29338548-Compound-17 DMFXCPQ TI TTHJTF7 DMFXCPQ TN Glycine transporter GlyT-1 (SLC6A9) DMFXCPQ MA Inhibitor DMFXCPQ RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMFXCPQ RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMFXK03 DI DMFXK03 DMFXK03 DN Aminocyclopentenone compound 3 DMFXK03 TI TTRA6BO DMFXK03 TN Bromodomain-containing protein 4 (BRD4) DMFXK03 MA Inhibitor DMFXK03 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFXK03 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFY78L DI DMFY78L DMFY78L DN Benzamide derivative 3 DMFY78L TI TT9NXW4 DMFY78L TN Sigma intracellular receptor 2 (TMEM97) DMFY78L MA Ligand DMFY78L RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMFY78L RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMFYKBJ DI DMFYKBJ DMFYKBJ DN 1,2,4-oxadiazole derivative 6 DMFYKBJ TI TT23XQV DMFYKBJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMFYKBJ MA Inhibitor DMFYKBJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMFYKBJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMFZ3S4 DI DMFZ3S4 DMFZ3S4 DN PMID25666693-Compound-86 DMFZ3S4 TI TTMI6F5 DMFZ3S4 TN Transient receptor potential cation channel V1 (TRPV1) DMFZ3S4 MA Antagonist DMFZ3S4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFZ3S4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFZ9Q3 DI DMFZ9Q3 DMFZ9Q3 DN Pitavastatin derivative 1 DMFZ9Q3 TI TTPADOQ DMFZ9Q3 TN HMG-CoA reductase (HMGCR) DMFZ9Q3 MA Inhibitor DMFZ9Q3 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMFZ9Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMFZM3X DI DMFZM3X DMFZM3X DN PMID26882240-Compound-3 DMFZM3X TI TTUX68I DMFZM3X TN Hypoxia-inducible factor 1 (HIF-1) DMFZM3X MA Inhibitor DMFZM3X RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMFZM3X RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMG0H73 DI DMG0H73 DMG0H73 DN Thiazole carboxamide derivative 12 DMG0H73 TI TTCZOF2 DMG0H73 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMG0H73 MA Inhibitor DMG0H73 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMG0H73 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMG0QZ1 DI DMG0QZ1 DMG0QZ1 DN US9522888, 618 DMG0QZ1 TI TTDYP7I DMG0QZ1 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMG0QZ1 MA Inhibitor DMG0QZ1 RN Substituted bicyclic compounds. US10166249. DMG0QZ1 RU http://www.freepatentsonline.com/US10166249.html DMG0ZSY DI DMG0ZSY DMG0ZSY DN Phenylate derivative 2 DMG0ZSY TI TT23XQV DMG0ZSY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMG0ZSY MA Inhibitor DMG0ZSY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMG0ZSY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMG14E3 DI DMG14E3 DMG14E3 DN Heteroaryl-azepine derivative 3 DMG14E3 TI TTWJBZ5 DMG14E3 TN 5-HT 2C receptor (HTR2C) DMG14E3 MA Agonist DMG14E3 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMG14E3 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMG18XH DI DMG18XH DMG18XH DN US9132129, Cpd023 DMG18XH TI TTH9LDP DMG18XH TN PC4 and SFRS1-interacting protein (PSIP1) DMG18XH MA Inhibitor DMG18XH RN Antiviral compounds. US9132129. DMG18XH RU http://www.freepatentsonline.com/US9132129.html DMG1EKV DI DMG1EKV DMG1EKV DN PMID25399762-Compound-Figure2-Artoxanthochromane DMG1EKV TI TT3WG5C DMG1EKV TN Monoamine oxidase type A (MAO-A) DMG1EKV MA Inhibitor DMG1EKV RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMG1EKV RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTT7PJU DMG1ESV TN Janus kinase 3 (JAK-3) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTBYWP2 DMG1ESV TN TYK2 tyrosine kinase (TYK2) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTRMX3V DMG1ESV TN Janus kinase 2 (JAK-2) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TT6DM01 DMG1ESV TN Janus kinase 1 (JAK-1) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1RNL DI DMG1RNL DMG1RNL DN Pyrazolo[1,5-a]pyrimidine derivative 28 DMG1RNL TI TTF8P9I DMG1RNL TN Diacylglycerol acyltransferase 1 (DGAT1) DMG1RNL MA Inhibitor DMG1RNL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMG1RNL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMG1SYN DI DMG1SYN DMG1SYN DN PMID25666693-Compound-147 DMG1SYN TI TTMI6F5 DMG1SYN TN Transient receptor potential cation channel V1 (TRPV1) DMG1SYN MA Antagonist DMG1SYN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMG1SYN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMG1TIF DI DMG1TIF DMG1TIF DN Heteroaryl-azepine derivative 14 DMG1TIF TI TTWJBZ5 DMG1TIF TN 5-HT 2C receptor (HTR2C) DMG1TIF MA Agonist DMG1TIF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMG1TIF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMG2ES1 DI DMG2ES1 DMG2ES1 DN PMID25435285-Compound-39 DMG2ES1 TI TTXJ47W DMG2ES1 TN Metabotropic glutamate receptor 2 (mGluR2) DMG2ES1 MA Antagonist DMG2ES1 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG2ES1 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG2JEK DI DMG2JEK DMG2JEK DN PMID25468267-Compound-47 DMG2JEK TI TTV8CRH DMG2JEK TN Lysine-specific demethylase 4C (KDM4C) DMG2JEK MA Inhibitor DMG2JEK RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMG2JEK RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMG2PCZ DI DMG2PCZ DMG2PCZ DN PMID28067079-Compound-95 DMG2PCZ TI TTHS256 DMG2PCZ TN Metabotropic glutamate receptor 5 (mGluR5) DMG2PCZ MA Modulator DMG2PCZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG2PCZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMG3T7E DI DMG3T7E DMG3T7E DN US8933095, 1 DMG3T7E TI TTT3IXG DMG3T7E TN Kynurenine oxoglutarate transaminase II (AADAT) DMG3T7E MA Inhibitor DMG3T7E RN KAT II inhibitors. US8933095. DMG3T7E RU http://www.freepatentsonline.com/US8933095.html DMG4EOP DI DMG4EOP DMG4EOP DN Peptide analog 34 DMG4EOP TI TT68GPI DMG4EOP TN Proteasome beta-5 (PS beta-5) DMG4EOP MA Inhibitor DMG4EOP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG4EOP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG4EOP DI DMG4EOP DMG4EOP DN Peptide analog 34 DMG4EOP TI TTEAD9J DMG4EOP TN Proteasome beta-8 (PS beta-8) DMG4EOP MA Inhibitor DMG4EOP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG4EOP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG4FYP DI DMG4FYP DMG4FYP DN Resorcinol compound 1 DMG4FYP TI TTULVH8 DMG4FYP TN Tyrosinase (TYR) DMG4FYP MA Inhibitor DMG4FYP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMG4FYP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMG4T13 DI DMG4T13 DMG4T13 DN US10030004, Compound 11a DMG4T13 TI TTPKHTZ DMG4T13 TN Activin receptor type IB (ACVR1B) DMG4T13 MA Inhibitor DMG4T13 RN Compounds and methods of use. US10030004. DMG4T13 RU http://www.freepatentsonline.com/US10030004.html DMG4WQB DI DMG4WQB DMG4WQB DN Biphenyl derivative 1 DMG4WQB TI TTZJYKH DMG4WQB TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMG4WQB MA Inhibitor DMG4WQB RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMG4WQB RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMG5CXB DI DMG5CXB DMG5CXB DN Pyrazolo[1,5-a]pyrimidine derivative 22 DMG5CXB TI TTTDVOJ DMG5CXB TN Tropomyosin-related kinase A (TrkA) DMG5CXB MA Inhibitor DMG5CXB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMG5CXB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMG5HI1 DI DMG5HI1 DMG5HI1 DN Piperidinyl triazole derivative 6 DMG5HI1 TI TTTJZ4M DMG5HI1 TN Prolylcarboxypeptidase (PRCP) DMG5HI1 MA Inhibitor DMG5HI1 RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMG5HI1 RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMG5I41 DI DMG5I41 DMG5I41 DN PMID25656651-Compound-34c DMG5I41 TI TT3PJMV DMG5I41 TN Tyrosine-protein kinase ABL1 (ABL) DMG5I41 MA Inhibitor DMG5I41 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMG5I41 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMG5J9Z DI DMG5J9Z DMG5J9Z DN PMID25522065-Compound-20 DMG5J9Z TI TTX4RTB DMG5J9Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMG5J9Z MA Antagonist DMG5J9Z RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMG5J9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMG675B DI DMG675B DMG675B DN PMID29338548-Compound-36 DMG675B TI TTHJTF7 DMG675B TN Glycine transporter GlyT-1 (SLC6A9) DMG675B MA Inhibitor DMG675B RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMG675B RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMG6Q45 DI DMG6Q45 DMG6Q45 DN TDZD-8 DMG6Q45 TI TTRSMW9 DMG6Q45 TN Glycogen synthase kinase-3 beta (GSK-3B) DMG6Q45 MA Inhibitor DMG6Q45 RN Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. DMG6Q45 RU https://pubmed.ncbi.nlm.nih.gov/23099099 DMG6Q45 DI DMG6Q45 DMG6Q45 DN TDZD-8 DMG6Q45 TI TTRZQE3 DMG6Q45 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMG6Q45 MA Inhibitor DMG6Q45 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMG6Q45 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMG6W3O DI DMG6W3O DMG6W3O DN Imidazo pyridine derivative 6 DMG6W3O TI TTV1C0Z DMG6W3O TN Neuropeptide S receptor (NPSR) DMG6W3O MA Antagonist DMG6W3O RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMG6W3O RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMG7VF1 DI DMG7VF1 DMG7VF1 DN PMID29865878-Compound-61 DMG7VF1 TI TTEAD9J DMG7VF1 TN Proteasome beta-8 (PS beta-8) DMG7VF1 MA Inhibitor DMG7VF1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG7VF1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG84D3 DI DMG84D3 DMG84D3 DN Chalcone derivative 2 DMG84D3 TI TTA6ZN2 DMG84D3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMG84D3 MA Activator DMG84D3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMG84D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMG84D3 DI DMG84D3 DMG84D3 DN Chalcone derivative 2 DMG84D3 TI TT3Z6Y9 DMG84D3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMG84D3 MA Modulator DMG84D3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMG84D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMG8K1P DI DMG8K1P DMG8K1P DN PMID25980951-Compound-12 DMG8K1P TI TTR7B60 DMG8K1P TN X-linked inhibitor of apoptosis protein (XIAP) DMG8K1P MA Antagonist DMG8K1P RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMG8K1P RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMG8MCJ DI DMG8MCJ DMG8MCJ DN Diphenyl purine derivative 2 DMG8MCJ TI TT6OEDT DMG8MCJ TN Cannabinoid receptor 1 (CB1) DMG8MCJ MA Antagonist DMG8MCJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMG8MCJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMG8V31 DI DMG8V31 DMG8V31 DN Pyrazolopyrimidine derivative 6 DMG8V31 TI TTHS256 DMG8V31 TN Metabotropic glutamate receptor 5 (mGluR5) DMG8V31 MA Modulator DMG8V31 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG8V31 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMG9CPH DI DMG9CPH DMG9CPH DN PMID25666693-Compound-35 DMG9CPH TI TTMI6F5 DMG9CPH TN Transient receptor potential cation channel V1 (TRPV1) DMG9CPH MA Antagonist DMG9CPH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMG9CPH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMG9FYH DI DMG9FYH DMG9FYH DN PMID25435285-Compound-20 DMG9FYH TI TTXJ47W DMG9FYH TN Metabotropic glutamate receptor 2 (mGluR2) DMG9FYH MA Antagonist DMG9FYH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG9FYH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG9FYH DI DMG9FYH DMG9FYH DN PMID25435285-Compound-20 DMG9FYH TI TT8A9EF DMG9FYH TN Metabotropic glutamate receptor 3 (mGluR3) DMG9FYH MA Antagonist DMG9FYH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG9FYH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG9O7D DI DMG9O7D DMG9O7D DN Bicarboxylic and tricarboxylic ethynyl derivative 2 DMG9O7D TI TTHS256 DMG9O7D TN Metabotropic glutamate receptor 5 (mGluR5) DMG9O7D MA Modulator DMG9O7D RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG9O7D RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMGA0R6 DI DMGA0R6 DMGA0R6 DN Biphenyl mannoside derivative 19 DMGA0R6 TI TTTCRU2 DMGA0R6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGA0R6 MA Antagonist DMGA0R6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGA0R6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGA3U8 DI DMGA3U8 DMGA3U8 DN Peptide analog 45 DMGA3U8 TI TTDIGC1 DMGA3U8 TN Dipeptidyl peptidase 4 (DPP-4) DMGA3U8 MA Inhibitor DMGA3U8 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMGA3U8 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMGA3XL DI DMGA3XL DMGA3XL DN PMID28092474-Compound-32c DMGA3XL TI TT5ZKDI DMGA3XL TN Histone deacetylase 6 (HDAC6) DMGA3XL MA Inhibitor DMGA3XL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGA3XL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGA3XL DI DMGA3XL DMGA3XL DN PMID28092474-Compound-32c DMGA3XL TI TT6R7JZ DMGA3XL TN Histone deacetylase 1 (HDAC1) DMGA3XL MA Inhibitor DMGA3XL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGA3XL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGAQR5 DI DMGAQR5 DMGAQR5 DN PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 TI TTYGQ8A DMGAQR5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMGAQR5 MA Inhibitor DMGAQR5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGAQR5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGAQR5 DI DMGAQR5 DMGAQR5 DN PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 TI TTSBVFO DMGAQR5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMGAQR5 MA Inhibitor DMGAQR5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGAQR5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGATHZ DI DMGATHZ DMGATHZ DN Hydroxamate analog 1 DMGATHZ TI TTZHPB8 DMGATHZ TN Lysine-specific demethylase 4A (KDM4A) DMGATHZ MA Inhibitor DMGATHZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGATHZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGATHZ DI DMGATHZ DMGATHZ DN Hydroxamate analog 1 DMGATHZ TI TTV8CRH DMGATHZ TN Lysine-specific demethylase 4C (KDM4C) DMGATHZ MA Inhibitor DMGATHZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGATHZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGAW81 DI DMGAW81 DMGAW81 DN PMID28454500-Compound-41 DMGAW81 TI TTA6ZN2 DMGAW81 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMGAW81 MA Activator DMGAW81 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMGAW81 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMGAW81 DI DMGAW81 DMGAW81 DN PMID28454500-Compound-41 DMGAW81 TI TT3Z6Y9 DMGAW81 TN Cysteines of Keap1 (KEAP1 Cysteines) DMGAW81 MA Modulator DMGAW81 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMGAW81 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMGBFK3 DI DMGBFK3 DMGBFK3 DN PMID26651364-Compound-11b DMGBFK3 TI TTTCRU2 DMGBFK3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGBFK3 MA Antagonist DMGBFK3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGBFK3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGBR43 DI DMGBR43 DMGBR43 DN Pyridine derivative 15 DMGBR43 TI TTHS256 DMGBR43 TN Metabotropic glutamate receptor 5 (mGluR5) DMGBR43 MA Modulator DMGBR43 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMGBR43 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMGC7NW DI DMGC7NW DMGC7NW DN Peptide analog 63 DMGC7NW TI TTPLTSQ DMGC7NW TN Neutrophil elastase (NE) DMGC7NW MA Inhibitor DMGC7NW RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMGC7NW RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMGCE3Z DI DMGCE3Z DMGCE3Z DN PMID30280939-Compound-WO2015150568 DMGCE3Z TI TTOK0LR DMGCE3Z TN Toll-like receptor (TLR) DMGCE3Z MA Agonist DMGCE3Z RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMGCE3Z RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTQV3NX DMGCHW9 TN RET V804M mutant (RET V804M) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT2RTDH DMGCHW9 TN RET V804L mutant (RET V804L) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTB0IO2 DMGCHW9 TN RET Y791F mutant (RET Y791F) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTY0WT7 DMGCHW9 TN RET G691S mutant (RET G691S) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT8BF4A DMGCHW9 TN RET S891A mutant (RET S891A) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT5XA6U DMGCHW9 TN RET M918T mutant (RET M918T) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT4DXQT DMGCHW9 TN Proto-oncogene c-Ret (RET) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCMF5 DI DMGCMF5 DMGCMF5 DN Pyridine-2,4-dicarboxylic acid derivative 2 DMGCMF5 TI TT0RGE9 DMGCMF5 TN Lysine-specific demethylase 4 (KDM4) DMGCMF5 MA Inhibitor DMGCMF5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGCMF5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGCUJB DI DMGCUJB DMGCUJB DN PMID26651364-Compound-7c DMGCUJB TI TTTCRU2 DMGCUJB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGCUJB MA Antagonist DMGCUJB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGCUJB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGDLPZ DI DMGDLPZ DMGDLPZ DN Resorcinol compound 11 DMGDLPZ TI TTULVH8 DMGDLPZ TN Tyrosinase (TYR) DMGDLPZ MA Inhibitor DMGDLPZ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGDLPZ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGDMWA DI DMGDMWA DMGDMWA DN Imidazo quinoline derivative 1 DMGDMWA TI TTCZOF2 DMGDMWA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGDMWA MA Inhibitor DMGDMWA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGDMWA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGDQYW DI DMGDQYW DMGDQYW DN Resorcinol compound 2 DMGDQYW TI TTULVH8 DMGDQYW TN Tyrosinase (TYR) DMGDQYW MA Inhibitor DMGDQYW RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGDQYW RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGDZLP DI DMGDZLP DMGDZLP DN US10022354, Example 152 DMGDZLP TI TTIG67W DMGDZLP TN Lysine-specific demethylase 5A (KDM5A) DMGDZLP MA Inhibitor DMGDZLP RN IRE-1 inhibitors DMGDZLP RU http://www.freepatentsonline.com/US10022354.html DMGECO2 DI DMGECO2 DMGECO2 DN Quinazoline derivative 2 DMGECO2 TI TTPTXIN DMGECO2 TN Translocator protein (TSPO) DMGECO2 MA Ligand DMGECO2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMGECO2 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMGEFIW DI DMGEFIW DMGEFIW DN Heteroaryl-carboxamide derivative 2 DMGEFIW TI TTCZOF2 DMGEFIW TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGEFIW MA Inhibitor DMGEFIW RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGEFIW RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGEIZV DI DMGEIZV DMGEIZV DN Thiazole carboxamide derivative 28 DMGEIZV TI TTCZOF2 DMGEIZV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGEIZV MA Inhibitor DMGEIZV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGEIZV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGESCP DI DMGESCP DMGESCP DN Bicyclo-heptan-2-amine derivative 1 DMGESCP TI TT9NXW4 DMGESCP TN Sigma intracellular receptor 2 (TMEM97) DMGESCP MA Ligand DMGESCP RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMGESCP RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMGEWVP DI DMGEWVP DMGEWVP DN PMID29334795-Compound-25 DMGEWVP TI TT9JNIC DMGEWVP TN Histamine H3 receptor (H3R) DMGEWVP MA Inverse agonist DMGEWVP RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMGEWVP RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMGEYJW DI DMGEYJW DMGEYJW DN Pyridine and pyrimidine derivative 1 DMGEYJW TI TTSCIM2 DMGEYJW TN Extracellular lysophospholipase D (E-NPP2) DMGEYJW MA Inhibitor DMGEYJW RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMGEYJW RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMGEZT8 DI DMGEZT8 DMGEZT8 DN PMID28394193-Compound-30 DMGEZT8 TI TT9MZCQ DMGEZT8 TN Enhancer of zeste homolog 2 (EZH2) DMGEZT8 MA Inhibitor DMGEZT8 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGEZT8 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGF04T DI DMGF04T DMGF04T DN PMID27977313-Compound-46 DMGF04T TI TTR7UJ3 DMGF04T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMGF04T MA Inhibitor DMGF04T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMGF04T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMGFAS6 DI DMGFAS6 DMGFAS6 DN Pyrazolo[3,4-d]pyrimidine derivative 4 DMGFAS6 TI TTJGW1Z DMGFAS6 TN Phosphodiesterase 2A (PDE2A) DMGFAS6 MA Inhibitor DMGFAS6 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMGFAS6 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMGFORB DI DMGFORB DMGFORB DN Mycophenolic acid/nucleotide derivative 6 DMGFORB TI TTL7C8Q DMGFORB TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMGFORB MA Inhibitor DMGFORB RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMGFORB RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMGH0LQ DI DMGH0LQ DMGH0LQ DN Pyrazoline derivative 3 DMGH0LQ TI TT6OEDT DMGH0LQ TN Cannabinoid receptor 1 (CB1) DMGH0LQ MA Antagonist DMGH0LQ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMGH0LQ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMGH9B3 DI DMGH9B3 DMGH9B3 DN US9580418, Example 8 DMGH9B3 TI TTCGOIN DMGH9B3 TN PIM-3 protein kinase (PIM3) DMGH9B3 MA Inhibitor DMGH9B3 RN Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418. DMGH9B3 RU http://www.freepatentsonline.com/US9580418.html DMGHR4D DI DMGHR4D DMGHR4D DN PMID25980951-Compound-13 DMGHR4D TI TTR7B60 DMGHR4D TN X-linked inhibitor of apoptosis protein (XIAP) DMGHR4D MA Antagonist DMGHR4D RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGHR4D RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGHSR9 DI DMGHSR9 DMGHSR9 DN PMID25776143-Compound-1 DMGHSR9 TI TT4TFGN DMGHSR9 TN Vasopressin V1a receptor (V1AR) DMGHSR9 MA Agonist DMGHSR9 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMGHSR9 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMGI5Z8 DI DMGI5Z8 DMGI5Z8 DN PMID27967267-Compound-14 DMGI5Z8 TI TT1RS9F DMGI5Z8 TN Acetylcholinesterase (AChE) DMGI5Z8 MA Inhibitor DMGI5Z8 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMGI5Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMGIJZA DI DMGIJZA DMGIJZA DN US8546370, 17 DMGIJZA TI TTUMHT8 DMGIJZA TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DMGIJZA MA Inhibitor DMGIJZA RN Compounds and compositions as kinase inhibitors. US8546370. DMGIJZA RU http://www.freepatentsonline.com/US8546370.html DMGIPDH DI DMGIPDH DMGIPDH DN PMID26666989-Compound-Figure12bottommiddle01 DMGIPDH TI TT8BUGW DMGIPDH TN Glycogen phosphorylase (PYG) DMGIPDH MA Inhibitor DMGIPDH RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMGIPDH RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMGIV0M DI DMGIV0M DMGIV0M DN PMID25980951-Compound-19 DMGIV0M TI TTR7B60 DMGIV0M TN X-linked inhibitor of apoptosis protein (XIAP) DMGIV0M MA Antagonist DMGIV0M RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGIV0M RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGIV0M DI DMGIV0M DMGIV0M DN PMID25980951-Compound-19 DMGIV0M TI TTQ5LRD DMGIV0M TN Cellular inhibitor of apoptosis 1 (BIRC2) DMGIV0M MA Antagonist DMGIV0M RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGIV0M RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGIV3C DI DMGIV3C DMGIV3C DN PMID26651364-Compound-10d DMGIV3C TI TTTCRU2 DMGIV3C TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGIV3C MA Antagonist DMGIV3C RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGIV3C RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGK0FD DI DMGK0FD DMGK0FD DN Benzodihydroisofuran derivative 2 DMGK0FD TI TTTJZ4M DMGK0FD TN Prolylcarboxypeptidase (PRCP) DMGK0FD MA Inhibitor DMGK0FD RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMGK0FD RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMGKQXP DI DMGKQXP DMGKQXP DN Lycorine dimer salt derivative 1 DMGKQXP TI TT1RS9F DMGKQXP TN Acetylcholinesterase (AChE) DMGKQXP MA Inhibitor DMGKQXP RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMGKQXP RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMGLK92 DI DMGLK92 DMGLK92 DN Quinolinyl compound 2 DMGLK92 TI TT9O6WS DMGLK92 TN Glucagon receptor (GCGR) DMGLK92 MA Antagonist DMGLK92 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMGLK92 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMGM72Q DI DMGM72Q DMGM72Q DN A-substituted phenylpropionic acid derivative 1 DMGM72Q TI TTZMAO3 DMGM72Q TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGM72Q MA Agonist DMGM72Q RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGM72Q RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGN9IX DI DMGN9IX DMGN9IX DN 3-(phenoxymethyl) benzylamine derivative 2 DMGN9IX TI TTULVH8 DMGN9IX TN Tyrosinase (TYR) DMGN9IX MA Inhibitor DMGN9IX RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGN9IX RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TTJUALD DMGNRZU TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TT6VZ78 DMGNRZU TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TT6S2FE DMGNRZU TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNW34 DI DMGNW34 DMGNW34 DN PMID29649907-Compound-20 DMGNW34 TI TTS4UGC DMGNW34 TN Farnesoid X-activated receptor (FXR) DMGNW34 MA Agonist DMGNW34 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMGNW34 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMGNWJD DI DMGNWJD DMGNWJD DN Fused heterocyclic compound 7 DMGNWJD TI TT7RJY8 DMGNWJD TN Xanthine dehydrogenase/oxidase (XDH) DMGNWJD MA Inhibitor DMGNWJD RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMGNWJD RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMGO1CB DI DMGO1CB DMGO1CB DN Indazole derivative 6 DMGO1CB TI TTRZQE3 DMGO1CB TN Glycogen synthase kinase-3 alpha (GSK-3A) DMGO1CB MA Inhibitor DMGO1CB RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMGO1CB RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMGO1PA DI DMGO1PA DMGO1PA DN PMID29334795-Compound-57 DMGO1PA TI TT9JNIC DMGO1PA TN Histamine H3 receptor (H3R) DMGO1PA RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMGO1PA RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMGO9WY DI DMGO9WY DMGO9WY DN Amidopyrazole derivative 2 DMGO9WY TI TTKFVXR DMGO9WY TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMGO9WY MA Inhibitor DMGO9WY RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMGO9WY RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMGONY4 DI DMGONY4 DMGONY4 DN Bicyclic heteroaryl benzamide derivative 9 DMGONY4 TI TTTDVOJ DMGONY4 TN Tropomyosin-related kinase A (TrkA) DMGONY4 MA Inhibitor DMGONY4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMGONY4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMGOSN2 DI DMGOSN2 DMGOSN2 DN Fluorinated compound 1 DMGOSN2 TI TT7HF4W DMGOSN2 TN Cyclin-dependent kinase 2 (CDK2) DMGOSN2 MA Inhibitor DMGOSN2 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMGOSN2 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMGP5AR DI DMGP5AR DMGP5AR DN Antibodie derivative 10 DMGP5AR TI TTUTJGQ DMGP5AR TN Vascular endothelial growth factor receptor 2 (KDR) DMGP5AR RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGP5AR RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGPCSR DI DMGPCSR DMGPCSR DN Pyridine-2,4-dicarboxylic acid analog 4 DMGPCSR TI TTWAQBO DMGPCSR TN Lysine-specific demethylase 4E (KDM4E) DMGPCSR MA Inhibitor DMGPCSR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGPCSR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGPDEF DI DMGPDEF DMGPDEF DN US9475795, 19 DMGPDEF TI TTB9CIL DMGPDEF TN Prokineticin receptor-1 (PROKR1) DMGPDEF MA Inhibitor DMGPDEF RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DMGPDEF RU http://www.freepatentsonline.com/US9475795.html DMGQ1PK DI DMGQ1PK DMGQ1PK DN Peptide analog 32 DMGQ1PK TI TTSJMN8 DMGQ1PK TN Immunoproteasome complex (IP) DMGQ1PK MA Inhibitor DMGQ1PK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMGQ1PK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMGQMCZ DI DMGQMCZ DMGQMCZ DN Hydroxyqunoline analog 4 DMGQMCZ TI TTWAQBO DMGQMCZ TN Lysine-specific demethylase 4E (KDM4E) DMGQMCZ MA Inhibitor DMGQMCZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGQMCZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGQWKH DI DMGQWKH DMGQWKH DN N-(benzimidazole/indole) benzoic acid derivative 1 DMGQWKH TI TT5ZWB6 DMGQWKH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMGQWKH MA Inhibitor DMGQWKH RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMGQWKH RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMGR2JC DI DMGR2JC DMGR2JC DN PMID27109571-Compound-33 DMGR2JC TI TTMY6L1 DMGR2JC TN Fatty acid-binding protein (FABP) DMGR2JC MA Inhibitor DMGR2JC RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMGR2JC RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMGR6IJ DI DMGR6IJ DMGR6IJ DN Tihourea derivative 1 DMGR6IJ TI TTSXVID DMGR6IJ TN Nuclear factor NF-kappa-B (NFKB) DMGR6IJ MA Inhibitor DMGR6IJ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMGR6IJ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMGR6X1 DI DMGR6X1 DMGR6X1 DN Aromatic acetylene derivative 1 DMGR6X1 TI TT23XQV DMGR6X1 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMGR6X1 MA Inhibitor DMGR6X1 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMGR6X1 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMGRBAJ DI DMGRBAJ DMGRBAJ DN Cyclic compound 2 DMGRBAJ TI TTNBFWK DMGRBAJ TN Programmed cell death protein 1 (PD-1) DMGRBAJ MA Inhibitor DMGRBAJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMGRBAJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMGRD8B DI DMGRD8B DMGRD8B DN Benzimidazole derivative 11 DMGRD8B TI TTYLQ8V DMGRD8B TN Prostaglandin E synthase (PTGES) DMGRD8B MA Inhibitor DMGRD8B RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMGRD8B RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMGS2ET DI DMGS2ET DMGS2ET DN Pyrazoline derivative 1 DMGS2ET TI TT6OEDT DMGS2ET TN Cannabinoid receptor 1 (CB1) DMGS2ET MA Antagonist DMGS2ET RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMGS2ET RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMGSLHN DI DMGSLHN DMGSLHN DN Biaryl mannoside derivative 21 DMGSLHN TI TTTCRU2 DMGSLHN TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGSLHN MA Antagonist DMGSLHN RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGSLHN RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGSUIV DI DMGSUIV DMGSUIV DN Pyridine derivative 2 DMGSUIV TI TTOHSBA DMGSUIV TN Vascular endothelial growth factor A (VEGFA) DMGSUIV MA Inhibitor DMGSUIV RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGSUIV RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGTBO3 DI DMGTBO3 DMGTBO3 DN US10179791, Compound 171 DMGTBO3 TI TTDYP7I DMGTBO3 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMGTBO3 MA Inhibitor DMGTBO3 RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMGTBO3 RU http://www.freepatentsonline.com/US10179791.html DMGTIP6 DI DMGTIP6 DMGTIP6 DN US9682991, 23 DMGTIP6 TI TTCGOIN DMGTIP6 TN PIM-3 protein kinase (PIM3) DMGTIP6 MA Inhibitor DMGTIP6 RN Tricyclic compounds for use as kinase inhibitors. US9682991. DMGTIP6 RU http://www.freepatentsonline.com/US9682991.html DMGTSCP DI DMGTSCP DMGTSCP DN JWH-015 DMGTSCP TI TTMSFAW DMGTSCP TN Cannabinoid receptor 2 (CB2) DMGTSCP MA Agonist DMGTSCP RN Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. DMGTSCP RU https://pubmed.ncbi.nlm.nih.gov/18524639 DMGTSXL DI DMGTSXL DMGTSXL DN PMID28092474-Compound-33e DMGTSXL TI TT5ZKDI DMGTSXL TN Histone deacetylase 6 (HDAC6) DMGTSXL MA Inhibitor DMGTSXL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGTSXL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGTSXL DI DMGTSXL DMGTSXL DN PMID28092474-Compound-33e DMGTSXL TI TT6R7JZ DMGTSXL TN Histone deacetylase 1 (HDAC1) DMGTSXL MA Inhibitor DMGTSXL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGTSXL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGU914 DI DMGU914 DMGU914 DN PMID26666989-Compound-Figure11Ala up DMGU914 TI TT8BUGW DMGU914 TN Glycogen phosphorylase (PYG) DMGU914 MA Inhibitor DMGU914 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMGU914 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMGV4PT DI DMGV4PT DMGV4PT DN PMID27109571-Compound-35 DMGV4PT TI TTMY6L1 DMGV4PT TN Fatty acid-binding protein (FABP) DMGV4PT MA Inhibitor DMGV4PT RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMGV4PT RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMGV8T9 DI DMGV8T9 DMGV8T9 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 DMGV8T9 TI TTULVH8 DMGV8T9 TN Tyrosinase (TYR) DMGV8T9 MA Inhibitor DMGV8T9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGV8T9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGVT5Y DI DMGVT5Y DMGVT5Y DN PMID28766366-Compound-Scheme25-3 DMGVT5Y TI TTYGQ8A DMGVT5Y TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMGVT5Y MA Inhibitor DMGVT5Y RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGVT5Y RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGVT5Y DI DMGVT5Y DMGVT5Y DN PMID28766366-Compound-Scheme25-3 DMGVT5Y TI TTSBVFO DMGVT5Y TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMGVT5Y MA Inhibitor DMGVT5Y RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGVT5Y RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGVU7M DI DMGVU7M DMGVU7M DN PMID25666693-Compound-85 DMGVU7M TI TTMI6F5 DMGVU7M TN Transient receptor potential cation channel V1 (TRPV1) DMGVU7M MA Antagonist DMGVU7M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMGVU7M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMGVXCL DI DMGVXCL DMGVXCL DN PMID26004420-Compound-WO2012058134B DMGVXCL TI TTJ13ST DMGVXCL TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMGVXCL MA Inhibitor DMGVXCL RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMGVXCL RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMGWQVT DI DMGWQVT DMGWQVT DN PMID26924192-Compound-55 DMGWQVT TI TTE4BSY DMGWQVT TN Bromodomain and extraterminal domain protein (BET) DMGWQVT MA Inhibitor DMGWQVT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMGWQVT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMGWYJR DI DMGWYJR DMGWYJR DN Imidazo[1,2-b]pyridazine acetamide derivative 5 DMGWYJR TI TTPTXIN DMGWYJR TN Translocator protein (TSPO) DMGWYJR MA Ligand DMGWYJR RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMGWYJR RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMGXI95 DI DMGXI95 DMGXI95 DN PMID27841036-Compound-33 DMGXI95 TI TTVDSZ0 DMGXI95 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGXI95 MA Inhibitor DMGXI95 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMGXI95 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMGXOJK DI DMGXOJK DMGXOJK DN PMID25726713-Compound-37 DMGXOJK TI TT8J1S3 DMGXOJK TN Smoothened homolog (SMO) DMGXOJK MA Inhibitor DMGXOJK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMGXOJK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMGXUNA DI DMGXUNA DMGXUNA DN PMID29865878-Compound-40 DMGXUNA TI TTSJMN8 DMGXUNA TN Immunoproteasome complex (IP) DMGXUNA MA Inhibitor DMGXUNA RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMGXUNA RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMGY3OR DI DMGY3OR DMGY3OR DN Tricyclic pyrrolidine derivative 1 DMGY3OR TI TTWJBZ5 DMGY3OR TN 5-HT 2C receptor (HTR2C) DMGY3OR MA Agonist DMGY3OR RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMGY3OR RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMGY4WO DI DMGY4WO DMGY4WO DN Quinoline and quinazoline derivative 3 DMGY4WO TI TTOHSBA DMGY4WO TN Vascular endothelial growth factor A (VEGFA) DMGY4WO MA Inhibitor DMGY4WO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGY4WO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGYT81 DI DMGYT81 DMGYT81 DN Pyrrolo-pyrimidine derivative 6 DMGYT81 TI TT4DXQT DMGYT81 TN Proto-oncogene c-Ret (RET) DMGYT81 MA Inhibitor DMGYT81 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGYT81 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGYZQ2 DI DMGYZQ2 DMGYZQ2 DN 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 TI TTQVOEI DMGYZQ2 TN Angiotensin II receptor type-2 (AGTR2) DMGYZQ2 MA Agonist DMGYZQ2 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGYZQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGYZQ2 DI DMGYZQ2 DMGYZQ2 DN 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 TI TTZMAO3 DMGYZQ2 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGYZQ2 MA Agonist DMGYZQ2 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGYZQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGZ59Q DI DMGZ59Q DMGZ59Q DN Pyrazolo[1,5-a]pyrimidine derivative 26 DMGZ59Q TI TTTDVOJ DMGZ59Q TN Tropomyosin-related kinase A (TrkA) DMGZ59Q MA Inhibitor DMGZ59Q RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMGZ59Q RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMGZ61E DI DMGZ61E DMGZ61E DN PMID28092474-Compound-32a DMGZ61E TI TT6R7JZ DMGZ61E TN Histone deacetylase 1 (HDAC1) DMGZ61E MA Inhibitor DMGZ61E RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGZ61E RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGZ61E DI DMGZ61E DMGZ61E DN PMID28092474-Compound-32a DMGZ61E TI TT5ZKDI DMGZ61E TN Histone deacetylase 6 (HDAC6) DMGZ61E MA Inhibitor DMGZ61E RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGZ61E RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGZ9MW DI DMGZ9MW DMGZ9MW DN PMID28394193-Compound-13 DMGZ9MW TI TT9MZCQ DMGZ9MW TN Enhancer of zeste homolog 2 (EZH2) DMGZ9MW MA Inhibitor DMGZ9MW RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGZ9MW RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGZ9MW DI DMGZ9MW DMGZ9MW DN PMID28394193-Compound-13 DMGZ9MW TI TTJBYRU DMGZ9MW TN EZH2 Y641F mutant (EZH2 Y641F) DMGZ9MW MA Inhibitor DMGZ9MW RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGZ9MW RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGZER5 DI DMGZER5 DMGZER5 DN PMID25522065-Compound-14 DMGZER5 TI TTX4RTB DMGZER5 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMGZER5 MA Antagonist DMGZER5 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMGZER5 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMGZHRT DI DMGZHRT DMGZHRT DN Aryl carbamate analog 1 DMGZHRT TI TTUX68I DMGZHRT TN Hypoxia-inducible factor 1 (HIF-1) DMGZHRT MA Inhibitor DMGZHRT RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMGZHRT RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMGZUAY DI DMGZUAY DMGZUAY DN Pyrazole derivative 87 DMGZUAY TI TTSCIM2 DMGZUAY TN Extracellular lysophospholipase D (E-NPP2) DMGZUAY MA Inhibitor DMGZUAY RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMGZUAY RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMH02JL DI DMH02JL DMH02JL DN Quinoline derivative 11 DMH02JL TI TT473XN DMH02JL TN P2X purinoceptor 7 (P2RX7) DMH02JL MA Antagonist DMH02JL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMH02JL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMH02JL DI DMH02JL DMH02JL DN Quinoline derivative 11 DMH02JL TI TTQ6VDM DMH02JL TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMH02JL MA Antagonist DMH02JL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMH02JL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMH073T DI DMH073T DMH073T DN PMID25991433-Compound-O1 DMH073T TI TTR2TXZ DMH073T TN Jun N terminal kinase (JNK) DMH073T MA Inhibitor DMH073T RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMH073T RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMH0CQU DI DMH0CQU DMH0CQU DN PMID27454349-Compound-99 DMH0CQU TI TTK59TV DMH0CQU TN Vitamin D3 receptor (VDR) DMH0CQU MA Agonist DMH0CQU RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMH0CQU RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMH0LBI DI DMH0LBI DMH0LBI DN PMID26004420-Compound-WO2014126944B DMH0LBI TI TTJ13ST DMH0LBI TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH0LBI MA Inhibitor DMH0LBI RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH0LBI RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH1W89 DI DMH1W89 DMH1W89 DN Pyrazolo[1,5-a]pyridine derivative 1 DMH1W89 TI TTTDVOJ DMH1W89 TN Tropomyosin-related kinase A (TrkA) DMH1W89 MA Inhibitor DMH1W89 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMH1W89 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTKAWRQ DMH1W8F TN JAK-STAT signaling pathway (JAK-STAT pathway) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTJSQEF DMH1W8F TN Tyrosine-protein kinase (PTK) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTT7PJU DMH1W8F TN Janus kinase 3 (JAK-3) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTRMX3V DMH1W8F TN Janus kinase 2 (JAK-2) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTBYWP2 DMH1W8F TN TYK2 tyrosine kinase (TYK2) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TT6DM01 DMH1W8F TN Janus kinase 1 (JAK-1) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH249S DI DMH249S DMH249S DN PMID28074661-Compound-US20120264760C81 DMH249S TI TTL7C8Q DMH249S TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMH249S MA Inhibitor DMH249S RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMH249S RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMH26EO DI DMH26EO DMH26EO DN 1,3,4-oxadiazole derivative 2 DMH26EO TI TTNBFWK DMH26EO TN Programmed cell death protein 1 (PD-1) DMH26EO MA Inhibitor DMH26EO RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMH26EO RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMH2AYV DI DMH2AYV DMH2AYV DN Proline amide derivative 1 DMH2AYV TI TTTJZ4M DMH2AYV TN Prolylcarboxypeptidase (PRCP) DMH2AYV MA Inhibitor DMH2AYV RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMH2AYV RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMH2LFS DI DMH2LFS DMH2LFS DN Pyrazole derivative 23 DMH2LFS TI TT6OEDT DMH2LFS TN Cannabinoid receptor 1 (CB1) DMH2LFS MA Antagonist DMH2LFS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMH2LFS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMH3CK0 DI DMH3CK0 DMH3CK0 DN PMID25522065-Compound-37 DMH3CK0 TI TTX4RTB DMH3CK0 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMH3CK0 MA Antagonist DMH3CK0 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMH3CK0 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMH3FUR DI DMH3FUR DMH3FUR DN Phenylpropylamine derivative 3 DMH3FUR TI TT5TPI6 DMH3FUR TN Opioid receptor sigma 1 (OPRS1) DMH3FUR MA Ligand DMH3FUR RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMH3FUR RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMH3NOZ DI DMH3NOZ DMH3NOZ DN PMID25553724-Compound-WO2011127048 32 DMH3NOZ TI TTSXVID DMH3NOZ TN Nuclear factor NF-kappa-B (NFKB) DMH3NOZ MA Modulator DMH3NOZ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH3NOZ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH4DMY DI DMH4DMY DMH4DMY DN PMID25553724-Compound-US2011796857710 DMH4DMY TI TTSXVID DMH4DMY TN Nuclear factor NF-kappa-B (NFKB) DMH4DMY MA Inhibitor DMH4DMY RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH4DMY RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH4TY1 DI DMH4TY1 DMH4TY1 DN Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 TI TTP7EGM DMH4TY1 TN Dual specificity protein kinase TTK (MPS1) DMH4TY1 MA Inhibitor DMH4TY1 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMH4TY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMH4TY1 DI DMH4TY1 DMH4TY1 DN Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 TI TT5OU0D DMH4TY1 TN PRKR-like endoplasmic reticulum kinase (PERK) DMH4TY1 MA Inhibitor DMH4TY1 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMH4TY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMH57FG DI DMH57FG DMH57FG DN PMID30107136-Compound-Example48 DMH57FG TI TT23XQV DMH57FG TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMH57FG MA Inhibitor DMH57FG RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMH57FG RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMH5FEO DI DMH5FEO DMH5FEO DN A-substituted phenylpropionic acid derivative 2 DMH5FEO TI TTZMAO3 DMH5FEO TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMH5FEO MA Agonist DMH5FEO RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMH5FEO RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMH5N78 DI DMH5N78 DMH5N78 DN Spirocyclic diamine urea derivative 2 DMH5N78 TI TTDP1UC DMH5N78 TN Fatty acid amide hydrolase (FAAH) DMH5N78 MA Inhibitor DMH5N78 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMH5N78 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMH65CX DI DMH65CX DMH65CX DN N-quinolin-benzene sulphonamide derivative 2 DMH65CX TI TTSXVID DMH65CX TN Nuclear factor NF-kappa-B (NFKB) DMH65CX MA Inhibitor DMH65CX RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH65CX RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH7496 DI DMH7496 DMH7496 DN PMID25553724-Compound-WO2011127048 33 DMH7496 TI TTSXVID DMH7496 TN Nuclear factor NF-kappa-B (NFKB) DMH7496 MA Modulator DMH7496 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH7496 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH7DL5 DI DMH7DL5 DMH7DL5 DN US9422240, 1-298 DMH7DL5 TI TT9ISBX DMH7DL5 TN HIF-prolyl hydroxylase 2 (HPH-2) DMH7DL5 MA Inhibitor DMH7DL5 RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMH7DL5 RU http://www.freepatentsonline.com/US9422240.html DMH7E38 DI DMH7E38 DMH7E38 DN PMID26004420-Compound-WO2013062892D DMH7E38 TI TTJ13ST DMH7E38 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH7E38 MA Inhibitor DMH7E38 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH7E38 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH7JKI DI DMH7JKI DMH7JKI DN PMID26004420-Compound-US20140275020E DMH7JKI TI TTJ13ST DMH7JKI TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH7JKI MA Inhibitor DMH7JKI RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH7JKI RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH7JVA DI DMH7JVA DMH7JVA DN US8470836, 2 DMH7JVA TI TTOYT5L DMH7JVA TN Dipeptidyl-peptidase 7 (DPP7) DMH7JVA MA Inhibitor DMH7JVA RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMH7JVA RU http://www.freepatentsonline.com/US8470836.html DMH7PGC DI DMH7PGC DMH7PGC DN Cyclopentane carboxamide derivative 1 DMH7PGC TI TTTJZ4M DMH7PGC TN Prolylcarboxypeptidase (PRCP) DMH7PGC MA Inhibitor DMH7PGC RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMH7PGC RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMH7PGU DI DMH7PGU DMH7PGU DN Pyrazole derivative 11 DMH7PGU TI TT6OEDT DMH7PGU TN Cannabinoid receptor 1 (CB1) DMH7PGU MA Antagonist DMH7PGU RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMH7PGU RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTNR0UQ DMH7T8C TN Lysine-specific histone demethylase 1 (LSD) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTZHPB8 DMH7T8C TN Lysine-specific demethylase 4A (KDM4A) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTGP7BY DMH7T8C TN Monoamine oxidase type B (MAO-B) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7XL3 DI DMH7XL3 DMH7XL3 DN PMID26651364-Compound-5 DMH7XL3 TI TTTCRU2 DMH7XL3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMH7XL3 MA Antagonist DMH7XL3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMH7XL3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMH86F2 DI DMH86F2 DMH86F2 DN Quinazoline alkaloid derivative 1 DMH86F2 TI TT1RS9F DMH86F2 TN Acetylcholinesterase (AChE) DMH86F2 MA Inhibitor DMH86F2 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMH86F2 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMH86F2 DI DMH86F2 DMH86F2 DN Quinazoline alkaloid derivative 1 DMH86F2 TI TTEB0GD DMH86F2 TN Cholinesterase (BCHE) DMH86F2 MA Inhibitor DMH86F2 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMH86F2 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMH8E7S DI DMH8E7S DMH8E7S DN PMID26815044-Compound-30 DMH8E7S TI TTULVH8 DMH8E7S TN Tyrosinase (TYR) DMH8E7S MA Inhibitor DMH8E7S RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMH8E7S RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMH8GC6 DI DMH8GC6 DMH8GC6 DN PMID28350212-Compound-18 DMH8GC6 TI TTZS04O DMH8GC6 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMH8GC6 MA Inhibitor DMH8GC6 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMH8GC6 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMH8M1D DI DMH8M1D DMH8M1D DN PMID26004420-Compound-US20140309213A DMH8M1D TI TTJ13ST DMH8M1D TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH8M1D MA Inhibitor DMH8M1D RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH8M1D RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH8Q4T DI DMH8Q4T DMH8Q4T DN Azole benzene derivative 3 DMH8Q4T TI TT7RJY8 DMH8Q4T TN Xanthine dehydrogenase/oxidase (XDH) DMH8Q4T MA Inhibitor DMH8Q4T RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMH8Q4T RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMH942E DI DMH942E DMH942E DN Azetidine urea derivative 1 DMH942E TI TTDP1UC DMH942E TN Fatty acid amide hydrolase (FAAH) DMH942E MA Inhibitor DMH942E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMH942E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMH9EQ1 DI DMH9EQ1 DMH9EQ1 DN Heteroaryl-cyclopropylamine derivative 3 DMH9EQ1 TI TTGP7BY DMH9EQ1 TN Monoamine oxidase type B (MAO-B) DMH9EQ1 MA Inhibitor DMH9EQ1 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH9EQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH9EQ1 DI DMH9EQ1 DMH9EQ1 DN Heteroaryl-cyclopropylamine derivative 3 DMH9EQ1 TI TTNR0UQ DMH9EQ1 TN Lysine-specific histone demethylase 1 (LSD) DMH9EQ1 MA Inhibitor DMH9EQ1 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH9EQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH9ION DI DMH9ION DMH9ION DN VFEDEOUBYBLDKN-AAFJCEBUSA-N DMH9ION TI TT5U49F DMH9ION TN PRKACA messenger RNA (PRKACA mRNA) DMH9ION MA Inhibitor DMH9ION RN Purine derivatives. US8846696. DMH9ION RU http://www.freepatentsonline.com/US8846696.html DMH9N2T DI DMH9N2T DMH9N2T DN Tacrine-indole hybrid derivative 2 DMH9N2T TI TT1RS9F DMH9N2T TN Acetylcholinesterase (AChE) DMH9N2T MA Inhibitor DMH9N2T RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMH9N2T RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMHA18O DI DMHA18O DMHA18O DN PMID26004420-Compound-WO2014015495C DMHA18O TI TTJ13ST DMHA18O TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMHA18O MA Inhibitor DMHA18O RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMHA18O RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMHAJCM DI DMHAJCM DMHAJCM DN Isothiazolone derivative 1 DMHAJCM TI TTN9T81 DMHAJCM TN Arachidonate 15-lipoxygenase (15-LOX) DMHAJCM MA Inhibitor DMHAJCM RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMHAJCM RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMHAOF1 DI DMHAOF1 DMHAOF1 DN PMID26924192-Compound-20 DMHAOF1 TI TTRA6BO DMHAOF1 TN Bromodomain-containing protein 4 (BRD4) DMHAOF1 MA Inhibitor DMHAOF1 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMHAOF1 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMHAVYS DI DMHAVYS DMHAVYS DN Y-9680 DMHAVYS TI TTUWGRA DMHAVYS TN Protein kinase C zeta (PRKCZ) DMHAVYS MA Inhibitor DMHAVYS RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DMHAVYS RU http://www.freepatentsonline.com/US8889672.html DMHB5XG DI DMHB5XG DMHB5XG DN Carbamate derivative 5 DMHB5XG TI TTGX13H DMHB5XG TN Fatty-acid amide hydrolase 1 (FAAH1) DMHB5XG MA Inhibitor DMHB5XG RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHB5XG RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHBJFN DI DMHBJFN DMHBJFN DN 1,2,4-triazole derivative 4 DMHBJFN TI TT5TPI6 DMHBJFN TN Opioid receptor sigma 1 (OPRS1) DMHBJFN MA Inhibitor DMHBJFN RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMHBJFN RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMHBN5M DI DMHBN5M DMHBN5M DN PMID25666693-Compound-47 DMHBN5M TI TTMI6F5 DMHBN5M TN Transient receptor potential cation channel V1 (TRPV1) DMHBN5M MA Antagonist DMHBN5M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHBN5M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHBOK6 DI DMHBOK6 DMHBOK6 DN PMID29338548-Compound-47 DMHBOK6 TI TTHJTF7 DMHBOK6 TN Glycine transporter GlyT-1 (SLC6A9) DMHBOK6 MA Inhibitor DMHBOK6 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMHBOK6 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMHBWNS DI DMHBWNS DMHBWNS DN PMID25435285-Compound-15 DMHBWNS TI TTXJ47W DMHBWNS TN Metabotropic glutamate receptor 2 (mGluR2) DMHBWNS MA Antagonist DMHBWNS RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHBWNS RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHBWNS DI DMHBWNS DMHBWNS DN PMID25435285-Compound-15 DMHBWNS TI TT8A9EF DMHBWNS TN Metabotropic glutamate receptor 3 (mGluR3) DMHBWNS MA Antagonist DMHBWNS RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHBWNS RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHD51F DI DMHD51F DMHD51F DN Alkyl mannoside derivative 10 DMHD51F TI TTTCRU2 DMHD51F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHD51F MA Antagonist DMHD51F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHD51F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHD8RK DI DMHD8RK DMHD8RK DN Mycophenolic acid/nucleotide derivative 10 DMHD8RK TI TTL7C8Q DMHD8RK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMHD8RK MA Inhibitor DMHD8RK RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMHD8RK RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMHEAJQ DI DMHEAJQ DMHEAJQ DN Biaryl compound 1 DMHEAJQ TI TT23XQV DMHEAJQ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMHEAJQ MA Inhibitor DMHEAJQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMHEAJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMHEAJQ DI DMHEAJQ DMHEAJQ DN Biaryl compound 1 DMHEAJQ TI TT5YPJF DMHEAJQ TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMHEAJQ MA Inhibitor DMHEAJQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMHEAJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMHEPR3 DI DMHEPR3 DMHEPR3 DN PMID25666693-Compound-133 DMHEPR3 TI TTMI6F5 DMHEPR3 TN Transient receptor potential cation channel V1 (TRPV1) DMHEPR3 MA Antagonist DMHEPR3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHEPR3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHEQDT DI DMHEQDT DMHEQDT DN Benzimidazole derivative 16 DMHEQDT TI TTYLQ8V DMHEQDT TN Prostaglandin E synthase (PTGES) DMHEQDT MA Inhibitor DMHEQDT RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMHEQDT RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMHEX1Q DI DMHEX1Q DMHEX1Q DN 1,2-diamino cyclopentane-based derivative 16 DMHEX1Q TI TT9N02I DMHEX1Q TN Orexin receptor type 2 (HCRTR2) DMHEX1Q MA Antagonist DMHEX1Q RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHEX1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHEX1Q DI DMHEX1Q DMHEX1Q DN 1,2-diamino cyclopentane-based derivative 16 DMHEX1Q TI TT60Q8D DMHEX1Q TN Orexin receptor type 1 (HCRTR1) DMHEX1Q MA Antagonist DMHEX1Q RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHEX1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHF2OX DI DMHF2OX DMHF2OX DN US9409892, 19 DMHF2OX TI TT9ISBX DMHF2OX TN HIF-prolyl hydroxylase 2 (HPH-2) DMHF2OX MA Inhibitor DMHF2OX RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMHF2OX RU http://www.freepatentsonline.com/US9409892.html DMHFQLC DI DMHFQLC DMHFQLC DN Heteroaryl-substituted urea derivative 2 DMHFQLC TI TTDP1UC DMHFQLC TN Fatty acid amide hydrolase (FAAH) DMHFQLC MA Inhibitor DMHFQLC RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHFQLC RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHG4WD DI DMHG4WD DMHG4WD DN PMID25991433-Compound-A8 DMHG4WD TI TTHS0U8 DMHG4WD TN Stress-activated protein kinase JNK2 (JNK2) DMHG4WD MA Inhibitor DMHG4WD RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHG4WD RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHG4WD DI DMHG4WD DMHG4WD DN PMID25991433-Compound-A8 DMHG4WD TI TT0K6EO DMHG4WD TN Stress-activated protein kinase JNK1 (JNK1) DMHG4WD MA Inhibitor DMHG4WD RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHG4WD RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHGE1T DI DMHGE1T DMHGE1T DN Dihydropyrrolopyrazole derivative 1 DMHGE1T TI TTDIGC1 DMHGE1T TN Dipeptidyl peptidase 4 (DPP-4) DMHGE1T MA Inhibitor DMHGE1T RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMHGE1T RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMHGPU1 DI DMHGPU1 DMHGPU1 DN Pyrrolo-pyrrolone derivative 3 DMHGPU1 TI TTRA6BO DMHGPU1 TN Bromodomain-containing protein 4 (BRD4) DMHGPU1 MA Inhibitor DMHGPU1 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMHGPU1 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMHGRTX DI DMHGRTX DMHGRTX DN Tri-substituted urea derivative 1 DMHGRTX TI TTTDVOJ DMHGRTX TN Tropomyosin-related kinase A (TrkA) DMHGRTX MA Inhibitor DMHGRTX RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMHGRTX RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMHI3O1 DI DMHI3O1 DMHI3O1 DN PMID25684022-Compound-WO2012135799 43(1.5) DMHI3O1 TI TTCZOF2 DMHI3O1 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHI3O1 MA Inhibitor DMHI3O1 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHI3O1 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHI4L6 DI DMHI4L6 DMHI4L6 DN PMID25522065-Compound-48 DMHI4L6 TI TTX4RTB DMHI4L6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMHI4L6 MA Antagonist DMHI4L6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMHI4L6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMHI6RZ DI DMHI6RZ DMHI6RZ DN US8772478, 5 DMHI6RZ TI TTQICM2 DMHI6RZ TN ADAM metallopeptidase 33 (ADAM33) DMHI6RZ MA Inhibitor DMHI6RZ RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMHI6RZ RU http://www.freepatentsonline.com/US8772478.html DMHIA26 DI DMHIA26 DMHIA26 DN PMID26651364-Compound-115 DMHIA26 TI TTTCRU2 DMHIA26 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHIA26 MA Antagonist DMHIA26 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHIA26 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHIAVW DI DMHIAVW DMHIAVW DN Isoquinoline sulfonyl derivative 3 DMHIAVW TI TTMQO60 DMHIAVW TN Rho-associated protein kinase (ROCK) DMHIAVW MA Inhibitor DMHIAVW RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMHIAVW RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTHY57M DMHIBTZ TN Matrix metalloproteinase-13 (MMP-13) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTMX39J DMHIBTZ TN Matrix metalloproteinase-1 (MMP-1) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TT6X50U DMHIBTZ TN Matrix metalloproteinase-9 (MMP-9) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTLM12X DMHIBTZ TN Matrix metalloproteinase-2 (MMP-2) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIEBN DI DMHIEBN DMHIEBN DN 2-pyrazinone derivative 6 DMHIEBN TI TTPLTSQ DMHIEBN TN Neutrophil elastase (NE) DMHIEBN MA Inhibitor DMHIEBN RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMHIEBN RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMHIUWX DI DMHIUWX DMHIUWX DN PMID28766366-Compound-Scheme1WO2011135259 DMHIUWX TI TTSBVFO DMHIUWX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMHIUWX MA Inhibitor DMHIUWX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMHIUWX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMHIV24 DI DMHIV24 DMHIV24 DN 1,2-diamino cyclopentane-based derivative 7 DMHIV24 TI TT9N02I DMHIV24 TN Orexin receptor type 2 (HCRTR2) DMHIV24 MA Antagonist DMHIV24 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHIV24 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHIV24 DI DMHIV24 DMHIV24 DN 1,2-diamino cyclopentane-based derivative 7 DMHIV24 TI TT60Q8D DMHIV24 TN Orexin receptor type 1 (HCRTR1) DMHIV24 MA Antagonist DMHIV24 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHIV24 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHIV2L DI DMHIV2L DMHIV2L DN PMID27841036-Compound-36 DMHIV2L TI TTEBCY8 DMHIV2L TN Poly [ADP-ribose] polymerase (PARP) DMHIV2L MA Inhibitor DMHIV2L RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMHIV2L RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMHJ98M DI DMHJ98M DMHJ98M DN Benzimidazole derivative 9 DMHJ98M TI TTQR74A DMHJ98M TN Proteinase activated receptor 2 (PAR2) DMHJ98M MA Antagonist DMHJ98M RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMHJ98M RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMHJBRO DI DMHJBRO DMHJBRO DN PMID27019002-Compound-42b DMHJBRO TI TTNR0UQ DMHJBRO TN Lysine-specific histone demethylase 1 (LSD) DMHJBRO MA Inhibitor DMHJBRO RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMHJBRO RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMHJDU6 DI DMHJDU6 DMHJDU6 DN Indazoletriazolephenyl derivative 1 DMHJDU6 TI TTKFVXR DMHJDU6 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMHJDU6 MA Inhibitor DMHJDU6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMHJDU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMHJDU6 DI DMHJDU6 DMHJDU6 DN Indazoletriazolephenyl derivative 1 DMHJDU6 TI TTXAJWN DMHJDU6 TN IL-1 receptor-associated kinase 1 (IRAK1) DMHJDU6 MA Inhibitor DMHJDU6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMHJDU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMHJOP7 DI DMHJOP7 DMHJOP7 DN PMID25666693-Compound-97 DMHJOP7 TI TTMI6F5 DMHJOP7 TN Transient receptor potential cation channel V1 (TRPV1) DMHJOP7 MA Antagonist DMHJOP7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHJOP7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHKRVL DI DMHKRVL DMHKRVL DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMHKRVL TI TTJGW1Z DMHKRVL TN Phosphodiesterase 2A (PDE2A) DMHKRVL MA Inhibitor DMHKRVL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHKRVL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHKRVL DI DMHKRVL DMHKRVL DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMHKRVL TI TTJW4LU DMHKRVL TN Phosphodiesterase 10A (PDE10) DMHKRVL MA Inhibitor DMHKRVL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHKRVL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHL7SW DI DMHL7SW DMHL7SW DN PMID29757691-Compound-8c DMHL7SW TI TTEB0GD DMHL7SW TN Cholinesterase (BCHE) DMHL7SW MA Inhibitor DMHL7SW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMHL7SW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMHL7SW DI DMHL7SW DMHL7SW DN PMID29757691-Compound-8c DMHL7SW TI TT1RS9F DMHL7SW TN Acetylcholinesterase (AChE) DMHL7SW MA Inhibitor DMHL7SW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMHL7SW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMHLA5V DI DMHLA5V DMHLA5V DN Steroidal carboxamide derivative 1 DMHLA5V TI TT9JNIC DMHLA5V TN Histamine H3 receptor (H3R) DMHLA5V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHLA5V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHLJA7 DI DMHLJA7 DMHLJA7 DN Quinazoline derivative 14 DMHLJA7 TI TT4DXQT DMHLJA7 TN Proto-oncogene c-Ret (RET) DMHLJA7 MA Inhibitor DMHLJA7 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMHLJA7 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMHLQ2T DI DMHLQ2T DMHLQ2T DN PMID25684022-Compound-US20130053382 38(5-7) DMHLQ2T TI TTCZOF2 DMHLQ2T TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHLQ2T MA Inhibitor DMHLQ2T RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHLQ2T RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHM8WJ DI DMHM8WJ DMHM8WJ DN Pyrrolidine derivative 3 DMHM8WJ TI TTHS256 DMHM8WJ TN Metabotropic glutamate receptor 5 (mGluR5) DMHM8WJ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMHM8WJ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMHMEFY DI DMHMEFY DMHMEFY DN PMID25666693-Compound-150 DMHMEFY TI TTMI6F5 DMHMEFY TN Transient receptor potential cation channel V1 (TRPV1) DMHMEFY MA Antagonist DMHMEFY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHMEFY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHMTF7 DI DMHMTF7 DMHMTF7 DN Heterocycle-containing compound 3 DMHMTF7 TI TT9O6WS DMHMTF7 TN Glucagon receptor (GCGR) DMHMTF7 MA Antagonist DMHMTF7 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMHMTF7 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TTTIBOJ DMHN5KW TN Histamine H1 receptor (H1R) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TT3ROYC DMHN5KW TN Serotonin transporter (SERT) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TT9JNIC DMHN5KW TN Histamine H3 receptor (H3R) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHNPSO DI DMHNPSO DMHNPSO DN 1190312-92-5 DMHNPSO TI TTIG67W DMHNPSO TN Lysine-specific demethylase 5A (KDM5A) DMHNPSO MA Inhibitor DMHNPSO RN Histone demethylase inhibitors. US10174026. DMHNPSO RU http://www.freepatentsonline.com/US10174026.html DMHNYQU DI DMHNYQU DMHNYQU DN BDBM50011553 DMHNYQU TI TT6NI13 DMHNYQU TN MEK kinase kinase 4 (MAP4K4) DMHNYQU MA Inhibitor DMHNYQU RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMHNYQU RU http://www.freepatentsonline.com/US9592235.html DMHO3NB DI DMHO3NB DMHO3NB DN Pyrazolopyrimidine derivative 1 DMHO3NB TI TTHS256 DMHO3NB TN Metabotropic glutamate receptor 5 (mGluR5) DMHO3NB MA Modulator DMHO3NB RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMHO3NB RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMHOLQF DI DMHOLQF DMHOLQF DN Benzyl pyrrolyloxoacetamide derivative 2 DMHOLQF TI TTDP1UC DMHOLQF TN Fatty acid amide hydrolase (FAAH) DMHOLQF MA Inhibitor DMHOLQF RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHOLQF RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHOPE0 DI DMHOPE0 DMHOPE0 DN Biaryl mannoside derivative 18 DMHOPE0 TI TTTCRU2 DMHOPE0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHOPE0 MA Antagonist DMHOPE0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHOPE0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHP6J2 DI DMHP6J2 DMHP6J2 DN PMID25980951-Compound-37 DMHP6J2 TI TTR7B60 DMHP6J2 TN X-linked inhibitor of apoptosis protein (XIAP) DMHP6J2 MA Antagonist DMHP6J2 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMHP6J2 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMHP6J2 DI DMHP6J2 DMHP6J2 DN PMID25980951-Compound-37 DMHP6J2 TI TTQ5LRD DMHP6J2 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMHP6J2 MA Antagonist DMHP6J2 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMHP6J2 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMHP90Q DI DMHP90Q DMHP90Q DN PMID28870136-Compound-59 DMHP90Q TI TTK0O6Y DMHP90Q TN Ecto-5'-nucleotidase (CD73) DMHP90Q MA Inhibitor DMHP90Q RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMHP90Q RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMHPK31 DI DMHPK31 DMHPK31 DN PMID27788040-Compound-5 DMHPK31 TI TTV1C0Z DMHPK31 TN Neuropeptide S receptor (NPSR) DMHPK31 MA Antagonist DMHPK31 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMHPK31 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMHPQI2 DI DMHPQI2 DMHPQI2 DN SCHEMBL15198146 DMHPQI2 TI TTXHWA7 DMHPQI2 TN Ubiquitin-activating enzyme E1 (UBAE1) DMHPQI2 MA Inhibitor DMHPQI2 RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DMHPQI2 RU http://www.freepatentsonline.com/US10202389.html DMHPW3X DI DMHPW3X DMHPW3X DN PMID25666693-Compound-22 DMHPW3X TI TTMI6F5 DMHPW3X TN Transient receptor potential cation channel V1 (TRPV1) DMHPW3X MA Antagonist DMHPW3X RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHPW3X RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHQCEJ DI DMHQCEJ DMHQCEJ DN Thiazole carboxamide derivative 13 DMHQCEJ TI TTCZOF2 DMHQCEJ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHQCEJ MA Inhibitor DMHQCEJ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHQCEJ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHQM8W DI DMHQM8W DMHQM8W DN PMID25666693-Compound-132 DMHQM8W TI TTMI6F5 DMHQM8W TN Transient receptor potential cation channel V1 (TRPV1) DMHQM8W MA Antagonist DMHQM8W RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHQM8W RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHR43K DI DMHR43K DMHR43K DN Tlouidine sulfonamide derivative 1 DMHR43K TI TTUX68I DMHR43K TN Hypoxia-inducible factor 1 (HIF-1) DMHR43K MA Inhibitor DMHR43K RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMHR43K RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMHREX9 DI DMHREX9 DMHREX9 DN PMID25666693-Compound-94 DMHREX9 TI TTMI6F5 DMHREX9 TN Transient receptor potential cation channel V1 (TRPV1) DMHREX9 MA Antagonist DMHREX9 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHREX9 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHRUIZ DI DMHRUIZ DMHRUIZ DN Pyrazolo[4,3-c]pyridine derivative 1 DMHRUIZ TI TTTDVOJ DMHRUIZ TN Tropomyosin-related kinase A (TrkA) DMHRUIZ MA Inhibitor DMHRUIZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMHRUIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMHRV8J DI DMHRV8J DMHRV8J DN Imidazo bicyclic iminium derivative 4 DMHRV8J TI TT8J1S3 DMHRV8J TN Smoothened homolog (SMO) DMHRV8J MA Inhibitor DMHRV8J RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMHRV8J RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMHRY63 DI DMHRY63 DMHRY63 DN Tricyclic indole compound 2 DMHRY63 TI TTPTXIN DMHRY63 TN Translocator protein (TSPO) DMHRY63 MA Ligand DMHRY63 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMHRY63 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMHS3ZW DI DMHS3ZW DMHS3ZW DN PMID25991433-Compound-G1 DMHS3ZW TI TT0K6EO DMHS3ZW TN Stress-activated protein kinase JNK1 (JNK1) DMHS3ZW MA Inhibitor DMHS3ZW RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHS3ZW RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHSDUR DI DMHSDUR DMHSDUR DN Pyridopyrimidinone derivative 3 DMHSDUR TI TTK0FEA DMHSDUR TN Leucine-rich repeat kinase 2 (LRRK2) DMHSDUR MA Inhibitor DMHSDUR RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMHSDUR RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMHSGPU DI DMHSGPU DMHSGPU DN PMID25522065-Compound-23 DMHSGPU TI TTX4RTB DMHSGPU TN Melanin-concentrating hormone receptor 1 (MCHR1) DMHSGPU MA Antagonist DMHSGPU RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMHSGPU RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMHSJ65 DI DMHSJ65 DMHSJ65 DN PMID28092474-Compound-32k DMHSJ65 TI TT6R7JZ DMHSJ65 TN Histone deacetylase 1 (HDAC1) DMHSJ65 MA Inhibitor DMHSJ65 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHSJ65 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHSJ65 DI DMHSJ65 DMHSJ65 DN PMID28092474-Compound-32k DMHSJ65 TI TT5ZKDI DMHSJ65 TN Histone deacetylase 6 (HDAC6) DMHSJ65 MA Inhibitor DMHSJ65 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHSJ65 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHSNA5 DI DMHSNA5 DMHSNA5 DN Aminoazetidine derivative 2 DMHSNA5 TI TT6OEDT DMHSNA5 TN Cannabinoid receptor 1 (CB1) DMHSNA5 MA Antagonist DMHSNA5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHSNA5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMHT41B DI DMHT41B DMHT41B DN PMID25399762-Compound-Table1-C25 DMHT41B TI TTGP7BY DMHT41B TN Monoamine oxidase type B (MAO-B) DMHT41B MA Inhibitor DMHT41B RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHT41B RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHT4PF DI DMHT4PF DMHT4PF DN Peptide analog 28 DMHT4PF TI TT68GPI DMHT4PF TN Proteasome beta-5 (PS beta-5) DMHT4PF MA Inhibitor DMHT4PF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMHT4PF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMHT4PF DI DMHT4PF DMHT4PF DN Peptide analog 28 DMHT4PF TI TTEAD9J DMHT4PF TN Proteasome beta-8 (PS beta-8) DMHT4PF MA Inhibitor DMHT4PF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMHT4PF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMHTJ7N DI DMHTJ7N DMHTJ7N DN Sulfonamide derivative 18 DMHTJ7N TI TTZMAO3 DMHTJ7N TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMHTJ7N MA Agonist DMHTJ7N RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMHTJ7N RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTJS8PY DMHTJVA TN 5-HT 6 receptor (HTR6) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTO9X1H DMHTJVA TN 5-HT 7 receptor (HTR7) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTEX248 DMHTJVA TN Dopamine D2 receptor (D2R) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTJQOD7 DMHTJVA TN 5-HT 2A receptor (HTR2A) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTSQIFT DMHTJVA TN 5-HT 1A receptor (HTR1A) DMHTJVA MA Agonist DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTS5G DI DMHTS5G DMHTS5G DN Fused heterocyclic compound 4 DMHTS5G TI TT7RJY8 DMHTS5G TN Xanthine dehydrogenase/oxidase (XDH) DMHTS5G MA Inhibitor DMHTS5G RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMHTS5G RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMHTV47 DI DMHTV47 DMHTV47 DN Pyrazolo[1,5-a]pyrimidine derivative 3 DMHTV47 TI TT6OEDT DMHTV47 TN Cannabinoid receptor 1 (CB1) DMHTV47 MA Antagonist DMHTV47 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHTV47 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMHTVGM DI DMHTVGM DMHTVGM DN N-substituted pyrazole derivative 1 DMHTVGM TI TTXJ47W DMHTVGM TN Metabotropic glutamate receptor 2 (mGluR2) DMHTVGM MA Antagonist DMHTVGM RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHTVGM RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHUIXR DI DMHUIXR DMHUIXR DN Heteroaryl-carboxamide derivative 4 DMHUIXR TI TTCZOF2 DMHUIXR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHUIXR MA Inhibitor DMHUIXR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHUIXR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHV3ES DI DMHV3ES DMHV3ES DN PMID28092474-Compound-32v DMHV3ES TI TT5ZKDI DMHV3ES TN Histone deacetylase 6 (HDAC6) DMHV3ES MA Inhibitor DMHV3ES RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHV3ES RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHV3ES DI DMHV3ES DMHV3ES DN PMID28092474-Compound-32v DMHV3ES TI TT6R7JZ DMHV3ES TN Histone deacetylase 1 (HDAC1) DMHV3ES MA Inhibitor DMHV3ES RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHV3ES RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHV75N DI DMHV75N DMHV75N DN PMID28460551-Compound-1 DMHV75N TI TT8FYO9 DMHV75N TN Platelet-derived growth factor receptor alpha (PDGFRA) DMHV75N MA Inhibitor DMHV75N RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMHV75N RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMHVZ4M DI DMHVZ4M DMHVZ4M DN Methylsulfonylbenzamide derivative 2 DMHVZ4M TI TT4G2JS DMHVZ4M TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMHVZ4M MA Inhibitor DMHVZ4M RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMHVZ4M RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMHWNSD DI DMHWNSD DMHWNSD DN Pyrrolo[2,3-d]pyrimidine derivative 22 DMHWNSD TI TTGM6VW DMHWNSD TN Tyrosine-protein kinase BTK (ATK) DMHWNSD MA Inhibitor DMHWNSD RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMHWNSD RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMHWUEV DI DMHWUEV DMHWUEV DN PMID27539678-Compound-8 DMHWUEV TI TT3M2WO DMHWUEV TN Sphingosine kinase (SphK) DMHWUEV MA Inhibitor DMHWUEV RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMHWUEV RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMHWV67 DI DMHWV67 DMHWV67 DN PMID27321640-Compound-74 DMHWV67 TI TTJGW1Z DMHWV67 TN Phosphodiesterase 2A (PDE2A) DMHWV67 MA Inhibitor DMHWV67 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHWV67 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHX5VO DI DMHX5VO DMHX5VO DN Benzoimidazole derivative 2 DMHX5VO TI TTZCRP3 DMHX5VO TN ERK activator kinase (MEK) DMHX5VO MA Inhibitor DMHX5VO RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMHX5VO RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMHX8OF DI DMHX8OF DMHX8OF DN PMID27788040-Compound-6 DMHX8OF TI TTV1C0Z DMHX8OF TN Neuropeptide S receptor (NPSR) DMHX8OF MA Antagonist DMHX8OF RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMHX8OF RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMHXFCQ DI DMHXFCQ DMHXFCQ DN Benzothiazole analog 1 DMHXFCQ TI TTULVH8 DMHXFCQ TN Tyrosinase (TYR) DMHXFCQ MA Inhibitor DMHXFCQ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMHXFCQ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMHXFGU DI DMHXFGU DMHXFGU DN PMID26651364-Compound-48 DMHXFGU TI TTTCRU2 DMHXFGU TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHXFGU MA Antagonist DMHXFGU RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHXFGU RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHXKFB DI DMHXKFB DMHXKFB DN 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 DMHXKFB TI TT7HF4W DMHXKFB TN Cyclin-dependent kinase 2 (CDK2) DMHXKFB MA Inhibitor DMHXKFB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMHXKFB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMHXKFB DI DMHXKFB DMHXKFB DN 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 DMHXKFB TI TT1LVF2 DMHXKFB TN Cyclin-dependent kinase 9 (CDK9) DMHXKFB MA Inhibitor DMHXKFB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMHXKFB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMHXMB4 DI DMHXMB4 DMHXMB4 DN Piperidine derivative 2 DMHXMB4 TI TTQR74A DMHXMB4 TN Proteinase activated receptor 2 (PAR2) DMHXMB4 MA Antagonist DMHXMB4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMHXMB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMHXT12 DI DMHXT12 DMHXT12 DN PMID26293650-Compound-34 DMHXT12 TI TTH5TC2 DMHXT12 TN NF-kappa-B-activating kinase (TBK1) DMHXT12 MA Inhibitor DMHXT12 RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMHXT12 RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMHXWZB DI DMHXWZB DMHXWZB DN Pyridine-carboximide derivative 2 DMHXWZB TI TTF8P9I DMHXWZB TN Diacylglycerol acyltransferase 1 (DGAT1) DMHXWZB MA Inhibitor DMHXWZB RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMHXWZB RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMHYDM7 DI DMHYDM7 DMHYDM7 DN PMID25656651-Compound-36b DMHYDM7 TI TTIV39N DMHYDM7 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMHYDM7 MA Inhibitor DMHYDM7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMHYDM7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMHYDM7 DI DMHYDM7 DMHYDM7 DN PMID25656651-Compound-36b DMHYDM7 TI TTS7G69 DMHYDM7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMHYDM7 MA Inhibitor DMHYDM7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMHYDM7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMHYIAV DI DMHYIAV DMHYIAV DN 2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 DMHYIAV TI TTA592U DMHYIAV TN Urate anion exchanger 1 (URAT1) DMHYIAV MA Inhibitor DMHYIAV RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMHYIAV RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMHZ8N1 DI DMHZ8N1 DMHZ8N1 DN PMID26560530-Compound-50 DMHZ8N1 TI TT2F4OL DMHZ8N1 TN Tissue transglutaminase (TG2) DMHZ8N1 MA Inhibitor DMHZ8N1 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMHZ8N1 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMHZJEA DI DMHZJEA DMHZJEA DN US8937193-compound-7 DMHZJEA TI TTGT9C7 DMHZJEA TN Bcl-2-related protein A1 (BCL2A1) DMHZJEA MA Inhibitor DMHZJEA RN Apogossypolone derivatives as anticancer agents. US8937193. DMHZJEA RU http://www.freepatentsonline.com/US8937193.html DMHZLSO DI DMHZLSO DMHZLSO DN Pyrido[2,3-d]pyrimidine derivative 1 DMHZLSO TI TT6OEDT DMHZLSO TN Cannabinoid receptor 1 (CB1) DMHZLSO MA Antagonist DMHZLSO RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHZLSO RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMI04GC DI DMI04GC DMI04GC DN PMID29473428-Compound-17 DMI04GC TI TTZJYKH DMI04GC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI04GC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMI04GC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMI0AW7 DI DMI0AW7 DMI0AW7 DN Pyrrolo[1,2-f]triazine derivative 1 DMI0AW7 TI TTDIGC1 DMI0AW7 TN Dipeptidyl peptidase 4 (DPP-4) DMI0AW7 MA Inhibitor DMI0AW7 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMI0AW7 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMI0J7D DI DMI0J7D DMI0J7D DN Pyrazolopyrimidine derivative 3 DMI0J7D TI TTHS256 DMI0J7D TN Metabotropic glutamate receptor 5 (mGluR5) DMI0J7D MA Modulator DMI0J7D RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMI0J7D RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMI0WHE DI DMI0WHE DMI0WHE DN PMID30185082-Compound-28 DMI0WHE TI TT9NXW4 DMI0WHE TN Sigma intracellular receptor 2 (TMEM97) DMI0WHE MA Ligand DMI0WHE RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMI0WHE RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMI0YWU DI DMI0YWU DMI0YWU DN PMID25666693-Compound-13 DMI0YWU TI TTMI6F5 DMI0YWU TN Transient receptor potential cation channel V1 (TRPV1) DMI0YWU MA Antagonist DMI0YWU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMI0YWU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMI1BKA DI DMI1BKA DMI1BKA DN Coumarin/resveratrol hybrid derivative 1 DMI1BKA TI TTGP7BY DMI1BKA TN Monoamine oxidase type B (MAO-B) DMI1BKA MA Inhibitor DMI1BKA RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMI1BKA RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMI1OWK DI DMI1OWK DMI1OWK DN Imidazopyridine and triazolopyridine compound 4 DMI1OWK TI TTHS256 DMI1OWK TN Metabotropic glutamate receptor 5 (mGluR5) DMI1OWK MA Modulator DMI1OWK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMI1OWK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMI1Z7D DI DMI1Z7D DMI1Z7D DN PMID25656651-Compound-19b DMI1Z7D TI TTS7G69 DMI1Z7D TN Fusion protein Bcr-Abl (Bcr-Abl) DMI1Z7D MA Inhibitor DMI1Z7D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMI1Z7D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMI1Z7D DI DMI1Z7D DMI1Z7D DN PMID25656651-Compound-19b DMI1Z7D TI TTIV39N DMI1Z7D TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMI1Z7D MA Inhibitor DMI1Z7D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMI1Z7D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMI2T1D DI DMI2T1D DMI2T1D DN Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1 DMI2T1D TI TTZJYKH DMI2T1D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI2T1D MA Antagonist DMI2T1D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMI2T1D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMI30GA DI DMI30GA DMI30GA DN PMID26004420-Compound-WO2015017305D DMI30GA TI TTJ13ST DMI30GA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMI30GA MA Inhibitor DMI30GA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMI30GA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMI31OD DI DMI31OD DMI31OD DN Benzothiazine-carboxamide compound 3 DMI31OD TI TTQR74A DMI31OD TN Proteinase activated receptor 2 (PAR2) DMI31OD MA Antagonist DMI31OD RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMI31OD RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMI3ELU DI DMI3ELU DMI3ELU DN PMID29649907-Compound-39 DMI3ELU TI TTS4UGC DMI3ELU TN Farnesoid X-activated receptor (FXR) DMI3ELU MA Agonist DMI3ELU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMI3ELU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMI3QLT DI DMI3QLT DMI3QLT DN PMID26815044-Compound-H DMI3QLT TI TTULVH8 DMI3QLT TN Tyrosinase (TYR) DMI3QLT MA Inhibitor DMI3QLT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMI3QLT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMI3X14 DI DMI3X14 DMI3X14 DN Thiazole carboxamide derivative 4 DMI3X14 TI TTCZOF2 DMI3X14 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMI3X14 MA Inhibitor DMI3X14 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMI3X14 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMI3XPJ DI DMI3XPJ DMI3XPJ DN Imidazopyridine derivative 7 DMI3XPJ TI TTYLQ8V DMI3XPJ TN Prostaglandin E synthase (PTGES) DMI3XPJ MA Inhibitor DMI3XPJ RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMI3XPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMI3YO7 DI DMI3YO7 DMI3YO7 DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1 DMI3YO7 TI TTPTXIN DMI3YO7 TN Translocator protein (TSPO) DMI3YO7 MA Ligand DMI3YO7 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMI3YO7 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMI4KBC DI DMI4KBC DMI4KBC DN 2-PAM derivative 1 DMI4KBC TI TT1RS9F DMI4KBC TN Acetylcholinesterase (AChE) DMI4KBC MA Reactivator DMI4KBC RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMI4KBC RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMI4MJ2 DI DMI4MJ2 DMI4MJ2 DN Terpyridineplatinum(II) complexe 5 DMI4MJ2 TI TTR7UJ3 DMI4MJ2 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMI4MJ2 MA Inhibitor DMI4MJ2 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMI4MJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMI4US6 DI DMI4US6 DMI4US6 DN PMID28350212-Compound-19 DMI4US6 TI TTZS04O DMI4US6 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMI4US6 MA Inhibitor DMI4US6 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMI4US6 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMI4XBC DI DMI4XBC DMI4XBC DN Aryl azepine derivative 2 DMI4XBC TI TT9NXW4 DMI4XBC TN Sigma intracellular receptor 2 (TMEM97) DMI4XBC MA Ligand DMI4XBC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMI4XBC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMI5VZN DI DMI5VZN DMI5VZN DN 1,3,4-oxadiazole derivative 5 DMI5VZN TI TT23XQV DMI5VZN TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMI5VZN MA Inhibitor DMI5VZN RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMI5VZN RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMI61KF DI DMI61KF DMI61KF DN PMID27977313-Compound-47 DMI61KF TI TTR7UJ3 DMI61KF TN Cytoplasmic thioredoxin reductase (TXNRD1) DMI61KF MA Inhibitor DMI61KF RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMI61KF RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMI627Z DI DMI627Z DMI627Z DN Heteroaryl-carboxamide derivative 9 DMI627Z TI TTCZOF2 DMI627Z TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMI627Z MA Inhibitor DMI627Z RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMI627Z RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMI6VG9 DI DMI6VG9 DMI6VG9 DN Tetra-hydro-triazolopyrimidine derivative 2 DMI6VG9 TI TTPLTSQ DMI6VG9 TN Neutrophil elastase (NE) DMI6VG9 MA Inhibitor DMI6VG9 RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMI6VG9 RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMI732U DI DMI732U DMI732U DN Heteroaromatic ring derivative 1 DMI732U TI TTSCIM2 DMI732U TN Extracellular lysophospholipase D (E-NPP2) DMI732U MA Inhibitor DMI732U RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMI732U RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMI7KG4 DI DMI7KG4 DMI7KG4 DN Cyclic peptidomimetic derivative 3 DMI7KG4 TI TT23XQV DMI7KG4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMI7KG4 MA Inhibitor DMI7KG4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMI7KG4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMI7W3K DI DMI7W3K DMI7W3K DN Imidazole derivative 10 DMI7W3K TI TTN9T81 DMI7W3K TN Arachidonate 15-lipoxygenase (15-LOX) DMI7W3K MA Inhibitor DMI7W3K RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMI7W3K RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMI8CB3 DI DMI8CB3 DMI8CB3 DN PMID25666693-Compound-25 DMI8CB3 TI TTMI6F5 DMI8CB3 TN Transient receptor potential cation channel V1 (TRPV1) DMI8CB3 MA Antagonist DMI8CB3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMI8CB3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMI8ZBK DI DMI8ZBK DMI8ZBK DN PMID28092474-Compound-33p DMI8ZBK TI TT5ZKDI DMI8ZBK TN Histone deacetylase 6 (HDAC6) DMI8ZBK MA Inhibitor DMI8ZBK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMI8ZBK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMI8ZBK DI DMI8ZBK DMI8ZBK DN PMID28092474-Compound-33p DMI8ZBK TI TT6R7JZ DMI8ZBK TN Histone deacetylase 1 (HDAC1) DMI8ZBK MA Inhibitor DMI8ZBK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMI8ZBK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMI93AX DI DMI93AX DMI93AX DN PMID25468267-Compound-54 DMI93AX TI TT0RGE9 DMI93AX TN Lysine-specific demethylase 4 (KDM4) DMI93AX MA Inhibitor DMI93AX RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMI93AX RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIA3GH DI DMIA3GH DMIA3GH DN PMID27977313-Compound-18 DMIA3GH TI TTR7UJ3 DMIA3GH TN Cytoplasmic thioredoxin reductase (TXNRD1) DMIA3GH MA Inhibitor DMIA3GH RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMIA3GH RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMIAB94 DI DMIAB94 DMIAB94 DN Benzyl pyrrolyloxoacetamide derivative 1 DMIAB94 TI TTDP1UC DMIAB94 TN Fatty acid amide hydrolase (FAAH) DMIAB94 MA Inhibitor DMIAB94 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMIAB94 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMIAGPX DI DMIAGPX DMIAGPX DN US10022354, Example 5 DMIAGPX TI TTIG67W DMIAGPX TN Lysine-specific demethylase 5A (KDM5A) DMIAGPX MA Inhibitor DMIAGPX RN IRE-1 inhibitors DMIAGPX RU http://www.freepatentsonline.com/US10022354.html DMIAJMO DI DMIAJMO DMIAJMO DN Imidazopyridazine derivative 4 DMIAJMO TI TTQR74A DMIAJMO TN Proteinase activated receptor 2 (PAR2) DMIAJMO MA Antagonist DMIAJMO RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMIAJMO RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMIAV5M DI DMIAV5M DMIAV5M DN PMID25553724-Compound-US2011806744710 DMIAV5M TI TTSXVID DMIAV5M TN Nuclear factor NF-kappa-B (NFKB) DMIAV5M MA Inhibitor DMIAV5M RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIAV5M RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIBRE5 DI DMIBRE5 DMIBRE5 DN Quinazoline derivative 7 DMIBRE5 TI TTPTXIN DMIBRE5 TN Translocator protein (TSPO) DMIBRE5 MA Ligand DMIBRE5 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIBRE5 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIBZ2H DI DMIBZ2H DMIBZ2H DN PMID28394193-Compound-18 DMIBZ2H TI TT9MZCQ DMIBZ2H TN Enhancer of zeste homolog 2 (EZH2) DMIBZ2H MA Inhibitor DMIBZ2H RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMIBZ2H RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMIC86N DI DMIC86N DMIC86N DN Quinoline derivative 9 DMIC86N TI TTXJ47W DMIC86N TN Metabotropic glutamate receptor 2 (mGluR2) DMIC86N MA Antagonist DMIC86N RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIC86N RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMICBFK DI DMICBFK DMICBFK DN PMID27977313-Compound-Figure6C DMICBFK TI TTR7UJ3 DMICBFK TN Cytoplasmic thioredoxin reductase (TXNRD1) DMICBFK MA Inhibitor DMICBFK RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMICBFK RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMICDV6 DI DMICDV6 DMICDV6 DN PMID29671355-Compound-72a DMICDV6 TI TTTQGH8 DMICDV6 TN Histone deacetylase 4 (HDAC4) DMICDV6 MA Inhibitor DMICDV6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMICDV6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMICZLS DI DMICZLS DMICZLS DN Pyridine derivative 16 DMICZLS TI TTHS256 DMICZLS TN Metabotropic glutamate receptor 5 (mGluR5) DMICZLS MA Modulator DMICZLS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMICZLS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMIDN6T DI DMIDN6T DMIDN6T DN Pyrazole derivative 6 DMIDN6T TI TT6OEDT DMIDN6T TN Cannabinoid receptor 1 (CB1) DMIDN6T MA Antagonist DMIDN6T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIDN6T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIDUB4 DI DMIDUB4 DMIDUB4 DN Acyl piperidine derivative 3 DMIDUB4 TI TT2F4OL DMIDUB4 TN Tissue transglutaminase (TG2) DMIDUB4 MA Inhibitor DMIDUB4 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMIDUB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMIE0MR DI DMIE0MR DMIE0MR DN PMID25980951-Compound-21 DMIE0MR TI TTR7B60 DMIE0MR TN X-linked inhibitor of apoptosis protein (XIAP) DMIE0MR MA Antagonist DMIE0MR RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMIE0MR RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMIE0MR DI DMIE0MR DMIE0MR DN PMID25980951-Compound-21 DMIE0MR TI TTQ5LRD DMIE0MR TN Cellular inhibitor of apoptosis 1 (BIRC2) DMIE0MR MA Antagonist DMIE0MR RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMIE0MR RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMIE7U3 DI DMIE7U3 DMIE7U3 DN Mannoside derivative 1 DMIE7U3 TI TTTCRU2 DMIE7U3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIE7U3 MA Antagonist DMIE7U3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIE7U3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMIES9B DI DMIES9B DMIES9B DN Secondary and tertiary (hetero)arylamide derivative 2 DMIES9B TI TT3WG5C DMIES9B TN Monoamine oxidase type A (MAO-A) DMIES9B MA Inhibitor DMIES9B RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMIES9B RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMIEZ6L DI DMIEZ6L DMIEZ6L DN 1,3,4-oxadiazole derivative 6 DMIEZ6L TI TT23XQV DMIEZ6L TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMIEZ6L MA Inhibitor DMIEZ6L RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMIEZ6L RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMIF7KG DI DMIF7KG DMIF7KG DN PMID27977313-Compound-29 DMIF7KG TI TTR7UJ3 DMIF7KG TN Cytoplasmic thioredoxin reductase (TXNRD1) DMIF7KG MA Inhibitor DMIF7KG RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMIF7KG RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMIFH8T DI DMIFH8T DMIFH8T DN PMID25726713-Compound-32 DMIFH8T TI TT8J1S3 DMIFH8T TN Smoothened homolog (SMO) DMIFH8T MA Inhibitor DMIFH8T RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMIFH8T RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMIFTUN DI DMIFTUN DMIFTUN DN PMID27376512-Compound-Table1Example11 DMIFTUN TI TT6S2FE DMIFTUN TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMIFTUN MA Inhibitor DMIFTUN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMIFTUN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMIFV58 DI DMIFV58 DMIFV58 DN PMID26924192-Compound-31 DMIFV58 TI TTRA6BO DMIFV58 TN Bromodomain-containing protein 4 (BRD4) DMIFV58 MA Inhibitor DMIFV58 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMIFV58 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMIFVXE DI DMIFVXE DMIFVXE DN PMID25482888-Compound-16 DMIFVXE TI TTDIGC1 DMIFVXE TN Dipeptidyl peptidase 4 (DPP-4) DMIFVXE MA Inhibitor DMIFVXE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMIFVXE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMIFZLG DI DMIFZLG DMIFZLG DN Dihydropyridine compound 4 DMIFZLG TI TT4DXQT DMIFZLG TN Proto-oncogene c-Ret (RET) DMIFZLG MA Inhibitor DMIFZLG RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMIFZLG RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMIG0TQ DI DMIG0TQ DMIG0TQ DN Heteroaryl-pyrazole derivative 2 DMIG0TQ TI TTXJ47W DMIG0TQ TN Metabotropic glutamate receptor 2 (mGluR2) DMIG0TQ MA Antagonist DMIG0TQ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIG0TQ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMIGS81 DI DMIGS81 DMIGS81 DN Indole-based analog 1 DMIGS81 TI TTL53M6 DMIGS81 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMIGS81 MA Inhibitor DMIGS81 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMIGS81 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMIH0F4 DI DMIH0F4 DMIH0F4 DN Pyrazolo[3,4-d]pyrimidine derivative 5 DMIH0F4 TI TT4DXQT DMIH0F4 TN Proto-oncogene c-Ret (RET) DMIH0F4 MA Inhibitor DMIH0F4 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMIH0F4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMIHRG4 DI DMIHRG4 DMIHRG4 DN PMID25435179-Compound-WO2013059587(V, 1st set) DMIHRG4 TI TTSCO7R DMIHRG4 TN NAD-dependent deacetylase sirtuin (SIRT) DMIHRG4 MA Inhibitor DMIHRG4 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMIHRG4 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMIHRV9 DI DMIHRV9 DMIHRV9 DN Pyrrolidine derivative 11 DMIHRV9 TI TTSCIUP DMIHRV9 TN Oxytocin receptor (OTR) DMIHRV9 MA Antagonist DMIHRV9 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMIHRV9 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMIJGLB DI DMIJGLB DMIJGLB DN PMID27109571-Compound-19 DMIJGLB TI TTNT2S6 DMIJGLB TN Fatty acid-binding protein 5 (FABP5) DMIJGLB MA Inhibitor DMIJGLB RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMIJGLB RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMIJGLB DI DMIJGLB DMIJGLB DN PMID27109571-Compound-19 DMIJGLB TI TTHWMFZ DMIJGLB TN Fatty acid-binding protein 4 (FABP4) DMIJGLB MA Inhibitor DMIJGLB RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMIJGLB RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMIJQZV DI DMIJQZV DMIJQZV DN PMID28092474-Compound-33b DMIJQZV TI TT5ZKDI DMIJQZV TN Histone deacetylase 6 (HDAC6) DMIJQZV MA Inhibitor DMIJQZV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMIJQZV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMIJQZV DI DMIJQZV DMIJQZV DN PMID28092474-Compound-33b DMIJQZV TI TT6R7JZ DMIJQZV TN Histone deacetylase 1 (HDAC1) DMIJQZV MA Inhibitor DMIJQZV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMIJQZV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMIKAJC DI DMIKAJC DMIKAJC DN PMID27539678-Compound-11 DMIKAJC TI TTOHFIY DMIKAJC TN Sphingosine kinase 1 (SPHK1) DMIKAJC MA Inhibitor DMIKAJC RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMIKAJC RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMIKBV5 DI DMIKBV5 DMIKBV5 DN Isoxazoles and isoxazoline derivative 6 DMIKBV5 TI TTIY56R DMIKBV5 TN Kynurenine 3-hydroxylase (KMO) DMIKBV5 MA Inhibitor DMIKBV5 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMIKBV5 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMIKMBO DI DMIKMBO DMIKMBO DN Imidazopyridine acetamide analog 2 DMIKMBO TI TTPTXIN DMIKMBO TN Translocator protein (TSPO) DMIKMBO MA Ligand DMIKMBO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIKMBO RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIKRCM DI DMIKRCM DMIKRCM DN PMID28074661-Compound-US20120264760C88 DMIKRCM TI TTL7C8Q DMIKRCM TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMIKRCM MA Inhibitor DMIKRCM RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMIKRCM RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMIKSVG DI DMIKSVG DMIKSVG DN Azetidine derivative 3 DMIKSVG TI TT6OEDT DMIKSVG TN Cannabinoid receptor 1 (CB1) DMIKSVG MA Antagonist DMIKSVG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIKSVG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIKTVL DI DMIKTVL DMIKTVL DN PMID27841045-Compound-131 DMIKTVL TI TT7RJY8 DMIKTVL TN Xanthine dehydrogenase/oxidase (XDH) DMIKTVL MA Inhibitor DMIKTVL RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMIKTVL RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMIKUN9 DI DMIKUN9 DMIKUN9 DN Pyrazole and thiophene derivative 3 DMIKUN9 TI TTRA6BO DMIKUN9 TN Bromodomain-containing protein 4 (BRD4) DMIKUN9 MA Inhibitor DMIKUN9 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMIKUN9 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMIKZXD DI DMIKZXD DMIKZXD DN Mannoside derivative 9 DMIKZXD TI TTTCRU2 DMIKZXD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIKZXD MA Antagonist DMIKZXD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIKZXD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMILUT8 DI DMILUT8 DMILUT8 DN PMID26394986-Compound-57 DMILUT8 TI TTLRFIH DMILUT8 TN Signal transducer and activator of transcription 5 (STAT5) DMILUT8 MA Inhibitor DMILUT8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMILUT8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMILY1P DI DMILY1P DMILY1P DN US9598431, 2 DMILY1P TI TTGB2LZ DMILY1P TN RAR-related orphan receptor-beta (RORB) DMILY1P MA Inhibitor DMILY1P RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMILY1P RU http://www.freepatentsonline.com/US9598431.html DMIM8UF DI DMIM8UF DMIM8UF DN PMID26004420-Compound-WO2013062900B DMIM8UF TI TTJ13ST DMIM8UF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIM8UF MA Inhibitor DMIM8UF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIM8UF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIM9EY DI DMIM9EY DMIM9EY DN Resorcinol compound 4 DMIM9EY TI TTULVH8 DMIM9EY TN Tyrosinase (TYR) DMIM9EY MA Inhibitor DMIM9EY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMIM9EY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMIMFND DI DMIMFND DMIMFND DN PMID27019002-Compound-43b DMIMFND TI TTNR0UQ DMIMFND TN Lysine-specific histone demethylase 1 (LSD) DMIMFND MA Inhibitor DMIMFND RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIMFND RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMINBJM DI DMINBJM DMINBJM DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 DMINBJM TI TTJGW1Z DMINBJM TN Phosphodiesterase 2A (PDE2A) DMINBJM MA Inhibitor DMINBJM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMINBJM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMINBJM DI DMINBJM DMINBJM DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 DMINBJM TI TTJW4LU DMINBJM TN Phosphodiesterase 10A (PDE10) DMINBJM MA Inhibitor DMINBJM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMINBJM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTALN9W DMINE6V TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTZJYKH DMINE6V TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTXNCBV DMINE6V TN Tryptophan 2,3-dioxygenase (TDO) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINM8F DI DMINM8F DMINM8F DN Maleimides derivative 1 DMINM8F TI TTRZQE3 DMINM8F TN Glycogen synthase kinase-3 alpha (GSK-3A) DMINM8F MA Inhibitor DMINM8F RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMINM8F RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMINUDB DI DMINUDB DMINUDB DN PMID26651364-Compound-125 DMINUDB TI TTTCRU2 DMINUDB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMINUDB MA Antagonist DMINUDB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMINUDB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMINXMY DI DMINXMY DMINXMY DN CID 138805970 DMINXMY TI TT3KYWB DMINXMY TN Ribosomal protein S6 kinase alpha-6 (RSK6) DMINXMY MA Inhibitor DMINXMY RN Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366. DMINXMY RU http://www.freepatentsonline.com/US9771366.html DMIO8J3 DI DMIO8J3 DMIO8J3 DN PMID27019002-Compound-48 DMIO8J3 TI TTNR0UQ DMIO8J3 TN Lysine-specific histone demethylase 1 (LSD) DMIO8J3 MA Inhibitor DMIO8J3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIO8J3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIO8J3 DI DMIO8J3 DMIO8J3 DN PMID27019002-Compound-48 DMIO8J3 TI TT8VP2T DMIO8J3 TN Lysine-specific histone demethylase 1B (KDM1B) DMIO8J3 MA Inhibitor DMIO8J3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIO8J3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIOJD6 DI DMIOJD6 DMIOJD6 DN Pyrrolidine derivative 7 DMIOJD6 TI TT9O6WS DMIOJD6 TN Glucagon receptor (GCGR) DMIOJD6 MA Antagonist DMIOJD6 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMIOJD6 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMIPFO3 DI DMIPFO3 DMIPFO3 DN PMID25666693-Compound-69 DMIPFO3 TI TTMI6F5 DMIPFO3 TN Transient receptor potential cation channel V1 (TRPV1) DMIPFO3 MA Antagonist DMIPFO3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMIPFO3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMIPVYW DI DMIPVYW DMIPVYW DN Biphenyl derivative 4 DMIPVYW TI TT9JNIC DMIPVYW TN Histamine H3 receptor (H3R) DMIPVYW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMIPVYW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMIQ1PL DI DMIQ1PL DMIQ1PL DN Sulfonamide derivative 17 DMIQ1PL TI TT3M2WO DMIQ1PL TN Sphingosine kinase (SphK) DMIQ1PL MA Inhibitor DMIQ1PL RN Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549. DMIQ1PL RU https://www.ncbi.nlm.nih.gov/pubmed/29886770 DMIQ263 DI DMIQ263 DMIQ263 DN PMID29053063-Compound-7f DMIQ263 TI TTZ963I DMIQ263 TN Monoglyceride lipase (MAGL) DMIQ263 MA Inhibitor DMIQ263 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMIQ263 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMIQO8N DI DMIQO8N DMIQO8N DN US8791257, 4 DMIQO8N TI TTR93NU DMIQO8N TN Casein kinase II alpha prime (CSNK2A2) DMIQO8N MA Inhibitor DMIQO8N RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMIQO8N RU http://www.freepatentsonline.com/US8791257.html DMIQOY7 DI DMIQOY7 DMIQOY7 DN Diaryl morpholine derivative 1 DMIQOY7 TI TT6OEDT DMIQOY7 TN Cannabinoid receptor 1 (CB1) DMIQOY7 MA Antagonist DMIQOY7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIQOY7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TT0K1SC DMIQSDW TN 5-HT 2B receptor (HTR2B) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TTWJBZ5 DMIQSDW TN 5-HT 2C receptor (HTR2C) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TTJQOD7 DMIQSDW TN 5-HT 2A receptor (HTR2A) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIS4H0 DI DMIS4H0 DMIS4H0 DN PMID27376512-Compound-Figure3CM DMIS4H0 TI TTJUALD DMIS4H0 TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMIS4H0 MA Inhibitor DMIS4H0 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMIS4H0 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMIS97T DI DMIS97T DMIS97T DN Pyrazole derivative 2 DMIS97T TI TT6OEDT DMIS97T TN Cannabinoid receptor 1 (CB1) DMIS97T MA Antagonist DMIS97T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIS97T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMISJDH DI DMISJDH DMISJDH DN PMID26666989-Compound-Figure9bottomright DMISJDH TI TT8BUGW DMISJDH TN Glycogen phosphorylase (PYG) DMISJDH MA Inhibitor DMISJDH RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMISJDH RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMIT0H3 DI DMIT0H3 DMIT0H3 DN US9434727, 120 DMIT0H3 TI TT0C8BY DMIT0H3 TN Plasma retinol-binding protein (RBP4) DMIT0H3 MA Inhibitor DMIT0H3 RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DMIT0H3 RU http://www.freepatentsonline.com/US9434727.html DMITK03 DI DMITK03 DMITK03 DN Pyrrolo-pyrimidine derivative 4 DMITK03 TI TT4DXQT DMITK03 TN Proto-oncogene c-Ret (RET) DMITK03 MA Inhibitor DMITK03 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMITK03 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMITLPW DI DMITLPW DMITLPW DN Biphenyl mannoside derivative 10 DMITLPW TI TTTCRU2 DMITLPW TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMITLPW MA Antagonist DMITLPW RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMITLPW RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMITNWZ DI DMITNWZ DMITNWZ DN PMID25399762-Compound-Table1-C20 DMITNWZ TI TTGP7BY DMITNWZ TN Monoamine oxidase type B (MAO-B) DMITNWZ MA Inhibitor DMITNWZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMITNWZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMITOY6 DI DMITOY6 DMITOY6 DN US10087167, Compound 3003 DMITOY6 TI TTQFZWR DMITOY6 TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMITOY6 MA Inhibitor DMITOY6 RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMITOY6 RU http://www.freepatentsonline.com/US10087167.html DMITU83 DI DMITU83 DMITU83 DN PMID26560530-Compound-17 DMITU83 TI TT2F4OL DMITU83 TN Tissue transglutaminase (TG2) DMITU83 MA Inhibitor DMITU83 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMITU83 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMITVUY DI DMITVUY DMITVUY DN Pyridine derivative 8 DMITVUY TI TTOHSBA DMITVUY TN Vascular endothelial growth factor A (VEGFA) DMITVUY MA Inhibitor DMITVUY RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMITVUY RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMITX1G DI DMITX1G DMITX1G DN Citalopram derivative 1 DMITX1G TI TTTIBOJ DMITX1G TN Histamine H1 receptor (H1R) DMITX1G MA Inhibitor DMITX1G RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMITX1G RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMITX1G DI DMITX1G DMITX1G DN Citalopram derivative 1 DMITX1G TI TT3ROYC DMITX1G TN Serotonin transporter (SERT) DMITX1G MA Inhibitor DMITX1G RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMITX1G RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMIULVJ DI DMIULVJ DMIULVJ DN Xanthine derivative 1 DMIULVJ TI TTDIGC1 DMIULVJ TN Dipeptidyl peptidase 4 (DPP-4) DMIULVJ MA Inhibitor DMIULVJ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMIULVJ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTON5IT DMIUPSA TN Focal adhesion kinase 1 (FAK) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTT7PJU DMIUPSA TN Janus kinase 3 (JAK-3) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTRMX3V DMIUPSA TN Janus kinase 2 (JAK-2) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TTQ6VDM DMIUTQW TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TT5TPI6 DMIUTQW TN Opioid receptor sigma 1 (OPRS1) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TT9NXW4 DMIUTQW TN Sigma intracellular receptor 2 (TMEM97) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIV92A DI DMIV92A DMIV92A DN PMID26004420-Compound-WO2013028474A DMIV92A TI TTJ13ST DMIV92A TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIV92A MA Inhibitor DMIV92A RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIV92A RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIVJ2W DI DMIVJ2W DMIVJ2W DN PMID25468267-Compound-50 DMIVJ2W TI TT0RGE9 DMIVJ2W TN Lysine-specific demethylase 4 (KDM4) DMIVJ2W MA Inhibitor DMIVJ2W RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMIVJ2W RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIVJMO DI DMIVJMO DMIVJMO DN PMID25435285-Compound-25 DMIVJMO TI TTXJ47W DMIVJMO TN Metabotropic glutamate receptor 2 (mGluR2) DMIVJMO MA Antagonist DMIVJMO RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIVJMO RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TTT7PJU DMIVK7D TN Janus kinase 3 (JAK-3) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TTBYWP2 DMIVK7D TN TYK2 tyrosine kinase (TYK2) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TT6DM01 DMIVK7D TN Janus kinase 1 (JAK-1) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIWEZH DI DMIWEZH DMIWEZH DN PMID30273516-Compound-12 DMIWEZH TI TTCW0KX DMIWEZH TN Glutaminase (GLS) DMIWEZH MA Inhibitor DMIWEZH RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMIWEZH RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMIWQZ5 DI DMIWQZ5 DMIWQZ5 DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 DMIWQZ5 TI TTSXVID DMIWQZ5 TN Nuclear factor NF-kappa-B (NFKB) DMIWQZ5 MA Inhibitor DMIWQZ5 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIWQZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIWY93 DI DMIWY93 DMIWY93 DN Phthalazine ketone derivative 3 DMIWY93 TI TTVDSZ0 DMIWY93 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMIWY93 MA Inhibitor DMIWY93 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMIWY93 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMIX1K0 DI DMIX1K0 DMIX1K0 DN PMID25666693-Compound-130 DMIX1K0 TI TTMI6F5 DMIX1K0 TN Transient receptor potential cation channel V1 (TRPV1) DMIX1K0 MA Antagonist DMIX1K0 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMIX1K0 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMIX90M DI DMIX90M DMIX90M DN PMID27215781-Compound-11 DMIX90M TI TTMSFAW DMIX90M TN Cannabinoid receptor 2 (CB2) DMIX90M RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMIX90M RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMIXERP DI DMIXERP DMIXERP DN Benzimidazole and imidazopyridine derivative 1 DMIXERP TI TTCZOF2 DMIXERP TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMIXERP MA Inhibitor DMIXERP RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMIXERP RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMIXK7Y DI DMIXK7Y DMIXK7Y DN Pyridoindole derivative 2 DMIXK7Y TI TTS7G69 DMIXK7Y TN Fusion protein Bcr-Abl (Bcr-Abl) DMIXK7Y MA Inhibitor DMIXK7Y RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMIXK7Y RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMIXQRY DI DMIXQRY DMIXQRY DN PMID25468267-Compound-55 DMIXQRY TI TTV8CRH DMIXQRY TN Lysine-specific demethylase 4C (KDM4C) DMIXQRY MA Inhibitor DMIXQRY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMIXQRY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIXV6G DI DMIXV6G DMIXV6G DN Biaryl mannoside derivative 17 DMIXV6G TI TTTCRU2 DMIXV6G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIXV6G MA Antagonist DMIXV6G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIXV6G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMIXVNQ DI DMIXVNQ DMIXVNQ DN PMID26004420-Compound-US20140142115A DMIXVNQ TI TTJ13ST DMIXVNQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIXVNQ MA Inhibitor DMIXVNQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIXVNQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIY68N DI DMIY68N DMIY68N DN US8921389, 22 DMIY68N TI TT9ISBX DMIY68N TN HIF-prolyl hydroxylase 2 (HPH-2) DMIY68N MA Inhibitor DMIY68N RN Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389. DMIY68N RU http://www.freepatentsonline.com/US8921389.html DMIYCFE DI DMIYCFE DMIYCFE DN PMID27336223-Compound-15 DMIYCFE TI TT1Q3IE DMIYCFE TN Retinoic acid receptor gamma (RARG) DMIYCFE MA Agonist DMIYCFE RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMIYCFE RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMIYD41 DI DMIYD41 DMIYD41 DN Urea and carbamate bioisostere derivative 9 DMIYD41 TI TTL7C8Q DMIYD41 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMIYD41 MA Inhibitor DMIYD41 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMIYD41 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TTH6V3D DMIYUAN TN Cyclin-dependent kinase 1 (CDK1) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TT0PG8F DMIYUAN TN Cyclin-dependent kinase 4 (CDK4) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TT7HF4W DMIYUAN TN Cyclin-dependent kinase 2 (CDK2) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TTO0FDJ DMIYUAN TN Cyclin-dependent kinase 6 (CDK6) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYVOC DI DMIYVOC DMIYVOC DN 4-Carboxamido-isoindolinone derivative 5 DMIYVOC TI TTVDSZ0 DMIYVOC TN Poly [ADP-ribose] polymerase 1 (PARP1) DMIYVOC MA Inhibitor DMIYVOC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMIYVOC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMIYXS8 DI DMIYXS8 DMIYXS8 DN Benzoxazepine analog 1 DMIYXS8 TI TTPTXIN DMIYXS8 TN Translocator protein (TSPO) DMIYXS8 MA Ligand DMIYXS8 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIYXS8 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIZ64O DI DMIZ64O DMIZ64O DN PMID25553724-Compound-US2011799419010 DMIZ64O TI TTSXVID DMIZ64O TN Nuclear factor NF-kappa-B (NFKB) DMIZ64O MA Inhibitor DMIZ64O RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIZ64O RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIZL8D DI DMIZL8D DMIZL8D DN PMID26936077-Compound-34 DMIZL8D TI TTQR74A DMIZL8D TN Proteinase activated receptor 2 (PAR2) DMIZL8D MA Antagonist DMIZL8D RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMIZL8D RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMIZTKS DI DMIZTKS DMIZTKS DN Pyrimidine derivative 18 DMIZTKS TI TTNR0UQ DMIZTKS TN Lysine-specific histone demethylase 1 (LSD) DMIZTKS MA Inhibitor DMIZTKS RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIZTKS RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIZWM6 DI DMIZWM6 DMIZWM6 DN US8669361, 105 DMIZWM6 TI TTCGOIN DMIZWM6 TN PIM-3 protein kinase (PIM3) DMIZWM6 MA Inhibitor DMIZWM6 RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMIZWM6 RU http://www.freepatentsonline.com/US8669361.html DMJ02N1 DI DMJ02N1 DMJ02N1 DN PMID28394193-Compound-31 DMJ02N1 TI TT9MZCQ DMJ02N1 TN Enhancer of zeste homolog 2 (EZH2) DMJ02N1 MA Inhibitor DMJ02N1 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMJ02N1 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMJ04RQ DI DMJ04RQ DMJ04RQ DN Tacrine-caffeic acid hybrid derivative 1 DMJ04RQ TI TT1RS9F DMJ04RQ TN Acetylcholinesterase (AChE) DMJ04RQ MA Inhibitor DMJ04RQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMJ04RQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMJ0QLB DI DMJ0QLB DMJ0QLB DN PMID27410995-Compound-Figure3k DMJ0QLB TI TT7M3PI DMJ0QLB TN Ribosomal protein S6 kinase (S6K) DMJ0QLB MA Activator DMJ0QLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJ0QLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJ0WVR DI DMJ0WVR DMJ0WVR DN Heterocyclic derivative 14 DMJ0WVR TI TTCZOF2 DMJ0WVR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJ0WVR MA Inhibitor DMJ0WVR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJ0WVR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJ1C0A DI DMJ1C0A DMJ1C0A DN PMID30107136-Compound-Example52 DMJ1C0A TI TT23XQV DMJ1C0A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMJ1C0A MA Inhibitor DMJ1C0A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJ1C0A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJ1K4Y DI DMJ1K4Y DMJ1K4Y DN PMID27019002-Compound-31b DMJ1K4Y TI TTNR0UQ DMJ1K4Y TN Lysine-specific histone demethylase 1 (LSD) DMJ1K4Y MA Inhibitor DMJ1K4Y RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMJ1K4Y RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMJ1KFO DI DMJ1KFO DMJ1KFO DN PMID28454500-Compound-91 DMJ1KFO TI TTA6ZN2 DMJ1KFO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMJ1KFO MA Inhibitor DMJ1KFO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMJ1KFO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMJ1O5R DI DMJ1O5R DMJ1O5R DN PMID29671355-Compound-37 DMJ1O5R TI TTT6LFV DMJ1O5R TN Histone deacetylase 8 (HDAC8) DMJ1O5R MA Inhibitor DMJ1O5R RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJ1O5R RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJ1X53 DI DMJ1X53 DMJ1X53 DN PMID25991433-Compound-A3 DMJ1X53 TI TTHS0U8 DMJ1X53 TN Stress-activated protein kinase JNK2 (JNK2) DMJ1X53 MA Inhibitor DMJ1X53 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJ1X53 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJ1X53 DI DMJ1X53 DMJ1X53 DN PMID25991433-Compound-A3 DMJ1X53 TI TT0K6EO DMJ1X53 TN Stress-activated protein kinase JNK1 (JNK1) DMJ1X53 MA Inhibitor DMJ1X53 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJ1X53 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJ1Z7U DI DMJ1Z7U DMJ1Z7U DN PMID26815044-Compound-48 DMJ1Z7U TI TTULVH8 DMJ1Z7U TN Tyrosinase (TYR) DMJ1Z7U MA Inhibitor DMJ1Z7U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJ1Z7U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJ23AL DI DMJ23AL DMJ23AL DN PMID28394193-Compound-11 DMJ23AL TI TTJBYRU DMJ23AL TN EZH2 Y641F mutant (EZH2 Y641F) DMJ23AL MA Inhibitor DMJ23AL RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMJ23AL RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMJ2CIY DI DMJ2CIY DMJ2CIY DN Benzimidazole and imadazopyridine carboximidamide compound 2 DMJ2CIY TI TTZJYKH DMJ2CIY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ2CIY MA Inhibitor DMJ2CIY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ2CIY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ2CRO DI DMJ2CRO DMJ2CRO DN Indazole derivative 4 DMJ2CRO TI TTZJYKH DMJ2CRO TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ2CRO RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ2CRO RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ3201 DI DMJ3201 DMJ3201 DN PMID26651364-Compound-116 DMJ3201 TI TTTCRU2 DMJ3201 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJ3201 MA Antagonist DMJ3201 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJ3201 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJ37V2 DI DMJ37V2 DMJ37V2 DN Amidopyrazole derivative 5 DMJ37V2 TI TTKFVXR DMJ37V2 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMJ37V2 MA Inhibitor DMJ37V2 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMJ37V2 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMJ3AZ4 DI DMJ3AZ4 DMJ3AZ4 DN Benzimidazole derivative 15 DMJ3AZ4 TI TTYLQ8V DMJ3AZ4 TN Prostaglandin E synthase (PTGES) DMJ3AZ4 MA Inhibitor DMJ3AZ4 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMJ3AZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMJ3GX6 DI DMJ3GX6 DMJ3GX6 DN PMID26666989-Compound-Figure9toprightR02 DMJ3GX6 TI TT8BUGW DMJ3GX6 TN Glycogen phosphorylase (PYG) DMJ3GX6 MA Inhibitor DMJ3GX6 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMJ3GX6 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMJ3YDT DI DMJ3YDT DMJ3YDT DN PMID25666693-Compound-23 DMJ3YDT TI TTMI6F5 DMJ3YDT TN Transient receptor potential cation channel V1 (TRPV1) DMJ3YDT MA Antagonist DMJ3YDT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJ3YDT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJ3ZAI DI DMJ3ZAI DMJ3ZAI DN Lactam derivative 4 DMJ3ZAI TI TTF8P9I DMJ3ZAI TN Diacylglycerol acyltransferase 1 (DGAT1) DMJ3ZAI MA Inhibitor DMJ3ZAI RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMJ3ZAI RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMJ3ZP2 DI DMJ3ZP2 DMJ3ZP2 DN Pyrrolidine derivative 6 DMJ3ZP2 TI TT9O6WS DMJ3ZP2 TN Glucagon receptor (GCGR) DMJ3ZP2 MA Antagonist DMJ3ZP2 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJ3ZP2 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJ41UI DI DMJ41UI DMJ41UI DN Indoline derivative 1 DMJ41UI TI TT1RS9F DMJ41UI TN Acetylcholinesterase (AChE) DMJ41UI MA Inhibitor DMJ41UI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMJ41UI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMJ41UI DI DMJ41UI DMJ41UI DN Indoline derivative 1 DMJ41UI TI TTEB0GD DMJ41UI TN Cholinesterase (BCHE) DMJ41UI MA Inhibitor DMJ41UI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMJ41UI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMJ4ACP DI DMJ4ACP DMJ4ACP DN 1,2-diamino cyclopentane-based derivative 6 DMJ4ACP TI TT9N02I DMJ4ACP TN Orexin receptor type 2 (HCRTR2) DMJ4ACP MA Antagonist DMJ4ACP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMJ4ACP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMJ4ACP DI DMJ4ACP DMJ4ACP DN 1,2-diamino cyclopentane-based derivative 6 DMJ4ACP TI TT60Q8D DMJ4ACP TN Orexin receptor type 1 (HCRTR1) DMJ4ACP MA Antagonist DMJ4ACP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMJ4ACP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMJ4DRI DI DMJ4DRI DMJ4DRI DN PMID25656651-Compound-15b DMJ4DRI TI TTS7G69 DMJ4DRI TN Fusion protein Bcr-Abl (Bcr-Abl) DMJ4DRI MA Inhibitor DMJ4DRI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMJ4DRI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMJ4QD5 DI DMJ4QD5 DMJ4QD5 DN Pyrimidine derivative 11 DMJ4QD5 TI TTOHSBA DMJ4QD5 TN Vascular endothelial growth factor A (VEGFA) DMJ4QD5 MA Inhibitor DMJ4QD5 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJ4QD5 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJ4TZX DI DMJ4TZX DMJ4TZX DN Biphenyl derivative 2 DMJ4TZX TI TTZJYKH DMJ4TZX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ4TZX MA Inhibitor DMJ4TZX RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ4TZX RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ51VZ DI DMJ51VZ DMJ51VZ DN Benzothiazine-carboxamide compound 1 DMJ51VZ TI TTQR74A DMJ51VZ TN Proteinase activated receptor 2 (PAR2) DMJ51VZ MA Antagonist DMJ51VZ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMJ51VZ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMJ53DR DI DMJ53DR DMJ53DR DN US10035778, Example 16 DMJ53DR TI TTIF29E DMJ53DR TN Integrin beta-8 (ITGB8) DMJ53DR MA Inhibitor DMJ53DR RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DMJ53DR RU http://www.freepatentsonline.com/US10035778.html DMJ5LGA DI DMJ5LGA DMJ5LGA DN PMID25435285-Compound-41 DMJ5LGA TI TTXJ47W DMJ5LGA TN Metabotropic glutamate receptor 2 (mGluR2) DMJ5LGA MA Antagonist DMJ5LGA RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMJ5LGA RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMJ5X46 DI DMJ5X46 DMJ5X46 DN Heterocyclic derivative 1 DMJ5X46 TI TTHS256 DMJ5X46 TN Metabotropic glutamate receptor 5 (mGluR5) DMJ5X46 MA Modulator DMJ5X46 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMJ5X46 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMJ6CI5 DI DMJ6CI5 DMJ6CI5 DN PMID27977313-Compound-Figure4b DMJ6CI5 TI TTR7UJ3 DMJ6CI5 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMJ6CI5 MA Inhibitor DMJ6CI5 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMJ6CI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMJ6GU9 DI DMJ6GU9 DMJ6GU9 DN US10059720, Example 82 DMJ6GU9 TI TTY2KP7 DMJ6GU9 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMJ6GU9 MA Inhibitor DMJ6GU9 RN Pyridine derivative. US10059720. DMJ6GU9 RU http://www.freepatentsonline.com/US10059720.html DMJ6IE5 DI DMJ6IE5 DMJ6IE5 DN Pyrrolidinyl urea derivative 12 DMJ6IE5 TI TTTDVOJ DMJ6IE5 TN Tropomyosin-related kinase A (TrkA) DMJ6IE5 MA Inhibitor DMJ6IE5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMJ6IE5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMJ71Q0 DI DMJ71Q0 DMJ71Q0 DN Pyrimidine benzenesulfonamide derivative 3 DMJ71Q0 TI TTIY56R DMJ71Q0 TN Kynurenine 3-hydroxylase (KMO) DMJ71Q0 MA Inhibitor DMJ71Q0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMJ71Q0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMJ76RC DI DMJ76RC DMJ76RC DN US9580418, Example 11 DMJ76RC TI TTCGOIN DMJ76RC TN PIM-3 protein kinase (PIM3) DMJ76RC MA Inhibitor DMJ76RC RN Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418. DMJ76RC RU http://www.freepatentsonline.com/US9580418.html DMJ7F1Q DI DMJ7F1Q DMJ7F1Q DN Piperazine derivative 1 DMJ7F1Q TI TT6OEDT DMJ7F1Q TN Cannabinoid receptor 1 (CB1) DMJ7F1Q MA Antagonist DMJ7F1Q RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJ7F1Q RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJ80IZ DI DMJ80IZ DMJ80IZ DN Piperazine carbamate/urea derivative 5 DMJ80IZ TI TT9JNIC DMJ80IZ TN Histamine H3 receptor (H3R) DMJ80IZ MA Ligand DMJ80IZ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMJ80IZ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMJ8BAS DI DMJ8BAS DMJ8BAS DN PMID27539678-Compound-4 DMJ8BAS TI TT3M2WO DMJ8BAS TN Sphingosine kinase (SphK) DMJ8BAS MA Inhibitor DMJ8BAS RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMJ8BAS RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMJ8MXZ DI DMJ8MXZ DMJ8MXZ DN PMID25726713-Compound-26 DMJ8MXZ TI TT8J1S3 DMJ8MXZ TN Smoothened homolog (SMO) DMJ8MXZ MA Inhibitor DMJ8MXZ RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJ8MXZ RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJ8QTX DI DMJ8QTX DMJ8QTX DN Peptide analog 67 DMJ8QTX TI TTPLTSQ DMJ8QTX TN Neutrophil elastase (NE) DMJ8QTX MA Inhibitor DMJ8QTX RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMJ8QTX RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMJ8X7A DI DMJ8X7A DMJ8X7A DN Aromatic hydrazine carboxyimidoamide derivative 1 DMJ8X7A TI TTULVH8 DMJ8X7A TN Tyrosinase (TYR) DMJ8X7A MA Inhibitor DMJ8X7A RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJ8X7A RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJ8YZK DI DMJ8YZK DMJ8YZK DN Monofluorine derivative 1 DMJ8YZK TI TTZJYKH DMJ8YZK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ8YZK MA Antagonist DMJ8YZK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ8YZK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ91EM DI DMJ91EM DMJ91EM DN Peptide analog 17 DMJ91EM TI TT68GPI DMJ91EM TN Proteasome beta-5 (PS beta-5) DMJ91EM MA Inhibitor DMJ91EM RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJ91EM RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJ91EM DI DMJ91EM DMJ91EM DN Peptide analog 17 DMJ91EM TI TTEAD9J DMJ91EM TN Proteasome beta-8 (PS beta-8) DMJ91EM MA Inhibitor DMJ91EM RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJ91EM RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJ98VG DI DMJ98VG DMJ98VG DN 3-acylidene-2-oxoindole derivative 2 DMJ98VG TI TT2F4OL DMJ98VG TN Tissue transglutaminase (TG2) DMJ98VG MA Inhibitor DMJ98VG RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMJ98VG RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMJ9U0E DI DMJ9U0E DMJ9U0E DN Azetidine derivative 5 DMJ9U0E TI TTZJYKH DMJ9U0E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ9U0E MA Inhibitor DMJ9U0E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ9U0E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJA1XC DI DMJA1XC DMJA1XC DN PMID25772215-Compound-US02014179750M3 DMJA1XC TI TT1ZAVI DMJA1XC TN Prostaglandin E2 receptor EP2 (PTGER2) DMJA1XC MA Antagonist DMJA1XC RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMJA1XC RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMJADXV DI DMJADXV DMJADXV DN PMID27551786-Compound-II DMJADXV TI TT26PHO DMJADXV TN Mineralocorticoid receptor (MR) DMJADXV MA Antagonist DMJADXV RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMJADXV RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMJAUWG DI DMJAUWG DMJAUWG DN PMID28048944-Compound-4 DMJAUWG TI TTZN7RP DMJAUWG TN Rho-associated protein kinase 1 (ROCK1) DMJAUWG MA Inhibitor DMJAUWG RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMJAUWG RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMJAUWG DI DMJAUWG DMJAUWG DN PMID28048944-Compound-4 DMJAUWG TI TTGWKQJ DMJAUWG TN Rho-associated protein kinase 2 (ROCK2) DMJAUWG MA Inhibitor DMJAUWG RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMJAUWG RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMJAWOI DI DMJAWOI DMJAWOI DN Tricyclic compound 2 DMJAWOI TI TTT7PJU DMJAWOI TN Janus kinase 3 (JAK-3) DMJAWOI MA Inhibitor DMJAWOI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJAWOI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTT7PJU DMJAZ7D TN Janus kinase 3 (JAK-3) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTBYWP2 DMJAZ7D TN TYK2 tyrosine kinase (TYK2) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTRMX3V DMJAZ7D TN Janus kinase 2 (JAK-2) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TT6DM01 DMJAZ7D TN Janus kinase 1 (JAK-1) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJBGHL DI DMJBGHL DMJBGHL DN Azaindole derivative 6 DMJBGHL TI TT7RJY8 DMJBGHL TN Xanthine dehydrogenase/oxidase (XDH) DMJBGHL MA Inhibitor DMJBGHL RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJBGHL RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJBOL0 DI DMJBOL0 DMJBOL0 DN Benzoyl-piperidine derivative 1 DMJBOL0 TI TTJQOD7 DMJBOL0 TN 5-HT 2A receptor (HTR2A) DMJBOL0 MA Antagonist DMJBOL0 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMJBOL0 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMJBR86 DI DMJBR86 DMJBR86 DN Sulfonamide derivative 11 DMJBR86 TI TTA592U DMJBR86 TN Urate anion exchanger 1 (URAT1) DMJBR86 MA Inhibitor DMJBR86 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMJBR86 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMJBTZG DI DMJBTZG DMJBTZG DN Pyrrolo[2,3-b]pyridine derivative 4 DMJBTZG TI TTIV39N DMJBTZG TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMJBTZG MA Inhibitor DMJBTZG RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMJBTZG RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMJBY68 DI DMJBY68 DMJBY68 DN Aryl mannoside derivative 21 DMJBY68 TI TTTCRU2 DMJBY68 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJBY68 MA Antagonist DMJBY68 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJBY68 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJC4UZ DI DMJC4UZ DMJC4UZ DN Fused heterocyclic compound 11 DMJC4UZ TI TT7RJY8 DMJC4UZ TN Xanthine dehydrogenase/oxidase (XDH) DMJC4UZ MA Inhibitor DMJC4UZ RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJC4UZ RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJCAOD DI DMJCAOD DMJCAOD DN PMID27109571-Compound-37 DMJCAOD TI TTMY6L1 DMJCAOD TN Fatty acid-binding protein (FABP) DMJCAOD MA Inhibitor DMJCAOD RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCAOD RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCL53 DI DMJCL53 DMJCL53 DN PMID27109571-Compound-26 DMJCL53 TI TTHWMFZ DMJCL53 TN Fatty acid-binding protein 4 (FABP4) DMJCL53 MA Inhibitor DMJCL53 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCL53 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCL53 DI DMJCL53 DMJCL53 DN PMID27109571-Compound-26 DMJCL53 TI TTNT2S6 DMJCL53 TN Fatty acid-binding protein 5 (FABP5) DMJCL53 MA Inhibitor DMJCL53 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCL53 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCSL3 DI DMJCSL3 DMJCSL3 DN Imidazopyridine derivative 3 DMJCSL3 TI TTBYWP2 DMJCSL3 TN TYK2 tyrosine kinase (TYK2) DMJCSL3 MA Inhibitor DMJCSL3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJCSL3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJCVBM DI DMJCVBM DMJCVBM DN PMID25399762-Compound-Table1-C4 DMJCVBM TI TTGP7BY DMJCVBM TN Monoamine oxidase type B (MAO-B) DMJCVBM MA Inhibitor DMJCVBM RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMJCVBM RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMJCX8M DI DMJCX8M DMJCX8M DN Pyrazole derivative 15 DMJCX8M TI TT6OEDT DMJCX8M TN Cannabinoid receptor 1 (CB1) DMJCX8M MA Antagonist DMJCX8M RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJCX8M RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJD1S6 DI DMJD1S6 DMJD1S6 DN A1-10438 DMJD1S6 TI TT0C8BY DMJD1S6 TN Plasma retinol-binding protein (RBP4) DMJD1S6 MA Inhibitor DMJD1S6 RN Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215. DMJD1S6 RU http://www.freepatentsonline.com/US8853215.html DMJDC5T DI DMJDC5T DMJDC5T DN Benzothiazoline derivative 1 DMJDC5T TI TTULVH8 DMJDC5T TN Tyrosinase (TYR) DMJDC5T MA Inhibitor DMJDC5T RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJDC5T RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTEAD9J DMJDFS1 TN Proteasome beta-8 (PS beta-8) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT68GPI DMJDFS1 TN Proteasome beta-5 (PS beta-5) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTOUSTQ DMJDFS1 TN Proteasome beta-9 (PS beta-9) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT8EPLT DMJDFS1 TN Proteasome beta-1 (PS beta-1) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTPNACM DMJDFS1 TN Proteasome beta-10 (PS beta-10) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT49BVC DMJDFS1 TN Proteasome beta-2 (PS beta-2) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDG37 DI DMJDG37 DMJDG37 DN Ethynyl compound 2 DMJDG37 TI TTHS256 DMJDG37 TN Metabotropic glutamate receptor 5 (mGluR5) DMJDG37 MA Modulator DMJDG37 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMJDG37 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMJDTSN DI DMJDTSN DMJDTSN DN US9493490, L DMJDTSN TI TTAZ3MN DMJDTSN TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMJDTSN MA Inhibitor DMJDTSN RN Boron-containing small molecules. US9493490. DMJDTSN RU http://www.freepatentsonline.com/US9493490.html DMJEH0F DI DMJEH0F DMJEH0F DN PMID25666693-Compound-58 DMJEH0F TI TTMI6F5 DMJEH0F TN Transient receptor potential cation channel V1 (TRPV1) DMJEH0F MA Antagonist DMJEH0F RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJEH0F RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJETVH DI DMJETVH DMJETVH DN PMID25416646-Compound-Figure2-J DMJETVH TI TTZMAO3 DMJETVH TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJETVH MA Agonist DMJETVH RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMJETVH RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMJEV86 DI DMJEV86 DMJEV86 DN Pyrrolo-pyrimidine derivative 9 DMJEV86 TI TTK0FEA DMJEV86 TN Leucine-rich repeat kinase 2 (LRRK2) DMJEV86 MA Inhibitor DMJEV86 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMJEV86 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMJEX3D DI DMJEX3D DMJEX3D DN Heterocyclic-substituted 3-alkyl azetidine derivative 1 DMJEX3D TI TT6OEDT DMJEX3D TN Cannabinoid receptor 1 (CB1) DMJEX3D MA Antagonist DMJEX3D RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJEX3D RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJF6S0 DI DMJF6S0 DMJF6S0 DN Sphinx DMJF6S0 TI TTU3WV6 DMJF6S0 TN SRSF protein kinase 1 (SRPK1) DMJF6S0 MA Inhibitor DMJF6S0 RN Piperazine derivatives for treating disorders. US9695160. DMJF6S0 RU http://www.freepatentsonline.com/US9695160.html DMJFDNB DI DMJFDNB DMJFDNB DN Aryl mannoside derivative 22 DMJFDNB TI TTTCRU2 DMJFDNB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJFDNB MA Antagonist DMJFDNB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJFDNB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJFHVN DI DMJFHVN DMJFHVN DN Salicylic acid derivative 7 DMJFHVN TI TTH8FZW DMJFHVN TN Signal transducer and activator of transcription 3 (STAT3) DMJFHVN MA Inhibitor DMJFHVN RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMJFHVN RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMJFSOM DI DMJFSOM DMJFSOM DN PMID27336223-Compound-4 DMJFSOM TI TTW38KT DMJFSOM TN Retinoic acid receptor alpha (RARA) DMJFSOM MA Agonist DMJFSOM RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMJFSOM RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMJFYK1 DI DMJFYK1 DMJFYK1 DN Pyrrolo[2,3-d]pyrimidine derivative 2 DMJFYK1 TI TTIXKA4 DMJFYK1 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMJFYK1 MA Inhibitor DMJFYK1 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJFYK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJG1ZS DI DMJG1ZS DMJG1ZS DN Biaromatic compound 1 DMJG1ZS TI TTZMAO3 DMJG1ZS TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJG1ZS MA Agonist DMJG1ZS RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMJG1ZS RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMJG7M6 DI DMJG7M6 DMJG7M6 DN Azole benzene derivative 2 DMJG7M6 TI TT7RJY8 DMJG7M6 TN Xanthine dehydrogenase/oxidase (XDH) DMJG7M6 MA Inhibitor DMJG7M6 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJG7M6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJIDLU DI DMJIDLU DMJIDLU DN Quinazoline derivative 4 DMJIDLU TI TTPTXIN DMJIDLU TN Translocator protein (TSPO) DMJIDLU MA Ligand DMJIDLU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMJIDLU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMJIZPQ DI DMJIZPQ DMJIZPQ DN Resorcinol compound 19 DMJIZPQ TI TTULVH8 DMJIZPQ TN Tyrosinase (TYR) DMJIZPQ MA Inhibitor DMJIZPQ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJIZPQ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJIZWR DI DMJIZWR DMJIZWR DN PMID26004420-Compound-WO2014099633D DMJIZWR TI TTJ13ST DMJIZWR TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMJIZWR MA Inhibitor DMJIZWR RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMJIZWR RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMJK296 DI DMJK296 DMJK296 DN PMID25399762-Compound-Table1-C24 DMJK296 TI TTGP7BY DMJK296 TN Monoamine oxidase type B (MAO-B) DMJK296 MA Inhibitor DMJK296 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMJK296 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMJK98Z DI DMJK98Z DMJK98Z DN Pyrrolidine carboxamide derivative 1 DMJK98Z TI TTQHWNA DMJK98Z TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMJK98Z MA Inhibitor DMJK98Z RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJK98Z RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJK98Z DI DMJK98Z DMJK98Z DN Pyrrolidine carboxamide derivative 1 DMJK98Z TI TTEMWSD DMJK98Z TN von Hippel-Lindau disease tumor suppressor (VHL) DMJK98Z MA Inhibitor DMJK98Z RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJK98Z RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJKFVU DI DMJKFVU DMJKFVU DN US8614253, 29-1 DMJKFVU TI TTOJ9QL DMJKFVU TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMJKFVU MA Inhibitor DMJKFVU RN IRE-1 inhibitors. US9241942. DMJKFVU RU http://www.freepatentsonline.com/US9241942.html DMJKOFB DI DMJKOFB DMJKOFB DN PMID25522065-Compound-44 DMJKOFB TI TTX4RTB DMJKOFB TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJKOFB MA Antagonist DMJKOFB RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMJKOFB RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMJKS4X DI DMJKS4X DMJKS4X DN US10100051, Compound 1 DMJKS4X TI TT9ISBX DMJKS4X TN HIF-prolyl hydroxylase 2 (HPH-2) DMJKS4X MA Inhibitor DMJKS4X RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMJKS4X RU http://www.freepatentsonline.com/US10100051.html DMJKTYW DI DMJKTYW DMJKTYW DN US10174026, Example 99 DMJKTYW TI TTIG67W DMJKTYW TN Lysine-specific demethylase 5A (KDM5A) DMJKTYW MA Inhibitor DMJKTYW RN Histone demethylase inhibitors. US10174026. DMJKTYW RU http://www.freepatentsonline.com/US10174026.html DMJL1MB DI DMJL1MB DMJL1MB DN 67S DMJL1MB TI TTECBXN DMJL1MB TN Oxysterols receptor LXR-alpha (NR1H3) DMJL1MB MA Inhibitor DMJL1MB RN Piperazine derivatives as liver X receptor modulators. US10144715. DMJL1MB RU http://www.freepatentsonline.com/US10144715.html DMJLFEN DI DMJLFEN DMJLFEN DN PMID25666693-Compound-138 DMJLFEN TI TTMI6F5 DMJLFEN TN Transient receptor potential cation channel V1 (TRPV1) DMJLFEN MA Antagonist DMJLFEN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJLFEN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJLU8R DI DMJLU8R DMJLU8R DN Pyrazolo[1,5-a]pyrimidine derivative 20 DMJLU8R TI TTTDVOJ DMJLU8R TN Tropomyosin-related kinase A (TrkA) DMJLU8R MA Inhibitor DMJLU8R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMJLU8R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMJMCKD DI DMJMCKD DMJMCKD DN PMID25522065-Compound-8 DMJMCKD TI TTX4RTB DMJMCKD TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJMCKD MA Antagonist DMJMCKD RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMJMCKD RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMJMCNP DI DMJMCNP DMJMCNP DN 1,3,4-oxadiazole derivative 1 DMJMCNP TI TTNBFWK DMJMCNP TN Programmed cell death protein 1 (PD-1) DMJMCNP MA Inhibitor DMJMCNP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJMCNP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJMO72 DI DMJMO72 DMJMO72 DN PMID27215781-Compound-31 DMJMO72 TI TTMSFAW DMJMO72 TN Cannabinoid receptor 2 (CB2) DMJMO72 MA Agonist DMJMO72 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMJMO72 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TTNGILX DMJMTNL TN Adrenergic receptor alpha-1A (ADRA1A) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TTSQIFT DMJMTNL TN 5-HT 1A receptor (HTR1A) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TT34BHT DMJMTNL TN Adrenergic receptor alpha-1D (ADRA1D) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMWDV DI DMJMWDV DMJMWDV DN Cyclic sulfonamide derivative 1 DMJMWDV TI TT8J1S3 DMJMWDV TN Smoothened homolog (SMO) DMJMWDV MA Inhibitor DMJMWDV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJMWDV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJN37O DI DMJN37O DMJN37O DN Antibodie derivative 7 DMJN37O TI TTOHSBA DMJN37O TN Vascular endothelial growth factor A (VEGFA) DMJN37O MA Binder DMJN37O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJN37O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJN5CI DI DMJN5CI DMJN5CI DN Spiroimidazolone derivative 6 DMJN5CI TI TT9O6WS DMJN5CI TN Glucagon receptor (GCGR) DMJN5CI MA Antagonist DMJN5CI RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJN5CI RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJN72E DI DMJN72E DMJN72E DN Triazolo-pyrimidinedione derivative 1 DMJN72E TI TTDIGC1 DMJN72E TN Dipeptidyl peptidase 4 (DPP-4) DMJN72E MA Inhibitor DMJN72E RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMJN72E RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMJNCD6 DI DMJNCD6 DMJNCD6 DN Tricyclic heterocycle derivative 3 DMJNCD6 TI TTZC0KV DMJNCD6 TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DMJNCD6 MA Inhibitor DMJNCD6 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMJNCD6 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMJNE4V DI DMJNE4V DMJNE4V DN Pyridine-2,4-dicarboxylic acid analog 1 DMJNE4V TI TTWAQBO DMJNE4V TN Lysine-specific demethylase 4E (KDM4E) DMJNE4V MA Inhibitor DMJNE4V RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMJNE4V RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMJNOB9 DI DMJNOB9 DMJNOB9 DN BDBM50080559 DMJNOB9 TI TTDYP7I DMJNOB9 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMJNOB9 MA Inhibitor DMJNOB9 RN Pyridin-4-yl derivatives. US9617250. DMJNOB9 RU http://www.freepatentsonline.com/US9617250.html DMJO3RW DI DMJO3RW DMJO3RW DN PMID28092474-Compound-32n DMJO3RW TI TT6R7JZ DMJO3RW TN Histone deacetylase 1 (HDAC1) DMJO3RW MA Inhibitor DMJO3RW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMJO3RW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMJO3RW DI DMJO3RW DMJO3RW DN PMID28092474-Compound-32n DMJO3RW TI TT5ZKDI DMJO3RW TN Histone deacetylase 6 (HDAC6) DMJO3RW MA Inhibitor DMJO3RW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMJO3RW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMJOBUZ DI DMJOBUZ DMJOBUZ DN PMID29473428-Compound-72 DMJOBUZ TI TTZJYKH DMJOBUZ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJOBUZ MA Inhibitor DMJOBUZ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJOBUZ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJOD8I DI DMJOD8I DMJOD8I DN PMID25980951-Compound-40 DMJOD8I TI TTR7B60 DMJOD8I TN X-linked inhibitor of apoptosis protein (XIAP) DMJOD8I MA Antagonist DMJOD8I RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMJOD8I RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMJOG3W DI DMJOG3W DMJOG3W DN PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines DMJOG3W TI TTSBVFO DMJOG3W TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMJOG3W MA Inhibitor DMJOG3W RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMJOG3W RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMJON7D DI DMJON7D DMJON7D DN Triazole gold complexe 2 DMJON7D TI TTR7UJ3 DMJON7D TN Cytoplasmic thioredoxin reductase (TXNRD1) DMJON7D MA Inhibitor DMJON7D RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMJON7D RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMJOPEL DI DMJOPEL DMJOPEL DN PMID25482888-Compound-38 DMJOPEL TI TTDIGC1 DMJOPEL TN Dipeptidyl peptidase 4 (DPP-4) DMJOPEL MA Inhibitor DMJOPEL RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMJOPEL RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMJP0AG DI DMJP0AG DMJP0AG DN PMID28870136-Compound-40 DMJP0AG TI TTK0O6Y DMJP0AG TN Ecto-5'-nucleotidase (CD73) DMJP0AG MA Inhibitor DMJP0AG RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMJP0AG RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMJP0NB DI DMJP0NB DMJP0NB DN PMID25666693-Compound-143 DMJP0NB TI TTMI6F5 DMJP0NB TN Transient receptor potential cation channel V1 (TRPV1) DMJP0NB MA Antagonist DMJP0NB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJP0NB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJP16K DI DMJP16K DMJP16K DN Bicyclic pyrimidine derivative 2 DMJP16K TI TTDNFMT DMJP16K TN Platelet-activating factor acetylhydrolase (PLA2G7) DMJP16K MA Inhibitor DMJP16K RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DMJP16K RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DMJP1IK DI DMJP1IK DMJP1IK DN Bicyclic hexapeptide derivative 2 DMJP1IK TI TT8J1S3 DMJP1IK TN Smoothened homolog (SMO) DMJP1IK MA Inhibitor DMJP1IK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJP1IK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJPQNH DI DMJPQNH DMJPQNH DN US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide DMJPQNH TI TT7ALZG DMJPQNH TN Integrin-linked protein kinase 1 (ILK) DMJPQNH MA Inhibitor DMJPQNH RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMJPQNH RU http://www.freepatentsonline.com/US8754233.html DMJPW7C DI DMJPW7C DMJPW7C DN C06909 DMJPW7C TI TT5DOVB DMJPW7C TN Cytomegalovirus Protease (CMV UL80) DMJPW7C MA Inhibitor DMJPW7C RN Phosphonate compounds. US10071110. DMJPW7C RU http://www.freepatentsonline.com/US10071110.html DMJPYVS DI DMJPYVS DMJPYVS DN Steroid derivative 4 DMJPYVS TI TTUX68I DMJPYVS TN Hypoxia-inducible factor 1 (HIF-1) DMJPYVS MA Inhibitor DMJPYVS RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJPYVS RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJQBVH DI DMJQBVH DMJQBVH DN Thiazole carboxamide derivative 16 DMJQBVH TI TTCZOF2 DMJQBVH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJQBVH MA Inhibitor DMJQBVH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJQBVH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJQOAE DI DMJQOAE DMJQOAE DN US8975409, Example 9(3) DMJQOAE TI TTVSMOH DMJQOAE TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMJQOAE MA Inhibitor DMJQOAE RN Phenyl derivative. US8975409. DMJQOAE RU http://www.freepatentsonline.com/US8975409.html DMJRHS4 DI DMJRHS4 DMJRHS4 DN 2-pyrazinone derivative 4 DMJRHS4 TI TTPLTSQ DMJRHS4 TN Neutrophil elastase (NE) DMJRHS4 MA Inhibitor DMJRHS4 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMJRHS4 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMJRK9D DI DMJRK9D DMJRK9D DN 1313212-89-3 DMJRK9D TI TTNAFOU DMJRK9D TN Rotamase D (PPID) DMJRK9D MA Inhibitor DMJRK9D RN Inhibitors of cyclophilins and uses thereof. US8901295. DMJRK9D RU http://www.freepatentsonline.com/US8901295.html DMJRZLB DI DMJRZLB DMJRZLB DN PMID27410995-Compound-Figure3j DMJRZLB TI TT9ABMF DMJRZLB TN Serine/threonine-protein kinase Chk2 (RAD53) DMJRZLB MA Inhibitor DMJRZLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJRZLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJRZLB DI DMJRZLB DMJRZLB DN PMID27410995-Compound-Figure3j DMJRZLB TI TTUM2ZR DMJRZLB TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMJRZLB MA Inhibitor DMJRZLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJRZLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJS4RP DI DMJS4RP DMJS4RP DN PMID26882240-Compound-32 DMJS4RP TI TTUX68I DMJS4RP TN Hypoxia-inducible factor 1 (HIF-1) DMJS4RP MA Inhibitor DMJS4RP RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJS4RP RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJSH0F DI DMJSH0F DMJSH0F DN PMID30107136-Compound-Example43 DMJSH0F TI TT23XQV DMJSH0F TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMJSH0F MA Inhibitor DMJSH0F RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJSH0F RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJSIN8 DI DMJSIN8 DMJSIN8 DN Enzoxazolinone sulfonamide derivative 1 DMJSIN8 TI TT4G2JS DMJSIN8 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMJSIN8 MA Blocker DMJSIN8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMJSIN8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMJT1WG DI DMJT1WG DMJT1WG DN C-linked disaccharide biphenyl mannoside derivative 2 DMJT1WG TI TTTCRU2 DMJT1WG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJT1WG MA Antagonist DMJT1WG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJT1WG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJTN91 DI DMJTN91 DMJTN91 DN Heteroaryl-carboxamide derivative 8 DMJTN91 TI TTCZOF2 DMJTN91 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJTN91 MA Inhibitor DMJTN91 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJTN91 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJTO69 DI DMJTO69 DMJTO69 DN PMID25991433-Compound-B1 DMJTO69 TI TTVOE6D DMJTO69 TN Mitogen-activated protein kinase (MAPK) DMJTO69 MA Inhibitor DMJTO69 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJTO69 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJU0SO DI DMJU0SO DMJU0SO DN 4-(2-cyclohexylethoxy) aniline derivative 3 DMJU0SO TI TTA6ZN2 DMJU0SO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMJU0SO MA Inhibitor DMJU0SO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMJU0SO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMJUHXB DI DMJUHXB DMJUHXB DN PMID25726713-Compound-22 DMJUHXB TI TT8J1S3 DMJUHXB TN Smoothened homolog (SMO) DMJUHXB MA Inhibitor DMJUHXB RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJUHXB RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJUL1A DI DMJUL1A DMJUL1A DN PMID27376512-Compound-asCEBP-2 DMJUL1A TI TT6S2FE DMJUL1A TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMJUL1A MA Inhibitor DMJUL1A RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMJUL1A RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMJUMC6 DI DMJUMC6 DMJUMC6 DN Pyrrole derivative 5 DMJUMC6 TI TT6OEDT DMJUMC6 TN Cannabinoid receptor 1 (CB1) DMJUMC6 MA Antagonist DMJUMC6 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJUMC6 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJURBM DI DMJURBM DMJURBM DN Indoline derivative 12 DMJURBM TI TTOHSBA DMJURBM TN Vascular endothelial growth factor A (VEGFA) DMJURBM MA Inhibitor DMJURBM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJURBM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TT4YWTO DMJV1SY TN Histone deacetylase 3 (HDAC3) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TTSHTOI DMJV1SY TN Histone deacetylase 2 (HDAC2) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TT6R7JZ DMJV1SY TN Histone deacetylase 1 (HDAC1) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTXABCW DMJWH4B TN NT-3 growth factor receptor (TrkC) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTTDVOJ DMJWH4B TN Tropomyosin-related kinase A (TrkA) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTKN7QR DMJWH4B TN BDNF/NT-3 growth factors receptor (TrkB) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJX6DV DI DMJX6DV DMJX6DV DN Aromatic ring compound 1 DMJX6DV TI TT9O6WS DMJX6DV TN Glucagon receptor (GCGR) DMJX6DV MA Antagonist DMJX6DV RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJX6DV RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJX8WY DI DMJX8WY DMJX8WY DN PMID26004420-Compound-WO2014150132B DMJX8WY TI TTJ13ST DMJX8WY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMJX8WY MA Inhibitor DMJX8WY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMJX8WY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTT7PJU DMJXNO1 TN Janus kinase 3 (JAK-3) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTBYWP2 DMJXNO1 TN TYK2 tyrosine kinase (TYK2) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTRMX3V DMJXNO1 TN Janus kinase 2 (JAK-2) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TT6DM01 DMJXNO1 TN Janus kinase 1 (JAK-1) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJY0CD DI DMJY0CD DMJY0CD DN US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine DMJY0CD TI TT7ALZG DMJY0CD TN Integrin-linked protein kinase 1 (ILK) DMJY0CD MA Inhibitor DMJY0CD RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMJY0CD RU http://www.freepatentsonline.com/US8754233.html DMJY8XI DI DMJY8XI DMJY8XI DN Azetidine urea derivative 2 DMJY8XI TI TTDP1UC DMJY8XI TN Fatty acid amide hydrolase (FAAH) DMJY8XI MA Inhibitor DMJY8XI RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMJY8XI RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMJYQLC DI DMJYQLC DMJYQLC DN PMID29338548-Compound-44 DMJYQLC TI TTHJTF7 DMJYQLC TN Glycine transporter GlyT-1 (SLC6A9) DMJYQLC MA Inhibitor DMJYQLC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMJYQLC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMJYUN2 DI DMJYUN2 DMJYUN2 DN PMID29473428-Compound-59 DMJYUN2 TI TTZJYKH DMJYUN2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJYUN2 MA Inhibitor DMJYUN2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJYUN2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJZ1IG DI DMJZ1IG DMJZ1IG DN Amidopyrazole derivative 6 DMJZ1IG TI TTKFVXR DMJZ1IG TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMJZ1IG MA Inhibitor DMJZ1IG RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMJZ1IG RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMJZGT8 DI DMJZGT8 DMJZGT8 DN Chalcone derivative 5 DMJZGT8 TI TT2F4OL DMJZGT8 TN Tissue transglutaminase (TG2) DMJZGT8 MA Inhibitor DMJZGT8 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMJZGT8 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMJZREU DI DMJZREU DMJZREU DN PMID28117607-Compound-7 DMJZREU TI TTK0FEA DMJZREU TN Leucine-rich repeat kinase 2 (LRRK2) DMJZREU MA Inhibitor DMJZREU RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMJZREU RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMJZSWF DI DMJZSWF DMJZSWF DN PMID28447479-Compound-26 DMJZSWF TI TTSCIM2 DMJZSWF TN Extracellular lysophospholipase D (E-NPP2) DMJZSWF MA Agonist DMJZSWF RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMJZSWF RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMK02LS DI DMK02LS DMK02LS DN US9353089, 330 DMK02LS TI TTXMNHO DMK02LS TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMK02LS MA Inhibitor DMK02LS RN Compositions and methods for the treatment of malaria. US9353089. DMK02LS RU http://www.freepatentsonline.com/US9353089.html DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TTOUSTQ DMK0GTV TN Proteasome beta-9 (PS beta-9) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TT68GPI DMK0GTV TN Proteasome beta-5 (PS beta-5) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TT8EPLT DMK0GTV TN Proteasome beta-1 (PS beta-1) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TTEAD9J DMK0GTV TN Proteasome beta-8 (PS beta-8) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0RTV DI DMK0RTV DMK0RTV DN PMID28870136-Compound-56 DMK0RTV TI TTK0O6Y DMK0RTV TN Ecto-5'-nucleotidase (CD73) DMK0RTV MA Inhibitor DMK0RTV RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMK0RTV RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMK0S4I DI DMK0S4I DMK0S4I DN Tacrine-dihydropyridine hybrid derivative 1 DMK0S4I TI TT1RS9F DMK0S4I TN Acetylcholinesterase (AChE) DMK0S4I RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMK0S4I RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMK0SIM DI DMK0SIM DMK0SIM DN PMID27454349-Compound-94 DMK0SIM TI TTK59TV DMK0SIM TN Vitamin D3 receptor (VDR) DMK0SIM MA Agonist DMK0SIM RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMK0SIM RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMK0T9E DI DMK0T9E DMK0T9E DN SCHEMBL15295829 DMK0T9E TI TTVSMOH DMK0T9E TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMK0T9E MA Inhibitor DMK0T9E RN Sphingosine 1-phosphate receptor antagonists. US9663511. DMK0T9E RU http://www.freepatentsonline.com/US9663511.html DMK12OT DI DMK12OT DMK12OT DN Coumarin/resveratrol hybrid derivative 2 DMK12OT TI TTGP7BY DMK12OT TN Monoamine oxidase type B (MAO-B) DMK12OT MA Inhibitor DMK12OT RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMK12OT RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMK1QTH DI DMK1QTH DMK1QTH DN Tricyclic indole compound 10 DMK1QTH TI TTPTXIN DMK1QTH TN Translocator protein (TSPO) DMK1QTH MA Ligand DMK1QTH RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMK1QTH RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMK1UJV DI DMK1UJV DMK1UJV DN Aminopyrimidine derivative 1 DMK1UJV TI TTS7G69 DMK1UJV TN Fusion protein Bcr-Abl (Bcr-Abl) DMK1UJV MA Inhibitor DMK1UJV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMK1UJV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMK2FSY DI DMK2FSY DMK2FSY DN Pyrrolo-pyridinone derivative 5 DMK2FSY TI TT4G2JS DMK2FSY TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMK2FSY MA Inhibitor DMK2FSY RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK2FSY RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK2FSY DI DMK2FSY DMK2FSY DN Pyrrolo-pyridinone derivative 5 DMK2FSY TI TTAXZ0K DMK2FSY TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMK2FSY MA Inhibitor DMK2FSY RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK2FSY RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK2V6H DI DMK2V6H DMK2V6H DN Tricyclic pyrrolidine derivative 3 DMK2V6H TI TTWJBZ5 DMK2V6H TN 5-HT 2C receptor (HTR2C) DMK2V6H MA Agonist DMK2V6H RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMK2V6H RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMK31M6 DI DMK31M6 DMK31M6 DN Isothiocyanate derivative 1 DMK31M6 TI TT2F4OL DMK31M6 TN Tissue transglutaminase (TG2) DMK31M6 MA Inhibitor DMK31M6 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMK31M6 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMK39S5 DI DMK39S5 DMK39S5 DN PMID26560530-Compound-18 DMK39S5 TI TT2F4OL DMK39S5 TN Tissue transglutaminase (TG2) DMK39S5 MA Inhibitor DMK39S5 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMK39S5 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTTDVOJ DMK3GRZ TN Tropomyosin-related kinase A (TrkA) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTXABCW DMK3GRZ TN NT-3 growth factor receptor (TrkC) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTKN7QR DMK3GRZ TN BDNF/NT-3 growth factors receptor (TrkB) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3TMD DI DMK3TMD DMK3TMD DN PMID25656651-Compound-7 DMK3TMD TI TTS7G69 DMK3TMD TN Fusion protein Bcr-Abl (Bcr-Abl) DMK3TMD MA Inhibitor DMK3TMD RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMK3TMD RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMK3UJY DI DMK3UJY DMK3UJY DN Macrocycle derivative 5 DMK3UJY TI TT23XQV DMK3UJY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMK3UJY MA Inhibitor DMK3UJY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMK3UJY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMK3UJY DI DMK3UJY DMK3UJY DN Macrocycle derivative 5 DMK3UJY TI TT5YPJF DMK3UJY TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMK3UJY MA Inhibitor DMK3UJY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMK3UJY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMK4LOH DI DMK4LOH DMK4LOH DN Pyrrolo[2,3-d]pyrimidine derivative 14 DMK4LOH TI TTGM6VW DMK4LOH TN Tyrosine-protein kinase BTK (ATK) DMK4LOH MA Inhibitor DMK4LOH RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMK4LOH RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMK4Y71 DI DMK4Y71 DMK4Y71 DN N-acylpyrrolidine ether derivative 2 DMK4Y71 TI TTTDVOJ DMK4Y71 TN Tropomyosin-related kinase A (TrkA) DMK4Y71 MA Inhibitor DMK4Y71 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMK4Y71 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMK5G7D DI DMK5G7D DMK5G7D DN Spirolaxine derivative 1 DMK5G7D TI TTZMAO3 DMK5G7D TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMK5G7D MA Agonist DMK5G7D RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMK5G7D RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMK5HAC DI DMK5HAC DMK5HAC DN Tarizine derivative 1 DMK5HAC TI TT4G2JS DMK5HAC TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMK5HAC MA Inhibitor DMK5HAC RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK5HAC RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK5M8Q DI DMK5M8Q DMK5M8Q DN Isoxazoline derivative 2 DMK5M8Q TI TTDP1UC DMK5M8Q TN Fatty acid amide hydrolase (FAAH) DMK5M8Q MA Inhibitor DMK5M8Q RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMK5M8Q RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMK5YJI DI DMK5YJI DMK5YJI DN Pyrido/pyrrolo-fused pyrimidine derivative 1 DMK5YJI TI TTSCIM2 DMK5YJI TN Extracellular lysophospholipase D (E-NPP2) DMK5YJI MA Inhibitor DMK5YJI RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMK5YJI RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMK6PFQ DI DMK6PFQ DMK6PFQ DN Aryl mannoside derivative 8 DMK6PFQ TI TTTCRU2 DMK6PFQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMK6PFQ MA Antagonist DMK6PFQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMK6PFQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMK6RFS DI DMK6RFS DMK6RFS DN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 DMK6RFS TI TTRMX3V DMK6RFS TN Janus kinase 2 (JAK-2) DMK6RFS MA Inhibitor DMK6RFS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK6RFS RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK6RFS DI DMK6RFS DMK6RFS DN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 DMK6RFS TI TT6DM01 DMK6RFS TN Janus kinase 1 (JAK-1) DMK6RFS MA Inhibitor DMK6RFS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK6RFS RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK72JS DI DMK72JS DMK72JS DN PMID27788040-Compound-5c DMK72JS TI TTV1C0Z DMK72JS TN Neuropeptide S receptor (NPSR) DMK72JS MA Antagonist DMK72JS RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMK72JS RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMK75BT DI DMK75BT DMK75BT DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 DMK75BT TI TTSXVID DMK75BT TN Nuclear factor NF-kappa-B (NFKB) DMK75BT MA Inhibitor DMK75BT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMK75BT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMK7DJ2 DI DMK7DJ2 DMK7DJ2 DN Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 DMK7DJ2 TI TT1RWNJ DMK7DJ2 TN Tyrosine-protein kinase Lyn (JTK8) DMK7DJ2 MA Inhibitor DMK7DJ2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK7DJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK7DJ2 DI DMK7DJ2 DMK7DJ2 DN Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 DMK7DJ2 TI TTRMX3V DMK7DJ2 TN Janus kinase 2 (JAK-2) DMK7DJ2 MA Inhibitor DMK7DJ2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK7DJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK7DJR DI DMK7DJR DMK7DJR DN Carbamide derivative 11 DMK7DJR TI TTL7C8Q DMK7DJR TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMK7DJR MA Inhibitor DMK7DJR RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMK7DJR RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMK7F3A DI DMK7F3A DMK7F3A DN Pyrazolopyrimidine acetamide analog 2 DMK7F3A TI TTPTXIN DMK7F3A TN Translocator protein (TSPO) DMK7F3A MA Ligand DMK7F3A RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMK7F3A RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMK820T DI DMK820T DMK820T DN Pyrrolo-pyridinone derivative 1 DMK820T TI TT4DXQT DMK820T TN Proto-oncogene c-Ret (RET) DMK820T MA Inhibitor DMK820T RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMK820T RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMK8V7A DI DMK8V7A DMK8V7A DN Imidazo[1,2-b]pyridazine derivative 5 DMK8V7A TI TTTDVOJ DMK8V7A TN Tropomyosin-related kinase A (TrkA) DMK8V7A MA Inhibitor DMK8V7A RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK8V7A RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK90ED DI DMK90ED DMK90ED DN PMID25435179-Compound-WO2013059594(IV) DMK90ED TI TTSCO7R DMK90ED TN NAD-dependent deacetylase sirtuin (SIRT) DMK90ED MA Inhibitor DMK90ED RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMK90ED RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMK9DH7 DI DMK9DH7 DMK9DH7 DN PMID25980951-Compound-26 DMK9DH7 TI TTR7B60 DMK9DH7 TN X-linked inhibitor of apoptosis protein (XIAP) DMK9DH7 MA Antagonist DMK9DH7 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMK9DH7 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMK9FJG DI DMK9FJG DMK9FJG DN US9073931, E2 DMK9FJG TI TTECBXN DMK9FJG TN Oxysterols receptor LXR-alpha (NR1H3) DMK9FJG MA Inhibitor DMK9FJG RN Liver X receptor modulators. US9073931. DMK9FJG RU http://www.freepatentsonline.com/US9073931.html DMK9P7S DI DMK9P7S DMK9P7S DN Imidazole derivative 8 DMK9P7S TI TTTJZ4M DMK9P7S TN Prolylcarboxypeptidase (PRCP) DMK9P7S MA Inhibitor DMK9P7S RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMK9P7S RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMK9TJP DI DMK9TJP DMK9TJP DN PMID30273516-Compound-13 DMK9TJP TI TTCW0KX DMK9TJP TN Glutaminase (GLS) DMK9TJP MA Inhibitor DMK9TJP RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMK9TJP RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMK9XV8 DI DMK9XV8 DMK9XV8 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 DMK9XV8 TI TTULVH8 DMK9XV8 TN Tyrosinase (TYR) DMK9XV8 MA Inhibitor DMK9XV8 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMK9XV8 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKAFPC DI DMKAFPC DMKAFPC DN PMID29334795-Compound-62 DMKAFPC TI TT9JNIC DMKAFPC TN Histamine H3 receptor (H3R) DMKAFPC MA Inhibitor DMKAFPC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKAFPC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKAFPC DI DMKAFPC DMKAFPC DN PMID29334795-Compound-62 DMKAFPC TI TTEX248 DMKAFPC TN Dopamine D2 receptor (D2R) DMKAFPC MA Ligand DMKAFPC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKAFPC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKB7XV DI DMKB7XV DMKB7XV DN PMID25656651-Compound-28b DMKB7XV TI TT3PJMV DMKB7XV TN Tyrosine-protein kinase ABL1 (ABL) DMKB7XV MA Inhibitor DMKB7XV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKB7XV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKBZDP DI DMKBZDP DMKBZDP DN PMID27607364-Compound-4 DMKBZDP TI TTPTXIN DMKBZDP TN Translocator protein (TSPO) DMKBZDP MA Ligand DMKBZDP RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKBZDP RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKC6SA DI DMKC6SA DMKC6SA DN PMID26004420-Compound-WO2014085210C DMKC6SA TI TTJ13ST DMKC6SA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMKC6SA MA Inhibitor DMKC6SA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMKC6SA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMKCARH DI DMKCARH DMKCARH DN PMID25666693-Compound-53 DMKCARH TI TTMI6F5 DMKCARH TN Transient receptor potential cation channel V1 (TRPV1) DMKCARH MA Antagonist DMKCARH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKCARH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKCJE1 DI DMKCJE1 DMKCJE1 DN Pyrazole derivative 69 DMKCJE1 TI TTJQOD7 DMKCJE1 TN 5-HT 2A receptor (HTR2A) DMKCJE1 MA Antagonist DMKCJE1 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMKCJE1 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMKCYSD DI DMKCYSD DMKCYSD DN Isoxazoles and isoxazoline derivative 2 DMKCYSD TI TTIY56R DMKCYSD TN Kynurenine 3-hydroxylase (KMO) DMKCYSD MA Inhibitor DMKCYSD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMKCYSD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMKD470 DI DMKD470 DMKD470 DN PMID30185082-Compound-64 DMKD470 TI TT5TPI6 DMKD470 TN Opioid receptor sigma 1 (OPRS1) DMKD470 MA Ligand DMKD470 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKD470 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKD470 DI DMKD470 DMKD470 DN PMID30185082-Compound-64 DMKD470 TI TT9NXW4 DMKD470 TN Sigma intracellular receptor 2 (TMEM97) DMKD470 MA Ligand DMKD470 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKD470 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKDBQG DI DMKDBQG DMKDBQG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 DMKDBQG TI TTULVH8 DMKDBQG TN Tyrosinase (TYR) DMKDBQG MA Inhibitor DMKDBQG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMKDBQG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKDTO4 DI DMKDTO4 DMKDTO4 DN Quinoline and quinazoline derivative 1 DMKDTO4 TI TTUTJGQ DMKDTO4 TN Vascular endothelial growth factor receptor 2 (KDR) DMKDTO4 MA Inhibitor DMKDTO4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMKDTO4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMKDX6W DI DMKDX6W DMKDX6W DN Pyrrolidine carboxamide derivative 2 DMKDX6W TI TTTJZ4M DMKDX6W TN Prolylcarboxypeptidase (PRCP) DMKDX6W MA Inhibitor DMKDX6W RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMKDX6W RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMKDZMQ DI DMKDZMQ DMKDZMQ DN 4-Hydroxybenzylalcohol DMKDZMQ TI TTGP7BY DMKDZMQ TN Monoamine oxidase type B (MAO-B) DMKDZMQ MA Inhibitor DMKDZMQ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMKDZMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMKE5PB DI DMKE5PB DMKE5PB DN Aromatic hydrazine carboxyimidoamide derivative 4 DMKE5PB TI TTULVH8 DMKE5PB TN Tyrosinase (TYR) DMKE5PB MA Inhibitor DMKE5PB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMKE5PB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKE7YO DI DMKE7YO DMKE7YO DN Pyrazolo[1,5-a]pyrimidine derivative 25 DMKE7YO TI TTTDVOJ DMKE7YO TN Tropomyosin-related kinase A (TrkA) DMKE7YO MA Inhibitor DMKE7YO RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKE7YO RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKEOH8 DI DMKEOH8 DMKEOH8 DN 3-substituted-2-furancarboxylic acid hydrazide derivative 1 DMKEOH8 TI TT9O6WS DMKEOH8 TN Glucagon receptor (GCGR) DMKEOH8 MA Antagonist DMKEOH8 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMKEOH8 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMKES0G DI DMKES0G DMKES0G DN Biaryl mannoside derivative 11 DMKES0G TI TTTCRU2 DMKES0G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKES0G MA Antagonist DMKES0G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKES0G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKEVDL DI DMKEVDL DMKEVDL DN BDBM50173327 DMKEVDL TI TTTCXO0 DMKEVDL TN G protein-coupled receptor kinase 5 (GRK5) DMKEVDL MA Inhibitor DMKEVDL RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DMKEVDL RU http://www.freepatentsonline.com/US10023564.html DMKEX51 DI DMKEX51 DMKEX51 DN US8933228, Ref 2 DMKEX51 TI TT42OGM DMKEX51 TN Hematopoietic cell kinase (HCK) DMKEX51 MA Inhibitor DMKEX51 RN 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347. DMKEX51 RU http://www.freepatentsonline.com/US9724347.html DMKF26Z DI DMKF26Z DMKF26Z DN PMID26560530-Compound-13 DMKF26Z TI TT2F4OL DMKF26Z TN Tissue transglutaminase (TG2) DMKF26Z MA Inhibitor DMKF26Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMKF26Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMKF26Z DI DMKF26Z DMKF26Z DN PMID26560530-Compound-13 DMKF26Z TI TTXI2RA DMKF26Z TN Coagulation factor XIIIA (F13A1) DMKF26Z MA Inhibitor DMKF26Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMKF26Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMKF8HI DI DMKF8HI DMKF8HI DN Pyrrolo[3,2-c]pyridine derivative 1 DMKF8HI TI TTTDVOJ DMKF8HI TN Tropomyosin-related kinase A (TrkA) DMKF8HI MA Inhibitor DMKF8HI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMKF8HI RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMKFEO4 DI DMKFEO4 DMKFEO4 DN PMID28074661-Compound-US20120264760C86 DMKFEO4 TI TTL7C8Q DMKFEO4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMKFEO4 MA Inhibitor DMKFEO4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMKFEO4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMKFPJ7 DI DMKFPJ7 DMKFPJ7 DN Indomethacin analog 2 DMKFPJ7 TI TT5ZWB6 DMKFPJ7 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMKFPJ7 MA Inhibitor; Antagonist; Blocker DMKFPJ7 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMKFPJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMKFV67 DI DMKFV67 DMKFV67 DN Aromatic bicyclic compound 2 DMKFV67 TI TT6PKBN DMKFV67 TN Proto-oncogene c-Src (SRC) DMKFV67 MA Inhibitor DMKFV67 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKFV67 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKFV67 DI DMKFV67 DMKFV67 DN Aromatic bicyclic compound 2 DMKFV67 TI TTRMX3V DMKFV67 TN Janus kinase 2 (JAK-2) DMKFV67 MA Inhibitor DMKFV67 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKFV67 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKFX2G DI DMKFX2G DMKFX2G DN PMID25435285-Compound-16 DMKFX2G TI TTXJ47W DMKFX2G TN Metabotropic glutamate receptor 2 (mGluR2) DMKFX2G MA Antagonist DMKFX2G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMKFX2G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMKFX2G DI DMKFX2G DMKFX2G DN PMID25435285-Compound-16 DMKFX2G TI TT8A9EF DMKFX2G TN Metabotropic glutamate receptor 3 (mGluR3) DMKFX2G MA Antagonist DMKFX2G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMKFX2G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMKGJ1S DI DMKGJ1S DMKGJ1S DN Tetra-hydro-pyrazolopyrazine derivative 3 DMKGJ1S TI TTHS256 DMKGJ1S TN Metabotropic glutamate receptor 5 (mGluR5) DMKGJ1S MA Modulator DMKGJ1S RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMKGJ1S RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMKHF39 DI DMKHF39 DMKHF39 DN 1,2,3-triazole derivative 1 DMKHF39 TI TT6OEDT DMKHF39 TN Cannabinoid receptor 1 (CB1) DMKHF39 MA Antagonist DMKHF39 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMKHF39 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMKHO8T DI DMKHO8T DMKHO8T DN PMID25666693-Compound-27 DMKHO8T TI TTMI6F5 DMKHO8T TN Transient receptor potential cation channel V1 (TRPV1) DMKHO8T MA Antagonist DMKHO8T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKHO8T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKHTE1 DI DMKHTE1 DMKHTE1 DN PMID29338548-Compound-19 DMKHTE1 TI TTHJTF7 DMKHTE1 TN Glycine transporter GlyT-1 (SLC6A9) DMKHTE1 MA Inhibitor DMKHTE1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMKHTE1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMKHWN9 DI DMKHWN9 DMKHWN9 DN Pyrrolo-pyrimidine derivative 3 DMKHWN9 TI TT4DXQT DMKHWN9 TN Proto-oncogene c-Ret (RET) DMKHWN9 MA Inhibitor DMKHWN9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMKHWN9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMKIS26 DI DMKIS26 DMKIS26 DN PMID29473428-Compound-54 DMKIS26 TI TTZJYKH DMKIS26 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKIS26 MA Inhibitor DMKIS26 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKIS26 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKJ1HC DI DMKJ1HC DMKJ1HC DN PMID25684022-Compound-WO2008079988 DMKJ1HC TI TTCZOF2 DMKJ1HC TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMKJ1HC MA Inhibitor DMKJ1HC RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMKJ1HC RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMKJ27D DI DMKJ27D DMKJ27D DN Peptide analog 16 DMKJ27D TI TTSJMN8 DMKJ27D TN Immunoproteasome complex (IP) DMKJ27D MA Inhibitor DMKJ27D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMKJ27D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMKJ3PC DI DMKJ3PC DMKJ3PC DN Pyridazin-3(2H)-one derivative 1 DMKJ3PC TI TT9JNIC DMKJ3PC TN Histamine H3 receptor (H3R) DMKJ3PC MA Inverse agonist DMKJ3PC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKJ3PC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKJL5T DI DMKJL5T DMKJL5T DN Heteroaromatic ring derivative 3 DMKJL5T TI TTSCIM2 DMKJL5T TN Extracellular lysophospholipase D (E-NPP2) DMKJL5T MA Inhibitor DMKJL5T RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMKJL5T RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMKJN9G DI DMKJN9G DMKJN9G DN Quinolinyl pyrazinyl urea derivative 2 DMKJN9G TI TTRZQE3 DMKJN9G TN Glycogen synthase kinase-3 alpha (GSK-3A) DMKJN9G MA Inhibitor DMKJN9G RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMKJN9G RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TTNR0UQ DMKJOMC TN Lysine-specific histone demethylase 1 (LSD) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TT8VP2T DMKJOMC TN Lysine-specific histone demethylase 1B (KDM1B) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TTGP7BY DMKJOMC TN Monoamine oxidase type B (MAO-B) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TT3WG5C DMKJOMC TN Monoamine oxidase type A (MAO-A) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKLCZF DI DMKLCZF DMKLCZF DN US9216972, 94 DMKLCZF TI TTDYP7I DMKLCZF TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMKLCZF MA Inhibitor DMKLCZF RN Tricyclic heterocyclic compounds. US9216972. DMKLCZF RU http://www.freepatentsonline.com/US9216972.html DMKLJ6O DI DMKLJ6O DMKLJ6O DN US8586571, 12 DMKLJ6O TI TT0C8BY DMKLJ6O TN Plasma retinol-binding protein (RBP4) DMKLJ6O MA Inhibitor DMKLJ6O RN Heterocyclic compound. US8586571. DMKLJ6O RU http://www.freepatentsonline.com/US8586571.html DMKLO2H DI DMKLO2H DMKLO2H DN Fused benzoheterocycle amide derivative 1 DMKLO2H TI TTKFVXR DMKLO2H TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMKLO2H MA Inhibitor DMKLO2H RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMKLO2H RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMKLVE4 DI DMKLVE4 DMKLVE4 DN US10059720, Example 84 DMKLVE4 TI TTY2KP7 DMKLVE4 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMKLVE4 MA Inhibitor DMKLVE4 RN Pyridine derivative. US10059720. DMKLVE4 RU http://www.freepatentsonline.com/US10059720.html DMKLYCV DI DMKLYCV DMKLYCV DN US9127005, P0L DMKLYCV TI TT3T17P DMKLYCV TN Phospholipase D1 (PLD1) DMKLYCV MA Inhibitor DMKLYCV RN Isoform selective phospholipase D inhibitors. US9127005. DMKLYCV RU http://www.freepatentsonline.com/US9127005.html DMKM6BY DI DMKM6BY DMKM6BY DN Cyclopenta[d]pyrimidine derivative 1 DMKM6BY TI TTKN7QR DMKM6BY TN BDNF/NT-3 growth factors receptor (TrkB) DMKM6BY MA Inhibitor DMKM6BY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKM6BY RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKM6BY DI DMKM6BY DMKM6BY DN Cyclopenta[d]pyrimidine derivative 1 DMKM6BY TI TTXABCW DMKM6BY TN NT-3 growth factor receptor (TrkC) DMKM6BY MA Inhibitor DMKM6BY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKM6BY RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKM93Q DI DMKM93Q DMKM93Q DN US10150740, Example 4 DMKM93Q TI TTQFZWR DMKM93Q TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMKM93Q MA Inhibitor DMKM93Q RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DMKM93Q RU http://www.freepatentsonline.com/US10150740.html DMKMY4I DI DMKMY4I DMKMY4I DN PMID25656651-Compound-36d DMKMY4I TI TTIV39N DMKMY4I TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMKMY4I MA Inhibitor DMKMY4I RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKMY4I RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKMY4I DI DMKMY4I DMKMY4I DN PMID25656651-Compound-36d DMKMY4I TI TTS7G69 DMKMY4I TN Fusion protein Bcr-Abl (Bcr-Abl) DMKMY4I MA Inhibitor DMKMY4I RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKMY4I RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKN72Y DI DMKN72Y DMKN72Y DN PMID25666693-Compound-126 DMKN72Y TI TTMI6F5 DMKN72Y TN Transient receptor potential cation channel V1 (TRPV1) DMKN72Y MA Antagonist DMKN72Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKN72Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKNDMB DI DMKNDMB DMKNDMB DN US9024044, 3 DMKNDMB TI TTXL0GC DMKNDMB TN Enteropeptidase (TMPRSS15) DMKNDMB MA Inhibitor DMKNDMB RN Heteroarylcarboxylic acid ester derivative. US9024044. DMKNDMB RU http://www.freepatentsonline.com/US9024044.html DMKNITP DI DMKNITP DMKNITP DN Aminopyrimidine derivative 2 DMKNITP TI TTS7G69 DMKNITP TN Fusion protein Bcr-Abl (Bcr-Abl) DMKNITP MA Inhibitor DMKNITP RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKNITP RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKNU0Z DI DMKNU0Z DMKNU0Z DN PMID25666693-Compound-154 DMKNU0Z TI TTMI6F5 DMKNU0Z TN Transient receptor potential cation channel V1 (TRPV1) DMKNU0Z MA Antagonist DMKNU0Z RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKNU0Z RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKO4ZH DI DMKO4ZH DMKO4ZH DN PMID28270021-Compound-WO2014129431Example8-1 DMKO4ZH TI TTTDVOJ DMKO4ZH TN Tropomyosin-related kinase A (TrkA) DMKO4ZH MA Inhibitor DMKO4ZH RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMKO4ZH RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMKOSN5 DI DMKOSN5 DMKOSN5 DN PMID26161824-Compound-69 DMKOSN5 TI TT6OEDT DMKOSN5 TN Cannabinoid receptor 1 (CB1) DMKOSN5 MA Antagonist DMKOSN5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMKOSN5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMKP14O DI DMKP14O DMKP14O DN PMID30185082-Compound-54 DMKP14O TI TT9NXW4 DMKP14O TN Sigma intracellular receptor 2 (TMEM97) DMKP14O MA Ligand DMKP14O RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKP14O RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKP64Z DI DMKP64Z DMKP64Z DN PMID25399762-Compound-Figure3-Lycojaponicumin B DMKP64Z TI TT3WG5C DMKP64Z TN Monoamine oxidase type A (MAO-A) DMKP64Z MA Inhibitor DMKP64Z RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMKP64Z RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMKPAN3 DI DMKPAN3 DMKPAN3 DN Imidazo cyclohexylamine derivative 2 DMKPAN3 TI TTDIGC1 DMKPAN3 TN Dipeptidyl peptidase 4 (DPP-4) DMKPAN3 MA Inhibitor DMKPAN3 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMKPAN3 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMKPSIA DI DMKPSIA DMKPSIA DN Heterocyclic derivative 8 DMKPSIA TI TTCZOF2 DMKPSIA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMKPSIA MA Inhibitor DMKPSIA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMKPSIA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMKQ0GE DI DMKQ0GE DMKQ0GE DN SCHEMBL15198145 DMKQ0GE TI TTXHWA7 DMKQ0GE TN Ubiquitin-activating enzyme E1 (UBAE1) DMKQ0GE MA Inhibitor DMKQ0GE RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DMKQ0GE RU http://www.freepatentsonline.com/US10202389.html DMKQFTY DI DMKQFTY DMKQFTY DN Pyridino tricyclic compound 1 DMKQFTY TI TTZJYKH DMKQFTY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKQFTY MA Inhibitor DMKQFTY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKQFTY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKR5ZO DI DMKR5ZO DMKR5ZO DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 DMKR5ZO TI TTJW4LU DMKR5ZO TN Phosphodiesterase 10A (PDE10) DMKR5ZO MA Inhibitor DMKR5ZO RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKR5ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKR5ZO DI DMKR5ZO DMKR5ZO DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 DMKR5ZO TI TTJGW1Z DMKR5ZO TN Phosphodiesterase 2A (PDE2A) DMKR5ZO MA Inhibitor DMKR5ZO RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKR5ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKREJ2 DI DMKREJ2 DMKREJ2 DN Benzazepine derivative 2 DMKREJ2 TI TTWJBZ5 DMKREJ2 TN 5-HT 2C receptor (HTR2C) DMKREJ2 MA Agonist DMKREJ2 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMKREJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMKRUAN DI DMKRUAN DMKRUAN DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 DMKRUAN TI TTJW4LU DMKRUAN TN Phosphodiesterase 10A (PDE10) DMKRUAN MA Inhibitor DMKRUAN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKRUAN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKRUAN DI DMKRUAN DMKRUAN DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 DMKRUAN TI TTJGW1Z DMKRUAN TN Phosphodiesterase 2A (PDE2A) DMKRUAN MA Inhibitor DMKRUAN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKRUAN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKRUPW DI DMKRUPW DMKRUPW DN PMID29473428-Compound-39 DMKRUPW TI TTZJYKH DMKRUPW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKRUPW MA Antagonist DMKRUPW RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKRUPW RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKS7D9 DI DMKS7D9 DMKS7D9 DN US9656955, Example 652 DMKS7D9 TI TTYJRN5 DMKS7D9 TN N-acetylglucosaminyltransferase I (NAGAT1) DMKS7D9 MA Inhibitor DMKS7D9 RN Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955. DMKS7D9 RU http://www.freepatentsonline.com/US9656955.html DMKS7O3 DI DMKS7O3 DMKS7O3 DN Chlorobenzamide derivative 2 DMKS7O3 TI TT473XN DMKS7O3 TN P2X purinoceptor 7 (P2RX7) DMKS7O3 MA Antagonist DMKS7O3 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMKS7O3 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMKSNZG DI DMKSNZG DMKSNZG DN Isoxazole-based bicyclic compound 6 DMKSNZG TI TTE4BSY DMKSNZG TN Bromodomain and extraterminal domain protein (BET) DMKSNZG MA Inhibitor DMKSNZG RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMKSNZG RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMKT19M DI DMKT19M DMKT19M DN Diterpenoid derivative 2 DMKT19M TI TTA6ZN2 DMKT19M TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKT19M MA Activator DMKT19M RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKT19M RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKT19M DI DMKT19M DMKT19M DN Diterpenoid derivative 2 DMKT19M TI TT3Z6Y9 DMKT19M TN Cysteines of Keap1 (KEAP1 Cysteines) DMKT19M MA Modulator DMKT19M RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKT19M RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKT7MD DI DMKT7MD DMKT7MD DN Bicyclic heteroaryl carboxamide analog 2 DMKT7MD TI TTHS256 DMKT7MD TN Metabotropic glutamate receptor 5 (mGluR5) DMKT7MD MA Modulator DMKT7MD RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMKT7MD RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMKTFJ2 DI DMKTFJ2 DMKTFJ2 DN Pyrazole and thiophene derivative 1 DMKTFJ2 TI TTRA6BO DMKTFJ2 TN Bromodomain-containing protein 4 (BRD4) DMKTFJ2 MA Inhibitor DMKTFJ2 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMKTFJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMKTJAH DI DMKTJAH DMKTJAH DN Mannoside derivative 8 DMKTJAH TI TTTCRU2 DMKTJAH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKTJAH MA Antagonist DMKTJAH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKTJAH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKTMCH DI DMKTMCH DMKTMCH DN AC1LDDOQ DMKTMCH TI TT3ZS42 DMKTMCH TN Phosphodiesterase 1B (PDE1B) DMKTMCH MA Inhibitor DMKTMCH RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DMKTMCH RU http://www.freepatentsonline.com/US10092575.html DMKTNBC DI DMKTNBC DMKTNBC DN Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC TI TTA6ZN2 DMKTNBC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKTNBC MA Activator DMKTNBC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKTNBC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKTNBC DI DMKTNBC DMKTNBC DN Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC TI TT3Z6Y9 DMKTNBC TN Cysteines of Keap1 (KEAP1 Cysteines) DMKTNBC MA Modulator DMKTNBC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKTNBC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKTQX8 DI DMKTQX8 DMKTQX8 DN PMID27724045-Compound-29 DMKTQX8 TI TT473XN DMKTQX8 TN P2X purinoceptor 7 (P2RX7) DMKTQX8 MA Antagonist DMKTQX8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMKTQX8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMKU51G DI DMKU51G DMKU51G DN Thiazole derivative 3 DMKU51G TI TTA6ZN2 DMKU51G TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKU51G MA Inhibitor DMKU51G RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKU51G RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKU6C3 DI DMKU6C3 DMKU6C3 DN PMID25666693-Compound-18 DMKU6C3 TI TTMI6F5 DMKU6C3 TN Transient receptor potential cation channel V1 (TRPV1) DMKU6C3 MA Antagonist DMKU6C3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKU6C3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKU7GD DI DMKU7GD DMKU7GD DN PMID27376512-Compound-Table1Example8 DMKU7GD TI TT6S2FE DMKU7GD TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMKU7GD MA Inhibitor DMKU7GD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMKU7GD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMKULV8 DI DMKULV8 DMKULV8 DN Quinoline derivative 17 DMKULV8 TI TTPADOQ DMKULV8 TN HMG-CoA reductase (HMGCR) DMKULV8 MA Inhibitor DMKULV8 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMKULV8 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMKUT6S DI DMKUT6S DMKUT6S DN Indazole amide derivative 1 DMKUT6S TI TTKFVXR DMKUT6S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMKUT6S MA Inhibitor DMKUT6S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMKUT6S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMKVRTM DI DMKVRTM DMKVRTM DN PMID28394193-Compound-Figure5aVIII DMKVRTM TI TT9MZCQ DMKVRTM TN Enhancer of zeste homolog 2 (EZH2) DMKVRTM MA Inhibitor DMKVRTM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMKVRTM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMKWFVP DI DMKWFVP DMKWFVP DN PMID25991433-Compound-E1 DMKWFVP TI TT0K6EO DMKWFVP TN Stress-activated protein kinase JNK1 (JNK1) DMKWFVP MA Inhibitor DMKWFVP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMKWFVP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMKX5R8 DI DMKX5R8 DMKX5R8 DN PMID29130358-Compound-Figure16(9a) DMKX5R8 TI TTHY57M DMKX5R8 TN Matrix metalloproteinase-13 (MMP-13) DMKX5R8 MA Inhibitor DMKX5R8 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMKX5R8 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMKX5R8 DI DMKX5R8 DMKX5R8 DN PMID29130358-Compound-Figure16(9a) DMKX5R8 TI TTLM12X DMKX5R8 TN Matrix metalloproteinase-2 (MMP-2) DMKX5R8 MA Inhibitor DMKX5R8 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMKX5R8 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMKXD2V DI DMKXD2V DMKXD2V DN Benzo[d]oxazol-2(3H)-one derivative 1 DMKXD2V TI TT9JNIC DMKXD2V TN Histamine H3 receptor (H3R) DMKXD2V MA Inhibitor DMKXD2V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKXD2V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKXD2V DI DMKXD2V DMKXD2V DN Benzo[d]oxazol-2(3H)-one derivative 1 DMKXD2V TI TTEX248 DMKXD2V TN Dopamine D2 receptor (D2R) DMKXD2V MA Ligand DMKXD2V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKXD2V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKXRJ4 DI DMKXRJ4 DMKXRJ4 DN US8889696, 39 DMKXRJ4 TI TTUWGRA DMKXRJ4 TN Protein kinase C zeta (PRKCZ) DMKXRJ4 MA Inhibitor DMKXRJ4 RN Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696. DMKXRJ4 RU http://www.freepatentsonline.com/US8889696.html DMKXRYM DI DMKXRYM DMKXRYM DN 1,2,4-triazole [4,3-a]quinoxaline derivative 3 DMKXRYM TI TTJGW1Z DMKXRYM TN Phosphodiesterase 2A (PDE2A) DMKXRYM MA Inhibitor DMKXRYM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKXRYM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKXRYM DI DMKXRYM DMKXRYM DN 1,2,4-triazole [4,3-a]quinoxaline derivative 3 DMKXRYM TI TTJW4LU DMKXRYM TN Phosphodiesterase 10A (PDE10) DMKXRYM MA Inhibitor DMKXRYM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKXRYM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKXT7H DI DMKXT7H DMKXT7H DN Biaryl mannoside derivative 15 DMKXT7H TI TTTCRU2 DMKXT7H TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKXT7H MA Antagonist DMKXT7H RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKXT7H RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKXZUA DI DMKXZUA DMKXZUA DN Tetra-substituted urea derivative 2 DMKXZUA TI TTDP1UC DMKXZUA TN Fatty acid amide hydrolase (FAAH) DMKXZUA MA Inhibitor DMKXZUA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMKXZUA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMKXZYC DI DMKXZYC DMKXZYC DN PMID28350212-Compound-22 DMKXZYC TI TTZS04O DMKXZYC TN Gamma-secretase subunit APH-1A/1B (APH-1) DMKXZYC MA Inhibitor DMKXZYC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMKXZYC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMKYNB0 DI DMKYNB0 DMKYNB0 DN US8703720, 15 DMKYNB0 TI TTO3NYT DMKYNB0 TN Galectin-1 (LGALS1) DMKYNB0 MA Inhibitor DMKYNB0 RN Galactoside inhibitors of galectins. US8703720. DMKYNB0 RU http://www.freepatentsonline.com/US8703720.html DMKYOLV DI DMKYOLV DMKYOLV DN Peptide analog 7 DMKYOLV TI TTH8FZW DMKYOLV TN Signal transducer and activator of transcription 3 (STAT3) DMKYOLV MA Inhibitor DMKYOLV RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKYOLV RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKYX7J DI DMKYX7J DMKYX7J DN Pyrazolodihydropyridine derivative 1 DMKYX7J TI TTRZQE3 DMKYX7J TN Glycogen synthase kinase-3 alpha (GSK-3A) DMKYX7J MA Inhibitor DMKYX7J RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMKYX7J RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMKZ6MD DI DMKZ6MD DMKZ6MD DN Quinazoline derivative 6 DMKZ6MD TI TTPTXIN DMKZ6MD TN Translocator protein (TSPO) DMKZ6MD MA Ligand DMKZ6MD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKZ6MD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKZC4V DI DMKZC4V DMKZC4V DN US9586945, 19a DMKZC4V TI TTYJRN5 DMKZC4V TN N-acetylglucosaminyltransferase I (NAGAT1) DMKZC4V MA Inhibitor DMKZC4V RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DMKZC4V RU http://www.freepatentsonline.com/US9586945.html DMKZF8E DI DMKZF8E DMKZF8E DN PMID27215781-Compound-25 DMKZF8E TI TTMSFAW DMKZF8E TN Cannabinoid receptor 2 (CB2) DMKZF8E MA Agonist DMKZF8E RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMKZF8E RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMKZLCQ DI DMKZLCQ DMKZLCQ DN Bidentate pyrazolopyrimidine acetamide analog 4 DMKZLCQ TI TTPTXIN DMKZLCQ TN Translocator protein (TSPO) DMKZLCQ MA Ligand DMKZLCQ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKZLCQ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKZTVR DI DMKZTVR DMKZTVR DN PMID26666989-Compound-Figure9middle13 DMKZTVR TI TT8BUGW DMKZTVR TN Glycogen phosphorylase (PYG) DMKZTVR MA Inhibitor DMKZTVR RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMKZTVR RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMKZUO4 DI DMKZUO4 DMKZUO4 DN Piperazine carbamic compound 4 DMKZUO4 TI TTSINOV DMKZUO4 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMKZUO4 MA Inhibitor DMKZUO4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMKZUO4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMKZUO4 DI DMKZUO4 DMKZUO4 DN Piperazine carbamic compound 4 DMKZUO4 TI TTZ963I DMKZUO4 TN Monoglyceride lipase (MAGL) DMKZUO4 MA Inhibitor DMKZUO4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMKZUO4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DML1IXV DI DML1IXV DML1IXV DN Aryl oxyanilide derivative 1 DML1IXV TI TTPTXIN DML1IXV TN Translocator protein (TSPO) DML1IXV MA Ligand DML1IXV RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DML1IXV RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DML1U69 DI DML1U69 DML1U69 DN PMID25553724-Compound-WO2013082253 34 DML1U69 TI TTSXVID DML1U69 TN Nuclear factor NF-kappa-B (NFKB) DML1U69 MA Modulator DML1U69 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DML1U69 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DML25WY DI DML25WY DML25WY DN PMID27841045-Compound-137 DML25WY TI TT7RJY8 DML25WY TN Xanthine dehydrogenase/oxidase (XDH) DML25WY MA Inhibitor DML25WY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DML25WY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DML2B58 DI DML2B58 DML2B58 DN Alkyl mannoside derivative 3 DML2B58 TI TTTCRU2 DML2B58 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DML2B58 MA Antagonist DML2B58 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DML2B58 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DML2B7G DI DML2B7G DML2B7G DN Beta-cyclodextrin conjugate derivative 5 DML2B7G TI TTTCRU2 DML2B7G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DML2B7G MA Antagonist DML2B7G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DML2B7G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DML2E8S DI DML2E8S DML2E8S DN Pyrimidinyl compound 6 DML2E8S TI TTH5TC2 DML2E8S TN NF-kappa-B-activating kinase (TBK1) DML2E8S MA Inhibitor DML2E8S RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DML2E8S RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DML2PWF DI DML2PWF DML2PWF DN Tricyclic isoxazoloquinazoline derivative 3 DML2PWF TI TTP7EGM DML2PWF TN Dual specificity protein kinase TTK (MPS1) DML2PWF MA Inhibitor DML2PWF RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DML2PWF RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DML2PWF DI DML2PWF DML2PWF DN Tricyclic isoxazoloquinazoline derivative 3 DML2PWF TI TT5OU0D DML2PWF TN PRKR-like endoplasmic reticulum kinase (PERK) DML2PWF MA Inhibitor DML2PWF RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DML2PWF RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DML2VUC DI DML2VUC DML2VUC DN PMID28350212-Compound-25 DML2VUC TI TTZS04O DML2VUC TN Gamma-secretase subunit APH-1A/1B (APH-1) DML2VUC MA Inhibitor DML2VUC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DML2VUC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DML32R8 DI DML32R8 DML32R8 DN VX-148 DML32R8 TI TTL7C8Q DML32R8 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DML32R8 MA Inhibitor DML32R8 RN Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7. DML32R8 RU https://pubmed.ncbi.nlm.nih.gov/12183689 DML3KHF DI DML3KHF DML3KHF DN PMID25666693-Compound-39 DML3KHF TI TTMI6F5 DML3KHF TN Transient receptor potential cation channel V1 (TRPV1) DML3KHF MA Antagonist DML3KHF RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML3KHF RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML3PE4 DI DML3PE4 DML3PE4 DN Benzimidazole derivative 10 DML3PE4 TI TTQR74A DML3PE4 TN Proteinase activated receptor 2 (PAR2) DML3PE4 MA Antagonist DML3PE4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DML3PE4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DML47KS DI DML47KS DML47KS DN PMID29865878-Compound-62 DML47KS TI TTEAD9J DML47KS TN Proteasome beta-8 (PS beta-8) DML47KS MA Inhibitor DML47KS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML47KS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML48NA DI DML48NA DML48NA DN PMID25435285-Compound-50 DML48NA TI TTXJ47W DML48NA TN Metabotropic glutamate receptor 2 (mGluR2) DML48NA MA Antagonist DML48NA RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DML48NA RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DML49UI DI DML49UI DML49UI DN PMID27109571-Compound-23 DML49UI TI TTNT2S6 DML49UI TN Fatty acid-binding protein 5 (FABP5) DML49UI MA Inhibitor DML49UI RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DML49UI RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DML49UI DI DML49UI DML49UI DN PMID27109571-Compound-23 DML49UI TI TTHWMFZ DML49UI TN Fatty acid-binding protein 4 (FABP4) DML49UI MA Inhibitor DML49UI RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DML49UI RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DML4AVX DI DML4AVX DML4AVX DN PMID27841045-Compound-156 DML4AVX TI TT7RJY8 DML4AVX TN Xanthine dehydrogenase/oxidase (XDH) DML4AVX MA Inhibitor DML4AVX RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DML4AVX RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DML4C6D DI DML4C6D DML4C6D DN PMID27977313-Compound-42 DML4C6D TI TTR7UJ3 DML4C6D TN Cytoplasmic thioredoxin reductase (TXNRD1) DML4C6D MA Inhibitor DML4C6D RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DML4C6D RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DML4OYQ DI DML4OYQ DML4OYQ DN Pyrimidinedione derivative 1 DML4OYQ TI TTDIGC1 DML4OYQ TN Dipeptidyl peptidase 4 (DPP-4) DML4OYQ MA Inhibitor DML4OYQ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DML4OYQ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DML4XJ2 DI DML4XJ2 DML4XJ2 DN Peptide analog 27 DML4XJ2 TI TT68GPI DML4XJ2 TN Proteasome beta-5 (PS beta-5) DML4XJ2 MA Inhibitor DML4XJ2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML4XJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML4XJ2 DI DML4XJ2 DML4XJ2 DN Peptide analog 27 DML4XJ2 TI TTEAD9J DML4XJ2 TN Proteasome beta-8 (PS beta-8) DML4XJ2 MA Inhibitor DML4XJ2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML4XJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML5G6D DI DML5G6D DML5G6D DN PMID29473428-Compound-71 DML5G6D TI TTZJYKH DML5G6D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DML5G6D MA Inhibitor DML5G6D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DML5G6D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DML5I9K DI DML5I9K DML5I9K DN PMID26394986-Compound-50 DML5I9K TI TTH8FZW DML5I9K TN Signal transducer and activator of transcription 3 (STAT3) DML5I9K MA Inhibitor DML5I9K RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DML5I9K RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DML5KXB DI DML5KXB DML5KXB DN US20160326143, 3 DML5KXB TI TTW7OTG DML5KXB TN Leukotriene C4 synthase (LTC4S) DML5KXB MA Inhibitor DML5KXB RN COMPOUNDS AND USES. US20160326143. DML5KXB RU http://www.freepatentsonline.com/US20160326143.html DML5P6O DI DML5P6O DML5P6O DN Peptide analog 33 DML5P6O TI TT68GPI DML5P6O TN Proteasome beta-5 (PS beta-5) DML5P6O MA Inhibitor DML5P6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML5P6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML5P6O DI DML5P6O DML5P6O DN Peptide analog 33 DML5P6O TI TTEAD9J DML5P6O TN Proteasome beta-8 (PS beta-8) DML5P6O MA Inhibitor DML5P6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML5P6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML63B7 DI DML63B7 DML63B7 DN Aromatic hydrazine carboxyimidoamide derivative 3 DML63B7 TI TTULVH8 DML63B7 TN Tyrosinase (TYR) DML63B7 MA Inhibitor DML63B7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DML63B7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DML6PE0 DI DML6PE0 DML6PE0 DN PMID28394193-Compound-Figure3bII DML6PE0 TI TT9MZCQ DML6PE0 TN Enhancer of zeste homolog 2 (EZH2) DML6PE0 MA Inhibitor DML6PE0 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DML6PE0 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DML6V78 DI DML6V78 DML6V78 DN Pyrazolo-triazine derivative 2 DML6V78 TI TTQYF7G DML6V78 TN Cyclin-dependent kinase 7 (CDK7) DML6V78 MA Inhibitor DML6V78 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DML6V78 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DML6V78 DI DML6V78 DML6V78 DN Pyrazolo-triazine derivative 2 DML6V78 TI TT7HF4W DML6V78 TN Cyclin-dependent kinase 2 (CDK2) DML6V78 MA Inhibitor DML6V78 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DML6V78 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DML724H DI DML724H DML724H DN Tricyclic indole compound 11 DML724H TI TTPTXIN DML724H TN Translocator protein (TSPO) DML724H MA Ligand DML724H RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DML724H RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DML76MF DI DML76MF DML76MF DN PMID25666693-Compound-41 DML76MF TI TTMI6F5 DML76MF TN Transient receptor potential cation channel V1 (TRPV1) DML76MF MA Antagonist DML76MF RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML76MF RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML79XQ DI DML79XQ DML79XQ DN PMID28092474-Compound-32x DML79XQ TI TT6R7JZ DML79XQ TN Histone deacetylase 1 (HDAC1) DML79XQ MA Inhibitor DML79XQ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DML79XQ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DML79XQ DI DML79XQ DML79XQ DN PMID28092474-Compound-32x DML79XQ TI TT5ZKDI DML79XQ TN Histone deacetylase 6 (HDAC6) DML79XQ MA Inhibitor DML79XQ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DML79XQ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DML7ONU DI DML7ONU DML7ONU DN Resorcinol compound 29 DML7ONU TI TTULVH8 DML7ONU TN Tyrosinase (TYR) DML7ONU MA Inhibitor DML7ONU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DML7ONU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DML7SYH DI DML7SYH DML7SYH DN PMID25666693-Compound-131 DML7SYH TI TTMI6F5 DML7SYH TN Transient receptor potential cation channel V1 (TRPV1) DML7SYH MA Antagonist DML7SYH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML7SYH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML83KW DI DML83KW DML83KW DN Aminopyrimidine derivative 8 DML83KW TI TTH5TC2 DML83KW TN NF-kappa-B-activating kinase (TBK1) DML83KW MA Inhibitor DML83KW RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DML83KW RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TTGP7BY DML86IO TN Monoamine oxidase type B (MAO-B) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TT1RS9F DML86IO TN Acetylcholinesterase (AChE) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TT3WG5C DML86IO TN Monoamine oxidase type A (MAO-A) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TTEB0GD DML86IO TN Cholinesterase (BCHE) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML8FUD DI DML8FUD DML8FUD DN PMID29130358-Compound-Figure15(8) DML8FUD TI TTXPTJE DML8FUD TN Gelatinase (GEL) DML8FUD MA Inhibitor DML8FUD RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DML8FUD RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DML8RVS DI DML8RVS DML8RVS DN 1-Benzyl-3-bromo-1H-pyrrole-2,5-dione DML8RVS TI TTWME23 DML8RVS TN Regulator of G-protein signaling 8 (RGS8) DML8RVS MA Inhibitor DML8RVS RN Small molecule inhibitors of RGS proteins. US8865750. DML8RVS RU http://www.freepatentsonline.com/US8865750.html DML8W16 DI DML8W16 DML8W16 DN Benzimidazole derivative 1 DML8W16 TI TT6OEDT DML8W16 TN Cannabinoid receptor 1 (CB1) DML8W16 MA Antagonist DML8W16 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DML8W16 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DML9C64 DI DML9C64 DML9C64 DN Peptide analog 11 DML9C64 TI TT68GPI DML9C64 TN Proteasome beta-5 (PS beta-5) DML9C64 MA Inhibitor DML9C64 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML9C64 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML9C64 DI DML9C64 DML9C64 DN Peptide analog 11 DML9C64 TI TTEAD9J DML9C64 TN Proteasome beta-8 (PS beta-8) DML9C64 MA Inhibitor DML9C64 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML9C64 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML9TF7 DI DML9TF7 DML9TF7 DN Benzene sulfonamide derivative 11 DML9TF7 TI TT4G2JS DML9TF7 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DML9TF7 MA Inhibitor DML9TF7 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DML9TF7 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMLAH39 DI DMLAH39 DMLAH39 DN PMID25435179-Compound-WO2012106509Salermide DMLAH39 TI TTUF2HO DMLAH39 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMLAH39 MA Inhibitor DMLAH39 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMLAH39 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMLAHC1 DI DMLAHC1 DMLAHC1 DN PMID29338548-Compound-40 DMLAHC1 TI TTHJTF7 DMLAHC1 TN Glycine transporter GlyT-1 (SLC6A9) DMLAHC1 MA Inhibitor DMLAHC1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMLAHC1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMLAS7K DI DMLAS7K DMLAS7K DN PMID25399762-Compound-Table 5-8 DMLAS7K TI TT3WG5C DMLAS7K TN Monoamine oxidase type A (MAO-A) DMLAS7K MA Inhibitor DMLAS7K RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMLAS7K RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMLAY8B DI DMLAY8B DMLAY8B DN PMID27376512-Compound-asCEBP-1HPE DMLAY8B TI TT6S2FE DMLAY8B TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMLAY8B MA Inhibitor DMLAY8B RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMLAY8B RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMLAYG7 DI DMLAYG7 DMLAYG7 DN 1,2,4,5-tetra-substituted imidazole derivative 1 DMLAYG7 TI TT6OEDT DMLAYG7 TN Cannabinoid receptor 1 (CB1) DMLAYG7 MA Antagonist DMLAYG7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLAYG7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLBA4D DI DMLBA4D DMLBA4D DN Thiazolidine dione crystalline derivative 1 DMLBA4D TI TTZMAO3 DMLBA4D TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMLBA4D MA Agonist DMLBA4D RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMLBA4D RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMLBEPW DI DMLBEPW DMLBEPW DN Salicylic acid derivative 6 DMLBEPW TI TTH8FZW DMLBEPW TN Signal transducer and activator of transcription 3 (STAT3) DMLBEPW MA Inhibitor DMLBEPW RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMLBEPW RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMLBK8V DI DMLBK8V DMLBK8V DN Thiazole carboxamide derivative 7 DMLBK8V TI TTCZOF2 DMLBK8V TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLBK8V MA Inhibitor DMLBK8V RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLBK8V RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLBN1T DI DMLBN1T DMLBN1T DN Diaryl amine derivative 3 DMLBN1T TI TT6R7JZ DMLBN1T TN Histone deacetylase 1 (HDAC1) DMLBN1T MA Inhibitor DMLBN1T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLBN1T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLBN1T DI DMLBN1T DMLBN1T DN Diaryl amine derivative 3 DMLBN1T TI TT5ZKDI DMLBN1T TN Histone deacetylase 6 (HDAC6) DMLBN1T MA Inhibitor DMLBN1T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLBN1T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLBQUS DI DMLBQUS DMLBQUS DN PMID29649907-Compound-13 DMLBQUS TI TTS4UGC DMLBQUS TN Farnesoid X-activated receptor (FXR) DMLBQUS MA Agonist DMLBQUS RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMLBQUS RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TTRMX3V DMLBR4F TN Janus kinase 2 (JAK-2) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TTT7PJU DMLBR4F TN Janus kinase 3 (JAK-3) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TT6DM01 DMLBR4F TN Janus kinase 1 (JAK-1) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBZGO DI DMLBZGO DMLBZGO DN PMID26651364-Compound-45 DMLBZGO TI TTTCRU2 DMLBZGO TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLBZGO MA Antagonist DMLBZGO RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLBZGO RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLC5WA DI DMLC5WA DMLC5WA DN Pyridine derivative 17 DMLC5WA TI TTHS256 DMLC5WA TN Metabotropic glutamate receptor 5 (mGluR5) DMLC5WA MA Modulator DMLC5WA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLC5WA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLCPWT DI DMLCPWT DMLCPWT DN PMID25726713-Compound-25 DMLCPWT TI TT8J1S3 DMLCPWT TN Smoothened homolog (SMO) DMLCPWT MA Inhibitor DMLCPWT RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMLCPWT RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMLD49W DI DMLD49W DMLD49W DN Cyclohexyl carbamate derivative 4 DMLD49W TI TTULVH8 DMLD49W TN Tyrosinase (TYR) DMLD49W MA Inhibitor DMLD49W RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLD49W RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLD7JU DI DMLD7JU DMLD7JU DN 1,3,5-triazine derivative 1 DMLD7JU TI TTMSFAW DMLD7JU TN Cannabinoid receptor 2 (CB2) DMLD7JU RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLD7JU RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLD8K3 DI DMLD8K3 DMLD8K3 DN PMID28394193-Compound-21 DMLD8K3 TI TT9MZCQ DMLD8K3 TN Enhancer of zeste homolog 2 (EZH2) DMLD8K3 MA Inhibitor DMLD8K3 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMLD8K3 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMLDFVN DI DMLDFVN DMLDFVN DN PMID29671355-Compound-50 DMLDFVN TI TTTQGH8 DMLDFVN TN Histone deacetylase 4 (HDAC4) DMLDFVN MA Inhibitor DMLDFVN RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLDFVN RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLDMO8 DI DMLDMO8 DMLDMO8 DN Ethynyl compound 4 DMLDMO8 TI TTHS256 DMLDMO8 TN Metabotropic glutamate receptor 5 (mGluR5) DMLDMO8 MA Modulator DMLDMO8 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLDMO8 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLDPGY DI DMLDPGY DMLDPGY DN PMID25416646-Compound-Figure2-N DMLDPGY TI TTZMAO3 DMLDPGY TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMLDPGY MA Agonist DMLDPGY RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMLDPGY RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMLDXOB DI DMLDXOB DMLDXOB DN Carbamide derivative 19 DMLDXOB TI TTOHSBA DMLDXOB TN Vascular endothelial growth factor A (VEGFA) DMLDXOB MA Inhibitor DMLDXOB RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLDXOB RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLE5BK DI DMLE5BK DMLE5BK DN PMID25666693-Compound-146 DMLE5BK TI TTMI6F5 DMLE5BK TN Transient receptor potential cation channel V1 (TRPV1) DMLE5BK MA Antagonist DMLE5BK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLE5BK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLEH4U DI DMLEH4U DMLEH4U DN 2-pyrazinone derivative 2 DMLEH4U TI TTPLTSQ DMLEH4U TN Neutrophil elastase (NE) DMLEH4U MA Inhibitor DMLEH4U RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMLEH4U RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMLET14 DI DMLET14 DMLET14 DN Benzene sulfonamide derivative 9 DMLET14 TI TT4G2JS DMLET14 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMLET14 MA Blocker DMLET14 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMLET14 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMLEWY6 DI DMLEWY6 DMLEWY6 DN PMID28870136-Compound-53 DMLEWY6 TI TTK0O6Y DMLEWY6 TN Ecto-5'-nucleotidase (CD73) DMLEWY6 MA Inhibitor DMLEWY6 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMLEWY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMLF53V DI DMLF53V DMLF53V DN Resorcinol compound 8 DMLF53V TI TTULVH8 DMLF53V TN Tyrosinase (TYR) DMLF53V MA Inhibitor DMLF53V RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLF53V RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLFY57 DI DMLFY57 DMLFY57 DN Pyrimidinone derivative 5 DMLFY57 TI TTSCIM2 DMLFY57 TN Extracellular lysophospholipase D (E-NPP2) DMLFY57 MA Inhibitor DMLFY57 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMLFY57 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMLGBR6 DI DMLGBR6 DMLGBR6 DN PMID29671355-Compound-68b DMLGBR6 TI TTTQGH8 DMLGBR6 TN Histone deacetylase 4 (HDAC4) DMLGBR6 MA Inhibitor DMLGBR6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLGBR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLGBR6 DI DMLGBR6 DMLGBR6 DN PMID29671355-Compound-68b DMLGBR6 TI TTT6LFV DMLGBR6 TN Histone deacetylase 8 (HDAC8) DMLGBR6 MA Inhibitor DMLGBR6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLGBR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLGD52 DI DMLGD52 DMLGD52 DN PMID25656651-Compound-40 DMLGD52 TI TTS7G69 DMLGD52 TN Fusion protein Bcr-Abl (Bcr-Abl) DMLGD52 MA Inhibitor DMLGD52 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLGD52 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLGKYI DI DMLGKYI DMLGKYI DN PMID30185082-Compound-56 DMLGKYI TI TT9NXW4 DMLGKYI TN Sigma intracellular receptor 2 (TMEM97) DMLGKYI MA Ligand DMLGKYI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMLGKYI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMLGNB2 DI DMLGNB2 DMLGNB2 DN Triazolo-pyrimidinedione derivative 2 DMLGNB2 TI TTDIGC1 DMLGNB2 TN Dipeptidyl peptidase 4 (DPP-4) DMLGNB2 MA Inhibitor DMLGNB2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMLGNB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMLGYXW DI DMLGYXW DMLGYXW DN PMID28627961-Compound-31 DMLGYXW TI TTYLQ8V DMLGYXW TN Prostaglandin E synthase (PTGES) DMLGYXW MA Inhibitor DMLGYXW RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMLGYXW RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMLGZPO DI DMLGZPO DMLGZPO DN PMID26560530-Compound-34 DMLGZPO TI TT2F4OL DMLGZPO TN Tissue transglutaminase (TG2) DMLGZPO MA Inhibitor DMLGZPO RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMLGZPO RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMLH45M DI DMLH45M DMLH45M DN Carbamate derivative 13 DMLH45M TI TTZ963I DMLH45M TN Monoglyceride lipase (MAGL) DMLH45M MA Inhibitor DMLH45M RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLH45M RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLH637 DI DMLH637 DMLH637 DN PMID26004420-Compound-WO2014015495B DMLH637 TI TTJ13ST DMLH637 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMLH637 MA Inhibitor DMLH637 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMLH637 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMLH9AQ DI DMLH9AQ DMLH9AQ DN Cyclopropane 1-carboxylic acid derivative 9 DMLH9AQ TI TTIY56R DMLH9AQ TN Kynurenine 3-hydroxylase (KMO) DMLH9AQ MA Inhibitor DMLH9AQ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMLH9AQ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMLHC5V DI DMLHC5V DMLHC5V DN PMID25991433-Compound-N3 DMLHC5V TI TT3ZIJL DMLHC5V TN JNK-interacting protein peptide (pepJIP) DMLHC5V MA Inhibitor DMLHC5V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLHC5V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLHC5V DI DMLHC5V DMLHC5V DN PMID25991433-Compound-N3 DMLHC5V TI TT0K6EO DMLHC5V TN Stress-activated protein kinase JNK1 (JNK1) DMLHC5V MA Inhibitor DMLHC5V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLHC5V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLHGC9 DI DMLHGC9 DMLHGC9 DN Indole carboxamide derivative 1 DMLHGC9 TI TT473XN DMLHGC9 TN P2X purinoceptor 7 (P2RX7) DMLHGC9 MA Antagonist DMLHGC9 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMLHGC9 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMLHJ1E DI DMLHJ1E DMLHJ1E DN PMID26651364-Compound-5b DMLHJ1E TI TTTCRU2 DMLHJ1E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLHJ1E MA Antagonist DMLHJ1E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLHJ1E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLI1YR DI DMLI1YR DMLI1YR DN PMID25666693-Compound-59 DMLI1YR TI TTMI6F5 DMLI1YR TN Transient receptor potential cation channel V1 (TRPV1) DMLI1YR MA Antagonist DMLI1YR RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLI1YR RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLI7TG DI DMLI7TG DMLI7TG DN PMID28394193-Compound-42 DMLI7TG TI TT9MZCQ DMLI7TG TN Enhancer of zeste homolog 2 (EZH2) DMLI7TG MA Inhibitor DMLI7TG RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMLI7TG RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMLIRGM DI DMLIRGM DMLIRGM DN Thiazole carboxamide derivative 2 DMLIRGM TI TTCZOF2 DMLIRGM TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLIRGM MA Inhibitor DMLIRGM RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLIRGM RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLIVT6 DI DMLIVT6 DMLIVT6 DN Peptide analog 19 DMLIVT6 TI TT68GPI DMLIVT6 TN Proteasome beta-5 (PS beta-5) DMLIVT6 MA Inhibitor DMLIVT6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMLIVT6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMLIVT6 DI DMLIVT6 DMLIVT6 DN Peptide analog 19 DMLIVT6 TI TTEAD9J DMLIVT6 TN Proteasome beta-8 (PS beta-8) DMLIVT6 MA Inhibitor DMLIVT6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMLIVT6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMLIW1X DI DMLIW1X DMLIW1X DN Quinoline derivative 8 DMLIW1X TI TTXJ47W DMLIW1X TN Metabotropic glutamate receptor 2 (mGluR2) DMLIW1X MA Antagonist DMLIW1X RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLIW1X RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLJ2HE DI DMLJ2HE DMLJ2HE DN Undecylenic acid derivative 1 DMLJ2HE TI TT1WBIJ DMLJ2HE TN Calpain-1 (CAPN1) DMLJ2HE RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMLJ2HE RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMLJH5T DI DMLJH5T DMLJH5T DN Boronic acid derivative 2 DMLJH5T TI TTDP1UC DMLJH5T TN Fatty acid amide hydrolase (FAAH) DMLJH5T MA Inhibitor DMLJH5T RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLJH5T RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLJU5P DI DMLJU5P DMLJU5P DN BDBM50080570 DMLJU5P TI TTDYP7I DMLJU5P TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMLJU5P MA Inhibitor DMLJU5P RN Pyridin-4-yl derivatives. US9617250. DMLJU5P RU http://www.freepatentsonline.com/US9617250.html DMLJV01 DI DMLJV01 DMLJV01 DN US10034861, Example 1 DMLJV01 TI TT3ZS42 DMLJV01 TN Phosphodiesterase 1B (PDE1B) DMLJV01 MA Inhibitor DMLJV01 RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DMLJV01 RU http://www.freepatentsonline.com/US10034861.html DMLJYS1 DI DMLJYS1 DMLJYS1 DN Resorcinol compound 33 DMLJYS1 TI TTULVH8 DMLJYS1 TN Tyrosinase (TYR) DMLJYS1 MA Inhibitor DMLJYS1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLJYS1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLK29E DI DMLK29E DMLK29E DN 3-substituted-2-furancarboxylic acid hydrazide derivative 5 DMLK29E TI TT9O6WS DMLK29E TN Glucagon receptor (GCGR) DMLK29E MA Antagonist DMLK29E RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMLK29E RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMLKNWF DI DMLKNWF DMLKNWF DN Aryl piperazine derivative 9 DMLKNWF TI TTWJBZ5 DMLKNWF TN 5-HT 2C receptor (HTR2C) DMLKNWF MA Agonist DMLKNWF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLKNWF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLKNWF DI DMLKNWF DMLKNWF DN Aryl piperazine derivative 9 DMLKNWF TI TTJQOD7 DMLKNWF TN 5-HT 2A receptor (HTR2A) DMLKNWF MA Agonist DMLKNWF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLKNWF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLKP1O DI DMLKP1O DMLKP1O DN PMID28067079-Compound-98 DMLKP1O TI TTHS256 DMLKP1O TN Metabotropic glutamate receptor 5 (mGluR5) DMLKP1O MA Modulator DMLKP1O RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLKP1O RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLM6DT DI DMLM6DT DMLM6DT DN Pyrrolo-pyrazine derivative 3 DMLM6DT TI TTOU65C DMLM6DT TN Tyrosine-protein kinase SYK (SYK) DMLM6DT MA Inhibitor DMLM6DT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMLM6DT RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMLM6DT DI DMLM6DT DMLM6DT DN Pyrrolo-pyrazine derivative 3 DMLM6DT TI TTT7PJU DMLM6DT TN Janus kinase 3 (JAK-3) DMLM6DT MA Inhibitor DMLM6DT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMLM6DT RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMLMEPI DI DMLMEPI DMLMEPI DN PMID25666693-Compound-139 DMLMEPI TI TTMI6F5 DMLMEPI TN Transient receptor potential cation channel V1 (TRPV1) DMLMEPI MA Antagonist DMLMEPI RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLMEPI RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLMHR5 DI DMLMHR5 DMLMHR5 DN PMID29053063-Compound-11c DMLMHR5 TI TTZ963I DMLMHR5 TN Monoglyceride lipase (MAGL) DMLMHR5 MA Inhibitor DMLMHR5 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLMHR5 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLMHR5 DI DMLMHR5 DMLMHR5 DN PMID29053063-Compound-11c DMLMHR5 TI TTSINOV DMLMHR5 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMLMHR5 MA Inhibitor DMLMHR5 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLMHR5 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLMQD4 DI DMLMQD4 DMLMQD4 DN PMID26394986-Compound-21 DMLMQD4 TI TTH8FZW DMLMQD4 TN Signal transducer and activator of transcription 3 (STAT3) DMLMQD4 MA Inhibitor DMLMQD4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMLMQD4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMLMV1Y DI DMLMV1Y DMLMV1Y DN US10040779, Example 1 DMLMV1Y TI TTIG67W DMLMV1Y TN Lysine-specific demethylase 5A (KDM5A) DMLMV1Y MA Inhibitor DMLMV1Y RN Histone demethylase inhibitors. US10040779. DMLMV1Y RU http://www.freepatentsonline.com/US10040779.html DMLMV4O DI DMLMV4O DMLMV4O DN Boronic acid derivative 6 DMLMV4O TI TTDP1UC DMLMV4O TN Fatty acid amide hydrolase (FAAH) DMLMV4O MA Inhibitor DMLMV4O RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLMV4O RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLMXT6 DI DMLMXT6 DMLMXT6 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4 DMLMXT6 TI TTXJ47W DMLMXT6 TN Metabotropic glutamate receptor 2 (mGluR2) DMLMXT6 MA Antagonist DMLMXT6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLMXT6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLNA8P DI DMLNA8P DMLNA8P DN PMID28051882-Compound-XI DMLNA8P TI TT9NXW4 DMLNA8P TN Sigma intracellular receptor 2 (TMEM97) DMLNA8P MA Ligand DMLNA8P RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMLNA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMLOBAQ DI DMLOBAQ DMLOBAQ DN Ethinyl-pyrazole derivative 1 DMLOBAQ TI TTXJ47W DMLOBAQ TN Metabotropic glutamate receptor 2 (mGluR2) DMLOBAQ MA Antagonist DMLOBAQ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLOBAQ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLOIHD DI DMLOIHD DMLOIHD DN Aminoazetidine derivative 8 DMLOIHD TI TT6OEDT DMLOIHD TN Cannabinoid receptor 1 (CB1) DMLOIHD MA Antagonist DMLOIHD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLOIHD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLOVMP DI DMLOVMP DMLOVMP DN Biphenyl carboxamidopropanoic acid derivative 3 DMLOVMP TI TT9O6WS DMLOVMP TN Glucagon receptor (GCGR) DMLOVMP MA Antagonist DMLOVMP RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMLOVMP RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMLPMS7 DI DMLPMS7 DMLPMS7 DN Tricyclic compound 5 DMLPMS7 TI TTGWKQJ DMLPMS7 TN Rho-associated protein kinase 2 (ROCK2) DMLPMS7 MA Inhibitor DMLPMS7 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMLPMS7 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMLPO0K DI DMLPO0K DMLPO0K DN Pyrimidine derivative 19 DMLPO0K TI TT8J1S3 DMLPO0K TN Smoothened homolog (SMO) DMLPO0K MA Inhibitor DMLPO0K RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMLPO0K RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMLPOUR DI DMLPOUR DMLPOUR DN Carbamide derivative 16 DMLPOUR TI TTOHSBA DMLPOUR TN Vascular endothelial growth factor A (VEGFA) DMLPOUR MA Inhibitor DMLPOUR RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLPOUR RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLPQ7E DI DMLPQ7E DMLPQ7E DN Imidazole derivative 7 DMLPQ7E TI TT6OEDT DMLPQ7E TN Cannabinoid receptor 1 (CB1) DMLPQ7E MA Antagonist DMLPQ7E RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLPQ7E RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLPWK3 DI DMLPWK3 DMLPWK3 DN US9434727, 40 DMLPWK3 TI TT0C8BY DMLPWK3 TN Plasma retinol-binding protein (RBP4) DMLPWK3 MA Inhibitor DMLPWK3 RN Substituted 4-phenylpiperidines, their preparation and use. US9777010. DMLPWK3 RU http://www.freepatentsonline.com/US9777010.html DMLQ7PG DI DMLQ7PG DMLQ7PG DN Diazepinone derivative 2 DMLQ7PG TI TTHS256 DMLQ7PG TN Metabotropic glutamate receptor 5 (mGluR5) DMLQ7PG MA Modulator DMLQ7PG RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLQ7PG RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLQ8N1 DI DMLQ8N1 DMLQ8N1 DN AphanamgrandiolA DMLQ8N1 TI TT3WG5C DMLQ8N1 TN Monoamine oxidase type A (MAO-A) DMLQ8N1 MA Inhibitor DMLQ8N1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMLQ8N1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMLQCYV DI DMLQCYV DMLQCYV DN PMID28766366-Compound-Scheme13INDY DMLQCYV TI TTSBVFO DMLQCYV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMLQCYV MA Inhibitor DMLQCYV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMLQCYV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMLR03U DI DMLR03U DMLR03U DN PMID28092474-Compound-32y DMLR03U TI TT5ZKDI DMLR03U TN Histone deacetylase 6 (HDAC6) DMLR03U MA Inhibitor DMLR03U RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLR03U RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLR03U DI DMLR03U DMLR03U DN PMID28092474-Compound-32y DMLR03U TI TT6R7JZ DMLR03U TN Histone deacetylase 1 (HDAC1) DMLR03U MA Inhibitor DMLR03U RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLR03U RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLR8MS DI DMLR8MS DMLR8MS DN Isoxazoline derivative 1 DMLR8MS TI TTDP1UC DMLR8MS TN Fatty acid amide hydrolase (FAAH) DMLR8MS MA Inhibitor DMLR8MS RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLR8MS RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLRA3C DI DMLRA3C DMLRA3C DN Thiazole carboxamide derivative 3 DMLRA3C TI TTCZOF2 DMLRA3C TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLRA3C MA Inhibitor DMLRA3C RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLRA3C RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLRTFX DI DMLRTFX DMLRTFX DN Thiazole carboxamide derivative 25 DMLRTFX TI TTCZOF2 DMLRTFX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLRTFX MA Inhibitor DMLRTFX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLRTFX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLRY53 DI DMLRY53 DMLRY53 DN Tetra-azabenzo[e]azulene derivative 1 DMLRY53 TI TT4TFGN DMLRY53 TN Vasopressin V1a receptor (V1AR) DMLRY53 MA Inhibitor DMLRY53 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMLRY53 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMLS827 DI DMLS827 DMLS827 DN Pyrazolo[1,5-a]pyridine derivative 2 DMLS827 TI TTTDVOJ DMLS827 TN Tropomyosin-related kinase A (TrkA) DMLS827 MA Inhibitor DMLS827 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMLS827 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMLSK97 DI DMLSK97 DMLSK97 DN N-quinolin-benzene sulphonamide derivative 1 DMLSK97 TI TTSXVID DMLSK97 TN Nuclear factor NF-kappa-B (NFKB) DMLSK97 MA Inhibitor DMLSK97 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMLSK97 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMLSUH3 DI DMLSUH3 DMLSUH3 DN Isothiazolidine derivative 1 DMLSUH3 TI TT473XN DMLSUH3 TN P2X purinoceptor 7 (P2RX7) DMLSUH3 MA Antagonist DMLSUH3 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMLSUH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMLSWKR DI DMLSWKR DMLSWKR DN Phenylpurine acetamide analog 1 DMLSWKR TI TTPTXIN DMLSWKR TN Translocator protein (TSPO) DMLSWKR MA Ligand DMLSWKR RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMLSWKR RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMLT8PA DI DMLT8PA DMLT8PA DN PMID25991433-Compound-K1 DMLT8PA TI TT0K6EO DMLT8PA TN Stress-activated protein kinase JNK1 (JNK1) DMLT8PA MA Inhibitor DMLT8PA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLT8PA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLTKMS DI DMLTKMS DMLTKMS DN PMID28092474-Compound-32r DMLTKMS TI TT6R7JZ DMLTKMS TN Histone deacetylase 1 (HDAC1) DMLTKMS MA Inhibitor DMLTKMS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLTKMS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLTKMS DI DMLTKMS DMLTKMS DN PMID28092474-Compound-32r DMLTKMS TI TT5ZKDI DMLTKMS TN Histone deacetylase 6 (HDAC6) DMLTKMS MA Inhibitor DMLTKMS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLTKMS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLTR9E DI DMLTR9E DMLTR9E DN PMID25656651-Compound-23c DMLTR9E TI TTS7G69 DMLTR9E TN Fusion protein Bcr-Abl (Bcr-Abl) DMLTR9E MA Inhibitor DMLTR9E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLTR9E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLTZKX DI DMLTZKX DMLTZKX DN Dihydroisoxazole derivative 2 DMLTZKX TI TT2F4OL DMLTZKX TN Tissue transglutaminase (TG2) DMLTZKX MA Inhibitor DMLTZKX RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMLTZKX RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMLUFB2 DI DMLUFB2 DMLUFB2 DN PMID25656651-Compound-20b DMLUFB2 TI TTS7G69 DMLUFB2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMLUFB2 MA Inhibitor DMLUFB2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLUFB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLUPV1 DI DMLUPV1 DMLUPV1 DN Thieno[2,3-c]pyridine derivative 1 DMLUPV1 TI TTZJYKH DMLUPV1 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMLUPV1 MA Inhibitor DMLUPV1 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMLUPV1 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMLUWCD DI DMLUWCD DMLUWCD DN PMID25435179-Compound-WO2013059594(III) DMLUWCD TI TTSCO7R DMLUWCD TN NAD-dependent deacetylase sirtuin (SIRT) DMLUWCD MA Inhibitor DMLUWCD RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMLUWCD RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMLUYR0 DI DMLUYR0 DMLUYR0 DN Terpyridineplatinum(II) complexe 2 DMLUYR0 TI TTR7UJ3 DMLUYR0 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMLUYR0 MA Inhibitor DMLUYR0 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMLUYR0 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMLUZ3K DI DMLUZ3K DMLUZ3K DN Biphenyl mannoside derivative 24 DMLUZ3K TI TTTCRU2 DMLUZ3K TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLUZ3K MA Antagonist DMLUZ3K RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLUZ3K RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLV6IY DI DMLV6IY DMLV6IY DN PMID26004420-Compound-WO2015017305F DMLV6IY TI TTJ13ST DMLV6IY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMLV6IY MA Inhibitor DMLV6IY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMLV6IY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMLV9UR DI DMLV9UR DMLV9UR DN Bis-sulfonamide derivative 1 DMLV9UR TI TTR7UJ3 DMLV9UR TN Cytoplasmic thioredoxin reductase (TXNRD1) DMLV9UR MA Inhibitor DMLV9UR RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMLV9UR RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMLVSEK DI DMLVSEK DMLVSEK DN PMID30280939-Compound-WO200606195 DMLVSEK TI TTOK0LR DMLVSEK TN Toll-like receptor (TLR) DMLVSEK MA Agonist DMLVSEK RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMLVSEK RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMLVY7A DI DMLVY7A DMLVY7A DN Imidazo triazine derivative 1 DMLVY7A TI TTJGW1Z DMLVY7A TN Phosphodiesterase 2A (PDE2A) DMLVY7A MA Inhibitor DMLVY7A RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMLVY7A RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMLW7YO DI DMLW7YO DMLW7YO DN Tetra-hydro-oxazolopyridine derivative 6 DMLW7YO TI TTHS256 DMLW7YO TN Metabotropic glutamate receptor 5 (mGluR5) DMLW7YO MA Modulator DMLW7YO RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLW7YO RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLW95Y DI DMLW95Y DMLW95Y DN PMID25666693-Compound-54 DMLW95Y TI TTMI6F5 DMLW95Y TN Transient receptor potential cation channel V1 (TRPV1) DMLW95Y MA Antagonist DMLW95Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLW95Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLWIJ7 DI DMLWIJ7 DMLWIJ7 DN Selenium compound 2 DMLWIJ7 TI TTZHPB8 DMLWIJ7 TN Lysine-specific demethylase 4A (KDM4A) DMLWIJ7 MA Inhibitor DMLWIJ7 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMLWIJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMLWSNA DI DMLWSNA DMLWSNA DN PMID25991433-Compound-D2 DMLWSNA TI TTHS0U8 DMLWSNA TN Stress-activated protein kinase JNK2 (JNK2) DMLWSNA MA Inhibitor DMLWSNA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLWSNA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLWSNA DI DMLWSNA DMLWSNA DN PMID25991433-Compound-D2 DMLWSNA TI TT0K6EO DMLWSNA TN Stress-activated protein kinase JNK1 (JNK1) DMLWSNA MA Inhibitor DMLWSNA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLWSNA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLX183 DI DMLX183 DMLX183 DN Indirubin derivative 2 DMLX183 TI TTRZQE3 DMLX183 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMLX183 MA Inhibitor DMLX183 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMLX183 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMLX26R DI DMLX26R DMLX26R DN PMID28766366-Compound-Scheme27LeucettineL41 DMLX26R TI TTSBVFO DMLX26R TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMLX26R MA Inhibitor DMLX26R RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMLX26R RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMLXG43 DI DMLXG43 DMLXG43 DN US8569313, Inhibitor 19 DMLXG43 TI TTPRO7W DMLXG43 TN Suppressor of tumorigenicity 14 protein (ST14) DMLXG43 MA Inhibitor DMLXG43 RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMLXG43 RU http://www.freepatentsonline.com/US8569313.html DMLXQET DI DMLXQET DMLXQET DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 DMLXQET TI TT6OEDT DMLXQET TN Cannabinoid receptor 1 (CB1) DMLXQET RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLXQET RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLXQET DI DMLXQET DMLXQET DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 DMLXQET TI TTMSFAW DMLXQET TN Cannabinoid receptor 2 (CB2) DMLXQET RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLXQET RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLXSHW DI DMLXSHW DMLXSHW DN PMID29671355-Compound-28 DMLXSHW TI TT5ZKDI DMLXSHW TN Histone deacetylase 6 (HDAC6) DMLXSHW MA Inhibitor DMLXSHW RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLXSHW RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLXSHW DI DMLXSHW DMLXSHW DN PMID29671355-Compound-28 DMLXSHW TI TT6R7JZ DMLXSHW TN Histone deacetylase 1 (HDAC1) DMLXSHW MA Inhibitor DMLXSHW RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLXSHW RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLY3RE DI DMLY3RE DMLY3RE DN US8877733, 28 DMLY3RE TI TTQFZWR DMLY3RE TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMLY3RE MA Inhibitor DMLY3RE RN 1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733. DMLY3RE RU http://www.freepatentsonline.com/US8877733.html DMLY7I3 DI DMLY7I3 DMLY7I3 DN PMID27607364-Compound-59 DMLY7I3 TI TTPTXIN DMLY7I3 TN Translocator protein (TSPO) DMLY7I3 MA Ligand DMLY7I3 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMLY7I3 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMLZ1UB DI DMLZ1UB DMLZ1UB DN Diarylamine and arylheteroarylamine pyrazole derivative 3 DMLZ1UB TI TTJQOD7 DMLZ1UB TN 5-HT 2A receptor (HTR2A) DMLZ1UB MA Agonist DMLZ1UB RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLZ1UB RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLZBRM DI DMLZBRM DMLZBRM DN US10179791, Compound 296 DMLZBRM TI TTDYP7I DMLZBRM TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMLZBRM MA Inhibitor DMLZBRM RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMLZBRM RU http://www.freepatentsonline.com/US10179791.html DMLZDAK DI DMLZDAK DMLZDAK DN ZINC19658740 DMLZDAK TI TTB9CIL DMLZDAK TN Prokineticin receptor-1 (PROKR1) DMLZDAK MA Inhibitor DMLZDAK RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US10167273. DMLZDAK RU http://www.freepatentsonline.com/US10167273.html DMLZMIG DI DMLZMIG DMLZMIG DN Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 DMLZMIG TI TTOHSBA DMLZMIG TN Vascular endothelial growth factor A (VEGFA) DMLZMIG MA Inhibitor DMLZMIG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLZMIG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLZRAI DI DMLZRAI DMLZRAI DN Quinoxaline derivative 3 DMLZRAI TI TTSXVID DMLZRAI TN Nuclear factor NF-kappa-B (NFKB) DMLZRAI MA Inhibitor DMLZRAI RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMLZRAI RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMLZV70 DI DMLZV70 DMLZV70 DN PMID28594589-Compound-TABLE3C1 DMLZV70 TI TTZCRP3 DMLZV70 TN ERK activator kinase (MEK) DMLZV70 MA Inhibitor DMLZV70 RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMLZV70 RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMM06K5 DI DMM06K5 DMM06K5 DN Tetra-hydro-pyrrolopyrimidinedione derivative 1 DMM06K5 TI TTPLTSQ DMM06K5 TN Neutrophil elastase (NE) DMM06K5 MA Inhibitor DMM06K5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMM06K5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMM0BVE DI DMM0BVE DMM0BVE DN PMID28447479-Compound-23 DMM0BVE TI TTSCIM2 DMM0BVE TN Extracellular lysophospholipase D (E-NPP2) DMM0BVE RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMM0BVE RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMM0R65 DI DMM0R65 DMM0R65 DN Cyclopropyl-spiro piperidine derivative 2 DMM0R65 TI TT4G2JS DMM0R65 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMM0R65 MA Blocker DMM0R65 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMM0R65 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMM1I8R DI DMM1I8R DMM1I8R DN Indazole derivative 5 DMM1I8R TI TTIV39N DMM1I8R TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMM1I8R MA Inhibitor DMM1I8R RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMM1I8R RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMM1I8R DI DMM1I8R DMM1I8R DN Indazole derivative 5 DMM1I8R TI TTZJTWA DMM1I8R TN ABL T315I mutant (ABL T315I) DMM1I8R MA Inhibitor DMM1I8R RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMM1I8R RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMM1LKF DI DMM1LKF DMM1LKF DN Bicyclic heteroaryl benzamide derivative 7 DMM1LKF TI TTTDVOJ DMM1LKF TN Tropomyosin-related kinase A (TrkA) DMM1LKF MA Inhibitor DMM1LKF RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMM1LKF RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMM2N4T DI DMM2N4T DMM2N4T DN 1607004-34-1 DMM2N4T TI TTYG6BU DMM2N4T TN Aggrecanase-1 (ADAMTS4) DMM2N4T MA Inhibitor DMM2N4T RN Aggrecanase inhibitors. US9206139. DMM2N4T RU http://www.freepatentsonline.com/US9206139.html DMM2RYG DI DMM2RYG DMM2RYG DN Pyrazole derivative 25 DMM2RYG TI TT6OEDT DMM2RYG TN Cannabinoid receptor 1 (CB1) DMM2RYG MA Antagonist DMM2RYG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMM2RYG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMM2WA4 DI DMM2WA4 DMM2WA4 DN Peptide analog 48 DMM2WA4 TI TTDIGC1 DMM2WA4 TN Dipeptidyl peptidase 4 (DPP-4) DMM2WA4 MA Inhibitor DMM2WA4 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMM2WA4 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMM30LJ DI DMM30LJ DMM30LJ DN PMID29334795-Compound-55 DMM30LJ TI TT9JNIC DMM30LJ TN Histamine H3 receptor (H3R) DMM30LJ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMM30LJ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMM3FJO DI DMM3FJO DMM3FJO DN PMID26815044-Compound-47 DMM3FJO TI TTULVH8 DMM3FJO TN Tyrosinase (TYR) DMM3FJO MA Inhibitor DMM3FJO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMM3FJO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMM3QEW DI DMM3QEW DMM3QEW DN PMID25553724-Compound-US2011000295210 DMM3QEW TI TTSXVID DMM3QEW TN Nuclear factor NF-kappa-B (NFKB) DMM3QEW MA Inhibitor DMM3QEW RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMM3QEW RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMM3SWV DI DMM3SWV DMM3SWV DN Biphenyl derivative 3 DMM3SWV TI TTZJYKH DMM3SWV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMM3SWV MA Inhibitor DMM3SWV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMM3SWV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMM3VA8 DI DMM3VA8 DMM3VA8 DN PMID27376512-Compound-Table1Example16 DMM3VA8 TI TT6S2FE DMM3VA8 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMM3VA8 MA Inhibitor DMM3VA8 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMM3VA8 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMM45AC DI DMM45AC DMM45AC DN PMID25980951-Compound-20 DMM45AC TI TTR7B60 DMM45AC TN X-linked inhibitor of apoptosis protein (XIAP) DMM45AC MA Antagonist DMM45AC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMM45AC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMM45AC DI DMM45AC DMM45AC DN PMID25980951-Compound-20 DMM45AC TI TTQ5LRD DMM45AC TN Cellular inhibitor of apoptosis 1 (BIRC2) DMM45AC MA Antagonist DMM45AC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMM45AC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMM4GLH DI DMM4GLH DMM4GLH DN US8470836, 8 DMM4GLH TI TTOYT5L DMM4GLH TN Dipeptidyl-peptidase 7 (DPP7) DMM4GLH MA Inhibitor DMM4GLH RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMM4GLH RU http://www.freepatentsonline.com/US8470836.html DMM4TBH DI DMM4TBH DMM4TBH DN PMID29649907-Compound-2 DMM4TBH TI TTS4UGC DMM4TBH TN Farnesoid X-activated receptor (FXR) DMM4TBH MA Agonist DMM4TBH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMM4TBH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMM5BDS DI DMM5BDS DMM5BDS DN Isoquinoline sulfonamide derivative 1 DMM5BDS TI TTMQO60 DMM5BDS TN Rho-associated protein kinase (ROCK) DMM5BDS MA Inhibitor DMM5BDS RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMM5BDS RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMM5EI4 DI DMM5EI4 DMM5EI4 DN PMID25666693-Compound-93 DMM5EI4 TI TTMI6F5 DMM5EI4 TN Transient receptor potential cation channel V1 (TRPV1) DMM5EI4 MA Antagonist DMM5EI4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMM5EI4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMM5G7S DI DMM5G7S DMM5G7S DN PMID28350212-Compound-20 DMM5G7S TI TTZS04O DMM5G7S TN Gamma-secretase subunit APH-1A/1B (APH-1) DMM5G7S MA Inhibitor DMM5G7S RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMM5G7S RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMM6FOW DI DMM6FOW DMM6FOW DN PMID27744724-Compound-22 DMM6FOW TI TTL53M6 DMM6FOW TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMM6FOW MA Inhibitor DMM6FOW RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMM6FOW RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMM6WAB DI DMM6WAB DMM6WAB DN US10087167, Compound 3002 DMM6WAB TI TTQFZWR DMM6WAB TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMM6WAB MA Inhibitor DMM6WAB RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMM6WAB RU http://www.freepatentsonline.com/US10087167.html DMM72LS DI DMM72LS DMM72LS DN Benzazepine derivative 4 DMM72LS TI TTWJBZ5 DMM72LS TN 5-HT 2C receptor (HTR2C) DMM72LS MA Agonist DMM72LS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMM72LS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMM73VG DI DMM73VG DMM73VG DN PMID29865878-Compound-59 DMM73VG TI TTEAD9J DMM73VG TN Proteasome beta-8 (PS beta-8) DMM73VG MA Inhibitor DMM73VG RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMM73VG RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMM78UR DI DMM78UR DMM78UR DN H3K7T DMM78UR TI TTSCO7R DMM78UR TN NAD-dependent deacetylase sirtuin (SIRT) DMM78UR MA Inhibitor DMM78UR RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMM78UR RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMM78VS DI DMM78VS DMM78VS DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 DMM78VS TI TT6OEDT DMM78VS TN Cannabinoid receptor 1 (CB1) DMM78VS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM78VS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM78VS DI DMM78VS DMM78VS DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 DMM78VS TI TTMSFAW DMM78VS TN Cannabinoid receptor 2 (CB2) DMM78VS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM78VS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM7N5E DI DMM7N5E DMM7N5E DN Benzothiazine-carboxamide compound 5 DMM7N5E TI TTQR74A DMM7N5E TN Proteinase activated receptor 2 (PAR2) DMM7N5E MA Antagonist DMM7N5E RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMM7N5E RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMM7OR3 DI DMM7OR3 DMM7OR3 DN Pyrazole derivative 19 DMM7OR3 TI TT6OEDT DMM7OR3 TN Cannabinoid receptor 1 (CB1) DMM7OR3 MA Antagonist DMM7OR3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMM7OR3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMM83WL DI DMM83WL DMM83WL DN PMID30280939-Compound-US20170128558 DMM83WL TI TTOK0LR DMM83WL TN Toll-like receptor (TLR) DMM83WL MA Agonist DMM83WL RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMM83WL RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMM8CL4 DI DMM8CL4 DMM8CL4 DN Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1 DMM8CL4 TI TTJGW1Z DMM8CL4 TN Phosphodiesterase 2A (PDE2A) DMM8CL4 MA Inhibitor DMM8CL4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMM8CL4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMM8IDC DI DMM8IDC DMM8IDC DN BDBM50061612 DMM8IDC TI TTCGOIN DMM8IDC TN PIM-3 protein kinase (PIM3) DMM8IDC MA Inhibitor DMM8IDC RN Azole compounds as PIM inhibitors. US9321756. DMM8IDC RU http://www.freepatentsonline.com/US9321756.html DMM8K7R DI DMM8K7R DMM8K7R DN Peptide analog 50 DMM8K7R TI TTDIGC1 DMM8K7R TN Dipeptidyl peptidase 4 (DPP-4) DMM8K7R MA Inhibitor DMM8K7R RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMM8K7R RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMM92KW DI DMM92KW DMM92KW DN Tetra-hydro-quinoline derivative 1 DMM92KW TI TTVDSZ0 DMM92KW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMM92KW MA Inhibitor DMM92KW RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMM92KW RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMM9E1U DI DMM9E1U DMM9E1U DN PMID28074661-Compound-US20100022547C81 DMM9E1U TI TTL7C8Q DMM9E1U TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMM9E1U MA Inhibitor DMM9E1U RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMM9E1U RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMM9F8D DI DMM9F8D DMM9F8D DN Phytocannabinoid/aminoalkylindole derivative 1 DMM9F8D TI TTMSFAW DMM9F8D TN Cannabinoid receptor 2 (CB2) DMM9F8D RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM9F8D RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM9F8D DI DMM9F8D DMM9F8D DN Phytocannabinoid/aminoalkylindole derivative 1 DMM9F8D TI TT6OEDT DMM9F8D TN Cannabinoid receptor 1 (CB1) DMM9F8D RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM9F8D RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM9I1R DI DMM9I1R DMM9I1R DN 4-Carboxamido-isoindolinone derivative 1 DMM9I1R TI TTVDSZ0 DMM9I1R TN Poly [ADP-ribose] polymerase 1 (PARP1) DMM9I1R MA Inhibitor DMM9I1R RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMM9I1R RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMM9J34 DI DMM9J34 DMM9J34 DN Benzonaphthyridine derivative 1 DMM9J34 TI TTCZOF2 DMM9J34 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMM9J34 MA Inhibitor DMM9J34 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMM9J34 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMAE3C DI DMMAE3C DMMAE3C DN PMID27998201-Compound-2 DMMAE3C TI TTF2LRI DMMAE3C TN Cathepsin B (CTSB) DMMAE3C MA Inhibitor DMMAE3C RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMMAE3C RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMMAF2S DI DMMAF2S DMMAF2S DN Dipeptide analog 2 DMMAF2S TI TT2F4OL DMMAF2S TN Tissue transglutaminase (TG2) DMMAF2S MA Inhibitor DMMAF2S RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMAF2S RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMAS3G DI DMMAS3G DMMAS3G DN Aromatic ring compound 2 DMMAS3G TI TT9O6WS DMMAS3G TN Glucagon receptor (GCGR) DMMAS3G MA Antagonist DMMAS3G RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMMAS3G RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMMB60X DI DMMB60X DMMB60X DN Biaryl mannoside derivative 2 DMMB60X TI TTTCRU2 DMMB60X TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMB60X MA Antagonist DMMB60X RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMB60X RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMB6XC DI DMMB6XC DMMB6XC DN PMID27019002-Compound-37a DMMB6XC TI TTNR0UQ DMMB6XC TN Lysine-specific histone demethylase 1 (LSD) DMMB6XC MA Inhibitor DMMB6XC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMB6XC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMBFQH DI DMMBFQH DMMBFQH DN Pyrimidine derivative 12 DMMBFQH TI TTUTJGQ DMMBFQH TN Vascular endothelial growth factor receptor 2 (KDR) DMMBFQH MA Inhibitor DMMBFQH RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMBFQH RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMBUGK DI DMMBUGK DMMBUGK DN 4-pyridone derivative 1 DMMBUGK TI TTPLTSQ DMMBUGK TN Neutrophil elastase (NE) DMMBUGK MA Inhibitor DMMBUGK RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMBUGK RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMC31N DI DMMC31N DMMC31N DN PMID27019002-Compound-21b DMMC31N TI TTNR0UQ DMMC31N TN Lysine-specific histone demethylase 1 (LSD) DMMC31N MA Inhibitor DMMC31N RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMC31N RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMC31N DI DMMC31N DMMC31N DN PMID27019002-Compound-21b DMMC31N TI TTZHPB8 DMMC31N TN Lysine-specific demethylase 4A (KDM4A) DMMC31N MA Inhibitor DMMC31N RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMC31N RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMC31R DI DMMC31R DMMC31R DN Aryl mannoside derivative 5 DMMC31R TI TTTCRU2 DMMC31R TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMC31R MA Antagonist DMMC31R RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMC31R RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMC3AG DI DMMC3AG DMMC3AG DN Tetra-hydro-quinoline derivative 4 DMMC3AG TI TTE4BSY DMMC3AG TN Bromodomain and extraterminal domain protein (BET) DMMC3AG MA Inhibitor DMMC3AG RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMMC3AG RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMMCDR7 DI DMMCDR7 DMMCDR7 DN Betais-sulfonylamino derivative 1 DMMCDR7 TI TTYLQ8V DMMCDR7 TN Prostaglandin E synthase (PTGES) DMMCDR7 MA Inhibitor DMMCDR7 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMMCDR7 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMMCHOW DI DMMCHOW DMMCHOW DN Pyrazole derivative 78 DMMCHOW TI TTXJ47W DMMCHOW TN Metabotropic glutamate receptor 2 (mGluR2) DMMCHOW MA Antagonist DMMCHOW RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMMCHOW RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMMCNVO DI DMMCNVO DMMCNVO DN US9694002, 129 DMMCNVO TI TTANOZH DMMCNVO TN SCN1A messenger RNA (SCN1A mRNA) DMMCNVO MA Inhibitor DMMCNVO RN Substituted benzamides and methods of use thereof. US9694002. DMMCNVO RU http://www.freepatentsonline.com/US9694002.html DMMCS9P DI DMMCS9P DMMCS9P DN Matairesinol derivative 1 DMMCS9P TI TTUX68I DMMCS9P TN Hypoxia-inducible factor 1 (HIF-1) DMMCS9P MA Inhibitor DMMCS9P RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMMCS9P RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMMCTAK DI DMMCTAK DMMCTAK DN Oxetane 3,3-dicarboxamide compound 2 DMMCTAK TI TTOHSBA DMMCTAK TN Vascular endothelial growth factor A (VEGFA) DMMCTAK MA Inhibitor DMMCTAK RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMCTAK RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMCWH9 DI DMMCWH9 DMMCWH9 DN Isoflavone derivative 1 DMMCWH9 TI TTJOMH6 DMMCWH9 TN Zinc finger protein GLI1 (Gli1) DMMCWH9 MA Inhibitor DMMCWH9 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMCWH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMCWH9 DI DMMCWH9 DMMCWH9 DN Isoflavone derivative 1 DMMCWH9 TI TT8J1S3 DMMCWH9 TN Smoothened homolog (SMO) DMMCWH9 MA Inhibitor DMMCWH9 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMCWH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMCYI5 DI DMMCYI5 DMMCYI5 DN 1,2,4,5-tetra-substituted imidazole derivative 2 DMMCYI5 TI TT6OEDT DMMCYI5 TN Cannabinoid receptor 1 (CB1) DMMCYI5 MA Antagonist DMMCYI5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMCYI5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMDJH8 DI DMMDJH8 DMMDJH8 DN PMID27539678-Compound-16 DMMDJH8 TI TTOHFIY DMMDJH8 TN Sphingosine kinase 1 (SPHK1) DMMDJH8 MA Inhibitor DMMDJH8 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMMDJH8 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMMDK6B DI DMMDK6B DMMDK6B DN PMID28454500-Compound-93 DMMDK6B TI TTA6ZN2 DMMDK6B TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMMDK6B MA Inhibitor DMMDK6B RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMMDK6B RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMMDYAV DI DMMDYAV DMMDYAV DN N-phenyl-pyridine-2-carboxamide derivative 1 DMMDYAV TI TT23XQV DMMDYAV TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMDYAV MA Inhibitor DMMDYAV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMDYAV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMELYI DI DMMELYI DMMELYI DN 4-amino-3,5-di-substituted-thiazole derivative 1 DMMELYI TI TT7HF4W DMMELYI TN Cyclin-dependent kinase 2 (CDK2) DMMELYI MA Inhibitor DMMELYI RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMELYI RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMETW5 DI DMMETW5 DMMETW5 DN Epoxysuccinate derivative 3 DMMETW5 TI TTG5QB7 DMMETW5 TN Calpain-2 (CAPN2) DMMETW5 MA Inhibitor DMMETW5 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMMETW5 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMMF4XO DI DMMF4XO DMMF4XO DN PMID27607364-Compound-141 DMMF4XO TI TTPTXIN DMMF4XO TN Translocator protein (TSPO) DMMF4XO MA Ligand DMMF4XO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMF4XO RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMF8A1 DI DMMF8A1 DMMF8A1 DN 2-(substituted ethynyl)quinoline derivative 3 DMMF8A1 TI TTHS256 DMMF8A1 TN Metabotropic glutamate receptor 5 (mGluR5) DMMF8A1 MA Antagonist DMMF8A1 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMMF8A1 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMMF9U6 DI DMMF9U6 DMMF9U6 DN Aryl pyrimidine derivative 6 DMMF9U6 TI TTIY56R DMMF9U6 TN Kynurenine 3-hydroxylase (KMO) DMMF9U6 MA Inhibitor DMMF9U6 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMMF9U6 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMMFBI3 DI DMMFBI3 DMMFBI3 DN Dihydropyrido phthalazinone derivative 3 DMMFBI3 TI TTEBCY8 DMMFBI3 TN Poly [ADP-ribose] polymerase (PARP) DMMFBI3 MA Inhibitor DMMFBI3 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMMFBI3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMMFC0V DI DMMFC0V DMMFC0V DN US9409892, 136 DMMFC0V TI TT9ISBX DMMFC0V TN HIF-prolyl hydroxylase 2 (HPH-2) DMMFC0V MA Inhibitor DMMFC0V RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMMFC0V RU http://www.freepatentsonline.com/US9409892.html DMMFCRU DI DMMFCRU DMMFCRU DN Imidazopyridine acetamide analog 5 DMMFCRU TI TTPTXIN DMMFCRU TN Translocator protein (TSPO) DMMFCRU MA Ligand DMMFCRU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMFCRU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMFI5G DI DMMFI5G DMMFI5G DN Hypersulfated disaccharide compound 1 DMMFI5G TI TTPLTSQ DMMFI5G TN Neutrophil elastase (NE) DMMFI5G MA Inhibitor DMMFI5G RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMFI5G RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMFILA DI DMMFILA DMMFILA DN PMID25399762-Compound-Table1-C21 DMMFILA TI TTGP7BY DMMFILA TN Monoamine oxidase type B (MAO-B) DMMFILA MA Inhibitor DMMFILA RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMFILA RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMFK2Q DI DMMFK2Q DMMFK2Q DN PMID25726713-Compound-24 DMMFK2Q TI TT8J1S3 DMMFK2Q TN Smoothened homolog (SMO) DMMFK2Q MA Inhibitor DMMFK2Q RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMMFK2Q RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMMFZKC DI DMMFZKC DMMFZKC DN 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1 DMMFZKC TI TT2F4OL DMMFZKC TN Tissue transglutaminase (TG2) DMMFZKC MA Inhibitor DMMFZKC RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMFZKC RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMGBLC DI DMMGBLC DMMGBLC DN Phenylpurine acetamide analog 2 DMMGBLC TI TTPTXIN DMMGBLC TN Translocator protein (TSPO) DMMGBLC MA Ligand DMMGBLC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMGBLC RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMGLOA DI DMMGLOA DMMGLOA DN Pyrazole derivative 83 DMMGLOA TI TTDP1UC DMMGLOA TN Fatty acid amide hydrolase (FAAH) DMMGLOA MA Inhibitor DMMGLOA RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMGLOA RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMGLOA DI DMMGLOA DMMGLOA DN Pyrazole derivative 83 DMMGLOA TI TTZ963I DMMGLOA TN Monoglyceride lipase (MAGL) DMMGLOA MA Inhibitor DMMGLOA RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMGLOA RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMGQ7Z DI DMMGQ7Z DMMGQ7Z DN PMID26666870-Compound-16 DMMGQ7Z TI TTJOMH6 DMMGQ7Z TN Zinc finger protein GLI1 (Gli1) DMMGQ7Z MA Inhibitor DMMGQ7Z RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMGQ7Z RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMGWKE DI DMMGWKE DMMGWKE DN Pyrazole derivative 39 DMMGWKE TI TT6OEDT DMMGWKE TN Cannabinoid receptor 1 (CB1) DMMGWKE MA Antagonist DMMGWKE RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMGWKE RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMH27J DI DMMH27J DMMH27J DN Carbamate derivative 12 DMMH27J TI TTZ963I DMMH27J TN Monoglyceride lipase (MAGL) DMMH27J MA Inhibitor DMMH27J RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMH27J RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMHL2C DI DMMHL2C DMMHL2C DN PMID26560530-Compound-6 DMMHL2C TI TT2F4OL DMMHL2C TN Tissue transglutaminase (TG2) DMMHL2C MA Inhibitor DMMHL2C RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMHL2C RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMHLA9 DI DMMHLA9 DMMHLA9 DN PMID26004420-Compound-WO2013062892E DMMHLA9 TI TTJ13ST DMMHLA9 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMMHLA9 MA Inhibitor DMMHLA9 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMMHLA9 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMMI4KQ DI DMMI4KQ DMMI4KQ DN PMID27109571-Compound-11 DMMI4KQ TI TTHWMFZ DMMI4KQ TN Fatty acid-binding protein 4 (FABP4) DMMI4KQ MA Inhibitor DMMI4KQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMMI4KQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMMI7DY DI DMMI7DY DMMI7DY DN PMID28092474-Compound-34c DMMI7DY TI TT6R7JZ DMMI7DY TN Histone deacetylase 1 (HDAC1) DMMI7DY MA Inhibitor DMMI7DY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMMI7DY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMMI7DY DI DMMI7DY DMMI7DY DN PMID28092474-Compound-34c DMMI7DY TI TT5ZKDI DMMI7DY TN Histone deacetylase 6 (HDAC6) DMMI7DY MA Inhibitor DMMI7DY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMMI7DY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMMIKFU DI DMMIKFU DMMIKFU DN PMID29649907-Compound-15 DMMIKFU TI TTS4UGC DMMIKFU TN Farnesoid X-activated receptor (FXR) DMMIKFU MA Agonist DMMIKFU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMMIKFU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMMIOZ5 DI DMMIOZ5 DMMIOZ5 DN Pyrazole derivative 53 DMMIOZ5 TI TT6OEDT DMMIOZ5 TN Cannabinoid receptor 1 (CB1) DMMIOZ5 MA Antagonist DMMIOZ5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMIOZ5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMJ0YN DI DMMJ0YN DMMJ0YN DN Cyclopropylamine derivative 11 DMMJ0YN TI TT32XQJ DMMJ0YN TN Monoamine oxidase (MAO) DMMJ0YN MA Inhibitor DMMJ0YN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMJ0YN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMJ0YN DI DMMJ0YN DMMJ0YN DN Cyclopropylamine derivative 11 DMMJ0YN TI TTNR0UQ DMMJ0YN TN Lysine-specific histone demethylase 1 (LSD) DMMJ0YN MA Inhibitor DMMJ0YN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMJ0YN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMJ1FN DI DMMJ1FN DMMJ1FN DN Triazolo[4,3-b]pyridazine derivative 2 DMMJ1FN TI TTTDVOJ DMMJ1FN TN Tropomyosin-related kinase A (TrkA) DMMJ1FN MA Inhibitor DMMJ1FN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMMJ1FN RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMMJ5SN DI DMMJ5SN DMMJ5SN DN PMID28766366-Compound-Scheme12-1 DMMJ5SN TI TTSBVFO DMMJ5SN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMMJ5SN MA Inhibitor DMMJ5SN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMJ5SN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMJ81G DI DMMJ81G DMMJ81G DN Tricyclic compound 6 DMMJ81G TI TTGWKQJ DMMJ81G TN Rho-associated protein kinase 2 (ROCK2) DMMJ81G MA Inhibitor DMMJ81G RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMMJ81G RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMMJEWB DI DMMJEWB DMMJEWB DN Quinoline and quinazoline derivative 7 DMMJEWB TI TTOHSBA DMMJEWB TN Vascular endothelial growth factor A (VEGFA) DMMJEWB MA Inhibitor DMMJEWB RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMJEWB RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMJK0L DI DMMJK0L DMMJK0L DN PMID26815044-Compound-126 DMMJK0L TI TTULVH8 DMMJK0L TN Tyrosinase (TYR) DMMJK0L MA Inhibitor DMMJK0L RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMJK0L RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMJTUW DI DMMJTUW DMMJTUW DN Imatinib and nilotinib derivative 1 DMMJTUW TI TTUNARX DMMJTUW TN Carbonic anhydrase (CA) DMMJTUW MA Inhibitor DMMJTUW RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMMJTUW RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMMJVTW DI DMMJVTW DMMJVTW DN PMID27774822-Compound-Figure10Compound4 DMMJVTW TI TTJNBQA DMMJVTW TN Activin receptor-like kinase 2 (ALK-2) DMMJVTW MA Inhibitor DMMJVTW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMMJVTW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMMJVTW DI DMMJVTW DMMJVTW DN PMID27774822-Compound-Figure10Compound4 DMMJVTW TI TTRMX3V DMMJVTW TN Janus kinase 2 (JAK-2) DMMJVTW MA Inhibitor DMMJVTW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMMJVTW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMMKNP7 DI DMMKNP7 DMMKNP7 DN Thiazole carboxamide derivative 14 DMMKNP7 TI TTCZOF2 DMMKNP7 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMKNP7 MA Inhibitor DMMKNP7 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMKNP7 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMML258 DI DMML258 DMML258 DN US8846654, 251 DMML258 TI TTIS4OW DMML258 TN Phosphodiesterase 8 (PDE8) DMML258 MA Inhibitor DMML258 RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMML258 RU http://www.freepatentsonline.com/US8846654.html DMML4PA DI DMML4PA DMML4PA DN PMID29130358-Compound-Figure17(12) DMML4PA TI TTXZ0KQ DMML4PA TN Matrix metalloproteinase-12 (MMP-12) DMML4PA MA Inhibitor DMML4PA RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMML4PA RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMML4PA DI DMML4PA DMML4PA DN PMID29130358-Compound-Figure17(12) DMML4PA TI TT6X50U DMML4PA TN Matrix metalloproteinase-9 (MMP-9) DMML4PA MA Inhibitor DMML4PA RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMML4PA RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMMLDUI DI DMMLDUI DMMLDUI DN Pyrazolo[1,5-a]pyrimidine derivative 12 DMMLDUI TI TT6OEDT DMMLDUI TN Cannabinoid receptor 1 (CB1) DMMLDUI MA Antagonist DMMLDUI RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMLDUI RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMLJ5E DI DMMLJ5E DMMLJ5E DN PMID25482888-Compound-50 DMMLJ5E TI TTDIGC1 DMMLJ5E TN Dipeptidyl peptidase 4 (DPP-4) DMMLJ5E MA Inhibitor DMMLJ5E RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMMLJ5E RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMMLQAS DI DMMLQAS DMMLQAS DN (-)-deprenyl DMMLQAS TI TT32XQJ DMMLQAS TN Monoamine oxidase (MAO) DMMLQAS MA Inhibitor DMMLQAS RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMLQAS RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMN8OY DI DMMN8OY DMMN8OY DN Amidine compound 5 DMMN8OY TI TTQR74A DMMN8OY TN Proteinase activated receptor 2 (PAR2) DMMN8OY MA Antagonist DMMN8OY RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMMN8OY RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMMNKFX DI DMMNKFX DMMNKFX DN Pyrrole derivative 2 DMMNKFX TI TT6OEDT DMMNKFX TN Cannabinoid receptor 1 (CB1) DMMNKFX MA Antagonist DMMNKFX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMNKFX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMNVZ5 DI DMMNVZ5 DMMNVZ5 DN 1,2,4-tri-substituted imidazoline derivative 1 DMMNVZ5 TI TT6OEDT DMMNVZ5 TN Cannabinoid receptor 1 (CB1) DMMNVZ5 MA Antagonist DMMNVZ5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMNVZ5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMNXA1 DI DMMNXA1 DMMNXA1 DN PMID26815044-Compound-121 DMMNXA1 TI TTULVH8 DMMNXA1 TN Tyrosinase (TYR) DMMNXA1 MA Inhibitor DMMNXA1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMNXA1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMNZ2U DI DMMNZ2U DMMNZ2U DN Alkyl mannoside derivative 11 DMMNZ2U TI TTTCRU2 DMMNZ2U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMNZ2U MA Antagonist DMMNZ2U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMNZ2U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMO3F1 DI DMMO3F1 DMMO3F1 DN PMID25399762-Compound-Table1-C19 DMMO3F1 TI TTGP7BY DMMO3F1 TN Monoamine oxidase type B (MAO-B) DMMO3F1 MA Inhibitor DMMO3F1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMO3F1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMO6JY DI DMMO6JY DMMO6JY DN Thiazole carboxamide derivative 23 DMMO6JY TI TTCZOF2 DMMO6JY TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMO6JY MA Inhibitor DMMO6JY RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMO6JY RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMOGL8 DI DMMOGL8 DMMOGL8 DN Gold-complexed thiosaccharide derivative 3 DMMOGL8 TI TTH8FZW DMMOGL8 TN Signal transducer and activator of transcription 3 (STAT3) DMMOGL8 MA Inhibitor DMMOGL8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMOGL8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMOSKZ DI DMMOSKZ DMMOSKZ DN Carbamate derivative 6 DMMOSKZ TI TTGX13H DMMOSKZ TN Fatty-acid amide hydrolase 1 (FAAH1) DMMOSKZ MA Inhibitor DMMOSKZ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMMOSKZ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMMOSVD DI DMMOSVD DMMOSVD DN Flavonoid derivative 4 DMMOSVD TI TTH8FZW DMMOSVD TN Signal transducer and activator of transcription 3 (STAT3) DMMOSVD MA Inhibitor DMMOSVD RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMOSVD RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMOTWK DI DMMOTWK DMMOTWK DN Biphenyl mannoside derivative 28 DMMOTWK TI TTTCRU2 DMMOTWK TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMOTWK MA Antagonist DMMOTWK RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMOTWK RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMOV67 DI DMMOV67 DMMOV67 DN PMID25522065-Compound-30 DMMOV67 TI TTX4RTB DMMOV67 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMMOV67 MA Antagonist DMMOV67 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMMOV67 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMMOVGU DI DMMOVGU DMMOVGU DN PMID27019002-Compound-43a DMMOVGU TI TTNR0UQ DMMOVGU TN Lysine-specific histone demethylase 1 (LSD) DMMOVGU MA Inhibitor DMMOVGU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMOVGU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMP09F DI DMMP09F DMMP09F DN PMID29649907-Compound-38 DMMP09F TI TTS4UGC DMMP09F TN Farnesoid X-activated receptor (FXR) DMMP09F MA Agonist DMMP09F RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMMP09F RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMMP2RT DI DMMP2RT DMMP2RT DN Benzothiazine-carboxamide compound 2 DMMP2RT TI TTQR74A DMMP2RT TN Proteinase activated receptor 2 (PAR2) DMMP2RT MA Antagonist DMMP2RT RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMMP2RT RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMMP7HX DI DMMP7HX DMMP7HX DN PMID25399762-Compound-Table1-C1 DMMP7HX TI TTGP7BY DMMP7HX TN Monoamine oxidase type B (MAO-B) DMMP7HX MA Inhibitor DMMP7HX RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMP7HX RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMP9N7 DI DMMP9N7 DMMP9N7 DN Peptidomimetic analog 1 DMMP9N7 TI TTH8FZW DMMP9N7 TN Signal transducer and activator of transcription 3 (STAT3) DMMP9N7 MA Inhibitor DMMP9N7 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMP9N7 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMPJ3E DI DMMPJ3E DMMPJ3E DN Biaryl mannoside derivative 31 DMMPJ3E TI TTTCRU2 DMMPJ3E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMPJ3E MA Antagonist DMMPJ3E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMPJ3E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTDP1UC DMMQ0ZO TN Fatty acid amide hydrolase (FAAH) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTSINOV DMMQ0ZO TN Monoacylglycerol lipase ABHD6 (ABHD6) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTZ963I DMMQ0ZO TN Monoglyceride lipase (MAGL) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ3UG DI DMMQ3UG DMMQ3UG DN PMID28394193-Compound-54 DMMQ3UG TI TT9MZCQ DMMQ3UG TN Enhancer of zeste homolog 2 (EZH2) DMMQ3UG MA Inhibitor DMMQ3UG RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMMQ3UG RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TTL4Q97 DMMQFCN TN Cyclin-dependent kinase 5 (CDK5) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TT1LVF2 DMMQFCN TN Cyclin-dependent kinase 9 (CDK9) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TTH6V3D DMMQFCN TN Cyclin-dependent kinase 1 (CDK1) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TT7HF4W DMMQFCN TN Cyclin-dependent kinase 2 (CDK2) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMRT0Q DI DMMRT0Q DMMRT0Q DN PMID25435179-Compound-WO2012006391H3K9TSu DMMRT0Q TI TTSCO7R DMMRT0Q TN NAD-dependent deacetylase sirtuin (SIRT) DMMRT0Q MA Inhibitor DMMRT0Q RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMMRT0Q RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMMRTAL DI DMMRTAL DMMRTAL DN Pyrazole derivative 8 DMMRTAL TI TT6OEDT DMMRTAL TN Cannabinoid receptor 1 (CB1) DMMRTAL MA Antagonist DMMRTAL RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMRTAL RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMRTWG DI DMMRTWG DMMRTWG DN Biphenyl mannoside derivative 14 DMMRTWG TI TTTCRU2 DMMRTWG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMRTWG MA Antagonist DMMRTWG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMRTWG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMRUVT DI DMMRUVT DMMRUVT DN PMID25435179-Compound-EP20142759295NP-1 DMMRUVT TI TTSCO7R DMMRUVT TN NAD-dependent deacetylase sirtuin (SIRT) DMMRUVT MA Inhibitor DMMRUVT RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMMRUVT RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMMRXEQ DI DMMRXEQ DMMRXEQ DN Boronic acid derivative 1 DMMRXEQ TI TTDP1UC DMMRXEQ TN Fatty acid amide hydrolase (FAAH) DMMRXEQ MA Inhibitor DMMRXEQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMMRXEQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMMS4EI DI DMMS4EI DMMS4EI DN Benzyl phenyl ether derivative 2 DMMS4EI TI TT23XQV DMMS4EI TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMS4EI MA Inhibitor DMMS4EI RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMS4EI RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMSHX4 DI DMMSHX4 DMMSHX4 DN US9623028, Compound 79 DMMSHX4 TI TTV298Y DMMSHX4 TN Calmodulin-dependent kinase II (CAMKK2) DMMSHX4 MA Inhibitor DMMSHX4 RN Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028. DMMSHX4 RU http://www.freepatentsonline.com/US9623028.html DMMSPX7 DI DMMSPX7 DMMSPX7 DN Azetidine-benzoxazin-3(4H)-one derivative 2 DMMSPX7 TI TTZ963I DMMSPX7 TN Monoglyceride lipase (MAGL) DMMSPX7 MA Inhibitor DMMSPX7 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMSPX7 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMSTNA DI DMMSTNA DMMSTNA DN Peptide analog 60 DMMSTNA TI TTQAJF1 DMMSTNA TN Cathepsin G (CTSG) DMMSTNA MA Inhibitor DMMSTNA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMSTNA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMSTNA DI DMMSTNA DMMSTNA DN Peptide analog 60 DMMSTNA TI TTPLTSQ DMMSTNA TN Neutrophil elastase (NE) DMMSTNA MA Inhibitor DMMSTNA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMSTNA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMSVW5 DI DMMSVW5 DMMSVW5 DN Oxindole derivative 1 DMMSVW5 TI TTJGW1Z DMMSVW5 TN Phosphodiesterase 2A (PDE2A) DMMSVW5 MA Inhibitor DMMSVW5 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMMSVW5 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMMT98V DI DMMT98V DMMT98V DN US9127005, P2C DMMT98V TI TT3T17P DMMT98V TN Phospholipase D1 (PLD1) DMMT98V MA Inhibitor DMMT98V RN Isoform selective phospholipase D inhibitors. US9127005. DMMT98V RU http://www.freepatentsonline.com/US9127005.html DMMTVN4 DI DMMTVN4 DMMTVN4 DN Resorcinol compound 30 DMMTVN4 TI TTULVH8 DMMTVN4 TN Tyrosinase (TYR) DMMTVN4 MA Inhibitor DMMTVN4 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMTVN4 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMU01R DI DMMU01R DMMU01R DN Heteroaryl-cyclopropylamine derivative 4 DMMU01R TI TTZHPB8 DMMU01R TN Lysine-specific demethylase 4A (KDM4A) DMMU01R MA Inhibitor DMMU01R RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMU01R RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMU01R DI DMMU01R DMMU01R DN Heteroaryl-cyclopropylamine derivative 4 DMMU01R TI TTNR0UQ DMMU01R TN Lysine-specific histone demethylase 1 (LSD) DMMU01R MA Inhibitor DMMU01R RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMU01R RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMV5A9 DI DMMV5A9 DMMV5A9 DN PMID26651364-Compound-49 DMMV5A9 TI TTTCRU2 DMMV5A9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMV5A9 MA Antagonist DMMV5A9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMV5A9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMV5KI DI DMMV5KI DMMV5KI DN PMID29473428-Compound-70 DMMV5KI TI TTZJYKH DMMV5KI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMMV5KI MA Inhibitor DMMV5KI RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMMV5KI RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMMVETJ DI DMMVETJ DMMVETJ DN PMID25776143-Compound-4 DMMVETJ TI TT4TFGN DMMVETJ TN Vasopressin V1a receptor (V1AR) DMMVETJ MA Inhibitor DMMVETJ RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMMVETJ RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMMVG2O DI DMMVG2O DMMVG2O DN Pyrano[2,3-b]pyridine derivative 1 DMMVG2O TI TT6OEDT DMMVG2O TN Cannabinoid receptor 1 (CB1) DMMVG2O MA Antagonist DMMVG2O RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMVG2O RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMVHY4 DI DMMVHY4 DMMVHY4 DN Benzothiazine derivative 1 DMMVHY4 TI TTTN5QW DMMVHY4 TN Serine/threonine-protein kinase pim-1 (PIM1) DMMVHY4 MA Inhibitor DMMVHY4 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMVHY4 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMVHY4 DI DMMVHY4 DMMVHY4 DN Benzothiazine derivative 1 DMMVHY4 TI TT1LVF2 DMMVHY4 TN Cyclin-dependent kinase 9 (CDK9) DMMVHY4 MA Inhibitor DMMVHY4 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMVHY4 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMVPSY DI DMMVPSY DMMVPSY DN Tacrine-caffeic acid hybrid derivative 2 DMMVPSY TI TT1RS9F DMMVPSY TN Acetylcholinesterase (AChE) DMMVPSY MA Inhibitor DMMVPSY RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMMVPSY RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMMVQW8 DI DMMVQW8 DMMVQW8 DN PMID25470667-Compound-Figure4-1A DMMVQW8 TI TTF8P9I DMMVQW8 TN Diacylglycerol acyltransferase 1 (DGAT1) DMMVQW8 MA Inhibitor DMMVQW8 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMMVQW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMMVQW8 DI DMMVQW8 DMMVQW8 DN PMID25470667-Compound-Figure4-1A DMMVQW8 TI TTRHEQ4 DMMVQW8 TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMMVQW8 MA Inhibitor DMMVQW8 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMMVQW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMMWK3E DI DMMWK3E DMMWK3E DN Azetidinyl-piperazine derivative 1 DMMWK3E TI TTZ963I DMMWK3E TN Monoglyceride lipase (MAGL) DMMWK3E MA Inhibitor DMMWK3E RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMWK3E RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMX0N5 DI DMMX0N5 DMMX0N5 DN Pyrrolo-pyrrolone derivative 5 DMMX0N5 TI TTRA6BO DMMX0N5 TN Bromodomain-containing protein 4 (BRD4) DMMX0N5 MA Inhibitor DMMX0N5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMMX0N5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMMX1ZE DI DMMX1ZE DMMX1ZE DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 DMMX1ZE TI TT6OEDT DMMX1ZE TN Cannabinoid receptor 1 (CB1) DMMX1ZE MA Agonist DMMX1ZE RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMMX1ZE RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMMX1ZE DI DMMX1ZE DMMX1ZE DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 DMMX1ZE TI TTMSFAW DMMX1ZE TN Cannabinoid receptor 2 (CB2) DMMX1ZE MA Agonist DMMX1ZE RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMMX1ZE RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMMX5I6 DI DMMX5I6 DMMX5I6 DN PMID29130358-Compound-Figure9(1) DMMX5I6 TI TTXPTJE DMMX5I6 TN Gelatinase (GEL) DMMX5I6 MA Inhibitor DMMX5I6 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMMX5I6 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMMX6V4 DI DMMX6V4 DMMX6V4 DN Heteroaryl-carboxamide derivative 5 DMMX6V4 TI TTCZOF2 DMMX6V4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMX6V4 MA Inhibitor DMMX6V4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMX6V4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMXNY8 DI DMMXNY8 DMMXNY8 DN Mannoside derivative 5 DMMXNY8 TI TTTCRU2 DMMXNY8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMXNY8 MA Antagonist DMMXNY8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMXNY8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMXQJU DI DMMXQJU DMMXQJU DN Bromo benzyl ether derivative 1 DMMXQJU TI TT23XQV DMMXQJU TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMXQJU MA Inhibitor DMMXQJU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMXQJU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMYH82 DI DMMYH82 DMMYH82 DN PMID28074661-Compound-US20169447134C85 DMMYH82 TI TTL7C8Q DMMYH82 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMMYH82 MA Inhibitor DMMYH82 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMMYH82 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMMYW2L DI DMMYW2L DMMYW2L DN Pyrimidinyl compound 7 DMMYW2L TI TTH5TC2 DMMYW2L TN NF-kappa-B-activating kinase (TBK1) DMMYW2L MA Inhibitor DMMYW2L RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMMYW2L RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMMZ1WL DI DMMZ1WL DMMZ1WL DN PMID26651364-Compound-107 DMMZ1WL TI TTTCRU2 DMMZ1WL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMZ1WL MA Antagonist DMMZ1WL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMZ1WL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMZ8LE DI DMMZ8LE DMMZ8LE DN Heteroaryl-azepine derivative 10 DMMZ8LE TI TTWJBZ5 DMMZ8LE TN 5-HT 2C receptor (HTR2C) DMMZ8LE MA Agonist DMMZ8LE RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMMZ8LE RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMMZGC8 DI DMMZGC8 DMMZGC8 DN PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 TI TTYGQ8A DMMZGC8 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMMZGC8 MA Inhibitor DMMZGC8 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMZGC8 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMZGC8 DI DMMZGC8 DMMZGC8 DN PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 TI TTSBVFO DMMZGC8 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMMZGC8 MA Inhibitor DMMZGC8 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMZGC8 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMZHB1 DI DMMZHB1 DMMZHB1 DN PMID25726713-Compound-57 DMMZHB1 TI TT8J1S3 DMMZHB1 TN Smoothened homolog (SMO) DMMZHB1 MA Inhibitor DMMZHB1 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMMZHB1 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMMZO8Y DI DMMZO8Y DMMZO8Y DN PMID25482888-Compound-37 DMMZO8Y TI TTDIGC1 DMMZO8Y TN Dipeptidyl peptidase 4 (DPP-4) DMMZO8Y MA Inhibitor DMMZO8Y RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMMZO8Y RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMN082G DI DMN082G DMN082G DN 6EP DMN082G TI TTIG67W DMN082G TN Lysine-specific demethylase 5A (KDM5A) DMN082G MA Inhibitor DMN082G RN Histone demethylase inhibitors. US9714230. DMN082G RU http://www.freepatentsonline.com/US9714230.html DMN0FCA DI DMN0FCA DMN0FCA DN PMID25666693-Compound-108 DMN0FCA TI TTMI6F5 DMN0FCA TN Transient receptor potential cation channel V1 (TRPV1) DMN0FCA MA Antagonist DMN0FCA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN0FCA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN0XJQ DI DMN0XJQ DMN0XJQ DN Isoflavone derivative 8 DMN0XJQ TI TTJOMH6 DMN0XJQ TN Zinc finger protein GLI1 (Gli1) DMN0XJQ MA Inhibitor DMN0XJQ RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMN0XJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMN0XJQ DI DMN0XJQ DMN0XJQ DN Isoflavone derivative 8 DMN0XJQ TI TT8J1S3 DMN0XJQ TN Smoothened homolog (SMO) DMN0XJQ MA Inhibitor DMN0XJQ RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMN0XJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMN13BI DI DMN13BI DMN13BI DN PMID25726713-Compound-31 DMN13BI TI TT8J1S3 DMN13BI TN Smoothened homolog (SMO) DMN13BI MA Inhibitor DMN13BI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN13BI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN1B3F DI DMN1B3F DMN1B3F DN PMID26004420-Compound-WO2014150132A DMN1B3F TI TTJ13ST DMN1B3F TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMN1B3F MA Inhibitor DMN1B3F RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMN1B3F RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMN1J09 DI DMN1J09 DMN1J09 DN Benzothiazole analog 5 DMN1J09 TI TTULVH8 DMN1J09 TN Tyrosinase (TYR) DMN1J09 MA Inhibitor DMN1J09 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN1J09 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN27QB DI DMN27QB DMN27QB DN PMID25991433-Compound-N1 DMN27QB TI TT0K6EO DMN27QB TN Stress-activated protein kinase JNK1 (JNK1) DMN27QB MA Inhibitor DMN27QB RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMN27QB RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMN27QB DI DMN27QB DMN27QB DN PMID25991433-Compound-N1 DMN27QB TI TTXKZ8Q DMN27QB TN JNK-interacting protein 1 peptide (pepJIP1) DMN27QB MA Inhibitor DMN27QB RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMN27QB RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMN2910 DI DMN2910 DMN2910 DN PMID28454500-Compound-34 DMN2910 TI TTA6ZN2 DMN2910 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMN2910 MA Activator DMN2910 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMN2910 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMN2910 DI DMN2910 DMN2910 DN PMID28454500-Compound-34 DMN2910 TI TT3Z6Y9 DMN2910 TN Cysteines of Keap1 (KEAP1 Cysteines) DMN2910 MA Modulator DMN2910 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMN2910 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMN2B87 DI DMN2B87 DMN2B87 DN 5-azolone derivative 1 DMN2B87 TI TTG5QB7 DMN2B87 TN Calpain-2 (CAPN2) DMN2B87 MA Inhibitor DMN2B87 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMN2B87 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMN2K10 DI DMN2K10 DMN2K10 DN PMID30107136-Compound-Example12 DMN2K10 TI TT23XQV DMN2K10 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMN2K10 MA Inhibitor DMN2K10 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN2K10 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN2K10 DI DMN2K10 DMN2K10 DN PMID30107136-Compound-Example12 DMN2K10 TI TT5YPJF DMN2K10 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMN2K10 MA Inhibitor DMN2K10 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN2K10 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN2VZW DI DMN2VZW DMN2VZW DN Peptidomimetic analog 2 DMN2VZW TI TTH8FZW DMN2VZW TN Signal transducer and activator of transcription 3 (STAT3) DMN2VZW MA Inhibitor DMN2VZW RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMN2VZW RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMN37BI DI DMN37BI DMN37BI DN 4-PAM derivative 1 DMN37BI TI TT1RS9F DMN37BI TN Acetylcholinesterase (AChE) DMN37BI MA Reactivator DMN37BI RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMN37BI RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMN3WID DI DMN3WID DMN3WID DN Cyclohexane carboxamide derivative 1 DMN3WID TI TTTJZ4M DMN3WID TN Prolylcarboxypeptidase (PRCP) DMN3WID MA Inhibitor DMN3WID RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMN3WID RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMN3ZEF DI DMN3ZEF DMN3ZEF DN PMID28092474-Compound-32i DMN3ZEF TI TT6R7JZ DMN3ZEF TN Histone deacetylase 1 (HDAC1) DMN3ZEF MA Inhibitor DMN3ZEF RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMN3ZEF RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMN3ZEF DI DMN3ZEF DMN3ZEF DN PMID28092474-Compound-32i DMN3ZEF TI TT5ZKDI DMN3ZEF TN Histone deacetylase 6 (HDAC6) DMN3ZEF MA Inhibitor DMN3ZEF RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMN3ZEF RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMN42OT DI DMN42OT DMN42OT DN PMID25726713-Compound-11 DMN42OT TI TT8J1S3 DMN42OT TN Smoothened homolog (SMO) DMN42OT MA Inhibitor DMN42OT RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN42OT RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN43Q5 DI DMN43Q5 DMN43Q5 DN Peptide analog 70 DMN43Q5 TI TTQAJF1 DMN43Q5 TN Cathepsin G (CTSG) DMN43Q5 MA Inhibitor DMN43Q5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMN43Q5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMN43Q5 DI DMN43Q5 DMN43Q5 DN Peptide analog 70 DMN43Q5 TI TTPLTSQ DMN43Q5 TN Neutrophil elastase (NE) DMN43Q5 MA Inhibitor DMN43Q5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMN43Q5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMN4C2O DI DMN4C2O DMN4C2O DN PMID26815044-Compound-52 DMN4C2O TI TTULVH8 DMN4C2O TN Tyrosinase (TYR) DMN4C2O MA Inhibitor DMN4C2O RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN4C2O RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN4FRE DI DMN4FRE DMN4FRE DN US8772478, 3 DMN4FRE TI TTQICM2 DMN4FRE TN ADAM metallopeptidase 33 (ADAM33) DMN4FRE MA Inhibitor DMN4FRE RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMN4FRE RU http://www.freepatentsonline.com/US8772478.html DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTRA6BO DMN4SE5 TN Bromodomain-containing protein 4 (BRD4) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTHE657 DMN4SE5 TN Bromodomain-containing protein 3 (BRD3) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTDP48B DMN4SE5 TN Bromodomain-containing protein 2 (BRD2) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN51XF DI DMN51XF DMN51XF DN Ureido-phenyl-substituted triazine derivative 1 DMN51XF TI TTTDVOJ DMN51XF TN Tropomyosin-related kinase A (TrkA) DMN51XF MA Inhibitor DMN51XF RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMN51XF RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMN53R0 DI DMN53R0 DMN53R0 DN Pyrazole derivative 62 DMN53R0 TI TTH8FZW DMN53R0 TN Signal transducer and activator of transcription 3 (STAT3) DMN53R0 MA Inhibitor DMN53R0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMN53R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMN580F DI DMN580F DMN580F DN Heterocyclic derivative 10 DMN580F TI TTCZOF2 DMN580F TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMN580F MA Inhibitor DMN580F RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMN580F RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMN5H3C DI DMN5H3C DMN5H3C DN PMID26815044-Compound-32 DMN5H3C TI TTULVH8 DMN5H3C TN Tyrosinase (TYR) DMN5H3C MA Inhibitor DMN5H3C RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN5H3C RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN5YUK DI DMN5YUK DMN5YUK DN Sulfonamide derivative 7 DMN5YUK TI TTZJYKH DMN5YUK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMN5YUK MA Inhibitor DMN5YUK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMN5YUK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMN64AK DI DMN64AK DMN64AK DN Pyrimidine derivative 22 DMN64AK TI TT8J1S3 DMN64AK TN Smoothened homolog (SMO) DMN64AK MA Inhibitor DMN64AK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN64AK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN692C DI DMN692C DMN692C DN PMID25666693-Compound-3 DMN692C TI TTMI6F5 DMN692C TN Transient receptor potential cation channel V1 (TRPV1) DMN692C MA Antagonist DMN692C RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN692C RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN6GTZ DI DMN6GTZ DMN6GTZ DN 4-Methoxybenzaldehyde DMN6GTZ TI TTGP7BY DMN6GTZ TN Monoamine oxidase type B (MAO-B) DMN6GTZ MA Inhibitor DMN6GTZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMN6GTZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMN6TG7 DI DMN6TG7 DMN6TG7 DN PMID26560530-Compound-8 DMN6TG7 TI TT2F4OL DMN6TG7 TN Tissue transglutaminase (TG2) DMN6TG7 MA Inhibitor DMN6TG7 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMN6TG7 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMN73KO DI DMN73KO DMN73KO DN PMID26666989-Compound-Figure9middle05 DMN73KO TI TT8BUGW DMN73KO TN Glycogen phosphorylase (PYG) DMN73KO MA Inhibitor DMN73KO RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMN73KO RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMN7I9C DI DMN7I9C DMN7I9C DN Macrocycle derivative 1 DMN7I9C TI TT23XQV DMN7I9C TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMN7I9C MA Inhibitor DMN7I9C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN7I9C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN7I9C DI DMN7I9C DMN7I9C DN Macrocycle derivative 1 DMN7I9C TI TT5YPJF DMN7I9C TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMN7I9C MA Inhibitor DMN7I9C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN7I9C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN97QF DI DMN97QF DMN97QF DN Peptide analog 14 DMN97QF TI TTOUSTQ DMN97QF TN Proteasome beta-9 (PS beta-9) DMN97QF MA Inhibitor DMN97QF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMN97QF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMN9KTJ DI DMN9KTJ DMN9KTJ DN Azole derivative 3 DMN9KTJ TI TTDP1UC DMN9KTJ TN Fatty acid amide hydrolase (FAAH) DMN9KTJ MA Inhibitor DMN9KTJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMN9KTJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMN9LDH DI DMN9LDH DMN9LDH DN PMID25666693-Compound-117 DMN9LDH TI TTMI6F5 DMN9LDH TN Transient receptor potential cation channel V1 (TRPV1) DMN9LDH MA Antagonist DMN9LDH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN9LDH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN9VQM DI DMN9VQM DMN9VQM DN Pyrimidine derivative 1 DMN9VQM TI TT4G2JS DMN9VQM TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMN9VQM MA Blocker DMN9VQM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMN9VQM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMN9VQM DI DMN9VQM DMN9VQM DN Pyrimidine derivative 1 DMN9VQM TI TTAXZ0K DMN9VQM TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMN9VQM MA Blocker DMN9VQM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMN9VQM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMNA941 DI DMNA941 DMNA941 DN Phthalazinone derivative 1 DMNA941 TI TTYLQ8V DMNA941 TN Prostaglandin E synthase (PTGES) DMNA941 MA Inhibitor DMNA941 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMNA941 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMNAJWQ DI DMNAJWQ DMNAJWQ DN Piperazine urea derivative 3 DMNAJWQ TI TTQR74A DMNAJWQ TN Proteinase activated receptor 2 (PAR2) DMNAJWQ MA Antagonist DMNAJWQ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMNAJWQ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMNATSQ DI DMNATSQ DMNATSQ DN PMID25666693-Compound-75 DMNATSQ TI TTMI6F5 DMNATSQ TN Transient receptor potential cation channel V1 (TRPV1) DMNATSQ MA Antagonist DMNATSQ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNATSQ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNBAZH DI DMNBAZH DMNBAZH DN Enol carbamate derivative 1 DMNBAZH TI TTDP1UC DMNBAZH TN Fatty acid amide hydrolase (FAAH) DMNBAZH MA Inhibitor DMNBAZH RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNBAZH RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNBCKI DI DMNBCKI DMNBCKI DN Pyrazole derivative 85 DMNBCKI TI TTZ963I DMNBCKI TN Monoglyceride lipase (MAGL) DMNBCKI MA Inhibitor DMNBCKI RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNBCKI RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNBT3K DI DMNBT3K DMNBT3K DN PMID29338548-Compound-28 DMNBT3K TI TTHJTF7 DMNBT3K TN Glycine transporter GlyT-1 (SLC6A9) DMNBT3K MA Inhibitor DMNBT3K RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMNBT3K RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMNBW8P DI DMNBW8P DMNBW8P DN Aryl carboxamide derivative 4 DMNBW8P TI TT4G2JS DMNBW8P TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMNBW8P MA Inhibitor DMNBW8P RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMNBW8P RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMNC0RX DI DMNC0RX DMNC0RX DN Aryl methoxyacrylate derivative 2 DMNC0RX TI TTUX68I DMNC0RX TN Hypoxia-inducible factor 1 (HIF-1) DMNC0RX MA Inhibitor DMNC0RX RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMNC0RX RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMNC5S0 DI DMNC5S0 DMNC5S0 DN Biaryl mannoside derivative 20 DMNC5S0 TI TTTCRU2 DMNC5S0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNC5S0 MA Antagonist DMNC5S0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNC5S0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNCHBL DI DMNCHBL DMNCHBL DN Isoflavone derivative 7 DMNCHBL TI TTJOMH6 DMNCHBL TN Zinc finger protein GLI1 (Gli1) DMNCHBL MA Inhibitor DMNCHBL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMNCHBL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMNCHBL DI DMNCHBL DMNCHBL DN Isoflavone derivative 7 DMNCHBL TI TT8J1S3 DMNCHBL TN Smoothened homolog (SMO) DMNCHBL MA Inhibitor DMNCHBL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMNCHBL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMND8R0 DI DMND8R0 DMND8R0 DN Benzoic acid linked peptide analog 1 DMND8R0 TI TTULVH8 DMND8R0 TN Tyrosinase (TYR) DMND8R0 MA Inhibitor DMND8R0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMND8R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNDAT0 DI DMNDAT0 DMNDAT0 DN Benzothiazole analog 4 DMNDAT0 TI TTULVH8 DMNDAT0 TN Tyrosinase (TYR) DMNDAT0 MA Inhibitor DMNDAT0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNDAT0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNDF1Z DI DMNDF1Z DMNDF1Z DN PMID30185082-Compound-57 DMNDF1Z TI TT9NXW4 DMNDF1Z TN Sigma intracellular receptor 2 (TMEM97) DMNDF1Z MA Ligand DMNDF1Z RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMNDF1Z RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMNDF1Z DI DMNDF1Z DMNDF1Z DN PMID30185082-Compound-57 DMNDF1Z TI TT5TPI6 DMNDF1Z TN Opioid receptor sigma 1 (OPRS1) DMNDF1Z MA Ligand DMNDF1Z RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMNDF1Z RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMNDPEA DI DMNDPEA DMNDPEA DN Carbamate derivative 1 DMNDPEA TI TTDP1UC DMNDPEA TN Fatty acid amide hydrolase (FAAH) DMNDPEA MA Inhibitor DMNDPEA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNDPEA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TTHS0U8 DMNDVC9 TN Stress-activated protein kinase JNK2 (JNK2) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TT0K6EO DMNDVC9 TN Stress-activated protein kinase JNK1 (JNK1) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TT056SO DMNDVC9 TN Stress-activated protein kinase JNK3 (JNK3) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNE9AX DI DMNE9AX DMNE9AX DN PMID29649907-Compound-10 DMNE9AX TI TTS4UGC DMNE9AX TN Farnesoid X-activated receptor (FXR) DMNE9AX MA Agonist DMNE9AX RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMNE9AX RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMNEBXL DI DMNEBXL DMNEBXL DN PMID25666693-Compound-116 DMNEBXL TI TTMI6F5 DMNEBXL TN Transient receptor potential cation channel V1 (TRPV1) DMNEBXL MA Antagonist DMNEBXL RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNEBXL RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNEGA0 DI DMNEGA0 DMNEGA0 DN PMID26394986-Compound-Figure16 DMNEGA0 TI TTH8FZW DMNEGA0 TN Signal transducer and activator of transcription 3 (STAT3) DMNEGA0 MA Inhibitor DMNEGA0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMNEGA0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMNEKOZ DI DMNEKOZ DMNEKOZ DN Dihydropyrimidinone derivative 4 DMNEKOZ TI TTJOW1I DMNEKOZ TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMNEKOZ MA Inhibitor DMNEKOZ RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMNEKOZ RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMNET19 DI DMNET19 DMNET19 DN Pyrimidine derivative 5 DMNET19 TI TTOHSBA DMNET19 TN Vascular endothelial growth factor A (VEGFA) DMNET19 MA Inhibitor DMNET19 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMNET19 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMNEY58 DI DMNEY58 DMNEY58 DN ML272 DMNEY58 TI TT3T17P DMNEY58 TN Phospholipase D1 (PLD1) DMNEY58 MA Inhibitor DMNEY58 RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMNEY58 RU http://www.freepatentsonline.com/US9453017.html DMNG0WH DI DMNG0WH DMNG0WH DN Heterocyclic derivative 19 DMNG0WH TI TTCZOF2 DMNG0WH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMNG0WH MA Inhibitor DMNG0WH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMNG0WH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMNGD2S DI DMNGD2S DMNGD2S DN PMID25666693-Compound-110 DMNGD2S TI TTMI6F5 DMNGD2S TN Transient receptor potential cation channel V1 (TRPV1) DMNGD2S MA Antagonist DMNGD2S RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNGD2S RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNGY8R DI DMNGY8R DMNGY8R DN Tacrine-phenothiazine hybrid derivative 1 DMNGY8R TI TT1RS9F DMNGY8R TN Acetylcholinesterase (AChE) DMNGY8R MA Inhibitor DMNGY8R RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMNGY8R RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMNH891 DI DMNH891 DMNH891 DN PMID27967267-Compound-51 DMNH891 TI TT1RS9F DMNH891 TN Acetylcholinesterase (AChE) DMNH891 MA Reactivator DMNH891 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMNH891 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMNH8GW DI DMNH8GW DMNH8GW DN 1,2-diamino cyclopentane-based derivative 1 DMNH8GW TI TT9N02I DMNH8GW TN Orexin receptor type 2 (HCRTR2) DMNH8GW MA Antagonist DMNH8GW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMNH8GW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMNH8GW DI DMNH8GW DMNH8GW DN 1,2-diamino cyclopentane-based derivative 1 DMNH8GW TI TT60Q8D DMNH8GW TN Orexin receptor type 1 (HCRTR1) DMNH8GW MA Antagonist DMNH8GW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMNH8GW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMNHCMY DI DMNHCMY DMNHCMY DN PMID28394193-Compound-23 DMNHCMY TI TT9MZCQ DMNHCMY TN Enhancer of zeste homolog 2 (EZH2) DMNHCMY MA Inhibitor DMNHCMY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMNHCMY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMNI03Z DI DMNI03Z DMNI03Z DN PMID25522065-Compound-49 DMNI03Z TI TTX4RTB DMNI03Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMNI03Z MA Antagonist DMNI03Z RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMNI03Z RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMNI0M1 DI DMNI0M1 DMNI0M1 DN Aminoazetidine derivative 1 DMNI0M1 TI TT6OEDT DMNI0M1 TN Cannabinoid receptor 1 (CB1) DMNI0M1 MA Antagonist DMNI0M1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNI0M1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNI0PH DI DMNI0PH DMNI0PH DN Isoxazole-based bicyclic compound 4 DMNI0PH TI TTE4BSY DMNI0PH TN Bromodomain and extraterminal domain protein (BET) DMNI0PH MA Inhibitor DMNI0PH RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMNI0PH RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMNIE4M DI DMNIE4M DMNIE4M DN AKOS020330656 DMNIE4M TI TTIG67W DMNIE4M TN Lysine-specific demethylase 5A (KDM5A) DMNIE4M MA Inhibitor DMNIE4M RN Histone demethylase inhibitors. US10179769. DMNIE4M RU http://www.freepatentsonline.com/US10179769.html DMNIER3 DI DMNIER3 DMNIER3 DN Pyrazolo[1,5-a]pyrimidine derivative 17 DMNIER3 TI TTTDVOJ DMNIER3 TN Tropomyosin-related kinase A (TrkA) DMNIER3 MA Inhibitor DMNIER3 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNIER3 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNIKTA DI DMNIKTA DMNIKTA DN PMID27539678-Compound-12 DMNIKTA TI TTOHFIY DMNIKTA TN Sphingosine kinase 1 (SPHK1) DMNIKTA MA Inhibitor DMNIKTA RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMNIKTA RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMNIPE6 DI DMNIPE6 DMNIPE6 DN Benzo[d]oxazole derivative 1 DMNIPE6 TI TTA6ZN2 DMNIPE6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMNIPE6 MA Inhibitor DMNIPE6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMNIPE6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMNISGE DI DMNISGE DMNISGE DN PMID25522065-Compound-36 DMNISGE TI TTX4RTB DMNISGE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMNISGE MA Antagonist DMNISGE RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMNISGE RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMNIWVG DI DMNIWVG DMNIWVG DN N-(phenylamino)-benzoate derivative 1 DMNIWVG TI TT5ZWB6 DMNIWVG TN Dihydrodiol dehydrogenase type I (AKR1C3) DMNIWVG MA Inhibitor; Antagonist; Blocker DMNIWVG RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMNIWVG RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMNIZAR DI DMNIZAR DMNIZAR DN Benzoic acid linked peptide analog 5 DMNIZAR TI TTULVH8 DMNIZAR TN Tyrosinase (TYR) DMNIZAR MA Inhibitor DMNIZAR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNIZAR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNIZD7 DI DMNIZD7 DMNIZD7 DN PMID27774824-Compound-Figure12Example61 DMNIZD7 TI TTGM6VW DMNIZD7 TN Tyrosine-protein kinase BTK (ATK) DMNIZD7 MA Inhibitor DMNIZD7 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMNIZD7 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMNIZD7 DI DMNIZD7 DMNIZD7 DN PMID27774824-Compound-Figure12Example61 DMNIZD7 TI TTT7PJU DMNIZD7 TN Janus kinase 3 (JAK-3) DMNIZD7 MA Inhibitor DMNIZD7 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMNIZD7 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMNJ2R9 DI DMNJ2R9 DMNJ2R9 DN Isoquinoline derivative 5 DMNJ2R9 TI TTMQO60 DMNJ2R9 TN Rho-associated protein kinase (ROCK) DMNJ2R9 MA Inhibitor DMNJ2R9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMNJ2R9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMNJVR6 DI DMNJVR6 DMNJVR6 DN Heterocyclic-tetracyclic tetrahydrofuran derivative 1 DMNJVR6 TI TTYSN63 DMNJVR6 TN 5-HT 2 receptor (5HT2R) DMNJVR6 MA Antagonist DMNJVR6 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNJVR6 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNK2DQ DI DMNK2DQ DMNK2DQ DN PMID25656651-Compound-15c DMNK2DQ TI TTS7G69 DMNK2DQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMNK2DQ MA Inhibitor DMNK2DQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNK2DQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT4YWTO DMNKABH TN Histone deacetylase 3 (HDAC3) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TTSHTOI DMNKABH TN Histone deacetylase 2 (HDAC2) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT6R7JZ DMNKABH TN Histone deacetylase 1 (HDAC1) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT5ZKDI DMNKABH TN Histone deacetylase 6 (HDAC6) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKH07 DI DMNKH07 DMNKH07 DN PMID27215781-Compound-13 DMNKH07 TI TTMSFAW DMNKH07 TN Cannabinoid receptor 2 (CB2) DMNKH07 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMNKH07 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMNKRSZ DI DMNKRSZ DMNKRSZ DN PMID28766366-Compound-Scheme24Paprotrain DMNKRSZ TI TTSBVFO DMNKRSZ TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMNKRSZ MA Inhibitor DMNKRSZ RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMNKRSZ RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMNKW1E DI DMNKW1E DMNKW1E DN PMID25666693-Compound-111 DMNKW1E TI TTMI6F5 DMNKW1E TN Transient receptor potential cation channel V1 (TRPV1) DMNKW1E MA Antagonist DMNKW1E RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNKW1E RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNKXJ2 DI DMNKXJ2 DMNKXJ2 DN PMID28870136-Compound-62 DMNKXJ2 TI TTK0O6Y DMNKXJ2 TN Ecto-5'-nucleotidase (CD73) DMNKXJ2 MA Inhibitor DMNKXJ2 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMNKXJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMNKYL9 DI DMNKYL9 DMNKYL9 DN Benzamide derivative 4 DMNKYL9 TI TT9NXW4 DMNKYL9 TN Sigma intracellular receptor 2 (TMEM97) DMNKYL9 MA Ligand DMNKYL9 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMNKYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMNMU3R DI DMNMU3R DMNMU3R DN PMID25399762-Compound-Table1-C17 DMNMU3R TI TTGP7BY DMNMU3R TN Monoamine oxidase type B (MAO-B) DMNMU3R MA Inhibitor DMNMU3R RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMNMU3R RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMNO2BP DI DMNO2BP DMNO2BP DN Quinoline derivative 2 DMNO2BP TI TT0K1SC DMNO2BP TN 5-HT 2B receptor (HTR2B) DMNO2BP MA Antagonist DMNO2BP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNO2BP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNO2BP DI DMNO2BP DMNO2BP DN Quinoline derivative 2 DMNO2BP TI TTWJBZ5 DMNO2BP TN 5-HT 2C receptor (HTR2C) DMNO2BP MA Agonist DMNO2BP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNO2BP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNOAQB DI DMNOAQB DMNOAQB DN PMID28870136-Compound-44 DMNOAQB TI TTK0O6Y DMNOAQB TN Ecto-5'-nucleotidase (CD73) DMNOAQB MA Inhibitor DMNOAQB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMNOAQB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMNOD4A DI DMNOD4A DMNOD4A DN PMID25666693-Compound-101 DMNOD4A TI TTMI6F5 DMNOD4A TN Transient receptor potential cation channel V1 (TRPV1) DMNOD4A MA Antagonist DMNOD4A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNOD4A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNOJGW DI DMNOJGW DMNOJGW DN PMID26413912-Compound-84 DMNOJGW TI TTGX13H DMNOJGW TN Fatty-acid amide hydrolase 1 (FAAH1) DMNOJGW MA Inhibitor DMNOJGW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNOJGW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNOJGW DI DMNOJGW DMNOJGW DN PMID26413912-Compound-84 DMNOJGW TI TTDP1UC DMNOJGW TN Fatty acid amide hydrolase (FAAH) DMNOJGW MA Inhibitor DMNOJGW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNOJGW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNPBRG DI DMNPBRG DMNPBRG DN Antibodie derivative 3 DMNPBRG TI TTOHSBA DMNPBRG TN Vascular endothelial growth factor A (VEGFA) DMNPBRG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMNPBRG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMNPC0H DI DMNPC0H DMNPC0H DN PMID25468267-Compound-51 DMNPC0H TI TT0RGE9 DMNPC0H TN Lysine-specific demethylase 4 (KDM4) DMNPC0H MA Inhibitor DMNPC0H RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMNPC0H RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMNQF9S DI DMNQF9S DMNQF9S DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4 DMNQF9S TI TTULVH8 DMNQF9S TN Tyrosinase (TYR) DMNQF9S MA Inhibitor DMNQF9S RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNQF9S RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNQLJU DI DMNQLJU DMNQLJU DN Azetidinyl-piperidine derivative 2 DMNQLJU TI TTZ963I DMNQLJU TN Monoglyceride lipase (MAGL) DMNQLJU MA Inhibitor DMNQLJU RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNQLJU RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNQUKP DI DMNQUKP DMNQUKP DN Alkyl mannoside derivative 2 DMNQUKP TI TTTCRU2 DMNQUKP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNQUKP MA Antagonist DMNQUKP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNQUKP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNR6KL DI DMNR6KL DMNR6KL DN PMID27828716-Compound-18 DMNR6KL TI TTRZQE3 DMNR6KL TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNR6KL MA Inhibitor DMNR6KL RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMNR6KL RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMNRG0P DI DMNRG0P DMNRG0P DN Purine derivative 2 DMNRG0P TI TT6OEDT DMNRG0P TN Cannabinoid receptor 1 (CB1) DMNRG0P MA Antagonist DMNRG0P RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNRG0P RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNROIP DI DMNROIP DMNROIP DN PMID25980951-Compound-41 DMNROIP TI TTR7B60 DMNROIP TN X-linked inhibitor of apoptosis protein (XIAP) DMNROIP MA Antagonist DMNROIP RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMNROIP RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMNROIP DI DMNROIP DMNROIP DN PMID25980951-Compound-41 DMNROIP TI TTQ5LRD DMNROIP TN Cellular inhibitor of apoptosis 1 (BIRC2) DMNROIP MA Antagonist DMNROIP RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMNROIP RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMNRU35 DI DMNRU35 DMNRU35 DN PMID27788040-Compound-6c DMNRU35 TI TTV1C0Z DMNRU35 TN Neuropeptide S receptor (NPSR) DMNRU35 MA Antagonist DMNRU35 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMNRU35 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMNSK7U DI DMNSK7U DMNSK7U DN Aryl mannoside derivative 9 DMNSK7U TI TTTCRU2 DMNSK7U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNSK7U MA Antagonist DMNSK7U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNSK7U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNTAYK DI DMNTAYK DMNTAYK DN PMID25416646-Compound-Figure2-K DMNTAYK TI TTZMAO3 DMNTAYK TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMNTAYK MA Agonist DMNTAYK RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMNTAYK RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMNTOZV DI DMNTOZV DMNTOZV DN 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1 DMNTOZV TI TT6OEDT DMNTOZV TN Cannabinoid receptor 1 (CB1) DMNTOZV MA Antagonist DMNTOZV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNTOZV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNTQL5 DI DMNTQL5 DMNTQL5 DN PMID28270010-Compound-Figure24-a DMNTQL5 TI TTTDVOJ DMNTQL5 TN Tropomyosin-related kinase A (TrkA) DMNTQL5 MA Inhibitor DMNTQL5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNTQL5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNTQL5 DI DMNTQL5 DMNTQL5 DN PMID28270010-Compound-Figure24-a DMNTQL5 TI TT7MRDV DMNTQL5 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMNTQL5 MA Inhibitor DMNTQL5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNTQL5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNTRIZ DI DMNTRIZ DMNTRIZ DN PMID28092474-Compound-33j DMNTRIZ TI TT6R7JZ DMNTRIZ TN Histone deacetylase 1 (HDAC1) DMNTRIZ MA Inhibitor DMNTRIZ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMNTRIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMNTRIZ DI DMNTRIZ DMNTRIZ DN PMID28092474-Compound-33j DMNTRIZ TI TT5ZKDI DMNTRIZ TN Histone deacetylase 6 (HDAC6) DMNTRIZ MA Inhibitor DMNTRIZ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMNTRIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMNTVFH DI DMNTVFH DMNTVFH DN PMID25666693-Compound-7 DMNTVFH TI TTMI6F5 DMNTVFH TN Transient receptor potential cation channel V1 (TRPV1) DMNTVFH MA Antagonist DMNTVFH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNTVFH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNTZ93 DI DMNTZ93 DMNTZ93 DN Thiadiazolidindione derivative 3 DMNTZ93 TI TTRZQE3 DMNTZ93 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNTZ93 MA Inhibitor DMNTZ93 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMNTZ93 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMNUA21 DI DMNUA21 DMNUA21 DN PMID28270021-Compound-WO2010077680 109 DMNUA21 TI TTTDVOJ DMNUA21 TN Tropomyosin-related kinase A (TrkA) DMNUA21 MA Antagonist DMNUA21 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMNUA21 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMNUR8E DI DMNUR8E DMNUR8E DN PMID28074661-Compound-US20100022547C88 DMNUR8E TI TTL7C8Q DMNUR8E TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMNUR8E MA Inhibitor DMNUR8E RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMNUR8E RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMNV0OA DI DMNV0OA DMNV0OA DN N-oxalyl-D-tyrosine derivative 8 DMNV0OA TI TTWAQBO DMNV0OA TN Lysine-specific demethylase 4E (KDM4E) DMNV0OA MA Inhibitor DMNV0OA RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMNV0OA RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMNW37Y DI DMNW37Y DMNW37Y DN PMID29338548-Compound-27 DMNW37Y TI TTHJTF7 DMNW37Y TN Glycine transporter GlyT-1 (SLC6A9) DMNW37Y MA Inhibitor DMNW37Y RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMNW37Y RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMNWCUJ DI DMNWCUJ DMNWCUJ DN PMID28394193-Compound-26 DMNWCUJ TI TT9MZCQ DMNWCUJ TN Enhancer of zeste homolog 2 (EZH2) DMNWCUJ MA Inhibitor DMNWCUJ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMNWCUJ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMNWRA0 DI DMNWRA0 DMNWRA0 DN PMID26666989-Compound-Figure9middle04 DMNWRA0 TI TT8BUGW DMNWRA0 TN Glycogen phosphorylase (PYG) DMNWRA0 MA Inhibitor DMNWRA0 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMNWRA0 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMNX5EU DI DMNX5EU DMNX5EU DN Benzoic acid linked peptide analog 4 DMNX5EU TI TTULVH8 DMNX5EU TN Tyrosinase (TYR) DMNX5EU MA Inhibitor DMNX5EU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNX5EU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNXAUZ DI DMNXAUZ DMNXAUZ DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 DMNXAUZ TI TTSXVID DMNXAUZ TN Nuclear factor NF-kappa-B (NFKB) DMNXAUZ MA Inhibitor DMNXAUZ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMNXAUZ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMNXBPQ DI DMNXBPQ DMNXBPQ DN Cyclopropane 1-carboxylic acid derivative 1 DMNXBPQ TI TTIY56R DMNXBPQ TN Kynurenine 3-hydroxylase (KMO) DMNXBPQ MA Inhibitor DMNXBPQ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMNXBPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMNXCZT DI DMNXCZT DMNXCZT DN Quinoline derivative 20 DMNXCZT TI TTSCO7R DMNXCZT TN NAD-dependent deacetylase sirtuin (SIRT) DMNXCZT MA Inhibitor DMNXCZT RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMNXCZT RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMNXJ8G DI DMNXJ8G DMNXJ8G DN Xanthine/amino piperidine compound 1 DMNXJ8G TI TTDIGC1 DMNXJ8G TN Dipeptidyl peptidase 4 (DPP-4) DMNXJ8G MA Inhibitor DMNXJ8G RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMNXJ8G RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMNXVY9 DI DMNXVY9 DMNXVY9 DN PMID25656651-Compound-36a DMNXVY9 TI TTIV39N DMNXVY9 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMNXVY9 MA Inhibitor DMNXVY9 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNXVY9 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNXVY9 DI DMNXVY9 DMNXVY9 DN PMID25656651-Compound-36a DMNXVY9 TI TTS7G69 DMNXVY9 TN Fusion protein Bcr-Abl (Bcr-Abl) DMNXVY9 MA Inhibitor DMNXVY9 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNXVY9 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNXYZP DI DMNXYZP DMNXYZP DN PMID27774822-Compound-Figure10Example19 DMNXYZP TI TTT7PJU DMNXYZP TN Janus kinase 3 (JAK-3) DMNXYZP MA Inhibitor DMNXYZP RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMNXYZP RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMNXYZP DI DMNXYZP DMNXYZP DN PMID27774822-Compound-Figure10Example19 DMNXYZP TI TTRMX3V DMNXYZP TN Janus kinase 2 (JAK-2) DMNXYZP MA Inhibitor DMNXYZP RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMNXYZP RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMNZD8T DI DMNZD8T DMNZD8T DN US9670220, 76 DMNZD8T TI TTDYP7I DMNZD8T TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMNZD8T MA Inhibitor DMNZD8T RN Fused heterocyclic derivatives as S1P modulators. US9670220. DMNZD8T RU http://www.freepatentsonline.com/US9670220.html DMNZO7V DI DMNZO7V DMNZO7V DN PMID29053063-Compound-7c DMNZO7V TI TTZ963I DMNZO7V TN Monoglyceride lipase (MAGL) DMNZO7V MA Inhibitor DMNZO7V RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNZO7V RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNZUHX DI DMNZUHX DMNZUHX DN Pyrazole derivative 67 DMNZUHX TI TTJQOD7 DMNZUHX TN 5-HT 2A receptor (HTR2A) DMNZUHX MA Antagonist DMNZUHX RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNZUHX RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMO02EL DI DMO02EL DMO02EL DN PMID28270021-Compound-WO2014078408Example1 DMO02EL TI TTTDVOJ DMO02EL TN Tropomyosin-related kinase A (TrkA) DMO02EL MA Inhibitor DMO02EL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMO02EL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMO054V DI DMO054V DMO054V DN Pyrazolo[3,4-d]pyrimidine derivative 2 DMO054V TI TTJGW1Z DMO054V TN Phosphodiesterase 2A (PDE2A) DMO054V MA Inhibitor DMO054V RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMO054V RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMO0QME DI DMO0QME DMO0QME DN PMID27967267-Compound-27 DMO0QME TI TT1RS9F DMO0QME TN Acetylcholinesterase (AChE) DMO0QME RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMO0QME RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMO108N DI DMO108N DMO108N DN PMID29865878-Compound-58 DMO108N TI TTEAD9J DMO108N TN Proteasome beta-8 (PS beta-8) DMO108N MA Inhibitor DMO108N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMO108N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMO1920 DI DMO1920 DMO1920 DN 7-azaindole derivative 8 DMO1920 TI TTVDSZ0 DMO1920 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMO1920 MA Inhibitor DMO1920 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMO1920 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMO19Y6 DI DMO19Y6 DMO19Y6 DN Aryl mannoside derivative 4 DMO19Y6 TI TTTCRU2 DMO19Y6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMO19Y6 MA Antagonist DMO19Y6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMO19Y6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMO1I4W DI DMO1I4W DMO1I4W DN Pyrrolidinyl urea derivative 9 DMO1I4W TI TTTDVOJ DMO1I4W TN Tropomyosin-related kinase A (TrkA) DMO1I4W MA Inhibitor DMO1I4W RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMO1I4W RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMO1NAR DI DMO1NAR DMO1NAR DN PMID27828716-Compound-21 DMO1NAR TI TTRZQE3 DMO1NAR TN Glycogen synthase kinase-3 alpha (GSK-3A) DMO1NAR MA Inhibitor DMO1NAR RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMO1NAR RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMO1Y30 DI DMO1Y30 DMO1Y30 DN Heterocyclic-substituted 3-alkyl azetidine derivative 3 DMO1Y30 TI TT6OEDT DMO1Y30 TN Cannabinoid receptor 1 (CB1) DMO1Y30 MA Antagonist DMO1Y30 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO1Y30 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTT7PJU DMO1ZIG TN Janus kinase 3 (JAK-3) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TT6DM01 DMO1ZIG TN Janus kinase 1 (JAK-1) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTRMX3V DMO1ZIG TN Janus kinase 2 (JAK-2) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTBYWP2 DMO1ZIG TN TYK2 tyrosine kinase (TYK2) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO36RL DI DMO36RL DMO36RL DN PMID26560530-Compound-35 DMO36RL TI TT2F4OL DMO36RL TN Tissue transglutaminase (TG2) DMO36RL MA Inhibitor DMO36RL RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMO36RL RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMO3MJ7 DI DMO3MJ7 DMO3MJ7 DN Pyrazolo[1,5-a]pyrimidine derivative 2 DMO3MJ7 TI TT6OEDT DMO3MJ7 TN Cannabinoid receptor 1 (CB1) DMO3MJ7 MA Antagonist DMO3MJ7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO3MJ7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO3QDW DI DMO3QDW DMO3QDW DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 5 DMO3QDW TI TTV8CRH DMO3QDW TN Lysine-specific demethylase 4C (KDM4C) DMO3QDW MA Inhibitor DMO3QDW RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMO3QDW RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMO41ZB DI DMO41ZB DMO41ZB DN Imidazopyridine acetamide analog 1 DMO41ZB TI TTPTXIN DMO41ZB TN Translocator protein (TSPO) DMO41ZB MA Ligand DMO41ZB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMO41ZB RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMO45G3 DI DMO45G3 DMO45G3 DN Heteroaryl-pyrazole derivative 3 DMO45G3 TI TTXJ47W DMO45G3 TN Metabotropic glutamate receptor 2 (mGluR2) DMO45G3 MA Antagonist DMO45G3 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMO45G3 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMO45VP DI DMO45VP DMO45VP DN PMID29649907-Compound-4 DMO45VP TI TTS4UGC DMO45VP TN Farnesoid X-activated receptor (FXR) DMO45VP MA Agonist DMO45VP RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMO45VP RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMO4JYK DI DMO4JYK DMO4JYK DN PMID29338548-Compound-45 DMO4JYK TI TTHJTF7 DMO4JYK TN Glycine transporter GlyT-1 (SLC6A9) DMO4JYK MA Inhibitor DMO4JYK RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMO4JYK RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMO4Q95 DI DMO4Q95 DMO4Q95 DN PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 TI TTYGQ8A DMO4Q95 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMO4Q95 MA Inhibitor DMO4Q95 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO4Q95 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO4Q95 DI DMO4Q95 DMO4Q95 DN PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 TI TTSBVFO DMO4Q95 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMO4Q95 MA Inhibitor DMO4Q95 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO4Q95 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO4YAB DI DMO4YAB DMO4YAB DN Acrylamide compound 1 DMO4YAB TI TT9JNIC DMO4YAB TN Histamine H3 receptor (H3R) DMO4YAB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMO4YAB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMO5479 DI DMO5479 DMO5479 DN PMID28394193-Compound-40 DMO5479 TI TT9MZCQ DMO5479 TN Enhancer of zeste homolog 2 (EZH2) DMO5479 MA Inhibitor DMO5479 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMO5479 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMO64LA DI DMO64LA DMO64LA DN Amide derivative 1 DMO64LA TI TT6OEDT DMO64LA TN Cannabinoid receptor 1 (CB1) DMO64LA MA Antagonist DMO64LA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO64LA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO6KZ5 DI DMO6KZ5 DMO6KZ5 DN PMID28766366-Compound-Scheme5 DMO6KZ5 TI TTYGQ8A DMO6KZ5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMO6KZ5 MA Inhibitor DMO6KZ5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO6KZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO6KZ5 DI DMO6KZ5 DMO6KZ5 DN PMID28766366-Compound-Scheme5 DMO6KZ5 TI TTSBVFO DMO6KZ5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMO6KZ5 MA Inhibitor DMO6KZ5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO6KZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO6M1Q DI DMO6M1Q DMO6M1Q DN Pyrazole derivative 61 DMO6M1Q TI TTCZOF2 DMO6M1Q TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMO6M1Q MA Inhibitor DMO6M1Q RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMO6M1Q RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMO6NWD DI DMO6NWD DMO6NWD DN Carbamate derivative 3 DMO6NWD TI TTDP1UC DMO6NWD TN Fatty acid amide hydrolase (FAAH) DMO6NWD MA Inhibitor DMO6NWD RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMO6NWD RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMO7310 DI DMO7310 DMO7310 DN 1-phenyl-1,3,4-triazole derivative 2 DMO7310 TI TTA6ZN2 DMO7310 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMO7310 MA Inhibitor DMO7310 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMO7310 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMO7310 DI DMO7310 DMO7310 DN 1-phenyl-1,3,4-triazole derivative 2 DMO7310 TI TT956B0 DMO7310 TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMO7310 MA Modulator DMO7310 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMO7310 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMO74I9 DI DMO74I9 DMO74I9 DN PMID27599163-Compound-82 DMO74I9 TI TTPTXIN DMO74I9 TN Translocator protein (TSPO) DMO74I9 MA Ligand DMO74I9 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMO74I9 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMO7ZRW DI DMO7ZRW DMO7ZRW DN Sulfamoylamide derivative 1 DMO7ZRW TI TTZJYKH DMO7ZRW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMO7ZRW MA Inhibitor DMO7ZRW RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMO7ZRW RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMO8JE7 DI DMO8JE7 DMO8JE7 DN Fused heterocyclic compound 8 DMO8JE7 TI TT7RJY8 DMO8JE7 TN Xanthine dehydrogenase/oxidase (XDH) DMO8JE7 MA Inhibitor DMO8JE7 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMO8JE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMO8UKD DI DMO8UKD DMO8UKD DN Five-membered heteroaromatic compound 1 DMO8UKD TI TTZJYKH DMO8UKD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMO8UKD MA Inhibitor DMO8UKD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMO8UKD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMO913H DI DMO913H DMO913H DN PMID25482888-Compound-15 DMO913H TI TTDIGC1 DMO913H TN Dipeptidyl peptidase 4 (DPP-4) DMO913H MA Inhibitor DMO913H RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMO913H RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMO97LR DI DMO97LR DMO97LR DN PMID26815044-Compound-127 DMO97LR TI TTULVH8 DMO97LR TN Tyrosinase (TYR) DMO97LR MA Inhibitor DMO97LR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMO97LR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMO9Q8J DI DMO9Q8J DMO9Q8J DN Pyrrolo-pyrazine derivative 2 DMO9Q8J TI TTT7PJU DMO9Q8J TN Janus kinase 3 (JAK-3) DMO9Q8J MA Inhibitor DMO9Q8J RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMO9Q8J RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMO9RE8 DI DMO9RE8 DMO9RE8 DN Beta-cyclodextrin conjugate derivative 4 DMO9RE8 TI TTTCRU2 DMO9RE8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMO9RE8 MA Antagonist DMO9RE8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMO9RE8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOA8E4 DI DMOA8E4 DMOA8E4 DN Pyrazoline derivative 2 DMOA8E4 TI TT6OEDT DMOA8E4 TN Cannabinoid receptor 1 (CB1) DMOA8E4 MA Antagonist DMOA8E4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOA8E4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOASLQ DI DMOASLQ DMOASLQ DN PMID29473428-Compound-53 DMOASLQ TI TTZJYKH DMOASLQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOASLQ MA Inhibitor DMOASLQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOASLQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOAU09 DI DMOAU09 DMOAU09 DN PMID25991433-Compound-C2 DMOAU09 TI TTVOE6D DMOAU09 TN Mitogen-activated protein kinase (MAPK) DMOAU09 MA Inhibitor DMOAU09 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMOAU09 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMOAXKF DI DMOAXKF DMOAXKF DN Benzamide derivative 16 DMOAXKF TI TTYLQ8V DMOAXKF TN Prostaglandin E synthase (PTGES) DMOAXKF MA Inhibitor DMOAXKF RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMOAXKF RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMOAY3Q DI DMOAY3Q DMOAY3Q DN Isoquinoline carboxamide derivative 1 DMOAY3Q TI TTPTXIN DMOAY3Q TN Translocator protein (TSPO) DMOAY3Q MA Ligand DMOAY3Q RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMOAY3Q RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMOAYEV DI DMOAYEV DMOAYEV DN Heteroaryl-carboxamide derivative 7 DMOAYEV TI TTCZOF2 DMOAYEV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOAYEV MA Inhibitor DMOAYEV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOAYEV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOB8LU DI DMOB8LU DMOB8LU DN PMID27998201-Compound-15 DMOB8LU TI TTDZN01 DMOB8LU TN Cathepsin K (CTSK) DMOB8LU MA Inhibitor DMOB8LU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMOB8LU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMOB8LU DI DMOB8LU DMOB8LU DN PMID27998201-Compound-15 DMOB8LU TI TTUMQVO DMOB8LU TN Cathepsin S (CTSS) DMOB8LU MA Inhibitor DMOB8LU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMOB8LU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMOBFAU DI DMOBFAU DMOBFAU DN Quinazoline derivative 1 DMOBFAU TI TTDIGC1 DMOBFAU TN Dipeptidyl peptidase 4 (DPP-4) DMOBFAU MA Inhibitor DMOBFAU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOBFAU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOCF4Y DI DMOCF4Y DMOCF4Y DN Cyclopropylamine derivative 4 DMOCF4Y TI TTNR0UQ DMOCF4Y TN Lysine-specific histone demethylase 1 (LSD) DMOCF4Y MA Inhibitor DMOCF4Y RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMOCF4Y RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMOD9BY DI DMOD9BY DMOD9BY DN PMID28766366-Compound-Scheme25-4 DMOD9BY TI TTYGQ8A DMOD9BY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMOD9BY MA Inhibitor DMOD9BY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMOD9BY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMOD9BY DI DMOD9BY DMOD9BY DN PMID28766366-Compound-Scheme25-4 DMOD9BY TI TTSBVFO DMOD9BY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMOD9BY MA Inhibitor DMOD9BY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMOD9BY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMODL3P DI DMODL3P DMODL3P DN PMID28627961-Compound-41 DMODL3P TI TTYLQ8V DMODL3P TN Prostaglandin E synthase (PTGES) DMODL3P MA Inhibitor DMODL3P RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMODL3P RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMODPFU DI DMODPFU DMODPFU DN PMID27599163-Compound-76 DMODPFU TI TTPTXIN DMODPFU TN Translocator protein (TSPO) DMODPFU MA Ligand DMODPFU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMODPFU RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMODT8F DI DMODT8F DMODT8F DN PMID26924192-Compound-54 DMODT8F TI TTE4BSY DMODT8F TN Bromodomain and extraterminal domain protein (BET) DMODT8F MA Inhibitor DMODT8F RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMODT8F RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMODTSC DI DMODTSC DMODTSC DN Phthalazine derivative 2 DMODTSC TI TTEBCY8 DMODTSC TN Poly [ADP-ribose] polymerase (PARP) DMODTSC MA Inhibitor DMODTSC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMODTSC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMOE2FZ DI DMOE2FZ DMOE2FZ DN Pyrimidinyl compound 3 DMOE2FZ TI TTH5TC2 DMOE2FZ TN NF-kappa-B-activating kinase (TBK1) DMOE2FZ MA Inhibitor DMOE2FZ RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMOE2FZ RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMOE5N0 DI DMOE5N0 DMOE5N0 DN PMID25514969-Compound-12 DMOE5N0 TI TT4EB85 DMOE5N0 TN Cholesterol 24-hydroxylase (CYP46A1) DMOE5N0 MA Inhibitor DMOE5N0 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMOE5N0 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMOEFD3 DI DMOEFD3 DMOEFD3 DN Disulfiram analog 1 DMOEFD3 TI TTZHPB8 DMOEFD3 TN Lysine-specific demethylase 4A (KDM4A) DMOEFD3 MA Inhibitor DMOEFD3 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMOEFD3 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOENP4 DI DMOENP4 DMOENP4 DN PMID27774822-Compound-Figure3CompoundI-165 DMOENP4 TI TTRMX3V DMOENP4 TN Janus kinase 2 (JAK-2) DMOENP4 MA Inhibitor DMOENP4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMOENP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMOENP4 DI DMOENP4 DMOENP4 DN PMID27774822-Compound-Figure3CompoundI-165 DMOENP4 TI TTBYWP2 DMOENP4 TN TYK2 tyrosine kinase (TYK2) DMOENP4 MA Inhibitor DMOENP4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMOENP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMOEYVT DI DMOEYVT DMOEYVT DN PMID27454349-Compound-92 DMOEYVT TI TTK59TV DMOEYVT TN Vitamin D3 receptor (VDR) DMOEYVT MA Agonist DMOEYVT RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMOEYVT RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMOFI09 DI DMOFI09 DMOFI09 DN Bicyclic heteroaryl amide derivative 1 DMOFI09 TI TT473XN DMOFI09 TN P2X purinoceptor 7 (P2RX7) DMOFI09 MA Antagonist DMOFI09 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMOFI09 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMOG72B DI DMOG72B DMOG72B DN Heteroaryl-azepine derivative 12 DMOG72B TI TTWJBZ5 DMOG72B TN 5-HT 2C receptor (HTR2C) DMOG72B MA Agonist DMOG72B RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOG72B RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOG8XT DI DMOG8XT DMOG8XT DN Aryl mannoside derivative 12 DMOG8XT TI TTTCRU2 DMOG8XT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOG8XT MA Antagonist DMOG8XT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOG8XT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOGIAU DI DMOGIAU DMOGIAU DN PMID29130358-Compound-LonimacranthoideVII DMOGIAU TI TTLM12X DMOGIAU TN Matrix metalloproteinase-2 (MMP-2) DMOGIAU MA Inhibitor DMOGIAU RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMOGIAU RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMOGIAU DI DMOGIAU DMOGIAU DN PMID29130358-Compound-LonimacranthoideVII DMOGIAU TI TT6X50U DMOGIAU TN Matrix metalloproteinase-9 (MMP-9) DMOGIAU MA Inhibitor DMOGIAU RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMOGIAU RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMOGKSW DI DMOGKSW DMOGKSW DN PMID25656651-Compound-36c DMOGKSW TI TTIV39N DMOGKSW TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMOGKSW MA Inhibitor DMOGKSW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMOGKSW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMOGKSW DI DMOGKSW DMOGKSW DN PMID25656651-Compound-36c DMOGKSW TI TTS7G69 DMOGKSW TN Fusion protein Bcr-Abl (Bcr-Abl) DMOGKSW MA Inhibitor DMOGKSW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMOGKSW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMOGLBZ DI DMOGLBZ DMOGLBZ DN Macrocyclic peptide analog 2 DMOGLBZ TI TT23XQV DMOGLBZ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOGLBZ MA Inhibitor DMOGLBZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOGLBZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOHBCN DI DMOHBCN DMOHBCN DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12 DMOHBCN TI TTULVH8 DMOHBCN TN Tyrosinase (TYR) DMOHBCN MA Inhibitor DMOHBCN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMOHBCN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMOHERV DI DMOHERV DMOHERV DN Benzimidazole derivative 12 DMOHERV TI TTYLQ8V DMOHERV TN Prostaglandin E synthase (PTGES) DMOHERV MA Inhibitor DMOHERV RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMOHERV RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMOHITL DI DMOHITL DMOHITL DN Indoline derivative 19 DMOHITL TI TTOHSBA DMOHITL TN Vascular endothelial growth factor A (VEGFA) DMOHITL MA Inhibitor DMOHITL RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMOHITL RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMOIKB3 DI DMOIKB3 DMOIKB3 DN 5-Hydrazino-1H-tetrazole DMOIKB3 TI TTLQUZS DMOIKB3 TN Cystathionine gamma-lyase (CTH) DMOIKB3 MA Inhibitor DMOIKB3 RN Cystathionine--lyase (CSE) inhibitors. US9725426. DMOIKB3 RU http://www.freepatentsonline.com/US9725426.html DMOISDH DI DMOISDH DMOISDH DN PMID25666693-Compound-99 DMOISDH TI TTMI6F5 DMOISDH TN Transient receptor potential cation channel V1 (TRPV1) DMOISDH MA Antagonist DMOISDH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMOISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMOJ52P DI DMOJ52P DMOJ52P DN PMID26394986-Compound-44 DMOJ52P TI TTH8FZW DMOJ52P TN Signal transducer and activator of transcription 3 (STAT3) DMOJ52P MA Inhibitor DMOJ52P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMOJ52P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMOJ8P1 DI DMOJ8P1 DMOJ8P1 DN Pyrano[2,3-b]pyridine derivative 2 DMOJ8P1 TI TT6OEDT DMOJ8P1 TN Cannabinoid receptor 1 (CB1) DMOJ8P1 MA Antagonist DMOJ8P1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOJ8P1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOJ936 DI DMOJ936 DMOJ936 DN PMID26815044-Compound-114 DMOJ936 TI TTULVH8 DMOJ936 TN Tyrosinase (TYR) DMOJ936 MA Inhibitor DMOJ936 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMOJ936 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMOJAZ9 DI DMOJAZ9 DMOJAZ9 DN Sulfonylated piperazine derivative 3 DMOJAZ9 TI TT6OEDT DMOJAZ9 TN Cannabinoid receptor 1 (CB1) DMOJAZ9 MA Antagonist DMOJAZ9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOJAZ9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOJDQF DI DMOJDQF DMOJDQF DN Peptide analog 44 DMOJDQF TI TTDIGC1 DMOJDQF TN Dipeptidyl peptidase 4 (DPP-4) DMOJDQF MA Inhibitor DMOJDQF RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOJDQF RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOJTLU DI DMOJTLU DMOJTLU DN Pyrimidine derivative 31 DMOJTLU TI TTDIGC1 DMOJTLU TN Dipeptidyl peptidase 4 (DPP-4) DMOJTLU MA Inhibitor DMOJTLU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOJTLU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOJVK6 DI DMOJVK6 DMOJVK6 DN PMID26651364-Compound-105 DMOJVK6 TI TTTCRU2 DMOJVK6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOJVK6 MA Antagonist DMOJVK6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOJVK6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TT1LVF2 DMOK7CW TN Cyclin-dependent kinase 9 (CDK9) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TTH6V3D DMOK7CW TN Cyclin-dependent kinase 1 (CDK1) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TTL4Q97 DMOK7CW TN Cyclin-dependent kinase 5 (CDK5) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TT7HF4W DMOK7CW TN Cyclin-dependent kinase 2 (CDK2) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOKC41 DI DMOKC41 DMOKC41 DN Carbamate derivative 15 DMOKC41 TI TTZ963I DMOKC41 TN Monoglyceride lipase (MAGL) DMOKC41 MA Inhibitor DMOKC41 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMOKC41 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMOKG3Q DI DMOKG3Q DMOKG3Q DN US9181182, 34 DMOKG3Q TI TTDYP7I DMOKG3Q TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMOKG3Q MA Inhibitor DMOKG3Q RN S1P receptors modulators. US9181182. DMOKG3Q RU http://www.freepatentsonline.com/US9181182.html DMOKJEP DI DMOKJEP DMOKJEP DN Biphenyl mannoside derivative 3 DMOKJEP TI TTTCRU2 DMOKJEP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOKJEP MA Antagonist DMOKJEP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOKJEP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOMGU5 DI DMOMGU5 DMOMGU5 DN Disulfiram analog 2 DMOMGU5 TI TTZHPB8 DMOMGU5 TN Lysine-specific demethylase 4A (KDM4A) DMOMGU5 MA Inhibitor DMOMGU5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMOMGU5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOMTBE DI DMOMTBE DMOMTBE DN Macrocycle derivative 8 DMOMTBE TI TT23XQV DMOMTBE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOMTBE MA Inhibitor DMOMTBE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOMTBE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOMTBE DI DMOMTBE DMOMTBE DN Macrocycle derivative 8 DMOMTBE TI TT5YPJF DMOMTBE TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMOMTBE MA Inhibitor DMOMTBE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOMTBE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMON5RD DI DMON5RD DMON5RD DN Heteroaryl-azepine derivative 5 DMON5RD TI TTWJBZ5 DMON5RD TN 5-HT 2C receptor (HTR2C) DMON5RD MA Agonist DMON5RD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMON5RD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMONAZI DI DMONAZI DMONAZI DN PMID26651364-Compound-119 DMONAZI TI TTTCRU2 DMONAZI TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMONAZI MA Antagonist DMONAZI RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMONAZI RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMONCT1 DI DMONCT1 DMONCT1 DN Pyridoindole derivative 3 DMONCT1 TI TTS7G69 DMONCT1 TN Fusion protein Bcr-Abl (Bcr-Abl) DMONCT1 MA Inhibitor DMONCT1 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMONCT1 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMONDMG DI DMONDMG DMONDMG DN Benzothiazepine analog 9 DMONDMG TI TTPTXIN DMONDMG TN Translocator protein (TSPO) DMONDMG MA Ligand DMONDMG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMONDMG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMONEJ4 DI DMONEJ4 DMONEJ4 DN PMID28074661-Compound-US20100022547C86 DMONEJ4 TI TTL7C8Q DMONEJ4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMONEJ4 MA Inhibitor DMONEJ4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMONEJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMONJLT DI DMONJLT DMONJLT DN PMID25522065-Compound-45 DMONJLT TI TTX4RTB DMONJLT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMONJLT MA Antagonist DMONJLT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMONJLT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMONQ4L DI DMONQ4L DMONQ4L DN Azetidine-1-carboxamide derivative 2 DMONQ4L TI TT6OEDT DMONQ4L TN Cannabinoid receptor 1 (CB1) DMONQ4L MA Antagonist DMONQ4L RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMONQ4L RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMONWYI DI DMONWYI DMONWYI DN PMID25468267-Compound-53 DMONWYI TI TT0RGE9 DMONWYI TN Lysine-specific demethylase 4 (KDM4) DMONWYI MA Inhibitor DMONWYI RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMONWYI RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOPF9N DI DMOPF9N DMOPF9N DN Carbamate derivative 7 DMOPF9N TI TTDP1UC DMOPF9N TN Fatty acid amide hydrolase (FAAH) DMOPF9N MA Inhibitor DMOPF9N RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOPF9N RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOPNJ6 DI DMOPNJ6 DMOPNJ6 DN Azole derivative 2 DMOPNJ6 TI TTDP1UC DMOPNJ6 TN Fatty acid amide hydrolase (FAAH) DMOPNJ6 MA Inhibitor DMOPNJ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOPNJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOPR7A DI DMOPR7A DMOPR7A DN PMID26666989-Compound-Figure9middle03 DMOPR7A TI TT8BUGW DMOPR7A TN Glycogen phosphorylase (PYG) DMOPR7A MA Inhibitor DMOPR7A RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMOPR7A RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMOPUFM DI DMOPUFM DMOPUFM DN N-(benzimidazole/indole) benzoic acid derivative 2 DMOPUFM TI TT5ZWB6 DMOPUFM TN Dihydrodiol dehydrogenase type I (AKR1C3) DMOPUFM MA Inhibitor DMOPUFM RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMOPUFM RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TT0K1SC DMOQ726 TN 5-HT 2B receptor (HTR2B) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TTWJBZ5 DMOQ726 TN 5-HT 2C receptor (HTR2C) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TTJQOD7 DMOQ726 TN 5-HT 2A receptor (HTR2A) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQBN4 DI DMOQBN4 DMOQBN4 DN Macrocycle derivative 4 DMOQBN4 TI TT23XQV DMOQBN4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOQBN4 MA Inhibitor DMOQBN4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOQBN4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOQBN4 DI DMOQBN4 DMOQBN4 DN Macrocycle derivative 4 DMOQBN4 TI TT5YPJF DMOQBN4 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMOQBN4 MA Inhibitor DMOQBN4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOQBN4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOQHA9 DI DMOQHA9 DMOQHA9 DN Aminoazetidine derivative 3 DMOQHA9 TI TT6OEDT DMOQHA9 TN Cannabinoid receptor 1 (CB1) DMOQHA9 MA Antagonist DMOQHA9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOQHA9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOQJMU DI DMOQJMU DMOQJMU DN Piperidinyl triazole derivative 4 DMOQJMU TI TTTJZ4M DMOQJMU TN Prolylcarboxypeptidase (PRCP) DMOQJMU MA Inhibitor DMOQJMU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMOQJMU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMOR9ZA DI DMOR9ZA DMOR9ZA DN Bis-indolylmaleimide derivative 1 DMOR9ZA TI TTCZOF2 DMOR9ZA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOR9ZA MA Inhibitor DMOR9ZA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOR9ZA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMORBE3 DI DMORBE3 DMORBE3 DN Carbamide derivative 6 DMORBE3 TI TTL7C8Q DMORBE3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMORBE3 MA Inhibitor DMORBE3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMORBE3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMORFPT DI DMORFPT DMORFPT DN Cyclohexyl carbamate derivative 1 DMORFPT TI TTULVH8 DMORFPT TN Tyrosinase (TYR) DMORFPT MA Inhibitor DMORFPT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMORFPT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMORK8H DI DMORK8H DMORK8H DN PMID25772215-Compound-US02014179750TG7-170 DMORK8H TI TT1ZAVI DMORK8H TN Prostaglandin E2 receptor EP2 (PTGER2) DMORK8H MA Antagonist DMORK8H RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMORK8H RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMORSH9 DI DMORSH9 DMORSH9 DN Thiazole carboxamide derivative 20 DMORSH9 TI TTCZOF2 DMORSH9 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMORSH9 MA Inhibitor DMORSH9 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMORSH9 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOS03R DI DMOS03R DMOS03R DN Biphenyl mannoside derivative 5 DMOS03R TI TTTCRU2 DMOS03R TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOS03R MA Antagonist DMOS03R RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOS03R RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOS7ZP DI DMOS7ZP DMOS7ZP DN PMID27724045-Compound-33 DMOS7ZP TI TT473XN DMOS7ZP TN P2X purinoceptor 7 (P2RX7) DMOS7ZP MA Antagonist DMOS7ZP RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMOS7ZP RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMOT1FQ DI DMOT1FQ DMOT1FQ DN Sterol derivative 3 DMOT1FQ TI TTPADOQ DMOT1FQ TN HMG-CoA reductase (HMGCR) DMOT1FQ MA Inhibitor DMOT1FQ RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMOT1FQ RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMOTG2Y DI DMOTG2Y DMOTG2Y DN Dihydropyrido pyrazinone compound 2 DMOTG2Y TI TTIYVQP DMOTG2Y TN Polo-like kinase 1 (PLK1) DMOTG2Y MA Inhibitor DMOTG2Y RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMOTG2Y RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMOTGEK DI DMOTGEK DMOTGEK DN Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1 DMOTGEK TI TTCZOF2 DMOTGEK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOTGEK MA Inhibitor DMOTGEK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOTGEK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOU84B DI DMOU84B DMOU84B DN Benzyl amine derivative 1 DMOU84B TI TT5L2VC DMOU84B TN Kallikrein-related peptidase (KLK) DMOU84B MA Inhibitor DMOU84B RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMOU84B RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMOU8T3 DI DMOU8T3 DMOU8T3 DN Fused aryl carbocycle derivative 4 DMOU8T3 TI TT9NXW4 DMOU8T3 TN Sigma intracellular receptor 2 (TMEM97) DMOU8T3 MA Ligand DMOU8T3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMOU8T3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMOUT1F DI DMOUT1F DMOUT1F DN Mannoside derivative 7 DMOUT1F TI TTTCRU2 DMOUT1F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOUT1F MA Antagonist DMOUT1F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOUT1F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOV86T DI DMOV86T DMOV86T DN Terpyridineplatinum(II) complexe 4 DMOV86T TI TTEP6RV DMOV86T TN Glutathione reductase (GR) DMOV86T MA Inhibitor DMOV86T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMOV86T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMOV86T DI DMOV86T DMOV86T DN Terpyridineplatinum(II) complexe 4 DMOV86T TI TTR7UJ3 DMOV86T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMOV86T MA Inhibitor DMOV86T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMOV86T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMOV9XA DI DMOV9XA DMOV9XA DN Azaindazole derivative 3 DMOV9XA TI TTK0FEA DMOV9XA TN Leucine-rich repeat kinase 2 (LRRK2) DMOV9XA MA Inhibitor DMOV9XA RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMOV9XA RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMOVEZF DI DMOVEZF DMOVEZF DN VAPBGCRAUJRZPO-UHFFFAOYSA-N DMOVEZF TI TTI1FPZ DMOVEZF TN Epithelial discoidin domain receptor 1 (DDR1) DMOVEZF MA Inhibitor DMOVEZF RN Benzamide derivative. US9695118. DMOVEZF RU http://www.freepatentsonline.com/US9695118.html DMOVJ35 DI DMOVJ35 DMOVJ35 DN Imidazo pyridine derivative 5 DMOVJ35 TI TTV1C0Z DMOVJ35 TN Neuropeptide S receptor (NPSR) DMOVJ35 MA Antagonist DMOVJ35 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMOVJ35 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMOVPWD DI DMOVPWD DMOVPWD DN PMID29473428-Compound-6 DMOVPWD TI TTZJYKH DMOVPWD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOVPWD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOVPWD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOW01E DI DMOW01E DMOW01E DN Azole derivative 4 DMOW01E TI TTDP1UC DMOW01E TN Fatty acid amide hydrolase (FAAH) DMOW01E MA Inhibitor DMOW01E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOW01E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOWFA5 DI DMOWFA5 DMOWFA5 DN Thieno[3,2-c]pyridine-7-carboxamide derivative 2 DMOWFA5 TI TTCZOF2 DMOWFA5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOWFA5 MA Inhibitor DMOWFA5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOWFA5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOWULJ DI DMOWULJ DMOWULJ DN PMID25991433-Compound-J6 DMOWULJ TI TTVOE6D DMOWULJ TN Mitogen-activated protein kinase (MAPK) DMOWULJ MA Inhibitor DMOWULJ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMOWULJ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMOX8E3 DI DMOX8E3 DMOX8E3 DN PMID26882240-Compound-7 DMOX8E3 TI TTUX68I DMOX8E3 TN Hypoxia-inducible factor 1 (HIF-1) DMOX8E3 MA Inhibitor DMOX8E3 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMOX8E3 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMOXHZJ DI DMOXHZJ DMOXHZJ DN Imidazole derivative 6 DMOXHZJ TI TT6OEDT DMOXHZJ TN Cannabinoid receptor 1 (CB1) DMOXHZJ MA Antagonist DMOXHZJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOXHZJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOXIZC DI DMOXIZC DMOXIZC DN Sulfonamide derivative 8 DMOXIZC TI TTZJYKH DMOXIZC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOXIZC MA Inhibitor DMOXIZC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOXIZC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOXJ7Q DI DMOXJ7Q DMOXJ7Q DN Phytocannabinoid/aminoalkylindole derivative 2 DMOXJ7Q TI TTMSFAW DMOXJ7Q TN Cannabinoid receptor 2 (CB2) DMOXJ7Q RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMOXJ7Q RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMOXJ7Q DI DMOXJ7Q DMOXJ7Q DN Phytocannabinoid/aminoalkylindole derivative 2 DMOXJ7Q TI TT6OEDT DMOXJ7Q TN Cannabinoid receptor 1 (CB1) DMOXJ7Q RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMOXJ7Q RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMOY5EK DI DMOY5EK DMOY5EK DN 2-(substituted ethynyl)quinoline derivative 1 DMOY5EK TI TTHS256 DMOY5EK TN Metabotropic glutamate receptor 5 (mGluR5) DMOY5EK MA Antagonist DMOY5EK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMOY5EK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMOYMWZ DI DMOYMWZ DMOYMWZ DN PMID28447479-Compound-11 DMOYMWZ TI TTSCIM2 DMOYMWZ TN Extracellular lysophospholipase D (E-NPP2) DMOYMWZ MA Inhibitor DMOYMWZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMOYMWZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMOZ4FS DI DMOZ4FS DMOZ4FS DN US8933095, 18 DMOZ4FS TI TTT3IXG DMOZ4FS TN Kynurenine oxoglutarate transaminase II (AADAT) DMOZ4FS MA Inhibitor DMOZ4FS RN KAT II inhibitors. US8598200. DMOZ4FS RU http://www.freepatentsonline.com/US8598200.html DMOZ84C DI DMOZ84C DMOZ84C DN US10077269, Example 6 DMOZ84C TI TT6A59G DMOZ84C TN Phosphodiesterase 4C (PDE4C) DMOZ84C MA Inhibitor DMOZ84C RN Imidazopyridazine compounds. US9598421. DMOZ84C RU http://www.freepatentsonline.com/US9598421.html DMOZHGU DI DMOZHGU DMOZHGU DN PMID28270021-Compound-WO2015042088Example12 DMOZHGU TI TTTDVOJ DMOZHGU TN Tropomyosin-related kinase A (TrkA) DMOZHGU MA Inhibitor DMOZHGU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMOZHGU RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMOZKAH DI DMOZKAH DMOZKAH DN PMID27109571-Compound-5 DMOZKAH TI TTMY6L1 DMOZKAH TN Fatty acid-binding protein (FABP) DMOZKAH MA Inhibitor DMOZKAH RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMOZKAH RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMOZTUE DI DMOZTUE DMOZTUE DN Mycophenolic acid/nucleotide derivative 1 DMOZTUE TI TTL7C8Q DMOZTUE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMOZTUE MA Inhibitor DMOZTUE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMOZTUE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMP04Z6 DI DMP04Z6 DMP04Z6 DN 879325-11-8 DMP04Z6 TI TTOJ9QL DMP04Z6 TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMP04Z6 MA Inhibitor DMP04Z6 RN IRE-1 inhibitors. US9040714. DMP04Z6 RU http://www.freepatentsonline.com/US9040714.html DMP0TBO DI DMP0TBO DMP0TBO DN US9006244, E2b DMP0TBO TI TTECBXN DMP0TBO TN Oxysterols receptor LXR-alpha (NR1H3) DMP0TBO MA Inhibitor DMP0TBO RN Liver X receptor modulators. US9006244. DMP0TBO RU http://www.freepatentsonline.com/US9006244.html DMP130R DI DMP130R DMP130R DN PMID26004420-Compound-WO2013039802B DMP130R TI TTJ13ST DMP130R TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMP130R MA Inhibitor DMP130R RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMP130R RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMP1MDV DI DMP1MDV DMP1MDV DN Pyrazino[2,1-a]isoquinolin derivative 1 DMP1MDV TI TTA6ZN2 DMP1MDV TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMP1MDV MA Activator DMP1MDV RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMP1MDV RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMP1MDV DI DMP1MDV DMP1MDV DN Pyrazino[2,1-a]isoquinolin derivative 1 DMP1MDV TI TT3Z6Y9 DMP1MDV TN Cysteines of Keap1 (KEAP1 Cysteines) DMP1MDV MA Modulator DMP1MDV RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMP1MDV RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TTQ6VDM DMP1NKI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TT5TPI6 DMP1NKI TN Opioid receptor sigma 1 (OPRS1) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TT9NXW4 DMP1NKI TN Sigma intracellular receptor 2 (TMEM97) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1RV5 DI DMP1RV5 DMP1RV5 DN Picolinamido propanoic acid derivative 3 DMP1RV5 TI TT9O6WS DMP1RV5 TN Glucagon receptor (GCGR) DMP1RV5 MA Antagonist DMP1RV5 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMP1RV5 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMP29I0 DI DMP29I0 DMP29I0 DN Urea and carbamate bioisostere derivative 6 DMP29I0 TI TTL7C8Q DMP29I0 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMP29I0 MA Inhibitor DMP29I0 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMP29I0 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMP2AXV DI DMP2AXV DMP2AXV DN Imidazopyridine derivative 4 DMP2AXV TI TTT7PJU DMP2AXV TN Janus kinase 3 (JAK-3) DMP2AXV MA Inhibitor DMP2AXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMP2AXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMP2AXV DI DMP2AXV DMP2AXV DN Imidazopyridine derivative 4 DMP2AXV TI TTGM6VW DMP2AXV TN Tyrosine-protein kinase BTK (ATK) DMP2AXV MA Inhibitor DMP2AXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMP2AXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMP2JF0 DI DMP2JF0 DMP2JF0 DN Macrocycle derivative 7 DMP2JF0 TI TT23XQV DMP2JF0 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMP2JF0 MA Inhibitor DMP2JF0 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMP2JF0 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMP2JF0 DI DMP2JF0 DMP2JF0 DN Macrocycle derivative 7 DMP2JF0 TI TT5YPJF DMP2JF0 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMP2JF0 MA Inhibitor DMP2JF0 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMP2JF0 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMP2LDC DI DMP2LDC DMP2LDC DN Benzamide derivative 14 DMP2LDC TI TTYLQ8V DMP2LDC TN Prostaglandin E synthase (PTGES) DMP2LDC MA Inhibitor DMP2LDC RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMP2LDC RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMP2QDM DI DMP2QDM DMP2QDM DN Isosteric imidazolyl pyrimidine derivative 1 DMP2QDM TI TT6R7JZ DMP2QDM TN Histone deacetylase 1 (HDAC1) DMP2QDM MA Inhibitor DMP2QDM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP2QDM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP2QDM DI DMP2QDM DMP2QDM DN Isosteric imidazolyl pyrimidine derivative 1 DMP2QDM TI TT7HF4W DMP2QDM TN Cyclin-dependent kinase 2 (CDK2) DMP2QDM MA Inhibitor DMP2QDM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP2QDM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP3GRA DI DMP3GRA DMP3GRA DN Lactol derivative 2 DMP3GRA TI TTPADOQ DMP3GRA TN HMG-CoA reductase (HMGCR) DMP3GRA MA Inhibitor DMP3GRA RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMP3GRA RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMP3JF4 DI DMP3JF4 DMP3JF4 DN Diphenyl purine derivative 4 DMP3JF4 TI TT6OEDT DMP3JF4 TN Cannabinoid receptor 1 (CB1) DMP3JF4 MA Antagonist DMP3JF4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMP3JF4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TT8EPLT DMP3MXK TN Proteasome beta-1 (PS beta-1) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TTOUSTQ DMP3MXK TN Proteasome beta-9 (PS beta-9) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TT68GPI DMP3MXK TN Proteasome beta-5 (PS beta-5) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TTEAD9J DMP3MXK TN Proteasome beta-8 (PS beta-8) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3RCH DI DMP3RCH DMP3RCH DN US8846654, 294 DMP3RCH TI TTIS4OW DMP3RCH TN Phosphodiesterase 8 (PDE8) DMP3RCH MA Inhibitor DMP3RCH RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMP3RCH RU http://www.freepatentsonline.com/US8846654.html DMP4VYQ DI DMP4VYQ DMP4VYQ DN PMID25522065-Compound-19 DMP4VYQ TI TTX4RTB DMP4VYQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMP4VYQ MA Antagonist DMP4VYQ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMP4VYQ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMP52HJ DI DMP52HJ DMP52HJ DN Biphenyl mannoside derivative 9 DMP52HJ TI TTTCRU2 DMP52HJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP52HJ MA Antagonist DMP52HJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP52HJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP580J DI DMP580J DMP580J DN PMID25656651-Compound-11b DMP580J TI TTS7G69 DMP580J TN Fusion protein Bcr-Abl (Bcr-Abl) DMP580J MA Inhibitor DMP580J RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMP580J RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMP59OX DI DMP59OX DMP59OX DN PMID27376512-Compound-Figure2aExample1 DMP59OX TI TTJUALD DMP59OX TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMP59OX MA Inhibitor DMP59OX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP59OX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP59OX DI DMP59OX DMP59OX DN PMID27376512-Compound-Figure2aExample1 DMP59OX TI TT3FDAV DMP59OX TN DNA [cytosine-5]-methyltransferase 3-like (DNMT3L) DMP59OX MA Inhibitor DMP59OX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP59OX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP5KEW DI DMP5KEW DMP5KEW DN PMID29649907-Compound-36 DMP5KEW TI TTS4UGC DMP5KEW TN Farnesoid X-activated receptor (FXR) DMP5KEW MA Agonist DMP5KEW RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMP5KEW RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMP5SA2 DI DMP5SA2 DMP5SA2 DN Peptide analog 49 DMP5SA2 TI TTDIGC1 DMP5SA2 TN Dipeptidyl peptidase 4 (DPP-4) DMP5SA2 MA Inhibitor DMP5SA2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMP5SA2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMP5Y19 DI DMP5Y19 DMP5Y19 DN PMID25399762-Compound-Figure3-Aspeverin DMP5Y19 TI TT3WG5C DMP5Y19 TN Monoamine oxidase type A (MAO-A) DMP5Y19 MA Inhibitor DMP5Y19 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMP5Y19 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMP65Z4 DI DMP65Z4 DMP65Z4 DN Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 TI TTGP7BY DMP65Z4 TN Monoamine oxidase type B (MAO-B) DMP65Z4 MA Modulator DMP65Z4 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMP65Z4 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMP65Z4 DI DMP65Z4 DMP65Z4 DN Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 TI TTHS256 DMP65Z4 TN Metabotropic glutamate receptor 5 (mGluR5) DMP65Z4 MA Modulator DMP65Z4 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMP65Z4 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMP6QEC DI DMP6QEC DMP6QEC DN Aryl mannoside derivative 16 DMP6QEC TI TTTCRU2 DMP6QEC TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP6QEC MA Antagonist DMP6QEC RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP6QEC RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP6TUQ DI DMP6TUQ DMP6TUQ DN Pyridoindole derivative 1 DMP6TUQ TI TTS7G69 DMP6TUQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMP6TUQ MA Inhibitor DMP6TUQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMP6TUQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMP6WCX DI DMP6WCX DMP6WCX DN PMID27019002-Compound-49 DMP6WCX TI TTNR0UQ DMP6WCX TN Lysine-specific histone demethylase 1 (LSD) DMP6WCX MA Inhibitor DMP6WCX RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMP6WCX RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMP7C5L DI DMP7C5L DMP7C5L DN PMID25726713-Compound-18 DMP7C5L TI TT8J1S3 DMP7C5L TN Smoothened homolog (SMO) DMP7C5L MA Antagonist DMP7C5L RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMP7C5L RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMP7DL6 DI DMP7DL6 DMP7DL6 DN PMID27376512-Compound-Figure3CN DMP7DL6 TI TTJUALD DMP7DL6 TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMP7DL6 MA Inhibitor DMP7DL6 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP7DL6 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP7S9E DI DMP7S9E DMP7S9E DN PMID29671355-Compound-27 DMP7S9E TI TT6R7JZ DMP7S9E TN Histone deacetylase 1 (HDAC1) DMP7S9E MA Inhibitor DMP7S9E RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMP7S9E RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMP7S9E DI DMP7S9E DMP7S9E DN PMID29671355-Compound-27 DMP7S9E TI TT5ZKDI DMP7S9E TN Histone deacetylase 6 (HDAC6) DMP7S9E MA Inhibitor DMP7S9E RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMP7S9E RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMP89E4 DI DMP89E4 DMP89E4 DN PMID25666693-Compound-145 DMP89E4 TI TTMI6F5 DMP89E4 TN Transient receptor potential cation channel V1 (TRPV1) DMP89E4 MA Antagonist DMP89E4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMP89E4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMP8I02 DI DMP8I02 DMP8I02 DN Pyrrolo-pyrazine derivative 1 DMP8I02 TI TTT7PJU DMP8I02 TN Janus kinase 3 (JAK-3) DMP8I02 MA Inhibitor DMP8I02 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMP8I02 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTH8FZW DMP8RQ4 TN Signal transducer and activator of transcription 3 (STAT3) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTLRFIH DMP8RQ4 TN Signal transducer and activator of transcription 5 (STAT5) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTN7R6K DMP8RQ4 TN Signal transducer and activator of transcription 1 (STAT1) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP9742 DI DMP9742 DMP9742 DN Biaryl mannoside derivative 16 DMP9742 TI TTTCRU2 DMP9742 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP9742 MA Antagonist DMP9742 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP9742 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP98CL DI DMP98CL DMP98CL DN Carbamate derivative 10 DMP98CL TI TTDP1UC DMP98CL TN Fatty acid amide hydrolase (FAAH) DMP98CL MA Inhibitor DMP98CL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMP98CL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMP98CL DI DMP98CL DMP98CL DN Carbamate derivative 10 DMP98CL TI TTZ963I DMP98CL TN Monoglyceride lipase (MAGL) DMP98CL MA Inhibitor DMP98CL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMP98CL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMP9Z34 DI DMP9Z34 DMP9Z34 DN Sulfonamide-thiadiazole derivative 1 DMP9Z34 TI TT2LVK8 DMP9Z34 TN Carbonic anhydrase IX (CA-IX) DMP9Z34 MA Inhibitor DMP9Z34 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMP9Z34 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMPA26U DI DMPA26U DMPA26U DN Resorcinol compound 10 DMPA26U TI TTULVH8 DMPA26U TN Tyrosinase (TYR) DMPA26U MA Inhibitor DMPA26U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPA26U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPA3IX DI DMPA3IX DMPA3IX DN PMID26651364-Compound-110 DMPA3IX TI TTTCRU2 DMPA3IX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPA3IX MA Antagonist DMPA3IX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPA3IX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPA9OY DI DMPA9OY DMPA9OY DN PMID29671355-Compound-47d DMPA9OY TI TTTQGH8 DMPA9OY TN Histone deacetylase 4 (HDAC4) DMPA9OY MA Inhibitor DMPA9OY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPA9OY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPAE8N DI DMPAE8N DMPAE8N DN PMID26882240-Compound-1 DMPAE8N TI TTUX68I DMPAE8N TN Hypoxia-inducible factor 1 (HIF-1) DMPAE8N MA Inhibitor DMPAE8N RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPAE8N RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPAE8N DI DMPAE8N DMPAE8N DN PMID26882240-Compound-1 DMPAE8N TI TT9MZCQ DMPAE8N TN Enhancer of zeste homolog 2 (EZH2) DMPAE8N MA Inhibitor DMPAE8N RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPAE8N RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPAI5C DI DMPAI5C DMPAI5C DN Phenylpyrrolidinone derivative 1 DMPAI5C TI TT5OU0D DMPAI5C TN PRKR-like endoplasmic reticulum kinase (PERK) DMPAI5C MA Inhibitor DMPAI5C RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMPAI5C RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMPAQLZ DI DMPAQLZ DMPAQLZ DN PMID29130358-Compound-Figure16(9b) DMPAQLZ TI TTHY57M DMPAQLZ TN Matrix metalloproteinase-13 (MMP-13) DMPAQLZ MA Inhibitor DMPAQLZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMPAQLZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMPAQLZ DI DMPAQLZ DMPAQLZ DN PMID29130358-Compound-Figure16(9b) DMPAQLZ TI TTLM12X DMPAQLZ TN Matrix metalloproteinase-2 (MMP-2) DMPAQLZ MA Inhibitor DMPAQLZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMPAQLZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMPB4L6 DI DMPB4L6 DMPB4L6 DN Quinoline derivative 4 DMPB4L6 TI TTXJ47W DMPB4L6 TN Metabotropic glutamate receptor 2 (mGluR2) DMPB4L6 MA Antagonist DMPB4L6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMPB4L6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMPBMEU DI DMPBMEU DMPBMEU DN Fused aryl carbocycle derivative 8 DMPBMEU TI TT9NXW4 DMPBMEU TN Sigma intracellular receptor 2 (TMEM97) DMPBMEU MA Ligand DMPBMEU RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMPBMEU RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMPBNFM DI DMPBNFM DMPBNFM DN PMID28117607-Compound-5 DMPBNFM TI TTK0FEA DMPBNFM TN Leucine-rich repeat kinase 2 (LRRK2) DMPBNFM MA Inhibitor DMPBNFM RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMPBNFM RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMPCLZB DI DMPCLZB DMPCLZB DN Imidazo pyridine derivative 3 DMPCLZB TI TT0PG8F DMPCLZB TN Cyclin-dependent kinase 4 (CDK4) DMPCLZB MA Inhibitor DMPCLZB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMPCLZB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMPCYSW DI DMPCYSW DMPCYSW DN 2-(substituted ethynyl)quinoline derivative 2 DMPCYSW TI TTHS256 DMPCYSW TN Metabotropic glutamate receptor 5 (mGluR5) DMPCYSW MA Antagonist DMPCYSW RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPCYSW RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPDF9B DI DMPDF9B DMPDF9B DN US9006244, E2a DMPDF9B TI TTECBXN DMPDF9B TN Oxysterols receptor LXR-alpha (NR1H3) DMPDF9B MA Inhibitor DMPDF9B RN Liver X receptor modulators. US9006244. DMPDF9B RU http://www.freepatentsonline.com/US9006244.html DMPDTG0 DI DMPDTG0 DMPDTG0 DN Imidazo[1,2-b]pyridazine derivative 3 DMPDTG0 TI TTTDVOJ DMPDTG0 TN Tropomyosin-related kinase A (TrkA) DMPDTG0 MA Inhibitor DMPDTG0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPDTG0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPDTG0 DI DMPDTG0 DMPDTG0 DN Imidazo[1,2-b]pyridazine derivative 3 DMPDTG0 TI TTSZ6Y3 DMPDTG0 TN Proto-oncogene c-Ros (ROS1) DMPDTG0 MA Inhibitor DMPDTG0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPDTG0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPDTHQ DI DMPDTHQ DMPDTHQ DN PMID27537201-Compound-Figure13b DMPDTHQ TI TTPADOQ DMPDTHQ TN HMG-CoA reductase (HMGCR) DMPDTHQ MA Inhibitor DMPDTHQ RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMPDTHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMPDX3L DI DMPDX3L DMPDX3L DN PMID25726713-Compound-58 DMPDX3L TI TT8J1S3 DMPDX3L TN Smoothened homolog (SMO) DMPDX3L MA Inhibitor DMPDX3L RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMPDX3L RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMPE7M8 DI DMPE7M8 DMPE7M8 DN PMID25666693-Compound-55 DMPE7M8 TI TTMI6F5 DMPE7M8 TN Transient receptor potential cation channel V1 (TRPV1) DMPE7M8 MA Antagonist DMPE7M8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPE7M8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPF2UG DI DMPF2UG DMPF2UG DN Mannoside derivative 3 DMPF2UG TI TTTCRU2 DMPF2UG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF2UG MA Antagonist DMPF2UG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF2UG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPF37N DI DMPF37N DMPF37N DN Biaryl mannoside derivative 10 DMPF37N TI TTTCRU2 DMPF37N TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF37N MA Antagonist DMPF37N RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF37N RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPF86L DI DMPF86L DMPF86L DN PMID26651364-Compound-6c DMPF86L TI TTTCRU2 DMPF86L TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF86L MA Antagonist DMPF86L RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF86L RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPFAST DI DMPFAST DMPFAST DN Five membered heterocyclic benzamide derivative 1 DMPFAST TI TTTDVOJ DMPFAST TN Tropomyosin-related kinase A (TrkA) DMPFAST MA Inhibitor DMPFAST RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMPFAST RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMPFLGO DI DMPFLGO DMPFLGO DN PMID25399762-Compound-Table1-C2 DMPFLGO TI TTGP7BY DMPFLGO TN Monoamine oxidase type B (MAO-B) DMPFLGO MA Inhibitor DMPFLGO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMPFLGO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMPFMSJ DI DMPFMSJ DMPFMSJ DN PMID25553724-Compound-WO2013082253 31 DMPFMSJ TI TTSXVID DMPFMSJ TN Nuclear factor NF-kappa-B (NFKB) DMPFMSJ MA Modulator DMPFMSJ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMPFMSJ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMPG3Y8 DI DMPG3Y8 DMPG3Y8 DN Antibodie derivative 11 DMPG3Y8 TI TTOHSBA DMPG3Y8 TN Vascular endothelial growth factor A (VEGFA) DMPG3Y8 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMPG3Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMPG8MF DI DMPG8MF DMPG8MF DN PMID26293650-Compound-35 DMPG8MF TI TTH5TC2 DMPG8MF TN NF-kappa-B-activating kinase (TBK1) DMPG8MF MA Inhibitor DMPG8MF RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMPG8MF RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMPGMX2 DI DMPGMX2 DMPGMX2 DN Imidazole derivative 4 DMPGMX2 TI TT6OEDT DMPGMX2 TN Cannabinoid receptor 1 (CB1) DMPGMX2 MA Antagonist DMPGMX2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPGMX2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPGY0M DI DMPGY0M DMPGY0M DN US9024044, 1 DMPGY0M TI TTXL0GC DMPGY0M TN Enteropeptidase (TMPRSS15) DMPGY0M MA Inhibitor DMPGY0M RN Heteroarylcarboxylic acid ester derivative. US9227949. DMPGY0M RU http://www.freepatentsonline.com/US9227949.html DMPH05Y DI DMPH05Y DMPH05Y DN US9453017, 2 DMPH05Y TI TT3T17P DMPH05Y TN Phospholipase D1 (PLD1) DMPH05Y MA Inhibitor DMPH05Y RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMPH05Y RU http://www.freepatentsonline.com/US9453017.html DMPH4JV DI DMPH4JV DMPH4JV DN PMID28766366-Compound-Scheme4Upper DMPH4JV TI TTYGQ8A DMPH4JV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMPH4JV MA Inhibitor DMPH4JV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPH4JV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPH4JV DI DMPH4JV DMPH4JV DN PMID28766366-Compound-Scheme4Upper DMPH4JV TI TTSBVFO DMPH4JV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMPH4JV MA Inhibitor DMPH4JV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPH4JV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPHCJ5 DI DMPHCJ5 DMPHCJ5 DN Polyhydroxy benzamide derivative 1 DMPHCJ5 TI TTULVH8 DMPHCJ5 TN Tyrosinase (TYR) DMPHCJ5 MA Inhibitor DMPHCJ5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPHCJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPHK87 DI DMPHK87 DMPHK87 DN Imidazopyridine acetamide analog 4 DMPHK87 TI TTPTXIN DMPHK87 TN Translocator protein (TSPO) DMPHK87 MA Ligand DMPHK87 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMPHK87 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMPHL3J DI DMPHL3J DMPHL3J DN Fused ring compound 1 DMPHL3J TI TTZMAO3 DMPHL3J TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMPHL3J MA Agonist DMPHL3J RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMPHL3J RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMPHMTR DI DMPHMTR DMPHMTR DN PMID27109571-Compound-6 DMPHMTR TI TTMY6L1 DMPHMTR TN Fatty acid-binding protein (FABP) DMPHMTR MA Inhibitor DMPHMTR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHMTR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPHTC0 DI DMPHTC0 DMPHTC0 DN PMID27109571-Compound-24 DMPHTC0 TI TTNT2S6 DMPHTC0 TN Fatty acid-binding protein 5 (FABP5) DMPHTC0 MA Inhibitor DMPHTC0 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHTC0 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPHTC0 DI DMPHTC0 DMPHTC0 DN PMID27109571-Compound-24 DMPHTC0 TI TTHWMFZ DMPHTC0 TN Fatty acid-binding protein 4 (FABP4) DMPHTC0 MA Inhibitor DMPHTC0 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHTC0 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPI2S9 DI DMPI2S9 DMPI2S9 DN Purine derivative 3 DMPI2S9 TI TT6OEDT DMPI2S9 TN Cannabinoid receptor 1 (CB1) DMPI2S9 MA Antagonist DMPI2S9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPI2S9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPI86D DI DMPI86D DMPI86D DN PMID28270021-Compound-WO2016054807Example80 DMPI86D TI TTTDVOJ DMPI86D TN Tropomyosin-related kinase A (TrkA) DMPI86D MA Inhibitor DMPI86D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMPI86D RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMPICE1 DI DMPICE1 DMPICE1 DN US8901295, F673 DMPICE1 TI TTNAFOU DMPICE1 TN Rotamase D (PPID) DMPICE1 MA Inhibitor DMPICE1 RN Inhibitors of cyclophilins and uses thereof. US8901295. DMPICE1 RU http://www.freepatentsonline.com/US8901295.html DMPIM9L DI DMPIM9L DMPIM9L DN PMID28870136-Compound-48 DMPIM9L TI TTK0O6Y DMPIM9L TN Ecto-5'-nucleotidase (CD73) DMPIM9L MA Inhibitor DMPIM9L RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMPIM9L RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMPIXAO DI DMPIXAO DMPIXAO DN PMID28394193-Compound-25 DMPIXAO TI TT9MZCQ DMPIXAO TN Enhancer of zeste homolog 2 (EZH2) DMPIXAO MA Inhibitor DMPIXAO RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMPIXAO RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMPJH6L DI DMPJH6L DMPJH6L DN PMID28350212-Compound-24 DMPJH6L TI TTZS04O DMPJH6L TN Gamma-secretase subunit APH-1A/1B (APH-1) DMPJH6L MA Inhibitor DMPJH6L RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMPJH6L RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTTQGH8 DMPJN0M TN Histone deacetylase 4 (HDAC4) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTYHPU6 DMPJN0M TN Histone deacetylase 10 (HDAC10) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT8M4E1 DMPJN0M TN Histone deacetylase 9 (HDAC9) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT4YWTO DMPJN0M TN Histone deacetylase 3 (HDAC3) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT8K17W DMPJN0M TN Histone deacetylase 11 (HDAC11) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTMUEK1 DMPJN0M TN Histone deacetylase 7 (HDAC7) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTSHTOI DMPJN0M TN Histone deacetylase 2 (HDAC2) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT6R7JZ DMPJN0M TN Histone deacetylase 1 (HDAC1) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTT6LFV DMPJN0M TN Histone deacetylase 8 (HDAC8) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT5ZKDI DMPJN0M TN Histone deacetylase 6 (HDAC6) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJSB2 DI DMPJSB2 DMPJSB2 DN PMID28092474-Compound-33l DMPJSB2 TI TT5ZKDI DMPJSB2 TN Histone deacetylase 6 (HDAC6) DMPJSB2 MA Inhibitor DMPJSB2 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMPJSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMPJSB2 DI DMPJSB2 DMPJSB2 DN PMID28092474-Compound-33l DMPJSB2 TI TT6R7JZ DMPJSB2 TN Histone deacetylase 1 (HDAC1) DMPJSB2 MA Inhibitor DMPJSB2 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMPJSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMPK7IU DI DMPK7IU DMPK7IU DN PMID28594589-Compound-TABLE3C12 DMPK7IU TI TTZCRP3 DMPK7IU TN ERK activator kinase (MEK) DMPK7IU MA Inhibitor DMPK7IU RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMPK7IU RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMPLAWQ DI DMPLAWQ DMPLAWQ DN Biaryl mannoside derivative 30 DMPLAWQ TI TTTCRU2 DMPLAWQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPLAWQ MA Antagonist DMPLAWQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPLAWQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPLZSE DI DMPLZSE DMPLZSE DN Carbamate derivative 16 DMPLZSE TI TTZ963I DMPLZSE TN Monoglyceride lipase (MAGL) DMPLZSE MA Inhibitor DMPLZSE RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMPLZSE RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMPLZSE DI DMPLZSE DMPLZSE DN Carbamate derivative 16 DMPLZSE TI TTDP1UC DMPLZSE TN Fatty acid amide hydrolase (FAAH) DMPLZSE MA Inhibitor DMPLZSE RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMPLZSE RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMPM8VB DI DMPM8VB DMPM8VB DN US10053465, 12 DMPM8VB TI TTIEMFN DMPM8VB TN TYRO3 tyrosine kinase receptor (TYRO3) DMPM8VB MA Inhibitor DMPM8VB RN Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333. DMPM8VB RU http://www.freepatentsonline.com/US9708333.html DMPMN92 DI DMPMN92 DMPMN92 DN Thiazole carboxamide derivative 17 DMPMN92 TI TTCZOF2 DMPMN92 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMPMN92 MA Inhibitor DMPMN92 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMPMN92 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMPNCOL DI DMPNCOL DMPNCOL DN US8933228, 3 DMPNCOL TI TT42OGM DMPNCOL TN Hematopoietic cell kinase (HCK) DMPNCOL MA Inhibitor DMPNCOL RN Respiratory formulations and compounds for use therein. US8933228. DMPNCOL RU http://www.freepatentsonline.com/US8933228.html DMPNG9C DI DMPNG9C DMPNG9C DN PMID28048944-Compound-21 DMPNG9C TI TTZN7RP DMPNG9C TN Rho-associated protein kinase 1 (ROCK1) DMPNG9C MA Inhibitor DMPNG9C RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPNG9C RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPNJ4X DI DMPNJ4X DMPNJ4X DN PMID26394986-Compound-56 DMPNJ4X TI TTLRFIH DMPNJ4X TN Signal transducer and activator of transcription 5 (STAT5) DMPNJ4X MA Inhibitor DMPNJ4X RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMPNJ4X RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMPOI27 DI DMPOI27 DMPOI27 DN PMID28270010-Compound-Figure17-1 DMPOI27 TI TTTDVOJ DMPOI27 TN Tropomyosin-related kinase A (TrkA) DMPOI27 MA Inhibitor DMPOI27 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPOI27 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPOR3G DI DMPOR3G DMPOR3G DN AC1LE05K DMPOR3G TI TTOJ9QL DMPOR3G TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMPOR3G MA Inhibitor DMPOR3G RN IRE-1 inhibitors. US9693992. DMPOR3G RU http://www.freepatentsonline.com/US9693992.html DMPOVZ6 DI DMPOVZ6 DMPOVZ6 DN BDBM50379214 DMPOVZ6 TI TTIET93 DMPOVZ6 TN Activated CDC42 kinase 1 (ACK-1) DMPOVZ6 MA Inhibitor DMPOVZ6 RN Kinase modulators for the treatment of cancer. US9416123. DMPOVZ6 RU http://www.freepatentsonline.com/US9416123.html DMPQ175 DI DMPQ175 DMPQ175 DN PMID25553724-Compound-WO2011152671 2 DMPQ175 TI TTSXVID DMPQ175 TN Nuclear factor NF-kappa-B (NFKB) DMPQ175 MA Inhibitor DMPQ175 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMPQ175 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMPQ2L9 DI DMPQ2L9 DMPQ2L9 DN 936563-93-8 DMPQ2L9 TI TTX6F0Q DMPQ2L9 TN Tyrosine-protein kinase CSK (CSK) DMPQ2L9 MA Inhibitor DMPQ2L9 RN Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. US9278100. DMPQ2L9 RU http://www.freepatentsonline.com/US9278100.html DMPQF78 DI DMPQF78 DMPQF78 DN 2,2-bipyridyl derivative 3 DMPQF78 TI TT0RGE9 DMPQF78 TN Lysine-specific demethylase 4 (KDM4) DMPQF78 MA Inhibitor DMPQF78 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMPQF78 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMPQKXR DI DMPQKXR DMPQKXR DN PMID27788040-Compound-5b DMPQKXR TI TTV1C0Z DMPQKXR TN Neuropeptide S receptor (NPSR) DMPQKXR MA Antagonist DMPQKXR RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPQKXR RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPQX8R DI DMPQX8R DMPQX8R DN PMID29865878-Compound-60 DMPQX8R TI TTSJMN8 DMPQX8R TN Immunoproteasome complex (IP) DMPQX8R MA Inhibitor DMPQX8R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMPQX8R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMPR9GA DI DMPR9GA DMPR9GA DN PMID28394193-Compound-17 DMPR9GA TI TT9MZCQ DMPR9GA TN Enhancer of zeste homolog 2 (EZH2) DMPR9GA MA Inhibitor DMPR9GA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMPR9GA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMPRF1K DI DMPRF1K DMPRF1K DN Heteroaryl-carboxamide derivative 1 DMPRF1K TI TTCZOF2 DMPRF1K TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMPRF1K MA Inhibitor DMPRF1K RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMPRF1K RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMPRGLZ DI DMPRGLZ DMPRGLZ DN Triazole piperazine derivative 1 DMPRGLZ TI TTDIGC1 DMPRGLZ TN Dipeptidyl peptidase 4 (DPP-4) DMPRGLZ MA Inhibitor DMPRGLZ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMPRGLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMPRIS0 DI DMPRIS0 DMPRIS0 DN Bicyclo-heptan-2-amine derivative 4 DMPRIS0 TI TT9NXW4 DMPRIS0 TN Sigma intracellular receptor 2 (TMEM97) DMPRIS0 MA Ligand DMPRIS0 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMPRIS0 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMPSWXU DI DMPSWXU DMPSWXU DN PMID25980951-Compound-3 DMPSWXU TI TTR7B60 DMPSWXU TN X-linked inhibitor of apoptosis protein (XIAP) DMPSWXU MA Antagonist DMPSWXU RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMPSWXU RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMPSWXU DI DMPSWXU DMPSWXU DN PMID25980951-Compound-3 DMPSWXU TI TTQ5LRD DMPSWXU TN Cellular inhibitor of apoptosis 1 (BIRC2) DMPSWXU MA Antagonist DMPSWXU RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMPSWXU RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMPT2ZS DI DMPT2ZS DMPT2ZS DN US9108950, 1 DMPT2ZS TI TT42OGM DMPT2ZS TN Hematopoietic cell kinase (HCK) DMPT2ZS MA Inhibitor DMPT2ZS RN 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950. DMPT2ZS RU http://www.freepatentsonline.com/US9108950.html DMPT3V9 DI DMPT3V9 DMPT3V9 DN PMID28048944-Compound-19 DMPT3V9 TI TTGWKQJ DMPT3V9 TN Rho-associated protein kinase 2 (ROCK2) DMPT3V9 MA Inhibitor DMPT3V9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPT3V9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPT3V9 DI DMPT3V9 DMPT3V9 DN PMID28048944-Compound-19 DMPT3V9 TI TTZN7RP DMPT3V9 TN Rho-associated protein kinase 1 (ROCK1) DMPT3V9 MA Inhibitor DMPT3V9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPT3V9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPTK0G DI DMPTK0G DMPTK0G DN Resorcinol compound 3 DMPTK0G TI TTULVH8 DMPTK0G TN Tyrosinase (TYR) DMPTK0G MA Inhibitor DMPTK0G RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPTK0G RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPTRQD DI DMPTRQD DMPTRQD DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2 DMPTRQD TI TTV1C0Z DMPTRQD TN Neuropeptide S receptor (NPSR) DMPTRQD MA Antagonist DMPTRQD RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPTRQD RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPTZ69 DI DMPTZ69 DMPTZ69 DN Diazepinone derivative 3 DMPTZ69 TI TTHS256 DMPTZ69 TN Metabotropic glutamate receptor 5 (mGluR5) DMPTZ69 MA Modulator DMPTZ69 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPTZ69 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPU19H DI DMPU19H DMPU19H DN PMID25666693-Compound-149 DMPU19H TI TTMI6F5 DMPU19H TN Transient receptor potential cation channel V1 (TRPV1) DMPU19H MA Antagonist DMPU19H RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPU19H RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPUG2M DI DMPUG2M DMPUG2M DN Ethynyl compound 7 DMPUG2M TI TTHS256 DMPUG2M TN Metabotropic glutamate receptor 5 (mGluR5) DMPUG2M MA Modulator DMPUG2M RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPUG2M RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPUH4Z DI DMPUH4Z DMPUH4Z DN Diaminopyridine analog 4 DMPUH4Z TI TTKFVXR DMPUH4Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMPUH4Z MA Inhibitor DMPUH4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMPUH4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMPULIC DI DMPULIC DMPULIC DN 4-(2-cyclohexylethoxy) aniline derivative 4 DMPULIC TI TTA6ZN2 DMPULIC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMPULIC MA Inhibitor DMPULIC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMPULIC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMPUXL3 DI DMPUXL3 DMPUXL3 DN Bipyridine derivative 1 DMPUXL3 TI TT1LVF2 DMPUXL3 TN Cyclin-dependent kinase 9 (CDK9) DMPUXL3 MA Inhibitor DMPUXL3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMPUXL3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTSHTOI DMPV0KZ TN Histone deacetylase 2 (HDAC2) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTYHPU6 DMPV0KZ TN Histone deacetylase 10 (HDAC10) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTTQGH8 DMPV0KZ TN Histone deacetylase 4 (HDAC4) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT8K17W DMPV0KZ TN Histone deacetylase 11 (HDAC11) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTMUEK1 DMPV0KZ TN Histone deacetylase 7 (HDAC7) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT8M4E1 DMPV0KZ TN Histone deacetylase 9 (HDAC9) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT4YWTO DMPV0KZ TN Histone deacetylase 3 (HDAC3) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTUELN5 DMPV0KZ TN Histone deacetylase 5 (HDAC5) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT6R7JZ DMPV0KZ TN Histone deacetylase 1 (HDAC1) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTT6LFV DMPV0KZ TN Histone deacetylase 8 (HDAC8) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT5ZKDI DMPV0KZ TN Histone deacetylase 6 (HDAC6) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV9L2 DI DMPV9L2 DMPV9L2 DN PMID25666693-Compound-67 DMPV9L2 TI TTMI6F5 DMPV9L2 TN Transient receptor potential cation channel V1 (TRPV1) DMPV9L2 MA Antagonist DMPV9L2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPV9L2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPVDSC DI DMPVDSC DMPVDSC DN Pyrazole derivative 38 DMPVDSC TI TT6OEDT DMPVDSC TN Cannabinoid receptor 1 (CB1) DMPVDSC MA Antagonist DMPVDSC RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPVDSC RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPVSG9 DI DMPVSG9 DMPVSG9 DN PMID29649907-Compound-3 DMPVSG9 TI TTS4UGC DMPVSG9 TN Farnesoid X-activated receptor (FXR) DMPVSG9 MA Agonist DMPVSG9 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMPVSG9 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMPVW2Q DI DMPVW2Q DMPVW2Q DN PMID30280939-Compound-US20179642901 DMPVW2Q TI TTOK0LR DMPVW2Q TN Toll-like receptor (TLR) DMPVW2Q MA Agonist DMPVW2Q RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMPVW2Q RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMPVZ6W DI DMPVZ6W DMPVZ6W DN PMID28766366-Compound-Scheme27LeucettineL41derivatives DMPVZ6W TI TTSBVFO DMPVZ6W TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMPVZ6W MA Inhibitor DMPVZ6W RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPVZ6W RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPW1GI DI DMPW1GI DMPW1GI DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2 DMPW1GI TI TT9NXW4 DMPW1GI TN Sigma intracellular receptor 2 (TMEM97) DMPW1GI MA Ligand DMPW1GI RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMPW1GI RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMPW9ES DI DMPW9ES DMPW9ES DN Aminocyclopentenone compound 5 DMPW9ES TI TTRA6BO DMPW9ES TN Bromodomain-containing protein 4 (BRD4) DMPW9ES MA Inhibitor DMPW9ES RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMPW9ES RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMPWFJN DI DMPWFJN DMPWFJN DN Biphenyl carboxylic acid derivative 1 DMPWFJN TI TTL53M6 DMPWFJN TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMPWFJN MA Inhibitor DMPWFJN RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMPWFJN RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMPWKAH DI DMPWKAH DMPWKAH DN Bidentate pyrazolopyrimidine acetamide analog 1 DMPWKAH TI TTPTXIN DMPWKAH TN Translocator protein (TSPO) DMPWKAH MA Ligand DMPWKAH RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMPWKAH RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMPWS9N DI DMPWS9N DMPWS9N DN Peptidomimetic analog 3 DMPWS9N TI TTH8FZW DMPWS9N TN Signal transducer and activator of transcription 3 (STAT3) DMPWS9N MA Inhibitor DMPWS9N RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMPWS9N RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMPWYL8 DI DMPWYL8 DMPWYL8 DN PMID28350212-Compound-13 DMPWYL8 TI TTZS04O DMPWYL8 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMPWYL8 MA Inhibitor DMPWYL8 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMPWYL8 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMPXAGD DI DMPXAGD DMPXAGD DN Alkaloid derivative 4 DMPXAGD TI TTUX68I DMPXAGD TN Hypoxia-inducible factor 1 (HIF-1) DMPXAGD MA Inhibitor DMPXAGD RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPXAGD RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPXK1C DI DMPXK1C DMPXK1C DN Isoxazole-based bicyclic compound 15 DMPXK1C TI TTE4BSY DMPXK1C TN Bromodomain and extraterminal domain protein (BET) DMPXK1C MA Inhibitor DMPXK1C RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMPXK1C RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMPXVWE DI DMPXVWE DMPXVWE DN Urea and carbamate bioisostere derivative 3 DMPXVWE TI TTL7C8Q DMPXVWE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMPXVWE MA Inhibitor DMPXVWE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMPXVWE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMPXZYN DI DMPXZYN DMPXZYN DN PMID29324067-Compound-38 DMPXZYN TI TTGP7BY DMPXZYN TN Monoamine oxidase type B (MAO-B) DMPXZYN MA Inhibitor DMPXZYN RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMPXZYN RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMPY1QC DI DMPY1QC DMPY1QC DN PMID25666693-Compound-136 DMPY1QC TI TTMI6F5 DMPY1QC TN Transient receptor potential cation channel V1 (TRPV1) DMPY1QC MA Antagonist DMPY1QC RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPY1QC RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPY8NU DI DMPY8NU DMPY8NU DN PMID25482888-Compound-69 DMPY8NU TI TTDIGC1 DMPY8NU TN Dipeptidyl peptidase 4 (DPP-4) DMPY8NU MA Inhibitor DMPY8NU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMPY8NU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMPYCIM DI DMPYCIM DMPYCIM DN PMID25991433-Compound-A9 DMPYCIM TI TTHS0U8 DMPYCIM TN Stress-activated protein kinase JNK2 (JNK2) DMPYCIM MA Inhibitor DMPYCIM RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMPYCIM RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMPYCIM DI DMPYCIM DMPYCIM DN PMID25991433-Compound-A9 DMPYCIM TI TT0K6EO DMPYCIM TN Stress-activated protein kinase JNK1 (JNK1) DMPYCIM MA Inhibitor DMPYCIM RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMPYCIM RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMPZ0U8 DI DMPZ0U8 DMPZ0U8 DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 DMPZ0U8 TI TTIXKA4 DMPZ0U8 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMPZ0U8 MA Inhibitor DMPZ0U8 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMPZ0U8 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMPZ81S DI DMPZ81S DMPZ81S DN Oxazolo[3,4-a]pyrazine derivative 1 DMPZ81S TI TTV1C0Z DMPZ81S TN Neuropeptide S receptor (NPSR) DMPZ81S MA Antagonist DMPZ81S RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPZ81S RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPZECW DI DMPZECW DMPZECW DN 1,2-diamino cyclopentane-based derivative 11 DMPZECW TI TT60Q8D DMPZECW TN Orexin receptor type 1 (HCRTR1) DMPZECW MA Antagonist DMPZECW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMPZECW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMPZECW DI DMPZECW DMPZECW DN 1,2-diamino cyclopentane-based derivative 11 DMPZECW TI TT9N02I DMPZECW TN Orexin receptor type 2 (HCRTR2) DMPZECW MA Antagonist DMPZECW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMPZECW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMPZKQN DI DMPZKQN DMPZKQN DN Phenylpyrrolidinone derivative 3 DMPZKQN TI TT5OU0D DMPZKQN TN PRKR-like endoplasmic reticulum kinase (PERK) DMPZKQN MA Inhibitor DMPZKQN RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMPZKQN RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMPZS16 DI DMPZS16 DMPZS16 DN US9714230, 46 DMPZS16 TI TTIG67W DMPZS16 TN Lysine-specific demethylase 5A (KDM5A) DMPZS16 MA Inhibitor DMPZS16 RN Histone demethylase inhibitors. US9604961. DMPZS16 RU http://www.freepatentsonline.com/US9604961.html DMQ027F DI DMQ027F DMQ027F DN Tetra-hydro-pyrazolopyrazine derivative 2 DMQ027F TI TTHS256 DMQ027F TN Metabotropic glutamate receptor 5 (mGluR5) DMQ027F MA Modulator DMQ027F RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQ027F RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQ08BM DI DMQ08BM DMQ08BM DN Pyrazole derivative 60 DMQ08BM TI TT6OEDT DMQ08BM TN Cannabinoid receptor 1 (CB1) DMQ08BM MA Antagonist DMQ08BM RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMQ08BM RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMQ0RGB DI DMQ0RGB DMQ0RGB DN Steroid derivative 2 DMQ0RGB TI TTUX68I DMQ0RGB TN Hypoxia-inducible factor 1 (HIF-1) DMQ0RGB MA Inhibitor DMQ0RGB RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMQ0RGB RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMQ0VK4 DI DMQ0VK4 DMQ0VK4 DN Piperidine derivative 5 DMQ0VK4 TI TT9NXW4 DMQ0VK4 TN Sigma intracellular receptor 2 (TMEM97) DMQ0VK4 MA Ligand DMQ0VK4 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMQ0VK4 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMQ0VK4 DI DMQ0VK4 DMQ0VK4 DN Piperidine derivative 5 DMQ0VK4 TI TT5TPI6 DMQ0VK4 TN Opioid receptor sigma 1 (OPRS1) DMQ0VK4 MA Ligand DMQ0VK4 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMQ0VK4 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMQ0VK9 DI DMQ0VK9 DMQ0VK9 DN Sulfamic acid ester derivative 1 DMQ0VK9 TI TTZJYKH DMQ0VK9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQ0VK9 MA Inhibitor DMQ0VK9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMQ0VK9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMQ1FAH DI DMQ1FAH DMQ1FAH DN 2-piperidine thiazole derivative 1 DMQ1FAH TI TT3M2WO DMQ1FAH TN Sphingosine kinase (SphK) DMQ1FAH MA Inhibitor DMQ1FAH RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMQ1FAH RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMQ1LGV DI DMQ1LGV DMQ1LGV DN US9346821, B-42 DMQ1LGV TI TTXL0GC DMQ1LGV TN Enteropeptidase (TMPRSS15) DMQ1LGV MA Inhibitor DMQ1LGV RN Heterocyclic carboxylic acid ester derivative. US9346821. DMQ1LGV RU http://www.freepatentsonline.com/US9346821.html DMQ2MKT DI DMQ2MKT DMQ2MKT DN N-acylpiperidine ether derivative 5 DMQ2MKT TI TTTDVOJ DMQ2MKT TN Tropomyosin-related kinase A (TrkA) DMQ2MKT MA Inhibitor DMQ2MKT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ2MKT RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQ2U54 DI DMQ2U54 DMQ2U54 DN Pyrrolo-pyridazine derivative 1 DMQ2U54 TI TTK0FEA DMQ2U54 TN Leucine-rich repeat kinase 2 (LRRK2) DMQ2U54 MA Inhibitor DMQ2U54 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMQ2U54 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMQ2X6O DI DMQ2X6O DMQ2X6O DN Fused aryl carbocycle derivative 9 DMQ2X6O TI TT9NXW4 DMQ2X6O TN Sigma intracellular receptor 2 (TMEM97) DMQ2X6O MA Ligand DMQ2X6O RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMQ2X6O RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMQ3K5B DI DMQ3K5B DMQ3K5B DN Tacrine-indole hybrid derivative 1 DMQ3K5B TI TT1RS9F DMQ3K5B TN Acetylcholinesterase (AChE) DMQ3K5B MA Inhibitor DMQ3K5B RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQ3K5B RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTZ963I DMQ3TGM TN Monoglyceride lipase (MAGL) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTDP1UC DMQ3TGM TN Fatty acid amide hydrolase (FAAH) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTSINOV DMQ3TGM TN Monoacylglycerol lipase ABHD6 (ABHD6) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ4TUE DI DMQ4TUE DMQ4TUE DN BDBM50061601 DMQ4TUE TI TTCGOIN DMQ4TUE TN PIM-3 protein kinase (PIM3) DMQ4TUE MA Inhibitor DMQ4TUE RN Azole compounds as PIM inhibitors. US9321756. DMQ4TUE RU http://www.freepatentsonline.com/US9321756.html DMQ4ULC DI DMQ4ULC DMQ4ULC DN N-acylpyrrolidine ether derivative 1 DMQ4ULC TI TTTDVOJ DMQ4ULC TN Tropomyosin-related kinase A (TrkA) DMQ4ULC MA Inhibitor DMQ4ULC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ4ULC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQ5AIT DI DMQ5AIT DMQ5AIT DN PMID26004420-Compound-US20140275020D DMQ5AIT TI TTJ13ST DMQ5AIT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMQ5AIT MA Inhibitor DMQ5AIT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMQ5AIT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMQ5AJ6 DI DMQ5AJ6 DMQ5AJ6 DN Selenium compound 3 DMQ5AJ6 TI TTZHPB8 DMQ5AJ6 TN Lysine-specific demethylase 4A (KDM4A) DMQ5AJ6 MA Inhibitor DMQ5AJ6 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMQ5AJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMQ5TYK DI DMQ5TYK DMQ5TYK DN Resorcinol compound 5 DMQ5TYK TI TTULVH8 DMQ5TYK TN Tyrosinase (TYR) DMQ5TYK MA Inhibitor DMQ5TYK RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQ5TYK RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQ5UEA DI DMQ5UEA DMQ5UEA DN PMID28766366-Compound-Scheme16DMAT DMQ5UEA TI TT84OS6 DMQ5UEA TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMQ5UEA MA Inhibitor DMQ5UEA RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQ5UEA RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQ5UEA DI DMQ5UEA DMQ5UEA DN PMID28766366-Compound-Scheme16DMAT DMQ5UEA TI TTSBVFO DMQ5UEA TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMQ5UEA MA Inhibitor DMQ5UEA RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQ5UEA RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQ6WEN DI DMQ6WEN DMQ6WEN DN PMID28048944-Compound-11 DMQ6WEN TI TTGWKQJ DMQ6WEN TN Rho-associated protein kinase 2 (ROCK2) DMQ6WEN MA Inhibitor DMQ6WEN RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMQ6WEN RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMQ704Z DI DMQ704Z DMQ704Z DN Quinazoline derivative 16 DMQ704Z TI TTUTJGQ DMQ704Z TN Vascular endothelial growth factor receptor 2 (KDR) DMQ704Z MA Inhibitor DMQ704Z RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMQ704Z RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMQ704Z DI DMQ704Z DMQ704Z DN Quinazoline derivative 16 DMQ704Z TI TT4DXQT DMQ704Z TN Proto-oncogene c-Ret (RET) DMQ704Z MA Inhibitor DMQ704Z RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMQ704Z RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMQ75BN DI DMQ75BN DMQ75BN DN Benzimidazole derivative 8 DMQ75BN TI TTQR74A DMQ75BN TN Proteinase activated receptor 2 (PAR2) DMQ75BN MA Antagonist DMQ75BN RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMQ75BN RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TTHS0U8 DMQ7BV4 TN Stress-activated protein kinase JNK2 (JNK2) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TT0K6EO DMQ7BV4 TN Stress-activated protein kinase JNK1 (JNK1) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TT056SO DMQ7BV4 TN Stress-activated protein kinase JNK3 (JNK3) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7ODW DI DMQ7ODW DMQ7ODW DN US10100051, Compound 10 DMQ7ODW TI TT9ISBX DMQ7ODW TN HIF-prolyl hydroxylase 2 (HPH-2) DMQ7ODW MA Inhibitor DMQ7ODW RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMQ7ODW RU http://www.freepatentsonline.com/US10100051.html DMQ7Z5F DI DMQ7Z5F DMQ7Z5F DN PMID26004420-Compound-US20140142115C DMQ7Z5F TI TTJ13ST DMQ7Z5F TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMQ7Z5F MA Inhibitor DMQ7Z5F RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMQ7Z5F RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMQ83EV DI DMQ83EV DMQ83EV DN PMID27109571-Compound-40 DMQ83EV TI TTMY6L1 DMQ83EV TN Fatty acid-binding protein (FABP) DMQ83EV MA Inhibitor DMQ83EV RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQ83EV RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQ84KW DI DMQ84KW DMQ84KW DN Macrocycle derivative 6 DMQ84KW TI TT23XQV DMQ84KW TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMQ84KW MA Inhibitor DMQ84KW RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQ84KW RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQ84KW DI DMQ84KW DMQ84KW DN Macrocycle derivative 6 DMQ84KW TI TT5YPJF DMQ84KW TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMQ84KW MA Inhibitor DMQ84KW RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQ84KW RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQ8EYV DI DMQ8EYV DMQ8EYV DN PMID29473428-Compound-43 DMQ8EYV TI TTZJYKH DMQ8EYV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQ8EYV MA Inhibitor DMQ8EYV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMQ8EYV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMQ8X94 DI DMQ8X94 DMQ8X94 DN Boronic acid derivative 3 DMQ8X94 TI TTDP1UC DMQ8X94 TN Fatty acid amide hydrolase (FAAH) DMQ8X94 MA Inhibitor DMQ8X94 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMQ8X94 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMQ9ATN DI DMQ9ATN DMQ9ATN DN Quinoline carboxamide derivative 6 DMQ9ATN TI TTPTXIN DMQ9ATN TN Translocator protein (TSPO) DMQ9ATN MA Ligand DMQ9ATN RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQ9ATN RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQ9CBS DI DMQ9CBS DMQ9CBS DN PMID28270021-Compound-WO2010077680 495 DMQ9CBS TI TTTDVOJ DMQ9CBS TN Tropomyosin-related kinase A (TrkA) DMQ9CBS MA Antagonist DMQ9CBS RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ9CBS RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQAC4K DI DMQAC4K DMQAC4K DN PMID27539678-Compound-7 DMQAC4K TI TTOHFIY DMQAC4K TN Sphingosine kinase 1 (SPHK1) DMQAC4K MA Inhibitor DMQAC4K RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMQAC4K RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMQARW2 DI DMQARW2 DMQARW2 DN SCHEMBL16365841 DMQARW2 TI TT78309 DMQARW2 TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMQARW2 MA Inhibitor DMQARW2 RN Substituted benzylpyrazoles. US9765058. DMQARW2 RU http://www.freepatentsonline.com/US9765058.html DMQAV30 DI DMQAV30 DMQAV30 DN PMID29649907-Compound-14 DMQAV30 TI TTS4UGC DMQAV30 TN Farnesoid X-activated receptor (FXR) DMQAV30 MA Agonist DMQAV30 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMQAV30 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMQAZMC DI DMQAZMC DMQAZMC DN PMID28270021-Compound-WO2010077680 201 DMQAZMC TI TTTDVOJ DMQAZMC TN Tropomyosin-related kinase A (TrkA) DMQAZMC MA Antagonist DMQAZMC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQAZMC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQB03U DI DMQB03U DMQB03U DN PMID25514969-Compound-13 DMQB03U TI TT4EB85 DMQB03U TN Cholesterol 24-hydroxylase (CYP46A1) DMQB03U MA Inhibitor DMQB03U RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMQB03U RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMQB4DR DI DMQB4DR DMQB4DR DN Biphenyl mannoside derivative 2 DMQB4DR TI TTTCRU2 DMQB4DR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQB4DR MA Antagonist DMQB4DR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQB4DR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQB4LE DI DMQB4LE DMQB4LE DN PMID25482888-Compound-11 DMQB4LE TI TTDIGC1 DMQB4LE TN Dipeptidyl peptidase 4 (DPP-4) DMQB4LE MA Inhibitor DMQB4LE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQB4LE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQBFI2 DI DMQBFI2 DMQBFI2 DN PMID25666693-Compound-26 DMQBFI2 TI TTMI6F5 DMQBFI2 TN Transient receptor potential cation channel V1 (TRPV1) DMQBFI2 MA Antagonist DMQBFI2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQBFI2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQBH81 DI DMQBH81 DMQBH81 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 DMQBH81 TI TTJW4LU DMQBH81 TN Phosphodiesterase 10A (PDE10) DMQBH81 MA Inhibitor DMQBH81 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQBH81 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQBH81 DI DMQBH81 DMQBH81 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 DMQBH81 TI TTJGW1Z DMQBH81 TN Phosphodiesterase 2A (PDE2A) DMQBH81 MA Inhibitor DMQBH81 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQBH81 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQD4X2 DI DMQD4X2 DMQD4X2 DN BK7 DMQD4X2 TI TT42OGM DMQD4X2 TN Hematopoietic cell kinase (HCK) DMQD4X2 MA Inhibitor DMQD4X2 RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DMQD4X2 RU http://www.freepatentsonline.com/US9765037.html DMQD6IL DI DMQD6IL DMQD6IL DN Schiff base compound 1 DMQD6IL TI TTGP7BY DMQD6IL TN Monoamine oxidase type B (MAO-B) DMQD6IL RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMQD6IL RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMQD6IL DI DMQD6IL DMQD6IL DN Schiff base compound 1 DMQD6IL TI TT3WG5C DMQD6IL TN Monoamine oxidase type A (MAO-A) DMQD6IL RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMQD6IL RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMQDA3I DI DMQDA3I DMQDA3I DN Imidazopyridine acetamide analog 7 DMQDA3I TI TTPTXIN DMQDA3I TN Translocator protein (TSPO) DMQDA3I MA Ligand DMQDA3I RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQDA3I RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQDGZL DI DMQDGZL DMQDGZL DN PMID29649907-Compound-27 DMQDGZL TI TTS4UGC DMQDGZL TN Farnesoid X-activated receptor (FXR) DMQDGZL MA Agonist DMQDGZL RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMQDGZL RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMQDL43 DI DMQDL43 DMQDL43 DN Pyrrole derivative 4 DMQDL43 TI TT6OEDT DMQDL43 TN Cannabinoid receptor 1 (CB1) DMQDL43 MA Antagonist DMQDL43 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMQDL43 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMQDRUT DI DMQDRUT DMQDRUT DN PMID28394193-Compound-16 DMQDRUT TI TT9MZCQ DMQDRUT TN Enhancer of zeste homolog 2 (EZH2) DMQDRUT MA Inhibitor DMQDRUT RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQDRUT RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQEL1W DI DMQEL1W DMQEL1W DN US9266828, C DMQEL1W TI TTH9WF6 DMQEL1W TN Dibasic-processing enzyme (Furin) DMQEL1W MA Inhibitor DMQEL1W RN Inhibitors of Furin and other pro-protein convertases. US9266828. DMQEL1W RU http://www.freepatentsonline.com/US9266828.html DMQEYTJ DI DMQEYTJ DMQEYTJ DN Diamine derivative 2 DMQEYTJ TI TTULVH8 DMQEYTJ TN Tyrosinase (TYR) DMQEYTJ MA Inhibitor DMQEYTJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQEYTJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQF0RY DI DMQF0RY DMQF0RY DN N-oxalylglycine derivative 3 DMQF0RY TI TT0RGE9 DMQF0RY TN Lysine-specific demethylase 4 (KDM4) DMQF0RY MA Inhibitor DMQF0RY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMQF0RY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMQF1UM DI DMQF1UM DMQF1UM DN Egonol compound 1 DMQF1UM TI TTEB0GD DMQF1UM TN Cholinesterase (BCHE) DMQF1UM MA Inhibitor DMQF1UM RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQF1UM RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQF1UM DI DMQF1UM DMQF1UM DN Egonol compound 1 DMQF1UM TI TT1RS9F DMQF1UM TN Acetylcholinesterase (AChE) DMQF1UM MA Inhibitor DMQF1UM RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQF1UM RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQF2XN DI DMQF2XN DMQF2XN DN Biphenyl carboxamidopropanoic acid derivative 2 DMQF2XN TI TT9O6WS DMQF2XN TN Glucagon receptor (GCGR) DMQF2XN MA Antagonist DMQF2XN RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMQF2XN RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMQF62D DI DMQF62D DMQF62D DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1 DMQF62D TI TTJGW1Z DMQF62D TN Phosphodiesterase 2A (PDE2A) DMQF62D MA Inhibitor DMQF62D RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQF62D RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQF90E DI DMQF90E DMQF90E DN Resorcinol compound 34 DMQF90E TI TTULVH8 DMQF90E TN Tyrosinase (TYR) DMQF90E MA Inhibitor DMQF90E RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQF90E RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQFDU8 DI DMQFDU8 DMQFDU8 DN PMID26651364-Compound-46 DMQFDU8 TI TTTCRU2 DMQFDU8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQFDU8 MA Antagonist DMQFDU8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQFDU8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQGA1I DI DMQGA1I DMQGA1I DN Tetra-hydro-oxazolopyridine derivative 5 DMQGA1I TI TTHS256 DMQGA1I TN Metabotropic glutamate receptor 5 (mGluR5) DMQGA1I MA Modulator DMQGA1I RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQGA1I RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQGFKY DI DMQGFKY DMQGFKY DN Biphenyl mannoside derivative 22 DMQGFKY TI TTTCRU2 DMQGFKY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQGFKY MA Antagonist DMQGFKY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQGFKY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQGI0R DI DMQGI0R DMQGI0R DN Pyrrolo[2,3-d]pyrimidine derivative 32 DMQGI0R TI TTGM6VW DMQGI0R TN Tyrosine-protein kinase BTK (ATK) DMQGI0R MA Inhibitor DMQGI0R RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMQGI0R RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMQGTJ5 DI DMQGTJ5 DMQGTJ5 DN PMID26815044-Compound-51 DMQGTJ5 TI TTULVH8 DMQGTJ5 TN Tyrosinase (TYR) DMQGTJ5 MA Inhibitor DMQGTJ5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQGTJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQGTYE DI DMQGTYE DMQGTYE DN PMID25666693-Compound-141 DMQGTYE TI TTMI6F5 DMQGTYE TN Transient receptor potential cation channel V1 (TRPV1) DMQGTYE MA Antagonist DMQGTYE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQGTYE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQGUMN DI DMQGUMN DMQGUMN DN PMID25991433-Compound-J1 DMQGUMN TI TTVOE6D DMQGUMN TN Mitogen-activated protein kinase (MAPK) DMQGUMN MA Inhibitor DMQGUMN RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQGUMN RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQGYWV DI DMQGYWV DMQGYWV DN Bicyclic heteroaryl benzamide derivative 6 DMQGYWV TI TTTDVOJ DMQGYWV TN Tropomyosin-related kinase A (TrkA) DMQGYWV MA Inhibitor DMQGYWV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQGYWV RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQHAU1 DI DMQHAU1 DMQHAU1 DN N-arylmethyl-N-phenyl cyclic urea derivative 1 DMQHAU1 TI TTTDVOJ DMQHAU1 TN Tropomyosin-related kinase A (TrkA) DMQHAU1 MA Inhibitor DMQHAU1 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMQHAU1 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMQHCDZ DI DMQHCDZ DMQHCDZ DN Pyrazolo[3,4-c]pyridine derivative 1 DMQHCDZ TI TTSCIM2 DMQHCDZ TN Extracellular lysophospholipase D (E-NPP2) DMQHCDZ MA Inhibitor DMQHCDZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMQHCDZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TTRMX3V DMQHYMJ TN Janus kinase 2 (JAK-2) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TTT7PJU DMQHYMJ TN Janus kinase 3 (JAK-3) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TT6DM01 DMQHYMJ TN Janus kinase 1 (JAK-1) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQI1YN DI DMQI1YN DMQI1YN DN PMID25666693-Compound-78 DMQI1YN TI TTMI6F5 DMQI1YN TN Transient receptor potential cation channel V1 (TRPV1) DMQI1YN MA Antagonist DMQI1YN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQI1YN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQIUD9 DI DMQIUD9 DMQIUD9 DN PMID28870136-Compound-58 DMQIUD9 TI TTK0O6Y DMQIUD9 TN Ecto-5'-nucleotidase (CD73) DMQIUD9 MA Inhibitor DMQIUD9 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMQIUD9 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMQIYM6 DI DMQIYM6 DMQIYM6 DN PMID27454349-Compound-101 DMQIYM6 TI TTK59TV DMQIYM6 TN Vitamin D3 receptor (VDR) DMQIYM6 MA Agonist DMQIYM6 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMQIYM6 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMQJ38W DI DMQJ38W DMQJ38W DN Poly-substituted miazine derivative 1 DMQJ38W TI TTPADOQ DMQJ38W TN HMG-CoA reductase (HMGCR) DMQJ38W MA Inhibitor DMQJ38W RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMQJ38W RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMQJ3TC DI DMQJ3TC DMQJ3TC DN PMID29671355-Compound-36 DMQJ3TC TI TTT6LFV DMQJ3TC TN Histone deacetylase 8 (HDAC8) DMQJ3TC MA Inhibitor DMQJ3TC RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMQJ3TC RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMQJ3TC DI DMQJ3TC DMQJ3TC DN PMID29671355-Compound-36 DMQJ3TC TI TT8K17W DMQJ3TC TN Histone deacetylase 11 (HDAC11) DMQJ3TC MA Inhibitor DMQJ3TC RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMQJ3TC RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMQJ5S8 DI DMQJ5S8 DMQJ5S8 DN BDBM50382283 DMQJ5S8 TI TTOYT5L DMQJ5S8 TN Dipeptidyl-peptidase 7 (DPP7) DMQJ5S8 MA Inhibitor DMQJ5S8 RN FAP inhibitors. US9346814. DMQJ5S8 RU http://www.freepatentsonline.com/US9346814.html DMQJF15 DI DMQJF15 DMQJF15 DN PMID28870136-Compound-36 DMQJF15 TI TTK0O6Y DMQJF15 TN Ecto-5'-nucleotidase (CD73) DMQJF15 MA Inhibitor DMQJF15 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMQJF15 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMQJF4P DI DMQJF4P DMQJF4P DN Beta-cyclodextrin conjugate derivative 3 DMQJF4P TI TTTCRU2 DMQJF4P TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQJF4P MA Antagonist DMQJF4P RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQJF4P RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQJK70 DI DMQJK70 DMQJK70 DN Tricyclic heterocycle derivative 6 DMQJK70 TI TTDIGC1 DMQJK70 TN Dipeptidyl peptidase 4 (DPP-4) DMQJK70 MA Inhibitor DMQJK70 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQJK70 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQJV3L DI DMQJV3L DMQJV3L DN PMID25399762-Compound-Table1-C7 DMQJV3L TI TTGP7BY DMQJV3L TN Monoamine oxidase type B (MAO-B) DMQJV3L MA Inhibitor DMQJV3L RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMQJV3L RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMQJW9R DI DMQJW9R DMQJW9R DN Heterocyclic derivative 12 DMQJW9R TI TTCZOF2 DMQJW9R TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMQJW9R MA Inhibitor DMQJW9R RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMQJW9R RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMQJZLI DI DMQJZLI DMQJZLI DN PMID25726713-Compound-19 DMQJZLI TI TT8J1S3 DMQJZLI TN Smoothened homolog (SMO) DMQJZLI MA Inhibitor DMQJZLI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQJZLI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQK4IX DI DMQK4IX DMQK4IX DN PMID28270021-Compound-WO2013009582Example76 DMQK4IX TI TTTDVOJ DMQK4IX TN Tropomyosin-related kinase A (TrkA) DMQK4IX MA Inhibitor DMQK4IX RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQK4IX RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQKLX0 DI DMQKLX0 DMQKLX0 DN PMID25991433-Compound-H3 DMQKLX0 TI TT0K6EO DMQKLX0 TN Stress-activated protein kinase JNK1 (JNK1) DMQKLX0 MA Inhibitor DMQKLX0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQKLX0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQKOMR DI DMQKOMR DMQKOMR DN Tarnylcypromine derivative 1 DMQKOMR TI TTNR0UQ DMQKOMR TN Lysine-specific histone demethylase 1 (LSD) DMQKOMR MA Inhibitor DMQKOMR RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQKOMR RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQL1TV DI DMQL1TV DMQL1TV DN Triazolo-pyridine derivative 3 DMQL1TV TI TTJW4LU DMQL1TV TN Phosphodiesterase 10A (PDE10) DMQL1TV MA Inhibitor DMQL1TV RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQL1TV RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQL1TV DI DMQL1TV DMQL1TV DN Triazolo-pyridine derivative 3 DMQL1TV TI TTJGW1Z DMQL1TV TN Phosphodiesterase 2A (PDE2A) DMQL1TV MA Inhibitor DMQL1TV RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQL1TV RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TT6DM01 DMQL34C TN Janus kinase 1 (JAK-1) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTRMX3V DMQL34C TN Janus kinase 2 (JAK-2) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTBYWP2 DMQL34C TN TYK2 tyrosine kinase (TYK2) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTT7PJU DMQL34C TN Janus kinase 3 (JAK-3) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TT0K6EO DMQL5B7 TN Stress-activated protein kinase JNK1 (JNK1) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TTHS0U8 DMQL5B7 TN Stress-activated protein kinase JNK2 (JNK2) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TT056SO DMQL5B7 TN Stress-activated protein kinase JNK3 (JNK3) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQLBAJ DI DMQLBAJ DMQLBAJ DN PMID25522065-Compound-38 DMQLBAJ TI TTX4RTB DMQLBAJ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQLBAJ MA Antagonist DMQLBAJ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMQLBAJ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMQLJU2 DI DMQLJU2 DMQLJU2 DN Imidazo[1,2-b]pyridazine acetamide derivative 7 DMQLJU2 TI TTPTXIN DMQLJU2 TN Translocator protein (TSPO) DMQLJU2 MA Ligand DMQLJU2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQLJU2 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQLZUW DI DMQLZUW DMQLZUW DN Cyclohexane carboxamide derivative 3 DMQLZUW TI TTTJZ4M DMQLZUW TN Prolylcarboxypeptidase (PRCP) DMQLZUW MA Inhibitor DMQLZUW RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMQLZUW RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMQM6ZS DI DMQM6ZS DMQM6ZS DN Epoxysuccinate derivative 6 DMQM6ZS TI TTG5QB7 DMQM6ZS TN Calpain-2 (CAPN2) DMQM6ZS MA Inhibitor DMQM6ZS RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMQM6ZS RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMQMBY9 DI DMQMBY9 DMQMBY9 DN PMID26651364-Compound-7a DMQMBY9 TI TTTCRU2 DMQMBY9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQMBY9 MA Antagonist DMQMBY9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQMBY9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQNVUB DI DMQNVUB DMQNVUB DN PMID29338548-Compound-16 DMQNVUB TI TTHJTF7 DMQNVUB TN Glycine transporter GlyT-1 (SLC6A9) DMQNVUB MA Inhibitor DMQNVUB RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMQNVUB RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMQOAJP DI DMQOAJP DMQOAJP DN PMID27967267-Compound-39 DMQOAJP TI TT1RS9F DMQOAJP TN Acetylcholinesterase (AChE) DMQOAJP MA Inhibitor DMQOAJP RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQOAJP RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQOF53 DI DMQOF53 DMQOF53 DN PMID29334795-Compound-66 DMQOF53 TI TT9JNIC DMQOF53 TN Histamine H3 receptor (H3R) DMQOF53 MA Inhibitor DMQOF53 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQOF53 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQOF53 DI DMQOF53 DMQOF53 DN PMID29334795-Compound-66 DMQOF53 TI TTEX248 DMQOF53 TN Dopamine D2 receptor (D2R) DMQOF53 MA Ligand DMQOF53 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQOF53 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQOGHN DI DMQOGHN DMQOGHN DN Fluorinated donepezil derivative 1 DMQOGHN TI TT1RS9F DMQOGHN TN Acetylcholinesterase (AChE) DMQOGHN MA Inhibitor DMQOGHN RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQOGHN RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQOSH5 DI DMQOSH5 DMQOSH5 DN PMID25666693-Compound-112 DMQOSH5 TI TTMI6F5 DMQOSH5 TN Transient receptor potential cation channel V1 (TRPV1) DMQOSH5 MA Antagonist DMQOSH5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQOSH5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQOVKF DI DMQOVKF DMQOVKF DN PMID25482888-Compound-72 DMQOVKF TI TTDIGC1 DMQOVKF TN Dipeptidyl peptidase 4 (DPP-4) DMQOVKF MA Inhibitor DMQOVKF RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQOVKF RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQP3TD DI DMQP3TD DMQP3TD DN PMID25666693-Compound-10 DMQP3TD TI TTMI6F5 DMQP3TD TN Transient receptor potential cation channel V1 (TRPV1) DMQP3TD MA Antagonist DMQP3TD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQP3TD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQPIK4 DI DMQPIK4 DMQPIK4 DN PMID30107136-Compound-Example41 DMQPIK4 TI TT23XQV DMQPIK4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMQPIK4 MA Inhibitor DMQPIK4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQPIK4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQPKCD DI DMQPKCD DMQPKCD DN PMID28454500-Compound-50 DMQPKCD TI TTA6ZN2 DMQPKCD TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMQPKCD MA Activator DMQPKCD RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQPKCD RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQPKCD DI DMQPKCD DMQPKCD DN PMID28454500-Compound-50 DMQPKCD TI TT3Z6Y9 DMQPKCD TN Cysteines of Keap1 (KEAP1 Cysteines) DMQPKCD MA Modulator DMQPKCD RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQPKCD RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQPOGC DI DMQPOGC DMQPOGC DN PMID25666693-Compound-52 DMQPOGC TI TTMI6F5 DMQPOGC TN Transient receptor potential cation channel V1 (TRPV1) DMQPOGC MA Antagonist DMQPOGC RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQPOGC RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQPTEJ DI DMQPTEJ DMQPTEJ DN Indanone and indandione derivative 1 DMQPTEJ TI TTV1C0Z DMQPTEJ TN Neuropeptide S receptor (NPSR) DMQPTEJ MA Antagonist DMQPTEJ RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMQPTEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMQPU7K DI DMQPU7K DMQPU7K DN PMID27019002-Compound-46 DMQPU7K TI TTNR0UQ DMQPU7K TN Lysine-specific histone demethylase 1 (LSD) DMQPU7K MA Inhibitor DMQPU7K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQPU7K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQPU7K DI DMQPU7K DMQPU7K DN PMID27019002-Compound-46 DMQPU7K TI TT8VP2T DMQPU7K TN Lysine-specific histone demethylase 1B (KDM1B) DMQPU7K MA Inhibitor DMQPU7K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQPU7K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQRECT DI DMQRECT DMQRECT DN Dihydroisoxazole derivative 1 DMQRECT TI TT2F4OL DMQRECT TN Tissue transglutaminase (TG2) DMQRECT MA Inhibitor DMQRECT RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMQRECT RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMQRFXT DI DMQRFXT DMQRFXT DN PMID25666693-Compound-57 DMQRFXT TI TTMI6F5 DMQRFXT TN Transient receptor potential cation channel V1 (TRPV1) DMQRFXT MA Antagonist DMQRFXT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQRFXT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQRFZK DI DMQRFZK DMQRFZK DN PMID28394193-Compound-56 DMQRFZK TI TTJW2UQ DMQRFZK TN EZH2 Y641N mutant (EZH2 Y641N) DMQRFZK MA Inhibitor DMQRFZK RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQRFZK RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQRFZK DI DMQRFZK DMQRFZK DN PMID28394193-Compound-56 DMQRFZK TI TT9MZCQ DMQRFZK TN Enhancer of zeste homolog 2 (EZH2) DMQRFZK MA Inhibitor DMQRFZK RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQRFZK RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQRO6G DI DMQRO6G DMQRO6G DN US8546370, 102 DMQRO6G TI TTUMHT8 DMQRO6G TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DMQRO6G MA Inhibitor DMQRO6G RN Compounds and compositions as kinase inhibitors. US8546370. DMQRO6G RU http://www.freepatentsonline.com/US8546370.html DMQS8CF DI DMQS8CF DMQS8CF DN Aryl mannoside derivative 15 DMQS8CF TI TTTCRU2 DMQS8CF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQS8CF MA Antagonist DMQS8CF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQS8CF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQSCHA DI DMQSCHA DMQSCHA DN Triazolo-benzodiazepine derivative 2 DMQSCHA TI TT9JNIC DMQSCHA TN Histamine H3 receptor (H3R) DMQSCHA MA Ligand DMQSCHA RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQSCHA RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQSTG9 DI DMQSTG9 DMQSTG9 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 DMQSTG9 TI TTJGW1Z DMQSTG9 TN Phosphodiesterase 2A (PDE2A) DMQSTG9 MA Inhibitor DMQSTG9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQSTG9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQSTG9 DI DMQSTG9 DMQSTG9 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 DMQSTG9 TI TTJW4LU DMQSTG9 TN Phosphodiesterase 10A (PDE10) DMQSTG9 MA Inhibitor DMQSTG9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQSTG9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQT7HV DI DMQT7HV DMQT7HV DN Benzenamine derivative 4 DMQT7HV TI TTNR0UQ DMQT7HV TN Lysine-specific histone demethylase 1 (LSD) DMQT7HV MA Inhibitor DMQT7HV RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQT7HV RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQTRFX DI DMQTRFX DMQTRFX DN PMID27967267-Compound-49 DMQTRFX TI TT1RS9F DMQTRFX TN Acetylcholinesterase (AChE) DMQTRFX MA Reactivator DMQTRFX RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQTRFX RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQTVPC DI DMQTVPC DMQTVPC DN Epoxysuccinate derivative 8 DMQTVPC TI TTG5QB7 DMQTVPC TN Calpain-2 (CAPN2) DMQTVPC MA Inhibitor DMQTVPC RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMQTVPC RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMQU10C DI DMQU10C DMQU10C DN PMID30185082-Compound-14 DMQU10C TI TT9NXW4 DMQU10C TN Sigma intracellular receptor 2 (TMEM97) DMQU10C MA Ligand DMQU10C RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMQU10C RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMQU9XP DI DMQU9XP DMQU9XP DN PMID27109571-Compound-20 DMQU9XP TI TTNT2S6 DMQU9XP TN Fatty acid-binding protein 5 (FABP5) DMQU9XP MA Inhibitor DMQU9XP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQU9XP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQU9XP DI DMQU9XP DMQU9XP DN PMID27109571-Compound-20 DMQU9XP TI TTHWMFZ DMQU9XP TN Fatty acid-binding protein 4 (FABP4) DMQU9XP MA Inhibitor DMQU9XP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQU9XP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQUE6D DI DMQUE6D DMQUE6D DN PMID29865878-Compound-43 DMQUE6D TI TT68GPI DMQUE6D TN Proteasome beta-5 (PS beta-5) DMQUE6D MA Inhibitor DMQUE6D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMQUE6D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMQUE6D DI DMQUE6D DMQUE6D DN PMID29865878-Compound-43 DMQUE6D TI TTEAD9J DMQUE6D TN Proteasome beta-8 (PS beta-8) DMQUE6D MA Inhibitor DMQUE6D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMQUE6D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMQUEDK DI DMQUEDK DMQUEDK DN Pyrimidine derivative 20 DMQUEDK TI TT8J1S3 DMQUEDK TN Smoothened homolog (SMO) DMQUEDK MA Inhibitor DMQUEDK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQUEDK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQURWZ DI DMQURWZ DMQURWZ DN Indole-based analog 14 DMQURWZ TI TTUM2ZR DMQURWZ TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMQURWZ MA Inhibitor DMQURWZ RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMQURWZ RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMQV6R0 DI DMQV6R0 DMQV6R0 DN PMID28766366-Compound-Scheme7WO2012/098070bottom DMQV6R0 TI TTYGQ8A DMQV6R0 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMQV6R0 MA Inhibitor DMQV6R0 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQV6R0 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQV6R0 DI DMQV6R0 DMQV6R0 DN PMID28766366-Compound-Scheme7WO2012/098070bottom DMQV6R0 TI TTSBVFO DMQV6R0 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMQV6R0 MA Inhibitor DMQV6R0 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQV6R0 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQVLP8 DI DMQVLP8 DMQVLP8 DN Pyrazolo[1,5-a]pyrimidine derivative 23 DMQVLP8 TI TTTDVOJ DMQVLP8 TN Tropomyosin-related kinase A (TrkA) DMQVLP8 MA Inhibitor DMQVLP8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMQVLP8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTALN9W DMQVMNJ TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTZJYKH DMQVMNJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTXNCBV DMQVMNJ TN Tryptophan 2,3-dioxygenase (TDO) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVYL0 DI DMQVYL0 DMQVYL0 DN Isoquinoline sulfonamide derivative 2 DMQVYL0 TI TTMQO60 DMQVYL0 TN Rho-associated protein kinase (ROCK) DMQVYL0 MA Inhibitor DMQVYL0 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMQVYL0 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMQVZ01 DI DMQVZ01 DMQVZ01 DN PMID26882240-Compound-14 DMQVZ01 TI TTUX68I DMQVZ01 TN Hypoxia-inducible factor 1 (HIF-1) DMQVZ01 MA Inhibitor DMQVZ01 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMQVZ01 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMQVZY5 DI DMQVZY5 DMQVZY5 DN Aminoarylpyridine derivative 1 DMQVZY5 TI TT1LVF2 DMQVZY5 TN Cyclin-dependent kinase 9 (CDK9) DMQVZY5 MA Inhibitor DMQVZY5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMQVZY5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMQW470 DI DMQW470 DMQW470 DN PMID28074661-Compound-US20100022547C80 DMQW470 TI TTL7C8Q DMQW470 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMQW470 MA Inhibitor DMQW470 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMQW470 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMQWJ12 DI DMQWJ12 DMQWJ12 DN Aryl urea derivative 2 DMQWJ12 TI TTDP1UC DMQWJ12 TN Fatty acid amide hydrolase (FAAH) DMQWJ12 MA Inhibitor DMQWJ12 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMQWJ12 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMQWODI DI DMQWODI DMQWODI DN N-substituted pyrazole derivative 2 DMQWODI TI TTXJ47W DMQWODI TN Metabotropic glutamate receptor 2 (mGluR2) DMQWODI MA Antagonist DMQWODI RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMQWODI RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMQWPSF DI DMQWPSF DMQWPSF DN PMID28454500-Compound-59 DMQWPSF TI TTA6ZN2 DMQWPSF TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMQWPSF MA Inhibitor DMQWPSF RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQWPSF RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQWPSF DI DMQWPSF DMQWPSF DN PMID28454500-Compound-59 DMQWPSF TI TTGIZLN DMQWPSF TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMQWPSF MA Modulator DMQWPSF RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQWPSF RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQX8SD DI DMQX8SD DMQX8SD DN 1,2-diamino cyclopentane-based derivative 32 DMQX8SD TI TT9N02I DMQX8SD TN Orexin receptor type 2 (HCRTR2) DMQX8SD MA Antagonist DMQX8SD RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMQX8SD RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMQX8SD DI DMQX8SD DMQX8SD DN 1,2-diamino cyclopentane-based derivative 32 DMQX8SD TI TT60Q8D DMQX8SD TN Orexin receptor type 1 (HCRTR1) DMQX8SD MA Antagonist DMQX8SD RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMQX8SD RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMQXCT1 DI DMQXCT1 DMQXCT1 DN Imidazo bicyclic iminium derivative 9 DMQXCT1 TI TT8J1S3 DMQXCT1 TN Smoothened homolog (SMO) DMQXCT1 MA Inhibitor DMQXCT1 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQXCT1 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQYKT2 DI DMQYKT2 DMQYKT2 DN Tetra-hydro-oxazolopyridine derivative 3 DMQYKT2 TI TTHS256 DMQYKT2 TN Metabotropic glutamate receptor 5 (mGluR5) DMQYKT2 MA Modulator DMQYKT2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQYKT2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQYWBR DI DMQYWBR DMQYWBR DN PMID26077642-Compound-Figure3H DMQYWBR TI TTZC0KV DMQYWBR TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DMQYWBR MA Inhibitor DMQYWBR RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMQYWBR RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMQZJDF DI DMQZJDF DMQZJDF DN PMID26651364-Compound-106 DMQZJDF TI TTTCRU2 DMQZJDF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQZJDF MA Antagonist DMQZJDF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQZJDF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR0ANI DI DMR0ANI DMR0ANI DN Bis-sulfonamide derivative 2 DMR0ANI TI TTR7UJ3 DMR0ANI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMR0ANI MA Inhibitor DMR0ANI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMR0ANI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMR0E5W DI DMR0E5W DMR0E5W DN PMID26651364-Compound-123 DMR0E5W TI TTTCRU2 DMR0E5W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMR0E5W MA Antagonist DMR0E5W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMR0E5W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR0F4H DI DMR0F4H DMR0F4H DN ZINC959121 DMR0F4H TI TTU3WV6 DMR0F4H TN SRSF protein kinase 1 (SRPK1) DMR0F4H MA Inhibitor DMR0F4H RN Piperazine derivatives for treating disorders. US9695160. DMR0F4H RU http://www.freepatentsonline.com/US9695160.html DMR0JDW DI DMR0JDW DMR0JDW DN Ureido-phenyl-substituted triazine derivative 2 DMR0JDW TI TTTDVOJ DMR0JDW TN Tropomyosin-related kinase A (TrkA) DMR0JDW MA Inhibitor DMR0JDW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMR0JDW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMR0P1U DI DMR0P1U DMR0P1U DN PMID25399762-Compound-Table1-C15 DMR0P1U TI TTGP7BY DMR0P1U TN Monoamine oxidase type B (MAO-B) DMR0P1U MA Inhibitor DMR0P1U RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMR0P1U RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMR0PUA DI DMR0PUA DMR0PUA DN PMID28394193-Compound-10 DMR0PUA TI TTJBYRU DMR0PUA TN EZH2 Y641F mutant (EZH2 Y641F) DMR0PUA MA Inhibitor DMR0PUA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMR0PUA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMR0WM1 DI DMR0WM1 DMR0WM1 DN PMID25666693-Compound-125 DMR0WM1 TI TTMI6F5 DMR0WM1 TN Transient receptor potential cation channel V1 (TRPV1) DMR0WM1 MA Antagonist DMR0WM1 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMR0WM1 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMR0Y3K DI DMR0Y3K DMR0Y3K DN Isoquinoline derivative 1 DMR0Y3K TI TTMSFAW DMR0Y3K TN Cannabinoid receptor 2 (CB2) DMR0Y3K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMR0Y3K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMR0ZU6 DI DMR0ZU6 DMR0ZU6 DN Pyrrolo-pyrimidine derivative 10 DMR0ZU6 TI TTK0FEA DMR0ZU6 TN Leucine-rich repeat kinase 2 (LRRK2) DMR0ZU6 MA Inhibitor DMR0ZU6 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMR0ZU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMR1QP4 DI DMR1QP4 DMR1QP4 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3 DMR1QP4 TI TTJGW1Z DMR1QP4 TN Phosphodiesterase 2A (PDE2A) DMR1QP4 MA Inhibitor DMR1QP4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMR1QP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMR1YH9 DI DMR1YH9 DMR1YH9 DN PMID25553724-Compound-WO2013082253 33 DMR1YH9 TI TTSXVID DMR1YH9 TN Nuclear factor NF-kappa-B (NFKB) DMR1YH9 MA Modulator DMR1YH9 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMR1YH9 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMR1Z3I DI DMR1Z3I DMR1Z3I DN US9522888, 412 DMR1Z3I TI TTDYP7I DMR1Z3I TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMR1Z3I MA Inhibitor DMR1Z3I RN Substituted bicyclic compounds. US10166249. DMR1Z3I RU http://www.freepatentsonline.com/US10166249.html DMR2GW1 DI DMR2GW1 DMR2GW1 DN Indazolyl-thiadiazolamine derivative 1 DMR2GW1 TI TTGWKQJ DMR2GW1 TN Rho-associated protein kinase 2 (ROCK2) DMR2GW1 MA Inhibitor DMR2GW1 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMR2GW1 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMR2UGC DI DMR2UGC DMR2UGC DN BDBM50444062 DMR2UGC TI TTIEMFN DMR2UGC TN TYRO3 tyrosine kinase receptor (TYRO3) DMR2UGC MA Inhibitor DMR2UGC RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DMR2UGC RU http://www.freepatentsonline.com/US9649309.html DMR39ZY DI DMR39ZY DMR39ZY DN Chlorobenzamide derivative 1 DMR39ZY TI TT473XN DMR39ZY TN P2X purinoceptor 7 (P2RX7) DMR39ZY MA Antagonist DMR39ZY RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMR39ZY RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMR3AVK DI DMR3AVK DMR3AVK DN Dihydropyridine compound 3 DMR3AVK TI TT4DXQT DMR3AVK TN Proto-oncogene c-Ret (RET) DMR3AVK MA Inhibitor DMR3AVK RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMR3AVK RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMR3J9A DI DMR3J9A DMR3J9A DN PMID25684022-Compound-US20120277229 40(1.2) DMR3J9A TI TTCZOF2 DMR3J9A TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMR3J9A MA Inhibitor DMR3J9A RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMR3J9A RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMR3Z49 DI DMR3Z49 DMR3Z49 DN US9650366, 12 DMR3Z49 TI TTXEZJ4 DMR3Z49 TN Tyrosine-protein kinase EIF2AK2 (p68) DMR3Z49 MA Inhibitor DMR3Z49 RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DMR3Z49 RU http://www.freepatentsonline.com/US9650366.html DMR43JE DI DMR43JE DMR43JE DN PMID27841045-Compound-144 DMR43JE TI TT7RJY8 DMR43JE TN Xanthine dehydrogenase/oxidase (XDH) DMR43JE MA Inhibitor DMR43JE RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMR43JE RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMR4LPO DI DMR4LPO DMR4LPO DN Dihydrothieno [2,3-e]indazole derivative 4 DMR4LPO TI TTRPDBG DMR4LPO TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMR4LPO MA Inhibitor DMR4LPO RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMR4LPO RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMR4MSH DI DMR4MSH DMR4MSH DN PMID25684022-Compound-US20120277229 39(1.1) DMR4MSH TI TTCZOF2 DMR4MSH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMR4MSH MA Inhibitor DMR4MSH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMR4MSH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMR4PQN DI DMR4PQN DMR4PQN DN Dihydropyrido phthalazinone derivative 2 DMR4PQN TI TTVDSZ0 DMR4PQN TN Poly [ADP-ribose] polymerase 1 (PARP1) DMR4PQN MA Inhibitor DMR4PQN RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMR4PQN RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMR58TX DI DMR58TX DMR58TX DN PMID28621580-Compound-WO2014079545C69 DMR58TX TI TTOHSBA DMR58TX TN Vascular endothelial growth factor A (VEGFA) DMR58TX MA Inhibitor DMR58TX RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMR58TX RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMR5O7T DI DMR5O7T DMR5O7T DN Pyrazolo[1,5-a]pyrimidine derivative 13 DMR5O7T TI TT6OEDT DMR5O7T TN Cannabinoid receptor 1 (CB1) DMR5O7T MA Antagonist DMR5O7T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMR5O7T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMR5V2A DI DMR5V2A DMR5V2A DN Benzo[d]oxazole derivative 2 DMR5V2A TI TTA6ZN2 DMR5V2A TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMR5V2A MA Inhibitor DMR5V2A RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMR5V2A RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMR63O2 DI DMR63O2 DMR63O2 DN PMID25666693-Compound-122 DMR63O2 TI TTMI6F5 DMR63O2 TN Transient receptor potential cation channel V1 (TRPV1) DMR63O2 MA Antagonist DMR63O2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMR63O2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMR648Z DI DMR648Z DMR648Z DN Aryl mannoside derivative 14 DMR648Z TI TTTCRU2 DMR648Z TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMR648Z MA Antagonist DMR648Z RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMR648Z RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR6ODL DI DMR6ODL DMR6ODL DN US9475795, 89 DMR6ODL TI TTB9CIL DMR6ODL TN Prokineticin receptor-1 (PROKR1) DMR6ODL MA Inhibitor DMR6ODL RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DMR6ODL RU http://www.freepatentsonline.com/US9475795.html DMR6P8T DI DMR6P8T DMR6P8T DN US9346821, B-13 DMR6P8T TI TTXL0GC DMR6P8T TN Enteropeptidase (TMPRSS15) DMR6P8T MA Inhibitor DMR6P8T RN Heterocyclic carboxylic acid ester derivative. US9346821. DMR6P8T RU http://www.freepatentsonline.com/US9346821.html DMR6QCE DI DMR6QCE DMR6QCE DN Pyrrolo-pyridone derivative 1 DMR6QCE TI TTRMX3V DMR6QCE TN Janus kinase 2 (JAK-2) DMR6QCE MA Inhibitor DMR6QCE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMR6QCE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMR6QCE DI DMR6QCE DMR6QCE DN Pyrrolo-pyridone derivative 1 DMR6QCE TI TT6DM01 DMR6QCE TN Janus kinase 1 (JAK-1) DMR6QCE MA Inhibitor DMR6QCE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMR6QCE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMR6VIG DI DMR6VIG DMR6VIG DN Pyrazole derivative 70 DMR6VIG TI TTJQOD7 DMR6VIG TN 5-HT 2A receptor (HTR2A) DMR6VIG MA Antagonist DMR6VIG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMR6VIG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMR6XF4 DI DMR6XF4 DMR6XF4 DN Benzothiazepine analog 10 DMR6XF4 TI TTRA6BO DMR6XF4 TN Bromodomain-containing protein 4 (BRD4) DMR6XF4 MA Inhibitor DMR6XF4 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMR6XF4 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMR6YAD DI DMR6YAD DMR6YAD DN N-alkyl-4-oxazolecar boxamide derivative 2 DMR6YAD TI TTDP1UC DMR6YAD TN Fatty acid amide hydrolase (FAAH) DMR6YAD MA Inhibitor DMR6YAD RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMR6YAD RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMR74ET DI DMR74ET DMR74ET DN Picolinamido propanoic acid derivative 2 DMR74ET TI TT9O6WS DMR74ET TN Glucagon receptor (GCGR) DMR74ET MA Antagonist DMR74ET RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMR74ET RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMR7A58 DI DMR7A58 DMR7A58 DN PMID25656651-Compound-26c DMR7A58 TI TTS7G69 DMR7A58 TN Fusion protein Bcr-Abl (Bcr-Abl) DMR7A58 MA Inhibitor DMR7A58 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMR7A58 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMR7MBY DI DMR7MBY DMR7MBY DN PMID27841045-Compound-143 DMR7MBY TI TT7RJY8 DMR7MBY TN Xanthine dehydrogenase/oxidase (XDH) DMR7MBY MA Inhibitor DMR7MBY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMR7MBY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMR7QKL DI DMR7QKL DMR7QKL DN 2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL TI TTXNCBV DMR7QKL TN Tryptophan 2,3-dioxygenase (TDO) DMR7QKL MA Inhibitor DMR7QKL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMR7QKL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMR7QKL DI DMR7QKL DMR7QKL DN 2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL TI TTZJYKH DMR7QKL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMR7QKL MA Inhibitor DMR7QKL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMR7QKL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMR7V9E DI DMR7V9E DMR7V9E DN PMID27828716-Compound-17 DMR7V9E TI TTRZQE3 DMR7V9E TN Glycogen synthase kinase-3 alpha (GSK-3A) DMR7V9E MA Inhibitor DMR7V9E RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMR7V9E RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMR8HSU DI DMR8HSU DMR8HSU DN PMID25726713-Compound-60 DMR8HSU TI TT8J1S3 DMR8HSU TN Smoothened homolog (SMO) DMR8HSU MA Inhibitor DMR8HSU RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMR8HSU RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMR8OVI DI DMR8OVI DMR8OVI DN PMID25726713-Compound-45 DMR8OVI TI TT8J1S3 DMR8OVI TN Smoothened homolog (SMO) DMR8OVI MA Inhibitor DMR8OVI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMR8OVI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMR9B2D DI DMR9B2D DMR9B2D DN PMID26004420-Compound-WO2012058116A DMR9B2D TI TTJ13ST DMR9B2D TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMR9B2D MA Inhibitor DMR9B2D RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMR9B2D RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMR9GLW DI DMR9GLW DMR9GLW DN PMID27215781-Compound-12 DMR9GLW TI TTMSFAW DMR9GLW TN Cannabinoid receptor 2 (CB2) DMR9GLW RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMR9GLW RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMR9IE5 DI DMR9IE5 DMR9IE5 DN EEC DMR9IE5 TI TTXLEG7 DMR9IE5 TN Matrix metalloproteinase-10 (MMP-10) DMR9IE5 MA Inhibitor DMR9IE5 RN Pseudodipeptides as MMP inhibitors. US8691753. DMR9IE5 RU http://www.freepatentsonline.com/US8691753.html DMRANS2 DI DMRANS2 DMRANS2 DN PMID28051882-Compound-Figure9 DMRANS2 TI TT9NXW4 DMRANS2 TN Sigma intracellular receptor 2 (TMEM97) DMRANS2 MA Ligand DMRANS2 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMRANS2 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMRAS8L DI DMRAS8L DMRAS8L DN Pyrazolopyrimidine acetamide analog 1 DMRAS8L TI TTPTXIN DMRAS8L TN Translocator protein (TSPO) DMRAS8L MA Ligand DMRAS8L RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMRAS8L RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMRAXD1 DI DMRAXD1 DMRAXD1 DN PMID26560530-Compound-7 DMRAXD1 TI TT2F4OL DMRAXD1 TN Tissue transglutaminase (TG2) DMRAXD1 MA Inhibitor DMRAXD1 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMRAXD1 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMRB7LI DI DMRB7LI DMRB7LI DN PMID30280939-Compound-WO2013119856 DMRB7LI TI TTOK0LR DMRB7LI TN Toll-like receptor (TLR) DMRB7LI MA Agonist DMRB7LI RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMRB7LI RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMRBFUA DI DMRBFUA DMRBFUA DN Z90308237 DMRBFUA TI TT3RMNA DMRBFUA TN Chymotrypsin-C (CLCR) DMRBFUA MA Inhibitor DMRBFUA RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMRBFUA RU http://www.freepatentsonline.com/US9695194.html DMRBI5X DI DMRBI5X DMRBI5X DN Cyclohexyl azetidine derivative 1 DMRBI5X TI TT6DM01 DMRBI5X TN Janus kinase 1 (JAK-1) DMRBI5X MA Inhibitor DMRBI5X RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMRBI5X RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMRBYAV DI DMRBYAV DMRBYAV DN Diaryl amine derivative 2 DMRBYAV TI TT6R7JZ DMRBYAV TN Histone deacetylase 1 (HDAC1) DMRBYAV MA Inhibitor DMRBYAV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRBYAV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMRBYAV DI DMRBYAV DMRBYAV DN Diaryl amine derivative 2 DMRBYAV TI TT5ZKDI DMRBYAV TN Histone deacetylase 6 (HDAC6) DMRBYAV MA Inhibitor DMRBYAV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRBYAV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMRC4O7 DI DMRC4O7 DMRC4O7 DN US9598431, 3 DMRC4O7 TI TT1TYN7 DMRC4O7 TN Nuclear receptor ROR-alpha (RORA) DMRC4O7 MA Inhibitor DMRC4O7 RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMRC4O7 RU http://www.freepatentsonline.com/US9598431.html DMRCM1O DI DMRCM1O DMRCM1O DN PMID28447479-Compound-22 DMRCM1O TI TTSCIM2 DMRCM1O TN Extracellular lysophospholipase D (E-NPP2) DMRCM1O RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMRCM1O RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMRCPKV DI DMRCPKV DMRCPKV DN PMID25399762-Compound-Table1-C8 DMRCPKV TI TTGP7BY DMRCPKV TN Monoamine oxidase type B (MAO-B) DMRCPKV MA Inhibitor DMRCPKV RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRCPKV RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRD1XJ DI DMRD1XJ DMRD1XJ DN Tricyclic pyrrolidine derivative 2 DMRD1XJ TI TTWJBZ5 DMRD1XJ TN 5-HT 2C receptor (HTR2C) DMRD1XJ MA Agonist DMRD1XJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMRD1XJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMRDUS9 DI DMRDUS9 DMRDUS9 DN PMID26004420-Compound-WO2014015495A DMRDUS9 TI TTJ13ST DMRDUS9 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMRDUS9 MA Inhibitor DMRDUS9 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMRDUS9 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMRE2I3 DI DMRE2I3 DMRE2I3 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 1 DMRE2I3 TI TT1LVF2 DMRE2I3 TN Cyclin-dependent kinase 9 (CDK9) DMRE2I3 MA Inhibitor DMRE2I3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRE2I3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRE6GP DI DMRE6GP DMRE6GP DN PMID28092474-Compound-33 DMRE6GP TI TTBH0VX DMRE6GP TN Histone deacetylase (HDAC) DMRE6GP MA Inhibitor DMRE6GP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRE6GP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMREZ9I DI DMREZ9I DMREZ9I DN PMID28270021-Compound-WO2016054807Example71 DMREZ9I TI TTTDVOJ DMREZ9I TN Tropomyosin-related kinase A (TrkA) DMREZ9I MA Inhibitor DMREZ9I RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMREZ9I RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TTGP7BY DMRF58Q TN Monoamine oxidase type B (MAO-B) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TT3WG5C DMRF58Q TN Monoamine oxidase type A (MAO-A) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TTNR0UQ DMRF58Q TN Lysine-specific histone demethylase 1 (LSD) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRFEH4 DI DMRFEH4 DMRFEH4 DN Indoline derivative 15 DMRFEH4 TI TTOHSBA DMRFEH4 TN Vascular endothelial growth factor A (VEGFA) DMRFEH4 MA Inhibitor DMRFEH4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMRFEH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMRFXMB DI DMRFXMB DMRFXMB DN 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 DMRFXMB TI TTCZOF2 DMRFXMB TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMRFXMB MA Inhibitor DMRFXMB RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMRFXMB RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMRG1NL DI DMRG1NL DMRG1NL DN Atorvastatin lactole derivative 1 DMRG1NL TI TTPADOQ DMRG1NL TN HMG-CoA reductase (HMGCR) DMRG1NL MA Inhibitor DMRG1NL RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMRG1NL RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMRGOZ8 DI DMRGOZ8 DMRGOZ8 DN PMID25666693-Compound-92 DMRGOZ8 TI TTMI6F5 DMRGOZ8 TN Transient receptor potential cation channel V1 (TRPV1) DMRGOZ8 MA Antagonist DMRGOZ8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMRGOZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMRGV83 DI DMRGV83 DMRGV83 DN PMID29671355-Compound-22 DMRGV83 TI TT5ZKDI DMRGV83 TN Histone deacetylase 6 (HDAC6) DMRGV83 MA Inhibitor DMRGV83 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMRGV83 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMRGV83 DI DMRGV83 DMRGV83 DN PMID29671355-Compound-22 DMRGV83 TI TT6R7JZ DMRGV83 TN Histone deacetylase 1 (HDAC1) DMRGV83 MA Inhibitor DMRGV83 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMRGV83 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMRH2EJ DI DMRH2EJ DMRH2EJ DN Pyrazole derivative 34 DMRH2EJ TI TT6OEDT DMRH2EJ TN Cannabinoid receptor 1 (CB1) DMRH2EJ MA Antagonist DMRH2EJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMRH2EJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMRH7ZY DI DMRH7ZY DMRH7ZY DN PMID27967267-Compound-52 DMRH7ZY TI TT1RS9F DMRH7ZY TN Acetylcholinesterase (AChE) DMRH7ZY MA Reactivator DMRH7ZY RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMRH7ZY RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMRHAU4 DI DMRHAU4 DMRHAU4 DN Pyrido[3,2-d]pyrimidine derivative 2 DMRHAU4 TI TTTDVOJ DMRHAU4 TN Tropomyosin-related kinase A (TrkA) DMRHAU4 MA Inhibitor DMRHAU4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMRHAU4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMRHBLD DI DMRHBLD DMRHBLD DN Isoquinoline derivative 2 DMRHBLD TI TTMSFAW DMRHBLD TN Cannabinoid receptor 2 (CB2) DMRHBLD RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMRHBLD RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMRHNIL DI DMRHNIL DMRHNIL DN US8759338, 1 DMRHNIL TI TTCGOIN DMRHNIL TN PIM-3 protein kinase (PIM3) DMRHNIL MA Inhibitor DMRHNIL RN Heterocyclic kinase inhibitors. US8759338. DMRHNIL RU http://www.freepatentsonline.com/US8759338.html DMRHNOY DI DMRHNOY DMRHNOY DN PMID25399762-Compound-Figure1-Chukrasone A DMRHNOY TI TT3WG5C DMRHNOY TN Monoamine oxidase type A (MAO-A) DMRHNOY MA Inhibitor DMRHNOY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRHNOY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRHPN0 DI DMRHPN0 DMRHPN0 DN PMID29053063-Compound-17 DMRHPN0 TI TTZ963I DMRHPN0 TN Monoglyceride lipase (MAGL) DMRHPN0 MA Inhibitor DMRHPN0 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMRHPN0 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMRHQLF DI DMRHQLF DMRHQLF DN US10179791, Compound 176 DMRHQLF TI TTDYP7I DMRHQLF TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMRHQLF MA Inhibitor DMRHQLF RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMRHQLF RU http://www.freepatentsonline.com/US10179791.html DMRHVWA DI DMRHVWA DMRHVWA DN N6-cyclopropyllydine derivative 1 DMRHVWA TI TTNR0UQ DMRHVWA TN Lysine-specific histone demethylase 1 (LSD) DMRHVWA MA Inhibitor DMRHVWA RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRHVWA RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRHZF3 DI DMRHZF3 DMRHZF3 DN PMID27774822-Compound-Figure8Example5 DMRHZF3 TI TTRMX3V DMRHZF3 TN Janus kinase 2 (JAK-2) DMRHZF3 MA Inhibitor DMRHZF3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMRHZF3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMRHZF3 DI DMRHZF3 DMRHZF3 DN PMID27774822-Compound-Figure8Example5 DMRHZF3 TI TTT7PJU DMRHZF3 TN Janus kinase 3 (JAK-3) DMRHZF3 MA Inhibitor DMRHZF3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMRHZF3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMRIEH3 DI DMRIEH3 DMRIEH3 DN PMID25399762-Compound-Figure1-Sarcaboside A DMRIEH3 TI TT3WG5C DMRIEH3 TN Monoamine oxidase type A (MAO-A) DMRIEH3 MA Inhibitor DMRIEH3 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRIEH3 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRIPVG DI DMRIPVG DMRIPVG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8 DMRIPVG TI TTULVH8 DMRIPVG TN Tyrosinase (TYR) DMRIPVG MA Inhibitor DMRIPVG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRIPVG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRIWKV DI DMRIWKV DMRIWKV DN PMID26161698-Compound-32 DMRIWKV TI TT1LVF2 DMRIWKV TN Cyclin-dependent kinase 9 (CDK9) DMRIWKV MA Inhibitor DMRIWKV RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRIWKV RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRJ1KY DI DMRJ1KY DMRJ1KY DN PMID25991433-Compound-G5 DMRJ1KY TI TT0K6EO DMRJ1KY TN Stress-activated protein kinase JNK1 (JNK1) DMRJ1KY MA Inhibitor DMRJ1KY RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMRJ1KY RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMRJ30G DI DMRJ30G DMRJ30G DN PMID25522065-Compound-10 DMRJ30G TI TTX4RTB DMRJ30G TN Melanin-concentrating hormone receptor 1 (MCHR1) DMRJ30G MA Antagonist DMRJ30G RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMRJ30G RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMRJKIQ DI DMRJKIQ DMRJKIQ DN Imidazoleisoindoles derivative 2 DMRJKIQ TI TTZJYKH DMRJKIQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMRJKIQ MA Inhibitor DMRJKIQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMRJKIQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMRK1W7 DI DMRK1W7 DMRK1W7 DN PMID25666693-Compound-17 DMRK1W7 TI TTMI6F5 DMRK1W7 TN Transient receptor potential cation channel V1 (TRPV1) DMRK1W7 MA Antagonist DMRK1W7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMRK1W7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMRK4AT DI DMRK4AT DMRK4AT DN Triazole derivative 7 DMRK4AT TI TTSCIUP DMRK4AT TN Oxytocin receptor (OTR) DMRK4AT MA Antagonist DMRK4AT RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMRK4AT RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMRK4IE DI DMRK4IE DMRK4IE DN Aryl piperazine derivative 15 DMRK4IE TI TTWT5K7 DMRK4IE TN 5-HT 1 receptor (5HT1R) DMRK4IE MA Agonist DMRK4IE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMRK4IE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMRK4IE DI DMRK4IE DMRK4IE DN Aryl piperazine derivative 15 DMRK4IE TI TTSQIFT DMRK4IE TN 5-HT 1A receptor (HTR1A) DMRK4IE MA Agonist DMRK4IE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMRK4IE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMRKIA1 DI DMRKIA1 DMRKIA1 DN PMID29338548-Compound-46 DMRKIA1 TI TTHJTF7 DMRKIA1 TN Glycine transporter GlyT-1 (SLC6A9) DMRKIA1 MA Inhibitor DMRKIA1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMRKIA1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMRKLTE DI DMRKLTE DMRKLTE DN PMID30107136-Compound-Example4 DMRKLTE TI TT23XQV DMRKLTE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMRKLTE MA Inhibitor DMRKLTE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMRKLTE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMRKVP9 DI DMRKVP9 DMRKVP9 DN Pyrazolo[3,4-d]pyrimidine derivative 3 DMRKVP9 TI TTJGW1Z DMRKVP9 TN Phosphodiesterase 2A (PDE2A) DMRKVP9 MA Inhibitor DMRKVP9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMRKVP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMRKWPQ DI DMRKWPQ DMRKWPQ DN PMID29473428-Compound-60 DMRKWPQ TI TTZJYKH DMRKWPQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMRKWPQ MA Inhibitor DMRKWPQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMRKWPQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMRL0WA DI DMRL0WA DMRL0WA DN US9340511, 6 DMRL0WA TI TT9ISBX DMRL0WA TN HIF-prolyl hydroxylase 2 (HPH-2) DMRL0WA MA Inhibitor DMRL0WA RN Process for making isoquinoline compounds. US9340511. DMRL0WA RU http://www.freepatentsonline.com/US9340511.html DMRLC4X DI DMRLC4X DMRLC4X DN Urea and carbamate bioisostere derivative 16 DMRLC4X TI TTL7C8Q DMRLC4X TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMRLC4X MA Inhibitor DMRLC4X RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMRLC4X RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMRLE65 DI DMRLE65 DMRLE65 DN C-linked disaccharide biphenyl mannoside derivative 4 DMRLE65 TI TTTCRU2 DMRLE65 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRLE65 MA Antagonist DMRLE65 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRLE65 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRLSKV DI DMRLSKV DMRLSKV DN PMID28766366-Compound-Scheme23MPPDerivatives DMRLSKV TI TTSBVFO DMRLSKV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMRLSKV MA Inhibitor DMRLSKV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMRLSKV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMRLU8I DI DMRLU8I DMRLU8I DN PMID28627961-Compound-30 DMRLU8I TI TTYLQ8V DMRLU8I TN Prostaglandin E synthase (PTGES) DMRLU8I MA Inhibitor DMRLU8I RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMRLU8I RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMRLWP9 DI DMRLWP9 DMRLWP9 DN PMID27019002-Compound-47 DMRLWP9 TI TTNR0UQ DMRLWP9 TN Lysine-specific histone demethylase 1 (LSD) DMRLWP9 MA Inhibitor DMRLWP9 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRLWP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRLWP9 DI DMRLWP9 DMRLWP9 DN PMID27019002-Compound-47 DMRLWP9 TI TT8VP2T DMRLWP9 TN Lysine-specific histone demethylase 1B (KDM1B) DMRLWP9 MA Inhibitor DMRLWP9 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRLWP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRLWZI DI DMRLWZI DMRLWZI DN Palmarumycin derivative 2 DMRLWZI TI TTR7UJ3 DMRLWZI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMRLWZI MA Inhibitor DMRLWZI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMRLWZI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMRLZD2 DI DMRLZD2 DMRLZD2 DN PMID25772215-Compound-US02014179750TG6-129 DMRLZD2 TI TT1ZAVI DMRLZD2 TN Prostaglandin E2 receptor EP2 (PTGER2) DMRLZD2 MA Antagonist DMRLZD2 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMRLZD2 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMRM3E9 DI DMRM3E9 DMRM3E9 DN Biaryl mannoside derivative 25 DMRM3E9 TI TTTCRU2 DMRM3E9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRM3E9 MA Antagonist DMRM3E9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRM3E9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRM5I1 DI DMRM5I1 DMRM5I1 DN Dibenzo [c,f]-[2,7]naphthyridine derivative 1 DMRM5I1 TI TTCZOF2 DMRM5I1 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMRM5I1 MA Inhibitor DMRM5I1 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMRM5I1 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMRMED4 DI DMRMED4 DMRMED4 DN Azetidine-benzoxazin-3(4H)-one derivative 1 DMRMED4 TI TTZ963I DMRMED4 TN Monoglyceride lipase (MAGL) DMRMED4 MA Inhibitor DMRMED4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMRMED4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMRML9B DI DMRML9B DMRML9B DN Isoxazoles and isoxazoline derivative 1 DMRML9B TI TTIY56R DMRML9B TN Kynurenine 3-hydroxylase (KMO) DMRML9B MA Inhibitor DMRML9B RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMRML9B RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMRMTF6 DI DMRMTF6 DMRMTF6 DN Tetra-hydro-pyrazolopyrazine derivative 4 DMRMTF6 TI TTHS256 DMRMTF6 TN Metabotropic glutamate receptor 5 (mGluR5) DMRMTF6 MA Modulator DMRMTF6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMRMTF6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMRN2QI DI DMRN2QI DMRN2QI DN Pyrazolodiazepine derivative 1 DMRN2QI TI TT2F4OL DMRN2QI TN Tissue transglutaminase (TG2) DMRN2QI MA Inhibitor DMRN2QI RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMRN2QI RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMRN5F4 DI DMRN5F4 DMRN5F4 DN US8933095, 16 DMRN5F4 TI TTT3IXG DMRN5F4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMRN5F4 MA Inhibitor DMRN5F4 RN KAT II inhibitors. US8933095. DMRN5F4 RU http://www.freepatentsonline.com/US8933095.html DMRNBP3 DI DMRNBP3 DMRNBP3 DN PMID27539678-Compound-3 DMRNBP3 TI TT3M2WO DMRNBP3 TN Sphingosine kinase (SphK) DMRNBP3 MA Inhibitor DMRNBP3 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMRNBP3 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMRPD8U DI DMRPD8U DMRPD8U DN US8524917, 60 DMRPD8U TI TTDYP7I DMRPD8U TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMRPD8U MA Inhibitor DMRPD8U RN 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917. DMRPD8U RU http://www.freepatentsonline.com/US8524917.html DMRPJBF DI DMRPJBF DMRPJBF DN PMID30273516-Compound-38 DMRPJBF TI TTCW0KX DMRPJBF TN Glutaminase (GLS) DMRPJBF MA Inhibitor DMRPJBF RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMRPJBF RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMRPT5O DI DMRPT5O DMRPT5O DN Indazole amide derivative 2 DMRPT5O TI TTKFVXR DMRPT5O TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMRPT5O MA Inhibitor DMRPT5O RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMRPT5O RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMRQ1ZB DI DMRQ1ZB DMRQ1ZB DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 6 DMRQ1ZB TI TTV8CRH DMRQ1ZB TN Lysine-specific demethylase 4C (KDM4C) DMRQ1ZB MA Inhibitor DMRQ1ZB RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMRQ1ZB RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMRQ2G4 DI DMRQ2G4 DMRQ2G4 DN US9359293, TB DMRQ2G4 TI TTLKF5M DMRQ2G4 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMRQ2G4 MA Inhibitor DMRQ2G4 RN Methods of treatment using modulators of SIRT2. US9359293. DMRQ2G4 RU http://www.freepatentsonline.com/US9359293.html DMRQ74I DI DMRQ74I DMRQ74I DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3 DMRQ74I TI TTVDSZ0 DMRQ74I TN Poly [ADP-ribose] polymerase 1 (PARP1) DMRQ74I MA Inhibitor DMRQ74I RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMRQ74I RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMRQHDF DI DMRQHDF DMRQHDF DN PMID27109571-Compound-38 DMRQHDF TI TTMY6L1 DMRQHDF TN Fatty acid-binding protein (FABP) DMRQHDF MA Inhibitor DMRQHDF RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMRQHDF RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMRS1WG DI DMRS1WG DMRS1WG DN Biaryl mannoside derivative 5 DMRS1WG TI TTTCRU2 DMRS1WG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRS1WG MA Antagonist DMRS1WG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRS1WG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRSCJ7 DI DMRSCJ7 DMRSCJ7 DN Piperazinyl norbenzomorphane compound 4 DMRSCJ7 TI TT9NXW4 DMRSCJ7 TN Sigma intracellular receptor 2 (TMEM97) DMRSCJ7 MA Ligand DMRSCJ7 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMRSCJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMRSP2M DI DMRSP2M DMRSP2M DN US8614253, 32-4 DMRSP2M TI TTOJ9QL DMRSP2M TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMRSP2M MA Inhibitor DMRSP2M RN IRE-1 inhibitors. US9493435. DMRSP2M RU http://www.freepatentsonline.com/US9493435.html DMRT7I8 DI DMRT7I8 DMRT7I8 DN Pyrazoline derivative 4 DMRT7I8 TI TT6OEDT DMRT7I8 TN Cannabinoid receptor 1 (CB1) DMRT7I8 MA Antagonist DMRT7I8 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMRT7I8 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMRTBKC DI DMRTBKC DMRTBKC DN PMID29338548-Compound-21 DMRTBKC TI TTHJTF7 DMRTBKC TN Glycine transporter GlyT-1 (SLC6A9) DMRTBKC MA Inhibitor DMRTBKC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMRTBKC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMRTDOA DI DMRTDOA DMRTDOA DN 2,2-bipyridyl derivative 1 DMRTDOA TI TT0RGE9 DMRTDOA TN Lysine-specific demethylase 4 (KDM4) DMRTDOA MA Inhibitor DMRTDOA RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMRTDOA RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMRTJSC DI DMRTJSC DMRTJSC DN Urea and carbamate bioisostere derivative 2 DMRTJSC TI TTL7C8Q DMRTJSC TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMRTJSC MA Inhibitor DMRTJSC RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMRTJSC RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMRTL63 DI DMRTL63 DMRTL63 DN US8536181, C17 DMRTL63 TI TT9ISBX DMRTL63 TN HIF-prolyl hydroxylase 2 (HPH-2) DMRTL63 MA Inhibitor DMRTL63 RN Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. US8778412. DMRTL63 RU http://www.freepatentsonline.com/US8778412.html DMRTQ4I DI DMRTQ4I DMRTQ4I DN PMID29865878-Compound-44 DMRTQ4I TI TT68GPI DMRTQ4I TN Proteasome beta-5 (PS beta-5) DMRTQ4I MA Inhibitor DMRTQ4I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMRTQ4I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMRTQ4I DI DMRTQ4I DMRTQ4I DN PMID29865878-Compound-44 DMRTQ4I TI TTEAD9J DMRTQ4I TN Proteasome beta-8 (PS beta-8) DMRTQ4I MA Inhibitor DMRTQ4I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMRTQ4I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMRTZC4 DI DMRTZC4 DMRTZC4 DN PMID25772215-Compound-US02014179750TG7-76 DMRTZC4 TI TT1ZAVI DMRTZC4 TN Prostaglandin E2 receptor EP2 (PTGER2) DMRTZC4 MA Antagonist DMRTZC4 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMRTZC4 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMRTZE4 DI DMRTZE4 DMRTZE4 DN Antibodie derivative 5 DMRTZE4 TI TTOUZN5 DMRTZE4 TN Gremlin-1 (Gremlin-1) DMRTZE4 MA Inhibitor DMRTZE4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMRTZE4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMRU0BL DI DMRU0BL DMRU0BL DN PMID27215781-Compound-4 DMRU0BL TI TTMSFAW DMRU0BL TN Cannabinoid receptor 2 (CB2) DMRU0BL MA Agonist DMRU0BL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMRU0BL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMRUCK8 DI DMRUCK8 DMRUCK8 DN Golden phosphorous acetyletic compound 3 DMRUCK8 TI TTR7UJ3 DMRUCK8 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMRUCK8 MA Inhibitor DMRUCK8 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMRUCK8 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMRUTJZ DI DMRUTJZ DMRUTJZ DN US8846654, 11 DMRUTJZ TI TTIS4OW DMRUTJZ TN Phosphodiesterase 8 (PDE8) DMRUTJZ MA Inhibitor DMRUTJZ RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMRUTJZ RU http://www.freepatentsonline.com/US8846654.html DMRVE7Z DI DMRVE7Z DMRVE7Z DN PMID25553724-Compound-US20138552206 5 DMRVE7Z TI TTSXVID DMRVE7Z TN Nuclear factor NF-kappa-B (NFKB) DMRVE7Z MA Inhibitor DMRVE7Z RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMRVE7Z RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMRVIPL DI DMRVIPL DMRVIPL DN Aryl mannoside derivative 11 DMRVIPL TI TTTCRU2 DMRVIPL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRVIPL MA Antagonist DMRVIPL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRVIPL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRVQ5Z DI DMRVQ5Z DMRVQ5Z DN US9598431, 1 DMRVQ5Z TI TTGB2LZ DMRVQ5Z TN RAR-related orphan receptor-beta (RORB) DMRVQ5Z MA Inhibitor DMRVQ5Z RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMRVQ5Z RU http://www.freepatentsonline.com/US9598431.html DMRWG2E DI DMRWG2E DMRWG2E DN Pyrrolo[2,3-d]pyrimidine derivative 10 DMRWG2E TI TTH6V3D DMRWG2E TN Cyclin-dependent kinase 1 (CDK1) DMRWG2E MA Inhibitor DMRWG2E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRWG2E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRWG2E DI DMRWG2E DMRWG2E DN Pyrrolo[2,3-d]pyrimidine derivative 10 DMRWG2E TI TT0PG8F DMRWG2E TN Cyclin-dependent kinase 4 (CDK4) DMRWG2E MA Inhibitor DMRWG2E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRWG2E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRWGHN DI DMRWGHN DMRWGHN DN PMID27019002-Compound-31a DMRWGHN TI TTNR0UQ DMRWGHN TN Lysine-specific histone demethylase 1 (LSD) DMRWGHN MA Inhibitor DMRWGHN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRWGHN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRWNAY DI DMRWNAY DMRWNAY DN Monoamine derivative 1 DMRWNAY TI TTULVH8 DMRWNAY TN Tyrosinase (TYR) DMRWNAY MA Inhibitor DMRWNAY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRWNAY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRX748 DI DMRX748 DMRX748 DN PMID27019002-Compound-20a DMRX748 TI TTNR0UQ DMRX748 TN Lysine-specific histone demethylase 1 (LSD) DMRX748 MA Inhibitor DMRX748 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRX748 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRX748 DI DMRX748 DMRX748 DN PMID27019002-Compound-20a DMRX748 TI TT32XQJ DMRX748 TN Monoamine oxidase (MAO) DMRX748 MA Inhibitor DMRX748 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRX748 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRXCYF DI DMRXCYF DMRXCYF DN US9586942, 3* DMRXCYF TI TTYJRN5 DMRXCYF TN N-acetylglucosaminyltransferase I (NAGAT1) DMRXCYF MA Inhibitor DMRXCYF RN Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942. DMRXCYF RU http://www.freepatentsonline.com/US9586942.html DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TT36ETB DMRXKJZ TN Cathepsin L (CTSL) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTUMQVO DMRXKJZ TN Cathepsin S (CTSS) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTG5QB7 DMRXKJZ TN Calpain-2 (CAPN2) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTDZN01 DMRXKJZ TN Cathepsin K (CTSK) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXMCH DI DMRXMCH DMRXMCH DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 DMRXMCH TI TTULVH8 DMRXMCH TN Tyrosinase (TYR) DMRXMCH MA Inhibitor DMRXMCH RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRXMCH RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRXN94 DI DMRXN94 DMRXN94 DN Aromatic bicyclic compound 3 DMRXN94 TI TTRMX3V DMRXN94 TN Janus kinase 2 (JAK-2) DMRXN94 MA Inhibitor DMRXN94 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMRXN94 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMRXN94 DI DMRXN94 DMRXN94 DN Aromatic bicyclic compound 3 DMRXN94 TI TT6PKBN DMRXN94 TN Proto-oncogene c-Src (SRC) DMRXN94 MA Inhibitor DMRXN94 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMRXN94 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMRY2HL DI DMRY2HL DMRY2HL DN Quinoline derivative 1 DMRY2HL TI TTPADOQ DMRY2HL TN HMG-CoA reductase (HMGCR) DMRY2HL MA Inhibitor DMRY2HL RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMRY2HL RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMRY7KV DI DMRY7KV DMRY7KV DN KRDULPYOVRWKMA-UHFFFAOYSA-N DMRY7KV TI TTIEMFN DMRY7KV TN TYRO3 tyrosine kinase receptor (TYRO3) DMRY7KV MA Inhibitor DMRY7KV RN Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465. DMRY7KV RU http://www.freepatentsonline.com/US10053465.html DMRZELF DI DMRZELF DMRZELF DN Benzimidazolone acetamide derivative 1 DMRZELF TI TTPTXIN DMRZELF TN Translocator protein (TSPO) DMRZELF MA Ligand DMRZELF RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMRZELF RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMRZMH5 DI DMRZMH5 DMRZMH5 DN PMID25522065-Compound-21 DMRZMH5 TI TTX4RTB DMRZMH5 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMRZMH5 MA Antagonist DMRZMH5 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMRZMH5 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMS0169 DI DMS0169 DMS0169 DN Indole and benzimidazole derivative 1 DMS0169 TI TTN9T81 DMS0169 TN Arachidonate 15-lipoxygenase (15-LOX) DMS0169 RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMS0169 RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMS0EMU DI DMS0EMU DMS0EMU DN BDBM50444059 DMS0EMU TI TTIEMFN DMS0EMU TN TYRO3 tyrosine kinase receptor (TYRO3) DMS0EMU MA Inhibitor DMS0EMU RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DMS0EMU RU http://www.freepatentsonline.com/US9649309.html DMS0P9E DI DMS0P9E DMS0P9E DN Five-membered heteroaromatic compound 3 DMS0P9E TI TTZJYKH DMS0P9E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMS0P9E MA Inhibitor DMS0P9E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMS0P9E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMS103B DI DMS103B DMS103B DN PMID28092474-Compound-32s DMS103B TI TT6R7JZ DMS103B TN Histone deacetylase 1 (HDAC1) DMS103B MA Inhibitor DMS103B RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMS103B RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMS103B DI DMS103B DMS103B DN PMID28092474-Compound-32s DMS103B TI TT5ZKDI DMS103B TN Histone deacetylase 6 (HDAC6) DMS103B MA Inhibitor DMS103B RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMS103B RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMS1FKC DI DMS1FKC DMS1FKC DN PMID25522065-Compound-43 DMS1FKC TI TTX4RTB DMS1FKC TN Melanin-concentrating hormone receptor 1 (MCHR1) DMS1FKC MA Antagonist DMS1FKC RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMS1FKC RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMS1GJD DI DMS1GJD DMS1GJD DN Tetra-cyclic compound 1 DMS1GJD TI TTJSQEF DMS1GJD TN Tyrosine-protein kinase (PTK) DMS1GJD MA Inhibitor DMS1GJD RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMS1GJD RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMS1O0G DI DMS1O0G DMS1O0G DN 4-pyridone derivative 2 DMS1O0G TI TTPLTSQ DMS1O0G TN Neutrophil elastase (NE) DMS1O0G MA Inhibitor DMS1O0G RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMS1O0G RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMS1TOX DI DMS1TOX DMS1TOX DN Quinoline derivative 5 DMS1TOX TI TTXJ47W DMS1TOX TN Metabotropic glutamate receptor 2 (mGluR2) DMS1TOX MA Antagonist DMS1TOX RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMS1TOX RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMS3CDT DI DMS3CDT DMS3CDT DN Isoxazole-based bicyclic compound 14 DMS3CDT TI TTE4BSY DMS3CDT TN Bromodomain and extraterminal domain protein (BET) DMS3CDT MA Inhibitor DMS3CDT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMS3CDT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMS3PRT DI DMS3PRT DMS3PRT DN Quinoxaline derivative 4 DMS3PRT TI TTSXVID DMS3PRT TN Nuclear factor NF-kappa-B (NFKB) DMS3PRT MA Inhibitor DMS3PRT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMS3PRT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMS3ROL DI DMS3ROL DMS3ROL DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL TI TTJW4LU DMS3ROL TN Phosphodiesterase 10A (PDE10) DMS3ROL MA Inhibitor DMS3ROL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMS3ROL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMS3ROL DI DMS3ROL DMS3ROL DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL TI TTJGW1Z DMS3ROL TN Phosphodiesterase 2A (PDE2A) DMS3ROL MA Inhibitor DMS3ROL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMS3ROL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMS3WEJ DI DMS3WEJ DMS3WEJ DN Heteroaryl-azepine derivative 15 DMS3WEJ TI TTWJBZ5 DMS3WEJ TN 5-HT 2C receptor (HTR2C) DMS3WEJ MA Agonist DMS3WEJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMS3WEJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMS3YPJ DI DMS3YPJ DMS3YPJ DN Tetra/penta-cyclic pyridophthalazinone derivative 1 DMS3YPJ TI TTEBCY8 DMS3YPJ TN Poly [ADP-ribose] polymerase (PARP) DMS3YPJ MA Inhibitor DMS3YPJ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMS3YPJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMS415A DI DMS415A DMS415A DN US10149841, Compound 9 DMS415A TI TT9ISBX DMS415A TN HIF-prolyl hydroxylase 2 (HPH-2) DMS415A MA Inhibitor DMS415A RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMS415A RU http://www.freepatentsonline.com/US10149841.html DMS42KH DI DMS42KH DMS42KH DN PMID30107136-Compound-Example7 DMS42KH TI TT23XQV DMS42KH TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS42KH MA Inhibitor DMS42KH RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS42KH RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS4I6B DI DMS4I6B DMS4I6B DN Pyrrolo-benzo-diazine derivative 1 DMS4I6B TI TT4G2JS DMS4I6B TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMS4I6B MA Blocker DMS4I6B RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMS4I6B RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMS4RLZ DI DMS4RLZ DMS4RLZ DN PMID26882240-Compound-4 DMS4RLZ TI TTUX68I DMS4RLZ TN Hypoxia-inducible factor 1 (HIF-1) DMS4RLZ MA Inhibitor DMS4RLZ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMS4RLZ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMS527F DI DMS527F DMS527F DN Benzamide derivative 12 DMS527F TI TT473XN DMS527F TN P2X purinoceptor 7 (P2RX7) DMS527F MA Antagonist DMS527F RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMS527F RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTIRY6K DMS5896 TN Cellular inhibitor of apoptosis 2 (BIRC3) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTQ5LRD DMS5896 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTR7B60 DMS5896 TN X-linked inhibitor of apoptosis protein (XIAP) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5EHL DI DMS5EHL DMS5EHL DN 1-phenyl-1,3,4-triazole derivative 1 DMS5EHL TI TTA6ZN2 DMS5EHL TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMS5EHL MA Inhibitor DMS5EHL RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMS5EHL RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMS5EHL DI DMS5EHL DMS5EHL DN 1-phenyl-1,3,4-triazole derivative 1 DMS5EHL TI TT956B0 DMS5EHL TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMS5EHL MA Modulator DMS5EHL RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMS5EHL RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMS5UFX DI DMS5UFX DMS5UFX DN Biphenyl mannoside derivative 1 DMS5UFX TI TTTCRU2 DMS5UFX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMS5UFX MA Antagonist DMS5UFX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMS5UFX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMS65IT DI DMS65IT DMS65IT DN Macrocyclic peptide analog 1 DMS65IT TI TT23XQV DMS65IT TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS65IT MA Inhibitor DMS65IT RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS65IT RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS68DP DI DMS68DP DMS68DP DN Cyclohexyl carbamate derivative 5 DMS68DP TI TTULVH8 DMS68DP TN Tyrosinase (TYR) DMS68DP MA Inhibitor DMS68DP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMS68DP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMS6EDU DI DMS6EDU DMS6EDU DN PMID26394986-Compound-53 DMS6EDU TI TTH8FZW DMS6EDU TN Signal transducer and activator of transcription 3 (STAT3) DMS6EDU MA Inhibitor DMS6EDU RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMS6EDU RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMS6HOG DI DMS6HOG DMS6HOG DN Heteroaryl-azepine derivative 7 DMS6HOG TI TTWJBZ5 DMS6HOG TN 5-HT 2C receptor (HTR2C) DMS6HOG MA Agonist DMS6HOG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMS6HOG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMS6UD2 DI DMS6UD2 DMS6UD2 DN PMID29649907-Compound-40 DMS6UD2 TI TTS4UGC DMS6UD2 TN Farnesoid X-activated receptor (FXR) DMS6UD2 MA Agonist DMS6UD2 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMS6UD2 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMS6XT4 DI DMS6XT4 DMS6XT4 DN Tricyclic indole compound 13 DMS6XT4 TI TTVDSZ0 DMS6XT4 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS6XT4 MA Inhibitor DMS6XT4 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMS6XT4 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMS7RYP DI DMS7RYP DMS7RYP DN PMID25553724-Compound-US2012819831110 DMS7RYP TI TTSXVID DMS7RYP TN Nuclear factor NF-kappa-B (NFKB) DMS7RYP MA Inhibitor DMS7RYP RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMS7RYP RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMS7ZLK DI DMS7ZLK DMS7ZLK DN BDBM50158703 DMS7ZLK TI TTIG67W DMS7ZLK TN Lysine-specific demethylase 5A (KDM5A) DMS7ZLK MA Inhibitor DMS7ZLK RN Histone demethylase inhibitors. US9714230. DMS7ZLK RU http://www.freepatentsonline.com/US9714230.html DMS842X DI DMS842X DMS842X DN US9434725, 113 DMS842X TI TTCGOIN DMS842X TN PIM-3 protein kinase (PIM3) DMS842X MA Inhibitor DMS842X RN 5-azaindazole compounds and methods of use. US9434725. DMS842X RU http://www.freepatentsonline.com/US9434725.html DMS8GIU DI DMS8GIU DMS8GIU DN Imidazo bicyclic iminium derivative 5 DMS8GIU TI TT8J1S3 DMS8GIU TN Smoothened homolog (SMO) DMS8GIU MA Inhibitor DMS8GIU RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMS8GIU RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMS8KMB DI DMS8KMB DMS8KMB DN Indoline derivative 8 DMS8KMB TI TT5OU0D DMS8KMB TN PRKR-like endoplasmic reticulum kinase (PERK) DMS8KMB MA Inhibitor DMS8KMB RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMS8KMB RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMS8NFJ DI DMS8NFJ DMS8NFJ DN Piperidinyl pyrazole derivative 4 DMS8NFJ TI TTTJZ4M DMS8NFJ TN Prolylcarboxypeptidase (PRCP) DMS8NFJ MA Inhibitor DMS8NFJ RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMS8NFJ RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMS8OR3 DI DMS8OR3 DMS8OR3 DN Pyrimidine derivative 2 DMS8OR3 TI TTYLQ8V DMS8OR3 TN Prostaglandin E synthase (PTGES) DMS8OR3 MA Inhibitor DMS8OR3 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMS8OR3 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMS8OTG DI DMS8OTG DMS8OTG DN PMID28117607-Compound-21 DMS8OTG TI TTK0FEA DMS8OTG TN Leucine-rich repeat kinase 2 (LRRK2) DMS8OTG MA Inhibitor DMS8OTG RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMS8OTG RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMS8VYE DI DMS8VYE DMS8VYE DN Biaryl compound 2 DMS8VYE TI TT23XQV DMS8VYE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS8VYE MA Inhibitor DMS8VYE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS8VYE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS8VYE DI DMS8VYE DMS8VYE DN Biaryl compound 2 DMS8VYE TI TT5YPJF DMS8VYE TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMS8VYE MA Inhibitor DMS8VYE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS8VYE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS9KCF DI DMS9KCF DMS9KCF DN PMID26077642-Compound-Vif1 DMS9KCF TI TTXU3EQ DMS9KCF TN Herpesvirus ubiquitin-specific protease (HAUSP) DMS9KCF MA Inhibitor DMS9KCF RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMS9KCF RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMS9O6I DI DMS9O6I DMS9O6I DN Peptide analog 31 DMS9O6I TI TT68GPI DMS9O6I TN Proteasome beta-5 (PS beta-5) DMS9O6I MA Inhibitor DMS9O6I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMS9O6I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMS9O6I DI DMS9O6I DMS9O6I DN Peptide analog 31 DMS9O6I TI TTEAD9J DMS9O6I TN Proteasome beta-8 (PS beta-8) DMS9O6I MA Inhibitor DMS9O6I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMS9O6I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMS9Q3U DI DMS9Q3U DMS9Q3U DN PMID29334795-Compound-56 DMS9Q3U TI TT9JNIC DMS9Q3U TN Histamine H3 receptor (H3R) DMS9Q3U RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMS9Q3U RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMS9QA7 DI DMS9QA7 DMS9QA7 DN PMID27998201-Compound-22 DMS9QA7 TI TTF2LRI DMS9QA7 TN Cathepsin B (CTSB) DMS9QA7 MA Inhibitor DMS9QA7 RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMS9QA7 RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMS9W6O DI DMS9W6O DMS9W6O DN US9073936, 3 DMS9W6O TI TT3ZS42 DMS9W6O TN Phosphodiesterase 1B (PDE1B) DMS9W6O MA Inhibitor DMS9W6O RN Organic compounds. US9598426. DMS9W6O RU http://www.freepatentsonline.com/US9598426.html DMSA86Y DI DMSA86Y DMSA86Y DN US9365572, 5 DMSA86Y TI TTYXEPL DMSA86Y TN Ribosomal protein S6 kinase alpha-5 (RSK5) DMSA86Y MA Inhibitor DMSA86Y RN PI3K and/or mTOR inhibitor. US9365572. DMSA86Y RU http://www.freepatentsonline.com/US9365572.html DMSAD9B DI DMSAD9B DMSAD9B DN PMID29649907-Compound-42 DMSAD9B TI TTS4UGC DMSAD9B TN Farnesoid X-activated receptor (FXR) DMSAD9B MA Agonist DMSAD9B RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSAD9B RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSAO52 DI DMSAO52 DMSAO52 DN PMID29865878-Compound-41 DMSAO52 TI TTSJMN8 DMSAO52 TN Immunoproteasome complex (IP) DMSAO52 MA Inhibitor DMSAO52 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSAO52 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSB09X DI DMSB09X DMSB09X DN Oxetane 3,3-dicarboxamide compound 1 DMSB09X TI TTOHSBA DMSB09X TN Vascular endothelial growth factor A (VEGFA) DMSB09X MA Inhibitor DMSB09X RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMSB09X RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMSBRHJ DI DMSBRHJ DMSBRHJ DN US8759338, 2 DMSBRHJ TI TTCGOIN DMSBRHJ TN PIM-3 protein kinase (PIM3) DMSBRHJ MA Inhibitor DMSBRHJ RN Heterocyclic kinase inhibitors. US8759338. DMSBRHJ RU http://www.freepatentsonline.com/US8759338.html DMSC8B6 DI DMSC8B6 DMSC8B6 DN PMID25980951-Compound-17 DMSC8B6 TI TTQ5LRD DMSC8B6 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMSC8B6 MA Antagonist DMSC8B6 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMSC8B6 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMSC9MH DI DMSC9MH DMSC9MH DN PMID29649907-Compound-11 DMSC9MH TI TTS4UGC DMSC9MH TN Farnesoid X-activated receptor (FXR) DMSC9MH MA Agonist DMSC9MH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSC9MH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSCWZF DI DMSCWZF DMSCWZF DN PMID29865878-Compound-39 DMSCWZF TI TTSJMN8 DMSCWZF TN Immunoproteasome complex (IP) DMSCWZF MA Inhibitor DMSCWZF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSCWZF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSD04W DI DMSD04W DMSD04W DN Quinazolinedione derivative 1 DMSD04W TI TTVDSZ0 DMSD04W TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSD04W MA Inhibitor DMSD04W RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMSD04W RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMSD2TN DI DMSD2TN DMSD2TN DN Cyclohexyl carbamate derivative 6 DMSD2TN TI TTULVH8 DMSD2TN TN Tyrosinase (TYR) DMSD2TN MA Inhibitor DMSD2TN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSD2TN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSD354 DI DMSD354 DMSD354 DN US9611221, Example 9 DMSD354 TI TTIG67W DMSD354 TN Lysine-specific demethylase 5A (KDM5A) DMSD354 MA Inhibitor DMSD354 RN Histone demethylase inhibitors. US9611221. DMSD354 RU http://www.freepatentsonline.com/US9611221.html DMSD4G0 DI DMSD4G0 DMSD4G0 DN N,N-bis(5-pyrazoyl)urea derivative 1 DMSD4G0 TI TTTDVOJ DMSD4G0 TN Tropomyosin-related kinase A (TrkA) DMSD4G0 MA Inhibitor DMSD4G0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSD4G0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSD647 DI DMSD647 DMSD647 DN PMID30273516-Compound-15 DMSD647 TI TTCW0KX DMSD647 TN Glutaminase (GLS) DMSD647 MA Inhibitor DMSD647 RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMSD647 RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMSDRA4 DI DMSDRA4 DMSDRA4 DN PMID25684022-Compound-WO2012135799 42(1.4) DMSDRA4 TI TTCZOF2 DMSDRA4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSDRA4 MA Inhibitor DMSDRA4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSDRA4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSDRNQ DI DMSDRNQ DMSDRNQ DN Aryl 1,2-diamine derivative 1 DMSDRNQ TI TTZJYKH DMSDRNQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSDRNQ MA Inhibitor DMSDRNQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSDRNQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSDVI1 DI DMSDVI1 DMSDVI1 DN Pyrazole derivative 36 DMSDVI1 TI TT6OEDT DMSDVI1 TN Cannabinoid receptor 1 (CB1) DMSDVI1 MA Antagonist DMSDVI1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMSDVI1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMSEIL0 DI DMSEIL0 DMSEIL0 DN PMID28350212-Compound-1 DMSEIL0 TI TTZS04O DMSEIL0 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSEIL0 MA Inhibitor DMSEIL0 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSEIL0 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSEKZG DI DMSEKZG DMSEKZG DN Peptide analog 71 DMSEKZG TI TTQR74A DMSEKZG TN Proteinase activated receptor 2 (PAR2) DMSEKZG MA Agonist DMSEKZG RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSEKZG RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSFL5B DI DMSFL5B DMSFL5B DN PMID28350212-Compound-15 DMSFL5B TI TTZS04O DMSFL5B TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSFL5B MA Inhibitor DMSFL5B RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSFL5B RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSG71Z DI DMSG71Z DMSG71Z DN Quinoline derivative 18 DMSG71Z TI TTSCO7R DMSG71Z TN NAD-dependent deacetylase sirtuin (SIRT) DMSG71Z MA Inhibitor DMSG71Z RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMSG71Z RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMSGF8T DI DMSGF8T DMSGF8T DN Pyridine derivative 1 DMSGF8T TI TTZJYKH DMSGF8T TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSGF8T MA Inhibitor DMSGF8T RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSGF8T RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSGO7D DI DMSGO7D DMSGO7D DN Aryl oxyanilide derivative 3 DMSGO7D TI TTPTXIN DMSGO7D TN Translocator protein (TSPO) DMSGO7D MA Ligand DMSGO7D RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMSGO7D RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMSGWTX DI DMSGWTX DMSGWTX DN PMID28092474-Compound-32j DMSGWTX TI TT6R7JZ DMSGWTX TN Histone deacetylase 1 (HDAC1) DMSGWTX MA Inhibitor DMSGWTX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSGWTX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSGWTX DI DMSGWTX DMSGWTX DN PMID28092474-Compound-32j DMSGWTX TI TT5ZKDI DMSGWTX TN Histone deacetylase 6 (HDAC6) DMSGWTX MA Inhibitor DMSGWTX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSGWTX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSHIT2 DI DMSHIT2 DMSHIT2 DN PMID27774822-Compound-Figure9Example15 DMSHIT2 TI TTBYWP2 DMSHIT2 TN TYK2 tyrosine kinase (TYK2) DMSHIT2 MA Inhibitor DMSHIT2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSHIT2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSI09Y DI DMSI09Y DMSI09Y DN US9707205, 40 DMSI09Y TI TTDYP7I DMSI09Y TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMSI09Y MA Inhibitor DMSI09Y RN S1P receptors modulators and their use thereof. US9707205. DMSI09Y RU http://www.freepatentsonline.com/US9707205.html DMSI7F2 DI DMSI7F2 DMSI7F2 DN PMID26560530-Compound-1 DMSI7F2 TI TT2F4OL DMSI7F2 TN Tissue transglutaminase (TG2) DMSI7F2 MA Inhibitor DMSI7F2 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMSI7F2 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT7MRDV DMSIERF TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT8FYO9 DMSIERF TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TTX41N9 DMSIERF TN Tyrosine-protein kinase Kit (KIT) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT4DXQT DMSIERF TN Proto-oncogene c-Ret (RET) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIKM2 DI DMSIKM2 DMSIKM2 DN PMID25435285-Compound-38 DMSIKM2 TI TTXJ47W DMSIKM2 TN Metabotropic glutamate receptor 2 (mGluR2) DMSIKM2 MA Antagonist DMSIKM2 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMSIKM2 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TT0PG8F DMSIOUA TN Cyclin-dependent kinase 4 (CDK4) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TTO0FDJ DMSIOUA TN Cyclin-dependent kinase 6 (CDK6) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TT8J1S3 DMSIOUA TN Smoothened homolog (SMO) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TTCJG29 DMSIOUA TN Serine/threonine-protein kinase mTOR (mTOR) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIRC2 DI DMSIRC2 DMSIRC2 DN Imidazo[1,2-b]pyridazine derivative 6 DMSIRC2 TI TTTDVOJ DMSIRC2 TN Tropomyosin-related kinase A (TrkA) DMSIRC2 MA Inhibitor DMSIRC2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSIRC2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSJ1C0 DI DMSJ1C0 DMSJ1C0 DN 2-piperidine thiazole derivative 2 DMSJ1C0 TI TT3M2WO DMSJ1C0 TN Sphingosine kinase (SphK) DMSJ1C0 MA Inhibitor DMSJ1C0 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMSJ1C0 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMSJHV3 DI DMSJHV3 DMSJHV3 DN Peptide analog 12 DMSJHV3 TI TTSJMN8 DMSJHV3 TN Immunoproteasome complex (IP) DMSJHV3 MA Inhibitor DMSJHV3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSJHV3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TT6DM01 DMSJWZ3 TN Janus kinase 1 (JAK-1) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TTT7PJU DMSJWZ3 TN Janus kinase 3 (JAK-3) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TTRMX3V DMSJWZ3 TN Janus kinase 2 (JAK-2) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTWAQBO DMSKCEH TN Lysine-specific demethylase 4E (KDM4E) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTZHPB8 DMSKCEH TN Lysine-specific demethylase 4A (KDM4A) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTV8CRH DMSKCEH TN Lysine-specific demethylase 4C (KDM4C) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKE2O DI DMSKE2O DMSKE2O DN PMID28350212-Compound-35 DMSKE2O TI TTZS04O DMSKE2O TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSKE2O MA Inhibitor DMSKE2O RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSKE2O RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSKWBE DI DMSKWBE DMSKWBE DN PMID25991433-Compound-C3 DMSKWBE TI TTVOE6D DMSKWBE TN Mitogen-activated protein kinase (MAPK) DMSKWBE MA Inhibitor DMSKWBE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMSKWBE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMSL3MB DI DMSL3MB DMSL3MB DN PMID25399762-Compound-Table 7-Vanillic acid DMSL3MB TI TTGP7BY DMSL3MB TN Monoamine oxidase type B (MAO-B) DMSL3MB MA Inhibitor DMSL3MB RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMSL3MB RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMSLBT3 DI DMSLBT3 DMSLBT3 DN US9346821, A-20 DMSLBT3 TI TTXL0GC DMSLBT3 TN Enteropeptidase (TMPRSS15) DMSLBT3 MA Inhibitor DMSLBT3 RN Heterocyclic carboxylic acid ester derivative. US9346821. DMSLBT3 RU http://www.freepatentsonline.com/US9346821.html DMSLJE8 DI DMSLJE8 DMSLJE8 DN Aminopyridine derivative 3 DMSLJE8 TI TT6AXLY DMSLJE8 TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DMSLJE8 MA Inhibitor DMSLJE8 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMSLJE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMSLJE8 DI DMSLJE8 DMSLJE8 DN Aminopyridine derivative 3 DMSLJE8 TI TTK0FEA DMSLJE8 TN Leucine-rich repeat kinase 2 (LRRK2) DMSLJE8 MA Inhibitor DMSLJE8 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMSLJE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMSLYVT DI DMSLYVT DMSLYVT DN Resorcinol compound 15 DMSLYVT TI TTULVH8 DMSLYVT TN Tyrosinase (TYR) DMSLYVT MA Inhibitor DMSLYVT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSLYVT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSM53I DI DMSM53I DMSM53I DN Pyrido[2,3-d]pyrimidine derivative 2 DMSM53I TI TT6OEDT DMSM53I TN Cannabinoid receptor 1 (CB1) DMSM53I MA Antagonist DMSM53I RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMSM53I RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMSMBCO DI DMSMBCO DMSMBCO DN Chalcone derivative 1 DMSMBCO TI TTA6ZN2 DMSMBCO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMSMBCO MA Activator DMSMBCO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMSMBCO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMSMBCO DI DMSMBCO DMSMBCO DN Chalcone derivative 1 DMSMBCO TI TT3Z6Y9 DMSMBCO TN Cysteines of Keap1 (KEAP1 Cysteines) DMSMBCO MA Modulator DMSMBCO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMSMBCO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMSME2B DI DMSME2B DMSME2B DN PMID29130358-Compound-Figure11(3) DMSME2B TI TTLM12X DMSME2B TN Matrix metalloproteinase-2 (MMP-2) DMSME2B MA Inhibitor DMSME2B RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSME2B RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSME2B DI DMSME2B DMSME2B DN PMID29130358-Compound-Figure11(3) DMSME2B TI TTULVH8 DMSME2B TN Tyrosinase (TYR) DMSME2B MA Inhibitor DMSME2B RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSME2B RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSMXK3 DI DMSMXK3 DMSMXK3 DN Azaindole derivative 1 DMSMXK3 TI TT3PJMV DMSMXK3 TN Tyrosine-protein kinase ABL1 (ABL) DMSMXK3 MA Inhibitor DMSMXK3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSMXK3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNMZ2 DI DMSNMZ2 DMSNMZ2 DN Biaryl mannoside derivative 28 DMSNMZ2 TI TTTCRU2 DMSNMZ2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSNMZ2 MA Antagonist DMSNMZ2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSNMZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TT6DM01 DMSNQEJ TN Janus kinase 1 (JAK-1) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TTRMX3V DMSNQEJ TN Janus kinase 2 (JAK-2) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TTT7PJU DMSNQEJ TN Janus kinase 3 (JAK-3) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNUVZ DI DMSNUVZ DMSNUVZ DN PMID25656651-Compound-19a DMSNUVZ TI TTS7G69 DMSNUVZ TN Fusion protein Bcr-Abl (Bcr-Abl) DMSNUVZ MA Inhibitor DMSNUVZ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSNUVZ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNUVZ DI DMSNUVZ DMSNUVZ DN PMID25656651-Compound-19a DMSNUVZ TI TTIV39N DMSNUVZ TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMSNUVZ MA Inhibitor DMSNUVZ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSNUVZ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNY3W DI DMSNY3W DMSNY3W DN Pyrazole derivative 71 DMSNY3W TI TTJQOD7 DMSNY3W TN 5-HT 2A receptor (HTR2A) DMSNY3W MA Antagonist DMSNY3W RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMSNY3W RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMSO2F8 DI DMSO2F8 DMSO2F8 DN PMID26651364-Compound-8d DMSO2F8 TI TTTCRU2 DMSO2F8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSO2F8 MA Antagonist DMSO2F8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSO2F8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSOQG7 DI DMSOQG7 DMSOQG7 DN Peptide analog 35 DMSOQG7 TI TTSJMN8 DMSOQG7 TN Immunoproteasome complex (IP) DMSOQG7 MA Inhibitor DMSOQG7 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSOQG7 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTTDVOJ DMSOT1R TN Tropomyosin-related kinase A (TrkA) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTXABCW DMSOT1R TN NT-3 growth factor receptor (TrkC) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTKN7QR DMSOT1R TN BDNF/NT-3 growth factors receptor (TrkB) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSP5IA DI DMSP5IA DMSP5IA DN PMID28092474-Compound-32l DMSP5IA TI TT5ZKDI DMSP5IA TN Histone deacetylase 6 (HDAC6) DMSP5IA MA Inhibitor DMSP5IA RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSP5IA RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSP5IA DI DMSP5IA DMSP5IA DN PMID28092474-Compound-32l DMSP5IA TI TT6R7JZ DMSP5IA TN Histone deacetylase 1 (HDAC1) DMSP5IA MA Inhibitor DMSP5IA RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSP5IA RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSPCLD DI DMSPCLD DMSPCLD DN Resorcinol compound 31 DMSPCLD TI TTULVH8 DMSPCLD TN Tyrosinase (TYR) DMSPCLD MA Inhibitor DMSPCLD RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSPCLD RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSPG8Y DI DMSPG8Y DMSPG8Y DN PMID26004420-Compound-WO2014099633E DMSPG8Y TI TTJ13ST DMSPG8Y TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMSPG8Y MA Inhibitor DMSPG8Y RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMSPG8Y RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMSQ5J8 DI DMSQ5J8 DMSQ5J8 DN PMID25684022-Compound-WO2011137219 37(4-6) DMSQ5J8 TI TTCZOF2 DMSQ5J8 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSQ5J8 MA Inhibitor DMSQ5J8 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSQ5J8 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSQK50 DI DMSQK50 DMSQK50 DN Heterocyclic-carboxamide derivative 2 DMSQK50 TI TTCZOF2 DMSQK50 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSQK50 MA Inhibitor DMSQK50 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSQK50 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSQODK DI DMSQODK DMSQODK DN US8614253, 32-5 DMSQODK TI TTOJ9QL DMSQODK TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMSQODK MA Inhibitor DMSQODK RN IRE-1 inhibitors. US8614253. DMSQODK RU http://www.freepatentsonline.com/US8614253.html DMSR0X6 DI DMSR0X6 DMSR0X6 DN 1,3,4-oxadiazole derivative 3 DMSR0X6 TI TT23XQV DMSR0X6 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMSR0X6 MA Inhibitor DMSR0X6 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSR0X6 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSR218 DI DMSR218 DMSR218 DN PMID25666693-Compound-37 DMSR218 TI TTMI6F5 DMSR218 TN Transient receptor potential cation channel V1 (TRPV1) DMSR218 MA Antagonist DMSR218 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMSR218 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMSR5FO DI DMSR5FO DMSR5FO DN Pyrazolopyridines and imidazopyridine derivative 1 DMSR5FO TI TTCZOF2 DMSR5FO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSR5FO MA Inhibitor DMSR5FO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSR5FO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSR918 DI DMSR918 DMSR918 DN Benzothiazine-carboxamide compound 4 DMSR918 TI TTQR74A DMSR918 TN Proteinase activated receptor 2 (PAR2) DMSR918 MA Antagonist DMSR918 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSR918 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSRB8M DI DMSRB8M DMSRB8M DN Quinoline derivative 14 DMSRB8M TI TTRZQE3 DMSRB8M TN Glycogen synthase kinase-3 alpha (GSK-3A) DMSRB8M MA Inhibitor DMSRB8M RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMSRB8M RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMSRKON DI DMSRKON DMSRKON DN Aromatic ethylene derivative 1 DMSRKON TI TT23XQV DMSRKON TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMSRKON MA Inhibitor DMSRKON RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSRKON RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSRYIP DI DMSRYIP DMSRYIP DN PMID25435285-Compound-53 DMSRYIP TI TTXJ47W DMSRYIP TN Metabotropic glutamate receptor 2 (mGluR2) DMSRYIP MA Antagonist DMSRYIP RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMSRYIP RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMST6C2 DI DMST6C2 DMST6C2 DN PMID26560530-Compound-49 DMST6C2 TI TT2F4OL DMST6C2 TN Tissue transglutaminase (TG2) DMST6C2 MA Inhibitor DMST6C2 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMST6C2 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMST6IF DI DMST6IF DMST6IF DN US9422240, 1-297 DMST6IF TI TT9ISBX DMST6IF TN HIF-prolyl hydroxylase 2 (HPH-2) DMST6IF MA Inhibitor DMST6IF RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMST6IF RU http://www.freepatentsonline.com/US9422240.html DMSTC9Z DI DMSTC9Z DMSTC9Z DN Dihydropyrido pyrimidine derivative 1 DMSTC9Z TI TTSCIM2 DMSTC9Z TN Extracellular lysophospholipase D (E-NPP2) DMSTC9Z MA Inhibitor DMSTC9Z RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMSTC9Z RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMSTD28 DI DMSTD28 DMSTD28 DN BDBM50173306 DMSTD28 TI TTAZ3MN DMSTD28 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMSTD28 MA Inhibitor DMSTD28 RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DMSTD28 RU http://www.freepatentsonline.com/US10023564.html DMSTKH6 DI DMSTKH6 DMSTKH6 DN PMID26651364-Compound-126a DMSTKH6 TI TTTCRU2 DMSTKH6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSTKH6 MA Antagonist DMSTKH6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSTKH6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSU1PC DI DMSU1PC DMSU1PC DN Quinazolinone derivative 1 DMSU1PC TI TTL7C8Q DMSU1PC TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMSU1PC MA Inhibitor DMSU1PC RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMSU1PC RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMSU80N DI DMSU80N DMSU80N DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1 DMSU80N TI TT9NXW4 DMSU80N TN Sigma intracellular receptor 2 (TMEM97) DMSU80N MA Ligand DMSU80N RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMSU80N RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMSUD5X DI DMSUD5X DMSUD5X DN Peptidomimetic analog 6 DMSUD5X TI TTQR74A DMSUD5X TN Proteinase activated receptor 2 (PAR2) DMSUD5X MA Agonist DMSUD5X RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSUD5X RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSV42L DI DMSV42L DMSV42L DN Imidazole derivative 9 DMSV42L TI TTTJZ4M DMSV42L TN Prolylcarboxypeptidase (PRCP) DMSV42L MA Inhibitor DMSV42L RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMSV42L RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMSVMUT DI DMSVMUT DMSVMUT DN Cyclic compound 1 DMSVMUT TI TTNBFWK DMSVMUT TN Programmed cell death protein 1 (PD-1) DMSVMUT MA Inhibitor DMSVMUT RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSVMUT RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSVQMO DI DMSVQMO DMSVQMO DN PMID25656651-Compound-31a DMSVQMO TI TTIV39N DMSVQMO TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMSVQMO MA Inhibitor DMSVQMO RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSVQMO RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSW0HB DI DMSW0HB DMSW0HB DN PMID26651364-Compound-5g DMSW0HB TI TTTCRU2 DMSW0HB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSW0HB MA Antagonist DMSW0HB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSW0HB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSW3GB DI DMSW3GB DMSW3GB DN Resorcinol compound 22 DMSW3GB TI TTULVH8 DMSW3GB TN Tyrosinase (TYR) DMSW3GB MA Inhibitor DMSW3GB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSW3GB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSWI67 DI DMSWI67 DMSWI67 DN Polycyclic compound 1 DMSWI67 TI TTYLQ8V DMSWI67 TN Prostaglandin E synthase (PTGES) DMSWI67 MA Inhibitor DMSWI67 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMSWI67 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMSWJPO DI DMSWJPO DMSWJPO DN PMID29649907-Compound-35 DMSWJPO TI TTS4UGC DMSWJPO TN Farnesoid X-activated receptor (FXR) DMSWJPO MA Agonist DMSWJPO RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSWJPO RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSWM9Q DI DMSWM9Q DMSWM9Q DN PMID28870136-Compound-41 DMSWM9Q TI TTK0O6Y DMSWM9Q TN Ecto-5'-nucleotidase (CD73) DMSWM9Q MA Inhibitor DMSWM9Q RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMSWM9Q RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMSX09A DI DMSX09A DMSX09A DN PMID28766366-Compound-Scheme8NCGC-00010037 DMSX09A TI TTSBVFO DMSX09A TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMSX09A MA Inhibitor DMSX09A RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMSX09A RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMSX47Q DI DMSX47Q DMSX47Q DN Phenylpyrrolidinone derivative 4 DMSX47Q TI TT5OU0D DMSX47Q TN PRKR-like endoplasmic reticulum kinase (PERK) DMSX47Q MA Inhibitor DMSX47Q RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMSX47Q RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMSXB58 DI DMSXB58 DMSXB58 DN Cyclopropane 1-carboxylic acid derivative 2 DMSXB58 TI TTIY56R DMSXB58 TN Kynurenine 3-hydroxylase (KMO) DMSXB58 MA Inhibitor DMSXB58 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMSXB58 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMSXG78 DI DMSXG78 DMSXG78 DN US9217012, 10 DMSXG78 TI TT405FP DMSXG78 TN FAP-1 messenger RNA (PTPN13 mRNA) DMSXG78 MA Inhibitor DMSXG78 RN Inhibitors of protein tyrosine phosphatases. US9217012. DMSXG78 RU http://www.freepatentsonline.com/US9217012.html DMSXH8K DI DMSXH8K DMSXH8K DN Pyrrolo[2,3-d]pyrimidine derivative 18 DMSXH8K TI TTGM6VW DMSXH8K TN Tyrosine-protein kinase BTK (ATK) DMSXH8K MA Inhibitor DMSXH8K RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMSXH8K RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMSXJVY DI DMSXJVY DMSXJVY DN PMID27172114-Compound-49 DMSXJVY TI TTIY56R DMSXJVY TN Kynurenine 3-hydroxylase (KMO) DMSXJVY MA Inhibitor DMSXJVY RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMSXJVY RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMSXKP6 DI DMSXKP6 DMSXKP6 DN PMID29473428-Compound-52 DMSXKP6 TI TTZJYKH DMSXKP6 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSXKP6 MA Inhibitor DMSXKP6 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSXKP6 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSYD3X DI DMSYD3X DMSYD3X DN US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine DMSYD3X TI TT7ALZG DMSYD3X TN Integrin-linked protein kinase 1 (ILK) DMSYD3X MA Inhibitor DMSYD3X RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMSYD3X RU http://www.freepatentsonline.com/US8754233.html DMSYD6Z DI DMSYD6Z DMSYD6Z DN Fused heterocyclic compound 12 DMSYD6Z TI TTA592U DMSYD6Z TN Urate anion exchanger 1 (URAT1) DMSYD6Z MA Inhibitor DMSYD6Z RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMSYD6Z RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMSYGHO DI DMSYGHO DMSYGHO DN PMID25399762-Compound-Figure1-Neonectrolide A DMSYGHO TI TT3WG5C DMSYGHO TN Monoamine oxidase type A (MAO-A) DMSYGHO MA Inhibitor DMSYGHO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMSYGHO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMSYRI3 DI DMSYRI3 DMSYRI3 DN US10174026, Example 2 DMSYRI3 TI TTIG67W DMSYRI3 TN Lysine-specific demethylase 5A (KDM5A) DMSYRI3 MA Inhibitor DMSYRI3 RN Histone demethylase inhibitors. US10174026. DMSYRI3 RU http://www.freepatentsonline.com/US10174026.html DMSYUHK DI DMSYUHK DMSYUHK DN US8889696, Staurosporine DMSYUHK TI TTCGOIN DMSYUHK TN PIM-3 protein kinase (PIM3) DMSYUHK MA Inhibitor DMSYUHK RN Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696. DMSYUHK RU http://www.freepatentsonline.com/US8889696.html DMSYX4U DI DMSYX4U DMSYX4U DN Diamine derivative 3 DMSYX4U TI TTULVH8 DMSYX4U TN Tyrosinase (TYR) DMSYX4U MA Inhibitor DMSYX4U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSYX4U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSZ0GE DI DMSZ0GE DMSZ0GE DN PMID27977313-Compound-45 DMSZ0GE TI TTR7UJ3 DMSZ0GE TN Cytoplasmic thioredoxin reductase (TXNRD1) DMSZ0GE MA Inhibitor DMSZ0GE RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMSZ0GE RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMSZA9L DI DMSZA9L DMSZA9L DN PMID29130358-Compound-Figure17(11) DMSZA9L TI TTXZ0KQ DMSZA9L TN Matrix metalloproteinase-12 (MMP-12) DMSZA9L MA Inhibitor DMSZA9L RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSZA9L RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSZA9L DI DMSZA9L DMSZA9L DN PMID29130358-Compound-Figure17(11) DMSZA9L TI TT6X50U DMSZA9L TN Matrix metalloproteinase-9 (MMP-9) DMSZA9L MA Inhibitor DMSZA9L RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSZA9L RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSZLYD DI DMSZLYD DMSZLYD DN PMID27336223-Compound-13 DMSZLYD TI TT1Q3IE DMSZLYD TN Retinoic acid receptor gamma (RARG) DMSZLYD MA Agonist DMSZLYD RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMSZLYD RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMSZWAM DI DMSZWAM DMSZWAM DN PMID26394986-Compound-52 DMSZWAM TI TTH8FZW DMSZWAM TN Signal transducer and activator of transcription 3 (STAT3) DMSZWAM MA Inhibitor DMSZWAM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMSZWAM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT0QLO DI DMT0QLO DMT0QLO DN PMID25726713-Compound-63 DMT0QLO TI TT8J1S3 DMT0QLO TN Smoothened homolog (SMO) DMT0QLO MA Inhibitor DMT0QLO RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMT0QLO RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMT1DJP DI DMT1DJP DMT1DJP DN Pyrazole derivative 30 DMT1DJP TI TT6OEDT DMT1DJP TN Cannabinoid receptor 1 (CB1) DMT1DJP MA Antagonist DMT1DJP RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMT1DJP RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMT1EH9 DI DMT1EH9 DMT1EH9 DN Gold-complexed thiosaccharide derivative 1 DMT1EH9 TI TTH8FZW DMT1EH9 TN Signal transducer and activator of transcription 3 (STAT3) DMT1EH9 MA Inhibitor DMT1EH9 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMT1EH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT21JG DI DMT21JG DMT21JG DN Resorcinol compound 26 DMT21JG TI TTULVH8 DMT21JG TN Tyrosinase (TYR) DMT21JG MA Inhibitor DMT21JG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMT21JG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMT2B5A DI DMT2B5A DMT2B5A DN PMID28092474-Compound-32b DMT2B5A TI TT5ZKDI DMT2B5A TN Histone deacetylase 6 (HDAC6) DMT2B5A MA Inhibitor DMT2B5A RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMT2B5A RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMT2B5A DI DMT2B5A DMT2B5A DN PMID28092474-Compound-32b DMT2B5A TI TT6R7JZ DMT2B5A TN Histone deacetylase 1 (HDAC1) DMT2B5A MA Inhibitor DMT2B5A RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMT2B5A RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMT2D5H DI DMT2D5H DMT2D5H DN PMID29338548-Compound-26 DMT2D5H TI TTHJTF7 DMT2D5H TN Glycine transporter GlyT-1 (SLC6A9) DMT2D5H MA Inhibitor DMT2D5H RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMT2D5H RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMT2W97 DI DMT2W97 DMT2W97 DN PMID27744724-Compound-Fomula2 DMT2W97 TI TTL53M6 DMT2W97 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMT2W97 MA Inhibitor DMT2W97 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMT2W97 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMT2Z0I DI DMT2Z0I DMT2Z0I DN Hexahydro naphthalene derivative 1 DMT2Z0I TI TTPADOQ DMT2Z0I TN HMG-CoA reductase (HMGCR) DMT2Z0I MA Inhibitor DMT2Z0I RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMT2Z0I RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMT3AL5 DI DMT3AL5 DMT3AL5 DN PMID29338548-Compound-22 DMT3AL5 TI TTHJTF7 DMT3AL5 TN Glycine transporter GlyT-1 (SLC6A9) DMT3AL5 MA Inhibitor DMT3AL5 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMT3AL5 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMT46PS DI DMT46PS DMT46PS DN Isoxazole-based bicyclic compound 5 DMT46PS TI TTE4BSY DMT46PS TN Bromodomain and extraterminal domain protein (BET) DMT46PS MA Inhibitor DMT46PS RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMT46PS RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMT47DF DI DMT47DF DMT47DF DN US10092575, Example 141 DMT47DF TI TT3ZS42 DMT47DF TN Phosphodiesterase 1B (PDE1B) DMT47DF MA Inhibitor DMT47DF RN Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367. DMT47DF RU http://www.freepatentsonline.com/US10105367.html DMT4P7K DI DMT4P7K DMT4P7K DN PMID27336223-Compound-12 DMT4P7K TI TT1Q3IE DMT4P7K TN Retinoic acid receptor gamma (RARG) DMT4P7K MA Agonist DMT4P7K RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMT4P7K RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMT4ZP9 DI DMT4ZP9 DMT4ZP9 DN Pyrazolo[1,5-a]pyrimidine derivative 24 DMT4ZP9 TI TTTDVOJ DMT4ZP9 TN Tropomyosin-related kinase A (TrkA) DMT4ZP9 MA Inhibitor DMT4ZP9 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMT4ZP9 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMT57C4 DI DMT57C4 DMT57C4 DN Pyrazolo[3,4-d]pyrimidine derivative 1 DMT57C4 TI TTJGW1Z DMT57C4 TN Phosphodiesterase 2A (PDE2A) DMT57C4 MA Inhibitor DMT57C4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMT57C4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMT58QE DI DMT58QE DMT58QE DN Lactam derivative 2 DMT58QE TI TTF8P9I DMT58QE TN Diacylglycerol acyltransferase 1 (DGAT1) DMT58QE MA Inhibitor DMT58QE RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMT58QE RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMT5E7M DI DMT5E7M DMT5E7M DN Isoquinoline sulfonyl derivative 2 DMT5E7M TI TTMQO60 DMT5E7M TN Rho-associated protein kinase (ROCK) DMT5E7M MA Inhibitor DMT5E7M RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMT5E7M RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMT6CNM DI DMT6CNM DMT6CNM DN PMID26666989-Compound-Figure9middle11 DMT6CNM TI TT8BUGW DMT6CNM TN Glycogen phosphorylase (PYG) DMT6CNM MA Inhibitor DMT6CNM RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMT6CNM RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMT6EDP DI DMT6EDP DMT6EDP DN 1,2,4-oxadiazole derivative 4 DMT6EDP TI TT23XQV DMT6EDP TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMT6EDP MA Inhibitor DMT6EDP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMT6EDP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMT6HXB DI DMT6HXB DMT6HXB DN US9156852, 1 DMT6HXB TI TTU98HG DMT6HXB TN Discoidin domain-containing receptor 2 (DDR2) DMT6HXB MA Inhibitor DMT6HXB RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DMT6HXB RU http://www.freepatentsonline.com/US9156852.html DMT6O1N DI DMT6O1N DMT6O1N DN Pyrimidine-4(3H)-one derivative 1 DMT6O1N TI TTJOW1I DMT6O1N TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMT6O1N MA Inhibitor DMT6O1N RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMT6O1N RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMT7GQ1 DI DMT7GQ1 DMT7GQ1 DN PMID26004420-Compound-WO2013039802A DMT7GQ1 TI TTJ13ST DMT7GQ1 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMT7GQ1 MA Inhibitor DMT7GQ1 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMT7GQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMT7U1O DI DMT7U1O DMT7U1O DN PMID28460551-Compound-6 DMT7U1O TI TTWTSCV DMT7U1O TN RAC-alpha serine/threonine-protein kinase (AKT1) DMT7U1O MA Inhibitor DMT7U1O RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMT7U1O RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMT7U1O DI DMT7U1O DMT7U1O DN PMID28460551-Compound-6 DMT7U1O TI TT6PKBN DMT7U1O TN Proto-oncogene c-Src (SRC) DMT7U1O MA Inhibitor DMT7U1O RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMT7U1O RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMT7ZEL DI DMT7ZEL DMT7ZEL DN Flavonoid derivative 3 DMT7ZEL TI TTH8FZW DMT7ZEL TN Signal transducer and activator of transcription 3 (STAT3) DMT7ZEL MA Inhibitor DMT7ZEL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMT7ZEL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TTRMX3V DMT842O TN Janus kinase 2 (JAK-2) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TT6DM01 DMT842O TN Janus kinase 1 (JAK-1) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TTT7PJU DMT842O TN Janus kinase 3 (JAK-3) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT85AH DI DMT85AH DMT85AH DN PMID27774824-Compound-Figure7Example10 DMT85AH TI TT6DM01 DMT85AH TN Janus kinase 1 (JAK-1) DMT85AH MA Inhibitor DMT85AH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMT85AH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMT85AH DI DMT85AH DMT85AH DN PMID27774824-Compound-Figure7Example10 DMT85AH TI TTRMX3V DMT85AH TN Janus kinase 2 (JAK-2) DMT85AH MA Inhibitor DMT85AH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMT85AH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMT8WVZ DI DMT8WVZ DMT8WVZ DN US10065972, Example 396 DMT8WVZ TI TTT3IXG DMT8WVZ TN Kynurenine oxoglutarate transaminase II (AADAT) DMT8WVZ MA Inhibitor DMT8WVZ RN Bicyclic or tricyclic heterocyclic compound. US10065972. DMT8WVZ RU http://www.freepatentsonline.com/US10065972.html DMT9EJL DI DMT9EJL DMT9EJL DN PMID25666693-Compound-88 DMT9EJL TI TTMI6F5 DMT9EJL TN Transient receptor potential cation channel V1 (TRPV1) DMT9EJL MA Antagonist DMT9EJL RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMT9EJL RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTA3D8 DI DMTA3D8 DMTA3D8 DN PMID29338548-Compound-23 DMTA3D8 TI TTHJTF7 DMTA3D8 TN Glycine transporter GlyT-1 (SLC6A9) DMTA3D8 MA Inhibitor DMTA3D8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMTA3D8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMTAZBC DI DMTAZBC DMTAZBC DN PMID27215781-Compound-34 DMTAZBC TI TTMSFAW DMTAZBC TN Cannabinoid receptor 2 (CB2) DMTAZBC RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMTAZBC RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMTB3KS DI DMTB3KS DMTB3KS DN Azetidine derivative 2 DMTB3KS TI TTZCRP3 DMTB3KS TN ERK activator kinase (MEK) DMTB3KS MA Inhibitor DMTB3KS RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMTB3KS RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMTBG39 DI DMTBG39 DMTBG39 DN Ethylaminopyrimidine derivative 1 DMTBG39 TI TTGX13H DMTBG39 TN Fatty-acid amide hydrolase 1 (FAAH1) DMTBG39 MA Inhibitor DMTBG39 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMTBG39 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMTBG39 DI DMTBG39 DMTBG39 DN Ethylaminopyrimidine derivative 1 DMTBG39 TI TTDP1UC DMTBG39 TN Fatty acid amide hydrolase (FAAH) DMTBG39 MA Inhibitor DMTBG39 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMTBG39 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMTBWC9 DI DMTBWC9 DMTBWC9 DN Bicyclic heteroaryl benzamide derivative 1 DMTBWC9 TI TTTDVOJ DMTBWC9 TN Tropomyosin-related kinase A (TrkA) DMTBWC9 MA Inhibitor DMTBWC9 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTBWC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTC129 DI DMTC129 DMTC129 DN Indolinone derivative 1 DMTC129 TI TTCZOF2 DMTC129 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTC129 MA Inhibitor DMTC129 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTC129 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTCPNY DI DMTCPNY DMTCPNY DN PMID26004420-Compound-WO2013028474C DMTCPNY TI TTJ13ST DMTCPNY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMTCPNY MA Inhibitor DMTCPNY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMTCPNY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMTCPSQ DI DMTCPSQ DMTCPSQ DN 2,2-dimethylbenzopyran derivative 3 DMTCPSQ TI TTUX68I DMTCPSQ TN Hypoxia-inducible factor 1 (HIF-1) DMTCPSQ MA Inhibitor DMTCPSQ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMTCPSQ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMTD0RK DI DMTD0RK DMTD0RK DN PMID26004420-Compound-WO2014085210B DMTD0RK TI TTJ13ST DMTD0RK TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMTD0RK MA Inhibitor DMTD0RK RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMTD0RK RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMTD1X8 DI DMTD1X8 DMTD1X8 DN PMID27109571-Compound-2 DMTD1X8 TI TTMY6L1 DMTD1X8 TN Fatty acid-binding protein (FABP) DMTD1X8 MA Inhibitor DMTD1X8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTD1X8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTD3C1 DI DMTD3C1 DMTD3C1 DN Pyrazolo-triazine derivative 1 DMTD3C1 TI TTQYF7G DMTD3C1 TN Cyclin-dependent kinase 7 (CDK7) DMTD3C1 MA Inhibitor DMTD3C1 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTD3C1 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTDIA6 DI DMTDIA6 DMTDIA6 DN Phenylpropylamine derivative 2 DMTDIA6 TI TT5TPI6 DMTDIA6 TN Opioid receptor sigma 1 (OPRS1) DMTDIA6 MA Ligand DMTDIA6 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMTDIA6 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMTDPHY DI DMTDPHY DMTDPHY DN Biaryl mannoside derivative 27 DMTDPHY TI TTTCRU2 DMTDPHY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTDPHY MA Antagonist DMTDPHY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTDPHY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TTQ6VDM DMTE0S3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TT5TPI6 DMTE0S3 TN Opioid receptor sigma 1 (OPRS1) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TT9NXW4 DMTE0S3 TN Sigma intracellular receptor 2 (TMEM97) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE8QO DI DMTE8QO DMTE8QO DN US8592455, 90 DMTE8QO TI TTCGOIN DMTE8QO TN PIM-3 protein kinase (PIM3) DMTE8QO MA Inhibitor DMTE8QO RN Kinase inhibitors and methods of their use. US8592455. DMTE8QO RU http://www.freepatentsonline.com/US8592455.html DMTEJRB DI DMTEJRB DMTEJRB DN Phenylpropionic acid derivative 1 DMTEJRB TI TTZMAO3 DMTEJRB TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMTEJRB MA Agonist DMTEJRB RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMTEJRB RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTU1E82 DMTEYQJ TN Apoptosis regulator Bcl-xL (BCL-xL) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTL53M6 DMTEYQJ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTJGNVC DMTEYQJ TN Apoptosis regulator Bcl-2 (BCL-2) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTFG4J DI DMTFG4J DMTFG4J DN 1,2-diamino cyclopentane-based derivative 26 DMTFG4J TI TT9N02I DMTFG4J TN Orexin receptor type 2 (HCRTR2) DMTFG4J MA Antagonist DMTFG4J RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTFG4J RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTFG4J DI DMTFG4J DMTFG4J DN 1,2-diamino cyclopentane-based derivative 26 DMTFG4J TI TT60Q8D DMTFG4J TN Orexin receptor type 1 (HCRTR1) DMTFG4J MA Antagonist DMTFG4J RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTFG4J RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTFLVN DI DMTFLVN DMTFLVN DN PMID27977313-Compound-43 DMTFLVN TI TTR7UJ3 DMTFLVN TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTFLVN MA Inhibitor DMTFLVN RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTFLVN RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTFNGM DI DMTFNGM DMTFNGM DN Sulfonamide derivative 16 DMTFNGM TI TT5ZKDI DMTFNGM TN Histone deacetylase 6 (HDAC6) DMTFNGM MA Inhibitor DMTFNGM RN Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549. DMTFNGM RU https://www.ncbi.nlm.nih.gov/pubmed/29886770 DMTG6X9 DI DMTG6X9 DMTG6X9 DN 2-pyrazinone derivative 7 DMTG6X9 TI TTPLTSQ DMTG6X9 TN Neutrophil elastase (NE) DMTG6X9 MA Inhibitor DMTG6X9 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMTG6X9 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMTGEFW DI DMTGEFW DMTGEFW DN 4-Carboxamido-isoindolinone derivative 4 DMTGEFW TI TTVDSZ0 DMTGEFW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTGEFW MA Inhibitor DMTGEFW RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMTGEFW RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMTGELI DI DMTGELI DMTGELI DN Pyrrolo[2,3-d]pyrimidine derivative 13 DMTGELI TI TTGM6VW DMTGELI TN Tyrosine-protein kinase BTK (ATK) DMTGELI MA Inhibitor DMTGELI RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMTGELI RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TTH6V3D DMTGIP7 TN Cyclin-dependent kinase 1 (CDK1) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TT7HF4W DMTGIP7 TN Cyclin-dependent kinase 2 (CDK2) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TTL4Q97 DMTGIP7 TN Cyclin-dependent kinase 5 (CDK5) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTHG87 DI DMTHG87 DMTHG87 DN Quinoline derivative 16 DMTHG87 TI TTPADOQ DMTHG87 TN HMG-CoA reductase (HMGCR) DMTHG87 MA Inhibitor DMTHG87 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMTHG87 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMTHKES DI DMTHKES DMTHKES DN Benzoic acid linked peptide analog 6 DMTHKES TI TTULVH8 DMTHKES TN Tyrosinase (TYR) DMTHKES MA Inhibitor DMTHKES RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMTHKES RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMTHS3L DI DMTHS3L DMTHS3L DN Amidopyrazole derivative 3 DMTHS3L TI TTKFVXR DMTHS3L TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMTHS3L MA Inhibitor DMTHS3L RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMTHS3L RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMTHXUC DI DMTHXUC DMTHXUC DN Phenylthioacetate derivative 1 DMTHXUC TI TTA592U DMTHXUC TN Urate anion exchanger 1 (URAT1) DMTHXUC MA Inhibitor DMTHXUC RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTHXUC RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTI5E3 DI DMTI5E3 DMTI5E3 DN PMID27977313-Compound-17 DMTI5E3 TI TTR7UJ3 DMTI5E3 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTI5E3 MA Inhibitor DMTI5E3 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTI5E3 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTIM1E DI DMTIM1E DMTIM1E DN PMID26161698-Compound-34 DMTIM1E TI TTQYF7G DMTIM1E TN Cyclin-dependent kinase 7 (CDK7) DMTIM1E MA Inhibitor DMTIM1E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTIM1E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTIQYD DI DMTIQYD DMTIQYD DN PMID27172114-Compound-47 DMTIQYD TI TTIY56R DMTIQYD TN Kynurenine 3-hydroxylase (KMO) DMTIQYD MA Inhibitor DMTIQYD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMTIQYD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMTJ0DP DI DMTJ0DP DMTJ0DP DN Imidazole derivative 11 DMTJ0DP TI TTN9T81 DMTJ0DP TN Arachidonate 15-lipoxygenase (15-LOX) DMTJ0DP MA Inhibitor DMTJ0DP RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMTJ0DP RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMTJ0LB DI DMTJ0LB DMTJ0LB DN PMID27724045-Compound-14 DMTJ0LB TI TT473XN DMTJ0LB TN P2X purinoceptor 7 (P2RX7) DMTJ0LB MA Antagonist DMTJ0LB RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMTJ0LB RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMTJ1G8 DI DMTJ1G8 DMTJ1G8 DN 2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1 DMTJ1G8 TI TTPADOQ DMTJ1G8 TN HMG-CoA reductase (HMGCR) DMTJ1G8 MA Inhibitor DMTJ1G8 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMTJ1G8 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMTJBCG DI DMTJBCG DMTJBCG DN Thiazole carboxamide derivative 21 DMTJBCG TI TTCZOF2 DMTJBCG TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTJBCG MA Inhibitor DMTJBCG RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTJBCG RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTJEU5 DI DMTJEU5 DMTJEU5 DN PMID29130358-Compound-LonimacranthoideVI DMTJEU5 TI TTVKILB DMTJEU5 TN Prostaglandin G/H synthase 2 (COX-2) DMTJEU5 MA Inhibitor DMTJEU5 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMTJEU5 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMTJHAK DI DMTJHAK DMTJHAK DN PMID25435285-Compound-26 DMTJHAK TI TTXJ47W DMTJHAK TN Metabotropic glutamate receptor 2 (mGluR2) DMTJHAK MA Antagonist DMTJHAK RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTJHAK RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTJHC2 DI DMTJHC2 DMTJHC2 DN PMID27215781-Compound-27 DMTJHC2 TI TTMSFAW DMTJHC2 TN Cannabinoid receptor 2 (CB2) DMTJHC2 MA Agonist DMTJHC2 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMTJHC2 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTIRY6K DMTJRCS TN Cellular inhibitor of apoptosis 2 (BIRC3) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTR7B60 DMTJRCS TN X-linked inhibitor of apoptosis protein (XIAP) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTQ5LRD DMTJRCS TN Cellular inhibitor of apoptosis 1 (BIRC2) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTK9M6 DI DMTK9M6 DMTK9M6 DN PMID28454500-Compound-57 DMTK9M6 TI TTA6ZN2 DMTK9M6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTK9M6 MA Inhibitor DMTK9M6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTK9M6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTK9M6 DI DMTK9M6 DMTK9M6 DN PMID28454500-Compound-57 DMTK9M6 TI TTGIZLN DMTK9M6 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMTK9M6 MA Modulator DMTK9M6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTK9M6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTKFX7 DI DMTKFX7 DMTKFX7 DN PMID27109571-Compound-8 DMTKFX7 TI TTHWMFZ DMTKFX7 TN Fatty acid-binding protein 4 (FABP4) DMTKFX7 MA Inhibitor DMTKFX7 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTKFX7 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTKLEP DI DMTKLEP DMTKLEP DN PMID28092474-Compound-32g DMTKLEP TI TT5ZKDI DMTKLEP TN Histone deacetylase 6 (HDAC6) DMTKLEP MA Inhibitor DMTKLEP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMTKLEP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMTKLEP DI DMTKLEP DMTKLEP DN PMID28092474-Compound-32g DMTKLEP TI TT6R7JZ DMTKLEP TN Histone deacetylase 1 (HDAC1) DMTKLEP MA Inhibitor DMTKLEP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMTKLEP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMTL73W DI DMTL73W DMTL73W DN PMID25726713-Compound-27 DMTL73W TI TT8J1S3 DMTL73W TN Smoothened homolog (SMO) DMTL73W MA Inhibitor DMTL73W RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMTL73W RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMTLO1E DI DMTLO1E DMTLO1E DN Peptide analog 22 DMTLO1E TI TTSJMN8 DMTLO1E TN Immunoproteasome complex (IP) DMTLO1E MA Inhibitor DMTLO1E RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMTLO1E RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMTM82B DI DMTM82B DMTM82B DN Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 DMTM82B TI TTTDVOJ DMTM82B TN Tropomyosin-related kinase A (TrkA) DMTM82B MA Inhibitor DMTM82B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTM82B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTMFNK DI DMTMFNK DMTMFNK DN Vinyl sulfone derivative 1 DMTMFNK TI TTA6ZN2 DMTMFNK TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTMFNK MA Activator DMTMFNK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTMFNK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTMFNK DI DMTMFNK DMTMFNK DN Vinyl sulfone derivative 1 DMTMFNK TI TT3Z6Y9 DMTMFNK TN Cysteines of Keap1 (KEAP1 Cysteines) DMTMFNK MA Modulator DMTMFNK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTMFNK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTMG02 DI DMTMG02 DMTMG02 DN US8569313, Inhibitor 15 DMTMG02 TI TTPRO7W DMTMG02 TN Suppressor of tumorigenicity 14 protein (ST14) DMTMG02 MA Inhibitor DMTMG02 RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMTMG02 RU http://www.freepatentsonline.com/US8569313.html DMTMJ7S DI DMTMJ7S DMTMJ7S DN Azole derivative 6 DMTMJ7S TI TTF8P9I DMTMJ7S TN Diacylglycerol acyltransferase 1 (DGAT1) DMTMJ7S MA Inhibitor DMTMJ7S RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMTMJ7S RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMTMWKX DI DMTMWKX DMTMWKX DN Pyrrolo[2,3-d]pyrimidine derivative 23 DMTMWKX TI TTGM6VW DMTMWKX TN Tyrosine-protein kinase BTK (ATK) DMTMWKX MA Inhibitor DMTMWKX RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMTMWKX RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMTMYJ6 DI DMTMYJ6 DMTMYJ6 DN N-oxalyl-D-tyrosine derivative 9 DMTMYJ6 TI TTWAQBO DMTMYJ6 TN Lysine-specific demethylase 4E (KDM4E) DMTMYJ6 MA Inhibitor DMTMYJ6 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMTMYJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMTN25V DI DMTN25V DMTN25V DN PMID25666693-Compound-43 DMTN25V TI TTMI6F5 DMTN25V TN Transient receptor potential cation channel V1 (TRPV1) DMTN25V MA Antagonist DMTN25V RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTN25V RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTN79G DI DMTN79G DMTN79G DN PMID25435285-Compound-42 DMTN79G TI TTXJ47W DMTN79G TN Metabotropic glutamate receptor 2 (mGluR2) DMTN79G MA Antagonist DMTN79G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTN79G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTOA1Q DI DMTOA1Q DMTOA1Q DN PMID29334795-Compound-21 DMTOA1Q TI TT9JNIC DMTOA1Q TN Histamine H3 receptor (H3R) DMTOA1Q RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMTOA1Q RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMTOFGH DI DMTOFGH DMTOFGH DN PMID25656651-Compound-23b DMTOFGH TI TTS7G69 DMTOFGH TN Fusion protein Bcr-Abl (Bcr-Abl) DMTOFGH MA Inhibitor DMTOFGH RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTOFGH RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTOHNQ DI DMTOHNQ DMTOHNQ DN PMID29053063-Compound-7a DMTOHNQ TI TTZ963I DMTOHNQ TN Monoglyceride lipase (MAGL) DMTOHNQ MA Inhibitor DMTOHNQ RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMTOHNQ RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMTOJCG DI DMTOJCG DMTOJCG DN PMID26560530-Compound-46 DMTOJCG TI TT2F4OL DMTOJCG TN Tissue transglutaminase (TG2) DMTOJCG MA Inhibitor DMTOJCG RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMTOJCG RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMTP02Q DI DMTP02Q DMTP02Q DN PMID25684022-Compound-WO2009153313 DMTP02Q TI TTCZOF2 DMTP02Q TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTP02Q MA Inhibitor DMTP02Q RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTP02Q RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTPBNY DI DMTPBNY DMTPBNY DN PMID26651364-Compound-10a DMTPBNY TI TTTCRU2 DMTPBNY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTPBNY MA Antagonist DMTPBNY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTPBNY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTPGRO DI DMTPGRO DMTPGRO DN Indoline derivative 10 DMTPGRO TI TT5OU0D DMTPGRO TN PRKR-like endoplasmic reticulum kinase (PERK) DMTPGRO MA Inhibitor DMTPGRO RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMTPGRO RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMTPJI8 DI DMTPJI8 DMTPJI8 DN PMID25522065-Compound-18 DMTPJI8 TI TTX4RTB DMTPJI8 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMTPJI8 MA Antagonist DMTPJI8 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMTPJI8 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMTQ26G DI DMTQ26G DMTQ26G DN PMID25666693-Compound-79 DMTQ26G TI TTMI6F5 DMTQ26G TN Transient receptor potential cation channel V1 (TRPV1) DMTQ26G MA Antagonist DMTQ26G RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTQ26G RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTQBUD DI DMTQBUD DMTQBUD DN Pyrimidine derivative 30 DMTQBUD TI TTDIGC1 DMTQBUD TN Dipeptidyl peptidase 4 (DPP-4) DMTQBUD MA Inhibitor DMTQBUD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMTQBUD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMTQNYZ DI DMTQNYZ DMTQNYZ DN Pyrazolo[1,5-a]pyrimidine derivative 8 DMTQNYZ TI TT6OEDT DMTQNYZ TN Cannabinoid receptor 1 (CB1) DMTQNYZ MA Antagonist DMTQNYZ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMTQNYZ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMTQRVC DI DMTQRVC DMTQRVC DN PMID27376512-Compound-asCEBP-1 DMTQRVC TI TT6S2FE DMTQRVC TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMTQRVC MA Inhibitor DMTQRVC RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMTQRVC RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMTR6BX DI DMTR6BX DMTR6BX DN Biphenyl mannoside derivative 21 DMTR6BX TI TTTCRU2 DMTR6BX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTR6BX MA Antagonist DMTR6BX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTR6BX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTROIQ DI DMTROIQ DMTROIQ DN PMID25991433-Compound-O2 DMTROIQ TI TTQBR95 DMTROIQ TN Stress-activated protein kinase 2a (p38 alpha) DMTROIQ MA Inhibitor DMTROIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMTROIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMTRPE6 DI DMTRPE6 DMTRPE6 DN Phenylpyridine derivative 2 DMTRPE6 TI TT1LVF2 DMTRPE6 TN Cyclin-dependent kinase 9 (CDK9) DMTRPE6 MA Inhibitor DMTRPE6 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTRPE6 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTRZI7 DI DMTRZI7 DMTRZI7 DN US9522888, 695 DMTRZI7 TI TTDYP7I DMTRZI7 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMTRZI7 MA Inhibitor DMTRZI7 RN Substituted bicyclic compounds. US9522888. DMTRZI7 RU http://www.freepatentsonline.com/US9522888.html DMTS8O9 DI DMTS8O9 DMTS8O9 DN Fluorophenyl-substituted heterocyclic amide analog 1 DMTS8O9 TI TT473XN DMTS8O9 TN P2X purinoceptor 7 (P2RX7) DMTS8O9 MA Antagonist DMTS8O9 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMTS8O9 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMTSPVF DI DMTSPVF DMTSPVF DN Epoxysuccinate derivative 7 DMTSPVF TI TTG5QB7 DMTSPVF TN Calpain-2 (CAPN2) DMTSPVF MA Inhibitor DMTSPVF RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMTSPVF RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMTSQXE DI DMTSQXE DMTSQXE DN PMID26394986-Compound-12 DMTSQXE TI TTH8FZW DMTSQXE TN Signal transducer and activator of transcription 3 (STAT3) DMTSQXE MA Inhibitor DMTSQXE RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTSQXE RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTSX7J DI DMTSX7J DMTSX7J DN Piperidinyl triazole derivative 1 DMTSX7J TI TTTJZ4M DMTSX7J TN Prolylcarboxypeptidase (PRCP) DMTSX7J MA Inhibitor DMTSX7J RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMTSX7J RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMTUA6E DI DMTUA6E DMTUA6E DN PMID25656651-Compound-42 DMTUA6E TI TT3PJMV DMTUA6E TN Tyrosine-protein kinase ABL1 (ABL) DMTUA6E MA Inhibitor DMTUA6E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTUA6E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTUA6E DI DMTUA6E DMTUA6E DN PMID25656651-Compound-42 DMTUA6E TI TTZJTWA DMTUA6E TN ABL T315I mutant (ABL T315I) DMTUA6E MA Inhibitor DMTUA6E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTUA6E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTUC9E DI DMTUC9E DMTUC9E DN PMID28870136-Compound-49 DMTUC9E TI TTK0O6Y DMTUC9E TN Ecto-5'-nucleotidase (CD73) DMTUC9E MA Inhibitor DMTUC9E RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMTUC9E RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMTUNW4 DI DMTUNW4 DMTUNW4 DN PMID27977313-Compound-5 DMTUNW4 TI TTR7UJ3 DMTUNW4 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTUNW4 MA Inhibitor DMTUNW4 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTUNW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTUQV0 DI DMTUQV0 DMTUQV0 DN PMID29334795-Compound-24 DMTUQV0 TI TT9JNIC DMTUQV0 TN Histamine H3 receptor (H3R) DMTUQV0 MA Inverse agonist DMTUQV0 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMTUQV0 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMTUS0Y DI DMTUS0Y DMTUS0Y DN Imidazopyridine and triazolopyridine compound 1 DMTUS0Y TI TTHS256 DMTUS0Y TN Metabotropic glutamate receptor 5 (mGluR5) DMTUS0Y MA Modulator DMTUS0Y RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTUS0Y RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTV5NU DI DMTV5NU DMTV5NU DN PMID27998201-Compound-11 DMTV5NU TI TTF2LRI DMTV5NU TN Cathepsin B (CTSB) DMTV5NU MA Inhibitor DMTV5NU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMTV5NU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMTVAJ0 DI DMTVAJ0 DMTVAJ0 DN Pyrazole derivative 63 DMTVAJ0 TI TTH8FZW DMTVAJ0 TN Signal transducer and activator of transcription 3 (STAT3) DMTVAJ0 MA Inhibitor DMTVAJ0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTVAJ0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTVAUP DI DMTVAUP DMTVAUP DN PMID25666693-Compound-156 DMTVAUP TI TTMI6F5 DMTVAUP TN Transient receptor potential cation channel V1 (TRPV1) DMTVAUP MA Antagonist DMTVAUP RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTVAUP RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTVZWM DI DMTVZWM DMTVZWM DN PMID26924192-Compound-50 DMTVZWM TI TTE4BSY DMTVZWM TN Bromodomain and extraterminal domain protein (BET) DMTVZWM MA Inhibitor DMTVZWM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMTVZWM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMTWAH3 DI DMTWAH3 DMTWAH3 DN Isoflavone derivative 2 DMTWAH3 TI TTJOMH6 DMTWAH3 TN Zinc finger protein GLI1 (Gli1) DMTWAH3 MA Inhibitor DMTWAH3 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMTWAH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMTWAH3 DI DMTWAH3 DMTWAH3 DN Isoflavone derivative 2 DMTWAH3 TI TT8J1S3 DMTWAH3 TN Smoothened homolog (SMO) DMTWAH3 MA Inhibitor DMTWAH3 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMTWAH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMTWAJX DI DMTWAJX DMTWAJX DN Flavonoid derivative 5 DMTWAJX TI TTH8FZW DMTWAJX TN Signal transducer and activator of transcription 3 (STAT3) DMTWAJX MA Inhibitor DMTWAJX RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTWAJX RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTWI1H DI DMTWI1H DMTWI1H DN BDBM50158803 DMTWI1H TI TTIG67W DMTWI1H TN Lysine-specific demethylase 5A (KDM5A) DMTWI1H MA Inhibitor DMTWI1H RN Histone demethylase inhibitors. US9617242. DMTWI1H RU http://www.freepatentsonline.com/US9617242.html DMTWIE2 DI DMTWIE2 DMTWIE2 DN BC11-28 DMTWIE2 TI TTIS4OW DMTWIE2 TN Phosphodiesterase 8 (PDE8) DMTWIE2 MA Inhibitor DMTWIE2 RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DMTWIE2 RU http://www.freepatentsonline.com/US9173884.html DMTX1G4 DI DMTX1G4 DMTX1G4 DN Pyrrolo[2,3-d]pyrimidine derivative 3 DMTX1G4 TI TTTDVOJ DMTX1G4 TN Tropomyosin-related kinase A (TrkA) DMTX1G4 MA Inhibitor DMTX1G4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTX1G4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTX21L DI DMTX21L DMTX21L DN Sulfonamide derivative 1 DMTX21L TI TT6OEDT DMTX21L TN Cannabinoid receptor 1 (CB1) DMTX21L MA Antagonist DMTX21L RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMTX21L RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMTXDSG DI DMTXDSG DMTXDSG DN Succinamide derivative 1 DMTXDSG TI TTA592U DMTXDSG TN Urate anion exchanger 1 (URAT1) DMTXDSG MA Inhibitor DMTXDSG RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTXDSG RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTXGYS DI DMTXGYS DMTXGYS DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1 DMTXGYS TI TTHS256 DMTXGYS TN Metabotropic glutamate receptor 5 (mGluR5) DMTXGYS MA Modulator DMTXGYS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTXGYS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTXZUF DI DMTXZUF DMTXZUF DN 2-(substituted ethynyl)quinoline derivative 4 DMTXZUF TI TTHS256 DMTXZUF TN Metabotropic glutamate receptor 5 (mGluR5) DMTXZUF MA Antagonist DMTXZUF RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTXZUF RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTYHCU DI DMTYHCU DMTYHCU DN PMID25435285-Compound-37 DMTYHCU TI TTXJ47W DMTYHCU TN Metabotropic glutamate receptor 2 (mGluR2) DMTYHCU MA Antagonist DMTYHCU RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTYHCU RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTYL68 DI DMTYL68 DMTYL68 DN Disulfide compound 1 DMTYL68 TI TTR7UJ3 DMTYL68 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTYL68 MA Inhibitor DMTYL68 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTYL68 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTYN2D DI DMTYN2D DMTYN2D DN Pyrazolo[1,5-a]pyrimidine derivative 16 DMTYN2D TI TTTDVOJ DMTYN2D TN Tropomyosin-related kinase A (TrkA) DMTYN2D MA Inhibitor DMTYN2D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMTYN2D RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMTYPBM DI DMTYPBM DMTYPBM DN 2,2-bipyridyl derivative 4 DMTYPBM TI TT0RGE9 DMTYPBM TN Lysine-specific demethylase 4 (KDM4) DMTYPBM MA Inhibitor DMTYPBM RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMTYPBM RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMTYQOF DI DMTYQOF DMTYQOF DN PMID25991433-Compound-B2 DMTYQOF TI TTVOE6D DMTYQOF TN Mitogen-activated protein kinase (MAPK) DMTYQOF MA Inhibitor DMTYQOF RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMTYQOF RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMTZ6K9 DI DMTZ6K9 DMTZ6K9 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 DMTZ6K9 TI TT7HF4W DMTZ6K9 TN Cyclin-dependent kinase 2 (CDK2) DMTZ6K9 MA Inhibitor DMTZ6K9 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTZ6K9 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTZ6K9 DI DMTZ6K9 DMTZ6K9 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 DMTZ6K9 TI TT1LVF2 DMTZ6K9 TN Cyclin-dependent kinase 9 (CDK9) DMTZ6K9 MA Inhibitor DMTZ6K9 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTZ6K9 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTZCLG DI DMTZCLG DMTZCLG DN Pyrazolopyridine derivative 5 DMTZCLG TI TTBYWP2 DMTZCLG TN TYK2 tyrosine kinase (TYK2) DMTZCLG MA Inhibitor DMTZCLG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMTZCLG RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMTZDUV DI DMTZDUV DMTZDUV DN 1,2-diamino cyclopentane-based derivative 14 DMTZDUV TI TT9N02I DMTZDUV TN Orexin receptor type 2 (HCRTR2) DMTZDUV MA Antagonist DMTZDUV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTZDUV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTZDUV DI DMTZDUV DMTZDUV DN 1,2-diamino cyclopentane-based derivative 14 DMTZDUV TI TT60Q8D DMTZDUV TN Orexin receptor type 1 (HCRTR1) DMTZDUV MA Antagonist DMTZDUV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTZDUV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTZK6V DI DMTZK6V DMTZK6V DN Pyridopyrimidine derivative 1 DMTZK6V TI TTZCRP3 DMTZK6V TN ERK activator kinase (MEK) DMTZK6V MA Inhibitor DMTZK6V RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMTZK6V RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMTZNSM DI DMTZNSM DMTZNSM DN PMID27414413-Compound-Figure8right DMTZNSM TI TTA592U DMTZNSM TN Urate anion exchanger 1 (URAT1) DMTZNSM MA Inhibitor DMTZNSM RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTZNSM RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TT4G2JS DMTZRCW TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TTZOVE0 DMTZRCW TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TTAXZ0K DMTZRCW TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRFP DI DMTZRFP DMTZRFP DN PMID25776143-Compound-2 DMTZRFP TI TT4TFGN DMTZRFP TN Vasopressin V1a receptor (V1AR) DMTZRFP MA Agonist DMTZRFP RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMTZRFP RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMTZVY3 DI DMTZVY3 DMTZVY3 DN PMID27109571-Compound-28 DMTZVY3 TI TTNT2S6 DMTZVY3 TN Fatty acid-binding protein 5 (FABP5) DMTZVY3 MA Inhibitor DMTZVY3 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTZVY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTZVY3 DI DMTZVY3 DMTZVY3 DN PMID27109571-Compound-28 DMTZVY3 TI TTHWMFZ DMTZVY3 TN Fatty acid-binding protein 4 (FABP4) DMTZVY3 MA Inhibitor DMTZVY3 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTZVY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU04PM DI DMU04PM DMU04PM DN Carbamide derivative 14 DMU04PM TI TTOHSBA DMU04PM TN Vascular endothelial growth factor A (VEGFA) DMU04PM MA Inhibitor DMU04PM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMU04PM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMU07MO DI DMU07MO DMU07MO DN BDBM50158791 DMU07MO TI TTIG67W DMU07MO TN Lysine-specific demethylase 5A (KDM5A) DMU07MO MA Inhibitor DMU07MO RN Histone demethylase inhibitors. US9725441. DMU07MO RU http://www.freepatentsonline.com/US9725441.html DMU0S2W DI DMU0S2W DMU0S2W DN Phenylpropylamine derivative 5 DMU0S2W TI TT5TPI6 DMU0S2W TN Opioid receptor sigma 1 (OPRS1) DMU0S2W MA Ligand DMU0S2W RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMU0S2W RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMU0YST DI DMU0YST DMU0YST DN Biphenyl mannoside derivative 12 DMU0YST TI TTTCRU2 DMU0YST TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMU0YST MA Antagonist DMU0YST RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMU0YST RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMU15FW DI DMU15FW DMU15FW DN Triazole derivative 6 DMU15FW TI TTSCIUP DMU15FW TN Oxytocin receptor (OTR) DMU15FW MA Antagonist DMU15FW RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMU15FW RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMU18W6 DI DMU18W6 DMU18W6 DN PMID28870136-Compound-39 DMU18W6 TI TTK0O6Y DMU18W6 TN Ecto-5'-nucleotidase (CD73) DMU18W6 MA Inhibitor DMU18W6 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMU18W6 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMU1PEZ DI DMU1PEZ DMU1PEZ DN PMID25522065-Compound-6 DMU1PEZ TI TTX4RTB DMU1PEZ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMU1PEZ MA Antagonist DMU1PEZ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMU1PEZ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMU21PD DI DMU21PD DMU21PD DN US10023583, Example 13 DMU21PD TI TTY2KP7 DMU21PD TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMU21PD MA Inhibitor DMU21PD RN Bicyclic pyridine compound. US10023583. DMU21PD RU http://www.freepatentsonline.com/US10023583.html DMU26R7 DI DMU26R7 DMU26R7 DN US8609715, B-61 DMU26R7 TI TTXL0GC DMU26R7 TN Enteropeptidase (TMPRSS15) DMU26R7 MA Inhibitor DMU26R7 RN Heteroarylcarboxylic acid ester derivative. US8609715. DMU26R7 RU http://www.freepatentsonline.com/US8609715.html DMU2WGL DI DMU2WGL DMU2WGL DN N-alkyl-4-oxazolecar boxamide derivative 1 DMU2WGL TI TTDP1UC DMU2WGL TN Fatty acid amide hydrolase (FAAH) DMU2WGL MA Inhibitor DMU2WGL RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMU2WGL RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMU3APC DI DMU3APC DMU3APC DN Resorcinol compound 23 DMU3APC TI TTULVH8 DMU3APC TN Tyrosinase (TYR) DMU3APC MA Inhibitor DMU3APC RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMU3APC RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMU3MQB DI DMU3MQB DMU3MQB DN PMID28870136-Compound-51 DMU3MQB TI TTK0O6Y DMU3MQB TN Ecto-5'-nucleotidase (CD73) DMU3MQB MA Inhibitor DMU3MQB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMU3MQB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMU3PAR DI DMU3PAR DMU3PAR DN Imidazo[1,5-a]pyridine derivative 2 DMU3PAR TI TTZJYKH DMU3PAR TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMU3PAR MA Inhibitor DMU3PAR RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMU3PAR RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMU3XBH DI DMU3XBH DMU3XBH DN PMID25991433-Compound-G2 DMU3XBH TI TT0K6EO DMU3XBH TN Stress-activated protein kinase JNK1 (JNK1) DMU3XBH MA Inhibitor DMU3XBH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU3XBH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU4QYR DI DMU4QYR DMU4QYR DN PMID27998201-Compound-7 DMU4QYR TI TT36ETB DMU4QYR TN Cathepsin L (CTSL) DMU4QYR MA Inhibitor DMU4QYR RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMU4QYR RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMU4QYR DI DMU4QYR DMU4QYR DN PMID27998201-Compound-7 DMU4QYR TI TTUMQVO DMU4QYR TN Cathepsin S (CTSS) DMU4QYR MA Inhibitor DMU4QYR RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMU4QYR RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMU51T4 DI DMU51T4 DMU51T4 DN Pyrrolidinyl urea derivative 5 DMU51T4 TI TTTDVOJ DMU51T4 TN Tropomyosin-related kinase A (TrkA) DMU51T4 MA Inhibitor DMU51T4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMU51T4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMU59IJ DI DMU59IJ DMU59IJ DN Pyrazole derivative 32 DMU59IJ TI TT6OEDT DMU59IJ TN Cannabinoid receptor 1 (CB1) DMU59IJ MA Antagonist DMU59IJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMU59IJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTPMQSO DMU5GKC TN ALK tyrosine kinase receptor (ALK) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TT4DXQT DMU5GKC TN Proto-oncogene c-Ret (RET) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTSZ6Y3 DMU5GKC TN Proto-oncogene c-Ros (ROS1) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTGJCWZ DMU5GKC TN Fms-like tyrosine kinase 3 (FLT-3) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5JC0 DI DMU5JC0 DMU5JC0 DN HouttuynoidA DMU5JC0 TI TT3WG5C DMU5JC0 TN Monoamine oxidase type A (MAO-A) DMU5JC0 MA Inhibitor DMU5JC0 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMU5JC0 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMU5KWC DI DMU5KWC DMU5KWC DN Indoline derivative 6 DMU5KWC TI TT5OU0D DMU5KWC TN PRKR-like endoplasmic reticulum kinase (PERK) DMU5KWC MA Inhibitor DMU5KWC RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMU5KWC RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMU61XP DI DMU61XP DMU61XP DN PMID29671355-Compound-69 DMU61XP TI TTBH0VX DMU61XP TN Histone deacetylase (HDAC) DMU61XP MA Inhibitor DMU61XP RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMU61XP RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMU65YX DI DMU65YX DMU65YX DN N-quinolin-benzene sulphonamide derivative 3 DMU65YX TI TTSXVID DMU65YX TN Nuclear factor NF-kappa-B (NFKB) DMU65YX MA Inhibitor DMU65YX RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMU65YX RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMU690T DI DMU690T DMU690T DN PMID27109571-Compound-31 DMU690T TI TTNT2S6 DMU690T TN Fatty acid-binding protein 5 (FABP5) DMU690T MA Inhibitor DMU690T RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMU690T RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU690T DI DMU690T DMU690T DN PMID27109571-Compound-31 DMU690T TI TTHWMFZ DMU690T TN Fatty acid-binding protein 4 (FABP4) DMU690T MA Inhibitor DMU690T RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMU690T RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU6LS4 DI DMU6LS4 DMU6LS4 DN Heterocyclic derivative 7 DMU6LS4 TI TTCZOF2 DMU6LS4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMU6LS4 MA Inhibitor DMU6LS4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMU6LS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMU6ST7 DI DMU6ST7 DMU6ST7 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2 DMU6ST7 TI TTJGW1Z DMU6ST7 TN Phosphodiesterase 2A (PDE2A) DMU6ST7 MA Inhibitor DMU6ST7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMU6ST7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TT0K6EO DMU75ZX TN Stress-activated protein kinase JNK1 (JNK1) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TT056SO DMU75ZX TN Stress-activated protein kinase JNK3 (JNK3) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TTHS0U8 DMU75ZX TN Stress-activated protein kinase JNK2 (JNK2) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU7YC2 DI DMU7YC2 DMU7YC2 DN Antibodie derivative 2 DMU7YC2 TI TTOHSBA DMU7YC2 TN Vascular endothelial growth factor A (VEGFA) DMU7YC2 MA Binder DMU7YC2 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMU7YC2 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMU8CAD DI DMU8CAD DMU8CAD DN US10092575, Example 101 DMU8CAD TI TT3ZS42 DMU8CAD TN Phosphodiesterase 1B (PDE1B) DMU8CAD MA Inhibitor DMU8CAD RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DMU8CAD RU http://www.freepatentsonline.com/US10092575.html DMU8ENF DI DMU8ENF DMU8ENF DN PMID28766366-Compound-Scheme15-2 DMU8ENF TI TTSBVFO DMU8ENF TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMU8ENF MA Inhibitor DMU8ENF RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMU8ENF RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMU8FC1 DI DMU8FC1 DMU8FC1 DN 1-phenyl-1,3,4-triazole derivative 3 DMU8FC1 TI TTA6ZN2 DMU8FC1 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMU8FC1 MA Inhibitor DMU8FC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMU8FC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMU8FC1 DI DMU8FC1 DMU8FC1 DN 1-phenyl-1,3,4-triazole derivative 3 DMU8FC1 TI TT956B0 DMU8FC1 TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMU8FC1 MA Modulator DMU8FC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMU8FC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMU8LPN DI DMU8LPN DMU8LPN DN Epoxysuccinate derivative 1 DMU8LPN TI TTG5QB7 DMU8LPN TN Calpain-2 (CAPN2) DMU8LPN MA Inhibitor DMU8LPN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMU8LPN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMU8OIL DI DMU8OIL DMU8OIL DN Acyl oxymethyl acrylamide ester derivative 2 DMU8OIL TI TTR7UJ3 DMU8OIL TN Cytoplasmic thioredoxin reductase (TXNRD1) DMU8OIL MA Inhibitor DMU8OIL RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMU8OIL RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMU8ZI3 DI DMU8ZI3 DMU8ZI3 DN PMID25656651-Compound-33b DMU8ZI3 TI TT3PJMV DMU8ZI3 TN Tyrosine-protein kinase ABL1 (ABL) DMU8ZI3 MA Inhibitor DMU8ZI3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMU8ZI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMU9A7V DI DMU9A7V DMU9A7V DN Triazolo-phthalazine derivative 1 DMU9A7V TI TTJGW1Z DMU9A7V TN Phosphodiesterase 2A (PDE2A) DMU9A7V MA Inhibitor DMU9A7V RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMU9A7V RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMU9XMV DI DMU9XMV DMU9XMV DN 1,2,4-triazole derivative 3 DMU9XMV TI TT5TPI6 DMU9XMV TN Opioid receptor sigma 1 (OPRS1) DMU9XMV MA Inhibitor DMU9XMV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMU9XMV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMU9Y4B DI DMU9Y4B DMU9Y4B DN Aryl pyrimidine derivative 2 DMU9Y4B TI TTIY56R DMU9Y4B TN Kynurenine 3-hydroxylase (KMO) DMU9Y4B MA Inhibitor DMU9Y4B RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMU9Y4B RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMU9YPV DI DMU9YPV DMU9YPV DN US8741907-compound-3 DMU9YPV TI TTN34SQ DMU9YPV TN Phosphodiesterase 3B (PDE3B) DMU9YPV MA Inhibitor DMU9YPV RN Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes. US9067945. DMU9YPV RU http://www.freepatentsonline.com/US9067945.html DMUA740 DI DMUA740 DMUA740 DN Hydrazide derivative 1 DMUA740 TI TT6OEDT DMUA740 TN Cannabinoid receptor 1 (CB1) DMUA740 MA Antagonist DMUA740 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUA740 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUAC1T DI DMUAC1T DMUAC1T DN PMID29671355-Compound-71a DMUAC1T TI TTTQGH8 DMUAC1T TN Histone deacetylase 4 (HDAC4) DMUAC1T MA Inhibitor DMUAC1T RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUAC1T RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUASHT DI DMUASHT DMUASHT DN Aminoazetidine derivative 9 DMUASHT TI TT6OEDT DMUASHT TN Cannabinoid receptor 1 (CB1) DMUASHT MA Antagonist DMUASHT RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUASHT RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUB4QL DI DMUB4QL DMUB4QL DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 DMUB4QL TI TTJGW1Z DMUB4QL TN Phosphodiesterase 2A (PDE2A) DMUB4QL MA Inhibitor DMUB4QL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUB4QL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUB4QL DI DMUB4QL DMUB4QL DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 DMUB4QL TI TTJW4LU DMUB4QL TN Phosphodiesterase 10A (PDE10) DMUB4QL MA Inhibitor DMUB4QL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUB4QL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUB7RV DI DMUB7RV DMUB7RV DN Ring-fused compound 1 DMUB7RV TI TTA592U DMUB7RV TN Urate anion exchanger 1 (URAT1) DMUB7RV MA Inhibitor DMUB7RV RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMUB7RV RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMUBDYG DI DMUBDYG DMUBDYG DN Bicyclic heteroaryl benzamide derivative 4 DMUBDYG TI TTTDVOJ DMUBDYG TN Tropomyosin-related kinase A (TrkA) DMUBDYG MA Inhibitor DMUBDYG RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUBDYG RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUBG20 DI DMUBG20 DMUBG20 DN Benzoic acid linked peptide analog 2 DMUBG20 TI TTULVH8 DMUBG20 TN Tyrosinase (TYR) DMUBG20 MA Inhibitor DMUBG20 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUBG20 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUBM1Y DI DMUBM1Y DMUBM1Y DN PMID28447479-Compound-4 DMUBM1Y TI TTSCIM2 DMUBM1Y TN Extracellular lysophospholipase D (E-NPP2) DMUBM1Y MA Inhibitor DMUBM1Y RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMUBM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT8K17W DMUBOEX TN Histone deacetylase 11 (HDAC11) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTSHTOI DMUBOEX TN Histone deacetylase 2 (HDAC2) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTTQGH8 DMUBOEX TN Histone deacetylase 4 (HDAC4) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT6R7JZ DMUBOEX TN Histone deacetylase 1 (HDAC1) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTUELN5 DMUBOEX TN Histone deacetylase 5 (HDAC5) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTT6LFV DMUBOEX TN Histone deacetylase 8 (HDAC8) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT5ZKDI DMUBOEX TN Histone deacetylase 6 (HDAC6) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBSFV DI DMUBSFV DMUBSFV DN PMID28350212-Compound-7 DMUBSFV TI TTZS04O DMUBSFV TN Gamma-secretase subunit APH-1A/1B (APH-1) DMUBSFV MA Inhibitor DMUBSFV RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMUBSFV RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMUBZO3 DI DMUBZO3 DMUBZO3 DN PMID25553724-Compound-US20130116324 2 DMUBZO3 TI TTSXVID DMUBZO3 TN Nuclear factor NF-kappa-B (NFKB) DMUBZO3 MA Inhibitor DMUBZO3 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMUBZO3 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMUCIPE DI DMUCIPE DMUCIPE DN US9650366, 9 DMUCIPE TI TTXEZJ4 DMUCIPE TN Tyrosine-protein kinase EIF2AK2 (p68) DMUCIPE MA Inhibitor DMUCIPE RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DMUCIPE RU http://www.freepatentsonline.com/US9650366.html DMUCW9Y DI DMUCW9Y DMUCW9Y DN Boronic acid derivative 5 DMUCW9Y TI TTDP1UC DMUCW9Y TN Fatty acid amide hydrolase (FAAH) DMUCW9Y MA Inhibitor DMUCW9Y RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMUCW9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMUD7H8 DI DMUD7H8 DMUD7H8 DN Unii-I92MU0V408 DMUD7H8 TI TT42OGM DMUD7H8 TN Hematopoietic cell kinase (HCK) DMUD7H8 MA Inhibitor DMUD7H8 RN Respiratory formulations and compounds for use therein. US8933228. DMUD7H8 RU http://www.freepatentsonline.com/US8933228.html DMUD7IB DI DMUD7IB DMUD7IB DN PMID26004420-Compound-US20140031349D DMUD7IB TI TTJ13ST DMUD7IB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMUD7IB MA Inhibitor DMUD7IB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMUD7IB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMUDE89 DI DMUDE89 DMUDE89 DN US20160326143, 38 DMUDE89 TI TTW7OTG DMUDE89 TN Leukotriene C4 synthase (LTC4S) DMUDE89 MA Inhibitor DMUDE89 RN Compounds and uses. US9657001. DMUDE89 RU http://www.freepatentsonline.com/US9657001.html DMUDKE0 DI DMUDKE0 DMUDKE0 DN PMID29649907-Compound-34 DMUDKE0 TI TTS4UGC DMUDKE0 TN Farnesoid X-activated receptor (FXR) DMUDKE0 MA Agonist DMUDKE0 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMUDKE0 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMUE7R5 DI DMUE7R5 DMUE7R5 DN N-oxalyl-D-tyrosine derivative 4 DMUE7R5 TI TTWAQBO DMUE7R5 TN Lysine-specific demethylase 4E (KDM4E) DMUE7R5 MA Inhibitor DMUE7R5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMUE7R5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMUEI4N DI DMUEI4N DMUEI4N DN Tetra-azabenzo[e]azulene derivative 2 DMUEI4N TI TT4TFGN DMUEI4N TN Vasopressin V1a receptor (V1AR) DMUEI4N MA Inhibitor DMUEI4N RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMUEI4N RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMUF5AC DI DMUF5AC DMUF5AC DN Carbamide derivative 17 DMUF5AC TI TTOHSBA DMUF5AC TN Vascular endothelial growth factor A (VEGFA) DMUF5AC MA Inhibitor DMUF5AC RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMUF5AC RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMUF63N DI DMUF63N DMUF63N DN Pyridopyrimidinone derivative 2 DMUF63N TI TTK0FEA DMUF63N TN Leucine-rich repeat kinase 2 (LRRK2) DMUF63N MA Inhibitor DMUF63N RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMUF63N RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMUFSQ2 DI DMUFSQ2 DMUFSQ2 DN Imidazolidine-2,4-dione derivative 1 DMUFSQ2 TI TT6OEDT DMUFSQ2 TN Cannabinoid receptor 1 (CB1) DMUFSQ2 MA Antagonist DMUFSQ2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUFSQ2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUG69Q DI DMUG69Q DMUG69Q DN Diamine derivative 1 DMUG69Q TI TTULVH8 DMUG69Q TN Tyrosinase (TYR) DMUG69Q MA Inhibitor DMUG69Q RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUG69Q RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUG6YT DI DMUG6YT DMUG6YT DN Antibodie derivative 6 DMUG6YT TI TTUTJGQ DMUG6YT TN Vascular endothelial growth factor receptor 2 (KDR) DMUG6YT MA Binder DMUG6YT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMUG6YT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMUG7E9 DI DMUG7E9 DMUG7E9 DN C-linked disaccharide biphenyl mannoside derivative 5 DMUG7E9 TI TTTCRU2 DMUG7E9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUG7E9 MA Antagonist DMUG7E9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUG7E9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUG9X0 DI DMUG9X0 DMUG9X0 DN PMID27414413-Compound-Figure6right DMUG9X0 TI TTA592U DMUG9X0 TN Urate anion exchanger 1 (URAT1) DMUG9X0 MA Inhibitor DMUG9X0 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMUG9X0 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMUGC53 DI DMUGC53 DMUGC53 DN PMID29338548-Compound-29 DMUGC53 TI TTHJTF7 DMUGC53 TN Glycine transporter GlyT-1 (SLC6A9) DMUGC53 MA Inhibitor DMUGC53 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMUGC53 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMUGZNL DI DMUGZNL DMUGZNL DN Aminopyridine derivative 2 DMUGZNL TI TTK0FEA DMUGZNL TN Leucine-rich repeat kinase 2 (LRRK2) DMUGZNL MA Inhibitor DMUGZNL RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMUGZNL RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMUHEP8 DI DMUHEP8 DMUHEP8 DN PMID25726713-Compound-56 DMUHEP8 TI TT8J1S3 DMUHEP8 TN Smoothened homolog (SMO) DMUHEP8 MA Inhibitor DMUHEP8 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMUHEP8 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMUHFLQ DI DMUHFLQ DMUHFLQ DN N-oxalylglycine derivative 1 DMUHFLQ TI TT0RGE9 DMUHFLQ TN Lysine-specific demethylase 4 (KDM4) DMUHFLQ MA Inhibitor DMUHFLQ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMUHFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMUHNS7 DI DMUHNS7 DMUHNS7 DN PMID29649907-Compound-24 DMUHNS7 TI TTS4UGC DMUHNS7 TN Farnesoid X-activated receptor (FXR) DMUHNS7 MA Agonist DMUHNS7 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMUHNS7 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMUHSAZ DI DMUHSAZ DMUHSAZ DN Unii-R228S06soh DMUHSAZ TI TTVSMOH DMUHSAZ TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMUHSAZ MA Inhibitor DMUHSAZ RN Sphingosine 1-phosphate receptor antagonists. US9663511. DMUHSAZ RU http://www.freepatentsonline.com/US9663511.html DMUI385 DI DMUI385 DMUI385 DN PMID28394193-Compound-Figure3bIII DMUI385 TI TT9MZCQ DMUI385 TN Enhancer of zeste homolog 2 (EZH2) DMUI385 MA Inhibitor DMUI385 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMUI385 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMUIK3W DI DMUIK3W DMUIK3W DN Pyrrolo-pyridone derivative 3 DMUIK3W TI TT6DM01 DMUIK3W TN Janus kinase 1 (JAK-1) DMUIK3W MA Inhibitor DMUIK3W RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUIK3W RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUIK3W DI DMUIK3W DMUIK3W DN Pyrrolo-pyridone derivative 3 DMUIK3W TI TTBYWP2 DMUIK3W TN TYK2 tyrosine kinase (TYK2) DMUIK3W MA Inhibitor DMUIK3W RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUIK3W RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUILMD DI DMUILMD DMUILMD DN C-linked disaccharide biphenyl mannoside derivative 6 DMUILMD TI TTTCRU2 DMUILMD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUILMD MA Antagonist DMUILMD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUILMD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUJ3XK DI DMUJ3XK DMUJ3XK DN Dihydrothieno [2,3-e]indazole derivative 1 DMUJ3XK TI TTRPDBG DMUJ3XK TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMUJ3XK MA Inhibitor DMUJ3XK RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMUJ3XK RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMUJFCK DI DMUJFCK DMUJFCK DN Benzoimidazole derivative 1 DMUJFCK TI TTZCRP3 DMUJFCK TN ERK activator kinase (MEK) DMUJFCK MA Inhibitor DMUJFCK RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMUJFCK RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMUKBGD DI DMUKBGD DMUKBGD DN Imidazopyridine derivative 5 DMUKBGD TI TTYLQ8V DMUKBGD TN Prostaglandin E synthase (PTGES) DMUKBGD MA Inhibitor DMUKBGD RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMUKBGD RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMUKFJ0 DI DMUKFJ0 DMUKFJ0 DN PMID25776143-Compound-8 DMUKFJ0 TI TT4TFGN DMUKFJ0 TN Vasopressin V1a receptor (V1AR) DMUKFJ0 MA Antagonist DMUKFJ0 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMUKFJ0 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMUKIEJ DI DMUKIEJ DMUKIEJ DN PMID30280939-Compound-WO2013148426 DMUKIEJ TI TTOK0LR DMUKIEJ TN Toll-like receptor (TLR) DMUKIEJ MA Agonist DMUKIEJ RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMUKIEJ RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMUKNXF DI DMUKNXF DMUKNXF DN Benzothiazole analog 2 DMUKNXF TI TTULVH8 DMUKNXF TN Tyrosinase (TYR) DMUKNXF MA Inhibitor DMUKNXF RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUKNXF RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUKOGJ DI DMUKOGJ DMUKOGJ DN PMID27109571-Compound-13 DMUKOGJ TI TTNT2S6 DMUKOGJ TN Fatty acid-binding protein 5 (FABP5) DMUKOGJ MA Inhibitor DMUKOGJ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUKOGJ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUKOGJ DI DMUKOGJ DMUKOGJ DN PMID27109571-Compound-13 DMUKOGJ TI TTHWMFZ DMUKOGJ TN Fatty acid-binding protein 4 (FABP4) DMUKOGJ MA Inhibitor DMUKOGJ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUKOGJ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUL84D DI DMUL84D DMUL84D DN PMID26560530-Compound-33 DMUL84D TI TT2F4OL DMUL84D TN Tissue transglutaminase (TG2) DMUL84D MA Inhibitor DMUL84D RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMUL84D RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMULJOS DI DMULJOS DMULJOS DN Isoxazoles and isoxazoline derivative 3 DMULJOS TI TTIY56R DMULJOS TN Kynurenine 3-hydroxylase (KMO) DMULJOS MA Inhibitor DMULJOS RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMULJOS RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMULTAI DI DMULTAI DMULTAI DN Imidazo[1,2-b]pyridazine derivative 1 DMULTAI TI TTTDVOJ DMULTAI TN Tropomyosin-related kinase A (TrkA) DMULTAI MA Inhibitor DMULTAI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMULTAI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMULTAI DI DMULTAI DMULTAI DN Imidazo[1,2-b]pyridazine derivative 1 DMULTAI TI TTSZ6Y3 DMULTAI TN Proto-oncogene c-Ros (ROS1) DMULTAI MA Inhibitor DMULTAI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMULTAI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUM3YW DI DMUM3YW DMUM3YW DN PMID25522065-Compound-25 DMUM3YW TI TTX4RTB DMUM3YW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUM3YW MA Antagonist DMUM3YW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMUM3YW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMUM5L6 DI DMUM5L6 DMUM5L6 DN PMID27828716-Compound-BIO-acetoxime DMUM5L6 TI TTRZQE3 DMUM5L6 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUM5L6 MA Inhibitor DMUM5L6 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUM5L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TTRMX3V DMUMPZX TN Janus kinase 2 (JAK-2) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TT6DM01 DMUMPZX TN Janus kinase 1 (JAK-1) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TTT7PJU DMUMPZX TN Janus kinase 3 (JAK-3) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMYKX DI DMUMYKX DMUMYKX DN PMID25666693-Compound-24 DMUMYKX TI TTMI6F5 DMUMYKX TN Transient receptor potential cation channel V1 (TRPV1) DMUMYKX MA Antagonist DMUMYKX RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMUMYKX RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMUNFAT DI DMUNFAT DMUNFAT DN Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 DMUNFAT TI TT4G2JS DMUNFAT TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUNFAT MA Blocker DMUNFAT RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMUNFAT RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMUNFAT DI DMUNFAT DMUNFAT DN Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 DMUNFAT TI TTZOVE0 DMUNFAT TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUNFAT MA Blocker DMUNFAT RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMUNFAT RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMUNLK8 DI DMUNLK8 DMUNLK8 DN Pyrazole derivative 33 DMUNLK8 TI TT6OEDT DMUNLK8 TN Cannabinoid receptor 1 (CB1) DMUNLK8 MA Antagonist DMUNLK8 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUNLK8 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUNME2 DI DMUNME2 DMUNME2 DN Methylbenzenesulfonamide derivative 1 DMUNME2 TI TTOHFIY DMUNME2 TN Sphingosine kinase 1 (SPHK1) DMUNME2 MA Inhibitor DMUNME2 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMUNME2 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TT6DM01 DMUNSYX TN Janus kinase 1 (JAK-1) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTBYWP2 DMUNSYX TN TYK2 tyrosine kinase (TYK2) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTRMX3V DMUNSYX TN Janus kinase 2 (JAK-2) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTT7PJU DMUNSYX TN Janus kinase 3 (JAK-3) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNXAR DI DMUNXAR DMUNXAR DN PMID29053063-Compound-7d DMUNXAR TI TTZ963I DMUNXAR TN Monoglyceride lipase (MAGL) DMUNXAR MA Inhibitor DMUNXAR RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMUNXAR RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMUO25Y DI DMUO25Y DMUO25Y DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 DMUO25Y TI TTJGW1Z DMUO25Y TN Phosphodiesterase 2A (PDE2A) DMUO25Y MA Inhibitor DMUO25Y RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUO25Y RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUO25Y DI DMUO25Y DMUO25Y DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 DMUO25Y TI TTJW4LU DMUO25Y TN Phosphodiesterase 10A (PDE10) DMUO25Y MA Inhibitor DMUO25Y RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUO25Y RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUOI92 DI DMUOI92 DMUOI92 DN Heterocyclic derivative 11 DMUOI92 TI TTCZOF2 DMUOI92 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMUOI92 MA Inhibitor DMUOI92 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMUOI92 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMUOW3T DI DMUOW3T DMUOW3T DN Metal complex derivative 1 DMUOW3T TI TTR7UJ3 DMUOW3T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMUOW3T MA Inhibitor DMUOW3T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMUOW3T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMUOZEJ DI DMUOZEJ DMUOZEJ DN Z223457004 DMUOZEJ TI TT3RMNA DMUOZEJ TN Chymotrypsin-C (CLCR) DMUOZEJ MA Inhibitor DMUOZEJ RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMUOZEJ RU http://www.freepatentsonline.com/US9695194.html DMUP0WH DI DMUP0WH DMUP0WH DN Aryl alkanolamine derivative 2 DMUP0WH TI TT5TPI6 DMUP0WH TN Opioid receptor sigma 1 (OPRS1) DMUP0WH MA Antagonist DMUP0WH RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMUP0WH RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMUP4DX DI DMUP4DX DMUP4DX DN Picolinamido propanoic acid derivative 1 DMUP4DX TI TT9O6WS DMUP4DX TN Glucagon receptor (GCGR) DMUP4DX MA Antagonist DMUP4DX RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMUP4DX RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMUPL0W DI DMUPL0W DMUPL0W DN PMID25514969-Compound-11 DMUPL0W TI TT4EB85 DMUPL0W TN Cholesterol 24-hydroxylase (CYP46A1) DMUPL0W MA Inhibitor DMUPL0W RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMUPL0W RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMUPN01 DI DMUPN01 DMUPN01 DN AR-A014418 DMUPN01 TI TTRSMW9 DMUPN01 TN Glycogen synthase kinase-3 beta (GSK-3B) DMUPN01 MA Inhibitor DMUPN01 RN Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. DMUPN01 RU https://pubmed.ncbi.nlm.nih.gov/18929433 DMUPN01 DI DMUPN01 DMUPN01 DN AR-A014418 DMUPN01 TI TTRZQE3 DMUPN01 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUPN01 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUPN01 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUPNHA DI DMUPNHA DMUPNHA DN Pyrazole derivative 21 DMUPNHA TI TT6OEDT DMUPNHA TN Cannabinoid receptor 1 (CB1) DMUPNHA MA Antagonist DMUPNHA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUPNHA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUPRX2 DI DMUPRX2 DMUPRX2 DN US8791257, 17 DMUPRX2 TI TTR93NU DMUPRX2 TN Casein kinase II alpha prime (CSNK2A2) DMUPRX2 MA Inhibitor DMUPRX2 RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMUPRX2 RU http://www.freepatentsonline.com/US8791257.html DMUPT9A DI DMUPT9A DMUPT9A DN Amidine compound 1 DMUPT9A TI TTQR74A DMUPT9A TN Proteinase activated receptor 2 (PAR2) DMUPT9A MA Antagonist DMUPT9A RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMUPT9A RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMUQ04C DI DMUQ04C DMUQ04C DN PMID25684022-Compound-US20120277229 44(1.4) DMUQ04C TI TTCZOF2 DMUQ04C TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMUQ04C MA Inhibitor DMUQ04C RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMUQ04C RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMUQ9CF DI DMUQ9CF DMUQ9CF DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 DMUQ9CF TI TTIXKA4 DMUQ9CF TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMUQ9CF MA Inhibitor DMUQ9CF RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMUQ9CF RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMUQI15 DI DMUQI15 DMUQI15 DN BDBM50363782 DMUQI15 TI TTLKF5M DMUQI15 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMUQI15 MA Inhibitor DMUQI15 RN Aroyl thiourea derivatives. US9365508. DMUQI15 RU http://www.freepatentsonline.com/US9365508.html DMUQSM1 DI DMUQSM1 DMUQSM1 DN PMID26651364-Compound-117b DMUQSM1 TI TTTCRU2 DMUQSM1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUQSM1 MA Antagonist DMUQSM1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUQSM1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUR3FY DI DMUR3FY DMUR3FY DN PMID27109571-Compound-15 DMUR3FY TI TTNT2S6 DMUR3FY TN Fatty acid-binding protein 5 (FABP5) DMUR3FY MA Inhibitor DMUR3FY RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUR3FY RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUR3FY DI DMUR3FY DMUR3FY DN PMID27109571-Compound-15 DMUR3FY TI TTHWMFZ DMUR3FY TN Fatty acid-binding protein 4 (FABP4) DMUR3FY MA Inhibitor DMUR3FY RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUR3FY RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMURYO0 DI DMURYO0 DMURYO0 DN Tetra-hydro-naphthalene derivative 1 DMURYO0 TI TTDP1UC DMURYO0 TN Fatty acid amide hydrolase (FAAH) DMURYO0 MA Inhibitor DMURYO0 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMURYO0 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMURZHA DI DMURZHA DMURZHA DN PMID30273516-Compound-14 DMURZHA TI TTCW0KX DMURZHA TN Glutaminase (GLS) DMURZHA MA Inhibitor DMURZHA RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMURZHA RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMUS4Z0 DI DMUS4Z0 DMUS4Z0 DN Five membered heterocyclic benzamide derivative 3 DMUS4Z0 TI TTTDVOJ DMUS4Z0 TN Tropomyosin-related kinase A (TrkA) DMUS4Z0 MA Inhibitor DMUS4Z0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUS4Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUS7O3 DI DMUS7O3 DMUS7O3 DN 1,3-dihydroxy phenyl derivative 1 DMUS7O3 TI TT23XQV DMUS7O3 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMUS7O3 MA Inhibitor DMUS7O3 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMUS7O3 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMUTE5S DI DMUTE5S DMUTE5S DN Pyridyl compound 1 DMUTE5S TI TTA6ZN2 DMUTE5S TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMUTE5S MA Activator DMUTE5S RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUTE5S RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUTE5S DI DMUTE5S DMUTE5S DN Pyridyl compound 1 DMUTE5S TI TT3Z6Y9 DMUTE5S TN Cysteines of Keap1 (KEAP1 Cysteines) DMUTE5S MA Modulator DMUTE5S RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUTE5S RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUTF17 DI DMUTF17 DMUTF17 DN 1,2-diamino cyclopentane-based derivative 28 DMUTF17 TI TT9BPT3 DMUTF17 TN Orexin receptor (HCRTR) DMUTF17 MA Antagonist DMUTF17 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMUTF17 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMUTKNW DI DMUTKNW DMUTKNW DN Tacrine-indole hybrid derivative 3 DMUTKNW TI TT1RS9F DMUTKNW TN Acetylcholinesterase (AChE) DMUTKNW MA Inhibitor DMUTKNW RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMUTKNW RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMUVC25 DI DMUVC25 DMUVC25 DN US9493490, D DMUVC25 TI TTAZ3MN DMUVC25 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMUVC25 MA Inhibitor DMUVC25 RN Boron-containing small molecules. US9493490. DMUVC25 RU http://www.freepatentsonline.com/US9493490.html DMUVPR8 DI DMUVPR8 DMUVPR8 DN Tri-substituted urea derivative 2 DMUVPR8 TI TTTDVOJ DMUVPR8 TN Tropomyosin-related kinase A (TrkA) DMUVPR8 MA Inhibitor DMUVPR8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUVPR8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUVYWE DI DMUVYWE DMUVYWE DN Maleimides derivative 2 DMUVYWE TI TTRZQE3 DMUVYWE TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUVYWE RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUVYWE RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUWZD9 DI DMUWZD9 DMUWZD9 DN PMID28766366-Compound-Scheme8NCGC-00189310 DMUWZD9 TI TTSBVFO DMUWZD9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMUWZD9 MA Inhibitor DMUWZD9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMUWZD9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMUX0SG DI DMUX0SG DMUX0SG DN PMID26004420-Compound-WO2012058134A DMUX0SG TI TTJ13ST DMUX0SG TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMUX0SG MA Inhibitor DMUX0SG RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMUX0SG RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMUXNKG DI DMUXNKG DMUXNKG DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 1 DMUXNKG TI TT6OEDT DMUXNKG TN Cannabinoid receptor 1 (CB1) DMUXNKG MA Antagonist DMUXNKG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUXNKG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUXO47 DI DMUXO47 DMUXO47 DN PMID25666693-Compound-21 DMUXO47 TI TTMI6F5 DMUXO47 TN Transient receptor potential cation channel V1 (TRPV1) DMUXO47 MA Antagonist DMUXO47 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMUXO47 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMUXQST DI DMUXQST DMUXQST DN Pyrazinylpyridine derivative 1 DMUXQST TI TT1LVF2 DMUXQST TN Cyclin-dependent kinase 9 (CDK9) DMUXQST MA Inhibitor DMUXQST RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMUXQST RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMUY4LS DI DMUY4LS DMUY4LS DN PMID28454500-Compound-12 DMUY4LS TI TTA6ZN2 DMUY4LS TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMUY4LS MA Activator DMUY4LS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUY4LS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUY4LS DI DMUY4LS DMUY4LS DN PMID28454500-Compound-12 DMUY4LS TI TT3Z6Y9 DMUY4LS TN Cysteines of Keap1 (KEAP1 Cysteines) DMUY4LS MA Modulator DMUY4LS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUY4LS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUY53P DI DMUY53P DMUY53P DN PMID29671355-Compound-18 DMUY53P TI TT6R7JZ DMUY53P TN Histone deacetylase 1 (HDAC1) DMUY53P MA Inhibitor DMUY53P RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUY53P RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUY53P DI DMUY53P DMUY53P DN PMID29671355-Compound-18 DMUY53P TI TT5ZKDI DMUY53P TN Histone deacetylase 6 (HDAC6) DMUY53P MA Inhibitor DMUY53P RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUY53P RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUYVOP DI DMUYVOP DMUYVOP DN PMID25514969-Compound-Figure2-3 DMUYVOP TI TT4EB85 DMUYVOP TN Cholesterol 24-hydroxylase (CYP46A1) DMUYVOP MA Inhibitor DMUYVOP RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMUYVOP RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMUZ4L3 DI DMUZ4L3 DMUZ4L3 DN Tricyclic indole compound 4 DMUZ4L3 TI TTPTXIN DMUZ4L3 TN Translocator protein (TSPO) DMUZ4L3 MA Ligand DMUZ4L3 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMUZ4L3 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMUZ85A DI DMUZ85A DMUZ85A DN PMID30107136-Compound-Example60 DMUZ85A TI TT23XQV DMUZ85A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMUZ85A MA Inhibitor DMUZ85A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMUZ85A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMUZQLR DI DMUZQLR DMUZQLR DN Benzene sulfonamide derivative 2 DMUZQLR TI TTIY56R DMUZQLR TN Kynurenine 3-hydroxylase (KMO) DMUZQLR MA Inhibitor DMUZQLR RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMUZQLR RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMUZR3X DI DMUZR3X DMUZR3X DN Heteroaryl-azepine derivative 9 DMUZR3X TI TTWJBZ5 DMUZR3X TN 5-HT 2C receptor (HTR2C) DMUZR3X MA Agonist DMUZR3X RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMUZR3X RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMV0EIA DI DMV0EIA DMV0EIA DN PMID25980951-Compound-28 DMV0EIA TI TTR7B60 DMV0EIA TN X-linked inhibitor of apoptosis protein (XIAP) DMV0EIA MA Antagonist DMV0EIA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMV0EIA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMV0QJ4 DI DMV0QJ4 DMV0QJ4 DN Amidine compound 3 DMV0QJ4 TI TTQR74A DMV0QJ4 TN Proteinase activated receptor 2 (PAR2) DMV0QJ4 MA Antagonist DMV0QJ4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMV0QJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMV0R2X DI DMV0R2X DMV0R2X DN PMID28870136-Compound-42 DMV0R2X TI TTK0O6Y DMV0R2X TN Ecto-5'-nucleotidase (CD73) DMV0R2X MA Inhibitor DMV0R2X RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMV0R2X RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMV15GM DI DMV15GM DMV15GM DN PMID30107136-Compound-Example50 DMV15GM TI TT23XQV DMV15GM TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV15GM MA Inhibitor DMV15GM RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV15GM RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV172W DI DMV172W DMV172W DN Macrocyclic peptide analog 3 DMV172W TI TT23XQV DMV172W TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV172W MA Inhibitor DMV172W RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV172W RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV1AGC DI DMV1AGC DMV1AGC DN PMID28394193-Compound-35 DMV1AGC TI TT9MZCQ DMV1AGC TN Enhancer of zeste homolog 2 (EZH2) DMV1AGC MA Inhibitor DMV1AGC RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMV1AGC RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMV1ER2 DI DMV1ER2 DMV1ER2 DN Imidazole derivative 3 DMV1ER2 TI TT6OEDT DMV1ER2 TN Cannabinoid receptor 1 (CB1) DMV1ER2 MA Antagonist DMV1ER2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMV1ER2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMV1OR0 DI DMV1OR0 DMV1OR0 DN US9694002, 495 DMV1OR0 TI TTANOZH DMV1OR0 TN SCN1A messenger RNA (SCN1A mRNA) DMV1OR0 MA Inhibitor DMV1OR0 RN Substituted benzamides and methods of use thereof. US9694002. DMV1OR0 RU http://www.freepatentsonline.com/US9694002.html DMV1QUX DI DMV1QUX DMV1QUX DN Alkyl mannoside derivative 9 DMV1QUX TI TTTCRU2 DMV1QUX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMV1QUX MA Antagonist DMV1QUX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMV1QUX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMV1RQX DI DMV1RQX DMV1RQX DN Tricyclic compound 10 DMV1RQX TI TTAIQSN DMV1RQX TN Receptor-interacting protein 1 (RIPK1) DMV1RQX MA Inhibitor DMV1RQX RN Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256. DMV1RQX RU https://www.ncbi.nlm.nih.gov/pubmed/27568917 DMV1SCA DI DMV1SCA DMV1SCA DN Fluorinated donepezil derivative 2 DMV1SCA TI TT1RS9F DMV1SCA TN Acetylcholinesterase (AChE) DMV1SCA MA Inhibitor DMV1SCA RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMV1SCA RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMV1WND DI DMV1WND DMV1WND DN PMID27744724-Compound-4 DMV1WND TI TTL53M6 DMV1WND TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV1WND MA Inhibitor DMV1WND RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV1WND RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV2D5M DI DMV2D5M DMV2D5M DN PMID29649907-Compound-8 DMV2D5M TI TTS4UGC DMV2D5M TN Farnesoid X-activated receptor (FXR) DMV2D5M MA Agonist DMV2D5M RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMV2D5M RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMV2D5M DI DMV2D5M DMV2D5M DN PMID29649907-Compound-8 DMV2D5M TI TTSDVTR DMV2D5M TN G-protein coupled bile acid receptor 1 (GPBAR1) DMV2D5M MA Agonist DMV2D5M RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMV2D5M RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMV2UQ5 DI DMV2UQ5 DMV2UQ5 DN Cyclic peptidomimetic derivative 1 DMV2UQ5 TI TT23XQV DMV2UQ5 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV2UQ5 MA Inhibitor DMV2UQ5 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV2UQ5 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV2W9Z DI DMV2W9Z DMV2W9Z DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 DMV2W9Z TI TTSXVID DMV2W9Z TN Nuclear factor NF-kappa-B (NFKB) DMV2W9Z MA Inhibitor DMV2W9Z RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMV2W9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMV2Y84 DI DMV2Y84 DMV2Y84 DN Pyrimidine derivative 15 DMV2Y84 TI TTDCBX5 DMV2Y84 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMV2Y84 MA Inhibitor DMV2Y84 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMV2Y84 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMV30QO DI DMV30QO DMV30QO DN Thiazole carboxamide derivative 27 DMV30QO TI TTCZOF2 DMV30QO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMV30QO MA Inhibitor DMV30QO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMV30QO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TTHS0U8 DMV3H98 TN Stress-activated protein kinase JNK2 (JNK2) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TT0K6EO DMV3H98 TN Stress-activated protein kinase JNK1 (JNK1) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TT056SO DMV3H98 TN Stress-activated protein kinase JNK3 (JNK3) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3X64 DI DMV3X64 DMV3X64 DN PMID26004420-Compound-WO2010129379C DMV3X64 TI TTJ13ST DMV3X64 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV3X64 MA Inhibitor DMV3X64 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV3X64 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV46DG DI DMV46DG DMV46DG DN PMID26815044-Compound-93 DMV46DG TI TTULVH8 DMV46DG TN Tyrosinase (TYR) DMV46DG MA Inhibitor DMV46DG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMV46DG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMV4AHL DI DMV4AHL DMV4AHL DN US9422240, 1-282 DMV4AHL TI TT9ISBX DMV4AHL TN HIF-prolyl hydroxylase 2 (HPH-2) DMV4AHL MA Inhibitor DMV4AHL RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMV4AHL RU http://www.freepatentsonline.com/US9422240.html DMV4DQI DI DMV4DQI DMV4DQI DN Benzimidazole derivative 13 DMV4DQI TI TTYLQ8V DMV4DQI TN Prostaglandin E synthase (PTGES) DMV4DQI MA Inhibitor DMV4DQI RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMV4DQI RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMV4HQ5 DI DMV4HQ5 DMV4HQ5 DN PMID26004420-Compound-WO2015017305E DMV4HQ5 TI TTJ13ST DMV4HQ5 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV4HQ5 MA Inhibitor DMV4HQ5 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV4HQ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV4I0K DI DMV4I0K DMV4I0K DN Cyclopropylamine derivative 12 DMV4I0K TI TT32XQJ DMV4I0K TN Monoamine oxidase (MAO) DMV4I0K MA Inhibitor DMV4I0K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMV4I0K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMV4I0K DI DMV4I0K DMV4I0K DN Cyclopropylamine derivative 12 DMV4I0K TI TTNR0UQ DMV4I0K TN Lysine-specific histone demethylase 1 (LSD) DMV4I0K MA Inhibitor DMV4I0K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMV4I0K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMV4OTD DI DMV4OTD DMV4OTD DN Benzothiazepine analog 4 DMV4OTD TI TTPTXIN DMV4OTD TN Translocator protein (TSPO) DMV4OTD MA Ligand DMV4OTD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMV4OTD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMV509A DI DMV509A DMV509A DN PMID25666693-Compound-105 DMV509A TI TTMI6F5 DMV509A TN Transient receptor potential cation channel V1 (TRPV1) DMV509A MA Antagonist DMV509A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMV509A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMV5XR7 DI DMV5XR7 DMV5XR7 DN 6-Phenylquinazolin-4-amine DMV5XR7 TI TT6NI13 DMV5XR7 TN MEK kinase kinase 4 (MAP4K4) DMV5XR7 MA Inhibitor DMV5XR7 RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMV5XR7 RU http://www.freepatentsonline.com/US9592235.html DMV6FL8 DI DMV6FL8 DMV6FL8 DN US8481733, 106 DMV6FL8 TI TTIET93 DMV6FL8 TN Activated CDC42 kinase 1 (ACK-1) DMV6FL8 MA Inhibitor DMV6FL8 RN Substituted imidazopyr- and imidazotri-azines. US8481733. DMV6FL8 RU http://www.freepatentsonline.com/US8481733.html DMV6GIC DI DMV6GIC DMV6GIC DN PMID26394986-Compound-51 DMV6GIC TI TTH8FZW DMV6GIC TN Signal transducer and activator of transcription 3 (STAT3) DMV6GIC MA Inhibitor DMV6GIC RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMV6GIC RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMV6H95 DI DMV6H95 DMV6H95 DN C-linked disaccharide biphenyl mannoside derivative 1 DMV6H95 TI TTTCRU2 DMV6H95 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMV6H95 MA Antagonist DMV6H95 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMV6H95 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMV6MLC DI DMV6MLC DMV6MLC DN PMID27744724-Compound-27 DMV6MLC TI TTU1E82 DMV6MLC TN Apoptosis regulator Bcl-xL (BCL-xL) DMV6MLC MA Inhibitor DMV6MLC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV6MLC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV6MLC DI DMV6MLC DMV6MLC DN PMID27744724-Compound-27 DMV6MLC TI TTL53M6 DMV6MLC TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV6MLC MA Inhibitor DMV6MLC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV6MLC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV6U9Y DI DMV6U9Y DMV6U9Y DN Pyrimidine derivative 9 DMV6U9Y TI TTOHSBA DMV6U9Y TN Vascular endothelial growth factor A (VEGFA) DMV6U9Y MA Inhibitor DMV6U9Y RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMV6U9Y RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMV6YXJ DI DMV6YXJ DMV6YXJ DN Pyrrolidinyl urea derivative 10 DMV6YXJ TI TTTDVOJ DMV6YXJ TN Tropomyosin-related kinase A (TrkA) DMV6YXJ MA Inhibitor DMV6YXJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV6YXJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV7AX9 DI DMV7AX9 DMV7AX9 DN Indazole derivative 2 DMV7AX9 TI TTZJYKH DMV7AX9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMV7AX9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMV7AX9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMV7BF2 DI DMV7BF2 DMV7BF2 DN US10053465, 5 DMV7BF2 TI TTIEMFN DMV7BF2 TN TYRO3 tyrosine kinase receptor (TYRO3) DMV7BF2 MA Inhibitor DMV7BF2 RN Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333. DMV7BF2 RU http://www.freepatentsonline.com/US9708333.html DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT1LVF2 DMV7DFM TN Cyclin-dependent kinase 9 (CDK9) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TTH6V3D DMV7DFM TN Cyclin-dependent kinase 1 (CDK1) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT7HF4W DMV7DFM TN Cyclin-dependent kinase 2 (CDK2) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT0PG8F DMV7DFM TN Cyclin-dependent kinase 4 (CDK4) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7ISR DI DMV7ISR DMV7ISR DN PMID26004420-Compound-WO2013039802C DMV7ISR TI TTJ13ST DMV7ISR TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV7ISR MA Inhibitor DMV7ISR RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV7ISR RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV7IX4 DI DMV7IX4 DMV7IX4 DN Fused thiophene derivative 1 DMV7IX4 TI TTC7A6G DMV7IX4 TN Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935) DMV7IX4 MA Inhibitor DMV7IX4 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMV7IX4 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMV7IX4 DI DMV7IX4 DMV7IX4 DN Fused thiophene derivative 1 DMV7IX4 TI TTK0FEA DMV7IX4 TN Leucine-rich repeat kinase 2 (LRRK2) DMV7IX4 MA Inhibitor DMV7IX4 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMV7IX4 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMV7P4N DI DMV7P4N DMV7P4N DN PMID27744724-Compound-6 DMV7P4N TI TTL53M6 DMV7P4N TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV7P4N MA Inhibitor DMV7P4N RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV7P4N RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV7PNF DI DMV7PNF DMV7PNF DN PMID25684022-Compound-WO2006015124 DMV7PNF TI TTCZOF2 DMV7PNF TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMV7PNF MA Inhibitor DMV7PNF RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMV7PNF RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMV7SQH DI DMV7SQH DMV7SQH DN PMID25553724-Compound-US20138552206 4 DMV7SQH TI TTSXVID DMV7SQH TN Nuclear factor NF-kappa-B (NFKB) DMV7SQH MA Inhibitor DMV7SQH RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMV7SQH RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMV7TMB DI DMV7TMB DMV7TMB DN Benzimidazole derivative 6 DMV7TMB TI TTTDVOJ DMV7TMB TN Tropomyosin-related kinase A (TrkA) DMV7TMB MA Inhibitor DMV7TMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV7TMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV7TMB DI DMV7TMB DMV7TMB DN Benzimidazole derivative 6 DMV7TMB TI TTPMQSO DMV7TMB TN ALK tyrosine kinase receptor (ALK) DMV7TMB MA Inhibitor DMV7TMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV7TMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV9BQN DI DMV9BQN DMV9BQN DN PMID28092474-Compound-32o DMV9BQN TI TT6R7JZ DMV9BQN TN Histone deacetylase 1 (HDAC1) DMV9BQN MA Inhibitor DMV9BQN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMV9BQN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMV9BQN DI DMV9BQN DMV9BQN DN PMID28092474-Compound-32o DMV9BQN TI TT5ZKDI DMV9BQN TN Histone deacetylase 6 (HDAC6) DMV9BQN MA Inhibitor DMV9BQN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMV9BQN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMVA15O DI DMVA15O DMVA15O DN PMID29130358-Compound-Figure17(10) DMVA15O TI TTXZ0KQ DMVA15O TN Matrix metalloproteinase-12 (MMP-12) DMVA15O MA Inhibitor DMVA15O RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMVA15O RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMVA15O DI DMVA15O DMVA15O DN PMID29130358-Compound-Figure17(10) DMVA15O TI TT6X50U DMVA15O TN Matrix metalloproteinase-9 (MMP-9) DMVA15O MA Inhibitor DMVA15O RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMVA15O RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMVA7BC DI DMVA7BC DMVA7BC DN Tricyclic indole compound 9 DMVA7BC TI TTPTXIN DMVA7BC TN Translocator protein (TSPO) DMVA7BC MA Ligand DMVA7BC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMVA7BC RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMVA8KL DI DMVA8KL DMVA8KL DN Isoxazole-based bicyclic compound 12 DMVA8KL TI TTE4BSY DMVA8KL TN Bromodomain and extraterminal domain protein (BET) DMVA8KL MA Inhibitor DMVA8KL RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMVA8KL RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMVA95G DI DMVA95G DMVA95G DN Pyrrolo-pyrimidine derivative 5 DMVA95G TI TT4DXQT DMVA95G TN Proto-oncogene c-Ret (RET) DMVA95G MA Inhibitor DMVA95G RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMVA95G RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTS7G69 DMVABXI TN Fusion protein Bcr-Abl (Bcr-Abl) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTX41N9 DMVABXI TN Tyrosine-protein kinase Kit (KIT) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTI7421 DMVABXI TN Platelet-derived growth factor receptor beta (PDGFRB) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVAKUI DI DMVAKUI DMVAKUI DN Golden phosphorous acetyletic compound 1 DMVAKUI TI TTEP6RV DMVAKUI TN Glutathione reductase (GR) DMVAKUI MA Inhibitor DMVAKUI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVAKUI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVAKUI DI DMVAKUI DMVAKUI DN Golden phosphorous acetyletic compound 1 DMVAKUI TI TTR7UJ3 DMVAKUI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVAKUI MA Inhibitor DMVAKUI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVAKUI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVARUE DI DMVARUE DMVARUE DN Resorcinol compound 13 DMVARUE TI TTULVH8 DMVARUE TN Tyrosinase (TYR) DMVARUE MA Inhibitor DMVARUE RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVARUE RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVASXW DI DMVASXW DMVASXW DN PMID25399762-Compound-Table1-C11 DMVASXW TI TTGP7BY DMVASXW TN Monoamine oxidase type B (MAO-B) DMVASXW MA Inhibitor DMVASXW RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMVASXW RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMVB42P DI DMVB42P DMVB42P DN US8975409, Example 13 DMVB42P TI TTVSMOH DMVB42P TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMVB42P MA Inhibitor DMVB42P RN Phenyl derivative. US8975409. DMVB42P RU http://www.freepatentsonline.com/US8975409.html DMVBAUC DI DMVBAUC DMVBAUC DN Bromo benzyl ether derivative 2 DMVBAUC TI TT23XQV DMVBAUC TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMVBAUC MA Inhibitor DMVBAUC RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMVBAUC RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMVBJKH DI DMVBJKH DMVBJKH DN PMID27537201-Compound-Figure15a DMVBJKH TI TTPADOQ DMVBJKH TN HMG-CoA reductase (HMGCR) DMVBJKH MA Inhibitor DMVBJKH RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMVBJKH RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMVBPGI DI DMVBPGI DMVBPGI DN Quinoline derivative 6 DMVBPGI TI TTXJ47W DMVBPGI TN Metabotropic glutamate receptor 2 (mGluR2) DMVBPGI MA Antagonist DMVBPGI RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMVBPGI RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMVBPML DI DMVBPML DMVBPML DN PMID28766366-Compound-Scheme9EHT3356 DMVBPML TI TTYGQ8A DMVBPML TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVBPML MA Inhibitor DMVBPML RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVBPML RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVBPML DI DMVBPML DMVBPML DN PMID28766366-Compound-Scheme9EHT3356 DMVBPML TI TTSBVFO DMVBPML TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVBPML MA Inhibitor DMVBPML RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVBPML RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVBQJ1 DI DMVBQJ1 DMVBQJ1 DN Bicyclic heteroaryl benzamide derivative 8 DMVBQJ1 TI TTTDVOJ DMVBQJ1 TN Tropomyosin-related kinase A (TrkA) DMVBQJ1 MA Inhibitor DMVBQJ1 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVBQJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVBZKF DI DMVBZKF DMVBZKF DN Tetra-hydro-naphthalene derivative 3 DMVBZKF TI TTDP1UC DMVBZKF TN Fatty acid amide hydrolase (FAAH) DMVBZKF MA Inhibitor DMVBZKF RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMVBZKF RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMVC51O DI DMVC51O DMVC51O DN Benzothiazepine analog 11 DMVC51O TI TTRA6BO DMVC51O TN Bromodomain-containing protein 4 (BRD4) DMVC51O MA Inhibitor DMVC51O RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMVC51O RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMVCBSK DI DMVCBSK DMVCBSK DN PMID28270021-Compound-WO2014078408Example26 DMVCBSK TI TTTDVOJ DMVCBSK TN Tropomyosin-related kinase A (TrkA) DMVCBSK MA Inhibitor DMVCBSK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVCBSK RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVCKZT DI DMVCKZT DMVCKZT DN Phenylpropylamine derivative 1 DMVCKZT TI TT5TPI6 DMVCKZT TN Opioid receptor sigma 1 (OPRS1) DMVCKZT MA Ligand DMVCKZT RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMVCKZT RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMVCQKB DI DMVCQKB DMVCQKB DN PMID28870136-Compound-69 DMVCQKB TI TTK0O6Y DMVCQKB TN Ecto-5'-nucleotidase (CD73) DMVCQKB MA Inhibitor DMVCQKB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMVCQKB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMVCWXD DI DMVCWXD DMVCWXD DN US10022354, Example 151 DMVCWXD TI TTIG67W DMVCWXD TN Lysine-specific demethylase 5A (KDM5A) DMVCWXD MA Inhibitor DMVCWXD RN IRE-1 inhibitors DMVCWXD RU http://www.freepatentsonline.com/US10022354.html DMVD5TA DI DMVD5TA DMVD5TA DN Azachalcone derivative 1 DMVD5TA TI TT2F4OL DMVD5TA TN Tissue transglutaminase (TG2) DMVD5TA MA Inhibitor DMVD5TA RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMVD5TA RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMVDBHT DI DMVDBHT DMVDBHT DN PMID27724045-Compound-19 DMVDBHT TI TT473XN DMVDBHT TN P2X purinoceptor 7 (P2RX7) DMVDBHT MA Antagonist DMVDBHT RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMVDBHT RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMVDKXY DI DMVDKXY DMVDKXY DN PMID25666693-Compound-45 DMVDKXY TI TTMI6F5 DMVDKXY TN Transient receptor potential cation channel V1 (TRPV1) DMVDKXY MA Antagonist DMVDKXY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVDKXY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVEP6Y DI DMVEP6Y DMVEP6Y DN Pyrazolo[1,5-a]pyrimidine derivative 18 DMVEP6Y TI TTTDVOJ DMVEP6Y TN Tropomyosin-related kinase A (TrkA) DMVEP6Y MA Inhibitor DMVEP6Y RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMVEP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMVEQ2P DI DMVEQ2P DMVEQ2P DN PMID26560530-Compound-26 DMVEQ2P TI TT2F4OL DMVEQ2P TN Tissue transglutaminase (TG2) DMVEQ2P MA Inhibitor DMVEQ2P RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMVEQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMVF1BI DI DMVF1BI DMVF1BI DN Pyridine derivative 9 DMVF1BI TI TTOHSBA DMVF1BI TN Vascular endothelial growth factor A (VEGFA) DMVF1BI MA Inhibitor DMVF1BI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVF1BI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TT0K6EO DMVF1D6 TN Stress-activated protein kinase JNK1 (JNK1) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TTHS0U8 DMVF1D6 TN Stress-activated protein kinase JNK2 (JNK2) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TT056SO DMVF1D6 TN Stress-activated protein kinase JNK3 (JNK3) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF63N DI DMVF63N DMVF63N DN Biaryl mannoside derivative 4 DMVF63N TI TTTCRU2 DMVF63N TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMVF63N MA Antagonist DMVF63N RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMVF63N RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMVFBHD DI DMVFBHD DMVFBHD DN US9187437, 24 DMVFBHD TI TTDYP7I DMVFBHD TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVFBHD MA Inhibitor DMVFBHD RN Substituted oxadiazole compounds. US9187437. DMVFBHD RU http://www.freepatentsonline.com/US9187437.html DMVFSJZ DI DMVFSJZ DMVFSJZ DN Benzamide derivative 9 DMVFSJZ TI TT9NXW4 DMVFSJZ TN Sigma intracellular receptor 2 (TMEM97) DMVFSJZ MA Ligand DMVFSJZ RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMVFSJZ RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMVFSJZ DI DMVFSJZ DMVFSJZ DN Benzamide derivative 9 DMVFSJZ TI TT5TPI6 DMVFSJZ TN Opioid receptor sigma 1 (OPRS1) DMVFSJZ MA Ligand DMVFSJZ RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMVFSJZ RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMVFTIL DI DMVFTIL DMVFTIL DN PMID26651364-Compound-122 DMVFTIL TI TTTCRU2 DMVFTIL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMVFTIL MA Antagonist DMVFTIL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMVFTIL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMVG275 DI DMVG275 DMVG275 DN PMID28766366-Compound-Scheme15-1 DMVG275 TI TTSBVFO DMVG275 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVG275 MA Inhibitor DMVG275 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVG275 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVG7A5 DI DMVG7A5 DMVG7A5 DN PMID27539678-Compound-17 DMVG7A5 TI TTOHFIY DMVG7A5 TN Sphingosine kinase 1 (SPHK1) DMVG7A5 MA Inhibitor DMVG7A5 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMVG7A5 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMVGQXK DI DMVGQXK DMVGQXK DN US9682991, 2 DMVGQXK TI TTCGOIN DMVGQXK TN PIM-3 protein kinase (PIM3) DMVGQXK MA Inhibitor DMVGQXK RN Tricyclic compounds for use as kinase inhibitors. US9682991. DMVGQXK RU http://www.freepatentsonline.com/US9682991.html DMVHL3W DI DMVHL3W DMVHL3W DN 1,2-diamino cyclopentane-based derivative 34 DMVHL3W TI TT9N02I DMVHL3W TN Orexin receptor type 2 (HCRTR2) DMVHL3W MA Antagonist DMVHL3W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVHL3W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVHL3W DI DMVHL3W DMVHL3W DN 1,2-diamino cyclopentane-based derivative 34 DMVHL3W TI TT60Q8D DMVHL3W TN Orexin receptor type 1 (HCRTR1) DMVHL3W MA Antagonist DMVHL3W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVHL3W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVHLQM DI DMVHLQM DMVHLQM DN Phenylpyridine derivative 1 DMVHLQM TI TT1LVF2 DMVHLQM TN Cyclin-dependent kinase 9 (CDK9) DMVHLQM MA Inhibitor DMVHLQM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVHLQM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVI83P DI DMVI83P DMVI83P DN US8614253, 29-19 DMVI83P TI TTOJ9QL DMVI83P TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMVI83P MA Inhibitor DMVI83P RN IRE-1 inhibitors. US9493435. DMVI83P RU http://www.freepatentsonline.com/US9493435.html DMVIFXR DI DMVIFXR DMVIFXR DN Boronic acid derivative 4 DMVIFXR TI TTDP1UC DMVIFXR TN Fatty acid amide hydrolase (FAAH) DMVIFXR MA Inhibitor DMVIFXR RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMVIFXR RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMVISYC DI DMVISYC DMVISYC DN Carboxamide derivative 9 DMVISYC TI TTG5QB7 DMVISYC TN Calpain-2 (CAPN2) DMVISYC MA Inhibitor DMVISYC RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMVISYC RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMVIY73 DI DMVIY73 DMVIY73 DN PMID28117607-Compound-4 DMVIY73 TI TTK0FEA DMVIY73 TN Leucine-rich repeat kinase 2 (LRRK2) DMVIY73 MA Inhibitor DMVIY73 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVIY73 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVIZTY DI DMVIZTY DMVIZTY DN Cyclohexyl carbamate derivative 3 DMVIZTY TI TTULVH8 DMVIZTY TN Tyrosinase (TYR) DMVIZTY MA Inhibitor DMVIZTY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVIZTY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVJDRI DI DMVJDRI DMVJDRI DN PMID28766366-Compound-Scheme2WO2012/098065upper DMVJDRI TI TTYGQ8A DMVJDRI TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVJDRI MA Inhibitor DMVJDRI RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVJDRI RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVJDRI DI DMVJDRI DMVJDRI DN PMID28766366-Compound-Scheme2WO2012/098065upper DMVJDRI TI TTSBVFO DMVJDRI TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVJDRI MA Inhibitor DMVJDRI RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVJDRI RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVKCQU DI DMVKCQU DMVKCQU DN Pyrrolo[2,3-b]pyridine derivative 1 DMVKCQU TI TTTDVOJ DMVKCQU TN Tropomyosin-related kinase A (TrkA) DMVKCQU MA Inhibitor DMVKCQU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVKCQU RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVKO9C DI DMVKO9C DMVKO9C DN PMID25522065-Compound-12 DMVKO9C TI TTX4RTB DMVKO9C TN Melanin-concentrating hormone receptor 1 (MCHR1) DMVKO9C MA Antagonist DMVKO9C RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMVKO9C RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMVKZU2 DI DMVKZU2 DMVKZU2 DN Quinazoline derivative 12 DMVKZU2 TI TTQR74A DMVKZU2 TN Proteinase activated receptor 2 (PAR2) DMVKZU2 MA Antagonist DMVKZU2 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMVKZU2 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMVL25C DI DMVL25C DMVL25C DN PMID25726713-Compound-39 DMVL25C TI TT8J1S3 DMVL25C TN Smoothened homolog (SMO) DMVL25C MA Inhibitor DMVL25C RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMVL25C RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMVL2G3 DI DMVL2G3 DMVL2G3 DN Pyridine derivative 10 DMVL2G3 TI TTOHSBA DMVL2G3 TN Vascular endothelial growth factor A (VEGFA) DMVL2G3 MA Inhibitor DMVL2G3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVL2G3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVL57U DI DMVL57U DMVL57U DN US9388139, 12 DMVL57U TI TTN34SQ DMVL57U TN Phosphodiesterase 3B (PDE3B) DMVL57U MA Inhibitor DMVL57U RN Derivatives of celeboxib, use thereof and preparation thereof. US9388139. DMVL57U RU http://www.freepatentsonline.com/US9388139.html DMVLP8H DI DMVLP8H DMVLP8H DN Peptide analog 55 DMVLP8H TI TTQAJF1 DMVLP8H TN Cathepsin G (CTSG) DMVLP8H MA Inhibitor DMVLP8H RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMVLP8H RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMVLP8H DI DMVLP8H DMVLP8H DN Peptide analog 55 DMVLP8H TI TTPLTSQ DMVLP8H TN Neutrophil elastase (NE) DMVLP8H MA Inhibitor DMVLP8H RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMVLP8H RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMVLQ2P DI DMVLQ2P DMVLQ2P DN Aromatic bicyclic compound 1 DMVLQ2P TI TTRMX3V DMVLQ2P TN Janus kinase 2 (JAK-2) DMVLQ2P MA Inhibitor DMVLQ2P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMVLQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMVLQ2P DI DMVLQ2P DMVLQ2P DN Aromatic bicyclic compound 1 DMVLQ2P TI TT6PKBN DMVLQ2P TN Proto-oncogene c-Src (SRC) DMVLQ2P MA Inhibitor DMVLQ2P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMVLQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMVLXRB DI DMVLXRB DMVLXRB DN PMID27019002-Compound-41 DMVLXRB TI TTNR0UQ DMVLXRB TN Lysine-specific histone demethylase 1 (LSD) DMVLXRB MA Inhibitor DMVLXRB RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMVLXRB RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMVM31E DI DMVM31E DMVM31E DN PMID27967267-Compound-28 DMVM31E TI TT1RS9F DMVM31E TN Acetylcholinesterase (AChE) DMVM31E RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMVM31E RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMVMD2O DI DMVMD2O DMVMD2O DN Imidazolidine-2,4-dione derivative 2 DMVMD2O TI TT6OEDT DMVMD2O TN Cannabinoid receptor 1 (CB1) DMVMD2O MA Antagonist DMVMD2O RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVMD2O RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVMNP1 DI DMVMNP1 DMVMNP1 DN US10166249, Example 695 DMVMNP1 TI TTDYP7I DMVMNP1 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVMNP1 MA Inhibitor DMVMNP1 RN Substituted bicyclic compounds. US10166249. DMVMNP1 RU http://www.freepatentsonline.com/US10166249.html DMVMSQ2 DI DMVMSQ2 DMVMSQ2 DN PMID25656651-Compound-30a DMVMSQ2 TI TTS7G69 DMVMSQ2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMVMSQ2 MA Inhibitor DMVMSQ2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVMSQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVMT26 DI DMVMT26 DMVMT26 DN PMID25399762-Compound-Table1-C9 DMVMT26 TI TTGP7BY DMVMT26 TN Monoamine oxidase type B (MAO-B) DMVMT26 MA Inhibitor DMVMT26 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMVMT26 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMVN5BD DI DMVN5BD DMVN5BD DN PMID27724045-Compound-15 DMVN5BD TI TT473XN DMVN5BD TN P2X purinoceptor 7 (P2RX7) DMVN5BD MA Antagonist DMVN5BD RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMVN5BD RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMVNY5I DI DMVNY5I DMVNY5I DN Pyrrolo-pyridine derivative 2 DMVNY5I TI TT6AXLY DMVNY5I TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DMVNY5I MA Inhibitor DMVNY5I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVNY5I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVNY5I DI DMVNY5I DMVNY5I DN Pyrrolo-pyridine derivative 2 DMVNY5I TI TTK0FEA DMVNY5I TN Leucine-rich repeat kinase 2 (LRRK2) DMVNY5I MA Inhibitor DMVNY5I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVNY5I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVOEN7 DI DMVOEN7 DMVOEN7 DN Cyclic compound 3 DMVOEN7 TI TTNBFWK DMVOEN7 TN Programmed cell death protein 1 (PD-1) DMVOEN7 MA Inhibitor DMVOEN7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMVOEN7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMVOTKN DI DMVOTKN DMVOTKN DN Thiazole carboxamide derivative 8 DMVOTKN TI TTCZOF2 DMVOTKN TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMVOTKN MA Inhibitor DMVOTKN RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMVOTKN RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TT0K6EO DMVOWS5 TN Stress-activated protein kinase JNK1 (JNK1) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TT056SO DMVOWS5 TN Stress-activated protein kinase JNK3 (JNK3) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TTHS0U8 DMVOWS5 TN Stress-activated protein kinase JNK2 (JNK2) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TT0K1SC DMVOYJ8 TN 5-HT 2B receptor (HTR2B) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TTWJBZ5 DMVOYJ8 TN 5-HT 2C receptor (HTR2C) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TTJQOD7 DMVOYJ8 TN 5-HT 2A receptor (HTR2A) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVP16K DI DMVP16K DMVP16K DN PMID30259754-Compound-pyrrole[2,3-d]azepines DMVP16K TI TTS4UGC DMVP16K TN Farnesoid X-activated receptor (FXR) DMVP16K MA Agonist DMVP16K RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DMVP16K RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DMVP7DL DI DMVP7DL DMVP7DL DN PMID29473428-Compound-58 DMVP7DL TI TTZJYKH DMVP7DL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMVP7DL MA Inhibitor DMVP7DL RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVP7DL RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT8M4E1 DMVPMWJ TN Histone deacetylase 9 (HDAC9) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTUELN5 DMVPMWJ TN Histone deacetylase 5 (HDAC5) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTTQGH8 DMVPMWJ TN Histone deacetylase 4 (HDAC4) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTMUEK1 DMVPMWJ TN Histone deacetylase 7 (HDAC7) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTT6LFV DMVPMWJ TN Histone deacetylase 8 (HDAC8) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT4YWTO DMVPMWJ TN Histone deacetylase 3 (HDAC3) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTSHTOI DMVPMWJ TN Histone deacetylase 2 (HDAC2) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT6R7JZ DMVPMWJ TN Histone deacetylase 1 (HDAC1) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTYHPU6 DMVPMWJ TN Histone deacetylase 10 (HDAC10) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT8K17W DMVPMWJ TN Histone deacetylase 11 (HDAC11) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT5ZKDI DMVPMWJ TN Histone deacetylase 6 (HDAC6) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPR1D DI DMVPR1D DMVPR1D DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11 DMVPR1D TI TTULVH8 DMVPR1D TN Tyrosinase (TYR) DMVPR1D MA Inhibitor DMVPR1D RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVPR1D RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVQ3IX DI DMVQ3IX DMVQ3IX DN US9453017, 1 DMVQ3IX TI TT3T17P DMVQ3IX TN Phospholipase D1 (PLD1) DMVQ3IX MA Inhibitor DMVQ3IX RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMVQ3IX RU http://www.freepatentsonline.com/US9453017.html DMVQ4NS DI DMVQ4NS DMVQ4NS DN Pyrimidine benzenesulfonamide derivative 2 DMVQ4NS TI TTIY56R DMVQ4NS TN Kynurenine 3-hydroxylase (KMO) DMVQ4NS MA Inhibitor DMVQ4NS RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMVQ4NS RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMVQSYT DI DMVQSYT DMVQSYT DN PMID26004420-Compound-US20140031349A DMVQSYT TI TTJ13ST DMVQSYT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMVQSYT MA Inhibitor DMVQSYT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMVQSYT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TTOUSTQ DMVQTR2 TN Proteasome beta-9 (PS beta-9) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TT8EPLT DMVQTR2 TN Proteasome beta-1 (PS beta-1) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TT68GPI DMVQTR2 TN Proteasome beta-5 (PS beta-5) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TTEAD9J DMVQTR2 TN Proteasome beta-8 (PS beta-8) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQU9T DI DMVQU9T DMVQU9T DN PMID25666693-Compound-140 DMVQU9T TI TTMI6F5 DMVQU9T TN Transient receptor potential cation channel V1 (TRPV1) DMVQU9T MA Antagonist DMVQU9T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVQU9T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVQXZJ DI DMVQXZJ DMVQXZJ DN Pyrazole-3-carboxamide derivative 1 DMVQXZJ TI TT0K1SC DMVQXZJ TN 5-HT 2B receptor (HTR2B) DMVQXZJ MA Antagonist DMVQXZJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVQXZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVR04K DI DMVR04K DMVR04K DN Indandione derivative 2 DMVR04K TI TTV1C0Z DMVR04K TN Neuropeptide S receptor (NPSR) DMVR04K MA Antagonist DMVR04K RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMVR04K RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMVR9TJ DI DMVR9TJ DMVR9TJ DN PMID27841045-Compound-135 DMVR9TJ TI TT7RJY8 DMVR9TJ TN Xanthine dehydrogenase/oxidase (XDH) DMVR9TJ MA Inhibitor DMVR9TJ RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMVR9TJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMVREIM DI DMVREIM DMVREIM DN PMID25666693-Compound-120 DMVREIM TI TTMI6F5 DMVREIM TN Transient receptor potential cation channel V1 (TRPV1) DMVREIM MA Antagonist DMVREIM RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVREIM RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVRJZX DI DMVRJZX DMVRJZX DN PMID28870136-Compound-55 DMVRJZX TI TTK0O6Y DMVRJZX TN Ecto-5'-nucleotidase (CD73) DMVRJZX MA Inhibitor DMVRJZX RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMVRJZX RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMVRX7S DI DMVRX7S DMVRX7S DN Indole-based analog 11 DMVRX7S TI TTBH0VX DMVRX7S TN Histone deacetylase (HDAC) DMVRX7S MA Inhibitor DMVRX7S RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVRX7S RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVRX7S DI DMVRX7S DMVRX7S DN Indole-based analog 11 DMVRX7S TI TT7HF4W DMVRX7S TN Cyclin-dependent kinase 2 (CDK2) DMVRX7S MA Inhibitor DMVRX7S RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVRX7S RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVS1TU DI DMVS1TU DMVS1TU DN PMID26666989-Compound-Figure9topright01 DMVS1TU TI TT8BUGW DMVS1TU TN Glycogen phosphorylase (PYG) DMVS1TU MA Inhibitor DMVS1TU RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMVS1TU RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMVS7CJ DI DMVS7CJ DMVS7CJ DN PMID28270021-Compound-WO2013009582Example16 DMVS7CJ TI TTTDVOJ DMVS7CJ TN Tropomyosin-related kinase A (TrkA) DMVS7CJ MA Inhibitor DMVS7CJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVS7CJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVSFNE DI DMVSFNE DMVSFNE DN PMID25666693-Compound-12 DMVSFNE TI TTMI6F5 DMVSFNE TN Transient receptor potential cation channel V1 (TRPV1) DMVSFNE MA Antagonist DMVSFNE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVSFNE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTR7B60 DMVSW5N TN X-linked inhibitor of apoptosis protein (XIAP) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTHZ8TA DMVSW5N TN Melanoma inhibitor of apoptosis protein (ML-IAP) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTQ5LRD DMVSW5N TN Cellular inhibitor of apoptosis 1 (BIRC2) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSXUM DI DMVSXUM DMVSXUM DN Imidazole derivative 5 DMVSXUM TI TT6OEDT DMVSXUM TN Cannabinoid receptor 1 (CB1) DMVSXUM MA Antagonist DMVSXUM RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVSXUM RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVTARK DI DMVTARK DMVTARK DN Heteroaryl-carboxamide derivative 10 DMVTARK TI TTCZOF2 DMVTARK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMVTARK MA Inhibitor DMVTARK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMVTARK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMVTPHY DI DMVTPHY DMVTPHY DN PMID27607364-Compound-63 DMVTPHY TI TTPTXIN DMVTPHY TN Translocator protein (TSPO) DMVTPHY MA Ligand DMVTPHY RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVTPHY RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVTZ6S DI DMVTZ6S DMVTZ6S DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 2 DMVTZ6S TI TT6OEDT DMVTZ6S TN Cannabinoid receptor 1 (CB1) DMVTZ6S MA Antagonist DMVTZ6S RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVTZ6S RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVU9RG DI DMVU9RG DMVU9RG DN Fused heterocyclic compound 1 DMVU9RG TI TT7RJY8 DMVU9RG TN Xanthine dehydrogenase/oxidase (XDH) DMVU9RG MA Inhibitor DMVU9RG RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMVU9RG RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMVUJGI DI DMVUJGI DMVUJGI DN Azole derivative 7 DMVUJGI TI TTF8P9I DMVUJGI TN Diacylglycerol acyltransferase 1 (DGAT1) DMVUJGI MA Inhibitor DMVUJGI RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMVUJGI RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMVUNYD DI DMVUNYD DMVUNYD DN Quinoline carboxamide derivative 4 DMVUNYD TI TTPTXIN DMVUNYD TN Translocator protein (TSPO) DMVUNYD MA Ligand DMVUNYD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVUNYD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVUSF3 DI DMVUSF3 DMVUSF3 DN Pyrazolopyrimidine derivative 5 DMVUSF3 TI TTHS256 DMVUSF3 TN Metabotropic glutamate receptor 5 (mGluR5) DMVUSF3 MA Modulator DMVUSF3 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMVUSF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMVUWLK DI DMVUWLK DMVUWLK DN Indazole derivative 3 DMVUWLK TI TTXNCBV DMVUWLK TN Tryptophan 2,3-dioxygenase (TDO) DMVUWLK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVUWLK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVUWLK DI DMVUWLK DMVUWLK DN Indazole derivative 3 DMVUWLK TI TTZJYKH DMVUWLK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMVUWLK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVUWLK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVUWYB DI DMVUWYB DMVUWYB DN PMID27599163-Compound-79 DMVUWYB TI TTPTXIN DMVUWYB TN Translocator protein (TSPO) DMVUWYB MA Ligand DMVUWYB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMVUWYB RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMVW25O DI DMVW25O DMVW25O DN Pyrimidine derivative 8 DMVW25O TI TTOHSBA DMVW25O TN Vascular endothelial growth factor A (VEGFA) DMVW25O MA Inhibitor DMVW25O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVW25O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVWF6I DI DMVWF6I DMVWF6I DN PMID25772215-Compound-EP20082149552C9 DMVWF6I TI TT1ZAVI DMVWF6I TN Prostaglandin E2 receptor EP2 (PTGER2) DMVWF6I MA Antagonist DMVWF6I RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVWF6I RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVX2D0 DI DMVX2D0 DMVX2D0 DN Pyrazole derivative 24 DMVX2D0 TI TT6OEDT DMVX2D0 TN Cannabinoid receptor 1 (CB1) DMVX2D0 MA Antagonist DMVX2D0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVX2D0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TT68GPI DMVX71N TN Proteasome beta-5 (PS beta-5) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TT49BVC DMVX71N TN Proteasome beta-2 (PS beta-2) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TTPNACM DMVX71N TN Proteasome beta-10 (PS beta-10) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX7YB DI DMVX7YB DMVX7YB DN Imidazo[1,2-b]pyridazine acetamide derivative 2 DMVX7YB TI TTPTXIN DMVX7YB TN Translocator protein (TSPO) DMVX7YB MA Ligand DMVX7YB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVX7YB RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVX7YT DI DMVX7YT DMVX7YT DN Pyrazole N-1 aryl and heteroaryl derivative 1 DMVX7YT TI TTKFVXR DMVX7YT TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMVX7YT MA Inhibitor DMVX7YT RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMVX7YT RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMVX9NK DI DMVX9NK DMVX9NK DN AC1LOJYQ DMVX9NK TI TTLKF5M DMVX9NK TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMVX9NK MA Inhibitor DMVX9NK RN Small molecule activators of NRF2 pathway. US9737525. DMVX9NK RU http://www.freepatentsonline.com/US9737525.html DMVXTIL DI DMVXTIL DMVXTIL DN PMID27998201-Compound-10 DMVXTIL TI TTDZN01 DMVXTIL TN Cathepsin K (CTSK) DMVXTIL MA Inhibitor DMVXTIL RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVXTIL RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVY0JT DI DMVY0JT DMVY0JT DN Pyrazole derivative 68 DMVY0JT TI TTJQOD7 DMVY0JT TN 5-HT 2A receptor (HTR2A) DMVY0JT MA Antagonist DMVY0JT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVY0JT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVY6B9 DI DMVY6B9 DMVY6B9 DN PMID27109571-Compound-14 DMVY6B9 TI TTNT2S6 DMVY6B9 TN Fatty acid-binding protein 5 (FABP5) DMVY6B9 MA Inhibitor DMVY6B9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMVY6B9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMVY6B9 DI DMVY6B9 DMVY6B9 DN PMID27109571-Compound-14 DMVY6B9 TI TTHWMFZ DMVY6B9 TN Fatty acid-binding protein 4 (FABP4) DMVY6B9 MA Inhibitor DMVY6B9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMVY6B9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMVY6PX DI DMVY6PX DMVY6PX DN PMID28766366-Compound-Scheme9EHT6840 DMVY6PX TI TTYGQ8A DMVY6PX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVY6PX MA Inhibitor DMVY6PX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVY6PX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVY6PX DI DMVY6PX DMVY6PX DN PMID28766366-Compound-Scheme9EHT6840 DMVY6PX TI TTSBVFO DMVY6PX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVY6PX MA Inhibitor DMVY6PX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVY6PX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVYG0U DI DMVYG0U DMVYG0U DN PMID28594589-Compound-TABLE3C2 DMVYG0U TI TTZCRP3 DMVYG0U TN ERK activator kinase (MEK) DMVYG0U MA Inhibitor DMVYG0U RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMVYG0U RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMVYO09 DI DMVYO09 DMVYO09 DN PMID27977313-Compound-27 DMVYO09 TI TTR7UJ3 DMVYO09 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVYO09 MA Inhibitor DMVYO09 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVYO09 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVYP8K DI DMVYP8K DMVYP8K DN Phenylalanine derivative 1 DMVYP8K TI TT36ETB DMVYP8K TN Cathepsin L (CTSL) DMVYP8K MA Inhibitor DMVYP8K RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVYP8K RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVYP8K DI DMVYP8K DMVYP8K DN Phenylalanine derivative 1 DMVYP8K TI TTUMQVO DMVYP8K TN Cathepsin S (CTSS) DMVYP8K MA Inhibitor DMVYP8K RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVYP8K RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVYQXH DI DMVYQXH DMVYQXH DN US8470836, 6 DMVYQXH TI TTOYT5L DMVYQXH TN Dipeptidyl-peptidase 7 (DPP7) DMVYQXH MA Inhibitor DMVYQXH RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMVYQXH RU http://www.freepatentsonline.com/US8470836.html DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTDZN01 DMVZ0ND TN Cathepsin K (CTSK) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TT36ETB DMVZ0ND TN Cathepsin L (CTSL) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTF2LRI DMVZ0ND TN Cathepsin B (CTSB) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTUMQVO DMVZ0ND TN Cathepsin S (CTSS) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTJOKD1 DMVZ0ND TN Cathepsin F (CTSF) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ5EP DI DMVZ5EP DMVZ5EP DN 1,2-diamino cyclopentane-based derivative 31 DMVZ5EP TI TT9N02I DMVZ5EP TN Orexin receptor type 2 (HCRTR2) DMVZ5EP MA Antagonist DMVZ5EP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVZ5EP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVZ5EP DI DMVZ5EP DMVZ5EP DN 1,2-diamino cyclopentane-based derivative 31 DMVZ5EP TI TT60Q8D DMVZ5EP TN Orexin receptor type 1 (HCRTR1) DMVZ5EP MA Antagonist DMVZ5EP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVZ5EP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVZ8KD DI DMVZ8KD DMVZ8KD DN Pyrazole derivative 18 DMVZ8KD TI TT6OEDT DMVZ8KD TN Cannabinoid receptor 1 (CB1) DMVZ8KD MA Antagonist DMVZ8KD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVZ8KD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVZA0U DI DMVZA0U DMVZA0U DN PMID30273516-Compound-22a DMVZA0U TI TTCW0KX DMVZA0U TN Glutaminase (GLS) DMVZA0U MA Inhibitor DMVZA0U RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMVZA0U RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMVZPIO DI DMVZPIO DMVZPIO DN PMID28447479-Compound-27 DMVZPIO TI TTSCIM2 DMVZPIO TN Extracellular lysophospholipase D (E-NPP2) DMVZPIO MA Agonist DMVZPIO RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMVZPIO RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMW039D DI DMW039D DMW039D DN Aminopyrimidine derivative 4 DMW039D TI TTS7G69 DMW039D TN Fusion protein Bcr-Abl (Bcr-Abl) DMW039D MA Inhibitor DMW039D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMW039D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMW0TM1 DI DMW0TM1 DMW0TM1 DN PMID27454349-Compound-96 DMW0TM1 TI TTK59TV DMW0TM1 TN Vitamin D3 receptor (VDR) DMW0TM1 MA Agonist DMW0TM1 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMW0TM1 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMW1PL7 DI DMW1PL7 DMW1PL7 DN NG7 DMW1PL7 TI TTI1FPZ DMW1PL7 TN Epithelial discoidin domain receptor 1 (DDR1) DMW1PL7 MA Inhibitor DMW1PL7 RN Fused 2-aminothiazole compounds. US8765747. DMW1PL7 RU http://www.freepatentsonline.com/US8765747.html DMW21U4 DI DMW21U4 DMW21U4 DN PMID28092474-Compound-32d DMW21U4 TI TT6R7JZ DMW21U4 TN Histone deacetylase 1 (HDAC1) DMW21U4 MA Inhibitor DMW21U4 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW21U4 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW21U4 DI DMW21U4 DMW21U4 DN PMID28092474-Compound-32d DMW21U4 TI TT5ZKDI DMW21U4 TN Histone deacetylase 6 (HDAC6) DMW21U4 MA Inhibitor DMW21U4 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW21U4 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW2C19 DI DMW2C19 DMW2C19 DN PMID25435285-Compound-40 DMW2C19 TI TTXJ47W DMW2C19 TN Metabotropic glutamate receptor 2 (mGluR2) DMW2C19 MA Antagonist DMW2C19 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMW2C19 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMW2JG8 DI DMW2JG8 DMW2JG8 DN Pyrrolidinyl urea derivative 8 DMW2JG8 TI TTTDVOJ DMW2JG8 TN Tropomyosin-related kinase A (TrkA) DMW2JG8 MA Inhibitor DMW2JG8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMW2JG8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMW2LD5 DI DMW2LD5 DMW2LD5 DN Nicotinyl hydroxamic acid derivative 1 DMW2LD5 TI TTULVH8 DMW2LD5 TN Tyrosinase (TYR) DMW2LD5 MA Inhibitor DMW2LD5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMW2LD5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTKAWRQ DMW2LZ0 TN JAK-STAT signaling pathway (JAK-STAT pathway) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTJSQEF DMW2LZ0 TN Tyrosine-protein kinase (PTK) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTT7PJU DMW2LZ0 TN Janus kinase 3 (JAK-3) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTBYWP2 DMW2LZ0 TN TYK2 tyrosine kinase (TYK2) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTRMX3V DMW2LZ0 TN Janus kinase 2 (JAK-2) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TT6DM01 DMW2LZ0 TN Janus kinase 1 (JAK-1) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2N5D DI DMW2N5D DMW2N5D DN PMID27109571-Compound-1 DMW2N5D TI TTMY6L1 DMW2N5D TN Fatty acid-binding protein (FABP) DMW2N5D MA Inhibitor DMW2N5D RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMW2N5D RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMW2S0J DI DMW2S0J DMW2S0J DN PMID30185082-Compound-63 DMW2S0J TI TT9NXW4 DMW2S0J TN Sigma intracellular receptor 2 (TMEM97) DMW2S0J MA Ligand DMW2S0J RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMW2S0J RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMW2ZRM DI DMW2ZRM DMW2ZRM DN PMID28270021-Compound-WO2016054807Example112 DMW2ZRM TI TTTDVOJ DMW2ZRM TN Tropomyosin-related kinase A (TrkA) DMW2ZRM MA Inhibitor DMW2ZRM RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMW2ZRM RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMW38MK DI DMW38MK DMW38MK DN PMID28092474-Compound-33d DMW38MK TI TT5ZKDI DMW38MK TN Histone deacetylase 6 (HDAC6) DMW38MK MA Inhibitor DMW38MK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW38MK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW38MK DI DMW38MK DMW38MK DN PMID28092474-Compound-33d DMW38MK TI TT6R7JZ DMW38MK TN Histone deacetylase 1 (HDAC1) DMW38MK MA Inhibitor DMW38MK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW38MK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW3EMH DI DMW3EMH DMW3EMH DN 7-azaindole derivative 4 DMW3EMH TI TT056SO DMW3EMH TN Stress-activated protein kinase JNK3 (JNK3) DMW3EMH MA Inhibitor DMW3EMH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMW3EMH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMW3JH0 DI DMW3JH0 DMW3JH0 DN Quinoline and quinazoline derivative 8 DMW3JH0 TI TTOHSBA DMW3JH0 TN Vascular endothelial growth factor A (VEGFA) DMW3JH0 MA Inhibitor DMW3JH0 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMW3JH0 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMW3JZV DI DMW3JZV DMW3JZV DN Isoxazoles and isoxazoline derivative 4 DMW3JZV TI TTIY56R DMW3JZV TN Kynurenine 3-hydroxylase (KMO) DMW3JZV MA Inhibitor DMW3JZV RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMW3JZV RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMW3PJV DI DMW3PJV DMW3PJV DN Pyrazole derivative 86 DMW3PJV TI TT5TPI6 DMW3PJV TN Opioid receptor sigma 1 (OPRS1) DMW3PJV MA Inhibitor DMW3PJV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMW3PJV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMW3X1I DI DMW3X1I DMW3X1I DN PMID27788040-Compound-5a DMW3X1I TI TTV1C0Z DMW3X1I TN Neuropeptide S receptor (NPSR) DMW3X1I MA Antagonist DMW3X1I RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMW3X1I RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMW4B1U DI DMW4B1U DMW4B1U DN Carbamate derivative 9 DMW4B1U TI TTDP1UC DMW4B1U TN Fatty acid amide hydrolase (FAAH) DMW4B1U MA Inhibitor DMW4B1U RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMW4B1U RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMW4B1U DI DMW4B1U DMW4B1U DN Carbamate derivative 9 DMW4B1U TI TTZ963I DMW4B1U TN Monoglyceride lipase (MAGL) DMW4B1U MA Inhibitor DMW4B1U RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMW4B1U RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMW4J0P DI DMW4J0P DMW4J0P DN Chloroacetyl ester derivative 1 DMW4J0P TI TT2F4OL DMW4J0P TN Tissue transglutaminase (TG2) DMW4J0P MA Inhibitor DMW4J0P RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMW4J0P RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMW4JB0 DI DMW4JB0 DMW4JB0 DN Cycloalkyl nitrile pyrazolo pyridone derivative 2 DMW4JB0 TI TTRMX3V DMW4JB0 TN Janus kinase 2 (JAK-2) DMW4JB0 MA Inhibitor DMW4JB0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMW4JB0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMW4JB0 DI DMW4JB0 DMW4JB0 DN Cycloalkyl nitrile pyrazolo pyridone derivative 2 DMW4JB0 TI TT6DM01 DMW4JB0 TN Janus kinase 1 (JAK-1) DMW4JB0 MA Inhibitor DMW4JB0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMW4JB0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMW4NXV DI DMW4NXV DMW4NXV DN Benzene sulfonamide derivative 5 DMW4NXV TI TTIY56R DMW4NXV TN Kynurenine 3-hydroxylase (KMO) DMW4NXV MA Inhibitor DMW4NXV RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMW4NXV RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMW502M DI DMW502M DMW502M DN Peptide analog 66 DMW502M TI TTPLTSQ DMW502M TN Neutrophil elastase (NE) DMW502M MA Inhibitor DMW502M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMW502M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMW57UB DI DMW57UB DMW57UB DN Alkyl mannoside derivative 1 DMW57UB TI TTTCRU2 DMW57UB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMW57UB MA Antagonist DMW57UB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMW57UB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMW59Q4 DI DMW59Q4 DMW59Q4 DN Thiazole carboxamide derivative 19 DMW59Q4 TI TTCZOF2 DMW59Q4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMW59Q4 MA Inhibitor DMW59Q4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMW59Q4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMW5DC1 DI DMW5DC1 DMW5DC1 DN 1,2,3,4-tetrahydroisoquinoline derivative 1 DMW5DC1 TI TTA6ZN2 DMW5DC1 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMW5DC1 MA Inhibitor DMW5DC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW5DC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW5DC1 DI DMW5DC1 DMW5DC1 DN 1,2,3,4-tetrahydroisoquinoline derivative 1 DMW5DC1 TI TTGIZLN DMW5DC1 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMW5DC1 MA Modulator DMW5DC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW5DC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW5GI3 DI DMW5GI3 DMW5GI3 DN Carbamide derivative 2 DMW5GI3 TI TTO9X1H DMW5GI3 TN 5-HT 7 receptor (HTR7) DMW5GI3 MA Inhibitor DMW5GI3 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMW5GI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMW5SD6 DI DMW5SD6 DMW5SD6 DN BDBM50011552 DMW5SD6 TI TT6NI13 DMW5SD6 TN MEK kinase kinase 4 (MAP4K4) DMW5SD6 MA Inhibitor DMW5SD6 RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMW5SD6 RU http://www.freepatentsonline.com/US9592235.html DMW5YJB DI DMW5YJB DMW5YJB DN Quinoline carboxamide derivative 1 DMW5YJB TI TTH8FZW DMW5YJB TN Signal transducer and activator of transcription 3 (STAT3) DMW5YJB MA Inhibitor DMW5YJB RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMW5YJB RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMW60HU DI DMW60HU DMW60HU DN PMID27109571-Compound-10 DMW60HU TI TTHWMFZ DMW60HU TN Fatty acid-binding protein 4 (FABP4) DMW60HU MA Inhibitor DMW60HU RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMW60HU RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMW62LX DI DMW62LX DMW62LX DN Thiazole carboxamide derivative 1 DMW62LX TI TTCZOF2 DMW62LX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMW62LX MA Inhibitor DMW62LX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMW62LX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMW6R0H DI DMW6R0H DMW6R0H DN Isoquinolone derivative 1 DMW6R0H TI TT5ZWB6 DMW6R0H TN Dihydrodiol dehydrogenase type I (AKR1C3) DMW6R0H MA Inhibitor; Antagonist; Blocker DMW6R0H RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMW6R0H RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMW7981 DI DMW7981 DMW7981 DN PMID25666693-Compound-33 DMW7981 TI TTMI6F5 DMW7981 TN Transient receptor potential cation channel V1 (TRPV1) DMW7981 MA Antagonist DMW7981 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMW7981 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMW7HKS DI DMW7HKS DMW7HKS DN Aryl sulphoxide imine derivative 1 DMW7HKS TI TTZJYKH DMW7HKS TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMW7HKS MA Inhibitor DMW7HKS RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMW7HKS RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMW7T45 DI DMW7T45 DMW7T45 DN PMID29649907-Compound-23 DMW7T45 TI TTS4UGC DMW7T45 TN Farnesoid X-activated receptor (FXR) DMW7T45 MA Agonist DMW7T45 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMW7T45 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMW86YI DI DMW86YI DMW86YI DN 3-phenyl propanoic derivative 1 DMW86YI TI TTA6ZN2 DMW86YI TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMW86YI MA Inhibitor DMW86YI RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW86YI RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW86YI DI DMW86YI DMW86YI DN 3-phenyl propanoic derivative 1 DMW86YI TI TTHQJI6 DMW86YI TN Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE) DMW86YI MA Modulator DMW86YI RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW86YI RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW8V4R DI DMW8V4R DMW8V4R DN PMID30185082-Compound-55 DMW8V4R TI TT9NXW4 DMW8V4R TN Sigma intracellular receptor 2 (TMEM97) DMW8V4R MA Ligand DMW8V4R RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMW8V4R RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMW8XD2 DI DMW8XD2 DMW8XD2 DN PMID25666693-Compound-72 DMW8XD2 TI TTMI6F5 DMW8XD2 TN Transient receptor potential cation channel V1 (TRPV1) DMW8XD2 MA Antagonist DMW8XD2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMW8XD2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMW94IQ DI DMW94IQ DMW94IQ DN Benzothiazine-carboxamide compound 6 DMW94IQ TI TTQR74A DMW94IQ TN Proteinase activated receptor 2 (PAR2) DMW94IQ MA Antagonist DMW94IQ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMW94IQ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMW98RI DI DMW98RI DMW98RI DN Aminopyrimidine derivative 7 DMW98RI TI TTH5TC2 DMW98RI TN NF-kappa-B-activating kinase (TBK1) DMW98RI MA Inhibitor DMW98RI RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMW98RI RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMW9P6U DI DMW9P6U DMW9P6U DN ZINC915379 DMW9P6U TI TTLKF5M DMW9P6U TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMW9P6U MA Inhibitor DMW9P6U RN Small molecule activators of NRF2 pathway. US9737525. DMW9P6U RU http://www.freepatentsonline.com/US9737525.html DMWA7RB DI DMWA7RB DMWA7RB DN Isoxazole-based bicyclic compound 9 DMWA7RB TI TTE4BSY DMWA7RB TN Bromodomain and extraterminal domain protein (BET) DMWA7RB MA Inhibitor DMWA7RB RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWA7RB RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWABOJ DI DMWABOJ DMWABOJ DN Imidazo [1,2-a]pyridine compound 1 DMWABOJ TI TTUX68I DMWABOJ TN Hypoxia-inducible factor 1 (HIF-1) DMWABOJ MA Inhibitor DMWABOJ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMWABOJ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMWAL5Q DI DMWAL5Q DMWAL5Q DN US9409892, 59 DMWAL5Q TI TT9ISBX DMWAL5Q TN HIF-prolyl hydroxylase 2 (HPH-2) DMWAL5Q MA Inhibitor DMWAL5Q RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMWAL5Q RU http://www.freepatentsonline.com/US9409892.html DMWALOT DI DMWALOT DMWALOT DN PMID25522065-Compound-41 DMWALOT TI TTX4RTB DMWALOT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMWALOT MA Antagonist DMWALOT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMWALOT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMWAU49 DI DMWAU49 DMWAU49 DN Cyclic sulfonamide derivative 4 DMWAU49 TI TT8J1S3 DMWAU49 TN Smoothened homolog (SMO) DMWAU49 MA Inhibitor DMWAU49 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMWAU49 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMWAYXP DI DMWAYXP DMWAYXP DN Piperidinyl pyrazole derivative 1 DMWAYXP TI TTTJZ4M DMWAYXP TN Prolylcarboxypeptidase (PRCP) DMWAYXP MA Inhibitor DMWAYXP RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMWAYXP RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMWB2YX DI DMWB2YX DMWB2YX DN 4-aryl quinol derivative 5 DMWB2YX TI TTR7UJ3 DMWB2YX TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWB2YX MA Inhibitor DMWB2YX RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWB2YX RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWC1IY DI DMWC1IY DMWC1IY DN PMID26560530-Compound-47 DMWC1IY TI TT2F4OL DMWC1IY TN Tissue transglutaminase (TG2) DMWC1IY MA Inhibitor DMWC1IY RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMWC1IY RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMWC3P5 DI DMWC3P5 DMWC3P5 DN Lactol derivative 1 DMWC3P5 TI TTPADOQ DMWC3P5 TN HMG-CoA reductase (HMGCR) DMWC3P5 MA Inhibitor DMWC3P5 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMWC3P5 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMWCM2I DI DMWCM2I DMWCM2I DN PMID26560530-Compound-24 DMWCM2I TI TT2F4OL DMWCM2I TN Tissue transglutaminase (TG2) DMWCM2I MA Inhibitor DMWCM2I RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMWCM2I RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMWCT04 DI DMWCT04 DMWCT04 DN 3-substituted-1,2,4-oxadiazole derivative 1 DMWCT04 TI TT23XQV DMWCT04 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMWCT04 MA Inhibitor DMWCT04 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMWCT04 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMWD1FP DI DMWD1FP DMWD1FP DN PMID25772215-Compound-US02014179750TG6-10-1 DMWD1FP TI TT1ZAVI DMWD1FP TN Prostaglandin E2 receptor EP2 (PTGER2) DMWD1FP MA Antagonist DMWD1FP RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMWD1FP RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMWD20L DI DMWD20L DMWD20L DN Schiff base compound 2 DMWD20L TI TTGP7BY DMWD20L TN Monoamine oxidase type B (MAO-B) DMWD20L RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMWD20L RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMWDGCH DI DMWDGCH DMWDGCH DN US10040779, Example 4 DMWDGCH TI TTIG67W DMWDGCH TN Lysine-specific demethylase 5A (KDM5A) DMWDGCH MA Inhibitor DMWDGCH RN Histone demethylase inhibitors. US10040779. DMWDGCH RU http://www.freepatentsonline.com/US10040779.html DMWE6NZ DI DMWE6NZ DMWE6NZ DN PMID27607364-Compound-61 DMWE6NZ TI TTPTXIN DMWE6NZ TN Translocator protein (TSPO) DMWE6NZ MA Ligand DMWE6NZ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMWE6NZ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMWEJ6U DI DMWEJ6U DMWEJ6U DN Dihydropyrido phthalazinone derivative 4 DMWEJ6U TI TTEBCY8 DMWEJ6U TN Poly [ADP-ribose] polymerase (PARP) DMWEJ6U MA Inhibitor DMWEJ6U RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMWEJ6U RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMWESZ1 DI DMWESZ1 DMWESZ1 DN US10100051, Compound 2 DMWESZ1 TI TT9ISBX DMWESZ1 TN HIF-prolyl hydroxylase 2 (HPH-2) DMWESZ1 MA Inhibitor DMWESZ1 RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMWESZ1 RU http://www.freepatentsonline.com/US10100051.html DMWF2VG DI DMWF2VG DMWF2VG DN Biaryl mannoside derivative 8 DMWF2VG TI TTTCRU2 DMWF2VG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMWF2VG MA Antagonist DMWF2VG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMWF2VG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMWF4S7 DI DMWF4S7 DMWF4S7 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 DMWF4S7 TI TTJW4LU DMWF4S7 TN Phosphodiesterase 10A (PDE10) DMWF4S7 MA Inhibitor DMWF4S7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWF4S7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWF4S7 DI DMWF4S7 DMWF4S7 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 DMWF4S7 TI TTJGW1Z DMWF4S7 TN Phosphodiesterase 2A (PDE2A) DMWF4S7 MA Inhibitor DMWF4S7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWF4S7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWFHKR DI DMWFHKR DMWFHKR DN 4-oxadiazole derivative 1 DMWFHKR TI TTO9X1H DMWFHKR TN 5-HT 7 receptor (HTR7) DMWFHKR MA Inhibitor DMWFHKR RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMWFHKR RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMWFTCN DI DMWFTCN DMWFTCN DN Pyrazole derivative 72 DMWFTCN TI TTJQOD7 DMWFTCN TN 5-HT 2A receptor (HTR2A) DMWFTCN MA Antagonist DMWFTCN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMWFTCN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMWG95Z DI DMWG95Z DMWG95Z DN PMID25656651-Compound-26b DMWG95Z TI TTS7G69 DMWG95Z TN Fusion protein Bcr-Abl (Bcr-Abl) DMWG95Z MA Inhibitor DMWG95Z RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMWG95Z RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMWG98Z DI DMWG98Z DMWG98Z DN US9353089, 135 DMWG98Z TI TTXMNHO DMWG98Z TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMWG98Z MA Inhibitor DMWG98Z RN Compositions and methods for the treatment of malaria. US9353089. DMWG98Z RU http://www.freepatentsonline.com/US9353089.html DMWGAQU DI DMWGAQU DMWGAQU DN PMID25666693-Compound-34 DMWGAQU TI TTMI6F5 DMWGAQU TN Transient receptor potential cation channel V1 (TRPV1) DMWGAQU MA Antagonist DMWGAQU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMWGAQU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMWGIJS DI DMWGIJS DMWGIJS DN Mycophenolic acid/nucleotide derivative 8 DMWGIJS TI TTL7C8Q DMWGIJS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWGIJS MA Inhibitor DMWGIJS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWGIJS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWGIS7 DI DMWGIS7 DMWGIS7 DN PMID25666693-Compound-109 DMWGIS7 TI TTMI6F5 DMWGIS7 TN Transient receptor potential cation channel V1 (TRPV1) DMWGIS7 MA Antagonist DMWGIS7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMWGIS7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMWGV8N DI DMWGV8N DMWGV8N DN PMID28870136-Compound-43 DMWGV8N TI TTK0O6Y DMWGV8N TN Ecto-5'-nucleotidase (CD73) DMWGV8N MA Inhibitor DMWGV8N RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMWGV8N RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMWH3FP DI DMWH3FP DMWH3FP DN Cyclic peptidomimetic derivative 2 DMWH3FP TI TT23XQV DMWH3FP TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMWH3FP MA Inhibitor DMWH3FP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMWH3FP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMWHAKG DI DMWHAKG DMWHAKG DN PMID27977313-Compound-30 DMWHAKG TI TTR7UJ3 DMWHAKG TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWHAKG MA Inhibitor DMWHAKG RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWHAKG RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWHCOE DI DMWHCOE DMWHCOE DN Thiazole carboxamide derivative 6 DMWHCOE TI TTCZOF2 DMWHCOE TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWHCOE MA Inhibitor DMWHCOE RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWHCOE RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWHN1O DI DMWHN1O DMWHN1O DN AKOS020330481 DMWHN1O TI TTIG67W DMWHN1O TN Lysine-specific demethylase 5A (KDM5A) DMWHN1O MA Inhibitor DMWHN1O RN Histone demethylase inhibitors. US9611221. DMWHN1O RU http://www.freepatentsonline.com/US9611221.html DMWI6V3 DI DMWI6V3 DMWI6V3 DN Peptide analog 13 DMWI6V3 TI TT68GPI DMWI6V3 TN Proteasome beta-5 (PS beta-5) DMWI6V3 MA Inhibitor DMWI6V3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMWI6V3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMWI6V3 DI DMWI6V3 DMWI6V3 DN Peptide analog 13 DMWI6V3 TI TTEAD9J DMWI6V3 TN Proteasome beta-8 (PS beta-8) DMWI6V3 MA Inhibitor DMWI6V3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMWI6V3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMWIMN9 DI DMWIMN9 DMWIMN9 DN PMID27977313-Compound-7 DMWIMN9 TI TTR7UJ3 DMWIMN9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWIMN9 MA Inhibitor DMWIMN9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWIMN9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWIYFQ DI DMWIYFQ DMWIYFQ DN Dihydropyrido phthalazinone derivative 1 DMWIYFQ TI TTVDSZ0 DMWIYFQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMWIYFQ MA Inhibitor DMWIYFQ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMWIYFQ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMWJDEO DI DMWJDEO DMWJDEO DN Heterocyclic derivative 5 DMWJDEO TI TTCZOF2 DMWJDEO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWJDEO MA Inhibitor DMWJDEO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWJDEO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWJRY7 DI DMWJRY7 DMWJRY7 DN PMID26882240-Compound-8 DMWJRY7 TI TTUX68I DMWJRY7 TN Hypoxia-inducible factor 1 (HIF-1) DMWJRY7 MA Inhibitor DMWJRY7 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMWJRY7 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMWJXRO DI DMWJXRO DMWJXRO DN PMID26666989-Compound-Figure11Ala down DMWJXRO TI TT8BUGW DMWJXRO TN Glycogen phosphorylase (PYG) DMWJXRO MA Inhibitor DMWJXRO RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMWJXRO RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMWJZU9 DI DMWJZU9 DMWJZU9 DN BDBM50158794 DMWJZU9 TI TTIG67W DMWJZU9 TN Lysine-specific demethylase 5A (KDM5A) DMWJZU9 MA Inhibitor DMWJZU9 RN Histone demethylase inhibitors. US10040779. DMWJZU9 RU http://www.freepatentsonline.com/US10040779.html DMWKDET DI DMWKDET DMWKDET DN US8829193, 1 DMWKDET TI TTCGOIN DMWKDET TN PIM-3 protein kinase (PIM3) DMWKDET MA Inhibitor DMWKDET RN PIM kinase inhibitors and methods of their use. US8829193. DMWKDET RU http://www.freepatentsonline.com/US8829193.html DMWKI89 DI DMWKI89 DMWKI89 DN Thiazole carboxamide derivative 10 DMWKI89 TI TTCZOF2 DMWKI89 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWKI89 MA Inhibitor DMWKI89 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWKI89 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWKSF3 DI DMWKSF3 DMWKSF3 DN Pyrrolidinyl urea derivative 11 DMWKSF3 TI TTTDVOJ DMWKSF3 TN Tropomyosin-related kinase A (TrkA) DMWKSF3 MA Inhibitor DMWKSF3 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMWKSF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMWKVZD DI DMWKVZD DMWKVZD DN PMID27537201-Compound-Figure17 DMWKVZD TI TTPADOQ DMWKVZD TN HMG-CoA reductase (HMGCR) DMWKVZD MA Inhibitor DMWKVZD RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMWKVZD RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMWKXN4 DI DMWKXN4 DMWKXN4 DN Carbamide derivative 7 DMWKXN4 TI TTL7C8Q DMWKXN4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWKXN4 MA Inhibitor DMWKXN4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWKXN4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWKYU4 DI DMWKYU4 DMWKYU4 DN PMID27744724-Compound-3 DMWKYU4 TI TTL53M6 DMWKYU4 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMWKYU4 MA Inhibitor DMWKYU4 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMWKYU4 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMWL5V0 DI DMWL5V0 DMWL5V0 DN Pyrimidine derivative 33 DMWL5V0 TI TTDIGC1 DMWL5V0 TN Dipeptidyl peptidase 4 (DPP-4) DMWL5V0 MA Inhibitor DMWL5V0 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMWL5V0 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMWLPEB DI DMWLPEB DMWLPEB DN Naphthalene derivative 1 DMWLPEB TI TTA6ZN2 DMWLPEB TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMWLPEB MA Inhibitor DMWLPEB RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMWLPEB RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMWLPEB DI DMWLPEB DMWLPEB DN Naphthalene derivative 1 DMWLPEB TI TTGIZLN DMWLPEB TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMWLPEB MA Modulator DMWLPEB RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMWLPEB RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMWM03O DI DMWM03O DMWM03O DN PMID27109571-Compound-9 DMWM03O TI TTHWMFZ DMWM03O TN Fatty acid-binding protein 4 (FABP4) DMWM03O MA Inhibitor DMWM03O RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMWM03O RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMWMPE2 DI DMWMPE2 DMWMPE2 DN PMID29338548-Compound-31 DMWMPE2 TI TTHJTF7 DMWMPE2 TN Glycine transporter GlyT-1 (SLC6A9) DMWMPE2 MA Inhibitor DMWMPE2 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMWMPE2 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMWMRKJ DI DMWMRKJ DMWMRKJ DN Isoxazole-based bicyclic compound 3 DMWMRKJ TI TTE4BSY DMWMRKJ TN Bromodomain and extraterminal domain protein (BET) DMWMRKJ MA Inhibitor DMWMRKJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWMRKJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWMV48 DI DMWMV48 DMWMV48 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 2 DMWMV48 TI TTV8CRH DMWMV48 TN Lysine-specific demethylase 4C (KDM4C) DMWMV48 MA Inhibitor DMWMV48 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMWMV48 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMWMZE4 DI DMWMZE4 DMWMZE4 DN PMID26394986-Compound-11 DMWMZE4 TI TTH8FZW DMWMZE4 TN Signal transducer and activator of transcription 3 (STAT3) DMWMZE4 MA Inhibitor DMWMZE4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMWMZE4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMWN17V DI DMWN17V DMWN17V DN Imidazopyrimidinone derivative 1 DMWN17V TI TTSCIM2 DMWN17V TN Extracellular lysophospholipase D (E-NPP2) DMWN17V MA Inhibitor DMWN17V RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMWN17V RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMWNKQ8 DI DMWNKQ8 DMWNKQ8 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1 DMWNKQ8 TI TTJGW1Z DMWNKQ8 TN Phosphodiesterase 2A (PDE2A) DMWNKQ8 MA Inhibitor DMWNKQ8 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWNKQ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWNR8I DI DMWNR8I DMWNR8I DN Urea and carbamate bioisostere derivative 10 DMWNR8I TI TTL7C8Q DMWNR8I TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWNR8I MA Inhibitor DMWNR8I RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWNR8I RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWNZTI DI DMWNZTI DMWNZ